<SEC-DOCUMENT>0001490978-25-000014.txt : 20250226
<SEC-HEADER>0001490978-25-000014.hdr.sgml : 20250226
<ACCEPTANCE-DATETIME>20250226160957
ACCESSION NUMBER:		0001490978-25-000014
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250226
DATE AS OF CHANGE:		20250226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Schrodinger, Inc.
		CENTRAL INDEX KEY:			0001490978
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				954284541
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39206
		FILM NUMBER:		25670085

	BUSINESS ADDRESS:	
		STREET 1:		1540 BROADWAY
		STREET 2:		24TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		503-299-1150

	MAIL ADDRESS:	
		STREET 1:		1540 BROADWAY
		STREET 2:		24TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sdgr-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:6d57be63-fef2-4aee-a5b8-ca771b86978e,g:704293bf-0912-4e44-b70a-e4f74457db02,d:9fcbc0760d8f4d2fbc4bc276bb5428c7-->
<html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sdgr="http://www.schrodinger.com/20241231" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sdgr-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-37">0001490978</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-38">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-39">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-40">false</ix:nonNumeric><ix:nonNumeric contextRef="c-293" name="ecd:TrdArrAdoptionDate" id="f-1125">November 26, 2024</ix:nonNumeric><ix:nonNumeric contextRef="c-293" name="ecd:TrdArrExpirationDate" id="f-1126">December 31, 2025</ix:nonNumeric><ix:nonNumeric contextRef="c-293" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1127">400</ix:nonNumeric><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrAdoptionDate" id="f-1128">December 17, 2024</ix:nonNumeric><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrExpirationDate" id="f-1129">December 31, 2025</ix:nonNumeric><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1130">379</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sdgr-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="target"><xbrli:measure>sdgr:target</xbrli:measure></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>sdgr:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>sdgr:program</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>sdgr:vote</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>sdgr:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:UnallocatedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:UnallocatedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-23</xbrli:startDate><xbrli:endDate>2023-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:July2024AgreementWithBillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:July2024AgreementWithBillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:July2024AgreementWithBillMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MaintenanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MaintenanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MaintenanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:ProfessionalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-22</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-22</xbrli:startDate><xbrli:endDate>2020-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-11-12</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:SoftwareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sdgr:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sdgr:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sdgr:TheATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sdgr:TheATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sdgr:TwentyTwentyStockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sdgr:SharebasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">sdgr:SharebasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:SoftwareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:SoftwareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:SoftwareSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:DrugDiscoverySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:DrugDiscoverySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:DrugDiscoverySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sdgr:APACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sdgr:APACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sdgr:APACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:RobertAbelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:RobertAbelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:KarenAkinsanyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001490978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:KarenAkinsanyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39206</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Schrodinger, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">95-4284541</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">1540 Broadway</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11" continuedAt="f-11-1">24</ix:nonNumeric></span><ix:continuation id="f-11-1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Floor</span></ix:continuation></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">NY</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">212</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">295-5800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">SDGR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#168;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#168;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">&#168;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 28, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-30">790,263,620</ix:nonFraction> based upon the closing sale price of the registrant&#8217;s common stock on that date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;19, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">63,874,200</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">9,164,193</ix:nonFraction> shares of limited common stock outstanding.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-33" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></div></ix:nonNumeric><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Auditor Firm Id:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-34">185</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Auditor Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-35">KPMG LLP</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Auditor Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-36">Portland, OR</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_19">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_22">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_22">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_22">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_25">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_25">Cybersecurity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_25">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_31">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_31">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_31">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_34">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_34">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_34">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_37">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_37">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_37">126</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_40">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_43">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_43">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_43">127</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_46">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_46">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_46">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_49">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_49">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_49">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_85">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_85">149</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_88">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_88">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_88">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_175">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_175">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_175">150</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_178">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_178">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_178">150</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_181">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_181">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_181">151</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_187">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_187">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_187">151</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_190">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_193">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_193">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_193">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_196">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_196">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_196">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_199">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_199">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_199">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_202">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_202">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_202">152</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_205">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_205">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_205">152</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_211">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_214">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_214">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_214">153</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_217">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_217">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_217">157</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within the meaning of the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report include, among other things, statements about:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential advantages of our physics-based computational platform;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our strategic plans to accelerate the growth of our software business and acquire new customers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our research and development efforts for our proprietary drug discovery programs and our computational platform, including the initiative to expand our computational platform to predict toxicology risk in early drug discovery;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our drug discovery collaborations, including the initiation, timing, progress and results of such collaborations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our estimates or expectations regarding any milestone or other payments we may receive from drug discovery collaborations, including pursuant to our collaboration agreement with Novartis Pharma AG;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our proprietary drug discovery programs, including the initiation, timing, progress, and results of our preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to submit investigational new drug applications to the U.S. Food and Drug Administration for our proprietary drug discovery programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to discover and develop product candidates and to maximize their commercial potential by</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing such product candidates ourselves or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to leverage the synergies between our businesses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of, the ability to submit applications for and the ability to obtain and maintain regulatory approvals for any product candidates we or one of our collaborators may develop;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential advantages of our drug discovery collaborations and our proprietary drug discovery programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the rate and degree of market acceptance of our software solutions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the rate and degree of market acceptance and clinical utility of any product we or any of our collaborators may develop;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our estimates regarding the potential market opportunity for our software solutions and any product candidate we or any of our collaborators may develop;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our sales and marketing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to identify technologies with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our expectations related to the use of our cash, cash equivalents, and marketable securities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our expectations related to the key drivers of our performance;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the impact of government laws and regulations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our competitive position and expectations regarding developments and projections relating to our competitors and any competing products, technologies, or therapies that are or become available;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to maintain and establish collaborations or obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our reliance on key personnel and our ability to identify, recruit, and retain skilled personnel; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential impact of geopolitical and global economic developments and public health epidemics or pandemics.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report, particularly in "Risk Factor Summary" and "Risk Factors" below, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, in-licensing arrangements, joint ventures, or investments we may make or enter into.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report are made as of the date of this Annual Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Annual Report involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, surveys and studies, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the context </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requires, we use the terms "company," "we," "us," and "our" in this Annual Report to refer to Schr&#246;dinger, Inc. and its consolidated subsidiaries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks of which you should be aware before making an investment decision. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled "Risk Factors", together with the other information in this Annual Report.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We have a history of significant operating losses, and we expect to incur losses over the next several years.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to increase sales of our software, increase revenue from our drug discovery collaborations, or if we and our current and future collaborators are unable to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our quarterly and annual results may fluctuate significantly, which could adversely impact the value of our common stock.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower prices, our business and operating results will suffer.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A significant portion of our revenues are generated by sales to life sciences industry customers, and factors that adversely affect this industry could adversely affect our software sales.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The markets in which we participate are highly competitive, and if we do not compete effectively, our business and operating results could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may never realize a return on our investment of resources and cash in our drug discovery collaborations.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Although we believe that our computational platform has the potential to identify more promising molecules than traditional methods and to accelerate drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or our collaborators.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may not be successful in our efforts to identify, discover or develop product candidates and may fail to capitalize on programs, collaborations, or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">As a company, we have very limited experience in clinical development, which may adversely impact the likelihood that we will be successful in advancing our programs.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We will likely require additional capital to fund our operations. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We rely on, and plan to continue to rely on, third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration or other comparable foreign regulatory authorities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other intellectual property licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to obtain, maintain, enforce, and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our internal information technology systems, or those of our third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We are pursuing multiple business strategies and expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our multiple business units and our growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our executive officers, directors, and principal stockholders, if they choose to act together, have the ability to influence all matters submitted to stockholders for approval.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our actual operating results may differ significantly from our guidance.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_19"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are transforming the way therapeutics and materials are discovered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Traditional drug discovery and development efforts are complex, lengthy and capital-intensive, and are prone to high failure rates. Traditional drug discovery relies upon many iterations of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. One of the primary reasons for long timelines, high costs, and high failure rates in drug discovery is that predicting properties of molecules in advance of chemical synthesis is extremely complex and not amenable to traditional approaches.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several decades and with the concerted efforts of our scientists and software engineers, we have developed a physics-based computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. This key capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties, reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development. Furthermore, we believe that development candidates with more optimized property profiles will have a higher probability of success in clinical development. Additionally, since the physics underlying the properties of drug molecules and materials is the same, we have been able to extend our computational platform to materials science applications in fields such as aerospace, energy, semiconductors, electronic displays, and chemicals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2024, 19 of the top 20 pharmaceutical companies, measured by 2023 revenue, licensed our solutions, accounting for $74.7 million, or 41%, of our software revenue in 2024. We had 235, 222, and 227 customers with an annual contract value, or ACV, of at least $100,000, which represented 87%, 83%, and 82% of our total ACV, for the years ended December 31, 2024, 2023, and 2022, respectively. The widespread adoption of our software, supported by our global team of sales, technical, and scientific personnel, has driven steady growth in our software revenue. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate this scaling-up will drive future revenue growth. Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an ACV at higher thresholds. For the year ended December&#160;31, 2024, we had 61 customers with an ACV of at least $500,000 compared to 54 for the year ended December&#160;31, 2023. Furthermore, the number of customers with an ACV of at least $1.0 million increased to 31 for the year ended December&#160;31, 2024, compared to 27 and 18 for the years ended December&#160;31, 2023 and 2022, respectively. We also had eight customers with an ACV of at least $5.0 million for the year ended December&#160;31, 2024, compared to four customers for each of the years ended December&#160;31, 2023 and 2022. In addition, our customer retention rate for our customers with an ACV of at least $100,000 for the year ended December&#160;31, 2024 was 95% and was 92% or higher for each of the previous 10 fiscal years. Our customer retention rate for our customers with an ACV of at least $500,000 was 100% for the year ended December&#160;31, 2024 and 98% for the year ended December&#160;31, 2023. We believe the growth in the number of our larger customers demonstrates that companies are increasingly recognizing the power and appreciating the scientific and financial benefits of using our platform at scale while the retention in our customer base is indicative of the continued value of our platform. See "Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Key Factors Affecting Our Performance" for additional information regarding ACV and customer retention rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also leverage our platform and capabilities across a portfolio of collaborative and proprietary drug discovery programs spanning a wide range of disease targets and indications. Our drug discovery group, which we refer to as the Schr&#246;dinger therapeutics group, is comprised of a multidisciplinary team of approximately 180 experts in protein science, biochemistry, biophysics, medicinal and computational chemistry, and discovery scientists with expertise in preclinical and early clinical development. We have entered into drug discovery collaborations with biopharmaceutical companies under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease and tuberculosis. When we engage in drug discovery with these collaborators, we typically provide access to our platform and platform experts who assist the drug discovery collaborator in identifying molecules that have activity against one or more specified protein targets. Our collaboration agreements typically include upfront consideration, discovery, development, commercial and regulatory milestones, and royalties from future sales of commercialized products. We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones, and we have the potential to generate drug discovery revenue from commercial and regulatory milestones, option fees, and royalties under our collaboration agreements. We also rely on collaborators for the development and potential commercialization of product candidates we discover internally when we believe it will help maximize clinical and commercial opportunities for the product candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in November 2024, we entered into a research collaboration and license agreement with Novartis Pharma AG, or Novartis, pursuant to which we and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. We are eligible to receive up to $2.272 billion in total milestones across the initial programs, of which no milestone revenue has been recognized as revenue as of December&#160;31, 2024, as well as a tiered percentage royalty on net sales of each product commercialized by Novartis ranging from mid-single-digits to low double-digits, subject to certain specified reductions. See &#8220;&#8212;Collaboration Agreement with Novartis Pharma AG&#8221; for additional information relating to this agreement. We also entered into a three-year software agreement with Novartis that substantially increased Novartis' access to our computational predictive modeling technology and enterprise informatics platform.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics. In June 2022, the U.S. Food and Drug Administration, or FDA, cleared our first investigational new drug application, or IND, for our MALT1 inhibitor, which we refer to as SGR-1505. We have initiated dosing in a Phase 1 clinical trial of SGR-1505, which is designed as an open-label, multi-center dose escalation trial in patients with relapsed or refractory B-cell malignancies. The trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, maximum tolerated dose and/or recommended dose of SGR-1505. Exploratory cohorts will evaluate additional pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity and safety to establish the recommended dose. We anticipate reporting initial data from the trial in the second quarter of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a Phase 1 clinical trial of SGR-1505 in 73 healthy volunteers to gather additional data, including data relating to the safety, tolerability, and pharmacokinetics of SGR-1505, as well as the effect of food and drug-drug interactions. In the healthy volunteer trial, SGR-1505 was generally well tolerated with no drug-related serious adverse events or dose limiting toxicities observed. In the trial, we observed that SGR-1505 achieved greater than 90 percent inhibition of IL-2 secretion in an activated T cell whole blood assay at 100 mg twice a day (n=4), confirming target engagement and meeting the pharmacodynamic goals for the trial. Inhibition of IL-2 secretion is a marker for target engagement and pathway modulation as it is tightly linked to MALT1 and the downstream NF-&#954;B signaling. The data supported continued evaluation of SGR-1505 in the ongoing Phase 1 clinical trial in patients with relapsed or refractory B-cell malignancies. In addition, in August 2023, the FDA granted orphan drug designation to SGR-1505 for the potential treatment of mantle cell lymphoma.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the FDA cleared our IND for our CDC7 inhibitor, which we refer to as SGR-2921. In July 2024, the FDA granted Fast Track designation to SGR-2921 in patients with relapsed or refractory acute myeloid leukemia, or AML. In addition, in January 2025, the FDA granted orphan drug designation to SGR-2921 in patients with relapsed or refractory AML. We have initiated dosing in a Phase 1 clinical trial of SGR-2921, which is designed as an open-label, multi-center dose-escalation clinical trial in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome. The trial is designed to evaluate the safety and tolerability of SGR-2921 as a monotherapy and to identify the recommended Phase 2 dose, including the maximum tolerated dose. Secondary and exploratory objectives of the trial include evaluating the pharmacokinetics and pharmacodynamics of SGR-2921 and investigating preliminary anti-tumor activity. We anticipate reporting initial data from the trial in the second half of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we also submitted an IND to the FDA for our novel Wee1/Myt1 inhibitor, which we refer to as SGR-3515, and the FDA cleared the IND in April 2024. We recently initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors. The trial is a dose-escalation trial designed to evaluate the safety, tolerability, and recommended Phase 2 dose of SGR-3515. Secondary and exploratory objectives of the trial include </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluating the pharmacokinetics and preliminary anti-tumor activity of SGR-3515. We anticipate reporting initial data from the trial in the second half of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, we generated total revenue of $207.5 million and had a net loss of $187.1 million.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered. We aim to do this by:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">Advancing the science that underlies our computational platform:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are the leader in the field of physics-based computational drug discovery, and we believe our computational platform is far ahead of that of our nearest competitors. We intend to maintain our industry-leading position by introducing new capabilities and refining our software to further strengthen our technology and advance the science underlying our platform. For example, in 2024, we launched an initiative to expand our computational platform to predict toxicology risk early in drug discovery, which is being funded by $19.5 million in grants from the Bill &amp; Melinda Gates Foundation. The goal of this initiative is to develop a computational solution designed to improve the properties of novel drug development candidates and reduce the risk of development failure associated with binding to off-target proteins, which can be associated with serious side effects.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">Growing and expanding our software business:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have experienced steady growth in our software revenues, achieving $180.4 million in revenue in 2024, an increase of 13% compared to 2023, primarily driven by broad adoption of our software solutions by the biopharmaceutical industry. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.46pt">Advancing our collaborative programs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to continue to work with our collaborators on advancing our collaborative programs through discovery research stages. Our collaboration agreements typically include upfront consideration, discovery, development, commercial and regulatory milestones, and royalties from future sales of commercialized products. We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones, and we have the potential to generate drug discovery revenue from commercial and regulatory milestones, option fees, and royalties under our collaboration agreements. We achieved drug discovery revenue of $27.2 million in 2024. We also benefit from our equity positions in certain of our collaborators. For example, in 2024, we received $47.6 million for the equity stake that we owned in Morphic Holding, Inc., or Morphic, one of our drug discovery collaborators and co-founded companies, in connection with Morphic's acquisition by Eli Lilly and Company, or Lilly, for approximately $3.2 billion.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.46pt">Progressing our proprietary drug discovery programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We plan to progress the development of our proprietary drug discovery programs, including SGR-1505, SGR-2921 and SGR-3515, and continue to advance new programs where we can leverage our computational platform to identify novel molecules. As we progress these programs, we plan to strategically evaluate on a program-by-program basis advancing them into preclinical and clinical development ourselves, entering into collaborations to co-develop them with leading industry partners, or out-licensing them to maximize clinical and commercial opportunity. </span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">Leveraging the synergies between our businesses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that there are significant synergies within our business. We leverage the feedback that we receive from our software customers, collaborators, and internal drug discovery experts to improve the functionality of our platform, which we believe supports increased customer adoption of our solutions and more rapid advancement of our collaborative and proprietary drug discovery programs. In addition, the success of our collaborators in advancing drug discovery programs provides significant validation of our platform and approach, which we believe increases the attractiveness of our platform to customers, helps us establish new collaborations, and validates the potential of our own proprietary drug discovery programs. Central to our ability to pursue these distinct lines of business is a firewall policy consisting of a set of well-established protocols and technology measures designed to ensure that the intellectual property of our software customers and drug discovery collaborators remains confidential and segregated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Traditional drug discovery and development efforts are complex, lengthy and capital-intensive, and are prone to high failure rates. Traditional drug discovery involves experimental screening of existing libraries of molecules to find molecules with detectable activity, or "hit molecules," followed by many iterations of chemical synthesis to optimize those hit molecules to a development candidate that can be advanced into human clinical trials. Efforts to optimize initial hit molecules for a drug discovery project involve costly and iterative synthesis and testing of molecules seeking to identify a molecule with the required property profile. The optimal profile has an acceptable balance of properties such as potency, selectivity, solubility, bioavailability, half-life, permeability, drug-drug interaction profile, synthesizability, and toxicity. These properties are often inversely correlated, meaning that optimizing one property often de-optimizes others. The challenge of optimizing hit molecules is amplified by the limited number of molecules that can be feasibly tested across these properties with traditional methods. As a result, this optimization process often fails to yield a molecule with a satisfactory property profile to be a development candidate, which is why many drug discovery programs fail to advance into clinical development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Being able to predict molecular properties before initiating costly and time-consuming experimental synthesis would accelerate drug discovery, reduce costs, and increase the probability of success. If it were possible to accurately predict critical properties of molecules, fewer molecules would have to be experimentally synthesized and tested. As a result, larger pools of molecules could be analyzed allowing for more selective synthesis of molecules, leading to higher-quality molecules. In addition, with predictive computational methods, better selections of molecules would be synthesized through exploration of larger portions of chemical space, leading to higher-quality molecules that would in turn have a higher probability of progressing through clinical development and obtaining regulatory approval for commercial sale.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been many attempts to improve the efficiency of the drug discovery process by using computational methods to predict properties of molecules. One of the primary computational methods that many companies have attempted to deploy is machine learning, often referred to as artificial intelligence, or AI. One of the main benefits of machine learning is its ability to rapidly process data at scale. However, machine learning on its own has significant limitations and has therefore had a limited impact on improving the efficiency of the drug discovery process. Machine learning requires input data, referred to as a training set, to build a predictive model. This model is expected to accurately predict properties of molecules similar to the training set, but cannot extrapolate to molecules that are not similar to the training set. Accordingly, since the number of possible molecules that could be synthesized is effectively infinite, machine learning can only cover a minuscule fraction of the total number of molecules that could potentially be synthesized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other primary computational method that has been explored to improve drug discovery involves using fundamental, "first-principles" physics-based methods, which require a deep and thorough understanding of the specific property to be computed. However, physics-based methods are difficult to develop and can be slow compared to machine learning. Further, to apply such methods to design molecules that will bind with high affinity to a particular protein target, the three-dimensional structure of that protein must be generated with sufficient atomic detail to enable application of these physics-based approaches, which is referred to as being "structurally enabled," and such structures have been historically difficult to obtain and are only available today for a relatively small subset of the universe of human proteins. Another factor preventing computational chemistry from realizing its promise has been limited compute speed. However, despite all of these challenges, physics-based methods have a significant advantage over machine learning in that they do not require a training set and can, in principle, compute properties of molecules that are well beyond existing industry experience and data.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several decades and with the concerted effort of hundreds of our scientists and software engineers, we have developed a computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. We have built our platform on a foundation of rigorous, physics-based methods, combined with the rapid data processing and scaling advantages of machine learning, that together provide a significant advantage over traditional methods. We believe that physics-based simulation has reached an inflection point as a result of the increased availability of massive computing power, combined with a more sophisticated understanding of models and algorithms and the growing availability of high-resolution protein structures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have demonstrated that our software platform can have a transformative impact on the drug discovery process by:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reducing the average time and cost required to identify a development candidate; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increasing the probability of drug discovery programs entering clinical development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our drug discovery efforts to date, including in our collaborative programs, we believe that the development candidates discovered using our platform have a higher probability of successfully progressing through clinical development than the industry average.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown below, we achieve these outcomes by tightly integrating our predictive physics-based methods, which have a high degree of accuracy, with machine learning, which is highly scalable. In addition, our platform enables real-time collaboration on drug discovery projects to inform decision-making and maximize the impact of the predictive capabilities of our computational platform.</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g1.jpg" alt="Picture4.jpg" style="height:268px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our computational platform provides the following significant technological advantages over traditional approaches to drug discovery, which we believe enable shorter timelines, lower costs, and higher probability of success of drug discovery efforts:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Speed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform is able to evaluate molecules in hours rather than the weeks it typically takes to screen, synthesize and test molecules in the laboratory.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Scale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform can explicitly evaluate billions of molecules per day, whereas traditional drug discovery methods only synthesize and evaluate approximately one thousand molecules per year, thereby increasing the probability that we find a novel molecule with the desired property profile.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Quality.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In a peer-reviewed study, our platform was tested against traditional methods for selecting tight-binding molecules and resulted in an eight-fold increase in the number of molecules with the desired affinity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our computational platform includes a broad array of capabilities:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Faster Lead Discovery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the ability to rapidly identify potent molecules suitable for hit-to-lead and lead optimization efforts by virtually screening extremely large libraries of molecules, as well as physics-based replacement of the central core of a molecule, known as scaffold hopping, to identify novel, highly potent molecules unavailable in library collections;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Accurate Property Prediction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the ability to assess key properties of drug-like molecules using physics-based calculations with accuracy comparable to that of experimental laboratory assays, to facilitate optimization of drug properties, including drug potency, selectivity, and bioavailability;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Optimizing Protein Structures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the ability to refine and optimize protein structure models to increase the number of targets amenable to structure-based drug design;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Large-Scale Molecule Exploration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the ability to computationally ideate and explore novel, high-quality drug-like molecules for consideration by discovery project teams utilizing computational enumeration and generative machine learning techniques that are trained and constructed to yield molecules that are synthetically feasible;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Large-Scale Molecule Evaluation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the ability to scale our calculations of key drug properties to ultra-large idea sets of billions of molecules to enable more rapid and successful identification of high-quality drug candidate molecules; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Integrated Data Management and Visualization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the ability to generate, access, and analyze the data derived from complex calculations integrated with assay data through a powerful and user-friendly graphical interface.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of our scientific advances has come through customer adoption, in citations of publications in peer reviewed journals and in the progress of our collaborative and proprietary drug discovery programs. For example, the initial paper describing our ligand-protein docking program, Glide, published in 2004 is one of the most cited papers in the history of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Medicinal Chemistry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a premier journal in its field. Glide continues to be broadly used as a hit-finding technology throughout the biopharmaceutical industry by our customers. We have made many similar scientific advances in fields including druggability assessment, affinity calculation, protein structure refinement, and molecule ideation and design. These advances were achieved by our team of hundreds of Ph.D.-level scientists and software engineers with extensive input from our Scientific Advisory Board, which includes thought leaders in computational chemistry, physics-based simulations, statistical mechanics, and machine learning.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our computational platform is also applicable to new problems of interest and new fields of study. Since the underlying physics that drives a biologic to bind to its target is no different than the physics that drives a small drug molecule to bind to a protein, we have been able to apply our technologies to the discovery of biologics and we continually work to increase our platform's capabilities in biologics. Similarly, the physics underlying the properties of materials is no different than the physics underlying the properties of drug molecules. Therefore, we have applied our computational platform to materials science applications, including in the fields of aerospace, energy, semiconductors, electronic displays, and chemicals.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Software Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the leading provider of computational software solutions for drug discovery to the biopharmaceutical industry. In 2024, 19 of the top 20 pharmaceutical companies, measured by 2023 revenue, licensed our solutions, accounting for $74.7 million, or 41%, of our software revenue in 2024. Additionally, in 2024, our software was used by researchers around the world at more than 1,818 academic institutions. The widespread adoption of our software is supported by an approximately 240-person global team of sales, technical, and scientific personnel. Our direct sales operations span across the United States, the European Union, United Kingdom, Japan, India, and South Korea, and we have sales distributors in other important markets, including China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a diverse and large existing customer base, ranging from startup biotechnology companies to the largest global pharmaceutical companies as well as an increasing number of materials science customers. Our ten largest software customers represented approximately 39% of our software revenue in 2024, including one customer that makes up 11% of total software revenue. We continue to expand our customer base as we provide education and information to increase the awareness of the potential of our computational platform across different industries. As of December 31, 2024, we had 1,752 active customers, which we define as the number of customers who had an ACV of at least $1,000 in a given fiscal year. Included in the number of customers are entities we derive software contribution revenue from, which for the year ended December 31, 2024, consisted of Gates Ventures, LLC and the Bill &amp; Melinda Gates Foundation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had 235, 222, and 227 customers with an ACV of at least $100,000 for the years ended December 31, 2024, 2023, and 2022, respectively. We believe there is a significant opportunity to expand the adoption of our platform within our customer base. For example, in November 2024, we entered into an expanded, three-year, software agreement with Novartis, which is more fully described in "&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">." The three-year agreement substantially increases Novartis' access to our computational predictive modeling technology and enterprise informatics platform to industry-leading scale. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth. Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an ACV at higher thresholds. For the year ended December&#160;31, 2024, we had 61 customers with an ACV of at least $500,000 compared to 54 for the year ended December&#160;31, 2023. In addition, we had 31, 27, and 18 customers for the years ended December 31, 2024, 2023, and 2022, respectively, with an ACV of at least </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 million. Furthermore, we also had eight customers with an ACV of at least $5.0 million for the year ended December&#160;31, 2024, compared to four customers for each of the years ended December&#160;31, 2023 and 2022. For the year ended December 31, 2024, our top 10 customers, measured by ACV, accounted for $73.1 million of our total ACV compared to $51.0 million for the year ended December 31, 2023. Our ACV was $190.8 million and $154.2 million for the years ended December&#160;31, 2024 and 2023, respectively. We believe biopharmaceutical companies are increasingly recognizing and appreciating the scientific and financial benefits of using our platform at scale.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we believe our sales and marketing approach and the quality of our software solutions result in long-term relationships and high retention with our largest customers. This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest software customers in 2024 being nearly 21 years. Furthermore, our ability to expand our customer relationships over time is exemplified by our ability to retain our customers with an ACV of at least $100,000. For the year ended December 31, 2024, our year-over-year customer retention rate for our customers with an ACV of at least $100,000 was 95% and was 92% or higher for each of the previous 10 fiscal years. Our customer retention rate for our customers with an ACV of at least $500,000 was 100%, 98%, 100% for the years ended December&#160;31, 2024, 2023, and 2022, respectively. We believe our high retention rate for our customer base coupled with our ability to expand our customers&#8217; use of our software will continue to drive revenue growth. The figures below show the different ways in which we are accelerating our growth.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g2.jpg" alt="acv2025.jpg" style="height:420px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Key Factors Affecting Our Performance" for additional information regarding ACV and customer retention rate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Software Solutions for Drug Discovery</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization pursuant to agreements with terms typically for one year. Our licenses give our customers the ability to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">execute a certain number of calculations across specified software solutions. Certain of our key software solutions are highlighted below, along with the particular stage of drug discovery in which they are employed.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Target Identification and Validation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the identification and evaluation of a protein target that might be worthwhile to pursue as the subject of a drug discovery campaign.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">WaterMap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. From this analysis, one can infer the druggability of a protein, as well as uncover opportunities to significantly increase binding affinity by exploiting the water structure in the binding site.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">SiteMap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows binding site identification and evaluation to help locate potential protein binding sites, including allosteric sites, and predict the approximate druggability of those sites.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">GlideEM, PrimeX and Phenix/OPLS4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enable optimization of intermediate quality experimental protein structures to a quality sufficient to drive structure-based drug discovery.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Hit Discovery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: the identification of hit molecules.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">FEP+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our free energy calculation software. In hit discovery, this software can be used to replace the central core of earlier known tight binding molecules to identify novel, highly potent molecules unavailable in library collections. Often these molecules have much higher binding affinity and have a better property profile than typical hit molecules. FEP+ can also be used to calculate absolute binding affinities, which enables the software to evaluate and triage diverse molecules sharing no common peripheral features in a hit discovery context.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">Glide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our virtual screening program that is used to screen libraries of molecules to find hit molecules likely to bind a particular protein target in a specific conformation.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">GlideWS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our next-generation virtual screening program that utilizes a more accurate and robust description of protein-ligand interaction solvation effects. This and other novel features enable GlideWS to more reliably find hit molecules for challenging protein targets when screening libraries of molecules.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">Shape</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> uses the three-dimensional structure and shape of earlier known hit molecules to find new hits when screening libraries of molecules.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">DeepAutoQSAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> uses modern machine-learning methods trained to earlier known hit molecules to find novel hits when screening libraries of molecules.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">IFD-MD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> can computationally predict the binding mode of molecules to a binding site of a protein, including predicting how the conformation of the protein binding site may reorganize upon binding the molecule.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Hit to Lead and Lead Optimization:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hit to lead is the stage at which small molecule hits are evaluated and undergo limited optimization to identify promising lead molecules. Lead optimization improves on the property profile of lead molecules by designing new analogs with improved potency, reduced off-target activities, and favorable physicochemical/metabolic properties.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">FEP+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our free energy calculation software. In the hit to lead and lead optimization phases of drug discovery, FEP+ is used to predict the binding affinity of ligands to proteins with accuracy approaching that of physical experiments. It allows precise rank-ordering of large libraries of virtual molecules so that only the most potent molecules are synthesized in a program, which can save time and reduce cost. FEP+ can also be used to calculate the binding selectivity, solubility, and mutational resistance profiles of molecules, which are key properties for the optimization of bioavailability, toxicology, and efficacy.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">DeepAutoQSAR </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uses modern machine-learning methods to produce predictive quantitative structure-activity relationship, or QSAR, models. This allows more accurate methods, such as FEP+, to be applied at a much greater scale but with less accuracy to much larger sets of molecules than would otherwise be possible and enables predictive QSAR models of other properties to be developed and deployed on drug discovery projects.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">AutoDesigner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an enumeration tool that enables the rapid exploration of synthetically tractable ligands. When AutoDesigner is deployed in conjunction with multiparameter optimization, machine learning, and FEP+ simulations, it provides a streamlined approach to create and evaluate large sets of synthetically tractable, lead-like, potent ligands.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Software Solutions Used Throughout the Drug Discovery Process:</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">LiveDesign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our user-friendly enterprise informatics solution that enables interactive and collaborative molecule design, aggregation and sharing of data, and end-to-end discovery project </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="padding-left:99pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">coordination between chemists, modelers, and biologists. LiveDesign Biologics is our informatics solution for drug discovery teams designing biologics, which builds upon our LiveDesign offering.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.46pt">Maestro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our user-friendly modeling environment, which allows expert modelers to utilize our advanced modeling solutions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Software Solutions for Materials Science</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sell software licenses to customers engaged in molecule design for industrial purposes. The software solutions for our materials science customers leverage much of the same technology as our software for biopharmaceutical companies. In addition, similar to traditional drug discovery efforts, traditional approaches to discovering new molecules in these fields also suffer from long timelines, and it can take as long as 10 to 20 years to bring new materials to the market. We are focused on leveraging our technology to transform the way new materials are discovered, and we believe that materials science industries are only beginning to recognize the potential of computational methods. We are continuing to build a team of subject matter experts to further drive adoption of our computational platform in each of the following areas in which we currently operate:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">mobile electronics and displays</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;organic electronics (OLED);</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">aerospace and defense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;polymers, composites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">microelectronics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;semiconductors, thin film processing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">oil and gas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;catalysis, reactivity;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;alternative energy, batteries; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">consumer packaged goods</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;soft matter, formulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our ongoing efforts to further advance our software solutions for materials science applications, in June 2020, we entered into a three-year agreement with Gates Ventures, LLC, or Gates Ventures, to develop and apply atomistic simulations methods to improve battery performance. In August 2023, we extended the agreement with Gates Ventures for an additional three-year term at an increased scale. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also collaborate with a number of materials science companies to help accelerate the discovery and development of new materials. For example, in 2022, we entered into a collaboration with Eonix LLC, or Eonix, to accelerate the discovery and design of materials for safer, energy dense lithium ion batteries. Under the terms of this collaboration, we received an equity stake in Eonix, and will be eligible to receive additional equity upon the successful completion of certain technical milestones. In 2023, we also entered into a research collaboration with Copernic Catalysts, Inc. to help accelerate the discovery and development of sustainable catalysts for applications in e-fuels and bulk chemicals.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Drug Discovery Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using our computational platform in both our collaborative and proprietary drug discovery programs. The figure below illustrates the advantages in time, cost, and molecule quality of our computational drug design approach over traditional drug discovery approaches.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g3.jpg" alt="Flow graphic.jpg" style="height:211px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreements typically include upfront consideration, discovery, development, commercial and regulatory milestones, and royalties from future sales of commercialized products. We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones, and we have the potential to generate drug discovery revenue from commercial and regulatory milestones, option fees, and royalties under our collaboration agreements. As of December 31, 2024, we had 18 active collaborative drug discovery programs. We define an active collaborative drug discovery program as a program that we are actively progressing for, or together with, a collaborator of ours, or a program that our collaborator is progressing and which we are eligible to receive milestone payments, option fees, and/or future royalties. Furthermore, as of December 31, 2024, we had an aggregate of 13 collaborative programs for which we were eligible to receive future royalties on commercial sales, if any, of collaborative programs that receive marketing approval compared to 12 programs as of December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track the aggregate number of collaborators which we have collaborated with, or partnered with, for drug discovery and development since 2018, and as of December 31, 2024, we have had 19 collaborators. The number of collaborators is a cumulative number and we only include those collaborations from which we have derived revenue since the fiscal year ended December 31, 2018. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our drug discovery revenue-generating collaborations are an important component of our business, our strategy is also to invest in our proprietary drug discovery programs including SGR-1505, SGR-2921 and SGR-3515, which we describe in more detail below under "&#8212;Our Proprietary Drug Discovery Business." We evaluate our proprietary drug discovery programs individually to determine the advisability of entering into preclinical and clinical development ourselves to co-develop them with leading industry partners, entering into collaborations, or out-licensing programs to optimize their development and clinical and commercial potential. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to pursue additional proprietary drug discovery programs as our existing programs advance through discovery and development stages, internally or with partners, and we will continue to evaluate new collaborative programs that fit our selection criteria and where the collaborator&#8217;s particular expertise, resources or intellectual property has the potential to create substantial value.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.363%"><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Drug Discovery Collaborations</span></div></div><div style="display:inline-block;max-width:7.272%;min-width:6.272%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.365%"></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last decade, leveraging our platform and expertise, we have steadily developed a portfolio of drug discovery collaborative programs. We have entered into a number of collaborations with leading biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutics areas, including without limitation, various programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease and tuberculosis. Many of these programs are pursuing novel molecules for targets where a low-dose small molecule inhibitor or activator with optimal drug-like properties has been difficult to achieve or where selectivity for the target of interest has been difficult to achieve relative to other proteins. We have developed our pipeline of collaborative programs by selectively entering into drug discovery collaborations with leading biopharmaceutical companies. Among the factors that we use to embark on collaborations are whether the targets are well-validated, have high therapeutic potential, and are amenable to the strengths of our computational platform, and whether or not the collaborator brings complementary capabilities, all of which we believe contribute to an increased probability of success. Certain of these programs have provided us with significant income and have the potential to produce additional milestone payments, option fees, and royalties in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through access to the maximum potential scale of our computational platform and our drug discovery and software development teams, our collaborators receive the following key benefits:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Immediate utilization of our platform:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ability to immediately and efficiently leverage the full benefits of our computational platform, without the need for training or ramp-up time, thereby enabling accelerated drug discovery.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Access to massive compute power</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Ability to run our computational software at scale, thereby avoiding the time and cost needed to build such computational infrastructure on their own.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Early access to cutting-edge functionality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Real-time access to emerging solutions as they are being developed.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Target exclusivity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Under our collaboration agreements, we agree to design drugs for a particular protein target or targets using our computational platform and know-how exclusively for the collaborator.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current collaborators include, but are not limited to, Ajax Therapeutics, Inc., BMS, Bright Angel Therapeutics Inc., Eli Lilly and Company, or Lilly, Novartis, Otsuka Pharmaceutical Co., Ltd., or Otsuka, Sanofi S.A., and Structure Therapeutics Inc. (formerly ShouTi, Inc.). Our opportunity to receive further potential revenues from any of the programs under these collaborations is generally limited to research funding payments, development, regulatory, and commercial milestones, option fees, and royalties on commercial sales, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of our collaboration agreements with BMS, Otsuka, Novartis, and Lilly, which are described below, our collaborative agreements typically have the following characteristics:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Control/Ownership. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the programs being pursued under these collaborations are fully owned and controlled by each respective collaborator. We are not responsible for advancing their preclinical or clinical development or their commercialization, if approved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Stakes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have received equity consideration in certain of our collaborators, and from time to time, we have also made additional equity investments in certain of these collaborators. Unless otherwise noted, the following table presents our equity stakes in collaborators on an issued and outstanding basis as of December 31, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:85.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ajax Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Angel Therapeutics Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lakshmi, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nimbus Therapeutics, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Structure Therapeutics Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3%</span></td></tr></table></div><div style="padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:53.68pt">Represents our equity in the entity, which holds the rights to any future payments received in connection with Gilead Sciences, Inc.&#8217;s acquisition of Nimbus&#8217; ACC inhibitor program, on a fully diluted basis.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:53.68pt">Represents our equity in the entity, which holds the rights to any future payments received in connection with Takeda's acquisition of Nimbus' TYK-2 inhibitor program, on a fully diluted basis.</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:53.68pt">On a fully diluted basis</span></div><div style="padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:53.68pt">Based on the number of ordinary shares outstanding as of October 31, 2024, as reported on Structure Therapeutics Inc.'s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission, or SEC, on November 13, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also receive distributions on account of our equity stakes in our collaborators. For example, in February 2023, Nimbus announced the closing of the acquisition by Takeda of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its TYK2 program, which includes the TYK2 inhibitor, NDI-034858, which is being evaluated for the treatment of multiple immune-mediated diseases following positive results from the Phase 2b clinical trial in psoriasis. We received an aggregate of $147.2 million in cash distributions related to the Takeda acquisition in 2023. Furthermore, in 2024, we received $47.6 million for the equity stake that we owned in Morphic, one of our drug discovery collaborators and co-founded companies, in connection with Morphic's acquisition by Lilly for approximately $3.2 billion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Rights.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to our equity stakes in certain of our collaborators, we also have rights to various payments on a collaborator-by-collaborator agreement basis including research funding payments, discovery, development, and commercial milestones, option fees, and potential royalties in the single-digit range. Under certain of our collaboration agreements, we are also eligible to receive a percentage of our collaborators&#8217; sublicense revenue. Many of our collaborative programs are currently still in the discovery and preclinical development stages. Generally, the size of the payments we are eligible to receive from a collaborative program increases as the program advances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, our current collaboration agreements typically also contemplate additional program targets being added, allowing our collaborators to potentially increase the number of programs under our current collaboration agreements, subject to our pre-existing exclusivity obligations and interests.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, because these collaborations are not under our control, we cannot predict whether or when we might achieve any event-based increases in research funding payments, milestone payments, royalty or other payments under these collaborations or estimate the full amount of such payments, and we may never receive any such payments. For a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further discussion of the risks we face with respect to receipt of any of these payments, please refer to "Risk Factors&#8212;Risks Related to Drug Discovery&#8212;We may never realize a return on our investment of resources and cash in our drug discovery collaborations".</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Work with Our Collaborators.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Generally, our existing collaboration agreements provide that we agree to design drugs for a particular target or targets using our computational platform and know-how exclusively for the collaborator. The collaborator retains the intellectual property related to any molecules developed under the collaboration. Generally, our collaborators are not contractually required to provide us with, nor do we expect generally to receive, access to nonpublic information regarding key developments related to the advancement of these collaboration programs, such as clinical trial results, including safety and efficacy data, regulatory communications, or commercialization plans and strategies. To the extent we do receive such information, our collaboration agreements generally require us to maintain the confidentiality of information we receive under the collaboration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborations described above, we also have collaboration agreements with BMS, Otsuka, Novartis, and Lilly which are described below:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2020, we entered into an exclusive, worldwide collaboration and license agreement with BMS pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. Under the agreement, we were initially responsible, at our own cost and expense, for the discovery of small molecule compounds directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. In December 2022, we and BMS entered into an amendment to the agreement to include an additional target in neurology on terms similar to the original agreement. As a result of BMS electing not to proceed with further development of certain targets, there is one remaining neurology target under the agreement. Under the terms of the agreement, we received a $55.0 million upfront payment from BMS in November 2020, an additional upfront payment in December 2022, and a program fee in December 2024. As of December&#160;31, 2024, we are eligible to receive up to $482.0 million from BMS in total milestone payments for the one remaining neurology target currently subject to the collaboration. As of December&#160;31, 2024, we have recognized $32.0 million in revenue related to milestones under this agreement. We are also entitled to a tiered percentage royalty on annual net sales of any product commercialized by BMS under the agreement ranging from mid-single digits to low-double digits, subject to certain specified reductions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lilly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2022, we entered into a collaboration with Lilly, under which we are responsible for the discovery and optimization of small molecule compounds addressing an immunology target. Lilly will be responsible for the completion of preclinical development, clinical development and commercialization. Under the terms of the agreement, we received an upfront payment, and we are eligible to receive up to $420.0 million in discovery, development and commercial milestone payments. We are also eligible to receive low single- to low double-digit royalties on net sales of any products emerging from the collaboration in all markets. In February 2025, we expanded our research collaboration with Lilly to add an undisclosed target to the collaboration. The terms of the expanded collaboration with respect to the additional target are similar to the terms for the existing target. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In December 2022, we entered into a multi-part agreement with Otsuka, together with Otsuka&#8217;s subsidiary Astex Pharmaceuticals, which includes a collaboration for the discovery and development of a program focused on an emerging central nervous system, or CNS, disease target. In January 2025, we announced that we have expanded the collaboration with Otsuka to add an undisclosed target to the collaboration. Under the collaboration, we are responsible for drug design through lead optimization and Otsuka will be responsible for all other drug discovery and clinical development activities. We received an upfront payment and will be eligible to receive discovery, development and regulatory milestone payments, as well as tiered royalties on net sales of any products emerging from the drug discovery collaboration in all markets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we entered into a research collaboration and license agreement with Novartis, pursuant to which we and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. Under the terms of the agreement, we received a $150.0 million upfront payment from Novartis in January 2025. As of December&#160;31, 2024, we are eligible to receive up to $2.272 billion from Novartis in total milestone payments across the initial programs. Such milestones consist of up to $892.0 million in discovery and development milestones and up to $1.38 billion in commercial milestones. No revenue had been recognized related to milestones under this agreement as of December&#160;31, 2024. We are also entitled to a tiered percentage royalty on annual net sales of each product commercialized by Novartis under the agreement ranging </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from mid single-digits to low double-digits, subject to certain specified reductions. See "&#8212;Collaboration Agreement with Novartis Pharma AG" for additional information relating to this agreement. </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Proprietary Drug Discovery Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics. Our initial programs were focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Since then, we have expanded into other therapeutic areas, including immunology and neurology. Our strategy is to pursue a number of proprietary programs and strategically evaluate on a program-by-program basis advancing them into preclinical and clinical development ourselves, entering into collaborations to co-develop them with leading industry partners, or out-licensing them to maximize their clinical and commercial opportunities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our proprietary drug discovery programs: </span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g4.jpg" alt="10kpipelinev2.jpg" style="height:354px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Approach to Target Selection</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selection of targets is based on an extensive analysis of human targets and drug discovery programs. We analyze targets using automated methods at scale. The key steps we take in prioritizing programs involve:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Structural and modeling enablement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We use our computational platform to analyze protein structure quality as well as druggability of binding sites across thousands of target proteins in parallel. For a subset of high-quality structures of interest, we confirm amenability to our computational platform.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Evaluation of therapeutic potential</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our selection of targets is strongly influenced by the level of validation of the target, including analysis of human genetics and prior clinical data.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Identification of unsolved design challenges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We determine whether there are property profile challenges that could be solved by the application of our computational platform and provide a clinically meaningful differentiated, novel, high value product opportunity.</span></div><div style="padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Assessment of potential value of pathways and mechanisms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We evaluate industry and commercial interest as well as the clinical utility with the aim of prioritizing programs with high commercial and therapeutic potential.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using this comprehensive analysis, we have identified a large number of protein targets that we believe are amenable to our technology. We continue to evaluate a number of additional targets using this analysis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SGR-1505: Our MALT1 Inhibitor</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing SGR-1505, our novel MALT1 inhibitor, for the treatment of patients with relapsed or refractory B-cell malignancies. Constant activation of nuclear factor-kappa B, or NF-&#954;B, a key signaling molecule in B cells, is a hallmark of several subtypes of lymphoma. MALT1 is a key mediator of the NF-&#954;B signaling pathway, the main driver of a subset of B-cell lymphomas, and functions by forming a complex with CARMA1 (Caspase recruitment domain-containing protein 11 also known as CARD-containing MAGUK protein 1) and BCL10 (B-cell lymphoma/leukemia 10) to mediate antigen receptor-induced lymphocyte activation. MALT1 is considered a potential therapeutic target for several subtypes of lymphomas and leukemias.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activated B-cell, or ABC, a subtype of diffuse large B-cell lymphoma, or ABC-DLBCL, is the most common type of aggressive non-Hodgkin&#8217;s B-cell lymphoma. ABC-DLBCL is associated with a number of mutations that trigger a constitutively active NF-&#954;B signaling pathway, which often is mediated by increased MALT1 protease activity. Among these mutations is a gain of function mutation or amplification of MALT1, which has also been identified in ABC-DLBCL patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilized our physics-based computational platform to enable the identification and advancement of multiple novel series of MALT1 inhibitors from hit finding to lead optimization. Combining multi-parameter optimization, FEP+, and machine learning, we were able to prioritize tight-binding compounds with drug-like properties, and identified multiple novel and distinct chemical series which showed strong anti-tumor activity, ultimately enabling us to select SGR-1505 as our development candidate in under two years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Development of SGR-1505</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figures below, in preclinical studies, SGR-1505 showed anti-tumor activity in a MALT1 enzymatic assay and strong anti-proliferative effect on cell viability in a Bruton's tyrosine kinase, or BTK, inhibitor resistant OCI-LY3 B-cell non-Hodgkin&#8217;s lymphoma cell line, when compared to ibrutinib, a covalent BTK inhibitor.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g5.jpg" alt="23_093_Graphic-1.jpg" style="height:286px;margin-bottom:5pt;vertical-align:text-bottom;width:571px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figures below, in preclinical studies, SGR-1505 also demonstrated strong anti-tumor activities as a single agent in BTK inhibitor resistant OCI-LY3 cells and in BTK sensitive OCI-LY10 B-cell non-Hodgkin&#8217;s lymphoma </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cell-line derived xenograft (CDX) models.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g6.jpg" alt="23_093_Graphic-2.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">TPGS = D-alpha-tocopheryl polyethylene glycol succinate, a solvent used in co-administration for drug dosing in animals; TID = three times a day dosing; SDD = spray dried dispersion; SEM = scanning electron microscopy, a method used to measure cell volume</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as shown in the figures below, SGR-1505 demonstrated strong anti-tumor activity in combination with ibrutinib in BTK inhibitor sensitive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in viv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o models, such as the ABC-DLBCL patient-derived xenograft (PDX) model LY2298 and the OCI-LY10 CDX model. Beyond ABC-DLBCL disease models, as shown in the figures below, SGR-1505 also demonstrated single agent anti-tumor activity in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mantle cell lymphoma REC-1 CDX model. SGR-1505 also showed strong combination effects with venetoclax (an inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2)) on inhibition of cancer cell viability in the OCI-LY10 CDX model.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g7.jpg" alt="23_093_Graphic-3.jpg" style="height:204px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">QD = once per day dosing; BID = twice a day dosing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These data suggest that targeting MALT1 with SGR-1505 may expand therapeutic options for patients with selected B-cell lymphomas, such as ABC-DLBCL, with the possibility of expanding into other B-cell lymphomas such as mantle cell lymphoma. In addition, SGR-1505, in combination with BTK inhibitors, demonstrated potential to overcome drug-induced resistance to BTK inhibitors in samples derived from patients with relapsed/refractory B-cell lymphomas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a series of biochemical and cell-based assays, we compared the potency of SGR-1505 against JNJ-6633, a MALT1 inhibitor advanced into Phase 1 clinical development by Johnson &amp; Johnson, as measured by IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> values, which are measures of the potency of a compound in inhibiting specific biological functions. As shown in the graphic below, SGR-1505 demonstrated better potency in all assays tested.</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g8.jpg" alt="Picture1.jpg" style="height:203px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">All competitor data is internally generated by contract research organizations, using commercially available tools or synthesized by third-party research chemists using publicly available structure information.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development of SGR-1505</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1 Clinical Trial of SGR-1505 in Patients with Relapsed or Refractory B-cell Malignancies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared our IND for SGR-1505 in June 2022. We have initiated dosing in a Phase 1 clinical trial of SGR-1505, which is designed as an open-label, multi-center dose escalation clinical trial in patients with relapsed or refractory B-cell malignancies. We anticipate enrolling up to 52 patients in the United States and Europe with confirmed mature B-cell malignancies who are 18 years or older and have a life expectancy of equal to or greater than 12 weeks. SGR-1505 will be administered orally. The trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, maximum tolerated dose and/or recommended dose of SGR-1505. Exploratory cohorts will evaluate additional pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity and safety to establish the recommended dose. We anticipate reporting initial data from the trial in the second quarter of 2025. In August 2023, the FDA granted orphan drug designation to SGR-1505 for the potential treatment of mantle cell lymphoma.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1 Clinical Trial of SGR-1505 in Healthy Volunteers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a Phase 1 clinical trial of SGR-1505 in 73 healthy volunteers to gather additional data, including data relating to the safety, tolerability, pharmacokinetics of SGR-1505, as well as the effect of food and drug-drug interactions. SGR-1505 was generally well tolerated with no drug-related serious adverse events or dose limiting toxicities observed. Adverse events were primarily Grade 1 and not treatment related. Bilirubin elevations occurred in 16% of healthy volunteers but were not deemed to be clinically relevant. These elevations were primarily Grade 1 and none were Grade 3 or 4. All bilirubin elevations reversed upon discontinuation of SGR-1505.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figure below, we observed greater than 90 percent inhibition of IL-2 secretion in an activated T cell whole blood assay in the cohort of healthy volunteers who received doses of SGR-1505 at 100 mg twice a day for 10 days (n=4), confirming target engagement and meeting the pharmacodynamic goals for the study. Inhibition of IL-2 secretion is a marker for target engagement and pathway modulation as it is tightly linked to MALT1 and the downstream NF-&#954;B signaling.</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g9.jpg" alt="Chart 1.jpg" style="height:374px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">QD = once a day dosing, Q12H = twice a day dosing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data from the healthy volunteer trial support continued evaluation of SGR-1505 in our ongoing Phase 1 clinical trial in patients with relapsed or refractory B-cell malignancies.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SGR-2921: Our CDC7 Inhibitor</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing SGR-2921, our novel CDC7 inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia or high risk myelodysplastic syndrome. CDC7 is a serine/threonine protein kinase that has been shown to play important roles in DNA replication initiation and in response to replication stress and DNA damage. CDC7 levels are high in certain tumors, including acute myeloid leukemia, or AML, and are thought to be linked to these cancer cells&#8217; proliferative capacity and ability to bypass normal DNA damage responses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDC7 phosphorylates and activates the enzymes responsible for DNA replication initiation and proteins involved in replication stress response. Disruption of CDC7 activity in cancer cells leads to delayed DNA replication, increased replication stress, cell cycle abnormalities, and cell death.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The antiproliferative potential of CDC7 inhibition was validated by a third party in Phase 1 clinical trials of a CDC7 inhibitor in which responses were observed in patients, including those with duodenal, esophageal and cervical cancer. Prior to this positive result, existing CDC7 inhibitors were not sufficiently tight-binding (as measured by their affinity for the target), lacked selectivity, and demonstrated poor pharmacokinetic properties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to maximize the anti-cancer activities of CDC7 inhibitors, very tight-binding inhibitors are required to achieve durable clinical impact as monotherapy or in the context of clinical combinations. Using our computational platform, we identified multiple tight-binding, selective, and novel CDC7 inhibitor series, and selected SGR-2921 as our development candidate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Development of SGR-2921</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in Tables 1 and 2 below, SGR-2921 demonstrated inhibition of recombinant human CDC7 in a biochemical kinase assay and in a biophysical assay, as measured by the average IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> value, which is a measure of the potency of a compound in inhibiting specific biological functions. Table 1 also shows that SGR-2921 demonstrated strong binding affinity to CDC7 with an average equilibrium dissociation constant, or KD, which is a measure of binding affinity between a protein and a binding partner, in the picomolar range. Further, SGR-2921 showed inhibition of the phosphorylation of the serine in position 53, or S53, of the protein MCM2, or pMCM2, a downstream substrate of CDC7, in COLO205, a colorectal cancer cell line, and in two acute myeloid leukemia cell lines, MV-4-11 and MOLM-16.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table 1 Average IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of CDC7 Kinase Activity and Binding Affinity to CDC7 for SGR-2921</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.848%"><tr><td style="width:1.0%"/><td style="width:32.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Compound</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:115%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> [nM]</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">KD [pM]</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SGR-2921</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#177;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0054</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Cell Based IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Values of pMCM2 (S53) by SGR-2921</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:24.279%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.003%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cell line</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COLO205 [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (nM)]</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MV-4-11 [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (nM)]</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MOLM-16 [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (nM)]</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pMCM2 (S53)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.19&#177;0.41</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.92&#177;0.40</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.62&#177;0.52</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SGR-2921 also showed anti proliferative activity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in COLO205, MV-4-11 and MOLM-16 cell lines. Table 3 summarizes the average IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> value from the individual assays.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Cell Based Viability IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Values of SGR-2921</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:23.975%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cell line</span></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COLO205 [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (nM)]</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MV-4-11 [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (nM)]</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MOLM-16 [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (nM)]</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell viability</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.90&#177;3.72</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107.55&#177;12.42</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.81&#177;7.29</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figures below, SGR-2921 showed tumor growth inhibition resulting in tumor regression in the COLO205 colorectal cancer CDX model, which is a colorectal cancer cell line derived xenograft model, at doses that did not result in significant body weight loss. SGR-2921 also showed a dose-dependent increase in plasma drug concentration and a dose-dependent decrease in intratumoral pMCM2 in the COLO205 CDX model. In mouse models of AML, SGR-2921 also showed strong anti-tumor activity at doses that were tolerated.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g10.jpg" alt="Business - STG - SGR-2921 Our CDC7 Inhibitor (under table 3).jpg" style="height:511px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SGR-2921 also showed strong anti-proliferative activity in leukemia cell samples derived from AML patients that varied with respect to mutational status of driver mutations in key genes that are hallmarks of clinical AML, including TP53, FLT3, IDH, or NPM, as well as whether the patient samples were derived from a patient naive to treatment or were relapsed or refractory following previous AML treatments. We observed that the cell samples were generally sensitive to SGR-2921, as measured by their IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> values, and we observed that patient samples which contained TP53, or p53, mutations demonstrated particular sensitivity to SGR-2921.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SGR-2921 showed potent anti-proliferative activity in AML patient-derived samples ex vivo independently of driver mutations, including in p53 mutated AML</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g11.jpg" alt="Picture22.jpg" style="height:220px;margin-bottom:5pt;vertical-align:text-bottom;width:468px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, as shown in the figures below, in preclinical models SGR-2921 showed single-agent activity and activity in combination with decitabine, which is a type of chemotherapy medication used for the treatment of myelodysplastic syndromes, in standard-of-care resistant models representing difficult-to-treat disease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SGR-2921 combination treatment with decitabine in patient derived AML samples resulted in synergistic activity ex vivo, particularly in p53 mutant models</span></div><div style="text-align:center"><img src="sdgr-20241231_g12.jpg" alt="decitabine.jpg" style="height:205px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">ZIP, or zero interaction potency, synergy score is a model used to capture the drug interaction relationships by comparing the change in the potency of the dose-response curves between individual drugs and their combinations</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development of SGR-2921</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared our IND for SGR-2921 in July 2023. We have initiated dosing in our Phase 1 clinical trial of SGR-2921, which is designed as an open-label, multi-center dose escalation clinical trial in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. We anticipate enrolling up to 144 patients in the United States and Europe with a confirmed diagnosis of refractory acute myeloid leukemia or high-risk myelodysplastic syndrome who are 18 years or older and have a life expectancy equal to or greater than 8 weeks. SGR-2921 will be administered orally. To evaluate the effect of CYP3A4 inhibition on SGR-2921 exposure, patients will be enrolled into one of two staggered, parallel study treatment arms. Treatment Arm A will evaluate increasing dose levels of SGR-2921. Treatment Arm B will evaluate increasing dose levels of SGR-2921 with the concomitant administration of azole antifungals that are strong CYP3A4 inhibitors. Safety and tolerability must be demonstrated in treatment Arm A, at the first two dose levels before initiating treatment Arm B.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients will be treated at increasing doses of SGR-2921 until all dose levels have been investigated or any dose level is found to exceed the maximum tolerated dose. A recommended Phase 2 dose will be selected from one of the tolerable dose levels which will not exceed the maximum tolerated dose. The trial is designed to evaluate the safety and tolerability of SGR-2921 as a monotherapy and to identify the recommended Phase 2 dose, including the maximum </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tolerated dose. Secondary and exploratory objectives of the trial include evaluating the pharmacokinetics and pharmacodynamics of SGR-2921 and investigating preliminary anti-tumor activity. We anticipate reporting initial data from the Phase 1 clinical trial of SGR-2921 in the second half of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the FDA granted Fast Track designation to SGR-2921 in patients with relapsed or refractory acute myeloid leukemia. In addition, in January 2025, the FDA granted orphan drug designation to SGR-2921 in patients with relapsed or refractory acute myeloid leukemia.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SGR-3515: Our Wee1/Myt1 Inhibitor </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing SGR-3515, our novel Wee1/Myt1 inhibitor for the treatment of solid tumors. Wee1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle allowing time for DNA repair before cell division takes place. Inhibition of Wee1 allows for accumulation of DNA damage, triggering DNA breakage and apoptosis in tumor cells. Third party Wee1 inhibitors have shown clinically meaningful tumor regression with partial responses and stable disease in ovarian and uterine cancer in clinical trials. A third party Wee1 inhibitor is currently being studied in combination with chemotherapy. Myt1 inhibition is a potential cancer therapy as inhibition of Myt1 forces cells into premature unchecked mitosis resulting in cell death.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biological functions of Wee1 and Myt1 are independent, yet partially overlapping. Emerging data suggests that Myt1 has a synthetic lethal relationship with Wee1 and high Myt1 protein levels are associated with resistance to Wee1 inhibitors. Concurrent loss of function of Wee1 and Myt1 confers selective vulnerability in cancer cells and could offer increased anti-tumor activity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified a number of tight-binding, selective Wee1/Myt1 inhibitor series using our computational platform and ultimately selected SGR-3515 as our development candidate. We believe SGR-3515's physicochemical properties make it well suited for combinations with DNA damage response inhibitors such as poly (ADP-ribose) polymerase, or PARP and other targeted therapies for the treatment of ovarian, colorectal, breast, and other solid tumors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing third party Wee1 inhibitors may have off-target effects resulting from inhibition of other kinases and proteins, some of which are liver enzymes responsible for elimination of drug and drug metabolites from the body, potentially making dosing and combinations more challenging. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Development of SGR-3515</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the table below, in preclinical studies, we have benchmarked SGR-3515 against ZN-c3, a Wee1 inhibitor being advanced by Zentalis Pharmaceuticals, Inc., or Zentalis, and RP-6306, a PKMyt1 inhibitor being advanced by Repare Therapeutics, or Repare.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SGR-3515 demonstrated an improved selectivity profile against broad kinomes compared to ZN-c3 and RP-6306. SGR-3515 also showed better target engagement activity against Wee1 and Myt1 in cells and better potency, as demonstrated by lower IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values in a cell viability assay in the A427 non-small cell lung cancer cells, in each case, as compared to ZN-c3 and RP-6306. We also believe SGR-3515 has lower potential for drug-drug interaction liabilities associated with CYP3A4 liver enzyme inactivation.</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g13.jpg" alt="Screenshot 2025-02-18 at 3.54.14&#8239;PM.jpg" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All competitor data is internally generated by contract research organizations, using commercially available tools or synthesized by third-party research chemists using publicly available structure information. ND = not determined; K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> was measured in kinase activity assay.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the first figure below, in cell line derived xenograft models, SGR-3515 demonstrated superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> anti-tumor activity related to single inhibition of Wee1 or My1 as compared to ZN-c3 and RP-6306. As shown in the second figure below, SGR-3515 also showed stronger target engagement of both Wee1 and Myt1 in the tumor as compared to ZN-c3 and RP-6306.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><img src="sdgr-20241231_g14.jpg" alt="Screenshot 2025-02-18 at 3.54.50&#8239;PM.jpg" style="height:162px;margin-bottom:5pt;vertical-align:text-bottom;width:612px"/></div><div style="text-align:center;text-indent:36pt"><img src="sdgr-20241231_g15.jpg" alt="Screenshot 2025-02-18 at 3.55.00&#8239;PM.jpg" style="height:223px;margin-bottom:5pt;vertical-align:text-bottom;width:508px"/></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">n=6 per group, mean +/- SEM. Tumor PD samples were taken 8 hours post-last dose on day 28 except SGR-3515 treated tumor</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> samples taken on day 18 with minimal amount of tumor volume. Tumor PD samples are tissue samples that are collected for measuring target engagement in vivo by determining percent inhibition of CDK1-Y15 and CDK1-T14 phosphorylation by Wee1 and Myt1 respectively. </span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">****P&lt;0.001, ***P&lt;0.005, **P&lt;0.01</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the figures below, we observed that SGR-3515 sustained strong anti-tumor activity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> leading to full tumor regression at the 40 mpk and 60 mpk dose levels with an intermittent dosing schedule. SGR-3515 dosed intermittently was also shown to allow recovery from mechanism-based hematological toxicity compared to continuous dosing as measured by red blood cell counts.</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g16.jpg" alt="Screenshot 2025-02-18 at 3.55.21&#8239;PM.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:579px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">A427 (NSCLC) xenograft model. N=6 per group, mean +/- SEM. Red blood cell counts were measured on the last day of the study. ****P&lt;0.001</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development of SGR-3515</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared our IND for SGR-3515 in April 2024. We have initiated dosing in our Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors. The trial is a dose-escalation trial designed to evaluate the safety, tolerability, and recommended Phase 2 dose of SGR-3515. Secondary and exploratory objectives of the trial include evaluating the pharmacokinetics and preliminary anti-tumor activity of SGR-3515. We anticipate reporting initial data from the trial in the second half of 2025.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Proprietary Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also progressing a number of other programs in the areas of oncology, immunology, and neurology and a number of undisclosed programs in multiple therapeutic areas. All of these programs are currently in the discovery stage, and we have not yet identified a development candidate for any of these programs, except for SGR-4174, our SOS1 inhibitor, as well as a development candidate for our EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">C797S </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program, both of which are in preclinical development. A number of these programs are discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SOS1 (SGR-4174).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SOS1 plays a critical role in cell signaling pathways and is involved in the activation and regulation of the KRAS gene. Oncogenic mutant KRAS stimulates the growth of several cancers, such as lung, pancreatic, and colon cancer. Inhibition of SOS1 is considered a potential therapeutic strategy for the treatment of KRAS-driven cancers. Previously, SGR-4174, a SOS1 inhibitor, was being advanced in collaboration with BMS, after which it was returned to us based on BMS' portfolio prioritization decisions. Our current plan is to seek to advance this program through a collaboration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">C797S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EGFR inhibitors are first-line standard of care agents for advanced non-small cell lung cancer patients with activating EGFR mutations. We have identified multiple EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">C797S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitors with potential to treat patients whose disease progressed following first-line treatment, potentially achieving deeper, more durable responses through new combination regimens. In February 2025, we announced that we have identified a development candidate for our EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">C797S </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRMT5-MTA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> PRMT5-MTA inhibition has demonstrated clinical responses in both hematologic and solid tumors with improved safety versus PRMT5 inhibitors due to a synthetic lethal targeting of cancer cells with MTAP-deletions. We have identified selective, potent PRMT5-MTA inhibitors with potential applications in solid tumors, brain metastases and primary CNS tumors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NLRP3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NLRP3 is a validated target, and mutations in the NLRP3 gene are associated with a broad spectrum of inflammatory and auto-immune diseases. We have identified structurally distinct, selective, NLRP3 inhibitors with anti-inflammatory activity in preclinical models, and we are continuing to optimize brain-penetrant lead molecules.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LRRK2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LRRK2, a genetically validated target, is a large multifunctional kinase enzyme and mutations in the LRRK2 gene have been shown to be associated with the development of Parkinson&#8217;s disease. In 2022, we generated cryo-electron microscopy structures of LRRK2, which have helped us to accelerate the identification of novel LRRK2 inhibitors. We received a $2.8 million research grant in 2024 from The Michael J. Fox Foundation for Parkinson's Research to investigate modes of safely inhibiting the LRRK2 protein for the treatment of Parkinson's Disease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified a large number of protein targets that we believe are amenable to our computational platform, and now have a significant inventory of targets that we can potentially advance into discovery programs. We intend to pursue targets with strong biological validation and therapeutic potential that currently lack protein structures of sufficient quality to permit the use of our computational platform for drug discovery. We are actively pursuing strategic alliances with collaborators, as well as progressing internal initiatives, that enable us to generate high-quality protein structures for these targets, which will enable us to initiate additional discovery efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial programs were focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Genomic instability of malignant cells leads to genetic mutations that can drive resistance to kinase inhibitors, creating the need for second and third generation drugs targeting the same disease. Our computational platform has been shown to be capable of predicting the impact that mutations in the kinase domain have on drug binding, potency, and drug sensitivity. Use of our platform to assess and evaluate the impact of clinical mutations on drug potency can be a powerful tool for drug discovery. We believe that deploying our platform at scale with access to genomic profiling data for patients puts us in a strong position to predict the impact of active-site resistance mutations with clinically relevant accuracy to optimize the design of molecules that are robust against common resistant mutations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technical Details of Our Key Technologies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Calculation of key drug properties using physics-based methods</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several decades and with the concerted effort of hundreds of our scientists and software engineers, we have developed a physics-based computational platform that is capable of predicting the binding affinity of a drug molecule with a high degree of accuracy. The binding affinity of a drug molecule to a target protein is the key driving force of its in vivo efficacy. Specifically, when a drug binds to a target protein, the affinity with which it binds directly affects the extent to which it will modulate the function of the protein. Therefore, the ability to predict the binding affinity of a drug molecule to a target protein with a high degree of accuracy can significantly accelerate discovery of new efficacious medicines.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accurately calculating the binding affinity of a drug molecule to a protein is enormously complex and requires a full characterization of all the physical contributions to the binding. These contributions include the deformation and/or rigidification of the small molecule into the bound conformation (&#916;G(1) in the figure below) and the rigidification of the protein in the bound conformation (&#916;G(2)), the removal of waters surrounding the molecule (&#916;G(3)) and the removal of waters within the protein binding site (&#916;G(4)), and finally the interactions achieved between the molecule and protein when binding to form the protein-molecule complex (&#916;G(5)).</span></div><div style="margin-top:12pt;text-align:center"><img src="sdgr-20241231_g17.jpg" alt="PastedGraphic-2.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a solution to consistently assess all of these contributions to binding with a high degree of accuracy, building on a method called "free energy perturbation." Free energy perturbation perturbs, or transforms, an initial molecule into another molecule of interest and evaluates how that transformation changes binding affinity to a particular protein target. Our solution for conducting these calculations is called FEP+. FEP+ is enabled by the following differentiated constituent technologies:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">classical molecular mechanics force field with broad coverage of drug-like molecules with a high degree of accuracy;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">an automated workflow allowing for force field coverage to be extended on the fly utilizing our accurate quantum mechanics software;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">computationally efficient molecular dynamics engine that runs on graphic processing units;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">efficient, enhanced sampling methods that allow the calculation to be converged with reduced simulation times;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">automated atom-mapping and interaction-mapping assignment; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ability to scale these calculations to leverage large cloud computing environments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of these constituent technologies are necessary to achieve the accuracy, scalability and applicability of our free energy perturbation implementation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a notable peer-reviewed study including approximately 3,000 molecules across approximately 90 distinct projects, FEP+ exhibited an error profile that indicates its affinity predictions approach the accuracy of running a laboratory experiment. FEP+ is also able to perform these computations more rapidly than experimental assays. Computational assessment of a molecule utilizing FEP+ requires only a few hours. In comparison, it often takes weeks to synthesize a drug-like molecule and assay its binding affinity for the target of interest in a laboratory. As a result, our FEP+ solution can be used to explore very large numbers of molecules to identify drug candidates much more rapidly than would be possible solely using experimental approaches.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a peer-reviewed article published in collaboration with a large biopharmaceutical company, the ability of FEP+ to prioritize molecules for synthesis expected to bind more tightly than an initial hit was compared with several other industry-standard approaches. We found that FEP+ succeeded in prioritizing the synthesis of molecules with improved binding affinity with eight times greater success than any other technique tested. This evidence supports the essential role that FEP+ can play in advancing drug discovery programs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enumeration of extremely large libraries of molecules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed methods to enumerate extremely large libraries of molecules of interest with our AutoDesigner software solution, thereby allowing our software customers, our drug discovery collaborators, and the Schr&#246;dinger therapeutics group to explore a much larger portion of project-relevant chemical space than is possible through manual design. The chemical enumeration technology we have developed incorporates the most commonly used chemical reactions and can, in a fully automated fashion, computationally explore billions of variations of a molecule of interest.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scaling accurate physics-based calculations to extremely large libraries of molecules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although FEP+ calculations have been shown to be accurate, it is not possible to apply these calculations to billions of molecules given the current availability of computing resources. To address this problem, we developed an approach that leverages the accuracy of FEP+, but allows for exploration of billions of molecules rapidly by leveraging machine learning. We have succeeded in integrating our physics-based molecule scoring with highly computationally efficient modern machine-learning methods. This combined approach allows us to apply our physics-based calculations to much larger sets of molecules than would otherwise be computationally tractable. This allows us to both increase the speed and likelihood of identifying clinically viable molecules.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advances in deep learning, a type of machine learning, in the past several years have required very large data sets as input to train the model. In a drug discovery program, the experimental data is typically sparse and expensive to procure, which is particularly problematic given that relevant drug-like chemical space is effectively infinitely large, estimated to be 10&#x5E;60 molecules. For this reason, we believe that it would be extremely difficult to realize competitive advantage in a drug discovery program by using a platform exclusively based on machine learning or deep learning. Instead, we have developed an approach to integrate physics-based and machine-learning based scoring methodologies that allows the machine learning model to interactively prioritize additional molecules for physics-based analyses, known as active learning. Active learning retains the computational efficiency of machine learning while also taking advantage of the accuracy of the physics-based method. One can evaluate the utility of any particular prediction method with regard to both its accuracy and its computational efficiency. Modern machine learning methods, such as deep learning, do provide a small improvement over conventional machine learning methods. However, for much of its history, conventional molecular simulations were much less computationally efficient than machine learning but not that much more accurate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing FEP+, we were able to resolve deficiencies in early attempts to develop physics-based methods. FEP+ calculations are much more accurate than either conventional machine learning or modern machine learning when scoring molecules structurally distinct from the training set data. In addition, by integrating FEP+ with our machine learning implementation, which we refer to as DeepAutoQSAR, we developed a solution that we refer to as Active Learning FEP+. Active Learning FEP+ combines the accuracy of free energy calculations with the speed of machine learning calculations and can be used to explore up to billions of molecules within a day. By further combining this functionality with our ability to enumerate large sets of molecules provided by PathFinder and our ability to build and manage complex workflows utilizing cloud resources, we are able to deploy these capabilities at scale to advance projects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Active Learning FEP+ is depicted in the figure below.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g18.jpg" alt="g0na1tfcz5u2000019.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FEP+ is used to build a local model for a large library of molecules instead of relying on experimental data to provide the training set for the machine learning model. That machine learning model is then used to filter the large library of molecules down to a number that is small enough to be able to prioritize with FEP+. The result is that we can prioritize one billion molecules in as little as a day, rather than one million days.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapid identification of novel active hit molecules suitable to initiate hit-to-lead and lead optimization efforts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several hit-finding technologies we have developed are routinely used to identify active hit molecules to initiate small molecule drug discovery programs. In our hit-finding campaigns, we and our software customers typically utilize:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">modern machine learning models trained to the two-dimensional structures of known active molecules using our software solution, DeepAutoQSAR;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">shape-based methods trained to the known or computationally deduced three-dimensional bioactive conformations of known active molecules using our software solution, Shape;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">structure-based docking methods that evaluate the number and kind of interactions possible utilizing a static atomistic representation of the experimentally determined three-dimensional structure of the target protein receptor using our software solutions, Glide and WScore; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">free energy calculations using our software solution FEP+, which provides a fully dynamic atomistic representation of the target protein receptor.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Computational analysis of the energetic properties of water molecules occupying molecule binding sites in proteins</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subtle structural variations in molecules can have a profound impact on binding affinity to the protein target. The effects of these structural variations can be explained by a detailed examination of the thermodynamics of binding, including the free energy changes resulting from displacing water molecules in the binding site. Our computational software solution WaterMap maps the locations and energetic properties of water molecules that occupy protein binding sites, provides insight into the properties of the binding site, and quantitatively describes the water-mediated forces driving the binding of small molecules. Further, such an analysis can be used to assess the propensity of drug-like molecules to bind to the protein target with high affinity. WaterMap presents the computed results graphically for easy visualization of the water molecules occupying a binding site and their energetic properties. This makes interpretation of binding affinity data more intuitive and provides insights to possible design routes to improve potency and selectivity.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall market for molecular discovery and design software is global, rapidly evolving, competitive, and subject to changing technology and shifting customer interests and priorities. The solutions and applications offered by our competitors vary in size, breadth, and scope.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competitive factors in our market include, among other things, accuracy of computations, level of customer satisfaction and functionality, ease of use, breadth and depth of solution and application functionality, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brand awareness and reputation, modern and adaptive technology platform, integration, security, scalability and reliability of applications, total cost, ability to innovate and respond to customer needs rapidly, and ability to integrate with legacy enterprise infrastructures and third-party applications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we compete favorably on the basis of these factors and that the effort and investment required to develop a computational, physics-based platform similar to ours will hinder new entrants that are unable to invest the necessary capital and time, and lack the breadth and depth of technical expertise required to develop competing technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software solutions face competition from competitors in the business of selling or providing simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a brand of Dassault Syst&#232;mes SE, or BIOVIA, Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, Cadence Design Systems, Inc., Optibrium Limited, Cyrus Biotechnology, Inc., Molsoft LLC, Insilico Medicine, Inc., Iktos, XtalPi Inc., AbCellera, Inductive Bio, Inc., Chemaxon, PerkinElmer, Inc., and Simulations Plus, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have competitors in materials science, such as BIOVIA and Materials Design, Inc., and in enterprise software for the life sciences, such as BIOVIA, Certara USA, Inc., Chemaxon, Revvity, Inc. and Dotmatics, Inc. In some cases, these competitors are well-established providers of these solutions and have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. In addition, there are academic consortia that develop physics-based simulation programs for life sciences and materials applications. In the life sciences industry, the most prominent academic simulation packages include AMBER, CHARMm, GROMACS, GROMOS, OpenMM, and OpenFF. These packages are primarily maintained and developed by graduate students and post-doctoral researchers, often without the intent of commercialization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition from solutions that biopharmaceutical companies develop internally, smaller companies that offer products and services directed at more specific markets than we target, enabling these competitors to focus a greater proportion of their efforts and resources on these markets. In addition, we are facing increasing competition from companies utilizing AI and other computational approaches for drug discovery. Some of these competitors are involved in drug discovery themselves and/or with partners, and others develop software or other tools utilizing AI which can be used, directly or indirectly, in drug discovery.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Discovery Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and strong emphasis on proprietary and novel products and product candidates. While we believe that our computational platform, technology, knowledge, experience, and scientific resources provide us with competitive advantages, our drug discovery business faces potential competition from many sources, including major pharmaceutical companies, specialty biopharmaceutical companies, technology companies, academic institutions and government agencies, and public and private research institutions. Any product candidates that we or one of our collaborators successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of the product candidates we develop, if approved, are likely to be their efficacy, safety, tolerability, convenience and price, the level of branded and generic competition and the availability of adequate reimbursement from third-party payors. If any of our product candidates are approved and successfully commercialized, it is likely that we will face increased competition as a result of other companies pursuing development of similar products or products that address similar diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, there is intense competition in the field of oncology, which is a focus of our drug discovery efforts. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We also face competition in finding and establishing clinical trial sites, enrolling subjects for clinical trials, accessing combination studies and recruiting credible principal investigators and advisors from key clinical disciplines and academic centers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, with respect to our MALT1 inhibitor, SGR-1505, which we are advancing for the treatment of patients with relapsed or refractory B-cell malignancies, we are aware of several MALT1 inhibitors in clinical development, including by AbbVie Inc., Ono Pharmaceutical Co., Ltd., HotSpot Therapeutics, and Recursion Pharmaceuticals, Inc. In addition, we are also aware of other therapeutics, such as bi-specifics and CAR-Ts, both approved and in clinical development, for the treatment of B-cell lymphomas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our CDC7 inhibitor, SGR-2921, which we are advancing for the treatment of relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, we are aware of several CDC7 inhibitors in Phase 1 clinical development, including by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lin BioScience, Inc., and Cancer Research UK.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our Wee1/Myt1 inhibitor, SGR-3515, which we are advancing for the treatment of solid tumors, we are aware of several Wee1 inhibitors in clinical development, including by Zentalis, Debiopharm International SA, IMPACT Therapeutics, Inc., Shouyao Holdings Co. Ltd., BioCity Biopharma, and Aprea Therapeutics, Inc., as well as a Myt1 inhibitor in clinical development being advanced by Repare. Furthermore, we are also aware of a Wee1/Myt1 inhibitor in preclinical development being advanced by Acrivon Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large pharmaceutical and biotechnology companies, in particular, have extensive experience in building and accessing networks of expert investigators, designing and conducting clinical trials, obtaining regulatory approvals, and manufacturing and commercializing biotechnology products. These companies also have significantly greater research and development and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreement with Novartis Pharma AG</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we entered into a research collaboration and license agreement with Novartis, pursuant to which, we and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, during the research term, we are responsible, together with Novartis, for the discovery of small molecule compounds directed against specified targets pursuant to mutually agreed research plans, which we refer to as project plans. Under the agreement, we and Novartis have agreed to pursue multiple initial project plans. The agreement also includes mechanisms pursuant to which Novartis may, subject to specified conditions, add additional project plans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research term for each project plan will generally extend for four years or such earlier time as a development candidate is designated for such project plan or the project plan is terminated. We and Novartis may mutually agree to extend the research term for any project plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the identification of a development candidate in any project plan, Novartis will be solely responsible for the further preclinical and clinical development, manufacturing and commercialization of products containing all compounds resulting from such project plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the research collaboration and license agreement, Novartis paid us an initial upfront fee of $150.0 million in January 2025, and we are eligible to receive up to $2.272 billion in total milestone payments across the initial project plans. Such milestones consist of up to $892.0&#160;million in discovery and development milestones and up to $1.38&#160;billion in commercial milestones. We are also entitled to receive additional milestones in the event that additional project plans are added to the agreement. We are also entitled to a tiered percentage royalty ranging from mid-single-digits </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to low double-digits on products commercialized by Novartis under the agreement, subject to certain specified reductions. To date we have not received any milestone payments under our agreement with Novartis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a collaboration target-by-collaboration target basis, during a specified period and subject to specified exceptions, we are prohibited from researching, developing, manufacturing, modifying, improving or commercializing, ourselves or with a third party, any small molecule directed against such collaboration target.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will expire (1) on a collaboration product-by-collaboration product and country-by-country basis on the expiration of the applicable royalty term for such collaboration product in such country, (2) on a collaboration target-by-collaboration target basis upon the expiration of all royalty terms for all collaboration products directed against such collaboration target and (3) in its entirety upon expiration of all payment obligations under the agreement with respect to all collaboration products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement contains customary termination provisions, including by either party upon an uncured material breach or upon the occurrence of certain events of insolvency. Additionally, Novartis may terminate the agreement, in its entirety or on a collaboration target-by-collaboration target basis, for convenience or for safety reasons; provided that certain customary rights and obligations will survive termination.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements with Columbia University</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Master License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2024, our wholly-owned subsidiary, Schr&#246;dinger, LLC, entered into a master license agreement, or the Master License Agreement, with The Trustees of Columbia University in the City of New York, or Columbia University, that amended and restated our existing license agreements with Columbia University, which we refer to as the Prior Columbia License Agreements and which are more fully described below. The Prior Columbia License Agreements provided for our rights and obligations with respect to certain patents, software code, technology and improvements that it licenses from Columbia University and that are used in, and integrated into, our software solutions and computational platform. The Prior Columbia License Agreements are described in more detail below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Master License Agreement was adopted to modify and streamline the royalties payable pursuant to the Prior Columbia License Agreement, to modify certain other terms of the Prior Columbia License Agreements and to create a single Master License Agreement that, from and after the effective date of the Master License Agreement, governs all of the intellectual property licensed from Columbia University to us and our affiliates. Each Prior Columbia License Agreement will remain in full force and effect with respect to any services agreement entered into by us or our affiliates under such Prior Columbia License Agreement prior to the effective date, but the Prior Columbia License Agreements will otherwise be of no further force or effect from and after the effective date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Master License Agreement, Columbia University granted us and our affiliates an exclusive license (subject to specified non-commercial rights retained by Columbia University, on behalf of itself and other institutions, and any rights of the United States government), under Columbia University&#8217;s rights in specified software, or the Licensed Software, and patents, or the Licensed Patents, to develop, make, use, market, license, sell, distribute and otherwise commercially exploit products that incorporate any of the Licensed Software or are covered by any of the Licensed Patents, including the following Company software solutions: the electronic structure software program PS-GVB v1.0, the IMPACT software program used in the Glide ligand-protein docking program, the PrimeX protein modelling program, the QSite QM/MM program, the Combiglide automated library generation program, the Prime and PrimeX protein modelling programs, the Membrane Permeability model and the products that implement the water site analysis method, or collectively, the Licensed Products. We are restricted from distributing the Licensed Software source code without the prior written consent of Columbia University, which is not to be unreasonably withheld or delayed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay Columbia University a low single-digit percentage royalty on consideration, subject to certain exclusions and deductions, received by us or our affiliates for sales, licenses, leasing or rentals of Licensed Products or services provided using Licensed Products. We are obligated to pay royalties on a Licensed Product-by-Licensed Product basis until: (1) with respect to each Licensed Product that incorporates any Licensed Software identified in the Master License Agreement as of the Effective Date, twenty years after the Effective Date or (2) with respect to each Licensed Product that incorporates any Licensed Software added to the Master License Agreement after the Effective Date, twenty years after such addition, each, a Royalty Term. In addition, if we incorporate specified Licensed Software improvements into a Licensed Product, then the Royalty Term for such Licensed Product will be extended for an additional </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ten years per incorporated improvement. If we or our affiliates receive consideration for specified services provided using Licensed Products in the form of equity securities, or Services Project Securities, then (1) if and when such securities may be transferred to Columbia University under applicable state and federal securities laws, we have agreed to transfer, assign or otherwise cause to be delivered to Columbia University a number of such Services Project Securities equal to the applicable royalty rate multiplied by the total number of Services Project Securities, or the Columbia Securities, and (2) until such time as the Columbia Securities are transferred, assigned or delivered to Columbia University, at the time we receive cash consideration as a result of owning Services Project Securities, whether on account of a dividend, distribution, sale or otherwise, we have agreed to pay Columbia University a portion of such proceeds that is equal to the applicable royalty rate multiplied by such amount received in cash.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Master License Agreement, we have agreed to indemnify Columbia University for losses incurred in any third-party action arising out of the exercise of any rights granted to us under the Master License Agreement or as a result of any breach of the Master License Agreement by us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Master License Agreement will expire on the expiration of the last to expire Royalty Term. We may terminate any license granted under the Master License Agreement for any reason upon 180 days written notice to Columbia University. In addition, either party may terminate the Master License Agreement, or one or more licenses granted under the Master License Agreement, for the other party&#8217;s material breach, following a customary notice and cure period, and Columbia University may terminate the Master License Agreement upon the occurrence of certain events of insolvency for us. Upon termination of the Master License Agreement, (1) we will have the right, for 18 months or such longer period as the parties may reasonably agree, to sell Licensed Products, continue the development and maintenance of Licensed Products and use Licensed Products to the extent needed to perform any services required to be performed as of the date of termination and (2) any third party that has licensed any Licensed Product from us will retain the right to use such Licensed Product, and we will have the right to continue to provide support to such third parties in connection with their use of such Licensed Products.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prior Columbia License Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to entering into the Master License Agreement described above, we entered into several license agreements with Columbia University, or the Prior Columbia License Agreements. The Prior Columbia License Agreements establish our rights and obligations with respect to certain patents, software code, technology, and improvements thereto that we license from Columbia University and that are used in, and integrated into, our software solutions, and our physics-based computational platform. The terms of the Prior Columbia License Agreements remain in effect for arrangements that were entered prior to the effective date of the Master License Agreement. The terms of the Master License Agreement supersede the terms of the Prior Columbia License Agreements for arrangements entered into starting from the effective date of the Master License Agreement. Our rights and obligations under, and the terms and conditions of, the Prior Columbia License Agreements that we consider material to the operation of our business are described more fully below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2008, we entered into an amendment, or the Royalty Amendment, to certain Prior Columbia License Agreements, including each of the agreements described below. The Royalty Amendment simplified the royalties payable under each agreement on gross revenues generated from the use of any product which contains any code or software, or is covered by any patent, that we license from Columbia University, or a Licensed Product, in connection with a services agreement. We also pay royalties under the Prior Columbia License Agreements on gross revenues generated from the sale, licensing or renting of our Licensed Products, which we calculate on a product-by-product basis. In the event that one or more Licensed Products are sold together with other products for a single aggregate license fee, we have agreed to pay to Columbia University the applicable royalty on the gross revenues attributable to each Licensed Product based on the relative list prices of each product covered by such license fee.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the royalties payable by us to Columbia University in connection with our services agreements, see "&#8212;Services Royalty Amendment" below.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PS-GVB License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 1994, we entered into a license agreement, or the 1994 Columbia Agreement, with Columbia University, which was amended on September 9, 2004 and November 1, 2008. The technology licensed under the 1994 Columbia Agreement is incorporated into our Jaguar quantum mechanical program, which we market and distribute as part of our physics-based computational platform. The 1994 Columbia Agreement grants us a worldwide, exclusive, license to the software code developed by Columbia University and incorporated into the electronic structure software program PS-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GVB v1.0, or the PS-GVB Code, and all improvement to the PS-GVB v1.0 software program and PS-GVB Code developed by Columbia University, or the PS-GVB Improvements, including all PS-GVB Code and PS-GVB Improvements that are incorporated into any new products, new releases, and new versions related to the software, or the New PS-GVB Module Code, in each case, to reproduce, use, execute, copy, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may only sublicense the PS-GVB Code, the PS-GVB Improvements, and the New PS-GVB Module Code, or the Licensed PS-GVB Software, to the extent they are incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 1994 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and non-profit research institutions to conduct research using the Licensed PS-GVB Software.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for entering into the 1994 Columbia Agreement, we have agreed to pay royalties to Columbia University in the low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable PS-GVB v1.0 software program on our, and our affiliates&#8217;, gross revenues from the sale, licensing, or renting of the PS-GVB v1.0 software program, including any improvements and modifications thereto, regardless of whether such improvement or modification is marketed as a new version, new release, or new product, excluding any sales to Columbia University and any revenue generated under services agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 1994 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party&#8217;s material breach of the agreement and such party&#8217;s failure to cure such breach. Upon termination, any third party that has licensed the Licensed PS-GVB Software from us will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Multipole RESPA License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 1998, we entered into a license agreement, or the 1998 Columbia Agreement, with Columbia University, which was amended on September 4, 2004, and November 1, 2008. The 1998 Columbia Agreement grants us a worldwide, non-exclusive, license to the Fast Multipole RESPA code developed at Columbia University, or the RESPA Code, which was incorporated into the IMPACT software program used in our Glide ligand-protein docking program, PrimeX protein modelling program, QSite QM/MM program, and Combglide automated library generation program, and all improvements to the IMPACT software program, including any new versions and new releases thereof, that are developed by Columbia University, or the IMPACT Improvements, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may sublicense the RESPA Code and the IMPACT Improvements, or the Licensed IMPACT Software, to the extent it is incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 1998 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and non-profit research institutions to conduct, research using the Licensed IMPACT Software.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for entering into the 1998 Columbia Agreement, we have agreed to pay royalties to Columbia University in the low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable IMPACT software program on our, and our affiliates&#8217;, gross revenues from the sale, licensing, or renting of the IMPACT software program, including any improvements and modifications thereto and any new versions and new releases thereof, excluding any sales to Columbia University and revenue generated under services agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 1998 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party&#8217;s material breach of the agreement and such party&#8217;s failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 1998 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protein Folding License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2001, we entered into a license agreement, or the 2001 Columbia Agreement, with Columbia University, which was amended on September 9, 2004 and November 1, 2008. The technology licensed under the 2001 Columbia Agreement is incorporated into our Prime protein modelling program, which we market and distribute as part of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our physics-based computational platform. The 2001 Columbia Agreement grants us a worldwide, exclusive license to the protein folding code developed by Columbia University, or the Folding Code; all improvements to the Folding Code and to any of our products, software, or code that incorporates any part of the Folding Code, including any improvements thereto and new versions or new releases thereof, that are developed by Columbia University, or the Folding Code Improvements; and the issued patent covering the Folding Code, or the Folding Code Patent, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may sublicense the Folding Code, the Folding Code Improvements and the Folding Code Patent, or the Licensed Folding Code Software, to the extent it is incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 2001 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and non-profit research institutions to conduct, research using the Licensed Folding Code Software.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for entering into the 2001 Columbia Agreement, we paid Columbia University a one-time, nominal license fee. In addition, we have paid royalties to Columbia University in low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable product, software program, or code on our, and our affiliates&#8217;, gross revenues from the sale, licensing, or renting of any commercial product, software program, or code incorporating the Licensed Folding Code Software, excluding any sales to Columbia University and revenues generated under services agreements. Our obligation to pay any royalty under the 2001 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, terminated with the expiration of the last to expire patent licensed under the 2001 Columbia Agreement in January 2014.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2001 Columbia Agreement and the licenses granted thereunder may be terminated by Columbia University only upon our material breach of the agreement and our failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 2001 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PLOP License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2003, we entered into a license agreement, or the 2003 Columbia Agreement, with Columbia University, which was amended on November 1, 2008. The technology licensed under the 2003 Columbia Agreement is incorporated into our Prime and PrimeX protein modelling programs and our Membrane Permeability model, which we market and distribute as part of our physics-based computational platform. The 2003 Columbia Agreement grants us a worldwide, exclusive license to the protein local optimization program software code, or the PLOP Code, developed at Columbia University and the University of California and all software code comprising improvements to the PLOP Code that are developed by Columbia University or the University of California, or the PLOP Improvements, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. Pursuant to an interinstitutional agreement between Columbia University and the University of California, the University of California granted Columbia University the sole right to license the PLOP Code and PLOP Improvements and has agreed not to license the PLOP Code or PLOP Improvements to any third party for as long as the interinstitutional agreement remains in effect. We may sublicense the PLOP Code and PLOP Improvements to the extent they are incorporated into a product that is sold directly by us or that is distributed on our behalf. We are restricted from distributing the PLOP Code and PLOP Improvements source code without the prior written consent of Columbia University.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columbia University and the University of California retain the right to use, and to permit other academic and non-profit research institutions to use, the PLOP Code and PLOP Improvements for teaching and academic research purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for entering into the 2003 Columbia Agreement, we paid Columbia University a one-time, nominal license fee. In addition, we have agreed to pay royalties to Columbia University in low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable product, software program, or code on our, and our affiliates&#8217;, gross revenues from the sale, licensing, leasing, or renting any commercial product, software program, or code incorporating the PLOP Code or any PLOP Improvements, excluding any sales to Columbia University or the University of California and revenues generated under services agreements. Our obligation to pay any royalty under the 2003 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, expired pursuant to its terms on June 19, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columbia University is responsible for the copyright registration of the PLOP Code and PLOP Improvements. We are responsible for paying all reasonable copyright registration and attorney fees in connection with such copyright registrations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2003 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party&#8217;s material breach of the agreement and such party&#8217;s failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 2003 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Water Site Analysis License</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2008, we entered into a software and patent license agreement, or the 2008 Columbia Agreement, with Columbia University, which was amended on November 1, 2008. The 2008 Columbia Agreement grants us a worldwide license, exclusive in the field of computational chemistry software and related services, to (a) certain software that implements the water site analysis method, or the Water Site Software; (b) all patent rights covering the Water Site Software, or the Water Site Patents; and (c) any products that incorporate or include the Water Site Software, or that is covered by the Water Site Patents, or the Water Site Products, in each case, to reproduce, modify, distribute, and perform and display in connection with the development, marketing, and sale of our products and services, to conduct research using the Water Site Software, and to conduct backup disaster recovery. Our Water Site Products include our WaterMap Core program, which we market and distribute as part of our physics-based computational platform. We are restricted from distributing the Water Site Software source code without the prior written consent of Columbia University. Under the 2008 Columbia Agreement, Columbia University retains the right to use, and to permit other entities and individuals to use, the Water Site Software and Water Site Patents for academic and non-commercial educational purposes in the field of computational chemistry software and related services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for entering into the 2008 Columbia Agreement, we paid Columbia University a one-time, nominal license fee. In addition, we have agreed to pay royalties to Columbia University in low-double digit percentages on our, and our affiliates&#8217;, gross revenues from the sale, licensing, leasing, or renting of any Water Site Product, excluding any sales to Columbia University and revenues generated under services agreement. The royalties under the 2008 Columbia Agreement are paid on a product-by-product basis and vary based on whether or not the gross revenues are generated in countries of manufacture or sale in which the Water Site Product is covered by a Water Site Patent. In the event that there are multiple royalties payable on a single product, we are required to (i) pay the higher of the two royalties, if there are no more than two royalties payable on the particular Water Site Product or (ii) negotiate in good faith with Columbia University on a single royalty, if there are more than two royalties payable on the particular Water Site Product. In the event that we take action against Columbia University with respect to the validity or enforceability of any Water Site Patents, excluding any defensive actions or claims, the royalties paid under the 2008 Columbia Agreement will increase by a specified amount. Our obligation to pay any royalty under the 2008 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, will terminate on May 27, 2028.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columbia University is responsible for the prosecution and maintenance of the Water Site Patents in the jurisdictions that we specify. If we decide to discontinue the prosecution or maintenance of any Water Site Patent in any jurisdiction, but Columbia University objects to such discontinuation, our license to use such Water Site Patent will terminate in that jurisdiction; provided that, if we are using the Water Site Patent or Water Site Software in the jurisdiction at issue, Columbia University is obligated to discuss in good faith whether the licenses should instead be non-exclusive. Columbia University is also responsible for the enforcement of the Water Site Patent at its own expense and in its sole judgment; provided that, if we provide Columbia University with evidence of infringement of a Water Site Patent by a third party, and Columbia University fails to take appropriate enforcement action, we may initiate legal proceedings against the alleged infringer. We are responsible for reimbursing Columbia University for their reasonable expenses in connection with prosecuting and maintaining the Water Site Patents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the 2008 Columbia Agreement will expire on a product by product and country by country basis upon the later of (i) the expiration of the last issued Water Site Patent, (ii) fifteen years from the date of the first commercial sale of a Water Site Product in a given country, and (iii) the expiration of the Water Site Software copyright. Columbia University may terminate the 2008 Columbia Agreement if we fail to cure a material breach, become subject to a voluntary or involuntary petition for bankruptcy or any other proceeding relating to insolvency, receivership or liquidation, or initiate any proceeding or assert any claim challenging the validity or enforceability of the Water Site Patents. Upon termination, any third party that has licensed a Water Site Product from us will retain the right to use such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, subject to the terms of their existing license agreement with us, and we will have the right to continue to provide support to any such third parties for the duration of their license agreement.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Services Royalty Amendment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2008, we entered into the Royalty Amendment with Columbia University, which amended and simplified our royalty obligations under each of the Columbia License Agreements described in each of the foregoing sections. Pursuant to the Royalty Amendment, we have agreed to pay royalties to Columbia University in mid-single digit percentages on the service fees generated from services (excluding certain gross revenue, including revenue generated under agreements with Columbia University) that we, or our affiliates, perform using one or more Licensed Products under an agreement with a third party. Upon termination of any of the Columbia License Agreements for any reason other than our material breach, we will have the right to continue to use the Licensed Products to provide services under existing third-party service agreements, until the expiration or termination of such agreements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including by seeking, maintaining, and defending patent rights, whether developed internally or jointly, or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation, collaboration opportunities, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in our field.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to our future commercial success to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business; defend and enforce our intellectual property rights, in particular our patent, trademark, and copyright rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing any products we develop may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our software, technology, computational platform, and any product candidates we develop. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any products we develop will be protected or remain protectable by enforceable patents. Moreover, any patents that we hold or may hold may be challenged, circumvented or invalidated by third parties. See "Risk Factors&#8212;Risks Related to Our Intellectual Property" for a more comprehensive description of risks related to our intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to file patent applications directed to our key software and our key programs in an effort to secure our intellectual property positions vis-a-vis this software and these programs. The patent portfolio for our software business includes at least 12 published patent families. As of January 24, 2025, we owned or held exclusive license rights to approximately 40 patents and patent applications, including approximately 14 issued or allowed U.S. cases, five pending U.S. non-provisional patent applications, 18 issued or allowed non-U.S. cases, including nine granted European patents which have been validated among multiple individual European Patent Convention nations, eight non-European patents, and two pending foreign patent applications relating to our computational platform. While we believe that the specific and generic claims contained in our wholly-owned and licensed pending U.S. and non-U.S. applications provide protection for various aspects of our computational platform, third parties may nevertheless challenge such claims. Any patents that are issued or that may issue from these families are expected to expire between 2026 and 2038, absent any adjustments or extensions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;24, 2025, there were approximately 10 published patent families related to our proprietary drug discovery business, and several of our drug discovery collaborators have filed patent applications related to our collaborations that include employees of ours as inventors, including over 100 compound patents and patent applications since 2010. We do not own any intellectual property rights related to these inventions. As of January&#160;24, 2025, we wholly-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owned approximately 12 pending U.S. patent applications, including U.S. provisional and U.S. non-provisional patent applications, and approximately 100 pending non-U.S. patent applications, including international patent applications filed under the Patent Cooperation Treaty, related to our proprietary drug discovery business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application, absent any adjustments or extensions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents we may obtain in the future may be entitled to patent term extensions. If our use of product candidates or the product candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or product candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, as of January&#160;24, 2025, we had approximately 64 copyright registrations covering our proprietary software code, and we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, service providers, employees, and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See "Risk Factors&#8212;Risks Related to Our Intellectual Property" for a more comprehensive description of risks related to our intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own numerous trademarks registered in the United States and foreign jurisdictions, including "Schr&#246;dinger" and "LiveDesign". We pursue additional trademark registrations to the extent we believe doing so would be beneficial to our competitive position.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize our software solutions in various jurisdictions around the world through our software sales organization. We have sales operations in the United States, Europe, Japan, India, and South Korea and we also have established distribution channels in other important markets, including China. These efforts are led by our approximately 240-person global team of sales, technical, and scientific personnel. Our marketing strategy leverages our strong base of scientific publications to support the continued growth of our computational platform into computational chemistry markets across industries and academia worldwide.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Discovery Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not established a commercial organization or developed distribution capabilities given the current stage of development of our proprietary drug discovery programs. We plan to enter into agreements with biopharmaceutical companies that contribute to our ability to efficiently advance development candidates that we discover internally using our computational platform through to commercialization. We expect to utilize a variety of types of collaboration, distribution, and other arrangements with one or more of these third parties to develop and ultimately commercialize our development candidates. Over time, we may also create a commercial organization for drug product sales if and as we advance the development of any product candidates that we determine to commercialize ourselves.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities for the production of any product candidates, nor do we have plans to develop our own manufacturing operations. We rely and expect to continue to rely on third-party contract manufacturers for all of our required raw materials, drug substance, and finished drug product for the preclinical and clinical development of any development candidates we develop ourselves. We do not currently have any agreements with third-party manufacturers for the long-term supply of any of our product candidates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approvals</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources and may have a significant impact on our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approval and Regulation of Drugs in the United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, drug products are approved and regulated under the Federal Food, Drug and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable regulatory requirements at any time during the product development process, including non-clinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval, and/or administrative or judicial sanctions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">preclinical testing including laboratory tests, animal studies, and formulation studies, which must be performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with current good clinical practices, or GCP;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">preparation and submission to the FDA of a new drug application, or NDA, for a drug product which includes not only the results of the clinical trials, but also detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling for one or more proposed indication(s);</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with current good manufacturing practices, or cGMP, requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">payment of user application and program fees pursuant to the Prescription Drug User Fee Act, or PDUFA;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approval of an NDA for the new drug product authorizing marketing of the new drug product for particular indications in the United States; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct any post- approval studies required by the FDA.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage, including in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical tests include laboratory evaluations of product chemistry, formulation, and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. These studies are generally referred to as IND-enabling studies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity and long-term toxicity studies may continue after the IND is submitted. With passage of the FDA&#8217;s Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the Public Health Service Act, or PHSA, that required animal testing in support of an NDA. While animal testing may still be conducted, the FDA was authorized to rely on alternative non-clinical tests, including cell-based assays, microphysiological systems or bioprinted or computer models.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The IND and IRB Processes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their voluntary informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In addition to reviewing an IND to assure the safety and rights of patients, the FDA also focuses on the quality of the investigation and whether it will be adequate to permit an evaluation of the drug&#8217;s safety and efficacy. In support of a request for an IND, sponsors must submit a protocol for each clinical trial, and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In these cases, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials, or parts of the trial, can begin.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical trial or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol may not be allowed to proceed, while other protocols may be allowed. No </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, a clinical trial may only resume after the FDA has so notified the sponsor of its decision to lift the hold. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the clinical trial can proceed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring committee, or DMC. The DMC provides authorization as to whether or not a trial may move forward at designated check points based on access that only the DMC maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or the competitive environment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expanded Access</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called "compassionate use," is the use of investigational new products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient INDs for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or Treatment IND Application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational product for the requested treatment will not interfere with the initiation, conduct or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no obligation for a sponsor to make its investigational products available for expanded access; however, as required by amendments to the FDCA included in the 21st Century Cures Act passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests with respect to product candidates in development to treat serious diseases or conditions, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 trial for a covered investigational product; or 15 days after the investigational product receives designation from the FDA as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Right to Try Act, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Clinical Trials in Support of an NDA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population. A Phase 2 trial may be further subdivided to Phase 2a and Phase 2b trials. A Phase 2a trial is typically an exploratory (non-pivotal) study that has clinical efficacy, pharmacodynamics, or biological activity as the primary endpoint. A Phase 2b trial is a definite dose range finding study with efficacy as the primary endpoint.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug. Such Phase 3 studies are referred to as "pivotal."</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other "pivotal study" of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In June 2024, the FDA issued draft guidance outlining the general requirements for diversity action plans. Unlike most guidance documents issued by the FDA, the diversity action plan guidance, when finalized, will have the force of the law because FDORA specifically dictates that the form and manner for submission of diversity action plans are specified in FDA guidance. In January 2025, in response to an executive order issued by President Trump on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website. The implications of this action are not yet known. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as post-marketing clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any post-marketing clinical trial requirement or to request a change in the product labeling. Failure to exhibit due diligence with regard to conducting post-marketing clinical trials could result in withdrawal of approval for products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FDA released a final guidance entitled "Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics," which outlines how sponsors can utilize an adaptive trial design in the early stages of oncology product development (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in INDs and assessed by FDA. Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and time.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials Outside the United States in Support of FDA Approval</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our clinical development program, we are and may in the future conduct trials at sites outside the United States. When a foreign clinical trial is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acceptance by the FDA of trial data from clinical trials conducted outside the United States in support of US approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign trial data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the trial is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the trial through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interactions with FDA during the Clinical Development Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. A development and safety update report, or DSUR, detailing the results of the clinical trials must be submitted annually to the FDA within 60 days of the anniversary date that the IND was filed. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND, or pre-IND application meeting, at the end of a Phase 2 clinical trial, or EOP2 meeting, and before an NDA is submitted, or pre-NDA meeting. Meetings at other times may also be requested. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND application and pre-NDA meetings, as well as Type B end of phase meetings, such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. Finally, a type D meeting is focused on a narrow set of issues (should be limited to no more than two focused topics) and should not require input from more than three disciplines or divisions. Finally, Initial Targeted Engagement for Regulatory Advice on CBER products, or INTERACT, meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. For example, at an EOP2 meeting, a sponsor may discuss its Phase 2 clinical results and present its plans for the pivotal Phase 3 clinical trial(s) that it believes will support the approval of the new product. Such meetings may be conducted in person, via teleconference/videoconference or written response only with minutes reflecting the questions that the sponsor posed to the FDA and the FDA&#8217;s responses. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure. In September 2023, the FDA issued draft guidance outlining the terms of such meetings in more detail.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting Clinical Trial Results</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The PHSA grants the Secretary of Health and Human Services the authority to issue a notice of noncompliance to a responsible party to failure to submit clinical trial information as required. The responsible party is allowed 30 days to correct the noncompliance and submit the required information. As of December 19, 2024, the FDA has issued six notices of non-compliance, signaling its willingness to enforce the reporting requirements. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. In addition to civil monetary penalties, violations may also result in other regulatory action, such as injunction and/or criminal prosecution or disqualification from federal grants.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing and Compliance with cGMP Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies often complete additional preclinical studies. They must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s regulations require that pharmaceutical products be manufactured in approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Studies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act, or PREA, applications and certain types of supplements to applications must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor must submit an initial pediatric study plan within 60 days of an EOP2 meeting or as may be agreed between the sponsor and the FDA. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after the FDA&#8217;s receipt of the study plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. Pursuant to the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, the FDA must send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. FDASIA further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#8217;s response.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in the PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under the PREA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Review Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs changes the standards for approval but they may help expedite the development or approval process of product candidates.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Fast Track designation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Breakthrough therapy designation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Priority review.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Accelerated approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months until the study is completed; and use expedited procedures to withdraw accelerated approval of an NDA or BLA if certain conditions are not met, including where a confirmatory trial fails to verify the product&#8217;s clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval trial of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the FDA Commissioner or the Commissioner&#8217;s designee and a written appeal, among other things. In March 2023, the FDA issued draft guidance that outlines its views and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidance relating to accelerated approval. This guidance describes the FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the agency plans to interpret whether such a study needs to be underway at the time of approval. While this guidance is currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Regenerative advanced therapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filing and Review of an NDA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain approval to market a drug product in the United States, a NDA must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed drug product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the drug product to the satisfaction of the FDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NDA is a vehicle through which sponsors formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. Biologic License Applications, or BLAs, are submitted for licensure of biologic products under the PHSA. Under federal law, the fee required for the submission and review of an application under the Prescription Drug User Fee Act, or the PDUFA, is substantial (for example, for federal fiscal year 2025 this application fee is approximately $4.3 million), and the sponsor of an approved application is also subject to an annual program fee, currently more than $403,889 per eligible prescription product for federal fiscal year 2025. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of the application within 60 calendar days of its receipt, and must inform the sponsor within that period of time whether the application is sufficiently complete to permit substantive review. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refusal to File determination to the sponsor. The FDA may request additional information rather than accept the application for filing and, the application may be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing, and 90% of applications for NMEs that have been designated for priority review are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the ten-month and six-month review periods run from the date that the FDA receives the application. The review process and the PDUFA goal date may be extended by the FDA for three additional months to consider new information or clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the PDUFA goal date. The FDA seeks to meet these timelines for review of an application but its ability to do so may be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated in recent years as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a result. For example, during the past decade, the U.S. government has shut down several times and certain regulatory agencies, including the FDA, have had to furlough critical employees and stop critical activities, including the review of both NDAs and BLAs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of an application, the FDA typically will inspect the facility or facilities where the product is being or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Under the FDA Reauthorization Act of 2017, the FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain applications, including applications for products in shortage or those for which approval is dependent on remediation of conditions identified in the inspection report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the data in the application. With passage of FDORA, Congress clarified FDA&#8217;s authority to conduct inspections by expressly permitting inspection of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to FDA as well as other persons holding study records or involved in the study process. To ensure cGMP and GCP compliance by its employees and third-party contractors, a sponsor may incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA will review a sponsor&#8217;s financial relationship with the principal investigators who conducted the clinical trials in support of the application. That is because, under certain circumstances, principal investigators at a clinical trial site may also serve as scientific advisors or consultants to a sponsor and receive compensation in connection with such services. Depending on the level of that compensation and any other financial interest a principal investigator may have in a sponsor, the sponsor may be required to report these relationships to the FDA. The FDA will then evaluate that financial relationship and determine whether it creates a conflict of interest or otherwise affects the interpretation of the trial or the integrity of the data generated at the principal investigator&#8217;s clinical trial site. If so, the FDA may exclude data from the clinical trial site in connection with its determination of the approvability of the product candidate. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition of approval, the FDA may require a sponsor to develop a REMS. A REMS uses risk-minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, the seriousness of the disease, the expected benefit of the product, the expected duration of treatment, the seriousness of known or potential adverse events, and whether the product is a NME. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that review, evaluate and provide a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but the FDA considers such recommendations carefully when making decisions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The FDA&#8217;s Decision on an NDA</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. Ultimately, the FDA will determine whether the expected benefits of the drug product outweigh its potential risks to patients, and the agency will issue either a complete response letter, or CRL, or an approval letter.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trials and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond. For those seeking to challenge FDA&#8217;s CRL decision, the FDA has indicated that sponsors may request a formal hearing on the CRL or they may file a request for reconsideration or a request for a formal dispute resolution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a new product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, or require that post-approval studies, including post-marketing clinical trials, be conducted to further assess the drug&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including a REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS programs can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. The FDA may require a REMS before or after approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. After approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes, and adding labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new prescription product, the manufacturer, the approved product and the product&#8217;s manufacturing locations are subject to pervasive and continuing regulation by the FDA, governing, among other things, monitoring and record-keeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, with manufacturing processes, or failure to comply with regulatory requirements, may result in: revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information, although it may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug product. Moreover, with passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors certain information about products in development to help expedite patient access upon product approval. In addition, in January 2025, the FDA published final guidance outlining its policies governing the distribution of scientific information to healthcare providers about unapproved uses of approved products. The final guidance calls for such communications to be truthful, non-misleading and scientifically sound and to include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use of the approved product. If a company engages in such communications consistent with the guidance&#8217;s recommendations, the FDA indicated that it will not treat such communications as evidence of unlawful promotion of a new intended use for the approved product. While this guidance only applies to communications about unapproved uses of approved products, it may be helpful in understanding the FDA&#8217;s approach to communications about unapproved products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products, as well as adverse public relations and reputational harm. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementing regulations, as well as the Drug Supply Chain Security Act, or DSCSA, which regulate the distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of drug distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. Manufacturers were required by November 2023 to have such systems and processes in place to comply with the DSCSA, but, so as not to disrupt supply chains, the FDA has granted certain exemptions from enhanced drug distribution security requirements for eligible trading partners for particular periods of time.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017, but have not yet been approved or licensed by the FDA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the term "same disease or condition" in the statute means the designated "rare disease or condition" and could not be interpreted by the FDA to mean the "indication or use." Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the "indication or use." Although there have been legislative proposals to overrule this decision, they have not been enacted into law. In January 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Section 505(b)(2) NDAs </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new product. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the sponsor to rely, in part, on the FDA&#8217;s previous findings of safety and effectiveness for a similar product, or published literature. Specifically, Section 505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied upon by the sponsor for approval of the application &#8220;were not conducted by or for the sponsor and for which the sponsor has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221; </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(2) authorizes the FDA to approve an NDA based on safety and efficacy data that were not developed by the sponsor. NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the Section 505(b)(2) sponsor can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the sponsor may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) sponsor.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Drugs and Regulatory Exclusivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, a sponsor must submit an abbreviated new drug application, or ANDA, to the FDA. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA or 505(b)(2) application until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of regulatory exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. This interpretation of the FDCA by the FDA was confirmed with enactment of the Ensuring Innovation Act in April 2021. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the sponsor may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the sponsor and are essential to the approval of the application.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of regulatory exclusivity. For drug products, the six-month period of exclusivity may be attached to the term of any existing patent or regulatory exclusivity. This six-month exclusivity may be granted if an NDA or BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of non-patent exclusivity for drugs and biologics, or patent protection that covers a drug product, are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration and Extension</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch- Waxman Act, which permits a patent restoration of up to five years for patent term lost during the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of the IND and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it, may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Compliance</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to prevent fraud and abuse in the healthcare industry. Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to healthcare providers and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal Open Payments (or federal "sunshine" law), which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare &amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services for re-disclosure to the public, as well as ownership and investment interests held by certain healthcare providers and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laws and regulations prohibiting bribery and corruption such as the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, such as Medicare and Medicaid. Ensuring compliance is time consuming and costly. Similar healthcare laws and regulations exist in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General are aggressive in reviewing privacy and data security protections for consumers. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which became effective on January 1, 2020, requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, allow consumers to opt out of certain data sharing with third parties and provide a new cause of action for data breaches. Additionally, effective as of January 1, 2023, the California Privacy Rights Act, or CPRA, will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and individually identifiable health information. These provisions may apply to some of our business activities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, a number of other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws that will go into effect in the near future. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2025. These laws may impact our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our product candidates, if approved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Insurance Coverage and Health Care Reform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate of ours or one of our collaborators is approved, sales of the product will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payer not to cover a product could reduce market acceptance once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#8217;s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In international markets, reimbursement and health care payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and adequate reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of health care costs also has become a priority of federal, state, and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on coverage, reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products including those that we or our collaborators may develop. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain approval in the future to market in the United States any product candidates we may develop, we may be required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the PPACA, which, among other things, includes changes to the coverage and payment for drug products under government health care programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which went into effect in April 2013. Under current legislation, the actual reductions in Medicare payments may vary up to four percent.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the four percent Statutory Pay-As-You-Go Act of 2010, or PAYGO, sequester for two years, through the end of 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the four percent cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the two percent Budget Control Act of 2011 Medicare sequester for six months into 2032 and lowers the payment reduction percentages in years 2030 and 2031.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, the Tax Act repealed the "individual mandate." The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the PPACA after finding that the plaintiffs do not have standing to challenge the constitutionality of the PPACA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first Trump Administration, the Congress and administration sought to overturn the PPACA and related measures. Shortly after taking office in January 2025, President Trump revoked a number of executive orders issued by President Biden, including at least two executive orders that were designed to further implement the PPACA. We anticipate similar efforts to undermine the PPACA, and litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, the Trump administration issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed legislation establishing workgroups to examine the impact of a state importation program. Several other states have passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. In January 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. Florida now has authority to import certain products from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each product selected for importation, which must be approved by the FDA. Florida will also need to relabel the products and perform quality testing of the products to meet FDA standards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the Inflation Reduction Act of 2022, or IRA, has been delayed by Congress to January 1, 2032.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. In August 2024, the HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. On January 17, 2025, CMS announced its selection of 15 additional drugs covered by Part D for the second cycle of negotiations. Following the change in administrations, CMS issued a public statement on January 29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program. The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated "maximum fair price" under the law or for taking price increases that exceed inflation. In addition to the drug price negotiation program, the IRA established inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate of inflation. On December 9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs. The new law also caps Medicare out-of-pocket drug costs at an estimated $2,000 beginning in 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA includes a provision exempting orphan drugs from Medicare price negotiation but this exclusion has been interpreted by CMS in final guidance issued in July 2023 to apply only to those orphan drugs with an approved indication (or indications) for a single rare disease or condition. The final guidance clarifies that CMS will consider only active designations/approvals when evaluating a drug for the exclusion, such that designations/indications withdrawn before the selected drug publication date will not be considered. CMS also clarified that, if a drug loses its orphan drug exclusion status, the agency will use the earliest date of approval/licensure to determine whether the product is a qualifying single source drug subject to price negotiations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Merck filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce and pharmaceutical companies, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. HHS has generally won the substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal, and, on October 30, 2024, the Court of Appeals for the Third Circuit heard oral argument in these cases. Litigation involving these and other provisions of the IRA will continue with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. Additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Medicinal Products in the European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, a sponsor must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales, and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. The process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with GLP principles as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#8211; e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Approval</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014, or the Clinical Trials Regulation, became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC, or the Clinical Trials Directive. The Clinical Trials Regulation aims at simplifying and streamlining the authorization, conduct and transparency </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one member state of the European Union, or EU Member State, will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the European Medicines Agency, or the EMA, and available to clinical trial sponsors, competent authorities of the EU Member States and the public.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All ongoing clinical trials in the European Union approved under the prior Clinical Trials Directive, or CTD, must be transitioned to the Clinical Trials Information System by January 31, 2025. This date marks the end of a three-year transition period that began when the Clinical Trials Regulation became applicable in the European Union on January 31, 2022. Clinical trials that were started under the Clinical Trials Directive and subject to transition to the Clinical Trials Regulation will, by January 31, 2025, have to comply with the obligations of the Clinical Trials Regulation even if these are not included in the previous study protocol, such as (i) obligations of notification via Clinical Trials Information System; (ii) safety reporting rules; (iii) archiving requirement; and (iv) transparency requirements. The failure to transition ongoing clinical trials to the Clinical Trials Regulation by January 31, 2025 can result in corrective measures under Article 77 Clinical Trials Regulation, including revocation of the authorization of the clinical trial or suspension of the clinical trial as well as criminal sanctions and fines under national law of EU Member States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond streamlining the process, the Clinical Trials Regulation includes a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors, and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (EU Member States concerned). Part II is assessed separately by each EU Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Clinical Trials Regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific study site after the applicable ethics committee has issued a favorable opinion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EU Clinical Trials Register.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRIME Designation in the European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization for a product under European Union regulatory systems, a sponsor must submit a marketing authorization application, or MAA, either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, sponsors have to demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver, or (3) a deferral for one or more of the measures included in the PIP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the European Economic Area (i.e. the European Union as well as Iceland, Liechtenstein and Norway), or the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products, and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the sponsor also be used in certain other cases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the sponsor in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of European Union law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use, or the Standing Committee. The Standing Committee is composed of representatives of the EU Member States and chaired by a non-voting European Commission representative. The European Parliament also has a related "droit de regard". The European Parliament&#8217;s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exceptional Circumstances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may grant a so-called "marketing authorization under exceptional circumstances". Such authorization is intended for products for which the sponsor can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the sponsor cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the sponsor must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk- benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a "normal" marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conditional Marketing Authorization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may also grant a so-called "conditional marketing authorization" prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i) the risk-benefit balance of the product candidate is positive, (ii) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data, (iii) the product fulfills an unmet medical need, and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted a European Union marketing authorization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, information about clinical trials in support of a marketing application must be submitted within specific timeframes to the European Union (EudraCT) website: https://eudract.ema.europa.eu/ and other countries.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Data Protection in the European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance with the centralized authorization procedure. Data exclusivity prevents sponsors for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the European Union market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests, and clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products was published in April 2023 and includes, among other things, provisions that would potentially reduce the duration of regulatory data protection. The European Parliament requested several amendments in April 2024. At this time, the proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry in the long term, if and when adopted.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods of Authorization and Renewals</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the European Union market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Requirements after Marketing Authorization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Decisions for Approved Products</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Data Protection Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. The General Data Protection Regulation, or GDPR, is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-US Privacy Shield. The European Commission adopted the adequacy decision in July 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the European Union to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU, commonly referred to as Brexit, took place on January 31, 2020. The EU and the United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, which entered into force on May 1, 2021. As of January 1, 2021, the Medicines and Healthcare Products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol, as amended by the so called Windsor Framework agreed in February 2023. As of January 1, 2025, the changes introduced by the Windsor Framework resulted in the MHRA being responsible for approving all medicinal products destined for the United Kingdom market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the EU. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2024 on, a new international recognition procedure, or IRP, applies which intends to facilitate approval of pharmaceutical products in the UK. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include EMA and regulators in the EEA member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S.).The RR assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion or an MRDC positive end of procedure outcome is an RR authorisation for the purposes of IRP. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 3, 2025, we had 891 full-time employees, including a total of 384 employees with Ph.D. degrees. Of these full-time employees, 626 of these employees are located in the United States and 265 of these employees are located in our offices outside of the United States. Additionally, as of February&#160;3, 2025, 33.6% of our full-time employees </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">self-identified as female, 0.4% self-identified as non-binary, and 0.7% chose not to disclose their gender, and 37.5% of our executive team self-identified as female. Further, 40.7% of our new hires since January 1, 2025 self-identify as female, 0.9% self-identify as non-binary, and 0.9% have chosen not to disclose their gender. As of February&#160;3, 2025, 55.1% of our full-time employees in the United States self-identified as White, 28.6% self-identified as Asian, 4.6% self-identified as having two or more races, 3.8% self-identified as Black or African American, 3.2% self-identified as Hispanic or Latino, 0.2% self-identified as American Indian or Alaskan Native, 0.2% self-identified as Native Hawaiian or Other Pacific Islander, and 4.3% chose not to disclose their race or ethnicity. Our employees are our greatest asset and we strive to create a work environment that is inclusive, challenging and rewarding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to embedding a long-term, formal Environmental, Social, and Governance, or ESG, strategy within our business, a commitment we refer to as Corporate Sustainability. In 2022, we completed a "double materiality assessment," where we worked to determine the ESG-related topics most important to both our company and our stakeholders. The assessment was informed by both internal and external stakeholders and by key ESG standards and frameworks such as the Global Reporting Initiative, Sustainability Accounting Standards Board and United Nations Sustainable Development Goals. This assessment serves as the foundation for our annual Corporate Sustainability Report and continues to serve as the foundation for our comprehensive, data-driven, Corporate Sustainability strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our workplace philosophy is focused on maintaining an inclusive workplace for employees with a wide range of perspectives, experiences and backgrounds, and ensuring that our employees feel safe, heard, comfortable, and valued. We continue to focus many of our recruiting efforts on attracting a broad candidate pipeline of top talent in the science and technology industries. Further, we utilize a standardized interviewing model to reduce unconscious bias and to create a consistent hiring process across our open positions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A selected group of senior leaders, Employee Resource Group, or ERG, representatives and passionate employees meet monthly to discuss strategy, priorities, and goals for best supporting our workforce. This group also regularly seeks feedback from employees and provides a forum for voices to be heard across all levels of the organization. We currently have employee-led ERGs that provide spaces for all employees to advance inclusivity and create opportunities for education and awareness. While membership in our ERGs directly comprises approximately one-third of our employees, these forums provide an environment for community support, professional development, and educational opportunities for our entire employee population.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an industry known for its fierce competition for talent, we have been able to maintain high retention and low turnover rates. For the year ended December 31, 2024, our employee retention rate was 93.1%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our financial resources, our industry-leading position in the field of physics-based computational drug discovery and materials science research and our developing proprietary drug discovery programs, we believe that we will continue to be able to fill open positions in support of our software, drug discovery and materials science businesses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strategically recruit talent through various methods. Prospective employees are identified by leveraging our current employee network and our existing and growing relationships with computational chemistry professors and labs, and by hosting networking events. We maintain a strong presence at industry conferences and post job openings to industry-specific online career forums. Employee learning and development is a high priority for our company, and we believe it is essential for its growth and success. We offer employees cross-departmental rotations, leadership training and workshops, mentoring and reverse-mentoring programs and online learning with curated learning paths.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing our employees with compensation that meets the expectations of the market and industry norms. We monitor our compensation programs closely using comprehensive industry surveys and data to guide us, and we provide what we consider to be a competitive mix of incentives, including competitive salaries and bonuses, a 401(k) retirement plan with an employer matching contribution, participation in our equity programs, and health and welfare benefits, including, for example, access to a variety of mental health, family care, and reproductive health benefits for our employees based in the United States. We routinely review our compensation practices and analyze the equity of our compensation decisions for all employees. A small number of our employees who are located in Europe and Japan are covered by some type of collective bargaining agreement. We consider our relations with our employees to be good.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the value of in-person collaboration and relationship building while also being mindful of the needs and priorities our employees have outside of the workplace. We have long supported a hybrid work schedule, and our employees have the option of working remotely three days per week. This allows our employees to develop a work schedule that best suits their individual needs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company culture encourages engagement, both among our employees and within the communities we live and work. Internally, we have a well-regarded mentorship program and learning opportunities for hard and soft skills. We also have a variety of communications channels that allow employees to stay informed and connected, and an annual performance review process that emphasizes regular connections and real-time feedback between employees and managers. In our local communities, we are focused on giving back through educational outreach to students and educators to increase awareness, interest and literacy for students in STEM, among other social impact areas of focus. To further our community engagement efforts, we provide an annual paid volunteer day benefit and matching gift program and we have established a social impact platform to provide employees access to local volunteer opportunities in various local currencies and languages.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 1540 Broadway, 24th Floor, New York, New York 10036, and our telephone number is (212) 295-5800. Our website address is www.schrodinger.com. The information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC and any reference to our website address is intended to be an inactive textual reference only.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to trademarks, service marks, and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks, and trade names appearing in this Annual Report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, and trade names referred to in this Annual Report are listed without the &#174; and &#8482; symbols.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also disclose information to the public concerning our software, drug discovery programs, computational platform and other items through a variety of disclosure channels in order to achieve broad, non-exclusionary distribution of information to the public. Some of the information distributed through these disclosure channels may be considered material information. Investors and others are encouraged to review the information we make public in the locations below. This list may be updated from time to time.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:41.5pt">For information concerning our software, drug discovery programs, computational platform, please visit: www.schrodinger.com.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:41.5pt">For information provided to the investment community, including news releases, events and presentations, and filings with the SEC, please visit ir.schrodinger.com.</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:41.5pt">For additional information, please follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These websites and social media channels, and the contents thereof, are not incorporated by reference into this Annual Report nor deemed filed with the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report and our other public filings with the SEC. The risks described below are not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating results, and financial condition to suffer materially.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of significant operating losses, and we expect to incur losses over the next several years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a history of significant operating losses. Our net loss for the year ended December&#160;31, 2024 was $187.1 million. Our net income for the year ended December 31, 2023 was $40.7 million. Our net loss for the year ended December 31, 2022 was $149.2 million. As of December 31, 2024, we had an accumulated deficit of $525.5 million. The net income we generated in the year ended December 31, 2023 was primarily due to the $147.2 million cash distributions we received from Nimbus Therapeutics, LLC, or Nimbus, on account of our equity stake in Nimbus, following the acquisition by Takeda Pharmaceuticals Company, Limited, or Takeda, of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its TYK2 inhibitor NDI-034858 and the non-cash gain on our investment in Structure Therapeutics Inc., or Structure Therapeutics, which, following Structure Therapeutics' initial public offering in February 2023, we valued based on the closing price of its American Depositary Shares as of December 31, 2023. However, the potential for future distributions from, or gains in the fair value of, our equity stakes in our drug discovery collaborators are difficult to predict due to the inherent uncertainty of the events which may trigger such distributions or gains. We therefore expect that gain on equity investments and fair value gains and losses will fluctuate significantly in future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our operating expenses will increase substantially in the foreseeable future as we continue to invest in our proprietary drug discovery programs, sales and marketing infrastructure, and our computational platform. We are still in the early stages of development of our own proprietary drug discovery programs. We have no drug products approved or licensed for commercial sale, and as such, have not generated any revenue from our own drug product sales to date. We expect to continue to incur significant expenses and operating losses over the next several years. Our operating expenses and net income or loss may fluctuate significantly from quarter to quarter and year to year and you should not rely upon the results of any quarterly or annual periods as indications of future results. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue to invest in and develop our computational platform and software solutions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue our research and development efforts for our proprietary drug discovery programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">conduct preclinical studies and initiate and conduct clinical trials for any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">prepare and make regulatory submissions for any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain, expand, enforce, defend, and protect our intellectual property;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hire additional software engineers, programmers, sales and marketing, and other personnel to support our software business and other commercial operations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hire additional clinical, quality control, regulatory, chemical, manufacturing and control and other scientific personnel; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">add operational, financial, and management information systems and personnel to support our operations as a public company.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to increase sales of our software, increase revenue from our drug discovery collaborations, or if we and our current and future collaborators are unable to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve and maintain profitability, we must succeed in significantly increasing our software sales and increasing revenue from our drug discovery collaborations, or we and our current or future collaborators must succeed in developing, and eventually commercializing, a drug product or drug products that generate significant revenue. We currently generate revenues from the sales of our software solutions and from achieving milestones under our collaborative drug discovery programs, and we expect to continue to derive most of our revenue from sales of our software and from achieving such milestones until such time as our or our collaborators&#8217; drug development and commercialization efforts are successful, if ever. As such, increasing sales of our software to existing customers, successfully marketing our software to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new customers, and achieving milestones under our drug discovery collaborations are critical to our success. Demand for our software solutions may be affected by a number of factors, including continued market acceptance by the biopharmaceutical industry, market adoption of our software solutions beyond the biopharmaceutical industry including for materials science applications, the ability of our platform to identify more promising molecules and accelerate and lower the costs of discovery as compared to traditional methods, timing of development and release of new offerings by our competitors, technological change, and the rate of growth in our target markets. If we are unable to continue to meet the demands of our customers, our business operations, financial results, and growth prospects will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achieving success in drug development will require us or our current or future collaborators to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing, and selling any products for which we or they may obtain regulatory approval. We are only in the early stages of most of these activities, and none of our current drug discovery collaborators have completed clinical development of any product candidate. We and our drug discovery collaborators may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve and sustain profitability, or even if our collaborators do, we may not receive option fees, milestone payments, or royalties from them that are significant enough for us to achieve and sustain profitability. Because of the intense competition in the market for our software solutions and the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict when, or if, we will be able to achieve or sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, increase sales of our software, develop a pipeline of product candidates, enter into collaborations, or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue has and may continue to fluctuate from quarter-to-quarter and year-to-year. For example, our total revenues decreased by 4% from $216.7 million in the fiscal year ended December 31, 2023 to $207.5 million in the fiscal year ended December 31, 2024, and increased by 20% from $181.0 million in the fiscal year ended December 31, 2022 to $216.7 million in the fiscal year ended December 31, 2023. Although we have experienced revenue growth in certain periods, we have also experienced revenue loss in certain periods, and we may not be able to sustain revenue growth and we may experience certain periods of revenue decline. You should not consider our revenue growth in prior periods as indicative of our future performance. As we grow our business, our revenue growth rates may decrease in future periods.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual results may fluctuate significantly, which could adversely impact the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations, including our revenues, gross margin, profitability, and cash flows, have historically varied from period to period, and we expect that they will continue to do so. As a result, period-to-period comparisons of our operating results may not be meaningful, and our quarterly and annual results should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside of our control. Factors that may cause fluctuations in our quarterly and annual financial results include, without limitation, those listed elsewhere in this "Risk Factors" section and those listed below:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">customer renewal rates and the timing and terms of customer renewals, including the seasonality of customer renewals of our on-premise software arrangements, for which revenue historically has been recognized at a single point in time in the first and fourth quarter of each fiscal year;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to attract new customers for our software;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the addition or loss of large customers, including through acquisitions or consolidations of such customers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount and timing of operating expenses related to the maintenance and expansion of our business, operations, and infrastructure;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">network outages or security breaches;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">industry and market conditions, including within the life sciences industry;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general economic conditions, including the impact of increasing or decreasing inflation and interest rates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to collect receivables from our customers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of software purchased by our customers, including the mix of on-premise and hosted software sold during a period;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">variations in the timing of the sales of our software, which may be difficult to predict;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the pricing of our solutions and in our pricing policies or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and success of the introduction of new software solutions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers, or strategic collaborators;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the fair value of or receipt of distributions or proceeds on account of the equity interests we hold in our drug discovery collaborators, such as Structure Therapeutics and Nimbus;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of our drug discovery collaborators in developing and commercializing drug products for which we are entitled to receive milestone payments or royalties;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of the recognition of milestones achieved under our collaborative programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">variations in the number and size of milestones achieved under our collaborative programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of recognition of revenue of any payments from entering into collaborations or out-licensing our proprietary drug discovery programs, such as under our collaboration agreement with Novartis Pharma AG, or Novartis; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of expenses related to our drug discovery programs, the development or acquisition of technologies or businesses and potential future charges for impairment of goodwill from acquired companies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we recognize revenues from our hosted software solutions ratably over the term of the agreement, a significant upturn or downturn in sales of our hosted software solutions may not be reflected immediately in our operating results. As a result of these factors, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance and that our interim financial results are not necessarily indicative of results for a full year or for any subsequent interim period.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will likely require additional capital to fund our operations. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to devote substantial financial resources to our ongoing and planned activities, including the development of drug discovery programs and continued investment in our computational platform. We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we advance our proprietary drug discovery programs, initiate or progress preclinical and Investigational New Drug, or IND,-enabling studies, submit IND applications, initiate and progress clinical trials and invest in the further development of our computational platform. In addition, if we decide to complete clinical development and seek regulatory approval on our own, we expect to incur significant additional expenses. Furthermore, we incur additional costs associated with operating as a public company, as compared to when we were a private company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current drug discovery collaborators, from whom we are entitled to receive milestone payments upon achievement of various development, regulatory, and commercial milestones as well as royalties on commercial sales, if any, under the collaboration agreements that we have entered into with them, face numerous risks in the development of drugs, including the conduct of preclinical and clinical testing, obtaining regulatory approval, and achieving product sales. In addition, the amounts we are entitled to receive upon the achievement of such milestones tend to be smaller for near-term development milestones and increase if and as a collaborative product candidate advances through regulatory development to commercialization and will vary depending on the level of commercial success achieved, if any. We do not anticipate receiving significant milestone payments from many of our drug discovery collaborators for several years, if at all, and our drug discovery collaborators may never achieve milestones that would result in significant cash payments to us. In addition, while we have equity stakes in a number of our collaborators, the value of these equity stakes can vary significantly based on a number of factors beyond our control, and there can be no assurance that we can rely on such equity as capital to fund our operations. For these reasons we may need, or choose, to obtain additional capital to fund our continuing operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had cash, cash equivalents, restricted cash, and marketable securities of $367.5 million. In January 2025, we received the upfront payment of $150.0 million from Novartis in connection with entering into our research collaboration and license agreement with Novartis. We believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 24 months. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plans may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the growth of our software revenue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and extent of spending to support research and development efforts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the continued expansion of software sales and marketing activities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and receipt of payments from our drug discovery collaborations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">spending to support, advance, and broaden our proprietary drug discovery programs; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and receipt of any distributions or proceeds we may receive from our equity stakes in our drug discovery collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations and invest in our computational platform, we may not be able to compete successfully, which would harm our business, operations, and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or drug programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures, or declaring dividends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on terms that may not be favorable to us or agree to exploit a drug development target exclusively for one of our collaborators when we may prefer to pursue the drug development target for ourselves.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our estimates, judgments or assumptions relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, our beliefs of what could occur in the future considering available information and various other factors that we believe to be reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant judgment, assumptions and estimates used in preparing our consolidated financial statements include, with respect to revenue, determining the allocation of the transaction price and measurement of progress, including (1) the constraint on variable consideration, (2) the identification of performance obligations and the allocation of the transaction price to the performance obligations using their standalone selling price basis, and (3) the appropriate input or output based method to recognize collaboration revenue and the extent of progress to date.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on our reputation, business, financial position, and profit.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Software</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower prices, our business and operating results will suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to derive a significant portion of our software revenues from renewal of existing license agreements. As a result, maintaining the renewal rate of our existing customers and selling additional software solutions to them is critical to our future operating results. Factors that may affect the renewal rate for our customers and our ability to sell additional solutions to them include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the price, performance, and functionality of our software solutions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the availability, price, performance, and functionality of competing software solutions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effectiveness of our professional services;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to develop or acquire complementary software solutions, applications, and services;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the stability, performance, and security of our technological infrastructure; </span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the business environment of our customers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of our customers to continue to adopt computational approaches to drug discovery, which can be impacted by changes in our customer&#8217;s management and/or scientific personnel; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the decisions of our customers to discontinue or reduce the amount of drug discovery they undertake internally.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We deliver our software through either (i) a product license that permits our customers to install the software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access the cloud-based software solution on their own hardware without taking control of the licenses. Our customers have no obligation to renew their product licenses or subscriptions for our software solutions after the license term expires, which is typically after one year, and many of our contracts may be terminated or reduced in scope either immediately or upon notice. In addition, our customers may negotiate terms less advantageous to us upon renewal, which may reduce our revenues from these customers. Factors that are not within our control may contribute to a reduction in our software revenues. For instance, our customers may reduce the number of their employees who are engaged in research and who would have use of our software, which would result in a corresponding reduction in the number of user licenses needed for some of our solutions and thus a lower aggregate renewal fee. The loss, reduction in scope, or delay of a large contract, or the loss or delay of multiple contracts, could materially adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operating results also depend, in part, on our ability to sell new software solutions and licenses to our existing customers. For example, the willingness of existing customers to license our software will depend on our ability to scale and adapt our existing software solutions to meet the performance and other requirements of our customers, which we may not do successfully. If our customers fail to renew their agreements, renew their agreements upon less favorable terms or at lower fee levels, or fail to purchase new software solutions and licenses from us, our revenues may decline and our future revenues may be negatively impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our software sales cycle can vary and be long and unpredictable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of sales of our software solutions is difficult to forecast because of the length and unpredictability of our sales cycle. We sell our solutions primarily to biopharmaceutical companies, and our sales cycles can be as long as nine to twelve months or longer. Further, the length of time that potential customers devote to their testing and evaluation, contract negotiation, and budgeting processes varies significantly, depending on the size of the organization and the nature of their needs. In addition, we might devote substantial time and effort to a particular unsuccessful sales effort, and as a result, we could lose other sales opportunities or incur expenses that are not offset by an increase in revenue, which could harm our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our revenues are generated by sales to life sciences industry customers, and factors that adversely affect this industry could adversely affect our software sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our current software sales are to customers in the life sciences industry, in particular the biopharmaceutical industry. Demand for our software solutions could be affected by factors that adversely affect the life sciences industry. The life sciences industry is highly regulated and competitive and has experienced periods of considerable consolidation. Consolidation among our customers could cause us to lose customers, decrease the available market for our solutions, and adversely affect our business. In addition, changes in regulations that make investment in the life sciences industry less attractive or drug development more expensive could adversely impact the demand for our software solutions. For these reasons and others, selling software to life sciences companies can be competitive, expensive, and time consuming, often requiring significant upfront time and expense without any assurance that we will successfully complete a software sale. Accordingly, our operating results and our ability to efficiently provide our solutions to life sciences companies and to grow or maintain our customer base could be adversely affected as a result of factors that affect the life sciences industry generally.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also intend to continue leveraging our solutions for broad application to industrial challenges in molecule design, including in the fields of aerospace, energy, semiconductors, electronic displays, and chemicals. However, we believe the materials science industry is in the very early stages of recognizing the potential of computational methods for molecular discovery, and there can be no assurance that the industry will adopt computational methods such as our platform. Any factor adversely affecting our ability to market our software solutions to customers outside of the life sciences industry, including in these new fields, could increase our dependence on the life sciences industry and adversely affect the growth rate of our revenues, operating results, and business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The markets in which we participate are highly competitive, and if we do not compete effectively, our business and operating results could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall market for molecular discovery and design software is global, rapidly evolving, competitive, and subject to changing technology and shifting customer interests and priorities. Our software solutions face competition from competitors in the business of selling or providing simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a brand of Dassault Syst&#232;mes SE, or BIOVIA, Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, Cadence Design Systems, Inc., Optibrium Limited, Cyrus Biotechnology, Inc., Molsoft LLC, Insilico Medicine, Inc., Iktos, XtalPi Inc., AbCellera, Inductive Bio, Inc., Chemaxon, PerkinElmer, Inc., and Simulations Plus, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have competitors in materials science, such as BIOVIA and Materials Design, Inc., and in enterprise software for the life sciences, such as BIOVIA, Certara USA, Inc., Chemaxon, Revvity, Inc., and Dotmatics, Inc. In some cases, these competitors are well-established providers of these solutions and have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. In addition, there are academic consortia that develop physics-based simulation programs for life sciences and materials applications. In the life sciences industry, the most prominent academic simulation packages include AMBER, CHARMm, GROMACS, GROMOS, OpenMM, and OpenFF. These packages are primarily maintained and developed by graduate students and post-doctoral researchers, often without the intent of commercialization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded with the goal of applying machine learning technologies to drug discovery.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors are able to devote greater resources to the development, promotion, and sale of their software solutions and services. It is possible that our focus on proprietary drug discovery will result in loss of management focus and resources relating to our software business, thereby resulting in decreasing revenues from our software business. Furthermore, third parties with greater available resources and the ability to initiate or withstand substantial price competition could acquire our current or potential competitors. Our competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their product offerings or resources. If our competitors&#8217; products, services, or technologies become more accepted than our solutions, if our competitors are successful in bringing their products or services to market earlier than ours, if our competitors are able to respond more quickly and effectively to new or changing opportunities, technologies, or customer requirements, or if their products or services are more technologically capable than ours, then our software revenues could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are facing increasing competition from companies utilizing artificial intelligence, or AI, and other computational approaches for drug discovery. Some of these competitors are involved in drug discovery themselves and/or with partners, and others develop software or other tools utilizing AI which can be used, directly or indirectly, in drug discovery. To the extent these other AI approaches to drug discovery prove to be successful, or more successful, than our approach, the demand for our platform could be adversely affected, which could affect our software demand as well as reduce the demand for us as a collaborator in drug discovery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to decrease our prices or modify our pricing practices in order to attract new customers or retain existing customers due to increased competition. Pricing pressures and increased competition could result in reduced sales, reduced margins, losses, or a failure to maintain or improve our competitive market position, any of which could adversely affect our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform, often in response to our customers&#8217; requirements. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect our margins and operating results and that such investments may not generate sufficient revenues to offset liabilities assumed and expenses associated with these new investments. The software industry changes rapidly as a result of technological and product developments, which may render our solutions less desirable. For example, in recent years, a number of companies have entered the drug discovery industry utilizing different AI approaches. While we believe we compete favorably and are meaningfully differentiated from such approaches with the combination of our physics-based computational platform and machine learning capabilities, the success of other such AI approaches to drug discovery could impact the demand for our solutions. We believe that we must continue to invest a significant amount of time and resources in our platform and software solutions to maintain and improve our competitive position. If we do not achieve the benefits anticipated from these investments, if the achievement of these benefits is delayed, if technological developments render our solutions less desirable, or if a slowdown in general computing power impacts the rate at which we expect our physics-based simulations to increase in power and domain applicability, our revenue and operating results may be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to collect receivables from our customers, our operating results may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the majority of our current customers are well-established, large companies and universities, we also provide software solutions to smaller companies. Our financial success depends upon the creditworthiness and ultimate collection of amounts due from our customers, including our smaller customers with fewer financial resources. If we are not able to collect amounts due from our customers, we may be required to write-off significant accounts receivable and recognize bad debt expenses, which could materially and adversely affect our operating results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defects or disruptions in our solutions could result in diminishing demand for our solutions, a reduction in our revenues, and subject us to substantial liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software business and the level of customer acceptance of our software depend upon the continuous, effective, and reliable operation of our software and related tools and functions. Our software solutions are inherently complex and may contain defects or errors. Errors may result from our own technology or from the interface of our software solutions with legacy systems and data, which we did not develop. The risk of errors is particularly significant when a new software solution is first introduced or when new versions or enhancements of existing software solutions are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">released. We have from time to time found defects in our software, and new errors in our existing software may be detected in the future. Any errors, defects, disruptions, or other performance problems with our software could hurt our reputation and may damage our customers&#8217; businesses. If that occurs, our customers may delay or withhold payment to us, cancel their agreements with us, elect not to renew, make service credit claims, warranty claims, or other claims against us, and as a result, we could lose future sales. The occurrence of any of these events could result in diminishing demand for our software, a reduction of our revenue, an increase in collection cycles for accounts receivable, require us to increase our warranty provisions, or incur the expense of litigation or substantial liability.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely upon third-party providers of cloud-based infrastructure to host our software solutions. Any disruption in the operations of these third-party providers, limitations on capacity, or interference with our use could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource substantially all of the infrastructure relating to our hosted software solutions to third-party hosting services. Customers of our hosted software solutions need to be able to access our computational platform at any time, without interruption or degradation of performance, and we provide them with service-level commitments with respect to uptime. Our hosted software solutions depend on protecting the virtual cloud infrastructure hosted by third-party hosting services by maintaining its configuration, architecture, features, and interconnection specifications, as well as the information stored in these virtual data centers, which is transmitted by third-party internet service providers. Any limitation on the capacity of our third-party hosting services could impede our ability to onboard new customers or expand the usage of our existing customers, which could adversely affect our business, financial condition, and results of operations. In addition, any incident affecting our third-party hosting services&#8217; infrastructure that may be caused by cyber-attacks, natural disasters, fire, flood, severe storm, earthquake, power loss, telecommunications failures, terrorist or other attacks, and other similar events beyond our control could negatively affect our cloud-based solutions. A prolonged service disruption affecting our cloud-based solutions for any of the foregoing reasons would negatively impact our ability to serve our customers and could damage our reputation with current and potential customers, expose us to liability, cause us to lose customers, or otherwise harm our business. We may also incur significant costs for using alternative equipment or taking other actions in preparation for, or in reaction to, events that damage the third-party hosting services we use.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that our service agreements with our third-party hosting services are terminated, or there is a lapse of service, elimination of services or features that we utilize, interruption of internet service provider connectivity, or damage to such facilities, we could experience interruptions in access to our platform as well as significant delays and additional expense in arranging or creating new facilities and services and/or re-architecting our hosted software solutions for deployment on a different cloud infrastructure service provider, which could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our security measures are breached or unauthorized access to customer data is otherwise obtained, our solutions may be perceived as not being secure, customers may reduce the use of or stop using our solutions, and we may incur significant liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our solutions involve the collection, analysis, and storage of our customers&#8217; proprietary information and sensitive proprietary data related to the discovery efforts of our customers. As a result, unauthorized access or security breaches, as a result of third-party action, employee error, malfeasance, or otherwise could result in the loss of information, litigation, indemnity obligations, damage to our reputation, and other liability. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. In addition, if our employees fail to adhere to practices we have established to maintain a firewall between our drug discovery group, which we refer to as the Schr&#246;dinger therapeutics group, and our teams that work with software customers, or if the technical solutions we have adopted to maintain the firewall malfunction, our customers and collaborators may lose confidence in our ability to maintain the confidentiality of their intellectual property, we may have trouble attracting new customers and collaborators, we may be subject to breach of contract claims by our customers and collaborators, and we may suffer reputational and other harm as a result. Any or all of these issues could adversely affect our ability to attract new customers, cause existing customers to elect not to renew their licenses, result in reputational damage or subject us to third-party lawsuits or other action or liability, which could adversely affect our operating results. Our insurance may not be adequate to cover losses associated with such events, and in any case, such insurance may not cover all of the types of costs, expenses, and losses we could incur to respond to and remediate a security breach.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure to offer high-quality technical support services could adversely affect our relationships with our customers and our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers depend on our support organization to resolve technical issues relating to our solutions, as our software requires expert usage to fully exploit its capabilities. Certain of our customers also rely on us to troubleshoot problems with the performance of the software, introduce new features requested for specific customer projects, inform them about the best way to set up and analyze various types of simulations and illustrate our techniques for drug discovery using examples from publicly available data sets. We may be unable to respond quickly enough to accommodate short-term increases in customer demand for these support services. Increased customer demand for our services, without corresponding revenues, could increase costs and adversely affect our operating results. In addition, our sales process is highly dependent on the reputation of our solutions and business and on positive recommendations from our existing customers. Any failure to offer high-quality technical support, or a market perception that we do not offer high-quality support, could adversely affect our reputation, our ability to sell our solutions to existing and prospective customers and our business and operating results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our solutions utilize third-party open-source software, and any failure to comply with the terms of one or more of these open-source software licenses could adversely affect our business or our ability to sell our software solutions, subject us to litigation, or create potential liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our solutions include software licensed by third parties under any one or more open-source licenses, including the GNU General Public License, the GNU Lesser General Public License, the Affero General Public License, the BSD License, the MIT License, the Apache License, and others, and we expect to continue to incorporate open-source software in our solutions in the future. Moreover, we cannot ensure that we have effectively monitored our use of open-source software or that we are in compliance with the terms of the applicable open-source licenses or our current policies and procedures. There have been claims against companies that use open-source software in their products and services asserting that the use of such open-source software infringes the claimants&#8217; intellectual property rights. As a result, we and our customers could be subject to suits by third parties claiming that what we believe to be licensed open-source software infringes such third parties&#8217; intellectual property rights, and we may be required to indemnify our customers against such claims. Additionally, if an author or other third party that distributes such open-source software were to allege that we had not complied with the conditions of one or more of these licenses, we or our customers could be required to incur significant legal expenses defending against such allegations and could be subject to significant damages, enjoined from the sale of our solutions that contain the open-source software and required to comply with onerous conditions or restrictions on these solutions, which could disrupt the distribution and sale of these solutions. Litigation could be costly for us to defend, have a negative effect on our business, financial condition, and results of operations, or require us to devote additional research and development resources to change our solutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of open-source software may entail greater risks than use of third-party commercial software, as open-source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open-source licenses require that source code for software programs that interact with such open-source software be made available to the public at no cost and that any modifications or derivative works to such open-source software continue to be licensed under the same terms as the open-source software license. The terms of various open-source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market our solutions. By the terms of certain open-source licenses, we could be required to release the source code of our proprietary software, and to make our proprietary software available under open-source licenses, if we combine our proprietary software with open-source software in a certain manner. In the event that portions of our proprietary software are determined to be subject to an open-source license, we could be required to publicly release the affected portions of our source code, re-engineer all or a portion of our solutions, or otherwise be limited in the licensing of our solutions, each of which could reduce or eliminate the value of our solutions. Disclosing our proprietary source code could allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of sales. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our revenue, business, results of operations, and financial condition and the market price of our shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Drug Discovery</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never realize a return on our investment of resources and cash in our drug discovery collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our computational platform to provide drug discovery services to collaborators who are engaged in drug discovery and development. These collaborators include start-up companies, pre-commercial biotechnology companies, and large-scale pharmaceutical companies. When we engage in drug discovery with these collaborators, we typically provide access to our platform and platform experts who assist the drug discovery collaborator in identifying molecules that have activity against one or more specified protein targets. We historically have not received significant initial cash consideration for these services, except for the upfront payment of $55.0 million we received from Bristol-Myers Squibb Company, or BMS, upon entry into our collaboration agreement with BMS and the upfront payment of $150.0 million that we received in January 2025 from Novartis in connection with our entry into the research collaboration and license agreement with Novartis. However, we have received equity consideration in certain of our collaborators and/or the right to receive option fees, cash milestone payments upon the achievement of specified development, regulatory, and commercial sales milestones for the drug discovery targets, and potential royalties. From time to time, we have also made additional equity investments in our drug discovery collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never realize a return on our investment of resources and cash in our drug discovery collaborations. Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. Our drug discovery collaborators may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates. In addition, our ability to realize return from our drug discovery collaborations is subject to the following risks:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to our collaborations and may not perform their obligations as expected;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators may not pursue development or commercialization of any product candidates for which we are entitled to option fees, milestone payments, or royalties or may elect not to continue or renew development or commercialization programs based on results of clinical trials or other studies, changes in the collaborator&#8217;s strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators may delay clinical trials for which we are entitled to milestone payments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding our collaborators&#8217; product candidates being developed or commercialized and, consequently, may have limited ability to inform our stockholders about the status of, and likelihood of achieving, milestone payments or royalties under such collaborations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with any product candidates and products for which we are entitled to milestone payments or royalties if the collaborator believes that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product candidates discovered in drug discovery collaborations with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause our collaborators to cease to devote resources to the commercialization of any such product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">existing drug discovery collaborators and potential future drug discovery collaborators may begin to perceive us to be a competitor more generally, particularly as we advance our proprietary drug discovery programs, and therefore may be unwilling to continue existing collaborations with us or to enter into new collaborations with us;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a drug discovery collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution, or marketing of a product candidate or product, which may impact our ability to receive milestone payments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disagreements with drug discovery collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation, or the preferred course of development, might cause delays or terminations of the research, development, or commercialization of product candidates for which we are eligible to receive milestone payments, or might result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disputes or legal proceedings that could jeopardize or invalidate our or their intellectual property or proprietary information or expose us and them to potential litigation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators may infringe, misappropriate, or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborators could suffer from operational delays as a result of global health impacts, such as the recent COVID-19 pandemic; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug discovery collaborations may be terminated prior to our receipt of any significant value from the collaboration, which has happened to us in the past and may happen to us again in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug discovery collaborations may not lead to development or commercialization of product candidates that results in our receipt of option fees, milestone payments, or royalties in a timely manner, or at all. If any drug discovery collaborations that we enter into do not result in the successful development and commercialization of drug products that result in option fees, milestone payments, or royalties to us, we may not receive return on the resources we have invested in the drug discovery collaboration. Moreover, even if a drug discovery collaboration initially leads to the achievement of milestones that result in payments to us, it may not continue to do so.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on collaborators for the development and potential commercialization of product candidates we discover internally when we believe it will help maximize clinical and commercial opportunities for the product candidate. For example, under our research collaboration and license agreement with Novartis, we are responsible, together with Novartis, for the discovery of small molecule compounds directed against specified targets pursuant to mutually agreed research plans. After the identification of a development candidate in any project plan, Novartis will be solely responsible for the further preclinical and clinical development, manufacturing and commercialization of products containing all compounds resulting from such project plan. We cannot be certain that we will successfully identify development candidates for Novartis to develop and commercialize under our research collaboration and license agreement. Further, Novartis may not achieve the discovery, development, and commercial milestones for those development candidates that would result in additional payments to us.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize returns on our equity investments in our drug discovery collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize returns on our equity investments in our drug discovery collaborators. None of the drug discovery collaborators in which we hold equity generate revenue from commercial sales of drug products. They are therefore dependent on the availability of capital on favorable terms to continue their operations. In addition, if the drug discovery collaborators in which we hold equity raise additional capital, our ownership interest in and degree of control over these drug discovery collaborators will be diluted, unless we have sufficient resources and choose to invest in the drug discovery collaborator further or successfully negotiate contractual anti-dilution protections for our equity investment. The financial success of our equity investment in any collaborator will likely be dependent on a liquidity event, such as a public offering, acquisition, or other favorable market event reflecting appreciation in the value of the equity we hold. The capital markets for public offerings and acquisitions are dynamic, and the likelihood of liquidity events for the companies in which we hold equity interests could significantly worsen. Further, valuations of privately held companies are inherently complex due to the lack of readily available market data. If we determine that any of our investments in such companies have experienced a decline in value, we may be required to record an impairment, which could negatively impact our financial results. The fair value of our equity interests in public companies, such as Structure Therapeutics, may fluctuate significantly in future periods since we determine the fair value of such equity interests based on the market value of such companies&#8217; common stock as of a given reporting date. All of the equity we hold in our drug discovery collaborators is subject to risk of partial or total loss of our investment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our drug discovery collaborators have significant discretion in determining when to make announcements, if any, about the status of our collaborations, including about clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug discovery collaborators have significant discretion in determining when to make announcements about the status of our collaborations, including about preclinical and clinical developments and timelines for advancing the collaborative programs. While as a general matter we intend to periodically report on the status of our collaborations, our drug discovery collaborators, and in particular, our privately-held collaborators, may wish to report such information more or less frequently than we intend to or may not wish to report such information at all. The price of our common stock may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decline as a result of the public announcement of unexpected results or developments in our collaborations, or as a result of our collaborators withholding such information.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we believe that our computational platform has the potential to identify more promising molecules than traditional methods and to accelerate drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or our collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific approach focuses on using our platform technology to conduct "computational assays" that leverage our deep understanding of physics-based modeling and theoretical chemistry to design molecules and predict their key properties without conducting time-consuming and expensive physical experiments. Our computational platform underpins our software solutions, our drug discovery collaborations and our own proprietary drug discovery programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the results of certain of our drug discovery collaborators suggest that our platform is capable of accelerating drug discovery and identifying high quality product candidates, these results do not assure future success for our drug discovery collaborators or for us with our proprietary drug discovery programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our drug discovery collaborators are able to develop product candidates that demonstrate potential in preclinical studies, we or they may not succeed in demonstrating safety and efficacy of product candidates in human clinical trials. For example, in collaboration with us, Nimbus was able to identify a unique series of acetyl-CoA carboxylase, or ACC, allosteric protein-protein interaction inhibitors with favorable pharmaceutical properties that inhibit the activity of the ACC enzyme. Nimbus achieved proof of concept in a Phase 1b clinical trial of its ACC inhibitor, firsocostat, and later sold the program to Gilead Sciences, Inc., or Gilead Sciences, in a transaction valued at approximately $1.2 billion, comprised of an upfront payment and earn outs. Of this amount, $601.3 million has been paid to Nimbus to date, and we received a total of $46.0 million in cash distributions in 2016 and 2017. In December 2019, Gilead Sciences announced topline results from its Phase 2 clinical trial which included firsocostat, both as a monotherapy and in combination with other investigational therapies for advanced fibrosis due to nonalcoholic steatohepatitis, in which the primary endpoint was not met. Gilead Sciences is currently evaluating firsocostat in a Phase 2b clinical trial in combination with Novo Nordisk A/S&#8217;s semaglutide, a GLP-1 receptor agonist, for compensated cirrhosis due to nonalcoholic steatohepatitis. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify, discover or develop product candidates and may fail to capitalize on programs, collaborations, or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial, and human resources. As an organization, we are advancing SGR-1505, our clinical-stage MALT1 inhibitor, SGR-2921, our clinical-stage CDC7 inhibitor, and SGR-3515, our clinical-stage Wee1/Myt1 inhibitor. We have not yet advanced any other programs into clinical development, and we may fail to identify additional product candidates for development. Similarly, a key element of our business plan is to expand the use of our computational platform through an increase in software sales and drug discovery collaborations. A failure to demonstrate the utility of our platform by successfully using it ourselves to discover internal product candidates could harm our business prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited resources, we focus our research programs on protein targets where we believe our computational assays are a good substitute for experimental assays, where we believe it is theoretically possible to discover a molecule with properties that are required for the molecule to become a drug and where we believe there is a meaningful commercial opportunity, among other factors. The focus of our initial proprietary drug discovery programs was in the area of oncology, and we have only recently begun expanding into other therapeutic areas, including neurology and immunology. We may forego or delay pursuit of opportunities with certain programs, collaborations, or product candidates or for indications that later prove to have greater commercial potential. However, the development of any product candidate we pursue may ultimately prove to be unsuccessful or less successful than another potential product candidate that we might have chosen to pursue on a more aggressive basis with our capital resources. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, partnership, licensing, or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research programs may show initial promise in identifying potential product candidates internally or with collaborators, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our research methodology or that of any collaborator may be unsuccessful in identifying potential product candidates that are successful in clinical development;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the product candidates unmarketable or unlikely to receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our current or future collaborators may change their development profiles for potential product candidates or abandon a therapeutic area; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">new competitive developments may render our product candidates obsolete or noncompetitive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on contract research organizations to synthesize any molecules with therapeutic potential that we discover. If such organizations do not meet our supply requirements, or if such organizations do not otherwise perform satisfactorily, development of any product candidate we may develop may be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely and expect to continue to rely on third parties to synthesize any molecules with therapeutic potential that we discover, including SGR-1505, SGR-2921 and SGR-3515. Reliance on third parties may expose us to different risks than if we were to synthesize molecules ourselves. Our reliance on these third parties will reduce our control over these activities but will not relieve us of our responsibilities. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or synthesize molecules in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements, and we may not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us to progress viable product candidates for IND submissions or the necessary clinical trials and we will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates. The facilities of these third parties may also be affected by natural disasters, such as floods or fire, or geopolitical developments or public health pandemics or such facilities could face production issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement third-party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased expense, and may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or any third party may also encounter shortages in the raw materials or active pharmaceutical ingredient, or API, necessary to synthesize any molecule we may discover in the quantities needed for preclinical studies or clinical trials, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API. Even if raw materials or API are available, we may be unable to obtain sufficient quantities at an acceptable cost or quality. The failure by us or the third parties to obtain the raw materials or API necessary to synthesize sufficient quantities of any molecule we may discover could delay, prevent, or impair our development efforts and may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to establish or maintain collaborations to develop and commercialize any of the product candidates we discover internally, we may have to alter our development and commercialization plans for those product candidates and our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to rely on future collaborators for the development and potential commercialization of product candidates we discover internally when we believe it will help maximize the clinical and commercial opportunities of the product candidate. We face significant competition in seeking appropriate collaborators for these activities, and a number of more established companies may also be pursuing such collaborations. These established companies may have a competitive advantage over us due to their size, financial resources, and greater clinical development and commercialization expertise. Whether we reach a definitive agreement for such collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical studies and clinical trials, the likelihood of approval by the U.S. Food and Drug Administration, or FDA, or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop any product candidates or bring them to market.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company, we have very limited experience in clinical development, which may adversely impact the likelihood that we will be successful in advancing our programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we have very limited experience in clinical development. Our limited experience in designing, conducting and completing clinical development activities may adversely impact the likelihood that we will be successful in advancing our programs. Further, any predictions you make about the future success or viability of our proprietary drug discovery programs may not be as accurate as they could be if we had a history of conducting and completing clinical trials and developing our own product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other "pivotal study" of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In June 2024, the FDA issued draft guidance outlining the general requirements for diversity action plans. Unlike most guidance documents issued by the FDA, the guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of diversity action plans are specified in FDA guidance. In January 2025, in response to an executive order issued by President Trump on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website. The implications of this action are not yet known.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory landscape related to clinical trials in the European Union, or EU, recently evolved. The EU Clinical Trials Regulation, or CTR, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive applied until January 31, 2025. Additionally, sponsors were still permitted to choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. Beginning January 31, 2025, all ongoing trials are subject to the provisions of the CTR.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our proprietary drug discovery business grows, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. Our proprietary drug discovery business will need to transition to a business capable of supporting significant clinical development activities. We may not be successful in such a transition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in future clinical trials for any other product candidate we develop is critical to our success. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the severity of disease; size of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of clinical trial investigators with appropriate competencies and experience; support staff; the number of ongoing clinical trials in the same indication that compete for the same patients; proximity of patients to clinical sites; the number and availability of trial sites; the ability to comply with the eligibility and exclusion criteria for participation in the clinical trial; ability to obtain and maintain patient consents; patient compliance; the ability to monitor patients during and after treatment; and the impact of any health pandemic or epidemic. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product candidates. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products with competitors that have more clinical development experience than we do.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on, and plan to continue to rely on, third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on, and plan to continue to rely on, third-party contract research organizations, or CROs, in addition to other third parties such as research collaboratives and consortia, clinical data management organizations, medical institutions and clinical investigators, to conduct our ongoing, planned and future clinical trials, including for SGR-1505, SGR-2921 and SGR-3515. These contract research organizations and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such standards. We and these third parties are required to comply with current good clinical practices, or cGCP, which are regulations and guidelines enforced by the FDA for all of our products in clinical development. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that a given regulatory authority will determine that any of our clinical trials comply with cGCP regulations. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently rely on foreign CROs and contract manufacturing organizations, or CMOs, and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be subject to U.S. legislation, including sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. Moreover, in September 2024, the U.S. House of Representatives passed the BIOSECURE Act (H.R. 7085), and the Senate advanced a substantially similar bill (S.3558), which legislation, if passed and enacted into law, would restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, specifically named Chinese biotechnology companies and authorizes the U.S. government to impose such restrictions on entities transacting with additional Chinese biotechnology companies as a condition of U.S. government contract, grant, and loan funding. The legislation passed by the House of Representatives contains a grandfathering provision that would prevent disruption to the provision of services or products furnished under contracts with the targeted biotechnology companies entered before the effective date of the legislation until January 1, 2032. It is possible some of our contractual counterparties could be impacted by this legislation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities for the production of any product candidates, nor do we have plans to develop our own manufacturing operations. We rely and expect to continue to rely on third-party contract manufacturers for all of our required raw materials, drug substance, and finished drug product for the preclinical and clinical development of any product candidates we develop ourselves and for any commercial supply of approved products, if any. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conduct preclinical studies and clinical trials of our product candidates, we will need to identify suitable manufacturers with the capabilities to manufacture our compounds in large quantities in a manner consistent with existing regulations. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. If our manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any agreements with third-party manufacturers for the long-term supply of any of our product candidates. In the future, we may be unable to enter into agreements with third-party manufacturers for commercial supplies of our product candidates, or may be unable to do so on acceptable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including reliance on the third party for regulatory compliance and quality assurance; the possible breach of the manufacturing agreement by the third party; the possible misappropriation of our proprietary information, including our trade secrets and know-how; and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. If the third parties that we engage to supply any materials or manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would experience delays in advancing these trials while we identify and qualify replacement suppliers, and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them or any approved drug we may use in combination trials, it will be more difficult for us to develop our product candidates and compete effectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future results of operations and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse or unacceptable side effects are identified during the development or commercialization of our product candidates, we may need to abandon or limit our development and/or commercialization efforts for such product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If serious adverse events or undesirable side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. We, the FDA, comparable foreign regulatory authorities or an independent institutional review board may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, adverse events which had initially been considered unrelated to the study treatment may later, even following approval and/or commercialization, be found to be caused by the study treatment. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the U.S. Food and Drug Administration or other comparable foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for their intended uses. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. The results of our product candidates in preclinical studies may not be indicative of future results in our ongoing or later stage clinical trials. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, preclinical studies and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret trial results as we do, and more trials than we anticipated could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, initial, "topline", and preliminary data from our clinical trials that we announce or publish in the future may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, initial, preliminary or topline data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. We will also have to make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, initial, topline or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data we previously published. As a result, interim, initial, topline and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse differences between interim data and final data could significantly harm our reputation and business prospects and may cause volatility in the price of our common stock.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We conduct, and we intend to continue to conduct, clinical trials for our product candidates at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct, and we intend to continue to conduct, clinical trials for our product candidates at trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study satisfies certain conditions. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with cGCPs. The FDA must be able to validate the data from the trial, including, if necessary, through an onsite inspection. The trial population must also have a similar profile to the U.S. population and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful, except to the extent the disease being studied does not typically occur in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our product candidates or potential product candidates in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the conduct of clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include: clinical practice patterns and standards of care that vary widely among countries; non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials; administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema; foreign exchange rate fluctuations; and diminished protection of intellectual property in some countries.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and any current or future collaborators are unable to successfully complete clinical development, obtain regulatory approval for, or commercialize any product candidates, or experience delays in doing so, our business may be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our development efforts for our own proprietary drug discovery programs. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our and any current or future collaborators&#8217; development and commercialization programs will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful completion of necessary preclinical studies to enable the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful enrollment of patients in, and the completion of, the clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acceptance by the FDA or other regulatory agencies of regulatory filings for any product candidates we and our current or future collaborators may develop;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expanding and maintaining a workforce of experienced scientists and other technical specialists to continue to develop any product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for any product candidates we and our current or future collaborators may develop;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">making arrangements with third-party manufacturers for, or establishing, clinical and commercial manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing sales, marketing, and distribution capabilities for drug products and successfully launching commercial sales, if and when approved;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acceptance of any product candidates we and our current or future collaborators may develop, if and when approved, by patients, the medical community, and third-party payors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining coverage, adequate pricing, and adequate reimbursement from third-party payors, including government payors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patients&#8217; willingness to pay out-of-pocket in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">any restrictions resulting from a health epidemic or pandemic and its collateral consequences may result in internal and external operational delays and limitations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining a continued acceptable safety profile following receipt of any regulatory approvals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these factors are beyond our control, including clinical outcomes, the regulatory review process, potential threats to our intellectual property rights, and the manufacturing, marketing, and sales efforts of any current or future collaborator. Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If we or our current or future collaborators are unable to develop, receive marketing approval for, and successfully commercialize any product candidates, or if we or they experience delays as a result of any of these factors or otherwise, we may need to spend significant additional time and resources, which would adversely affect our business, prospects, financial condition, and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any product candidate that we may develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate we may develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payers and others in the medical community. Sales of medical products depend in part on the willingness of physicians to prescribe the treatment, which is likely to be based on a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination by these physicians that the products are safe, therapeutically effective and cost-effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that any of our product candidates, if approved for commercial sale, is safe, therapeutically effective and cost-effective as compared with competing treatments. Efforts to educate the medical community and third-party payers on the benefits of any product candidates we may develop may require significant resources and may not be successful. If any product candidates we may develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential advantages and limitations compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effectiveness of sales and marketing efforts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the clinical indications for which the product is approved;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of market introduction of competitive products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the availability of third-party coverage and adequate reimbursement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the prevalence and severity of any side effects; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">any restrictions on the use of our products, if approved, together with other medications.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no product candidates that have been approved for commercial sale, the use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">decreased demand for any product candidates we may develop;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significant costs to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduced resources of our management to pursue our business strategy; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability to commercialize any product candidates we may develop.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have insurance coverage in countries in which we conduct clinical trials and will need to increase our insurance coverage if we conduct clinical trials in additional countries or of additional product candidates or if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition with respect to our and our collaborators&#8217; product candidates from many biopharmaceutical and biotechnology companies. The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates that are competitive with or superior to our product candidates. Any product candidates that we successfully develop and commercialize, internally or with our collaborators, will compete with existing therapies and new therapies that may become available in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, there is intense competition in the field of oncology, which is a focus of our drug discovery efforts. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We also face competition in finding and establishing clinical trial sites, enrolling subjects for clinical trials, assessing combination studies and recruiting credible principal investigators and advisors from key clinical disciplines and academic centers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, with respect to our MALT1 inhibitor, SGR-1505, which we are advancing for the treatment of patients with relapsed or refractory B-cell malignancies, we are aware of several MALT1 inhibitors in clinical development, including by AbbVie Inc., Ono Pharmaceutical Co., Ltd., HotSpot Therapeutics, and Recursion Pharmaceuticals, Inc. In addition, we are also aware of other therapeutics, such as bi-specifics and CAR-Ts, both approved and in clinical development, for the treatment of B-cell lymphomas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our CDC7 inhibitor, SGR-2921, which we are advancing for the treatment of relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, we are aware of several CDC7 inhibitors in Phase 1 clinical development, including by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lin BioScience, Inc., and Cancer Research UK.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our Wee1/Myt1 inhibitor, SGR-3515, which we are advancing for the treatment of advanced solid tumors, we are aware of several Wee1 inhibitors in clinical development, including by Zentalis Pharmaceuticals, Debiopharm International SA, IMPACT Therapeutics, Inc., Shouyao Holdings Co. Ltd., BioCity Biopharma, and Aprea Therapeutics, Inc., as well as a Myt1 inhibitor in clinical development being advanced by Repare Therapeutics Inc. Furthermore, we are also aware of a Wee1/Myt1 inhibitor in preclinical development being advanced by Acrivon Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large pharmaceutical and biotechnology companies, in particular, have extensive experience in building and accessing networks of expert investigators, designing and conducting clinical trials, obtaining regulatory approvals, and manufacturing and commercializing biotechnology products. These companies also have significantly greater research and development and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal year ended December 31, 2024, sales to customers outside of the United States accounted for approximately 45% of our total revenues. Operating in international markets requires significant resources and management attention and subjects us to regulatory, economic, and political risks that are different from those in the United States. We have limited operating experience in some international markets, and we cannot assure you that our expansion efforts into other international markets will be successful. Our experience in the United States and other international markets in which we already have a presence may not be relevant to our ability to expand in other markets. Our international expansion efforts may not be successful in creating further demand for our solutions outside of the United States or in effectively selling our solutions in the international markets we enter. In addition, we face risks in doing business internationally that could adversely affect our business, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the need to localize and adapt our solutions for specific countries, including translation into foreign languages;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">data privacy laws which require that customer data be stored and processed in a designated territory or handled in a manner that differs significantly from how we typically handle customer data;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulties in staffing and managing foreign operations, including employee laws and regulations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">different pricing environments, longer sales cycles, and longer accounts receivable payment cycles and collections issues;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differences in healthcare systems, drug regulation and reimbursement, and drug discovery and development practices and technologies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">new and different sources of competition;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">weaker protection for intellectual property and other legal rights than in the United States and practical difficulties in enforcing intellectual property and other rights outside of the United States;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laws and business practices favoring local competitors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance challenges related to the complexity of multiple, conflicting, and changing governmental laws and regulations, including employment, tax, reimbursement and pricing, privacy and data protection, and anti-bribery laws and regulations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the transfer of funds;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in social, political, and economic conditions or in laws, regulations, and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse tax consequences, including the potential for required withholding taxes;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">global health pandemics or epidemics, such as the recent COVID-19 pandemic; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unstable regional, economic and political conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international agreements may provide for payment denominated in local currencies and our local operating costs are denominated in local currencies. Therefore, fluctuations in the value of the U.S. dollar and foreign currencies may impact our operating results when translated into U.S. dollars.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, with respect to our proprietary drug discovery programs, the ongoing war between Russia and Ukraine may impact the ability of our CROs in the region to produce materials we require to conduct certain of our preclinical studies. If we are unable to obtain alternative sources for such materials that we require, the ability for us to timely execute and complete certain of our preclinical studies may be adversely impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to manage our technical operations infrastructure, our existing customers, and our internal drug discovery team, may experience service outages, and our new customers may experience delays in the deployment of our solutions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant growth in the number of users and data that our operations infrastructure supports. We seek to maintain sufficient excess capacity in our operations infrastructure to meet the needs of all of our customers and to support our proprietary drug discovery programs. We also seek to maintain excess capacity to facilitate the rapid provision of new customer deployments and the expansion of existing customer deployments. In addition, we need to properly manage our technological operations infrastructure in order to support version control, changes in hardware and software parameters and the evolution of our solutions. However, the provision of new hosting infrastructure requires adequate lead-time. We have experienced, and may in the future experience, website disruptions, outages, and other performance problems. These types of problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in usage, and denial of service issues. In some instances, we may not be able to identify the cause or causes of these performance problems within an acceptable period of time. If we do not accurately predict our infrastructure requirements, our existing customers may experience service outages that may subject us to financial penalties, financial liabilities, and customer losses. If our operations infrastructure fails to keep pace with increased sales and usage, customers and our internal drug discovery team may experience delays in the deployment of our solutions as we seek to obtain additional capacity, which could adversely affect our reputation and adversely affect our revenues.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">tax</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> laws or in their implementation or interpretation could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax law may adversely affect our business or financial condition. The Tax Cuts and Jobs Act, or the 2017 Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, significantly revises the Internal Revenue Code of 1986, as amended, or the Code. The 2017 Tax Act, among other things, contains significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and limitation of the deduction for net operating losses, or NOLs, to 80% of current-year taxable income for losses arising in taxable years beginning after December 31, 2017 (though any such NOLs may be carried forward indefinitely). In addition, beginning in 2022, the 2017 Tax Act eliminates the option to deduct research and development expenditures currently and requires corporations to capitalize and amortize them over five years or 15 years (for expenditures attributable to foreign research).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the CARES Act, as part of Congress&#8217;s response to the COVID-19 pandemic, economic relief legislation was enacted in 2020 and 2021 containing tax provisions. The Inflation Reduction Act, or IRA, was also signed into law in August 2022. The IRA introduced new tax provisions, including a one percent excise tax imposed on certain stock repurchases by publicly traded companies. The one percent excise tax generally applies to any acquisition of stock by the publicly traded company (or certain of its affiliates) from a stockholder of the company in exchange for money or other property (other than stock of the company itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. Regulatory guidance under the 2017 Tax Act, the IRA, and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. Additional tax legislation may be enacted, and any such additional legislation could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the 2017 Tax Act, the IRA, and additional tax legislation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our NOLs and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had federal NOLs of approximately $204.5</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and state NOLs of approximately $129.5</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, which, if not utilized, generally begin to expire in 2025. As of December 31, 2024, we also had federal orphan drug credits and federal research and development tax credit carryforwards of approximately $31.3</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and state research and development tax credit carryforwards of approximately $2.7</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million. Unused credits begin to expire in 2025 and generally expire over time if they remain unused. These NOLs, orphan drug credits, and research and development tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, a corporation that undergoes an "ownership change," generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. We have performed an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">analysis through December 31, 2024 and determined that no such ownership change occurred in the periods presented. If such an ownership change were to occur in the future, our ability to use our NOLs and research and development tax credit carryforwards may be materially limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes, such as suspension of the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. As described above in "Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition," the 2017 Tax Act, as amended by the CARES Act, includes changes to U.S. federal tax rates and rules governing NOL carryforwards that may significantly impact our ability to utilize NOLs to offset taxable income in the future. In addition, state NOLs generated in one state cannot be used to offset income generated in another state. For these reasons, we may be unable to use a material portion of our NOLs and other tax attributes.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international operations subject us to potentially adverse tax consequences.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our taxable income in various jurisdictions worldwide based upon our business operations in those jurisdictions. These jurisdictions include Germany, United Kingdom, Japan, India and South Korea. The international nature and organization of our business activities are subject to complex transfer pricing regulations administered by taxing authorities in various jurisdictions. The relevant taxing authorities may disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, and our position were not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added, or similar taxes, and we could be subject to tax liabilities with respect to past or future sales, which could adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not collect sales and use, value added, and similar taxes in all jurisdictions in which we have sales, based on our belief that such taxes are not applicable or that we are not required to collect such taxes with respect to the jurisdiction. Sales and use, value added, and similar tax laws and rates vary greatly by jurisdiction. Certain jurisdictions in which we do not collect such taxes may assert that such taxes are applicable, which could result in tax assessments, penalties, and interest, and we may be required to collect such taxes in the future. Such tax assessments, penalties, and interest or future requirements may adversely affect our results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unanticipated changes in our effective tax rate could harm our future results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and various foreign jurisdictions, and our domestic and international tax liabilities are subject to the allocation of expenses in differing jurisdictions. Forecasting our estimated annual effective tax rate is complex and subject to uncertainty, and there may be material differences between our forecasted and actual tax rates. Our effective tax rate could be adversely affected by changes in the mix of earnings and losses in countries with differing statutory tax rates, certain non-deductible expenses as a result of acquisitions, the valuation of deferred tax assets and liabilities, and changes in federal, state, or international tax laws and accounting principles. Increases in our effective tax rate would reduce our profitability or in some cases increase our losses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to income tax audits by many tax jurisdictions throughout the world. Although we believe our income tax liabilities are reasonably estimated and accounted for in accordance with applicable laws and principles, an adverse resolution of one or more uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have acquired, and we may again in the future acquire, companies, businesses, solutions or technologies, which could divert our management&#8217;s attention, result in additional dilution to our stockholders, and otherwise disrupt our operations and adversely affect our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired, and we may again in the future acquire, businesses, solutions, or technologies that we believe could complement or expand our solutions, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have limited experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations, and technologies successfully, effectively manage the combined business following the acquisition or preserve the operational synergies between our business units that we believe currently exist. We cannot assure you that following any acquisition we would achieve the expected synergies to justify the transaction, due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">inability to integrate or benefit from acquired technologies or services in a profitable manner;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unanticipated costs or liabilities associated with the acquisition;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acquisition-related costs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulty integrating the accounting systems, operations, and personnel of the acquired business;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulty converting the customers of the acquired business onto our solutions and contract terms, including disparities in the revenues, licensing, support, or professional services model of the acquired company;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">diversion of management&#8217;s attention from other business concerns;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse effects to our existing business relationships with business partners and customers as a result of the acquisition;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential loss of key employees;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">use of resources that are needed in other parts of our business; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">use of substantial portions of our available cash to consummate the acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business, and financial position may suffer.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are primarily conducted at our facilities in New York, New York, Portland, Oregon, and Hyderabad, India, and our internal hosting facility located in Clifton, New Jersey. The occurrence of natural disasters or other catastrophic events could disrupt our operations. Any natural disaster or catastrophic event in our facilities or the areas in which they are located could have a significant negative impact on our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other intellectual property licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a number of license agreements pursuant to which we have been granted exclusive and non-exclusive worldwide licenses to certain patents, software code, and software programs to, among other things, reproduce, use, execute, copy, operate, sublicense, and distribute the licensed technology in connection with the marketing and sale of our software solutions and to develop improvements thereto. In particular, the technology that we license from Columbia University pursuant to our license agreements with them are used in and incorporated into a number of our software solutions which we market and license to our customers. For further information regarding our license agreements with Columbia University, see "Item 1. Business&#8212;License Agreements with Columbia University." Our license agreements with Columbia University and other licensors impose, and we expect that future licenses will impose, specified royalty and other obligations on us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements with them and might therefore terminate the license agreements, thereby delaying our ability to market and sell our existing software solutions and develop and commercialize new software solutions that utilize technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could market products and technologies similar to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of rights granted under the license agreement and other interpretation related issues;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the sublicensing of patent and other rights under any collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our collaborators; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. For example, our counterparties have in the past and may in the future dispute the amounts owed to them pursuant to payment obligations. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may experience delays in the development and commercialization of new software solutions and in our ability to market and sell existing software solutions, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our obligations under our existing or future drug discovery collaboration agreements may limit our intellectual property rights that are important to our business. Further, if we fail to comply with our obligations under our existing or future collaboration agreements, or otherwise experience disruptions to our business relationships with our prior, current, or future collaborators, we could lose intellectual property rights that are important to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to collaboration agreements with biopharmaceutical companies, pursuant to which we provide drug discovery services but have no ownership rights, or only co-ownership rights, to certain intellectual property generated through the collaborations. We are also party to a research collaboration and license agreement with Novartis for the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas, which also provides for joint ownership rights to certain intellectual property generated through the collaboration in certain scenarios. We may enter into additional collaboration agreements in the future, pursuant to which we may have no ownership rights, or only co-ownership rights, to certain intellectual property generated through the future collaborations. If we are unable to obtain ownership or license of such intellectual property generated through our prior, current, or future collaborations and overlapping with, or related to, our own proprietary technology or product candidates, then our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing collaboration agreements contain certain exclusivity obligations that require us to design compounds exclusively for our collaborators with respect to certain specific targets over a specified time period. Our future collaboration agreements may grant similar exclusivity rights to future collaborators with respect to target(s) that are the subject of such collaborations. Existing or future collaboration agreements may also impose diligence obligations on us. For example, existing or future collaboration agreements may impose restrictions on us from pursuing the drug development targets for ourselves or for our other current or future collaborators, thereby removing our ability to develop and commercialize, or to jointly develop and commercialize with other current or future collaborators, product candidates, and technology related to the drug development targets. Under our collaboration with Novartis, for example, we are prohibited from researching, developing, manufacturing, modifying, improving or commercializing any small molecule directed against collaboration targets ourselves or with a third party during a specified period and subject to specified exceptions. In spite of our best efforts, our prior, current, or future collaborators might conclude that we have materially breached our collaboration agreements. If these collaboration agreements are terminated, or if the underlying intellectual property, to the extent we have ownership or license of such intellectual property, fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technology identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a collaboration agreement, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of ownership or license granted under the collaboration agreement and other interpretation related issues;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which our technology and product candidates infringe on intellectual property of the collaborator of which we do not have ownership or license under the collaboration agreement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the assignment or sublicense of intellectual property rights and other rights under the collaboration agreement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our diligence obligations under the collaboration agreement and what activities satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our current or future collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, collaboration agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have owned, co-owned, or in-licensed under the collaboration agreements prevent or impair our ability to maintain our current collaboration arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, maintain, enforce, and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop, including SGR-1505, SGR-2921, and SGR-3515, and any trade secrets and know-how relevant to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and any product candidates we may develop that are important to our business and by in-licensing intellectual property related to our technology and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that we co-own with third parties or license from third parties. Therefore, these co-owned and in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of software and biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain, and laws of non-U.S. countries may not protect our rights to the same extent as the laws of the United States or vice versa. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we, our collaborators, and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in jurisdictions outside the United States, a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported co-owner of our patent rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such co-ownership.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, patents have a limited lifespan. In the United States, and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a jurisdiction-by-jurisdiction basis; however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or in-license may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates, including generic versions of such drugs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may not be aware of all third-party intellectual property rights or prior art potentially relating to our computational platform, technology, and any product candidates we may develop. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing of the priority application, or in some cases not published at all. Therefore, neither we nor our collaborators, or our licensor can know with certainty whether either we, our collaborators, or our licensor were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we, our collaborators, or our licensor were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our owned, co-owned, and in-licensed patent rights are highly uncertain. Moreover, our owned, co-owned, and in-licensed pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned, co-owned, or in-licensed current or future patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value of, or narrow the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scope of, our patent rights. For example, recent Supreme Court decisions have served to curtail the scope of subject matter eligible for patent protection in the United States, and many software patents have since been invalidated on the basis that they are directed to abstract ideas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to pursue protection based on our pending provisional patent applications, we will need to file Patent Cooperation Treaty applications, non-U.S. applications, and/or U.S. non-provisional patent applications prior to applicable deadlines. Even then, as highlighted above, patents may never issue from our patent applications, or the scope of any patent may not be sufficient to provide a competitive advantage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we, our collaborators, or our licensors may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate, our patent rights or allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us. If the breadth or strength of protection provided by our owned, co-owned, or in-licensed current or future patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future technology or product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned, co-owned, and in-licensed current and future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. In particular, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned, co-owned, or in-licensed current or future patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned, co-owned, and in-licensed current or future patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors, and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of software, biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cases decided by the U.S. Supreme Court have involved questions of when claims reciting abstract ideas, laws of nature, natural phenomena and/or natural products are eligible for a patent, regardless of whether the claimed subject matter is otherwise novel and inventive. These cases include Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 12-398 (2013) or Myriad; Alice Corp. v. CLS Bank International, 573 U.S. 13-298 (2014); and Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, 566 U.S. 10-1150 (2012). In response to these cases, federal courts have held numerous patents invalid as claiming subject matter ineligible for patent protection. Moreover, the USPTO has issued guidance to the examining corps on how to apply these cases during examination. As a result of these decisions, obtaining broad patents in the United States covering software innovations is more challenging than before.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change or be interpreted in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend any patents that may issue in procedures in the USPTO or in courts.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various deadlines and procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these deadlines and requirements. We may miss a filing deadline for patent protection on these inventions.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be paid. While an inadvertent lapse can be cured in some cases by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if a third-party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patent applications that we own or may in-license may not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patents, should they issue, that we may own or in-license, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or in-license, should any patents issue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or may in-license;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we, or our future licensors or collaborators, might not have been the first to file patent applications covering a particular invention;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent covering such trade secrets or know-how;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, our prior, existing, or future collaborators, and our existing or future licensors, may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate, or otherwise violate our, our prior, current and future collaborators&#8217;, or our current and future licensors&#8217; issued patents or other intellectual property. As a result, we, our prior, current, or future collaborators, or our current or future licensor may need to file infringement, misappropriation, or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could assert that the patents we, our collaborators, or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defenses alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, interference proceedings, derivation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings, and equivalent proceedings in non-U.S. jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse result in any such proceeding could put one or more of our owned, co-owned, or in-licensed current or future patents at risk of being invalidated or interpreted narrowly and could put any of our owned, co-owned, or in-licensed current or future patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned, co-owned, or in-licensed current or future patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products in a non-infringing manner and have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties, or brought by us or by our collaborators or licensor, or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us bring any product candidates to market.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our collaborators and licensor to develop, manufacture, market, and sell any product candidates we may develop and for our collaborators, licensor, customers, and partners to use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the software, pharmaceutical, and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, and derivation proceedings before the USPTO and similar proceedings in non-U.S. jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and non-U.S. issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as any product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, be forced to indemnify our customers, licensor, or collaborators or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to take a license or, if we are found to infringe, misappropriate, or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing any product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign any product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our employees, consultants, and contractors were previously employed at universities or other software or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require that our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for any product candidates and technology, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors, collaborators, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may inadvertently or intentionally breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position may be materially and adversely harmed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidates or any of our future product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of our competing products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments, to the FDCA, a company may file an ANDA, seeking approval of a generic version of an approved innovator product. Under the Hatch-Waxman Amendments, a company may also submit an NDA under section 505(b)(2) of the FDCA that references the FDA&#8217;s prior approval of the innovator product or preclinical studies and/or clinical trials that were not conducted by, or for, the sponsor and for which the sponsor has not obtained a right of reference. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Amendments also provide for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, third parties may file an ANDA or NDA under Section 505(b)(2) as early as the so-called &#8220;NCE-1&#8221; date that is one year before the expiry of the five-year period of New Chemical Entity exclusivity or more generally four years after NDA approval. The third parties are allowed to rely on the safety and effectiveness data of the innovator&#8217;s product, may not need to conduct clinical trials and can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, the major portion of revenues for that product may be dramatically reduced in a very short period of time. If we are not successful in defending our patents and regulatory exclusivities, we will not derive the expected benefit from them. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the Orange Book. If there are patents listed in the Orange Book for the applicable, approved innovator product, a generic or 505(b)(2) sponsor that seeks to market its product before expiration of the patents must include in their applications what is known as a &#8220;Paragraph IV&#8221; certification, challenging the validity or enforceability, or claiming non-infringement, of the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if any of our product candidates that are regulated as drugs are approved, competitors could file ANDAs for generic versions of these products or 505(b)(2) NDAs that reference our products. If there are patents listed for such drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA sponsor does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a new drug application from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act, or PREA, applications and certain types of supplements to applications must contain data to assess the safety and effectiveness of the product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of EMA, or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any of our product candidates for which we are seeking regulatory approval in the United States or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may determine that we must provide additional evidence and data before approving a BLA or NDA for our product candidates. For example, the FDA reviews an application to determine whether there is &#8220;substantial evidence&#8221; to support a finding of effectiveness for the proposed product for its intended use(s), The FDA has interpreted this evidentiary standard to generally require at least two adequate and well-controlled clinical trials to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional confirmatory evidence may satisfy this standard. The FDA issued draft guidance in September 2023 that outlines considerations for relying on confirmatory evidence in lieu of a second clinical trial to demonstrate effectiveness. In the event that we submit a BLA or NDA on the basis of one clinical trial and confirmatory evidence, the FDA could determine that such information is not sufficient to support approval of the application and the agency could require us to conduct an additional trial in support of a BLA or NDA</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court in 2024. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for example, the court overruled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., which for 40 years required federal courts to defer to permissible agency interpretations of statutes that are silent or ambiguous on a particular topic. The U.S. Supreme Court stripped federal agencies of this presumptive deference and held that courts must exercise their independent judgment when deciding whether an agency such as the FDA acted within its statutory authority under the Administrative Procedure Act, or the APA. Additionally, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corner Post, Inc. v. Board of Governors of the Federal Reserve System</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The decision appears to give prospective plaintiffs a personal statute of limitations to challenge longstanding agency regulations. Another decision, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities and Exchange Commission v. Jarkesy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell any product candidates we may develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying local regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our product candidates in any jurisdiction, which would materially impair our ability to generate revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the UK as a result of the withdrawal of the UK from the EU, commonly referred to as Brexit. The UK is no longer part of the European Single Market and EU Customs Union. As of January 1, 2025, the Medicines and Healthcare Products Regulatory Agency, or MHRA, is responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britain and Northern Ireland). At the same time, a new international recognition procedure, or IRP, will apply, which intends to facilitate approval of pharmaceutical products in the UK. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include EMA and regulators in the EU/European Economic Area member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S.). However, the concrete functioning of the IRP is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals may force us or our collaborators to restrict or delay efforts to seek regulatory approval in the UK for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the European Union pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our collaborators, may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our product candidates. If we, or our collaborators, are not able to use such pathways, we, or they, may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we, or they, receive them at all. In addition, even if an accelerated approval pathway is available to us, or our collaborators, it may not lead to expedited approval of our product candidates, or approval at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Similar risks to those described above are also applicable to any application that we, or our collaborators, may submit in other jurisdictions outside of the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the FDA or foreign regulatory agencies will agree with our, or our collaborators&#8217;, surrogate endpoints or intermediate clinical endpoints in any of our, or their, clinical trials, or that we, or our collaborators, will decide to pursue or submit any NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from the FDA or comparable foreign regulatory agencies, we, or our collaborators, will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, there can be no assurance that we will satisfy all FDA requirements, including new provisions, that govern accelerated approval. For example, with passage of the FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded and to submit progress reports on its post-approval studies to FDA every six months until the study is completed. Moreover, FDORA established expedited procedures authorizing FDA to withdraw an accelerated approval if certain conditions are met, including where a required confirmatory study fails to verify and describe the predicted clinical benefit or where evidence demonstrates the product is not shown to be safe or effective under the conditions of use. The FDA may also use such procedures to withdraw an accelerated approval if a sponsor fails to conduct any required post-approval study of the product with due diligence, including with respect to &#8220;conditions specified by the Secretary.&#8221; The new procedures include the provision of due notice and an explanation for a proposed withdrawal, and opportunities for a meeting with the FDA Commissioner or the FDA Commissioner&#8217;s designee and a written appeal, among other things. We will need to fully comply with these and other requirements in connection with the development and approval of any product candidate that qualifies for accelerated approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the FDA issued draft guidance that outlines its thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024 and January 2025, the FDA issued additional draft guidances relating to accelerated approval. These guidances describe FDA&#8217;s views on what it means to conduct a confirmatory trial with due diligence and how the FDA plans to interpret whether such a study needs to be underway at the time of approval. While these guidances are currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, a failure to obtain and maintain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. In July 2024, the FDA granted Fast Track designation to SGR-2921 in patients with relapsed or refractory acute myeloid leukemia.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate is intended to treat a serious condition and, if approved, offers a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a Committee for Medicinal Products for Human Use rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug exclusivity to one of our products, the FDA must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Congress passed the FDARA, which, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by the FDA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to obtain orphan drug designation in the European Union, we would need to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. There is no assurance that we would be able to meet that standard for any of our product candidates. Further, if we do obtain orphan drug designation for a candidate product in the EU, we will not be able to maintain that designation if we are not able to show, to the satisfaction of the EU regulatory authorities, that the product candidate is of significant benefit to patients over available commercial products for the indication in the EU and any additional products that are ahead of our product candidate in clinical development for the indication.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we may develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market such products, which could materially impair our ability to generate revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we may develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition and prospects. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we may develop and generate revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on such medicines, manufacturers or manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the labeling or marketing of a medicine;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the distribution or use of a medicine;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">requirements to conduct post-marketing clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receipt of warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of the medicines from the market;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">recall of medicines;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">suspension of any ongoing clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal to permit the import or export of our medicines;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any product candidates we may develop receive marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to healthcare practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our ability to develop and market new drug products may be impacted by litigation challenging the FDA&#8217;s approval of another company&#8217;s drug product. In April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a REMS. The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market but did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone, which the FDA authorized in 2016 and 2021, were arbitrary and capricious. In June 2024, the Supreme Court reversed that decision after unanimously finding that the plaintiffs (anti-abortion doctors and organizations) did not have standing to bring this legal action against the FDA. On October 11, 2024, the Attorneys General of three states (Missouri, Idaho and Kansas) filed an amended complaint in the district court in Texas challenging FDA&#8217;s actions. On January 16, 2025, the district court agreed to allow these states to file an amended complaint and continue to pursue this challenge.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the outcome of this litigation, our ability to develop new drug product candidates and to maintain approval of existing drug products could be delayed, undermined or subject to protracted litigation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new product candidates and services from being developed or commercialized in a timely manner, which could negatively impact our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, disruptions may result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with the change in presidential administrations in 2025, there is substantial uncertainty as to how, if at all, the new administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. There is also uncertainty as to how other measures being implemented by the Trump Administration across the government will impact our activities and those of the FDA and its operations. For example, the potential loss of FDA personnel could lead to further disruptions and delays in FDA review of our product candidates. Similarly, efforts by the new administration to substantially reduce research funding by the National Institutes of Health of medical research could have substantial direct or indirect impacts on our research activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for any of our product candidates that do receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through the first half of 2032 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indeed, under current legislation, the actual reductions in Medicare payments may vary up to 4%. The Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 sequester for two years, through the end of 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into 2032 and lowers the payment reduction percentages in 2030 and 2031.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts for Jobs Act in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. In June 2021, the United States Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the statute.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. During the first Trump Administration, the Congress and administration sought to overturn the ACA and related measures. Shortly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after taking office in January 2025, President Trump revoked numerous executive orders issued by President Biden, including at least two executive orders that were designed to further implement the ACA. We anticipate similar efforts to undermine the ACA, and the accompanying uncertainty, for the foreseeable future</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. While the HTA entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The HTA intends to boost cooperation among European Union member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the European Union level for joint clinical assessments in these areas. It will permit European Union member states to use common HTA tools, methodologies, and procedures across the European Union, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual European Union member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed, as well as impact our ability to find collaborators for our drug discovery programs on commercially acceptable terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have been the subject of considerable discussion in the United States. There have been several Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, the Department of Health and Human Services, or HHS, and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed laws allowing for the importation of drugs from Canada and a few states have passed legislation establishing working groups to examine the impact of a state importation program. Several states have submitted Section 804 Importation Program proposals to the FDA. In January 2024, the FDA approved Florida's plan for Canadian drug importation. Florida now has authority to import certain drugs from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each drug selected for importation, which must be approved by the FDA. Florida will also need to relabel the drugs and perform quality testing of the products to meet FDA standards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, HHS finalized a regulation that would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the IRA has been delayed by Congress until January 1, 2032.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, the HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. On January 17, 2025, CMS announced its selection of 15 additional drugs covered by Part D for the second cycle of negotiations. Thereafter, following the change in administrations, CMS issued a public statement on January 29, 2025, declaring that lowering the cost of prescription drugs is a top priority of the new administration and CMS is committed to considering opportunities to bring greater transparency in the negotiation program. The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We would be fully at risk of government action if our products or those of our partners are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these provisions of the IRA may cause some companies to shift their research portfolio and priorities more towards large molecules (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., biologics such as antibodies) rather than small molecules. Although we do have applications of our technology to biologics, we do not yet have the same validation or value for large molecule discovery as we do for small molecule discovery. Accordingly, if the IRA causes the pharmaceutical industry to pivot investment and portfolio strategy away from small molecule drug discovery and towards biologics, it could have a material adverse effect on the expected value of our drug discovery programs and also on the perceived value of using our software to develop product candidates. In addition, if investment levels and development interest in small molecule therapeutics decreased, it may become more difficult for us to enter into collaborations on commercially acceptable terms, or at all, for our proprietary drug discovery programs. If we are unable to find suitable collaborators and/or partners for our programs, we may be forced to fund and undertake development or commercialization activities on our own for more programs than we would otherwise expect to, or plan for, which could adversely affect our business and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, Merck &amp; Co., Inc., filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, other parties, including the U.S. Chamber of Commerce and other pharmaceutical companies also filed lawsuits in various courts with similar constitutional claims against HHS and CMS.  HHS has generally won substantive disputes in these cases, and various federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry. Certain of these cases are now on appeal, and on October 30, 2024, the Court of Appeals for the Third Circuit heard oral argument in three of these cases. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated "maximum fair price" under the law or for taking price increases that exceed inflation. In addition to the drug price negotiation program, the IRA established inflation rebate programs under Medicare Part B and Part D. These programs require manufacturers to pay rebates to Medicare if they raise their prices for certain Part B and Part D drugs faster than the rate of inflation. On December 9, 2024, with issuance of its 2025 Physician Fee Schedule final regulation, CMS finalized its rules governing the IRA inflation rebate programs. The new law also caps Medicare out-of-pocket drug costs at an estimated $2,000 a year beginning in 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for approved products, any of which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. This may be increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer, and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data and employee data, is subject to the European Union General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to any clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that such rules should apply to transfers of personal data from any clinical trial sites located in the EEA to the United States. In October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which serves as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022, and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision permits companies in the United States who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the European Union to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business internationally.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the withdrawal of the United Kingdom from the European Union, the United Kingdom&#8217;s Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the United Kingdom and the European Union have determined, through separate "adequacy" decisions, that data transfers between the two jurisdictions are in compliance with the United Kingdom&#8217;s Data Protection Act 2018 and the GDPR, respectively. In October 2023, the United Kingdom and the United States implemented a U.S.-U.K. "data bridge," which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the United Kingdom to the United States. Any changes or updates to these developments have the potential to impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric, or health data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#8217;s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors, or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation, and significant fines and penalties against us, and could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns. The Federal Trade Commission, or FTC, and state Attorneys General are aggressive in reviewing privacy and data security protections for consumers. For example, the FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be "unfair" under Section 5 of the Federal Trade Commission Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The agency is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States are also active in creating specific rules relating to the processing of personal information. For example, the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by GDPR. Because of this, we may need to engage in additional activities (e.g., data mapping) to identify the personal information we are collecting and the purposes for which such information is collected. In addition, we will need to ensure that our policies recognize the rights granted to consumers (as that phrase is broadly defined in the CCPA and can include business contact information), including granting consumers the right to opt-out of the sale of their personal information. Many other states are considering similar legislation. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023 and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, a number of other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business activities. There are also states that are considering or have already passed comprehensive privacy laws that will go into effect in the near future. There are also states that are specifically regulating health information that may affect our business. For example, Washington state recently passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. The rise in these types of lawsuits creates potential risk for our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are not determined to have violated these laws, investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, and the collaborators who use our computational platform, may be subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations. Failure to comply with such laws and regulations, may result in substantial penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and the collaborators who use our computational platform, may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our software solutions and any products for which we obtain marketing approval. Such healthcare laws and regulations include, but are not limited to, the federal health care Anti-Kickback Statute; federal civil and criminal false claims laws, such as the federal False Claims Act; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA; the Federal Food, Drug, and Cosmetic Act; the federal Physician Payments Sunshine Act; and analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and transparency laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. Violations of applicable healthcare laws and regulations may result in significant civil, criminal, and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements, and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of non-compliance with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished profits, and future earnings.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, be precluded from developing, manufacturing, and selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA, and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed, or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we further expand our operations outside of the United States, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements, and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations, and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also need to carefully navigate the current administration&#8217;s implementation of the FCPA and related statutes. On February 10, 2025, President Trump issued an Executive Order directing the Attorney General to review the guidelines and policies governing FCPA investigations and enforcement actions. Per the Executive Order, this review will result in new DOJ FCPA guidelines intended to enhance American economic competitiveness and to safeguard national security interests. During the 180-day review period, any new FCPA investigations and enforcement actions are to be suspended absent authorization from the Attorney General, and all existing FCPA investigations and enforcement actions will be reviewed. Additionally, after the Attorney General issues revised guidelines, the Executive Order directs her to assess whether &#8220;remedial measures&#8221; related to past FCPA actions are warranted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA, or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA, and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, and liquidity. The U.S. Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, U.S., or other authorities could also have an adverse impact on our reputation, our business, results of operations, and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government has recently made statements and taken certain actions that may lead to potential changes to U.S. and international trade policies, including imposing several rounds of tariffs and export control restrictions affecting certain products manufactured in China. In March 2018, the Trump administration announced the imposition of tariffs on steel and aluminum entering the United States and in June 2018, the Trump administration announced further tariffs targeting goods imported from China. Recently both China and the United States have each imposed tariffs indicating the potential for further trade barriers, including the U.S. Commerce Department adding numerous Chinese entities to its &#8220;unverified list,&#8221; which requires U.S. exporters to go through more procedures before exporting goods to such entities. It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry, and it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, some of our manufacturers and suppliers are located in China. Trade tensions and conflicts between the United States and China have been escalating in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regulations and policies of the governments of the United States or China, or due to geopolitical unrest and unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereby potentially disrupting their supply of material to us. For example, in February 2024, U.S. lawmakers called for investigations into and the imposition of possible economic sanctions against Chinese biotechnology companies WuXi AppTec and WuXi Biologics, or collectively WuXi, over alleged ties to the Chinese military.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in September 2024, the U.S. House or Representatives passed the BIOSECURE Act (H.R. 7085), and the Senate has advanced a substantially similar bill, which legislation, if passed by the Senate and enacted into law, would restrict the ability of U.S. biotechnology companies like us to purchase services or products from, or otherwise collaborate with, specifically named Chinese biotechnology companies, including WuXi, and authorizes the U.S. government to impose such restrictions on entities' transactions with additional Chinese biotechnology companies as a condition of U.S. government contract, grant and loan funding. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies to contract with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise received funding from, the U.S. government. Such disruptions could have adverse effects on the development of our product candidates and our business operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately, or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance, or codes of conduct. Furthermore, our employees may, from time to time, bring lawsuits against us for employment issues, including injury, discrimination, wage and hour disputes, sexual harassment, hostile work environment, or other employment issues. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal information technology systems, or those of our third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information (including but not limited to intellectual property, proprietary business information, and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors and other contractors and consultants who have access to our confidential information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, given the size and complexity of our internal information technology systems and those of our third-party vendors and other contractors and consultants, and the increasing amounts of confidential information that they maintain, our information technology systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information), which may compromise our system infrastructure, or that of our third-party vendors and other contractors and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consultants or lead to data leakage. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures that are effective against all such security threats. For example, third parties have in the past and may in the future illegally pirate our software and make that software publicly available on peer-to-peer file sharing networks or otherwise. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or those of our third-party vendors and other contractors and consultants, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our software could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any significant system failure, accident, or security breach to date, and believe that our data protection efforts and our investment in information technology reduce the likelihood of such incidents in the future, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party vendors and other contractors and consultants, it could result in a material disruption of our programs and the development of our services and technologies could be delayed. Furthermore, significant disruptions of our internal information technology systems or those of our third-party vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. Further, sophisticated cyber attackers (including foreign adversaries engaged in industrial espionage) are skilled at adapting to existing security technology and developing new methods of gaining access to organizations&#8217; sensitive business data, which could result in the loss of sensitive information, including trade secrets. For example, attackers have used artificial intelligence and machine learning to launch more automated, targeted and coordinated attacks against targets. Additionally, actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change-related risks and uncertainties and legal or regulatory responses to climate change could negatively impact our business, financial condition, results of operations, prospects and reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to increasing climate-related risks and uncertainties, many of which are outside of our control. Climate change may result in more frequent severe weather events, potential changes in precipitation patterns, and extreme variability in weather patterns, which can disrupt our operations as well as those of our vendors, suppliers, and collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Climate-related macroeconomic trends, including the transition to a lower carbon economy, the effects of carbon pricing, changes in public sentiment, and the potential enactment of climate-related rules and regulations, continue to evolve and may increase our legal, compliance and business costs. Further, increases in climate-related litigation instituted against companies, the cost of climate-related insurance premiums, and the implementation of a more robust business continuity plan and a disaster recovery plan could increase the costs necessary to maintain our operations or achieve any sustainability commitments we may make, which could harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We annually assess the impacts of our operations and of our customers on the climate. The execution and achievement of any future commitments that we may make or of any goals that we may set relating to climate change are subject to risks and uncertainties. Given the focus on sustainable investing and corporate sustainability, if we fail to adopt policies and practices to enhance environmental initiatives, our reputation and our customer and stakeholder relationships could be negatively impacted, which may make it more difficult for us to compete effectively or to gain access to financing on acceptable terms when needed, which would negatively affect our business, financial condition, results of operations, prospects, and reputation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical, financial, operational, scientific, software engineering, and other business expertise of our executive officers, as well as the other principal members of our management, scientific, clinical, and software engineering teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain "key person" insurance for any of our executives or other employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of the services of our executive officers or other key employees could impede the achievement of our development and sales goals in our software business and the achievement of our research, development, and commercialization objectives in our drug discovery business. In either case, the loss of the services of our executive officers or other key employees could seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals with the breadth of skills and experience required to successfully develop, gain regulatory approval of, and commercialize products in the life sciences industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal, and sales and marketing personnel, as well as software engineers and computational chemists, will also be critical to our success. In the technology industry, there is substantial and continuous competition for engineers with high levels of expertise in designing, developing, and managing software and related services, as well as competition for sales executives, data scientists, and operations personnel. Competition to hire these individuals is intense, and we may be unable to hire, train, retain, or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical and technology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors to assist us in formulating our research and development and commercialization strategy and advancing our computational platform. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited and our business would be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are pursuing multiple business strategies and expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our multiple business units and our growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we are pursuing multiple business strategies simultaneously, including activities in research and development, software sales, and collaborative and proprietary drug discovery. We believe pursuing these multiple business strategies offers financial and operational synergies, but these diversified operations place increased demands on our limited resources. Furthermore, we have recently experienced, and we expect to continue to experience, significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical and regulatory affairs. To manage our multiple business units and our ongoing and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and our management team&#8217;s limited attention and limited experience in managing a company with such ongoing and anticipated growth, we may not be able to effectively manage our multiple business units and the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations has led to and may continue to lead to significant costs and may divert our management and business development resources. Our management, personnel, and systems may not be adequate to support this future growth. Any inability to manage our multiple business units and growth could delay the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">execution of our business plans or disrupt our operations and the synergies we believe currently exist between our business units. In addition, adverse developments in one of these business units may disrupt these synergies.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares of common stock began trading on the Nasdaq Global Select Market on February 6, 2020. Prior to February 6, 2020, there was no public market for our common stock, and we cannot assure you that an active trading market for our shares will be sustained. As a result, it may be difficult for our stockholders to sell their shares without depressing the market price of our common stock, or at all.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors, and principal stockholders, if they choose to act together, have the ability to influence all matters submitted to stockholders for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2025, our executive officers and directors and our stockholders who beneficially owned more than 5% of our outstanding common stock, in the aggregate, beneficially owned shares representing approximately 51.0% of our common stock and all of our limited common stock, or, if the holder of our limited common stock exercised its right to convert each share of its limited common stock for one share of our common stock, approximately 57.1% of our common stock. As a result, if these stockholders were to choose to act together, they would be able to influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would influence the election of directors and approval of any merger, consolidation, or sale of all or substantially all of our assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This concentration of ownership control may:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delay, defer, or prevent a change in control;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">entrench our management and board of directors; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delay or prevent a merger, consolidation, takeover, or other business combination involving us that other stockholders may desire.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This concentration of ownership may also adversely affect the market price of our common stock.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is likely to continue to be, volatile. Since our initial public offering in February 2020 and through February&#160;19, 2025, the intraday price of our common stock has fluctuated from a low of $15.85 to a high of $117.00. As a result of volatility, our stockholders may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our investment in, and the success of, our software solutions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of our research and development efforts for our proprietary drug discovery programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiation and progress of preclinical studies and clinical trials for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">results of or developments in preclinical studies and clinical trials of any product candidates we may develop or those of our competitors or potential collaborators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of our drug discovery collaborators and any milestone or other payments we receive from such collaborators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">guidance or announcements by us with respect to our anticipated financial or operational performance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales of common stock by us, our executive officers, directors or principal stockholders, or others, or the anticipation of such sales;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">equity or debt financing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">market conditions in the biopharmaceutical sector;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general economic, industry, and market conditions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the societal and economic impact of public health epidemics; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the other factors described in this "Risk Factors" section.</span></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation, or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#8217;s attention and resources.</span></div><div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our actual operating results may differ significantly from our guidance.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have released, and may in the future release, guidance in our annual or quarterly earnings conference calls or releases, or otherwise, regarding our future performance that represents our management&#8217;s estimates as of the date of such guidance. Our guidance, which includes forward-looking statements, has been and will be based on projections prepared by our management. Neither our registered public accountants nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person expresses any opinion or any other form of assurance with respect to the projections.</span></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. The principal reason that we have released, and would continue to release, guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties.</span></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying any guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Our actual results have, and may in the future, vary from our guidance and the variations may be material.</span></div><div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we expect that we will make public statements regarding the expected timing of certain milestones and key events, such as the commencement and completion of preclinical and IND-enabling studies and clinical trials in our proprietary drug discovery programs as well as developments and milestones under our collaborations. For example, Structure Therapeutics has also made public statements regarding its expectations for the development of programs under collaboration with us, and Structure Therapeutics and other collaborators may in the future make additional statements about their goals and expectations related to collaborations with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future collaborators&#8217; drug discovery and development programs, the amount of time, effort, and resources committed by us and our current and future collaborators, and the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that our or our current and future collaborators&#8217; programs will advance or be completed in the time frames we or they announce or expect. If we or any collaborators fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected and the price of our common stock could decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price and trading volume for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We do not have control over these analysts. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analyst will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span></div><div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash, cash equivalents, and marketable securities and may not use them effectively.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the deployment and use of our cash, cash equivalents, and marketable securities and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock or in ways that our stockholders may not agree with. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations, and prospects and could cause the price of our common stock to decline.</span></div><div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings to fund the development and expansion of our business. Any determination to pay dividends in the future will be at the discretion of our board of directors. As a result, capital appreciation of our common stock, if any, will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock, impair our ability to raise capital through the sale of additional equity securities, and make it more difficult for our stockholders to sell their common stock at a time and price that they deem appropriate. As of February&#160;19, 2025, we had outstanding 63,874,200 shares of common stock and 9,164,193 shares of limited common stock. All of our outstanding shares of common stock, including shares of common stock issuable upon the conversion of shares of our limited common stock, are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act of 1933, as amended, in the case of our affiliates. In addition, certain of our executive officers, directors and affiliated stockholders have entered or may enter into Rule 10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule 10b5-1 plan may be amended or terminated in some circumstances. Our executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also filed a universal shelf registration statement on Form S-3 which allows us to offer and sell an indeterminate number of shares of common stock, preferred stock, depositary shares or warrants, or an indeterminate principal amount of debt securities, from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale. Moreover, certain holders of our common stock and our limited common stock have rights, subject to specified conditions, to include their shares in registration statements that we may file for ourselves or other stockholders and may require us to file Form S-3 registration statements covering their shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to an amended and restated sales agreement with Leerink Partners LLC (formerly SVB Securities LLC), or Leerink Partners, as sales agent, with respect to an "at the market" offering program, or the ATM, under which we could offer and sell, from time to time pursuant to our Form S-3, shares of our common stock having an aggregate offering price of up to $250.0 million, through Leerink Partners. The number of shares that are sold by Leerink Partners after we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">request that sales be made will fluctuate based on the market price of our common stock during the sales period and limits we set with Leerink Partners. Therefore, it is not possible to predict the number of shares that will be ultimately issued by us, if any, pursuant to the amended and restated sales agreement. As of December&#160;31, 2024, we have sold 323,085 shares of common stock for total net proceeds of $8.7 million, and have $241.1 million of common stock remaining available for sale under the ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have filed registration statements on Form S-8 to register shares of common stock that we may issue under our equity compensation plans. Shares registered under such registration statements are available for sale in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements and exercise of options.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. The Securities Exchange Act of 1934, as amended, or the Exchange Act, Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time and resources to these compliance initiatives, potentially at the expense of other business concerns, which could harm our business, financial condition, results of operations, and prospects. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs, and have made and will continue to make some activities more time-consuming and costly compared to when we were a private company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We frequently evaluate our compliance with these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a public company, we are obligated to develop and maintain proper and effective internal control over financial reporting. Any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting on an annual basis. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Pursuant to Section 404, we are also required to have our independent registered public accounting firm issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. In addition, if we have an unremediated material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm. For example, in connection with the audit of our consolidated financial statements for the year ended December 31, 2022, we and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting. While we remediated this material weakness as of December 31, 2023, we cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. If in the future we again identify a material weakness, we cannot assure you that any measures we may take in the future will be sufficient to remediate such material weakness or avoid the identification of additional material weaknesses in the future. If the steps we take do not remediate a future material weakness in a timely manner, there could be a reasonable possibility that this control deficiency or others could result in a material misstatement of our annual or interim financial statements that would not be prevented or detected on a timely basis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, or results of operations. If we are unable to conclude in the future that our internal control over financial reporting is effective, or if we or our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, the market price of shares of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and our bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish a classified board of directors such that only one of three classes of directors is elected each year;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limit who may call stockholder meetings to the board of directors or to the secretary at the request of the holders of at least 25% of the outstanding shares of our common stock and limited common stock; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a "poison pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers, and employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers, or employees, which may discourage such lawsuits against us and our directors, officers, and employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition, and operating results.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_25"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_28"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity.</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-41" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-42" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-43">We have certain processes for assessing, identifying and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, as well as secure our networks and systems.</ix:nonNumeric> Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and refine our practices.</ix:nonNumeric> We <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-44">engage certain external parties</ix:nonNumeric>, including consultants, computer security firms and risk management advisors, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-45">We consider the internal risk oversight programs of third-party service providers before engaging them in order to help protect our company from any related vulnerabilities.</ix:nonNumeric> As part of our overall risk mitigation strategy, we also maintain cybersecurity insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-46">We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect our company or our business strategy, results of operations or financial condition.</ix:nonNumeric></span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-50" continuedAt="f-50-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-49" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-48" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-51" continuedAt="f-51-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-52">The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.</ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-53" continuedAt="f-53-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-51-1"><ix:continuation id="f-50-1">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-54">vice president of information security</ix:nonNumeric> leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats.</ix:continuation></ix:continuation> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-55" escape="true">Our vice president of information security has over 15 years of information security experience, including in developing, overseeing and managing information technology and information security teams. He has been with our company since 2017 and has served as our vice president of information security since April 2023. He previously served as our executive director of information security from January 2022 through April 2023, senior director of information security from February 2019 through January 2022 and director of information security from June 2017 through February 2019. Prior to joining our company, our vice president of information security worked at several technology companies and served in roles of increasing responsibility with respect to information security during his tenure.</ix:nonNumeric></span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-53-1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a cybersecurity awareness program, which covers timely and relevant topics, including social engineering and phishing, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks throughout our information security systems. These tools are integrated into our comprehensive security framework, used to bolster our employee-based cybersecurity programs and are regularly updated to respond to evolving threats.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_31"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal facilities consist of office space. We occupy approximately 136,047 square feet of office space in New York, New York under a lease that currently expires in December 2037, 35,000 square feet of office space in Portland, Oregon under a lease that currently expires in September 2026, and 48,987 square feet of office space in Hyderabad, India under a lease that currently expires in April 2028. Additionally, we lease office space at our other office locations around the world. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_37"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_43"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol "SDGR" since February 6, 2020. Prior to that date, there was no public market for our common stock. Our limited common stock is not listed or traded on any stock exchange.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following performance graph and related information shall not be deemed to be "soliciting material" or to be "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, nor shall such information be incorporated by reference into any future filing under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total return on our common stock with the cumulative total return of the Nasdaq composite and the Nasdaq Biotechnology Index from February 6, 2020 (the first date that shares of our common stock were publicly traded on the Nasdaq Global Select Market) through December 31, 2024. The graph assumes an investment of $100 on February 6, 2020, in each of the foregoing indices and in our common stock. Data for each of the indices and our common stock assumes that all dividends were reinvested on the day of issuance, if any. The comparisons are not intended to forecast or be indicative of future performance of our common stock.</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="sdgr-20241231_g19.jpg" alt="Stock Performance Graph 2024 Image.jpg" style="height:403px;margin-bottom:5pt;vertical-align:text-bottom;width:744px"/></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2025, there were approximately 87 holders of record of our common stock and one holder of record of our limited common stock. The actual number of stockholders is greater than this number of holders of record and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock or our limited common stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved.]</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations covers fiscal 2024 and fiscal 2023 items and year-over-year comparisons between fiscal 2024 and fiscal 2023. Discussions of fiscal 2022 items and year-over-year comparisons between fiscal 2023 and 2022 that are not included in this Form 10-K can be found in "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that was filed with the SEC on February&#160;28, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a result of many factors, including those factors set forth in "Risk Factors" of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For further information regarding our forward-looking statements, see "Cautionary Note Regarding Forward-Looking Statements and Industry Data" in this Annual Report.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_52"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are transforming the way therapeutics and materials are discovered. Our differentiated, physics-based computational platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. Our software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. We are applying our computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding, we have been primarily focused on developing our computational platform, which is capable of predicting critical properties of molecules with a high degree of accuracy, as well as advancing drug discovery programs both with our collaborators and on our own. We have devoted substantially all of our resources to introducing new capabilities and refining our software, conducting research and development activities, recruiting skilled personnel, and providing general and administrative support for these operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last decade, we have entered into a number of collaborations with leading biopharmaceutical companies that have provided us with significant revenue and have the potential to produce additional milestone payments, option fees, and future royalties. In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics. In June 2022, the U.S. Food and Drug Administration, or FDA, cleared our first investigational new drug application, or IND, for our MALT1 inhibitor, which we refer to as SGR-1505. We have initiated dosing in a Phase 1 clinical trial of SGR-1505, which is designed as an open-label, multi-center dose escalation trial in patients with relapsed or refractory B-cell malignancies. The trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, maximum tolerated dose and/or recommended dose of SGR-1505. Exploratory cohorts will evaluate additional pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity, and safety to establish the recommended dose. We anticipate reporting initial data from the trial in the second quarter of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also completed a Phase 1 clinical trial of SGR-1505 in 73 healthy volunteers to gather additional data, including data relating to the safety, tolerability and pharmacokinetics of SGR-1505, as well as the effect of food and drug-drug interactions. In the healthy volunteer trial, SGR-1505 was generally well tolerated with no drug-related serious adverse events or dose limiting toxicities observed. In the trial, we observed that SGR-1505 achieved greater than 90 percent inhibition of IL-2 secretion in an activated T cell whole blood assay at 100mg twice a day (n=4), confirming target engagement and meeting the pharmacodynamic goals for the trial. Inhibition of IL-2 secretion is a marker for target engagement and pathway modulation as it is tightly linked to MALT1 and the downstream NF-&#954;B signaling. The data supported continued evaluation of SGR-1505 in the ongoing Phase 1 clinical trial in patients with relapsed or refractory B-cell malignancies. In addition, in August 2023, the FDA granted orphan drug designation to SGR-1505 for the potential treatment of mantle cell lymphoma.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the FDA cleared our IND for our CDC7 inhibitor, which we refer to as SGR-2921. In July 2024, the FDA granted Fast Track designation to SGR-2921 in patients with relapsed or refractory acute myeloid leukemia, or AML. In addition, in January 2025, the FDA granted orphan drug designation to SGR-2921 in patients with relapsed or refractory AML. We have initiated dosing in a Phase 1 clinical trial of SGR-2921, which is designed as an open-label, multi-center dose-escalation clinical trial in patients with relapsed or refractory AML or high-risk myelodysplastic syndrome. The trial is designed to evaluate the safety and tolerability of SGR-2921 as a monotherapy and to identify the recommended Phase 2 dose, including the maximum tolerated dose. Secondary and exploratory objectives of the trial include evaluating the pharmacokinetics and pharmacodynamics of SGR-2921 and investigating preliminary anti-tumor activity. We anticipate reporting initial data from the trial in the second half of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we also submitted an IND to the FDA for our novel Wee1/Myt1 inhibitor, which we refer to as SGR-3515, and the FDA cleared the IND in April 2024. We recently initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors. The trial is a dose-escalation trial designed to evaluate the safety, tolerability and recommended Phase 2 dose of SGR-3515. Secondary and exploratory objectives of the trial include evaluating the pharmacokinetics and preliminary anti-tumor activity of SGR-3515. We anticipate reporting initial data from the trial in the second half of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we launched an initiative to expand our computational platform to predict toxicity associated with binding to off-target proteins. The goal of this initiative is to develop a computational solution to improve the properties of drug development candidates and reduce the risk of development failure. The project is being funded initially by $19.5 million in grants from the Bill &amp; Melinda Gates Foundation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations to date principally from the sale of our equity securities, including our initial public offering and our follow-on public offering, and to a lesser extent, from sales of our software solutions and from upfront payments, research funding and milestone payments from our drug discovery collaborations, and from distributions on account of, or proceeds from the sale of, our equity stakes in our collaborators. In 2023, on account of our equity stake in Nimbus Therapeutics, LLC, or Nimbus, we received an aggregate of $147.2 million in cash distributions from Nimbus in connection with Takeda&#8217;s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its TYK2 inhibitor NDI-034858.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2024, Morphic Holding, Inc., or Morphic, one of our drug discovery collaborators and co-founded companies, was acquired by Eli Lilly and Company, or Lilly, for $57.00 per share, or approximately $3.2 billion. In connection with the acquisition, we received $47.6 million for the 834,968 shares of Morphic we owned. We are also entitled to low single-digit royalties on our clinical development programs under our collaboration agreement with Morphic, including MORF-057.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently conduct our operations through two reportable segments: software and drug discovery. The software segment is focused on selling our software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software segment generates revenue from software product licenses, hosted software subscriptions, software maintenance, professional services, and contributions. The revenue we generate through our software solutions from each of our customers varies largely depending on the type and number of software licenses our customers purchase from us. The licenses that our customers purchase from us provide them the ability to perform a certain number of calculations used in the design of molecules for drug discovery or materials science. The amount we charge per license depends on the specific software products our customers purchase from us, and the number of licenses needed to perform calculations per software product varies. With the exception of certain limited products, the number of licenses a customer requires is typically based on the scale at which they are running our software products and is not based on how many users have access to the software. As customers increase the number of licenses they purchase from us, they will typically be able to run a greater number of simultaneous instances of our products, thereby increasing the number of calculations they will be able to perform in parallel, subject to having enough computational capacity. We deliver our software through either (i) a product license that permits our customers to install the software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access our cloud-based software solution on their own hardware without taking control of licenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreements typically include upfront consideration, discovery, development, commercial and regulatory milestones, and royalties from future sales of commercialized products. We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones, and we have the potential to generate drug discovery revenue from commercial and regulatory milestones, option fees, and royalties under our collaboration agreements. In the future, we may also derive drug discovery revenue from our collaborations from option fees, the achievement of regulatory and commercial milestones, and royalties on commercial drug sales. In addition to revenue from our collaborations, we may also derive drug discovery revenue from collaborating on or out-licensing our proprietary drug discovery programs when we believe it will help maximize the clinical and commercial opportunities for the program.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company, or BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. After mutual agreement on the targets(s) of interest, we are responsible for the discovery of development candidates. Once a development candidate meeting specified criteria for a target has been identified, BMS will be solely responsible for the development, manufacturing and commercialization of such development candidate. We are eligible to receive up to $482.0 million in total milestone payments for the one remaining neurology target currently subject to the collaboration, of which we have recognized $32.0 million as of December&#160;31, 2024, as well as a tiered percentage royalty on net sales of each product commercialized by BMS ranging from mid-single digits to low-double digits, subject to certain specified reductions. See "Collaboration and License Agreement" in Note 3 to our consolidated financial statements for additional information relating to this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we entered into a collaboration with Lilly under which we are responsible for the discovery and optimization of small molecule compounds addressing an immunology target. Lilly will be responsible for the completion of preclinical development, clinical development and commercialization. Under the terms of the agreement, we received an upfront payment and we are eligible to receive up to $420.0 million in discovery, development and commercial milestone payments. We are also eligible to receive low single- to low double-digit royalties on net sales of any products emerging from the collaboration in all markets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we entered into a research collaboration and license agreement with Novartis Pharma AG, or Novartis, pursuant to which we and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. Under the terms of the research collaboration and license agreement, Novartis paid us an initial upfront fee of $150.0 million in January 2025 and we will be eligible to receive up to $2.272&#160;billion in total milestone payments across the initial programs. Such milestones consist of up to $892.0 million in discovery and development milestones and up to $1.38 billion in commercial milestones. We are also entitled to a tiered percentage royalty on net sales of each product commercialized by Novartis ranging from mid </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">single-digits to low double-digits, subject to certain specified reductions. No milestone revenue has been recognized as of December&#160;31, 2024. In November 2024, we also entered into an expanded three-year software agreement with Novartis that substantially increases Novartis' access to our computational predictive modeling technology and enterprise informatics platform. See "Collaboration and License Agreement" in Note 3 to our consolidated financial statements for additional information relating to this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, we generated total revenue of $207.5 million and had a net loss of $187.1 million.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_58"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Factors Affecting Our Performance</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ability to drive additional revenue from our software solutions from existing customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our large existing base of customers represents a significant opportunity for us to expand our revenue through increased utilization of our software. We had 1,752 and 1,785 active customers for the years ended December 31, 2024 and 2023, respectively. We define the number of active customers as the number of customers who had an annual contract value, or ACV, of at least $1,000 in the fiscal year. Included in the number of customers are entities we derive software contribution revenue from, which for the year ended December 31, 2024, consisted of Gates Ventures, LLC and the Bill &amp; Melinda Gates Foundation. We use $1,000 as a threshold for defining our active customers as this amount will generally exclude customers who only license our PyMOL software, which is our open-source molecular visualization system broadly available at low cost. The revenue that we generate through our software solutions from each of our customers varies depending on the number of licenses for each software solution that each customer purchases from us. Accordingly, we work with our customers to improve their experience and increase the utility of our platform in order to expand the scale at which they deploy our platform in their business. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an ACV at higher thresholds. For the year ended December 31, 2024, we had 61 customers with an ACV of at least $500,000 compared to 54 for the year ended December 31, 2023. Furthermore, we had 31, 27, and 18 customers with an ACV of at least $1.0 million for the years ended December 31, 2024, 2023, and 2022, respectively. We also had eight customers with an ACV of at least $5.0 million for the year ended December&#160;31, 2024, compared to four customers for each of the years ended December&#160;31, 2023 and 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, we define ACV as the contract value billed during the applicable period. For contracts with a duration of more than one year that are billed upfront, ACV in each period represents the total billed contract value divided by the term. ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. ACV is not intended to be a replacement for, or forecast of, revenue. Our ACV was $190.8 million and $154.2 million for the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ability to retain our customer base for our software solutions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another important driver of our performance is our ability to retain our customer base. We had 235, 222, and 227 customers with an ACV of at least $100,000 for the years ended December 31, 2024, 2023, and 2022, respectively. For the year ended December 31, 2024, our year-over-year customer retention rate for such customers was 95% and was 92% or higher for each of the previous 10 fiscal years. Our customer retention rate for our customers with an ACV of at least $500,000 was 100% for the year ended December 31, 2024 and 98% for the year ended December 31, 2023. We calculate year-over-year customer retention for our customers with an ACV of at least $100,000 or $500,000 by starting with the number of such customers we had in the previous fiscal year. We then calculate how many of these customers were active customers in the current fiscal year. We then divide this number by the number of customers with an ACV of at least $100,000 or $500,000, as applicable, that, we had in the previous fiscal year to arrive at the year-over-year customer retention rate for such customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our sales and marketing approach and the quality of our software solutions result in long-term relationships and high retention with our largest customers. This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest software customers in 2024 being nearly 21 years. Furthermore, we have significantly penetrated the pharmaceutical industry, with 19 of the top 20 pharmaceutical companies, measured by 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue, licensing our software in 2024. Our ability to continue to grow our software revenue is dependent upon our ability to retain customers through the continued support and investment in our sales and marketing efforts and the ongoing enhancement of our software solutions.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advancement of our collaborative programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a number of collaborations with leading biopharmaceutical companies to advance drug discovery. We will seek to enter into additional collaboration agreements, driven by the synergies we expect to achieve between our platform and the capabilities and expertise of our potential collaborators. We believe that our collaborations will be a significant driver of value for us in the form of equity stakes, research fees, preclinical, clinical, and commercial milestone payments, and option fees, as well as royalties on any potential future sales of products, if approved. We continue to work with our current collaborators to advance existing programs through discovery research stages and initiate additional programs. However, we do not generally exercise control over the development programs of our collaborators and depend on our collaborators' decisions with respect to clinical development and commercialization. Our ability to continue to derive value from our collaborations will be driven by our capability to make progress in these programs, whether our collaborators successfully advance such programs beyond the discovery stage, and the strategic priorities of our collaboration partners. We track the aggregate number of collaborative programs for which we are eligible to receive any amount of royalties on sales and as of December&#160;31, 2024, we had an aggregate of 13 collaborative programs for which we are eligible to receive future royalties compared to 12 collaborative programs as of December&#160;31, 2023.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ability to progress and expand our pipeline of proprietary drug discovery programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing our pipeline of proprietary programs through preclinical and clinical development. Our initial programs were focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Since then, we have expanded into other therapeutic areas, including immunology and neurology. We have initiated dosing in a Phase 1 clinical trial of SGR-1505 in patients with relapsed or refractory B-cell malignancies, a Phase 1 clinical trial of SGR-2921 in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome, and a Phase 1 clinical trial for SGR-3515 in patients with advanced solid tumors. We anticipate reporting initial data from the Phase 1 clinical trial of SGR-1505 in patients with relapsed or refractory B-cell malignancies in the second quarter of 2025, and from each of the Phase 1 clinical trial of SGR-2921 in patients with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome and the Phase 1 clinical trial for SGR-3515 in patients with advanced solid tumors in the second half of 2025. We continue to advance new programs where we can leverage our computational platform to discover novel molecules, including our programs targeting PRMT5-MTA, EGFR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">C797S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NLRP3, and LRRK2. As we progress and expand our pipeline of proprietary programs, we will strategically evaluate on a program-by-program basis advancing them ourselves, entering into collaborations to co-develop them with leading industry partners, or out-licensing them to maximize their probability of clinical and commercial success.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_61"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Products and Services Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software business generates revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On-premise software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our on-premise software license arrangements grant customers the right to use our software on their own in-house servers or their own cloud instances for a specified term, typically for one year, though in recent years, we have entered into a small number of large multi-year on-premise software license agreements. We recognize revenue for on-premise software license fees upfront, either upon transfer of control of the license or the effective date of the agreement, whichever is later.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hosted software. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hosted software revenue consists primarily of fees to provide our customers with hosted licenses, which allows these customers to access our cloud-based software solution on their own hardware without taking control of the licenses, and is recognized ratably over the term of the arrangement, which is typically one year, though in recent years, we have entered into a small number of large multi-year hosted software license agreements. When a customer enters into a hosted arrangement for which revenue is recognized over time, the amount paid upfront that is not recognized in the current period is included in deferred revenue in our statement of financial position until the period in which it is recognized.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software maintenance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Software maintenance includes technical support, updates, and upgrades related to our on-premise software licenses. Software maintenance revenue is recognized ratably over the term of the arrangement. Software maintenance activities are performed in connection with the use of our on-premise software, and may fluctuate from period to period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Professional services include training, technical setup, installation or assisting customers with modeling services, where we use our software to perform tasks such as virtual screening on behalf of our customers. These services are generally not related to the core functionality of our software and are recognized as revenue when resources are consumed. Since each professional services agreement represents a unique, ad hoc engagement, professional services revenue may fluctuate from period to period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software contribution revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Software contribution revenue consists of funds received under non-reciprocal agreements with Gates Ventures, LLC and the Bill &amp; Melinda Gates Foundation. The agreement with Gates Ventures, LLC was originally entered into in June 2020 and further extended through August 2026. The agreement is an unconditional non-exchange contribution without restrictions. Revenue is recognized annually, when invoiced, in accordance with Accounting Standard Codification, or ASC, Topic 958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Not-for-Profit Entities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or Topic 958,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the agreement is not an exchange transaction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we entered into a one-year agreement with the Bill &amp; Melinda Gates Foundation to initially fund our initiative to accelerate the expansion of our computational platform to predict toxicity associated with binding to off-target proteins. In November 2024, we entered into an expansion of the agreement which extends the funding and effort for this initiative through April 2026. Revenue is recognized as conditions are met and on a cost reimbursement basis in accordance with Topic 958.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Discovery Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate drug discovery revenue through the performance of specified research and development activities under our collaboration agreements and upon the achievement of discovery and development milestones, and we have the potential to generate drug discovery revenue from commercial and regulatory milestones, option fees, and royalties under our collaboration agreements. The majority of our current collaborations are in the discovery and preclinical development stages. Milestone payments typically increase in magnitude as a program advances. However, our focus is increasingly on investing in our proprietary drug discovery programs, which may result in a smaller number of collaborative programs over time and, as a result, fewer milestone payments on account of those collaborative programs. In addition to revenue from our collaborations, we may also derive drug discovery revenue from out-licensing our proprietary drug discovery programs when we believe it will help maximize the probability of clinical and commercial success of the program. Overall, we expect that our drug discovery revenue will fluctuate from period to period due to the inherently uncertain nature of the timing of milestone achievements and our dependence on the program decisions of our collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery contribution revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contribution revenue consists of funds received under agreements with the Bill &amp; Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women&#8217;s health. Revenue is recognized as conditions are met in accordance with Topic 958.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software products and services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cost of revenues for software includes personnel-related expenses (comprised of salaries, benefits, and stock-based compensation) for employees directly involved in the delivery of software solutions, maintenance and professional services, royalties paid for products sold and services performed using third-party licensed software functionality, and allocated overhead (facilities and information technology support) costs. Pursuant to various third-party arrangements, we license technology that is used in our software. These arrangements require us to pay royalties based on sales volume, and such royalty payments represented 3.5% and 4.1% of software revenues in the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue for drug discovery includes personnel-related expenses and costs of third-party contract research organizations, or CROs, that support discovery activities in our collaborations, royalties paid for services performed using third-party licensed software functionality, allocated compute capacity and overhead costs. While we have incurred costs associated with discovery efforts since late 2017, we have recognized and expect to continue to recognize </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenues in the future if and when milestones are deemed probable or achieved. Generally, drug discovery costs of revenue for collaborations are incurred in advance of the revenue milestone achievement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty payments to third-parties represented 9.5% and 3.5% of drug discovery revenues in the years ended December 31, 2024 and 2023, respectively. We expect our drug discovery costs of revenue to trend lower over time as we shift our focus to proprietary drug discovery programs. However, these trends will be impacted by the number and stage of our collaborative programs, especially in the case of new collaborative programs.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit represents revenue less cost of revenues. Gross margin is gross profit expressed as a percentage of revenue. Our software products and services gross margin may fluctuate from period to period as our revenue fluctuates, and as a result of changes in sales mix between on-premise and hosted software solutions due to timing of recognition. For example, the cost of royalties due for sales of our hosted software arrangements are recognized upfront, whereas the associated hosted software revenue for these arrangements is recognized over the term of the underlying agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the gross margin of our drug discovery business will fluctuate significantly from period to period depending on factors such as the timing of recognition of milestones, the number and mix of collaborative programs, and their respective stages of development, we expect the gross margins to generally trend higher over time as more programs advance to later stages of development, the milestones increase in size and our ongoing research and development obligations to such programs decline in cost.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense accounts for a significant portion of our operating expenses. We recognize research and development expense as incurred. Research and development expense consists of drug discovery and development program costs and costs incurred for continuous development of the technology and science that supports our computational platform, primarily:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation for employees engaged in research and development functions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with third-party CROs and consultants involved in our proprietary drug discovery programs; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">allocated compute capacity on our proprietary drug discovery programs and overhead (facilities and information technology support) costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expense to increase in absolute dollars as we continue to invest in activities related to discovery and development of our proprietary drug discovery programs, in advancing our computational platform, and as we incur expenses associated with hiring additional personnel directly involved in such efforts. The amount to which our research and development expense may increase in the future will also be dependent on our development plans for our proprietary drug discovery programs, including the timing of any partnering, collaboration or out-licensing decisions. At this time, we do not know, nor can we reasonably estimate, the nature, timing, or costs of the efforts that will be necessary to complete the development of any of our proprietary drug discovery programs.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expense consists primarily of personnel-related costs for our sales and marketing staff and application scientists supporting our sales efforts, including salaries, benefits, bonuses, and stock-based compensation. Other sales and marketing costs include promotional events that promote and expand knowledge of our company and platform, including industry conferences and events and our annual user group meetings in the United States and Europe, advertising, and allocated overhead costs. Due to the inherent scientific complexity of our software solutions, a high level of scientific expertise is needed to support our sales and marketing efforts. We plan to make focused investments in sales and marketing over the foreseeable future to foster the growth of our business as we aim to expand software sales to existing customers and increase our customer base.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists of personnel-related expenses associated with our executive, legal, finance, human resources, information technology, and other administrative functions, including salaries, benefits, bonuses, and stock-based compensation. General and administrative expense also includes professional fees for external legal, accounting and other consulting services, allocated overhead costs, and other general operating expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur additional expenses as a result of operating as a public company, including costs to comply with the rules and regulations applicable to companies listed on a U.S. securities exchange and costs related to compliance and reporting obligations pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In addition, as a public company, we expect to continue to incur increased expenses such as insurance and professional services. As a result, we expect the dollar amount of our general and administrative expense to increase for the foreseeable future.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Equity Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on equity investments consists of realized gains in the form of cash distributions from our equity investments.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value gains and losses consist of adjustments to the fair value of our equity investments, which may include Nimbus, Structure Therapeutics Inc., or Structure Therapeutics, and Morphic. We remeasure our investments at each period end.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that fair value gains and losses will fluctuate significantly in future periods.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of interest earned on our cash equivalents and marketable securities, interest expense, and transactional foreign exchange gains and losses.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of U.S. federal and state income taxes and income taxes in certain foreign jurisdictions in which we conduct business. We maintain a full valuation allowance on our federal and state deferred tax assets as we have concluded that it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December&#160;31, 2024 and 2023</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations data for the years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.060%"><tr><td style="width:1.0%"/><td style="width:38.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Software products and services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,127)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cost of revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,609)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(209,296)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177,448)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,848)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Gain on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(147,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,778)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,585&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196,782)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(185,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(228,630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227,843)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/M &#8211; not meaningful</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.393%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On-premise software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hosted software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software maintenance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software contribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total software products and services</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159,124&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug discovery services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug discovery contribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,542&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,368)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)%</span></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Software Products and Services Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On-premise software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in revenues for on-premise software during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily attributable to a decrease in multi-year customer contracts with upfront revenue recognition in the current period versus the comparable period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hosted software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in revenues for hosted software during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily due to customers switching from on premise to hosted software purchases, as well as increased spend from existing hosted customers and growth in new customers purchasing hosted software subscriptions, for which revenue is recognized ratably over the period of the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software maintenance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software maintenance revenues remained consistent during the year ended December 31, 2024 as compared to the year ended December 31, 2023 primarily due to the fluctuation of on-premise software renewal periods, including multi-year customer arrangements, in the current period versus the comparable period, as well as increased spend from existing customers. Software maintenance revenue is recognized ratably over the period of the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services revenues remained consistent during the year ended December 31, 2024 as compared to the year ended December 31, 2023 primarily due to the progress and completion of technology and modeling service projects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software contribution revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in software contribution revenues during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was due to the agreements with the Bill &amp; Melinda Gates Foundation entered into during the year ended December 31, 2024, aimed to accelerate the expansion of our computational software platform, and the extension of the agreement with Gates Ventures, LLC.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Discovery Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in revenues for drug discovery services during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily due to the timing and amount of collaboration milestones achieved, including $25.0 million received from BMS during the year ended December 31, 2023, as well as BMS electing not to proceed with further development for two programs during 2023, which resulted in increased revenue recognition due to the accelerated completion of our obligations related to such programs during the year ended December 31, 2023. This decrease was partially offset by collaboration milestones achieved in 2024, as well as the progress of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing and new collaborations. We expect that our revenue will fluctuate from period to period due to the inherently uncertain nature of the timing of milestone achievement and our dependence on the program decisions of our collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery contribution revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in drug discovery contribution revenue during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was due to fluctuation in allotted funds spent under an agreement with the Bill &amp; Melinda Gates Foundation, aimed at accelerating drug discovery in women&#8217;s health, which began in November 2021.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenues</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"/><td style="width:38.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software products and services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software products and services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in cost of revenues for software products and services during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was attributable to increases of approximately $4.3 million in cloud computing expense and approximately $3.3 million in personnel-related expense, partially offset by a decrease of approximately $0.2 million in royalty expense. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software products and services gross margin.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in software gross margin during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily due to an increase in expenses related to our agreement with the Bill &amp; Melinda Gates Foundation to accelerate the expansion of our computational software platform, partially offset by an increase in revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The decrease in cost of revenues for drug discovery during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was attributable to decreases of approximately $7.9 million in third-party CRO costs due to the discontinuation of certain collaboration projects and approximately $0.9 million in personnel-related expense reflecting the redeployment of our discovery organization towards proprietary drug discovery programs, partially offset by approximately $0.6 million in royalty expense and approximately $0.3 million in cloud computing expense.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant portion of our research and development costs have been external preclinical and clinical CRO costs, which we track on a program-by-program basis related to a product candidate, once the candidate has been identified. Our internal research and development costs are primarily personnel-related costs, rent expense, and other indirect costs and are not tracked on a program-by-program basis. All other research and development costs are related to non-program related costs. The following table summarizes our research and development expense for the years ended December 31, 2024 and 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.393%"><tr><td style="width:1.0%"/><td style="width:49.887%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.928%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.928%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.928%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External costs by program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGR-1505</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,693</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGR-2921</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGR-3515</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 17.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other early development candidates and unallocated costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total external costs for programs in preclinical and clinical development</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,284</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,670</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal costs for discovery, preclinical and clinical development:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,949</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,313</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total internal costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,495</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,964</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,531</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,132</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$201,785</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$181,766</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20,019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in external costs of $0.6 million during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily attributable to an increase in costs associated with the ongoing Phase 1 clinical trial and other development activities for SGR-2921, as well as other external research costs to support our early-stage product candidates, partially offset by a decrease in costs for SGR-1505 and SGR-3515 due to timing of work performed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in internal costs for programs in discovery, preclinical and clinical development of $8.5 million during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily attributable to an increase in personnel-related expense and rent expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in all other research and development expense during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was attributable to increases of approximately $4.8 million in personnel-related expense, approximately $3.5 million in cloud computing expense, approximately $1.4 million related to office rent, approximately $0.7 million related to professional services, and approximately $0.5 million in other expenses.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing Expense</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"/><td style="width:38.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in sales and marketing expense during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was attributable to increases of approximately $2.1 million in personnel-related expense, approximately $0.6 million in travel and entertainment expense, and approximately $0.3 million in cloud computing expense, partially offset by decreases of approximately $0.1 million related to office facilities and approximately $0.2 million in other expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.787%"><tr><td style="width:1.0%"/><td style="width:38.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expense during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was attributable to increases of approximately $5.0 million of personnel-related expense, approximately $2.2 million related to professional services, and approximately $0.4 million in cloud computing expense, partially offset by decreases of approximately $4.3 million in royalties related to cash distributions we received from Nimbus, approximately $0.5 million in amortization related to the acceleration of customer relationship intangible assets, approximately $0.4 million in travel and entertainment expense, approximately $0.1 million related to office facilities, and approximately $1.8 million in other expenses.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Equity Investments</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.727%"><tr><td style="width:1.0%"/><td style="width:43.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no gain on equity investments during the year ended December 31, 2024. The gain on equity investments during the year ended December 31, 2023 was due to the realized gain on our equity investment in Nimbus following the closing of Takeda's acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor, NDI-034858.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"/><td style="width:42.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value during the year ended December 31, 2024 was primarily due to an unrealized gain on our investment in Morphic of $23.5 million, partially offset by an unrealized loss on our investment in Structure Therapeutics of $18.1 million. The change in fair value during the year ended December 31, 2023 was due to an unrealized gain on our investment in Structure Therapeutics of $49.8 million, an unrealized gain on our investment in Nimbus of $1.9 million, and an unrealized gain on our investment in Morphic of $1.8 million.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"/><td style="width:42.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other income during the year ended December 31, 2024 as compared to the year ended December 31, 2023 was primarily attributable to a decrease of approximately $1.2 million in interest income on our investment portfolio and a decrease of approximately $0.6 million primarily related to unfavorable foreign currency fluctuations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"/><td style="width:42.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.105%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the year ended December 31, 2024 represents state income tax obligations and taxes in foreign jurisdictions for which we conduct business. Income tax expense for the year ended December 31, 2023 represents our federal and certain state income tax obligations and taxes in foreign jurisdictions for which we conduct business. As of December 31, 2024, we have a full valuation allowance on our U.S. federal and state deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we had federal and state net operating loss carryforwards of approximately $204.5 million and $129.5 million, respectively. The state net operating loss carryforwards will expire between 2025 and 2044, if not utilized. The federal net operating loss carryforwards are limited to 80% of taxable income generated in a given year and carry forward indefinitely. At December 31, 2024, we had federal orphan drug credits and federal research and development tax credit carryforwards of approximately $31.3 million and state research and development tax credit carryforwards of approximately $2.7 million. These carryforwards will expire between 2025 and 2044, if not utilized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our management has evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets, which are composed principally of net operating loss carryforwards and research and development credit carryforwards. Management has determined that it is more likely than not that we will not realize the benefits of our federal and state deferred tax assets and, as a result, a valuation allowance of $177.2 million and $136.0 million has been established at December 31, 2024 and 2023, respectively. The change in the valuation allowance for the years ended December 31, 2024 and 2023 was $41.2 million and $1.9 million, respectively. We recorded income tax expense of $1.4 million and $2.2 million for the years ended December 31, 2024 and 2023, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">141</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our selected unaudited quarterly results of operations data for each of the eight quarters in the period ended December 31, 2024. The information for each of these quarters has been prepared on the same basis as our audited annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements included elsewhere in this Annual Report. Historical results are not necessarily indicative of the results that may be expected for the full fiscal year or any other period.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software products and services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">79,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">68,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">88,317&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">47,334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36,598&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">74,126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42,569&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64,782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cost of revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software products and services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">24,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17,708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16,576&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">21,379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19,089&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">57,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">49,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">50,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">50,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">50,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">51,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">40,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sales and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">24,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84,842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">86,150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">86,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87,171&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">79,832&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">74,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">76,194&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(20,712)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(68,422)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(52,729)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(67,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(29,621)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(56,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(61,133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(30,501)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(Loss) gain on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">147,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(22,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">40,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(18,541)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30,196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,235)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,891)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8,718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">44,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">185,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(39,253)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(38,226)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(53,964)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(54,268)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(31,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(64,911)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(16,153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">155,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(20,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(40,216)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(38,136)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(54,047)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(54,724)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(30,670)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(62,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">129,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:53.68pt">Includes stock-based compensation as indicated in the table located further below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">On-premise software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">53,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">19,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Hosted software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software maintenance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.6pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Revenue from contracts </span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;&#160;&#160;with customers</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">74,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">68,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software contribution </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total software products</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;&#160;&#160;and services revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">79,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">68,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery contribution </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total drug discovery revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">88,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">47,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">74,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">35,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64,782&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">March&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">46,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">47,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">57,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">62,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Margin:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three Months Ended </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">March&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">June&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software products and services</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;&#160;&#160;gross margin</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Stock-based compensation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cost of revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software products and</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;&#160;&#160;services</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total stock-based</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;&#160;&#160;compensation expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,808&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,218&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">September&#160;30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Depreciation and <br/>&#160;&#160;&#160;amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cost of revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Software products and services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Drug discovery</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total depreciation and amortization</span></div><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;&#160;&#160;expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Revenue Trends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On-premise software revenue is subject to seasonality that generally favors the first and fourth quarter of each year, primarily due to the timing of customer renewals for on-premise software arrangements, for which revenue is recognized at a single point in time. Hosted software revenue grew more steadily over the periods presented, as existing customers and new customers increased their spend on hosted solutions, for which revenue is recognized ratably over the term of the contract. As a result, a portion of the software products and services revenue we reported in each period was attributable to sales we made in prior periods. Software maintenance revenue is related to on-premise software sales and also is recognized ratably over the term of the underlying agreement. Therefore, increases or decreases in customer sales, customer expansion, or renewals in a period may not be immediately reflected in revenue for the period. Our professional services arrangements are typically project-based and, therefore, fluctuated based on individual customer needs and ongoing project support. Drug discovery revenue fluctuated from period to period based on the achievement of specific collaboration milestones, as well as advancements of collaborative services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments typically increase in magnitude as a program advances.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Deferred Revenue Trends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of the unearned portion of customer billings, which is recognized as revenue in accordance with our revenue recognition policy, as well as the unearned portion of unbilled collaboration milestones that are deemed probable in advance of actual achievement. Deferred revenue balances have fluctuated based on the measurement of progress toward completion for service projects, the timing of sales, shifts in product mix, and fluctuations to the number and size of milestones that were deemed probable in advance of actual achievement.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Gross Margin Trends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our software products and services gross margin experienced fluctuations over the periods presented due to increased headcount and the product mix for software and services, as the cost of royalties due on sales of our hosted software is recognized upfront, while the associated revenue is recognized over the term of the related agreement. Currently, gross margin is less meaningful for measuring the operating results of our drug discovery business.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Operating Expense Trends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses generally increased during the periods presented due to increased headcount and personnel-related expenses involved in research and development, sales and marketing, general and administrative activities, and CRO costs related to our proprietary drug discovery programs. These increases in headcount across our operations have supported the overall growth and management of our business. CRO cost increases were driven by the expansion and progression of our proprietary drug discovery programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quarterly Other (Expense) Income Trends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income during the periods presented consisted primarily of fair value gains and losses related to our equity investments in Morphic and Structure Therapeutics, and, to a lesser degree, interest income.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Note 14 &#8211; Segment Reporting in our audited consolidated financial statements for additional information regarding our segments.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_73"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a history of significant operating losses and have incurred negative cash flows from operations from inception through the year ended December&#160;31, 2024. As of December&#160;31, 2024, we had an accumulated deficit of $525.5 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have funded our operations to date principally from the sale of our equity securities, including our initial public offering and our follow-on public offering, and to a lesser extent, from sales of our software solutions and from upfront payments, research funding and milestone payments from our drug discovery collaborations, and from distributions on account of, or proceeds from the sale of, our equity stakes in our collaborators. Our operating cash flows are impacted by the magnitude and timing of our software sales and by the magnitude and timing of our drug discovery milestone achievements and research funding fees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2024, we filed a universal shelf registration statement on Form S-3 which allows us to offer and sell an indeterminate number of shares of common stock, preferred stock, depositary shares or warrants, or an indeterminate principal amount of debt securities, from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, we entered into an amended and restated sales agreement with Leerink Partners LLC (formerly SVB Securities LLC), or Leerink Partners, as sales agent, with respect to an at-the-market offering program, or the ATM, under which we could offer and sell, from time to time pursuant to our Registration Statement on Form S-3, shares of common stock, having an aggregate offering price of up to $250.0 million through Leerink Partners. The amended and restated sales agreement amends and restates the original sales agreement that we entered into with Leerink Partners with respect to the ATM in May 2023, which is no longer in effect. As of December&#160;31, 2024, 323,085 shares of common stock, were sold under the ATM for total net proceeds of $8.7 million and gross proceeds of $8.9 million, before deducting sales agent commissions. As of December&#160;31, 2024, we had $241.1 million of common stock remaining available for sale under the ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had cash, cash equivalents, restricted cash, and marketable securities of $367.5 million. In January 2025, we received the upfront payment of $150.0 million from Novartis in connection with entering into our research collaboration and license agreement with Novartis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash, cash equivalents, and marketable securities as of December&#160;31, 2024, together with the upfront payment we received from Novartis, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 24 months. Our future capital requirements will depend on many factors, including the growth of our software revenue, the timing and extent of spending to support research and development efforts, the continued expansion of software sales and marketing activities, the timing and receipt of milestone payments from our collaborations, as well as spending to support, advance, and broaden our proprietary drug discovery programs. Furthermore, our capital requirements will also change depending on the timing and receipt of any distributions we may receive from our equity stakes in our drug discovery collaborators. The potential for these distributions, and the amounts which we may be entitled to receive, are difficult to predict due to the inherent uncertainty of the events which may trigger such distributions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to utilize the existing cash, cash equivalents, and marketable securities on hand primarily to fund our software and drug discovery activities. With respect to our proprietary drug discovery programs, as part of our strategy we may choose to advance them into preclinical and clinical development ourselves, enter into collaborations to co-develop them with leading industry partners, or out-license them to maximize their clinical and commercial opportunities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to seek additional equity or debt financing. In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to maintain or expand our operations and invest in our platform, we may not be able to compete successfully, which would harm our business, operations and financial condition. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations as of December&#160;31, 2024 include lease obligations of $177.5 million, consisting of our continuing rent obligations through December 2037, primarily for our office located in New York, New York for $136.0 million, which expires in December 2037. In addition, see Note 6 &#8211; Commitments and Contingencies to our consolidated financial statements appearing in Item 8 of this Annual Report for more information relating to our operating lease obligations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we entered into an agreement with a third-party to establish an exclusive integrated drug discovery dedicated facility in Hyderabad, India. The agreement contains a minimum payment obligation, which totals $21.8 million over five years after the date of first occupancy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into a five-year agreement with a third-party cloud provider for compute power. The agreement contains a minimum payment obligation, which totals $60.0 million over the five years after the date we entered into the agreement. There is no annual commitment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into agreements in the normal course of business with CRO vendors for research, preclinical studies, and clinical trials, professional consultants for expert advice, and other vendors for various products and services. These contracts do not contain any minimum purchase commitments and are cancellable at any time by us, generally upon 30 days prior written notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. We have also agreed to pay volume-based royalties to third-parties for use of software functionality under various licensing and related agreements. See Note 2 &#8211; Significant Accounting Policies to our audited consolidated financial statements appearing in Item 8 of this Annual Report for more information relating to our royalty obligations.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of our cash flows for the periods shown:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.212%"><tr><td style="width:1.0%"/><td style="width:67.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,349&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, operating activities used approximately $157.4 million of cash, primarily due to a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $187.1 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which included changes to our operating assets and liabilities of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $13.1 million, a $5.7 million non-cash gain on changes in fair value, and $1.4 million of non-cash operating expenses, depreciation and investment accretion costs. These items were partially offset by $49.9 million of stock-based compensation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, operating activities used approximately $136.7 million of cash, due to a $147.2 million gain from equity investments, of which the cash received is included in investing activities, $53.5 million of non-cash gain on changes in fair value, $22.4 million in changes in our operating assets and liabilities, and $2.1 million of non-cash operating expenses. These items were offset by a net income of $40.7 million, including depreciation and investment accretion costs and $47.8 million in stock-based compensation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, investing activities provided approximately $148.8 million of cash, consisting of $110.4 million provided by marketable securities maturities, net of purchases, and $48.8 million primarily provided by the disposition of equity investments. These items were partially offset by $7.3 million in cash used for purchases of property and equipment and $3.1 million primarily used for purchases of our equity investment in Ajax Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, investing activities provided approximately $193.0 million of cash, consisting of $147.2 million cash distributions received, on account of our equity investment in Nimbus, from Nimbus in connection with Takeda&#8217;s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its TYK2 inhibitor NDI-034858 and $63.3 million provided by marketable securities maturities, net of purchases. These items were partially offset by $13.4 million in cash used for purchases of property and equipment, and $4.1 million used for purchases of our equity investment in Structure Therapeutics.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, financing activities provided approximately $10.1 million of cash, consisting of $8.7 million attributable to net proceeds received from the ATM and $1.4 million attributable to proceeds received from stock option exercises.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, financing activities provided approximately $9.0 million of cash, primarily attributable to proceeds from stock option exercises.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_76"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the first and fourth quarter of each year have been our largest quarters for software products and services revenue, primarily due to the timing of customer renewals of on-premise software arrangements, for which revenue is recognized at a single point in time. Seasonality has been a less significant factor for our hosted software arrangements, for which revenue is recognized ratably over time. Seasonality has not been a factor for our drug discovery revenues. Historical seasonality may not be indicative of future periods.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_79"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those that are both most important to the portrayal of a company's financial condition and results, and that require management's most difficult, subjective, and complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience, known trends and events, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the consolidated financial statements prospectively from the date of change in estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note 2 &#8211; Significant Accounting Policies to our consolidated financial statements appearing in Item 8 of this Annual Report, we believe the following critical accounting estimates used in the preparation of our consolidated financial statements require the most difficult, subjective and complex judgments and estimates and have had, or are reasonably likely to have a material impact on our financial condition or results of operations.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or Topic 606, except for contracts that are within the scope of other standards, such as contribution grants and certain collaboration arrangements. In accordance with Topic 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for arrangements that we determine are within the scope of Topic 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is applied to determine the allocation of the transaction price and measurement of progress, including (1) the constraint on variable consideration, (2) the identification of performance obligations and allocation of the transaction price to the performance obligations using their standalone selling price, or SSP, and (3) the appropriate input or output based method to recognize collaboration revenue and the extent of progress to date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable consideration:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our revenue may include upfront payments for the performance of services in the future, which have both fixed and variable consideration. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, regulatory or commercial milestones in our collaboration agreements may include some, but not necessarily all, of the following types of events:</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completion of preclinical research and development work leading to selection of product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiation of Phase 1, Phase 2, and Phase 3 clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">filing of regulatory applications for marketing approval in the United States, Europe or Japan;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">marketing approval in major markets, such as the United States, Europe, or Japan;</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">commercial milestones and/or commercial royalties; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achievement of certain other technical, scientific, or development criteria.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes research, development, or regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as certain regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on an SSP basis consistent with the allocation objectives of Topic 606, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which may affect license, collaboration, and other revenues and earnings in the period of adjustment. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is a risk that we may not earn all of the milestone payments from each of our collaborators. We recognized $14.1 million and $27.7 million from drug discovery milestones for the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software performance obligations and transaction price allocation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At contract inception, we assess the goods or services promised within each contract that falls under the scope of Topic 606 to identify distinct performance obligations, which requires the most difficult, subjective, and complex judgments based on the nature of each transaction. We allocate the transaction price to each distinct performance obligation on an SSP basis. We determine the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. We typically have more than one SSP for individual software license performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, we may use information such as the size and geographic region of the customer in determining the SSP. We may also estimate SSP based on management judgment by considering available data such as internal cost and margin objectives, pricing strategies, market/competitive conditions, historical profitability data, as well as other observable inputs. We establish SSP ranges for our products and services and reassess them periodically. The determination of SSP required significant management judgment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration agreement performance obligations, transaction price allocation, and measurement of progress: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement, we utilize judgment to assess the nature of the performance obligations to determine </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether they are distinct or a single combined performance obligation. We allocate the transaction price to each performance obligation based on the relative SSP of each performance obligation at inception. We determine the SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant judgment is used to determine the inputs for total costs to perform the research activities, which may include the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed by third-parties to complete the research plan. Revenue is recognized on a proportional performance basis over the period of service, using input-based measurements to estimate the performance. Changes to these assumptions may have a material effect on the amount and timing of revenue recognized. We recognized revenue of $8.3 million and $25.1 million related to collaboration agreements with proportional performance measurement for the years ended December 31, 2024 and 2023, respectively.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_82"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 &#8211; Significant Accounting Policies to our consolidated financial statements appearing elsewhere in this Annual Report for a discussion of recently issued accounting pronouncements.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_85"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents and marketable securities, are in the form of U.S. Treasury and corporate bonds and a money market fund that is invested in U.S. Treasury and corporate bonds. Due to the nature of these investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of this investment portfolio.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to market risk related to changes in foreign currency exchange rates. We maintain bank accounts denominated in Japanese yen, British pound sterling, Indian rupee, European Union euro, and Korean Republic won to accommodate deposits of amounts due from certain customers. We also contract with certain vendors that are located outside of the United States whose invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. Our hedging activity related to our foreign currency exchange rate risk is immaterial. Our cash balances and outstanding vendor invoices denominated in foreign currencies were not material as of December 31, 2024 and 2023, and our market risk associated with foreign currency exchange rates was deemed insignificant. An immediate 10% change in foreign exchange rates would not have a material effect on our consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">149</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_91"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_94">Reports of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_94">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_94">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">Consolidated Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">23</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">Consolidated Statements of Operations for the Years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">(Loss) </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">Income</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">for the Years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">Consolidated Statements of Stockholders&#8217; Equity for the Years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">Consolidated Statements of Cash Flows for the Years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">, and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_112">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_112">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_112">10</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-1</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schr&#246;dinger, Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Schr&#246;dinger, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive (loss) income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 26, 2025 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identification of performance obligations in complex or unusual revenue arrangements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 3(a) and 3(b) to the consolidated financial statements, the Company reported on-premise software revenue of $104,020 thousand, hosted software revenue of $35,253 thousand, software contribution revenue of $8,016 thousand, and drug discovery services revenue of $25,143 thousand for the year ended December 31, 2024. As discussed in Note 3(d), the Company&#8217;s contracts with customers often include promises to transfer multiple products and services. At contract inception, the Company assesses the products and services promised within each contract to determine distinct performance obligations that should be accounted for separately.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the determination of distinct performance obligations in complex or unusual revenue arrangements as a critical audit matter. There was subjective auditor judgment in evaluating whether promised products and services in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complex or unusual revenue arrangements are separate performance obligations or inputs into a combined performance obligation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the revenue process, including controls related to the determination of distinct performance obligations. For a selection of complex or unusual revenue arrangements, we evaluated whether the performance obligations identified by the Company were capable of being distinct in the context of the contract by obtaining an understanding of the Company&#8217;s product and service offerings, obtaining and inspecting contracts, and evaluating the application of the revenue recognition accounting guidance for the selected contract.</span></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2010.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portland, Oregon</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 26, 2025</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:20pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schr&#246;dinger, Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Schr&#246;dinger, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive (loss) income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements), and our report dated February 26, 2025 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portland, Oregon</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 26, 2025</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-4</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except for share and per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-56">147,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-57">155,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">15,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">5,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">204,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">307,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-62">210</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-63">220</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">235,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">65,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Unbilled and other receivables, net of allowance for unbilled receivables of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:AllowanceForUnbilledReceivablesCurrent" scale="3" id="f-66">100</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sdgr:AllowanceForUnbilledReceivablesCurrent" scale="3" id="f-67">100</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:UnbilledAndOtherReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">19,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sdgr:UnbilledAndOtherReceivablesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">23,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">12,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">9,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">634,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">567,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-74">24,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-75">23,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-76">43,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-77">83,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-78">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-79">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Right of use assets - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-80">111,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-81">117,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">4,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">6,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-84">823,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-85">802,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">10,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">16,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accrued payroll, taxes, and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">42,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">31,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">111,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">56,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Lease liabilities - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">16,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">10,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">11,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">191,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">133,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred revenue, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">108,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">9,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Lease liabilities - operating leases, long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">101,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">111,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other liabilities, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-102">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-103">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-104">401,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-105">254,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 6)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-106"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-107"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-108"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-109">0.01</ix:nonFraction></ix:nonFraction> par value. Authorized <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-111">10,000,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-115">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-118"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-119">0.01</ix:nonFraction></ix:nonFraction> par value. Authorized <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-120"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-121">500,000,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-123">63,710,409</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-125">62,977,316</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-126">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-127">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Limited common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-128"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-129">0.01</ix:nonFraction></ix:nonFraction> par value. Authorized <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-131">100,000,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-132"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-133"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-134"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-135">9,164,193</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-136">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-137">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-138">946,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-139">885,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-140">525,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-141">338,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-142">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-143">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-144">421,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">548,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-146">823,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">802,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except for share and per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Revenues:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software products and services</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-148">180,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-149">159,124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-150">135,578</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-151">27,174</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-152">57,542</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-153">45,377</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total revenues</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-154">207,539</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-155">216,666</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-156">180,955</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cost of revenues:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-157">36,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-158">29,514</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-159">29,576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-160">38,556</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-161">46,460</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-162">50,357</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total cost of revenues</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-163">75,456</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-164">75,974</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-165">79,933</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 35.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Gross profit</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-166">132,083</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-167">140,692</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-168">101,022</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-169">201,785</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-170">181,766</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-171">126,372</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Sales and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-172">39,917</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-173">37,226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-174">30,642</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-175">99,677</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-176">99,148</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-177">90,825</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-178">341,379</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-179">318,140</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-180">247,839</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 35.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-181">209,296</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">177,448</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">146,817</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other income (expense)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Gain on equity investments</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-185">147,213</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-186">11,825</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change in fair value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">5,683</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">53,461</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">18,084</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other income</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-190">17,902</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-191">19,693</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-192">3,953</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 34pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total other income (expense)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">23,585</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-194">220,367</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-195">2,306</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 35.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-196">185,711</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">42,919</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">149,123</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-199">1,412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-200">2,199</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-201">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net (loss) income</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-202">187,123</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">149,186</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 59.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net (loss) income per share attributable to common and limited common stockholders, basic:</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-205">2.57</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-206">0.57</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-207">2.10</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 59.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-208">72,670,295</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-209">71,776,301</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-210">71,173,419</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 59.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net (loss) income per share of common and limited common stockholders, diluted:</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-211">2.57</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-212">0.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-213">2.10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 59.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-214">72,670,295</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-215">74,986,816</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-216">71,173,419</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive (Loss) Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net (loss) income attributable to common and limited common stockholders</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">187,123</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">149,186</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Changes in market value of investments, net of tax:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized (loss) gain on marketable securities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-220">61</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-221">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-222">1,731</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Comprehensive (loss) income</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-223">187,184</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">43,383</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-225">150,917</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_106"></div><hr style="page-break-after:always"/><div style="min-height:9pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except for share amounts)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.817%"><tr><td style="width:1.0%"/><td style="width:25.605%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.495%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.464%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Limited common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>paid-in</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>other<br/>comprehensive</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(loss) income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Balance at December&#160;31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-226">61,834,515</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-227">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-228">9,164,193</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-229">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">786,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">229,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-232">651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">557,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Change in unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-234">1,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-235">1,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuances of common stock upon stock option exercises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-236">329,224</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-237">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-238">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-239">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-240">39,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-241">39,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-242">149,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">149,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Balance at December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-244">62,163,739</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-245">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-246">9,164,193</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-247">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">828,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">379,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">2,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">447,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Reclassification of non-controlling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Change in unrealized gain on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-253">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-254">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuances of common stock upon stock option exercises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-255">800,336</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-256">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-257">9,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-258">9,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuance of common stock upon vesting of RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-259">13,241</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-260">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-261">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-262">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-263">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Balance at December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-264">62,977,316</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-265">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-266">9,164,193</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-267">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">885,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">338,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-270">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">548,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Change in unrealized loss on marketable securities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-272">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-273">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuances of common stock upon stock option exercises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-274">169,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-275">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-276">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-277">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuance of common stock upon vesting of RSUs and PRSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-278">240,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-279">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-280">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuance of common stock in ATM offering, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-281">323,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-282">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-283">8,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-284">8,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-285">49,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-286">49,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-287">187,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-288">187,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Balance at December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-289">63,710,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-290">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-291">9,164,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-292">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">946,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">525,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-295">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">421,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-297">187,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-298">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-299">149,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Adjustments to reconcile net (loss) income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Gain on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-301">147,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-302">11,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Changes in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-303">5,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-304">53,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-305">18,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-306">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-307">5,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-308">4,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-309">49,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-310">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-311">39,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Noncash investment (accretion) amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:InvestmentAmortizationNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-312">7,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:InvestmentAmortizationNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-313">7,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="sdgr:InvestmentAmortizationNoncashExpense" scale="3" id="f-314">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-315">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-316">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-317">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(Increase) decrease in assets, net of acquisition:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-318">169,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-319">10,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-320">23,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Unbilled and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-321">3,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-322">9,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-323">4,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Reduction in the carrying amount of right of use assets - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" format="ixt:num-dot-decimal" scale="3" id="f-324">8,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" format="ixt:num-dot-decimal" scale="3" id="f-325">7,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" format="ixt:num-dot-decimal" scale="3" id="f-326">7,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-327">3,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-328">8,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-329">7,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(Decrease) increase in liabilities, net of acquisition:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-330">6,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-331">7,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-332">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Accrued payroll, taxes, and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-333">10,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-334">6,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-335">6,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-336">155,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-337">18,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-338">1,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Lease liabilities - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-339">10,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-340">3,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-341">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-342">1,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-343">5,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-344">1,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-345">157,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-346">136,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-347">119,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-348">7,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-349">13,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-350">8,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Purchases of equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-351">3,072</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-352">4,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="f-353">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Distribution from equity investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-355">147,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="f-356">11,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Proceeds from disposition and sale of equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-357">48,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Acquisition, net of acquired cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-362">6,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-363">251,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-364">320,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-365">271,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Proceeds from maturity of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-366">361,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-367">383,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-368">364,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-369">148,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-370">193,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-371">90,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Issuances of common stock upon stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-372">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-373">9,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-374">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Payment of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-375">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-376">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Issuance of common stock in ATM offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-378">8,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Principal payments on finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-381">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-382">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-384">10,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-385">9,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-386">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-387">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-388">65,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-389">27,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Cash and cash equivalents and restricted cash, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-390">161,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-391">95,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-392">123,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Cash and cash equivalents and restricted cash, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-393">162,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-394">161,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-395">95,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow and noncash information</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-396">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-397">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-398">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Purchases of property and equipment in accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-399">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-400">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-401">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Purchases of property and equipment in accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="f-402">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="f-403">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" scale="3" id="f-404">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Acquisition of right of use assets - operating leases, contingency resolution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" format="ixt:num-dot-decimal" scale="3" id="f-405">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" scale="3" id="f-406">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" format="ixt:num-dot-decimal" scale="3" id="f-407">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Acquisition of right of use assets - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" format="ixt:num-dot-decimal" scale="3" id="f-409">15,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" format="ixt:num-dot-decimal" scale="3" id="f-410">34,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Acquisition of lease liabilities - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-412">15,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-413">34,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%">Acquisition of right of use assets in exchange for lease liabilities - finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" scale="3" id="f-415">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except for share and per share amounts and note 3(c))</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_115"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-417" continuedAt="f-417-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-417-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schr&#246;dinger, Inc. (the "Company") has developed a differentiated, physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. The Company's software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company is also applying its computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, the Company uses its computational platform to discover novel molecules for its pipeline of proprietary drug discovery programs, which the Company is advancing through preclinical and clinical development.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_118"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-418" continuedAt="f-418-1" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-418-1" continuedAt="f-418-2"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-419" continuedAt="f-419-1" escape="true">Recently Issued Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="f-419-1" continuedAt="f-419-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 280) &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This standard is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this new standard for the year ended December 31, 2024 with no material impact on its consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires public business entities to disclose specific categories in the tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. This standard is effective for annual periods beginning after December 15, 2024, and interim periods within annual periods beginning after December 15, 2025, on a prospective basis, with early adoption permitted. The Company has not yet adopted ASU 2023-09 and is still evaluating the impact of the adoption on its consolidated financial statements.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><ix:continuation id="f-419-2" continuedAt="f-419-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40) &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Disaggregation of Income Statement Expenses</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-419-3">. which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. This standard is effective for annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027, on a prospective basis, with early adoption and retrospective application permitted. The Company has not yet adopted ASU 2024-03 and is still evaluating the impact of the adoption on its consolidated financial statements.</ix:continuation> </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="sdgr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" id="f-420" continuedAt="f-420-1" escape="true">Basis of Presentation and Use of Estimates</ix:nonNumeric></span></div><ix:continuation id="f-420-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue and estimates regarding the progress of completing performance obligations under collaboration agreements. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-421" continuedAt="f-421-1" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><ix:continuation id="f-421-1" continuedAt="f-421-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of Schr&#246;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-418-2" continuedAt="f-418-3"><ix:continuation id="f-421-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="sdgr:CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" id="f-422" continuedAt="f-422-1" escape="true">Cash and Cash Equivalents and Marketable Securities and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="f-422-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents were cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-423">102,054</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-424">85,497</ix:nonFraction> as of December&#160;31, 2024 and 2023, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation&#8217;s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of letters of credit held with the Company&#8217;s financial institution related to facility leases and is classified as current in the Company&#8217;s balance sheets based on the maturity of the underlying letters of credit. The Company also has restricted cash related to a certificate of deposit held as collateral for its credit card facility. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-425" continuedAt="f-425-1" escape="true">Accounts Receivable</ix:nonNumeric></span></div><ix:continuation id="f-425-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December&#160;31, 2024 and 2023. Interest is not charged on accounts receivable.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-426" continuedAt="f-426-1" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-426-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-427" continuedAt="f-427-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-427-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. The Company did <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="INF" name="us-gaap:InterestCostsCapitalized" format="ixt:fixed-zero" scale="0" id="f-428"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:InterestCostsCapitalized" format="ixt:fixed-zero" scale="0" id="f-429">not</ix:nonFraction></ix:nonFraction> capitalize any interest during 2024 and 2023. Maintenance and repairs are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated using the straight&#8209;line method over the estimated useful lives of the assets, which range from <ix:nonNumeric contextRef="c-53" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-430">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-54" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-431">10</ix:nonNumeric> years. Amortization of leasehold improvements is calculated using the straight&#8209;line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are reviewed for impairment as discussed below under "Accounting for the Impairment of Long&#8209;Lived Assets."</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-432" continuedAt="f-432-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-432-1" continuedAt="f-432-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess purchase price over the fair value of net assets acquired which is not allocable to separately identifiable intangible assets. Other identifiable intangible assets are separately recognized if the intangible asset is obtained through contractual or other legal right or if the intangible asset can be sold, transferred, licensed or exchanged.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but tested for impairment at least annually, and more frequently if events or circumstances indicate the carrying amount more likely than not exceeds the fair value. The Company has the option to qualitatively or quantitatively assess its goodwill for impairment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its goodwill for impairment on October 1 of each year. In 2024, the Company evaluated its goodwill using a qualitative process. If the qualitative factors determine that it is more likely than not that the fair value exceeds the carrying amount, goodwill is not impaired. If the qualitative assessment determines it is more likely than not the fair value is less than the carrying amount, the Company would further evaluate for potential impairment. This </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-418-3" continuedAt="f-418-4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-432-2">qualitative assessment indicated that it was more likely than not the Company's reporting unit&#8217;s fair value exceeded its carrying value.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt-sec:numwordsen" scale="3" id="f-433"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt-sec:numwordsen" scale="3" id="f-434"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt-sec:numwordsen" scale="3" id="f-435">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of goodwill was recognized for the years ended December 31, 2024, 2023, and 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="f-436" continuedAt="f-436-1" escape="true">Accounting for the Impairment of Long&#8209;Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-436-1">Long-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-437"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-438"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-439">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment was identified for the years ended December 31, 2024, 2023, and 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StandardProductWarrantyPolicy" id="f-440" continuedAt="f-440-1" escape="true">Warranties</ix:nonNumeric></span></div><ix:continuation id="f-440-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(k)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-441" continuedAt="f-441-1" escape="true">Concentrations</ix:nonNumeric></span></div><ix:continuation id="f-441-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables and contract assets, which represent contracted unbilled receivables.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer&#8217;s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, one customer accounted for <ix:nonFraction unitRef="number" contextRef="c-55" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-442">68</ix:nonFraction>% of total accounts receivable. As of December&#160;31, 2023, two customers accounted for <ix:nonFraction unitRef="number" contextRef="c-56" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-443">15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-57" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-444">11</ix:nonFraction>% of total accounts receivable, respectively. As of December&#160;31, 2024, three customers accounted for <ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-445">33</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-446">23</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-60" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-447">16</ix:nonFraction>% of total contract assets, respectively. As of December&#160;31, 2023, two customers accounted for <ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-448">42</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-62" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-449">22</ix:nonFraction>% of total contract assets, respectively. For the year ended December&#160;31, 2024, one customer accounted for <ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-450">10</ix:nonFraction>% of total revenues. For the year ended December&#160;31, 2023, two customers accounted for <ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-451">26</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-452">11</ix:nonFraction>% of total revenues, respectively. For the year ended December 31, 2022, one customer accounted for <ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-453">16</ix:nonFraction>% of total revenues.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(l)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="sdgr:RoyaltiesPolicyPolicyTextBlock" id="f-454" continuedAt="f-454-1" escape="true">Royalties</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-454-1">Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company&#8217;s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections.</ix:continuation> Royalty expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="f-455">9,342</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="f-456">13,349</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="f-457">9,191</ix:nonFraction> for the years ended December&#160;31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(m)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="sdgr:SoftwareDevelopmentCostsPolicyPolicyTextBlock" id="f-458" continuedAt="f-458-1" escape="true">Software Development Costs</ix:nonNumeric></span></div><ix:continuation id="f-458-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(n)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="sdgr:ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" id="f-459" continuedAt="f-459-1" escape="true">Research and Development and Advertising</ix:nonNumeric></span></div><ix:continuation id="f-459-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2024, 2023, and 2022.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-418-4" continuedAt="f-418-5"><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(o)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-460" continuedAt="f-460-1" escape="true">Stock&#8209;Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-460-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates stock&#8209;based compensation expense utilizing fair value&#8211;based methodologies and recognizes expense over the vesting period of such awards. For performance-based restricted stock units, the Company records stock-based compensation expense with a cumulative catch-up at the time when performance conditions are considered probable of achievement, and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(p)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommissionsPolicy" id="f-461" continuedAt="f-461-1" escape="true">Commissions</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-461-1">Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company&#8217;s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order.</ix:continuation> Commission expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:CommissionExpense" format="ixt:num-dot-decimal" scale="3" id="f-462">1,803</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:CommissionExpense" format="ixt:num-dot-decimal" scale="3" id="f-463">1,636</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:CommissionExpense" format="ixt:num-dot-decimal" scale="3" id="f-464">2,291</ix:nonFraction> in 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(q)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-465" continuedAt="f-465-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-465-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the benefit of a tax position in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(r)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-466" continuedAt="f-466-1" escape="true">Comprehensive (Loss) Income</ix:nonNumeric></span></div><ix:continuation id="f-466-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income includes net (loss) income and changes in equity related to changes in unrealized gains or losses on marketable securities.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(s)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-467" continuedAt="f-467-1" escape="true">Equity Investments</ix:nonNumeric></span></div><ix:continuation id="f-467-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments over which the Company has significant influence may be accounted for under equity method accounting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with Accounting Standards Codification ("ASC") Topic 323 ("Topic 323"), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost less impairment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with ASC Topic 321 ("Topic 321"), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information regarding the Company&#8217;s equity investments, see Note 5, Fair Value Measurements and Note 11, Equity Investments.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(t)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-468" continuedAt="f-468-1" escape="true">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="f-468-1" continuedAt="f-468-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding equity of the Company consists of common stock and limited common stock. Under the Company&#8217;s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-468-2"><ix:continuation id="f-418-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undistributed earnings allocated to the participating securities are subtracted from net income in determining net income (loss) attributable to common and limited common stockholders. Basic net income (loss) per share is computed by dividing net income (loss) attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company&#8217;s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.</span></div></ix:continuation></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_124"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-469" continuedAt="f-469-1" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="f-469-1" continuedAt="f-469-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company&#8217;s performance obligations are satisfied either over time or at a point in time, which can result in different revenue recognition patterns.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="f-470" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the timing of the Company&#8217;s revenue recognition patterns:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services &#8211; point in time</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-67" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-471">51.4</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-68" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-472">49.1</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-473">47.3</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services &#8211; over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-474">35.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-475">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-476">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug Discovery &#8211; point in time</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-477">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-478">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-479">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug Discovery &#8211; over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-480">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-481">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="3" name="sdgr:TimingOfRevenueRecognitionPercentage" scale="-2" id="f-482">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Software Products and Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts that can include various combinations of licenses, products and services, most of which are distinct and are accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price ("SSP") basis. Revenue is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's software business derives revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On-premise software. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's on-premise software license arrangements grant customers the right to use its software on their own in-house servers or their own cloud instances for a specified term, typically for <ix:nonNumeric contextRef="c-79" name="sdgr:RevenueArrangementsContractTerm" format="ixt-sec:durwordsen" id="f-483">one year</ix:nonNumeric>, though in recent years, the Company has entered into a small number of large multi-year on-premise software license agreements. The Company recognizes revenue for on-premise software license fees upfront, either upon transfer of control of the license or the effective date of the agreement, whichever is later. In instances where the timing of the transfer of control differs from the timing of invoicing, the Company considers whether a significant financing component exists.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company's updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront or annually.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hosted software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hosted software revenue consists primarily of fees to provide the Company's customers with hosted licenses, which allows these customers to access the Company's cloud-based software solution on their own hardware without taking control of the licenses, and is recognized ratably over the term of the arrangement, which is typically <ix:nonNumeric contextRef="c-80" name="sdgr:RevenueArrangementsContractTerm" format="ixt-sec:durwordsen" id="f-484">one year</ix:nonNumeric>, though in recent years, the Company has entered into a small number of large multi-year hosted software license agreements. When a customer enters into a hosted arrangement for which revenue is recognized over time, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-469-2" continuedAt="f-469-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amount paid upfront that is not recognized in the current period is included in deferred revenue in the Company's statement of financial position until the period in which it is recognized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software maintenance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software maintenance includes technical support, updates, and upgrades related to the Company's on-premise software licenses. Software maintenance revenue is recognized ratably over the term of the arrangement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software maintenance activities are performed in connection with the use of the Company's on-premise software.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services include training, technical setup, installation or assisting customers with modeling services, where the Company uses its software to perform tasks such as virtual screening on behalf of the Company&#8217;s customers. These services are generally not related to the core functionality of the Company's software and are recognized as revenue when resources are consumed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software contribution revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software contribution revenue consists of funds received under non-reciprocal agreements with Gates Ventures, LLC and the Bill &amp; Melinda Gates Foundation. The agreement with Gates Ventures, LLC was originally entered into in June 2020 and further ext</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended through August 2026. The agreement is an unconditional non-exchange contribution without restrictions. Revenue is recognized annually, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hen invoiced, in accordance with ASC Topic 958, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Topic 958"), as the agreement is not an exchange transaction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with Gates Ventures, LLC initially covered the period from June&#160;23, 2020 through June&#160;22, 2023 for total consideration of up to $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognitionAmount" format="ixt:num-dot-decimal" scale="3" id="f-485">3,000</ix:nonFraction>. The agreement was then extended through August 13, 2026 and provides for total additional consideration of up to $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognitionAmount" format="ixt:num-dot-decimal" scale="3" id="f-486">6,000</ix:nonFraction>. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-487">2,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-488">1,800</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-489">1,000</ix:nonFraction> related to these agreements during the years ended December&#160;31, 2024, 2023, and 2022, respectively. As of December&#160;31, 2024, the Company had <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="INF" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="0" id="f-490">no</ix:nonFraction> deferred revenue balance related to this agreement. As of December&#160;31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-491"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-492">no</ix:nonFraction></ix:nonFraction> accounts receivable related to this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company entered into a <ix:nonNumeric contextRef="c-88" name="sdgr:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-493">one-year</ix:nonNumeric> agreement with the Bill &amp; Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins. In November 2024, the Company and the Bill &amp; Melinda Gates Foundation entered into an amendment to the agreement to expand the original term of the agreement to April 30, 2026 and provide supplemental funds on terms similar to the original agreement. Revenue is recognized as conditions are met and on a cost reimbursement basis in accordance with Topic 958. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-494">6,016</ix:nonFraction> related to these agreements during the year ended December&#160;31, 2024. As of December&#160;31, 2024, the Company had a $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-495">8,484</ix:nonFraction> deferred revenue balance related to these agreements. As of December&#160;31, 2024, the Company had <ix:nonFraction unitRef="usd" contextRef="c-90" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="f-496">no</ix:nonFraction> accounts receivable related to these agreements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-497" continuedAt="f-497-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue recognized from the sources of software products and services revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">On-premise software</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-498">104,020</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-499">104,511</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-500">84,487</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hosted software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-501">35,253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-502">20,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-503">14,890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software maintenance</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-504">23,279</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-505">23,066</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-506">19,996</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-507">9,797</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-508">9,366</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-509">15,205</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue from contracts with customers</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-510">172,349</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-511">157,324</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-512">134,578</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-513">8,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-514">1,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-515">1,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total software revenue</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-516">180,365</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-517">159,124</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-518">135,578</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Drug Discovery</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from drug discovery and collaboration services contracts includes revenue from research services and the achievement of milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research services revenue is generally recognized over time, typically by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input method based on the services promised to the customer, such as costs incurred and hours expended. This method of recognizing revenue requires the Company to make estimates of the work required to complete the performance obligation in order to determine the progress towards </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-469-3" continuedAt="f-469-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion. Payments for research services are generally due upfront at the start of a contract or periodically through the contract term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is generally entitled to receive variable consideration as certain milestones are achieved. The Company estimates the amount of variable consideration using the most likely amount method. The Company evaluates milestones on a case-by-case basis, including whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable or the event is outside of the Company's control, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is deemed probable of being achieved or the event occurs. Upon removal of the constraint on variable consideration, revenue may be recognized at a point in time or over time by applying the allocation guidance of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Topic 606").</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were <ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="sdgr:MilestonePaymentYetToBeAchieved" format="ixt:fixed-zero" scale="3" id="f-519">no</ix:nonFraction> milestones not yet achieved that were determined to be probable of achievement. As of December 31, 2023 and 2022, milestones not yet achieved that were determined to be probable of achievement totaled $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="sdgr:MilestonePaymentYetToBeAchieved" scale="3" id="f-520">350</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="sdgr:MilestonePaymentYetToBeAchieved" format="ixt:num-dot-decimal" scale="3" id="f-521">4,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="sdgr:RevenueRecognizedForMilestonePayment" scale="3" id="f-522">350</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="sdgr:RevenueRecognizedForMilestonePayment" format="ixt:num-dot-decimal" scale="3" id="f-523">3,939</ix:nonFraction> of those milestones were recognized as revenue for the years ended December 31, 2023, and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery contribution revenue</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discovery </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contribution revenue consists of funds received under an agreement with the Bill &amp; Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women's health. The initial agreement began in November 2021 and expired in September 2023. In September 2023, the Company entered into a new agreement with the Bill &amp; Melinda Gates Foundation to perform services aimed at accelerating drug discovery in women's health that expires in October 2025. Revenue is recognized as costs are incurred in accordance with Topic 958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had deferred revenue balances related to these agreements of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredRevenue" scale="3" id="f-524">949</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-525">1,581</ix:nonFraction>, respectively.</span></div><ix:continuation id="f-497-1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue recognized from the sources of drug discovery revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery services revenue from contracts with customers</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-526">25,143</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-527">54,720</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-528">43,427</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-529">2,031</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-530">2,822</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-531">1,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total drug discovery revenue</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-532">27,174</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-533">57,542</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-534">45,377</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bristol Myers-Squibb. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2020, the Company entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company ("BMS"), pursuant to which the Company and BMS agreed to collaborate in the discovery, research and preclinical development of new small molecule compounds for disease indications in oncology, neurology, and immunology therapeutics areas. Under the agreement, the Company was initially responsible, at its own cost and expense, for the discovery of small molecule compounds directed to <ix:nonFraction unitRef="target" contextRef="c-115" decimals="INF" name="sdgr:ContractWithCustomerNumberOfSpecifiedBiologicalTargets" format="ixt-sec:numwordsen" scale="0" id="f-535">five</ix:nonFraction> specified biological targets pursuant to a mutually agreed research plan for each such target. In December 2022, the Company and BMS entered into an amendment to the agreement to include an additional target in neurology on terms similar to the original agreement. As a result of BMS electing not to proceed with further development of certain targets, there is <ix:nonFraction unitRef="target" contextRef="c-116" decimals="INF" name="sdgr:ContractWithCustomerNumberOfNeurologyTargetRemaining" format="ixt-sec:numwordsen" scale="0" id="f-536">one</ix:nonFraction> remaining neurology target under the agreement, as amended, as of December&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a development candidate meeting specified criteria for a target under the agreement has been identified by the Company, BMS will be solely responsible for the further development, manufacturing and commercialization of such development candidate at its own cost and expense. The Company is solely responsible for the development of any programs that have been returned by BMS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, as amended, BMS paid the Company an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-537">55.0</ix:nonFraction> million in November 2020, an additional upfront payment in December 2022, and a program fee in December 2024. As of December&#160;31, 2024 the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="sdgr:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="6" id="f-538">482.0</ix:nonFraction> million in total milestone payments related to the <ix:nonFraction unitRef="target" contextRef="c-116" decimals="INF" name="sdgr:ContractWithCustomerNumberOfNeurologyTargetRemaining" format="ixt-sec:numwordsen" scale="0" id="f-539">one</ix:nonFraction> remaining neurology target currently subject to the collaboration, consisting of up to $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="sdgr:RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" scale="6" id="f-540">257.0</ix:nonFraction> million in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="sdgr:RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" scale="6" id="f-541">225.0</ix:nonFraction> million in the aggregate for </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-469-4" continuedAt="f-469-5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the achievement of certain specified commercial milestones. As of December&#160;31, 2024, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-542">32.0</ix:nonFraction> million in revenue related to milestones under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to a tiered percentage royalty on annual net sales ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration and license agreement in accordance with Topic 606 and concluded that BMS is a customer based on the agreement structure. At inception, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-115" decimals="INF" name="sdgr:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-543">one</ix:nonFraction> performance obligation for each of the <ix:nonFraction unitRef="program" contextRef="c-119" decimals="INF" name="sdgr:CollaborativeAgreementNumberOfPrograms" format="ixt-sec:numwordsen" scale="0" id="f-544">five</ix:nonFraction> programs initially covered under the agreement, which includes research activities for each program and a license grant for the underlying intellectual property. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price at the onset of the agreement was $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-545">55.0</ix:nonFraction> million. Additional consideration to be paid to the Company upon the achievement of future milestone payments was excluded from the transaction price as they represent milestone payments that were not considered probable as of the inception date such that there is not a significant risk of revenue reversal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-546">55.0</ix:nonFraction> million to each performance obligation based on the SSP of each performance obligation at inception. The Company determined the estimated SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-547">10.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-548">43.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-549">22.1</ix:nonFraction> million, respectively, of revenue associated with the agreement based on the research activities performed and milestones achieved. As of December&#160;31, 2024 and 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-550">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-551">7.3</ix:nonFraction> million, respectively, of deferred revenue related to the agreement, which was classified as either current or non-current in the consolidated balance sheet based on the period the services are expected to be performed. As of December&#160;31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-116" decimals="INF" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" format="ixt:fixed-zero" scale="3" id="f-552">no</ix:nonFraction> outstanding receivables for this collaboration.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2024, the Company entered into a research collaboration and license agreement with Novartis Pharma AG ("Novartis"), pursuant to which the Company and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. The Company also entered into an expanded <ix:nonNumeric contextRef="c-124" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-553">three-year</ix:nonNumeric> software agreement with Novartis that substantially increases Novartis' access to the Company&#8217;s computational predictive modeling technology and enterprise informatics platform. Under Topic 606, the research collaboration and license agreement as well as the <ix:nonNumeric contextRef="c-124" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-554">three-year</ix:nonNumeric> software agreement ("the agreements") are collectively accounted for as a single contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the research collaboration and license agreement, once a development candidate has been identified, Novartis will be solely responsible for the further development, manufacturing and commercialization of such development candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis agreed to pay the Company an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-555">150.0</ix:nonFraction> million under the terms of the research collaboration and license agreement, and the Company will be eligible to eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="sdgr:RevenueRemainingPerformanceObligationVariableConsiderationAmount" scale="9" id="f-556">2.272</ix:nonFraction> billion in total milestone payments across the initial programs. Such milestones consist of up to $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="sdgr:RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" scale="6" id="f-557">892.0</ix:nonFraction>&#160;million in discovery and development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-7" name="sdgr:RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" scale="9" id="f-558">1.38</ix:nonFraction>&#160;billion in commercial milestones. The Company is also entitled to a tiered percentage royalty ranging from mid-single-digits to low double-digits on products commercialized by Novartis under the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-469-5" continuedAt="f-469-6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, subject to certain specified reductions. As of December&#160;31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-559">no</ix:nonFraction> revenue has been recognized related to milestones under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the research collaboration and license agreement in accordance with Topic 606 and concluded that Novartis is a customer based on the agreement structure. The promises identified by the Company include research activities for each program under the agreement, a license grant for the underlying intellectual property, and software licenses and services. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract. Software licenses and services provided under the agreement are considered distinct and are accounted for as separate performance obligations in accordance with Topic 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the transaction price for the agreements to each performance obligation based on the SSP of each performance obligation at inception. The Company determined the estimated SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-560">0.6</ix:nonFraction> million of revenue associated with the research collaboration and license agreement. As of December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-561">116.7</ix:nonFraction> million of deferred revenue, net of contract assets, related to the agreements, which was classified as either current or non-current in the condensed consolidated balance sheet based on the period the services are expected to be performed. As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" scale="6" id="f-562">150.0</ix:nonFraction> million outstanding receivables for this collaboration.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Significant Judgments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments and estimates are required under Topic 606. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company&#8217;s arrangements may be dependent on contract-specific terms and may vary in some instances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contracts with customers often include but are not limited to promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates, as well as collaborative research services, licenses to intellectual properties, and customer options. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company's term-based software license arrangements, may include multiple software licenses, a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised licenses and services are separate distinct performance obligations. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable consideration. For collaborative arrangements, under which the Company is eligible to receive variable consideration in the form of milestones payments, judgment is required to evaluate whether the milestones are considered probable of being achieved. If it is probable that a significant revenue reversal would not occur, the constraint is removed and value of the associated milestone is included in the estimated transaction price using the most likely amount method based on contractual requirements and historical experience. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a relative SSP basis consistent with the allocation objectives of Topic 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required to determine the SSP for each distinct performance obligation. The Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-469-6" continuedAt="f-469-7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for individual software license performance obligations due to the stratification of those items by volume of sales, classes of customers and other relevant circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP. Professional service revenue is recognized as costs and hours are incurred, and judgment is required in estimating both the project status and the costs incurred or hours expended.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company's judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required to determine the total costs to perform research activities, which include the length of time required, the internal hours expected to be incurred on the services, and the number and costs of various studies that may be performed by third parties to complete the research plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the Company has not experienced significant returns or refunds to customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates related to revenue recognition may require significant judgment and a change in these estimates could have an effect on the Company's results of operations during the periods involved.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Contract Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables, contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing. A deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company's time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements where the milestones are deemed probable in a period prior to when the milestone is achieved, the Company records a contract asset for the full value of the milestone.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are included in unbilled and other receivables within the consolidated balance sheets and are transferred to receivables when the Company invoices the customer.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-563" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"/><td style="width:70.956%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.557%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.560%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,<br/>2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,<br/>2023</span></div></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract assets</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="f-564">16,564</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="f-565">21,107</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, short-term:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-566">75,660</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-567">44,218</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-568">36,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-569">12,013</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, long-term:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-570">14,393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-571">2,407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-572">94,421</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-573">6,636</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024 and 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-574">53,438</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-575">64,120</ix:nonFraction> of revenue, respectively, that was included in deferred revenue at the end of the respective preceding periods. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue approximately <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-576">51</ix:nonFraction>% of its December&#160;31, 2024 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in deferred revenue were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="f-577">59,519</ix:nonFraction> as of December&#160;31, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-469-7"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms and conditions vary by contract type, although terms typically require payment within <ix:nonNumeric contextRef="c-134" name="sdgr:ContractWithCustomersPaymentTerms" format="ixt-sec:durday" id="f-578">30</ix:nonNumeric> to <ix:nonNumeric contextRef="c-135" name="sdgr:ContractWithCustomersPaymentTerms" format="ixt-sec:durday" id="f-579">60</ix:nonNumeric> days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company&#8217;s products and services, not to facilitate financing arrangements.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Deferred Sales Commissions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied the practical expedient for sales commission expense, as any material compensation paid to sales representatives to obtain a contract relates to a period of one year or less. The Company has not capitalized any costs related to sales commissions.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_130"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-580" continuedAt="f-580-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-580-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-581" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December&#160;31,</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-582">23,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-583">22,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-584">3,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-585">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-586">6,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-587">6,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-588">10,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-589">8,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right of use asset - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="f-590">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="f-591">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-592">45,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-593">41,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-594">20,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-595">18,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-596">24,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-597">23,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-598">6,159</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-599">4,965</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-600">3,831</ix:nonFraction>, respectively, and is included within cost of revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_136"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-601" continuedAt="f-601-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-601-1" continuedAt="f-601-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various inputs are used in determining the fair value of the Company&#8217;s financial assets and liabilities. These inputs are summarized into the following three broad categories:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; quoted prices in active markets for identical securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; significant unobservable inputs, including the Company&#8217;s own assumptions in determining fair value</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. Marketable securities, which consist primarily of corporate and U.S. government agency bonds, are classified as available for sale and fair value did not differ significantly from carrying value as of December&#160;31, 2024 and 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-602" continuedAt="f-602-1" escape="true">The following table presents information about the Company&#8217;s assets measured at fair value as of December&#160;31, 2024:</ix:nonNumeric></span></div><ix:continuation id="f-602-1" continuedAt="f-602-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-603">162,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-606">162,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-608">204,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-610">204,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-611">36,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-614">36,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-615">198,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-616">204,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-618">403,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-601-2"><ix:continuation id="f-602-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets measured at fair value as of December&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-619">161,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-622">161,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-624">307,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-626">307,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-627">79,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-629">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-630">81,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-631">240,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-632">307,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-633">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-634">550,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s investment in Nimbus Therapeutics, LLC (&#8220;Nimbus&#8221;), classified as Level 3 in the fair value hierarchy, was recorded as an equity method investment under Topic 323 using the hypothetical liquidated book value method (&#8220;HLBV method&#8221;) through June 30, 2023, as further described in Note 11, Equity Investments. Significant unobservable inputs used to determine Nimbus&#8217; fair value under the HLBV method were the entity's annual financial statements and the Company&#8217;s liquidation preference. Following the dilution of the Company's investment in Nimbus during the year ended December 31, 2023, the fair value of the Company's investment was recorded under Topic 321 as a non-marketable equity security as the Company no longer exercises significant influence over Nimbus. This change in accounting method resulted in an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-635"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:num-dot-decimal" scale="3" id="f-636">1,928</ix:nonFraction></ix:nonFraction> and subsequent removal from the Level 3 fair value hierarchy table during the year ended December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses arising from changes in fair value of the Company&#8217;s equity investments are classified within change in fair value in the consolidated statements of operations. Realized gains arising from distributions receivable from the Company's equity investments are classified within gain on equity investments in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information regarding the Company&#8217;s equity investments, see Note 11, Equity Investments.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_139"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-637" continuedAt="f-637-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-637-1" continuedAt="f-637-2"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has multiple operating leases for office space and a finance lease for equipment that expire at various dates through 2037. The Company has elected the package of practical expedients under the transition guidance of ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to exclude short-term leases from the balance sheet and to combine lease and non-lease components. The Company classifies finance lease right of use assets under property and equipment, net and finance short-term and long-term lease liabilities under other accrued liabilities and other liabilities, long-term, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon inception of a lease, the Company determines if an arrangement is a lease, if it is classified as an operating or finance lease, if it includes options to extend or terminate the lease, and if it is reasonably certain that the Company will exercise the options. Lease cost, representing lease payments over the term of the lease and any capitalizable direct costs less any incentives received, is recognized on a straight-line basis over the lease term as lease expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. Upon execution of a new lease, the Company performs an analysis to determine its incremental borrowing rate using its current borrowing rate, adjusted for various factors including level of collateralization and lease term. As of December&#160;31, 2024, the remaining weighted average lease term for operating and finance leases was <ix:nonNumeric contextRef="c-5" name="sdgr:FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" format="ixt-sec:duryear" id="f-638">11</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-637-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, operating lease right of use assets increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:IncreaseInRightOfUseAssetsDueToContingencyResolution" format="ixt:num-dot-decimal" scale="3" id="f-639">2,952</ix:nonFraction> due to contingency resolutions associated with office leases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable and short-term lease costs for the Company's operating and finance leases were immaterial for the year ended December&#160;31, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-640" continuedAt="f-640-1" escape="true">Additional details of the Company's operating and finance leases are presented in the following table:</ix:nonNumeric></span></div><ix:continuation id="f-640-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-641">18,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-642">16,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-643">11,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="sdgr:OperatingAndFinanceLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-644">17,718</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="sdgr:OperatingAndFinanceLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-645">12,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="sdgr:OperatingAndFinanceLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-646">3,275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-647" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating and finance lease liabilities as of December&#160;31, 2024 under noncancelable leases were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" format="ixt:num-dot-decimal" scale="3" id="f-648">17,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-649">17,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" format="ixt:num-dot-decimal" scale="3" id="f-650">15,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" format="ixt:num-dot-decimal" scale="3" id="f-651">14,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" format="ixt:num-dot-decimal" scale="3" id="f-652">14,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-653">97,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-654">177,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-655">59,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:OperatingAndFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-656">118,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:OperatingAndFinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-657">16,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:OperatingAndFinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-658">101,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the Company&#8217;s financial position or results of operations or cash flows.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-22</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-659" continuedAt="f-659-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-659-1" continuedAt="f-659-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-660" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) is comprised of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-661">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-662">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-663">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-664">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-665">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-666">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-667">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-668">963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-669">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-670">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-671">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-672">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-679">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-682">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-685">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-686">2,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-687">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-688" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of (loss) income before income taxes by tax jurisdiction were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-689">190,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-690">39,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-691">150,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-692">4,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-693">3,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-694">1,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-695">185,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-696">42,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-697">149,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-698" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-699">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-700">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-701">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-702">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-703">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-704">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation" format="ixt:fixed-zero" scale="-2" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation" scale="-2" id="f-706">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation" scale="-2" id="f-707">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-708">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-709">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-710">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return-to-provision adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" scale="-2" id="f-711">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" scale="-2" id="f-712">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" scale="-2" id="f-713">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-714">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-715">14.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-716">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax contingencies, net of reversals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-717">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-718">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies" scale="-2" id="f-719">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-720">22.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-721">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-722">28.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-723">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-724">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-726">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-727">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the year ended December&#160;31, 2024 represents the Company's income tax obligations in certain states and taxes in foreign jurisdictions in which it conducts business. Income tax expense for the years ended December 31, 2023 represents the Company's federal and certain state income tax obligations and taxes in foreign jurisdictions for which it conducts business. Income tax expense for the year ended December 31, 2022 represents the Company's income tax obligations in certain states and taxes in foreign jurisdictions in which it conducts business. As of December&#160;31, 2024, the Company has a full valuation allowance on U.S. federal and state deferred tax assets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-659-2" continuedAt="f-659-3"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total change in valuation allowance for the year ended December&#160;31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-729">41,195</ix:nonFraction>, which was primarily due to temporary differences for capitalized research and development expenses and share based compensation, partially offset by adjustments to equity method investments.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-730" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-731">51,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-732">44,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-733">67,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-734">62,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-735">13,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-736">5,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-737">37,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-738">71,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-739">43,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-740">5,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-741">5,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-742">6,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-743">27,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sdgr:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-744">32,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="sdgr:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-745">28,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-746">29,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-747">21,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-748">18,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-749">214,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-750">188,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-751">170,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-752">177,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-753">136,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-754">137,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-755">36,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-756">52,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-757">32,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" format="ixt:num-dot-decimal" scale="3" id="f-758">7,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" format="ixt:num-dot-decimal" scale="3" id="f-759">18,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" format="ixt:num-dot-decimal" scale="3" id="f-760">4,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-761">652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-762">1,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-763">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-764">29,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-765">32,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-766">26,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal and state net operating loss ("NOL") carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-770">204,474</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-771">129,490</ix:nonFraction>, respectively. The state NOL carryforwards will expire between 2025 and 2044, if not used by the Company to reduce income taxes payable in future periods. Utilization of post-2017 federal NOL carryforwards is limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December&#160;31, 2024, the Company had federal orphan drug credits and federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-772">31,294</ix:nonFraction> and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-773">2,736</ix:nonFraction>. The federal and state carryforwards, with the exception of $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="sdgr:DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-774">2,223</ix:nonFraction> indefinite state credits will expire between 2025 and 2044, if not utilized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of NOLs and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through December 31, 2024 and determined no such ownership change has occurred in the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign operations as the Company considers these earnings to be indefinitely reinvested. The determination of a hypothetical unrecognized deferred tax liability as of December&#160;31, 2024 is not practicable because of the complexity and variety of assumptions necessary to compute the tax.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-659-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-775" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-776">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-777">2,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-778">1,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions taken in prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-779">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-780">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-781">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions taken in prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-783">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-784">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-785">648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-786">515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-787">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-788">3,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-789">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-790">2,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next 12 months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries file U.S. federal income tax returns and various state, local and foreign income tax returns. As of December&#160;31, 2024, the Company&#8217;s statutes of limitations are open for all federal and state tax returns filed after the years ended December&#160;31, 2021 and 2020, respectively. NOL and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_148"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-791" continuedAt="f-791-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-791-1" continuedAt="f-791-2"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-792">500,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-793">0.01</ix:nonFraction> per share. Holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-176" decimals="INF" name="sdgr:NumberOfVotesForCommonShare" format="ixt-sec:numwordsen" scale="0" id="f-794">one</ix:nonFraction> vote per share, to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#8217;s preferred stock, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company entered into an amended and restated sales agreement with Leerink Partners LLC ("Leerink Partners"), as sales agent, with respect to an at-the-market offering program (the "ATM") under which the Company could offer and sell, from time to time pursuant to its Registration Statement on Form S-3, shares of common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="0" id="f-795">250,000</ix:nonFraction>, through Leerink Partners. The amended and restated sales agreement amends and restates the original sales agreement that the Company entered into with Leerink Partners with respect to the ATM in May 2023, which is no longer in effect. During the year ended December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-796">323,085</ix:nonFraction> shares of common stock were sold under the ATM for total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-797">8,691</ix:nonFraction> and gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-798">8,868</ix:nonFraction>, before deducting sales agent commissions. As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="sdgr:SaleOfStockRemainingValueOfSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="3" id="f-799">241,132</ix:nonFraction> of common stock remaining available for sale under the ATM.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Limited Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-800">100,000,000</ix:nonFraction> shares of limited common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-801">0.01</ix:nonFraction> per share. Holders of limited common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-10" decimals="INF" name="sdgr:NumberOfVotesForCommonShare" format="ixt-sec:numwordsen" scale="0" id="f-802">one</ix:nonFraction> vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to the same dividend rights as holders of common stock, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company's preferred stock, if any. Holders of the Company's limited common stock have the right to convert each share of limited common stock into <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="sdgr:RightToExchangeEachShareOfLimitedCommonStockToCommonStock" format="ixt-sec:numwordsen" scale="0" id="f-803">one</ix:nonFraction> share of the Company's common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limited common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the limited </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-791-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-804">10,000,000</ix:nonFraction> shares of undesignated preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-805">0.01</ix:nonFraction> per share. The Company's board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_151"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-806" continuedAt="f-806-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-806-1" continuedAt="f-806-2"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plans</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company's stock incentive plans included the 2010 Stock Plan (the "2010 Plan"), the 2020 Equity Incentive Plan (the "2020 Plan"), the 2021 Inducement Equity Incentive Plan, as amended (the "2021 Plan"), and the 2022 Equity Incentive Plan, as amended (the "2022 Plan") (together, the "Plans").</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and cash-based awards to employees, directors, consultants or advisors. Shares of common stock subject to outstanding awards granted under the 2020 Plan and the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company are available for issuance under the 2022 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who were not previously an employee or director of the Company or who are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person&#8217;s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). Neither consultants nor advisors are eligible to participate in the 2021 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provided for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, consultants or advisors. As of June 15, 2022, the effective date of the 2022 Plan, <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:fixed-zero" scale="0" id="f-807">no</ix:nonFraction> further awards will be made under the 2020 Plan. Any options or awards outstanding under the 2020 Plan are governed by the terms of the 2020 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Plan provided for the granting of incentive stock options and nonstatutory stock options to employees, directors, consultants or advisors. As of the effective date of the 2020 Plan, no further awards will be made under the 2010 Plan. Any options or awards outstanding under the 2010 Plan are governed by the terms of the 2010 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-808">6,391,224</ix:nonFraction> shares available for grant under the Plans. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-809" continuedAt="f-809-1" escape="true">The following table presents classification of stock-based compensation expense within the consolidated statements of operations:</ix:nonNumeric></span></div><ix:continuation id="f-809-1"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-810">4,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-811">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-812">5,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-813">16,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-814">15,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-815">11,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-816">3,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-817">3,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-818">2,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-819">24,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-820">23,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-821">19,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-822">49,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-823">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-824">39,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each restricted stock unit ("RSU") represents the right to receive <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" format="ixt-sec:numwordsen" scale="0" id="f-825">one</ix:nonFraction> share of the Company's common stock upon vesting. The fair value of RSUs granted by the Company was calculated based upon the Company's closing stock price on the date of the grant, and the stock-based compensation expense is recognized over the vesting period. RSUs generally vest </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-806-2" continuedAt="f-806-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over <ix:nonNumeric contextRef="c-194" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-826">four years</ix:nonNumeric> with <ix:nonFraction unitRef="number" contextRef="c-195" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-827"><ix:nonFraction unitRef="number" contextRef="c-196" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-828"><ix:nonFraction unitRef="number" contextRef="c-197" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-829"><ix:nonFraction unitRef="number" contextRef="c-198" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-830">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the grants vesting at the end of the first year and the remaining vesting annually over the following three years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-831" continuedAt="f-831-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity was as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"/><td style="width:61.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-832">773,814</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-833">26.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-834">1,244,993</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-835">24.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-836">231,188</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-837">29.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-838">105,071</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-839">24.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-840">1,682,548</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-201" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-841">24.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value for each RSU granted during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-842">24.78</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-843">26.09</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-844">26.86</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="f-845">32,264</ix:nonFraction> of unrecognized compensation cost related to RSUs granted under the Plans, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-194" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-846">2.90</ix:nonNumeric> years. During the years ended December&#160;31, 2024 and 2023, <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-847">231,188</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-848">13,241</ix:nonFraction> RSUs vested, respectively. The fair value of RSUs vested during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="f-849">5,822</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="f-850">355</ix:nonFraction>, respectively. <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="0" id="f-851">No</ix:nonFraction> RSUs vested during year ended December 31, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 and February 2023, the Company awarded performance-based restricted stock units ("PRSUs") under the 2022 Plan. Each PRSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" format="ixt-sec:numwordsen" scale="0" id="f-852">one</ix:nonFraction> share of common stock upon the achievement of specified performance goals. The fair value of PRSUs granted by the Company was calculated based upon the Company's closing stock price on the date of the grant, and the stock-based compensation expense is recognized when the grant date is determined and performance conditions are probable of achievement. At the point when performance conditions are considered probable of achievement, the Company records stock-based compensation expense with a cumulative catch-up expense in the period first recognized and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company awarded to all executive officers PRSUs for a maximum of <ix:nonFraction unitRef="shares" contextRef="c-205" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-853">180,000</ix:nonFraction> shares (based on <ix:nonFraction unitRef="number" contextRef="c-205" decimals="2" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" scale="-2" id="f-854">150</ix:nonFraction>% achievement of the applicable performance conditions outlined in the awards), with a target award of <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-855">120,000</ix:nonFraction> PRSUs (based on <ix:nonFraction unitRef="number" contextRef="c-206" decimals="2" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" scale="-2" id="f-856">100</ix:nonFraction>% achievement of the applicable performance conditions), and a threshold award of <ix:nonFraction unitRef="shares" contextRef="c-207" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-857">60,000</ix:nonFraction> PRSUs (based on <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" scale="-2" id="f-858">50</ix:nonFraction>% achievement of the applicable performance conditions). All such PRSUs were considered granted under ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Topic 718") in March 2024. Such PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company awarded to certain executive officers PRSUs for a maximum of <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-859">62,693</ix:nonFraction> shares (based on <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" scale="-2" id="f-860">150</ix:nonFraction>% achievement of the applicable performance conditions outlined in the awards), with a target award of <ix:nonFraction unitRef="shares" contextRef="c-209" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-861">41,795</ix:nonFraction> PRSUs (based on <ix:nonFraction unitRef="number" contextRef="c-209" decimals="2" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" scale="-2" id="f-862">100</ix:nonFraction>% achievement of the applicable performance conditions), and a threshold award of <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-863">20,898</ix:nonFraction> PRSUs (based on <ix:nonFraction unitRef="number" contextRef="c-210" decimals="2" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" scale="-2" id="f-864">50</ix:nonFraction>% achievement of the applicable performance conditions). All such PRSUs were considered granted under Topic 718 in February 2023. Such PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the Company awarded <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-865">90,000</ix:nonFraction> PRSUs to an executive officer of which <ix:nonFraction unitRef="shares" contextRef="c-212" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-866">30,150</ix:nonFraction> PRSUs were considered granted under Topic 718 at the time the PRSUs were awarded. In March 2024 and 2023, of the <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-867">90,000</ix:nonFraction> PRSUs awarded in August 2022, an additional <ix:nonFraction unitRef="shares" contextRef="c-213" decimals="-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-868">14,850</ix:nonFraction></span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-869">45,000</ix:nonFraction> PRSUs were considered granted under Topic 718, respectively. During the year ended December 31, 2024, the Company's compensation committee determined the achievement of the awards set to vest upon the certification by the Company's compensation committee following the filing of the Company's </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-806-3" continuedAt="f-806-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Of the <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="0" name="sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" format="ixt:num-dot-decimal" scale="0" id="f-870">36,000</ix:nonFraction> PRSUs that were eligible to vest, the Company's compensation committee determined that the applicable performance conditions had been met for <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-871">9,000</ix:nonFraction> of the PRSUs, which vested during the year ended December 31, 2024, and that the applicable performance conditions had not been met for <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-872">27,000</ix:nonFraction> PRSUs, which were forfeited during the year ended December 31, 2024. The remaining <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-873">54,000</ix:nonFraction> PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and following the filing of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ending December 31, 2025.</span></div><ix:continuation id="f-831-1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based restricted stock unit activity was as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"/><td style="width:61.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-874">116,945</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-216" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-875">24.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-876">134,850</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-877">26.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-878">9,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-879">28.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-880">54,000</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-217" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-881">22.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-882">188,795</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-218" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-883">25.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value for each PRSU granted during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-884">26.08</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-885">22.48</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-220" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-886">28.55</ix:nonFraction>, respectively. During the year ended December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-887">9,000</ix:nonFraction> PRSUs vested. The fair value of PRSUs vested during the year ended December&#160;31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="f-888">241</ix:nonFraction>. <ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-889"><ix:nonFraction unitRef="shares" contextRef="c-220" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-890">No</ix:nonFraction></ix:nonFraction> PRSUs vested during the years ended 2023 and 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options must be granted at an exercise price not less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="sdgr:MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" scale="-2" id="f-891">100</ix:nonFraction>% of the fair market value per share at the grant date. The board of directors or compensation committee determines the exercise price of the Company&#8217;s stock options based on the closing price of the common stock as reported on the Nasdaq Global Select Market on the date of the grant. The maximum contractual term of options granted under the Plans is typically <ix:nonNumeric contextRef="c-135" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-892">10</ix:nonNumeric> years, options generally vest over <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-893">four years</ix:nonNumeric> with <ix:nonFraction unitRef="number" contextRef="c-221" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-894"><ix:nonFraction unitRef="number" contextRef="c-222" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-895"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-896"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-897">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the shares underlying the option vesting at the end of the first year and the remaining vesting monthly over the following three years. In March 2024 and February 2023, the Company granted the chief executive officer premium priced options to purchase <ix:nonFraction unitRef="shares" contextRef="c-225" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-898">87,271</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-899">65,525</ix:nonFraction> shares of common stock, respectively, with exercise prices equal to <ix:nonFraction unitRef="number" contextRef="c-226" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-900">110</ix:nonFraction>% of the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-901">169,820</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-902">800,336</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-903">329,224</ix:nonFraction> options under the Plans were exercised for total proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-904">1,488</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-905">9,440</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-906">2,110</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value included several assumptions that require management&#8217;s judgment. The expected terms of options granted to employees during the years ended December&#160;31, 2024, 2023, and 2022 were calculated using an average of historical exercises. Estimated volatility for 2024, 2023, and 2022 incorporated a calculated volatility derived from the historical closing prices of shares of common stock of similar entities whose share prices were publicly available for the expected term of the option. The risk-free interest rate was based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur; as such, the Company does not estimate forfeitures at the time of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-806-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-907" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following are the weighted average valuation assumptions used for option awards during the periods presented:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-911">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-912">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-913">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-914">5.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-17" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-915">4.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-18" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-916">4.78</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-917">4.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-918">3.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-18" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-919">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-920" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity was as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-921">11,274,277</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-922">30.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-923">1,264,176</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-924">25.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-925">169,820</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-926">8.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-927">226,832</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-928">31.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-929">220,648</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-930">47.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-931">11,921,153</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-932">29.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-933">6.31</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-934">30,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-935">8,873,733</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-936">30.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-937">5.65</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-938">30,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-939">14.88</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-940">15.79</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-941">13.67</ix:nonFraction>, respectively. The intrinsic value of options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-942">2,365</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-943">16,213</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-944">6,548</ix:nonFraction>, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-945">40,480</ix:nonFraction></span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of unrecognized compensation cost related to unvested stock options granted under the Plans, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-946">2.07</ix:nonNumeric> years. The fair value of shares vested during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-947">39,422</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-948">46,877</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-949">43,559</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-29</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-950" continuedAt="f-950-1" escape="true">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="f-950-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-951" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following table presents the calculation of basic and diluted net (loss) income per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to common and limited common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-952">187,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-953">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-954">149,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-955">72,670,295</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-956">71,776,301</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-957">71,173,419</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-958">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="f-959">3,210,515</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="f-960">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-961">72,670,295</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-962">74,986,816</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-963">71,173,419</ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share attributable to common and limited common stockholders, basic:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-964">2.57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-965">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-966">2.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share of common and limited common stockholders, diluted:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-967">2.57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-968">0.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-18" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-969">2.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for the years ended December&#160;31, 2024 and 2022, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares and limited common shares outstanding would have been anti-dilutive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, in order to calculate diluted net income per share, the weighted average shares used to compute net income is adjusted by the effect of dilutive securities, including awards under the Plans. Diluted net income per share is computed by dividing the resulting net income by the weighted average number of fully diluted common and limited shares outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-970" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares subject to outstanding common stock options and unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-971">13,603,701</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-972">6,351,996</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-973">11,013,177</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_160"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-974" continuedAt="f-974-1" escape="true">Equity Investments</ix:nonNumeric></span></div><ix:continuation id="f-974-1" continuedAt="f-974-2"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Nimbus</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously provided collaboration services for Nimbus Therapeutics, LLC ("Nimbus") under the terms of a master services agreement executed on May 18, 2010, as amended. Collaboration agreements are separate from the transaction that resulted in equity ownership and related fees are paid in cash to the Company. Nimbus was previously recorded as an equity method investment under the HLBV method, as the entity is a limited liability company and the Company was determined to have significant influence due to the Company's collaboration with Nimbus on a number of drug discovery targets, as well as the Company's level of ownership in Nimbus. During the period ended September 30, 2023, the Company's equity ownership in Nimbus was diluted to the point that the Company no longer has significant influence over the entity. As the Company no longer has significant influence over Nimbus, after June 30, 2023, the equity investment in Nimbus is valued as a non-marketable equity security.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the Nimbus investment was $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-975">2,436</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-976">1,928</ix:nonFraction>, respectively. The Company has no obligation to fund Nimbus' losses in excess of its investment. During the year ended </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-974-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, the Company reported an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="f-977">508</ix:nonFraction> on the Nimbus investment. During the year ended December&#160;31, 2023, the company reported a realized gain of $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-978">147,213</ix:nonFraction> on the Nimbus investment, which reflected the total cash distribution the Company received from Nimbus on account of Takeda's acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor NDI-034858, as well as an unrealized gain of $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-979">1,928</ix:nonFraction> on the Nimbus investment due to the change in accounting method. The Company reported <ix:nonFraction unitRef="usd" contextRef="c-231" decimals="INF" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-980">no</ix:nonFraction> gains or losses on the Nimbus investment during the year ended December 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Morphic</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;15, 2024, the Company disposed of its equity stake in Morphic Holding, Inc. ("Morphic") for aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-981">47,588</ix:nonFraction> in connection with Eli Lilly and Company's acquisition of Morphic. Prior to the disposition of the Morphic investment, the Company accounted for its investment in Morphic at fair value based on the share price of Morphic&#8217;s common stock at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, the Company reported a mark-to-market gain of $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-982">23,474</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-983">1,778</ix:nonFraction>, respectively, on the Morphic investment. During the year ended December 31, 2022, the Company reported a mark-to-market loss of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-984">17,226</ix:nonFraction> on the Morphic investment. As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Morphic was <ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-985">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-986">24,114</ix:nonFraction>, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Ajax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="sdgr:NumberOfPreferredSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-987">631,377</ix:nonFraction> shares of Series B preferred stock of Ajax Therapeutics, Inc. ("Ajax") for $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-988">1,700</ix:nonFraction> in cash. In April 2024, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="sdgr:NumberOfPreferredSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-989">1,416,450</ix:nonFraction> shares of Series C preferred stock of Ajax for $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-990">3,000</ix:nonFraction> in cash. The Company has concluded that its equity investment in Ajax should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ajax. During the year ended December&#160;31, 2024, the Company recorded an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="f-991">202</ix:nonFraction> on the Ajax investment. <ix:nonFraction unitRef="usd" contextRef="c-241" decimals="INF" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:fixed-zero" scale="0" id="f-992"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="INF" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:fixed-zero" scale="0" id="f-993">No</ix:nonFraction></ix:nonFraction> gain or loss was recorded on the Ajax investment during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Ajax was $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-994">4,498</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-995">1,700</ix:nonFraction>, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Structure Therapeutics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company purchased <ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="sdgr:NumberOfPreferredSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-996">494,035</ix:nonFraction> shares of Series B preferred stock of Structure Therapeutics for $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-997">2,000</ix:nonFraction> in cash. In April 2022, the Company purchased an additional <ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="sdgr:NumberOfPreferredSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-998">148,210</ix:nonFraction> shares of Series B preferred stock for $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="f-999">600</ix:nonFraction> in cash. On February 7, 2023, Structure Therapeutics completed its initial public offering ("IPO"). Immediately upon the closing of Structure Therapeutics' IPO, all of the outstanding Series B preferred stock automatically converted into ordinary shares on a <ix:nonFraction unitRef="number" contextRef="c-247" decimals="0" name="us-gaap:PreferredStockConvertibleConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1000">one</ix:nonFraction>-for-one basis. The Company purchased <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="sdgr:NumberOfSharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1001">275,000</ix:nonFraction> American Depository Shares ("ADSs") at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-248" decimals="2" name="sdgr:AmericanDepositorySharesPurchasedPricePerShare" scale="0" id="f-1002">15.00</ix:nonFraction> per ADS in the IPO. Each ADS represents <ix:nonFraction unitRef="number" contextRef="c-249" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" format="ixt-sec:numwordsen" scale="0" id="f-1003">three</ix:nonFraction> ordinary shares. The Company accounts for its investment in Structure Therapeutics at fair value based on the closing price of Structure Therapeutics' ADSs as of the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company recorded a mark-to-market loss of $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1004">18,096</ix:nonFraction> on the Structure Therapeutics investment. During the year ended December 31, 2023, the Company recorded a mark-to-market gain of $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1005">49,755</ix:nonFraction> on the investment. During the year ended December 31, 2022, the Company recorded a loss of $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="f-1006">858</ix:nonFraction> on the Structure Therapeutics investment under the hypothetical liquidation book value method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Structure Therapeutics was $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1007">36,202</ix:nonFraction></span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-1008">55,509</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_163"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1009" continuedAt="f-1009-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-1009-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers a 401(k) employee savings plan to its U.S.&#8209;based employees. The Company made discretionary matching contributions equal to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1010">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1011">4</ix:nonFraction>% of compensation contributed by employees for the years ended December&#160;31, 2024, 2023, and 2022. Matching contributions during 2024, 2023, and 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1012">4,478</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1013">4,135</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1014">3,243</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-31</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1015" continuedAt="f-1015-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-1015-1"><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Board Member</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, the Company paid consulting fees of $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-1016">428</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-1017">420</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="f-1018">410</ix:nonFraction>, respectively, to a member of its board of directors.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bill &amp; Melinda Gates Foundation, an entity under common control with Bill &amp; Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations. Revenue recognized for licenses and services provided by the Company under this grant were $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1019">111</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1020">253</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1021">387</ix:nonFraction> for the years ended December&#160;31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1022">2,031</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1023">2,822</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1024">1,949</ix:nonFraction>, respectively, in drug discovery contribution revenue related to funds received under agreements with the Bill &amp; Melinda Gates Foundation, aimed at accelerating drug discovery in women&#8217;s health. As of December&#160;31, 2024 and 2023, restricted cash on hand related to the arrangement was $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1025">1,021</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1026">2,251</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1027">6,016</ix:nonFraction> in software contribution revenue related to funds received under agreements with the Bill &amp; Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins. As of December&#160;31, 2024, restricted cash on hand related to the arrangement was $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1028">8,606</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-264" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1029"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1030">no</ix:nonFraction></ix:nonFraction> receivables due from the Bill &amp; Melinda Gates Foundation related to any of these agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gates Ventures, LLC is an entity under the control of William H. Gates III, who may be deemed to be the beneficial owner of more than <ix:nonFraction unitRef="number" contextRef="c-266" decimals="2" name="sdgr:PercentageOfVotingSecurities" scale="-2" id="f-1031">5</ix:nonFraction>% of the Company&#8217;s voting securities. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1032"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1033"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1034">1,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> in contribution revenue in connection with its entry into an agreement with Gates Ventures, LLC annually from June 2020 to June 2022. In August 2023, the Company renewed the agreement with Gates Ventures, LLC and recognized $<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1035">1,800</ix:nonFraction> in contribution revenue upon extension of the agreement and $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="sdgr:SoftwareContributionRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1036">2,000</ix:nonFraction> in contribution revenue upon the first anniversary of the extension. As of December&#160;31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-272" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1037"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1038">no</ix:nonFraction></ix:nonFraction> receivables due from Gates Ventures, LLC.</span></div></ix:continuation><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_169"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1039" continuedAt="f-1039-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-1039-1" continuedAt="f-1039-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that its chief executive officer ("CEO") is its chief operating decision maker ("CODM"). The Company&#8217;s CEO evaluates the financial performance of the Company based on <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1040">two</ix:nonFraction> reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company&#8217;s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments. Segment gross profit is derived by deducting cost of sales from U.S. GAAP revenue. Cost of sales are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount or by expenses directly incurred to support the Software or Drug Discovery segments. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain cost items are not allocated to the Company&#8217;s reportable segments. These cost items primarily consist of non-drug discovery program related compensation and general operational expenses associated with the Company&#8217;s research and development, sales and marketing, and general and administrative. These costs are incurred by both segments and due to the integrated nature of the Company&#8217;s Software and Drug Discovery segments, any allocation methodology would be subjective and may not provide meaningful analysis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue is primarily earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><ix:continuation id="f-1039-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1041" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is financial information with respect to the Company&#8217;s reportable segments for the years presented:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1042">180,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1043">159,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1044">135,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1045">27,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1046">57,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1047">45,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1048">207,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1049">216,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1050">180,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment cost of revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1051">36,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1052">29,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1053">29,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1054">38,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1055">46,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1056">50,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1057">75,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1058">75,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1059">79,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1060">143,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1061">129,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1062">106,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" sign="-" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1063">11,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1064">11,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" sign="-" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1065">4,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1066">132,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1067">140,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-1068">101,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unallocated (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1069">201,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1070">181,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1071">126,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1072">39,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1073">37,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1074">30,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1075">99,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1076">99,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1077">90,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-1078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1079">147,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1080">11,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1081">5,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1082">53,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1083">18,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1084">17,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1085">19,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1086">3,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1087">1,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1088">2,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1089">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1090">187,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1091">40,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1092">149,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1093" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1094">114,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1095">161,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1096">123,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1097">25,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1098">24,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1099">21,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1100">65,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1101">29,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1102">34,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1103">1,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1104">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1105">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1106">207,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1107">216,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1108">180,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-33</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_175"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_178"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of December&#160;31, 2024. The term "disclosure controls and procedures," means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on such evaluation of our disclosure controls and procedures as of December&#160;31, 2024, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company, as such term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed by, or under the supervision of, our principal executive officer and principal financial officer and effected by our board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed our internal control over financial reporting as of December&#160;31, 2024, using the criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">set forth by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of its evaluation, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2024. Our independent registered public accounting firm, KPMG LLP, has issued an attestation report on the effectiveness of our internal control over financial reporting, which is included in Item 8 of this Annual Report.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fourth quarter of 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud due to inherent limitations of internal controls. Because of such limitations, there is risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting or disclosure controls and procedures. However, these inherent limitations are known features of the disclosure and financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">150</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_181"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(b) Director and Officer Trading Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.</span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1109" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes, for the fourth quarter of 2024, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a <ix:nonNumeric contextRef="c-292" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1110">Rule 10b5-1 trading arrangement</ix:nonNumeric>, or (2) a "<ix:nonNumeric contextRef="c-292" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1111"><ix:nonNumeric contextRef="c-292" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1112">non-Rule 10b5-1 trading arrangement</ix:nonNumeric></ix:nonNumeric>" (as defined in Item 408(c) of Regulation S-K):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name and Title</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Action Taken (Date of Action)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Type of Trading Arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nature of Trading Arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Duration of Trading Arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Aggregate Number of Shares of Common Stock</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-293" name="ecd:TrdArrIndName" id="f-1113">Robert Abel</ix:nonNumeric> <ix:nonNumeric contextRef="c-293" name="ecd:TrdArrIndTitle" id="f-1114">Executive Vice President, Chief Scientific Officer, Platform</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adoption</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonNumeric contextRef="c-293" name="ecd:TrdArrAdoptionDate" id="f-1115">November&#160;26, 2024</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-293" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1116">Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares</ix:nonNumeric></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sale</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until <ix:nonNumeric contextRef="c-293" name="ecd:TrdArrExpirationDate" id="f-1117">December&#160;31, 2025</ix:nonNumeric>, or such earlier date upon which all transactions are completed or expire without execution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Up to <ix:nonFraction unitRef="shares" contextRef="c-294" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1118">107,605</ix:nonFraction> shares</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrIndName" id="f-1119">Karen Akinsanya</ix:nonNumeric>, <ix:nonNumeric contextRef="c-295" name="ecd:TrdArrIndTitle" id="f-1120">President of R&amp;D, Therapeutics</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adoption</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonNumeric contextRef="c-295" name="ecd:TrdArrAdoptionDate" id="f-1121">December&#160;17, 2024</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-295" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1122">Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sale</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until <ix:nonNumeric contextRef="c-295" name="ecd:TrdArrExpirationDate" id="f-1123">December&#160;31, 2025</ix:nonNumeric>, or such earlier date upon which all transactions are completed or expire without execution</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Up to <ix:nonFraction unitRef="shares" contextRef="c-296" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1124">121,178</ix:nonFraction> shares</span></div></td></tr></table></div></ix:nonNumeric><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_187"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">151</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_190"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_193"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 10 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December&#160;31, 2024 pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code on our website, www.schrodinger.com. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. Our website is not incorporated by reference into this Annual Report and you should not consider any information contained in or accessible from our website to be a part of this Annual Report.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_196"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December&#160;31, 2024 pursuant to General Instruction G(3) of Form 10-K.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_199"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 12 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December&#160;31, 2024 pursuant to General Instruction G(3) of Form 10-K.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_202"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 13 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December&#160;31, 2024 pursuant to General Instruction G(3) of Form 10-K.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_205"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 14 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2025 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December&#160;31, 2024 pursuant to General Instruction G(3) of Form 10-K.</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_208"></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">152</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_211"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_214"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:51.34pt">Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are included in the page</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s herein</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and are filed as part of this Annual Report.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_94">Reports of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_94">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">Consolidated Balance Sheets as of December 31, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">4</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97"> and 202</a>3</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_97">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">Consolidated Statements of Operations for the Years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">, and 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_100">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">Consolidated Statements of Comprehensive </a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">(Loss) </a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">Income</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103"> </a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">for the Years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">4</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">, and 202</a>2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_103">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">Consolidated Statements of Stockholders&#8217; Equity for the Years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">4</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">, and 202</a>2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_106">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">Consolidated Statements of Cash Flows for the Years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">4</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">, 202</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">, and 202</a>2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_109">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_112">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_112">10</a></span></div></td></tr></table></div><div style="margin-top:18pt;padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:51.34pt">Financial Statement Schedules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:18pt;padding-left:99pt;text-align:justify;text-indent:-63pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:51.34pt">Exhibits</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report are listed below.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description of Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">File No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Filed Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520029889/d133373dex31.htm">Restated Certificate of Incorporation, as amended</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7/31/2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097823000029/sdgr-20230413xexx31arbylaw.htm">Amended and Restated Bylaws of Schr&#246;dinger, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4/13/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520014624/d766269dex41.htm">Specimen Stock Certificate evidencing the shares of common stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/27/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520014624/d766269dex42.htm">Amended and Restated Share Exchange Agreement, dated January 24, 2020, by and between the Registrant and Bill &amp; Melinda Gates Foundation Trust</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/27/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000156459021010727/sdgr-ex43_186.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3/4/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097824000018/sdgr-20231231xexx101arira.htm">Amended and Restated Investors&#8217; Rights Agreement, dated as of November 9, 2018, by and among the Registrant and the other parties thereto, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/28/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex102.htm">2010 Stock Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex103.htm">Form of Notice of Stock Option Grant and Stock Option Agreement under 2010 Stock Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520014624/d766269dex104.htm">2020 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/27/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022006713/sdgr-ex105_247.htm">Form of Stock Option Agreement and Form of Restricted Stock Unit Agreement for U.S. Participants under the 2020 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/24/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459020053292/sdgr-ex102_8.htm">Form of Stock Option Agreement for Non-U.S. Participants under the 2020 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11/12/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022006713/sdgr-ex106_246.htm">Form of Restricted Stock Unit Agreement for Non-U.S. Participants under the 2020 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/24/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000072/sdgr-20240630xex1042020esp.htm">2020 Employee Stock Purchase Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7/31/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000046/sdgr-20240331x10xqex1035th.htm">Fifth Amended and Restated Director Compensation Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5/1/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex108.htm">Senior Executive Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022029714/sdgr-ex102_6.htm">Amended and Restated Executive Severance and Change in Control Benefits Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/18/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex1010.htm">Employment Agreement, dated May 11, 2010, by and between the Registrant and Ramy Farid</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022029714/sdgr-ex101_7.htm">Employment Agreement, dated August 16, 2022, by and between the Registrant and Geoffrey Porges</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/18/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097823000024/sdgr-20221231xexx1015.htm">Employment Agreement, dated March 17, 2003, by and between the Registrant and Jenny Herman</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/28/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex1014.htm">Employment Agreement, dated May 14, 2018, by and between the Registrant and Karen Akinsanya</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex1016.htm">Employment Agreement, dated April 27, 2010, by and between the Registrant and Yvonne Tran</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520005504/d766269dex1017.htm">Employment Agreement, dated September 11, 2006, by and between the Registrant and Patrick Lorton</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1019.htm">Employment Agreement, dated March 9, 2009, by and between the Registrant and Robert Abel</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097824000018/sdgr-2023x1231xexx1019duga.htm">Employment Agreement, dated July 28, 2023, by and between the Registrant and Margaret Dugan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/28/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000072/sdgr-20240630xex101friesne.htm">Consultant Agreement, dated July 1, 1999, between the Registrant and Richard A. Friesner, as amended</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7/31/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1021.htm">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000156459021018181/sdgr-ex101_6.htm">Office Lease Agreement, dated April 5, 2021, by and between the Registrant and SPUSV5 1540 Broadway, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4/8/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022028010/sdgr-ex101_13.htm">First Amendment to Lease, dated May 19, 2022, by and between the Registrant and SPUSV5 1540 Broadway, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000072/sdgr-2024x0630xex102nyleas.htm">Second Amendment to Lease, dated June 13, 2024, by and between the Registrant and SPUSV5 1540 Broadway, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7/31/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1023.htm">Lease, dated August 6, 2008, between One Main Place Portland &#8211; Oregon, Inc., Landlord, and Registrant, Tenant, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459021043687/sdgr-ex102_15.htm">Office Lease Amendment, dated May 6, 2021, by and between Registrant and MADISON-OFC ONE MAIN PLACE OR LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/12/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1024.htm">Agreement, dated as of May 5, 1994, between The Trustees of Columbia University in the City of New York and Registrant, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1025.htm">Agreement, dated as of July 15, 1998, between The Trustees of Columbia University in the City of New York and Registrant, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1026.htm">Agreement, dated as of September 2001, between The Trustees of Columbia University in the City of New York and Schr&#246;dinger, LLC, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1027.htm">Agreement, dated as of June 19, 2003, between The Trustees of Columbia University in the City of New York and Schr&#246;dinger, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1028.htm">Software and Patent License Agreement, dated May 27, 2008, between The Trustees of Columbia University in the City of New York and Schr&#246;dinger, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000119312520005504/d766269dex1029.htm">Services Royalty Amendment, dated November 1, 2008, by and between The Trustees of Columbia University in the City of New York and Schr&#246;dinger, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000078/ex101_schrodingercolumbiam.htm">Master License Agreement, dated as of September 11, 2024, by and between Schr&#246;dinger, LLC and The Trustees of Columbia University.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9/12/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000119312520014624/d766269dex1033.htm">Global Bonus Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">333-235890</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1/27/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459020038584/sdgr-ex102_138.htm">Independent Contractor Agreement, dated June 23, 2020, by and between the Registrant and Gates Ventures, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097823000109/sdgr-20230930x10xqex101gat.htm">Amendment #1 to the Independent Contractor Agreement, dated August 14, 2023, by and between the Registrant and Gates Ventures, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11/1/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097822000012/sdgr-20220930x10xqex104ind.htm">2021 Inducement Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11/3/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459021010727/sdgr-ex1039_368.htm">Nonstatutory Stock Option Agreement under 2021 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.39</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3/4/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022028010/sdgr-ex103_62.htm">Form of Option Agreement for Non-U.S. Participants under the 2021 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097823000048/sdgr-20230331xxexx101usind.htm">Form of Restricted Stock Unit Agreement for U.S. Participants under 2021 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5/4/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097823000048/sdgr-20230331xxexx102nonxu.htm">Form of Restricted Stock Unit Agreement for Non-U.S. Participants under 2021 Inducement Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5/4/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000072/sdgr-20240630xex1032022pla.htm">Schr&#246;dinger, Inc. 2022 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7/31/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022028010/sdgr-ex104_60.htm">Form of Option Agreement for U.S. Participants under the 2022 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022028010/sdgr-ex105_61.htm">Form of Option Agreement for Non-U.S. Participants under the 2022 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022028010/sdgr-ex106_58.htm">Form of Restricted Stock Unit Agreement for U.S. Participants under the 2022 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000156459022028010/sdgr-ex107_59.htm">Form of Restricted Stock Unit Agreement for Non-U.S. Participants under the 2022 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001490978/000149097824000020/exhibit11-arsalesagreement.htm">Amended and Restated Sales Agreement, dated as of February 28, 2024, by and between Schr&#246;dinger, Inc. and Leerink Partners LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/29/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">R</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">esearch </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">Collaboration </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">and License Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">dated as of November 11, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm"> by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">Schr&#246;dinger</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx1048novar.htm">, Inc. and Novartis Pharma AG</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx191global.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1131">Schr&#246;dinger, Inc. Global Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sdgr-20241231xexx211.htm">Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx231.htm">Consent of KPMG LLP, independent registered public accounting firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="sdgr-20241231xexx322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1490978/000149097824000018/sdgr-20231231x10xkxexx971c.htm">Schr&#246;dinger, Inc. Clawback Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">001-39206</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2/28/2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover page formatted as Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">X</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Schr&#246;dinger, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contract or compensatory plan or arrangement filed in response to Item 15(a)(3) of the Instructions to the Annual Report on Form 10-K.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_217"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">157</span></div></div></div><div id="i9fcbc0760d8f4d2fbc4bc276bb5428c7_220"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">SCHR&#214;DINGER, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: February&#160;26, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Ramy Farid</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ramy Farid, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i9fcbc0760d8f4d2fbc4bc276bb5428c7_7">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Ramy Farid </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and Chief Executive Officer, Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ramy Farid, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Geoffrey Porges, MBBS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Executive Vice President and Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Geoffrey Porges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Jenny Herman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Vice President, Finance and Corporate Controller</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jenny Herman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Michael Lynton</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Michael Lynton</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Jeffrey Chodakewitz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Jeffrey Chodakewitz, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Richard Friesner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Richard Friesner, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Gary Ginsberg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gary Ginsberg</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Rosana Kapeller-Libermann</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Rosana Kapeller-Libermann, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Arun Oberoi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Arun Oberoi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Gary Sender</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gary Sender</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Nancy Thornberry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 26, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nancy Thornberry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">159</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>2
<FILENAME>sdgr-20241231xexx1048novar.htm
<DESCRIPTION>EX-10.48
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5d4cd516e50e4f6283a4b1e49242bc73_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONFIDENTIAL </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">EXECUTION COPY</font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.48</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">RESEARCH COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BY AND BETWEEN</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SCHR&#1254;DINGER, INC.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AND</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOVARTIS PHARMA AG</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">dated as of November 11, 2024</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 2 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i5d4cd516e50e4f6283a4b1e49242bc73_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONFIDENTIAL </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">EXECUTION COPY</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">TABLE OF CONTENTS</font></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">Page</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GOVERNANCE&#160;&#160;&#160;&#160;26</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Steering Committee&#160;&#160;&#160;&#160;26</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subcommittees and Working Groups&#160;&#160;&#160;&#160;28</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Discontinuation of JSC&#160;&#160;&#160;&#160;29</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Limitations on Authority of the JSC&#160;&#160;&#160;&#160;29</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Minutes&#160;&#160;&#160;&#160;29</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alliance Managers&#160;&#160;&#160;&#160;29</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESEARCH COLLABORATION&#160;&#160;&#160;&#160;30</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Research Collaboration&#59; Project Plan&#160;&#160;&#160;&#160;30</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Research Term&#160;&#160;&#160;&#160;31</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Replacement Collaboration Targets and Additional &#91;**&#93;&#160;&#160;&#160;&#160;32</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional Collaboration Targets&#160;&#160;&#160;&#160;34</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gatekeeper&#160;&#160;&#160;&#160;34</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Discovery Milestone Event and Development Candidate Designation&#160;&#160;&#160;&#160;35</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Conduct of the Projects&#160;&#160;&#160;&#160;35</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Project Costs and Expenses&#160;&#160;&#160;&#160;36</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Project Records&#160;&#160;&#160;&#160;36</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disclosure of Results of each Project&#160;&#160;&#160;&#160;36</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Research Efforts&#160;&#160;&#160;&#160;37</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Materials Transfer&#160;&#160;&#160;&#160;37</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subcontracting&#160;&#160;&#160;&#160;38</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subsequent Activities&#160;&#160;&#160;&#160;38</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Use of Novartis Datasets&#59; Maintenance of Novartis Dedicated Tenancy&#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEVELOPMENT AND REGULATORY MATTERS&#160;&#160;&#160;&#160;38</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transfer&#160;&#160;&#160;&#160;38</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Efforts&#160;&#160;&#160;&#160;39</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Reports&#160;&#160;&#160;&#160;40</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Matters&#160;&#160;&#160;&#160;40</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Use of Debarred Person&#160;&#160;&#160;&#160;40</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Standards of Conduct&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMMERCIALIZATION&#160;&#160;&#160;&#160;41</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization Efforts&#160;&#160;&#160;&#160;41</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MANUFACTURING&#160;&#160;&#160;&#160;41</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Generally&#160;&#160;&#160;&#160;41</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Manufacturing Technology Transfer&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GRANT OF RIGHTS AND LICENSES&#160;&#160;&#160;&#160;42</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">License Grants&#160;&#160;&#160;&#160;42</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicensing&#160;&#160;&#160;&#160;43</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Other Rights&#160;&#160;&#160;&#160;43</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Software Exclusions&#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PAYMENTS&#160;&#160;&#160;&#160;44</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upfront Payment&#160;&#160;&#160;&#160;44</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Discovery Milestone Payments&#160;&#160;&#160;&#160;44</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Milestones for Collaboration Compounds and Collaboration Products&#160;&#160;&#160;&#160;45</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sales Milestone Payments&#160;&#160;&#160;&#160;50</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty Payments to Schr&#1255;dinger&#160;&#160;&#160;&#160;53</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty Payments and Reports&#160;&#160;&#160;&#160;58</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment Method&#160;&#160;&#160;&#160;58</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Taxes&#160;&#160;&#160;&#160;58</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Foreign Exchange&#160;&#160;&#160;&#160;59</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Records&#160;&#160;&#160;&#160;59</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inspection of Records&#160;&#160;&#160;&#160;59</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Late Payments&#160;&#160;&#160;&#160;61</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payments to or Reports by Affiliates&#160;&#160;&#160;&#160;61</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Diagnostic Products&#160;&#160;&#160;&#160;61</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Monetization Transaction &#91;**&#93;&#160;&#160;&#160;&#160;61</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTELLECTUAL PROPERTY OWNERSHIP, PATENT PROSECUTION AND ENFORCEMENT&#160;&#160;&#160;&#160;61</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ownership of Intellectual Property&#160;&#160;&#160;&#160;61</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prosecution and Maintenance of Product Specific Patents and Joint Patents&#160;&#160;&#160;&#160;64</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Exclusivity&#160;&#160;&#160;&#160;66</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prosecution, Maintenance and Enforcement of Other Patents&#160;&#160;&#160;&#160;66</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Competitive Infringement of Product Specific Patents or Joint Patents Parties&#160;&#160;&#160;&#160;66</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Third Party Rights&#160;&#160;&#160;&#160;67</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patent Challenges&#160;&#160;&#160;&#160;68</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patent Contacts&#160;&#160;&#160;&#160;69</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- ii -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Personnel Obligations&#160;&#160;&#160;&#160;69</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further Action&#160;&#160;&#160;&#160;69</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Orange Book and Other Equivalent Listing&#160;&#160;&#160;&#160;70</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TRADEMARKS&#160;&#160;&#160;&#160;70</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collaboration Product Trademarks&#160;&#160;&#160;&#160;70</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Use of Name&#160;&#160;&#160;&#160;70</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further Actions&#160;&#160;&#160;&#160;70</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXCLUSIVITY&#160;&#160;&#160;&#160;70</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exclusivity Regarding Development and Commercialization of Collaboration Compounds&#160;&#160;&#160;&#160;70</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exceptions&#160;&#160;&#160;&#160;71</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acquisition of Distracting Product&#160;&#160;&#160;&#160;71</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change of Control&#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONFIDENTIALITY&#160;&#160;&#160;&#160;73</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidentiality&#160;&#160;&#160;&#160;73</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Authorized Disclosure&#160;&#160;&#160;&#160;74</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Publicity&#59; Terms of Agreement&#160;&#160;&#160;&#160;76</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidentiality Term&#160;&#160;&#160;&#160;77</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Publications&#160;&#160;&#160;&#160;77</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effect of Change of Control of Schr&#1255;dinger&#160;&#160;&#160;&#160;78</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination of Prior CDA&#160;&#160;&#160;&#160;79</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TERM AND TERMINATION&#160;&#160;&#160;&#160;79</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HSR Filing&#59; Effectiveness of Agreement&#59; Term&#160;&#160;&#160;&#160;79</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination by Novartis at Will or for a Safety Concern&#160;&#160;&#160;&#160;81</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination by Either Party for Breach&#160;&#160;&#160;&#160;82</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Termination by Either Party for Insolvency&#160;&#160;&#160;&#160;83</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty Increase for Patent Challenge&#160;&#160;&#160;&#160;83</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effects of Termination of this Agreement&#160;&#160;&#160;&#160;84</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Remedies in Lieu of Termination&#160;&#160;&#160;&#160;88</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effects of Expiration of Agreement&#160;&#160;&#160;&#160;88</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other Remedies&#160;&#160;&#160;&#160;89</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Survival&#160;&#160;&#160;&#160;89</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REPRESENTATIONS AND WARRANTIES&#160;&#160;&#160;&#160;90</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mutual Representations, Warranties and Covenants&#160;&#160;&#160;&#160;90</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- iii -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Representations, Warranties, and Covenants by Schr&#1255;dinger&#160;&#160;&#160;&#160;91</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Representations, Warranties, and Covenants as of &#91;**&#93;, and upon Approval of new Project Plans&#160;&#160;&#160;&#160;92</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Other Representations or Warranties&#160;&#160;&#160;&#160;93</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INDEMNIFICATION AND LIMITATION OF LIABILITY&#160;&#160;&#160;&#160;93</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification by Schr&#1255;dinger for Third Party Claims&#160;&#160;&#160;&#160;93</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification by Novartis for Third Party Claims&#160;&#160;&#160;&#160;94</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification Procedures&#160;&#160;&#160;&#160;94</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LIMITATION OF LIABILITY&#160;&#160;&#160;&#160;95</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insurance&#160;&#160;&#160;&#160;95</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DISPUTE RESOLUTION&#160;&#160;&#160;&#160;96</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Disputes&#59; Resolution by Executive Officers&#160;&#160;&#160;&#160;96</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Arbitration&#160;&#160;&#160;&#160;96</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award&#160;&#160;&#160;&#160;97</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Costs&#160;&#160;&#160;&#160;97</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WAIVER OF JURY TRIAL&#160;&#160;&#160;&#160;97</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Injunctive Relief&#160;&#160;&#160;&#160;97</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidentiality&#160;&#160;&#160;&#160;98</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Survivability&#160;&#160;&#160;&#160;98</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Excluded Claims&#160;&#160;&#160;&#160;98</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">MISCELLANEOUS&#160;&#160;&#160;&#160;98</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Entire Agreement&#59; Amendments&#160;&#160;&#160;&#160;98</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Export Control&#160;&#160;&#160;&#160;98</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights in Bankruptcy&#160;&#160;&#160;&#160;98</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Force Majeure&#160;&#160;&#160;&#160;100</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notices&#160;&#160;&#160;&#160;100</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Independent Contractors&#160;&#160;&#160;&#160;101</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maintenance of Records&#160;&#160;&#160;&#160;101</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Third Party Beneficiaries&#160;&#160;&#160;&#160;101</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assignment&#160;&#160;&#160;&#160;101</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law&#160;&#160;&#160;&#160;102</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance by Affiliates&#160;&#160;&#160;&#160;102</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further Actions&#160;&#160;&#160;&#160;102</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compliance with Applicable Law&#160;&#160;&#160;&#160;102</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Severability&#160;&#160;&#160;&#160;102</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Waiver&#160;&#160;&#160;&#160;103</font></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interpretation&#160;&#160;&#160;&#160;103</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- iv -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:108pt;padding-right:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Counterparts&#160;&#160;&#160;&#160;103</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LISTING OF SCHEDULES AND EXHIBITS</font></div><div style="text-align:justify"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule&#160;1.200 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Schr&#246;dinger Platform<br>Schedule 1.203&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Schr&#1255;dinger Product Specific Patents</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 3.1(b)(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Project Plan &#8211; &#91;**&#93;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 3.1(b)(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Project Plan &#8211; &#91;**&#93;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 3.1(b)(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Project Plan &#8211; &#91;**&#93;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 3.1(b)(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Project Plan &#8211; &#91;**&#93;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 3.7(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis Third Party Risk Management</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 3.15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis Datasets&#59; Novartis Dedicated Tenancy</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bank Account Details</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule&#160;12.3(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schedule 13.6(b)(iii)(B)&#160;&#160;&#160;&#160;Baseball Arbitration Terms</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annex 1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Material Transfer Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- v -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i5d4cd516e50e4f6283a4b1e49242bc73_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONFIDENTIAL </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">EXECUTION COPY</font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESEARCH COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">This Research Collaboration and License Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of November 11, 2024 (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Execution Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and among </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a corporation organized under the laws of the State of Delaware, having its principal place of business at 1540 Broadway, 24th Floor, New York, New York, 10036 (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#246;dinger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland, with a place of business at Lichtstrasse 35, 4056 Basel, Switzerland (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Schr&#1255;dinger and Novartis are sometimes referred to herein individually as a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Novartis and its Affiliates (as hereinafter defined) are in the business of discovering, developing, manufacturing, marketing and selling pharmaceutical products worldwide. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Schr&#1255;dinger is a software and drug discovery and development company that has technology and expertise relating to the discovery and development of compounds directed to certain Targets using its proprietary computational platform technology and drug discovery and development capabilities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Schr&#1255;dinger and Novartis desire to collaborate in the performance of research projects for the purpose of discovery and development of Collaboration Compounds and Collaboration Products suitable for development for human therapeutic uses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW THEREFORE</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 1.&#160;&#160;&#160;&#160;DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As used in this Agreement, the terms with initial letters capitalized, whether used in the singular or plural form, shall have the meanings set forth in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Definitions) or, if not listed below, the meaning designated in places throughout this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Standards</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Novartis, International Financial Reporting Standards (IFRS) and, with respect to Schr&#246;dinger, generally accepted accounting principles as applicable in the United States (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case, as generally and consistently applied throughout such Party&#8217;s organization. Each Party shall promptly notify the other Party in writing if such Party changes the Accounting Standards pursuant to which its </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">records are maintained&#59; it being understood that each Party may only use internationally recognized accounting principles (e.g., IFRS, GAAP, etc.) as its Accounting Standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Achieve(ment of) the DC Criteria</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to a given Project for a Collaboration Target (&#91;**&#93;), a Collaboration Compound Directed Against such Collaboration Target demonstrates the DC Criteria for such Project as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determined &#91;**&#93;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquired Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.6(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.6(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer Background Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.6(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer Future Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.6(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.7&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Acquirer Background Technology and Acquirer Future Technology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.8&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquisition Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Acquisition of Distracting Product).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.9&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adaptive Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial that does not meet the criteria for a Registrational Trial at the time such Clinical Trial is initiated and includes a prospectively planned opportunity for such Clinical Trial to be modified based on interim analyses to change to a Registrational Trial following an analysis of interim data from subjects in such Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.10&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Collaboration Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Additional Collaboration Targets). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.11&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional &#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.12&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.13&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party, for so long as such control continues. For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under the common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or ownership of more than fifty percent (50%) of the voting stock of such entity, in the case of any other type of legal entity, or by contract or otherwise, or status as a general partner in any partnership or any other arrangement whereby the Person controls or has the right </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 2 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to control the board of directors or equivalent governing body of a corporation or other entity. The Parties acknowledge that, in the case of entities organized under the laws of certain countries where the maximum percentage ownership permitted by law for a foreign investor is less than fifty percent (50%), such lower percentage shall be substituted in the preceding sentence&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such foreign investor has the power to direct the management and policies of such entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.14&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.15&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Alliance Managers).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.16&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any applicable federal, state, local or foreign law, statute, ordinance, principle of common law, or any rule, regulation, standard, guidance, judgment, order, writ, injunction, decree, arbitration award, agency requirement, license or permit of any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.17&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all inventions and other Information conceived, discovered, developed, reduced to practice, identified or otherwise made (a) solely by or on behalf of Novartis or its Affiliates or Sublicensees, (b) solely by or on behalf of Schr&#1255;dinger or its Affiliates, or (c) jointly by or on behalf of both (i) Novartis or any of its or its Affiliates or Sublicensees and (ii) Schr&#1255;dinger or any of its Affiliates, in each case ((a), (b) and (c)), in the performance of activities under this Agreement, including activities relating to the Exploitation of the Collaboration Compounds and Collaboration Products under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.18&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Auditor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.11(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.19&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Available Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.3(c)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.20&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Background IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, any and all Information (including any and all data, models, structures and structure activity relationships, composition of matter, and all variants derived) and Intellectual Property Rights (including all Patents) that are (a) Controlled by such Party or its Affiliates prior to the Effective Date or (b) that become Controlled by such Party or its Affiliates during the Term independently of this Agreement and without the use of or reliance on the other Party&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankrupt Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Rights in Bankruptcy).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.22&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Royalty Rate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty on Collaboration Products).</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 3 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.23&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day that is not a Saturday, Sunday or a day on which banking institutions in New York, New York, Basel, Switzerland, or Cambridge, Massachusetts are required by Applicable Law to remain closed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.24&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.25&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Year</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the one (1) year period beginning on January 1 and ending on December 31, except for the first year which will be begin on the Effective Date and end on December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.26&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party&#58; (a) a merger, reorganization, combination or consolidation of such Party (or, if applicable, a parent company of such Party) with a Third Party that results in the holders of beneficial ownership of the voting securities or other voting interests of such Party (or, if applicable, a parent company of such Party) immediately prior to such merger, reorganization, combination or consolidation ceasing to hold beneficial ownership of at least fifty percent (50%) of the combined voting power of the surviving entity or the applicable parent of the surviving entity immediately after such merger, reorganization, combination or consolidation&#59; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities or other voting interest of such Party or a parent company of such Party&#59; or (c) the sale or other transfer (in one (1) transaction or a series of related transactions) to a Third Party of all or substantially all of such Party&#8217;s or its parent company&#8217;s assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.27&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification Procedure).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.28&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Acquired Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a compound or product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directed Against a Collaboration Target or &#91;**&#93; for which Novartis or its Affiliate acquires rights to Develop or Commercialize in the Field as the result of a license, option, collaboration, merger, acquisition or combination with, from, or of a Third Party, and with respect to which one or more INDs was submitted for filing with the FDA (or foreign equivalent) prior to the effective date of such license, collaboration, merger, acquisition or combination or the exercise of the such option (such transaction, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Acquisition Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). For clarity, in the case of a Clinical Acquisition Transaction that is an option, the closing date of such Clinical Acquisition Transaction shall be deemed to be the date of option exercise.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.29&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Acquisition Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.28</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.30&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any human clinical investigation of a Collaboration Compound or Collaboration Product as defined in 21 CFR 312.3(b) or a clinical trial of a Collaboration Product as defined in Article 2.2(2) of Regulation (EU)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No. 536&#47;2014.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 4 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.31&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CMC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means chemistry, manufacturing and controls with respect to Collaboration Compounds or Collaboration Products, including the chemistry, manufacturing and controls section of Regulatory Materials for the Collaboration Products and all data contained or referenced therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.32&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Compound</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to each Collaboration Target,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) any Small Molecule conceived, identified, derived or generated by (i) either Party under an applicable Project Plan or (ii) Schr&#1255;dinger prior to the Effective Date or during the Term, in each case (i) or (ii), that is Directed Against such Collaboration Target&#59; (b) any Small Molecule Directed Against a Collaboration Target not falling within the scope of (a) that is (i) conceived, identified, derived or generated by or on behalf of Novartis or its Affiliates, (ii) owned or otherwise controlled by Novartis or its Affiliates and optimized by or on behalf of Novartis or its Affiliates, or (iii) &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.33&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Compound Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the definition of &#8220;Confidential Information&#8221; in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.42</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.34&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.35&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical product containing, comprising or incorporating a Collaboration Compound as an active ingredient (whether alone or as a Combination Product) for use in the Field in the Territory in all presentations, formulations, and dosage forms. For the purpose of any payment obligations pursuant to this Agreement, (a) all products that contain one (1) and the same Collaboration Compound (without any other Collaboration Compound or other active ingredient or any co-packaged component), will be deemed a single Collaboration Product, (b) and in the case of any Combination Product, (i) all products that contain one (1) and the same Collaboration Compound and the same other active ingredient(s) (without any other Collaboration Compound), will be deemed a single Collaboration Product&#59; (ii) all products that contain the same combination of two (2) or more Collaboration Compounds (without any other active ingredient or co-packaged component) will be deemed a single Collaboration Product&#59; and (iii) all products that contain the same combination of two (2) or more Collaboration Compounds and the same other active ingredient(s), will be deemed a single Collaboration Product&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in the case of (ii) or (iii), if such Combination Product includes Collaboration Compounds Directed Against more than one Collaboration Target, such Collaboration Product shall only be considered to be Directed Against one (1) such Collaboration Target for purposes of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which one (1) Collaboration Target Schr&#1255;dinger may designate in its sole discretion by providing written notice to Novartis no later than the date of Schr&#1255;dinger&#8217;s issuance of the first invoice in respect of such Collaboration Product in accordance with the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; it being understood and agreed that Schr&#1255;dinger&#8217;s designation of such Collaboration Target will apply to all payment obligations Novartis has in respect of such Collaboration Product under this Agreement, and that once Schr&#1255;dinger has designated a Collaboration Target for such Collaboration Product, Schr&#1255;dinger may not change such designation.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 5 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.36&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each of the (a) Initial Collaboration Targets&#59; (b) Replacement Collaboration Targets&#59; and (c) Additional Collaboration Targets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.37&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Combination Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.140(g)(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.38&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialize</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities directed to the marketing, promotion, sale (and offer for sale or contract to sell), distribution, importation or other commercial exploitation (including pricing and reimbursement activities) for a product in the Territory. Commercialization shall include commercial activities conducted in preparation for product launch and interacting with Regulatory Authorities regarding any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.39&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Novartis&#8217; obligations under this Agreement, the carrying out of such obligations or tasks with &#91;**&#93; and other relevant scientific, technical and commercial factors, but without regard to the obligations (including &#91;**&#93;) to Schr&#246;dinger or the rights of Schr&#246;dinger hereunder. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Schr&#246;dinger&#8217;s obligations under this Agreement, the carrying out of such obligations or tasks with &#91;**&#93;, but in any case, at least commensurate with the level of efforts Schr&#246;dinger uses in relation to other similar collaborations with Third Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.40&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competitive Infringement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Notification).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.41&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.42&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Party, and subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality), all non-public Information of such Party that is disclosed to the other Party under this Agreement or the Prior CDA or generated under or in connection with the Project Plan, which may include specifications, know-how, trade secrets, technical information, models, business information, inventions, discoveries, methods, procedures, formulae, protocols, techniques, data, and unpublished Patent applications, whether disclosed in oral, written, graphic, or electronic form&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, notwithstanding the foregoing, (a) the existence and terms of this Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the Receiving Party with respect thereto, (b) subject to clause (c) with respect to Collaboration Compound Information, joint inventions shall be deemed to be the Confidential Information of both Parties, and both Parties shall be deemed to be the Disclosing Party with respect thereto, (c) any Information specifically relating to Collaboration Compounds, Collaboration Products or the Exploitation thereof (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Compound Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be deemed the Confidential Information of Novartis, and Novartis shall be deemed to be the Disclosing Party, and Schr&#246;dinger shall be deemed to be the Receiving Party, with respect thereto, (d) the Schr&#1255;dinger Platform, Schr&#1255;dinger&#8217;s Background IP and Schr&#1255;dinger-Owned Arising IP shall be the Confidential Information of Schr&#1255;dinger and Schr&#1255;dinger will have no obligation to disclose the Schr&#1255;dinger Platform to Novartis, subject to Novartis&#8217; right to access the Schr&#1255;dinger Platform as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and (e) with respect to a Reversion </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 6 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compound or Reversion Product, any intellectual property that is the subject of the reversion licenses set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(ii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and that is solely and specifically related to Reversion Compound or Reversion Product shall be the Confidential Information of Schr&#246;dinger, subject to Novartis maintaining certain rights with respect thereto as agreed upon under this Agreement. For clarity, any use or disclosure thereof that is authorized under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) shall not be restricted by, or be deemed a violation of, such Prior CDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.43&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Material, Information, Patent or Intellectual Property Right, that a Party or its Affiliate (a) owns such Material, Information, Patent or Intellectual Property Right, or (b) has a license or right to use to such Material, Information, Patent or Intellectual Property Right other than as a result of licenses granted under this Agreement, in each case ((a) or (b)) with the ability to grant to the other Party access, a right to use, or a license, or a sublicense (as applicable) to such Material, Information, Patent or Intellectual Property Right on the terms and conditions set forth herein, without violating the terms of any agreement or other arrangement with any Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, right to use or (sub)license. Schr&#246;dinger and its Affiliates shall not be deemed to Control any Material, Information, Patent or other Intellectual Property Right licensed to Schr&#246;dinger pursuant to a Schr&#246;dinger New In-License entered into after the Effective Date unless such Schr&#246;dinger New In-License becomes a Collaboration In-License in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, with respect to Acquirer Technology, the definition of &#8220;Control&#8221; is subject to the terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Effect of Change of Control of Schr&#1255;dinger). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.44&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conversion Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the definition of &#8220;Converted Trial&#8221; in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.45</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.45&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Converted Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an Adaptive Trial that is modified to meet and otherwise satisfies the criteria for a Registrational Trial based on pre-specified analyses following an analysis of interim data from subjects in such Adaptive Trial. For clarity, an Adaptive Trial shall only constitute a Converted Trial if, from and after the date following FDA&#8217;s approval of the new or amended IND for such Clinical Trial as a Registrational Trial or an equivalent approval of a non-US Regulatory Authority, a patient is dosed in such Adaptive Trial (such date with respect to such Converted Trial, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conversion Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.46&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Convicted Individual</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Convicted Entity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 21 U.S.C. &#167; 335a(a) or (b), or 42 U.S.C. &#167; 1320a-7(a) or (b), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.47&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covenant Not To Sue</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(B). </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 7 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.48&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cover</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covered</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covering</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a compound or product and a Patent, that, in absence of a (sub)license under, or ownership of, such Patent, the making, using, offering for sale, selling or importing of such compound or product would infringe such Patent as issued or, with respect to a pending Claim included in such Patent, as if such pending Claim were to issue without modification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.49&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cure Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Termination by Either Party for Breach).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.50&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DC Criteria</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for a given Project for a Collaboration Target (&#91;**&#93;), the experimental parameters set forth in the applicable Project Plan, specifically the criteria that define the characteristics required for a Collaboration Compound to achieve Development Candidate status for the Collaboration Target (&#91;**&#93;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.51&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.52&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Debarred Entity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a corporation, partnership, or association that has been debarred by the FDA pursuant to 21 U.S.C. &#167; 335a(a) or (b), or 21 CFR Section 312.70, or an employee, partner, shareholder, member, or a subsidiary or Affiliate of a Debarred Entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.53&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Debarred Individual</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an individual who has been debarred by the FDA pursuant to 21 U.S.C. &#167; 335a(a) or (b) or 21 CFR Section 312.70 or an employer, employee or partner of a Debarred Individual.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.54&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Develop</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities that relate to obtaining, maintaining or expanding Regulatory Approval of a compound or product and to supporting appropriate usage for such compound or product. This includes&#58; (a) preclinical&#47;nonclinical research and testing, toxicology, and Clinical Trials and (b) preparation, submission, review, and development of data or other Information and Regulatory Materials for the purpose of submission to a Governmental Authority to obtain, maintain or expand Regulatory Approval of a product (including contacts with Regulatory Authorities).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.55&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Candidate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for a given Project Plan for a Collaboration Target, a Collaboration Compound Directed Against such Collaboration Target which (i) has been designated &#91;**&#93; or (ii) has otherwise been selected &#91;**&#93; to advance to &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.56&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.57&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.58&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Directed Against</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Compound, Collaboration Product or other compound or product, and a Target, that the Collaboration Compound or Collaboration Compound contained, comprised or incorporated in such Collaboration Product, or the compound or compound contained, comprised or incorporated in </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 8 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such other product binds to and modulates such Target (a) as its primary intended mechanism of action and (b) with an &#91;**&#93;, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the case of &#91;**&#93;, if a Collaboration Compound or other compound meets the aforementioned requirements for &#91;**&#93;, it will be deemed to meet the definition of &#8220;Directed Against&#8221; for purposes of the &#91;**&#93;. The foregoing criteria for a Collaboration Compound, Collaboration Product or other compound or product, to be Directed Against a particular Collaboration Target may be replaced or modified from time to time by amendment of this Agreement pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Entire Agreement), and the JSC shall have the right to recommend such potential amendments for consideration by the Parties.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.59&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality), subject to the proviso in the definition of Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.60&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discontinued Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Collaboration Target for which the activities under this Agreement are discontinued by Novartis under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Discontinued Targets shall be deemed Terminated Targets.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.61&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Criteria</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the steps or criteria to determine whether a Discovery Milestone Event has been achieved, as such steps or criteria are set forth in this Agreement or relevant Project Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.63&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.64&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Distracting Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Acquisition of Distracting Product).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.65&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOJ</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.66&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dollar</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">$</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the lawful currency of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.67&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Effectiveness of the Agreement&#59; Term).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.68&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency and any successor agency thereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.69&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Excluded Claims). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.70&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Individual</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Entity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (A) an individual or entity, as applicable, who has been excluded, debarred, suspended, or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG&#47;HHS) of the U.S. Department of Health and Human Services or (B) is an individual or entity, as applicable, who has been excluded, debarred, suspended, or is otherwise </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 9 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA), in either case including as provided in accordance with 42 U.S.C. &#167; 1320a-7(a) or (b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.71&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exclusivity Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity Regarding Development and Commercialization of Collaboration Compounds).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.72&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Execution Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date specified in the preamble of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.73&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, in the case of Novartis, &#91;**&#93; of Novartis or his, her, or their designee (or the officer then serving in a substantially equivalent capacity, or his, her, or their designee), and in the case of Schr&#1255;dinger, Schr&#1255;dinger&#8217;s &#91;**&#93; or his, her, or their designee (or the officer then serving in a substantially equivalent capacity, or his, her, or their designee).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.74&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expert</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a mutually acceptable, disinterested, conflict-of-interest-free individual not affiliated with either Party or its Affiliates who, with respect to a dispute concerning a financial, commercial, scientific or regulatory matter possesses appropriate expertise to resolve such dispute. The Expert (or any of the Expert&#8217;s current or former employers) (a) shall not be or have been at any time an Affiliate, employee, consultant (during the previous &#91;**&#93;), officer or director of either Party or any of its Affiliates, or (b) shall not own equity or debt in either Party or any of its Affiliates (other than equity or debt owned through a broad based mutual fund or exchange trade fund).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.75&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exploit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exploitation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a compound, product or process, to research, Develop, Manufacture, Commercialize, make, have made, import, use, sell or offer for sale, commercialize, import, export or otherwise dispose of such compound, product or process.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.76&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FD&#38;C Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Act</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States Federal Food, Drug, and Cosmetic Act, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.77&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States Food and Drug Administration and any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.78&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the prevention, treatment, and diagnosis of any and all indications, including Indications, in humans or animals. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.79&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Product and a country, the first sale in an arms&#8217; length transaction to a Third Party that is not a Related Party with respect to such Collaboration Product, as applicable, in such country after Regulatory Approval of such Collaboration Product has been obtained in such country (but not withstanding any other term or condition of this Agreement, without regard to whether Pricing Approval of such Collaboration Product has been obtained in such country). Sales or transfers of reasonable quantities of a Collaboration Product for Development, including proof of concept studies or </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 10 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other Clinical Trial purposes, or for compassionate, named patient, treatment IND or similar use, shall not be considered a First Commercial Sale, even if reimbursed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.80&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Force Majeure).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.81&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form Project Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Other Project Plans).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.82&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.83&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Future In-Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.84&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gatekeeper</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Gatekeeper). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.85&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gatekeeper Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Gatekeeper). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.86&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.87&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Generic Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Product in a country, any pharmaceutical product that (a) (i) is approved in reliance, in whole or in part, on the prior Regulatory Approval (or on safety or efficacy data submitted in support of such prior Regulatory Approval) of such Collaboration Product as determined by the applicable Regulatory Approval, including any product authorized for sale (1) in the U.S. pursuant to Section 505(b)(2) or Section 505(j) of the Act (21 U.S.C. 355(b)(2) and 21 U.S.C. 355(j), respectively), (2) in the EU pursuant to a provision of Articles 10, 10a or 10b of Parliament and Council Directive 2001&#47;83&#47;EC as amended (including an application under Article 6.1 of Parliament and Council Regulation (EC) No 726&#47;2004 that relies for its content on any such provision), or (3) in any other country or jurisdiction pursuant to all equivalents of such provisions, including any amendments and successor statutes with respect to the subsections (1) through (3) thereto or (ii) is otherwise substitutable under Applicable Law for such Collaboration Product when dispensed without the intervention of a physician or other health care provider with prescribing authority and (b) is sold in the same country as such Collaboration Product by a Third Party that is not a Sublicensee of Novartis or its Affiliates and did not acquire such product in a chain of distribution that included any of Novartis, its Affiliates or its and their Sublicensees. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.88&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;.     </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.89&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GLP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means good laboratory practice as required by the FDA under 21 C.F.R. Part 58 and all applicable FDA rules, regulations, orders, and guidances, and the requirements with respect to good laboratory practices set forth in European Union Directive 2004&#47;10&#47;EC and in the OECD (Organization for Economic Cooperation and Development Council) Principles on Good Laboratory Practice, or as otherwise required by Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.90&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;.    </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 11 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.91&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court, tribunal or other entity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.92&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Handoff</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.93&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HSR Filing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (HSR and Other Governmental Filings).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.94&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.95&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICC Rules</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.96&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93; Project</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Additional &#91;**&#93;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.97&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.98&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.99&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IND</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) an application submitted to the FDA to permit the conduct of a Clinical Trial in accordance with the requirements of U.S. Code of Federal Regulations Title 21 part 312, including all supplements and amendments thereto, or (b) the equivalent application to the applicable Regulatory Authority in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.100&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification Procedures).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.101&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification Procedures).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.102&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indication</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Product, any use to which such Collaboration Product is intended to be put for the treatment, prevention, or cure of a distinct recognized disease, condition, or syndrome, or for the relief of symptoms associated with a recognized disease or condition which, (a) for a Clinical Trial for such Collaboration Product, would be the use of such Collaboration Product for which such Clinical Trial is intended to determine safety or effectiveness and (b) if the NDA for such Collaboration Product is approved in the U.S., would be reflected in the &#8220;Indications and Usage&#8221; section of labeling pursuant to 21 C.F.R. &#167;201.57(c)(2) or, to the extent applicable, any comparable labeling section outside the U.S., in each case ((a) and (b)), subject to the following&#58;</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 12 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a single Indication includes the primary disease and all variants or subdivisions or sub-classifications within such primary disease as recognized by major disease and treatment guidelines&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;separate Indications shall not be considered to exist solely as a result of the conduct of separate Clinical Trials of a Collaboration Product in combination with another pharmaceutical or biological product where a Clinical Trial had been initiated or Regulatory Approval was obtained for such Collaboration Product for use as monotherapy or in combination with a different pharmaceutical or biological product&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the approved use of such Collaboration Product for such disease or condition in a different line of treatment or a different temporal position in a treatment algorithm for the same disease or condition (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">i.e.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, first line therapy v. second line therapy) with respect to a disease or condition shall not constitute separate Indications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.103&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indirect Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.104&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any data, results, discoveries and information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, technical information, business information, unpublished patent applications, practices, techniques, methods, processes, creations, inventions, developments, specifications, formulations, formulae, software, source code, object code, algorithms, marketing reports, expertise, stability, technology, test data (including pharmacological, biological, chemical, biochemical, toxicological, and clinical test data), manufacturing (including CMC) data, analytical and quality control data, stability data, studies and procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.105&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Collaboration Targets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.106&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial &#91;**&#93; Project</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.107&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Project Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.108&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Replacement Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Initial Replacement Period). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.109&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Research Term).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.110&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Clinical Trial means the &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.111&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvency Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Insolvency).</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 13 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.112&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all intellectual property and proprietary rights arising under the laws of the United States or any other relevant jurisdiction, whether registrable or not, including (a) Patents, (b) copyrights, copyright registrations, and applications for copyright registrations, (c) rights to authorship and moral rights, (d) invention rights, rights to trade secrets, and rights to know-how and expertise, discoveries, information, data and material, and all derivatives, modifications and improvements thereof, (e) rights to trademarks (including goodwill), databases, and mask works, and any applications, registrations, and other rights with respect thereto, and (f) all other intellectual property rights and all rights and forms of protection of a similar nature or having equivalent or similar effect to any of the foregoing, in each case ((a) to (f)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.113&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Jointly-Owned Arising IP). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.114&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.115&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Jointly-Owned Arising IP). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.116&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Establishment of JSC). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.117&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Jointly-Owned Arising IP).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.118&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.119&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC Disbandment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Discontinuation of JSC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.120&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC Dispute</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.121&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Information Controlled by Schr&#1255;dinger or its Affiliate(s) as of the Effective Date or thereafter during the Term that is necessary or reasonably useful to research, Develop, Manufacture, Commercialize, make, have made, use, offer for sale, sell, or import Collaboration Compounds or Collaboration Products. &#8220;Licensed Know-How&#8221; includes all know-how within or embodied by the Schr&#246;dinger Platform, Schr&#246;dinger Platform Inventions and, to the extent Controlled by Schr&#246;dinger or its Affiliate(s), all chemical, structural, manufacturing process, biological, pharmacological, toxicological, clinical, assay and other methods of screening, structure activity relationship information or other know-how that relates to Collaboration Compounds or Collaboration Products (including its composition, formulation, or method of use, manufacture, preparation or administration). </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 14 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.122&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Materials</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Materials Controlled by Schr&#1255;dinger or its Affiliate(s) as of the Effective Date or thereafter during the Term that are necessary or reasonably useful to Exploit Collaboration Compounds or Collaboration Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.123&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Patents that cover Licensed Know-How.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.124&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licensed Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Schr&#1255;dinger Product Specific Patents, Schr&#246;dinger&#8217;s right, title and interest in and to the Joint Patents, Licensed Materials and Licensed Know-How (including Schr&#246;dinger&#8217;s right, title and interest in and to the Joint Arising Know-How) and any other Licensed Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.125&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lien</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any lien, pledge, encumbrance, mortgage, security interest, purchase option, call or similar right, conditional and installment sale agreements, charges or claims of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.126&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limited Assignment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(A).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.127&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing Authorization Application</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an NDA or similar application for Regulatory Approval for a Collaboration Product in a country or region of the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.128&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major Market</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.129&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Major European Market</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any of the following countries&#58; &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.130&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities related to the manufacturing of a product or any component or ingredient thereof, including test method development and stability testing, formulation, process development, process qualification and validation, manufacturing scale-up whether before or after Regulatory Approval, manufacturing any product in bulk or finished form for development or commercialization (as applicable), including filling and finishing, packaging, labeling, shipping and holding, in-process and finished product testing, release of a product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of a product, and regulatory activities related to any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.131&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Licensed Know-How relating to the then-current process for the Manufacture of Collaboration Compounds or Collaboration Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.132&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Technology Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Manufacturing Technology Transfer).</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 15 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.133&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materially Distinct Project Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Project Plan for a Collaboration Target (whether an Initial Project Plan or a new Project Plan under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) that contains &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.134&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all biological materials, chemical compounds and other materials (i) arising out of a Party&#8217;s activities under this Agreement and provided by such Party to the other Party for use by the other Party or (ii) otherwise provided by a Party for use by the other Party, in each case ((i) or (ii)), to conduct activities pursuant to this Agreement, including Transferred Compounds, Clinical Trial samples, cell lines, compounds, lipids, assays, viruses and vectors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.135&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Maximum Fair Price</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Selected IRA Drug, the price negotiated pursuant to Section 1194 (and updated pursuant to Section 1195(b), as applicable) under the IRA during the period commencing on the date such price comes into effect and ending on the date such drug is no longer a Selected IRA Drug.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.136&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MHLW</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Japanese Ministry of Health, Labour and Welfare, and any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.137&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MHRA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the UK&#8217;s Medicines and Healthcare products Regulatory Agency and any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.138&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Monetization Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.139&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NDA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a new drug application submitted to FDA in accordance with section 355 of the Act (21 U.S.C. &#167; 355) and 21 C.F.R. part 314, including all amendments and supplements thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.140&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, the net sales recorded by Related Party(ies) for a Collaboration Product sold to Third Parties other than Sublicensees, as determined in accordance with Novartis&#8217; Accounting Standards, less a deduction &#91;**&#93; for direct expenses related to the sales of such Collaboration Product, distribution and warehousing expenses and uncollectible amounts on previously sold products. The deductions booked on an accrual basis by Novartis and its Affiliates under its Accounting Standards to calculate the recorded net sales from gross sales include, without limitation, the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to the calculation of Net Sales&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.141&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 16 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.142&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Novartis-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Novartis-Owned Arising IP).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.143&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification by Schr&#1255;dinger for Third Party Claims).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.144&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification by Schr&#1255;dinger for Third Party Claims).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.145&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Internal Collaboration Compound</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Collaboration Compound under clause (b) of the &#8220;Collaboration Compound&#8221; definition, or clauses &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.146&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Other Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.4(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Novartis Other Patents).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.147&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Prosecuted Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Novartis&#8217; First Right). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.148&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Research License</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.149&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Sole Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Novartis-Owned Arising IP).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.150&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Outside Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Effectiveness of the Agreement&#59; Term).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.151&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the definition set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.152&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) all patents and patent applications, including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, converted provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications in (a) and (b), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including adjustments, revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications in (a), (b) and (c), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patents of addition to any of such foregoing patent applications and patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.153&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.7(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 17 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.154&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Contact</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Patent Contacts).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.155&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Prosecution Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the direct out-of-pocket costs (including the reasonable fees and expenses incurred to outside counsel and other Third Parties, including filing, Prosecution and maintenance fees incurred to Governmental Authorities) recorded as an expense by a Party or any of its Affiliates (in accordance with the applicable Accounting Standards and its customary accounting practices) after the Effective Date and during the Term and pursuant to this Agreement, in connection with the preparation, filing, Prosecution, maintenance and extension of Patents, including costs of Patent interference, appeal, opposition, reissue, reexamination, revocation, petitions or other administrative proceedings with respect to Patents and filing and registration fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.156&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payment Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any (a) Product Specific Patent that is (i) Controlled by Schr&#246;dinger as of the Effective Date or (ii) assigned to Novartis pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Ownership of Arising IP) and the claims of which are invented solely or jointly by Schr&#246;dinger or invented solely</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by Novartis during the Research Term with respect to the applicable Collaboration Target (&#91;**&#93;) or (b) any Joint Patent listed by Novartis in the FDA Orange Book  (and any foreign equivalents in any country) with respect to an applicable Collaboration Product pursuant to Section 9.11 (Orange Book and Other Equivalent Listing).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.157&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture company, Governmental Authority, association or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.158&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 1 Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial of a Collaboration Compound or Collaboration Product, the principal purpose of which is to evaluate the safety, tolerability, pharmacokinetics and&#47;or pharmacodynamics of such Collaboration Compound or Collaboration Product as described in 21 C.F.R. 312.21(a), as amended from time to time, or a similar clinical study prescribed by the relevant Regulatory Authorities or Applicable Law in a country other than the U.S.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.159&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a controlled Clinical Trial of a Collaboration Compound or a Collaboration Product, the principal purpose of which is to evaluate the effectiveness of such Collaboration Compound or Collaboration Product for a particular Indication or Indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with such a Collaboration Compound or a Collaboration Product, as described in 21 C.F.R. &#167; 312.21(b), as amended from time to time, or a similar clinical study prescribed by the relevant Regulatory Authorities or Applicable Law in a country other than the U.S. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.160&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase 3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a controlled Clinical Trial of a Collaboration Compound or a Collaboration Product, the principal purpose of which is to evaluate the efficacy and safety of such Collaboration Compound or Collaboration Product, which is prospectively-</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 18 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">designed to demonstrate statistically whether such Collaboration Compound or Collaboration Product is effective and safe for use in a particular Indication in a manner sufficient to file a NDA to obtain Regulatory Approval to market the product, as further described in 21 C.F.R. &#167; 312.21(c), or a similar clinical study prescribed by the relevant Regulatory Authorities or Applicable Law in a country other than the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.161&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Platform IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(1). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.162&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pricing Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means in any country where an applicable Governmental Authority, in parallel with or subsequent to the granting of any other Regulatory Approval, authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.163&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior CDA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain Non-Disclosure Agreement entered into by Novartis and Schr&#1255;dinger effective as of &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.164&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Marks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Collaboration Product Trademarks).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.165&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Specific Infringement Action</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Enforcement of Product Specific Patents and Joint Patents).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.166&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Specific Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Information that specifically relates to a Collaboration Compound or the Exploitation of such Collaboration Compounds alone or in combination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.167&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Specific Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Patents that Cover any Product Specific Know-How. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.168&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Target, all activities outlined in one or more applicable Project Plan(s). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.169&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Overview). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.170&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Plan Start Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Research Term).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.171&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Research Term).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.172&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Additional Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Additional Collaboration Targets).</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 19 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.173&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.174&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.175&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement Target Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.176&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecute</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  (Novartis&#8217; First Right).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.177&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publication</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publications).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.178&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality), subject to the proviso in the definition of Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.179&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Registrational Trial</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Product, a Clinical Trial (whether or not designated a Phase 3 Clinical Trial) for such Collaboration Product with a sufficient number of subjects, (a) the results of which, together with prior data and information concerning such Collaboration Product, are intended to establish that such Collaboration Product is safe and effective for its intended Indication in a specified patient population&#59; and (b) that forms the basis (alone or with one (1) or more additional Registrational Trials) of an effectiveness claim in support of Regulatory Approval of an NDA for such Collaboration Product for its intended Indication. For clarity, a Converted Trial shall only constitute a Registrational Trial for purposes of this Agreement from and after the Conversion Date with respect to such Converted Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.180&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any and all licenses, registrations, authorizations and approvals (including approvals of NDAs and MAAs, supplements and amendments, pre- and post- approvals, and labeling approvals, but excluding for the purposes of milestone payments any Regulatory Approval received in the EU in a conditional manner) necessary for the Commercialization of a Collaboration Product in a given country, extra national territory, province, state or other regulatory jurisdiction, including, any applicable Pricing Approvals in such country, extra national territory, province, state or other or regulatory jurisdiction. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.181&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular country, extra-national territory, province, state, or other regulatory jurisdiction, any applicable Governmental Authority with authority over the Development, Manufacture or Commercialization of Collaboration Products in or for such country, extra-national territory, province, state, or other regulatory jurisdiction, including the FDA, the EMA, the European Commission, the MHRA and the MHLW, and in each case including any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.182&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Exclusivity Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Product in any country or jurisdiction in the Territory, any exclusivity (including, for clarity, new chemical entity exclusivity, new use or indication exclusivity, new formulation exclusivity, </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 20 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">orphan drug exclusivity, pediatric exclusivity or any applicable data exclusivity) conferred by the applicable Regulatory Authority(ies) in such country which confers an exclusive commercialization period during which Novartis, its Affiliates or Sublicensees have the exclusive right to market and sell the Collaboration Product in such country, which right precludes the receipt of Regulatory Approval of any Third Party product that is deemed to be a Generic Product of such Collaboration Product, in each case, under Applicable Law, excluding any rights conferred by or based on any Patents.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.183&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Materials</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means regulatory applications, submissions, dossiers, notifications, registrations, Regulatory Approvals or other filings or communications made to or with, or other approvals granted by, a Regulatory Authority that are necessary or reasonably desirable in order to Develop, Manufacture or Commercialize a Collaboration Product in a particular country or regulatory jurisdiction. Regulatory Materials include INDs, MAAs and NDAs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.184&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Related Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Novartis, its Affiliates and its and their respective Sublicensees (and such Sublicensees&#8217; Affiliates) of one or more Collaboration Products. For clarity, Related Party shall not include any distributors, wholesalers or the like unless such entity is an Affiliate of Novartis. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.185&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Replacement Collaboration Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.186&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Research Term). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.187&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Compound</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Collaboration Compound Directed Against a Terminated Target for which the Parties have submitted a &#91;**&#93; pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (other than any Novartis Internal Collaboration Compound). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.188&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Collaboration Product that (a) contains a Reversion Compound and (b) was the subject of Development or Commercialization by Novartis or its Affiliates in the Terminated Territory as of the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.189&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, on a Collaboration Product-by-Collaboration Product and country-by-country basis, the period commencing on the First Commercial Sale of such Collaboration Product in such country and ending on the latest of (a) &#91;**&#93; after the First Commercial Sale of such Collaboration Product in such country, (b) the expiration of the last Valid Claim of a Payment Patent (if applicable) Covering the composition of matter or approved method of use or treatment of such Collaboration Product (or of any Collaboration Compound in such Collaboration Product) in such country, and (c) expiration of the last Regulatory Exclusivity Period for such Collaboration Product in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.190&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Safety Concern</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Collaboration Compound or Collaboration Product, &#91;**&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">an effect that is considered to be generally related to either the </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 21 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mechanism of action or the basic chemical structure of such Collaboration Compound or Collaboration Product which has led or is reasonably expected to lead to (a) the issuance by the FDA or the EMA of a non-approvable letter or non-approval letter or a requirement to withdraw the Product from the Market, (b) a Regulatory Authority or safety data review board for a Clinical Trial or Clinical Trials of such Collaboration Compound or Collaboration Product has required termination or suspension of a Clinical Trial or Clinical Trials of such Collaboration Compound or Collaboration Product&#59; or (c) that Novartis documented policies and procedures recommend that&#160;termination of the further Development of such Collaboration Compound or Collaboration Product is warranted because there is an unacceptable risk for harm in humans either based upon the observation of serious adverse effects in humans after such Collaboration Compound or Collaboration Product has been administered to or taken by humans or based upon pre-clinical </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or animal data that is predictive of serious adverse effects in humans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.191&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.192&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.193&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.194&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Schr&#1255;dinger-Owned Arising IP).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.195&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification by Novartis for Third Party Claims).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.196&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Indemnification by Novartis for Third Party Claims).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.197&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger New In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.198&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Other Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Schr&#1255;dinger Other Patents).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.199&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.200&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#246;dinger Platform</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Schr&#1255;dinger&#8217;s or any of its Affiliates&#8217; proprietary physics-based, computational software products and program that can predict critical properties of molecules, excluding any Collaboration Compound Information. The Schr&#1255;dinger Platform consists of the software products and programs set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.200</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Schr&#246;dinger Platform).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.201&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Platform Inventions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.1(b)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Schr&#246;dinger-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 22 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.202&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Platform IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;(Schr&#246;dinger-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.203&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Product Specific Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Product Specific Patents (including all claims and the entire scope of claims therein) Controlled as of the Effective Date by Schr&#246;dinger, including those in the list attached hereto as </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.203</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.204&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Research License</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(License to Schr&#1255;dinger).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.205&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Sole Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  (Schr&#1255;dinger-Owned Arising IP).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.206&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#246;dinger Technology Services</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the following services and activities&#58; (a) services provided by Schr&#246;dinger&#8217;s applications scientists in connection with their customer service activities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> demonstrating to and training Schr&#246;dinger customers on such technology, applying certain Information of the Schr&#246;dinger Platform to set up, run and interpret calculations on behalf of its customers, running FEP+ outlier analyses and assisting Schr&#246;dinger customers with research projects using the Schr&#246;dinger Platform where such projects do not involve compound design or conducting virtual screens of compounds), (b) services provided by Schr&#246;dinger&#8217;s Technology Services group </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(e.g</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., installing the Schr&#246;dinger Platform for Schr&#246;dinger customers, configuring such customers&#8217; systems environments and migrating data), (c) sales activities (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., activities involving the promotion, marketing, selling and demonstration of the Schr&#246;dinger Platform and related services for purposes other than the virtual screening of compounds directed against the Target), (d) technical and scientific support of the Schr&#246;dinger Platform, (e) technology development activities related to the Schr&#246;dinger Platform, and (f) other technology related services offered or provided by Schr&#246;dinger to its customers that are not specifically defined herein, and in each case ((a) to (f)), that (i) do not constitute compound design or conducting virtual screens of compounds with respect to the Target and (ii) are conducted by Schr&#246;dinger personnel that are not involved in Schr&#246;dinger drug discovery business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.207&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.208&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selected IRA Drug</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a drug that was selected for Medicare price negotiation and published by the Secretary of the U.S. Department of Health and Human Services, in each case, under the Inflation Reduction Act, or IRA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.209&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.210&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Small Molecule</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a pharmaceutical organic compound that has a molecular weight of &#91;**&#93; Daltons or less (that is not primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site specific genetic manipulation techniques), including any salt or ester of the active ingredient, as a single </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 23 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">entity or in combination with another active ingredient&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that &#8220;Small Molecule&#8221; will exclude any pharmaceutical compound that is &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.211&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subject Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Effect of Change of Control of Schr&#246;dinger).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.212&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subject Personnel</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.213&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Third Party (excluding distributors and wholesalers) to whom Novartis or any of its Affiliates or Sublicensees has granted a sublicense under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Licenses to Novartis) hereof, excluding any Third Party granted such rights to settle or avoid litigation or any Patent dispute related to (a) the alleged infringement by a Collaboration Product or the Exploitation thereof of any Patents or other intellectual property of a Third Party or (b) the alleged non-infringement, invalidity or unenforceability of or challenge against any Patents covering or claiming a Collaboration Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.214&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suitability Analysis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Suitability Analysis).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.215&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suitability Analysis Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Suitability Analysis).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.216&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) any specific DNA or protein identified by its ENSEMBL GENE ID or unique UniProt number, and (b) if applicable, its genomic mutant identifier.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.217&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all taxes, imposts, duties, withholdings, assessments, levies, fees, duties or other charges imposed, collected or withheld by a Governmental Authority, in each case in the nature of a tax, whether direct or indirect, and together with any interest, penalties, additional amounts and additions related thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.218&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Effectiveness of the Agreement&#59; Term).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.219&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Terminated Territory</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to each Terminated Target, all terminated Major Markets, or in the case of termination of this Agreement in its entirety, all countries of the world.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.220&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Terminated Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a former Collaboration Target with respect to which this Agreement has been terminated. Terminated Targets shall include Discontinued Targets. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.221&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Termination by Either Party for Breach). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.222&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Territory</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means worldwide.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 24 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.223&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person other than Schr&#1255;dinger or Novartis or an Affiliate of either of Schr&#1255;dinger or Novartis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.224&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party IP Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) if Novartis or any of its Affiliates is a party to an agreement with a Third Party for a license or other right to any Third Party IP Rights with respect to a Collaboration Compound or Collaboration Product in one or more countries in the Territory, upfront payments, milestone payments, royalties, and other consideration paid to such Third Party in respect of such agreement, in each case in this clause (a), to the extent reasonably allocable to such Third Party IP Rights in such country(ies), (b) if Novartis agrees to pay any amounts to a Third Party in order to obtain a sublicense or other right to any Third Party IP Rights with respect to a Collaboration Compound or Collaboration Product in one or more countries in the Territory pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(2)8.5(c)(iii)(B)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, such amounts or (c) if Novartis defends an infringement claim pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Third Party Rights) in the Territory with respect to a Collaboration Compound or Collaboration Product, reasonable out-of-pocket costs of defending or settling such infringement claim pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Third Party Rights) that are borne by Novartis or its Affiliates and its Sublicensees (including royalties, milestones and other consideration paid and any damages or other awards assessed in connection therewith).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.225&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party IP Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patent, know-how or other intellectual property right of a Third Party in the Field in any country in the Territory that is necessary for the research, Development, Manufacture, Commercialization, sale, offering for sale, importation, or other Exploitation of Collaboration Compounds or Collaboration Products by Novartis or any of its Affiliates or any of its or their Sublicensees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.226&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Title 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.3(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.227&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferred Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.228&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.229&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America and its territories, districts and possessions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.230&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Unavailable</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Target, as applicable, that (a) is the subject of and specifically identified in (i) an active agreement between Schr&#1255;dinger or any of its Affiliates and a Third Party, or (ii) a pre-existing, ongoing, and currently active Bona Fide Negotiation between Schr&#1255;dinger or any of its Affiliates and a Third Party that grants (or shall grant) such Third Party rights to such Target that would preclude the granting of exclusive rights to Novartis as contemplated in this Agreement, each (i) or (ii), as determined by the Gatekeeper, based on the Gatekeeper&#8217;s review and request of evidence provided by Schr&#1255;dinger, including underlying documents and communications&#59; or (b) is the subject of a pre-existing, ongoing and active Bona Fide Internal Program of Schr&#1255;dinger or any of its Affiliates. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bona Fide Negotiation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93;. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bona Fide Internal Program</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, &#91;**&#93;.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 25 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.231&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Unavailable Targets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Gatekeeper). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.232&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a claim (a) contained in an issued, unexpired and granted Product Specific Patent, whose validity, enforceability, or patentability has not been affected by (i) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer or (ii) a holding, finding, or decision of invalidity, unenforceability, or non-patentability in a final judgment that has not been appealed within the time allowed by law or from which there is no further appeal&#59; or (b) contained in a pending patent application that is filed and prosecuted in good faith and has not been pending for more than &#91;**&#93; from its first substantive office action of such pending patent application from the patent office of an applicable country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.233&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Work Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all data, information, results, materials, inventions, technology and other Information conceived of by or on behalf of either Party or its Affiliates or its or their respective employees, agents or independent contractors (whether solely, jointly or with one (1) or more Third Party(ies)) in the course of conducting its activities under this Agreement that specifically relate to the Collaboration Targets, Collaboration Compounds or Collaboration Products, including (a) Collaboration Target structure-based compound design information for such Collaboration Compounds or Collaboration Products and (b) any proprietary data generated under this Agreement that is used to fit specific parameters of a model (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to parameterize a QSAR model) to specific classes and types of compounds&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Work Product excludes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any data, information, results, materials, inventions or other Information that may constitute Novartis-Owned Arising IP except in the event assigned by Schr&#246;dinger to Novartis pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.234&#160;&#160;&#160;&#160;&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Working Group</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Subcommittees and Working Groups). </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 2.&#160;&#160;&#160;&#160;GOVERNANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Establishment of JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within &#91;**&#93; of the Effective Date, the Parties will establish a joint research committee to act as a forum to review, discuss and oversee the Parties&#8217; activities under this Agreement, with the roles set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Role of JSC) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Each Party will initially appoint &#91;**&#93; representatives to the JSC. The JSC may change its size from time to time by mutual consent of its members, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the JSC will consist at all times of an equal number of representatives of each of Schr&#1255;dinger and Novartis. The JSC membership and procedures are further described in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Joint Steering Committee). Each Party may at any time appoint different JSC representatives by written notice to the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Membership of JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of Schr&#1255;dinger and Novartis will designate representatives with appropriate expertise to serve as members of the JSC. Each of Schr&#1255;dinger and Novartis will select from their representatives a co-chairperson for the JSC, and either Party </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 26 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may change its designated co-chairperson from time to time upon written notice to the other Party. The co-chairpersons of the JSC, with assistance and guidance from the Alliance Managers, will be responsible for calling meetings and preparing and circulating an agenda in advance of each meeting, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the co-chairperson will call a meeting of the JSC promptly upon the reasonable written request of the other co-chairperson to convene such a meeting. The Alliance Managers or other employees or consultants of a Party who are not representatives of such Party on the JSC may attend meetings of the JSC with the prior written consent of the other Party, not to be unreasonably withheld, conditioned or delayed&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such attendees (i)&#160;shall not vote or otherwise participate in the decision-making process of the JSC and (ii)&#160;are bound by obligations of confidentiality and non-disclosure at least as protective of the other Party as those set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Role of JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition to its overall responsibility for monitoring and providing a forum to discuss and oversee the Parties&#8217; activities under this Agreement, the JSC will be responsible for (i) overseeing, reviewing and discussing the conduct and progress of each Project and the termination of such activities&#59; (ii) reviewing and approving any addition or modification of Project Plan(s) for the Initial Collaboration Target(s) after the Effective Date&#59; (iii) reviewing and approving the Project Plan(s) for each Additional Collaboration Target or Replacement Collaboration Target&#59; (iv) evaluating and determining whether a Collaboration Compound has satisfied the DC Criteria&#59; (v) reviewing, discussing and approving any addition of or modification to any DC Criteria associated as defined in each Project Plan&#59; (vi) coordinating the review of any Proposed Replacement Target(s) as well as their conversion to any Replacement Collaboration Target(s)&#59; (vii) determining how to facilitate the flow of information between the Parties with respect to each Project&#59; (viii) attempting to resolve issues presented to it by, and disputes within, any Working Group, as applicable&#59; (ix) coordinating and prioritizing resources and activities within and between all Project Plans and their respective timelines, including discussing but not deciding (subject to the other terms and conditions of this Agreement, including clauses (ii) and (iii) of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Role of JSC), and the related final decision-making principles set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)(ii)(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) &#91;**&#93;&#59; and (ix) carrying out such other responsibilities as expressly delegated to the JSC as set forth in this Agreement or as may be mutually agreed by the Parties in writing from time to time. As needed, the JSC shall establish Working Groups in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Subcommittees and Working Groups) that will report to the JSC to further the objectives and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JSC will hold meetings at such times and places as the chairperson may determine. The JSC will meet at least &#91;**&#93; during the Term or as otherwise mutually agreed upon by the Parties until the JSC is discontinued in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Discontinuation of JSC). The meetings of the JSC need not be in person and may be by telephone or any other method determined by the JSC. Each Party will bear its own costs associated with attending such meetings, including any costs relating to travel or such Party&#8217;s participation in such meetings. </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 27 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Decisions of the JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Decisions of the JSC shall be by unanimous vote, with each Party having collectively one (1) vote, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if, after attempts to amicably resolve any disagreement at the JSC, the Parties are unable to agree on a matter within the decision-making authority of the JSC within &#91;**&#93; after it has met and attempted to reach such decision (each such dispute, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC Dispute</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then either Party may, by written notice to the other, have such JSC Dispute referred to the Executive Officers for resolution. If the Executive Officers are unable to resolve the JSC Dispute within &#91;**&#93;, or such other longer time the Executive Officers may otherwise agree upon, after such JSC Dispute is referred to them, then such JSC Dispute shall be resolved as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Schr&#246;dinger shall have final decision-making authority over any matter that relates specifically to the operation of the Schr&#246;dinger Platform or the day-to-day operation for its conduct of the Project Plans (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#91;**&#93;)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Novartis shall have final decision-making authority with respect to any matter within the purview of the JSC other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">matters in subsection (i) immediately above</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Novartis shall not use its final decision-making authority to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;require Schr&#1255;dinger to violate any Applicable Law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;amend the terms and conditions of this Agreement or modify or waive its compliance with the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;approve an initial Project Plan for an Additional Collaboration Target, a Replacement Collaboration Target or an additional &#91;**&#93;, or amend any existing Project Plan (including changing or establishing, or adopting any new Discovery Milestone Criteria or DC Criteria for a Collaboration Target) in a manner that would result in (1) &#91;**&#93; for each of the &#91;**&#93; Target or if applicable its Replacement Collaboration Target, or the &#91;**&#93; Target, or if applicable its Replacement Collaboration Target, &#91;**&#93; for each of the &#91;**&#93; Target or the &#91;**&#93; Target, as applicable, (2) &#91;**&#93;, in the aggregate, &#91;**&#93;, in the aggregate, or (3) &#91;**&#93;)&#59; in each case ((1), (2), or (3)), unless Novartis agrees in writing to &#91;**&#93; set forth in each of (1), (2), or (3), as applicable. &#91;**&#93; set forth in this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)(ii)(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be substantiated and evidenced by Schr&#1255;dinger, and Novartis shall have the right to request further information and evidence relating to such &#91;**&#93;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;determine any other matter that is expressly required to be determined by mutual agreement of the Parties pursuant to the terms of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any other unresolved matter within the purview of the JSC where neither Party has final-decision making authority will be resolved in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Disputes&#59; Resolution by Executive Officers).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subcommittees and Working Groups</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. From time to time, the JSC may establish and delegate duties to other committees, subcommittees or directed teams (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Working </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 28 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Group</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on an &#8220;as needed&#8221; basis to oversee particular projects or activities, which delegations shall be reflected in the minutes of the meetings of the JSC. Such Working Groups may be established on an ad hoc basis for purposes of a specific project, or on such other basis as the JSC may determine, and shall be constituted and shall operate as the JSC may determine&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that each Working Group shall have equal representation from each Party, shall be subject to decision-making shall be by consensus, with each Party&#8217;s representatives on the applicable Working Group collectively having one (1) vote on all matters brought before the Working Group. Each Working Group and its activities shall be subject to the direction, review and approval of, and shall report to, the JSC. In no event shall the authority of the Working Group exceed that specified for the JSC in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Governance). Any matter not resolved by a Working Group shall be referred to the JSC for resolution in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discontinuation of JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Unless otherwise agreed to by the Parties, the JSC shall automatically discontinue upon the expiration of all the Research Terms or the effective date of a Change of Control of Schr&#246;dinger (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC Disbandment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Thereafter, the JSC shall have no further roles or responsibilities under this Agreement. Upon the JSC Disbandment, Novartis shall provide Schr&#1255;dinger with &#91;**&#93; reports describing Novartis&#8217; ongoing research and Development activities and efforts for the Collaboration Compounds until the first occurrence of the First Commercial Sale of a Collaboration Product in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Development Reports), upon which Novartis shall provide quarterly royalty reports to Schr&#1255;dinger in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Payments and Reports).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limitations on Authority of the JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JSC will have solely the roles and responsibilities assigned to it in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Governance). Without limiting </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC), the JSC will have no authority to amend, modify or waive compliance with this Agreement. The JSC shall have no authority to alter, or waive compliance by a Party with, a Party&#8217;s obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Minutes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties shall alternate responsibility for preparing and circulating minutes of each meeting of the JSC, setting forth, inter alia, an overview of the discussions at the meeting and a list of any actions, decisions or determinations approved by the JSC. Such minutes shall be effective only after such minutes have been approved by both Parties in writing. Definitive minutes of all JSC meetings shall be finalized no later than &#91;**&#93; after the meeting to which the minutes pertain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Managers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Parties will appoint one (1) representative who possesses a general understanding of Development issues to act as its alliance manager (each, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The role of the Alliance Manager is to act as a primary point of contact between the Parties to assure a successful relationship between the Parties. The Alliance Managers will attend all meetings of the JSC and support the chairperson of the JSC in the discharge of their responsibilities. An Alliance Manager may bring any matter to the attention of the JSC if such Alliance Manager reasonably believes that such matter warrants such attention. </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 29 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party. An Alliance Manager may designate a substitute to temporarily perform the functions of such Alliance Manager upon written notice to the other Party&#8217;s Alliance Manager. Each Alliance Manager will be charged with creating and maintaining a collaborative work environment within the JSC and each committee. Each Alliance Manager also will&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;provide a single point of communication both internally within the Parties&#8217; respective organizations and between the Parties, including during such time as the JSC is no longer constituted&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;plan and coordinate any cooperative efforts under this Agreement, if any, and internal and external communications&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;take responsibility for ensuring that the activities of the JSC, such as the conduct of required meetings of the JSC, occur as set forth in this Agreement and that relevant action items, if any, resulting from such meetings are appropriately carried out or otherwise addressed&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;be the point of first referral in all matters of conflict resolution.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 3.&#160;&#160;&#160;&#160;RESEARCH COLLABORATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Collaboration&#59; Project Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Research Term for each Collaboration Target (&#91;**&#93;), the Parties shall collaborate in carrying out the research activities under such Collaboration Target&#8217;s (or &#91;**&#93;) Project Plan(s) (as defined below) for purposes of discovering, researching and preclinically Developing the Collaboration Compounds until Achievement of the DC Criteria and designation of one or more Development Candidates for such Collaboration Target (or &#91;**&#93;). As of the Effective Date, Novartis has designated, and the Parties have agreed to conduct research collaboration activities as provided under this Agreement for the Initial Collaboration Targets, including for certain &#91;**&#93; as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, subject to the right of Novartis to request the replacement of one or more Initial Collaboration Targets under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Replacement Collaboration Targets and Additional &#91;**&#93;) or exercise its option to add Additional Collaboration Targets under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Additional Collaboration Targets). During the Project Research Term for each Project, the Parties shall prepare and collaborate to conduct such Project to identify Collaboration Compounds for the applicable Collaboration Target (or &#91;**&#93;) in accordance with one or more written plans for such Project (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Each Project Plan shall detail (i) the allocation of responsibilities and activities between Schr&#1255;dinger and Novartis with respect to carrying out the Project, including the testing and iterative optimization process and compound synthesis&#59; (ii) the DC Criteria and requirements for the Achievement of the DC Criteria&#59; (iii) any additional Discovery Milestone Criteria, as applicable&#59; (iv) an estimated timeline for performance of such activities and (v) the &#91;**&#93; for such Project Plan. Subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Additional &#91;**&#93;), each Party shall initiate its activities </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 30 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under each Project Plan promptly following the adoption of such Project Plan. Each &#91;**&#93; selected as the subject of a Project as of the Effective Date or pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Additional &#91;**&#93;) shall be the subject of a separate Project Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Project Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Project Plans for (i) &#91;**&#93;, (ii) &#91;**&#93;, (iii) &#91;**&#93;, and (iv) &#91;**&#93; are attached hereto as </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.1(b)(i)-(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Project Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Project Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each subsequent Project Plan proposed by either Party for any existing Collaboration Target (including any new &#91;**&#93; Project), Additional Collaboration Target, or Replacement Collaboration Target shall be prepared by Schr&#246;dinger, in consultation with Novartis, and submitted to the JSC for review and discussion and shall be subject to approval by the JSC subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC). Each such subsequent Project Plan must be on substantially the same form as the Initial Project Plans, including the form of the DC Criteria, and additional Discovery Milestone Criteria (if applicable) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form Project Plan</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Plans for Additional Collaboration Target and Replacement Collaboration Target Project</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within &#91;**&#93; after the delivery of a Suitability Analysis pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for a Proposed Additional Target or a Proposed Replacement Target, Schr&#246;dinger shall prepare, in consultation with Novartis, for review and discussion by the JSC in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Role of JSC), an initial draft of a Project Plan for such Proposed Additional Target or Proposed Collaboration Target based on the Form Project Plan&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the final and full Project Plan for such Target shall be adopted by the JSC within &#91;**&#93; after the delivery of such Suitability Analysis. Any adoption by the JSC of an initial Project Plan for an Additional Collaboration Target or Replacement Collaboration Target is subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Plans for Additional &#91;**&#93; Projects</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon Novartis&#8217; issuance of the notice set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, within &#91;**&#93; after Novartis&#8217; written request, Schr&#246;dinger shall prepare, in consultation with Novartis, for review and discussion by the JSC in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Role of JSC), an initial draft of a Project Plan for any new &#91;**&#93; Project based on the Form Project Plan&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the final and full Project Plan for such Collaboration Target shall be adopted by the JSC within &#91;**&#93; after such Novartis request. Any adoption by the JSC of an initial Project Plan for a new &#91;**&#93; Project is subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendments to the Project Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Project Research Term for each Project, the applicable Project Plan will be reviewed by the JSC and may be updated and amended from time to time, as the JSC determines. Any amendments to the Project Plan are subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. With respect to each Project Plan, the research term (a) shall commence on, as applicable, (i) the Effective Date with respect to each Initial Project Plan or (ii) </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 31 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the date on which such Project Plan is approved by the JSC with respect to each Project Plan that is not an Initial Project Plan (each of (i) or (ii), the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Plan Start Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) and (b) unless otherwise earlier terminated in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Term and Termination) of this Agreement, shall expire on the earliest of (i) the expiration of the fourth (4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of such Project Plan Start Date&#59; (ii) the Handoff of such Project Plan&#59; and (iii) the termination of such Project Plan by the JSC (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Initial Research Term may be mutually extended in writing by both Parties for an additional period of time agreed in writing by the Parties (an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; together with the Initial Research Term, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The research term with respect to each Collaboration Target shall begin on, as applicable, (i) the Effective Date with respect to each Initial Collaboration Target&#59; (ii) the date on which a Proposed Additional Target is deemed an Additional Collaboration Target&#59; or (iii) the date on which a Proposed Replacement Target is deemed a Replacement Collaboration Target and expire upon the expiration of the last-to-expire Project Research Term with respect to a Project Plan for such Collaboration Target (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). For clarity, if Novartis exercises its option to replace any Initial Collaboration Target with a Replacement Collaboration Target pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Replacement Collaboration Target and Additional &#91;**&#93;), a new Initial Research Term for the Replacement Collaboration Target will apply with respect to such Project. For clarity, the Collaboration Target consisting of the &#91;**&#93; shall have a single Research Term and no &#91;**&#93; shall have a separate Research Term, and the Research Term for the &#91;**&#93; shall expire upon the expiration of the last-to-expire Project Research Term with respect to a Project Plan for any &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Replacement Collaboration Targets and Additional &#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Replacement Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the remainder of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Replacement Collaboration Target and Additional &#91;**&#93;), at any time prior to the end of the period of &#91;**&#93; from the Effective Date of the Agreement (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Replacement Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), at the request of Novartis, the Parties may upon mutual written agreement, substitute and replace &#91;**&#93;, with a mutually-agreed new Collaboration Target in accordance with the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Target Replacement Procedure), and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Gatekeeper)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, for clarity, the Research Term of the replaced Collaboration Target is still effective at the time of such substitution and replacement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Replacement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the remainder of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Replacement Collaboration Targets and Additional &#91;**&#93;), with respect to each Initial Collaboration Target, or Additional Collaboration Target, in each case, for which no Collaboration Compound has Achieved the DC Criteria and the JSC has determined that no Collaboration Compound has met or is likely to meet the criteria set forth in the DC Criteria of such Collaboration Target, then Novartis may, at any time during the Research Term of such Collaboration Target, nominate with respect to each such Collaboration Target up to &#91;**&#93; to replace such Collaboration Target in accordance with the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Target Replacement Procedure) (for clarity, all &#91;**&#93; shall be treated as one Collaboration Target and can &#91;**&#93; be replaced by up to &#91;**&#93;). If a Collaboration Target is replaced with a Replacement </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 32 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collaboration Target pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, such Replacement Collaboration Target &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Target Replacement Procedure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the case that Novartis desires to replace any Collaboration Target in accordance </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Other Replacement), Novartis shall provide written notice to Schr&#1255;dinger, through the JSC, of Novartis&#8217; basis for its determination that no Collaboration Compound has met or is likely to meet the criteria set forth in the DC Criteria of such Collaboration Target (such notice, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the JSC shall discuss in good faith such basis. In the case that following such good faith discussion, Novartis still desires to replace any Collaboration Target based upon such determination, or in the case that Novartis desires to replace any Collaboration Target in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Initial Replacement Period), Novartis shall send to the Gatekeeper written notice of the identity of the new Target candidate to replace such Collaboration Target (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which notice shall include such Target&#8217;s identity, for such Proposed Replacement Target (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Target Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Availability Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Gatekeeper Notice notifies Novartis that the Proposed Replacement Target is not on the Unavailable Target list in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Gatekeeper) (such Target, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Available Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Novartis may instruct Schr&#246;dinger by written notice to conduct a Suitability Analysis pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Suitability Analysis) (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suitability Analysis Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Upon delivery by Novartis to Schr&#246;dinger of a Suitability Analysis Notice with respect to any Proposed Replacement Target, and until the earlier of the date that (A) such Proposed Replacement Target becomes a Replacement Collaboration Target or (B) Novartis notifies Schr&#246;dinger of its final determination pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Final Determination) not to effect a replacement by such Proposed Collaboration Target, such Proposed Replacement Target will be deemed a Collaboration Target for purposes of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suitability Analysis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If a Proposed Replacement Target is an Available Target, promptly (but in no event greater than &#91;**&#93; following)) written notice by Novartis, and in any event prior to the JSC&#8217;s approval of the Project Plan for replacement of such Collaboration Target, Schr&#1255;dinger will assess the suitability of the Proposed Replacement Target for the Schr&#1255;dinger Platform in accordance with any technical parameters proposed by Novartis and agreed upon by both Parties, which comprises &#91;**&#93; (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suitability Analysis</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Schr&#1255;dinger shall report the results of each Suitability Analysis to the JSC. Novartis shall pay Schr&#1255;dinger a fee of &#91;**&#93; Dollars ($&#91;**&#93;) for each Suitability Analysis for each Proposed Replacement Target within &#91;**&#93; from the date of receipt of Schr&#1255;dinger&#8217;s invoice delivered upon or following the completion of such Suitability Analysis and the delivery to Novartis of the corresponding Suitability Analysis report&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Suitability Analysis for &#91;**&#93; Available Targets conducted by Schr&#1255;dinger shall be provided to Novartis &#91;**&#93;. Upon delivery </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 33 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by Schr&#246;dinger to Novartis of a negative Suitability Analysis report with respect to any Proposed Replacement Target, and until &#91;**&#93; thereafter, the exclusivity obligations of Schr&#1255;dinger pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity) shall apply with respect to such Proposed Replacement Target, and for clarity, shall not apply to Novartis with respect to such Proposed Replacement Target.     </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Final Determination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Within &#91;**&#93; from the date of receipt of a Suitability Analysis Notice, the JSC shall meet, consider and discuss in good faith the potential replacement of the applicable Collaboration Target with the applicable Proposed Replacement Target, and if Novartis determines to effect such replacement, a suitable Project Plan will be prepared pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.1(c)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Proposed Replacement).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Replacement Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JSC shall record the date of approval of the Project Plan for the Proposed Replacement Target in the minutes of the JSC. From and after the date on which the Project Plan for the Proposed Replacement Target is approved, (A) such Proposed Replacement Target shall become the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Replacement Collaboration Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and Collaboration Target hereunder and (B) the applicable Initial Collaboration Target shall no longer be the Collaboration Target and such Target shall become a Discontinued Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional &#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial &#91;**&#93; Projects</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; are the Projects with respect to &#91;**&#93;, as set forth in the respective Initial Project Plans or any amendment thereto adopted pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Amendments to the Project Plans). Upon Novartis&#8217; notice to the JSC that in addition to or in place of the conduct of one (1) or more of the Initial &#91;**&#93; Projects, it desires the conduct of one or more Project(s) with respect to &#91;**&#93;&#59; and (C) any other mutually-agreed upon agonist or antagonist of a monovalent or multivalent combination of &#91;**&#93; (each, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional &#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and each Initial &#91;**&#93; Project or Additional &#91;**&#93; Project, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;**&#93; Project</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Parties shall adopt a Project Plan for such Additional &#91;**&#93; Project pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(c)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Project Plans for Additional &#91;**&#93; Projects) and shall be subject to the terms and conditions of this Agreement, including applicable limitations on Novartis&#8217; final decision-making authority set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)(ii)(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Collaboration Targets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the period which commences on the Effective Date and ends on &#91;**&#93;, Novartis may propose additional Targets for inclusion in this Agreement as Collaboration Targets (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Additional Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by providing written notice to the Gatekeeper of the identity of the Proposed Additional Target. If the Gatekeeper informs Novartis that such Proposed Additional Target is not on the list of Unavailable Targets and Schr&#1255;dinger does not reasonably reject to the selection of such Proposed Additional Target as an Additional Collaboration Target, within &#91;**&#93; from the date of receipt of the Gatekeeper Notice, the Parties shall meet to discuss the timing, roles and responsibilities of each Party, economics, and the Project Plan of such Proposed Additional Target. From and after the date on which the Project Plan for the Proposed Additional Target is approved by the JSC, such Proposed Additional Target shall become a Collaboration Target included in this Agreement (each, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Collaboration Target</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Any replacement of an Additional </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 34 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collaboration Target shall be made in accordance with the procedure and requirements set out in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Other Replacement) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Target Replacement Procedure).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon delivery by Novartis to Schr&#246;dinger of a Suitability Analysis Notice with respect to any Proposed Additional Target, and until the earlier of the date that (A) such Proposed Additional Target becomes an Additional Collaboration Target or (B) either Party notifies the other of its final determination not to effect the addition of such Proposed Additional Target as an Additional Collaboration Target, such Proposed Additional Target will be deemed a Collaboration Target for purposes of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gatekeeper. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In order to enable Novartis to exercise its rights under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Replacement Collaboration Target and Additional &#91;**&#93;) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Additional Collaboration Target), Schr&#1255;dinger shall maintain an up-to-date list of Targets that are Unavailable (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Unavailable Targets</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and shall promptly provide such list and any updates thereto to the Gatekeeper. Within &#91;**&#93; after the Effective Date, the Parties shall engage a mutually agreed, independent, third-party gatekeeper (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gatekeeper</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in order to maintain the confidentiality of the identity of Unavailable Targets, Proposed Replacement Targets and Proposed Collaboration Targets. Each of the Parties will enter into a written agreement with such Gatekeeper with customary terms and conditions that are consistent with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Gatekeeper), including appropriate confidentiality obligations. The Parties shall share equally the fees and expenses of the Gatekeeper. The Gatekeeper shall not (a) identify to Schr&#246;dinger any information with respect to inquiries by Novartis, including the identity of the applicable Proposed Replacement Target or Proposed Additional Target or (b) provide to Novartis any information regarding any Unavailable Target. Within &#91;**&#93; after the date of the engagement of the Gatekeeper, Schr&#246;dinger shall deliver to the Gatekeeper in writing an initial list of Unavailable Targets. The Gatekeeper shall promptly confirm in writing to Novartis that it is in receipt of Schr&#246;dinger&#8217;s initial list of Unavailable Targets (without identifying any Unavailable Targets). Schr&#246;dinger shall promptly provide the Gatekeeper with an updated list of Unavailable Targets in the event of any changes to the list of Targets falling with the list of Unavailable Targets. Within &#91;**&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">following Gatekeeper&#8217;s receipt of a Proposed Replacement Target Notice or Proposed Additional Target from Novartis, the Gatekeeper shall determine whether or not the Proposed Replacement Target or Proposed Additional Target nominated by Novartis was an Available Target as of &#91;**&#93; of such nomination by Novartis and notify Novartis in writing (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gatekeeper Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) whether the applicable Proposed Replacement Target or Proposed Additional Target is or is not on the Unavailable Target list. If such Proposed Replacement Target or Proposed Additional Target is not on the Unavailable Target list, the Gatekeeper will promptly inform both Parties in writing with a confirmation of such Proposed Replacement Target or Proposed Additional Target&#8217;s identity and that it is an Available Target and the Parties will proceed with the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.3(c)(ii)-(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3.3(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Event and Development Candidate Designation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties shall promptly provide &#91;**&#93; and shall provide &#91;**&#93; shall promptly &#91;**&#93;. Within &#91;**&#93; after the date of delivery of any &#91;**&#93;&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 35 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.7&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conduct of the Projects</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Project and each Party&#8217;s performance of its activities under this Agreement will be conducted by each Party in good scientific manner, and in compliance with Applicable Law. Each Party shall use Commercially Reasonable Efforts to ensure that its Affiliates and Third Party contractors (as applicable) perform any activities under each Project in good scientific manner and in compliance in all material respects with the requirements of Applicable Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Party will maintain laboratories, offices and all other facilities at its own cost and expense and risk necessary to carry out its responsibilities under each Project Plan. Each Party agrees to make its employees reasonably available at their respective places of employment to consult with the other Party on issues relating to the performance of the applicable Project pursuant to its Project Plan. Novartis and Schr&#1255;dinger will cooperate with each other in carrying out each Project in accordance with its Project Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Schr&#246;dinger shall comply with the terms of the Third Party Risk Management guidelines as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.7(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and shall ensure that its Affiliates and subcontractors comply with any applicable terms as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.7(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Costs and Expenses</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise agreed to by the Parties or the JSC, each Party will be responsible for all of its expenses incurred in the conduct of its activities under each Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.9&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Party will maintain, and cause its Affiliates and subcontractors to maintain, records of all work conducted in the performance of each Project and all results, data, inventions and developments made in the performance of each Project, which records will be complete and accurate in all material respects. Such records will be in sufficient detail and in good scientific manner appropriate for Patent and regulatory purposes. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In order to protect the Parties&#8217; Patent rights under U.S. law in any patentable inventions conceived or reduced to practice during or as a result of each Project, each Party agrees to maintain a policy that requires its employees to record and maintain all material data and Information developed during each Project in such a manner as to enable the Parties to use such records to establish the earliest date of invention or diligence to reduction to practice. At a minimum, the policy shall require such individuals to record all patentable inventions generated by them in standard laboratory notebooks (paper or electronic) or other suitable means that are dated and corroborated by non-inventors on a regular, contemporaneous basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.10&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure of Results of each Project</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 36 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">To the JSC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will furnish to the JSC, at each JSC meeting, to the extent applicable to such Party, an update on such Party&#8217;s progress under each Project Plan, including a summary of any material Work Product generated by such Party under such Project Plan. Such Party will provide the JSC with such other Work Product as any member of the JSC may reasonably request that are in such Party&#8217;s possession or Control&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Schr&#1255;dinger will not be required to transfer any Information to the JSC relating specifically to the Schr&#1255;dinger Platform or Schr&#1255;dinger Platform Inventions. Novartis will furnish to the JSC, at each JSC meeting, to the extent applicable, a report summarizing Novartis&#8217; progress on Novartis Internal Collaboration Compounds, which reports shall be sufficient in content to keep Schr&#1255;dinger reasonably informed regarding the progress and results of Development activities such Novartis Internal Collaboration Compounds. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">To the Joint Teams</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. With respect to each Project, during the applicable Project Research Term, the Parties will periodically &#91;**&#93; will be established, owned, and controlled by Novartis, and which Novartis may change at any time in its reasonable discretion upon reasonable notice to Schr&#246;dinger &#91;**&#93; specifically relating to the Schr&#1255;dinger Platform or Schr&#1255;dinger Platform Inventions. Schr&#246;dinger shall promptly &#91;**&#93;, regardless of whether included in any report to the JSC. Subject to the foregoing limitation regarding Schr&#1255;dinger &#91;**&#93;, (i) within &#91;**&#93; of termination of the applicable Project Research Term (and again after the completion of activities set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), Schr&#1255;dinger will &#91;**&#93; and (ii) upon request by Novartis during or following the relevant Project Research Term (it being understood that Novartis may make such request after issuance of a &#91;**&#93;), Schr&#246;dinger will provide Novartis with such other Information and such additional access to records with respect to Project(s), in each case, as Novartis may reasonably request for the conduct or evaluation of such Project(s) or for the purpose of Patent and regulatory filings relating to the Product Specific Patents or to the Collaboration Compounds or Collaboration Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.11&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research Efforts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall use Commercially Reasonable Efforts to carry out its respective activities under each Project Plan under the timelines set forth in such Project Plan. If, notwithstanding a Party&#8217;s use of Commercially Reasonable Efforts, such Party fails to perform or complete activities under a Project due to scientific or technical factors, such Party shall not be deemed to be in breach of this Agreement solely as a result of such failure. The Parties acknowledge and agree that (a) certain activities under each Project are experimental in nature and as such, nothing in this Agreement shall be construed as a guarantee or warranty by Schr&#246;dinger that, notwithstanding Schr&#246;dinger&#8217;s use of Commercially Reasonable Efforts, Schr&#246;dinger will be able to deliver Collaboration Compounds for the Collaboration Target that will meet the objectives of the Project (including the DC Criteria) or that the Materials, Information or other results produced in connection therewith will meet the objectives of each Project and (b) that neither Party shall be in breach of its obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Research Efforts) to the extent, notwithstanding its use of Commercially Reasonable Efforts, it is not able to achieve one or more objectives under a Project Plan because of scientific infeasibility or impossibility.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 37 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.12&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If applicable, in order to facilitate the activities under each Project Plan, each Party shall provide to the other Party (or to the other Party&#8217;s designated subcontractor, such as a contract research organization) certain Materials for use by the other Party in furtherance of the applicable Project to the extent specified in the applicable Project Plan or otherwise mutually agreed by the Parties in writing, in each case, pursuant to a material transfer agreement in the form attached hereto as </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Annex 1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Material Transfer Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). A Party shall provide Materials directly to the other Party&#8217;s designated subcontractor only if specifically memorialized in such an executed material transfer agreement and, in such event, (a) the provision of such Materials shall be in accordance with the other Party&#8217;s reasonable instructions, (b) the handling of such Materials by the designated subcontractor will be subject to the terms of the applicable bilateral agreement between such other Party and such subcontractor, and (c) payment for the subcontractor&#8217;s services in respect of such Materials will be at the sole expense of such other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.13&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subcontracting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the oversight of the JSC, each Party may (sub)contract any of the work for which it is responsible in the performance of a Project&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that any subcontracting by Schr&#246;dinger will require the prior written consent of Novartis, except for those subcontractors listed on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or in the Project Plan. In the case of any (sub)contracting of Project activities by a Party to a Third Party, such Third Party must have entered into a written agreement with such Party that is consistent with the terms of this Agreement, including intellectual property assignment provisions consistent with the terms set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Ownership of Intellectual Property) and terms and conditions protecting and limiting use and disclosure of Information that are consistent with the terms set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) of this Agreement, and that, in the case of subcontracting by Schr&#246;dinger, provides reasonable audit rights exercise by Schr&#246;dinger on behalf of Novartis with the right to disclose audit findings to Novartis&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the term of such Third Party&#8217;s obligations regarding the use and disclosure of Information shall be as long as reasonably negotiated with such Third Party, but in any event no less than &#91;**&#93; after the date of expiration or earlier termination of the applicable subcontract agreement between the subcontracting Party and such Third Party. Each Party is responsible for compliance by such Third Party with the applicable terms and conditions of this Agreement in the same way and to the same extent as such Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.7(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> sets forth additional terms regarding subcontracting and the due diligence and monitoring of subcontractors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.14&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subsequent Activities</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the reversion rights of Schr&#1255;dinger as provided under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Reversion) and Schr&#1255;dinger&#8217;s allocated activities under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties acknowledge and agree that following the Project Research Term for a given Project Plan, Novartis shall have the sole right, and Schr&#246;dinger shall have no responsibility for all further research, Development, regulatory (subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), Manufacturing (subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), and Commercialization activities of the Collaboration Compounds and Collaboration Products that result from such Project and shall be responsible for all costs associated therewith in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Development and Regulatory Matters), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Commercialization) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Manufacturing).</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 38 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.15&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of Novartis Datasets&#59; Maintenance of Novartis Dedicated Tenancy</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Schr&#246;dinger shall, and shall ensure that its Affiliates and subcontractors, comply with the terms and guidelines set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 4.&#160;&#160;&#160;&#160;DEVELOPMENT AND REGULATORY MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For each given Project of each Collaboration Target (&#91;**&#93;), Schr&#1255;dinger will promptly (but no later than &#91;**&#93;)) following &#91;**&#93; designation of a Development Candidate in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Discovery Milestone Event and Development Candidate Designation) (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Handoff</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), transfer to Novartis or its designated Affiliate (i) a copy of all Licensed Know-How related to such Development Candidate and other Collaboration Compounds, if any, in Schr&#1255;dinger&#8217;s possession and Control as of such Handoff, including any documentation (whether held in paper or electronic format) or similar removable media (including e-mails, documents, spreadsheets, copies of standard operating procedures or technical specifications)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Schr&#1255;dinger will not be required to transfer any Information relating specifically to the Schr&#1255;dinger Platform or Schr&#1255;dinger Platform Inventions or the Exploitation thereof&#59; and (ii) any tangible embodiments of such Development Candidate or other Collaboration Compounds, if any, that have been synthesized by or on behalf of Schr&#1255;dinger or its Affiliates under the Project (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferred Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case, in Schr&#1255;dinger&#8217;s possession and Control as of the Handoff. Following the initial transfer of Licensed Know-How and Transferred Compounds in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and during any remaining period of the applicable Project Research Term (and again after the completion of activities set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), Schr&#1255;dinger will transfer to Novartis or its designated Affiliate any additional Licensed Know-How, Development Candidates or other Collaboration Compounds that have been identified by or on behalf of Schr&#1255;dinger or its Affiliates under the Project or in Schr&#1255;dinger&#8217;s possession and Control during such Project Research Term  (and again after the completion of activities set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and that have not already been transferred to Novartis or its designated Affiliate in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For each Project, following its Project Research Term and for the Term, in the event that Novartis reasonably believes additional Licensed Know-How is necessary for the continued Development, Manufacture or Commercialization of any Development Candidate or Collaboration Compound resulting from such Project, Novartis may reasonably request a copy of such additional Licensed Know-How from Schr&#246;dinger. Following such request, Novartis and Schr&#1255;dinger will discuss in good faith and Schr&#1255;dinger will transfer to Novartis (i) a copy of such additional Licensed Know-How in Schr&#1255;dinger&#8217;s possession and Control, including any documentation (whether held in paper or electronic format) or similar removable media (including e-mails, documents, spreadsheets, copies of standard operating procedures or technical specifications)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Schr&#1255;dinger will not be required to transfer any Information relating to the Schr&#1255;dinger Platform or Schr&#1255;dinger Platform Inventions or the </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 39 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exploitation thereof and (ii) any additional Transferred Compounds in Schr&#1255;dinger&#8217;s possession and Control and not yet transferred to Novartis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Party shall be responsible for all internal and out-of-pocket costs and expenses incurred by such Party or its Affiliates in connection with its performance under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Transfer).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Following the Handoff of a given Project, Schr&#246;dinger shall remain responsible for the completion of all remaining activities allocated to Schr&#246;dinger under the applicable Project Plan, unless the Parties mutually agree to amend such Project Plan with respect to such remaining activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Efforts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For each Project, following its Handoff, Novartis shall be solely responsible, directly or through its Affiliates or Sublicensees, at its own expense for all further Development of the Collaboration Compounds and Collaboration Products resulting from such Project in the Field in the Territory during the Term, including any remaining activities allocated to Novartis under the applicable Project Plan (including responsibility for all funding, resourcing and decision-making).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;On a Collaboration Target-by-Collaboration Target basis, from and after the first Handoff, Novartis, by itself or through its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to further research, Develop, and seek to obtain Regulatory Approval for at least one (1) Collaboration Product Directed Against such Collaboration Target for &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Reports</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following the first Handoff for a given Collaboration Target (&#91;**&#93;), Novartis shall furnish to Schr&#1255;dinger, by &#91;**&#93; each Calendar Year during the Term, a report summarizing its material global research, Development and regulatory efforts for Collaboration Compounds and Collaboration Products. Such reports will be sufficient in content to keep Schr&#1255;dinger reasonably informed regarding the progress and results of Development activities for Collaboration Compounds and Collaboration Products in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Matters</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Following the Handoff of any Project, Novartis shall, at its sole cost and expense, have sole responsibility and decision-making authority with respect to regulatory matters for Collaboration Compounds and Collaboration Products resulting from such Project, including the content of any regulatory filing or dossier, pharmacovigilance, labeling, and the decision to file or withdraw any IND or MAA or to cease or suspend any Clinical Trial. Novartis shall have sole responsibility for preparing and submitting all Regulatory Materials for Collaboration Products in the Field in the Territory, including preparing, submitting and holding all INDs and MAAs for Collaboration Products. Schr&#1255;dinger shall reasonably cooperate with Novartis and provide to Novartis all Licensed Know-How, in each case as may be reasonably requested by Novartis and necessary for Novartis, in order to prepare or support any Regulatory </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 40 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Materials for Collaboration Products in the Field in the Territory and interactions with any Regulatory Authority in connection with Development or Regulatory Approval of Collaboration Products. Novartis will own all Regulatory Materials for Collaboration Products, and all such Regulatory Materials shall be submitted in the name of Novartis (or its Affiliate or Sublicensee, as applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Use of Debarred Person</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Term, each Party agrees that it will not use any employee or consultant that is debarred by any Regulatory Authority or, to the best of such Party&#8217;s knowledge, is the subject of debarment proceedings by any Regulatory Authority. If a Party learns that any employee or consultant performing on its behalf under this Agreement has been debarred by any Regulatory Authority or has become the subject of debarment proceedings by any Regulatory Authority, such Party will promptly notify the other Party and will prohibit such employee or consultant from performing on its behalf under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Standards of Conduct</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall perform and shall use Commercially Reasonable Efforts to ensure that its Affiliates, Sublicensees and Third Party contractors perform, its Development, Manufacturing and Commercialization activities with respect to Collaboration Compounds and Collaboration Products in good scientific manner, and in compliance in all material respects with the requirements of Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 5.&#160;&#160;&#160;&#160;COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Efforts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis shall have the exclusive right (subject to any reversion to Schr&#1255;dinger under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) to Commercialize Collaboration Compounds and Collaboration Products Directed Against the applicable Collaboration Target (&#91;**&#93;) in the Field in the Territory at its sole cost and expense (including having an Affiliate or Third Party Commercialize on its behalf). On a Collaboration Target-by-Collaboration Target basis, following Regulatory Approval of a Collaboration Product Directed Against such Collaboration Target, Novartis, by itself or through its Affiliates or Sublicensees, will use Commercially Reasonable Efforts to Commercialize at least one (1) Collaboration Product Directed Against such Collaboration Target for &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 6.&#160;&#160;&#160;&#160;MANUFACTURING</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Generally</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Following the Handoff of each Project, Novartis shall, at its cost and expense, have the exclusive right for the Manufacture (including having a Third Party Manufacture on its behalf) of Collaboration Compound and Collaboration Products resulting from such Project (including all such Manufacturing for use in Clinical Trials and for Commercialization), including all activities related to Developing the process, analytics and formulation for the manufacture of clinical and commercial quantities of such Collaboration Compounds or Collaboration Products, the production, manufacture, processing, filling, finishing, packaging, labeling, inspection, receiving, holding and shipping of such Collaboration Compounds or Collaboration Products, or any raw materials or packaging materials with respect </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 41 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">thereto, or any intermediate of any of the foregoing, including process and cost optimization, process qualification and validation, commercial manufacture, stability, in-process and release testing, quality assurance and quality control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Technology Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition to the technology transfer obligations of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Transfer), at Novartis&#8217; request after the applicable Handoff and during the Term, (a) the Parties shall cooperate in good faith to identify the Manufacturing Technology and (b) Schr&#1255;dinger shall use Commercially Reasonable Efforts to transfer all Information within the Manufacturing Technology to Novartis or its permitted designees in order to enable Novartis and its designees to obtain the regulatory or governmental approvals necessary to authorize Novartis and its designees to Manufacture the applicable Collaboration Compounds or Collaboration Products for clinical and commercial supply in the Territory (clauses (a) and (b) together, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Technology Transfer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Parties shall conduct the Manufacturing Technology Transfer in accordance with a mutually agreed transfer plan, including the timelines set forth therein, and Novartis shall be fully responsible, at its own cost, for obtaining all licenses, permits and other certifications required by the applicable Regulatory Authorities in order to complete such Manufacturing Technology Transfer. Each Party shall be fully responsible for its and its Affiliates internal and out-of-pocket costs in connection with the Manufacturing Technology Transfer.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 7.&#160;&#160;&#160;&#160;GRANT OF RIGHTS AND LICENSES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Grants. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Licenses to Novartis and its Affiliates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Schr&#1255;dinger hereby grants to Novartis and its Affiliates as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;with respect to each Collaboration Target, during the Research Term of such Collaboration Target, a fully paid-up, royalty-free</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">exclusive license, with the right to grant sublicenses through multiple tiers of Sublicensees as provided in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Sublicensing), under Schr&#246;dinger&#8217;s Intellectual Property Rights to use or practice any Patent or Information Controlled by Schr&#1255;dinger or its Affiliates as of the Effective Date and during the Research Term, that is necessary or reasonably useful for Novartis or its Affiliates to conduct its activities under the Project Plan of such Collaboration Target solely to conduct such activities consistent with its obligations under the applicable Project Plan (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Research License</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;with respect to each Collaboration Target and through the Term (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in the case of expiration of this Agreement, such license grant shall become non-exclusive and survive as and to the extent set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Effects of Expiration of Agreement)), an exclusive (even as to Schr&#1255;dinger), worldwide license, with the right to grant sublicenses through multiple tiers of Sublicensees as provided in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Sublicensing), </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 42 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under the Licensed Technology, to Exploit Collaboration Compounds and Collaboration Products within the Field throughout the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a non-exclusive, fully paid-up and royalty free, perpetual, irrevocable, worldwide license, with the right to grant sublicenses through multiple tiers, in connection with a grant of rights with respect to a product or compound controlled by Novartis or any of its Affiliates or sublicensees, under the Schr&#1255;dinger-Owned Arising IP and related Licensed Technology of Schr&#1255;dinger to the extent necessary for Novartis or its Affiliates to practice Novartis&#8217; Background IP that is disclosed or provided by Novartis to Schr&#246;dinger or its Affiliates under the Project Plans or any improvement, derivation, enhancement or other modification of such Background IP of Novartis, to Exploit products which are neither Collaboration Compounds nor Collaboration Products&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;a non-exclusive, worldwide right and license, until the expiration of the last-to-expire Research Term, to access and use (but not to reproduce, distribute, publicly display, modify, or create derivative works of) the Schr&#1255;dinger Platform to the extent necessary or reasonably useful for Novartis or its Affiliates for the purposes of carrying out the Project Plans. For clarity, the right and license granted under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is separate from any other right or license granted in respect of the Schr&#1255;dinger Platform to Novartis under any other agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License to Schr&#1255;dinger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novartis hereby grants to Schr&#1255;dinger, as of the Effective Date and during the Research Term of each Collaboration Target (&#91;**&#93;) (or to the extent necessary for activities authorized by Novartis or required to be conducted by Schr&#1255;dinger beyond the Research Term, including the activities pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, during the Term), a fully paid-up, royalty-free, non-exclusive license, with the right to grant sublicenses through multiple tiers of Sublicensees as provided in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Sublicensing), under Novartis&#8217; Intellectual Property Rights to Exploit any Patent or Information Controlled by Novartis or its Affiliates as of the Effective Date and during such Research Term, that is (i) necessary for Schr&#1255;dinger or its Affiliates to conduct its activities under the Project Plan for such Collaboration Target (&#91;**&#93;) and (ii) is either (A) Novartis-Owned Arising IP or (B) Novartis&#8217; Background IP, to the extent licensable to Schr&#246;dinger pursuant to the terms of this Agreement without triggering any additional payments, liabilities, or obligations for Novartis or its Affiliates under any agreements to which they are a party, except, in the case of any payment obligations, if such payments are Third Party IP Payments for purposes of the royalty reductions set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Reductions), in each case ((i) or (ii)), solely for Schr&#1255;dinger or its Affiliates to conduct its activities under the applicable Project Plan, consistent with its obligations under such Project Plan (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Research License&#8221;)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall have the right to sublicense, through multiple tiers, the licenses granted to it by the other Party under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Licenses to Novartis) or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Licenses to Schr&#1255;dinger), as applicable, to (a) its Affiliates or subcontractors (in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Subcontracting)), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Schr&#246;dinger must obtain Novartis&#8217; </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 43 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prior written consent for such sublicensing, such consent not be unreasonably withheld, conditioned or delayed or (b) other Third Parties, with the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that (i) Novartis shall promptly provide Schr&#1255;dinger of the existence and identity of any Sublicensee of the license granted to Novartis under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Licenses to Novartis) and (ii) the right to sublicense of the licensed Party with respect to the Novartis Research License and Schr&#1255;dinger Research License shall be limited to the Affiliates and subcontractors performing the activities under the applicable Project Plan on behalf of such licensed Party in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Subcontracting). Each Party shall be responsible for the performance of any of its sublicensees (including Sublicensees, with respect to Novartis) that are exercising rights under a sublicense of the licenses granted to such Party hereunder, and the grant of any such sublicense shall not relieve such sublicensing Party of its obligations under this Agreement, except to the extent they are satisfactorily performed by any such sublicensee(s) (including Sublicensee(s), with respect to Novartis). Each sublicense agreement with a sublicensee (including a Sublicensee, with respect to Novartis) shall be subject to the applicable terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Other Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the licenses and rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by a Party to the other Party. All rights with respect to Information, Patents or other Intellectual Property Rights that are not specifically granted herein are reserved to the owner thereof. Further, the licenses and other rights granted to Novartis herein are subject to the rights retained by the counterparty to each Collaboration In-License, to the extent such agreements are applicable. Neither Party nor any of its Affiliates will use or practice any Information or Patents licensed or provided to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Software Exclusions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Agreement, Novartis acknowledges that Schr&#246;dinger and its Affiliates have certain Information, Patents or other Intellectual Property Rights that consist of, or with respect to Patents claim, software, source code or object code related to the Schr&#246;dinger Platform or Schr&#246;dinger Platform Inventions, including Schr&#246;dinger Platform IP. It is understood and agreed that (a) both Parties or their respective Affiliates will perform activities under this Agreement pertaining to the use of such software, source code or object code related to the Schr&#246;dinger Platform or Schr&#246;dinger Platform Inventions and (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any such activities conducted by Novartis or its Affiliates will be pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 8.&#160;&#160;&#160;&#160;PAYMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Upfront Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis shall pay Schr&#1255;dinger an upfront payment of One Hundred and Fifty Million Dollars ($150,000,000) no later than &#91;**&#93; after the Effective Date and </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 44 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">upon receipt of the invoice from Schr&#246;dinger (which shall not be received before the Effective Date). Such payment shall be noncreditable, nonrefundable and not subject to set-off.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;With respect to each Collaboration Target, Novartis shall pay to Schr&#1255;dinger a one-time pre-clinical milestone payment set forth in Table 1 below (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for each Collaboration Compound generated under such Collaboration Target to achieve the below specified research milestone event (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Such payments shall be noncreditable, nonrefundable and not subject to set-off.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Table 1</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"></td><td style="width:38.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Event</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Discovery Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:39.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$&#91;**&#93; Dollars) for each Collaboration Compound Directed Against the &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="padding-left:39.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:39.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$&#91;**&#93; Dollars) for each Collaboration Compound Directed Against the &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="padding-left:39.12pt;padding-right:3.12pt"><font><br></font></div><div style="margin-bottom:10pt;padding-left:39.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">$&#91;**&#93; Dollars) for each Collaboration Compound Directed Against an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;After &#91;**&#93;, Schr&#246;dinger shall invoice Novartis the corresponding Discovery Milestone Payment for such &#91;**&#93;, and Novartis shall pay such amount within &#91;**&#93; after the date of receipt of such invoice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If the &#91;**&#93; in respect of such Collaboration Target (or in the case of the Collaboration Target consisting of the &#91;**&#93;, the applicable &#91;**&#93;), then Novartis shall provide written notice to Schr&#246;dinger of such &#91;**&#93; within &#91;**&#93; after &#91;**&#93;, and, in the event that Novartis does not provide notice to Schr&#246;dinger pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Schr&#246;dinger shall invoice Novartis for a Discovery Milestone Payment to Schr&#1255;dinger for &#91;**&#93;, or in the case of the &#91;**&#93;, the same &#91;**&#93; as such &#91;**&#93;, and Novartis shall pay such amount within &#91;**&#93; after the date of receipt of such invoice&#59; it being understood that if Novartis later submits a &#91;**&#93; for such Collaboration Compound pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Discovery Milestone Payment to Schr&#1255;dinger for such Collaboration Compound shall be deemed paid and Novartis will not need to pay the Discovery Milestone Payment for such Collaboration Target upon &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 45 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160; If a &#91;**&#93; has occurred as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and Novartis does not make an election under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(d)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(d)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below, Schr&#1255;dinger shall invoice Novartis for a Discovery Milestone Payment pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Novartis may elect, by written notice to Schr&#1255;dinger within &#91;**&#93;, to either&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;notify Schr&#246;dinger in writing that Novartis or its Affiliate will &#91;**&#93;, in which case, within &#91;**&#93; (or such longer period as may be agreed by the Parties) after &#91;**&#93;, Novartis or its Affiliate will &#91;**&#93;, giving due consideration to ethical concerns and requirements under Applicable Law&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;notify Schr&#246;dinger in writing that it is &#91;**&#93;, in which case, within &#91;**&#93; (or such longer period as may be agreed by the Parties) after Schr&#246;dinger&#8217;s receipt of such notice, Novartis and its Affiliates will cease all such activities, giving due consideration to ethical concerns and requirements under Applicable Law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestones for Collaboration Compounds and Collaboration Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;With respect to each Materially Distinct Project Plan for a Collaboration Target, Novartis shall pay to Schr&#1255;dinger each of the milestone payments set forth in Table 2 below (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) after the first time a Collaboration Compound or Collaboration Product Directed Against a Collaboration Target (&#91;**&#93;) under such Materially Distinct Project Plan to achieve the below specified Development or regulatory milestone event (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Such payments shall be noncreditable, nonrefundable and not subject to set-off.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Table 2</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Development Milestone Event</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Development Milestone Payment</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr></table></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 46 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93; </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">4.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93; </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">5.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93; </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">6.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr></table></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 47 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">7.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">8.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">9.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 4.12pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:20.77pt;padding-right:2.77pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) for an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;With respect to each Materially Distinct Project Plan for a Collaboration Target (&#91;**&#93;), each Development Milestone Payment shall be paid only once upon the first time a Collaboration Compound or Collaboration Product Directed Against such Collaboration Target (&#91;**&#93;) under such Materially Distinct Project Plan to achieve the applicable Development Milestone Event, regardless of whether the same Development Milestone Event is subsequently achieved again with respect to the same or a different Collaboration Compound or Collaboration Product directed to the same Collaboration Target (&#91;**&#93;) under such Materially Distinct Project Plan and regardless of whether additional Clinical Trials are subsequently conducted, or additional Regulatory Approvals are subsequently obtained, with respect to the same or a different Collaboration Compound or Collaboration Product directed to such Collaboration Target (&#91;**&#93;) under such Materially Distinct Project Plan. The maximum amount payable under </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 48 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Development Milestones for Collaboration Compounds and Collaboration Products) with respect to each Collaboration Target (&#91;**&#93;) is &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, for the purposes of construing the payments specified in the above table, with respect to each Collaboration Compound or Collaboration Product developed under a Collaboration Target (&#91;**&#93;) under a Materially Distinct Project Plan, if any of the Development Milestone Events &#91;**&#93; through &#91;**&#93; specified in the above table &#91;**&#93; is skipped (i.e., a later Development Milestone Payment is payable before an earlier Development Milestone Payment &#91;**&#93;), then the skipped Development Milestone Event(s) will be deemed to have been achieved and payable (subject to the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) upon the achievement of the subsequent Development Milestone Event(s). Further, to the extent a Collaboration Compound or corresponding Collaboration Product achieves &#91;**&#93; is skipped (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#91;**&#93;) any such skipped Development Milestone Event will be deemed to have been achieved and payable (subject to the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)  upon the receipt of such &#91;**&#93;. If any of Development Milestone Events &#91;**&#93; is achieved (or if a Collaboration Compound or corresponding Collaboration Product achieves &#91;**&#93;) without Development Milestone Event &#91;**&#93; having become achieved, Development Milestone Event 4 will be deemed to have been achieved and payable (subject to the process set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) upon such achievement of Development Milestone Event &#91;**&#93; or upon receipt of such &#91;**&#93;, as applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Novartis shall provide Schr&#1255;dinger with written notice of its achievement of each Development Milestone Event within &#91;**&#93; after such Development Milestone Event is achieved or deemed achieved pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. After receipt of such notice of achievement, and, for clarity, subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Schr&#246;dinger shall invoice Novartis the corresponding Development Milestone Payment for such Collaboration Target, and Novartis shall pay such amount within &#91;**&#93; after the date of receipt of such invoice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Milestone Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;With respect to each Collaboration Product, Novartis shall pay to Schr&#1255;dinger each of the sales-based milestone payments set forth in Table 3 below (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Milestone Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) after the total annual Net Sales in a Calendar Year of such Collaboration Product in the Territory first achieves or exceeds the following specified thresholds  (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Milestone Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), it being understand and agreed, for clarity, that Sales Milestone Event #&#91;**&#93; and Sales Milestone Event #&#91;**&#93; are applicable only with respect to Collaboration Products Directed Against the &#91;**&#93;, and Sales Milestone Payment #&#91;**&#93; and Sales Milestone Payment #&#91;**&#93; are each payable only following first achievement of the corresponding Sales Milestone Event by each Collaboration Product Directed Against the &#91;**&#93;. Such payments shall be noncreditable and nonrefundable. Such payments shall be noncreditable, nonrefundable and not subject to set-off. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Table 3</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 49 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:13.63pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"></td><td style="width:3.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Sales Milestone Event</font></div><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(First Achievement of Annual Net Sales for Each Collaboration Product)</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Sales Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93; Dollars ($&#91;**&#93;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93;Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93; Dollars ($&#91;**&#93;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93;Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93; Dollars ($&#91;**&#93;)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93;Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr></table></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 50 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:13.63pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"></td><td style="width:3.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">4.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93; Dollars ($&#91;**&#93;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93; Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to &#91;**&#93;Target or its Replacement Collaboration Target</font></div><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">5.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93; Dollars ($&#91;**&#93;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">6.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;**&#93; Dollars ($&#91;**&#93;)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;$&#91;**&#93; Dollars) if such Collaboration Product is directed to an &#91;**&#93; or its Replacement Collaboration Target</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The maximum amount payable under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Sales Milestone Payments) with respect to each Collaboration Product developed under each Project Plan of each Collaboration Target is &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Novartis shall provide Schr&#1255;dinger with written notice of such first achievement of each Sales Milestone Event as part of delivery of the Royalty Report for the Calendar Quarter in which such Sales Milestone Event is achieved. After receipt of such Royalty Report, and, for clarity, subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Schr&#246;dinger shall invoice Novartis the corresponding Sales Milestone Payment for such Collaboration Product, and Novartis shall pay such amount within &#91;**&#93; after the date of receipt of such invoice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;More than one of the Sales Milestone Payments for a Collaboration Product or different Collaboration Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Sales Milestone Payments) may be payable for a given Calendar Quarter if more than one of the corresponding Sales Milestone Events are first achieved in the same Calendar Quarter. For example, if more than one Sales </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 51 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone Event specified above is first achieved in the same Calendar Quarter, then Novartis shall pay to Schr&#1255;dinger each corresponding Sales Milestone Payment for such Sales Milestone Events.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Payments to Schr&#1255;dinger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the other provisions of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Payments) and other provisions of this Agreement, on a Collaboration Product-by-Collaboration Product and country-by-country basis, Novartis shall pay to Schr&#1255;dinger royalties based on the Net Sales of each Collaboration Product during the applicable Royalty Term for such Collaboration Product in such country. The royalty payable with respect to each particular Collaboration Product shall be based on the level of total annual Net Sales of such Collaboration Product in the Territory in a given Calendar Year by Novartis, its Sublicensees and their Affiliates, with the royalty rates tiered based upon the level of such total annual Net Sales of such Collaboration Product in the Territory in such Calendar Year. Royalties shall be calculated by multiplying the applicable royalty rates by the corresponding amounts of the portion of Net Sales of the applicable Collaboration Product during the Royalty Term within each of the Net Sales tiers during such Calendar Year as set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty on Collaboration Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. On a Collaboration Product-by-Collaboration Product basis, Novartis will pay to Schr&#1255;dinger royalties on Net Sales of each Collaboration Product sold by Novartis, its Sublicensees and their Affiliates in the Territory based on the Net Sales tiers and royalty rates as set forth in Table 4 below (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Royalty Rate</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Table 4</font></div><div style="padding-left:45.9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.737%"><tr><td style="width:1.0%"></td><td style="width:39.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Royalty Rate</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Portion of Total Aggregate Net Sales in the Territory<br>for Each Collaboration Product in a Given Calendar Year during the Royalty Term</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;&#91;**&#93;% (&#91;**&#93; Percent)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Less than or equal to $&#91;**&#93; Dollars)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;&#91;**&#93;% (&#91;**&#93; Percent)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Greater than $&#91;**&#93; Dollars) and less than or equal to $&#91;**&#93; Dollars) </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;&#91;**&#93;% (&#91;**&#93; Percent)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Greater than $&#91;**&#93; Dollars) and less than or equal to $&#91;**&#93; Dollars)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;&#91;**&#93;% (&#91;**&#93; Percent)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Greater than $&#91;**&#93; Dollars) and less than or equal to $&#91;**&#93; Dollars)</font></div></td></tr></table></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 52 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:45.9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.737%"><tr><td style="width:1.0%"></td><td style="width:39.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;&#91;**&#93;% (&#91;**&#93; Percent)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Greater than $&#91;**&#93; Dollars) and less than or equal to $&#91;**&#93; Dollars)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21.12pt;padding-right:3.12pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#9679;&#160;&#160;&#160;&#160;&#91;**&#93;% (&#91;**&#93; Percent)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.12pt;padding-right:3.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Greater than $&#91;**&#93; Dollars)</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the Net Sales thresholds in the tables above shall be determined on a Collaboration Product-by-Collaboration Product basis.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By way of example, if the total annual Net Sales of a Collaboration Product are &#91;**&#93; Dollars ($&#91;**&#93;), the amount of royalties payable hereunder shall be calculated as follows (subject to any applicable reductions under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Reductions))&#58; &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Reductions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing and subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Floor), on a Collaboration Product-by-Collaboration Product and country-by-country basis, in the event that, and in such case from and after the date on which, such Collaboration Product is not Covered by a Valid Claim of a Payment Patent Covering the composition of matter or approved method of use or treatment of such Collaboration Product (or of any Collaboration Compound in such Collaboration Product) in such country, for the remaining part of the Royalty Term, the Base Royalty Rate as applied to the sale of such Collaboration Product in each such country shall be reduced by &#91;**&#93; percent (&#91;**&#93;%).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Generic Competition</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Floor), on a Collaboration Product-by-Collaboration Product and country-by-country basis, if one or more Generic Products have been sold in such country with respect to such Collaboration Product, then the Base Royalty Rate as applied to the sale of such Collaboration Product in such country for such Calendar Quarter shall be reduced as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;by &#91;**&#93; percent (&#91;**&#93;%), in the event that in any Calendar Quarter the decline in Net Sales of such Collaboration Product from the Pre-Generic Quarterly Sales Average is equal to or greater than &#91;**&#93; percent (&#91;**&#93;%) but less than &#91;**&#93; percent (&#91;**&#93;%)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;by &#91;**&#93; percent (&#91;**&#93;%), in the event that in any Calendar Quarter the decline in Net Sales of such Collaboration Product from the Pre-Generic Quarterly Sales Average in such country is equal to or greater than &#91;**&#93; percent (&#91;**&#93;%) but less than &#91;**&#93; percent (&#91;**&#93;)%&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;by &#91;**&#93; percent (&#91;**&#93;%), in the event that in any Calendar Quarter such Generic Product(s), the decline in Net Sales of such Collaboration Product from the Pre-Generic Quarterly Sales Average in such country is equal to or greater than &#91;**&#93; percent (&#91;**&#93;%).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 53 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pre-Generic Quarterly Sales Average</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Collaboration Product in a country, the average quarterly Net Sales such Collaboration Product achieved in such country in the four (4) consecutive Calendar Quarters immediately prior to the Calendar Quarter in which the first Generic Product with respect to such Collaboration Product is sold in such country.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party License Payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;Schr&#246;dinger shall bear all Third Party license payments, milestones, royalties and other payments owed in consequence of the use of the Schr&#246;dinger Platform hereunder involving intellectual property (including Patents) that is Controlled by Schr&#246;dinger as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;If, on a Collaboration Product-by-Collaboration Product and country-by-country basis, Novartis, in its good faith judgment, believes that it is necessary or reasonably useful to obtain a license or other right from any Third Party Patent, know-how or other intellectual property rights in order to research, Develop, Manufacture, Commercialize, sell, offer for sale, import, or other Exploit any given Collaboration Compound or Collaboration Product, Novartis shall have the right to enter into such licenses or other agreement with such Third Party with respect to such Third Party Patent, know-how or other intellectual property rights. After the Effective Date and during the Term, if Schr&#1255;dinger acquires from any Third Party Patent, know-how or other intellectual property rights that are necessary for or solely relate to the research, Development, Manufacture, Commercialization, sale, offering for sale, importation, or other Exploitation of Collaboration Compounds or Collaboration Products in the Field in the Territory, without the prior written consent of Novartis to such acquisition of such rights and the terms and conditions thereof, then Schr&#246;dinger shall be solely responsible for all upfront payments, milestone payments, royalties, and other consideration paid to such Third Party in respect of such agreement, and Schr&#246;dinger shall be deemed to Control such Third Party Patent, know-how or other intellectual property rights. If, after the Effective Date and during the Term, Schr&#1255;dinger, in its good faith judgment, acquires any Third Party Patent, know-how or other intellectual property rights that are necessary or reasonably useful to the research, Development, Manufacture, Commercialization, sale, offering for sale, importation, or other Exploitation of Collaboration Compounds or Collaboration Products or to the practice of the Schr&#246;dinger Platform in the Field in the Territory (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Future In-Licensed IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then unless Schr&#246;dinger is solely responsible for all consideration paid for such Third Party Patent, know-how or other intellectual property rights pursuant to the immediately preceding sentence, the following shall apply&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;If such Future In-Licensed IP is specifically related to the Schr&#246;dinger Platform (such intellectual property, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Platform IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Schr&#246;dinger will be responsible for any license fees, milestones, royalties or other payments owing to such Third Party with respect to such Platform IP.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 54 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;If any Future In-Licensed IP that is not Platform IP may be included within the Licensed Technology or Product Specific Patents, then Schr&#1255;dinger shall disclose the terms and conditions of the agreement under which such Future In-Licensed IP was acquired (subject to applicable confidentiality obligations and reasonable redaction of provisions that do not relate to the use of intellectual property in-licensed thereunder) (such agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger New In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to enable Novartis to evaluate and elect, in its sole discretion, whether or not to include such Future In-Licensed IP within the Licensed Technology or Product Specific Patents, as applicable. If Novartis so elects to include such Future In-Licensed IP as Licensed Technology or Product Specific Patents, as applicable, then (A) such Schr&#1255;dinger New In-License shall become a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, (B) Future In-Licensed IP in-licensed under such Schr&#1255;dinger New In-License will be deemed &#8220;Controlled&#8221; by Schr&#1255;dinger or its Affiliates for purposes of this Agreement and will be included in the Licensed Technology or Product Specific Patents, as applicable, (C) Novartis shall be responsible for payments that become due under such Collaboration In-License with respect to the Development, Manufacturing and Commercialization of a Collaboration Compound or Collaboration Product by Novartis, its Sublicensees and its and their Affiliates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Novartis may elect, in the case of an exclusive Schr&#1255;dinger New In-License, to receive only a non-exclusive sublicense thereunder, in which case the Parties shall agree to a reasonable allocation of such payments to account for the non-exclusive nature of such sublicense, (D) Novartis agrees to comply with any obligations under such Collaboration In-License that apply to Novartis, including any obligation to make such payments. If Novartis does not elect to include such Future In-Licensed IP, then (1) Schr&#1255;dinger may use such Future In-Licensed IP in the course of performing any Project Plan activities, unless the use of such Future In-Licensed IP by Schr&#1255;dinger would make it necessary or useful for Novartis to take a sublicense under such Schr&#1255;dinger New In-License in order for Novartis or its Affiliates to Exploit a Collaboration Compound or Collaboration Product, (2) such Schr&#1255;dinger New In-License shall not become a Collaboration In-License hereunder, (3) such Future In-Licensed IP shall not be deemed &#8220;Controlled&#8221; by Schr&#1255;dinger or its Affiliates for purposes of this Agreement and will be excluded from Licensed Technology or Product Specific Patents, and (4) Novartis shall have no right or license under any rights granted under such Schr&#1255;dinger New In-License. Schr&#1255;dinger shall provide Novartis with a reasonably detailed invoice for any payments to be made by Novartis pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> under any Collaboration In-License, and Novartis shall pay the undisputed portion of such invoices to Schr&#1255;dinger within &#91;**&#93; of receipt thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Novartis may deduct up to &#91;**&#93; percent (&#91;**&#93;%) of the amounts of any Third Party IP Payments by Novartis from royalties that are due and payable by Novartis to Schr&#1255;dinger under this Agreement, subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Floor).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Floor), if, during the Royalty Term for a Collaboration Product in the U.S., such Collaboration Product is designated as a Selected IRA Drug by the Secretary of the U.S. Department of Health and Human Services, and Novartis, its Affiliate or its or their Sublicensee is required to negotiate a Maximum Fair </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 55 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Price that will apply to sales of such Collaboration Product (the Calendar Quarter in which such designation event occurs, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Event Quarter</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, the Base Royalty Rate as applied to the sale of such Collaboration Product in the U.S. after the Event Quarter shall be reduced as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.&#160;&#160;&#160;&#160;by &#91;**&#93; percent (&#91;**&#93;%), in the event that in any Calendar Quarter after the Event Quarter, the decline in U.S. Net Sales of such Collaboration Product from the average quarterly Net Sales such Collaboration Product achieved in the U.S. in the four (4) consecutive Calendar Quarters immediately prior to the Event Quarter is equal to or greater than &#91;**&#93; percent (&#91;**&#93;%) but less than &#91;**&#93; percent (&#91;**&#93;%)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.&#160;&#160;&#160;&#160;by &#91;**&#93; percent (&#91;**&#93;%), in the event that in any Calendar Quarter after the Event Quarter, the decline in the U.S. Net Sales of such Collaboration Product from the average quarterly Net Sales such Collaboration Product achieved in the U.S. in the four (4) consecutive Calendar Quarters immediately prior to the Event Quarter is equal to or greater than &#91;**&#93; percent (&#91;**&#93;%) but less than &#91;**&#93; percent (&#91;**&#93;)%&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.&#160;&#160;&#160;&#160;by &#91;**&#93; percent (&#91;**&#93;%), in the event that in any Calendar Quarter after the Event Quarter, the decline in the average U.S. Net Sales of such Collaboration Product from the average quarterly Net Sales such Collaboration Product achieved in the U.S. in the four (4) consecutive Calendar Quarters immediately prior to the Event Quarter is equal to or greater than &#91;**&#93; percent (&#91;**&#93;)%. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Royalties payable by Novartis to Schr&#1255;dinger under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Payments to Schr&#1255;dinger) shall be paid on a Collaboration Product-by-Collaboration Product and country-by-country basis for the duration of the Royalty Term for such Collaboration Product in such country. For clarity, upon expiration of the Royalty Term for such Collaboration Product in such country, Novartis shall have a fully-paid-up, perpetual and sublicensable (through multiple tiers) non-exclusive license under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.1(a)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the making, using, selling, offering for sale and importing of such Collaboration Product in such country and shall not owe royalties on any Collaboration Product sold in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Floor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, in no event shall the royalties payable to Schr&#1255;dinger pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty on Collaboration Products) during the Royalty Term for a Collaboration Product in any given Calendar Quarter be reduced (including due to any or all reductions under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Reductions)) to less than &#91;**&#93; percent (&#91;**&#93;%) of the amounts otherwise payable by Novartis for such Collaboration Product in such Calendar Quarter.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty reductions under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Royalty Reductions) not exhausted in any Calendar Quarter may be carried into future Calendar Quarters, subject to the foregoing sentence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Payments and Reports</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All amounts payable to Schr&#1255;dinger pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Royalty Payments to Schr&#1255;dinger) shall be paid in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 56 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Payment Method). Within &#91;**&#93; after the end of the Calendar Quarter in which the applicable Net Sales were recorded, Novartis shall deliver to Schr&#246;dinger a royalty report providing a statement, on a Collaboration Product-by-Collaboration Product and country-by-country basis, of&#58; (a) the amount of Net Sales of Collaboration Products in the Territory during the applicable Calendar Quarter calculated in Dollars and, if applicable outside of the United States, local currency, (b) a calculation of the amount of royalty payment due in Dollars on such Net Sales for such Calendar Quarter, including any reductions applied pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Royalty Payments to Schr&#1255;dinger). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Within &#91;**&#93; after receipt of each royalty report, Schr&#246;dinger shall invoice Novartis the corresponding royalties, and Novartis shall pay such amount within &#91;**&#93; after the date of receipt of such invoice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payment Method</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All payments due under this Agreement to Schr&#1255;dinger shall be made by electronic funds transfer in immediately available funds to an account designated by Schr&#1255;dinger. All payments hereunder shall be made in Dollars.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Taxe</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">s. Except as otherwise provided in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Taxes), each Party shall be responsible for its own taxes (including taxes imposed on or measured by Net Sales, capital, franchise or similar taxes pursuant to Applicable Laws).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indirect Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All amounts set forth in this Agreement shall be exclusive of any value added (VAT), goods and services (GST), sales, turnover, use, excise, consumption, and other similar indirect Taxes (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indirect Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Schr&#246;dinger shall issue all invoices in full compliance with the Indirect Tax laws and regulations applicable at Schr&#246;dinger&#8217;s place of business. If any Indirect Taxes are due based on local law, Schr&#246;dinger shall be allowed to add the amount of Indirect Taxes to the amounts set forth in this Agreement and invoice the net amount plus the applicable Indirect Taxes. The Parties shall issue invoices for all amounts payable under this Agreement consistent with all Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Withholding Taxes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;In the event that any payments made by Novartis to Schr&#246;dinger pursuant to this Agreement shall become subject to withholding taxes under the Applicable Laws of any jurisdiction, or if it is unclear whether Applicable Laws require such withholding, including extra-territorial taxation, Novartis shall be authorized to deduct and withhold the amount of such taxes for the account of Schr&#246;dinger to the extent required by Applicable Laws and pay the withholding tax to the relevant tax authority, so that only the correspondingly reduced amount less withholding tax is paid out to Schr&#246;dinger. Novartis shall deliver to Schr&#246;dinger proof of the withholding tax payment. Any such amounts withheld and paid to any such tax authority shall be deemed to have been paid to Schr&#246;dinger for purposes of this Agreement, in full satisfaction of Novartis&#8217; obligation with respect to such amounts.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 57 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Novartis and Schr&#246;dinger shall make all reasonable efforts to obtain relief or reduction of withholding tax under the applicable tax treaties, including the submission or issuance of requisite forms and information. If a special procedure is required for treaty relief by law, a treaty relief based on a tax treaty will only be taken into account if Schr&#246;dinger submits an exemption certificate to Novartis in accordance with legal requirements at the time of the payment to Schr&#246;dinger. If no withholding tax deduction has been made but tax authorities subsequently take the position that a withholding tax deduction should have been made, Schr&#246;dinger shall provide, at its expense, all reasonable support to Novartis to obtain relief or reduction of withholding under the Applicable Laws and tax treaties, including the submission or issuance of requisite forms and information. All refunds of withholding taxes granted by the competent tax authority and related interest shall be paid to Novartis. If a refund of withholding taxes is not possible, Schr&#246;dinger shall repay the corresponding amount to Novartis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Foreign Exchange</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All payments to be made by a Party under this Agreement shall be made in Dollars, and all payments made by Novartis to Schr&#246;dinger under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to a bank account set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 8.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Bank Account Details). Any payment which falls due on a date which is not a Business Day in the location from which the payment will be made may be made on the next succeeding Business Day in such location. The rate of exchange to be used in computing the amount of currency equivalent in Dollars for the payment due shall be made by using Novartis&#8217; then-current standard exchange rate methodology as applied in its external reporting for the conversion of foreign currency sales into Dollars.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.10&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis shall keep, and shall cause its Affiliates and Sublicensees to keep, complete, true and accurate books of accounts and records sufficient to determine and establish the amounts payable incurred under this Agreement, and compliance with the other terms and conditions of this Agreement. Such books and records shall be kept reasonably accessible and shall be made available for inspection for a &#91;**&#93; period in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Inspection of Records) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.11&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inspection of Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;A Party may, upon written request, cause an internationally-recognized independent accounting firm which is reasonably acceptable to the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Auditor</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to inspect the relevant records of the other Party and its Affiliates to verify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the payment obligations hereunder, with respect to Novartis, or to verify the &#91;**&#93; referenced in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)(ii)(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or verify the &#91;**&#93; the limits set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)(ii)(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with respect to Schr&#1255;dinger, such Net Sales and royalties and the related reports, statements and books of accounts, as applicable. Before beginning its audit, the Auditor shall execute an agreement acceptable to the audited Party pursuant to which the Auditor agrees to keep confidential all information reviewed during the audit. The Auditor shall have the right to disclose to the auditing Party only its conclusions regarding any payments under this Agreement.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 58 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The audited Party and its Affiliates shall make their records available for inspection by the Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from the auditing Party. The records shall be reviewed solely to verify the accuracy of payments made by the audited Party. Such inspection right shall not be exercised more than &#91;**&#93; and not more frequently than &#91;**&#93; with respect to records covering any specific period of time. In addition, the auditing Party shall only be entitled to audit the books and records of the audited Party from the &#91;**&#93; prior to the Calendar Year in which the audit request is made. The auditing Party agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, which information shall constitute the Confidential Information of the audited Party, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Auditor shall provide its audit report and basis for any determination to the audited Party at the time such report is provided to the auditing Party before it is considered final&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">at least &#91;**&#93; prior to the provision of such report, the Auditor shall provide its draft audit report and basis for any determination to the audited Party to verify the exclusion of any Confidential Information and to allow for the reasonable review and provision of comments by the audited Party. The audited Party shall have the right to request a further determination by such Auditor as to matters which the audited Party disputes within &#91;**&#93; after receipt of such report. The audited Party will provide the auditing Party and the Auditor with a reasonably detailed statement of the grounds upon which it disputes any findings in the audit report and the Auditor shall undertake to complete such further determination within &#91;**&#93; after the dispute notice is provided, which determination shall be limited to the disputed matters. Any matter that remains unresolved shall be resolved in accordance with the dispute resolution procedures contained in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by the audited Party, the underpaid or overpaid amount shall be settled promptly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">within &#91;**&#93; after receiving the audit report, including, in the case of any overpayment, at the audited Party&#8217;s election, by (i) submission of an invoice to the auditing Party, which shall be promptly paid by the auditing Party, or (ii) offset by the audited Party against future royalties or milestone payments hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The auditing Party shall pay for such audits, as well as its expenses associated with enforcing its rights with respect to any payments hereunder&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the audit for a period shows an under-reporting or an underpayment of at least &#91;**&#93; percent (&#91;**&#93;%) of the total payments due for the applicable audit period, the fees and expenses charged by the Auditor (including reasonable out-of-pocket costs) shall be paid by the audited Party, which shall be made within &#91;**&#93; after receiving appropriate invoices and other support for such audit-related costs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 59 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.12&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Late Payments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement shall bear interest at a rate equal to the lesser of&#58; (a) &#91;**&#93; percentage points above the CME Term Secured Overnight Financing Rate (USD SOFR) on the first day of each Calendar Quarter in which such payments are overdue,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (b) the maximum rate permitted by Applicable Law&#59; in each case calculated on the number of days such payment is delinquent, compounded monthly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.13&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Payments to or Reports by Affiliates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any payment required under any provision of this Agreement to be made to either Party or any report required to be made by any Party shall be made to or by an Affiliate of that Party if designated in writing by that Party as the appropriate recipient or reporting entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.14&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Diagnostic Products</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The milestones and royalty amounts in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Payments) shall not apply to the Development and Commercialization of Collaboration Products for diagnostic use or for uses solely for (and not for any other purposes) screening patients who have been diagnosed with a disease, state or condition for eligibility to be treated for such disease, state or condition with a Collaboration Product or for monitoring patients who are or have been treated with a Collaboration Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.15&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Monetization Transaction &#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If Schr&#246;dinger intends to grant a Third Party a security interest in or to otherwise sell, assign, or otherwise transfer its rights to receive payments with respect to any Collaboration Product under this Agreement to a Third Party in connection with a royalty monetization transaction (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Monetization Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then Schr&#246;dinger will provide Novartis notice of such intent &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 9.&#160;&#160;&#160;&#160;INTELLECTUAL PROPERTY OWNERSHIP, PATENT PROSECUTION AND ENFORCEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ownership of Intellectual Property</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Background IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the licenses and rights granted in this Agreement, each Party will retain all rights in and to its Background IP. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ownership of Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, Schr&#1255;dinger shall solely own (A) any and all Arising Know-How that is solely conceived, discovered, developed, identified or otherwise made by or on behalf of Schr&#1255;dinger or its Affiliates (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Sole Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and all Intellectual Property Rights in and to such Schr&#1255;dinger Sole Arising Know-How, in each case, other than Novartis-Owned Arising IP, and (B) any Arising Know-How (to the extent not included in Schr&#1255;dinger Sole Arising Know-How)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that solely and specifically relates to the Schr&#1255;dinger Platform, including Arising Know-How that constitutes improvements, modifications, enhancements or derivatives thereto (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Platform Inventions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and all Intellectual Property Rights in and to </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 60 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Schr&#1255;dinger Platform Inventions (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Platform IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> ((A) and (B) collectively,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, Novartis shall own any and all (A) Arising Know-How that is solely conceived, discovered, developed, identified or otherwise made solely by or on behalf of Novartis or its Affiliates (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Sole Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and all Intellectual Property Rights in and to such Novartis Sole Arising Know-How, (B) any Product Specific Patent that Covers Arising Know-How, and (C) any Product Specific Know-How within Arising Know-How ((A)-(C), collectively,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, the Parties shall jointly own and have an equal undivided joint interest in (A) any and all Arising Know-How (other than Schr&#1255;dinger-Owned Arising IP and Novartis-Owned Arising IP) that is conceived, discovered, developed, identified or otherwise made jointly by or on behalf of both (1) Schr&#246;dinger or any of its or its Affiliates or their respective agents or independent contractors and (2) Novartis or any of its Affiliates or Sublicensees or their respective agents or independent contractors (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Arising Know-How</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (B) any and all Intellectual Property Rights in and to such Joint Arising Know-How, including any and all Patents that claim the Joint Arising Know-How (such Patents, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly-Owned Arising IP</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Subject to the rights and licenses granted under this Agreement, it is understood that neither Party shall have any obligation to account to the other Party for profits, or to obtain any approval of the other Party to license, assign or otherwise Exploit such Joint Patents, Joint Arising Know-How, or other Jointly-Owned Arising IP, by reason of joint ownership thereof, and each Party hereby waives any right it may have under the Applicable Law of any jurisdiction to require any such approval or accounting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assignment. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novartis shall (and shall cause its Affiliates to), and hereby does, for no additional consideration, assign all rights worldwide in and to Schr&#1255;dinger-Owned Arising IP to Schr&#1255;dinger as necessary to effectuate the ownership thereof as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Ownership of Arising IP). Novartis shall cause all Affiliates and their respective employees, independent contractors, contract research organizations, consultants, and others who perform activities for Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under this Agreement to be under an obligation to assign (or, if Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is unable to cause such Person or entity to agree to such assignment obligation despite Novartis&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">using Commercially Reasonable Efforts to negotiate such assignment obligation, provide a license under) their rights in any inventions and Intellectual Property Rights within the Schr&#1255;dinger-Owned Arising IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to Schr&#1255;dinger, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit, and public institutions which have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall be obtained). Schr&#1255;dinger shall (and shall cause its Affiliates to), and hereby does, for no additional consideration, assign all rights worldwide in and to Novartis-Owned Arising IP to Novartis as necessary to effectuate the ownership thereof as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Ownership of Arising IP). Schr&#1255;dinger shall cause all Affiliates and their respective </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 61 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">employees, independent contractors, contract research organizations, consultants, and others who perform activities for Schr&#1255;dinger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under this Agreement to be under an obligation to assign (or, if Schr&#1255;dinger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is unable to cause such Person or entity to agree to such assignment obligation despite Schr&#1255;dinger&#8217;s using Commercially Reasonable Efforts to negotiate such assignment obligation, provide a license under) their rights in any inventions and Intellectual Property Rights within the Novartis-Owned Arising IP (including Product Specific Patents that Cover Arising Know-How and Product Specific Know-How within the Arising Know-How) to Novartis, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit, and public institutions which have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, shall be obtained). Each Party assigning Patents or Information pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will take all actions and provide the other Party with all reasonably requested assistance to effect such assignment and will execute any and all documents necessary to perfect such assignment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventorship. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Determination of Inventorship</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Inventorship for patentable inventions and discoveries conceived during the course of the performance of activities pursuant to this Agreement shall be determined in accordance with U.S. Patent laws for determining inventorship and other Applicable Law in the U.S. without regard to conflict of law, irrespective of where or when such conception, discovery, development or making occurs. If U.S. law otherwise would not apply to the conception, reduction to practice, discovery, development or other making of any inventions or discoveries hereunder, each Party shall, and does hereby, assign, and shall cause its Affiliates and its and their Sublicensees to so assign, to the other Party, without additional compensation, such right, title and interest in and to any inventions or discoveries as well as any and all Intellectual Property Rights with respect thereto, as is necessary to fully effect, as applicable, the sole ownership or the joint ownership provided for in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Ownership of Intellectual Property). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JRA Exception.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the America Invents Act Joint Research Agreement exception codified at 35 U.S.C. &#167; 102(c) when exercising its rights under this Agreement with respect to Patents arising from the Exploitation of the Schr&#246;dinger Platform under any Project Plan only with prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed). In the event that a Party intends to invoke such exception, once agreed to by the other Party, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to any filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#8220;joint research agreement&#8221; as defined 35 U.S.C. &#167; 100(h).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure of Inventions.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> No later than &#91;**&#93; after the applicable Party&#8217;s intellectual property department receives notice of a development or conception described below, (i) Schr&#246;dinger will promptly disclose in writing to Novartis any and all inventions and </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 62 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">discoveries conceived, discovered, developed, identified or otherwise made by or on behalf of Schr&#1255;dinger or its Affiliates (or their respective employees, contractors or agents) resulting from or arising out of the performance of this Agreement during the Term that are Licensed Technology or Product Specific Know-How and (ii) Novartis will promptly disclose in writing to Schr&#246;dinger any and all (A) inventions and discoveries that are conceived, discovered, developed, identified or otherwise made by or on behalf of Novartis or its Affiliates, or Sublicensees (or their respective employees, contractors or agents) resulting from or arising out of the performance of this Agreement during the Term that are Schr&#1255;dinger Platform Inventions arising during the Term with respect to the applicable Collaboration Target, (B) inventions that are conceived, discovered, developed, identified or otherwise made by or on behalf of Novartis or its Affiliates, or Sublicensees (or their respective employees, contractors or agents) resulting from or arising out of the performance of a Project Plan under this Agreement during the Term that are Joint Arising Know-How or Product Specific Know-How arising during the Term with respect to the applicable Collaboration Target, and (C) filing of a Patent relating to such Novartis Internal Collaboration Compounds.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Work Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject and to the extent consistent with the ownership of Information and Intellectual Property Rights set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Ownership of Arising IP), as between the Parties, any Work Product created by a Party shall be owned by such Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution and Maintenance of Product Specific Patents and Joint Patents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis&#8217; First Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis will have the first right, but not the obligation, to draft, file, prosecute and maintain (including any oppositions, interferences, reissue proceedings, reexaminations and post-grant proceedings) in all jurisdictions in the Territory (such activities with respect to Patents being the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, with the term &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecute</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; having the corresponding meaning) (i) all Product Specific Patents that are (A) Controlled by Schr&#246;dinger as of the Effective Date  (i.e., Schr&#246;dinger Product Specific Patents) or (B) assigned to Novartis pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the claims of which are solely conceived, discovered, developed, identified or otherwise made by or on behalf of Schr&#1255;dinger or its Affiliates and (ii) all Joint Patents (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Prosecuted Patents&#8221;)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and, for clarity, Novartis shall have the sole right, but not the obligation, to Prosecute all other Patents within the Novartis-Owned Arising IP and Schr&#246;dinger shall have the sole right, but not the obligation, to Prosecute all Patents within the Schr&#246;dinger-Owned Arising IP. Subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Novartis shall bear one hundred percent (100%) of the Patent Prosecution Costs for Novartis Prosecuted Patents. Novartis shall have lead responsibility and decision-making control for such Prosecution of Novartis Prosecuted Patents. For clarity, each Party will bear its own internal costs (i.e., those costs that are not Patent Prosecution Costs) with respect to its Prosecution activities for the Product Specific Patents and Joint Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Prosecution Backup Right</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that Novartis elects not to Prosecute in any country any Patent within the Novartis Prosecuted Patents, Novartis will give Schr&#246;dinger at least &#91;**&#93; notice before any relevant deadline and provide such information as </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 63 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reasonably requested relating to such</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novartis Prosecuted Patent. Schr&#246;dinger will then have the right to assume responsibility, using patent counsel of its choice, for the Prosecution of such Novartis Prosecuted Patent&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Schr&#1255;dinger shall not have the right to Prosecute any such Novartis Prosecuted Patent to the extent that the notice provided pursuant to the foregoing sentence states that Novartis is ceasing such Prosecution to benefit a Collaboration Product or provides a reasonable justification for such election not to Prosecute. If Schr&#246;dinger assumes responsibility for the Prosecution for any such Novartis Prosecuted Patent(s) as set forth above, then the Patent Prosecution Costs incurred by Schr&#246;dinger in the course of such Prosecution will thereafter be borne by Schr&#246;dinger. The Parties will cooperate in such Prosecution pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Cooperation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cooperation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will provide the other Party all reasonable assistance and cooperation in the Prosecution of the Novartis Prosecuted Patents in all respects, including providing any necessary powers of attorney and executing any other required documents or instruments for such Prosecution, as necessary to Prosecute the Novartis Prosecuted Patents. Each Party will provide the other Party with copies of any material documents it receives or prepares in connection with such Prosecution and will inform the other Party of the progress of it. Before filing in connection with such Prosecution any document with a patent office, each Party will provide a copy of the document to the other Party sufficiently in advance to enable the other Party to comment on it, and the first Party will give due consideration to such comments and whether to incorporate any of such comments in the first Party&#8217;s filings or responses to the extent such comments are provided sufficiently in advance of any applicable filing deadlines. In particular, each Party agrees to provide the other Party with all information in its possession necessary or desirable to enable the other Party to comply with the duty of candor&#47;duty of disclosure requirements of any patent authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Term Extensions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties will confer regarding the desirability of seeking in any country any patent term extension, supplemental Patent certificate or related extension of rights with respect to the Product Specific Patents and Joint Patents related to Collaboration Compounds and Collaboration Products. Novartis shall have the sole right, but not the obligation, to apply for any patent term extension, supplemental Patent certificate or related extension of rights with respect to the Product Specific Patents and Joint Patents, or any Patent with respect to any Collaboration Compound or Collaboration Product. Neither Party will proceed with such an extension until the Parties have consulted with one another and agreed to a strategy therefor, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that in the case where the Parties are unable to reach consensus, Novartis will have the final decision-making authority with respect to such decision, including whether or not to seek an extension for any Product Specific Patent or Joint Patent. Without limiting the foregoing, Schr&#1255;dinger covenants that it will not seek Patent term extensions, supplemental protection certificates, or similar rights or extensions for the Product Specific Patents or Joint Patents, or any Patent with respect to any Collaboration Compound or Collaboration Product, without the prior written consent of Novartis. Each Party will cooperate fully with and provide all reasonable assistance to the other Party and use all Commercially Reasonable Efforts consistent with its obligations under Applicable Law (including any </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 64 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">applicable consent order or decree) in connection with obtaining any such extensions for the Product Specific Patents or Joint Patents consistent with such strategy. To the extent reasonably and legally required in order to obtain any such extension in a particular country, each Party will make available to the other a copy of the necessary documentation to enable such other Party to use the same for the purpose of obtaining the extension in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Exclusivity</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As applicable, Novartis will have the sole right and authority for securing, maintaining and enforcing exclusivity rights that may be available under Applicable Law in a country for a Collaboration Product, such as any data, market, pediatric, orphan drug or other Regulatory Exclusivity Periods. Schr&#1255;dinger will cooperate fully with and provide all reasonable assistance to Novartis and use all Commercially Reasonable Efforts consistent with its obligations under Applicable Law (including any applicable consent order or decree) to seek, maintain and enforce all Regulatory Exclusivity Periods available for the Collaboration Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prosecution, Maintenance and Enforcement of Other Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Other Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis will have the sole right and authority with respect to all Patents within Novartis-Owned Arising IP and its Background IP each of which does not constitute a Novartis Prosecuted Patent (each such Patent, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Other Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in any jurisdiction, including Prosecution and enforcement. Novartis will be responsible for all costs incurred by it (including all Patent Prosecution Costs) in the course of Prosecuting and enforcing each such Novartis Other Patent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Other Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As between the Parties, Schr&#1255;dinger will have the sole right and authority with respect to all Patents within Schr&#1255;dinger-Owned Arising IP and its Background IP each of which does not constitute a Schr&#1255;dinger Product Specific Patent or a Joint Patent (each such Patent, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Other Patent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including Prosecution and enforcement. Schr&#1255;dinger will be responsible for all costs incurred by it (including all Patent Prosecution Costs) in the course of Prosecuting and enforcing each such Schr&#1255;dinger Other Patent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competitive Infringement of Product Specific Patents or Joint Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notification</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties will promptly notify each other of any actual, threatened, alleged or suspected infringement by a Third Party of the Product Specific Patents or Joint Patents by reason of the making, using, offer to sell, selling or importing of a compound or product that would be competitive with a Collaboration Compound or Collaboration Product (a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competitive Infringement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). A notice under 42 U.S.C. 262(l), 21 U.S.C. 355(b)(3), or 21 U.S.C. 355(j)(2)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(however such sections may be amended from time to time during the Term) with respect to a Collaboration Compound or Collaboration Product will be deemed to describe an act of Competitive Infringement, regardless of its content. As permitted by Applicable Law, each Party will promptly notify the other Party in writing of any such Competitive Infringement </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 65 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of which it becomes aware and, upon request, can provide evidence in such Party&#8217;s possession demonstrating such Competitive Infringement. In particular, each Party will notify and provide the other Party with copies of any allegations of Patent invalidity, unenforceability or non-infringement of any Product Specific Patents or Joint Patents Covering a Collaboration Compound or Collaboration Product (including methods of use or manufacture thereof). Such notification and copies will be provided by the Party receiving such certification to the other Party as soon as practicable and, unless prohibited by Applicable Law, at least within &#91;**&#93; after the Receiving Party receives such certification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Enforcement of Product Specific Patents and Joint Patents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis will have the sole right, but not the obligation, to bring and control, at its cost and expense, an appropriate suit or other action before any government or private tribunal against any Person or entity allegedly engaged in any Competitive Infringement of any Product Specific Patents or Joint Patents (or to settle or otherwise secure the abatement of such Competitive Infringement) (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Specific Infringement Actions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The foregoing right of Novartis shall include the right to perform all actions of a reference product sponsor set forth in 42 U.S.C. 262(l), 21 U.S.C. 355(b)(3), or 21 U.S.C. 355(j)(2)(B) (however such sections may be amended from time to time during the Term). Schr&#1255;dinger will have the right, at its own cost and expense and by counsel of its choice, to be represented in (but not control) any Product Specific Infringement Action. At Novartis&#8217; request, Schr&#1255;dinger will join any Product Specific Infringement Action as a party (at Novartis&#8217; cost and expense) if doing so is necessary for the purposes of establishing standing or is otherwise required by Applicable Law to pursue such action. Schr&#1255;dinger will provide to Novartis reasonable assistance in such enforcement, at Novartis&#8217; request and cost and expense, including joining such action as a party plaintiff if required by Applicable Law to pursue such action. The enforcing Party will keep Schr&#1255;dinger regularly informed of the status and progress of such enforcement efforts and will reasonably consider Schr&#1255;dinger&#8217;s comments on any such efforts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Settlement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may settle any Product Specific Infringement Action, and shall have the right to grant (sub)licenses under the Product Specific Patents and Joint Patents in its sole discretion, and Schr&#1255;dinger shall reasonably cooperate with such efforts.  For the avoidance of doubt, Schr&#1255;dinger may not settle any Product Specific Infringement Action. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expenses and Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In bringing a Product Specific Infringement Action under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Competitive Infringement of Product Specific Patents and Joint Patents by Third Parties) against any Third Party engaged in Competitive Infringement of the Product Specific Patents or Joint Patents, Novartis will be solely responsible for any costs and expenses incurred by Novartis as a result of such Product Specific Infringement Action. If Novartis recovers monetary damages from such Third Party in such Product Specific Infringement Action, such recovery will first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith, including attorneys&#8217; fees. If such recovery is insufficient to cover all such costs and expenses of both Parties, it will be shared pro-rata in </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 66 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proportion to the relative amount of such costs and expenses incurred by each Party. If after such reimbursement any funds remain from such damages, then one hundred percent (100%) of such amount of any recovery remaining shall be retained by or paid to Novartis&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that to the extent any such amount is awarded as imputed Net Sales of Collaboration Products, then such amount shall be paid to Novartis and treated as Net Sales with respect to the applicable periods and territories for which such recovery was calculated, for purposes of calculating Sales Milestone Payments under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Sales Milestone Payment) and royalties payable to Schr&#1255;dinger pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Payments to Schr&#1255;dinger) (for the avoidance of doubt, such imputed Net Sales as received by Novartis shall be pro-rated across the applicable periods and territories for which such recovery was calculated for purposes of calculating Sales Milestone Payments and royalties payable to Schr&#246;dinger pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Rights</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Parties will promptly notify each other of any written allegation that any activity pursuant to this Agreement infringes or misappropriates the Patent rights of any Third Party. In addition, the Parties will notify each other if either Party desires to obtain a license or otherwise pursue a defense or settlement with respect to any Third Party Patent that may be considered to Cover Collaboration Compounds or Collaboration Products or their Manufacture or use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 9.6(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.6(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">9.6(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with respect to any Third Party Patent under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.6(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and without limiting the right of a Party against whom a claim of infringement of any Third Party Patent is filed to seek indemnification for such claim pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability), as between the Parties, notwithstanding any right of the Indemnifying Party to control as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification Procedure), Novartis will have the sole right to seek a license, at its cost and expense, with respect to such Third Party Patent that Covers the composition, formulation, method of use or method of Manufacture of any Collaboration Compound or Collaboration Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the case a claim of infringement of a Patent is brought against a Party in a suit or other action or proceeding with respect to any Third Party Patent under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.6(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, such Party will have the right, at its own cost and expense and by counsel of its own choice, to prosecute and defend any such claim in such suit or other action or proceeding. If both Parties are named, Novartis will have the right, at its own cost and expense and by counsel of its own choice, to prosecute and defend any such claim in such suit or other action or proceeding so long as both Parties are named in the same suit or action or proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Without the prior written consent of the other Party (not to be unreasonably withheld, conditioned or delayed), neither Party will settle any claim under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Third Party Rights) in any manner that would impose any material obligations, restriction or limitation on the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 67 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Parties will reasonably cooperate with one another in prosecuting or defending any action pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Third Party Rights).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Challenges</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Parties will promptly notify each other in the event that any Third Party files, or threatens to file, any paper in a court, Patent office or other Governmental Authority, seeking to invalidate, reexamine, oppose or compel the licensing of any Joint Patent or Product Specific Patent including challenges brought as defenses in Product Specific Infringement Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(any such Third Party action being a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As between the Parties, Novartis will have the first right, but not the obligation, to bring and control, at its cost and expense (but without limiting its right to seek indemnification, if applicable), any effort in defense of such a Patent Challenge against a Novartis Prosecuted Patent, and in the case where such Patent Challenge is made in connection with a Product Specific Infringement Action, such Patent Challenge will be considered part of the Product Specific Infringement Action under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement). In the case where Novartis controls the defense of such Patent Challenge, Schr&#1255;dinger will have the right, at its own cost and expense and by counsel of its choice, to be represented in (but not control) any such effort. If Novartis fails to take action to defend such Patent Challenge within &#91;**&#93; of the time limit for bringing such defense (or within such shorter period to the extent that a delay in bringing such defense would limit or compromise the outcome of such defense of such Patent Challenge), then Schr&#1255;dinger will have the right, but not the obligation, to bring and control any effort in defense of such Patent Challenge at its own cost and expense (but without limiting its right to seek indemnification, if applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Schr&#1255;dinger will have the sole right, but not the obligation, to bring and control, at its cost and expense, any effort in defense of such a Patent Challenge related to any Schr&#1255;dinger&#8217;s Background IP, Schr&#1255;dinger-Owned Arising IP, or Patent Challenges that are not subject to Novartis&#8217; first right in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.7(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Contacts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will designate Patent counsel representatives who will be responsible for coordinating the activities between the Parties in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement) (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent Contact</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Each Party will designate its initial Patent Contact within &#91;**&#93; following the Effective Date and will promptly thereafter notify the other Party of such designation. If at any time a vacancy occurs for any reason, the Party that appointed the prior incumbent will as soon as reasonably practicable appoint a successor. Each Party will promptly notify the other Party of any substitution of another Person as its Patent Contact. The Patent Contacts will, from time to time, coordinate the respective Patent strategies of the Parties relating to this Agreement. In particular the Patent Contacts will review and update the list of Product Specific Patents and Joint Patents from time to time to ensure that all Collaboration Compounds or Collaboration Products being Developed or Commercialized are Covered.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 68 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.9&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Personnel Obligations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Prior to receiving any Confidential Information or beginning work under each Project, each employee, agent or independent contractor of Novartis or Schr&#1255;dinger or of either Party&#8217;s respective Affiliates will be bound in writing by non-disclosure and invention assignment obligations which are consistent with the obligations of Novartis or Schr&#1255;dinger under this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that where necessary in the case of a Third Party, (a) such Third Party shall agree to grant Novartis or Schr&#1255;dinger, as the case may be, an exclusive license, or an option to obtain an exclusive license, with the right to grant sublicenses with respect to resulting inventions and Patents relating to the Collaboration Compounds or Collaboration Products or the Exploitation thereof&#59; (i) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that such obligation to obtain ownership or an exclusive license will not apply to any improvements to the proprietary core or platform technology owned or in-licensed by such Third Party&#59; and (ii) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, further, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if such improvements are necessary or reasonably useful to research, Develop, Manufacture or Commercialize Collaboration Compounds or Collaboration Products with respect to which such Third Party conducted its activities under such contract, then such Party shall use reasonable efforts to obtain a sublicensable non-exclusive license under such improvements for such purposes&#59; and (b) the period of time with respect to non-disclosure obligations may be shorter, if customary. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.10&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Further Action</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party will, upon the reasonable request of the other Party, provide such assistance and execute such documents as are reasonably necessary for such Party to exercise its rights and perform its obligations pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that neither Party will be required to take any action pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement) that such Party reasonably determines in its sole judgment and discretion conflicts with or violates any applicable court or government order or decree or Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.11&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Orange Book and Other Equivalent Listing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis will have the sole right to make any patent listing filings in the FDA Orange Book (and any foreign equivalents in any country) with respect to the Collaboration Product and any Product Specific Patents or Joint Patents.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 10.&#160;&#160;&#160;&#160;TRADEMARKS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Collaboration Product Trademarks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis will have the sole right to select (including the creation, searching and clearing), register, maintain, police, and enforce of all trademarks,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">domain names, INNs, and USANs developed for use in connection with the marketing, sale or distribution of Collaboration Compounds and Collaboration Products in the Field in the Territory (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Marks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). As between the Parties, Novartis shall own all Product Marks, and all trademark registrations for said marks.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Use of Name</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party shall, without the other Party&#8217;s prior written consent, use any trademarks or other marks of the other Party (including the other Party&#8217;s corporate </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 69 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">name), advertising taglines or slogans confusingly similar thereto, in connection with such Party&#8217;s marketing or promotion of Collaboration Compounds or Collaboration Products under this Agreement or for any other purpose, except as may be expressly authorized in writing in connection with activities under this Agreement and except to the extent required to comply with Applicable Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Further Actions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall, upon the reasonable request of the other Party, provide such assistance and execute such documents as are reasonably necessary for such Party to exercise its rights or perform its obligations pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Trademarks)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that neither Party shall be required to take any action pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Trademarks) that such Party reasonably determines in its sole judgment and discretion conflicts with or violates any applicable court or government order or decree or Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 11.&#160;&#160;&#160;&#160;EXCLUSIVITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exclusivity Regarding Development and Commercialization of Collaboration Compounds</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the remaining terms of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity), during the Exclusivity Period for each Collaboration Target, Schr&#246;dinger shall not, for itself, or with, through or for its Affiliates or any Third Party (including through the grant of any license, option or other right to any Third Party), engage in (or, via such grant, enable), directly or indirectly, any research, Development, Manufacture, modification, improvement or Commercialization of Small Molecules that are Directed Against such Collaboration Target anywhere in the Territory, other than in connection with its activities under this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As used herein, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exclusivity Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, for a given Collaboration Target, the period commencing on (a) the Effective Date with respect to each Initial Collaboration Target or (b) the date on which each additional Collaboration Target is deemed a Collaboration Target, and expiring on the date that is the earliest of (i) the date of Initiation of a Registrational Trial with respect to such Collaboration Target, (ii) the date of the termination or expiration of the Research Term for such Collaboration Target, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that prior to the expiration or termination of such Research Term, no &#91;**&#93; for any Collaboration Compound Directed Against such Collaboration Target was issued pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1(v)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), (iii) the date of the termination or expiration of the Research Term for such Collaboration Target, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that during the Research Term, Novartis acquires rights to a Clinical Acquired Product Directed Against such Collaboration Target through a Clinical Acquisition Transaction that closes prior to any issuance of a &#91;**&#93; pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for any Collaboration Compound Directed Against such Collaboration Target, (iv) the date of closing of a Clinical Acquisition Transaction pursuant to which Novartis acquires rights to a Clinical Acquired Product Directed Against such Collaboration Target, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, prior to such closing date, Novartis has issued a &#91;**&#93; for a Collaboration Compound Directed Against such Collaboration Target pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (v) &#91;**&#93; following the designation of such Collaboration Target as a Discontinued Target, or (vi) the effective date of termination of such Collaboration Target if such termination occurs due to termination by Novartis under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Novartis at Will or for a Safety Concern),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by either Party under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Breach), or by either Party under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;13.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 70 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Termination by Either Party for Insolvency). For clarity, no &#91;**&#93; shall have a separate Exclusivity Period. For the avoidance of doubt, for the purposes this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> only, a &#91;**&#93; for a Collaboration Compound Directed Against any &#91;**&#93; will be deemed a &#91;**&#93; with respect to the &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exceptions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The restrictions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity Regarding Development and Commercialization of Collaboration Compounds) shall not apply to (i) Schr&#246;dinger&#8217;s or its or any of its Affiliates&#8217; exercise of its rights or performance of its obligations under and in accordance with this Agreement&#59; (ii) in the case of the Collaboration Target consisting of the &#91;**&#93;, any Small Molecules that are for non-oral administration&#59; or (iii) performance of Schr&#246;dinger Technology Services for Third Parties, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that (A) Schr&#246;dinger keeps separate the day-to-day operational activities with respect to providing such Schr&#246;dinger Technology Services from the day-to-day operational activities for the Collaboration Compounds and Collaboration Products under this Agreement, (B) Schr&#246;dinger does not use any of Novartis&#8217; Confidential Information or Information relating to the Collaboration Compounds and Collaboration Products hereunder in the performance of such Schr&#246;dinger Technology Services for Third Parties, and (C) such Schr&#246;dinger Technology Services relate generally to the Schr&#246;dinger Platform and do not relate specifically to any of the Collaboration Targets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Parties hereby acknowledge and agree that the restrictions set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity Regarding Development and Commercialization of Collaboration Compounds) shall not apply to any activities intended by Schr&#246;dinger or any of its Affiliates to ensure its compliance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity Regarding Development and Commercialization of Collaboration Compounds) (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, counter-screening).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquisition of Distracting Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the provisions of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity Regarding Development and Commercialization of Collaboration Compounds), if Schr&#246;dinger or any of its Affiliates, during the applicable Exclusivity Period, acquires rights to develop or commercialize a compound or product in the Field as the result of a license, collaboration, merger, acquisition or combination with or of a Third Party other than a Change of Control of Schr&#246;dinger (each, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquisition Transaction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and on the date of the closing of such Acquisition Transaction, such compound or product is being researched, Developed, Manufactured, modified, improved or Commercialized and such activities would, but for the provisions of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, would constitute a breach of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (for clarity, after taking account of the exceptions set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) (such compound or product, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Distracting Product</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Schr&#246;dinger will not be in breach of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as a result of such Acquisition Transaction unless and until Schr&#246;dinger fails to comply with the following terms and conditions with respect to each such Distracting Product&#58;  Within &#91;**&#93; after the closing of such Acquisition Transaction notify Novartis in writing of such acquisition and either&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 71 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;request that such Distracting Product be included in this Agreement as a Collaboration Product on terms to be negotiated, in which case, the Parties will discuss the matter in good faith for a period of &#91;**&#93; (or such longer period as may be mutually agreed by the Parties in writing) and, if unable to reach agreement on the terms on which such Distracting Product would be included hereunder within such period, Schr&#246;dinger or its Affiliate will elect to take the action specified in either clause (b) or (c) below&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the time periods specified in such clauses will be tolled for so long as the Parties are engaged in discussion under this clause (a)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;notify Novartis in writing that Schr&#246;dinger or its Affiliate will divest its rights (which may include an exclusive sublicense) to such Distracting Product, in which case, within &#91;**&#93; (or such longer period as may be agreed by the Parties) after the closing of the Acquisition Transaction, Schr&#246;dinger or its Affiliate will divest or exclusively sublicense such Distracting Product, giving due consideration to ethical concerns and requirements under Applicable Law&#59; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;notify Novartis in writing that it is ceasing all such development and commercialization activities with respect to the Distracting Product, in which case, within &#91;**&#93; (or such longer period as may be agreed by the Parties) after Novartis&#8217;s receipt of such notice, Schr&#246;dinger and its Affiliates will cease all such activities, giving due consideration to ethical concerns and requirements under Applicable Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commencing immediately upon the closing of the Acquisition Transaction, and during the discussion period under clause (a), prior to the time of divestiture pursuant to clause (b) or prior to the termination of activities pursuant to clause (c), as applicable, Schr&#246;dinger and its Affiliates will segregate all activities relating to the Distracting Product from the applicable Project or research, Development and Commercialization or other activities with respect to, Collaboration Compounds or Collaboration Products under this Agreement, including that (i)&#160;no personnel involved in performing research, development or commercialization activities with respect to such Distracting Product have access to non-public plans or Information relating to the applicable Project or research, Development or Commercialization of Collaboration Compounds or Collaboration Products under this Agreement (except for senior management personnel who may review and evaluate plans and Information regarding the development and commercialization of such Distracting Product in connection with portfolio decision-making and except for support personnel, including those in human resources, legal, financial, or accounting roles, in each case, who are not engaged in the execution of research, Development, Manufacturing or Commercialization activities and not part of Schr&#246;dinger&#8217;s internal project team for the applicable Collaboration Compounds or Collaboration Products) and (ii)&#160;no personnel involved in performing Development or Commercialization activities with respect to Collaboration Compounds or Collaboration Products under this Agreement have access to non-public plans or Information relating to the development or commercialization of such Distracting Product (except for senior management personnel who may review and evaluate plans and information regarding the Development and commercialization of such Distracting Product in </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 72 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">connection with portfolio decision-making and except for support personnel, including those in human resources, legal, financial, or accounting roles, in each case, who are not engaged in the execution of research, Development, Manufacturing or Commercialization activities and not part of Schr&#246;dinger&#8217;s internal project team for the applicable Collaboration Compounds or Collaboration Products). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If there is a Change of Control of Schr&#246;dinger, the obligations of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity Regarding Development and Commercialization of Collaboration Compounds) will not apply to any program, compound or product of the Acquirer that is ongoing as of the effective date of such Change of Control&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, immediately upon the closing of such Change of Control, and thereafter for so long as such Acquirer maintains any program, compound or product that but for this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> would constitute a breach of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (or any right, title or interest in any intellectual property with respect thereto), (a) Schr&#246;dinger, on the one hand, and the Acquirer, on the other hand, establish and enforce internal processes, policies, procedures and systems to segregate Information relating to any such program, compound or product from any Confidential Information of Novartis, including that no personnel who conduct any activities under such program or with such compound or product shall access any such Confidential Information or non-public data, (b) the Acquirer does not use, directly or indirectly, the Schr&#246;dinger Platform or any Confidential Information of Novartis in such program or with such compound or product, (c) no personnel who were employees or consultants of Schr&#246;dinger prior to the Change of Control will conduct any activities under such program or with such compound or product (except for senior management personnel who may review and evaluate plans and information regarding the development and commercialization of such compound or product in connection with portfolio decision-making and except for support personnel, including those in human resources, legal, financial, or accounting roles, in each case, who are not engaged in the execution of research, Development, Manufacturing or Commercialization activities and not part of Schr&#246;dinger&#8217;s internal project team for the applicable Collaboration Compounds or Collaboration Products), and (d) such Acquirer shall institute technical and administrative safeguards to ensure the requirements set forth in foregoing clauses (a) through (c) are met.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 12.&#160;&#160;&#160;&#160;CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to this Agreement except for that portion of such Confidential Information that the Receiving Party can demonstrate by competent written proof&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;was already known to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality or any restriction on its use to the Disclosing Party, at </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 73 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the time of disclosure by the other Party&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> this exception shall not apply with respect to Collaboration Compound Information or Confidential Information that is deemed to be the Confidential Information of both Parties under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without obligations of confidentiality or restrictions on its use to the Disclosing Party with respect thereto&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> this exception shall not apply with respect to Confidential Information that is deemed to be the Confidential Information of both Parties under this Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;is subsequently independently discovered or developed by or on behalf of the Receiving Party or its Affiliates without the aid, application, or use of Confidential Information of the Disclosing Party, as demonstrated by documented evidence prepared contemporaneously with such independent development&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> this exception shall not apply with respect to Collaboration Compound Information or Confidential Information that is deemed to be the Confidential Information of both Parties under this Agreement.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any combination of features or disclosures will not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party, and any individual feature or disclosure will not be deemed to fall within the foregoing exclusions merely because a broader or related combination of such feature or disclosure is published or available to the general public unless the individual feature or disclosure itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Authorized Disclosure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the obligations of confidentiality and non-use set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality), each Party may disclose Confidential Information of the Disclosing Party to the extent such disclosure is reasonably necessary in the following situations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;filing or prosecuting Patents in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publicity&#59; Terms of Agreement), regulatory filings and other filings with Governmental Authorities (including Regulatory Authorities), including </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 74 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">filings with the FDA, as necessary for the Development or Commercialization of a Collaboration Compound or Collaboration Product, as required in connection with any filing, application or request for Regulatory Approval&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that reasonable measures will be taken to seek confidential treatment of such information, if available&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;prosecuting or defending litigation&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publicity&#59; Terms of Agreement), complying with Applicable Law, including regulations promulgated by securities exchanges&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;disclosure of this Agreement (including its material terms) to any bona fide potential or actual investor, stockholder, investment banker, lender, acquirer, merger partner or other actual financial partner and their representatives and advisors (including attorneys and accountants) on a reasonable need-to-know basis&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each disclosee must be bound by obligations of confidentiality and non-use at least as equivalent in scope as and no less restrictive than those set forth in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) prior to any such disclosure (but of shorter duration, if customary)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;disclosure of the stage of research or Development of Collaboration Compounds or Collaboration Products under this Agreement (but no other Collaboration Compound Information) to any bona fide potential or actual investor, stockholder, investment banker, lender, acquirer, merger partner or other potential or actual financial partner and their representatives and advisors (including attorneys and accountants)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that each recipient of such Confidential Information must be bound by obligations of confidentiality and non-use at least as equivalent in scope as and no less restrictive than those set forth in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) prior to any such disclosure (but of shorter duration, if customary)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;disclosure of data generated under this Agreement on a &#8220;need to know basis&#8221; to any bona fide potential or actual investor, stockholder, investment banker, lender, acquirer, merger partner or other potential or actual financial partner and their representatives and advisors (including attorneys and accountants)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that each disclosee must be bound by obligations of confidentiality and non-use at least as equivalent in scope as and no less restrictive than those set forth in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) prior to any such disclosure (but of shorter duration, if customary)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;solely on a &#8220;need to know basis&#8221; to actual research and Development collaborators, subcontractors, advisors (including attorneys and accountants) or to bona fide potential subcontractors who have entered into good faith discussions with such Party that are subject to obligations of confidentiality and non-use at least as equivalent in scope as and no less restrictive than those set forth in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity), in each case, in connection with each Project&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;disclosure pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publications)&#59; and</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 75 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;made in response to a valid order of a court of competent jurisdiction or other Governmental Authority of competent jurisdiction or, if in the reasonable opinion of the Receiving Party&#8217;s legal counsel, such disclosure is otherwise required by law (other than by reason of filing with securities regulators, which shall be governed by </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the Receiving Party shall first have given prompt written notice (and to the extent possible, at least &#91;**&#93; notice)) to the Disclosing Party and given the Disclosing Party a reasonable opportunity to take whatever action the Disclosing Party deems necessary to protect its Confidential Information (for example, quash such order or obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order or required to be disclosed be held in confidence by such court or Governmental Authority or, if disclosed, be used only for the purposes for which the order was issued or such disclosure was required by law)&#59; and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, further, that</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Confidential Information disclosed in response to such court or governmental order or as required by law shall be limited to the information that is legally required to be disclosed in response to such court or governmental order or by such law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 12.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12.2(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12.2(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, it will, except where impracticable, (A) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">give reasonable advance notice to the other Party of such disclosure (including as to the form and terms of such disclosure), (B) give the other Party copies of any such disclosure, (C) give the other Party a reasonable opportunity to review and comment on any such disclosure (including the form and terms thereof) and consider such comments in good faith, and (D) use reasonable efforts to secure confidential treatment of such information. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder, except as permitted in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Authorized Disclosure).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Authorized Disclosure) shall limit either Party in any way from disclosing to any Third Party such Party&#8217;s U.S. or foreign income tax treatment and the U.S. or foreign income tax structure of the transactions relating to such Party that are based on or derived from this Agreement, as well as all materials of any kind (including opinions or other tax analyses) relating to such tax treatment or tax structure, except to the extent that nondisclosure of such matters is reasonably necessary in order to comply with applicable securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publicity&#59; Terms of Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Parties agree that the existence and terms of this Agreement are the Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Authorized Disclosure) and this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publicity&#59; Terms of Agreement). Except as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">12.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each Party agrees not to issue any press release or other public announcement disclosing the terms of this Agreement or the transaction contemplated hereby without the prior written consent of the other Party. Notwithstanding the foregoing, the Parties agree that Schr&#1255;dinger shall issue a press release to </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 76 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">announce the execution of this Agreement in the form attached hereto as </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule&#160;12.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Press Release), and thereafter, Schr&#1255;dinger and Novartis may each disclose to Third Parties the information contained in such press release without the need for further approval by the other Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the case of a press release or governmental filing concerning the terms of this Agreement or the transaction contemplated hereby required by Applicable Law (where reasonably advised by the Disclosing Party&#8217;s counsel), the Disclosing Party shall give prior advance notice (to the extent it reasonably can) of the proposed text of such release or filing to the other Party for its prior review not later than &#91;**&#93; prior to such release or filing and shall consider and incorporate in good faith any comments provided by the other Party in connection therewith.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Parties acknowledge that either or both Parties may be obligated to with the SEC or other Governmental Authorities, or otherwise disclose, under Applicable Law or the rules of the securities exchange on which the securities of such Party are listed a copy of this Agreement or other disclosure with respect to its subject matter. Each Party shall be entitled to make such a required filing or disclosure, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that it requests confidential treatment of at least the financial terms and sensitive technical terms hereof and thereof to the extent such confidential treatment is reasonably available to such Party. In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for which such Party intends to seek confidential treatment not less than &#91;**&#93; (or a shorter period of time if required by Applicable Law) prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), and shall reasonably consider the other Party&#8217;s comments thereon to the extent consistent with the legal requirements, with respect to the filing Party, governing disclosure of material agreements and material information that must be publicly filed, and shall only disclose Confidential Information which it is advised by counsel or the applicable Governmental Authority is legally required to be disclosed. No such notice shall be required under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous filing made by either Party hereunder or otherwise approved by the other Party and such information remains accurate as of such time.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each Party shall require each of its Affiliates to which Confidential Information of the other Party is disclosed as permitted hereunder to comply with the covenants and restrictions set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) through </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publicity&#59; Terms of Agreement) as if each such Affiliate were a Party to this Agreement and shall be fully responsible for any breach of such covenants and restrictions by any such Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The non-use and non-disclosure obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) shall expire in &#91;**&#93; following expiration or earlier termination of this Agreement&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the non-use and non-disclosure obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) shall continue to apply to Confidential Information to the extent it is otherwise </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 77 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">protected by law or regulation (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, trade secret or data privacy) for as long as it remains a trade secret, it is subject to data privacy requirements, or such law or regulation requires.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publications</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party shall publicly present or publish results of studies carried out under each Project (each such presentation or publication a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publication</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) without the opportunity for prior review by the other Party, except to the extent otherwise required by Applicable Law, in which case </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publicity&#59; Terms of Agreement) shall apply with respect to disclosures required by the SEC or for regulatory filings. The submitting Party shall provide the other Party the opportunity to review any proposed Publication at least &#91;**&#93; prior to the earlier of its presentation or intended submission for publication. The submitting Party shall consider the comments of the other Party in good faith but will retain the sole authority to submit the manuscript for Publication&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the submitting Party agrees to delay such Publication for up to &#91;**&#93; as necessary to enable the Parties to file a Patent if such Publication might adversely affect such Patent. The submitting Party shall provide the other Party a copy of the Publication at the time of the submission or presentation. From and after delivery of a &#91;**&#93; with respect to a Collaboration Target, (a) Novartis shall have the sole right to publicly present or publish results of studies with respect to Collaboration Compounds or Collaboration Products Directed Against such Collaboration Target in its sole discretion and (b) Schr&#1255;dinger shall have no right to publicly present or publish results of studies with respect to Collaboration Compounds or Collaboration Products Directed Against such Target without Novartis&#8217; prior written approval (which shall not be unreasonably withheld, conditioned or delayed). Notwithstanding the foregoing, order and inclusion of authors or acknowledgement of contributions to any publication arising from each Project conducted under this Agreement will be determined in accordance with scientific and academic custom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing contained in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publications) shall prohibit the inclusion of Confidential Information of the other Party in a Patent application claiming or Covering the Manufacture, use, sale or formulation of a Collaboration Compound&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the non-filing Party is given an opportunity to review, comment upon and approve the information to be included prior to submission of such Patent application, where and to the extent required by </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement) hereof. Notwithstanding the foregoing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novartis shall not have the right to publish or present Schr&#1255;dinger&#8217;s Confidential Information without Schr&#1255;dinger&#8217;s prior written consent, and Schr&#1255;dinger shall not have the right to publish or present Novartis&#8217; Confidential Information without Novartis&#8217; prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Parties recognize that independent investigators have been engaged, and will be engaged in the future, to conduct Clinical Trials. The Parties recognize that such investigators operate in an academic environment and may release Information regarding such studies in a manner consistent with academic standards&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that each Party will use reasonable efforts to prevent publication prior to the filing of relevant Patent applications and to ensure that no Confidential Information of either Party is disclosed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 78 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effect of Change of Control of Schr&#1255;dinger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that Schr&#1255;dinger undergoes a Change of Control with a Third Party (an Acquirer as defined below), then&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Material, Information, Patents or other intellectual property of such Acquirer owned or controlled by such Acquirer or any of such Acquirer&#8217;s Affiliates prior to such acquisition (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer Background Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case, (i) shall not be deemed &#8220;Controlled&#8221; by Schr&#1255;dinger or its Affiliates and shall be excluded from the Licensed Technology and Product Specific Patents, and (ii) shall not be disclosed to Novartis or its Affiliates, used in connection with activities under this Agreement or used in connection with or incorporated into and Collaboration Product, in each case ((i) or (ii)), except to the extent Novartis or its Affiliates otherwise have rights with respect to such Acquirer Background Technology&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if, notwithstanding the foregoing clause (ii), Acquirer Background Technology is disclosed to Novartis or its Affiliates or used by or on behalf of Schr&#1255;dinger (or any of its Affiliates or its or their sublicensees under the grant of rights in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) in connection with or incorporated into a Collaboration Product, then (A) Schr&#1255;dinger shall be deemed to Control the Acquirer Background Technology that is so disclosed, used or incorporated and (B) the foregoing clause (ii) shall no longer apply to Novartis and its Affiliates and its and their Sublicensees with respect to such Acquirer Background Technology&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Material, Information, Patents or other intellectual property that, following such Change of Control, that (i) is created, conceived, developed, made or otherwise acquired or Controlled by the Acquirer or any of such Acquirer&#8217;s Affiliates (other than the Acquired Party) (A) without use of the Schr&#246;dinger Platform, Licensed Know-How or Novartis&#8217; Confidential Information (including any data, results, or other Information from, or that is used in conducting, a Project) (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subject Information</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (B) without the use of the Acquired Party&#8217;s personnel working on or performing, or who have worked on or performed, a Project (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subject Personnel</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) has been held subject to firewalls established to prevent access and sharing between Subject Personnel and Acquirer&#8217;s and its Affiliates&#8217; personnel working on such other intellectual property  (such Material, Information, Patents or other intellectual property, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer Future Technology</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case, (I) shall not be deemed &#8220;Controlled&#8221; by Schr&#1255;dinger or its Affiliates and shall be excluded from the Licensed Technology or Product Specific Patents, and (II) shall not be disclosed to Novartis or its Affiliates, used in connection with activities under this Agreement or used in connection with or incorporated into and Collaboration Product, in each case ((I) or (II)), except to the extent Novartis or its Affiliates otherwise have rights with respect to such Acquirer Future Technology&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if, notwithstanding the foregoing clause (II), Acquirer Future Technology is disclosed to Novartis or its Affiliates or used by or on behalf of Schr&#1255;dinger (or any of its Affiliates or its or their sublicensees under the grant of rights in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) in connection with or incorporated into and Collaboration Product, then (X) Schr&#1255;dinger shall be deemed to Control the Acquirer Future Technology that is so disclosed, used or incorporated and (Y) the foregoing clause (II) shall no longer apply to Novartis and its Affiliates and its and their Sublicensees with respect to such Acquirer Future Technology.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 79 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;As used herein, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquirer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Third Party involved in the Change of Control, and any Affiliate of such Third Party that was not an Affiliate of the Acquired Party immediately prior to the effective date of the Change of Control&#59; and &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acquired Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Party that was the subject of such Change of Control, together with any entity that was its Affiliate immediately prior to the effective date of the Change of Control, and any of their successors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.7&#160;&#160;&#160;&#160;As of the effective date of the Change of Control transaction, the JSC shall disband pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and Novartis shall have no obligation to disclose to Schr&#246;dinger any Information with respect to Collaboration Compounds, Collaboration Products or their Exploitation other than pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Payments).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Prior CDA</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement terminates, as of the Effective Date, the Prior CDA. All Information exchanged between the Parties under the Prior CDA shall be deemed Confidential Information of the corresponding Party under this Agreement and shall be subject to the terms of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 13.&#160;&#160;&#160;&#160;TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HSR Filing&#59; Effectiveness of Agreement&#59; Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HSR Filing</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Schr&#1255;dinger and Novartis will, as promptly as practicable (but no later than &#91;**&#93; after the Execution Date), prepare and file with the FTC and DOJ, the Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) required for the transactions contemplated hereby, together with all required documentary attachments thereto (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HSR Filings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).&#160;Notwithstanding the foregoing, the Parties may, upon mutual agreement, delay the filing of any of the HSR Filings if they reasonably believe that such delay would result in obtaining any clearance required under the HSR Act for the consummation of this Agreement and the transactions contemplated hereby more expeditiously. Each of Schr&#1255;dinger and Novartis will cooperate in the antitrust clearance process, including by furnishing to each other&#8217;s counsel such necessary information and reasonable assistance as the other may reasonably request in connection with its preparation of any filing or submission that is necessary under the HSR Act and to furnish promptly with the FTC and DOJ any information reasonably requested by them in connection with such filings.&#160;Each Party will be responsible for its own fees, costs and expenses associated with any HSR Filings or in connection with its obligations pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Schr&#1255;dinger and Novartis will each use commercially reasonable efforts to promptly obtain the expiration or termination of the HSR waiting period as it relates to this Agreement and the transactions contemplated hereby and will keep each other apprised of the status of any communications with, and any inquiries or requests for additional information from, the FTC or DOJ and will comply promptly with any such inquiry or request. As used in </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 80 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;commercially reasonable efforts&#8221; will not include, and will not require, proposing, negotiating, committing to or effecting, by consent decree, hold separate order, or otherwise, (A) the sale, divestiture, disposition, licensing or sublicensing of any of a Party&#8217;s or its Affiliates&#8217; assets, properties or businesses, (B) behavioral limitations, conduct restrictions or commitments with respect to such assets, properties or business, or of any of the rights or obligations of a Party under this Agreement, or (C) defending through litigation any claim asserted in court by any Third Party that would restrain, prevent or delay the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Parties will instruct their respective counsel to cooperate with each other and use commercially reasonable efforts to facilitate and expedite the identification and resolution of any issues arising under the HSR Act at the earliest practicable dates. Such commercially reasonable efforts and cooperation shall include counsel&#8217;s undertaking to (A) keep each other informed of communications, inquiries and requests from and to personnel of the FTC or DOJ, including by providing copies thereof to the other Party (subject to reasonable redactions for privilege or confidentiality concerns), and (B) confer with each other regarding appropriate contacts with and response to such personnel of the FTC or DOJ and the content of any such contacts or presentations. Each of Schr&#1255;dinger and Novartis will consult with the other Party, to the extent practicable, in advance of participating in any substantive meeting or discussion with the FTC or DOJ with respect to any such filings, applications, investigation, or other inquiry and, to the extent permitted by the DOJ or FTC, give the other Party the opportunity to attend and participate in such meeting or discussion. Each Party will provide the other Party the opportunity to review in advance, and will consider in good faith the other Party&#8217;s reasonable comments in connection with, the content of any presentations, white papers or other written materials to be submitted to the FTC or DOJ. Notwithstanding any of the foregoing, the final determination as to the appropriate course of action shall be made by Novartis. For clarity, the Parties&#8217; rights and obligations hereunder apply only in so far as they relate to this Agreement and to the transactions contemplated under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effectiveness of the Agreement&#59; Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except for the Parties&#8217; rights and obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which will be effective as of the Execution Date, this Agreement will not become effective until the applicable waiting period (and any extensions thereof), including any timing agreement entered into with the United States Federal Trade Commission (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or the Antitrust Division of the United States Department of Justice (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOJ</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under the HSR Act shall have expired or terminated (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). As of the Effective Date, all other provisions of this Agreement will become effective automatically without the need for further action by the Parties. Notwithstanding any other provisions of this Agreement to the contrary, if the Effective Date has not occurred on or before the date that is &#91;**&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">after the Execution Date (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Outside Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then either Party, by written notice to the other, may terminate this Agreement, which will then become void and of no further effect as of such notice, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Outside Date shall automatically be extended up to &#91;**&#93; for a period of &#91;**&#93; each if the Effective Date shall not have occurred within such &#91;**&#93; period or such initial &#91;**&#93; extension period, as applicable. Subject to the foregoing provisions in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, this Agreement shall become effective on the </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 81 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date and, unless earlier terminated pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Term and Termination), shall continue until it expires as follows (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58; (i) on a Collaboration Product-by-Collaboration Product and country-by-country basis, on the date of the expiration of the Royalty Term under this Agreement in such country with respect to such Collaboration Product&#59; (ii) on a Collaboration Target-by-Collaboration Target basis, upon the expiration of all applicable Royalty Terms under this Agreement with respect to all Collaboration Products Directed Against such Collaboration Target in all countries in the Territory&#59; and (iii) in its entirety, upon the expiration of all payment obligations under this Agreement with respect to all Collaboration Products in all countries in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination by Novartis at Will or for a Safety Concern</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">At Will</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis may terminate this Agreement in its entirety or on a Collaboration Target-by-Collaboration Target basis, at any time after the Effective Date, for any reason or no reason, upon (a) sixty (60) days&#8217; prior written notice to Schr&#246;dinger in the case where a &#91;**&#93; for a Collaboration Compound Directed Against such Collaboration Target has not been delivered to Novartis in accordance with the applicable Project Plan for such Collaboration Target, (b) ninety (90) days&#8217; prior written notice to Schr&#246;dinger in the case where Novartis has delivered a &#91;**&#93; for a Collaboration Compound Directed Against such Collaboration Target but Regulatory Approval has not been obtained for any applicable Collaboration Compound for such Collaboration Target in either the U.S. or the EU, or (c) upon one hundred and eighty (180) days&#8217; prior written notice to Schr&#246;dinger following Regulatory Approval of such Collaboration Product. For clarity, following any such notice of termination under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, milestone payments will be due on Sales Milestones achieved during the period between the notice of termination and the effective date of termination with respect to this Agreement as a whole, or the applicable Collaboration Target(s) if terminated with respect to one (1) or more Collaboration Target(s), as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination for Safety Concerns</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis may elect, in its sole discretion, to terminate this Agreement, in its entirety or on a Collaboration Target-by-Collaboration Target basis, upon five (5) Business Days&#8217; prior written notice to Schr&#246;dinger if Novartis determines in good faith that a Safety Concern exists with respect to a Collaboration Product Directed Against such Collaboration Target and that it is not advisable for Novartis to continue to Develop or Commercialize such Collaboration Product due to such Safety Concern. Prior to the effective date of any termination pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2(b), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novartis shall use reasonable efforts to discuss the applicable Safety Concern(s) with Schr&#1255;dinger. Following such written notice to Schr&#246;dinger under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, no milestone payments will be due on milestones achieved during the period between the notice of termination and the effective date of the termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination by Either Party for Breach</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 82 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Termination by Either Party for Breach), in the event that a Party materially breaches this Agreement, the other Party may terminate this Agreement in its entirety or on a Collaboration Target-by-Collaboration Target or Project-by-Project basis if such breach shall have continued for &#91;**&#93; (or &#91;**&#93; in the case of a breach as a result of undisputed non-payment)) after written notice shall have been provided to the breaching Party by the non-breaching Party requiring such breach to be remedied and stating an intention to terminate if not so cured (such period, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cure Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and such notice, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160; Except as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Termination by Either Party for Breach), any such termination shall become effective at the end of such Cure Period unless the breaching Party has cured any such breach prior to the expiration of the Cure Period (or, if such material breach cannot be cured within such Cure Period, then such Cure Period shall be extended for an additional &#91;**&#93; only if the alleged breaching Party has not commenced and diligently continues good faith efforts to cure such breach during such extension period). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;In the event that Novartis materially breaches its obligations under the Agreement and such breach relates to (A) a Project, Schr&#246;dinger may only terminate such Project, (B) an &#91;**&#93;, Schr&#246;dinger may only terminate such &#91;**&#93;, (C) a Collaboration Target, Schr&#246;dinger may only terminate such Collaboration Target, or (D) a particular Major Market, Schr&#246;dinger may only terminate such Major Market.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If the alleged breaching Party disputes the existence or materiality of a breach specified in a Termination Notice provided by the other Party in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Termination by Either Party for Breach), and such alleged breaching Party provides the other Party notice of such dispute within the applicable Cure Period after receiving such Termination Notice, then the matter will be resolved as provided in&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution) and the non-breaching Party shall not have the right to terminate this Agreement under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Breach) or seek any remedy in lieu of termination pursuant to</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> Section 13.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Remedies in Lieu of Termination) unless and until such dispute has been submitted to arbitration in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution) and it has been finally determined under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration) that this Agreement has been materially breached, and the breaching Party fails to cure such breach within &#91;**&#93; following such arbitrators&#8217; decision under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration) (or if such breach cannot be cured within such &#91;**&#93; period, if the alleged breaching Party has not commenced and diligently continues good faith efforts to cure such breach, except to the extent such breach involves the failure to make a payment when due, which breach must be cured within &#91;**&#93; following such arbitrators&#8217; decision). Except as provided in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, during the pendency of any such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and the Cure Period set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 83 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For clarity, milestone payments by Novartis will be due on milestones achieved during the period between the notice of termination under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Breach) and the effective date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination by Either Party for Insolvency</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Party shall have the right to terminate this Agreement upon written notice if the other Party incurs an Insolvency Event&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the case of any involuntary bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or if such proceeding is not dismissed or stayed within &#91;**&#93; after the filing thereof. &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvency Event</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means circumstances under which a Party (a) has a receiver or similar officer appointed over all or a material part of its assets or business&#59; (b) passes a resolution for winding-up of all or a material part of its assets or business (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court enters an order to that effect&#59; (c) has entered against it an order for relief recognizing it as a debtor under any insolvency or bankruptcy laws (or any equivalent order in any jurisdiction)&#59; or (d) enters into any composition or arrangement with its creditors with respect to all or a material part of its assets or business (other than relating to a solvent restructuring).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Increase for Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If, during the Term, in a particular country, Novartis or its Affiliate or Sublicensee, directly or indirectly by actively assisting any Third Party, (a) commences any inter partes review, post-grant review, interference opposition or similar proceeding with respect to, or opposes any extension of or the grant of a supplementary protection certificate with respect to any Payment Patent owned by Schr&#1255;dinger or its Affiliates or (b) institutes, actively participates as an adverse party in, or otherwise provides material support to, any action, suit or other proceeding to limit the scope of or invalidate any Payment Patent owned by Schr&#1255;dinger or its Affiliates or to obtain a ruling that any claim within any Payment Patent owned by Schr&#1255;dinger or its Affiliates is unenforceable or not patentable ((a) or (b), a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Patent Challenge</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), and after &#91;**&#93; written notice from Schr&#1255;dinger, Novartis does not rescind (or cause to be rescinded) such Schr&#1255;dinger Patent Challenge, Schr&#1255;dinger will have the right to (i) increase all future royalties payable by Novartis hereunder by &#91;**&#93; percent (&#91;**&#93;%) with respect to the applicable Collaboration Products in such country Covered by the Patent rights subject to the Schr&#1255;dinger Patent Challenge and (ii) Novartis shall reimburse Schr&#1255;dinger for all of Schr&#1255;dinger&#8217;s expenses (including reasonable attorneys&#8217; fees and costs) incurred in connection with defending such challenge. For the avoidance of doubt, such increase in milestones and royalties shall be applied before any reductions under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Payments) or remedies available under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Remedies in Lieu of Termination). Notwithstanding the foregoing&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Schr&#1255;dinger Patent Challenges shall not include Novartis or any of its Affiliates or Sublicensees&#58; (i)  exercising any rights or performing any obligations with respect to such Payment Patent owned by Schr&#1255;dinger or its Affiliates under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; (ii) seeking to limit the scope or making any assertion of invalidity, non-infringement, or unenforceability as a defense or counterclaim in any court or administrative </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 84 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proceeding as a result of Schr&#1255;dinger or its Affiliates asserting infringement of Payment Patents owned by Schr&#1255;dinger or its Affiliates&#59; (iii) responding to compulsory discovery, subpoenas or other requests for information in a judicial or arbitration proceeding&#59; or (iv) complying with any Applicable Law or court order.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not apply if Novartis or its Affiliate&#58; (i) acquires a Third Party, whether by stock purchase, merger, asset purchase, or otherwise, that has an existing Schr&#1255;dinger Patent Challenge, whether in a court or administrative proceeding, against a Patent right in the such Payment Patents owned by Schr&#1255;dinger or its Affiliates, or where such Third Party asserts invalidity, non-infringement or unenforceability as a defense in any court or administrative proceeding as a result of Schr&#1255;dinger or its Affiliates asserting infringement of a Patent right in such Payment Patents owned by Schr&#1255;dinger or its Affiliates&#59; (ii) licenses a product for which the licensor has an existing Patent Challenge, whether in a court or administrative proceeding, against a Patent right in such Payment Patents owned by Schr&#1255;dinger or its Affiliates, or where such licensor asserts invalidity, non-infringement or unenforceability as a defense in any court or administrative proceeding as a result of Schr&#1255;dinger or its Affiliates asserting infringement of a Patent right in such Payment Patents owned by Schr&#1255;dinger or its Affiliates&#59; or (iii) with respect to any such Schr&#1255;dinger Patent Challenge by any such Sublicensee, terminates the sublicense granted to such Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">within &#91;**&#93; of Schr&#1255;dinger&#8217;s notice to Novartis under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, nothing in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Royalty Increase for Patent Challenge) prevents Novartis or any of its Affiliates or Sublicensees from asserting any Schr&#1255;dinger Patent Challenge.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effects of Termination of this Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">In General</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon termination of this Agreement, in whole or in part, by a Party pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Novartis at Will or for a Safety Concern) through</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Insolvency), the following terms will apply&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;With respect to any Collaboration Target for which this Agreement has been terminated such Collaboration Target shall become a Terminated Target and (B) subject to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each Party&#8217;s rights and obligations under this Agreement with respect to the research, Development, Manufacture, Commercialization or other Exploitation of such Terminated Target(s) shall automatically cease as of the effective date of termination. Either Party and its Affiliates will be free to, alone or for or with any Third Party, research, develop, Manufacture or commercialize any compound, product or companion diagnostic for such Terminated Target. For clarity, if this Agreement is terminated in its entirety all Collaboration Targets shall be Terminated Targets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Novartis&#8217; payment obligations with respect to Collaboration Compounds or Collaboration Products Directed Against any Terminated Target shall survive&#59; </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 85 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the applicable Collaboration Compound or Collaboration Product either (A) was the subject of a &#91;**&#93; during the Term or (B) with respect to any Collaboration Compound or Collaboration Product that is Covered by any Product Specific Patent or that uses or was discovered using Schr&#246;dinger Arising IP, Product Specific Know-How or Licensed Know-How, Achieved the DC Criteria within &#91;**&#93; after the effective date of termination with respect to the applicable Collaboration Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;All licenses granted by either Party to the other Party will terminate except as otherwise permitted and negotiated under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Within &#91;**&#93; after the effective date of termination, each Party shall destroy all tangible items comprising, bearing or containing any Confidential Information of the other Party that are in its or its Affiliates&#8217; Control&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such Party may retain one (1) copy of such Confidential Information for its legal archives, and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that such Party shall not be required to destroy electronic files containing Confidential Information that are made in the ordinary course of its business information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Schr&#1255;dinger shall remain entitled to receive all payments that accrued but were unpaid before the effective date of such termination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;The JSC (and all Working Groups and committees) will be dissolved as of the effective date of such termination&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;Certain provisions herein will survive termination, in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Survival).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Pre-DC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the case of termination of this Agreement, in its entirety or with respect to a Terminated Target (and for clarity, not in the event of termination with respect to a Project or &#91;**&#93;) by Schr&#1255;dinger under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Breach) or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Insolvency) or by Novartis under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (At Will), in each case, prior to issuance of a &#91;**&#93;, effective upon Schr&#1255;dinger&#8217;s written notification to Novartis, within &#91;**&#93; of the effective date of such termination, of its election under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;Conditioned upon and concurrent with Schr&#1255;dinger&#8217;s grant of the Covenant Not To Sue in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below, Novartis will, and hereby does assign to Schr&#1255;dinger, without additional compensation, all right, title and interest in and to any Novartis-Owned Arising IP that was solely conceived, discovered, developed, identified, or otherwise made by or on behalf of Schr&#1255;dinger or its Affiliates, or their respective employees, agents or independent contractors and that is specifically related to one (1) or more Collaboration </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 86 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compounds Directed Against such Terminated Target (other than any Novartis Internal Collaboration Compounds)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if the Terminated Territory is less than worldwide, then Novartis shall assign to Schr&#1255;dinger only patents in the Terminated Territory and not any other Novartis-Owned Arising IP For the avoidance of doubt, the foregoing assignment does not apply to any Novartis-Owned Arising IP solely or jointly conceived, discovered, developed or otherwise made by or on behalf of Novartis or its Affiliates or their respective employees, agents or independent contractors (such assignment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Limited Assignment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;Conditioned upon and concurrent with Novartis&#8217; Limited Assignment in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> above, Schr&#1255;dinger, on behalf of itself and its Affiliates and sublicensees, and its and their respective successors and assigns, hereby covenants that it and its Affiliates and its sublicensees, and its and their respective successors and assigns, shall not commence or cause to be commenced any action or proceeding claiming or otherwise alleging infringement of the Novartis-Owned Arising IP assigned to Schr&#1255;dinger under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> against Novartis or any of its Affiliates or its and their respective shareholders, directors, officers, employees, agents, representatives, successors and assigns, licensees, sublicensees, customers, partners, and contractors, with respect to use of such Novartis-Owned Arising IP, provided that such use was for Novartis&#8217; &#91;**&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covenant Not To Sue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Rights Post-DC and Pre-Phase 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the case of termination of this Agreement, in its entirety or with respect to a Terminated Target (and for clarity, not in the event of termination with respect to a Project or an &#91;**&#93;) by Schr&#1255;dinger under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or by Novartis under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case, after issuance of a &#91;**&#93; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and prior to Initiation of a Phase 1 Clinical Trial, upon Schr&#1255;dinger&#8217;s written notification to Novartis, within &#91;**&#93; of the effective date of such termination, of its election under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;Novartis will, and hereby does, provide Schr&#1255;dinger the Limited Assignment in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">13.6(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Schr&#1255;dinger will, and hereby does, grant Novartis the Covenant Not To Sue in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case, pursuant to the terms and conditions specified therein.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;Schr&#1255;dinger will have the option to enter into good faith negotiations with Novartis for a license grant under Novartis-Owned Arising IP that specifically relates to Reversion Compounds or Reversion Products (other than any Novartis Internal Collaboration Compounds and other than any Patents and Information relating to manufacturing technology or any active pharmaceutical ingredient that is not a Reversion Compound) that is necessary to Exploit Reversion Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Rights Post-Phase 1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the case of termination of this Agreement, in its entirety or with respect to a Terminated Target (and for clarity, not in the event of termination with respect to a Project or an &#91;**&#93;) by Schr&#1255;dinger under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or by Novartis under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.2(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case, after Initiation of a Phase 1 Clinical </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 87 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Trial, upon Schr&#1255;dinger&#8217;s written notification to Novartis, within &#91;**&#93; of the effective date of such termination, of its election under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;Novartis will, and hereby does, provide Schr&#1255;dinger the Limited Assignment in Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">13.6(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Schr&#1255;dinger will, and hereby does, grant Novartis the Covenant Not To Sue in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case, pursuant to the terms and conditions specified therein.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;The Parties will, within &#91;**&#93; following the receipt by Novartis of Schr&#1255;dinger&#8217;s written notification as provided above in this Section </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">13.6(b)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, negotiate in good faith with respect to and enter into, on reasonable financial terms, a reversion license granting Schr&#1255;dinger an exclusive, perpetual, irrevocable (other than for non-payment), fully-transferrable license, with the right to grant multiple tiers of sublicenses, under the Novartis-Owned Arising IP that specifically relates to Reversion Compounds or Reversion Products (other than any Novartis Internal Collaboration Compounds and other than any Patents and Information relating to manufacturing technology or any active pharmaceutical ingredient that is not a Reversion Compound) that is necessary to Exploit Reversion Products for which a Phase 1 Clinical Trial was Initiated prior to the effective date of termination, in the Field in the Terminated Territory for the purpose of Exploiting such Reversion Products in the Field in the Terminated Territory. In the event there is a dispute regarding the terms in the reversion license to be negotiated between the Parties pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, such dispute will be submitted to fast-track, binding baseball arbitration in accordance with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Upon Schr&#1255;dinger&#8217;s written request, in the event of worldwide termination with respect to one or more Reversion Products, Novartis shall transfer all existing and available clinical material for such Reversion Products, including the Reversion Compounds therein, to Schr&#1255;dinger in consideration for Schr&#246;dinger&#8217;s payment of Novartis&#8217;s fully burdened Manufacturing cost and transfer cost (including shipping). If a Reversion Product is marketed in any country of the Terminated Territory on the date of the notice of termination of this Agreement, upon the request of Schr&#1255;dinger, Novartis shall transfer all existing and available amount of such Reversion Product to Schr&#1255;dinger in consideration for Schr&#246;dinger&#8217;s payment of Novartis&#8217;s fully burdened Manufacturing cost and transfer costs (including shipping).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approvals</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the effective date of termination is after First Commercial Sale of a Reversion Product in the Terminated Territory, then, to the extent permitted by Applicable Law, Novartis or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees) will use Commercially Reasonable Efforts to transfer Regulatory Approvals of such Reversion Product in the Terminated Territory to Schr&#1255;dinger or its designee, or to otherwise obtain for Schr&#246;dinger the benefit of such Regulatory Approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Study Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis shall assign and transfer all clinical study agreements that are solely related to the Terminated Products in the </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 88 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Terminated Territory, to the extent such Third Party agreements have not been cancelled and are assignable without Novartis paying any consideration or commencing litigation in order to effect an assignment of any such agreement. To the extent the foregoing is not permitted under the terms of any Third Party agreements, Novartis shall notify Schr&#1255;dinger and provide necessary introductions to such Third Parties via e-mail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(F)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trademarks</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the effective date of termination is after Initiation of a Phase 3 Clinical Trial, then, Novartis will promptly transfer and assign to Schr&#1255;dinger all of Novartis&#8217;s and its Affiliates&#8217; rights, title and interests in and to trademarks (including Product Marks) owned or in-licensed by Novartis or its Affiliates solely used to identify the Reversion Products (but not any house marks, or logos or any trademark of Novartis or its Affiliates, containing the word &#8220;Novartis&#8221; or any such Affiliate) owned by Novartis and used for the Reversion Products in the Field in the Terminated Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(G)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Schr&#1255;dinger so requests, and to the extent permitted under Novartis&#8217;s obligations to Third Parties on the effective date of termination, Novartis will transfer, assign, or otherwise sublicense to Schr&#1255;dinger (or, alternatively, add Schr&#1255;dinger as an additional party to) any Third Party agreements and rights thereunder relating solely to the Exploitation of the Reversion Products in the Terminated Territory to which Novartis is a party, to the extent such Third Party agreements have not been cancelled and are assignable without Novartis paying any consideration or commencing litigation in order to effect an assignment of any such agreement, subject to any required consents of such Third Party, which Novartis will use reasonable efforts to obtain promptly (but, for clarity, without paying any consideration or commencing any litigation to obtain such consent). To the extent the foregoing is not permitted under the terms of any Third Party agreements, Novartis shall notify Schr&#1255;dinger and provide necessary introductions to such Third Parties via e-mail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Further Assurances</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis will execute all documents and take all such further actions as may be reasonably requested by Schr&#1255;dinger in order to give effect to the foregoing clauses in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reversion Rights for &#91;**&#93;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For clarity, the termination of an &#91;**&#93; shall not trigger any reversion rights in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, unless and until all &#91;**&#93; have been terminated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.7&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Remedies in Lieu of Termination</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that Novartis would have the right to terminate this Agreement with respect to a Collaboration Product pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Breach), then, in lieu of exercising such termination right and effective as of the date on which such termination would have taken place after a termination notice has been provided to Schr&#246;dinger, Novartis may instead, notwithstanding any other term of this Agreement, on written notice to Schr&#246;dinger and in respect of such Collaboration Product&#58; (a) reduce the amount of any Discovery Milestone Payment, Development Milestone Payment for the applicable Territory, Sales Milestone Payment for the applicable Territory or royalties </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 89 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(each as payable by Novartis to Schr&#246;dinger in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Payments) and subject to the Royalty Floor) shall be reduced by &#91;**&#93; percent (&#91;**&#93;%) and (b)  Novartis shall have the right to offset the amount of any damages (subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Limitation of Liability)) it has suffered as a result of Schr&#246;dinger&#8217;s breach against any such Discovery Milestone Payment, Development Milestone Payment, Sales Milestone Payment or royalties (each as payable by Novartis to Schr&#246;dinger in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Payments))&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for clarity, that such remedy shall be available only after expiration of the Cure Period set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Schr&#1255;dinger does not dispute the existence or materiality of a breach pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effects of Expiration of Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon the expiration of the Royalty Term (i.e., in the case where there is no earlier termination pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Term and Termination)), on a Collaboration Product-by-Collaboration Product and country-by-country basis, the license granted to Novartis under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.1(a)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to Licensed Technology shall convert to a fully paid-up, perpetual and irrevocable and non-exclusive license. Certain provisions herein will survive expiration, in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Survival).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.9&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Remedies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Term and Termination), expiration or earlier termination of this Agreement for any reason shall not release either Party from any liability or obligation (including payments) that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to survive such termination. Subject to and without limiting the terms and conditions of this Agreement (including </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Limitation of Liability)), expiration or termination of this Agreement shall not preclude any Party from (a) claiming any other damages, compensation or relief that it may be entitled to upon such expiration or termination, (b) any right to receive any amounts accrued under this Agreement prior to the expiration or termination date but which are unpaid or become payable thereafter and (c) any right to obtain performance of any obligation provided for in this Agreement which shall survive expiration or termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.10&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Survival</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Termination or expiration of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration of this Agreement. Notwithstanding anything to the contrary and without limiting the provisions of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Other Remedies), the following provisions shall survive and apply after expiration or termination of this Agreement, in addition to any other terms and conditions that are expressly stated to survive termination or expiration of this Agreement, where applicable for the time periods set forth therein&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Use of Novartis Datasets&#59; Maintenance of Novartis Dedicated Tenancy), and the corresponding </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in accordance with its terms)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.1(a)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Licenses to Novartis) (in accordance with its terms)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(a)(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Licenses to Novartis)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Sublicensing) (solely to the extent applicable to surviving license grants)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (No Other Rights)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Upfront Payment) through </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.14</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Diagnostic Products) (with respect to payment obligations arising before termination or expiration of this Agreement)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Discovery Milestone Payments) through </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.14</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Diagnostic Products) (with respect to payment obligations </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 90 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">arising after such termination or expiration pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(a)(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in each case, to the extent Novartis or its Affiliate continues to Develop or Commercialize Collaboration Products after the effective date of termination)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Ownership of Intellectual Property)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Cooperation)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Further Action)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Use of Name)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Exclusivity) (solely with respect to a Terminated Target that is a Discontinued Target, and in such case solely for &#91;**&#93; following the effective date of termination)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 12.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) through </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Publications) (for the time period set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (HSR Filing&#59; Effectiveness of Agreement&#59; Term)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Effects of Termination of this Agreement)&#59;  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.8</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Effects of Expiration of Agreement)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Other Remedies)&#59; this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Survival)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (No Other Representations or Warranties)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability) (except for </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Insurance))&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 17</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Miscellaneous) (except for </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Further Actions) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Maintenance of Records, which </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply only during the Term and thereafter until the later of (a) the &#91;**&#93; of expiration or termination of the Agreement and (b) expiration of any retention period specified by Applicable Law))&#59; and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Definitions) (to the extent the definitions are embedded in the foregoing listed surviving Articles and Sections).  If this Agreement is terminated with respect to one or more Projects but not in its entirety, then following such termination the foregoing provisions of this Agreement will survive such termination with respect to such terminated Projects(s) (to the extent they would survive and apply in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.10</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Survival) in the event the Agreement expires or is terminated in its entirety), and all provisions not surviving in accordance with the foregoing will terminate upon termination of this Agreement with respect to the applicable Project and be of no further force and effect. All provisions not surviving in accordance with the foregoing shall terminate upon expiration or termination of this Agreement and be of no further force and effect.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 14.&#160;&#160;&#160;&#160;REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Mutual Representations, Warranties and Covenants</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party hereby represents and warrants to the other Party as of the Execution Date and the Effective Date, and, where denoted below, covenants to the other Party as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;It has the full corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder. It has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 91 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;It is not a party to any agreement, outstanding order, judgment or decree of any court or Governmental Authority that would prevent it from granting the rights granted to the other Party under this Agreement or performing its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;It has all rights, authorizations, and licenses necessary to meet its obligations under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;In the course of the Development of Collaboration Compounds and Collaboration Compounds, such Party has not used prior to the Effective Date and shall not use, during the Term, any employee, agent or independent contractor who has been debarred by any Regulatory Authority, or, to such Party&#8217;s knowledge, is the subject of debarment proceedings by a Regulatory Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;It has not, and will not, after the Effective Date and during the Term, grant any right to any Third Party that would conflict with the rights granted to the other Party hereunder, and there are no agreements to which it or any of its Affiliates is a party relating to Collaboration Compounds, Collaboration Products, or Product Specific Patents that would limit the rights granted to the other Party under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Neither Party nor any of its employees or agents performing hereunder have ever been, are currently, or are the subject of a proceeding that could lead to it or such employees or agents becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual. If, during the Term, such Party, or any of its employees or agents performing hereunder, become or are the subject of a proceeding that could lead to a Person becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual, such Party shall immediately notify the other Party, and the notified Party shall have the option, at its sole discretion, to either&#58;  (1) prohibit such Person from performing work under this Agreement or (2) terminate all work being performed or to be performed by the notifying Party pursuant to this Agreement. This provision shall survive termination or expiration of this Agreement. For purposes of this provision, the following definitions shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representations, Warranties, and Covenants by Schr&#1255;dinger</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Without limiting any of the representations, warranties and covenants set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Mutual Representations, Warranties, and Covenants), Schr&#1255;dinger hereby represents and warrants to Novartis, as of the Execution Date and the Effective Date, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;It is the sole owner of all right, title and interest in and to (free and clear from any Liens of any kind) its Product Specific Patents.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 92 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Patents within the Licensed Technology existing as of the Effective Date and set forth on </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.203</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> represent all Patents within its or its Affiliates&#8217; ownership or Control relating to the Collaboration Compounds or the Exploitation thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Schr&#1255;dinger has the legal right and power to grant the licenses, rights, and interests granted to Novartis hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Schr&#1255;dinger has no knowledge of any threatened or pending actions, lawsuits, claims or arbitration proceedings that could reasonably adversely affect the practice or use of the Schr&#1255;dinger Platform or use of Materials provided by Schr&#1255;dinger as contemplated under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Schr&#1255;dinger&#8217;s Background IP and Schr&#1255;dinger Platform IP is free and clear from any Liens, and Schr&#1255;dinger has and will retain throughout the Term sufficient legal or beneficial title, ownership or license thereunder to grant the licenses and ownerships to Novartis as purported to be granted pursuant to this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Neither Schr&#1255;dinger nor any of its Affiliates, nor, to Schr&#1255;dinger&#8217;s knowledge, any of its or their (sub)licensees) has received any written notice from any Third Party asserting or alleging that (i) the practice of Schr&#1255;dinger&#8217;s Background IP or Schr&#1255;dinger Platform IP, (ii) the Schr&#1255;dinger Platform or the operation or use thereof, or (iii) any data or materials used to develop the Schr&#1255;dinger Platform, in each case ((i)-(iii)), infringes, misappropriates, or otherwise violates any Patent or other intellectual property or proprietary rights of a Third Party. Schr&#1255;dinger will promptly notify Novartis in the event Schr&#1255;dinger or any of its Affiliates, or to Schr&#1255;dinger&#8217;s knowledge any of its or their (sub)licensees, receives any such written notice from a Third Party during the Term and reasonably cooperate with Novartis in assessing and mitigating any resulting risks to a Project or to Novartis&#8217; ability to Exploit any Collaboration Compound or Collaboration Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;To Schr&#1255;dinger&#8217;s knowledge, (i) the practice of Schr&#1255;dinger&#8217;s Background IP and Schr&#1255;dinger Platform IP, (ii) the Schr&#1255;dinger Platform and the operation and use thereof, and (iii) its performance under this Agreement, in each case ((i)-(iii)), does not and will not infringe, misappropriate, or otherwise violate any Patent or other intellectual property or proprietary rights of any Third Party. Other than data provided by Novartis, Schr&#1255;dinger has or will procure, as applicable, all rights and licenses necessary for the use of any data, materials or other Information used, or that will be used, by Schr&#1255;dinger to train and otherwise develop the Schr&#1255;dinger Platform under or in furtherance of any Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;There are no pending and, to Schr&#1255;dinger&#8217;s knowledge, no threatened, actions, suits, proceedings, judgments or settlements, nor any pending reissues, reexaminations, inter partes reviews, post grant reviews, interferences, oppositions, or similar proceedings, with respect to any Patents within Schr&#1255;dinger&#8217;s Background IP or the Schr&#1255;dinger Platform IP.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 93 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;No claim has been filed or served, and no written threat of a claim or litigation has been made by any Person, nor has any judicial or agency proceeding been instituted, against Schr&#1255;dinger that alleges that any issued any Patents within Schr&#1255;dinger&#8217;s Background IP or the Schr&#1255;dinger Platform IP are invalid or unenforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;To Schr&#1255;dinger&#8217;s knowledge, all of its or its Affiliates&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Patents within Schr&#1255;dinger&#8217;s Background IP or the Schr&#1255;dinger Platform IP are subsisting and are not invalid or unenforceable, in whole or in part.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Schr&#1255;dinger has not and will not grant any license or any option for a license under, or any right, title or interest in or to, Schr&#1255;dinger&#8217;s Background IP or the Schr&#1255;dinger Platform IP to any Third Party to research, Develop, Manufacture, Commercialize or otherwise Exploit any Collaboration Compound in any country in the Territory that conflicts with (or reasonably would be expected to conflict with) the licenses and ownership granted, or to be granted, by Schr&#1255;dinger to Novartis under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;There are no amounts that Novartis or its Sublicensees will be required to pay to a Third Party as a result of the Exploitation of any Collaboration Compounds or Collaboration Products that arise out of any agreement to which Schr&#1255;dinger or any of its Affiliates is a party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Schr&#1255;dinger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">has not entered into a government funding relationship that would result in rights to any Collaboration Compounds or Collaboration Products residing in the United States government, National Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the United States government as set forth in Public Law 96 517 (35 U.S.C. 200 204) or any similar obligations under the laws of any other country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;Schr&#1255;dinger has conducted the required technical analysis for the Collaboration Targets that are the subject of the Initial Project Plans and has determined suitability to proceed with such Initial Project Plans.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representations, Warranties, and Covenants as of &#91;**&#93;, and upon Approval of new Project Plans</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Party makes the representations, warranties, and covenants set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Mutual Representations, Warranties, and Covenants) to the other Party, as applicable, and Schr&#1255;dinger makes the representations, warranties, and covenants set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Representations, Warranties, and Covenants by Schr&#1255;dinger) (i) as of the delivery date of the &#91;**&#93; and (ii) upon approval of each new Project Plan, unless and to the extent a Party notifies the other Party that any of the representations, warranties, and covenants made by it in either </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Mutual Representations, Warranties, and Covenants) or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Representations, Warranties, and Covenants by Schr&#1255;dinger),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">are not true and correct in any material respects and the notifying Party provides reasonable written disclosure against such </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 94 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">representation, warranty, or convent, which notice must be issued to the other Party no later than &#91;**&#93; of the delivery date of the &#91;**&#93; or prior to approval of the Project Plan, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Novartis covenants that, as of the delivery of the &#91;**&#93; under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Discovery Milestone Event and Development Candidate Designation) it will have conducted a reasonable freedom to operate search.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Other Representations or Warranties</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EXCEPT AS EXPRESSLY STATED IN THIS </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE 14</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (REPRESENTATIONS AND WARRANTIES), NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, OR THAT ANY OF THE DEVELOPMENT OR COMMERCIALIZATION EFFORTS WITH REGARD TO ANY COMPOUND OR PRODUCT WILL BE SUCCESSFUL, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 15.&#160;&#160;&#160;&#160;INDEMNIFICATION AND LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnification by Schr&#1255;dinger for Third Party Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Schr&#1255;dinger shall defend, indemnify, and hold Novartis, its Affiliates and Sublicensees, and its and their respective officers, directors, employees, and agents (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all damages, losses, liabilities, or other amounts payable to a Third Party, as well as any reasonable attorneys&#8217; fees and costs of litigation incurred by such Novartis Indemnitees, all to the extent arising out of or resulting from any claims, suits, proceedings or causes of action brought by such Third Party (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novartis Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) against such Novartis Indemnitee that arise out of or result from&#58; (a) a breach of any of Schr&#1255;dinger&#8217;s representations, warranties, covenants and obligations under this Agreement&#59; (b) the infringement, misappropriation, or violation of any Third Party Patent or other intellectual property or proprietary right by the Schr&#1255;dinger Platform or otherwise by Schr&#1255;dinger or its (sub)licensees and its and their Affiliates in the performance of Schr&#1255;dinger&#8217;s obligations under this Agreement&#59; (c) Schr&#1255;dinger&#8217;s use of any Future In-Licensed IP that Novartis had, pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5(c)(iii)(B)(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">elected not to include as Licensed Technology or Product Specific Patents&#59; (d) the gross negligence, recklessness or willful misconduct of, or violation of Applicable Law by, any Schr&#1255;dinger Indemnitees in connection with this Agreement&#59; and (e) the research or preclinical Development of Collaboration Compounds or Collaboration Products in the Field in the Territory by or on behalf of Schr&#1255;dinger&#8217;s or its Affiliates before the Effective Date or during the Term. The foregoing indemnity obligation shall not apply to the extent that any Novartis Claim is subject to indemnity pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification by Novartis for Third Party Claims).</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 95 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnification by Novartis for Third Party Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Novartis shall defend, indemnify, and hold Schr&#1255;dinger, its Affiliates, and Sublicensees hereunder and its and their respective officers, directors, employees, and agents (collectively, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Indemnitees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all damages, losses, liabilities, or other amounts payable to a Third Party, as well as any reasonable attorneys&#8217; fees and costs of litigation incurred by such Schr&#1255;dinger Indemnitees, all to the extent arising out of or resulting from any claims, suits, proceedings or causes of action brought by such Third Party (collectively, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schr&#1255;dinger Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) against such Schr&#1255;dinger Indemnitee that arise out of or result from&#58; (a) the Exploitation of any Collaboration Compounds or Collaboration Products in the Field in the Territory by or on behalf of Novartis or its Sublicensees and its and their Affiliates during the Term&#59; (b) a breach of any of Novartis&#8217; representations, warranties, covenants and obligations under this Agreement&#59; or (c) the gross negligence, recklessness or willful misconduct of or violation of Applicable Law by, any Novartis Indemnitees in connection with this Agreement. The foregoing indemnity obligation shall not apply to the extent that any Schr&#1255;dinger Claim is subject to indemnity pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification by Schr&#1255;dinger for Third Party Claims).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnification Procedures</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Party claiming indemnity under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability) (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promptly after learning of the claim, suit, proceeding or cause of action for which indemnity is being sought (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (it being understood and agreed, however, that the failure or delay by an Indemnified Party to give such notice of a Claim shall not affect the indemnification provided hereunder except to the extent the Indemnifying Party shall have been prejudiced as a result of such failure or delay to give such notice), and, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Indemnifying Party is not contesting the indemnity obligation, shall permit the Indemnifying Party to control and assume the defense of any litigation relating to such Claim and disposition of any such Claim unless the Indemnifying Party is also a party (or likely to be named a party) to the proceeding in which such Claim is made and the Indemnified Party gives notice to the Indemnifying Party that it may have defenses to such Claim or proceeding that are in conflict with the interests of the Indemnifying Party, in which case the Indemnifying Party shall not be so entitled to assume the defense of the case. If the Indemnifying Party does assume the defense of any Claim, it (a) shall act diligently and in good faith with respect to all matters relating to the settlement or disposition of any Claim as the settlement or disposition relates to Parties being indemnified under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability), (b) shall cause such defense to be conducted by counsel reasonably acceptable to the Indemnified Party and (c) shall not settle or otherwise resolve any Claim without prior notice to the Indemnified Party and the consent of the Indemnified Party (such consent not to be unreasonably conditioned, withheld or delayed) if such settlement involves anything other than the payment of money by the Indemnifying Party (including, for example, any settlement admitting fault or wrongdoing of the Indemnified Party, or consenting to any injunctive relief). The Indemnified Party shall reasonably cooperate with the Indemnifying Party in its defense of any Claim for which the Indemnifying Party has assumed the defense in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification Procedures), and shall have the </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 96 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">right, at its own cost and expense, to be present in person or through counsel at all legal proceedings giving rise to the right of indemnification&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that, the Indemnifying Party shall pay such costs and expenses of the Indemnified Party if (x) the employment thereof has been specifically authorized in writing by the Indemnifying Party, (y) the Indemnifying Party has failed to assume the defense and employ counsel and the Indemnified Party controls the defense in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Indemnification Procedure) or (z) the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such Claim such that the representation by the same counsel of both Parties and any respective Indemnified Parties is prohibited under Applicable Law, ethical rules or equitable principles. So long as the Indemnifying Party is diligently defending the Claim in good faith, the Indemnified Party shall not settle any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIMITATION OF LIABILITY</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EXCEPT FOR (A) INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION PURSUANT TO </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 15.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (INDEMNIFICATION BY SCHR&#1254;DINGER FOR THIRD PARTY CLAIMS) OR </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">15.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (INDEMNIFICATION BY NOVARTIS FOR THIRD PARTY CLAIMS) HEREUNDER, (B) A BREACH OF </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (EXCLUSIVITY) OR </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (INTELLECTUAL PROPERTY ONWERHSIP&#59; PATENT PROSECUTION AND ENFORCEMENT), (C) ANY BREACH OF </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (CONFIDENTIALITY)  BY A PARTY OR ITS AFFILIATES OR ITS OR THEIR LICENSEES OR SUBLICENSEES AND THEIR AFFILIATES, OR (D) DAMAGES THAT ARE DUE TO THE FRAUD OR WILLFUL MISCONDUCT OF THE LIABLE PARTY IN CONNECTION WITH THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT, IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insurance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall procure and maintain at its own cost, with financially stable and reputable insurers, adequate insurance protection that is usual and customary for its respective business operations and reasonably necessary to cover its actual and potential </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 97 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">insurable liabilities under this Agreement. Any deductible associated with a Party&#8217;s third-party insurance policy shall be the responsibility of that Party and cannot be passed on to the other Party. Schr&#1255;dinger acknowledges and agrees that Novartis may fulfill some or all of its foregoing obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Insurance) by means of self-insurance to the same extent, where permitted by law. It is understood that such insurance, or self-insurance, shall not be construed to create a limit of either Party&#8217;s liability, including with respect to its indemnification obligations under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 16.&#160;&#160;&#160;&#160;DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disputes&#59; Resolution by Executive Officers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Parties recognize that disputes as to certain matters may from time to time arise during the Term that relate to decisions to be made by the Parties herein or to the Parties&#8217; respective rights or obligations hereunder. It is the desire of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to arbitration or litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution) if and when a dispute arises under this Agreement, subject to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Waiver of Jury Trial).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accordingly, other than a matter within the final decision-making authority of Novartis or Schr&#1255;dinger, or Novartis or Schr&#1255;dinger jointly, or otherwise to be escalated to the Executive Officers as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Decisions of the JSC), any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement shall be promptly presented to the Alliance Managers for resolution. If the Alliance Managers are unable to resolve such dispute within &#91;**&#93; after a matter has been presented to them, then upon the request of either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person or virtual meeting between the Executive Officers of each Party within &#91;**&#93; after receipt by the other Party of such written notice. If the matter is not resolved within &#91;**&#93; following presentation to the Executive Officers, then either Party may invoke the provisions of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arbitration</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any dispute, controversy or difference, other than an Excluded Claim, that is not resolved pursuant to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Disputes), shall be settled by binding arbitration to be conducted as set forth below in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Either Party, following the end of the &#91;**&#93; period referenced in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Disputes&#59; Resolution by Executive Officers), may refer such issue to be resolved solely and exclusively by final arbitration by submitting a written notice of such request to the other Party. In any proceeding under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration), there shall be three (3) arbitrators. The arbitration will be conducted by a panel of three (3) arbitrators in accordance with the Rules of Arbitration (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICC Rules</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of the International Chamber of Commerce (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICC</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The claimant shall nominate an arbitrator in its request for arbitration. The respondent shall nominate an </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 98 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">arbitrator within &#91;**&#93; of the receipt of the request for arbitration. The two (2) arbitrators nominated by the Parties shall together, within &#91;**&#93; of the appointment of the later-nominated arbitrator, select a third arbitrator as the chairperson of the arbitration panel. If any of the three (3) arbitrators are not nominated within the time prescribed above, then the ICC shall appoint the arbitrator(s) in accordance with the ICC Rules. The arbitrators shall have significant experience in the pharmaceutical industry and shall not include any current or former employee, consultant, officer or director of Novartis or Schr&#1255;dinger (or their respective Affiliates), or otherwise have any current or previous relationship with Novartis or Schr&#1255;dinger or their respective Affiliates. The seat of the arbitration shall be New York City, New York, and the language of the arbitration shall be English. The arbitrators shall render their opinion within &#91;**&#93; of the close of the proceedings. No arbitrator (nor the panel of arbitrators) shall have the power to award punitive damages under this Agreement and such award is expressly prohibited. Decisions of the panel of arbitrators shall be final and binding on the Parties. Judgment on the award so rendered may be entered in any court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Nothing in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration) shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or other interim equitable relief concerning an issue, in each case, if necessary to protect the interests of such Party without the necessity of posting bond.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The existence of the arbitration, any non-public information provided in the arbitration, and any submissions, orders or awards made in the arbitration shall not be disclosed to any non-party except the tribunal, the ICC, the Parties, their counsel, experts, witnesses, accountants, auditors, insurers, reinsurers, and any other person necessary to the conduct of the arbitration except to the extent that disclosure may be required to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Award</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution), and agrees that, subject to the Federal Arbitration Act, judgment may be entered upon the final award in a court of competent jurisdiction and that other courts may award full faith and credit to such judgment in order to enforce such award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Costs</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall bear its own legal fees in connection with any arbitration procedure. The arbitrators may in their discretion assess the arbitrators&#8217; cost, fees and expenses (and those of any Expert hired by the arbitrators) against the Party losing the arbitration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WAIVER OF JURY TRIAL</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. EXCEPT AS LIMITED BY APPLICABLE LAW OR WITH RESPECT TO AN EXCLUDED CLAIM (AS SUCH TERM IS DEFINED IN </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 16.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 99 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Injunctive Relief</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Dispute Resolution) will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. For the avoidance of doubt, nothing in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.6</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Injunctive Relief) shall otherwise limit a breaching Party&#8217;s opportunity to cure a material breach as permitted in accordance with </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Breach) or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.4</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Termination by Either Party for Insolvency). No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.7&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The arbitration proceeding shall be confidential, and the arbitrators shall issue appropriate protective orders to safeguard each Party&#8217;s Confidential Information. Except as required by Applicable Law, no Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written consent of the other Party. The existence of any dispute submitted to arbitration, and any award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by Applicable Law. Notwithstanding the foregoing, each Party shall have the right to disclose information regarding the arbitration proceeding to the same extent as it may disclose Confidential Information of the other Party under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 12</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Confidentiality) above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Survivability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.9&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 16.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Arbitration), any controversy or claim arising under this Agreement that concerns (a) the validity or infringement of a Patent, trademark, copyright or trade secret, or (b) any antitrust, anti-monopoly or competition Applicable Laws or regulation, whether or not statutory (each, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Claim</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), may be brought in any court having jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Article 17.&#160;&#160;&#160;&#160;MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.1&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Entire Agreement&#59; Amendments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, including the Exhibits hereto (which are incorporated into and made a part of this Agreement), sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior agreements and understandings between the Parties with respect to the subject matter hereof, including the Prior </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 100 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CDA. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties with respect to the subject matter hereof other than as are set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized representative of each Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.2&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Export Control</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is made subject to any restrictions concerning the export of products or technical information from the U.S. or other countries which may be imposed upon or related to Schr&#1255;dinger or Novartis from time to time. Each Party agrees that it shall not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.3&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rights in Bankruptcy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All rights and licenses granted under or pursuant to this Agreement by one Party to the other are, for all purposes of Section 365(n) of Title 11 of the United States Code (&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Title 11</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in Title 11, and, in the event that a case under Title 11 is commenced by or against either Party (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankrupt Party</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the other Party, to the extent as a licensee of such rights under this Agreement, shall have all of the rights set forth in Section 365(n) of Title 11 to the maximum extent permitted thereby. During the Term, each Party shall create and maintain current copies to the extent practicable of all such intellectual property licensed to such Party hereunder. Without limiting the Parties&#8217; rights under Section 365(n) of Title 11, if a case under Title 11 is commenced by or against the Bankrupt Party, the other Party shall be entitled to a copy of any and all such intellectual property licensed to such Party hereunder and all embodiments of such intellectual property, and the same, if not in the possession of such other Party, shall be promptly delivered to it (i) before this Agreement is rejected by or on behalf of the Bankrupt Party, within &#91;**&#93; after the other Party&#8217;s written request, unless the Bankrupt Party, or its trustee or receiver, elects within &#91;**&#93; to continue to perform all of its obligations under this Agreement, or (ii) after any rejection of this Agreement by or on behalf of the Bankrupt Party, if not previously delivered as provided under clause (i) above. All rights of the Parties under this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and under Section 365(n) of Title 11 are in addition to and not in substitution of any and all other rights, powers, and remedies that each Party may have under this Agreement, Title 11, and any other Applicable Law. The non-Bankrupt Party shall have the right to perform the obligations of the Bankrupt Party hereunder with respect to such intellectual property, but neither such provision nor such performance by the non-Bankrupt Party shall release the Bankrupt Party from any such obligation or liability for failing to perform it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Parties agree that they intend the foregoing non-Bankrupt Party rights to extend to the maximum extent permitted by law and any provisions of applicable contracts </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 101 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with Third Parties, including for purposes of Title 11, (i) the right of access to any intellectual property (including all embodiments thereof) of the Bankrupt Party or any Third Party with whom the Bankrupt Party contracts to perform an obligation of the Bankrupt Party under this Agreement, and, in the case of the Third Party, which is necessary for the Development, Regulatory Approval, Manufacture and Commercialization of Collaboration Products and (ii) the right to contract directly with any Third Party described in (i) in this sentence to complete the contracted work. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any intellectual property provided pursuant to the provisions of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.3</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be subject to the licenses set forth elsewhere in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;In the event that after the Effective Date Schr&#1255;dinger enters into a license agreement with a Third Party with respect to intellectual property that will be sublicensed to Novartis hereunder, Schr&#1255;dinger will use Commercially Reasonable Efforts to enable Novartis to receive a direct license from any such Third Party in the event that such license agreement between Schr&#1255;dinger and such Third Party is terminated or rejected under Section 365(a) of Title 11 during the Term solely on account of Schr&#1255;dinger becoming a Bankrupt Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Intellectual Property Ownership&#59; Patent Prosecution and Enforcement), in the event that Schr&#1255;dinger is the Bankrupt Party, Novartis may take appropriate actions in connection with the filing, Prosecution, maintenance and enforcement of any Product Specific Patents licensed to Novartis under this Agreement without being required to consult with Schr&#1255;dinger before taking any such actions, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such actions are consistent with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.4&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by Force Majeure (defined below) and the nonperforming Party promptly provides notice of such prevention to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the Party affected by such Force Majeure shall take reasonable efforts to remove the condition constituting such Force Majeure. The Party affected by such Force Majeure also shall notify the other Party of the anticipated duration of such Force Majeure and any actions being taken to avoid or minimize its effect after such occurrence. For purposes of this Agreement, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include conditions beyond the reasonable control of the Parties, including an act of God, acts of terrorism, voluntary or involuntary compliance with any regulation, law or order of any government, war, acts of war (whether war be declared or not), labor strike or lockout, civil commotion, epidemic or pandemic arising after the Effective Date, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the affected Party promptly notifies the other Party in writing stating the nature of the cause of non-performance, its anticipated duration and any action being taken to avoid or minimize its effect. The affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and to mitigate the effect of such occurrence </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 102 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and shall continue performance in accordance with the terms of this Agreement whenever such causes are removed. The nonperforming Party shall promptly provide notice of such resumed performance to the other Party. The payment of invoices due and owing hereunder shall in no event be delayed by the payer because of a Force Majeure affecting the payer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.5&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.5</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Notices), and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable international expedited delivery service, or (b) five (5) Business Days after mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested.</font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Schr&#1255;dinger&#58;&#160;&#160;&#160;&#160;Schr&#1255;dinger, Inc.</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1540 Broadway, 24th Floor</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York, 10036</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; General Counsel</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With a copy to&#58;&#160;&#160;&#160;&#160;Ice Miller LLP</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1500 Broadway #2900</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, NY 10036</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; &#91;**&#93;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Novartis&#58;&#160;&#160;&#160;&#160;Novartis Pharma AG</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Lichtstrasse 35 </font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CH-4056 Basel, Switzerland</font></div><div style="padding-left:162pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Head of CB&#38;D</font></div><div style="padding-left:126pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; &#91;**&#93;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With a copy to&#58;&#160;&#160;&#160;&#160;Novartis Pharma AG</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Lichtstrasse 35 </font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      CH-4056 Basel, Switzerland</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Attention&#58; Global Head of Legal Transactions</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Email&#58; &#91;**&#93;</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:108pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Novartis Pharma AG</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Lichtstrasse 35 </font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      CH-4056 Basel, Switzerland</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      Attention&#58; Head of BD&#38;L</font></div><div style="padding-left:144pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">      &#91;**&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furthermore, a copy of any notices required or given under </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Enforcement of Product Specific Patents and Joint Patents) of this Agreement shall also be addressed to the </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 103 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Senior Vice President, Innovation Law of Novartis at the address set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.5(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Enforcement of Product Specific Patents and Joint Patents).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.6&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Independent Contractors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.7&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Maintenance of Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall maintain complete and accurate records of all work conducted under this Agreement and all results, data and developments made pursuant to its efforts under this Agreement. Such records shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance of this Agreement in sufficient detail and in good scientific manner appropriate for Patent and regulatory purposes. Each Party shall keep and maintain all records required by Applicable Law with respect to Collaboration Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.8&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Third Party Beneficiaries</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as expressly set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article 15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Indemnification and Limitation of Liability), there are no express or implied Third Party beneficiaries hereunder. The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other Person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.9&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assignment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party may assign this Agreement or assign or transfer any rights or obligations hereunder without the prior written consent of the other, which consent will not be unreasonable withheld, conditioned or delayed, except that a Party may make such an assignment or transfer without the other Party&#8217;s consent (a) to any Affiliate of such Party, or (b) to any Third Party in connection with the sale of all or substantially all of the business or assets of such Party to which this Agreement relates (with such business and assets, in the case of Schr&#1255;dinger, to include ownership of or an exclusive license to the Licensed Technology with respect to the Collaboration Compounds and Collaboration Products and Product Specific Patents), whether in a merger, combination, reorganization, sale of stock, sale of assets, spin-off, or other transaction&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in each case (a) and (b) that the assigning Party provides written notice to the other Party of such assignment and the assignee shall have agreed in writing to be bound (or is otherwise required by operation of Applicable Law to be bound) in the same manner as such assigning Party hereunder. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Assignment) shall be null, void and of no legal effect. For clarity, the provisions of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Assignment) shall not apply to or encompass sublicensing of the rights licensed to a Party under this Agreement. Subject to the terms of this Agreement and without limiting </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.13</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Subcontracting), each Party and its Affiliates and, in the case of Novartis, its Sublicensees, shall have the right to enter into </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 104 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subcontracts in connection with the exercise of its rights and the performance of its obligations under this Agreement and this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (Assignment) shall not apply with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.10&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governing Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by and construed and enforced under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise make this Agreement subject to the substantive law of another jurisdiction. For clarification, any dispute relating to the inventorship, scope, validity, enforceability or infringement of any Patent right shall be governed by and construed and enforced in accordance with the Patent laws of the applicable jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.11&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance by Affiliates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of this Agreement, each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.12&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Further Actions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.13&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance with Applicable Law</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party shall comply with Applicable Law in the course of performing its obligations or exercising its rights pursuant to this Agreement. Notwithstanding anything to the contrary in this Agreement, neither Party nor any of its Affiliates shall be required to take, or shall be penalized for not taking, any action that such Person reasonably believes is not in compliance with Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.14&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Severability</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any one or more of the provisions of this Agreement are held to be invalid or unenforceable by an arbitrator or any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.15&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No Waiver</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 105 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.16&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interpretation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The captions and headings to this Agreement are for convenience only and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections or Exhibits mean the particular Articles, Sections or Exhibits of this Agreement and references to this Agreement include all Exhibits hereto. Unless context otherwise clearly requires, whenever used in this Agreement&#58; (a) the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; shall be construed as incorporating also the phrase &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;&#59; (b) the word &#8220;day&#8221; shall mean calendar day (unless Business Day is specified)&#59; (c) the word &#8220;notice&#8221; shall mean notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement&#59; (d) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement (including any Exhibits)&#59; (e) provisions that require that a Party, the Parties, or the JSC hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise&#59; (f) words of any gender include the other gender&#59; (g) words using the singular or plural number also include the plural or singular number, respectively&#59; (h) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof&#59; (i) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221; and (j) except where the context dictates otherwise &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and&#47;or&#8221;. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. This Agreement should be interpreted in its entirety and the fact that certain provisions of this Agreement may be cross-referenced in a Section shall not be deemed or construed to limit the application of other provisions of this Agreement to such Section and vice versa. In the event of a conflict or inconsistency between this Agreement and any Schedule, Appendix, or Exhibit hereto, the terms of this Agreement will apply&#59; provided that in the event of a conflict or inconsistency between this Agreement and either of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedules 3.7(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> or </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the terms of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.7(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 3.15</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall control, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.17&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counterparts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in counterparts with the same effect as if both Parties had signed the same document, each of which shall be deemed an original, shall be construed together and shall constitute one and the same instrument. This Agreement may be executed and delivered through the email of pdf copies of the executed Agreement.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#91;signature page follows&#93;</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 106 -</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i5d4cd516e50e4f6283a4b1e49242bc73_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">In Witness Whereof</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have caused this Agreement to be executed by their duly authorized representatives effective as of the Effective Date.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOVARTIS PHARMA AG</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Guillaume Vignon&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;Guillaume Vignon&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;Global Head of BD&#38;L Transactions&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ian James Hiscock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;Ian James Hiscock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;Head of Global IP Litigation and Transactions&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SCHR&#1254;DINGER, INC.</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Ramy Farid&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ramy Farid&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font><br></font></div><div style="padding-left:3.12pt;padding-right:3.12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;President &#38; CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">- 107 -</font></div><div style="padding-left:36pt"><font><br></font></div></div></div><div id="i5d4cd516e50e4f6283a4b1e49242bc73_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 13.6(b)(iii)(B)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Baseball Arbitration Terms</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1.&#160;&#160;&#160;&#160;Arbitration will be conducted in New York City, New York under the ICC Rules. To the extent the ICC Rules conflicts with the express language in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the express language in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall control. The Parties will appoint a single arbitrator to be selected by mutual agreement. If the Parties are unable to agree on an arbitrator within &#91;**&#93; after such matter is referred to baseball arbitration, the Parties will request that the ICC select the arbitrator satisfying the requirement of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The arbitrator will be a professional in business or licensing experienced in the supply of pharmaceutical products with at least &#91;**&#93; of experience in the pharmaceutical and life sciences industries, including the conduct of licensing arrangements (as applicable).</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2.&#160;&#160;&#160;&#160;The cost of the arbitration will be borne equally by the Parties. Except in a proceeding to enforce the results of the arbitration or as otherwise required by Applicable Law, neither Novartis nor Schr&#1255;dinger nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written agreement of Novartis and Schr&#1255;dinger.  </font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3.&#160;&#160;&#160;&#160;Within &#91;**&#93; after such matter is referred to arbitration, each Party will provide the arbitrator with its proposal and written memorandum in support of such proposal regarding the dispute, as well as any documentary evidence it wishes to provide in support thereof (each a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Brief</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the arbitrator will provide each Party&#8217;s Brief to the other Party after it receives it from both Parties.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4.&#160;&#160;&#160;&#160;Within &#91;**&#93; after a Party submits its Brief, the other Party will have the right to respond thereto. The response and any material in support thereof will be provided to the arbitrator and the other Party. </font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5.&#160;&#160;&#160;&#160;The arbitrator will have the right to meet with the Parties as necessary to inform the arbitrator&#8217;s determination and to perform independent research and analysis. Within &#91;**&#93; of the receipt by the arbitrator of both Parties&#8217; responses (or expiration of the &#91;**&#93; period if any Party fails to submit a response), the arbitrator will deliver his&#47;her decision regarding the dispute in writing.</font></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify;text-indent:-21.6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6.&#160;&#160;&#160;&#160;Notwithstanding any other provisions hereof, the arbitrator will select one Party&#8217;s proposal that the arbitrator determines best gives effect to the intent of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.6(b)(iii)(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The arbitrator will accept only one of the proposals submitted by the Parties (without making any changes to such proposal) and will render such proposal as the arbitrator&#8217;s final decision. The arbitrator will not have authority to reach any other </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:39.6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">decision. The arbitrator&#8217;s decision will be final and binding on the Parties, absent manifest error.  </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div></div></div><div id="i5d4cd516e50e4f6283a4b1e49242bc73_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>sdgr-20241231xexx191global.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5b7cdb6774744883b9f254133136bb25_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Approved by the Board of Directors on February 19, 2025</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCHR&#214;DINGER, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Global Insider Trading Policy</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND AND PURPOSE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Why Have We Adopted This Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#63;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The U.S. federal securities laws prohibit any member of the Board of Directors (a &#8220;Director&#8221;), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), an &#8220;executive officer&#8221;) or employee of Schr&#246;dinger, Inc. (together with its subsidiaries, the &#8220;Company&#8221;) from purchasing or selling Company securities on the basis of material nonpublic information concerning the Company, or from tipping material nonpublic information to others.  These laws impose severe sanctions on individuals who violate them.  In addition, the Securities and Exchange Commission (the &#8220;SEC&#8221;) has the authority to impose large fines on the Company and on the Company&#8217;s Directors, executive officers and controlling stockholders if the Company&#8217;s employees engage in insider trading and the Company has failed to take appropriate steps to prevent it (so-called &#8220;controlling person&#8221; liability).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This insider trading policy is being adopted in light of these legal requirements, and with the goal of helping&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">prevent inadvertent violations of the insider trading laws&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">avoid embarrassing proxy disclosure of reporting violations by persons subject to Section 16 of the Exchange Act&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">promote compliance with the Company&#8217;s obligation to publicly disclose information related to its insider trading policies and procedures and the use of certain trading arrangements by Company insiders&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">avoid the appearance of impropriety on the part of those employed by, or associated with, the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">protect the Company from controlling person liability&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">protect the reputation of the Company, its Directors and its employees.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As detailed below, this policy applies to family members and certain other persons and entities with whom Directors and employees have relationships.  While the provisions in Sections 2 and 3 of this policy are not applicable to transactions by the Company itself, transactions by the Company will only be made in accordance with applicable U.S. federal securities laws, including those relating to insider trading.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">What Type of Information is &#8220;Material&#8221;&#63;</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information concerning the Company is considered material if there is a substantial likelihood that a reasonable stockholder would consider the information important in making an investment decision with respect to the Company&#8217;s securities.  Stated another way, there must be a substantial likelihood that a reasonable stockholder would view the information as having significantly altered the &#8220;total mix&#8221; of information available about the Company.  Material information can include positive or negative information about the Company.  Information concerning any of the following subjects, or the Company&#8217;s plans with respect to any of these subjects, would often be considered material&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">the Company&#8217;s liquidity, cash burn rate, sales, revenues or earnings (including forecasts)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a significant merger or acquisition involving the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a change in control of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a significant licensing or collaboration agreement or serious discussions regarding such an agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a significant change in management or the Board of Directors of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">the public or private sale of a significant amount of securities of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a default on outstanding debt or preferred stock of the Company or a bankruptcy filing&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a new product release or a significant development, invention or discovery&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">information concerning U.S. Food and Drug Administration actions or other significant regulatory developments, including significant new clinical trial results&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">information concerning significant clinical trials or non-clinical studies, including the timing of and findings and data from such trials and studies&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">the loss, delay or gain of a significant contract, sale or order or other important development regarding customers, collaborators or suppliers&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">any litigation or disputes to which the Company may be a party&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a significant operational issue or investigation of a potential such issue, including cybersecurity incidents and product defects&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a conclusion by the Company or a notification from its independent auditor that any of the Company&#8217;s previously issued financial statements should no longer be relied upon&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a change in or disagreement (within the meaning of Item 304 of Regulation S-K) with the Company&#8217;s independent auditor&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">the Company&#8217;s decision to commence or terminate the payment of cash dividends&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">the establishment of a program to repurchase securities of the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">a stock split.       </font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This list is illustrative only and is not intended to provide a comprehensive list of circumstances that could give rise to material information.  If you have questions as to whether information is material or nonpublic as described below, please contact your supervisor, the Chief Financial Officer or the Chief Legal Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">When is Information &#8220;Nonpublic&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#63;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information concerning the Company is considered nonpublic if it has not been disseminated in a manner making it available to investors generally.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information will generally be considered nonpublic unless (1) the information has been disclosed in a press release, in a public filing made with the SEC (such as a Report on Form 10-K, Form 10-Q or Form 8-K), or through a news wire service or daily newspaper of wide circulation, and (2) a sufficient amount of time has passed so that the information has had an opportunity to be digested by the marketplace.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROHIBITIONS RELATING TO TRANSACTIONS IN THE COMPANY&#8217;S SECURITIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Section 2 applies to the following individuals and entities (collectively, &#8220;Covered Persons&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all Directors&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all employees&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all family members of Directors and employees who share the same address as, or are financially dependent on, the Director or employee and any other person who shares the same address as the Director or employee (other than (x) an employee or tenant of the Director or employee or (y) another unrelated person whom the Company&#8217;s Chief Legal Officer determines should not be covered by this policy)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all corporations, limited liability companies, partnerships, trusts or other entities controlled by any of the above Covered Persons, unless the entity has implemented policies or procedures designed to ensure that such Covered Person cannot influence transactions by the entity involving Company securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibition on Trading While Aware of Material Nonpublic Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as provided in Section&#160;4, no Covered Person may&#58;</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schr&#246;dinger GmbH applicability&#58; Employees of Schr&#246;dinger GmbH or those affiliated with Schr&#246;dinger GmbH may also contact the Managing Director of Schr&#246;dinger GmbH to provide guidance as to whether certain information is material or nonpublic.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">purchase, sell or gift (which term, as used in this policy, includes charitable donations) any securities of the Company while such Covered Person is aware of any material nonpublic information concerning the Company or recommend doing so to someone else&#59; or</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">tip or otherwise disclose to someone else any material nonpublic information concerning the Company if the recipient may use that information to purchase, sell or gift Company securities or tip that information to others.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, no Covered Person who, in the course of service to the Company, learns of material nonpublic information about another company (1) with which the Company does business, such as the Company&#8217;s distributors, vendors, customers and suppliers, or (2) that is involved in a potential transaction or business relationship with the Company, may purchase, sell or gift that other company&#8217;s securities until the information becomes public or is no longer material, or tip or otherwise disclose to someone else such information if the recipient may use that information to purchase, sell or gift that other company&#8217;s securities or tip that information to others.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Policy After Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If an individual or entity ceases to be a Covered Person at a time when such individual or entity is aware of material nonpublic information concerning the Company, the prohibitions on purchasing, selling and gifting of securities in Section&#160;2.2(a) shall continue to apply until that information has become public or is no longer material.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibition on Pledges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Covered Person may purchase Company securities on margin, borrow against Company securities held in a margin account, or pledge Company securities as collateral for a loan.  However, an exception may be granted in extraordinary situations where a Covered Person wishes to pledge Company securities as collateral for a loan (other than a margin loan) and clearly demonstrates the financial capacity to repay the loan without resort to the pledged securities.  Any Covered Person who wishes to pledge Company securities as collateral for a loan must submit a request for approval to the Chief Financial Officer or the Chief Legal Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In addition, any such request by a Director or executive officer must also be reviewed and approved by the Audit Committee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibition on Short Sales, Derivative Transactions and Hedging Transactions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> No Covered Person may engage in any of the following types of transactions with respect to Company securities&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">short sales, including short sales &#8220;against the box&#8221;&#59; or</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schr&#246;dinger GmbH applicability&#58; Any person covered by Section 2 employed by or affiliated with Schr&#246;dinger GmbH who wishes to pledge Company securities as collateral for a loan must submit a request for approval to the Managing Director of Schr&#246;dinger GmbH. The Managing Director of Schr&#246;dinger GmbH, following consultation with and agreement of the Chief Legal Officer or the Chief Financial Officer, may grant an exception.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">purchases or sales of puts, calls or other derivative securities&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">purchases of financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds) or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL PROHIBITIONS APPLICABLE TO DIRECTORS, EXECUTIVE OFFICERS AND DESIGNATED EMPLOYEES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Further Restricted Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Section 3 applies to the following Covered Persons, who are subject to certain additional restrictions as set forth herein (collectively, &#8220;Further Restricted Insiders&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all Directors&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all executive officers&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">such other employees as are designated from time to time by the Board of Directors, the Chief Executive Officer, the Chief Financial Officer or the Chief Legal Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as being subject to this Section 3 (the &#8220;Designated Employees&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all family members of Directors, executive officers and Designated Employees who share the same address as, or are financially dependent on, the Director, executive officer or Designated Employee and any other person who shares the same address as the Director, executive officer or Designated Employee (other than (x) an employee or tenant of the Director, executive officer or Designated Employee or (y) another unrelated person whom the Chief Legal Officer determines should not be covered by this policy)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all corporations, limited liability companies, partnerships, trusts or other entities controlled by any of the above Further Restricted Insiders, unless the entity has implemented policies or procedures designed to ensure that such Further Restricted Insider cannot influence transactions by the entity involving Company securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regular Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as provided in Section&#160;4, no Further Restricted Insider may purchase, sell or gift any securities of the Company during the period beginning two weeks prior to the end of each fiscal quarter and ending upon the completion of the second full trading day after the public announcement of earnings for such quarter (a &#8220;regular blackout period&#8221;).</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schr&#246;dinger GmbH applicability&#58; The Managing Director of Schr&#246;dinger GmbH may also designate, from time to time, Designated Employees.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate News Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may from time to time notify Directors, executive officers and other specified employees that an additional blackout period (a &#8220;corporate news blackout period&#8221;) is in effect in view of significant events or developments involving the Company.  In such event, except as provided in Section 4, no person who is notified of a corporate news blackout period may purchase, sell or gift any securities of the Company during such corporate news blackout period or inform anyone else that a corporate news blackout period is in effect.  (In this policy, regular blackout periods and corporate news blackout periods are each referred to as a &#8220;blackout period.&#8221;)</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Awareness of Material Non-Public Information when a Blackout Period is Not in Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Even if no blackout period is then in effect, if a Further Restricted Insider is aware of material nonpublic information the prohibitions contained in Section&#160;2.2(a) apply.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice and Pre-Clearance of Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Transaction Clearance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Further Restricted Insider may purchase, sell, gift, transfer, or otherwise acquire or dispose of securities of the Company,  either directly or indirectly, other than in a transaction permitted under Section 4, unless such Further Restricted Insider pre-clears the transaction with either the Chief Financial Officer or the Chief Legal Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  A request for pre-clearance shall be made in accordance with the procedures established by the Chief Legal Officer. The Chief Financial Officer and the Chief Legal Officer shall have sole discretion to decide whether to clear any contemplated transaction. (The Chief Legal Officer shall have sole discretion to decide whether to clear transactions by the Chief Financial Officer or by Further Restricted Insiders subject to this Section 3 as a result of their relationship with the Chief Financial Officer, and the Chief Financial Officer shall have sole discretion to decide whether to clear transactions by the Chief Legal Officer or by Further Restricted Insiders subject to this Section 3 as a result of their relationship with the Chief Legal Officer.)  All transactions that are pre-cleared must be effected within three business days of receipt of the pre-clearance unless a longer or shorter period has been specified by the Chief Legal Officer or the Chief Financial Officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> A pre-cleared transaction (or any portion of a pre-cleared transaction) that has not been effected during the three business day period must be pre-cleared again prior to execution.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notwithstanding receipt of pre-clearance, if the Further Restricted Insider becomes aware of material non-public information or becomes subject to a blackout period before the transaction is effected, the transaction may not be completed. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Post-Transaction Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Further Restricted Insider who is subject to reporting obligations under Section 16 of the Exchange Act shall also notify the Chief Financial Officer or the Chief Legal Officer (or such person&#8217;s designee) of the occurrence of any purchase, </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schr&#246;dinger GmbH applicability&#58; A Further Restricted Insider employed by or affiliated with Schr&#246;dinger GmbH must pre-clear transactions with the Managing Director of Schr&#246;dinger GmbH. The Managing Director of Schr&#246;dinger may, following consultation with and agreement of either the Chief Legal Officer or the Chief Financial Officer, pre-clear such transactions.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schr&#246;dinger GmbH applicability&#58; Following consultation with and agreement of the Chief Legal Officer or the Chief Financial Officer, the Managing Director of Schr&#246;dinger GmbH may specify a period longer or shorter than three business days to effect pre-cleared trades by persons employed by or affiliated with Schr&#246;dinger GmbH.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">sale, gift, transfer, or other acquisition or disposition of securities of the Company as soon as possible following the transaction, but in any event within one business day after the transaction.  Such notification may be oral or in writing (including by e-mail) and should include the identity of the Further Restricted Insider, the type of transaction, the date of the transaction, the number of shares involved, the purchase or sale price, and whether the transaction was effected pursuant to a contract, instruction or written plan that is intended either to satisfy the affirmative defense conditions of Rule 10b5-1(c) (and if so, the date of adoption of such contract, instruction or written plan) or to constitute a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deemed Time of a Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For purposes of this Section 3.3, a purchase, sale, gift, transfer, or other acquisition or disposition shall be deemed to occur at the time the person becomes irrevocably committed to it (for example, in the case of an open market purchase or sale, this occurs when the trade is executed, not when it settles).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCEPTIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The prohibitions in Sections&#160;2.2(a) and 3.2 on purchasing, selling and gifting of Company securities do not apply to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations, in each case in a manner permitted by the applicable equity award agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the securities so acquired may not be sold (either outright or in connection with a &#8220;cashless&#8221; exercise transaction through a broker) while the Covered Person is aware of material nonpublic information or during an applicable blackout period&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">acquisitions or dispositions of Company common stock under the Company&#8217;s 401(k) or other individual account plan that are made pursuant to standing instructions, in a form approved by the Company, not entered into or modified while the Covered Person is aware of material nonpublic information or during an applicable blackout period&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">other purchases of securities from the Company (including purchases under the Company&#8217;s employee stock purchase plan pursuant to standing instructions, in a form approved by the Company) or sales of securities to the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if the transaction involves the exercise of stock options or other equity awards, the transaction must be permitted by the first bullet above&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">bona fide gifts that are approved in advance by the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">purchases, sales or gifts made pursuant to a binding contract, written plan or specific instruction which satisfies the applicable affirmative defense conditions of Rule 10b5-1(c), including as applicable the requirements applicable to an eligible sell-to-cover transaction as defined in Rule 10b5-1(c)(1)(ii)(D)(3), or for </font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which the affirmative defense is available under Rule 10b5-1(c) because such plan was adopted prior to February 27, 2023, met the affirmative defense conditions in effect at the time of adoption, and was not modified or changed on or after February 27, 2023 (a &#8220;trading plan&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> such trading plan&#58; (1) is in writing and (2) was submitted to the Company for review prior to its adoption&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">purchases, sales or gifts made pursuant to a binding contract, written plan or specific instruction which satisfies the definition of a &#8220;non-Rule 10b5-1 trading arrangement&#8221; as such term is defined in Item 408(c) of Regulation S-K, provided such non-Rule 10b5-1 trading arrangement&#58; (1) is in writing and (2) was submitted to the Company for review prior to its adoption.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Partnership Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this policy is intended to limit the ability of a venture capital partnership or other similar entity with which a Director is affiliated to distribute Company securities to its partners, members or other similar persons.  It is the responsibility of each affected Director and the affiliated entity, in consultation with their own counsel (as appropriate), to determine the timing of any distributions, based on all relevant facts and circumstances and applicable securities laws.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Underwritten Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this policy is intended to limit the ability of any Covered Person to sell Company securities as a selling stockholder in an underwritten public offering pursuant to an effective registration statement in accordance with applicable securities law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REGULATION BTR</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Company is required to impose a &#8220;pension fund blackout period&#8221; under Regulation&#160;BTR, each Director and executive officer shall not, directly or indirectly sell, purchase or otherwise transfer during such blackout period any equity securities of the Company acquired in connection with such person&#8217;s service as a Director or officer of the Company, except as permitted by Regulation&#160;BTR.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PENALTIES FOR VIOLATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Violation of any of the foregoing rules is grounds for disciplinary action by the Company, including termination of employment.  In addition to any disciplinary actions the Company may take, insider trading can also result in administrative, civil or criminal proceedings which can result in significant fines and civil penalties, being barred from service as an officer or director of a public company, or imprisonment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPANY ASSISTANCE AND EDUCATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Education</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall take reasonable steps designed to ensure that all Directors and employees of the Company are educated about, and periodically reminded of, the federal securities law restrictions and Company policies regarding insider trading.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall provide reasonable assistance to all Directors and executive officers, as requested by such Directors and executive officers, in connection with the filing of Forms 3, 4 and 5 under Section 16 of the Exchange Act.  However, the ultimate responsibility, and liability, for timely filing remains with the Directors and executive officers.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  None of the Company, the Chief Financial Officer, the Chief Legal Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or the Company&#8217;s other employees will have any liability for any delay in reviewing, or refusal of, a request to allow a pledge submitted pursuant to Section&#160;2.3, a request for pre-clearance submitted pursuant to Section 3.3(a) or a trading plan submitted pursuant to Section 4.1.  Notwithstanding any pre-clearance of a transaction pursuant to Section 3.3(a) or review of a trading plan pursuant to Section 4.1, none of the Company, the Chief Financial Officer, the Chief Legal Officer or the Company&#8217;s other employees assumes any liability for the legality or consequences of such transaction or trading plan to the person engaging in or adopting such transaction or trading plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Schr&#246;dinger GmbH applicability&#58; In addition to the above-listed individuals, the Managing Director of Schr&#246;dinger GmbH will not have any liability for any delay in reviewing, or refusal of, a request to allow a pledge submitted pursuant to Section 2.3, a request for pre-clearance submitted pursuant to Section 3.3(a) or a trading plan submitted pursuant to Section 4.1.</font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>sdgr-20241231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i93594d0462b14402a297d161a178c82f_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 21.1</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">List of Subsidiaries</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Name</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Schr&#246;dinger, LLC</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Schr&#246;dinger GmbH</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Synaptic Science LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Schr&#246;dinger, KK</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Reo Discovery Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Schr&#246;dinger Technologies Ltd</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Schr&#246;dinger India Private Limited</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Schrodinger Korea LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">South Korea</font></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>sdgr-20241231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i965259648ddf4d94af00f723a209e86a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Consent of Independent Registered Public Accounting Firm</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (Nos. 333-236297, 333-253864, 333-262982, 333-265696, 333-266533, 333-268131, and 333-281139) on Form S-8 and in the registration statement (No. 333-277479) on Form S-3 of our reports dated February 26, 2025, with respect to the consolidated financial statements of Schr&#246;dinger, Inc. and the effectiveness of internal control over financial reporting.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; KPMG LLP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Portland, Oregon<br>February&#160;26,&#160;2025</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>sdgr-20241231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if241e72e7ffe4625a1f4bfbfadace850_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Ramy Farid, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">I have reviewed this Annual Report on Form 10-K of Schr&#246;dinger, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:37.37pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:36.75pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:37.37pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:36.75pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:37.37pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:36.75pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; February&#160;26, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Ramy Farid</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ramy Farid</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>sdgr-20241231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia0bd5f4da2244b899ddc66228be25f86_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Geoffrey Porges, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">I have reviewed this Annual Report on Form 10-K of Schr&#246;dinger, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:37.37pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:36.75pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:37.37pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:36.75pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:37.37pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:162pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:162pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:36.75pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; February&#160;26, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey Porges</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Geoffrey Porges</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>sdgr-20241231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i75cd6a5cd64b4f3b8fb738d95739c4b5_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Schr&#246;dinger, Inc. (the &#8220;Company&#8221;) hereby certifies, to his knowledge, that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; February&#160;26, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Ramy Farid</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ramy Farid</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>sdgr-20241231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i62a2e28e088a42718693135d01b96229_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Schr&#246;dinger, Inc. (the &#8220;Company&#8221;) hereby certifies, to his knowledge, that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December&#160;31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.58pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; February&#160;26, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Geoffrey Porges</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Geoffrey Porges</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>sdgr-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:6d57be63-fef2-4aee-a5b8-ca771b86978e,g:704293bf-0912-4e44-b70a-e4f74457db02-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sdgr="http://www.schrodinger.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.schrodinger.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdgr-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdgr-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdgr-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdgr-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.schrodinger.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossIncome" roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome">
        <link:definition>9952154 - Statement - Consolidated Statements of Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952155 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.schrodinger.com/role/DescriptionofBusiness">
        <link:definition>9952157 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.schrodinger.com/role/SignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.schrodinger.com/role/RevenueRecognition">
        <link:definition>9952159 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.schrodinger.com/role/PropertyandEquipment">
        <link:definition>9952160 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.schrodinger.com/role/FairValueMeasurements">
        <link:definition>9952161 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.schrodinger.com/role/CommitmentsandContingencies">
        <link:definition>9952162 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.schrodinger.com/role/IncomeTaxes">
        <link:definition>9952163 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.schrodinger.com/role/StockholdersEquity">
        <link:definition>9952164 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.schrodinger.com/role/StockBasedCompensation">
        <link:definition>9952165 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders" roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders">
        <link:definition>9952166 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInvestments" roleURI="http://www.schrodinger.com/role/EquityInvestments">
        <link:definition>9952167 - Disclosure - Equity Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.schrodinger.com/role/EmployeeBenefitPlan">
        <link:definition>9952168 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.schrodinger.com/role/RelatedPartyTransactions">
        <link:definition>9952169 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.schrodinger.com/role/SegmentReporting">
        <link:definition>9952170 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.schrodinger.com/role/RevenueRecognitionTables">
        <link:definition>9955512 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.schrodinger.com/role/PropertyandEquipmentTables">
        <link:definition>9955513 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.schrodinger.com/role/FairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.schrodinger.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955515 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.schrodinger.com/role/IncomeTaxesTables">
        <link:definition>9955516 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.schrodinger.com/role/StockBasedCompensationTables">
        <link:definition>9955517 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables" roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables">
        <link:definition>9955518 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.schrodinger.com/role/SegmentReportingTables">
        <link:definition>9955519 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesDetails" roleURI="http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails">
        <link:definition>9955520 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails">
        <link:definition>9955521 - Disclosure - Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionSoftwareProductsandServicesDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails">
        <link:definition>9955522 - Disclosure - Revenue Recognition - Software Products and Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails">
        <link:definition>9955523 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDrugDiscoveryDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails">
        <link:definition>9955524 - Disclosure - Revenue Recognition - Drug Discovery (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails">
        <link:definition>9955525 - Disclosure - Revenue Recognition - Schedule of Drug Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionCollaborationandLicenseAgreementDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails">
        <link:definition>9955526 - Disclosure - Revenue Recognition - Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionCollaborationandLicenseAgreementDetails_1" roleURI="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails_1">
        <link:definition>9955526 - Disclosure - Revenue Recognition - Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofContractBalancesDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails">
        <link:definition>9955527 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>9955528 - Disclosure - Revenue Recognition- Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails_1" roleURI="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails_1">
        <link:definition>9955528 - Disclosure - Revenue Recognition- Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetails" roleURI="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
        <link:definition>9955529 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.schrodinger.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>9955530 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails" roleURI="http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails">
        <link:definition>9955531 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>9955532 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>9955533 - Disclosure - Commitments And Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesSummaryofOperatingLeasesDetails" roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails">
        <link:definition>9955534 - Disclosure - Commitments And Contingencies - Summary of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails">
        <link:definition>9955535 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1" roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1">
        <link:definition>9955535 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofIncomeTaxExpenseDetails" roleURI="http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails">
        <link:definition>9955536 - Disclosure - Income Taxes - Summary of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails" roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails">
        <link:definition>9955537 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails" roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails">
        <link:definition>9955538 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955539 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails" roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails">
        <link:definition>9955540 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9955541 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.schrodinger.com/role/StockholdersEquityDetails">
        <link:definition>9955542 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>9955543 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails" roleURI="http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails">
        <link:definition>9955544 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockActivityDetails" roleURI="http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails">
        <link:definition>9955545 - Disclosure - Stock-Based Compensation - Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails" roleURI="http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails">
        <link:definition>9955546 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>9955547 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails" roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails">
        <link:definition>9955548 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails" roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails">
        <link:definition>9955549 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInvestmentsDetails" roleURI="http://www.schrodinger.com/role/EquityInvestmentsDetails">
        <link:definition>9955550 - Disclosure - Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.schrodinger.com/role/EmployeeBenefitPlanDetails">
        <link:definition>9955551 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.schrodinger.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955552 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.schrodinger.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>9955553 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" roleURI="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails">
        <link:definition>9955554 - Disclosure - Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofRevenuesbyGeographicAreaDetails" roleURI="http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails">
        <link:definition>9955555 - Disclosure - Segment Reporting - Schedule of Revenues by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sdgr_LimitedCommonStockMember" abstract="true" name="LimitedCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_UnallocatedCommonStockMember" abstract="true" name="UnallocatedCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_UnbilledAndOtherReceivablesCurrent" abstract="false" name="UnbilledAndOtherReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_AllowanceForUnbilledReceivablesCurrent" abstract="false" name="AllowanceForUnbilledReceivablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_SoftwareProductsAndServicesMember" abstract="true" name="SoftwareProductsAndServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_DrugDiscoveryMember" abstract="true" name="DrugDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_InvestmentAmortizationNoncashExpense" abstract="false" name="InvestmentAmortizationNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" abstract="false" name="IncreaseDecreaseInUnbilledAndOtherReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" abstract="false" name="IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" abstract="false" name="NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" abstract="false" name="NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" abstract="false" name="NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" abstract="false" name="NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" abstract="false" name="BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" abstract="false" name="CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sdgr_RoyaltiesPolicyPolicyTextBlock" abstract="false" name="RoyaltiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" abstract="false" name="SoftwareDevelopmentCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" abstract="false" name="ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="sdgr_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sdgr_ContractAssetsMember" abstract="true" name="ContractAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sdgr_CommissionExpense" abstract="false" name="CommissionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_TimingOfRevenueRecognitionPercentage" abstract="false" name="TimingOfRevenueRecognitionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sdgr_OnPremiseSoftwareMember" abstract="true" name="OnPremiseSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_HostedSoftwareMember" abstract="true" name="HostedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" abstract="true" name="AgreementWithGatesVenturesLimitedLiabilityCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" abstract="true" name="July2024AgreementWithBillMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_RevenueArrangementsContractTerm" abstract="false" name="RevenueArrangementsContractTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sdgr_SoftwareContributionRevenueRecognitionAmount" abstract="false" name="SoftwareContributionRevenueRecognitionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_SoftwareContributionRevenueRecognized" abstract="false" name="SoftwareContributionRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sdgr_ProfessionalServicesMember" abstract="true" name="ProfessionalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" abstract="true" name="RevenueFromContractWithCustomerBeforeSoftwareContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_SoftwareContributionMember" abstract="true" name="SoftwareContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_DrugDiscoveryServicesMember" abstract="true" name="DrugDiscoveryServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_DrugDiscoveryContributionMember" abstract="true" name="DrugDiscoveryContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_MilestonePaymentYetToBeAchieved" abstract="false" name="MilestonePaymentYetToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_RevenueRecognizedForMilestonePayment" abstract="false" name="RevenueRecognizedForMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_NovartisPharmaAGMember" abstract="true" name="NovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_ResearchCollaborationAndLicenseAgreementMember" abstract="true" name="ResearchCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_SoftwareAgreementMember" abstract="true" name="SoftwareAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_OncologyNeurologyAndImmunologyProductMember" abstract="true" name="OncologyNeurologyAndImmunologyProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" abstract="false" name="ContractWithCustomerNumberOfSpecifiedBiologicalTargets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" abstract="false" name="ContractWithCustomerNumberOfNeurologyTargetRemaining" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sdgr_CollaborativeAgreementNumberOfPrograms" abstract="false" name="CollaborativeAgreementNumberOfPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sdgr_ContractWithCustomersPaymentTerms" abstract="false" name="ContractWithCustomersPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sdgr_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_CashCashEquivalentsAndRestrictedCashMember" abstract="true" name="CashCashEquivalentsAndRestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" abstract="false" name="FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" abstract="false" name="IncreaseInRightOfUseAssetsDueToContingencyResolution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_OperatingAndFinanceLeasePayments" abstract="false" name="OperatingAndFinanceLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" abstract="false" name="LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_OperatingAndFinanceLeaseLiability" abstract="false" name="OperatingAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" abstract="false" name="EffectiveIncomeTaxRateReconciliationSection162Limitation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" abstract="false" name="DeferredTaxLiabilitiesDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_VotingCommonStockMember" abstract="true" name="VotingCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_TheATMMember" abstract="true" name="TheATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_NumberOfVotesForCommonShare" abstract="false" name="NumberOfVotesForCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" abstract="false" name="SaleOfStockRemainingValueOfSharesAvailableForIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" abstract="false" name="RightToExchangeEachShareOfLimitedCommonStockToCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sdgr_TwentyTwentyStockPlanMember" abstract="true" name="TwentyTwentyStockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_SharebasedCompensationAwardTrancheFourMember" abstract="true" name="SharebasedCompensationAwardTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EligiblePerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" abstract="false" name="MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sdgr_PerformanceRestrictedStockUnitsMember" abstract="true" name="PerformanceRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sdgr_NimbusTherapeuticsLLCMember" abstract="true" name="NimbusTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_MorphicHoldingIncMember" abstract="true" name="MorphicHoldingIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_AjaxTherapeuticsIncMember" abstract="true" name="AjaxTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_StructureTherapeuticsMember" abstract="true" name="StructureTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_NumberOfPreferredSharesPurchased" abstract="false" name="NumberOfPreferredSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sdgr_NumberOfSharesPurchased" abstract="false" name="NumberOfSharesPurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sdgr_AmericanDepositorySharesPurchasedPricePerShare" abstract="false" name="AmericanDepositorySharesPurchasedPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="sdgr_BillAndMelindaGatesFoundationTrustMember" abstract="true" name="BillAndMelindaGatesFoundationTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_GatesVenturesLLCMember" abstract="true" name="GatesVenturesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_PercentageOfVotingSecurities" abstract="false" name="PercentageOfVotingSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="sdgr_SoftwareSegmentMember" abstract="true" name="SoftwareSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_DrugDiscoverySegmentMember" abstract="true" name="DrugDiscoverySegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="sdgr_UnallocatedAbstract" abstract="true" name="UnallocatedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sdgr_APACMember" abstract="true" name="APACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_RobertAbelMember" abstract="true" name="RobertAbelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sdgr_KarenAkinsanyaMember" abstract="true" name="KarenAkinsanyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>sdgr-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:6d57be63-fef2-4aee-a5b8-ca771b86978e,g:704293bf-0912-4e44-b70a-e4f74457db02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8bbe6005-be59-459e-bf7d-d183f41e1cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_59d02430-55c9-4c5e-80d7-993b236be968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8bbe6005-be59-459e-bf7d-d183f41e1cb3" xlink:to="loc_us-gaap_Liabilities_59d02430-55c9-4c5e-80d7-993b236be968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d142c09f-5dc5-4f72-925b-b8e78da40c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8bbe6005-be59-459e-bf7d-d183f41e1cb3" xlink:to="loc_us-gaap_StockholdersEquity_d142c09f-5dc5-4f72-925b-b8e78da40c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f3c999d6-810b-47df-a71e-942a4c6499a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8bbe6005-be59-459e-bf7d-d183f41e1cb3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f3c999d6-810b-47df-a71e-942a4c6499a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_367aed17-9736-4531-80fc-35481f712b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0b454644-57cc-438d-ab27-308b44f54a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_367aed17-9736-4531-80fc-35481f712b84" xlink:to="loc_us-gaap_PreferredStockValue_0b454644-57cc-438d-ab27-308b44f54a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6e1b25dd-1e5f-4953-bcc7-9940e88003c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_367aed17-9736-4531-80fc-35481f712b84" xlink:to="loc_us-gaap_CommonStockValue_6e1b25dd-1e5f-4953-bcc7-9940e88003c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ac52684-1663-4256-9e85-6708f0637d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_367aed17-9736-4531-80fc-35481f712b84" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ac52684-1663-4256-9e85-6708f0637d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2234477-923d-4ad4-a126-7c187f1fe832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_367aed17-9736-4531-80fc-35481f712b84" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2234477-923d-4ad4-a126-7c187f1fe832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff436ddb-7cd5-4ec8-95c6-83a6e9df8ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_367aed17-9736-4531-80fc-35481f712b84" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff436ddb-7cd5-4ec8-95c6-83a6e9df8ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4eb477cb-ae5e-4dd5-a0e1-45a694598eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4eb477cb-ae5e-4dd5-a0e1-45a694598eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_408b610d-0983-48ab-b675-49a8c7d092f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_408b610d-0983-48ab-b675-49a8c7d092f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_09f6c0ca-be21-4328-bb21-7749529e3f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:to="loc_us-gaap_Goodwill_09f6c0ca-be21-4328-bb21-7749529e3f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f1d8923-7111-4843-8d95-dcc4e2b4797c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:to="loc_us-gaap_AssetsCurrent_1f1d8923-7111-4843-8d95-dcc4e2b4797c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_745546ec-fd0f-4985-8cc2-57673c5a7ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:to="loc_us-gaap_EquityMethodInvestments_745546ec-fd0f-4985-8cc2-57673c5a7ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5d082fe5-1772-4013-92bb-1dab227ad3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c222c4c-fefa-4146-b7e2-a64586e6f879" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5d082fe5-1772-4013-92bb-1dab227ad3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e5ce9d9-7f96-4cdd-bd31-33a6dd94956f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e5ce9d9-7f96-4cdd-bd31-33a6dd94956f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2ff72c31-7896-4617-9d67-d3a64af85c46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:to="loc_us-gaap_RestrictedCashCurrent_2ff72c31-7896-4617-9d67-d3a64af85c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_557768af-db68-4a6a-92ec-033b9e92c6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_557768af-db68-4a6a-92ec-033b9e92c6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_08e832e3-5c05-421b-9d9c-840c0abce169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_08e832e3-5c05-421b-9d9c-840c0abce169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnbilledAndOtherReceivablesCurrent_9bdca341-4feb-4b8b-a848-033ff8e023ef" xlink:href="sdgr-20241231.xsd#sdgr_UnbilledAndOtherReceivablesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:to="loc_sdgr_UnbilledAndOtherReceivablesCurrent_9bdca341-4feb-4b8b-a848-033ff8e023ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_257d754e-5101-4ca4-bdff-98c5b8335c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9e50b447-e929-45a9-a8f0-3ad39f3188e9" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_257d754e-5101-4ca4-bdff-98c5b8335c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b76975a-7f8d-4962-8ae1-040d86666c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_46afce42-cc7c-4f3e-a0f7-efc52512a6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b76975a-7f8d-4962-8ae1-040d86666c9f" xlink:to="loc_us-gaap_AccountsPayableCurrent_46afce42-cc7c-4f3e-a0f7-efc52512a6b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_a33c0bf6-eb18-44d5-b47f-3e1d96300991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b76975a-7f8d-4962-8ae1-040d86666c9f" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_a33c0bf6-eb18-44d5-b47f-3e1d96300991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_763e3740-7d8d-4f34-8777-6f76fd112fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b76975a-7f8d-4962-8ae1-040d86666c9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_763e3740-7d8d-4f34-8777-6f76fd112fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_11bde8e5-5281-4671-a788-e649ee7cbfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b76975a-7f8d-4962-8ae1-040d86666c9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_11bde8e5-5281-4671-a788-e649ee7cbfdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_421ce110-3bf6-4580-8cd1-60d7bfbb978c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2b76975a-7f8d-4962-8ae1-040d86666c9f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_421ce110-3bf6-4580-8cd1-60d7bfbb978c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_de79e81d-da94-4acd-855a-af22e6646ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7fb0a9c1-8f96-4aba-991c-85af11379971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_de79e81d-da94-4acd-855a-af22e6646ed5" xlink:to="loc_us-gaap_LiabilitiesCurrent_7fb0a9c1-8f96-4aba-991c-85af11379971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_12080c2a-de9a-48a9-a15a-986e058a8df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_de79e81d-da94-4acd-855a-af22e6646ed5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_12080c2a-de9a-48a9-a15a-986e058a8df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_845d3a13-488d-49da-896f-407af1cf00da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_de79e81d-da94-4acd-855a-af22e6646ed5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_845d3a13-488d-49da-896f-407af1cf00da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1a3f6385-c63f-48aa-b8f6-895e976ca5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_de79e81d-da94-4acd-855a-af22e6646ed5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1a3f6385-c63f-48aa-b8f6-895e976ca5fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8765a616-6f2b-4ff6-9e98-8f750d61a576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_1f4f8448-9d3d-4258-99a8-bc35a304f362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8765a616-6f2b-4ff6-9e98-8f750d61a576" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_1f4f8448-9d3d-4258-99a8-bc35a304f362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_34f29ddd-a742-4fd1-a354-79f550077f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8765a616-6f2b-4ff6-9e98-8f750d61a576" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_34f29ddd-a742-4fd1-a354-79f550077f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_78ee5663-4986-45aa-909b-47dcae9ef154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8765a616-6f2b-4ff6-9e98-8f750d61a576" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_78ee5663-4986-45aa-909b-47dcae9ef154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eec693cd-8394-4e76-a659-74b743b33542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4fdf7d96-27be-4d95-815a-fe3cf1f64a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eec693cd-8394-4e76-a659-74b743b33542" xlink:to="loc_us-gaap_OperatingIncomeLoss_4fdf7d96-27be-4d95-815a-fe3cf1f64a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_de61c722-2ef2-40cb-b30b-f67d9ec36579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eec693cd-8394-4e76-a659-74b743b33542" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_de61c722-2ef2-40cb-b30b-f67d9ec36579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_61946340-597a-4859-b267-3e5b3f533524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5b2bdff4-a41e-465e-b482-1a10927f7a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_61946340-597a-4859-b267-3e5b3f533524" xlink:to="loc_us-gaap_GrossProfit_5b2bdff4-a41e-465e-b482-1a10927f7a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2388075b-5d65-4d9b-9913-b7e251a0aa05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_61946340-597a-4859-b267-3e5b3f533524" xlink:to="loc_us-gaap_OperatingExpenses_2388075b-5d65-4d9b-9913-b7e251a0aa05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_202a817d-93d1-43fa-8f6e-3c6a58175dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_545322ea-5396-4cf0-89f0-15b1fd62d5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_202a817d-93d1-43fa-8f6e-3c6a58175dcc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_545322ea-5396-4cf0-89f0-15b1fd62d5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ba82fca6-6387-490c-b1f5-d6510bbf31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_202a817d-93d1-43fa-8f6e-3c6a58175dcc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ba82fca6-6387-490c-b1f5-d6510bbf31fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_386d953b-9662-4994-9808-63d1a8dc8012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8b7c6aa5-806e-4430-99dd-c8932215a56c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_386d953b-9662-4994-9808-63d1a8dc8012" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8b7c6aa5-806e-4430-99dd-c8932215a56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_f35182a9-2f11-44a2-9540-b573b414228c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_386d953b-9662-4994-9808-63d1a8dc8012" xlink:to="loc_us-gaap_SellingAndMarketingExpense_f35182a9-2f11-44a2-9540-b573b414228c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6881945d-4074-459a-b9e3-366f6c658772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_386d953b-9662-4994-9808-63d1a8dc8012" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6881945d-4074-459a-b9e3-366f6c658772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9e0f4bbd-9c88-4190-9345-32eb85b15f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8d1d8f64-c4de-41d5-9242-93b3f3290b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9e0f4bbd-9c88-4190-9345-32eb85b15f2d" xlink:to="loc_us-gaap_Revenues_8d1d8f64-c4de-41d5-9242-93b3f3290b06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_2e9907c3-49f8-4c7d-8b47-1c6a224139ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9e0f4bbd-9c88-4190-9345-32eb85b15f2d" xlink:to="loc_us-gaap_CostOfRevenue_2e9907c3-49f8-4c7d-8b47-1c6a224139ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c97fef08-4583-4bc3-afa2-e279b724cfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3933e8ab-c13d-4874-a7e6-544954c7e7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c97fef08-4583-4bc3-afa2-e279b724cfc6" xlink:to="loc_us-gaap_NetIncomeLoss_3933e8ab-c13d-4874-a7e6-544954c7e7b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d142d869-9d1c-412e-af75-7f73895ff19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c97fef08-4583-4bc3-afa2-e279b724cfc6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d142d869-9d1c-412e-af75-7f73895ff19e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ffc8106-689f-45d0-b833-9b57b05cbc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_54e5516b-6612-41d6-8aea-edd13c6094d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ffc8106-689f-45d0-b833-9b57b05cbc8c" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_54e5516b-6612-41d6-8aea-edd13c6094d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_91e877fa-2e8f-4c3c-b002-fb5749f3b6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ffc8106-689f-45d0-b833-9b57b05cbc8c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_91e877fa-2e8f-4c3c-b002-fb5749f3b6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7ceeed15-5ff1-4c8d-af79-76e6fb0138c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ffc8106-689f-45d0-b833-9b57b05cbc8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7ceeed15-5ff1-4c8d-af79-76e6fb0138c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_74debb0f-b5b8-46dd-b6e3-26dfa3b067af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ffc8106-689f-45d0-b833-9b57b05cbc8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_74debb0f-b5b8-46dd-b6e3-26dfa3b067af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73d86dfb-aa1a-4e62-9336-63ae172e7236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73d86dfb-aa1a-4e62-9336-63ae172e7236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2b4d5c26-5e47-43be-abe3-38a48a12d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2b4d5c26-5e47-43be-abe3-38a48a12d51e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_ac4e5261-bf04-4fbf-901d-d0c6c287bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_ac4e5261-bf04-4fbf-901d-d0c6c287bfb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_354d820d-18a7-47f0-9ffb-c47e2ba5fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_354d820d-18a7-47f0-9ffb-c47e2ba5fd75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c3b4828d-765d-4eaf-aabf-b591de822485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c3b4828d-765d-4eaf-aabf-b591de822485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7fb8405f-fd38-48bb-9064-1b39296d5e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7fb8405f-fd38-48bb-9064-1b39296d5e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2e553e8a-1edb-463d-9e76-acf46781c6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_55fff5a1-b2ca-479a-9bee-e12d2552cedd" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2e553e8a-1edb-463d-9e76-acf46781c6dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_58d918d3-a84b-46db-a36e-a47012ad95db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_ProfitLoss_58d918d3-a84b-46db-a36e-a47012ad95db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d61013ed-f03a-472a-a314-6e1e67dc1694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d61013ed-f03a-472a-a314-6e1e67dc1694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2ad0d1bc-b7cb-4478-bd4e-15c201234f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2ad0d1bc-b7cb-4478-bd4e-15c201234f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_8b6ccd9d-fb97-4f5e-8e79-e5d7e0d6ed43" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_8b6ccd9d-fb97-4f5e-8e79-e5d7e0d6ed43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fe757d22-3a9f-44c3-847f-717dfc700207" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_fe757d22-3a9f-44c3-847f-717dfc700207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6d121b0f-5e14-46de-a091-c1b584e5cbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6d121b0f-5e14-46de-a091-c1b584e5cbfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_923decad-707f-4cad-a600-f6bb3120f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_923decad-707f-4cad-a600-f6bb3120f99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_1561aaeb-1744-4ade-ab73-6e5eaf522166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_1561aaeb-1744-4ade-ab73-6e5eaf522166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_548920a7-9436-4651-899d-49c838ebae04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_548920a7-9436-4651-899d-49c838ebae04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d0dd4e52-44b3-4d8c-b2a2-f2df8e4c36a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d0dd4e52-44b3-4d8c-b2a2-f2df8e4c36a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a0caa8fe-de6b-4c8e-9adf-7e620b42b3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_ShareBasedCompensation_a0caa8fe-de6b-4c8e-9adf-7e620b42b3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4c123215-b9d2-4f11-b3b8-682ff80d795a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4c123215-b9d2-4f11-b3b8-682ff80d795a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2e02398a-8e17-4112-96c9-790c7543698e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2e02398a-8e17-4112-96c9-790c7543698e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_ca2576c3-9471-4604-9e6d-a8dcd6c9dc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_ca2576c3-9471-4604-9e6d-a8dcd6c9dc8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_InvestmentAmortizationNoncashExpense_c4153a60-122f-49bb-ba19-21b806d9d06c" xlink:href="sdgr-20241231.xsd#sdgr_InvestmentAmortizationNoncashExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_sdgr_InvestmentAmortizationNoncashExpense_c4153a60-122f-49bb-ba19-21b806d9d06c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_c4e374e5-d11c-49b0-857f-81ae53c9c4f4" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c9e67f1-de70-47e7-8521-f0fd89e23605" xlink:to="loc_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_c4e374e5-d11c-49b0-857f-81ae53c9c4f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b416606f-23e6-48e7-9816-4f28324efb55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e42f9563-7f6f-4d83-83bb-b87e03ed98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b416606f-23e6-48e7-9816-4f28324efb55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e42f9563-7f6f-4d83-83bb-b87e03ed98b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_437ec9c1-449e-48fc-87b9-1a3e49d15949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b416606f-23e6-48e7-9816-4f28324efb55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_437ec9c1-449e-48fc-87b9-1a3e49d15949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ce92225-0432-4fa8-a497-0f0effb9d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b416606f-23e6-48e7-9816-4f28324efb55" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8ce92225-0432-4fa8-a497-0f0effb9d7a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofDrugRevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_778cdb40-9d93-47b1-91df-0a3b98475bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_c644571e-5fe9-4b54-a2d7-7173338bcc10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_778cdb40-9d93-47b1-91df-0a3b98475bb0" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_c644571e-5fe9-4b54-a2d7-7173338bcc10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71a28026-92c5-4695-96b8-6b93c4826fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_778cdb40-9d93-47b1-91df-0a3b98475bb0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_71a28026-92c5-4695-96b8-6b93c4826fd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_08c10cd5-c3f7-4e41-a2d0-6f2caa8d8243" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ba2a87ba-d5f8-4134-94f0-722c807984f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_08c10cd5-c3f7-4e41-a2d0-6f2caa8d8243" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ba2a87ba-d5f8-4134-94f0-722c807984f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c0d960b-88cb-4e05-91cf-e9b8048c10c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_08c10cd5-c3f7-4e41-a2d0-6f2caa8d8243" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6c0d960b-88cb-4e05-91cf-e9b8048c10c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b2b3a4c5-eda8-467c-9efb-cd249434f6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cb19ba88-d27e-4ed2-a470-85fd36e45119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b2b3a4c5-eda8-467c-9efb-cd249434f6a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cb19ba88-d27e-4ed2-a470-85fd36e45119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_065e87bb-57bd-46ba-b56f-66ee82367474" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b2b3a4c5-eda8-467c-9efb-cd249434f6a6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_065e87bb-57bd-46ba-b56f-66ee82367474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_dba3cbd6-dae4-4983-8eb2-1d6f5b284679" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiability_b9de42c3-e0b7-4165-8b00-cb320905d230" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_dba3cbd6-dae4-4983-8eb2-1d6f5b284679" xlink:to="loc_sdgr_OperatingAndFinanceLeaseLiability_b9de42c3-e0b7-4165-8b00-cb320905d230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_413f6851-3fc4-4ace-9fb9-0f3f333d6267" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_dba3cbd6-dae4-4983-8eb2-1d6f5b284679" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_413f6851-3fc4-4ace-9fb9-0f3f333d6267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiability_67c116eb-a2f0-4586-96e5-534d146f6810" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_e4a6229c-7126-4028-943a-09fcd583c66e" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_OperatingAndFinanceLeaseLiability_67c116eb-a2f0-4586-96e5-534d146f6810" xlink:to="loc_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_e4a6229c-7126-4028-943a-09fcd583c66e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_5223cf56-9280-4cd4-8a19-09ce7938ef04" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_OperatingAndFinanceLeaseLiability_67c116eb-a2f0-4586-96e5-534d146f6810" xlink:to="loc_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_5223cf56-9280-4cd4-8a19-09ce7938ef04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_8c9e2588-2841-4a53-a801-23b79485b5c0" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_8c9e2588-2841-4a53-a801-23b79485b5c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_0f9cbfdc-6e86-4433-a304-c7773f4ccf2c" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_0f9cbfdc-6e86-4433-a304-c7773f4ccf2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_c70d49e0-f558-405c-a1de-98af70f3323e" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_c70d49e0-f558-405c-a1de-98af70f3323e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_19240b09-5a98-439c-82ab-d219b27e3f06" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_19240b09-5a98-439c-82ab-d219b27e3f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_19f6d838-ba71-4029-92c1-a68ab36212d1" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_19f6d838-ba71-4029-92c1-a68ab36212d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_2512d26f-2fbd-481c-9ff0-9136ffaa33cb" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_9f6dfd2c-fc16-437c-b738-50880a1e407a" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_2512d26f-2fbd-481c-9ff0-9136ffaa33cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesSummaryofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61ffd8f6-c974-4d8f-8f5c-cb5562e93235" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3e2c5406-7cc9-40a1-ad51-ecf0802fa910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61ffd8f6-c974-4d8f-8f5c-cb5562e93235" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3e2c5406-7cc9-40a1-ad51-ecf0802fa910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_46eee7e8-274a-4602-8b13-6fd7b80ec287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61ffd8f6-c974-4d8f-8f5c-cb5562e93235" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_46eee7e8-274a-4602-8b13-6fd7b80ec287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7e651d1c-92f1-472f-a28d-05a0431e8f47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_61ffd8f6-c974-4d8f-8f5c-cb5562e93235" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7e651d1c-92f1-472f-a28d-05a0431e8f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_acd6c88f-35fb-4aff-b2c2-b880fa0bcc97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ac1106c3-884a-4f48-bf18-f97e64a645c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_acd6c88f-35fb-4aff-b2c2-b880fa0bcc97" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ac1106c3-884a-4f48-bf18-f97e64a645c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ebeb700a-692e-4dd0-97da-975318cc1615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_acd6c88f-35fb-4aff-b2c2-b880fa0bcc97" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_ebeb700a-692e-4dd0-97da-975318cc1615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2091869c-daa8-4c73-a8cf-4a9d5bc99968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_acd6c88f-35fb-4aff-b2c2-b880fa0bcc97" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2091869c-daa8-4c73-a8cf-4a9d5bc99968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f533da0-c834-402b-af7e-ad692156c901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_76ddf20b-4b75-43cd-a5f0-84f82037a032" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4f533da0-c834-402b-af7e-ad692156c901" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_76ddf20b-4b75-43cd-a5f0-84f82037a032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3f7b70c6-33b3-4abe-9baf-6d748d7b17f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4f533da0-c834-402b-af7e-ad692156c901" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3f7b70c6-33b3-4abe-9baf-6d748d7b17f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_be074eba-67d7-4f5f-bd63-ee2d50be5d24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d04ceee5-a6f2-4cc8-a21f-3ea71085a504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_be074eba-67d7-4f5f-bd63-ee2d50be5d24" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d04ceee5-a6f2-4cc8-a21f-3ea71085a504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c3c7bd29-6389-41d3-b309-baefcd4d097c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_be074eba-67d7-4f5f-bd63-ee2d50be5d24" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c3c7bd29-6389-41d3-b309-baefcd4d097c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_72d42323-b62f-444d-81ae-795a13649950" xlink:href="sdgr-20241231.xsd#sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_72d42323-b62f-444d-81ae-795a13649950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_de916220-d603-4595-9862-88dcec39d291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_de916220-d603-4595-9862-88dcec39d291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c4323510-803f-42ff-8215-08868d8621d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c4323510-803f-42ff-8215-08868d8621d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_9123c0c3-e3af-453e-a276-7800c80e1cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_9123c0c3-e3af-453e-a276-7800c80e1cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9512b643-7ea4-4568-86d1-fcae5e3270ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9512b643-7ea4-4568-86d1-fcae5e3270ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9a1d0ca4-ec70-46ec-bffb-85c17f095c48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9a1d0ca4-ec70-46ec-bffb-85c17f095c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_657dea7c-5cf8-4deb-9b99-0e5036a7960c" xlink:href="sdgr-20241231.xsd#sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_657dea7c-5cf8-4deb-9b99-0e5036a7960c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_29c8a792-a736-4d86-a8e6-a59a7038e592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_29c8a792-a736-4d86-a8e6-a59a7038e592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e16d1567-4ba1-47f5-9aa9-a2a916bb64d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f27d2551-2423-48bc-a134-61ba1f705eae" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e16d1567-4ba1-47f5-9aa9-a2a916bb64d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c419da55-9547-4df2-8c68-a6a8b75db7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a2c7c037-6bbb-4273-8509-f4fa98b399fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c419da55-9547-4df2-8c68-a6a8b75db7c4" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a2c7c037-6bbb-4273-8509-f4fa98b399fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_984fa084-c6d8-44b6-bdf0-2e63b41f8d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c419da55-9547-4df2-8c68-a6a8b75db7c4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_984fa084-c6d8-44b6-bdf0-2e63b41f8d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_fcaecb7e-5427-4121-b7cd-344467373d3c" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c419da55-9547-4df2-8c68-a6a8b75db7c4" xlink:to="loc_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_fcaecb7e-5427-4121-b7cd-344467373d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d2933e43-d8a7-4f97-92e0-427cff5fbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c419da55-9547-4df2-8c68-a6a8b75db7c4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d2933e43-d8a7-4f97-92e0-427cff5fbc74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d711ea55-0fda-4759-9431-f43acd502c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7addf199-15d0-4ff5-9202-b050b58be538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d711ea55-0fda-4759-9431-f43acd502c1d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7addf199-15d0-4ff5-9202-b050b58be538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_11de75ed-8b38-4276-8389-d79ca38b801e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d711ea55-0fda-4759-9431-f43acd502c1d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_11de75ed-8b38-4276-8389-d79ca38b801e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2cc964f1-ae38-4e5a-93fc-b479c1e91f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4cfa5439-14f1-40a4-a7a3-e63818874606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2cc964f1-ae38-4e5a-93fc-b479c1e91f4f" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4cfa5439-14f1-40a4-a7a3-e63818874606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ccdc78e-2495-4bb4-afa1-8b9479862ada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2cc964f1-ae38-4e5a-93fc-b479c1e91f4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ccdc78e-2495-4bb4-afa1-8b9479862ada" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"/>
  <link:calculationLink xlink:role="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15d9a995-5e60-4f52-af6f-3b68ac5dc068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15d9a995-5e60-4f52-af6f-3b68ac5dc068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6e8e82dc-7152-42d7-97b2-b872b750ca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6e8e82dc-7152-42d7-97b2-b872b750ca1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_5749a682-2b35-492a-bb3b-72b27d46dad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_SellingAndMarketingExpense_5749a682-2b35-492a-bb3b-72b27d46dad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_44d17f65-f0ae-4d55-9b66-eb7f5f8f85c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_GrossProfit_44d17f65-f0ae-4d55-9b66-eb7f5f8f85c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e1e0b333-8294-433d-b935-b27fe9aa326f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e1e0b333-8294-433d-b935-b27fe9aa326f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_211f77a5-4ab9-4ea1-828d-dc3270d1b15f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_211f77a5-4ab9-4ea1-828d-dc3270d1b15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1866d492-50f7-4bf2-a5d0-7063304d085c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1866d492-50f7-4bf2-a5d0-7063304d085c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f0516642-f016-4f6c-b1c2-8b429f1fc870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5d287f3d-dd98-4495-99a1-cfedb3a316be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f0516642-f016-4f6c-b1c2-8b429f1fc870" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>sdgr-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:6d57be63-fef2-4aee-a5b8-ca771b86978e,g:704293bf-0912-4e44-b70a-e4f74457db02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.schrodinger.com/role/Cover" xlink:type="simple" xlink:href="sdgr-20241231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:to="loc_us-gaap_ClassOfStockDomain_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:to="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_401f9c7d-701c-4da9-a21e-92ffd3316a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:to="loc_us-gaap_CommonStockMember_401f9c7d-701c-4da9-a21e-92ffd3316a8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_924333fb-13a5-4f5b-8863-e8bcda147fc5" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:to="loc_sdgr_LimitedCommonStockMember_924333fb-13a5-4f5b-8863-e8bcda147fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f31b8797-484a-4340-96f0-c2ad4e77d68f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentType_f31b8797-484a-4340-96f0-c2ad4e77d68f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_596a1f13-f177-4c47-bbe4-309a3de62814" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentAnnualReport_596a1f13-f177-4c47-bbe4-309a3de62814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_68e081e6-d06f-4042-957e-e4d4c15bbe6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentPeriodEndDate_68e081e6-d06f-4042-957e-e4d4c15bbe6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_81e6c05a-8b6a-4bda-91d2-162b546a6dfc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_CurrentFiscalYearEndDate_81e6c05a-8b6a-4bda-91d2-162b546a6dfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_853da971-0d49-4535-ba1e-c6ba8a7be496" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentTransitionReport_853da971-0d49-4535-ba1e-c6ba8a7be496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_600620a3-2600-48e7-82f7-54e3e5ba9073" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityFileNumber_600620a3-2600-48e7-82f7-54e3e5ba9073" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_82e502fd-abe4-4650-a5f9-a6e955559701" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityRegistrantName_82e502fd-abe4-4650-a5f9-a6e955559701" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6e3a2d4e-c073-49b5-a0e5-e0104dfeea78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6e3a2d4e-c073-49b5-a0e5-e0104dfeea78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f33793aa-3efb-4141-9a9d-dee838d01161" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityTaxIdentificationNumber_f33793aa-3efb-4141-9a9d-dee838d01161" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_61cb1497-e830-4424-8fb5-441cecc83db2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressAddressLine1_61cb1497-e830-4424-8fb5-441cecc83db2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_19a5c67d-6fde-4416-9e99-483f73e867a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressAddressLine2_19a5c67d-6fde-4416-9e99-483f73e867a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fc253eec-ae5a-4e10-91db-9b7c02437cc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressCityOrTown_fc253eec-ae5a-4e10-91db-9b7c02437cc1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0329d8e9-0ce0-494b-b627-4928d75eab2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressStateOrProvince_0329d8e9-0ce0-494b-b627-4928d75eab2f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_13f561be-067a-4f23-a582-f84642437ce3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressPostalZipCode_13f561be-067a-4f23-a582-f84642437ce3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ca232e01-0cb4-47db-afe9-e78cebb38a28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_CityAreaCode_ca232e01-0cb4-47db-afe9-e78cebb38a28" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_afa05d68-1612-453c-bf21-bbbfec086b77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_LocalPhoneNumber_afa05d68-1612-453c-bf21-bbbfec086b77" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bcca21c9-9dbb-44df-848f-573308b03a29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_Security12bTitle_bcca21c9-9dbb-44df-848f-573308b03a29" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_135c3ae3-c9ef-46a3-9c9d-b9f3d25ea26c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_TradingSymbol_135c3ae3-c9ef-46a3-9c9d-b9f3d25ea26c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c80944a1-8cb3-4014-8a55-2963fa7ada1f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_SecurityExchangeName_c80944a1-8cb3-4014-8a55-2963fa7ada1f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_87089e37-3d77-4dd5-b8b8-9ba42dec420e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_87089e37-3d77-4dd5-b8b8-9ba42dec420e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0d7373b8-d2c0-4734-bfd8-19effe046426" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityVoluntaryFilers_0d7373b8-d2c0-4734-bfd8-19effe046426" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d80d1505-07e3-4fb5-acbd-54979b786bd5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityCurrentReportingStatus_d80d1505-07e3-4fb5-acbd-54979b786bd5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_71b6fd2c-7128-412b-91d5-06b2b20b4ed0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityInteractiveDataCurrent_71b6fd2c-7128-412b-91d5-06b2b20b4ed0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0ec68b2f-0c72-4f62-9243-5cd40ef9a227" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityFilerCategory_0ec68b2f-0c72-4f62-9243-5cd40ef9a227" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dcbb5e07-3d8d-4309-a63c-4784300f204a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntitySmallBusiness_dcbb5e07-3d8d-4309-a63c-4784300f204a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a2c87f3-71c4-45af-a9bb-592b7dfbbac0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a2c87f3-71c4-45af-a9bb-592b7dfbbac0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f23df1f3-d529-459e-a883-fe1b1dffa9b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f23df1f3-d529-459e-a883-fe1b1dffa9b3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_fa7893a3-225d-40dd-91e1-6fab450057b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_fa7893a3-225d-40dd-91e1-6fab450057b5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_63a575b6-b22a-49ba-a788-0ffab4c6298c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityShellCompany_63a575b6-b22a-49ba-a788-0ffab4c6298c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_08b07d8a-8b62-40cc-993a-044a6047e013" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityPublicFloat_08b07d8a-8b62-40cc-993a-044a6047e013" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_73fc7bb5-74a8-45cc-86e7-f13f30d71c9c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_73fc7bb5-74a8-45cc-86e7-f13f30d71c9c" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_90da1453-566b-4c44-80a1-d3b349999458" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_90da1453-566b-4c44-80a1-d3b349999458" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_753cd0c7-36eb-4f9b-95ab-1aa0243f640e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AuditorFirmId_753cd0c7-36eb-4f9b-95ab-1aa0243f640e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6480e933-9b29-4995-9bb5-daac88d10e12" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AuditorName_6480e933-9b29-4995-9bb5-daac88d10e12" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6193efb4-4b81-4c5c-93ed-8cc86ac614df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AuditorLocation_6193efb4-4b81-4c5c-93ed-8cc86ac614df" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b85ce9eb-432b-448b-9cc2-e0804695b4fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityCentralIndexKey_b85ce9eb-432b-448b-9cc2-e0804695b4fc" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cbe865df-5fcf-4113-9096-494a053bd7b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentFiscalYearFocus_cbe865df-5fcf-4113-9096-494a053bd7b3" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_30ae1cb1-3780-4609-85cc-c91e7053d9a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_30ae1cb1-3780-4609-85cc-c91e7053d9a9" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_04055589-957b-44f1-b74d-f2a7d90660e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AmendmentFlag_04055589-957b-44f1-b74d-f2a7d90660e2" xlink:type="arc" order="38"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:to="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2badfdaa-a1f9-43eb-b462-dd32b0391463_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:to="loc_us-gaap_ClassOfStockDomain_2badfdaa-a1f9-43eb-b462-dd32b0391463_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:to="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedCommonStockMember_90c7812e-c395-438d-b910-cd5c061b3202" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:to="loc_sdgr_UnallocatedCommonStockMember_90c7812e-c395-438d-b910-cd5c061b3202" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_67721d13-9076-47ea-bffc-a6269ee8733e" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:to="loc_sdgr_LimitedCommonStockMember_67721d13-9076-47ea-bffc-a6269ee8733e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:to="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b589b543-0caf-4860-975d-47f85bc6ef18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b589b543-0caf-4860-975d-47f85bc6ef18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_0487d1dc-9f07-4740-83ca-8c2a5dafea5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_RestrictedCashCurrent_0487d1dc-9f07-4740-83ca-8c2a5dafea5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8fc3b091-4f75-445b-9701-5e8c67a466ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8fc3b091-4f75-445b-9701-5e8c67a466ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6d023f03-3bf8-4a49-95ad-c4da523e5c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6d023f03-3bf8-4a49-95ad-c4da523e5c94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnbilledAndOtherReceivablesCurrent_4a500d00-e77f-42ea-8eb6-9571f2a53754" xlink:href="sdgr-20241231.xsd#sdgr_UnbilledAndOtherReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_sdgr_UnbilledAndOtherReceivablesCurrent_4a500d00-e77f-42ea-8eb6-9571f2a53754" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1c323cbf-76a5-4c93-a569-175c5f373a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1c323cbf-76a5-4c93-a569-175c5f373a23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77513449-5550-43eb-a363-26968bc2408e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_AssetsCurrent_77513449-5550-43eb-a363-26968bc2408e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_cd502473-c7a3-4a82-a79f-c90e675f46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_cd502473-c7a3-4a82-a79f-c90e675f46dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dbafe339-b264-4400-a007-2550d76f653e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_EquityMethodInvestments_dbafe339-b264-4400-a007-2550d76f653e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4ade4f7d-556f-4b86-9d1c-f05102b45ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_Goodwill_4ade4f7d-556f-4b86-9d1c-f05102b45ba3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b6113ff-691c-4552-9ec0-bc70dcfcfd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b6113ff-691c-4552-9ec0-bc70dcfcfd3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_78af6b1d-8eb4-44e9-8f47-7309b52c3537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_78af6b1d-8eb4-44e9-8f47-7309b52c3537" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ab67a192-5646-4981-a869-8df88739b6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_Assets_ab67a192-5646-4981-a869-8df88739b6cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_30aa2042-578a-444c-9269-667ac04341b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_AccountsPayableCurrent_30aa2042-578a-444c-9269-667ac04341b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_535593cc-fd49-44b4-a109-3f0660fd9afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_535593cc-fd49-44b4-a109-3f0660fd9afa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83d5ef9-b47c-49f8-b776-01161596ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83d5ef9-b47c-49f8-b776-01161596ffe2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4271e012-c3ae-4fd6-92e1-de3721cc064c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4271e012-c3ae-4fd6-92e1-de3721cc064c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f587a829-28d6-469e-9115-8fcf454b592a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f587a829-28d6-469e-9115-8fcf454b592a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c196b3fc-6ffa-4177-9140-2a2bbabd5146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_LiabilitiesCurrent_c196b3fc-6ffa-4177-9140-2a2bbabd5146" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_91412875-12a5-4fc1-8183-65522951e5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_91412875-12a5-4fc1-8183-65522951e5a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d4aef5ae-2081-4a67-9350-4d4f42f5cc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d4aef5ae-2081-4a67-9350-4d4f42f5cc7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_53ca599a-a476-472d-be7b-f106ce80f605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_53ca599a-a476-472d-be7b-f106ce80f605" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_76ab264e-3d66-42c7-b3b6-3f440c6489d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_Liabilities_76ab264e-3d66-42c7-b3b6-3f440c6489d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0265d064-327c-4af7-b968-4c8ae86eac40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0265d064-327c-4af7-b968-4c8ae86eac40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5f994bd4-8ea4-4363-b470-84f42004e55d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_PreferredStockValue_5f994bd4-8ea4-4363-b470-84f42004e55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1c0a4521-85f6-4914-a952-3bea6170dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_CommonStockValue_1c0a4521-85f6-4914-a952-3bea6170dfbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7e7f6912-46a5-4484-aab1-d9a146428612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7e7f6912-46a5-4484-aab1-d9a146428612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5da51403-bb6e-4a6e-b032-ab23f64fc745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5da51403-bb6e-4a6e-b032-ab23f64fc745" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20cb61a6-5f6e-475b-a445-0a6c2f4c27f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20cb61a6-5f6e-475b-a445-0a6c2f4c27f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93e0f0ff-d4f6-4f28-a341-84e3ddeabdce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_StockholdersEquity_93e0f0ff-d4f6-4f28-a341-84e3ddeabdce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8854ad1f-dec0-4722-9765-e5004bf227c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8854ad1f-dec0-4722-9765-e5004bf227c9" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7aa35da4-6d69-4600-ba84-ba84249a77d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:to="loc_us-gaap_ClassOfStockDomain_7aa35da4-6d69-4600-ba84-ba84249a77d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:to="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedCommonStockMember_77306251-edc6-4c8b-b083-271c821c0d9b" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:to="loc_sdgr_UnallocatedCommonStockMember_77306251-edc6-4c8b-b083-271c821c0d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_c4307e61-22ae-45a4-bcc4-d3113b3a4fc2" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:to="loc_sdgr_LimitedCommonStockMember_c4307e61-22ae-45a4-bcc4-d3113b3a4fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bedee1d1-a464-465a-a25e-5914f94dbac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bedee1d1-a464-465a-a25e-5914f94dbac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AllowanceForUnbilledReceivablesCurrent_094d9e78-2b04-4c34-abbb-828edc7227c9" xlink:href="sdgr-20241231.xsd#sdgr_AllowanceForUnbilledReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_sdgr_AllowanceForUnbilledReceivablesCurrent_094d9e78-2b04-4c34-abbb-828edc7227c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d6d076ad-9017-4b39-b05c-5c7b0b0d4663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d6d076ad-9017-4b39-b05c-5c7b0b0d4663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bd53318a-3c79-41ce-a989-d850d93f5528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bd53318a-3c79-41ce-a989-d850d93f5528" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e6f510cc-8e1d-4321-87f6-cbf781a2148e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e6f510cc-8e1d-4321-87f6-cbf781a2148e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b0c72fa7-3f33-45ff-ab76-dc7ea1ef8a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b0c72fa7-3f33-45ff-ab76-dc7ea1ef8a98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5326e7e4-b4ff-4fcc-b559-5546b080af2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5326e7e4-b4ff-4fcc-b559-5546b080af2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e0c22d99-b2cf-4271-a5f2-e6b2d5df0a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e0c22d99-b2cf-4271-a5f2-e6b2d5df0a6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bbc73543-1471-4267-94f5-7253b66ed4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockSharesIssued_bbc73543-1471-4267-94f5-7253b66ed4f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5c66603d-43c8-4a46-987f-a6fcfad5953a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5c66603d-43c8-4a46-987f-a6fcfad5953a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:to="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_60ea5bd5-63db-4af3-84b0-4b3b0d917abb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:to="loc_srt_ProductsAndServicesDomain_60ea5bd5-63db-4af3-84b0-4b3b0d917abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:to="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_fbb56f0f-f20d-4997-8e76-105a870b1c37" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_fbb56f0f-f20d-4997-8e76-105a870b1c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_4a769e16-60f4-4aaa-9cf7-83897f589e3b" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:to="loc_sdgr_DrugDiscoveryMember_4a769e16-60f4-4aaa-9cf7-83897f589e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0f094472-1e6f-497d-a741-2efdda4b3d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_RevenuesAbstract_0f094472-1e6f-497d-a741-2efdda4b3d63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5229c4fc-81b6-41b8-8269-d168e0372ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_0f094472-1e6f-497d-a741-2efdda4b3d63" xlink:to="loc_us-gaap_Revenues_5229c4fc-81b6-41b8-8269-d168e0372ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_17e75db3-2eda-47fc-be39-6d8663f897fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:to="loc_us-gaap_CostOfRevenue_17e75db3-2eda-47fc-be39-6d8663f897fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5587e3ff-88dd-4044-8b99-df62a7ec3646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:to="loc_us-gaap_GrossProfit_5587e3ff-88dd-4044-8b99-df62a7ec3646" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5daf019e-8f80-46f8-90fa-a8e7c8dfbcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5daf019e-8f80-46f8-90fa-a8e7c8dfbcf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_f4dc8afc-64d2-46b7-a521-cb623ada2afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_SellingAndMarketingExpense_f4dc8afc-64d2-46b7-a521-cb623ada2afd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_56d279ab-2dfb-4fa5-9326-c3c0f8272300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_56d279ab-2dfb-4fa5-9326-c3c0f8272300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cbdbe560-42c1-4f3f-ac3c-d3aa6fc1ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_OperatingExpenses_cbdbe560-42c1-4f3f-ac3c-d3aa6fc1ce44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0c73399-1edd-435c-a9f1-f6a3c264f425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_OperatingIncomeLoss_e0c73399-1edd-435c-a9f1-f6a3c264f425" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2fe39f55-4f18-4cc5-b026-3aa03af7e843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2fe39f55-4f18-4cc5-b026-3aa03af7e843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6ee68548-e198-47ac-8c8d-9bec2e391b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6ee68548-e198-47ac-8c8d-9bec2e391b94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8bb40712-1c14-4784-90dc-151033220670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8bb40712-1c14-4784-90dc-151033220670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_69f6a0e9-708a-45e6-82dc-ac5cc619fa72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_69f6a0e9-708a-45e6-82dc-ac5cc619fa72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_695e648f-f5b2-49fb-969e-ba57cb290856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_695e648f-f5b2-49fb-969e-ba57cb290856" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_13a15cb5-5508-4ec9-b689-a070c9fc5ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_13a15cb5-5508-4ec9-b689-a070c9fc5ad1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64ac421c-6647-4364-9965-cb7774d64a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_NetIncomeLoss_64ac421c-6647-4364-9965-cb7774d64a3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ae8d86fd-1edf-40e0-a2ce-9a6764fb8cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ae8d86fd-1edf-40e0-a2ce-9a6764fb8cc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_661ec555-97ff-4da3-89d7-93afcf7e76dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_661ec555-97ff-4da3-89d7-93afcf7e76dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_321f198c-2ff9-4c99-8eda-466d706bb8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_321f198c-2ff9-4c99-8eda-466d706bb8cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ade53e79-0b91-46f9-a269-2ea41d16dbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ade53e79-0b91-46f9-a269-2ea41d16dbf3" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ad4561d-5f98-4e64-8ad5-61855ea31e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6ad4561d-5f98-4e64-8ad5-61855ea31e8f" xlink:to="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46fb9653-6047-44e1-a497-d74851f83087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:to="loc_us-gaap_EquityComponentDomain_46fb9653-6047-44e1-a497-d74851f83087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:to="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c1834df7-0468-4415-9286-c943ca0d06ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_CommonStockMember_c1834df7-0468-4415-9286-c943ca0d06ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_d9996570-6989-4134-860d-0f7768f789e1" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_sdgr_LimitedCommonStockMember_d9996570-6989-4134-860d-0f7768f789e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d0e6bc31-31bc-4fb4-a079-61c2ed2fab75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d0e6bc31-31bc-4fb4-a079-61c2ed2fab75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66b4ec6f-87ee-4654-b678-a3d4efda205e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_RetainedEarningsMember_66b4ec6f-87ee-4654-b678-a3d4efda205e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6fa8012-309e-465d-a302-c244e5cde099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6fa8012-309e-465d-a302-c244e5cde099" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ad4561d-5f98-4e64-8ad5-61855ea31e8f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ff7a4d31-34ec-45cf-89df-ab22885bdb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_SharesOutstanding_ff7a4d31-34ec-45cf-89df-ab22885bdb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1640932f-d842-473b-b85a-4a143dd08c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockholdersEquity_1640932f-d842-473b-b85a-4a143dd08c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_9382e6c1-ec4f-405f-9b4f-d41856cc3ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_9382e6c1-ec4f-405f-9b4f-d41856cc3ac5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ae2a666-fa99-4cef-9cab-c1a8ac431167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ae2a666-fa99-4cef-9cab-c1a8ac431167" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5679257-9b56-40c1-9682-52a5b2701c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5679257-9b56-40c1-9682-52a5b2701c4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7ab1fc24-7bb3-4699-b8d0-7f1a5d286e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7ab1fc24-7bb3-4699-b8d0-7f1a5d286e78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b0c8496f-5004-42fe-851e-334fd8832a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b0c8496f-5004-42fe-851e-334fd8832a3b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_f714593f-5644-4ef0-85a0-d8ca8ce27f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_f714593f-5644-4ef0-85a0-d8ca8ce27f63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b05394a6-9a92-4937-9544-7f473f44f76c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b05394a6-9a92-4937-9544-7f473f44f76c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d6a79b9-b63c-4ece-8a01-1f62c798f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d6a79b9-b63c-4ece-8a01-1f62c798f2cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_58e03a9f-970e-4577-9dc0-54e7b4e45706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_58e03a9f-970e-4577-9dc0-54e7b4e45706" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28a9d402-425c-4ed3-b126-89454031e647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_ProfitLoss_28a9d402-425c-4ed3-b126-89454031e647" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2ddafb4b-a1d6-478d-9243-44558e6d3192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_28579bd6-4420-4baa-a814-99c4321df805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:href="sdgr-20241231.xsd#sdgr_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:href="sdgr-20241231.xsd#sdgr_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_265eaf55-6d28-4395-9f6e-681c5d3d9d37_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:to="loc_srt_RangeMember_265eaf55-6d28-4395-9f6e-681c5d3d9d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:to="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3e6ab68-7ff1-45a6-87f7-5bee91615acb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:to="loc_srt_MinimumMember_c3e6ab68-7ff1-45a6-87f7-5bee91615acb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0d06186-de4d-4014-9059-39ff7b87b57f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:to="loc_srt_MaximumMember_e0d06186-de4d-4014-9059-39ff7b87b57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e9f1aa7d-a333-4023-acdb-5b20eebfb714_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e9f1aa7d-a333-4023-acdb-5b20eebfb714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_746e26cc-cfad-4a9b-95d0-ef911078f50d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_746e26cc-cfad-4a9b-95d0-ef911078f50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_08018de8-d0a5-44bf-9fe6-30f59b906f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_746e26cc-cfad-4a9b-95d0-ef911078f50d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_08018de8-d0a5-44bf-9fe6-30f59b906f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3b9779c2-b4b4-48dc-9050-df1388e3b54a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3b9779c2-b4b4-48dc-9050-df1388e3b54a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2a8f2e2d-4274-4efc-a5e7-7fee083d8553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:to="loc_us-gaap_AccountsReceivableMember_2a8f2e2d-4274-4efc-a5e7-7fee083d8553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_26a56d62-7bd1-4370-8f02-75c360438405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:to="loc_us-gaap_SalesRevenueNetMember_26a56d62-7bd1-4370-8f02-75c360438405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractAssetsMember_d448f4c4-905a-4d6f-9ea6-268b2368a0c8" xlink:href="sdgr-20241231.xsd#sdgr_ContractAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:to="loc_sdgr_ContractAssetsMember_d448f4c4-905a-4d6f-9ea6-268b2368a0c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8e1c550e-a99f-4bfc-9759-04a76940c01c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:to="loc_srt_NameOfMajorCustomerDomain_8e1c550e-a99f-4bfc-9759-04a76940c01c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:to="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerAMember_46355834-dc95-4b3c-80bc-39a72aad73a2" xlink:href="sdgr-20241231.xsd#sdgr_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:to="loc_sdgr_CustomerAMember_46355834-dc95-4b3c-80bc-39a72aad73a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerBMember_3daf6c88-f86d-48f0-b925-d12522feb4df" xlink:href="sdgr-20241231.xsd#sdgr_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:to="loc_sdgr_CustomerBMember_3daf6c88-f86d-48f0-b925-d12522feb4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerCMember_04523304-b025-416b-9b8a-8c77efc7d95c" xlink:href="sdgr-20241231.xsd#sdgr_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:to="loc_sdgr_CustomerCMember_04523304-b025-416b-9b8a-8c77efc7d95c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_727a227c-f3c4-4d5b-aba4-0c34d4a94799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_727a227c-f3c4-4d5b-aba4-0c34d4a94799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_91be02a1-9f26-44c7-81b3-810b8acf962a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_InterestCostsCapitalized_91be02a1-9f26-44c7-81b3-810b8acf962a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4652dd7d-2ba3-4ea3-a4f1-588c19d84adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4652dd7d-2ba3-4ea3-a4f1-588c19d84adc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_7cd2e7d6-101f-4c24-a4d9-26c5bbb6f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_7cd2e7d6-101f-4c24-a4d9-26c5bbb6f56e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6f934913-e79e-4d89-9807-27d632d27d05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6f934913-e79e-4d89-9807-27d632d27d05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f7cc3c0c-5690-4219-b6db-0a7423c255cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f7cc3c0c-5690-4219-b6db-0a7423c255cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_ddf68eb1-fdaf-474f-9519-f19bc438858f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_RoyaltyExpense_ddf68eb1-fdaf-474f-9519-f19bc438858f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CommissionExpense_60b18346-efa9-4e19-89f2-631d303f09b4" xlink:href="sdgr-20241231.xsd#sdgr_CommissionExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_sdgr_CommissionExpense_60b18346-efa9-4e19-89f2-631d303f09b4" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7355fd12-5511-403c-969a-1e5287bae2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7355fd12-5511-403c-969a-1e5287bae2f4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:to="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4271c763-691c-4511-813f-51e63aaae5a1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:to="loc_srt_ProductsAndServicesDomain_4271c763-691c-4511-813f-51e63aaae5a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:to="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_fc44dcb6-e9cb-43cf-8402-74f55063cc07" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_fc44dcb6-e9cb-43cf-8402-74f55063cc07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_a156f91f-71b5-4a90-8e04-ef2c0ec45b82" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:to="loc_sdgr_DrugDiscoveryMember_a156f91f-71b5-4a90-8e04-ef2c0ec45b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_43b0dc8a-0261-47da-ac89-335cc2a369e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_43b0dc8a-0261-47da-ac89-335cc2a369e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_3be7660e-a343-4441-9402-fccc55c1e21c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:to="loc_us-gaap_TransferredOverTimeMember_3be7660e-a343-4441-9402-fccc55c1e21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TimingOfRevenueRecognitionPercentage_bec16de5-f842-4728-9b60-a3e0c9b98e77" xlink:href="sdgr-20241231.xsd#sdgr_TimingOfRevenueRecognitionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7355fd12-5511-403c-969a-1e5287bae2f4" xlink:to="loc_sdgr_TimingOfRevenueRecognitionPercentage_bec16de5-f842-4728-9b60-a3e0c9b98e77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionSoftwareProductsandServicesDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_704dca0d-fc5f-4fb5-803c-7350eb055c34_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:to="loc_srt_ProductsAndServicesDomain_704dca0d-fc5f-4fb5-803c-7350eb055c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:to="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OnPremiseSoftwareMember_26298917-5e37-4382-8454-f97f7e8a0dbb" xlink:href="sdgr-20241231.xsd#sdgr_OnPremiseSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:to="loc_sdgr_OnPremiseSoftwareMember_26298917-5e37-4382-8454-f97f7e8a0dbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_HostedSoftwareMember_54af6903-42c0-4a90-b518-831ab574d298" xlink:href="sdgr-20241231.xsd#sdgr_HostedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:to="loc_sdgr_HostedSoftwareMember_54af6903-42c0-4a90-b518-831ab574d298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_021f1706-ac46-435d-9397-e0de26e13c4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_021f1706-ac46-435d-9397-e0de26e13c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_a64fe287-d36c-4af4-9a14-32791abef2c9" xlink:href="sdgr-20241231.xsd#sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:to="loc_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_a64fe287-d36c-4af4-9a14-32791abef2c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_ecbd2fc9-5ed2-4d2b-9165-5b6d9f39baff" xlink:href="sdgr-20241231.xsd#sdgr_July2024AgreementWithBillMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:to="loc_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_ecbd2fc9-5ed2-4d2b-9165-5b6d9f39baff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b9f04d1c-c0b3-4e26-b609-caf8f8134224_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:to="loc_srt_RangeMember_b9f04d1c-c0b3-4e26-b609-caf8f8134224_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d0999db-4e31-4a66-afd4-12b688c39d01" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:to="loc_srt_RangeMember_6d0999db-4e31-4a66-afd4-12b688c39d01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ebbb22d-900d-4ae3-88de-499acdf94534" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6d0999db-4e31-4a66-afd4-12b688c39d01" xlink:to="loc_srt_MaximumMember_7ebbb22d-900d-4ae3-88de-499acdf94534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueArrangementsContractTerm_e9f261c9-fd8c-4220-b496-906813d910b3" xlink:href="sdgr-20241231.xsd#sdgr_RevenueArrangementsContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_RevenueArrangementsContractTerm_e9f261c9-fd8c-4220-b496-906813d910b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognitionAmount_46d7fe06-8985-4218-a1f1-35307db812eb" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognitionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_SoftwareContributionRevenueRecognitionAmount_46d7fe06-8985-4218-a1f1-35307db812eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognized_cd15ef79-7354-4b94-8de1-5e90b20c2bda" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_SoftwareContributionRevenueRecognized_cd15ef79-7354-4b94-8de1-5e90b20c2bda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_7fb455ad-e58a-43af-98fc-91aa627bb760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_us-gaap_DeferredIncome_7fb455ad-e58a-43af-98fc-91aa627bb760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_966535d2-9659-4351-9a19-5a7fcf87ddb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_966535d2-9659-4351-9a19-5a7fcf87ddb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeArrangementTerm_3cab91d7-b514-4250-9f87-84b4df446100" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_CollaborativeArrangementTerm_3cab91d7-b514-4250-9f87-84b4df446100" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:to="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7a2d4232-915a-4e4c-aa09-3a6ad3462de2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:to="loc_srt_ProductsAndServicesDomain_7a2d4232-915a-4e4c-aa09-3a6ad3462de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:to="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OnPremiseSoftwareMember_5b39c054-c1aa-4a50-8339-354268732652" xlink:href="sdgr-20241231.xsd#sdgr_OnPremiseSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_OnPremiseSoftwareMember_5b39c054-c1aa-4a50-8339-354268732652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_HostedSoftwareMember_f575bca9-975d-4d3f-b71e-f3c11850a3f0" xlink:href="sdgr-20241231.xsd#sdgr_HostedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_HostedSoftwareMember_f575bca9-975d-4d3f-b71e-f3c11850a3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaintenanceMember_3fac6aef-419a-4877-80b1-b2851dad949c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaintenanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_us-gaap_MaintenanceMember_3fac6aef-419a-4877-80b1-b2851dad949c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ProfessionalServicesMember_18be97a5-8f56-4cda-a1e8-698d0c123abe" xlink:href="sdgr-20241231.xsd#sdgr_ProfessionalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_ProfessionalServicesMember_18be97a5-8f56-4cda-a1e8-698d0c123abe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_a89493ff-9acc-4f0f-8b75-d557455375b4" xlink:href="sdgr-20241231.xsd#sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_a89493ff-9acc-4f0f-8b75-d557455375b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionMember_399d50b5-d81c-40a9-a8d9-cf59ce5b7c5e" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_SoftwareContributionMember_399d50b5-d81c-40a9-a8d9-cf59ce5b7c5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_4eb60c41-021c-4dd0-9a06-fb2b1ed9d797" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_4eb60c41-021c-4dd0-9a06-fb2b1ed9d797" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff2324c4-8f64-4220-9c90-47165bfd3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff2324c4-8f64-4220-9c90-47165bfd3bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_7242aa50-1983-4bc0-b2a1-013355cc82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_7242aa50-1983-4bc0-b2a1-013355cc82d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ed4c0e1d-cbd0-41c4-9b21-0ed6ae1f9402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_Revenues_ed4c0e1d-cbd0-41c4-9b21-0ed6ae1f9402" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionDrugDiscoveryDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:to="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb64d24f-b765-4d52-96ed-2e69f6c894dd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:to="loc_srt_ProductsAndServicesDomain_eb64d24f-b765-4d52-96ed-2e69f6c894dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:to="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_e75a78f0-7ff7-450b-8304-38621455f4a1" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_e75a78f0-7ff7-450b-8304-38621455f4a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember_36362e23-b94c-45f5-ac96-1d1b5e7f0946" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:to="loc_sdgr_DrugDiscoveryContributionMember_36362e23-b94c-45f5-ac96-1d1b5e7f0946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MilestonePaymentYetToBeAchieved_4b6c3da9-4c72-4c58-b8da-ac759528079f" xlink:href="sdgr-20241231.xsd#sdgr_MilestonePaymentYetToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_sdgr_MilestonePaymentYetToBeAchieved_4b6c3da9-4c72-4c58-b8da-ac759528079f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRecognizedForMilestonePayment_710d0899-1000-431f-b1b0-faa8c63fd788" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRecognizedForMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_sdgr_RevenueRecognizedForMilestonePayment_710d0899-1000-431f-b1b0-faa8c63fd788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_839cc282-80f4-46fe-9738-06cc8d6ed40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_us-gaap_DeferredRevenue_839cc282-80f4-46fe-9738-06cc8d6ed40e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofDrugRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:to="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_523c39d4-49f7-49de-9cae-96829150e388_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:to="loc_srt_ProductsAndServicesDomain_523c39d4-49f7-49de-9cae-96829150e388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:to="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_2f1c04a0-868f-433f-b4e0-8ecf7b1d722f" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:to="loc_sdgr_DrugDiscoveryMember_2f1c04a0-868f-433f-b4e0-8ecf7b1d722f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_1b43b0cb-59a8-46df-bd6d-7fc85401a3d9" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_1b43b0cb-59a8-46df-bd6d-7fc85401a3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember_2751a8e8-8107-46ab-a9b3-bc480f44fefe" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:to="loc_sdgr_DrugDiscoveryContributionMember_2751a8e8-8107-46ab-a9b3-bc480f44fefe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a660145-410e-4df9-afd9-f5040520fe8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a660145-410e-4df9-afd9-f5040520fe8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_662bbca0-999a-4559-8686-914fa1cb432b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_662bbca0-999a-4559-8686-914fa1cb432b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b714c940-e4ce-4de2-9020-884685ea3452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_Revenues_b714c940-e4ce-4de2-9020-884685ea3452" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionCollaborationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f95c195-ed06-4a79-8d86-b890f2a6ecb4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f95c195-ed06-4a79-8d86-b890f2a6ecb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BristolMyersSquibbMember_36288071-a928-4287-8be5-03c829023f65" xlink:href="sdgr-20241231.xsd#sdgr_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:to="loc_sdgr_BristolMyersSquibbMember_36288071-a928-4287-8be5-03c829023f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NovartisPharmaAGMember_438743d8-b8ca-4458-ac46-d129cb6856f6" xlink:href="sdgr-20241231.xsd#sdgr_NovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:to="loc_sdgr_NovartisPharmaAGMember_438743d8-b8ca-4458-ac46-d129cb6856f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e132d5d-6eb1-424f-ab6c-142bf6459266_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e132d5d-6eb1-424f-ab6c-142bf6459266_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember_05ffb3f8-7a54-4518-bed1-e4c2e37c08b5" xlink:href="sdgr-20241231.xsd#sdgr_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember_05ffb3f8-7a54-4518-bed1-e4c2e37c08b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareAgreementMember_93e49d4f-6804-4407-9dce-8c79757ad4eb" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_SoftwareAgreementMember_93e49d4f-6804-4407-9dce-8c79757ad4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborationAndLicenseAgreementMember_a571751d-58db-4beb-893e-29f7ad673a9d" xlink:href="sdgr-20241231.xsd#sdgr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_CollaborationAndLicenseAgreementMember_a571751d-58db-4beb-893e-29f7ad673a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1843cd90-7b41-4d2f-b769-7c191dec8fee_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:to="loc_srt_ProductsAndServicesDomain_1843cd90-7b41-4d2f-b769-7c191dec8fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:to="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OncologyNeurologyAndImmunologyProductMember_e3da75ed-a85a-4e81-85de-5b6460794bf9" xlink:href="sdgr-20241231.xsd#sdgr_OncologyNeurologyAndImmunologyProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_OncologyNeurologyAndImmunologyProductMember_e3da75ed-a85a-4e81-85de-5b6460794bf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_4924e42c-062e-4f9d-95a4-9a4ceb48f54e" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_4924e42c-062e-4f9d-95a4-9a4ceb48f54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_9f11c419-7b8a-4329-ae1c-49c5b3a21f9d" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_9f11c419-7b8a-4329-ae1c-49c5b3a21f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d1b0d29a-77c0-4b53-a063-bb789ea1173b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d1b0d29a-77c0-4b53-a063-bb789ea1173b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e483dc93-9c4d-48e0-9c94-dad24eee95e7" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e483dc93-9c4d-48e0-9c94-dad24eee95e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_7cc13806-8ce5-4622-9ee9-b4fbecd2f4e5" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_7cc13806-8ce5-4622-9ee9-b4fbecd2f4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_61d10e27-6732-4eb4-9876-602a160e72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerLiability_61d10e27-6732-4eb4-9876-602a160e72a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_584f07ac-de95-43d5-a295-db93bfcd5d08" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_584f07ac-de95-43d5-a295-db93bfcd5d08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_3fa41bb9-0d37-4da2-bbff-79ca0c38730a" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_3fa41bb9-0d37-4da2-bbff-79ca0c38730a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_dd5ff14f-ba47-4df9-b8cf-d5d951f5e46f" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_dd5ff14f-ba47-4df9-b8cf-d5d951f5e46f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f50ff65-5e9a-428f-bd43-833dfec6a030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f50ff65-5e9a-428f-bd43-833dfec6a030" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPerformanceObligations_9fedeaa5-93f2-4990-941f-3c9664318a23" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_NumberOfPerformanceObligations_9fedeaa5-93f2-4990-941f-3c9664318a23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeAgreementNumberOfPrograms_dd1fc96f-c4e9-4a6d-83f0-cf5552d3ebdd" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeAgreementNumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_CollaborativeAgreementNumberOfPrograms_dd1fc96f-c4e9-4a6d-83f0-cf5552d3ebdd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_63bc951b-57f2-48ed-b13f-c2faf491f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_63bc951b-57f2-48ed-b13f-c2faf491f8ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ef66e86-c1a8-4847-bdc0-40d49a848697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ef66e86-c1a8-4847-bdc0-40d49a848697" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_55b66fa9-3ac5-43bd-909c-0c2caf44290a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_55b66fa9-3ac5-43bd-909c-0c2caf44290a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fd416eb4-eaf5-416e-9796-81d38ab122f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fd416eb4-eaf5-416e-9796-81d38ab122f1" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails_1" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionCollaborationandLicenseAgreementDetails_1"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f95c195-ed06-4a79-8d86-b890f2a6ecb4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f95c195-ed06-4a79-8d86-b890f2a6ecb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BristolMyersSquibbMember_36288071-a928-4287-8be5-03c829023f65" xlink:href="sdgr-20241231.xsd#sdgr_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:to="loc_sdgr_BristolMyersSquibbMember_36288071-a928-4287-8be5-03c829023f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NovartisPharmaAGMember_438743d8-b8ca-4458-ac46-d129cb6856f6" xlink:href="sdgr-20241231.xsd#sdgr_NovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:to="loc_sdgr_NovartisPharmaAGMember_438743d8-b8ca-4458-ac46-d129cb6856f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e132d5d-6eb1-424f-ab6c-142bf6459266_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1e132d5d-6eb1-424f-ab6c-142bf6459266_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember_05ffb3f8-7a54-4518-bed1-e4c2e37c08b5" xlink:href="sdgr-20241231.xsd#sdgr_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember_05ffb3f8-7a54-4518-bed1-e4c2e37c08b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareAgreementMember_93e49d4f-6804-4407-9dce-8c79757ad4eb" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_SoftwareAgreementMember_93e49d4f-6804-4407-9dce-8c79757ad4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborationAndLicenseAgreementMember_a571751d-58db-4beb-893e-29f7ad673a9d" xlink:href="sdgr-20241231.xsd#sdgr_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_CollaborationAndLicenseAgreementMember_a571751d-58db-4beb-893e-29f7ad673a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1843cd90-7b41-4d2f-b769-7c191dec8fee_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:to="loc_srt_ProductsAndServicesDomain_1843cd90-7b41-4d2f-b769-7c191dec8fee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:to="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OncologyNeurologyAndImmunologyProductMember_e3da75ed-a85a-4e81-85de-5b6460794bf9" xlink:href="sdgr-20241231.xsd#sdgr_OncologyNeurologyAndImmunologyProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_OncologyNeurologyAndImmunologyProductMember_e3da75ed-a85a-4e81-85de-5b6460794bf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_4924e42c-062e-4f9d-95a4-9a4ceb48f54e" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_4924e42c-062e-4f9d-95a4-9a4ceb48f54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_9f11c419-7b8a-4329-ae1c-49c5b3a21f9d" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_9f11c419-7b8a-4329-ae1c-49c5b3a21f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e483dc93-9c4d-48e0-9c94-dad24eee95e7" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e483dc93-9c4d-48e0-9c94-dad24eee95e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_7cc13806-8ce5-4622-9ee9-b4fbecd2f4e5" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_7cc13806-8ce5-4622-9ee9-b4fbecd2f4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_61d10e27-6732-4eb4-9876-602a160e72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerLiability_61d10e27-6732-4eb4-9876-602a160e72a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_584f07ac-de95-43d5-a295-db93bfcd5d08" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_584f07ac-de95-43d5-a295-db93bfcd5d08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_3fa41bb9-0d37-4da2-bbff-79ca0c38730a" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_3fa41bb9-0d37-4da2-bbff-79ca0c38730a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_dd5ff14f-ba47-4df9-b8cf-d5d951f5e46f" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_dd5ff14f-ba47-4df9-b8cf-d5d951f5e46f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f50ff65-5e9a-428f-bd43-833dfec6a030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f50ff65-5e9a-428f-bd43-833dfec6a030" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPerformanceObligations_9fedeaa5-93f2-4990-941f-3c9664318a23" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_NumberOfPerformanceObligations_9fedeaa5-93f2-4990-941f-3c9664318a23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeAgreementNumberOfPrograms_dd1fc96f-c4e9-4a6d-83f0-cf5552d3ebdd" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeAgreementNumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_CollaborativeAgreementNumberOfPrograms_dd1fc96f-c4e9-4a6d-83f0-cf5552d3ebdd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_63bc951b-57f2-48ed-b13f-c2faf491f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_63bc951b-57f2-48ed-b13f-c2faf491f8ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ef66e86-c1a8-4847-bdc0-40d49a848697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ef66e86-c1a8-4847-bdc0-40d49a848697" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_55b66fa9-3ac5-43bd-909c-0c2caf44290a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_55b66fa9-3ac5-43bd-909c-0c2caf44290a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fd416eb4-eaf5-416e-9796-81d38ab122f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fd416eb4-eaf5-416e-9796-81d38ab122f1" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:to="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b412506b-d950-49a3-9cb0-fd058177811e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:to="loc_srt_ProductsAndServicesDomain_b412506b-d950-49a3-9cb0-fd058177811e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:to="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_7df20127-a83a-498c-bf60-af6e6557df02" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_7df20127-a83a-498c-bf60-af6e6557df02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_c0f0a859-bc9e-4475-9f09-860ebc7affc8" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:to="loc_sdgr_DrugDiscoveryMember_c0f0a859-bc9e-4475-9f09-860ebc7affc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_32fc898e-df09-46c3-9524-b0fd19451652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_32fc898e-df09-46c3-9524-b0fd19451652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_4b367769-6695-4ceb-8853-20b19a0ff1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueAndCreditsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_4b367769-6695-4ceb-8853-20b19a0ff1f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_15bd9c62-f74a-4dee-95b6-8137167b5ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_4b367769-6695-4ceb-8853-20b19a0ff1f6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_15bd9c62-f74a-4dee-95b6-8137167b5ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_93e5363f-073f-4441-bbd0-062b36216165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_93e5363f-073f-4441-bbd0-062b36216165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e64e47a3-4434-49d7-8ca1-e12be495f2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_93e5363f-073f-4441-bbd0-062b36216165" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e64e47a3-4434-49d7-8ca1-e12be495f2a0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:to="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_376ca333-2bee-4f66-b032-5779a4cfbb4c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:to="loc_srt_RangeMember_376ca333-2bee-4f66-b032-5779a4cfbb4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:to="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_784c9eeb-a195-45dd-915c-c60d01befd43" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:to="loc_srt_MinimumMember_784c9eeb-a195-45dd-915c-c60d01befd43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_96123c50-cf69-45a3-8a40-5a499dc8c9b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:to="loc_srt_MaximumMember_96123c50-cf69-45a3-8a40-5a499dc8c9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_003975ae-7de4-4516-bbd9-f091cdbd6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_003975ae-7de4-4516-bbd9-f091cdbd6ea2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_128df270-36b6-4db1-b875-293129eeb9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_128df270-36b6-4db1-b875-293129eeb9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_6e44867f-11f1-4f85-a129-a3e70d384172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_6e44867f-11f1-4f85-a129-a3e70d384172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b659d73b-fb51-4ffb-82ea-53915e0ea447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b659d73b-fb51-4ffb-82ea-53915e0ea447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomersPaymentTerms_28119f6e-785e-47ae-8cde-d562b485cf2f" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomersPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_sdgr_ContractWithCustomersPaymentTerms_28119f6e-785e-47ae-8cde-d562b485cf2f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails_1" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionContractBalancesDetails_1"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:to="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_376ca333-2bee-4f66-b032-5779a4cfbb4c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:to="loc_srt_RangeMember_376ca333-2bee-4f66-b032-5779a4cfbb4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:to="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_784c9eeb-a195-45dd-915c-c60d01befd43" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:to="loc_srt_MinimumMember_784c9eeb-a195-45dd-915c-c60d01befd43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_96123c50-cf69-45a3-8a40-5a499dc8c9b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:to="loc_srt_MaximumMember_96123c50-cf69-45a3-8a40-5a499dc8c9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_128df270-36b6-4db1-b875-293129eeb9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_128df270-36b6-4db1-b875-293129eeb9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_6e44867f-11f1-4f85-a129-a3e70d384172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_6e44867f-11f1-4f85-a129-a3e70d384172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b659d73b-fb51-4ffb-82ea-53915e0ea447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b659d73b-fb51-4ffb-82ea-53915e0ea447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomersPaymentTerms_28119f6e-785e-47ae-8cde-d562b485cf2f" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomersPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_sdgr_ContractWithCustomersPaymentTerms_28119f6e-785e-47ae-8cde-d562b485cf2f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_351b1ee6-b02f-4117-ac6c-84e85c2af571_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_351b1ee6-b02f-4117-ac6c-84e85c2af571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_09807f5a-28c8-46a1-a700-79ed9228c52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_us-gaap_ComputerEquipmentMember_09807f5a-28c8-46a1-a700-79ed9228c52e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5836a476-ea8c-450e-a5d9-d4e6e9aa4b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5836a476-ea8c-450e-a5d9-d4e6e9aa4b8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_dd3e96d9-5e3d-42a7-980d-ae3815e77226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_dd3e96d9-5e3d-42a7-980d-ae3815e77226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LabEquipmentMember_0f3ede10-1648-4c1f-9891-66ff7b19ebb9" xlink:href="sdgr-20241231.xsd#sdgr_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_sdgr_LabEquipmentMember_0f3ede10-1648-4c1f-9891-66ff7b19ebb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9acc546e-6c0d-4609-bf49-f002c640560f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9acc546e-6c0d-4609-bf49-f002c640560f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_8ab46f88-fc63-488f-be0b-21757ebc21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_8ab46f88-fc63-488f-be0b-21757ebc21ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b05f77d2-1805-4fa5-a537-2ba80a287082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b05f77d2-1805-4fa5-a537-2ba80a287082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6b9b5d88-bf90-4c2f-86d0-ac424772bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6b9b5d88-bf90-4c2f-86d0-ac424772bdc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_14121471-8abd-4cf3-a389-6934c32cf937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_14121471-8abd-4cf3-a389-6934c32cf937" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c045c0b2-efc9-4ce3-91b3-9c1a2a76a426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c045c0b2-efc9-4ce3-91b3-9c1a2a76a426" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f39d4cf3-296a-421e-a843-91b5e729386b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f39d4cf3-296a-421e-a843-91b5e729386b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1a634f54-4b22-4919-8947-854f35cf4fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1a634f54-4b22-4919-8947-854f35cf4fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_474ac1c0-7163-404b-bafb-aeebd58608c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_474ac1c0-7163-404b-bafb-aeebd58608c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2bdb779e-ce97-409e-98d8-a73f72efa028" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2bdb779e-ce97-409e-98d8-a73f72efa028" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2c49735d-8e4b-4a19-b2e8-e93433867f9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2c49735d-8e4b-4a19-b2e8-e93433867f9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CashCashEquivalentsAndRestrictedCashMember_b30042a1-f783-4258-adcd-4724042b034a" xlink:href="sdgr-20241231.xsd#sdgr_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:to="loc_sdgr_CashCashEquivalentsAndRestrictedCashMember_b30042a1-f783-4258-adcd-4724042b034a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesAssetsMember_6423288e-2888-4f76-a65f-0fa576871968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuritiesAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:to="loc_us-gaap_SecuritiesAssetsMember_6423288e-2888-4f76-a65f-0fa576871968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_0b4f1942-c2a1-4374-91f8-c679ffe2e486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_0b4f1942-c2a1-4374-91f8-c679ffe2e486" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d9b1f7b1-51b0-4811-ba54-328fffac93e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c045c0b2-efc9-4ce3-91b3-9c1a2a76a426" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d9b1f7b1-51b0-4811-ba54-328fffac93e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b6d7f594-b1bf-4daa-939d-5830fe744abb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b6d7f594-b1bf-4daa-939d-5830fe744abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f5946921-4d52-4afb-99eb-f5a5d971036a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:to="loc_us-gaap_DomesticCountryMember_f5946921-4d52-4afb-99eb-f5a5d971036a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d96702bc-b384-45a3-9e12-b0fedea0e5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d96702bc-b384-45a3-9e12-b0fedea0e5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9f78f1e-b5c9-4197-bf7a-c28f7868a5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9f78f1e-b5c9-4197-bf7a-c28f7868a5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c77d7096-bdfb-445f-8c79-2a36497d4487" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c77d7096-bdfb-445f-8c79-2a36497d4487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7f9fb74f-ee7e-47fe-b942-59c8444bdc94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7f9fb74f-ee7e-47fe-b942-59c8444bdc94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_63229e87-ee68-457d-abd8-ed3ccc0e0cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_63229e87-ee68-457d-abd8-ed3ccc0e0cfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_5dcfda09-618f-4af0-bcdf-e0def6837d11" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_5dcfda09-618f-4af0-bcdf-e0def6837d11" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4665344f-5790-40b4-bf3e-976cbab460b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:to="loc_us-gaap_ClassOfStockDomain_4665344f-5790-40b4-bf3e-976cbab460b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:to="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_VotingCommonStockMember_3b0bd756-0244-4ab5-9b03-401b4108f17a" xlink:href="sdgr-20241231.xsd#sdgr_VotingCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:to="loc_sdgr_VotingCommonStockMember_3b0bd756-0244-4ab5-9b03-401b4108f17a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_43def4af-f604-4aff-8603-4bde6b357a18" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:to="loc_sdgr_LimitedCommonStockMember_43def4af-f604-4aff-8603-4bde6b357a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_45f8804c-f303-46f0-818a-da15ee744024_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_45f8804c-f303-46f0-818a-da15ee744024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e5b5a81-c5f5-4815-97b3-5e448884201c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e5b5a81-c5f5-4815-97b3-5e448884201c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TheATMMember_0b283266-faca-4641-ac2f-d4d2dfee4a35" xlink:href="sdgr-20241231.xsd#sdgr_TheATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e5b5a81-c5f5-4815-97b3-5e448884201c" xlink:to="loc_sdgr_TheATMMember_0b283266-faca-4641-ac2f-d4d2dfee4a35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90969707-012b-4e0b-9e7a-68100db5a5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90969707-012b-4e0b-9e7a-68100db5a5b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e3d82bc8-09b7-4852-b5bc-154bb692a639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e3d82bc8-09b7-4852-b5bc-154bb692a639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfVotesForCommonShare_c05d2d2f-908c-4b5a-a272-6920c6560a10" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfVotesForCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_sdgr_NumberOfVotesForCommonShare_c05d2d2f-908c-4b5a-a272-6920c6560a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_adfdf453-f873-42fc-9985-7291a4d5fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_adfdf453-f873-42fc-9985-7291a4d5fbb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59e267ce-cfdf-4f07-b1e4-8951f1e6d481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59e267ce-cfdf-4f07-b1e4-8951f1e6d481" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49c3d6af-0768-44ce-8023-05c2d676538a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49c3d6af-0768-44ce-8023-05c2d676538a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_a9db738c-f44f-449f-9034-ed911233ee9a" xlink:href="sdgr-20241231.xsd#sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_a9db738c-f44f-449f-9034-ed911233ee9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_34528c4f-2ddd-4c05-88aa-6727b6d5b89b" xlink:href="sdgr-20241231.xsd#sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_34528c4f-2ddd-4c05-88aa-6727b6d5b89b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_debac3b1-fb0c-4d84-a60e-161f8c22a5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_debac3b1-fb0c-4d84-a60e-161f8c22a5f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d5f21e7-92fb-4ece-8946-497c4479f000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d5f21e7-92fb-4ece-8946-497c4479f000" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c0dd119-9569-4615-ad4d-c3a2be237f20_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:to="loc_srt_RangeMember_2c0dd119-9569-4615-ad4d-c3a2be237f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47d06c44-b1b6-42f6-a408-080967a1b2c0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:to="loc_srt_RangeMember_47d06c44-b1b6-42f6-a408-080967a1b2c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_480e5dd6-65a0-4fa0-8ee8-2304aa5a9360" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_47d06c44-b1b6-42f6-a408-080967a1b2c0" xlink:to="loc_srt_MaximumMember_480e5dd6-65a0-4fa0-8ee8-2304aa5a9360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0c61e148-50c6-40f6-bc82-b83ea07a0e3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:to="loc_us-gaap_PlanNameDomain_0c61e148-50c6-40f6-bc82-b83ea07a0e3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ba70581-6dd3-4c71-b088-f4bc0db4e37a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:to="loc_us-gaap_PlanNameDomain_9ba70581-6dd3-4c71-b088-f4bc0db4e37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TwentyTwentyStockPlanMember_8ae2e576-8c5e-42f7-a089-d7b15562b1d7" xlink:href="sdgr-20241231.xsd#sdgr_TwentyTwentyStockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9ba70581-6dd3-4c71-b088-f4bc0db4e37a" xlink:to="loc_sdgr_TwentyTwentyStockPlanMember_8ae2e576-8c5e-42f7-a089-d7b15562b1d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1a13fd93-33e7-42d1-9770-e6b34db510ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:to="loc_us-gaap_VestingDomain_1a13fd93-33e7-42d1-9770-e6b34db510ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:to="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_710315f0-1850-4ccb-ba35-ab007bec0481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_710315f0-1850-4ccb-ba35-ab007bec0481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b36f1502-44c3-4cfb-91fe-d73e04d72db6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b36f1502-44c3-4cfb-91fe-d73e04d72db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_4f356c26-68a5-4c48-b902-a9436f7e0d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_4f356c26-68a5-4c48-b902-a9436f7e0d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SharebasedCompensationAwardTrancheFourMember_9a9ad854-0417-491f-81df-38ac1158fc49" xlink:href="sdgr-20241231.xsd#sdgr_SharebasedCompensationAwardTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_sdgr_SharebasedCompensationAwardTrancheFourMember_9a9ad854-0417-491f-81df-38ac1158fc49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1800b953-acfe-4694-98d7-6066a147bb4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1800b953-acfe-4694-98d7-6066a147bb4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f2830bb-d5b1-4dc2-858a-a69dd17fc7df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f2830bb-d5b1-4dc2-858a-a69dd17fc7df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_ce4ecbfb-159d-4871-ac65-f4ffffa3cf12" xlink:href="sdgr-20241231.xsd#sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_ce4ecbfb-159d-4871-ac65-f4ffffa3cf12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PerformanceBasedRestrictedStockUnitsMember_0bf7bb55-08fc-4641-8740-f064da9e1e1e" xlink:href="sdgr-20241231.xsd#sdgr_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_sdgr_PerformanceBasedRestrictedStockUnitsMember_0bf7bb55-08fc-4641-8740-f064da9e1e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6fbff52d-403f-4208-a9db-f81709cb5ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6fbff52d-403f-4208-a9db-f81709cb5ed2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2b4a0aa-32f3-427f-a45d-cc0e920afcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2b4a0aa-32f3-427f-a45d-cc0e920afcf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_465b0f67-08fd-4b2f-968d-2d66fd89e03b" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_465b0f67-08fd-4b2f-968d-2d66fd89e03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_781e1194-0a3a-49f6-ab97-c832d3643f94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_781e1194-0a3a-49f6-ab97-c832d3643f94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8a598cd4-b905-4a3e-824c-1727fe369c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8a598cd4-b905-4a3e-824c-1727fe369c4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36afef19-d5c7-4ae9-b602-26b24339b1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36afef19-d5c7-4ae9-b602-26b24339b1b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_aaf6f320-e759-4e41-95f1-05c7946f02d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_aaf6f320-e759-4e41-95f1-05c7946f02d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6363921a-0fa9-4542-b33e-2039124a4140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6363921a-0fa9-4542-b33e-2039124a4140" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86046d21-a5d1-4185-83a3-1789d4b4771a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86046d21-a5d1-4185-83a3-1789d4b4771a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e5adf78b-df33-4eb2-95fe-149573f1a0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e5adf78b-df33-4eb2-95fe-149573f1a0cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3f91e16-7243-4ca9-b81e-b675d9cfb6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3f91e16-7243-4ca9-b81e-b675d9cfb6b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_e3799f6d-1a71-4f2f-a223-d522670f25b5" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_e3799f6d-1a71-4f2f-a223-d522670f25b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_97e3aea8-d9ee-4240-8758-929770e048ea" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_97e3aea8-d9ee-4240-8758-929770e048ea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2e7e0b9-61c2-4dba-8d4d-a62977056616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2e7e0b9-61c2-4dba-8d4d-a62977056616" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_545bbacb-9ff9-46cf-8d82-a653038b6d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_545bbacb-9ff9-46cf-8d82-a653038b6d27" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_a322f506-979d-46b1-9afd-52fa5d54a6d7" xlink:href="sdgr-20241231.xsd#sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_a322f506-979d-46b1-9afd-52fa5d54a6d7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_27644a3a-b33b-414a-bf4a-0a38e309647b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_27644a3a-b33b-414a-bf4a-0a38e309647b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43dec513-5482-48b2-869b-bf18cf2c9e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43dec513-5482-48b2-869b-bf18cf2c9e95" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_350f2272-d6d0-4cf6-8658-fb811fc74ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_350f2272-d6d0-4cf6-8658-fb811fc74ba2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf55a617-18ab-47fd-9073-b7b85c64cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf55a617-18ab-47fd-9073-b7b85c64cc55" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2fb98307-1cc3-4392-aa74-349b39bcc79b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2fb98307-1cc3-4392-aa74-349b39bcc79b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11c534ae-6bcf-46b8-bb5b-e3aae79ae8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11c534ae-6bcf-46b8-bb5b-e3aae79ae8c5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ae1ac56c-b49c-41ea-a1aa-2d63a1cd014f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ae1ac56c-b49c-41ea-a1aa-2d63a1cd014f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_655c9215-212f-444b-9e0f-30bb2670b8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_655c9215-212f-444b-9e0f-30bb2670b8cf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_204fd3ec-4f56-4d12-b5dc-47b798c17e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_204fd3ec-4f56-4d12-b5dc-47b798c17e0b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5f46a3a1-0358-474b-a84a-4c05e346bc72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5f46a3a1-0358-474b-a84a-4c05e346bc72" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37f34c00-3958-40a9-ae32-dbc0412c78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37f34c00-3958-40a9-ae32-dbc0412c78b4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5b03f31a-a5a8-421c-b292-77edf2069524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5b03f31a-a5a8-421c-b292-77edf2069524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_171028bb-8344-4b6e-b5a3-eb57cfa79373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_CostOfSalesMember_171028bb-8344-4b6e-b5a3-eb57cfa79373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bd16e87d-2972-4b23-a5da-00ba3cb0eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bd16e87d-2972-4b23-a5da-00ba3cb0eb6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_0fbdf3a0-c1d2-4fb5-91f7-875238b903d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_0fbdf3a0-c1d2-4fb5-91f7-875238b903d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6df5b946-4309-47c5-b83e-7e2e45b7dbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6df5b946-4309-47c5-b83e-7e2e45b7dbb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_69c20b46-a11e-4a47-96c9-bde910209616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37f34c00-3958-40a9-ae32-dbc0412c78b4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_69c20b46-a11e-4a47-96c9-bde910209616" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:to="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f610ae6-ebbd-4723-b02a-fab60c12badf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f610ae6-ebbd-4723-b02a-fab60c12badf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ec4909f4-cc4e-4090-b0f5-8f9a7281bc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:to="loc_us-gaap_RestrictedStockMember_ec4909f4-cc4e-4090-b0f5-8f9a7281bc65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PerformanceRestrictedStockUnitsMember_8d80f6c7-39b4-44b1-a3e6-4e427e6ce272" xlink:href="sdgr-20241231.xsd#sdgr_PerformanceRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:to="loc_sdgr_PerformanceRestrictedStockUnitsMember_8d80f6c7-39b4-44b1-a3e6-4e427e6ce272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c547b300-50e3-46fc-a196-2bae6144b237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c547b300-50e3-46fc-a196-2bae6144b237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5804e061-ab72-4961-a26b-502c5a23a3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5804e061-ab72-4961-a26b-502c5a23a3e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20de273f-b8ed-4ebf-96d0-16c46aa385c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20de273f-b8ed-4ebf-96d0-16c46aa385c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fadcaabc-530c-4f0a-b03a-12529fad26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fadcaabc-530c-4f0a-b03a-12529fad26bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fcc7c9b9-33e0-4ff0-a669-09f24cfbd2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b382871-992c-4905-b126-98366841160a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b382871-992c-4905-b126-98366841160a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_792ec0b1-0dd5-4129-a5c1-514155bff7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_792ec0b1-0dd5-4129-a5c1-514155bff7dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_55c83010-71d8-47eb-9f6e-a30f49c757a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_55c83010-71d8-47eb-9f6e-a30f49c757a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a6692c6-532d-4e52-b9a0-9848c53ce844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a6692c6-532d-4e52-b9a0-9848c53ce844" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b26a83e-9317-4344-9dc9-c8b7037e24fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/EquityInvestmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#EquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/EquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_47b0cd48-59f6-4176-ab86-83ddef32987f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:to="loc_us-gaap_ClassOfStockDomain_47b0cd48-59f6-4176-ab86-83ddef32987f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:to="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_84e4e7b4-8b7c-44c6-b3b4-ff4881522ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_84e4e7b4-8b7c-44c6-b3b4-ff4881522ee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_671e9423-2751-4ecd-89dc-557f04cfd1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_us-gaap_CommonStockMember_671e9423-2751-4ecd-89dc-557f04cfd1cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_51deb46b-d72e-4d0a-993e-7bc54df57bb6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_dei_AdrMember_51deb46b-d72e-4d0a-993e-7bc54df57bb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_b2e0cf9c-93b9-425b-ab59-d3ddbf71e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_b2e0cf9c-93b9-425b-ab59-d3ddbf71e5f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67c90c5-f7f0-40b9-9012-65524bb7cf16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a67c90c5-f7f0-40b9-9012-65524bb7cf16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NimbusTherapeuticsLLCMember_d94cb87c-9d53-4475-923b-7c78c6d69541" xlink:href="sdgr-20241231.xsd#sdgr_NimbusTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_NimbusTherapeuticsLLCMember_d94cb87c-9d53-4475-923b-7c78c6d69541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MorphicHoldingIncMember_a3309024-c88a-4666-a45a-643901bde90a" xlink:href="sdgr-20241231.xsd#sdgr_MorphicHoldingIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_MorphicHoldingIncMember_a3309024-c88a-4666-a45a-643901bde90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AjaxTherapeuticsIncMember_3c79d858-87ca-442f-a969-07a4ceebe7ac" xlink:href="sdgr-20241231.xsd#sdgr_AjaxTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_AjaxTherapeuticsIncMember_3c79d858-87ca-442f-a969-07a4ceebe7ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_StructureTherapeuticsMember_4cda5ddc-47fb-43e3-8fc1-fe012e218e15" xlink:href="sdgr-20241231.xsd#sdgr_StructureTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_StructureTherapeuticsMember_4cda5ddc-47fb-43e3-8fc1-fe012e218e15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f1889488-ed0a-4738-9d73-7993865ea1b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f1889488-ed0a-4738-9d73-7993865ea1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_StructureTherapeuticsMember_4f715933-31b8-44aa-83bc-a225c39daf5f" xlink:href="sdgr-20241231.xsd#sdgr_StructureTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f1889488-ed0a-4738-9d73-7993865ea1b2" xlink:to="loc_sdgr_StructureTherapeuticsMember_4f715933-31b8-44aa-83bc-a225c39daf5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_3ef2a821-d821-4a61-a7b2-908d4b862791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_3ef2a821-d821-4a61-a7b2-908d4b862791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0d237f89-c9c1-4728-baf5-d38d2d89bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0d237f89-c9c1-4728-baf5-d38d2d89bc03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_19d9bcdb-84f2-4864-a682-9f5a5b919b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_19d9bcdb-84f2-4864-a682-9f5a5b919b3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_7cfa4cae-2a03-4c4c-8271-18725a5ac933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_7cfa4cae-2a03-4c4c-8271-18725a5ac933" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_754e7f66-e238-48b7-af63-1c6921d61a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_754e7f66-e238-48b7-af63-1c6921d61a36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_46609708-1c2f-437f-a148-abdf1a55d100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_46609708-1c2f-437f-a148-abdf1a55d100" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPreferredSharesPurchased_b74fa738-a445-43e0-b52c-89bc77eebdfe" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPreferredSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_sdgr_NumberOfPreferredSharesPurchased_b74fa738-a445-43e0-b52c-89bc77eebdfe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_847d65a0-f2e5-4e91-98ab-9e594e0c5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_847d65a0-f2e5-4e91-98ab-9e594e0c5d87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09679b68-36d7-4d3c-939e-ae58f27c4f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09679b68-36d7-4d3c-939e-ae58f27c4f5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_d3acd5b3-898f-443d-b1a8-90f9c9a40344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_d3acd5b3-898f-443d-b1a8-90f9c9a40344" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfSharesPurchased_6eeb87a3-2275-448c-9707-2eabe6ab5b87" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_sdgr_NumberOfSharesPurchased_6eeb87a3-2275-448c-9707-2eabe6ab5b87" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AmericanDepositorySharesPurchasedPricePerShare_eb03845f-0799-4807-8902-765af50c880c" xlink:href="sdgr-20241231.xsd#sdgr_AmericanDepositorySharesPurchasedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_sdgr_AmericanDepositorySharesPurchasedPricePerShare_eb03845f-0799-4807-8902-765af50c880c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_869ed7d2-45d0-485c-aea0-f461f21d0132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_869ed7d2-45d0-485c-aea0-f461f21d0132" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_559b5cc4-106f-4dae-bc82-f72b0ac9b538_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:to="loc_us-gaap_RelatedPartyDomain_559b5cc4-106f-4dae-bc82-f72b0ac9b538_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:to="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_04e29cee-f7c0-4d3a-9954-fe347a99eb32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:to="loc_srt_DirectorMember_04e29cee-f7c0-4d3a-9954-fe347a99eb32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0e601fc8-ab3e-4528-9757-9b0c6bf5dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:to="loc_us-gaap_RelatedPartyMember_0e601fc8-ab3e-4528-9757-9b0c6bf5dfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46f24eba-6aed-4260-b707-910c5a8a264f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:to="loc_srt_RangeMember_46f24eba-6aed-4260-b707-910c5a8a264f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83d5f3e7-6a68-409d-815c-23ce557bc0ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:to="loc_srt_RangeMember_83d5f3e7-6a68-409d-815c-23ce557bc0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7fd67e5-48cc-4286-bd03-461cb99d198e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_83d5f3e7-6a68-409d-815c-23ce557bc0ab" xlink:to="loc_srt_MinimumMember_f7fd67e5-48cc-4286-bd03-461cb99d198e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19ae798e-4e33-4a3e-8a9c-ba75969fa40b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19ae798e-4e33-4a3e-8a9c-ba75969fa40b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BillAndMelindaGatesFoundationTrustMember_d37cdf3e-b9e5-443c-a8a1-94c5d0d2f3ea" xlink:href="sdgr-20241231.xsd#sdgr_BillAndMelindaGatesFoundationTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:to="loc_sdgr_BillAndMelindaGatesFoundationTrustMember_d37cdf3e-b9e5-443c-a8a1-94c5d0d2f3ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_GatesVenturesLLCMember_a246d3c7-89bb-4bb4-a153-0095cb2adf38" xlink:href="sdgr-20241231.xsd#sdgr_GatesVenturesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:to="loc_sdgr_GatesVenturesLLCMember_a246d3c7-89bb-4bb4-a153-0095cb2adf38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c054518-f229-41d6-ac6d-923404bacfae_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:to="loc_srt_ProductsAndServicesDomain_9c054518-f229-41d6-ac6d-923404bacfae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:to="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember_a84652e1-bb30-4cb2-8a84-84923ee7575b" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:to="loc_sdgr_DrugDiscoveryContributionMember_a84652e1-bb30-4cb2-8a84-84923ee7575b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionMember_7de0cd03-69f2-45f7-aca5-287385587e79" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:to="loc_sdgr_SoftwareContributionMember_7de0cd03-69f2-45f7-aca5-287385587e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_dfcbab57-04fc-428f-b5ae-2d02b0ac9246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_dfcbab57-04fc-428f-b5ae-2d02b0ac9246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e844fb5-6ff4-4d97-ba90-301474fdc314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e844fb5-6ff4-4d97-ba90-301474fdc314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_9f52372b-98b3-429f-8857-d08dd9b76c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_9f52372b-98b3-429f-8857-d08dd9b76c08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f941d069-edab-4005-a740-b5a1a4730877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RestrictedCashCurrent_f941d069-edab-4005-a740-b5a1a4730877" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognized_6c7962ef-0053-4029-8d39-b9642896d8a7" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_sdgr_SoftwareContributionRevenueRecognized_6c7962ef-0053-4029-8d39-b9642896d8a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_261b16a8-9371-42d8-b57f-0c3d215f34ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_261b16a8-9371-42d8-b57f-0c3d215f34ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PercentageOfVotingSecurities_a1fc3bc6-a289-4d9c-9c24-ee9fe5ead302" xlink:href="sdgr-20241231.xsd#sdgr_PercentageOfVotingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_sdgr_PercentageOfVotingSecurities_a1fc3bc6-a289-4d9c-9c24-ee9fe5ead302" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb53accc-ac16-4dcd-9432-ac82919bfe23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:to="loc_us-gaap_SegmentDomain_fb53accc-ac16-4dcd-9432-ac82919bfe23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:to="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareSegmentMember_acb30f83-365b-4ba3-9a4f-61c6080a885f" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:to="loc_sdgr_SoftwareSegmentMember_acb30f83-365b-4ba3-9a4f-61c6080a885f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoverySegmentMember_388b108f-2e87-4e6f-8aff-c01aae29012f" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoverySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:to="loc_sdgr_DrugDiscoverySegmentMember_388b108f-2e87-4e6f-8aff-c01aae29012f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_4bab9059-1bad-4227-a2a1-b8db2291b642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_4bab9059-1bad-4227-a2a1-b8db2291b642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f31608e-fb49-4eea-baf1-06d4d2e08fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_4bab9059-1bad-4227-a2a1-b8db2291b642" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f31608e-fb49-4eea-baf1-06d4d2e08fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_3d916adf-87ff-4385-b00f-e484e6f890ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_CostOfRevenueAbstract_3d916adf-87ff-4385-b00f-e484e6f890ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a5222055-9468-460d-8148-72901959d60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_3d916adf-87ff-4385-b00f-e484e6f890ec" xlink:to="loc_us-gaap_CostOfRevenue_a5222055-9468-460d-8148-72901959d60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_471fdefa-182c-4726-9e14-261bc9f94cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfitAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_GrossProfitAbstract_471fdefa-182c-4726-9e14-261bc9f94cc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e99f0cac-828d-4a6a-bb12-1b927a8a5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GrossProfitAbstract_471fdefa-182c-4726-9e14-261bc9f94cc1" xlink:to="loc_us-gaap_GrossProfit_e99f0cac-828d-4a6a-bb12-1b927a8a5e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c65dcd5-b683-4c63-9a28-65e9a70bd03e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c65dcd5-b683-4c63-9a28-65e9a70bd03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6541558a-775e-4424-99cb-876d3be6f4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6541558a-775e-4424-99cb-876d3be6f4dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_973b303d-c3e5-404a-9879-6a75cf5c6cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_973b303d-c3e5-404a-9879-6a75cf5c6cf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d6193799-3dce-4696-87a1-eb257b754c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d6193799-3dce-4696-87a1-eb257b754c44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7600b549-a116-402f-9bc7-ad2f6eb6de45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7600b549-a116-402f-9bc7-ad2f6eb6de45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e922993c-66ab-4587-86cd-e550f06974b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e922993c-66ab-4587-86cd-e550f06974b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b03c90fe-8169-4706-ac92-1b6e5fd0dda6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b03c90fe-8169-4706-ac92-1b6e5fd0dda6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_809f617a-a1b4-4cec-97c3-657b035b364f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_ProfitLoss_809f617a-a1b4-4cec-97c3-657b035b364f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_36eab744-ce4a-4c46-9ccd-b379e2a8698d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_36eab744-ce4a-4c46-9ccd-b379e2a8698d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:to="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32ff1d3f-b788-4625-a483-3daf3a325f69_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:to="loc_srt_SegmentGeographicalDomain_32ff1d3f-b788-4625-a483-3daf3a325f69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:to="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b998a69-c527-49da-b000-aa3630e66ced" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_country_US_2b998a69-c527-49da-b000-aa3630e66ced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_APACMember_fe8ab20b-cf80-42cf-9af2-3b97d0205103" xlink:href="sdgr-20241231.xsd#sdgr_APACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_sdgr_APACMember_fe8ab20b-cf80-42cf-9af2-3b97d0205103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_049afe19-e82a-4bab-a668-66598de09956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_us-gaap_EMEAMember_049afe19-e82a-4bab-a668-66598de09956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_3a9bf532-f959-4f00-871b-01c10b94579e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_us-gaap_NonUsMember_3a9bf532-f959-4f00-871b-01c10b94579e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_204d449d-31fb-45c3-a992-678cac27770a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_36eab744-ce4a-4c46-9ccd-b379e2a8698d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_204d449d-31fb-45c3-a992-678cac27770a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RobertAbelMember_5c9f311f-facb-4e3b-9235-bf994e150d57" xlink:href="sdgr-20241231.xsd#sdgr_RobertAbelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sdgr_RobertAbelMember_5c9f311f-facb-4e3b-9235-bf994e150d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_KarenAkinsanyaMember_7d9d82df-7d41-40d2-910f-1a6c2026f427" xlink:href="sdgr-20241231.xsd#sdgr_KarenAkinsanyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sdgr_KarenAkinsanyaMember_7d9d82df-7d41-40d2-910f-1a6c2026f427" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>sdgr-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:6d57be63-fef2-4aee-a5b8-ca771b86978e,g:704293bf-0912-4e44-b70a-e4f74457db02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sdgr_SignificantAccountingPoliciesLineItems_a3da7551-44df-436e-8c60-8f4d47c1fab6_terseLabel_en-US" xlink:label="lab_sdgr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sdgr_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_sdgr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sdgr_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_sdgr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SignificantAccountingPoliciesLineItems" xlink:href="sdgr-20241231.xsd#sdgr_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems" xlink:to="lab_sdgr_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_4f753034-6b17-48f8-8777-9d964dcb3d0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31cdae53-9915-49d7-b3b0-a7676942eb90_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_48c967a9-dc45-4366-807b-d4d7def9d4a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4c02af5b-2e78-4a11-a972-722cec25e654_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1a3a42d0-f99f-4ed7-95db-b442a12405ab_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_1c0f26aa-aec4-4221-a0cf-59df011920de_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_305b7146-e6cb-4012-8cdf-cdf6d1810824_terseLabel_en-US" xlink:label="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right to exchange limited common stock to common stock, share</link:label>
    <link:label id="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_label_en-US" xlink:label="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right To Exchange Each Share Of Limited Common Stock To Common Stock</link:label>
    <link:label id="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_documentation_en-US" xlink:label="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right to exchange each share of limited common stock to common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" xlink:href="sdgr-20241231.xsd#sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" xlink:to="lab_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_caaee5ab-b378-4e3c-afc5-91c4c636f2ba_terseLabel_en-US" xlink:label="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards, research, not subject to expiration</link:label>
    <link:label id="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_label_en-US" xlink:label="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Not Subject To Expiration</link:label>
    <link:label id="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_documentation_en-US" xlink:label="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" xlink:to="lab_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cc2fe380-55fd-4f52-bcbc-755e0f668310_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommissionsPolicy_e13eb61f-a481-474a-b26c-df3cee3190b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommissionsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions</link:label>
    <link:label id="lab_us-gaap_CommissionsPolicy_label_en-US" xlink:label="lab_us-gaap_CommissionsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commissions, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommissionsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommissionsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommissionsPolicy" xlink:to="lab_us-gaap_CommissionsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_662f517a-d3e3-4c62-b01e-ef4b48478fdd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_17768538-7c99-4b62-bc3a-6f62054d2101_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_bb1b4597-b118-4a49-86b9-f23d23d990aa_terseLabel_en-US" xlink:label="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Gates Ventures, LLC</link:label>
    <link:label id="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_label_en-US" xlink:label="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Gates Ventures Limited Liability Company [Member]</link:label>
    <link:label id="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_documentation_en-US" xlink:label="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement with Gates Ventures, Limited Liability Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" xlink:href="sdgr-20241231.xsd#sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" xlink:to="lab_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f7907298-5a8b-4cbf-b340-0c850d5bddef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_236b425c-3dc0-4b04-be95-d70db6de6c67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_78f204e7-aa8a-47fd-b930-597a2509c7cf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ffa1301d-0c64-4087-b21a-ea4d30018ca0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_299f8f27-e409-4555-a866-e96fad1c283e_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gain</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CustomerBMember_87dd2bdd-6e18-4730-a7e6-5cf825d57af8_terseLabel_en-US" xlink:label="lab_sdgr_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_sdgr_CustomerBMember_label_en-US" xlink:label="lab_sdgr_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_sdgr_CustomerBMember_documentation_en-US" xlink:label="lab_sdgr_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerBMember" xlink:href="sdgr-20241231.xsd#sdgr_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CustomerBMember" xlink:to="lab_sdgr_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9c2859db-c9a0-4e1a-92c8-b07befd126e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dfb81239-df29-4c25-9723-ababc57b17d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f9690088-a752-4428-935c-ba7ce921116a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_ee46103e-9ff6-461b-ba80-45a24fe39eaa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_19988820-f025-4ea8-b90d-554e944375ae_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_BillAndMelindaGatesFoundationTrustMember_a0212ca9-0373-4794-ab06-9ca393c61608_terseLabel_en-US" xlink:label="lab_sdgr_BillAndMelindaGatesFoundationTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMGFT</link:label>
    <link:label id="lab_sdgr_BillAndMelindaGatesFoundationTrustMember_label_en-US" xlink:label="lab_sdgr_BillAndMelindaGatesFoundationTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation Trust [Member]</link:label>
    <link:label id="lab_sdgr_BillAndMelindaGatesFoundationTrustMember_documentation_en-US" xlink:label="lab_sdgr_BillAndMelindaGatesFoundationTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill and Melinda gates foundation trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BillAndMelindaGatesFoundationTrustMember" xlink:href="sdgr-20241231.xsd#sdgr_BillAndMelindaGatesFoundationTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_BillAndMelindaGatesFoundationTrustMember" xlink:to="lab_sdgr_BillAndMelindaGatesFoundationTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired_f59f0ab5-0e26-41d1-867c-d63419c256c3_terseLabel_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of right of use assets in exchange for lease liabilities - finance leases</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired_label_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Operating Lease Acquired</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired_documentation_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Operating Lease Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" xlink:to="lab_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_92843a64-4b94-4372-84ae-d8bc55445b2e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_OncologyNeurologyAndImmunologyProductMember_735c8ecb-b756-4225-a605-0995078e5876_terseLabel_en-US" xlink:label="lab_sdgr_OncologyNeurologyAndImmunologyProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology, Neurology, and Immunology Product</link:label>
    <link:label id="lab_sdgr_OncologyNeurologyAndImmunologyProductMember_label_en-US" xlink:label="lab_sdgr_OncologyNeurologyAndImmunologyProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology, Neurology, And Immunology Product [Member]</link:label>
    <link:label id="lab_sdgr_OncologyNeurologyAndImmunologyProductMember_documentation_en-US" xlink:label="lab_sdgr_OncologyNeurologyAndImmunologyProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology, Neurology, And Immunology Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OncologyNeurologyAndImmunologyProductMember" xlink:href="sdgr-20241231.xsd#sdgr_OncologyNeurologyAndImmunologyProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_OncologyNeurologyAndImmunologyProductMember" xlink:to="lab_sdgr_OncologyNeurologyAndImmunologyProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_91698e69-0a0d-4f9c-ac00-d9db668c06f6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments to purchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_705ad228-b205-4bec-9e1a-ae40370dc75d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3637acdd-e8a6-4713-92d3-6061f3bbdddc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_b252df2a-0700-445e-a4db-02bf10345356_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_571b3da1-6ad4-46ba-8eb7-7977890c0e55_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mark-to-market gain (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_163ca62f-b258-4109-b9e5-befd52fc48bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0bfc1167-d6bc-44e3-b436-bdd3bc6df924_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4ecd3239-127a-4c3d-ac1b-fc557eb4ee53_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities - operating leases</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a393c198-97dc-40bc-ba55-cf8a73d65b96_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon vesting of RSUs and PRSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9a22378a-e4f7-467e-b623-a068017af916_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_be0a5374-c970-434a-a335-c2ed56cfd5c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of common stock upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8d1e56ef-6037-4067-8817-560601ee80b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_03445661-e8bb-421d-8953-382e9eb39b9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4ea06646-31a7-45af-bb3c-67f19953fc17_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_48a52a7d-8e60-4e09-bfe2-f70175bb613a_terseLabel_en-US" xlink:label="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of neurology targets remaining</link:label>
    <link:label id="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_label_en-US" xlink:label="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Number Of Neurology Target Remaining</link:label>
    <link:label id="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_documentation_en-US" xlink:label="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Number Of Neurology Target Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" xlink:to="lab_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_d6afe5a4-0054-434a-9046-9f2a40295600_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CollaborativeAgreementNumberOfPrograms_3ef1fc66-52b3-454b-ae8e-f04c4d929a00_terseLabel_en-US" xlink:label="lab_sdgr_CollaborativeAgreementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of programs under agreement</link:label>
    <link:label id="lab_sdgr_CollaborativeAgreementNumberOfPrograms_label_en-US" xlink:label="lab_sdgr_CollaborativeAgreementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Number Of Programs</link:label>
    <link:label id="lab_sdgr_CollaborativeAgreementNumberOfPrograms_documentation_en-US" xlink:label="lab_sdgr_CollaborativeAgreementNumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreement number of programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeAgreementNumberOfPrograms" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeAgreementNumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CollaborativeAgreementNumberOfPrograms" xlink:to="lab_sdgr_CollaborativeAgreementNumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ded03ddf-1af7-457c-a780-5e2b11909211_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f7d70d2e-ebd2-4878-8c9b-60748d1a9905_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_99de6bf9-7e01-497d-b593-9d7f3ca8e5b6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset - finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7dceeb05-6dc0-415a-b389-be32ae3b4ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c99338e4-e3f7-4266-a61b-f2219854dc15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_fe14517a-60ff-4dd8-88a8-3a3b90d81ba7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities - operating leases, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LimitedCommonStockMember_0cbf8aa8-48b3-49ed-9bfc-e2a7cd657de0_terseLabel_en-US" xlink:label="lab_sdgr_LimitedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limited common stock</link:label>
    <link:label id="lab_sdgr_LimitedCommonStockMember_label_en-US" xlink:label="lab_sdgr_LimitedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Limited Common Stock [Member]</link:label>
    <link:label id="lab_sdgr_LimitedCommonStockMember_documentation_en-US" xlink:label="lab_sdgr_LimitedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Limited common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LimitedCommonStockMember" xlink:to="lab_sdgr_LimitedCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_babb6f47-eda3-4bf1-a47d-33267887b0e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_b2a81398-4f45-42b5-bec8-23b7e723b179_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e96093ca-4e23-4a33-9654-1e166bc71355_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a18ed84a-181e-4479-bff3-2f8a718713fb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RevenueRecognizedForMilestonePayment_c713281d-9fee-46c1-9a06-80eaeed27a38_terseLabel_en-US" xlink:label="lab_sdgr_RevenueRecognizedForMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized with milestones</link:label>
    <link:label id="lab_sdgr_RevenueRecognizedForMilestonePayment_label_en-US" xlink:label="lab_sdgr_RevenueRecognizedForMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognized For Milestone Payment</link:label>
    <link:label id="lab_sdgr_RevenueRecognizedForMilestonePayment_documentation_en-US" xlink:label="lab_sdgr_RevenueRecognizedForMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognized for milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRecognizedForMilestonePayment" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRecognizedForMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RevenueRecognizedForMilestonePayment" xlink:to="lab_sdgr_RevenueRecognizedForMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e1f6bc53-187b-4d51-9066-20d4ccf47152_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution_060d2b93-70be-4754-a2fc-340223a7590e_terseLabel_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of right of use assets - operating leases, contingency resolution</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution_label_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Lease, Contingency Resolution</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution_documentation_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Lease, Contingency Resolution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" xlink:to="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e2adcd6b-6b0a-4248-ac1b-457027023adc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_221c09ed-e4d6-4156-a5f5-29d83b441634_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_72ec578e-f8a1-41cb-9741-46193abea6e0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions taken in prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1abe4a17-70a1-49c6-b7c5-20ce902915e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5735146b-0a86-4e9e-a8eb-c3d292600f5b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b82cf2e0-14ba-4642-af45-8dc14e2a9a8b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f22a0ea3-9b42-463a-9be0-d5d87f624ffc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_eaf8d105-61e1-4b8a-a757-9fd16631bb94_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfitAbstract_e173ca10-75d9-4ec4-ad5f-942074ed01dc_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment gross profit:</link:label>
    <link:label id="lab_us-gaap_GrossProfitAbstract_label_en-US" xlink:label="lab_us-gaap_GrossProfitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfitAbstract" xlink:to="lab_us-gaap_GrossProfitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NovartisPharmaAGMember_d25e7b19-2cbf-4ad3-b75c-7686c280f597_terseLabel_en-US" xlink:label="lab_sdgr_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:label id="lab_sdgr_NovartisPharmaAGMember_label_en-US" xlink:label="lab_sdgr_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_sdgr_NovartisPharmaAGMember_documentation_en-US" xlink:label="lab_sdgr_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NovartisPharmaAGMember" xlink:href="sdgr-20241231.xsd#sdgr_NovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NovartisPharmaAGMember" xlink:to="lab_sdgr_NovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_df76b88c-c320-4efe-a5a2-f3ee92a5f5e2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_db299f34-f00e-43ed-b8dd-f745ef4ddaf4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_7fed26d6-37e3-477c-a338-a9fb069e6b6f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6d03d8f2-b048-43db-ac38-fc16e8300dad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f6922050-f346-4d34-8e33-d23ee8da5073_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f27d0896-2e54-4875-8859-90a3b83f8d49_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract_d6c7d4ed-a38c-478f-9ca0-fe6b02424351_terseLabel_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, weighted average remaining contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_902a0231-7962-445f-938b-3d2ed6c693bd_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_13594048-64ee-4848-b9c8-2d7ee2b2250c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock_f574803a-7c81-437e-ada8-c5dc94eb0845_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software Development Costs</link:label>
    <link:label id="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software development costs policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" xlink:to="lab_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ad932cab-98c5-4309-9d87-798bcd9a97a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2023</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f59cf8f6-26c1-4f34-9a35-f00fa35d83ed_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f4463e38-8831-43ca-8888-5d9e3f13486a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_68dcdf1d-3bb6-4ba3-8fd7-723f85b3eac2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_100a4606-74eb-435f-9e09-70312871c70d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_38201a6c-4f3d-45fa-b94d-cdcf751dc17f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_47099d04-d023-4662-9721-9b8aaa0e1fcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65e7ad93-70b1-4754-98bd-cf3cafc1ed59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_04f572ab-7b01-4e41-9dde-8bbb822f6a8d_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EMEA</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_9c734ba1-00b9-42bc-9444-18eef83bed30_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7916c22f-2daf-442f-8ccf-f00a33d7e023_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to outstanding common stock options and unvested RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_GatesVenturesLLCMember_d6dadab3-27b0-4308-b1a2-5459e05be335_terseLabel_en-US" xlink:label="lab_sdgr_GatesVenturesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gates Ventures, LLC</link:label>
    <link:label id="lab_sdgr_GatesVenturesLLCMember_label_en-US" xlink:label="lab_sdgr_GatesVenturesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gates Ventures, LLC [Member]</link:label>
    <link:label id="lab_sdgr_GatesVenturesLLCMember_documentation_en-US" xlink:label="lab_sdgr_GatesVenturesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gates Ventures, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_GatesVenturesLLCMember" xlink:href="sdgr-20241231.xsd#sdgr_GatesVenturesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_GatesVenturesLLCMember" xlink:to="lab_sdgr_GatesVenturesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DrugDiscoveryContributionMember_8d70b408-6cb2-46f0-a6ee-cad09cf65a5d_terseLabel_en-US" xlink:label="lab_sdgr_DrugDiscoveryContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug discovery contribution</link:label>
    <link:label id="lab_sdgr_DrugDiscoveryContributionMember_label_en-US" xlink:label="lab_sdgr_DrugDiscoveryContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Discovery Contribution [Member]</link:label>
    <link:label id="lab_sdgr_DrugDiscoveryContributionMember_documentation_en-US" xlink:label="lab_sdgr_DrugDiscoveryContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug discovery contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DrugDiscoveryContributionMember" xlink:to="lab_sdgr_DrugDiscoveryContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aa88f6db-c060-47ce-94ab-4da9315734d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_01bc0e1a-e47b-41c4-879e-14fc1fc17e2f_totalLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_11d0ff14-027a-491a-9564-b9bcf079b41b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Timing of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RoyaltiesPolicyPolicyTextBlock_0e2ba428-24a1-4506-be44-b6f1adf6d263_terseLabel_en-US" xlink:label="lab_sdgr_RoyaltiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_sdgr_RoyaltiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sdgr_RoyaltiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Policy [Policy Text Block]</link:label>
    <link:label id="lab_sdgr_RoyaltiesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sdgr_RoyaltiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RoyaltiesPolicyPolicyTextBlock" xlink:href="sdgr-20241231.xsd#sdgr_RoyaltiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RoyaltiesPolicyPolicyTextBlock" xlink:to="lab_sdgr_RoyaltiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_800ac69a-0811-4b29-bb2b-04c422945cad_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5b0a0c9d-aa43-4d70-9893-c27824a38a7e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NumberOfVotesForCommonShare_cc84db85-90cb-4069-a109-c749dc8e12be_terseLabel_en-US" xlink:label="lab_sdgr_NumberOfVotesForCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes for common share</link:label>
    <link:label id="lab_sdgr_NumberOfVotesForCommonShare_label_en-US" xlink:label="lab_sdgr_NumberOfVotesForCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Votes For Common Share</link:label>
    <link:label id="lab_sdgr_NumberOfVotesForCommonShare_documentation_en-US" xlink:label="lab_sdgr_NumberOfVotesForCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of votes for common share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfVotesForCommonShare" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfVotesForCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NumberOfVotesForCommonShare" xlink:to="lab_sdgr_NumberOfVotesForCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_092743eb-dc93-4247-ba9f-cea60fecd723_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3fd97955-a783-40a1-9a9d-9bc7f463f481_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c2dded23-f116-4279-8ada-1a86502302ac_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CollaborationAndLicenseAgreementMember_3cc65854-763e-4cff-9c34-e8e3795a871b_terseLabel_en-US" xlink:label="lab_sdgr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement</link:label>
    <link:label id="lab_sdgr_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sdgr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sdgr_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sdgr_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborationAndLicenseAgreementMember" xlink:href="sdgr-20241231.xsd#sdgr_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CollaborationAndLicenseAgreementMember" xlink:to="lab_sdgr_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_306a2a96-4678-4a24-8d8b-6673fb3e1f17_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8df07b8c-a777-476d-95f9-e4e53809d5a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_InvestmentAmortizationNoncashExpense_a0063068-2d7f-45e8-84da-49dd285a5bdd_negatedLabel_en-US" xlink:label="lab_sdgr_InvestmentAmortizationNoncashExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncash investment (accretion) amortization</link:label>
    <link:label id="lab_sdgr_InvestmentAmortizationNoncashExpense_label_en-US" xlink:label="lab_sdgr_InvestmentAmortizationNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Amortization Noncash Expense</link:label>
    <link:label id="lab_sdgr_InvestmentAmortizationNoncashExpense_documentation_en-US" xlink:label="lab_sdgr_InvestmentAmortizationNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Amortization Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_InvestmentAmortizationNoncashExpense" xlink:href="sdgr-20241231.xsd#sdgr_InvestmentAmortizationNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_InvestmentAmortizationNoncashExpense" xlink:to="lab_sdgr_InvestmentAmortizationNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_8381e08e-b495-4d20-9ada-124e620a4b47_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2519a5af-d9dc-4bc4-8071-e854d4e179a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b2e62eca-b9e2-40f4-a02c-8196fd5e1583_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8dc6c980-7fe2-4ec2-9445-353ae8777535_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_42d6e499-3068-47b3-83a4-85bc67fce411_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_0576853a-9411-4527-bffe-f1c540ca4ebf_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_89c46e8e-cc67-409e-95e6-b2300ecf52b0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_aba7b2b0-3164-42c0-84c3-6ea6c483b831_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3e9a3526-73f1-4873-a97a-ba5370cb6ba1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cc504e58-e9b4-44bb-ab05-5e7414214a55_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9004e6fe-fe68-4526-8790-cdcf477bc9e1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NumberOfSharesPurchased_2ad4973c-8dbd-47c3-ba85-62537bf81b91_terseLabel_en-US" xlink:label="lab_sdgr_NumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares purchased</link:label>
    <link:label id="lab_sdgr_NumberOfSharesPurchased_label_en-US" xlink:label="lab_sdgr_NumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Purchased</link:label>
    <link:label id="lab_sdgr_NumberOfSharesPurchased_documentation_en-US" xlink:label="lab_sdgr_NumberOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfSharesPurchased" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NumberOfSharesPurchased" xlink:to="lab_sdgr_NumberOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaintenanceMember_9b1c00cd-ce86-4d3e-bed2-287709e7ffa3_terseLabel_en-US" xlink:label="lab_us-gaap_MaintenanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software maintenance</link:label>
    <link:label id="lab_us-gaap_MaintenanceMember_label_en-US" xlink:label="lab_us-gaap_MaintenanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maintenance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaintenanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaintenanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaintenanceMember" xlink:to="lab_us-gaap_MaintenanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_14a2d98c-9ec6-47cb-a552-fd844ba2cba3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll, taxes, and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payroll Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49d4547c-eef8-4c13-898f-9165036038cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6405109a-bd03-4811-aaf2-8054347013c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_23abe2cd-f307-4784-912b-7f67d104b964_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0158c976-f333-4abd-a96f-95b4db3a482d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4478bec2-56e2-45a3-9600-b7bc481f346a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_7b82bfed-661b-48d4-a5db-2a036ff2ba13_terseLabel_en-US" xlink:label="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of stock options must be granted at exercise price of fair market value</link:label>
    <link:label id="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_label_en-US" xlink:label="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Percentage Of Stock Options Must Be Granted At Exercise Price Of Fair Market Value</link:label>
    <link:label id="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_documentation_en-US" xlink:label="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum percentage of stock options must be granted at exercise price of fair market value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" xlink:href="sdgr-20241231.xsd#sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" xlink:to="lab_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee6b0cc8-9e94-4c8d-92f9-e8aee103cf24_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, December 31, 2021 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_85ca7998-24c6-49d2-9eca-da4d0db73e0c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b2e0c5f3-5f56-4130-a51b-a8ab48e3f800_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ff82e2d4-1df4-4ec8-992c-4d0d9e4d73b9_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_df561bfe-7f60-436f-b3d0-e1f084e39624_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f6497030-0fed-42f5-9ed2-efd113285130_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_f0013c7f-dd0e-47c1-baab-41e15e7b6c1a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Software contribution</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_91006827-4b01-4a81-a55b-01b183afaf33_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug discovery contribution</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_38a31507-d324-4836-8d99-70fb5edef277_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_469bee77-f7ad-4733-80c8-3453eda7f91d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_4f2aad35-4e14-4c7a-8f80-5867bfe1f7d3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 to level 1</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RevenueArrangementsContractTerm_8d99386d-ddb4-4044-b100-0364741343a7_terseLabel_en-US" xlink:label="lab_sdgr_RevenueArrangementsContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract term for software arrangements</link:label>
    <link:label id="lab_sdgr_RevenueArrangementsContractTerm_label_en-US" xlink:label="lab_sdgr_RevenueArrangementsContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Arrangements, Contract Term</link:label>
    <link:label id="lab_sdgr_RevenueArrangementsContractTerm_documentation_en-US" xlink:label="lab_sdgr_RevenueArrangementsContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Arrangements, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueArrangementsContractTerm" xlink:href="sdgr-20241231.xsd#sdgr_RevenueArrangementsContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RevenueArrangementsContractTerm" xlink:to="lab_sdgr_RevenueArrangementsContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fbfa4bdc-420c-477a-b215-5fc98a6bfe72_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fd0105c1-f5f6-471f-b333-3272be0c1c59_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_d63978fa-4539-4a51-a54e-5af9059e1579_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_90a04b50-e225-46b5-92ea-ff74ed1947ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cc493c85-fbbe-416d-8dc7-a912b1159599_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e295543b-a629-4b17-aca4-70b2955fe2f6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_288220d9-ddcf-4e96-a8db-5395b1216e00_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of common stock upon stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ea2be1dc-00f3-4652-9972-a6045e56e745_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4817f0e-e915-4e99-bb42-b7378337079b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_21b5753f-4db1-47c5-af66-a07429fbc7eb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_528a06a2-d920-4878-b7b8-5054efc0a1dc_terseLabel_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e055d4c4-ab11-4263-a79a-a2d30bdbfb78_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare_8aeb379b-b8c5-4fe3-83f7-27abb4c38744_terseLabel_en-US" xlink:label="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (in USD per share)</link:label>
    <link:label id="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare_label_en-US" xlink:label="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares Purchased, Price Per Share</link:label>
    <link:label id="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare_documentation_en-US" xlink:label="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares Purchased, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AmericanDepositorySharesPurchasedPricePerShare" xlink:href="sdgr-20241231.xsd#sdgr_AmericanDepositorySharesPurchasedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_AmericanDepositorySharesPurchasedPricePerShare" xlink:to="lab_sdgr_AmericanDepositorySharesPurchasedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d2b4b5bc-6bcf-497b-8129-23da604b40b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition, net of acquired cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_9c961899-8b56-4e8e-9b47-1fa87b03158c_terseLabel_en-US" xlink:label="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:label id="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_label_en-US" xlink:label="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Section162 Limitation</link:label>
    <link:label id="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_documentation_en-US" xlink:label="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation, section 162 limitation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" xlink:href="sdgr-20241231.xsd#sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" xlink:to="lab_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01bd0da6-8717-4895-99ff-7b6e4407c387_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebf43e0c-ad0e-4944-b1df-9972cd489b8a_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CollaborativeArrangementTerm_d8f7c661-bdfa-4a46-abde-e6259253041a_terseLabel_en-US" xlink:label="lab_sdgr_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_sdgr_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_sdgr_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_sdgr_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_sdgr_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeArrangementTerm" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CollaborativeArrangementTerm" xlink:to="lab_sdgr_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3d9d8241-c206-4b87-81b8-c540b3e36351_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9ea56879-33b5-479b-a8e4-c94f25f78ae8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d0ca1a6c-8ea2-44f3-9265-3ad9c86399b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_79493f29-edcc-4639-b356-bff105b786c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d0329558-9d3a-4829-9b0d-6ca63a74ff91_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_1341be56-8e5e-4b30-bf34-1cac7a470c01_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_OnPremiseSoftwareMember_c819fb89-c2f4-4427-8326-1595754cb6a6_terseLabel_en-US" xlink:label="lab_sdgr_OnPremiseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">On-premise software</link:label>
    <link:label id="lab_sdgr_OnPremiseSoftwareMember_label_en-US" xlink:label="lab_sdgr_OnPremiseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">On Premise Software [Member]</link:label>
    <link:label id="lab_sdgr_OnPremiseSoftwareMember_documentation_en-US" xlink:label="lab_sdgr_OnPremiseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">On premise software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OnPremiseSoftwareMember" xlink:href="sdgr-20241231.xsd#sdgr_OnPremiseSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_OnPremiseSoftwareMember" xlink:to="lab_sdgr_OnPremiseSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4f644e16-c89e-4cf7-bb40-c843fb15c8ab_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8d9ba1a1-0f81-434e-ad3a-5921bcbb4b3d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4ca114d4-8c95-4fb3-bf1c-413884130b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DeferredTaxAssetsLeaseLiabilities_1f50d80c-fae0-4c9c-87c7-68a39a54caf7_terseLabel_en-US" xlink:label="lab_sdgr_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_sdgr_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_sdgr_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label id="lab_sdgr_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_sdgr_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxAssetsLeaseLiabilities" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_sdgr_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_eb595967-4daf-4f4c-a414-1d0f3793b3bc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_68d86811-e821-4def-937a-766434636908_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c31009cc-2b78-470a-a5c5-83b5d0c5a0ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $210 and $220</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_27509bee-6c89-4d5e-bf00-dd9d8ee94784_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_f394baa5-0e96-4a9f-84fe-9cc1067ff621_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9238c5cc-f39a-4805-aebe-05cadb7d49ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_be147a88-d04c-47aa-b2cb-eaa7c187328f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues From External Customers And Long Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ed37e713-36d6-4c7f-b4f4-64128f3f2959_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_1c00d658-453c-4e29-9515-ce4dee4e2ffa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0c6512b3-59c4-4abb-81cd-27b4a02604cc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5dcce4a9-0335-45f6-8072-4882f61e442d_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember_8101ef6a-df50-4899-8909-f28d17c4eae2_terseLabel_en-US" xlink:label="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember_label_en-US" xlink:label="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Restricted Cash [Member]</link:label>
    <link:label id="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember_documentation_en-US" xlink:label="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CashCashEquivalentsAndRestrictedCashMember" xlink:href="sdgr-20241231.xsd#sdgr_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CashCashEquivalentsAndRestrictedCashMember" xlink:to="lab_sdgr_CashCashEquivalentsAndRestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b14b42d1-30e6-4de1-98bc-427bf3f282b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discretionary matching contributed by employees</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareAgreementMember_73a27bbe-96aa-423f-97ee-0460db48fa0b_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software Agreement</link:label>
    <link:label id="lab_sdgr_SoftwareAgreementMember_label_en-US" xlink:label="lab_sdgr_SoftwareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Agreement [Member]</link:label>
    <link:label id="lab_sdgr_SoftwareAgreementMember_documentation_en-US" xlink:label="lab_sdgr_SoftwareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareAgreementMember" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareAgreementMember" xlink:to="lab_sdgr_SoftwareAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5a440c98-395a-48aa-bf29-ce014f1dcc2b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_535c2744-d52e-479f-b15f-8bb3933f2031_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_TheATMMember_0c723e33-d89b-49d5-a367-f6565b510766_terseLabel_en-US" xlink:label="lab_sdgr_TheATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The ATM</link:label>
    <link:label id="lab_sdgr_TheATMMember_label_en-US" xlink:label="lab_sdgr_TheATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The ATM [Member]</link:label>
    <link:label id="lab_sdgr_TheATMMember_documentation_en-US" xlink:label="lab_sdgr_TheATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TheATMMember" xlink:href="sdgr-20241231.xsd#sdgr_TheATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_TheATMMember" xlink:to="lab_sdgr_TheATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_ba9a90fc-6195-473a-9106-1d82d7cd734c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value By Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4bc9e71-dfbb-4be1-aab5-b227e2e36fd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_83cd8468-69cb-4467-8d12-efdd85f6b680_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_41529ed8-98bc-4d5a-bbce-386b75eba72c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_385293db-ef0c-4a94-8fc1-439ee8c917ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Information with Respect to Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_847e23c5-e4ab-4766-b3fd-908c2910802e_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_d9621697-8896-4b58-aa44-7574b31f72fe_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_3039c942-09a7-43ad-81f9-36c97e663ce2_negatedLabel_en-US" xlink:label="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unbilled and other receivables</link:label>
    <link:label id="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_label_en-US" xlink:label="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Unbilled And Other Receivables</link:label>
    <link:label id="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_documentation_en-US" xlink:label="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in unbilled and other receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" xlink:to="lab_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_835a0859-d4d1-475d-9184-4cc67cc6dacc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, December 31, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_PerformanceRestrictedStockUnitsMember_ee4ac28a-1f9e-4354-a607-7a75bf99032d_terseLabel_en-US" xlink:label="lab_sdgr_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:label id="lab_sdgr_PerformanceRestrictedStockUnitsMember_label_en-US" xlink:label="lab_sdgr_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units [Member]</link:label>
    <link:label id="lab_sdgr_PerformanceRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_sdgr_PerformanceRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PerformanceRestrictedStockUnitsMember" xlink:href="sdgr-20241231.xsd#sdgr_PerformanceRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_PerformanceRestrictedStockUnitsMember" xlink:to="lab_sdgr_PerformanceRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ae80c198-afd6-4580-a602-980e5f10937b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSU's vested during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a8891b39-c841-41ec-b884-4791cbeb6398_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4f351de8-281d-48de-ba23-1207c0e68abf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8112e7f0-6617-45f5-b651-40f7c51514e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_10e09993-34e6-4443-95f1-9c2afae7a673_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_885ec1c6-5fcf-4c31-8d17-5dfff3d02dac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_9bfbc6b0-8864-453f-b24f-e65a2608efa4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7ca9ab7b-c2ed-48ff-9f4d-bd3d8bd8256f_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_b5f55ae4-3a0b-4720-8033-0cc32a55f4cc_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_fd6c11ea-adaa-47e1-8d34-7b2b374f45b2_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6f9e06f2-ae77-44ce-909d-14c1f1b9523b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6aef84dc-32a2-48a4-9703-2bb475e9b64b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_30c6e8c1-ecbc-4350-accc-29b60a6b6a26_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_197b7a79-80a6-43b7-bd96-bdaa52f9e286_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, long-term:</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract" xlink:to="lab_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_366e1b01-0e62-4d59-bc76-a80e506f6afc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74352bd4-a0c5-4c22-a1ee-27a93a93c4f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ede28ba4-4bd5-445c-a7c2-3239d73b6327_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Weighted Average Valuation Assumptions Used for Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fa3206ef-7264-4519-8a43-5b2a714b8645_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_991dd3bb-5ecc-48c2-8ad3-1de45e2a04cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions amount</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_922eb2df-2ed8-458d-9c0f-2a812d20f431_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5df45075-e837-4a2b-a417-6c3ebbaee88f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_13f6e1fd-db37-40a0-af39-8f48593361c6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DrugDiscoveryMember_f05f1a07-7f2e-46dc-b841-d04ba51c3bd3_terseLabel_en-US" xlink:label="lab_sdgr_DrugDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug discovery</link:label>
    <link:label id="lab_sdgr_DrugDiscoveryMember_label_en-US" xlink:label="lab_sdgr_DrugDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Discovery [Member]</link:label>
    <link:label id="lab_sdgr_DrugDiscoveryMember_documentation_en-US" xlink:label="lab_sdgr_DrugDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug discovery.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DrugDiscoveryMember" xlink:to="lab_sdgr_DrugDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_9e46a47a-369c-4c2b-9351-00ad8e86fc90_terseLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Five</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_APACMember_bb51bf28-b217-44eb-ac7c-d7c4ddd6b621_terseLabel_en-US" xlink:label="lab_sdgr_APACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APAC</link:label>
    <link:label id="lab_sdgr_APACMember_label_en-US" xlink:label="lab_sdgr_APACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APAC [Member]</link:label>
    <link:label id="lab_sdgr_APACMember_documentation_en-US" xlink:label="lab_sdgr_APACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">APAC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_APACMember" xlink:href="sdgr-20241231.xsd#sdgr_APACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_APACMember" xlink:to="lab_sdgr_APACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ff393cc4-8040-4927-be36-d501bc837bc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_7e241c0f-9fbb-41d3-aff9-52bf35adfc76_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4b98a5be-925a-48f1-9717-7e3a36603ecb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_7406949f-cd87-4507-9f12-d0b3bbacdad3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_81838b4e-a0d0-47dc-8c4a-e2665a6d947b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_0b20d5e3-0ebb-470d-b782-1c9b9cc5a9a2_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9c66b556-54d8-4c00-bf26-da201ed2d7e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_980e4435-5765-4baf-bff0-9fb5e55b64b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueAndCreditsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, short-term:</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueAndCreditsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueAndCreditsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract" xlink:to="lab_us-gaap_DeferredRevenueAndCreditsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ce756cdf-7f67-4747-b743-d5c057a53885_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d9f7c070-436b-47d3-bf2b-cc4db4e70736_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_c0383975-b344-4be2-b159-a18834bb25f5_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember_86820723-bfb5-410d-8d98-748756690cf0_terseLabel_en-US" xlink:label="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock Units</link:label>
    <link:label id="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PerformanceBasedRestrictedStockUnitsMember" xlink:href="sdgr-20241231.xsd#sdgr_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_sdgr_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73d743b8-3b7a-4f45-b7d2-e1003d1ff1f8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_51d1587b-0fbd-46b9-ae39-0fe1ff7f1ed4_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warranties</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f26ab521-c613-4fc8-9bc9-6fcf31b97cab_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share of common and limited common stockholders, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3d50747c-e94a-46bb-b707-7116fa095a81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d1bf1be3-9ba9-4720-8707-9d3fb5f1a00d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_cb6f0312-27b2-48e1-ab2a-15c154d963d7_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6e5abea8-2c17-4bfe-8049-fbea6e1ece23_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0f35e6e2-ba30-41db-bc79-1cd0634984da_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_461c4c81-9299-45bc-8a68-2290d6a9a6cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_86d69bb7-53c5-4cc6-b673-7a906608a2cf_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_284b07c0-71ad-4946-bda9-f68f1adc70e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected to be recognized over a weighted average period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0b032e87-14fd-4b17-b4ad-ca2a18516d2b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting rights (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_db76d449-4e3a-401b-b5cc-32878384e813_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_97837f52-bf52-44a6-8c8a-f7b20d9bbfd7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discretionary matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_0a796469-16a1-4f74-b50b-56fd1a9c9f56_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ad7c25c5-dca8-4e5a-aee3-485c06982593_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9131a169-6a78-4f19-b8e9-6580b0e8804a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_df09373b-5f8a-45ce-b9f0-63f740ddb89c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_28f893ca-6eb3-4a03-a060-6a078b98c494_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation Of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e19fb40f-2302-4545-8472-4e3656e8fef8_terseLabel_en-US" xlink:label="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of specified biological target</link:label>
    <link:label id="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_label_en-US" xlink:label="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Number Of Specified Biological Targets</link:label>
    <link:label id="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_documentation_en-US" xlink:label="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Number Of Specified Biological Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" xlink:to="lab_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareProductsAndServicesMember_93f810f4-960c-4239-8488-8c207dc4183e_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software products and services</link:label>
    <link:label id="lab_sdgr_SoftwareProductsAndServicesMember_label_en-US" xlink:label="lab_sdgr_SoftwareProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Products And Services [Member]</link:label>
    <link:label id="lab_sdgr_SoftwareProductsAndServicesMember_documentation_en-US" xlink:label="lab_sdgr_SoftwareProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software products and services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareProductsAndServicesMember" xlink:to="lab_sdgr_SoftwareProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5b58d4a9-a6e6-4ad0-aa05-c1c4a7edd661_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6afc45ac-a98e-4259-94b1-f3bed387c176_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ab76e484-bfea-4cc8-bfd9-44b726f328ec_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_d5d61740-cee7-423d-97b5-49a47ea4b1c5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_76420268-d871-4d2e-b77d-7bdfd9379a55_negatedLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4a6e72b9-4e2e-4bca-9c6b-3601d6593e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of vested shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e491c740-f60c-4057-9dd8-5b864659c983_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_93260a51-a43e-44bc-bfa4-5806bb0f32b9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_789ef1c7-c789-4c19-84d8-90716b145855_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_ab184be0-a37a-47a9-bc65-9de35d1117bb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_340de8c0-e24b-4ad5-baea-2542904aee5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_309e41d0-77be-4355-bd12-bb69d71d40dc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_95de0e07-6d03-4b8e-9c04-526e77c95bb5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0192eb40-b02c-4a23-beeb-f2e9cde10522_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_dcee3e64-ae8c-4206-9bc9-3f20308ff941_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow and noncash information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_c9145e57-edc5-4898-8fa6-82ae8e427a7d_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e4d09070-6ea4-4db1-8b6d-8cf46da4a5ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost expected to be recognized over a weighted average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d208cef0-9a85-4094-820c-f5f41268ebc1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a367279-cbba-4724-b3f6-a51838d7d8ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug discovery services revenue from contracts with customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_2576b311-05c7-402d-86cc-f8e6fbc13e49_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in liabilities, net of acquisition:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_307bcdf3-8e4e-4618-95c2-ee579d3aa9b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a4718c4f-9ede-4108-98ba-10ade11027bf_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_dbce5a3e-cc69-4046-a10b-8866252f8691_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcf86342-4592-4752-9fa7-233f49679bf7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_818e341b-e512-4401-aa90-f0b6e49055c5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest costs capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_78861f79-9320-4ecf-97df-de5f45a14e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_fd7e8608-f9bd-4c69-a09f-11cf64d47436_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_0ad6c263-ea63-4118-9c83-bb82cea252b4_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c0ec978-d903-4ed0-bd21-c1004b7c1426_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_12d858eb-6fcf-4088-9e7c-1bd0080ef457_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a33c5134-4bc8-4759-9755-64bfa12489a3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareContributionRevenueRecognized_b83c6657-70b9-497a-ac9d-c8c28ae8f937_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareContributionRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software contribution revenue recognition</link:label>
    <link:label id="lab_sdgr_SoftwareContributionRevenueRecognized_label_en-US" xlink:label="lab_sdgr_SoftwareContributionRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Contribution Revenue Recognized</link:label>
    <link:label id="lab_sdgr_SoftwareContributionRevenueRecognized_documentation_en-US" xlink:label="lab_sdgr_SoftwareContributionRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software contribution revenue recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognized" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareContributionRevenueRecognized" xlink:to="lab_sdgr_SoftwareContributionRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2dd95fec-edbf-40f1-8a1b-629a47cccaf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_f9c5754e-1eda-4efb-891c-06e5b6738195_negatedLabel_en-US" xlink:label="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_label_en-US" xlink:label="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Depreciation And Amortization</link:label>
    <link:label id="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="lab_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_75513f57-7210-4d5f-8971-fe8299cf9668_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_b0cf35f2-b4d8-4bdd-952d-d22501229852_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_cb7da307-68d0-4d7c-89a5-1e14cc469c5c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_827c11b5-7e04-4dd8-adfe-1271e79656a0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ContractWithCustomersPaymentTerms_e6433e83-b3c3-42dd-8af7-c5b831fb7ec8_terseLabel_en-US" xlink:label="lab_sdgr_ContractWithCustomersPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customers, payment terms</link:label>
    <link:label id="lab_sdgr_ContractWithCustomersPaymentTerms_label_en-US" xlink:label="lab_sdgr_ContractWithCustomersPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customers Payment Terms</link:label>
    <link:label id="lab_sdgr_ContractWithCustomersPaymentTerms_documentation_en-US" xlink:label="lab_sdgr_ContractWithCustomersPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with customers, payment terms.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomersPaymentTerms" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomersPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ContractWithCustomersPaymentTerms" xlink:to="lab_sdgr_ContractWithCustomersPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4ba43f37-2dae-44e4-b909-4a6ca46fddac_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e61dbf60-b054-4e83-8e69-20df39f11e23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bb22d517-c521-429c-b59b-40ffa4da165a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6281c558-98d9-45c6-ac3b-d2f3ef8fc5ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ca4ef123-929e-48a1-871b-b48f7b8747c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities_639c72f7-738e-4e4d-91f3-9906b73db9a1_terseLabel_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of lease liabilities - operating leases</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities_label_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Finance Lease, For Lease Liabilities</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities_documentation_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Finance Lease, For Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" xlink:to="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_d63d07cd-4137-4b73-8ecf-c5e0a221b20e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon vesting of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_35827a1c-01b3-4af3-8236-a19d4fe6e186_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7b1143f7-7cdb-47f4-b471-027004058280_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_2c37a239-f1d2-43b9-84d3-6b6491703322_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_UnallocatedCommonStockMember_2b7b1aa4-e344-40bd-b392-8be28f0f5366_terseLabel_en-US" xlink:label="lab_sdgr_UnallocatedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_sdgr_UnallocatedCommonStockMember_label_en-US" xlink:label="lab_sdgr_UnallocatedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated Common Stock [Member]</link:label>
    <link:label id="lab_sdgr_UnallocatedCommonStockMember_documentation_en-US" xlink:label="lab_sdgr_UnallocatedCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedCommonStockMember" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_UnallocatedCommonStockMember" xlink:to="lab_sdgr_UnallocatedCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d9c5acbb-3ff8-44cb-9005-9d875d5840b9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b1af207f-ec14-401d-8863-ec89f4728329_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_84024af9-e507-4aac-a352-540b104c800b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8489c91c-0ff7-4f52-9b72-5f812fa31b59_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_990a6036-172d-4383-a251-514dd54cd0f8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_aa3354d9-a5f8-4ae0-92b4-c80a32684511_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_38944d0d-8781-4a3c-9e18-75e99ff10cfd_terseLabel_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible to vest (in shares)</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_label_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Eligible To Vest, Number</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_documentation_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Eligible To Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" xlink:to="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_68df5349-3f9f-4c2e-a0a3-d1c8ba28cd27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3164d266-e932-4fa9-964a-eb84a9dc1a14_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3a93f498-cd53-4517-9485-2e9a4afcb031_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_6abb3a27-4fd7-4149-a79d-4df79becb20f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a121b7c8-f9ce-43ea-a459-27cf4adfd9bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d6e7014-95a3-4b61-b58b-7caafe9a7e6b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_45ca31ec-73b9-4456-84cc-10f320457d9a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8b6fbe8f-5ea9-4a03-8e86-c816b57d9a89_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_be2e3869-6dd4-4905-97a2-c1403546c719_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_a80676a6-02fc-4272-8bff-3ab097ba2f84_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_97be2cda-b52a-46fc-ac4f-df5a064e5d80_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, long-term</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_616c4a6f-3e4b-402e-bb0b-555d47fa6737_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1b04d880-5fa6-42c1-9b65-a7ef225e27dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning, January 1, 2023 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b66a8a4a-76db-484f-b3f2-09972a4f928c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2023 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a0709263-3452-4371-bd26-0c15b6756f0e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be823836-3b25-4491-9895-880218a96fae_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning, January 1, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ed9eff1-6a3b-4dde-85e1-5da39c389b91_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending, December 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_b0f43114-440d-4a1e-9ac8-385f981e2183_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_a8ae0342-6cb5-48ae-bf65-9064f6e67e41_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_c394907b-c1e7-49b3-8df6-24c3aab70186_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments to purchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_aa755ccd-9036-43d1-a0c3-e222fb6d8f9d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_76dbde32-9ae0-4e13-ba3b-04017b607999_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_a5b89ec4-e286-4412-885b-9c13f5614923_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution from equity investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AdrMember_f1611861-d73d-4904-809f-c447ec6fa902_terseLabel_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADR</link:label>
    <link:label id="lab_dei_AdrMember_label_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AdrMember" xlink:to="lab_dei_AdrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ebf0f327-99e5-4cb1-8c2a-7dbd257722a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_bf898314-23f9-4e54-948d-1426743a4144_terseLabel_en-US" xlink:label="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible Performance Based Restricted Stock Units</link:label>
    <link:label id="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Performance Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" xlink:href="sdgr-20241231.xsd#sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DrugDiscoverySegmentMember_5103d3c0-1093-4bae-b9f5-6b7f5f6ded6f_terseLabel_en-US" xlink:label="lab_sdgr_DrugDiscoverySegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug discovery</link:label>
    <link:label id="lab_sdgr_DrugDiscoverySegmentMember_label_en-US" xlink:label="lab_sdgr_DrugDiscoverySegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Discovery Segment [Member]</link:label>
    <link:label id="lab_sdgr_DrugDiscoverySegmentMember_documentation_en-US" xlink:label="lab_sdgr_DrugDiscoverySegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug Discovery Segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoverySegmentMember" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoverySegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DrugDiscoverySegmentMember" xlink:to="lab_sdgr_DrugDiscoverySegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0996f5b7-454b-4308-b0d5-9d653654af6e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_02e65b13-40e4-48f2-8db0-1d668a29a0b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll, taxes, and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RobertAbelMember_label_en-US" xlink:label="lab_sdgr_RobertAbelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Robert Abel [Member]</link:label>
    <link:label id="lab_sdgr_RobertAbelMember_documentation_en-US" xlink:label="lab_sdgr_RobertAbelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Robert Abel</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RobertAbelMember" xlink:href="sdgr-20241231.xsd#sdgr_RobertAbelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RobertAbelMember" xlink:to="lab_sdgr_RobertAbelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_87e93e81-dc24-427f-8226-1cd167a7136f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of common stock upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_b05aba18-b9cf-4c30-852e-841d57b3c6b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d4134ed1-b37c-4d8c-9d9d-ed1104ce3476_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_66f25e34-2ab2-438a-add6-5278f86919b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_457777d6-96b7-46eb-91bf-03159f5879a3_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_BristolMyersSquibbMember_c986b579-35f6-4e5a-ae8a-8b75e2c4b666_terseLabel_en-US" xlink:label="lab_sdgr_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMS</link:label>
    <link:label id="lab_sdgr_BristolMyersSquibbMember_label_en-US" xlink:label="lab_sdgr_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_sdgr_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_sdgr_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BristolMyersSquibbMember" xlink:href="sdgr-20241231.xsd#sdgr_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_BristolMyersSquibbMember" xlink:to="lab_sdgr_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_72b166e4-e059-4723-a7d1-b25e71a6ddad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ed5641ea-6877-499e-866f-e0b069f299fc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ContractAssetsMember_78af24ab-4903-4e80-a84b-2163d0e78bf2_terseLabel_en-US" xlink:label="lab_sdgr_ContractAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:label id="lab_sdgr_ContractAssetsMember_label_en-US" xlink:label="lab_sdgr_ContractAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Assets [Member]</link:label>
    <link:label id="lab_sdgr_ContractAssetsMember_documentation_en-US" xlink:label="lab_sdgr_ContractAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractAssetsMember" xlink:href="sdgr-20241231.xsd#sdgr_ContractAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ContractAssetsMember" xlink:to="lab_sdgr_ContractAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_227a5a53-4c05-4522-bb00-a353196729a4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_30925c49-d4df-420d-9029-95e7e335c7a9_terseLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Two</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_437ab54e-8cb7-401c-8ef8-59e80ab4c45d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_a337deb7-d30f-42fd-a2a1-733c4134521a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_28b8429c-8993-4368-818b-894c6bf6093a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a5bb39a2-40da-4478-af55-c5bfa86a7047_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock_bc914fad-282e-4c4b-9fe6-11c9a0c17113_terseLabel_en-US" xlink:label="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Marketable Securities and Restricted Cash</link:label>
    <link:label id="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Marketable Securities And Restricted Cash Policy [Policy Text Block]</link:label>
    <link:label id="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and marketable securities and restricted cash policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" xlink:href="sdgr-20241231.xsd#sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" xlink:to="lab_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_UnbilledAndOtherReceivablesCurrent_a62446ef-b0f3-46e6-a344-ce3d5acbed68_terseLabel_en-US" xlink:label="lab_sdgr_UnbilledAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled and other receivables, net of allowance for unbilled receivables of $100 and $100</link:label>
    <link:label id="lab_sdgr_UnbilledAndOtherReceivablesCurrent_label_en-US" xlink:label="lab_sdgr_UnbilledAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled And Other Receivables Current</link:label>
    <link:label id="lab_sdgr_UnbilledAndOtherReceivablesCurrent_documentation_en-US" xlink:label="lab_sdgr_UnbilledAndOtherReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unbilled and other receivables current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnbilledAndOtherReceivablesCurrent" xlink:href="sdgr-20241231.xsd#sdgr_UnbilledAndOtherReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_UnbilledAndOtherReceivablesCurrent" xlink:to="lab_sdgr_UnbilledAndOtherReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e9fbfeae-ec51-433e-929f-877c9935c2cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_TwentyTwentyStockPlanMember_cc23a8b1-dc8d-47ed-9851-43dbb157916b_terseLabel_en-US" xlink:label="lab_sdgr_TwentyTwentyStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twenty Twenty Stock Plan</link:label>
    <link:label id="lab_sdgr_TwentyTwentyStockPlanMember_label_en-US" xlink:label="lab_sdgr_TwentyTwentyStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Stock Plan [Member]</link:label>
    <link:label id="lab_sdgr_TwentyTwentyStockPlanMember_documentation_en-US" xlink:label="lab_sdgr_TwentyTwentyStockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty twenty stock plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TwentyTwentyStockPlanMember" xlink:href="sdgr-20241231.xsd#sdgr_TwentyTwentyStockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_TwentyTwentyStockPlanMember" xlink:to="lab_sdgr_TwentyTwentyStockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_f405035d-84d1-478a-9bc4-33bf9f5f65d5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f26f92ab-66c3-49df-9d6c-53f6826f913f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuances of common stock upon stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ba6be398-2f93-498d-9ec5-670ecd0887c4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to vested stock options granted</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_59017b75-51be-412f-bbf0-07bf928a201e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on equity investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f0dc14a0-7493-4019-8db8-b7e91e5a7591_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on equity investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bdcee4ff-8f70-467a-9a3f-e8f6e6efe26b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_14af81e3-4d8b-4322-a281-49e37af75513_terseLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year One</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiability_1e3ee8af-393d-46b3-8075-f1758aeb1c14_totalLabel_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiability_label_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiability" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_OperatingAndFinanceLeaseLiability" xlink:to="lab_sdgr_OperatingAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_54388184-d34b-4c75-a4bd-a7e1d6331aef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_HostedSoftwareMember_cb41b5ea-6032-45dd-ad3b-652c16daf407_terseLabel_en-US" xlink:label="lab_sdgr_HostedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hosted software</link:label>
    <link:label id="lab_sdgr_HostedSoftwareMember_label_en-US" xlink:label="lab_sdgr_HostedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hosted Software [Member]</link:label>
    <link:label id="lab_sdgr_HostedSoftwareMember_documentation_en-US" xlink:label="lab_sdgr_HostedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hosted software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_HostedSoftwareMember" xlink:href="sdgr-20241231.xsd#sdgr_HostedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_HostedSoftwareMember" xlink:to="lab_sdgr_HostedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_AllowanceForUnbilledReceivablesCurrent_ba642be1-ddf1-4650-bf0f-053ec654957f_terseLabel_en-US" xlink:label="lab_sdgr_AllowanceForUnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for unbilled receivable</link:label>
    <link:label id="lab_sdgr_AllowanceForUnbilledReceivablesCurrent_label_en-US" xlink:label="lab_sdgr_AllowanceForUnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Unbilled Receivables Current</link:label>
    <link:label id="lab_sdgr_AllowanceForUnbilledReceivablesCurrent_documentation_en-US" xlink:label="lab_sdgr_AllowanceForUnbilledReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance for unbilled receivables current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AllowanceForUnbilledReceivablesCurrent" xlink:href="sdgr-20241231.xsd#sdgr_AllowanceForUnbilledReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_AllowanceForUnbilledReceivablesCurrent" xlink:to="lab_sdgr_AllowanceForUnbilledReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_18db93c8-4de2-4fff-bf43-2ea980e87052_terseLabel_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement percent</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_label_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Achievement Percent</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_documentation_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Achievement Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" xlink:to="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_014ab74c-3270-42e8-8b52-ca8a5c4b1345_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LabEquipmentMember_3955bf76-af30-410f-b4af-3cf66e628c4e_terseLabel_en-US" xlink:label="lab_sdgr_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_sdgr_LabEquipmentMember_label_en-US" xlink:label="lab_sdgr_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_sdgr_LabEquipmentMember_documentation_en-US" xlink:label="lab_sdgr_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lab Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LabEquipmentMember" xlink:href="sdgr-20241231.xsd#sdgr_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LabEquipmentMember" xlink:to="lab_sdgr_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c5e27264-310f-4d88-b308-106914d58979_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1237a60e-9b86-4a15-a09f-d455459a0609_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_fcea1a43-0105-4b98-bbfa-df215b78ee14_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareContributionRevenueRecognitionAmount_2c09a16b-a968-4117-946d-c377e6f8ee21_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareContributionRevenueRecognitionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software contribution revenue recognition amount</link:label>
    <link:label id="lab_sdgr_SoftwareContributionRevenueRecognitionAmount_label_en-US" xlink:label="lab_sdgr_SoftwareContributionRevenueRecognitionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Contribution Revenue Recognition Amount</link:label>
    <link:label id="lab_sdgr_SoftwareContributionRevenueRecognitionAmount_documentation_en-US" xlink:label="lab_sdgr_SoftwareContributionRevenueRecognitionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software contribution revenue recognition amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognitionAmount" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognitionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareContributionRevenueRecognitionAmount" xlink:to="lab_sdgr_SoftwareContributionRevenueRecognitionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_a71fa58a-f95e-4d9f-80dd-a17ff8797922_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bdeff996-78bf-435f-9360-a31c49655da1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_eb0809ad-7220-47dd-b1ba-9105bb19d637_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_VotingCommonStockMember_eea4412f-b3d4-4212-ad28-9c95f42d6a22_terseLabel_en-US" xlink:label="lab_sdgr_VotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting Common Stock</link:label>
    <link:label id="lab_sdgr_VotingCommonStockMember_label_en-US" xlink:label="lab_sdgr_VotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voting Common Stock [Member]</link:label>
    <link:label id="lab_sdgr_VotingCommonStockMember_documentation_en-US" xlink:label="lab_sdgr_VotingCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Voting common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_VotingCommonStockMember" xlink:href="sdgr-20241231.xsd#sdgr_VotingCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_VotingCommonStockMember" xlink:to="lab_sdgr_VotingCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock_caa94444-11f2-435c-ad0d-7ee29b7cd7ce_terseLabel_en-US" xlink:label="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development and Advertising</link:label>
    <link:label id="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development And Advertising Policy [Policy Text Block]</link:label>
    <link:label id="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development and advertising policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" xlink:href="sdgr-20241231.xsd#sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" xlink:to="lab_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8ab16737-1418-4907-8eb8-8a3df9a704b4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_86212540-3f82-43ee-a0b3-a15d169c0ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_c83c246e-c4d3-4a96-bdb5-fb8ab5a1605b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5326723e-ee94-4691-876e-dbfeb42ba60f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_4a11b5ef-c7b7-4105-916f-15c40c5d61d9_verboseLabel_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of lease payments</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_sdgr_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_275f70aa-759e-49d3-bf10-c48e703eb100_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_4adcdac9-86c4-4ab5-8d42-249042ab3201_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in market value of investments, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NumberOfPerformanceObligations_0b2c049d-7187-4d82-9025-bd943fb81494_terseLabel_en-US" xlink:label="lab_sdgr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_sdgr_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_sdgr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:label id="lab_sdgr_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_sdgr_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPerformanceObligations" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NumberOfPerformanceObligations" xlink:to="lab_sdgr_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_568f1715-e9f7-4a7f-8b8f-1980fdb7a4fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_83245d82-c8df-426f-8b9d-78f84f940b80_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6b297d6-e7b1-4122-9533-c2606f08f1cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0bdf67bd-6cf7-4d45-b937-d769228f1f18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_f0dd3c51-a278-45c0-8d61-27c73249dd0b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:to="lab_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b6ed3241-4748-421d-bce1-b7215f64e0bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bef3a5e6-23d5-4b03-9481-47405df1101e_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6c9c858d-2044-427c-a098-d273bdc58fa1_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4f9ee251-a8f4-40df-aba9-b4e2d97b5bd9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_a31d20ee-e99f-44b6-87ed-98358a990946_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for the Impairment of Long Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_098c3ea5-52e3-4193-82ac-822cfefb644e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7ab17f07-0268-4874-8380-905ffcfd9dbf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_26144e75-6119-4c41-969d-1bf52746fba9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3c3c8aa7-2ec8-4360-ad64-99e6aa792e87_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7fcc1026-e2ad-485d-b2db-3f7e9d76c6ea_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in ATM offering, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncome_6b4c4d87-9a02-4bc5-909f-2d357d9515ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncome" xlink:to="lab_us-gaap_DeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NumberOfPreferredSharesPurchased_1c03af75-b54f-4d6c-9afb-7d08852c06dc_terseLabel_en-US" xlink:label="lab_sdgr_NumberOfPreferredSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of preferred shares purchased</link:label>
    <link:label id="lab_sdgr_NumberOfPreferredSharesPurchased_label_en-US" xlink:label="lab_sdgr_NumberOfPreferredSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Preferred Shares Purchased</link:label>
    <link:label id="lab_sdgr_NumberOfPreferredSharesPurchased_documentation_en-US" xlink:label="lab_sdgr_NumberOfPreferredSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of preferred shares purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPreferredSharesPurchased" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPreferredSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NumberOfPreferredSharesPurchased" xlink:to="lab_sdgr_NumberOfPreferredSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bd52e993-2c8d-493f-9fb4-c2220b63609b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_55068585-8b8a-47cb-ad0b-125b5c0f711f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dd4cab27-173f-496f-8bc6-20bf7918fdb3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_OperatingAndFinanceLeasePayments_35167e55-a650-4d8e-84d3-25e8a4d8734e_terseLabel_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for leases</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeasePayments_label_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Payments</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeasePayments_documentation_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeasePayments" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_OperatingAndFinanceLeasePayments" xlink:to="lab_sdgr_OperatingAndFinanceLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_32f23766-af34-4b75-bdb3-2ea7be382324_terseLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, After Year Five</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_394b4753-689c-4396-950b-00483129c11b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CommissionExpense_458313be-684c-421c-a845-3cb7979c9c10_terseLabel_en-US" xlink:label="lab_sdgr_CommissionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission expense</link:label>
    <link:label id="lab_sdgr_CommissionExpense_label_en-US" xlink:label="lab_sdgr_CommissionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commission Expense</link:label>
    <link:label id="lab_sdgr_CommissionExpense_documentation_en-US" xlink:label="lab_sdgr_CommissionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commission expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CommissionExpense" xlink:href="sdgr-20241231.xsd#sdgr_CommissionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CommissionExpense" xlink:to="lab_sdgr_CommissionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_30544348-cde0-4337-834c-7fd25af1cab2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_113a98d0-8ac1-4fb1-9e55-d637587f5ef4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a982d1ab-b215-448c-ac9b-03984dc6410a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_03f59ab9-63a5-4f73-8c4b-bd3c4c6d89f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c9bb9025-523b-467d-904c-fab857c3ecab_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_StructureTherapeuticsMember_602a00b4-8f97-4676-b797-19ada56450e5_terseLabel_en-US" xlink:label="lab_sdgr_StructureTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Structure Therapeutics</link:label>
    <link:label id="lab_sdgr_StructureTherapeuticsMember_label_en-US" xlink:label="lab_sdgr_StructureTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Structure Therapeutics [Member]</link:label>
    <link:label id="lab_sdgr_StructureTherapeuticsMember_documentation_en-US" xlink:label="lab_sdgr_StructureTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Structure therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_StructureTherapeuticsMember" xlink:href="sdgr-20241231.xsd#sdgr_StructureTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_StructureTherapeuticsMember" xlink:to="lab_sdgr_StructureTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_49dd22a4-decb-4a3e-90ee-ed4a3c1ee5ae_terseLabel_en-US" xlink:label="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">July 2024 Agreement With Bill &amp; Melinda Gates Foundation</link:label>
    <link:label id="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_label_en-US" xlink:label="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">July 2024 Agreement With Bill &amp; Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">July 2024 Agreement With Gates Ventures Limited Liability Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" xlink:href="sdgr-20241231.xsd#sdgr_July2024AgreementWithBillMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" xlink:to="lab_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases_3cb1e9cd-d0a0-4643-9cd2-253afee1ba95_terseLabel_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of right of use assets - operating leases</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases_label_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Leases</link:label>
    <link:label id="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases_documentation_en-US" xlink:label="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Or part noncash acquisitions of right of use assets in exchange for lease obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" xlink:to="lab_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d6581b0b-0b0e-49ae-8284-ceb3c4ed2ab3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f1594c69-bb63-4b0c-aedd-2cc1ee1c1be3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_778a1e8b-c61a-483b-bb90-cf27d3bb8e2c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_75beacd1-ded1-40fa-9a6a-4a2ed6972bb4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_56d63861-7d88-4966-8ab1-830440b4d3d0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_DrugDiscoveryServicesMember_d553d43d-5442-4d6a-bdb5-87e58f1267cd_terseLabel_en-US" xlink:label="lab_sdgr_DrugDiscoveryServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug Discovery Services</link:label>
    <link:label id="lab_sdgr_DrugDiscoveryServicesMember_label_en-US" xlink:label="lab_sdgr_DrugDiscoveryServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Discovery Services [Member]</link:label>
    <link:label id="lab_sdgr_DrugDiscoveryServicesMember_documentation_en-US" xlink:label="lab_sdgr_DrugDiscoveryServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug discovery member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_DrugDiscoveryServicesMember" xlink:to="lab_sdgr_DrugDiscoveryServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0956689e-440f-45a6-9590-2e7f21e9bc8b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_UnallocatedAbstract_8f6659ee-5611-445f-b79a-56980556e384_terseLabel_en-US" xlink:label="lab_sdgr_UnallocatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unallocated (expense) income:</link:label>
    <link:label id="lab_sdgr_UnallocatedAbstract_label_en-US" xlink:label="lab_sdgr_UnallocatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated [Abstract]</link:label>
    <link:label id="lab_sdgr_UnallocatedAbstract_documentation_en-US" xlink:label="lab_sdgr_UnallocatedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedAbstract" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_UnallocatedAbstract" xlink:to="lab_sdgr_UnallocatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a28c7f1f-2264-42ea-98ae-fa9853ac65d1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_81949237-4974-4fc4-83c6-379753d9192e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_d847f24d-7e40-4f47-ba87-cb8495759c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of (Loss) Income Before Income Taxes by Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_220b8878-1e51-42fe-b5c6-850ea6dced18_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b786be46-65ed-4d2d-8d72-9f652b489eb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8b47deab-9a5c-47b3-8f20-63fdd2554701_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6b81ebe0-1af0-41cc-a8b4-9a1ee9f7a9d8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9f09c347-9250-496e-a8d3-beffbd5b07ec_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_129c4bce-2015-4e21-b211-06ca8254159e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_620e3aaa-e796-4a03-ab24-dc2bf2d6af5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase) decrease in assets, net of acquisition:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_c207a3d6-3af9-4baa-8c4b-eaba4674f392_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment revenues:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0ab6e825-4d35-46aa-b812-f8f8faf676cc_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_75d8ec24-9730-45af-8ba0-4c6865d93768_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_15084ab1-f26f-4948-be0c-b5e4c81c2ccf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8ba6b6ae-b103-4da0-b17c-415099184535_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_e6d1ab25-4cad-4cdb-aa35-97c086d0ebf2_terseLabel_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research, development and regulatory milestones, amount</link:label>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_label_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Research, Development and Regulatory Milestones, Amount</link:label>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_documentation_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Research, Development and Regulatory Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" xlink:to="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6fe7d67e-fd30-4b80-a85b-f66e1a7e7126_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_97b31e33-2e5e-4f3b-88d5-16bd5bcce0cd_terseLabel_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration, commercial milestones, amount</link:label>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_label_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestones, Amount</link:label>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_documentation_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" xlink:to="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_7c150624-09b2-4f22-a58b-cc4a68ec5bb4_terseLabel_en-US" xlink:label="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return-to-provision adjustments</link:label>
    <link:label id="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_label_en-US" xlink:label="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Return To Provision Adjustments</link:label>
    <link:label id="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_documentation_en-US" xlink:label="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation return-to-provision adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:href="sdgr-20241231.xsd#sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="lab_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21ddc9eb-5761-493e-bbd1-8da148dcc64a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, December 31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_AjaxTherapeuticsIncMember_519df4f1-8917-4976-b416-09bafc085f03_terseLabel_en-US" xlink:label="lab_sdgr_AjaxTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ajax Therapeutics, Inc</link:label>
    <link:label id="lab_sdgr_AjaxTherapeuticsIncMember_label_en-US" xlink:label="lab_sdgr_AjaxTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ajax Therapeutics Inc [Member]</link:label>
    <link:label id="lab_sdgr_AjaxTherapeuticsIncMember_documentation_en-US" xlink:label="lab_sdgr_AjaxTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ajax Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AjaxTherapeuticsIncMember" xlink:href="sdgr-20241231.xsd#sdgr_AjaxTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_AjaxTherapeuticsIncMember" xlink:to="lab_sdgr_AjaxTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_92e94d68-1e49-4584-a2e9-9bf1f21273c6_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84910f8b-b504-41ba-92a6-1010d7488601_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_19f98cb5-1eea-47c3-a1e0-0e66cb8478d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb04265f-3240-4774-a30d-b0f8e0d8af25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average per share grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_494d374f-b359-470d-8180-b4d0fc4ffe6d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-marketable equity security</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_c2ab7e4f-f33a-4b55-bbdf-8c809eaabaf7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_44d5c8cb-3f27-443d-bced-6fc23eadbf3e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenue expected to be recognized</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0de45905-339f-41b8-af96-0674133be580_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4d667b85-bd7c-46bd-9e20-48083041ac00_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_c249c1b5-0422-4cf3-9178-379d628f3630_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution_acb686db-03bb-406d-95df-d0fde474289a_terseLabel_en-US" xlink:label="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in right of use assets due to contingency resolution</link:label>
    <link:label id="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution_label_en-US" xlink:label="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Right Of Use Assets Due To Contingency Resolution</link:label>
    <link:label id="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution_documentation_en-US" xlink:label="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase In Right Of Use Assets Due To Contingency Resolution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" xlink:to="lab_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b5ac623a-6db5-482a-b981-141bd02fa685_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesAssetsMember_693d7fdc-28cc-4858-ac97-a36818c7279f_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_SecuritiesAssetsMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities (Assets) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuritiesAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesAssetsMember" xlink:to="lab_us-gaap_SecuritiesAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e13ae4df-9e00-4422-bb37-64f8bbdbef0e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f2202fac-6af8-4ab0-b005-e0a1c135a7d2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_3767df36-e9f0-4eab-8aa9-7607330ea72b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SharebasedCompensationAwardTrancheFourMember_a69d4aba-38bf-4d97-b176-5cfb6e26ecae_terseLabel_en-US" xlink:label="lab_sdgr_SharebasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Four</link:label>
    <link:label id="lab_sdgr_SharebasedCompensationAwardTrancheFourMember_label_en-US" xlink:label="lab_sdgr_SharebasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Award Tranche Four [Member]</link:label>
    <link:label id="lab_sdgr_SharebasedCompensationAwardTrancheFourMember_documentation_en-US" xlink:label="lab_sdgr_SharebasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation award tranche four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SharebasedCompensationAwardTrancheFourMember" xlink:href="sdgr-20241231.xsd#sdgr_SharebasedCompensationAwardTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SharebasedCompensationAwardTrancheFourMember" xlink:to="lab_sdgr_SharebasedCompensationAwardTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cd4f0bb2-f2f3-4f0f-a4f0-501e5e433479_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9aa5a59c-eadb-4a46-95cb-899c70ec3580_negatedLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4e790f9b-6449-4c3a-a433-2ef6f795a433_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bdefcd7d-3107-4408-952a-4cd8ea0d8b52_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_31ba9444-3ca1-404d-8984-b58c950cdd71_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0f42d81f-6afb-49cf-be4e-d6cb432fdfbf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposition and sale of equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_df8328e7-454a-464b-91fd-07c22aff6fa2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_PercentageOfVotingSecurities_5e69ff19-938c-4ab2-a091-5b91a87c8402_terseLabel_en-US" xlink:label="lab_sdgr_PercentageOfVotingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting securities</link:label>
    <link:label id="lab_sdgr_PercentageOfVotingSecurities_label_en-US" xlink:label="lab_sdgr_PercentageOfVotingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Voting Securities</link:label>
    <link:label id="lab_sdgr_PercentageOfVotingSecurities_documentation_en-US" xlink:label="lab_sdgr_PercentageOfVotingSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of voting securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PercentageOfVotingSecurities" xlink:href="sdgr-20241231.xsd#sdgr_PercentageOfVotingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_PercentageOfVotingSecurities" xlink:to="lab_sdgr_PercentageOfVotingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_74d92e27-d410-434e-83d1-18d003bf1c51_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_NimbusTherapeuticsLLCMember_41d1a74c-7397-428f-abe0-c03f93faa574_verboseLabel_en-US" xlink:label="lab_sdgr_NimbusTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Nimbus Therapeutics, LLC</link:label>
    <link:label id="lab_sdgr_NimbusTherapeuticsLLCMember_label_en-US" xlink:label="lab_sdgr_NimbusTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nimbus Therapeutics L L C [Member]</link:label>
    <link:label id="lab_sdgr_NimbusTherapeuticsLLCMember_documentation_en-US" xlink:label="lab_sdgr_NimbusTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nimbus Therapeutics LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NimbusTherapeuticsLLCMember" xlink:href="sdgr-20241231.xsd#sdgr_NimbusTherapeuticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_NimbusTherapeuticsLLCMember" xlink:to="lab_sdgr_NimbusTherapeuticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ac904cf8-d9a6-4845-b5ed-e42d974add1d_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_f521e203-41b2-4ecf-b604-e1b1aa2c5a9d_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Point in Time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_310e1542-8259-4623-b0f5-c2a6e082e8ab_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_2467b6f0-4d04-4891-8377-4f0430eb95a5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_7e6eba43-ecf0-4b07-bdd0-33e6f7a4cb40_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_974d2983-4849-4c04-8ee2-3a6569067ca9_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_2aaaf29b-2932-4fe2-8a10-184eb45471f2_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total segment gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b4ad715a-58a6-41bc-ad29-6d67de6a44b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_08478123-fa8b-4bc9-a6ac-8adc70ccd0f4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_6a39ff09-bad6-4db3-8540-32a7301ba3f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9e4471bd-888a-4e60-98bb-d5ec6ecfd4d3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_719a2896-a0c1-4d59-9b24-a24707da0682_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eedd62b5-aab6-4f68-94ca-979b928fbbb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5cf10917-9aa4-4fd6-bb83-1097a23422c4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_77214c43-456c-4ab8-b907-a5665a151c37_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4b014669-8972-4d85-86db-c77e7b887b6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in ATM offering, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9153b69c-fc7b-48cc-af9e-c2b0ee3a0388_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9667ee0d-9e88-4295-bda0-04b98bc06fa6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2bb2ab51-98f4-48dc-9586-1a8f52326b81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Classification of Stock Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_feae160e-3bc9-4b5a-8efe-abf971dd1af0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c7ab550-8df5-4097-a02c-7ed2a51fc90d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e1f5ad5b-ba17-492a-b99c-ba02513976de_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_f290f754-6a04-4de1-aa5f-a8efc39d381f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_82bc0636-9c24-4502-a206-3f9ad5e33c5c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_56d32147-4f34-4f1c-9d8a-a9bd5e5ab815_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c36e81e7-b64d-4f9a-a3fe-8352a126f4be_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d45d6831-1d84-478a-a3ec-0608bf026aaa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_1c2066ad-f6a1-499f-a055-c3eb088eb7e5_negatedLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm_f4ef1346-f432-4adf-9aaf-ca42291237e9_terseLabel_en-US" xlink:label="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm_label_en-US" xlink:label="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance And Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm_documentation_en-US" xlink:label="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance And Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:href="sdgr-20241231.xsd#sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:to="lab_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a1a325a6-93ef-44b9-a075-9bf487c22706_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_03c5bb06-a1f9-4a89-8953-f893ae647463_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_31efc316-613b-45ac-8c97-a123b90a9af8_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on equity investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_07b865f4-d33c-4293-afd8-7cce8b96459a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f2d1b6b6-1d17-4cf0-b873-47496fb86f96_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SignificantAccountingPoliciesTable_cec6d8c1-e0bd-4309-9cbb-c9a34e3e042e_terseLabel_en-US" xlink:label="lab_sdgr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sdgr_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_sdgr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sdgr_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_sdgr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SignificantAccountingPoliciesTable" xlink:href="sdgr-20241231.xsd#sdgr_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable" xlink:to="lab_sdgr_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6d962ff6-221c-4528-8b51-5051caa64a1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cbf829af-5804-4074-aa1f-5a689cbe03ad_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_979f0ac1-245d-4c2c-b19c-a103bc13313c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f798051-4208-48d5-94d1-72e8e6d8ea5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_57cadda7-d868-4877-8556-0713808d6756_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to common and limited common stockholders, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_3f170cd8-288f-4750-8037-2d9708c989cc_terseLabel_en-US" xlink:label="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available to issue in transaction</link:label>
    <link:label id="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_label_en-US" xlink:label="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Remaining Value Of Shares Available For Issuance</link:label>
    <link:label id="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Remaining Value Of Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" xlink:href="sdgr-20241231.xsd#sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" xlink:to="lab_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_233caa2d-6138-4c02-b5b5-d318e0ea8193_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f178c1b2-6da1-4af6-963d-4f919d207e64_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in ATM offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember_b6f63c3c-6526-451e-be13-6e0c1f128326_terseLabel_en-US" xlink:label="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research, Collaboration and License Agreement</link:label>
    <link:label id="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Collaboration and License Agreement [Member]</link:label>
    <link:label id="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research, Collaboration and License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember" xlink:href="sdgr-20241231.xsd#sdgr_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember" xlink:to="lab_sdgr_ResearchCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71fc7c97-a42a-4336-ab78-27fae93bad6f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e2753366-268b-4393-a55d-8efe51bcf771_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_76fb992a-4b82-4467-b6f8-d853fdf32304_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_71e47613-8960-49be-8acd-e9e416995ed3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_a42eac35-cc46-4dec-bb74-6e0f9c612559_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareContributionMember_632c8d96-a29c-4d26-acc0-8d56d5d0fa81_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software contribution</link:label>
    <link:label id="lab_sdgr_SoftwareContributionMember_label_en-US" xlink:label="lab_sdgr_SoftwareContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Contribution [Member]</link:label>
    <link:label id="lab_sdgr_SoftwareContributionMember_documentation_en-US" xlink:label="lab_sdgr_SoftwareContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionMember" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareContributionMember" xlink:to="lab_sdgr_SoftwareContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4bfd0b5b-db94-4003-b132-9ab135b37f73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2fea26f6-62b1-4c8a-831e-bca311d6c91f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_df159df4-9d6f-4aa5-aee6-341b09786135_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_SoftwareSegmentMember_461b2277-ce3d-40dd-ba88-5873c8928d8c_terseLabel_en-US" xlink:label="lab_sdgr_SoftwareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_sdgr_SoftwareSegmentMember_label_en-US" xlink:label="lab_sdgr_SoftwareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Segment [Member]</link:label>
    <link:label id="lab_sdgr_SoftwareSegmentMember_documentation_en-US" xlink:label="lab_sdgr_SoftwareSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software Segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareSegmentMember" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_SoftwareSegmentMember" xlink:to="lab_sdgr_SoftwareSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_038cae97-5c53-40b5-9f10-ee2bf3815010_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cca61e0d-7b21-4db0-832f-934bb4a12ea4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3e07da1c-b5f8-439d-93a0-0af2ec3ce172_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ca37f144-23d3-4937-bfc0-8776e954ad40_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested stock options granted</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1ff8a945-072e-4851-9f8e-e0216448867e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_548b903c-678b-4c93-8db2-8cf1733a4485_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_f26e2540-0434-42fe-8cf6-1c9177322d5b_terseLabel_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity award conversion rate to shares (in shares)</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_label_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Award Conversion Upon Achievement, Number Of Shares Per Award</link:label>
    <link:label id="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_documentation_en-US" xlink:label="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Award Conversion Upon Achievement, Number Of Shares Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" xlink:to="lab_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fd6d6ee8-b4ba-4ebe-8b68-f704fe07de85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b4caa913-f176-47b9-9c1f-b3a51672de50_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bbdfa48a-55f2-44ce-89b7-7fe61cc6d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_cceea678-fd06-4c92-8dd8-7d2b899a4afc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_becbdc29-309b-4fb8-94fc-31799676cf29_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_863f8321-d0d5-4b76-90c6-9b97327f4834_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_46bbedea-a68a-4c2b-a31b-39d10cbcc22c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7e5d85a2-2ac8-4275-bf83-104aad08bdf4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_992b16e8-ffa6-4bc4-9603-fa30507bb9ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4c3175e2-1516-428e-bc63-bb8c1c9d8100_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_cab44e5a-061e-49e7-9862-1867881add31_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_d4551977-efcf-4970-bc3b-3a08c22beb07_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total software revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_b3a1ea08-24d6-4c75-9c09-e95d204ee76c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_05fb0019-4dee-471b-b55a-458d9bbc48fa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_ProfessionalServicesMember_fd9ee9be-3509-4c4d-a918-a7acf2d4cb7d_terseLabel_en-US" xlink:label="lab_sdgr_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_sdgr_ProfessionalServicesMember_label_en-US" xlink:label="lab_sdgr_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional Services [Member]</link:label>
    <link:label id="lab_sdgr_ProfessionalServicesMember_documentation_en-US" xlink:label="lab_sdgr_ProfessionalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Professional services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ProfessionalServicesMember" xlink:href="sdgr-20241231.xsd#sdgr_ProfessionalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_ProfessionalServicesMember" xlink:to="lab_sdgr_ProfessionalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_KarenAkinsanyaMember_label_en-US" xlink:label="lab_sdgr_KarenAkinsanyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Karen Akinsanya [Member]</link:label>
    <link:label id="lab_sdgr_KarenAkinsanyaMember_documentation_en-US" xlink:label="lab_sdgr_KarenAkinsanyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Karen Akinsanya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_KarenAkinsanyaMember" xlink:href="sdgr-20241231.xsd#sdgr_KarenAkinsanyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_KarenAkinsanyaMember" xlink:to="lab_sdgr_KarenAkinsanyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_cfeb466f-e0c0-47a7-89f6-b2397458116d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues by Geographic Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_26107582-7b65-45ef-af51-d7043ad37c13_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax contingencies, net of reversals</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3e6ce4b4-7f2e-4b3a-a6dc-a69fe0676af8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_MorphicHoldingIncMember_2e20079b-fa3d-4a57-a34f-92c7dc27488c_terseLabel_en-US" xlink:label="lab_sdgr_MorphicHoldingIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Morphic Holding, Inc.</link:label>
    <link:label id="lab_sdgr_MorphicHoldingIncMember_label_en-US" xlink:label="lab_sdgr_MorphicHoldingIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Morphic Holding Inc [Member]</link:label>
    <link:label id="lab_sdgr_MorphicHoldingIncMember_documentation_en-US" xlink:label="lab_sdgr_MorphicHoldingIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Morphic holding Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MorphicHoldingIncMember" xlink:href="sdgr-20241231.xsd#sdgr_MorphicHoldingIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_MorphicHoldingIncMember" xlink:to="lab_sdgr_MorphicHoldingIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3b979806-850f-447b-b8f2-a8ce20f307c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_06f9d9a3-c44b-4705-bffe-520b68300542_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_MilestonePaymentYetToBeAchieved_0d1ab287-0f90-4f3a-88fe-f8bed17d1175_terseLabel_en-US" xlink:label="lab_sdgr_MilestonePaymentYetToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment yet to be achieved</link:label>
    <link:label id="lab_sdgr_MilestonePaymentYetToBeAchieved_label_en-US" xlink:label="lab_sdgr_MilestonePaymentYetToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Yet To Be Achieved</link:label>
    <link:label id="lab_sdgr_MilestonePaymentYetToBeAchieved_documentation_en-US" xlink:label="lab_sdgr_MilestonePaymentYetToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment yet to be achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MilestonePaymentYetToBeAchieved" xlink:href="sdgr-20241231.xsd#sdgr_MilestonePaymentYetToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_MilestonePaymentYetToBeAchieved" xlink:to="lab_sdgr_MilestonePaymentYetToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a0066fba-eddf-4418-99cf-fc3ea192c7eb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9173407c-6fc8-459b-b6b0-ade56512569b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c99bce00-9428-49c9-9008-deb23959d3d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to common and limited common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb765849-3eca-446d-8260-7efa2e920a49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_39e9445d-9637-4888-8283-b3e33a9f73c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0269204f-3dd1-4fc8-a860-e2b23bf8d9b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5c649c57-e21a-4f44-ae6b-85febc7c3b18_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_ecac3480-4289-4173-9abe-1492447513d0_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_18b3edb3-282a-4317-b763-ae18ee1f2e22_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2ce01729-b26a-42c6-b0f2-a945f59b3c3c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_61971b4d-39d0-4b39-bdc4-c0ab71be0713_terseLabel_en-US" xlink:label="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:label id="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_label_en-US" xlink:label="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer Before Software Contribution [Member]</link:label>
    <link:label id="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_documentation_en-US" xlink:label="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer before software contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" xlink:href="sdgr-20241231.xsd#sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" xlink:to="lab_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8ccc1ab2-f544-4959-8c6d-24393a8e6b5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fee201c5-168f-459b-87be-fd475097e864_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9c9ee870-52ee-4c08-8df8-76d47334f262_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_41cec01a-e197-40c4-bf81-640e117cd403_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2fb62ff5-de98-4e59-b738-36b89ac0e20b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c7de44d5-579f-4be8-abc1-c631a1bc2aa8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c55d7a9e-b222-4269-aab6-c31bada8bee8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, December 31, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f2793e17-1323-4631-8a8f-10403ae70bd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9ec3476f-e4ab-48e6-808f-a7f7d7e1c6c5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_379e010c-838d-4af6-b7c3-57a949fed235_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CustomerCMember_9ac4ebe4-7369-45ae-ab1c-591d53c570b8_terseLabel_en-US" xlink:label="lab_sdgr_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_sdgr_CustomerCMember_label_en-US" xlink:label="lab_sdgr_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_sdgr_CustomerCMember_documentation_en-US" xlink:label="lab_sdgr_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerCMember" xlink:href="sdgr-20241231.xsd#sdgr_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CustomerCMember" xlink:to="lab_sdgr_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_e0b46861-4c0d-4e61-b7f4-9e79c603c297_terseLabel_en-US" xlink:label="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
    <link:label id="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]</link:label>
    <link:label id="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of presentation and use of estimates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:href="sdgr-20241231.xsd#sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:to="lab_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_800cd15f-a237-4046-b683-bfac64e0f6bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSU's not vested during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea5e945f-eddd-4e5b-9728-bdd973a61c10_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3d51060-cc7b-4fbd-bcc1-30e82a1df43b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f5c8c53b-fcd4-497a-b771-b89e175baf41_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0c754948-2262-426b-8fdd-d456c6455dad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_TimingOfRevenueRecognitionPercentage_fbb4037f-b480-43b5-8cf8-df4aea25c613_terseLabel_en-US" xlink:label="lab_sdgr_TimingOfRevenueRecognitionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of revenue recognition</link:label>
    <link:label id="lab_sdgr_TimingOfRevenueRecognitionPercentage_label_en-US" xlink:label="lab_sdgr_TimingOfRevenueRecognitionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing Of Revenue Recognition Percentage</link:label>
    <link:label id="lab_sdgr_TimingOfRevenueRecognitionPercentage_documentation_en-US" xlink:label="lab_sdgr_TimingOfRevenueRecognitionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Timing of revenue recognition, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TimingOfRevenueRecognitionPercentage" xlink:href="sdgr-20241231.xsd#sdgr_TimingOfRevenueRecognitionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_TimingOfRevenueRecognitionPercentage" xlink:to="lab_sdgr_TimingOfRevenueRecognitionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1bebfe8b-393f-4335-a6da-9b5a98b57c6a_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions taken in prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_93bd70ff-9a4c-411f-a7b1-1dec450d76d0_terseLabel_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, long-term</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_e3c9aa3c-8d77-49f4-9863-a733fb1bd9cb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1ea00520-756f-475c-afd7-62ded36bca7b_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b318b890-9bcf-4eb3-a57e-8933c6991b8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_a63b77cf-a72c-41a5-9431-a9bdb536e9b5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_c93b9eb6-5886-4404-bd41-24693e1f2c0d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total segment cost of revenues</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_069727f1-6a3e-4901-832a-7a97e64863d1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_11932a22-5554-4ce2-8cda-6e357e303022_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6ff74e76-1444-4e5d-907c-c1b99800eb58_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_b21e11bb-a662-4ad6-9e64-c8aacb8be955_terseLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Three</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a525ad2f-0e09-4107-aa04-1bf2fb11c7c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_c4cf2b0f-f855-4649-ab53-d5d95183de22_terseLabel_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration amount</link:label>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bbe44220-ee15-4601-acc7-39da7c97704a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_205b694d-ecaf-410e-a13f-fb047900094d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_24215a9c-c45d-48a7-ae2d-6a8b01725886_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_415c354b-5559-4953-8674-66b5875ace1e_negatedLabel_en-US" xlink:label="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reduction in the carrying amount of right of use assets - operating leases</link:label>
    <link:label id="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_label_en-US" xlink:label="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Reduction In The Carrying Amount Of Right Of Use Assets, Operating</link:label>
    <link:label id="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_documentation_en-US" xlink:label="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in reduction in the carrying amount of right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" xlink:to="lab_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dd6a68ad-70ad-465e-b10c-5b76e3f05d21_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_06406f55-5ea4-457c-88c7-b4014fcdacbd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_7791e454-3c06-45bd-8020-6e023e66c2bb_terseLabel_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_label_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Four</link:label>
    <link:label id="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_documentation_en-US" xlink:label="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" xlink:to="lab_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ef19592b-5ac6-4ff6-a72f-d026b09faa13_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1221ee9e-bd03-49fb-87eb-90dbab586fc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_db7c061d-fc21-4681-b159-ab2d955c08ba_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_255d8f92-5cb9-41e9-bf5b-17da36a177be_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8c579387-6ec6-4800-a4a8-38121dcd74e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_sdgr_CustomerAMember_271a3b66-16c7-4f16-848d-8e57d02398c6_terseLabel_en-US" xlink:label="lab_sdgr_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_sdgr_CustomerAMember_label_en-US" xlink:label="lab_sdgr_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_sdgr_CustomerAMember_documentation_en-US" xlink:label="lab_sdgr_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerAMember" xlink:href="sdgr-20241231.xsd#sdgr_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sdgr_CustomerAMember" xlink:to="lab_sdgr_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_6ca5327f-3e13-4d97-9593-09953ca4b2ca_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6fc3ae1d-c4df-4760-9755-42699f58023a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3e5a2078-5fc6-467b-8b59-da8545fb4deb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_155ae997-c5e6-4c62-a34b-a05db8809c98_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4ceebd4b-528c-410e-abdc-f2adb47b8f48_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_ed1c7e7d-85a7-413e-a4e6-dc4221acebad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsatisfied performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b8cbd363-3667-4c62-9ada-a51f4d8d7a92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_b1458f19-ef5c-4d1a-96b3-d23f9c3ff007_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenues:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_0d64da6a-f20b-4232-894b-9340c62380c6_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment cost of revenues:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>sdgr-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:6d57be63-fef2-4aee-a5b8-ca771b86978e,g:704293bf-0912-4e44-b70a-e4f74457db02-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.schrodinger.com/role/Cover" xlink:type="simple" xlink:href="sdgr-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4b334036-9ab2-4b8e-a26c-df738d447938" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4b334036-9ab2-4b8e-a26c-df738d447938" xlink:to="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c6936a95-2c2e-4bb2-a88d-34e2b0c9105d" xlink:to="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_401f9c7d-701c-4da9-a21e-92ffd3316a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:to="loc_us-gaap_CommonStockMember_401f9c7d-701c-4da9-a21e-92ffd3316a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_924333fb-13a5-4f5b-8863-e8bcda147fc5" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1a6c03a-92c8-4820-8b60-cbcf93e9d73c" xlink:to="loc_sdgr_LimitedCommonStockMember_924333fb-13a5-4f5b-8863-e8bcda147fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5e56fa7d-31d6-4a4c-950b-f5dc1d7f69bc" xlink:to="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f31b8797-484a-4340-96f0-c2ad4e77d68f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentType_f31b8797-484a-4340-96f0-c2ad4e77d68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_596a1f13-f177-4c47-bbe4-309a3de62814" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentAnnualReport_596a1f13-f177-4c47-bbe4-309a3de62814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_68e081e6-d06f-4042-957e-e4d4c15bbe6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentPeriodEndDate_68e081e6-d06f-4042-957e-e4d4c15bbe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_81e6c05a-8b6a-4bda-91d2-162b546a6dfc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_CurrentFiscalYearEndDate_81e6c05a-8b6a-4bda-91d2-162b546a6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_853da971-0d49-4535-ba1e-c6ba8a7be496" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentTransitionReport_853da971-0d49-4535-ba1e-c6ba8a7be496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_600620a3-2600-48e7-82f7-54e3e5ba9073" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityFileNumber_600620a3-2600-48e7-82f7-54e3e5ba9073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_82e502fd-abe4-4650-a5f9-a6e955559701" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityRegistrantName_82e502fd-abe4-4650-a5f9-a6e955559701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6e3a2d4e-c073-49b5-a0e5-e0104dfeea78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6e3a2d4e-c073-49b5-a0e5-e0104dfeea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f33793aa-3efb-4141-9a9d-dee838d01161" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityTaxIdentificationNumber_f33793aa-3efb-4141-9a9d-dee838d01161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_61cb1497-e830-4424-8fb5-441cecc83db2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressAddressLine1_61cb1497-e830-4424-8fb5-441cecc83db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_19a5c67d-6fde-4416-9e99-483f73e867a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressAddressLine2_19a5c67d-6fde-4416-9e99-483f73e867a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fc253eec-ae5a-4e10-91db-9b7c02437cc1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressCityOrTown_fc253eec-ae5a-4e10-91db-9b7c02437cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0329d8e9-0ce0-494b-b627-4928d75eab2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressStateOrProvince_0329d8e9-0ce0-494b-b627-4928d75eab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_13f561be-067a-4f23-a582-f84642437ce3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityAddressPostalZipCode_13f561be-067a-4f23-a582-f84642437ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ca232e01-0cb4-47db-afe9-e78cebb38a28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_CityAreaCode_ca232e01-0cb4-47db-afe9-e78cebb38a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_afa05d68-1612-453c-bf21-bbbfec086b77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_LocalPhoneNumber_afa05d68-1612-453c-bf21-bbbfec086b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bcca21c9-9dbb-44df-848f-573308b03a29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_Security12bTitle_bcca21c9-9dbb-44df-848f-573308b03a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_135c3ae3-c9ef-46a3-9c9d-b9f3d25ea26c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_TradingSymbol_135c3ae3-c9ef-46a3-9c9d-b9f3d25ea26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c80944a1-8cb3-4014-8a55-2963fa7ada1f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_SecurityExchangeName_c80944a1-8cb3-4014-8a55-2963fa7ada1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_87089e37-3d77-4dd5-b8b8-9ba42dec420e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_87089e37-3d77-4dd5-b8b8-9ba42dec420e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0d7373b8-d2c0-4734-bfd8-19effe046426" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityVoluntaryFilers_0d7373b8-d2c0-4734-bfd8-19effe046426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d80d1505-07e3-4fb5-acbd-54979b786bd5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityCurrentReportingStatus_d80d1505-07e3-4fb5-acbd-54979b786bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_71b6fd2c-7128-412b-91d5-06b2b20b4ed0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityInteractiveDataCurrent_71b6fd2c-7128-412b-91d5-06b2b20b4ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0ec68b2f-0c72-4f62-9243-5cd40ef9a227" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityFilerCategory_0ec68b2f-0c72-4f62-9243-5cd40ef9a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dcbb5e07-3d8d-4309-a63c-4784300f204a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntitySmallBusiness_dcbb5e07-3d8d-4309-a63c-4784300f204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a2c87f3-71c4-45af-a9bb-592b7dfbbac0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a2c87f3-71c4-45af-a9bb-592b7dfbbac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_f23df1f3-d529-459e-a883-fe1b1dffa9b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_f23df1f3-d529-459e-a883-fe1b1dffa9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_fa7893a3-225d-40dd-91e1-6fab450057b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_fa7893a3-225d-40dd-91e1-6fab450057b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_63a575b6-b22a-49ba-a788-0ffab4c6298c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityShellCompany_63a575b6-b22a-49ba-a788-0ffab4c6298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_08b07d8a-8b62-40cc-993a-044a6047e013" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityPublicFloat_08b07d8a-8b62-40cc-993a-044a6047e013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_73fc7bb5-74a8-45cc-86e7-f13f30d71c9c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_73fc7bb5-74a8-45cc-86e7-f13f30d71c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_90da1453-566b-4c44-80a1-d3b349999458" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_90da1453-566b-4c44-80a1-d3b349999458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_753cd0c7-36eb-4f9b-95ab-1aa0243f640e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AuditorFirmId_753cd0c7-36eb-4f9b-95ab-1aa0243f640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_6480e933-9b29-4995-9bb5-daac88d10e12" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AuditorName_6480e933-9b29-4995-9bb5-daac88d10e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6193efb4-4b81-4c5c-93ed-8cc86ac614df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AuditorLocation_6193efb4-4b81-4c5c-93ed-8cc86ac614df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b85ce9eb-432b-448b-9cc2-e0804695b4fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_EntityCentralIndexKey_b85ce9eb-432b-448b-9cc2-e0804695b4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cbe865df-5fcf-4113-9096-494a053bd7b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentFiscalYearFocus_cbe865df-5fcf-4113-9096-494a053bd7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_30ae1cb1-3780-4609-85cc-c91e7053d9a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_30ae1cb1-3780-4609-85cc-c91e7053d9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_04055589-957b-44f1-b74d-f2a7d90660e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_0a76ea15-e05b-4460-8fb1-319577ce94b0" xlink:to="loc_dei_AmendmentFlag_04055589-957b-44f1-b74d-f2a7d90660e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_51886ae3-1925-45c9-b664-1b2218330c25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51886ae3-1925-45c9-b664-1b2218330c25" xlink:to="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2badfdaa-a1f9-43eb-b462-dd32b0391463" xlink:to="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedCommonStockMember_90c7812e-c395-438d-b910-cd5c061b3202" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:to="loc_sdgr_UnallocatedCommonStockMember_90c7812e-c395-438d-b910-cd5c061b3202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_67721d13-9076-47ea-bffc-a6269ee8733e" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dbad993a-901d-4df9-ae32-dd07ece1e616" xlink:to="loc_sdgr_LimitedCommonStockMember_67721d13-9076-47ea-bffc-a6269ee8733e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_03971283-983c-4462-9929-9535a9c32e73" xlink:to="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:to="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b589b543-0caf-4860-975d-47f85bc6ef18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b589b543-0caf-4860-975d-47f85bc6ef18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_0487d1dc-9f07-4740-83ca-8c2a5dafea5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_RestrictedCashCurrent_0487d1dc-9f07-4740-83ca-8c2a5dafea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8fc3b091-4f75-445b-9701-5e8c67a466ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8fc3b091-4f75-445b-9701-5e8c67a466ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6d023f03-3bf8-4a49-95ad-c4da523e5c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6d023f03-3bf8-4a49-95ad-c4da523e5c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnbilledAndOtherReceivablesCurrent_4a500d00-e77f-42ea-8eb6-9571f2a53754" xlink:href="sdgr-20241231.xsd#sdgr_UnbilledAndOtherReceivablesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_sdgr_UnbilledAndOtherReceivablesCurrent_4a500d00-e77f-42ea-8eb6-9571f2a53754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1c323cbf-76a5-4c93-a569-175c5f373a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1c323cbf-76a5-4c93-a569-175c5f373a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77513449-5550-43eb-a363-26968bc2408e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_133e82c6-2bdd-4f2e-a0d5-cb070220466b" xlink:to="loc_us-gaap_AssetsCurrent_77513449-5550-43eb-a363-26968bc2408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_cd502473-c7a3-4a82-a79f-c90e675f46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_cd502473-c7a3-4a82-a79f-c90e675f46dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dbafe339-b264-4400-a007-2550d76f653e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_EquityMethodInvestments_dbafe339-b264-4400-a007-2550d76f653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4ade4f7d-556f-4b86-9d1c-f05102b45ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_Goodwill_4ade4f7d-556f-4b86-9d1c-f05102b45ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b6113ff-691c-4552-9ec0-bc70dcfcfd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b6113ff-691c-4552-9ec0-bc70dcfcfd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_78af6b1d-8eb4-44e9-8f47-7309b52c3537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_78af6b1d-8eb4-44e9-8f47-7309b52c3537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ab67a192-5646-4981-a869-8df88739b6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1dd1043e-7fed-4ad5-9645-e089b394e665" xlink:to="loc_us-gaap_Assets_ab67a192-5646-4981-a869-8df88739b6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21b041d7-665c-45f1-9d8a-945262ca1656" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_30aa2042-578a-444c-9269-667ac04341b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_AccountsPayableCurrent_30aa2042-578a-444c-9269-667ac04341b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_535593cc-fd49-44b4-a109-3f0660fd9afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_535593cc-fd49-44b4-a109-3f0660fd9afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83d5ef9-b47c-49f8-b776-01161596ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a83d5ef9-b47c-49f8-b776-01161596ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4271e012-c3ae-4fd6-92e1-de3721cc064c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4271e012-c3ae-4fd6-92e1-de3721cc064c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f587a829-28d6-469e-9115-8fcf454b592a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f587a829-28d6-469e-9115-8fcf454b592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c196b3fc-6ffa-4177-9140-2a2bbabd5146" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_90cf3434-d0c3-4f80-a40d-6f8b5e258ef9" xlink:to="loc_us-gaap_LiabilitiesCurrent_c196b3fc-6ffa-4177-9140-2a2bbabd5146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_91412875-12a5-4fc1-8183-65522951e5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_91412875-12a5-4fc1-8183-65522951e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d4aef5ae-2081-4a67-9350-4d4f42f5cc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d4aef5ae-2081-4a67-9350-4d4f42f5cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_53ca599a-a476-472d-be7b-f106ce80f605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_53ca599a-a476-472d-be7b-f106ce80f605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_76ab264e-3d66-42c7-b3b6-3f440c6489d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_Liabilities_76ab264e-3d66-42c7-b3b6-3f440c6489d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0265d064-327c-4af7-b968-4c8ae86eac40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0265d064-327c-4af7-b968-4c8ae86eac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5f994bd4-8ea4-4363-b470-84f42004e55d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_PreferredStockValue_5f994bd4-8ea4-4363-b470-84f42004e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1c0a4521-85f6-4914-a952-3bea6170dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_CommonStockValue_1c0a4521-85f6-4914-a952-3bea6170dfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7e7f6912-46a5-4484-aab1-d9a146428612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7e7f6912-46a5-4484-aab1-d9a146428612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5da51403-bb6e-4a6e-b032-ab23f64fc745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5da51403-bb6e-4a6e-b032-ab23f64fc745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20cb61a6-5f6e-475b-a445-0a6c2f4c27f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_db8c1c81-ba13-467b-9e3c-0086488aaa3c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20cb61a6-5f6e-475b-a445-0a6c2f4c27f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_93e0f0ff-d4f6-4f28-a341-84e3ddeabdce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_StockholdersEquity_93e0f0ff-d4f6-4f28-a341-84e3ddeabdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8854ad1f-dec0-4722-9765-e5004bf227c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b4d91aba-cee8-443e-a5a6-614d7bac3fa0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8854ad1f-dec0-4722-9765-e5004bf227c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_294dbee1-5c51-4a1d-9bd2-a0ca307969eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_294dbee1-5c51-4a1d-9bd2-a0ca307969eb" xlink:to="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7aa35da4-6d69-4600-ba84-ba84249a77d7" xlink:to="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedCommonStockMember_77306251-edc6-4c8b-b083-271c821c0d9b" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:to="loc_sdgr_UnallocatedCommonStockMember_77306251-edc6-4c8b-b083-271c821c0d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_c4307e61-22ae-45a4-bcc4-d3113b3a4fc2" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6c97f2f2-1864-48bc-bfb6-2ac38e773308" xlink:to="loc_sdgr_LimitedCommonStockMember_c4307e61-22ae-45a4-bcc4-d3113b3a4fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3587141-8104-4f5f-a74b-5a48381f6735" xlink:to="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bedee1d1-a464-465a-a25e-5914f94dbac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bedee1d1-a464-465a-a25e-5914f94dbac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AllowanceForUnbilledReceivablesCurrent_094d9e78-2b04-4c34-abbb-828edc7227c9" xlink:href="sdgr-20241231.xsd#sdgr_AllowanceForUnbilledReceivablesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_sdgr_AllowanceForUnbilledReceivablesCurrent_094d9e78-2b04-4c34-abbb-828edc7227c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d6d076ad-9017-4b39-b05c-5c7b0b0d4663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d6d076ad-9017-4b39-b05c-5c7b0b0d4663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bd53318a-3c79-41ce-a989-d850d93f5528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bd53318a-3c79-41ce-a989-d850d93f5528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e6f510cc-8e1d-4321-87f6-cbf781a2148e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e6f510cc-8e1d-4321-87f6-cbf781a2148e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b0c72fa7-3f33-45ff-ab76-dc7ea1ef8a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b0c72fa7-3f33-45ff-ab76-dc7ea1ef8a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5326e7e4-b4ff-4fcc-b559-5546b080af2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5326e7e4-b4ff-4fcc-b559-5546b080af2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e0c22d99-b2cf-4271-a5f2-e6b2d5df0a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e0c22d99-b2cf-4271-a5f2-e6b2d5df0a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bbc73543-1471-4267-94f5-7253b66ed4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockSharesIssued_bbc73543-1471-4267-94f5-7253b66ed4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5c66603d-43c8-4a46-987f-a6fcfad5953a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3b5d01c4-a3b4-40d2-9b9a-b8a35b3bfccc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5c66603d-43c8-4a46-987f-a6fcfad5953a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d5e7aaa2-7942-4f7c-bd3d-8ed2b53c436c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d5e7aaa2-7942-4f7c-bd3d-8ed2b53c436c" xlink:to="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:to="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60ea5bd5-63db-4af3-84b0-4b3b0d917abb" xlink:to="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_fbb56f0f-f20d-4997-8e76-105a870b1c37" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_fbb56f0f-f20d-4997-8e76-105a870b1c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_4a769e16-60f4-4aaa-9cf7-83897f589e3b" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7c3f0880-fdcc-4ae9-9f11-60424a88ade1" xlink:to="loc_sdgr_DrugDiscoveryMember_4a769e16-60f4-4aaa-9cf7-83897f589e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_558a4b74-4141-4396-a56e-73b28f941d6a" xlink:to="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_0f094472-1e6f-497d-a741-2efdda4b3d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_RevenuesAbstract_0f094472-1e6f-497d-a741-2efdda4b3d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5229c4fc-81b6-41b8-8269-d168e0372ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0f094472-1e6f-497d-a741-2efdda4b3d63" xlink:to="loc_us-gaap_Revenues_5229c4fc-81b6-41b8-8269-d168e0372ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_17e75db3-2eda-47fc-be39-6d8663f897fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:to="loc_us-gaap_CostOfRevenue_17e75db3-2eda-47fc-be39-6d8663f897fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5587e3ff-88dd-4044-8b99-df62a7ec3646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_a6e74f49-1b44-49d2-8711-26f4092568db" xlink:to="loc_us-gaap_GrossProfit_5587e3ff-88dd-4044-8b99-df62a7ec3646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5daf019e-8f80-46f8-90fa-a8e7c8dfbcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5daf019e-8f80-46f8-90fa-a8e7c8dfbcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_f4dc8afc-64d2-46b7-a521-cb623ada2afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_SellingAndMarketingExpense_f4dc8afc-64d2-46b7-a521-cb623ada2afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_56d279ab-2dfb-4fa5-9326-c3c0f8272300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_56d279ab-2dfb-4fa5-9326-c3c0f8272300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cbdbe560-42c1-4f3f-ac3c-d3aa6fc1ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f31e4744-9054-467c-9dc7-d4d8fa5580e2" xlink:to="loc_us-gaap_OperatingExpenses_cbdbe560-42c1-4f3f-ac3c-d3aa6fc1ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0c73399-1edd-435c-a9f1-f6a3c264f425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_OperatingIncomeLoss_e0c73399-1edd-435c-a9f1-f6a3c264f425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2fe39f55-4f18-4cc5-b026-3aa03af7e843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2fe39f55-4f18-4cc5-b026-3aa03af7e843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6ee68548-e198-47ac-8c8d-9bec2e391b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6ee68548-e198-47ac-8c8d-9bec2e391b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8bb40712-1c14-4784-90dc-151033220670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8bb40712-1c14-4784-90dc-151033220670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_69f6a0e9-708a-45e6-82dc-ac5cc619fa72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_69f6a0e9-708a-45e6-82dc-ac5cc619fa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_695e648f-f5b2-49fb-969e-ba57cb290856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7294d723-308a-4213-920c-ff8a8d4db98c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_695e648f-f5b2-49fb-969e-ba57cb290856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_13a15cb5-5508-4ec9-b689-a070c9fc5ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_13a15cb5-5508-4ec9-b689-a070c9fc5ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64ac421c-6647-4364-9965-cb7774d64a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_NetIncomeLoss_64ac421c-6647-4364-9965-cb7774d64a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ae8d86fd-1edf-40e0-a2ce-9a6764fb8cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ae8d86fd-1edf-40e0-a2ce-9a6764fb8cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_661ec555-97ff-4da3-89d7-93afcf7e76dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_661ec555-97ff-4da3-89d7-93afcf7e76dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_321f198c-2ff9-4c99-8eda-466d706bb8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_321f198c-2ff9-4c99-8eda-466d706bb8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ade53e79-0b91-46f9-a269-2ea41d16dbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bf662c8b-faa6-4b80-a3b2-6b88523bdc9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ade53e79-0b91-46f9-a269-2ea41d16dbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9d792da1-b900-47e3-99dd-fef420b414e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_81bb7427-4add-492a-bd3b-f6e85e25ac57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9d792da1-b900-47e3-99dd-fef420b414e7" xlink:to="loc_us-gaap_NetIncomeLoss_81bb7427-4add-492a-bd3b-f6e85e25ac57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_35638f86-4c65-4b82-962d-597846b60dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9d792da1-b900-47e3-99dd-fef420b414e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_35638f86-4c65-4b82-962d-597846b60dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0465faa2-98d9-4ba2-be57-56b0d54d1733" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_35638f86-4c65-4b82-962d-597846b60dcf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0465faa2-98d9-4ba2-be57-56b0d54d1733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7e77d400-ec5b-4ad9-b85a-17e6c83fa6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_35638f86-4c65-4b82-962d-597846b60dcf" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7e77d400-ec5b-4ad9-b85a-17e6c83fa6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e13a0c28-fb78-4a09-be0c-d3c1450fe705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e13a0c28-fb78-4a09-be0c-d3c1450fe705" xlink:to="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46fb9653-6047-44e1-a497-d74851f83087" xlink:to="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c1834df7-0468-4415-9286-c943ca0d06ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_CommonStockMember_c1834df7-0468-4415-9286-c943ca0d06ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_d9996570-6989-4134-860d-0f7768f789e1" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_sdgr_LimitedCommonStockMember_d9996570-6989-4134-860d-0f7768f789e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d0e6bc31-31bc-4fb4-a079-61c2ed2fab75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d0e6bc31-31bc-4fb4-a079-61c2ed2fab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66b4ec6f-87ee-4654-b678-a3d4efda205e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_RetainedEarningsMember_66b4ec6f-87ee-4654-b678-a3d4efda205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6fa8012-309e-465d-a302-c244e5cde099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cef6e742-2e59-4dea-837a-60afed325190" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e6fa8012-309e-465d-a302-c244e5cde099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ad4561d-5f98-4e64-8ad5-61855ea31e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_93de70f6-5f03-4d74-87b9-c6ef90aa6fad" xlink:to="loc_us-gaap_StatementLineItems_6ad4561d-5f98-4e64-8ad5-61855ea31e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ad4561d-5f98-4e64-8ad5-61855ea31e8f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ff7a4d31-34ec-45cf-89df-ab22885bdb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_SharesOutstanding_ff7a4d31-34ec-45cf-89df-ab22885bdb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1640932f-d842-473b-b85a-4a143dd08c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockholdersEquity_1640932f-d842-473b-b85a-4a143dd08c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_9382e6c1-ec4f-405f-9b4f-d41856cc3ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_9382e6c1-ec4f-405f-9b4f-d41856cc3ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ae2a666-fa99-4cef-9cab-c1a8ac431167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ae2a666-fa99-4cef-9cab-c1a8ac431167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5679257-9b56-40c1-9682-52a5b2701c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d5679257-9b56-40c1-9682-52a5b2701c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7ab1fc24-7bb3-4699-b8d0-7f1a5d286e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7ab1fc24-7bb3-4699-b8d0-7f1a5d286e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b0c8496f-5004-42fe-851e-334fd8832a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b0c8496f-5004-42fe-851e-334fd8832a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_f714593f-5644-4ef0-85a0-d8ca8ce27f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_f714593f-5644-4ef0-85a0-d8ca8ce27f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b05394a6-9a92-4937-9544-7f473f44f76c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b05394a6-9a92-4937-9544-7f473f44f76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d6a79b9-b63c-4ece-8a01-1f62c798f2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d6a79b9-b63c-4ece-8a01-1f62c798f2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_58e03a9f-970e-4577-9dc0-54e7b4e45706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_58e03a9f-970e-4577-9dc0-54e7b4e45706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28a9d402-425c-4ed3-b126-89454031e647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_ProfitLoss_28a9d402-425c-4ed3-b126-89454031e647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2ddafb4b-a1d6-478d-9243-44558e6d3192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_SharesOutstanding_2ddafb4b-a1d6-478d-9243-44558e6d3192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_28579bd6-4420-4baa-a814-99c4321df805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3bfe02f9-08a0-4742-b1f0-ba4615ddb8f4" xlink:to="loc_us-gaap_StockholdersEquity_28579bd6-4420-4baa-a814-99c4321df805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sdgr-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_451d24ed-5e68-4551-8f0b-d66f2548139f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_451d24ed-5e68-4551-8f0b-d66f2548139f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_86bed1d0-e668-417e-855d-d2d5f393b715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_451d24ed-5e68-4551-8f0b-d66f2548139f" xlink:to="loc_us-gaap_ProfitLoss_86bed1d0-e668-417e-855d-d2d5f393b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_451d24ed-5e68-4551-8f0b-d66f2548139f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61363a58-d16e-4f19-a9f4-163820f06c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61363a58-d16e-4f19-a9f4-163820f06c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_1ad87c74-0358-4e1d-8ffa-193063bd6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_1ad87c74-0358-4e1d-8ffa-193063bd6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f99a5d6e-e634-4751-8b97-7a7b2927a63b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f99a5d6e-e634-4751-8b97-7a7b2927a63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ec30096-2dd8-4a6d-93f1-b14f7a2d88e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_ShareBasedCompensation_7ec30096-2dd8-4a6d-93f1-b14f7a2d88e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_InvestmentAmortizationNoncashExpense_604f322c-cdca-41e0-94b2-7cb4112bb0e7" xlink:href="sdgr-20241231.xsd#sdgr_InvestmentAmortizationNoncashExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_sdgr_InvestmentAmortizationNoncashExpense_604f322c-cdca-41e0-94b2-7cb4112bb0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_be9949bb-b0ef-41d6-a4be-d4966c713139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_be9949bb-b0ef-41d6-a4be-d4966c713139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_ceddbdcf-6b78-40e4-8381-2408e4ba6e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_ceddbdcf-6b78-40e4-8381-2408e4ba6e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11d707b8-a323-474a-9515-ec149e502023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_ceddbdcf-6b78-40e4-8381-2408e4ba6e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_11d707b8-a323-474a-9515-ec149e502023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_42d02569-38d0-4c32-a703-a8a268baea22" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_ceddbdcf-6b78-40e4-8381-2408e4ba6e4e" xlink:to="loc_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables_42d02569-38d0-4c32-a703-a8a268baea22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_226af9ea-1e93-41b0-bfd1-c732a0e44ef0" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_ceddbdcf-6b78-40e4-8381-2408e4ba6e4e" xlink:to="loc_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating_226af9ea-1e93-41b0-bfd1-c732a0e44ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c8a26a6-1b7a-4886-bf81-3b8db66ce5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_ceddbdcf-6b78-40e4-8381-2408e4ba6e4e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c8a26a6-1b7a-4886-bf81-3b8db66ce5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9017ab91-b371-44bd-943e-cb6ccf34ae9b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8e87ccb6-57fe-4252-aaad-cdb3f2c57113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8e87ccb6-57fe-4252-aaad-cdb3f2c57113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cc17673e-7bf6-4280-b557-191d0552f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cc17673e-7bf6-4280-b557-191d0552f1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_95650d4a-9f93-43ee-8840-ab7cd8a1727c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_95650d4a-9f93-43ee-8840-ab7cd8a1727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a2602fa4-598d-4314-8d39-16c343ffb82e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a2602fa4-598d-4314-8d39-16c343ffb82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_47638162-dd6d-460e-a2a5-11e8394461f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_0c5a1aa5-3124-4cde-9ae1-73d7ecc809df" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_47638162-dd6d-460e-a2a5-11e8394461f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56259ae4-d8cd-4337-84d0-06b3aa9569c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_451d24ed-5e68-4551-8f0b-d66f2548139f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56259ae4-d8cd-4337-84d0-06b3aa9569c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6dd77bb8-8264-4110-8c3e-a898240bd1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6dd77bb8-8264-4110-8c3e-a898240bd1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9ff16599-0d0a-4d8f-abb1-1383f69e80aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9ff16599-0d0a-4d8f-abb1-1383f69e80aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_86533405-e96f-4dd8-ad0a-44323365f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_86533405-e96f-4dd8-ad0a-44323365f10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e442edde-5eb4-4d90-9565-84aeee1da87d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e442edde-5eb4-4d90-9565-84aeee1da87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7d21893d-ac10-426b-9eaf-db6fc9b64076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7d21893d-ac10-426b-9eaf-db6fc9b64076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9bf7be75-f591-4b74-81e7-928d249d06f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9bf7be75-f591-4b74-81e7-928d249d06f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cbe15897-fb2f-419e-a592-1469d1c73b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cbe15897-fb2f-419e-a592-1469d1c73b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_baaec213-8a02-4d4f-ae8b-8cdb357a6cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3d55071-3232-4ec9-a34d-8c26c8ae6a42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_baaec213-8a02-4d4f-ae8b-8cdb357a6cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_100624ed-ff56-4491-ba68-d629116457a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_100624ed-ff56-4491-ba68-d629116457a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7106bfa3-f147-4554-8acd-0771eb42185f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_7106bfa3-f147-4554-8acd-0771eb42185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_158ab165-f84e-4329-a4a6-da77ce7878c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_158ab165-f84e-4329-a4a6-da77ce7878c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d977f29d-18b1-4f1b-88c0-482fcb1ff689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d977f29d-18b1-4f1b-88c0-482fcb1ff689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8487d47-361e-433f-affe-ba9cd957f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0e50187d-94ad-449c-b9a5-f86e9bdfdcc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8487d47-361e-433f-affe-ba9cd957f2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00dd9e81-21f3-4748-a942-559b5282f270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_00dd9e81-21f3-4748-a942-559b5282f270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ceb0baf-89fa-4aeb-be41-e66e3d30fa14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ceb0baf-89fa-4aeb-be41-e66e3d30fa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e10707b-d9c0-4f50-90a6-21a8cf8ccf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e10707b-d9c0-4f50-90a6-21a8cf8ccf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_76b3579e-2515-46e0-804d-6d931f4c3e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_76b3579e-2515-46e0-804d-6d931f4c3e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_14f3572b-2b32-4420-8c65-3f566106d726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_76b3579e-2515-46e0-804d-6d931f4c3e0a" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_14f3572b-2b32-4420-8c65-3f566106d726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_afac4a2a-5772-4e19-9ac4-fb9a76a9d8c2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a862489-42d6-4168-b1f9-99a5d1f72e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5a862489-42d6-4168-b1f9-99a5d1f72e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_4fb9fb07-b3d4-4e99-94a3-79a92052986c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_4fb9fb07-b3d4-4e99-94a3-79a92052986c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution_bff562c0-c5ea-4586-8428-462da9f3bf0d" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:to="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution_bff562c0-c5ea-4586-8428-462da9f3bf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases_249290cb-c1a6-40cb-8e77-452efb70ba58" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:to="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases_249290cb-c1a6-40cb-8e77-452efb70ba58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities_92574f24-8cf2-49c0-bd6e-7d6d347f264b" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:to="loc_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities_92574f24-8cf2-49c0-bd6e-7d6d347f264b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired_7c8dc3bc-15ef-4fc3-a889-b8fbe7dd1ef3" xlink:href="sdgr-20241231.xsd#sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_62f25b2b-7cbf-4c3a-ad0b-7109eb8e2098" xlink:to="loc_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired_7c8dc3bc-15ef-4fc3-a889-b8fbe7dd1ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="sdgr-20241231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad70e4d2-8567-4605-af89-3aacf84e5fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_46e4895f-9901-4325-aff2-af5b595b65f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad70e4d2-8567-4605-af89-3aacf84e5fc8" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_46e4895f-9901-4325-aff2-af5b595b65f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d46292e8-de56-4396-af1b-0160616b97be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a3fa324a-5d46-49e7-b13e-2fa877029efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d46292e8-de56-4396-af1b-0160616b97be" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a3fa324a-5d46-49e7-b13e-2fa877029efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognition" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4edc6832-2a04-4598-8daf-17e1cb6c6283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4bf9687d-8ffb-4469-b77d-ff1789e823f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4edc6832-2a04-4598-8daf-17e1cb6c6283" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4bf9687d-8ffb-4469-b77d-ff1789e823f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="sdgr-20241231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_60673662-d786-4eb1-a2cc-13755b0a49fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_358299eb-75da-4ca6-876c-2b8ec5093870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_60673662-d786-4eb1-a2cc-13755b0a49fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_358299eb-75da-4ca6-876c-2b8ec5093870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="sdgr-20241231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a1cd8f06-8db6-4bf3-bfae-e5418dbb0ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_a0055c60-cb6b-4445-8200-fd406d766d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a1cd8f06-8db6-4bf3-bfae-e5418dbb0ebd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_a0055c60-cb6b-4445-8200-fd406d766d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_791e1e67-6ac1-4ccf-80ea-75ea63b7b8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_90c2ece8-091c-4967-9da2-e286cd80df7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_791e1e67-6ac1-4ccf-80ea-75ea63b7b8c9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_90c2ece8-091c-4967-9da2-e286cd80df7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7691b059-e0e6-44d7-be6c-d9f05a592f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_72066792-c13a-48a1-8492-e02d48761fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7691b059-e0e6-44d7-be6c-d9f05a592f72" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_72066792-c13a-48a1-8492-e02d48761fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2d7d18d6-a409-456a-9cc8-a8f87ecc7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_70bc4241-4a54-4201-a4b7-bc38614de004" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2d7d18d6-a409-456a-9cc8-a8f87ecc7a81" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_70bc4241-4a54-4201-a4b7-bc38614de004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f50deb9-8007-43b3-b297-5a1126445d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_58097c67-c7a4-4d70-bbb2-fca81fec7ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f50deb9-8007-43b3-b297-5a1126445d4f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_58097c67-c7a4-4d70-bbb2-fca81fec7ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders" xlink:type="simple" xlink:href="sdgr-20241231.xsd#NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_657b5110-f563-4bed-8266-139883756a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_39b94653-e62f-42ed-b281-03c1a0f8373c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_657b5110-f563-4bed-8266-139883756a6f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_39b94653-e62f-42ed-b281-03c1a0f8373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/EquityInvestments" xlink:type="simple" xlink:href="sdgr-20241231.xsd#EquityInvestments"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/EquityInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e686df7-b703-42fb-8201-5dbcd756a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_062a9b70-5eaf-461b-b9ad-73ab1732694b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e686df7-b703-42fb-8201-5dbcd756a0d1" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_062a9b70-5eaf-461b-b9ad-73ab1732694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sdgr-20241231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bd6935f2-a55a-49d7-b121-2be2eb729854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d7cfb53f-f007-4cec-935e-e8688fd3c3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bd6935f2-a55a-49d7-b121-2be2eb729854" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d7cfb53f-f007-4cec-935e-e8688fd3c3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_424ed6b6-1459-4731-ac07-17b46ca1b62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7660fe1c-50b7-485b-ac04-50c3eb4daf49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_424ed6b6-1459-4731-ac07-17b46ca1b62d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7660fe1c-50b7-485b-ac04-50c3eb4daf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReporting" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_72f053e9-968b-4ee8-9e87-093adc127cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_ab9018ca-09bf-4c66-9f24-b34a54f17763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_72f053e9-968b-4ee8-9e87-093adc127cd1" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_ab9018ca-09bf-4c66-9f24-b34a54f17763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5968b205-05d7-4f9a-822d-a32ccff5d5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5968b205-05d7-4f9a-822d-a32ccff5d5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_c0c64928-6946-4da8-b591-c74c36a60b9f" xlink:href="sdgr-20241231.xsd#sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_c0c64928-6946-4da8-b591-c74c36a60b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_865a3667-a331-4848-ac08-7d4917d11418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_865a3667-a331-4848-ac08-7d4917d11418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock_e1c2eeb4-609e-48f0-a8a3-e324f68c73f3" xlink:href="sdgr-20241231.xsd#sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock_e1c2eeb4-609e-48f0-a8a3-e324f68c73f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_474e9779-a396-427e-9467-53f2d92864e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_474e9779-a396-427e-9467-53f2d92864e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_03dec7e1-7ac9-45e3-b25f-c33e498defda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_03dec7e1-7ac9-45e3-b25f-c33e498defda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_453313a0-7cea-4e9a-b5b1-574650df5b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_453313a0-7cea-4e9a-b5b1-574650df5b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_88959d9e-ff40-4d05-bce0-017d81cdb150" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_88959d9e-ff40-4d05-bce0-017d81cdb150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_82282e50-ecc6-4520-baee-def6c1ee5119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_82282e50-ecc6-4520-baee-def6c1ee5119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_18861d8d-819d-4815-9da4-9c1ef4bbc09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_18861d8d-819d-4815-9da4-9c1ef4bbc09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_eb5a3317-d42c-4188-bad7-069d9a91d490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_eb5a3317-d42c-4188-bad7-069d9a91d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RoyaltiesPolicyPolicyTextBlock_5fbe7ae3-6c0d-4a50-b09a-6d17fdc0dc28" xlink:href="sdgr-20241231.xsd#sdgr_RoyaltiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_sdgr_RoyaltiesPolicyPolicyTextBlock_5fbe7ae3-6c0d-4a50-b09a-6d17fdc0dc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock_3b9f199a-0c63-40dc-a477-518cb87b1a3d" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock_3b9f199a-0c63-40dc-a477-518cb87b1a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock_958e2a85-e39b-4c30-b173-4a786aa1113e" xlink:href="sdgr-20241231.xsd#sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock_958e2a85-e39b-4c30-b173-4a786aa1113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_69800de4-ed37-419b-8a71-32d652387884" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_69800de4-ed37-419b-8a71-32d652387884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommissionsPolicy_2e85bfe7-4866-48b0-94ac-288c054f03ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommissionsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_CommissionsPolicy_2e85bfe7-4866-48b0-94ac-288c054f03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_93d1e2d9-ffca-4006-b632-6c026e259104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_93d1e2d9-ffca-4006-b632-6c026e259104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d22dd083-74dc-45a3-90e0-3dae2f2183b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d22dd083-74dc-45a3-90e0-3dae2f2183b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_0a214e5b-0ddd-4016-a2aa-644745656179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_0a214e5b-0ddd-4016-a2aa-644745656179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_10af2398-3848-4f44-b092-887abf536c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a996ec95-0029-48f3-95d7-e3ebfcd74cb8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_10af2398-3848-4f44-b092-887abf536c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2649afa-6502-4770-aa52-069e977fd90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_6a8a976b-820a-438f-bc7c-b7618cfb4f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2649afa-6502-4770-aa52-069e977fd90c" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_6a8a976b-820a-438f-bc7c-b7618cfb4f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f8f03ff1-b1a3-4899-8830-0966ea33d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2649afa-6502-4770-aa52-069e977fd90c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_f8f03ff1-b1a3-4899-8830-0966ea33d31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_176d65eb-c4cf-4b1d-86f4-ce490afba0db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2649afa-6502-4770-aa52-069e977fd90c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_176d65eb-c4cf-4b1d-86f4-ce490afba0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a17d4f8b-2e86-4fed-a649-bb1d617e1b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_83ab5b17-2abd-46f4-935c-ed364120a22b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a17d4f8b-2e86-4fed-a649-bb1d617e1b53" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_83ab5b17-2abd-46f4-935c-ed364120a22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9fd4f0f0-a4f1-48df-8a68-1cd8f09ad1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_85041ea9-4daf-4d95-a0e2-b0f0feec5b64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9fd4f0f0-a4f1-48df-8a68-1cd8f09ad1f6" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_85041ea9-4daf-4d95-a0e2-b0f0feec5b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea198a17-fd32-40a3-a023-1630f3c93334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c7456056-fc7c-47fe-9096-6224a06e776c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea198a17-fd32-40a3-a023-1630f3c93334" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c7456056-fc7c-47fe-9096-6224a06e776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_943d8c81-ef13-4f4f-9c8a-89f2e6c3d06c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ea198a17-fd32-40a3-a023-1630f3c93334" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_943d8c81-ef13-4f4f-9c8a-89f2e6c3d06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e25b621d-0d42-4d80-b5a5-cd04283f1e48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_942b9470-42dd-47e5-b1a6-8a4e9607cf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e25b621d-0d42-4d80-b5a5-cd04283f1e48" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_942b9470-42dd-47e5-b1a6-8a4e9607cf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_28e3b1c4-9b36-4b50-ae8d-bc428a835be8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e25b621d-0d42-4d80-b5a5-cd04283f1e48" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_28e3b1c4-9b36-4b50-ae8d-bc428a835be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f604d9af-871d-47b0-96b1-564df1992260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e25b621d-0d42-4d80-b5a5-cd04283f1e48" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f604d9af-871d-47b0-96b1-564df1992260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a71f3243-9eb5-423b-b031-d84638f68313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e25b621d-0d42-4d80-b5a5-cd04283f1e48" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a71f3243-9eb5-423b-b031-d84638f68313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b3a5f52e-17ca-4c5f-a472-246fac3b98eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e25b621d-0d42-4d80-b5a5-cd04283f1e48" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b3a5f52e-17ca-4c5f-a472-246fac3b98eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_976345a4-519f-421c-b7a3-5073cd20e77f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0f06da01-a88f-4f97-ad89-63d9df1725f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_976345a4-519f-421c-b7a3-5073cd20e77f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0f06da01-a88f-4f97-ad89-63d9df1725f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9015e319-97ef-4c95-b343-2458a89ee88b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_976345a4-519f-421c-b7a3-5073cd20e77f" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9015e319-97ef-4c95-b343-2458a89ee88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_249fe2b7-039e-4ea8-a7bc-d3e8f7a8051c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_976345a4-519f-421c-b7a3-5073cd20e77f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_249fe2b7-039e-4ea8-a7bc-d3e8f7a8051c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_54faf7d4-119c-4ad4-99f3-4f5958cf6861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_976345a4-519f-421c-b7a3-5073cd20e77f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_54faf7d4-119c-4ad4-99f3-4f5958cf6861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b8a5664-468e-44b5-a22e-68f080c418e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f81ea5f7-c030-4f00-bb9e-c4a0707dcb68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8a5664-468e-44b5-a22e-68f080c418e7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f81ea5f7-c030-4f00-bb9e-c4a0707dcb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f263eed3-f080-4393-81e9-139e4e47792b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8a5664-468e-44b5-a22e-68f080c418e7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f263eed3-f080-4393-81e9-139e4e47792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2649911a-1456-419e-bd91-e6b1d10b65b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_88f3533a-61f4-4c2c-a6f6-ce360fcecb65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2649911a-1456-419e-bd91-e6b1d10b65b9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_88f3533a-61f4-4c2c-a6f6-ce360fcecb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_30d7c48e-8a88-4d91-92b0-3286a1393904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2649911a-1456-419e-bd91-e6b1d10b65b9" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_30d7c48e-8a88-4d91-92b0-3286a1393904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1cbbe9f1-3002-4484-b5eb-fb1ff01a71b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:href="sdgr-20241231.xsd#sdgr_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cbbe9f1-3002-4484-b5eb-fb1ff01a71b0" xlink:to="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_265eaf55-6d28-4395-9f6e-681c5d3d9d37" xlink:to="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3e6ab68-7ff1-45a6-87f7-5bee91615acb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:to="loc_srt_MinimumMember_c3e6ab68-7ff1-45a6-87f7-5bee91615acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e0d06186-de4d-4014-9059-39ff7b87b57f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_81c76564-d4c8-4b70-aa74-dbe5f6fcfcb7" xlink:to="loc_srt_MaximumMember_e0d06186-de4d-4014-9059-39ff7b87b57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_746e26cc-cfad-4a9b-95d0-ef911078f50d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e9f1aa7d-a333-4023-acdb-5b20eebfb714" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_746e26cc-cfad-4a9b-95d0-ef911078f50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_08018de8-d0a5-44bf-9fe6-30f59b906f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_746e26cc-cfad-4a9b-95d0-ef911078f50d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_08018de8-d0a5-44bf-9fe6-30f59b906f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3b9779c2-b4b4-48dc-9050-df1388e3b54a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2a8f2e2d-4274-4efc-a5e7-7fee083d8553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:to="loc_us-gaap_AccountsReceivableMember_2a8f2e2d-4274-4efc-a5e7-7fee083d8553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_26a56d62-7bd1-4370-8f02-75c360438405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:to="loc_us-gaap_SalesRevenueNetMember_26a56d62-7bd1-4370-8f02-75c360438405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractAssetsMember_d448f4c4-905a-4d6f-9ea6-268b2368a0c8" xlink:href="sdgr-20241231.xsd#sdgr_ContractAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c36cb66-0d97-48ed-a53c-8b54f05789e6" xlink:to="loc_sdgr_ContractAssetsMember_d448f4c4-905a-4d6f-9ea6-268b2368a0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_8e1c550e-a99f-4bfc-9759-04a76940c01c" xlink:to="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerAMember_46355834-dc95-4b3c-80bc-39a72aad73a2" xlink:href="sdgr-20241231.xsd#sdgr_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:to="loc_sdgr_CustomerAMember_46355834-dc95-4b3c-80bc-39a72aad73a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerBMember_3daf6c88-f86d-48f0-b925-d12522feb4df" xlink:href="sdgr-20241231.xsd#sdgr_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:to="loc_sdgr_CustomerBMember_3daf6c88-f86d-48f0-b925-d12522feb4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CustomerCMember_04523304-b025-416b-9b8a-8c77efc7d95c" xlink:href="sdgr-20241231.xsd#sdgr_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8a115658-decb-4eb7-97c6-98f4a9683410" xlink:to="loc_sdgr_CustomerCMember_04523304-b025-416b-9b8a-8c77efc7d95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:href="sdgr-20241231.xsd#sdgr_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesTable_06442146-9211-44f0-bec0-cb19c22508c0" xlink:to="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_727a227c-f3c4-4d5b-aba4-0c34d4a94799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_727a227c-f3c4-4d5b-aba4-0c34d4a94799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_91be02a1-9f26-44c7-81b3-810b8acf962a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_InterestCostsCapitalized_91be02a1-9f26-44c7-81b3-810b8acf962a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4652dd7d-2ba3-4ea3-a4f1-588c19d84adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4652dd7d-2ba3-4ea3-a4f1-588c19d84adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_7cd2e7d6-101f-4c24-a4d9-26c5bbb6f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_7cd2e7d6-101f-4c24-a4d9-26c5bbb6f56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6f934913-e79e-4d89-9807-27d632d27d05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_6f934913-e79e-4d89-9807-27d632d27d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f7cc3c0c-5690-4219-b6db-0a7423c255cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f7cc3c0c-5690-4219-b6db-0a7423c255cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_ddf68eb1-fdaf-474f-9519-f19bc438858f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_us-gaap_RoyaltyExpense_ddf68eb1-fdaf-474f-9519-f19bc438858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CommissionExpense_60b18346-efa9-4e19-89f2-631d303f09b4" xlink:href="sdgr-20241231.xsd#sdgr_CommissionExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_SignificantAccountingPoliciesLineItems_b5ec3c6f-7766-4876-b313-aa8a8c27a269" xlink:to="loc_sdgr_CommissionExpense_60b18346-efa9-4e19-89f2-631d303f09b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d70f425e-546e-4bdf-9750-58bfc319ab29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d70f425e-546e-4bdf-9750-58bfc319ab29" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:to="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4271c763-691c-4511-813f-51e63aaae5a1" xlink:to="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_fc44dcb6-e9cb-43cf-8402-74f55063cc07" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_fc44dcb6-e9cb-43cf-8402-74f55063cc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_a156f91f-71b5-4a90-8e04-ef2c0ec45b82" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8b44b0a9-ee6a-4d6e-be17-3f9656f69fe3" xlink:to="loc_sdgr_DrugDiscoveryMember_a156f91f-71b5-4a90-8e04-ef2c0ec45b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_5ea537bd-6d6d-442b-a0ea-b665cbf6bb9c" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_43b0dc8a-0261-47da-ac89-335cc2a369e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_43b0dc8a-0261-47da-ac89-335cc2a369e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_3be7660e-a343-4441-9402-fccc55c1e21c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_880d5656-4e4a-4785-ac50-257f757c5f45" xlink:to="loc_us-gaap_TransferredOverTimeMember_3be7660e-a343-4441-9402-fccc55c1e21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7355fd12-5511-403c-969a-1e5287bae2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a7b0bbc5-ed60-4c63-a7bf-3c5ee9b2bfaf" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7355fd12-5511-403c-969a-1e5287bae2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TimingOfRevenueRecognitionPercentage_bec16de5-f842-4728-9b60-a3e0c9b98e77" xlink:href="sdgr-20241231.xsd#sdgr_TimingOfRevenueRecognitionPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7355fd12-5511-403c-969a-1e5287bae2f4" xlink:to="loc_sdgr_TimingOfRevenueRecognitionPercentage_bec16de5-f842-4728-9b60-a3e0c9b98e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionSoftwareProductsandServicesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f080247f-452b-431a-90e6-22807130f387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f080247f-452b-431a-90e6-22807130f387" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_704dca0d-fc5f-4fb5-803c-7350eb055c34" xlink:to="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OnPremiseSoftwareMember_26298917-5e37-4382-8454-f97f7e8a0dbb" xlink:href="sdgr-20241231.xsd#sdgr_OnPremiseSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:to="loc_sdgr_OnPremiseSoftwareMember_26298917-5e37-4382-8454-f97f7e8a0dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_HostedSoftwareMember_54af6903-42c0-4a90-b518-831ab574d298" xlink:href="sdgr-20241231.xsd#sdgr_HostedSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_16f6f5e1-8d7d-42d5-8a1a-dd303ed76f74" xlink:to="loc_sdgr_HostedSoftwareMember_54af6903-42c0-4a90-b518-831ab574d298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_021f1706-ac46-435d-9397-e0de26e13c4e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_a64fe287-d36c-4af4-9a14-32791abef2c9" xlink:href="sdgr-20241231.xsd#sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:to="loc_sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember_a64fe287-d36c-4af4-9a14-32791abef2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_ecbd2fc9-5ed2-4d2b-9165-5b6d9f39baff" xlink:href="sdgr-20241231.xsd#sdgr_July2024AgreementWithBillMelindaGatesFoundationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0858b55-0e2c-4511-811f-cdae6516280a" xlink:to="loc_sdgr_July2024AgreementWithBillMelindaGatesFoundationMember_ecbd2fc9-5ed2-4d2b-9165-5b6d9f39baff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d0999db-4e31-4a66-afd4-12b688c39d01" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b9f04d1c-c0b3-4e26-b609-caf8f8134224" xlink:to="loc_srt_RangeMember_6d0999db-4e31-4a66-afd4-12b688c39d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ebbb22d-900d-4ae3-88de-499acdf94534" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6d0999db-4e31-4a66-afd4-12b688c39d01" xlink:to="loc_srt_MaximumMember_7ebbb22d-900d-4ae3-88de-499acdf94534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cd4d019d-6cc4-4ca6-9e9d-a9a0ba734494" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueArrangementsContractTerm_e9f261c9-fd8c-4220-b496-906813d910b3" xlink:href="sdgr-20241231.xsd#sdgr_RevenueArrangementsContractTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_RevenueArrangementsContractTerm_e9f261c9-fd8c-4220-b496-906813d910b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognitionAmount_46d7fe06-8985-4218-a1f1-35307db812eb" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognitionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_SoftwareContributionRevenueRecognitionAmount_46d7fe06-8985-4218-a1f1-35307db812eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognized_cd15ef79-7354-4b94-8de1-5e90b20c2bda" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_SoftwareContributionRevenueRecognized_cd15ef79-7354-4b94-8de1-5e90b20c2bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_7fb455ad-e58a-43af-98fc-91aa627bb760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_us-gaap_DeferredIncome_7fb455ad-e58a-43af-98fc-91aa627bb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_966535d2-9659-4351-9a19-5a7fcf87ddb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_966535d2-9659-4351-9a19-5a7fcf87ddb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeArrangementTerm_3cab91d7-b514-4250-9f87-84b4df446100" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5cc308ef-a3a8-4f30-9ea9-74c2d8106bd5" xlink:to="loc_sdgr_CollaborativeArrangementTerm_3cab91d7-b514-4250-9f87-84b4df446100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a14a7b21-d8c4-40e9-818c-06d197ef4b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a14a7b21-d8c4-40e9-818c-06d197ef4b0e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:to="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7a2d4232-915a-4e4c-aa09-3a6ad3462de2" xlink:to="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OnPremiseSoftwareMember_5b39c054-c1aa-4a50-8339-354268732652" xlink:href="sdgr-20241231.xsd#sdgr_OnPremiseSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_OnPremiseSoftwareMember_5b39c054-c1aa-4a50-8339-354268732652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_HostedSoftwareMember_f575bca9-975d-4d3f-b71e-f3c11850a3f0" xlink:href="sdgr-20241231.xsd#sdgr_HostedSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_HostedSoftwareMember_f575bca9-975d-4d3f-b71e-f3c11850a3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaintenanceMember_3fac6aef-419a-4877-80b1-b2851dad949c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaintenanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_us-gaap_MaintenanceMember_3fac6aef-419a-4877-80b1-b2851dad949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ProfessionalServicesMember_18be97a5-8f56-4cda-a1e8-698d0c123abe" xlink:href="sdgr-20241231.xsd#sdgr_ProfessionalServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_ProfessionalServicesMember_18be97a5-8f56-4cda-a1e8-698d0c123abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_a89493ff-9acc-4f0f-8b75-d557455375b4" xlink:href="sdgr-20241231.xsd#sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember_a89493ff-9acc-4f0f-8b75-d557455375b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionMember_399d50b5-d81c-40a9-a8d9-cf59ce5b7c5e" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_SoftwareContributionMember_399d50b5-d81c-40a9-a8d9-cf59ce5b7c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_4eb60c41-021c-4dd0-9a06-fb2b1ed9d797" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52451666-8c1b-4a89-b796-2b0be88b0a52" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_4eb60c41-021c-4dd0-9a06-fb2b1ed9d797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_aff08d13-ddd2-4291-a746-3eae69c25110" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff2324c4-8f64-4220-9c90-47165bfd3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff2324c4-8f64-4220-9c90-47165bfd3bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_7242aa50-1983-4bc0-b2a1-013355cc82d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_7242aa50-1983-4bc0-b2a1-013355cc82d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ed4c0e1d-cbd0-41c4-9b21-0ed6ae1f9402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c22204ed-bbab-42f6-89da-dd2f660c91ef" xlink:to="loc_us-gaap_Revenues_ed4c0e1d-cbd0-41c4-9b21-0ed6ae1f9402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionDrugDiscoveryDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3fd73aa4-76de-4b4d-9883-5bb519fff8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3fd73aa4-76de-4b4d-9883-5bb519fff8f8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:to="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eb64d24f-b765-4d52-96ed-2e69f6c894dd" xlink:to="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_e75a78f0-7ff7-450b-8304-38621455f4a1" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_e75a78f0-7ff7-450b-8304-38621455f4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember_36362e23-b94c-45f5-ac96-1d1b5e7f0946" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82e8ca4b-1548-4fad-978d-95414a36be86" xlink:to="loc_sdgr_DrugDiscoveryContributionMember_36362e23-b94c-45f5-ac96-1d1b5e7f0946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_30e01eda-2f26-4332-8278-b5f67776a826" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MilestonePaymentYetToBeAchieved_4b6c3da9-4c72-4c58-b8da-ac759528079f" xlink:href="sdgr-20241231.xsd#sdgr_MilestonePaymentYetToBeAchieved"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_sdgr_MilestonePaymentYetToBeAchieved_4b6c3da9-4c72-4c58-b8da-ac759528079f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRecognizedForMilestonePayment_710d0899-1000-431f-b1b0-faa8c63fd788" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRecognizedForMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_sdgr_RevenueRecognizedForMilestonePayment_710d0899-1000-431f-b1b0-faa8c63fd788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_839cc282-80f4-46fe-9738-06cc8d6ed40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_11c2dfc3-0408-407f-bbed-b2136bb8f75c" xlink:to="loc_us-gaap_DeferredRevenue_839cc282-80f4-46fe-9738-06cc8d6ed40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofDrugRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a347dfe0-b2b4-4efd-a456-aadb8ea1b60a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a347dfe0-b2b4-4efd-a456-aadb8ea1b60a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:to="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_523c39d4-49f7-49de-9cae-96829150e388" xlink:to="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_2f1c04a0-868f-433f-b4e0-8ecf7b1d722f" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:to="loc_sdgr_DrugDiscoveryMember_2f1c04a0-868f-433f-b4e0-8ecf7b1d722f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_1b43b0cb-59a8-46df-bd6d-7fc85401a3d9" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_1b43b0cb-59a8-46df-bd6d-7fc85401a3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember_2751a8e8-8107-46ab-a9b3-bc480f44fefe" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93e48eda-83a2-4b51-b2d0-41ffc3dcbca0" xlink:to="loc_sdgr_DrugDiscoveryContributionMember_2751a8e8-8107-46ab-a9b3-bc480f44fefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_325e43dd-e723-4c7d-8545-f305b8183756" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a660145-410e-4df9-afd9-f5040520fe8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4a660145-410e-4df9-afd9-f5040520fe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_662bbca0-999a-4559-8686-914fa1cb432b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_662bbca0-999a-4559-8686-914fa1cb432b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b714c940-e4ce-4de2-9020-884685ea3452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_559de61b-0fbe-4a9e-b646-70c467311396" xlink:to="loc_us-gaap_Revenues_b714c940-e4ce-4de2-9020-884685ea3452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionCollaborationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_35a25f52-bc3e-41b2-9807-6407bf5dbea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_35a25f52-bc3e-41b2-9807-6407bf5dbea1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6f95c195-ed06-4a79-8d86-b890f2a6ecb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BristolMyersSquibbMember_36288071-a928-4287-8be5-03c829023f65" xlink:href="sdgr-20241231.xsd#sdgr_BristolMyersSquibbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:to="loc_sdgr_BristolMyersSquibbMember_36288071-a928-4287-8be5-03c829023f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NovartisPharmaAGMember_438743d8-b8ca-4458-ac46-d129cb6856f6" xlink:href="sdgr-20241231.xsd#sdgr_NovartisPharmaAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf497656-fd30-4fc9-93a3-285b489e3fb8" xlink:to="loc_sdgr_NovartisPharmaAGMember_438743d8-b8ca-4458-ac46-d129cb6856f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1e132d5d-6eb1-424f-ab6c-142bf6459266" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember_05ffb3f8-7a54-4518-bed1-e4c2e37c08b5" xlink:href="sdgr-20241231.xsd#sdgr_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_ResearchCollaborationAndLicenseAgreementMember_05ffb3f8-7a54-4518-bed1-e4c2e37c08b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareAgreementMember_93e49d4f-6804-4407-9dce-8c79757ad4eb" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_SoftwareAgreementMember_93e49d4f-6804-4407-9dce-8c79757ad4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborationAndLicenseAgreementMember_a571751d-58db-4beb-893e-29f7ad673a9d" xlink:href="sdgr-20241231.xsd#sdgr_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7248d71b-a0ea-4ad9-a377-720a94cf84d9" xlink:to="loc_sdgr_CollaborationAndLicenseAgreementMember_a571751d-58db-4beb-893e-29f7ad673a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1843cd90-7b41-4d2f-b769-7c191dec8fee" xlink:to="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OncologyNeurologyAndImmunologyProductMember_e3da75ed-a85a-4e81-85de-5b6460794bf9" xlink:href="sdgr-20241231.xsd#sdgr_OncologyNeurologyAndImmunologyProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_OncologyNeurologyAndImmunologyProductMember_e3da75ed-a85a-4e81-85de-5b6460794bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryServicesMember_4924e42c-062e-4f9d-95a4-9a4ceb48f54e" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_DrugDiscoveryServicesMember_4924e42c-062e-4f9d-95a4-9a4ceb48f54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_9f11c419-7b8a-4329-ae1c-49c5b3a21f9d" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7490d12a-e1a1-473f-af27-772909ca01d9" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_9f11c419-7b8a-4329-ae1c-49c5b3a21f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d1b0d29a-77c0-4b53-a063-bb789ea1173b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_d1b0d29a-77c0-4b53-a063-bb789ea1173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_3ee55bd3-83c8-45e1-9ea7-d6bed472df1a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e483dc93-9c4d-48e0-9c94-dad24eee95e7" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets_e483dc93-9c4d-48e0-9c94-dad24eee95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_7cc13806-8ce5-4622-9ee9-b4fbecd2f4e5" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining_7cc13806-8ce5-4622-9ee9-b4fbecd2f4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_61d10e27-6732-4eb4-9876-602a160e72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerLiability_61d10e27-6732-4eb4-9876-602a160e72a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_584f07ac-de95-43d5-a295-db93bfcd5d08" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount_584f07ac-de95-43d5-a295-db93bfcd5d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_3fa41bb9-0d37-4da2-bbff-79ca0c38730a" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount_3fa41bb9-0d37-4da2-bbff-79ca0c38730a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_dd5ff14f-ba47-4df9-b8cf-d5d951f5e46f" xlink:href="sdgr-20241231.xsd#sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount_dd5ff14f-ba47-4df9-b8cf-d5d951f5e46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f50ff65-5e9a-428f-bd43-833dfec6a030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5f50ff65-5e9a-428f-bd43-833dfec6a030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPerformanceObligations_9fedeaa5-93f2-4990-941f-3c9664318a23" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPerformanceObligations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_NumberOfPerformanceObligations_9fedeaa5-93f2-4990-941f-3c9664318a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CollaborativeAgreementNumberOfPrograms_dd1fc96f-c4e9-4a6d-83f0-cf5552d3ebdd" xlink:href="sdgr-20241231.xsd#sdgr_CollaborativeAgreementNumberOfPrograms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_sdgr_CollaborativeAgreementNumberOfPrograms_dd1fc96f-c4e9-4a6d-83f0-cf5552d3ebdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_63bc951b-57f2-48ed-b13f-c2faf491f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_63bc951b-57f2-48ed-b13f-c2faf491f8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ef66e86-c1a8-4847-bdc0-40d49a848697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4ef66e86-c1a8-4847-bdc0-40d49a848697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_55b66fa9-3ac5-43bd-909c-0c2caf44290a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_55b66fa9-3ac5-43bd-909c-0c2caf44290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fd416eb4-eaf5-416e-9796-81d38ab122f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1dad00c2-0e97-4f3f-bc07-3a4d114e5735" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_fd416eb4-eaf5-416e-9796-81d38ab122f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionScheduleofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cf6cc76d-e4ba-4186-b45d-8a3d18796d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cf6cc76d-e4ba-4186-b45d-8a3d18796d21" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:to="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b412506b-d950-49a3-9cb0-fd058177811e" xlink:to="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareProductsAndServicesMember_7df20127-a83a-498c-bf60-af6e6557df02" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:to="loc_sdgr_SoftwareProductsAndServicesMember_7df20127-a83a-498c-bf60-af6e6557df02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryMember_c0f0a859-bc9e-4475-9f09-860ebc7affc8" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc544594-eb36-4488-a94d-9757687e1297" xlink:to="loc_sdgr_DrugDiscoveryMember_c0f0a859-bc9e-4475-9f09-860ebc7affc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bffd98a-b8d9-4e6a-895b-5e8a291ca36a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_32fc898e-df09-46c3-9524-b0fd19451652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_32fc898e-df09-46c3-9524-b0fd19451652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_4b367769-6695-4ceb-8853-20b19a0ff1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueAndCreditsCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_4b367769-6695-4ceb-8853-20b19a0ff1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_15bd9c62-f74a-4dee-95b6-8137167b5ded" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsCurrentAbstract_4b367769-6695-4ceb-8853-20b19a0ff1f6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_15bd9c62-f74a-4dee-95b6-8137167b5ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_93e5363f-073f-4441-bbd0-062b36216165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3d51f9d4-1d8b-45df-9701-6270b90f9d0f" xlink:to="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_93e5363f-073f-4441-bbd0-062b36216165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e64e47a3-4434-49d7-8ca1-e12be495f2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract_93e5363f-073f-4441-bbd0-062b36216165" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e64e47a3-4434-49d7-8ca1-e12be495f2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ca5d472a-82b9-404d-ac8f-ea2edd1f25ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ca5d472a-82b9-404d-ac8f-ea2edd1f25ae" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:to="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_376ca333-2bee-4f66-b032-5779a4cfbb4c" xlink:to="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_784c9eeb-a195-45dd-915c-c60d01befd43" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:to="loc_srt_MinimumMember_784c9eeb-a195-45dd-915c-c60d01befd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_96123c50-cf69-45a3-8a40-5a499dc8c9b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cfcc6229-6eaf-4c67-8455-0c341cba4f2b" xlink:to="loc_srt_MaximumMember_96123c50-cf69-45a3-8a40-5a499dc8c9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_003975ae-7de4-4516-bbd9-f091cdbd6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_003975ae-7de4-4516-bbd9-f091cdbd6ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_44b1e72a-8499-4ae7-97e0-f2d333ce6095" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_128df270-36b6-4db1-b875-293129eeb9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_128df270-36b6-4db1-b875-293129eeb9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_6e44867f-11f1-4f85-a129-a3e70d384172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_6e44867f-11f1-4f85-a129-a3e70d384172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b659d73b-fb51-4ffb-82ea-53915e0ea447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b659d73b-fb51-4ffb-82ea-53915e0ea447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ContractWithCustomersPaymentTerms_28119f6e-785e-47ae-8cde-d562b485cf2f" xlink:href="sdgr-20241231.xsd#sdgr_ContractWithCustomersPaymentTerms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_e70885b1-6a3d-43c8-b518-e4c1ae4b2abe" xlink:to="loc_sdgr_ContractWithCustomersPaymentTerms_28119f6e-785e-47ae-8cde-d562b485cf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8caf0471-f4cf-46e8-a9e6-bc6af319f787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8caf0471-f4cf-46e8-a9e6-bc6af319f787" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_351b1ee6-b02f-4117-ac6c-84e85c2af571" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_09807f5a-28c8-46a1-a700-79ed9228c52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_us-gaap_ComputerEquipmentMember_09807f5a-28c8-46a1-a700-79ed9228c52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5836a476-ea8c-450e-a5d9-d4e6e9aa4b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5836a476-ea8c-450e-a5d9-d4e6e9aa4b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_dd3e96d9-5e3d-42a7-980d-ae3815e77226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_dd3e96d9-5e3d-42a7-980d-ae3815e77226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LabEquipmentMember_0f3ede10-1648-4c1f-9891-66ff7b19ebb9" xlink:href="sdgr-20241231.xsd#sdgr_LabEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_960ab91a-686c-4a3f-a697-5e3e5e67be8f" xlink:to="loc_sdgr_LabEquipmentMember_0f3ede10-1648-4c1f-9891-66ff7b19ebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d7eb5b9-b8ac-477b-b787-d4cec03b8201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9acc546e-6c0d-4609-bf49-f002c640560f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9acc546e-6c0d-4609-bf49-f002c640560f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_8ab46f88-fc63-488f-be0b-21757ebc21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_8ab46f88-fc63-488f-be0b-21757ebc21ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b05f77d2-1805-4fa5-a537-2ba80a287082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b05f77d2-1805-4fa5-a537-2ba80a287082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6b9b5d88-bf90-4c2f-86d0-ac424772bdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6b9b5d88-bf90-4c2f-86d0-ac424772bdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_14121471-8abd-4cf3-a389-6934c32cf937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_380e95fb-4e63-4570-9032-12eef1925f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_14121471-8abd-4cf3-a389-6934c32cf937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fc094de1-67a9-4015-9e21-9feaf91b0c58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a1603eff-c52b-4a20-bb93-9eb1c53f7113" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fc094de1-67a9-4015-9e21-9feaf91b0c58" xlink:to="loc_us-gaap_Depreciation_a1603eff-c52b-4a20-bb93-9eb1c53f7113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_59d028b8-d78e-499c-b30a-5c5535f6967a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_59d028b8-d78e-499c-b30a-5c5535f6967a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f39d4cf3-296a-421e-a843-91b5e729386b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1a634f54-4b22-4919-8947-854f35cf4fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1a634f54-4b22-4919-8947-854f35cf4fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_474ac1c0-7163-404b-bafb-aeebd58608c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_474ac1c0-7163-404b-bafb-aeebd58608c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2bdb779e-ce97-409e-98d8-a73f72efa028" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53b50120-b5db-4ff8-bc45-079c21c0cef5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2bdb779e-ce97-409e-98d8-a73f72efa028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2c49735d-8e4b-4a19-b2e8-e93433867f9e" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_CashCashEquivalentsAndRestrictedCashMember_b30042a1-f783-4258-adcd-4724042b034a" xlink:href="sdgr-20241231.xsd#sdgr_CashCashEquivalentsAndRestrictedCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:to="loc_sdgr_CashCashEquivalentsAndRestrictedCashMember_b30042a1-f783-4258-adcd-4724042b034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesAssetsMember_6423288e-2888-4f76-a65f-0fa576871968" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuritiesAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:to="loc_us-gaap_SecuritiesAssetsMember_6423288e-2888-4f76-a65f-0fa576871968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_0b4f1942-c2a1-4374-91f8-c679ffe2e486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3281717f-0b44-40b2-a249-53949565f0d6" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_0b4f1942-c2a1-4374-91f8-c679ffe2e486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c045c0b2-efc9-4ce3-91b3-9c1a2a76a426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_e17c4c66-d5d3-4dc7-b3eb-a658e28dd123" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c045c0b2-efc9-4ce3-91b3-9c1a2a76a426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d9b1f7b1-51b0-4811-ba54-328fffac93e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c045c0b2-efc9-4ce3-91b3-9c1a2a76a426" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d9b1f7b1-51b0-4811-ba54-328fffac93e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_10fad4fb-db07-4979-b20f-a38fc38a2e18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_5ab7b7f5-4e7a-464b-b510-f2291917271d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10fad4fb-db07-4979-b20f-a38fc38a2e18" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_5ab7b7f5-4e7a-464b-b510-f2291917271d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_e9f60654-31ad-4664-9498-f38acc72ac12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10fad4fb-db07-4979-b20f-a38fc38a2e18" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_e9f60654-31ad-4664-9498-f38acc72ac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbde3796-05fa-4653-8adb-d8cd59a41aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm_210c7105-8e8d-4388-96f2-6ba499324eed" xlink:href="sdgr-20241231.xsd#sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbde3796-05fa-4653-8adb-d8cd59a41aef" xlink:to="loc_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm_210c7105-8e8d-4388-96f2-6ba499324eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution_30cc795f-deef-40f3-bcf1-e0deedb68191" xlink:href="sdgr-20241231.xsd#sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbde3796-05fa-4653-8adb-d8cd59a41aef" xlink:to="loc_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution_30cc795f-deef-40f3-bcf1-e0deedb68191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsAndContingenciesSummaryofOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f8cbd3a-ffdf-4227-93cd-4a38f0df7ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_73fd804c-1aec-4562-a939-6a0d8d76fdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f8cbd3a-ffdf-4227-93cd-4a38f0df7ae2" xlink:to="loc_us-gaap_LeaseCost_73fd804c-1aec-4562-a939-6a0d8d76fdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeasePayments_d63b76ed-d7c1-4c9b-a978-e429433a7003" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4f8cbd3a-ffdf-4227-93cd-4a38f0df7ae2" xlink:to="loc_sdgr_OperatingAndFinanceLeasePayments_d63b76ed-d7c1-4c9b-a978-e429433a7003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fb1d156-17de-495d-a30b-d77ad72f0e01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0fb1d156-17de-495d-a30b-d77ad72f0e01" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_fc0f10e8-2dbf-4ebf-89ce-98c09092603b" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne_fc0f10e8-2dbf-4ebf-89ce-98c09092603b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_4cd68303-bdc9-449f-bf9e-a4dd50ded45c" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo_4cd68303-bdc9-449f-bf9e-a4dd50ded45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_cbfe652d-2035-434c-837f-2a7fcd16f84e" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree_cbfe652d-2035-434c-837f-2a7fcd16f84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_59b217bf-b3ca-4955-8fa4-7f31910beafc" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour_59b217bf-b3ca-4955-8fa4-7f31910beafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_910610a8-7270-4999-b9d2-128ffba13983" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive_910610a8-7270-4999-b9d2-128ffba13983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_069563f4-ff90-46ca-a6a2-4c0e0a8a8f75" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive_069563f4-ff90-46ca-a6a2-4c0e0a8a8f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_f8f2ee1d-4d44-42f3-863c-a55cfb71d065" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid_f8f2ee1d-4d44-42f3-863c-a55cfb71d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_4e0a557f-9fc4-4403-beeb-24517ebac583" xlink:href="sdgr-20241231.xsd#sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount_4e0a557f-9fc4-4403-beeb-24517ebac583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiability_1079e028-f69e-4859-98a4-2d6f84b82b4f" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_OperatingAndFinanceLeaseLiability_1079e028-f69e-4859-98a4-2d6f84b82b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_0fdfd707-e172-4186-aacc-f6321d5bfd69" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_OperatingAndFinanceLeaseLiabilityCurrent_0fdfd707-e172-4186-aacc-f6321d5bfd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_fbd9126b-04a9-42fb-8be6-4ca38df48337" xlink:href="sdgr-20241231.xsd#sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b7cdbadc-cf68-4860-ab54-3f635df478b0" xlink:to="loc_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent_fbd9126b-04a9-42fb-8be6-4ca38df48337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesSummaryofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_39fe3d5a-b56e-4120-b533-f638bd82cc89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_750e4201-d869-415f-b470-c4f30553cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39fe3d5a-b56e-4120-b533-f638bd82cc89" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_750e4201-d869-415f-b470-c4f30553cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_aba21c4e-48a0-4196-a583-afc7d1072306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_750e4201-d869-415f-b470-c4f30553cca5" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_aba21c4e-48a0-4196-a583-afc7d1072306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4091bb1c-a286-43c7-b0a3-ccc17714de93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_750e4201-d869-415f-b470-c4f30553cca5" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4091bb1c-a286-43c7-b0a3-ccc17714de93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b861f619-eeef-4742-8f9f-0e1e248604c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_750e4201-d869-415f-b470-c4f30553cca5" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b861f619-eeef-4742-8f9f-0e1e248604c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70ffcc5a-6848-4a16-ad72-145e00ffb10c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_750e4201-d869-415f-b470-c4f30553cca5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_70ffcc5a-6848-4a16-ad72-145e00ffb10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_682ac418-5d05-4201-ade1-1b6c096ce89c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39fe3d5a-b56e-4120-b533-f638bd82cc89" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_682ac418-5d05-4201-ade1-1b6c096ce89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_62adc2d0-ff0a-4936-93c8-e3c3a154dfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_682ac418-5d05-4201-ade1-1b6c096ce89c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_62adc2d0-ff0a-4936-93c8-e3c3a154dfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_abcd522d-b8b7-4c5a-8465-3e14004790d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_682ac418-5d05-4201-ade1-1b6c096ce89c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_abcd522d-b8b7-4c5a-8465-3e14004790d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a13ee260-49ba-44b6-b77d-7170daf4d9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_682ac418-5d05-4201-ade1-1b6c096ce89c" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a13ee260-49ba-44b6-b77d-7170daf4d9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_821327e8-0def-4ce1-bfc6-ac9dca289bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_682ac418-5d05-4201-ade1-1b6c096ce89c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_821327e8-0def-4ce1-bfc6-ac9dca289bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a7900df8-1a01-4325-bd97-e72584c2854a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39fe3d5a-b56e-4120-b533-f638bd82cc89" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a7900df8-1a01-4325-bd97-e72584c2854a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f10dcf44-90c2-41d7-9de8-8079d5f841fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6066f6c5-5cec-49cd-af45-b73f0487f64c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f10dcf44-90c2-41d7-9de8-8079d5f841fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6066f6c5-5cec-49cd-af45-b73f0487f64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bf16a0fe-4e06-44fa-844d-e2189768958c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f10dcf44-90c2-41d7-9de8-8079d5f841fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bf16a0fe-4e06-44fa-844d-e2189768958c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_09bb49db-b169-4886-8114-cc09826e40ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f10dcf44-90c2-41d7-9de8-8079d5f841fd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_09bb49db-b169-4886-8114-cc09826e40ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_28d0403d-7c2d-4f06-b895-a51504b186ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_28d0403d-7c2d-4f06-b895-a51504b186ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2b682a15-ab40-4565-921c-8267bb8b102a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2b682a15-ab40-4565-921c-8267bb8b102a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_7509e9ae-ed53-4fd1-8e51-9fc619b7aecb" xlink:href="sdgr-20241231.xsd#sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation_7509e9ae-ed53-4fd1-8e51-9fc619b7aecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_85926d92-032d-4ae1-9d32-73e171027cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_85926d92-032d-4ae1-9d32-73e171027cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_96a1dc2b-a1d3-4493-a98a-94782daca1dc" xlink:href="sdgr-20241231.xsd#sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_96a1dc2b-a1d3-4493-a98a-94782daca1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8a370dd9-357b-4e1f-aade-003c24454636" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8a370dd9-357b-4e1f-aade-003c24454636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_9c8f4673-3f01-40cf-95b6-b278d4e68e40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies_9c8f4673-3f01-40cf-95b6-b278d4e68e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_23226ca3-4c99-4bc8-ab86-0855e67ab9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_23226ca3-4c99-4bc8-ab86-0855e67ab9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_82450ffc-a525-4a79-b8da-ab7ff654552e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_82450ffc-a525-4a79-b8da-ab7ff654552e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2e48b177-791b-455a-800b-a7f63cf67139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09781d4f-5147-45ff-8894-a2bd9a26954b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2e48b177-791b-455a-800b-a7f63cf67139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_311a1cf0-3915-4aa3-95cd-c84b2ea5346f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_311a1cf0-3915-4aa3-95cd-c84b2ea5346f" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b6d7f594-b1bf-4daa-939d-5830fe744abb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f5946921-4d52-4afb-99eb-f5a5d971036a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:to="loc_us-gaap_DomesticCountryMember_f5946921-4d52-4afb-99eb-f5a5d971036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d96702bc-b384-45a3-9e12-b0fedea0e5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9bff3fe4-be57-49a8-8656-2c29f4f4b6de" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d96702bc-b384-45a3-9e12-b0fedea0e5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_e1a00808-cb01-44b5-9989-7e1cc9c67fbc" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9f78f1e-b5c9-4197-bf7a-c28f7868a5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9f78f1e-b5c9-4197-bf7a-c28f7868a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c77d7096-bdfb-445f-8c79-2a36497d4487" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c77d7096-bdfb-445f-8c79-2a36497d4487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7f9fb74f-ee7e-47fe-b942-59c8444bdc94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_7f9fb74f-ee7e-47fe-b942-59c8444bdc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_63229e87-ee68-457d-abd8-ed3ccc0e0cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_63229e87-ee68-457d-abd8-ed3ccc0e0cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_5dcfda09-618f-4af0-bcdf-e0def6837d11" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9342d219-56a0-4bb2-b16d-9ec2b95590fa" xlink:to="loc_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration_5dcfda09-618f-4af0-bcdf-e0def6837d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_edf84e97-1db0-4716-9332-b4dcc8fb646f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_edf84e97-1db0-4716-9332-b4dcc8fb646f" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0dd14f09-1e0f-4cdc-ab40-4a83194d8c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0dd14f09-1e0f-4cdc-ab40-4a83194d8c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0dcdfc61-8b55-4d66-bbf9-6b2cf7df55d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0dcdfc61-8b55-4d66-bbf9-6b2cf7df55d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_92fdbc63-a8c2-4466-bb7f-5ab39a5360c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_92fdbc63-a8c2-4466-bb7f-5ab39a5360c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d02c2911-165a-4167-bb49-a064c9ed821b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d02c2911-165a-4167-bb49-a064c9ed821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxAssetsLeaseLiabilities_da8c0580-0777-480f-987d-b534e1b26572" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_sdgr_DeferredTaxAssetsLeaseLiabilities_da8c0580-0777-480f-987d-b534e1b26572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9f1e79a9-e40a-4b2f-a74e-5ab750f9f761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9f1e79a9-e40a-4b2f-a74e-5ab750f9f761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fca13e54-f388-43b9-bc43-c44e17b3afa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fca13e54-f388-43b9-bc43-c44e17b3afa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8c1271ab-41cb-42a8-847a-0b3b1c857b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8c1271ab-41cb-42a8-847a-0b3b1c857b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7b4de4cc-d3b9-45fc-802b-2edef59064a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_8b9672f2-6bd6-4b78-9f12-bf5291733619" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7b4de4cc-d3b9-45fc-802b-2edef59064a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db7a0ce-d9ae-451a-8d1d-6986ac1e55de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_edf84e97-1db0-4716-9332-b4dcc8fb646f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db7a0ce-d9ae-451a-8d1d-6986ac1e55de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_e3f78e7a-9c64-4612-a619-8cb81372cf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db7a0ce-d9ae-451a-8d1d-6986ac1e55de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_e3f78e7a-9c64-4612-a619-8cb81372cf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_594e9ec8-e6d9-4786-9129-2e5cd4b0abea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db7a0ce-d9ae-451a-8d1d-6986ac1e55de" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_594e9ec8-e6d9-4786-9129-2e5cd4b0abea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_e5f354f9-9d62-4218-bc4d-51c8a0e62ab1" xlink:href="sdgr-20241231.xsd#sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db7a0ce-d9ae-451a-8d1d-6986ac1e55de" xlink:to="loc_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization_e5f354f9-9d62-4218-bc4d-51c8a0e62ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_482f931a-ad03-4c45-963e-1b1748c0dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_7db7a0ce-d9ae-451a-8d1d-6986ac1e55de" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_482f931a-ad03-4c45-963e-1b1748c0dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b164435-5565-4ae0-98bd-7141cc04bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b164435-5565-4ae0-98bd-7141cc04bba8" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7302353c-1688-4e19-8ad2-b5fbf848494b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7302353c-1688-4e19-8ad2-b5fbf848494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e2e22a28-fc75-4258-96a7-89cd30025f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e2e22a28-fc75-4258-96a7-89cd30025f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6e4fe122-c9cd-489e-b520-a67007221ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6e4fe122-c9cd-489e-b520-a67007221ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2231f72a-83c2-40b2-9be2-a2ac458d8974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2231f72a-83c2-40b2-9be2-a2ac458d8974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_058da8f0-c683-4318-a487-d3c90e6c1614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ea9150f7-4146-4b7d-83b4-735147f5942a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_058da8f0-c683-4318-a487-d3c90e6c1614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b99a9b4c-0e90-4588-94c1-9730235c2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b99a9b4c-0e90-4588-94c1-9730235c2fdd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4665344f-5790-40b4-bf3e-976cbab460b1" xlink:to="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_VotingCommonStockMember_3b0bd756-0244-4ab5-9b03-401b4108f17a" xlink:href="sdgr-20241231.xsd#sdgr_VotingCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:to="loc_sdgr_VotingCommonStockMember_3b0bd756-0244-4ab5-9b03-401b4108f17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_LimitedCommonStockMember_43def4af-f604-4aff-8603-4bde6b357a18" xlink:href="sdgr-20241231.xsd#sdgr_LimitedCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7f6facae-c913-46f2-80e4-3dbc75ef5332" xlink:to="loc_sdgr_LimitedCommonStockMember_43def4af-f604-4aff-8603-4bde6b357a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e5b5a81-c5f5-4815-97b3-5e448884201c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_45f8804c-f303-46f0-818a-da15ee744024" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e5b5a81-c5f5-4815-97b3-5e448884201c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TheATMMember_0b283266-faca-4641-ac2f-d4d2dfee4a35" xlink:href="sdgr-20241231.xsd#sdgr_TheATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0e5b5a81-c5f5-4815-97b3-5e448884201c" xlink:to="loc_sdgr_TheATMMember_0b283266-faca-4641-ac2f-d4d2dfee4a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_da71072d-b549-4c39-9b47-b254127c5511" xlink:to="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90969707-012b-4e0b-9e7a-68100db5a5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90969707-012b-4e0b-9e7a-68100db5a5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e3d82bc8-09b7-4852-b5bc-154bb692a639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e3d82bc8-09b7-4852-b5bc-154bb692a639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfVotesForCommonShare_c05d2d2f-908c-4b5a-a272-6920c6560a10" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfVotesForCommonShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_sdgr_NumberOfVotesForCommonShare_c05d2d2f-908c-4b5a-a272-6920c6560a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_adfdf453-f873-42fc-9985-7291a4d5fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_adfdf453-f873-42fc-9985-7291a4d5fbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59e267ce-cfdf-4f07-b1e4-8951f1e6d481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59e267ce-cfdf-4f07-b1e4-8951f1e6d481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49c3d6af-0768-44ce-8023-05c2d676538a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49c3d6af-0768-44ce-8023-05c2d676538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_a9db738c-f44f-449f-9034-ed911233ee9a" xlink:href="sdgr-20241231.xsd#sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance_a9db738c-f44f-449f-9034-ed911233ee9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_34528c4f-2ddd-4c05-88aa-6727b6d5b89b" xlink:href="sdgr-20241231.xsd#sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock_34528c4f-2ddd-4c05-88aa-6727b6d5b89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_debac3b1-fb0c-4d84-a60e-161f8c22a5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_debac3b1-fb0c-4d84-a60e-161f8c22a5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d5f21e7-92fb-4ece-8946-497c4479f000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_39e960a1-c7c2-4ee5-9f33-8002d9ab0164" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8d5f21e7-92fb-4ece-8946-497c4479f000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bcb735b-d648-444e-a934-8fe43bc2282f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6bcb735b-d648-444e-a934-8fe43bc2282f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47d06c44-b1b6-42f6-a408-080967a1b2c0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2c0dd119-9569-4615-ad4d-c3a2be237f20" xlink:to="loc_srt_RangeMember_47d06c44-b1b6-42f6-a408-080967a1b2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_480e5dd6-65a0-4fa0-8ee8-2304aa5a9360" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_47d06c44-b1b6-42f6-a408-080967a1b2c0" xlink:to="loc_srt_MaximumMember_480e5dd6-65a0-4fa0-8ee8-2304aa5a9360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ba70581-6dd3-4c71-b088-f4bc0db4e37a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0c61e148-50c6-40f6-bc82-b83ea07a0e3d" xlink:to="loc_us-gaap_PlanNameDomain_9ba70581-6dd3-4c71-b088-f4bc0db4e37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_TwentyTwentyStockPlanMember_8ae2e576-8c5e-42f7-a089-d7b15562b1d7" xlink:href="sdgr-20241231.xsd#sdgr_TwentyTwentyStockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9ba70581-6dd3-4c71-b088-f4bc0db4e37a" xlink:to="loc_sdgr_TwentyTwentyStockPlanMember_8ae2e576-8c5e-42f7-a089-d7b15562b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1a13fd93-33e7-42d1-9770-e6b34db510ac" xlink:to="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_710315f0-1850-4ccb-ba35-ab007bec0481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_710315f0-1850-4ccb-ba35-ab007bec0481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b36f1502-44c3-4cfb-91fe-d73e04d72db6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b36f1502-44c3-4cfb-91fe-d73e04d72db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_4f356c26-68a5-4c48-b902-a9436f7e0d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_4f356c26-68a5-4c48-b902-a9436f7e0d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SharebasedCompensationAwardTrancheFourMember_9a9ad854-0417-491f-81df-38ac1158fc49" xlink:href="sdgr-20241231.xsd#sdgr_SharebasedCompensationAwardTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b92b8e4d-dbb2-42f6-a32d-6c04a165c16d" xlink:to="loc_sdgr_SharebasedCompensationAwardTrancheFourMember_9a9ad854-0417-491f-81df-38ac1158fc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1800b953-acfe-4694-98d7-6066a147bb4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f2830bb-d5b1-4dc2-858a-a69dd17fc7df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f2830bb-d5b1-4dc2-858a-a69dd17fc7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_ce4ecbfb-159d-4871-ac65-f4ffffa3cf12" xlink:href="sdgr-20241231.xsd#sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember_ce4ecbfb-159d-4871-ac65-f4ffffa3cf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PerformanceBasedRestrictedStockUnitsMember_0bf7bb55-08fc-4641-8740-f064da9e1e1e" xlink:href="sdgr-20241231.xsd#sdgr_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_sdgr_PerformanceBasedRestrictedStockUnitsMember_0bf7bb55-08fc-4641-8740-f064da9e1e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6fbff52d-403f-4208-a9db-f81709cb5ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2b8591-8702-43e2-954c-13990cef123c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6fbff52d-403f-4208-a9db-f81709cb5ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_edeeda51-3262-4793-a737-137e56821a56" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2b4a0aa-32f3-427f-a45d-cc0e920afcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a2b4a0aa-32f3-427f-a45d-cc0e920afcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_465b0f67-08fd-4b2f-968d-2d66fd89e03b" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward_465b0f67-08fd-4b2f-968d-2d66fd89e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_781e1194-0a3a-49f6-ab97-c832d3643f94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_781e1194-0a3a-49f6-ab97-c832d3643f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8a598cd4-b905-4a3e-824c-1727fe369c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8a598cd4-b905-4a3e-824c-1727fe369c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36afef19-d5c7-4ae9-b602-26b24339b1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_36afef19-d5c7-4ae9-b602-26b24339b1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_aaf6f320-e759-4e41-95f1-05c7946f02d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_aaf6f320-e759-4e41-95f1-05c7946f02d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6363921a-0fa9-4542-b33e-2039124a4140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6363921a-0fa9-4542-b33e-2039124a4140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86046d21-a5d1-4185-83a3-1789d4b4771a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_86046d21-a5d1-4185-83a3-1789d4b4771a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e5adf78b-df33-4eb2-95fe-149573f1a0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e5adf78b-df33-4eb2-95fe-149573f1a0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3f91e16-7243-4ca9-b81e-b675d9cfb6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3f91e16-7243-4ca9-b81e-b675d9cfb6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_e3799f6d-1a71-4f2f-a223-d522670f25b5" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent_e3799f6d-1a71-4f2f-a223-d522670f25b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_97e3aea8-d9ee-4240-8758-929770e048ea" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber_97e3aea8-d9ee-4240-8758-929770e048ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2e7e0b9-61c2-4dba-8d4d-a62977056616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2e7e0b9-61c2-4dba-8d4d-a62977056616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_545bbacb-9ff9-46cf-8d82-a653038b6d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_545bbacb-9ff9-46cf-8d82-a653038b6d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_a322f506-979d-46b1-9afd-52fa5d54a6d7" xlink:href="sdgr-20241231.xsd#sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue_a322f506-979d-46b1-9afd-52fa5d54a6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_27644a3a-b33b-414a-bf4a-0a38e309647b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_27644a3a-b33b-414a-bf4a-0a38e309647b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43dec513-5482-48b2-869b-bf18cf2c9e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43dec513-5482-48b2-869b-bf18cf2c9e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_350f2272-d6d0-4cf6-8658-fb811fc74ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_350f2272-d6d0-4cf6-8658-fb811fc74ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf55a617-18ab-47fd-9073-b7b85c64cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf55a617-18ab-47fd-9073-b7b85c64cc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2fb98307-1cc3-4392-aa74-349b39bcc79b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2fb98307-1cc3-4392-aa74-349b39bcc79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11c534ae-6bcf-46b8-bb5b-e3aae79ae8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11c534ae-6bcf-46b8-bb5b-e3aae79ae8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ae1ac56c-b49c-41ea-a1aa-2d63a1cd014f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ae1ac56c-b49c-41ea-a1aa-2d63a1cd014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_655c9215-212f-444b-9e0f-30bb2670b8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_655c9215-212f-444b-9e0f-30bb2670b8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_204fd3ec-4f56-4d12-b5dc-47b798c17e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_204fd3ec-4f56-4d12-b5dc-47b798c17e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5f46a3a1-0358-474b-a84a-4c05e346bc72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ada877a4-23cd-4523-b266-05d333a8bafe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_5f46a3a1-0358-474b-a84a-4c05e346bc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c24ade7a-151b-48d2-9e18-275c1bb1dafc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c24ade7a-151b-48d2-9e18-275c1bb1dafc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5b03f31a-a5a8-421c-b292-77edf2069524" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_171028bb-8344-4b6e-b5a3-eb57cfa79373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_CostOfSalesMember_171028bb-8344-4b6e-b5a3-eb57cfa79373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bd16e87d-2972-4b23-a5da-00ba3cb0eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bd16e87d-2972-4b23-a5da-00ba3cb0eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_0fbdf3a0-c1d2-4fb5-91f7-875238b903d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_0fbdf3a0-c1d2-4fb5-91f7-875238b903d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6df5b946-4309-47c5-b83e-7e2e45b7dbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_aac5a6d1-e4fa-456a-b6b9-a3b705a04886" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6df5b946-4309-47c5-b83e-7e2e45b7dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37f34c00-3958-40a9-ae32-dbc0412c78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_abe01d9b-1796-4998-b8af-6351cfad2791" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37f34c00-3958-40a9-ae32-dbc0412c78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_69c20b46-a11e-4a47-96c9-bde910209616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_37f34c00-3958-40a9-ae32-dbc0412c78b4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_69c20b46-a11e-4a47-96c9-bde910209616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_058f62bb-bf29-432e-9079-a814c3a8fc56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_058f62bb-bf29-432e-9079-a814c3a8fc56" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:to="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0f610ae6-ebbd-4723-b02a-fab60c12badf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ec4909f4-cc4e-4090-b0f5-8f9a7281bc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:to="loc_us-gaap_RestrictedStockMember_ec4909f4-cc4e-4090-b0f5-8f9a7281bc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PerformanceRestrictedStockUnitsMember_8d80f6c7-39b4-44b1-a3e6-4e427e6ce272" xlink:href="sdgr-20241231.xsd#sdgr_PerformanceRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7531648-4bad-486d-9d1d-3294fc92fc23" xlink:to="loc_sdgr_PerformanceRestrictedStockUnitsMember_8d80f6c7-39b4-44b1-a3e6-4e427e6ce272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f78ea61-967c-4735-aeaa-678d066cf321" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c547b300-50e3-46fc-a196-2bae6144b237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c547b300-50e3-46fc-a196-2bae6144b237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5804e061-ab72-4961-a26b-502c5a23a3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5804e061-ab72-4961-a26b-502c5a23a3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20de273f-b8ed-4ebf-96d0-16c46aa385c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20de273f-b8ed-4ebf-96d0-16c46aa385c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fadcaabc-530c-4f0a-b03a-12529fad26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fadcaabc-530c-4f0a-b03a-12529fad26bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fcc7c9b9-33e0-4ff0-a669-09f24cfbd2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e57a1be3-0f72-43da-a779-8a88decef78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fcc7c9b9-33e0-4ff0-a669-09f24cfbd2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ccfb6cfa-4f0c-4e06-908b-64e0da7d284f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b382871-992c-4905-b126-98366841160a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b382871-992c-4905-b126-98366841160a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_792ec0b1-0dd5-4129-a5c1-514155bff7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_792ec0b1-0dd5-4129-a5c1-514155bff7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_55c83010-71d8-47eb-9f6e-a30f49c757a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_55c83010-71d8-47eb-9f6e-a30f49c757a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a6692c6-532d-4e52-b9a0-9848c53ce844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3a6692c6-532d-4e52-b9a0-9848c53ce844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b26a83e-9317-4344-9dc9-c8b7037e24fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2d5c9a07-9f19-4ad6-8dac-e0eccfa3f425" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7b26a83e-9317-4344-9dc9-c8b7037e24fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f7d4ddd-d750-4462-9ad2-8bed390ee435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f53e485a-1aa1-46fb-88ca-35bee350f4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f7d4ddd-d750-4462-9ad2-8bed390ee435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f53e485a-1aa1-46fb-88ca-35bee350f4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fa1d23e8-1247-4e4b-9adc-21b2840fb81b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f53e485a-1aa1-46fb-88ca-35bee350f4b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fa1d23e8-1247-4e4b-9adc-21b2840fb81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc191caf-20f2-4dcb-8eee-174deeb78c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f53e485a-1aa1-46fb-88ca-35bee350f4b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc191caf-20f2-4dcb-8eee-174deeb78c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cfb2f4a7-3d18-45e1-9d45-d1ae860119f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f53e485a-1aa1-46fb-88ca-35bee350f4b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cfb2f4a7-3d18-45e1-9d45-d1ae860119f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6f92cf3c-de7c-4ef5-bf84-7e23ae74f6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f53e485a-1aa1-46fb-88ca-35bee350f4b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6f92cf3c-de7c-4ef5-bf84-7e23ae74f6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e193ff62-4859-40f9-8b18-552adba5224c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e193ff62-4859-40f9-8b18-552adba5224c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25edb07f-f9d7-4081-8ebe-1a8851dacbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25edb07f-f9d7-4081-8ebe-1a8851dacbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6fef43f-6eab-4968-a5d7-8eb3b189e123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c6fef43f-6eab-4968-a5d7-8eb3b189e123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_67d5ccbf-df2a-4889-8b85-59709ea2066e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_67d5ccbf-df2a-4889-8b85-59709ea2066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_79d3b914-63a1-424b-8d55-65d20bbc97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_79d3b914-63a1-424b-8d55-65d20bbc97fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9eb82e49-3ec9-439f-ba3d-f161e55bfd95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7d98337c-53e0-40b5-99e7-47da747705f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9eb82e49-3ec9-439f-ba3d-f161e55bfd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bbab5c12-687c-463c-bf84-c58ca610160c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bbab5c12-687c-463c-bf84-c58ca610160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b76a42bc-02a0-42f4-9f35-d923634dbe80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b76a42bc-02a0-42f4-9f35-d923634dbe80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49ac8406-c9d2-4742-bc17-7bb04cd778bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_49ac8406-c9d2-4742-bc17-7bb04cd778bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f25f7390-9ad8-4ab5-825b-842d94855d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f25f7390-9ad8-4ab5-825b-842d94855d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a5a75030-3848-413d-a432-b6a23ddd89f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a5a75030-3848-413d-a432-b6a23ddd89f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bf5b39b6-8263-4e60-9dba-f85af17d2381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bf5b39b6-8263-4e60-9dba-f85af17d2381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5aaa08d-ff16-420d-b5ed-3667ad69977b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a7d6b1e-9401-4ac1-b674-587131a2ed54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5aaa08d-ff16-420d-b5ed-3667ad69977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8eba9ad7-e0a4-4843-9007-4cb7f09fd61f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8eba9ad7-e0a4-4843-9007-4cb7f09fd61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract_6711292e-1a61-44f8-b792-f1c2c0805ed9" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract_6711292e-1a61-44f8-b792-f1c2c0805ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20065a2a-0562-471e-9e42-c43bb420c8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract_6711292e-1a61-44f8-b792-f1c2c0805ed9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20065a2a-0562-471e-9e42-c43bb420c8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f133e4f3-ef89-4bbe-a429-6bd341e3a298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f133e4f3-ef89-4bbe-a429-6bd341e3a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_cf8642ed-2dc5-490e-9c41-665811a4b3b4" xlink:href="sdgr-20241231.xsd#sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_cf8642ed-2dc5-490e-9c41-665811a4b3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_404ffd7d-ba13-41fe-9f51-d034e8189dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_cf8642ed-2dc5-490e-9c41-665811a4b3b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_404ffd7d-ba13-41fe-9f51-d034e8189dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4efe90a5-ae4f-4b6b-b8e0-9529ac333cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffcd0f0b-62c0-42a1-a825-b6f85358af05" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4efe90a5-ae4f-4b6b-b8e0-9529ac333cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6219e894-1317-4083-a04d-62910015aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_252c6b3e-17c5-4a48-8384-78a568720801" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6219e894-1317-4083-a04d-62910015aebc" xlink:to="loc_us-gaap_NetIncomeLossAbstract_252c6b3e-17c5-4a48-8384-78a568720801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34237967-f9fb-4102-b800-a5cc7054d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_252c6b3e-17c5-4a48-8384-78a568720801" xlink:to="loc_us-gaap_NetIncomeLoss_34237967-f9fb-4102-b800-a5cc7054d0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81dfa9f3-ca8f-4730-9e6f-4e30a1dd2c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6219e894-1317-4083-a04d-62910015aebc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81dfa9f3-ca8f-4730-9e6f-4e30a1dd2c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_adda2d21-f428-4156-ace1-8e28c0b21799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81dfa9f3-ca8f-4730-9e6f-4e30a1dd2c94" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_adda2d21-f428-4156-ace1-8e28c0b21799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_98e82e9d-31ba-4ba3-9be9-9e5e89ffd1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81dfa9f3-ca8f-4730-9e6f-4e30a1dd2c94" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_98e82e9d-31ba-4ba3-9be9-9e5e89ffd1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b96b6be9-0470-4f6f-bca7-5951f4b2f911" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_81dfa9f3-ca8f-4730-9e6f-4e30a1dd2c94" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b96b6be9-0470-4f6f-bca7-5951f4b2f911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ce951aa2-5fad-4d21-929d-6b78ccc7f5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6219e894-1317-4083-a04d-62910015aebc" xlink:to="loc_us-gaap_EarningsPerShareBasic_ce951aa2-5fad-4d21-929d-6b78ccc7f5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aecff0c0-7552-41d0-9276-d2b9fde8ff6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6219e894-1317-4083-a04d-62910015aebc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aecff0c0-7552-41d0-9276-d2b9fde8ff6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6fbba8c5-8c63-4632-a56e-a86c1b2d172f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e72ad70a-e79a-4ce2-86e0-d6c2135db455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6fbba8c5-8c63-4632-a56e-a86c1b2d172f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e72ad70a-e79a-4ce2-86e0-d6c2135db455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/EquityInvestmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#EquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/EquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4a8b741c-441a-444d-92d4-888832693c88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4a8b741c-441a-444d-92d4-888832693c88" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_47b0cd48-59f6-4176-ab86-83ddef32987f" xlink:to="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_84e4e7b4-8b7c-44c6-b3b4-ff4881522ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_84e4e7b4-8b7c-44c6-b3b4-ff4881522ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_671e9423-2751-4ecd-89dc-557f04cfd1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_us-gaap_CommonStockMember_671e9423-2751-4ecd-89dc-557f04cfd1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_51deb46b-d72e-4d0a-993e-7bc54df57bb6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_dei_AdrMember_51deb46b-d72e-4d0a-993e-7bc54df57bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_b2e0cf9c-93b9-425b-ab59-d3ddbf71e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79509419-8c81-4d34-9f7f-74e5e931f143" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_b2e0cf9c-93b9-425b-ab59-d3ddbf71e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a67c90c5-f7f0-40b9-9012-65524bb7cf16" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NimbusTherapeuticsLLCMember_d94cb87c-9d53-4475-923b-7c78c6d69541" xlink:href="sdgr-20241231.xsd#sdgr_NimbusTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_NimbusTherapeuticsLLCMember_d94cb87c-9d53-4475-923b-7c78c6d69541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_MorphicHoldingIncMember_a3309024-c88a-4666-a45a-643901bde90a" xlink:href="sdgr-20241231.xsd#sdgr_MorphicHoldingIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_MorphicHoldingIncMember_a3309024-c88a-4666-a45a-643901bde90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AjaxTherapeuticsIncMember_3c79d858-87ca-442f-a969-07a4ceebe7ac" xlink:href="sdgr-20241231.xsd#sdgr_AjaxTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_AjaxTherapeuticsIncMember_3c79d858-87ca-442f-a969-07a4ceebe7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_StructureTherapeuticsMember_4cda5ddc-47fb-43e3-8fc1-fe012e218e15" xlink:href="sdgr-20241231.xsd#sdgr_StructureTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_83c812ff-017b-4de3-86f4-b8c7694fd727" xlink:to="loc_sdgr_StructureTherapeuticsMember_4cda5ddc-47fb-43e3-8fc1-fe012e218e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f1889488-ed0a-4738-9d73-7993865ea1b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d7725ae-c6fa-4224-acc3-f786fa0fb0ef" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f1889488-ed0a-4738-9d73-7993865ea1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_StructureTherapeuticsMember_4f715933-31b8-44aa-83bc-a225c39daf5f" xlink:href="sdgr-20241231.xsd#sdgr_StructureTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f1889488-ed0a-4738-9d73-7993865ea1b2" xlink:to="loc_sdgr_StructureTherapeuticsMember_4f715933-31b8-44aa-83bc-a225c39daf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_dbd71419-2eb0-4e24-afc9-a88058e10860" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_3ef2a821-d821-4a61-a7b2-908d4b862791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_3ef2a821-d821-4a61-a7b2-908d4b862791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0d237f89-c9c1-4728-baf5-d38d2d89bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0d237f89-c9c1-4728-baf5-d38d2d89bc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_19d9bcdb-84f2-4864-a682-9f5a5b919b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_19d9bcdb-84f2-4864-a682-9f5a5b919b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_7cfa4cae-2a03-4c4c-8271-18725a5ac933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_7cfa4cae-2a03-4c4c-8271-18725a5ac933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_754e7f66-e238-48b7-af63-1c6921d61a36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_754e7f66-e238-48b7-af63-1c6921d61a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_46609708-1c2f-437f-a148-abdf1a55d100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_46609708-1c2f-437f-a148-abdf1a55d100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfPreferredSharesPurchased_b74fa738-a445-43e0-b52c-89bc77eebdfe" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfPreferredSharesPurchased"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_sdgr_NumberOfPreferredSharesPurchased_b74fa738-a445-43e0-b52c-89bc77eebdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_847d65a0-f2e5-4e91-98ab-9e594e0c5d87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_847d65a0-f2e5-4e91-98ab-9e594e0c5d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09679b68-36d7-4d3c-939e-ae58f27c4f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_09679b68-36d7-4d3c-939e-ae58f27c4f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_d3acd5b3-898f-443d-b1a8-90f9c9a40344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_d3acd5b3-898f-443d-b1a8-90f9c9a40344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_NumberOfSharesPurchased_6eeb87a3-2275-448c-9707-2eabe6ab5b87" xlink:href="sdgr-20241231.xsd#sdgr_NumberOfSharesPurchased"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_sdgr_NumberOfSharesPurchased_6eeb87a3-2275-448c-9707-2eabe6ab5b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_AmericanDepositorySharesPurchasedPricePerShare_eb03845f-0799-4807-8902-765af50c880c" xlink:href="sdgr-20241231.xsd#sdgr_AmericanDepositorySharesPurchasedPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_sdgr_AmericanDepositorySharesPurchasedPricePerShare_eb03845f-0799-4807-8902-765af50c880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_869ed7d2-45d0-485c-aea0-f461f21d0132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_349b5789-a40a-4d08-bf09-44ec62745ede" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_869ed7d2-45d0-485c-aea0-f461f21d0132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03a9db29-e340-412b-b4f1-d94804972809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4ceb8fcb-870d-41cc-ac38-a38811af4897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03a9db29-e340-412b-b4f1-d94804972809" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4ceb8fcb-870d-41cc-ac38-a38811af4897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_7ab66008-e704-4916-b467-fb50b281cbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03a9db29-e340-412b-b4f1-d94804972809" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_7ab66008-e704-4916-b467-fb50b281cbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_76557f11-2078-4452-aab5-7a446c6278a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03a9db29-e340-412b-b4f1-d94804972809" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_76557f11-2078-4452-aab5-7a446c6278a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ef9d0fce-e174-4af3-9b1d-3d713ba607c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ef9d0fce-e174-4af3-9b1d-3d713ba607c9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_559b5cc4-106f-4dae-bc82-f72b0ac9b538" xlink:to="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_04e29cee-f7c0-4d3a-9954-fe347a99eb32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:to="loc_srt_DirectorMember_04e29cee-f7c0-4d3a-9954-fe347a99eb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_0e601fc8-ab3e-4528-9757-9b0c6bf5dfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0e785ca7-101e-4f39-8bc2-5938697973d2" xlink:to="loc_us-gaap_RelatedPartyMember_0e601fc8-ab3e-4528-9757-9b0c6bf5dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83d5f3e7-6a68-409d-815c-23ce557bc0ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46f24eba-6aed-4260-b707-910c5a8a264f" xlink:to="loc_srt_RangeMember_83d5f3e7-6a68-409d-815c-23ce557bc0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7fd67e5-48cc-4286-bd03-461cb99d198e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_83d5f3e7-6a68-409d-815c-23ce557bc0ab" xlink:to="loc_srt_MinimumMember_f7fd67e5-48cc-4286-bd03-461cb99d198e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_19ae798e-4e33-4a3e-8a9c-ba75969fa40b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_BillAndMelindaGatesFoundationTrustMember_d37cdf3e-b9e5-443c-a8a1-94c5d0d2f3ea" xlink:href="sdgr-20241231.xsd#sdgr_BillAndMelindaGatesFoundationTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:to="loc_sdgr_BillAndMelindaGatesFoundationTrustMember_d37cdf3e-b9e5-443c-a8a1-94c5d0d2f3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_GatesVenturesLLCMember_a246d3c7-89bb-4bb4-a153-0095cb2adf38" xlink:href="sdgr-20241231.xsd#sdgr_GatesVenturesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722d4706-ee70-4663-86c6-2a661a5639e5" xlink:to="loc_sdgr_GatesVenturesLLCMember_a246d3c7-89bb-4bb4-a153-0095cb2adf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9c054518-f229-41d6-ac6d-923404bacfae" xlink:to="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoveryContributionMember_a84652e1-bb30-4cb2-8a84-84923ee7575b" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoveryContributionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:to="loc_sdgr_DrugDiscoveryContributionMember_a84652e1-bb30-4cb2-8a84-84923ee7575b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionMember_7de0cd03-69f2-45f7-aca5-287385587e79" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5d4c4c6-634d-4333-bcbe-e83ae21ac3fe" xlink:to="loc_sdgr_SoftwareContributionMember_7de0cd03-69f2-45f7-aca5-287385587e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6a705d2f-6578-4eff-9182-7df019fd24c2" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_dfcbab57-04fc-428f-b5ae-2d02b0ac9246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_dfcbab57-04fc-428f-b5ae-2d02b0ac9246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e844fb5-6ff4-4d97-ba90-301474fdc314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3e844fb5-6ff4-4d97-ba90-301474fdc314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_9f52372b-98b3-429f-8857-d08dd9b76c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_9f52372b-98b3-429f-8857-d08dd9b76c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f941d069-edab-4005-a740-b5a1a4730877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_RestrictedCashCurrent_f941d069-edab-4005-a740-b5a1a4730877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareContributionRevenueRecognized_6c7962ef-0053-4029-8d39-b9642896d8a7" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareContributionRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_sdgr_SoftwareContributionRevenueRecognized_6c7962ef-0053-4029-8d39-b9642896d8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_261b16a8-9371-42d8-b57f-0c3d215f34ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_261b16a8-9371-42d8-b57f-0c3d215f34ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_PercentageOfVotingSecurities_a1fc3bc6-a289-4d9c-9c24-ee9fe5ead302" xlink:href="sdgr-20241231.xsd#sdgr_PercentageOfVotingSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_d4900e97-cc6a-4009-a974-e7b070fd63a1" xlink:to="loc_sdgr_PercentageOfVotingSecurities_a1fc3bc6-a289-4d9c-9c24-ee9fe5ead302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8fdf8625-0da3-4301-93b5-2696a93ba32b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6dd5dd16-ccdd-439a-9658-6440afc003a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8fdf8625-0da3-4301-93b5-2696a93ba32b" xlink:to="loc_us-gaap_NumberOfReportableSegments_6dd5dd16-ccdd-439a-9658-6440afc003a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9773ed14-4440-4069-a3a5-b73194d4f64d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9773ed14-4440-4069-a3a5-b73194d4f64d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fb53accc-ac16-4dcd-9432-ac82919bfe23" xlink:to="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_SoftwareSegmentMember_acb30f83-365b-4ba3-9a4f-61c6080a885f" xlink:href="sdgr-20241231.xsd#sdgr_SoftwareSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:to="loc_sdgr_SoftwareSegmentMember_acb30f83-365b-4ba3-9a4f-61c6080a885f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_DrugDiscoverySegmentMember_388b108f-2e87-4e6f-8aff-c01aae29012f" xlink:href="sdgr-20241231.xsd#sdgr_DrugDiscoverySegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e7755dc9-853d-4c58-996a-ea14587eaf2f" xlink:to="loc_sdgr_DrugDiscoverySegmentMember_388b108f-2e87-4e6f-8aff-c01aae29012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589a3086-8683-4687-80a2-d5161c9b1c84" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_4bab9059-1bad-4227-a2a1-b8db2291b642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_4bab9059-1bad-4227-a2a1-b8db2291b642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f31608e-fb49-4eea-baf1-06d4d2e08fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_4bab9059-1bad-4227-a2a1-b8db2291b642" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f31608e-fb49-4eea-baf1-06d4d2e08fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_3d916adf-87ff-4385-b00f-e484e6f890ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_CostOfRevenueAbstract_3d916adf-87ff-4385-b00f-e484e6f890ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_a5222055-9468-460d-8148-72901959d60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_3d916adf-87ff-4385-b00f-e484e6f890ec" xlink:to="loc_us-gaap_CostOfRevenue_a5222055-9468-460d-8148-72901959d60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfitAbstract_471fdefa-182c-4726-9e14-261bc9f94cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfitAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_GrossProfitAbstract_471fdefa-182c-4726-9e14-261bc9f94cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e99f0cac-828d-4a6a-bb12-1b927a8a5e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GrossProfitAbstract_471fdefa-182c-4726-9e14-261bc9f94cc1" xlink:to="loc_us-gaap_GrossProfit_e99f0cac-828d-4a6a-bb12-1b927a8a5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:href="sdgr-20241231.xsd#sdgr_UnallocatedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c65dcd5-b683-4c63-9a28-65e9a70bd03e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c65dcd5-b683-4c63-9a28-65e9a70bd03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_6541558a-775e-4424-99cb-876d3be6f4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_6541558a-775e-4424-99cb-876d3be6f4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_973b303d-c3e5-404a-9879-6a75cf5c6cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_973b303d-c3e5-404a-9879-6a75cf5c6cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d6193799-3dce-4696-87a1-eb257b754c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d6193799-3dce-4696-87a1-eb257b754c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7600b549-a116-402f-9bc7-ad2f6eb6de45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7600b549-a116-402f-9bc7-ad2f6eb6de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e922993c-66ab-4587-86cd-e550f06974b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e922993c-66ab-4587-86cd-e550f06974b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b03c90fe-8169-4706-ac92-1b6e5fd0dda6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sdgr_UnallocatedAbstract_f1dfce57-c408-4c94-9d6b-31cc0937a89d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b03c90fe-8169-4706-ac92-1b6e5fd0dda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_809f617a-a1b4-4cec-97c3-657b035b364f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5c2cd685-e75e-4f31-8a42-4a64b32f144d" xlink:to="loc_us-gaap_ProfitLoss_809f617a-a1b4-4cec-97c3-657b035b364f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails" xlink:type="simple" xlink:href="sdgr-20241231.xsd#SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dd3b7e25-72f9-42de-a458-4d66a34ae44c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dd3b7e25-72f9-42de-a458-4d66a34ae44c" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:to="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_32ff1d3f-b788-4625-a483-3daf3a325f69" xlink:to="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b998a69-c527-49da-b000-aa3630e66ced" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_country_US_2b998a69-c527-49da-b000-aa3630e66ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_APACMember_fe8ab20b-cf80-42cf-9af2-3b97d0205103" xlink:href="sdgr-20241231.xsd#sdgr_APACMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_sdgr_APACMember_fe8ab20b-cf80-42cf-9af2-3b97d0205103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_049afe19-e82a-4bab-a668-66598de09956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_us-gaap_EMEAMember_049afe19-e82a-4bab-a668-66598de09956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_3a9bf532-f959-4f00-871b-01c10b94579e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_84c29a32-4607-4c7f-993f-c9820c89aebb" xlink:to="loc_us-gaap_NonUsMember_3a9bf532-f959-4f00-871b-01c10b94579e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_36eab744-ce4a-4c46-9ccd-b379e2a8698d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_53c892b5-adc4-4a07-be62-32a4ca2d7aa2" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_36eab744-ce4a-4c46-9ccd-b379e2a8698d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_204d449d-31fb-45c3-a992-678cac27770a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_36eab744-ce4a-4c46-9ccd-b379e2a8698d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_204d449d-31fb-45c3-a992-678cac27770a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_RobertAbelMember" xlink:href="sdgr-20241231.xsd#sdgr_RobertAbelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sdgr_RobertAbelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_sdgr_KarenAkinsanyaMember" xlink:href="sdgr-20241231.xsd#sdgr_KarenAkinsanyaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_sdgr_KarenAkinsanyaMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sdgr-20241231_g1.jpg
<TEXT>
begin 644 sdgr-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %] Z@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_\ )O\ Y(/J57_H(G_Y)_\ (G!_\)1XY_Z%"W_\&"_X4?\ "4>.?^A0M_\
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M)_\ (G!_\)1XY_Z%"W_\&"_X4?\ "4>.?^A0M_\ P8+_ (5WE%'UB'_/J/\
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M\1^(_AXP3Q'&=:T4' U>U3]Y$/65/3W%/V$*W\"6O9[_ ">S_!^1/URMAO\
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M , 9?_B:[G[/'_<7_OD4?9X_[B_]\BCGPW_/M_\ @7_VH>QQ_P#S^C_X _\
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M#"O=/V3?A'\--8^"/AC6[;PQI>H7]U;?Z;=7D"SR&=25<$MG&".@]J],U_\
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MP?3K7R-XK_9A^+O[/$UIXRM(EF.G2>:-0T60S-;$?Q.F,[#T/!'K7T=\$?\
M@H3X>US2_L?Q$5=!U6&//]H6\;/;76!_=&2CGTZ'L1TKZW-/KE=RQ6757.G)
M6:B[VZ;?TSYO+_JM%+#XZFHS6J;5K_,^L_$""3P_JBL,JUK*"/\ @!K\Y_\
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MM7N*RJ?'+U-\/_!AZ+\C@/@[_P @G6_^PO<_^AUZ!7G_ ,'?^03K?_87N?\
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ML_XR>)?$GB_4;E-+MB)[E(7Q(0[$0VZ$_<4*IY'I[UZ-^U%^Q'X6\"_#:_\
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M-_'I^J_,X<=_NE7_  R_)FKX3_Y%?2?^O6+_ -!%:O<5E>$_^17TG_KUB_\
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M%9^/_#WC+P3+J6DZQ8WEO=6+2IY4ZDC*$X(SD$>AKX$_X)U_\EZU/_L$S_\
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MF>2!D\GJ37N5%%?+XC$5,55E6JN\F?04:,,/35*FK)!1117.;!1110 4444
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M2FT]-4DOU9S4?:XW&0Q#IN$8)[[NYW]%%%?)GT@4444 %%%% !1110 4444
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M2?P^9*THW=L ]J^7M.L_!7P?\!_\(#\>OV;O$&CZFCG?XVTN>2"_)\S=O7S
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MQMX?DU\-L_LU=2A,^[^[LW9W>W6NNO+VWT^TFNKN>.UMH5+R33.$1%'4LQX
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M:?JCRLV_W"M_A?Y'>Q_ZM?I3J;'_ *M?I3JXCU%L>??%K_6>%/\ L-6_\Z]
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M%  )8\D\=:L444 %%%% !1110 4444 %<!\;?^1)7_K^MO\ T8*[^N ^-O\
MR)*_]?UM_P"C!7;@O]YI^J/*S;_<*W^%_D=['_JU^E.IL?\ JU^E.KB/46QY
M]\6O]9X4_P"PU;_SKT"O/_BU_K/"G_8:M_YUZ!7;5_W>E\_S/*PW^^8C_MW\
MA:***XCU@HHHH **** "BBB@ HHHH R?%T3S^%-:CC1I)'LIE5$&2Q,;  #N
M:_'C]BGXW?%S]COPSXHT4?L\>-?% UG4%O?._LZ\MO*VILVX^SMGUS7[.T4
M?'7[//[<'Q#^,WQ6TKPIK_P \3^!=+O$F:37-2CN!# 4C9U#;[=%^8J%'S=3
M7FO[!/P^\4^%_P!M7]HC5]9\-:QI.E:A-,;*_OK"6&"Y!O&8&.1E"OQS\I/%
M?H?10!^=GP'^'OBG2_\ @JM\6?$MYX:UBT\.7=I<+;ZQ/82I:3$I;X"3%=C$
MX/0]C7G_ .SOJ?C?]E_]O3XK66K_  Q\2ZOI_CK7GBM=4L;20V\$$MZ\JW!D
M"E60)+DX/&.:_5.B@#\<;CX%0?LC_M >/8OB5\!-0^,G@+7+A[G0]6TRR:Z>
M &1G5>.%)#[65B#E01D5]-_L<^!=:OO /Q.\6WGP)\/_  BAU'2[JQT2#3;.
M>'5+V!D9MLT;NQQD1@?*I9LX&!S]YT4 ?!O_  1]\!^(_ 'P&\76?B;P[JOA
MN]F\1O,EOJUE+:R.GV: !PLB@D9!&>G!KYPU+X@>,/A;_P %5/BKXI\'^$KK
MQP^GQ.^J:+8'%S+8FWMED:(<[G5C&P4 YQBOV!KY>^'_ .QM>>"?VTO&7QU?
MQ1!=6GB"TDMET5;,J\.Y8%R9=Y!_U)_A'WO:@#Y@^'&B_$']M[]NSPO\7=3\
M!ZMX!\ >"XX_(_MN%HI9GB+NBC<!N=I7R=N0JIUSU[3]E3X>^)]%_P""E7QX
M\0ZEX:U>PT*^2[%GJMU82QVMQFXA(\N5E"MD G@GH:_0RB@#\[/^"A7P]\5>
M*OVN_P!G?5-$\,ZQK.F:?=1->7NGV$L\-L!>QL3(Z*0@P">2.!5[]M?6O$EC
M\8HH/B3^S_8_%CX.-;E;'6/#NGRRZQ:.RC(:57^3:X;C"J0P.<\5^@M% 'Y0
M_L(_ G69_P!L*Y\?> / GBGX9_!^WL98)K3Q2SK+=EXMOE+OY<>80XY8+L^]
MGBN)L?@G!^R)\:?'VF_%+]GW4/C%X0UBY-SH&M:78M<F)=[LJ@CA=RN RMA@
M4!&1U_92B@#XV_X)X^"=6BT[Q)XQUGX)^&_@ZFHL+?2X--MIH+^XM=Q?_2$D
M=L ?( <*6(8[0,5]DT44 %%%% !1110 4444 %%%% !1110!P'Q%_P"1N\"_
M]A%__0!7?UP'Q%_Y&[P+_P!A%_\ T 5W]=U?^#1]'_Z4SRL+_O6)]8_^D1"B
MBBN$]4*Y3XJ?\DZ\0?\ 7H]=77*?%3_DG7B#_KT>NG#?QZ?JOS.''?[I5_PR
M_)FKX3_Y%?2?^O6+_P!!%:O<5E>$_P#D5])_Z]8O_016KZ5E4^.7J;X?^##T
M7Y' ?!W_ )!.M_\ 87N?_0Z] KS_ .#O_()UO_L+W/\ Z'7H%=.-_P!XGZG#
ME7^XTO0****XCU0HHHH **** "BBB@ K\T_AK^VI^TK\>/B-\3OA]\/O#WA.
MYU70=1F6#6=25X+>QM8YY(PKKN/F2R84#L-K$CT_2ROS2_X)7PO'^T=^TVSQ
MLN=67:64C/\ IEY0!5^!_P"W)^TS\?AK_P -_#'@_P ,#XE:#<2MJ7B"_9HK
M&V@1]FPQ G,I<%002I SC@FO8?V%_P!MKQ+\9K/XDZ'\5+*PTGQ'X#W37][8
MH8X6A4R+(67) 9#&>0<$'M7D_P#P3 A>/]JK]IMGC9 =2."RD9_TVZKDOV)/
M!$_Q!^-W[8GA=6:T;7+2]TZ.=E("F6>Y0'\-PH [;PS^V-^U!^U9J?B36_@-
MX.\/Z=X%T6=K>*?7<&:]8#<%RS@;RI4E5 "[@"V:]D_9'_;WA^-'@?QW_P )
M[I"^%/&7@&&2?7;*$'8\48<-(BL<JP:-E9"3@XYY%?*W[&/[8FC_ +"G@GQ3
M\)OC'X9U[0]=TW5)KNU-K9>8+G>J@IR1W3*ORI##GCG8_8S^ WC'X[6W[2'Q
M0U#2)O#-G\2=.O\ 3M$M;H%#*T\C2E^0/D4K&F_H26QTH ZWX3_M??M6?M'-
MK_Q#^'7@GPO_ ,*XTBZ>--'U)REU?*@#-%'-GF7:1DX"@M@9Z5QG_!*OXF:;
MX)\.?M)>/=>1]/TS3Y8=5NX>KQJ/M3F,=,MGY1ZFJ/[#O[:>A_LF_"?7OA%X
M[\+^(H/'^F:M<O8:3:V#227LLF (<<%6WKC)X(8$9KGOV%?AKX@^+_P/_:T\
M))9-IWB368XDCLY04VW0:X<0DGI\Z[/;- 'JN@_M??M:_%KX?Z]\9O!'A+PG
M:?#33))I8M(O TEY<V\)/FLK;@6*@-DC;R#M!Q6Y^UE^T)IW[3W_  2WUSQW
M86ATZ2ZNK"WO;%FW?9[F.^A$B!NZ]"#Z,*^,_A/J?P'\"_!_5M#^*VF?$*S^
M*>E37$'_  CEE?W%K;WQ+'8@ &(^NU\CL2,YQ7TW\6O 6D^#_P#@D[XD?0?!
M.M>!+36-2L=271-;O?M=RH:\MP),[5*JX4,%(! P3UH F^+7Q;N/@[_P3/\
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M .OK3_\ TKBKZ[KY&_X*K(TG[$_C)45G8W6G\*"3_P ?<5 'F-G^UNO[)O\
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MRN4>,?\ @HY^U]\0O"-[XYU?P=\,_ \DD,>G:/(8WF:.8P@D9P7=E=BS9P
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MG:"$ 7&<&OM*B@#\JOB1\)_VG/BQ\.Y?AYXS^ ?A'Q)XIE!M_P#A94MS;K<
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M95?E96Y/ ->HZ/K%AXATFSU/2[R#4-.O(EGM[JVD$D4T;#*LK#@@@YR*^1O
M>G_%'5OC-^T+;> ]6\):?ILGB>&.X_MZQGNIDD.F6H+*J.J%=N/E;J0<\5'X
M2^%>I> _BWHGPVT[QCXCDT7P1X#M]6@TS3[TVL6I7_VV;YY8T_@8J5\L'&"!
MS@4 ?9%8VO>,='\,W^CV6IWT=I=:O.UK8Q.#F>58VE95P.H1';_@-?"GP/\
MBA\1]3NOAMXB.OV]YK_B W9U?2[SQ6]X=0<6\KM;QZ:(MMH\,JH."H4 JQ)8
M9?X4U:PUO6/V;?$<WQ'U3Q)XPUJ]O;W5M+OM2,JQ7/\ 9USYK+;$_P"C&%R8
M@JA1@\@D9H ^[_#?B+3_ !;H5EK&E7'VO3KV(36\VQEWH>APP!'XBI+;7M.O
M-8O=*@O8)=2LDCDN;5'!DA63=L++U ;:V,]<&OASX;^-+CXB:?X7M/B%\3-:
M\+:1;?#JTURRO[;6&L9+Z\>287-T\H(,S0A(L1DE1OR5.:]$_9O72KO]I+Q_
MJB^)]2UG4-1\,Z!>0/?W,D#7\3PRAK@VA("\JO1<(78#&XT ?2VF>+M(UCQ!
MK.AV=['/JNC^3]OM5SNM_-0O%N_WE!/%:]?"GQ(\7:_X7_:H^(C2WT^@?#&3
M4_#L7BG7M*N3%?6NZT86RDC_ %5LTFU990=P# # +$9'C+XG?$"Z\6_$;5U\
M2P:#K&@^*ET[24O?%CVMO;VRO$((FTM8F^TK<*Q._P"9GWC:1MX /T"S17R+
MK'B_QE;_ !BOO@LNN:JE_K?B2W\1V6J"=_.M_#Y3S[N%).JA)XC;J.RSJ*[+
M]J;7&L?'?P9T:Z\8ZAX-T#7-<NK74YM/OFLS=(+.1XX&E!!0,ZKR"#V!!.:
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MNH7=R_FIERKY'W#0!]S44E+0 5P_QH_Y)OJOUA_]&I7<5P_QH_Y)OJOUA_\
M1J5UX/\ WFG_ (E^9YF9_P"XU_\ #+\F=?IO_(.M?^N2_P A5FJVF_\ (.M?
M^N2_R%6:YI;L]"G\""BBBI+.,^)OQ@\(?!W3;&_\7ZPFD6U]<?9+8M%)*TTN
MTML545F)VJQZ=C57X:_'+P7\7KB_@\*:M)J4MBJO.KV4]OL#$@<RHN>AZ5X[
M^VGJ%QIOB;X%W%IXBT[PG=+XO?R]8U6-9+:W)T^Z!+JSH"",K]X<L*3Q)XVD
M_P"%->/KCQ!\>=%U&>SM8[FSU;P;#';7.GRJW[L%(YY#-YDGEH(S@/DKSNH
M^GZR/$GB[2/"*Z:=7OH[$:E?1:;:>9G][<R9\N,8'4X/Y5\,+\5_%FL_#&SU
M/QQX[U?P+XYOO'^E:3XJTNVN/LB>'K1PP2"%22$CFCVR&8_>9SS\G&IKVN2+
MXZ7PUIWB*]\4^$-$^)OAD:3>:A?->M'<2PS/<VJW+DM($81G!8E?,(SQ0!]U
M45\+^&?B)JO_  CO@'QK%X^U>_\ B?K7C--)U;PC)J)>W$+W3Q7%G]@SB)8(
M1Y@D"AALW%B&K%D\0^-M#^ /A?Q?%XV\0:K=>,?%[:/JU[J&O-:V]AIZ7EVJ
M)%-M*VI8QQ1&;&[#XR." #] ZQ_#OB[2/%@U/^R+Z.^_LR^ETV[\O/[FYCQY
MD9SW&X?G7B?[)NN>(+R]^(&DZKK-KJFEZ7J,$=A;1ZX^M3Z?OA#2V\EVR+YF
M#AE!+%0V">@KY_DUN#PK:_&?Q+H'C_4K?X@:=\3)H=+\,6^IE8)WDN+=?L[6
M0.)O.5GRQ!(VY!78: /M&;XQ>#[>^%G+K4,5R9[RV$<B.I:2TC\RY R.=B<D
M]/3-7_"_Q$\/>,YTBT;44OVDT^VU5#&C!6M;@$P2 D8(8*3CJ,<@5\8Z]XDO
M]>^(49U/4IK]K/Q+X^LK;[1)N\F"/3ODB7T503@=JR--^)OB7PY\/;:QL/$M
M]H^B1^!O ,5Q>6\F1I%K=2217=W&.0C&, &3^' ;^&@#]"**^$OB=XRU?P<O
MQ+\+^ _B+K5[X?M8/#4\.LMJC7T^E7EUJT<$T$=TY8L)(,.8V)V[B> V*VOB
M%=:]\/-:^+'@K2OB5J.F6$=EH&H65]XHU:>0P37%S-'-;_;,-);I.(@OF=(V
M<L,"@#[4I*^??V2?&$NL0^-] NSK2:CH>I1+/:ZEK:ZW;VPE@5U2UOA\TL?!
M.V3YT+8/4"O%_$'Q$U6+PYXP\;OX_P!7M/BCIGCAM'T_PBNH,MN85ODAALOL
M&<2++;GS#(5+'=O# +0!]?Z'\4O#/B;QMK?A+2]2%[KNBJIU&"**0I;E@"$:
M3;LWX925!R 1D5U=?.W[)/A6UT3Q!\:[F#4-4NF;QW?6[1WNH2W$:[8;9LA7
M8@/ER"W4@*"< 5XOK,WBF\L;SQ3'\1_%5IJ4OQ<?PK#'#J1%M;Z;)>>2]ND)
M&PG:3M=@64[=I&T"@#[QK(\0>+M(\+W&CP:I?1V<VKWJZ=8I)G,]PR.XC7'?
M;&YY_NU\::EXJUKPOKFM^ ;CQSKMCX+B^)-MHUWKEUJ;O>V5C-I:W0M_MC'?
M&LEP50.6R ^T$9%03>)+F3XC:/H%AK]WXO\ "_AWXH6$&AZE?W9NI/,?1KR2
M:S%PQ)F$<F &))7=M).* /NFBOS^^"OQ-^(>M:I\.O$=SXC@_M_7-7G@U;3[
MWQ8]Q]L7;,9+1-*$6+9X2JX(*[=IW,=_._X'\6?VA\+]%\63?%;Q$_Q2\06&
MKB[\.Q7KSI)=I;SL;86@R+3[.R#:ZJI!4 D[^0#[8U;5+70]+O-2OIEMK*SA
M>XGF;I'&BEF8^P )IFAZW9>)-%L-6TVX6[TZ^@2ZMKA,[9(G4,C#/8@@U\5^
M)OC:OBSPO\)=*L/&@U:;4OAKK=[KEK;WHE,\JZ7#M>Y /WQ)YOWN<[_>N(;Q
MSXNNK.UT@Z[_ ,(]H^@?#W0[W1Y#XN;0DC,EGNDOBHC;[6%=0A5LJH&-N7H
M_1BEKX!^(7Q,\5V-P/%&O>,)]433O#^CWM_9^%/$4FDWND2L@>6:&QF18K^.
M?.<,-V 4 !P*^][&Z6^LX+E P2:-9%#J58 C(R#T//2@">BBB@ K@/C;_P B
M2O\ U_6W_HP5W]<!\;?^1)7_ *_K;_T8*[<%_O-/U1Y6;?[A6_PO\CO8_P#5
MK]*=38_]6OTIU<1ZBV//OBU_K/"G_8:M_P"=>@5Y_P#%K_6>%/\ L-6_\Z]
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M -6BBB@ HK$D\9Z-#XR@\*/?*OB">Q?4H[+8VYK='6-I-V-N S*,9SSTK;H
M**** "BBB@#@/B+_ ,C=X%_["+_^@"N_K@/B+_R-W@7_ +"+_P#H KOZ[J_\
M&CZ/_P!*9Y6%_P!ZQ/K'_P!(B%%%%<)ZH5RGQ4_Y)UX@_P"O1ZZNN4^*G_).
MO$'_ %Z/73AOX]/U7YG#CO\ =*O^&7Y,U?"?_(KZ3_UZQ?\ H(K5]*RO"?\
MR*^D_P#7K%_Z"*U>XK*I\<O4WP_\&'HOR. ^#O\ R"=;_P"PO<_^AUZ!7G_P
M=_Y!.M_]A>Y_]#KT"NG&_P"\3]3ARK_<:7H%%%%<1ZI5M-+L[">ZGMK2"VFN
MY!+<20Q*K3.%"AG('S'  R>P I5TVT74&OQ:PB_:(0-=",>:8P20A;&=N23C
MIDU9HH Q-/\  _AS2=>NM;L?#^EV6LW61<:C;V4<=Q-DY.^0+N;\34=K\/\
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M08.1Y;LI*X//!HNO WAN^\10^(+CP_I=QKT( BU26RC:ZC Z!92NX?@:W**
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M&L>$/CO<>-_%>H:;X_L=<AM-"T?^TY8A_9F;=K80V@;9+%*#*SOM;D-DC:,
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M^&]?U:SU34_#^E:CJ=EC[+>7=E%+-!@Y&QV4E>>>#6Y110 4444 %<!\;?\
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M^)5UXN\$_#C0?$.N:GJ6HQZ)J5S<3:OXJ.@V$D4-_);1SRSQJ9KBX58P-JY
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MYDN9[,I;7(E!*A'(P[ *-PZKE<UIW.BZ=>W:75Q86L]TB&-9I(59U4]5#$9
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M'B.XU7_A&;&+1KQ(/@6_CZ\6UN->-V=--B+-#"DC1D2?8C>>:$).S.W/R8H
M_0O3=&T_1HY$T^QMK%)&WNMM"L89O4X R?>N8;XD>'KK5+R&RBN=7OM/U6+0
M;S[#9O*UI/*B28D..(PKHS-]T9&:^+/#/A#_ (3K3_AMX<U#6IM<\$7WQ"U!
M+>'1S>VUD+%=-E9K6*21_,EM?.#8;.W^%> *ETOPWH7P_P#B=XKT7P_:2:/J
MJ_%[P^\MM TPD?37AA*,23\T1D\W)R1G(/2@#[Z2QMHUA5;>)1#_ *H*@'E\
M8^7TX]*9;Z796<A>"T@A<EF+1Q*IRWWCP.IP,^N*_.SX8MXBF^(OAJ?5_$.E
MZ?\ %,^,Y!JEO'!J$VN2VXN9-]O,F[R5LS;[<.!Y:KM8'=FNE^"6H6GA_P#:
M&T&.UEB\8ZAJ&LZI!<WT<EY9>(=.5O-=AJUJY:*6!" B/\H'[LJ#DT ?>D-O
M%;ILBC2),D[44 9)R3Q[U)2"EH **** "BBB@ K@/C=_R)*_]?UM_P"C!7?U
MP'QJ^?PI:0_Q3:C;(!_P,&NW!?[S3]4>5FO^XUO\+.]C_P!6OTIU-0;5 ]J=
M7$>HMCS[XM?ZSPI_V&K?^=>@5Y_\6OO>%/\ L-6_\Z] %=M7_=Z7S_,\K#?[
MYB/^W?R%HHHKB/6.5^*FK:QH?PW\2W_AZ73X->M]/FDL)-6E$5J)PA\OS&)
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ME-?0#?L[_#MO'(\7GPO:G71=_P!H>;N?ROM>,?:?)W>7YV/^6FW=WSFK>I?
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M?D:4\MP=.7,J2OW>OYW&+&%4*H  X  I]%%<AZ04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)NH 6DIDU
MQ';Q-)*ZQ1J,EW8 #\37$:M\6-/^TFPT&VF\1ZGT\JR&8T/^T_0"MJ=&I6=H
M*_\ 75]#EKXJCADG5E:^RZOT6[^1V.H:E:Z39RW=Y.EM;1#+R2'  KS8+??&
M&^5G22P\&0R;@K9634&![^B?Y^E^R\ ZEXHO(M0\9W*W C.^'1[<XMXCVW?W
MS7H,<:Q*J(H5%& JC  ]JZE.&%_AOFGWZ+T[OSZ=.YY[IU<P_C+DI?R]9?XN
MR\MWU[#;>W2UACABC6.*-0JHHP% Z "I:**\\]E*VB"BBB@84C#-+10!YIKV
MCWWP\UR;Q%H5N]UI5R=VIZ9%U'_3:,>OJ*[G0/$%AXETV*^TZX6YMY!]Y3RI
M]".Q]JT2,UP&M?#V[TG4Y-9\'W*:;?N<SV,@_P!&N?J/X3[BN]3AB$HU7:2V
M?1^3_1_>>+*E5P,G/#QYJ;U<>J?5Q_6/S78] HK@M'^*UHMTNG^([63P[JG3
M;<C]S(?5'Z$?6NYAGCN(EDB=98VY#(P(/T(KGJ4:E%VFK?E\F=^'Q5'%*]*5
M[;KJO5;KYDE%)FBL#K%HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **2C=0 M)G-8/B/QSHGA6,MJ%]''+T6W
M0[Y6/H%'-<C)-XH^)G[N".7PMX>?[TTO_'W<+Z ?P UUT\-.:YY>['N_T[_(
M\VOCJ=.7LJ:YY_RK?Y]$O-EGQ3XNO/$6H2^&/"S[[P_+>:DO,=FG?![O[5UG
MA7PQ9>$=&AT^R0[$^9Y&^](YZNQ[DT_P[X9T[PKIJ6.FVZP0+R>[.W]YCW-:
ME%6M%Q]E2TC^+?=_HN@8?#34WB,0[U'IY179?J^OIH+1117(>D%%%% !1110
M 4444 %)BEHH Q]>\(Z/XFBV:GI\-WZ,ZX<?1AR*Y7_A5ESI)SX?\3ZGI8'2
M"5Q/%^35Z%25TT\35IKEC+3MNON>AP5L#AJ\N></>[K1_>K,\_\ [,^(UC\L
M6L:1J"_WKBV:-O\ QTT>9\2UX\GP^WOYD@_I7H-%:?6GUA%_+_(P_L]+X:LU
M_P!O7_.YY_YOQ,_YX>'_ /O[+_A1YOQ,_P">'A__ +^R_P"%>@44?6E_S[C]
MW_!#^SW_ ,_I_P#@7_ //_-^)G_/#P__ -_9?\*/-^)G_/#P_P#]_9?\*] H
MH^M+_GW'[O\ @A_9[_Y_3_\  O\ @'G_ )OQ,_YX>'_^_LO^%'F_$S_GAX?_
M ._LO^%>@44?6E_S[C]W_!#^SW_S^G_X%_P#S_S?B9_SP\/_ /?V7_"CS?B9
M_P \/#__ ']E_P *] HH^M+_ )]Q^[_@A_9[_P"?T_\ P+_@'G_F_$S_ )X>
M'_\ O[+_ (4>;\3/^>'A_P#[^R_X5Z!11]:7_/N/W?\ !#^SW_S^G_X%_P
M\_\ -^)G_/#P_P#]_9?\*/-^)G_/#P__ -_9?\*] HH^M+_GW'[O^"']GO\
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MWXF?\\/#_P#W]E_PH\WXF?\ /#P__P!_9?\ "O0**/K2_P"?<?N_X(?V>_\
MG]/_ ,"_X!Y_YOQ,_P">'A__ +^R_P"%'F_$S_GAX?\ ^_LO^%>@44?6E_S[
MC]W_  0_L]_\_I_^!?\  //_ #?B9_SP\/\ _?V7_"CS?B9_SP\/_P#?V7_"
MO0**/K2_Y]Q^[_@A_9[_ .?T_P#P+_@'G_F_$S_GAX?_ ._LO^%'F_$S_GAX
M?_[^R_X5Z!11]:7_ #[C]W_!#^SW_P _I_\ @7_ //\ S?B9_P \/#__ ']E
M_P */-^)G_/#P_\ ]_9?\*] HH^M+_GW'[O^"']GO_G]/_P+_@'G_F_$S_GA
MX?\ ^_LO^%'F_$S_ )X>'_\ O[+_ (5Z!11]:7_/N/W?\$/[/?\ S^G_ .!?
M\ \_\WXF?\\/#_\ W]E_PH\WXF?\\/#_ /W]E_PKT"BCZTO^?<?N_P""']GO
M_G]/_P "_P" >?\ F_$S_GAX?_[^R_X4>;\3/^>'A_\ [^R_X5Z!11]:7_/N
M/W?\$/[/?_/Z?_@7_ //_-^)G_/#P_\ ]_9?\*/-^)G_ #P\/_\ ?V7_  KT
M"BCZTO\ GW'[O^"']GO_ )_3_P# O^ >?^;\3/\ GAX?_P"_LO\ A1YOQ,_Y
MX>'_ /O[+_A7H%%'UI?\^X_=_P $/[/?_/Z?_@7_  #S_P WXF?\\/#_ /W]
ME_PH\WXF?\\/#_\ W]E_PKT"BCZTO^?<?N_X(?V>_P#G]/\ \"_X!Y_YOQ,_
MYX>'_P#O[+_A1YOQ,_YX>'_^_LO^%>@44?6E_P ^X_=_P0_L]_\ /Z?_ (%_
MP#S_ ,WXF?\ /#P__P!_9?\ "CS?B9_SP\/_ /?V7_"O0**/K2_Y]Q^[_@A_
M9[_Y_3_\"_X!Y_YOQ,_YX>'_ /O[+_A1YOQ,_P">'A__ +^R_P"%>@44?6E_
MS[C]W_!#^SW_ ,_I_P#@7_ //_-^)G_/#P__ -_9?\*/-^)G_/#P_P#]_9?\
M*] HH^M+_GW'[O\ @A_9[_Y_3_\  O\ @'G_ )OQ,_YX>'_^_LO^%'F_$S_G
MAX?_ ._LO^%>@44?6E_S[C]W_!#^SW_S^G_X%_P#S[=\2WX*>'XO]K=(WZ8H
M&A_$#4/^/GQ%IVG+TQ9VFX_FQKT"EH^M/I"*^2_6X?V=%_'5F_\ MYK\K' 1
M?"&SOI!)KVK:EK[@Y\NYF*Q?]\+79:7HMAHML+>PM(;.$?P0H%'Z5=HK&I7J
MU5:<M.W3[MCIH8/#X=\U*"3[[O[WJ)2T45@=H4444 %%%% !1110 4F*6B@"
MEJFCV.M6K6]_:0WD!_Y9S(&'ZUQDGPCM;"5I?#^KZCH#GGR[>4O%_P!\-7H%
M)713Q%6DK0EIVZ?=L<5;!X?$/FJ03??9_>M3S_\ L;XAV/$&OZ7J"]/]*M2C
M?FII=_Q+7CRO#[_[6^0?IBN_I:U^M/K"+^7^5CF_LY+X:LU_V\W^=SS_ ,WX
MF?\ /#P__P!_9?\ "CS?B9_SP\/_ /?V7_"O0**/K2_Y]Q^[_@A_9[_Y_3_\
M"_X!Y_YOQ,_YX>'_ /O[+_A1YOQ,_P">'A__ +^R_P"%>@44?6E_S[C]W_!#
M^SW_ ,_I_P#@7_ //_-^)G_/#P__ -_9?\*/-^)G_/#P_P#]_9?\*] HH^M+
M_GW'[O\ @A_9[_Y_3_\  O\ @'G_ )OQ,_YX>'_^_LO^%'F_$S_GAX?_ ._L
MO^%>@44?6E_S[C]W_!#^SW_S^G_X%_P#S_S?B9_SP\/_ /?V7_"CS?B9_P \
M/#__ ']E_P *] HH^M+_ )]Q^[_@A_9[_P"?T_\ P+_@'G_F_$S_ )X>'_\
MO[+_ (4>;\3/^>'A_P#[^R_X5Z!11]:7_/N/W?\ !#^SW_S^G_X%_P  \_\
M-^)G_/#P_P#]_9?\*/-^)G_/#P__ -_9?\*] HH^M+_GW'[O^"']GO\ Y_3_
M / O^ >?^;\3/^>'A_\ [^R_X4>;\3/^>'A__O[+_A7H%%'UI?\ /N/W?\$/
M[/?_ #^G_P"!?\ \_P#-^)G_ #P\/_\ ?V7_  H\WXF?\\/#_P#W]E_PKT"B
MCZTO^?<?N_X(?V>_^?T__ O^ >?^;\3/^>'A_P#[^R_X4>;\3/\ GAX?_P"_
MLO\ A7H%%'UI?\^X_=_P0_L]_P#/Z?\ X%_P#S_S?B9_SP\/_P#?V7_"CS?B
M9_SP\/\ _?V7_"O0**/K2_Y]Q^[_ ((?V>_^?T__  +_ (!Y_P";\3/^>'A_
M_O[+_A1YOQ,_YX>'_P#O[+_A7H%%'UI?\^X_=_P0_L]_\_I_^!?\ \_\WXF?
M\\/#_P#W]E_PH\WXF?\ /#P__P!_9/\ "O0**/K2_P"?<?N_X(?V>_\ G]/_
M ,"_X!Y_Y/Q*N>#<Z#: ]2J22$?GBD;P#XCU;C6?&-T8N\.FQ" '\>M>@TE'
MUN:^",5Z)!_9M*6E2<I>LG;[DTCFO#WPX\/^&Y!-:V"R7?>ZN#YLI_X$>GX5
MTN*6BN:=2=1\TW=GH4:-+#QY*45%>2L%%%%9FP4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sdgr-20241231_g10.jpg
<TEXT>
begin 644 sdgr-20241231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (H I0# 2(  A$! Q$!_\0
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M>=&'\N0?==<]&&3@CGFJ[:#I36,E@VG69LY9#*]L8$\MWW;RQ7&"=WS9]>:
M/@[Q9\)_#'BK2?VP/%^IP33Z_H6I7<^F7:7DD9TZ:#2X)DEB"L C[]N6ZD*
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M0=/\">.+^TL+2#3[N5]2TLW@_P!#:XW#RY Q**P3&TN/O &J'PO_ &KO$_Q
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M6.ZR%XS$*L_L?^$O$L/C+XM>-]?FUN\MO%%[IXL;[Q#8+875TMO;%'D%J/\
M4Q;GVHIY*KD\FN_\7?LYZ-XO^/GA?XGW-[,ESHMA-92:6$!@O&(=8I7_ -J,
M33 <?Q^U 'D7Q:_:0MO%UK/'9Z!:ZUX5T^[\)2^?+<RPNUYJ-Y&Z &,CB*(Q
M2%3U+@'BO*/B1XO^(\GAOXTS7M[:ZH=.^*>B6FDVMO=SQ,&%Q9%8-S<)"59<
MX'WFD.",5[[X7_8GT7PG\'3X"M?$5[*K>)[7Q(^IS0JTS_9[F*6& C/W5C@C
MB![ 9J[X@_9+;7-<\92#QA<0:%XC\1:;XI;3?L,;-;7MK) S;9<Y9)!;H-I'
MRY)!H W/A7\5O&U[\8/$?PZ\>Z9H4.J6.DVVNV=]X=EF:"2WEEDB,3K*-P=&
MC^\.&##@=*\^_:G^'^LZ_P#%#0-=U?P+J/Q:^&]II,EM/X3TB_6&:UOFE#"\
M:W:1%N08QL +90@D YKW"T^%<%K\;=1^(PU"1KB\T&'0S8>6-BK'.\PDW=<D
MOC'M7*_$SX"ZMX@^(</C_P #>-KCP)XP_L\:5>2M91W]G?VRN7C66!R/F1G<
MJZL#\Q!R* /G#_A8FG>$?V?_ !)H_P +O%'B31FU;QGIOAP:7X@@DBU#P8+Z
M:**2-!,2P0*7>,DE07^4X%;GQI^&_P $OV<WTB[@F\7>!?%%CY&ICQMI=KJ&
MI;D67:ZWTV6CD60!E993_$&&.*]@TC]DW1K_ ,'^.M-\=:U>^--<\<203:UK
MC(MG)O@4+;?9DCXA$. 4P2<Y))K"U_\ 99\=?$#07\'^-_C5JGB'P#*JQ76G
MPZ/;6M_?PJ0?*N+M<D@X^8HB$^HH \6^)5UX%F_:D^,5YX\^'GBCX@Z;8:;H
M]Q;R:%:SW4>GQFV=I"RI*NW=PW ).TUZ-^RKXXTGX7?"O7O%_BC78_"'PO\
M$6M_:?!EEXAU9;F6TLWB7Y#*7;;O=9'6+<2@X->\>#_A);^#_BEXW\9PZA+/
M)XGAT^%[)HP%MQ:Q-&N&SEMP;)STQ6-\,/V>](^%VH>+K:SN%O\ PAK>I'5[
M3PW>6J/!I5PX_?\ D$]$=\OLQA26QUH \[^.VC_"W7M//Q5\=^);KQ3X0N-+
MAM/#F@Z?<R".:X=F826B0N&GN9B453@E0HQ@9->37NFZEH%E\%-._:*GUEO!
M,/AJZ^V;Y9YH!K!E4V\6H20<NZ6QVJ6X:17/)KW#XC_LQ>(_%?QBT_Q[X?\
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M;X1_"V'X3Z3KMC!?R:BNJ:Y?:VSR1A#&US*9#&,=0N<9[UW- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (*??MU:O\-_'5E\*O#>C6<KZ?+I^MWVH7P9\RQRK<0Q(H(^7Y%W$]<X&.M
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MMP5 W_ 2:TJ935A?DES+RN].]E=I>MC*&:IZ5*;3]5^<N6_RN?25KJUC>_\
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M*!QQN&:^ZX_".A17UA>IHNGI>:?";>SN%M8Q);1$8*1MC*+[# KY]_X*)?\
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M(B*JHH4L/-=BQY)/IQ6/KG[+>@ZQINJVTUY=W:7R:<'MYF"QR?8[9X(U) R
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M=TY_V?N[1P>OM7T7113Q6,K8R:G6=VE8RP>!P^ @Z>&CRINX4445Q'<%%%%
M'P#^VMJUA%^T59VKZYI_A&]3P]!(=2N=5U6)[J,W$H$7EV/"A2"<R<G?QT-?
M>.B<Z+8$2"4?9X_W@+$-\HYRW/Y\U\C_ !G\)>/]6^+-YKT'A#X@V%ZUN--A
MU'X?>(M/BM+^V25WA:=+A Z.-YSG(&3@FOJ'X>WOB'4/"MI-XGTF+1-5;(:Q
MCO!=M&@X7?*%56<CD[1C)XS0!TE%%% !7S/_ ,%$O^38=2_[#6C_ /IP@KZ8
MKYG_ ."B7_)L.I?]AK1__3A!0!]*Q?ZM/H*?3(O]6GT%/H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^/\ ]M/X@W'P3CBUP_'C4/!M
MWJM]9Q6?AW[/92(MN9HH[F1%>%I"%C+ON)(!&/:OI/XC?%;PK\)]'74?%&KP
MZ='*WEV\&#)<74G:.&)07D<_W5!-?E#_ ,% /V:_C=^T9\5(/B?H'PVUQ_#]
M_:Q6%GI<TD;W]ND></+;JQ,*N6+!<DCG=B@#]%/#/Q>\&?"?P-;:KXC^,9\=
MVVM,+G2KF8037-RA4 1V\-K&&EY!Z*3DTX^//BY\5OD\&>%(OAWH<G37_&B;
M[YU_O0Z?&V5/H9G7K]VO/_\ @G/^RK=?LZ_!*S/B_1;"W\>7\\MU/,$22XM(
M6P$MS*,] "Q53C+GK7UK0!XYX?\ V7_#2ZI!K?C:^U#XF^)(6WI?^)Y!-# W
M_3"U4"&(>F$S[U[#'&L4:HBA$4855&  .PIU% !1110 4444 %%%% !1110
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M\DAFNVMXVFDMSF-G*C<4_P!DG./:OA[]K?3;RU_:2&I&WNK6QN/#EK MY:^
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M0!YE\.?V?]!\#:P_B34KF\\9>.)EVS>)M>837(!ZI"N-EO'Z)&%'KFO3Z**
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MA:>I6&WC))))RSLQY9F))+'DUU= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7YT?M2OJNF_M0WFKVW@_P FV%[I=G_:0N-6\W49"L;(
M$2W<0GY3(JAN,Q-NQD5^BS9VG R<<5^>_C>3Q+J'QZUS7?B#X:T>9+74M(MX
MX5^(-W;QZ()6V0!HHD$9,K*9,-W;!."* /T(J&^622RN%A57E:-@BN2%+8.
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M:=JJ1B1[*ZB</%,%)&<,.1GD$CO0!AZ'^T1X,U;4IK&?5(=-N6U&?3[..ZD
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M!]* +U%%% !7S/\ \%$O^38=2_[#6C_^G""OIBOF?_@HE_R;#J7_ &&M'_\
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MM$I"F$[3LW,IPN" #ZD\3_%;POX/70)=3U6W@LM;G:WM+[S5^SEA&TF6DSM
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M'!KS3]NC]ISX4^.?@QJ?@_0/'NBZKXH&O:9%_95M<;I]\=_#YB[<=5VMGZ4
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M?33MT):;M9V/D#]D#]B'4_@#\'H-$OO%^J:5XHFNI+N]FT2Y0VQ9L!0JNAR
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MHFGV,-OI5G"L$%J%RB(HP!S_ %J]):PS+MDBCD7(;#*#R.A_"I:* $ "@ #
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M,;1'TW,,GM73'$UHJRF[=NGW&,J-.3NXJY[Z/!OQ2T+!TOQ_I^NQ+T@\0:0
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MO_Q= 'U!17R#X/\ V]O$?CZUU"Y\/_L]>/M5@T^^FTVZ>W>V(BN8B!)$<O\
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MZ@HKY!\._M[>(_%FJ:]IND?L]>/;^^T*Z%EJ4$+VQ:UF*APC_/UVD'\:WO\
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ME)"#FYN6 5I6R?O$*H_"M75-4L]$TVZU#4+J&QL;6-II[FX<)'$BC+,S'@
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M2I!6!6#'D$GJ.*[#XG?L[0^)M4^&JV$$<^BZ%97WA[4;5I!$[Z9=V9@9D(&
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M%A9VZ3W%];002-L262955FSC )."<]J^$Y-:UGX+_#7X7>+_  Y:37%UX\\
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M ?A4E%)R<MP"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<NGVH&U1I"WD,(RJX!8*SC<#C%24?:^I>)M(T?09-;O]4L[/1HXA,VH33JD
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M_"5743W$R01M/HU[$F]V"J"S0@#)(')[U]#4:K<$T]@HKSVS_:"^'.H>./\
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M**S+?Q-I5UXAO-"AOX)-8LX([FXLE;,D44A8([#L&*-C_=- &G1110 4444
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M<#@4M% '@?[,?_(]?'S_ +'N7_TBM*]\KP/]F/\ Y'KX^?\ 8]R_^D5I7OE
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MI-N6?8Q?*D [@WRG&O\ 'S3?&GB#5- M]+U#Q)H%O#X5U;4)XO#UPZ ZA''
M;:)Y%'S88OA?X\$<C(H ]M\8^!?#WQ!TM--\2:/9ZU8I*LZ0WD0<)(,@.O\
M=8 D9'."?6F+>>&/AWI^D:,LVF^'K-L6FGV.Y($.,8CC7@=QP/6ODCS/'_A[
M7]'TW7-?\=R^#]3@T:]UJ]@>>2_CN9;:Z,T=OY:^8D9FCA\R.$?(,<*&-<7:
M#QM\9OA'INM:8VH:]K>A7MG9Z/J/B"VDE9YI-:+M+.% 8B*&WM@Y'(#.#CF@
M#[A\4?"KP=XVUJQU?7_#6F:OJ=B MO=7ELLCHH;>%R1R WS '@'GK702:G9Q
M:C#I[W4*7TT;31VQ<"1T4J&8+U(!903VW#UKX-\=>//&FC^!M;G\1:[\0M"U
M?2?#C26SZ?YS9UL74JW;3&-=GD<0^3OQ%Y3';\P./4OVBK9_^%C> ]8OKOQ=
MIEI%X7U2+^TO"<-PTOVMS:M#%(\*LP#,A(4X#,H!R,B@#Z=AUFPN'ODCO8)'
ML&V7:K("8&V!\/\ W3M8-SV(-36-];ZI9P7=G/'=6LZ"2*:%@R2*1D,I'!!'
M>OAB\U+XE7#:A%\1)O%^C:/=6;FXE\-6LHEDU0Z59^7$?(0L4+F?Y?N&0%6Z
M 5]8? '3[G2?@?X!LKVWFM+NWT.SBFM[A-DD;K"H*LO8@]1VH [ZBBB@ HHH
MH **** "BBB@ HHHH \'U;]C_P +:AX)O-!MM8UK2[MO%4WC*QUJTF07>GZC
M(Y8O$2I7:-S+M8'(8BN:UK_@G]X!U3POX=T2VUCQ%I,6FZ;<:+?W-G>*)M8L
M;B<7%S!=,4.1)*-Y9<$9('&,?3M% %:QT^VTVQMK.VA6*VMHUABC X1%   ^
M@ KPC]C7_D5_B1_V4'7O_2BO8_''BIO!/A:_UI='U37S:J&_L[1;?S[N;+ 8
MC3(W$9SUZ UX9^PIK!\0?#GQOJAL;O3#>>.=;G^Q:A'Y=Q!NG!V2+D[7'0C-
M 'TA1110 4444 %%%% !1110 4444 %%%% 'SG_P4&F6W_93\5S2';%#<Z;*
M[8)VJM_ 6/T !->,3?M7?"1I7(^(6CD9/_+5O\*^[KJUAOH&AN(8[B%OO1RJ
M&4_4&L[_ (1/0_\ H#:?_P" L?\ A7H87&3PMU%7N>-F&5T\P<74DURWV\S\
MW/CY^T!\/?'7P[&B:!XPT_5]5NM6TSR;.V=FDDQ>PL<#'8 G\*_3@]#@9-9B
M^%=%C9671[!64Y#"V0$'UZ5J5EB<3+%34Y*W0WP&!AE])TH-M-WU/@/1_$D'
MA[5=%\/^%KJ]U*0^+$FG^$/BWP_Y]QIDK7ADFN;:]1%*+&6>X21F==O&>:LM
MXZA^&/P*\0_#?4?L-E\15U#5'U72/$'ARZU%?%#33321/#Y6/.$X>(!\G;T(
M&VOO.BN0](^&M.\-_&'6-:^,^H^"K^V\+:Y_9NAM-X>N]'6:.ZE&E)YD$4LC
M81@-T:Y#*& W=Z[+PSXFTSPO^S;I,I\+6^I_ 73?#BK<VNJ>?+KC/&-K6TEI
MY05G\\;"-P&>>!7UG10!^?LOB'2/B98W7Q=N/$EA:>-+/6='NUTN'3+BYTS0
M[6$S+;0WI"JT@S/*9)USY;E=HVKDU]$^+K?"^WUCQ)?VVES>,?'/B;4I?#GB
M.XTJXCTS3+(PVZ7-X%VM)Y3O&-B\-.RY) )-?H510!\?Z]\(_!&G_"SX"ZGX
M823Q0=%\2:-:Z=KDT4GF>4]\&N)1&0!'N;=D[1A?ESBOJG1_%FDZ_JNLZ;87
MBW%]H\Z6U_"%8&&1HUD53D<Y1E.1D<UKU3LM(LM-NKVXM;6*">]E$US(BX:9
MPH0,Q[D*JCZ"@#PWX/\ @+2? ?[3'Q7BT32?[-L[W2M(NYI0KM]IN'DO3([2
M-DN_(SR<#:.!BO*/BII_BC5/&GQ"UBW\3^,-/GT[QOH6D:;#IU_/%;PV4\5J
MMT$B'R,&$TF6(.TC(*D&OM6B@#X$U;Q#;^$?BA8^#_&GC?Q=H_P^L_$FO6L3
MG5;Q7FA6RL9H8Y;A3YKQI)++L.X\D+D]*Y_0]:^)-EXML_$GB"76X_",.CZ,
MWBB[MTEAUN?3Q>WJVDN]1N "&"2X5?WA1FZ<Y^_]3\&:1K'BK0_$=W;&35]%
MCN(K&?S& C6<()1M!PV1&G4'&.*W* &0R)-"DD;!XV4,K#N".#3Z** "BBB@
M HHHH **** /(OC_ / [6?C!-X1O_#GCB?P!KWAN^EO+;5;73HKR0B2%HGCQ
M(0 I5N?7 KIOA'X/\4^"?#,FG^+O'$WC_5#<-(-4GT^*R98R!B/RXR1Q@\]>
M:X']J7XY>)O@['X,L?"MGX;.I^)-1DLAJ7B[439:;:".%I3O<<EFVD*!W'TJ
MK^RGX1>*R\1>,-4;PZ_B;6M0F:^E\(:]<ZEITN2K XE<A'!+<*!@''>@#W^B
MBB@ HHHH \!_9GE2'QM\?GD=8T7QU*2S' '^A6G>O<?[:T__ )_K;_O\O^-?
M/7P/T71O$.J_M&Z?XAM[>ZT2;QK.+R*[QY1C%C:$[\] ,9_"OG[X;^*_V</%
M7[3'B706\.Z6GAN]@MK/1;JZBVV;W41?S2I)^42;EVL?O;.V1GU<'@OK4*D_
M>]Q7T5_U6O7T1P8G$^PE".GO::NWZ,_1('/(Y%+4-F(%M8EMBGD*H5/+(*A0
M, "IJ\H[PHHHH **** "BBB@ JK8ZI9ZDURMG=P736TI@G$,BOY4@QE&P?E8
M9'!YYKROXH>"/BWKJZ\WA'XB:;HEO<0,MC92Z('DB8IC'VCS,@ELG=LXSTXK
MY!_8S^!?QX\.^-/%URFL3>!K-96M]0DUBT-ZM_= YWI&67?C.?-#<AL<]O:P
M^7TJV'G6E7BG&VFO7Y?E<\VKBZE.K&FJ3:=]=/\ /\['Z.5B^(_&WA[P?]F_
MM[7M,T3[4_EP?VC>1V_FM_=7>PW'D<#UIG@O3=?TG08K?Q+K4&OZJKL7OK:R
M%HC*3\H\L,V,#C.>:^;OVI;72[3XFVVJW5S<:+?-X?:SBNM6\,'7=%U.,S,S
MVA1 9(9P=IRI7>K@?-MX\>246TG<]&+NKM6/I'Q%X\\->$?LO]N^(=*T7[6<
M6_\ :%[%!YQ]$WL-W4=/6H=:^)'A'PW?)9ZMXIT72[R1%D2WO=0AAD93T8*S
M D'L:^/M$OH?!?\ ;E_X[\&6?A_5M<\/:3%X=76M#NM8TZSM([94FTX+&&D1
MED\QC&2&;S%R6VG&%H_PY^)7BRW\0ZAH/AC0_#^I0^!])@3P]K6@-=1R[/M0
M%M;R3N3$WE[?E??AF4-4C/O>\U2RT_3Y+^ZNX+:PC3S7NII52)4QG<6)P![U
MER>/O#$>FV&H/XCTE+#4'\JSNFOHA%<OG&V-MV'/L,U\VW/BBU\&_L[Z(^I^
M!9_%'POTO2M.&DV=X]S)K=U>1&(117=IY&V,)*K;V+,H$>=I'%>0ZSH-C8Z
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MQODCCY<=Z\@^ _[0OQ2^,FJ&6Y^%6EZ)X:M=6O-'U#4E\4+<2P36TC12%(1
M-XWK@?,,@YH ^CJ*** "BBB@ HHHH **** "BBB@#Q[]KCXM:W\#_@#XF\9^
M'(K.;6=/^SK;IJ",\.9+B.,E@I!/#GH:^,#^VY^T*"1]H\ _^"JZ_P#CU?:?
M[6'PAUCX[? ;Q+X*T"[L;'5]1^SM!/J)<0*8YXY3N* M@A".!WKXX/[!_P ?
MR2?[4^''_@3?_P#QJOLN'WD2C4_ME.^G+;F\[_#\CY;.EG#=/^RFK:\U^7RM
MO\S+NOV]?CSH<VGW%^? ]S927]K;31V^FW*R%99DC.TF; (#5^G%?FG<_P#!
M/?XY:U-I\.HZS\/X;&*^MKJ9K6>],NV*9)"%#18R=N.:_2L\@CI7#GSRIXF/
M]D7]GRZWO\5WWUVL=F3K,50?]IVY[Z6MM9=O.Y\P^!?VG/%_CGQTUG9V/A-[
M>+6Y=*O/"+:B\'B2Q@29HC=O')A' "B4H@^XPPQ/%7[?XZ?$SQEH%_XW\':!
MX5E\%Q7=Q!IEAJ^H20:EK<<$C1O)$^!%"79'\M7SG +%<\4=8_9G\>>+M4T3
M3O$OB3PWK6C:/K$.IVOBF73''B8113B9(/.#"-3P(VD'5,_+DU5\5?LJ^+[K
MPGJGP]TN_P#!>I?#VZN;N?3CXFT:2ZO]"%RSLZV^'$<A0RN8V;:5R <XKYL]
MTL>+/VFO%-K\0?'&C6%_\/\ PU8^&H+*41^,-1DM[FY,]J)V V': I)3(#<C
MO7JGACXK:UXR^ .F>/M)\(74VO:EI$=_;>&Y9A%(TSJ-L9D8 !<G.XC[O.,\
M5Y]8?L8>&KRV\=:=XE6UUS3]=LM,LK"\>W OK#[)9I LR2XRLF]!("N,$5KM
M\"?$_P#P@JZF->M'^-4&E'3(/%LDES]C+@&-;A[3?Y>_RSD_*1OYZ4 <IJW[
M3OC?POXGOO NI:)X;O?&C:AI>GVE]87DPTJ"2]69MER67>CHL#,%'+AX\;<U
MLZ+\=OB!XRAU/2M#T+PU#K7AS4KS3O$>M7VH2?V1:&"..1&0J/,/FK*#@X\O
M8^XG SB:)^S3XVM?A%J/@N_7P'="6\@OW>>RNKO^UY@VZ=[Z25S)YC_*1+&0
MR%1C@ 5A7W['OC2S\*V>AZ)JOA.+2=0U>XUOQ+H$EK<PZ?J$C*B6]J!$P<V\
M8C!96.96Y?()% '91_M6ZQ?^#?A'K5EX%O-GC6^L;>^O)9 ++38Y[@0Y60X:
M5F/S1@+RI#-CH?HR1BD;,JEV )"CJ?:O+_%'PTU[QQX)\$V&J7.D6&KZ+KFG
M:M=#2X9%LV6UG#^5"K'<H*@ 9Z5UGA^Z\2WVL^*H-7MK:RTN&Z2+1[BVSYLL
M)A0N\@)(R)"X& !A>GJ >7?#;XZ^*M;^,7_"">*=&T.SOY]+FU9K/1M0:ZN=
M&19$6.*^XV[I%D#*4.,JPP1AJV/%W[5OPZ\#>*K_ $#5]1OH;S3[J&RO9H=,
MN)K>VGF0/!&\J(5#2;@%&<DD#N*QO!OP2\;M\4O#7BOQMXAT34W\,6MY:VE]
MI-@UO>ZJ)PJ;[PD[0%50=B94O\W& */$W[.>HZ]>^,IX]8M8AKWBW2?$<8:)
MCY4=FML&B;U9OLYP>@W"@#1;]K;X??8=-DCEUF?4-0NKNRAT:'1[EM0$]LJ-
M/&T 3<K*DB/R "IR#5"P_:P\,77C*[M?M4$_AV;3-,N]'NK19)+K4)KN69!"
MD(&XE?*Y&,K\V[&#7!^*/@_\0O"/[0FBZ_X/ETN\EU;5=<U66;4[69K2VBEL
M[&%(I70[E<M S*1UQBH=+_8;O/#FMV?BK2O$ELGCG1[.U.DZP\#JL=U]IN)[
MU7C!Q]GN!<O&4&2JXYR* /K=3N4'&/8TM-CW^6GF!1)@;MO(SWQ3J "BBB@
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M/X=>.%UR6UGUE?'6MB]EL$9+=YO/&\QJQ)"YZ G- 'TA7SW^Q/\ \D]\;?\
M8^^(O_3A+7T)7SW^Q/\ \D]\;?\ 8^^(O_3A+0!]"4444 %%%% !1110 444
M4 %%%% !17S7_P %&+VYT_\ 8[\>SVES-:3JMH%FMY&C<9NH0<,""."17Y"M
M;W 8_P#$VUK_ ,&US_\ '*]S+<GKYHINBTN6V]^OHGV/+QF84L"XJHF[]O\
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M4?\ "T-.B(%UIVLV/J9].EP/Q (K"G]>H_P)-?X9?Y,[JE? 5/XR7_;T;?\
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M$2OS=\UZ_14%'*Z#\+_#'AF^U^ZT[28;=M=C@BOXN6BECAA$$:",G:JB,!<
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MVB7Y25T]M]+'Z?T445^:GW04444 %%%% $-Y<1VMG/-*K-%'&SNJH6)4#)
MY)]J^</BU^VAX>\&^"=#USP-'IGBVSOKN2SGN)KQ[2VTQHXRWEW.V)Y(I&*[
M%1D&3G.,<_1.L7$EKI%]/#)%#+' [I)."8T8*2"V.< ]<=J^"?V?_A_K7QBU
MSQ!XR\=^,[.POS;1-IWB_P /ZSIJ7JW0=_,V&T 5[3:$Q'=J[^N.: /M[X;>
M,)/B!\/_  [XEETJZT.75K"&];3;T8FMBZ!C&WN,^@KI*XOX6^,M)\2Z(VG6
M7C*P\<:KHJQVFJ:G8&/#S[ <NL9*(S#DJ#QFNTH XGXO_%_P_P#!'P>?$OB4
MWAL#=0V4<6GVKW-Q--*X2-$C0;F))Z"O./%7[;/PY\$Z/H-_K</B/3CJUO-?
M?8YM#N%NK*SBE$4EU=1;=T,(=E&]ASGC-:O[5GP[N_B1X!TRSM? >G?$A++5
MK>^GT#4-4DTXRHFX%H958+YBE@0)#M//?%?)5]^R%\;-'\(11V6E6.O7OB+P
MCJ_@VYT^[UL'_A&K6[OUN;?]](";F.&,%"%^8GID4 ?HQ:W45[;0W$$BS03(
M)(Y$.0RD9!'L17@G[&W'A?XD@\'_ (6#KW_I16_XH_9ITGQMH_A:TU'Q1XNT
MN70M,BTY?^$=U^YTZ.8(JC>ZQ, S?+U/.*Y#]A718?#?PY\<:3;SW5U!8^.M
M;MXY[Z=I[B15G #22-R['NQY- 'E/@C_ )+E\?O^QLC_ /2*"O1%ZUYWX(_Y
M+E\?O^QLC_\ 2*"O1%ZU]S@/]VAZ'Y'F_P#OU7U_1&M_P3S_ .3._A[_ +E[
M_P"EUQ7T97SG_P $\_\ DSOX>_[E[_Z77%?1E?#O<_6H_"@HHHI%!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'RM^WI%%JVD_#[0;7PU)J_B;4M8E&CZHGB$Z%_9<J6[N[B[
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MHKY,_13J:*X+P;\?/AO\0]:&C^&/'.@Z]JK1M*+/3[^.64HOWF"J<X&:[V@
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M*&W_ +-\@Z7;;/['=GL]OE+CR&;DQ_W2><8KS']KCQGXO^'W@6+Q!H'C71?
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M#_J&W/\ Z*:N1^"__']\4_\ LH&N?^E%=;XY_P"1'\1_]@VY_P#135]WA?\
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M ?3M%>"?\+9^.W_1!;7_ ,+.U_\ C=1W7QB^.5G:S7$OP%MA%$C2,1XRM2<
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M + Z_P#H;UXC\*?^1^^.?_90M0_]$V]?DN6?[S\F?5<0?[C\T>A7G_'C<_\
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M)GA0/FP:_/:PD:7Q=\1G>-H7;QGK3-&Q!*$W;DJ<=QTK]/OV1_\ DV#X6?\
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MTT==I+S.9?G)!(C3:Q)^]G Y%?(/B[_DI'C_ /[&?4__ $I>L#Q ?^)#J?\
MUZR_^@&OFL/PS1KX2&(=1IN-[67:Y]/6SJI3Q$J*@K)V_$_<?PS\9=4\9>"]
M.\3Z/X"UJYT_4M,GU2R22>VCDF0%#;)@R?*T\;^8N3A0"&(/%>F6\C2P1N\9
MB=E!,;$$J2.AQZ5YU^S1_P FY?"S_L5M+_\ 22*O2:_/CZP**** "BBB@ HH
MHH **** /F#XU?L,VOQC\9>*]<_X65XK\,6GB8V+ZEI&D_9_LTSVBJL#'?&6
MR"H;KUKVCX2?#W5?AMX:ETO5_&VM^/+E[AIAJ6O>5YZ*0 (QY:*-HP3R,\FN
MWHH **** *6L:+I_B+3+C3=5L;;4].N%V36EY"LL4J^C(P((^HJU%$D$:1QH
ML<: *J*,!0.@ ["GUF>)[>]N_#6K0:<_EZA):3);/G&V4H0AS]<4 <;\)_"_
MA;P_KGCZ\\.>((M;N=:UQM2U2**ZBF^QW)BCB,6$Y3B('#<Y)KT6O@3_ ()\
M^%YM-^)$,VG>%]2\-6^E>!+;1O%)OM/DM!<Z\M[([$EP/.D6,MF09X<<U]]T
M 0-8V[7B7;6\372(8UG*#>JD@E0W4 D#CVJ>BB@""[L;:_C6.ZMXKE%=9%69
M P#*<JP![@\@]JGHHH :Z+(C(ZAE88*L,@CTIEK:P6-M%;VT,=O;Q*$CBB4*
MB*.@ ' %2T4 %06]C;VLD\D%O%#)._F2M&@4R-@#<Q'4X &3Z5/10 5YGXCT
MCP8OQQ\,^)=2\46EAXJL=,N=*L]'FO88VN([F2)BWEL=[-N@ 7'J>M>F5\!?
M&[PW+9_MK6GB+1=,U3Q!XWFU31;>VT?6O"<5SIITU 3-<VVH%6,!B)=BVY"'
M&-K<&@#[]J"[LK>_B$5S!%<QAE<),@8;@<@X/<$ BIZ* "D90RE6 *D8(/0T
MM% $-I:06%M';VT,=O;QC:D4*!44>@ X%3444 00V5O;33S0V\44L[!I9$0!
MI"!@%B.IQQS4]%% $$EE;RW45R\$3W,098YF0%T!Z@'J <#/TJ>BB@#@OBYX
M)T#XN^')O NK:O\ 8IKI[?4/)M9HQ=%(+B.4,$;)V;XU4G'?&<UU6A>)]'\4
M033:-JUCJ\,,IAEDL;E)UCD'5&*DX8>AYKXZ^)WP=U33?VI_B#J/A2+6KO6_
M$OPOU<1:E=323)'?/+MMX(7/RQ*O&V-<8R34?_!/G04MO%WBO4=!\-7_ (7\
M++X:\/Z7=07FG26*S:Q!!(MVPC=1N=20'D ^8D<F@#[<J&SL[?3[:.WM8([:
MWC&$BA0(B]^ .!4U% !4$-C;V]Q/<16\4<]P5,TJ( TF!@;CU.!P,U/10 44
M44 %%%% !1110 4444 %%%% !7YZ?\%%KZP7XHS1^)[^YLK"S^'&H7_A+;<2
M0K_PD:WD(B:#81NN!&1M7G@GBOT+JGJ&CV&K-;M?6-M>M;2": W$*R&)QT9<
MCY3[CF@#R?7-6^-$'AWPBWA'0_"VIS2:5"^JMXCO[BVE2ZV+N"B.-@1G.<XY
MKROX2^"_VD_A/IOB&TMO#WPYOEUC7;W7':36+Q?+>YDWF,8@Y"] :^N** /A
MK1O@3^T9HWC/QSXA32/AW++XJU1=3EA;5KP"W80I%L4^3R,(#D^M;X^&_P"T
M@/\ F ?#C_P<7O\ \9KO=!_;,\%:?\1/B3X6\>^*/#7@ZX\-ZTMA81WVH+#-
M=6YMXI/-97/]]W7CCY:Z?_AL;X&?]%:\'_\ @XA_^*KMAC*].*A"5DO0\NKE
M>#K3=2I3NWYO_,\C^ _@/]I+X$_"C0? UGH'PYU6VTD3!+R;6+Q'D\R:24Y
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MK'J-TRPL45-H)AY'RY_&N?;_ ()C_'AE(^V^!^1C_C_N?_C-?H-_PV-\#/\
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MD.0"$;"_+Z\UY=.K.C+G@[,Z:^'I8F'LZT;H\UF^&/[2$T,D9T'X<@.A3/\
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M*LJ]6BG)N[=WO]YY?\&?"?[2?P;^%?A;P/:>'?ASJ-MH-A'81W<VLWBO*J#
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MX<>&/"%OX:^&]];Z%IUOIR7,FM7JM*L480,0(."<9Q7HO_#8WP,_Z*UX/_\
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MKVI16.OR^*]97556[L8V:T46\47E!F!+#,9;M]ZNU_X5SX4_Z%C1O_!?%_\
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MH]K%;P7EQ#EHA*%7E0^U^.I10>.*** /3J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>sdgr-20241231_g11.jpg
<TEXT>
begin 644 sdgr-20241231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $F G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHJOJ$TMO8W,L$1GFCC9DB7J[ $A1]3Q0!Y[:_M"
M>$M0\02Z/8IKNHSQ7S:<]S9Z!>S6@G5]CK]H6(QX5L@MNP,')XKTD,&) ()'
M!]J^2_@3X/\ %O@WPCI:SZ9\11XMBM;N_FT[4+Z"+1)+^02S-$VUR0AE<@$#
MK@UR&@_"3XBK_;%[!H6L:58W.C:?#J5O:@6MU?L]^LFH(A-S(SR+ KJLCLK-
MO(7J* /LW5O%FE:'J&C65Y=K%=:O.]M91A2WFNL3RL,@8 "1N<G X]ZUJ^4K
MKX+-XBU:SFM_AU=Z/X5TO3M8U6TT&]OMZW&H2+%!;(8PY$6Z..1S&#M!D!/S
M9KK_ !?X#\3Z7^S[\._#$<&I:ZFG2:5!XEM;28&\N[*- +B-6+ MEPFX!LE
MP!YH ]HT[Q9I6K:SK&E6MVLM]I#0K>QX($32H'C&XC!)4@\'N/6I/^$DTO\
MX23^P!>Q'61:_;C9 _O!!OV>81V&[C\#Z5\@>&?@UJWAVZFU#6?AYK6I>%M4
MO]8U"/PE:W*.UO=,T,-@)QYH7RQ;1-M^8K&S]N#7IG[.OPKUKPCX[UC4_%NE
M2/K]OX?TG28=<=Q*MPB1NTR+)NRQ5V5#N SY2GG- 'T(TBKG<P&!DY/;UI2P
M R3@5\=>)_@GXLDT[1O$=SI6H75_K'B'4=2\26<2"^F^SLTAL;;R3/&K0)B(
ME V VUB" :YNX\%:UKE]>>#;GPSK7B?5-#\)"PM(UO52#2M4OYI9T$Q67"B&
M(0;9 7V*N 22"0#[I+!< D FD\Q=H;<NTXPV>#GI7Q_XN^!?C2\T/5M>NXM0
MU#Q#/XDM[6ZDB?[1-)H=O!' PBA,J B=X5DD0,K,KL#D\52\3?"CQBOP]TFP
MC\,:Q?/]JU'4[/3)$A>RC>7$<=E<6Z3[H$=09%E25O)9VZ]* /L[<-P7(R>0
M*AO+ZWT^UGN;F9(+>",RRR2' 1 "2Q]  #^5?)&D_"GQTOQ8^VZE8:N9K36(
M+RUU"/9-';:;!;KLMTNGGW/N8-&\?E;F+LS'&#6'XA_9[\7Q_#V(Q:#>7>O7
MW@[4EUQENC++=7U_<PDV_P TF&\A&N&0# !50.M 'V=I6K6>MZ;9W]C<)<VE
MY"MQ!*O22-@"K#V((_.K;,%QD@9.!D]37RWH_P ,M5L_CQH5SIW@_4;#0+":
M&W47<@6&RLX+5EAFM9XY00')5)+1T8$EFR.II_M2>!?'7C[Q3JT.C^&+F[$%
MC9V^BWUN X!DG!N9O,:X1;>2( $%8V=@!@]@ ?1GC[XB:'\,]$BU77IYH;::
MYBLX4M;:2YFFFD.$C2*-6=F)SP >AKDY/VE/ D>AS:D][J,9AOXM,?3WT>[6
M_%S*ADCC^RF+S260%@0N" 3G@UF_&SX=Z_\ $/Q9\,]-TV_U#2-+TF_N-7O-
M;LQ \L,L5NT=NNV9'5B[3,?NG[AZ<5QOBCX9ZA\._B9X)UBSTGQ-X_@^W7NL
MZYJVZWFNY+I;46UHA4F)%15DDVJ@ &TYZY(!ZKI?QX\$ZMIEM?1:PT,,VJQZ
M(R75K-!+;WKC*031R(&B9LKC> #N7!^89Z#1/'FA^)/$FMZ%IE\M[J&B-''J
M"PHQCMY'&X1E\;=^W!*@Y (R!D5\Z:_\-?'WQ$A\964WAY?#TWQ)NXC>WEQ+
M'*/#NG6L*1PR85B)+YRI= I*QG:2WR8/H_PCTO7/A3\ Y=/7PD\WB;15NH_L
M=O*I;6KE7;;=>:S<FX.V1F<Y!=L]* .\L/B9X9U3X@:IX(M=5CF\3Z79Q7]Y
M8*K9AAD)",6QMR?0'(!!(Y%8EO\ M!?#^Y^%-]\28_$=N?!5EYHGU4HX13'(
M8G&W;N)WC: !R2,9S7@VG? _XG?#35+?Q+'/:^*O$%_H6O)J<FG6WV>5M0NE
MCGA#N\I#J)8EB3 4*H':N<N/V9?%R^&7^'*Z*Q\$:?JVGW-MME0I=O/]G6XE
M9=V0ELB7+8(^9Y5(!VT ?8/AGQQHOC"XU6#2;S[5+I<T=M>+L9?*E>%)E0Y
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M% !4$-C;6]Q<3Q6\44]P0TTB( TA "@L>^  .>PJ>B@ HHHH **** "BBB@
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M;-\9=,T!?BKXENM2C\5:$Y\!2:4ZZ7 -T1\Q;GR]I;!#XWGER.W !^FU%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\'_ /!0SX8^([7_ (1_QG+\1M:N/#MQXQT*&/P:\,0L86\Y%\P/C?G*
MENO5C7WA7P5_P4-^-RWL_A_X;_\ "%^*H6M?&.A7'_"32V &CR?O5?8D^_);
MYMN-O4'TH ^]:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HKYD_:(_X*&_"7]FGQY:^$/$MQJ=_K;JD
MEW#I-J)A8QN,JTI++R1SM7+8(..17T%X-\8:/\0/"NE>)/#]]'J>BZI;I=6E
MW#]V2-AD'V^AY!XH P?B;\;? 7P9M;.X\<>+=*\+Q7CE+;^T;A8S,1UVCJ<=
MSC S74Z'KFG>)M'M-5TF^M]3TR\C$UO>6L@DBE0\AE8<$5^:G_!4C]BWXK?'
M#XIZ#XU\"Z<_BC35TR/3)=-CG1);219';>%=@"K!QDCD%>>U?6O[!OP0\3?L
M]_LU>'?!_BZX677(Y9[J:WCE\Q+02R%A"&'!VYYQQDG&1S0!]"4444 %%%%
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MM3OK"P;5+ZVM9)H+&-MK7$BJ2L8/8L0!^-:5%7&2C)-JZ[=P/ _V4_CAX_\
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M6C"-(B2%=CN@D0LJL2H89%>+_P#!1K_DB_A+_L>=#_\ 2F@#ZIHHHH ****
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M*C@XI)/AW922,W]JZX"Q8X759@/FN!.>-W9AM'HGR=.*ZNB@#EO^%>V>[/\
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M" KC[I+$<DTEU\.+*[:[9M5UU#<^?N\O5IU"^:$#;,-\NW8-N/NY;'4UUE%
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MAWQ1)?+J'B*39;?9+?S$B7>$WR'(P-S <9/7BO!?^"E'A^/6Y_A66^&>I?$
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MEGIBMKFK>)/!L/C*UL;#3[.&^DAG\IY(6D#SMOD$>0%#]0#7ZLU\#:;=:/\
M$'X"?&+XCSV/PO\ #GC&:ZU2R6*_TR-3;6$$VV2RU##*TDDHA8D_]-5P#@4
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M3Z;U9%X^[LR.2:Z#5M6LM!TRZU'4KN&PL+6-II[JYD$<<2 9+,QX  [FN/\
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M78P9N?O;\'@"GW?AWQ+,MP(/%K6Y?SO+/]G1-Y>X)Y?7KL*OU^]OYZ"NIHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!H3]JOPO\ %SPA\.KOPG\+SKWBBUN[NR>.\O3 J6ZAI-[$Y!P1C .:[O\
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MNEL-0TV_1?WCHX(VR_/&'=&+J17Z+Z3H]KHMF+>UACB4G?(R1JAED/WI&V@
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M:HL]?AM]2/PX41QW-HMYA'OQ;2!+T1Y_U"J1$R=W*OCY<U],UXIJ'Q]OK/\
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MUZ2UDU+2[6_>U+F$W$8?RRZ%'(R.,HS*?8D=ZOQ:?*K$D#H1UIO]FS>B_G0
MW23;Z79VFG65I':65O&L$,$0VI&BC"JH[    5#JD=EK<<$>H:?!>QP3QW,2
MSJ&"2H=R. 1]Y2 0>Q%6X=/E216(& ?6F?V;-Z+^= %?18;'P_8Q:?IFGP:?
M9(S,EO;J$12S%F( &!EF)^II=<ALO$&GW.FZG80:A83C9+;7"AXY #G#*>",
M@5873YE8'"]?6B33YF=B N"<]: *FEP6&A_;/[/TZWLOMEPUW<>0H3S9FQND
M; Y8X&3WQ6C)J31N5V _C5?^S9O1?SJ2:PF>0D 8^M "_P!JM_SS'YT^34F3
M;\@.1GK4']FS>B_G3Y+"5MN .% ZT +_ &JW_/,?G3FU)E5#Y8^;/>H?[-F]
M%_.G-I\S(@P,C.>?>@#&L?#F@:9J4>H6FA6-M?QR7$JW,<*K('G8-,V[&<N5
M4MZ[1Z5O?VDWEAM@Y..M0?V;-Z+^=/\ [/E\D+@9W$]: .9D^,7AB'Q</"[Z
MK;KXB-PML--.[SB[0F9<#'*^6K-N^Z,8SGBNJ&I,8V;8."!UKR.Z_9XENOC]
M:?%?^W)$U>VMO[+2S$"F$Z<8SN@/.=YE/F>9U&-O3->L+82B)EP,D@]: %_M
M5O\ GF/SIZ:DS*YV#Y1GK4']FS>B_G3X]/E59 0/F&!S[T +_:K?\\Q^=/CU
M)G)&P#@GK4']FS>B_G3H]/E5CD#H1UH S]8T_2_$$EL^IZ5:Z@UMYGDFYC$G
ME[T,;XR.-R,RGU!([U<TEK?2[.TT^RM([2RMXU@AAB&$C11A54=@   *=_9L
MWHOYTZ'3YDD5B!@'UH J:I#8ZY';)J&GV]ZEO<1W4*SJ'"3(<HX!'#*>0>QI
M=#M['P[I\.G:7I]OI]C&S&.WME"1IN8LV% P,LQ/XU8_LV;T7\Z5=/F5E.%X
M.>M &K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45A:I>2PW,VV1@JKNP#Z#-?.7@/\
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ME37KDMY.(H2)6!(.>?>@#H**YK[;<?\ /9_SJ4WD_P!G4^:V=Q[^PH Z"BO
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sdgr-20241231_g12.jpg
<TEXT>
begin 644 sdgr-20241231_g12.jpg
M_]C_X  02D9)1@ ! 0  D "0  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        "0     0   )     !  .@ 0 #     0 !  "@
M @ $     0   ZB@ P $     0   20     _^T .%!H;W1O<VAO<" S+C
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M .1Z/^(59A_S\A]\O_D0_P"(EX#^2?W+_P"2/Z&**_GG_P"&W/VH?^AV;_P
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M_B)> _DG]R_^2/Z&**_GG_X;<_:A_P"AV;_P L/_ )'H_P"&W/VH?^AV;_P
ML/\ Y'H_XA5F'_/R'WR_^1#_ (B7@/Y)_<O_ )(_H8HK^>?_ (;<_:A_Z'9O
M_ "P_P#D>C_AMS]J'_H=F_\  "P_^1Z/^(59A_S\A]\O_D0_XB7@/Y)_<O\
MY(_H8HK^>?\ X;<_:A_Z'9O_   L/_D>C_AMS]J'_H=F_P# "P_^1Z/^(59A
M_P _(??+_P"1#_B)> _DG]R_^2/Z&**_GG_X;<_:A_Z'9O\ P L/_D>O7_@-
M^UK^T)XR^*6E^'?$GBQKS3[BWU%Y(OL=DF6@L9YHSN2!6&'13P><8/&16&)\
M,<?2IRJRG"T4WN^FO\IKA_$7!5:D:<82NVELNOS/VYHK^><_MN?M09/_ !6S
M?^ %A_\ (]'_  VY^U#_ -#LW_@!8?\ R/6__$*LP_Y^0^^7_P B9?\ $2\#
M_)/[E_\ )']#%%?SS_\ #;G[4/\ T.S?^ %A_P#(]'_#;G[4/_0[-_X 6'_R
M/1_Q"K,/^?D/OE_\B'_$2\!_)/[E_P#)']#%%?SS_P##;G[4/_0[-_X 6'_R
M/1_PVY^U#_T.S?\ @!8?_(]'_$*LP_Y^0^^7_P B'_$2\!_)/[E_\D?T,45_
M//\ \-N?M0_]#LW_ ( 6'_R/1_PVY^U#_P!#LW_@!8?_ "/1_P 0JS#_ )^0
M^^7_ ,B'_$2\!_)/[E_\D?T,45_//_PVY^U#_P!#LW_@!8?_ "/1_P -N?M0
M_P#0[-_X 6'_ ,CT?\0JS#_GY#[Y?_(A_P 1+P'\D_N7_P D?T,45^!_@?\
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M> _DG]R_^2/Z&**_GG_X;<_:A_Z'9O\ P L/_D>C_AMS]J'_ *'9O_ "P_\
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M :CXT?Q8QUF#Q%:V*7'V.SXMY+:61DV>1LY90<[<\=<5XU_PVY^U#_T.S?\
M@!8?_(]84?#''SYK3AH[;O\ ^1-:OB+@H*+<):J^R_S/Z&**_GG_ .&W/VH?
M^AV;_P  +#_Y'H_X;<_:A_Z'9O\ P L/_D>M_P#B%68?\_(??+_Y$R_XB7@/
MY)_<O_DC^ABBOYY_^&W/VH?^AV;_ , +#_Y'H_X;<_:A_P"AV;_P L/_ )'H
M_P"(59A_S\A]\O\ Y$/^(EX#^2?W+_Y(_H8HK^>?_AMS]J'_ *'9O_ "P_\
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M'\D_N7_R1_0Q17\\_P#PVY^U#_T.S?\ @!8?_(]'_#;G[4/_ $.S?^ %A_\
M(]'_ !"K,/\ GY#[Y?\ R(?\1+P'\D_N7_R1_0Q17XI?L[?M8?M >./C%H/A
M?Q3XK:^TN\2_,L)L[./<8;&>9/FC@5AAT4\'G&#QD5^U:$E%)ZD"OC^(>'JV
M6UHT:[3;5]+]VNJ78^IR//:684G6HII)VUMV3Z-]QU%%%>">T%%%% !1110
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M% !1110 4444 %%%% '_T?W\K\<_^"C7^O\ !7^]J'_HP5^QE?CG_P %&O\
M7^"O][4/_1@K[?P\_P"1M2_[>_\ 26?(<=_\BRK\OS1^8]%%%?TJ?ST%%%%
M'H]E\8/BEIUPEW8>*+^WF33TTI629@181_<M^/\ EFO85F6_Q&\>VEUHE]::
M_>P7/AN'[/ILD<S(]I$224B92"JDDY'?O7%T5SK"4OY%]R-WBJO\S^\[SQ1\
M4?B-XTUBS\0>*O$E]J6HZ<0;6>6=M]N5(8&+!&PY .5QSSUK4\3?&SXN>,]/
MFTKQ5XMU'5+*X,320SSLT;- =T;;>F5/.>N>37E]%)8*BN6T%[NVBT].Q3QE
M9\UYO7?5Z^O<])\2_&/XJ^,=!C\+>*O%FHZII,04"VGN'>-MOW=XS\^.V[..
MU<KXE\5>)/&6J'6_%6I3:K?LB1F>X<N^R-=J+D]E P*P**JEA:4/@BEZ)+??
M[R*N)J3^.3?J^P4445N8A7OMK_R;!J?_ &-EG_Z1S5X%7OMK_P FP:G_ -C9
M9_\ I'-7!F&T/\4?S._+_BG_ (7^1YIX'^(7C;X:ZQ_;_@36;C1;XKL:2!N'
M3KM=&!5U]F!%7O'_ ,5/B)\4[V#4/B!KUQK4MJI6$2D+'$&QNV1H%1<X&2%&
M<#/2O/Z*W>$I.I[9P7-WLK_?N<ZQ57V?LN9\O:^GW'5WWCGQ9J7A+3_ E_J4
MDV@Z5.]S:VA"[(II 0S @;LD$]3BNG^'_P ;/BM\+(9K7P!XENM(MKAM\D"[
M98&?^]Y4JNF[_: S[UY;12J8.C.#IR@G%ZM65K^@X8NK&2G&;376[N=OXY^)
M7CWXF:@FJ>/==NM;N(@1&;A\I&&ZB-!A$!QR% S73>!OCS\7OAIHK>'? OB:
MXT?3FE:<PQ)$09' #,2R,>0!WKR*BE/ T)4U2E33BNEE;[MAPQM:,W5C-J3Z
MW=_O.R\<_$+QG\2]877_ !UJLFL:@D:PB:4*&$:]%^0*.,^E7;[XJ?$34O$V
ME^,[O7KDZYHL,5O9WB,(Y8(8,^6BE .!N/7KG!S7 452PE)145!66BT6B>Z]
M"7BJK;DY.[U>O7N>F^/OC+\4/BC)92>/O$5QJXTX[K='")'&W]X1QJJ;CW8C
M)]:Y?Q;XP\3>.]:?Q'XNOWU+4I(XHFFD"ABD*A(UPH ^50!TKFJ**.$I4TE3
M@E;:R2M?>WJ%7%5:C;G)N^]WO;8]T^$'_(H?%G_L6!_Z<;2O)O#GB7Q!X0UF
MV\1>%]0FTO4[0[HKBW<I(A/7!'8]P>#WKUGX0?\ (H?%G_L6!_Z<;2O"ZYL/
M!2J5HR5U=?\ I*.BO)QITFGK9_\ I3/5OB!\<OBU\4[2#3_'WB:ZU>TMFWI
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MT#\9_ASHC>'/!7BR[TS3"6(MQLD2,MR3&)%;R\DY.S'//6MK]I/_ )*/9?\
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MO[D'^K&6?\^%^/\ F>%?\.UOA)_T.VL_]]6?_P 9H_X=K?"3_H=M9_[ZL_\
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MFOI;12?L.L<_\NO_ +42N>R?6L8<0YFI2:Q#N]]%V+EPWES23H+3U_S/"O\
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M !FO=<GUHR?6C_6/-?\ H)?W(/\ 5C+/^?"_'_,\*_X=K?"3_H=M9_[ZL_\
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M  [6^$G_ $.VL_\ ?5G_ /&:]UR?6C)]:/\ 6/-?^@E_<@_U8RS_ )\+\?\
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M7MK-',L_VA('5EN%@;&Z#:=Z@@ G KP^QD^,5CH>G6\L6KZ5X:GU349+C5M
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MG_7M;_\ HL5SM=%XH_Y"B?\ 7M;_ /HL5SM9T?@14]PHHHK0D**** "BBB@
MHHHH *Z35?\ D!Z-_N3?^AUS==)JO_(#T;_<F_\ 0ZSGNOZZ%QV9S=%%%:$!
M1110 4444 %%%% !1110!TJ?\BC-_P!?B?\ H#5S5=*G_(HS?]?B?^@-7-5G
M3Z^I<N@4445H0%%%% !1110 4444 %='H?\ QXZQ_P!>O_M1*YRNCT/_ (\=
M8_Z]?_:B5G5V*CN<Y1116A(4444 %%%% !1110 4444 =7X'_P"1JT__ 'G_
M /1;55_;$_Y-W\6?]<X?_1R5:\#_ /(U:?\ [S_^BVJK^V)_R;OXL_ZYP_\
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M>@U5VM7MI-1M]^Y#&D[7"JWEL%9H@IQU%9WQ!\/_ !0\1_%'1[AO#4.L^!M
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M%%% !1110 4444 %%%% !1110 5T:?\ (IR_]?B?^@-7.5T:?\BG+_U^)_Z
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M#_X\=8_Z]?\ VHE<Y71Z'_QXZQ_UZ_\ M1*SJ[%1W.<HHHK0D**** "BBB@
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M_/Y<?]\+1_PA^A_\_EQ_WPM7]:@3[-GFM%>E?\(?H?\ S^7'_?"T?\(?H?\
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MK4!>S9\:>'_V<_!N@^,(O%PN[B]:TN[R]MX)H[?Y)K[/G>9,L0FE3YB%1W(
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MQX8TBZO%EFN9T811KA54C"J *R_^$/T/_G\N/^^%J*6)BHI#E3=SS6BO2O\
MA#]#_P"?RX_[X6C_ (0_0_\ G\N/^^%J_K4!>S9YK17I7_"'Z'_S^7'_ 'PM
M'_"'Z'_S^7'_ 'PM'UJ >S9YK17I7_"'Z'_S^7'_ 'PM'_"'Z'_S^7'_ 'PM
M'UJ >S9YK17I7_"'Z'_S^7'_ 'PM'_"'Z'_S^7'_ 'PM'UJ >S9YK72:K_R
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M^^%H_P"$/T/_ )_+C_OA:/K4 ]FSS6BO2O\ A#]#_P"?RX_[X6C_ (0_0_\
MG\N/^^%H^M0#V;/-:*]*_P"$/T/_ )_+C_OA:/\ A#]#_P"?RX_[X6CZU /9
ML\UKH]#_ ./'6/\ KU_]J)73_P#"'Z'_ ,_EQ_WPM:NG>&-(@MK^..YG830[
M6)500-RG(]^*BIBHM#C3=SR"BO2O^$/T/_G\N/\ OA:/^$/T/_G\N/\ OA:O
MZW 7LV>:T5Z5_P (?H?_ #^7'_?"T?\ "'Z'_P _EQ_WPM'UJ >S9YK17I7_
M  A^A_\ /Y<?]\+1_P (?H?_ #^7'_?"T?6H![-GFM%>E?\ "'Z'_P _EQ_W
MPM'_  A^A_\ /Y<?]\+1]:@'LV>:T5Z5_P (?H?_ #^7'_?"T?\ "'Z'_P _
MEQ_WPM'UJ >S9@>!_P#D:M/_ -Y__1;5[+XX@^T^%[Z#^\H_F*Y/P[X:TFQU
MJVN[:YF>2,MA750IRI'./K7HNL6_VK3IH.NX?UKP\W:J)I=CU,JG[.K";Z-,
M^4?^$?']T4?\(^/[HKVS_A'_ /8H_P"$?_V*^!_L5]C]6_UG\R/X56'V&UU!
M<8WO'^@:O6:YCPU8?8(IQC&\K^F:IZ-\0_!/B'Q#?^%-%UFWO-6TS/VBWC;+
MI@X/LVTG#;2<'@X-?59=1Y*,8=KGYUG>)]MB9U>]OR.SHHHKM/*"BBB@ KGO
M"O\ R H/]Z7_ -&-70USWA7_ ) 4'^]+_P"C&H Z&BBB@#__U_W\KSF;_CT'
M_7>?_P!"KT:O.9O^/0?]=Y__ $*M:/Q$SV*-4-5U2PT33+O6=5G6VLK&)YYY
M7.%2.,;F8_0"K]<9\1I+.+P!XCDU'29]>M%T^X\[3[4@3W4>P[HHBQ #L.F3
MUKK.4^:?!'[;WPL\=>)M'\/6ND:YH]MXHDEAT+5M4LOLVEZK+$<%+:<.['./
MXD'IUXK6\??M8:-X'\2W_@+3?"FK>.?%NDQK-?V'AB!]16QA;HUS*R0A#CJH
M#$9&<9X_-GP-X_T'P5>_##3_ (%^,V\=Z9>:U!"/ /B'3K>ZU/0%>3;)(DH5
MF@:-3GS%*C(SCK7T=X5^)$'[.WC?X\>#_&^OZ;X)\6^*-?FUW0=7\0QS-I=W
M;72J(E:2/ES'ALHI!!)QT-2I&K@CZ'N/VS? %O\ "&'XU6^FWFJZ+)J*:2]I
M8#?J45](X00O;SB!=V6'1SP1C/2M'X??M8:?XM^)5G\,?%_@/Q'\/-2UI)'T
M@^(;,VOV]H03)'& 6 =5!/4C ZYXKX \??$OXA?%K]EV_O?%BZ;I@A\>:5:Z
M;J.C::^GVMRKW"[KR.&=B9"9#NRP&3PW>O;]'T3Q9X&_;)\.^'OVE_&-_P"-
MKJ*WN9_ VJW$=M96;W3JR3PS10QJ!<;<[?F/'X4<P<JL?>WQ=^*_A;X+^"+K
MQSXM=S;0R1P0PQ*7FN+B9ML<,2J"2S'VX )/ KPZR_;/^&;>!O$OBOQ'I^I^
M%=5\)M;Q7VAZO;-;:B)KOBWC2-=^\S'A,=R-VW-<E\1?COXT^&?P]USQS^U3
M\-=!TW3=*E@.@V]OJ4.KO>ZFQ?RE"21 0LBC?Y@Y5=Q'3GY"EB^%WQ+^"_C_
M .+?C?XEV6J?$/5[W2M9O9= A?4H= 6TE7[#!+#&-Q@1L"=\'&">QHYA*/<_
M0GPW^U=\/O$'@KQ9XMU"RU'PK=>!X([C6-,UZW:SO;6*8 Q,43S=PDR A7.2
M<<4_X4?M3>#OB[KUSX/TW1=6\->(([%-4MK/Q!;?8#>Z>Y %U RF7=%R,$@$
M]<8R1\-?!GQM87OC_P"-7[07QOUC1O'?A"VT#2K:_P!0L+(_V-J$\1+);6\-
MT")60E02PQO/;%>@?LN>+OAU^T3\5-:^+'C3Q)HUQXEUO1Y='T?PA93[Y=+T
M!6S()@N/WLF?G"XVACC&< N-Q/M#X:?M"_#GXN>./%G@7P)<2ZC+X/$(N[U
MALI7E)!2"0.2Y0@ACM"YX!.#7N-?"?[/_A_P_P"$_P!J[XR^&O"]A!I>F:?I
MFAQP6ML@CCB0(> HZ9/)/4GD\U]V52,V@K17_D%O_P!=1_(UG5HK_P @M_\
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MD;5K"&W,EZB,US$B;YDQE"TBC+KC[N21CI5ZO*?@18:OI?P2\ :;KX9=2M=
MTR.X#YWK(MM&"K9_B7H?<5ZM7')6=B K17_D%O\ ]=1_(UG5HK_R"W_ZZC^1
MI#1G4444""OA']O;X;^(O&?P<\2:^WBNYTWPSX=TB:YFT>U4(-0O5<>6\\O4
MQ("/W8ZL,GCBONZO,?C1X N/BK\)_%7PXM+Q=/F\16+VB7#H76(N0=Q4$$CC
MIFM*4K23&CX_^)=I;^*/AC^S7\--67S="\4ZKHD>IP$D1W5K;6+3_9Y ",H[
MJI([XKSOXXF+X$^.?C.GPOA30;36?AS)J3VUF/)@BO[><0"Y1%P%=HWVDC'
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M.#+<V]KJ3,([C!),5P%^?^\.AK(^%@M=._;B4)X(D^$MG=^&+BRLM/D5%7Q
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MID_4=>ZMEW_K]=#N?Q/M_5OPLPHHHH *Y[PK_P @*#_>E_\ 1C5T-<]X5_Y
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MDZ^OL>U<****0PKGO"O_ " H/]Z7_P!&-70USWA7_D!0?[TO_HQJ .AHHHH
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M?&+5_B'X0U_3?#6J3?#/2-;NEO(/M,,V&,SP1*TB[ S'E_F8+[\U]TR?LT?
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M)JQ-1112$=7X'_Y&K3_]Y_\ T6U=)^T1_P DEUGZP?\ HU:YOP/_ ,C5I_\
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M_HQJ .AHHHH _]/]_*\#\:?\>]K_ -=KC_T*O?*\"\:?\>]K_P!=KC_T*NS
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MN_VC/!.I>*9=4,/]@7,-A<7\#:<(0/L]L801#*)<DAL$GYLXK](2Q.,G..E
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M7TK[#!(.0<$4 D'(/-.Y2E8_-_QQX+\1_M$:A\7?&GA72KVUTV[\+VNA:/\
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MFF$VTPMKF>T2ZMV;>8;E('19HRPR4D# ^E?HF1Y7]2PU/#<UU&^NV[;V^?\
M6Q]CEF!6&PZH)WMU^=_Z_JWE7AOX_>(=;^)%GHTNEVB>&-5UB_T"UECD=KP7
MNG6YG>1_^69A?9(JX&1A3GFOJNO+M,^#7P[T?QJWC_3M,,.K$NRXFE^SQR2Q
MK%)+';EO)25T159U4,0,$UZC7KO9?U_6O^1VJ]W_ %_6G^84444AA7/>%?\
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MWA_Q"/AC_H74_P#P%'UQ_P -J?%S_H%^'_\ P E_^2*/^&U/BY_T"_#_ /X
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MTOO#_B$7#'_0NI?^ H^NO^&U?BY_T"_#_P#X 2?_ !^C_AM7XN?] OP__P"
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M+=F.Z6(,0#O' )X'85S/_"W_ !#_ - W2_\ P&;_ ..5S?CG_D*V7_8,L/\
MT0M<;7O8O/\ &QJRC&M*U^Y^<Y=PCEDJ$)2P\6VET/5O^%O^(?\ H&Z7_P"
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MUXP_Z!^E?^ K?_'*\3HH_P!;LS_Z")?>P_MO%_\ /UGMG_"^O&'_ $#]*_\
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M10 4444 %%%% 'K_ ,-/^10^)_\ V+R?^G"UKQ"O;_AI_P BA\3_ /L7D_\
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MM.K_ &F/S=[R$A;UH0P5<JX[ 5^TN]AP&Z<XS^M&]NF[WZ_K2^LOL',?DO\
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M)'S1,'C964@JR, RD'@BG]8>ET',?B?X2^&GA/Q]XT^/?A/X-:=J/A[2=/\
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M6#C'3C?BAXB\,^-_!G[/_P )/$MQK6MRZ5XVN(KGQ==7U[J++&\,<BVT<IM
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M2DFM]5R17;NFCX HK[__ .'=OQ8_Z&/1/^^KG_XS1_P[M^+'_0QZ)_WU<_\
MQFN;_5S&_P#/IGO_ /$:>%?^@^'_ )-_D? %%??_ /P[M^+'_0QZ)_WU<_\
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MS1_P[K^+'_0QZ)_WU<__ !FC_5[&_P#/IA_Q&OA7_H/A_P"3?Y'Y_45^@/\
MP[K^+'_0QZ)_WU<__&:/^'=?Q8_Z&/1/^^KG_P",T?ZO8W_GTP_XC7PK_P!!
M\/\ R;_(_/ZBOT!_X=U_%C_H8]$_[ZN?_C-'_#NOXL?]#'HG_?5S_P#&:/\
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MK%HI97B+/W'L_P F?"=%?4__  R;XY_Z"^G?G-_\;H_X9-\<_P#07T[\YO\
MXW7!_J=F?_/A_A_F?*?ZN8W_ )],^6**^I_^&3?'/_07T[\YO_C='_#)OCG_
M *"^G?G-_P#&Z/\ 4[,_^?#_  _S#_5S&_\ /IGRQ17U/_PR;XY_Z"^G?G-_
M\;H_X9-\<_\ 07T[\YO_ (W1_J=F?_/A_A_F'^KF-_Y],^6**^I_^&3?'/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sdgr-20241231_g13.jpg
<TEXT>
begin 644 sdgr-20241231_g13.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9("P0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"?SR^]?Y!_;%?^5?C_F?JO\ \-E?!S_H=8?_  !NO_C5'_#97P<_Z'6'_P
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M8PG\\OO7^0?VQ7_E7X_YGZK_ /#97P<_Z'6'_P  ;K_XU1_PV5\'/^AUA_\
M &Z_^-5^5%%'^K&$_GE]Z_R#^V*_\J_'_,_5?_ALKX.?]#K#_P" -U_\:H_X
M;*^#G_0ZP_\ @#=?_&J_*BBC_5C"?SR^]?Y!_;%?^5?C_F?JO_PV5\'/^AUA
M_P# &Z_^-4?\-E?!S_H=8?\ P!NO_C5?E111_JQA/YY?>O\ (/[8K_RK\?\
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M!NO_ (U7Y444?ZL83^>7WK_(/[8K_P J_'_,_5?_ (;*^#G_ $.L/_@#=?\
MQJC_ (;*^#G_ $.L/_@#=?\ QJORHHH_U8PG\\OO7^0?VQ7_ )5^/^9^J_\
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M_P!Y_P"E<37YT?5'I_\ PE^D?\_@_P"^&_PH_P"$OTC_ )_!_P!\-_A7F%%
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M?]\-_A1_PE^D?\_@_P"^&_PKS"B@#T__ (2_2/\ G\'_ 'PW^%'_  E^D?\
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MS^#_ +X;_"O,** /3_\ A+](_P"?P?\ ?#?X4?\ "7Z1_P _@_[X;_"O,**
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MP)9,;MH5AQ^(KR>ND\ _\AQO^N+?S% 'HE%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 8WC3_D3M=_Z\)__ $6U?BQ7[3^-/^1.
MUW_KPG_]%M7XL5^@\+?!6]5^I\QG/Q0^?Z!1117W1\V%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7J?[+7_ "<)X%_["*_^@M7EE>I_LM?\
MG">!?^PBO_H+5QXS_=JG^%_D;T/XT/5?F?IW\1O]58_[S_TKB:[;XC?ZJQ_W
MG_I7$U^('Z(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !72>
M ?\ D.-_UQ;^8KFZZ3P#_P AQO\ KBW\Q0 [X@_\AJ+_ *X+_P"A-7,UTWQ!
M_P"0U%_UP7_T)JYF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KI
M/ /_ "'&_P"N+?S%<W72> ?^0XW_ %Q;^8H ]$HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#&\:?\ (G:[_P!>$_\ Z+:OQ8K]
MI_&G_(G:[_UX3_\ HMJ_%BOT'A;X*WJOU/F,Y^*'S_0****^Z/FPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "ND\ _\AQO^N+?S%<W72> ?^0XW_7%OYB@#T2BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** ,;QI_R)VN_]>$__HMJ_%BOVG\:
M?\B=KO\ UX3_ /HMJ_%BOT'A;X*WJOU/F,Y^*'S_ $"BBBONCYL**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O4_V6O^3A/ O_817_T%J\LK
MU/\ 9:_Y.$\"_P#817_T%JX\9_NU3_"_R-Z'\:'JOS/T[^(W^JL?]Y_Z5Q-=
MM\1O]58_[S_TKB:_$#]$"BBB@ HHHH **** "BBB@ HHHH ^3?\ @I!\5_\
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MZ4J-=U)<DD#5C[=_9A^.<'[0/PFT_P 2^6EMJD;FSU.VC/RQW* %MO<*P97
M/0-C)Q7K-?GU_P $I-9F/_"Q])9B;=?L-TB_W6/G*Q_$!/RK]!:XJT5";BBE
ML%%%%8C"BBB@ HHHH **** "ND\ _P#(<;_KBW\Q7-UTG@'_ )#C?]<6_F*
M'?$'_D-1?]<%_P#0FKF:Z;X@_P#(:B_ZX+_Z$U<S0 4444 %%%% !1110 44
M44 %?*__  4G_P"3:IO^PO:?^SU]45\K_P#!2?\ Y-JF_P"PO:?^SUK2_B1]
M1/8^%/V'/^3JO /_ %\7'_I+-7[)U^-G[#G_ "=5X!_Z^+C_ -)9J_9.NG%_
M&O04=@HHHKA*/R%_X*$?\G5>*O\ KA9?^DL5?:O_  3=_P"39[3_ +"MW_-:
M^*O^"A'_ "=5XJ_ZX67_ *2Q5]J_\$W/^39[3_L*W?\ -:]*K_ C\B%N>B_M
M??\ )LWQ$_[!;_\ H2U^4'[-'_)PWPU_[&*P_P#1Z5^KW[7YQ^S-\1/^P6__
M *$M?E#^S1_R<-\-?^QBL/\ T>E&&_AR![G[)?%[_DD_C7_L"7O_ *(>OP_\
M#>*)/ _C;P_XCA@6ZET?4;?4$@=BJR-%(L@4D= =N,^]?N!\7O\ DD_C7_L"
M7O\ Z(>OPMTNR.I:G9V@.TW$R19]-S ?UHPGPRN$CZ;T_P#9W^._[84TGC_5
M&A^S7N6M+G6;DP1-'DX6WB 8K&.W !ZY/)KP7XB_#GQ)\'/&MUX>\1V;Z7K-
MDRN-CY5@>4DC<<$'J".X(X(('[J:7IMKHVFVFGV4*6UG:0I!!#&,+'&JA54#
MT  %?G3_ ,%5K&./QOX"O H$TVG7$+-CDJDJD#\Y&_.G1KN<^6V@-'O_ /P3
M]^.6I_&#X276GZ_=RZAKOARX6UDO)FW// ZEH6=NI8;74D\G8"2237EG_!5O
M_D7OAS_U]7O_ *!#6;_P2?<[_BBF?EQI9_\ 2NM+_@JW_P B]\.?^OJ]_P#0
M(:S45'$V7]:#Z'Q'X%^(7BC1?"OB+P1X:%P3XNGLX;E+)6:XN%B\T+;J%Y(=
MIN0.3M Z$@]UX;_8Y^*%QXV\+:3KW@[5M(TW5[Z*WEOFB#I!&6R[.RDA"$#'
M#8Z5Z#_P30\)VOB#]H.YU*ZB64Z+H\]W;EAG;,SQQ _]\225^JM:UJ[IRY8H
M25SY?_;3_:5/[-_@'3- \+"*'Q1JL1AL25#+86R *9=IZMR%0'C().=N#^</
MPY^%/Q"_:9\:7R:/#<^(-5/[^_U/4+@[(\YPTLKGJ<$ <DX.!P<>F_\ !1+Q
M!/K/[46NVDK[H])L[.SA']U3 LQ'_?4S5O\ [)'[9/A?]F_X?ZCHE[X5O]5U
M.^U!KR6]M9(T!38B(AW<X7:Q_P"!GUJJ<73I7@KM@]6>8?&;]E+XD?L]VEKK
M&O64+::TJJFJZ5<&6**7JH8X5D/H2 ">AS7U]_P3_P#VM-6^(%X_PY\9WSZC
MJ\,#3Z3J=PQ::X1!EX9&/+,J_,&/) ;)X&>.^,?_  41\'?%;X6^)_"4G@K5
M8VU6QDMX99YHF2*;&8I"/]EPK<<\5\I?LW^(IO"GQ\^'^I0L5*:W:Q.5."8Y
M)!'(/Q1V'XTW&56FU46HMGH?IS^W#\?-1^!'PC2;07$/B+6KC[!9W!&?LR[2
MTDP!X+   9[N#SC%?FU\&?@1X[_:F\6:N-(NH;F[@"W&HZKK5VV 7)"EVPSL
MS;6Z ]#G%?H;_P % O@EK/Q?^$-I=^';5[_6/#]T;P640W23P,A654'=Q\C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'WC\O0'=F_L':+\2OA9X_P!=T;6O GBK3- \1:;)$]Q=:-<Q10W,2,\+LS(
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M[MTOKF_)GU/0]X21I?XIH,X#;NK*3G=DC.[ RI2C1FX-Z#>J/=?!W[+G[/\
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M\5^*?[)_Q)^'.IWCS:'=Z_IHD9DU73$-PLBY^\ZKET/KN'7N>M<?\(OB-?\
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M_'NOV$^/?_)#OB#_ -@"_P#_ $G>OQ[KGX7_ (%3U_0USC^)#T/5?V6?#?\
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MZ.:>74JE-SPT[V/RJHH(P:*^U/GPHHHH **** "BBB@ HHHH **** "BBB@
MKU/]EK_DX3P+_P!A%?\ T%J\LKU/]EK_ ).$\"_]A%?_ $%JX\9_NU3_  O\
MC>A_&AZK\S]._B-_JK'_ 'G_ *5Q-=M\1O\ 56/^\_\ 2N)K\0/T0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "ND\ _\AQO^N+?S%<W72>
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M!DA0<D#GBOM2">*Z@CFAD2:&10Z21L&5E(R"".H(I3IRA\2"]R2BBOB35_\
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MM:34[A[=$M95C*%5#9.[KUK1TY*7);45SV:BOAG_ (>J^%_^A$U?_P #(O\
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M?$;_ %5C_O/_ $KB:_$#]$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG6TR:-%*KZIJFTB*UASEOFQ@R$9"KU)]@2/VNM;:.RMH;>%!'#$@C1!T50,
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M> ?^0XW_ %Q;^8H ]$HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6]7PO&NASW4:%5=C;1@.!V!-L>OJ*Z4J//'D%K;4\S_X)K>!['Q5\?KC4[^
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M63V#+V445U*<.:#T!'W[7X)>.O\ D=O$/_81N/\ T:U?O;7X)>.O^1V\0_\
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M9+<W6I>&+69HKSPY?,=L0W'>(MW,3@[C@<9SD&OV*GGCM8))II%BAC4N\CL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\<\C(RJ]2>@/Z]^'/#VG^$M T[1=*MEM-,T^W2UMH$Z)&BA5'Y#K6B    ,
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M!_Y#47_7!?\ T)JYFNF^(/\ R&HO^N"_^A-7,T %%%% !1110 4444 %%%%
M!1110 4444 -=%D1D=0RL,%2,@CTK\+_ (H>%KGX2_&#Q%HD:M#+HFK2I;,P
MY*))F)_H5V,/K7[I5^;O_!3WX/OI7BW1/B-8VQ^QZI$-.U&1!PMQ&/W3-[O'
ME?\ MC[UVX6=I\KZDR/T)\%^)K?QKX/T/Q!:8^RZK8P7T6#G"R(' _\ 'J^,
M?^"JO_(B^!/^PE<?^BA7I?\ P3Q^(\7C?]G;3M*>7?J/AN>33IE8_-Y98R0M
M]-C[!_US-?3E8I^QJ>@]T?E5_P $R_\ DXRZ_P"P#=?^C(:_56BBE5J>TES6
M!*QX?^UQ^SQ;_M"?"^XL;>.-/$^F;KK2+EL#]YCYH6/99  #Z$*?X:_'NSN]
M6\$>)HKF!I])US2;L.K8*2V\\;^AZ,K+T/I7[Z45I2KNFN5JZ$U<\K_9J^.-
MC\?_ (5:;XDA\N+4T'V75+1#_J+I0-P _NMD.OLP[@U^,WCK_D=O$/\ V$;C
M_P!&M7[VT44ZRI-M+<&KGF'[,'_)NGPV_P"P!9_^BEKT^BBN9N[;*"BBBD 4
M444 <C\6/AEI/QA^'VL^$M:0_8M1AV"51EX) <QRK_M*P!]\8/!-?CK\:?V?
MO&_[/?B=[;7+">.U27-CK=JK?9K@ _*R2#[K=#M.&'Y$_MQ45U:PWUO)!<0Q
MW$$@VO%*H96'H0>#712K.EIT$U<_$/Q;^T5\3?B!X;3PYKWC/5M5TCY0;267
M_6X/ D( :3G!^8GD"OIG]AS]C/7-3\7:9\0?&^F3:3HNFR+=:;I]Y&4FO)Q@
MQR,A&5C4X8$X+$+C(S7Z$Z9X \+Z)>_;-.\-Z187><_:+6QBCDSZ[E4&M^M9
MXF\>6"L*QR?Q5^&^E?%WX?:WX1UE3]@U.#RC(@^:)P0R2+[JX5A].>*_'?XS
M_L^>.OV=O%!CUBQN8K2*;=8Z_9!OL\V#E&20?<?C.TD,/R)_;2HYX(KJ%X9H
MTFB<;6CD4,K#T(/6LJ59TM.@VKGXD>*/VF?BEXT\,MX>UKQQJU_H[IY<EL\H
M'G+Z2, &<>S$UZE^RG^Q5XD^,NOV&M>)=/N=$\"PNLTL]RABEU!1SY<(/)4]
M#)T S@D\5^H]E\./"6FWHO+3POHMK=@[A/#I\*2 ^NX+FNBK:6)TM!6%8BMK
M:&RMHK>WB2"")!''%&H544#   Z #M7YS_MX_L>ZW%XMU'XD>"M,EU33-1)N
M-6T^S0O-;3_QSJ@Y9'^\V,E6W$\'C]':*YJ=1TY<R&U<_#SP=^T)\2OASX:G
M\-^'O&&J:/I#ELVD,@'E%C\WED@M&2<D[".<GK70?L[?LS>+/VA_%EM':VES
M:^'%F#:CKLR$11IG+A&/#RGLHSR03@9-?L)J/P_\+ZQ?&]O_  WI%]>$[OM%
MS8Q229]=Q4FMN"".UA2&&-(HD 5(T4*J@=  .@KJ>*T?+&S%RE/P]H%AX5T'
M3M%TNW6UTW3[>.UMH%Z1QHH55_  5\[?ML?LJO\ M!>%K75= $4?C31D86PD
M(5;V \FW9CP#GE"> 2P. Q(^F:*XXS<)<RW*/PLT_5/'GP!\:RM:RZMX,\2V
MP,4BD-!)M)Y5E/#J< \@@X!]*LZ]XK^(O[1/BVSCU&[U?QKKK#RK:W1#*R*3
MDA(T&%'<X '<U^W&M>&M(\20K#J^E66JQ+G;'>VZ3*,]<!@:-%\-:1X;A:'2
M-*LM*B;EH[*W2%3]0H%=OUI;\NI'*?//[$G[+,W[/OA.\U3Q (G\8ZTJ?:4C
M8.MG"O*P!AU;)RY'!(4#(7)^@_%>OP>%/"^L:W<D"VTVSFO)2QP-L:%S^BUJ
MU\T?\%!OB8G@']GC4].BFV:EXDE72X%!Y\L_-,V/3RU*GWD%<FM6>O4K9'YA
M_"WPG>?%GXN^'="*M<W&M:I&EPW?8S[I7/L%WL?H:_=)5"*%4!5 P .@K\WO
M^"87P?FU/Q?K7Q&OK8BQTR)M.T^1Q]ZYD \UE_W8SM/_ %U]J_2*NC%2O/E7
M040HHHKB*"BBB@ HHHH **** "BBB@ HHHH *Z3P#_R'&_ZXM_,5S==)X!_Y
M#C?]<6_F* /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH QO&G_(G:[_UX3_\ HMJ_%BOVG\:?\B=KO_7A/_Z+:OQ8K]!X6^"M
MZK]3YC.?BA\_T"BBBONCYL**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O4_V6O\ DX3P+_V$5_\ 06KRRO4_V6O^3A/ O_817_T%JX\9_NU3
M_"_R-Z'\:'JOS/T[^(W^JL?]Y_Z5Q-=M\1O]58_[S_TKB:_$#]$"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD#]KO\ 8:N_CSXWLO%?
MA74M-T;5)(/(U-;_ ,P)<%,"*0%%8[MN5.>RIZ&OK^BKA.4'>(K7.2^$^B>(
M?#7PX\/:1XKO+74=?L+1+6YO+-F:.?9\JOEE!W%0I;(^]FNMHHJ6[NXPHHHI
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<F86TIMU1[@(?+
M65BJ%L< D D#/< U+10!\,?#'_@G_P")X/CG!X]^(_B#1M>@%])JMQ;67FLU
MQ=%BZ;@Z* @<[B,GA0N,&ON>BBM)SE-WD*U@HHHK,84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !72> ?\ D.-_UQ;^8KFZZ3P#_P AQO\ KBW\
MQ0 [X@_\AJ+_ *X+_P"A-7,UTWQ!_P"0U%_UP7_T)JYF@ HHHH **** "BBB
M@ HHHH **** "BBB@ KD?BQ\-=+^+WP\UOPEK"_Z'J4!C$H7+0R#F.5?=6"L
M/IBNNHIIM.Z ^0/V0?V2/B#^S;X[U&_U#Q!H>H^'M4M/(N[2SDF\S>IW12*&
MC )4EEY/1VKZ_HHJIS<WS,6P4445 PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0?VO_V2?B#^TEXZTV^T
M[Q!H>G>'M+M?(M+2\DF\SS&.Z61@L9 )PJ\'HB^]?7U%7";@^9"W.1^$_P -
M=+^$/P\T/PEI"_Z)IMN(S*1AII#S)*WNS%F/UQ77445+;;NQA1112 **** "
MBBB@ HHHH **** "BBB@ KI/ /\ R'&_ZXM_,5S==)X!_P"0XW_7%OYB@#T2
MBBB@ HHHH *;(_EQLV,[03BG5'<?\>\O^Z?Y4 <3J7QC\->&[;[9XDU73O"^
MF[@AO]8OHK: .>B[W(&3S@9[5E_\-1?!G_HKG@3_ ,*6R_\ CM?'?_!2C_DV
MN3_L,6G\GK\H:[*5!5(\S9+=C^B+_AJ+X,_]%<\"?^%+9?\ QVC_ (:B^#/_
M $5SP)_X4ME_\=K^=VBMOJL>XN8_HB_X:B^#/_17/ G_ (4ME_\ ':/^&HO@
MS_T5SP)_X4ME_P#':_G=HH^JQ[AS']$7_#47P9_Z*YX$_P#"ELO_ ([1_P -
M1?!G_HKG@3_PI;+_ ..U_.[11]5CW#F/Z(O^&HO@S_T5SP)_X4ME_P#':/\
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M@3_PI;+_ ..T?\-1?!G_ **YX$_\*6R_^.U_.[11]5CW#F/Z(O\ AJ+X,_\
M17/ G_A2V7_QVC_AJ+X,_P#17/ G_A2V7_QVOYW:*/JL>X<Q_1%_PU%\&?\
MHKG@3_PI;+_X[1_PU%\&?^BN>!/_  I;+_X[7\[M%'U6/<.8_HB_X:B^#/\
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M1?!G_HKG@3_PI;+_ ..U_.[11]5CW#F/Z(O^&HO@S_T5SP)_X4ME_P#':/\
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M@3_PI;+_ ..T?\-1?!G_ **YX$_\*6R_^.U_.[11]5CW#F/Z(O\ AJ+X,_\
M17/ G_A2V7_QVC_AJ+X,_P#17/ G_A2V7_QVOYW:*/JL>X<Q_1%_PU%\&?\
MHKG@3_PI;+_X[1_PU%\&?^BN>!/_  I;+_X[7\[M%'U6/<.8_HB_X:B^#/\
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M7\[M%'U6/<.8_HB_X:B^#/\ T5SP)_X4ME_\=H_X:B^#/_17/ G_ (4ME_\
M':_G=HH^JQ[AS']$7_#47P9_Z*YX$_\ "ELO_CM'_#47P9_Z*YX$_P#"ELO_
M ([7\[M%'U6/<.8_HB_X:B^#/_17/ G_ (4ME_\ ':/^&HO@S_T5SP)_X4ME
M_P#':_G=HH^JQ[AS']$7_#47P9_Z*YX$_P#"ELO_ ([1_P -1?!G_HKG@3_P
MI;+_ ..U_.[11]5CW#F/Z(O^&HO@S_T5SP)_X4ME_P#':/\ AJ+X,_\ 17/
MG_A2V7_QVOYW:*/JL>X<Q_1%_P -1?!G_HKG@3_PI;+_ ..T?\-1?!G_ **Y
MX$_\*6R_^.U_.[11]5CW#F/Z(O\ AJ+X,_\ 17/ G_A2V7_QVC_AJ+X,_P#1
M7/ G_A2V7_QVOYW:*/JL>X<Q_1%_PU%\&?\ HKG@3_PI;+_X[1_PU%\&?^BN
M>!/_  I;+_X[7\[M%'U6/<.8_I-CU73OB+X-FN?#VJ:?JVE:I;RQ6^I6-RL\
M#J0R%D=,JV#D<'L1FOBS_AVOKG_0[Z?_ . +_P#Q5=C^P+XIU*']E3X<VZ3A
M85BN$"[%/'VN8=<5]BU6&Q^(R]RC0E:^^B>WJ<];"TL39U%>Q\$_\.U]<_Z'
M?3__  !?_P"*H_X=KZY_T.^G_P#@"_\ \57WM17=_;^8?S_@O\CF_LS"_P O
MXL^"?^':^N?]#OI__@"__P 51_P[7US_ *'?3_\ P!?_ .*K[VHH_M_,/Y_P
M7^0?V9A?Y?Q9\$_\.U]<_P"AWT__ , 7_P#BJ/\ AVOKG_0[Z?\ ^ +_ /Q5
M?>U%']OYA_/^"_R#^S,+_+^+/@G_ (=KZY_T.^G_ /@"_P#\51_P[7US_H=]
M/_\  %__ (JOO:BC^W\P_G_!?Y!_9F%_E_%GP3_P[7US_H=]/_\  %__ (JC
M_AVOKG_0[Z?_ . +_P#Q5?>U%']OYA_/^"_R#^S,+_+^+/@G_AVOKG_0[Z?_
M . +_P#Q5'_#M?7/^AWT_P#\ 7_^*K[VHH_M_,/Y_P %_D']F87^7\6?!/\
MP[7US_H=]/\ _ %__BJ/^':^N?\ 0[Z?_P" +_\ Q5?>U%']OYA_/^"_R#^S
M,+_+^+/@G_AVOKG_ $.^G_\ @"__ ,51_P .U]<_Z'?3_P#P!?\ ^*K[VHH_
MM_,/Y_P7^0?V9A?Y?Q9\$_\ #M?7/^AWT_\ \ 7_ /BJ/^':^N?]#OI__@"_
M_P 57WM11_;^8?S_ (+_ "#^S,+_ "_BSX)_X=KZY_T.^G_^ +__ !5'_#M?
M7/\ H=]/_P# %_\ XJOO:BC^W\P_G_!?Y!_9F%_E_%GP3_P[7US_ *'?3_\
MP!?_ .*H_P"':^N?]#OI_P#X O\ _%5][44?V_F'\_X+_(/[,PO\OXL^"?\
MAVOKG_0[Z?\ ^ +_ /Q5'_#M?7/^AWT__P  7_\ BJ^]J*/[?S#^?\%_D']F
M87^7\6?!/_#M?7/^AWT__P  7_\ BJ/^':^N?]#OI_\ X O_ /%5][44?V_F
M'\_X+_(/[,PO\OXL^"?^':^N?]#OI_\ X O_ /%4?\.U]<_Z'?3_ /P!?_XJ
MOO:BC^W\P_G_  7^0?V9A?Y?Q9\$_P##M?7/^AWT_P#\ 7_^*H_X=KZY_P!#
MOI__ ( O_P#%5][44?V_F'\_X+_(/[,PO\OXL^"?^':^N?\ 0[Z?_P" +_\
MQ5'_  [7US_H=]/_ / %_P#XJOO:BC^W\P_G_!?Y!_9F%_E_%GP3_P .U]<_
MZ'?3_P#P!?\ ^*H_X=KZY_T.^G_^ +__ !5?>U%']OYA_/\ @O\ (/[,PO\
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M/[?S#^?\%_D']F87^7\6?!/_  [7US_H=]/_ / %_P#XJC_AVOKG_0[Z?_X
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M*K[VHH_M_,/Y_P %_D']F87^7\6?!/\ P[7US_H=]/\ _ %__BJ/^':^N?\
M0[Z?_P" +_\ Q5?>U%']OYA_/^"_R#^S,+_+^+/@G_AVOKG_ $.^G_\ @"__
M ,51_P .U]<_Z'?3_P#P!?\ ^*K[VHH_M_,/Y_P7^0?V9A?Y?Q9\$_\ #M?7
M/^AWT_\ \ 7_ /BJZWX3?L'ZQ\-OB-H'B>7Q98WT>EW(N#;):NADP",;BQQU
MZXK[)JAKEU)9:1=3PMLE1,JV,X-1//,?4BX2GH]-E_D5'+L-&2DHZKS90\1>
M'YO$$=N/,CMS$23U;.<>P]*Q/^%=3_\ /['_ -\'_&M#P7K=YJ\EV+J7S1&%
M*_*!C.?0>U=37@'I'#?\*ZG_ .?V/_O@_P"-'_"NI_\ G]C_ .^#_C7<T4 <
M-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW_"NI_P#G]C_[X/\
MC1_PKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-'_"NI_\ G]C_ .^#
M_C7<T4 <-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW_"NI_P#G
M]C_[X/\ C1_PKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-'_"NI_\
MG]C_ .^#_C7<T4 <-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW
M_"NI_P#G]C_[X/\ C1_PKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-
M'_"NI_\ G]C_ .^#_C7<T4 <-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^
M-=S10!PW_"NI_P#G]C_[X/\ C1_PKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V
M/_O@_P"-'_"NI_\ G]C_ .^#_C7<T4 <-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?
MV/\ [X/^-=S10!PW_"NI_P#G]C_[X/\ C1_PKJ?_ )_8_P#O@_XUW-% '#?\
M*ZG_ .?V/_O@_P"-'_"NI_\ G]C_ .^#_C7<T4 <-_PKJ?\ Y_8_^^#_ (T?
M\*ZG_P"?V/\ [X/^-=S10!PW_"NI_P#G]C_[X/\ C1_PKJ?_ )_8_P#O@_XU
MW-% '#?\*ZG_ .?V/_O@_P"-'_"NI_\ G]C_ .^#_C7<T4 <-_PKJ?\ Y_8_
M^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW_"NI_P#G]C_[X/\ C1_PKJ?_ )_8
M_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-'_"NI_\ G]C_ .^#_C7<T4 <-_PK
MJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW_"NI_P#G]C_[X/\ C1_P
MKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-'_"NI_\ G]C_ .^#_C7<
MT4 <-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW_"NI_P#G]C_[
MX/\ C1_PKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-'_"NI_\ G]C_
M .^#_C7<T4 <-_PKJ?\ Y_8_^^#_ (T?\*ZG_P"?V/\ [X/^-=S10!PW_"NI
M_P#G]C_[X/\ C1_PKJ?_ )_8_P#O@_XUW-% '#?\*ZG_ .?V/_O@_P"-'_"N
MI_\ G]C_ .^#_C7<T4 <-_PKJ?\ Y_8_^^#_ (UI>'_"<VAWQN#.DV4*;<%>
MN/KZ5T]8GBW4KC2]*$UM)Y<GF!<[0>,'UH J>(?"DVNWJ7 G2#;&$VX+="3G
MMZUF?\*ZG_Y_8_\ O@_XUN>#]3N=5TR2:ZD\R02E0=H'& >WUK=H X;_ (5U
M/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&_P"%=3_\_L?_ 'P?\:/^%=3_
M //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C_A74_P#S^Q_]\'_&NYHH X;_
M (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&_P"%=3_\_L?_ 'P?\:/^
M%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C_A74_P#S^Q_]\'_&NYHH
M X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&_P"%=3_\_L?_ 'P?
M\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C_A74_P#S^Q_]\'_&
MNYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&_P"%=3_\_L?_
M 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C_A74_P#S^Q_]
M\'_&NYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&_P"%=3_\
M_L?_ 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C_A74_P#S
M^Q_]\'_&NYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&_P"%
M=3_\_L?_ 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C_A74
M_P#S^Q_]\'_&NYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:* .&
M_P"%=3_\_L?_ 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\'_&C
M_A74_P#S^Q_]\'_&NYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_QKN:
M* .&_P"%=3_\_L?_ 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['_P!\
M'_&C_A74_P#S^Q_]\'_&NYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?_?!_
MQKN:* .&_P"%=3_\_L?_ 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74__/['
M_P!\'_&C_A74_P#S^Q_]\'_&NYHH X;_ (5U/_S^Q_\ ?!_QH_X5U/\ \_L?
M_?!_QKN:* .&_P"%=3_\_L?_ 'P?\:/^%=3_ //['_WP?\:[FB@#AO\ A74_
M_/['_P!\'_&C_A74_P#S^Q_]\'_&NYHH X;_ (5U/_S^Q_\ ?!_QK2\/^$YM
M#OC<&=)LH4VX*]<?7TKIZQ/%VI7&EZ4LUM)Y<AD"YV@\8/K0!LJ20=P /L<T
MZL+P?J5QJNF2374GF2"4J#M XP/3ZUNT %%%% !4=Q_Q[R_[I_E4E1W'_'O+
M_NG^5 'YX_\ !2C_ )-KD_[#%I_)Z_*&OU>_X*4?\FUR?]ABT_D]?E#7JX;X
M#.6X4445UB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +NA_\ (;T_
M_KXC_P#0A7ZK_P#!2'_DV:\_["EI_P"A-7Y4:'_R&]/_ .OB/_T(5^J__!2'
M_DV:\_["EI_Z$U<E;^) :V9^3=%%%=8@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /V5_8*_P"37?AW_NW'_I9-7VW7Q)^P5_R:[\._]VX_]+)J^VZ\
M.I\;]31;!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R_$W_( OO\ KF:U*R_$W_( OO\ KF: .<^'/^MOO]U/ZUV]<1\.?];??[J?
MUKMZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_'O_(#7
M_KLO\C725S?CW_D!K_UV7^1H 9\/O^0++_UW;_T%:Z>N8^'W_(%E_P"N[?\
MH*UT] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1V8TSPS]K?\ ;1\)?LHZ);I?0MKWBR_C,EAH-O*$9DY'FS/@^7'D$ X)8@@
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MLPV/W'HHHKA*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N;\>_\ (#7_ *[+_(UTE<WX]_Y :_\ 79?Y&@!GP^_Y
M LO_ %W;_P!!6NGKF/A]_P @67_KNW_H*UT] !1110!^-'Q4_P""JWQN^'/Q
M\\8:'#/HE]X>T+Q->626,NG*KRVT-TZ",R Y!*+C<.><U^LOP?\ BOH'QO\
MAMH/C?PQ<_:='U>W$\><;XFZ/$X'1T8,K#U4U^ _CGX7:E\:OVW/'_@G1I8H
M=6U?Q?K4-HTYPC2K/<.BL>P8J%SVSGG%>_?\$Q?VJ[[]G'XP7OPE\=/+IGAK
M7;\VC1WN4_LG50?+RP/W5<J(WST(0G #9 /VLKYU_;Z^-WBC]GK]FW6?&G@^
M:V@URUO+2&-[N 31A9)E5LJ>.AKZ*KXW_P""M/\ R97XD_["6G_^E"T 7?\
M@FI^TIXV_:?^$'B7Q%XZN+.YU*PUU["%K*U6!1$+>%P"!U.Z1N:K_P#!2_\
M:;\<?LO?"_PIKG@6YL[:_P!1U@V4[7MJLZF/R)'P >ARHYKS3_@B=_R;MXU_
M[&J3_P!)+:JG_!;;_DA?@'_L8S_Z2RT ?+.F_P#!4;]J;6;47.GPV5];$E1-
M;>'/,0D=1E015A_^"G_[56GCS;G3K01_]-_#3*OY\5]S?\$B_P#DS+2/^PO?
M_P#HVOM&@#\?OA=_P6N\<:7J<4'Q#\$:-K>F[@LD^A&2RNHQGYFVR/(CD?W?
MD^HK]0_@C\<O!W[0W@*T\7^"-574])G8QR*R[)K:48W12H>4<9''0@@@D$$^
M?_M4?L8?#_\ :D\'WUIJVDVFF^*Q"W]F^);:$+<VTV/EWE<&6//5&R,$XVM@
MC\GOV%_B]XB_8Y_;"/@KQ%));Z5J&JGPOK]B)#Y*S>:8HK@9P#LDP=^/]6SX
M^]0!^[]%%% !575=4L]#TR\U+4+F*RL+.%[BXN9W"1Q1HI9G8G@  $D^U6J_
M/3_@L3^T.W@+X0Z7\,M)NS%K'BZ0S7_E-AH].B894XY'FR;5]"L<@/6@"3]E
M?]HOXG?MD_M;>*O$&AZ_>:#\"O"_R1:8EO&O]H.0RP*[LA<,Y#S, ?E553OD
M^X_\%"/COXK_ &<_V=KCQAX,GM;?6DU.UM0]W;B9-DA;=\I[\#FK?_!/[X*1
M? S]E;P7I+VHMM8U2V&M:H2N':XN 'VO[I'Y<?\ VSKS'_@K[_R9S>?]ARQ_
MF] &Y_P33_:6\;?M/_"3Q-X@\=7%G<ZC8:XUA UE:K HB%O$^"!U.YVYKZ]K
M\[O^")O_ ";YXX_[&AO_ $DMZ^F_VN?VNO"?[)7P]?6=9==0\07BM'H^@Q2!
M9KV4#J?[D2Y!9\<< 98@$ /VN?VN?"?[)7P]?6M:==0\07BM'H^@Q2!9KV4#
MJ?[D2Y!9R.,@#+$ _$_[('[5_P"UA^U_\0)+;3+_ $+0_!]E,&U;6SHBM%:H
M3D0Q;C^\E(Z+DX'+''7YR^"GP.^*?_!3CXZZEXQ\7:E<6WAR*=5U77-F(;6(
M<K96:'(W 'A>0H.]\EOG_:_X6_"SPQ\&/ VF>$?!^E0Z/H6GQ[(H(ADLW\4C
MMU=V/)8\DT =5&I2-59VD8  NV,M[G  _*N6\??%?P=\*X]*D\8>)M,\,PZI
M<_8[.;5+E8(Y9MI;;O; '"GDD#H.I%=77S_^UM^QKX-_:ZTG18?%VLZWHYT(
M3R6<VE7$<<:F0)O:1)$8-Q&OH0,\C)H ^>/V]_C[\3? '[1_P-T+X?>,9],\
M.>+WM[>6"SCAECNF:\1"P9D8\I*HX-?:NJ?&3P+HOCK2_!=[XMTB#Q=J;LEI
MHANT-W(0C.<Q@[E&U206 !Z#D@5_/M\2/!=WH?C3Q%;?"?Q=XA\=^"OAVXOH
M_$4<;6T>G,TT:--!MD8*#+Y>)$VEMF[&U=U???[ _P"P?\*/'=OX5^->E?$_
MQ%XKU;3[Z.],$<45BUK?QL'>*Z0F5V.<9 <!U8')5N0#]0**R_$'BC1O"=I'
M=:WJ]AHUM(_E)-J%RD",^"=H9R 3@$X]C6#_ ,+G^'W_ $/7AK_P;V__ ,70
M!V5%<;_PN?X??]#UX:_\&]O_ /%T?\+G^'W_ $/7AK_P;V__ ,70!V5%5=+U
M6RURPAOM.O+?4+*8;HKFUE62.09QE64D'IVKY/\ V^?V\/\ ACW3M%TW2O#?
M]O\ BG7H)IK.2[DV65LJ%5+2!3O<Y880;<\_,.A /1_VOOVJ_#G[*'PKO/$&
MIS0W/B&ZC>'0]&+?/>W..,@<B)"07;L,#[S*#XI_P2^_:C^(7[3WA?Q[?>/]
M3MM2N-)O;6&T-M9QVX1720L"$ SRHZU^;GC3X/?'/]I7P#XT_:&^(MS=1:%I
MMFMQ;WNJH8_MBM*J)#90<;809,[@ G7&YB:^RO\ @A[_ ,B-\5?^PE8_^BI:
M /TWK@?CC\;O"O[/7PWU3QKXPO?LFEV2X2*/!FNICG9!$I(W.Q' Z  DD $C
MOJ_&S_@L-\5=5^('[0GAKX5Z86FL]!M87^R1GF:_N\$9'?$?DA?3>_\ >H U
MM4_X*B_M&?'3Q/?6?P9^':0Z=$0(X;#29M7O(E.<--(/W:YP3]P 8/)QFKW@
M7_@K'\8/A!XYA\/_ !X\ _Z*2IN%739-,U2",\>8L<A"2#C(&%SS\U?I)^SK
M\"?#_P"SG\)M"\%^'[2"$6D"&^NXT"O?76T"6>0]2S,._0!5'  KS'_@H1^S
MMH_Q]_9O\4&6PCD\3^'K&;5]&O53,T<L2&1X5/7;*JE"IXR5;JHP >]^ _'6
MA?$SP=I'BGPUJ,6JZ%JMNMS:7<)^5T/J.H8'(*GD$$$ @U>\0:W;>&M!U+5[
MQMEGI]M+=S-Z(B%F/Y U^97_  10^--UJ&E^-_A9?W#2PZ>$UW2XV.?+1V$=
MRH]%WF%@/5W/>OL;]OGQO_PK_P#8[^*FIB3RY)]'?3(R#@[KIEMN/?\ ?9_"
M@#\VV_X+7?&<L=OA'P(%SP#9WI/_ *54G_#ZWXT?]"CX#_\  *]_^2Z]C_X(
ME?#BWD\%_$SQC>6D5P+O4+72;=YHPVWR8VED SZ_:(L_[HK],O[!TS_H'6G_
M 'X7_"@#\V_V*_\ @IS\3/VD/VB_#?@#Q'X>\)V&D:E%=O+<:7;7*7"F*VDE
M7:7N'7ED .5/&>E?IG52#2;&UE$D-G;PR#H\<2J1^(%6Z "BBJ>LZQ9>'M'O
MM5U&X2TT^Q@DNKFXD^[%$BEG8^P )_"@"Y17G'PO_:+^&OQHAUF7P3XQTWQ#
M%HZ1R:A);.0MLK[RK.6  !\M^?\ 9->5>+O^"E7[./@S5Y--N_B3:WUS&VUV
MTFRN;V$>XFBC:-A_NL: /IRBO-/@[^TI\,?C_;2R^ /&6G>(GA4/+:Q,T5S$
MIXW/!(%D49XR5Q7I= 'Y!?M7_P#!2_XW?"+]HSQ[X.\.ZCH\6B:/J+6UHD^E
MI(X0*IY8GD\FOL;_ ()N_M9:U^U5\)=;N_%DUI)XNT/4S;7?V2$1(]O(@>"3
M8.!DB5?^V>:_,?\ :(\+V/CC_@ISJOAS4T,FFZQX[L=/ND!P6BEF@C<?]\L:
M](_X)G>*M0_9P_;@\0?"S7Y?(75VN_#URK?*AO;9V>%_^!;)$7U\X4 ?M/11
M6%XZ\8Z?\//!6O>*-6D\K3-%L)]0N6SR(XHR[8]\*<>] 'YH?M[?\%*OB)\&
M/VB-3\#?#>\TN#2]%M((;Y[NR6X9[QU\Q\,3P%1XUQV96KZ8_P"":_[1_C3]
MIWX):_XG\<W%I<ZK9^(9M-B:RMA @A6VMI "HZG=*_/TK\=;[POJWQB\"_&'
MXWZ\7:5-8MDWY.U[R]N'E?;ZA$1ACMYBU^G7_!%+_DV'Q;_V.%Q_Z165 'IW
M_!1S6?BY\/?A%:_$7X4>*;O1Y/#4_FZUIL5O%-'=6;%1YI#HQ_=L!D#'R.Y/
MW17K?[+/[0^C?M/?!G1/&^E;(+F9?L^IZ>K9-E>(!YL1[XY#*3U1E/>O3M9T
M>R\1:/?:5J5M'>Z=?026MS;2C*2Q.I5T8=P5)!^M?D5^Q+XJN_V+?V^/%_P2
MUN[D3PWKM\=*@:=L+YW^LTZ<C^])'($X[S+_ ': /V"HHHH *YOQ]_R U_Z[
M+_(UTE<WX^_Y :_]=E_D: &_#_\ Y LO_7=O_05KIJYGX?\ _(%E_P"N[?\
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M.7/3C'N/9GYY_L__ !WO-#_;*\/?$O4YO*?4O$;SZDY;A8KR1DG/N%69B/\
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M-PF?S<#\:QH_Q(C>P_\ X)'Z7'8?LKW5PJX>]\17<[GU(B@C'Z(*^UZ^+_\
M@DM?)=_LHM$K!FM=?O(F'H2L3X_)P?QK[0HK?Q) MC\L/^"S^FQQ>+?A=J 7
M][/8W\#-ZB.2%@/_ "*?SKZ@LO&%S9_\$R(]:64_;(_AOY*2GJ'%EY0;Z@X/
MUKYD_P""T-\DGB/X5688&2*TU&4KZ!WMP#_XX?RKZ%O]#=/^"5BVJJP;_A74
M=V0.N/LRS'],UT/^'3OW%U/A3]@K]I+PM^RQX8^*?B_6K?\ M37;B/3]/T?2
M8G"2W;L;AY/F(.R-=D99L'&5&"2!7?7G[4O[:_QBM6\2^$?#NLZ3X<D436Z:
M%X:5X)$SP8Y)HY'E_P" L0?2O*?^";GP.T?XX?M(6T/B&U6^T3P_8R:U/9RH
M&BN722-(HY >"N^0,5/#!"#P37[C1QI#&J(H1% 5548  Z "KK3C">UWYB6I
M^4_P)_X*G^/? WC-?#/QQTTW]BDWV>[U!; 6>HZ>^<$RP*JJX'=0BL!DC<?E
M/ZGZ3JUEKVEV>I:==17VGWD*7%O<P.'CEC8!E=6'!!!!!]Z^!?\ @KG\$-&U
M?X5Z;\3;6TCM_$.D7L5C=W,48!N;67*J)#U)1PFTGH'8=QCM_P#@E!\0+WQE
M^RZ=+OIFF?PWK$^F6[.<D0%(YD&?0&9U'H% K&I&,X*I%6[C6]C[.HHHKD*"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R
M_$W_ " +[_KF:U*R_$W_ " +[_KF: .<^'/^MOO]U/ZUV]<1\.?];??[J?UK
MMZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#C?BA\(/"/QHT:PTCQIHT6O:797R:C%9SNXC,R(Z*7"D;@!(
MWRG(/<&MBXTBQT#PA<:=IEE;Z=I]M9O'!:6D2Q11($.%5% "CV K:JAK_P#R
M M1_Z]I/_033N]@/Q\_X)"_\G1ZK_P!BO=_^E%M7[)5^-O\ P2%_Y.CU7_L5
M[O\ ]*+:OV2KJQ7\0F.P4445R%!117FOQ[_:#\'?LX^!YO$OB_4/(C.4L["'
M#7-]*!GRXDR,GIDG"J#DD4TFW9 :WQA^+WAKX&?#[5/&'BJ]6STNQ3(0$>;<
M2D'9#$I^\[$8 ^I. "1^/W[-_@_Q)^W%^VE)XQUBU/\ 9D>J)KVM2*I,-O;Q
ML#!:@]]PC2(=]JLW.TU+K.M_&#_@I_\ &N.SLK<Z=X;L'S'!N8Z?HENQQYDC
M8'F3,!UQN<C "J/E_6']G?\ 9Y\*_LU?#NV\*^&("W(FOM1F \^^GQ@R2$?D
M%'"C@=R>W3#Q:^T_P)W/3Z***X2@HHHH **** "BBB@ HHHH **** "BBB@
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M#?#?P_I'@&TLK3PA%:1OIPL&#12Q.-PE#\[R^=Q<DEBV23FNOK\F_P#@DO\
MMK?V7=VWP/\ &E_BTN'8^%[ZX?B.0DEK(D]F.6C_ -K<O.Y /UDH *YCXG?#
MW3?BQ\/]?\'ZQ/>VVEZU:/9W,NG7+6\ZHPP=KCI[@Y!&0P()!Z>B@#YU_9?_
M &)/!7[-GPF\1^" 1XJ3Q)),-9O;Z (;V!@R1P,H)PBQ,5QGEF=N-V!4_9!_
M8;\,_L@W7BJ[T37]6UJYUV<C9=2>7!!;*[-#'Y2G:\BAL&5N3SM"!B#]*T4
M?-O[=O[*.H_M>_"[1/"FF>(+7P[/I^LIJC7-W TRNJP31[ %((.90<^U?#7_
M  X_\6_]%1T7_P %DW_Q=?H/^UM^U7HG[(O@'2O%6O:+J&N6NH:FFEI!IS(K
MJ[12R;CO(&,1$?B*^4/^'W'PY_Z)[XH_[_6W_P 70!Y/_P ./_%O_14=%_\
M!9-_\71_PX_\6_\ 14=%_P#!9-_\77K'_#[CX<_]$]\4?]_K;_XNC_A]Q\.?
M^B>^*/\ O];?_%T ?:?[-7PDN?@1\"_"'@*\U&+5KG0[4V[WL$9C24F1WR%)
M)'WL?A5OQU\ /A]\3O&FA>*O%OA:Q\1:SH<3Q:<^HJ9HK<,P9B(B=C-E5(9E
M)&.,5-\#?BU8_'7X3^&_'FF65QIMCKEN;B*UNRIEC =DPQ4D9RIZ5W= 'S=_
MP474)^Q/\4U4 *-/A  [?Z3#7RS_ ,$/?^1%^*O_ &$K'_T5+7U/_P %&/\
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M3 M-<D'@MQ/*,@C< ",<5K4J-)*.[$D>77'_  2U_9\\.>3I&N_$C6[;7K@
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M!7Y:5I1DY038/<*UO"?A/5_'7B73?#^@:?-JNLZC,MO:V=NN7E<] .P]23P
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M9W7E/%YL9QAMKJK#Z$ URQ3]M)VT'T/+:***ZA!1110 4444 %%%% !1110
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M0 #C&X?-.B:E^WM\(M*7PE9:?X@O+2 ""WF>SM-4\I0,#9<$2?*   &8@#C
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M\%)_^"=7B;XP^.K'XB_"30XM3UW4<6^O:4MU!:^8RK^[NU:9T0D@!'&<G"$
MY<T =!_P1._Y-V\:_P#8U2?^DEM53_@MM_R0OP#_ -C&?_266O3O^"77[/OC
M[]G3X,>*-"^(>@_\(]JM[X@>]@M_MEO<[X3;0(&W0R.H^9&&"0>.G2J__!4C
M]GCX@_M&?"CPCHWP\\/_ /"0ZE8:V;NY@^VV]MLB\B1-VZ:1 ?F8# )//2@!
MW_!(O_DS+2/^PO?_ /HVOM&OPT\+_L1?MP>!])32_#FG>)M TQ&9ULM+\;VE
MM"&;EB$2\ R>YQ6H_P"R%^WIJ(\JZN/&)B/7S_'T#+^0O#_*@#]6OVD?VH/
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M265U8IGY\)&"2692<%0#O.K#E;3$DQ?^"T'_ "+/PK_Z_-0_] @K\M*_4O\
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MCCX=_P"1@TS_ *^HO_0Q7['?\%8O^32T_P"P[9?^@RU^./AW_D8-,_Z^HO\
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MVX_]+)J^VZ^)/V"O^37?AW_NW'_I9-7VW7AU/C?J:+8****S&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !67XF_Y %]_P!<S6I67XF_Y %]
M_P!<S0!SGPY_UM]_NI_6NWKB/AS_ *V^_P!U/ZUV] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5S?CW_D!K_UV7^1KI*YOQ[_R U_Z[+_(
MT ,^'W_(%E_Z[M_Z"M=/7,?#[_D"R_\ 7=O_ $%:Z>@ HHHH **** "BBB@
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MP[L^-G_0#T__ ,&D/_Q5>B?\/4/&W_0F:!_W\G_^*H_X>H>-O^A,T#_OY/\
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M .*H_P"'J'C;_H3- _[^3_\ Q5%Z_9!H>=_\.[/C9_T ]/\ _!I#_P#%4?\
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MSXV?] /3_P#P:0__ !5'_#NSXV?] /3_ /P:0_\ Q5>B?\/4/&W_ $)F@?\
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MS0/^_D__ ,51>OV0:'G?_#NSXV?] /3_ /P:0_\ Q5'_  [L^-G_ $ ]/_\
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MQM_T)F@?]_)__BJ/^'J'C;_H3- _[^3_ /Q5%Z_9!H>=_P##NSXV?] /3_\
MP:0__%4?\.[/C9_T ]/_ /!I#_\ %5Z)_P /4/&W_0F:!_W\G_\ BJ/^'J'C
M;_H3- _[^3__ !5%Z_9!H>=_\.[/C9_T ]/_ /!I#_\ %4?\.[/C9_T ]/\
M_!I#_P#%5Z)_P]0\;?\ 0F:!_P!_)_\ XJC_ (>H>-O^A,T#_OY/_P#%47K]
MD&AYW_P[L^-G_0#T_P#\&D/_ ,51_P .[/C9_P! /3__  :0_P#Q5>B?\/4/
M&W_0F:!_W\G_ /BJ/^'J'C;_ *$S0/\ OY/_ /%47K]D&AYW_P .[/C9_P!
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M^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\ PF^D_P#/9_\
MOV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\ PF^D_P#/
M9_\ OV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\ PF^D
M_P#/9_\ OV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\
MPF^D_P#/9_\ OV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D*
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M^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\ PF^D_P#/9_\
MOV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\ PF^D_P#/
M9_\ OV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\ PF^D
M_P#/9_\ OV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D* +O\
MPF^D_P#/9_\ OV:/^$WTG_GL_P#W[-4O^%>6G_/U-^0H_P"%>6G_ #]3?D*
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M[-'_  F^D_\ /9_^_9JE_P *\M/^?J;\A1_PKRT_Y^IOR% %W_A-])_Y[/\
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M)(Q<)A@,<@_X4 ;7P_/_ !)9?^N[?^@K73US'P^&-%F_Z[M_Z"M=/0 4444
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MI_\ U\1_^A"OU7_X*0_\FS7G_84M/_0FK*M_$@"V9^3=%%%=8@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /V5_8*_Y-=^'?^[<?^EDU?;=?$G[!7_)
MKOP[_P!VX_\ 2R:OMNO#J?&_4T6P4445F,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "LOQ-_P @"^_ZYFM2LOQ-_P @"^_ZYF@#G/AS_K;[
M_=3^M=O7$?#G_6WW^ZG]:[>@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *YOQ[_ ,@-?^NR_P C725S?CW_ ) :_P#79?Y&@!GP^_Y LO\
MUW;_ -!6NGKF/A]_R!9?^N[?^@K73T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+1/$MI%JMM%!&$BCD_U<R #@'>A?';S!7R97Z[?\%2/!%C\8/V7_  M\4-"
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[*_L%?\FN_#O\
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M:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?LC_P2Y\.V?PY_8^O_&%PN3JU]?:K,X'S
M>3;CR0OT!@D/_ S7X]:UJUSK^LW^IWCF6[O;B2YF<GEG=BS'\R:_9S]E<*?^
M"8UL-.^:0^&-<V?]=?-N]W_C^:_%>N2CK.;\QOH?1'_!/;_D\CX9_P#7Y/\
M^DLU?I'_ ,%(OVI-9_9M\ :-:^#WAL?&'BF22!-3:)7>VM8 "[*"""VZ90NX
M$#<Y S7YN?\ !/;_ )/(^&?_ %^3_P#I+-7TG_P6<D8^.?AE&3\BZ=>,![F6
M//\ (4JD5*M%,:V/B!/CY\2X_$":X/B#XG_MA'WK>G5[@RYSGJ7Z>W2OV0^
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M35]MU\2?L%?\FN_#O_=N/_2R:OMNO#J?&_4T6P4445F,**** "BBB@ HHHH
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M"M=/7,?#[_D"R_\ 7=O_ $%:Z>@ HHHH **** "BBB@ HHHH **** "BBB@
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MRUF"\49Z&:#8?_2=:_0^LZL>2;2!;!7P%_P5H_:%OO 7P^T;X<:'=RV>H>*
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M$TC.B%/L\GW=Q4'=T XXJ:\)2LX;@F87_!5;XN?\+!_:3;PW:S>9IGA"S2P
M4Y4W,F)9V'OS'&?>*O0_^",__)3?B)_V![?_ -'5\">+?$]_XU\4ZQXAU27S
M]2U6\FOKF3^]+(Y=S^;&O<_V,_VN?^&1O$_B+5_^$4_X2O\ M>SCM/)_M'['
MY6U]V[/E2;L],8%5*F_9<D0OJ;'_  4Q_P"3U?B#_NZ=_P"F^VKY?KU#]ICX
MV_\ #17QJ\0?$#^QO^$?_M86P_L[[5]I\KRK>.'_ %FQ-V?+W?=&,XYQFO/-
M#T6]\2:UI^DZ; UUJ%_<1VMM GWI)78*BCW)('XUK!<L$F(_8K_@FC:P?";]
MB&[\6ZPWD:;<W>I>(96(P5@A41,?RM6/TQ7XXZI?R:KJ=W>S<S7,SS/_ +S,
M2?YU^MW[<WB?3_V6?V'?#OPET^Z#ZSJ]C!H<;1G!>&((UY/CT<_*1_TW]J_(
MBL*&O-/NQOL%%%%=0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH NZ'_R&]/_ .OB/_T(5^J__!2'_DV:\_["EI_Z$U?E1H?_ "&]
M/_Z^(_\ T(5^J_\ P4A_Y-FO/^PI:?\ H35R5OXD!K9GY-T445UB"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K]L?\ @HG_ ,F%ZU_USTG_ -*8*_$ZOVQ_X*)_\F%Z
MU_USTG_TI@KDK?'#U*6S/(/^"/OQ2BU_P+XV^&.I,L_V"8:I:02_,'MYAY<Z
M8_NJZH3[S&OSO_:$^%TOP7^-GC/P7(K+'I.HR16Q?J]NQWP,?]Z)D/XUZ!^P
M7\6_^%._M1^#-3GF\G2]2G_L:_).%\FXP@+'T63RG/\ N5]G?\%!/V5Y?B?^
MUC\'[VPMV^R>,I5T?59(AR@MCYCR$_WC;%\>T%%_9U7?9ANC5\ '_ACO_@F!
M>ZZ?]#\4>)[-KR(_=D^TWP$=N1[QP>6^#WC:O/O^"+__ ",WQ4_Z\]/_ /0Y
MZ9_P6#^*<*ZIX%^%FF,L5GIMN=8O+>+A%9@8;9,#H519CCTD6G_\$7_^1F^*
MG_7GI_\ Z'/633]C*3ZAU/F?_@HC_P GF?$K_KYM?_2."OLK_@CY\8EUGP9X
MM^&&H3"2;2I?[6T^.0YS;2D),@']U9-C?6<U\:_\%$?^3S/B5_U\VO\ Z1P5
MSW[&GQD_X45^T;X/\33S^1I+7(L-3).%^RS?NY&;V3*R?6,5O*'/12\A;,S?
MVK?A$WP-_:"\:>$$B,5A:WS3Z?QP;24"6'![X1PI]U-?I7_P3]\,Z?\ LS?L
M5:Y\3]?B\J?5H9_$%P&^5VM849;:(>N[:S+_ -=Q7)_\%0_V<+GXD_$WX/ZY
MHT!%UK^H1^$KR=%R%+OYENY^BFY))[(/2M#_ (*K_$>R^%GP \(_"70,6<>K
MM%&UM&?]5IUF$V(?0&3R<>OE-6+G[6,8=]_D/8_*WQ=XHU#QOXJUCQ#JLWGZ
MGJUY-?74O]Z61R['\V-?L1\$/^44UW_V(^N_^@W=?C#7[/?!#G_@E-=X_P"A
M'UW_ -!NZTQ&T?42/QAHHHKK$>D_LS?\G(?"G_L;-)_]+(J_0[_@LW_R(/PU
M_P"PG=_^BDK\\?V9O^3D/A3_ -C9I/\ Z615^AW_  6;_P"1!^&O_83N_P#T
M4E<E3^+ ?0_*BBBBNL04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?LK^P5_R:[\._P#=
MN/\ TLFK[;KXD_8*_P"37?AW_NW'_I9-7VW7AU/C?J:+8****S&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%SJ(1@1B.6XD:,_1DV-_P*OINL:B2FTAH****S&%%%% !1110 4444 %%%%
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M3Q!XD6&\^(FKPA+EXR'33H3@_9XV[L2 78<$@ <+EOKBBBN64G-\S*"BBBH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\??\
M@-?^NR_R-=)7-^/O^0&O_79?Y&@!OP__ .0++_UW;_T%:Z:N9^'_ /R!9?\
MKNW_ *"M=-0 4444 %1W'_'O+_NG^525'<?\>\O^Z?Y4 ?GC_P %*/\ DVN3
M_L,6G\GK\H:_5[_@I1_R;7)_V&+3^3U^4->KAO@,Y;A11176(**** "BBB@
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M?\%F_P#D0?AK_P!A.[_]%)7Y445,J?--2OL%] HHHK4 HHHH **** "BBB@
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MU15C;6;#30WVM98@!'>0JO+$*JJP7YAL5@#EB/TDHK2G-TY<R$U<_*WX;?\
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M1110 4444 %%%% !1110 4444 %%%% %W0_^0WI__7Q'_P"A"OU7_P""D/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!67XF_Y %]_US-:E9?B;_D 7W_7,T <Y\.?];??[J?UKMZXCX<_ZV^_W4_K7
M;T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUE^)O^0!??\ 7,UQ']N>(/\ GI<?]^O_ *U17>KZU/;21W#SF%AA@T>!C\J
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M:%QAD=20RD>H((J"@ HHHH **** "BBB@ HHHH **** "BBB@"[H?_(;T_\
MZ^(__0A7ZK_\%(?^39KS_L*6G_H35^5&A_\ (;T__KXC_P#0A7ZK_P#!2'_D
MV:\_["EI_P"A-7)6_B0&MF?DW11176(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#]E?V"O^37?AW_NW'_I9-7VW7Q)^P5_R:[\._\ =N/_ $LFK[;K
MPZGQOU-%L%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K+\3?\ ( OO^N9K4K+\3?\ ( OO^N9H YSX<_ZV^_W4_K7;UQ'PY_UM]_NI
M_6NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\>_P#(
M#7_KLO\ (UTE<WX]_P"0&O\ UV7^1H 9\/O^0++_ -=V_P#05KIZYCX??\@6
M7_KNW_H*UT] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-^/O\
MD!K_ -=E_D:Z2N;\??\ (#7_ *[+_(T -^'_ /R!9?\ KNW_ *"M=-7,_#__
M ) LO_7=O_05KIJ "BBB@ J.X_X]Y?\ =/\ *I*CN/\ CWE_W3_*@#\\?^"E
M'_)M<G_88M/Y/7Y0U^KW_!2C_DVN3_L,6G\GK\H:]7#? 9RW"BBBNL04444
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M8F$RWB&Y/F'Y>5$O/?/O7Y]UO3ES1O:Q(4445H 4444 %%%% !1110 4444
M%%%% %W0_P#D-Z?_ -?$?_H0K]5_^"D/_)LUY_V%+3_T)J_*C0_^0WI__7Q'
M_P"A"OU7_P""D/\ R;->?]A2T_\ 0FKDK?Q(#6S/R;HHHKK$%%%% !1110 4
M444 %%%?IO\ \$Q/@Y\)/CE\'-?@\6^!]'USQ+H>JF.2ZN8R9&MI4#1%B"/X
MEF7Z**SJ35./,P2N?F117=?';P$?A=\9_&_A,(8X=(UBZM8 >\*R-Y3?BFT_
MC7"U:=U< HK]?OV'_P!C#X7ZC^S)X1\0>/O!NE:SKVN;[\W6HJ=PCED*VZ*<
MC@H(R!ZN:^+O^"DWP&T?X%_M QQ>&=*BT?PSK6F07UI:6P(BA=<Q2HN?>,.?
M^NE8QK1E-P0['RE117Z+?\$LOV7?!GQ<\(^./%/CKPS9^)+-+Z#3=.2^0E8G
M2,R3$8(Y(EA_*KG-4X\S$E<_.FBO5/VII/#1_:%\>6_@[2[71O#5EJ<EA96E
MDN(@L&(BZ_[[(SY_VJ\KJT[JX!1113 **** "BBB@ HHHH **]]_9 _9)\1?
MM3>/X;2WBFL?"%A*CZSK)7"11Y!,49(PTS#@#MG<>!S]'_\ !5CX(> O@YHG
MPO7P5X4TSPV;N2_CN7L( CSB-;;9O;JQ&YN3SR?6LG42FH=0MU/SSHHHK4 H
MHHH **_0+_@G]^SUX:\)?#GQ/^T-\5M-M[KPKI5G.-)L-0@66.X"@K+/Y;C#
M$M^YC!ZL6[A37Q!\2/&C_$7QYKOB633[/2?[2NGG2PT^%8H+9"?DB15  55"
MKTYQD\DUG&?-)I= L<Y1116@!1110 45K^$/"&L^/O$^F>'?#VGS:KK6I3+;
MVMG ,O(Y[<\ =R20  22 *_4?X(?\$N?AW\,?"<7BKXXZQ#J-[ GGW5FU_\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<WX]_P"0&O\
MUV7^1KI*YOQ[_P @-?\ KLO\C0 SX??\@67_ *[M_P"@K73US'P^_P"0++_U
MW;_T%:Z>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBO)/VH_P!HK0OV7_@]J_C;6BL\\0^SZ9IV_:]]>,#Y<0]N"S'L
MJL><8(!ZW17Y%_\ !.#]KGXN?&_]K=-+\9>-M0U;1;RPO[QM+8JMLC@!E"(!
M\H7. .PK]=* "BOE/]O#]NC3/V0?"]C::=9VVO>/=85FT_2YY"(K>(9!N9PO
MS;-WRA007(;!&TD?!OA#QO\ M[?M6V?_  DWA:_UNT\/SNWV>XLY+31K3;_T
MR+%'E4=-P+]"">#0!^SU%?BSJ7[6?[97[%_B73T^*,5YJFDW+?+:^(XH;NVN
M@/O+'>0$D. "<"0XR"5(K]3/V8OVD_#'[4_PLL_&7AK?;'>;;4-,G8--87*@
M%HF(X888,K#AE8' .0 #UJBN0^+7Q5\.?!+X>:UXU\67OV#0])A\V:0#<[DD
M*D:+_$[L551W)'3K7Y,WO[</[5G[9GCS4-*^">F7.@:3:KN^PZ+'#OBB9L(]
MS>3X"N><;2@.#@'!- '[*T5^,'BGXX?MO_L77MAK/Q N+_5/#TLJQDZR8-3L
M9CG/EM/$2\3'!P-Z$X.,XK],OV2?VJ/#G[6GPNB\4Z-$=-U.VD^S:MHTDF^2
MQN,9QNP-R,/F5\#(R."&  /;:*;)(D,;.[!$4%F9C@ #J2:_*#]I+_@I]\0_
MB;\43\-_V<+4O$]S]CMM:M;,75[J<@^\8$<%(XN&^8J25&[*#B@#]8:*_&WQ
M$G_!0OX0Z))XYU34/$<UA;C[3=1"ZLM2$*#DE[5"^%P"3A<*.3BOKC_@GY_P
M4.@_:F$_@_Q?:VNC?$.R@\]#:Y6WU2%?OO&ISLD7@LF3D'<O 8* ?;5%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?C[_D
M!K_UV7^1KI*YOQ]_R U_Z[+_ "- #?A__P @67_KNW_H*UTU<S\/_P#D"R_]
M=V_]!6NFH **** "H[C_ (]Y?]T_RJ2H[C_CWE_W3_*@#\\?^"E'_)M<G_88
MM/Y/7Y0U^KW_  4H_P"3:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!1110 4444 %
M%%% !1110 4444 %%%% 'VO_ ,$C;J"W_:HO(YE!DG\-W<<)/9_-MV)_[Y5O
MSK=_X+&6TR_M">$9V)\A_"\2(.P9;NY+?HRU\\_L5_%6/X-_M-^!?$-U.MMI
MC7HL+^21L(EO< PN['T3>'_X!7WY_P %>_@Q>>*_AMX9^(>F6WGGPU-):ZD8
MQEA:SE-DA_V4D4#V\[/3...7NUTWU*Z'Y*T445V$A17V9_P3:_9,T3]HKQAX
MFU3QOH\VI>"])LOLX42RP++>R$;0LB,I)1 [$ \%DSP>> _;R^#7P_\ @+\<
MF\'^ )]0E@M["*?48[^Y6?[/<2%F$2$*" (_+;YBQ^?K6?M$Y\G4+'ZL>(/
M'BSX4?L11^#?A;ITMQXQL_#]OI]E%9R)%(;B78MQ.K.556S)-+G(YZ<XK\IV
M_P"">'[1+$D_#6\)/))O[/G_ ,C5^M'[3/QA\2^"OV4M2^)7P_>UEU*WLK+4
MX/M%OYT3VTCQ;SMR.D<A;/8+7YJ?\/8_CO\ \]O#G_@K_P#LZXJ/M+-QL6[&
MO^RU^R3^T;\$?C]X*\6_\(#?6.GVNHQ1:E(M]:$&RD8)< J)3N_=LQ P>0".
M0*]P_P""RW@&TF\'?#_QLD2)?6U_+HTLH'S21R1M-&I/HIAD(_ZZ&O ]*_X*
MG?M":[JEIINFQ:'?ZA>3);VUK;:.TDLTC$*J(H?+,20 !R2:XW]JS]I/X]?%
M7P;8>&/BSX8E\/:9!J*7T'VC09M/=ITCD0#=)U^65^/\*UY:CJ*4K"TL?6/_
M  1C_P"1'^)O_81L_P#T5)7Y\?M0?\G+_%O_ +&[5_\ TMEK]!_^",?_ "(_
MQ-_["-G_ .BI*_/C]J#_ ).7^+?_ &-VK_\ I;+3A_&D#V/U3\:?\HI+?_L0
M+#_T5#7XOU^T'C3_ )126_\ V(%A_P"BH:_%^C#[2]084445UDG[/?MW?\HZ
M)/\ KQT3_P!'6]?C'$_E2H^U7VD':W0^Q]J_9S]N[_E'1)_UXZ)_Z.MZ_'[P
M%X.OOB)XX\/^%M,V_P!H:UJ$&G6Y?[H>6144GV!;)]JY,/I!^HV?0GQ:_;M^
M+?[2WPYC^&NHZ7I4EK<W,,I70-/F2ZN1%DK$5$C*4W;6PJ Y0=JX/PS^QK\<
M/%I3^S_A;XF57^Z]]8M9H??=-L&/?-?JKK$7PG_X)D_ 2UU*WT,:GJTK+8+=
M10HNH:Q=LK.?,E()2/Y6..50   D@'X]\9?\%B/B;JID3PYX3\-^'X6SM>Z$
MU[,@[8;<BY^J4H3D_P"%'0=NY]!_\$U?V3?BE^SGKWBS5/'-G9Z1I^LV4,*:
M?'?)<3^=&Y*LPCW( %9QG<3STKX@_P""E<*P_MJ_$0*  W]GM@>ITZVS^M?9
M/_!-/]HWXI?M%_$_QY?^./$4VKZ9IVF0+#:1P1P6T$LDIVX2-0-VV-^3DXSS
M7QU_P4Q&/VU?B#[KIW_IOMJFGS>V?-O;_('L?HU_P36U&/2/V(/#5]-GR;5]
M3G?'7:MU,3^@K\7_ !MXNU'Q_P",-:\2ZO.USJ>K7DM[<2N<DN[%C^ S@#L
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MK_DJGC/_ +#5[_Z/>N4KJ_BU_P E4\9_]AJ]_P#1[URE=BV1(4444P"BBB@
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M>O?V\/CY?:\=7;XFZS%<;BPAA*);#)SCR OED?537Z._L8?M+6'[<_PJ\4^
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MVF;Q5JVG-8SWUO$FZTM3(CN_FR?)""40;S@] IR13P\;QFP9_0%17Y%^)_\
M@FG^TWJ,"ZW>>-M,\0:P 7\A_$-V]T#UP))8PN?^!X]ZP?@#^W/\6?V5?B0/
M!?Q:;6-7\/V\ZV^H:;KA:2_T]3C][!(V690,$(249?NXR&J?8<R]R5PN?LE1
M5/1]7L]?TFRU33KF.\T^]@2YMKF(Y26)U#(ZGN"""/K5RN0H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LO
MQ-_R +[_ *YFM2LOQ-_R +[_ *YF@#G/AS_K;[_=3^M=O7$?#G_6WW^ZG]:[
M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\L/BO^QQ\5_C3^W5/XH\6^";AOAW?^(85EO!>V[QOID&U%RJ2%T#
MQQ#@@$%^<&OU/HK6G4=-MH35R.WMXK2WB@@B2&")0D<<:A510,  #H .U>%_
MMS^#-$\:?LI_$:+7(H733M*GU2SEE',-U A>)E/4$L-G'4.1T)KWBOS)_P""
MI'[8VGWVF7'P8\'7PNYFF4^)+VV?*)L.5LP1U;<%9\=-H7DE@'1BY35@9E_\
M$8]>OU\1?$W1=S-ICVMG>%3]U)0\B CT+*QSZ[!Z5TW_  6@NM03PO\ "RWC
M+?V5)>:A). ?E,RI (L^^UIOS->R?\$T/V:;_P" WP:N=:\0VK6?BGQ;)%>3
MVLBX>UMD4_9XG'4/\[N1VW@$ J:]:_:X^$7@;XR?!+6=*\?ZK#X=T>SQ?1:]
M-(J#39U!5)<L0"/G*E2?F#$#!((VE4BJ_-T%;0X[_@G'I.AZ9^Q]X$DT2.)3
M>)<7%](B@-)=>>ZR%R.I&T*,_P *+7J/[1VB:)XA^ GQ!L?$<<3Z,VAWDD[3
M*"(]D3.L@S_$C*K ]BHK\;/A#^UKXW_8Z\4:WX=^'OB?2/'GA&2Z+K'<V4_V
M.Y<@#SHT;RY8WP IP=IQ_& #6C\?_P!OOXH_M(:<O@S7I]*\$>&;B=$OK?3[
M:=0Z[@0;AB9)&5"-VU ,X^ZQ K1X>;GS)Z"OH>H_\$<KW4(_CUXQM(F;^RY?
M#;RW"Y^7S5NH!$3[X>7'U-?7/_!4GXH77P[_ &6[W3K"X-O>>*+^+1F*'Y_(
M*O)-CV*Q[#[28[UL?\$^?@/\/?A%\))-5\%>*+/QU>ZZRMJ7B&SXC9D!VP*F
M=T83><JV&)8D@<*OS_\ \%H=0,?ASX566>)KO49L>NQ+<?\ M2INJF(0]D=M
M_P $C?A#8^&?@;J/CZ:U1M9\37TL,5T0"RV<#>6$4]1F42DXZX3/W17W;+$D
M\3Q2HLD;J59'&0P/4$=Q7S__ ,$_[!--_8[^&42*$5K"68@>KW$KD_B6)KZ#
MKFJOFFV-;'XJ>+[9/V+_ /@HTKZ*IL?#]KK<$Z01G:@T^\53+$!_=199$&>A
MC![9K]JZ_&?_ (*Y62V?[5%C,B[6N?#=I,Q'<B:X3/Y(/RK]A?#%\VI^&M)O
M&8LUQ:0S%CW+(#G]:WKZQA+R$C3HHHKC*"BBB@ HHHH **** "BBB@ HHHH
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MK'QF_P""0&@^(]8GU7X:^+3X;M[AVD.D:I";FWCSR!%*I#JH[!@Y_P!JN2\
M?\$:=2.JVTOC;XA6BZ:CYFM=!M7:65?199<!#[E&^E?#W@C]I;XK?#?3X=/\
M-?$+Q%I&G0?ZJQAU"0V\?^[$25'X"NEU[]MWX[^)+)K2\^*.OI"PVG['.+5B
M/]Z(*WZUCR5EHI#NC]4?B_\ 'GX4?\$^/@_;^$?#<%J^M6\#?V5X9@FWSRRM
MD^?<MG<JEN2[<MC"]./Q8\9^,-6^('BS5_$NNW;7VL:K<R7=U</QOD<Y.!T
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M=WJ.HW<^H:A>3/<7-W=2M++/*[%G=W8DLS$DDDY)))JHTVIN?<+Z'[+^-/\
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MPEN4\VU_)KBWY]JR/^"N?Q)_X2G]H;2_"D,NZU\+Z4B2)G[MS<'S7_./[/\
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M[0/^0[IW_7S'_P"A"J-7M _Y#NG?]?,?_H0KI$?L'_P5Z_Y-=TG_ +&BT_\
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ML5PS;G*XZ S1NV.V>.,5^VNH:A:Z58W%[>W,-G9V\;2S7%Q($CB11EF9CP
M,DFOQ-^-FL+^W)^WA'I_A=9;C1=0O[?2+:YC!;_0H.)KGV3 EE'L1WI8723?
M2P,_:ORK/Q)HJ+=VL5U97D*L]M<QAT=6 .UE(P?H:S/"OPY\)^!)[V;PUX8T
M;P]-?;3=2:5I\5LUQMSM\PHHW8W-C.<9->;_ +8Z>,[;]FWQC>_#W4KO2/%&
MF6R7UM+8<2F.)U:9%X/)B$F .<@5\?\ _!,/]L75O&7BOQ%X%^)/B^]U?6=3
M:.[T.YU>Y,A=U!6:W5F/!(V,JCKA^_7&-.4H.2Z#N?I57YE_\%E?AYIL=I\/
MO'$%M'%JLDL^D74Z\/-&%$D(/KL(EY_V_I7Z:5^0W_!53]H/2?B[\1O#7P^\
M)SIK-OX;:4W5U8OYJ37LQ1?)3;D,8P@!QGYI&7JM7ADW45A/8^VO^":WB6[\
M2_L=>"&O':66Q:[L$=NICCN)!&/HJE5_X#7T_7CW[(GPEN?@A^SEX(\(7Z"/
M5+2S,]\G]RXF=II4SWVM(5S_ +->PUE4:<VT-!11168PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\3?\@"^_ZY
MFM2LOQ-_R +[_KF: .<^'/\ K;[_ '4_K7;UQ'PY_P!;??[J?UKMZ "BBB@
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M;X#.6X4445UB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -?PCXLU;P'XH
MTKQ%H-[)IVLZ9<I=6EU%C='(AR#@\$>H/!&0<@U^F7@/_@JI\-_B3X/.@?&W
MP%YCLJB8VUG'J.GW)'\9AE.Z,YZ#Y_J*_+:BLITXU-P3L?K'IO[8W[%WPRND
MUSPMX)M3K,6989-+\+)'<QOZ))*$"'_=8"OD_P#;'_X*">)/VH+,>&M,T\^%
MO L<JS-8>;YEQ>R*<JT[@ ;0<$1KP#R2Q"D?)E%3&C&+ONQW"BBBMQ!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %W0_\ D-Z?_P!?$?\
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MW7AU/C?J:+8****S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWQ?:'?96]O&186$G:1=X#2R#^%F"A<Y"Y 8?;]%:2KSDK;!8****YQA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5E^)O^0!??\ 7,UJ5E^)O^0!??\ 7,T <Y\.?];??[J?UKMZXCX<_P"M
MOO\ =3^M=O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2WGBSP')=ZQJ%QJ$K2:E?%BTLC.<G['_ +58/_#E3XW_ /0T_#__ ,&-]_\
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M^0VLV/F8_P"_V/UKQ/XF_!+QY\&KY+3QMX3U3PY)(<127D!$,I[[)1E'_P"
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M_#%_QK_Z)]J7_?R'_P"+HYX=T%CQ6BO:O^&+_C7_ -$^U+_OY#_\71_PQ?\
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M .B?:E_W\A_^+HYX=T%CQ6BO:O\ AB_XU_\ 1/M2_P"_D/\ \71_PQ?\:_\
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MPH UJ*R?^$JTG_G]C_(_X4?\)5I/_/['^1_PH UJ*R?^$JTG_G]C_(_X4?\
M"5:3_P _L?Y'_"@#6HK)_P"$JTG_ )_8_P C_A1_PE6D_P#/['^1_P * -:B
MLG_A*M)_Y_8_R/\ A1_PE6D_\_L?Y'_"@#6HK)_X2K2?^?V/\C_A1_PE6D_\
M_L?Y'_"@#6HK)_X2K2?^?V/\C_A1_P )5I/_ #^Q_D?\* -:BLG_ (2K2?\
MG]C_ "/^%'_"5:3_ ,_L?Y'_  H UJ*R?^$JTG_G]C_(_P"%'_"5:3_S^Q_D
M?\* -:BLG_A*M)_Y_8_R/^%'_"5:3_S^Q_D?\* -:BLG_A*M)_Y_8_R/^%'_
M  E6D_\ /['^1_PH UJ*R?\ A*M)_P"?V/\ (_X4?\)5I/\ S^Q_D?\ "@#6
MHK)_X2K2?^?V/\C_ (4?\)5I/_/['^1_PH UJ*R?^$JTG_G]C_(_X4?\)5I/
M_/['^1_PH UJ*R?^$JTG_G]C_(_X4?\ "5:3_P _L?Y'_"@#6HK)_P"$JTG_
M )_8_P C_A1_PE6D_P#/['^1_P * -:BLG_A*M)_Y_8_R/\ A1_PE6D_\_L?
MY'_"@#6HK)_X2K2?^?V/\C_A1_PE6D_\_L?Y'_"@#6HK)_X2K2?^?V/\C_A1
M_P )5I/_ #^Q_D?\* -:BLG_ (2K2?\ G]C_ "/^%'_"5:3_ ,_L?Y'_  H
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M_"5:3_S^Q_D?\* -:BLG_A*M)_Y_8_R/^%'_  E6D_\ /['^1_PH UJ*R?\
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M)_Y_8_R/^%'_  E6D_\ /['^1_PH UJ*R?\ A*M)_P"?V/\ (_X4?\)5I/\
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MYYI7(554>I)%?I_\)O\ @E_\-OA9X%'BWX]^(DFEBC66[LUO_L6FV>?^6;S
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MO_X/A_\ (U?GO11]7I]@NS]"/^'L$7_1+W_\'P_^1J/^'L$7_1+W_P#!\/\
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M_P 'P_\ D:C_ (>P1?\ 1+W_ /!\/_D:OSWHH^KT^P79^A'_  ]@B_Z)>_\
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M?]$O?_P?#_Y&K\]Z*/J]/L%V?H1_P]@B_P"B7O\ ^#X?_(U'_#V"+_HE[_\
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MK_A7)_Z" _[\_P#V5'_"N3_T$!_WY_\ LJ[6B@#BO^%<G_H(#_OS_P#94?\
M"N3_ -! ?]^?_LJ[6B@#BO\ A7)_Z" _[\__ &5'_"N3_P!! ?\ ?G_[*NUH
MH XK_A7)_P"@@/\ OS_]E1_PKD_]! ?]^?\ [*NUHH XK_A7)_Z" _[\_P#V
M5'_"N3_T$!_WY_\ LJ[6B@#BO^%<G_H(#_OS_P#94?\ "N3_ -! ?]^?_LJ[
M6B@#BO\ A7)_Z" _[\__ &5'_"N3_P!! ?\ ?G_[*NUHH XK_A7)_P"@@/\
MOS_]E1_PKD_]! ?]^?\ [*NUHH XK_A7)_Z" _[\_P#V5'_"N3_T$!_WY_\
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M &5'_"N3_P!! ?\ ?G_[*NUHH XK_A7)_P"@@/\ OS_]E1_PKD_]! ?]^?\
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M=K10!Q7_  KD_P#00'_?G_[*C_A7)_Z" _[\_P#V5=K10!Q7_"N3_P!! ?\
M?G_[*C_A7)_Z" _[\_\ V5=K10!Q7_"N3_T$!_WY_P#LJ/\ A7)_Z" _[\__
M &5=K10!Q7_"N3_T$!_WY_\ LJ/^%<G_ *" _P"_/_V5=K10!Q7_  KD_P#0
M0'_?G_[*C_A7)_Z" _[\_P#V5=K10!Q7_"N3_P!! ?\ ?G_[*C_A7)_Z" _[
M\_\ V5=K10!Q7_"N3_T$!_WY_P#LJ/\ A7)_Z" _[\__ &5=K10!Q7_"N3_T
M$!_WY_\ LJ/^%<G_ *" _P"_/_V5=K10!Q7_  KD_P#00'_?G_[*C_A7)_Z"
M _[\_P#V5=K10!Q7_"N3_P!! ?\ ?G_[*C_A7)_Z" _[\_\ V5=K10!Q7_"N
M3_T$!_WY_P#LJ/\ A7)_Z" _[\__ &5=K10!Q7_"N3_T$!_WY_\ LJ/^%<G_
M *" _P"_/_V5=K10!Q7_  KD_P#00'_?G_[*C_A7)_Z" _[\_P#V5=K10!Q7
M_"N3_P!! ?\ ?G_[*C_A7)_Z" _[\_\ V5=K10!Q7_"N3_T$!_WY_P#LJ/\
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M &5'_"N3_P!! ?\ ?G_[*NUHH XK_A7)_P"@@/\ OS_]E1_PKD_]! ?]^?\
M[*NUHH XK_A7)_Z" _[\_P#V5'_"N3_T$!_WY_\ LJ[6B@#BO^%<G_H(#_OS
M_P#94?\ "N3_ -! ?]^?_LJ[6B@#BO\ A7)_Z" _[\__ &5'_"N3_P!! ?\
M?G_[*NUHH XK_A7)_P"@@/\ OS_]E1_PKD_]! ?]^?\ [*NUHH XK_A7)_Z"
M _[\_P#V5'_"N3_T$!_WY_\ LJ[6B@#BO^%<G_H(#_OS_P#94?\ "N3_ -!
M?]^?_LJ[6B@#BO\ A7)_Z" _[\__ &5'_"N3_P!! ?\ ?G_[*NUHH XK_A7)
M_P"@@/\ OS_]E1_PKD_]! ?]^?\ [*NUHH XK_A7)_Z" _[\_P#V5'_"N3_T
M$!_WY_\ LJ[6B@#BO^%<G_H(#_OS_P#94?\ "N3_ -! ?]^?_LJ[6B@#BO\
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M<)M\O;USWR?2O1ZYOQ]_R U_Z[+_ "- #/A\,:+-_P!?#?\ H*UT]<S\/_\
MD"R_]=V_]!6NFH **** "H[C_CWE_P!T_P JDJ.X_P"/>7_=/\J /SQ_X*4?
M\FUR?]ABT_D]?E#7ZO?\%*/^3:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!7[/_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _97]@K_ )-=^'?^[<?^
MEDU?;=?$G[!7_)KOP[_W;C_TLFK[;KPZGQOU-%L%%%%9C"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K+\3?\@"^_P"N9K4K+\3?\@"^_P"N
M9H YSX<_ZV^_W4_K7;UQ'PY_UM]_NI_6NWH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPA_X*/\ PG^-_P .8O _Q]TJ*TNW@6*\N[NS-SIM\R])<("\,A(#?=P#R&'
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M(PJC.&D.<'@ G.V924%=@?(U6)=.NX+=)Y;6:.!^5D>,A6^AZ&OV9\2_%_\
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MXPVWL+KW)78KGZST4U'61%=&#*PR&!R"/6G5RE!1110 4444 %%%% !1110
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M";/VFHHKQ[]J?]I/1/V7OA9=>*M4B^WW\K_9=+TM7"M>7)!(7/\ "B@%F;'
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MTE<WX]_Y :_]=E_D: &?#[_D"R_]=V_]!6NGKF/A]_R!9?\ KNW_ *"M=/0
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M-?\ KLO\C0 WX?\ _(%E_P"N[?\ H*UTU<S\/_\ D"R_]=V_]!6NFH ****
M"H[C_CWE_P!T_P JDJ.X_P"/>7_=/\J /SQ_X*4?\FUR?]ABT_D]?E#7ZO?\
M%*/^3:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!1110 4444 %%%;?@WP1X@^(GB"
M#0_#&C7NO:Q.&:*QT^%I97"J68A1S@ $F@#$HK5\4^%=7\$Z_>:'KVG7&DZO
M9L$N+*Z0I+$Q .&4]#@CCWK*H **** "BBMO1_ _B/Q%:&ZTKP_JFIVH8H9[
M.RDE3<.HW*I&>1Q[T 8E%:6M^&=8\-2Q1ZOI5]I4DH+1I>VSPEP.I 8#(K-H
M ***TM$\,ZQXEEECTC2K[59(@&D2RMGF* ]"0H.!0!FT5K:WX1UWPRD3ZQHN
MHZ4DQ(C:^M9(0Y'4#<!G&1TK1\ ?"_Q;\5=3N-.\'^'M0\27]O#]HEMM-@,T
MB1Y"[RHYQEE&?4CUI76X',458U'3KK1]0NK"^MI;.]M96@GMYT*212*2K(RG
MD$$$$'IBJ], HHHH **** "BBGV]O+=SQP01O--*P1(XU+,[$X  '))/:@!E
M%;NK> O$V@V3WFI^'=6TZT0@-<7=C+%&"3@ LR@<FL*@ HHHH ***UM$\(Z[
MXF25]'T74=52$@2-8VLDP0GH#M!QG!ZT 9-%*Z-&[*RE64X*D8(-)0 459T[
M3+S6+R.TL+2>]NI#A(+:,R.WT4 DUMZQ\-/%_AZR-YJOA76],M -QN+S3IHH
MP/7<R@4K@<W1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "OKKPM^
MQIH?Q9_8T3XE_#FYUG7_ (C:;>-%K?AY98I42-7<,(8EC$A<H891EFR-X )K
MY@M/ WB2_P!*_M2V\/ZK<:9L:3[;%92-#M7.YMX7&!@Y.>,&NA^#WQJ\??!/
MQ(-2^'_B"^T34KC;$\5J!+'<\X57A8,DG). RG!/&#6<DVO=8'IW['/[-GC?
MXI_'OPD+?0=1LM'T?5;>_P!4U.YMWBAMHH9!(RER!^\;;M51SDYZ D>Y_&+]
MJ/P]9_\ !3K0/&UI?1R>&O#ES#H%SJ"$>68RDD-S*"/O*AN)>>X3CC%>1_&#
M]L_]I7Q5X6ETGQ;K.JZ#HE\GV69(=(33A<Y'*F41J_(!RH8 C(QC-?+U1R.;
MO+T'<^N_^"A?[.GBSPC^T;XB\1V&A7NI^&/%=R-2T_4;&!IXWDD"F2,E </Y
MA; /4%2,YKU&70K[]D[_ ()H^(=)\50MI/C/XDZH/LFE3X%Q%;D0AO,3JN(8
MG8YY4S(#@G%?.7PI_;O^-GP;\-6_A[P]XP9]$MD*6UEJ-I#=BW'8(TBEU4=E
MW;1Z5YK\6/C/XU^./B4Z]XX\076OZD%\N-IMJQPIG.R.-0$C7/.% R>3S24)
MNT9;(+G%4445T"+NA_\ (;T__KXC_P#0A7ZK_P#!2'_DV:\_["EI_P"A-7Y4
M:'_R&]/_ .OB/_T(5^J__!2'_DV:\_["EI_Z$U<E;^) :V9^3=%%%=8@HHHH
M **** "BBB@ HHHH *^_/^".'_)=?&G_ &+9_P#2J"O@.OOS_@CA_P EU\:?
M]BV?_2J"L*_\-C6Y]V_#CXM[?VR?BY\-+N;AK#3=>T^,GO\ 9XH;@#_R7.!Z
M,:_'K]L+X3?\*5_:0\<>&(H?(TY+YKS3U PHM9P)8E'KM#[/JAKZR_:,^+7_
M  I+_@JAIGBF6;R=.B&G6NH,3A?LLULL4I/KM5R_U05O_P#!9#X38D\#?$JT
MAX8/H-_(!W^::W/_ *4#/LM<]/W)Q[-#>I^95?K'^QA:P_LI_P#!/[Q;\5K^
M)(=7UB*?58/-&"V/]'L8C[-(=P]IJ_+WX=>";[XE>/?#OA33!F_UJ_@L(3C(
M5I'"[C[#.3[ U^DG_!5WQO8_#;X0?#GX,: ?L]HR1W$L"GE+.U00VZ-ZAF)/
MUAK:M[SC3[B7<]Q_:3NIK[_@FC?7-Q*TUQ-X1TJ225SEG8_9B23W))K\Q/V2
MOV3KK]K'6_$&CZ;XKL/#NIZ5;QW8@O8'D-Q$S%69=IXV-L!S_P ]%K]-OVB/
M^48]Q_V)VD?RMJ_+S]B_XR_\*+_:/\'^(YY_(TF6Y_L[4R3A?LL_[MV;V0E9
M/K&*RHW]G+EWN-G-?M#_  ,UC]G/XK:KX'UJXBOKBR2*6*]@0K%<Q2('5U!Y
MQR5/NIKS:OU'_P""Q?P?^UZ-X,^)MG!F2TD;0]1=1DF-]TMNQ] &$PSZR**_
M,31M(O/$&L6.EZ? UU?WT\=M;P)]Z21V"HH]R2!732GSP4A-6/J;]F__ ()Y
M>)/VA?A--\0?^$JTSPIHJW$\4?\ :,$C^9%"!OFRIP%#;U^L;5['_P $X_V,
M]3U;Q)X+^.%KXHLGT2PU"]1=.:V=9Y502P!LYP,[@V#TZ5[W^V)K-G^R+^P1
MI_P^T>=8]2U"RA\,P/'P9-Z%KV;'^VHFR>S3"OA#_@G?XRU^#]JKX;Z%'KFI
M1Z(]Y<;M-6[D%LV;:9CF/.T\\].O-<_-.I"4D]![,_0W]N7]AS6_VL_$WA?5
M-*\3V&@)H]G+;/'>6[R&0NX8$;3QTK\<?B'X0F^'OC_Q-X6N+A+N?0]3N=,D
MN(U*K*T,K1E@#R 2N<>]?HA_P5Z\<>(_"?C_ .'L6A^(-4T:*;3+EI$T^]D@
M5R)5 +!&&3]:_-2\O)]0NY[JZGDN;J=VEEGF<N\CL<LS,>22222:O#J7(FWH
M)GZ]_#O5OV;_ -@3X4Z#XAN6@N/'NJZ/;W<D:LMYK-PTL2N44<"",D]]BD 9
M+$5ZO^P[^T_K/[57A_QOXEU/3[?1[&SUD66G:= =Y@@$*-\\F 7<EB2< >@%
M?A2[M*Y9V+L>K,<DU^MO_!&W_DBOCG_L8!_Z315C6I*,')N[&F?F)\:O^2R>
M//\ L/W_ /Z425QE=G\:O^2R>//^P_?_ /I1)7&5WK9$A1113 _3C_@D'\#X
MK:T\4?%[5HT15W:/I;RX 10%>YEYZ?\ +- WM(*^$/VD?BI)\:_CIXT\9EV>
MWU/49&M-W5;5/W<"_A$B"OU4TNT3X"_\$KW>V;R;B;P8UR95X9;C45W9SZJU
MT!_P$5^,5<M+WYRG\AO8]G_92_9FU+]JOXB:AX2TO6K70KBSTN35&N;R)I$9
M4EAB* +SDF8'/L:]=\+?\$QOB/XL^,GBCP;:ZC8PZ%X<GAM[SQ3<1NEO)(\$
M<WEPQ_>D<+*,C@#NPR >E_X(\?\ )S/B7_L4;K_TLLJ]T_X*B?M?ZY\,Y['X
M7>!M3?1]3O[4WFMZC:'9/%"YQ%#&XY1F"LS$?-MV $!C2G.?M.2([*USE=4_
MX(NRIII.F_%A)M053\EUH)CB=NPW+<,5'OAJ^'?C_P#LV^.OV:O%,>B>---6
M#[0I>SU&T<RVEX@."8Y,#D<95@&&1D#(SA> /C/XW^&'BV'Q-X:\3:CINL1S
M"9IUN&83MW$JDD2 C@A@017[ ^)X=*_X*!?L)?VH;)/[?N-.>\MHXEYM=7M@
MRE4SDA7=63N2DOK0Y3I-<[NF&C/QH\ ^#;_XB>-] \+:6N[4=9OH;"#(R \C
MA 3[#.3[ U^U/[6?Q$LOV*_V08].\%QKIEVL47AW0C& ##*Z,6G/JX1)9-W.
M7(SU-?E]_P $^=,BU;]L?X9P2D*B7LUP"W]Z.VFD7]4%?8/_  6BU.:+0OA1
MIZEOL\]SJ5PX'W=T:VRKGWQ*WZTJOO58P>P+:Y^7UY>7&HWD]W=SR75U.[2R
MSS.7>1V.69F/)))))/6H:**["3ZU_P""?'[8%I^S)XWU>R\575Z? NKVS/-!
M;(93!=H 8Y53/5@#&<8SE"3A:Y']N/XZ>!/VBOC&/&?@C2-5TGS[..WU!M4C
MCC:ZECRJ2A4=L?N]J\GHB\=:^>**S]G'FY^H7Z'ZQ_\ !&G_ ))5\0?^PU#_
M .B!7Y\_M>_\G2_%C_L9K_\ ]'M7Z#?\$:?^25?$'_L-0_\ H@5^?/[7O_)T
MOQ8_[&:__P#1[5A3_C2*>QY%7IW[./QZU[]G+XJZ3XOT.=Q'$XBU"R!^2]M2
M1YD3#H<@94]F"GM7F-%=32:LR3]J/^"DGPSTCXV_LFR^,],"WMYX>CBUW3+R
M(?ZRTDV"89_N&)A)]8EK\E?V??\ DO7PV_[&73?_ $JCK]D_AFW_  E?_!.'
M3X+GY5G^'4UDQ?\ NK8O$#^2BOQL_9]_Y+U\-O\ L9=-_P#2J.N.@[1E'L4S
M]1?^"Q/_ ";7X7_[&VW_ /2.\K\]/V2/V2/$W[57C@6-@'TSPO8NK:OKC)E+
M=#SY:=GE8=%[=3P*_7']M;]FW4?VI? _@_PC9W\>EV4'B6'4=3O6Y:&U2VN4
M8QK_ !.6D10.GS9/ -=O\*+'X9_!R6Q^#O@^ZT_3]3TW3_[0.BQRAKIHBP5K
MB7NS,Q!)/)R.,8K"%;DIVCN.UV>$_'S]H+X=?\$\/@_IW@;P1IMK-XF:W/\
M9FB!MQ!/#7EXPY()&><,Y&!@ E?QT\>^/=?^)_B[4O$_B?4Y]7UO493+<74Y
MR6/8 =%4# "C      KW[_@H/\!_%7P<^/NKZEKNH7OB#2O$TTFH:;K=ZV]Y
M5R-T#GH'BRJX&!MV$  X'S%791A&,>9:MDL*_43]C/PQ^S[^SQ^SQX2^-'C^
MXL8_&.J+<3P2ZF_VBXC,=S+$HL[8#.<1C+A202?F4<#\NZ5G9PH9BP48&3G
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M!1110 4444 %%%% !1110!^RO[!7_)KOP[_W;C_TLFK[;KXD_8*_Y-=^'?\
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M8N9!&EM;1YV^I=CPBCDEF(  ))K]A]6>Q_X)\_L%G3+G4(CXFBL9;:WDA/\
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M )&_XH?]>-C_ .C)J_-^OT@_X(P_\C?\4/\ KQL?_1DU<]?^&QK<^8/V_/\
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M%&;#X-"_\#?#BXM]5\= -#>:F,26^D'H5 Z23C^[]U#][)!6MK_@I1^UY>?
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M]/2&>5!A9)SEYF'L9&<CV->A5E4ES3;!!11168PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LOQ-_R +[_ *YFM2LOQ-_R
M +[_ *YF@#G/AS_K;[_=3^M=O7$?#G_6WW^ZG]:[>@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%/VR?C-J?P#_9T\6>,
M=%A276+>.*VLVE^[%+-(L2RD=]F_=CH2H!XK\FOV,OVE? /[/OCS6_'GCG0=
M<\7>,;DLME=0-$RV_F9,\S-(X+2N3C=V!;D[SC]K?'_P\\.?%/PO<^'/%>DP
M:WHERR/-97&=CE&#*3@@\, ?PKR?_A@WX _]$PT;\Y?_ (NNJG4A&#C);DM'
MSO\ \/DOAU_T(OBC_OJV_P#CE?!?P._:&TCX6?M<P_%N^TR]O-(34M3O386Y
M3[1MN8;A$')"Y!F4GGL<5^OG_#!OP!_Z)AHWYR__ !=?EA^S)\+_  KXR_;^
MM_!&M:+;ZAX4;6=:MSI<N[RC'#;W;1+P<X4QH1S_  BNBDZ5I<JZ"=S]3/V4
M?VP_#O[6MOXFET#0]3T4:"ULLPU(QGS/.$A7;L8]/*.<^HK\F_VR_"#O^W%X
MYT.X(M?[1U^$[VZ*MRL3AORD!K]IOA9\"O 7P2CU)/ WAFS\-KJ1C-V+3=^^
M,>[9G<3TWM^=?F]_P5S^"&H:!\1-"^+.EP2#3=3@BT_4+B+.8+R+/E.Q[;XP
M #ZPGU&<Z$HJJU'1,;V/U.T'0M/\+Z'I^CZ3:1V&F:?;I:VMK",)%$BA44#T
M  %+KNAV'B;1-0TC5;6.^TR_MY+6ZM9AE)8G4JZ,/0@D5X;^R#^UEX9_:7^'
M.ES1ZG:P>-;:W6/6-%>0+.DRC#2HAY:)C\P9<@9P>016A^U;^U-X8_9F^'.I
M:G?:A:R^*9K=UT;12^Z:ZN,84E!R(U)!9C@8X!R0#R\DN;EZC/S"_P""<$MU
MX+_;KTO0K68RV\RZKI=PZ'*R11P2R GVWP1G\J]8_P""SFB2P>./AGK!7]Q<
MZ=>6@;_:BEC8C\IA6=_P2,^#6I>(_BIKWQ2U""7^RM(MI+&TN7X$][-CS,'O
MLB+;O>5:^H?^"H_P3N_BK^SJ=;TJU:ZU?PC<G5-B#+M:%"MR /8;)#[1&NZ4
MTL0B>A[E^ROJ\>N?LT?"N\C.0WAC3D;_ 'TMT1A_WTIKU.OS\_X)8_M3:!K?
MPPM/A-KNI0:?XFT664:5'<R!/M]K(YDVQDGYI$9W&SKMVD9PV/L3XV?''PE\
M ? U]XG\6ZG%9VT,;&WM=X^T7LH'RQ0H3EF)Q[#J2 ":XJD&IN)2V/R8_:G4
M^._^"G%Q8VB&8S^)=%T]4'.66.UC;_QX-7VU_P %9-$EU7]DZ2ZC7<FF:[97
M<A_NJ1)#G\YE'XU\B_\ !/CP/K/[2'[8VL?%?6("MAI-Y<Z]>2!28S>3L_DP
M*3_=+LX]!#CN*_3[]HWX5+\;O@;XT\$X3[1JVGNEJ9#A5N4(D@8GT$J1D^PK
MJJ24)P7:PEL?-G_!(O5X]0_9<U"U4_O+#Q'=0LN>?FA@D!_\?_0U]MU^07_!
M,[]HFP_9Z^)WBGX;^/YO^$=LM9N%C6>_/EI8ZC"6C:.4GA X)4L> T:@X!)'
MZT:]XJT;POX?N-=U?5;/3-&MXO/EO[J=8X43&=Q<G&*QKQ:J/S&MC\O_ /@L
MYJ\<WCGX9:6#^]MM.O+EAGM++&H_]$FOT$_9:T:7P_\ LU_"VPGC,-Q#X:T_
MS8SU5S;HS ^X)-?E%\6==G_X*&?MQV&G>&UG_P"$=EDBTNUN3&0T.FP%GFN6
M!^[DM,Z@X^^BGDU^U-K:Q65K#;P1K%!"@CCC48"J!@ ?05=;W:<8/<2WN2T4
M45QE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S
M?CW_ ) :_P#79?Y&NDKF_'O_ " U_P"NR_R- #/A]_R!9?\ KNW_ *"M=/7,
M?#[_ ) LO_7=O_05KIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!,9I:_##]L.[\<_LH_MZS^)IK[4[[2U
MUV/Q7H\4]W(8+BV>;S7@7)(55;S82,< =,$5^R/P6^.7@WX_^![+Q1X+UFWU
M2QN(U::!)%\^SD(!,,Z Y1QG!!^HR""0#5^*GA73O''PS\5>']62&33=3TNY
MM9Q<*"@5HV!8_3.<]L9K\7?^"/FK7>G_ +8,-M;LP@O]!OH+E0>"@\N09_X'
M&E?H-_P4._;2\+_ ?X2^(/"NE:O::A\1=<LY+&TTR!_,>SCE!22XFQPFU2VT
M-RS8X(#$?-W_  1>_9[U"UO/$WQBU6U>WL9[9M$T4R+CS\R*]S,N>RF..,,.
MI,@_A- 'R]^V/^T/'\<OVQ+^;XAQ:@W@+PMJ\VCQ:-I+KYHM()F6386*J))F
M3+.>0& Y"**^T-%_X+._"7PYH]CI6E_#7Q-8:;8P);6UK;_95CAB10J(H$G
M   'M7U=K?["/P#\1ZS?ZMJ7PQT>\U&_N)+JYN)#+NEE=BSN</U+$G\:I?\
M#OC]G7_HE.B?G+_\70!^2?\ P4'_ &R/#O[8/B'P;J'A[0M4T./0[6X@F34S
M&3(9'1@5V,>!M/6OLW]D?_@J%X(N-&^#GP='A'Q -9%II'A;^T"T'V?SQ'%;
M^9]_=LW#/3..U?.O_!6GX#^ /@7XN^'5KX"\+V?AFWU&QO)+J.SW8E99(PI.
MXGH"?SK[W_9+_8]^#47P<^#GCM?A_I:^+CX?T?6?[6S)YOVPVT4IF^]C=O.[
MIC- 'UQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM>*_&EKI)T.+7;^2_P#[/-QY_DLYRWS[5W9;)^Z.M<3164:<(.\4%[A7UO\
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M]IN)P.0B@#$<>>=H]LEB :]QHHK)R<G=C"BBBI **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N;\>_\ (#7_ *[+_(UTE<WX]_Y
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MV/\ P67\;QZ=LO/A[H$]_MQY\%U/%%N]?+.XX]MWXU,85*6D=4/1GH7[ ?\
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MDD>5MSL7;U8Y--HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -Z
MR\?^*--\-W'AZS\2:O:Z!<EC-I4%]*EK+G&[=$&VMG SD=A6#110 4444 %%
M%% !1110 4444 %%%% '[*_L%?\ )KOP[_W;C_TLFK[;KXD_8*_Y-=^'?^[<
M?^EDU?;=>'4^-^IHM@HHHK,84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %9?B;_D 7W_ %S-:E9?B;_D 7W_ %S- '.?#G_6WW^ZG]:[>N(^
M'/\ K;[_ '4_K7;T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7-^/?^0&O_79?Y&NDKF_'O_(#7_KLO\C0 SX??\@67_KNW_H*UT]<Q\/O
M^0++_P!=V_\ 05KIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI^(]RB6US93#1+N=@"822[1 G_EI"^)8_8$<!!GU'_AMW]G3_H8[;_P0W?\
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MK6ML$O[B%U ,#2#&5X8;B"VUMH(48KQ6OUR_X;=_9T_Z&.V_\$-W_P#&*/\
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MV_\ !#=__&*/^&W?V=/^ACMO_!#=_P#QBCVT_P"1A;S/R-HK]<O^&W?V=/\
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MO,_(VBOUR_X;=_9T_P"ACMO_  0W?_QBC_AMW]G3_H8[;_P0W?\ \8H]M/\
MD86\S\C:*_7+_AMW]G3_ *&.V_\ !#=__&*/^&W?V=/^ACMO_!#=_P#QBCVT
M_P"1A;S/R-HK]<O^&W?V=/\ H8[;_P $-W_\8H_X;=_9T_Z&.V_\$-W_ /&*
M/;3_ )&%O,_(VBOUR_X;=_9T_P"ACMO_  0W?_QBC_AMW]G3_H8[;_P0W?\
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M?_QBC_AMW]G3_H8[;_P0W?\ \8H]M/\ D86\S\C:*_7+_AMW]G3_ *&.V_\
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M_P"_R_XT >E45YK_ ,(GKG_/!O\ O\O^-'_")ZY_SP;_ +_+_C0!Z517FO\
MPB>N?\\&_P"_R_XT?\(GKG_/!O\ O\O^- 'I5%>:_P#")ZY_SP;_ +_+_C1_
MPB>N?\\&_P"_R_XT >E45YK_ ,(GKG_/!O\ O\O^-'_")ZY_SP;_ +_+_C0!
MZ517FO\ PB>N?\\&_P"_R_XT?\(GKG_/!O\ O\O^- 'I5%>:_P#")ZY_SP;_
M +_+_C1_PB>N?\\&_P"_R_XT >E45YK_ ,(GKG_/!O\ O\O^-'_")ZY_SP;_
M +_+_C0!Z517FO\ PB>N?\\&_P"_R_XT?\(GKG_/!O\ O\O^- 'I5%>:_P#"
M)ZY_SP;_ +_+_C1_PB>N?\\&_P"_R_XT >E45YK_ ,(GKG_/!O\ O\O^-'_"
M)ZY_SP;_ +_+_C0!Z517FO\ PB>N?\\&_P"_R_XT?\(GKG_/!O\ O\O^- 'I
M5%>:_P#")ZY_SP;_ +_+_C1_PB>N?\\&_P"_R_XT >E45YK_ ,(GKG_/!O\
MO\O^-'_")ZY_SP;_ +_+_C0!Z517FO\ PB>N?\\&_P"_R_XT?\(GKG_/!O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1170S?#OQ7;Z>]]+X8UF.Q2(S-<OI\HC6,#)<MMP%QSGIB@#GJ*** "BBB@
MHJ_HOA[5/$ER]MI.FWFJ7")YC0V4#S.JY W$*"<9(&?<57O]/NM*O);2]MIK
M.[A;;)!<1E'0^A4\@_6@""BBI+>VENYTA@B>::0[4CC4LS'T '6@".BNIO/A
M5XUT^R-Y=>#]?MK, L;B;3)TC '4[BN*Y:B]P"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHK:T;P3XB\1VC76DZ!JFJ6RN8S-96<DR!@ 2NY5(S@CC
MW% &+12NC1L58%6!P01@@UM:CX&\2:/IW]H7_A_5;*P^4_:KFRDCBY^[\Q4#
MG(Q0!B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
MLK^P5_R:[\._]VX_]+)J^VZ^)/V"O^37?AW_ +MQ_P"EDU?;=>'4^-^IHM@H
MHHK,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%5M1U*TTBSDN[ZZ@LK6,9>>XD$:*/=B0!0!9HKGM#^(O
MA3Q-=FTT?Q/HVK70S^XL=0BF?CK\JL370T; %%%(S!022 !R2>U "T5S@^)'
MA(ZG_9H\4Z*=0R!]D&H0^;D\ ;-V?TKHZ=K %%%%( HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R_$W_( O
MO^N9K4K+\3?\@"^_ZYF@#G/AS_K;[_=3^M=O7$?#G_6WW^ZG]:[>@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **P=?\>^&/"DHBUOQ'I.CRD9":A?10,1ZX=A5[1?$&E^)+3[5I.I6>J6V
M<>=93I,F?3<I(IV8&A1112 **HZMKFFZ!:FYU/4+73K<=9KN98D_-B!5?0/%
MNA>*XGDT36M/UB-,;GL+J.<+GIDH30!K4444 %%17-U#90//<31P0H,M)*P5
M5'N3TK%TCX@>%_$-\UEI?B32-2O%)!M[.^BED!')!56)H WZ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\
M>_\ (#7_ *[+_(UTE<WX]_Y :_\ 79?Y&@!GP^_Y LO_ %W;_P!!6NGKF/A]
M_P @67_KNW_H*UT] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !7-^/O^0&O_79?Y&NDKF_'W_(#7_KLO\
M(T -^'__ "!9?^N[?^@K735S/P__ .0++_UW;_T%:Z:@ HHHH *CN/\ CWE_
MW3_*I*CN/^/>7_=/\J /SQ_X*4?\FUR?]ABT_D]?E#7ZO?\ !2C_ )-KD_[#
M%I_)Z_*&O5PWP&<MPHHHKK$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M);;3K?Q0UM_:"#2PJVNNP%=W 7Y1*1RK@?,3M;J&7\@B"I((P1U!K[5_8_\
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MZE^V!>?!AO'VH26,FCK?:;JUJL$C7%P$$CPD#Y>(Q(V1_<]Z\O\ VV?V4_\
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MUIX:*0W^D:9;Z'I<JC86NI,1M<?[XS+,?5@<]:JM-Q2C'=B2.+^+?[:OP/\
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M0?IK_P $=_A7':P>._BEJ*+%#&JZ)93R<*J@+-<MD]!_J!G_ 'J]H_X*V?\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110!^RO[!7_)KOP[_P!VX_\
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M5!ZLQPH'<D"OR$_X)]ZI<_!C]O23P<;AEMKJ?4_#=T7_ (_*WNF1Z^9;H/\
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MKW>'X"Q"XG!S[?(Q_&OS7_X)]?\ )XWPS_Z_9O\ TFFKFIZ1J16R&^A]+?\
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M^$?_  NC]IOP5H<\/G:7:W0U34 1E?L]O^\*M[.P2/\ [:5^C/[3,$7[7_\
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M(OSE\L?C7S55O2-5NM!U:RU.QF:WO;*=+F"9>J2(P96'T(!HDN:+0'W_ /\
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M-BGLSLRH#U 8MSMK]=/VG].^*OAWX16/@[]G[PK!#>31?8OMT%W;6<>D6JJ
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M<[_XI_L3?&;X3^(KG3+[P)K&LV\;[8M4T*REO;2<'[K*\:G&?[K!6]17TO\
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MNYQEW9B6=S@99B3P.>*ZNL:M3VCTV0TK!1116(PHHHH **** "BBB@ HHHH
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MF_GQAIIF\CDGL.BC@  5+_PY4^"'_0T_$#_P8V/_ ,AT?\.5/@A_T-/Q _\
M!C8__(= 'I/_  ]5_9H_Z'RY_P#!%?\ _P 9KU[X"_M2_#;]IF'6Y?AWKLFM
MIHS0K>F2QGMO+,H<Q_ZU%W9\M^F<8YZBOEC_ (<J?!#_ *&GX@?^#&Q_^0Z^
M@_V4_P!C'P3^Q_;^)8?!NJ:_J:Z^]N]T==N()2AA$@39Y4,>,^:V<YZ#&.X!
M^=?_  5W^ FO> /CCI_QHT2*8:/KBVR7%_ #_H6HP(J1[C_#OCCC*GN4?VS]
MN?LN?\%&_A9\=/!.FGQ!XGTKP7XUCA5-1TK6;E+2-Y@ &>WDD(5T8Y(4'<!P
M1QD_3_BGPKH_CCP]?Z#X@TRUUG1K^(PW5C>Q"2*9#V93Q[^Q (KX/^(__!&'
MX3^)]5FO?"OB37_!L<K%OL *7UM%[)YF) /]Z1J /5_VF?\ @HQ\)_@9X*U&
M;1/%.D^-?&#Q/'IVCZ)=I>*)\?*;AXV*QH"02"0Q&=H)Z?"W_!)CX%>(/BC^
MT'?_ !HUN&0Z-H3W4B7TB86\U*X1E95['8DKNQ'0F/UX^C_AW_P1>^%/AO5(
M;SQ5XGU_QA'$P;[ "EC;R^H?9F0C_==3[U]X^$O"&B> O#=AX?\ #FEVNBZ+
M81"&VL;*(1Q1*.P ]\DGJ223DF@#YY_X**_L]7G[1?[,VM:5HUM]J\3:+*NM
M:5"!EYI(E8/$ON\3R #NVSZU\7?\$M/VZ?"_PL\,W/PB^).J1^';.*\DN=%U
M>^.RVB,AS+;3,>(OGW.K-QEW!(PN?UNKY$_:/_X)B_"/]H;Q!=^)0E]X,\3W
M;&2ZOM#9!%=2$\O-"ZE2QY)9=A).6)H [3XZ_MX?![X(>"+S6I/&6C>)M3\H
MFQT30]0BNKB[DQ\B_NRWEH3C,C8 &<9. ?SK_P"":7PF\1?M*_M9:S\;_%-O
M(^EZ1?7&K37>PK#<:I,24A3VC$ADP/N[8P>&%?0O@S_@BC\-=(U2&Y\1^-O$
M7B*VCD#FSMXXK))5!^X[ .V#W*E3Z$5]Y_#[X=^&OA3X2L/#'A'1K70=!L5*
MV]E:+A%R<DDG)9B2268DDG))- '1T444 %%%% !1110 4444 %%%% !1110
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M%'MJ?<+,^-J*^R?^'6WQ-_Z&7PG_ .!%U_\ &*/^'6WQ-_Z&7PG_ .!%U_\
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M^!%U_P#&*/;4^X69\;45]D_\.MOB;_T,OA/_ ,"+K_XQ1_PZV^)O_0R^$_\
MP(NO_C%'MJ?<+,^-J*^R?^'6WQ-_Z&7PG_X$77_QBC_AUM\3?^AE\)_^!%U_
M\8H]M3[A9GQM17V3_P .MOB;_P!#+X3_ / BZ_\ C%'_  ZV^)O_ $,OA/\
M\"+K_P",4>VI]PLSXVHK[)_X=;?$W_H9?"?_ ($77_QBC_AUM\3?^AE\)_\
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M%'MJ?<+,^-J*^R?^'6WQ-_Z&7PG_ .!%U_\ &*/^'6WQ-_Z&7PG_ .!%U_\
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M4)1--8LS1-NGDD&TLJGHX'('.:^AO^%A6'_/"Y_[Y7_&O(F[R;1:.IHKEO\
MA85A_P \+G_OE?\ &C_A85A_SPN?^^5_QJ!G4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5R
MW_"PK#_GA<_]\K_C1_PL*P_YX7/_ 'RO^- '4T5RW_"PK#_GA<_]\K_C1_PL
M*P_YX7/_ 'RO^- '4UE^)O\ D 7W_7,UE?\ "PK#_GA<_P#?*_XU4U?QM9ZA
MIEQ;1PSJ\B[06"X_G0 SX<_ZV^_W4_K7;UYKX4U^#0GN6GCD<2A0/+ .,9]2
M/6NA_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN
M?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^
M%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH
M_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5
M_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'
M_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%
MA6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P :
M .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y
M_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_
M #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IH
MKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^
M5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN
M?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^
M%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH
M_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5
M_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'
M_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%
MA6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P :
M .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y
M_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_
M #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IH
MKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^
M5_QH_P"%A6'_ #PN?^^5_P : .IHKEO^%A6'_/"Y_P"^5_QH_P"%A6'_ #PN
M?^^5_P : .IKF_'O_(#7_KLO\C47_"PK#_GA<_\ ?*_XUE>)O%=KK6G"WABF
M1Q(&RX&,#/H?>@#7^'W_ "!9?^N[?^@K73UY_P"%_%5KHFGO!-%,[M*7S&!C
M& .Y]JU_^%A6'_/"Y_[Y7_&@#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?
M\: .IHKEO^%A6'_/"Y_[Y7_&C_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE
M?\:/^%A6'_/"Y_[Y7_&@#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .
MIHKEO^%A6'_/"Y_[Y7_&C_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/
M^%A6'_/"Y_[Y7_&@#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKE
MO^%A6'_/"Y_[Y7_&C_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6
M'_/"Y_[Y7_&@#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A
M6'_/"Y_[Y7_&C_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"
MY_[Y7_&@#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A6'_/
M"Y_[Y7_&C_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"Y_[Y
M7_&@#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A6'_/"Y_[
MY7_&C_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"Y_[Y7_&@
M#J:*Y;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A6'_/"Y_[Y7_&
MC_A85A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"Y_[Y7_&@#J:*
MY;_A85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A6'_/"Y_[Y7_&C_A8
M5A_SPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"Y_[Y7_&@#J:*Y;_A
M85A_SPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A6'_/"Y_[Y7_&C_A85A_S
MPN?^^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"Y_[Y7_&@#J:*Y;_A85A_
MSPN?^^5_QH_X6%8?\\+G_OE?\: .IHKEO^%A6'_/"Y_[Y7_&C_A85A_SPN?^
M^5_QH ZFBN6_X6%8?\\+G_OE?\:/^%A6'_/"Y_[Y7_&@#J:YOQ]_R U_Z[+_
M "-1?\+"L/\ GA<_]\K_ (UD^)O%=KK6G"WABF1Q('RX&, 'T/O0!L_#_P#Y
M LO_ %W;_P!!6NFKF/A\<Z++_P!=V_\ 05KIZ "BBB@ J*Z7=:S ]"A'Z5+4
M=Q_Q[R_[I_E0!\4_MD?&'Q!\#O@V_B;PR;4:F-0@MLW</FIL?=GC(YX%?"7_
M  \H^,?_ #TT'_P7?_9U]:_\%*/^3:Y/^PQ:?R>ORAKTL/",H7:(;U/JG_AY
M1\8_^>F@_P#@N_\ LZ/^'E'QC_YZ:#_X+O\ [.OE:BNGV5/L3=GU3_P\H^,?
M_/30?_!=_P#9T?\ #RCXQ_\ /30?_!=_]G7RM11[*GV"[/JG_AY1\8_^>F@_
M^"[_ .SH_P"'E'QC_P">F@_^"[_[.OE:BCV5/L%V?5/_  \H^,?_ #TT'_P7
M?_9T?\/*/C'_ ,]-!_\ !=_]G7RM11[*GV"[/JG_ (>4?&/_ )Z:#_X+O_LZ
M/^'E'QC_ .>F@_\ @N_^SKY6HH]E3[!=GU3_ ,/*/C'_ ,]-!_\ !=_]G1_P
M\H^,?_/30?\ P7?_ &=?*U%'LJ?8+L^J?^'E'QC_ .>F@_\ @N_^SH_X>4?&
M/_GIH/\ X+O_ +.OE:BCV5/L%V?5/_#RCXQ_\]-!_P#!=_\ 9T?\/*/C'_ST
MT'_P7?\ V=?*U%'LJ?8+L^J?^'E'QC_YZ:#_ ."[_P"SH_X>4?&/_GIH/_@N
M_P#LZ^5J*/94^P79]4_\/*/C'_STT'_P7?\ V='_  \H^,?_ #TT'_P7?_9U
M\K44>RI]@NSZI_X>4?&/_GIH/_@N_P#LZ/\ AY1\8_\ GIH/_@N_^SKY6HH]
ME3[!=GU3_P /*/C'_P ]-!_\%W_V='_#RCXQ_P#/30?_  7?_9U\K44>RI]@
MNSZI_P"'E'QC_P">F@_^"[_[.C_AY1\8_P#GIH/_ (+O_LZ^5J*/94^P79]4
M_P##RCXQ_P#/30?_  7?_9T?\/*/C'_STT'_ ,%W_P!G7RM11[*GV"[/JG_A
MY1\8_P#GIH/_ (+O_LZ/^'E'QC_YZ:#_ ."[_P"SKY6HH]E3[!=GU3_P\H^,
M?_/30?\ P7?_ &='_#RCXQ_\]-!_\%W_ -G7RM11[*GV"[/JG_AY1\8_^>F@
M_P#@N_\ LZ/^'E'QC_YZ:#_X+O\ [.OE:BCV5/L%V?5/_#RCXQ_\]-!_\%W_
M -G1_P /*/C'_P ]-!_\%W_V=?*U%'LJ?8+L^J?^'E'QC_YZ:#_X+O\ [.C_
M (>4?&/_ )Z:#_X+O_LZ^5J*/94^P79]4_\ #RCXQ_\ /30?_!=_]G1_P\H^
M,?\ STT'_P %W_V=?*U%'LJ?8+L^J?\ AY1\8_\ GIH/_@N_^SH_X>4?&/\
MYZ:#_P""[_[.OE:BCV5/L%V?5/\ P\H^,?\ STT'_P %W_V='_#RCXQ_\]-!
M_P#!=_\ 9U\K44>RI]@NSZI_X>4?&/\ YZ:#_P""[_[.C_AY1\8_^>F@_P#@
MN_\ LZ^5J*/94^P79]4_\/*/C'_STT'_ ,%W_P!G1_P\H^,?_/30?_!=_P#9
MU\K44>RI]@NSZI_X>4?&/_GIH/\ X+O_ +.C_AY1\8_^>F@_^"[_ .SKY6HH
M]E3[!=GU3_P\H^,?_/30?_!=_P#9T?\ #RCXQ_\ /30?_!=_]G7RM11[*GV"
M[/JG_AY1\8_^>F@_^"[_ .SH_P"'E'QC_P">F@_^"[_[.OE:BCV5/L%V?5/_
M  \H^,?_ #TT'_P7?_9T?\/*/C'_ ,]-!_\ !=_]G7RM11[*GV"[/JG_ (>4
M?&/_ )Z:#_X+O_LZ/^'E'QC_ .>F@_\ @N_^SKY6HH]E3[!=GU3_ ,/*/C'_
M ,]-!_\ !=_]G1_P\H^,?_/30?\ P7?_ &=?*U%'LJ?8+L^J?^'E'QC_ .>F
M@_\ @N_^SH_X>4?&/_GIH/\ X+O_ +.OE:BCV5/L%V?5/_#RCXQ_\]-!_P#!
M=_\ 9T?\/*/C'_STT'_P7?\ V=?*U%'LJ?8+L^J?^'E'QC_YZ:#_ ."[_P"S
MH_X>4?&/_GIH/_@N_P#LZ^5J*/94^P79]4_\/*/C'_STT'_P7?\ V='_  \H
M^,?_ #TT'_P7?_9U\K44>RI]@NSZI_X>4?&/_GIH/_@N_P#LZ/\ AY1\8_\
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MC_YZ:#_X+O\ [.C_ (>4?&/_ )Z:#_X+O_LZ^5J*/94^P79]4_\ #RCXQ_\
M/30?_!=_]G1_P\H^,?\ STT'_P %W_V=?*U%'LJ?8+L^J?\ AY1\8_\ GIH/
M_@N_^SH_X>4?&/\ YZ:#_P""[_[.OE:BCV5/L%V?5/\ P\H^,?\ STT'_P %
MW_V='_#RCXQ_\]-!_P#!=_\ 9U\K44>RI]@NSZI_X>4?&/\ YZ:#_P""[_[.
MC_AY1\8_^>F@_P#@N_\ LZ^5J*/94^P79]4_\/*/C'_STT'_ ,%W_P!G1_P\
MH^,?_/30?_!=_P#9U\K44>RI]@NSZI_X>4?&/_GIH/\ X+O_ +.C_AY1\8_^
M>F@_^"[_ .SKY6HH]E3[!=GU3_P\H^,?_/30?_!=_P#9T?\ #RCXQ_\ /30?
M_!=_]G7RM11[*GV"[/JG_AY1\8_^>F@_^"[_ .SH_P"'E'QC_P">F@_^"[_[
M.OE:BCV5/L%V?5/_  \H^,?_ #TT'_P7?_9T?\/*/C'_ ,]-!_\ !=_]G7RM
M11[*GV"[/JG_ (>4?&/_ )Z:#_X+O_LZ/^'E'QC_ .>F@_\ @N_^SKY6HH]E
M3[!=GU3_ ,/*/C'_ ,]-!_\ !=_]G1_P\H^,?_/30?\ P7?_ &=?*U%'LJ?8
M+L^J?^'E'QC_ .>F@_\ @N_^SH_X>4?&/_GIH/\ X+O_ +.OE:BCV5/L%V?5
M/_#RCXQ_\]-!_P#!=_\ 9T?\/*/C'_STT'_P7?\ V=?*U%'LJ?8+L^J?^'E'
MQC_YZ:#_ ."[_P"SH_X>4?&/_GIH/_@N_P#LZ^5J*/94^P79]4_\/*/C'_ST
MT'_P7?\ V='_  \H^,?_ #TT'_P7?_9U\K44>RI]@NSZI_X>4?&/_GIH/_@N
M_P#LZ/\ AY1\8_\ GIH/_@N_^SKY6HH]E3[!=GU3_P /*/C'_P ]-!_\%W_V
M='_#RCXQ_P#/30?_  7?_9U\K44>RI]@NSZI_P"'E'QC_P">F@_^"[_[.C_A
MY1\8_P#GIH/_ (+O_LZ^5J*/94^P79]4_P##RCXQ_P#/30?_  7?_9T?\/*/
MC'_STT'_ ,%W_P!G7RM11[*GV"[/JG_AY1\8_P#GIH/_ (+O_LZ/^'E'QC_Y
MZ:#_ ."[_P"SKY6HH]E3[!=GU3_P\H^,?_/30?\ P7?_ &='_#RCXQ_\]-!_
M\%W_ -G7RM11[*GV"[/JG_AY1\8_^>F@_P#@N_\ LZ/^'E'QC_YZ:#_X+O\
M[.OE:BCV5/L%V?5/_#RCXQ_\]-!_\%W_ -G1_P /*/C'_P ]-!_\%W_V=?*U
M%'LJ?8+L^J?^'E'QC_YZ:#_X+O\ [.C_ (>4?&/_ )Z:#_X+O_LZ^5J*/94^
MP79]4_\ #RCXQ_\ /30?_!=_]G1_P\H^,?\ STT'_P %W_V=?*U%'LJ?8+L^
MJ?\ AY1\8_\ GIH/_@N_^SH_X>4?&/\ YZ:#_P""[_[.OE:BCV5/L%V?5/\
MP\H^,?\ STT'_P %W_V='_#RCXQ_\]-!_P#!=_\ 9U\K44>RI]@NSZI_X>4?
M&/\ YZ:#_P""[_[.C_AY1\8_^>F@_P#@N_\ LZ^5J*/94^P79]4_\/*/C'_S
MTT'_ ,%W_P!G1_P\H^,?_/30?_!=_P#9U\K44>RI]@NSZI_X>4?&/_GIH/\
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MW_??_P!:C_A!-+])O^^__K5T5% '._\ "":7Z3?]]_\ UJ/^$$TOTF_[[_\
MK5T5% '._P#"":7Z3?\ ??\ ]:C_ (032_2;_OO_ .M7144 <[_P@FE^DW_?
M?_UJ/^$$TOTF_P"^_P#ZU=%10!SO_"":7Z3?]]__ %J/^$$TOTF_[[_^M714
M4 <[_P ()I?I-_WW_P#6H_X032_2;_OO_P"M7144 <[_ ,()I?I-_P!]_P#U
MJ/\ A!-+])O^^_\ ZU=%10!SO_"":7Z3?]]__6H_X032_2;_ +[_ /K5T5%
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M_P#6H_X032_2;_OO_P"M7144 <[_ ,()I?I-_P!]_P#UJ/\ A!-+])O^^_\
MZU=%10!SO_"":7Z3?]]__6H_X032_2;_ +[_ /K5T5% '._\()I?I-_WW_\
M6H_X032_2;_OO_ZU=%10!SO_  @FE^DW_??_ -:C_A!-+])O^^__ *U=%10!
MSO\ P@FE^DW_ 'W_ /6H_P"$$TOTF_[[_P#K5T5% '._\()I?I-_WW_]:C_A
M!-+])O\ OO\ ^M7144 <[_P@FE^DW_??_P!:C_A!-+])O^^__K5T5% '._\
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M_P#UJZ*B@#G?^$$TOTF_[[_^M1_P@FE^DW_??_UJZ*B@#G?^$$TOTF_[[_\
MK4?\()I?I-_WW_\ 6KHJ* .=_P"$$TOTF_[[_P#K4?\ "":7Z3?]]_\ UJZ*
MB@#G?^$$TOTF_P"^_P#ZU8_BKPQ9:1I@GMQ)YGF!?F;(Q@UW5<WX]_Y :_\
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M#G?^$$TOTF_[[_\ K4?\()I?I-_WW_\ 6KHJ* .=_P"$$TOTF_[[_P#K4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB3]@K_DUWX=_[MQ_Z635]MUX=3XWZFBV"BBBLQA1110 4444 %%%% !1110
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ML04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS6I67XF_Y %]_P!<S0!SGPY_UM]_NI_6NWKB/AS_ *V^_P!U/ZUV] !1110
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MZUZ5UXH%"2W+=6=2ZD][?AL,!)&312T8IF(E%%% $L%T\!R&(]JV;345G #
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M LO_ %W;_P!!6NFH **** "H[C_CWE_W3_*I*CN/^/>7_=/\J /SQ_X*4?\
M)M<G_88M/Y/7Y0U^KW_!2C_DVN3_ +#%I_)Z_*&O5PWP&<MPHHHKK$%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '[*_L%?\ )KOP[_W;C_TLFK[;KXD_8*_Y-=^'
M?^[<?^EDU?;=>'4^-^IHM@HHHK,84444 %%%% !1110 4444 %-=UC0LQ"J.
MI-$DBQ(7<[5'4FN?O]0:\? ^6(=!Z_6J2N,?J&IFZ)1/EB_G7F7QDM-='A6Y
MU/0]>GT26PB+L(1GS3[UWU9OB/14\1:%?:;)(T4=U'Y9=>HK>-HL9\_ZQ\4O
M$/PDB\)W&LZQ=>(8]:MA,8C"6<N4W;1@<*.N3V%>P?"JZU?5O#:ZKK&I1:@^
MHD7$*VW^J@0\J@/? .,T7'PQT^[U/PW>7$C3'1;;[,D;J"LB[=N3QZ5/X%\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M216-O%;0_:E_=Q* ,[:S7/.+G)Z?TA4W*<M3K:,=_3N:4BH;F=;6$SRNL42
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0&O_ %V7^1H 9\/O^0++_P!=V_\ 05KIZYCX??\ (%E_Z[M_Z"M=/0 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M21_WUBN*\ >(=9_L?6Y=7#QRV!:WA$_!,I&-HS^&*ZRXV>%O"UGIEMEM0O\
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M!KZY "Y!_=Q#[B?EU]Z-6C.NZ]:>'[<$6$&VXOF7HJ@_NXOJS $_[*FNU7&
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M;FO,CF4^:]2-T?9XO@G!SI6H2?-YO0_4)M*@T_PWXMTFTC*Q6LAN8T7H PW
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M\R$<\CK65D_A4MI+Y,PYX;@U4D.,U>QKCFEI%Z4M9FP4444 %<WX^_Y :_\
M79?Y&NDKF_'W_(#7_KLO\C0 WX?_ /(%E_Z[M_Z"M=-7,_#_ /Y LO\ UW;_
M -!6NFH **** "H[C_CWE_W3_*I*CN/^/>7_ '3_ "H _/'_ (*4?\FUR?\
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MJ8/3 )/!KJJM^S<GH>"J=2K)1C&\MM#VC1[.'P_XNN(;8@6FK(+M%4\"0#!
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MWG/Z"K6BVL<^O2O'&#::9 +.W[#=CYC_ $K(T*W&L^,+JUGD6/2-.NGND0L
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M)0,<5S'C[X@Z%\-O#\^JZ]?):VJ A59OFD;'"J.YKDM:N/%.M>/[2XT.[?\
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MO^Z?Y4 ?GC_P4H_Y-KD_[#%I_)Z_*&OU>_X*4?\ )M<G_88M/Y/7Y0UZN&^
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M2,<*J@=22:_1_P"#G_!(. Z!%J_Q<\8S:1*R"272M":)?LPZXDN9 RD]B%3
MP<,>M9G_  1X^#MEK/BCQA\2-0MQ--HRQZ7I;.,A)959IW'HP01J#Z2M7E7_
M  4D_:AUWXK_ !JU[P/8ZC<VW@GPQ=MIPTY'VQW-Y$Q6::0#[Q#[E7.0 @(
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MV/XU$W4HM.][C5F?&_PT_P""3G@WPUX;L]0^,OC^73]4N "=/TJZ@M((&/\
MRS,TRL93TR5"\\#(Y,7QR_X)$Z;9>#[K6_A-XHU#4[^")KE-)UMHY1>(%W;8
M9HD7#G^$,I#$C++UK\]OBC\4O$OQD\:ZCXI\5ZI/JFJWLC.6E<E(4))$4:D_
M)&N<!1P!7Z4_\$;_ (BZQK?A/X@^$+^^FNM+T6:SN].AE<L+?S_/$J)G[JDQ
M(VT<99CU)RYJI"//S K/0_*R2-X9&CD4HZDJRL,$$=017L_[,?[)OC;]J;Q-
M-I_AJ&.RTFR*G4-<O0PMK4'HO R\A&<(/J2HYJM^V%H47AS]J7XIV4 "Q?\
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MS7X\VUM+>7$5O!&TT\KB..-!EG8G  '<DUO1FYPN]Q-6/L_]B7_@G[9?M/\
MP]UOQ?XB\0W_ (<TVWOOL5E]DA1O.V(&E=B_\(WH 1W#>E?(GC*STC3O%VM6
MGA^[FU#0[>]FBL;RX $D\"N1'(P' +* <#IFOU_^.5W%^Q1_P3MM_"UI(EOK
M]QIJ:%&T9P7OKH,]W(I'H#<.I[;5K\:*5*3FW+IT!Z!11170(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#]E?V"O\ DUWX=_[MQ_Z635]M
MU\2?L%?\FN_#O_=N/_2R:OMNO#J?&_4T6P4445F,***@OI#%:2,HRV, 4 8%
M[/Y]U(X.03@?057I2"O!&#25T%)H*..XS12XI,+C%R%;<%&?X1TSFLGQ=HT^
MO^&[W3X9S#),N!N/RGD'!]JV&'!]Q7+_ !'TW6M3T$1Z%,8;A6&\*V"PV^OU
MQ6<T^70B:7+H<MX-^%&I>%[%7AUV2VNB2WV.-=]J#GH >WOBMR^^(W_"'PP)
MXK@%C+(2JW-O\\+8QT[C\JJZ)XHU7P9X4MY/%=K*PA7$E[ =Z_\  NF*L31>
M&/C#HMM/%=_:+>/=M>WDV/SC(/IT'%5SOE4;:D[*RW.PL-0MM3MX[BTF2XAD
M&Y70Y!%6'!4 G[IZ&N&N? ]MX3T*>3P]=W&FF!#,J!O-1\#)!7C.<5@^$OCO
M;7UP;76;1[.:/Y7NH/FB]BQXVGVYH=E97U*4DGKN=]K/A'3/$%Q;SWT'FR0'
M*?[-+J_AFQU8B:2$I=QKB.Y@.R4 =/F'/X5I6U[;WD4<MO*DL<@W(R'.X>HJ
M1ONY/ / )IM<JT*L>-^%?B-XKC\376EW6E3ZM8QL02@Q+"O8G. WYGI7I^D>
M)]/UEI(HI@+J/AX)?E=/;'?\*XOQCI/B^7Q9;7VDMNL4*YC,I5<?Q \=^*X3
MQ@;7Q+\1[5;G53H&H "-YF.&4CLC5G>7*[HPYI1TL>^:@LK6LT4)$<[(1'QP
M&QQ7SXGQ.\2?#?QG<Z7J5TDJR$%OM#,50GN, G'TKUK3XM?\,C8ER/$=AM^4
M@XG'OWW5%;Z=X1\<ZPE_):0R:U9G#+,@$D1_VA3JTY2:E%E5(N236YCS>(/$
M?BJ&.UD\+V=]92\FYDD;;[%<C(/OBF3:5X@@EBM]4T.'6-$QETF;S)[<]BA;
MD_G7J/F$'[_/UQFJFI:Q::3Y37EVEMYC;4#G!9O0&NAU>7<U;2U9Y;/!<QSQ
MZKX>N)-02U!5H&)\^/'_ "S8'[R_7IVKNO"/B[3OB#H(N;9A(4)CGB<%6AD!
MP01V^M<YXWUW1-+UZWC\Z;3=6N579=V_N>-W3<,]JSK][SPI>IK368L[N9@+
MFYMQF&^7&!O_ +K=,=?2CFC4T0E)-V1Z$);BQ9XI8YI;0#B8=5_7)^M8!+>#
MM2-S XET/46+2Y8_N9"?O?0\YKIM#UNVUW38;RU?S(VR&'=2.JGT/:J&K:)+
MJ"7$*10_8I5(D@DY##V]#[U%^71@^[1\_P#Q(_:AMOA?XVO;+62^HP+\LEE;
MQJY$?\))/7OQ7E_Q7/A[]H_PY!JG@1)8-9T;=++H]PVTF$CDHH)48Y/%>)?&
M+1]0\/\ Q4\2Z?JGFF0SO)&TQ)+Q'H=QZ]*Z7]DZ'4+7XO66H6UM-<Z-;6\O
MV];?+!4*D#/M7A+$RJ5W0DFXL_2J628?+LMCF=&J_:+5=KOH>R_LT_L[^+?
M6L3>+;V%%:[MOL_]G%R3)$W4@]B,]/:OJ+X<ZK<7.GW>F7EO+;75C*R>7-C<
M8R24Q_P'%-\!:HPN)]+D<201_O[*8?\ +6)NY]P21^%6->ODT#Q5INH20[[>
M_P#]#ED'&QNJM^2X_&O<HTU1AR1V/@\9C*V.KNO7=Y/<@\5SR6OB_1)X8C+)
M%:SLJ?WL%*X'P[XTU+Q=9>/7NH0ES#9J$7:5 ^_@<@9KT?56SX_T+)R1;3D?
MFE9GBZ7=-XE4Y.[3D()]/GK"O"Z6IC2C>5SG/A6_B'4?&D_]NQNB6UD#"9
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MU<S\/_\ D"R_]=V_]!6NFH **** "H[C_CWE_P!T_P JDJ.X_P"/>7_=/\J
M/SQ_X*4?\FUR?]ABT_D]?E#7ZO?\%*/^3:Y/^PQ:?R>ORAKU<-\!G+<****Z
MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK%[C;G.U79I#D_*H5<Y*@F(DI)06[!=S\POV>KN*_P#VX_!EU;@+!/XVCDC
MZ!3=9'Z&OL3_ (+22,-,^$: _*9M5)'N%M,?S-?#W['I)_:I^%))R3XDLO\
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MYH6/BCQ%'XVM]0MKJZO/%'V@!<$LY?=T(K].O&T&LR^';JZENUMA'&=EG$0
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MMCI]S%)#?3J P*\"0_PUJ?$'XA6_@'3H;F6(SM*V F[ !]_2LR?X=3:KK_\
M:\P@TNX"J$>W&9%]>>5].U=-#X,TM( MU;)>,!AIKD[F;W/:G&,XPY9L:<K?
MJ6?"^OQ^)M L]4CB>".X3<$D'(YQ_2M,MC'OZ<UF#5K.T<VT*@1Q+TB7(7V
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M23WJ.BJC",-(H0 D$$'!%?7OP6_X*@?&#X3:1;:-J,EAXXTJW41Q#7%<W4:
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MR5S5R6I>M88O!7A:7[0P>4AFD91RTK]0/7DUG:5:R^#O#5M"8O/UJ^*IN/\
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M"CZ(.OY4L6N7=T_EZ59+;68'-Y.-D?X#K^E9-AI5U<7336E@S%SEKO4V)/\
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M>';.3[+F:.>9T_Y9V\9!8>VX?+^-.\-6W]E:7?>(=546]W?9N)1WBB'^KB_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH\*E47[IN0<9)_V>/QK,^QWD<5D^K2OJN@,H=%A4LP;J%<CJ!_2MF^U>_N$
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M4N%&2P ZY)Z5IHUN)7>Y)13(Y XR#D>M/J "BBB@04444 %%%% !2$9S2T4
M;%D^;9<U8JEI[ PXSWJX.*P>YU+86N;\??\ (#7_ *[+_(UTE<WX^_Y :_\
M79?Y&D,;\/\ _D"R_P#7=O\ T%:Z:N9^'_\ R!9?^N[?^@K734 %%%% !4=Q
M_P >\O\ NG^525'<?\>\O^Z?Y4 ?GC_P4H_Y-KD_[#%I_)Z_*&OU>_X*4?\
M)M<G_88M/Y/7Y0UZN&^ SEN%%%%=8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"9/P@\-> _V>?&?Q@\<Z;9W%C>>=-%+?6JS"&PLU<R2(&!Y:3S00.OE+6?\
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M79_&?X<7/PA^+'BSP9=[C)HNHS6B.XP9(PQ\N3_@2%6_X%7&5Z2=]2#] /\
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M_79?Y&NDKF_'O_(#7_KLO\C0 SX??\@67_KNW_H*UT]<Q\/O^0++_P!=V_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.\>(-,_Z^HO_0Q7[ ?\%?/^37M'_P"QIM/_ $FNJ=1)58- MCX*_P"":O\
MR>O\./KJ/_IMNJ^E?^"LGBV_\ _'3X->)=+?R]2T>"2_MVSQYD5S&ZY]LKS7
MS5_P35_Y/7^''UU'_P!-MU7O?_!9K_DH?PV_[!=U_P"CEIR_CKT_S#H>S?\
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M^F:Z+_@BO][XQ_31_P#V^KY'_;DO)]/_ &R/B3=6TK07,&L++%*APR,L<9#
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M_L*V/_HRHE'D=-?UT#N?B=1117H$A1110 4444 %%%% !1110 4444 %%%%
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M,1"0#\>*2YE\16L1:.&SO6"_+^\\LL?I@T[-RO<EKR+,^A:-:0Y>U@AA0<<
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M^_ZYF@#G/AS_ *V^_P!U/ZUVQZ5Q/PY_UM]_NI_6NV/2@")^]59JMO567H:
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MKK^V/LMI?6O]K_VYY&[[1--+N\G[.V-OG8QOYVYXS@76@Y12BNHDSYY_9?\
MA!)\=OCSX.\&"-GL[Z]62_9>-EI'F2<Y['8K >Y [U^E?_!6OXLQ^!_@7HGP
M^TYUM[GQ/=KYL,7 6RMMKE<#H#(8 .Q"L*^ _P!CC]J;3OV3O&.M^)IO!/\
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M]O\ [<^U;?+;=M\O[.F<^N[CWK6K"4IQ:Z"1\3T445T""BBB@ HHHH ****
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M8D X;Y2<_6M66XAMD#SNL8/0EL _C2LDKHK1*Y-W/M130P)XP0>].H&%%%%
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M_=89%.'0TE2:C0"GW0JCV%,:$)O:, .W.3W/O4M':@#-DMYVCWW5^(CU*I@
MC\>:YR+Q!X=FUAX$O6U*]4[1;(2V#W-=3=:9;7I9IT+,5(Y.1BN'\)_"FQ\%
M^)+W6X+J2YFF5UCMW4#:K$$\]^@J)76I+OLCIIVO+@QI9Z9';K_STG[?E2)I
MU\#+)J&IB-,86-,*N/7/6I[N[N%B,ES=16$'^S\Q_*LB&XMWVF.WN-7>1L"2
M0?(/P)Z5:;:T1&B^)EAH](C&TP/>R.=H/S-N_/BKJ>?#&J9M],M%& "0'Q[
M\54NS=I$KW5U;:7 G2.)0Y'Z9'X56!L9<S+;37X SYERV8_J 3_2J49/=D\T
M5HD2W-W#=HR6@EU&X;@&4%4^O8&K^FV%GX?B>6>6(2OS)*QPQ/M[5CVLFJZ]
M)$8IH]/TR,Y8H@^<>BD]*GN-+T^=U*))?M&V<S.63/U-)VCH$;R9K?\ "0QR
M BUADN<^B[1^9K(EOM7U5FB26"PME/[V1#RH^IXS39]77;(LDB.$'*HPCBB]
MBW&:\K^(OQ@TSPA9JDMW;ZB'^9U@E C49Z84\_B*4IQ@KR'[V\=3U!->M-,L
M##IB?:"&*^<<[6.>3ZD_2JS6K/>)=ZG++=3]8+)3P/<@?UKY(\0_MR)HV]/#
MGAM+R:+Y?/O7\N*(?[ 7/YUF^&_^"C6D2NMMK.@75L[MBXOK1O,W#T!8@@?2
ML%C<.G9R2/;609I.*J*BVGLK'V)=ZC<+,)VE4SH=F(QF.$'LOJWYBMWPWH#6
MK-J%P"UW-W?[RIZ5R_PB\5Z)\4M @\2:-<)/I^<06RXS&>^__:/%>BW5[%:0
M2332+#$B_.SGI74YJ2]UZ'C>SG";C45FNG8E\P=1T ZFN+U?Q/=:U.=/T$J2
M'\N>]<'9&.^T]S^E5KZYO_&@D%K)-8Z*JD><!A[CMA?0>_6KG@(I_P (M!%%
M&(Q#++$<#DE7(R?KCK4VTN6M78S_ !!X.TNP\.7<QB::[1=XNG<^86/<D']*
MKV?AR/PEX@T"SL;B<1S)*9HFE9E; 7U/7FM[QA+MTN&/'-Q<I;E3Z'/^%5K]
MB_Q"T>-APEK,WXX'^%-.Z!Z,Z@#YP.WI6'K,']J^(4L"0T$=HTK*.SDE0?U%
M;H&Z5<5C>&KB&^UW7KG(,L<JP$>B[0?YUP5[W44;1;2N>1^._P!J_P +_"&V
MM-+O8[C5=7B)A>SM\!E"\;CG'I78> ?B-H'Q^\)G4M&G>VNK=\=0);=_?\OI
MQ7S=^T]^RYKOB[XNW.O>'(TN?[1@1I(7;:P**%RI_G7L'[)GP$U+X,^'-3EU
MF13K&JNC26R'Y(U3.W\?F.37G0=3G<)+1'T-;#9='+XU:<W[6^J/6=(N[VZ$
MEI-.8=1@'SQ2J"&'9@:TTU<Z</+OU$9SA94!*-4'B/1)KV#[5I\@M]3A&8W/
M(;_9/J#6/IWBJ\U"UEBOM*\R2$[)D@.2C#G)!Q]>*Z7/E?*SP4G9G5"6#4K=
MON3HP(8=ORKE9])O/",_VC30;C23DS61^]'[I_A1!+%+:&\M+IC;,2#<(/FB
M(/(9>_IFM73M96.W19Y1=1?\_$9X.?7O77"?*9N%]BNGC/1WMUE2Z,F1G9&A
M9@?0@#@TYO$-Q<)BQTJ>=R,J\A"K^/.:IW?A?^SKV36="CB$[D/+#MPLH]AV
M/O6KHNOVVMQ-Y3E+B,XF@?AD;T-=RDFC"S3U,HOXI0BY:&QD7/S6B,V<>Q/?
M\:2Y\?6-A<);W=M<6US)_ ZX!_X%T_6NE9E3)=E3TRP%9UU=Z3J\KV$LMO<.
M.6C< X^F:K0->C*<GB:$1$WFFW,-JP^^P613^ S6)=7GAN>X,EE*Z3K\TC6.
MX[?JO3\,5LS^&;NQ&_2;YX<<^1<'S(W'ISG ^E85Q;VEC*TM[ISZ+(Q^>ZLL
MB)F]3C!/XBFG%LG5[HJW.AIK:E(6L=?@(PT-T/)G]^!C]:O:.FG>$+,VEK:S
MZ'%DL8Y%WQY]2PS_ #I#HD[;;J(0:S PRMS;GR9_TZ_B:RM?CO\ 6-+N]&T_
M5C:7<RX%EJ:XQ_P/G-$TG[UB79+0]#T?5(-1MU*7=O<..\+@@U=!Y('!_2O"
M_"WA=/AOHEW=>(?M7G;O,%U9L1"G&,#!Y]>172>#_'=_XETZ]FT6ZBU1(?D\
MB]3RV4D9!!4'-8\R2]X<9Z:[GJ. JG)'7G I<YYKR3P%XM\36>J7R>+[2:PM
M68^3)(H()]L9XKT8^)])1[:/^T(-UP<1#=RU)2TNRU*ZU-6B@\45984&BC!Q
MQ2O8"O>W]MIUM)<74\=M#&,M)*P50/J:K:CK^FZ18?;;V]@MK0@$2R. ISTP
M>]><?&TGQ)<:9X3AMY;TW)-Q=6\/7REY7.<#!(85PVC>(]-U_4/#FF^)8%":
M6TEE):W:YB2Y&YHU<=#\ACP?6NF-+W.>YE*I:5K'OVG^(]*U33WO[34+>>S0
M$O,D@(3Z^GXTS1/%>D>(_,_LW4(+PQ_>$;<C\/3WKYQUW4%%[K%C9Z;:Z?I\
M5]"^J_V2[&%H< #C  .2N<>]>O:(_@^V^(=K!H5F@U!K!F9[)=L"Q97 ?'!)
MXQWZTI0<28S;6IZ5:+NNXNXS6Y63I2B2??G.!G-:U<,W=G9#8****S+"LOQ-
M_P @"^_ZYFM2LOQ-_P @"^_ZYF@#G/AS_K;[_=3^M=O7$?#G_6WW^ZG]:[>@
M"-JKRBK+=Z@D% %";@YIX.123"FQ\@&KBR)*Y4U;5[30K*2]OIA!;Q\EV]>P
M]S[5B6_Q%TBYAG=6N4D@ :2![=A(5)QN"]2"?3I47Q'TZ[O=/LKBTMFOVL+N
M.[>R7&9U4Y*C/&?052M)Y?%'C>UU2WT^YM+*TLI(FFNXFB:5W(.P*PR<;>OO
M73&,7N<E24_LFC8?$;0M3,9BGF6.658$DDA90TC':J@_4U:UCQGI.A2W<=Y=
M&-[6-'E0*20&X7&.I)KAKSPOJEUX1T>R6TGAE&N)-(4X>*/S,^9_*L_Q=X0U
M.VU#7S$FH:C%)!;[)]N]R0P)"XZD"M/9TY,Q=6K%;'?O\0](AL9+J7[7#$DB
MQ8>W8,[MR  >3Q6AH7B;3O$9F2TG8S08,L,D;(Z9Z9![<5P>I65YKNG6MO9C
M6C)'J<,K37L&QHT"$%ER.GK]:Z#PCHMYH_C#Q"UYYUTD\<+Q:A*H!<98&/CC
MY>#^-*4()#C5J-H[8=*,"@45SG6& *. /3'?THI.>E%@,[5(=2GM[C[+<)$=
MA\H!-QWXX)S[UYY\.=(\1/-J5SXUDF>%7"6T=PX"YR=Q 4X(Z8S7I=W>16:Y
MF9@&R%5%+,:\P\3_ !.UJP\<:?HMIH:&UN65%DO24)SUD'!X4<FLYM*SN1)I
M:MGH O([:)SINF&0 =501J?KGDU7FOW1%%[J,5FQP3;VHR5'8$\G\JY/QE\0
MM&\*- NL:G<ZC+)DBWTV+*J!U)(/05NZ>':%=0M[2VTF"=%87%VV^0IC(^7L
M>>Y[UJDI=;LE2Z(E@1GN9);33I9I'&!<ZD^(UQZ#DG]*=>78"_\ $PU@_+U@
ML4P/IGD_K43YU 8A^TZLX&3-*?)MQSZ_X9ID6G1LXZ7SJ<F*V79"OU<]?SJT
MHK4GWY$N@WEQ>0RMI&G&TMR^#=7['?+@?> !R1Z9(^E8_B7Q9IWA+39]0\4:
MX(XER?+B<0H /4@Y)/U-5O'/Q"M/ GA_5M8UN=;BWLD+1VNG,",#IN;H,GCD
MU^;GQ5^*FL_%SQ#+?ZK(8[4N3;:9$W[J!>P/J<=S7!C,8L-&_?8^HR/(JN<5
M7&]H15Y/]#Z]U;]MOX::7>".TBU#5U)PITRT_=,?]J21E8_E7">/OV_-/6]-
MGH>F37T[J#&NI$6MM /]Q=QD/_ @!Z5\1ZSKODZW:V7G"WVNI8J,C)YJGXY9
MV^RSBRF^RA<\+]T]SGWZUX3S:LG9'WTN#\OH8ZA0JMN,DWKMIZ?YGV)HG[=_
MBFTVK>>&M,ELV?$ILY7@GE']U7)<*/<+7T3\(/CIX;^-,<%AIA.F:R"7;2KL
MC_10/X\])2>Q_,"OS"^'VMIJ5S)832>?,J%H2>&91U7Z@<_A7<Z3J5[X2UFW
MO]*NI(+ZW<21S*VUL]?RK6AFM=-.H[IE9APEEU:I/#86+A4BKVWB_O/V"TW3
MX=+M(X$7/\3,>6=N[$^M8VO>*O[,N(["QMCJ.K3 F.U1L!1_>=NBJ.I[^E>:
M?"7XUWGQH^'>EW&BPE=5,9AU*[9"(;2120<9^^S'D*.@Y)'&>Z\"V20:,LLF
M7OI'9;BX8Y9V!/7O^'2OHU+GBI]S\AG3E1FZ4U9IM?<0>#+'^T+1=:U&0W6L
MR.Z.V?DAPQ!6,?PC]?>K_BXA].MK;.#<74:C\#G_ -EJ/PC(I?7+>,*T5OJ$
MBH5.>IR?U-0^*]1@MO$'AFUF)"SW,A1L?*&5>GX[C5;R]TSTY"\AW^-RO_/'
M3_YN/\*WHB%F);A0,DUSUL"_CK4F_NV4(_-B?Z5IZO=FQT6^N5&2L1"CU-95
M7:%RX;F58Z9_;WA;5R7W'49)S&X.#@':G/\ P &ORR\7#Q>WC^\?5Y=1F\21
M7+PQ2(',ZX)""(CVQTK]4/ L3Z58OH<V_P VQVE"W5D8;@?H&+#\*R$TZ72O
M%5_(NC6FJ1*1<@>4@N$!ZF,GEL''''MD\5XTZ2FHR6A]!EF9?V=.4G!235M2
M_P"!=/U+4_AMH=IXG1'U9K&+[8C#.)MHR0>QSWI\7B./0[G^Q-=,A)3,%TZ9
M2XC]"0.&'0^O!K>TC6K368B]M+G'WHW4JZ>S*>0?J*37M(CUNP:%^)%.Z.0=
M4;L:Z6GR^Z>/)\TG)F3O-N#/IU\]Q:9SY:$/Y7U'<?K5RSUUWF1+FW\N$CBZ
M4YB?V'<?C6!!937@E@M_*TSQ/9?,  1%,.F2/XE/0^E4-/UUKUMEU!+I.IH?
M+GL6<-$[]]K=,^F<9IQJ6T>Y#1J>(?"]Y;%K_P /7#VIE.^XM8" DX[D9!VO
M[CKWI^A:3HNMV[3NL][,I_>Q7SLSQMZ%20!^5:&B7R6<4GG ^1NVB0$_NV_N
MNO\ ">?I3M:\.?VC*-2TV?[%J"C"S ?))[..ZGU'->A3K=&82CU1HP6\%JGE
MV\,4"'@I&@4?CBL+6? VFZJI>,3Z;*3DR6$ACW'W4<'\16-;^+=8FE>VU1[#
MPW<QY$D,S&61_P#;CQ@,#UZY]0#6-XO\96OAO0Y=5.K:K=2QG;%-]E>.$L>Q
MRN,>O-=6L=3-\O4V)_#K:+'F?2%U&$=;S3V,5W&/4C=AOP(^E53IT^I3F2RU
MR358PN%T^\E:!X_^!* <_4-4W@CXDW>L:!;:CJVGR06KDK]NME+QY']Y1\R_
M7&/<5U<^DZ5X@B6Y"Q39'RW%M(-_YC^M2IO<2MT.6CU"[M?]&N+A[<G_ )<=
M<A$T3?[LJX_,UC>,-6D\,^'KF_L-(O=.U!"!')IDAFMWR>2 /;/!7\:[2?2M
M7L(]EO)#K5D/O6M[\L@'^R^,'\<?6LRV.FM=>5;W5UX;OSG-O<C",?8'Y6'T
M-5):,'=JQB> _&'BB]\.)JE\UE=09;=;RXMIP,\$\D GK@@5OZC\4=+T;19M
M1NX;JV9!D12IQ)_NNN5Q[Y%<Q\0]%232S9ZXD-NMRP\K4M+<;F;_ &H203^&
M:R?AOXE:76$\#/8MJ6DVZNIENH65]I))D8,,8)X !XKF<N7W5]Y"<OA/3O _
MC2T\?Z%'J=DK+'YC1LK')##&?J.1S71USJ^"=+LH]NGK)I.#Q]C;:,_3G^5<
MO\/M&\;Z;XJU.37[P76FL6\I]RX<9^7: 3C\<4:QLC;5:,]*HIO>G5;5B@J"
M\N([2UFN)6V1PH9&8]  ,FIZSO$.C1>(M$O-,GDDB@ND\N1H6 ;:2,@'WZ?C
M0M]=A'BNB?'*_%AXOGN9[>[GCM'U+2X0 %2,-LV.1UPQ4D]<&M&;Q)K/@;5M
M..H>+QJMQ/&7NM.NK7;&Y*Y40.B  ^S,>*[74OA)X;U)M-W6@MEL8I+<?9P%
M$L3QF-DDQU!!S]0#5&'X-:=Y^FR7NJ:EJ<&G/NM+>=P5C[<\ GCUKM<Z3=UH
M<_+/:YG>&X/%>IZ;I'BA_%$:&^=)IM-GB06JPOG$:$88.!CG)R<\5ZE]X<<C
MU-<#:?""SM);*)M2OY]*LYS<V^F22#RHVYQSU(&>!_A7?)SDXQGL>M<M1QWB
MS:-[ZEB 5=B%5(15V,<5QG63+TJ6HUJ2@ KF_'O_ " U_P"NR_R-=)7-^/?^
M0&O_ %V7^1H 9\/O^0++_P!=V_\ 05KIZYCX??\ (%E_Z[M_Z"M=/0 4@I:*
M *UXO[HD=15(<_A6C.-T9%9P'45<3.2ZGGC03>+O$NLPW%_<6,.GX2&&)MI^
M[G>?7FN8>YU#5?#^C7\NI7,<TFI?V?*T3X66-9"H;ZG ->EZMX*TW5KPW4OF
MQ3LOEN\+E2Z^AQ5C_A%-,-C9V?V<"WM)%EA0?PL.AKJC/E.&5/G9P3^)-0T/
M4O$VGPPWFHPVT:>5*I!\K*9.:Y[1=7U#5]1A6YDU&[3[%&^RUD"[6+<DYKV1
M= LDEOY!%A[X 3G^]@8_E6,?AMHJRK)''+ Z1B+,<A7*@YJE5BMT0Z-1[,\\
MUK5;J+5/$!\S5<V<:>08&!6,X_B_K7K/AN:>XT&RDN)1/,T2LTB]&.*9;^%=
M.MEO%6(G[6NV8L<[QC'-7K"PATRTAMK<;88E"*N>@J)24HZ&L*<HRNRT.12[
M: .*6LCH&D8--8#OR/0T\\U6NKD6L$DC*6"*7PO).!GB@#.\0Z#IFOV0CU.V
MCFMHSOS)P%([Y[5C67B/1+V,PZ?J0DM[<>6+:T&2N.,5S.A>/K;Q]-J=F]A>
M2% 0(D/R[3Q@GL?8UR/PF%YH^OZS:):#2K;YGEN[@9:( X"9Z5BW>2ML82J<
MKT6YZT':1_-@L8K<H.);M^?KBHUF$J@7=[/?S-U@M$(3\Z\^\/>&KJ;QK/JZ
MZNWB&S^8+%#(2I)Z;NPQ7I"P7S1NTY6PM@V$BM1EF^IK:+35UH&LB![@V*$0
MV]O8D]-_[R4_0"J<]K)J2-)JMU-!9J<E6;:[CTP.@K12!K67_5+I]L%RUU,<
MN?;FN,\?>.;OPZ;:+2-(>_-R=OVJX0D,<]!_C5.=E="<8PUDSMQ/;)8J8H8K
M*V(&))!\[>F!UJI)([1^:-T*'_EO<\NW^ZO:ELS'$MLVPWNH2A5:23[D1(Z>
MG%;4M@ME&TLL;7MPW'(X_#T%1?J:K78^4OVP?$E]I?A*QTVQ8QQ:G(R7$DN=
MTB+@D9[<XKX@N45"RKE%/1.[U]D?MUW\26OAB5+N&X$-R\5Q;Q-Q!N&5)QTZ
M8R:^1YH8[J5IH'1W/)*-N4#ZU\QF,Y2JV;T/U7@^K'"QE*?PROJNEM^;MY&6
MW 4G&[HL8Z5/%$8UP>6SR32M 89"6P9#U-1R3F5BD7./O,.@KRK*Y^OJ=X*<
M>NQZ_P#LO_$V^\ _%O3K.T8R0:Q_HCVY;"M(>4)].]??&O\ A62#PYJ6H73B
MZU81F;SVZ1[2& 4=AQ7YJ_!O2IKOXI^&H[4;KF*Z%UD\EMO&/_'A7Z4?%[Q/
M=^&?A[-/:VGVJ\NU%JL6>[J<G\,&OJ<MDUAXR?=GX/QI"E',W[/JDWZG;6TO
MVJW@F5@WF1AAGOD"L;3P;CQ=JLI.4A@2,>QY.*/A]J4NL>#M*NIK9K.9H50Q
M/U&./Z5@:!=2VGBG5+O<S6NI2/&%)X1XUQ^M>HO>NSX24O=6AT7@=S_8()ZM
M-*?_ !XTWQQ>O9:% $4OYUS&&0=2@.6-'@AQ)X:MR%926?(8?[1J?5VBN_$N
MG6,R?NO(D8Y]2,?XUS8AWCRK<V@D6?$MFNJ>'9#'@LBB:)AS\R_,,?@,50\$
M6GASRY-1T>"*"YNE#S ##YZ\@^]6_"\KQVUQI=Q\T]DQCY_BC/W3^7\JS-+\
M/6\XOK($VMW:SL8IH3M;8W*_45Q-)-,UM=W.P,:31LK@,C#D8X-<+?:3<^%=
M47[-?RVVG7+?)N^9(7]"/0UM#6;W0V$>I0F>WZ"\A7('^\!TK7Q::W8G.RZM
MI5(RO(-.24EJ-'*WNH_9;Q+?5&BMKB;'D78_U,_^RWH:FM;]M/F=8(&M"&RT
M;'=&_NI]*@O+2WM\>'M91KFQN#BSNBN[:>RD]F':L8Q7OA^_^PW)>XB090_Q
M,O\ >3W'=:%4:T8K';WNCVWB6R221?*FZQS1-\R-Z@UE6_B"?19UL=<Q$HXB
MOLX23Z^AIVGWQ98W@F5=_P!UQ_JY?8_W36A(;?Q%#-I^J6(C!X\N7!WCU%=M
M.KT9BXWV*\WBS3D#"!Y;V3H5MXRU4KGQU;Z=(C:K:3:;:R,$CFFQ@D]B!R*R
M+[2[_P ,7(ADO9DT,\)+;H \/LQZD>]9GCKX1MXPBL+NPUB=1"-_DR/OCE']
M#78[6T,&VCMI=!TS61]KLY/*E/(N;5L'\>U9M[I6H6Z'[=:1:[;CHZ?),H_K
M^%<+HWC"(^-(_#EG:7.CZC"OELWWHI& [CT/K7H%SXU;03MUVU>V4<"Z@0O$
MWY<C\:F.Y%[F=';6]\"EA?[6'WM/U%,X]AGFN<\6^!M-UIH%UBUO=*,&=DEJ
MYD@YZY') KL;W7_#VJP!ID>1&^[.(7X]]P%-C2YTZR>ZT_5(;[30-QBNV! '
MLW^-:2LUJ.R:U//O&VJ:EH5EI46GZ;9:K:J0GVFU!W*!T! Y''>KNM^#G^).
MDP)H7B9[:2 JTD$C;U0]QQS^-8%SKM]X@\?I;-I_]DZ)< H;N)@(V!')#CC-
M=;X>TK1O@_/(GV_[4VH$!#,^7QVY'&/>N5W>O0E*^^QOKKFH>!O#Z?VK8R7<
M-I#A[JV.[( ZD=:N> /B#9?$'3IKJSBDA\I]C)(,'U'Z5KQ7<&JQ^2Z':Z_-
M$Z\$?UJ32M%L-#@:&PM8[6-B6*QC&36G*V[K8UM8O Y-+35ZTZKE:^@V KB_
MBMI6J:]X<31]*4JU],L<]QQB*+JQ([UVE&1ZTHMQ=T)J^AX!-\/?%'A35)$M
M+<:Y8VEY#JT(4!%D;!62,#L1PP^M5]?\+^*?'.L:G<06=[;:;);>8D>HE1NF
M617" #D+P1SZU]#$@< G\*0X)!/88KH]M.6MC+V:Z' >'/$NM^(==TZ%] DT
MNRMH3]IFNP-V_& L>.WO7H<"EI%!ZYIA16YZ5/IZ[I_85S2=^AM!:FRHPH%+
M2+TI:YSJ"N;\??\ (#7_ *[+_(UTE<WX^_Y :_\ 79?Y&@!OP_\ ^0++_P!=
MV_\ 05KIJYGX?_\ (%E_Z[M_Z"M=-0 4444 %1W'_'O+_NG^525'<?\ 'O+_
M +I_E0!^>/\ P4H_Y-KD_P"PQ:?R>ORAK]7O^"E'_)M<G_88M/Y/7Y0UZN&^
M SEN%%%%=8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_0K]A
M3X!^%_AC\&O%7[17Q9TBVU#0[6RE71=+U&!)$F4':9=C@@M))B&//JQZ,IJ)
MS4%<#\]:*V_''BN;QSXPUGQ!<6EI82ZE=27)M+"%88( QR(XT4 *JC  ]!6)
M5@%%>V?LB_LTZI^U!\7;'PY;^;;:#:XN]:U%!_Q[6P/(!Z>8Y^51ZDG&%-?9
M_P#P4Z_9L^&7P9_9]\.ZKX+\&Z=X?U.3Q+;64EW:JWF/";2Z8HS$G(+1H3[J
M*RE549*'5CL?F)117N7[)7[*'B+]JWQ[)I&F3#2M!T]5EU;69$WK:QL3M55R
M-\C[6VKD="20!6C:BKL1X;17Z[>)?A!^Q;^R%':Z+XWBLM5\1-&KNFJ^?J=[
M(,<.\,0*1 ]1E$![9J6+]D/]E3]K_P &ZA>?"B[M]$U.!L&_T1YDDMG(^436
M4Y'R'_=0G!VMP:YOK"WL[=QV/R$HKN?C7\'?$/P&^).L>"_$L'E:AI\GR3(#
MY5S">8YHSW1AR.XY!P00+GP!^!GB']HKXG:9X+\-JB75UF6XNY0?*L[=<>9,
M^.PR !W8J!R:Z.96YN@CSJBOV O?V6?V2_V.O"NGS?$Z6TU?5;A<"[UYIKF>
MZ8#YC%9PY 0'OL.,@,YZT>%_@U^QC^U_:7FE>![6PT_7(HB^W1_/TR^@'=UA
MD 24#N=CJ,C.,US_ %A;V=NX['X_T5[;^UG^RSKW[*GQ&&@ZE.-3T:^1KC2=
M71-BW40.&#+D[9$) 9<GJI'#"O$JZ4U)70@HHKVW]BKP=HOC_P#:B\ ^'_$6
MG0:OHM]=RI<V5R,QRJ()6 (^H!_"ANR; \2HK[G_ ."J'P8\$?!OQ;X MO!/
MAJQ\-P7UC=27,=BA42LLB!2<D] 3^=?#%3"2G%20/0***^P/^"9OP]^'WQ&^
M+OB>Q^(NF:5JFE0:&T]O'J[A8UF^T0C*Y(^;:6_ FG*7*G(#X_HKW_\ ;P\)
M^%/!'[3_ (KT?P39V-AX;@BLC;6^FL&@4M:1,^T@GJY8GGJ37@%$7S), HHH
MJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBNI^%OPY
MU3XN_$+0?!NB/;QZKK-TMK;O=N4B5CW8@$@  G@$^U#=M0.6HKZC_;8_9!TW
M]DG3?AY8Q:W<:_K>M0WDVI73((X T9A"K$G)"C>W+$D]>.@^7*F,E-70!111
M5 %%%% !1110 445<T72;C7M8L-,M INKV>.VA#G +NP5<GL,D4 4Z*^P/VJ
M_P!A&+]E/X#>&_$6KZ^=:\8:IK*6=S':+MLK:(P2N43<-SMN1?G.WC@*.I^/
MZF,E-70!1115 %%%% !1110 45]3_P#!-OX:>%_BO^T>-"\7Z):Z_I']CW4_
MV.\4LGF*8]K8!ZC)_.G_ /!2CX9^%OA/^T:FA^$-$M?#^D'1;6X^R6:E4\QF
ME#-@GJ<#\JSYUS\@6ZGRK17VO_P39\3>!?%GB+Q!\&_B%X>TG4['Q7;RG2]0
MNK2,W,%SY9$D23%=R;XQN4@C:\8QR]?.W[2/P(UC]G'XN:SX+U?=,EN_G6%Z
M5PMY:,3Y4H^H!# =&5AVH4[R<6%CS&BBBM "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#]E?V"O^37?AW_NW'_I9-7VW7Q)^P5_R:[\._P#=N/\
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M!'!<CIQV%6]1^'6A:]:6RZEIRS218?=YCABW?<P.2/8\5TT,2Q(D2*$15"@
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ME71 ;3'-Y>0E<>;=RY()/\2QKA1[[O05ZC\0-4=K[2;&(*\$4R7NH CI;JP
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M Z5!:?$[3=?UJ71=$=;N]12S,V1&H!P2#W_"L_P=\)E\/:I?75[J3W\4Q^6
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MUZWQ29W5PR6]O)+D(L:%N!Z"O(&^(&@::NCP3W\7G7$4\R\_Q-G&3VS7HWQ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV-=[X\_X)-_&OPCI$M_IDWA_Q;Y2EFL]*O)$N2 ,G:LT:*WT#9/85H?M,_\
M!3/XA^)O&NI:-\,]53P=X+TZ9[2SEL($-Q>1H=HE9V4[ <954"X! ))YKT#_
M ()]?M[_ !#\5_&72?AW\0-8;Q/I>NB2*SO[N-%N;2X6-I%!=0"Z/L*X;)!*
MD$ $%2E62Y]/0>A^=&JZ5>Z'J=UIVHVD]AJ%I*T%Q:W,9CEAD4X9&4\@@@@@
MTW3M.N]7O[>QL;6:]O;F188+:WC,DDKL<*JJ,EB20 !R:^[?^"OOPRL/"WQK
M\->+K)!#+XGTYUO$48#SVQ5/,^ICDB7_ (![U'_P2OF^%/@[Q7XC\9^/O%?A
M_1/$-N$L=$@UJ\BM_+# F:=3(0 Q&Q P.0#(.]:^T_=\]A6UL<9\._\ @EA\
M<_'>G0WU[9:/X/AE4.D>OWK+,0?6.%)&4^S[3ZXKJ->_X) _&+3;-Y]/UWPE
MJ\BC/V:*\GBD<^B[X0OYL*I_M:?\%&_B-XO^*.N:5\/?%,WAKP7IMT]I92:0
M562^"$J;AIL;L.02JJ0 I7@GFN+^"G_!1CXQ_#3Q?IMSK?BR]\8>'?.1;_3=
M983M)#N&\I(1O1PN<'.,XR".*S_?-7T#0\%^)OPI\6_!OQ3-X<\9Z%=:!J\2
MA_(N0")$)(#HZDJZD@_,I(X//%<I'&TLBHBEW8A551DD]@!7[ _\%=? .E^(
M?V?M$\7E%.J:'JL<4%PO\4%PI61/<%DB8?[OO7R/_P $I_AQH?C_ /::EN];
MMHKW_A'=(EU:RMYE#+]I$T,:28/!V>:6'HVT]JJ-6]/G86UL9_PW_P""6_QR
M^(.E6VHW5AI/A"WN '2/Q!=M'/M/<Q1)(R'_ &7"GU K<\9?\$D_C9X;T^2Z
MTNY\->*"@)%IIU^\4[8]!-&B?^/UZ9_P4E_:S^,?P[^-\_@OP[J]]X,\,6UI
M!/:W-@@CEU$O&&>3SL;L*Y:/:I ^3)R:\7_9L_X*)_%'X<_$?1?^$P\77_BK
MP;<W,<&J6^L/]H>*%FPTT<A!<,@); .&Q@CH1"=:4>96'H?+/BCPKK'@G7[W
M0_$&F76C:Q9/Y=Q8WL1BEB;&<%3SR""#W!!'!K+K[F_X*9?&OX,_'F]\*:Y\
M/M=76/%%@9++4)8["X@66V(W1Y>6-0Q1]P&,\2'TJY_P2H_9GTSXH^.]6^(?
MB6R2^T?PO)'%I]K.H:*:^8;M[ \$1+A@#_$Z'^&M?:6ASR5A6UL>9_![_@FQ
M\:_C!I%OJZ:39>$M*N%WP7'B6=[=Y5[$1(CR 'L64 ]0<5V7C'_@DC\:?#FF
M27FEWGAKQ.Z+G['87TD4[<=A-&B?^/UZ/^W9_P %&O&.F_$G6/A_\+]3&@:;
MH=PUGJ&LP1AKJYN4)66-&8$)&C97(&XE2=VTC/@?P<_X*._&CX7^)[2\U7Q/
M=^-M$#_Z7I.MR"7SD)YV3$%XV'8@D#NI'%9)UI+F5O0-#YP\3^%M8\%:]>Z)
MK^F7>C:O9OY=Q97L+12Q-UP5//0@CU!!%9D<;2R*B*7=B%55&23V %?KW_P4
M"^$/AG]I7]F"P^-/A:W4ZQI>FQ:M!=A DESIS@-+%+ZF,,7&?NE' ^\:^3?^
M"4_PXT/Q_P#M-2W>MVT5[_PCND2ZM96\RAE^TB:&-),'@[/-+#T;:>U7&JG!
MS?0+:F?\-_\ @EO\<OB#I5MJ-U8:3X0M[@!TC\07;1S[3W,422,A_P!EPI]0
M*W/&7_!)/XV>&]/DNM+N?#7B@H"1::=?O%.V/031HG_C]>F?\%)?VL_C'\._
MC?/X+\.ZO?>#/#%M:03VMS8((Y=1+QAGD\[&["N6CVJ0/DR<FO%_V;/^"B?Q
M1^'/Q'T7_A,/%U_XJ\&W-S'!JEOK#_:'BA9L--'(07#("6P#AL8(Z$0G6E'F
M5AZ'RSXH\*ZQX)U^]T/Q!IEUHVL63^7<6-[$8I8FQG!4\\@@@]P01P:RZ^YO
M^"F7QK^#/QYO?"FN?#[75UCQ18&2RU"6.PN(%EMB-T>7EC4,4?<!C/$A]*^&
M:Z(2<HIM6)85]K?\$\?V5/'GBWXC>!?BWI\-@W@_2]8<7$DET%G'EJ0V(\<_
M>'>OBFOK/_@G]\>O'_A_XW_#WX?:?XFN[7P;?:P3<Z0BIY4N]26R2N[G:._:
MIJWY'RC6Y]N_\%'OV2/B!^TYJO@.?P3!I\T>CPWB77VZ[$!!D:$IMR#G_5M7
MY&>._!FI?#KQIKGA;6%B35=&O);&Z6%]Z"6-BK;6[C(/-?J=_P %3?V@OB'\
M$-8^'47@;Q3>>'(]1@OFNUM50^:4: (3N4]-[=/6O@W]F?X6:G^U]^TYI^F>
M(KV>\74[F;5]?OP0LCPJ=\S9 X9V(0$#@R ]JPH-QIWEL-[E#X#?L=_%/]HU
M#=^$?#Y&BJYC?6M2D^S688'!"N>9".X0,1WQ7T#??\$>OC!;:>TT'B3P;=W*
MJ2;9+NZ7=[*S6X&?K@>]?47[>'[7P_9!\+^'OAQ\,["QTSQ%=6(DAQ;@P:39
M M'&T<?W2[,K!0<@;&)!R*_._1OV\_CYHFO#5H_B7J]U-N#-;WI2>W8 YV^4
MRE #T.T TXRJU%S1LD+1'GWQA^!7CGX"^(AHOCGP]<Z)=R M!*^'@N5'5HI5
M)1P,C.#D9&0#7!U^V/P\\2^&/^"F'[)VHVGB'3+?3==BD>SN!""W]G:@BAHK
MB GY@C!E.,]"Z$M@D_DO\*_ABNL_M%^%?A]XE0VJS^)[;1-2B#8*_P"DK%*@
M/K]X ^N*TIU.9-2W0-';_ C]A7XN?M#:,FM^'-$@L/#TA*Q:OK-Q]F@F(.#Y
M8PSN 01N52N01G(Q7M.H_P#!'SXQ6FGF>V\1>#KZX5<FVCO+E&8^BLUN ?Q*
MU]8?\%'?C3XY_9H^$7@_3_A?;+X=TJ[EDL+C5+*U4KIT4<:"&",$%8]X+X.,
M@1<8-?F_X7_;K^._A378=4A^)6M:@Z.':UU2;[5;R#NK1OD8(],'T(/-9QE5
MJ+FC9(-$<'\8?@3XZ^ OB%=&\<^'KG0[J4%H)),/!<J,9:*524<#(S@Y&1D"
MO2_V1?V5/'GQZ\06WB3PI#82:9X>U>T-\UW=")Q\XD^48.[Y5-?7'[5/[8_P
M0_:2_9*_LO5-72W^(<UE!J-KI45A<R&QU%0"\8F\O9M/[R/.[E6R?;XD_9J^
M/7C_ .%'C'2=&\)>)KO1-+UC5[07]M;JA6X_>*GS;E)^Z2./6K4IR@]+,.I^
ML'_!1#]G3QC^TI\*_#N@>"XK.74+'6EOIA>W(A41""5."0<G+KQ7XW_&3X0>
M(?@3\0=0\&>*8[>/6[%(GF6UF\V,"2-9%PV!GY6%?KI_P4]^,?C/X*_!WPOJ
MW@C7[GP]J-UKRVLUQ;!"SQ&WF;:=P(QE5/X5^3]C+XS_ &J/C;HUIJ^JRZSX
MK\2WMMI[:A<JN0/EC#L% &U$&3CLM98?F4;O8;#X*?LZ?$+]H369=/\  WAV
MXU;R"/M-XQ$5K;9Z>9*Q"J2,X7.XX. :^I(/^"//Q?DL!+)XF\&0W1 (MS=W
M1 ]BPM^OTR/>OL;]H+XK>&/^"<O[-VA:#X(TFVDUBY)L](MKE<K/*JJ9[NX*
MX+D94G!!+.@&%Z?F/>_MX?'R^UXZNWQ-UF*XW%A#"42V&3G'D!?+(^JFJ4ZE
M36&B%HC!^._[*7Q,_9QN(O\ A-/#SVVG3OY<&K6;B>SE;GY1(OW6."0KA6(!
M.,5Y%7[,?L8?M+6'[<_PJ\4^ /B9I-E?:W96J1:@BIMBU*V?*B=5'^KD5@,[
M<88HR[<X7\J_VAOA%<_ CXT^+/ MQ(TZZ1>%+>=\;I;=U$D#G'&6C="0.A)%
M:4ZCDW"6Z!HR_A;\(?&/QK\4)X>\%:#=:_JK+YC16X 6),@;Y'8A47) W,0,
MD"OK:Q_X(_\ QDN=,^T3Z]X.L[HJ&%I)>W+,/9F6W*@_0D>]?8_PUT7PY_P3
MO_8KD\2ZAIR7/B(V<5[J2X$<U]J,V!%;%L$A(RX3OA5=L9)S^;WB_P#X*#_'
MGQ9XIEUI/'M]HJ^:9(=.TI5AM85/1-F#O '_ #TW'U)K-3J5&^38=DMSZ&_8
M%_9]\=_L]?MIQ:-XXT*72IIM OGMKE6$MM=*&BRT4JY5L9&1U&1D#->??\%:
MO^3K4_[%^S_]#FK[-_X)Z_MG7/[3FGWOASQI;6K>/?#UN+F/4(HE7[=;L1&\
MH4#$;J657VX4[UP!R!\9?\%:O^3K4_[%^S_]#FJ(.3K>]O8.A\@>&?$6H>$/
M$>EZ[I-PUIJFF745Y:SIUCEC8,C?@0*_4_\ X*"^![/]IK]D?P;\;/#]J/[1
MTJSBU&:-.6%E.J^?&<=3%)M/L%D]:_)ZOV._X)K75O\ %_\ 8@U7P5J<AEM+
M:YU+P_*K<D03H)?RQ<L!],=JTK^[::Z"78_'&BKNN:1<>'M:U#2[L!;NQN)+
M:8 Y =&*M^H-4JZA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^R
MO[!7_)KOP[_W;C_TLFK[;KXD_8*_Y-=^'?\ NW'_ *635]MUX=3XWZFBV"BB
MBLQA5>[3(5O0XJQ39%WHPIK<F2NK&8WWC24I.325TF/0****8!1110 4444
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M@IH%UK_B!DCUNYB!E!8%;= "0H([\\UZQX&E/B&?4-<N XNFE,$<3\>3& "
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MY;GK&]?&?[0'[%>H6^HW6O> (1=6\S>;-HWF /&<<^43U''W>O6OM]F"@D\
M=ZYO7?$SB\&F:3$M[J9&6!/[N$?WG/\ 2L*E"%=.,D>EE^98G*ZZQ&&E9_FN
MQ^./CSX5>(=/U5X6\-ZO:ZJ1E[/^SIF$GK@JI_.IO"'[+OQ3\:WMK;6/A&YM
M!<[O)FU!A C;>3][![^E?JMH_P#9OAG4?$.O:WJ$;E9/(DN[DX!VCY@@[#/
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M(@HHHH ?#$995'OFMM1MP!TK/TV/DO\ A6@.M8S>MC>"T'4445)H%<WX^_Y
M:_\ 79?Y&NDKF_'W_(#7_KLO\C0 WX?_ /(%E_Z[M_Z"M=-7,_#_ /Y LO\
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M5\37>5/F7/AR:9OJ\UIS_P "D4?]=!_=%>?&#C!58[EWUL?F37WU_P $</\
MDO/C/_L6F_\ 2J"N _X*,_LG']GSXHGQ#H%GY7@3Q-*\UHL:_)8W/WI;;T"]
M70?W20/N$UW_ /P1P_Y+SXS_ .Q:;_TJ@KJJ24Z3DB5N>5_\%./^3T/''_7'
M3O\ TA@K[_\ ^">5P]G^P':3Q,5DBCU=U([$33$5\ ?\%./^3T/''_7'3O\
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MSNC4YQGKZFOC3]MOQAX*^+7[;/A;5?"VN6&O:'J"Z5!=WMDV^/S!.4=6/<A
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M-1S+3D;<N:TBWL9R74=1115IF84444P"BBB@ HHHH **** "BB@GIQDF@ )
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M0I63*CN:5O$(HE7%24+TI:Y]SH04444#"N;\??\ (#7_ *[+_(UTE<WX^_Y
M:_\ 79?Y&@!OP_\ ^0++_P!=V_\ 05KIJYGX?_\ (%E_Z[M_Z"M=-0 4444
M%1W'_'O+_NG^525'<?\ 'O+_ +I_E0!^>/\ P4H_Y-KD_P"PQ:?R>ORAK]7O
M^"E'_)M<G_88M/Y/7Y0UZN&^ SEN%%%%=8@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\\?V?B[PA?"UU"$&*:"8%H+N$D;HI4R-RG [@@@$$$ UP-%=%DU81^K^E?\
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M7= U[4/"VN:?K&DW<MAJFGSI=6MU"</#*C!E93Z@@&J%%*,5%<J _2[XA_\
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M^U?K5H-0@30/"VGL7L=!M9FD0.<CS97('F28. <  9P!EB?)/AA\3/$/P?\
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M-0C\16'@&P?6D82(;3P?"DZ..0RE@J!L_P 0.?>OR<HJ70@W=:!<^X?VO?\
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MJ*?2**6@ HHHH *YOQ[_ ,@-?^NR_P C725S?CW_ ) :_P#79?Y&@!GP^_Y
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MMBVB$40'?J:HZ?;[W\P]!P*U,\=*RE+H;0CU!>E+2#I2U!J%%%% !7-^/O\
MD!K_ -=E_D:Z2N;\??\ (#7_ *[+_(T -^'_ /R!9?\ KNW_ *"M=-7,_#__
M ) LO_7=O_05KIJ "BBB@ J.X_X]Y?\ =/\ *I*CN/\ CWE_W3_*@#\\?^"E
M'_)M<G_88M/Y/7Y0U^KW_!2C_DVN3_L,6G\GK\H:]7#? 9RW"BBBNL04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %==\+_BUXO\ @MXG'B+P5KEQ
MH&L>2]N;F!5;=&V-R,K@JPR <$'D ]0*Y&BDU?1@:_B[Q9JOCOQ/J?B'7+D7
MNL:E.US=W(B2+S96.6<J@"@D\G Y))ZFLBBBF 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >B^!OVA_B'\-/ ^M>$/"_B6?1?#^L^8;^VM8(
M0\^]!&V92GF#Y1CAACG&,FO.J**5DM@"BBBF 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?LK^P5_P FN_#O_=N/_2R:NR_:6_X* ^&OV8/B9;>#
M_$/A/6;^2XLH;^._LWB\IHG=TR Q!R&C<'Z5QO[!7_)KOP[_ -VX_P#2R:O+
M/^"S'P_\S2_AUXWACQY,UQHUS)CKO430C\-D_P"=>3&,95G&7F7T/T?U37;'
M1]"N]9N9U33;6V>[EG!RHB52Y;Z;037QI\)/^"J7@3XL_$SPYX-@\)ZYI-QK
M=XEC#>7<D)C21^$#!6SRV%X[FL7XH_M _P#&JS3/$27.=3UW0;;PT'W<R3$_
M9;G\=D5P?PK\U;OX>Z_\(O!?PJ^*T3LBZY>W5WIQQCRY+*X102?=N1[#BKI4
M8R3YO0&S]X?CK\8=*^ ?PIU[QWK-O-=Z?I*1L]M;%1)*SRI$BKN(&2SBN0_9
M6_:BTS]JSPAJ_B/1O#^HZ%I^GWW]GYU!T8S2"-7;;L)Z!TZ_WJ^9/^"JOQ>M
M-4_9<\!V^ES?N/&=];ZE'S_K+1(/-_\ 0I8#7>_LH:_X<_9'_8"\.>+_ !=(
M]I:7$#:U<+"@::YDN9,VZ1J2-SM'Y('.."20 2,O9KV=^K8[ZGV52,H=2#T-
M?F:/^"J7Q2U^'4/$OAOX(27W@2P=Q<W^+J<1*.?WERB>7&<8)!!QGK7V3^RO
M^U1X8_:K\"S:YH4,VF:E8.D&J:1<L&DM)&7*D,.'1L-M? SM.0""*B5*<%=H
M+IGJTB&-RI[4VOC7]J3_ (*-VWPN^)+?#KX>>%)?'?C&WE^S76&<PQ3D B"-
M(P7FD&<,!MVGC).0.;^$'_!2V_G^)-CX&^,G@"Y^'FJ7KQPPW;)+$L<CMA/.
MAF4/&C$_?R0.XQDCHC";C>QBU8^[J^:OVIOV[/!W[+NOZ5H5_IUUXDUJ\B:X
MFL].FC5K2/@(TF[H7^; ]%)[C/2_MA^*OB;X5^$2O\)-/GU#QC?:C#8QBWM!
M<O#$ZN7D ;Y5QM'SN-HSS7Y%_M3_ +/WC;X)WWAO4_B+K/\ :OB_Q7#/J%[&
MTQN)("K*H628D^8YSSCY1C +#FM*<%+<#]U= U9-?T+3=4CC:*.]MH[E8V.2
MH=0P!^F:OUSOPX_Y)YX7_P"P5:_^B5KHJQ$8GC7P3HGQ%\,WGA[Q'I\6JZ->
M!1/:3$A7VL'7D$$890<@]J\9_:$_:%\'?L3>!_#>/"<KZ1?7#V=M8Z&D4"0E
M4W$D' Y_.OH&OSX_X+%?\DT^'O\ V%Y__1-7!)R28'NG[+7[<WA7]J?Q1K.@
MZ/HFI:'J&G68OMFH/&WG1[PC%=A/W2R9S_>%=E^U!^TYH'[+/@G3O$6N:?=Z
ML+^_6P@L[%D$I)C=R_S$#: F#[L*_+O]CZ^E^ '[7_PR,\C)I?BK2[.,NQQY
MJ7]LNT?07.T?\ KV+_@J;XBE^(WQ]^&?POL9B?(B1Y-G.V>\F6, CU5(E;Z/
M[UHZ47-+H%M3Z>_9I_;]\*_M,^.-1\,:7X=U30I[+3)-4>YU"6(QE$EBC*C:
M2<YF!_ UZKXMU[4?%.DSII1:STR1Q +HY5YB3C"=P,]^*_,;_@F;I6GC]IGQ
M;#=.T.GV?AZ\;:[=56\M0%;U'3([XKZ*^"?[=5[\1OVAF^'OCCPU:>%XM.6\
MC@2UN6=?M5N"Q5@RC(*I(1[A<=:)PLWRK831]KVXLO!GAV/>!%'#&H;NSMC\
MR2:P(2EM+<>+_$M[#IFGVL1DC^V2K%#:Q]2\C,0!QW/2OF7]HO\ ;53X6:3'
MXBCT:/5Y?MZVFG:1=2&)7&UF>=F )X  QZNM>3?MA?M1>-/'G[(GAJ/4_ L6
MG67C^W:\N+FWEED73X8+R![=BQ7!\T*",D<,,9-9QBY6:Z@NY]U?!OXL>%?C
M/I6LZ[X3U,ZS8V>HR:8]Z(V2-I$2-V\K=@LN)%&[ !(.,C!,/QJU+5K+PK=2
M:9=1V=O;(T]_<RR+&L,*C+,68@*  2237Y]_\$ROV@/$GAJ_TKX7VG@][[P]
MK.LW-W<>(AYFVU?[*OR<*4_Y8IU(^_\ 2O1OVB?A+\?/VH/CGXA\ V-Q/X9^
M#]C=0[]2FB\FWN?W,;NQ&0]TP<L H.P,HR5()K.=)N;BW9%M75C1_9+^,G@?
M]HCXQR:=8Z3J5EJ.AZ?+J;7MQ*GV>X"3QQ[@OWE)\U6P?0U]@Z!<6GC77I=4
MCD-QI]@[0VZD$*9/XFQW[BORP_X)?6MU-^T%XETZTSFX\.SP22?W(_M=J6/Y
M+CZFOUC\,P0:7?ZM8QA8K>*5=H P,;!D_P!:N5*-)M1,K*+T*7CS5DM[:RTH
M2/\ :=4F\D!.H7J3].,?C71P00Z18)%&!%;P)A 3P% Z&N'D":KJ@UE@67[7
M]GMF;LHR&Q]2*W/'8>\TM-+B<QRZ@X@R.JKW;]*AJ]AI[G">*_&6D^"?#:^+
M=7F-KYM\DP=LDF//"\?C7$^"OVD/#?Q<UO5XM/F>+5+IX[&WM;A<,T);YF&/
MJ:R_VF_AUKWCRUD@T>9'TWP];([6;,0)9.<JOJ>*\"^"?P[\7_#KQK9:_J'A
MR[TRZL0\ZV]\F/,1AC(QG\ZX:U>K"LHQC>)[&'H8.6!JUJTK3C:R[WW/M'7!
M%JEIKMG*JR6R20:=$I'4?(6Q^9KN_"7A/3?!^EBSTZU%M&>64,3N/J2:^<]/
M^*?B/6)]'LK;1E#I>F:X8@GS,DX[=@1^5?4MJ[RV\;RKY<C*"R^A[BNA2C.6
MB/%@X/5(D49..]>7?$'Q5I>D^.;.#5I5>P:$V\UNZ[EVOP3TZ>M>I(O[P$=!
MUKSK_A%]%\=^)]275;8S&&8/;NK8#IGH?[P&.GO7'B9.Z2.C5J\=SP^+]BKP
M5:_%J&YEU>X.BW&+RVT9MIC9\YVEB=V.!Q^%>[W.G6^BZ3KSQG[-#8W,#*@X
M5$54X'X4GB#X3RZWXPL-52]>&&V9&V=#\IS@>@.*N:BMMK6O^(O#-TC*MY:B
M5#V;@#^8KB<>5;'56Q>(Q#2JR<K=S&3XN^%H/&=O);WXD75H-K%,[5<8"@^G
M&:].L+8VUJ(F(^4D+CT[5X)8?#;PAX1@T6\OY$FNDO#&XD; .,@97V('-?02
MNLBAE;<IY!]:NBY/1LY8-O<CN(OM4#POC8ZE"/:N2\/Q-#I4EO)N:ZTN=D!9
MLMM/S']#795SZM#I_BR6&0JJ7\61GC<XZ_H*W;LTC0\WUOPAK5O\6+/68=0,
M6C7^ T8/R [>5(Z<XK%^-.HQZ+!)X:N8VALKR3[3;2Y(3'\2G'(Y8=/2O8+K
M3VGTV\L$.Z6$^; 3UZY '\J\M^+6CZE\2='TF73;1+JYM)-ES'& 98W!Y'^[
MGK7-5CHT8STBTNIZ+\+?#_\ 8?@73;-Y4N5:/>9$7A\BLGP[X*TKP?XFOK<6
M86'42SQ2LQP,_>3'0?\ UZ[/PS:36/A_3K:X1(YXH%1TB^Z"!T%)X@T==8LB
MBDQSQL)(I5/*L*U=).*OT*C%)+F,C2Y&\.:H=+NI?]#E)-K(W\/?8372S0PW
M,9BFA2=3U6097\JX?6_%6EW?AV6WOYH4U5$8) _#^:H^7'Z&J?P@\4>(/$5I
M<KK5OM6+Y8Y@,9QVHC42?*T-S5ST:*%(8PL<:QH!@(HV@#V I_3OFBBNBUMB
M[6"BBBD 4$\444 ,EC$H((R,<Y[UYSXR^#_ASQ/JBZAJ>D0Z@(5XC=02/<'^
ME>DC'>D9>.F">]6IK9H+R6L6T_(QM#AT_3]*M[738(K:UB&U(XD"A1Z8[5I8
MQQ6;J&E2+.+JTD,,J\M&/NRCT-6+._2\4_*8I5^]&W5:[8NZV.=_%>Q:HH S
M15@%:&FV_P#RU(]A5*"$SR!5_$^E;:((U"J, <"LINVA<5U'4445B:A1110
M4444 %9?B;_D 7W_ %S-:E9?B;_D 7W_ %S- '.?#G_6WW^ZG]:[>N(^'/\
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MZVZM+,9&&!E$#'!//2O3/'OBM8]>CL]-2.]OM+MI+U+0'_EI]P''<JK,V/\
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M8S7NE.V3;R;H_P#<;D5;\4P"Y\.:A&0&#1'*GN*@"K_PE4,HR&DL\L/6M'5
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M7Y0U^KW_  4H_P"3:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^RO[!7_)KOP[_W;C_TLFKT+_@HY\/_ /A/_P!D7QHL<?F7
M>C+%K,'&=OD.#*?^_)FKSW]@K_DUWX=_[MQ_Z635]C>*_#MKXP\+ZQH-\NZQ
MU2SFL9UQG,<J%&_1C7BR?+5;\S3H?S_:U\:;[Q)^S?X-^%$:RR#2?$-]J6P
MD.LL<0@51W(>2[R/]L>M?HO^W9^SQ'X=_P""?OA32[:!3>_#Y-/ED>,9+@H(
M+@_1GE$A_P!W-?.G[//_  3>^,FA_'WP7?\ C/P='8^$M-U:*]O;[^U+.9&C
MA;S%'EI,SD.R*N-N?GYQSC]8/BMX&@^)OPR\5>$KG:(M;TRXL-S?P&2-E5OJ
MI((]Q755J14H\K\R4C\*O'7Q.U+]H+P_\"/AY;%Y;_0K#^P4# X-Q/>M'&%]
M1Y*V@^H([5]L?\%=K1O"'P:^$?A734:/0;6ZEB"@X5?(MTCA!'^Z\GY&O./V
M._\ @GS\7O!/[1_@SQ)X]\'+H_AK1KE[^6Y.IV=Q^]CC8P )%,S?ZWRSG'&#
M7Z!?M<_LT:?^U-\)9_"MQ=KI>JVTZWVEZBT>\07"@C# <E&5F4X]0<$J!1.I
M&-2-ME^H):'QQ^SS\4OVI?#'P(\(:)X+^!7AS6?!PTU?L=W-<(#>1299I'7[
M4O+EF+ J.2<BKW_!-_\ 9S^+_P #OCEXGU3QAX+N/#?AK5M&FB"B\@>$7 GB
M>)=J2,>%\T D<9//-<CX3\$_MR_ WP!-\,O#NA17V@D2P6.H6]Q9SO:HY.[R
M96E5HP221YBY7/&.,?3O[ G[*OC7]GSP[J>I>/\ Q+=ZAKFIHD46B)J$EQ::
M=$#N/!;8TK'&2HPH7 8[C4SDE&5FM01^;W[&_B_XHV/[0^N^)?A]X*L/'?CA
MK*\N)[/5)0OV<231B:=29(SOR^SJ>)6XKV;]J;X5?M1_M3W?AZ[\1?!2QT6[
MT9)HXKC2KR /*DA0[7+W#9"E"5]-[>M>C?&+]AWXO_!3X_W'Q7_9XD@O5O;B
M:[?23+#"]J93F6 I,RI+"V20 0R\ #*JQQK7]G7]J[]JKXMZ/X@^)U]/\-]&
MT]!";C3[M+9XH=Q9UMX89&8R,?XY".W)"A:UYXM\Z:_45C]!OA;%J\/PS\(I
MX@ADM]>72+1=0AF<.Z7(A3S59@2"0^X$@G/K7YM_\%C?^1\^&_\ V#;O_P!&
MI7ZCVEDNFVL%HAD,<"+$IED:1B ,#+,26/'4DDU\%_\ !2K]E_XF_'_Q;X)O
M? 7AK^WK;3K&XANG^WVMMY;M(I48FE0G(!Z9K.DUS79!]K_#C_DGGA?_ +!5
MK_Z)6NBK&\%:?<:1X,T&QNX_*NK6PMX)H]P;:ZQJ&&1D'!!Z5\$?L[ZQ\9M!
M_;]U;PAX]\1ZY-H\MKJ.K6ND76L_:[9;1I6%N^Q)'5.V%;# 8X&14I<UV(_1
M#I7Y\?\ !8DY^&GP^_["\_\ Z)K]!BZ@<D8]Z^#O^"H7A'7/BSX1\&Z1X3T_
M^V+K3]1FGNA'-&@B#1A5!+L!D^E$&E--AL?+'[5WA]_#WP:_9B^(.ER>3J47
MAJWL7E7K&\&R>W/YR2_]\UK_ +-NN2_M.?M^3?$'4L+IVG-)K<JS?=CAA1(8
M%'T9HL#V/O7T'\6?V9=;\5?\$_?#FA+I;W'CG2+73KJ.TDFCW(\8$4D8?=L
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M4&FVD5M;1K#!$NU(TZ**FJEMJ-!1113&%%%% !1110 9XI&Z=*6D)P,FA;W
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MNM0C-OHYPT=GG#2]P7]O:NDM-'T^RN&N8+"WBG9=K2I& [#ZU;CB$2A% "J
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MP78<]3Z\<5Z91FHE'F$U<CMDDCM8EE;=(J@,WJ:DH)S15+3084444P"BBB@
MHHHH ***='&97"KU- #H(#,^!]WN:TE4(H51@#M211"% H_$T^MDK %%%%4
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M)IH 1#(P51DFM*" 0+CJQZFB"W$*^K'J:EK5*P!1115 %%%% !1110 4444
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M38F,M[<S'G@5H1QB,8 P*54"8Q3JVBK(044450!1110 4444 %%%% !1110
M5S?C[_D!K_UV7^1KI*YOQ]_R U_Z[+_(T -^'_\ R!9?^N[?^@K735S/P_\
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M HI*F@MFF.>B^M- ,BB:5]JC_P"M6C! L"\<D]33HXUB7:HP*?6J5@"BBBJ
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MR:9<SI:V5Q</DI&A9@.N!3F!Y&<&N/\ BY;ZM<>!9[?1Y3%=W,J0@@X9@W&
M>QK.MI3N::[H^0OVJ=3\*^%?#\?AFVTDW7B*^A6^-S(Y'V4$Y!7Z\\5U_P#P
M3\\%>&I-(O/$4,D]SXDM_P#1I_/P!$&&?E ]17:?$G]DR3XOZ1HE_?ZK_9?B
M:TMQ;S7 CWK(@/"L/4?UKTCX$? K3?@?X=DL+2Y>]N[A_,N;EQC>V,# ["O(
MA3<JG.T?6?6L)3RA8:@Y*HW>2Z-??Z'J%%%%=9\X%%%% !1110 A;!K!\2>-
MM,\+2017CR-<3@F."%"[L!U.!VK>(R#[UYQXDN)/"WQ'&M7=A/?Z;<6 MTD@
MC\PP2*Q/3T(/6LZDN57 Z63XA:%#X>_MR2]5--#;#*0<ALXP1ZYJQ<>,=+MM
M6TW37NE6[U",RVZ'^-1W%>4ZCH_B'Q_-96D6D0:/I^Z2Y=)T^5P>%W ?Q=ZQ
MF\/^)II-)DN--DDO]!@D6.9>DI1LJ%/^TO%<[Q$N:RCH*Q[)??$70=-U2ZT^
M>]5;NU,8FC SMWG"_G6A:>)["_U6YTZVE\ZYMT$D@3D*#TR?7VKY\UWP/XAO
MTO+H6,R7^JQV\TLBC+1.9CQ]57%>G_"_1[WP3?:AX;NK=[B,C[7;ZJ1DSAC\
MRR'^\#^E%.K4G*S5D!Z5G-%(.E+STQD^U=MM1(*<J%S@5-#:-)RW JXD*QC"
MC\ZI1;!LAM[18P"W)JR!BD YYIU;I6$%%%%, HHHH **** "BBB@ HHHH **
M** "N;\??\@-?^NR_P C725S?C[_ ) :_P#79?Y&@!OP_P#^0++_ -=V_P#0
M5KIJYGX?_P#(%E_Z[M_Z"M=-0 4444 %1W'_ ![R_P"Z?Y5)4=Q_Q[R_[I_E
M0!^>/_!2C_DVN3_L,6G\GK\H:_5[_@I1_P FUR?]ABT_D]?E#7JX;X#.6X44
M45UB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@!,4M%%*R 3 HQ2T460"8H(!I:*+(! ,4M%%, HHHH ****
M"BBB@ HHHH 3%&*6B@!,"C%+10 F*6BB@ HHHH *3&:6B@!,48%+10 @&*,4
MM% "8I:**5@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %<WX^_
MY :_]=E_D:Z2N;\??\@-?^NR_P C0 WX?_\ (%E_Z[M_Z"M=-7,_#_\ Y LO
M_7=O_05KIJ "BBB@ J.X_P"/>7_=/\JDJ.X_X]Y?]T_RH _/'_@I1_R;7)_V
M&+3^3U^4-?J]_P %*/\ DVN3_L,6G\GK\H:]7#? 9RW"BBBNL04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]C_C7=1J\D;6N2U<_(VBOUR^P?LE_P![X6?]_P"Q_P :/L'[)?\ >^%G_?\
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M@_9+_O?"S_O_ &/^-'UC^ZPL?D;17ZY?8/V2_P"]\+/^_P#8_P"-'V#]DO\
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M\+/^_P#8_P"-'V#]DO\ O?"S_O\ V/\ C1]8_NL+'Y&T5^N7V#]DO^]\+/\
MO_8_XT?8/V2_[WPL_P"_]C_C1]8_NL+'Y&T5^N7V#]DO^]\+/^_]C_C1]@_9
M+_O?"S_O_8_XT?6/[K"Q^1M%?KE]@_9+_O?"S_O_ &/^-'V#]DO^]\+/^_\
M8_XT?6/[K"Q^1M%?KE]@_9+_ +WPL_[_ -C_ (T?8/V2_P"]\+/^_P#8_P"-
M'UC^ZPL?D;17ZY?8/V2_[WPL_P"_]C_C1]@_9+_O?"S_ +_V/^-'UC^ZPL?D
M;17ZY?8/V2_[WPL_[_V/^-'V#]DO^]\+/^_]C_C1]8_NL+'Y&T5^N7V#]DO^
M]\+/^_\ 8_XT?8/V2_[WPL_[_P!C_C1]8_NL+'Y&T5^N7V#]DO\ O?"S_O\
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M@_9+_O?"S_O_ &/^-'UC^ZPL?D;17ZY?8/V2_P"]\+/^_P#8_P"-'V#]DO\
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M\+/^_P#8_P"-'V#]DO\ O?"S_O\ V/\ C1]8_NL+'Y&T5^N7V#]DO^]\+/\
MO_8_XT?8/V2_[WPL_P"_]C_C1]8_NL+'Y&T5^N7V#]DO^]\+/^_]C_C1]@_9
M+_O?"S_O_8_XT?6/[K"Q^1M%?KE]@_9+_O?"S_O_ &/^-'V#]DO^]\+/^_\
M8_XT?6/[K"Q^1M%?KE]@_9+_ +WPL_[_ -C_ (T?8/V2_P"]\+/^_P#8_P"-
M'UC^ZPL?D;17ZY?8/V2_[WPL_P"_]C_C1]@_9+_O?"S_ +_V/^-'UC^ZPL?D
M;17ZY?8/V2_[WPL_[_V/^-'V#]DO^]\+/^_]C_C1]8_NL+'Y&T5^N7V#]DO^
M]\+/^_\ 8_XT?8/V2_[WPL_[_P!C_C1]8_NL+'Y&T5^N7V#]DO\ O?"S_O\
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MT>9XD]-1_P"^7H ]*HKS7S/$GIJ/_?+T>9XD]-1_[Y>@#TJBO-?,\2>FH_\
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MZ/,\2>FH_P#?+T >E45YKYGB3TU'_OEZ/,\2>FH_]\O0!Z517FOF>)/34?\
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ME#7JX;X#.6X4445UB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2]Y\/I/ U]=WJZ-'?K=_:K1X-IE-OLQNZ_ZMNE?%=3!N4;M6!A1115@%%%%
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M4K22W9USC*AP"1GN*R*_0K_@LK_R5KP!_P!@.7_T>U?GK13ESQ4@>@4445H
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M7[&'["/B7]I;7+36]9@N-"^'$$N;G5&&R2^VGF&V!^\21@R8VKSU8;:^ZO\
M@J!X>T[PE^Q=:Z)H]G%I^E:=JFGVMK:PC"11(KJJCV  K&59*:@AVZGXU444
M5T""K6EZ3?:Y?1V6G6=QJ%Y)G9;VL322/@$G"J"3@ GZ"JM?3_\ P3/_ .3U
MOA[_ +NH_P#INN:F3Y8M@?.>M^%]9\,O$FL:3?:4TP)C6^MGA+@=2-P&<9'3
MUK,K](?^"S__ "-GPM_Z\K__ -&0U^;U33ESQ4@>@5T=I\-?%]_:PW-KX5UN
MYMID$D<T.G3.CJ1D,I"X(([BOMK_ ()]_P#!/N3XHS6'Q(^)%@T7@Z-A-I>C
M3J0VJD=))!V@]!_RT_W?O>L_M]?\%"H? T%]\+OA/?1KK**;75=>LB FG@#:
M;>W(X\T#AG'$?0?-RF;JWGR05QV/RMN;::RN9;>XB>"XB<QR12J59&!P5(/(
M(/&*CI7=I79W8N['+,QR2?4TE= C3\,^&-6\9Z]9:)H6G7.KZO>OY=M96<9D
MEE;!.%4<DX!/X5TFO_ _XA>%]9ETC5/!.O6>IQ1)-):/I\ID1'W!&8!3@':V
M,]<&OJC_ ())?#3_ (2S]HV^\4SQ;[3PMI<DR/C(6YG_ ',8_P"_9G/_  &O
M??V6OVD?^$S_ ."COQ>TYKK?I7B&*2QT\!OE=M.(2(J/1HA</_P*N>=5Q;26
MR'8_*O4=-O-'O9;._M9[&[B.)+>YC,<B'&<%2 1P15>OM+_@K-X!_P"$6_:@
M778H]L'B72+>\9P, S19MW'U"Q1'_@5?%M:PESQ4A/0T]$\+ZSXF>5-'TF^U
M5H0#(MC;/,4!Z$[0<9P>OI3=;\-ZOX:FCAU?2[W2I9%WI'>V[PLRYQD!@,BO
MU:_X)7^&;'X3_LP>-OBAK0-O;:C<3W<LX7)^PV,;?,/HYN?R%5/^"O\ \/H?
M$_PE\#_$+3PMP-*OFLY)HN0UM=(&1R?[H>)0/^NOO6'MOWG)8=M+GY/U;TK2
M+[7;Z.RTVRN-0O),E+>UB:61L#)PJ@DX )_"JE??'_!'OX??V[\;_%/BV6+?
M;^'](%O&V/N3W+X4_P#?N*8?C6\Y<D7(2/AG6_#&L>&9(DUC2;[2GE!:-;ZV
M>$N!U(# 9K-K[ _X*G_$G_A.?VJ;_289?,LO"]A;Z6@4_+YI!FE/UW2A#_US
M]J^/Z(-RBFP"BBBK **** "BBB@ HHHH *V;CP5XAM/#T.OSZ#J<.A3D+%JD
MEG(MK(22 %E*[3R".#V-?27[&'["/B7]I;7+36]9@N-"^'$$N;G5&&R2^VGF
M&V!^\21@R8VKSU8;:^ZO^"H'A[3O"7[%UKHFCV<6GZ5IVJ:?:VMK",)%$BNJ
MJ/8 "N>59*:@AVZGXU4445T""K6EZ3?:Y?1V6G6=QJ%Y)G9;VL322/@$G"J"
M3@ GZ"JM?3__  3/_P"3UOA[_NZC_P"FZYJ9/EBV!\YZWX7UGPR\2:QI-]I3
M3 F-;ZV>$N!U(W 9QD=/6LROTA_X+/\ _(V?"W_KRO\ _P!&0U^;U33ESQ4@
M>@5T=I\-?%]_:PW-KX5UNYMID$D<T.G3.CJ1D,I"X(([BOMK_@GW_P $^Y/B
MC-8?$CXD6#1>#HV$VEZ-.I#:J1TDD':#T'_+3_=^]ZS^WU_P4*A\#07WPN^$
M]]&NLHIM=5UZR(":> -IM[<CCS0.&<<1]!\W*9NK>?)!7'8_*VYMIK*YEM[B
M)X+B)S')%*I5D8'!4@\@@\8J.E=VE=G=B[L<LS'))]325T""BBB@#L/&?P>\
M;_#O1]+U;Q-X5U70]+U09L;V]M6CAN1M##8Y&&RI!&.HYKCZ_3/]BS6M(_;-
M_97\3?L_^,K@?VWX=A%QH=](-TD,&2(9%[GR9#L(XS'*J>M?G1XY\%ZM\.?&
M.M>%]=M_LNL:1=R6=U%G($B,02#W4XR#W!![UE"=VXO= ?KS^P5_R:[\._\
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MN11$IRN0P4$;54X(&U^T'_P3C\>?LM^'Y/B/X"\:W&NVNC?Z1=364+V&H6"
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M5<K\7/B]\ ?C#_P3?\6:9XR\)^*Y+_P]<SB%=5LHVCAD?!(@O+8LRX8!L9+
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MY"F_";(WS@$9SC[PKU[_ (=(_'3_ *#/A+_P:7'_ ,8KI="$79S%=G['T5\
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M^NR_R- #/A]_R!9?^N[?^@K73US'P^_Y LO_ %W;_P!!6NGH **** "BBB@
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M%% !1110 4444 %%%% !1110 5S?C[_D!K_UV7^1KI*YOQ]_R U_Z[+_ "-
M#?A__P @67_KNW_H*UTU<S\/_P#D"R_]=V_]!6NFH **** "H[C_ (]Y?]T_
MRJ2H[C_CWE_W3_*@#\\?^"E'_)M<G_88M/Y/7Y0U^KW_  4H_P"3:Y/^PQ:?
MR>ORAKU<-\!G+<])_9I\0Z;X2_:&^&NLZPZ1:78^(K">YFE.%B19T)D/LOWO
M^ U^J'_!4[X'>,?C!\(/#]]X0L;G6I/#U_)=7>DV:F2::)X]OF(@&7*$?='.
M'8X.*_&:OT%_9._X*GWWPT\/Z?X1^*&G7GB+1[*-8+37+ AKZ&,<*DJ.P$H
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M?"#_ (59^U%K=];0>5I/BJ-=<MRH^42.2MPN?7S5=\=A(M1?\$UO@]_PM?\
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M'_!%?K\8_P#N#?\ M]4\\O8<U]?^".VIPWP6_P""5.I^.->\1:EXO\03^%O
M]AJEW9V#>2OV_48(9GC$YW?)"C!<AB&SU"[2"?<8_P#@E%\"?%>F7$'ACQWX
MAGO[<;6N8=3L[Q8V_P"FB)"/0\ K7S/_ ,%/?VC?$GCCXZ:W\/;75;BV\&^'
M#%;'3H)"D5U<[%>2651]\JS;%!R!LR,$G/RI\+/B?X@^#OCO2/%GAJ_FT_5-
M.G64&)RJRH""T3@?>1APRG@@TU&K./-S6#0](_:Q_9)\3_LG^,+/3=8N8=8T
M74U>32]9MT*+<*A =60DE)%W+E<D888)YQYA\./ASX@^+/C72O"?A?3Y-3UO
M4IA%! G0=V=CT5% +,QX !-?KI_P58T73_$_[)4&NM K7&GZK9W=K,1\R"4-
M&PSZ$.,CU ]!7RQ_P1YGTF/]H#Q1'=F,:M)X><6)DQD@3Q&4+[XVGCG ;MFG
M&JW2<WNA6U/5?#W_  2:^&O@;0+6^^*WQ0N;>X?'F-93V^G6@?&2BR3JY?'/
M/RDCL*O:A_P2G^#?Q$T:XN?AG\4-0DN4'^N-Y::K:JQ'RAA"J,,XZ[C]*\I_
MX*9?LZ?&#Q!\=-4\:V^C:KXM\&3V\*:=)ID3W(TZ-(D$D3Q)DQCS [[L;6WY
MSG('R-\"/C'K_P"SO\6]$\6Z6]S#-IUTHOK .8OM=ON FMY 1T9<CD':<$<@
M5$5.<>93U'HAWQ_^ 'BO]F_XA7'A+Q;;Q+=",7%K>6S%K>\@)(66-B <95@0
M0""""*_4'_@G3^RKX2^%UMH?Q,TGQE)K&O\ B3PE"+O1F:$K:^>;>=\;3N^5
MD"\^O/-?"O[:/[:<'[78\-@>!X_"TNA//Y5U_:/VJ2:.4)N1OW2 #,:D=<<^
MM>E_\$=_^3F/$_\ V*-S_P"EME55.=TKRT8+<^H_VN?V%_ /QF^(OB'Q[K?Q
M$FT'6&L$SI:-;@#R80%^^=WS!1^=?CE7UG_P5(_Y/%\2_P#7C8?^DR5\F5I1
M34$VQ/<*]E_8S_Y.L^%7_8PVG_H8KQJO9?V,_P#DZSX5?]C#:?\ H8K67PL2
MW/O;_@LU_P DZ^&__85N?_1*U^4E?O!^VK^R+<?M;^&_#6E0>*(_#!T>[EN3
M+)8FZ\W>@7;@2)C&,YYKY*_X<N:C_P!%9M?_  0-_P#)%<=&K"$$I,IIW/S4
MK]V_V.Y;B]_82\&GQ.Y>,^'[F.5ICG_1 TRQ Y[" (/3 KP3X<?\$<O">A:U
M;WGC/QW?^*+.)P[:=86 L$EQ_"[F21BI[[=I]"*W_P#@H1^V%X3^%'PFU'X4
M^!KZSN?%&I6?]E2V^F,IAT>R*['5BO"N4!C6,<J#N.,+N56:K-0@"TU/S1_9
M7_Y.<^$G_8VZ5_Z5Q5^CW_!9'_DB7@?_ +&'_P!MI:_.']E?_DYSX2?]C;I7
M_I7%7Z/?\%D?^2)>!_\ L8?_ &VEJZG\6 NA^2%%%%=@@K]P?CU_RC8U#_L2
M+#_T5!7X?5^_%Y\,)OC1^QEHW@B"^33'UOPKIMJ;R1"XA4Q0EFVCJ0 <#(R<
M<CK7'B'9Q;[E(_&C]F']F'Q5^U%X_CT#0(S::9;E9-4UJ5"8+&$GJ?[SM@A4
M!RQ!Z ,P_5'XG_%3X7_\$U?@=8^&/#=C%=^()XF?3])+@W-_.1AKN[<<A,CD
M\9P$0 #Y>S\->)/@I^Q1'X&^$-MJ$&CZAKLXCA1\///*PQ]JNW&-OF.H0,>,
MD!0%0[?DG_@JW^RC?'46^-7AX7%[;.D5MX@M2S2&VV@)%<(#TC(VHP' .TX^
M9B,G/VTTI:1_,-D?GY\4OBGXF^,WC?4?%GBW4Y-4UF^?+R/PD:#[L<:]$11P
M%'3ZY-<G117H)6T1)]Y?\$[/'/P.^#7@/Q5\0/B5)I*>*[+4EATG[0GVF^\L
M1*W^C0<D'<2/, &,X+ 5['\)/^"AOB+]I7]LGP!X4T&R?PQ\/VGO6DM)&#7>
MH;+&X9#.PX50RJPC7(!&2S8&/RJKZ7_X)M_\GJ?#?_?O_P#TWW-<]2E&TIO5
MC3/<O^"RO_)6_ '_ & Y/_2AJ_/:OT)_X+*_\E;\ ?\ 8#D_]*&K\]JJA_#0
M/<****W$?0G[!OP0B^/'[2GAO1[Z(3:)I>=9U.-AD200,I$9'</(T2'V<U[]
M_P %@?BS_P )!\5_#'@"UFW6OAVQ-[=HI_Y>;C!"L/58DC(_ZZFNW_X(Q^#[
M<K\3/%4B;KH&STR%\?=0^9)(/Q(B_P"^:^+/VSO%#^,/VJ_BGJ$A+%->N;)2
M>ZV[?9U_\=B%<J]ZMZ#Z'C-?N!^V3_RCO\1?]@'2_P#T=;5^']?T"?$;X0R?
M'K]E%? 46J+HLFLZ+81B_>#SA%L,,F=FY<YV8ZCK48AI2@WW!'\_=%?I7_PY
M<U'_ **S:_\ @@;_ .2*U_#G_!%^RBOHWU[XIW%U9 C?!IVBK!(P[XD>9P/^
M^#6OUBGW"S.H_P""-MQJDGP?\=Q3N[:/'KB?958DA93 OG8]./)KX%_;?2SC
M_:U^*0L=OD_VU*6VXQYA ,G3OOW5^KWQ(^+'PI_X)Y_ N'P[HQMA?VD#C2?#
MPG$EY?W#9/FS$<A2QRTA   PO\*U^(7B3Q!?^+?$.J:YJLYNM3U.ZEO;J=NL
MDLCEW8_5F)K.C>4Y5.C&^Q^V'QZ_Y1L:A_V)%A_Z*@K\/J_<'X]?\HV-0_[$
MBP_]%05^'U&&V?J#"BBBNPD_9W_@DE_R:G-_V,-Y_P"BX:_*/4? NO?$OXYZ
MQX9\,Z;/J^MZCK=U#;6D RS'SGR2>BJ!DEC@  DD 5^KG_!)+_DU.;_L8;S_
M -%PUN^!OA9\+O\ @GSX(\4?$;QAJ,4_B'5KJ62[U01[IY3)(SI96:'DCUZ;
MBI9BJJ OG*IR3GW9=KV,[X$? GX<_P#!.GX,ZAXU\;ZE:R^)I8 -3U@+N=F/
M*V5FIP2"1[%R-S850$_,[]K7]KGQ1^U5XU-[J!?3/"]B[#2="23,=NIX\R3L
M\K#JW;H,"OT\_;?^ %I^V5^S_I'B;P/?G4]7TV ZMH7D2GR=1AD12\.WH'95
M7:2,AEVG 8X_$Z>"2UFDAFC:*:-BCQNI5E8'!!!Z$&M*"4KS>XF,KZ(_80L?
MAK<_'B.Z^*YTD>%-/TVXO3_;<H6V,ZE/+#*3B0\G$9#;CV-?.]%=<ES*Q)^E
M'[47_!5.&72;CPA\#[1]-LQ']F;Q-/!Y+)&!@"TA_@XX#N 1V0$!J]Y_X*M$
MM^R(23DG6;')/T>OQ>K]H?\ @JS_ ,FAG_L,V/\ )ZXIPC3G!1*O>Y^+U%%%
M=Y(5]/\ _!,__D];X>_[NH_^FZYKY@KZ?_X)G_\ )ZWP]_W=1_\ 3=<UG4^"
M7H"W/H+_ (+/_P#(V?"W_KRO_P#T9#7.?\$^_P#@GU)\4)K#XD?$FP:+P=&P
MFTO1IU(;52.1+(.T'H/^6G^[][[W^.?[)7A[]H/XM^!O%'BZ1;SP_P"%K>X_
MXDI7Y;V=WC9?-/\ SR7825_B) /&0=SP+\</AC^T#>^./A_X:UF/4SHT1T[4
M(;-S"KPR(49K>12"R*2R;TQA@,<%2?/55JFHQ^9=M3XO_;[_ ."AL6B0WWPM
M^$E^D<\:FTU;Q%8L MN!\IMK5E_B'1I!]WHO/*_E\2222<DU[/\ M9?LUZQ^
MR_\ %F]\,WOF76C7&;K1]39>+NV)XR1QYB?=<>HST92?&*[Z48QC[I+"BBGV
M]O)=SQP0QM+-(P1(T&2S$X  ]<UJ(_4G]A)%_9W_ &!_B1\6IU$&H:H+NZLY
M&&-X@4V]JOXW!E'_  *OS]_9P^)+?"GX^^!?&$LS)#I^KPR7<A/)MW;9/S[Q
MN_YU^@'_  4+GC^ /[$OPQ^$%I(L=W??9K>Z5#Q+':1K).WXW#Q-^)K\M:YJ
M2YU*3ZC9^L?_  6/\!?VI\+_  +XQBCW2:3JDNG2LHY\NXCW@GV#6X'U?WK\
MG41I'5$4L[' 51DD^E?LMXXN?^&G?^"73ZIG[5J4?AF.]DDZL;K3V!G(]V-O
M*,>CU^:_[%'PT_X6Q^U%\/\ 0Y(O.LH]174;M2,J8;<&=E;V;RPG_ Q4T)<L
M&GT&]S]$_P!K!E_9?_X)NZ3X&A86VJ7UE9>'F"G[TT@\Z\./1@EQ_P!]BM/X
M=K_PU?\ \$Q6T=O]+UB'P_)IRIU;[98'-OD^K>3"Q/\ MUX!_P %D/B5_:/C
MOP-X$MY<QZ78RZK=(IX,D[^7&#[JL+'Z2^]=9_P1J^)7FZ7\0/ $\O,,L.N6
M<9/4,/)G/X%+?_OJL.5JES];W'UL?E[7["?\$I_"EK\.?V5]=\<:IBVBUC4+
MF_DN6&,6EJGEY_!TN#^-?FC^U7\-1\(_VB_'_A6.+R;6SU662TC QMMI<30C
M\(Y$%?I[^T-<?\,P_P#!-&U\,H?LNJW.B6GA\ITW7%R ;L?BIN36]9\T8Q74
M2/R-^(OC.Z^(OC_Q)XJO<_:]:U&XU"0$YVF61GV_0;L?A7U-^R;_ ,$V?%O[
M0NB6WBOQ%J)\%^#K@;K65X/-O+Y/[\49("QGL['GJ%8<UXE^R=\)8?CC^T/X
M)\'7:L^FWM[YM\%[VT*--*N>VY(V7/JPK](?^"H_[1>K_!+X?>&/A]X)N3H-
MWK\<AN+K3W\F2TL8=B+%%MQL#EL9&,+&P_BXJI-IJG#=B2ZF4?\ @F/^S7#>
M#0)?B3K(\0'C[.=?L%N=PX.(?)SC/;&?>OFO]K#_ ()G^*?@'H-WXM\*ZFWC
M/PC:*9+P&#R[VQC'61T!(>,=W7!'4J ":^+68LQ9B22<DGO7ZR?\$I?VBM;^
M*/AKQ/\ #3Q?>OKO]B6T=QITU\WFR&S8^7) Y/WD0[,9SQ(5Z!0(DJE)<W-<
M>C/R;KWW]E;]C/QM^U7J\YT;R]&\,V4@COM?O48PQMP?+C4<RR8(.T$  C<R
MY&<O]J_X+CX1?M-^+_ VCV[&T&H(^F0*/^6-PJRPQKZ[1($SZK7ZK?&?7K;]
M@;]B.*R\*10+JUA;0:38SE0!+?S?ZVY8?Q-GS9<'@E0.E74JM)<F[$D>0_\
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MD^K;CU-?#-;)^UA==2=F?I1^U%_P53AETFX\(? ^T?3;,1_9F\33P>2R1@8
MM(?X.. [@$=D! :O>?\ @JT2W[(A).2=9L<D_1Z_%ZOVA_X*L_\ )H9_[#-C
M_)ZY9PC3G!1*O>Y^+U%%%=Y(5]/_ /!,_P#Y/6^'O^[J/_INN:^8*^G_ /@F
M?_R>M\/?]W4?_3=<UG4^"7H"W/H+_@L__P C9\+?^O*__P#1D-<Y_P $^_\
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M]+)J^VZ\VI\;]2UL%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5<V7_!5-/)YS\18<X_VKE=W_ *$:,/JI+R!G[5T445QE!1110 4444 %%%%
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ML,CCL1T(/(((/(KYQ_X*!_LI)^TE\)GO=&M5;QUX=1[K2V48:ZCQF2U)[[P
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M44 %%%% !7-^/O\ D!K_ -=E_D:Z2N;\??\ (#7_ *[+_(T -^'_ /R!9?\
MKNW_ *"M=-7,_#__ ) LO_7=O_05KIJ "BBB@ J.X_X]Y?\ =/\ *I*CN/\
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M3:D-'Y4=W V5(XP%4]/2OR9_8=_Y.V^%O_89C_DU31_A2^?Y ]SZ]_X+2?\
M(2^$?_7+5?YVE6/^"*_7XQ_]P;_V^JO_ ,%I/^0E\(_^N6J_SM*L?\$5^OQC
M_P"X-_[?4O\ F&_KN'VCXR_;58M^UA\5"3D_V]<#_P >KQ6O:?VT_P#DZ_XJ
M?]AZY_\ 0J\6KMA\*)/VA_X*/?\ )B,G^_I7_H:5^/G@3QWKWPR\7:9XG\,:
ME-I&N:;*)K:[AQE&Z$$'(92"05((()!!!K]@_P#@H]_R8C)_OZ5_Z&E?&/\
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M47R%;^%6WG<1R0,9 + _FA\"/C3KW[/_ ,4-&\:^'I/]+L9,36S,1'=P-Q)
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M/SK[O\.Z7HWQL?X4?%>/;OLM,EU"P4<E?MUM&'&>V%R#[U^,O[??Q)_X6?\
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M,A DC)Y!4D@'#8-.LG4A&:!::'K_ ,==>C\+_!/Q_J\K!4L= O[C+'&2MNY
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M#G_6WW^ZG]:[>N(^'/\ K;[_ '4_K7;T %%%% !1110 4444 %%%% !1110
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MCC_R0'QC_P!C/)_Z2V]=U6,8T7R[-DK<J_\ !9+_ )(IX&_[&$_^DTM>A?\
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MT$_J=6F(DM(+H)=PHHHKD*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YOQ]_R U_Z[+_(UTE<WX^_Y :_]=E_D: &_#__
M ) LO_7=O_05KIJYGX?_ /(%E_Z[M_Z"M=-0 4444 %1W'_'O+_NG^525'<?
M\>\O^Z?Y4 ?GC_P4H_Y-KD_[#%I_)Z_*&OU>_P""E'_)M<G_ &&+3^3U^4->
MKAO@,Y;A7J_P-_:D^)?[.MW*_@GQ)-8V4[;I],N%$]G,?4Q/D!N -RX;'&<5
MY1174TFK,1^A.@_\%E/'EK;Q+K'@'P]J,JC#R6=Q/;!CZX8R8K&\<?\ !7_X
MI:]826WASP[X?\+2/G_2RCWDR?[N\A,_[R&O@^BLO8T][#NS?\<^/O$?Q,\2
MW7B#Q5K-YKVLW1S+>7LI=R.RCLJCLHP . !6!116VPCW/]GK]L_XH?LTJUIX
M5U:*[T%W,KZ%JT9GLRYZLH!5HR>^QESWS7TZW_!9CQH=/V+\.]!%]C_7&\F,
M?_?'7_QZOSOHK*5*$G=H+L][_:&_;<^*7[2<+:?XCU:'3O#A97&@Z/&8+1F4
MY!?)9Y"" ?G8@$9 %>"445:BHJR ^G/B5_P4&^(GQ3^!4GPHU;1O#%OX=>TL
M[,W5G:W"W>RVDB>,[FG9,DPKGY.03@#C'S'111&*CH@/HO\ 9Z_;T^*W[.>F
MQ:-HVHVVN>&HR?+T77(VFAAR<GRF5E>/OP&VY).TFOH2]_X++^-7L0EI\/-!
M@O.\LUW/)'_WP-I_\>K\\**ATH2=V@NSV3]H']K;XE?M*WB?\)AK0_LF&7SK
M;1-/3R+*!L$!@F268 D!G+, 2,X->-T45HDHJR ]8^ 7[47Q$_9KU>:\\%:S
M]GM+E@UWI5XGG6=T0, O&2,'_:4JV.,XKZUC_P""RWC@:7Y<GP]\/MJ.!_I"
MW4XASW/EY)Q[;Z_/*BLY4H3=V@N>Y?M$?MF_$[]IAUM_%&JQV6@HP>/0=(1H
M+(,.C,I9FD;N"[-CMBO#:**T2459 ?9GPB_X*I?%GX8^$K'P]?V.C>+[6QB6
M"VN]4CE6Z6-1A5:1' ? P,E=QQR37C7QD_:H\2?&GXW:-\4-3TC1M.US2C:&
M&VL8I1;R&WE,D9D#2%F))P<,O &,'FO&**A4XIW2"Y]#_M+_ +<?CO\ :I\-
M:1HGBS2?#NGVFF79O(7T:VGB=G*%,,9)I 1@GH!]:^>***J,5%60'K/[-W[3
M/B[]EOQE>^(_",6G7=Q>V36-Q::M%));R(75PQ5)$.X%1@[N,GUI?VD?VFO%
MW[4GC*Q\1^+HM.M+BQLEL;>TTF*2.WC0.SE@KR.=S%N3NYPOI7DM%'+&_-;4
M KZ*_9I_;G\>?LK^%M5T'PGI/AW4+/4;W[=*^LVT\LBOL5,*8YXP!A1U!.<\
MU\ZT42BI*S TO$^OW'BOQ+JVMW:11W>I7<MY,D((17D<NP4$D@98XR3]:]Q_
M9G_;A^(W[+ME=Z7X=>PU;P]=2FX?2-7B:2))2 "\;(RLA( SS@XY&>:^?**'
M%25F@/IS]J3]O;Q=^U3X.T_PSKOAO0=(TZROTU&*:P68W'F+')'C<TA7:1(V
M1MSD+SQ7S'17ZO\ [,/[(7[,?C/X3^!_'6KK97>K#2[6?5;.[U\_9DNU0>:9
M8MXVY=6)1CMP<;<<5E*4:,=A[GHO[*_BO4?V</\ @G/8^+_%DWF#3],NM6L+
M6<8(BEE9K2'/?S&="/02@=J_&;6-7N_$&KWVJ:A.UU?WL[W-Q._WI)'8LS'W
M))-??'_!2_\ ;)\/_$RRT[X5_#N_@O\ PQITRW&IZC8D?9KB1!B*"$CAHTR6
M)'REMF/N\_GY4T8M)S:U8,****Z1!7T]^SO_ ,%#?BG^SQH,7AZSEL?$_AJ!
M=MMINMHS_9!G)$4B,K*/]DEE'8"OF&BIE%25I(#]!]=_X+)>/;O33%I'@/P]
MIUZ5Q]HNIY[E0>Y" I^I/XU\T+^V;\5+GXW:'\4]5U[^W?$>BR2-96]^A%E$
MCHR/$L,90*C*Q!VD$]22>:\/HJ(TH1V079[9^TW^UEXI_:LU'0K_ ,6:)X?T
MR]TB*6"*?1+>>)I8W*MMD\R:3(4@E<8QO;KGBWX&_9=^-]OX TSXQ>#=%NUT
M."&;4;?6])U*&.XMU@9UD<()!*"#&_13D#WKPBOT*_X)X?MX>%?A-X,E^%_Q
M+D:RT#SY)=,U9H3-#"LIS)!,B@D(7+,&P1\[!L#!I3O"/N(:UW//O"G_  5@
M^.OAO2X[2\E\.^))$7:+O5M-83'TSY$D2D^^/KFG?#7]IKXO?M>_M2?"C2/$
M.LM<:7:^)++4AHFF1"WLT2WE6>1V0<N52-R"Y8CG&,U]/:[_ ,$[/V9_BOJL
MVN>#_B$VDV=R?/:RT+6K2YM$!Y.P.K,@YZ%B!V Z5TW@RQ_97_X)\:;J&L6?
MBB#6?%,UNT9E:]CU'59DSGRHXX@$B5B ,D(#@;F...9SIV]R.OH/4\S_ ."S
M_B"%-)^%VAJX-Q)/?WKH.JJJPHI/U+-_WR:_._X2_&'Q?\#O&$/B;P5K,VBZ
MM&AB9XP'2:,D$QR(P*NA('!'4 C! -=9^U/^T;J_[3_Q9OO%VI0FPL406FF:
M;OW"TM5)*J3@;F)9F8]RQQP !Y!733ARP46)[GZ$Z)_P64\>6UELU;P#X>O[
MH* )K6XGMU)]2I+_ ) BO'?CM_P4@^+_ ,<-*N=%^W6GA#0+A3'-9: CQ/.A
MXVR3,S.1C((4JI!Y!KY8HIJE!.Z079]/^#/^"A7Q$\&_ E/A*-#\+:SX7&G7
M&EM)JEI<O<O;S%]REDN%7Y1(57"C 5>I&:\*^%7Q(U/X0?$30/&>C06ESJFB
MW*W=O#?(SP.X! #A65B.>S"N5HJE"*O9;B/<?VGOVOO&7[6$_AR7Q=INAZ<V
MA+<+;#18)H@XF,9;?YDLF<>4N,8ZGKV?^S!^V)XS_9./B7_A$=,T+4?[?^S?
M:O[;MYI=GD>;LV>7-'C/G-G.>@QCG/A=%')'EY;:!<Z?XG_$+4?BQ\0O$'C'
M5X;6VU/6KM[VXBLD984=CDA S,0/JQ^M<Q115I6T ^G/C7_P4&^(GQX^$S?#
MW7]&\,6>BDVY\_3;6X2X_<D%/F>=UYP,_+^5?->FZE=Z-J-K?V%S+97UK*L\
M%S;N4DBD4@JZL.000"".F*KT5,8J*LD!]M?#7_@K1\7O!>CP:=KUCHOC18>!
M>ZA$\-VR]@SQ,%;ZE,GN372^+/\ @L7\1=3T^2#0/!GA_0KAQ@75Q)+=LGNJ
MY1<_4$>QKX HK/V--N]AW9T_Q'^)OBCXN^*[KQ+XPUJZU[6KG >YN6^ZHSA$
M485$&3A5  R<"H_AW\0_$'PI\9Z7XK\+:E)I6NZ;)YMO<Q@'&00RE3D,K*2"
MI&""0:YRBM;*UA'WM;?\%B_BI#I20R^$?"4]^J@&Z:*Y5&/J8Q-U^A%?!][<
M_;+R>X\J.#S9&D\J($(F3G"@DG [<U#14QA&'PH+A73?#+X@:C\*OB#X?\8:
M3#:W&IZ)>1WUO%>JS0NZ'(#A64D?1@?>N9HJ]P/H+]IK]MKQS^U7HNB:9XMT
MKP]IUOI-Q)<P-HMO/$S,ZA2&,DT@(P.P%?/M%%3&*BK( HHHJ@-[P!XSO?AS
MXZ\.^*]-BMY]1T+4;?4[:*[5FA>6&19$#A2I*DJ,@$''<5]F?\/B/C-_T+/@
M3_P O?\ Y+KX5HJ)0C/XD%S[J_X?$?&;_H6? G_@!>__ "71_P /B/C-_P!"
MSX$_\ +W_P"2Z^%:*CV-/L.[._\ CM\:=;_:#^)VJ>.O$5KI]EJ^HI"DL.EQ
MO' HBB6)=JN[L/E0$Y8\YZ=*]I\7?\%&OB3XS^"$WPMO=$\*Q>'Y=+ATAKFW
MM+D7?DQJBJP8W!7=A!D[,=>!7RO15N$7;385PHHHJP/=/V9OVR/'_P"RHVLQ
M^$AIFH:?JH1I].UJ*66W65>DJ".2,J^/E)S@C&0<+BI^TM^U3X@_:FU;2=5\
M4^'/#6EZMIT36ZW^AVT\,L\1.1'*9)I P4[BO (W-SS7BU%1R1YN:VH!7<?!
M+XOZS\!?BAHGCOP_;6-YJ^DF8P0ZE&[V[>9"\+;E1T8_+(Q&&'('7I7#T535
MU9@>Q_M,?M3^*_VJO$6CZSXLT_1M/NM+M6LX4T:&6)&0N7)822R$G)[$?2O'
M***$E%60!1113 ]9_95^-!^ 'Q[\)>-) S:?9W)AU"-,DM:RJ8YL#N55BP']
MY5K[/_X*^_"B*\D\#_%S2"MS8WT T>\N(3N1N&FM9 1U#*TPSZ*E?FO7Z8_L
M;_%70OVLOV:/$7[.OC^_AM=:T_3\:'J%RP!:!"# P)ZO;N$&!C='@=F-<U5<
MLE473<:['YG5]4?$O_@HU\2?BI\&;WX9ZMHGA6WT&[M(+)[BRM+E;H)"R,I#
M-<,N28US\O<\"OFSQ9X7U#P3XGU;P_JT(M]3TRZDM+F,'<!(C%3@]QD<$<$8
M-95;N,96;$%%%%4 4444 ?:OA3_@K+\7?!_A?1]!L_#G@J6STNSAL87GL;PR
M,D2!%+$70!.%&< #/85J_P##XCXS?]"SX$_\ +W_ .2Z^%:*Q]C3[#NS[J_X
M?$?&;_H6? G_ ( 7O_R77@_[3W[7_C+]K"7PY)XNTS0M.;0EN%MO[%@FB#^=
MY>_?YDLF<>4N,8ZGKV\-HJE3A%W2%<^F_P!G;_@H'\0_V9OA^W@_POHWAB_T
MQKR2^,NKVMQ)-O<*",QSH,?(,?+GKS7SCKFKS:_K6H:I<*B7%[<27,BQ A S
ML6( ))QD]R:I452BDVT@"NY^"OQG\3? +XB:9XS\)W$<.JV193%<*S07,3##
MQ2J""R,.H!!! (((!'#44VDU9@?4?Q\_X*%^.OVC_A_/X1\7^$O!9L7E2X@N
M[.RNDN;65>DD3-<L <%E.5((8C%?+E%%*,5%60!7TY^T#_P4&^(G[2'PY_X0
MOQ-HWABQTO[3%=>=I-K<1S[X\[1F2=UQ\QS\M?,=%#BFTWT ****H KN_@;\
M9-:^ 'Q0T;QYX>M;"\U?2A,(8-3C>2W;S87A;<J.C'Y9&(PPY Z]*X2BDU=6
M8'MG[3G[6WB_]J[4- O/%NFZ)ITNBQ30VXT6":)6$A4MO\R63)^08QCOUKQ.
MBBA)15D 5]B?#;_@J=\8OAKX$T;PM%8>&->MM+MQ:PWVM6ES+=/&O"*[)<(K
M;5PH.W.%&<G)/QW14RA&?Q(#Z,^!_P"T;X"\&>+OB-KOC7X7Z/K2^)K9EL=-
ML+*-[32YV+%FA6X+F-<L,!6XQ@8  &C\,OVX+[X5?LO^(/@_HWA*W236X[Q+
MKQ!]N82%K@;&81!,9$05!\W\(/M7K7_!*2));GXU;T5\>&EQN&<<RU\$5FE&
M4G%K:PPHHHK<1T'P]\<ZG\,O'6@>+=&,8U71;Z&_MA,"8V>-PP5P""5.,$ C
M()Y%?0?Q_P#^"BGQ,_:+^'%UX)\0Z7X:TS2+J>*>=]'M;B.:3RVW*A,D[C;N
M"G&,Y4<U\N45+C%M-H HHHJ@/K3X-_\ !3'XJ?!'X9:+X'T;2O"VHZ9I$;Q6
MUSJMI<R7.QI&<!F2X12%WX'R] !S7RC>WL^I7MQ=W4K3W,\C2RRN<EW8Y)/N
M234-%2HQBVTMP"O:_P!GO]L+XF_LT221>$=8CET:9S+-H>IQF>RD?NP7(9&.
M!DHRDX&<XKQ2BFTI*S _1!?^"S'C3^S]A^'>@F^P/WPO)A%G_<Z_^/5\Y?M#
M?MT?%7]I"TDTO7M4@TCPVY4MH6BQM!;2$$$&0EF>3D X9BH(! %?/E%9QI0B
M[I!=A7=?!_XW^-O@-XH&O^"-=GT6_90DRH \-RF<[)8V!5U^HXZC!YKA:*T:
M3T8'Z#Z!_P %DO'MIIZQZQX#\/:E>!<?:+6>>V5CV)0E_P <$?A7FGQE_P""
MH'QB^*^C2Z/I\UAX'TZ8,DQT!'6YE4_PF9V9E^L>P^]?(=%9*C33ND.[ G)R
M>M%%%;""OIS]H'_@H-\1/VD/AS_PA?B;1O#%CI?VF*Z\[2;6XCGWQYVC,D[K
MCYCGY:^8Z*EQ3:;Z %%%%4 5W?P-^,FM? #XH:-X\\/6MA>:OI0F$,&IQO);
MMYL+PMN5'1C\LC$88<@=>E<)12:NK,#VS]IS]K;Q?^U=J&@7GBW3=$TZ718I
MH;<:+!-$K"0J6W^9+)D_(,8QWZUXG110DHJR *^Q/AM_P5.^,7PU\":-X6BL
M/#&O6VEVXM8;[6K2YENGC7A%=DN$5MJX4';G"C.3DGX[HJ90C/XD!^@7_!,K
M1O"_QM_:!^)6H^)? _AF:UN=,^VQZ1_9RS65I(UPF[R(YS(4')P,\ X&!@5]
M%?%_]H/]DSX*?$C6/ WB;X6:2-8TLQ+<M:^#[*6']Y$DJX; )^61<\=<U\\_
M\$:_^2P^//\ L I_Z4)7AW_!2#_D]/XD?]=+'_T@MJY''GK.+>EBNA]\ZE^S
M'^S7^V[\+;_6?A;9:5X?U:(&.'4-#M#8M9W&W<([FU 52IXS\N2,E&[U^1'B
M_P )ZKX$\4ZMX=URT>QU?2[F2TNK=^J2(Q5A[C(X(X(P17W#_P $<M?O;;X]
M^,-%25QI]YX:>[EA!.UI8KJ!8V(]0)I!G_:KSG_@J+HUOI7[87B6:!50W]E8
MW4H7^_Y"H3^(C!JZ=X5'3O= ]5<I_P#!-GX-M\6OVH= N[B(OI'A8?V]=-CC
M?$P^SKGU,QC;'<(U=E_P57^.L/Q,^.UMX/TV82Z5X+B>TD=3E7O9"K7'_? 2
M./V9'KV7X3ZWI/\ P3T_8IF\67#6L_Q5\=!9;2Q9E=XF*$VZNO79"C&5P<?/
M)L/4&OS*U+4;K6-1NK^]GDNKVZE>>>>5MSR2,2S,Q[DDDGZU45SU'/HM$+96
M/V-_8*_Y-=^'?^[<?^EDU?;=?$G[!7_)KOP[_P!VX_\ 2R:OMNO,J?&_4M;!
M11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MIZOH]AX@TN[TS5+.#4=.NXVAN+2ZC$D4R,,%64Y!!'8U<HH ^&OB5_P2.^%/
MB[5)K_PUJ^M>"S*Q8V4#+=6J?[BR#>.>V\CT K)\$_\ !'CX;Z-J,5SXE\6Z
M]XD@C(;['"L=E')ZAR-SX/\ LLI]Z^^Z*W]O4M:XK(P/ O@+P]\,_"]EX<\+
M:1:Z'HEFNV"SM$VJOJ3W9B>2Q))/))-;]%%8;C/D?X[?\$R_A+\:-:NM=LDO
M?!.N7+&2>71"@MIW/5W@8%03U.PIDY)R3FO*?#__  1J\$VFH+)K7Q!UW4K,
M')@LK2&U=AZ;V\S^7Y5^AU%;*M42LF*R.#^#OP.\$_ 7PN- \$:%!HUBS!YG
M4EYKE\8WRR,2SGZG Z  <5WE%%9-MN[&?EC\<OV=O"GP[_X*&_""'PAJ.JZI
MXC\1^)QXJUNUO9HI5M5^VBX_=*D:E5Q'<'#%CM4<]S^IU>*?#?\ 9+\%?#CX
MR>*_BA')J.M^+M=GDD2[U>Y-Q]@C?&Z*#/('\())(3" @9S[76M2?/9=A(\[
M^-OP"\$?M#>%/[ \;Z,FI6T;%[:Y1C'<6DA&-\4@Y4],CD' R"*^-;[_ ((T
M^")-5,EI\0M?M]-W$BVFM8))0OIY@VC/OLK]#J*4:LX*T6%CP7]G']BGX9_L
MR%KWPWI\^H^(I$:*37M6D$MUL/5$P%2-?]U02.I->]445$I.3NQF5XJ\*Z/X
MW\/7^@Z_IMOJ^CW\1AN;*[C#QRH>Q!_ @]00".17PWXZ_P""/?PVUW5I;OPU
MXJUSPO;2L6^PR+'>Q1\_=0MM<#']YF/O7WS151J2A\+%8^0O@=_P3$^$OP=U
M^WUZ^^W^-]7MG62V.M%/LT$BG(=844!CG^^6 XP >:^O:**4IRF[R8Q&4,I!
M (/!![U\9?&;_@E;\)_B?KEQK.AW&H>!+^Y<O-!I022R9CU80N/D)]$95_V:
M^SJ*(SE!WBP/A+X=?\$AOA?X7U>VO_$VOZUXP2!MQL'V6EM*?1PF7(]@XK[?
MT+0M.\,:-9:1I%E!INEV4*P6UG:QB.*&-1A551P !5ZBB4Y3^)BL%%%%0,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\3?\ ( OO^N9K4K+\
M3?\ ( OO^N9H YSX<_ZV^_W4_K7;UQ'PY_UM]_NI_6NWH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1AD$ D$]QV
MKX9G_P""/WP=N9Y)I?%/CR261B[NVH666).23_HE?<]%7&<H?"Q6/A7_ (<[
M_!G_ *&;QW_X'V7_ ,B4?\.=_@S_ -#-X[_\#[+_ .1*^ZJ*T]M4_F"R/GC]
MF?\ 8=\"?LK>(]7UKPGJWB+4+K4[06<R:S<P2HJ!P^5$<,9!R.Y/TKWG7-#T
M[Q-H]YI6KV-OJ>F7D9AN+.[B$D4R'@JRL""#Z&KU%92DY.[8SX4^(_\ P2(^
M%GBG5)K[PQKFM^#1*Q8V,;+>6T?^X),./Q<^V*A^'_\ P2"^&'AS4X;SQ-XB
MUSQ;'$0WV+Y+."3!Y#[,N1_NNOUK[QHK7V]2UKBLC+\,^&-(\%Z#9:)H.FVN
MD:191B*VLK.(1Q1+Z*HX'))]R2:U***P&?,O[1G_  3Y^%O[1>L3:_>P7?AG
MQ1,/WVK:*RH;DXP#-&RE7(_O#:Q[L<"O$_#?_!&_P!8Z@DVM^.?$&K6JN&^S
M6L$-KN4?PLQ#GGU&#Z8K]!J*V5:I%63%9'*?#+X6>%?@YX2MO#/@W1;?0M%M
MR66W@R2[G&7=F)9W.!EF)/ YXKJZ**R;OJQA1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_'O_(#7_KLO\C725S?
MCW_D!K_UV7^1H 9\/O\ D"R_]=V_]!6NGKF/A]_R!9?^N[?^@K73T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
M+OAG_@GA\.?"OQZ/Q;M-:\42>(SJ]QK/V6:[MC9^=,SLZ[1;A]@,C8&_/ Y-
M?45%4I.-[, HHHJ0/$?VF/V0O ?[5=CHT/BXZE8W>DR.UMJ.C2QQ7(1A\T3-
M)&X*$A6QC(*\$9.=']FK]F/PO^RSX0U+PYX4O]7U"QO[XZA+)K,T4LHD,:1X
M4QQQC;B,=03DGFO7:*OGER\M] /'OVE_V7?"O[5'A?2M!\6:AK&GV>FWGVZ%
M]&FBBD9]C)AC)%(",,>@!SWKYV_X<[_!G_H9O'?_ ('V7_R)7W5151JSBK)B
ML?#$/_!'OX+QN&;Q%XXE']U]0M,?I:@UZE\,O^"=GP*^%U_!J%MX1_M[482&
MCN?$%PUX%(Z'RCB+.><[,CM7TK10ZM1Z-A9#418T5$4*JC 4#  IU%%9#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N;\??\@-?^NR_R-=)7-^/O^0&O_79?Y&@!OP__ .0++_UW;_T%:Z:N9^'_
M /R!9?\ KNW_ *"M=-0 4444 %1W'_'O+_NG^525#>-MM)R.H1C^E 'YY_\
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MCT?6:869^7M%?J%_PZW^%W_0Q>+_ /P+M?\ Y'H_X=;_  N_Z&+Q?_X%VO\
M\CT?6:869^7M%?J%_P .M_A=_P!#%XO_ / NU_\ D>C_ (=;_"[_ *&+Q?\
M^!=K_P#(]'UFF%F?E[17ZA?\.M_A=_T,7B__ ,"[7_Y'H_X=;_"[_H8O%_\
MX%VO_P CT?6:869^7M%?J%_PZW^%W_0Q>+__  +M?_D>C_AUO\+O^AB\7_\
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M )'H_P"'6_PN_P"AB\7_ /@7:_\ R/1]9IA9GY>T5^H7_#K?X7?]#%XO_P#
MNU_^1Z/^'6_PN_Z&+Q?_ .!=K_\ (]'UFF%F?E[17ZA?\.M_A=_T,7B__P "
M[7_Y'H_X=;_"[_H8O%__ (%VO_R/1]9IA9GY>T5^H7_#K?X7?]#%XO\ _ NU
M_P#D>C_AUO\ "[_H8O%__@7:_P#R/1]9IA9GY>T5^H7_  ZW^%W_ $,7B_\
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M_P#\"[7_ .1Z/K-,+,_+VBOU"_X=;_"[_H8O%_\ X%VO_P CT?\ #K?X7?\
M0Q>+_P#P+M?_ )'H^LTPLS@_^"-?_)8?'G_8!3_TH2L+]NS]ECXM_$7]J_QW
MX@\-> -:UG1;V2S-O?6MONBEVV4"-@Y[,K#Z@U]=_LT?LN>&/V5O$NKZWX3U
M+5M0N]3M!9S)K,D4J*@</E1''&0<@=2?I7T0?B!JI!'EV@]Q$W_Q=<DJUJCG
M$JVA\C?\$TOV0O%G[/L_BCQ[\0[2+P_?W]BMC:6,LZ-)!;[Q+-),5)5,F.+
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MPL+4/^>%M_WRW_Q5 'H-%>??\+"U#_GA;?\ ?+?_ !5'_"PM0_YX6W_?+?\
MQ5 'H-%>??\ "PM0_P">%M_WRW_Q5'_"PM0_YX6W_?+?_%4 >@T5Y]_PL+4/
M^>%M_P!\M_\ %4?\+"U#_GA;?]\M_P#%4 >@T5Y]_P +"U#_ )X6W_?+?_%4
M?\+"U#_GA;?]\M_\50!Z#17GW_"PM0_YX6W_ 'RW_P 51_PL+4/^>%M_WRW_
M ,50!Z#17GW_  L+4/\ GA;?]\M_\51_PL+4/^>%M_WRW_Q5 'H-%>??\+"U
M#_GA;?\ ?+?_ !5'_"PM0_YX6W_?+?\ Q5 'H-%>??\ "PM0_P">%M_WRW_Q
M5'_"PM0_YX6W_?+?_%4 >@T5Y]_PL+4/^>%M_P!\M_\ %4?\+"U#_GA;?]\M
M_P#%4 >@T5Y]_P +"U#_ )X6W_?+?_%4?\+"U#_GA;?]\M_\50!Z#17GW_"P
MM0_YX6W_ 'RW_P 51_PL+4/^>%M_WRW_ ,50!Z#17GW_  L+4/\ GA;?]\M_
M\51_PL+4/^>%M_WRW_Q5 'H-%>??\+"U#_GA;?\ ?+?_ !5'_"PM0_YX6W_?
M+?\ Q5 'H-%>??\ "PM0_P">%M_WRW_Q5'_"PM0_YX6W_?+?_%4 >@T5Y]_P
ML+4/^>%M_P!\M_\ %4?\+"U#_GA;?]\M_P#%4 >@T5Y]_P +"U#_ )X6W_?+
M?_%4?\+"U#_GA;?]\M_\50!Z#17GW_"PM0_YX6W_ 'RW_P 51_PL+4/^>%M_
MWRW_ ,50!Z#17GW_  L+4/\ GA;?]\M_\51_PL+4/^>%M_WRW_Q5 'H-%>??
M\+"U#_GA;?\ ?+?_ !5'_"PM0_YX6W_?+?\ Q5 'H-%>??\ "PM0_P">%M_W
MRW_Q5'_"PM0_YX6W_?+?_%4 >@T5Y]_PL+4/^>%M_P!\M_\ %4?\+"U#_GA;
M?]\M_P#%4 >@T5Y]_P +"U#_ )X6W_?+?_%4?\+"U#_GA;?]\M_\50!Z#7-^
M/?\ D!K_ -=E_D:PO^%A:A_SPMO^^6_^*JEJ_BN[UJT%O-%"B!@V8P0<CZD^
MM '3_#[_ ) LO_7=O_05KIZ\PT;Q3=:):M!!'"Z,Y<F0$G. .Q'I5[_A86H?
M\\+;_OEO_BJ /0:*\^_X6%J'_/"V_P"^6_\ BJ/^%A:A_P \+;_OEO\ XJ@#
MT&BO/O\ A86H?\\+;_OEO_BJ/^%A:A_SPMO^^6_^*H ]!HKS[_A86H?\\+;_
M +Y;_P"*H_X6%J'_ #PMO^^6_P#BJ /0:*\^_P"%A:A_SPMO^^6_^*H_X6%J
M'_/"V_[Y;_XJ@#T&BO/O^%A:A_SPMO\ OEO_ (JC_A86H?\ /"V_[Y;_ .*H
M ]!HKS[_ (6%J'_/"V_[Y;_XJC_A86H?\\+;_OEO_BJ /0:*\^_X6%J'_/"V
M_P"^6_\ BJ/^%A:A_P \+;_OEO\ XJ@#T&BO/O\ A86H?\\+;_OEO_BJ/^%A
M:A_SPMO^^6_^*H ]!HKS[_A86H?\\+;_ +Y;_P"*H_X6%J'_ #PMO^^6_P#B
MJ /0:*\^_P"%A:A_SPMO^^6_^*H_X6%J'_/"V_[Y;_XJ@#T&BO/O^%A:A_SP
MMO\ OEO_ (JC_A86H?\ /"V_[Y;_ .*H ]!HKS[_ (6%J'_/"V_[Y;_XJC_A
M86H?\\+;_OEO_BJ /0:*\^_X6%J'_/"V_P"^6_\ BJ/^%A:A_P \+;_OEO\
MXJ@#T&BO/O\ A86H?\\+;_OEO_BJ/^%A:A_SPMO^^6_^*H ]!HKS[_A86H?\
M\+;_ +Y;_P"*H_X6%J'_ #PMO^^6_P#BJ /0:*\^_P"%A:A_SPMO^^6_^*H_
MX6%J'_/"V_[Y;_XJ@#T&BO/O^%A:A_SPMO\ OEO_ (JC_A86H?\ /"V_[Y;_
M .*H ]!HKS[_ (6%J'_/"V_[Y;_XJC_A86H?\\+;_OEO_BJ /0:*\^_X6%J'
M_/"V_P"^6_\ BJ/^%A:A_P \+;_OEO\ XJ@#T&BO/O\ A86H?\\+;_OEO_BJ
M/^%A:A_SPMO^^6_^*H ]!HKS[_A86H?\\+;_ +Y;_P"*H_X6%J'_ #PMO^^6
M_P#BJ /0:*\^_P"%A:A_SPMO^^6_^*H_X6%J'_/"V_[Y;_XJ@#T&BO/O^%A:
MA_SPMO\ OEO_ (JC_A86H?\ /"V_[Y;_ .*H ]!HKS[_ (6%J'_/"V_[Y;_X
MJC_A86H?\\+;_OEO_BJ /0:*\^_X6%J'_/"V_P"^6_\ BJ/^%A:A_P \+;_O
MEO\ XJ@#T&BO/O\ A86H?\\+;_OEO_BJ/^%A:A_SPMO^^6_^*H ]!HKS[_A8
M6H?\\+;_ +Y;_P"*H_X6%J'_ #PMO^^6_P#BJ /0:*\^_P"%A:A_SPMO^^6_
M^*H_X6%J'_/"V_[Y;_XJ@#T&BO/O^%A:A_SPMO\ OEO_ (JC_A86H?\ /"V_
M[Y;_ .*H ]!HKS[_ (6%J'_/"V_[Y;_XJC_A86H?\\+;_OEO_BJ /0:YOQ]_
MR U_Z[+_ "-87_"PM0_YX6W_ 'RW_P 55+6/%=WK5H+>:*%$#!\Q@@Y'U)]:
M .H^'_\ R!9?^N[?^@K735S'P^.=%F_Z^&_]!6NGH **** "HKD9MI0>1L/\
MJEJ.X_X]Y?\ =/\ *@#X!_X*&^(=5\,_L\R7NCZE>:3>?VK:I]HL9WADVG?D
M;E(.#Z5^8/\ PN7Q_P#]#SXD_P#!O<?_ !=?I=_P4H_Y-KD_[#%I_)Z_*&O4
MPR3@9O<[#_A<OC__ *'GQ)_X-[C_ .+H_P"%R^/_ /H>?$G_ (-[C_XNN/HK
MKY5V$=A_PN7Q_P#]#SXD_P#!O<?_ !='_"Y?'_\ T//B3_P;W'_Q=<?11RKL
M!V'_  N7Q_\ ]#SXD_\ !O<?_%T?\+E\?_\ 0\^)/_!O<?\ Q=<?11RKL!V'
M_"Y?'_\ T//B3_P;W'_Q='_"Y?'_ /T//B3_ ,&]Q_\ %UQ]%'*NP'8?\+E\
M?_\ 0\^)/_!O<?\ Q='_  N7Q_\ ]#SXD_\ !O<?_%UQ]%'*NP'8?\+E\?\
M_0\^)/\ P;W'_P 71_PN7Q__ -#SXD_\&]Q_\77'T4<J[ =A_P +E\?_ /0\
M^)/_  ;W'_Q='_"Y?'__ $//B3_P;W'_ ,77'T4<J[ =A_PN7Q__ -#SXD_\
M&]Q_\71_PN7Q_P#]#SXD_P#!O<?_ !=<?11RKL!V'_"Y?'__ $//B3_P;W'_
M ,71_P +E\?_ /0\^)/_  ;W'_Q=<?11RKL!V'_"Y?'_ /T//B3_ ,&]Q_\
M%T?\+E\?_P#0\^)/_!O<?_%UQ]%'*NP'8?\ "Y?'_P#T//B3_P &]Q_\71_P
MN7Q__P!#SXD_\&]Q_P#%UQ]%'*NP'8?\+E\?_P#0\^)/_!O<?_%T?\+E\?\
M_0\^)/\ P;W'_P 77'T4<J[ =A_PN7Q__P!#SXD_\&]Q_P#%T?\ "Y?'_P#T
M//B3_P &]Q_\77'T4<J[ =A_PN7Q_P#]#SXD_P#!O<?_ !='_"Y?'_\ T//B
M3_P;W'_Q=<?11RKL!V'_  N7Q_\ ]#SXD_\ !O<?_%T?\+E\?_\ 0\^)/_!O
M<?\ Q=<?11RKL!V'_"Y?'_\ T//B3_P;W'_Q='_"Y?'_ /T//B3_ ,&]Q_\
M%UQ]%'*NP'8?\+E\?_\ 0\^)/_!O<?\ Q='_  N7Q_\ ]#SXD_\ !O<?_%UQ
M]%'*NP'8?\+E\?\ _0\^)/\ P;W'_P 71_PN7Q__ -#SXD_\&]Q_\77'T4<J
M[ =A_P +E\?_ /0\^)/_  ;W'_Q='_"Y?'__ $//B3_P;W'_ ,77'T4<J[ =
MA_PN7Q__ -#SXD_\&]Q_\71_PN7Q_P#]#SXD_P#!O<?_ !=<?11RKL!V'_"Y
M?'__ $//B3_P;W'_ ,71_P +E\?_ /0\^)/_  ;W'_Q=<?11RKL!V'_"Y?'_
M /T//B3_ ,&]Q_\ %T?\+E\?_P#0\^)/_!O<?_%UQ]%'*NP'8?\ "Y?'_P#T
M//B3_P &]Q_\71_PN7Q__P!#SXD_\&]Q_P#%UQ]%'*NP'8?\+E\?_P#0\^)/
M_!O<?_%T?\+E\?\ _0\^)/\ P;W'_P 77'T4<J[ =A_PN7Q__P!#SXD_\&]Q
M_P#%T?\ "Y?'_P#T//B3_P &]Q_\77'T4<J[ =A_PN7Q_P#]#SXD_P#!O<?_
M !='_"Y?'_\ T//B3_P;W'_Q=<?11RKL!V'_  N7Q_\ ]#SXD_\ !O<?_%T?
M\+E\?_\ 0\^)/_!O<?\ Q=<?11RKL!V'_"Y?'_\ T//B3_P;W'_Q='_"Y?'_
M /T//B3_ ,&]Q_\ %UQ]%'*NP'8?\+E\?_\ 0\^)/_!O<?\ Q='_  N7Q_\
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M_P#]#SXD_P#!O<?_ !='_"Y?'_\ T//B3_P;W'_Q=<?11RKL!V'_  N7Q_\
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M_P#T//B3_P &]Q_\77'T4<J[ =A_PN7Q_P#]#SXD_P#!O<?_ !='_"Y?'_\
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MNR_Y](/^_2_X5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J* *O\
M9=E_SZ0?]^E_PH_LNR_Y](/^_2_X5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](
M/^_2_P"%6J* *O\ 9=E_SZ0?]^E_PH_LNR_Y](/^_2_X5:HH J_V79?\^D'_
M 'Z7_"C^R[+_ )](/^_2_P"%6J* *O\ 9=E_SZ0?]^E_PH_LNR_Y](/^_2_X
M5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J* *O\ 9=E_SZ0?]^E_
MPH_LNR_Y](/^_2_X5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J*
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MO^%']EV7_/I!_P!^E_PJU10!5_LNR_Y](/\ OTO^%']EV7_/I!_WZ7_"K5%
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M_P ^D'_?I?\ "C^R[+_GT@_[]+_A5JB@"K_9=E_SZ0?]^E_PH_LNR_Y](/\
MOTO^%6J* *O]EV7_ #Z0?]^E_P */[+LO^?2#_OTO^%6J* *O]EV7_/I!_WZ
M7_"C^R[+_GT@_P"_2_X5:HH J_V79?\ /I!_WZ7_  H_LNR_Y](/^_2_X5:H
MH J_V79?\^D'_?I?\*/[+LO^?2#_ +]+_A5JB@"K_9=E_P ^D'_?I?\ "C^R
M[+_GT@_[]+_A5JB@"K_9=E_SZ0?]^E_PH_LNR_Y](/\ OTO^%6J* *O]EV7_
M #Z0?]^E_P */[+LO^?2#_OTO^%6J* *O]EV7_/I!_WZ7_"C^R[+_GT@_P"_
M2_X5:HH J_V79?\ /I!_WZ7_  H_LNR_Y](/^_2_X5:HH J_V79?\^D'_?I?
M\*/[+LO^?2#_ +]+_A5JB@"K_9=E_P ^D'_?I?\ "C^R[+_GT@_[]+_A5JB@
M"K_9=E_SZ0?]^E_PH_LNR_Y](/\ OTO^%6J* *O]EV7_ #Z0?]^E_P */[+L
MO^?2#_OTO^%6J* *O]EV7_/I!_WZ7_"C^R[+_GT@_P"_2_X5:HH J_V79?\
M/I!_WZ7_  H_LNR_Y](/^_2_X5:HH J_V79?\^D'_?I?\*/[+LO^?2#_ +]+
M_A5JB@"K_9=E_P ^D'_?I?\ "C^R[+_GT@_[]+_A5JB@"K_9=E_SZ0?]^E_P
MH_LNR_Y](/\ OTO^%6J* *O]EV7_ #Z0?]^E_P *Y[QQ96]OHRM%!%$WFJ-R
M( >AKJZYOQ]_R U_Z[+_ "- #?A__P @67_KNW_H*UTU<S\/_P#D"R_]=V_]
M!6NFH **** "H[C_ (]Y?]T_RJ2H[C_CWE_W3_*@#\\?^"E'_)M<G_88M/Y/
M7Y0U^KW_  4H_P"3:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>.H-);1+:\N[F"&SDF$KB.*5D5F8 #<0N2!P,XR<9/J]#3B[, HHHI %%%%
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ML04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (5_#K]FGPWX6\2^-M-T?Q"M]=YT^X+>8/,N&*=%(Y!'YU^@E?F#^PE^P?\
M##XT_ OPYX_\1KK)U]KZXR;2^$<7[F<A/EV'LHSS7U7^WK^T[-^S+\%GOM':
M/_A+M;E.GZ1Y@#>2VTF2X*GAA&N, \;G3((S4U8J52T-VQK8]%^+7[3'PO\
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M%&'NI-?E+^RC\./'G[1^J3_!SPYK1T/PM?3C6]<N-A9%CA 16< @R8+@+'D
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M +,WP'\+_%?]L)/AMKHO#X;-YJ<!%M/LFVP1S-'\^#SF-<\<\U^M?P:_9O\
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M?L _"I/C9^Q!\;?!A17N-3U!A:;NBW26T4D!_"5$S[9KT:,N2ES>9+W/L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<WX^_Y
M :_]=E_D:Z2N;\??\@-?^NR_R- #?A__ ,@67_KNW_H*UTU<S\/_ /D"R_\
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M;W59%3_@-*2]C%VZL>Y\J_\ !&KXB_:?"_Q \"S2_-9W<&LVL9/)65?*EQ[
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MUV]<1\.?];??[J?UKMZ "BBB@#Y0_P""H7_)FWBW_K[T_P#]*XJ\K_X(V_\
M)%O'/_8P#_TFBKU3_@J%_P F;>+?^OO3_P#TKBKRO_@C;_R1;QS_ -C /_2:
M*NR/^[OU)ZGS?\8HV_8T_P""DD'B2)3::!<ZK'K0VC"FQO-R70 ]%+7"@?[
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M4K1_4JAMV7\ 9'_.O8M0\77X_P""3(U(R2BY/@N/3RY/S&,LMM^13]*^9/\
M@K)\5+7XF?''PMX#\/R?VK/X:MY()DM?WA^W7+IN@4#JP6.$$#^)BO4&OOO7
M?@!<M^Q'<?"6#$^K1>$!IL>" )+U( 5Y]#,H_ UL_=ITU+N+JSX]_P""+VA0
M2:C\5M98(;F&+3K.,_Q*CFX=_H"8T^NWVK]0:_'O_@DS\7M/^''QPU_P7K3_
M & ^++:."V>8[ +RW9V2)@>A99)0/]H!<9:OV$K/$IJH[@MCYA_X*5:%!K?[
M&OCMYM@DL397<+N/NNMW"IQ[E6=?^!5X+_P1DU2XF^'_ ,2M-9F^R6^IVEQ&
MI^Z'DB=7Q[XB3/T%=E_P5F^,NF>$_@)'X 699=<\5W4+?9U<;HK6"596D8>A
MD2-1GKEL?=-+_P $C/AY=^%_V>-6\1W:&/\ X275WFME(QN@A41!OQD$P_ >
MM4M,.[]6'4^7?^"P_P#R<SX:_P"Q1M?_ $LO:_6_P=_R*.A_]>,'_HM:_)'_
M (+$*1^TQX9;'!\(VP!_[?+VOUL\$RI/X,T"2-@R/I]NRL.A!C7!HJ_PH MS
M\*OV@O&VI0?MR>-?$<-@NN:CI/C.9[>PG1G6X^R7.V.-E4ABI$*@@$'%?3'_
M  ]-^/7_ $2C2/\ P67_ /\ ':\@_:NL[[]FG_@H+=^*Y+:9K5=?M?%EMMX-
MU"\BRRJO_ Q-'_P$U^SW@[Q=I/C[PKI7B/0KR/4-'U2V2ZM;F,\/&PR/H>Q!
MY!!!Y%;59148MQOH)'Y?/_P5+^/,BE6^$VCLK#!!TN_((_[^UY=_P3:TOQ'X
M=_;)\+32Z%J6EZ?J$.H6\Y>TD2)$-K+(JEF'3?&F,GJ!7[%>/_'6C?#+P7K/
MBKQ!=I9:/I-L]U<3.0/E4<*N>K,<*J]22 .37R]^R)_P4$D_:M\?77ABW^'5
MQH'V2S>]N=1&J"YAB0,JJ"/*0[F9@ /J>QK-5+PERPT'8X/_ (+(?\D+\%?]
MC(/_ $EGKU#_ ()?V$5G^QKX0FC0*]W=:A-*0/O,+N5,G_@**/PKR_\ X+(?
M\D+\%?\ 8R#_ -)9Z]9_X)E?\F6^!/\ KKJ/_I?<5+_W=>H=3ZDK\7/A4H@_
MX*LWBH-JCQ]K  'IYMS7[1U^+WPP_P"4K=Y_V/\ J_\ Z-N:,/M/T!GZ\_%/
M_DF/B_\ [ ]Y_P"B'K\L/^"./_)?/&7_ &++_P#I5;U^J'Q14O\ #/Q<JC).
MD78 _P"V+U^5G_!'*51^T!XPC+ .WAB1@O<@7=MG^8I4OX4P>Z/U"^.G_)$O
MB%_V+VH?^DTE?F;_ ,$:_P#DL/CS_L I_P"E"5^F7QT_Y(E\0O\ L7M0_P#2
M:2OS-_X(U_\ )8?'G_8!3_TH2G3_ (,P>Z/U,\<^.M ^&OA34?$OB?5(-&T/
M3X_-N;RX)VH,X P,EB20 H!))  )-?!_Q"_X+%^"]"OY[3P7X%U+Q-;QDJE[
M?7:Z?&_^TJ!)&V_[P4^PK@_^"RGC?6E\2> /"*S30^'C93:F\2L1'<7!D\L%
MAW**O'IYK>M?2O["G[+?PT\'_ /P5XF3P[I6N^)-=TV#5+O6+ZW2YE5Y4#F*
M,N#Y:IG;A<9*DG)I1A"$%.>MPZV/F*/_ (*9?M!_%N7['\-OA5:,TQVK+9Z=
M=:E(GON!5!CN67%?/O[.EUXGO/\ @H'X7N/&B-%XNE\62/JZ,B(5NBS^:"J?
M*/FSPO%?N%KFMZ7X/\/WVK:I=0:7I&G6[W%Q<RD)'!$BY9CZ  5^'WP#\;Q?
M$#_@H9H/BR)6CM]<\:S:A$C]52:>1U4_0.!6]*2DI<L;:"9^M'[:G_)I_P 5
M/^P#<?\ H-?&?_!%?[OQC^NC_P#M]7V9^VI_R:?\5/\ L W'_H-?&?\ P17^
M[\8_KH__ +?5C#^!(?4_3>BBBN,H*YOQ[_R U_Z[+_(UTE<WX]_Y :_]=E_D
M: &?#[_D"R_]=V_]!6NGKF/A]_R!9?\ KNW_ *"M=/0 4444 %%%% !1110
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M;6]4T#Q9H4&I3/I<$4<EM*+=7:)T<\LDBJI!'9NQXK\^JUC.,[\HK6"BBBK
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MVC_P3$_94\"?'[4O%7B+QO:3:O%X=GM4MM*:3;:S-()&+3 ?,X'EC"Y"G)W
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M+;5K/!/)C#!VC!/.,)R22.34LG['_P"U9^UYXHL+OXK:A-HVFVIPMWKTL2+
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M^'7BGQ;X#UZ32?'?A74;=K" S>0EP"C/\DPP8I05!5B<=CM^\/9]1US_ (*
MZQ8R>$YK3Q&@(:%[N"TL8'93Q@7B@>_S*X/?/2O3_P#@C)_R(7Q+_P"PG:?^
MBGK]&:ZZM9QFTTF)+0^ /V)O^";-S\)O%5I\0_BA=6VH^*K1_/T[2+67SH;2
M4C_732$8DE!/ 7*J1NRQQM^_Z**Y)SE4=Y#M8_/+]M#_ ()F7'Q)\57_ (_^
M%-Q:Z?KUY(;G4-!N7\F*XFZF6"3&$=CRRMA223N7H?(-+\1_M_>"K >&8;+Q
M)<)&H@CN)]/LKYT &.+EE?=Q_$S'V.:_6RBM57:5I)/U"Q^4GPG_ .":?Q4^
M-WCT^,OCUK4^FVUS()KN![Q;G5+S'1-R[HX4QQU)4  (.H_4OP_H&G>%-"T_
M1M(LXM/TK3X$MK6T@7:D,2*%55'H !6A16<ZDJFX)6/AG_@I#^Q7XI_:+E\/
M^+_ JP7WB'2;5K"XTJ>986NH-Y=#&[$*&5F?(8@$-P<C!\Q_8H^'?[6'@#XP
M^#K+QE:>)$^&FFB:VN[+4-6A>WAB-NZ1;4,I+*C^60%!QC@5^FE%4JTE#D:"
MW4^?OVP/V/\ P]^U?X-M[6ZN!HWBG3 [:5K*1[_+W?>BE7JT3$#@'*D CN&_
M/[PU\$/VSOV1KJ[TWP-!J%YHDDQDQHKP:E93D=76"4%HR1U.Q&/'H*_8*BB%
M:4%R[H+'Y#^)?@5^V=^UY>6&F^/EN],\/K(),:O);Z?90$=':WA >1ADX)1F
M&>H%?H)^R5^RAX=_93\ OI.G2#5/$%^5EU?6GCV/=.N=JJN3MC3<0JY[DGDF
MO=**)UI37+L@L?(/_!2SX#>.OV@/A1X7T;P#H?\ ;VI66MB[G@^UP6VR+R)4
MW;IG0'YF48!)YZ5Z'^PO\,/$WP<_9B\)^$O&&F_V1X@L9+UKBS\^*?8)+N:1
M/GB9D.5=3P3UYYKWNBH=1N')T"W4*_,;P'^QO\8-&_X*"7/Q*O/"'D^"G\7Z
MEJBZI_:=FV;:62<QR>4)C)R'7C;D9Y YK].:*(5'"]NH6(+VSAU&SGM;A!)!
M/&T4B'^)6&"/R-?C9XI_8"_:*_9^^)MQJ7PQAU#4[6*1UT_7] U"."=H6/"2
MH75E.,!A@J2#@D5^S5%53JRIWMU!JY\N? 'PM\8M2_8_\5^'?BA:7T_C^[MM
M4M+5=1OH9YKE)83Y.9%<JOS.R ,1@+S@8KQ+_@FA^RC\5/V?OB3XMU7Q]X6_
ML&POM)6UMY?[0M;G?()E8KB&5R. 3D@"OT0HH]J[25MPL?-/[<7['MO^UAX%
MT^/3[V#2?&&B.\FF7MSN\ET?'F02[02%;:I# $J5Z8)!^'/AOX<_;;_99T]_
M#'AOPYJ5YH*3-Y-FL%OJ=JI+$EHB"S1JQ);&5&3DC.:_7FBG"LXQY6KH+'Y@
MK^S;^UI^V%<6MI\8?$9\%^"5D666Q;R4,H!S\MK!]YAV,Q&.HSTKF_%7_!/?
MXH?!3]I_0_$WPC\(3^)_!FAWNG:C:37>KV4<TC1",SQN)98SEG63D*!AQCI7
MZQ452Q$ELE;L*QY=^T]X-UGXB_L]>/O#7A^R-]KFJZ1-;6EH94C\R1APNYV"
MCZD@>]?,W_!,']FKXD?L[K\2O^%@^'/^$?\ [8_LW[#_ *=;7/G>5]J\S_4R
M/MQYJ?>QG=QG!Q]U45DJC4'#HQV"BBBLQA7-^/?^0&O_ %V7^1KI*YOQ[_R
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M444 %%%% !1110 4444 %%%% !1110!^E/\ P1=_Y#OQ8_Z]M-_]"N:^;O\
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M>"/$>H@_^!4E%/\ BS&]C#\ ?\CYX;_["5M_Z-6OUD_X+$_\FV^%O^QMM_\
MTCO*_)_X<0/=?$/PO#&,O)JMJBCU)F4"OU@_X+$_\FV^%O\ L;;?_P!([RBK
M_$@"V/G+_@D3\';/QG\8?$/CC4K9+F'PI:1I9B09"7=P6"R =RL<<H]BX/4"
ML+_@I[^TKKGQ#^-.J_#RQO[BU\'>&72VDL4?;'=W@&Z260#[VTML4'(&PD8+
M&O>_^",5U;/X*^)ULI7[9'J%E)(,\[&CE"?JK_K7P+^UO:W5G^U%\6([S=YI
M\3ZC(-W7RVN':/\ \<*T17-7;?0.AQ/P]^(OB/X5>+;'Q-X4U>YT76K)MT5U
M;-@X[JPZ,IZ%6!!'!%?NFOQ6@^.'[%&L^.8(/LHUGP=?S2VX.1%,+>5)4![@
M2*X![@"OP)K]E/V2;>ZM_P#@E[<BZW /X?\ $#PJW:,R79'X$Y/XTL1%64O,
M$?C717TI^P'\3/AS\*?C=>ZS\4)+6+PX^BSVT;7FG/?)]H:6$I^[1'(.U7^;
M''KS7Z'_ /#:_P"QS_S^:%_X1]S_ /(M:SJ2B[*+8DC\7*_2G_@B[_R'?BQ_
MU[:;_P"A7-1_MQ?M+?LZ?$W]G_4M"^'%QI<GBB6]M9(EM?#LUF_EK)E_WC0(
M!QVSS4G_  1=_P"0[\6/^O;3?_0KFLZDG.BVU8:W/F[_ (*2_P#)ZOQ'_P![
M3_\ TWVU?,]?3'_!27_D]7XC_P"]I_\ Z;[:OF>MZ?P1]"7N%?N9_P $U)GU
M+]BGP+%<KNC4ZA ,_P 2?;KC_$C\*_#.OW8^$]H_[*_[ ^G2ZJ/L-]X?\+SZ
ME/#-P4NY1)<>4?\ :\V79CUKGQ.L4O,J)^-7P&C2']H3X=I&^]%\4:<JMZ@7
M<>#7[&_\%%/CUK'P"_9VN;_PY=G3_$6MWT>D6=Y'_K+8.KR22)Z,$C90>Q<$
M<@5^-O[/O_)>_AK_ -C-IO\ Z51U^DW_  66D8?"CX?Q@_(VMRL1ZD0''\S1
M52E5BF"V/S'3XN>.(TU5!XQUXIJT,EOJ"-J4S+=QN,.LH+?.".H;-?IW_P $
M:_\ DD7C[_L.Q_\ I.M?DQ7ZS_\ !&O_ ))%X^_[#L?_ *3K58A6IL2W/S1^
M/'_)<?B)_P!C'J/_ *4R5B> /^1\\-_]A*V_]&K6Y\>E*?'/XBJ>"/$>H@_^
M!4E8_P .('NOB'X7AC&7DU6U11ZDS*!70OA%U/U@_P""Q/\ R;;X6_[&VW_]
M([ROG+_@D3\';/QG\8?$/CC4K9+F'PI:1I9B09"7=P6"R =RL<<H]BX/4"OH
MW_@L3_R;;X6_[&VW_P#2.\KD/^",5U;/X*^)ULI7[9'J%E)(,\[&CE"?JK_K
M7GQ;6'=B^IX)_P %/?VE=<^(?QIU7X>6-_<6O@[PRZ6TEBC[8[N\ W22R ?>
MVEMB@Y V$C!8U\E?#WXB^(_A5XML?$WA35[G1=:LFW175LV#CNK#HRGH58$$
M<$5VW[6]K=6?[47Q8CO-WFGQ/J,@W=?+:X=H_P#QPK7DU=T(I02(9^^R_%:#
MXX?L4:SXY@@^RC6?!U_-+;@Y$4PMY4E0'N!(K@'N *_ FOV4_9)M[JW_ ."7
MMR+K< _A_P 0/"K=HS)=D?@3D_C7XUUAAU9R2[E,****ZR3]P?V7?^4<NC?]
MBKJ/\[BOP^K]P?V7?^4<NC?]BKJ/\[BOP^KDH?%/U*>R/WJ\%?$5?A'^P/X4
M\9&)9Y-$^'MA>10O]V25;"/RT/LS[1^-?AS\0OB/XF^*WBF\\1^+-9N]<UBZ
M8E[F[D+%1DD(@Z(@SPJX ["OU]^*S%?^"4MD0<'_ (0#1A_Y!M:_%ZEATO>?
MF#/T/_X(_?%K78/B=XC^'EQ?S3^'+K29-3M[.5RR6]S'+$I,8/W=RRMNQU*K
MZ5Y+_P %1_#5EX>_:[UV:S@6#^U+"SOYE08#2F/8S8]3Y8)]22>];W_!)+_D
MZN?_ +%Z\_\ 1D-0_P#!6;_D[ _]@&S_ /0I::TKNW8.A[__ ,$7_P#D6/BI
M_P!?FG_^@3U\"_M4_P#)SGQ;_P"QLU7_ -*Y:^^O^"+_ /R+'Q4_Z_-/_P#0
M)Z^!?VJ?^3G/BW_V-FJ_^E<M.'\:0NA^B?\ P2#^#5CHOPS\0?$R\MU;5]8O
M'TVSF=1F*TAVE]I[;Y20W_7%:^"_VN?VF/$'[2?Q6U;4[S4)O^$9M;F2+1=*
M64FWMX%.U7"]#(X&YFQDDXZ  ?JE_P $UKN.+]B+P=);0&YG@;4]\*$;I)!>
MW#!?J05%>)G_ (*Y_"Y20?A;K (Z@BU_QK&,I>TE)1N/H?FO\*?BSXI^"GC6
MQ\4^$-5FTK5K5A\T9^29,@M%*O1T;'*GZ]0#7ZT?MS>%-)_::_8;LOB/:6:Q
MZGI^FVOB>P889X8I$0W,);KM$;,2/[T2^E>?_P##W3X7?]$NU?\ *U_QKG?B
MU_P59\!_$/X1>,?!MGX#URRDUO1;S2X)'E@\N%YH7C5B >@+ \>E5+GG)2Y;
M6#0\0_X)0_\ )VUI_P!@6]_DE?1O_!6?]I#Q-X$G\,?#CPOK%SH8U*S?5-5G
ML93%--"7,<46]<$(3'*6 /S84'@$'YR_X)0_\G;6G_8%O?Y)6M_P5XD9_P!J
M33 Q)">&+15'H//N3_,FJ:3KJ_8.A\B:C\1?%6K^&_\ A'K_ ,2:M?:$+A;L
M:;<WLDENLRJRB0(Q(#;789 Z&ONKX5_\%'_!/P:_91A^'WA/PWKFF>-K+27@
MM=1:&W>T:_DR9+ACYF[AW9@"C?=53Q7YZ5^F?[(/_!-SPB/AQ9_$KXVR,(+B
MW&I0:+-=_9K2VM-H=9;IP0V2/FV[E"CALDD+I6Y$O?$K]#\U=4U2\UO4;G4-
M0NYKZ^N9#+/<W,ADDE<G)9F/))/<U]L_\$G_ !-XUTC]H&#2K"'5I_!6K6ER
MFI!(I'L89$B,D4KG&Q'W($#<$[]O>OH'4?VS/V-OA#*\'A/P#9:Y<0':MQHG
MAB!=Q'_3:X\MF'OS[9KI_P!GG_@I(O[0OQ]\-_#WP]X#&@Z#=Q7+S7UY>"29
M5BMY)%"1HH5/F51]YN">E93G*4&N70:1\S?\%AM&M;+]H/POJ$,*13WWAR/S
MW48,C)<3*&/J=I SZ*!VKW[_ ()'_"C3O"7P6\0?$N_AB34M;NY;:*\?DQ6-
MOC< >P,HD+>OEIZ"O$?^"R/_ "6SP/\ ]B\?_2F6OJG]B&/[=_P3@TRWT]2;
MI])UN+:O+>:;F[Q^/*_I42;]A%=Q]3\L_P!IW]I#Q+^TI\2]2U_6+^X;1XYY
M%TC2F8B&QMMWR*J=-Y4*6;JQ]@ &_LM?M :O^SC\8=#\3V-Y<1Z3]HCAUBRB
M.5N[,L!*I7H6"DLI/1@#7D=%=W*N7EZ$'V3_ ,%#OVI_AC^U#=^%+WP;I^MP
M:UHWG6]Q>ZC:Q0Q7%L^&51B1F)5P2 5'^L:OKW_@CQ_R;-XE_P"QNNO_ $CL
MJ_(34]'O]%N#!J-C<V$X_P"65U$T;?DP!K]>_P#@CQ_R;-XE_P"QNNO_ $CL
MJY*T5"E9%+5GY(>,?^1NUS_K^G_]&-7ZV?\ !';_ )-K\4?]C;<?^D=G7Y)^
M,?\ D;M<_P"OZ?\ ]&-7ZV?\$=O^3:_%'_8VW'_I'9U6(_ABCN?E[:>"[CXC
M?'Y/"EJQ2XUOQ+_9R.!G:9;G9N_#=G\*_73]MWXP)^QQ^R[I6A> D_LC4KH1
M:#HLD2@FSB1,R3<CE@BX!Z[Y W8U^9_[-T\%O^W1X.:XQY9\9!!D_P ;7#!/
M_'B*^R/^"S]K=/X6^%ERC$64=[J$<J^LC) 4/Y+)^=34]ZI"+V&MC\NM2U*[
MUG4+F_O[J:^OKF1I9[FYD,DDKL<LS,<DDGDDU^@W_!*?]J+7=/\ B-#\(==U
M&YU'P_JMO*^BQSOO^P7$2-*T:$\K&\:R';G 95P!N;/YXU]"?\$_K2ZO?VQ?
MAE':,4E6^EE8C_GFEO*T@_%%85T58J4&F);GJ/\ P5;^#5C\-_V@;3Q+I5LM
MK8>+[,WTT<:A4^V1MLG( _O Q.?5G8]Z^Y_^"8EQ':?L7^&9YG$<45UJ+NYZ
M*HN9"37SE_P6DNXGU'X1VH \^.+59&/?:QM /U1J]S_X)],5_P""?D# X(AU
M@@C_ *ZS5QS;E0C<I;GY8?M&?M"^*/VC/B-J?B+7]2N9K%KB3^S-,>0^186Y
M;Y(XTZ [0NY@,L1DYKUK_@FI\6M<^'_[4'AC0[2_F70?$LKV&HZ?O/E2DQ.8
MGV]-ZN%PW7!8=&-?*5>X_L/?\G;?"W_L,Q_R:NR<4H->1*W/J;_@LSX:LK/Q
M]\-]>BA5+[4-.N[2>4#!=()(V3/T\]_SK\Z*_2__ (+2?\A+X1_]<M5_G:5^
M:%30_AH'N%?8W_!*'_D[:S_[ U[_ "2OCFOL;_@E#_R=M9_]@:]_DE55^!B6
MYVG_  6/_P"2\^#/^Q:7_P!*IZ^!:^^O^"Q__)>?!G_8M+_Z53U\"TJ/\-#>
MX5Z]^R!_R=-\*/\ L9;#_P!'+7D->O?L@?\ )TWPH_[&6P_]'+6DOA8C[D_X
M+2?\@OX2?]=M4_\ 0;6OG/\ 8#_:P\ _LIZGXIU'Q5X=UC5M3U=(;:"]TJ.%
MVMH$+,Z 2.GWV*$\_P#+-:^C/^"TG_(+^$G_ %VU3_T&UKYI_85_8CN?VJM>
MOM6UNZN-)\!:3)Y-W=6A47%U<%0P@B+ A< JS,0< J ,MD<E/E]A[VW_  2G
MN>8_M3_M!:K^TC\8M;\4W=S='1S.\.CV%PV!:68.(UV@D*Q&&;&<L3R:XSX6
MZUXP\.>.=*U7P(VIKXFM)EEM?[)C>28D$';M0$LIZ%2""#@@@U^JGC'Q'^Q;
M^R-J+>&;OPOHNL>([!0)[5-*_MB\C;'_ "TFFRB/ZKO!&>@&*X+Q'_P5W\%>
M%=.ELOAM\*YXU/$;:B\-A$OH3% 'W?3</K5*HVK0AH*Q[-_P4WLHO$G[%-[J
MM]9>3>VMWIM]'',F'MY7D6-A@\@A974_4U^>G_!-'_D]?X=_34?_ $W7-?HQ
M_P %'KZ?5/V%=?O+F-8KBX_LJ:6-.BLUS"2!GL":_.?_ ()H_P#)Z_P[^FH_
M^FZYK.E_!E\_R&]S[;_X*K_M,ZW\+?".A?#_ ,+7]QI6J^(TDN=0OK9MDB62
M_)Y2L.1YC$Y(P<1D=&-?D9:7<]A=0W-M-);W,+B2*:)BKQL#D,I'(((R"*^Z
MO^"Q,=PO[1GA5W8FV;PK (QV#"[NMW\UKX0K>A%*FK">Y^U?["_Q9?\ ;!_9
M9UKP[\0&_MK4+-I=!U2:8 O=P/&#%,W^WM8KNZ[HMW4U^06N>$;GP!\6K_PQ
M>'==Z+K;Z=*V,9>*<QDX]RM?I+_P1BT^>/P5\3KYC_HTVH64*#_;2.4M^DB5
M\+?M+7<%[^V#\0Y;?:8O^$PNURIR"5NBI/XD&LZ?NU)Q6PWL?I-_P5\_Y->T
M?_L:;3_TFNJ^3O\ @D)_R=%J_P#V*]W_ .E%K7UC_P %?/\ DU[1_P#L:;3_
M -)KJOD[_@D)_P G1:O_ -BO=_\ I1:UG#^ P>Y@_P#!5C_D[K4O^P18_P#H
M!K[5_P""17_)K-__ -C+=_\ HFWKXJ_X*L?\G=:E_P!@BQ_] -?:O_!(K_DU
MF_\ ^QEN_P#T3;TZG\!?(%N?CGJW_(4O/^NS_P#H1K]E/"W_ "BBF_[$*\_]
M%RU^->K?\A2\_P"NS_\ H1K]E/"W_***;_L0KS_T7+6F(VCZB1^,-?MC\/[R
M/]N/_@GN^F7,BW7B"ZTA]-G:0Y9=4M<&*1CV+ND4A]I*_$ZOT1_X(^?&7^Q?
M'GBCX:7L^VUUN#^U-/1CP+F$8E51ZO$0Q]H*JO&\>9;H$?GC/!);320S1M%+
M&Q1T<896!P01V-?K]_P3K\)Z?^SG^QOK_P 4?$$?D2:O'/KMP3\KFRMT98(Q
MZEL2.OKYPKX[_; _9EO+/]NU_!6C0^1;>.=1M[_3V"_+&MW(1,V.RI*)SCLJ
MBOK'_@J5\0;#X/\ [-_A3X3>'R+1-8,-J+=#S'IUFJ84XZ9?R![A7'K45)>T
M48KJ-:'Y5^-O%VH>/_&.N>)M6D\W4]8O9K^Y?L9)'+MCVR< >E8M%%=A(444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[*_L
M%?\ )KOP[_W;C_TLFK[;KXD_8*_Y-=^'?^[<?^EDU?;=>'4^-^IHM@HHHK,8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XE\,OV,?A#\
M'O'@\9>$_"SZ9XC"RJ+MM2NIAB0$/\DDK+SD]N.U>VT4U)K1, HHHI %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E^)O^0!??]<S6I67X
MF_Y %]_US- '.?#G_6WW^ZG]:[>N(^'/^MOO]U/ZUV] !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\4/@U_RE%;_ +'S5?\
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M&O\ UV7^1H ;\/\ _D"R_P#7=O\ T%:Z:N9^'_\ R!9?^N[?^@K734 %%%%
M!4=Q_P >\O\ NG^525'<?\>\O^Z?Y4 ?GC_P4H_Y-KD_[#%I_)Z_*&OU>_X*
M4?\ )M<G_88M/Y/7Y0UZN&^ SEN%%%%=8@HHHH **** "BBB@ HHHH ****
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MYP<4-:,^I_VU_P!A/XT_&+]ISQIXO\*>%8=1\/ZDUF;:Y?5+6$OLLX(G^1Y
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M_P""</[%>N? W69_B3\2(X=#UN\@_L[2-&GE7S81(1N>3L)&"A50$D!GR 2
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MMWX<_;!^'&DZA$(;^P\6VEK<1!@VR1+@*PR,@X(/(XKW[_A\1\9O^A9\"?\
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M+=@Z/%]MM\,I'!7:<Y'&*_-/_@FC_P GK_#OZ:C_ .FZYIVC_P#!0OXB:7\
MQ\(I]#\+:MX8&DR:-Y]_:7+79MV#*/G6X5=R!@%(3C:O7%>-_ [XQZU\ ?BC
MHWCSP]:V%YJ^E>?Y$&IQO);MYL,D+;E1T8X61B,,.0.O2IA3E&G* -ZGZU_\
M%'/V3-2_:3\'Z5JW@\07/C;PPLC#3C(J/>VLN"8P2>&#1Y3=@'YQG)K\MO#?
M[(OQG\5>)5T*S^&?B:&],HB=[W3);:"(DXR\LBA%7ODGH.*]%UC_ (*-_%[4
M?C+;?$FTFTC1=4338M)N-,T^WE_L^]@CDED03122N2P:9\,K*0.F,G/M4O\
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MFK[;KXD_8*_Y-=^'?^[<?^EDU?;=>'4^-^IHM@HHHK,84444 %%%% !1110
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M@/\ L]^(/'8L;+5=:T:UMY)+7<Z6\DCRQ1O@_>"_.2._ S7R_P#\$N_V1_\
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M=YI]K=Z:WB+48VLYX5>$J$N,*4(Q@8&!CL*_9_\ X4YX!_Z$?PW_ ."FW_\
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M -=E_D: &?#[_D"R_P#7=O\ T%:Z>N8^'W_(%E_Z[M_Z"M=/0 4444 %%%%
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M1GV,F&,D4@(PQZ '/>OG;_ASO\&?^AF\=_\ @?9?_(E3"=-T^28:WN=]<?\
M!3[]G>&,LGC&\G/]R/1;P'_QZ("OG/\ :4_X*UZ=J_A74/#_ ,(]+U*VU"\B
M:!_$6J*L)ME((+01*S$O@\.Q7:>=IKU&'_@CW\%XW#-XB\<2C^Z^H6F/TM0:
M]2^&7_!.SX%?"Z_@U"V\(_V]J,)#1W/B"X:\"D=#Y1Q%G/.=F1VH3H1U5V&I
M\C?\$N_V0-5OO%-O\9_&-A+:Z=:JS>'[>[4B2[F<8-V0?^6:J6VD_>9MP^Z"
M?U.IJ(L:*B*%51@*!@ 4ZL*E1U)<S&E8****R&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5S?C[_D!K_UV7^1KI*YOQ]_
MR U_Z[+_ "- #?A__P @67_KNW_H*UTU<S\/_P#D"R_]=V_]!6NFH **** "
MH[C_ (]Y?]T_RJ2H[C_CWE_W3_*@#\\?^"E'_)M<G_88M/Y/7Y0U^KW_  4H
M_P"3:Y/^PQ:?R>ORAKU<-\!G+<****ZQ!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >V_L>_M(3_LO?&>R\6&UDU#1[B!]/U6SB($DMLY5B4SQO5D1QGKM(R-V1
M^D7Q$\#?LL_M])9^*!XTM]+\2B);=KJSOX[#4"H^['-;SJ=V,D!MN>,!R *_
M'"BL9TN9\R=F-,_6_P -?L%?LP? ?4XO$OC/QVFM)8$3K:>(M7M8[0L#E28D
M56DYQ\A)#="ISBO!?^"A'[?>E_&W1A\-_ATTQ\'I,LFI:J\9B&HE"#''&A 9
M8E8!LL 695P %RWP514QHZ\TG=A<****Z!!1110 4444 %%%% !1110 4444
M %%%% !7MO['O[2$_P"R]\9[+Q8;634-'N('T_5;.(@22VSE6)3/&]61'&>N
MTC(W9'B5%)I25F!^Q_Q$\#?LL_M])9^*!XTM]+\2B);=KJSOX[#4"H^['-;S
MJ=V,D!MN>,!R *Y_PU^P5^S!\!]3B\2^,_'::TE@1.MIXBU>UCM"P.5)B15:
M3G'R$D-T*G.*_)"BN;V+6BD[#N?>O_!0C]OO2_C;HP^&_P .FF/@])EDU+57
MC,0U$H08XXT(#+$K -E@"S*N  N6^"J**WA!07*A/4****L HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OU^^ _P"R+^RS/X+\)?$6X_LRYE.FV>H7,&I>
M(/,L[6X,2R.)8VDQPV<I(2."".M?D#1652#FK)V!.Q]Q_P#!2W]L;2?CIKFF
M^!/!-Z+[P;H<QN;G4(N(K^\P4!C]8XU+ -T8NQ&0%)^'***J$%"/*@W"BBBK
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M]E?V"O\ DUWX=_[MQ_Z635]MU\2?L%?\FN_#O_=N/_2R:OMNO#J?&_4T6P44
M45F,**** "BBB@ HHHH **** "OPN^!<'_"]O^"A.C76IR&\74O%UQJTA?D.
ML+R7(7']W$07'3'%?NC7X8_L8;?AY^W[X3LKEO(-GKM_I1$G!#O%<6X7GN68
M#ZFNW#_#-^1+/W.HHHKB*$(# @C(/!!JII.C:?H%C'9:98VVG6<?W+>TA6*-
M?HJ@ 5<IJ.LBAE8,I[@Y% #J_-G_ (*L_LF_VI8?\+G\+V>;NU1(/$=O"O,D
M0PL=W@=TX1_]G8> K&OTFJMJ6FVNLZ==:??6\5Y8W43P3V\RADEC8%65@>""
M"01[UI3FZ<N9":N?G7^QU_P4'T?P[^RKX@@\;W@G\2^ K-8[*"23$NJV[$):
MHI/)97*Q,<'"[&.>:\'_ &,/@/K?[;7[0NM?$SX@AM0\-V5]]OU6213Y=]='
M#16: _\ +-0%W*/NQJJ\;@:\+_:A^"NG_!_]I[Q5\/-&N7?2[;4($LWF&6BB
MN(HID0\_-L$P7/?;GC-?N=\$?@[H/P&^&6B>"O#L6VQTZ+#SLH$EU,>9)G]6
M9LGV& . !7;4<:4>:&\B5J=RB+&H50%4#  & !7SI_P41_Y,S^)7_7M:_P#I
M9!7T;7SE_P %$?\ DS/XE?\ 7M:_^ED%<5/XX^I3V/E?_@BQ_J/C!_O:1_*]
MK]-:_ #]FC]E7XA_M,)XC;P)=:?;#13;B\^W7KV^[SO-\O;M5MW^J?.>G'K7
MMW_#JW]H,\'5= _\',W_ ,;KMK4X2FVY6)3/U9^*WQL\$_!3PY=ZUXQ\0V.C
MV\$9D6"69?M$Y R$BBSND8]@!^G-?B_\%;35/VKOV[=-UJ"RDBCU3Q.WB&[B
MSO%K9QS^>RLW3A%6,'N2OKBO8?#'_!'CXHZI?*?$7C#PQI%JQ&^2T>XO)AZG
M88XU/_?=?H'^RW^Q_P""?V5-!NH- $VJ:]?JJW^NWP'GS@'(15'$<8/.T=>-
MQ8@8A2IT8OE=VQZL]TJIJNIVVB:7>:C>2>5:6D+W$TF,[412S'\ #5NL[Q'H
M-IXJ\/:IHNH*[6&I6LMG<+&Y1C'(A1@&'(.&/(Z5PE'PW\7O^"N?PXT#P_=1
M_#_3=2\4Z\Z,MM)>6YM;.)L<.Y8[V .#M"C."-R]:\=_X)X?LL>,/B?\7XOC
M[X^B>#2_M<^KV3W"A9-5O96<F8(,;8U9B^< %MNT$9Q]3>)/^"7W[/VMZ#)8
M6/A:\T&[\LI'J5CJMR\R,>C8ED=&Y[%:_/A/$7Q%_P"":'[3$V@QZM-J?AY9
M([B:TY6VUC3G;B01$D)+A64,.5=",LN=WHPY)1<:6C\R'YG[<5\R_P#!1/XS
M?\*<_9@\1M:S^3K/B+&A6.TX8&93YS#N-L*RX/9BOK7T9H>LVGB/1=/U:PE\
MZQO[>.ZMY,8WQNH93CW!%?D'_P %:?C-_P )O\=-/\#V4^_3?"-IMF53\IO9
MPKR?7;&(5]CO'K7-0ASU$BGL>W?\$>/@W_9?A+Q;\3;V#;/JDPT?3G8<B"(A
MYF'J&D*+]837 ?\ !8+X.G0_'7A3XFV$)2#6(?[*OY$&,7,(W0L3_>:,LH]H
M*[_X%?\ !2OX$_!3X/\ A+P1::/XP9=&L(X)98].M@LLY^::0?Z1_'(SM_P*
MN7_:X_X*"?!3]H_X$>(/!EOI7BN#5Y?+NM,N;K3[<1PW4;;D+$7!(##<A(!(
M#GBNE*I[;GMH3I8^V?V./C6/CY^SQX3\433B;5U@^P:KSEA=PX21CZ;\+)CT
MD%>UU^2W_!(3XV_\(W\2-?\ AG?W&VR\10?;]/1CP+R%?G51ZO#DG_K@*_2+
M]H/XXZ%^SO\ "K6/&NO,'BM$\NTLPVU[RY8'RH4]V(R3SA0S=%-<M6FXU'%%
M)Z'SA_P4I_:Y/P4\!CP%X6O"OCGQ+ 5>6!OWFGV395I!CD22<HG<8=N"JYT_
M^"?/[)"_L\_":X\1>(;,1^/?$EJ);L2+\]A;8W1VP]&Z,_\ M8'.P&OE_P#8
M9^&TO[3'QUUKX^?%C4[*6WM+_P ZRM;R946ZO1@IM1CD0VZ[ HZ;@@R=K"OU
M#OO&GA\V5Q_Q/=,_U;?\OD?I]:TJ?NX^SC\Q+74_(7_@D=_R=3=_]BY>?^C8
M*_9JOQ=_X).ZE::5^U%=S7MU!9PGP[=KYD\@1<^;!QDGK7[,:?JEEJT32V-W
M!>1*VTO;RK(H/7!(/7D4\5_$".Q:HHHKC*"O'_VPO^35_BO_ -BW??\ HEJ]
M@KQ_]L+_ )-7^*__ &+=]_Z):KA\2 _/W_@C1_R5'XA_]@:#_P!'U^L5?D[_
M ,$:/^2H_$/_ + T'_H^OUBK?$_Q63'8*_#[P;_RD\/_ &4V[_\ 2^2OW!K\
M/O!O_*3P_P#93;O_ -+Y*K#?:] 9^X-%%%<91X#^WGX1M?&7[)'Q(MKF 3-9
M::VIPD]8Y+=A*&![<(1]"1WKXE_X(S>*;BW\>_$;PYYF;6[TRWU#RSV>*4QY
M'IQ/S]!Z5]Z?MD:S#H/[*OQ6N9Y%C23P[>6H+?WIHS"H_%I /QK\]?\ @C;I
M$LWQI\<ZH$8P6WA\6S/V#2W,3*/Q$+?D:[:?\"5R7N?9?_!3/_DRSQ[_ -=-
M._\ 2^WKP+_@C#_R)_Q0_P"O^Q_]%S5[[_P4S_Y,L\>_]=-._P#2^WKP+_@C
M#_R)_P 4/^O^Q_\ 1<U*/^[R]?\ (.I^D%%%%<904444 %%%% !1110 4444
M %9?B;_D 7W_ %S-:E9?B;_D 7W_ %S- '.?#G_6WW^ZG]:[>N(^'/\ K;[_
M '4_K7;T %%%% !6-XS\.)XQ\'Z[H$L[6T>JV$]BTR+N,8EC9"P'<C=G%;-%
M&P'X=_MS_L7Z9^R*G@IM.\37?B+_ (2 WHD^U6JP^3Y'D8QM8YSYQ_[YKZ!_
M9G_X)A:#XY\!?#SXE2^.]1M;J]AM=8-@EA&R*P8/L#%\XXQG%7?^"T_^J^#W
M^]K'_ME7V9^Q9_R:A\*_^P#;?^@UZ$JL_91E?5D6U/'/^"C?[9-_^SIX5T_P
MKX0G2'QQK\3RB[(#'3K4';YH4@@N[!E3/ V.>H%?)G[-/_!-[Q9^TQH2?$;X
MC>++S1-/UK%U:LZF[U'4$/\ RV=G;Y%;^$MN+#G &">/_;^EN/B3^WWJGAZ6
M0R0+=:5HMNN?N(\,)8?]_)I#^-?M/IVG6ND:?:V%E!':V5K$L$$$2[4CC4!5
M51V    ]JER]C3CR[L>[/RP^/?\ P26U7P%X:NO$OPN\4WGB&[TX&Y.CW\2Q
M7;(HW%H94(#2#&0NU<]CG /H/_!,_P#;>UKXC:I_PJGQ_J,FJ:PENTVB:Q=/
MNGN5C&9+>5CR[A075CR0KAB2!G]%Z_$7Q78CX-_\%-$BTB-+*WM_'5K*D, P
MJPW,T;M&H'0%)F7 Z XIPDZ\7&>Z!Z'WG_P5>_Y-)N_^PU9?S>OSW^ GPZ^)
M_P"V7X8\._"3PY=0:3X,\'+-?7MU=2.+99KB>1Q+(J@EY"I*(F. KG(#-7Z$
M?\%7O^32;O\ [#5E_-ZY;_@CSH$%E^SSXGU<(!=W_B26)W]8XK>#8/P:20_C
M13ER4.9;W%NS%_99_P""9>N_ /\ :&T7QIK?B72_$&AZ5:SRVXM4DAF-VR^6
M@:-@1L"N[9#'YE'%?H5117).<JCO(I*P5^('_!1S6;SQ_P#MM^(])$YECLSI
M^CV8;D1@P1LRC_MK-(?QK]OZ_#3]NF(^!OV\_%MZX*QQ:II^IJQ'# P02DCU
MYW#\#73A?C?H*1^W'AGP_:>$_#>DZ'IZ>78:9:165NG]V.- BC\E%:=,AF2X
MB26)UDC=0RNIR&!Y!!I]<1052L=%T[3+BZGL["VM)[IS+<2P0JC3/W9R!EC[
MFKM-5U8L P)4X8 ]#C//YB@!U?)G_!1#]D]?VBOA4=8T*T$GCOPW&]Q8>6OS
MWL'66U/J3C<G^T,<!V-?6=%5&3@U) ?E#_P2[_:[L?AW_;7PQ\<:HFFZ (I]
M5TJ\O'VI:/&I>YA)/0,JM(!_>5^I<5Y=?'Q3_P %,?VP62V-Q8>&(VVHY&1I
M6DQ/]XCIYKELX[R28^Z.+'_!4GX):'\)OC_!JV@*+6V\66K:I<62KA(;GS"L
MK)[.</CLQ;L0!^@7_!.7X':%\)?V;_#VLV*B?6_%UI#K&HWS+AFWKF*$>B1J
MV .[,YXW8'HRE&"]K'=D>1]%^#/!VD?#[PGI/AK0+*/3M&TNW2UM;:/HB*,#
M)[D]23R223R:=XQ_Y%'7/^O&?_T6U;%8_C'_ )%'7/\ KQG_ /1;5YO4L_&W
M_@E#_P G;6G_ &!;W^25^U5?SK? +X*>*OC]\08_"?@Z>UM]:>VEN0]Y<- F
MQ,;OF4$YY'&*^F/^'5W[0G_04T#_ ,',W_QNO2KTXRG=RL0F?KSXI\9:#X&T
MJ74_$6M6&A:=$I9[K4;E((U _P!IB!7X??MD?%A?VNOVJ6E\%VTVHVDAM_#V
MB#!#W8#L%<*0"H>21R ><$$X.0/5=*_X)#_&;5[Q&U?Q'X4L(3]^5KVXGD ]
ME$.#_P!]"OM/]DS_ ()X^#?V9M5C\37E_)XO\:K&4BU&XA$,%F&!#>1%EL,0
M2"[$G'3;D@YQ=.A>2=V/5GTEX \+)X&\!^&_#<<GFIH^FVVGK(!C<(HEC!_'
M;6_117!N4?(?QD_X*=_"3X3:MK^A0QZQXC\2Z/=36$UA9VOE1"XB<HZM-(0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHMS/;.J6ELKE940J0K*P.#P5(/2OV*KLKM.$/0E=0KYR_P""B/\ R9G\2O\
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M\,]#^,7P^USP;XDMS<Z/J]N8)@I =#D%)$)!PZ,%93@X*CK7Y*:A\!OVB_\
M@GY\2[SQ#X$L[SQ#H+_NSJ6F6;7EI>6X.X)=P+EHB/4XP2=C\YKJIQA4@X[2
M)>A^RU?C7_P5L\::5XJ_:7TW2]+EBNKG0M#AL;V2(Y99VEEE\H^ZK(AQV+D=
M171ZU_P4=_:8^).G/X?\,^!+?2]5N$,+7.A:'=SWBL>\2N[A3CU5B.H(KN?V
M+?\ @G1XHN?'MK\4?C7')'<0W/\ :-KH=[-YUU=W1;>)[MLG #?-L)+,WW\
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M\9]-I%>8?\%5_P!G#6?BQX(\+>+O".@WVO\ B/1+EK*XLM*M7N+B:TF&0P1
M681R*.@X$K'M72_\$P-0\=Z1\%M0\#>._"7B+PU/X>O"VFRZYI<]HL]K.6?8
MAE0;BD@DSCH)$KKE/FIQJ)ZH76Q\R_\ #FKQW_T4#P[_ . \_P#A3)O^"-WC
MJ&&20^/_  \0BEL"WG[?A7ZT5#>J7LYU4$L8V  ZGBLOK-3N%D?SX?LP_LZ:
MI^U!\2)?!VD:M9Z-=QV$M^;F]1V0JC(I7"\Y.\?E7[$_L.?LP:O^RG\,]:\,
MZSK-EK=Q?ZN^I)/8HZHJF&*/:0PSG,9/XBOB3_@EY\%?B'\/_P!I.ZU/Q1X#
M\3>&]-.@74(O-7T>XM83(9(2$WR(!N(!P,YX-?K/6F)J-OE3T!(****X2@KQ
M_P#;"_Y-7^*__8MWW_HEJ]@KRO\ :JT;4/$7[-GQ,TS2K&YU/4KOP_>0VUG9
MPM+--(T3!41%!+,3P !DU</B0'YX_P#!&C_DJ/Q#_P"P-!_Z/K]8J_,K_@DW
M\(_'7PX^(_CJY\6>"_$/A>VN=)AC@FUG2I[1)7$V2JF1%#''.!7Z:UMB&G4=
MB5L%?A]X-_Y2>'_LIMW_ .E\E?N#7X:_%?X._'#P[^U-XX\9^$/AUXU%U;^+
MM0U+2]5M/#ES/&?]+D>.5"8F1U(((/(((ZU>&^TO(&?N517XW?\ "]OV\/\
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MMQ%H&FSVL<\9XV3W4SD!#GD;E4]"".*^QOV#?V%H?V8=.N?$OB:>VU3Q_J<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQ]_P @-?\ KLO\
MC725S?C[_D!K_P!=E_D: &_#_P#Y LO_ %W;_P!!6NFKF?A__P @67_KNW_H
M*UTU !1110 5'<?\>\O^Z?Y5)4=Q_P >\O\ NG^5 'YX_P#!2C_DVN3_ +#%
MI_)Z_*&OU>_X*4?\FUR?]ABT_D]?E#7JX;X#.6X4445UB"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^_Y :_\ 79?Y&NDKF_'W_(#7_KLO\C0 WX?_ /(%E_Z[M_Z"M=-7,_#_ /Y
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M**TC_H2M'_\  &#_  H_X45I'_0E:/\ ^ ,'^%'UM=@Y3\ Z*_?S_A16D?\
M0E:/_P" ,'^%'_"BM(_Z$K1__ &#_"CZVNP<I^ =%?OY_P **TC_ *$K1_\
MP!@_PH_X45I'_0E:/_X P?X4?6UV#E/P#HK]_/\ A16D?]"5H_\ X P?X4?\
M**TC_H2M'_\  &#_  H^MKL'*?@'17[^?\**TC_H2M'_ / &#_"C_A16D?\
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M5I'_ $)6C_\ @#!_A1];78.4_ .BOW\_X45I'_0E:/\ ^ ,'^%'_  HK2/\
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MI'_0E:/_ . ,'^%'UM=@Y3\ Z*_?S_A16D?]"5H__@#!_A1_PHK2/^A*T?\
M\ 8/\*/K:[!RGX!T5^_G_"BM(_Z$K1__  !@_P */^%%:1_T)6C_ /@#!_A1
M];78.4_ .BOW\_X45I'_ $)6C_\ @#!_A1_PHK2/^A*T?_P!@_PH^MKL'*?@
M'17[^?\ "BM(_P"A*T?_ , 8/\*/^%%:1_T)6C_^ ,'^%'UM=@Y3\ Z*_?S_
M (45I'_0E:/_ . ,'^%'_"BM(_Z$K1__  !@_P */K:[!RGX!T5^_G_"BM(_
MZ$K1_P#P!@_PH_X45I'_ $)6C_\ @#!_A1];78.4_ .BOW\_X45I'_0E:/\
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M/_X P?X4?\**TC_H2M'_ / &#_"CZVNP<I^ =%?OY_PHK2/^A*T?_P  8/\
M"C_A16D?]"5H_P#X P?X4?6UV#E/P#HK]_/^%%:1_P!"5H__ ( P?X4?\**T
MC_H2M'_\ 8/\*/K:[!RGX!T5^_G_  HK2/\ H2M'_P# &#_"C_A16D?]"5H_
M_@#!_A1];78.4_ .BOW\_P"%%:1_T)6C_P#@#!_A1_PHK2/^A*T?_P  8/\
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M2J*\U_L'Q!_SSN/^_P /\:/[!\0?\\[C_O\ #_&@#TJBO-?[!\0?\\[C_O\
M#_&C^P?$'_/.X_[_  _QH ]*HKS7^P?$'_/.X_[_  _QH_L'Q!_SSN/^_P /
M\: /2J*\U_L'Q!_SSN/^_P /\:/[!\0?\\[C_O\ #_&@#TJBO-?[!\0?\\[C
M_O\ #_&C^P?$'_/.X_[_  _QH ]*HKS7^P?$'_/.X_[_  _QH_L'Q!_SSN/^
M_P /\: /2J*\U_L'Q!_SSN/^_P /\:/[!\0?\\[C_O\ #_&@#TJBO-?[!\0?
M\\[C_O\ #_&C^P?$'_/.X_[_  _QH ]*HKS7^P?$'_/.X_[_  _QH_L'Q!_S
MSN/^_P /\: /2J*\U_L'Q!_SSN/^_P /\:/[!\0?\\[C_O\ #_&@#TJBO-?[
M!\0?\\[C_O\ #_&C^P?$'_/.X_[_  _QH ]*HKS7^P?$'_/.X_[_  _QH_L'
MQ!_SSN/^_P /\: /2J*\U_L'Q!_SSN/^_P /\:/[!\0?\\[C_O\ #_&@#TJB
MO-?[!\0?\\[C_O\ #_&C^P?$'_/.X_[_  _QH ]*HKS7^P?$'_/.X_[_  _Q
MH_L'Q!_SSN/^_P /\: /2J*\U_L'Q!_SSN/^_P /\:/[!\0?\\[C_O\ #_&@
M#TJN;\>_\@-?^NR_R-<S_8/B#_GG<?\ ?X?XU'-X=UR1<2032+GH9 W]: .G
M^'W_ "!9?^N[?^@K73UYC#X=UR-2([>:-<YP) O]:D_L'Q!_SSN/^_P_QH ]
M*HKS7^P?$'_/.X_[_#_&C^P?$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/
M[!\0?\\[C_O\/\: /2J*\U_L'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS
M7^P?$'_/.X_[_#_&C^P?$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0
M?\\[C_O\/\: /2J*\U_L'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?
M$'_/.X_[_#_&C^P?$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[
MC_O\/\: /2J*\U_L'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/
M.X_[_#_&C^P?$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\
M/\: /2J*\U_L'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/.X_[
M_#_&C^P?$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\/\:
M/2J*\U_L'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/.X_[_#_&
MC^P?$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\/\: /2J*
M\U_L'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/.X_[_#_&C^P?
M$'_/.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\/\: /2J*\U_L
M'Q!_SSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/.X_[_#_&C^P?$'_/
M.X_[_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\/\: /2J*\U_L'Q!_
MSSN/^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/.X_[_#_&C^P?$'_/.X_[
M_#_&@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\/\: /2J*\U_L'Q!_SSN/
M^_P_QH_L'Q!_SSN/^_P_QH ]*HKS7^P?$'_/.X_[_#_&C^P?$'_/.X_[_#_&
M@#TJBO-?[!\0?\\[C_O\/\:/[!\0?\\[C_O\/\: /2J*\U_L'Q!_SSN/^_P_
MQH_L'Q!_SSN/^_P_QH ]*KF_'W_(#7_KLO\ (US/]@^(/^>=Q_W^'^-1S>'=
M<D7$D$TBYZ&0-_6@#J/A_P#\@67_ *[M_P"@K735@>"["XT[2I8[F)HG,Q8*
MWIM7_ UOT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sdgr-20241231_g14.jpg
<TEXT>
begin 644 sdgr-20241231_g14.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,*"W(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P/B#JEUH?@+Q+J
M5E+Y-[9Z9<W$$FT-LD2)F4X((."!P1BM^H;RS@U&TGM;J%+BVG1HI895#)(C
M##*0>"""1BK@U&2;V%)-II'Y:_\ #;'QG_Z'+_REV7_QFC_AMCXS_P#0Y?\
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MQ &3#Z5^E_AN[EU#P[I5U._F3SVL4LCX W,4!)P..IK\9?%7_(T:Q_U^3?\
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MN2YEL]5:XA<QS13F1''56#9!_.OV4^'G_(@>&?\ L&6O_HI:_&:]_P"/R?\
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M!\6^%[B0O:6$L-[:@\[/-WK(OTS&AQZEO6M3_@I#_P DT\+?]A<_^B7KA/\
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MZRW@?_=^R3'^8%<].K+,\GJ2Q&LHWU\TKI_H:S@L'CX*EHG;\=#Z3_X*0?\
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MXA^%[:\P+.;5+6.;<,C89E#?IFIX?H04JV)DKN.B_&Y6:5)6IT5LSZ<^$O\
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M K]MK#_CQM_^N:_RI\4Q5Z,^KO\ I_F+)F[5(^GZD]%%%?"'T@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAX[,P"&T5A_>7+&3'H2 >ZFOJA$6-%1%"HHP%48 'I7#F69X?ZLL#@O@ZO\
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MJS^T)^Q3IGQE\42^)]*UH^']:N$47226_G07!50JM@,I1L  D9!P.,Y)\_\
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ME]7E>U[Z-;V[I''EF&JX=S]JK7MV\R2BBBOD3W HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M::_XLM%7[?>Z@S&SLF90PC"(0TDF""?F4+P/F.0OSI\/_P#@K;\5]&U2VO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5N^)>LZM=7?@#PKIVB>%()O+CN=4M9+J>3T\QPXC0D<[ "1G[QZU]"?L.?\
M!1>;]HGQ:/ GC;2;+1_%DT+S:?>:;N6VOMBEGC*,S%) @9_O$$*WW< %.A.,
M>9H+H^Y:*YWXA_$'0/A7X,U7Q7XGU"/2]#TR$S7-S("<#( 50.69B0H4<DD
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M98G^($=@I ,4M%<I1^%__!3'_D]7X@?[FG?^F^VK]GO@Q_R1[P+_ -@&P_\
M2=*_&'_@IC_R>K\0/]S3O_3?;5^SWP8_Y(]X%_[ -A_Z3I7;7_AP)6YV5%%%
M<104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!I<9P379/EKQ:CNB5H?KS^WUXYO/A[^R/\1-3T^5H+V>SCTZ.1#AE%S-'
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M*=_\GG>-?^O?3_\ TBAKZC_X(O\ _(L_%3_K\T__ - GKY<_X*=_\GG>-?\
MKWT__P!(H:N/^\2]/\@>Q^D/['/[+?PZT']F+P8NI^#=$UG4?$.CP:EJEWJ6
MGQ3RW!N$$NQF=2=J!PH4<#;GJ23Z!^T+\#?@]X^\ 6*_%"RL[3POX;B/V6XG
MU&2P@L5*JG!21%Z*J@-GT YYZOX!*$^!/PX4< >&]- _\!8Z_/#_ (++>+]<
M7Q+\/O"XFEB\.&SGU$Q*Q"3W/F>7EAW*(!CT\UO6N2"E4J6N5LCT+P9^VW^R
MW^R/X2F\*_#>'6O$D/VB2>6;3K(EIY6/62><Q%@!A00&^51C/4_GO^U=\<=+
M_:*^,VI^-]*\,CPM#>PQ1R6IF65YG0;?.<A5&Y@%!'/W>IK[V_X)R_ SX ^(
MO@19^+M>L- \1^,8YISK']ONDRZ?ME81+Y$AV(IC".'*DDL>>,+\=_\ !0/X
MA^#_ (B_M':C-X%>RF\-Z78V^EP3Z;&J6LK1ABYBV@ H&<J&'!VY&003V4U%
M5&DG?N2]C]@OV8;6WU[]E[X2_P!HVL-X!X6TPA;B,.,BUC //?'\Z_%;X:6\
M4G[:/A6!HD:!OB!:(8BH*E?[148QTQCM7[7?LER)+^R]\)F0Y \+::O'J+9
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M>N68@ ]% 4< 5^&_QC\'6VF_M&^./"NEQ)9V=OXKOM+M8D7Y8HUO'C10!V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$L_X2S^V;J*Y\W^S?L?D[$*[<>;)NSG.<BOHRBCGER\E] /F+]M3]BK_ (;
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MJ\0?$#_A97_"/_VL+8?V=_8/VGRO*MXX?]9]I3=GR]WW1C..<9K[/\%^'?\
MA$/!VA:%]H^U_P!EV$%C]HV;/-\N-4W;<G&=N<9.,]36S15RG*22?05@HHHJ
M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >0?M2? _7/VA_A?<>"=)\:_\(39WTJG4;E---Y)<P+SY(_?1[%+;
M2QYR!CH3GYY_9I_X);Z'\!_BMIWC;6O&?_":R:6K26%BVCBT2*YXV3,?/DW%
M!N*C PVUL_+7W+16BJ2C'E3T%8*^*OVJ?^"9FA_M&?$Z3QMI7B[_ (0F^O(%
M348$TD7B74R\";_71[&*@ ]<[0>#G/VK12C.4'>(]SP_]DK]GG7?V9OA[/X-
MU'QU_P )MI$5P9M-WZ6;-[%6R9(P?.DW(6.X#C!+]<C'@W[1?_!*CP;\6/$M
M[XE\&:X_@35+V1IKFQ^R"XL99"<ED0,K1$DDG!*^BBONFBFJDE+F3U%8_+WP
ME_P1DO?[4B?Q/\2H!IJOF2'2=-8S2)Z!Y'PA]RK?0U^AGP=^#?A7X$>!+'PE
MX/TX:?I5MEF9CNFN)3C=+*^/G=L#)]     !VU%.=6<_B86L?$G[5'_!-;_A
MIGXOWOCK_A8O_"-_:;:"V^P?V']JV^6FW=YGVA,YZXV\>]?6GPO\%_\ "M_A
MIX2\)?;/[1_L#2+32OMGE>5Y_D0I%YFS+;=VS.W)QG&3UKIZ*ESE)*+>B ^*
M/VK?^";?_#3OQ<N/''_"Q/\ A&O-LX+3[!_8GVO'E@C=YGVA.N>FWBOJSX4>
M!?\ A6'PP\)>#_MO]I?V!I5KIGVWRO*\_P F)8]^S<VW.W.-QQGJ:ZNBASE)
M*+V0'R/^T]_P3=^'_P"T-K=UXET^[G\$^+KDEKF^L85EM[MS_'- 2N7]65E)
MR2VXU\T:=_P1BUYM45;[XG:=%IP;F6WTJ1YB/]PR  _\"-?J?16D:U2*LF%D
M>,?LU?LG>!?V7/#T]CX6M9;K5+P+]OUN_(>ZNL=%R  B ]$4 =SD\U-^TQ\7
MOA7\-/!T6E?%V98O#'B7S;!HYK&>ZAEPH+*WE*S*<'(/!!&0017L->._M5?L
MVZ/^U'\*;GPEJ5RVFWL4PO-,U)%WFUN55E#%<C<I5F5EST;(P0"(3YI7FP/@
MSPK_ ,$[?@A^T5K&J7OP>^-=P^E6;(]SILVF&ZFM5D+;%W.T+!3M8 LI/R\D
MGFJ_[<G[+7PW_9,_9:T?1O#\CWWBO6_$5N\^IZBZF\N8HH)RX10 $B5G3(4=
M73<6.#7GP_X)W_M1_!WQ%-=^!P\EP 8QJOA7Q$EDSIUQF22%\=.,59LO^"<W
M[3?QF\1P7/Q NFLB,(VJ^)]?7494CZD*(Y)6/LI(&>XZUWW5TW/0GY'O_P#P
M1ETF:'X=_$C4V0B"YU6UMD?L6CA9F'X"9?SKLOVG?^"97_#1_P 9]:\??\+(
M_P"$>_M*.W3^S_["^U>7Y4*19\S[2F<[,_=&,XYZU],?LZ? ;0_V;_A3I?@G
M0I'NH[<M/=WTJA9+RY?'F2L!G&<  9.%51DXR?3*Y)57[1S@5;0P? 7A?_A"
M/ OASPY]I^V_V1IMMI_VGR_+\WRHECW[<G;G;G&3C/4UYM^U%^ROX3_:I\%0
M:)XB>;3]0L9&FTW5[-5,UI(PPPP>&C;"[DXSM'((!'L]%8J33NAGY:6G_!&'
M6?[95+KXH6(TD'YIH=(?SR/0(9=H/ON->F_$;_@D%X(\0:/X:LO!_BVZ\)S:
M=#+'J%[>V']H2ZF[,I61L2Q+&5PPPHP01P""3]_45LZ]1]161YK^SI\)+_X%
M?![0/ M_XC_X2IM&22&'4C9_92T)D9D0IYDGW VT'=T4<5\D>&/^"47_  CG
MQLTGXA?\+2^T?8/$,.O?V=_PCVWS-ER)_*\S[4<9QMW;3ZX[5^@-%9JI*+;3
MW"P5^=7QW_X)'6OCKQ]J_B3P1XTBT"VU2Y>[ETC4;(R1P2.Q9_*D1@=F2<(5
MXZ;CV_16BB$Y0=XA:Y\Z?L5?LFW/[)?@G6]%NO%"^)9M6O%O7,5F;>.!@FPA
M<NQ;( Y..G2OHNBBIE)R=V,X7XW?!W0OCW\,=:\#^(_.33-3109[8@302(X=
M)$)! *LH/(P1D'@FOSLE_P"",&MC6-D?Q1L#I6[_ %[:.XG S_SS\W;G'^W7
MZFT5<*LX*T6*USSK7?@=H'C7X'P?#'Q4&US1QI=OIL\Y'E22-$BA9UZ['#('
M'7!]17Y_>(/^",>I?VX_]A_$RU_L9GRG]H:8WVB-?0['VN1Z_+GT%?J-11&K
M.'PL+'P?-_P28\%6_P '+GPIIGB>:#Q5>W<%S=^*[W3A<.8X]W[B* 2H(D8L
M"?G))49)P /:?V-/V2/^&1_"OB'1?^$K_P"$K_M:]2\\_P#L[['Y6V/9MV^;
M)N]<Y'TKZ'HH=6<E9L+'PG^TG_P2_P#^&A?C7XD^(/\ PLO^P/[8-N?[._L'
M[3Y/E6\4/^L^TINSY6[[HQG'.,G[7\)Z%_PB_A;1M&\_[3_9UE#:>?LV>9Y:
M!-VW)QG&<9./6M6BIE.4DD^@6/S^\7_\$HO^$K^-FM_$+_A:7V7^TO$,^O?V
M=_PCV_R_,N6G\KS/M0SC=MW;1G&<=J_0!AN4CU%+11*<IVYGL!^?_P $/^"4
M?_"FOBUX6\;_ /"T?[8_L.]2\^P_\(]Y'G[<_+YGVIMO7KM/TK[M\2^&M*\8
MZ!?Z)K=A!JFD7\+6]U9W*!XY8V&"I!K3HIRG*;O)A8_.3XK?\$=-!UC5Y[[X
M?^-9_#UK*[.-*U:V-W'%GHJ3*RL%'0!@Q]6-4?AC_P $;M/L-8@N_'OCQ]5L
M(V#-IFB6A@,OLT[L2!V("9QT(K]*:*T]O4M:X61C^$/"&B^ ?#.G>'O#NFV^
MD:+I\0AM;*U7:D:CT]22223R2222237QG^T[_P $RO\ AH_XSZUX^_X61_PC
MW]I1VZ?V?_87VKR_*A2+/F?:4SG9G[HQG'/6ON2BLHSE!WBPL8/@+PO_ ,(1
MX%\.>'/M/VW^R--MM/\ M/E^7YOE1+'OVY.W.W.,G&>IK>HHJ!A7PG^TG_P2
M_P#^&A?C7XD^(/\ PLO^P/[8-N?[._L'[3Y/E6\4/^L^TINSY6[[HQG'.,G[
MLHJX3E!WB+<RO">A?\(OX6T;1O/^T_V=90VGG[-GF>6@3=MR<9QG&3CUKX3\
M7_\ !*+_ (2OXV:W\0O^%I?9?[2\0SZ]_9W_  CV_P OS+EI_*\S[4,XW;=V
MT9QG':OT!HIQG*&L6%A&&Y2/45\ ?!#_ ()1_P#"FOBUX6\;_P#"T?[8_L.]
M2\^P_P#"/>1Y^W/R^9]J;;UZ[3]*_0"BE&<H)J+W S/$OAK2O&.@7^B:W80:
MII%_"UO=6=R@>.6-A@J0:_/?XK?\$=-!UC5Y[[X?^-9_#UK*[.-*U:V-W'%G
MHJ3*RL%'0!@Q]6-?HW13A4E#X6%KGYK?#'_@C=I]AK$%WX]\>/JMA&P9M,T2
MT,!E]FG=B0.Q 3..A%?HCX0\(:+X!\,Z=X>\.Z;;Z1HNGQ"&ULK5=J1J/3U)
M)))/))))))-;%%$ZDI_$PM8\2_:C_9+\'?M5>%K;3_$/G:=J]AO;3=;LP#-;
M%L;E(/#QG RAQTX*GFOB72?^",6J?V\%U/XG6G]BJ^3)::4WVEU]-K2;5)]<
MMCT-?J/151JS@K)A9,^!OBU_P21\*>,V\-P>#_%Q\%:;I&FBRDBETD7\]]-Y
MLDC7,LOGQ9=MX7&W " #   ^Q_@W\//^%2_"KPIX,_M#^U?["TZ&P^W>3Y/G
M^6H7?LW-MSCIN/UKLJ*F524E:3"Q\+?M%_\ !*CP;\6/$M[XE\&:X_@35+V1
MIKFQ^R"XL99"<ED0,K1$DDG!*^BBO)O"7_!&2]_M2)_$_P 2H!IJOF2'2=-8
MS2)Z!Y'PA]RK?0U^H5%6J]1*UPLCB?@[\&_"OP(\"6/A+P?IPT_2K;+,S'=-
M<2G&Z65\?.[8&3Z     #Y<_:K_X)L_\--_%Z[\<_P#"Q?\ A&_/M(+7[!_8
M?VK;Y:[=WF?:$SGTV\>]?;-%1&<HOF3U"QR_PL\$?\*T^&7A'PA]M_M+^P-(
MM-*^V>5Y7G^1"L?F;-S;=VW.W)QG&3UKJ***AZZC/DO]LK]A*Z_:Y\7:!JS_
M !!_X1:RT>Q:UBL/[&^V;I'D+/+O^T1XR!&N-O\ !G/.!\]_\.5_^JQ_^6O_
M /=E?IQ16L:TXJR8K(_,?_ARO_U6/_RU_P#[LK[I_9H^"?\ PSM\%/#OP^_M
MG_A(/[(-R?[1^R_9O-\VYEF_U>]]N/-V_>.<9XS@>GT4IU9S5I,+6"BBBLAA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !17)_$?XK^#OA!H7]L^-?$NF^&=-+;%GU&X6,2-_=0'EVX/"@GBN0
M^&7[6GP>^,>M_P!C^#OB#HVM:L066Q24Q3R ==B2!2^/]D&@#UNBLOQ+XHT?
MP9H=YK6O:I::-I%FADN+Z^F6&&)1W9F( KR+PK^W!\"/&OB.WT+1_B?H5UJM
MQ((88'E:(2N3@*KNJJQ)X !Y[4 >XT4A8!=Q(VXSG/&*\0UC]M[X#Z#XHE\/
M7_Q3\/0:K%*8)(_M):.-P<%6E ,:D'@Y;CO0![A14-I=P7]K%<VTT=Q;S()(
MYHF#(ZD9!!'!!'>O+?BA^U;\(O@OK2:/XT\?Z/H6K,H?[#+*9)T4]"R(&*@]
MBP&: /6**P/ _C[PW\3/#EMK_A37+'Q#HUQGRKW3YUEC8C@C(Z$'@@\CO6_0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 44C,%4DD #DD]J\<^(/[8?P<^%]R]MXA\?:1:7:'!MTF\QP?^ YH ]DHKQ3
MP#^V?\%_B7=K::#\0-)N+MC@6\LOEN3_ ,"P*]ICD65%=&#HPR&4Y!'K0 ZB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10!_5"I# $'(/(-+7YM> O\ @LM\-]*\(Z'8:[X<\43ZI;VL<-U/!! R,Z@
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M7FT368KVWC2[@568*V[(PP(YP.U>Q_ ?6[[Q+\%O ^K:G<M>:C>Z/:SW%PX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R7Q+^+'A#X
M.^&Y->\:>(+'P[I:9 FO90ID;&=J+U=O9037P)\7/^"U/@_0KZZL?A[X-OO$
MXB;:FIZI,+.WD_VEC 9R/][:?:@#]***_'F/_@MOX_$X9_AYX=:'/*+<S@X^
MN?Z5[G\(?^"S_P ._%-];6'COPQJ?@R23AM1MG%[:*WJP 611]%;WH _1.BN
M=\!?$3PS\4?#D&O^$M<LO$&CS\)=V,PD3. 2IQT89&0<$9KHJ "BBB@#\IOV
MS?V /V@OVF?V@/$?C&'^PO[#+K::/;S:H5,5I&-J?+M^4L<NP]7-8-C^Q)^W
M)IEE!9V?Q1OK2T@18H8(/&-RD<: 8"JHX  X %?KO10!\8?M@_L(7_[4OP:\
M#QG5H;'XG^&-.B@&H7DC/%>,8T$\<L@!8Y="RO@\D_WC7S!XC_8Y_;3^-GAC
M1?AMXZ\3Z?%X(TUXP)I[Z)E98QM1I/*7S)MHZ!^^">>:_6ZB@#Y\3]B_P?\
M\,D#X"R32RZ+]B\K^T2@$PNO,\T7('0-YOS8STXSBO@!?V!/VNO"/@O5_A!H
M/B/2Y_AIJET99S'?I'#("022&3S5!VJ60<$COW_8*B@#PK]D?]EC2/V8/@?!
MX&$R:Q>7;/<ZQ>%,+=3R*%< ==@4!0#V&3R37PYK7_!/G]H3]FKXH>(M6_9T
M\1VR^'=;C>W$<MS''<00,<B*02J58H?NR*=W?@DU^K%% 'Q5_P $]/V#K_\
M9?.M^,/&U_!JGC_6X_(86LADBLX"P=UWG&]W8 LV,#: .I)^U:** /-OVEO^
M3=OB=_V+6H_^DTE?''_!$_\ Y-]\:_\ 8RM_Z30U]C_M+?\ )NWQ._[%K4?_
M $FDKXX_X(G_ /)OOC7_ +&5O_2:&@#]$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 44R25(5+.ZHHZEC@5YQXW_:5
M^%'PWCE;Q+\1O#.DO']ZWFU2$S_A$&+G\!0!Z57YX_\ !0[_ (*27WP&\0/\
M.?ALMO)XOB17U/5KF,21V 9<K'&AX:0@AB3PHP,$GCU#Q3_P57_9Y\.*PM?$
MFH>(I1TBTG3)7+?0N$'ZU^)WQU\<GXF_&?QQXLVW,::UK-W?11WB[9HXI)6:
M-6&3@A2HQDXQ0!Z"O[>?[0::Q_:0^+/B0W&[?Y9N<P9_ZXX\O'MMQ7Z6?\$[
M_P#@HY=_M"ZP?A[\1$M[?QKY33:?J5L@BBU%%&71DZ+*!D\<, > 1S^+->C?
MLY6/BG5/COX#L/!.K'0?%5YJ]O:Z?J@3>+221PGFE<'*J&)(P<@&@#^F*J]W
MJ-I8+NN;J&V7UED"C]:^%4_X)X?%[Q-F;QC^U?XVNY).9+?2EEMXA[#_ $C&
M/^ "I[#_ ()(^ KJ;S?%/Q#\=^*F/+?:=25 W_CI/ZT ?6OB/XW_  Z\'Q-)
MKOCWPSHZ#DF^U>WA_P#0G%>5^(?^"AW[.OAK>+KXJ:/<,O;3TFO,_0Q(P_6N
M,T;_ ()2?LXZ7(DEQX2U#5W4YS?ZU=<_41N@->M^&_V._@=X3@CBTWX4>$T"
M?=>XTJ*XD_%Y S'\30!X9J?_  5Q^!%O.\.F-XEUYAT-CI#8;Z;RI_2L.?\
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M_L^?LV_";]I3P5X$GO\ QCKWCB::*XM8X+XW*6KDY02YY7(&<>A![UJ  _\
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MV2W=O,N+B0[IKA_[SMU- 'I=%%% !1110 4444 %%%% !1110 4444 %%%%
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M,KN&>IS7U#110 4444 %%%% !1110 4444 %%%% !1110!YM^TM_R;M\3O\
ML6M1_P#2:2OCC_@B?_R;[XU_[&5O_2:&OL?]I;_DW;XG?]BUJ/\ Z325\<?\
M$3_^3??&O_8RM_Z30T ?HA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHR2<<"OTXHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=(</")H@964CHWEI( >Q(/:OBCX3_P#!/_PEXX_X)[>(?BY?/?\ _"="PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Y\19_$]KX$U
MV;P7:V-[XL2TD;3+?4W*6TD^/D60CD#/T^HZU\1:_P#%?]NSPKI%SJNL^#?A
MEI6FVR[YKN\U&***-?5F:Z %?H!7X#_\%#/VM?$'[1'QEUK18[]X? OA^]DL
M],TV)\1R-&2C7#XX9V.[![*0!W) /H#2?^"G7[0>L^-KGPO _P *4OH%!^U3
MW@CLY"<?*D[7(1CST!['TKZ%TWXA?M[:C';7,'@3X;W%G,%=)X[Y&C=#_$&6
MZ.1CN,U^)5?H1_P2B_:ZU_P3\5=,^$NN:A)?>#_$!>'3H;ARQT^\Y9?+)Z(_
MS KTW$$8YR ?LU9&X:S@-TL:71C7S5B)*!\?,%)Y(SG%3444 %%%% !1110
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M30!YK^PEXJUW6?V3OVJ? HFDNM'L_#$NIVJ#E896BG$FW_?6-3C_ &*^A?\
M@B)?PO\ ##XDV88>?'J]O*R]]K0D _FIKZ6_8L_8PT?]E3X3ZCX>O+B#Q!KV
MOGS-<O/) AF&UE6!5/)C568?-U+,<#.!\@7W_!/#]HK]GKQWXIE_9^\:VEMX
M6\0!HF26\%O<10DDJKAT(+)N8"1#NQSQDB@#G/\ @GM"/%'_  4B^,6J6,@>
MR$.N2B5>597OXU4Y]\Y_"J'_  1RMI/#G[3/Q'T._!AU&#298'A?A@\5TJN,
M>QK[)_X)]?L.2_LD^']:U/Q%J5OJ_C;7MJ74EIDPVT"G*Q(S %B6.YFP.P X
MR?&OC[_P3Z^+/A3]HK4?C#^SSXFL])U/599;FYL;J40/#-+GSPI9622-R=VU
M@,$^P- 'B_Q=L)O%?_!9/0K73U,LMOK^ERR!.<+!!'+(3]%1B?I7U[^VS^S9
M\??C1X_T35/A/\2I/!6BVNF_9KJT36KNR$L_F.V_;"I!^4J,GGBN8_8@_8(\
M9?"OXNZQ\8OC!K]OKOCR]67[/%;2F?RY)<B6:20@ L5.T*HP 3ST ^]* /RI
M_P"&"OVT?^B^3_\ A5ZE_P#$5QWQB_8M_:S\(?"SQ5K?BGXU3:QX=L-.FN-0
ML#XEU"87$*J2Z;'7:V1Q@\5^P]>._MB_\FK_ !5_[%V\_P#19H ^7O\ @BN#
M_P ,S>*?3_A*I_\ TEMJ_0.OS]_X(K_\FR>*/^QJG_\ 26VK] J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7'_!5K3M58)X4^"OQ!\0N_W";$1AO^^=]/\ ^&V/VD_$\1_X1?\ 92UB O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)^SG^V/JO[./C[Q1+XCT6>::VLIKN9I!%.L1FADB9\LJRIP4R0&([Y)_5>@
MKQW]L7_DU?XJ_P#8NWG_ *+->Q5X[^V+_P FK_%7_L7;S_T6: /E_P#X(K_\
MFR>*/^QJG_\ 26VK] J_/W_@BO\ \FR>*/\ L:I__26VK] J "BBB@ HHHH
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M +)5&;]L3X719QK<\O\ N6<O^%=U;?!SP):8\GP;H4>/33XO_B:U(/ ?AJU
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MKE&#CU4YKX\_:(_: \:^!/VU_@SX!T?5%MO#'B';_:-H8E8RYFVGYB,CCTH
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M)'NK]YU,3.CD;6XSF->: /?Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M/-OVEO\ DW;XG?\ 8M:C_P"DTE?''_!$_P#Y-]\:_P#8RM_Z30U]C_M+?\F[
M?$[_ +%K4?\ TFDKXX_X(G_\F^^-?^QE;_TFAH _1"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<_M)^#]7\>?![6M%T.T-]J=P\!C@#JF[;,C-RQ X )ZU\2_\,D_%;_H5F_\
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MXP^#)KKQ_K/COX4>)+Q;.[@UR<S2VQ)Y*D]& RPVXSMP<YKI_P!L37;#3O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW'J^G6HM4TP0J87 61<ELY_Y:'MVKZ!HHH ^9OVG/V%/"_[27C/0?%[:Y?\
MA+Q1I&/+U+3(U9Y I!0G)'*D#!S5WXK_ +&>F_&#XE?#CQMK/B>]75?!J1*@
MCMUVWC(^_<WS?+D^F:^C** "BBB@ K&\8^#]'\?^&=1\/Z_81:GI&H0M!<6L
MRY5U(_0]P>QK9HH ^$3_ ,$M?[!^WZ=X,^-/BOPIX7O&8OHT40E4*>JAQ(N/
MP6OI#]F[]F#P;^S#X,;0/"T,L\EP_FWNI7A#7%TY[L0.GH*]>HH ^/OBS_P3
M@\.^,/B3=^// OC/6/A=XCOB6O'TA!)#,Y.6;9N7!)Y/)&>U3_!?_@G-X7^'
MGQ%C\>^,?%6J_$[Q7 !]FNM90)%"1T81[FY';G R>*^NJ* /+/VB?V</"'[3
M/@.3PQXLMY B.)K2^MB%GM)1T="1Z9!'<'Z&OE\?\$KEUM-/TOQ;\:/%/B?P
MC92*\>A2PB-2JGA2YD;/_?-?>=% &%H'@?0O#/A"U\+Z;ID%MH%M;"TCL0N8
MQ$!C:0>O%?'VN?\ !,'2]+\5:IJWPT^)WB+X9V>I.9+C2[",3P GJ$&],#TS
MDCUK[>HH ^?OV7_V+_!W[,1U/4=/NKSQ'XJU1BU[K^IG,\@_N@9.U<\]223U
MZ5X;\2/AO:ZG_P %-/ .M>']0U#4=4M["6ZU^S$+"VT^W$;) Q?H6=G?C_8K
M[SJM'IMI%?2WJ6T*7DJA))U0!W49P"W4@9/YT 6:^2_VJ_\ @GQHW[5?CZR\
M3ZSXTU71VLK=;>WL[6!72/')8$L#DGFOK2B@#X _X=*V8_YK5XT_[^-_\=KZ
M*_9@_97MOV:] US2AXMU;QC%JLPE=]8)8QC:%*C+-P<?K7NM% 'Q1XO_ ."9
M>EGQUK/B7X<?$K7OABVL.9+VPTV(30,QZ[1O3:,Y/?&3BO5OV7/V,O"/[+_]
MJZA87MYXD\5:KQ?:]J7^ND7.=JC)V@G!/)S@<U] T4 %>&?$_P#93TCXG_'O
MP)\4KO6;JSU'PF08+&*(-'/APWS-G(Z>E>YT4 ><?M!_!6Q_:#^%6K^!]2U"
M;3+340H>YMT#NF#V!(K4^#OPSM?@Y\,?#W@NRNY+^TT:U%K'<S*%>0 GD@=.
MM=G10!\\_![]D?1O@-X[^)WC;3];N]2N_&&9[BVGB5$@(,C84@G/^L/Y5\!?
ML4_LC67[0EQ\3M?LO%VL>!O%6C>(Y(K75M).[,;M+N1TW+N&5'>OU_N(5N8)
M(7SLD4H<>A&*\M^ W[-?A#]G2+Q''X3%Z%UZ\^W7GVV?S?WF6/R\# ^<\4 >
M4? ?_@GUX;^$_P 1/^$^\3^*-4^)/C*,?Z-J.L)L6V/]Y$W-\WIS@>E=W\3_
M -E32/B=\?/ GQ3NM9NK/4?">/(L8H@T<^'W_,V<C\J]RHH \A_:;_9H\-?M
M1?#UO"_B%Y+-HY1/:ZC;H&FMG'=<]CW&:Z;X+?#>X^$7PUT7PA/KUQXD32HO
ML\-_=QA)6B!)56P3G:#@'T KN** &30QW$+Q2HLL3J5='&58'J".XKXP^*O_
M  2\\#^+O&4_BGP1XGUGX8ZQ<$M-_8QW0LQ.20@9",_[V/:OM*B@#\_8_P#@
MD)X;\1ZHU]X_^*/B?QI.(RD;NBP,G''+/)Q[<5Z?^R;^S1\4_P!G#Q-JWA:^
M\;V?B/X2QVY&DV\L!6\B8Y^7 X4#ZMGVKZSHH ^ M2_X)'>'[GQ1KFMV'Q1\
M2Z--JUY+>31V,8C&7=GQE9!D L>M/LO^"0G@N[O87\3?$7Q;XDM(V#&UFF"A
MO8EB_'X5]]44 <K\-/AAX9^$/A*T\-^$])@T?2+8?+#".6/=F/5F/J:ZJBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KEM>^%7@KQ3J3ZAK7@_0-7OW 5[J_TR">5@!@ N
MRDG ]ZXSQY^U;\,/A;\3[?P#XP\3V_AK7KJPBU&V.HJ8[>:.222, 2_=#!HF
MR&(ZC&><>HZ9JMEK=E'>:=>6]_:2C*7%K*LD;CU#*2#0!R'_  HCX:?]$\\*
M?^"2V_\ B*UO#GPT\(>#KU[S0/"NB:'>/&8FN--TZ&WD9"02I9%!(R <>PKI
M*I:OK6GZ!8R7NJ7UMIUG&,O<7<RQ1J/=F( H NT5Y5\-_P!J'X:_&#Q_JO@_
MP5XE@\2ZKI5I]LO9+!6>WB7S @7S<;68D]%)X')'%>JT %%%% 'YP?MA_L<_
M%S]JG]KO1&U:.6V^#%J;>VCNK6\B+P1>6'N)/)+9#M(60,0> I[8KYB_;^_9
ME\,?L->./ASKGPNU_5+'5;HRW(@NKD230O"Z%)58 ?*2V"#QQ]:_4S]K+]K#
MPI^R=\.Y->UQUO=9N08]*T2.3;->R_KM1<Y9CP!QR2 ?SR_9=_9T^(/[?GQM
M7XX_&!IH?!EM<K-9VCJ5CO0CDI;6Z'[MNI^\W\7(R220 =O_ ,%9OV@-=B^"
M_P *O!,$\FG7OBVR75];AB.PE%CBV1'OM,CN2/\ IF*\B_:T_P""?V@_LZ?L
MN>#?BAX6UC5?^$F@DLO[6>:8!29X\B2+: 8RDFT#D\'KD5T?_!:S39;3XR?#
M&^*%;*31I(8SCY=T=QE@/H)$_,5],_\ !3+4K?\ X=\JV]0+M](6'_:.4? _
MX"I/X4 <K\4/VOO$B_\ !+/1O'T-^P\7Z_!%X>?45.V19M[Q32@CHY2&0Y[,
MV:^9/A=_P3[\/^/OV!O$/QEOK_4AXU6RO]8L524>08;8OE'4C+%A%)SGJ14O
MQ&T*\M_^"/7PVG<,$'BR2X(/_/-Y;L*?IG'YU]@?LX:W9P_\$E;BY:1/*M?!
MNNQR\]&'VO@_F/SH XS_ ()B?M-ZE+^R-X_'B.ZEU(_#J.:XM9;B0LYM?(:5
M(B3SA61U'H" . *^:/V'/V9;'_@H%X[^*'C3XIZUJ=Q/"\;F2RE$;M<SF1L\
M@@(@3 0<<@=!6M_P3MT6[U+]D;]J;[.K-YNB^6@4=66VG8C\J]:_X(=W$9\-
M?%B#(\T7>GN1WP4F']* .._X);>.=;^#G[5OC[X&WNI27>AM+?0QPN?D6[M)
M2OF(/X=Z!\@=<+GI7ZY5^-7[)$+ZO_P5I\97-K^\@BUWQ#.[+R-GF3#/YL*^
ME_VO/V=/VJ?B+\<-5UOX5^//[!\&S6]LEO9?VY+:[9%B D/EJA RP)Z\T ?6
MO[2W_)NWQ._[%K4?_2:2OCC_ ((G_P#)OOC7_L96_P#2:&O"/B/^RA^VKH7P
M^\2ZEXC^)GVWP_::;<3ZA;?\))-)YMNL;&1=I3#94$8[U[I_P1.#?\*!\;DG
MY3XD.!_V[0T ?HG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK:1I%EH&EVFFZ;:Q6.GVD2P6]M @2.*-1A54#H !5R@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *@OKZVTRSFN[R>.UM84+R33
M,%1%'4DGH*Q?'7C[0_AOH$NL:_?)96:<+GEY&[*B]6/L*^>K71_&7[65_%>Z
MQ]H\)_#2-M\%DA*SZB,\,?;WZ#L#UKDK8A4WR07--]/U?9'13H\ZYY.T5U_R
M+?B;XK>*/V@]9N?"?PQ$FG^'4(CU+Q/*I7Y2>5B[CCICYC_LCFO8/A1\&_#W
MPAT7['I$'FWDOS76HS@&>X;U+=AZ*.!]<FNG\,^%]*\':+;:3HUE%I^GVZ[8
MX8A@?4GJ2>Y/)K4I4L.U+VM5WG^"\D.I637LZ:M'\_4****[#F"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/\ :?\
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M_8_\*?LL'76\-ZQKVK/K'E";^V;WSE0)NQL4  'YCD]>E>[4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G!^T1
M_P $\_BIX8^)/B3XI?L^_$#4+#6]8OI=3O-!EO?LK/-(Y=Q%)Q&RY8X24# _
MB-?H_10!^.\7[>O[9'P"M&L/'G@;^V5B;;]NU_0)488[>;;-&C?4Y/O2V?\
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M[;GPA_:#U-M+\*>)E_M<+N&G7\?D3./]D$D-] <U[Q0 4444 %%%% !1110
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M=E;Z=80+LBM;2)8HXQZ*J@ 5<HH **** "BBB@ HHHH **** "BBB@ HHHH
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MA!R3CZK_ &>?V?O"O[-7PTT_P;X4MMMM#^\NKV50)[VX( >:4CJQP..@  '
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OF#_@HK_R;?J'_ %^VW_HU:]C^.'A3Q)XV^&6LZ/X2U<:)KURJ""\)
M*A<.I89'(RH(S[U^=/[0WP ^,/P[^'-QJ_C/Q8FKZ(DT:/;+=-)EF8!3@CL2
M*\;,JTX4IP4&TUOT1^G\#99A<3F.'Q=3%PA.%2-H._-*UGITUV1\K4445^>G
M]HA77_!W_DK/@W_L,6G_ *.6N0K7\(:=>ZQXKT>QTV;[/J-S>10V\Q.-DC.
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M(K\Q?V )$\#?M\?''POK$BVNJW<4TENDQVM+B>-]JYZG:V<#LI]* /T,\/\
MPA\$^%]#AT?3/"ND6VG1((U@%G&01[Y&3^-?G!^WW\%(_P!D+XB>$?CI\*X6
MT!&U!8M4LK8X@W$YSM[*W0CU-?J5+/' %,LBQAF"@L<9). /J37PK_P6#\5:
M?IO[--IH,KJ=2UC5(%M8OXCL8,QQ]!0!QO\ P52\6V7Q!_9G^%7B2P.^PUB^
MM[Z'/]R6.-P#^#5]D_#?X/>!+SX;^%GG\':%*\FDVK.SZ?$2Q,*Y).VO@/\
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M_P""<LO[(WQ1U+Q?)XV3Q&+S2I--^RK8&#;NEB??NWG_ )YXQCO0!]M4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *;)&LL;HPRK J><<&G44 ?C#_P42^ O[/\ ^S+)
M_9^B1>)-6^(FNE[Y+2;5@;6QA9C^]D^3<V6R%7/."2W'/Y[^<_\ ?;\Z^D/^
M"C6MZGK?[:'Q-;5'D9[6^CM+='/"0)#&(P!V!7#?\")[U\VT ?2'[&^@? SX
M@^,O^$6^,EQJGAX78+67B&VU9;:UC<#/ESAT(4$='W 9X(YR/TAC_;\^#7P
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ML*^Y_P!@C]LH?M2_!O4]8\1I;:;XG\-R"#6?)&R%T*%TN%&3M5@KY'8HW;%
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M24JJLFC@QV)I5X*,'U-^BBBOHSQ0HHHH **** "BBB@ HHHH **** "BBB@
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M56A.$=VF?1<.XNC@<WPN*Q#M"$XMOLD]=C\5**^^_P#AUJ__ $.Z_P#@+_\
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MIZ3IREI8"2&)"CH01D-TZCO7Z/44 ?F=\7->^,__  4!U_PYX,TKX>:Y\-/
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M@^!/B'_A9!@^QC4EMF:RSC;YP.,GCGTS73?L_?LAZY\"_P!D7XE6>J1/J'Q
M\6:;=W%Y;6_[PB5HF"1+CJ>>W>OM^W4I!&IZA0#^524 ?%O[!WP#NY?V)/\
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M]>/M;_@H5^R#<_M9_"BRMM"FM[;QCH$[W>EM=-LCG#@"6!FP=NX*I!Z;D7.
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M-7]BCQ?\'/$/B/XJ?%!/LWC+6TD@M]/>19)(4D<2332D9 D=@  #P,YZX'Z
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MF_9]AN-#TC5;QXKK2KB,7=O?R(QWR^3CY%9]S* <KN." <#TI?\ @K'^TR%
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MK/AAXH^)G[1'CSX_:Y8RV&DW;WIMI)D*_:KJ[F\R3R\]51=P)]64>N #V?\
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M?:?KV^6IT7I4/A]Z7X+_ #/,OA3^SMX:^&,G]I.KZ[XED8R3:S?_ #RESU*
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M:PO$LZ]*NG>"35IJ*L[K_GW._P"!^@O_  \"^"7_ $,UU_X*[G_XBE7_ (*
M?!)F _X2:Y&3C)TNY_\ B*_+D?%#Q*/$Q\0#4%_M8Q>09_LT6-GILV;?QQFO
M2?@O\9_%^O?&#P/IM_J<-U8WFN65O<0/8V^V2-YT5E.(^A!(KQ89S6G)1TU?
M;_[8_4\5X7Y9AZ,JRYVHQ;?[U+97:7[E_?IZ'[ V-[#J5E;W=L_FV]Q&LL;X
M(W*PR#@^QJ>FDJB\X51^ %<]K?Q'\)^&\C5O$VD::1U%U?11D?@6K[%R45>3
M/YDA2G6ERTHM^2U?X'1T5X=XK_;7^#/A&8PW'C6VOYQ_!I<,EV/^^XU*_K7!
MW7_!0SPI?S&+PMX-\5^)WZ9M[((#^I/Z5R2QN&@[.:_/\CZ.APMG>)CSPPDU
M'NURK[Y61]6T5\EK^TW\<O&\IA\&_ F[L1VNO$5P8H\>N'$0_)C0='_:X\93
M;KG5_"?@FW;K':H)67])/_0JCZ[&7\.$I>B?ZV.K_5;$4O\ ?,11I/M*I%O[
MH<S/K2L_5_$.E>'XA+JFI6FG1GH]W.L0/XL17RV_[)WQ=\72@^+OCYK*6_\
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MGQ?U'Q[?^.M2T.YO(((#96UC'*BB- @.XL#SC- 'C/\ PH#_ ()Y?]#W8?\
MA2S5[Q^QS\,/V5O!?Q+U&]^"'B6VUCQ4^ER17$$.KR796U,D99MC<#YQ&,^_
MO7A6J?\ !#S0FLI?[.^*VHQW>T^6;K1XWCW=L[90<?2L+_@E?\+])^#W[4_Q
M.\(>(;NYB^).A64UB((I$:QNK3S82TB?*'#AEC/7!63H"#0!^K=%%% !1110
M 4444 %%%% !1110 4444 %%%% 'FW[2W_)NWQ._[%K4?_2:2OCC_@B?_P F
M^^-?^QE;_P!)H:^Q_P!I;_DW;XG?]BUJ/_I-)7QQ_P $3_\ DWWQK_V,K?\
MI-#0!^B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHXNO.HEMS2<K>EVPHHHK8\P**** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)F@!:**3- "T444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1F[5.&RHXW#KD=017W!7YF_M 6L7A?\ X*R_"R^T_P#=W&L1VJW>SJW\'/\
MP%10!^F5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8$8/8<D]<8YKPWX;_MG_ +'GBGQ%;Z=XF_9_TWPC:3N(UU)M/M[J&+)QF0*
MP7U(#?2N0_8;^ 7AK]M+]IGXJ>*?BC/)JXTZZ:\;1S*8S=2RS. 7((;RXPFW
M:.[+R,8/UI^U[_P3N^!Z_ ;Q?KOA[PQ:>"M;T339K^UU"QE=$+1KNV2*S%6#
M8*^OS=: /KKX3^#O W@[P?;I\.]+TG2_#6H'^T(1HD:+;SEU7]Z-O!RJKSZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.E:%X@\166E:OJ 5;2TN'(>8YVC;QZ\5V=?%/[:OPA@^*/[0/P:72-#U:_\
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M]K'1/#_@2+X+?$*Y3PIXQ\,SRVD":F_E+<1^8Q RV &4DKC." ".M=]\:/\
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MX9MO#_A+1;70])MQA+>V7&?=B>6/N30!T]%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"@"2BOS//[77Q/!_Y' _^ UO_P#$4?\ #77Q/_Z' _\ @-;_ /Q%>-_:<?\
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M,/\ P\8^#?\ S_:O_P""YO\ &O2?@M^TMX*^/EWJEOX3GO)I--2.2X^U6QB
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M_P %"OA5IQ,6CR:OXHN2<+#IE@PW'ZR;:Q$_:A^-/Q$E=? /P1O+.T ^6_\
M$LK0JP[$*PC'Y,U?3&@>!?#?A2-$T70-,TE4&%%E:1Q8'_ 0*W:/8XF?QU;?
MX5;\7</[4R3#?[K@.=]ZM1R_\E@H+\6?)*^ ?VJOB#$Z:QX[T+P-9S</%I<
MDG1?]E@N0?HX/O7!?'?]C&'P?\&O%/BSQ#\0_$WC+6]-L_.C:_G(A+[E&2K%
MVQR>-U?>=8OC+P?I/C_POJ/A[7;8WFD:A'Y-S )&CWKD'&Y2".0.AK.I@*<X
M--N3MI=M_P# _ [,%QCC,+BJ4Z<84J2E%R5.G&+:35U>W,]--9'X/45^N_\
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MW#%BV6_$D_C7=444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR>T]M'EVOS*U^VY]K_L-?&+X>_"CX3:M/XAB63Q$^K2M"MO9>;<M#Y40 #D
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M(_#70/!/AR$Q:5H]LMNC.!OF;J\KXX+.Q+'W-=E0 57O^+&Y_P"N;?R-<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFNZQH68A5'))H =
M138Y%F0.C!E/(([TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&I? ?]N/XD_!R+46U31/)O(6D4_*TMM(ICE(' ;8S*?<^U 'ZW4444 %%%%
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M:CX0?VW_ ,*O\+CQ'#:0:T+"(7$=DQ:($+A<$_[.TGWS6U_PBFB?] >P_P#
M5/\ "M15"*%4!5 P !P!7I8#+G@I2ES7N?*<2\8XSB>E3I8J$5R-M-)WU6JW
M>G^2%HHHKV3X$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFN2
M$8CKB@#X2_;*_P""D7@7]G#Q-<>#_#/A:Q\;>,[=@+\.5BM+$D9VNX4EY.1E
M!C&>6!XKY\^'/_!94MXDM8?'?PJT5-#ED"S76AL1/ A_B$<@(DQZ;E^M8O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCU(50N?TH _*/4KK6O\ @EU^U3!' ;BY^#/BN;>8BI9(%)P<''WX\YQW K[
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MZ?;L1YCLLJLQ4=>%!YKKOVAO^"??AGXR_$&W^('A_7]1\ ^.(FW/JND-M,S
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M!AD>0>85([$%\5X9X-_X)NVMQ\1M+\8?%'XAZ[\4+O2R#9VVL2%XU*G*YSU
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MZ9)Z_P 9/X56^+G[(FE?%GX_> _BC=:Y=65]X3D1X;*)%,<VV0/\Q/(Z8XH
M^@!TI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,W_@IE
M^QQX[U?XD:7\<OA/#>WFNVB1#4;332?M<,L/,5U"!RW "LHY&T'!R<?IE7PE
M^W+_ ,%,H_V8?&R^!?"?ARW\1>*8H$N+VXU&1TM;4.,HFU,,[%<$\@#(Y)R
M ?%UQ_P4L_:LU32&\*16:QZR\?V4WEMX><:CNQ@D+RH?W"=>F*^K?^"6W['_
M (Q^%^I^(OBQ\2K2:P\3:]"UM9V=\=UVL3N))9IL\JSLJX!^; ).,U\[C_@M
M%\9V^9? _@X@]"+2\_\ DBOIG]@/_@H+\0?VK/C!JOA/Q7X<T#2-/M-&EU%)
M]+@N$D,BS0H%)DE<8Q(W;/ YH _0"BBB@ HHHH **** "BBB@ HHHH ****
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MN/4X#UQ3Q^%AO47RU_(^FH\(Y[7CS+"RBN\K07_D[1]D5^7/_!3#_DOVG_\
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MK*WOA&+B".<1N)$$BAMK#D,,]"/6IZ** "BBB@ HHHH **** "BBB@ HHHH
M\G\8?LT^#_&_QK\-?%+48[H^)_#\(@LVCG98@H8M\R9P>6->L444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7Y6?ME^%]'_9T_P""@/@[XU>.
M]+MO$7PZULJLULRQSRP3I;F+<8'/SA#Y<@(&./[P&?U3K\>/VP_@[JG[2/\
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MM[ A,?K7/+$48?%-+YH]G#Y)FF*_@86I+TA)_H>]45\EM_P43\-:O+)'X6\
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MBWS.,M(](A\9W%_YBBV,8*<';OX[?G75CQ/I9/\ Q^)^1_PJQ_8UA_SY6_\
MWZ7_  H&CV .196^?^N2_P"%;U*D*EN:^BL<U.C4I74;:N^S+?6EHHKD.X**
M** $*@]0#56;2K*Y.9;2%SZE!FK=%--K83BGNC*E\+Z9+UM57W0D55?P5IS?
M=,T9_P!E_P#$5OT5HJU1;29BZ%)[Q1^:O[?NFC2_C#IT(FDF7^RHR#(<D?._
M%?,U?L/XY^"'@/XCZLFI>)O#MIJU_'$(5FG=PP0$D#AAW)KRWQK^R?\ #:SD
MM9=.\*V2I+*$:/S)/E_\>Z5]]EV>T(484)Q=TM]+?F?-8S 5(N56-K=NI^95
M?H?\%?V2OAM\0/@UX2UC5]'E.I7EBDLT]O<-$6;)Y.*].L/V1_A);6RI-X0L
M)Y>K.TDG)]OGKU7P[H&G>%M$L])TBU2RTVTC$4%O&25C4=ADDUP9GGRQ$(QP
MKE%I[[?DSLPF6^SDY5K-6V/G/4/V!?!L+_:/#GB/Q)X;O5^Y+!=JZK^&T-_X
M]5$_LS?&'PQ()/#OQA;4-O1-8M"Q^FYC)_2OJNBO"6;8NUIRYEYI/\T>B\#0
M;NHV]&T?+\I_:G\+1AXHO"?BM4_Y9 ")V'XM&/UI7_:;^*OA5%'BKX'ZHRK_
M *RYTB9I4'OA4<?FU?3]%+Z]3G_%H1?I>+_!_H5]7E'X*C7K9_FCYF@_;T\&
M6^T:UX=\2Z&2<-]HL@0O_CU=QH'[77PC\1;!!XSL[61OX+^.2VV_4NH'ZUZS
M=:=:7R%+FVAN$/!66,,#^=<3X@^ ?PX\41.FH^"=$E+_ 'I([-(I/^^T ;]:
M/:8"?Q4Y1]))_FOU#EQ,=I)^JM^3.ATKQUX;UR-7T[Q!I=^C?=:VO(Y ?R:M
MQ6# $$$'H17S[J?["WPHO=QM=-U#2G/1K._D^7_OLM6"?V)[W0T;_A%/BSXL
MT CE4,QD0>G".E'L,#/X:S7K'_)L/:8B.]-/T?\ FD?4-%?, ^&W[2GA>/R]
M+^)&C>(8(_N#4[4+(P]R8R?S8TL7CW]IGPU&1J'@#0O$:)R9+*Z6-V'L/,_]
MEH_L_F_AUH/YV_-(/K-OBA)?*_Y7/IZO#OCM^T!X>^#'B&QLM<O]5ADOK?SX
MDL;<2*%#;3D[UYR*X^']LW6]!W)XQ^$'BG0W3AI;>)I8S[@LB#'T)KY>_;#^
M->A?&WQ3X?U'0X;ZV2SL6@GBOX?+=7,A;U.>#7J9;E%:6)2KQ]S75-/\5<XL
M9C*;HOD>OS7^1] 7'[;WP\NX]DU_XAE3.=KV"D?^C:E'[<_@$  :GXC '_3B
MO_QVOSYHK[#^P\+MK^'^1\_]<J;_ .?^9^R7PE\86GQ \"Z?XDT^YN;FPU'>
M\)NT"2 *[(01D]U/>NQKQC]C?_DVOP5_UQN/_2F6O9Z_,,7!4\14@MDVON9]
MGAW>E!]T@HHHKD-PHHHH **** "N2\5^%_,22\LT^?!,D2CK[CWKH[_4K?3(
MEDN9/+5CM'!.3^%9TGBS3&C8"X.2"/N-_A731]I!\T$<E?V,XN%1HX;P%X=?
M6+?S) 4M4D.X]V/H*]#?P]IKH$-E" !@;5P?S%<_X6UVQTS3##/+Y;^8S;0I
M/!QZ5T%EX@L=0G$,$VZ0@D*5(S73BIU9U'))I(Y,'"A"E&+:;92E\&6#',9F
M@;L4?I^=1_V%JUK_ ,>VK,X'19@3_C7145R>VGU=_74[7AZ?16]-#G3<>(;,
M@O;P7B=]AP?YC^5 \6/ <7>FW$!]0,C^0KHJ0C/7FCVD7\45\M ]E./PS?SU
M,BW\6:9<=9_*;TD4C]>E:4-Y;W !BGCD!_NN#4<^EV=T#YMM$^>Y09_.LV;P
M=ITF2BR0GU1SQ^='[I]U^(?OX]G^'^9N45SO_"-7MIS9ZK,N.B2\C_/X49\1
M6IY%O=K^1_I1[.+^&2_(/;27Q0?YG145SO\ PDUW:G%[I4T>/XX^1_G\:FA\
M8:;)]]WA/HZ'^E#HU.UQK$4GN[>NGYFY574-1M],@$MP^Q"=H."<G\*6WU.T
MN@#%<Q29[!QG\JF>-)EVNJNOHPR*RM9^\C5OF7N,R/\ A,-+_P">[?\ ?MO\
M*/\ A,-+_P">[?\ ?MO\*=K=Y8:-;;WMXFE;[D809)_PKD? 6NV\BS07T467
ME)25E''3@UW0HQG3=11=EY_\ \^>(G3JQI.2N_)_YG96?B73[ZX2"&8M(W0%
M",UJ5%':P1,&2&-&]54 U+7%+EO[IZ$%-+WV%%%%06%%%% !1110 44G2H?M
MMO\ \]XO^^Q32;V$VEN3T5!]MM_^>\7_ 'V*/MMO_P ]XO\ OL4<K["YEW)Z
M*.M%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K\C_P#@I?\ ##X]?$_]I2*Y\)>"_$.LZ!H4%M)HVK:/IA+V\I17?9<(
MN[B09QN^4\C%?KA7YD_MQ_\ !13XL_L\_M#:QX*\)Z?HUQHMI:VTT;WEB\LA
M:2,,V6#@=3Z4 ?/]GXN_X*!V-M'!':_$ADC4*#+I7F-CW9HR3]2:^J/^">OB
M3]J76/C+J\/QLM_%<7A8:)*UN=<T\00_:O.AVX8(,ML,G&>F:^5Y/^"Q'QZB
M&7TSPR@_VM-D'_M2OJ[_ ()W_MO?%O\ :D^)^JZ9XQT:P@\+VVE37$6H:?IT
MD49N5EA41^:6*D[9&.WKWH _0BBBB@ HHHH **** *VI:C:Z/I]U?WUQ':65
MK$TT\\S!4C102S,3P  "2:_G^_;Z_:IU+]J?XM2ZI:+-#X#T>233]"C(8)(!
M@R3-V+N<'CHNP=LG[<_X*W_M3W&BPZ=\#=!NCID^MI%<Z[J<C%(XK5GQ'%D<
MD,06?_94#G)Q\=?MEW_P;TGX2_!_P5\)/$=IXE.AQWLNM7MO!)&\]U+Y):5R
MZ+G)4@>BJH[4 ?JC^U9\>[W]G+]BL>*M).W7IM-L=-TQSC$=Q-&H$G/78H=P
M.Y4"OS-\*?L5>-/BQ^RUXC_:4OO'E^_B6U%UJL%M<!Y)[B"W+>;*;@ON#_(Y
M4 ?P=>>/H[_@H1\7_"GQH_8$\+:CX)UN+7-.TOQ!I^G7\L*.@BN%LI"4.Y1D
MC<O(XYKV7]FZ>U3_ (),2.Y7R4\%:[YOIG_2\YH 9_P3E_:YU'XF?LN>)M3\
M<7TFI:OX#$OVR_E/[VYM%A,L;.W\3@*ZD]]H)R237Q-\$_@UXX_X*H?$WQ]X
MI\6^-I]#M-)57MXA$US#;O*7\FWBC+J$C4(<D<G'<G-;G_!/2"[D_9%_:I,&
M[!T3"X]1;SEOTKV+_@AXR?\ "+?%A?\ EI]MT\GZ;)O_ *] %+_@E?\ 'CQE
MX7^,OB[]G_QEJDNJ6VF"Y73S<RM(UI/;2[)8HV)_U;#+ =BG'4U^IE?C3^RB
MKS?\%;_&#6_,8U_Q"S;>FW?-_7%?2_[7OQ/_ &PO#'QPU73_ (/^&KK4O R6
M]LUM<1:3!<*TAB4RC>W)P^: /K;]I;_DW;XG?]BUJ/\ Z325\<?\$3_^3??&
MO_8RM_Z30UX-\1_C'^WIJ'P^\2VOBCPA>6_AJ;3;B/4Y6T.W0);&-A*2PY&$
MW<BO=O\ @B<6_P"% ^-P?N_\)(<?^ T- 'Z)T444 %%%% !1110 4444 %%%
M% !1110 56U#4;32;*:\OKF&SM(5+R3W$@1$7U+'@"K-?A1_P4C_ &S-;^.O
MQ9UCP=H>KRQ?#OP_<O:06ULQ1+Z=#MDGDQ]\;@0H/  R!DF@=NI^PD7[57P9
MGU7^S(_BMX,>^SCR!KMMN)]/O]?:O3K6[@OK:.XMIH[BWE4,DL3!E<'H01P1
M7\KE?:?[ _\ P4)U/]F/4;OP]XPDU3Q%\/[B&1X;&W(FGLKD+E/(#L $<C:5
MR!D[NH.01^ZM0W5W!8V[SW,T=O @W/+*X55'J2>!7P,_[4W[5_Q\8_\ "J/@
MI'X$T*9/W.M>,6(D<'I(JN$&,<X"N/<U):_\$Y?B'\9;@:G^T#\<M<\2RNH_
MXD7AYS;V47J 2 I]/EB7ZF@#VOXQ?\%"O@7\%Y#:ZEXTM]=U8J2NF^'1]OER
M.-K-'E$/L[ ^U>(']N+X^_'Z5K'X%? J[L+1D+?\)+XR)BMPIX#("8T)[X#N
M?]FOH_X/?L4_!?X&QH_ACP)IO]H  '4]23[9=$CN))=Q3/HFT>U>W(BQJ%4!
M5 P !@ 4 ? *_L*_'CX\;&^.OQXOXM'D7,_AWPF/*B?/56;"Q_G&]>Y_"?\
MX)\? CX/O;W&E^!;/5M1A "W^O?Z=*3_ 'L/\@;W51CMBOHF:XBMHVDFD2*-
M1EG=@ !ZDFO-?$G[3?PJ\)^8-1\?:&LD9(:*WNUGD!]-L>XUG.I"FKS:7J=F
M'P>)QDN7#4Y3?]U-_D>EQ1)!$D<:+'&@"JB# 4#H .U/KY?\0_\ !1;X0Z*C
M_8[C5M<E' 2QL2-WXR%17F/B+_@I9JEXC)X6^&LV3]RYU:\(&/>-%'_H=<,\
MRPE/>:?IK^1]/2X/SRHE*>'=-=YN,%_Y,T/_ ."IQ_XIKP%_U]W/_H"5^=Q
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MT36-,_97M[_6/$L'BEM9U6?4+>[ANYKAHHC'%'Y,AE565U>-P5Y Z@G-?8-
M!1110 4444 %%%% 'E'Q#_99^&'Q6^(6C>./%/A=-5\4Z.838W[7<\9A\J3S
M(_E1PIP_/(/O7JQ&1@]*6B@#YJ\;?\$Y?V>_'_BV?Q'JOP_@74;B0S7"V-[<
M6L,SGJ6BCD51GJ< 9[U[]X3\(Z+X$\.V.@^'=+M=&T:QC$5M96<8CBB4=@!_
M/O6O10!X+\9?V&?@I\>_$A\0^,/!<-UKC ++?V=U-:23 =/,\IU#GME@3CO7
MI'PI^#O@SX(>%8O#G@?P_:>'M(1BYAM@2TCGJ[NQ+.WNQ)KLJ* "O'?VQ?\
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M)\33PF+C5K.T;/\ (\_'4IUJ#A!7>A^7-%?=7_#M6S_Z'F?_ , !_P#%T?\
M#M6S_P"AYG_\ !_\77Z!_;V7_P#/S\'_ )'S/]G8K^7\45/@#X2^/%G\'O#>
MM>!/%ND7.AS)*\6@ZI" 8@)G!4,4.<L"?O+]ZO0_^%V?'SP;*/\ A(_A)%KU
ML/O2:%.2WU 7S/Y5[?\ !_X=I\)_AQHOA-+TZBFFI(@N6CV%]TCO]W)Q]_'7
MM795\%B,QIU*TW*E&46W9V:=KZ:IK\3Z2EA90IQ2FT[+K=?C<^:]+_;O\$Q7
M36/BG1?$'A#4H^)(+^SW!3^!W?FHKTCPU^TK\,/%>P6/C725E<@"*[G%N^?3
M$FVN_P!2T73]9B\K4+&VOH^FRYA60?D0:\U\2_LK_"KQ4LOVSP9812R9)ELM
MULX/KF,C]:Y^?+ZGQ0E#T::_%+\S7EQ,=I*7JK?D>J0S1W$:R1.LD;#*LAR"
M/4&GU\PW'["^EZ/)YW@[QUXF\,2J<JJ7/F(/P&T_J:8WPQ_:-\"3K)X?^(NF
M>+[-1S::Y#L=O;)4G_Q\4?5,//\ A5U_V\G'_-?B'MZL?CI/Y-/_ "/J&BOE
M[_A?'QT\(%D\3?!\:JJ=9]#G+!A[!3)5[2/V\/ PE6U\3Z3K_A&_!Q)%?V1=
M$/U4[OS44GE>*M>G%27]UI_D[@L91VD[>J:_,^B[YK6. O>&%85(RTY 4?B:
MS?M_A[_GYTS_ +^1_P"-?,W[5?QT\!?$/]GCQ%9>'_%%AJ-]*UJR6BR;96 N
M(R<(P!X )_"OSOKV<NR*>+I.=2;@T[6MZ>:.#%9A&C-1C%2TWN?M3]O\/?\
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M@ITZ].*CS)^I;AGBN%W12)(OJC BI*P9?!E@S;HFFMS_ +#_ .-1CPW?6_\
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MEG@;<A_,'T-=N(5:DHMM['G85T*SDE%7N^G0G10BA5&% P!3J**\T]<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQUC7IKW3(YN-T'DPQF11V5G1L>NW/>ONZH[>WBL[>*"")(((E"1Q1J%5% P
M .  .U24 %%%% !1110 4444 %%%% !1110 4444 %>._MB_\FK_ !5_[%V\
M_P#19KV*O'?VQ?\ DU?XJ_\ 8NWG_HLT ?+_ /P17_Y-D\4?]C5/_P"DMM7Z
M!5^?O_!%?_DV3Q1_V-4__I+;5^@5 !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7>Y^FG[/W[3FD?&OQS+HFG0:Q;36]F]ZQO=GELJLB;?E8G.9 ?PKZ/K\X/\
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M/TX  KY8N?\ @GUJ?A#]MK1OC/\ #75M&\*>&%DCFU304CDC:5G#1W21HB[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?%E@VIZA):QRQ+'+L"-O4J>BYX!KZ8'B_P K_CZTZZ@/LN?YXK?AA2WB6.)
MB*,!1T%/KPL5C7C*GM*RN]OD>W0PDL/#EA/\$8">-=-8\F5/]Y/\#5A/%&ER
MC!N5 /9E-:<EO%*/GC1_]Y0:KOH]B_WK2$_\ %<=Z3Z/[SHM77VD_E_P3$U7
M1_!WB>$PZGI^CZG&W6.\MXI ?P85YYXC_9$^$/BTF1O"UM93'_EKI<[V^/\
M@*-M_2O59?"^ER];15_W25_D:K2>"M.;[HEB_P!U_P#'-=-+$.E_"J2C_7DS
M*=.<_CA&7]>A\_WG[!_A^SF$WAGQEXE\-3+]UH+K>%_+:?UJ.;X(?'WP0ZGP
ME\78_$$'\4'B* Y^@+"7/YK7O_\ PA_E?ZG4;F,>F?\ #%!\.ZE'_JM7D_X$
M#_C7=_:-:6DZBDO[T4_TO^)S_5TOAIM>DO\ @GS\?''[3?A%_P#B8^"M#\4Q
M#^+3Y0K'\F'_ *#7R1^U=XX\1^/?B/;7WBCPE<>#M3BL(X/L-P[,74,Y$@)5
M>"21WZ=:_3D6/B&+[M_!(/1U_P#L:_/3]OS[;_PN>Q%]Y?G#28<&/H1YDE>[
MDM:G5Q:M3BG9ZQNOPO8\_'1E&CJY6OUM^9\TT445^@'SI^J'['WB#2V_9]\'
MV8U*T-W%!(LD G7S$/G.<%<Y'!'6O<@0PR""/45\+?!']ESP-\0O@_X=UK4-
M$U4:G=Q.TUY8WK)O(D=00I#*. .@[5TH_8U@TEL^'O%?C/11GA1<A@/^^52O
MRS%X/"U,14?MG%W>\?/R?Z'UE'%U(4XKDOHNK_R/L6BOCJ3]GSXI::/^)1\6
M?$<>.@N5D;^3U9M?"O[2^AC;9_$*PU&,=%U"P!)_$PL?UKD>60?P5X_.Z_0W
M6/\ YJ;/KRBODK_A/_VH?#C!9?#'AWQ-&.KQ+Y;'_P B1_RJVG[27QJT]?\
MB9?!6:7;]YK.9B/P W5F\JK?8E%^DE^MC18^D]TU\F?55%?+,?[:^KZ>=NM?
M"+Q19L/O&%"X_5!_.I(?^"@G@>*81:EX?\1Z2QZFXM4P/R?/Z5/]DXWI3OZ-
M/\F7]>P_67X,^HJ*\$L/VW/A3?JI&O&!C_!/;RH1^)3'ZUT&G?M2_#K56"VW
MB.P=CV-RBG]2*PEE^+C\5)KY#6-P[VFCUNBN'L_C#X=U$@6M[!<D]!#<1O\
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MU3Z5JD.K6HFA/LR'JI]#5\DN7GMH9^T@Y\E]2Y1114&@4444 %%%% !1110
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M[?UKV.YL;:]7;<6\4Z^DJ!A^M<AX@^"7P_\ %19M5\&:)=R-UE:QC63_ +[
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MP_:(\?>$_BQXHT/3=;$.FZ=?R06T1MHF*(#QR5R?J:X@?M5?$H3)*==C+H,
MFR@/_LE?9X7(*BA[2Z?,O/K\CYO%9A*I+D2M9_D?JSI&KPZQ;"6(X<</&3RI
MJ_7Y7>'OVOOBG;:Q:>7X@B7?*J,/L$'*D@$?<K]3+5S+:PNQRS("3[XKY_,L
MLJ9=*/.TU*]K>1[F"Q:Q47IJB6BBBO%/1"BBB@ HHHH **** "BBB@ HHHH
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M3^?O[>W@*P_8:_:P^&/QB^'-K'H-CK$TUQ>:38KLA,L+QBZ15'RJDT-P%V#
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M %%%% !2$XK-\3^(+3PEX;U77+]_+L=-M);RX;TCC0NQ_(&OQE^%7AWXR?\
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/A#)_P S1M_WK28?^RU#PN.ZT7_X#_P"N;#=*G_DW_!/3_*\1ITFMW^H'^%
MG\21];>VD_'_ .N*\YC_ &Q?A%)_S.$"_P"]!*/_ &6K</[6OPCG.%\;V"_[
MZ2+_ #6I>&Q2WH/_ ,!97-1Z5O\ R9'>?VGKR??TN-O]UQ_C2'Q#J<7^LT64
M_P"XQ/\ 2N2A_:<^%4_W?'>CC_?GV_S%7X?V@?AG<?<\>^'C]=2B'\VK-T:J
M^*@_N95X_9K?D;P\6RK_ *S2KI/P/^ KA?BA^TOX7^$D-H=?CO;>6]#_ &=5
M@+ABN,YQTZBNIC^-'P_E^YXW\.M]-4@_^*KX[_X*'>+=#\4#P6=&UFPU81?:
M?,-C=)-LSY>,[2<=#7=E^#AB<5&E5IM)W[]CGQ-6=&DYQJ)OT1V=U^V;\/;^
MX::?4+]I&ZDV;U/I?[:?P\TJZ$T.I7N>C*;)\,/0U^?-%?>O)<*URZV_KR/F
M%B:BES7U/V ^&_QW\)?%/0I-6T2[F:UCF-N_GV[H0X56(Z=,,.:ZY?%&EOTN
MU'U4C^E?-'_!/"SM[CX)ZJTL$<K?VY,,N@)_U,/K7T^^BZ>_6R@_","OSC&T
M:&&Q,Z,;V3\CZZA.O5I1G=:^HU->TY^E[#^+@?SJ5=4LFZ7<!^DB_P"-5G\,
MZ8_6S0?[I(_D:B;PEI3'_CV(^DC?XUPVH]W^!O>OV7XFB+VW;I<1'Z.*>+B)
MNDB'Z,*QV\&Z6>D3CZ2&F'P5IQZ&9?H__P!:CEI?S/[O^"'-6_E7W_\  -T.
MIZ$'Z&G5SQ\%VH^[<7"_\"%)_P (<@^[?W*_\"HY*?\ -^ <]7^3\3HJQ=;\
M56.CVVXW$,DS<)&'')]3[56?PG($;;JMTO'J?\:_&Z]U.]-W,#>3MAV',K>O
MUKW<KRJ&8.7[RW+;IWO_ )'GXS&U,.DN2S?F?K%;^+)(-2-[]KC>1OO@N,,/
M2O0-*\06.L6Z207$98G!CWC<#Z5^*_\ :5W_ ,_4_P#W\/\ C7H'[/NI7;?&
M_P "H;J8HVLVH*F0X/[P=>:][%</1]FYJIJEV[?,\O"YA.$^5JZ9^O5%%%?G
MI]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117&?&C7KCPO\(/&^L6DC0W5AHMY<Q2+U5TA<J1[@@4 ?&G
M[0/_  5U\(_"OX@7_A/P=X1NO'UQIDKPWU_'>BVME="0ZQ$(Y<+@@M@#CC(Y
MKZ#_ &2?VQ_!O[7GA6]U#P]#<:3K&F%%U+1;UE,MN6SM967AT.U@&P.G(%?#
M?_!$GPI9:OJ7Q=\1WUO%=WJ1V%BDLR!F"2FX>49/][8F?7%<O^PE;1_#'_@J
M%\0_"6EYM])^UZ[IB0(<+Y45P7C7'MY:T ?L/7CO[8O_ ":O\5?^Q=O/_19J
M'XG_ +9/P;^#7BZ?PQXS\<V>A:[!&DLEG-!,S*KKN4Y5".0<]:\'_:;_ &]/
M@+XW_9[^(6@:'\1;#4-7U+1;FVM+5+><-+(R$*H)C Y/J: .=_X(K_\ )LGB
MC_L:I_\ TEMJ_0*ORB_X)9_M8_"?X$_ ;7]"\=^,K3P]JUQXAFO(K:>&5V:$
MV\"A\HA&-R,/PK[*_P"'CO[./_14-._\!KG_ .-T ?2=%?-G_#QW]G'_ **A
MIW_@-<__ !NC_AX[^SC_ -%0T[_P&N?_ (W0!])T5\V?\/'?V<?^BH:=_P"
MUS_\;H_X>._LX_\ 14-._P# :Y_^-T ?2=%?-G_#QW]G'_HJ&G?^ US_ /&Z
M/^'CO[./_14-._\  :Y_^-T ?2=%?-G_  \=_9Q_Z*AIW_@-<_\ QNC_ (>.
M_LX_]%0T[_P&N?\ XW0!])T5\V?\/'?V<?\ HJ&G?^ US_\ &Z/^'CO[./\
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M US_ /&Z/^'CO[./_14-._\  :Y_^-T ?2=%?-G_  \=_9Q_Z*AIW_@-<_\
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M4-._\!KG_P"-T ?2=%?-G_#QW]G'_HJ&G?\ @-<__&Z/^'CO[./_ $5#3O\
MP&N?_C= 'TG17S9_P\=_9Q_Z*AIW_@-<_P#QNC_AX[^SC_T5#3O_  &N?_C=
M 'TG17S9_P /'?V<?^BH:=_X#7/_ ,;H_P"'CO[./_14-._\!KG_ .-T ?2=
M%?-G_#QW]G'_ **AIW_@-<__ !NC_AX[^SC_ -%0T[_P&N?_ (W0!])U^-'Q
M;_Y*MXS_ .PU>?\ H]Z_03_AX[^SC_T5#3O_  &N?_C=<I=?MB_L>7MS+<7'
MB7PI-/,YDDEDTB1F=B<DDF'DDU[^4YE'+9SE*-^9'FXW"/%**3M8_/JNV^"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD1) H)0F.0 '#*<>XK]B?VV/^32_BM_V +G_ -!KYJ_X(K_\FR>*?^QKG_\
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M'ZIT445^*'WX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'P3\5_^"6'P!\)?"WQAKFG:)J\>H:9H]Y>V[OJ\S*)(X7="03R,J.*^5?\
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M,HH ^,_^'2'[.G_0"UK_ ,',W^-'_#I#]G3_ * 6M?\ @YF_QK[,HH ^,_\
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M?9E% 'QG_P .D/V=/^@%K7_@YF_QH_X=(?LZ?] +6O\ P<S?XU]F44 ?&?\
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MF_QK[,HH ^,_^'2'[.G_ $ M:_\ !S-_C1_PZ0_9T_Z 6M?^#F;_ !K[,HH
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M'[.G_0"UK_P<S?XT?\.D/V=/^@%K7_@YF_QK[,HH ^,_^'2'[.G_ $ M:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPEUO3(+]K5'+K$9$#%0Q SC/6@#KZ*** "BBB@ HHHH **** "BBB@ HHHH
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M<_\ !:"QTK4H7U_X*^(='T*Y^:VOSJ"M+,F?O+&\**>/20_6OO+X-?&/PO\
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M]L5]J_M<_&(? ;]G'QWXS280W]EI[PZ><\_;)2(H,#OB1U8^RFOPZUGX/O\
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M+HFG^'-*M=,TJQM]-TZU01P6EI$L442CHJJH  ]A5V@ HHHH **** "BBB@
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M_ +]AWX@?#']NGQ=\8=6O-#D\+:M/J<D$-K=2-= 7#[H]R&,*..OS'\:TO\
M@HW^R=\7?VLKKPGI'@S4= L/">DQR7-Q%J=Y+#)/=N=H)5(F!5$48.>KO[4
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M5^$7[._[0?[-OA'6#\-_".I^(]/LXM-UWSM-B:X6\B4(SR#&<R8$@/</ZY
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M ><_\%&]$\1>)/\ @H_X4TGPCJ*Z1XJOH='M]*OVE:(6]TTK+%(74$KM8@Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >1?M#_LJ_#K]J#0K;3O'6CM<S6F[['J5G
M+Y-W:[NNQP#P<#Y6!7CI7G?[/'_!.3X/?LW^)X_$NB6>I:[XB@)-MJ.O7*S/
M:Y&"8T1$0''\14GT(KZAHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M->A_L[?LJ?#K]E[0;C3O VD-;S7>W[9J=Y)YUW=;>F^3 X')VJ H)/%>O44
M%%%% !1110 4444 %%%% !1110!%=VZW=K- S.BRHR%HSA@",9![&OC.?_@D
M;^SY<SR32:=X@:21B[,=8?DDY/:OM&B@#Y!\(_\ !*[X#^"?%6C^(=,T_7$U
M+2KN*]MFEU5V421N'7(QR,@<5]?444 >'>.?V-_AQ\0_CGHOQ;UBUU%_&.D2
M6TMK+#>LD :!MT>8\8//7UKW&BB@ HHHH **** "BBB@ HHHH **** /G+X]
M_L#_  I_:2\<CQ9XUM]8N=66UCLU^RZBT,2QH20 H&!RQ)KSC_AT/^SS_P!
MWQ!_X.'_ ,*^U** /,/"G[-O@'PG\%8OA0FC+JG@A(GA.GZHWVC>K.7.6/.0
MQR".00,=*^:KC_@CM\!)_$_]J+)XHAL?,WG1H]33[-_N[C$9=O\ P//O7W)1
M0!SOP_\ A[X=^%GA#3O"_A72H-%T+3T\NWL[<8503DDD\DDDDDY))YKHJ**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXS_X*/?M
MC^,?V1=-\!7'A&PTJ^?7IKV.Y&IQ.X40B$KMVLN/]:V<^U?9E?ES_P %R/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXD^-?BK]H#X8?!?X+6D5Q>3^'[F:QM8E.?M<MQ,JVZX[^6AV GH&- 'Z6_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"1'[/BW?G'3M>:/.?(.JOM_EG]:^H_A1\(/!_P $/!]OX8\$Z';:#H\)+^3
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O&
M_P!I;]E#P#^U9X9L](\;6ER);!VDL=3TZ4175J6 #!&*L"K87*L"#@>E>R44
M ?F0G_!$'PX-6#/\5M6;2-^3:C2HQ,5]/,\S;GWV?A7W!^SI^S)X%_9<\'3>
M'O ]C-%%<RB>\OKV42W5VX& TC@ <#@   9.!R:]7HH **** "BBB@ HHHH
M^#/C[_P2>\/?'KXY:W\0+OQ_J&CVVLSQW%WI5MIZ.P8(J-LE+X&[;GE#@GO7
MUC\"O@3X2_9T^'EGX-\&6<EKI5N[2O)</YD]Q*WWI)'P-S' [      5Z%10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>sdgr-20241231_g15.jpg
<TEXT>
begin 644 sdgr-20241231_g15.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +R!K(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9) 'J:6@ HHHH ***3<-Q&1D<XH 6BBB@ HHHH **0$,,@@@]Q2T %%(""2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1QD"10%1L>H+@CW -?IZZ+(I5@&4C!!&0177F>91RS%6HTDY-)MO\EVV_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4_Y-QT/_ *^KO_T<U?,W[9?PK\:^*/C]K>HZ-X0U[5]/D@M0EW8Z9//$Q$*
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MJ*^L/VB?@99?'GP$^CRSK9:I:R?:=.O67(CEP1M;OL8'!Q['G&*_.K5_@_\
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M[?-=N^W8VH3]O67LJ*4.[16_X*'_ /)"K#_L.6__ *)GKY[_ .">?_)=[O\
M[ EQ_P"C8:^F/V[?"VM>+_@S96.@Z1?ZW>KK,$K6VG6SW$@013 L50$X!(&?
M<5X9^PK\,_&'A'XT75]KOA36]%LFTB>(7.HZ=-;QES)$0NYU R0#Q[&C!U(+
M):L7)7UT#$1D\P@TM-#[_K\;?C!_R5OQO_V'+[_TH>OV2K\G_BI\%_B%J/Q/
M\87=IX$\37-K/K%Y+%/#H]PZ2(T[E65@F""""".M8\,U(4ZM7G:6BW+S>,I0
MARJ^K/TN^#'_ "1[P+_V ;#_ -)TK\O/VEP5^/WCP'_H+3']:_4GX2V5QIOP
MJ\&6EW!+:W=OHME%-!,A1XW6! RLIY!!!!!Z8KX4_;*_9W\6VOQ6U;Q7HNB7
MNLZ%K!6X,FGP-,UO+L D615!(!*E@V,88#.12R*O3IXZJIRM>]OO'F5.4\-!
MQ6UOR/L;]EZ19?V?? C*00-,1>/4$@_RKU&ORD^"</Q/A\9^%;'3+7Q5-HMC
MJUO=2:? MQ]E0+,K.63[@'!R37ZMUY.;X+ZI7;YU+F;>G34[<#B/;T[<MK60
M5\J_\%&O^2*Z%_V,$/\ Z37-?55?-7[>_A/7/&/PBT:ST#1M0UR\CUR*9[?3
M;5[B14%O< L50$@991GIDCUK#*9*..I.3LKFN-3>'FEV/GO_ ()S?\ENUO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*\/PR3RS,OR&9T:.-,_WOF9_^ 5^EE8G@_P5H7@#0X='\.Z7;Z3IL.2L%NN
M2>K,3RS'N223ZUMU\YFF/_M#$>U2LDK+T/5P>&^JTN2]WNPHHHKR3N"BBB@
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M-['&8Y)B<?W!7S/X:M#^V5^WG +A'N=/\7^+7N9H\D,-.61I&7U&VVC(_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOD@; 0I /(- 'Z<?!+Q7/X[^#/@+Q+=,6NM9T"PU&5CW>:WCD8_FQJ'X]_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG\0Z'I,_PSU6[6..$6R*"C$[>C>8@;:0'/&0/49 /UVHKB_@S\4M,^-7PO\
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MO_CE?JY10!^4?_#S#]J+_HB%G_X*+[_XY1_P\P_:B_Z(A9_^"B^_^.5^KE%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1\._^NNE?^@&OU8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M? %OA'K6JWFKS3Q:?JMI8SS)&)EV.T3(A653]X$'@DYK[S_X)J_LRZO^S5\
MY+;Q/;"S\5>(+TZG?6V06MDV*D4+$=U"DGT+D=J^LZ* "ORU_P""N?\ R7WX
M _\ 7=O_ $J@K]2J_+7_ (*Y_P#)??@#_P!=V_\ 2J"@#]2J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX7_Z&/2?_ V/_P"*H_X6#X7_ .ACTG_P-C_^*K\XO^''NA?]%7U'_P $\?\
M\=H_X<>Z%_T5?4?_  3Q_P#QV@#]'?\ A8/A?_H8])_\#8__ (JC_A8/A?\
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M-C_^*K\XO^''NA?]%7U'_P $\?\ \=H_X<>Z%_T5?4?_  3Q_P#QV@#]'?\
MA8/A?_H8])_\#8__ (JC_A8/A?\ Z&/2?_ V/_XJOSB_X<>Z%_T5?4?_  3Q
M_P#QVC_AQ[H7_15]1_\ !/'_ /': /T=_P"%@^%_^ACTG_P-C_\ BJ/^%@^%
M_P#H8])_\#8__BJ_.+_AQ[H7_15]1_\ !/'_ /':/^''NA?]%7U'_P $\?\
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M_P"%@^%_^ACTG_P-C_\ BJ/^%@^%_P#H8])_\#8__BJ_.+_AQ[H7_15]1_\
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M8])_\#8__BJ_.+_AQ[H7_15]1_\ !/'_ /':/^''NA?]%7U'_P $\?\ \=H
M_1W_ (6#X7_Z&/2?_ V/_P"*H_X6#X7_ .ACTG_P-C_^*K\XO^''NA?]%7U'
M_P $\?\ \=H_X<>Z%_T5?4?_  3Q_P#QV@#]'?\ A8/A?_H8])_\#8__ (JC
M_A8/A?\ Z&/2?_ V/_XJOSB_X<>Z%_T5?4?_  3Q_P#QVC_AQ[H7_15]1_\
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M_P#)??@#_P!=V_\ 2J"@#]2J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1?\ !'3X9Z-=M)JWQBN]*>=C(JWD%O%G)[;I!FL?_ATK\&?^B])_WU9__':
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\M_:>^*.L_!;X$>+O&GA[3[?5-9TBV$UM:74;O'(Q=5PRH0QX)
MZ$5ZE4<T$=S$T<L:RQMP4=00?P- 'X6_M$?M_?$_]IKX<W'@[Q;\,-!2R>19
MX;NRL+U+BVE7H\9:9AGJ.000:ZGX>?\ !5;]H7P)X3T[0KKPGH_B5;"!+>._
MU32[L7+HHPN]HY55C@ 9V@G&3D\U^KOQT^)_@3]GKX;ZEXT\5VMM%IMF JQ0
MVR-+<2'[L: XRQ/X>M?G[X#_ ."JFN?%3XW>#O#&C_"OP]H?AG7-8AT\W.H+
M)<W)C>0*65E\M V#TPP!]: .B_96_P""EOQ?^.'Q[\)^"?$?@30=)T75II([
MB\M+&\CEC"Q.X*L\S*.5 Y!ZU^F%?(?P#_;G\%?%3]HKQE\)Y_#UOH.O:+JE
M[9Z5?Q[6CU*."1D)'R@H^%)QR"._:OKR@ HHHH **Y#XJ?%GPI\%/!MWXI\9
M:Q!HNBVV T\QR78]$11RS'L!S7SMX"_X*D_ /Q_XLM= @\07FEW%W*(8+G5+
M)X('8G !<\+D\?-B@#ZXHK#\9^-]"^'OA34/$OB+4[?2M"L(3/<7MPX$:)VY
M[Y)  '4D8KY>\*?\%4?@!XL\6V^@Q>(+ZP:XE$,5[?6$D5LS'@9<_=!]3B@#
MZ]HK(\1>+='\)>&;WQ%J^HV]AHEG ;J>^F<")(@,[MWI_/-?*NC?\%6/V?=9
M\5Q:(OB&_M5EF$*:A<Z?(EL23@$MCA?<C% 'V#14-I=P7]K#<VTJ3V\R"2.6
M-MRNI&001U!%34 ?E/\ M"?\IB/AW_UUTK_T U^K%?E/^T)_RF(^'?\ UUTK
M_P! -?JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:\5_86^!L'B#_@GOI/@?Q,+NSL?%-E>-<_9F$<ZPW+L05+*0#M/&0?I7,?\
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M4]%% 'Y3_M"?\IB/AW_UUTK_ - -?JQ7Y3_M"?\ *8CX=_\ 772O_0#7ZL4
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M+_9Z\0^)-9LWMSXNU$26\,R8\RTBCV(^#V9GEQZ@ ]Z^K_%/[,'PC\;^*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH^Y(3DEL=0.F<&OO"@ HHHH **** "BBB@ HHHH **** /RG_:$_Y3$?#O\
MZZZ5_P"@&OU8K\I_VA/^4Q'P[_ZZZ5_Z :_5B@ HHHH **** "BBB@ HHHH
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M)\%O@W\)?%^A?M$:8VJ^&-+6.-(Y@#X@; 'FJH+BX!0*OS@@_>)!/&A\$O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>/_ +6WQIN_V?OV?_%GC?3K:.[U+3X MI'*"8_-
M=@JE@.H!.<>U>P5ROQ1^&NA_&#P#K7@_Q);&ZT;5K<V\Z*=K =0RGL00"#[4
M ?FG8>$?V\/$7@.W^)D'Q4TR'3;G3AK,5D+NW51 R>:%V^28_N^K?CWKVCX,
M?#[P'_P4N_9KTKQ=\3O"MI!XVAEFTNYU[24%O<F2$@!U<?>4JRG8VX [L8KS
MJ;_@B]:K?M96WQ:U>+PNS[C8FV&_'TW;"??%?>WP-^"WAS]GWX9:1X'\+0O%
MI6G*Q\R9MTL\C$L\CGNS$GZ< <"@#XT^'7[-_P"TA^R!\0/#>F^!/%Y^(GPA
MGU*WMKS2=2.9M.M7E59'1&/R[5)/[LX_V3UK]"*** "BBB@ HHHH **** "B
MBB@ HHHH _*?]H3_ )3$?#O_ *ZZ5_Z :_5BORG_ &A/^4Q'P[_ZZZ5_Z :_
M5B@ HHHH **** "BBB@ HHHH **** *.MZYIWAG1[S5M7O[;2]+LHFGN;V\E
M6*&&-1EG=V("@#J2:\N_X;"^!O\ T5WP7_X/+?\ ^+KL_BM\,=#^,WP[UWP5
MXDCEET36;?[/<K!)Y<@&X,"K=B&4$?2OCC_AS5\$O^@EXG_\#4_^(H ^E/\
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M / U/_B*/^'-7P2_Z"?B?_P-3_XB@#Z5_P"&PO@;_P!%=\%_^#RW_P#BZ/\
MAL+X&_\ 17?!?_@\M_\ XNOFK_AS5\$O^@GXG_\  U/_ (BC_AS5\$O^@GXG
M_P# U/\ XB@#Z5_X;"^!O_17?!?_ (/+?_XNC_AL+X&_]%=\%_\ @\M__BZ^
M:O\ AS5\$O\ H)^)_P#P-3_XBC_AS5\$O^@GXG_\#4_^(H ^E?\ AL+X&_\
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M/^'-7P2_Z"?B?_P-3_XB@#Z5_P"&PO@;_P!%=\%_^#RW_P#BZ/\ AL+X&_\
M17?!?_@\M_\ XNOFK_AS5\$O^@GXG_\  U/_ (BC_AS5\$O^@GXG_P# U/\
MXB@#Z5_X;"^!O_17?!?_ (/+?_XNC_AL+X&_]%=\%_\ @\M__BZ^:O\ AS5\
M$O\ H)^)_P#P-3_XBC_AS5\$O^@GXG_\#4_^(H ^E?\ AL+X&_\ 17?!?_@\
MM_\ XNC_ (;"^!O_ $5WP7_X/+?_ .+KYJ_X<U?!+_H)^)__  -3_P"(H_X<
MU?!+_H)^)_\ P-3_ .(H ^E?^&PO@;_T5WP7_P"#RW_^+H_X;"^!O_17?!?_
M (/+?_XNOFK_ (<U?!+_ *"?B?\ \#4_^(H_X<U?!+_H)^)__ U/_B* /I7_
M (;"^!O_ $5WP7_X/+?_ .+H_P"&PO@;_P!%=\%_^#RW_P#BZ^:O^'-7P2_Z
M"?B?_P #4_\ B*/^'-7P2_Z"?B?_ ,#4_P#B* /I7_AL+X&_]%=\%_\ @\M_
M_BZ/^&PO@;_T5WP7_P"#RW_^+KYJ_P"'-7P2_P"@GXG_ / U/_B*/^'-7P2_
MZ"?B?_P-3_XB@#Z5_P"&PO@;_P!%=\%_^#RW_P#BZU_"?[27PH\=ZY;Z+X<^
M(_A;7-7N,^38V&K02S28&3M16)/'I7RG_P .:O@E_P!!/Q/_ .!J?_$5V?P>
M_P""77PA^#'Q%T;QGI4^NWNJZ3+Y]JEY>*8EDP0&("C.,GC- 'V#1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G^(=;M_#>A:AJM
MV2+:R@>XDQU(522![\5H5F>)M"@\3^'M2TBY)6"^MWMW9>H#*1D?3-3*]GR[
MC5KJ^Q^?7B[]L'XBZ[KLUWINK?V)8[SY-G;0HP5<\;BRDDXZ_P J^JOV7?CK
M=?&3PW>Q:O'&FMZ:RK,\0VK,C?=?'8\8-?('C']EOXB>%M?DL(/#MWK-LSD0
M7NGQ^;'(N>"2/N>^[']:^M?V4/@;J/PB\.7]WKH2/6M392]NC!A B]%)'!.3
MSCBOEL \8\3^]O;K?;^O0]_%K#>P]RU^ECWBBBBOJSY\**** "BBB@ HHHH
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MX_\  /\ P4I\$?$O2?B=JN@>'->N]+\&6'VV&X%LQ_M/J-J!0=A+;?O<X))
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M:LUT>C"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZZ5_Z :_5BORG_:$_P"4Q'P[_P"NNE?^@&OU8H **** "BBB@ HHHH ****
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M ?B/IFB6_A/0U2/1=0TZWCCEO&8DD[HP ZA>I==^3R37V/110 4444 %%%%
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M9-"L=9L9+>4F2-Y7!# %D\S!X_O-S0!X5^R'XO\ BO\ L8?M<:3\ ?B#JO\
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M]._X*1?#*'XUECXX&HV1E+SP3'R<'R_FA9DZ>^:_<6@ HHHH **** "BBB@
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M ((M?$:\UWX'^-/"U]<-+;>'-5CGMFD;_50W$9)0>@#PR-_P,T ?HK7Y:_\
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M/[3_ ."D/_0 3_P(TK_X_7ZHT4 ?E=_:?_!2'_H )_X$:5_\?H_M/_@I#_T
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M8SZJ?2O3O''_  2)^!GC/QK/K\4GB/P];W,OG3Z/I-[$EFS$Y(4/$SH">P;
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M** "BBB@ KC/C3_R1WQU_P!@*^_])WKLZXSXT_\ )'?'7_8"OO\ TG>@"O\
M ?\ Y(A\/_\ L 6'_I.E=W7FWPDUNR\-?L[>#=6U&9;:PLO#-G<3RMT1%MD+
M'\A7QKXM_P""HNNKXEE'AKPEIAT&.0A#J3R&XF4'[V48*A/IAL5Q8G&4<);V
MKM<^IR/AG,^(G/\ L^GS*&[;26NRN^I^B=%>7_L\_'G2?V@_ :>(-.@:QN8I
M/(O+%VW&"7&<9[@CD&O4*Z:=2-6*G!W3/!Q>$KX"O/"XF/+.#LT^C"BBBM#D
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRG]J7XLZE\"_@+XM\
M=:1:VU]J&BVZ7$=M=AO*D_>*I5MI!Z$\BO5JS]?T#3?%.C7FDZQ8P:GIEY&8
MKBTNHP\<J'JK*>"* /E?]G?]LSX*_MI6%A8ZKIFG6'C*!/F\.^(8HIF5R!N-
MM(PQ*F>X"MQRHXKZVCC2&-8XU"(@"JJC  '0"OR;_;V_X)X> /@YHMU\2O '
MC*U\ 7$#&<>']2NBJ3N.<6;CYT?.<(<KR,% ,5Y#\'/^"N?QB^&7A6/0]7L]
M+\=K!Q!?:QYBW2+_ '6=&&\>[#/OC% '[B45^9_[*W_!53QO\?OCWX3\!:IX
M*T'2[#6)I(Y;NTDG,L86)W!4,Q'50.?6OTPH **** "BBB@ HHHH **** "B
MBB@#\I_VA/\ E,1\._\ KKI7_H!K]6*_*?\ :$_Y3$?#O_KKI7_H!K]6* "B
MBB@ HHHH **** "BBB@ HHHH \^^,'P"\ _'K3+*P\=^&[3Q!;V4AEMOM (:
M)B,':P((SWKRG_AV_P#L[_\ 1.+'_O[+_P#%5]+T4 ?-'_#M_P#9W_Z)Q8_]
M_9?_ (JC_AV_^SO_ -$XL?\ O[+_ /%5]+T4 ?-'_#M_]G?_ *)Q8_\ ?V7_
M .*H_P"';_[._P#T3BQ_[^R__%5]+T4 ?-'_  [?_9W_ .B<6/\ W]E_^*H_
MX=O_ +.__1.+'_O[+_\ %5]+T4 ?-'_#M_\ 9W_Z)Q8_]_9?_BJ/^';_ .SO
M_P!$XL?^_LO_ ,57TO10!\T?\.W_ -G?_HG%C_W]E_\ BJ/^';_[._\ T3BQ
M_P"_LO\ \57TO10!\T?\.W_V=_\ HG%C_P!_9?\ XJC_ (=O_L[_ /1.+'_O
M[+_\57TO10!\T?\ #M_]G?\ Z)Q8_P#?V7_XJC_AV_\ L[_]$XL?^_LO_P 5
M7TO10!\T?\.W_P!G?_HG%C_W]E_^*H_X=O\ [.__ $3BQ_[^R_\ Q5?2]% '
MS1_P[?\ V=_^B<6/_?V7_P"*H_X=O_L[_P#1.+'_ +^R_P#Q5?2]% 'F?P=_
M9N^&_P  _M[>!/"UGH$M^%%S+ "7E"] 6))P/2O3*** "BBB@ HHHH ****
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M5NUQWQ?^%6A_&[X<:YX)\1BX_L;5X/(G:TE\N51D$,K8(!! /((]0: /+?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4#  ' %8V@>-?#WBJ2>/1->TS6)(#B9+"\CG,?\ O!"<?C6U0 4444 %%%%
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MM7TF5VG2%3_R\0H3\LBG!.W&X @YX(_2V3_@KC^SQ)$ZMJ6NLI!4J=);D?\
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M)'!KB;O]LKX;V7PGU_XC27.I_P#"-:)JSZ+=N-.D\T7*RB(@)U*[B.>/SXH
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M8_%P?#;S;S_A)SHIU[R_LC^5]E#A,[\8W98<?UXKDG_;!^'2?"2;XD&YU/\
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M=MSYG3=GM7"M^V=\-5^$$'Q+-SJG_"+S:N-$23^S9/.^TE]F/+QG;D=?Z\4
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MSP:_4>+]F6\@B2./XN?$&.- %5%U&$!0.@ \F@#V^BO$O^&:K_\ Z*]\0_\
MP90__&:[OX;_  [G^'MM?13^+-?\5&Y=6#Z[<),T. 1A-J+@'/.<]!0!V5%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ9ZU>?P%\03J'Q(F7X@JMMKEMY?AR'^SE/\ 84GDE?,)W?OOGP^#CIBO3Z*
M/)4^'/Q*$?PP!^)2EM!<MXF/]F+_ ,3]=@  ^;]USGIGKGJ*D/P]^(WV?XF)
M_P +&7S-=8'PT_\ 9J_\2$;",'YOWWS$'G'W?>O5J* /,&\!?$$WOPVD'Q!
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M><KSD]*]@HH \Q;P'\0#XG^(=Z/B"JZ5K5FD/A^P_LY3_8DPBVM*6W?O<O\
M-@X]*HVGPX^)<.B_#2VF^):RWVA3*_B2Z_LQ1_;L84@H!N_=<XY&?7K7KE%
M'F#^ OB";WXD2K\0E6#7+?R_#D7]G*?["D\DKO)W?OOGP^#CIBJB_#KXD@?#
M#/Q)4G06)\3?\2Q?^)^"@  ^;]U@Y/&>N>HKUJB@#RD_#SXCFT^)D8^(Z^=K
MK[O#4G]FK_Q(5V$8/S?OOF(/..GO4[> OB =0^&\H^((%MH<3IXCA_LY?^)Z
MYC55;.[]SA@S8&?O>U>GUX'^T3^V-X0_9[O8M)N[>XU[Q%+&)?[-LV5?*0]&
MD<\+GL,$^V*QJU84(\]1V1Z67Y=B\UQ"PN"IN<WT7Y]DO-Z&W-\-/B>^A?$V
MU3XGJM_KUVTWAJ[_ ++7_B0PGI$1N_>^F3CIGJ:V%\#>/!XG\ 7I\>AM*T>P
M:WU^P_L]1_;5P8@HFW;OW7S@OM&>N*X;]GC]L[PC^T#J+Z/!:7/A_P 0JAD6
MPO'5UF4=3'(,;L=P0#]:^@J*5:G7CSTW=!F.6XS*<0\+CJ;A-='^:Z->:/';
MOX:?%";P;\0M.A^*"Q:WK-^UQX?U3^RU/]BVY92(2F[]Y\H9=QQUS6T? _CO
M_A/O!6J_\)X#X=TK3)+76M&_L]?^)M<E,+/OW?N\-\VT ],=S7I%%;'FGC4G
MPQ^*;?#GQ?HZ_%-5\3:EJDEUI&N?V4F-,M2R%;?R]V'P%<;LC[WM72R>#O&C
M?$OPWK2^-0OA:QTI[34M!^PKF^NC]VX\W.4Q_=P>GO7H%% 'B#_"GXMGX6^(
M-#'Q;4>+;S6'O+#Q#_8Z8L[,N"MMY6[#84$;LCK7:OX3\8-\5[/7E\8 >$(M
M+:UF\.?8ES+=%@1<>;G(P,C;CO7=44 >)3_"KXLO\*KK0D^+2IXNDUC[9%XB
M_LA,1V?G;OLWE;L?<^7=FNM_X0[QI_PMB;7O^$U'_"(-HWV)/#GV%<K>[@?M
M7FY] 1MQWZ\5Z!10!XNOPN^*H^%MAH9^*JGQ9#JXO)_$/]DKB:S\XO\ 9O*W
M8'R$+NSVZ5U/_"'>-/\ A:.I:Y_PFH_X12?1UL[;P_\ 85S;W@))N?,S\V>/
MEQ^-=_10!XG9?"SXL0_#/PQHLWQ867Q38:LMYJ>O?V2F+^T$I8VWE[OE^0A=
MV3TZ5UL7@_QHGQ'\1ZPWC0-X9OM-2VT[0_L*YL;D9W3^9GY\Y'RD#I7?T4 >
M*Q_"WXK+\/\ P1I+?%96\1:5JD=WK6L_V2N-5M06+6_E[OW>05&[)Z5T<?@C
MQTOC;QMJ;>.P="U6PCM]%TG^SU_XE-PJD--OS^\R2#MP*]'HH \@B^&WQ.3P
MA\/]/?XG*VM:->I/K^I_V6O_ !.8 &S$$W?N\Y7G)Z5HOX"^(#>)?B'>K\00
MNEZU9I#X>L?[.4_V),(MK2[MW[W+_-@X]*].HH \CM/AQ\2X='^&EO-\2UEO
M="F5_$ES_9BC^W4"D% -W[KGN,^O6KK> OB";SXDR#XA*L.N0>7X;C_LY3_8
M4GDE=Y.[]]\^'P<=,5Z?10!Y,OPZ^)(_X5CGXDJ?[!9CXF_XEB_\3\%  !\W
M[K!!/&>N>U.;X>?$<V7Q,C'Q(43Z[)N\-2_V8O\ Q(5V$8(W?OOF(/..GO7J
M]% 'F+> _B =2^'$P^((%KH<+IXC@_LY?^)ZYC558'=^ZPP9L#/WO:LR?X:?
M$]] ^)EHGQ/5=1UV\:;PU>?V6O\ Q(83TB*[OWN.F3CUZFO8:* /-E\#^/!X
MI\ WQ\>AM)T>P:WU[3_[/4?VU<&(*)MV[]U\X+[1GTK&N_AG\4)O!?Q!TV'X
MH+%KFLW[7&@:I_9:G^QK<LI$)3=^\^4,N[C[V:]BHH \W/@CQW_PL#P7JW_"
M>#_A'-+TR2UUG1O[/7_B:W13"W'F;OW>&^;: >F.YK!D^&'Q3;X;^+M&7XIJ
MOB?4M4>ZTG7?[)3&FVI9"MOY>[#X"N-V1][VKV:B@#@)/!WC1OB7X<UI?&@7
MPM9:4]IJ.@_85S?79/%QYN<IC^[@]/>N.?X4_%P_"S7M"'Q<4>+;S6'O+'Q#
M_8Z8L[,R K;>5NPV%!&[(ZU[A10!PK^$_%[?%>UUY?& 'A"/2FM)?#GV)<R7
M18$7'FYR, $;<=ZD^$GA7Q9X0\-W-GXR\6#QEJCWL\\=^+,6VR!FS'%M!.=H
MXS7;44 %%%% !1110 4444 %%%% !1110 4444 %>+?MG>.+_P"''[+?Q(U_
M2IFMM1MM)D2"9#AHV<B/<#V(#$@^M>TU\X_\%$_^3,?B?_V#U_\ 1R4 ?$'_
M  2]_8;^'OQI^&^I?$CXAZ7_ ,)*SZG)8V.G3RNL""-4+2.%(+DL^,$X^4\'
M-?=_B']@?]GWQ+IILKGX5:!;QXP)+" VLH]]\14G\2:_)K]E[_@I1XM_9;^%
M<7@;1_"6E:Q91WDUX+F\FD60M(1D87C Q7K?_#[/XA?]$^\/_P#@3-0!+^S;
MX-D_9)_X*EWGPST&_N)_#NH>9:*L[99[>2V%S$'Q@,R'Y<XYP3WK]@Z_#W]F
MKXZ:E^TC_P %,?!7C[5M-M])OM1G*/:VK,T:>78O&,%N>0N:_<*@ HHHH **
M** "BBB@ HHHH **** /RG_:$_Y3$?#O_KKI7_H!K]6*_*?]H3_E,1\._P#K
MKI7_ * :_5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *^#O\ @IM\4M=T5/#?@O3[F:RTO4K>2[OC$Q7[1A@JQDCJHY)'
M?(K[QKQ?]IK]F;1_VCO#-K:W-T=,UG3RS6.H*F[9NQN1AW4X'Y"N#'TJE;#R
MA2W9]CPAF&"RO.J&+S!7IQ;Z7L[-*5O)Z_BM3\D/AY\0=;^&'BW3_$7A^]EL
MM0M) P,;$+(N?F1QW4C@@U^Y.A:B=7T/3K]HS$UU;QSF-NJ[E#8_6O@GP%_P
M3WT#P/XVL[GQ_P"/M'N;.V99QI:LMNT^#\N_>V=AQS@<U]Q)\0/"<:*B^)=&
M55& !?Q<#_OJO-RC"U\-&7M=$]D?;>).?Y3GE;#_ -G/GE!/FE9K1VLM4F[:
MOROZG14F1G'>O$_VC_C[I_PZ^#GB'6O#FMZ9>:XD0BM%ANHY61W(7?M!.=H)
M/X"OR'U#Q=K>J^('UV\U>^N=::43'4)+AS/O'1M^<@C QSQBM\=F<<%-0Y;M
M_(\GA+@2OQ3AZF*]NJ4(OE7N\S;LGM=66JUU]#]Y:*^8_P!BW]H<?$'X.0MX
MQUZS36M-N&LVN+ZZ2.2XC !1VW$9.#@GOC/6O>_^%A^%?^AFT?\ \#XO_BJ]
M2C5C7IQJ1V9\#F>7U<JQM7 U[<U-M.VWJO4_&7X_>$-8\$?&/Q;INN12I>G4
M9[@2R _OXY)&99 >X8'/YCM7OG_!-3PAK&H?&B]\0V\4J:-I^GRP7-Q@A&>0
MKLCSW/&['^R*^_/%&@?"_P"+<]M::W#X:\3W2Y6!)9(9IAW(0@[@.,D"NO\
M#?A;1_!VEQZ;H6EV>CZ?&<K;6,"Q1@]SA0!D^M>!1R=TL2JW-[J=_,_8LS\2
MXX_(Y9:L/:K./))W7+:UFTM]>BZ=W8U****^E/PH**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP1GL%K]DJ "BBB@ HHHH **** "BBB@ HHHH _*?]H3_ )3$?#O_ *ZZ5_Z
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M.?@36FG0MM/]UAMRK>S 'VIJI!RY%)7[=298'%0H+%2I25-[2Y7ROT=K&/\
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MV?M6?!3XM?L%_&V#XR:)XN;5[;7]6FN9-1A5HBTSN97M[F/)#(P)P>AQV(%
M'[&?#KP;;_#GX?\ AGPI:SR75KH6F6VF13R@!Y$AB6-68#C)"@UT5<I\*/']
MK\5?ACX4\96<9AMM>TNVU)(B<F/S8U<H?=22/PKJZ "BBB@ HHHH **** "B
MBB@ K\M?^"N?_)??@#_UW;_TJ@K]2J_+7_@KG_R7WX _]=V_]*H* /U*HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG>SB[IVW6J3NKKH>*_M8?"A_&_P&\4:;X<TFW;5Q$L\45O HDE",&9%P,DD
MX'<X%?CQ)!+#,T,D;I*IVF-E(8'TQ7[[US%Y\+_!^H:R=6N?"VCW&IE_,-W+
M8QM(6_O%B,D^_6N',,L^N352,K-:'U?!O':X7PU3"5:'M(R?,K.S3LDT]'IH
MO3S/G[]@/X47/A?X%QW/B/28TGU:[>]MH;N &18"JA6(89&[!(]L'O7TK_PB
M^C?] FQ_\!D_PK3Z45ZU"DJ%*-)=#\ZS;,9YMCZV/J*SJ2;LNGD?AS\;-3U#
M5_BYXON-4C\F]_M2XC>';M$061E5 .P  'X5]!?\$U=?UBS^.5WI5H\C:3>:
M;+)>1 G8"A78Y]\G'_ J^N?C?^PWX#^-?B5_$$T][H&KSG-S/IQ3;<'&,LK
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MV-PZ'*M*D2B0CVW;L>U=_110 4444 %%%% !1110 4444 %?EK_P5S_Y+[\
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MZ#VF?^!D?_Q5 &U16+_PFOAW_H/:9_X&1_\ Q5'_  FOAW_H/:9_X&1__%4
M;5%8O_":^'?^@]IG_@9'_P#%4?\ ":^'?^@]IG_@9'_\50!M45B_\)KX=_Z#
MVF?^!D?_ ,51_P )KX=_Z#VF?^!D?_Q5 &U16+_PFOAW_H/:9_X&1_\ Q5'_
M  FWAW_H/:9_X&1__%4 ;5%8O_":^'?^@]IG_@9'_P#%4?\ ":^'?^@]IG_@
M9'_\50!M45B_\)KX=_Z#VF?^!D?_ ,51_P )KX=_Z#VF?^!D?_Q5 &U16+_P
MFOAW_H/:9_X&1_\ Q5'_  FOAW_H/:9_X&1__%4 ;5%8O_":^'?^@]IG_@9'
M_P#%4?\ ":^'?^@]IG_@9'_\50!M45B_\)KX=_Z#VF?^!D?_ ,51_P )KX=_
MZ#VF?^!D?_Q5 &U16+_PFOAW_H/:9_X&1_\ Q5'_  FOAW_H/:9_X&1__%4
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M[3/_  ,C_P#BJ -JBL7_ (37P[_T'M,_\#(__BJ/^$U\._\ 0>TS_P #(_\
MXJ@#:HK%_P"$U\._]![3/_ R/_XJC_A-?#O_ $'M,_\  R/_ .*H VJ*Q?\
MA-?#O_0>TS_P,C_^*H_X37P[_P!![3/_  ,C_P#BJ -JBL7_ (37P[_T'M,_
M\#(__BJN:=KFFZP9!8:A:WICP7%M,LFW/3."<=#0!>HHHH **** "BBB@ K#
M\<W][I7@K7[W34,FH6VGSS6Z@9)D6-BO'U K<K/\0/=QZ#J3:>NZ_6VD-N,
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MG+X:_M ^++W68_ 'QJT#PE=<236#Z,A=HQP&#-%(2 3TW'!-3_&'X<W?PO\
M'VJZ)/;2P6D<[M9.Y9A);DGRR&8DM\N 223D'-=W^RW\";/XP>)[J3Q'IMQ=
M^%;2%O-,=S-;"28XV*)(G1N.20#V&:^0H8BH\?K!7;MML?25:,%A/B>B[G9?
M\,\?MJ?]'(:'_P"":+_Y&H_X9X_;4_Z.0T/_ ,$T7_R-7M__  P_\&?^A8O_
M /PHM3_^2:\:_:%^%?P,^"5M:6D/@V^U/7KQ#)%;-XEU-4CC!QO<_:,X)R !
MUP:^LJU848.=1V2/GJ=.562A!795_P"&>/VU/^CD-#_\$T7_ ,C4?\,\?MJ?
M]'(:'_X)HO\ Y&KJ/@=^V1%=ZKI7A;7-&@TRP;9:6ES;3.XBZ*BOO)8]AN))
M]:^O>M9T,32Q,>:D[EUJ$Z#Y9H^&O^&>/VU/^CD-#_\ !-%_\C5]??#'2/$N
M@> -#T_QAK,7B'Q/;VP34-4AC$:7,N3EPH50!TXP*ZBBNDP"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /SK_X+7^'KF^^ W@G6(HV>WT_Q#Y4Q49""6WDVD^V8\?4BJW[2'Q'
MT6[_ ."1>E/%?0/)JNF:3IUM&)!N>9+F%G4#U58G)';%?=WQ9^%7ASXV?#[6
M/!GBNR%_H>J1>7-&#M92"&5T;^%E8 @]B*^#M*_X(O\ AZ'Q';)JOQ5U[5?!
M-M.9X?#WV-8Y!GL9O,*C/0E8@3[4 =W^PO\ !F?QU_P3=@\$WEY)HW_"4VFH
MHMX(O,:&.>1PL@7(W<'.,CZUY+_PY#LO^BSZA_X(5_\ DFOTL\,^&]-\'>'M
M.T/1[1+'2]/@2VMK:,?+'&HP *TZ /R[?_@A[8M(KCXR7NX'ECX?4G\#]IJ7
M_AR'9?\ 19]0_P#!"O\ \DU^G]% 'Y@?\.0[+_HL^H?^"%?_ ))H_P"'(=E_
MT6?4/_!"O_R37Z?T4 ?F!_PY#LO^BSZA_P""%?\ Y)H_X<AV7_19]0_\$*__
M "37Z?T4 ?F!_P .0[+_ *+/J'_@A7_Y)H_X<AV7_19]0_\ !"O_ ,DU^G]%
M 'Y@?\.0[+_HL^H?^"%?_DFC_AR'9?\ 19]0_P#!"O\ \DU^G]% 'Y@?\.0[
M+_HL^H?^"%?_ ))H_P"'(=E_T6?4/_!"O_R37Z?T4 ?F!_PY#LO^BSZA_P""
M%?\ Y)KY1_9-_8AC_:7^+GQ%\%S>-[KP^GA.5XUO8['[0;G$[Q9*&5=OW,]3
MUK][#TK\Q/\ @E[X<U;1_P!J?X^W-_I=[8V\]Q*8I;FW>-)/],F/RD@ \'/%
M #/^'(=E_P!%GU#_ ,$*_P#R31_PY#LO^BSZA_X(5_\ DFOT_HH _,#_ (<A
MV7_19]0_\$*__)-'_#D.R_Z+/J'_ ((5_P#DFOT_HH _,#_AR'9?]%GU#_P0
MK_\ )-'_  Y#LO\ HL^H?^"%?_DFOT_HH _,#_AR'9?]%GU#_P $*_\ R31_
MPY#LO^BSZA_X(5_^2:_3^B@#\P/^'(=E_P!%GU#_ ,$*_P#R31_PY#LO^BSZ
MA_X(5_\ DFOT_HH _,#_ (<AV7_19]0_\$*__)-'_#D.R_Z+/J'_ ((5_P#D
MFOT_HH _/&7_ ()A^)?"WA^PL="\>6/B.6 >6SZK9O9$(/NX*-+N(Z<@5!X@
M_P""3^I>/_#UI;:S\3DT*X#>9-;Z9I1N8R>V)&EC)_[Y%?HK17L3S;%U,/\
M5I2]W;SMVN<,<%0A5]JEJ?F!_P .0[+_ *+/J'_@A7_Y)H_X<AV7_19]0_\
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M+_HL^H?^"%?_ ))K]/Z*Y*E6=:3G4DVWU9M"$::Y8JR/S _X<AV7_19]0_\
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M2:_3^B@#\P/^'(=E_P!%GU#_ ,$*_P#R31_PY#LO^BSZA_X(5_\ DFOT_HH
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M1%C4*H"J!@ #  KV<SSQ8_#JA&%K[Z_D<&$R[ZM5]HY7['Y;_P##:O[;?_1
MM0_\)F]H_P"&U?VV_P#H@6H?^$S>U^I5%?)GM'Y:_P##:O[;?_1 M0_\)F]H
M_P"&U?VV_P#H@6H?^$S>U^I5% 'Y:_\ #:O[;?\ T0+4/_"9O:/^&U?VV_\
MH@6H?^$S>U^I5% 'Y:_\-J_MM_\ 1 M0_P#"9O:/^&U?VV_^B!:A_P"$S>U^
MI5% 'Y:_\-J_MM_]$"U#_P )F]H_X;5_;;_Z(%J'_A,WM?J510!^6O\ PVK^
MVW_T0+4/_"9O:RO%/[?O[8?@O0+S6M>^"\FB:1:)ON+^_P##UW%#"N<99F(
M'/>OU?KYR_X*'_\ )FGQ/_[!O_M1: /B3P3_ ,%#?VNOB)X?AUSPO\'_ /A(
M]'F9TCU#3- NYX'9258!U)!(((//:M[_ (;5_;;_ .B!:A_X3-[7T/\ \$F_
M^3*/"O\ U_ZC_P"E3U]AT ?EK_PVK^VW_P!$"U#_ ,)F]H_X;5_;;_Z(%J'_
M (3-[7ZE44 ?EK_PVK^VW_T0+4/_  F;VC_AM7]MO_H@6H?^$S>U^I5% 'Y:
M_P##:O[;?_1 M0_\)F]H_P"&U?VV_P#H@6H?^$S>U^I5% 'Y:_\ #:O[;?\
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M,'P[N?!%E96\$FGS3Z5/9BXD9G#J#)PV %.!TS7UI10 4444 %%%% !1110
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M "FE%+;BH+>N.:=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2
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M,C:>E_PS_P $MOCD=/C\ ZY\;&M_A0)LS:9I]S<,)(MV["V[ (">O)(!YYH
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M01GD!LG;GH:]< V@#TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBO@O\
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M.?#/VB?V</'7_!.WXLI\:O@R\]QX#DEQJ.FY9UM8W;+03K_% 3]U_P"$@="
M:Z[]H?PAIO\ P4J^%/A_XO\ P=NS!\3?"D(M-0T$3^5=HF3(L8;(P5<NT;C
M;<PSD8 !Y3X:^'7C#X _M7+X?^"7QCN?$6GZ)$+GQ=J^L KI6G(K?O8[D[RD
M@QG@$,#P"",U^L_PC^+WA?XW^#D\3^$-275M':XEM1=(A0,\;;6P#S@]1[$5
M^1OPB\=?%_3/@5K7[//A/]GR^L/%.O&6UUCQ%>VDZ-+YA(::=I$P"%. 2VT
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ME)HF7:RM[$$BO&/V@/VB/A]^Q1\(K![R)(8;.U2PT+P[:/B698T"I&N<D(H
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M 'KO@4^!_P#@KCH/B8^-='U?PE/X,U40Z:VD:B0XMYDX\Q75HV<M$^3LR 0
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M%C.5#8Y /IFN+^,_QJ\(_ +P'?>+O&>J)INDVHPH'S37$A^[%$G5W/8?4D@
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M^R5X"_:7\#7&AZ[I5M9ZBD173]9M8%6XLWQ\I4C&5]4/!KX=_P""87C+Q?\
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MLN^,OVA/BK;_ +27QU,D]W)*MYX>T.="J)MYAEV'[L:<%%[D!CGO^E%(JA5
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M 4 /GGCMH))I7$<4:EW8]  ,DU\.ZC_P5]^#.D?$'5/#US::VVF64[0+K=O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'DDDGK5#X/?"/PW\#/AWI'@OPI9"RT;38RJ G+RN3EY';^)V8DD^_H *[.@
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MS@ #*^&W[-6J?\% ?CHGC"+X:Q?"SX6M?2:AJ5U$)#/J3R2&27;*_+,Y) V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$MXWNIWFE954 %Y')9FXY)))K,^'7P[\/?"CP7I?A3PMIL.DZ'IL0BM[:$8
M[EB>[$DDD\DDFNDH **** "BBB@ HHHH *0D $DX I:^-_\ @J%XW^+7@CX
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MFNXKG3+MK6$SS._D>9Y14@!L,?NY+8)%?)?[,ND^$-._:H;PE^U19ZG=7MK
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M,!V;@\  >YS7NE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7>H:+IX*F2;.=L1Z+$_.Y#^'7@ ^T;:VCL[:*"%!'#$@1$48"J!@#\JEHHH
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MY.32T %?+/[;W[7&N_L\V_AKPQX"\-'Q;\1_%#2?V=8&-Y4BB3&^1D0AF.2
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M\C'UA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_!S5O^"F?Q/^*VL^,_B5?>']9T.X5-*T>!?,6!&:0*WEEAB--BJ=O)+<D<9
M/V51UD0,C!E(R&!R"*^6_P!O#]B?3?VMO!$,]G,-.\<Z-$_]E7CL?*D!Y,$@
MZ;6(^]U!]J^)_A-^TM\7/^"=OQBB^&7QF>ZU_P !3R!8+Z1FF\N$G"W-K(W+
M(/XHSTY'!%?K?H6N6'B;1K+5M*NXK[3;V%9[>YA;<DD;#*L#Z$&@#\QOV!_V
MR[WX4ZL/V<OCC9G1I]/<Z;I=YJ*X6+L+2?/!0YPC],$ \8(]PT'_ ()L:1X%
M_:NTWXJ^!?%%QX6\-#?<W6@V60S3$_ZN-NGD/DDJ>1C X/R^N_M"?L4_#/\
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M4*HR>3P*K^!_ ^A?#?PMI_ASPUID&D:+81B*WM+==JH/ZD]23R:W: "BBB@
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MW_"OB'XQ^%/BY=^'VLM3EM--\+Z?J<UI$#&JOL"QL$!PZC+@ENYQ7LO[%?\
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M^Z&W(=3D$XQTS7W"JA1@  >@I:* "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH ***\A_:Y^*6K_!;]FWQ]XTT"(2ZSI>GEK0LNX1R.ZQB0CN$W[\?[-
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ME99%/_+;G:=O&!WSQ]8444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>&=&LM"TN+E+2PA6*,'UP._O6Y0 4444 %%%% !1110 4444 %%%% !1110
M5%=7,5E;37$SB.&)#([GHJ@9)_*I:I:UI46N:-?:;/GR+R"2WDQUVNI4_H:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7P!^.&KQ_$KP;XP @@FOA]HBE27<(Y4WC(^=2C(W0\@D $@%;]N3]H?]G_\
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MB\^%'A"?Q K)K<FE6S7BO]X2F-=V??/6NPHZ44 %%%% !1110 4444 %%%%
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M (I?'^Q^.W[1,T%KJ^D0B+1="@"+Y9 8*S(F0BKN8@$EBQR>E?H+10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7YG?\ !:+PCK-QHWPO\3Z5
M;S3?8]0EL]\"%F29]K1<#N2IQ[BOTQJIJ.DV.L1Q1WUI!>1PRI/&L\8<)(IR
MK@'H0>0>U 'P7^PA^PIJ&C:N?C3\:1)KGQ(U1_MEI9ZB?,-ANY\R0'K,<\#H
M@X'-??\ 110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>sdgr-20241231_g16.jpg
<TEXT>
begin 644 sdgr-20241231_g16.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9N"VP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*\;-Z[I_E<QHUZ>(3E3=T%%%%<1T!1110 4444 %%%% !1110 4444 %%%%
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M#(7S,#@."0& X^8$=2!SW_!1[_DE/AK_ +#2_P#HB6OGH9=4^NK!5M&WOO\
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ME2< X,<B)D.I[$>H*GH:_6#PSK1\1^'=,U4VEQI[7MM'.;2[C:.:$LH)1U8
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M2,\;BH/6OSC\!?#KQS^T?XSNXM/>;6=4V^?>:CJ5P=D2DX!>1LGD\ #)ZX&
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M'C&<$U^K6H7]OI5A<WMW*MO:6T3332N<*B*"68^P )KQ<SRV>755"_,I;/\
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M[MZ7T/HZ/-[*//O97"LF7Q9H<$KQR:SI\<B$JR/=("I'4$9X-:U?EO\ ML>
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MI&K@W..SM^9WW_!-O_D1?&'_ &$HO_15?7-_JEEI4:R7MW!9QL=JO<2J@)]
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MCOPE\:/A;;^)M8U;6K.]DNIH#%8R0K& C8!PT;'/XUYC^VO_ ,G-^,_^W/\
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M1_@GX&M/#VDJ))!^]O+UEP]U.1\SMZ#L!V  YZG[+,<P>5X:-%3YJK6[_/\
MR1X.$PJQE5U.6T%_5O\ ,ROVF$$7[/?CE!T72I /R%?DA7ZX_M.?\F_^//\
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MY3[+'.]1[=]_T6[^1Y>'C&IC>?#*T%]VQ]*T445^='U04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MYF?M]:?)9?M!W4SJP6[TZUF0GN #'D?BA_*OTSKY _X*%?"6Y\0^&-)\<:=
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M$Z6!T:RN@?\ OV3_ $K[._;/_P"3:/&G^Y:_^E<-?%_[!_\ R<5I/_7G=_\
MHHU]I?MF(7_9I\: #)\NV/Y74)KULV_Y'%#_ +<_]*.'!?[A4_[>_(^$/V-_
M^3E/!7_76X_])I:_5FOR=_9(U&VTK]HOP5<7<\=M!]IEC,DK!5#/!(BC)]68
M#ZFOU:@O[6ZGF@AN8IIH,>;'&X9H\]-P'3.#U]*YN)T_K4'_ '?U9ME#7L9+
MS_1'Y%?M$_\ )=_'_P#V&[K_ -&M7Z;?LX_\D&\ _P#8&MO_ $ 5^9/[1/\
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M@_\ D15/F%?_ )&,/D?1'_!0;_D@D7_88MO_ $"6OFS_ ()^?\E]/_8)N?\
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M^NWP>LX]1^ _@BTEYBG\-6,3_1K5 ?YU^2_C#PQ?> _%^K:%? QWVEW<EL[
M8R48@,/8X!!]"*ZN'I1]MB8_:O\ JS'-$_9TGTM_D?LIX:\/6/A+P_IVBZ9
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MWI5C]@SX^Z!X&M=7\%^)=0M](M[RZ^W6-[=/LB,A14DC=SPN1&A7. 3N&<D
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M@K<X_)*^3/VV_&>F>-/CQ?R:3=1WEKI]I#8-/"P9&D3<SA2.N"Y7ZJ:^M/V
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M\QA_O5^@?[*WPY_X5E\#_#NG2Q>5J%Y%_:-Z",'S9<-@^ZIL3_@%?G+^SO\
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ME_WS_.EPK_R^_P"W?_;AYS_R[^?Z'[;63%[.!CR3&I/Y5-5>P_X\;;_KFO\
M(58KX-[GTB"LKQ3XITKP5H%[K>MWL6G:79QF2:XE. H]/4DG  ')) ')K4)
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MT.C:?Y4;8^[-.V ?^^$E'XU]7B::P'UG'1WDE;UV_.QXM&3Q/LL.]DW]V_\
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MI36$3;T5[CO"WP#^'7@N:&?1_!FCVMS"P>*Y>V66:-@<@K(^6!SW!KD_VO\
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M@BUCW;&YY&]F<^X"'O6#_P %)O\ D3?!G_7_ #_^BQ7=*M&OGT7'9:?<G?\
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M%/Q4^$FDK/X2\-WOB/3(A:ZDEQI\#7!93A96RN6#K@[CU.X=0:F^/7B#X'_
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M46:6-NR(&8+O!=BQ8X5<\_A7T%_P31S]M^(7IY=A_.XJC_P47\6:/<ZEX/\
M"VG30M>:6MQ/=6\&,6XD\L1J0.A(1CCL,'N*O_\ !-%@+OXAK_$4L"/SN/\
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M3B]?+U/3Q]2G]5E=[['-_P#!/+79]/\ C5?Z<K'[-J&DRB1.VY'1E;\!N'_
MC75?\%*?^1F\#_\ 7G<_^AI4'_!.7P#<W?B_Q#XQEB9;"SM/[.A<]'FD97;'
M^ZJ#/_705/\ \%*?^1F\#_\ 7G<_^AI7TLI1EG\>7HM?7E9Y*366._?]4:G_
M  34TB CQYJC1JUROV.VCD(Y5#YK, ?0D)_WR*^M/BW:I??"KQG;R*&CET6\
M1@?0P.*^6_\ @FK_ ,B]XZ_Z^K3_ - DKZJ^)W_)-?%G_8(N_P#T2]?.9LV\
MUEZQ_)'JX%+ZG'T?YL_(GX:,4^(_A5AP1JUH1_W^6OV<K\8?AO\ \E$\+?\
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MX41ESG!"@&K=%;8_,ZV8J*JI+EOM?KZM]C/#8.GA7)P;U[GY@>(_V,_C%?\
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MVZ_:89MX57#']V[8QN'7%>_^.]-N=9\$>(=/LX_.N[O3KB"&/<%WNT3*HR2
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M%;6T8CCC7T50  /I5JBBN9MMW9ML%%%%( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :Z+(C(ZAD88*L,@CTKR'Q/^R/\)?%ET]U
M=^#K6VN'.2^G2R6HS_N1LJ_I7L%%;TJ]6@[TI.+\G8SG3A45IQ3]3PC3_P!B
M'X/6$ZRMX:ENBIR%N-0N&7\0'&?QKV'PQX2T7P7I4>F:#I5II%@G(M[.%8US
MZD <D]R>36M15U<57KJU6;EZMLF%&G3UA%+T04445RFP4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7"?%#X(>#/C+'8+XMT@ZDUAYGV5
MUN986BW[=_W&7.=B]<]*[NBM*=2=*2G3;375:$RA&:Y9*Z/'_"7[(_PG\&W\
M5]9>$K>YO(CE)-0FDN@#Z[)&*9'KMS7KX&!2T5=6O5KOFJR<GYNY,*<*:M!)
M>@4445@:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,'0U,J4.;DB]0N]SZ"^(_P#P48^!/PUUB?2KKQ:VM7\#%)H]#M7NT1@<$>:
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M;@C.#D<#'/US_P $N/%=]XG_ &1]%AOIVN#I.H7>G0,YR1$K"15SZ#S,#T
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M.H3<WU52#ZU](>$/&.B>/_#ECK_AS5;76M&O8_,M[VSD#QR#ZCH0>"#R"""
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_%1_%4]_LFG?^AW%-_X+0?\ (S?"O_KSU#_T."OJ?]B_]A__ (9"U'Q7=?\
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MW>87/E^;]I.,;_O;.<=*^Y:*\XS:Y1+0****YB@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&>FZ1X)^$WA;6YW73M3\2PW6HF)"[-;0 >9A1]X_O!@>M7?^"G7P7^&?@_\
M9PNO&.F:)I/@_P 8Z->VS:)J.C6\=E</,9!F,&,*6^7<WMMR,8KT"?XT?#N%
MOV==*^,7AF+4?B#XDTBSNM-U74=-CDCM+YH8C+^\?F-S(5X ZE: .'T[]O\
M^#>FZ[I>G^+/A+K_ ($T;4&6.RUW7_#:06LH[-TSMZ'(SBOJ3XT:?XU\2_"&
MZL_A'K&G:+XBO%@6PU2=5>W@@9EWN@P0?W>=O![5YQ_P40B\,O\ L?\ Q#/B
M9;8P+8YLC,!N%WN'D^7G^+=CIVS6Y^PO#K%O^R%\*4UWS/[0&APG][]X0DDP
M@_\ ;+RZ /B+X??L\']G/_@I7\(]+O/$NH>,/$.LZ'>:OK&LZBV7N+ITNT8J
M#DA0$4<DGJ?8?1W_  5=\;)X2_8]URR\PQ2Z_J%II:,#T!D\U_\ QR)Q^-<K
M\9/^4LWP4_[%.Y_E>U[E^UQ\4?A3\-M#\)I\6O#47B+1=5U9+:S:ZTZ.[@M;
MG'RR/OX3Y2WS#G :@#YG\%_MT?![X;>"?"=AJ7PA\3VO@^VL[>PC\77GAI%M
M)BJ!=X9AE@<$]23Z5][^!=>T#Q3X1TK5_"T]I<^'[V!9[*6R 6)HVY!4#I]/
M6N9^-\7A:;X%^,!XB2S;PK_8MP;@3!?)\KRB1CMZ8QWQBOG7_@DXNJ6?['.D
MOJSNE@VJ7KZ89SC%KYF!C/;S/-_.@#[-KQ+]KC]F^3]J7X8VW@L^)IO#5B-2
MAOKMHK?SOM21AL0L-RX7<5;//*#BO:T=9%#*0RGD$'(-<3\:/C%X:^ WPYU;
MQIXLO!9Z3IZ9(7F2>0\)%&O\3L> /J3@ F@#D_CH/AS\(OV9_$=IXGL-.M?
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M_P!K,4C-C^\S_C7MO[)W[9UI^T</%'A_4?"UQX'^)7A]"=1T&[Y)/3>I*JQ
M; (89&1USF@#S#XH?M(_%S]HCX]:_P#![]GV[L_#FG>&G,/B+QM=PB;R902K
M11!@P!#!EX!8E3@J!DMUG]DS]J7P-IDNO>$OVEM4\3^(+=#*-(UJU!M;@@9*
M .SJ,]!E1]163_P1I2"[^#/Q U2<^;KUWXGD^W3/S(X$*,NX]?O/(?J37N7[
M0_[5WC'X*^.XM T'X)^*?B%9/9QW1U;1E8PJ[,P,9PC?,-H/7^(4 1?LC?M3
MZC^T?\#?$.J:SIRZ!XY\-O<:=K%G$I5$N$0D2(K9*@X/RG.&5ASBOE+]D33/
MVE_VLOAKJ'C&V_:+U#PY%;:M-IOV.33(9R=B1MNW #KYF,8[5]*?LR_M=VG[
M2NG?%31H_ -SX"U#PO"R7UI=2*9&GD$P<,H52K!HVSGG)KXT_P""?/CK]I/P
MS\$]7M_A'X \,^*?#!UZYDEN]7NS%.+CRXMZ "5. H0CCN>: /8_C=#^U?\
ML=^$C\1Y/C!9_$[PQID\7]JZ3J6EQ1,8F<+D$+NQD@95P1G/(S7WI\+_ !U;
M?$_X<>&/%]E$T%KKNFV^HQ1/]Y%EC5PI]QNQ7Y@:M\3/CE^WIX]OO@!X]OO#
M/P@6SG2;5M(6"9+Z_1"'VQ;V<2 8#@*5!&&RP%??'C/XT_"?]C3P9X,\+^*?
M$ \.Z8EB+#2EEAEF:2*W1$.2BGD!DZ^M '>_&#X@-\+/AAXE\6)IMSK$NDV4
MES%86D;/)<.!\J *">3@9QQUKXQ\!^!OVM?C;\/(?BC+\9H_ VJ:C"VH:5X/
M@T>%K6.$Y:..8L"<L,?>#D C)SP/JCX*?M1_#+]HF[U:U\ ^)(]?FTN..2[1
M;>6/RU<L%/SJ,Y*MT]*X7]KGPW^T3XITV33O@MK/AW0]*DT]UNY+Y3_:$DQ+
M I Q4H@V8Y(SD\$8H D_8?\ VF-2_:/^"EYKOB6S@L/$N@ZA/I&KBV&(9)HE
M5O,0<X!5QD=B#CC%?,/P4\3_ +6'[5\/C#Q=X*^,>F>%?"UKXAN]-L+*]T:V
ME;RD*LI5O()*@.!DDG(-=O\ \$_=8TC4OV8_B%\-O!FB77AWXE: ]U;ZU::S
M<B1YM2F1T6=I H^4M'MQM^41XYZGEO@A_P $XOC%HGPKM=%UOX[ZWX#GM))I
M+/1O";%;>)W<L9)I$9#*S$YYY P,\8 !]7?LT>!?C5X*BU\?&'XAZ?X]>X,!
MTTV-A':_90N_S=VR--V[*=<XVGI7SQ^W%_P42M_A]HGBCP3\)A<:[XYLH734
M]8M(6>VT% 0KR,V,&0$A1_"&(R21M/1_L-?'3XA2?%'X@_ ;XKZDOB#Q7X-5
M;FSUW&'O;0LJ_O#_ !$>9$0QY(<YR1D])^W7\//#/@?]C+XSW&@:#8:1<:G;
M+=WT]K J274S7419Y&ZL<D]30![#^S'XDU/QC^SU\/-<UJ\DU'5M0T2VN+J[
MFQOED9 68X[DU\?#QW^TE^T=^TA\8-!^%?Q2L/!GA3P;?PV$<-[I5O.K.597
M"L868D-&Q.3W%?5O[(.[_AE?X7;?O?\ ".VF,^OE"OD3X1_\$]?C3)?^.;KQ
M+\8-0^'-KKNMSZJ;+P=)F2ZED)(DEF!1MHS@)SW/&>0#Z1_9S^&O[0_@[QE>
MWGQ:^*NE^.?#[V316]A9:9%;/'<;T(D+)"A("AQC/\72OHRO@S]FSXH?$_X$
M?M63?L[?$_Q5+X^T_4M/;4?#OB&[!^U%55F*.Q))!5).&+$%.#@U]YT %?G]
MX3\??'7]N+Q_XVN? 7Q!7X2_"_PYJ+Z59W%IIZ7%YJ,J=9&+\@$8; ( #*,$
MY-?H#7GGQF^-/@G]G/P)?>*O%M_!I.G1YV11J/.NY<<1QH.7<X_#J2 ,T ?,
MWP.^-?Q9^$/[4L/P$^+^O6OCJ+6-/;4= \3PVR6\[JH8E)50 'B-^N2".I!X
MI>*_BK\7?VJ_VCO&GPU^$OC*/X<>"_ K"UUKQ'#:)<W5U>$D&- WW0K*Z\$?
M<8DG(%5OV3/ ?C3]I#]H2[_:=\?Z9)X<TD6;6'@[0IO]:EJ00)G]BK.<_P 1
MD)'RA<G_  2S'GWW[0-[<<ZE/XXN?M!/WC\TAY_%FH W/@E\9OBG\%OVF+?X
M$_&7Q!;^-8=<LFO_  SXK2V6WEF"YW0RJH )^1NN2"!R0PQ]K5\(?MPC[-^V
ME^RC<6W%XVJ7<;%>ICW09'TY;\S7W?0!EW7BK1;'[=]IU>PM_L"A[OS;E%^S
MJ1D&3)^48]<57\-^.O#?C*QFO= \0:7K=G"<2W&G7D<\<9]&9&('XU^;-A\!
M])_:(_X*=?&_P[XKN+V?P;8V]EJ=]H]O=/!%?RI;6R0K*4()53([8!'(K$^*
M?[*GAOP-^W[X0^%7@6\U/P=X$\=Z$+C7=)TV^E59XHWF:2$,S%@K_9T[\9;&
M <4 ?IYX=^(OA3Q?>W-GH7B;1]:N[;_7V^GW\4\D7;YE1B1^-:5QK^F6=X]I
M/J-I#=I$9V@DG576,=7*DYV^_2OS8_:F_9Y\$_LE_'3]GOQ9\*=-E\(WFH>(
MUTN^AMKN:2.YB)C'S"1FY*LZGG!#<]*M_M-?!O\ X7W_ ,%/?#/@Z\U"\L?#
MUSX-AGUE+*=HGN;2.:X<PDJ<[7<1@^W/:@#]"_#/Q"\+>-);B+P]XDTC79;<
MXF33;Z*X:/\ W@C''XU\O_%/XP>,M#_X*1?"+X?6.O7%MX-U?P]<W=_I"JGE
M3RK'>%7)(W9!CCZ'^$5X_P#MQ_LU>%/V3O!_ASXV_!NP/@;Q!X7U2UBNXM/G
MD\B]MI'"%9$9CD[BH/\ >5FW9XQR_P"UY^T#IOPG_;G^"GQ3O[&XO;2+P*]W
M'8VHS)+)/'>+%&/3+R*">PR: /TWU/Q%I6BRP1:AJ=G82SG$27,Z1M)_NAB,
M]1TK1K\_?V&? EO^U=XGN_VDOB1K%OXH\2I>26>C>'4)-KX=$;<*8S_RUP0R
MYZ;M_+'*_H%0!\7_ !F^(WQL^-'[2UY\'/A;JDGPV\/:)8K>ZSXPN-.\Z2<M
MMQ';[QM(RP'RX)(;Y@!@XO@_XK?&#]F']I_P3\*/BAXRA^)OA/QPCQZ3KLEF
MEM>6EPN<*X3[REMH.XG[P((P17V9XY7Q!_PAVMGPD+$>*#9R#36U(-]F%QM/
MEF7;R4#8) YQ7YK7D_COX*?MK> ?&W[4:Q>)DU%CIGA?6M"F":5I,[G:=T!0
M-D>8.6.1DM\Y7Y0#]-]<\0:7X8TZ74-8U*TTJPBYDNKV=88D^K,0!7R'^W'^
MT-JWA;2?@[J/PU\9PBRUKQC;:=>W6D3Q7$=S Q&Z,L-PQ].:\Y\8^$;?]M'_
M (*$^(_ GC:>ZN_AQ\.=,CF708;AXH;NZ<(=TFT@]9#D@@X0#.":\]_;I_9%
M\(? 7Q[\'/$WP^MIO#^AZGXML;34-#BN9'M3<"56BF1'8[6VB13VZ8QSD _5
M2JVHZG9Z/92WE_=065I$NZ2>XD$<:#U+$@"K-?GK\;M#F_; _;[C^#7B/4+R
M'X:^#-(35]0TBTG:$:C.P1@'92#C]Z@SU 5L$%LT ?=7A?XA>%O&_F_\([XD
MTC7O)XD_LR^BN-GUV,<5J7&L6%I>P6<][;PWDX+16\DJK)(!U*J3DX]J_.W]
MMW]E;PK^RS\/K+XV?!2VE\ >*/"E[;M-'87,K6]Y \@0K(CL0>2N>S L#GC&
M#^V%:R?M'_M$?LK16FH7OAZT\::&T]Q+83&.>.UN(XY)HU?L3&S)GWZ4 ?HO
MH_Q,\(>(-9FTC2_%6BZEJL)(DL;34(I9TQURBL2/RJM\7?'MO\+?A=XK\77)
M7RM&TV>]PQP&9$)5?Q; _&OSW_;]_8Z^&O[.'P,L?B1\+=*N/!GBSPYJ=H8;
M^SOYW>4,^/G\QVRP.#N&#VZ<5[;^WCXJN_&/[/G@'P+:2>7K'Q-U73-+*QGE
M87VRSMCT  S]: .A_9R^*[?!O]BOPQ\0_C/XOO)KC48#JUSJ&JRO/+MN'+V\
M*#DG]V8P%'<FO$/@3^V[XW_:(_;K\/Z3!:ZCX5^&=SHMW<:=I%W%L;48U5]M
MW)D<Y9"%VG "]SDU]VZO\+O"OB7PII?AO6M L-6T33O(:WL+R 20(T( C.P\
M';@8R*^./$D$=M_P5Y\%Q0QK%$G@5U5$&%4#[3@ #I0!]&?M*_M5>"OV7_#<
M%]XFN);G5[\.NEZ)9H7N;^1<#:@'099<L>.>YXKP/_@G)^T;\0?VAO&_QMN_
M'<L]H=.U&SCL]!E38NE ^>&A (!R/+4-NY)!-?7^L_#SPSXB\3Z3XBU70;#4
MM<TE'2POKJ!9)+4.07\LG.TG:.1SQ7Q;_P $Z_\ DXW]K;_L;A_Z/O* /NC5
M]9T_P_I\U_JE];:;8PC=)<W<JQ1H/4LQ %?'W_!0+]HK4O!_P5\&^(OA;XVM
MT>\\7V>FW%_HMQ#<J\+13L\18;AR54^O%>??&70%_;$_X*'_ /"G_$]Y=_\
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M^T'-XNU_Q_XF2TN/%UQ,C3:5;?N8]BDNY1=\I<MD'"X&.:^XOV9OAYKWPX\
M2V/B#XG7OQ7N;B[>>+6[U@Q6/"KY2G>^0"">O>O@K]MG]D7X1_#'XT?LWZ-X
M8\'0:5IGB?Q7'I^KVZ75PXNH#/:J4):0E>)'&5(//6OTK^''PV\-_"3PA9>%
M_"6F)H^@V6[R+..1Y FYBS<N2QR23R: .FHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J*YN8;.%IKB5((5Y:21@JCZDU+7"?&[X-Z%\?/AKJW@CQ)-?0:
M1J03S9=-G\F=2KAE*L01U X((/<4 ?%/_!6_]JB?P#\,-$\ >$=61=1\5F5]
M0O+&<%H;*/:#'E3P9&?'^ZC#O7XT5]S_ /!1S]@G1/V4])\(^(?!-SKNJ^'=
M0DFL]0GUF>.=K:X 5H0"D: *Z^9U!Y3KR*^&* %1VC8,I*L#D$'!!K]R_P#@
ME]^U4_QE^ DVD>+M7B/B7PG<+8275Y.JO=6S+N@D)8\L KH?]P'O7X9U^A?_
M  3S_P""='AO]ICX7ZSXT\?7GB+2+)[_ .R:0-'N8H//1%_?2-YD3[EW,%!&
M.4?K0!^S4,T=Q$DD3K)&XW*Z'((]0:?7,_#/X?:7\*/ .@^#]%>YDTK1K5+.
MV>]F\V9D4<%VP,G\ /0"NFH ^"?V]K*;X&?M$?!/]H2P1H[2SU%?#NO/&,!K
M:4/MW^VQIAD]"%]J^DOVL_C/!\%/V;?&?C:*X5;B'3S'I[ \R7$V(X=OJ=S@
M_0$]JT_VGOA#;_';X"^-/!,T:R2ZE8/]E)&2ERF)(6'N)$6OSD\"_$_5?VVI
M?V;O@K?K))+X5GEO_&J')XT\F&$R^[H #ZO-[4 >P_ WXG:;^PI\"?AQ\/AX
M6U;QS\8O&T3:]-X<T:,&X#S?-F9C]S8NU3UY1SP.:]V^"W[:$7CSXIM\,?'?
M@;6?A=X_DMS=V>G:NRR0WT:C+>3*O#$#)QT.#@Y&*^6OC[X:\0-_P4Y6"T^(
MS_"B?6/"D<.B:^;**9)2I4-;+YORJ6VR'/7("_Q<Z=[\-#I/[9GP=L_'7Q_U
M/XB>.[":2ZTRPM="A*PP_P :S21,/+5@"1N!QM)XSR 8/[-'[3.L?"?XH?M"
M^$?"7PR\1?$KQ/>?$35]3>WTA52"UMQ,4#22G(!+*P [_I7VU^RY^U+H?[3_
M (;UJ[L=)U#PWKV@WIL-8T'54VW%E-S@-P.#M8=B"K @8KQG_@G1:0IXM_:<
MN1&HN)/B?JD;R8^8JLC%03Z LWYFJW[#JB/]K;]K]% 5!KVEMM'3)6\R: /M
MJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *YSQ]=0IX-UQ&FC5OL<OREAG[IKHZ\K^*'PDT;5='\0:K
M+/?)<26\DA5)5V9V^A4G]:]' 1I2Q$?;2<5=;*_7U1E4<E%\J/!/M,7_ #U3
M_OH4?:(O^>J?]]"N7_X5MI?_ #VN_P#OXO\ \32_\*VTO_GO=_\ ?Q?_ (FO
MV_V>&_Y^/[O^">!>?8[/1KF(:O8_O4_UZ?Q#^\*^OX[B*8D1R(Y'7:P-?"^E
M?#/2Y-4LU,]WAID!Q(O]X?[-?8/A+X;:7X,O9;JRENY99$\L_:) P SGH /2
MO@N**>&7LVJCO9V5M]NMST<(YZZ'5UG>(VOT\/:HVE*'U06LIM%;&#-L.P'/
M^UBM&N?^(&NZCX7\#:_K&D:;_;&IV%C-=6VG[BOVAT0L(\@'&<8K\\/3/RK_
M &,8/V:_%MOXCM?VA)+27XSW6K7']HMXZFF@&-V%6-W*QJ<YR"0V?;%?7G[,
M/[-,W[/'Q@\::YX'\4V-Q\"-;L?M%KH:7KW1LKL%&WQN<C8%\T?>)(9<YVBN
M=^$_B_\ 9[_;Y^&D.N_$/PIX2M?&6^6WU33+J=8;ZT=7(&)@8Y2I7:<@]R.U
M>0_LW^%M#^%?[?6O?"OX0^)KW7OA5J7AZXEUS3Q>?;+73IBAVA9.1N5RB@DE
ML2$$F@#1_9H^$&G_ /!0[QKXM^-WQ9:\UKPC%JDNG>%_"4EP\=I! G\<@4@D
MX*\ @%MY.1@#TGX^?\$Z_#\46C^*OV?DL_AC\2M'O(Y8+FVNY(;2>/<-RRI\
MXX R,#GD-D'CCO\ @G3\4-'_ &=9?&/[._Q&U&W\,^+-"UJ>;3I-080P:G;R
M$8>)VX). P!()5QC.&QP'[>_P0^#7P[\%^-_'6F?%[Q"?B%JEVUYI^A1^)(Y
M89)Y9PSHD$<>\(%9R/F &!SZ@'H?[>/A[1?%_P"T[^RCI/Q#@TZXTB\.I)J\
M,TI2T8[+8L-Q((3>."2.U;GQP_9D_8OT/X7>(KV]@\+^'?(LI7AU#2=8/VN*
M4*=AB02GS'W8PFU@3Q@UY1\8O ^F?$_QE^PCX9\9V#ZMIFJ:/<0ZA:7<DB-,
M/L]J2&8$,#D#N#6[^V3_ ,$[?"/PM\,6OQ5^#/A&U34O"DBW^I>%[P/J%GJ5
MJAS(3%.S\JN20",J"1A@#0![S_P2^U[Q7XA_8]\+7'BM[F>6.XNH-.N+O)EE
MLED(C))Y(!WJ#_=5:]3_ &J/A;XO^-'P;U3P=X+\3Q^$=0U.6..ZU%P^[[*#
MF6-"O*E\!<^A8=Z\LT;QGXJ_:Y_9L\&>(/@%XZL/A==B01ZA#_9\5VMJ44J]
MIY;*0FUL$' RI4]#6-=_$+XJ?L2?#G5?&7QM\:3?&#3+F_M+&#^R--ALCI@?
M?NED*JN4)"COR0.] 'SC^V!\*_@I\!?#O@CP]\%I8+;]H+3=9M+>Q3P]>O/J
M,K])?M8#-@-D'# ') 'R[A7;_P#!3WQ;X:N?%_[/7@_XCW#0>&'OGU?Q$D:R
MLS1*B1D 1?/DYE4;>?F[5T__  4$\'? N_\ V<==^)NG+H>F>.+DPZEH7B'1
M72+4+N\=TV@-&=TNY2=V<X&6X*Y&[IWQ5^'D?CO]G?1/C1X)@G^).K^%+2ZM
M?%VL0Q^1;W9M\R1,6Z.9 1@C 9U^M '.?LG>'?V*/&/Q5L;CX7Z"^B_$#2&-
MW8VNK76HV]PV 07BCGF*2X&25&2!R0*U_P#@H5I'QW\=>&?&NFZ!<Z?X/^$6
MC:*]_J&IK*&OM9<1EFME4$E(P0 ?NYSU8<5SG[;R>'-4_:U_9OM/ PLY/B&F
MMF6\;2]ID2Q#1G]]L[8$N,]MW:OJO]L'_DUOXI?]B_=_^BS0!Y=^S-XV'PV_
MX)N^&O%18*VC>#[B^3/=XUE9!^+ #\:^ OV:)/V+;;X3^&T^+^F7^J^-;MI'
MU/5E75!;V[-*VQ':%U7(7&2JGW.:^YO@?XDT+PA_P3'\,:QXG\-R^+O#MIX9
M\S4-&B17:YA\QMPPQ ( Y/L#6[IOBW]GOQ!^Q?=:U#IF@:-\-KK0YI)M)"Q"
M2W)C;=#@?-YP;(&/F+8([4 >]?!_POX-\&_#70-)^'Z6R>#8;<-IGV2Z:YB,
M+$L"LK,Q8').2QKL:^-/^";_ (EC^''[#W@R^\>:Q;:!92W-U]BGU>X6!?(>
M9S$H9R!S\Q4>F*^R4=945T8,C#(8'((]: /F[]LOX\:YX$TG1?AQ\.XA?_%?
MQW(=/TB%?F^P0GY9KYQ_"L:EB"> 1DY"D5X'_P $M?/^&GP;^.9OKG^T+G0O
M$EV9[A\_OWAMP68YYY*D_C2Z3\(OVJ?!/[1_C_XH6?@WP=XNU/6I#9Z;>:SJ
MY4V%@K'RXH44C8"NW/?(/J<\+_P3R3XJ^)[?XW:!)H&BIX6U75M5CUJ\2Z)N
M;?47MRJQ0IG#1[BHW'UH ZS]C/\ 9/\ !?[5_P $=:^*_P 6M.D\6>*O'5_?
M/#J%U<2>9801S/"BP88!"'C<@^@4=!SZM_P3,\>:[JWPS\:^ O$.H3ZM>_#[
MQ)<Z##>W3EY'MU8[%)/7:58#T&!VK*_X)C_%7PYH7[(=MX;UO5[+2-4\#WNI
M6FKV]Y,L3VX-U+/O8,<[<2D9]5([5#_P2WMIM=\/?&/Q\(G33/%_C:]OK%V&
M/,B#L2P]1E\9]0?2@#VC]J[]KC0OV2].\*:CK^C7VK66NW[V):P(WP;4W;MI
M^]GH *\:O/\ @IQ;>!=>TZV^)WPA\8_#S3-9MY+C1[R^@\V2\*@8C\I0&#L2
M@QVWKG .:;_P4GM8KWQ?^S;!/&LL3^.H0R,,@\)3O^"B=G!=_%;]EU9HDD7_
M (38###/'[DX_,#\J .D\"?M\WFI_&/POX#\=_"7Q-\-7\5AO[#O=9QBX8#.
MUE &T\@$=5)&0,U1O_\ @H9=:M\4/%OPX\#_  D\1>-O&/A[4)[26WLYXHX/
M)CX,[RM@("W 4\D]^@JE^WFH_P"&@OV3VQ\P\73@'N 1;Y_E7/\ [#7C3PMI
M'[4O[4FBWM[:6/B2Y\3"ZB%PZH\]LC3 A">H1FR1_MB@#J]:_:NT/]I']D_]
MH2P32-0\)>,?#GA75K?6?#6KKMN;4FSG"L/[RDJPSU!'(&03S/P7_:L\.?LV
M?L2?!2*ZL;OQ-XLUNPBMM(\+Z3AKR\8R$%@O.%&>N.3@"O)/$VH6GCO]H3]M
MCQ1X6D2Z\,6GPUOM.N[VV.Z"6[%E@@,.&.Z*0Y_V37E?P*\)Z[^R!HGP5_:3
MU:=O&G@[6;8Z7JT$T&^70K>1BL+0,Q., 'I@9RO\60 ?L5X5U+4=9\.:=?:M
MI3:'J5Q LD^FO,LS6S$9*%UX8COCBO@7XEZ/=?MV_MNZ_P#"O6-5O;#X3?#>
MVBEU/3;&<Q-JMVP4D.1T7<Q3U"QMC!;(_0+1=9L?$6D66J:9=1WNG7L*7%O<
MPME)8V&58'T((K\_='\3V/[('_!1SQ[-XWF&D>#?BG:Q76EZ[/Q;1W*X+1R-
MT0^9YBY/3<A. V0 >I_&+_@FI\(/$G@*ZB\#>&D\">,+"(SZ/K>BSRQS13J,
MH'RQW@D $GYAG@@U\N?$GX]ZY\>/^"4'BR7Q5+]I\4^'=9L]$U"Z[W)BO(=D
MK?[14@,>[*3WKZQ^/'_!1;X;? GQ9JGAK64U)[@:.=0TW5;. 3V5],58K DB
MD_-D*-V-H)()&*^(Y_AOK'@[_@DGXZ\1:W;/977C'Q#::W!!*,,+=KR%8W(_
MV\%AZJRGO0!]IZ!_P3>_9U\3^ -(:Y^'-O#=7FG0N]W:W]U'*KM&I+J1+C.3
MGH1[5PW[#FN>(?@C^TE\3?V:]<UV]\2Z-HUHNN>'+^_??+':EHU:)C])H^!@
M H^  0!]/^%OC-X!\/?#;0KK4O&F@6-O;Z7;F5YM2A4)B)<Y^:OE']C6^'[0
MO[;_ ,9?CMI,4A\$V]@GAG1[N9"OVQMT1:5 1TQ;D\\@3+D9S@ ^_P"BBB@
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M/CGXBZ79R"2+2-3U!E@..S9+-C_=*GWK[EHH SM)\.Z9H6@VNB:?86]II%K
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M5H%U^R%XH\$6&E:G!H]OI\$%AIGAF#?<[XI8V@BC4*W!=4#''"EB2.M?05%
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M]FG]G;0?V7OAFG@GPY?ZAJ6FI=RW@GU)D:7=)MR,HJC'RCM7F7BG]FKP_P#
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M[_95N=-TJ]U"VL/&<4UW-:V[RI;I]IM#ND*@A1@$Y.!P:^WJ0@'M2T %%%%
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M#PK\9?C'^T3<_%+P/>F-_%@N-$U-WGLI7B82[S#+&RET/RY&2O0XSBOT.HH
M\U\)_LX?#CP-\*=4^&^A>%K;3?!VJVL]G?V$$D@>ZCFC,<OF3;O,9F4D;]VX
M=B,"K<7P&\!Q?![_ (59_P ([#+X"%D=/&CSS2RJ(#SM$C.9,@G(;=N! (((
M%=_10!S/PW^''A_X1^"]-\)^%;.73M TU&CM+66[FN3$I8L5$DSNY&6. 6(
MX&  *K?$_P"$7@WXS^&I- \;^'+'Q)I3G(@O8\F-NFY'&&1O]I2#[UU]% 'R
MWH'_  3)_9Q\/WDUPGP_&H,\;1+'J6I75S'$K#!"*\I /HQ!(/((-;G@[]A?
MX<^&OA1XB^&6IR:WXL\!ZO?1WJ:-K&J3E;,1E62*%XV1E4.H;@C/?/?Z(HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:,=W/J,NIM.=/,4DIC&QV&R1\8X#$C)X&*_3"@ HHHH **** "BBB@ HHHH
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MI;'6O*?AA^V3\2?V1_#5E\/?CQ\+?$NHKHL8L]/\5>'81=0W<"#$>[)520H
MW!LXQE0<T :_CO\ X*3^)O"_AJZU7Q=^S!XNT_0;5HWFN]5E"V\;%P$+%H,
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M0T 9G[27[=7AKX#^++3P/HGA_5/B-\2+M0\7AK0Q\\8(ROFN VS(Y "L<<D
M$&O+-5_;L^/'P^LCX@\=?LOZKI_A)!YEQ=:=JHGGM8NI=T\OL/[VP>XKG?\
M@E%I,?Q.NOBQ\;]>C2\\6Z_X@EM!<2#<UO%M65D0GH#YB+CTC4=J^P?B3^T;
M\*_A=K!T#QMXWT/0-1FMQ,;'4KE4=XFR VT]5.&'X&@"7X3?'WPI\</A-'\0
M/!UTVH:2\,CM#*/+FAEC7+PRKSM<'CN.01D$$_)/PZ_X*6?$WXN:+/K'@O\
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M/#GPCL/$VI>$])T^ULK*>\TG"7$]O"@5X\YP/,QR3GJ>#7R7X!^"GA+X ?\
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MS\10[_M.LI9+:"?+$K^Z4D+A2!UYQF@#L**** "BBB@ HHHH **** "BBB@
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MV2*Y4E>Y_'=2?M)N=DKN]ELO)>1P_P :?C%X;^ WPWUCQIXJO%M-*TZ/.W<
M\\A^Y%&/XG8\ ?4] :^0_P!D#X->)?VBOB9)^TU\8[%DO+G'_"&>'IU(BTZT
MY,<^P]R#E2>N2_=<1_M\_LV?'+X]?&+P??\ A'3-!\1> /#T$5VFB:Y?>3;S
MWV]]YEC5E9UV>6!\PX+#N:W(/%/[>%M#'#%X#^$\44:A$1+B<!0!@ #[1TJC
M,YC]IGP3H_Q(_P""E7PG\+^(+1+[1M5\(ZG:W4#_ ,2-!=#CT(Z@]B!7$_#G
MQOJO[*NF_&']EWQ[>23Z<?#NJW_@;69_E6ZMFMYF,!]&/) ' 99!W7/N.G_
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M/@KKGBKXA?$/Q#'XM^*GBR3.H7\"XM[:($$119 )R0,G & H  &2 ?45%%%
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M.+X9_#KQI;>,M=U#Q!\2O%UM(LL.J>+K[[48G4Y5E3 &0>06W8/2@#YR\2_
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MM$MA:V\]^ZM.Z@DY<JJJ3SV45Y_^T#^R)X1_:!U_1/$UUJ>M^$O&>B(8]/\
M$OAJ[%M>1)DGRR2K!DRS<8_B/(R: /G_ /:UBM-'_P""@O[,VHZ J1>++VYF
MMM0-OQ)+8<JWF8Y*A&FQGL#Z5E?LM_\ (X_MQ?\ 8PZI_*YKZ"^"'[%7A3X/
M^/[CQ_J.O^(/B#X^EA-NOB#Q3=+<36\9&TK" H" KD=S@D9P2*Z'P#^RUX6^
M'6I_%:^T[4=7GE^(][<7VJK=2Q,L#S"3<(-L8V@>8V-^X\#DT >6_P#!*_\
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ML/#NAP>59VJ?-(WWYG_BD<]V)Y_0<5Z])+ TU7E_$E\*[+^;_P"1^_L<,_\
M:).FOA6_GY?Y_<;^F:;:Z-IUM86-O':V=M&L4,$2[51 ,  >@%6:**\EMMW9
MW;#'E2,X9U4^YQ2?:(O^>J?]]"N6\::+X;N9X+O79O(8KY:,9F0$#G'!]Z\[
M\3:?X0M[O2%TV]#PR7(6Z(N&;$??OQ7HT,+&LEJ__ =/ON>3B<;/#MZ1T_O6
M?W6/;?M$7_/5/^^A4E>8VWA[X?W5Q'##>B65V"HBW3DD^G6O3(HUAC5%&%4
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MH51V P*=110 4444 %%%% #(XDBSL14SUVC%/HHH 8D21DE$52>I QFGT44
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MRK/T#PQI'A6UFMM&TRTTJWFF>XDBLX5B1Y&^\Y"@ L>YK3HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^3_P#@J3_R9-X[_P"NEE_Z515]85\G_P#!4G_DR;QW_P!=++_T
MJBH Z;_@GC_R9;\*O^P8_P#Z/EKZ*KYU_P"">/\ R9;\*O\ L&/_ .CY:^BJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4&OO^O-_@M^SM\/?V?-*N;#P'X:MM#CNF#7,R%I)IR.F^1B6(&3@9P,FO2*
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M\*]\+?\ 0M:/_P" $7_Q-=!14.$6[M&\:]6*Y8S:7JSG_P#A7OA;_H6M'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1N(QD[0*]D_:(_X)Q_#OQC\.KC4O@[HEGX1^(FG&.[T74=*NV@C>16!VNP)
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MJ&F)<W7B<RN;U+UX]YD5L]%<_=Q@@<YS71?\$S?BWKGQ*_9]GTCQ/=27VO\
M@_5)]!GNIF+/*D>#&6)Y) .W)_NB@#ZWHKCOC!\4M)^"GPT\0>.-<ANI])T6
MW^TW$=DBO,R[@N%#$ G+#J17R_KO_!5'X;VFGKJ>@^$/&WB_1H+:*YU+5-'T
MM7MM-WH&\N:1G"[U!PP!P""-QH ^T:*^2/$/_!3#X81:7I=SX-TCQ/\ $NZO
M+(:A/8^%]-,\NG19(/VG) C8$$%>>F>A!/HWPE_;"\ _&?X)^(?B9X>>_;3/
M#]O<3ZIIMQ"J7ML88C*R%-VTDJ/E(;!]>#@ ]QIDLJ01/+*ZQQHI9G8X"@=2
M37QO;?\ !4/P#XDTVUN?!7@7Q[X\E-O]JO[;0='$[:8FY@!<$/M#$+NP"1@C
M)!R![)\+_P!H[P1^TQ\'==\1^"K^2>&&UG@O+&[C\JZLY?+8[)4R<'T()![$
MX- 'I_A;QAH7CG25U3P[K-AKNFL[1B\TVY2>(LOWEWH2,CN*V*^%/^"8OC;0
M_AS^PI)XD\2:E!I&B:=JVI3W-Y<MM1%$@_,GH .22 .37TK^SQ^T/I7[2?A2
MX\3>'_#VOZ3X?$QAM;_6[:.!;[!(9H5$C,R@C&X@#/ R0< 'JU<KXZ^*W@SX
M86L5QXO\5Z-X9AE)$;ZK?1VX<CJ%WD9_"L;]H+XLV_P-^#'BWQS<1B;^QK%Y
MXH6.!++]V-/Q<J*^-/V/_P!C/2/V@/"=O\;_ ([B?QWXK\6%KVTL-0E;[+96
MA8^4 @(!W#Y@/NA2H SDD ^V_ ?QH\ _%(RKX/\ &>A>)GB&Z2/2M0BN'0>K
M*K$C\:Z'Q%XETGPAH]QJVNZG::/I=N 9KV_G6&&,$@#<[$ 9) Y/4U\0?M7_
M + GA3PIX&U#XD_!6TD^'WQ \+0MJ=LVC2O'%=)&-SQE,D E0<$=>AR#6-\:
M?CJ_[1G_  2?U[QK=*D>J7%G!;:@B=!<Q7D22$#L&*[@/1A0!]?#]ISX0$X'
MQ1\'$_\ 8<MO_BZ[K0?$FD^*M.CU#1M3L]6L9!E+FRG6:-OHRD@U\7_LY?\
M!/[X#>./@#\/]=UKP%;7FK:GH=K=75R;F96DE>)2S</@9)[5Y'\9?AJ?^"9_
MQP\ _$'X<ZA?V_PN\3:BNDZ_X<GG::*-CSE,GG*;V4GE6C/)#8 !^GU%-CD6
M6-70AD8 @CN*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %49]<TVUU&'3YM0M8;^89BM9)E660<\JI.3T/3TKSG]IOXR:A\!O
M@YK'C#2?#D_BS5;>2"WM-(MRP>>6:58UQM5B<%LX R<8XK\I_AOK?Q4\2?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)M7=NP-WKCFEHH
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MU^>G_!(OX5W=G\(U\<'QEK\UI->W]C_PC,ESG3499%_?B/\ YZ'')]Z_0N@
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MA#GFK34;=7_P+F527+'X;GQO\2?V+8_ ?C[P/X=C\5M=Q^)[V2U6=K':;8*
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M\5.52\&DG9O>R3OZNYR8">'JOE4;25W^/Z'IE%%%?%'OA1110 4444 %%%%
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MQ7R;I7[&O[0W[-US<V/P$^*FFW7@N61I8?#WBZ-F^R[CDJC!'!]<C9GN">:
M.+_:4\&_M4_LX_!KQ!\0[[]H==9M=),&ZQM]*2-Y/-GCA&&((&#(#T[5C_\
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M(&NI6TKQ3%+NTR=;B2)G@9%;<K",,0<#)/!Y)^M?V8_V0[GX'^&O&VI^(O$
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MD\Y8U] 5\O7HRP]25*>Z.D****P **** "BBB@ HHHH **** "BBB@ HHHH
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M::QH4GA/QWX8NOL.N:)*2?)DRPW+GD#*L"#R"I'/!/SVG[<_[17P.@6#XQ_
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MFOQ U_QM\/KSQ=9-#;^)+@W5S87BR(,+*>=CH6^7H"IH _6:BBOA?]HKQ_\
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MLK-(R$M(@^_C8, G'7(-?,7_  3BMH;+]H7]K&WMXD@@B\6*D<4:A511/>
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M10!\_P#[8?[(>E?M@>$="T'5?$-YX=BTJ]:]2:S@25I"4*;2&(P.<UZQ\+O
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MEECD'HRL""/K7GVC_LQ_"#P]JT>J:7\+/!NGZC$V^.ZMM!M8Y$;U5A'D'Z4
M?&__  3PT+Q!K.I?M'?%"\\+7_AGPOXXNY=0T5;^,1-)$SW4A"KQE5$J#<!M
M/8G!KIO^".'_ ":]KO\ V-=Y_P"B;>ONMX8Y(6B=%:)EVE",J1TQCTK*\+^#
MM \$:>]AX<T/3M L7D,S6VF6D=M&TA !<J@ +$ <]>!0!\'_ /!0/X.ZW\%?
M'&C?M/\ PL@-GKVC2HGB:TMAM2]MCA?-D4?>X^1_8JW\)->V:E\+O@[_ ,%%
M?A=X%\<ZY97&K:?';RR6D<%X\#6LLFP3Q2!3]Y6C"GZ9'!KZ4U#3[75K&XLK
MZVAO+.X0Q36]Q&)(Y$(P593P01V-9WA;P9X?\#:<^G^&]#TWP_8/(9FM=+M(
M[:)G( +%4 &2 !GKP* /F[_AES2OV0/A5\0O$'[/N@;?&]U8(\=MJ<\MW'<^
M2Q?8$+ [BK.!@\DBLWX,_P#!23X3^)O@[9:YXX\76'ACQ;96WEZUHETC1W"7
M*##B*+!+AB,@+GJ <$$5]>5Y[X@_9W^%GBSQ"VO:U\-_">KZV[!WU&]T6VFG
M9AT)=D))'J30!\2?L/:7XZO]'_:4^-7@[0?[-_X3"ZDN_"6F:E"0EV\1GD5B
M@(^5C(J @X)W<\5ZK^SS_P %'_A]XK^%_G_%+Q)IW@?Q]I1D@UG1[U'MV$B,
M1F)#DMD ?*,L#D8Z9^Q+>WBM((X8(TAAC4*D<:A54#H !T%<)XL_9^^&'CS6
MCK'B7X=^%=?U8X!OM3T:WN)CCIEW0DX]S0!\A_L*VM[\:_VJOC)^T);:=<Z;
MX-UF)=%T62YC,9OE5H]TH![ 0)SZN1U!KVW_ (**_P#)E7Q4_P"P='_Z415]
M#6&GVNE64-G96T5G:0((XH($"1QJ.@51P!["H-<T'3?$^E7&EZQI]KJNFW*[
M9[.^A6:&49!PR,"",@'D=J /)_V2Q.?V3OAG]E*+<_\ "-6OE&094/Y0QD=Q
MG%>'?LY_\%!]/FD\4>$OC_J.E?#KXAZ%?R126]RC6UM/ ,;6C9BP)Z]_F!!&
M<U]G:9I=EHFG6]AIUI!86-L@B@M;:-8XHD'1550  /05ROCGX*?#[XG74-SX
MO\#^'?%%S NV*?6-+@NG0>@9U) ]J /B3X3ZY#^UQ_P467XK>#X9Y?A[X%T=
M],36WB:.._N721-J9 )_US'Z("<;A7U_\._VC_!/Q1^)?C'P'H-W=3>(?";B
M/5(IK9HT1MQ7Y6/#<@]*[[P[X9TCPAI%OI6A:59:+I=N-L-EI]ND$,8]%1
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MT=-)\+:!IGAS2U8NMEI-I';0ACU.Q !D^M;E 'PC^SK_ ,I1_P!I'_L$V/\
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M 'C/B+_@L'\&[:X-GX7T/Q?XSOFXB33]-6)'_&1PX_[X-<ZW_!0WX]^.R5\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]%BO3R[^._\ #/\ ])9R8K^'\X_FCZ'HHHKS#K"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* ,GQ;XEL
M_!GA?5M?U LMCIEK+=S%1SL12QQ[\5^9.J_\%,O%VK6MEXW\3? .SN_!=Y-<
M6W@S694:607OS(H+OPVXKAM@0\'&<5^G7B;P]9^+?#NJ:)J*&2PU&VDM)U4X
M)1U*M@]C@U\X?LO_ +%B_ WPCXA\&>+-=@^(W@TZG'?>'M/U2UW+IBC>S81B
MP5R[Y)4X.,X!)H \0^$_[97[0/P[^,_@CPI\?_!VF:=H'CJ0PZ3>Z?#Y3VTG
MRX7Y78%1O0,K#<-P.3C!_1&OBCXW_ G3!^UOH7Q9^*_Q6TW1_A_H/E3>&O"]
MY<E"ERL48D.&PJJ9$#G;N+84'%>Z?\-B_!'_ **CX9_\#TH ].\0>%M&\5V@
MM=:TJSU:V#!Q%>0+*H(.00&!Y!&:U*S?#?B72O&.AV>LZ)?P:II5Y&);>\MG
M#QRH>A4CJ*TZ "BBB@ HHHH **** "OD_P#X*D_\F3>._P#KI9?^E45?6%?)
M_P#P5)_Y,F\=_P#72R_]*HJ .F_X)X_\F6_"K_L&/_Z/EKZ*KYU_X)X_\F6_
M"K_L&/\ ^CY:^BJ "BBB@#Y5_;.\.MX=\0>"/B3:J4^P7(TO474?\N\A.QC[
M*2W_ 'T*]*\3^$+']H;X,S:/>,(]2C4>3=?QV]T@^20'MGC/L2*['XN>!(?B
M7\-O$'AN903?6KI$3_#*!E&_!@*\+_9/\?2S:!IB7Q,=P&;1M1C?@QW<'"L?
M=D*$GU9O2OHZ-25;!IP?OTGIZ;_Y_<CR\3%4ZJJ/X9>[+Y[/Y/3YG>?LT?%:
M\\:^'KWPUXE'V;QOX8D^PZG _#2A>$F'J& Y([\]"*]GKYR_:+\,:A\-_%^E
M_&?PM;L]WIH%MX@LHA_Q^61(!<@=63U] I_AKWGPOXET_P 8^'M/UK2YUN=/
MOH5GAD4]5(S^8Z$>M>=BZ<9)8FDK1ET[2ZK]5Y'30DU>E/=?BNC_ ,S4HHHK
MS3K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBO)?VG_ -H_P[^RU\*KKQMXBBENXQ.EG9V-N0)+
MNY<,5C4G@?*CL3V"F@#R7]LO_@H9X5_9.O4\.1Z1=>)_&]Q;K<0Z:A,,$2-D
M*\DN#Z'Y5!)QVZU\/2?'#]NS]J,G4/"FBZWH6A7+;H/['L5TVUV?[,\Y#2#W
MWG^E=C+_ ,%-_A9XEU+6O'.L_ R,_%F*WAM]#-ZWVM;I=^$ <Q@QE=Q;Y5^;
MH#G%>F? 3_@IUXYO_C#H'@+XW?#/_A I/$<T=OIEZMG=615Y&VQ;XK@DLC,0
MN]2 ">F.@!\_Q_ K_@H%H[?;K?5/$TL_W]B^(K=SD?[+2XK;\/?M]?M5?LOZ
ME;V_QF\!7^O: SA6FU?3FM)2._E7<:^6Q[X8/]17Z^U!>V-MJ5I+:W=O%=6L
MRE)(9D#HZGJ"IX(H \J_9F_:;\(?M4^ )/%/A'[7%#;7'V.\M+V+9+;3A%<H
M3T;AU.02.:]<KDOA]\*/"'PIAU6'PAX?LO#UOJEV;Z[@L(_+CDF*JA?:. <*
MHXP.*ZV@ HHHH **** "BBB@ HHHH **** "OQP_X)\?\I-_B%_UU\0?^E5?
ML?7XX?\ !/C_ )2;_$'_ *Z^(/\ TJH _8^BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **YWX@_$+P[\*_!^I^*?%>K6^BZ%IT1EN+NY?:JCH%
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MY:^6^@:=S(UTA!BF08/(7>IP.0WL, '[^T5^?<?[>_[1OCCY/!/[*NNPJ_\
MJ[O73<1Q-_WU%$O_ (_1-XH_X*$^/!BW\+>!OA\C_=8M#*RCWW37'/X?A0!^
M@E(S*@RQ"CU)K\]?^&7_ -M7QMSXB_:"L="1_OQZ6A7\A%$@IT7_  2U\8^)
MWW^./VD/&&KHW^LM[-713_P)YF'_ (Y0!]T^(_B%X6\'P^=KWB71]$AQGS-1
MOXK=<?5V%>(_$W]OGX%^"_#FL/!\4O#M_JL=K*;6'3+G[:7F"'8H,(<<MCJ<
M5Y7X<_X(]_ C2I1-J\_BOQ3,3F1M3U54#G_MC'&?U_&O4M#_ ."=7[.WA^!H
M[;X9:9-E2H>]DEN6''4&1VY]Z /Y]-;UB[\0ZS?ZI?S-/>WL[W,\KG)=W8LQ
M)]R35*O;?VNOV9?$/[+_ ,7M5\.ZI:2'19YGN-'U)5/DW=L6.W#=-ZCY67J"
M/0@GQ*@#JOA5XTUSX=?$GPUXD\-8.NZ;?PSV:-G;)(&&$;!!PWW3R.">:_70
M^+_^"A/C8 P>%?!'@I7Y'$3%?^^YIJ^"_P#@GC^RSKG[0OQST74FL)4\&>'+
MN+4-4U&1<1$HP9(%)X9V8#@=%R3VS^_H&!0!^>O_  SY^W/XQYUCXX:+X>#?
M>%BNTCZ>7"*5/^";?QD\4L&\8?M3>)I$;_60:;#. WMN-PH_\=-?H510!\%:
M?_P1U^%=U*MSXI\:^.?%-X/O-<:A#&C?AY3-_P"/UZ#H'_!++]G+0=I_X0NX
MU)QU?4-3N)=WU&\+^E?6E% 'B>@?L4_ KPSM-A\+/#:E?XIK)9B?KOS7I&@?
M#7PCX4V_V)X6T71]O3[!I\,./^^5%=)10 4444 ?+7[>'[$NF_M=>"+62QN(
MM(\<Z,&.F:A*/W<J'EK>7'.QCR&'*GGD$@_CAX\_8;^/'P\UF33K_P"%OB74
M"K;4NM%TZ74+>3G@K)"K#GT.#[5_1I10!^&G[,/_  2O^*'Q7\2:?>^/M(N_
M /@Y)%DNCJ"^5?SQ@Y,<<)^9"1QN<#&<X/2OVU\)^%=*\#^&=+\/Z'9QZ?H^
MF6Z6EI:Q?=CC084>_ ZGDUK44 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y<_\%)/ASK?QS_;+^$?
MPWU7Q _AKP;K%B4M+V92T"7.Z0RX7(#2$+$@&?XE]:_4:O@[_@H3^Q1\5/VJ
MO''AZ\\)>)M/L/#FFV05M/U*\FC476]B95149<[2HW=>* .!7_@B%X1"C=\3
MM9)[D:=$/_9Z^O\ ]D;]EO3OV2OAO?>$-,URZU^WNM1DU$W-W"L3*S1QIMPI
M(Q^[!_&O@&#_ ()O_M;6L*10_&?RHD&%1/$VH*JCT "U]T?L1?!?XB_ SX4Z
MAH/Q,\3GQ9KTVJR7<5Z;^:\VP-'&JIOE&X896..G/O0!]#4444 %%9^O:_IG
MA;1[K5=8O[;2],M$,D]W=RB.*)1W9CP!7YY^)O\ @J-<>+OVM/!?P]^&":=J
M'@B[U&WT[4-6O+9VDNG>3#M =PVH!@ D')R>F,@'Z.45\Z_MO?M=6G[(GPQM
M-:CTU=;\1:M<FRTK3I'*1LX7<TDA'.Q1C(')+*.,Y'R9JO\ P4%_:4^!4WA;
MQ+\9?AAH]GX#U^941["-XIXPR[L ^:X5PN6V.,D*>1S@ _3VBODG]M#]NJ']
MG;P%X/G\(Z7%XF\6^,U$FC6DY;REA(0^:X4AFR9$4*",DGGBO*OA!^WU\6?"
M/Q_\/?"[]H7P5IOAJ?Q*L1TV_P!-5H_+:4E8MX,CJRLPV9!!4]<]@#]"Z^>/
M^"A'_)F'Q6_[!0_]'1U]#U\\?\%"/^3,/BM_V"A_Z.CH YG_ ()>?\F4^!/]
MZ[_]*9*^K:^4O^"7G_)E/@3_ 'KO_P!*9*^K: "BBB@ HHHH **** "BBB@
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M*S_!'X;>+KSP_:OK'BN:RF,%S>:/;*;974X8([LOF8(/*@J>Q->]?LZ?M1>
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M^9G_ *U^@-% 'YZ_\,^_MV^)/^0O\>=$TO=U^P6\:8^GEVR4G_# W[2&O_\
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M?%;_ +!0_P#1T= ',?\ !+LY_8J\"_[UW_Z4R5]75\I?\$O/^3*? G^]=_\
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MJ>?0/#7Q0U[PQX(DN[#P_#.K7NG+.WV47BY#F-.P7./KG&!BO%4FDC<,KLK
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M9[_D%%%%>&>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]MKQ%\%[[P5X#^%FGVVL?$#QCY;6<MTGF)!%(X2+:A(#.[G W': #D'/'!_
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M[/NCV,-6AB*?/!6"BBBO-.L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M<+YF R2$<@-]['!)  &O\&_@'\$/V%M"NO[/OK'0+G5#_I&L>(K^,75R%QA
MS;<("<[4 &3DY- 'T716;H'B32?%>F1ZCHNIV>KV$A(2ZL9UFC8CJ RDC-:5
M 'S+XO\ ^";G[//COQ5K'B36_ DEYK.KW<M]>W UJ_C\V:1R[MM6<*N6).
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M).?#'X+^)+/Q)XBO;KQ]K5FXEM8[^)8K.&0='\D$[R.V\D \XR 1]P@!0
M!P *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)>?\F4^!/]Z[_P#2F2OJVOE+_@EY_P F4^!/]Z[_ /2F2OJV@ HHHH ****
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M=7'RW>JXLH0?7HV1^(J,6/[2?CD@S:AX8^'UHYY6WC-U<*/QWJ3^(KZ,  &
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXTUF^U_Q5%IJ2:C?ZE,TUP\KDR%7=B6;9O"9/)"#- 'I]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 445Y#^UE\<[7]G3X!^+/&LQ5KVVMC!IL+'_77D@VPK] QW'_ &5:@#Y
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$="$%3T447N,****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 E%%% !2U^=O[:/[2GQA\9?M'VG[/7P+F7
M2]:6T2?4M45E60,\8EP)&!$:)&5)(!)+8'2O O!7QI_:'T+]D/Q=XMTCQ5J>
MM:_X0^(3_P!LW]W>?:3'916:(T863[T)D<$@ 8QG% '['45YI^S9\7/^%Z_
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MO[R^)?YKR?R:.-T'3?-0=O+I_P #Y'4 Y&1R*6OF%O#7Q1_9G(D\-R7'Q)\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SU^UM_P A+X1?]CE8_P#H8KZ%KYZ_:V_Y
M"7PB_P"QRL?_ $,5]"UZ5?\ W6A_V]^9R4OXU3Y?D%%%%>:=84444 %%%% !
M1110 4444 %%%% !1110 4444 %?+OQ@_P""</P9^./Q!U3QIXHL=8EUS4BK
M7#VNI-%&2JA1A0.. *]:UO\ :+^&_ACXGI\/=:\6Z?HWBV2WCNH;#47, G1R
M0OER. C,2#\H;=[5Z+%*D\8>-UD1N0RG(/XT ?%W_#H?]GG_ *!OB#_P</\
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MD#..*]2E3HYC-4X+DJ/M\+_6/XKT..<IX6+E)\T%]Z_S_,]4_:)_Y+G\#/\
ML*7/_H,=?0]?B)/J%U<S>=+<2R2[BV]G).3U.:^P/V"OCZ^CZU)\/M<NV:RU
M!S-IDLSY\J?^*+)[/U'^T/\ :KWLQR.I2PD90GS>S3TMNKMWWZ7/.PN81G6:
ME&W,^_E8^^Z***^&/H0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /GK]K;_ )"7PB_['*Q_]#%?0M?/7[6W_(2^$7_8Y6/_ *&*^A:]
M*O\ [K0_[>_,Y*7\:I\OR"BBBO-.L**** "BBB@ HHHH **** "BBB@ HHHH
M **** /EK]L/_@G]X(_:U\K6+FZN?#?C6VA$$&M6W[Q)(QG;'-$3AE!)P5VL
M,]2.*^%M3_8O_;0_9W9H_A[XKU'7M'B;]W_8&N;,+VS;SLOY+NK]CJ* /Q9%
MS_P4-UZ8:<%\>Q,/EW^7#:K_ -_<*/QW5V7A3_@F!^T'\<-1CO?C3\0YM*LF
M8-+;W&I-JET?7"AO*!]]QK]=** /+OV=_P!G'P7^S#X!7PIX*M)H;1Y?M-W=
M74QEGNYRJJ97/0$A5&%  QP*]1HHH **** "BBB@ HHHH **** "BBB@ K\<
M/^"?'_*3?XA?]=?$'_I57['U^.'_  3X_P"4F_Q"_P"NOB#_ -*J /V/HHHH
M ***JZIJ=IHFF7>HW]Q'9V-I"\]Q<3-M2*-069F/8  DGVH ^"?^"G/C'4?B
M=XB^&_[-OA*?=K_C+4(KO4PN2+>S5R$9\?PY620^T/N*^XO ?@O3?ASX+T/P
MOH\0ATS2+.*RMTQCY$4*"?<XR?<U\$_L Z/>?M)?M(_%']I;68'&EO=/HOAI
M9QRL8 #, >FV+RU^LCCL:_12@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ KXC_;K_ &#[W]J_QYHVLI\2;7PE9V-@+7^S;JV,RR.'9O-
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ML G& :^$/VX_%EQ\;/CG^ROX:UAC-I6J:/IE_<6['Y7DO)U24GZK$!^=:_\
MP48\+:)\!?VNO@3XK\&Z39^'9W\DRQ:; L".8+E "50 $E'VD]P * /UFKYX
M_P""A'_)F'Q6_P"P4/\ T='75_&K]J[X7?L[WFDVOQ!\3KX?N-4B>:T0V=Q/
MYB*0&.8D8#!(ZXKY/_;'_;^^ _Q2_9C^(/A3PQXZ74]>U33_ "+2T&FW<?FO
MYB'&YX@HX!ZD4 >O_P#!+S_DRGP)_O7?_I3)7U;7RC_P2[.?V*? G^]=_P#I
M3)7U=0 4444 %%%% !1110 4444 %%%% !1110 4444 >/?M6?#Z;Q]\'M2:
MP4_VWHSKJ^GNOWA+#EB!CN5W >Y%==\'/'T/Q.^&?A_Q)$P+WMJIF _AE'RR
M#\&!KL9$65&1P&5A@@]Q7S=^SG(WPO\ B[\0/A5<DQVBS?V[HH;H;>0C>J^R
MDKP.^ZO1A^^PLH=8:KT>C_1_>+J?2=%%%><,*Y/XE^%_^$G\,S+$FZ\M\S0^
MI('*_B/UQ7645K2J2HS52.Z,:U*->G*E/9GR(1@X/6O3_@EX8^V:E-K$R9BM
MODASW<CD_@/YUD?$CP9+IGC!8K.(M%J+AH%4?Q$X*_F?UKT/P!K"^'1'X6U2
MW73[^(GRGS\ER"<Y!]?\^U?88W$.IA;T=Y+YVZ_Y'P>7X14L;:OHHOY-]/\
M-'H%%%%?%'Z$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'+J^TOQ"D;31Z9K$*Q23HOWFC*LRM@<D9SC)Q@&@#Z4KY/\ ^"I/_)DWCO\
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MC'4OCC. 3Q7J_P#P1:\.ZC?:W\6?&:V!T_P_>R06EO&H(B\W>\A1/78K*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+(WC'^TXO-$8MB?LNR3?_K_D^]L]_P!:^&_M?_!27_GC=_\ ?.CT 9VLV/\
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M;:?:K'_!1+PIJ'[/_P"U+\&OC=;:3<WWA#1OL-K>26R9\O[-+]PGH"\3';G
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MQQC#'//M7J==E.HJL>9)KU5CQ\3AGA9\DI1E_A::_ ****U.0**** "BBB@
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M*^CRO$>UI>S>\?RZ'YMQ5EWU3%^W@O=J:_/K]^_WEFBBBO9/B0HHHH ****
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M[^/OQ+Y\3>.].\!:=( 6T_PU;EYE]O-)W#/M(1[5N^%_V-_AWHMR+[6+>_\
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M44 %%%% !1110 5^.'_!/C_E)O\ $+_KKX@_]*J_8^OQP_X)\?\ *3?XA?\
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M:A:WNJW.I27XCLYFECMD>.-1%N8#D%&/''- 'TS1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M)2T4 )1110!^3/[6GBNX_90_X*9:5\7_ !1H-QK?A#4K2%[=XU#8 M1;2!"W
MR^9&R[PN1P5]:N_MQ?\ !27X7?'3X#:EX \$:9J>NZSKCPH)+VS\F.SVR*VX
M9Y:3C "C').>Q[+]O#]JS7/A;\:]3\'^/OA)I_Q&^#LMO;36[7MJ\4D<C1+Y
MK17&&3(8G@KG(QD5I?LG^-_V(/$NO66H^%M TOPEXO#!H;+Q0A6:*3_ID\C-
M&3_NMGZ4 ?4O[$W@75_AQ^RU\.]!UQ'AU2WTQ'FAD^]$7)<(?H"!7N%1V\\5
MU DL$B2PN 4>-@58>H(ZBI* %HHHH **** "BBB@ KY/_P""I/\ R9-X[_ZZ
M67_I5%7UA7R?_P %2?\ DR;QW_UTLO\ TJBH Z;_ ()X_P#)EOPJ_P"P8_\
MZ/EKZ*KYU_X)X_\ )EOPJ_[!C_\ H^6OHJ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KP7X^?!G5YM7MOB5\.F6R\?:2-TD '[O58!]Z&1>,MC@>O3K@CWJ
MBMZ-:5"?/'_@-=GY >>_!3XSZ3\:/"BZE9(UCJ=NWDZCI<Q_>V<PZJ1UQG.#
MCGV.0/0J^<_C;\+]<^'_ (J/Q;^&L&[6;<9US0DR(]4MQRS #_EH!Z<GJ.1@
M^N?"OXI:'\7_  A:>(-"GWP2C;-;O@2VTH^]&X[$?KP1P:Z,11CR^WH_ _\
MR5]G^CZB.PHHHK@&4]5TFTUNRDM+V%9X'&"K=O<'L:\4\<^'O$/@QE:WU*\G
MT@?+#(LK#RAV5@.GU[_I7N]5=4TZ'5]/N+.X7=#,A1A]>]=^$Q<L-+76/5?U
MU/,QV"CBX.SM+HU^3\CYA_X2C5_^@G=_]_F_QKH_ 2ZUXL\016IU6]2W0>9-
M(DQRJCT]R<"N8UW2)M!U>ZL+@8D@<KGU'8_B,&O;_@YH,.F>%UO%=)+B].]V
M4@[0. O]3]:^JQU:G0P_M()7>VG<^)RZA5Q&*5*;=HZO7MT^\[Q1M4#).!C)
MI:**^&/TD**** "BBB@ JBVA::[%FT^U9B<DF!22?RJ]133:V%9,H?V!I?\
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M1B_U7Q$+#_;W_P"!H_X5[\7H?]7XXMY/]X'^JT?6:G6E+\/\P_LW#O;%P_\
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M.:ZVBBO1C",-(JQ\U5K5:SO5DY>KN%%%%68A1110 4444 %%%% !7A_[1O\
MR'?A]_V%5_\ 0DKV%]?TN-RCZE:*ZG!5IU!!_.O%/VA=5LKO7/ 307EO,L>J
M*SF.56"C<G)P>*\_&R7L):]OS1]%D=.:Q\&T]I?^DL]ZHK._X2/2?^@I9_\
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M,P^*W_8*'_HZ.@#F?^"7G_)E/@3_ 'KO_P!*9*^K:^4O^"7G_)E/@3_>N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU_X)X_\ )EOPJ_[!C_\ H^6OHJ@ HHHH **** "BBB@ HHHH **** "BBB@
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M6UU#>P)/;RI/#(-R21L&5AZ@CK7'7PU7#NU16OL^C]'LS>G5A55X,YKXK?\
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MH'X"CGP5/X82GZNR^Y:_B/EQ$MY*/HK_ )_Y'S1KNI?M#_%K1=0TJV\)^'_
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M6)((D+%MJ* %&3R> .M6J\1VOH>B%%%%( HHHH **** "BBB@ HHHH ****
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M? FA^)+,CR=1M4G*@YV.1\R_@V1^%=#<6\=W;RP3()(I5*.C#(92,$&OG/\
M98N9/A]XM\=_"6\D.-$O#?Z4'/+6<IR /]TD9]VKTH_OL*X]8._R>C^YV?S8
MNI](4445YHPHHHH **** "BBB@ IDT23Q/%(H>-P593T(-/HH#<\<\%?#^QD
M\;Z[;7:+=6MC\B1..#OS@GZ#/XUTTO@G5O"\C7'A?4&\C.YM,O#NC;V4]O\
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MIU?%G_!6WPYJWBC]E!;+1M+O-7O/^$@LW^SV-N\TFT)+D[5!.!D<^] '??\
M!.:-)OV)?AA'(JNCV$ZLK#((-S-D$51_:S_:A^'G[$?@V[O[#2-*/C?64"V.
MBV,*0R7++G;+/L (B0L>3U)(')-'[%U_>?"[]@;PCJ.J:/?B\T31+R\ETLV[
MK=.8Y9W$8C(W;FP !CN*_'[Q3J_Q4^(WQUE^)GCGX9:WXPN9;T7<FD7^E78M
M&13^[@(5<^4O V]P.<Y.0#[B_P""6GP$\8>*/B#XK_:+\<Q26LNLK<+I@E38
MUX\S;IIPO\,8X5?7)QP.> _X)(9O/VN?B?<W/S79L+IBS<G<UVNZOH/]CO\
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MH(<.CYXZD4 ?KFSJBEF(51U). *;#/'<+NBD21?5&!%?FA_P4B^(/BWXG?M
M?"O]GC2-:GT#3O$#6IUE[&0CS6GE\O#8P61%5F"G@D\]!CA?#7AO4_\ @G3^
MWCX"\!^'O%&J:MX \8_9H+BRU"08)GD,(8J %W)(%8, #@D4 ?K;7R?_ ,%2
M?^3)O'?_ %TLO_2J*OJ^OD__ (*DG_C";QW_ -=++_TJBH Z?_@GC_R9;\*O
M^P8__H^6OHJOG7_@GC_R9;\*O^P8_P#Z/EKZ*H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Y_P =^!=&^)'A:^\/Z[:+=Z==IM93]Y#V
M93V8'D&OE*V^/FN?L>W\_@+QU8WWBG1H0)-!UB A7DMO^>;%N"4X'!XZ=,5]
MFU\"_P#!2[_D9O!'_7I<_P#H:5[N5)8BK]5JJ\):^C2W0GW.Z_X>3^$/^A5U
MG_OY%_C5K2?^"BGA?6M4M+"U\'Z]<7-S*L,<4)C=V9C@ *#R?:OSJKN?@7_R
M67P5_P!A>V_]&"OJZF2X*$')1>B[LB[/V/B?S8D<JR%@#M;J/8T^BBOS<T"N
M,\4^$+F.^_MWP^PMM6C&9(NB7*]U8>M=G16U*K*E+FC_ ,/ZF%:C"O'EE\NZ
M?=&!X2\76WBFT?:IM[Z$[;BTDX>-O\/>M^N0\6>#I;JZ76=%D%GK<(SD<+./
M[K?XU<\(>,(O$D4D$T9M-5M_EN+1^&4^H]16U2E&4?:T=NJZK_@=F<]*M.$E
M1K_%T?27_![K[CHZ***XSO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,*1QDYR<X[UV=%57QD\0FIQCKK=12?WBIT(TFN5O[V%%%%<!TA1110 4444
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M  28^.GQ5^,OA?QBGQ!U74=>TG3/LJ:5J>HP'?(6\SS5\_ \TC:F<DD9Y/-
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M\F8?%;_L%#_T='0!S/\ P2\_Y,I\"?[UW_Z4R5]6U\I?\$O/^3*? G^]=_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC/S ,21^)KT.@!:*** /RL_X+>:%</<_";5RC_8,WUI)*!\J/F%@">Q(W?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?QS%YGA[Q#INL@#++9W22,OU4'(_$5^I86K@I_[M*+?D]?\ ,_E[-<-G5/\
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MG!D 8_,!D9'I0!^NO[/?AKQ;X.^#'A/1O'>HG5O%UG9+%J5Z;AKCSI1U;S&
M+?4BO0Z\9_8UM[:V_9>^&Z6FL/K]N=(A9-0D!#39&<D$D@]N?2O9Z "BBB@
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MQEIGB="+679<K]^VE^61#WXK=KYB<)4Y<LU9GV%.I"K'G@[H****@T"BBB@
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M=.9\&\58YF0>I0.#^ -?IG^S%X(^#.E>#1XL^#&CZ38Z'XBC1WNM+4KYVPL
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M#_P,#/ZUY%XE_83^&>L2&XTM-3\-7@.Y)M,NSA3Z[7#?IBOHFBOHJV"PU?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444E !7GOQI^/O@;]GO0+'6O'FM+HFG7MS]C@F:)Y-\NQGVX4$_=5C^%
M>AU^=?\ P6S_ .2 >!O^QG7_ -))Z +G[5&M_MC:M\7+F^^!EU<O\.+JQM)[
M!XK?3V5F:%3(<SH7Y8GK7@'CCX2?M]_'C1'\(>,KB\?P]?.JW,<KV%K"P!!_
M>&!0S*.N.0<=*ZKPC_P6BT[PSX5T?2&^&UU.;"TBMC*-04!]B!<XV]\5K_\
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M:\2^ ]/\0RBZ7?8:FG*7ML=K@]LXZ_SK&C\4ZUX,D$'B2 WMAG:NJ6RYP/\
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M-6-R&M1I/%X.:KT/YH]/\<=XOUT\SUFBBBO4/F HHHH **** "BBB@ HHHH
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M\U/K[?G1]5<OX4E+YV?W.P?7%#^-!Q^5U]ZNCNJ*YO2?B'X?UDA8=1BBE/\
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M]*4444 %%%% !1110!'/!'=020S(LL,BE'1AD,I&""/2ORWU?_@FM\=?V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@4E5)QD]AFFFT[H#\9?B_86VE?%GQK96<$=K:6VMWL,,$2A4C19W"JH'0
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M?6%?)_\ P5)_Y,F\=_\ 72R_]*HJ .F_X)X_\F6_"K_L&/\ ^CY:^BJ^=?\
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MK*O356*:3[A1116)N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ*$XM--7C+T3O9I]4]R<+A:=.?OJZ?S1P3>'/VA/V4<#0KO_ (6OX#@Y6TN
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MHJ.WN(KJ%)H)$FB<962-@RL/4$=:DK]$/YZ:MHPHHHH$%%%% !1110 4444
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M"",N[G>O 4<FO6PF-K^VIPG*ZNM]>OGL*Q^1-%=1_P *M\9_]"CKO_@MF_\
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M:^)/VL/VOOVB_BG\"]?\-^//@H_A#PO=M ;K5SI=[#Y)69&3YY&*C+ #GUH
M_1#_ ()X_P#)EOPJ_P"P8_\ Z/EKZ*KYS_X)W$G]BSX59&/^):__ */EKZ,H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!" P((R#VK\H?BE\1?$WPJ^,_CW3_  ?KE[X<L)-5E+6V
MG2F*,D'CY1QWK]7Z_'W]I+_DO'CG_L*3?SKZOA^,9U:D9*ZM^I,A_P#PTQ\5
M/^A]US_P+:OI_P#8*^+/C'X@^/?$5IXD\2:AK5M!IRRQQ7DQ=4;S ,C/?%?"
ME?6/_!.G6]/TGXH:]#>WUO:2W>G".W2>0(96$@.U<]3CG KZ/,\/26#J.$%>
MW1+N2MS]&J*.M%?F)H%%%% !1110 4444 %%%% '$_$WP5;^(=#N+F"W0:E
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M&OU.K\Y?VI_^"J^N_L\?'+Q'X!L_A]IVLV^DM&JWL^HR1/)NC5^5"$#[V.M
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MK:ZN-'OHK^&UNYK&9X6R$FB8K(A]P16M5SA*G)PFK-=&)--704445 PHHHH
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MGFYWP9F&0X7ZWBI0<;I>ZVW=W[I=CVFBBBO?/@@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KYX_X*$?\F8?%;_L%#_T='7T/7SQ_P4(_Y,P^*W_8
M*'_HZ.@#F?\ @EY_R93X$_WKO_TIDKZMKY2_X)>?\F4^!/\ >N__ $IDKZMH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@^]7:X6G%V>YZ,9*24HNZ84444B@HHHH **** "BBB@ HHHH **** "BBB@
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M^"?'_*3?XA?]=?$'_I57US_P]Z_9[_Y_O$/_ (*3_P#%5\6_\$V/%FG^)O\
M@HOXCUFR:0V6MIK=S:%TVL4DE\U=P[':/SH _:BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NHZ79ZO;&WO;:*ZA/
M\$J@BO/]3^#_ -@N3?>%M2FT>ZZF(L3&WMGJ/QS7I5%=E#%UL-_#EIVW3^6Q
M$H1EN>61?$3Q%X-=8/%FDM-;YVK?VHX/U[']#[51\;_"GX5_M)6#?VMI]K?7
MP3:+R ^1>P^GS#DX]\BO7I8DGC:.1%D1AAE89!'TKAO$/P?TC5)/M.G-)HU^
M#N66U.%S[K_ABO6PV.I0JJM2;H5%M*#=ONW7R?R,)TVUROWEV9\KZW\,/C1^
MR)%_:/@+Q4/&G@N.0*-"U=2TB*>B!<^@ZQE?]WM5O7_^"C.A7WPL\1(-)O\
MPWX^CMC!;Z=<*703,0NY9,#&W);# 'Y<5Z9\8+GQIX/\'F'4T36]+%PF+F/F
M1>#U[_F#]:_.;]H;Q_;>.?&H%E$J6UA'Y'F%0&>3^/)[@'@?2OVKAW+*'%<H
M5<SI1J2B[^TA:+=K:325I7V=TGYG@XJK+!IJC)I/H]?N/;_^"??[0T/@'QIJ
MGA/Q%>,FD:[FX@G?+>5=K].SKD?55]37Z):1\1?#VNW\=E8Z@)[F3.U!&XS@
M9ZD5^&=A?3Z9>P7=M(8KB!Q)&Z]58'(-?:GP _;$\-V_BW29O&$,F@A<I)>Q
MJTMN25(SP-RC)]#CUKT>.N"OKM>>:8.#<G'WE&VZ6CM:[NM-.WF99=C_ &<5
M1J/3S/T=HK,\/>)](\7:9#J.B:I9ZO82C<ES93K+&P^JDBM.OYEG"5.3A-6:
MZ,^L335T%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH X_QA\(/!7CT.=>
M\,Z;J,C=9I(%$O\ WV,-^M>+>(?V$?"8N6O_  9KVM>"=4'*26EP98A^!(?\
MGKZ9HKAK8'#8C6I33??K]ZU/<P>>9EEZY<-7DH]KWC_X"[K\#\BOVAO"NN^"
M_BKJFC^(]=;Q)JEND(;47!#2J8U*9SSD @=3TKS:O>?VW_\ DXWQ%_UQM?\
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M?/'_  4(_P"3,/BM_P!@H?\ HZ.@#F?^"7G_ "93X$_WKO\ ]*9*^K:^4O\
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M74-];1W$$BRPR*&5U.014U<#5M&>FFFKH****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KY/\ ^"I/_)DWCO\ ZZ67_I5%7UA7
MR?\ \%2?^3)O'?\ UTLO_2J*@#IO^">/_)EOPJ_[!C_^CY:^BJ^=?^">/_)E
MOPJ_[!C_ /H^6OHJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^"?'_*3?X@_]=?$'_I50!^Q]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!XY^UC=ZM9_!G4GT*R>_P!6
M:5([:)&5<,P(W$D@8'7\*_*Z3X _$.5V=_#D[.Q)+&>+)/\ WW7Z]_&/2KS6
M/!_V>QMI;N?[0C>7"I9L#.3@5X9_P@'B3_H!W_\ WX;_  K]KX+XCEDN E3I
MJ%Y2;?-OTMU6AX./PJQ%1-WT1^>K?L_?$%5)/AN? ])HC_[/7LO[*'A6/3?&
M[^&/B1X9CG\,7ZLQ^WQAQ!*%(['<H8=QT*CWKZE_X0#Q)_T [_\ [\-_A6]X
M#^&][/XMLCK.@3FR <.UQ 0H^4XY[5];F?&DL7@JM&MRI-/6+:DGT:UW70XJ
M6 4*D91O\]CA=8_8GO/"]_)XC^!7Q N_#$SGS%TV6Y,UJQ[ .,DCV</]:99_
MM??$?X)7D6D?&[P#<B%<*/$>BQAHIA_>P#Y9/<A64_[(KWZ^^#TNEW#77A?5
M[C2I<Y$#N63Z9ZX^N:HWWC'7=%MGT_QIX<CU73W&U[B.-7CD'N.5/TX^E?FT
M,X6915/'PCBUWE[E9>DU\7SYKGJ.A[)WIMP_&/W=/P.C^&GQL\$_%[34O/"G
MB&SU/(R]L'V7$7L\389?Q&#V)KN*^1/%G[)'PN^)]X-;^'^L3_#_ ,3 [U_L
MYS&A?U,)(V_6,@>QK'/Q _:*_9E41>+=&3XI^$(N!JUCEKJ)!_?*C=^+J?\
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M%>;/+<'4DYSI)M^1])1XDSC#TXTJ6*FHQ5DD]$ELCYJ_X=^_"S^]KG_@<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+7T57SK_ ,$\?^3+?A5_V#'_ /1\M?15 !1110 4444 %%%% !1110 4444
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M^*NA?\(O\2_%&D?:Y[_[#J4]O]JNFW2R[7(W,>Y..:Y6OL:>0X.4%*[U7?\
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M/NH[F/OM/S+[$=1^-:%<<HN+Y9*S.^,HS2E%W04445)04444 %%%% !1110
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M "BBB@ KYX_X*$?\F8?%;_L%#_T='7T/7SQ_P4(_Y,P^*W_8*'_HZ.@#F?\
M@EY_R93X$_WKO_TIDKZMKY2_X)>?\F4^!/\ >N__ $IDKZMH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?)_\ P5)_Y,F\=_\
M72R_]*HJ^L*^3_\ @J3_ ,F3>._^NEE_Z514 =-_P3Q_Y,M^%7_8,?\ ]'RU
M]%5\Z_\ !/'_ ),M^%7_ &#'_P#1\M?15 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+DR/=85%9W_!2C0-*^"_[6WP(\5>%=.MM$NV\HR+81+"KF"Z0*2% !.U]OT
M% 'ZPU\\?\%"/^3,/BM_V"A_Z.CKI/CG^UQ\+_V;[W2+3X@^()-%N-5A>>T1
M+&>XWJI 8YC1L8)'6ODS]L+_ (*&_ GXK_LS_$#PEX9\82W^O:KI_D6ELVEW
M40D?S$;&YXPHX!ZF@#VG_@EY_P F4^!/]Z[_ /2F2OJVOS,_81_;Z^"/P5_9
MB\)^$/%_BR73-?L3<&XMETRYF";YW9?F2,J>".AKZ _X>G_LU_\ 0]S_ /@F
MO?\ XU0!]9T5\F?\/3_V:_\ H>Y__!->_P#QJC_AZ?\ LU_]#W/_ .":]_\
MC5 'UG17R9_P]/\ V:_^A[G_ /!->_\ QJC_ (>G_LU_]#W/_P"":]_^-4 ?
M6=%?)G_#T_\ 9K_Z'N?_ ,$U[_\ &J/^'I_[-?\ T/<__@FO?_C5 'UG17R9
M_P /3_V:_P#H>Y__  37O_QJC_AZ?^S7_P!#W/\ ^":]_P#C5 'UG17R9_P]
M/_9K_P"A[G_\$U[_ /&J/^'I_P"S7_T/<_\ X)KW_P"-4 ?6=%?);?\ !5#]
MFP#/_"=3GV&C7G_QJ@?\%4/V;",_\)W./8Z->?\ QJ@#ZTHKY,_X>G_LU_\
M0]S_ /@FO?\ XU1_P]/_ &:_^A[G_P#!->__ !J@#ZSHKY,_X>G_ +-?_0]S
M_P#@FO?_ (U1_P /3_V:_P#H>Y__  37O_QJ@#ZSHKY,_P"'I_[-?_0]S_\
M@FO?_C5'_#T_]FO_ *'N?_P37O\ \:H ^LZ*^3/^'I_[-?\ T/<__@FO?_C5
M'_#T_P#9K_Z'N?\ \$U[_P#&J /K.BODS_AZ?^S7_P!#W/\ ^":]_P#C5'_#
MT_\ 9K_Z'N?_ ,$U[_\ &J /K.BODS_AZ?\ LU_]#W/_ .":]_\ C5(W_!5#
M]FQ1G_A.IS[#1KS_ .-4 ?6E%?)8_P""I_[-A'_(]SC_ +@U[_\ &J7_ (>G
M_LU_]#W/_P"":]_^-4 ?6=%?)G_#T_\ 9K_Z'N?_ ,$U[_\ &J/^'I_[-?\
MT/<__@FO?_C5 'UG17R9_P /3_V:_P#H>Y__  37O_QJC_AZ?^S7_P!#W/\
M^":]_P#C5 'UG17R9_P]/_9K_P"A[G_\$U[_ /&J/^'I_P"S7_T/<_\ X)KW
M_P"-4 ?6=%?)G_#T_P#9K_Z'N?\ \$U[_P#&J/\ AZ?^S7_T/<__ ()KW_XU
M0!]9T5\F?\/3_P!FO_H>Y_\ P37O_P :H_X>G_LU_P#0]S_^":]_^-4 ?6=%
M?);?\%4/V;%'_(]7!^FC7G_QJ@?\%3_V;,?\CW/_ .":]_\ C5 'UI17R9_P
M]/\ V:_^A[G_ /!->_\ QJC_ (>G_LU_]#W/_P"":]_^-4 ?6=%?)G_#T_\
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M1@#GN3BOIB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK\O_ (Y_MT?&_P"+_P"TCJWPE_9XLK>%-&::":[,<<DUT\1Q-(7D^6.-6^4
M<D\D\@  _4"BO@#]@+]NGQQ\4OBAKWP>^+UG;P^-M.$SVUY%$L#R-"<302(O
MREE&6#+C(!R#C-??] !7XX?\$^/^4F_Q"_ZZ^(/_ $JK]CZ_'#_@GQ_RDW^(
M/_77Q!_Z54 ?L?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^)__ ")Z7_7U?^DS/;:***_3S^8PHHHH **** "BBB@ HHHH **** "BBB@
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M_P"B6Z'_ -\/_P#%5] T4 ?/W_# G[/O_1+=#_[X?_XJC_A@3]GW_HENA_\
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MJOH&BO$*/G[_ (8$_9]_Z);H?_?#_P#Q5'_# G[/O_1+=#_[X?\ ^*KZ!HH
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M3?#VQU;7M2L&EN[V6YN%:5_-D7)"R #@ <#M7MG_  [@_9N_Z)9IW_@9=_\
MQV@"C_P\R_9R_P"BAP_^ 5Q_\11_P\R_9R_Z*'#_ . 5Q_\ $5>_X=P?LW?]
M$LT[_P #+O\ ^.T?\.X/V;O^B6:=_P"!EW_\=H H_P##S+]G+_HH</\ X!7'
M_P 11_P\R_9R_P"BAP_^ 5Q_\15[_AW!^S=_T2S3O_ R[_\ CM'_  [@_9N_
MZ)9IW_@9=_\ QV@"C_P\R_9R_P"BAP_^ 5Q_\11_P\R_9R_Z*'#_ . 5Q_\
M$5>_X=P?LW?]$LT[_P #+O\ ^.T?\.X/V;O^B6:=_P"!EW_\=H H_P##S+]G
M+_HH</\ X!7'_P 11_P\R_9R_P"BAP_^ 5Q_\15[_AW!^S=_T2S3O_ R[_\
MCM'_  [@_9N_Z)9IW_@9=_\ QV@"C_P\R_9R_P"BAP_^ 5Q_\11_P\R_9R_Z
M*'#_ . 5Q_\ $5>_X=P?LW?]$LT[_P #+O\ ^.T?\.X/V;O^B6:=_P"!EW_\
M=H H-_P4T_9R49_X6%$?I8W'_P 10/\ @IG^SD1G_A84(^MC<?\ Q%?.G_!1
MG]C3X,?!K]EG7O%'@SP)9Z%KUO>V<45[#<7#LJO.JL,/(1R"1TKT/]E']@_X
M#>/_ -G'X>^(O$'PZL=2UK4M)BN+N[DNKE6ED.<L0LH _ 4 >D_\/,OV<O\
MHH</_@%<?_$4?\/,OV<O^BAP_P#@%<?_ !%7O^'<'[-W_1+-._\  R[_ /CM
M'_#N#]F[_HEFG?\ @9=__': */\ P\R_9R_Z*'#_ . 5Q_\ $4?\/,OV<O\
MHH</_@%<?_$5>_X=P?LW?]$LT[_P,N__ ([1_P .X/V;O^B6:=_X&7?_ ,=H
M H_\/,OV<O\ HH</_@%<?_$4?\/,OV<O^BAP_P#@%<?_ !%7O^'<'[-W_1+-
M._\  R[_ /CM'_#N#]F[_HEFG?\ @9=__': */\ P\R_9R_Z*'#_ . 5Q_\
M$4?\/,OV<O\ HH</_@%<?_$5>_X=P?LW?]$LT[_P,N__ ([1_P .X/V;O^B6
M:=_X&7?_ ,=H H_\/,OV<O\ HH</_@%<?_$4?\/,OV<O^BAP_P#@%<?_ !%7
MO^'<'[-W_1+-._\  R[_ /CM'_#N#]F[_HEFG?\ @9=__': */\ P\R_9R_Z
M*'#_ . 5Q_\ $4C?\%-/V<E&?^%A1'Z6-Q_\15__ (=P?LW?]$LT[_P,N_\
MX[7RE_P4N_8^^#OP3_9IF\2>"/ ]GH&MC5K6W%Y#<3NWEL6W+AY&'.!VH ^G
MA_P4S_9R(S_PL.'_ , ;C_XBE_X>9?LY?]%#A_\  *X_^(KB/V<_V!?@#XR^
M GP]U[6?AO87VK:EH5G=W=T]U<@RRO"K,Q E &22>!7HO_#N#]F[_HEFG?\
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M/,OV<O\ HH</_@%<?_$4?\/,OV<O^BAP_P#@%<?_ !%7O^'<'[-W_1+-._\
M R[_ /CM'_#N#]F[_HEFG?\ @9=__': */\ P\R_9R_Z*'#_ . 5Q_\ $4?\
M/,OV<O\ HH</_@%<?_$5>_X=P?LW?]$LT[_P,N__ ([1_P .X/V;O^B6:=_X
M&7?_ ,=H H-_P4T_9R49_P"%A1'Z6-Q_\10/^"F?[.1'_)0X?_ *X_\ B*^4
M_P#@IY^R+\(?@=^SS9^(/ W@FT\/:P^M6]LUU!<3NQC9)"5P\C#DJ.W:OH;X
M(?\ !/W]GWQ1\%_ &LZI\-+"[U/4?#^GWEU<-=W0,LLEM&[L0)0!EB3P,<T
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M?_$4?\-S_!O_ *&>7_P7W'_Q%3_\,/\ P4_Z$O\ \JM[_P#'J/\ AA_X*?\
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MX;G^#?\ T,\O_@ON/_B*/^&Y_@W_ -#/+_X+[C_XBI_^&'_@I_T)?_E5O?\
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M??\ QZOV1HH _&[_ (>C?M6?]$\TG_PF;[_X]1_P]&_:L_Z)YI/_ (3-]_\
M'J_9&B@#\;O^'HW[5G_1/-)_\)F^_P#CU87B'_@K=^TCH-Q%%JF@>'-$ED7<
MD5SH=Q$7&<9 DFR?3BOVNK\>?^"VW_)9_AU_V 9/_2EZ *G_  ]&_:L_Z)YI
M/_A,WW_QZC_AZ-^U9_T3S2?_  F;[_X]7[(T4 ?C=_P]&_:L_P"B>:3_ .$S
M??\ QZC_ (>C?M6?]$\TG_PF;[_X]7[(T4 ?C=_P]&_:L_Z)YI/_ (3-]_\
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M)YI/_A,WW_QZOJ__ (([_P#)H'_<PWO_ *#%7W%0!^-W_#T;]JS_ *)YI/\
MX3-]_P#'J/\ AZ-^U9_T3S2?_"9OO_CU?LC10!^-W_#T;]JS_HGFD_\ A,WW
M_P >H_X>C?M6?]$\TG_PF;[_ ./5^R-% 'XW?\/1OVJ_^B>:3_X3-]_\>H_X
M>C?M6?\ 1/-)_P#"9OO_ (]7[(T4 ?C=_P /1OVK/^B>:3_X3-]_\>H_X>C?
MM6?]$\TG_P )F^_^/5^R-% 'XW?\/1OVK/\ HGFD_P#A,WW_ ,>H_P"'HW[5
MG_1/-)_\)F^_^/5^R-% 'XHZ9_P5M_:1U+6);&ST#P[J%]'NWV,6AW#R)@\Y
M59MPQTYK=_X>C?M6?]$\TG_PF;[_ ./5>_X)^_\ *3?XB_\ 7/6__2E*_8.@
M#\;O^'HW[5G_ $3S2?\ PF;[_P"/4?\ #T;]JS_HGFD_^$S??_'J_9&B@#\;
MO^'HW[5G_1/-)_\ "9OO_CU'_#T;]JS_ *)YI/\ X3-]_P#'J_9&B@#\;O\
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M@O\ H%:%_P"$S>?_ !^C_AX3^T%_T"M"_P#"9O/_ (_7ZF44?V[E?_0KI_\
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M)/\ @HGX\N?V65EA\400RP^);K4GB^P-,I5)BH8<+O51SDEP2.* /K;]B/\
M;9U_X_>+O%OP[^(?AB+PM\0_#!8W4-J2(I DGER J2=K*V.A((.17V#7Y?\
M_!,J_@T#]IWXM:)\2K;4(?CM>22RWMQ=.A@DCWAY0@48#%F5LC(*XVX Y_4"
M@ HHHH **** "BBB@ HHHH *^8/VT/VYO"'[+7@W4;:WU&SU;XB30E=.T&-Q
M(T;D?++<!3\D8SG!P6Z#N1]/U\._MK_LB_#C2?AC\<?B]-I3ZIXVU#1Y)8[J
M^??'9D(B9A3&%.!]XY/)P10!Z]^PW\>]?_:)_9XT[QSXJCLX-4GNKF*1;&,Q
MQ!8W(& 2>WO7RS-_P4(^._QY\;^*;?\ 9Z^&EAKWA;PZY$M_?_-).N6VM\TB
M %PI*HN6Q7K_ /P2;C2;]C'1(Y%#H^H7RLK#((,IR"*G_:O_ &FOAI^P?X*O
M=.\'>'=%M/'FNH9+/0](M([=2V-JW-P(P/D'8'EB,#C) !T'["7[: _:W\*:
MW'JNC+H'B_P]*D6I6<)8Q,'W;9$W<KRC J<D$=>:^I*^'O\ @EO^S3XE^#O@
M#Q%XW\;0S6?BGQO-'=O97"[988%+LID7^%W:1F(/08S@Y%?<- !1110 4444
M %%%% !1110!\E_MN_M\^%?V8?"M[I>BZC8ZW\2I@$M-&1O-%J3UDN0I^0 =
M%)#-Q@8R1Z-^QM\9]9^//[-GA3Q]XF6TM]6U);EKD6:&.%1'<2Q@@$G'RH,\
M^M?-/[=_[(7PX\#_  0^-GQ3@TI]0\;:T5NVU"^?S/LI>>,,L"X 3CC/+8)Y
MYKK?V)+J>R_X)CZ;<6I(N8M$UEXRO4,)[G% 'G/BC_@H9\8_C%\1?%>B_LY_
M#FT\3>'_  L&-[JVH#<9@"PW*"Z*H8JVQ<EV"DXZ@?17[#/[71_:T^'6I:AJ
M.CC0?$^B7*V>IV4>XQ$L"4DCW<@'##!R05/M7YK?\$\/"'Q^\?>#/'MG\'_%
MVF^";"SNHKJ_O;J 237UR8V$4 )1L* K$GC!?OGC[R_X)O\ [5OB/]H/PQXN
M\,^-[>WC\9^#KJ.WN[FVB6);F-S(H8JO <-$X., _*: /LJBBB@ HHHH ***
M* "BBB@!KNL:,S$*JC))Z 5^;=]_P4*^./QV^(7BC3/V=_AK8^(/#GAUV$U_
MJ'S27"AF"O\ -(BKOVDJ@RV/T_21T61&1U#(PP589!'I7R)^U5^TA\,?V#/!
MM[#X5\.:)9>.M>CWV>BZ3:1V_FL,JMQ<",#Y%).,\L<@=R "7]BK]N^V_:2\
M%^+)?%FE1>%/$OA!#-J\2,WD&$!B95#?,NTHP93G&!SSQ\X:A_P4O^._Q B\
M7^./AA\+]/O/A9X7GVW=W?!GF\KKN<B1>=OS$(K; 1D]S#^SS^SAXN^$7[%7
MQ[^)/C.&:P\6>-M!NITL9EVS0VQ1V+R#^%I#(6VGD #."2!M?\$Z[.UE_P""
M;'Q;$BJPFFUH39[XL(L9_"@#[:_9=_:&T?\ :?\ @WI'CK2(&L3<%[>]L';<
MUI<H<21D]QR&![JRG Z5ZS7YV_\ !%"XG?X"^.(&)^S1^)"T?IN-M%N_DM?H
ME0 4444 %%%% !1110 5#>7<5A:3W,[B."%&DD<]%4#)/Y"IJCN+>*\MY8)X
MDF@E4I)'(H974C!!!Z@CM0!^:47_  4*_:!^/7B+Q3=_ 7X76&L>#O#SD275
M\-\TRC)!YD0;F R(T#, 1UKZ7_87_;)A_:[\":I=7FDKH7BG0YDM]3LHF+1'
M<"4D3/(!VL-IY!!Y-<3^UU^U'\//V&_!=[X:\!>'M'M?B!KRF2TT71[2.!(F
M8;%N;A8P.F!M7JQ '3)'G?[''@F3]@3]E'QO\7/BA%-::WK?EWSZ4PQ.!RMM
M P_ADD>0DY^Z&YQ@T >D?\%#/V\'_91TC2-#\*QV6H^.]383^1>*7BM;4$@N
MZ@@Y8C"C/9CVY^A_V=/B!J7Q5^!7@;QAK"0IJFM:3!>W*VRE8P[KD[02<#\:
M_%CXGMHGQ5^ ?CSXU^-_&>@:I\5O%.KVZ:=X=@U.&2[TZQ60AOW 8NG"JH!'
M"KD_>-?K/^P7XV\/>*?V6_AY8:-KNG:M?:3HEI;:A;65TDTEG+L^Y*JDE&X/
M#8/% 'T+1110 4444 %%%% !1110!E>*_$UAX+\,:MK^JS?9]-TRUDO+F4_P
MQHI9C^0-?FK9_P#!0S]I+XQ6'B;QM\*/A-IUW\.M!E=9I[L&69E10[ GS$+N
M$(8K&IVAA[9_374],L]:T^YL-0M8;ZQN8S%/;7,8DCE0C!5E/!!'8U\+?MK_
M +5/@S]EOP;??"'X4:%IX^('B%6B72-"M$2.P,ZA/-=(Q@S."-J8R>">,9 /
M0?@U_P % ?#OQ(_9/\2_&+4]+?39_"XD@U;287WYN%52BQL?X9/,0 GH20>F
M:^9A_P %$?VG)/AX_P 8T^%6A_\ "I4N=AF+-YGE^9Y><^9OQN.W?LVYKN?A
M;^SWX?\ V4?^"<OCRW^,<,X7Q#$VH:Q96A'VB&201QVT"$\>8K!#D\!F.>!7
MQS!H7[2<W[#EP]O'(?@$)3<&U+P_;_L8GW%NF[RPXR?IG&V@#]G?@;\6]-^.
MOPH\-^.M)ADMK/6;43BWE.6A?)#H3WPP(SWQ7=UX3^P]KO@O7_V7O LO@&*Y
MM_#L%G]G2"\8-/'*C$2B0C@MOW'(X.>*]VH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM?\.Z5XKTFXTO6M-M-7
MTVX7;-9WT"S12#T9&!!_&LOP7\-/"/PXMIK?PIX8T?PU!,VZ6/2;&*V5SZL$
M49-=+10 5XY^UQ\#+[]H_P" WB'P!IVIV^CW>IM R7ETC/&GES)(<A>>0N/Q
MKV.OBW]JG]O[6?A7\8+/X2_"WP,?B#X_DB66Y@9W\NWW+O"!$^9FV?,>0%!'
M7L ?0G[,_P );OX$_ KP?X"OK^'4[O0[0V\EW;J5CE)D=\@'D?>KTZODW]B_
M]N?_ (:6USQ%X,\5>&&\$_$3P_N-WI9=F215;8Y4, R,C8#(<XR#D\X^LJ "
MBBB@ HHHH **** "BBB@ HHHH \0_;)_9^U#]ISX$:KX!TS5;;1;N\N;:=;N
M[C9XU$4H<@A>><8KL/@%\-KGX/?!GPAX*O+R+4+K0]/CLY+J!2J2E?X@#R!5
M[XO?%;0/@E\.=<\:>)KH6ND:3;F:3&-\K=$C0=W9L*!ZFOF__@G_ /ML^(/V
MQ)O'CZSX?TW0;?0I+;[(MB\C.Z2^;Q(6)!($:\@#J: /L&BBB@ HHHH ****
M "BBB@ HHHH *\#_ &V/V;M1_:H^"DG@C2]8M=#NFOX+S[5>1LZ8C)RN%YR<
MU[Y7PE\<_P#@HAXOT[X\:I\)?@K\-?\ A87B+1@PU&XGD?RU=0/,5$3!PA(4
MNS#YN .A(!]=_!OP-/\ #'X3^$/"-S=1WMQH>E6VGR7,2E4E:.,(6 /(!QFN
MRKY1_8L_;D/[3NL>)O"'B7PL_@OX@>'!OO-,\QGCD0/L=EW ,C*Y"LK9QN&"
M><?5U !1110 4444 %%%% !1110 445X)^UM^U[X1_98^'^H:EJ%]:WOBJ2%
MAI6@B3,MS,1\I=0<K&#RS<<# Y(H J?MQ?LQZG^U?\'[;P;I6M6FA7,6IQ7Q
MN;R-G0JBN"N%YS\WZ5[!\,/"<O@'X:>$O#$\Z74^BZ1::;)/&"%D:&%(RP!Y
M )7/XUY)^Q!^T9K'[4/P+B\<Z]IECI%\^H7%H;?3R_E!8]N#\Y)S\WK7S9XK
M_P""G/CWQU\0_$6@_ ;X2/X^TGP^[+=:M,97\Y58KO1(\;58J=N6)8<X'2@#
M]%**^9_V)OVU],_:\\.ZR)-%?PSXKT)T34M*:7S4VMD+)&Q ."58$$94COD$
M_3% !1110 4444 %%%% !1110 5\U_MV_LIZK^UQ\,=%\+Z3KEGH$]AJR:BU
MQ>Q/(KJ(I$V@+SGYP?PJ_P#M?_MD^$OV5? -_>W-Y::EXQEB*Z5X?$F9)Y3P
MK2!3E8AU8G&0,#DBM']B_P"/VK?M+_ 72O'>MZ=9:5?W=S<0O;6&_P I1&Y4
M$;B3R!ZT >L>!?#\GA+P1X>T.:59Y=,TZWLGE0$*YCB5"P![';FKVN:)8^)-
M'O=*U.W6[T^\B:"X@?.V1&&&4X]17PG\6/\ @I'XNO\ XM:[X!^!/PQ?XCWG
MA\N-2U"0R-&&0[7")'@X# KN+<GH#U/L_P"Q/^V58_M<>$M7EGT1O#7BG0YE
M@U/2S(9$&[.UT8@'!*L,$9!&.>M--IW0';?\,E?"'_H1M._[ZD_^*H_X9*^$
M/_0C:=_WU)_\57KM%=7UO$?\_)?>Q61B^$/!NB^ M"@T7P_I\6F:7 6:.VA)
MVJ6)+=23R236U117+*3D[R=V,****0!1110 445\"?%S_@I)XON?C1K?PU^!
MOPP?XB:EH32)J%],TA3=&=LFR-,':K?+O9N3T&,$@'K_ .W=^R3JW[7/@GPO
MH>DZ]9:!+I&J'4'EO8GD61?+9-H"]^<U]%^'=,;1?#^F:>[B1[2VB@9U'#%5
M"Y'Y5\N_L7?MWP?M/:KXB\)^(_#3^"O'WA]#->::TA>.2-7".R[@&0HY 9&Z
M;AR><>-?$'_@J%XWU?Q_XLTSX-?"@^-_#?A/>=4UB9I6W(A(:15CX1,JV"2Q
M(&<#I0!^A6N:)8^)='O=*U.V2\TZ]A:"XMWSMD1AAE./4&O,/^&2OA#_ -"-
MIW_?4G_Q54?V2OVH="_:Q^%47BW2+5]+O()S9ZEI<K[VM;@ $J&P-RD,"&P.
M#Z@BO:ZVA6JTE:G)KT;0'D7_  R5\(?^A&T[_OJ3_P"*KT7PGX0T?P+H5OHV
M@V$>FZ7;[C%;1$[5R23U)/4FMBBG.O5JJTYMKS;8!1116 !1110 4444 <KX
M]^%OA3XGV]I!XIT6#68;5R\*3E@$8C!(P1VKYA_:9_X)^6WQ)L/#\7POO-,^
M'MQ9W+R7\KQ22_:HR!A.IQ@Y/XUY]\0/^"EWCCQ+\5_$7@SX$?"EOB#'X>DD
MCO=3F:1UD*,5=D2/&$W A6+?-U KV7]B;]N&Q_:SM->TK4- ?PGXUT C[?I3
M2F1&0L5WH2 PPPVLK#*DCDYKHAB*U-<L)M+R; ](L/V3_A18FVE7P5IXN8=K
M"0-)]\8Y^]ZBO6P H ' '%?/O[:G[6NE_LD_"MM=>*#4O$M_)]GTC29G($\G
M5G;'.Q!R2/4#O6K^QI\>-5_:3_9^T'Q]K6GV>EZCJ$US'):V&_RE$4[QC&XD
M\A03S45*M2K;VDF_5W ]NHHHK( HHHH **** "BBB@ KD_'OPI\)_%"*SC\4
MZ);ZREFS- LY8>66QNQ@CK@?E75L0H)/ ')K\\?&7_!3'Q]XR^)?B/PS\"/A
M(WCZP\/2.EYJDS2R"4*Q4LB1XVJ2IVDL2V,X'2KC.4'S0=F!Z#^TM_P3YB^)
M$OAAOAAJ&F?#Y+&:1]25HI)/MJ'9M7J<8PW_ 'U7NMM^RE\)K.XBGA\$:?'-
M$X='#295@<@_>]:\R_8]_;MT/]IOP?XGN]6TEO!WB'PJAEUFPEE,D<<0#$RH
MQ .!L8%2,@CO7SM<?\%2_BKXW3Q+XH^&?P2_MOX<>'W8W>JWDDIE$2C)=BF%
M0[?F*@/M'4UO];Q'_/R7WL5C]+Z*\?\ V5OVDM%_:H^$=EXVT>SETQVE>TO=
M.F<.UK<)@LFX ;AAE(; R",@'(KV"N484444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %17-K#>0M%<0QSQ-U21
M0RG\#4M% #5144*H"J!@ # %.HHH *^ ?V6/V#OB!\%?VQO%7Q4UR^T6;P]J
MCZHT,-G<.UP/M$^^/<I0#@=>:^]M0U&UTFQGO;ZYBL[.W0R37$[A(XU R69C
MP /4UY?X6_:R^#7C;Q,OA[0OB9X9U/6G?RX[.#48RTS?W8^<2'_=)H ]8HHH
MH **** "BBB@ HHHH **** "O@;_ (*+_L)^/_VL/B%X3USPA?:+:6FE:8UG
M.NIW#QN7,K/E0J-D8-??-<_X\\?^'?AAX6O/$GBK5[;0M#LP#/>W;;43)  ]
M222!@<T =!17+?#?XG^%OB_X7B\1^#M:M]?T.61XDO;7=L9T.&'(!X-=30 4
M444 %%%% !1110 4444 %>+_ +8GP=UKX^?L[^*_ WAZ:T@U?5$A6&2^<I$-
MLJ.=Q )'"GM7M%<5\2OC7X"^#EG#<^-_%VD>&(IL^4-1NEC>7'78I.YOP!H
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M%%% !1110 4444 %%%% !7Y9?LL.VN?\%</C#=7X\VXMEU-82_)4)+#$N/\
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M^-?!7C/P[IF@?$3PM<&/49=,M4MTO!YC(S,J\!U=6#8X.01BOFOPAX,^./\
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MLEK\%/ANOCC7=/US0_'FMPSV.HZ7JF(XX8DN"8RL10,I*HIR2<YH ^Z****
M"BBB@ HHHH **** $90ZE6&5(P0>]?*GQY^*_P &O^">_@?5]:T3PQH^D^)M
M='^B:%H\*6\FHS*#M:0*/EC4L27([X&20*^I-0NC8V%S<B*2<PQ-((HEW.^
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M'5B$<&--ACX50" -W5F/>@#]3?\ @DA_R9CHG_85O_\ T;7V;7YA_P#!'O\
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M=:36L'BBZ<Z6';Y%MX7"".,==B9"YP 3N[YK^D:OYVOVIOV@X/C))\/+/3_
M+> =)\(:9_9MEIYF:3S8PX8-ED4YXY/.2237[A_LG_'N[_:3^#=CXWO?#S^%
M[BXNKBW;3I)#(5\M]H;)53SUZ4 >Q4444 %%%% !1110 5Y;^TYX,\:_$3X&
M>*_#/P^U&TTCQ1JMK]E@O;RXD@2)&8"3#HK,&*;@,#OU%>I5GZ_K^G>%=$O]
M8U>]AT[2[&%[BYN[APD<,:C+,Q/0 "@#\M]%_P""6G@GX7?LM>-_$OQFU%K3
MQO96MY>1:CIVHL;2S$:$P!5VCS6=@,AAD[@HP>3#_P $J/$OCZ__ &9/C]I.
MB37-S_9UD\GAR,L2(M1DM;CY(\],LD!(Z D'^(UP7QO^.OQ _P""G'QJM_AE
M\/'_ +$^&]C<>:TMTWE1O&K8-Y='J1_<B]2.,\C[VNO">E_L,?L1^+;?X=>7
MJ&H^'-(N+[[855WN+QQ@W,H&<@$AL'HL87H* /R[_9(\!_L]>*? _P 4;GX]
M:_-I'C.SW?V=%=WLMO,#L8L\:C_73>8,%&#=OE.37US_ ,$4(O$\7@?XA?:D
MO!X0>]@;3GN 1$T^UA*8\\= F['<"O%?V%OV,O!O[9_PY^(OQ"^(_B;5;GQ3
M_:TUOYEO=*CQ.84F^U2Y4[@S2, .!^[;\/4_^".OQ3\2_P#"4?$#X6W.J3:S
MX4T5#=Z<\C%TMF\XQL(R?NH_WMHXSDCDG(!^H]%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5Y)^TC^TYX._99\)Z;XB\:"_.GZA>BPA
M_L^ 3/YIC=^02,#"-S7K=?G?_P %LO\ DWKP3_V-"?\ I)<4 =?%_P %A/@)
M)(%8^)(P3]YM-&!^3U]*? S]I#X>_M&Z%/JG@/Q##J\=L56ZMBICN+8G./,C
M;# '!P>AP<$X->#_ +*_[)?P:\>?LM_#N^U[X9^&M2U#4-#@DNKV33HQ<2NR
M\L9  V[WSFOB3P=HH_8C_P""HVE^%/"]S/%X7U;4;?33:/(6W6EZ%"QL3][R
MY&0@GGY!0!^T%%?%/[9__!1(?L^^-+/X<^!/#7_":?$2[$8-LQ8Q6[2?ZM-B
M?/)(V1A!C@CGM7D.G_\ !3?XP?!CQMH^G_M!?"9/#>AZK_J[W3X989(UR-SJ
M'=UDVY&5!!&?H* /TTHKY"_;._;[L?V<_"OA!O"&EP>,?$/C"$7.D!I2MMY#
M;=LK$<MN+* HQGGD8Y\5U_\ ;I_:H^">JZ%>_%+X(Z>WAW4[@0*FB+(UPQ(S
ML5EEE ?&2%8#.#[X /L_]HW]I;PA^R[X/LO$OC,7QTZ[O!8Q_P!GP"5_,*LP
MR"1QA3S7;?#OQUIOQ.\":!XMT?S?[*UJRBO[7STV2>7(H9=PR<'!Z5\D_P#!
M1GXW:/X2_9P\&^+;OP!I'C2QU;4;=XM)\76;@6_F6[N&:/ADD ^4@],D52^+
M_P"V)J_[.W[$GPC^(/A7PIHD+ZU;V, T;$B6EG&]LTFR(*00%V@#)Z4 ?<M%
M?F-XC_X*1?M :Y\,[;XB^"/@W:CP)9VD1U+6]2CEDCEG"J)VB59%(A63<H;Y
MN!R0<@?3_P"S-^V[H/QO_9NUGXIZY9CPVOASSH]:MU<R)&T<8?=&>"0RL, \
MY..>I /IJBOS&\(_\%)/V@?CAXCUK5/A1\%K77O!&DR_OEE\Q[DH.=OFAU7S
M"O.Q58C(Z]^[_98_X*2>(?VD/VGC\/SX3L]#\.R6T\R-,9/MT3QQ@M&_.W(?
M<.@X':@#[^HHK\[_ (Z?\%)_'$_Q[NOA/\!_ MKXRUG3KB2TNKJ]5Y!--'Q*
ML:(R;40@@NS8X/;D@'TQ\?OVSOA_^S=XU\.>%_%HU0ZGKT8DM/L-J)4P9/+^
M8[ACYJ]V1Q(BN.C#(K\*/VS/C?XR^,/QY^&5K\0_!,O@7QIX?\FSO[$L3#,'
MN0Z2Q$Y^4@GNPXZFOT2_;2_;BUS]G77/"W@;P)X.?Q;XXUV*-X1.DGV:(.VR
M- %P9)&(/R@C P2>: /L>BOS&O/^"DOQX^!?Q#\.:3\=/A5IFB:/K##9)8!X
MI?+W!6=&,LB,4W#*\'D<C->I?M$?M[^+?V>_VI?"G@C5?#^D2?#[Q!]CN(=:
M)D%PMO*VR1CSMRCACC'3'K0!]ST5\P_M[?M?3?LC?"_1M:T>QLM8\0ZSJ*VE
MG97K,(S$J%Y93M()"_(/K(*]=^ /C#Q+\0?@YX4\3>+M/M=*U[5[)+V:RL]W
MEPK)\R+\Q)SL*Y]\T >@T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>(?^".NO:)KVJCX;_&2\\->&]5S%<Z=/#,'\DYS&[12J)EYQA@/>OK']C?\
M8L\,?L?^%]0M=,OYM>\0:J4.HZQ<1",R!<[8T0$[$!).,DDGDU]%44 %%%%
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M&5I D)8B)BQ /S* WT84 >H4444 %%%% !1110 4444 %%%% !1110 4444
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MZC,2 <NV_*@#DXKY/U;_ (+5_"FSUEK:R\'^*M0L%?:;T+!'N']Y4:3/YX-
M'Z'45Y1^SS^TYX!_:=\+2ZWX'U7[5]F94O+"X7R[JT8C($B>AP<,,@X.#P:\
M$^.W_!5KX1_!7QAJ'ABWM-7\8ZKI\C073:0D8MXI5.&3S'8;B#D':",B@#[2
MKR/XS?M6_"[]G_5[#2_'GBB+0;Z^@-Q;Q20R.7C#;2?E4]Z\,^ /_!53X3?'
M/QI8>%9;/5O!^L:A((+,ZNL9@FE/W4$B,<$G@;@,G KRW_@J#=? *W^)7A ?
M%RQ\;76K'2G-FWA>6W2(0^:<A_-YW;O3M0!^C5A?0:G8V]Y;.);:XC66)Q_$
MK#(/Y&IZ\ ^.W[5/@[]DSX.^$/$^MZ=J^H:+J+6^G6<-BD;SKFW:1"^YE'W8
MR#@]37A7B[_@L=\'= T72+K3=(U_7KZ^@$TMC!'%&UGDD;)79]N[C.%W=1F@
M#[THKP#]EC]MCX>_M;6VHQ^%'O=/UG3D66ZT?5(U2X2,G D7:S*RYP"0>"1G
M&17._M0?\%#OAA^RWKB^'M8^W^(?$_EB632='16:W4C*F5W957/7&2<<XH ^
MH:*^"M)_X+(_!J]\(W.JW6D>(K'4X)4C.C&")YI%;/SH^\(0,<Y(/(XKZT^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO@@VN?$3Q/\ $^\M&%AHT']FZ=)(O!N)>9"I]5C !_ZZ5^OU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFF21@;9&QU<+(JG/?-?T%? ;X5VGP2^#OA'P1:%771M/BMI94&!+-C,K_P#
MG+'\: .]HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1CIRS'')( '<D 5JU^+W_!1_]H77?CE\?[KX=Z+-/-X<\-WW]E6NFVV?],U
M'9+(RC[S"0M$OH%.,;VS-*G[25@;L?:7BO\ X*S_  ,\.ZC):V*^)O$L:''V
MK2M-18F^GGRQ-_X[7HGP0_;\^#GQXUFWT71M=GT?7K@[;?2]>@^S2SMV5&!:
M-F_V0Y8]A7B_P<_X)*?#;1/!]FWQ"N-2\1^)IH@]T+6[-M:V[D?<C"?,VWIN
M9CNQG '%?+O[7_\ P3G\1?!_QOHDOPJTW7O&.@ZP7\JWMK9KFZTZ9"#MD:-<
M;"&!5SC[K ] 6W4*,GRIBU/V5HKR3]E2_P#B%?? KPROQ1TNXTOQI;1-;7?V
MJ6-Y+A48B.9MC-AF3;N!P=P8D<BKGQH_:6^&W[/MK#)XY\46ND7$Z%X+%5::
MZF7.,K#&"VW/&X@+[UR<KORK4H]/HKY1\,?\%//@#XEU=-/?Q+>Z,9&V)<ZI
MILL<!/;+J&"CW; '<BOJ33-3L]:TZVU#3KN"_L+J-9H+JVD$D4J,,JRLI(8$
M<@BB491^) 6J*\%^(G[<GP9^%/Q!OO!/B;Q5+I_B2R>*.>T73+J4*TD:2(-Z
M1E3E9%/!XS7O5#BUJT 45X+\.OVY/@S\5OB#8^"?#/BJ74/$EZ\L<%HVF740
M9HXWD<;WC"C"QL>3SBNG^.'[3?PZ_9R&BGQ_KDFB_P!L>=]BV64]SYGE>7YG
M^J1MN/-3KC.>.AI\DKVMJ!ZG17@WC;]N/X,^ /!>@^)M5\7H+/7;87FFVD%M
M*]Y<0DD!_)V[D4D'YG"@X(SFD^"W[<7P>^/6N1Z'X9\3^5K\JEHM+U.V>UFE
MQU"%AL=N^U6)P"<8!HY)6O85SWJN?L/'_AS5?%^H>%K+6K*\\0Z? MS>:=!*
M'EMHV.%,@'W"3T!P2.<8KP?]O3]H?0O@K\%M;TB;Q%=^'_&'B+3+J/0'LXYO
M,>5-@8K+&I$1'F+R2O7@\5^>O_!-K]I'P-\ ?'7CG5OB'KLVF1ZM8PQPSFUG
MNFFE$I9L^6K'/.<GK6L*+E!R!L_:*BN1\7?%OP?X!\#Q^,/$GB"ST/PY)$DL
M=[>OY8D#KN154_,SD<A "QP>*^<;C_@JC\ (;X0)K>L3Q?\ /U'I$PC_ "8!
MO_':R4)2V0SZ\HK@_A#\=? GQXT*35_ OB.UUZUA*K.D6Y)K=B,@21. Z$X.
M,@9P<9Q7>5+36C *\B_:3_:?\'?LM>$;'7O%HO;H7US]EM-/TQ$DN9VQN9E5
MW0;5&,DGC<HZD"O7:_'K]H;7Y_VSO^"AVC> XGDF\,Z3JJZ"D2,<?9[=B]_*
M,<9;9-ANZI'Z5K2@IO79";L?IS/\?M TSX"Q?%O5['5-&\-OIT6J-;74"F\C
M@D*["T:.PR0RG 8\'GGBO!?^'KOP&_Y_/$'_ (*C_P#%5Z'^WC;Q6G[&_P 2
MH((UAABTN-$C0855$T0  [ "OS'_ ."=W[,G@S]IOQQXLTKQF-0-KIFG1W4'
M]GW(A;>TNTY.TY&*UITX2@YRZ";/OJV_X*K_  #G?:^IZW;C^])I,A'_ (Z2
M:]Z^#O[1?PY^/ME<7'@3Q59ZZUL ;BV4/#<0@]"\,BJX7/&[&">AKYIUS_@D
M;\%[_2[B'3K_ ,3:7>NA$-U]NCF$;=B4:/YAZC(^HZU^=?[/FJZU^S[^VAX>
MTW2M0^U7.G>*AX=NI+4GR[V!KK[-* ,\AADJ#G!VGJ!5*G3J)\CU07:W/VI^
M//Q^\)_LX^#+?Q1XQDNXM*GO4L$:RMS,_FNCN/ER.,1MS]*\!_X>N_ ;_G\\
M0?\ @J/_ ,56)_P5\_Y->T;_ +&FT_\ 2:ZKYJ_X)W?L8_#C]I;X:^)M;\:0
M:G+?:?J_V. V-X85$?DH_(P<G+'FIA3A[/GF%W>Q]>:9_P %3_@!J%U'#-KF
MK:>KD S76DS%%]SL#''X5].>"/'GAWXD^&[77_"VLV>O:-<Y\J]L91)&2#@J
M2.C \%3@@]17P-^TE_P2[^%OA#X,^+/%'A/4=9T?5]!TVXU-!>WBS6\ZQ1EV
MC<% 1D*0"",$C.:\L_X(Z>-->@^+_B[PI'/-)X:N=$?4IK<L3'%<QSPQI(!T
M!*R.IQR<+_=H=.$H.<'L%WU/UJKYD^,'_!1?X)_!S6+C2+O7[CQ)JULQ2>T\
M.6XNO*8<%6E++%N!!!4.2#U KS3_ (*H?M+:I\(_AOI7@?PU>R6&N>*Q*;J[
M@8K)!8I@.%(Y4R,P7(_A60=P:^</V#O^"=6D?'?P2/B!\0KN_M_#]S-)#IFE
MV#"%[H(VUIGD()";@ZA5 )*DY QE0IQY>>H] ;Z(^K?!7_!5WX&>+=4BLKV3
MQ!X5$C!5N=:T]/)!/3+022E1[D #N:^N]&UK3_$6E6FJ:5>V^I:;=QK-;W=I
M*)(ID(R&5E)!!]17YQ_M:_\ !+7PKH?PVU3Q1\)8]4@UK28C<R:#+,UXE[$O
M+B+(,@E R0,L&QMP"<UU/_!+'PS\9OASIWB#PUXX\):QHW@>:,7VERZNH@:V
MNMP$D:Q.1*%D5MWW=H,9/!<Y)PIN//!@F^I] :#^VIX(U?\ :-U#X*WFG:WH
M/BVUEDABFU.&%+2[=5#J(G65F_>1G>FY5R.."0#] 5^6_P#P5O\  %WX'^)/
MP]^+GA]I-/OYO]"FO;?Y6BNK=A+;29_O%2P!](17Z#_L_P#Q8MOCC\&/"7CB
MV58_[7L5EGB3I%<*2DZ#V65'4>PJ)P2BIQZC1Z#1116 PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KY9_P""G'_)E_CC_KMIW_I=!7U-
M7RS_ ,%./^3+_''_ %VT[_TN@K2G\<?43V/RK_9>^-WQB^#(\42?";3KF^6_
M%M_:C6^CF_$8C\WRMV%.S.^7TS@^E=KXA_X*+?M$>-X9O#3^+8-(DOF^Q2&T
MLK:RE4L=I'G, 8CDX+;EV]<BOHK_ ((L?Z[XP_[NC_\ M[74_P#!4?\ 8^@\
M3>')OB_X0TY(]:TQ,^(+:VCP;NV'_+S@=7C_ (CW3DGY.?0<X>UY9+YDVT*O
M[ O_  3K\0_##QU8_$KXE?9;74+!&;2=#MIUN&25UV^?+(A*<*S;54MR0Q(V
M@%O_  6#^-&J:%X=\)_#;39S;V>M"34]4*,0TL<;!88C_L%]['U,:>ASS7_!
M+']K^YCU./X->,-2>>VG4OX:N[I\F)P,M9[C_"0"T8[$,H^\H&?_ ,%EO!%]
M%XT^'_C!8';39]/ETEYQRJ2QR&55/H665B/78?2LTI>W7.'30D_94_9H_96U
M#X(:3JGQ/\:^&;[QAK,!N9X+KQ9'9/I@8G9&L23(0X7:6\P$[B1C'%>"_"?Q
M=;?LD_MQV]MX/\4P>(O!ZZQ'I<NH6=U'/!?:;<,GWGC)1V0.I)''F1=NE?17
M[)G[%?[.G[0/P/T?Q1<ZIJHUZWMMFO6T>KI%]DN%R'9D*Y1&QO4GC!Z\&N:\
M'?#W]BS5_C'!X,TFZ\=S:['JZZ?9744@GM+R<2!5:)XE8F,L/O$ 8YZ<U?,K
MR3NP/0_^"Q7Q:U/2/#O@OX>6,_D6&KM+J>I*IPTJQ,JPH?\ 9W,[$>J(>U._
M8C_X)U?#/QK\"=&\9_$72Y_$6K^(H6NH(!>S6\5E 6(CVB)D+.R@,2Q(&0 .
M"3S'_!9CP1>+K7PZ\81VTCZ>]O<:3/< ?)'(&$L2GT+!I2/]P^E?2W_!/;X_
M>$?&W[,OA/2#KMC::[X:LO[.U#3[FX6.6)8B0DF&(RC1A3N' .1G*FLFW&BG
M ?4_+;]M;]GVV_9J^.^H^$M-NI[O0I;:+4-+:Y;=*EO(6^1C@ E761<]P >I
M-?MM^SK_ ,F^_#'_ +%?2_\ TDBK\>?^"DWQDT+XS_M,7=YX;O8M3TC1=-@T
M:._MV#17#H\DDC(P^\H>9EST.W(R"#7[#?LZ_P#)OOPQ_P"Q7TO_ -)(J*[;
MIQYMP6YZ'7XD?\%3O^3P=>_[!UA_Z(%?MO7XD?\ !4[_ )/!U[_L'6'_ *(%
M1A?C^02V-G0O$_[<,7A_3ETF'QX=)6VB%IY&FJR>3L'E[3Y?(VXQ7A?Q6N?B
M*WQ'TF]^/EEXTN"[ O#JYDM;F2V##>+9ID**/]U2N:_93X:?M5?!K3?AOX5M
M;KXI^$;>YM])M(I89-9MU>-UA4,I&[((((Q7R=_P4^_:>^$WQ*^#VG>#_#/B
M"P\7>(QJD-]'-IC>=#9QJDBNQF'RY8-MV D\Y.,#.\*C<K<HFC[2_94^(?P^
M^(_P0\.WGPRB^Q>%[&$:?'ILB[9K&2-1NAE&3\XW ELG=NW9.[-?DG\1?^4E
MES_V4>V_]+HZ^M?^"-&B:M:_#OXBZI<)(NBWFI6L-F6&%::.-S,5]>)(1GV]
MJ^2OB+_RDLN?^RCVW_I='4TX\M2:0/8^X?\ @K%\>-4^&?PAT3P;H=U)97OC
M&:>.[N(CAA90A/-C!'(WM+&">ZAQWKQ+]@7_ ()X^#?C'\*H/B)\1?MFH6VJ
MS31Z9I5I<M;QB&.0QM+(RX<L9$<!00 %SSNX[;_@LMX!OM1\)_#OQE;0F2QT
MNZNM.O'4$[#.L;Q$^@S#(,^K*.]=Y_P3&_:0\&ZS^SUH_@/4-<L=*\4>&Y+B
M%K.^N%A:Y@>9Y4ECW$;@!)L(&2"F3@,,RFXT$X?,?4^,_P!O7]DNV_9 \>>%
M]?\  VIW\.@ZLSRV+2S_ .DZ?=P%&(608)'SJRMU&&!)P"?N[0_VQ]1E_P""
M><WQDG$;^*K33FL')0%6U$3BU24KTP79)2HXP2*^6?\ @K1^T%X6^(VM>$/!
M/A?5;;6VT-KB\U*[LI1+"DL@14B#C@LH5RV#@;E'4$#U#1_V>]?7_@DO?^'V
MLY!X@N[4^)ULRIWB-;I;D*%ZEC;Q@[>N6QUJI>]"#GO<75V/EW]A?]EM?VRO
MBCXHUCQMJU]+HFE;+S5)HYO]*O[F=G*(9&S@'RY69N3P ,;LCW']NW_@G1X*
M^%/PAO?B!\.!>Z:=%:,ZCI=U<M<1RP.ZQ^8C/EE=6921D@KG&".>/_X).?M
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M]8M_$7[$\VJVC;K2^O--NH6/='8,OZ$5P/\ P1J_Y)-\0/\ L-Q?^B%KN/\
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M ,%)_P!HO4X[K19_%$&BW$A:VE,.EV]M/$3\I&]ES&1_>X*]<C&:^AOV&?\
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M$]SXR\47>O>"=(@2UMGU*%'GDO'(; N-N]PD:DL&8\R)T[\_LI<G.QW/0O\
M@J[X?BUG]DF\O)%R^DZS97D9QT+,T!_28USO_!(+Q3/K'[..N:1/)O&C^()D
M@7^Y%)#%)C_OLRG\:[#_ (*F:K'I_P"Q[X@@=@K7VH6%N@/\1$ZRX'X1D_A7
M ?\ !'709;+X"^+=5DC*)?\ B%HXR?XUCMXN1[9=A^!K5?P'ZBZGWO1117(4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?B+XDT6'49],L"6BMYF@65XF?)"-RV$)W<<]L^:_M#?\%'/"/ASX->,-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#P\F\6_P#1M'Q'_P# *3_XW1_P\F\6_P#1M'Q'_P# *3_XW0!]T45\+_\
M#R;Q;_T;1\1__ *3_P"-T?\ #R;Q;_T;1\1__ *3_P"-T ?=%%?"_P#P\F\6
M_P#1M'Q'_P# *3_XW1_P\F\6_P#1M'Q'_P# *3_XW0!]T45\+_\ #R;Q;_T;
M1\1__ *3_P"-T?\ #R;Q;_T;1\1__ *3_P"-T ?=%%?"_P#P\F\6_P#1M'Q'
M_P# *3_XW1_P\F\6_P#1M'Q'_P# *3_XW0!]T45\+_\ #R;Q;_T;1\1__ *3
M_P"-T?\ #R;Q;_T;1\1__ *3_P"-T ?=%%?"_P#P\F\6_P#1M'Q'_P# *3_X
MW1_P\F\6_P#1M'Q'_P# *3_XW0!]T45\+_\ #R;Q;_T;1\1__ *3_P"-T?\
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M$?\ \ I/_C='_#R;Q;_T;1\1_P#P"D_^-T ?=%%?"_\ P\F\6_\ 1M'Q'_\
M *3_ .-T?\/)O%O_ $;1\1__  "D_P#C= 'W117PO_P\F\6_]&T?$?\ \ I/
M_C='_#R;Q;_T;1\1_P#P"D_^-T ?=%%?"_\ P\F\6_\ 1M'Q'_\  *3_ .-T
M?\/)O%O_ $;1\1__  "D_P#C= 'W117PO_P\F\6_]&T?$?\ \ I/_C='_#R;
MQ;_T;1\1_P#P"D_^-T ?=%%?"_\ P\F\6_\ 1M'Q'_\  *3_ .-T?\/)O%O_
M $;1\1__  "D_P#C= 'W117PO_P\F\6_]&T?$?\ \ I/_C='_#R;Q;_T;1\1
M_P#P"D_^-T ?=%%?"_\ P\F\6_\ 1M'Q'_\  *3_ .-T?\/)O%O_ $;1\1__
M  "D_P#C= 'W117PO_P\F\6_]&T?$?\ \ I/_C='_#R;Q;_T;1\1_P#P"D_^
M-T ?=%%?"_\ P\F\6_\ 1M'Q'_\  *3_ .-T?\/)O%O_ $;1\1__  "D_P#C
M= 'W117PO_P\F\6_]&T?$?\ \ I/_C='_#R;Q;_T;1\1_P#P"D_^-T ?=%%?
M"_\ P\F\6_\ 1M'Q'_\  *3_ .-T?\/)O%O_ $;1\1__  "D_P#C= 'W117P
M#XD_X*JWW@NRBO?$?P#\;^'["298!=ZG&8(M[9PNYT R<'CV-??%G<"\M()P
M-HE17 /;(S0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !17A?AO]LSX<>+OVA;WX
M-:1=7M]XLLUE,TT,*M9JT:;Y$\S=]Y>A&.H(KT7XJ_%KPG\$_!=YXK\9ZQ#H
MFB6N%>>7+%F/W410"68]@ 30!U]%?,'P8_X*/?!'XY>-;?PIH>N7FGZU=OY=
MG#K%H;=;M^RQODC<>RD@GL":^GZ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG@AB0".X&*J?M>Z78?!?_@I[\)-9\,V<&CG5!ITUS'91B)'9[B2W<X7 ^9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y9_\
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M\/=-TG7-/T_S;6\A>4O$^]1D9<CH3VK[YKYV_P""A?\ R9G\4O\ L%_^U$H
MY+_@E:,?L1^!_P#KOJ'_ *635];5\D_\$K?^3(_ _P#UWU#_ -+)J^MJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM>\!ZIX7U(CPOJM[ ZPW"+/,HWMM4ME4C.]#QG.#TK]M:* .-^#?@[6/A_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH J:M_R"[S_ *XO_P"@FOS,_P""+O\ R&?CC_U^
MV7_H5U7Z9ZM_R"[S_KB__H)K\S/^"+O_ "&?CC_U^V7_ *%=4 ?I]1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!^6'QH_Y3)^ _\ KE9_^D\M?J?7Y8?&C_E,GX#_ .N5
MG_Z3RU^I] !1110 4444 %%%% !1110 4444 >#_ +='B_6? 7[)_P 1-?\
M#VI7&D:S964;VU[:OMDB8SQJ2I[<$C\:^8/A#^RM\?\ XJ_"SPEXR'[4GB'3
MAK^EVVI"S-DTGD^;&K[-WG#=C=C.!7T1_P %%O\ DRSXH_\ 7A%_Z4Q5V/[(
M'_)JWPC_ .Q6T[_TG2@#YT_X88_: _Z.Q\0?^"YO_C]'_##'[0'_ $=CX@_\
M%S?_ !^ONFB@#X6_X88_: _Z.Q\0?^"YO_C]'_##'[0'_1V/B#_P7-_\?K[I
MHH ^%O\ AAC]H#_H['Q!_P""YO\ X_1_PPQ^T!_T=CX@_P#!<W_Q^ONFB@#X
M6_X88_: _P"CL?$'_@N;_P"/T?\ ##'[0'_1V/B#_P %S?\ Q^ONFB@#X6_X
M88_: _Z.Q\0?^"YO_C]'_##'[0'_ $=CX@_\%S?_ !^ONFB@#X6_X88_: _Z
M.Q\0?^"YO_C]'_##'[0'_1V/B#_P7-_\?K[IHH ^%O\ AAC]H#_H['Q!_P""
MYO\ X_1_PPQ^T!_T=CX@_P#!<W_Q^ONFB@#X6_X88_: _P"CL?$'_@N;_P"/
MT?\ ##'[0'_1V/B#_P %S?\ Q^ONFB@#X6_X88_: _Z.Q\0?^"YO_C]>?>%+
M#XO_   _;X^$/PZ\3_&;6OB#HOB"RN[^XAN4:&(A8+H*C(7;=AH@V<^GI7Z5
M5\&?'_\ Y2N?L[_]@"\_]%7] 'WG1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'PW_P6"_Y-9TG_L:K'_T7/7VOHG_(%L/^O>/_ -!%?%'_  6"_P"36=)_
M[&JQ_P#1<]?:^B?\@6P_Z]X__010!=HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^=O^"A?_ "9G\4O^
MP7_[42OHFOG;_@H7_P F9_%+_L%_^U$H Y+_ ()6_P#)D?@?_KOJ'_I9-7UM
M7R3_ ,$K?^3(_ __ %WU#_TLFKZVH **** "BBB@ HHHH **** "BN!^,_QU
M\%?L^^%8?$?CO6#HVDS7*V<<PMY9RTK*S!0L:L>B,<XQQ7B/_#T+]F__ *'R
M;_P37O\ \9H ^K**^4_^'H7[-_\ T/DW_@FO?_C-'_#T+]F__H?)O_!->_\
MQF@#ZLHKY2'_  5$_9N)('CV4D=1_8][_P#&:7_AZ%^S?_T/DW_@FO?_ (S0
M!]645\I_\/0OV;_^A\F_\$U[_P#&:4?\%0?V;R0/^$\E_P#!->__ !F@#ZKH
MJKI6IVNMZ99ZC92B>SNX4G@E (#HRAE///((JU0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH_X+!?\ )K.D_P#8U6/_ *+GK[7T3_D"V'_7O'_Z"* +M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S
MM_P4+_Y,S^*7_8+_ /:B5]$U\[?\%"_^3,_BE_V"_P#VHE ')?\ !*W_ ),C
M\#_]=]0_]+)J^MJ^2?\ @E;_ ,F1^!_^N^H?^EDU?6U !1110 4444 %%%%
M!1110!3U71K#7+7[-J5E;W]ON#>3=1+(F1T.&!&:Q_\ A6GA'_H5]&_\ (O_
M (FNDHH YO\ X5IX1_Z%?1O_   B_P#B:/\ A6GA'_H5]&_\ (O_ (FNDHH
M^%_V1_!?A^^_:]_:EM;G0].N+:UU/3E@AEM(V2(&.7(4$87\*^Q/^%:>$?\
MH5]&_P# "+_XFOE3]CS_ )/(_:N_["NF_P#HN6OL^@#F_P#A6GA'_H5]&_\
M "+_ .)H'PU\(@_\BOHW_@!%_P#$UTE% #418U"J J@8  P *=110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8+%))>SB<,LQP<FW[:?]?([7/Q"_NZ1^;56U+4?'NE:?<7DRZ5Y4"&1MNXG
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MM85\!7P\.>HM/4Z</F>&Q53V=)N_H=51117G'JA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !117RU^UO_ ,%!? ?[*EW_ &#=07/B
M/QI)"L\>BV?RB-6SL:60C"@XZ#)]N: /J6BOR/O_ -LW]M3XYO\ :OA[\.[S
MPYHTIS!+9:(9-R]LS7 *-]0!44/Q4_X*(^#I%O[W0M5UB!#N:VDT>SG##T*P
M@/\ D: /UUHK\T/AA_P5NUCPKKD'A_X\_#F^\)7+$(^I6=K+%L_VGMY?FQ[J
MQ^E?HOX0\7:1X]\,:9XBT&^CU+1M3MTN;2[BSMEC89##//YT ;%%%% !1110
M 4444 ?EA\:/^4R?@/\ ZY6?_I/+7ZGU^6'QH_Y3)^ _^N5G_P"D\M?J?0 4
M444 %%%% !17S3_P4=US4?#G[&OQ"U'2=0NM+U"&.T,5W93-#*F;N$':ZD$9
M!(X/>OPD_P"%Z?$G_HH/BK_P=7/_ ,70!_3C7#?&GX<7OQ9^'.J>&-/\5ZMX
M*N[SRRFM:)+Y=U#M=6(5L@X;&TX(X)K^<?\ X7I\2?\ HH/BK_P=7/\ \71_
MPO3XD_\ 10?%7_@ZN?\ XN@#]DO^'='C3_HZ#XF_^!\G_P =H_X=T>-/^CH/
MB;_X'R?_ !VOQM_X7I\2?^B@^*O_  =7/_Q='_"]/B3_ -%!\5?^#JY_^+H
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MI/\ V-5C_P"BYZ^U]$_Y MA_U[Q_^@B@"[1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SM_P %"_\ DS/XI?\
M8+_]J)7T37SM_P %"_\ DS/XI?\ 8+_]J)0!R7_!*W_DR/P/_P!=]0_]+)J^
MMJ^2?^"5O_)D?@?_ *[ZA_Z635];4 %%%% !1110 5^;W[0/_!7*_P#@A\9_
M%O@2/X9VVKQZ%?/9B]?6&B,V,?,4\DXZ],FOTAK^=7]OC_D\7XK_ /8:E_D*
M /L?_A^-J?\ T2*T_P#!\W_QBC_A^-J?_1(K3_P?-_\ &*_+JB@#]1?^'XVI
M_P#1(K3_ ,'S?_&*/^'XVI_]$BM/_!\W_P 8K\NJ* /U%_X?C:G_ -$BM/\
MP?-_\8H_X?C:G_T2*T_\'S?_ !BORZHH ^XOA%_P4\O?A1\8/BIX[C^'\&I2
M>.KJVN7L6U5HQ9^4KK@/Y1WYW^@QBO8_^'XVI_\ 1(K3_P 'S?\ QBORZHH
M_47_ (?C:G_T2*T_\'S?_&*/^'XVI_\ 1(K3_P 'S?\ QBORZHH _47_ (?C
M:G_T2*T_\'S?_&*/^'XVI_\ 1(K3_P 'S?\ QBORZHH _47_ (?C:G_T2*T_
M\'S?_&*^G?V&?V_;O]L7Q-XETFX\%P^%QH]I'<B6+4#<^;N<KC!C7&,>]?@[
M7Z6_\$1?^2E?$C_L%6__ *-- 'Z]T444 %%%% !1110 4444 %%%% !1110
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MUV7A7QAHGCC2AJ>@:I;:OIY<QBYM) Z;AU&1W&17XJ5^F/\ P3__ .3?HO\
ML*7/_LM>-FN2TL!A_;0FV[I:V.[!X^>)J\DDEH?25%%%?('N!1110 4444 <
M)\9_^1(D_P"N\?\ ,U\_U] ?&?\ Y$B3_KO'_,U\_P!?:Y/_ +M\W^A^>9]_
MO?R7ZA1117MGSH4444 %%%% !1110 4444 %%%% !7NOP,_Y%2Z_Z^V_]!6O
M"J]U^!G_ "*EU_U]M_Z"M>-FW^ZOU1[^1_[XO1GHU%%%?$'Z,%%%% !1110
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ML_\ P!3_ .(KW'[5!_SVC_[Z%(;J#'^NC_[Z%9?5X_S/[V>C_;6(_P"?5/\
M\%0_^1/EKX677Q@^*>D:A?VGCV"S2SO7LF2:SC)9E"G<,)T^:NU_X5U\:_\
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M /0K:-_WW+_C7#_J]C_Y5]Z.G^T\-W_ _0>BOSX_X>0^+_\ H5M&_P"^Y?\
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MP#\"_A%:PKIO@/3]7O4 S?Z[&+Z9B/XOWF54_P"Z!7M\/@[0;>W%O%HFG10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN>OM?1/^0+8?]>\?_H(KXH_X+!?\FLZ3_P!C58_^BYZ^U]$_Y MA_P!>\?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#XR_P""A'[2WQA_9^O?!,?PK\-+X@CU2.[:_+:3
M-?>48S%Y?^K(VYWOUZX]J^0?^'D7[7G_ $3B/_PE;S_XJOM_]KSP9^TW?>,=
M'\1_ CQ-I=MI=II_DWOA_4)$5KJ<2.P=1)&4Y4JN2Z]*\$_X;Q_:?^"#M%\7
M/V?I]3LX0/-U+1D>-,>OG1^="?H"* /G/XG_ +;W[4_Q:^'VO^#=;^'4BZ3K
M5H]G<FU\,7B2A&Z[6).#^%?=G_!*'P[JWA?]DFQL=9TR\TB]&KWKFVO[=X)
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MCW_!1/\ Y(AIG_8<A_\ 1,U?G#7ZIP[_ +BO5GQV:?[P_1!1117TYY 4444
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M_#_@AS'[8_\ ":>'O^@[IG_@9'_C5[3]7L=71WL;VWO40X9K>59 I]#@FOQ
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MT#7R/_P2X^%6L?"K]DS1XM=M9+'4=<OKC63:S+M>..38L>1V)2-6Q_M5]<4
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M-_.H:_/S^R(_"@HHHH*"BBB@ HHHH **** "BBB@#[&_87_Y%;Q-_P!?L?\
MZ+KZ=KYB_87_ .16\3?]?L?_ *+KZ=K[+ _[O$_F'BO_ )'6(]5_Z2@HHHKN
M/D@HHHH **** "BBB@ HHHH ^&_^"P7_ ":SI/\ V-5C_P"BYZ^U]$_Y MA_
MU[Q_^@BOBC_@L%_R:SI/_8U6/_HN>OM?1/\ D"V'_7O'_P"@B@"[1110 444
M4 %%%% !1110 4444 %?E7^VA_R<9XI^L/\ Z*6OU4K\J_VT/^3C/%/UA_\
M12U]=PS_ +W+_"_S1XF;?P%Z_HSQ"BBBOTT^2"BBB@ HHHH **** "BBB@ K
MZ._8#_Y.$M?^P;=?R6OG&OH[]@/_ ).$M?\ L&W7\EKR\T_W*M_A9UX3_>(>
MJ/TUHHHK\8/O0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKXR?"+P_
M\=OAQK'@CQ0EQ)H>J*BSBUF,4HV.KJ5;L0RJ:[6B@#\ZM3_X)-:KX%NWO_A!
M\;?$WA&X7F.&[D;&>P,D+)Q_P$TR&V_;\^!7$<^@?&+281PDWE&<K]?W,A/U
M9J]5_P""E?[3GBS]GSX9>'].\!GR?%WBJ_-A:W2QB22% !N,:G(+DLBC(.,G
MOBOE;]M/]HKXU7.L?!SX&Z%K-]X>\=W6CV']OM87@CGN-2F 18WFC/"C&\[3
M@F3GH* /KG]EG]L+Q]\8/B+<>!?B'\']6^'6LP6$EZ+RZ25;>?8RJ502(.N_
M/#-TKZSK\]/^"=OQD^*FA?&CQ[\ OB[J<NN:YX=@%Y;7EQ<?:)$&4W*)3RZ,
MLL;J6Y&>W0?H70 4444 %%%% !7SM_P4+_Y,S^*7_8+_ /:B5]$U\[?\%"_^
M3,_BE_V"_P#VHE ')?\ !*W_ ),C\#_]=]0_]+)J^MJ^2?\ @E;_ ,F1^!_^
MN^H?^EDU?6U !1110 4444 %?SJ_M\?\GB_%?_L-2_R%?T55_.K^WQ_R>+\5
M_P#L-2_R% '@-%%% !1110 4444 %%%% !1110 4444 %?I;_P $1?\ DI7Q
M(_[!5O\ ^C37YI5^EO\ P1%_Y*5\2/\ L%6__HTT ?KW1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?._Q _;7\&>"/VF/"/P2^
MSSZCXCUN58KNX1PL.G^9&S0J^<EG<A/E&,!P<]C]$5^1GB[XK^%?V<O^"D7Q
MR\7_ !!MA-?1:0UQX<>:W,NZZ-M 8 AP=I*@H'XQAAD4 6?VP?V\_ADWQ@UO
MP@GP+\,^/]*T:Y>TU#5M0 BN)I$.V7RF1"4"MD;B3DCH*^Z/V&[3X62? BRU
MOX1:5+H?AC7;F2_FTZ:=Y7MKK"QRQDL21@Q@8!QW'6OS-_89U'PK\-/@C\;_
M (Q?$J(75GK$)\-6'G6YF:\NIDDEEC7@X+$1Y8X'!YK[3_X(^:/J&F?LDM<7
MD;QVU_KUY<V8?O%MC3(]MZ/0!]PT444 %%%% !1110!4U;_D%WG_ %Q?_P!!
M-?F9_P $7?\ D,?''_K]LO\ T*ZK],]6_P"07>?]<7_]!-?F9_P1=_Y#/QQ_
MZ_;+_P!"NJ /T^HHHH **** "BBB@#\X?^"V_P#R1?X??]A^3_TG>OQUK]BO
M^"V__)%_A]_V'Y/_ $G>OQUH **** "BBB@ HHHH **** "BBB@ HHHH *_>
MW_@E/_R9/X._Z^K_ /\ 2J2OP2K][?\ @E/_ ,F3^#O^OJ__ /2J2@#Z[HHH
MH **** "BBB@#Y:_X*)_\D0TS_L.0_\ HF:OSAK]'O\ @HG_ ,D0TS_L.0_^
MB9J_.&OU3AW_ '%>K/CLT_WA^B"BBBOISR HHHH **** "BBB@ HHHH ****
M "OTQ_X)_P#_ ";]%_V%+G_V6OS.K],?^"?_ /R;]%_V%+G_ -EKY7B3_<?^
MWE^I[&5?[Q\F?25%%%?EQ]@%%%% !1110!PGQG_Y$B3_ *[Q_P S7S_7T!\9
M_P#D2)/^N\?\S7S_ %]KD_\ NWS?Z'YYGW^]_)?J%%%%>V?.A1110 4444 %
M%%% !1110 4444 %>Z_ S_D5+K_K[;_T%:\*KW7X&?\ (J77_7VW_H*UXV;?
M[J_5'OY'_OB]&>C4445\0?HP4444 %%%% 'A'[;_ /R;5XJ_WK7_ -*(Z_*N
MOU4_;?\ ^3:O%7^]:_\ I1'7Y5U^A\/?[I+_ !/\D1+<****^H)"BBB@ HHH
MH **** "BBB@ HHHH *_03_@FI_R(?C'_L)1?^BJ_/NOT$_X)J?\B'XQ_P"P
ME%_Z*KP<\_W&7JOS''<^QZ***_,C0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OA/\ ;3_X*2:M^RC\8(O!5EX#MO$D+Z9#J'VR
M74'@(+M(NW:(VZ;.N>]?=E?$G[8G[=?PU_9S^+,7A3Q;\,I/%VJ/IL-Z-06*
MV8"-V<!,R#/!0^W- 'R]KG_!9"7Q.8#K'P+T+53 =T1O;\S>6?5=T!Q^%-U[
M_@L;)XILK6SUCX&:)J=I:S)<007>HM)''(GW&53#@$=CVKL/^'LWP._Z(7-_
MWXLO_B:/^'LWP._Z(7-_WXLO_B: /N#]CK]H:Y_:?^"-CXZNM"B\.2SW=Q:_
M8(9S,JB)MH.XJO7TQ7MU>,_LD_&WPY^T%\&K/QAX6\.-X5TB>[N+=--98U*M
M&V&;$?R\GFO9J "BBB@#Y)_X*@?%GQ9\(/V5[_4?!]Q/8:AJ.I6^F7&HVN1)
M:6\@=G=6'W22BQ[NWF<<XK\[?&W[,$'PU_8_\-_M Z3\7M1E\:7CVUPUK'=X
M#/+)@QQN&W^9'R6SG[C<"OT _P""J'QP?X/_ +-4FGV^E66JW?BN[&DJNHPB
M:&&/8TCR[#P6&U0N>A.?X:^#?'7_  3CO_A_^QWIOQF3QI]OU"WL;77)M!FM
MP;00S%"%4EN6 =2<C!Y'U /U0_8Q^(GB#XK?LQ^ ?%'B@,==OK#_ $B5UVF<
MH[(LI'JZJ&_&O:J^0?V?_BKXP_:=_8*FO_!T=KX9\>G3Y](LGM"+:WANHL*C
MI@$(I&TX P.17S;_ ,,V?\% /^BG6_\ X/?_ +50 OQH_P"4R?@/_KE9_P#I
M/+7ZGU^(_P -?"/Q0\%_\%+OAQI?Q;UE-<\9K/#)+>)<^>#"89-B[]HZ#/&*
M_;B@ HHHH **** /ES_@IO\ \F1_$?\ ZYV?_I9#7\_5?T"_\%-_^3(_B/\
M]<[/_P!+(:_GZH **** "BBB@ HHHH **** "BBB@ K^A_\ X)Z_\F:_"[_L
M&?\ M1Z_G@K^A_\ X)Z_\F:_"[_L&?\ M1Z /HFBBB@ HHHH **** "BBB@
MHHHH *^#/C__ ,I7/V=_^P!>?^BK^OO.O@SX_P#_ "E<_9W_ .P!>?\ HJ_H
M ^\Z*** "BBB@ HHHH **** "BBB@ J*Z_X]9O\ </\ *I:BNO\ CUF_W#_*
M@:W1^4][_P ?D_\ UT;^=0U->_\ 'Y/_ -=&_G4-?GY_9$?A04444%!1110
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M_.K^WQ_R>+\5_P#L-2_R%?T55_.K^WQ_R>+\5_\ L-2_R% '@-%%% !1110
M4444 %%%% !1110 4444 %?I;_P1%_Y*5\2/^P5;_P#HTU^:5?I;_P $1?\
MDI7Q(_[!5O\ ^C30!^O=%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!X/^TE^VE\.?V5=2T2Q\<MJJSZQ#)-;?V=9B<;48!MQW#'+
M"OB_X]_M>?L4?M*ZA8:CXZ\/^)K[5+)/)BU"UL6MY_+SGRV9)1N7). <XR<8
MR:^D/VW[O]F&VUSPL/V@ #J!MIO[*S#>/^ZW+YG_ ![@CKM^]7S)_:O_  3;
M_NC_ ,!=7_\ B: )O%O[7'[%GBSX):?\)SH_BC2O!-E=PWL=GI^G^6[2(Q;+
M2&0L2V2&8G<03R*^\/V5OB;\/_BI\&=(U+X86,VF>#;)GTVSM)[;R#%Y6 1M
MR>.>N<GK7P3_ &K_ ,$V_P"Z/_ 75_\ XFONC]D.?X1W'P=@?X)C'@?[;.(_
MDG3]_D>9Q. _7'MZ4 >UT444 %?&G_!2;]KGQ5^S-X2\(Z1X%AA'BOQ;<SPV
M]]<1B1;9(O+#%5;Y2Y:9 -V0,'(K[+K\YO\ @L3XG\,WGA;P!X&;0YM9^(6J
MWK3:'<6\WEM8@LD;$_WO,8JH7@93.1M&0#S[QY^T9^UE^Q5XG\$ZU\7O$>C^
M-?"NORXGL+:&$-&!M,B!TAC*R!6R"-RY%?JK:W*7EK#<1Y\N5 ZY]",BOQ._
M:'^&OQB^ _B;X4>+_P!I*]'Q4\$VEPD2:;:ZFQ\A@ QB<F-<OA<YY#;""W>O
MT>_:J^.OQ+\&_"'P?XK^!WA'_A.;C6IHI# +"6YV6;P&1)-D; KSL'/KB@#Z
M-U;_ )!=Y_UQ?_T$U^9G_!%W_D,_''_K]LO_ $*ZJA=_MJ?ML2VLR2_ <I&R
M,&;_ (1Z]X&.3_K*E_X(F3SW%Y\9Y+B/RYGGT]Y%QC:Y-SD?G0!^I%%%% !1
M110 4444 ?G#_P %M_\ DB_P^_[#\G_I.]?CK7[%?\%M_P#DB_P^_P"P_)_Z
M3O7XZT %%%% !1110 4444 %%%% !1110 4444 %?O;_ ,$I_P#DR?P=_P!?
M5_\ ^E4E?@E7[V_\$I_^3)_!W_7U?_\ I5)0!]=T444 %%%% !1110!\M?\
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M#OBJGP TCX8:C^P;\<K/Q_=V=G;6?BB[N=&C-P(Y1>+:HL'DJ#ESDXQ@C!-
M'ZN?!;3O =C\.-)F^&EKIMKX.OD^VV0TE D#B3DL .A)Z]\]:[BOB3_@D#=:
MG<_L?6ZWYD-K#KE['8&3IY/R$[?;S#+^.:^VZ "BBB@#PO\ ;'_9;TW]K3X0
M3>$;J_.D:G;7"W^F:B$WB"X567YUXW(RLRD>X/45\*WW[#/[8OBGX?V7P@UG
MQYH'_"MK5DC#F]+J848%%XB$K*N 0C8' &< 8_5ZB@#S/]G'X%Z3^SA\(-"\
M!Z/.]Y#IZ%IKR1=K7,[G=)(1VR3P.<  9->F444 ?EA\:/\ E,GX#_ZY6?\
MZ3RU^I]?EA\:/^4R?@/_ *Y6?_I/+7ZGT %%%% !1110!\N?\%-_^3(_B/\
M]<[/_P!+(:_GZK^@7_@IO_R9'\1_^N=G_P"ED-?S]4 %%%% !1110 4444 %
M%%% !1110 5_0_\ \$]?^3-?A=_V#/\ VH]?SP5_0_\ \$]?^3-?A=_V#/\
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M** "BBB@ HHHH **** /AO\ X+!?\FLZ3_V-5C_Z+GK[7T3_ ) MA_U[Q_\
MH(KXH_X+!?\ )K.D_P#8U6/_ *+GK[7T3_D"V'_7O'_Z"* +M%%% !1110 4
M444 %%%% !1110 5^5?[:'_)QGBGZP_^BEK]5*_*O]M#_DXSQ3]8?_12U]=P
MS_O<O\+_ #1XF;?P%Z_HSQ"BBBOTT^2"BBB@ HHHH **** "BBB@ KZ._8#_
M .3A+7_L&W7\EKYQKZ._8#_Y.$M?^P;=?R6O+S3_ '*M_A9UX3_>(>J/TUHH
MHK\8/O0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\U_:0\8>+/ 'P0\
M6^(/ VEMK7BRPM/-T^P2T>Z,TFY1M$2?,_!/ KTJB@#\B_\ AO3]MO\ Z([>
M?^$3J'^-'_#>G[;?_1';S_PB=0_QK[V_;0_:OT[]DCX3MXDEL5UC7+Z;['I6
MFL^Q)9B"2TA'(10,G')X'&<CXN_9]_;7_:/\7_M1>#?#GQ$L/["T37M/O-3M
M]#32%@:YA2UG>(H6!D(+Q#&3DXH ]P_85_:2_:#^,_Q#UO2_BYX$G\+:);:=
M]HM;F7P_=:>))O,4;=\IPWRDG YXK[?KXQ_8&_;@UO\ :,U7Q1X&\>Z.FB^/
M/#Q:1A'$T/VB$/L;?$W*2(V 1T.1P,&OLZ@ HHHH _)[]M#4=)\8?\%,O WA
M/XNWIM?A7;06IA@NYS%9N'B=MSG( #7 $;-D?*N"0!7-_'"S\#_"'_@H7\*4
M_9]GL;*6[DM(M6L?#EP)+3<\Y5XR$)4;HN64<#@XR:_2;]H+]E'X;?M-Z=:6
M_CK0OMMQ9Y%KJ%M*T%S #U"NO.W_ &3D>U<E\ _V!/@[^SGXC_X2'POH4]SK
MZJ5BU'5;DW$D (P?+!PJDCC(&?>@#/\ VJOV!_!G[6WBG1]=\3:YK>E76F6A
MLXH]+>((RERV3O1CG)KX]_:B_P""5?PX^"'P#\9>.=(\3^);W4M%L_M$$%Y)
M 8G;>HPVV,''/8U^KU?.W_!0O_DS/XI?]@O_ -J)0!R7_!*P8_8C\#^\^H?^
MEDM?6U?)/_!*W_DR/P/_ -=]0_\ 2R:OK:@ HHHH **** "OYU?V^/\ D\7X
MK_\ 8:E_D*_HJK^=7]OC_D\7XK_]AJ7^0H \!HHHH **** "BBB@ HHHH **
M** "BBB@ K]+?^"(O_)2OB1_V"K?_P!&FOS2K]+?^"(O_)2OB1_V"K?_ -&F
M@#]>Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
M']H7]CKX9_M0:CHU[X]TV]OKC28I(;4VM]);A5<@MD*>>5'6OF#XR?L)_L:?
M '18M4\>2WF@P3$B".76KAIIR.NR-26;&1G XK]#:_)CQW\/_#_[5G_!5'Q7
MX+^*>J7%OX>T:U2+2](^TF#[6(X876!&R" _F22G;AB,X(Z@ V/!OP&_8/\
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M[_N*]6?'9I_O#]$%%%%?3GD!1110 4444 %%%% !1110 4444 %?IC_P3_\
M^3?HO^PI<_\ LM?F=7Z8_P#!/_\ Y-^B_P"PI<_^RU\KQ)_N/_;R_4]C*O\
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M3Z_+#XT?\ID_ ?\ URL__2>6OU/H **** "BBB@#Y<_X*;_\F1_$?_KG9_\
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M2U\XU]'?L!_\G"6O_8-NOY+7EYI_N5;_  LZ\)_O$/5'Z:T445^,'WH4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %?!GQ__P"4KG[._P#V +S_ -%7]?>=?!GQ_P#^4KG[._\
MV +S_P!%7] 'WG1110 4444 %%%% !1110 4444 %177_'K-_N'^52U%=?\
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M^<:^COV _P#DX2U_[!MU_):\O-/]RK?X6=>$_P!XAZH_36BBBOQ@^]"BBB@
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M#4O\A7]%5?SJ_M\?\GB_%?\ [#4O\A0!X#1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXF_Z_8__ $77T[7S%^PO_P BMXF_Z_8__1=?3M?98'_=XG\P\5_\CK$>J_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!X?H@HHHKZ<\@**** "BBB@ HHHH **** "BBB@ K],?\ @G__ ,F_1?\
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M .E$=?E77Z'P]_NDO\3_ "1$MPHHHKZ@D**** "BBB@ HHHH **** "BBB@
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M_P#@D]XH_9]\ ZQ\0?"OQ0BU"30(&OY(FM'L)@B<DQR+(PW#J <?6JDG@O\
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M%% !1110 5^5?[:'_)QGBGZP_P#HI:_52ORK_;0_Y.,\4_6'_P!%+7UW#/\
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M_:@_8!\--\.M3^'<&H>'M-FE:UFU33)Y84#N78Q7$#JK*6);DDC/;I6];_\
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M[]O_ .&VEZ!IME-9Z\9K:VBA<K:1D;E4 X_>>U:'_#P[X9?\^7B#_P !(_\
MXY7YN45F^'<"W=I_>6LTQ"TT^X_2/_AX=\,O^?+Q!_X"1_\ QRC_ (>'?#+_
M )\O$'_@)'_\<K\W**7^KF![/[P_M3$>7W'Z1_\ #P[X9?\ /EX@_P# 2/\
M^.4?\/#OAE_SY>(/_ 2/_P".5^;E%'^KF![/[P_M3$>7W'Z1_P##P[X9?\^7
MB#_P$C_^.5]'>&M?MO%7AW2]:LQ(MIJ-K%=PB48<)(H9<@$X."*_$ZOV0^"W
M_)'O W_8#LO_ $0E?-9WEF'P%.$J-]7U9ZV7XNKB9253H=G1117R)[84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YD?\%D?&.L3:I\
M*/A^-7;0?"NNW$LVHW;$^4662*-6DQ]Y8P[/M]QZ"NI\%?\ !(#X ZAH-E=-
MXR\2>)6EA5FO;+4[58)3CED"0MA3V&YOJ:^HOVJ_V4/"/[6?@.'P_P")6FL;
MRRD,^G:M:@>=:2$8/!X96&,J>N!T(!K\[=;_ .",/Q,TN[D3P[\2-'N;($^6
M;@3VSX]PNX?K0!UW[4/_  2Y^"7PF^$'B7Q7I'C[6= U73+22ZM8M:O[::"Y
MD521"%$:.6<C:,,2">AKZ(_X)0_$/Q!\0?V3+$^(+B:]DTC4[C2[2YN"6>2W
M149!D]=N]D'LH':OEKP?_P $6/&6IZE"WC;XE6$6GJP,B:;%+<2L.X!DV@?7
MFOTZ^#WPD\._ WX=:/X+\*VAM-&TR+9&&.YY&)R\CGNS,22?>@#LZ*** "BB
MB@ HHHH J:M_R"[S_KB__H)K\S/^"+O_ "&?CC_U^V7_ *%=5^F>K?\ (+O/
M^N+_ /H)K\S/^"+O_(9^./\ U^V7_H5U0!^GU%%% !1110 4444 ?G#_ ,%M
M_P#DB_P^_P"P_)_Z3O7XZU^Q7_!;?_DB_P /O^P_)_Z3O7XZT %%%% !1110
M 4444 %%%% !1110 4444 %?O;_P2G_Y,G\'?]?5_P#^E4E?@E7[V_\ !*?_
M ),G\'?]?5__ .E4E 'UW1110 4444 %%%% 'RU_P43_ .2(:9_V'(?_ $3-
M7YPU^CW_  43_P"2(:9_V'(?_1,U?G#7ZIP[_N*]6?'9I_O#]$%%%%?3GD!1
M110 4444 %%%% !1110 4444 %?IC_P3_P#^3?HO^PI<_P#LM?F=7Z8_\$__
M /DWZ+_L*7/_ ++7RO$G^X_]O+]3V,J_WCY,^DJ***_+C[ **** "BBB@#A/
MC/\ \B1)_P!=X_YFOG^OH#XS_P#(D2?]=X_YFOG^OM<G_P!V^;_0_/,^_P![
M^2_4****]L^="BBB@ HHHH **** "BBB@ HHHH *]U^!G_(J77_7VW_H*UX5
M7NOP,_Y%2Z_Z^V_]!6O&S;_=7ZH]_(_]\7HST:BBBOB#]&"BBB@ HHHH \(_
M;?\ ^3:O%7^]:_\ I1'7Y5U^JG[;_P#R;5XJ_P!ZU_\ 2B.ORKK]#X>_W27^
M)_DB);A1117U!(4444 %%%% !1110 4444 %%%% !7Z"?\$U/^1#\8_]A*+_
M -%5^?=?H)_P34_Y$/QC_P!A*+_T57@YY_N,O5?F..Y]CT445^9&@4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?)'[3_P#P4B\#
M?LK_ !,'@KQ#X9\0ZMJ!LHK[[1IBP&+9(6 'SR*<C8>U?6]?,W[:_P"Q7X8_
M:H\"7\R64%EX^L[8G2M95=KLRY*PRG^*-CD<_=SD>X!X+_P^S^%/_0C>,?\
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MIO\ \F1_$?\ ZYV?_I9#7\_5?T"_\%-_^3(_B/\ ]<[/_P!+(:_GZH ****
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M:?[E6_PLZ\)_O$/5'Z:T445^,'WH4444 %%%% !1110 4444 %%%% !1110
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MY"@#P&BBB@ HHHH **** "BBB@ HHHH **** "OTM_X(B_\ )2OB1_V"K?\
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MQW/L>BBBOS(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY/%^*_\ V&I?Y"OZ*J_G5_;X_P"3Q?BO_P!AJ7^0H \!HHHH **** "BBB@
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M:9_V'(?_ $3-7YPU^J<._P"XKU9\=FG^\/T04445].>0%%%% !1110 4444
M%%%% !1110 5^F/_  3_ /\ DWZ+_L*7/_LM?F=7Z8_\$_\ _DWZ+_L*7/\
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MI/\ V-5C_P"BYZ^U]$_Y MA_U[Q_^@BOBC_@L%_R:SI/_8U6/_HN>OM?1/\
MD"V'_7O'_P"@B@"[1110 4444 %%%% !1110 4444 %?E7^VA_R<9XI^L/\
MZ*6OU4K\J_VT/^3C/%/UA_\ 12U]=PS_ +W+_"_S1XF;?P%Z_HSQ"BBBOTT^
M2"BBB@ HHHH **** "BBB@ KZ._8#_Y.$M?^P;=?R6OG&OH[]@/_ ).$M?\
ML&W7\EKR\T_W*M_A9UX3_>(>J/TUHHHK\8/O0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *\Z_:#^*UY\$?A'KWC:R\.W7BJ725BE?2[,D2RQF55D8$*
MV-JLS=,87G'6O1:1E# @@$'@@]Z /A*S_;$_9/\ VO9_"[^/=0@TC4-!N6O;
M?0_&<?V>U$VW;N=SF"0#LK/SW6OK*U^.OPSGL%N+?Q_X6>R"_++'J]N8\?4/
MC%>0?&W_ ()S? [XZ7D^H:GX9?P_K,QW2:GX<E%I*Y[EEVM&Q/J4)KYQNO\
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M?]@O_P!J)0!R7_!*W_DR/P/_ -=]0_\ 2R:OK:ODG_@E;_R9'X'_ .N^H?\
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M)5^]O_!*?_DR?P=_U]7_ /Z524 ?7=%%% !1110 4444 ?+7_!1/_DB&F?\
M8<A_]$S5^<-?H]_P43_Y(AIG_8<A_P#1,U?G#7ZIP[_N*]6?'9I_O#]$%%%%
M?3GD!1110 4444 %%%% !1110 4444 %?IC_ ,$__P#DWZ+_ +"ES_[+7YG5
M^F/_  3_ /\ DWZ+_L*7/_LM?*\2?[C_ -O+]3V,J_WCY,^DJ***_+C[ ***
M* "BBB@#A/C/_P B1)_UWC_F:^?Z^@/C/_R)$G_7>/\ F:^?Z^UR?_=OF_T/
MSS/O][^2_4****]L^="BBB@ HHHH **** "BBB@ HHHH *]U^!G_ "*EU_U]
MM_Z"M>%5[K\#/^14NO\ K[;_ -!6O&S;_=7ZH]_(_P#?%Z,]&HHHKX@_1@HH
MHH **** /"/VW_\ DVKQ5_O6O_I1'7Y5U^JG[;__ ";5XJ_WK7_THCK\JZ_0
M^'O]TE_B?Y(B6X4445]02%%%% !1110 4444 %%%% !1110 5^@G_!-3_D0_
M&/\ V$HO_15?GW7Z"?\ !-3_ )$/QC_V$HO_ $57@YY_N,O5?F..Y]CT445^
M9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?
MGA_P4[_;4\8?"/7-$^%/PSGFLO%6LVZ7-WJ%HF^XCCD=DBAA&#B1RIY R!MQ
MR: /T/HKQ/\ 8RT_X@:1^S;X.L/B?%=)XSMH94NVOKCSYY%,SM$TCY)+>64!
MR<Y'-?#W[?\ \4_VD_V>_P!HJ;XF>'9[_3_AO'';6%HB2_:-.G"KN87$.<*S
M.T@#$ XQAJ /U-HKRK]E_P"/%A^TG\$_#OCRQ@%H]_&T=W:;L_9[A&*R)GTR
M,CV(KU6@ HHHH **\K_:;^/^C_LS?!S6O'>L0M>+:!8;2Q1MK75RYQ'&#VYR
M2>RJQYQ7YRS?MA_MH:K\.3\;+'1](@^'(G&S3X]/C=7B,FS.TDS,N[Y=P8>O
M2@#];J*\P_9K^,K_ ![^#7A[QI<:1/H-]?1%;O3KA&4PS(2K@;@"5)&0?0BO
M3Z /RP^-'_*9/P'_ -<K/_TGEK]3Z_+#XT?\ID_ ?_7*S_\ 2>6OU/H ****
M "BBB@#Y<_X*;_\ )D?Q'_ZYV?\ Z60U_/U7] O_  4W_P"3(_B/_P!<[/\
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M_P#R*WB;_K]C_P#1=?3M?,7["_\ R*WB;_K]C_\ 1=?3M?98'_=XG\P\5_\
M(ZQ'JO\ TE!1117<?)!1110 4444 %%%% !1110!\-_\%@O^36=)_P"QJL?_
M $7/7VOHG_(%L/\ KWC_ /017Q1_P6"_Y-9TG_L:K'_T7/7VOHG_ "!;#_KW
MC_\ 010!=HHHH **** "BBB@ HHHH **** "ORK_ &T/^3C/%/UA_P#12U^J
ME?E7^VA_R<9XI^L/_HI:^NX9_P![E_A?YH\3-OX"]?T9XA1117Z:?)!1110
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M3K_X8?M)Z+K7[/OQKTCQCX*M4C;Q%I]YKD<\[J6*RJ8H%*LI&"C$#!XR<9H
M_3NOG;_@H7_R9G\4O^P7_P"U$KZ)KYV_X*%_\F9_%+_L%_\ M1* .2_X)6_\
MF1^!_P#KOJ'_ *635];5\D_\$K?^3(_ _P#UWU#_ -+)J^MJ "BBB@ HHHH
M*_G5_;X_Y/%^*_\ V&I?Y"OZ*J_G5_;X_P"3Q?BO_P!AJ7^0H \!HHHH ***
M* "BBB@ HHHH **** "BBB@ K]+?^"(O_)2OB1_V"K?_ -&FOS2K]+?^"(O_
M "4KXD?]@JW_ /1IH _7NBBB@ HHHH **** /"OVV?\ DW+Q-_O6_P#Z.2OR
MQK]3OVV?^3<O$W^];_\ HY*_+&OTWAG_ '.7^)_DCY+-OXZ]/\PHHHKZX\0*
M*** "BBB@ HHHH **** "BBB@ K]D/@M_P D>\#?]@.R_P#1"5^-]?LA\%O^
M2/>!O^P'9?\ HA*^(XH_@TO5_D?09/\ '/T.SHHHK\[/J HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!X?H@HHHKZ<\@**** "BBB@ HHHH **** "BBB@ K],?\ @G__ ,F_1?\
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M .E$=?E77Z'P]_NDO\3_ "1$MPHHHKZ@D**** "BBB@ HHHH **** "BBB@
MK]!/^":G_(A^,?\ L)1?^BJ_/NOT$_X)J?\ (A^,?^PE%_Z*KP<\_P!QEZK\
MQQW/L>BBBOS(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\C?VZM<M?@W_ ,%-OA[X]\3VS2>&1!IUV9"A95C1GB=@.Y0C?CKT
M]:_7*O#_ -J_]DGPA^UKX%CT/Q$9-/U.S9I=,UJU4--9R$<\'AT; W(2,X'(
M(!H ]5\*^-= \<:+;:OX?UFQUC3;E!)%<V4ZR(P/N#^E?+/_  4P^-W@?P9^
MS+XN\,ZKJ=C>>(-=MA:6&DI*KSERP/F%1RJKC.X]P.]?$/B#_@C]\=/#&H30
M^&?%6A:KIV\B*6*_FM'*]BR%< ^P9OK7;?!3_@C9X@O_ !3;7_Q;\8V']F0N
MLDFE:+,\]S<@?P/*ZJ(P?50QZXQUH ^D?^"0WAG4?#_[(%K<WZ/'%JNM7E]:
M*XQF'$<8(]BT3FOMBLWPWX<TSPAH&GZ)HUE%IVE:? EM:VL"[4BC4850/8"M
M*@ HHHH _.W_ (+87<\?P \$VRY^SR^) \F.FY;:;;_Z$U>%^&-1_:Z\%?LH
M^'_BUX>\7:7I/@#0=-B-KX8@MHF<V49"&:1&C(?)!8Y?."2,=*^[O^"A7[-V
MI?M-_LZW^@Z"J/XFTN[CU?3(78*)Y(U=6BR>A:.1P,\;@N<#FOSQM?VJ?C!9
M_LM7/[-<WP>UF7Q*]JVAQZEY$P=;5GY4P>7R^TE0VX#!![<@'W[\(_VR[CXC
M_L6ZG\8[3P\EWX@T:SG^V:);,RI+=0XW*A 8A6!##@D9QSC-?,'_  ^#^(/_
M $0.Z_\  NX_^,5]9_\ !/K]GS5OV=/V;=)\.^(XUBU^^GEU*^M@0P@>3 $9
M/0D*JY]\U](?98/^>,?_ 'R* /Q.^'/QYU3]HG_@IC\.?&FK^&'\)WLT\-J=
M,=V<J$AD ;+*IYSZ5^VU?E=\9D6/_@LEX#"J%'E6? &/^7>6OU1H **** "B
MBB@#Y<_X*;_\F1_$?_KG9_\ I9#7\_5?T"_\%-_^3(_B/_USL_\ TLAK^?J@
M HHHH **** "BBB@ HHHH **** "OZ'_ /@GK_R9K\+O^P9_[4>OYX*_H?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_\ \F_1?]A2Y_\ 9:^5XD_W'_MY?J>QE7^\?)GTE1117Y<?8!1110 4444
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M\H?VT-4L-&_X*J_">_U6[@LM.M;;2Y9KFZD"11*)ISN9CP /4T >6ZQ^V/\
MM5_LG:/K'@_XEC4)+[7]-9M(O]:*2W%DY8 S13+G?@$@HQ.TE3QT/ >+OV<_
MVF/@WX LOCQJ.KZE9)-Y5[+>1:P[W]NLA&QYESG#97(R<9Y KZ _X+%_$7PA
M\0)OA*WAOQ'I.OFUEOQ<'3;R.?R@QM\;MI.,[3U]#7TW^VO\:?AWX@_8L\:Z
M/I7C;P]J.HR:1#'#96NI0R2NP:/A5#9)X[4 >O\ [$?QPU']H;]FKPEXRUD)
M_;4R26E^T8VK)-#(T;.!VW;0V.VZO=:^,?\ @D<Q;]C'10>VK7X'_?VOLZ@
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MU8VU;BXV?:S;^\****V/,"BBB@ HHHH *BNO^/6;_</\JEJ*Z_X]9O\ </\
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M_P $K?\ DR/P/_UWU#_TLFKZVKY)_P""5O\ R9'X'_Z[ZA_Z635];4 %%%%
M!1110 5_.K^WQ_R>+\5_^PU+_(5_157\ZO[?'_)XOQ7_ .PU+_(4 > T444
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MEZK\QQW/L>BBBOS(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8?&C_E,GX#_ZY6?_ *3RU^I] !1110 4444 ?+G_  4W_P"3(_B/_P!<[/\
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M[W+_  O\T>)FW\!>OZ,\0HHHK]-/D@HHHH **** "BBB@ HHHH *^COV _\
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M44 %%%% !1110 5^R'P6_P"2/>!O^P'9?^B$K\;Z_9#X+?\ )'O W_8#LO\
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M_P"3-?A=_P!@S_VH]?SP5_0__P $]?\ DS7X7?\ 8,_]J/0!]$T444 %%%%
M!7R1^UQ^V1X@_9X^(.F^'])T33M2M[K3DO6ENV<,&,CK@;2!C"#\Z^MZ_,;_
M (*>?\EOT#_L!1_^CYJ\G-*U2AAG.F[.Z/T?@#+<)FV=QPV-IJ<'&3L[[I:;
M&E_P]$\:?]"GHG_?<O\ \51_P]$\:?\ 0IZ)_P!]R_\ Q5?%=%?&_P!I8O\
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MM.7_ *%C5_\ OR?\*/\ A:<O_0L:O_WY/^%=?U*O_+^*_P SA_M##?S?@_\
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M%^*__8:E_D*_HJK^=7]OC_D\7XK_ /8:E_D* / :*** "BBB@ HHHH ****
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MPJP4445)84444 %%%% !1110 4444 %%%% !1110 4444 >;?M(_\D&\=?\
M8*F_]!J;]G?_ )(/\/\ _L!V?_HI:A_:1_Y(-XZ_[!4W_H-3?L[_ /)!_A__
M -@.S_\ 12UZ/_,%_P!O_H+J>AT445YPPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A3_@H[^Q-X^_
M:N\3^"-2\%WNDVB:):W$,YU&X>)M[NC*5VJW]TU\DZE_P22_:*UFW%OJ'BS0
M[Z ,&$5SK%Q(N1T.&C(S7[0T4 ?C+;_\$H/VD[."."#QII$$,:A4CCUNY55
MZ  )P*_1G]AWX)^,/@!\";;PGXXU*'5==CO[BY:X@N7N%,;L"HWN >,=*^@:
M* "BBB@ HHHH **** *FK?\ (+O/^N+_ /H)K\S/^"+O_(9^./\ U^V7_H5U
M7Z9ZM_R"[S_KB_\ Z":_,S_@B[_R&?CC_P!?ME_Z%=4 ?I]1110 4444 %%%
M% 'YP_\ !;?_ )(O\/O^P_)_Z3O7XZU^Q7_!;?\ Y(O\/O\ L/R?^D[U^.M
M!1110 4444 %%%% !1110 4444 %%%% !7[V_P#!*?\ Y,G\'?\ 7U?_ /I5
M)7X)5^]O_!*?_DR?P=_U]7__ *524 ?7=%%% !1110 4444 ?+7_  43_P"2
M(:9_V'(?_1,U?G#7Z/?\%$_^2(:9_P!AR'_T3-7YPU^J<._[BO5GQV:?[P_1
M!1117TYY 4444 %%%% !1110 4444 %%%% !7Z8_\$__ /DWZ+_L*7/_ ++7
MYG5^F/\ P3__ .3?HO\ L*7/_LM?*\2?[C_V\OU/8RK_ 'CY,^DJ***_+C[
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M%%%?F1H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'Y8?&C_E,GX#_P"N5G_Z3RU^I]?E
MA\:/^4R?@/\ ZY6?_I/+7ZGT %%%% !1110!\N?\%-_^3(_B/_USL_\ TLAK
M^?JOZ!?^"F__ "9'\1_^N=G_ .ED-?S]4 %%%% !1110 4444 %%%% !1110
M 5_0_P#\$]?^3-?A=_V#/_:CU_/!7]#_ /P3U_Y,U^%W_8,_]J/0!]$T444
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MW'_6NZA_U2?[HKA?C/\ \BC%_P!?<?\ 6NZA_P!4G^Z*[JG^[4_67Z'G4O\
M>ZOI']1]%%%<)Z(4444 %%%% !1110 4444 %?E7^VA_R<9XI^L/_HI:_52O
MRK_;0_Y.,\4_6'_T4M?7<,_[W+_"_P T>)FW\!>OZ,\0HHHK]-/D@HHHH **
M** "BBB@ HHHH *^COV _P#DX2U_[!MU_):^<:^COV _^3A+7_L&W7\EKR\T
M_P!RK?X6=>$_WB'JC]-:***_&#[T**** "BBB@ HHHH **** "BBB@ HHHH
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M9^FW_#P7X4?\]-9_\ /_ +*C_AX+\*/^>FL_^ '_ -E7YDT5E_8&#\_O_P"
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M\S7S_7T!\9_^1(D_Z[Q_S-?/]?:Y/_NWS?Z'YYGW^]_)?J%%%%>V?.A1110
M4444 %%%% !1110 4444 %>Z_ S_ )%2Z_Z^V_\ 05KPJO=?@9_R*EU_U]M_
MZ"M>-FW^ZOU1[^1_[XO1GHU%%%?$'Z,%%%% !1110!X1^V__ ,FU>*O]ZU_]
M*(Z_*NOU4_;?_P"3:O%7^]:_^E$=?E77Z'P]_NDO\3_)$2W"BBBOJ"0HHHH
M**** "BBB@ HHHH **** "OT$_X)J?\ (A^,?^PE%_Z*K\^Z_03_ ()J?\B'
MXQ_["47_ **KP<\_W&7JOS''<^QZ***_,C0**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/RP^-'_*9/P'_P!<K/\ ])Y:_4^ORP^-'_*9/P'_ -<K/_TGEK]3Z "BBB@
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MG_H+5TX;^/#U7YGBYW_R*\5_U[G_ .DL_:&BBBOU(_SY"BBB@ J*Z_X]9O\
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M^2U\XU]'?L!_\G"6O_8-NOY+7EYI_N5;_"SKPG^\0]4?IK1117XP?>A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MSM_P4+_Y,S^*7_8+_P#:B5]$U\[?\%"_^3,_BE_V"_\ VHE ')?\$K?^3(_
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M &9J]<K\?Q?^\5/\3_,T6P4445R#"BBB@ HHHH **** "BBB@ HHHH ****
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MA_\ 1,U?G#7ZIP[_ +BO5GQV:?[P_1!1117TYY 4444 %%%% !1110 4444
M%%%% !7Z8_\ !/\ _P"3?HO^PI<_^RU^9U?IC_P3_P#^3?HO^PI<_P#LM?*\
M2?[C_P!O+]3V,J_WCY,^DJ***_+C[ **** "BBB@#A/C/_R)$G_7>/\ F:^?
MZ^@/C/\ \B1)_P!=X_YFOG^OM<G_ -V^;_0_/,^_WOY+]0HHHKVSYT**** "
MBBB@ HHHH **** "BBB@ KW7X&?\BI=?]?;?^@K7A5>Z_ S_ )%2Z_Z^V_\
M05KQLV_W5^J/?R/_ 'Q>C/1J***^(/T8**** "BBB@#PC]M__DVKQ5_O6O\
MZ41U^5=?JI^V_P#\FU>*O]ZU_P#2B.ORKK]#X>_W27^)_DB);A1117U!(444
M4 %%%% !1110 4444 %%%% !7Z"?\$U/^1#\8_\ 82B_]%5^?=?H)_P34_Y$
M/QC_ -A*+_T57@YY_N,O5?F..Y]CT445^9&@4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?EA\:/^4R?@/_KE9_\ I/+7ZGU^6'QH_P"4R?@/_KE9_P#I/+7ZGT %%%%
M!1110!\N?\%-_P#DR/XC_P#7.S_]+(:_GZK^@7_@IO\ \F1_$?\ ZYV?_I9#
M7\_5 !1110 4444 %%%% !1110 4444 %?T/_P#!/7_DS7X7?]@S_P!J/7\\
M%?T/_P#!/7_DS7X7?]@S_P!J/0!]$T444 %%%% !7YC?\%//^2WZ!_V H_\
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M\F1^!_\ KOJ'_I9-7UM7R3_P2M_Y,C\#_P#7?4/_ $LFKZVH **** "BBB@
MK^=7]OC_ )/%^*__ &&I?Y"OZ*J_G5_;X_Y/%^*__8:E_D* / :*** "BBB@
M HHHH **** "BBB@ HHHH *_2W_@B+_R4KXD?]@JW_\ 1IK\TJ_2W_@B+_R4
MKXD?]@JW_P#1IH _7NBBB@ HHHH **** /"OVV?^3<O$W^];_P#HY*_+&OU.
M_;9_Y-R\3?[UO_Z.2ORQK]-X9_W.7^)_DCY+-OXZ]/\ ,****^N/$"BBB@ H
MHHH **** "BBB@ HHHH *_9#X+?\D>\#?]@.R_\ 1"5^-]?LA\%O^2/>!O\
ML!V7_HA*^(XH_@TO5_D?09/\<_0[.BBBOSL^H"BBB@ HHHH ^>_C'_R/5U_U
MRC_]!%<17;_&/_D>KK_KE'_Z"*XBOT3!_P"[T_1'Y1C_ />ZO^)_F%%%%=AP
MA1110 4444 %%%% !1110 4444 >A?!#_D<)?^O5_P":U[S7@WP0_P"1PE_Z
M]7_FM>\U\3F_^\_)'Z)D7^Y_-A1117BGT(4444 %>:?M*_\ ) ?'W_8'N/\
MT$UZ77FG[2O_ "0'Q]_V![C_ -!-=.&_CT_5?F!^/]%%%?L1D%%%% !1110
M4444 %%%% !1110 4444 ?K?^R9_R;MX(_Z\?_9FKURO(_V3/^3=O!'_ %X_
M^S-7KE?C^+_WBI_B?YFBV"BBBN084444 %%%% !1110 4444 %%%% !1110
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MNBBB@ HHHH **** /EK_ (*)_P#)$-,_[#D/_HF:OSAK]'O^"B?_ "1#3/\
ML.0_^B9J_.&OU3AW_<5ZL^.S3_>'Z(****^G/("BBB@ HHHH **** "BBB@
MHHHH *_3'_@G_P#\F_1?]A2Y_P#9:_,ZOTQ_X)__ /)OT7_84N?_ &6OE>)/
M]Q_[>7ZGL95_O'R9])4445^7'V 4444 %%%% '"?&?\ Y$B3_KO'_,U\_P!?
M0'QG_P"1(D_Z[Q_S-?/]?:Y/_NWS?Z'YYGW^]_)?J%%%%>V?.A1110 4444
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MC1_RF3\!_P#7*S_])Y:_4^ORP^-'_*9/P'_URL__ $GEK]3Z "BBB@ HHHH
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M#_L)I_Z"U=.&_CP]5^9XN=_\BO%?]>Y_^DL_:&BBBOU(_P ^0HHHH *BNO\
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M+\5_^PU+_(5_157\ZO[?'_)XOQ7_ .PU+_(4 > T444 %%%% !1110 4444
M%%%% !1110 5^EO_  1%_P"2E?$C_L%6_P#Z--?FE7Z6_P#!$7_DI7Q(_P"P
M5;_^C30!^O=%%% !1110 4444 >%?ML_\FY>)O\ >M__ $<E?EC7ZG?ML_\
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M ->K_P UKWFOB<W_ -Y^2/T3(O\ <_FPHHHKQ3Z$**** "O-/VE?^2 ^/O\
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M  34_P"1#\8_]A*+_P!%5X.>?[C+U7YCCN?8]%%%?F1H%%%% !1110 4444
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M_P!@*/\ ]'S5^G-?F-_P4\_Y+?H'_8"C_P#1\U>'G/\ NC]4?K/AA_R44/\
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M1110 4444 %%%% !1110 5^R'P6_Y(]X&_[ =E_Z(2OQOK]D/@M_R1[P-_V
M[+_T0E?$<4?P:7J_R/H,G^.?H=G1117YV?4!1110 4444 ?/?QC_ .1ZNO\
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MF=7Z8_\ !/\ _P"3?HO^PI<_^RU\KQ)_N/\ V\OU/8RK_>/DSZ2HHHK\N/L
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MR1%3P1T- 'Z'T5\K_P##S[]FO_HHJ_\ @JO?_C-'_#S[]FO_ ***O_@JO?\
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M:/AG_H)#_OT__P 32?\ "T?#/_02_P#(3_X4_J>)_P"?<ON8?ZRY)_T&TO\
MP9'_ #.KHKE?^%H^&?\ H)#_ +]/_P#$T?\ "T?#/_02'_?I_P#XFE]3Q/\
MS[E]S#_67)/^@VE_X,C_ )G545RO_"T?#/\ T$A_WZ?_ .)H_P"%H^&?^@D/
M^_3_ /Q-'U/$_P#/N7W,/]9<D_Z#:7_@R/\ F=57K7[)O_)Q_@#_ +":?^@M
M7SW_ ,+1\,_]!(?]^G_^)KT/]GGX]^!O _QL\'Z]K6MBSTJPOEFN)_L\K[$
M/.%4D]>PKHP^%Q"K0;IO=='W/)S?B+)JN6XF$,93;<)I)3C=MQ>BU/WBHKY7
M_P"'GW[-?_115_\ !5>__&:/^'GW[-?_ $45?_!5>_\ QFOT@_AD^J**^5_^
M'GW[-?\ T45?_!5>_P#QFC_AY]^S7_T45?\ P57O_P 9H ^J*BNO^/6;_</\
MJ^7/^'GW[-?_ $45?_!5>_\ QFF7'_!3S]FQX)57XBJ25( _LJ]]/^N- UN?
M)M[_ ,?D_P#UT;^=0UYG=?M-_#>2YF=?$(*LY(/V6;IG_<J/_AICX<?]#"/_
M  %F_P#B*^'^KUOY']S/ZOCG6667^TP_\#C_ )GJ%%>7_P##3'PX_P"AA'_@
M+-_\11_PTQ\./^AA'_@+-_\ $4?5ZW\C^YC_ +:RS_H)A_X''_,]0HKR_P#X
M:8^''_0PC_P%F_\ B*/^&F?AQ_T,(_\  6;_ .(H^KUOY']S#^VLL_Z"8?\
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M_P""J]_^,T?\//OV:_\ HHJ_^"J]_P#C-?-'UY]445\K_P##S[]FO_HHJ_\
M@JO?_C-'_#S[]FO_ ***O_@JO?\ XS0!]45^5?[:'_)QGBGZP_\ HI:^K/\
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M>_\ QFO3O@A^U5\,/VC;S5K7X?>)1K\^E1QRWBBTG@\I7+!#^\1<Y*MTSTH
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MX-+/_P".U_0#10!_/]_P[#_:2_Z)VW_@TL__ ([1_P .P_VDO^B=M_X-+/\
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M2O5Z/[2QO_/Z7WL/JE#^1?<?A_\ \,<_M@_]"1'_ .!EC_\ ':/^&.?VP?\
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M;?\ 1"[O_P "9_\ XS7ZCT4 ?EQ_P^(\;?\ 1"[O_P "9_\ XS1_P^(\;?\
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MZ?+/(+UWFB+^9*TF-HB.,;L=>U?M!10!^7'_  ^(\;?]$+N__ F?_P",T?\
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MRX_X?$>-O^B%W?\ X$S_ /QFC_A\1XV_Z(7=_P#@3/\ _&:_4>B@#\G/&/\
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MB^'&J>$Y/@S>::E\8B;E99G*;)%?IY0SG;C\:^7/^%L^*O\ H0]1_P"_,O\
M\17]$=%>AA\PQ.%AR4966^R%8_G<_P"%L^*O^A#U'_OS+_\ $4?\+9\5?]"'
MJ/\ WYE_^(K^B.BNK^V<=_S\_!?Y!9'\[G_"V?%7_0AZC_WYE_\ B*/^%L^*
MO^A#U'_OS+_\17]$=%']LX[_ )^?@O\ (+(_G<_X6SXJ_P"A#U'_ +\R_P#Q
M%177QC\265O)/<>";ZW@C&YY98Y%51ZDE,"OZ**\'_;M_P"3/OBS_P!@*?\
MI1_;.._Y^?@O\@LC\3+#XU>(-4MEN+/P;=WD#$@2VZR.A(Z\A<58_P"%L^*O
M^A#U'_OS+_\ $5^KG_!)?_DRWPW_ -A&_P#_ $>U?8]']LX[_GY^"_R"R/YW
M/^%L^*O^A#U'_OS+_P#$4?\ "V?%7_0AZC_WYE_^(K^B.BC^V<=_S\_!?Y!9
M'\[G_"V?%7_0AZC_ -^9?_B*/^%L^*O^A#U'_OS+_P#$5_1'11_;.._Y^?@O
M\@LC^=S_ (6SXJ_Z$/4?^_,O_P 17OO[.'_!03QC^SWH6KZ;%\([[61J%RMP
M9'::+9A=N,>4<U^TU%<]?,L5B(.G5G=/R7^06/RX_P"'Q'C;_HA=W_X$S_\
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MO]F__H0F_P#!G=?_ !RC_AUW^S?_ -"$W_@SNO\ XY7U;10!\I?\.N_V;_\
MH0F_\&=U_P#'*/\ AUW^S?\ ]"$W_@SNO_CE?5M% 'RE_P .N_V;_P#H0F_\
M&=U_\<H_X==_LW_]"$W_ (,[K_XY7U;10!\I?\.N_P!F_P#Z$)O_  9W7_QR
MC_AUW^S?_P!"$W_@SNO_ (Y7U;10!\I?\.N_V;_^A";_ ,&=U_\ '*^ /BS^
MR]\./#/_  4L\'_"K3M!,'@:_>R%QIOVJ5M_F0LS_.6W#)'8U^UE? _Q6_92
M^(_BC_@I'X0^+>GZ1!+X'TY[,W%ZUW&KKY<)5_W9.XX)]* /2_\ AUW^S?\
M]"$W_@SNO_CE'_#KO]F__H0F_P#!G=?_ !ROJVB@#Y2_X==_LW_]"$W_ (,[
MK_XY1_PZ[_9O_P"A";_P9W7_ ,<KZMHH ^4O^'7?[-__ $(3?^#.Z_\ CE'_
M  Z[_9O_ .A";_P9W7_QROJVB@#Y2_X==_LW_P#0A-_X,[K_ ..4?\.N_P!F
M_P#Z$)O_  9W7_QROJVB@#Y2_P"'7?[-_P#T(3?^#.Z_^.4?\.N_V;_^A";_
M ,&=U_\ '*^K:* /E+_AUW^S?_T(3?\ @SNO_CE'_#KO]F__ *$)O_!G=?\
MQROJVB@#Y2_X==_LW_\ 0A-_X,[K_P".4?\ #KO]F_\ Z$)O_!G=?_'*^K:*
M /E+_AUW^S?_ -"$W_@SNO\ XY1_PZ[_ &;_ /H0F_\ !G=?_'*^K:* /E+_
M (==_LW_ /0A-_X,[K_XY7-?$[_@FI^SUX>^&WBS5;#P.T-]8Z3=W,$G]I7)
MV2)"[*<&3!P0*^TJYKXF:-=>(_AQXKTFP02WU_I-W:P(6"AI'A95&3P.2.:
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M_P .N_V;_P#H0F_\&=U_\<KZMHH ^4O^'7?[-_\ T(3?^#.Z_P#CE'_#KO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_".B^!/#]IH7AW2[71=&M PM[&RB$4,09B[;5' RS,?J36O10 4444 %%%%
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M\Y_: ^!6@?M(?"_4O ?B>ZU"ST>_DAEEETN5(YP8I%D7#.CKC*C/R]*]&HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1CT;X_>*O%?[#W@GPIX8_9[^"CZ_H\T\EQJ$T%M+<0IQC:WEMYAE8X.]N %
M&<_+QW[&WP%^*/Q(_:.US]I/XRZ-'X3U6ZMOLFDZ L9CD5?+6+>R$ED547 #
MG<Q8G@ 9 /T!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK%HWQ/TR,-9WZ'RQ?*O*PRL._P#=?JI]NGH'[$+_ !?_ .%$Z7#\9[>.'Q)
M[0V[2/F\>W7A#<]O,X/(.2,$\YKUGX9:KJ.N_#CPMJ6L1F+5;O2[:>[0C!$K
M1*7X[<DUTI(4$DX [F@"MJ>IVFBZ=<W]_<Q65E;1M+-<3N$CC11DLS'@ #O7
MYM?$S]N7XT_M+?$K4O!W[*^B&XT32#B[\3301_Z0W(R&F^2.,G[N?F;&>!Q7
MU9^VM\"M;_:9^!&K>$_"?BA]&U0.+A88I0(+XH#_ */.1R%)P?J!D$5\9_\
M!-?]J73O@1J]U^SW\3="@\#Z_#J$D=MJ$T(A,]RS?ZFY;NQX"29P1M&>F0!_
MPU_X**_&+]G7XHVW@;]ISP^T=A<D :PEJL4]NI.!*#'^[GB'?;\PYY.,5^H&
MCZQ8^(-)L]3TVZBOM/O(EGM[F!PT<L;#*LI'4$$&OF__ (*)?"/PC\3_ -E[
MQA>^)1;VMWX?L9=3TS4WP'@G1<JBMZ2$!"O?<.X%<9_P25\0ZUKO[(.EQ:L9
M7@T_4KJTL))<G-N"& !/8,S@?3':@#[/HHHH **** "BBB@ HHHH **** "B
MBB@ KX!_X*)_ME>*/!WB73?@7\,+2YM_'?B,113:Q)^Y6".8[4CMW; +L<YD
MSA ,#+9V=%\>_P#@JW\-O@SX]OO"FFZ/J7C6ZTR4PZE=Z8R);V\@.&0.WWV4
M\''&>,UD?M/_  T\-?\ !13]F+1_BA\,Q+_PF&C+)=:3)M\NZ8H?WUD^/XMR
M@KSPP&#ACD C^"/Q)^$7_!.CX=6OPS^)'Q0?5_&%T_V[5+&*.:\AL990"T:(
MBMY:<Y.[!<DM@9P/I_X,:1\)/%WPAEM/AY;:-J?P_P!7>XDEM;)0]M(TS%I5
M=#]TDMRI QP,# KY+_9"_8!\.:K\*M3UW]H7PQ'JWQ&\874US,VM71-W!$P!
M4@A@4E)+.V/F&0#C!%<5_P $U]*N?A)^V3\:?A;X;UB77? -A;O,L^_?&LT<
MR+$<CC?MDD0D==GMP :<7[%OQ;_9-_:MT3Q!\ '6_P# 7B.Y$>HZ;J4Y%O90
MYW21W!Y)0#<8Y "P.%Y/WOTM&<#/7OBEJ*:ZAML>=-'%G@;V S^= '@O[7O[
M8?A7]DWP.;_40-6\47RE-)T"%\27,G3<YYV1@]6Q[ $U\,:E\</V^HO#W_"S
MSH @\+LOVL:3'I]NVR#KS!DS[<=SSCFJ7[?GP4\>_L__ +2&G?M$QC_A9'A-
M=1BN6M]9B%Q%II!PENZ 86+_ )YN ,-C/S<M^C/[-/[27A']J'X;VWBCPO<J
M'&(=0TN1AY]C-CF-U]/1NC#IWH \N_8=_;PT']K;0IM-O;6+P_X_TZ+??:2K
MDQSH#@S0$\E<XRIR5) R>"?JNOR7_:(\"Z9\ ?\ @J!\*=1^&FRQO_$FH6D^
MIZ18C"1^?,8;CY!PJR1EV(Z Y-?K10 4444 %%%% !1110 4444 %%%% !11
M7"?&OXU^%/V?_A]J'C'QCJ'V'2;3"A47=+/(?NQ1K_$[>GU)P 30!T/C/Q79
M>!?"6L>(M16=[#2[62\G6VB,LA1%+':HY)P.E?E)X4\<>+/^"@_QMN_B9XI\
M5-\,_@I\.;I;Q/)O1!+;D'*?-G_6N!\TG10=JYKZ1^"G_!5KX<?&?XF6'@B_
M\-ZMX9.L2BVL+S4=DD,[MPJ.!]W=T'49-?/GQM_X)L^,;7]I^WT'P%%?I\&_
M&M]#?ZU':3>5!811RAIHGSP<;F,0P3\V!]TT ?6ND_M;?LO?M&>/_#6C-XAT
MW5_$FC:@MUHDVIVDMN5N1P##+(J@D\?+GYB!P2!70?MI_L6>&_VM_!!1S%I'
MC;3XF.D:WLSM/40RXY:)C^*DY'<'Y8_X*+_L8_!;X>?L\3>-O!%E8>#/$'AV
M:""#[!<G%_F14,3@L2THR6W#YOE.<CI]O_LE^)M<\9?LS?#/6O$GF-K=[H-K
M+<R3??E.P 2-[NH5C_O4 >8?\$]=!^-WA#X4W_AWXQV\4:Z1=?8M%EEF\R[>
M!,JV\C(,8(7RVSDC.>-M?4\DBQ1L[L$1069F.  .I-*3BO*?VE/A???'GX,>
M)O!.@^+)_#&IZA!Y:WME(,G'/E28^;RW^ZV"#@]QD$ ^/_CY^WM\1OBK\4YO
MA5^RYI*:_J5GN_M'Q((DEC# X(B+_NUC!X,C_>)PHXR?.M&_;S_:+_9*^(6G
M:+^T9X9;5O#M^P!O(H(DF1<\O!+%^[EVYR4//NM87[!_Q]_X8=^*>O?!+XN^
M'K7PRVH7X*^(_*"NLI^5/-D_CMV'*OT7<<\$X_1_]IWX1^#?CE\#O$FB>+Q;
M+I'V*2\AU20@&PD1"R7*/VVXR><%<@\$T =[X'\;Z)\2/">E^)?#FH1:IHNI
M0K<6UU">'4_R(Z$'D$$&MVOSS_X(N>(=:U'X$>,=*O6DFT72]=VZ;,^=HWQ*
MTJ+GL#M;'K(?6OT,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 0D $DX KF/!'Q/\*?$EM67POK]CKC:3=-9
M7PLY@_D3+U1L?SZ5T5Y9PZA9SVMQ&);>>-HI(VZ,K#!!^H-?G1\>?#FI?\$R
M?#</B;X)^"$U#P_K&KBY\3ZQJ$AN9(( Q\JS QF.([F DY.< G)&0#K_ /@H
M'\>_'$OQ2\ ?L]?#35O^$:\1>,@DU]KN\H]O;O(Z(B,.5SY<C,1SA5 ZFNJ_
M9\_9UL_V"O#7CCQM\0OBMJ/B?2FB1I+B^\U+>W3C<?),C[I&<@ ]<8 ZFO!O
MVE/""_M^?#_PA\?O@-?R'XA^$T6WO-&CE"7L6QS*B#GB2-V=E[.KG'(Q7%^)
M_P!L/]H3]IOX5WWP._X4Q>CQGJL2Z;JNKR6DT,:1Y&YWC= L)..69L#D@=,
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MSX#>*O\ @H[KNI:W\;M<U^'0/!EC;Z#8Q6B^0)IU!$AW.I4R#9ND(&XLZYP
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M&-KX4^'GB%0-.T75G6" X/[N2#>1Y,:KE0>3)G)SPU>H?M'?#/X?_P#!1/\
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M!ST(^R_V1?V.= _9$TGQ-9:'KFIZRNM7QN2+U]L<$0R(D6,'&X*<-)U; Z
M#U\^!O#VK>)],\87GAVR'BFUM&MX-0G@1KJVC?!>,2#..1C@GO@X)ST= !11
M10 4444 %%%% !1110 4444 %%%% !1110 45P'QG^//@3]GWPN/$'CSQ#;Z
M%I[OY<(D#237#_W8XE!9SZX' Y.!6/\  ?\ :D^&?[2EA>W'@#Q+%J\MD0+J
MSEB>"YA!Z,T;@':?[PR,\9S0!X3^VI^RUXV^/'Q_^!_B'08;#4?#7AV[DDU:
MTU27%O$HEBDW%,$OO5"F #RHSP:\]_:T_9J^,7Q"_;-\*>+?A/H>B>''T+1/
M-@\47S 0//ETVR*$;+J'PHVGCDG P/H_]L#]L;PI^R1X(34-4*:KXEOLKI>@
MQ2A9;@CJ[=2D:]V(ZX R:\V^+O[37QU\0_![X=>/?@A\*KC5(-9C^V:I9ZO%
MNN($QM6,0[T=E8G>)5R"H4\!J /(?V:_VD?BWXQ^+WC+]F;XYW\]CXCOK&>*
MS\0:/Y<%W;L(]QV.J[65HR61]N1CWX[WX,_\$DOAU\-?&MGXA\1>)-6\>KIT
MWG6&F:E&D5K$P.074$^9@\XX4]P:@_9!_9B^*/B#]H+6?VB/CE;6NC>*[RW-
MOIF@VI4FV4H(][A68*!&-H4L6Y);!K[QH 0 *H    _*ORX^*/Q(^*/_  41
M_:#\0_"OX7>(W\'_  P\,R-#JFM0NR_:=K%&=MA!<,P8)&" 0NXD=OU%EC\V
M)TSC<I&17Y _L3?%.V_88_:R^(?PL^)9&CZ?K=XMO#K-P-L22*[&WE9CTBE2
M3[W121G R0 /^+/[!/QJ_8KTT_$KX4?$F_\ $D.F#[1J,$$+VTZ(O+.T.]TF
MC'.X'D#L>2.TD\&>'/\ @JY\ I/%^FP6GA?X[^%D6VNWA^6&\8 E _<1R ':
MW)1@1R!S]P_M3?%WQ5\*/A+)XD\$>%M/\:3,^V=;[4([:TMK8QLS7$DC$*4&
M #\PSNZU^3/["/@?]HGQWJOC[6_@7>:9X'TG4YUM]2O;K:+>'YFD2&#>DAR@
M<C(&0".1F@#N?A7X _:/_;3O--^#'Q!U#4="\">!KGR->OKB$I/*5(*1.Q_U
MT@7 7L 0QSQG]<OAS\/-!^%'@G2/"?AFQ33M$TN 06T"<X ZDGNQ.22>I)-7
M/"-CJ.G>&=+@UF:"YUI+6);^YMUPDTX0!W&><$CO6Q0 4444 %%%% !1110
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M_'O]IC1OCS\>](M?"8\/6PAT3P];@*^X!]K,@9B@#2.WSG<6QP !0!I^$_\
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M>"OA+_P4X_9\MM1T^X1;H(38ZDJC[;H]UCYHI%],XW)T88(/0T ?-5W^Q_\
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MMMX-U76+ZWCGL5BM;.)+&\N90WFJP+!@-['<VT[CDC/?H_\ @E#\"?$GP;^
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MU#Q+\!/VF/ /QRT+5;73?B%JNFPS7_AIR+LZ=/';+%(N0-K1,A*]0<@D=<@
M_8BBOC;_ ()@?&?4OC!\$-0O/$OQ /C+Q6-2FGN[&>,)/IB.V5C]60\LI'RC
M.T?=K[)H **** "BBB@ HHHH ***S]3\0Z7HLL$>H:E:6,DYVQ)<SK&9#Z*"
M1G\* -"OR^^'WP"C_:;_ &_/C;+\:/"VK:YH6B"2VTII!+'8Q('40IO0CYC"
MP=5!Y)8GG%?J "& (.0>A%>8?$K]I+X;_![QCX;\,>*_$MII&M^(IO*LX)#W
MQP\A'$:DX4,V 20/7 !^47[-/Q_\1?L;:_\ &W4/ GPO\2>-/AZ^LI;I>W$<
M\-MIT=N\P_?-Y3;9"LB#YMI 49'I]N6GQH\4_MP_LN76I_L]:O8?#_Q@VH"+
M6+?4F:.:UD #NJ2QH>7^4B3;\PR#M(.,WX]?\%*?A+\#_%_C+X<OX2U76+ZW
MB<2#3[2);2[NY03)&^Y@>K#<^ULDMUQSG_\ !)'X%>)/AA\*_%?BSQ)I\NBM
MXQOHKFQTN92KQVT0?;(5/(W&1L \[5![B@"7]GS]A3XD7GQCTCXK_M#^.;?Q
MMXDT)5_L;3K.1I(+=QRKN2B#*DDA57[V"2<5]W452UK6;'P[I%[JNIW45CIU
ME"]Q<W,[!4BC4$LS$]  ": 'ZGJ=IHVGW-_?W,5E96T;2S7$[A(XT49+,QX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 45S6N_$CPQX8\5:!X:U36[
M2RU_7FD33=/ED_>W)12[[5] !U/&<#J0*\Q_:Z_:NT#]DWX=0Z]J5I)K&M:C
M,;32-%@;;)>38R<GG:B@C<V#U  )(H ^2?\ @HC^S_\ %/X?_%&U_:1^%_B#
M5+^XTJ-!?Z;YAD?3XD&"T2=&MV&=Z8X)+<@G;Y]^RUH7@C_@I?\ '+X@^+OB
MU'))J=EIEE;Z=X;@OGB2)-A66:/!#$!UR!T!DYSQ75:G_P %*OCM\(-;T:[^
M-/P4ATGP7KIVPB""6&<H>H5G=E9PIR8V"D^U<Q^U)^RKKWP;U/2?VF_V=%O]
M*TYXTU2_T1+=HI[%'&YI!"1DPD'#QD?+UY7[H!S.OZ%\3/\ @DQ\;DUC1C<^
M*?@]KDX1XY"?+F3_ )YR$<1W"#.U\88#TR!]A6?[(GP:_:H^(/@3]HGP]+?Z
M;%/MU*>SLT-L-0F4_(TN,,CJX(8K]_'7N?1/V??B#I7[;_[--GJ/CCP08+/4
MU-O>Z;J4&;>X=",S0$\E">5;J"",\9KWW2]+L]$TVVT_3[6*RL;6-88+>! D
M<:*,!5 X  [4 6J*** "BBB@ HHHH **** "BBB@ HHKB?C#\9?"/P'\"WWB
MWQIJT>DZ/:X&XC=)-(?NQQ(.7<]@/<G !( .S:5$959U5FZ G!-?%7_!2#]E
M;QO\9=$T7QY\.M=U*+Q7X1!N+?18)RBS@'<9(,?=G&./[P&.N,_.G_!370?B
M/XSM_#?QT^'?C6]\0_"TVB&V.B3/%_99;@RG802K$8+'E6&UL8%>4?LX_'/]
ML;6_"<NN?#GQ!<?$+2]/?R[S3)YH+ZZMSV#PR$388#@ID'GG((H ^W_V ?V_
M+?X_6"> _'KII'Q0TU3$RS+Y2ZFJ<%U4XVRC'S)^(XR!Y!\9OV:?CS^V%^V)
M=:1X[:7PG\+O#,RW%C=Z;*3 UL6/EM Q WW+[?F8CY.>,!0?A?\ :4^)GCCQ
M#\2K'QEXA^'4_P +OB'!()[B_P!/M;BP^TR*05F,4GW9 1RZD9[CO7ZU?\$Y
M?VMM?_:D^%=T?%&BW,&NZ Z6EQK:0[;/421D,IZ"4#&]1QR",;L  ]&^(O[$
MWP8^+-S97GBSP3:ZOJ5M"D']HO+)'<S*BA099$8-(<#JQ)->F?#SX:>%_A/X
M:@\/^$-#L] TB'E;6RB"*3W9CU9CZG)KIJ^3OVX_VZ;#]EFQT_P]H&G+XF^)
M&M)NL-)Y9($)VK+*%^8Y;(5!RQ!Z 4 ?3GBN+6)_#.JQ^'I[6VUUK:06,UZA
M>%)MIV%U!!*YQG%?BE\"?%MK\%/VZ]1O/VHM(N;_ ,22SE8]7U%O,@LKEF_=
MW.S&'B(X5AP@P0../2_$7QQ_;_\  NE'X@:UX?O(O#BC[1+:'3;21(HNO[R!
M"9D4#J6 ([D5W^C^*_AQ_P %:OA=<Z!K-I;>"_C=H%N9;69.5D7NR$\O"6P&
M0_,A(()ZD _1'Q?X-\,?%[P1=:)KEC9^(/#FJP8:-P)(Y$8<,I'0]"&'(X(K
M\JOV<_#VJ_L3?\%,3\*]*U&6_P#"?B,FU:%FR7@DA::W9@./,C8 %L=-_P#>
MK!^"G[<GQ,_8(;Q-\(_B=X;NM=.EQ.NBQ2RX:VE_Y9@.?OVS=1CD=O2OHC]@
M3]F?QIX[^*-Y^TW\8RX\3:LKR:'ILJ;6A21-GGLO\(\LE(T[*23VH _1*BBB
M@ HHHH **** "J.N:YI_AK2+S5=5O(=/TZSB::XNKAPD<2*,EF)Z "KU? ?[
M</PR^/7[37QJT/X2Z+9GPW\(9H4O;WQ#!(7CN "/,$W3#*3A(?XN&)(^Z >:
MZU_P5@OO&'[6'AGPUX1T^UG^%DU\NC7/VZ+][J/G.J&X!/**O\*]QG=U 7CO
M^"B?_!.<_#^_N_BQ\+](6\\-^9]IUKPU&I(M#G+2Q!>3">=RCE.H^7[O-?\
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M:W-\02BLVH3VVF/>?ZN.0VX%H1GCE=H7W85^NJLK9P0<'!P>AKX;_P""B/[
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M_P""JVF?&D_#^V\0^ -7>7X?VUG<6VOZ7IR9F,<J-&\LG7S(MC$$ ?(?F]U
M///%G_!8S7XM9NM5\+_""?4OAY;7!@&KWLTL<DZ@XW;E0I&2.0IW>]>7?M#_
M  "\%?MJ?#[4/CO^S_:O!XAM\OXI\%[ MP),9:5$7@OC)^7B0#(^8$'ZW_X)
M[?';X4_%K]ES0O $[Z19ZEHVG?V=K'A_4#&OGJ 0TX5N'1\[B>Q)![9^=_\
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M,L3;62-YMQ<S$-<7<N #)*V!ECCV '  %>DT44 %%%% !1110 4444 %%%%
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M;E_9%M?V@((OV@_@-XABUWQ+9[+BXCT>]%RE[Y.-LENZDA9DVC*#KC@!OO>
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MQ#[]N_.Y/X<Y&!]W]&?@YXOUWQ[\,?#GB#Q+X>E\*ZY?VB376DS-N:W<CI[
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M3Z"OJS]B'X;_ +27A ZI-\<?'3:K80@V^GZ0QANI)#Q^_>Y"[\=@I.3U..A
M/I;5?A[X7UV]MKS4O#FE7]W; "">YLHY'B Z;21D8K>1%C4*JA5 P !@ 4ZB
M@ K\OOVVO^"B7BF_M_B;X!^'W@274_!^GQ7/A[7/%LL<S)!,ZM$^QDPB;6)
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M=N1CHQW.5..< _IG^U3^RUX4_:L^',OASQ%']FU"WW2Z7J\2YFL9B/O#U4X
M9>A '0@$?G7^S'^T+XO_ ."<WQ7NO@O\8[61? ]S<F2TU.-2Z6V\X%S$<?/"
MW\2]5.3C(((![M^PU^T_X)_:R^#@^!GQ,T^U_P"$DL-/&FR:;>KM34[>)0JO
M'GE94"C('(*[AWQ9_97_ &%/B3^RO^U%K%WX;\6QGX-W4!E>WN&WS79.1' T
M?&V2,\^<.HXQ\Q [+XE_\$\_ 7QC^.'A+XP^%M?E\-J;A-3OVT%PJZECYXYH
MI%/R,QQN89W D]>3]D@8 'IZT ?(GQY_X)Q>#?C%\;O#OQ)TS5+KP;JMM>)=
M:O\ V2/+:_*'<KJP(\N7( +C.1SUYKZZC3RT5020H RQR33J^>/V]/CUJ?[.
MO[-OB#Q/H>$UV9X]/L)F7<(993CS,>JJ&(SWQ0!W7QOU_P ,:IX+U_P7>^,/
M#>@ZWK=A-9VL6MS0.-\B%5)@D8;QD]*_)+Q)^S#\8/\ @FWKO@WXR:7-IGBN
MSC7;J<EC$9(+1G)!A<D9V.A $H PQ(XXW>S?!W_@ECH_[0'P)TKXA^+/'VLW
M/CWQ;9+JZWP=9H8C*-Z+(&RTAP1N^8<Y Z5>_P""=WC7Q;X5^+GC[]E;XJ!?
M$.E65O<)!;7I\^.,)C?&A;K#)&X=0>G& ,F@#ZAT;6?A)_P4S_9UDBEC257
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M@UTMI_P6H\$S^#$FN?A_K9\:)$0EC$\36AFQCB4G>%/ILSVH X/]CSXR>-O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>@ !.:_._P ;_P#!93P_HWBBY'AGX:ZOXE\%VEP+>;Q&US]G5SG&8T,;#GJ
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M#;K=W6FVP6TMW^[)<2,$B#?[.Y@3[ U^?G[*W[!0_;)\+7'QK^./B75]5O\
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MIX^\2::^A'QM>QW&GZ7(FQDM8_,*R;3RH8RD*#SM0'HPKZ]O/@1\.-1\3_\
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MX(:E\=O#/A7]KKX"K=VFO36\=]JFF61/VE)8OE::(#[SH4*.H^\%R ><]O\
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MA ]00#7P5_P1.TWPS+X ^(&J((9?&AU*.*ZD?F9+0Q@QXSR%9_-SCJ5&>@H
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M^#'Q5\1_$'PQX?2SUW6#E5)!AL P_>+;)C]V'.2?3H,+Q7L>MZ_IGAK3WO\
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M!GPR\>>,G\;:'XM\@3VQO9;R$QSR-&LB>: R.KJ<\8('?-?J):_!/X?66O\
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MC(E0N%/<;1U4XH H_&'_ ()X>#O%OP>\+?%3]F"^FLM>TVUBOK9;>[=SJ2J
M=RL3F.X4@\< G*D XK=^#/B31O\ @I[\$]9^&_Q3T.YT?XF^$4V#Q##:$>5+
MRJR\@!7)7$D)(#8)7'\+OV2/@Q\>?V/OVF[CX96-K)XK^#NJJ]^=4N&*6]M&
M.!*K<[)\E5:(??Z]!N'Z(Z3X:TG0;C4)],TRST^?49_M5Y):P+&US-M"^9(0
M!N;"@9//% 'P!_P3U7XZ? CXK:]\"/&WAN?5_!NEPM=6OB%3B&S4D^68Y&QY
MD<N#A/O*0>, @?HC28YS2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M' +L   .@50 .>Y)-O\ :A^-Y_9S^!OB?X@+H\FN/I,4>RR1P@9Y)%C0NW9
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MO@-\=/V2KC7K'Q5H.L^)8V@G\.FTN4;4%E:1 \9BSYBJ4+;E8 # /4"O5_\
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M5AP00:O54TK2K/0M,M-.TZUAL;"TB6"WMK= D<4:C"JJC@    "K= !1110
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MYJQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^/'PE35?#.^W^(GA*7^UM!NX#MF,B89H5;L6"@C_ &E6@#Y!_P""BOPEU/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;"^>=Q3:3GOF@#G9_P!A_P"%<W[1=O\ &9=&,/B:(&0VL3!;1[K/%VT8'^M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#G_ !+\/_#?C+4M$U#7-$LM5O=%N#=:=-=P
MB1K64KM+IGH<?R!Z@5\%_P#!:H.OP2\!RA284\0'>1V/D-C^1K]%*\C_ &H/
MV;]!_:E^%TO@O7[B:QB^UPWD%[; &2"1&Y*@\?,A=?\ @7M0!\!?#KXD?&/_
M (*"?&CPM_P@VH:E\.OA+X&DMV;4H#M>25$ );^&25AD!#E44\@Y.[]5T4JB
M@L6(&,GJ:Y;X7?"_PW\&_ ^E^$O">FQ:7HNGQ^7%#&.6/\3N>K,QY)/4FNKH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^+O^"M'@6[\
M5?LI3ZOI\$DUYX:U6VU3,*DND>3&[<= -X)/8#-?'L'P*^+/_!5'Q!JGQ-U*
M.Q\#^'=-TXV&AM-!N^VRH#B/<,,RERQ:4Y"YPH.#C]CKJUAOK:6VN88[BWF0
MQR12J&1U(P5(/!!'&#5;1-#T[PUI%II6DV-OIFF6<:PV]G:1".*% ,!548
M]!0!X/\ L)^"/BA\./V?-&\-_%,V":III:VT^VM #)!9KQ&DS*=K-P<%?X=N
M23FOH:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^,GPD
M\/\ QS^&VN>"?$T#3:3JL!B=HR!)"_5)$)Z,K ,/<<Y%=I10!^(O@VP\<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%+_B'<_%.W>WL/$DMS#!K<Z%A;QSS)+#.#C_ %9"[&(Z<_W37I?_  5?\/\
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MZ8X$63P,G$9_[9'N:_1B>VANK9[>:))8)%*/&Z@JRD8(([C%?E#X:^-&F_\
M!1;X#7?PI\:R0Z%\>_#2F\T"_FQ#_:%Q$.0IXVR, 5=/HX'RD+]N?L)_&'Q)
M\8_@#IEUXQTJ^TWQ/H\TFCW\E["T?VJ2$[3*N>N<8;_:#4 >7>&/^";.F_#G
M]KC3OBIX'\3W/A3PK'ONKKP_895GG)Y@4_=^SODEE/(QA<9!7[8HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HK@?CQKGC3PY\(_$VI?#S2;?6_&%O:,^GV5R^U6?N<?Q$#)"\;B ,C
M-?,?[!?_  4 A^/<1\ _$,1Z'\4].W1.LB"%-3"9W,J<;)1CYH_;*\9"@'TY
M\?O'MY\+/@AX\\7Z= +F_P!$T6[O[>)AE3)'$S+GVR 3[9K\ZOV#/V.OAO\
MM:?"77OB1\3[F^\8>,=9U.XBN9FOG1[0C&#\I^\<[N<C& !7ZC:UHUEXBT>^
MTK4K=+S3[Z![:YMY1E98W4JRD>A!(K\MKW]B#]I7]D?XD:MJ'[.GB!=2\*ZJ
MY(M+B:'=&F?E2:*<;'*YP)%YQZ9(H I_LT>%M=_8T_X*$77P-@U237O 7BFV
M=_LES\RM$T#R12,G02+L9&.,,,\=,?;7P6_88^&_P&^,OB3XB>%8+NTO=73R
MX=.\W%K8JW,HB4=0Q .&SMZ# KS#]CS]C#QGX2^*6J?&SXWZ]%XD^)^H1&&V
M@A*M%8(R[68L %W[?D 0!57=USQ]KT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 45R7Q9U7Q3HGPV\17_ ()TNWUKQ7;V<CZ=87<OEQS3 < G
M]0.,D 9&<CY!_83_ ."@\OQ>U&;X9_%=$T#XHV,KP))+&+=-1*DY39P$F7&"
MG1L9'<  ^POBKXNF\ ?#'Q;XFMK?[7<:-I-UJ$<'_/1HHF<+^)6OS*_8'_9<
M\!?MG^$?&?Q-^+=U>>,?%]_JTMO*C7KQ?91M5@P"D')W<9X 4 "OU8O+.#4;
M.>UN8DGMIXVBEBD&5=&&"I'<$'%?EOXF_83_ &@OV5?BMJGB3]FG75N?#NJN
M2=,FFB#PH3D12QS?)*JY(5_O >G4@&'\(?!FM?L&?\%%=&^&&BZQ<:MX$\:Q
MI_H4S;BT$OF+&TB]/,CD1AN Y7/3=@?;W@3]A'X9_#?]H?4/BYH%K<Z?JES$
MPCTN"399V\SY$LJ*/[P.-I^4<D#D8\H_9._8Q^(-M\9)OCG\?M?BU_XA^28=
M-T^W96BL05*EV* )D*6540;1N)R21C[CH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HK \>WVO:9X*UR[\+:=;ZMXCALY9-/L;J;RHIYPIV(S
M8. 3C_$=:^)/V)/^"ANH^/?%M[\*OC7!'X=^(]O=R0VMS+$+>.[;<?\ 1W3H
MDJ]!V<8[_> /N3Q;K;>&O"NLZNL#7+:?9378@7K(8T+;1]<8K\KOV#_V?_!G
M[=DWQ$^)OQBNKGQ9XGFU/[.+#[8\2VD;)N5@%(('.U1T 3I7ZRR1K+&R.H=&
M!#*PR"#VK\O?B+^P5\</V;OC'J7CK]F36E72=4D9WT9YHE:W#$DPLDW[N6($
M_*3\R\=QN(!R&B?#[5?^">W_  4*\&>%/">KW-_X&\<M!&VGSR;BT$TC1;)!
MT+Q.-ROC...[5]SZ/^PA\,O#W[2/_"Y-+M+C3M9V,_\ 9EJ_EV@N6R&N-HYW
M$$@K]TDYQFO&?V9/V,?B=KWQNMOCA^T7KT&L^+["(1Z1HUN4:.T(R%=]@"+M
MW,51!]YMQ.1S]Y4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!SX^(/AIO&K>$!KE@?%"VOVTZ1YZ_:1!NV^9LSG&:^._VK_P!D7XA?
M%3]LWX2?$OPC-8#2='BA6_FU)MT=F;>=I0?+SE_,$A "]UY(ZU\6_MC6?C:]
M_P""A/Q)\1?"07LNO^%+2UU:YET]]TD:Q6]NLQ"_Q %P&3N-W%?H9^PS^W-H
M/[5WA,:?J#0Z/\1--B']HZ23@3J./M$&>J$]1U4G!X() /"?^"V&G6K?"3X;
MZB84.HPZ^\$4^/F5&@9G4'T)1#^ KW/XV_M)?"'X3?!7P'X>^+OE:XGB73K&
M"71_LZW4AC:- ]Q(A/"*>=W4G[H)KRW_ (+.^$;_ %O]F[PYK-E"\T6B^(8G
MNB@SY<<L,L8<^V\QK]7%>>_L*?L,Z]\5-;T_XV_'@W&JW!CB;0]#U'DM&B@1
M33(> @ &R/'N>P(![]X)_P""8?[.EGXDL?&6FZ!=:I9R[+RSL+J_>:Q .&1@
MAY9>APY(]J^P(84MXDBB18XT4*J*,!0.@ IRJJ*%4!5 P !P!2T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?GG\ /V>/B/X4_X*5?%'
MQQK?AM-0\*7(N'@\07SX5%G*/#]GR#O=57RV P%&[GH#YS^T]I5MX)_X*X?"
M2]T*!+"ZU=--N+TP#;YSO-/ [''<QHH/K7ZI5^07_!5G5_$OPN_;4^''COP_
M 3J$6B6SZ9(T1D5KF&ZGRH7^(CS(SC_:% 'V?^U;X._9Z_:)\=:)\)?B#JUM
M:_$*X@>?2IK*01WMN,CY!)@KE^2(WSNP2!D USO[._\ P2Q^&/P$\?V?C&75
M-5\7ZOITGFZ<FJ"-(+5Q]V38@^9QV). >0,@$<;^P?\ L(ZEHVM#XV?&@RZS
M\1]4D^VV=C?'>; MR)9<]9CV'1![]/T"H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M*OVGOCWIO[-7P7U_QWJ,'VQK)%CM+,-M-Q<.=L:9[#)R3V -?F;XD\>_MNW?
MPT3]H;_A(VL/"C@7\>B6DB!8K,G*R&U*D-%@CEB7Q\QXYK]&OVP_V<U_:D^!
M^J>!TU!-*OI)H;NSO95+)%+&V1N Y((+#\:P_%?PN3X*_L,^)/!#ZM<^((]$
M\)7=K]NO0 \@$+X&!T4=%'.  ,GK0!XCX\M[S_@II_P3ZM-2TB&*S\96UP+Q
M;)6Q&U_;;TDB!/02([%<]-ZY[UXU^R;_ ,%/K/X$>!5^&7QL\/ZU9ZIX93[%
M9WEG:AI6C3@03QLRE77&T,,@C&<$9-[]@']I7PG^RU^P;KOBKQ1=B2:3Q)=Q
MZ;I,3CS[V;R(,(@[#NS= /P!^I_V>V\#?MO?"S2/B3XZ^#^F66MR2/#NU6Q2
M3SPAXEAD8;GC.<#=W!'.,D ^5/V1_P!E#0_VNOBIXC_:#UJRU7PEHS^*WU#1
MM,MG\G[9&HW99A@KB3:2R'DAU]Q^I\4,<";(T6-<DX48&3U-0:7I=GHFGV]A
MI]I#8V5N@CAM[>,)'&HZ!5' %6J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M17 4@I.(VR55\!PK#(_(GV=5"*%4!5 P .@H P,#I2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7+>+/A?X5\=:]X<UK7]#L]
M5U/P].]SI=Q<QAFM9&7:S+^0/U4'J!74T4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5ROQ6\)/X\^&7BOPY&P675=+N;)">@9XV4?J:ZJB@#\:/V%/\ @FOX
MA^)?B5O$'Q7L;S2?!.A7TL5OHMUN234;A&VOA3]V(% "W5\8' )K]CM-TVTT
M?3[:QL;>*TLK:-8H8(4"I&@& J@<  59HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>sdgr-20241231_g17.jpg
<TEXT>
begin 644 sdgr-20241231_g17.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'L Z@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6L'AP,!<ZIH>H&Z-FI(&^2)D5B@[E<XKURTM8+"UBMK:%+>WA4)'%&H544#
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M JC/<D@ =R: )J*** "BBL_7M>L/#.ES:CJ5P+:SAVAI-K,268*JA5!+,6(
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M9!P6P5P1DFNFNOA#X>UCQ)J6IZSI.FZM#/';QVUO=6:/]G$:LI )S\K9'RX
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MB'KJ8?\ 4Q_[H_E0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ&-V[&=V.-W7''2@"C\6O^25>,O^P->?^B'KJ8?]3'_NC^5<M\6O^25>,O\
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MS+C-RDU;M^H4445R&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2:1;?VCIUGI\VBZS9RRV\HA:9O,+QNK(X,N%(R,%P1]TBG_PSO<:YX5\3_\
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M>EZ/J3?#0:/XP^&NE^(H]2M)(ET71+H>)&D5@;J&Z(N&ERZB5)FF7:-S,V,
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MA D2C<N1]X9QEL$D Z7X6>.M4\7+I1U PG[3X9TW5I/*3;^_G,WF8Y^[^[7
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M0);)Y )"H^M?*OB#XT7EO>$12LQS_>KQ,5CU1ERH_4\@X-JYK2]IW/TC\/\
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M)2N1VK[.E+F@F?RGCZ*H8F=-;)ENBBBM3SRAJFI+8QDD\XKA]1^)4>GW&&D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML?0-%)2UY104444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''>/_\
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M<,[OC3QU_P (C>:)91:3>:Q?:Q</;6T%H8U^98VD)=G90JA58Y]NAX%,T;P
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MU^0'C;Q??:/X@O-,T^*%]*M93&D87!P#S@U^E/[,GQL\.?%KP#91:3)]GO\
M3H$AN;"0_/%@8S[@UIALSP^86J45R\VJB]U?6WR/QG,N%LURG#0Q>*I6IR2U
M72^U^Q['1117H'R@5Y%J'_%UOC1%IV/-\,>!76YNU9<QW6KR1YAC]"+>)_,(
M_OS1'JE>NUY):_LU>']/EO'L?$?C/3Q>74M[/'9>);J%'FD8M(Y57 RS$DT
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M-:%>//3=T?FN:93C,FQ#PN-ARR7XKNF%%%%;GD!1110 4444 %%%% !1110
M4444 %%%% !1110!PGQ1U2ST:\\%7NH7<%A9PZZ#)<74JQQIFTN@,LQ ') ^
MI%:/_"U_!/\ T..@?^#2#_XNNFFACN(]DL:RI_==014']DV/_/E;_P#?I?\
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M_9-C_P ^5O\ ]^E_PH P/^%K^"?^AQT#_P &D'_Q='_"U_!/_0XZ!_X-(/\
MXNM_^R;'_GRM_P#OTO\ A1_9-C_SY6__ 'Z7_"@# _X6OX)_Z''0/_!I!_\
M%T?\+7\$_P#0XZ!_X-(/_BZW_P"R;'_GRM_^_2_X4?V38_\ /E;_ /?I?\*
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M]+L;F]NYEM[2WC::::0X5$4$LQ/H ":K:9J7VJ-=W6L;XK?\DN\8?]@>\_\
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M\0)+NVUEH?*7)"R@'FO@L=A%BJ=E\2V/ON%.*L1POB95*<>:$OB7ZKS/A_\
MM9KZ1(+97N;B0[4CC&YB?0 5]4?"/P'-\%_A9KWB/6E$>L:A#N$/>) /E4^Y
MK?GT?PU\,=>N4L-*LU,;D+<QQC->8?'GXO/K6AQZ59++.)I,R^6I. .:_"\W
MI9IC\3#+'AI4Z;DG)O6Z3OHUI8_3\5QG_K=BL/EME3HRE'FN]TG=_P!=3R:^
MMUEC:Y=]\DC%F^IKU/\ 8I\07?A_]HS2+:U+>1J,<D%Q&IX*[=V3]"HKPT:P
M9@L<:O+(W"QHI))],5]6?LP^![;X%V,_Q?\ B(3I5L(3%I=E(/W\K-_$%Z]
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MLNWJR]Q7Q=86M_;:HQ;(96QS7HI65CXJ<G.3D^IS7CCPFDDES\FQG);BN/\
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M?/PQ_P"!=Q_\:H\[XB?\^?AC_P "[C_XU7:459S'%^=\1/\ GS\,?^!=Q_\
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MU.G#9K0Q-3V-G&?:2LSU*BBBO$/8"BBB@ HHHH **** "BBB@ HHHH ****
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M<5\=0S*O1EJ^9=F?UGG/A[DN;T$Z,%2G;24=/O6S_!^9[-\5O$WGZ5>W!?\
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MT)M-UJV#XYAN$XDA;U4_TZ5\S:I^P_X@@O&72O$UJUD3\OVF-MX^N.*^R**
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M.X+$N.94G>%31]U)*S3/R7)Y/#\V7U5:4-?)IO='2T445\J?2A1110 4444
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M;O6=4M8K-KJY=AMV+G' J?#JM"CCZSJ)./)=WV7O+7\0Q'PJQN_LM?M-:_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1O!')]Y0:DHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQV5PKO&#]UBO7:<'#=#@X-5.C.&MKI6U]5<2FF=;17E7Q:\?+X%^(7P[DO\
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M 4444 %%%% !1110 45S/BKXE>&/ ^/[<UNTTUB,A)I,,?PKE?\ AIGX9_\
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MK3HHH **** "BBB@ JIJS7RZ5>'2TMY-2$+FU2[=DA:7:=@=E!(7=C) )QG
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MUQ7045<).G)3CNB)Q4XN,MF?''[(OB"338_%'PEU>-K75(9)9H7;IN! (_\
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M3-+?2;6U.BQ2##O(P8L.XK:4\)6?MJLFY=CQ,+@^*LH@LHRS#PI4)-_O._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR8Y*JTB_*O)X QG( +WBCQ3+I]U#H^D0QW_B&Z7?%;N?W=O'G!N)\'(C!!
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MG@/QLC#P_-(6M[K&53)P'4_W?:OMJRO8-1M(;JVE6>WF4/'(AR&4C((KQO\
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MQMRQ<QPK@$DY)K1HHJI2<G>3NQ1BHJR5D%%%%2,**** "BBB@ HHHH ****
M.*^,K>+&^&^M0>![0W/B:ZB^S6C"=(?L^\[6F#.0-R*691W8+VR1X[XHT/QO
MK'P2OOAMIWP?ET[36TK^SK.8^([-C RJ/*E.,;F5U5R>I()[U]+T4 >*:OX=
M\>Z3XF\-?$72]&M]6UR708M(\1>&FO$@9L-YH>WF.8R\<CRC#$*RO]X8I]Y9
M^,_B9\1/ ]Y?>"Y?"?A[P]J$NJ7,FJ:C;2W%Q(;6:")4CMWD& 9MQ+..G2O:
M** /(/ _Q-U*W@M9=3T:[?0]6UZ\L[36)+Q)')DNYA;_ +G)(A*A$5@<CCY
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M<G8\:-UR<5V&M^'O&_AGQY9_$'0=#M]<GU31[?3?$'AW[8D$RO$SO'+;RO\
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MYG\M^(DX5.)<3*F[KW?_ $E&U2%0W49I:*],_-PHHHH **** "BBB@ HHHH
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M^&\/PP\1:#X1^UMH.G7NF:EX7M=5%Q-!'>/#-)+;W%PR"62.2  AF7<LC8/
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M8\.?!J6R\8:=XF\2>+]9\9ZGI4,D.F+J*6\$%GYB[9)1'!%&&E9,J7;.%9@
M,FN[VE'E:;3>O3?32VFEGOM\]C'EG=6O]_WW/(M%^+'Q7'PAT_XL:OJVA)I,
M-Q&MQX:M]+;==6OVL6[R_:#+E)2I,BJ%*C"J<Y)K;M[CQ)X/_:*^)OB/4_$5
MG=:#I?AFQU&ZL8-)*S26BOJC0PK)YQP\95B7V_/N VIC)]&E^!^CR_!L?#@W
MM\-(V"/[4&3[1@3";KMV_>&/N]*Z%/ .F_\ "8:_XAF,ES+K6F6NE75I,%:
MPP/<,N!C.6^U.&R2" .!SFY8FE:?+%:W6RVO&WZZ[B5.6EW_ ,/K_P  \6U'
MQY\5O#/PO7XM:EJVA76D1V,>LWG@Z#3F4Q63*'9([PRY:=(SG<4V,P("J"".
MBT+Q9X]\<?'#Q9HVGZSI>D^#_#5SITK*VFF:[O4GMDE>#>9 L8^\=^TGYU
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M%BDM[EX6D)XW!OW"@$$<,?;"G7HSNN5)7ELEM]G]?U",)JSOKIU^\\(\(_M
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MX\K>6XSD>2N,$=3G-=!7GU9JIRM+6VNEM;O]+'1%.-T%%%%8%A1110 4444
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>sdgr-20241231_g18.jpg
<TEXT>
begin 644 sdgr-20241231_g18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %? UT# 2(  A$! Q$!_\0
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M[P_*I5=6Z&@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG 5KK1P,6<FNQ(4[;& <K],BMXP:KHFI7TFGZ>M_:7DGG[!.L;128PV=W4'
M/%1?\(W>2:).9)8EU:6[%\&&2B2@C:OTP,?B:J,DGS-Z:?I^0I1;3BM[O\;_
M .:+'BU5BL["[0 36U["8V'8%@I'T(-=#7,RP:QKMS9Q7^G+86EO,L\I,ZR&
M5E^ZJXZ#/)S735C/2*CUU-(ZR;79?J%%%%9F@4444 %%%% !7">-/'(TPOIN
ME.K7G2688(B]AZM_+Z]-/QMXF_X1_2_+@8?;KD%8O]@=V_#M[_2O.?"/ADZ_
M=O<719;&$_O&SR[==N?Y_P#UZ[L-1BH^VJ[(XL16DY>RI[LBT3PQJ?B28W+N
MR6[,3)=3')8]\9Y8_P"<UZ=HWA;3=*539VB^8/\ EYF&YS[CT_# K9M+*.*&
M-!&L<2 ".(# 4#IQ5RLJ^*G5TV1I1PT*>N[(!:K_ !LS?C@?I3OL\/\ SS7\
M14N<=:;O3^\/SKF.D8;:$]$Q_NDBH9K(21LAVR(PP4E&0:M!E/ (/XTM 'GV
MO?#^SO TFG*+.ZZ^6?\ 5O\ 3T_#\JXO3M5UGP=JK1$218(\VW?[KCU]/Q%>
MYNBR+M89%<SXF\-0:W:>3+A;A 3!.!R/8^U=M#%/X*NL3CK87[=+1FMHFMVF
MO:>MW:/[.A/S(?0UI5X9H6KWGA#Q PF5PBMY=S#_ 'AZCW[@_P"->WP3Q75O
M'/"X>*10R,.X-9XFA[*6FSV-,/7]K'7=$E%%%<QT!1110 445$ES!)<2VZ3(
MTT0!D0-RN>F1[T 2T444 (2 ,FJ\DI;IPM)+)N/7"BB&'S,/(/E_A4_S- #$
M5Y?N#"_WFZ?AZU,+5?XW9OQP/TJ>B@"+[-#_ ,\U/U&:#;0G^#'^Z<5+10!6
M:V8?ZN3/L_\ C4661]K JW;W^E7J:Z+(NUAD4 1QS9X;KZU-5)T,3!6.5/W6
M_H:L0R9^4]>U $M075W'9P^;*LQ7./W4+R'\E!./>IZ:_,; >AH K6.HV^I1
M>;;><8\ AI('C# ]"-P&1]*L2RB)0S*[98+\B%CR<=NWOVK!T^VN0MAO6Z5(
M-/0^2':-3*.S>_L?Q%5+!M2\\@?:_+=H'8-',-C>8-ZYD8DC;U(P,5JZ:OH9
M\S2U.LHK L8KR*XLYG:\9I;B=)Q([E5CRY3Y3PO1<''?WI-4M[R:YU"2*2]7
MRH8C;B%V5=^6W8 X8XQD'-3R:VN/GTO8Z"BN<O(KFV2:VC-X;=KA<2EIY6C&
MS)QL8.PW#'7 S45D]VWV<ZH-1 \M!#Y*RCYPS [PI/;9]_(Q^-/V>E[ASV=C
MHHKJ*>W:>)B\8+#A3G*D@C'7J#4B.)(U<!@& (# @CZ@]*YJUM+NTBADB%V'
MEFNA*I9]JJ3(RG;T7D+@XYS[U)Y-\1-<%[WS8Y+?RDWOM(PF_P"7HW\6<YQS
MTYHY%?<2F[+^NQT=%<U8+J+:UNN9[@.)9-\?D2^68^=OS%_+Z;?NKN]>]=+4
MRC8I.X4445)04444 %%%% !1110 4444 %%%% !1110 4444 %-=MJ$TZH)S
MT7\: ("&=@@/S,>OH.YJZJA%"J, =*KVRY9Y/?:*LT 5K_[4=/N!8E!=^6WD
ME^F['&?QK&TG7H((9K76-1C@O8)2K1WDD22!3@J?EPK<$<@#TZ@ULW]['I]C
M-=2@E8USM7JQZ!1[DD ?6N3LEOKG6391RA)@3/J-PJ*WSG'R*2#PH 4?0U$Z
MB@M>IK2HRJMV=DE=MFY=:_93+]ETVY%[=S*P1+*:-G08Y?+':,<=>^.#4.AZ
MK<3W/V2YD:4/&\D,DB!)!Y;A)$D"_+N5BO(X.?Q-ZXT:&X2 ^=/'<0DE+B(A
M7&1@]L$'TQC@56\/C[$EQI$I)GMI"_F,>9T=BPD/J2<@^X/J*TZ&3W-JBBN2
MURPEUC7+JVM[:VN&6S1/.G=E^QN68ADP#ER"#QM/RKSS0D!UM<YXFT1-6TF>
MRVC>5WV['^%AV_I]#71*"J*"Q8@8)/>HKE<P[NZ'=_C^E.,G%J2%**DK,\"T
M>RM+K6[>RU)I8HI)/*9D."C'@=O7BO1_^%4Z-_S]WG_?2_X5QGC>S.G^*YY(
MP5$V)T/N>I_[Z!KV/2;T:EI%I>XQY\2N1Z$CG]:]/%5JBC&I!V3/-PU&#E*$
MU=HX_P#X53HW_/W>?]]+_A1_PJG1O^?N\_[Z7_"N\HKB^MUOYCL^JT?Y3@_^
M%4Z-_P _=Y_WTO\ A1_PJG1O^?N\_P"^E_PKO**/K=;^8/JM'^4X/_A5.C?\
M_=Y_WTO^%<SXA\!_9=;L-,T=III+A&=S*1A "!DX' KV*DP,YQSZU<,;5B[M
MW(G@Z4E9*QC^&_#=IX;T\6\ WS-@S3$<N?Z#T%;-%%<TI.3YI;G1&*BK+8**
M**DHBF;"X'4U!&GFRX/W5Y/N>PITS?.2>@J6W7;"N>K?,?QH EK!\42:Q!:+
M/I1?$2.\BQ[-Q( *YW#E?O9"_,>,5O5A^(;I3$NG>8469&DN74X,<"_>Y]6X
M4?4GM1>VK"S>B+*^(]#=%8:Q8889&;E!_6LR^UP79,NFW5TEM!((GO(4BDMR
MS8^\"=Q )&2F.IYXX7P]'=ZC$U]._DVK-BWMHXD "#CDXSCM^%3:OH'F137%
MC),LGF+.UH'Q#.Z$'##'<*!P0.YS4TIJ:YDC2O2=*7(W=KL:6E7KW]B))8Q'
M.CO%*BG(#JQ4X/IQD>Q%7:@L[N*_LX;J DQ2J&7(P1[$=B.A%3,P12S$!0,D
MD\ 51F+D9QGIUIKHLB%6'!KE/#.FW#2V^HFVA@39)NN58^=>AC\K2# QQ\W)
M/7M76TV"*2EE8@_>4X-7%;<H/K5>X7$J/_>^4_S']:? >"/2D!#-JEI!??8F
M:5KCR_-*1PN^%YY.T''W2!GJ>.M0/K>G&UWRF78[^3Y3VL@<L5)V["N[D ]N
M:DN]--U]M*SF)KFW6$,J\K@MSUY^]TXZ51L?#QM)TE,UNI6<3>7;VWE)Q&R8
M W''WLYR>GY %I-6TVWL[?R=XB8%8H8;9RRA3@CRU7*@'@Y QTJ&V\0VK6,,
M\[L6EWL!!"\@"!B QV@[1QU.!UIRZ1<6\GG6=Y''.6EW&6 NI5Y"^,!@<@G&
M<^O'I'!HEW9(IM-0C$S1^7-)+;[]XW,P( 8;3\[>H]J'<+698E\0:9#*T;SN
M2I4%DA=U!8 J-P!&3D8&>2<#FK5M?6]W;-<1,_EJ2&#QLC*1U!5@"#]15&'0
M8[>T>VBG(C,T$BY7) B$8 Z\Y\OK[U<BLO+%[^\S]JD+_=^[E%7'O]W/XT/9
MV!="FOB?2F0.)9]I02 _99<;#_']W[G^UT]ZLRZO90W?V9Y7W[@K,(G**3C
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MV5W"&,OM]<"O/X_BJ\N=NBN<?]-1_A7:^)/^1:U+G'^COS^%>'*C&U>2/;O
M&6]?I4T*2FG<NM4<+6.CUCXHG6+:72$T][62;Y?-,F=M<LPF=O*@N[IY N6Q
M(>*YR1GDU;<,[BW%=3IUNJ!E4[9MGS-@FMJ%.+35C*M-JSN2Z;XA?PKJ$=[(
M\UVR AXVDXY^M=G:_%I[J+S$T5\=SYH_PKR[7)%:%XHUX5AN?^\:GT#S)8EC
M!&T9SNZ=*4J495+%*I)4[GM'A7QO_P )-J,MH;!K<QQ>9N+YSR!_6NLD02(5
M/?H?2O+/AMA?$]PHX M6^7_@2UZM7-5@H2LC:G)RC=GFGQ$T,26RZO$F)H2(
M[C ZKV;\./P/M6+X>\>WFA:6MA]ECGC1B4+L05!YQ^>?SKU34[2.[AE@D4&.
MXC*,#_G_ #BO 7MIENFM0A,X?R]@&26SC'YUZ&#<:U/V=36QY^+4J53VD-+G
MH'_"U;K_ *!D'_?T_P"%'_"U;K_H&0?]_3_A7&?\(SX@_P"@-?\ _?AO\*/^
M$9\0?] :_P#^_#?X5T?5\+Y?>8?6,3Y_<=G_ ,+5NO\ H&0?]_3_ (4?\+5N
MO^@9!_W]/^%<9_PC/B#_ * U_P#]^&_PH_X1GQ!_T!K_ /[\-_A1]7POE]X?
M6,3Y_<=G_P +5NO^@9!_W]/^%<_/XNO'\2-K4 6WF8*"BG*D  8/J#BLS_A&
M?$'_ $!K_P#[\-_A5">SO+6\%I/;2QW)Q^Z="&YZ<5<*&'3]VQ$Z]=KWKGO7
MA[Q#:>(; 3P$+*N!+"3RA_J/0UI3-A=H[UR'@7P@^AQ?;[TM]ME3'E@\1J>Q
M]3753-\[$]!7B5XPC4:INZ/9HN;@G-:C8T\V7!^ZG)]SZ5%J&J-:7,-I;VDE
MW=3*SB)&5=J*0"Q+$8&2![Y^M7+==L*Y^\?F/U-9K_\ (X0?]>$G;_IHG>LT
M:B_VCJG_ $ I?_ F/_&C^T=4_P"@%+_X$Q_XUHQ7,$YD$,T<AC;:X1@=I]#C
MH:YCQ-<Z?=ZA:V<KVA6(.9I9K<W"0MQM0K]T,W)&><+QUH0C5&I:J1SH,HY_
MY^8_\:7^T=5_Z 4O_@3'_C5;PI=6TNEK$DDB3CYY+24D-!G'RA6^8)G)&<]<
M XQ5^]U:&TF%M$CW5ZPRMM#RV/5CT5?<X_&@"!M2U8#Y=!E)R/\ EYC_ ,:&
MU+5@K$:#*2!P/M4?/ZT)K@MW6+5K<V#L<+(S;H7/M)T!]FP?3-:_49% &98Z
MB=0DGL[NSDM+N)5=HG=6RK9PRE3R,J1[$5,I96(/WE.#5>+_ )&V[_Z\8/\
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MS-.X)>ZWJ3LVG&S8K[N,;5'OF(P:DY7T=C651.FH6U3>OEII^9T<7_(W7?\
MUX0?^C):OW0_<@^C#^>*H1?\C==_]>$'_HR6M"Z_U&/5E_F*MF94EN&MDWJ
M<G!!I$U=/XXB/]TYJ*^/[@>[5GT@-Z*^MY3@2 'T;BK-<Q4L5S-#]R0@>G:@
M#HJ*SH-55L+,NT_WATK05U==R,&![@T +1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ".BNI5U#*>H-4SI=L3D;Q[ U=HH I?V7;^K_ )T?
MV7;^K_G5VB@"E_9=OZO^=+]F2V7:F=I.>35RF2+N0COVH BM6X=/0Y'T/_U\
MU8JD&\N19.PX;Z5=!R,B@#$U^YN89+:-;BZM;219/-N+6#S75QC8N-K8!RW.
M.P'&:M:!#);^'["*:'RI4@4.F,$''.?<]3[UHT4[Z %<^;RV\.:H]O=3+%8W
MI::W+=$D_P"6B?0YW#W+>U=!6#IFCW]OK]UJ%[<K,KJZ1?O&8A2^X *1A,#
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M/SC*]F'2H* -VUOH[CY3\LG]T]_I5JN8!(.16M9:@'Q%,<-V;U^M &C1110
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MO^_J_P#Q-']H4?,/J-8\A\VCS:]>_P"%6Z!_SUOO^_J__$T?\*MT#_GK??\
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M,H1E\2N4K?1],M.;?3[6(^J0J#^>*L22[>%ZT2R;1@=35=5:5]B\8^\WI_\
M7I-M[C22V L6? !9O05(MLQY=\>R_P"-3I&L:[5&!_.G4AD0MH1U3/\ O$FC
M[-#_ ,\U_ 5+10! ;5?X&9?QR/UJ%TDBY<97^\O^%7:* *L<I7W6K((89%5Y
M8-N7C'U4=_I38I-I!!RIH MT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 444A( )/04 9^A\Z/ W]_<_YL3_6C1N;6=_[UW/\
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MK#H:MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML:C]*J:]_P B_J _O6[K^8(_K6A1]D/M!1114E!1110 4444 %%%% !1110
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MEH **** "BBB@ HI'=8T9W8*BC+,QP /6@$$9!R#T- "T444 %%%% !1110
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M:>-?&XE,FE:7+^[^[/.I^]ZJI]/4]_Y^@:I8_P!IZ7<67GR0><FWS(SAE_\
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M+[MMS=0I>QYN;WK[>1T-97B#P_9^(M.:TNUPPYBE ^:-O4?U%6_[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "NB,G%W6YSRBI*S&:39OI^D6=G(RL\$2QLR]"0,5
M=JK_ &C:_P#/7_QT_P"%']HVO_/7_P =/^%#=W=@E961:HJK_:-K_P ]?_'3
M_A1_:-K_ ,]?_'3_ (4AD\LBPQ/*YPB*68^PKPG387\3>+HQ<%C]JG:27G)V
M\L1^0Q7KVOW"WGA_4+:UDS/+ R(-IYR.GXUQ'@#0;VSU"XU"]M9(52(I&)5P
M6)/)'X#]:[L+.-.E.=]3BQ,74J0C;0])M$ 4N  /NJ!V JS3(5V0HOHHK'\2
M:.NK6<;27S6L=LWFN"H>-U'4.IZC&?IUKA.T;X=UBZU22Z6Z$(\L*\?E(5^5
MF< ').3\GM6[7,>' +>]@5T6%[O3()%C"; "A;=@9X_UB9'O[UTS,$1F8X51
MDFF]Q(6BL2T\3VMW-;(EM<JEPP6.4A"A)4L,[6)&0#VJM>Z]?1^)_P"Q[:.V
M5C&KIYR2DN#G)RJ[0!M(Y/:BS"YNW=Y;6%N9[N9(8@0"[G R3@"JEOX@TBZG
MCA@U&WDED.$0.,L<9K(U&\N;OP[J$DZQB6TN56-[61AEE9<D9 Z'(/4<&JM_
M)))\2]-MC-)Y 1I#$)I"I8(<$K]P'VZ]^].P7.SJK<+ME5QT;Y3]>U6JAN1F
MW8_W<-^52,(&X*^E35465(27<X7N<4O]HVO_ #U_\=/^% %JBJO]HVO_ #U_
M\=/^%']HVO\ SU_\=/\ A0!:HJK_ &C:_P#/7_QT_P"%']HVO_/7_P =/^%
M%JBJO]HVO_/7_P =/^%']HVO_/7_ ,=/^% %KH*I2,3DC[S' ^II_P!MMY!L
M23+'H-IIL8W7$8],G_/YT 6D41HJCH!BL/QE=7%EX7NY[68PS#:%<=1DUO5S
M7CXX\'7AV[L;>/7D54%>21,MF>6)X@\0>6QDUJ[4C@-D8-8+>)M4O[QK?4]0
MFN;=>0KG(SZUHR+'-I@E!YS\I/;V-<O91!]297X'):NZ=-1E&R.6$W*+N='$
MHOA)),/*C3&T;>M5+[5]1TAUFL)GLV;Y?W?!(K4MBGV21I$'EK@(I4YKF]:$
MK*LDQY9C@>@K2M&T&9TG[YU%IXCU^6S#_P!M73/C.U6%=_\ #74M1OQJ*ZA>
M27)3RRN\\KG=_A7EVA0JUN6?EE0E?:O1_A7())=7*@XS&-Q[_>K"I32I<UC:
M$VZG+<]'.#D$<$524%"4[H<?X5>JI.,7&?[R_P JXCJ+2G<H/K2U5%W!" DC
M[6],&C^T;7_GK_XZ?\* +5%5?[1M?^>O_CI_PH_M&U_YZ_\ CI_PH RO%'A:
MU\268#;8[R+F&;'3V/J/Y5NQJ4B13U50#5?^T;7_ )Z_^.G_  H_M&U_YZ_^
M.G_"J<Y.*B]D2H14G);LM455_M&U_P">O_CI_P */[1M?^>O_CI_PJ2BU157
M^T;7_GK_ ..G_"C^T;7_ )Z_^.G_  H XGXIZCY6F6>GHQ#3R&1P#_"O0'\3
M^E1_#C3!%I$MZ0?-NY/+4XZ(OI^.[\JL^,/#)\3W]M<V5[&DD<?ELDBL!C).
M0<=>>E=+HVGQZ9:6MC$<I;Q8W8QN/<_B<G\:[)58K#*G%ZO<Y(TI/$.<EHMC
M5 "J% P , 4M%%<9UF!XEUF;2FLXXH!(LSGS RY#*,?*/<YK;$,1&?*3_OD5
MSGV[49DO)9=0MH1:W+1M"=.DD9/F^0\,"V5*G(&.:BCUV^.@27HNHI(Q>");
MPV<BJ(N S&,D'AMPSG'&:B-.:G*3=T[678TG4@X1BHV:O=]SH[G3[.[@:&XM
MHI(VZJ5'/.?YBJ7_  C6C_\ /DO_ 'VW^-9>HZGJ>G7,<#:I!)<NZJD(TN7$
MA/;>&(!P"?PJW->ZA)K%_:Q7UO;+;HLJ1O9M(SQE1E@0PS\VX8 /3WK2S,BP
MWAC1F&UK%64]59V(/U&>:UE4*H50 H&  .E8>@ZC<WUU>))=)=0Q! )!:/ 5
M<YRI#'TVG\?I6[0QH1E#H5;H1@U20E>OWE.#^%7JIR#%PX]0&_I_2D!<!R,T
M51?4(X!L*L6'ITJN^K2'[D:K]3F@#6JM/?0P<9W-_=6L>2ZGE^_(V/0<"H:
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MILK@N5P!Y9KNOA1'<+<ZG)<(Z%RFT.,$]:PJSBZ-KFU.,E5O8]/JK<?ZY/\
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M 'NQ_P *L9R,BJS0L.G(J+9L/RED/L<?I0!>HJGYDP_Y:D_511OE/64CZ 4
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M"ZN@DNHN/O=1$/1??U/X?7K:**X*E2527-([H0C"/+$****@L**** "BBB@
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MF#73JJHH55"JHP !@ 4M%<\ZDIN\G<WA",%:*L%%%%06%%%% !1110 4444
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MNYI.+DK$LDT)D^RM-&)I$)$>X;B.A('7%<UX<U>RTKPZ;._N8H+C3B\4T;L
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MCV-;&BK,FFH)Y99268J98V1MN> 0Q+?]]'/K6A14.=U8:A9W"BBBH+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***SM3O
M[JTEM(+.TCN)KEV0>9-Y2KA2V20K'MC@=Z -&BN=B\33+!]IO-/6*![>2:+R
MY_,=BA *D;0!DG@Y/OBDOM4OE1;6[MTM+DSVSH;>X,BLAG16!)52#S@C&"#U
M/-"U:0&MINEP:6+H0-(WVFX:X?>0<,V,@8 XXK/N?"MG/<3R)=7UM%<-NGMX
M)]L<I/4D8XSWP1FHU\4-YDTK6$O]GQ>;FX42%AY>[)(*!<?*0,.3R..N+B:E
M?1FW^VV,$/VB98X_*N3(0"K-ELH,'Y>@R.>M4IR3NF2X*UF:,$$5M;QP0H$B
MC4*BKT '05)7-W&N^3J'VJ02+;V]O>;XD8MO,<D0!QZ]<>F32MXBOX[61Y-'
M*R*ZJ#NF$6#GEF,088QSA"/F'/7$WNK]RK6T.CHJ*UG%S:0SAHF$B!P8GWH<
MC^%L#(]\5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 U\[&QUQQBN8AT^[>*V\R;4MSZ>9)
M3Y\@(F&W'?@\M\O0XY!Q6QJ>I1::1+,9RJ0RRE(E4A@H!/7G//&#]:ELM0%W
M)-$]M/;318+1S;<E3G##:2,'![YXZ549-7L)J^YBN;YI7:3[?]N+QFVV!Q#M
MVKG=CY.N_.[GT[4R^COUE"AIX;5I9V8Q0RNQ;<-O$;*V,;N>GKVK7+7MK<7%
MW>W,2V$:R/L49*@;<=L\!6/U;V%1_P!O1HQ6YL;RV;RS(@E5#O&Y5 &UCR2P
M&#@_2J53;0GDTM?^OZ_R*J"=;N%=0;4'Q%%Y+PJZJ7_BWB,D YQG<<8Z=ZJS
MR7L]A]D\J]:2.WN$F+1OM9L';R>&SVQFM;^VT5)!-9W4-RA0"V<(7?<2%P58
MKR0>_&#G%)_;B8\L6-W]LW[?LGR>9TSG.[9C!'.[VZ\4>T\@Y;&?*NI-KK;I
M[B-1,GDK'!(R&/ SE@XC'.[.X9].U6?#YN1+<I,;MU 4^9<+(N6R<@*^<'ID
MJ=OIBFPSZKJ=M,UK-]F99Y8R)D&Y<<*,8(."2<]\#J#6I?WRZ?;+*T4LQ:18
MU2( LS,<#J0.I]:7/>*7H')9M_U_7Z&%:KJ;:I(T\]R) \NZ,02^64^;9AB_
ME]-OW5W9Z]ZC\C4HK*U5)-0\R>TC:=R[LRR;X\XS]TX+Y QTZ<5J0Z_')*JR
MV5W;H7:-I)0FU'4$E3AB>@/(!'O4-WKK'3+MX[:YM9/LLDUM),J8DVKG( )Q
MU!PP!]N#3534/9WTO_6G_#"7<=S 98T^V-:+)$'V.[2>7@[MISN)SC..<9JO
M-9M,]Q/;'456.Q_<%GE5RX9R <_,QZ<'L>15]_$5FFI"Q.YFWB-I \>%<XP-
MN[?W'(4CWX-/36T>/SOL=T+5F18[@[-LFY@H(&[=CY@>0.*%-CY49BC4Y-:W
M2S7$9\Y#&J6\I0QX!.6#B,?Q [AN].U);QS/?Z:94U%KM+EFNC(',*_NW (S
M\@'(QM]>>:T[C5 NHPPHQ1([AHIRP&"/),G'MT].E5E\6Z>T,TNR0*BAU_>1
M'S 6"@C#D+RP^_MZ^QP>TZ6%R&]145M,;BVCF,3Q%QG8Y4D?BI(_(FI:S+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ!#)/H5U%"K
MM(R@*$7)^\.@K2HIIV=Q-75C'FT:>\,TEY>(\K1&&,QP[ BD@G(+').T=Q]*
MGN=/N3>O=65VD#RQK'*)(?,!"DX(^88/S'U'M6C13YV+E1S5Q;-I#B&Q>Z4-
M;)$3]C:</MR!AE("-SU;Y>1[U>TW29+>R59)621[**V;9U0J&R0?^!?I6O13
M<VU8%%)W.?@\,^4)LS6RF2-(SY%KY8.UMVX_,22?7-7[G2_M"WX\[;]K"C[N
M=NT8]>:T:*'4D]P4$@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J*2WBEFAE=<R0DF,Y/!(P?T-2T4 4O[)
ML3%'$;=6CC1XU5B2-K_>!!ZYQWJ.'0M/A5@(Y9"S(Q>:XDE;Y&W*-S,2 &&<
M9Q[5HT4; 9\>B:?%=27"P-N<LQ0RN8\MG<1&3M!.3D@9.3ZFF#0-/%J]OBY,
M;,K#-Y*2A'38V[*8_P!DBM.B@#-AT'3(8?*6U#1E)499'9]PD(,F[<3G<0"<
MTT>'M.%N8=MR<L&\PWDQE!&0,2;MP&"> <<GU-:E% $=O!%:V\<$*!(HU"JH
M[ 5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!2O\ 3(=1&)FD7]T\7R$#A\9[=>*G2V1+
MR:Z!;?*B(P/3"[L8_P"^C4U% $-W"MQ9SPM&LJR1LIC9MH;(Q@GMGUK"L]+N
M;RY9[X7ZQ+"8U^UR1%P=RL"OE<<% <MSG%='11UN!EC1$*2&:\NIKERA%RY0
M.FTDK@*H7@D]N<G.:3^PT \P7MW]L+[OM>4\SIC&-NS& .-N._7FM6B@"K86
M*:? \:S2S%Y&D9Y2"Q8]>@ _"I+FV2Z6-7+ 1R+(-OJIR/PJ:B@"BVE6[C#%
MV7SS.02,$D$$=.F#5;_A'XGADBGO+N>,PO!&LC+^Y1A@[<*,G '+;C^9SKT4
M+0/,H+I2QWK3Q7=S'&[^8]NK+Y;-@<]-PZ#(! /IR<PC0T%O);"]N_LQ $46
M4Q 005*G;G@@8W$BM6B@#+@T*&-S)-<W%S(TQF=IBOS$Q^7@A5 QM[ #FB+1
MC%;- -3ORNT)$2Z9B (P!\OS= /GW<?4YU** *NGV,>G626T3,RJ68LP )+$
MDG   Y)X  JU110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>sdgr-20241231_g19.jpg
<TEXT>
begin 644 sdgr-20241231_g19.jpg
M_]C_X  02D9)1@ ! 0$ \ #P  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +?!4L# 2(  A$! Q$!_\0
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ML/\ W['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_W['^%
M%FBJW]FVG_/K#_W['^%']FVG_/K#_P!^Q_A0!9HJM_9MI_SZP_\ ?L?X4?V;
M:?\ /K#_ -^Q_A0!9HJM_9MI_P ^L/\ W['^%']FVG_/K#_W['^% %FBJW]F
MVG_/K#_W['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_P!^
MQ_A0!9HJM_9MI_SZP_\ ?L?X4?V;:?\ /K#_ -^Q_A0!9HJM_9MI_P ^L/\
MW['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_W['^% %FBJ
MW]FVG_/K#_W['^%']FVG_/K#_P!^Q_A0!9HJM_9MI_SZP_\ ?L?X4?V;:?\
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M#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_P!^Q_A0!9HJM_9MI_SZP_\
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ML/\ W['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_W['^%
M%FBJW]FVG_/K#_W['^%']FVG_/K#_P!^Q_A0!9HJM_9MI_SZP_\ ?L?X4?V;
M:?\ /K#_ -^Q_A0!9HJM_9MI_P ^L/\ W['^%']FVG_/K#_W['^% %FBJW]F
MVG_/K#_W['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_P!^
MQ_A0!9HJM_9MI_SZP_\ ?L?X4?V;:?\ /K#_ -^Q_A0!9HJM_9MI_P ^L/\
MW['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_W['^% %FBJ
MW]FVG_/K#_W['^%']FVG_/K#_P!^Q_A0!9HJM_9MI_SZP_\ ?L?X4?V;:?\
M/K#_ -^Q_A0!9HJM_9MI_P ^L/\ W['^%']FVG_/K#_W['^% %FBJW]FVG_/
MK#_W['^%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_P!^Q_A0
M!9HJM_9MI_SZP_\ ?L?X4?V;:?\ /K#_ -^Q_A0!9HJM_9MI_P ^L/\ W['^
M%']FVG_/K#_W['^% %FBJW]FVG_/K#_W['^%']FVG_/K#_W['^% %FBJW]FV
MG_/K#_W['^%']FVG_/K#_P!^Q_A0!9HJM_9MI_SZP_\ ?L?X4?V;:?\ /K#_
M -^Q_A0!9HJM_9MI_P ^L/\ W['^%']FVG_/K#_W['^% %FBL^_L+9+&Y9;:
M%6$;$$(,C@UH4 5KK_7V?_74_P#H#59JM=?Z^S_ZZG_T!JLT %%%% !1110
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M3D9R#CTB*9)XDEB=9(W 974Y# \@@]Q0 ^BBB@ HHHH **** "BBB@ HHHH
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MVNIV;'+6]Y"LL9^JL"*J>'/!GA_P?%)'H.A:;HD<ARZ:;9QVX;ZA ,T >)?
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MV%ND$2DG)(50 "30!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!6U+_ )!]U_UR;^1JS5;4O^0?=?\ 7)OY&K- %:Z_U]G_ -=3
M_P"@-5FJUU_K[/\ ZZG_ - :K- 'C/[26FZ;>:;X?NIX-8L]9L=1MI-+U[2+
M"2\:RD-U '5HXU?=N7D(Z%',8'WMH/)>/O"/Q+\6?#>RUS4)[+^V+E=)270U
MT66>>U9;ZWDD9&2YPH)5))%V'Y8MNX;0P^DZ* /GSQ!X7UM8_&'@MM/OKR^\
M2^(;+5;;5;>TD%FL&+5KAWD^9(C&;:4"-GWMF,*#NS4GA_PSJRR^%/!;:9J,
M<_A_Q3=ZS<ZG+;NMH]GYES+$ZS$;'>3[1$OEJQ9<2%L!>??Z* "D8%E(!*GU
M':EHH I?8)_^@E=?]\Q?_$4?8)_^@E=?]\Q?_$5=HH I?8)_^@E=?]\Q?_$4
M?8)_^@E=?]\Q?_$5=HH I?8)_P#H)77_ 'S%_P#$4?8)_P#H)77_ 'S%_P#$
M5=HH I?8)_\ H)77_?,7_P 11]@G_P"@E=?]\Q?_ !%7:* *7V"?_H)77_?,
M7_Q%'V"?_H)77_?,7_Q%7:* *7V"?_H)77_?,7_Q%'V"?_H)77_?,7_Q%7:*
M *7V"?\ Z"5U_P!\Q?\ Q%'V"?\ Z"5U_P!\Q?\ Q%7:* *7V"?_ *"5U_WS
M%_\ $4?8)_\ H)77_?,7_P 15VB@"E]@G_Z"5U_WS%_\11]@G_Z"5U_WS%_\
M15VB@"E]@G_Z"5U_WS%_\11]@G_Z"5U_WS%_\15VB@"E]@G_ .@E=?\ ?,7_
M ,11]@G_ .@E=?\ ?,7_ ,15VB@"E]@G_P"@E=?]\Q?_ !%'V"?_ *"5U_WS
M%_\ $5=HH I?8)_^@E=?]\Q?_$4?8)_^@E=?]\Q?_$5=HH I?8)_^@E=?]\Q
M?_$4?8)_^@E=?]\Q?_$5=HH I?8)_P#H)77_ 'S%_P#$4?8)_P#H)77_ 'S%
M_P#$5=HH I?8)_\ H)77_?,7_P 11]@G_P"@E=?]\Q?_ !%7:* *7V"?_H)7
M7_?,7_Q%'V"?_H)77_?,7_Q%7:* *7V"?_H)77_?,7_Q%'V"?_H)77_?,7_Q
M%7:* *7V"?\ Z"5U_P!\Q?\ Q%'V"?\ Z"5U_P!\Q?\ Q%7:* *7V"?_ *"5
MU_WS%_\ $4?8)_\ H)77_?,7_P 15VB@"E]@G_Z"5U_WS%_\11]@G_Z"5U_W
MS%_\15VB@"E]@G_Z"5U_WS%_\11]@G_Z"5U_WS%_\15VB@"E]@G_ .@E=?\
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M%'V"?_H)77_?,7_Q%7:* *7V"?\ Z"5U_P!\Q?\ Q%'V"?\ Z"5U_P!\Q?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *VI?\@^Z_P"N
M3?R-6:K:E_R#[K_KDW\C5F@"M=?Z^S_ZZG_T!JLU6NO]?9_]=3_Z U6: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFG?\^%M_WY7_  H_L33O^?"V_P"_*_X4 7:*I?V)IW_/A;?]^5_PH_L33O\
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MK_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H
MNT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8
MFG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-
M._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%
MM_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"
MV_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_
M  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\
MA1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15
M+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG
M?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33
MO^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_
MWY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_O
MRO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@
M"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1
M_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52
M_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\
M^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\
M+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY
M7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\
MK_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H
MNT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8
MFG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-
M._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%
MM_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"
MV_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_
M  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\
MA1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15
M+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG
M?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33
MO^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_
MWY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_O
MRO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@
M"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52_L33O^?"V_[\K_A1
M_8FG?\^%M_WY7_"@"[15+^Q-._Y\+;_ORO\ A1_8FG?\^%M_WY7_  H NT52
M_L33O^?"V_[\K_A1_8FG?\^%M_WY7_"@"[15:#3;2UD\R&UAB?INCC /Y@59
MH K:E_R#[K_KDW\C5FJVI?\ (/NO^N3?R-6: *UU_K[/_KJ?_0&JS5:Z_P!?
M9_\ 74_^@-5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7OCM
M.VJ?$Z[MSTM+-4'T$1E_]F->85ZA\58_,^,&NC_IS<_E99KR_P#AH ^@?V8)
M,Z9KZ?W9HC^:M_A7M]>$?LNR?+XD3T-N?_1M>[T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#,E]C[MXL.?JC-_2@#V/]EW_ %GB7Z6W_M6O>J\%_9=_UGB7Z6W_ +5KWJ@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K:E
M_P @^Z_ZY-_(U9JMJ7_(/NO^N3?R-6: *UU_K[/_ *ZG_P! :K-5KK_7V?\
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M^_R_XT?VUI__ #_6W_?Y?\: +M%4O[:T_P#Y_K;_ +_+_C1_;6G_ //];?\
M?Y?\: +M%4O[:T__ )_K;_O\O^-']M:?_P _UM_W^7_&@"[15+^VM/\ ^?ZV
M_P"_R_XT?VUI_P#S_6W_ '^7_&@"[15+^VM/_P"?ZV_[_+_C1_;6G_\ /];?
M]_E_QH NT52_MK3_ /G^MO\ O\O^-']M:?\ \_UM_P!_E_QH NT52_MK3_\
MG^MO^_R_XT?VUI__ #_6W_?Y?\: +M%4O[:T_P#Y_K;_ +_+_C1_;6G_ //]
M;?\ ?Y?\: +M%4O[:T__ )_K;_O\O^-']M:?_P _UM_W^7_&@"[15+^VM/\
M^?ZV_P"_R_XT?VUI_P#S_6W_ '^7_&@"[15+^VM/_P"?ZV_[_+_C1_;6G_\
M/];?]_E_QH NT52_MK3_ /G^MO\ O\O^-']M:?\ \_UM_P!_E_QH NT52_MK
M3_\ G^MO^_R_XT?VUI__ #_6W_?Y?\: +M%4O[:T_P#Y_K;_ +_+_C1_;6G_
M //];?\ ?Y?\: +M%4O[:T__ )_K;_O\O^-']M:?_P _UM_W^7_&@"[7D_[2
MG_(AV?\ V$8__1<E9_Q2^,5_X1\::;;:;+#<Z:D*37,2[6,N78%=V#M^4#IZ
MUC?&+QQ:^-/ACH-Y ! ]Q>EWM2X9HRBR*<^W/7'>@#V#X>\> _#F./\ B76_
M_HM:Z&N<\'ZA86?A/1+<WMNIBL8$(,JY&(U'K6M_;6G_ //];?\ ?Y?\: /%
M/V8_EN_$Z_\ 7O\ SEKWBO ?V;[VWL]2\3>?/'"&\G;YCA<X:3IFO<?[:T__
M )_K;_O\O^- %VBJ7]M:?_S_ %M_W^7_ !H_MK3_ /G^MO\ O\O^- %VBJ7]
MM:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!=HJE_;6G_\_P!;?]_E_P :/[:T
M_P#Y_K;_ +_+_C0!=HJE_;6G_P#/];?]_E_QH_MK3_\ G^MO^_R_XT 7:*I?
MVUI__/\ 6W_?Y?\ &C^VM/\ ^?ZV_P"_R_XT 7:*I?VUI_\ S_6W_?Y?\:/[
M:T__ )_K;_O\O^- %VBJ7]M:?_S_ %M_W^7_ !H_MK3_ /G^MO\ O\O^- %V
MBJ7]M:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!=HJE_;6G_\_P!;?]_E_P :
M/[:T_P#Y_K;_ +_+_C0!=HJE_;6G_P#/];?]_E_QH_MK3_\ G^MO^_R_XT 7
M:*I?VUI__/\ 6W_?Y?\ &C^VM/\ ^?ZV_P"_R_XT 7:*I?VUI_\ S_6W_?Y?
M\:/[:T__ )_K;_O\O^- %VBJ7]M:?_S_ %M_W^7_ !H_MK3_ /G^MO\ O\O^
M- %VBJ7]M:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!=HJE_;6G_\_P!;?]_E
M_P :/[:T_P#Y_K;_ +_+_C0!=HJE_;6G_P#/];?]_E_QH_MK3_\ G^MO^_R_
MXT 7:*I?VUI__/\ 6W_?Y?\ &C^VM/\ ^?ZV_P"_R_XT 7:*I?VUI_\ S_6W
M_?Y?\:/[:T__ )_K;_O\O^- %VBJ7]M:?_S_ %M_W^7_ !H_MK3_ /G^MO\
MO\O^- %VBJ7]M:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!=HJE_;6G_\_P!;
M?]_E_P :/[:T_P#Y_K;_ +_+_C0!=HJE_;6G_P#/];?]_E_QH_MK3_\ G^MO
M^_R_XT 7:*I?VUI__/\ 6W_?Y?\ &C^VM/\ ^?ZV_P"_R_XT 7:*I?VUI_\
MS_6W_?Y?\:/[:T__ )_K;_O\O^- %VBJ7]M:?_S_ %M_W^7_ !H_MK3_ /G^
MMO\ O\O^- %VBJ7]M:?_ ,_UM_W^7_&C^VM/_P"?ZV_[_+_C0!=HJE_;6G_\
M_P!;?]_E_P :/[:T_P#Y_K;_ +_+_C0!=HJE_;6G_P#/];?]_E_QH_MK3_\
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M_P#/];?]_E_QH_MK3_\ G^MO^_R_XT 7:*I?VUI__/\ 6W_?Y?\ &C^VM/\
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MIIF2,(N"ZY9MH%>CT4 %%%% "44M% "44M% "44M% "44M% "44M% "44M%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)P.?O+@GT->PU\O?LZR;/B)C^_9RK^JG^E?4- !1110 4444 %%%% !1110
M4444 %%%% !7ROX\\/:AXV^,6M6&FQK+<M(.&<* JHH)R?3%?5%>#_#G_2OV
M@/$\A_Y9_:OTE5: /88-#M-"\+MIEC$(;6&W=$1<]P2>OJ23^->.?LN_ZSQ+
M]+;_ -JU[M<+O@D7U4C]*\)_9=_UGB7Z6W_M6@#WJBBB@#P?X _+X[\6+_O?
M^C37O%>#_ ?Y?B'XM7_?_P#1QKWB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*VI?\@^Z_P"N3?R-6:K:E_R#[K_KDW\C5F@"M=?Z^S_ZZG_T!JLU6NO]?9_]
M=3_Z U6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\S_ &AI
M-GPYF']ZYB'ZD_TKTRO*_P!I"39\/X1_>OHQ_P"..?Z4 ;'P4T&UT7X?Z=)
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M':A%<>"+*-%F#?V@A_>0N@_U<G=@*]BKQO\ ::EV^%])C_O7A;\D;_&@#NO
M>I10^!_#T;)<;ET^W!VVTA'^K7N%YK@?VD;F.Z\)Z8R+,"MZ!^\A=!S&_=@/
M2O4_"L?D^%]'CQC99PK^2"LOXB^!8OB%H*:;+=-9F.=9TE5-^" PQC([,>]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'\#@IZCP[S_X#5XY^T=:^1\0(I,<364;_DSK_P"RU[9J,)C^#]U$H)*Z$R@
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M\)^%_''PQ\/S^'YY]1U^_AM;;PUJU^Q-]9>4X?S58@-'Y>'>5AAF"[26^1:
M/>Z*^</%^Z:3X@>+Y(0/%V@^*-/T_2I\_O;:VS9A88^X2<7,VY>C^:?;!X=W
M12>$/&*PB/Q?K'C2^TS4YP?WKVP>[C-H_<QQ);Q,J'[IB#=<D@'T?112,<*2
M!D^@[T +15+[?-_T#KK_ +ZB_P#BZ/M\W_0.NO\ OJ+_ .+H NT52^WS?] Z
MZ_[ZB_\ BZ/M\W_0.NO^^HO_ (N@"[15+[?-_P! ZZ_[ZB_^+H^WS?\ 0.NO
M^^HO_BZ +M%4OM\W_0.NO^^HO_BZ/M\W_0.NO^^HO_BZ /$_VHI#N\-QY./]
M(8C_ +]8_K7B,$#?:GC92K+&Y*D<C"$_TKV?]HJ1K_7/#4$EM+"")!M<KEMS
M(.,,?2N.\0:/+>?%K6=/MK5A-.UR(K<;<[FA<J.#CN.] '!R2;DB']U<?J3_
M %KZ>_9VA\KX=JW_ #TNY7_]!']*^8IK::V8K+$\3*Q0JZD$,.HY[BOJ/X'R
MRVOPTTH+93RAVF?>ACP?WK#NP/;TH ])HJE]OF_Z!UU_WU%_\71]OF_Z!UU_
MWU%_\70!=HJE]OF_Z!UU_P!]1?\ Q='V^;_H'77_ 'U%_P#%T 4-)\$:%H<-
M_#9:9#%#?'-S&0763KP0Q(QR>.G->0?LWW":=KOB72Y)%64^64C8X+;&<' [
M_>%>W?;YO^@==?\ ?47_ ,77S39P7O@SXY6\ES:36PGU%S"C8!>*5V12#G!X
M;'7&0: /J.BJ7V^;_H'77_?47_Q='V^;_H'77_?47_Q= %VBJ7V^;_H'77_?
M47_Q='V^;_H'77_?47_Q= %VBJ7V^;_H'77_ 'U%_P#%T?;YO^@==?\ ?47_
M ,70!=KXMF']J>.W&<_:-2/_ (]+_P#7K[$?4I8T9FTZZ 49/S1?_%U\>>#8
M)]0\::.T<+SLU_$Q5!DGYP3UXZ>M %CP/X"N_'.M7>E6\T=I=P0--_I&0N5=
M5*G )'WCV[5]<>'-*.A^'],TUG$K6EM' 7'1BJA<_I7.:%X)T[P[XGU'7;/3
M+];R^#"16DB,:[F#-M&[C) /4UT_V^;_ *!UU_WU%_\ %T 7:*I?;YO^@==?
M]]1?_%T?;YO^@==?]]1?_%T 7:*I?;YO^@==?]]1?_%T?;YO^@==?]]1?_%T
M 7:*I?;YO^@==?\ ?47_ ,71]OF_Z!UU_P!]1?\ Q= '@O[3MMMUW1+C'^LM
MGCS_ +K9_P#9J][TVW5=)M8'4,H@5"K#((V@8KB?B5\/U^(ZZ;YT5Y9-9LY#
M(L3[U;;D?ZP8^Z.:[1;V95"C3;H # ^:+_XN@":QT^UTNW\BSMH;2')/EP1A
M%R>IP!5BJ7V^;_H'77_?47_Q='V^;_H'77_?47_Q= %VD90RD$9!X-4_M\W_
M $#KK_OJ+_XNC[?-_P! ZZ_[ZB_^+H \4_9O8V&N>*-.8\KY9Q_N,ZG_ -"I
MOQD<:I\7O"FGQGS&4P!U7MNF/7\ #6=X(U8^$_BMXUE:WDV)!>3>5E<J%D$@
MSSC@ ]#57X$>'+[6/%+^)KFWEO;:U:11)O0LTY4=0S#HK$Y]<4 ?2M%4OM\W
M_0.NO^^HO_BZ/M\W_0.NO^^HO_BZ +M%4OM\W_0.NO\ OJ+_ .+H^WS?] ZZ
M_P"^HO\ XN@"[7GWQ6\!Z=JW@74Q!%#IS6V[42UO"J^8\<;\-C&<@D9]Z[3[
M?-_T#KK_ +ZB_P#BZJ:PKZQI-[82V%VL=U \#,K19 92I/W_ 'H ^</@/K^H
M6?CS3=,BNY4T^Y:4RVNX^6Q\ICNQTS\J\^U?4]?,/AWP\WPW^-6CV4OG7*@_
MNRRHCOYD;*.-Q ^8X^]VKZ1^WS?] ZZ_[ZB_^+H YGQQ\5]%\ 7UO9ZBEU+/
M-'YH6VC5MJY(R<L.X/Y5U.F:A#J^FVM];-NM[F)9HV(P2K $?H:^:/VB-0-]
MX\B0Q/ 8+*.,HY4GEG;/!/\ >%>M_!OQ=!JW@FPM+:*:ZN=/B6"X5"@V'G;]
MYAP0/T- 'HU%4OM\W_0.NO\ OJ+_ .+H^WS?] ZZ_P"^HO\ XN@"[15+[?-_
MT#KK_OJ+_P"+H^WS?] ZZ_[ZB_\ BZ +M%4OM\W_ $#KK_OJ+_XNC[?-_P!
MZZ_[ZB_^+H NT52^WS?] ZZ_[ZB_^+H^WS?] ZZ_[ZB_^+H NT52^WS?] ZZ
M_P"^HO\ XNC[?-_T#KK_ +ZB_P#BZ +M%4OM\W_0.NO^^HO_ (NC[?-_T#KK
M_OJ+_P"+H NT52^WS?\ 0.NO^^HO_BZ/M\W_ $#KK_OJ+_XN@"[15+[?-_T#
MKK_OJ+_XNC[?-_T#KK_OJ+_XN@"[15+[?-_T#KK_ +ZB_P#BZ/M\W_0.NO\
MOJ+_ .+H NT52^WS?] ZZ_[ZB_\ BZ/M\W_0.NO^^HO_ (N@"[15+[?-_P!
MZZ_[ZB_^+H^WS?\ 0.NO^^HO_BZ +M%4OM\W_0.NO^^HO_BZ/M\W_0.NO^^H
MO_BZ +M%4OM\W_0.NO\ OJ+_ .+H^WS?] ZZ_P"^HO\ XN@"[15+[?-_T#KK
M_OJ+_P"+H^WS?] ZZ_[ZB_\ BZ +M%4OM\W_ $#KK_OJ+_XNC[?-_P! ZZ_[
MZB_^+H NT52^WS?] ZZ_[ZB_^+H^WS?] ZZ_[ZB_^+H NT52^WS?] ZZ_P"^
MHO\ XNC[?-_T#KK_ +ZB_P#BZ +M%4OM\W_0.NO^^HO_ (NC[?-_T#KK_OJ+
M_P"+H NT52^WS?\ 0.NO^^HO_BZ/M\W_ $#KK_OJ+_XN@"[15+[?-_T#KK_O
MJ+_XNC[?-_T#KK_OJ+_XN@"[15+[?-_T#KK_ +ZB_P#BZ/M\W_0.NO\ OJ+_
M .+H NT52^WS?] ZZ_[ZB_\ BZ/M\W_0.NO^^HO_ (N@"[15+[?-_P! ZZ_[
MZB_^+H^WS?\ 0.NO^^HO_BZ +M%4OM\W_0.NO^^HO_BZ/M\W_0.NO^^HO_BZ
M +M%4OM\W_0.NO\ OJ+_ .+H^WS?] ZZ_P"^HO\ XN@"[15+[?-_T#KK_OJ+
M_P"+H^WS?] ZZ_[ZB_\ BZ +M%4OM\W_ $#KK_OJ+_XNC[?-_P! ZZ_[ZB_^
M+H NT52^WS?] ZZ_[ZB_^+H^WS?] ZZ_[ZB_^+H NT52^WS?] ZZ_P"^HO\
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MJ+7O#)UI9#%=:6C-M"Y\U&9<@G/&.OY^M ':?#_5Y=>\%:+?3OYD\ULAD?\
MO,!AC^)!KH*^</@C\1M9;Q)H?AII8SI.R6/RO+&[[KR!MW7.>/3';O7T?0 4
M44C,$4LQ"J!DD]!0 M%5['4+74H/.L[F&ZAR1YD$@=<CJ,BK% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME^*M4DT3PSJVH18,MK:2S)NZ;E0D?J!6I7*?%2;R/AUX@;UM67\^/ZT ?/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444A.!D\"@!::[K&C.[!549+,< #UKY9\>_MX:+IOGVOA31)]5G7>BWE
M\XA@##@,%7+.O?!*&O!YOVC/B'9R>(8O$%_=WD/B'2Y(1:W!\N.!)D_=S0KC
M"_*W&,9#9.>#7T^'X>QE:/--<OKN_E_F>/5S3#TW:+OZ;'H?[3VI:5\5OC]X
M&T'3M7CU;2Y4M[29M+N$E$32W++)AAN ?8%)STP,UH_&?]B>YAOM.N/AU"]Q
M;S8BN[.\ND'D$  2JS8)4\Y')ST!!P-[]D/]G_28]#T3XA:FMZ=:,DS6MO(P
M6!$RT:OLV[B?O$$G'(('>OJZNS%9I++JL,/@Y75--.^S=]=#"C@UBH2JXA6<
M[-6W2.#^$'P;T+X,Z!-IVC"::6Y<2W5W<L&DE8# '  "CG QQD]22:W?'?@G
M2_B-X4O_  ]K".^GWBA7\IMKJ0P964X."" >E;]%?*2Q%6=7V\I/GO>_6Y[4
M:4(P]FE[O8_+_P 2S-\(_'/Q \/Z8+E8W$VD03R2[94B%Q&X<D+\Q9(MO&/O
MY[8K[-_8S\0SZ]\$;..XG>>33[R>T#2')"Y$@&?82#\,5?\ B1^R[X/^(GB#
M5?$=W%=C6;RT:(+'.%A\T1[$E*XSN&%[XXY%?/'[,OQVT?X0?#GQ?;ZS+,MR
MMY'+96D4>YY97C93P<  >4N23W%?<XFM#.,O:H1;J1<+^KT/G*-.6 Q2=1VB
M^:WYE?P[\/V_:B^.WCV34]6N+:SM?/-M/&H?8HD\N!,$CY0HR0,9V^Y-8_QN
M_9.UWX66+ZOIDO\ ;OAZVMT>[O"4CDA<L%.8LYVY(QMW8&<],UZW^P'HK+H/
MB_6G!9KJ[AM0[?\ 3-6=O_1HKZ<\4>'[?Q9X;U71;O(M=1M9;60KU"NI4D>X
MSD?2L<5F];+\=["F_P!W"RM;R5_F:4<#3Q6&]I)>_*[O\SXR^-'Q\/C/]G+P
M;IMM>"35M5?R=5CC?+YMMH(<#D;V:-QZBO1?V:_V7=>^$_C>7Q'KM]I\Z&R:
M&WM[1G:17<J27W* , $<$YSUXY^6_!/P_NY/COIWA-(6OY+/7!:S[4QF.&;$
MKD=@%1B?85^H%&<55EM".$PK]VIS-^C>GX:!@8/%U'7K;QLE\MQ*6BBOA#Z0
M**** "BBB@ HHHH **** *VI?\@^Z_ZY-_(U9JMJ7_(/NO\ KDW\C5F@"M=?
MZ^S_ .NI_P#0&JS5:Z_U]G_UU/\ Z U6: "BBB@ HHHH **** "BLWQ)K"^'
M_#^HZFR[Q:6[S!"<;BJD@?B>*YSX3^/+GX@^')[^[MXK:>&Y: K#G:0%5@>2
M?[WZ4 =K1110 4444 %<-\;IO(^%^MGNRQ(/QE05W->:_M"7'D_#>X3_ )ZW
M$2?KN_\ 9: .$_9AM]VL:Y-C[D$:?FQ/_LM?0M><_ _PA9^'O"%OJ,'F&ZU2
M&.6<R,"!C.T+QP/F->C4 %%%% !1110 4444 %%%% 'S1X#\00^#-:^('FSQ
MV\B03K KL%+RK(P51GJ<GH/>O,]#U>?0-8L]1MCB>UE65?0X.<'V/3\:ZSXF
M>&9+7XJZCIXX^W7BRQMC_GL0WZ%B/PKB[NUDL;J:WE4I+"[1NIZA@<$4 ?:K
M>([;_A%3KRAFM/L7VX+_ !%-F_'UQ7@7PC^Q^.OB7XE>]LU>RU*UN)GMG;.
MT\; 9&.0<<C'2N\\3:Y_8?[/MDX;$MSI=M:)[[XU#?\ CN[\J9\ O -MH^@V
M_B)_,.HW\++M8C8D1?(P,=3M!Z]Z $\2_!?P[X>T?7]9L$N8YXM.N3% TH:)
M/W3 D C=T)ZDTS]GG4[:Q^'=W+=W,5K#'J,BF29PBC*1GJ?K7IWB"S_M#0=2
MM<9\^VDBQ_O(1_6ODB'4C_PJ^ZL V,:Q%,1GL89!_P"RC\J /36D63]J")T8
M.C $,IR"/L76O>J^3_@O<3WWQ6T.2:22=U61=SDL0JP.JC/H  !]!7UA0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#Q!
MIK:SH.I:>KB-KJVD@#GHI92N?UKY;^$?@NV\6>,;K2=41Q%%:RF15(#*P95X
M/J"?TKZSKB/"_P +;7POXVU;Q##>/(;X.!;% !%O<.W.>>1QP,4 ='X9\.6G
MA/0[72K'?]EMP0ID(+'+%B2<#G)-:E%% 'F_Q_T>35OAW/)$K.UE/'=%5&3M
M&5)_ .3^%6_@EXF'B3P#9 QF.33\6+9.=VQ%P1_P$BNQUC3UU;2;VQ<X6Z@>
M$GV92/ZUX9^S[XJ@T2WUS1+N40W89KF&%@?G*H?,'U 1?U]* /*O%GC#5O%V
MH23:E>RW"B1FCA9CY<6>RKT' 'Y5HPZWJ/C_ %3PMH=PJM;6ABLH(XUZ*2H9
MCZG"C/;BL>S\,ZEJ.@WVLP0^98V3JMQ)N *%B .,Y/)[=*Z2VM['X;_#6X^(
M=YK#66H&&ZMM+M%0;I;ED>.,J<Y.&)8X' 4GVK6E3E6J1IP5VW8B<U3BYRV1
MWOBX#2/VC=&N -OVHP<^NY3%_3%>V_VYIW]K#2_M]K_:93S?L?G+YVS^]LSG
M'OBO@#PCXD\876@IXFU74[^\OF=YM-O[Z4SM^[/&W?GY5D!^7IG/%1>*/AS\
M5?AC)8_%G69 -4:^6620R^=/&S#AI0HVB-A\F >,A2!D5]!1R>,Z]2A4K)2B
M[+S?^7<\RICG&G"I&FVGJ_)'Z(T5\M?!7]L2[\<>(M2L_$^G6.FV5KI<U^LU
MB'W$PJ'D!#,<@H'8>FW'/6NB^ G[5%O\3KCQ''XD.E>'!8E)K0O<>6'A9BIW
M%VP64[ 2, [QP*XZV48R@IN</AM?Y[6[F]/'4*G+RRWO^!]!T5\Q_M-_M23^
M [I?#/A"7;KZF.:XOVB26*.)D#JJ Y#,P93DC '3)/&/\*/VT-3\9?$#PUX>
MU;2+&SLKY4LYKI'8R-=%<*Z\A0K/M&W!(W?>.*N&2XR>'^LJ/NV;\[=[>?0F
M684(U?8MZ['UI1117AGHA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <O\1/'</P]T%-2FMFNS),L"0J^W+$$]<' PI[
M5Y#X%^*6M>+OB_9[[N:'2[EI46PW9C5!&Q7([MD YZ_AQ6U^T]>!-'T.TSS)
M/)+M_P!U0/\ V>O(K/3[[P)X\TR&\_T>]M;BWED5&!VAMK8R/]EL'\: /LFB
ML&]\=:#IWB"'1+C48XM4F*JEN58DEONC(& 3D=3WK>H **** "BBB@ HHHH
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M[+X)T"+&"MA #]?+7/ZUNU4TFW^RZ590=/+A1/R4"K= !1110 4444 %%%%
M!1110!R^O?#G1_$7B;3==NUF^W6!4Q^6X"/M;<NX8YP3VQ7BOQV^&LVC:E>>
M)H)8C87DZAH1GS$D8$L>F,$@G.>K=*^DJX+XY68O/ACJ_&6B\J5?PD7/Z$T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ@K)]A^5"[#SMV,A0>>G&,YKYMX+$QG.G[-WCOY'LK$4G&,N96>QZ-Y6H_\
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M #U\:\(Z1?\ [*?Q^T'_ (2R: VK0,TUQ8EY(S#*KIN&54G:XR1C^&O5Q-3
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M_P#/S:_^ [?_ !ROBCX8_MN:KX6\/Q:7X@TB/6DL;1(;:>*9HYYF5@H\UVW
M_)GD#)*\]<U]B^ _&=A\0O!^E>(M-+?8]0A$JJV-R-DAD..ZL&4^XKX['97B
M<OUK1]V]D^C/>P^,I8K2#U[&EY6H_P#/S:_^ [?_ !RCRM1_Y^;7_P !V_\
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M^ [?_'*/*U'_ )^;7_P';_XY5VJ^H:A;Z387-[>3+;VEM&TTTSG"HB@EF/L
M#32;=D!Y-\>?&FK>%]+L+&TU%;>ZNW,C26J-&ZQK[[CC)(_(UYUXHU:?QUJO
M@%;Z59S=0112,5(R3<-$Y;GDDIG(QUK@M:\87_C[4KS79GN[FVNIWFMDD!86
MMJSGRE..$&TH/3<WJ:?=7\_B6#2M)T262WUBTA-E',',92Y>5Y(V5AR,>;&<
MCH?I6[HN-1P?3=_.WYF2J)Q4EU-/0/B5)\&M)UKQ.M@+V93'I\<$F5&^0LXR
M>P A/Y5Y99_M%>-&\675_P")]5O[C2]2MIUDTLY%L$EB<1M'$2  K%6##G"Y
M^;NZ;X=_&/Q-GP;?:'K=U;RZBMRUS?6TGDB50R>8;AAC;AV.<FOMEO@!X&OK
M3P\NK>'[35;K1;*&Q@N+@-\R1J% =0<..,X8'J:^Q4<#E%'V==*I*=[N.K2Z
M;[?UV/!;Q..J<]-N"C;1]_U/C_1-:.O>==VID?2LB*.1@55IE&9  >X5X_S%
M?:_@;QM8_$+1!J/A[7+'4[.-S \D=K(I1U RK*S@@X(/(Y!!Z&O*?VBM!TWP
M_IWAFUTO3[73+57NBL%G"L48)\K)VJ ,G%?.'BSPK\3OV==5UQ=$N-7T_P -
M"YCN%U.US]GF7=B(NP&W=\P5D/4]01BO'PF#H9E4G"E+D:MRIO?H[Z;[;'?6
MQ%3"1C*:YEK>W3M\C] +R:ZT^SGNKF^LX;>!&EDD>W8!%49)/[SH *\<T/\
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MCC-=3Y6H_P#/S:_^ [?_ !RKM%<\JDZEN=MVT^1M&,8WY5:Y2\K4?^?FU_\
M =O_ (Y1Y6H_\_-K_P" [?\ QRKM%9E%+RM1_P"?FU_\!V_^.4>5J/\ S\VO
M_@.W_P <J[10!2\K4?\ GYM?_ =O_CE'E:C_ ,_-K_X#M_\ '*NT4 4O*U'_
M )^;7_P';_XY1Y6H_P#/S:_^ [?_ !RKM% %+RM1_P"?FU_\!V_^.4>5J/\
MS\VO_@.W_P <J[10!2\K4?\ GYM?_ =O_CE'E:C_ ,_-K_X#M_\ '*NT4 4O
M*U'_ )^;7_P';_XY1Y6H_P#/S:_^ [?_ !RKM% %+RM1_P"?FU_\!V_^.4>5
MJ/\ S\VO_@.W_P <J[10!2\K4?\ GYM?_ =O_CE'E:C_ ,_-K_X#M_\ '*NT
M4 4O*U'_ )^;7_P';_XY1Y6H_P#/S:_^ [?_ !RKM% %+RM1_P"?FU_\!V_^
M.4>5J/\ S\VO_@.W_P <J[10!2\K4?\ GYM?_ =O_CE'E:C_ ,_-K_X#M_\
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M#.R.1P (]AR<9)('I6Y\1_V>_$E]KMWK7AC39=8TW4M1EVVMG&SRV>\[U60
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M;5YH@=Q)VX*G\:^^_!/@+0/ASH[:5X<TZ/3+!I6G:)'9]TC  L2Q))P .O0
M5]A4J8?((QIPCSU9).[U5M=NJ/"A&KF;<I/E@KJW7H?*6@^&I/"5IXJT%Y5N
M9=-T[[(\J# <QW,"E@.PX)IOP_T%+;QWX<E2?S6U"^@NG3;CRML@CVYSSQ$&
MSQ][':N_\/Z.WB#XI?$+34QYMS;7\<>[IO,R[2?QQ7-_"72[IOBGI%I/"Z2V
M<LGFHPYCV*Q.?3YOU-?$2J2DY2;^+?[[GT*BDDET/K2BBBLRSPK]J+_4^&_]
MZX_E'7HWQ.\!I\3?AOJWAE[C[)]O@54GV[@CJRNA([C<HS[5YS^U%_J?#?\
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ME\Q%.1& HVIN9CSD\C).*[_Q)X;TWQ=H=WH^L6B7VFW:;)K>3(##((Y!!!!
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MFKWE_K%G.LVCW,1MH9@R!)U8LV5XR053*GUY%?8'B[X<ZB^M:C>V42?8B&N
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M9\3M#>;C=?:SI6^,V)?=N(\LQYV$_P .['..G%>UQQI#&L<:JB* JJHP !T
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M@=1@U]1?##]E?PMX'\ WU[XV3^W9-1M[::>UDC:+[&P&3&C*VXMN?!;(S@#
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M#/\ ]!&Y_P"^8O\ XBC[#/\ ]!&Y_P"^8O\ XB@"[15+[#/_ -!&Y_[YB_\
MB*/L,_\ T$;G_OF+_P"(H NT52^PS_\ 01N?^^8O_B*/L,__ $$;G_OF+_XB
M@"[15+[#/_T$;G_OF+_XBC[#/_T$;G_OF+_XB@"[15+[#/\ ]!&Y_P"^8O\
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MJNS.X%BP^8X.".0,?19/C:&$E/ZQ>SM:W<\+-, \<H<NZ,'P3J$?BG0)M'=
M]EKEJLJE3\R.$,D9'_ MOZ5?_9=_UGB7Z6W_ +5KR3]F?7KVWTNW.IR/G2M3
M^S88?-'&@3*?AEJ^BO&6FZ?X T-SX>C&E7&H72M*UN[;G4*QXYX )'3CFNC-
ML'?&QA#[7Z?\ \S*<9]7P=7VFOLW^#_X)T?C+QE;:'HL[V\J3W+LUN@BD!,;
M[3R?3'I7DLUYI.GV,7B;QOKZ6&D--Y >X=WFF<#(50 21].@!Z=:S(4CAE::
M_+0V<$3W=RY'(A1#([#_ ( I(KPWQI?G]J;XQ:-H7@^&?3M%M[7R+<7JD+"B
M[I)9F"EL9)P.<G" X)X]/"8"%%."E96O*79>7F>>\3/,IJK5CHM%'N_,]V^.
MW[76C>$=&6P\%WL&LZW>0"2.^MV62WM%)&"W4,^,_+V_B]#\[7GB+QO^UKXH
M\/:(PCEO=.LI/,<8CB^^2\[ <*2/*3CN!ZUZ!^S7^RW+JNM^()?B)X:N8K"U
MC%M;VUWOA$TI;+2(RD$A0F,@X._O7UAX%^%WA7X:V\T7AK1+?2Q-_K9$W/*X
M'0-(Q+$#T)P*BIBLOR=.EA8\]5;2T:U7>_;H>[&CB<=:=9\L'T]#YO\ @#^Q
MO]AFFU?XC6$<LJG;:Z0)PZJ00?-D:-L'I@+DC!.?2OKJBBOE<;CJ^/J>TK/T
M71>A[.'P]/#0Y*:_S"BBBO/.H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /DOQ-I>L?#SX@3ZP;&>"UA
MU-I+>9D(CE7>6"ANARO7\:^F]6\36^G^$;G7HL36R69NX^<;QLW*/QX_.N&_
M:,LYKKX?QR11EUM[V.60@?=7:ZY_-@/QKQ6;XKZS>>$[CP]</&VGM:PVT*J@
M#1^64YSU.0ISGU[4 ?0_PG\>7/Q!\.3W]W;Q6T\-RT!6'.T@*K \DG^+]*Z?
M7)/)T34)/[MO(WY*:^9_ ?Q6G^'GA 6]G:P74]QJ$DDBS$\1B.,<8/4G//MT
MK6\*_%+4_$>O>*OMMW*+*[TR\DM[-WW)"50LH7Z*&&<<T =#^S7917?AOQ#'
M/&LL,\RQ.C#AEV'(/X-7D?Q&\/V_A/QMJVEVH86T+KY8<Y(5E5P,_C7M7[,L
M>/".J2?WKXK^4:?XUQW[26@_8O%EEJ:+A+ZWVL<=9$.#_P".E/RH ]Q^'G_(
MA>'/^P?;_P#HM:Z&L_P[8_V7X?TRRQM^SVT4./\ =0#^E:% 'SO\0+ZY^&7Q
MH'B,VGVFTND\R./?M$F8A&XS@X(;GIW'K7N/A3Q+:^+_  _::M9AE@N%)V/]
MY6!(93]"#6-\5?"-MXN\'7T<L;-=6L3W%JR<,)%4D#Z'H1_A7F'[/_Q&6V>T
M\)2VC,T\LLD5T'X7Y=VTKC_9;G/<<4 :?BB:^\'^+M7>%C&]ZK-',IP0KL&)
M'N""*TO!OPYB\1V$>JW][(Z7'F9B4?-G)7<7)/.1GI74^,/#]KX\M0NG7MJ]
M[9RE&99 P7/5&VYP> >?2NBT'2QHNCV=B&#>3&%+#H6[G\\U]!4S#_9H^S=I
M[/T1\G2RF^,G[97I+6/:[=_\S+@^'^A0Z;%9/9+/'&Q??(3O+'J21C_#BO/)
M(;3P'\1@1YB64"EUW')(:(\ ]_F.*]FKQO6/$%E\4/%]YX?LX!::CIQD6*[F
MDRDX1L.N ,CGD=>AZ9KFP>+?.X5Y/EDFG\^IVYA@%[*-3"P2G!IK3>W0\T^+
MFM7GB.\M-2N1L21I(XE4_*H7:=H^FX'\:L^,-<N?BKJ/@W3;9U:Z:S6)VD)P
M)V8K(QZG'R _2D^*GAF\TC5M$T$NES>3 RHL.<;I'"*!D#J8Z?\ L^Z:+SXC
MQO*,-9VTLP5A_%PG_LYKDQDH2KR=/X>GR5COR^%2GAHJM\6K=^[=SV"W^!_A
MT^$XM'GMVCF;RI+B[MW(DDE12-P+9P/F;C&.:[C3=+MM*TJVTZ!/]%MX5@1&
MY^4# !]>*N45QGH%>QT^UTVW$%G;0VD()(C@C"+D\DX%>&ZQ_P 4_P#M*64_
MW8[TQ\=COB,7_H0S7O5>._'+P)K.J:KI?B308I+B\LD"/'#@R+M<NCJ/XN2>
M!STH ]+T'Q9I'B=KI=+OH[QK5]DP0$;"<XZCV/(XXJ7Q!XCTWPOIYOM5NEL[
M4,$\Q@3ECT  !)/!Z>E?,?P_\8W?P?UO41J>E7!EGMT'V60^4P.0RDY' VEN
MU2>,6N/BK\3H8--E"K?PPM MPYVQ#R [ XST.[..] 'T;8ZEH?Q"T.9K2:/4
M=/=C$S!2N&&#W ((R#4_AWPS9>%[1[>R#[9'WL\ARQ/U]!7BOP&\1'PEX@U'
MPEJT4EK=7$V8MXP!*JG*G_> &#WQ[BOH"M%4FH.FGH^ADZ--U%5<?>77J%%%
M%9FH4444 %%%% !1110 4444 %%<1XM^*5GX2\7:3H,UI),]]L+3J^!$'<HI
MQCGD&NWH **** "BJUYJ5IIWEF[NH;42-L3SI FYO09/)J2XN8;.!Y[B5((8
MQN>21@JJ/4D]* (]2U"'2=/NKVY;9;V\332-Z*H)/Z"OG2T_:/UV'5KR>>W@
MN+"4,(;4 (8?[I#8RWOGKVQ4WQ;^-D?B:RDT;0Q)'8.<7%Q(NUI<$_*N#]T\
M=>33?#?[.]]K6GV%_/J$5M;W5IYWEE3YB2,I*#&,8Y4GG/44 >7Z7XAU+1=2
M.H6-[-;7C$EIHV(+9.2#Z@D<BOIGX]7AA^&%XIX-Q)"G_CX;_P!EKQKQG\$M
M:\'Z/;WN?[38M(;@643.D"* 0Q.,X(SG@ 8K,\5?%;7?&6C-INI/#)!]H6=#
M'&$*85@$&.H^;OD\#F@#Z+^#=K]C^&>A)C&Z)I/^^G9OZUVE8_@_3SI7A/1K
M,C#06<4;?4(,_K6Q0 4444 %%%% !1110 4444 8?CC0SXD\(ZMIJC=)<6["
M,?[8&4_\> KSC]FSQ MSX=O]&D;$]G/YJ*>OEO\ X,#_ -]"O8Z^7/BW9W?P
M[^(MW<:-<S:<NH0^>K6[%" S?.H([;ESCW% 'U'17SMX5_:0U"UGM(-<M([F
MR2/9+<6ZG[0S <-RP4Y.,CCK7T!INH0:MIUK?6S;[>YB6:-B,$JP!'Z&@#$C
M^'VC+K4FIM"TLSR>;Y;MF-6ZY ^O/.:XC]I"WA3P5!<+%&+AKV.-I0HWE=CG
M;GKC(!Q[5T/QNOI+'X9ZP\4C1R.(HPRG!P95!'XC(KY>D\1:OJ&FQZ1+>75W
M:!U,-J[LX5AD+M';[Q&!ZUK.M4J6YI-VT,*>'I4K\D4KN_S.R\)^$_M7Q,\,
MP)9G[(]O:7C97*,! CNQ[8+ _B:^J:Q?!-C-IO@_0[2Y0Q7$-E#'(AZJP0 @
M_0UM5D;A1110!P_QE\,CQ-X!OT\TQ/9*U\G&0QC1CM/U!(_*L;]G74FO?A\8
M&S_HEW)$OT(5_P";FO1M6T]-8TF]L)&*1W4#P,R]0&4J3^M>#?"KQ5_PJSQ!
MK?ACQ PMK=2\ZS$<;U7.1[.@!'N .] 'T)39)%BC9V.%4$D^PKYN^)7QUNM<
MO+)/#5S=Z=:0?O))/N/*^>A )^4 =.^3GI6W^T9XRF^SZ5HELY2*XB%[,R'
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MU =2I(]^:NT4 >:^ ?@;IG@G5(-4:^N-0U&'<$8J(XQN!7[O)S@G^*O2J**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG>^2O7)2/R4_F#7.^%_BUK/@WP_#INE&&,"Z>XD>2,/N!" )ST'RMG'//44
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M+X&O)\2-5O=7L(#X>\V6:VB1P%?<V47:IR H)X.!P!TKV^B@!*6BB@ HHHH
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M%B.>2/P% 'K.J:I::+I\]]?3K;6D*[I)7Z**31]8L]>TV"_T^=;FSF&8Y5!
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MKM% %+^R8?\ GI=?^!4O_P 51_9,/_/2Z_\  J7_ .*J[10!2_LF'_GI=?\
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MI?\ XJKM% %+^R8?^>EU_P"!4O\ \51_9,/_ #TNO_ J7_XJKM% %+^R8?\
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MO[)A_P">EU_X%2__ !5']DP_\]+K_P "I?\ XJKM% %+^R8?^>EU_P"!4O\
M\51_9,/_ #TNO_ J7_XJKM% %+^R8?\ GI=?^!4O_P 51_9,/_/2Z_\  J7_
M .*J[10!2_LF'_GI=?\ @5+_ /%4?V3#_P ]+K_P*E_^*J[10!2_LF'_ )Z7
M7_@5+_\ %4?V3#_STNO_  *E_P#BJNT4 4O[)A_YZ77_ (%2_P#Q5']DP_\
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M:* *7]DP_P#/2Z_\"I?_ (JC^R8?^>EU_P"!4O\ \55VB@"E_9,/_/2Z_P#
MJ7_XJC^R8?\ GI=?^!4O_P 55VB@"E_9,/\ STNO_ J7_P"*H_LF'_GI=?\
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M2Z_\"I?_ (JC^R8?^>EU_P"!4O\ \55VB@"E_9,/_/2Z_P# J7_XJC^R8?\
MGI=?^!4O_P 55VB@"E_9,/\ STNO_ J7_P"*H_LF'_GI=?\ @5+_ /%5=HH
MI?V3#_STNO\ P*E_^*H_LF'_ )Z77_@5+_\ %5=HH I?V3#_ ,]+K_P*E_\
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M/[)A_P">EU_X%2__ !57:* *7]DP_P#/2Z_\"I?_ (JC^R8?^>EU_P"!4O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 5M2_Y!]U_UR;^1JS5;4O^0?=?]<F_
MD:LT 5KK_7V?_74_^@-5FJUU_K[/_KJ?_0&JS0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %;4O^0?=?\ 7)OY&K-5M2_Y!]U_UR;^1JS0!6NO]?9_]=3_ .@-5FJUU_K[
M/_KJ?_0&JS0 4444 >6_M#?$K4OAIX.M[G2Y(+&XO9I+;^U+R!IH+,B"61"R
M@C+.Z)&NX[0T@)R!M/?>&9=7ET>/^W8K>+4TDECD-KD12JLC*DJJ68H'0*^P
MLQ7?M+'&3SWQ@T;7/$7@/5],T.PTW59;RTGMY;'4I#$)5>-@I1]K ,&*D!EP
M>FY/O5C_  \^#J^'?#>EVNK7^H"ZL9Y9;>TTO6[Z*TM(FE+QVRJLB":.,$(#
M(O(&, ?* #TVBBH+ZW:ZL;B!6VM)&R!O0D$9H GHJE_8NG_\^%K_ -^5_P *
M/[%T_P#Y\+7_ +\K_A0!=HK,7P_8B[DD-G;&-D50GDKP06)/3OD?E4W]BZ?_
M ,^%K_WY7_"@"[15+^Q=/_Y\+7_ORO\ A4,/A^QCEN&:SMF61PRKY*_*-JC'
M3U!/XT :=%4O[%T__GPM?^_*_P"%17>@6,UK-''9VT<CHRJXA7Y21P>E &E1
M5+^Q=/\ ^?"U_P"_*_X4?V+I_P#SX6O_ 'Y7_"@"[16;-X?L9)(&6SMD5'W,
M/)7YAM88Z>I!_"I?[%T__GPM?^_*_P"% %VBJ7]BZ?\ \^%K_P!^5_PJ*'P_
M8QR3LUG;.LCAE7R5^4;0,=/4$_C0!I452_L73_\ GPM?^_*_X4?V+I__ #X6
MO_?E?\* +M%9MGX?L8+6&.2SMI9$0*SF%?F(')Z5+_8NG_\ /A:_]^5_PH N
MT5FW7A^QFC"QV=M&V]&W"%>@8$CIW (_&I?[%T__ )\+7_ORO^% %VBJ7]BZ
M?_SX6O\ WY7_  J)O#]BUU'(+.V$:HRE/)7DDK@].V#^= &E15+^Q=/_ .?"
MU_[\K_A1_8NG_P#/A:_]^5_PH NT5FP^'[&.2=FL[9UD<,J^2ORC:!CIZ@G\
M:E_L73_^?"U_[\K_ (4 7:*S;O0+&:UFCCL[:.1T95<0K\I(X/2I1HNG_P#/
MA:_]^5_PH NT52_L73_^?"U_[\K_ (5#/X?LI)(&6SMD"/N8>2OS#:1CIZD'
M\* -.BJ7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A0!=HK-7P_8BZDD-G;&-
MD50GDKP06R>G?(_*I?[%T_\ Y\+7_ORO^% %VBLVZT"QFM9HX[.VCD=&57$*
M_*2.#TJ4:+I__/A:_P#?E?\ "@"[15+^Q=/_ .?"U_[\K_A44WA^QDD@9;.V
M0(^YAY*_,-I&.GJ0?PH TJ*I?V+I_P#SX6O_ 'Y7_"C^Q=/_ .?"U_[\K_A0
M!=HK-A\/V,<L[-9VS+(X95\E?E&T#'3U!/XU+_8NG_\ /A:_]^5_PH NT52_
ML73_ /GPM?\ ORO^%16?A^Q@M88Y+.VDD1 K.85^8@<GI0!I452_L73_ /GP
MM?\ ORO^%177A^QFB"I9VT;;U;<(5Z!@2.G< C\: -*BJ7]BZ?\ \^%K_P!^
M5_PH_L73_P#GPM?^_*_X4 7:*S6\/V+744@L[81JC*4\E>22N#T[8/YU+_8N
MG_\ /A:_]^5_PH NT52_L73_ /GPM?\ ORO^%10^'[&.6=FL[9ED<,J^2ORC
M:!CIZ@G\: -*BJ7]BZ?_ ,^%K_WY7_"HKK0+&:UFCCL[:.1T95<0K\I(X/2@
M#2HJD-%T_P#Y\+7_ +\K_A1_8NG_ //A:_\ ?E?\* +M%9LWA^QDD@9;.V0(
M^YAY*_,-I&.GJ0?PJ7^Q=/\ ^?"U_P"_*_X4 7:*I?V+I_\ SX6O_?E?\*BA
M\/V,<L[-9VS*[AE7R5^4;0,=/4$_C0!I452_L73_ /GPM?\ ORO^%']BZ?\
M\^%K_P!^5_PH NT5FVOA^QAC97L[:0EW8$PKP"Q('3L"!^%2_P!BZ?\ \^%K
M_P!^5_PH NT5FW6@6,UK-''9VT<CHRJXA7Y21P>E2C1=/_Y\+7_ORO\ A0!=
MHJE_8NG_ //A:_\ ?E?\*BA\/V,<L[-9VS*[AE7R5^4;0,=/4$_C0!I452_L
M73_^?"U_[\K_ (4?V+I__/A:_P#?E?\ "@"[16;:^'[&&-E>SMI"7=@3"O +
M$@=.P('X5+_8NG_\^%K_ -^5_P * +M%9EUX?L9H@L=I;1MO5MPA7H&!(Z=P
M"/QJ;^Q=/_Y\+7_ORO\ A0!=HJE_8NG_ //A:_\ ?E?\*A;P_8M=12"TMA&J
M,I3R5Y)*X/3M@_G0!IT52_L73_\ GPM?^_*_X4?V+I__ #X6O_?E?\* +M%9
MEKX?L88V#VEM(2[L"85X!8D#IV! _"IO[%T__GPM?^_*_P"% %VBLVZT"QFM
M9HX[.VCD=&57$*_*2.#TJ4:)IX _T"V/_;%?\* +M%4O[%T__GPM?^_*_P"%
M0S^'[&22 K:6R!'W,/)7YAM(QT]2#^% &G15+^Q=/_Y\+7_ORO\ A1_8NG_\
M^%K_ -^5_P * +M%9J^'[$74DAL[8QLBJ$\E>""Q)Z=\C\JE_L73_P#GPM?^
M_*_X4 7:*I?V+I__ #X6O_?E?\*BM?#]C#&P>SMI"79@3"O +$@=.P(% &E1
M5+^Q=/\ ^?"U_P"_*_X5%=>'[&:(*EG;1MO5MPA7H&!(Z=P"/QH TJ*I?V+I
M_P#SX6O_ 'Y7_"C^Q=/_ .?"U_[\K_A0!=HK-;P_8M=12"SMA&J,I3R5Y)*X
M/3M@_G4O]BZ?_P ^%K_WY7_"@"[15+^Q=/\ ^?"U_P"_*_X5%#X?L8Y9V:SM
MF61PRKY*_*-H&.GJ"?QH TJ*I?V+I_\ SX6O_?E?\*BNO#]C-$%2SMHVWJVX
M0KT# D=.X!'XT :5%4O[%T__ )\+7_ORO^%']BZ?_P ^%K_WY7_"@"[16:WA
M^Q:ZBD%G;"-492GDKR25P>G;!_.I?[%T_P#Y\+7_ +\K_A0!=HJE_8NG_P#/
MA:_]^5_PJ*U\/V,,;![.VD)=F!,*\ L2!T[ @4 :5%4O[%T__GPM?^_*_P"%
M176@6,UK-''9VT;NA57$*_*2.#TH TJ*I#1-/ '^@6Q_[8K_ (4?V+I__/A:
M_P#?E?\ "@"[16;-X?L9)("MG;($?<P\E?F&TC'3U(/X5+_8NG_\^%K_ -^5
M_P * +M%4O[%T_\ Y\+7_ORO^%1+X?L1=/(;.V,;(JA/)7 (+9/3OD?E0!I4
M52_L73_^?"U_[\K_ (4?V+I__/A:_P#?E?\ "@"[16;;>'[&&-@]G;2$NS F
M%> 6) Z=@0/PJ7^Q=/\ ^?"U_P"_*_X4 7:*S;KP_8S1!4L[:-MZMN$*] P)
M'3N 1^-2_P!BZ?\ \^%K_P!^5_PH NT52_L73_\ GPM?^_*_X5$WA^Q:ZBD%
MG;"-492GDKR25P>G;!_.@#2HJE_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K
M_A0!=HK-MO#]C#&P>SMI"79@3"O +$@=.P('X5+_ &+I_P#SX6O_ 'Y7_"@"
M[15+^Q=/_P"?"U_[\K_A45IX?L8+6&.2TMI9%0*SF%?F..O2@#2HJE_8NG_\
M^%K_ -^5_P *BNO#]C-$%CM+:-MZMN$*] P)'3N 1^- &E15+^Q=/_Y\+7_O
MRO\ A1_8NG_\^%K_ -^5_P * +M%9L/A^QCEG9K.V978%5\E?E&T#'3U!/XU
M+_8NG_\ /A:_]^5_PH NT52_L73_ /GPM?\ ORO^%16F@6,-K%')9VTDBH%9
MS"OS''7I0!I452_L73_^?"U_[\K_ (5%=>'[&:(*EG;1MN4[A"O0,"1T[@$?
MC0!I452_L73_ /GPM?\ ORO^%']BZ?\ \^%K_P!^5_PH NT5FMX?L6NHI!9V
MP158%/)7DDK@].V#^=2_V+I__/A:_P#?E?\ "@"[15+^Q=/_ .?"U_[\K_A4
M5MX?L88V#V=M(2[,"85X!8D#IV'% &E15+^Q=/\ ^?"U_P"_*_X5%=:#8S6T
MT<=G;1NR%5<0K\I(X/2@#2HJBNB:> !]AMC_ -L5_P *7^Q=/_Y\+7_ORO\
MA0!=HK-F\/V,DD!6SMD"/N8>2OS#:1CIZD'\*E_L73_^?"U_[\K_ (4 7:*I
M?V+I_P#SX6O_ 'Y7_"HH?#]C'+.S6=LRNX*KY*_*-H&.GJ"?QH TJ*I?V+I_
M_/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X4 7:*S;3P_8P6L4<EG;2NJ@,YA7YC
MCKTJ7^Q=/_Y\+7_ORO\ A0!=HK,NO#]E-&JQV=M&P=&)\I>@8$CIW (_&IO[
M%T__ )\+7_ORO^% %VBJT&FVEK)OAM88GZ;HXPI_,"K- %;4O^0?=?\ 7)OY
M&K-5M2_Y!]U_UR;^1JS0!6NO]?9_]=3_ .@-5FJUU_K[/_KJ?_0&JS0 4444
M %%%% !7C7Q,\27NF^,IX=?U_7_"7A2.WB:RN]!T_P Y;J8[O,$TPAE,97Y=
MJ83/7+=![+7F>MR>,]:^)5WIMAX@C\+:5:6L,UHKZ8MR-28[C*2[$8"852B$
M-ALDC(H @^$.NZGJFL:E%;ZKK'B3PDMO')::MKMA]EG\\LV^)#Y47G1XP=VS
M@\;F[=_XHN-3M?#.KSZ+;QW>L1V<SV5O*<)+.$)C5CG@%L#\:X[PUX@U^\^)
MTEC?[ET\Z*)B( 'LY)UGVF2&3&>58;D)RI'?AF[#Q8NK-X5UD:"T:ZX;*86#
M38V"XV-Y1;/&-^W.: /!O^$PM=@S\2?'R^*L;SIO_".?\ML?ZK[+]DQMSQCS
M.G/F8^:O>_"]QJ5WX:TF?6;=+/6)+2%[VWB;<L4Y0&1 >X#9'X5P7AOP7J6B
M>'X98_$.O:O)?1;+O2O$MR&>=BAWI&P ,+C#8V,4./3#CJ_AC%JD'PV\)QZX
M9SK::3:+?&Z8M+]H$*"3>23EMV[)]<T 9OQ;U36M)\/6<FDRWEI ]XD>I7VF
MV8O+JTM"CEI8H<-O;>(U/RN0K,VUMN*\Y\/>+#-XBTF/P=XT\5^+IWO(8;[3
M]8TP_95MBX$TK3&VB\IE0LR_-\Q 7:<Y'H_Q6TW6]6T?2[72;W4-/M)-1C_M
M6XTE@MXMGL?/E'!(/F>5G;\VS?C)XK!\2>%_$6B:?I.GZ3J^HZ_';ZOIDQ:Z
MN1]NM(?MD8G9I%VF6)H?/4AP3R>6'"@'JE>-?$SQ)>Z;XRGAU_7]?\)>%([>
M)K*[T'3_ #ENICN\P33"&4QE?EVIA,]<MT'LM>9ZWX/UWQ)\2KN2]U[7]'T6
M*UA.E#1;A8H#(-QF\\;6W/G9@.-A7ID[J (/A#KNIZIK&I16^JZQXD\)+;QR
M6FK:[8?99_/+-OB0^5%YT>,'=LX/&YNWJ=>=>&K/Q#'\3I+F]F:]TA]%$(O[
M>3%O<S)/PQB!*I*%8@XX.,C^ZOHM 'SO>>,'^VWB^-_&_C#PCKC7$J1:7I.E
M8M4B$C",PN+67S\KM)8N<GC:OW:]9^%>I:[JGA-)O$"W!N1<3)!/>6OV6XN+
M<.1%++#@>6[+C*X'KM7.T<GX1\'^)85O]:UCQ9K5CXB6ZE\VWO)4DTG89#Y2
MQQ8 \LILY5@X.<D'(KI/A59ZS8Z?KT>M07%K(VLW,EM#-.9@D#;641N>J9+8
MZ8Z8'0 %OXHZCKVE^#;FX\.Q2O?B6%7>WMQ<310F11+)'$>)'5"S!>Y'0]#Y
M GC$K<0_\(5XZ\9>*?$:RHHTC5=()MIP77<)R;2+R!@'Y]Z;?0_=/KOQ2L]>
MU#P=/;^'KBXM;R2>!9YK(J+I+;S5\\P%OE$GE[MN?PYQ7&>-/!_B'1_AYJMC
MX;U[6-=GFM?/@M=1NC_:$3JRLLD4OROP0,QOGKP01L8 ]AKS#XOZYJFE:EI$
M4FI:MH'A.2*9K_5]#L?M5Q',"GE1M^[D,4; N2X0\J!E<Y/I]>>?$3PWK?B;
MQ5H%JFJZQI/ACRIS<RZ#/Y,YNLH(1*P!81;?,^[QNQNXQ0!S7PW\376H>-+.
M#P[XD\0>+_#<L<K:C-KVG>3':,%'EF&<P1%F+#!C^? );Y<<^T5YG+H_B2S\
M<^#ECU&XUK2;.XNH;J^$@618VMF*Q7*)A7.]8B'VCG&0#AG],H \3^('B>?3
M_&FIP>)O$_B/PAH<)B_LIM#T[S(;Q3$ID>2<02D.)"Z^6=GRJK?-GY>D^#^L
M:GJCZQ&VHZKKOAR$0?V;J^MV'V2ZG<[_ #DV^7'YB+B+$FQ=Q=A\VW<8KI_&
MVN_$;6[:S\0P>'=-TSR396$VEB==1C:)6>9Y"P;:)&:,K&05V G[PSH>"=>U
MK5/'GB.UU!9([&+3=.N84&'MO.D>Z65H)=H+QLD4#8/0D\ DT =AKDU];Z+?
MRZ7!'=:DEO(UK!*VU))0I**QSP"V 3[U\^0>,H9+>/\ M'XC>/;/Q>R!Y-+A
M\/<)/M_U2VXLV#)GC[YR.=_.ZOH#Q -1;0=2&D&-=6-M+]C:;[@FV'R]WMNQ
MFO.O"/@W6-%\.VMV_B/7=0U*ZC"7VE^)+E72>0J?,CC( \IL[MIC)3'9A@@
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M'$_S# /IAASG(">#M0^(LWC6X@\5Z=H]GHPT\/#)H]S)<(T_F8(9I(T8';V
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MX@DME:]B4 !9>X '%<;X1\&ZQHOAVUNW\1Z[J&I7482^TOQ)<JZ3R%3YD<9
M'E-G=M,9*8[,,$=/\)+?5K/X:^'H-=%R-7BM%2Y%XY>7>,@[F).3[Y.?6@"U
M\0-4\1:+X9EN_"^DV^MZLDL:K9W,QB5D9PK-N /W0=W3HIQDX%<-XBU7XU6^
MDRR6VA^$O-#Q_P#'AJ5Q-.%+J&*));JK';GJPKJ_BMJFO:5X55_#[K:W4UW!
M!-J#6QN/L,#.!)<>5_'M'// SD\ UR/C34/&O@[P3=8UP>(;M/)N(-2LK1(K
MF,>:N[S85W(\17<-Z@8[C&74 ]@K@O%VL_$.'Q8EAX8T#0[S239B<ZAJU_-
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MS:)*([P)L/E;6P6">9C=L&[&.VXUCZ]X=\1Z7>>&+33M5OM>L[+6+:2:XDG
MO+: AE=9BNWSHV##EAN&,G=]Y0#U6O,_B)#\0[77%O-"\06-AX<,:B1/[#:_
MN8'[L5$R%T_W06']TC)'IE>9ZWX/UWQ)\2KN2]U[7]'T6*UA.E#1;A8H#(-Q
MF\\;6W/G9@.-A7ID[J *W[/LGB_4_!]EJ_B/Q-;ZY;74;^3"NG&&6-A*PW-*
M96W@@<#:,9')Q7JM>=>&K/Q#'\3I+F]F:]TA]%$(O[>3%O<S)/PQB!*I*%8@
MXX.,C^ZOHM 'SU\7KSXK>%]%\27)\6V=MIXCDDL);'06=MN[Y8GF$^8I.>&*
M%3Q@Y.VO:O"6GZ[INEM%XAUFVUR_,I875K8?8T"8&%V>8_(.><]^G%<%X;N_
M'FJ7FL:Q=^(;&P^RWL\7_",7M@(X885D98BUR#YF710XD 9?FX4XQ71?#'6-
M7U;_ (2D:NEU$;76YH;:&\C57BA,44@3(&&4-(X#9.1C!(P: -[Q=;:W>>'+
MV+PY>VNG:VR@VMQ?0&:%6# D,H()! (R#QG.#C!\4L9OBKJ/Q$TK19?'%G87
MG]E7MS<03>&"(D*36BJ<"Z*R[O,;:ZM\H5P1DD+ZU\3K?7;SP/J,'AR::WU6
M0Q*);78)EA,J>>8M_P OF>5YFS/\6VN'\9>#?$&A_#/7K/PWKVM:_=76F7$E
MI::G='[>DX3,4L,V%D#+(8R4;(Z ;3PP![#7%?$RU\;S6MC-X-U.RL3$[?;8
M;FP%U)*AQM,0,L:[EP>"P!W=1C![6N ^)7A_6O$NN>&[.WU35])\.L;C^T)M
M#F$5QYV$%N&< L(O]=NV]]F>,D ',?!V;QSK?BCQ'=ZIXRMM4T6QU7[*]FV@
M/:22?Z!;OA"TQ,(623E"K99'Y&["^S5YI=:+XCT_Q?X,AAU"ZUO3;/49DN[Y
MI0LT5NUC/^ZN53"R R_9F5MN<A<\_,WI= 'A7Q>NOB=X;L_%-_!XJL['01:S
M2V#VN@M/+&?+8K%)()P8VS@"78R]"=IP#Z3\-;3Q';^&X)/$FN6VN7,\<<L<
MEOIYM/+4H/E8&1]YSGYN/I7*Z;X/\0WWB?Q)JVK>*=>TB[AO)&T^.&9#IBV8
M \HF(J58X!W[B'SG!4;6K9^'%KKUOXB\9/K$4D5M/>02V>)FDMW4VZ"1X<D[
M5:0,VWL3^) .]HHHH K:E_R#[K_KDW\C5FJVI?\ (/NO^N3?R-6: *UU_K[/
M_KJ?_0&JS5:Z_P!?9_\ 74_^@-5F@ HHHH **** "L+QGXTTSP'H;:IJCR^3
MYB010VT32S3RN=J1QHO+,QZ ?R%;M>%?M':/<:7:_P#"3S^)?$:V43VZ6>A:
M,UK%_IBN66;SIHWV# YX[=]VV@#K_@KK>DCPZGARS&IVM]I:EY;/6K%[.Y\N
M21V638W5"=PW*2,J0<'BO1J\<^$<=C;>-IOM&KZOKVN7N@6E\EUJUY%.]O;.
MS'R=L4,03YSG)!+ =1MQ7L$LR01/+*ZQQH"S.QP% Y))["@#R/QG\6/ ]IXZ
MMK#Q-XDLO#>H>%=5%W##=3KF\233WC#X_A7_ $MQCKF+/1A7I_A_7+3Q/H.F
MZS8.9+'4;:*[MW9<%HY$#J2.W!%>(?$KPAXYN/%GBO7-,O\ 7K"UCFLEAM]!
MCL@U]8^00X!="[S1SF1MKD#RR O+?+ZQ\+K)]-^&?A&TDMS:26^D6<36Y=7,
M16% 5W* K8QC(&#CB@#IZ\!\(?&[3+G6+3Q%>:-XB35==BTKP_<[=%N(].AN
M4NYHV*W#KMV^;=N.3G]V!]XXKWZOE/PK\2-=AL]'UY=0^(GB#6I+U$U2V7P[
M-+I#1B;9<K"J094(H?85;=N50W5L 'U96+XIUZZ\/6=M/:Z/>:T9+E(9(;+;
MOC0YS)@D A<=,]ZK_#_QM;?$+PO#KEI:W5E!+<7, @O8S',IAGDA.]#RI)C)
MVGD9P>:XW]HR.&3P1IJRP^:6UFS2/S+]K&W#L^T&>959EB^8@[1DY SS0!J?
M"G6O#.FZ3!X3TW7$NM2T\N);*[0V]XN]FD^:!\..&/.,8%>@5\\_"J\7QQ=:
MUX&U31O#OA:+342X&G^')G:ZM[B*Z=&D=C$H5B8U8-R660,"<G'T-0!Y=\:O
M$D%S9MX-31-?UF]U&V%V?[$MH9##%',GS,998UY; P"3SFNF^'/CBX\>:3?7
MMSH5YX>DMKZ:S%G?LIFPF,,P7*@G/0%AQU->;_';09-=\;:$1X?.J):64K&:
M3Q;)HD3;W \MA&A9R-H8$%1R<YK7_9CL5T_X>7L++#'=C6+W[5%;W[WL<<HD
MQM65_G8!0O+%B>3GG  ._P#&WBV+P/X:N]:N+"_U*"VV[[?381+.0S!<JA(S
M@D9YZ9KR7Q#\5'TOQ$?&(\ >-3-9Z9)8"WN-/CCA*O+&Y=G$C%<>6.BGK7ND
MDT<(4R.L89@HW$#))P!]37RQJ7@+Q/XJCE\CPSX_O9QJC7%M>ZYXI6&S5H[H
MLCFU,^]8UV_+B/. I'4&@#ZJKGOB%XO3P#X)UGQ%):M>IIMNUPUO&VUI .P.
M#S^%=#7/?$&ZT^S\$:W+JNE7&N::MI(+C3;6(2RW$9&&14)&20?44 >7^&OB
MIIWA^\UF&TT?61K6K:K-J$^E:O +.:W7['YF1RP8,EJP7GEL@[0,U[+H^JVV
MNZ39:E9OYEI>0)<0OC&Y'4,I_(BOGS2?#GAW7O&5AH<OP_\ &'A9K^TN@FNZ
MMK3>?Y@C"E!_I,QD/E,ZAF)*KD 8+$?0NE:9;:+I=GI]G&(;2TA2WAC'\*(H
M51^  H R/&_CK3/ &EP7NI"ZE-S<+:6MK8V[SW%S,P8K'&B@DMA6/IA2:PO@
MSK6E2>#=.\.6 U&"Y\.V-K83VNKV;6ETJK$$CD:-NSA"002.&&<@@<O^U5K#
MZ!\/].U&WN-1MKZTU,74$FEF%)L16\\LP$DH*IF".8;MK') VMD@Y6E_"Z2\
M^)FKVD'Q#\47&IZ3)H]_=M=7-M/%=6ZSR2I;2K'!&R',4WRAL 3*Y#;RM 'O
M=>%^(OBYIGB;Q2EA<^&_%\+^%]7ANU:ST"YNO/;[.PPP1#L'[XXY.0H(X->Z
M5XWXE^(EWX1^(FOV-W;:KXEAU.""'2].T2ZM\P$1MYBLIE22.1F.?,Z;=N""
MIH ]1\,ZO/K_ (=T[4KG3KC2+BZ@2:2QNQB6!B,E&]Q^'T'2M.L'P'!K-KX+
MT2'Q$ZR:ZEG$MZR-O'F[1N^;^(YZGN>:WJ /*-/\56FE>*+'Q3XOM+CP?J.L
M6,.D16-VZ31&19W90LB$G<3*!\RK7J]?._PRO_"_@BWLM3TSX?7L'AB2Y6SM
M_&5_+;R7$F^411R%"WFI$SL ,  !@=H&37T10!SOC;Q@O@W3K*?[%)?SWM_;
MZ?!!&ZIF25PH)9C@ <GWP .36)X DM?!NI+\/DD^TS6%A_:$=SN&7CDGD!#K
MCY"&Z<G(!/&,54_:"\2?\(Q\+M3N6T6QUV&5HX);?5 3:(K-_K)< _*"!Z?,
M5Y'6N<^ >M>%?[7O-+\(Z=I*6TFE6>HZA=:2&<0W+@CR)92S;B!DJN05&[(Y
MS0![77EWQJ\207-FW@U-$U_6;W4;879_L2VAD,,4<R?,QEEC7EL# )/.:]1K
MYU_:6B-]XPTA;;23J-WINC7FI-')KUSIJW,*LF^.-8!OED4#?@$8'KD"@#U_
MX<^.+CQYI-]>W.A7GAZ2VOIK,6=^RF;"8PS!<J"<] 6''4UU=>0_LPV]M;_#
M[4/LMQ:7"OK-XS?8;Z:]A4[P,+/* \@P =QSUY.<@>GZ]I\^K:+?V5K?2Z9<
MW$#QQ7L !>!R"%=0>"0<'!]* /,?''Q$\-Q_$#3'D36[MO"D\DM]=:9I4MU:
M6S2V[(5FD4':520.=H.!C..:]9M[B*\MXIX)4G@E4/')&P974C(((X(([U\J
MPZ8]OXI\;>'3XU\9?\2^PFO=3U*:_L;2VO;B.*W$PVBU9HUV2Q#>3GCOC=7T
MIX)FL;CP;H,NEP/;:8]A;M:P2?>CB,:E%/N%P/PH H_$+Q]8?#?1;;5M4,<6
MFM>0VMQ<RRB-+=9&V^8<]0#C@>OM7+_!?QMX+NM/A\)>%O$EOXDET^W>YDFM
MB" K2D_-CH<OT]*T?C-INJ>(_"0TS1C)*[7]H+^.S6"2Y2V\P%VC68&,.,!@
M6' !(Y KC_@[X;\2:'\3_$*^)+C6M8N(+$6T.KZK+;>7+']ID9/)6-%8@QF,
MMG[KAASD8 /;Z\?^.'BZ*WO(/".I66J2Z;K=DTL,VC:7/?7 FAFC9EV1@C;M
MP?7K[9]@KQ/XW>(KRP\=>'M+GU;Q5IVC7=E<2K#X1L'GNI[A'3[S+&Y"*C$X
M '/)XH ]$^'WCZT^(FE7E_9V=[8QVU[+9-#J$#03;DQG=&P#+UZ$9XKJ*\7^
M%/Q@N[W5-.\*:SIGB07]S/>"SU#6](ELFDM8OFC,A9$5Y"I&=@]"0"37M% '
MF5]XOTFR\8V'B#Q,MYX4-B+_ $2W?4HMMI<K-<P[)1./E3<+-2JN5)$G?@GT
M>TO(-0MH[BUFCN;>0;DEA<,C#U!'!%?(^J>+IOAYK/B/Q%8^'O#C1KK6L0Q:
MWXDU26>ZLYXYFD>-8Q#B'?O:2*)""Z 9)9@6^JM%\.VGA^?59+,.BZC=_;)(
MLC8DABCC.P ?*#Y88^K,Y[T 2>(M<MO#/A_4]8O!(;/3[66[F\I-[[(T+MM7
MN< X%>5^#?'UW#XZ: >!O$^FP>+M6-S+?:Q';Q0VOEZ:JJ!Y4LC,6%DO#!?]
M8>> #Z-X^9U\"^(VCM)-0D&FW)6TBN/L[SGRFPBRX_=EN@;MG/:OG+X>^$?[
M ^*WPZ6;2;72H[=KI(YE\9W&L37,PLI57,3*L:#9YS$JHYQ@J!L< ^JZ\D\=
M?$R+6K7Q7X27P=XQNOW4VF3WEAIL<D0\R+ ="91N&UPPKUNO)/C7;ZAK&H^'
M(M*LO%NKJ#=B:'PIJXTY P$?^OF,B $<[5+<G=QQ0!T/PK\;/XJM=1L&T'5-
M"716ALU&KQ"*:<&%&W[ 2 .<?>/3MTKNJ\O^ OA+4_"6DZ^E_I5_H\-[J;7E
MO;ZKJ@U"[.Z./S'ED5G7)D#D88\8SSDGU"@#QCQO\1],OOB%;Z'J6FZQ:6_A
MK6K*<ZQ;6PFLS)- 5C25L@Q@M< 9 ;H"< UV/P[^*%K\0 56SDL)9+2+4;>.
M20.9+61Y$1SCHVZ)PR\X^7DYK@?B8VB7/B[6ROPR\7>)]5M8XO,N=*N#;65S
M*(M\).+E-SIO $OELZ$?*<J*['X/^$- TW0['Q%HUG<V7]J:7:1QVMU=FZ%I
M BLZPQN23C=*Y)R=Q.?3 !Z'7C=G\4/"U]\2CX@C_MH6'V?^P_[6?2Y5TSS/
MM'7[1C'^L^3<?ESWKV2OCK3!;Z]X<\7/>>*O%EAX;T_7(A!8QW5E"DD,]T2F
MR(V\F65P3L+#=CD+TH ^Q:XCXG?%"'X96^F33Z-JFK+>W<5K_P 2ZTDGV;W"
MY.Q6.[GA<?,> <U>^'G@NZ\#Z3>V5WK]]XCDGO9;M;S40OG!7QA&*X4XQU 4
M<_=%4?C%>:AI_@>>XTZ^-A+'<V[RM'<10320"93-'%)(0BR-&&"[C@GC(SD
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MO7HE>'_M"WDMOXP^'45IJ6L:5=W-Y):R7.CM!&ZV\T]K;,2\J/TEGMSL"G<
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MDD)P ?ND@9]2_9RAAM_@SX>2WECGC_TAM\,SS)DW$I8"1P&< DC<>N,Y.<D
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M!KR/]HJU^W:]X+MX='@UR_E%^(+'4-1>TL[G$2.T+JB,9G;8-D9PIVL3D#@
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MMP#3_A'\/O,\47&M67C37[]-'UN]@U"QOYX+B"\N##L\P/%%$<@.F=P8 H5
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MH%E9@@PH&[.,#TQ0!R_PI;X:Z)>76A^!VT5+^2!+V\BT>87 *@[%+S#.<'(
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MSTZRB$%G:0I;P1 DA(T4*JY//  ZT >3?%CX4Z?)JE_XR'C;4?"$DD2)>?\
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M)ZG%^+FJ:]!INAZ-X;O8]+U;Q!J:Z:FHO$)3:1^1-/+*JDX+B.!]H/&2*W/
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M_+ECB,\#G'T-63J'A72=4U[2]:NK*.75=+\S['=9(>(2(4<<'D$$\'([]>:
M-:O$]>D^,'AO7M0:";0M3\/R7DMS97<FE3WMS:1NQQ&Z1SQL=JG:/+1R1G->
MV5X3XG^'/Q,^(7B#56UK5K.'PJMU)%9Z#;7DMFL]N&PKW$D*F1]Z@$KO4#)^
M4=* .F^!UUJVH+XGN]1U30M4MI[]7MF\/Q>3!&?)02JT19G23>#N#G=GTZ5W
M7BVZU&Q\*ZU<Z1#]HU:&RFDLX=N[?,(V,:X[Y; Q7*_"7POJO@^/6M-O-&T7
M1-*CGB_LV#0T"Q-'Y*;V;@,6W[LEQD^_6O0* /GV3P=KWB'4I-;UWX&^#]7U
MB^2%KJ[U+6UGD)2-4&U9+1O+P /E4@>N3S7L_@G6+;Q!X0T?4;.Q?3+6XM8W
MBLI(PA@7:,)M'  Z<<8%;=% '%?$#X7VOQ#U+0KJYU34],_LIYG4Z3=R6LK^
M8@7'FQL&4#'0=:S;+X1W'AO5M,O]$\4^(I&ANE-W#K6M7-]#-;X8.@CD9@&.
M1AN,8ZUZ/10 5Y5\:_%G@,VUOX>\3>(+R"\\Y+I=)T*:4W]QM!(C*0 RA&SV
MVY_O#!KU6L#6/ VC:UJ']HRVAMM5V>6-2LI&M[G;V4R(0S+_ ++$K[4 >2?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** *VI?\@^Z_P"N3?R-6:K:E_R#[K_KDW\C5F@"M=?Z^S_ZZG_T!JLU
M6NO]?9_]=3_Z U6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDUIQ_!KPDNF>(].DT^XNK+Q#,MQJ4-WJ-S.)91C$B[Y#Y;C:F&3:1Y:<_(N
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MT)O_ )2[K_XNC_A;'Q._Z$W_ ,I=U_\ %U[Q10!X/_PMCXG?]";_ .4NZ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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B\@^Z_P"N3?R-6:I7"W=Q;RQ>5"N]2N?-)QD8_NU=H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>sdgr-20241231_g2.jpg
<TEXT>
begin 644 sdgr-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"6OQ0^#^F>/?$FKZIK/PR&FW=YX9TG0_%^G7OC=;O0["_E6:[-W<?N]\1O\
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M[X92Z-/X"LM+U71=8T[Q-I\WAF?P_H\VGZE::W#JAELEDN+V=Y;@R^2^+/\
M@E?_ ,$^O'7QXTG]IGQA^R]X!\1?&O2-5\*>(5\7:G=>*KBTUGQ3X%LH=/\
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MWQCT'4_VA?&?C;Q!8>&IM1TCPO&A\"V-W?Q:7X;\2?:+9[']POA5_P $G?\
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MU/\ X( ^%O["T_P_X6_;.^-WAW3?A]^V5X^_;0^ FFZG\-/@'X]\/_"3QO\
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MT^.6YB+*X /P2_:6_:B_;6^$'_!<'2/#/[2/[:OQ<_8B^ 9\96>C?LM_VO\
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MXG\2WUWI&FZI>T ?MW+JFF016,\VHV$,&ISVUMILTMY;QQ:A<WB&2TM[&1Y
MEW/=1JSVT5N9))T4M$K $U)]OL1?#2S>VG]I&T:_&G?:8?MQL5F6W:]%IO\
MM!M%N&6!KD1^2)F6(OO(4_R5:O:?"FU\)^.IOC=H9G_9EU[X$?\ !0:P_P""
M:=AK'AW7[G2(?%NL_M,^(;WX4V7P+TV2P>_T7XF:UX-/@"[_ &:UT:"Q\6GX
M=PPCX;-%H%O=QQ>Z?#FSU2+X\?#_ $KXEV,LW_!2M?V_?@=K^M:I+IE[+\2V
M_9*@_9_\ V?Q OK77XK8O_PSR/!\?CO1-9@AOCX&'Q:DO+2[@7Q]/; @']-E
M%4-0FU*&)&TRQM;^8R /'=7[Z>B1[22ZRI8WY=MP $?E*""3O&,'(^W>+/\
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M_P!"EXF_+0/_ )?T =-17,_\)#>_]"EXF_+0/_E_1_PD-[_T*7B;\M _^7]
M'345S/\ PD-[_P!"EXF_+0/_ )?T?\)#>_\ 0I>)ORT#_P"7] '345S/_"0W
MO_0I>)ORT#_Y?T?\)#>_]"EXF_+0/_E_0!TU%<S_ ,)#>_\ 0I>)ORT#_P"7
M]'_"0WO_ $*7B;\M _\ E_0!TU%<S_PD-[_T*7B;\M _^7]'_"0WO_0I>)OR
MT#_Y?T =-17,_P#"0WO_ $*7B;\M _\ E_1_PD-[_P!"EXF_+0/_ )?T =-1
M7,_\)#>_]"EXF_+0/_E_1_PD-[_T*7B;\M _^7] '345S/\ PD-[_P!"EXF_
M+0/_ )?T?\)#>_\ 0I>)ORT#_P"7] '345S/_"0WO_0I>)ORT#_Y?T?\)#>_
M]"EXF_+0/_E_0!TU%<S_ ,)#>_\ 0I>)ORT#_P"7]'_"0WO_ $*7B;\M _\
ME_0!TU%<S_PD-[_T*7B;\M _^7]'_"0WO_0I>)ORT#_Y?T =-17,_P#"0WO_
M $*7B;\M _\ E_1_PD-[_P!"EXF_+0/_ )?T =-17,_\)#>_]"EXF_+0/_E_
M1_PD-[_T*7B;\M _^7] '345S/\ PD-[_P!"EXF_+0/_ )?T?\)#>_\ 0I>)
MORT#_P"7] '35\,_MX_$CX]?##X;>'/$/P376K*P7Q*D?Q'\3>#_  ;X?^(O
MCKPQX=>)(-,O?#_@7Q)>06>N65UKES:6?B"2QT_7M<LK&6+^R=&FFN'NK/[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2T#:!<"UM5D=A;VPN+BXG$$02(33S2A=\KLWFO\ P<R?\F._"/\ [.F\(?\
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M8?\ Z\\)_GA3^:^OHW]CK_D[O]E/_LY7X#_^K4\*5\Y5]&_L=?\ )W?[*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS'^)N39KF>899A,LJY=F4,%"G@ZM:K3J4YX:G6YY>WO)34I26CY7&VB:;?\
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MQG_SZ^&/_ _5?_E;1YGC/_GU\,?^!^J__*VNGHH YCS/&?\ SZ^&/_ _5?\
MY6T>9XS_ .?7PQ_X'ZK_ /*VNGHH YCS/&?_ #Z^&/\ P/U7_P"5M'F>,_\
MGU\,?^!^J_\ RMKIZ* .8\SQG_SZ^&/_  /U7_Y6T>9XS_Y]?#'_ ('ZK_\
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M5_P;SMXB'_!.70AI<&BR6W_"Y/BS\U_=7T,^_P#M33MP*6]G/'M!^Z0^2,9
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M+_E(?AS_ *_\#_\ J?2/[A\$?^3"YW_UZXO_ /4&9_F=T445_H.?P ?WF_\
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M?P1P_P#\C[)/^QOEO_J;1/\ 4J7H/H/Y4M(O0?0?RI:_Q</]B0HHHH ****
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MAEB)XC#8F%+_ #,_^"GW_*1#]LW_ +."^('_ *<S7PG7W9_P4^_Y2(?MF_\
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M_P"#D?\ Y2#>&_\ LVOX;_\ J:?%&OP!K^@O!K_DUG G_9.X'_TEGX)XQ_\
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MY/WB?^OG%_Y8H_T-\<O^3%8?_KSPG^>%/YKZ^C?V.O\ D[O]E/\ [.5^ _\
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MZ<S7PG7^NW!W_)(<*?\ 9-9#_P"JK"'^4'&7_)7<4?\ 909Q_P"K#$'[W_\
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M2#_"_CE_RD/PY_U_X'_]3Z1_</@C_P F%SO_ *]<7_\ J#,_S6****_T'/X
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M\1?^ GA+_P"9>@#I**YO^P]4_P"AQ\1?^ GA+_YEZ/[#U3_H<?$7_@)X2_\
MF7H Z2BN;_L/5/\ H<?$7_@)X2_^9>C^P]4_Z''Q%_X">$O_ )EZ .DHKF_[
M#U3_ *''Q%_X">$O_F7H_L/5/^AQ\1?^ GA+_P"9>@#I**YO^P]4_P"AQ\1?
M^ GA+_YEZ/[#U3_H<?$7_@)X2_\ F7H Z2BN;_L/5/\ H<?$7_@)X2_^9>C^
MP]4_Z''Q%_X">$O_ )EZ .DHKF_[#U3_ *''Q%_X">$O_F7H_L/5/^AQ\1?^
M GA+_P"9>@#I**YO^P]4_P"AQ\1?^ GA+_YEZ/[#U3_H<?$7_@)X2_\ F7H
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MVOK.*299;F!'\X_X)R?'OQY^T_\ L3?L_?'?XGMI#^/OB#X5U2]\33:%I_\
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MSI?CK_ZLGQ'7QM7V3_P44_Y/Z_;3_P"SI?CK_P"K)\1U\;5_;_"G_)+<-?\
M8@R?_P!5V&/XKXJ_Y*?B+_L>9M_ZGUS^AK_@VD_Y/S^)'_9K/CS_ -6?\&J_
MJJ_X*C?\H[/VR_\ LW_XA?\ IFFK^57_ (-I/^3\_B1_V:SX\_\ 5G_!JOZJ
MO^"HW_*.S]LO_LW_ .(7_IFFK^%_'+_E(?AS_K_P/_ZGTC^X?!'_ ),+G?\
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M8?\ Z\\)_GA3^:^OHW]CK_D[O]E/_LY7X#_^K4\*5\Y5]&_L=?\ )W?[*?\
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M_P#]2'4JX^O]'\)_NF%_[!Z/_IN)_G?C?]\Q?_837_\ 3LS^JS_@US_Y'_\
M;*_[$_X)?^GKXFU_0%_P5A_Y1O\ [9'_ &1'Q1_[:U_/[_P:Y_\ (_\ [97_
M &)_P2_]/7Q-K^@+_@K#_P HW_VR/^R(^*/_ &UK_.SQ;_Y27H_]E#X?_P#J
M#P\?Z#^$_P#RCM4_[$/&W_J3G1_FHT445_HV?YWG]\G_  ;L?\HW]"_[+-\6
MO_3IIU?NI7X5_P#!NQ_RC?T+_LLWQ:_].FG5^ZE?Y&^+W_)T./?^RHS?_P!2
MJA_K#X5?\FWX(_[)K*O_ %%IA1117YR??A1110 4444 %%%% !1110 4444
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M_1K_ (E3\+O^?O%'SS?"WZ=LL2[]/EIK_GQ+Z4?B2I22H<-V4FE_PFXC9/\
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M?$Y_H?XB_P#*,]/_ +)#@'_U,X;/Y$ZE@_U\/_76/_T-:BJ6#_7P_P#76/\
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M_P#JXS@*_P!"/_@@5_RB^^!G_8S_ !J_]7)XWK_/<K_0C_X(%?\ *+[X&?\
M8S_&K_U<GC>NSZ6G_)M,L_[+'*__ %4Y\<?T5/\ DXN9_P#9(YC_ .K7)#X3
M_P"#H#_D@O[+?_98_%O_ *@TM?QD5_9O_P '0'_)!?V6_P#LL?BW_P!0:6OX
MR*^C^C/_ ,FAR'_L.SW_ -7&,/GOI(_\G8SK_L R3_U5X8AN/^/>?_KC+_Z
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M0?0?RI:1>@^@_E2U_BX?[$A1110 4444 %%%% !1110 4444 %%%% !1110
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M5.=?^IU8_33_ ((V?\I-_P!D;_L>O$G_ *K3QQ7^D)7^;W_P1L_Y2;_LC?\
M8]>)/_5:>.*_TA*_C3Z7?_)><._]DC0_]7.<']@?10_Y(///^RKQ/_JIR@_S
M,_\ @I]_RD0_;-_[."^('_IS-?"=?=G_  4^_P"4B'[9O_9P7Q _].9KX3K^
MY^#O^20X4_[)K(?_ %580_B3C+_DKN*/^R@SC_U88@_>_P#X-PO^4B&H_P#9
MNWQ._P#4D^'5?WDU_!M_P;A?\I$-1_[-V^)W_J2?#JO[R:_S[^E3_P G3?\
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MZVL(9)!$DMU*D*/(06"*SD L54G YP">U>'_ !Z\8^%9?@7\:8XO$&E22/\
M";XCJB)>0LS,?!VL@*H#9))Z =:[LL_Y&67_ /8=A/\ U(IG%F7_ "+L?_V!
M8K_TQ4/\L&#_ %$/_7*/_P! 6I:B@_U,/_7*/_T 5+7^U1_C=/XY?XI?FS^S
MG_@U_P#^2!?M1_\ 99_"O_J!VM?='_!??_E&!\;_ /L:?@O_ .K>\&5\!?\
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MI8?\EUD'_9)X?_U<9P%?Z$?_  0*_P"47WP,_P"QG^-7_JY/&]?Y[E?Z _\
MP07\2^']-_X)C? ZTU#6=.L[F/Q-\:"\%Q=112H'^,/C:1"R,P(W(ZNO'*L"
M.M=GTM/^3:99_P!ECE?_ *J<^./Z*G_)Q<S_ .R1S'_U:Y(?%_\ P= ?\D%_
M9;_[+'XM_P#4&EK^,BO[(O\ @YPUS1]7^ _[+Z:9J=E?O%\8?%KR+:SQS,B_
M\(.Z[F"$D#+*,GC) [U_&[7T?T9_^30Y#_V'9[_ZN,8?/?21_P"3L9U_V 9)
M_P"JO#$-Q_Q[S_\ 7&7_ - :O]6;X"_\D-^#/_9*?AY_ZB.D5_E,W'_'O/\
M]<9?_0&K_5"^!/C#PM%\$/@Y%+X@TJ.2/X5_#U71KR$,K#PEI *L"V00>HK\
MM^F)_P BW@+_ +#N(?\ U'R@_3_HC_[[QM_V"Y+_ .GLP_R9_&#_ ,'(_P#R
MD&\-_P#9M?PW_P#4T^*-?@#7[X_\''&I6&J?M_\ ANYTZ\M[VW'[-WPXB,UM
M*LL8D7QE\3V9"R$C<%=&(SD!@>]?@=7]!>#7_)K.!/\ LG<#_P"DL_!/&/\
MY.CQO_V/<3_Z33/M[_@FE_RD(_8O_P"SCOA=_P"I):5_IM5_F/\ _!-F>&U_
MX* _L:7-S*D%O!^T7\,))II6"1Q1KXCM"SNQP%51U)X%?Z7/_":>$O\ H8M(
M_P# V'_XJOY-^E]_R5O"G_9.U_\ U9X@_J?Z)O\ R2G$W_8^H_\ J!2/\S?_
M (**?\G]?MI_]G2_'7_U9/B.OC:OL3_@H9/#=?MZ?MG7-M*D]O/^U#\<IH9H
MF#QRQ2?$?Q$\<B..&1U(96&00002*^.Z_M_A3_DE^&_^Q!D__JNPQ_%?%7_)
M3\1?]CS-O_4^N?T-?\&TG_)^?Q(_[-9\>?\ JS_@U7]57_!4;_E'9^V7_P!F
M_P#Q"_\ 3--7\H__  ;::GI^E?MV?$>YU*]MK&!OV7?'<2S74JPQM*WQ-^#C
MB,,Y +E(W8+U(1CVK^IC_@I[XK\-7G_!//\ ;'MK37-,N+B;X!?$".*&&[B>
M21WTB1$1$5B69F95  R20*_A?QR_Y2'X<_Z_\#_^I](_N'P1_P"3"YW_ ->N
M+_\ U!F?YK=%%%?Z#G\ ']YO_!N-_P HZS_V7GXJ?^B_#5>??\',G_)COPC_
M .SIO"'_ *JGXR5U'_!NMXBT+2O^">7V;4M6L+&X/QV^*4@AN;B.*0HT?AHJ
M^UR#M;L>AKS_ /X.5/$&AZM^Q%\)H-,U6QOIT_:B\(RO%:W$<TBQ+\*_C"C2
M%4)(0-(BECQEU'>O\Y,%_P I52_[.#C?_=@_T0Q__*,D?^R%P/\ Z5AS^(NF
MO]QO]UOY&G4U_NM_NG^1K_1Q;KU7YG^>$=UZK\S_ %$?V%?^3)/V/?\ LUSX
M _\ JJ?"=?R@?\'.7_)V_P  ?^S<X_\ U9GCFOZG?V&_%WA>W_8J_9"MY]>T
MN&>#]F#X"0S127D*R12Q_"OPJDD;J6RKHZE64\@@@U_*G_P<Q:IIVJ_M9? .
M?3;VVOH4_9VCC>6UE29%?_A9?CD[&9"0&QS@\XYZ5_G%X"?\G[Q/_7SB_P#+
M%'^AOCE_R8K#_P#7GA/\\*?S?5]&_L=?\G=_LI_]G*_ ?_U:GA2OG*OHG]D"
M6.#]K?\ 98FFD6*&']I'X%2RRN0J1QQ_%+PJ[R.QX544%F)X !-?Z#Y[_P B
M/.?^Q5F/_J)6/X(X?_Y'V2?]C?+?_4VB?ZER]!]!_*EKF/\ A-/"0&#XBT@8
M&#_IL/&.O\5=#;W$%U!%<VTL<]O.BR0S1,'CDC<95T89#*PY!!P17^+A_L23
M4444 %%%?.O[6_Q[C_9>_9H^-G[0!T)/%%U\+/ &M^)]'\,2W5Y80^)?$<4*
MVGACP]<7^G:9K6H6-MK?B*[TO3+F]L='U:\M(+J2XMM-OIHTM90#Z*HK\AO
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MK/B[Q7J7A/PAI7B:0W'BFW^'VA7.LO9>")-?O=EY/=>'(]/N].>*.#19]-M
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M ?'_ .#!))P !\2?#.22> !W-?ZGGVJV_P"?B#_O]'_\57\V_3#_ .1QP/\
M]BW.O_4K ']%?1(_Y$O&?_8TRK_U$Q1_G[?\' O_ "DV^*7_ &3WX._^H-85
M^*]?M-_P<!.DG_!33XI,CJZ_\*]^#PW(P89'@:PR,@D<5^+-?U?X4_\ )L^
M/^R0X?\ _59AC^6O%7_DY7'7_94YU_ZG5C]-/^"-G_*3?]D;_L>O$G_JM/'%
M?Z0E?YO/_!&YE3_@IM^R.SLJJ/'7B3+,0JC_ (MKXW'). .?6O\ 1_\ M5M_
MS\0?]_H__BJ_C3Z7?_)><._]DC0_]7.<']@?10_Y(///^RKQ/_JIRD_S.O\
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MS)?^":7_ "D(_8O_ .SCOA=_ZDEI7^FU7\F_2^_Y*WA3_LG:_P#ZL\0?U/\
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M:!_X)]._^1J/^$4\+?\ 0M:!_P""?3O_ )&K_/\ ?^'^_P#P4_\ ^BU>#O\
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MOP9[I^RZB2_M-_LX1R(DD<GQ^^#,<D<BJ\<D;_$CPTKHZ,"KHZDJZ,"K*2K
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MI50_UA\*O^3;\$?]DUE7_J+3"BBBOSD^_"BBB@ HHHH **** "BBB@ HHHH
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M4\!U_G'5\)]$7_DW_$'_ &6.+_\ 5)D9]S]+#_DNN'_^R3P__JXS@*_T(_\
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M ,$TO^4A'[%__9QWPN_]22TK_3:K^3?I??\ )6\*?]D[7_\ 5GB#^I_HF_\
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MCRBOZ@_^#7W_ )+I^U7_ -DF\ ?^IAJU?R^5_4'_ ,&OO_)=/VJ_^R3> /\
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MQ)_V5=3_ -5&5GV/TLO^2RX;_P"R97_JUQX5_?W_ ,&]7_*-+P%_V4_XP_\
MJ975?P"5_?W_ ,&]7_*-+P%_V4_XP_\ J975>O\ 2P_Y-C@_^RLRK_U7YP>3
M]%C_ )./C?\ LE\Q_P#4[*SG_P#@XN_Y1QZA_P!EO^$__I1KE?P25_>W_P '
M%W_*./4/^RW_  G_ /2C7*_@DK;Z*G_)K:G_ &5&<?\ J+EAE]*/_DY5'_LG
M,L_]2,<%?Z6W_!*C_E''^QK_ -D)\&?^DKU_FDU_I;?\$J/^4<?[&O\ V0GP
M9_Z2O7SOTO?^2-X7_P"RFE_ZJL:>_P#1,_Y*WBC_ +)VG_ZL\*?C1_P=#_\
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M[)/_ &)OBO\ ]6=XXK\=_P#@Z4_Y!/[$7_82_:(_])/@I7^<?AS_ ,I25_\
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M_)=</_\ 9)X?_P!7&<!7^A'_ ,$"O^47WP,_[&?XU?\ JY/&]?Y[E?Z$?_!
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M(1^Q?_V<=\+O_4DM*_TVJ_S)?^":7_*0C]B__LX[X7?^I):5_IM5_)OTOO\
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M=?W/P=_R2'"G_9-9#_ZJL(?Q)QE_R5W%'_909Q_ZL,0?O?\ \&X7_*1#4?\
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MBW%72:;5[-;F5>E&O1K4)N2A6I5*4W%I24:D'"3BVFE)*3LVFD]T]C^!6/\
MX(6_\%2TCC1OV8CE$13CXP? @C*J <'_ (6<,C(X.!QVI_\ PXO_ ."I7_1L
M+?\ AX/@1_\ /.K^M9?^"I.O:WX5GOO 7[,FI>,_&_P_\&?M ?$;X_>$8/B]
MX;L='\!>"OV;?BGK/PA\<7GPX\<)X9U#3?C%J_BKQ5X9\3R_"W3UT_P)IGB?
M2_#NJ2>(M?\ !>HQQ:;+]&:=^W1X?\0?M*_"CX ^&OA#\5=2\-_%CX!>+/CW
MX?\ CE>Z1;:-\.]8T_P_I/PXU^Q\&^"8KN9]:\=>)KW1?B1IM[K4VF6EKH/A
MFXCAT>XU>_URYN=-TW^H?^)N/$;_ *$G!7_AOSS_ .B+U_#MK_-3^BGX>-MO
M-^,;MM_\C#)NO_= /RU_X(P?L]?M9?\ !/WX6_&GP;\=?V4?BM?:Q\0OB'HO
MBG0F^'WC#]G?Q+91Z7IWAB#1YUU&XO?CEH;VUVUW&YC@2&=&@"R&8,Q1?I?_
M (*C>&/VA_VROV,/B3^S_P#"3]DSXW6GCOQ;K7P[U'29_&?B+]G+0_#RP>%?
M'WAWQ-J:WFIVOQ\U6>WD;3-+NQ:*EA,)KOR8',22-,GU-^RI^VQJW[0WQ7^*
M/P8\8_!Q?A+X\^&G@7X>?$C5M"LOBAX9^*.I>%-$^)M_XHM/#O@?XS6OAO3=
M-7X1_'&TM/#,FLZY\+[BX\46UKI&H6U[IGB_6$ANQ!T_[6O[3_Q+_9RTO5?$
M?@W]GF]^*W@[P-\+?'7QF^*WCK6OB5HOPH\&>$/!G@*."XOM!T76]6T#Q,OB
MGXH:U8_VEJ/A_P (W=OX8\//8:3<SZ[XZT$W&GI=_BF/\0<YS'Q I^(]?#99
M'.Z><Y9G<<+2HXJ.5_6LJ^J?5Z;HSQD\7]7G]3I>VC]=]I+FJ<E6G>/+^R8'
M@/*,OX%GX?4<1F,LFGE.89,\35K89YFL+F/UGVTU6AA(87V\/K53V4G@W37+
M#GI3M+F_B#_X<7_\%2O^C86_\/!\"/\ YYU'_#B__@J5_P!&PM_X>#X$?_/.
MK^QKPY_P4;MO%/Q'\-V^F_!/7[?]GWQ%\;O!G[,W_"[-6\7Z=IOB73/CMXZ^
M'>C>/-(\/W_P=DT2348O!]IJ7B#2/AIK7BQ_&*:MIWQ&GN-.7P;<^'[*X\2K
MZ+\)OV\?!OQ"O_VO+CQM\.?B#\!?!O[(VL:%:>(/$GQBL[;P[JOBWP[K'@A/
M&O\ PFVG^#87N];T'0;J O;>&K'6S%XH\1Q&UO!X?TU]0LK*;]K_ .)N/$?_
M *$G!7_AOSS_ .B'U_I:_C7_ !*EX=_]#?C'_P .&3?_ #@/!/\ @G=%\>?V
M5OV,/@3^S_\ $W]DKX[7/CKX:^']<TOQ#/X5U[]G'6/#\ESJ/C+Q)K]N=,U*
MY^/^FSW<(L=7M5D>2QMRMP)HPC*@=_@#_@M9^RY^V#_P4)L?V;[;X#?LI?$V
MQD^$UY\69_%)^(?C7]GGPRLJ>-X/AS'HW]D&Q^-VN_;61O"FJ?;A*+7[.&M"
MAF\YA%^Y/['W[2:_M:? O1_C8OPY\3_"=M6\9_%?PA+X!\:7-I/XLT*;X7_%
M+QA\,YO^$ACLHTMM-U;49?"3ZI>Z(CW+Z%->MH\U[?364EU+XW\5OVV?&'P;
M^+NBZ!XZ_9XUK0O@+KOQF\/_  &TOXV:IX_T>R\3Z]XS\0>"+GQI_P )5X3^
M#7]@S:AXB^$>ABSO]'\0^-%\9V/B"PFT3Q+KEOX%OO"F@W6O-^*9+X@YSD7'
MT_$7"87+*N=3S3.<V>%Q%'%3ROZQGE+'TL7!4:6,I8I4:<<QK/#Q>-<X2A2=
M6I649J?[+G7 >3Y[P-'@#%XC,:>31RW*,K6)P];#0S)X?):N!JX6;K5,)5PW
MMJDL!16(E]4Y)1E4]G3I-Q</XM?^'%__  5*_P"C86_\/!\"/_GG4^/_ ((8
M_P#!4E)(W/[,+85T8_\ %X/@1G"L"<?\7.ZX'%?V-?!__@HCJ?CZ..\\:?LU
M_$3PC;>.?V=(_P!J_P#9_P!&\#ZU8?%_Q[\8/@S-KWA_0H[6Y\%Z+I6@S>#/
MBHA\;_#_ %.[\##5/$^A66F>,+>>?QXLFB^(8M+\>\9_\%<-+\-_L^_LD_&<
M?"#PYX3\0_M63_$Z:V\"?&[XWV?PRTWX8Z/\);?6)/%]UXO\;^&/AU\58K_4
MM/NK+2].N;#0?#=[IMK<ZK-=3Z\-'TJXU27]J_XFX\1_^A)P5_X;L\_^B+U_
MI:_C2^BGX>)IK..,;IW7_"ADVZ_[H!]YVOQX\?P6UO ?V1/VEB88(HB?M?[-
M0R8XU0G'_#1QQDC.,G'J:_D4_P""@/\ P2H_X*)?M/?MD?'GX^?#;]ESQ#;^
M!OB9XITW6_#L/BCXG? '2/$$=I:^%/#VBS+J>FV_Q<U*"TG^VZ7=%$COK@/;
MF&4LK2&-/[5?!'BMO%GP_P#"GC>5-"F;Q%X2T;Q.\?@CQ)%X]\-RG5-)M]3*
M>$_%MGIVDP^,-'D\[&B:]:Z5IT>NV;6U]#8VJW*P)^9^O?\ !3'QE\.]1G\.
M?&#]D[Q1X \<^,/AUX4^(?P,^'T'Q3\+>(_%_BW_ (3_ .,_@OX$^!_!?Q?L
M8]#TJR^!7C/6?&WQ$\*27$$FH?$'PW9Z1#XQ:U\3:GK7@K5M#;\<\.?$G//#
M'-\;G60X3*L7BL?ET\LK4\VH8NO0C0GBL-BY3IQP>-P-15O:86G%2G5G!0E-
M.FY.,H_KOB!X=9)XD93@\FSS$YIA<+@L?#,*4\KKX6A7E6IX?$890J2Q6#QM
M-TG#$3DXQI0GSQ@U-14HR_D6_P"'%_\ P5*_Z-A;_P /!\"/_GG5^BW_  2M
M_P"";G[??[%O[8_A#X^?%_\ 98\77?@?0O"'C[0;V#P5\1_V?]>U]K[Q/H+Z
M;IK0:;=_&'2(9+=;ALW4IO4:&/YECD)VU^]'Q$_X*7WWPE^ 7QF^)GC7]F+X
MDZK\5OV?OBK+\)/BQ\(/AAKNF>.]!\+:C_PB_A7XA6OCZ]^+5YI?A72;#X3W
M7PW\:>'_ !2GBC7?#&B^()+VXF\(V7@V^\3I;Z?=]-X]_P""B^A>&/VM+;]E
MGPQX'\)^*]2TGQ=\+? OCF[U;X\_#GX?_$.+Q)\5-&TOQ5;Q?"CX0>*1%J_Q
M>L/ ?@SQ#X<\8_$6>U\0>%KZRT;5GMO!>F>.O$&F:CH<'Z7Q#])WCSB7(LWX
M?QV4<)4L'G678O+,55PN!SB&)IT,90E0JSH3JY[7I1JQA.3IRJ4:L%*SE":3
M3_.N'_HV\#<-YYE.?X'-.*JN,R?'X;,<-3Q6.RJIAIUL+5C5IPKPI9+1J2I2
ME%*<:=6G-Q;Y9Q=FOHJ[^._C^XM+JW7]D3]I56GMYH5)N_V:L RQL@)_XR.'
M +9/(^HK^%.3_@AC_P %26=V'[,+89V8?\7@^!'0DG_HIU?W]_&3QUXG^&WP
MY\0^+_!7PS\2_&+Q=8'2K+PY\.?"EUI^G:IXCUC7-9T_0[*.?6-6==.T'0=.
MFU%=6\4>(;M+F/0?#=AJNK+8ZC+:1V%S^?5C_P %%_B-KWB&X^"OA3]E^T\2
M_M4:3\4?BI\.]?\ AA8_';14^%5O8_!WX=?#;XF>+_%6B_'1_ #-K$0TSXP?
M#?PI:>'[OX:Z+KEE\1-=O/#?BFW\,Z=HFH>(5^&\-/%WB3PL6<KA_!9)C%GC
MR]XO^V,/CJ_L_P"S?KOL?J_U+,<!R<ZQU;VOM?:WY:7)R6GS_:^(WA1P[XG/
M)WG^,SG"?V)_:'U7^R<1@J'M/[1^I>W^L?6\OQW/R?4:7LO9^RY>:IS\]X<G
M\@__  XO_P""I7_1L+?^'@^!'_SSJ_>;_@BG^RY^V!_P3VT_]HZU^//[*7Q.
MOI/BQ??"JY\+_P#"O/&O[//B98H_!5O\08M8&K&^^-VA?8F=O%&F_8A$+H7
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M_4?&OQ#U'P[XPDT[4]>ENK?3/".DP>&+JVU.YBU:]UC6/#NC:-?:FGQ5I?\
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M)HOA[5X+^_32K";XL64-Y?M#$PM[>6\MDDD(5ID'-?V3?\+]\??]&A_M+?\
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ML)1I5IU)QP]?#^SE&LU%1<:[E=:WBEUNOX&_^&!OVYO^C-OVI?\ PP7Q3_\
MF5K]7_\ @B[\"_V@?V8/VX]!^*_QY_9P_:5^'7P]L_AG\1M"N?$NI_LZ_&S4
M+2/5M;M--BTNR-OH7@35;\R7CPS!'%H84\MO-ECRN[^IGQ3_ ,%-_P!F?P'\
M(M)^*_CU?B7X/O-3^,C?L_7/PFU+P'=ZC\7/#_Q>M/%.B>%M;\*>(= \-7FN
MZ!IUKX<;Q%H_B+6O&0\4S^ HO".HV'B*S\4WMCJ6F->>]_$G]JSX0_"SX\_
M+]FOQ)J6K7/Q:_:-NO&$?@/0M$TPZE!INF^"?">N^+M5\0^,KX7$,/AK0[RV
M\/:AI.@7%P)KK7]<BN+/2[.YATO6[O2_U3BGZ46?<4\.9WPYB.%LHPM'.\MQ
M>6U<31QN,G5H0Q5*5*56G"<>24X*5TI:-K4_,.&/HSY%PQQ#DW$.'XFS7%5L
MFS##9A3P];"82%*M/#5(U%3G.$N:,9\MG**;5[I/1$'_  UK\(/^?#XX_P#B
M+'[4'_SGJ_SU_B_^P_\ MI^(_BY\5?$6B?L@_M1:AHOB#XF>/M<T;4(OV?\
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M&V?UL_P.>YAF5:MEN(RUX?%8;#4J:AB*V&K.JIT6Y<T7ADE&UFIMO9'Y5_\
M!;#Q3=_M2?L27OPK^ ?PS_:"^(_C^7XJ_#OQ#'X:TO\ 9F_:'T^Z?1M%GU5M
M4OA<:[\,-*L!'9I<PLZ-=B9P_P"ZCD((K^03_A@;]N;_ *,V_:E_\,%\4_\
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M(M%L]-UV\BU_4_$.FW]AI.D7\6E:S=Z=];?$'QUX=^&'@7QC\1O%TU[;^%_
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M$/&6B:IX9/BR.YTKQWX&\:>&M<^WZ.MG<QW/AS6M<T:\^KOV3/V<_#_[)_P
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MVMWX#T;2-8ABU2.O\1/^"3NE_&;]G0_"_P 8^,M(^$?Q&T/X0^)O@/X"U?\
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M0?A+X;^'O@CQ OA9O$1\-63>*9K"WT.\U.*+31XS\<>-+:YD\772WD_ZP44
M>/\ Q_N/C=:_!CXCR_LVZ9X'U?X['PQ?0_"ZS^)6IW^D> U\67(2WL+[Q1>Z
M78ZCJ']E:6)9-3EM+6T>347M(].,MJETUW!^5OPW_9'_ &IO ]M\)/C/9_"K
MX?7O[2'PE^-'CKXE_$23XA?M(ZEXLU#]JNX^+OP<O?A7XV\6^)/B3HGP*T2P
M^%^O>%E3PI#\/_!FC_#S5_!.A>"?"D'@O1TT2TD@N$_;*B@#\P_"O[%7Q(\)
M_ ;]B?X9OXA\):QXL^!O[5%A^T7\7=4LY-3L?#]]<>(=4^,WC/Q[IW@A+NTD
MU"[L[#Q;\56L/#$>K1:=/=Z)8I=WRV-VS6HY3P3^Q9\2+7]KOX?_ !9N_@[^
MRO\ ![PW\)OC+^T1\6[[XR_!#^V=-^+7[1.G_&_0O&&BZ?X*^(WABY\(6)TB
M0WOB^U\;?%;5M5^(OC?3?$_CGP'X4U7PKHNBPWCIX<_6>B@#Y8_;'MOVJ-1^
M"&K:+^QVO@RV^,&O:YX?T=]?\:>(4\-IX4\$7E\/^$V\1^%+RZ\)>-])E\?V
MFBI-;>"X_$/AO5/#MIKEY;:OK-AJEEIDFCZC^=%E^Q7^TKX+\-Z1K'P1^$GP
M=\!^)O%G[-OQK_96^(7@OX@_M!^,/'[Z5<?%#QZ/B!8?M-ZI\5X/A#%K'Q6\
M9:GXHU;QGXB^*7A/5/#GAK4_$VI:Y9OIOBZW%HT2_M]10!^>>J?L8ZK_ ,)3
M^R)HFFZ];3_#/X _LH?'']FSQ-J4\TMGXIU%?'_@CX+^!_#>M:38QQ7%J918
M_#O5[K4FFOHVLYYK!(?M2O(T?@W_  3O_8*^)G[*7COPUJ/B#PI\&/AMX:^'
M/[,6B?LX:M<?!WQ-XIUR_P#VIO%GA[Q)X>OM$_:&^*^F:]X8\/1^'/$^A^&_
M#UWI6C:=>ZGX]\1VUS\0?&FE/XO/AG2?#\-[^PM% 'P7^WIX1_:[^(O@[P/\
M/?V8['PZ_A+Q3X@U*W_:&OG^+-W\&_B3<_#2+2F6'P=\+?'$'P_^(D?A74_&
MFJ3C3O$WC&#2(O$7ASPQ!?CP==:=XEU*PU_0_CO6_P!@OXZW^F>-OA=X%^'_
M ,$OA1\#?VFM*_9&'Q,\/6'Q&\0ZIJG[,\7[,[>%M'\0>"_AQ8VOPYLK#XNZ
M5XQ\!^!?"VA^$-;O=2^',OAOQ$VMZQKFG:G:O;+<?MQ10!\GV_P<\<Z;^V!\
M3_V@[*709_#7B;]ESX9_"/PYIT]Y=)J7_";>"?B/\8?&5[)J4"VIAM]"N;3Q
MUHD45Y#<RW+W":@K6J"*)YKO[&'P-UK]G;]FSX:?#7QA>6.K_$M;#4_&7QD\
M2:?/+=V_BSXT_$76M1\=_%GQ.E_<06UW?PZQX\\0Z[<6-S=P13C3/L-OY4,4
M$<,?U'10!^8_[>'PL_:U^-WC#P#\/O ?PZ\ _$G]D@:%>:O\;_AYJ7QRO_@K
MXJ^,GBV+5X#X?^'/BG6[;X6_$67_ (4A#IUM)J7C30-%ET?5/B%>75KX8UN^
MC\&0Z[I/B3A?#_[&7Q\@^+'AOPOJ%M\+=,_9V\/_ +;.M_MY6WBW3O%FNW/Q
M&AUWQ#X:U^[/P(C\!CP;9Z"+31/BEXHU/5(_B-'XT6TO? %CIND1>#;+69KC
M[+^N5% 'Y(_'O]AGXL?$_2/VQ+*R?X?>)-#^./[4W[/'QQM?A=XNUS6M'\)?
M&#X8?"#X<_!;PYXO^#/Q(U[2M!UC4?"-IXSU?X<:DUGJ6F:1XBM8C;:&-6L;
MG2KS5K)/I?\ 8,_9Z\7?LU_!KQ'X'\4:7X.\&V7B#XO?$CXC^"?A!\/-:U/Q
M-X&^!G@OQQJD&JV'PM\->)]7T7PW?>(8++5?[:\5ZKJ(\/:-I\?B+Q;K.G:+
M8KHEAITTWVO10!^6WQL^%'[77Q4_;"\):YXL^%7PW^)/[('PMU[X=^(/A9X-
M'QXO? 5PGQ#M)ENO$GQL^*W@O_A4GB=OB/KWPZN;@2_!SP$/&&B^$M,U/2AX
MMU-;GQ=-X?U7PIC?LL?L;_'CX9?$/]F_3/B=+\-8OA7^Q+\-OCC\,?A#XG\)
M>)M?UGQA\9;7XMZUX3M_#NO^,/"NI>%-%T_X<OX-^'WA.#2=?TNU\2^-SXB\
M9:A<ZGIU]8:-9P)=?K%10!^.OBK]B#XV6GPF\,VWAS1_"'B7XF^"OVR_VH_C
MYH5[H_QO^(WP#\8Z7X(^/7CWXM:SIT'@SXR>"/#'B6]T'5KC0_'.AV'Q#\+Z
M[X-\0^&_$F@1ZYIMK/9Z]9>&];M_N/\ 8G_9UG_9/_9;^$7P"O=7L]>U7P+H
MVKRZ_JNFR:M/I=SXG\7^*=>\<^*%TBYU^YN]?O-'MO$/B;4[32+W7;F;6[W3
M8+6[U9SJ$UR!]3T4 ?C%\0OV6?VLOVEOCC\<1^TG\/OAW??"?Q3X4^-WP5_9
MS\6>'/CC>2V?[.OPR^)7PUUWP)/\3H/@I-\*;0^./COXX749+/Q5XDU;XE6\
M'A7PIJDWA3P.-*T]_$TOBS&UW]GS_@I1:V'BSXJ^"-/^ /A#]H.\^"/P!_9'
MT$>'/BCK=[I>G_##X?\ BGQIXJ^+OQQT'7_%7PADT[1_B#XLE\16NF_"CP/K
MO@OQ5HW@F2-=<\6:EXH\B30;C]MJ* /PY7]B+]I+PKX5M+[X(?";X-_#W7_'
MG[+_ ,8OV2?B/X+\?_M >,OB"_A]_B+X\OO'NG?M+WOQ4A^$D6M?%SQGJGB+
MQ/X[\1?%/POK.A>&=7\5:UK>FW%EXQA^SW0'[!_#+P)!\)OA/\/?AEHL\NLV
MWPT^'GA/P)I-S>LMI/JL'@WPW8>'[">[=1<);2WT>FQ27#*LRPO*Y D"@-Z'
M10!^#]O^QY^V[\;;;XO^+_VC_ GP=L?VC_$-_P" _&/PR^+=I\<];\8?#CP1
M:?!#X^^!OC9\+OV<_!_PNMOA!X=U+P'\+O$MQX.M/^%G_$(>(O%GCOQ/XDC7
MQ%K5IKEMI_A;P]X<Z+XB_LX?\%"=3TWXHZYX.\/?##P_J7[7OQU_X3G]IGP=
MX'_:"U[P9XH\'?!CP3\&/A[\)?!7PJ^%_P :[KX.:I/%XI^(3>$+O4OB3\1-
M-\"Z!JWA?0[^YT+X?2VFNR6/C/3OV^HH ^#=;_9U\5:_H/[ %MX9\">!/@[I
M'[,OQ:T+QKXH^%V@>);C7O#W@_P?HOP!^+_PJT_PEX(UR+PWH0\1G2-1\<:!
M%:W-YHVA+/ID%_<NB7"+%/\ 6GQ4N_B38_#7QY=_!S2/"VO?%>#PGKK_  XT
M?QOJE]HG@W4/&HTZ<>'(/%.JZ99ZAJ5EX?.JFV;5I=/LYKTV*SI:A9W21.^H
MH _#KX>?LA?M>6FB>$?B_P",OAU\-;_]KKX<?M"^#OVB/%OC3Q5\?[[Q19?M
M/ZF_PL^)OP;\7>")M4T7X*:!:_ +PAX&\$?$*>W^"'A70_#/C'PUH+VL-OJ\
M+ZCJ?BCQ7K&'XG_8_P#VX8?"?@GX07?@3X1?%/X#>-/&WQJ_:'_:D^&FA_'S
M7OA*OQ(^+GQF^-WBCXFV7P5N_%%Y\'_&&K:[^SOX(T?6+6S\36=K9>$M8^,>
MJ1)8>)+?2O!+:UX6U_\ >&B@#\K/"_PH_; \5_MJVOQ;^/?P?^%_B#X/?#KQ
M!J6D_LTVGASX^WEKHWP,\*:CX4;0-9^)=W\*6^#L2_$#XW>*DNM7\/G7-2\;
MV&E>!_ VJ3>'_!5EID^I>*=2\1?9O[5#_M)_\*+\;6W[(]KX"F^/>H0:=IO@
MN^^).J2Z5X5T!+_4[2WUWQ)*T>A^(HK_ %?0]!?4;_PYI6H:5<:/?^((M-BU
MI)=)^V6\WT-10!^*?@7]D?\ :B^%L7PL^+7PL^$/PKT[XR>$?#_[2'PU^(WA
MCXJ?M(>)/'-Y\7V_:)N_A7XPU/\ :,\8?&K2?@CIU]??$2'XB?#>T?Q)X)'@
M"VTB;P5*^B^$-7\/6FD>&_#]MG^ ?V0OVN? ?CW]F/X5>,/ OPW^-/[)/[)/
M@WX#Z!\*;&'XWW_PY.J?$_P;X7TRU\:?M!_$[X=R?"GQ5+X[UWP=XB:^E^"?
MP]E\;Z;X6\.-I]OXMU%KWQI-HNJ^%?V\HH _+CX,_LO_ +12?MH:?^T]\8-&
M^!?@W7O#GPN^(7PH^(/Q'^#>M>*Y]=_:UTC5_$/AFY^$5QXW\ Z_H%I8?#'2
M_A)X?\/3W46EQ^,?'^HR^,=?U>#1M7MO#4EP^I>[?MQ:-^UWXI^%^A^#_P!D
M,>&K#7?%'BZSTWXI^)M2^('_  KCQGH'PH^PWTGB&/X3>)9_ 7Q%TO1/B+KU
MT+#1-,\4:IX;U!/".GW>IZ_I=G/X@M-(EMOM&B@#\-_%'[!GQ_/@3QMX#^#7
MPO\ @?\ "'P5^TW^R/X._9#^*O@C4_B[XM\52?L\Z5X%\5_%O[-\1O!?B6+X
M;17?QTU#Q-X(^+_B:]UG3?$8\!ZU<?$2#2]2U;Q+JMMJFOZG!VC?LR_MB_%/
MX_?$+5/C5H6@:!X%L=%^)GPA_96^*OPV^/48UW]E_P"&'B/PC=^#;?XL>&/A
M%K'P8GT_Q'^TGXXT_P"7Q'XYU[QM<P^"](U$^%_ UM8:7'XAE\5_LI10!^;W
M["/[%_Q%_9%\<_M)MKWQ7B\>?#;X@ZS\((_A5H</@_P9X4ET/0/AQ\%/ OPW
MDGU2U\)Z#I$5OJ F\-2:3#;QS7=O?:;IUEKUXQUW5-4D?](:** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#SCXL_%WX:? KP)JGQ-^+OC'
M1_ 7@+1;[P]INJ>)]=EEBTZTU#Q;XDTGPAX:LF,$4\\EUK7B;7='T6P@AADD
MGOM0MX@N&+ ^&WQ>^&GQ@M_&5W\,O&.D>,[7X>_$7QC\)/&=QHTDTT/A_P")
M/P]U$:1XV\'WLDL,2'5_#.J[M-U:* S16U]'-:M*9X)D3^;;_@Y!TC7_ !=K
MW[!'P]T?X9_&;XC67BCXO>*/''BS2/AS^VCJG[,GAS6OAO\ LX^&I_VA/B9X
M?U_PS'X@TK0+S75\.> H=;\+_&;6;2:[^%6I:;#9^&;_ $_Q3XLT1W^B/^#>
MOX;?%OX2?\$N[3QAXO\ A-\1O#'C[XU:OXR_:AT%OB9^T#<?'.\^,S_&W0=/
M^)OAGQ[8/=:KJ>H_#6+Q=%K6G:?X@\)ZQ-'XEU+Q9:>(/'OB5KC7_%U_=S '
M]!%?.'PF_:^_9E^/'Q.^+7P:^#7QJ\"_$KXF? G4O[&^+WA3PAJC:Q=> =96
M]GTV?1]=O+:%M+BU6RU&UN=/U+38+^>]TR^@EM-0@MKA&C'\B7[*W[</[07C
M;4_^";OQ%T+_ (* _&?XU_MV?M7?M=>)/@_^W?\ \$^-0USPQ_PBOP.^#UUJ
MWCW3/B-=6'P'T[PS:>,?V;A^S[H>DZ%K/A;XC:M?PCQ'<O/>WUWX@M+B2UM?
MTM_X-KO@]8?#_P"#G[>GB2U^(7Q2\8W%]_P4I_:X^'TUGX[\9/XDTQ8?ASX\
M%M:^+4M'L;=T\=^,8]7^U^/?$3S/)XEN;33+A[:V^S*' /Z3Z*_D1_98_;#N
M_'W[3]]XN_:G_P""F/Q^^"/[8L?_  4]^)O[-FB_\$ZO"]OHWBWP1J/P6TC6
MM2TCX:^!K[]G&U\(7GC#3/!'B7PS!8^)]1_:IN;R32[.ZE:XD\20-/";?Y@^
M&7_!3/XN7/P\_8-^">M?MC>*[O\ :IU#_@X#U7X,?&[X9S_$8S_%L_LW1_&C
MQAI-EX&^(?AYYSKEA\+M1TB\\-:3HD6L6UII&L@P6&CS74EC=PVH!_<;7,^&
M/&O@[QLFMR^#?%?ASQ7%X:\0ZEX1\0R^&]:T[6XM#\5:.MNVK^&]6ETVYN8]
M/U[2A=VPU/2;IHK^P>:..[@BD;;7\<GP/_;<^(W@S_@IGX4\ _&_]N#XN_M$
MWGQA_;6^*/P/\+67[)?[5GPB\8?#W1=#\3ZEXHTWP7\,OC=_P3_\9?#+1?C7
M\#/#OPELK>WA\5?&OP??:EINGZSI']H+XVUN&_1Q\9?LQ?%GQA^R;^R/\:/
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MX[ZO\/YOB%H_QRO_ /A!['4_BAH,UMKMYI?AGP]?WFFZ'X=1[U[73IY;MUB
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M]E_Q+\)/!_[07QO\!_";Q/\ '?Q2O@KX0Z+XOU5K"^\>>*&O=(TX:5HL:0S
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MP=J.OZ%\/OA6]QI?A;P[?:GIMS#H[:]=^'%\3?\ "%VND:#-<6]O:/$WB?\
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MVVGZE8-=2+<@']_-%?R]_M:^$_\ @MYJ/_!67]E?7?@-XD_91E^#EO\ #_\
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M?&/A73M&URXU[2M"T^_U'3;C4;_1I=-M_$+S  _MPHK^'G]A?]KK]NNVL_\
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M3]@[]N?]NWXQ_ML?!74O&?[5VF:!\9O&'[<WQM^%?[1?['GQ5_:?\ KI%G\
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MB\077CHOH][9#Q'JOBF^MK3PI?6OAS3M(L[6QBF8 _H9HHHH **** "BBB@
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MU/1M:US5KSP5X;N=3UG6?#DAE\/:MJM_-ICW6HZGH,I,NC7]Y+-=:7(2]C+
MW->AT4 8.G^%?#&DZUKOB32O#F@Z9XB\4G3V\3:]I^CZ?9:UXB;2;;[%I1UW
M5+:WCOM7.F69-IIYU">X-E;?N+;RXODI- \*>%O"D>J0^%O#6@>&HM;UG4/$
M>M1:!H^G:-'J_B'5G235-=U1-.MK9;_6=2>.-]0U2[$M]>.B-<3R%5(WZ* .
M _X51\+?^$5O_ O_  K7P!_PA&JWESJ.I^#O^$.\._\ "*ZEJ%Y<"[N[Z_\
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M1?![Q/'XIT+1[TZ_I&M69T34[V)8-66&UBOFMLBTO+:0ES]ET4 <CHWP_P#
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M[.WD@TF;6)IM5ETZ)DLY-2EDOGA-U(TIZVD)"@LQ 4 DDD   9))/  '))X
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MSKNYEDGG>25V<[E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZQ_X+O#7_P I*Z:B@#F?[%UK_H<=8_\ !=X:_P#E)1_8NM?]#CK'_@N\-?\
MRDKIJ* .9_L76O\ H<=8_P#!=X:_^4E']BZU_P!#CK'_ (+O#7_RDKIJ* .9
M_L76O^AQUC_P7>&O_E)1_8NM?]#CK'_@N\-?_*2NFHH YG^Q=:_Z''6/_!=X
M:_\ E)1_8NM?]#CK'_@N\-?_ "DKIJ* .9_L76O^AQUC_P %WAK_ .4E']BZ
MU_T..L?^"[PU_P#*2NFHH YG^Q=:_P"AQUC_ ,%WAK_Y24?V+K7_ $..L?\
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M=S+%U<?[1GPOF^(EI\-(/BGXLN-7OO$-CX-M?$%OX"FG^'DWCC4_#\7BK3O
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M]#CK'_@N\-?_ "DH_L76O^AQUC_P7>&O_E)7344 <S_8NM?]#CK'_@N\-?\
MRDH_L76O^AQUC_P7>&O_ )25TU% ',_V+K7_ $..L?\ @N\-?_*2C^Q=:_Z'
M'6/_  7>&O\ Y25TU% ',_V+K7_0XZQ_X+O#7_RDH_L76O\ H<=8_P#!=X:_
M^4E=-10!S/\ 8NM?]#CK'_@N\-?_ "DH_L76O^AQUC_P7>&O_E)7344 <S_8
MNM?]#CK'_@N\-?\ RDH_L76O^AQUC_P7>&O_ )25TU% ',_V+K7_ $..L?\
M@N\-?_*2C^Q=:_Z''6/_  7>&O\ Y25TU% ',_V+K7_0XZQ_X+O#7_RDH_L7
M6O\ H<=8_P#!=X:_^4E=-10!S/\ 8NM?]#CK'_@N\-?_ "DH_L76O^AQUC_P
M7>&O_E)7344 <S_8NM?]#CK'_@N\-?\ RDH_L76O^AQUC_P7>&O_ )25TU%
M',_V+K7_ $..L?\ @N\-?_*2C^Q=:_Z''6/_  7>&O\ Y25TU% ',_V+K7_0
MXZQ_X+O#7_RDH_L76O\ H<=8_P#!=X:_^4E=-10!S/\ 8NM?]#CK'_@N\-?_
M "DH_L76O^AQUC_P7>&O_E)7344 <S_8NM?]#CK'_@N\-?\ RDH_L76O^AQU
MC_P7>&O_ )25TU% ',_V+K7_ $..L?\ @N\-?_*2C^Q=:_Z''6/_  7>&O\
MY25TU% ',_V+K7_0XZQ_X+O#7_RDH_L76O\ H<=8_P#!=X:_^4E=-10!S/\
M8NM?]#CK'_@N\-?_ "DH_L76O^AQUC_P7>&O_E)7344 <S_8NM?]#CK'_@N\
M-?\ RDH_L76O^AQUC_P7>&O_ )25TU% ',_V+K7_ $..L?\ @N\-?_*2C^Q=
M:_Z''6/_  7>&O\ Y25TU% ',_V+K7_0XZQ_X+O#7_RDH_L76O\ H<=8_P#!
M=X:_^4E=-10!S/\ 8NM?]#CK'_@N\-?_ "DH_L76O^AQUC_P7>&O_E)7344
M<S_8NM?]#CK'_@N\-?\ RDJ[8:=J-K.9;KQ!J&IQ%&46UU::/!&&)!$@>PTZ
MTFW* 0%,I0@G*D@$;-% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7D/QO\ CW\'?V;? =S\3OCGX_T+X;>
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\[/VQ/
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MJFI1PL84'A%CU3I4U2PU.3B_[1Q$:E2<I5ZD(T8SJRY)2J%%%%?.GOA1110
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M:KE649EF5.C4<HTZM3 X*MBH4YRC[RA.5)1DX^\HMM:GI'_#SW_@GA_T>?\
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MZF)H9)X@?V71Q%:,8UJU+!9A4P\*M6,+052<8*4U!*/,W9)61_17%V<U>(O
MS-<^KT:>'KYSP-#,ZM"C*4J5&IC<#2Q$Z=.4_?<(2J.,7)N5DKMO4_@WHHHK
M_4D_S$/],O\ X)@_\H[_ -C'_LW;X8_^HW9U^('_  =&?\D]_8Y_['CXP?\
MJ/>"*_;_ /X)@_\ *._]C'_LW;X8_P#J-V=?B!_P=&?\D]_8Y_['CXP?^H]X
M(K_-#PL_Y2/PG_95\9?^H7$!_I%XH?\ */>-_P"R7X4_]2\C/X\ZCF_U4O\
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MWPQ_]1NSK\0/^#HS_DGO['/_ &/'Q@_]1[P17^:'A9_RD?A/^RKXR_\ 4+B
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M_P#EY0!T=%<Y_P (MIG_ #]>(_\ PL?%W_R\H_X1;3/^?KQ'_P"%CXN_^7E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _P G?XB?\E"\??\
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MV?VI?\&PW_)L/[1__9P%E_ZK;PE7Z9?\%DO^49/[7?\ V3W2O_4Y\)U^9O\
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M'FF?_)5 '1T5SG_"8^$?^AI\.?\ @\TS_P"2J/\ A,?"/_0T^'/_  >:9_\
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M^$?^AI\.?^#S3/\ Y*HVW!--73NGJFMFNYT=%<Y_PF/A'_H:?#G_ (/-,_\
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M1_\ V<!9?^JV\)5^F7_!9+_E&3^UW_V3W2O_ %.?"=?F;_P;#?\ )L/[1_\
MV<!9?^JV\)5^F7_!9+_E&3^UW_V3W2O_ %.?"=?YI<;_ /*3*_[.#PE_Z?R0
M_P!(>"O^4=*?_9!<2?\ J-FQ_F]T445_I:?YN'^@A_P;]_\ *,CX3?\ 8]?&
M7_U9?B&O-_\ @X]_Y1WVG_9P7PN_]-GC2O2/^#?O_E&1\)O^QZ^,O_JR_$->
M;_\ !Q[_ ,H[[3_LX+X7?^FSQI7^:6"_Y2@E_P!G3QO_ *N,0?Z1XW_E&^'_
M &;3 ?\ JIPQ_!O1117^EI_FX?Z9?_!,'_E'?^QC_P!F[?#'_P!1NSK\0/\
M@Z,_Y)[^QS_V/'Q@_P#4>\$5^W__  3!_P"4=_[&/_9NWPQ_]1NSK\0/^#HS
M_DGO['/_ &/'Q@_]1[P17^:'A9_RD?A/^RKXR_\ 4+B _P!(O%#_ )1[QO\
MV2_"G_J7D9_'G4<W^JE_ZYO_ .@FI*CF_P!5+_US?_T$U_IA'=>J_,_S?A\<
M?\4?S1_K'^ /^1$\%?\ 8I>'/_3/95_"/_P<3_\ *1_5O^R(?"C^?B:O[N/
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M-U>O9Z/H]K':6JW-_?37%]J-[*L9GO\ 4;^XN+[4+V6>]O)YKF>61N^HH 3
M]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EHH 3 ]!^0HP/0?D
M*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EHH 3 ]!^0HP/0?D*6B@!,#T'Y
M"C ]!^0I:* $P/0?D*,#T'Y"EHH 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:*
M $P/0?D*,#T'Y"EHH 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* &E001C&01
MD 9'N,@C([9!'M7X=_$/X:ZIX#\&?M0>$= U3Q!/X%?]O7X$ZK\6O%?Q.?Q5
M\4$NOAKJWPD^"-]XY\2^-8[O4(M0\3^$;37Y;&ZU_1Q>VGA*UT:TN-+U"UM/
M"=IJ%DO[C4W8GS#:N'^^-H^?("G=Q\V5 7G/  Z"OH^'>(:O#]>O4A1^LTL0
M\%*=!U(TX^TP./PV-I5EST:\'6IJC5IT)3ISC2G6]JX5%#V<_G^(,@I9]1H4
MY5OJU2@L9&%94W4E[/&8'$8.K2?+5HS5*;JTYUHPJ1E5ITG24Z;FJD/C+]A1
MK9?@QK=CI6D:!:^%])^+/Q,T[P;XB\(:+JOA?P7\0?#2:^US;>//!WA#4]3U
M:T\)>'M9O[G4;6VT7PO<Q^"S<Z;=ZIX2M;70]2LXE^SL#T'Y"A555554*J@*
MJJ %50,!5 P     !@#@4M>9FN._M/,L;F'LW2^N8BI7=.53VLHNH[MSJ*%.
M,YR=Y3<*5&ES-JE1I4^6G'T<KP7]FY=@L![15?JF'IT%4C3]E&2IQ45R4^>H
MX0BDHP4ZM6IRI>UK5:G-4EE:WK.C^&M&U;Q%X@U&RT?0M!TV^UG6M7U&:.UL
M-+TK3+:6]U#4+VYE*QV]I9VD,MQ<32,$CBC=V( -?*C?MM?!J]^%7@OXO>%+
M#QYXX\._$7XA>*OAKX)TKP]X66S\4:_KO@R\\96NOWL>C^+M1\+C3=#LX? G
MB#4?[1UJZTPOI\=G+]G66]@@/U\Z)(C1R(LD;J5='4,CJPPRLK JRD$@@@@C
M@BOSMN_V<?&FF_#_ ,.6&L_!'X(_'V\T#]H3]HKXER>"_B3K$EK!!H7Q:\=?
M$G6/#6L>%M4O_#OB/PW#XBM-'\7V-OK^G>(_#E[;_P!GW.K0Z3?VVIVMH]WZ
MN0X;(\1"?]J.JL1''8:-*"QV%PE&MA9X+-)U836*^KPB_KM'+H3Q,\?AZ=*C
M5G!QYZL*U+S,\Q&=4)P_LQ4G0E@L1*K)X+$XJK2Q,,;ED*<XO#>WG)?4JV83
MAAH8&O4JU:4)IN%.=*I]Z^%]:?Q+X>T?7YM!UWPQ+JUC#>OX?\3VEI9>(=(:
M9=QL=7M+&]U*SM[Z'I-%;W]W$K<+.XYK>P/0?D*\-_9I^&/B#X-? KX;_#+Q
M3J]IK6O>$M"DL;^YTZXU"[TFQ^T:C?:C;>'M#NM5"ZG<^'_"EG>6_AC0+C4(
MX+R?1M(L9;BVMI&:WB]SKQ<?3H4<=C:.%K0Q&%I8O$T\-B*<9QA7H0K3C1K0
MC4E.<85::C.,9SE-*24I2:;?L8&I7K8+!U<52E0Q-7"X>IB*$Y1E.C7G1A*M
M2G*$80E*G4<H2E"$8MQ;C&*:23 ]!^0HP/0?D*_B/_;Q_P""U7_!0?X-?MD_
MM(?"7X9_%'PGX9\ _#;XJ^)/!GA71C\+? .M2VND:#,EG;O=:KKVB:EJE[>7
M)1KFZEGNV3SY76WB@MUCA3Y+_P"'^G_!4#_HN'A3_P ,Q\*?_F5K^A\L^BUX
MC9KEN7YIA\PX3AA\RP.$S"A"MF69QK0HXS#T\32C6C3R6I"-6-.K%5(PJ5(*
M::C.22D_P',OI->'N59CC\LQ&!XIGB,OQF)P5>='+LNE1E5PM:="I*E*><4Y
MRIN<&X.=.$G&SE"+NE_H28'H/R%&!Z#\A7\I?_!%O_@JE^V?^V!^UYJWP;_:
M \>^&_&7@EO@[XQ\86MO9?#_ ,(^%=0L->\/:YX0M+.X@U#PQIFE2RPRVNM7
ML-S;7@N86_<R1+%)&6;^K6OR'CW@3.?#K/GP[GM7+Z^.6#PV.]IEM>OB,*Z.
M*]HJ:53$8;"5>>+I34XNBDFDXRDFF?K' _&^3^(&11X@R2ECJ.!EB\1@^3,:
M-&AB56PW)[1NG0Q&*I\C]I%PDJK;UO&+5C_)W^(G_)0O'W_8\>+_ /U(=2KC
MZ[#XB?\ )0O'W_8\>+__ %(=2KCZ_P!?,)_NF%_[!Z/_ *;B?Y,8W_?,7_V$
MU_\ T[,_JK_X-<P#\0/VR<@'_BCO@IU_[#?Q+K^@/_@J^!_P[@_;(X'_ "1#
MQ3V'I;5_/Y_P:Y_\E _;)_[$[X)_^GOXEU_0)_P5?_Y1P?MD?]D0\4_RMJ_S
MM\7/^4E\/_V4'A__ .H7#Y_H/X3_ /*.U3_L0\;?^I.='^:A1117^C1_G>?W
MQ?\ !NN ?^";^AY /_%Y_BUU'_43TVOW5P!T 'X5^%?_  ;K_P#*-_0_^RS_
M !:_].>FU^ZM?Y&^+W_)T./?^RHS?_U*J'^L/A5_R;?@C_LFLJ_]1:84445^
M<GWX4444 %%%% !1110 4444 ?FE_P %<O".O>(_V#?CQK>A?%/XH?#&;X=^
M#-9\?R+\+O$D/A*\\:2:!83RZ=X4\4ZY#IUSX@7P=/J<EIJ.M:5X;U3P_=Z_
M'I\>BZIJ,^@7NJZ7?_!O[5OB/3;;]J+]H?6M5\<:AIW[5G@'XU_\$\M"_8:\
M(7'CC6=$U;4?AOX[USX:V_Q&M_ /@BUU6TM?%WA?Q[XBU#XZ^'_C->)HNK6K
M>'/#31^)KFVL?"^ERV/]"E_86.J6=SIVIV5IJ.GWD307=C?VT-Y9W4#C#PW-
MK<))!/$XX:.5&1AP5-4KGP[X?O=8TSQ#>:%H]WK^B0WEOHVN7.F64^L:1;ZA
M&(K^#3-3E@>]L(;Z)5CO(K2>)+F-0DRNH H _G^_8'\1Z;<_M _LJ:EX5\;:
MCX@^/_Q,^'W[9>H?\%#=!E\<:SXAUS3_ !=X/^(WA?3_  FWQ3\'7NKWUMX'
MU3P5X_N=3\"_"Q+C2=!N(_!,NIZ)X>6[\.6I6W_H!U&[UBWE1=.T>'48F3<\
MLFJ1V)23<1L$;VLY<;0&W[E&3C;QDECX>T#2]2UC6=,T/1].UCQ#):RZ_JMC
MIEE::EKDMC";:QDUB^MX([K4Y+.W)M[5[V6=K>$F*$I&=M;% '+_ -I^*?\
MH5K7_P **'_Y74?VGXI_Z%:U_P#"BA_^5U=17Y]_M0?#FQ^(7QX^ O@/P]XE
M^)WACQEX[U&^\8>,]?\ "/Q9^)/AK3M!^#OP8FTC4O$$%IX1T+Q38^$_[7\<
M>)_$W@_P(^JWNASSC1]<UR\#RWNF6)A]3*,!1S+&?5J^)GA*:P^*Q,\1##K$
MJE3P>'J8NO.I3>(P[]G##T:TVZ<JE64HQITJ-6I.,3S<VQU7+L)]9HX>&*J/
M$87#0H3KRP[J5,9B*>%HPIU%0Q"YYUZU*"]I&G2C&4JE6M2IPE(^W/[3\4_]
M"M:_^%%#_P#*ZC^T_%/_ $*UK_X44/\ \KJ^5?!'_"PM)_;A^*NA^)/BCXA\
M8>$M9^ 7@KQCX5\$7-EIFD>%_A^DWQ(\:Z&;31;'3HA/J6I7EMIT4FL^)=;N
MKW5-2=8+:+[#IUE:6,7VE6>8X#^SZN'I_6*6)6(P."QL:E&-:,(K&8>%?V35
M>G2J.=%S=*I+D4)3A)TY3IN,Y7E^.^OTZ]3ZO5PSH8W&8.5.M*E*;>$KSH>U
MO1J5::A6455IKG<U"4544*BE"/+_ -I^*?\ H5K7_P **'_Y75\S^//VFO&?
MP[^,O@OX8Z[\#[N3P[XXU/73IWCVP^)'A.Y.G>"_"'A\>(?&OQ&USPBT$>L:
M9X5\*Q/;:=?32SFYN-7U70].LH9[O5[:*OL"OGG4/@8/$GQB^)WQ'\5ZG;W^
MC^,/@EH?P2\,:1:QSPW_ (;T*XU7Q=K'Q#NFNI"T'VCQ;=ZOX77?:HC+#X3L
M!<F0Q0!.G)9Y73JXN>;4*>(P\<#75&E*6+A5>*J2IT<//#2PN(P\?:8>=7ZU
M4CB74H5,/AZU+D]K4I2CSYQ#,ZE+"PRJM4P]=XVBZM2,<).DL+34ZU>&(CBJ
M%=^SKPI_582P_)7IUZ]&KS.E3J1EQGP#_:K'[04^M'PQ\-]1T_2[71=#\3:'
MJ\_C;P/K<%YH?B$RRZ99>++3PMJVMZA\.O'$VFFPUT>!_%%K#J1T;44F%S]L
ML=5L;'Z1_M/Q3_T*UK_X44/_ ,KJ^//V7_V3/$OP.\4Z!K?B'6_AS-8?#OX'
M:3^SYX)M?AOX+N_"$_B?PKI&MZ?J\'C#XE?:-2OH+SQ:J:/96]G8:6K:9I=S
MJ?BW4;>\E/B-K2P^ZZVXEIY+3S:M'(*D*F6\E)TN3ZRXQERVDN?%RE7G*:4:
MM3FY8PJU)THPC&FD8\.3SBIE5&6>PG#,>>HJO.L,I27-=>YA(QHQC!N5*G:\
MITZ<*LI2E-M\P-2\4$C/A>U R,G_ (2&$X'<X_LX9QZ9&:_/#QG\</VE/ASX
M]_: EC\>_"_Q]X)^ 7P1\4_$CQ;IFK?#Y_ %OIWCSQ'8:EJ?P;^&H\9I\0=7
MCOYSI&F3Z_XROFTK3G&FWWA6VM(K>[\3+)I_Z;5X3?\ [.?PTUCP]\<O#&N6
MNKZSI?[0OB"Z\1_$/[9JLL5\U[-X4\,^#K.'0M1T^.QO=&MM#TGPEHLF@F&>
M2[TS4('O(;LNRA'P_C\NP%7$O,\-2Q>'KT\-2]C4P6'Q4DI8W#+%5*=2LHUJ
M%2&7/&^PEAL1AIRQ4L-*=3DIM"S[ YACJ.'CEN)J83$4JE>K[:&+Q&&C>.#Q
M#PU.<*+E2KPGF"P7MHXBAB(+"K$QC3YZB/$_V3/C_P#$SXN6GQ/TOQ;8VFMZ
MKX \1^$K*QO=1\"^(_@1XJOM)\6>!]*\4R3^(/A1XTU#Q'XAT"VT_6+O4M$T
M#79;M-/\76.GS75A%OTV\NKSZZ_M/Q3_ -"M:_\ A10__*ZO/OA+\#]!^$U[
MXNUZ/Q3XZ^('C/QTV@1^*/'7Q'UJQUGQ-J6F^$[*ZL/"^B+_ &-H_A[0K#2-
M!AU#5);2WT[1+2:YOM6U34M4N-0U&^GNF]IKGSZOEV)S7$U\JI*C@IPPJA"-
M.-*'MH8/#T\7.G3C3HQC3JXR->K34:&&BX3BUA<*FL/2Z,CH8_#97AZ.9U95
M<9"6)YYSJ2JS]E/%UYX6%2I*I6E*I2PDJ%*HY5\1)3A)/$XAKV]3@/$%KJOB
MC0=;\,ZWX.M;S1?$6D:EH6KVA\2I$+K2]7LIM/O[8RQ6"2Q^?:7$L6^-UD3=
MN1E8 CX]L?V,PGA7QEX6U[QE\3_%:>)?@A<?LXZ#K.K>)_ =EJ_@'X.W107/
MAOP^V@_#_2K+4]1OHX;.WU+Q+XIM-;UF^@T^R1[B,K.]Q^@-%8X'.,RRV$Z>
M!Q4\/"I5I5I*,*4FJM"2E3G"52G.=)MI1J>RE!5Z?[JNJE/W#7&Y1EV8SA4Q
MN%AB)TZ56C%RE4BG3K1Y9PG&$XPJI:RI^UC-T:C]K1]G4]\XZRFU[3;.TTZP
M\'V%I8V%K!96=K!K\$<%M:6L206]O#&NFA4BAAC2.-% "HH4# JS_:?BG_H5
MK7_PHH?_ )75U%%><VVVVVVVVVW=MO5MMZMMZMO<]!)))))))))*R26B22T2
M2V1_)U_P5I_X+!?MI_LC?M@ZQ\$/@Y<?#?PSX/T3P!X&US[/KG@^V\8ZK>:I
MXELKO4+VZN-5NKNT1(U BMK>TM[6)(XX/,=I))6:OS._XB&O^"E/_0V_"'_P
MTFE?_+*H/^#A3_E)9XW_ .R4?"+_ -,-U7XB5_IUX8^&'AYF7AYP7F&8<&<.
M8W'8WAO*<5B\7BLKPM;$8G$5\)3J5:U:K4IRG.I4G)RDV]W9622/\VO$OQ,\
M0,M\0.,,OR_C#/\ !X'!<09EAL)A<-F->E0P]"EB)1ITJ5.$E&,(12226WJS
M^HO_ ()\_P#!;G]N_P#:!_;*^ WP5^)6I?"[Q#X(^)/BN\\.:[INF^ ;3PSJ
M30'PYK6HP7%AK5I?S/9W-M=:?!*/,@N(9HQ)!)$?,5T_L%_M/Q3_ -"M:_\
MA10__*ZO\X[_ ()"_P#*2W]C_P#[*?<_^H;XIK_29K^6/I/<-</\,<8Y#A.'
M<GR_)<+B.&:6)KX?+<-3PM&KB/[4S.DZTZ=*,8.JZ=.G!SMS.,(1;:BK?TY]
M&SB3/N)N#\YQG$&;X_.,50XBJX>CB,PQ$\36IT%EV7U%1C.HW)4U4J3FHWLI
M3D]Y._\ F@_\%3GFD_X**_MB/<PK;3M\:_$1E@687"Q/]FT_*"8)&)!C!W!%
MZXQQ7P+7Z ?\%5O^4CG[9/\ V6[Q%_Z2Z=7Y_P!?W]P5_P D9PC_ -DOP_\
M^JC!G\(<;?\ )9<5_P#91YU_ZLL2?N=_P;PS7D'_  44M)+"S2_N!\"_BF!;
MR7:V:E3=>$MS^<T,PRI"C9LR=V[("D'^\,:EXHR,^%[4#(R?^$AA.!W./[.Y
MQZ5_"1_P;I?\I'+/_LA/Q5_]*O"%?WO5_ /TJ_\ DZ,/^R9RC_U(S$_N_P"B
M_P#\FQ_[N+-O_36!/\HCXN%C\6?BH64(Q^)?CXL@8.$8^+-7+*'  8*<KN
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M%+;1;#43I+76IW.I:_H%M US?)/#;06\MW.1;2R31P1F%I?B'_B)'_X)[_\
M0!_:/_\ #9^&/_GBU^5'_!SS_P G._LW?]D'UC_U8.L5_,W7]T^%WT>O#[BW
M@'AOB/-UG<LRS7"5J^*>&S*%"ASPQN*H15*E]5GR15.E!6<I-M-MZG\3>)WC
M[QYPGQUQ!P]E/]C++\LQ-&CAEB,OE6K<D\)AJTO:5/K$>:3G4F[J*2322221
M_?=\.?\ @X0_8(^)GQ \$?#C1[#X]:7K/C[Q9X?\&:-?Z[\.=%M]&M]8\3:K
M:Z+I3:G<:=XVU2]M[-]0O;>*:>#3[IH5?S&B**Q'[E5_E>_LM?\ )SW[-O\
MV<!\%_\ U9/AFO\ 5"K\=^D'X8\,^&N8\-8?AK^T%2S;!9A6Q2Q^+CBG[3"U
M\-3INE)4:+@G&M)33YD[1:Y;/F_7/ 7Q(XC\1LMXBQ7$7U#VN5X[ T,,\#AI
M89>SQ&'K5*BJ)U:JF^:FG%KE:3DG=6L45_*W_P %6_\ @L]^UM^QO^V-XJ^
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MNWQ._P#4D^'5?WDU_!M_P;A?\I$-1_[-V^)W_J2?#JO[R:_S[^E3_P G3?\
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M[+=XB_\ 273J_/\ K] /^"JW_*1S]LG_ ++=XB_])=.K\_Z_N+@K_DC.$?\
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MAGTE_P#DU.%_['F2?^HN-/PLK]!_^"4/_*2#]CC_ ++/HW_ILU:OSXK]!_\
M@E#_ ,I(/V./^RSZ-_Z;-6K^\^./^2+XO_[)?B#_ -5.+/X:X&_Y+3A+_LI<
MC_\ 5GAC_2QHHHK_ !O/]=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\3_]E1_[R<O/X,^EG_R5W#'_ &3D_P#U9XL*_OG_ .#=K_E&[X>_[+'\6_\
MT\65?P,5_?%_P;NS0Q_\$WO#RR31(W_"X_BV</(BG']L67."0:]WZ5O_ ":^
MA_V5.4_^H>:'A_1:_P"3D8G_ +)K,O\ U*RXN_\ !P__ ,HV?%G_ &5OX1?^
MI%)7\"%?WU?\'#D\,G_!-KQ8J31.W_"V_A%\J2(Q_P"1BD[ DU_ K1]%'_DU
M^(_[*O-__4+* ^E+_P G(PW_ &366_\ J5F(5_I1?\$D/^4;/['?_9'=(_\
M3AJ=?YKM?Z3O_!)*X@3_ ()M?L=J\\*L/@[I&5:1%(_XF&I]06!%>']+S_DB
M>&?^RIC_ .JG,3VOHF_\EAQ+_P!DTO\ U:8$_)7_ (.@O^2$_LK_ /98?&/_
M *@[5_&97]E__!S_ "Q2? K]ECRY(Y,?&'QCG8ZMC_BAVZ[2<5_&A7W'T:/^
M30</_P#8;GW_ *N<:?%_21_Y.QG7_8!DG_JKPQ%/_J)O^N4G_H#5_JT? G_D
MB'P;_P"R5?#S_P!1'1Z_REY_]1-_URD_] :O]6+X%7-N/@C\' ;B$$?"KX>
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M*/:LR.KK_P *0^% W(P89SXFXR"17^<?T7/^3LX[_LGL\_\ 4[+C_0SZ2_\
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MQ\-?_+NNFHH YG^VM:_Z$[6/_!CX:_\ EW1_;6M?]"=K'_@Q\-?_ "[KIJ*
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M>']M4H<TIT_=B_:4IKE;YK1O:S5_[6/[:UK_ *$[6/\ P8^&O_EW1_;6M?\
M0G:Q_P"#'PU_\NZ_BG_XB;/VU/\ HB7[+O\ X(?BQ_\ /7K^G?\ X)A?M?\
MC7]N3]D?PE\?_B%X7\+^$?%NL>)_&WAO5-)\&_VLOAUCX5U^YTJWO;"#6]0U
M74[47=O'$\UO<ZG?%)Q(R3F-U1-^-O!?CKP_RBGGG$>$P%'+ZN.HY?&IA<RP
M^*J+$XBEB*U*+I4VI\CAAJMYI-1:BG;F1AP9XP<$\>9K4R;A[%XZMCZ6#JXZ
M4,3E]?#0^KT:E&E4DJD[QYE.O32BVFU=J]M?B#_@X0\3>);3_@G7KB6MCK_A
MI+WXP_"RRO;N#6-/A6[LWOM4G>PN1I&K37$]M-/;V\K021M TL$,CC,:LO\
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ML^6-UL[+LCW_ *)U2I+BSBA2G.2_U>I.TI2:NLRPR3LVU=)M)^;[G0?M>_\
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M&$ !!8' /XA_\&Z__*-_0_\ LL_Q:_\ 3GIM?NK7^1OB]_R=#CW_ +*C-_\
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MP((!!R*_S;:_TJ_^"LG_ "C=_;'_ .R*>)/_ $99U_FJ5_H)]$/_ )(OB?\
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M_8^.F:9IVG&;QO\ %X2FQLK:T,H7P]X)*B0V\49<*22 V0"<BOW/_P""8/\
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MD^EE_P EEPW_ -DRO_5KCPK^_O\ X-ZO^4:7@+_LI_QA_P#4RNJ_@$K^_O\
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M^GBRKW?I6_\ )KZ'_94Y3_ZAYH>']%K_ ).1B?\ LFLR_P#4K+BQ_P '#_\
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M\;_]@N1_^GLR/Y$_^#G[_DX3]E[_ +(UXQ_]3>&OYB*_IW_X.?O^3A/V7O\
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MEG&E-N3BHKELW=I/^B^BOXO_ /B)_P#V@_\ HUWX-_\ A9>-O_C%?4/[%?\
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M_L?_ .#H?_DDG[)'_93?B3_ZB.BU_'!7WOT:?^3/\._]A>??^KS'GPOTC_\
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M-85^*]?U?X4_\FSX _[)#A__ -5F&/Y:\5?^3E<=?]E3G7_J=6/TT_X(V?\
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M_LL_Q:_].>FU^ZM?A5_P;K_\HW]#_P"RS_%K_P!.>FU^ZM?Y&^+W_)T./?\
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M]_V6/XM_^GBRK\\O^(6U_P#H]M?_ !'@_P#SZZ_8[]B7]AC]H?\ 84^!=E\
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M#XXQ_'GX:_M8>#?&7B:+P?XA\&+HWCG]GG6QH?\ 9_B273);R[SH'Q\TR_\
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MG]K'P=X.\3W/A+P[X/DT;P/^SSK9T(6'AIM0-G=J=>^/>IW_ -LN!J,HN?\
M21!B*+RHD.\M_%7@+QEPWP7XAXK/.)<Q_LW*ZN39KA(8KZICL7?$8G%X*I1I
M^QP.&Q6(7/"E4ESNDH1Y;3E%N*?]D^./"'$/&'A_A\CX<R_^T<TAFN5XF6&^
MM8+"6H8:ABH5JGML=B,-0?)*I!<JJN<N:\(R2;7\-5?H/_P2A_Y20?L<?]EG
MT;_TV:M7[I_\0MK_ /1[:_\ B/!_^?77M/[.?_!N[XE_9I^.?PP^/GA']L/0
MO$'B;X5>*;;Q9HFB^)/V>=0_L'4KZUM[FVCMM5_LOXZ6>H?92MT[M]DNH)=Z
M)A]NX'^MN*O'_P ),RX8XCR[!<6>VQF/R'.,%A*/]A\1T_:XG%9?B*%"E[2K
ME%.E3]I5J0ASU9PIPOS3G&*DU_*?"O@/XK9;Q/P[F.-X6]C@\!GF58S%5O[;
MX>J>RP^&QU"M6J>SI9M.I/DIPE+DIPG.7+:$92:3_IUHKYH_X1_]L7M\6OV:
MO_$>_BA_]$V*^@- BUZ'1=+B\47VD:EXBCLH$UJ_T#2[S1-%O-15 +FXTO2-
M1UCQ!?:=9229:"TN];U2>%"$DO9V!<_YIG^C)KT444 %%%% '#?$/XG_  T^
M$7AU_%_Q7^(?@;X8^$H[VTTU_%'Q"\6Z!X+\.IJ.H.8["P;6O$FH:;IJWM[(
MK1VEJ;D3W+JRPQNP(KL;2[M;^UMKZQN;>\LKVWAN[.\M)H[BUN[6XC6:WN;:
MXA9XI[>>)TEAFB=XY8W5T9E8$_F]^VY:V7AOX\?L=?&GXA?#[Q9\1_@/\,Y/
MVAM&\?V'A3X:>)/C#+X8\9?$;X=Z/HOPX\6:G\//"&A^)_$>HV-S:Z=XX^'T
M6KV7AV_M](U#Q_9V^I36%AJ\]VGJ'[!'P_\ B;\-/V%/V?/A]XNL&\'_ !)\
M/?"6RL8M"\66<VHOX(DN/MUWX2\+^(M*L=4L9Y6\&Z+=:+H&JZ/::S92Q'2I
M]-@U"V:-9T /MFOX%O\ @XD_Y21:W_V13X3_ /HOQ%7]J0\/_MBX&?BU^S23
MCDC]GKXH $]\#_AILX'MDX]37XX_MM?\$,_B!^W7\<[KX^?$G]K+P=X.\3W?
MA3PYX1DT7P/^SSK9T);'PR+X6=TIU[X]ZGJ!O+@7\@N<W(@_=Q^5$AWEOW'Z
M/O&'#O!''E3.>)\Q_LS+99#F."6)^J8W&7Q-?$8"=*E[' 8;%5USQHU7SNDJ
M<>2TIQ;BG^+^//"?$'&? L<FX:P']I9E_;>7XMX?ZU@\);#T*6+C5J>VQV(P
MU#W'5@N3VG/+F]V+2=OX;*_0O_@DY_RDB_8Y_P"RQZ9_Z9]9K]S_ /B%M?\
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M=4:L^><(T_=LY\SBG_3GTA.">)N.>&,FR[A?+?[3QF%SR.,Q%'ZY@,%[/#+
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M;V&&HUXSJU/98?-*M>IR1N^2E2J3E9J,9.R?]%-?Y3WQZ_Y+M\;O^RP_$_\
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MBXA@_9XD\B&?5+V>^FB@\SXVO)Y,4MPR1>8[R>6J[V9LDY?_ !"VO_T>VO\
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MO_T>VO\ XCP?_GUU_:O_ !,9X-_]%BO_  P<3_\ SE\_S[,_C/\ XEZ\7_\
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M5]>NK2W9C'8VD]Z\%E !!;)'$ M?/:?L,?!NU_:$\6_M-:3XD^.?A[XF^/\
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M*\^(WP^^-OQ@^%6N6OBKPWX>\'?$[2M-\'>+;@>"[3XP^%O!32_#_1OB;>^
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M4%C%J^H>&/"NC^#-&:*UMXXK:PM[;0M"T^)K2RCAMY[P7.HS1O?7EU/+[!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>sdgr-20241231_g3.jpg
<TEXT>
begin 644 sdgr-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0F"_X# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+^BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T3^$?
M_)+?"/\ V"K;_P!%+76UR7PC_P"26^$?^P5;?^BEKK: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _+^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T3^$?_ "2WPC_V
M"K;_ -%+76UR7PC_ .26^$?^P5;?^BEKK: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _+^BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /T3^$?\ R2WPC_V"K;_T4M=;
M7)?"/_DEOA'_ +!5M_Z*6NMH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#\OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH _1/X1_\DM\(_\ 8*MO_12UUM<E\(_^26^$
M?^P5;?\ HI:ZV@ HHHH **** "BBB@ HHHH **** "BBB@!T<;2R*B*6=C@*
MHR23VKHO^%:^+/\ H6M6_P# .3_"L?1?^0Q8?]=X_P#T(5][9QUXH ^#=8\/
M:IX?DC34].NM/>0%D6ZA:,L!U(R.:SZ^F_VH-!^V^$].U1%R]C<[&/HD@P3_
M -]*GYU\U6=K)?7<-M"N^:9UC1?5B< ?F: -BS\!>)=1M8KFUT#4KFWE7='+
M%:NRL/4$#D5#JG@W7M#M?M.HZ-?6-ON"^;<6[HN3T&2.M?;VCZ;%HNCV.GQ<
M16L*0)]%4 ?RKS?]I3_DFK?]?D7_ +-0!\HT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %_2-!U+Q!,\6F6%SJ$L:[F2VB:0J,XR0!TJ36/#.K^'
MEB.J:9=Z<)<B,W4+1[\8SC(YQD?G7K/[+'_(U:Q_UY#_ -&+6W^U=_QZ^&O]
M^X_E'0!\\4444 %%%% !1110 4444 %%%% !4UG9SZA=16UM#)<7$K!(XHU+
M,S'H !U-0UU/PM_Y*-X;_P"OZ+_T(4 8VL>']4\/R1QZGI]UI[R#<BW431E@
M.XR.:SZ]S_:J_P"0YH/_ %[2?^A"O#* "BBB@ HHHH **** "BBB@ HHHH U
MM+\)ZWKEJ]UIVDWM];1L4::W@9U5@ 2"0.N"#^-9-?3?[-?_ "3/6/\ K_F_
M]$Q5\R4 %%%% !1110 4444 %36=G/J%U%;6L,EQ<2MMCBB4LS$]@!U-0UU?
MPI_Y*1X<_P"OV/\ G0!B:QX?U/P_+''J>GW.GR2#<BW,31EATR 16?7M_P"U
M1_R,FB?]>C?^AUXA0 4444 %%%% !1110!>TC0]1U^X>#3+&XU"9%WM';1-(
MP7(&2 .F2/SJ&^T^YTN\DM;RWDM;F,X>&9"KJ<9Y!Z5V'PE^(4'PWUZZU">S
MDO5FMC $C<*02ZMGG_=_6L7QUXDC\7>+=2UB*%K>.Z<.(G.2N% Z_A0!@T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?E_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'Z)_"/\ Y);X1_[!5M_Z*6NMKDOA'_R2WPC_
M -@JV_\ 12UUM !1110 4444 %%%% %W1-&N_$.K6NFV,1FN[F01QI[GN?0
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MG_H0KT3X::#=6?P3M;;2&C@U.\M))8YG)4"63.UB0"> 5[?PB@#E]4USX1^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y?T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!^B?PC_Y);X1_[!5M_P"BEKK:Y+X1_P#)+?"/_8*MO_12UUM !111
M0 4444 %%%% !G'(X->@:3\=O&>CZ>MG'J@GC1=J/<PK(ZC_ 'B,G\<UY_10
M!?US7M0\2:C)?ZG=R7MW)UDD/;T Z >PXJA110 4444 7-%_Y#%A_P!=X_\
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MKYW^&GCR;X>>*(M32/SX&0PW$(X+QD@G'N" 1]*^DS\6?A]XNTKRK^_M)('
M9[7482"I]P1@D>Q- 'E/P7\3>*?&OQ,L9K_4[V^L[5)9IU:0B)<QLJ_*/ESN
M8=OY5Z/^TIG_ (5L?^OR+^35C7WQV\'^#YK73O"^GPO:M.GVJ:"#R8DCW#>P
M& 7;&<<8]STIOQ8^*'@KQIX%U+3;76]]Z0LMNOV6<;G4@A<E,#(R.?6@#F/V
M6/\ D:M8_P"O(?\ HQ:V_P!J[_CU\-?[]Q_*.N)^ 7C31O!/B#4KG6KS[%!-
M:B-&\IY,MO!QA5/85J?M!?$'0/'%OH:Z)?\ VUK9IC+^YDCV[@F/OJ,]#TH
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M^LZ43^]AN1<[3W5T"_S3]17S=6_X(\97W@/Q!!JMCAG0%)(7)VRH>JG]#[$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\OZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _1
M/X1_\DM\(_\ 8*MO_12UUM<E\(_^26^$?^P5;?\ HI:ZV@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^G]0\*^'_CAX#MKG1OL.G:RNR222.%5=) "&CDP-
MVTDG!]@>:\[M_P!F;Q9)=".6;3X8L\S><S#'J %R?TKRW3M4O-(NEN;&[GLK
MA>!+;R&-Q^(.:Z"3XI>+Y(?*;Q'J6SIQ<,#^8YH ]T\7:KI'P3^&3>&[*Y6X
MU>YA=%7@.6<$/,P'W0.WT YP37S%3YIY+F9Y9I&EE<Y9W8EB?4DTR@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R_
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#]$_A'_R2WPC_ -@JV_\ 12UUM<E\(_\ DEOA'_L%6W_HI:ZV
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R_HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\AGC3#!0Q&&8'HP_.N6KZ;_9K_Y)GK'_ %_S?^B8J /F2BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGBNGB'T=,G_T 5QO[+ZEOB!?-V739/\ T;%7>?M2R!?!>E1]VU -^4;_ .-
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M1Z1I^BQW^IQ@-(%"EUR,@O*P)R>N!T]!Q1X=^)_@SXN70T;6]#BM+N?Y81<
M.'8_PI( &5O3IGUKYT\0:I+K6N:A?S.TDES.\I9NO+$U3M[B6TN(IX7:*:)@
MZ.IP58'((_&@#NOC!\,7^'&N1K [3:5>!GMI'^\N,;D;W&1SW!^M>N_LU_\
M),]8_P"O^;_T3%4W[0*IK/PEL=0=<2+-!.IZ$;U((_\ 'OTJ']FO_DF>L?\
M7_-_Z)BH ^:;6VEO+F*W@1I9I7$:(O5F)P /QKZ4TOP3X2^"7A>+5_$D,>HZ
MM)@?,@E/F8SLB4\#&/O'\QD"O(_@7I\>H?%+1$E&Y(VDFQ[K&S+_ ./ 5[U\
M5O@_<?$S4K&<:R-/@M8BBPFW,F6)R6SO'8*.G:@#D+?]I30-2N!::GX9:/3F
M.TN628 'N4*CCZ$UD_&+X3Z2OA]?%WA0(-/95DGMX>8]C=)$';DC*]O;!JY_
MPRC+_P!#,G_@"?\ XY7I_A?P"_A?X=7?AJZO1J<313H)/+\O".#\N,GN3^=
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M",_-_L@8..^1VR#U=Y^T9X>T&ZDM-$\+I-91G8)49+=6 XR%"'CTSC\*YO\
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MEW8]V)R37JG[,\C)\1I #@-8R@_]](?Z4 <=J&FCX=_$;[+>P_;(=+OD=HV
M_?1*P89SQ\RX_.OJ/P;XRTW7OA[=ZW::0ME8Q).S6*A<-L!+#@8Y^E?/'[0
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M)XTT.35Y/"=GI-AR8I+J&+]XHSN?[O"CU^OI7A/P7^$TGC[4OMU^C1Z%:O\
MO#T,[#GRU/IZG\.IXZ/X[?%B.X5O">@.L6G6^(KJ6'A7V\>4N/X1CGUQCH.0
M#S_XK:]I7B/QK=W&B6R0:>@6&/RHPBR;>"X4#@$_IBO8/!_PS\-_"_PDOB3Q
MC%'<WQ56,,R>8L);[L:IT9_4GICL 37BGPUT]-4\?^'[:4;HVO8BR^H# D?I
M7T_\6/AA/\3(-.@35AIL-JSNRF R>8Q  /WAC !_[ZH X)?VFM#EF^S2^%Y!
MIO3.]&./^N>W'3_:J'XF?"[0?%/A%O&'@Y(XU6,SRP6Z[8Y4&=Q"_P ++@Y
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M(Z7X!\6:=?7?B5;C54+?9[156'>2C C!8LW!)XQTKAOVH_\ D?M./_4,C_\
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M=XRTWP?X5LM1U'2%U6VFN$B2W8*0C%'8-\P(X"D?C7QI7TU^TG_R3'1_^O\
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MZ'J&4\?6M_X!ZI+IOQ0TE4=ECN1)!*J_Q*48@'_@04_A6_\ M06,=OXXL+A
M UQ8KO\ <J[C/Y8'X4 =!^T5X/T^3PSI'B/1[6"&!6"2&VC"*\<@!1S@=B,?
M\#KY]KZ9^%-RGQ+^#.H>'+APUS:QM: MV'WH6^@(Q_P"O"/!7A2;Q-XVT[1)
M(V1I+C9.O=$7F3\0 U 'MWAW1=-^'?P+DUB_T^UGU*XA-RC7$*NPDDPL0&1G
M &TD?6O(_A5\.IOB/XC^REV@L+=?-NIUZA<\*O\ M$_R)[8KTC]J#Q,JMI/A
MJV(6.)?M4R+T'58U_ ;CCW%=%^R[I\</@K4;L#][/?%"W^RJ+@?FS?G0 SQ#
M\0O!?P;N/[&T?0X[N_A $PAPI4XR \I!);IZX]NE)X?\?^"OC/,='UC1([+4
M)5_<^;@ECC)"2@ AO;C/OTK*U#]E^ZU*_N;R;Q0K37$C2N?L)Y9B2?\ EI[T
M_2?V8KG1]4L[Z'Q.HEMIDF3%D1RK C_EI[4 >3?%#X?S?#KQ,]@SM/9RKYMK
M.PY="<8/^T",'\#WKV/X,^#[#Q3\'KNVEM;87=T]Q MV\*L\>0 "#C/&:7]J
MBQ23P[HEZ1^\BNVA!]G0D_\ H K0^!-XVG_!J[NDX>![F5?JJY_I0 K?%#X>
M_#N8^&(+61H;8^3-)!;K)'N'#;V)RS9ZD U\Y^+]2M-8\4:G>:?;1VEC+.Q@
MAA0(JIG"_+VR #]360S%V+,2S$Y)/4TE !75^!_AEKOQ F<:7;JMM&=LEW<-
MLB4^F<$D^P!KE*]T\"?&G2_AW\,M.LEA;4M6:29_LR-M6,%S@NV#C/H 3].*
M ,^^_9?\26]N7M]0TZZD SY6YT)]@2N/SQ7FOB+P7KGA.8QZMIEQ9<X$CIF-
MOHX^4_@:]IT?]JI6N NJZ$4@)YDLYMS#_@+ 9_,5Z=H_Q>\':]:B2/7;.W!'
MS17L@@8>Q#XS^&: /E'1_ .LZQHM_K"6CPZ79PM,]U,"JO@?=3^\?IP.]9&C
MZ3=:]JEKI]E$9KNYD$<:#N3_ "'<GL*^B_C!\:?#LGAG4-$TNX&JW=Y$83);
MG]U$#U);HQ]AGZBD_9Q^'*:7I0\3WBJ]Y>*5M5Z^5%G!;ZMC\OJ: .MM+?2?
M@7\-F:0K(8%W2,.&NKAAT'U(P/11[5N_#K6;GQ%X*TK4[Q@US=1&5RHP,ECP
M!Z#I7BWQNTWQEX\\1?9[+0;XZ-8DI!A,"5OXI.O?H/;ZFO8_A?IMUH_@#1+.
M]@:WNH;<+)$XP5.3P: /C[QI_P CCKO_ %_S_P#HQJQJ[;XB>!]>TK6M:U6[
MTJXM].>^E9;AU^0AI#M/XYKB: "BNB^'_A'_ (3KQ79Z+]K^Q?:!(?/\OS-N
MU&;[N1G.W'7O7KW_  R>?^AH'_@O_P#MM 'S_17T!_PR>?\ H:!_X+__ +;1
M_P ,GG_H:!_X+_\ [;0!\_T5Z+\5OA"?AC;Z=*=6_M+[8[KC[/Y6S: ?[[9Z
MUYU0!VWP5T]=2^*/A^)QD+,TWXHC./U45]0?%31]1\1>"+_2M*0->7K1P@LV
MU54NI<L?3:#7S7\ 9!'\5]%S_$)U_P#(+U]2^-O$7_")^$]4U<()'M8&=$;H
M6Z*#[9(H \;M_P!E-/L8\_Q$RW1'/EVN4!].6R?TKR[XB_##6OA[>(;_ &W5
MG,V(KZ+)1S_=.>5;'8_AG%7-+^.'BZQUY-1GU::\C\S=+:2$>4ZYY4+T7CN*
M^HO&6B6WC;P3?6;H'CNK8R0LPY5]NY&_ XH ^'Z*** /I3]G.;2/$GA.XT^\
MTVRN+W3I<;Y;=&=HWRRDDC)P=P^@%>?_ +1/A&+PWXTBN[2!+>RU" 2*D:A4
M5U^5@ /;:?\ @59WP(\5?\(Q\0K)9'VVNH?Z'+GIEB-A_P"^@OX$U[9^T9X:
M_MOP"U[&FZXTR43C'7RS\KC]0W_ : /$O@5X53Q3\0K-9XEFL[-6NID=<J=O
M"@Y_VBO'H#7KW[0+:/X7\"M!:Z98P7VH2B"-X[=%=5'S.P('H O_  *H/V8/
M#?V'PQ?ZS(F)+^;RHR?^><>1D?5BP_X"*\Z_:,\4?V[X\-A&^ZVTN,0#'3S#
M\SG_ -!7_@- $GP/^$47CJ>75-5#?V-;/Y8B4E3<28!*Y'(4 C./7'K7NVL>
M*_!/PQ6&QN9+/2BRY6VM[<LVWIDJBDCZGK@]:7X,Z?'IOPQT".,8\RW\YO<N
MQ8_SKS_QI^SSJGB[Q3J6KOKL""ZE+HCPLQ1.BKG/8 "@#M=8\#^#OBUH/VNU
MCMI/-!\K4K-0LB-_M< G'=6_2OE'Q5X;N_"/B"]TB] \^U?:67HZD95A[$$'
M\:^J?A#\,[[X:V^I6]SJ<=_;W3)(B1H5$; $,>3W!7_OD5Y3^U)IR0>+-*O%
M #7%GL? ZE'//Y,!^% '5?!'X,Z6N@6NO:Y:)?7EXHE@@N%S'%'_  G:>&+#
M!YZ CWKK[KXO> =%OI--;4;>)XVV.(;5VC!!QC<JX/X5X%\-_"7CWQ)#YGA^
M\O-/T\'8;E[IX8?<  Y;\ <5WNC_ +*OW7U;7N/XHK.'^3L?_9: /3/%/PV\
M,_$+1M_V2V62>,/;ZC:HH<9&5;(^\.>AXKX\DLY+#57M)U EAF,3K[AL'^5?
M<OAG2+30-!LM.L)6FM+:,1QR.X<D#U(X-?&'C$!?B!K@' &J3@?]_6H ^O=?
M^'^C:SHM]81Z=96CW,+1"XCM4W1Y&-PXZBJ^D_\ "'>$5B\.6MSI=I,H"?9'
MFC\US_M G+,??DUTNH77V'3[FY(R(8FDQ] 3_2O@J]O)M0O)[JXD,L\SM)([
M=68G)/YT >O^$?!>F?%CXK:[=+!%;>'K.7>8+5?+$HR50#;TW;2Q(YZ^N1[!
MKWC'P3\)V@L)88+"9HPZ6UG:Y;;DC<2!Z@]3DUXQ^SGXZL/"NN7^GZE,MK!J
M2Q^7<2'"K(A; )[ ACR>X%>_^+?AWX>\>+$^K6*W$J)MCN(W*.J]<!@>1ST.
M1S0!EZ'KO@KXM6ES#!!:ZB8P#+!<VX610>C<C/X@U\\_&KX<P?#_ ,21K8.6
MTV\4R0QLV6B(/S(>Y R"">Q[XS7J&J?LSQVOFR^'/$-YI\KJ5,<_(8$YVEDV
MG' ['I7A?C3P5K'@?5OL>L0[)7&])E;<DHS]Y6[_ (\T 8%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y?T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%?57_!.OX)^"_CK\7O$&B^.
M-%_MS3+70I+R&#[5-;[9A<0(&W1.A/RNPP3CGI0!\JT5^V?_  [K_9Z_Z)\/
M_!SJ'_R11_P[K_9Z_P"B?#_P<ZA_\D4 ?B917[9_\.Z_V>O^B?#_ ,'.H?\
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M7"(Z[E((RK$9!!&>#0!Q]%?M?<?\$[?V>X[>1E^'P#*I(_XG.H>G_7Q7XH4
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M6H?#?5GN;9!=6DP"W%F[;5D Z$'LP[''<UZS>?%3X6^+I!=:UH4B7I WO);
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M+&.:*VN!&%6X4!QMC53D D=0>]=A\&?C3;?#^PN-*U2UFGL))3-'+;X+QL0
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MJ_=C4=$4=@/_ *_4UZ3\/_C%HWA7X;7OA^[MKZ2]F$X62&-#&-ZX&27!^O%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#\OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "NR^%OQA\
M8_!77+G6/!6MRZ%J5S;FTEN(HHY"T197*X=6'WD4],\5QM% 'T!_PWS\??\
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MABA([X93^(KX-T'3O%/@OXH:996%C<6GC72]7ACMK)X0TT=]',-B&-@06$@
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MZVN2^$?_ "2WPC_V"K;_ -%+76T %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_&%UJ2ADM% AM8WZK&N<9]R23^-<E110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'Y?T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7[%_\ !+O_ )-6M/\ L+WG_H2U^.E?L7_P2[_Y-6M/^PO>?^A+0!X3
M_P %A/\ D,?"W_KAJ7_H5M7YU5^BO_!83_D,?"W_ *X:E_Z%;5^=5 'ZC?\
M!(7_ ))OX_\ ^PM!_P"B:W_^"LGB^ZT;X$Z!H=M*T4>M:TOVD*?]9%#&[[#[
M;S&WU05@?\$A?^2;^/\ _L+0?^B:I_\ !7^0CP?\-D[&_O#^4<7^- 'YBUK>
M%?"^M>,O$%EH_A[3;O5M8NI EO:64;22NW7@#TZD]@,FLFOU0_X)-_"[2M.^
M%^O^/9+>.77=2U"33H[A@"T-M$J-L4]MSL2WKL3TH \2\)_\$S_C;\1[/3Y/
M&_B:ST"T@4B&UU*^DU"XMU;!(6-,QKG R!(.@KZ(^#O_  2U\%_#CQ)I'B'6
MO%FL>(]5TNZBO;=;>-+*W\V-PZEE^=R P'1Q4W_!1#]K;QE^SVOAK0/!2PZ?
MJ&LPS7,NL3P+,8D1@H2)7!3=DY)8' QQSFOA3X3_ !<^*?QV_:"^'NF:UXOU
M[Q#]H\064CV<EY)]G6-)E>1_)4A %168X7HIH _;74,?V?<[AE?*;/Y&OP1_
M9CT.'Q)^T3\-=.N$\RWF\067FH>C(LRLP/L0"*_>O5L_V7>;1EO)?'_?)K\
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MOPS\.Q^,/B/X4T&89BU35K2Q<9Q\LLR(>>W#5_0U=?\ 'K-_N-_*OYV?!GB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME]I?[/'_  3YT2\UJ"SM[3Q%/"5AA:<W>K7@X^2,.V40D#)&U.!GM7Y$Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'Z)_"/\ Y);X1_[!5M_Z*6NM
MKDOA'_R2WPC_ -@JV_\ 12UUM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0KU"K;3'=6LZ]P>JL*_./]O;]@G3/!NA7WQ)^&M@UIIUL?-UC0(%S';Q][B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\OZ**
M* "BBB@ HHHH **** "BBB@ HHHH _3O_@D#_P B;\2/^O\ L_\ T7)75?\
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M7ZN_LT_!6P^ ?P;\/^%+2"-+V.!9]3G0<W%XZ@RN3WY^49Z*JCM0!\O^%_\
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M1_\ )+?"/_8*MO\ T4M=;0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114-Y>
M6^GV[W%U/';0)C=+,X15R<#)/ Y(H FHK&_X33P]_P!!W3/_  ,C_P#BJ/\
MA-/#W_0=TS_P,C_^*H V:*QO^$T\/?\ 0=TS_P #(_\ XJC_ (33P]_T'=,_
M\#(__BJ -FBL;_A-/#W_ $'=,_\  R/_ .*H_P"$T\/?]!W3/_ R/_XJ@#9H
MK&_X33P]_P!!W3/_  ,C_P#BJ/\ A-/#W_0=TS_P,C_^*H V:*QO^$T\/?\
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MVWX/%O!>,A>+[+A(+C'52O16ZCMSP?8 ^9:*=)&\,CQR*R2(2K*PP01U!IM
M!1110 4444 %%%% !1110 4444 %%%% !3A&Y7<$8KZXXIM?37@/_DVG4/\
MKPO_ .<E 'S+1110 4444 %%%% !1110 4444 %*JEC@#)]!25V/P?\ ^2F>
M'?\ KZ'\C0!R#(T?#*5/N,4VO:_VIO\ D;-(_P"O'_VHU>*4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17N'PL^&FB:A\-=6\
M2WL!O+]8+E84E.8XBJ'#!>[>YSCC%>'T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^7]%%% !1110 4444 %%%% !1110 4444 ?IW_P2!_Y$
MWXD?]?\ 9_\ HN2NJ_X*W?\ )O?AC_L:8/\ TDNJY7_@D#_R)OQ(_P"O^S_]
M%R5[M^WA^SYXH_:0^%&B^'/"<FGQZA9ZW'J$AU&=HH_*6">,X*JW.9%XQZT
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MY_-* /F[_@KQ<.WQ0\!P$_(FCRN![M.0?_017P-7WI_P5V_Y*UX'_P"P(_\
MZ/>O@N@#^CRQ<R6-NS<EHU)_(5^ _P"T9_R<)\3_ /L:=4_]*Y:_?;3?^0?:
M_P#7)?Y"OP)_:-_Y.$^*'_8TZI_Z5RT >=T444 %%%% !1110 4444 %%%%
M!1110!^B?PC_ .26^$?^P5;?^BEKK:Y+X1_\DM\(_P#8*MO_ $4M=;0 4444
M %%%% '$?&Z1X?A/XHDC9D=;-F5E.""",$&O@;_A(-5_Z"5Y_P!_W_QK[W^.
M7_)(_%7_ %XO_2OSXH T/^$@U7_H)7G_ '_?_&C_ (2#5?\ H)7G_?\ ?_&L
M^B@#0_X2#5?^@E>?]_W_ ,:/^$@U7_H)7G_?]_\ &L^B@#0_X2#5?^@E>?\
M?]_\:/\ A(-5_P"@E>?]_P!_\:SZ* -#_A(-5_Z"5Y_W_?\ QH_X2#5?^@E>
M?]_W_P :SZ* -#_A(-5_Z"5Y_P!_W_QH_P"$@U7_ *"5Y_W_ '_QK/HH T/^
M$@U7_H)7G_?]_P#&C_A(-5_Z"5Y_W_?_ !K/HH T/^$@U7_H)7G_ '_?_&C_
M (2#5?\ H)7G_?\ ?_&L^B@#0_X2#5?^@E>?]_W_ ,:/^$@U7_H)7G_?]_\
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M^B@#0_X2#5?^@E>?]_W_ ,:/^$@U7_H)7G_?]_\ &L^B@#0_X2#5?^@E>?\
M?]_\:/\ A(-5_P"@E>?]_P!_\:SZ* -#_A(-5_Z"5Y_W_?\ QH_X2#5?^@E>
M?]_W_P :SZ* -#_A(-5_Z"5Y_P!_W_QH_P"$@U7_ *"5Y_W_ '_QK/HH T/^
M$@U7_H)7G_?]_P#&C_A(-5_Z"5Y_W_?_ !K/HH T/^$@U7_H)7G_ '_?_&C_
M (2#5?\ H)7G_?\ ?_&L^B@#0_X2#5?^@E>?]_W_ ,:/^$@U7_H)7G_?]_\
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MPRM<R @CL>:_2JO /VA/V>E\61S^)/#< 36U&^ZLXQ@78'5E'_/3_P!"^O4
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M]!>__P# E_\ &C_A*M:_Z"]__P"!+_XUET4 :G_"5:U_T%[_ /\  E_\:/\
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M_P"$JUK_ *"]_P#^!+_XUET4 :G_  E6M?\ 07O_ /P)?_&C_A*M:_Z"]_\
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M]_\ ^!+_ .-9=% &I_PE6M?]!>__ / E_P#&C_A*M:_Z"]__ .!+_P"-9=%
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M+_XT?\)5K7_07O\ _P "7_QK+HH U/\ A*M:_P"@O?\ _@2_^-'_  E6M?\
M07O_ /P)?_&LNB@#4_X2K6O^@O?_ /@2_P#C1_PE6M?]!>__ / E_P#&LNB@
M#4_X2K6O^@O?_P#@2_\ C1_PE6M?]!>__P# E_\ &LNB@#4_X2K6O^@O?_\
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M5K7_ $%[_P#\"7_QK+HH U/^$JUK_H+W_P#X$O\ XT?\)5K7_07O_P#P)?\
MQK+HH U/^$JUK_H+W_\ X$O_ (T?\)5K7_07O_\ P)?_ !K+HH U/^$JUK_H
M+W__ ($O_C1_PE6M?]!>_P#_  )?_&LNB@#4_P"$JUK_ *"]_P#^!+_XT?\
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M>&=6O;\7+75O*8X5@D"@_(",C'K6WI?P=\'>"M-MY_'>KHNH3KO^QK,45!Z
M+\S$>HX_G6Y^RQ_R*VL_]?H_] %> ^,-<N/$GBC4]1N9&DDGG=AN.=JYPJCV
M P/PH ]];X*> ?'FDRS^%;\V\J<"2"=IE5NP='.X?F*\'AT&/2/&L.D:\WV:
M""^6WO'4XVH' =@<=,9(.*[K]FJ^EMOB*;='(BN;2177/!QA@?J,?J:H_M#0
MK%\4M1*C!DBA9O<^6!_2@#Z"\&Z7X6L_A[=VNCWS7'A]DG$MPSDD @^9S@=!
M[5\Y?%+1_!FDKIO_  B6HO?F0R?:=\A;;C;L_A'7+?E7KGPB_P"2!ZK_ -<K
MW_T U\RT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^7]%%% !
M1110 4444 %%%% !1110 4444 ?8O["'[8W@S]E_P_XML?%6F:]J$NK74$T#
M:/;PR*JHC@AO,FCP<L,8S7U+_P /;/A#_P!"YXV_\ ;/_P"2J_)6B@#]:)/^
M"MGPC"G9X:\:LW8-96@'Y_:C7"^//^"O6G+8RQ^"_ -U+>,N([G7KI4CC/J8
MHMQ<>V]?K7YHT4 =]\9?CEXR^/?BIM>\9:L^H7*@I;VZ#9;VJ'^"*,<*.!D]
M3C))/-<#110!^C?[,W_!1SX:_!GX%^$_!>MZ'XJNM4TF"2*>:PM+9X&+3.XV
ME[A6(PXZJ.<U\L?MF?'30?VB/C3-XO\ #EIJ-EIKV%O:B+5(HXYMR!LG".XQ
MSQS7A=% !7K7[-/[2'B+]F;X@#Q%HD:7UG<1_9]1TN=RL5W#G.,C[K@\J^#@
MD\$$@^2T4 ?L#X8_X*E_!C6-+2?5#KF@7FW+VEQ8&;#>BO&6!'H3CZ"O'_V@
M/^"K%O>Z+=Z/\*-(N[>\G4QGQ!JZ*AA!&"T,()RW/#.1@C[IK\WJ* /U ^%/
M_!4CX:>#?A?X1T'6]'\9W^LZ7I-K97MW':VTBS3QPJDCAWN0S L"<L 3GD5^
M>_QR\<6'Q,^,7C+Q9I<-Q!IVLZK<7UO%=JJS*CN6 <*S -@\X)'O7#T4 >O?
M _XE?$W]F_Q#:^-?#&G:A;V5U$%F6[LI38ZA!G.UC@!AD<,I!!S@]:^[?#'_
M  5V\$W&EHWB+P/K]AJ.WYX]+D@NH2WLSO&0#]./>NT_X)H?';1O'7P.T_P-
M)=QP^*/"XDA>S=@'GM6D9XYD'=1OV''0J,XW#/HW[3_[&OA#]IVSTQ]1N;CP
M_K.FM(8-2T^)"75]NY)5(^<?*".00<\\D$ ^%/VE_P#@I=XB^,&@7?A3P/I$
MWA'1+Y3!=7DLPDOKJ-N#&-HQ$IY! +$CC< 2#^LMO&8[>)#U50#^5?%GPG_X
M)8^ O 'BS3M>UWQ%J7BU]/F2XAL9(([:V>13E3(H+,Z@@';N ..<C(KZ#_:4
M^/6B_L\_"W5O$NI7,(U'R7BTJP=AOO+HK\B!>I4$@L1T4$^E 'XD?'2]74OC
M;\0;M"&2X\0ZA*&7H0US(<_K7#U)<7$EU<23S.9)9&+N[=68G))_&HZ "OL7
M]A#]L;P9^R_X?\6V/BK3->U"75KJ":!M'MX9%541P0WF31X.6&,9KXZHH _6
MK_A[9\(?^A<\;?\ @#9__)5-D_X*V?",*=GAKQJS=@UE: ?G]J-?DO10!^EW
MCS_@KUIRV,L?@OP#=2WC+B.YUZZ5(XSZF*+<7'MO7ZU\'_&7XY>,OCWXJ;7O
M&6K/J%RH*6]N@V6]JA_@BC'"C@9/4XR23S7 T4 %>^?LL_MB>+?V7]5GCL(T
MUSPO>R"2]T.ZD*J6''F1.,^7)@8)P00!D' (\#HH _7_ ,*_\%3O@UK5E&^J
MKKWAVZ/$D-S8^<H/LT3-D?4 ^U8GQ _X*O\ PTT/2Y_^$3T76O$VJ=(EN(EL
M[;ZL[$O^ 3GU%?DW10!Z%\<OCIXJ_:"\=7/B?Q5=^;,W[NULX<BWLX<Y$42D
M\#U)Y)Y))K.^$OQ:\3?!/QQ8^*O"E^UCJ=J<%6R8KB,D;HI5S\R-CD>P(((!
M''44 ?J?\-/^"M7@O5-+2/QUX8U70M57 :720EW:OZM\S*Z?[N&_WJ]#NO\
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MYJ-O'<J%E6.:=Y%#@$@, PS@D9[FN5HH **** "BBB@ HHHH **** "BBB@
MHHHH _1/X1_\DM\(_P#8*MO_ $4M=;7)?"/_ ));X1_[!5M_Z*6NMH ****
M"BBB@#AOCE_R2/Q5_P!>+_TK\^*_0?XY?\DC\5?]>+_TK\^* "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#V?X!_'RX^'-Y'H^L.]QX;F?W9K1B?O+_L^J_B.>OVE8WUOJ5G#=6LR
M7%M,@DCEC8,KJ1D$'TK\QJ]F^ GQ\N/AS>)I&KN]QX;F?W9K1B?OK_L^J_B.
M>H!]M5X;^T!^S]%X\MY=>T&)(?$4:YEA&%6\4#H?1\=#WZ'L1[78WUOJ5G#=
MVDR7-M,@DCFC;<KJ1D$&IZ /S#N+>6SN)()XWAFC8H\<BE65@<$$'H0:CK[/
M_: _9_B\>6\NNZ%$D/B*-<R1#"K>*!T/H_H>_0]B/C2YMI;.XE@GB>&>)BCQ
MR*596!P00>AH CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M82DEN\G8,"&4'Z@M^1KP,$CD<&OHWP;\4O#?Q(\*+X;\9R1P7@54\^X;:DQ
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M H \D_X7]X[_ .@TO_@)!_\ $5NZ[XA^*]YX,FOM29FT"\MLR2F&V7=$XQR
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MBO7K_P 0:DPQ]HOYVE*KG.U03A5_V5P!Z5SU% !1110 4444 %%%% !1110
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M_0C56@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _1/X1_P#)+?"/_8*M
MO_12UUM<E\(_^26^$?\ L%6W_HI:ZV@ HHHH **** .&^.7_ "2/Q5_UXO\
MTK\^*_0?XY?\DC\5?]>+_P!*_/B@ HHHH **** "BBB@ HHHH **** "BBB@
M HKMOAK\$_'/QB.HCP7X:O?$1T[R_M?V-0?)\S=LSDCKL?\ [Y-4OB+\+O%?
MPEUN#1_&&AW6@:G-;K=QVUV &:)F90XP3P61Q_P$T <M117L%O\ LA_&2[T.
M+6(?A]J\FF26XNTN@B;#"5WA_O=-O- 'C]%:7AOP[J7B[7K#1=&LY-0U6_F6
MWMK6$#?+(QPJCW)KM_B!^S?\3/A7H/\ ;?BSP;J6A:5YRP?:KI5">8P)5>">
M3@_E0!YM114LUI/;PP2RPR1Q3J7B=T(6102I*GN,@CCN#0!%1110 45ZMX1_
M95^+7CWPY9:_X?\  FJ:KH]ZI>WO+=5*2 ,5)&6]01^%:Y_8G^.0&?\ A6FM
M?]\)_P#%4 >)45Z!XU_9]^)?PYL7OO$O@37]'L$^_>W%A((%^L@&T?B:\_H
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M[UOP("_\ KQF@ HHHH **** "BBB@ JYHW_(8L?^N\?_ *$*IU-92>3>0/\
MW9%;\C4R5XM'1AY*%:$GT:_,]_KC/BI_R ;;_KY'_H#5V=</\5I,:79)_>F+
M?DI_QKX/ *^)AZG]5\624<CQ+?\ +^J/,J***^^/Y,"BBB@ HHHH **** /6
M/V:?'W_"$_$BU@GDV:;JV+.?<<!6)_=O^#<>P8U]T5^8"L58$'!'((K] _@C
MX^'Q$^'>G:C))OOX1]EO.>?.0 $G_>&UO^!4 =Y1110 4444 %%%% !1110
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MX\_[#]__ .E$E '[$_LZ_MN?#K]I:\?0M.^U:-XD,3N=%U:-<SQ@?,8W4E9
M!R5X;&3MP":^*?\ @I+^R5I7PFU&Q^(?@VP33_#NK7'V;4-.MTQ%:71!97C
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M$9/7C@/ _P#P5B\%^)/&ECH^L^$=1\-Z7=3K!_:TUY'*L&XX#RIM&U1GD@G
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M]I68KY&2O ;#J&]&#>E?J[\'?V>?A=^Q7\+I?$6M"Q&IV%LL^K^*KZ+?+O.
M5AX+(A8A51!ELKG<U 'XRWW@_7],L1>WFAZE:69&1<3VDB1_]]$8K(K]DO ?
M_!2KX-_$;QC!X8(UG1OMLHMH+[6;2-+29FX"DK(Q4,>,NH'/)%>3_P#!0C]B
M'P__ ,(7J?Q.\!:5#HVI:6OVC6-+LHPD%S!GYYT0<(Z?>;& RACU'S 'YBT5
M^I__  2?^,G_  D'P[U[X=7T^Z\T"?[=8*QY-I,QWJH]$ER3_P!=A7R=_P %
M%OA)_P *N_:5UJ[MH?*TKQ,@UJVVCY1)(2)USZ^:KMCL'6@#YAHK]2O^"3/P
MC_L/X?>(_B'>0;;G7+C^S[%V'(MH3^\93Z-*2I]X17S?^VAXLU+]J#]L9/!O
MAUQ<PV-U%X9TT9_=^:),3RG'82,^6_NQ@]J /DNSL[C4+F.WM8)+FXD.$BA0
MN['T ')JYK'AG6/#VS^U=)OM,\S[GVRV>+=]-P&:_:71/"/PH_X)_?!.769[
M=8Q;HD5YJJP*^H:K<MT1><\G.$R%4 DX 9JPO@A^VU\+OVL]:O/ 5WH-Q:7=
MW"[1:9X@@AF@OXU!+*N"P+!06*D= <$X- 'XRT5]5?\ !0+]EFP_9W^(EAJ/
MAJ)XO!_B)9);6W8EOL<Z$>;"&/\ #AU9<G."1SMR?NG_ ()B_P#)I^D_]A.]
M_P#1M 'X]Z3H&J:\\J:9IMWJ+Q+OD6T@:4HOJ=H.!5*2-X9&C=&1U)5E88((
MZ@BOVCU;]H#X#_L:ZD? ESJ+6&KW5PVH:D+2R>XE$D[&0S7+HO4YX498+MPH
M7%8?[(O[6%E\;?CG\7O#L$T;:9]M74]!95V^=:QJEM*^" ?F*0R8//[UNF*
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M **** .X^"/Q,_X4W\5_#7C7^S?[7_L:Z^T_8?/\CSOE*[=^UMO7KM-?=/\
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M^THGE6JM_%,W"<=\'YC[*:["OC[]KKQ]_;7BRU\,VTFZTTI?,GVGAKAQG'_
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M"HL=M9AB_EC ST'))R<X]/2K7@/P?XQA\1:=?Z9HVHQO#,C^<T31)MR,@LV
M01G(H S/B!X!U#X=ZW_9]\4F61/,AN(L[9%SC/L01R/_ *QK>^$/PK@^)LFJ
MK-J$EA]B$1'EQA]V_?ZD8QM_6O2_VJK=&T709BH\Q;B1 V.<%02/T%9W[*/^
MN\3_ .[;?SEH R?"O[.S75K)J'B+5/['L-Y$2$*LCKD@,Q8X3/4#G\*W[O\
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MS[X+>-+OPGXXTZ))7^P7TR6UQ!N^5MQVJV/520<^F1WKT']J_P#UGA?Z7/\
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M9KFY0ONEC8_=C08!QQTZUG_\$=_]9\6OII/_ +>5YS_P5L_Y..\.?]BI;?\
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MEMI[=%"Q"3;ED< !2<;3C)(Y%?4=_P" _@)^TQ:RW1T[P?XV>9<R7NGO"]V
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M#7BA(HVOICB.TNHRWE.Y_A1@[J6[$H3@ D &+_P4N>Y;]KCQ,)SF);.Q%O\
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M"JL/1I2A'_7(T ?EUK^N7OB?7M1UC4IC<:AJ%S)=W,S=7ED8L[?B235"BB@
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ML)$57+C. 2?S-?2'B7]G;X%P>'=5EA\ ^"4F2TE9&33[8,&"$@CCKFOPRHH
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ML.1T(4\5[RW_  23^$_V78OB;QB+C_GJ;JU*_P#?/V?I^- 'Y-45]L_M!?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!^B?PC_Y);X1_[!5M_P"BEKK:Y+X1_P#)+?"/_8*MO_12
MUUM !1110 4444 <-\<O^21^*O\ KQ?^E?GQ7Z#_ !R_Y)'XJ_Z\7_I7Y\4
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M %W6=:U'Q%J=QJ6K7]UJ>HW#;YKN\F::65O5G8DD^Y-4J** /1O W[1OQ/\
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MA7Y=N,8XK@Z* "O5]%_:N^,7A_1DTJP^)/B."QC01QQF_=S&H& J,Q+* .
M0!7E%% %W6M:U'Q'JESJ>K7]UJFHW+^9/>7DS332MZL[$EC[DU2HHH *]4\/
M?M4_%_PKHL>DZ7\1O$-KIT2".*#[<[B) ,!4+9* #H%(%>5T4 7]>\0:IXJU
M>YU76M1N]7U2Z;=/>WT[332D  %G8DDX ')Z 5M>!OBEXQ^&=U)<>$_$^K>'
M99/]9_9MY)"LG^\JG#?B#7+44 >G>,/VG/BQX]TN33=>^(.OW^GR+LEM3>M'
M%*N,8=4P&'L<UYC110 4444 =/X/^*/C/X>PW,7A7Q=KOAF*Z96G31]2FM%E
M*Y"EQ&PW$9.,^IKH?^&EOB__ -%5\;?^%%>?_'*\WHH ](_X:6^+_P#T57QM
M_P"%%>?_ !RN;\8_$SQ?\1/L?_"5^*M;\3_8]_V;^V-1FN_(W[=^SS&.W=M7
M..NT>@KFZ* -;PQXNUSP3JT>J>'M8O\ 0M2C&%N].N7@E ]-R$'''2O2-0_:
M\^-.J6!L[CXF^)/((*GRKYHG(/4%UPQ_.O(:* ))[B6ZFDFFD>::1B[R2,69
MF)R22>IK0\,^*M9\%ZQ!JV@:M>Z)JD&?*O-/N'@F3/!PRD$9%9=% 'J'BC]J
M'XM>--%?2-9^(?B"^TV1/+DMFO7595[K)M(WCV;-<_X5^,?C[P)I9TWPUXX\
M2>'M.,AF-GI6K7%K"7( +;(W R0!SC/ KCZ* +>KZQ?^(-4NM2U2]N-2U&ZD
M,UQ>7DK2S3.3DL[L26)/<G-=5\/?C7X\^$_G#PAXMU;P_%,VZ6"RNF6&1O[S
M1YVD\=2,UQ5% '7>-/B]XW^(VK6NJ>)O%>KZW?VC![::\O'<V[ @YC&<(<@'
MY<<BI?$WQJ^(?C;29-*\1>//$VO:7(RN]EJ>L7%S"S*<J2CN5)!Y''%<910
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7NO[/O[/LGCJ:'Q!X
M@A:+P]&V88&RK7K _I&#U/?H.Y!^S[^S[)XZFA\0>((6B\/1MF&!LJUZP/Z1
M@]3WZ#N1]D001VL,<,,:Q0QJ$2.-0JJH&  !T % !!!':PQPPQK%#&H1(XU"
MJJ@8  '0 4^BO!?VA/VA$\&Q3^'?#LZR:\XVW%TIR+,'L/63_P!!^M !^T)^
MT(G@V*?P[X=G637G&VXNE.19@]AZR?\ H/UKX\EF>>5Y97:21V+,[')8GDDG
MN:)9GGE>65VDD=BS.QR6)Y))[FF4 %%%% !1110 4444 %%%% !1110 5]L?
M\$M_@=8_$3XL:KXSUBU6ZL/"<<3VD4J@HU[*6\M^>OEJCL/1BA["OB>OU7_X
M)&6\2_!?QE.#^_?Q!L<?[*VT)7]6:@#K?V__ -L34/V=]'TSPUX1>W'C+6H7
MG-S,@D_L^V!*B4(>"[,&"YR!L8D'BOS47]K3XSIJ_P#:0^)_BC[3_=.IRF+Z
M>5G9C_@->O\ _!42XNIOVJ+M+A<10Z/9I;GUCPS$_P#?;/\ E7R/0!^RO[!'
M[75Y^TEX5U/2?$_V=/&FAA&FDMT\M;VW;A9]G0,&!#A>,E2 -V!\4_\ !3+X
M&V/PI^-EKX@T:V2ST?Q;#)>FWC7:D=VC 7 4>C;XW^LC=!BM+_@D_/=1_M):
MO' NZ"3PU<B?T"BXMB#_ -];1^)KV_\ X*^0PMX#^'<S8^T+J5TB?[IB0M^J
MK0!\S_"7_@G/\2?C+\-='\;:+K?A6UTK5(GEAAO[NY2=0DC(=P6W90<H>C'C
M%.^!?_!.7XF_&GPW:^(IY+'PCH=V@EM9-6WF>XC/(D2)02$(Y!8KD8(!!S7Z
M,?L#\_LA_#H'D?9;C_TJFKX7_:4_X*)?$UOBWK6E^ =;3POX8T6\DL;6."S@
ME>Y,3%#+(9$;AB#A1@!=N03DT <'\??^">_Q,^!/A^X\1,;+Q5X>MEWW-YI!
M<R6J]WEB900OJR[@!R<5PG[+W[.OB3]HWQW/I?AN]TNQN-)A349VU666-6C$
MJ*0I2-R6RPZ@#WK]7_V,_C]+^U!\#?[6UZSM_P"V+6XETG5H4CQ!.P16WA#G
MY7CD7(Z9W <8K\VM8\4>)/V*_P!K#QKH/@"]73H&O5L5^U6Z3G['*T<T:?.#
MR%9!NZG'O0!^KW[1OPWU/XO?!'Q=X.T:>TMM3U>T\B":^=DA5MZMEBJLP&%/
M137XU?%C]G'QC^SM\8_#7@[4]4TF7Q'?+:WME>:9-*\$1DG:.,LSQ*P(>,DX
M4\8Z]*_8K]J+QYK/PQ^ /C7Q3X?N$M=9TRR$UM-)$LBJWF*,E6!!X)ZU^.6J
M?&[Q;\?/CMX)\1>,[Z+4-5@O+&QCEAMT@ B6YW@;4 &=TC<]>: /IK]IKX,?
MM0^%?@=XFU3XA?%+1O$7@^W6W^WZ;:W,KR3 W$2QX#6J XD*-]X<+WZ5\Q?L
MX_LO^*OVG]9UG3?"VH:/I\^EVZ7$S:Q-+&K*S%0%\N)R3D=P*_5?_@H9_P F
M=_$/_<L?_2^WKY(_X)!_\E"^(7_8+M__ $<: /'XO^"=7Q;N?BM=^!K6/2;R
M2RMX;F\UR&XE&G6ZR E5,CQJ[/@?=5">AZ<UWOC+_@D_\2]!\/S7^B^(-#\1
MWL*%VTV(R0228'W8V<;2?]XK]:^@O^"D'[6/BOX(2>'O!_@B\_L;5]4@;4+S
M5$1'E2$,8TC0," 696);J @ ZFNN_P""<?Q^\6?'3X6Z_P#\)EJ']KZKHNHK
M;QW[1JDDD+QAE#[0 2"&^;&2",Y(S0!^>_P%_89^)WQ\DO)K*PB\.:19W#VL
M^I:YOA7SD8K)&B!2[LI!!X !!!(/%>@?%C_@E_\ $[X=>&;O7-(U#3/&,%I&
M99[/3Q)'=[0,DI&RX? SP&W<< U[1_P40_;(\:_#'XC6?P_\ ZFWAP6=JEYJ
M5_;QHTTTDN66,%E.U0N&)'+%_0<_3'[#?QCUWXX?L\Z-X@\2SK>:[#<3V-U=
M*BIYYC?Y7*J  Q1ES@8)!/&: /Q&T>*XGUBQCM)!%=//&L4C=%<L-IZ=CBOO
MS]HCX)_M4>&O@OXIU/QU\5M%U[PG;VZMJ&G6US*TDZ>8@  -H@/S%3]X=*^5
M/C3H=MX;_:L\8:99Q+!9V_BVX6&)!A43[42JCV ('X5^MO[=G_)I/Q(_Z\8_
M_1\5 'Y8?LX_L8^-?VGM#U?5?"VJ:#86^EW*VLRZQ<3QNS,NX%1'"X(QZD5Z
M]_PZ3^+W_0R>"?\ P.O/_D6O"_@7^UI\0?V=='U/3/!MU8V]KJ,ZW$XN[-9B
M75=HP3T&*^\/V)?C9^T#^TIX@?6M>U6PTWX?Z;)MN;B'2HTDOI1S]GB8@X'(
M+L.@( Y.0 >!_P##I/XO?]#)X)_\#KS_ .1:^/\ P]X/UCQ=XJM/#FB6$VJZ
MU>7'V:WM+5=S2R9Q@>W!))P  2< 5^RO[:W[7EA^S3X+^QZ8\-YX\U:)AIMF
MV&%LG(-S*/[H.=H/WF&.@8C\POV4?VDK7]FGXB7_ (MNO":>++RYM6M(R][]
MF:W#L&D=#Y;@L=H'0<9'<T >X>$_^"3/Q,U?3X;G6_$?A_P_-(NYK/?)<RQ>
MS%5"9_W6(]ZP_B9_P2Y^*_@;1+C5-'NM)\8Q6Z&1[/37D2[('7;&Z@/QV#;C
MT )KK/B3^VU\=_VAO$%JGP:\/^(]#T&.%%D@TK3Q>2R39)9WG$9VJ.  "HP,
MGKQ]T_LCWGQ7O/A##_PN.T:V\5QW<B1/)Y(EFM=J&-Y!$=JON+K@@'" D9.2
M ?C7\"?@3X@_:#^(2>#?#]SI^GZJUO+<>9JTDD<06,#<"41VSS_=K]O]?\ Z
MAJGP'U'P3%-;+JMSX:DT9)G9A )FM3"&)"[MFXYSMSCMVK\BOB]\1M?_ &<?
MVS/B1KG@BXATO48]6O%1GMTF14G;>X"N".K?A7ZV>)/&>JZ=^SKJGBV"95UN
M#PK+JD<QC4J+A;0RAMN,8W#..E 'XS_M(?LL>*_V7]1T.R\5:AHVH2ZO%+-
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MT %%%% !1110!\5_M6> ?^$7\??VS;1[;#6@9C@<+.,"0?CD-]6/I7B=??\
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MZ)_"/_DEOA'_ +!5M_Z*6NMKDOA'_P DM\(_]@JV_P#12UUM !1110 4444
M<-\<O^21^*O^O%_Z5^?%?H/\<O\ DD?BK_KQ?^E?GQ0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %6-/T^YU:^@L[."2YNIW$<4,2EF=B<
M 4:?I]SJU]!9V<$ES=3N(XH8E+,[$X  K[7^ WP&MOAG8KJFJ+'=>)IT^9^&
M6T4CE$/KZM^ XZ@!\!O@-;?#.Q75-46.Z\33I\S\,MHI'*(?7U;\!QU]AHHH
M *^<OVA_VAQHBW/ACPQ<YU$YCO+^,_ZCU1#_ '_4]OKT/VA_VAQHBW/ACPQ<
MYU$YCO+^,_ZCU1#_ '_4]OKT^368LQ9B22<DF@ 9BS%F)))R2:2BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O=?V??V?9/'4T/B#Q!"T7AZ-LPP-E6
MO6!_2,'J>_0=R#]GW]GV3QU-#X@\00M%X>C;,,#95KU@?TC!ZGOT'<C[(@@C
MM88X88UBAC4(D<:A550,  #H * """.UACAAC6*&-0B1QJ%55 P  .@ I]%>
M"_M"?M")X-BG\.^'9UDUYQMN+I3D68/8>LG_ *#]: #]H3]H1/!L4_AWP[.L
MFO.-MQ=*<BS![#UD_P#0?K7QY+,\\KRRNTDCL69V.2Q/))/<T2S//*\LKM)(
M[%F=CDL3R23W-,H **** "BBB@ HHHH **** "BBB@ HHHH *_0?_@DE\5K7
M2?%'B_X?WLXCEU:./4].5C@/)$&69!ZL49&QZ1-7Y\5I^&?$VJ>#?$.G:[HE
M[+INK:?.MS:W4)P\<BG((_P/!'!XH _3+_@IW^R[KOQ &D_$KPGIUQJU[IMH
M;'5K*U7?)]F5F>.9$'+;2[A@,G!4XPI-?EXJ,SA I+DX"@<Y]*_5'X#_ /!5
M#P?X@TBUL/B?;3>&=;C4))JEG;O/97!Z;]B R1D_W<,.O(Z5[7_PUU^SE'=G
M7!XT\-B_(P;M;9OM)'I_J]] 'CG_  3)_9AUSX5Z+K7CWQ;I\^DZSK<*V=A8
M7(V2QV>5D:1UZJ7<)A6P0(\X^:O$O^"L7Q6M?$WQ.\->"+&<3#PW:R7%[L/"
MW%QL(0^ZQQH?^VE>L_M _P#!5'PSI.CW6F?"FVGUS69D*)K=_;M#:6V>-Z1.
M \C#L&55Z$[N5K\Q=:UJ^\1ZQ>ZKJEW+?ZE>S/<7-U.Q9Y9&)9F8]R22: /V
MU_8%_P"31/AS_P!>MQ_Z535^0/[0W@'4OAE\;/&?A_4[=[>:WU.=XMP.)(7<
MO%(I/4,C*?QK]?OV!?\ DT3X<_\ 7K<?^E4U>1^'_P!L#]GOXX3M:?%W0M!T
MWQ5HUQ):@Z]IBW5NX20C=#,4;:IZF-R.2?O8S0!:_P""4O@O4/#O[/VK:Q?0
M/;Q:YK,EQ9[^/,ACC2/>!Z%UD'OMKX=_;2\1P^)?VUO&-W"Z/%#JMK9[D((W
M00PPOSZAHV_E7VW^T!_P4C^'/P]\%7&C_"^ZC\2>(FM_LUDUG;-%8:>-NU7)
M90&VC&U$!'&"5K\G;B^N;J^DO9YY)KN20S//(Q9V<G)8D]23SF@#]ROVX%+_
M +)_Q* &3_9F?RE0U^*OPN_Y*9X1_P"PO9_^CDK]:_AC_P % O@O\4/A[;0>
M,M<L]$U6>S\G5M'UJT8PR-MQ( =K1R1L<X&<X."HZ5\1_M<?$/X0ZQ^T-\/]
M7^&<NFV_AK1XK6*__LC3&M+:-H[MY2RH(UWG:_)4'. .: /T!_X*&?\ )G?Q
M#_W+'_TOMZ^2/^"0?_)0OB%_V"[?_P!'&O2OVROVT_@U\5OV;/&7A7PMXQ_M
M37M06U%M:?V7>P^9LNX9&^>2%5&%1CR1T]:^=?\ @G'\>_ GP%\9>,;[QUKO
M]AVNH6$,-M)]CGN/,=9"Q&(8W(X]<4 =!_P5N8_\- >%QGC_ (1B$_\ DW=5
MZ_\ \$@O^1$^(G_82M?_ $4]?,__  42^-?@SXZ_&+0=<\#ZS_;>EVN@Q64T
M_P!EFM]LPN+ARNV5$8_*Z'(&.>O6O2?^"</[37PU^ OA/QG9>._$G]A7.H7T
M$ULGV&YN/,18V#',,;@8)'7% 'E__!2ABW[7GBP$Y MK #_P$BK[D_X)9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM&8L^T<M;M@/_P!\G:WL-WK7QG0 4444 %%%% !1110 4444 %%%% !1110
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M2XS<S>9D1IN)Y;'+,<>HXQ[4GPB^.)\?:D^DZG:0V>I;#)"\!/ER@=5P22&
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M>#PAXP6XL8A#8:DAG2-1A4D!PZ@=AR#_ ,"Q7N/[/_\ R2C1_P#>G_\ 1ST
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M%_T -4_\ Y/_ (FC_A"?$7_0 U3_ , Y/_B: ,6BMK_A"?$7_0 U3_P#D_\
MB:/^$)\1?] #5/\ P#D_^)H Q:*VO^$)\1?] #5/_ .3_P")H_X0GQ%_T -4
M_P# .3_XF@#%HK:_X0GQ%_T -4_\ Y/_ (FC_A"?$7_0 U3_ , Y/_B: ,6B
MMK_A"?$7_0 U3_P#D_\ B:/^$)\1?] #5/\ P#D_^)H Q:*VO^$)\1?] #5/
M_ .3_P")H_X0GQ%_T -4_P# .3_XF@#%HK:_X0GQ%_T -4_\ Y/_ (FC_A"?
M$7_0 U3_ , Y/_B: ,6BMK_A"?$7_0 U3_P#D_\ B:/^$)\1?] #5/\ P#D_
M^)H Q:*VO^$)\1?] #5/_ .3_P")H_X0GQ%_T -4_P# .3_XF@#%HK:_X0GQ
M%_T -4_\ Y/_ (FC_A"?$7_0 U3_ , Y/_B: ,6BMK_A"?$7_0 U3_P#D_\
MB:/^$)\1?] #5/\ P#D_^)H Q:*VO^$)\1?] #5/_ .3_P")H_X0GQ%_T -4
M_P# .3_XF@#%HK:_X0GQ%_T -4_\ Y/_ (FC_A"?$7_0 U3_ , Y/_B: ,6B
MMK_A"?$7_0 U3_P#D_\ B:/^$)\1?] #5/\ P#D_^)H Q:*VO^$)\1?] #5/
M_ .3_P")H_X0GQ%_T -4_P# .3_XF@#%HK:_X0GQ%_T -4_\ Y/_ (FC_A"?
M$7_0 U3_ , Y/_B: ,6BMK_A"?$7_0 U3_P#D_\ B:/^$)\1?] #5/\ P#D_
M^)H Q:*VO^$)\1?] #5/_ .3_P")H_X0GQ%_T -4_P# .3_XF@#%HK:_X0GQ
M%_T -4_\ Y/_ (FC_A"?$7_0 U3_ , Y/_B: ,6BMK_A"?$7_0 U3_P#D_\
MB:/^$)\1?] #5/\ P#D_^)H Q:*VO^$)\1?] #5/_ .3_P")H_X0GQ%_T -4
M_P# .3_XF@#%HK:_X0GQ%_T -4_\ Y/_ (FC_A"?$7_0 U3_ , Y/_B: ,6B
MMK_A"?$7_0 U3_P#D_\ B:/^$)\1?] #5/\ P#D_^)H Q:*VO^$)\1?] #5/
M_ .3_P")H_X0GQ%_T -4_P# .3_XF@#%JQI^GW.K7T%G9P275U.XCBAB4LSL
M3@ "M6'P'XEN)HXH_#VJ-)(P55^QR<DG '2OL+X#_ >V^&=BNJ:HL=UXFG3Y
MGX9;52.40^OJWX#CJ 'P&^ UM\,[%=4U18[KQ-.GS/PRVBD<HA]?5OP''7V&
MBB@ KYR_:'_:'&B+<^&/#%SG43F.\OXS_J/5$/\ ?]3V^O3:^/WQ2\06-K)X
M?\(:5J5S=3+BYU2VM)&2)3_#&P&"Q[L.GUZ?*+> _%#,6;P[JY).238R_P#Q
M- &"S%F+,223DDTE;W_" ^)_^A<U;_P!E_\ B:/^$!\3_P#0N:M_X R__$T
M8-%;W_" ^)_^A<U;_P  9?\ XFC_ (0'Q/\ ]"YJW_@#+_\ $T 8-%;W_" ^
M)_\ H7-6_P# &7_XFC_A ?$__0N:M_X R_\ Q- &#16]_P (#XG_ .A<U;_P
M!E_^)H_X0'Q/_P!"YJW_ ( R_P#Q- &#16]_P@/B?_H7-6_\ 9?_ (FC_A ?
M$_\ T+FK?^ ,O_Q- &#16]_P@/B?_H7-6_\  &7_ .)H_P"$!\3_ /0N:M_X
M R__ !- &#16]_P@/B?_ *%S5O\ P!E_^)H_X0'Q/_T+FK?^ ,O_ ,30!@T5
MO?\ " ^)_P#H7-6_\ 9?_B:/^$!\3_\ 0N:M_P" ,O\ \30!@T5O?\(#XG_Z
M%S5O_ &7_P")H_X0'Q/_ -"YJW_@#+_\30!@T5O?\(#XG_Z%S5O_  !E_P#B
M:/\ A ?$_P#T+FK?^ ,O_P 30!@T5O?\(#XG_P"A<U;_ , 9?_B:/^$!\3_]
M"YJW_@#+_P#$T 8-%;W_  @/B?\ Z%S5O_ &7_XFC_A ?$__ $+FK?\ @#+_
M /$T 8-%;W_" ^)_^A<U;_P!E_\ B:/^$!\3_P#0N:M_X R__$T 8-%;W_"
M^)_^A<U;_P  9?\ XFC_ (0'Q/\ ]"YJW_@#+_\ $T 8-%;W_" ^)_\ H7-6
M_P# &7_XFC_A ?$__0N:M_X R_\ Q- &#16]_P (#XG_ .A<U;_P!E_^)H_X
M0'Q/_P!"YJW_ ( R_P#Q- &#16]_P@/B?_H7-6_\ 9?_ (FC_A ?$_\ T+FK
M?^ ,O_Q- &#16]_P@/B?_H7-6_\  &7_ .)H_P"$!\3_ /0N:M_X R__ !-
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M\3_]"YJW_@#+_P#$T 8-%;W_  @/B?\ Z%S5O_ &7_XFC_A ?$__ $+FK?\
M@#+_ /$T 8-%;W_" ^)_^A<U;_P!E_\ B:/^$!\3_P#0N:M_X R__$T 8-%;
MW_" ^)_^A<U;_P  9?\ XFC_ (0'Q/\ ]"YJW_@#+_\ $T 8-%;W_" ^)_\
MH7-6_P# &7_XFC_A ?$__0N:M_X R_\ Q- &#16]_P (#XG_ .A<U;_P!E_^
M)H_X0'Q/_P!"YJW_ ( R_P#Q- &#16]_P@/B?_H7-6_\ 9?_ (FC_A ?$_\
MT+FK?^ ,O_Q- &#16]_P@/B?_H7-6_\  &7_ .)H_P"$!\3_ /0N:M_X R__
M !- &#16]_P@/B?_ *%S5O\ P!E_^)H_X0'Q/_T+FK?^ ,O_ ,30!@T5O?\
M" ^)_P#H7-6_\ 9?_B:/^$!\3_\ 0N:M_P" ,O\ \30!@T5O?\(#XG_Z%S5O
M_ &7_P")H_X0'Q/_ -"YJW_@#+_\30!@T5O?\(#XG_Z%S5O_  !E_P#B:/\
MA ?$_P#T+FK?^ ,O_P 30!@T5O?\(#XG_P"A<U;_ , 9?_B:/^$!\3_]"YJW
M_@#+_P#$T 8-%;W_  @/B?\ Z%S5O_ &7_XFC_A ?$__ $+FK?\ @#+_ /$T
M 8-%;W_" ^)_^A<U;_P!E_\ B:/^$!\3_P#0N:M_X R__$T 8-%;W_" ^)_^
MA<U;_P  9?\ XFC_ (0'Q/\ ]"YJW_@#+_\ $T 8-%;W_" ^)_\ H7-6_P#
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MR_; ^'_]H:+8^++6+,]B1;794<F%C\C'_=<X_P"!T ?)E%%% !1110 4444
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M!((&!T/ 'IROPX^ .F^&]/NAXAAL]:O;@@8,>Z.%1GA"0#DYY/'0?B >?_M
M_$#PYXXL=&&BW_VV:UDEWCR)(]JL%[NH[KVKU?\ 9_\ ^24:/_O3_P#HYZ^?
M?C)'X8L_%1LO"]I'#!;+MN)8I7=9)<\@9)&%Z<=R?2OH+]G_ /Y)1H_^]/\
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MGOB7_L&W'_HMJ^-_"/BF]\&>(+35[ KY\#?<?[KJ1AE/L17V1\2/^2>^)?\
ML&W'_HMJ^7?@S-X:;Q7]D\3VEO/:W2;(9K@D+'+GC/.,'D<]\>] 'NOA?]H;
MPIKT<:WL\FC71X,=TI*9]G'&/<XKMGC\/>-K/YET[7+;'7Y)U'X\XKA?B5\"
M=-\5:7;+H4%EHE];%MOEPA(Y0<9#[1G/ P>>_K7)_#O]GWQ!X:\5V&JWVJ6E
MO#:R"0K9N[/*!_"<J %/0^W:@"G\;O@GIWAW19?$&@HUM#"R_:;,L64*Q #)
MGD<D9'3![8KSKX8?$F[^&VMO=11?:K.X4)<VQ;;O /# ]F&3CZFOH']H/Q99
MZ'X#NM->16O]2 BBASSM# LY'H ,?4BO,_V>[;PEKDUUI>MZ;:7&K[_,M7N0
M6\U,<H 3MR,9Z9()]* /7?#OQS\'^(50?VHNG3MUAU >5C_@7W?UKH=4\,^'
M/&MKON[&QU6)Q@3A58_@XY'X&O,?BA^ST/$FH1W_ (;:RTQ]@26S9/*B..C+
ML4X..,8[5;^#/P:UCX?ZS<:CJ6I0,)(3$+2T9F5LD'<Q('3'8=^M 'EWQN^$
M\'P]N[6]TUW;2KQB@CD;<T,@YVY[@CIWX.:](_99_P"10U;_ *_O_::5D_M0
M^++.:WT[P]#(LMW'-]JG"G/E?*553[G<3CT ]:3]EC7H%76M&D=4N&9+J)2>
M7&-KX^GR_G0!R_[32D?$6$^MA$?_ !]ZK_LWQEOB9$1T6UF)_(#^M>O_ !A^
M#+_$:ZM-0L;R.SU""+R&$X)CD3)*\CD$$MV/7VJ/X5_"NR^%=XL^HZC%<ZWJ
M6;:!4!"A0-[*N>2<)DDXZ ?4 J_M0_\ )/['_L)Q_P#HJ6E_9@>-OA_>*OWU
MU&3?_P!^X\?I2?M0_P#)/['_ +"<?_HJ6N"_9N\>0:#K5UH=],L-MJ!5H'<X
M F'&W/\ M#]5 [T >I^/]8^&UGKYB\51VS:H(E.9K260[.=O*J1CK61H_CWX
M0^'[Y;S39;6SNE!42Q6$X8 C!'W*U/B]\&T^([6U]9W4=EJL">5NE4F.5,Y
M;'(().#@]?RQ_AG^SW;>&VNKCQ(++6)Y4\N.W5"\48R"6RP!+< 9P,#/K0!S
M?QX^)?A?QKX0M;32-2^V7D5ZDVS[/*F$V."<LH'4BL#X0?'#_A!++^R-5MY+
MK2MY>*2'!D@).2,$@%2>>N1D]:J?':S\)Z-KD&F>'+&&"ZAW&]EAD=E#=H\$
MD CDG'J!ZUZA\%='\$>*O"MM-'HFGR:M;H([R.:,2L''&_#YX;&>..H[4 =O
MH7Q5\)^)%46FN6HD;_EC<-Y+_3:^,_AFF^)?A9X6\7PL;O2H%E<9%U:J(I?K
MN7K^.17C_BK]F/4Y-9N)M"O;+^SY7+I#=,R/%DYV\*00/7]*]6^$G@*\^'?A
MF2POM06]EDF,Q6//EQ< ;5SSVSG ^E 'RS\1/!<W@'Q5=:3))Y\:XDAFZ%XV
M^Z3[]C[@US5>A_';Q7:>+/'\\UBZS6MI"MHLR\B0J6)(/<98C/?%>>4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y?T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!^B?PC_Y);X1_[!5M_P"BEKK:Y+X1_P#)+?"/_8*MO_12UUM !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %,FACN(S'+&LL;=5< @_A3Z* *?\ 8VG_ //C
M;?\ ?E?\*/[&T_\ Y\;;_ORO^%7** *?]C:?_P ^-M_WY7_"C^QM/_Y\;;_O
MRO\ A5RB@"G_ &-I_P#SXVW_ 'Y7_"C^QM/_ .?&V_[\K_A5RB@"G_8VG_\
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M%%% !1110 4444 %%%% !1110 4444 ?E_1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z)_"/_ ));X1_[
M!5M_Z*6NMKDOA'_R2WPC_P!@JV_]%+76T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!^7]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?HG\(_P#DEOA'_L%6W_HI:ZVN
M2^$?_)+?"/\ V"K;_P!%+76T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!^7]%?>__  Z'\;_]#WX?_P"_$_\ A1_PZ'\;_P#0]^'_ /OQ
M/_A0!\$45][_ /#H?QO_ -#WX?\ ^_$_^%'_  Z'\;_]#WX?_P"_$_\ A0!\
M$45][_\ #H?QO_T/?A__ +\3_P"%'_#H?QO_ -#WX?\ ^_$_^% 'P117WO\
M\.A_&_\ T/?A_P#[\3_X4?\ #H?QO_T/?A__ +\3_P"% 'P117WO_P .A_&_
M_0]^'_\ OQ/_ (4?\.A_&_\ T/?A_P#[\3_X4 ?!%%?>_P#PZ'\;_P#0]^'_
M /OQ/_A1_P .A_&__0]^'_\ OQ/_ (4 ?!%%?>__  Z'\;_]#WX?_P"_$_\
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M$45][_\ #H?QO_T/?A__ +\3_P"%'_#H?QO_ -#WX?\ ^_$_^% 'P117WO\
M\.A_&_\ T/?A_P#[\3_X4?\ #H?QO_T/?A__ +\3_P"% 'P117WO_P .A_&_
M_0]^'_\ OQ/_ (4?\.A_&_\ T/?A_P#[\3_X4 ?!%%?>_P#PZ'\;_P#0]^'_
M /OQ/_A1_P .A_&__0]^'_\ OQ/_ (4 ?!%%?>__  Z'\;_]#WX?_P"_$_\
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M+4\5?]!9O^_,?_Q-<G11]5H?\^U]R#ZYB?\ G[+[V=9_PM3Q5_T%F_[\Q_\
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M5:'_ #[7W(/KF)_Y^R^]G6?\+4\5?]!9O^_,?_Q-'_"U/%7_ $%F_P"_,?\
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M_P#C-?/=%'U:A_(ON0KL^A/^'@'Q]_Z*%/\ ^"VR_P#C-'_#P#X_?]%"G_\
M!;9?_&:^>Z2CZM0_D7W(=V?0O_#P#X_?]%"G_P#!;9?_ !FD_P"'@'Q^_P"B
MA3_^"VR_^,U\]T4?5J'\B^Y!=GT)_P / /C]_P!%"G_\%ME_\9H_X> ?'[_H
MH4__ (+;+_XS7SW24?5J'\B^Y"NSZ%_X> ?'[_HH4_\ X+;+_P",T?\ #P#X
M_?\ 10I__!;9?_&:^>J*/J]#^1?<AW9]"?\ #P#X_?\ 10I__!;9?_&:/^'@
M'Q^_Z*%/_P""VR_^,U\]TE+ZO0_D7W(+L^A?^'@/Q^_Z*%/_ ."VR_\ C-'_
M  \!^/W_ $4*?_P6V7_QFOGJBI^KT?Y%]R"[/H7_ (> _'[_ **%/_X+;+_X
MS1_P\"^/W_10I_\ P6V7_P 9KYZI*/J]'^1?<@NSZ%_X>!?'[_HH4_\ X+;+
M_P",T?\ #P+X_?\ 10I__!;9?_&:^>J*/J]'^1?<@YGW/H7_ (>!?'__ **'
M/_X+;+_XS1_P\"^/_P#T4.?_ ,%ME_\ &:^>:*/J]'^1?<@YGW/H7_AX%\?_
M /HH<_\ X+;+_P",T?\ #P+X_P#_ $4.?_P6V7_QFOGJDH^KT?Y%]R#F?<^A
MO^'@7Q__ .BAS_\ @MLO_C-'_#P+X_\ _10Y_P#P6V7_ ,9KYYHH^KT?Y%]R
M#F?<^A?^'@7Q_P#^BAS_ /@MLO\ XS1_P\"^/_\ T4.?_P %ME_\9KYYHI?5
MZ/\ (ON0<S[GT-_P\"^/_P#T4.?_ ,%ME_\ &*/^'@7Q_P#^BAS_ /@MLO\
MXQ7SS24OJ]'^1?<@YGW/H;_AX'\?_P#HH<__ (+;+_XQ1_P\#^/_ /T4.?\
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M**/J]'^1?<@YGW/H?_AX-^T#_P!%$G_\%ME_\8H_X>#?M _]%$G_ /!;9?\
MQBOG>BE]7H_R+[D',^Y]$?\ #P;]H'_HHD__ (+;+_XQ1_P\&_:!_P"BB3_^
M"VR_^,U\[T4O84?Y%]R#F?<^A_\ AX/^T#_T42?_ ,%ME_\ &:/^'@_[0/\
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MM11["E_(ON0<S[GT3_P\)_:"_P"BBS_^"RR_^,4?\/"OV@O^BBS_ /@LLO\
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M4?\ #PO]H/\ Z*+/_P""RR_^,5\Z44>PI?R+[D%V?17_  \+_:#_ .BBS_\
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M (Q7SG11[&E_*ON"[/HS_AX=^T+_ -%&G_\ !99?_&*3_AX?^T+_ -%&G_\
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MJ?\ *ON"[/HW_AXE^T/_ -%'N/\ P66/_P 8H_X>)?M#_P#11[C_ ,%EC_\
M&*^<:*/94_Y5]P79]'?\/$OVA_\ HH]Q_P""RQ_^,4G_  \2_:'_ .BCW'_@
MLL?_ (Q7SE24>QI_RK[@NSZ._P"'B7[0_P#T4>X_\%EC_P#&*/\ AXE^T/\
M]%'N/_!98_\ QBOG&BCV-/\ E7W!=GT=_P /$OVA_P#HH]Q_X++'_P",4?\
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MQ_X*['_XQ1_P\:_:*_Z*3<?^"NQ_^,5\VT4>SA_*@NSZ1_X>-?M%?]%)N/\
MP5V/_P 8H_X>-?M%?]%)N/\ P5V/_P 8KYNI*/9P_E079])?\/&OVBO^BDW'
M_@KL?_C%'_#QK]HO_HI-Q_X*['_XQ7S;11[.'\J"[/I'_AXU^T7_ -%)N/\
MP5V/_P 8H_X>-?M%_P#12;C_ ,%=C_\ &*^;:*7LX?RH+L^DO^'C7[1?_12;
MC_P5V/\ \8H_X>-?M%_]%)N/_!78_P#QBOFVDI>SAV079])_\/&OVB_^BDW'
M_@KL?_C%)_P\;_:+_P"BDW'_ (*['_XQ7S;12]G#L@NSZ2_X>-_M%_\ 12;C
M_P %=C_\8H_X>-_M%_\ 12;C_P %=C_\8KYMI*/9P[(+L^D_^'C?[1?_ $4J
MX_\ !78__&*/^'C?[1?_ $4FX_\ !78__&*^;**/9P[(+L^D_P#AXW^T7_T4
MJX_\%=C_ /&*3_AXY^T7_P!%*N/_  5V/_QBOFVDH]G#L@NSZ3_X>.?M%_\
M12KC_P %=C_\8H_X>.?M&?\ 12KC_P %=C_\8KYLHH]G#L@NSZ3_ .'CG[1G
M_12KC_P5V/\ \8H_X>.?M&?]%*N/_!78_P#QBOFRDH]G#L@NSZ3_ .'CG[1G
M_12KC_P5V/\ \8H_X>.?M&?]%*N/_!78_P#QBOFRBIY(=@NSZ3_X>.?M&?\
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M%=C_ /&*3_AY%^T=_P!%+N/_  5V/_QBOFJBCDCV&?2O_#R+]H[_ **7<?\
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M)/VC_P#HIEQ_X*K#_P",5\T44<L>P'TO_P /)/VC_P#HIEQ_X*K#_P",4?\
M#R3]H_\ Z*9<?^"JQ_\ C%?-%%'+'L!]+_\ #R3]H_\ Z*9<?^"JQ_\ C%)_
MP\D_:0_Z*9<?^"JQ_P#C%?-%%3RQ[ ?2_P#P\D_:0_Z*9<?^"NQ_^,4?\/)/
MVD/^BF7'_@KL?_C%?-%%'+'L!]+_ /#R3]I#_HIEQ_X*['_XQ2?\/)/VD/\
MHIEQ_P""NQ_^,5\T44<L>P'TO_P\D_:0_P"BF7'_ (*['_XQ2?\ #R7]I#_H
MIEQ_X*K'_P",5\T4E'+'L!],?\/)OVD/^BF7'_@KL?\ XQ2?\/)OVD/^BF7'
M_@KL?_C%?,]%'+'L!],?\/)OVD/^BF7'_@JL/_C%)_P\F_:1_P"BF7'_ (*K
M'_XQ7S/11RQ[ ?3'_#R;]I'_ **9<?\ @JL?_C%'_#R;]I'_ **9<?\ @JL/
M_C%?,])2Y8]@/IG_ (>3?M(_]%,N/_!58?\ QBC_ (>3?M(_]%,N/_!58?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'Y>?&S_DL/C;_L,W?_ *-:N*KM?C9_R6'QM_V&;O\ ]&M7%5D?JE#^%#T7
MY!2444C8***2D 4444@"BBDH **** "BBDH **** "BBDI %%%%( HHI*0!1
M110 4E%% !1124 %%%% !2444@"BBDI %%%% !1124 %%%% !1124 %%%)2
M***2D 4E%%( I*** "BBB@ I*** "BBB@ I*** "BBBD 4E%%2 4444 %)11
M0 444E !1110 444E !1114@%%%)0 4444 %%%)0,****!A2444#"DHHI %%
M%%2 4E%% !1110 4E%% !1110 4E%% !1112 *2BBD 444E( HHI* "DHHH
M*2BB@ HHI* "BBBD 4E%%( HHHH *2BB@ HHHH *2BB@ HHHI %)112 ***2
MD 4444 %%%)0 4444 %%%)0 4444 %%%)4@%%%%( I*** "BBDH **** "BB
MDH **** "BBDJ0"BBB@ I*** "BBB@ I*** "BBDH ***2D,*2BBI&%)110,
M***2@ HHHH *2BB@ HHHH *2BBD 4444@"DHHI %%%% !2444 %%%% !2444
M %%%)2 ****0!1124 %%%% !1124 %%%% !2444@"BBDI %%%%( HHI* "BB
MB@ HHI* "BBB@ HHI* "BBBI ***2D 444E !2444 %)124 %%%% !1124@"
MBBBD 444E !1110 4E%% !1110 4E%% !1112&%)114C"BBB@ I*** "BBB@
M I*** "BBDH ****0!1125(!1110 4E%% !1110 4E%% !1110 4E%%( HHH
MI %)110 4E%)0 4E%% !2444 %%%)2 ****0!1124@"BBB@ HHI* "BBB@ H
MHI* "BBB@#5\+02W/B&PC@E2"9I!MDD^Z#[UZ1KDNNV=OKES*+*_5@L!D0#/
M8<#\:\]\&I:R>(+87D$MQ;@DLD();I767\6@S+#%:W%Y8--=9=9<[54'K@UM
M#X3DJ_&C+UJWMXQH^G3:7+82JH:XD499AZBH9+>+6O%4=M8WQ^RPC,4EX>!C
MG%:J7%S_ &UJ>HV^K17B6*>7')< ?.N.@K#CWV>@WUY>:>LQOB1%.>-A]0*&
M..W]=?4CFEF\0>(VFN8#<0PG]Z+9>-H[BJ<T::WKWDVSF*!FVQ^<WW15BUD3
M2-#>:*[FM]0F.TQ!>"GY4EK%_9.BS7,]K'.+P>7%(S?-&?4"HWW--MO0J>(+
MHW-\(A##&81Y?[D<-CO676MHJ+ );XSQQRP\I'(N=YJ@RS7]Q)(L9=F)9@B]
M,U#[FBTT/W0HHHK] /Q\**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\N_C9_P EA\;?]AF[_P#1K5Q5=K\;/^2P
M^-O^PS=_^C6KBJQ9^J4/X4/1?D%%%)2-@HHHI %%%)0 4444 %%%)0 4444
M%%%)2 ****0!1124@"BBB@ I*** "BBDH **** "DHHI %%%)2 **** "BBD
MH **** "BBDH ***2D 444E( I***0!2444 %%%% !2444 %%%% !2444 %%
M%%( I***D HHHH *2BB@ HHI* "BBB@ HHI* "BBBI ***2@ HHHH ***2@8
M4444#"DHHH&%)112 ****D I*** "BBB@ I*** "BBB@ I*** "BBBD 4E%%
M( HHI*0!1124 %)110 4E%% !1124 %%%%( I***0!1110 4E%% !1110 4E
M%% !1112 *2BBD 444E( HHHH ***2@ HHHH ***2@ HHHH ***2I ****0!
M2444 %%%)0 4444 %%%)0 4444 %%%)4@%%%% !2444 %%%% !2444 %%%)0
M 444E(84E%%2,*2BB@8444E !1110 4E%% !1110 4E%%( HHHI %)112 **
M** "DHHH **** "DHHH ***2D 4444@"BBDH **** "BBDH **** "DHHI %
M%%)2 ****0!1124 %%%% !1124 %%%% !1124 %%%%2 444E( HHI* "DHHH
M *2BDH **** "BBDI %%%%( HHI* "BBB@ I*** "BBB@ I*** "BBBD,*2B
MBI&%%%% !2444 %%%% !2444 %%%)0 4444@"BBDJ0"BBB@ I*** "BBB@ I
M*** "BBB@ I***0!1112 *2BB@ I**2@ I*** "DHHH ***2D 4444@"BBDI
M %%%% !1124 %%%% !1124 %%%% !1125('8?"^*^D\1%["2&.5(F)\_H:[K
M5)-=BN(Y;VPL;U+6%G)C.,Y%<#\.X]-;4;DZBMPRB/Y/L^>#WSBNCUG^PQ',
MMI?ZA;R2,L123=C;WZUU4]('#45ZFWX'/ZA$L>C6UO)I,EO?7DQF$RC[R$DX
M ^A'Y57U".TOM2L]-M+N:*R4 -]HZ(W>M1[@?VM-<0:UYD.F1 6QF&<\8*BL
MQ9KBRTNZU*XC@N#J!*!FP67W J&:HBOOM?B#6DM5"7BVB[ 81M#(O>J&I2PZ
MAJ2Q6ZFUM\A=KG(4]":G,:Z+I?[V*:WU&;YHW!P#&:2U?^R=-:Z5X9I+@&(Q
M.,LH/>H>NYHM-B/6IF5HM-1HIH[8[5DC7ELU)'?/X?MT%G.R74G^OC=/NXZ5
M7TV".WC-W<F2'C,#*N0S"H8[>]URZD=$:>7[S$4M=UN.RV>Q^Y5%%%??GY"%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^7?QL_Y+#XV_[#-W_Z-:N*KM?C9_R6'QM_V&;O_P!&M7$U@S]4H?PH
M>B"BBBD;!1124 %%%% !1124 %%%% !1124@"BBBD 444E( HHHH *2BB@ H
MHI* "BBB@ I***0!1124@"BBB@ HHI* "BBB@ HHI* "BBDI %%%)2 *2BBD
M 4E%% !1110 4E%% !1110 4E%% !1112 *2BBI **** "DHHH ***2@ HHH
MH ***2@ HHHJ0"BBDH **** "BBDH&%%%% PI***!A2444@"BBBI *2BB@ H
MHHH *2BB@ HHHH *2BB@ HHHI %)112 ***2D 444E !2444 %)110 444E
M!1112 *2BBD 4444 %)110 4444 %)110 4444@"DHHI %%%)2 **** "BBD
MH **** "BBDH **** "BBDJ0"BBBD 4E%% !1124 %%%% !1124 %%%% !11
M25(!1110 4E%% !1110 4E%% !1124 %%%)2&%)114C"DHHH&%%%)0 4444
M%)110 4444 %)112 ****0!2444@"BBB@ I*** "BBB@ I*** "BBDI %%%%
M( HHI* "BBB@ HHI* "BBB@ I***0!1124@"BBBD 444E !1110 444E !11
M10 444E !1114@%%%)2 ***2@ I*** "DHI* "BBB@ HHI*0!1112 ***2@
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M_P#H6=8_\%\O_P 37[ T5U?55W/!_M^?_/M?>?C[_P *[\5_]"SK'_@OE_\
MB:/^%=^*_P#H6=8_\%\O_P 37[!44?5%W#^WY_\ /M?>?C[_ ,*[\5_]"SK'
M_@OE_P#B:/\ A7?BO_H6=9_\%\O_ ,37[!44OJ:_F#^WY_\ /O\ '_@'X^?\
M*[\5_P#0LZS_ ."^7_XFC_A7?BO_ *%C6?\ P7R__$U^P=%'U-?S!_;\_P#G
MW^/_  #\?/\ A7?BO_H6-8_\%\O_ ,31_P *[\5_]"QK'_@OE_\ B:_8.BCZ
MFOY@_M^?_/O\?^ ?CW_PKOQ7_P!"QK'_ (+Y?_B:/^%=^*_^A8UC_P %\O\
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M**2@ HHHH ***2@ HHHH *2BBD 444E( HHHI %%%)0 4444 %%%)0 4444
M%%%)0 4445(!1124@"BBDH *2BB@ I**2@ HHHH ***2D 4444@"BBDH ***
M* "DHHH **** "DHHH ****0PI***D84444 %)110 4444 %)110 444E !1
M112 ***2I **** "DHHH **** "DHHH **** "DHHI %%%%( I*** "DHI*
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MVCA"*JY98Q@ #O3_ +:ECF.VVRH<$M(G.<=*DH_<FBBBOT$_'PHHHH ****
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M<W_BQ]#>GL%%%%>":!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7R[^VE^Q;I?[2&@OK>B)!IGQ!L8L6UVP"QWR#I
M!,?_ $%_X>AXZ?45%:TZDJ4E.#U$U<_G1\2>&]4\'Z]?Z)K=A-IFK6,K07-I
M<IMDB<=01_G/6LVOV>_;2_8MTO\ :0T%];T1(-,^(-C%BVNV^6.^0=()C_Z"
M_P##T/'3\<O$GAO5/!^O7^B:W83Z9JUC*T%S:7"%9(G'4$?YSUKZ_"XJ.)C=
M;]4<\H\I]M?L&_MY/\-Y+'X=_$2^:3PDY$.EZS<,2=+)X$4A_P">'H?^6?\
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M4C"DHHH&%%%)0 4444 %)110 4444 %)179K\%O'[>"O^$P7P5KY\*>5Y_\
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M44@"DHHH *2BDH *2BB@ I*** "BBDI %%%%( HHI*0!1110 444E !1110
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M/))Q8PHHHJ "BBB@ HHHH **** "BBB@ HHHH *_,;_@H#_P3^_LW^TOB?\
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MG6#D1?VO)X8ABCP3C=YD;&<8ZYV@UDZZN^5-CL?EU7TY_P $T_\ D]?X=?\
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M(0\LS97]V.YV[6-:%C^T=^PIXHUB#PU<?#*UTJPD;RUUJ?P[%! ,\9:6-_/
MZ<E>,YXY-<OMM?=5QV/RWHK[D_;\_8*TKX#Z+9_$3X<W$UWX$NY$CNK.:?SS
M8M)S$\<G5X6X4%B2#MY8-QR_[ W[#J_M3:IJ>O\ B6[NM-\"Z/,MO*;/"S7U
MP5#&%&((154JSM@G#J!URM>TCR\_0+=#Y"HK]2]>^-O["_P-UJX\,V/PVM_&
M$EC(8)KRUT>/4XPZG:P\Z[E!DP1]Y<J>Q-=YX/\ @S^R1^W-X3U4>!= MO#F
MLV: 2_V5;'3;VQ+9".T(_=2*2.N'';(-1[:VKB[!8_'>DKL/B]\,]3^#?Q.\
M2^"M7^:_T6]DM6D"[1,H.4E [*Z%7'LPK],O ?[ '@#XV?L>_#J[TC1;'P_X
MOU>TT^ZU#Q(6D:58MP:X8(6VEV0$ 8 R1T'-:2J*"3?45C\G:2OU+3XB?L)?
ML^77_"*P^&;;QY=VI$-WJ\FEKJX>0##,992$/_;$;<]!71?&C]B7X)?M,? N
M]^(OP+M;73=7CM9;JQ_L4/';WKQ@EK66V;'E2'!48"$,03D5G[9+=-(=C\D:
M*549G"*I9B<!0.2?2OU+^"'[!OPF_9X^#T7Q._:*EAN;]H4N7TN^D=;6Q+KE
M+?RE^:XN.N5Y&<@*=NXZ3FH;BM<_+.OU[^%?_*'F]_[%K6?_ $LN:XZU^*7[
M"_Q^O?\ A")/!</@>:\;[-9ZW_94>E 2$81Q/"QV\GCSAM)QN!%>]^._@XW[
M/_\ P3E\;> 3J2ZPNCZ!JJQWRQ^7YL<D\TR$KDX;;(H.#C(..*YJE3FLFK.Y
M2/R+_9A^,5K\ ?CKX6\?7NFS:O;:.\[O9P2"-Y/,MY(AAB"!@R _A77_ +;'
M[36G_M6?%C3O%^FZ'<Z!!:Z-#IAM;J9969DFFD+Y4 8(F Q[54_8;\!Z!\3O
MVJ/ GAGQ1ID>L:#?RW2W-E,6"2A;29UR5(/#*IX/:O0O^"F_P@\'?!3X_:-H
M7@C0H/#^DS>'+>\DM;=G96F:YN59\N2<E40=?X:V?+[3S%T/D>BOM?\ 8!_8
M*MOVCH;OQQXYGGL? %A,UO%;P/Y4NI3* 7_>8^2),@,PY)R 1@D>_P#B3X[_
M +"7P]UB;P?%\.].UZV@<VTVKZ?H4=Y"I48)%S(_FN/]M-V>H)ZTI5+.R5PL
M<-_P1<_Y*!\3/^P7:?\ HUZ^0/VP/^3J/BS_ -C/J'_H]J_73]C_ /9V^&_P
M^\6:_P#$OX0:]'J/@'Q?IT*0:>LC2_8Y8Y"6578[\<X*2?.C @YS@?D5^V!_
MR=1\6?\ L9]0_P#1[UG3ES5&T-['D-)7Z4?LO?L"?#;PG\$8?C-^T#>,FE36
MBZC%I,LTD%O;6S8\IYO+_>22/E2L:D?>52&)P-VU_:V_8;L;K^RX_@[&]F#L
M&H2^$[21" <;MS2&7W^[G\:OVNMHJXK'Y=4J\L![U^KG[17[#7P:^-/P O\
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M7!1G3RW;+&-E1_O$E2O4[@!\+5O&2DKH04444Q!2444 %%%% !2444 %%%%
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M\[9G<Q ^3ICOS4'_  6$T^UT_P"-W@M;6VAME?P]N988P@)^TS<G ZU]L?\
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M_12^_P"40Z_]BU'_ .E:US5(\M.G%]T5U9^1N<\GFOU;_P""-O\ R3/XA_\
M87@_]$U^4E?JK_P1JN4;X>_$>W# RQZI:R,O<!H6 /\ XZ?RK?%?PF);GY@>
M+_\ D;-;_P"OZ?\ ]&-7T[_P2X_Y/ \/?]@^_P#_ $G:OG#XF:3<:!\2/%6F
M7<3075GJMU;RQN""K+,RD$?45]8_\$E_!M]KG[3-QKD4#G3]#T>XDGN-IV*\
MNV*-,_WF!<@>B-Z5I6?[I^@EN8__  52_P"3N-4_[!5C_P"BS7V+^UI=2_ +
M_@F_HWAO0Y6L)+K3]-T*21.&82H'N?QD"RAO]]J^.O\ @JG_ ,G<:I_V";'_
M -%FOL[X]:?/^U1_P3;TW6/#:#4-1ATJRU8V\8+,9K4!;N-1U++MG '4E0.]
M<<OAI7V*[GXY5^EW_!&WX@7[7_Q!\$S7+2::L,&L6UNW2.3=Y4K#_>!AS_N"
MOS1K]0?^".GPMU*PT_QS\0+NW,.FWXATFPD8$&8QL7F8?[()B&>Y##^$UTXJ
MWLG<2W/AW]L#_DZ;XK?]C)>_^CFKQ^O8/VP/^3IOBM_V,E[_ .CFKQ^MH?"A
M'OO[!G@^V\<?M=?#73;N/S;>+4&U KCC=;0R7"9]MT2U]&_\%C/'=]>?%3P3
MX.%RW]F6&CG5#;KT,\TTD>YO4A8!CTW'U-?-/[#GCFU^'?[6'PWUF^D\FT.H
MFQDD)P%%S$]L&;V!F!)[ 5]0_P#!8SX<:A;^/O!/CQ+<MI-WIIT66=>B3Q2R
M3*K>A996QZ^6WI7++^/&_8?0_.JOV)\0?$"_^)__  2CN_$6J7!N]1G\-?9[
MBX;[TKP7/D%V]6)BR3ZDU^.M?L1KGP]O_A;_ ,$H;SPYJEL;/4H/#;7-Q;M]
MZ)Y[GSRC>C#S<$=B#1B+>YZ@CY<_X)$^"[77OVBM9UVZB65]"T.62VW+G9-+
M(D6X'L?+,J_\"KW/]M3]@[XQ_M,?'&_\4:7K7AN+PW#;06>E6FHW]PDD,:H#
M)E5@906E,C<$\$5X9_P2)\;6GA_]HK6="NI5B?7M#EBM=QQOFBD278!W/EB4
M_P# :N?\%%O'GQE^"_[26K#2_'_C#1?"FMPPW^D0V6M7,5NJ^6B3(BJX52LJ
MN=HZ!U/<5G+F]N^5]!]#._X="_&K_H->"_\ P8W/_P C5]F_M;?#?6-0_P""
M>.HZ1XUFM]1\6^'='LKFXOK=VF5[JV:,/*K,JDET$@)('^L:ORD_X:I^-!X'
MQ:\;_P#A07?_ ,<KZ#^-7P3_ &G_  7\ 9?&OCOXJ7]UX2OK*W>\T2^\37LE
MQB<H%MY8)%V,^6&Y06 P?0TYQFY1YY+<"K_P2O\ C+_PKC]HQ?#-Y/Y6D^,;
M8V#!CA1=QYDMV/N?WD8]Y17/_P#!2[X0?\*K_:BUN]MH/*TGQ3&NN6Y4?*))
M"5N%SZ^:KOCL)%KYB\/Z]?>%]>TW6=,G:UU+3KF.\MIUZQRQL'1A]& /X5^L
M_P"V9\.A^VK^SC\(?'GA2!6U2YU"QCRHW?9X;YD@G1L?\\Y_*![ (]7/]W54
M^CT%T,_]@O2;/]EW]B'Q=\7M:@5;S5HYM559/E,D,(:*TA_X'*7(_P"NRU\"
M?LPZ*WQF_:T\#0^(&_M%]6\0IJ&H&8;OM)5S<2AAW#[6!_WC7VW_ ,%5?'UA
M\+_@U\/_ ()^'6^S6LL<4T\"GE+&U41VZ-ZAI!N^L%?"W[(OC:T^'G[37PWU
MZ_E6"QM]9ABN)G.U8HY3Y3.3Z*)"3[ U-.\H2J=6/R/U3_X*"?LP_$S]J/3O
M".B^#-5T;3]"TV2>ZOX-5O)H?/G8*L3!4B<'8OFX)Q_K#7Q=_P .@_C5_P!!
MKP7_ .#&Y_\ D:OHC_@JWJWQ.^'UIX+\9>"?%GB3P_H/[[3=471=3GMHDF)#
MP.ZQL 2P\U=Q_NJ,\BOSI_X:J^-'_16O&_\ X4-W_P#'*SHJIR+E:L#M<_83
M]D/]G/Q;\*_V<-7^%OQ,N]+UBVN)KN"W739Y)XEL;B-0T1\R-,'>TQQ@CYZ_
M,[_@G/8OI?[=7@2RD.9+:75(6XQRNGW0/\J[_P"$7PO_ &LOC-\(9/B1I7QD
MUK2_#ZM/M&L>++^WDDBA'SSK@,OE@AUR6!RC<8YKSK_@FY/)=?MP?#Z::5IY
MI&U-WE<DL['3KHDDGDDFFHM1J-NX=CNO^"NG_)TNG_\ 8M6G_H^XKZW^+^J3
M?L\?\$O=.MO#\O\ 9^H3>'=.L5E0;6\R\,9NF&.C$2SD'J"<]J^2/^"NG_)T
MVG_]BU:?^C[BOKGXE:7-^TM_P2_T]_#D:ZAJD?AVPNDAC.XF>R:,7*+ZMB&=
M0.I.!WJ'\%.^P=6?C77V-_P2K^(FH>$_VJ-/\/0W)CTSQ197-I=6Y^X[Q0O/
M$W^\#&P!]'8=Z^.:^S_^"4?PUU'Q9^T];^*(K?=I7A6QN+BYN&^ZLD\3P1(/
M]HAY&'M&U==:WLY7$MQO_!63P?:>&/VJOM]K&L9U[0[74I]HP#*'EMR?KM@0
M_C7U]^W!\1+_ , _\$\_#L.G7)M9O$%EI6BO(OWC#);>9*H_WDA93[,:^./^
M"K/C2T\5_M8W5E:R^;_8&CVFES$<@29DN"!]/M !]P1VK['_ &X?AW?^/O\
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MEA8#_>%?K)H/[1*ZE^WUXF^%(NL6-IX2MY%A)R#?+)YS >Y@N5_[]FL;X?\
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M45^B'XZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+NQG&=HSZ"NO#U(TY-R9+/<M*_X*&_L\V^EV<4GQ)M5DCA167^S[S@A0"/\
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M-_T/YKC6_#MHG^I[M<VZC^#J7C'W>67Y<A?TZHK:E5E1ES1$U<_FCHK](?\
M@H%_P3]_LW^TOB?\,--_T/YKC6_#MJG^I[M<VZC^#J7C'W>67Y<A?S=KZ2E5
MC6CS1,6K!1116P@KI/AOX'O/B1XZT7PU8Y$VH7"Q%P,^7'U=S[*H9OPKFZ^U
MO^"?_P +?+@U;Q[>P_-)G3M.W#^$$&:0?CM4'V<=ZNE#VDU$X<;B%A:$JG7I
MZGU[H.B6?AK1+#2=/A$%C8P);P1C^%%4*!^0J_117NGYBVV[L****!!1110
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M^&G_ &&(OZU^Z=?+YM_%CZ&]/8****\(T"BBB@ HHHH **** "BBB@ HHHH
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M&AV>7IU]J<\UNFP83$;,5&T<# XKEJ*0!1124@"BBBD 444E !1110 444E
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M%% !2444 %%%)2 ****0!1124@"BBB@ HHI* "BBB@ HHI* "BBB@ HHI*D
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M3-._XEORW&B^'[I/^/GNMQ<*?^6?0I&?O\,?EP'/V!_V!_[;_L[XF?$S3O\
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MKC(X/4$$9!!+E3G!7D@.VHHHK,84444 %%%% !2=.302%!)X%?E__P % /\
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M\AX1-Q.![DG\<"N.^!7_ "*-W_U_/_Z+CJC\>K]XM-TJS5L)-*\C#UV  ?\
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MTKJ-C%JFGW-G-GR;B-HGVG!VL,''YUAW_C;PWX7GCTR>]CM7B4*(8XV81C'
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M,A&5;.5<>H/>LROKL/'DI1BI<R[GPN+FYUY2<.5]NP4445TG(%%%% !1110
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M8'_8'_MO^SOB9\3-._XEORW&B^'[I/\ CY[K<7"G_EGT*1G[_#'Y<!S]@?\
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M_$W@:V?3?#FNM+;3Z8TS2K:W"!6!C9R6VNI)P2<%3C@@#Z*_X(U_\DC\??\
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M^9E)R=WN;!7S)_P4HN)K;]BWXAF$<L+!&;T4W]N#_A^-?3=>:?M+?"^3XS_
M7QQX,@"M>ZIILB6@D.%^TIB2#)[#S$3FG!VFFP/RM_X))6UK/^U9.]PV)H?#
MUY);#UD\R%2/^^&?\J_9VOY\/V8/C)=?LS_M!:!XJO+240Z?<O9:M9NA$@MW
MS'.NT\AU!+ <?,@![U^]W@/X@>'/B?X7LO$?A76+77-%O%W0W=H^Y3ZJ1U5A
MT*L 0>" :Z\5%\W-T)B:NL06UUI%]#>D"SD@=)MW385(;],U_.Y^SW-+:_M
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ME_\ @I__ ,GE^,/^O73_ /TCBK],_$'_ "CEO_\ LE;_ /II-?F9_P %/_\
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MQ:C\/?#SPU):OK%X8]-TA9WG^SQ>LDK<D*H+.YP.&. , ?N1^SI^S3!^SK\
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M?-IVE77AZ'4)8IKF2<F9KFYC+;G)(&V)..G'O7O_ /P1>Q_PD'Q6/?[+IO\
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M'TF/K0HX:;D]TTO5GTW^T@T:? ?QT91E?[*F _WBN%_7%?)7_!.K_DI7B?\
M[!'_ +6CKVK]O#XAP>%_@^?#R2XU'Q!.D*QJ?F$,;+)(WTR$7_@=>*?\$Z?^
M2E>)_P#L$?\ M:.O0J23Q$5V/E\+3<<KJR?5_P"1[E^V]\6=6^&OPWL+'0[J
M2PU'7+AH#=PMMDBA1<R;#U#$LHR.0"<<XKX+^'?Q6\1_#3Q=:Z_I.I7"W$<J
MO/$TI*729&Y) ?O CCGD=1R :^UO^"A'@V\USX;Z)KMK"9H]%O&%SM&3'%*H
M7?\ 3<J _P"\*^!-)TJ[UW5+/3;"!KF]NYD@@A0<N[$!5'U)%<N*E)5?R/6R
M>G2E@M4M;W_KT/V%UC3+#XD> [JQN$#Z=K6GE"&&?DECX/U&0?J*_-+]F#6-
M6TGXZ>$M(CU&[M[-]4 GM(IW6*1L$$L@.#T'4=A7Z9:;'!X*\%6L=U(J6VDZ
M>JRR9X"11C<?IA37Y@?LXWAO?VC/!]RW#3:J)"/=MQ_K73B?CI]_^&/*RO6A
MB%TM^C/OC]KS4KO2?V=_%MW8W4UE=1BUV3V\AC=<W<(.&!R,@D?C7Y?:MKFI
M:].D^IZA=:C,B[%DNYFE8+G. 6)XR3Q[U^G7[92EOV:_&('/RVA_*[A-?EO7
M/COXB7D>CD*7U>3Z\S_)'[+>&?\ D2M)_P"P?%_Z+%?DS\&_^2O>!O\ L.V/
M_I0E?K-X9_Y$K2?^P?%_Z+%?DS\&_P#DKW@;_L.V/_I0E;8O>G_78XLF^#$?
MUW/U9^*7BF7P1\-_$^OVX4W.G:=/<PAAD&14)3(]-V*_))/'.OKXN3Q.=6NI
M-?2X%T+]Y"TOF Y!)_ITQQ7ZE?M+?\D#\=?]@N7^5?DQ48Z3YHHZ,AA%TJDF
MM6[?@?M5#>+)I\=VWRHT0E/L,9K\@/B%\2=;^(WC:^\2ZE?3O>33F2#]X1]F
M3=E$C_NA1C&/3/7FOUL;_D2C_P!@_P#]IU^-%5CI.T48Y#"-ZLK:JR_,_8#X
M,Z]=>*/A+X.U:]E:>]N])MI9Y6.2\AC7<Q]R<G\:_*SQU,WAWXM>(9;18P]A
MK=PT*O&&3*3L5!4C!' X/%?I_P#LY_\ )"/ ?_8(M_\ T 5^>%GX'C^)7[4M
M[X:GD:*VU#Q+=).R<-Y0FD9\>AVJV/>C%7E"GW892XTZV(;V7Z-GHFG_ +4_
MQM^+/AC4_#>CZ*-4FNHO(?4M'T^47, )&3O1MB9&1D@8SP0:@^%/['WQAM?%
M6EZX(H/"LMK<)<"ZO+Y?,X8$_+%O)SR,-C/>OL_XD>*M'_9S^#E]JNE:'&-/
MTF..*VTVU'EH6=U1<G' W,"S')//4FOB>Z_;1^*_Q"\1:?I>FW=KHJWUU';I
M;:5: N^]PH7?)O;)SU!%34C"FU[63;+P]6MB(3>#IQA#JW_7_ /N[XU6ZW7P
M=\=0N/E;0KX?3_1WYK\Q_P!F[_DO7@3_ +"T'_H5?IW\9,_\*A\<XY/]A7W_
M *3O7YB?LW?\EZ\"?]A:#_T*JQ?\6!EE'^Z5_P"NA^@_[87_ ";?XT_ZXV__
M *4Q5^5]?JA^V%_R;?XT_P"N5O\ ^E,5?E=6&._B+T.[(?\ =I?XOT05]:?\
M$Y_^2F>)_P#L$?\ M:.ODNOK/_@G-_R4SQ/_ -@C_P!K1USX;^-$]',_]SJ>
MGZGNG[<7Q:U;X:_#:PL="NI+#4M<N&@-W"VV2*%%S)L/4,2R#(Y )QSBO@CX
M=_%?Q'\,_%UKX@TG4KE;B.57GB:5BETF1N20'[P8<<\CJ.0#7VQ_P4,\&7FN
M?#;1->M83-'HMXPN=HR8XI5"[_IN5 ?]X5\ Z3I5WKNJ6>FV$#7-[>3)!!"@
M^9W8A54?4D5OBY35;\CAR>G2E@M4M;W_ *]#]BM8TNP^)'@*ZL;A ^G:WIY0
MAN?DECX/U&X'ZBOS6_8_@>U_:;\(PR##QS7:-]1:S U^E^FQP>"?!-K'=R*E
MMI&GJLLF> D40W'Z84U^:?[(MT;[]J'PI<L,--<7<A'UMIC75B?XE+O?_(\C
M++_5L4EM;]&?H'^T)\0KGX6_!WQ+XCL2HU"V@6.U9@"%ED=8T;!Z[2^['^S7
MY@W?QK\?:A8ZI9WGC#6;VSU2,Q7=O=7CRQR*2"1M8D#ICC'''3BOT!_;JD*?
ML[ZL!T:\M5/_ ']!_I7YDUSXZ<E423Z'HY'1IO#RG)7=_P K'Z,?\$__  );
M:#\(9_$AC5K_ %V[D)EV\B&)C&J9]-PD/X^U>.?MQ_'CQ!/\1KKP/I&I7.F:
M-I4<7VI;60H;J9T$A+,O)55=1MZ9!)[8][_81\10:Q^S_I]A'(&GTF\N;65.
MZ[I#,/P(E_0^E?*7[<7@:_\ "_QUU35I8&73=<2*ZM9L$JQ6-4D7/]X,I./1
ME]:TJMQPL>3R_K[SFPJC4S2I[;5J]OT_ K?LJ_'KQ%X!^)VA:5/J=U>>'-6N
MXK&YL;B4NB&1@BRIN^Z59@3CJ 1Z8^W?VL_ MKXZ^ _B=)HE:YTNV;5;60CF
M-X5+MCZH'7_@5?G?^SOX'O\ X@?&3PKIUE TL<-]#>73X.V.")P\C$]N!@>I
M('>OTF_:2\36_A3X$^-KRX<)YNF36<63R9)E,2 >O+@_@:,*W*A-2V%FD8PQ
MM)TOB=OST/D;_@G+_P E-\3_ /8'_P#:T=>Z?MQ_%O5OAI\-;"QT*ZDL-2UR
MY: WD+;9(H47,FP]0Q+(,CD G'.#7A?_  3D_P"2F^)_^P/_ .UHZ]5_X*'>
M#+S7/AKH>O6L)FBT6\87.T9,<4RA=_TW(@/^\**;DL(W'<6)C"6;Q53;3\M/
MQ/B7X=?%CQ)\,_%UKX@TG4KE;B.57GB:5BETF1N20'[P8<<\CJ,$ U^L^L:7
M8?$KP%=6-P@?3M;T\H0PSA)8^#]1N!^HK\<M)TF[U[5;/3;"!KF^O)D@@A09
M9W8A54?4D5^R6FQP>"?!-K'=R*EMI&G(LLF> D40W'Z84TL VU)/8O/8QC*E
M*/Q:_I8^"O\ @G_X'AU/XQZOJE[$KOH-D_E _P $\C>7N_!!*/QKZ1_;(L_B
M'KW@?3M!\ Z?>W?]H3/_ &E+8N$=8548C))&%<MSCJ$QT)SX)_P3T\4(WQ4\
M7V4KK'+JEC]J16/+,DH) ]3B4GZ U]!?M9?&SQA\#?#^A:SX:TS3;^RN+B2V
MO9-1@ED$3%5,6-DB8SB3.<]!T[W1Y5A7=Z>1CC/:2S.*23>ED]MO\SYG_9S^
M%OQH^$OQ2T2_7PQJEIHMQ=1P:I$SKY3V[-M=F4-R4!+ ]01]:^F?VV/!T'BK
M]G_6[AHPUWH[Q:A;MW4JX5_P\MW_ ! KYX\*_MV?%WQMX@LM#T3PQX9U#5;U
M_+@MTMKA2YP2>6N    3DG Q4OQH^/'QY;P+KFC^,/AY8Z3HE[;FVNK^'3KD
MI$K$+D2B9D!R0!G/-1&=*-*48W:?D;U:.*J8NG5J*,9*VSU:N6?^";?_ ",W
MC?\ Z\[;_P!#>O6?VZOB]K7PS\ Z/IOA^^FTO4=;N9$:\MV*2I#$H+A&'*DL
MZ?,.<9]:\F_X)M_\C-XW_P"O.V_]#>KW_!2J0F\^'J=E2_/YFW_PHC)QP=U_
M6I%2G&IG"C)77^43Y4U7XM>--<TNTT[4O%.K:A:6ET+VW6ZNWD:&8 @.CL2R
MD GH<<FOT;_8KU6]UK]GW1+K4+RXOKIKBZ#3W,K2.0)G RS$GI7Y;U^GO[##
M _LY:%[7-W_Z/>L<#)NJ[OI_D=F>0C'"KE5O>_1GQY^UWXOUZW^/GC;3(M;U
M&/33)%&;-+N00[6MX]R[,XP<G(QW->M?\$Y_B1Y-]XB\#74N$G4:I9*Q_C7"
M3*/<CRSC_8:O#_VPE*_M(^-01C]] ?\ R6BKB_@_X^E^%_Q,\.^)HBVRPNE:
M=5ZO"WRRK^*,PK!573Q+D^[.R6&6(R]4TM7%??8^G_\ @HU\/_LVL>&?&EO'
MA+J-M,NV XWIEXB?<J9!]$%>E?\ !/OP#_PCGPDO/$<T>VZ\0799&(P3;PY1
M/_'_ #3]"*]._:*^'8^-'P3U?2M-$=U>R1)?::X(PTJ$.NT]/F7<N?\ ;K0U
MJ^T_]GWX%S3)M-IX:TA8H0W FD1 B ^[R%?Q:O55%1KRK/:Q\O+%RJX&&$7Q
M7M\NGXO\#X(_;@^(W_"=?'"^L()=^G^'XQIL0!X,H.Z8_7>2O_;,5\^U/?WT
M^IWUQ>74K3W5Q(TTLK=7=CEB?<DFJ]>!4FZDW)]3[JA15"E&DNB"OUM_9=_Y
M-]\"?]@U/YFOR1K];?V7?^3?? G_ &#4_F:]'+_XC]#Y_/\ ^!#U_0^#?VP/
MC+KGCSXN:_HIOYH= T6[DT^WL(Y"(RT9V22,!PS%PW)Z# KUW_@GS\8M;U#Q
M#JG@75;Z:_T\69OK W$A<V[(ZJ\:D\[6#YQT!0XZFOG_ /:J\%WO@GX\>+H;
MJ$Q1:A?2:E;/CY9(IF,@*_0LRGW4UZM_P3K\)W>H_%;6-?$)_L_3=-:!INWG
M2NNQ??Y4D/X#UK.G*?UK7>YOB*='^S-$K<JMZGI'_!2+PG;S>$?"?B=8U6[M
M[YM-:0#EDDC:10?8&)L?[QKJ?^"=_P#R0O4/^P[<?^B8*Q_^"D&N0V_PR\,:
M.7 N;O5_M2KW*10NK'\YDK8_X)W_ /)"]0_[#MQ_Z)@KN5OKCMV/&DY/*%?O
M^IYU^WM\<O$OA_QGI?@_P]K%YHMK#9+>7DEA,T,DTCLP5"RD':JJ#C."7YZ"
MOF'3M8\2?'/Q]X/T/Q%KM[JLL]S!I4-S=R&62**289.X\L1O)R<G@#H!7I'[
M>4A?]HK5 >B65J!_W[!_K7DWPC\10^$?BIX0UJZD\JTL=6M9YW](EE4N?^^<
MUYE>;E7:D]+GT."HQIX.$H1][EO\VC]9O&&N6'PA^%VJ:G:V:+I^@::SV]G'
M\J[8TQ'&/0'"BOR;\7?%SQAXX\12ZWJWB&_FU!Y/,1HYVC6'T$:J0$ ]!7ZN
M?&KPC<?$#X2^*] L0LEY?Z?*ELK-@-+C<@SZ%@.:_'BZM9K&ZFMKF%[>XA<Q
MR12*59&!P5(/0@]JZ\PE).*6QY60QIRC4D]97_ _2?\ 8;^-FK_%;P+JNF>(
M+E]0U;098H_MLIR\T$@;R]Y[L#&X+'DC&<G)/@7[?WA%?!7Q?T?Q1I+OI\^M
M6ADEDMV*-]HB(1G!'0E&CZ=P3WKU'_@G+X%O]&\(>)_$UY T-MK$\$%F7!!D
M2$2;W _NEI,9]4->?_\ !2#Q-;ZAX\\*:%$ZO/IMC+<3!3G89G4!3Z'$0/T8
M>M54;E@TY[_\'_(C#J,,VE&E\.M_NU_$]]_84U:]UGX"P7.H7EQ?7']HW*^=
M<RM(^ 5P,DYKY+_;/\7:[IO[1GBZRM-:U&ULU6T MX;J1(P#:0D_*#CDD_G7
MU3^P%_R;Y;_]A.Z_FM?('[;G_)S7B_\ W;/_ -(X:6(;^J0^7Y%8&*_M.LK=
M_P T>Y?\$S_^/?XB?[^G_P KFN:_X*2_\E \(_\ 8+D_]&FNE_X)G_\ 'O\
M$3_?T_\ E<US7_!27_DH'A'_ +!<G_HTTI?[BOZZE1_Y',OZ^RCT_P#X)O\
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M]9KGT@_]J5UXCVW]GR==^]I^:.'"^P_M6*PR]U7_ "9K?';_ )%:R_Z_5_\
M0'KPVO<OCM_R*UE_U^K_ .@/7AM;93_NJ]6<^>?[X_1'TK\-?^1%TC_KD?\
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MF/\ D:\"KWWXV?\ (E_]O,?\C7@5=.4?[M\V<F??[W\E^I]$_"+_ )$'3O\
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M<7_]!-?)]<62?#4^7ZGH\1?%2^?Z!1117TQ\>26UO)>7$4$*[Y96"(N<98G
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M7\*\XKZ'+*4Z.'2J;O4^5SBM3KXIRI:I*U^["BBBO5/%"BBB@ HHHH ****
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M%8Y?XG_#C1?B[\/]=\'>(H&GT?6+9K:=4(#KG!5T)!PRL%93@X*BOR2\6_\
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MN0!GD]%^MO\ @F?^S_X]_9]^'7B_2_'V@_V#?7^JI<VT7VRWN=\8A52V89'
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M#:QYYVEG8[<\XC4Y]*_5;]E7]G#2?V7_ (2V7A'3YQJ%^\C7>IZEY>PW=RP
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M_);S+G;)%K^G*PR,'!%SZ&OW/HIPQ$H*R06/PY_X=X_M1GD^"KO_ ,*/3_\
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MH7"P')&,=>/>L&:&2WE:.5#'(IP588(J'%QW+C)2V9'1114%!1124@"BBB@
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY-AI]N]S._HBJ2<>IXX'<T#2<G9'QQ_P4&^*FZ32/ %C-PN-1U':>_(AC/\
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M*** "DHHH **** "DHHH ***2@ HHHI %%%)4@%%%% !2444 %%%% !2444
M%%%% !2444@"BBBD 4E%% !244E !6_IOAMUL(M8O%!TU7 =5;YR,XX%6-&T
M?^R+6WUR^@CN+(MCRLC)]\5D:MJQU"XF$"M;VC/N6W!^5?PK2RBKR,N9R=H[
M&M?>*DTVZNH]!W6MG, &##D^_/2L.&QN[SR<)(R.^Q&(.W)K=L= MM$FAFU]
M&6WFC+((SDY[9Q5&[\3W#Z;_ &;!B.S20LAQ\^,\<TY?WON)CV@OF7+?P1(N
MJ-97MW!:LL7F!BV0?:JJ:#9-I$]R=2C%RCE%@QRP!QFJEKI&H:Q>QQ;':609
M5I?3ZFK,?A6=K2^FDGAB:U8HT;-\Q/M1Z1"[6\C4M]#U70=2L7TRZCN;J>,E
M1&<[1Z'-$EQ;W5M=V.HVA&N238-RW0$GO5./P[J&GR6$UK=QF>YX3RG^9?K5
MG[=J&FV][IMY9K,[.&EN<;F0''.:K;2UB-WO?\#*\0>&9]!NQ 72Y^0/OAY
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MQ_\  E/\:_G)HI?V6OY_P_X(>T\C^C;_ (2;1_\ H+6/_@2G^-'_  DVC_\
M06L?_ E/\:_G)I*/[+7\_P"'_!#VGD?T;_\ "3:/_P!!:Q_\"4_QH_X2;1_^
M@M8_^!*?XU_.111_9:_G_#_@A[3R/Z-_^$FT?_H+6/\ X$I_C1_PDVC_ /06
ML?\ P)3_ !K^<BDH_LM?S_A_P0YS^CC_ (2;1_\ H+6/_@2G^-'_  DVC_\
M06L?_ E/\:_G'HH_LM?S_A_P1\Y_1Q_PDVC_ /06L?\ P)3_ !H_X2;1_P#H
M+6/_ ($I_C7\XU%']EK^?\/^"'.?T<_\)-H__06L?_ E/\:/^$FT?_H+6/\
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M)-H__06L?_ E/\:/^$GT?_H+6/\ X$I_C7\X5%+^S5_/^ <Y_1[_ ,)/H_\
MT%K'_P "4_QH_P"$GT?_ *"UC_X$I_C7\X-%']FK^?\ #_@ASG]'W_"3Z/\
M]!:Q_P# E/\ &C_A)]'_ .@M8_\ @2G^-?S@TE']FK^?\/\ @ASG]'__  D^
MC_\ 06L?_ E/\:/^$GT?_H+6/_@2G^-?S@4E']FK^?\ #_@ASG]('_"3Z/\
M]!:Q_P# E/\ &C_A)]'_ .@M8_\ @2G^-?S?44?V:OY_P_X(<Y_2#_PD^C_]
M!:Q_\"4_QH_X2?1_^@M8_P#@2G^-?S>T4?V:OY_P_P""'.?TA?\ "3Z/_P!!
M:Q_\"4_QH_X2?1_^@M8_^!*?XU_-[24O[-7\_P"'_!#G/Z0_^$GT?_H+6/\
MX$I_C1_PD^C_ /06L?\ P)3_ !K^;RBE_9R_G_ .<_I#_P"$GT?_ *"UC_X$
MI_C1_P )/H__ $%K'_P)3_&OYNZ*/[.7\WX!SG](G_"3Z/\ ]!:Q_P# E/\
M&C_A)]'_ .@M8_\ @2G^-?S=T4?V<OYOP#G/Z1/^$GT?_H+6/_@2G^-'_"3Z
M/_T%K'_P)3_&OYNJ*/[.7\WX!SG](O\ PD^C_P#06L?_  )3_&C_ (2?1_\
MH+6/_@2G^-?S=44?V<OYOP#G/Z1?^$GT?_H+6/\ X$I_C1_PD^C_ /06L?\
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MNBC6=%W/,Q^!6.@HWLUU/V>HK\9_^$@U3_H)7?\ W_?_ !H_X2#5/^@E=_\
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M' VAI7+''IDUE4Q?/%Q2M<Z\+DJP]:-6<[VZ6_X)#1125YY].%%%% !2444
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MK1/^OZ_0RDN_]?UYEJYMX;S2;N$6ZW:>>-VK'MR,L:PM:\(RV=\\.GN=1C1
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MMOC=_P EC\;_ /89N_\ T<U<37*S]4H_PH^B"DHHJ38***2D 4444 %%%)0
M4444 %%%)0 444E( HHI*0!2444@"DHHH **** "DHHH **** "DHHH ****
M0!2445(!1110 4E%% !1124 %%%% !1124 %%%%2 444E !1110 444E PHH
MHH&%)110,*2BBD 4445(!2444 %%%% !2444 %%%% !2444 %%%%( I***0!
M1124@"BBDH *2BB@ I*** "BBDH ****0!2444@"BBB@ I*** "BBB@ I***
M "BBBD 4E%%( HHI*0!1110 444E !1110 444E !1110 444E2 4444@"DH
MHH ***2@ HHHH ***2@ HHHH ***2I **** "DHHH **** "DHHH ***2@ H
MHI*0PI***D84E%% PHHI* "BBB@ I*** "BBB@ I***0!1112 *2BBD 4444
M %)110 4444 %)110 4444@"DHHI %%%)0 4444 %%%)0 4444 %)112 ***
M2D 4444@"BBDH **** "BBDH **** "BBDH ****D HHI*0!1124 %%%)0 4
ME%)0 4444 %%%)2 ****0!1124 %%%% !2444 %%%% !2444 %%%%(84E%%2
M,**** "DHHH **** "DHHH ***2@ HHHI %%%)4@%%%% !2444 %%%% !244
M4 %%%% !2444@"BBBD 4E%% !244E !1UI*Z;PGIL\4<NLB&*>"UY,<A^]]*
MJ,>9V)E+E5RQ)<?\(IHL+:??I)->Q_OHMN2G'Z=<5C:#IZW=XL]W%(U@C?OI
M$' %5M4OO[6U*:X$:PB5LA%' K=U2Z/AW2TL;&^6>*Z3=,H7E3]:TNF[]$96
M<5;JS,UW4!=736MI-(VG1MB"-SP*T6@'A?39([NTCGFO$S%)G)2JGA^Q2W!U
M*_M))M.4%=R_WNU9\@FU>^98$DE&?D3DE5]*5[:]6.R^'HB33=,EU!FN'C>2
MUC(,SKU JQJFKH@FLM,DD73G(.Q^I-/U:]MK*,6NERSI&RXG5^[=Z+&QBTFW
M2\U*V\Z&="(E![^M*W1?,+W]Y_(99Z-#:MOU8R6T3Q[HMHSN-1S:\_V>VBMX
MT@:W8E95&&/UJK)-=:HR[F>5(Q@%N0BU?=;'1&EC=8]1:2+Y7!X1C2]-$/\
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MBOKO]B>#[E4;;/>'[,GT;[Q_[Y!_,56^#NB_V7X/CN'7$MZYF/KMZ*/R&?\
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ML-0@N">=BOA_Q4\C\JGU+1K#6(]E[9P72XQ^^C#8^A/2O+CBH1A["O17Y/\
MX<]B6"J3J?6,-7?H]5Z>AXMX^^*%EXOTDV$6ER)AQ)'<2R %"/\ 9 /4$CKW
MK!^&_AU/$WBRUMIEWVT8,\R^JKV^A) _&NQ^(WPGMM+TZ;5=&#HD/S36K-N
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MS_U\-7/5]/A_X,/1?D?'8G^/4]7^84445N<P4444 %%%% 'Y:_&[_DL?C?\
M[#-W_P"CFKB*[;XW_P#)8_&__89N_P#T:U<37(]S]4H_PH^B"BBDJ38****
M"BBDH **** "BBDH ***2D 444E( I***0!2444 %%%% !2444 %%%% !244
M4 %%%%( I***D HHHH *2BB@ HHI* "BBB@ HHI* "BBBI ***2@ HHHH **
M*2@84444#"DHHH&%)112 ****D I*** "BBB@ I*** "BBB@ I*** "BBBD
M4E%%( HHI*0!1124 %)110 4E%% !1124 %%%%( I***0!1110 4E%% !111
M0 4E%% !1112 *2BBD 444E( HHHH ***2@ HHHH ***2@ HHHH ***2I **
M**0!2444 %%%)0 4444 %%%)0 4444 %%%)4@%%%% !2444 %%%% !2444 %
M%%)0 444E(84E%%2,*2BB@8444E !1110 4E%% !1110 4E%%( HHHI %)11
M2 **** "DHHH **** "DHHH ****0!2444@"BBDH **** "BBDH **** "DH
MHI %%%)2 ****0!1124 %%%% !1124 %%%% !1124 %%%%2 444E( HHI* "
MBBDH *2BDH **** "BBDI %%%%( HHI* "BBB@ I*** "BBB@ I*** "BBBD
M,*2BBI&%%%% !2444 %%%% !2444 %%%)0 4444@"BBDJ0"BBB@ I*** "BB
MB@ I*** "BBB@ I***0!1112 *2BB@ I**2@ I*** )K6UEO+A888VED8\*H
MY-;GB*XL;6WAM-.^T0L!_I"R$C)]Q4GA:W-C9W&L1WL<%Q;Y"1,,EN*Q6:ZU
M[4F?8TUQ,V2J#K]*T^&/FS+XI>2-GPO8SV-K-K8BAGAM\J8I>^>XK%=FU74G
M?R]HE?<5C7.T5I>)+BTAC@L[&.:V,:XN$<_>;CM4^@B31M+FU:&XA$O^K\EP
M"2*=M>7L3?1SZLKZ_>16T::?IUW+)8XW/&_3?WI=/=-%TXWL5VT.HGY1"4_A
M/>JFCV)UK5"'FC@))D+/T]:=K%]<:WJ2H55W3]V@B7KBE?[7W#M]G[PTBS:X
MF>_N8&N+2-MTQSU)J&X:35KPQVD<AA!S'#G.T59U6:"SMX[.R:>-F'^DQN>"
MWTH@D31K$3Q32PZBQP8RN,+ZTO+[QWZ_<%U?1:5#Y&G7#LLT8$VY<<^E066E
M1GYK^1K2)D+1MM^\1VI;&S"1?;KV%Y+-F*Y4X):J\]Q/J#A2SM$APN[)""EY
ML?DB=]:=([<6T:V\D0V^8G5J;#I]]?R2K\P.TS,'.,^]27'V;26F@ CO'(!6
M8?P_2H&EOM69I/GD,:?,5XPM'DP\T2QZ7+Y=M*MT@:<[=N[E?K5@KJ5NI4D7
M-M9OG&05JK'I*^9;B2[C195W;L_=]C2?8V6U9X[M"3)L\O."?>C86Y/-=V\R
M73W5FT5Q+@Q%1M5?PJ_:M(+ZV^PWZW0BAW8N/NJ>Z\U6#ZE#<2-(([LPQ[3D
MA@HJIYEMY-LD]M);LS;GG7.67V%5>PK7+Z7*PVIF:&2UNY)O^/R/A0,\XJZH
MDN$>SMGCO;.!O/DEQMD(ZGFLR&8H-]O>"2WMY-T4$_5OPJ6Z8K]K%S9/'=W&
M)%: _*B_0=J$R6C7M-0'VB_N+:9;>)H<*MX,EN/X33H7>ST^PM(Q)IWVY/WU
MPQW+(,?SJE:LUY>6L2R1ZI#;Q%O+D&T#BH[6^6W6.]#2)<>84@AE7="%)QUJ
M[F?*;]K= 7T4L$7D6=@I26^M^K#'I4"R?:-!U3RT1[?S_,\^4[9FS@YQWZ\5
MG7*F&"]M=DDEU(1))+;,3&%/J*T))$U36(T_=ZG:VUN"QBPF#[^O2JOT)MU-
M.2X\[Q!HZ[V6..W+*-0'R].QK,DL;.\L=<U&[TY96$K".:W/R9!Q\OMFF0ZH
MWE1:G++Y\L<GDP6=POR[20.O]?:B\MFL["\LI(I$OI'$ZI;,6B52<]/:ANY*
M31FWGA"R^SZ.EK>_Z9>,%D24;0H(SFJUQX!U$:E<V=MY=TT"AV9&&,>GUKJ/
M,?4O$&E)NL]8\N$EH_N <#KUYK/ADCM;76KPP7EI<&0HC6SG8H]">]0X1[&B
MG/O_ %<X^31;Z*T^U-:R"WW;?,QQFJSVTT;*K1.I;H&4@FN[DD9M-TK2[?6@
MT=TX>594 "'KU^M: FU6Z\123D6-XFFH05X4'([>]9^S3+]J^IYA@\C%)7H"
MS7,.FW]_-H5O,FHOMBD4C,9/R@ 5#-;RB#3],_X1H+>1D2NPQF51US4^S\R_
M:>7XG"T8.,XX]<5Z$NJ;=6FU>'PTL=I;QF"6/C 8'DGCK3(VU2WLGLAH=O&=
M4<^2S8RN>U'L_/\  7M'V_$X:.QN)FC5()&:0X0*A.[Z>M:VF>"=6U2[FMH[
M;RI84WNLWRG':NHQXCU"866ZULYM&4/N& ?N\'WXK/O&FFLHM;N=>Q<S.(I(
MX3A]N<'I[4U32W%[23VM^9FQ^%88]$_M&XU&!/WFQK4$>9P<&M6.[T+1-5MK
MC2[*34HO+VR"9<KO.,8-5A=>'-+UH/!#-J5F8L?O.SGO5RU.KW%JNC"WATVT
MNV,D<TP (4<X!JDDMO\ ,F3;W_R+,T6H6TTUAJ-W%HVGW2-.L<?(.>W2LW2(
MQJ5D^F6%H'U"-]ZW3' P#US4%XUH(;J*[NY;[5HI1'#@EHRHZ8J]<33ZA=;M
M5E70G@M_W:QKCS.*>[)MI_7],DL;KSVAFCFEN==A)#"8_NDQ^%6=+EBN[DS/
MY]KJ+AS+-&OR]L*!CGO5%?)O+6PDDLY-/LTRAN(?O2GU([9JWI/F,IM]TD;V
M[E[<.-H*GIN-7'=$RV8_Q!J;6_AUG217=QY3>8NTD]SCUKS>NQ\?WF6M[9=J
MX^=E7DY]ZXVN>L[RL=%%6C<****P-@HHI*0PHHHJ2@HHI* "BBB@ HHI* "B
MBB@#]WZ***_2#\:"BBB@ HHHH **** /J7PE_P BKHW_ %Y0_P#HM:\.^,'_
M "/E]_N1?^@+79Z'\:-$TS1=/LY;74&EM[>.)BD:%254 X^?IQ7G'CSQ!;^*
M/$USJ-JDL<$BH LP ;A0#T)]/6OF<OP]6EBI3G&RL_S/L,TQ="M@X4Z<TVFO
MR9S]%%%?3'QX5[/\!/\ D&:M_P!=D_\ 037C%>@?#+X@:=X+L[Z*]ANI6GD5
ME^SHI  !'.6%>;F%.=7#RA!7>GYGK955A1Q<9U'9:_D=/\>_^0;I/_79_P#T
M$5XQ7H'Q-^(&G>-+.QBLH;J)H)&9OM"* 00!QAC7G]&7TYTL/&$U9Z_F&:U8
M5L7*=-W6GY'U#X*_Y$_1/^O.'_T 5X7\6/\ DH&J_6+_ -%)7;^'?C+HNDZ#
MIUE-:W[2V]ND3LD:%254 XR_2O-_&VN0>)/%%[J5JDD<$Y3:LP 8815.<$CJ
M/6O-R_#U:6*G.<;)I_FCU\TQ5"M@Z=.G*[37Y,S=+U"72=2M;V$XEMY%D7Z@
MYQ7U)#);>(-'5Q^\M+R#./5'7I^1KY1KW_X+WEQ=>#%2=2$@G>.%C_$O!_0D
MC\*O.*5Z<:RW3(R"M:K.@]I*_P!QUTDEMX=T5F/R6EE!T]$1>GY"OEO4K^75
M-0N;R8YEN)&D;ZDYKV[XV:[_ &=X:CL$;$M])@^OEK@G]=H_$UX13R>CRTY5
MGO+^OS%GU=2JQH1VBOQ?_ .R^&OA/2_&&H7-I?W%Q#-&@DC6$J-ZYPW)!Z9'
MYUV7C#X-VL.B;]!BEDOHFW,LDF3(F.0.V>A_.O(["_N-+O(KJUE:"XB;<DBG
MD&O7-!^.MNT(36+*2.4#_6VN&5OJI(Q^9K3&0QD*JJT'==OZW,<OJ8"I1='$
MJTOYOZV://-,TSQ3IMT$L;75;6;/W88Y$_/CI]:^B/#8U!=!L1JI!U#RAYV,
M?>]\<9]<=ZYC_A<OAGR]WGSY_N^0V?\ "N8\3_''SK=X-$MI(788^U7&,K_N
MJ,\^Y/X5YV(CBL<U%TN7S/6PL\'EJE-5^:_3_@=SE_B[=PW?CB\\DAO+1(W8
M=V"\_ET_"O4/@W_R(MM_UUD_]"KY^DD::1G=B[L=S,QR23U)KU#P#\4M*\*^
M&X=/N[>\DF1W8M"B%>3D=6'\J]''8:;PD:--7:M^1Y66XRFL=.O5?*I7_%HK
M_'?_ )&:P_Z\Q_Z&]:WP)U^/R;[1Y&VR;_M$0)^\, ,!], _B:XWXE>+K/QE
MK%M=V44\4<< B(N%4'.YCV)XYKF+&^N-,O(KJUE:"XB;<DB]0:TCA75P2H3T
M=OQ,9XV-',98BGK&_P!Z/H+XF>"9/&6DP_965;ZU9FB#G <$?,N>V<#\J\FT
M[X3^([W4$MY;%K2/=AYY67:H[G@\_A7;>'_CG:R0I'K%I)%.!@S6P#(WN5)R
M/PS6S/\ &CPW"F5DNIC_ '8X2#^I%>71EC\)'V,8773J>U7AEF.FL1*I9]=;
M7^_]#HF\*Z+'IT4%SI]I+#;Q!/,GB4D*HQDDCC@=:\(TBPTCQ3XZ>U<OI^G7
M,K+;BWP,?W!R#UQ^9K4\<?%BZ\46\EA9PFRL&/SDMF20>AQP![#\ZX)6*,&4
ME6!R".HKOP.$K4Z<G4E:4OP\SR\RQV'K5(1HQ3C'?S\O0]RU+X)Z0NCW,=@9
MS?[/W,L\N1N'."  .>G3O7E*^'O$FBWA6.PU&VN%.-T$;@GZ,O7\*[?PK\;I
M;.WBMM9MGNE0;1=0D>8?]X'@GWR*ZV+XS>&I$RTUQ&?[K0'/Z9KFC4Q^&;A.
M'.G\SLG2RS&*,Z=3V;7R_KU-#X;C7!X=_P")\9#<^8?*\[_6>7@8W>^<]>:X
M3X]W<,E]I%LI!N(XY'?U"L5"_P#H+5J:Y\=+&&%DTJSFN)^@DN $0>^ <GZ<
M5Y!JFJ76M:A->WDIFN)FW,Q_D/0#TIX'"57B/K-6/+Y>HLQQU!8582C+G>EW
MZ:[A:ZO?6,9CMKVXMXR=VV*5E&?7 -3?\))JW_04O?\ P(?_ !K.HKZ)PB]6
MCY15)I6399O-2O-0VBZNI[D+]WSI"^,^F37TKX%_Y$W1?^O2/_T$5\PU['X;
M^,FBZ/H&GV,UK?M+;P)$[1QH5) P<9<<5XN:4)U:<8THWLSZ#)<33HUIRK2M
M==23XB?#/5_%/B1[^S:V$#1(@\V0@Y Y[&N9'P0\0_\ /2Q'_;5O_B:[3_A>
MN@_\^FI?]^H__BZ0_';0NUGJ)_[9Q_\ Q=<-.IF-."A&&B\CTJM'*:U252=3
M5Z[_ / #X>_"F3PMJ0U+4+F.>Z12L4<&=J9&"<D#)P2.G<UU/CC7(O#_ (7O
M[J1@',9BB4_Q.P(4?U^@-<9=_'K3UC/V73+F5^PF=4'YC->:>+?&FH^,;I9+
MQU2&/_5V\>0B>_N?>E#!XK%5U5Q*LE_5AU,PP>"P[HX1W;_J[9L?!MHE\=6P
MD&7,4@C_ -[:?Z;J]K\96-YJ7A?4K6P8K=R1$)@X)]5S[C(_&OF2QOI]-O(;
MJVD,4\+!T=>H(KV;0_CEIMQ;(NJVTUK<CAFA7?&?<<Y'TY^M=&986M*M&O25
M[?H<N4XRA&A/#5I<M[Z^JM]YY5:>#];O;S[+%I=T9\[2&B*A?J3P/QKZ+\(Z
M&WAOPW8:<[!Y(4^=EZ;B2S8]LDUR.K?&_1;6%OL,-Q?3X^4%?+3\2>?TK%\,
M_&Y85O#KD4\TDDN^'[)&NU%P!MY8=,>_4UCBEC,;3UIV2Z=6=&#EE^7U7:KS
M-]>B1A?&Q"OC3)'WK:,C\V']*ZCPC\)_#FM:+9ZD9[RY$\88H9%55;HR\#/!
MR.O:N/\ B9XPTKQE<65S8074-Q$C1R&X10&7.5QACT);\ZH>"_B!?^"YG$(6
MYLY#E[:0D#/JI[&N_P!CB)8.$:3<9+H>;[?"1Q]2=9*<)==[&EXZ^&NH:#JT
MKZ;93W.F.=T30@R&/U5L<C![_2MGX7Q^+DUZV$@ODTI<^<MX&$>W!QMW=\XZ
M?RKI['XW:!<1K]HCNK63'S!HPP'T(//Y5)>?&OP[;QDQ&ZNF[+'%C]6(KAE6
MQDZ7L9T;O:_]=3T84,OIUOK%.O97O9/\/3R.E\97<-EX3U>6X($7V61<'N64
M@#\20/QKPWX4Z]'H7C"W,S!(+I3;.QZ#<05/_?0'YTSQQ\1K[QFRPE!:6$9W
M+;JV=Q]6/<_RKDJ[L'@73P\J=7>7X'FYAF4:N*A5H[0_$^I/%F@KXF\/WNFL
M_EF9/D?^ZP(93],@5\]W7P_\16EZ;5M(NI'W;0\49=#[[AQBNN\'_&B;2K6.
MSUB"2]BC&U+B,CS0/1@>&^N1^-=F/C-X:,>[SK@'^YY!S_A^M>?16-R^].,.
M9,]7$2R_-%&K.IR27]6U_0R=*^!^G2:+;#49;B+4BN96@D7:"3G&"#T&!^%>
M8>--#L_#FOSZ?9W3W:0@!W=0,/U*\=<<?CFN^\4?'#S[>2WT2VDB9QC[5<8#
M+_NJ,\^Y/X5Y/)(TTC.[,[L=S,QR23U)->G@88OF=3$/1]#Q\RJ8)1C2PL=5
MN_ZW]3Z#^$>NQZOX/MX-V;BR_<2+GG'53],<?@:Q?BS\/+S7KJ/5=+C$\ZH(
MYH 0&8#HPSU/;'L*\K\+^*+WPGJ:WEDXSC;)$WW9%]#_ (U[#IOQNT*Z@4W:
M7%E-CYE*;US[$=?Q KSJV&Q&%Q#KX=73_7H>KA\9A<;A%AL5+E:_39W.#\(_
M"G5]4U2%M2M'LK"-@TIF^5G /W0.O/K7OP 4  8%>3^*/CA!]F>#0X)#,PQ]
MIN% "^ZKW/U_6GZ#\:=)T_1;*VNX-0FNHHE660(C!FQR<E\GFL,51QN+2J3A
MZ+]3HP6(R_ MTJ<[WW;_ "/._B%_R.VL_P#7PU<]6KXJU6+7/$5_?P*Z0W$I
M=5D # 'UP3657U5%.-**>]D?%8B2E6G);-O\PHHHK8P"BBB@ HHHH _+3XW_
M /)8_&__ &&;O_T:U<37;?&__DLGC?\ [#-W_P"C6KB*XWN?JE'^%'T04444
MC8***2@ HHHH ***2@ HHI*0!1124@"DHHI %)110 4444 %)110 4444 %)
M110 4444@"DHHJ0"BBB@ I*** "BBDH **** "BBDH ****D HHI* "BBB@
MHHI*!A1110,*2BB@84E%%( HHHJ0"DHHH **** "DHHH **** "DHHH ****
M0!2444@"BBDI %%%)0 4E%% !2444 %%%)0 4444@"DHHI %%%% !2444 %%
M%% !2444 %%%%( I***0!1124@"BBB@ HHI* "BBB@ HHI* "BBB@ HHI*D
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MHHJ0"DHHH **** "DHHH **** "DHHH ****0!2444@"BBDI %%%)0 4E%%
M!2444 %%%)0 4444@"DHHI %%%% !2444 %%%% !2444 %%%%( I***0!112
M4@"BBB@ HHI* "BBB@ HHI* "BBB@ HHI*D HHHI %)110 444E !1110 44
M4E !1110 444E2 4444 %)110 4444 %)110 444E !1124AA2445(PI***!
MA1124 %%%% !2444 %%%% !2444@"BBBD 4E%%( HHHH *2BB@ HHHH *2BB
M@ HHHI %)112 ***2@ HHHH ***2@ HHHH *2BBD 444E( HHHI %%%)0 44
M44 %%%)0 4444 %%%)0 4445(!1124@"BBDH ***2@ I**2@ HHHH ***2D
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MBBB@ I**2@ HHI*0'[Q4445^DGXT%%%% !1110 4444 %%%% !1110 4444
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M& <\UFJD''G4E;N%F<)17JGQD_9?^)'P!T_3;WQSH,>CVVHRM#;.M];W&]U
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M"DHJYJ&CW^DQV4E[97%G'>P"ZM6GB9!/"69!(A(^9=R.NX<94CM2 IT44E(
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M4_9M92T>=GSO+"V3@_RH$65NVB>5EFDBG)\M8K@;MJ_4]*<L:1RKF%ECM_\
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W#X$?\BU?_\
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MZUZ=.:J14X[,S>F@445]P?L#_L.Z1\:-'N/B'\0O,'@^WF:*QTY93"+YH_\
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M#U)900M<SIO_  53^&_BK4%T7Q5\*)+;PQ*XB:9I8;X*A."SVYB48'4@,Q]
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M_8JT?XU1WOQ#\?P--X/TV<V]EISL8X[^91F1Y&R#Y297@?>;()PI!]F\6?\
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M;-#<P7Z07%O,F&1ED"LC ]P0016U.JJE]+-":L8M%?I]_P %;? ?AGPC\-/
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M6ZB9?-5,Y(0K)&P!/!+@<  ?6W_!-3]H3PA\0]-M/ FC^!(-!\0>'?#D O\
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M +DD;%6'X$&J%=(@HHHH ***2@ HHHH ***2@ HHHJ0"BBDI %%%)0 444E
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MREMVT2'RQ[;/NX]L5I_"N9[GXC:?-*Q>21IG9CU),3DFN,KK_A+_ ,E TO\
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M&[X:_P#7C>_^C(J]4_X)&?\ )"?%O_8R/_Z2V]*?_(OC_74/MGS#_P %4O\
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M7-K^RAH$:N?^)EKUE#<'.-R_9KB7G_@4:G\*_(VOUB_X*K?\FJ^"O^QCLO\
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MQ8OOV@/&/A*U\3:OX3\/:'>-86VF:5</:>;&H&)960AI/,!WC<<8*X KPO\
M9S^'GB3X]?'[PEHUJ+K5;J;48;B^NYF:7R+:.16EED8]@H/4\D@#D@5S6J2C
MS.5D/0_0;_@LLH_X5;\/3W&LS#_R!7C/_!,/]KSPI\&%U[X>^.;Z/1=&UB\7
M4+'5;CBWBN"BQR1S'^!65(\,?E&TY(R*]J_X+*1EOA-X DQPNMRJ?Q@;_"OE
M+]F7_@G_ '/[3'P:UGQQI/C:"SOK![JU30ET\RR274<8>.-I#(H0/OC^;:<;
MCQQ65/E="T]A]3Z]^(__  2H^%'Q66;Q%\.?%EQX9COB9HDLS'J.F<\_N@&#
M!2?20@=@ ,5\E_%[_@G5\=/@9H>J7NCRKXJ\-!?-NV\-W4@DV+G#2VQ"LV 3
M]S?@$G/6OFCPOX^\:_"76K@^']?UKPEJD$ICG2QNI;2174X9)%4CD$$%6'L:
M_4[_ ()B_M3?$WX]7'BO0O'$_P#;]CHUM#-;ZXUNL<J.[%?)D9 %<D L"1N^
M1LDY&*E[6BN:]T&C/S ^!OQ1N/@M\7O"GCBWM_M;:+?I<R6^=IFB^[(@/8LC
M, >Q-?KUXS^'O[/G_!2#P_I6L6OB#S==M+?9%<:9=)!JEG&26,,\#ALJ&)/*
MD=2K8))_/?Q_\!M$^+W_  4 \8_#;0M;M/"UEJ.MW:6]TUN988I@AEDB"!AC
MYQ(H&0,@#BN._:S_ &7];_9 ^)&F:1_:]QJUG=VB7MAKT5JUH)'!Q(B@.V&1
ML=&SAE/&:N:C4::=I"/I?XB_\$?_ !OX9G_M+X=>.+'6Y+=Q-!;Z@CZ?=(RG
M*[)%+J6! (8E/PKX@^+?@'QO\-?&EUH?Q T[4=-\0Q ,Z:BYD:1"2 Z29(D0
MD'#*2#@\\5[/\ /VY_CGX!\7:%ING^)]3\8V5Q=PVPT'6&-[]I#.%$4;OF1"
M<X&QA@XX(XK['_X+*Z/H[_"[P#JLJ1C7X]9DMK=\#>;9H&:4>X#I#],^])2J
M0FHSUN&ECX7^ &B_'[XS:7?> /AMJGB:]\--"UO?Z?'J4D6E6\,I8L) S")
M^7.T<M\V >:^B/"__!&_XBWVQO$'C?PWHZMR5L4GO'7ZAEC&?H?QKZB^&=['
M^S/_ ,$U[3Q=X"TVWN=:'AJ'6Y9!%O\ ,O)PAEFEZ;_*WGKT6$#H*_)GQS\?
M_B5\2IYY/$_COQ!K*S$EH+C4)?(&>RQ A%'LJ@41E.HWR:(>Q^N_[&'[(G@G
M]ESQOK\6F?$E?&'C"[T\17NFH8(?(A$BGS#;J[R+\V!N9L<D5^8/[=BA?VN_
MB@ /^8L3_P"0TK[%_P"".7PIUBQ;QO\ $&]LY+71[R"+2M/FD7'VE@Y>9D]5
M4K&N>A)(ZJ:^/OV\XS%^U]\3U(P?[4#?G%&?ZU%.ZK23=] >Q]\?L!>(K+]I
M[]B?Q3\)=<G5[S289]%9G^9DMIU9[6;_ ( ^]5]/(6OS4^%?P3U?X@?'[1/A
MA/!):ZI<:S_9E\@'S6ZQN1<M_P  1)&_X#7M?_!,GXR_\*J_:<TK3+N?RM'\
M61G19PQ^43,0ULV/7S0$'M*U?H5\/OV78_"'[>WQ$^*<MLL.AW.BP7=E(P 1
M+RY+1W+!O[P%M(S>@N1ZTI2]C*7GJ&Y\\?\ !7CXI6OA_0/ 7P>T39:VD,:Z
MM=VT/"QPQ@P6L?TXF.#_ '$->9_\$Q?VNO#'P)U;7_!?C>\72-!UZ>.ZM-6D
M!\FVNE78RRX^ZCKL^?HI3G@Y'S9^U7\8'^.W[0'C+Q@LK26%W>M#I^>UI$!'
M#QVRBAB/5C7KG[)_[ LW[5'PSUOQ7I_CFWTB[TVXFL_['.GF:1YEB5X]SF10
MJOO W8.,-QQ5\D8TN68NI]D_$O\ X);_  B^-+W/BGX=^*YO#8U)FG1M,>+4
M=++'DF-0P(!)SA9-HSP .*^3/BQ_P3;^.OP3TG4[WP]<+XNT$KONAX;N9$N&
M1<X,EL=K.1D\)YF,GWKY?T'QAXU^#_B*[CT;6M;\'ZU:3-!<I974MI,DB$JR
M.%(.0000?<5^G_\ P3#_ &KOBC\=/$7B;POXWNF\1Z7I6G)=PZW);JDT,AD5
M%@D=  ^]2[ L-W[IN3VB7M*2O>Z'HS\E6SN.<YSSFDKWC]NS1]'T']KCXFV>
MA)''IXU,2E(1A5F>*-YP .F)6DX[5X/79%\R3)"BBDI@%%%% !1124 %%%%2
M 444E( HHI* "BBDH *2BDH **** "BBDI %%%%( HHI* "BBB@ I*** "BB
MB@ I*** "BBBI&%)112&%%%% !2444 %%%% !2444 %%%)0 4444@"BBDJ0"
MBBB@ I*** "BBB@ I*** "BBB@ I***0!1112 *2BB@ I**2@ I*** "DHHH
M ***2D 445;TG3WU34(;:-E5G;&YN@H6KL@;LKLU]+^Q:;H<]T]S<6VJMQ"B
M@J&7CGIR.O?M6-8VYU"_BB:58C(V#(_0>YK;\9:C=--%IDX@VV8P&A'WN.M'
MAZ'^R["XU*[T[[5:LNQ'+#@^N*V:3DH]$8)M1YNK(_%FH7'FQ:;)=0W<%H $
MDA7 ;COR>1TJ3PZMSI%C<:J+6&>#:8_WC<@GN!7/*K7$VV-"S,>%49/T%;'B
M![*&&VMK);B)E7]]'+N'S?0U*EJYC<=% R88_M=TJ%EC\QNIX R:U_%%Q<0M
M!ISW$=Q#;J-IC7'YTWPY;O")]0>Q2^MH5PRR$ 9/?D5D-FZN3Y<>"[<(HSU[
M"IVCZE;R]#8T^%]/T.XO'LX9XIOW:R2$;D/J!BJ>@VKW6I1^7+'"Z?O TO3C
MFI=<^S0+#:VPGC\L?O8YL_?^E+9QO::-//)8K-%,=BSLPRI]A5=4NPNC?<K7
M$TVK:L6;;)+(^.!@&I-=8?VAY7V:.T:(!&6,Y!/K3-'@CDG>2:.5X(URQB'*
M^E&EV[7VK(L:++\Q;;*>"/>IU:]1Z)^A-K#2275O:^;#<B-0J&'I]*2ZCW:Q
M%%);_9MFT.L!W'CN,4R%5OM88_9?W>XDPQ'& *2SDCCOII%E:T558IQN/L*>
MX;:"!U:>ZEW7+*,A77K_ ,"-1E?]&MU(B^=]V]>7'UI%?_0I3YDH=WQ@#Y6'
MO4C8AN(LE8"B9W1C=D^]2,8\P\^5S("5&$^3@_X5 RA8T7"EG.=P/(]C3]Q\
MD R$>8V2"O'US32P69FRORC PO!J6,;(!N"#:H'4@G!]Z:W[QC@;4'8<T<JO
M<%O:D; PO'N<5)0GWL <=O2C('09-'L.G>DZ=*0 V3DFDX]:.3UHH ./2C//
M2BDY]: #\*./0T4E(!W'KC\*7G_9/UIN?QI./2@!<C/3'TI=QXYR!SAJ;GTH
MR6Z\T@'<#J,8'5:<K8Z%6 [,*CSCV-+GUPU,!X.UOXD*]U.>:4-TSMD ^8YX
M-1AMO<C_ !I>O;</:@!ZD*=NYHL_>]/:G;FD!^5)"PR>.1BHMW^T?4[N]!^8
M\IW&2M A[; &.UXRP&W'3\:=YS?.5N#T"C<.2/2HU;L'()X^8=!2C+?P(V5P
M,=O>@"9I)U+$21N(QM[=#3%:>)@0RYC&!C'0_P ZB;9S^[8?+Q]?6FMY7.-W
M08^O>BX6)RTP7!F \OE<-Z^E121HI8&;?P""HSDTUO*YQN/'&?6C<GS;8^"!
MC)Z5(QQD7#+''PP RW4?2ACY;,TGSR9P5;^=(S2$,,;%. 0!@4WY8VY^=L].
MU R6,D?*2PR,D8]JKLNUB/2G [1D\D\=:)OO9]:3V!#***2I*"BBB@ I**2@
M HHI*0!2445(!2444 %%%% '[R4445^EGXT%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >X? C_D6K_P#Z^S_Z M5_CU_R"M*_Z[/_ .@B
MN!\)_$;4O!MC-:V4%K+'+)YI-PC$YP!QAAQQ3/%WQ"U'QG;V\-[#:Q+ Q=3;
MHP))&.<L:^?6"J_7O;_9O^A]1+,*#R[ZMKS6_4YBBBBOH#Y<*ZSX5?\ (_:3
M_O2?^BVKDZT?#^N3^&]8M]1MDC>> L564$J<J5YP1V/K6->+J4IPCNTSHP\U
M3K0G+9-/\3Z1\:?\BAK?_7E-_P"@&O"/A?J<.E>-M/EG94B<M$7;H"RD#]<?
MG6EJGQFUK5M-NK*:UL%BN(FB=DC<, P(.,OUYK@J\G!8*=*C4I5?M?Y'N9CF
M-.MB*5:AKR]_4^K->TE->T:\T^1S&MQ&4WKU4]C^=>,V_P #=;>]\N6XM(K8
M'F=6+''J%QU^N*JZ#\9-;T>V6WG6+48UX5I\^8!Z;@>?Q!-7-4^.6KW<+1V=
MK;V)88\SF1A],\?F#7'0PN/PK<*5K/J=^)QF68U1J5KW73].Q['H.CV_A_2;
M?3K4YBMUVY)Y)/))]R3G\:\;^.ENR>*;.7'R26B@'W#OG^8_.L3PW\3-9\-M
M>-$8;Q[MQ)(UX&<[@,9!##KQ^0J'Q=X^O_&D5LE];6D9MV8H]NC!N<9'+'C@
M?E6N%P-?#XKVDG==7Z_\$PQF98;%8/V45RM6LO3_ (!V/P#N%6]UBW)^>2.-
MP/92P/\ Z$*] \>>$/\ A--%2R%Q]EDCF$R.5W#(!&"/HU?.^BZW>>'M0CO;
M&8PSIQG&00>H([BO0H?CU?K"!)I=L\O=ED95_+G^=+&8+$/$_6*'E_6H\!F&
M%CA/JN)VU[ZWUZ')>.O!K>"M2MK0W/VOS8!*9-FP [F! &3Z#\Z]E^$/_(@Z
M?_O2_P#HQJ\4\7^,KSQG>Q7%W%#%Y2E$6%2,#.><DYK5\.?%;5O#&D0Z=:V]
ME)!$6*M,CEN6).<,.Y]*Z<5A\1B,+&$OCOK^)R8+%X7"8V=2-U!JR_ T_CK_
M ,C=:?\ 7BG_ *,DKE/!GB)O"OB*UU#:SQ(2LJ+U9",'_'Z@4GBSQ9=^,=2C
MO;V.&*6.(0A8%(7 )/<GGYC6+7=0H<N&5&HNEF>;B<3S8N6(I/K='U?')9Z_
MI>Y&2[L;J,CCE74C!%>7ZE\!EDO&:QU3RK9FR(YHMS(/3(//Z5YWX<\9:MX5
M=CI]T8XV.7A<;HV_ ]#[C!KMH?CUJ"QXFTNVD?\ O([*/RYKPU@<9A)/ZM*Z
M?]=3Z.68X#'07UN-I+U_-:GI'@OP39^"[%X;=FFGEP9KAQ@N1TP.P&3Q[UY[
M\9_&L5YMT*RD$BQOON74Y&X=$_#J??'O7/\ B#XO:[K<+01/'IT#<$6P(<CT
M+$Y_+%<173A,OJ*K]8Q+O(Y,=FE)T/JN$C:/Z>7ZGH'P1_Y'*3_KT?\ ]"6O
M3?BQ_P D_P!5^D7_ *-2O"O"OBB[\(ZF;ZSCADE,9CVSJ2N"0>Q'/%;OB'XL
M:OXDT>XTVZMK*."?;N:%'###!AC+D=1Z56)P=6KC(UH[*WX,G!YA0HX&>'G?
MF?-^*.*KK_A+_P E TO_ +:_^BGKD*TO#NO7'AG6+?4K5(Y)X=VU9@2IRI4Y
MP0>A]:]>O!U*4X1W::/"PU2-*O"I+9-/\3Z,\=?\B;K7_7I)_P"@FOF&N[U;
MXQZUK&F75C-:V"Q7$;1.T<;A@",<9<\UPE>?EN&J86$HU.K/4S;&4L94C*EL
MD?17PC_Y$#3?K+_Z,:O.?CG_ ,C?;?\ 7DG_ *&]9_AWXK:OX9T>#3K6WLI(
M(2Q5ID<MRQ8YPP[GTK%\5^*[OQAJ27M['#%*D0B"P*0N 2>Y//S&L,/@ZM/&
M2K2^%W_$Z<5F%"K@(8>-^9*/X&C\+?\ D?M)_P!Y_P#T6U>\>,?^11UO_KQG
M_P#1;5\V:!K<_AW5[?4;9(WG@)*K*"5.01S@CU]:ZW4OC-K>J:;=64MK8+%<
M1-"[)&X8!@0<9?KS1CL'5KXB%2&RM^89;F%#"X6=*I>[;_)(X*BBBO>/F0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\LOCA_R63QO_V&
M;O\ ]'-7$5V_QP_Y+)XW_P"PS=_^CFKAZXGN?JE'^%'T0444E2;!2444@"DH
MHH **** "DHHH **** /3_V9?BAI7P8^.GA/QIK=O>76EZ3/)+/#IZ(\[!H9
M$&T.RJ3EQU8<9K]&_P#A[9\(/^A<\;?^ -G_ /)5?DI17'6PE+$24I[E*36Q
M^M3?\%;?A#V\-^-B?>QLQ_[=5E:Q_P %=OAY#:NVE>"_$U[<X^6.\-O;H?JR
MR2$?D:_*JBN;^SL/V_$KG9[C^T_^UUXO_:AUJV?6$ATCP_8L6L=#LV+11,>#
M(['F23'&[  &< 9.:_['_P :M#_9^^.6E^,_$5KJ%YI=K;7,+PZ9&DDQ:2(H
MN [HN,GGYJ\5HKM]E#V?LDK(B[O<^Z_VV_V[/ 7[27P?M/"GAG2/$ECJ,.KP
MW[2ZM;6\<7EI'*I ,<[G=F1>V.#S7D'[#/[1GAK]F7XI:SXE\46.JW]C>:-)
MIT<>D0Q22B1IX9 2))$&W$3=\Y(X]/G.BLHX:G&FZ2V8^9WN?9/[>'[97@K]
MJ#PSX4T[PKI>O:?/I-W-<3MK%O!&K*Z*H"^7-)DY'<"L3]@O]J_PC^RW?^-)
M_%>G:UJ":U%:);C1X(92IB,Q;?YDL>,^8N,9Z'I7RA11]6I^R]CT#F=[GU/^
MWE^U1X3_ &HM=\(WOA73]9T^+2+:XAG76((HV9I&0KL\N63(^4YSBNU_87_;
M=\"_LR?#77/#WBC2O$-_>WVKM?QR:1;021B,PQ)AC),AW9C/0$8(YKXCI*'A
MJ;I*CT#F=[GO7[:GQZ\/_M'?&8>+?#5GJ5CIHTV"S\K58HXYMZ,Y)PCN,?,.
M_P"%87[.'[3GC#]F7Q7+JOAN6.YL+S8FHZ1=Y,%VBDXSCE7&3M<<C)Z@D'R*
MBM52A[/V;5T*[O<_7'P5_P %7OA3KFGQ-XATK7O#-_\ \M(A MW"#_LR(0S#
MZH*Q?BA_P5H\#:/I4T7@3P_JGB'5V7$4VIQBUM$/8MAC(V/[H"Y_O"ORHI*X
M?[/H)WL7SLZOXG_%#Q)\8O&NH>*O%>HOJ6L7K O(1M2-1PL:*.%11P /YDFO
MI+]@G]K[P=^RW9^-HO%>FZYJ#:W)9M;_ -CP0RA!$)@V_P R6/&?-7&,]#TK
MY"HKKJ4H5(>S:T(NT[GTU^W9^TUX7_:>\<^'-9\+6&KV%KING-9S)K$,4;LY
ME9\J(Y) 1@CJ1]*\W_9?^*>D_!3X\>$_&NN6]Y=:5I,LTD\.GQH\[!X)(QM#
MLJGEQU8<9KRVDHC2C&G[);!?6Y^@O[8'_!0;X=_M ? O5O!?A[1O$]GJEW<6
MTR3:G:V\< $<JNV2D[MG X^6ODW]G?\ :,\5_LU^.!X@\-3+-!.HBU#2[@G[
M/>Q#.%<#HPR2K#E23U!(/EE%13P].G!TTM&/F;=S];/!O_!6#X4Z]I<*^)=$
MU[P]?NN)X5@2\MP?]EU8,P^L8I?%O_!5[X3>'],G3PWHFOZ]>HF+>'[-':6S
M-V#.SEE'TC/TK\DJ2N7^SZ%[ZE<[/5OVC/VD/%?[3'C9?$'B5X;>&WC,%AIE
MID06<1.2%R22S'!9CR2!T  'E-%%>C&*@E&*T$%>Y?LL?M;>*?V6_$MQ<Z7$
MFL>'M0*_VCHEQ(428KPLB/@^7( 2-V""."#@8\,HI3A&I%QDKH#].M<_;#_9
M'^,DR:[XZ\ 3)X@PIEDO-&62:0J  #+"_P"\7L-_8=!7+_%/_@ISX=\*^"V\
M)? CP</#D"H8X=2N[6*WBM,\LT-JF5+$G.YR.>2K5^=E%<2P=)-7NUV;T*YF
M3WU]<:G>W%Y=SR75W<2-+-/,Q9Y'8Y9F)Y)))))]:^U? /[;O@;PK^P[=?!J
M[TKQ#)XGETK4K%;N&V@-EYEQ//)&2YF#[0)5S\F<@X![_$=%=%2E&JDI=-17
M"DHHK41O> =>M_"OCKPYK5VDDEKINI6UY,D(!=DCE5V"@D G .,D?6OJ']OC
M]L#P;^U-8^"H?"FF:[I[:+)>/<'6;>&(,)1"%V>7+)G'EMG..HZU\@45E*E&
M4U-[H=PK[=_;6_;>\"_M(?!7P]X0\-:3XBL=2T_5K>_EEU6V@CA:..VGB(4Q
MS.=VZ52,@# //8_$-%$J<9RC)[H K[<^,?[;O@7XA?L8Z'\(].TKQ##XDL=+
MTFRDNKJV@6S+VHA$A5EF+X/EMMR@SD9 KXCHHG3C4:<N@'3_  T^)7B'X1^-
MM,\5^%[]M.UG3Y-\4H&58$89'7HRL"00>H-?H=I__!13X(?'#PO9Z9\:OAXW
MVZW&[<+)+^U5R &>)B1+$3Z ' XW&OS)HJ*M"%5IRW74$['Z:K^W]^SU\!=%
MO(?@[\.))=5N%V-)'9I8QR ?=\V9BTK@$Y"[3WY%? ?QH^-'BCX]>/+SQ;XM
MO%NM2G41QQ0KLAMH5SMBB7)VJ,GN2222222>&HJ:="%)\RW[L+W/M[]BO]N#
MP+^SC\$O$/@[Q+I/B*^U/4=6N+^*72K:"2%8Y+:")0QDF0[MT3$X4C!'/8?$
M%%%5&G&$I26["Y][_LW_ /!3<^$_!L'@KXMZ%<>+=%A@^R1ZI;+'+<-!C:(I
MXI"%F&WC=N!('(8\UWEO^TS^Q1X6U2+Q%I?PZ,VK1MYD<-OH"_NV'0JDCB)3
MZ$=*_,RDK"6$IMMJZOV8^9GU9^V!^WMX@_:8M5\.:782>%_!,4OFO9>=OGOF
M!!1IV  PI&1&,@'DEB%(^9/#?B/4_"'B#3];T:]ET[5M/G2YM;J X>*12"K#
M\1]*SJ2NB%.-./+%:"N?I3X/_P""E/PS^+'@FW\.?'CP&+^>/:7NK>RCO;.6
M0#'F^6Q#POR?N[NIY .*LV_[=G[-GP#T[49OA!\.)IM?N(]B3I8K:1OSG;).
M[-+M!YVA2#CMUK\S:2N;ZG2\[=KZ#YF=O\9OC%XD^.WQ"U+QAXIN5GU*\(58
MH@1#;1#[D,2DG:BCW)))))))/TY^Q7_P4)7]GKPN/ _C'1[K6_"*3/-9W.GE
M3<V6\[G38Y"R(6);[RD%F^]D ?%=%;SHPJ0Y&M!7/TZU;]KC]CC0+Y_$^D?#
M*'5?$6[SHX8?#L,6)<Y#'>0BG/.Y03WY-9?PG_X*P:;'KWC'4OB-H^M?9[^2
M!=%TOP_##/#8P(KA@[2RQEG8L"6QSC^$  ?FS25A]3I6L[L?,SI/AKXDMO!O
MQ&\*Z_>I-+9Z5JMK?3I;@&1HXID=@H) +84XR0,]Q7TS^W[^U]X._:JC\"KX
M3TW7-/.A&^-S_;-O#%O\[[/LV>7+)G'DMG..HZ]OD*BMY4XRFIO="N>D_ 'X
M_>*OV<O'T'BGPM.GF;?)O+&X!,%Y 2"8Y /< AAR",CO7WO??MZ?LT_'W2K-
MOBQ\/;B'5[>/R]UUIZ7HB!Y*Q7$9$FW/^ROTK\OJ*RJ4(5'S/1]T"=C],K[_
M (*-?!7X'^%+K2_@C\-W2^G.2\UHEC:LV.))&5FEE(_NG''\0K\[_B%\0=>^
M*?C+5/%/B;4)-3UK4I3+/<2?D%4=%51A0HX   KG:*=.C"E=QW!NY]L_LD?\
M%&)O@SX/@\!?$#1;CQ7X/A#16UQ RO=6D##F QOA98^3A2RE02,D8 ]5_P"&
MA/V&Y+HZTWPW"W^[S/L9T'Y<YS_J@_D]>W3\*_-"BHEA82;DKJ_9CYF?9O[7
M'_!0ZY^.'A%O ?@;0Y/"7@A@B7'G%!<W4:8*1;$RD48PORJ6SM R!D'XRHHK
M:G3C2CRQ0KW"O4?V:?CI>_LY_&#1O&UI9#4XK42075BS[//@D4JZAL'##A@<
M$949XKRVBKE%23B]A'Z>_&3_ (* ?LZ_%_X>Z[!J?@K5KOQ)?Z1<:?:W-YH=
MI+<V;R1,JLDQERH5FR"ISQG&:^#/@!\?_%7[./CZ#Q3X6G3S-ODWEC< F"\@
M)!,<@'N 0PY!&1W%>:T5A"A"G%Q6S'<_4&^_;U_9H^/VE6;?%GX>7$.KV\?E
M[KK3TO1$#R5BN(R)-N?]E?I5"^_X*.?!3X'^$[O2O@A\-W2^G;)>:T2QM68#
MAY&5FEE(S]TXX_B%?F916/U2GMK;M?0?,SHOB%\0=?\ BIXRU3Q3XFU"34]:
MU*4RSW$GY!5'154 *%'   %?5W['_P#P42N_@/X7C\#>-M'G\5>"U9A;R0.I
MNK*-OO1*C_++'DDA2RXW'G& /B^DK>=.%2/+):"O8_3&3]H;]AO4+IM;G^''
MEWY;>;0Z#@$DY_U:OY/6O)OVL/\ @HL_Q>\$R?#[X=:!)X0\%2HL%S),$2YN
M(5Z0+'&2D,? R%)) QD#(/Q/164<-"+4G=V[CYF=3\+/B'J'PG^(WAWQCI:)
M+?:+>QWD<4N0DNT_,C8YPPRIQV-?IIJ'_!3+]GOXAZ'93^-? .IZAJ%NNY;&
M^T>TOQ"YQN\J1W QP.<*3CI7Y14E54H0JM.6Z$G8[/P!\4-9^#OQ(M?%W@B^
MFTZ\T^X=[1YE!WPDD>7*N2&#(<,N>_!Z&OT+L?\ @HY\#OCEX6M-+^-7P[<7
MMO\ -_QY)J%HKD8+Q,2)8R?0#@<;C7Y@T4ZE&%2S>ZZ@G8_3NS_;V_9L^ .E
M:@?A#\-[B;6ITV"2.R2S24=A)<.S2[0>=NT_AUKX%^.GQR\4?M"?$*]\6^*K
MH2W<W[NWM8LB"SA!)6&)3G"C)]R22<DFO/J2E3H0IOF6X7/:?V6_VJ/%/[+/
MC275M$1-2T>^"QZIHMPY2*[12=I# $I(NYMK@'&2"""17VUKG[9O[(OQDFA\
M1>//A[-_PDJHIE^V:.DTLC*,!3+&W[U0.!YF.,<#I7Y>44JE"%27-L_(+M'Z
M9Z+_ ,%6/!V@_$73]/TSP=J.@?";2].EM[?3]+M+?[7-.63RF\KS$CBB11(-
MJN22V3V ^'/VG/BAI7QH^._B_P :Z);WEKI6L7*300Z@B).H$2(=X1F4'*GH
MQKR^DHA1A3?-$+MA1116PC[C_:^_;D\"?M ?L\>'_ ?A[2?$5GK&GWMG<2S:
MG;01VY6*"2-@K),[9)<8RHXSTKSS]@G]J+PK^RWXX\3:SXKT_6-0M=3TY;.%
M-'@BE=7$H?+"22, 8'8GZ5\O45@J,%!T^C'?6YZ%^T)\0M.^+'QL\9>,-(@N
MK;3-9U&2[MXKU%694;& X5F /T8U4^!OCBP^&?QD\%>+=4BN)].T35[74+B*
MS56F:..178(&*@M@<9('O7$4E:\JY>7H(^K/V^OVK/"7[5'B3PCJ'A/3M:T^
M'2+2>"==9@AB9F=U8%/+EDR,*>N*^4Z**4(*G%1CL/<*^A?V1OVS/$_[*>N7
M26MLNO>$]1=7O]$FE,>7 P)H7P=DF, \$,  1PI7YZI*<HJ:Y9+01^H.O?M<
M?L:?%*\;Q-XL^'DW_"0R'S9Q<Z(IGGDQCYWBDVR?5SZ=*\K_ &F_^"DEMXT^
M'\WPY^$/AR3P9X2FMQ:37DT:6]P8.C00PQ$I$A&03N)()&%KX2HKFCAJ<6GO
M8KF9K>$_%FK^!?$VF>(-!OI=,UG39UN;6[A.&CD4Y!]".Q!X()!!!K]'O"'_
M  4T^%_Q:\%6_ASX\> !>3IM,D]O91WUE+(!CS1&Y#POR?N[L9/S#.*_,NDJ
MZE*-3XA)V/U"TW]NK]ESX!VMU>_"KX<3W&NRQF-9;;3DM"ZDY*/<REI%3('
M5AP.*^$OVC/VD/%O[3/CH^(_%$T<<<"&'3],M01;V4).=J \EB>6<\L0.@
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M*N,%%MKJ(*]>_9?_ &E/$'[+OQ,B\5:+"NHVLL1M=1TJ:0I'>0$@[2P!VL"
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M>OAVVHW$83?<6MG%>VDT@&#,(W97@;V3=U/(Z5^9-)6DZ<:FXKGZBZ/^V/\
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M-7/)QK3270K9'QU7N?[)O[6GB;]E'QM<:KI,"ZQH>H(L6IZ'-*8X[E5SL=6
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MSW:E/W5'XGBF^IJ1@?EI.E%)2 ****0!2444@"BBBD 4E%% !1124 +1244
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M444 %)110 4444 %)110 4444@"DHHI %%%)2 **** "BBDH **** "BBDH
M**** "BBDJ0"BBBD 4E%% !1124 %%%% !1124 %%%% !1125(!1110 4E%%
M !1110 4E%% !1124 %%%)2&%)114C"DHHH&%%%)0 4444 %%%)0 4444 %)
M112 ****0!2444@"BBB@ I*** "BBB@ I*** "BBBD 4E%%( HHI* "BBB@
MHHI* "BBB@ I***0!1124@"BBBD!>77M373&TU=1NQIS'<;03MY)/KLSC]*H
MT4E !1110 444E !1110 444E !1114@%%%)2 ***2@ HHI* "DHI* "BBB@
M HHI*0!1112 ***2@ HHHH *2BB@ HHHH *2BB@ HHHJ1A2444AA1110 4E%
M7]'TEM7N3$)5A &XL_2FDY.R$VHJ[*MM;27DZ0PKOD8X"UL1Z39Z?!=)J;-%
M>(/W<:\_RI+G4K:ST]+2VAVWD,F3=(>ON#6;Y-WJ3/._F3 'YYFR<?4UKI';
M5F6LO)%S4O$=Q?K;*JBW\A<*T7!JI'I]S=*LQ1O*=MIF;ID^IK4\K3_#]W&T
MOEZFKQYVC&%-9UQK%S-:FT5]EKNW"(=O:B7]]ZA'^XM"_P#V3I^EWSPZA<^<
MOE[E,'(SZ&J[:U#'IXMH;.-75]PN#][@\=JK6.CW>I3-'%'\RKN.X[>/QJ?[
M%8VUE'/)<>9<;\-;@=L\T:]%9"LKZN[&W'B#4+NY6<SL)57:"@Q@?A4"VU]-
M#Y@29HI6QN.=K,:OG7K>SO9);&RC2-DV[9.>?6J$FK7<UN+<RMY.<B, 8S4R
M:ZNY23Z*Q<C\,7C7RVLIC@D*[QO?C'X5'_8JK87%PU["KQ-M\K.2W/:JPM[V
M^1Y\2S*G#.Q)Q[<U97P_.LMLMQ)';I-R&9AP/>BR>T17:WD3/I-@MQ;1C5%V
M.,N^.%-.ALX5EO)4UCRVA&(V[R<=N:JC3+5%NQ+?*LD1P@49#TXVNEQ_8V-U
M(^X_OE"_=^E/Y+[Q?-_<7T6XCT^&&+5HV6Z;YX3C*^Y/6M!FNKW4HK>6&UO;
M>R3D1G:&&._OQ6"L>C^;=9EG"#_4\=?KQ2*NG1V\#1W5PD[MMF ' 7\JM2M_
MPY'+?_ACIH=6#1G4+RWE$4;8M80 4!Z#H*6ZTG3[R0S7:[K^\_U=O#\NPX[_
M -36)'):>:\":K*MK#AX]XX+?E5NWU:97BU$W=O<W<G[E4<8*#/'2M5)/26O
M]?U8R<6M8E?4/ ]S:PP^2XN+B1MIA0?=^I_QK"OM/N--N6@N(S'*O5>M=G;W
M%Y9&:T@7??R?O);A'##!_P!ZM>'4(KR5$1%EBD3;+=2K@MCC'UJ71A+;0:K3
MCOJ>645WLWA#3=3M6-B7@=7P99B<$=\5BZEX&U"SFD$"?:H47=YBX''T]:PE
M1G'6US>-:$M+V.<I*<RLO!!'X4VN<W"BBBD 4E%% !244E !2444 %)110 4
M44E( HHHI %%%26\)GF1,,03SM&2!W-(#H?#%O\ V;;S:K=Z>+RS"E1N .#Z
MX-8/EOJ%ZRV\)+R.2L:#/4]!6UXDFMK*&*QTV^EFM-NYXV.1NIGAFWMXX[F^
MEO39W%NNZ''<_CUK=J[4.Q@G9.?</$3V<-K:V<-I);740_?;^,GWJKH-I;M(
M]S?1SFSC',D2G ;MDU1N[J74+IIIY#)(YY8UN:I,^BZ3#8VUZD\-ROF2HHY4
M\<9_STI74FY=$/5)1ZLQ-0NC>7;R;Y)%SA3(<G;V%:\\;Z/H(@N;)/,NOGCF
MR"<?TK.T>S6XN@\T,DMK'\TIC&<+3=6NDNKQ_(:0VR\1+(22H]*E:)R[E;M1
M[#=*LGOKQ$6%I@/F95Z[1UI^L7,%Q>-]ECDAMUX6.0YVU:TYX]/TV:Z2Z>"]
M^ZD87[P-9MK;R7MTD:*9)'/3UHZ)=Q]6^QJ0>=IN@R2F.%X[L[ 6Y9<53T6S
M>[O5VP"X5/F="<9%/UR6(W"Q0P-;")=K1L<_-W-%KY=MILTCI,LTGRQR(<+1
MIS6["Z7[E6[9+B^D*((49\!?[M6M:D96AM_/6=(T&"HQBHM'A>;4(RBHY3YR
MLAP#BF2LU[J+%456=_NKTZU/3U'U]";4"\5E:0EH67:7!C'S<GHQIEY$8HK5
M# D3%<[PV=WN?2EU7Y]1,8A6(KA"B=*6\1?[02-(C%MP"LA[T/J"Z#I%,VH(
MI2*;:@&(?E!X_G5<$?9V7=@-)_JP,G\ZGV^9J5QF(-M#96(X QWJ!&_<1*&S
MF3.Q1\WYT ++EGESYA.\ [_ZU$^?F &-S8P.14K+RWWE'F8_>'^=0GC;D#&2
M>O%)C1&QY)_#K2'TS1Z?GTI*@H2BBBD 4E%%( HHHI %)110 444E !1110
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MX;I7@/C31X/#OC'7=*MFD:VL;^>UB:0@L521E!) '.!Z5"DG)Q6Z QJ***H
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M;99HRT,K$=,,Z,<>^*_$3X\>!(_AC\:/&WA6 ,MKI6KW-M;;NODB0^43_P
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M(1\SL>Y)X"@ DL2  "20!7W3X1_X(]^,-1L8I?$GC[2-$N73<UO8V4E[L/\
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MT>/O^Q@U#_TIDJ:'-[:?-OH$MD<7245K>$9]'M?%6C3>(8;BYT&.]A?4(;0
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MBOH_PQ_P2Y^(?B'XS:[X(?6],MM*T.&WEO\ Q(L4CV^^9 Z0Q(0K22;3DC(
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MQD\ Z5XQ\.F=]$U/S6M7N8_+=T25X]Q7.0"4) /.",@'BOP9_;&_Y.J^*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,>BYE"JQ_P!UC5VZ\-_"[]KKX SZ3I$UM<^$-9A1D?2@D,MG,I#*=H'[N5&
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M +%Z[_\ 1L%<T(R6&J2DK<UV/JCB?^"CW_)Y?Q ^FG_^F^VKYIKZ6_X*/?\
M)Y?Q ^FG_P#IOMJ^::]*A_"AZ+\B7N%?K)^P.QC_ & _%S*<,IUD@_\ ;N*_
M)NOUB_8*_P"3 ?%__<9_])Q7+COX2]4..Y^3M?JC_P $?_\ DEOCW_L,Q?\
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MOX9\;Z:GG7.CW:S-!NV^=$04EBSCC?&SKGMNS7ZH_'[X'>"?^"BWPKT+QKX
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MQ9C_ /2JYKIE_O4?07V3X1K]:O\ @H!_RC_\'_[VC?\ I.:_)6OUJ_X* ?\
M*/\ \'?[VC?^DYI8C^)3]1+9GR!_P3%_Y/!\+_\ 7G?_ /I+)6E_P50_Y.RO
M_P#L$67_ *"U<C_P3O\ %5CX1_:\\"W&I7,=I:W37-CYLC!5\R6VD2)<G^](
M44>["OM/]NS]@7Q1\>/B-<_$+PUKVEV\<6DK'<Z=?B196:%7(\LHK!MPVC!Q
M@]ZF<HT\2G+16&M4<K_P1I_Y!/Q8_P"N^F?^@W5?GQ\:&+?&+QV2<DZ]?DG_
M +>'K]!_^"-/_()^+'_7?3/_ $&ZK\]_C/\ \E@\=?\ 8>OO_2AZ=/\ WBI\
M@>R/7/\ @G;_ ,GE?#C_ *[7G_I#<5ZA_P %=O\ DYC0?^Q5M?\ TJNZ\O\
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M-0/6M?XU?"7PE_P4=_9_\+>(? &L6>DZUI6^2RCN  EL\BJ)[.X5 3&<HA#
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M#_V4_P!ASP7^R;X=U][C4E\5:GJB*-0U75+9(85MX\L(UB+,$3)+,2QR0.P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RN^./\
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M G)4],]*X*OHW]B7]KB/]D?QQKVLW/AV7Q)9:O8+9R6T-V+=HV61763)1@V
M&&./O=:F5[>[N!]Z_P#!,G]B_P 6_ .\\0^.O'UI_8VNZG:#3++2?/61XK<R
M+)))+L)7+-''M&<@*V<9Q7G7_!9'XUQR-X0^%=A<[GC8Z[JL:'[IPT=LAQWP
M9F*GU0^E,\=?\%HI9M)GA\'?#9;;4G7$5YK6H^;%&?4PQHI;_OX*_./QYX[U
MWXF^,-5\4>)M1FU;7-3F,]U=S'EVX   X"@ *%'     %<T(2E/GF4VK61@T
ME%%=9)ZAX!_:@^+7POT^/3_"_P 0O$&DZ=& ([&.]=[>/'98GRJ_@*K?$/\
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M444 %%%% !2444 %%%% !2444 %%%%( I***0!1124@"BBDH ***2@ I***
M"BBDH ****D I*** "BBB@ I*** "BBB@ I*** "BBBD 4E%%( HHI*0!111
M0 444E !1110 444E !1110 444E2 4444@"DHHH ***2@ HHHH ***2@ HH
MHH ***2I **** "DHHH **** "DHHH ***2@ HHI*0!2445)04E%% PHHI*
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M** "BBDH&%%%% PI***!A2444@"BBBI *2BB@ HHHH *2BB@ HHHH *2BB@
MHHHI %)112 ***2D 444E !1124 %)110 444E !1114@%)110 4444 %)11
M0 4444 %)110 4444@"DHHI %%%)2 **** "BBDH **** "BBDH **** "BB
MDJ0"BBBD 4E%% !1124 %%%% !1124 %%%% !1125(!1110 4E%% !1110 4
ME%% !1124 %%%)2 *2BBI*"DHHH&%%%)0 4444 %%%)0 4444 %)112 ****
M0!2444@"BBB@ I*** "BBB@ I*** "BBBD 4E%%( HHI* "BBB@ HHI* "BB
MB@ I***0!1124@"BBBD 444E !1110 444E !1110 444E !1114@%%%)2 *
M**2@ HHI* "DHHH *2BB@ HHI*0!1112 ***2@ HHHH *2BB@ HHHH *2BB@
M HHHJ1A2444AA1110 4E%% !1110 5M>&HYX7GNXX%G2),,K5B5KV[6\.AR,
MMVZ7+M@Q+T(K6GI*_8SJ:QMW':6T1ENKNYM#-#@\+T4U#I*0*T\]S'(T2CY6
M7L?K4Q+V>@CR[M2)CAX1UI)&DL=!5$N(V2X;+1C[PJ]K>6IGO?ST(M(C$UU)
M.;D0O$"ZE^<FF6^_4+Y[B>-IT!W2;!4DRO9Z.D<ELH\X[EE[U'&ZVNFEXYW2
M:0[60=Q4[63]2M[M>A'Y9U+4!'!PI.$#GH*349O/N%C$21%/D^7H:? JVUB\
MLMNQ,G$<F<8--L8BL;W3P^;$O!Y[U.^G<?GV'7BBSMQ;-&OG?>,JG/'I3+>%
M;>+SIXV*L/W9'KZU%;PM=3DA"R+\S ?W:2ZE$\NV)6$0^ZA.<5-_M?</R$7?
M>W \R3EC@R-VI]Q,%40H%^0X\Q?XJ=+(MK#Y,3AQ(H+Y7E3Z5'!"NQI)&V8&
M4!'WC2\NH_,(80JK-*-T6[!4'!--FN&D41@D1 Y5?2DGF-Q,7("ENPZ5(RK:
M @C=-P593P*7IL/U&1P!5$DAPF<%<_-0UP%4I&N%W;@W\51LS7$I).68U(5C
MAX?YI5;[O\.*/0/4CP\ASRQ)ZT\VY57+,JE?X>]->9FW ?*A.=HZ41PO(R@#
M&[H6X%(8[]PN[EGXX/3FCSD4@K$OW=IW<\^M-\D!5+.!DX(')%)B->[,<^F.
M*6HA?M,F$ 8C;P,=JBY/O4OF(H8+&.N06ZBD>X=MV/E#=0HXI/U&(8'7.1MP
M,\T[9%&?F??E<C:.A]*B9BW).32B)SN.TC:,FCT0#O.V_<4+Q@]ZC9F;&23C
M@5)Y2KNW.,XR-O--:1%^XG;'S<T>H>@T1LP) X%/_=Q[A]]N,$=*C:1GY8YH
M6-I#A1FEZ!ZBR3&1B>@/8=*:J%N0.!U..E.VHG4[B1V[4CRE_;@# H]0]!V5
MA;Y?F<'[W:HF)/6E52W;CN:?N$73EO7M2 0((^7Z\$+ZTUG+>P["DSFG8"<G
MKU I# +MY;KU ]::S%C2$Y-+]WGOV]J0"_='^UZBF]:.IH)[#I0 ,<_3M1T^
MM)10 4E%%( HHI* "BBB@ HHI*D!?I6O8ZL70PS'YF^4/BL>BJC)Q>@G%2W.
MDF4-)-(8TFB2/8HDZY]JS'M+56MXY&DMY"/WI<9'X4FGZ@JE(I^8P<C Z&KM
MQ;O)N^5+B2;D9&=H]CVKH=IJZ,OAT9FM9P>2[BZ4LK[0FWDCUI[1V-O)(I=[
MA=OR,HVX;WHDMK5YF593 %3I(,Y;TJ-=.+^3B:',O;=]WZ^E8V[(OU8VXOVF
M6)51(1&NW,8P6^M5E4LP &2:M?8XXXR[SQG:^THIRQ'J*=)=00K-';QED8C;
M)(/F%3KU'Z#TC&F$O)N6\C8%8V4$?C5*:5II&=NK')P*221I&+.Q9CU)Y-36
M]MO5I7*A(^2K-@M["EOHA[:L=:VZJOGS>8D?.QE'5AVJ">9[B0R.=S'O3[JX
M$S;4!2$'*QYSBFV\)F;[K%%Y8J,X%#[(/-DMJPMXWFW[9.BH4SD'J:J_>-3W
M5P96"!V:*/A-PYQ1:D(QD+["@RN5SD^E+K8/,+QAN6-6214& RKC-)PMKU0E
MFZ8^85$S%V+'J3D\5)<-Q&@*,%'5!_.E?=@(%_T=C@?>ZYY_*DS\D>-H.>W6
ME;BW3A>23G/--<_NXQN!Z\ =*!CFSN;(;AN=QQ4;4]Q\[\ =_F.336Z9Y_&@
M!E%%)4@%%%% !1124AA1114E!1124 %%%% !1124 %%%% !244E !1124@"D
MHHJ0"DHHH ***2@ HHHH ***2@ HHHH ***2I **** "BBDH **** "BBB@#
M]Z****_33\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _*SXY?\EF\<?\ 8:N__1S5Q%=O\<O^2S>./^PU=_\
MHYJXBO/EN?JE'^%'T04E%%0;!1110 4E%% !1124 %%%% !1124 %%%%2 44
M4E !1110 444E PHHHH&%)110,*2BBD 4445(!2444 %%%% !2444 %%%% !
M2444 %%%%( I***0!1124@"BBDH ***2@ I*** "BBDH ****D I*** "BBB
M@ I*** "BBB@ I*** "BBBD 4E%%( HHI*0!1110 444E !1110 444E !11
M10 444E2 4444@"DHHH ***2@ HHHH ***2@ HHHH ***2I **** "DHHH *
M*** "DHHH ***2@ HHI*0!2445)04E%% PHHI* "BBB@ HHI* "BBB@ I***
M0!1112 *2BBD 4444 %)110 4444 %)110 4444@"DHHI %%%)0 4444 %%%
M)0 4444 %)112 ***2D 4444@"BBDH **** "BBDH **** "BBDH ****D H
MHI*0!1124 %%%)0 4E%% !2444 %%%)0 4445(!1124 %%%% !2444 %%%%
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M%%%( I*** "BBDH **** "BBDH **** "BBDJ0"BBB@ I*** "BBB@ I***
M"BBDH ***2D 4E%%24%)110,***2@ HHHH ***2@ HHHH *2BBD 4444@"DH
MHI %%%% !2444 %%%% !2444 %%%%( I***0!1124 %%%% !1124 %%%% !2
M444@"BBDI %%%%( HHI* "BBB@ HHI* "BBB@ HHI* "BBBI ***2D 444E
M!1124 %)110 4E%% !1124 %%%%2 444E !1110 4E%% !1110 4E%% !111
M4C"DHHI#"BBB@ I*** "BBB@ I*** "BBDH ?%_K$P-QR./6NBU%9&UJP5K!
M4.T?NUQ\U<[%_K%^;;R/F]*Z"ZP=9LR-2W';_KC_  <=*VI[/U1C4W7S&1;I
M/$$S)9 [<YB/:J=EY;7%W)+:M(H!P%Z(:LVYC.K7;27S# .)5_CJM9,R6%ZZ
MW@B)X\LCEZO_ (/8C_@=R/3V$=O=2BX,#@8"#^+VHM%:/3KF9H%D1L*'/533
MU66+0V)CCV2/P_\ %4$WE1Z;$%:02LV64_=Q[5GM;T+W^\=:,]O8SRI(@W?*
M489)^E1V<GV>&:59A')]T+MSD4^[5H;&!&@5"?F#YY-)=[H;*WB/ED-\^5Z_
M0U.WR'O\QEBWEF2?S$5D'"L,[LU';J))"[JS(O+%1TJ6XS#911GRR&._(Z_2
MHR1#:@ R+(_4=%(I;:#&X>[N,#+L>F>M)<2"1@J!E0<!2<T^-3#;M(4/S'".
M#T-,MT'S2,I:->N#CFI*'.3;Q[!N21AAP>F*9$@VF1QN0'!&<&FC][(-S8R>
M6/.*69PS8&W"\ J,9]Z5^H>0UF:5@.6/0"G<1CIN8CG(Z4<1J#P6/((/2F*I
MD;KCW-(8G+MR<GWIWRQ]?F8'D=J&?C:O [^]-5<\GA?7%(!3(V ,X / IH4M
MG SWI=P7&!SWS2%BV,DGM2 7RSW('&>M)Y?^TO3-)L8]O?FCRS[=,]: %VKW
M;MZ4A\OGDDXX^M)L/J.F>M&SK\PH 4LG.%[=Z0RGG& #UP*-JC/S9_"D.SG&
M30 A)/4T*I;&!2[P.B@<TC,6ZFD,7:!C<V/IS2;L=!CUIM+M[G@>]+T 0G/6
ME"]SP*,@=!GZTA)/)I +NXP/QIM*!FC..E "_=^O\J;11T^M(!?N].M-HHH
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M%%)0 4444 %%%)2 _>JBBBOTX_&@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /RL^.7_)9O''_8:N__ $<U</11
M7G2W9^J4?X4?1!1114FPF*,444 %)110 4444 %)114@%%%% !BC%%% "444
M4 %)1104%%%% Q,48HHI %)112 ****0"4444 %%%% "8HQ110 8HHHH 2BB
MBD 4444@$HHHI %)110 E%%% "4E%% !1110 E%%%)@%%%%( I,444 &****
M $HHHH **** $HHHH *,445(!BDHHI %)110 4444 %)110 48HHH ,4E%%
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M]-Q110 8HHHH *2BB@ HHHJ0"DHHI %&*** #%)BBB@ HHHH 2BBB@ HHHH
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$2 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>sdgr-20241231_g4.jpg
<TEXT>
begin 644 sdgr-20241231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M+]K/_P"<11_Q$L?\$3_^CT__ #7+]K/_ .<17^4'17T'^J>7?\_L;_X,H?\
MS,9>WGVC]S_S/]7S_B)8_P"")_\ T>G_ .:Y?M9__.(H_P"(EC_@B?\ ]'I_
M^:Y?M9__ #B*_P H.BC_ %3R[_G]C?\ P90_^9@]O/M'[G_F?ZOG_$2Q_P $
M3_\ H]/_ ,UR_:S_ /G$4?\ $2Q_P1/_ .CT_P#S7+]K/_YQ%?Y0=%'^J>7?
M\_L;_P"#*'_S,'MY]H_<_P#,_P!7S_B)8_X(G_\ 1Z?_ )KE^UG_ /.(H_XB
M6/\ @B?_ -'I_P#FN7[6?_SB*_R@Z*/]4\N_Y_8W_P &4/\ YF#V\^T?N?\
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M .:Y?M9__.(H_P"(EC_@B?\ ]'I_^:Y?M9__ #B*_P H.BC_ %3R[_G]C?\
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MM9__ #B*_P H.BC_ %3R[_G]C?\ P90_^9@]O/M'[G_F?ZOG_$2Q_P $3_\
MH]/_ ,UR_:S_ /G$4?\ $2Q_P1/_ .CT_P#S7+]K/_YQ%?Y0=%'^J>7?\_L;
M_P"#*'_S,'MY]H_<_P#,_P!7S_B)8_X(G_\ 1Z?_ )KE^UG_ /.(H_XB6/\
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M/MO.\*_XB6/^")__ $>G_P":Y?M9_P#SB*_A7_X+E_\ .'K_ +05_P#!/O\
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M_P":Y?M9_P#SB*/^(EC_ ((G_P#1Z?\ YKE^UG_\XBO\H.BC_5/+O^?V-_\
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M_@RA_P#,P>WGVC]S_P S_5\_XB6/^")__1Z?_FN7[6?_ ,XBC_B)8_X(G_\
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M_@RA_P#,P>WGVC]S_P S_5\_XB6/^")__1Z?_FN7[6?_ ,XBC_B)8_X(G_\
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M .:Y?M9__.(H_P"(EC_@B?\ ]'I_^:Y?M9__ #B*_P H.BC_ %3R[_G]C?\
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M?/\ B)8_X(G_ /1Z?_FN7[6?_P XBOTE_8[_ &X?V7?V^_AGKOQB_9*^)_\
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M2"BBOJ_]CO\ 8>_:B_;[^)NN_!W]DKX8?\+8^(_AKP)J?Q+UKP[_ ,)K\//
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M<)PJ1C.$HSA-*49PDI1E%JZE&2;4DUJFFTUJA;;A1115 %?NI^WS_P H3_\
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M?$&GV'P=\,7UOX>N8=1T;P5X@\#ZS=?\4WI45L/TH^ O[.G[0GPA_P""WO\
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M#]?O^#J/6]5\2_ME_L8^(]=O)-1UO7_^"8W[.NMZQJ$RQK-?ZKJOQ4_:&O\
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M44L+":Q/U7V:C&<U)\K<XN_Q*Z:;25]6FM+V>VK7+>^Q^UG_  3WLOVZ9O\
M@I)_P0\UK_@J/;_$$_LXIH4^D?L,7'QM7PXG@&WTZ+P/XH?X+1>&K:#;96OQ
M0OOBC#\'9=#NO&T$7QGUJQLO@C*9[WPUI_PJ:W\7OM-_;\U'_@Y3LS>0_&N3
M]IG3_P!OBWU*QF23Q#!KEI^SW;?$-U2:WN+>2**+X 2_LVRW%E>1I(/ 5_\
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M;C3V;4+EK'0? ^HQIIEA%IDVL?R5_ []H/XR?LW?&GP9^T1\%O'6H^"OC/\
M#_7KGQ-X4\=+9Z1X@O[#6[VTOK#4+N[T_P 4Z=KFB:VFI6.IZC9ZI9:]IFIV
M&IVM[=07]M<13R*WI'Q>_;?_ &IOCU^U!IO[9GQ;^+-_XS_:2T;Q'\/O%FC_
M !$O?#?@JPATK6_A8-%/@.73?!.C^&].^'MC8:%+X?TRZ_L2U\)Q:)JE\M[?
MZSIVHWNK:M/?9QRBI"M3M5C+#PP]+FC+F4ZF-HX66#A6DDG%0=*2G)\SDJD(
MM1>K'[16VL[O;91<E)K?>Z^YG]-G_!:3_AQ3_P /-_VI?^&M_P#A[1_PT/\
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M\%_\%(-=OO\ @A]JG_!6W4/A]HE[_P %)?A1X'UO_@F7I?[2QAMDU^?0=?\
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M=3_@N7_SAZ_[05_\$^__ 'K=?A77[J?\%R_^</7_ &@K_P""??\ [UNN*O\
M[[@?3%?^FX%+X9?]N_F?A77^@?\ LW_\F^?\&I'_ &6/XJ?^H-XUK_/PK]!/
M#?\ P5-_;P\(^'OV4?"OA[XZ_P!GZ#^Q!K.J^(/V7K#_ (5C\'+O_A6.KZW8
MWNFZI=_:K[X>W-[XT^U66HWD'V?XAW'BRUA\[S+>&*:.*1,LRP=7&1HQI2IQ
M=.5=R]HY)-5<)7H1MRQEM.K%N]O=4FKM),A)1=W?IMY2C+\D_F?Z&O[-%_\
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MU73H_"JCI_\ @W9_X5%_PQC_ ,%T_P#A?W_"Q_\ A27_  RI\-?^%J_\*?\
M^$8_X6G_ ,('_8G[1G_"2_\ "OO^$T_XI+_A+O[+^T?V'_PD?_$F^W^3]O\
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M'_B%=?"?_@GGXE^&'AGPW\<OB=\/_"&O>-_A5\,OVD=23P9I?QR^(GQ \#>
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MN]0-C=6/S=_P6)^ /BS]IK_@C#\!/VE?%'[1G[*7[7_[27[!/Q4\2>"OCO\
M%W]C[XRM\9?AQ>?"3XU>*C;Z?;W>JV6EV=W%XP\/7]S\$VU#2=>TS38=+TF?
MQ7K^G7L=A>I:7G\T7Q#_ ."IO[>/Q4^'7[2/PG\<_'B75/ ?[7GQ%TSXK_M%
MZ/9?#;X0>'+KXE^.=&M_!5KINI7OB#PS\/\ 1_$F@Z;;P?#SPC&?"_A/5]!\
M*3_V==-<:)*^MZZVI^1_ S]M?]IS]FWX4_M!_ _X,?$^7PC\*/VJ/"4/@CX\
M>"[GPEX#\6:;XX\.V^F>(M'MX(YO&GA?Q%J'A/4H-/\ %>N00^(?!-YX;\11
M/<VUPFJK=:7I4UCA3RG&1JX?$NO15;"_4J5*"YW!X>A15*O!U7!3@ZOM<3+E
MC!QDW2<FFFXG/&SC9V:E=Z7NW=:7L[6CJ]=[']9_[+?QB\,7'[,/_!'OX-?\
M%,?V;OVH_P!F[Q'H_B?P$/\ @E-_P4"_9 ^)?P_\>V5[>>,_%WA368YOB+\*
MTU;XA>&_#&MW6G6WPJ\'WGAGXE?"#XSZYXQT36?&\=IX!^'4=IXF35_>_@)\
M+X/@W\3O^#HSX??M]_&/XA_M Z'I?P@_9>U7X]_&+X(>!OA;\-/BOXY\#^+_
M (/_ !=\9)J/@SP,;>U^$WAWX@6?@[Q!I.D36EQ GAZ7Q#I]Y>7A<W,TC?RE
M_LH_\%FO^"F7[$7PHMO@=^S/^U/XB\!?"?3]9U;7=&\$:QX$^$GQ/TKPW?:]
M<F_UF#PF_P 6? 'CF]\):-JFK2WFO7OASPU=Z5X>N/$FJZ[XDDTLZ]K^M:C?
MX7[/7_!77_@HO^RS\1OCI\7?@K^TUXBT+XF?M+:KX<UKXX>-O%?@WX8?%?7_
M !_J?A%_$3^&[F_O?BWX'\<MIG]D+XKURWM8= &DVXLKFVL)(GLM+TJWLHJ9
M3BY?6E"6&A&HXNG%5*J]Y8^CBW*,IT:M3"*4:<W.G3JUZ4Z\_:*$$DDU.*Y=
M]-&[*]N1QMHTI:VLVD[*VI)^V)_PZ!_X5GH7_#O_ /X>2_\ "Y/^$[TS_A)?
M^&Q/^&8?^%9_\*S_ .$?\3_VS_87_"E?^*I_X3O_ (2G_A#/[,^W_P#%/_\
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M4G>3:ZMO[V%%%%=(@K]U/V^?^4)__! +_O*I_P"M9^#:_"NOW4_;Y_Y0G_\
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M"W*VIQTOS/1IW2>\5'NE+;>R=K)WW.=_;+_X=0_\(GX/_P"'>W_#PS_A.O\
MA(KK_A/_ /ALO_AF[_A$_P#A$_[-E^Q?\(?_ ,*1_P")Q_PD7]L>3]J_MK_B
M6_V;YOD_Z5LKM/V&?!O[8VE?!_XX_M#> / OQ@^,?[ 'PA\1^ I/V_O@?\+_
M -IW5O@GH?Q4^'E[=O;)X3^)OA+P'XTM/B7J_A/5]%U+7+2[\<:3\.O%VE^#
M-"/BK7+VYL-*T/Q%<V6'^V)_P5W_ ."AW[??PST+X._M:_M"?\+8^''AKQWI
MGQ+T7P[_ ,*G^!_@3[%XVT?P_P")_"VFZU_:_P -/AIX-UVY^S:%XR\26/\
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M2E4Y>>24I-!)IR;5]>^_G^/3IL%%%%=1(5_I)?\ !G?_ ,HS?CE_V?5\3/\
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MLX;_ *"*'_@VG_\ )>:^\+/L_N9\*T5]U?\ #KK_ (*9?]([/VZO_$1_C_\
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MONK_ (==?\%,O^D=G[=7_B(_Q_\ _G?4?\.NO^"F7_2.S]NK_P 1'^/_ /\
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M?9_<SX5HK[J_X==?\%,O^D=G[=7_ (B/\?\ _P"=]1_PZZ_X*9?]([/VZO\
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M]U?\.NO^"F7_ $CL_;J_\1'^/_\ \[ZC_AUU_P %,O\ I'9^W5_XB/\ '_\
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MIT?<_E\HK[J_X==?\%,O^D=G[=7_ (B/\?\ _P"=]1_PZZ_X*9?]([/VZO\
MQ$?X_P#_ ,[ZNWZSAO\ H(H?^#:?_P EYK[R;/L_N9\*T5]U?\.NO^"F7_2.
MS]NK_P 1'^/_ /\ .^H_X==?\%,O^D=G[=7_ (B/\?\ _P"=]1]9PW_010_\
M&T__ )+S7WA9]G]S/A6BONK_ (==?\%,O^D=G[=7_B(_Q_\ _G?4?\.NO^"F
M7_2.S]NK_P 1'^/_ /\ .^H^LX;_ *"*'_@VG_\ )>:^\+/L_N9\*T5]U?\
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M_P#$1_C_ /\ SOJ/^'77_!3+_I'9^W5_XB/\?_\ YWU'UG#?]!%#_P &T_\
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MK.&_Z"*'_@VG_P#)>:^\+/L_N9\*T5]U?\.NO^"F7_2.S]NK_P 1'^/_ /\
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MW:?IE]'XC\;6WA'PMI/BC7?#Y:7GIZ^5OR7W>0>[OIT_3_@>FA_0;_:VJ_\
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M_2WZ6]/(^UO[6U7_ *">H?\ @;<__'*/[6U7_H)ZA_X&W/\ \<KS/XI^._\
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M[[O^O^&7W!9=E_7_  R^XT/[6U7_ *">H?\ @;<__'*/[6U7_H)ZA_X&W/\
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M\#;G_P".5GT47?=_U_PR^X++LOZ_X9?<:']K:K_T$]0_\#;G_P".4?VMJO\
MT$]0_P# VY_^.5GT47?=_P!?\,ON"R[+^O\ AE]QH?VMJO\ T$]0_P# VY_^
M.4?VMJO_ $$]0_\  VY_^.5GT47?=_U_PR^X++LOZ_X9?<:']K:K_P!!/4/_
M  -N?_CE']K:K_T$]0_\#;G_ ..5GT47?=_U_P ,ON"R[+^O^&7W&A_:VJ_]
M!/4/_ VY_P#CE']K:K_T$]0_\#;G_P".5GT47?=_U_PR^X++LOZ_X9?<:']K
M:K_T$]0_\#;G_P".4?VMJO\ T$]0_P# VY_^.5GT47?=_P!?\,ON"R[+^O\
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M6?3Y/AA<_$7^T-0CU@.DL:::_B;3/"JR-+%+&]P;:!HW\[!_8[PC^R_^S3X
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MZA>^;<MJ=UX,G\*>.;"YO8;D:?+?75ZUA9V:M*LO]T/A?]F[X:HOAWQA\5/
MGPE^*WQ^7X%Z1\!/B/\ 'S4OA'X6L/&OQ)\%"RMW\7^%[^_U0^*?$]G\-?&/
MB0:CXENOAAJ/C'Q'X>M[K49([N;5[E)-1N)++]DW]E?3;7X36.G?LT?L_P"G
MV7P$B\4P? NSLO@U\.;6U^"\'CD1KXVA^$UO!X<CA^',7C!8HE\4Q^#TT9/$
M BC&K"["+@YM+6Z6^5DOS2?X XZW]/P:_1/[S^&[XKZ%^V;_ ,%1M9_X+,_&
MKX%?\$X=9_:^^"O[67C3PW^SA\!OVA;;]J7X,_"D_!CPQ^Q3J\5UX6USX;?#
M/QMYWBOXDV?C?Q1IWA?QYXGMO"NI:5I?B&^.M^!](UF>^U#Q.M?9G[1W[=GA
M3]JC]D/_ (-M_P!LSXF^-?#/A:)?^"A/P)?X^>-/%FO:5X:\->%_&_PB?5O!
MOQA\4^)]6UB]MM/\)^'Y_$'A/6_&,4^NWT$.G^%=4T[4+J]ELY$OY_[ OA;\
M(OA1\#?!FG?#CX*?##X>?![X>://J%UI'@+X6^"O#?P^\&:7<ZM?3ZGJMQIW
MA?PGIND:'8SZGJ5U<ZAJ$UM8Q27M]<3W=RTD\TDC>*ZK^P?^P[KO@6U^%VN?
ML:?LI:S\,['QEJOQ%LOAUJO[._PAU'P+9_$'7;1=/UOQU:^$;OP?-X?M_&6L
MV")9:KXGBT]-;U&T5;:[OIH5" OJM-FOT_&R78.5]_7M>Z>VG6_WFQ\&_P!L
M_P#8\_:+\3W_ ()_9\_:P_9J^.WC/2]!NO%6I^$?@W\=?A=\3_$^G>&+'4-+
MTF]\1W^@>"?%.N:K::#::KKFBZ9=:Q<6D>GV^H:OI=E+<)<ZA:13?D7^SK_R
ML>_\%$?^S$/V9?\ T[:#7ZZ?!O\ 8P_8\_9T\3W_ (V_9\_9/_9J^!/C/5-!
MNO"NI^+O@W\"OA=\,/$^H^&+[4-+U:]\.7^O^"?"VAZK=Z#=ZKH>BZG=:/<7
M<FGW&H:1I=[+;O<Z?:2P^J:=\)?A5H_Q(\1?&/2/AE\/M+^+WB_0=,\*^+?B
MIIW@SPY8_$CQ1X8T1XY-&\.>(O'%MIL7B?6]!TB2*)],T?4M4N=/L'CC:UMX
MF12%IKYI??=-_DQM7M?HT_N/YMOC]^S-\!/V;?\ @O[_ ,$98_@=\+?"_P .
M[CXLW_\ P5,^+GQ/U71[:>?Q#\0/B-X^^!GC3Q;XE\4>+_$NJ7&H>(?$%W+K
M.OZFNCVVIZG<:=X6T62U\,>%;/1?#.F:9I%G] ^(I#IG_!SK\/D\,NBS>)?^
M"/NO+\2(;2\=VET_3?VG=6?P]<ZK9+<^7 \5_;:1!93/;AY(W 4,I\Q/W&U[
MX1?"CQ3\0/ GQ9\3_##X>>(_BI\+8/$=K\,?B9KW@KPWJ_Q ^'-MXQTQ]$\7
M6_@3QGJ&FW'B/PA!XIT:672/$</A_4M/CUS3)'L-36ZM7:(_+_PP_8KT_P $
M?MU?M+_MV>)_'@\<>./C=\-/A-\$_AYX<_X1)-!@^"GPA^'%O/JNN^$K+77\
M1:Y=>+KKXA_$.ZD\<:[J9L/"UG9FRT32+;1)I=/N=8U(OI\K?^37"WYI_=;_
M "/N.BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /R _X*:_\%>/^& _C;\//@[_PSW_PMC_A)?@9X2^)
M?_"1_P#"V/\ A!/L7]L^+?'WA;^Q?[(_X5IXR^T_9O\ A#?MW]I?VI!YW]I?
M9?L$7V/[1=?G-_Q$M?\ 5EG_ )L;_P#B'KYY_P"#DO\ Y/9^"?\ V9S\-_\
MU;7QUK^>VO\ 1+PM\"O"OB3P]X3SS.N%OKN:9GE-+$X[%?VWQ'A_;UY5*D7/
MV&$S>AAJ=XQBN6C1IPTNHW;/\^_$WQO\4.'N/>*,DR?B?ZGEF6YG/#8+#?V+
MP]B/8T8TZ4E#VV*RFOB*EG)OFJU:D]=96L?U,?\ $2U_U99_YL;_ /B'H_XB
M6O\ JRS_ ,V-_P#Q#U_+/17WW_$M_@O_ -$;_P";%Q7_ //T^%_XF(\8O^BP
M_P#-?X6_^<A_4Q_Q$M?]66?^;&__ (AZ/^(EK_JRS_S8W_\ $/7\L]%'_$M_
M@O\ ]$;_ .;%Q7_\_0_XF(\8O^BP_P#-?X6_^<A_4Q_Q$M?]66?^;&__ (AZ
M/^(EK_JRS_S8W_\ $/7\L]%'_$M_@O\ ]$;_ .;%Q7_\_0_XF(\8O^BP_P#-
M?X6_^<A_4Q_Q$M?]66?^;&__ (AZ/^(EK_JRS_S8W_\ $/7\L]%'_$M_@O\
M]$;_ .;%Q7_\_0_XF(\8O^BP_P#-?X6_^<A_4Q_Q$M?]66?^;&__ (AZ/^(E
MK_JRS_S8W_\ $/7\L]%'_$M_@O\ ]$;_ .;%Q7_\_0_XF(\8O^BP_P#-?X6_
M^<A_4Q_Q$M?]66?^;&__ (AZ/^(EK_JRS_S8W_\ $/7\L]%'_$M_@O\ ]$;_
M .;%Q7_\_0_XF(\8O^BP_P#-?X6_^<A_4Q_Q$M?]66?^;&__ (AZ/^(EK_JR
MS_S8W_\ $/7\L]%'_$M_@O\ ]$;_ .;%Q7_\_0_XF(\8O^BP_P#-?X6_^<A_
M4Q_Q$M?]66?^;&__ (AZ/^(EK_JRS_S8W_\ $/7\L]%'_$M_@O\ ]$;_ .;%
MQ7_\_0_XF(\8O^BP_P#-?X6_^<A_4Q_Q$M?]66?^;&__ (AZ^QOVPO\ @N'_
M ,,U_P##+7_&,/\ PFG_  OW]CGX(_M+?\EJ_P"$<_X1/_A:G_"3_P#%%?\
M))==_MW^PO["_P"1C_XDW]J?:O\ D Z=Y'[[^*&OUL_X*R_\XT/^T2?[&O\
M[T>OELV\ ?"3"\3<)Y=0X3Y,'FBS[Z]1_M[B:7M_J6 HU\-^\GG,JM+V563E
M^YG3Y[\M3GC9'T^5>._BMB>&^*LPK<5<^+RW^P_J5;^P^&X^P^NX^I1Q/[N&
M3QI5/:4HQC^^A4Y+<U/DDVW^EG_$2U_U99_YL;_^(>C_ (B6O^K+/_-C?_Q#
MU_+/17U/_$M_@O\ ]$;_ .;%Q7_\_3YC_B8CQB_Z+#_S7^%O_G(?U,?\1+7_
M %99_P";&_\ XAZ/^(EK_JRS_P V-_\ Q#U_+/11_P 2W^"__1&_^;%Q7_\
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M_P _0_XF(\8O^BP_\U_A;_YR']3'_$2U_P!66?\ FQO_ .(>C_B):_ZLL_\
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M>C_B):_ZLL_\V-__ !#U_+/11_Q+?X+_ /1&_P#FQ<5__/T/^)B/&+_HL/\
MS7^%O_G(?U,?\1+7_5EG_FQO_P"(>C_B):_ZLL_\V-__ !#U_+/11_Q+?X+_
M /1&_P#FQ<5__/T/^)B/&+_HL/\ S7^%O_G(?UB>$O\ @Y.\#7NIVT7CO]D[
MQ7X;T=[A5O+_ ,)_%K2/&NI06I WS6^E:QX#\!6UU.IW;;:36;2-P 3=(20/
MW5_9>_:Z^ _[8?@27Q_\"_&47B*PT^Z33_$6A7]L^D>+?">HR*[PV7B3P_<L
M;NP-W'')+I]]$;G2=4CBG?3-0O!;7'E?YLU?;O\ P3U_:G\5_LD_M2?#3XA:
M-J=Y#X4U;Q%H_A+XFZ''<O%8>(? FNZC!8:NE[;^5/%/=:-'<'7-'E:!IK;4
MK&(0R1)-.6_/?$7Z+W!F)X?Q^,X%PF*R//<#AJN*PF#>88[,,!F<J$)5)8*M
M',\1B\11K8B,73PU>CB84Z=9Q=:E4IN3C]]X??28XPP^?8'"<;8K"YUDF-Q-
M+#8K%K+\%@,=ET:TXTXXRD\MH83#UJ5"4E4Q%"KAIU*E)2]C4IS24O\ 13HH
MHK_/$_T "BBB@ HHHH **** "N@U'_D ^'/^XO\ ^ED=<_70:C_R ?#G_<7_
M /2R.FMI>GZH3WCZ_HSGZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .@U'_D ^'/\ N+_^ED=<_70:C_R ?#G_ '%__2R.N?IO?Y1_)"6W
MSE^;"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "O4/!/_(*N/\
ML(2_^DUI7E]>H>"?^05<?]A"7_TFM*N&[]/U1,_A?R_-'84445J8A7S_ %]
M5\_UG4Z?/]#2GU^7ZA7\['[7ND_LAZM_P67>+]K_ /9K_P"&EO"D7_!,?X>2
M>$O#W_#$7Q._;A_X1SQ"?VJ?C MSK7_"&_##X)_&[4O!7GZ:9;'_ (2;4]'T
M6QNO,_LJ/4Y9YEM7_HGKY2MOV8OL_P"W'K7[9O\ PF^_^U_V4?#/[,7_  K?
M_A&MOV?_ (1SXO>+?BK_ ,)O_P )A_;[>;]L_P"$I_L'_A&O^$6B^S_8?[4_
MM^?[5_9UO"=K[[=-'NNI;_5?@T?CS^Q5\6_AE\,/A[_P4U_;?_8F^'[>&O\
M@G+XB^'?PW\9?L=^ O#/@R;X7>!/BK^T5\.? _Q&\(_&GQ'\#?@IKMMX1N/A
MKX?^)'CJU^#?PDDBU7P=X(TWQW\3?!WB'Q%;V45H;SQ/XD^?+'X*_L-_L_\
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MJ.C_ +-GP\T'X=^,_B'X8^#-GXN\-65GXAU"T^#_ ,.O$W@+P[XD\+6_A?\
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M_!OP:U[7]!\6R:]<1_#W6O"VE>%[O5]+\SP]XS2[OM5@C:2R73#-?^+^'/\
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M .> ?\0U\1?^B!XU_P#$5SW_ .8#\LZ*_4S_ (<J_P#!3/\ Z-J_\S)\ /\
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M_P"C:O\ S,GP _\ GJU^C/\ P44_X)@?MS?&C_AA7_A6GP/_ .$E_P"%3_\
M!.;]F/X*_$#_ (N7\(-&_L#XF^!/^$W_ .$K\-?\3_X@:5_:O]E?VK8?\3G1
M?[2\/WWG_P#$MU6\\J;R_C\Y\1/#^KQ;P7B:7'7!U3#81<1_6L13XGR2=##>
MWRVC3H?6*L<<Z='VU1.%+VDH^TFG&%Y*Q];D_A_Q[2X5XQPU7@CBZGB,5_J]
M]6H5.&LYA6Q'L,RJSK>PI2P2G6]C!J=7V<9>SBU*=DTS^9JBOU,_X<J_\%,_
M^C:O_,R? #_YZM'_  Y5_P""F?\ T;5_YF3X ?\ SU:^P_XB=X;?]'"X'_\
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M7_Q%<]_^8#\LZ*_4S_ARK_P4S_Z-J_\ ,R? #_YZM'_#E7_@IG_T;5_YF3X
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M_P#Z61US]=!J/_(!\.?]Q?\ ]+(ZY^F]_E'\D);?.7YL****0PHHHH ****
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M_P )3KW_ #_?^2MG_P#(]&G=_<O\PU[+[W_D<_170?\ "4Z]_P _W_DK9_\
MR/1_PE.O?\_W_DK9_P#R/1IW?W+_ ##7LOO?^1S]%=!_PE.O?\_W_DK9_P#R
M/1_PE.O?\_W_ )*V?_R/1IW?W+_,->R^]_Y'/T5T'_"4Z]_S_?\ DK9__(]'
M_"4Z]_S_ '_DK9__ "/1IW?W+_,->R^]_P"1S]%=!_PE.O?\_P!_Y*V?_P C
MT?\ "4Z]_P _W_DK9_\ R/1IW?W+_,->R^]_Y'/T5T'_  E.O?\ /]_Y*V?_
M ,CT?\)3KW_/]_Y*V?\ \CT:=W]R_P PU[+[W_D<_170?\)3KW_/]_Y*V?\
M\CT?\)3KW_/]_P"2MG_\CT:=W]R_S#7LOO?^1S]%=!_PE.O?\_W_ )*V?_R/
M1_PE.O?\_P!_Y*V?_P CT:=W]R_S#7LOO?\ D<_170?\)3KW_/\ ?^2MG_\
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M ,CT?\)3KW_/]_Y*V?\ \CT:=W]R_P PU[+[W_D<_170?\)3KW_/]_Y*V?\
M\CT?\)3KW_/]_P"2MG_\CT:=W]R_S#7LOO?^1S]%=!_PE.O?\_W_ )*V?_R/
M1_PE.O?\_P!_Y*V?_P CT:=W]R_S#7LOO?\ D<_170?\)3KW_/\ ?^2MG_\
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M_P )3KW_ #_?^2MG_P#(]&G=_<O\PU[+[W_D<_170?\ "4Z]_P _W_DK9_\
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ML_\ Y'HT[O[E_F&O9?>_\CGZ*Z#_ (2G7O\ G^_\E;/_ .1Z/^$IU[_G^_\
M)6S_ /D>C3N_N7^8:]E][_R.?HKH/^$IU[_G^_\ )6S_ /D>C_A*=>_Y_O\
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ML_\ Y'HT[O[E_F&O9?>_\CGZ*Z#_ (2G7O\ G^_\E;/_ .1Z/^$IU[_G^_\
M)6S_ /D>C3N_N7^8:]E][_R.?HKH/^$IU[_G^_\ )6S_ /D>C_A*=>_Y_O\
MR5L__D>C3N_N7^8:]E][_P CGZ*Z#_A*=>_Y_O\ R5L__D>C_A*=>_Y_O_)6
MS_\ D>C3N_N7^8:]E][_ ,@U'_D ^'/^XO\ ^ED=<_7<7NOZM#I.BW4=WMGN
M_P"TOM#^1;'S/L]RD<7RM"438A(^15W=6W'FL?\ X2G7O^?[_P E;/\ ^1Z;
MM?=[+HNR\Q*_9;OJ^[\CGZ*Z#_A*=>_Y_O\ R5L__D>C_A*=>_Y_O_)6S_\
MD>EIW?W+_,>O9?>_\CGZ*Z#_ (2G7O\ G^_\E;/_ .1Z/^$IU[_G^_\ )6S_
M /D>C3N_N7^8:]E][_R.?HKH/^$IU[_G^_\ )6S_ /D>C_A*=>_Y_O\ R5L_
M_D>C3N_N7^8:]E][_P CGZ*Z#_A*=>_Y_O\ R5L__D>C_A*=>_Y_O_)6S_\
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M5>,]:BTZVV7&L7^F>'[K3]$@GM9=7N[)+NU:;ZYK^>3_ (+-_">+XR_M/?\
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M@N8- DMKB&:3\S?VJOV[OV)+?X5_LZ?\%/OC]^PW^UUH7[6OPC^)/Q$^"/[
M?[+7Q]\">,_A)^U'\0/C-\5-*TKPGJ&F>$/@=H_C3Q1X2U3PYXHM;O39G^(W
MBGPUXROO"L&FPW7@71=1^)MQX$\)^*/S7^(O_!,G]H7]GW_@G/\  [XG_%OQ
M3^S-X7_;A\1_\%AO"/\ P4\\0?LM?$?XN> ?A5\!/B=\;O$W]K)HO[$GP]\9
M^,_%D'@C4_&UWX9T@76C6H\4:WITMV?B/X0T/Q'XK\.6^D^.)A)63>EW]^NM
MO1:WVZ6"[OI9JU]GI>V_XNV^A_4!^SE_P4,_8J_:R^!7BS]I?X#_ +17P_\
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M_P"1]?Z>G^D570>(/^8)_P!B_IO_ +6K_-5_X;F_;9_Z/#_:F_\ $@OBU_\
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M\2"^+7_S74?\-S?ML_\ 1X?[4W_B07Q:_P#FNH_XD\XE_P"BQR/_ ,(,?_\
M)!_Q-SPY_P!$AG?_ (78'_Y'U_IZ?Z15%?YNO_#<W[;/_1X?[4W_ (D%\6O_
M )KJ/^&YOVV?^CP_VIO_ !(+XM?_ #74?\2><2_]%CD?_A!C_P#Y(/\ B;GA
MS_HD,[_\+L#_ /(^O]/3_2*HK_-U_P"&YOVV?^CP_P!J;_Q(+XM?_-=1_P -
MS?ML_P#1X?[4W_B07Q:_^:ZC_B3SB7_HL<C_ /"#'_\ R0?\3<\.?]$AG?\
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M%?Q7@\ Z5?ZYHC>!V^.'P_UV#PI\1Q9^.0?"NC?\)C] _L,_M'?%K]K7X"^
M?VBO'_P2\(?!#P3\9_ 'P]^*7P=T32?C)JWQ4\:ZGX(\?^&XO$MI>?$73+CX
M._#70/ VJ&QOM)NM)TWPUXG^)5OJ>FZA]JU#4M OK=])=:I_=Y^@:/3OO^&_
MR:\SG?V@OV!OV>/V^/@;\+?AY_P4(^!GPU^,WBCPKH6@ZIK$^BZQXNTO_A%/
MB+=:1H9\?GX7?$[PP?AM\3-'\*ZYKVE11W,=C)X2C\6Z-IFBKXG\.(+2#3;.
ME\'?^"7G[!/[/_[.'Q7_ &3/@Y^SCX6\!_ KXZ>'O$GA3XP^&]*U[QS-XG^(
M^@>*M.U?2-5T_P 6?%74O%5]\6]66'2M?UC3= N+CQR;OPG8W\]KX5N-&@V(
MOQ;^QK^WKH7@SQ9^WOX,^-4_[9/Q+UCPC_P48_:;\.^#[SP9^R-^W+^U'X3\
M*?#O3)?!T/AGP-X>\>?!SX'_ !5\#>'])T!_[0:S^'^G^(K.7PW%>K.^A:?!
MJMM)=?FYI'[4/_"8_"#_ ()_>)OVC?VLOC?\)?@+\4O^"K'_  4K\(?%OQ]X
MS_:?^/'[(VL?\*E\)W'[7=]\'_ 'Q$^(J?$+X/\ Q-^'N@>$]=\/?#W1- ^'
MWB37_"\GAN_TK1O!,^A6,D!T,/73>UU]_EYVV%=;K=]=+[I6?WH_5OX.?\&^
M_P#P1]^ OQ/\&?&+X:?L8>&[/Q]\/M83Q!X2U#Q;\4OCS\3M$TS7(()X;+5I
M?!7Q/^*GC'P1JNH:3).-1T.ZUCPYJ$NA:Y:Z;XAT9K'7=*TS4;3[6_;#_8(_
M9 _;\\%:)\/_ -KOX&>%?C-X>\,:E/JWA:?5+SQ%X:\5>%+V\>P?4SX5\?>!
M]:\,>._#-KKG]E:7'XCT_0O$FGZ?XD@TS3K?7K748+&UCB_-S]G'XC_"B?\
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M1?!*^T3QOH.C:9XDTCQ3XC\-^+?BU\,M=@NX-?\ #'A$^.)]+L=5UFA^W?\
MMR_M W_[/G_!29_V4_@:?$_P]_94^%?QB^%GQ&_: MOCYJWPG^+GASXSV?P2
M?QAXLUC]G'X<Z/\ "WQ*OCRV_9^TOQKX.U[Q-XPU[XQ?!757\6:5XP\._#BQ
M\4Z[X.MI=9$K_E_7WA=?TGU/VXHK\7_V=O\ @H/\3=3UC3?@Q+\*O#6L^"_V
M:OV-?V0?VAOVIOVGOBO\>_$VAW>F^!OC-\)]<\3:MX@T3P?I'P3^)>M?$'XA
M:?%\.O&VN7FD^(/%WA'3?$%O87-[=>-].U*XBL9_0_AC_P %&?BKK<'[+OQ1
M^-'[)T?P7_9@_;4\3^&O!WP ^(D'QNB\?_&/PUKWQ8M9=>_9XB_:;^"-K\*_
M#7A;X.6GQG\-6PM(9O 'QT^.]UX%^)'B#P3\._%MC:R:_JGB#PTK!=:>>NWI
M_FC]7:*_!OPE_P %@OC[XJ^%?[+7QY@_8)T\?"7]KKX\ZG^RY\+8[/\ :HTZ
MX^*L7QF>3XLZ-X4UCQ!X&U'X&Z-X2TWX$ZUXN^%5_8ZU\1!\49OB'X>\+7%[
MXNM/@EXC>QTK0?$?N%U_P4^\5^$M)^-_P_\ B/\ LWZ?:?M>_"S]HWX,?LL^
M#O@-\,_C7_PL'X??%SXG?M'?#_0_B7\&M1T3XV>(OA5\,]:\,> 3X0U+7?$G
MQ5\2>)_@Q::G\.O#7@+QMJVE^&_'<^GZ;IFKNW^>Z] NN_\ 6C_4_72BOC+]
MG[]I_P <>._C%\4_V:?C[\)_#7P7_:"^&/@SP%\6(]%^'WQ2U3XU?"WQ_P#!
MWXE7_B;P]X?\;>!?B+K_ ,+/@EXFN;_1O&G@CQ?X/\<^%_$7PM\.77A[4K'1
MK[3;_P 1Z+XCL-23[-I#"BBB@ HHHH **** "BBB@#^.'_@Y+_Y/9^"?_9G/
MPW_]6U\=:_GMK^A+_@Y+_P"3V?@G_P!F<_#?_P!6U\=:_GMK_6WP1_Y-/P)_
MV(J'_IVL?Y2^,_\ R=+C;_L=5?\ TS1"BBBOU,_,0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *_6S_@K+_SC0_[1)_L:_\ O1Z_).OUL_X*R_\ .-#_
M +1)_L:_^]'KXC/?^2SX#].*?_570/M,C_Y(_CG_ +MG_P!6E8_).BBBOMSX
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#];/^"F7_ "1;_@EG
M_P!F"^!__4L\2U^2=?K9_P %,O\ DBW_  2S_P"S!? __J6>):_).OB/#K_D
MD\%_V,>(_P#UI<W/M?$+_DJ\9_V+N'/_ %F\H"BBBOMSXH**** "BBB@ KK_
M (?>+=8\ ^/?!'CKP_-<VVO>#/%WAOQ7HMQ9EA=PZMX>UBSU?3I;4J0WVA+N
MTA:'!!\P+BN0K[Q_X)Q_LE>*_P!K[]J3X=^"=-TN\D\">&/$&C>,OBSXA2WD
M?3M \$:)?+J-W:W5TI5(-1\5O8GPSH,>7D?4M06[,+V5A?20^/Q#FF69+D6;
MYKG-2E2RK 9?BL1CY5FE3EAX49<]*TOCG73]C2I).=:K4A2A&4YQB_7X?RW,
MLXSS*<KRBG5JYGCLPPN'P,:*?M(XB=:/)5O'X(4;>VJ56U&C3ISJSE&$)27^
MA_1117^*Y_LB%%%% !1110 4444 %=!J/_(!\.?]Q?\ ]+(ZY^N@U'_D ^'/
M^XO_ .ED=-;2]/U0GO'U_1G/T444AA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 =!J/_(!\.?\ <7_]+(ZY^N@U'_D ^'/^XO\ ^ED=<_3>_P H
M_DA+;YR_-A1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !7J'@G_D
M%7'_ &$)?_2:TKR^O4/!/_(*N/\ L(2_^DUI5PW?I^J)G\+^7YH["BBBM3$*
M^?Z^@*^?ZSJ=/G^AI3Z_+]0KXFM/V;O'-O\ \%&_$'[7SZKX4/PUU7]B;P?^
MS=;Z&M]K!\<IXY\/_'7QQ\3[W59M-.A+H"^%)= \36%I:WT?B:36'UB&[MY=
M"ALHX=0N/MFBL_U-/Z^X_%GPG_P3L^.OPD\1_$S]FOX3:[\((O\ @FC\1_C3
M\(OC]X9^'.M>)_&^D_%#]GF\T3XPZ+\5_CO^SK\)_!&E> -2^'M[^SK\6]6\
M,VUYX;TG_A.?!A^&L/C3XC>%],\+ZC8ZKI&N:5]@>$OV7O%FE_M[_M+_ +3?
MB*Y\$ZO\*OC;^R_^SO\  W2O"S3:E?\ B<ZU\*O&/QXUWQ@_BC1+[P_'X</A
M?6-*^*>B6>E-;:_JUWJ$MOK5OJFD:=;16DVH?<U%.[^__@?Y?U=AM_6W]?UH
M?GC^Q#^RS\8/V-O$_P </@OIWB3P9XH_8@NO%LOQ!_9,T.Z\0>)7^+G[/MMX
MN\F\\;_LZ-H<WA1/"6H? CPIXB_M+7/@KJMMXS/BGPCHVL7/@/5M(U?2=/T3
M5=,\[\-?\$T?A=\5_P!H[]KC]H[]NOX(?LM_M*^(/BS\0?!GA[]GW2/'GPT\
M._&FR^#W[-?PK\!:7H/@_P -VDGQ8\!#_A%?&7C+QSJGQ(^(?Q%TSPK#?:/)
MJGB/3;6/Q/KUII6G1:3^J5%*[_K^O(++[OZ_KL?@_P##K_@EG\8_@_\ M!?#
M2W^&VI? WP_^QS\#?^"BWC?]M+X*^ M.U3Q3H?BSX>_#[XV?LO?$[P!\5O@K
MX9\ Z1\-X_ /AOP_X9^/_CFY\9?#'1=(\5KHD?@?Q9XDLI)/#,GASP]X8U'S
M;0_^"-_QJ\,_LJ?MN_ JT^)?PSU[Q+\8?V@OA9:_LM7>N:IXJBT'X1_L._ [
M]JNR_:4^$OP/\3:Q%X&O=?M_$7A"Z\:_&ZUM[#1].\0^'#>:SX8M;?6+/3VN
MY=(_HIHIW=[^GX=?7N_-]Q67;R_)?HC\G?#WP2_;J^ _[8'[=GQM^#?PJ_9,
M^+_PW_:V^('P+\=>'/\ A9O[5WQA^!WC?PC_ ,*K_9J^&'P3UC2];\-^%OV)
MOC]H-[_:.O>"M4U;3;ZP\:?\@BXL/M5G!>27%M:_4O[3/[.>K_MI?L8?%#]G
M#XO7&D?"3Q9\;/A5/X:\0ZA\/-<O_BCX?^&_CN:&VU/2M6\.:QXB\+?"O4/B
M)H7A3Q=8Z;J21ZQX4\ 3^+=-L9+&\L/#IU!VM?KVBB^SZJWX6M^0S\>_%_[)
MG[:O[4WB_P"%OC+]JR3]FCX>WG[-_P (_CMI7PVTSX$?$;XI_$'3/C%\?OCS
M\"_%?P!U?XH^/!XX^#?PPE^"_@+PKX/\6>+)= ^&.A'XZZM<7_CV>6_^(?\
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MO+\^[/P-_P"(=/\ 8F_Z*C^U-_X6WPE_^<A1_P 0Z?[$W_14?VIO_"V^$O\
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M_P"(+>%?_1$9)_X*K?\ R[R_/NS\#?\ B'3_ &)O^BH_M3?^%M\)?_G(4?\
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ME_\ 2:TKR^O4/!/_ ""KC_L(2_\ I-:5<-WZ?JB9_"_E^:.PHHHK4Q"O'_\
MA*=>_P"?[_R5L_\ Y'KV"OG^LYMJUFUO^AI!)WND]M_F=!_PE.O?\_W_ )*V
M?_R/1_PE.O?\_P!_Y*V?_P CUS]?*O[6?[;G[+'[#'@C1OB)^U5\8-$^$OA?
MQ'K8\.^'9;W2O%'BC7/$&KB W-Q;Z'X0\#:%XG\7ZO#I]OY<VKW^GZ%<:?HT
M5Q:/JMU9K>6IF*<:M6<:=*-2I4F[1A34ISD^T8Q3DWY)-E-12NU%);MV27S9
M]E?\)3KW_/\ ?^2MG_\ (]'_  E.O?\ /]_Y*V?_ ,CU\C?"3]LO]EGXX_
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M?$[XE67BS0M$&B-?ZO97WPJ\%>-[2VT[9XCT:2QN]1FLX=6AO#-I+WL5M=O
MXX7&3]DH8?$R==2E1Y:-67MHQ5Y.E:+]HHK63A=):NR&W!7NX+EWO;2^U^U_
M,_1/_A*=>_Y_O_)6S_\ D>C_ (2G7O\ G^_\E;/_ .1Z^+C^W+^RI'^R9_PW
M/=?%[2]-_95/A9?&2_%G5_#_ (QT:TDT&77AX6LY(?"NJ^'+/QW-JFJ^)G@\
M/Z'X=B\+OXBU[6KS3],T;2KZ]U&QAN,CX^?\% ?V1?V8/@#\.OVH?CI\78_
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M>*=*T3Q%IGVB([_L>LZ1IU_#]V>UB;BB\N[^]A:/9=]EMW/</^$IU[_G^_\
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M_P#R/1_PE.O?\_W_ )*V?_R/7/T47?=_>PLNR^Y'0?\ "4Z]_P _W_DK9_\
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M_P#Y'H_X2G7O^?[_ ,E;/_Y'KGZ*+ON_O8679?<CH/\ A*=>_P"?[_R5L_\
MY'H_X2G7O^?[_P E;/\ ^1ZY^BB[[O[V%EV7W(Z#_A*=>_Y_O_)6S_\ D>C_
M (2G7O\ G^_\E;/_ .1ZY^BB[[O[V%EV7W(Z#_A*=>_Y_O\ R5L__D>C_A*=
M>_Y_O_)6S_\ D>N?HHN^[^]A9=E]R.@_X2G7O^?[_P E;/\ ^1Z/^$IU[_G^
M_P#)6S_^1ZY^BB[[O[V%EV7W(Z#_ (2G7O\ G^_\E;/_ .1Z/^$IU[_G^_\
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MO_)6S_\ D>C_ (2G7O\ G^_\E;/_ .1ZY^BB[[O[V%EV7W(Z#_A*=>_Y_O\
MR5L__D>C_A*=>_Y_O_)6S_\ D>N?HHN^[^]A9=E]R.@_X2G7O^?[_P E;/\
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MO^?[_P E;/\ ^1Z/^$IU[_G^_P#)6S_^1ZY^BB[[O[V%EV7W(Z#_ (2G7O\
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M?[_R5L__ )'KGZ*+ON_O8679?<CH/^$IU[_G^_\ )6S_ /D>C_A*=>_Y_O\
MR5L__D>N?HHN^[^]A9=E]R.@_P"$IU[_ )_O_)6S_P#D>C_A*=>_Y_O_ "5L
M_P#Y'KGZ*+ON_O8679?<CH/^$IU[_G^_\E;/_P"1Z/\ A*=>_P"?[_R5L_\
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M &;OVF?^"JW[!OA7_@IUHGQFC^*D6D_![]A7Q7^T9\,_A_\ M??\%%/V6_\
M@HQ^U%\)_CU87_A/PUX=\3ZDGPMC\)?%'2_@=XD\,^(9?&$FA^+?AC;?#;2K
M[P TUGX@75O'NIC5ZO\ P2'^)_\ P54\+?MC?L,ZI\8O&'QFUCX&_MG_  F\
M5>+/B7I_[6'_  5,_9*_:@'QKL4^$NH_$'0/C#^QM^SMI<G@KXR_!SP_X:\5
MI+K'BCP%X.T_XNW6D^ ]7B\,^--4TR#P5)XBC_IY_9-_X)B?L%_L/>"OB9\/
M?V9/V:_!/@'PI\94EMOBK9:S?>*OBA?^/](FTE]$;PMXH\0?%OQ#XZ\1:KX)
M73;B_BB\"W&JMX.@FUGQ!>P:''?>(M<N=0YC]DW_ ())?\$ZOV&_B9XH^,?[
M+?[+_A'X7?$WQ=8W6EZEXO'B/X@^-=1TW2[ZZGO-0TSP='\0_%_BVR^'VFZC
M)<&'4;#P%:^&[34+&"QTR\AGT[3=/M;8NK-)+7R\EYZ:J_74.5Z:[>=]+K39
M::>7W:'XS?#K]COX/_L<_P#!Q?\ LY:'\+I?'.OZY\7_ -B3]I+XT?%WXD?%
M+QMK/Q"^)/Q,^)7BCXC:IIU[XB\4>)=8D"(EEH>BZ+H.CZ'H-AHGAW3+#3%N
M+?21K&I:YJFJ_%G_  5HAC^*O[$W_!P[^U5+;R&/6/VQ/V0?V.?"%Q/(MQ#%
MX5_8P\=?!'PYXE31Y3<7'D6U[\8/B%\2?[8BMDMHY-7TTVMW&]YI16W_ + ]
M;_98^ WB+]I7P7^U_K'@3[9^T5\/?AIK?P?\'_$/_A)_&5O_ &1\.O$>IW.L
MZSX=_P"$2M?$,'@;4/MFI7ES<_VOJGAF]UVW\SR;34X($CB7R/QC_P $XOV,
MO'_[,/C;]C;Q?\&SK/[.7Q(\>Z[\4/'/@&7XB?%:UO/$OC[Q+\5'^->N>)=1
M\>V'CFU^)#7NH?$N0^(I(XO%\5I%&L6@V]M%X;@AT>-)V=WKM^#3_0.7=*UM
M;>MDO\[G\(?QVTS5-7\ ?M$?\$7KK0[J/X>?L#>.O^"J_P"WZ\<+7MG8>'_@
M7X:_8[\2?%S]C2UMX88X[>_GG^+'QPU6YUBV-W;VFF0?V+<BUOQJ4<(_53]F
M[]I[Q?\ \$W_ (9?\$4/VO?B/\6_B':_L,?'3_@GMKG[-GQL^'6I>-]<N?A+
MX&^-/@;P5K'QI^#OQ"T+P3JNK#PKHGQ&^)Z:)>?#;^W-+L[6YGT?0+J*YS)J
M%Y)??TT>(_\ @G!^Q7XM^*'[0'QHU_X'Z=>_%#]J3]G?4_V4?CQXOC\8_$:P
MO_'OP"UGP]HWA35/ 4L&G>,+33O#WV[P]X=T#3+CQ3X2L]!\:/#HFE/_ ,)$
M)]/M98OSG_X*%_\ !)KXJ_M0_!;]EW_@GI^S\W[-'PC_ .":_P .-1^'5U\4
MK+QK)\:/%_[3OA;3OA?K\MSHNA_ C7[_ %+7_#EW;:SX5N+SPSJNK^/=>L_%
M-J-2OIXM?O[*>XTJZ=T[?CIW2N_6]]?07*U=K?IWM>-D]NVI^ O[</P0_:'^
M+W_!(;_@G)^TW^TW^T1^U--\6_VH_P#@I=X3^,FJ>%(OC1XKU+PC\-O /[6U
M_K]_\*(?".E>)(=4A\*77P@^'7@OP?JGP430[7P_H'PTUGXI_$BQL/#]^NOQ
M2I]\_P#!P'_P3W^#_P +_P!D/X5?M%:_X^^/OQX^-7PG\6_L7_LV_#WQ]^T!
M\6]8^(&H^&_".C^/[>V\;>,+?3H+70M!O?BK\;)H-%U#XP_$#5-)OM5\0WOA
M[3#HB^&;2ZUZTUK^E3]I3]BO]E[]K[X#I^S+^T3\(M$^(?P/@N/"EWI_@;^T
M_$OA)-$NO!#Q'PM<^&_$'@;6_#/BOPS<:3;Q-IB3>']=TV2ZT.[U+P_?-<Z)
MJNIZ?=\SXX_X)^_LC?$C]F'X;_L:^-?A.^N?LW?"./X;0_#SX<R?$#XH63>'
MHOA";7_A748\8Z;XUL_'VJIX;%E:I&NM^*=2&I1PK'K U",LI+[>3;^3MI^>
MX^7?K=;ONE9?YW/S$_X+E:E?^!/BW_P17^+GA87,7CK0O^"M/P"^%VGW-D0M
MW<^"?C=I/B7PS\2?#4<D<$MT(_%>A:7;:/<1PEHY89&6:UNR(5C_ *!*_-O]
MKC]BSQG^U3^V!_P3X^*.LZSX+M/V>OV-O'GQ-^/7BSPM>W>M3>/?''QR;PWH
M^@? 5]#TZ'0#H&G>&?A_J4GB7QAKNL7OB<:G?:DFAZ/8^'S;M>:K!^DE+HN^
MOZ?Y?B-=?-_H@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _E)_P"#@;]I#]HCX/\ [7WP>\,_"3X]?&CX6^&[[]D[
MX?:[>^'_ (<_%+QQX(T2\UNY^)_QGT^YUBZTKPSKNF6%QJMQ8:9IME/J$UN]
MW+::?8VTDS0VEND?X5_\-S?ML_\ 1X?[4W_B07Q:_P#FNK];/^#DO_D]GX)_
M]F<_#?\ ]6U\=:_GMK_5;P8X?R'%>%O!&(Q.291B*]7)*,JM>OEN#JUJDO:U
M5S5*E2C*<Y625Y2;TW/\NO&#/L\PWB;QG0PV<YMAZ%+.:L:5&AF.,I4J<?94
M7RPITZT80C?6T4E<^IO^&YOVV?\ H\/]J;_Q(+XM?_-=1_PW-^VS_P!'A_M3
M?^)!?%K_ .:ZOEFBOT[_ %8X:_Z)[(__  TX#_YG/S;_ %EXC_Z'^=_^'7'?
M_+_)?<?4W_#<W[;/_1X?[4W_ (D%\6O_ )KJ/^&YOVV?^CP_VIO_ !(+XM?_
M #75\LT4?ZL<-?\ 1/9'_P"&G ?_ #.'^LO$?_0_SO\ \.N._P#E_DON/J;_
M (;F_;9_Z/#_ &IO_$@OBU_\UU'_  W-^VS_ -'A_M3?^)!?%K_YKJ^6:*/]
M6.&O^B>R/_PTX#_YG#_67B/_ *'^=_\ AUQW_P O\E]Q]3?\-S?ML_\ 1X?[
M4W_B07Q:_P#FNH_X;F_;9_Z/#_:F_P#$@OBU_P#-=7RS11_JQPU_T3V1_P#A
MIP'_ ,SA_K+Q'_T/\[_\.N._^7^2^X^IO^&YOVV?^CP_VIO_ !(+XM?_ #74
M?\-S?ML_]'A_M3?^)!?%K_YKJ^6:*/\ 5CAK_HGLC_\ #3@/_F</]9>(_P#H
M?YW_ .'7'?\ R_R7W'U-_P -S?ML_P#1X?[4W_B07Q:_^:ZC_AN;]MG_ */#
M_:F_\2"^+7_S75\LT4?ZL<-?]$]D?_AIP'_S.'^LO$?_ $/\[_\ #KCO_E_D
MON/J;_AN;]MG_H\/]J;_ ,2"^+7_ ,UU'_#<W[;/_1X?[4W_ (D%\6O_ )KJ
M^6:*/]6.&O\ HGLC_P##3@/_ )G#_67B/_H?YW_X=<=_\O\ )?<?4W_#<W[;
M/_1X?[4W_B07Q:_^:ZC_ (;F_;9_Z/#_ &IO_$@OBU_\UU?+-%'^K'#7_1/9
M'_X:<!_\SA_K+Q'_ -#_ #O_ ,.N._\ E_DON/J;_AN;]MG_ */#_:F_\2"^
M+7_S75^H?_!3S]JW]J/P/_P[S_X0K]I+X^^#_P#A,/\ @EY^R9XZ\6_\(M\8
MOB'X?_X2GQMX@_X3_P#M[QCXC_LGQ%:?VWXJUO[):?VOXAU/[5J^I?9;?[;>
M3>3'M_!:OUL_X*R_\XT/^T2?[&O_ +T>OC,[X=X?AQAP/2AD631IU5Q-[6G'
M+,%&%7V>64)0]I!4%&?))N4.9/E>JLS[')>(,^EPEQK4EG>;RJ4O]6_95)9E
MC7.ESYG5C/V<G6<H<\4HRY6N9))W2/CG_AN;]MG_ */#_:F_\2"^+7_S74?\
M-S?ML_\ 1X?[4W_B07Q:_P#FNKY9HK[/_5CAK_HGLC_\-. _^9SX[_67B/\
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M!8O#8VG3E/#QKU<-2IO$X*I42IXG#5_:4W2G.=)4L1&E6I_?^'OB[Q?P9G^
MQ4LZS/,<GGB:-/-<HQ^-Q.,PF)P=2<85Y4:6(J5%AL93IMU,/B:')-5(0A5]
MK0E4HS_TZ****_R=/]3PHHHH **** "BBB@ KH-1_P"0#X<_[B__ *61US]=
M!J/_ " ?#G_<7_\ 2R.FMI>GZH3WCZ_HSGZ***0PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .@U'_D ^'/^XO_ .ED=<_70:C_ ,@'PY_W%_\
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M6O$_B&#PIXRU[2?AW9PMX?\ "OC3Q)J&AZ%K7R!IG_!0C]IKX%_MS_MJZ_\
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M4W_A;?"7_P"<A1_Q#I_L3?\ 14?VIO\ PMOA+_\ .0K[G_B:;PG_ .@S//\
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M.;4I0?U''3KXCVD_9VA:G-<MT^9W2/X)**_L^_XAT_V)O^BH_M3?^%M\)?\
MYR%'_$.G^Q-_T5']J;_PMOA+_P#.0KZ7_B:;PG_Z#,\_\,M;_P"6'S?_ !+%
MXJ?] F2?^'FC_P#*_P"K/RO_ !@T5_9]_P 0Z?[$W_14?VIO_"V^$O\ \Y"C
M_B'3_8F_Z*C^U-_X6WPE_P#G(4?\33>$_P#T&9Y_X9:W_P L#_B6+Q4_Z!,D
M_P##S1_^5_U9^5_XP:*_L^_XAT_V)O\ HJ/[4W_A;?"7_P"<A1_Q#I_L3?\
M14?VIO\ PMOA+_\ .0H_XFF\)_\ H,SS_P ,M;_Y8'_$L7BI_P! F2?^'FC_
M /*_ZL_*_P#&#17]GW_$.G^Q-_T5']J;_P +;X2__.0H_P"(=/\ 8F_Z*C^U
M-_X6WPE_^<A1_P 33>$__09GG_AEK?\ RP/^)8O%3_H$R3_P\T?_ )7_ %9^
M5_XP:*_L^_XAT_V)O^BH_M3?^%M\)?\ YR%'_$.G^Q-_T5']J;_PMOA+_P#.
M0H_XFF\)_P#H,SS_ ,,M;_Y8'_$L7BI_T"9)_P"'FC_\K_JS\K_Q@T5_9]_Q
M#I_L3?\ 14?VIO\ PMOA+_\ .0H_XAT_V)O^BH_M3?\ A;?"7_YR%'_$TWA/
M_P!!F>?^&6M_\L#_ (EB\5/^@3)/_#S1_P#E?]6?E?\ C!HK^S[_ (AT_P!B
M;_HJ/[4W_A;?"7_YR%'_ !#I_L3?]%1_:F_\+;X2_P#SD*/^)IO"?_H,SS_P
MRUO_ )8'_$L7BI_T"9)_X>:/_P K_JS\K_Q@T5_9]_Q#I_L3?]%1_:F_\+;X
M2_\ SD*/^(=/]B;_ **C^U-_X6WPE_\ G(4?\33>$_\ T&9Y_P"&6M_\L#_B
M6+Q4_P"@3)/_  \T?_E?]6?E?^,&BO[/O^(=/]B;_HJ/[4W_ (6WPE_^<A1_
MQ#I_L3?]%1_:F_\ "V^$O_SD*/\ B:;PG_Z#,\_\,M;_ .6!_P 2Q>*G_0)D
MG_AYH_\ RO\ JS\K_A;_ ,%-/D^#?_!+6!N)5_X)_P#@"=EZXBNO%7B=X'W#
M*G>J,=H.Y<8=5) /Y)U_>U^T1_P1>_9<^/'AO]G/P_XO\>_'W3;+X!_ KPU\
M%_!\OAOQ3\.[.ZU+PMX>O]3OK*_\2OJGPLUB*\U^6749UNKK2X=&TYXTB$6E
M0,KN_P Q_P#$.G^Q-_T5']J;_P +;X2__.0KYKA#Z2/AEDN08;+L=BLYCB:6
M*S:O-4\HK5(<N.SC'XZC::J).]'$TVUO&3<7=IL^DXM^CMXDYSGN(S#!87*)
M8:KA,HHP=3-:5.;E@LGP&"JW@Z;:2K8>HD_M12DDDTC^,&BO[/O^(=/]B;_H
MJ/[4W_A;?"7_ .<A1_Q#I_L3?]%1_:F_\+;X2_\ SD*^E_XFF\)_^@S//_#+
M6_\ EA\W_P 2Q>*G_0)DG_AYH_\ RO\ JS\K_P 8-%?V??\ $.G^Q-_T5']J
M;_PMOA+_ /.0H_XAT_V)O^BH_M3?^%M\)?\ YR%'_$TWA/\ ]!F>?^&6M_\
M+ _XEB\5/^@3)/\ P\T?_E?]6?E?^,&BO[/O^(=/]B;_ **C^U-_X6WPE_\
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MLXT88?#8.I.*6)J*K4KSIJ=&G2INHL12]-HHHK^"C^Z HHHH **** "BBB@
MKH-1_P"0#X<_[B__ *61US]=!J/_ " ?#G_<7_\ 2R.FMI>GZH3WCZ_HSGZ*
M**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .@U'_D ^'/^XO_
M .ED=<_70:C_ ,@'PY_W%_\ TLCKGZ;W^4?R0EM\Y?FPHHHI#"BBB@ HHHH
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M+O\ AZ?YO[O,+OM^/I_F_N\SGZ*Z#^W_ /J">'__  6__;J/[?\ ^H)X?_\
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M  6__;J++O\ AZ?YO[O,+OM^/I_F_N\SGZ*Z#^W_ /J">'__  6__;J/[?\
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M+O\ AZ?YO[O,+OM^/I_F_N\SGZ*Z#^W_ /J">'__  6__;J/[?\ ^H)X?_\
M!;_]NHLN_P"'I_F_N\PN^WX^G^;^[S.?HKH/[?\ ^H)X?_\ !;_]NH_M_P#Z
M@GA__P %O_VZBR[_ (>G^;^[S"[[?CZ?YO[O,Y^BN@_M_P#Z@GA__P %O_VZ
MC^W_ /J">'__  6__;J++O\ AZ?YO[O,+OM^/I_F_N\SGZ*Z#^W_ /J">'__
M  6__;J/[?\ ^H)X?_\ !;_]NHLN_P"'I_F_N\PN^WX^G^;^[S.?HKH/[?\
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MR(I/+?;Z;7\XW_!=K]F?XD_M#_%3]A'Q/^SXO[)'[17Q_P#V==?^,?CO1O\
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M1?5]-\G^T=*7Q)X.U76=&;4K#[1!]ML1>FZM?/A\^*/S$W?QX_MY:[JVH?\
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MK44L[^9K+4K.[L;D175O-$G\TO\ P48_X+$?LE?MA?L_?"G]E[]D/]L?X?\
MP]T+]N+7_&/@OXJ_M-_$'5;W]GW2?@G^S1\-VM[CX\7^FR?'S1_ %S>?$+XH
M61?X-?#/1!IFWQ%=>(?%5YINJ:9<>'XM5MN3_P""$?P__P"&O?\ @@I\&/V9
M_A-^UYXC_9]\8:)\1OB58?'7Q#^S]KWA&[^/7@OP-KW[0?Q-\3WG@:UO;FXU
M#4O@KXJ^)?@Z>WN_"WCJ\T6?5M/TBXCUS2-'UG3[EXYERNUWIJEJG]_]?\.[
MW>FNC^]6T_'_ (.Y_2K<_M._LUV?PV\8_&6[_:%^!UK\(/AWXAU#PC\0/BM<
M_%GP%!\-O WBO2-<L_#&J^&/&/CF77U\+^&?$.F>)=1T_P /:AHNM:I9:E9:
MY?6>DW-M%?W4%N_"_"S]NW]B#XY^,[#X<_!+]LG]E3XQ?$+5;?4+S2_ ?PL_
M:&^$7Q!\9ZE::39RZCJMU8>%_"7B_5];O+?3=/MY[[4)[>QDBL[.&6YN6C@C
M=U_$W_@W4^!_PB\:?\$N/BU\"/B#\./!?Q-^#Z_MG_M)^%[WX<_$WPUHOQ!\
M'ZUHOA/QMX:F\/VGB'P]XML=6TC7?[,O-%TK4K9]4L[IHM4T^TU%"MY;Q3)Y
M3_P21^$'[(7B;XV_MV_\%LK?X5?!3]G;]G'X<ZM\4_@I^R58?"_X;^$?AM\.
M_ G[,_[/^C7T?QG_ &D;O2/AMX?T[1O$/B/XK7%EKD]SXF6WUG7M"T32_%G@
M^RU+4-"GTNTLVXVNM6U^-[67KO\ <%WI:VJN_):?\-ZM>9_3CK7Q;^%/AOXA
M>#/A'XB^)WP]T'XK_$>QU[5/AY\,=:\:>&]+^(7CS3/"MF^H^*-1\&>"[[4H
M/$GBBQ\-Z?')?:]=Z'IM];Z/9QO<ZA);P*SCJ/$GB3P[X-\.Z]XO\7Z]HOA7
MPGX5T75/$GBCQ1XDU2QT/P[X;\.Z'8SZGK6O:]K>ISVNFZ/HNCZ;:W.H:IJF
MH7-O8Z?8V\]W=SPV\,DB_P $_P"S+^U_X*_:-_X+Q_L!_P#!0WXO_M,_!_3;
M?]I#1_VK?#/@KX-WWQE^%M_-^R9\$]%^'/C;X>_LN_![XG7&D>*+^P\'_&3X
MQZ[XI\0>/;[P3?ZE%?WWC#XCVVAZ?IL?BF75]*B_H4_X.,/&OB/1_P#@G%<_
M"7PYJM]H#_M6_M$_L]_LN:]K^FRQ0WND^$/B7XZAO_%AA>6"Y0QZOH7AB]\.
M7L?D2^;8:U=1M&Z,ZD<;-+O;Y:V_KN+FT;[/3ST5OOO\C]=_&_[1_P"SQ\,_
MAAH?QN^)'QY^#'P_^"_B>W\/7?AOXN^-_BCX'\*?##Q#:>+K%=4\)W6A^/M>
MUVP\*:M;^)]-9=1\/36&K7$>M6++=Z:US;D2'N/ /Q"\ _%;P=H/Q#^%WCCP
M?\2?A_XJLSJ/A?QSX!\2Z+XQ\'>)-/$\UJ;[0?$WAV]U'1=8LQ<V\]N;K3[V
MX@$\$T1?S(W5?YW/^"W'[(_B[XM>,_\ @GI'^RMI7['OQP^+G[)T_P 3]:\#
M_P#!,']I_P 3^ ;/PM^T_P#"WQ!X5\(^!]3U+PE\./&OB;PUI7BVY^".B^&I
M=4M'\2ZCIWAO0-,?4M8M=;36=(B\)^-?QO\ '_QQ\+_"#_@AI_P5:^&_[.G@
M#]HK]B/XK:-^VU!X-_:N_9D^(WC#PS\1]!_9=TW]H?XF>'?#WB#P-^SOXP\
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M&OQ?\&[?P*\#_P##&'_!4K]F:\COO$'PV_X>@?MN_ JZA\67/_"0ZEK?@?\
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MC_B(L_;9_P"B7?LL_P#A$_%K_P"??1_Q*SXL?] >1_\ AZH__*P_XF=\*_\
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M_&#_ ,1%G[;/_1+OV6?_  B?BU_\^^C_ (B+/VV?^B7?LL_^$3\6O_GWT?\
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M)^+7_P ^^C_B5GQ8_P"@/(__  ]4?_E8?\3.^%?_ $%YW_X9JW_RS^K/RO\
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M*?C/\$_!OQ!\'VTWBOX=^)_VDO@[\&-&\2:=)IFF?;+/Q1XB\,^']9@^$O\
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M]*T]?$;WFIWMI80W%Q'^FE%%W=/MM?R"RU7?_*WY'YC_ +5W_!.OX8_\%'/
MG[-OC[X\3?'3]EW]I;X0:=9>,O!GQ2_9K^+&E_#OX]? OQ3XV\-Z2/B7\/\
M0_B+H4?C_P *7NFS7MNFAZM=Z>OB.V=M)-UX3\20VNH7E[J=C]G'_@DS^R'^
MSQ^S?\=_V9KS2O'W[0OAG]JC7O&'B?\ :?\ B#^TKXUG^)'QA^/OB#QF9X[S
M6?B%X]TZP\+3?VMH]K+%'X;U7POI_AK4]%U6W/C2WO&^(6H:SXNU/],**+NU
MKNP67;^F?@[\/_\ @WG_ &.O"7B[X6W?CGXY_MS_ +1'P4^!OC2Q\>_!?]C[
M]HG]I>]^(W[)7PPU_P /7%U+X''AGX4)X3T2ZETCP';7EQH^B:'K_B;6])UG
MP_<7V@>.[3QAI&KZS9ZC]C_MW?\ !,3X#_M\Z]\&?B%XQ\>?'_X _'/]G_4/
M$D_PG_:-_92^*+?!WXX>%=$\9Z4^D>,/"%OXM?0_$UA/X;\0P>0\XN-"DUS2
MC'J%IX;US1-+\5>-=/\ $OZ-T47=T[O3;^OS[]0LNW;\-ON/BC]A/]@CX'?\
M$^/A3XB^&'P:OOB'XOU'Q]\0_%/Q:^+/Q>^,WBT>/OC-\8_B9XONEFU?QI\2
M/&,>F:)::MK!M(;+3HAI>AZ-8NEI+JUY97?B?6?$FO:UY]\(/V,M*_8!_9^_
M;5MOV2K7XF?%OXD_'KXK?M%?M>Z5X1\<>+/A];ZGJO[0?Q5\(:1;VG@;PAK[
M:7\,?#'AGP9<:WX0\.VFB/XQU::ZT=KR_N]:\975N(FM/T8HI7?<=OPT/SJ_
MX)-_L>ZS^P?_ ,$^/V:_V:/%LB3_ !#\(>#KSQ%\5)H]1CUB(?%/XC^(=7^(
MGQ L+?5X&:WU6RT+Q-XGU#P[INIP$Q7^F:19W:M(9C(_Z*T44;@M$EV"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH _F'_X.>?\ FQ'_ +%_X^?^\-K^4>OZN/\ @YY_YL1_[%_X^?\
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M1110 4444 %%%% !1110 4444 %%%% '0:C_ ,@'PY_W%_\ TLCKGZZ#4?\
MD ^'/^XO_P"ED=<_3>_RC^2$MOG+\V%%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %>H>"?^05<?]A"7_P!)K2O+Z]0\$_\ (*N/^PA+_P"DUI5P
MW?I^J)G\+^7YH["BBBM3$*^?Z^@*^?ZSJ=/G^AI3Z_+]0K\WOCK\)OC5\)OV
MO]&_;F^ ?PQE^/EOXF^!&C?LT_M"? ?P_P")_ O@GXH:YX4\*_$C6/'OPI^)
MWP<USXGZ]X)^&&K>)_ >J^/_ (C:=XW\%_$#XC?#G3_$_@G7;74M%\63>)O!
M.A>$?%/Z0T5F:'X=_M&_LY_M5_MMG]HCXS^+_@A>?!2T\'?\$_\ ]KS]F7]C
M[]G;QEX[^%FN_&WQS\8_VI? NG:9\0_B'\7-<^'/CWQE\!_AYHP/P^\ _#WX
M1:#H_P 8?'SW6F^(/&_C?X@Z]\/9;BR\)VVA\:/V(OCC\7]/_P""6_@,Z/J'
MACPY\)OV=_VC?@U^T?XLTSQ%X1FO?A1/\6OV$M5^!6CWEOIK>)K6?QM/;?$.
M_@M;6/P?_;UG'>6=OJMY=6>CH-6C_;2BG?\ 7\59BLOZ^7^2/QE^'G@_]L/Q
MU^QUX;_X)S?%']D36/AN'_95\2?LF_&?]JF;XV_!6^^!$FD:?\&=2^#,'Q._
M9Y\-^%_%7CK]H'QW?>-+UM)\6>&_ 7QF^#7P BT/PY>:U!XJ\;VOB'0-,T7Q
M?R?A7X0?MF_&WPY_P3T_9O\ BS^S9>? /0_V*?BW\)_B;\=OCU>?$_X.^.?A
M7\8O^&5_".N^$?A]H_[,.@^#?'6O_&>\L_C3XXE\)^/;B^^/7PQ^!5Y\//AC
M8>)-(U*TUOQ[)I>B7?[C447\E^.GX_G<+;;Z;?*W^7YG\X_[&?[(W[87[$"?
ML@?'F[_9Q\0_&77- _9D^/\ ^RC\?_@#\//B1\"]-^+O@%?$G[57BO\ :*^#
M_P 5? VL_$3XI^!O@?X^\.7UK?ZMX8^(_ARY^,/AOQ/H \2>"M;\-6OB673?
M&.@V%7P%\ OCU^S/^U)\%/VQ/%7@OPYXX_:)_:)^*7[??Q%\8_L,>$?C=\$M
M(^.FB_"?]H#1_P!F672;/X/2_%/Q]\+_ (5?&#Q]^SGI7[/WPAT[]I&71_B)
M8>#+6[^(WB+4?!7C'QCI6B>"Y_&/](5>0_&7]GWX"_M&>'=-\(?M"?!'X0_'
M?PGHVM1>)-(\+_&7X:^#/BAX=TKQ%!8WVF0:]INB>-]%US3;'6H=-U34].BU
M2UMHKZ.QU&^M$G%O=W$<@G_P?33_ "\O4+?I^%O3L?S7:"/%_P 1O^">'_!9
MS]I'QSX=T'X$_$+X:_\ !1OXF_MJ?"*&7QIHOB'1_"/Q-_9!^$?[*/BGPQX<
MO_'WA&_N?"6N^(T^(OP6U_X&_%N?P1K?B'PY#\0_^%B^%?"_B'Q%%86>KWG[
MC?\ !-OX.>,O@Q^QW\*['XJ6$^G?'#XHGQ5^T1^T#;WL<J:E:_'3]HKQ9K/Q
ME^)NAZ@T[/<ROX,\1^,[GP'I[7,DD\.B^%M+M&D9;937O6H?LR_LW:MX.^&7
MP\U7]GWX(:GX ^"FN^'_ !1\&O VH?"CP'>^#OA+XF\)1W$/A7Q%\,O#-SH$
MFB^ ]=\,PW=U%X?U?PK9:5J&C1W-Q'IMQ;+-(&]OH;O;R_R2_0=ORM]]O\@H
MHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?D!_P68_X)T_&W]OS_AF
M#_A3OBCX6>&O^%3^'_B/_P )'_PLO6_%NC?;?^$[_P"%=?V1_8O_  BW@CQE
M]I^S?\(;JG]I?;O[-\GS[#[+]L\VX^R_B!_Q#I_ML_\ 14?V6?\ PMOBU_\
M.0K^U[Q!_P P3_L7]-_]K5S]?M7"?CYXA<%</Y?PSD>)RJGE>6+$_588G*Z6
M(KKZ[C,1F%?GK2FI3OB,76<;I<L'&"TB?C?%/@3P!QEGN.XDSO#YI4S/,EA/
MK,\/F57#T7]3P6&P%'DHQ@U"V'PM)2LWS3YI;RT_C!_XAT_VV?\ HJ/[+/\
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M ,+;XM?_ #D*_L^HH_XFF\6/^@S(_P#PRT?_ )8'_$L7A7_T"9W_ .'FM_\
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M@3.__#S6_P#E?]7?E;^,'_B'3_;9_P"BH_LL_P#A;?%K_P"<A1_Q#I_ML_\
M14?V6?\ PMOBU_\ .0K^SZBC_B:;Q8_Z#,C_ /#+1_\ E@?\2Q>%?_0)G?\
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M+_Z36E>7UZAX)_Y!5Q_V$)?_ $FM*N&[]/U1,_A?R_-'84445J8A7C_]O_\
M4$\/_P#@M_\ MU>P5\_UG-M6MY_FG^AI!+7Y?G?]$=!_;_\ U!/#_P#X+?\
M[=1_;_\ U!/#_P#X+?\ [=7/U\S?&']M7]C?]GGQ3;>!OC_^UI^S-\#?&U[H
MMIXDL_!_QA^//PL^&?BF[\.W]W?V%CKUMX?\:^*M$U:?1;V^TK5+*TU2*T>Q
MN;O3;^VAG>:SN$CB[_KY?Y(NR7X?I;\D?7/]O_\ 4$\/_P#@M_\ MU']O_\
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M&:)<G3M0%OJOB.ZTVQF-C>".=C:S["[_ *7:W^2_IA9?T^UO\E_3/L?^W_\
MJ">'_P#P6_\ VZC^W_\ J">'_P#P6_\ VZO@[PM_P4B_X)W>.O$_ASP3X)_;
MV_8N\8^,_&.O:/X5\(^$?"W[4GP.\0^)_%/B?Q#J%OI.@>'/#F@:3XZN]5US
M7M<U6\M-,T?1],M+K4-3U"ZM[*RMY[F>*)D^,W[:_AWX9?&:+]G7X>?!+XZ?
MM0_'2U^&8^,OB_X<? .U^$5K=?#KX7W?B"3PKX?\4^-_%WQY^,'P-^'%A=>,
M/$5IJVG>#O!.E>--9^(WB.'P_P"(M<T_P=)X<T/4M9MR[_+MY6_)!9=/+S[6
M_)'WE_;_ /U!/#__ (+?_MU']O\ _4$\/_\ @M_^W5^2G[0G_!4O1?V<OA!X
M.^/GBG]BC]N;7_A/XUMOAA9Z;K&E>"?@'X-\=VWQ ^+/BJR\#^&/@]=?L_\
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M /J">'__  6__;JY^BB[[_UI_D@LNW]:?Y(Z#^W_ /J">'__  6__;J/[?\
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M  6__;JY^BB[[_UI_D@LNW]:?Y(Z#^W_ /J">'__  6__;J/[?\ ^H)X?_\
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M5UCR(=);^R]'F\_389ML]EYBP[F<>5 /-'EPKC*IS@D\\UC_ -O_ /4$\/\
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MR067;^M/\D=!_;__ %!/#_\ X+?_ +=1_;__ %!/#_\ X+?_ +=7/T47??\
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MZN?HHN^_]:?Y(++M_6G^2.@_M_\ Z@GA_P#\%O\ ]NH_M_\ Z@GA_P#\%O\
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M\/7OB W6HZ/<ZM>^(O#EWI<^G7=T?"OCA^R'_P $@?V:_P#@DE^S9X>\1?\
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M2#KLVI>*]7\76EQ<Z-:Q1W;7LMJT'WO\<OA[K7AK_@CU_P %5O$?C7_@D3\
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M1::X^XTNFFK\49W):=XRQSBUW333ZH_KM_X)_?\ !=NW^,/C?0/@Y^UIX?\
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M<_[B_P#Z61US]-[_ "C^2$MOG+\V%%%%(84444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 ?S#_\ !SS_ ,V(_P#8O_'S_P!X;7\H]?Z
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M+_\ 'Q1_Q#2_]7I_^:Y?_CXH_P")D/!?_HLO_-=XK_\ G$'_ !+OXQ?]$?\
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MD4L;ADDCD1F1T=2KJ2K @D5TG]HZ#_T+G_E7O/\ XBC^T=!_Z%S_ ,J]Y_\
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MH/\ T+G_ )5[S_XBC^T=!_Z%S_RKWG_Q%%EW7X_Y!=]G^'^9S]%=!_:.@_\
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MJ]Y_\119=U^/^07?9_A_F<_170?VCH/_ $+G_E7O/_B*/[1T'_H7/_*O>?\
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MZ#_T+G_E7O/_ (BBR[K\?\@N^S_#_,Y^BN@_M'0?^A<_\J]Y_P#$4?VCH/\
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M?^5>\_\ B*++NOQ_R"[[/\/\SGZ*Z#^T=!_Z%S_RKWG_ ,11_:.@_P#0N?\
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MT4VV]_7^OZ[=@LETZ6^7](****0PHHHH **** "BBB@ HHHH **** "BBB@
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MA_\ 8%M?_0I:Y^F]_E'\D*.R]%^04444AA1110 4444 %%%% !1110 4444
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M'9I3C%RC.-XNVKV\FFO5?U9^3Z'X0_M:^&_BE^VW=_'+XP^!/@S\8O#OP=^
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M+\9_@7\?9/A[=_LB_M(_LQ>+K'P5\#?BI\2OBE\#OB+J/[8GB'XY^%=0\;?
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M%%% !1110 4444 %%%% !1110!T&H_\ (!\.?]Q?_P!+(ZY^N@U'_D ^'/\
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MN?\ E7O/_B*/[1T'_H7/_*O>?_$5S]%%WY?<O\@LO/[W_F=!_:.@_P#0N?\
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M )G0?VCH/_0N?^5>\_\ B*/[1T'_ *%S_P J]Y_\17/T47?E]R_R"R\_O?\
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MM8LX[G[#K>BWJQ:CHFKVU]I.I06]_97,$?\ 3E_P2._Y1:_\$[_^S,/V;_\
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M#>)O GB?3&\9^.]3^$E_9?#[X>67@?QMI\=FU[X8\*>%?$>DQ:7I]Q8_TW?
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MH_\ RS^KORM_9]_Q$6?L3?\ 1+OVIO\ PB?A+_\ /OH_XB+/V)O^B7?M3?\
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M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% '0:C_ ,@'PY_W%_\
MTLCKGZZ#4?\ D ^'/^XO_P"ED=<_3>_RC^2$MOG+\V%%%%(84444 %%%% !1
M110 4444 %%%% !1110 4444 %>H>"?^05<?]A"7_P!)K2O+Z]0\$_\ (*N/
M^PA+_P"DUI5PW?I^J)G\+^7YH["BBBM3$*^?Z^@*^?ZSJ=/G^AI3Z_+]0KX'
M^(7[8=S\*_VR?''P>\>MX7T'X _#C]@;Q+^V'XS\:_V)XHU3QKHUSX/^*=[X
M7\1-MT:_U&+4?"^G>"].O-6_L32O!E]XHN]6AQ8W]TLD6E/]\5^('[<WPF^*
MGB[]IC]L/7O"GPT^('B?0_$__!$#]H+X3>&]:\/>#?$>M:3XA^*FM>/_ !=>
MZ/\ #30]1TW3;FSU;X@:M9W-M=Z9X-L)KCQ'?VUQ!/:Z;+%+&[;X.G3J5)0J
MV473=FVDXMR@DXMZ*23=KI^C14FTKKNCZUL/^"I_[#NJ7^BZ7IGQ2\::CJ?C
M#P[)XK^&&G6/[.W[2UW?_'30(-1TG3;V_P#V<+.W^$$EQ^TI_9CZU9ZCK%K\
M!(_B->Z/X=BU3Q5JEM9^&="UO5M/Z>]_X*1?L9V/A3X1^,/^%MZAJ6G_ !WU
M'X@:#\)M%\/_  J^,WB?Q]XR\6?"N\@T[X@^ [/X7^'/A[JOQ)L/B3X6U&X&
MGZC\-=8\)Z=X]-]!?6=MX=GN=-U"*U^2O#'PF^(5K^TA_P $5=:D^&GC.VT#
MX0?L4_M.>%/B'JS^#=;AT?X7^*-=^$W[(^C>'_#?C._;35LO!.OZS/X>\3Z5
MH^CZY+IFHZA-H>O6-E;3/IFH10?,'[.'P.^-.D_MH?L]>*O$7P?^*&F>&/#7
M_!1W_@M[XYN_$>M?#_Q99:%H'@OXM:EJ3_"_QA<ZQ?:1%I^E>%_B;'>W#> ?
M$$MQ!I/C-+N9O#UWJ2SN7[%A,$XN2E67+2JU7%UZ3<O9_78QIQ?L%:4I8:E+
MF:?NU>51;Y9.>:79=.CZ^S\_[S^[U/TW\/\ _!47]AWQ0^@?V-\7]<EM-;\<
MVWPNU'6+WX)_'S1_#GPX^*%[XTO?A[8?#'XZ^)]8^%]AX=_9W^(^H>+K$Z7I
MW@/X[ZI\.?%FH1WVB:I9Z1/H_B+0=0U+V[4/VN_V>-+\(?M+>/+_ .(7D>%/
MV/\ 5?$FB?M%:K_PB?CB7_A7FI^$O NA_$OQ#;?88?#4FI>+?[/\$^)-%UKS
MO UGXFM[O[;_ &;8RW.K6]W80?BYX_\ @?\ &J3_ ()\_P#!2WPEI'P@^*+^
M.O'O_!5+QQ\2_!'AG3OA_P"+&\6^,_!4_P"VK\$?$^G_ ! \*Z-;:2=8\1>%
MIO">AWOB&S\5:1;7FDR>'M'NM6@OSINGS7$.+^T7I?Q3^&WPJ_X+C_ -?V>/
MVDOB#\1_VN/$/Q'^(7[/(^%?P%^*7Q"\"?$7PC\0?V4OAO\ #^>>W^*_AGPO
MJ'PQ\.>)/!^K^"/%IUKP#XQ\6^'?'>O3Z9IVA_#WP[XT\2^*_"&C:[2P.%J2
MM3G5TK.FTZM*3Y%4P:E4NJ<4HJGB*C;:<8^R=1OE4HJ>>:2NEK&^S6K4K+?J
MTK>MM]7^K_CS_@IA^QC\.-9\<^'O$?Q-\67>L_##P9X=^)'Q,L/!?P'_ &A?
MB7+\.?AOXJ\&6WQ"T;XC>/7^''PJ\5Q>#OA\_A"[BU;4?''B*33?"VA,EUIN
MNZMINJV5Y8P>@?%C]M_]F?X,ZCX:T7Q3X[USQ+KOBWX>77Q?T7P[\%?A9\7?
MVC?$A^$5I/9VC?%G5O#O[/G@/XGZUX=^%MU>7UO8Z7\1/$5AI7@W6;\7%CI.
MM7MW9WD,'YV? 7X0_$_1O&'_  5.O]5^&'CW2E^(O[*O['_AGP+>ZAX*\0V*
M^.];\*?L=^*/#6O>'_"5Q<Z9$/$^J>&_$]]_8&KZ5H[WUWH^O7G]E7EO;:A<
M>0_CW[#'_"Q_V'KSPK\3?V@?@/\ M(:UH?QY_P"":W_!.C0=$U3X6?L\?%SX
MS>,O 'Q6_9G^"^K>%/B?^SY\2/AM\+_!GBKXB_"[Q7>ZMXUL_%&A77BWPQX;
M^'5S?_\ "4Z+J7B32/%>AWNG30\'A7&3A*K.=.G0?LE5I<]>=:C1J2C2M1;A
M[)SJRDN6JY1I\ONRO(?-/2]ES.6O*_=Y797UZ_*WF?H]%^VSI6J?MA?#WX7^
M'_%GPDU;]F'QG^P1\4_VQ'^,UMK"W$!'@;XN?"'P=IVM6?CZ+Q.O@:+X9-X,
M\>Z]KNL7MSI4LR7%C8ZBOB.PTVTOK.[]-^#_ .W7^R]\=-=L_#G@#X@:U#JF
MM>!Y/B=X0_X6)\*_B_\ !C3?B5\-(([:>[^(WP@USXR> O 6A_&/P#8V5]I6
MIZCXS^%FH^+_  WIVD:YX>UB^U.WTOQ%HEW?_P [MS_P3S_:[\2?#B3X&K\,
M=9\(>/O'O_!)7_@H#X;M(PNWX=^"/B3\>?V_? /[07P^_9KU/XDZ7<7/P\TK
MQ/!X!U1_ \.DP>)6T9--\/ZQ?V!F\(:3<W47V_\ M2Z'\2?^"D-Q^SYX,^ W
MP5^/'[/^I_"[X/\ [4NJ_$KQ;\9_@G\0?@3%\(?$_P :?V0/B=^S_P""O@GX
M0\0>/O#GA/1/BGJQ\?\ Q"M;SQ'J_P $[_Q]\*]-TCX<6^O7'BNXLM1\%?VY
MK4P6#;@HUO=4:T9UH3AR4XTN=TJU6/+)S^LNU."C*&L;+GE.*!2EKI_+9=7=
M1NEM;ENV[WWZ69^@GAK_ (*=?L4^+_%_P^\"Z!\4O%-SXB^+^J:YI7P96Z^!
M'[0ND:+\;3X;T;Q'X@US6?@CXKUCX56'A7XQ^$--TGPO?W$_CKX9ZUXJ\%^;
MJ/A*RCUY[[QWX(MO$/LVB_M>_LZ>(_AM^S]\7="^)-KJWP]_:F\3>#O!WP$U
MVQ\/>+[B;X@^)_'>CZWXA\.Z/;:$GA\^(M"NCH?AKQ'JNN_\)3I.AQ>$;'P_
MK=QXNDT./2;]K?\ %76_C)#XT^*__!#[X.W/[.GQ\^%GC[X/_&E_#?Q!F^)O
MP4\;?#?PC\/O$/@S]COXR^$=9^&_@WQKXGT'1?!_Q@L]9N]$O]?T[Q9\#=4\
M??#Z'POX*LM5U?Q#I"^(O"5MJ_3_ +'_ ,$O&5E_P4H^(_[/6L:3#_PSY_P3
MF\8?'7X_?!"Y1([C3I?$/_!1.32_&_@'PU:1M:Q#3'^!FB:C^TSX1TZV:6XN
M1I/C+1;MWEC_ +/N(HJ8'#Q@YWK4G&A/$2C4JTI\T(5L1AX\CC3A=U*JPJAH
M_=JSG[T%&2%.3ML[R459-:N,9:W;V3E?;5):,_H5HHHKQS4**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#^.'_@Y+_Y/9^"?_9G/PW_]6U\=:_GMK^GK_@X&_9O_
M &B/C!^U]\'O$WPD^ OQH^*7ANQ_9.^'VA7OB#X<_"WQQXWT2SUNV^)_QGU"
MYT>ZU7PSH6IV%OJMO8:GIM[/I\UPEW%::A8W,D*PW=N\GX5_\,,_ML_]&>?M
M3?\ B/OQ:_\ F1K_ %6\&.(,APOA;P1A\3G>48>O2R2C&K0KYE@Z5:G+VM5\
MM2G4K1G"5FG:44]=C_+KQ@R'/,3XF\9U\-DV;8BA5SFK*E6H9=C*M*I'V5%<
MT*E.C*$XWTO%M7/EFBOJ;_AAG]MG_HSS]J;_ ,1]^+7_ ,R-'_##/[;/_1GG
M[4W_ (C[\6O_ )D:_3O]9^&O^BAR/_P[8#_YH/S;_5KB/_H09W_X:L=_\H\U
M]Y\LT5]3?\,,_ML_]&>?M3?^(^_%K_YD:/\ AAG]MG_HSS]J;_Q'WXM?_,C1
M_K/PU_T4.1_^'; ?_- ?ZM<1_P#0@SO_ ,-6._\ E'FOO/EFBOJ;_AAG]MG_
M *,\_:F_\1]^+7_S(T?\,,_ML_\ 1GG[4W_B/OQ:_P#F1H_UGX:_Z*'(_P#P
M[8#_ .: _P!6N(_^A!G?_AJQW_RCS7WGRS7W9_P3)\#Z_P"/_P!O?]E?2_#U
MK=7,^B_&#PEXXU-[:.5UL] \ :C'XQURZNI(HW$%J-.T6>W>2;9$\MQ#;&17
MG3,7P\_X)G_MZ?$O7;/0=%_95^,NA37<\<3:E\0_!>K_  RT*SC9PLEU>:SX
M_MO#MBD$"DRR+%+-<R(A6VM[B8I$_P#6;_P2X_X)<:#^PSX?O?'_ ,0+_2?&
M/[1/C+2_[.UO6=+267P]X$\/W#VMS+X0\*3W<45Q?3SW5M'-K_B5[:PDU)DA
MTZTLX=/LVN-3_)/&#Q?X0X7X0SO"8;.<MS7/\URW&9;EN5Y=C,/C:T:N/P]7
M#+&8R.'J5%A<)AHSE6E*NZ;KNFJ%%3G/W?U?PD\)>+>)N+,FQ>(R?,<KR+*\
MQP>8YCF>882O@J,J."Q%/$/"8.6(ITWB<7B7"-&,:"J*@JGMZW+"/O?KY111
M7^6Q_IN%%%% !1110 4444 %=!X@_P"8)_V+^F_^UJY^N@\0?\P3_L7]-_\
M:U-;2]/U0NJ]'^<3GZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_J8/_*=1_Q2O_4P?^4ZBWFOO]/\_P 'V"_D_N]/\_P?8Y^BN@_XI7_J8/\
MRG4?\4K_ -3!_P"4ZBWFOO\ 3_/\'V"_D_N]/\_P?8Y^LO7-#T7Q/HNL>&O$
MNCZ7XA\.^(=+U#0]?T#7-/M-6T77-%U:TFL-5T?6-*OX;BQU/2]3L;B>RU#3
M[V">TO+2>:VN89(9'1NT_P"*5_ZF#_RG4?\ %*_]3!_Y3J$FFFFD]&G>S3TU
M\K7_  ?8+^3^[T_S_!]CXE^#/["_[-/P$\2>$_%GP^\*^.KG6OA[X3O? OPR
M?XF?'?X^_''3?A-X0U.TTG3M2\/_  @T'XV_$[XA:#\)=.U'2-!T30K^'X<:
M;X7-YX>TG3O#UPTFBV<%@GJ?P7_9^^%7[/\ I_BNQ^&.AZU97'CSQ3+XU\=>
M)?%_COQ_\4O'OC7Q3)I6F:#%K'B_XC_%/Q1XS\?>)I].T#1-&\/Z+%K?B2^M
MM!\/Z3INAZ+!8:596UI%]#_\4K_U,'_E.H_XI7_J8/\ RG5I*K6J7YZU2?,H
MJ7/4E+F47S14KMW492;5[V?,UK>Z5E:T;?)*U[?\"_IY'/T5T'_%*_\ 4P?^
M4ZC_ (I7_J8/_*=6=O-??Z?Y_@^P[^3^[T_S_!]CGZ*Z#_BE?^I@_P#*=1_Q
M2O\ U,'_ )3J+>:^_P!/\_P?8+^3^[T_S_!]CGZ*Z#_BE?\ J8/_ "G4?\4K
M_P!3!_Y3J+>:^_T_S_!]@OY/[O3_ #_!]CGZ*Z#_ (I7_J8/_*=1_P 4K_U,
M'_E.HMYK[_3_ #_!]@OY/[O3_/\ !]CGZ*Z#_BE?^I@_\IU'_%*_]3!_Y3J+
M>:^_T_S_  ?8+^3^[T_S_!]CGZ*Z#_BE?^I@_P#*=1_Q2O\ U,'_ )3J+>:^
M_P!/\_P?8+^3^[T_S_!]CGZ*Z#_BE?\ J8/_ "G4?\4K_P!3!_Y3J+>:^_T_
MS_!]@OY/[O3_ #_!]CGZ*Z#_ (I7_J8/_*=1_P 4K_U,'_E.HMYK[_3_ #_!
M]@OY/[O3_/\ !]CGZ*Z#_BE?^I@_\IU'_%*_]3!_Y3J+>:^_T_S_  ?8+^3^
M[T_S_!]CGZ*Z#_BE?^I@_P#*=1_Q2O\ U,'_ )3J+>:^_P!/\_P?8+^3^[T_
MS_!]CGZ*Z#_BE?\ J8/_ "G4?\4K_P!3!_Y3J+>:^_T_S_!]@OY/[O3_ #_!
M]CGZ*Z#_ (I7_J8/_*=1_P 4K_U,'_E.HMYK[_3_ #_!]@OY/[O3_/\ !]CG
MZ*Z#_BE?^I@_\IU'_%*_]3!_Y3J+>:^_T_S_  ?8+^3^[T_S_!]CGZ*Z#_BE
M?^I@_P#*=1_Q2O\ U,'_ )3J+>:^_P!/\_P?8+^3^[T_S_!]CGZ*Z#_BE?\
MJ8/_ "G4?\4K_P!3!_Y3J+>:^_T_S_!]@OY/[O3_ #_!]CGZ*Z#_ (I7_J8/
M_*=1_P 4K_U,'_E.HMYK[_3_ #_!]@OY/[O3_/\ !]CGZ*Z#_BE?^I@_\IU'
M_%*_]3!_Y3J+>:^_T_S_  ?8+^3^[T_S_!]CGZ*Z#_BE?^I@_P#*=1_Q2O\
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M]3!_Y3J/^*5_ZF#_ ,IU%O-??Z?Y_@^P7\G]WI_G^#['/T5T'_%*_P#4P?\
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M7_J8/_*=1_Q2O_4P?^4ZBWFOO]/\_P 'V"_D_N]/\_P?8Y^BN@_XI7_J8/\
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M'^)]Q\1YK+4? $5]K6K?V3HMC)XDL-#?0?%-O=:YHFDSKX9UF[MK:RD^"?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .@\0?\ ,$_[%_3?_:U<_7Y
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MXQ7GB#6-1_LG3I/^$?\ !5QHT=E]L\1Z=>K/YOM/C3_@FQ\8_A5_P55\#_\
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M>Y\-WNOZ[X>UW6]/G\L\0?\ !*;]OWX[_LM?\$Q?@-^UG\0_V6OBWXI_8/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\</\
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M\2PZ3I.H^$OB8_@W5/A[I_C2>ZF\&/*UY!J>I_V7IFIK!_1!13YG^-_G=/\
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M/BSX^^%GA7PK??&7P=H'QG\5ZEXF\#P>+/#GCC2[#J_@=\/O!_\ P4%^)/\
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M?$SP1K=I9VV\":6/3_ASK7C;5;N=8MS06XM((YI L<MU;(S3)_4I_P $^/\
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ML?V!_P 2O[5_;'_('LOLWV?[%_QZ?O?)\_S/^7C[WF^7^[^[M[UC_P#%*_\
M4P?^4ZCQ!_S!/^Q?TW_VM7/TV]=ELGMY+\-/Q8HK1:O9/?T_#3\6=!_Q2O\
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MOVY?P?7S#_BE?^I@_P#*=1_Q2O\ U,'_ )3JY^BE?R7W>G^7XON.WF_O]/\
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M/^*5_P"I@_\ *=1_Q2O_ %,'_E.KGZ*+^2^[T_R_%]PMYO[_ $_R_%]SH/\
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MK:#9V^JV$T5_I<UY9NLY_DI^$_[&_P 98/\ @B+:_#CXO?L,_MH^+M6^&O\
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MB?\ 8!L/YS5S]-[_ "C^2%'9>B_(****0PHHHH **** "BBB@ HHHH ****
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ML=_\H\U]Y\LT5]3?\,,_ML_]&>?M3?\ B/OQ:_\ F1H_X89_;9_Z,\_:F_\
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M'/'O^#_R//Z*] _X07_J*?\ DC_]V4?\(+_U%/\ R1_^[*.27;\5_F'/'O\
M@_\ (\_HKT#_ (07_J*?^2/_ -V4?\(+_P!13_R1_P#NRCDEV_%?YASQ[_@_
M\CS^BO0/^$%_ZBG_ )(__=E'_""_]13_ ,D?_NRCDEV_%?YASQ[_ (/_ "//
MZ*] _P"$%_ZBG_DC_P#=E'_""_\ 44_\D?\ [LHY)=OQ7^8<\>_X/_(\_HKT
M#_A!?^HI_P"2/_W91_P@O_44_P#)'_[LHY)=OQ7^8<\>_P"#_P CS^BO0/\
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M %%/_)'_ .[*.27;\5_F'/'O^#_R//Z*] _X07_J*?\ DC_]V4?\(+_U%/\
MR1_^[*.27;\5_F'/'O\ @_\ (Y_Q!_S!/^Q?TW_VM7/UZAJ'A/[=]B_T_P K
M['I]M8?\>N_S/L^_][_Q\ILW[_N?-MQ]]L\9_P#P@O\ U%/_ "1_^[*;C+MT
M75=$O,2E%):]%T?^1Y_17H'_  @O_44_\D?_ +LH_P"$%_ZBG_DC_P#=E+DE
MV_%?YCYX]_P?^1Y_17H'_""_]13_ ,D?_NRC_A!?^HI_Y(__ '91R2[?BO\
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M91_P@O\ U%/_ "1_^[*.27;\5_F'/'O^#_R//Z*] _X07_J*?^2/_P!V4?\
M""_]13_R1_\ NRCDEV_%?YASQ[_@_P#(\_HKT#_A!?\ J*?^2/\ ]V4?\(+_
M -13_P D?_NRCDEV_%?YASQ[_@_\CS^BO0/^$%_ZBG_DC_\ =E'_  @O_44_
M\D?_ +LHY)=OQ7^8<\>_X/\ R//Z*] _X07_ *BG_DC_ /=E'_""_P#44_\
M)'_[LHY)=OQ7^8<\>_X/_(\_HKT#_A!?^HI_Y(__ '91_P (+_U%/_)'_P"[
M*.27;\5_F'/'O^#_ ,CS^BO0/^$%_P"HI_Y(_P#W91_P@O\ U%/_ "1_^[*.
M27;\5_F'/'O^#_R//Z*] _X07_J*?^2/_P!V4?\ ""_]13_R1_\ NRCDEV_%
M?YASQ[_@_P#(Y_7_ +NB?]@&P_G-7/UZA?\ A/[<+$?;_*^QV%O8_P#'KO\
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MHI_Y(_\ W91R2[?BO\PYX]_P?^1Y_17H'_""_P#44_\ )'_[LH_X07_J*?\
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MX]_P?^1Y_17H'_""_P#44_\ )'_[LH_X07_J*?\ DC_]V4<DNWXK_,.>/?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOIK?5WNM+WMOLK;'X:?"O]NCXF?!+]FOP[KGPUU3XJ?$[X6?M<_MP>*_ O\
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M*ZAPH5Z-.-)5*<)N-><Y2DIWC!QIJ+CRRBI.\9/EG&26EEJ[MIMZ.VG?K?\
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M&8?''B/Q'K,WQ9U;2M&OHO[2^+&DZ%\-_#WC=YXM1T3X:>%+)4BNOHROG/\
M9?\ V9?!/[)7PYU+X1?#'Q!XTOOAC'X[\9>+OA_X+\67V@:AI/P:\.>,=3_M
ML_"'X8R:-X:T#4;+X3^%=8N-6NO!&A>*[[Q;KOABRUB;PU9>)CX1TGPOH&@?
M1E>=5<'4FX6Y')N%H\GNMWBN6[Y6E9-7EJOBENZ5[*^]E?KJ%%%%9C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>sdgr-20241231_g5.jpg
<TEXT>
begin 644 sdgr-20241231_g5.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X0.!:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 Y+C M8S P," W.2YD831A-V4U968L(#(P,C(O,3$O
M,C(M,3,Z-3 Z,#<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](D$P0C@R.#8X,30V131#0SE%0D9&,D$W
M-S8R1#@U,T5$(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C8Q,S9$1D,W
M04$R.#$Q140Y03<R.$8T-$1",30W0S(Q(B!X;7!-33I);G-T86YC94E$/2)X
M;7 N:6ED.C8Q,S9$1D,V04$R.#$Q140Y03<R.$8T-$1",30W0S(Q(B!X;7 Z
M0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<" R,#(S($UA8VEN=&]S:"(^
M(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.F(R9#0V,S=E+3(P9F0M-#(R-RTY,F0U+34W,#%B869F,#DY-R(@<W12968Z
M9&]C=6UE;G1)1#TB861O8F4Z9&]C:60Z<&AO=&]S:&]P.C0Y8F$Q9&-E+3=B
M.#0M.#DT."UA-#$U+3-C965E,C(V,30R-R(O/B \+W)D9CI$97-C<FEP=&EO
M;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_
M/O_N  Y!9&]B90!DP     '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$!
M 0$! @$! @(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# __  !$( 2P"6 ,!$0 "$0$#$0'_Q #I  $  00#
M 0$             "0($!P@#!08!"@$!  $% 0$               8! @,%
M!P0($   !0," P0#"0D+!@@(#P   00%!@(#!Q$((10),1(3%4%1%F%Q@:$B
M,B,D%_"1L<'1,S2W>%)#U"4U594W&#@9X4)$)B<*\6)3@U2$I$6"8V1TE,27
M6'*RPM)SD[1E5D=G=Z<H&A$!  $"! ,#" 8%"@0%!0    $" Q$A! 4Q01)1
M80;P<8&Q(C(3!Y&AP=%"%/%2TB,5X6)R@K(S0U-C))+"<Q:BXH-TA)/3-$07
M_]H # ,!  (1 Q$ /P#]_
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M0!T36^M#Q4O)K=F]TY!Q5-"ZI M2K30NR/N<XUJ^3JJ-&O0&?RK%[106O$B
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MI4TQ9HC;%0K)'1JMICD4:43>1WC,SJLW;_#Q>(;Y@
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M#&$%MIC;0UL+4G._6F;&1L1LS58K6*#5J[R5(B34HZ:ERL^\9=NA^L!ZD
M                   4>'1^Y(!QG8LU'KX5OX;9%^34!7W*/W'X/R@/GA4?
M\G1]WP /GA6/W%O[Q /G@6?^1+XO_G .3PZ/W) */#H/Y]%OB0"KN4?N/P?E
M .Y1^X_!^4!]\.C]R0!X='[D@'G7N-Q^4(O+Y$QM$@;.93J_+GIM2NB'F4:D
MU215RBQ+<IYI&L+6GU=O:8#T%%LJ?\TOB/0!R@
M
M
M
M
M
M                                              *+AU%14='SM. #
MP<2R/!IPYS=GB4H9I [XYDAQ*=M[6JIOJ(M*":T3P;"[D1%RB[D'6S?T_<W0
M'OP
M                                       %-?S3^#\) (N>GT6F>>J.
M?KWQJ/O?8?B$!*0
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MRA19CF3(DYP><MII,(XJ354O\5>BI<F99\CL4:&>@"8T
M                                   'F9''T$E9G>//"7FV5[;%;0YH
M>:4)N<0+TYI%B7F41T+D9UI3_>#+74^/I :G1;8%M$@Z2 M\7P-#FYGQ:O4.
M<#9RNR18R1YR4/QR0U*-@<'MP:UE2)]+GDO,IE))%9^.G[I@,K8EVVX1P6ZR
MI[Q%BZ*X]<9ZK3KI:KCZ.^FO.1I%J]8B0_*JJY)E;UCNJNID"?E4:8[]SNV"
MU :F]*3^[IDK]K_=]^OF9 ),P
M '02!F12-E=&)RMW+S:\MZYJ7V+=Y4FO7T*Y,:5310J2]U6EJJIJ/B1F?X@T
M@3],[9:AKQG6@PBW(ZL-79!=Q>H3R>:65L).8NJ-XE?L\J*4]Y%[0K4I<X7^
MD_& S=C#:]@K#DSF&0<88RCT0ETVMJK,C=VRA5XM]"L=%KTI:T29:KK)F0N#
MXIY]6G2\LE4JS\<R[P#4CI^?U\]47]N%3^H_$ "4<
M                                    $9?2D_NX9$_:ZW<?KXF "30
M                           !QD=/'C\1BZ<8XK>JFO@J,M2%L3$Y\E].
M62H%        $7'3\_KYZHO[<*G]1^( $HX
M                              (R^E)_=PR)^UUNX_7Q, $F@
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M^OXC_( IHK*L@'(  (R^E)_=PR)^UUNX_7Q, $F@
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MQZH[XP^C"8Y^4QBU6O\ #>EW6/;X3Y_VH:RXIF,QP5D-JVY9>>UDF8),:^K
M667BX?/2:RA2JEBS&$V5D=/>G4?;Z/'1J3_E5)9N?Z19,CWNX::C=;/\9LX?
MF(C&8X<<L<L(QGC.-.?'CCC'MFOSX;G\C=SIF<OI_K\,9Y_3#>^V?"GAP[A:
M=O#AJ?NB,9WJ/B3'[Z)^WZ$[IJBNGX_;FNAE4
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MFT'B'=;UO*9KLSSGC%=4\:Y2:4?*+[O=(<^M87+-,U=_K=6JGHKF(7 R*
MBXZH6:<103#3!!)9FY@Q=F*52R,3C!D1N0Q^RE*<GR?$,G9)DIB[5B6&HW&:
M3.+KR2VDKOY?27*IE1F=ZGAJ'-TKY9EO*FWJ0YORXAD3.NSAE24Y*B#$[,91
M-C9X*]-C,CCUB$0I:^R&11>+KB275'+O-5+KS-^\:A/9,B 2@@ "+CI^?U\]
M47]N%3^H_$ "4<   ''\G0^/#UZ'[@Q6[<6(SG);,Q>C"E15J1<#U+7U:"M5
MZQ5&%7#TL4TWK<>Q/J8.SQAYESACUXA#NI5,Z^NM.\163MEWP7N'3%F54+HI
M,6!21F:5RCSTFLJ*="]'NCW;7N=5F]\7_P#7X8>OECCV3]C5;]M5&KIC41QC
M[H[X]7>\CMFRP^9+A2YJG-A,@RYC!]4X\RNU)B*RF*3LQ<'YI3$>OD<R0':<
M$A\"[M_3]Y&;=='1H;O\1SC37(F8^JG#G.$3,<LU-@UE5^/RM7X(\N4=_.6S
MUK_-^'\8U[>K@                                       $5O5B</
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MEP=$B[%^>JGW5R9:Z_ *UT]=&"_DJ%Z@
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MH;*]_O:F7H(M/OD0UEJ8JHB6\HJQO31R<X+P
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M<*BHC4(;GMY5**6^Q\GO7=?1P#7_ *4>O]G'(G?K[]7]KG=P6NO_ .N\P_&
MDT <=7^?_P"" B@ZDD#=IW:QBA1229QBRV4STKBB-J? ;%M^1L-4<1FL3<Y2
M9O<?YWF4=_3@>OO%V+Y1T:33T:F]-43.-,1&%7\[/'U>:>U\T_/G<=QHUVET
MVAHZL:)F?:ICAT\JH^WLR9VQ_M)QXO@<.7N3YG"EPO1MEO*2<LUY(M+S4&V)
M"YI9R,M)!SQ%Z=!#MS\6:JG4ZBU;BB;?7V3CQR=0V3PG1K-LTU_<*YMW9MQ.
M&&/&(_5J>LKV98A.JJNM\S,? M2/.V6CT^$I;QU'DI\8^(NJU?BN)KHG&/9M
MX<L,?8SR;"_X/\/T57;==$Q9JB,8ZKG9_2Q^MJ3M)VBX?=4.??$.?(J&S<[F
M:/)K;1E&>LMFZ@:71(D2&K)BD#;SJW15=^G4:JO=$L\5_-#Q/O%5C3WZZ>F*
M,<J+<3U3$=7X,J<HF(SP_6E#?#'RU\+4V[U[;Z)IO=41CU79RC^G<P].#;L]
MEN$M-;QY+4GVZJ<RY2OD7'U'+2,Q%J?&_B&C6VZXKIZHB<^FCLGETIMJ?!7A
M^=+73\.<)P_%<[8_GL&96V.8$6RS#W>8W2^=,G4HKA.CXLDRWETB0Y+3RKK)
MS=G) 1KFBT7U92F_._ )+L'C[Q!3MVNBJN,Z:/PV\.-7\S%"O%_@'8:]?H.F
MG".NOG<_T_\ 4AG+^Q%M@OW*KRK%R=;77<UT62::WZ>W_D%<HJ(B^ S$1CQ7
MXABF8Z__  V_V$Y_[(V*U7U5T8_UKG[;JI?M:V>P>*/\HD^(\;HF"-,;BZ.[
MO(T!N*=M;D26I8L4JU;TJ7:4E31KJ?Q\-<^V>(?$-=^F/B85S5'X;7;_ $?2
M\^Y;%X9LV)FNWPC.>J[^TUMZ=<(VHY7VQ0>2Q3'V(9@O;E<A8GYW*&Q]:N2.
MZ-[6*N3=#7M_/DM\E6)*N/'EKMKT"3_,74[C9\678KFJ*)IHX=.7[JB,IB.W
MZ^[!&O 5&TZGPS;B=/\ CK_'7^O5YDB[=BO'+/Q:H#"VO3^;HLQH.WMUY)'3
MJ.=1N6OBU5$U51&675Q=*O;/M5=5$_EXRQ_%5EP[WMD[>D24TTITR>S_ .;)
MDUCL]PA@N7NGW:?K>J;&%R)JJY]BZJ.NGC66A?\ TE1_@I,645W:^%,?3#-?
MN6+=O"J<O-/V-1=\N)6S-VU+-^/W9X>V!,OA+J\^:1Y54G7>+&;/M&E35Z4:
M+$"Q6U6[*I.>G-)C.GM,A)O!N]7=E\1Z>]=CJSFGT54S3/")SIQF?JYH=XZV
MF[O/AN_;LTX53\.8SC/"NB>=5/%UG3_Q4UX8VA8*A#.]/#XEI@S1)JW![O\
MCJ.8E]BF2*4J4N-*1O0K'4[*6QP.FFUIIKJ8KXTWBYO/B747K<=,XTQV^S31
M33$YQ3[V&/#*)PGABM\";3>V?PW8MWZ,:L:^<<[E4X93/F^[)N/W3UTI^55_
M\(J=/3VGJ0A>HG5UUV+MFU[%,U=4=499QSGT\$KLV-/1,VJ[F-V?YL^?MP1
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M#=TJ:-:^Z? ]#J[>';I^$12C]S-%F.R4WMVJ--U:F?QX>7U]B^%60
M                              1&]7C/L3P]M_A<<?L^MF$7?)^9<=1]
M(WN.0)1B-3DZ+I'<U\WQRFS%"F]>_P")$$@8TNBF0I^*6DO ,[7CZ@,F]+&:
M+9[L]B4A4Y%<<G-U4WRJTQU]7RF4Y'-KB[1/GA%'X<CRO,F]MD.6D,,0)O+T
MTB4)R\T*SKZ $DH  C+Z4G]W#(G[76[C]?$P 2: *:_FG\'X2 :[9U=*$;,S
M6JVAT<CM2:/.]^^B;*EJ*P@9W]&N5FL4_,1_44Q\1O-KB<*IF?9\OY7/O&%[
M257Z:\.7?V1$YX=S([;/8<L1I:R?V5.=ZT59)5#HWV5%HC+C94IR55:5EKV>
M@>#4:.JNY,S&+>;7OVBMZ.BF,.'?'V9#N_-ZUK7V&&51]*[*4BBVVK5"A.M1
MIE]::YRJE4DH6T&J2TUF1G:+M[?=&"UH]-.HIU-5'5-,XY53YL.,0]FKW"S?
ML56:=7$8QA_=X]DSR:X;9\13[$"S(I3/*D0GC;D";/N2+J-CBUV/7VV3R]6E
M6.Q$I-\<^:93Y8^5LZ$>G:? ;?=]9H=SLTZ:BUTUT1$8S7.<1G$<N>?;RQ:'
M9;=C9]15>_.4S3,9Q\+#Z\_1AZ&XA7;9E5W+M/93QUJT+0O7H>NHCWY'HF)B
M)C/RYI5^=T]==>%R.7*6CNXS)DRBN1L?MK*WP"ZD0W;#XT7)+(GQK77G%74M
M9E2922%C="1-YH%?R5!ZGS.A&.@^&MBHW"Q75C.<3$\^'9&.?'G$XN3?,;Q'
M8V_Q+MU$W.V?=GG-&/X9;NH;ERXCLU7Z"HOUVB.[;H["^'L[!!+L5T4SW.OZ
M>[IZJ_W<^UZ7E<A1*.9!A,IA<L:DC[&9,Q.S*^M"PBJ3.3<M2J$BQ*H+A\BN
MDS+7T'[P;7N%RQJJ:^%=,Q./KRP>3>=--[3SAV3ZO.TKZ:6(<>XGVI05+ 6!
M.PVY.Y2&3OM5-Q2HON3P;XZM!JEBE6=5PZR0M=E/V$6EHN E?S/WB_N_B?&<
M)HBFF(X91T43GE'&<>SEYYB/RUVJ-N\/SVS75/T53WSVI#2X_*+T]I>]_D$/
MNUU43%-,8XI]15UVW*+UP P)G]HGTCQ-,XYCID8WV22AG<XU;3R%]41]K1HW
MYM6MBAUK5IF]VK5&W&J*HD_+ZJ#+@9&7'VZ"[3;KCJY8X</NGZ<FBW[2U;CX
M?JT]'O3,?V_/3R[\^S-UVVV/Y$B&&H##LDL<?8Y!"XZQ1,[4;?%,@;%J".LJ
M-I3NU"E4WMM22I>:,SY;NGX'K/45U]VF[5/3SC/RPCRY]E/#^EJV[P[&GK]Z
M)GGC^..^>7HCN9_JIJ,J::?3V_ >I>YH-3\&B=#\*.'_ )L4@IFF-3-6.>'V
M(^(9)Y2KWM9$>;^',P-<3DN-X;CIMFSM%4MF+&\0U_FCLN4J5Q/AU4LJU,[V
M>54$1\R=W303/65V+GA.QHZ:Z?BT5=6'/#JJY?UL\^USS;KVIM>-KVIFF?@U
M8QCEEC1E/#NR^E(=9^;]WK,11T%7<I[U!E[@#Z5)%V *@   1!=3[9/E/>+8
MQ"UX]7)VI/ I&H?W1:IFZN.4W24&CH-(D:T;(YEYX2-*?*+STY4S,=2^5WC&
MQX2VJ_I+LQ%5VJ)X3CA3-?.**\O;RC&,)F>UQGYF^";OB?=;6NM1[-%&'IF*
M>VY3.?3V2D]Q^VN#7#8NWN]JNRZ((\SH5]BXXU/-5I>E;4B9536[<D@N.QTU
M6.*@RI-0>IZ$.9[K,7MYN:^GW:[E57T^79Z(=,\/6IL;/:T%7&BF(^CZL/3/
MG9 &%ND:_59109?LGR:U3\[]3,\/N/VQL0IK+!>L.<O6SME*)-JXY1*84PI$
M*^54I>94J'1&24C.]XVM/ / =+>.9@QQCF3XNR7A#"&):XTZDX/%S"6:)3E1
M%[<.R9$M=F&6(YDN<G*,R@XNJ;EYDF<U35I?^K@)9:/FE\/X3 5 (N.GY_7S
MU1?VX5/ZC\0 )1P       45=M/O_C(!H]O-[D,:<5;@TI'1>P1DY@=I*HH,
MN\6,IW>I@F02/7_1D#:\6G ^W@A$A\-6J];N%S:8GV=9$8>>U357'9SCMCT\
M)A/C.U$:"UNU']Y37ACW8TQZ^[FW/2U472IN45>):O6:;E%9&9EPTUX\-=3(
M1OKB=3<F?\.8CZ<8^SO3"U<IU>WVHC\5,?5AYG:B]F
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MJ=ZKIU4:.<KG5AV\HSX?:R3;[W;KW_A^#X!X,+<U=,)#3,3;IIJ][!=@L
M             0X]2K;S/\ESN#3G&>\_$^TE\N8.S#A%Y5Y.)+X[Q%\C/N/Y
M$L?86KJE4:J9WZ.N$(2D2@BJ+NJNW70@&8^G#&+[##L_.CWN3QON>GDVW%RJ
M4Y"F^)T"A#"&&7^QD$9_8UH2U/TCHU;F1H2*5?@*C+FEET!@CJ403>O,\U;=
MW+;PUN[[ L:VU&0(Y&6Y"UN4(E>XY-*FEFC2;<%4K?HVX,N*X?CI:XN")2E-
M5J[']/8O'9L ,6[)MLV["%9AF#D^-<VPU*E.!,SP[-N9).]E/8YF;<1+\R*Y
M+B;+,2CRY^7H'Q!CR%<T7CJ$S9JE6VF\^%D!F;I3QR>1&<=1^/Y-R*>5YRU[
MV'"T_P _**-<)]H+YX:Q6I)0<59U[@VMYDDKIL_0=O=X%Z0$QP        "W
MK,M./9^489KZ;7QOQ?RX+::8N8VYX-)<35ECG=AGO&MTZK#1DUJC&>HG:/3P
M2<:DE,%R$F3D1%I42UH;E'H_/B4ZRW%_9[>IXU4Y5?3&<_1'TH7LUVJ/$-S2
M?APF?J]6?;R;O6[E%SYGP\"+\ CB;*JJN[IPUU = HD+"F0&[J7IJ3-%%SP:
MW-0YI;+93>._RW@5*JE1)*:N\6FAF?'W0';)UB=9;HO)KM%^Q=M^):OVC*Y9
MN4^G0Z>W0!<>)1^Z(!1;46KGS*R,!8V%Z%815I5=A1;.\HMG<LW*;UKQTADF
M4I_DZD1T&>FGKX^^'7VY/'+B)0Y67UIK;T%V^F7N%+HW5(42E+IS"56I)62-
M*KIJ/B51EIZ> "\0/+2YIJ%C:Y('))>+Z-:WK$RY'<]):*4E5=!G\(#EMKD%
MVZHL65*:]?1U=Q78M7T]VZC,Z>8T5TD9\MV>GAV: /J5P0KZ;U:!9864)U-]
M+=K37+-\K2M*9$I3'W3/141F>I'V?A#L@                       02]9
MV?V3C.)\95SMABZ=OG$0S'(X=,L<XOR;'<I1Z(2@FGV5**Y!RGC?GEC<N66G
M#ER.I(J36=+Y\. ;G]-UPMR[;/%L@+Y#9F$EDSO)Z726?9]C'&E^\WL\H>$,
M>C#8P8F?9+'TD5AJ$O+VFP;FJ,DA'J?$!(6  (R^E)_=PR)^UUNX_7Q, $F@
M    #B,J==#+XSXBM.<=4'1$TX3P"HIT,B+@?O\ '[YBWJ^)E5&2VW;ILS[.
M2JG33MU,4JHC#*,UU--5,>UQ65RS;N:5UTVZ_P#F_P#@%]K4548X8PLN4::J
M?WD9^G[%P6M5-1%P(]-/@T_(+HRPE;-/Q--$4^6;QD_82EL-DD9H5FB-X9US
M=S=-HKO@DK2W+9W^[494GW.]Z^(S;?[%^*IX3,>MI?%&WWM3LERU;G">B8Y=
MF';Y8L)[6X(<)QO<T<S<//G-0Z$9VJ;))2X(S34EKKI3RG'4B$D\:[WI]UUM
M,Z6.F(ICMSF<.V([$'^3FPZK8]HKMZN>JJ:IY1^M/955ZV0II%'.VO.:0ZFW
M9E:*T7C(C.FRAE"!*1:-3J>I:J^!\HH/4TIGZAHM/?BW8Z+\8TX9^41*5:[0
M_EMPG4Z;*N9Q]&7;,_H8 49ZCCCG.#,Z9M>*%BA$HCMSQJ$]CDG:1<DL)(L3
M'H?>04M%W7U&8F5KP_<IV6[>KP]FF:_1&<?BYQ&>3ENK\<6=3\P;.@MQ[,UT
MTS&?'X>?^'RGOY-U;9]VFBH^-%-/$O?/3W^TQS.Q;N4ZRY3,Y8Y/H"[$W-13
M$</Y%^/4H                @OZDSIB]UWH;+H5DS8V];RKC#C7<%E^+^P\
M88I5.(<\1I5C>'*FUT:)0N;H>\8YDB";735IE/UHG9&@OV.-DP&ZVPMJQ,AQ
MW/7+$>U]_P!I*&09:?WF6XID;7&(VM]L?(HTB6OR2.0M\=6!E0N2!+:[J?ZL
M9G9\?P"UXAOI<M>)_G: *+:?P_\ ./W/NX (P>GY_7SU1?VX5/ZC\0 )1P
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MO\EPU.'AU3R%.G/58DO>!^D6 $G/1 PQ+=O^ =T.(YBYS>3N$.W^[F$22:Y
MLNAOF0D!*H>J.=DJ>=.>12)YJ6*$U].?*U$?#B1@)J@
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M_P G9$39!9H1!<>;>L<YIEF829TK,\.J5*_Y-5M<=A2*/<I:OGS#FEYKQ?\
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M;?MQ-$7:>$_H_1_*U>U:F;%[^'5<8G+Z,>SL[V:R[*/@_P#BF-<DZH
M         $//5\L9V3X98I%CFQLY?L4,JAWHS=!]VD*;Y3=D;.KMHKB,L95/
M3TVQVJ4=U-=+D5'UE4?A$G^46@#WW28Q\@@.SV%J&&VXM<8GCN\9!A\)<L?3
MW%9X^8'HZ4],428]R)*YH]0UE0+4-V^E36%1-A4J-4]FDCU,)%97,XU"&],Z
MRU_8XVW*G5N9DSA('A*RH%#N\+$B%I;$RQ9W**G%R7*"L)4Y<5!\/?#J8YE?
M',R?I/%8A/8?*9+"%9-TR8(_(FIT=XJXGWB)+(6I&MJ6L]1U)KA$2@J>/K[
M&@?3[I_V]=437T[XE'WCP?B#\@"44          6EWO]RKN:]_\ R_E :3[8
MZ"@&3]R6$:CY9,T3[[7(6GN&?@>R&8+"MY5I49::<DVSA*Y^KC>(23>::=38
MTVJC&:J:9BKSY8Y>?J[>')"/#E/Y3=]5;KR^)53,>C'S]L-UJJ>]W#(N/RO2
M(O;JZ+MW^K]2;7(_W5JK]7J^N%Z,BH
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MUAQKZL?1"88XW[D<Z>GZX78SJ@
MAPZL^+W2:8S1RW%*"=RW/L?LMUIEAV/IW,[$JL8O\_2?:%,H]AR,3B$EDY[C
MO-I$_P"D_5.<YCCX/@7@V&Z:5U\5;3H:I=XZ]1A*KEN2+L>:)-)'21S"Q%RF
M3PF9_:U4]/<C<6B4:4F2M 2H^4JM=EGC8(/=[DMFT0W2.4/M9#ETA3P:-KV!
M>[X_9F&!V;$F4QI\121I(IJX19PG\61FXI+1*Z69T2<TE+P#,@'CL%=/?$.&
ME3M2^/4AS6T7<:L&$8?&<OH(9(HW"<*1B4*YC'L>(F9)%6Y"]4M[\L*]4O<>
M:5J.43:F7@D9ACGI)M;<Q[8)LS,C8WLK.T;K]VS>U-+2A1M32VMZ3.\S)*D1
M(D)5($J.FGCI8+N\?<,!** ZAS=$;,A6.CE>MI&YO2J5[@KNW"*PD2I$]2M2
MI/4OFTD CVROU2]G&'GB%L;]DRAZO35<:9&KC#:K>4+19-4:,W*0J+=!4MZ
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M>W]+)X=U=.OVR+D^]:R^F>/"./IXLYE21=@\;>*@
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M+JR)&VF9O3=H9><*$Q*U:;PO'U,O&,-G  !%QT_/Z^>J+^W"I_4?B !*.
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M,@ZNJ#'^:LPR&>K,FHD36OVNP#*N1H[;VBG%]C6(Y^]R[-NW::8+B$7=\>9
MR.K=Z&^7,4J<FOVL=$R%%4KN6%MM('ZC@    'CY/'VV2M5UH=:;_)*.-PK"
ME4D.[IQ,CJ1F59EJ,NW:N[M]?QZ,(J^_+O>#=-HL>(-%.GO>[CW_ +5+$D4:
MDV)9/8B*.U<3PJ56SKCQW*U-\FF3)2I-6PEK5694.:$N82Z^FQ=(;/4:BK<L
M-57[V'F^Y#]BT=/AO5SH[?N3.&''CQ_6\I;#=\_<^/\ *-.G[E
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M+UGIV"&18H^-^9CC/G[,/+)/JZJOA? CWH^_'RS7(O90
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M]7$^ AU-%<:;H_%'WN@Q>HF_U1S^Y=#*R@
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M@                       ",OI2?W<,B?M=;N/U\3 !)H
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MFT_Z\ XRZD>P;B1[PMO?>HM>+<_VEQ?@6A?6/T[L(!]_Q*-@7SO[8NW?N?\
M[HQ;\//@./\ Q*-@?>HMEO'VZG4?YNW]JL6\6[\!KRJU]X@')_B1;"__ 'OM
MO_\ [1F+^'@/O^)'L%T[_P#;!V\=S3\]]J,6Y?\ ]*Y_N=@#[_B2;!B[_?WA
M;>"\*WXEW_:C%OHB]?Z?_E <7^)3L#_SMX^W#W/]JL5_&O <E/4CV$UT=^C>
M#M\NTZ_/3Y-B]XOA[J\R ??\2/81\W^U_M_\3]Q]ID8U_P#MWJ 4GU)-@VE?
M?WA;=Z#M%]*7VHQ;6U_VX /J2;!J::__ .X>W?Z/M_VH1?U?^?\ N@..OJ1;
M!*S*U_;$VZ55%67R+>58K?NZ^Y23AKZ?4 ^_XB^PHK?<_M>;>Z:.W^L>,6;/
MQKO0+:KD3/<K%$Q#S\DW\]/641YZC+WNWV^J6&2,Z]B=+'VH1ZQS;>\HS1JT
MYJO,"X+D2O3AZ_2/99N],]41[42\.HT\W/+S-:-MN1ND'M-JE/V'[C-NL3JE
M]3/;D-N]FAK<N<Y*E6338+SF0WC+],/3B-OXB\<[_P"(J8MZGIJZ9QB8BBG"
M8RB?=B>&/-'/#_RYT>P5S<MX^G'M_P"I/J;,+-__ $Z%MLN=W7;7;U%P_"+F
M<D0.[\:M<(]HZ]TIGJNX^B:8]23:W14UT]%'E];6+'LQZ+6+)8[9 @>5MI#7
M)I#;7VG1YM9#8G>TLI5K.;5ZV%C\XH2,UO$^Z1&781B1Z[QCO6JH^'<JQI[N
MFF<L.<4^K#Z,D/T'RTV+;JNNW3CAV]<Q]=V?M9SKW=]*^NBHJ\X[.ZST\3N5
M/N.JC]\S,]3,:FWNN[7)ZHJN9?ZC>U[5M>F]G"(CS5??*W+=WTJ=*RJS?LY+
MP_H[I^TF//"U/CIJ=6F@O_B7B/\ SKG_ !1]ZV/#?AJ)QBS'TW/VG%5NQZ49
M?_G?LNHN_P#C'[&5H_A[U0I_$?$7^==_XX^]EC9O#=.=5F,([)N?>U5F=KHN
MSW.$>SROW'8!;<@Q93'U;58BN9XPS,MA1$%)K&A0;"SNA(:JJ*B[3IXD?K&_
MT7S*\0Z/;YVV*HZ*HF/:Z:IP_I=$SSYSW(MK/E)H+V_4;S3C%5-43ECAPP_S
M>S+AWI #ZCVPFBDRJW@[?Z:"(B(KF3(N7 O1WC7$(73:UM%^=1<C]S5R]G[,
M\G1K5$?$BS;CVJ8^SO<M74BV$T:%7O V^4:_FSKR;&/I?^WC,L<?^)'L+_\
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MGK(BX!M G>$"R\K3HUB17?;KUA,NL)U:>^H2*3X\LK345?4U7'L,!W8
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MFSA),VHYC$\I-21$_.#@=+;!T:K5>X)DRM+YER'[R G3H^:7P_A,!4
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M*B38Q/"Z3<@IDU_*MAP^R:-?;LI6>VRRJ0>S'VP5+#1:Z(STO<@7+>" E0
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MI/A^^'I^$P'+X%&O>UN:^KOGZM/6 IY<OW=__P"L+\H!;36;=PZZ2^5[X"Y
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MH6$TYW[]=%IPJNE:UH.Z$H0
M
/                 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>sdgr-20241231_g6.jpg
<TEXT>
begin 644 sdgr-20241231_g6.jpg
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M^-;9##L43[NX6EASJK=74UGR\Z2K<;[7C%+*H*DGK3U((9O$OFA43)4F),?
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M3;V?-#W?A&@JH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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MLX^_W+>_\_3Y7M^Y0:]^WS^\/Q4%5 H% H% H% H% H% H% H% H% H% H%
MH% H% H%!3=9;>&EP:T&GAV?BA0/#L_%"@U[EOF]\?CH*?"L\WP?%0:^'9^*
M%!IX5GF^#XJ"KN6^;WQ^.@JH*;_FC[GPA0<.IETHWBLQ*94@<Q^)]'C/XBQC
M"&?374 -:\=/-4;>R_<Q-U)FGA%?N2W2> @7+VXD_ 4+%^S&7+XBV'  Z>2T
MJ 6U&>V_;:TI/;Q@IXHS]Q72LBO<Y/"/,S_G3<E@:5D@PM*SGV[$'>R%.$W(
M_P" %!$5XV7DG"[8[<DBQ5JI-\IE72[,<#>+.*["%YVR_)?FR9<D+3$.A_MM
M29N:THIDN[A2T>1[-#UW$1CMLR*L2G8CC279#4'$O.]19CB/1$8G9*8RL[W6
MH+US5!XW(5JT;OR@7\ ,9;&'.PYT4]IL*X823FZ;=:RV(YVN*.S^9&*Z$V/E
M=A;QH9$SA4VD5W/-&YEXD=XNB.EL#)E&52.---8;% V5S#F)9A+ &4"EL#A.
MZ2&H_P!F&G;$)%B;+I6V,,9DPRJ%(S0&'$DK.J+'495F">:Z>2<;'>;*SQ(F
MX&^;2SA7"F8[[[K<-V6W#?B#!MV=!G;<_FFXR[[W [KW9,C\.2$5DW<XK.N(
M+YMD=@RW!C/VR2A%;CRXH5Q1T69KV@1@(R";S)[>)+0YTW I@?\ 687FKPN;
M*?2?2U5R+LG0]N;W$,B0&6Q'\7VB,YT/) >,);3)D>.W?%MI*2Q%[?5V0H/D
ME@2(])X;,+<S+AILE36<Z:*IV T=RY@#(?=UL.1MY$9-.+7UN(W)1\A)[,>,
M:279$3T;2 FSW&TFL\LQI09<MM9ULU[M14P.Y!Q90+JQ$F0<2!F,Y\B2HDQS
MYPRAPNZ#IN0KND3FDC.-Q/IE(K)V@[N-ER ELHRWL18I&&\%@QE';R5@%>0%
MO)]:V6BQ4GWH677E,>;)F$U@,VC9;C".[=AT:) OO6I)V62+D+3@\)437BXE
M.39B6(:+I+8R;5FAM%=#5:[L8$%3+CR-EZQPRRMZV04VT?/7F,MYM(4T8^6(
MY\(<['?^[Y[8CNTZ#]MFYAS.J;K&$M1F_9'#->CEVH\7LP-B2/L9((B 3.H.
M57;<?-9O)U[F;UN'-C5T]S=P[<;N'O8A#J9KI$;G4+>E#TE-&<TAQ[?&Q)^U
M&:9;7I!DI=Q2O+DD;4X9&'D9XOF)FU!N%CN:3'B@$4XD:7R#Q;2/81*6Y\[=
M.*>.P[D"4Y7VC+TN]/Y;V4;E)G>$EN*3=NJU!LSSFF8$-*>CG4'DU#;<>#R1
M\&=%S-\DJ7WJ.;(4\1/'!;W;!O+Z:XZ"P>[/I,Q3NP>QR2%.9YJBQ\71SM/C
M]#<4<Y(ZR&6KFV<SP_MP\5/!%*/9A.]+S./.^I SVJ-AXN<(9RA3!987QW>+
M?D"X37Z:L5(&V+>)MR6I/F>15O?@A2HG[E=PC_668?FAZK<K0Z3@L\XRES>8
M[9C=N"TH\2R1-"3$]O%D@C:3L&XMEOR9[\P=.0^E%":#)C.E(M(,IYEME[N&
M-O%($,YII>JC4@,/9\B[+TUMG,>-K6&Q9QR.T3&I9\=F:PZ*U?=?:8M+:%@#
MZMQ?2RC#<S.Z-,3]G?<F6:!:2H=E]Q[=TYW,=1A=PR) RD@+$<N!'M=L=N62
MHIM]9-DEE6RK,<3>*+UV +C>.[)DSY,P699G1+AMOF;\#NW(;GI29;:/[MER
M$XH>"K$)*-('=N]'[4 F-[,Q.:$1-IU.9U!CF-Q8TG,YUA<+IF)1R6XL/>[M
MUH9$[0>F^S]JCY2Y57I^W [FY/:T%I.V>.G9/!^+<>"*X*2EI(7[X_8#;B*+
MHL02>!>56TDYE514<*FKG[DDI;>:#%AMQT$C= H% H% H% H% H% H% H% H
M% H% H.)%-)<W:? H4L.!VF^4+\SE_\ .=.\&H4&HII3P[<7)E.6LR>+B+@5
M+^!ASAJ/- '9WO?H-W$3PX\]Y@,)>S-E#Z7/CP_3Y.'#4SP'3V*"+>*_[Y'=
MU_4EVK?ZQIKH)5<?S+?:J)MBRL6CY[3'>'YON@''\-4S&YF/AC3TP-['<%PW
M %VH@/RK=/F#^+K5EEO+ W:S"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@HON[EHW>:@V;C&G98(^[^"@ULS]ZX+.YW?;^X*"NW)WKN[]WPT&[0*!0*!
M0;63_C]S[O>H,&]XVU1Y;H&(NM%+G!YQ]A,8<!YO)J 22R),HZ"7YFJ&W 2Q
MVN 2(CVE^9  UKI],WN+:WZVZ=\Z^?E*7?MM<!.+;\QT=E*4NN62DA';A!*(
M%7.12\(E#]HB;5%058E:"@<]8G;A_.!X>[6/4=[CW=TSR\L^-==/'2#T//%O
MQCF<4_J^,65XRB/<O*2J=E'96E-]%4(@GO+'&>.6ZOM\U)3MV][R(3?I2-X,
M9K3*Y\QV2F9(Z78FNO.2N ,)O :+Y YR%BX=9VYAC;NXUPO#:EN3<V]4YNYW
M,Y-UNXA7;V\,LS5V 7:ZI;"(G>PI@;RGEVFNW;4VX$6D-+3&<I'C!Y-<V'N8
M2&,[AS@(<-TDH0W^[;9&VCO1_0]FQ.F2>G _/L=(D&UN0BQER//%SC92NY(T
MZF#[=J[->*-)<9Z"C6'&DNEF>F%ECU@IX;<7-%L9'($H$L1%NRNWW/Z7U0Q.
M.)U2_P!$_=BAJ['CTZK3OM_@G<*GO':LELV/H!2%G'M\:CT>*TJX'"MDL:ZI
M-Q>=F2XS9>>34_!AQIX02JT([UDC::4:K/@G=BKP0U2.\)'C-[,.!-XT$[A9
MDW4N_8;$;9V=S%*NVXY(LCR4R?LTW:7.U%QKQO/C:A93*)2SI;AMM5LH2%1P
M?G+:9U&I$W8[DF)/,A)39C%9?>[%_//;C,R0RH$BR)=@D9%K9"VWS@UYF?$*
MSJ0>TGL]50CC8^K:>[LRN<43^8H1Q%,.8X&5?7L<Y=ZPYMM:K+C7=@X9!FKZ
MW)[$E:(8]W/O)A;1V\Z$1JVN?<E)[!VUH*L[G7,+"25##;'J&:#%<"_D,9O&
M*%\!S,(=2VH13,*)UEY!DHRU9SE5MOHY("^])-GS;C,<0%8<C\CMXA5E06IQ
M%,9:6G# 4PITGJ"*KD5!%!OI;D(*'K,T>))F4OCPY Z%NQEKK,DU_<HZ(2G^
M<&FVT%R=3\E&$=-C9E##WRE4G;'"S.EW:?\ 51QN6''(L+V66GX04VI;F/8E
M:QQ)RG<73K+%<MA4+0LQ(O5>ZA3"W#LD'6K24E%#$QQ^CGMM3"VVM-Z-5VQ5
M@Z:K]W%*R*GOTLQ7#)M^XQY;B4)3)*C*+*!==2B"$F6X2!'"=R9%8+7;7VSU
M-MA&].;V"@IDH#MGP,7;JAKS],1X*RARUNV:W2V9[I2L#W=CQ9;E;\8;7'ON
M"0G5]<7<VKR.9.>IHF3/J9''GS^.&</2IZHLXR?-\A-'=-*TPR(UST6]/!MM
M!->FV!FPLM-'<[NBNW&F9+3,B2QVZ04\L:XU^,[TU%5SIT^F945'+F2II1M,
M7K2H&;&Y_:$Q'YU9-C$CFX;5G U'-#>\QQS@[215X9&::D>.[-G:9MV./T^F
MF[&V0<:.E8%[&W<9H<60QCQ'1Q6Y/#S#:'G$6HPE"Y$EIL2;MUWVNZ;W=TP!
M:VR)8B^'MU*B?8N],ON>WKJS,6LL@1XEE&_$RVAY%-H*:@I.%03BN)"LPY<]
M]Q4 "X)^^H8J[UHWCK:^]HP3G>X-Q\8;&.H&X5MQ1['V&3\)/<RV]D/.QP8+
M)^9JN-'5%%=FI."Q&3C!3)A730VE>6,A>. 0N!LO?^^!W%^HQ$FYY:F62<,<
MH$+'8 D<I%[+@Q].W%-.SMG21(K3BA20&LQ&0HJ$>3(M*:,DGC&4V:2CN/&6
M4SV3.7R9*#S@Q#&,]1UMQG^-S6WS=@\(0;SCZ6*O(;_,[7=X\+2Z\LK)WGMX
MSN'C1_[>UURR*2G&:D6&;CYU\/Z,\ ICD3\F.S..?OX>Z&0"\Q%4A($4.]Q[
M;M]%W3".=4&1''&\(N&$-V3ODM%@91V Y6NX%O-!R>WUO<0T8?=6[K)F/MP@
MI$2N+#DNQFBY;!ANLR7AZ+.D*T9G8VQIBMV:D24FJ9*R-/9B)69.)U;49E9.
MVX]-[^.;<&E)AISK2^Y[70APUF1L5Q94,W*A L&$H<MM-8,P4$FM H% H% H
M% H% H% H% H% H% H% H% H(IXK_OD=W7]27:M_K&FN@E4QZ>& :^2HI\O2
M9T2\P75.Z?W6(W"[E]O[]VJ;O\+<BEG./.:4T @KFXKM8H"O%3=JJJ)A$\-L
MH>@VB7$# ]XR&FH!J%>CZ9U/966S6VEWK\(\D)0]X$ [F9&Z=LSQPW9A4G!N
MR;+2^U"'I(:!$U'IL[,<1*R-)L<MS*30E*S**4ZG"T\*&JV7#=B.):EGPY;+
M[+[\=W"RQ$7:<! /GW>]7IF)!#>0R((E*.E3J R!.C_NC:4H;G:6!A,I *?#
M,([1MNKO8S!C23E^#T27DY(>CQ6+_5B3>K&U:T"ZL7-%[[U*H7AF24NIK$([
MP4UD-.6)#CK<%)76.()48?8J]W$:CG)'&R%<E7;PY$*0TO$:=:FDR),J#B;"
M 63[TA,4LA_&53[,BAI?E"O<IN3ZBKUC;?= %Y2?F8MH6U*84&#H<B[9/,;@
M)O./\.QUCNZ/YQ1]Y*:?02C7F%8W$+BTW\2&GYEM1QG$K&F6(UAK-ZWPA?V!
M>H#OEB_<\_V]NE8#C9VSF#H@D9WNC,8V^3JJKZ##$00'%3K:<S(\A(45*K=>
MCB?;T,.0H>3,CAS'S%Q>\F32<)I),F%$,UNK/&,KRO%FUB0H<D6=B2>PMXFS
M%R."((@(EKT&6FPY-VNW>U8<4M8R+557]G9L41Z675*\H24$Q)MM-Y3JM:8Q
MD"X80B1:<(;W9WZBFYR'%=W[HHJQ/]X=3,C.LDNI.W&'MNQ+;.X7'MF#II@P
M@5W&SH6>%PMQ"=!/,EM!:)*Y<D8<^ QG(Y3%V2@R)Z;DL[A8GW=1E#LCPG.$
MJLV>8=1(^C#<\\;GJVDR.MO&W5/W%$8U45>-U @^T%+4)G>T6K#K7#9]TIKA
M()\HQZCF"BC>2SYRH9-37M03LO4/EM^(C2F;(WLFP9^2ND'TJ1)UOC_)N=OE
M55*D#J:D%'@+'O>E[;&SP4;$7\,2VE]I3NZ74$2S$V3=2F+.G-?N!Q/692>>
M8MH?3L;<Q[980>FY9T;G59G([Q8KRWE2DH89@>.=:9>ZYQ0\NKR.<06.F$#@
M9 ,%B09%*W".<+<JE\D/S;CN[94:Q3O/@;:2A[Q=L3MB-\MMA]0_<5&CE9GU
M:F0C("%+NW.<$+;UO**0B3+LUI?:(1CS.Y29-YKQ4X2RG")(\-P39[*V4[=P
M'1Y*-6>8GEIDN=(2)^!L-I8>^YA(>ZS<S'Y(]T8OEKG945D+<^AM9W%\151;
MR"ZC.57()6<J2R^+AQ80H(-ID@O=XP=C&SG-$[/WD%Y3?71;W<.N=,:<H;BW
M*]<N[=<9VT;"V;'034E)85VS,)DZ16@2$RVPF>QYL9_E"]M_,T$['3#PY3&Z
MC?"NP6W]TK8V'JC4VSX8D3-S2#N.9F(SN&(D)1MGY3B-D;L221,Z$T,K3S,G
M$H9;B)5$.*^+*)/Q,F,R-@3;T"@4"@4"@4"@4"@4"@4&P8_)_,[_ +%!Y7Y.
MW2[ID"8)3286G_<%)40J"8@9Y@?Q^/3.=;V]DCDX)#>DY5;S(^HR9]F*A'<>
M&S>!)P%_7PJI;](=N&@ZLL;M-WN S-R=?.VX!,BB.4:3U#I\2649Q@\X]WT@
M([Z2$=ILV0S8,@;9") 1-Y2Q0N!9+]:E<W/_ +#09#0/N3WS+NX..DXZX7NM
MS\YY%G=KSOM9>"";2X*B6*&>P[E>)WD45R35U:XJ#WN3RX+!8T:%5YW,7_8:
M"0S:ON\W(/\ W9S;M-W*1)%D?.J*(@C>7""_%3Z7G@E+B=([@<B*63#0+B$E
M"3.)WU=U_P#"#+P\E!)SCR>)CLO^[S?AH-V@4"@^<Q\P/=^"@QXFK<O"NWM%
M5%V7)$;S2PI"-G739!14+05<Z<%VG?2TJT!/GN\;#P0  TUX<*V=AT>W=3\$
M5]=/Q_!R>K]9GI5*QIVI_+/;5MPENA@O<.AI2W$DCMIV8UA+];E4P@I%16\1
M#O !@3:1I:H$Q(Z\>';YZ;[H\;:8B^*?;X>9T?K,]4K,=OLC\V/SUZF< L+=
M=FV<F&C.+GD9 .0VBOQRL2,<[L8,:+D]&BI2+4YZ&4E6S.\LGKF,U;G-K)!&
M4&ZAX/E*B@3'0!UG6<2Q.J; $E2N>CIFQWN76F9BD60X?1MR).#7&9VUNJ58
MG+.?)(;(0Y(*&#!O!F;:DSE%-%644X@WCBJ7N*%% QF ;0#Y]JO58V[;N'G#
MK(9++GIB'MP\-NF>X&6)8C8NV&U+,9LI0;"<ZEIJ+20XW+@L,(N5XIM^4J?
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MFF8FVQ'+&S,=;Q15]7.-T73ADQ"*XCYHCB3,1Y2Q8LIC'\JX E9H% H% H%
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MW<ZRQB)93;B&R1YPUG)!E+YL(#98.2\!L +X;:]W^U3<S>[6WMPE!KNY1C;
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M"RP4(J:87,*955S9DXZ5M.E3(B2#0!N"X. \1K*;8]:%PZJF::RDJ0H% H%
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M<DUNX\;?^3\W_C?2<?<J!L^)D&X0  T ;@'6T $.P>^%PY@MNLQ=X+;M./>
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M@S 2-S!Z-MB1'=;N*:1MFJ;4@@M*TBL=")7\\F9RB%:<N;"6ECWKBI\_]$7
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M9[9S^-\/]%:J&MD2/U\DDMZC*$V<AI:>)(+[>8\^N:@GLH% H% H% H% H%
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MGX%(R2E!XI!0R;N#B;N($"F/!KY-*RW6;FNU[?Q$E-GS0]WX1K1%5 H% H%
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MG0LN'P.8P:<SH(^S09%T"@BGBO\ OD=W7]27:M_K&FN@E5Q_,M]J@KH% H%
MH% H-F^\+1U[P>]PK6R?^+;Z?<,(6;OFCAZ3RK;=4R-I_(/U#$OF63B[$B\E
MM5-3SALZ52UTVXKA$@"$I"E9N4,?OD,/ *Z&3'=\J*\*0ED\_9#9<9M-7?4@
M.I&9;102MQI4<"^>+IZ43P .EHB9&T.:U ?1\ !WC(\  ?)KV8N5%6#F/+-N
M]HKCSX+W?MUVIJEH8_I2QIN3Y.[?-@ 7"!4Z%I^)&,X"/DS@"^;*YNPOK6Y;
M;R?Y^/E!$+,]+_9EM@VQ/W>RIP/#[7CM1/;BE=B&5!'Q&;C@L]O(#:5TAL%3
M1L14"B>G'E?*8Y?40YK-5^[W.3)9%>-/*G=VXG!,7W;1[0]\:Y-F7)PE/#@J
M[EOF]\?CJQ!W+?-[X_'054"@4"@4"@4&FM53EB.*:-:M04"@^4W^3^_0>4^>
MV_-[DZE\Q$XH<\B.N/78\6-'LM2(@LR1LSDB P3=##>!1B-_^528SSI%ND$G
MT10+%?S52-<QXU!ZM<?;?[8?!0;M H%!$+$?]]AO"_J/[8?\O9(H)>J!0*!0
M*!0*!0*!0*!049+PQV#</DH,0=RFX9&CA-NCQIBKNC< _D-9+1;'30)EE9WW
M*!DH:*DGDK%;[N0;3*3#XAS2DH\N4#NB'TH\*W=C=BOS1%U.7O\ "G\=6?\
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MTO4=O&'88<DZ9*1'KI'I\/1]A/?1F"WV^E,]"P(K>3L19/3\.A4D7T\;-=H
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M_70J;B7U*A&35Q7>+F;#H:[.2R.5Y+!=')W+Y0TBDL9\D&,BCAAY<+N6$,O
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M=,:1/N\QV%Z;C'Q)[J78<VDIR0ZG.W#UR1)<W.&WG(FB ]KH82?1+N_($B@
MZBCD-"Q41])SV_-JG%B^7DYIX]I/)<.(X+:FWIO.YQ))=SR7)[BQ9W%)<D+(
M%U>4I/529?FQ* <-C;81)B%@@D(Q82R63#3!@ -?&JR^_FOB(TM[=O<,?=DS
MBD(J^-RJ>]8 F&,",E3X\)8;*^^$)"((F5LK* SD@F5-FR*ZIC:N<XE9O1]!
M'3WV\B+L<:Q,_P !)1D\._&-O?#0?CK6Y;OGQ=WQ/X)\F(+(E!'+O294%II9
MAZ.S[0<^J.B8Q\%-_0*,3YAP*QP;4]%)"?*9:[_4=K==LL<W32*1Q\=/;VT%
MS#,?K[RP9#,IKN.Y"R8A#(Q4 R92VJ)<;;?1W J=X%!;M ;N("(%N' .RN9&
M>++HY8^.OIDJM+M\9\-->0YDRL%+8Z4J8GB71TWU"9* <RM@&<V3P%BQ4F='
MFR0+9K,/F]ZKM]N;KL%G/QIKZ=/)#,[YW"\?>#W^%<=+<[@>S[WQ5L(5T"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'G"ZY!! 4GUMDN4W2UX55TUMS0LH,_
M2 _YE8K6P!RK; W#249ADZEJ)MUR$%OCE -& $.3^@#,/"@E5V_S$V6/L1B*
M<I2PK$0M)M0$UWB\"\@+RFN+C/2": 4.'/K"X5K^4"T>T_A/I9KQL?[/08 -
M?J[R1*F,XCQ;M\;YM_)^:=Y --=X2.63RY."()*L]5!=-FR!)2Y21GH1=V'D
MT_\ -2H_G&?72@[7#W5W3974(WDNZ*S*3M6F9]R#$T=/XFIJB[*6>1XMCH[)
M"_ZXCTFA:BB*!%N**>4Y43)OFR?'\L%!P6R+<A&NZ'JG;PI#BD'>+?);/ML#
M=R_7AB.I@*W/DW[,)L;@27DGIJD=*#C-XA\< [>'LT$ZV/YEOM4%= H% H%!
M'')TC[OD'=M&\1,]R019&4GD'<Z$VUPMAY9GFBH,<?5FYP)5QL@N@G'#[A];
MY1*Y^6T+!B]FKKK.?XX[NWD:LQ9/EF-H7:AIX2H]D1G(!:^W'C.K)NW!<=,:
M  )J43 .?6#]VG L6 P9'CH%1R3E^&([=O0,0\SPW0[I0P%XO**&UN#C0CST
MK/%'#/.[Q3PX@$>,<[^CX_(G_P#](K/-&OVC!65UT8\D1.LUX=QWL!=IW3+V
MCP)U7)[E9C,9:S2$U(3C)X)CH<[G7G(>Q.Z5%5YD9!<YOGKQ XO.(DWL "8'
M7]FX!Y.MEW]T[3D\:Q-/#6(_"OKX=TQI+T$66@&MWGX_'7"0W:#;\2S\8*KM
MK;QX);@U92NB :QNBL>8V_$L[.\%5_,^7I<EH/D\VG'\%8YILG6./\#[EGIG
MD)7C)D+CW26<?>V)N)Z@LK"8GJJ:E9\"0D%#IPV: P?^2;$ +:> '$:W]E-^
M?X8C7A&L?9Y^XJY")WFMR T$UUK+0/,N]7Q83Q!)/J10^8R))PN5-IQJZ\E\
MD!N*&0 0'3Y0<?8JZE@R69.6-:1KK'&NM:3QK70U[UT.\/>U\G9[G_#6O,9?
MEQ;37U&E4>/4+><2L2,T);D>13<?+>=QHZ>SC)9W+K5S*-QM>1_K$4#U+Q."
M"%XO#R5[#Z-V'6M[GRQABMD1%?T>?C,)EDXP'U#*9'#54VM(B 98AI&YMON!
M8=Q;."DG&]3?->MEH\!TYJ CY=?O5Y7J.VZQL_F67VSSVS'^&D:^.L=Y#YE/
M<Y :9==ARRRSCF8.PLC'_K%FU'_]2>LJNG;W3DBR^&-VJ#WJ-]0>+6/.<*(:
M;"Z/)UI7(D/<TYW"54F\=-$153S<%M 5/IP<\C7<WB,CJ A]#]_ZA]*?2&'J
M6&;LU\VS-LTB-::128F9C7OUB8\I:F2VLUB*QV\WH8:)O I-EO*.(O@)X5!"
M2#V$B7[O@D<!U,*F@*6#I^:VZZ!PKY;E_5ZVWWNUA5-GZ0K(=:<I55.(BR30
ME# D+9I*4"J.K&"@'L*<L&2UX)2F),>!WU<=TS>#KH.E!Y$)>:KD2=XSA?\
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M,F>EG<24G/<0M/%S84\BXT5>?B&=9ZRWT@TK'6^V#*1:TPO]1-VY8-@5P<P
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MT9HHY>XLFDL%Y0N2OQEL&(2!0 Y$H-I>T!+E>[: <I:(<.'DKB99K=IJ=[F
MJFS](5D.D/NY,P,UT95HPH$43&W%^Y8/I64SA5$Y)M3#=RF<2[R6,5&U0(D@
MRB6'  W /90>6Z,8!G)][J(KF/;#"3TW,Q2GNE'R/&6^I5&B;&BJCM4H<[I%
M?B=[D3B9*,FNIO$.*48<38- 'T7I&@:T'K#QC\[V/P=M!NT"@4$0L1_WV&\+
M^H_MA_R]DB@EZH% H% H% H% H.K9W4WL9C(1R+R/8>LR"6RE/7";B.X3 _O
M02UQWO =]C0/P5%F.[),7Q&E4L$9;>KCW.2&K;7(B4U!'CUO9L.+=',*)G\
M$=-.#_[$H_<!,=/M'>%O!6,E]10"8=O,9\-7YL<7V\O\W:>WVD\7Q+&U7< E
MSK%#]B9^P"PXMA1KKS 8$8&HB>)\[A8[GM;(*A0XODY)3B-BVG_5WT3.7* &
MN4>8\>K,&YM^3RW5F.'X(2-XP\/%_P 3C^#R>>N?-WS,DQWU^]+H+X?26S4\
MOFRVF#ZPL9A(-UODK/%5%E6TUM*E"MMH"(6B/I6?L*V]M;NUVL6Y(F[]%=>V
MOI\)&(&V1B2.;?TON:7[&NM6V/P_E0<1(^;/8&LO<L3-JR8423A+D/S$YA])
M_.OH:[74<]D;>W';,3%-/133U>:->]GMG)X#);*7SXPS%L^,<>;!D#Q0RX-!
MU+Z"/9Q\]>=QZ1!+KR.QFDWS-YQ#;:.D&<N+PLAA/(%B^8?;$ 'A3)PDAV^S
MYH>[\(U(JH%1,TBHI$:HNS4TA- ..@U9BNK:3X.OKCD0FR5 ^X%E,1" W^$!
MU4/EB. <XCP+A<:NM#6X/-V4P8[K\LT&RA.MN.<M>:;BXD+Y;'D\+*92#Y50
MPVYNW0;BEUX=M6;S:WX[HF^*3Q]W>.S]E877<MIQ:UF@H% H% H% H% H% H
M% H% H% H%!Y^>IBIM_<XH$V[$#6GN8'%![MDB+WZGP=DA%(P,J0106VLEDQ
M\&IT(Z 2$HKE1*&$W_G:"6/9RWI :6U^ &U*V(F6DI!BQG([V+IAI*/$,*^2
M2K+39<J:0M$*ZT!TUY;T3CI@T"@RCH%!%/%?]\CNZ_J2[5O]8TUT$JN/YEOM
M4%=!3==W=.&NM8S,6P-F[-K\RSOTMNYAUY><J*TT15<CE4R""@(98PHK*RKG
MBZ>E)J>4L$R:4SILW=W2I.T \O9]X:LMP\D4CM]I-4?>9QRIOBRYB#&-NF%M
MI Y1)GY'PV&T24I\+7!J<+1\ C:H,&.% G;H"R8MYM3#/H6  UK8MOY)_J[=
MO056.=<M[58,WM[58>:ZFC,DC&C%F=DFFZE-)>$N@.%W%6"=1TXTJ%4&ZVT^
MX+@YDUGYD>:'\X'7C6_M_P!QN.AWY.,5GOCNF/9P]NJK1,EBO\0._P!SR=_%
M[O ?OUY[%=D_;332:T[O%:W;K^Z _)'R:5-UM_[7X?U?FRJQQ;VYEB.62C\4
M$4.2<;M2Q#*H8S\?N$LE$T\T)ODE4TK<I<0!$4N3R@6,:Z7>%Q[:W\G3=_CZ
M;&:+8UB.^WONIXZ(7G<+R;#1)WG',O(R"3QV]_*96%0L0PAV?KCEP<*KP;68
ML\NWFAC8Z=TS94$Q<+Q"V7Q+;@+I:AE(&&8US.=NE% L5-\KG..):]7(%ORP
M#@%PZ_>TV]C@B<D<TTQUBOGK&GE71,3W]Z&_IISIU"GU,LWHKS:N"Y)S\^YE
M/[2F^JL]+39 %51B1LH!H@0$>=]1^#Z/Y-*^G?5NP^GHQ1&.>6D1$4B_A_AB
M-=/*.%!-<)3=N:"W],0BBZ?P=*=*L(?_ )6>31[*^:X<?1<-\Z3-/\_O%B-R
MD,;OI0@>5F,W9C9]CI=#.4DI")H[8,M711-\KRQ;ZV>L!4$;70?2 U'WZZ/0
M>J=,P;ZS/DQ4BV9G]5VFG&E/"O")G4U84=+G91)K>C1]&=Q#M<:JBN!T&!:[
M71)*7C"'FP(YM71G!ZV*$[K=1%<*9J]#]<]=V.]V]N'%9%(G76Z::Q,=UNOM
M*>*:EE1;'D>X.693.;[9Q:!XN5)2RQ<]G'34>:5-!/FP$>S6X:^>3GYN,ZHH
MXF7(W/2>RUAE$7@KLHJX"A]'6CZ.03CITXC*Y4X25$NSG;! IZPL,ZCF#B&G
MLULX=Q%G&(F:^RG?PGA[1]T7,15CMI)K65'BJ/84C"6*)ZPKDDTD=Q)Y0L4*
M%DT;26E@V@!7M\NNE5;K+&6*Q%)[>A*YO=M[1_#6GBQTU/0M;(<-QI+&)/+R
M&TDMUX$J[Q")95 P.##=<-MW9;>&OYN%6[?+-L5C1#MK6::"RT,@W&TG8TE&
M3,7@D2&#*8S8<-GF 3-UX\-?/3<99NBLZI=HJ4*>Y;YO?'XZ"J@4"@^,W^3[
MG=[_ (@_,X??H//$_-Z>[B&-XDZ)3776O(6T@I/K&;$@R'($<2@XDK;@LN-+
M;2.JQ@E.%LNE-(\DH'E4F8_Q8:*E#2EQST'H;\3P\??LL"_L]SVJ#"O/U"]I
MMN2=;"\LI)\=MZPTVY+(DB*KG]3.A\&^5:;82?0?Y4+JJ>'EBQ=.YGO&>%!U
M@_U-]H"8GD#QR2CEFF57!SI8-)SY5V."[;72C:<2K)Z4! #T?HC>7#F' ;,*
M%H  Y:"X31WR;:7K+ PTWI)(G7:8-N--13EZ>I%V>Z%]HI8++N0&D]C-EK?7
M%QO(QK$:-EBYFX2Q8:##B%50@J]:C> 93#Z>>+#L?VOXQ,$#14[A#/\ 7V2-
M2X&BAN[6X/,(4$QU H% H% H% H/DR&+^\-F.SO\=/N :#QO[W=^T-YNLNS-
MI$5P1CR2,X,>"$G/,>,H56L"!(\JK[;.6RPE-(C=<"VO1R@E,I<J9,#H5.9A
M\?0,( 'JMCL?_HW7W3KQ]'V^L>LF&X@9L',!#C=CE,Q9%12^?Q3AW)XRVNK!
MV^TVNN9?.Z:K*ZX3XB8-&+N-UX\-.P/'X\]=[=;X3V[DKOAI:'EXC]WP5GBM
MI91"VSY?9=GDL 7%\BJLK)FY,;+=3[@RJBXK:#H7#Y&A0E:(Z&C \"H:B(CP
MUV-GM^?),SIIK/A$=_;3Q2X)J,!6#,I.QVJ.+,_ELJ!;"?*82^8@ST[7T=#;
MY<X%UN@ /I6<0 38A[M6WYZ7Q%OZ8E#>8$:K+'5%P\9D-PN8LOJAA9/)ZFCL
MXCA]8G"I,K<8YI$0DP]KH3#3CQ]RL-YN/F8ZTTC\O)*\(6V^;WQK6L_3"%0T
MO_2%9!0? ;-XR9?,8,WX\>$OC'*9R#^Q8/*/G\E+?BX"T37GJ)GLX :S2D%L
MN%PZ&,GJA,-&,YZT"?$WS17NZD^Z/9WM:M_:5MUX=_:ON2[NYGVT622N4G@Y
MT)L$+A^2<7U0HE8+] #\UYPW;SEVEW9AU&JL.*>6G&4,']T,YY'S"DAD(!90
M2Z[K&ZH94?ZPL!458Z 0*FK3)DTJG3K: #HD0R\KG+&NVN_T;9<^6)OF(LKX
MZS/='&./AXT2[/T]4^0"^TR'C<D-UCMESJS.;Q[$GLA&,I6 &SZL)%6Z:7QO
M/*'.NI110#.;, .FN;V!K7ZYR?.NBVNDTXUU[Z>$>NE=*5B3N9VCYJXUUL71
M21K62"@4"@4"@4"@4"@4"@4"@4"@4"@4$2V3H][/'9+6X27YL8_VPO&>Y>4)
M,S*"@INANBU4\VV&XVBC/*6M=<32)X@G^J,Q@#!@.:^FH)-6&QVU'#.;+#9J
M9C16FT$4@W6XDXLIC*">CI18"A,J!DY=<<N[E@ &HB(\/9H.Z4"@BGBO^^1W
M=?U)=JW^L::Z"57'\RWVJ"N@HR=@>W^ :QNMYAY[NL%O=V[[0YIVR(DN[GMP
MD0GY,7M78SH@6E3P3<4%"RRD&UP4DD2O B>/NHX4+<P6$37F"NWT[8?.LFZ(
MB9IIK/'V\*_CIXM.]G,P(7>^Z,6I(FY[ ?2XB32R0H1#MH-*PJG.$"A8F+?D
M7<&K$@'ZZ/A0M\,P"-_BI*'+Z1XYC40U,\Q96V-9F=>W;UZG<S>>C^CV-DG$
M9>"^AMDC9BPE2)0QE*X#&<= M*)J2DE-3QZX- TP8 NX<.RJ<..Z^/AX]NW"
M33O>>#<!N1WL*O439V.(&<[;HK]>M9&C\JZ8Y!*)*C86$IM_:&<.*QL@H'R2
M'SW_ $@&AHH5_>]?7OISIFWR_2.7+?&D<W&O=/'C'Y*?0G#L.[Q3H7Y+&[MP
M1+.'A 8=$B+>?W1)M5,#2ODMTX;+KH^*;8GM5?PEI<A[P#O$R_8(1?I/^CV(
M\5SW/3EU,U$:BR_#CIS1,QZ?S-8020) >\,]U(W;>_)@7R[5 ^L*CG5VI):7
M@S9VNK^N?JDEI+>YU3Y(ASP9?T?^]*^R]3ZMTS;?2=O-9%UW)37GXUT_EGOI
M]X] #=VV1$AG/6QULWO%9\7QP6W\I&WBK!F#M ?7-V0D5N\V@!7Q?]Q?%DZT
MCMVT%XC!//A3\Q!$]7).A;PDN^PAXQ$D=N#3!GN2B?(:DP$->!D [ K3V^ZK
MEI,:?A[#@Q^AR'Y1C5QO%1<TM)#Y1WPX5!V*227CFUJ&,#@.E4@ES1-5*.I4
M]# DD?FX@(<?+QKH[G>[;=6Q9%8BVVG?PTT^RE3BR@"WB-NGD#CK[7PUR9VF
MWO\ B\?3[TQ.E'6G6UDAWH:@WUO 9RI:GB\(WC*&S)+/< =H :)76&[;AU\]
M;6UW>]PW<]ED1?YW13W=R'2HNA6/8<)GR# 1\Z.4/Y@S&2V155%/"&8<]YOZ
M$#QO)W0&\R.@A['LZW9NI;_=TMS6_#7QM\*>!Z%X "M*RVNL@(Z5EDNFV*P0
MUJQ -*TU#2L8MB/2&E)MB?2%9!0*!0*#Y#'ZSY?<]W[NR@\HTS1VK3)U0Y$?
M)>&5A9PQ//D?-?UPPX5+/!@+WJ=*;:QZ^E@'1.+);ZR^$[F_\8"V53E"F'%R
M]!ZMLWRL=_<^;DQ?L=!#S)?3BE"3)AW(R6;E-B-G%*[MVZR%&N!NLU3'.R7Q
MMD7P<<?&G84.GP3W,2<)R[+@5@[1#L >R@MB<Z2T@Y'!N$?A">D%/D;>NW'@
MS=U2@+"-9V[G:SO7R)S6)BG/?H9;;R&6RIY05'F@->-XXZ#07#C/I0([2<D:
MLQS/\@]=K<./N4)*CZ*#K6' ZE)P2^S3K.5D*0'4)[TYJMPFK&S!3EO2C9K-
MZ1^1"@MWLSV[0GMJZON\:/X'CAL1<RS.S+;,M96TUBF<F0R*QI^205.J-W>-
MY YO(!/%:/ETQ<-!H)XZ!0*!0*!0<"J+R(CC9:K+22DCG_)>L% H1'+Y_P [
MT :CY-U];K>"737G)+"8;+5I%=[S;S=8Z"7O5%AUJ"Q@QH1,B5MOONN$[K?S
M0AW-+<&'4R9,:66AQTJRW!,?YNWFC5ASE79SW@$QL9][QVW[:E'$(Y7MF(F4
M+<!+B.;U'^1"4H$P/Q(UU(E_T@:+ OB6'Z#!@UUK.8Y9IWH6U2MEDF1WN4CN
M5(B;6VML1Q$[%<T:-1OJ#==!Y\&T!]KJ*L.%X*SJ'O'S3W$$G+]/S/I?CY1,
M<1UK>OW5M]OQ3-9GV<-.'#3\YK5*4_'W[+;+KK/IOV7[M1KFY,D=W XL4)5D
MQYLV26HV$QQEE+,\2JPH(3++-LMG6E(4;DM4RTZ)VT2J>/-9>:-& ]&#CV5V
MMCLL48)NNBL6S/CY36)K]L)UB5WV.R3I4]F>;Q,EU=\*^+PLN?'8/(-M)$1_
M0+?X:@2"[YV?M,CV^SS<V>VV[DMTMCMV[ZB[H6VZ=GOC7.LQV;:VD=_;S)C5
M4'L5.*(F>:!Q*DI$DL@;4E W@(D2.$P:.GSN8"Q(I@*6C<9SF3-]PVE2UMMF
MHB(AH%878K]SDBRR-9_+T'!;5ESE#4CJ=Z''\M1N^5C&4Y_U:TWD@N(]C+6\
M,YF\JD'LF02EO#CV#6UEV6^V&+GY?@K_ $^^9(XKE*)H"),X< OG-B6*F#(8
M"_Y;,)70>6+6\.(CPJS!9=DRV[>Z:1=-*^GMXB-**NJQM>E=_K<<D<CW;3@;
M?K %3&Z&V:+^GI!L29E*)DR/K)>6%JTZ6TY<L5$1#MKO[WZ+CIF&-[=2EVO?
M7N_KFGVE63!N9)-=),UFCB&'!C3>5SY?K)*PBQ4K,7 N-P&OJ]R2D\#I+3M+
M\J5-#[5<W;X,$;F)ONIK&L5K$]U//U>HC35%ILZ@@?\ :-G564MQTX83+Q6/
M&;J&@(4C-Q#-HYPKSBMRCAD!JW<F+<._H\H8]%-<KA]'KUW7>K8\NRLQVVS2
MDUK/#A2L4UKY33QDT2^-3;I#K34[UPJS2J\Y\@=_,[GL:4GPZLUVG> ?K"Z3
MBFH@.G[0(!7@OW>2>T>XH[P^6A<[VN<;))=5&F74"N8EF-H&),Y@"!LJ:)FB
MP6GR"B1 .4,#IP\FM8QN;HFO&>WD:N%BJ./LL9R*S"CF<#A1V^EI**@@OBFV
MF$Y(1R@$BA0+R!%.$UH3+!J.?40&K=W=&2.WD+N %:.&VFLDJJV$% H% H%
MH% H% H% H% H% H% H*>Y;YO?'XZ"J@4"@BGBO^^1W=?U)=JW^L::Z"53&(
M=RWVO9J/EV]R:2IR7VX[+[O=\M96Q$:3P*3+%V>MR:!#N1&:2*CJ$CS.]-<,
M?P^V,H?6-9S@/%55Q ;@;+43P#TM0,^B@%1ACFWN2V9TI'AX(NF^8K35Y6>K
M.SH$2MS&W9U]02&9#W/309/I#W=A:+U3U'$C"B$162:5";)2>?35!;.D'7RA
MDVH&-#:K7TCZ1Z+DW?2\W+3C2*QWUNUGXXK'#33TZZ:]^2<<ZP].306)UE1F
M-7!'S?*;=H[,-9 QI:F["I9R2*21[DLI:5*)3>M/"WT8\0(W:!F-<WKH&@<*
M\9OL&#!EFVVZ+KXGPX:^F?129E=BQQ$<R[#"V^L1EJ'UE,EU)\/O)B #;^?I
MSZQNHX/#4"ALWJ11B6O[ 5+%@]O2M/<=2SXK.2RM/")B/#OI7[5U^.VM'1G=
M#;?79<29".S7(B4XD3):71FPF.1")HJ015>1!53"Z4*%<>Y-P\EAYH1N$1TK
M<V=^;'TBZWD_VYK=7NXQY=NYP>I;O'CZS9;,TG2/^'ULL,?= ;;=..@_!I7&
MLOC>;>:SWZ^VODZLV_\ V.>.'Y/HR6V9/D7>V'MU97EU6K6IT+1,DN3ZVIL>
ML\@Z?%YH7 40B>!> QP](]:A:!X>/#MJW]U-*5^[W)77JI"GN6^;WQ^.@TTM
MU[_O^[K[?;05T"@4"@4"@4"@4"@4"@4"@ZRXUE(;:(K.)?/%DM#;R4HKRPI&
M! "Z<D(Y0T>5C9P  /0B)(N(B(!Y*#RV[CXJ-RWN[)3IMX@B6)@./Z18>>S2
MD'!M"0C$+NIKG#3:."Z1W('WRG"*&G-7Q3!10%-$?V#P*#U88?F_,^X/9[*#
MZ*!0*"(6(_[[#>%_4?VP_P"7LD4$O5 H% H%!3?\T?N\H5$SK$#S(_[R5NE1
M8 @J($!+VX,#<7(K^>6?!C^LJ(7<2K&#:;1I&63R\!8F2N7D=/>1X03N8 2Y
M0R("&H^3L].Q1?6OZ:5]OW_AWC/W8S!^2=83@+</N$C\@S%10:Z.]XVVH)S7
M+,Z'=NV<\%QLF!./;28$5E]!=HH"HJ);FBAK-Z/@P>36S7\M8C02UV!W+?QO
MP>QH-<K+N*3IV^PHJ&ZVVT?UGN:5-MTS-)2M,]7Z*8<PM%J$?K$^E(/%+(_B
M^$12"NM_=6W2:M$!((EH\1#03)D.%H>:Z,<7:RBK&%5@)UJ$W,^4EI%4W4LM
MO4#+GQ/XJB8/2AT+ DMWDM22(FB.74O^^AKT4[W%;M_E64CX:4I7T]W'QU\Y
M3KQEGA;DPX[ [P]P/BKRMT_-SS/=$CAG"L^HT146;4P^K6)9 P?N3TSEN?.
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M#=.GHA%);]H_)#W?AJ_GM%6M.>T*F)KK 4B(C@%2% H% H% H% H% H% H%
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MIZ.Z-:<6+K^.Z=8K[?[7I%;K2W;N@F))3=;'B1+SC_BR/VN5PY\6'@ V\ZM
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M2=>T>4.[!IQ[^NH@'G_X:QPW3=;2'0R4HWZS8E H% H% H% H% H% H% H%
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MU8Q*!0*!0*#:'NA\Z_C]WEXZT'BA8NZ;JO/?KB[BF#&D&L>-#CW14^%C\B2
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MQJ!_:];&O^W<B_Z!YM_S&H']KUL:_P"W<B_Z!YM_S&H-/[7K8O\ ]O9#_P!
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MH,O_ .R;Z;X_*'9[#^O;_B93_P .UH*+^D_TX,7TE^SR& LQ_2^(*,:U]O\
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M;]_4&=;'9C7CAH-EALI#3FRT6<C)[?;* EV!811T9)+ 3)IA2T1N$+"16S0
MX_#0=RH% H% H%!A4U=BFW-CS2$YMMI+.-W$W&\'NW$8ZZE\_'3(D"1RH$7R
M^F3'YU0N;C:=CQ) . X?*E@N$,V70/I<XB&/<?2WLWR=0217:V':];I]DE!3
MMKYY0.HRJ7AE>7H(%8>*LPV2[!0[4%8D=M XC?K; 7-:_0>!VX:"4W%CLOL^
M79@[_P#S?$/;\]!O>%C_ &O'^X_J4#PL?[7C_<?U*!X6/]KQ_N/ZE!KX./\
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M?Z<,%HB',?KN%W;\=!R5!$;N-VA-&=M_NW9W8HC4R6:-\>":)2GW I+Y#"I
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D!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>sdgr-20241231_g7.jpg
<TEXT>
begin 644 sdgr-20241231_g7.jpg
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MXI-DM-7&)S='A\=(6*+"@Z1E=4969J;69R@X:"D1  (! @0"!P8#! <' @<
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M[?/!)IMQ:94WTMF6(H;?D#&C(!QUM5<0$]A2'Y\=*85 +36H)-V#'RX9M1U
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M3.RV;UJ>7DEJQQ^(N!^.);3!;WNJWA)-=S"3(IY KB$%=0]J,&/[' -* Z>
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MR6=GR_>"@.= * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MB,)R*AM"07PT%Y<(!GN/HZ&YT14527+B%IGFR!$Y>=)B%P_M@#3T\* SN@%
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M3KE,E'W O)FG"91B=OG!]/N.9M,YFX?RV3C0%Q6H!VCI0"@% * 4 H!0"@%
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M/%\!PD=)Y\1DH<*&<5N8L:*F<-U^$P7,8;[;[+[+AMOM$! 1 : ^B@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H#TW8_$_'X>J@(0J'3TVEJN=PGU"*+C:TX#X'\SES/5_WN=-XJVJ4W
M7'[TVN!LH>BP;]@3S)0J-IS+BTTH#D8Z=VS8R=.&[X*;&&S.0P%2R>0/.!/0
MT<P3*HY,JO-UO$UFU-;3VM)(!( 64XL55!Y/'[1PX@1;WU1%'4*0CM-8\:M<
MHWFV0Z@&W=9 MS)E4/'%=Q/M75W$NJBNM'%!26UIP'SF4R<,&30FC0W#Q]
M6Z',AC'@S7E<0&<UF(P.(MXO@!GS\.7+\UV%===-=/36%JXKCZ@?GA'?GUDQ
MZFX;>QZ<J9;M$ .5^L*]=-<L"!Y9SHOH)IU%G\\!_P!F\F\L[WHUUXUN;>FM
MNUYM:+K[>ZOA3/Q)6=":/5#W.[K-I,<Q!+NWB.3\K8W,M/V$W5%R,BIRP=+R
MO+<9N OM;?A]1$IE/$VB@[CD)$;B[X&3&7L37=E/& OL(6Z:D@KOS]5?J**:
MRB1HW=J*4WG=$FZ@Y![W>DF.O)A09S;+(@KJ'G7(IO%(:,5J+@@=1>#HVI,]
M\)&0DEF2B@E/=/3RN6TEEP*J@!M9+ZL>X0^?R(N.%L"*7D18="FRW0_AD&RY
M#(&F/"RFBQI':;&T O(@]GTS,TC*"TH7N3.C)]J8G7WFS^ GS1M- W5LNZHL
MC2O*&:(-QT%*,/("'%T#W$9]<K@2DTG(4NRH6@-L("&:CVU.3U1KV35(LU9B
MK0OP69TXR+?/XKL]ICV8N!\.X+JK3+#LS[CXM2MLR&>389=3 :2"M.5=G4NI
M9VT]7+M&;YW<L_O<_;>[XZ;&VQKV;EEPP:-EW2:7LV./%3EB.?PU?W? Q(CU
M4MW[C:%SS1-EK#0,%^>'6CC;KZEN4DA8!]2A$#BE]36+;K-O5AZZ-&^C-C)C
M(&3*<15E;*>*8S)-)ONS>"!O::>I#+,:JFQ\LV=L=[J)[JHV8<B.;$=<$CEE
M5#47@^8':2G%<:>ZL,/-$=LFM1NS I.G.57SC6P9D1K&\GB8L/.'$P#W].3>
M9(\YJKS;$_N#"GNU4PL(Y%#:4V^GM]85R=D5H3LDF\M>EH"$75_*%9:QWYKK
ML./E[<MN.VT-!"@*5H=ZL74E<RBC$U50,+X+4V;76DL92L1-9<)-)'>._#'"
M,IHBP;;[$:%T>'%F"5TDHIY!4M7C]]A,XK85(L7+WE\@%L71^W=[F=T:0=,S
M4Z34IMK-M/V8RZJ2(9B3#%(,3=!+[<D?+N7VQE_+$5OH;IP0ZH-1$-VW6%\B
MBE N\J>,&+QPW6@7:4 H!0"@% * 4 H!0"@% * 4 H!0"@% * K'EC^EGV??
MJ>[N?T]V]T!9GET'341 ./'70 N ;1M$=-+N AZZJNMQI)9H$#]U'38V/;TU
MQH.?<QMS8DHN)AG^=;RXH8#B4JVWWB6RYR2J;03B9G7$DQD+XQO+'!SX[NZ
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MD98+T)LY+<QI*[UJ=[U*"(3T-F"Y<.:]- 6!4 H!0"@% * 4 H!0"@% * 4
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MK$YR2FY>9VW.& 4O'$379,>DY+<6:0CZ-/I);<RDV5:1$-K-TI>J%;EW&.7
M7 V@P.K$<G3<%*VWF?(78+CVM*I;=PV7(E%H8E22#K\B6'&Q'-BJ60F[=A>&
M?<ZKN\O*V).7&&@LBY8+I66X\8+<KXF$0.OD#?V^]DL<[@VE ^TC;U$,:Q9*
M\0GX79:(HH;0-+D.SFR9VG20I@>$;/QT;9K?K64DJ)U5Q962G&\KGQ83>43(
M'#^$W@P@1?7.I$S"3GW$S]$&RC9VX9D-O1JI*=)!AN1ZSI.<:6P-P;_:3[69
M(P2R_P"'%)>>ATWM7Q2&R44JOX%M134Y.,CCS9DNPS8!>-N(W7R,T-AV+=-
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MO5VN$IY@5=ES>8S&C(+B(N&/\<90NM%2SK8,$I"K(C8(JG)\WI8Y)3<:$;'
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M'C0/A^R/X: :CZA^U^&@/- * \:!\/V1_#0#4?4/VOPT!YH#QH'P_9'\- =
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M"N'%0%JE * K'ZHG\0-K/Z^&U[]*3M 6:V]MWQ_?&@.= * 4 H!0"@% * 4
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M/#*X3/%R*R4+AA4HP,Y$?(&.RSV:X;@TR_24!$^,NC[M18$ZS5.[@!U2NK3
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M6 "Q4H5  #0+;0T[1'UUH.=JY1]9.1E%00* \#6$VUD#$'V'^8[SOL_'%IN
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M>U#;Q!\+[R]Q%[1:K0S/SZMX?N<$GFDM%S2<\5]Q"Y3SI7'"XK!%1.GG$>M
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M;Q**Y<%9=4AGRN$NT\YA-*DRAS#E'/GU'%A$"TW;\XW"\H1B5U.K X2;D<;
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MSR>)\\?N#A@P<=>/PCNMKV.YO+?E9I5Z8KI7 '5LC==#;U9: ]L#N2DPJY\
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M0U+U[FO,/.\C=215>?\ [<YP20'><^'6O;&])*G#ITZR#.[+ L"J0>R@% *
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M/E&M7/66[5NLU\?H;*]ME+C<+SI^[7@OS$/D225:W<@JL?&]F\M7E,.:TLV
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M0Z2,_P!-J.;3NL:]?#QJ1GW";TT",RR'@0Y-B]QKBOE,F\.-KN!+5,&%'20
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MDM_]_-O?#X0^*@+-/,"/]OD_[ZP?AH#CSZ==^*=)7_\ &2W#_P"%0'+G2/\
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M AZ/3J(5H)1\Z"62.QMVN6XYOB?761D* 4 H!0"@(86_T@^;]4##_KDH"9]
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MR]MM-%2VXADA-W@9, 52$8FGD"@W7]FEH?9J@]9E] * 4 H!0'&_\4?D^Z%
M5N[N=A!/= _\+T+2PK1Q:Z(:4=N<M)!!KI;H]_(8/OU'DBU*0#1TZG"RG207
MDD?X1+\T/*F\OLXCAPT!W*WTL^GVZ'$==[@VN1XKNH]D/Y#:^?%QF%G**@:M
M.*OM?G5UUMR@=#4QX&@7".GJH"$^^+IN=--J0TG6KA2(-J!E0E"+32?(RZLN
M7!<H)[0?2,\':RRQ4'8G'CY1Y,EO**><$![I4IFRY\_L^&@)AIW2WZ<RR3+*
MB;MHCDZFJ); =('T]2=&8B=(', &"YLD9*.<2)LD>*" @.#6VX+O2'$ /NOZ
M4/3RLLONMVML,1TU_P 8/$=?_P T!Z: A=#'3RZ8*[N7W/M9-+0S*2[D.L8T
M5@I/<;FSJT$X6>@VMQ[E@*>^]P!:XG2;QYSG+@'*&\W+YZ FC9THNG?=;K_-
M<8/]_O /_"<: B%O@Z;O3396WIV"MMV,-L6=?/-],19>4#;ZRXFVH$UTHLF@
M ";HMTO44-)-EOG" :9LG'MH"1S!Z;73(DMEM5^LB (P>+/=B(G+K8=2&M.\
MZE+R.?+VFRBJE&_>@1Y([:.H>OTT!D1WI8=.=/)F#IW;#'98H5QF#)LT=4W0
M7P%\!8!$R8,&C;HNM+$K0#6[U!Q[* @ WMG?1_09559;67AMR7HGW*)[':>W
MUE9'VMW-PFX(X4UEG/=4::M[[BFGB;C=2L43S1@ +% .8,. <PY\V@@6%X^E
M'T\\GX^UEB6W^G4^\/M:.<?76*N>:L<A1+\.!%_=)TQNFZK,-8V^(*#$>WV=
M=PK7>+)@]P"XUTL]L#N]W3QWSYDM^YZIRBM'VX2)Y3(@7$!#P>(^@<HZ9RJU
MT]YB[%^YC#)=WU-E1QT[.ETZS#A8C>B"('^](@R(#*E7 A.-RGE-MN[R$F;M
M*NTJ2=5PHRXHD;N9\ Q[3IEXT\[5M5?_  D>3IN'S-HYNE1T[L%@YLFUF/L5
MEGTF3)<H.G$' .T1%S6Z#\=//U:R^1#TNEGG_P 16TJ;7.C.S96/[DG(_=O
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MP('*:&2_LHAXO]D5V.P/T\]&[FNY.>O];F[?@4\EW@R;9G:IU09.+)N65>H
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M2]_[C5W)UZERKV+#V'0:7:K&E=;-OR:=O/\ %LV1?@N&T+;;NZ/Q /J]8\.
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MLA-<8*$LM)ZQD;>]LM-4LJ)JP5CLXOI#J:JZVFH>4$G$85<!4P(J@8,9?/\
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M>8*TX#WG)1-QS=(YS HH(JA-N I/@Z1)*H-AC^]*N3+>8J!E,*<WFQX/']%
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MFC*ZGB;B9E(,%K1#)[(5U->=VVLE-Q4P+C472YT\F0CYTAF;QS!RO>536(<
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MY"D1PE+@ $417'#Y<E%_VJ44Q4!8=0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
6 H!0"@% * 4 H!0"@% * 4 H!0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>sdgr-20241231_g8.jpg
<TEXT>
begin 644 sdgr-20241231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #/ G # 2(  A$! Q$!_\0
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MKT/Q)^Q+\2/#_B#P]H,,OA[7M;UC4O[';3]'U>.XET^]$9D:&Y _U>U 26Y
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M=%C(Z,V2YW?-\S;F /(! K@:Z5L(****8!1110 4444 %%%% !1110 4444
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M_='Y5U5C\)_%^J:3X>U.R\,W][8^(;R33](EMH?,^W7$?WXHU')9>_%%I?S
M=G_PS3K?_0Y?#[_PJ[7_ .*H_P"&:=;_ .AR^'W_ (5=K_\ %5@?$_\ 9_\
MB'\%H[&7QQX-U+PW!?$BVGNXU,<C 9*AU)&X#^$G-<#Y:_W1^5"4GJI >N_\
M,TZW_P!#E\/O_"KM?_BJ/^&:=;_Z'+X??^%7:_\ Q5>0,8E.&V ^^*["3X/^
M,8_A_9>.6\,W@\'WMT+*VU@(I@EG+%!&.<YW*PZ=11:2WD!U_P#PS3K?_0Y?
M#[_PJ[7_ .*H_P"&:=;_ .AR^'W_ (5=K_\ %5QGQ$^%'BSX1ZS;Z3XS\.W?
MAO4[B 745K>JH=XB2 XP3QD$?A7*^6O]T?E1:3^T ZBO3/\ AF'XQ_\ 1*?&
M7_@EG_\ B:/^&8?C'_T2GQE_X)9__B:OFCW \SHKTS_AF'XQ_P#1*?&7_@EG
M_P#B:/\ AF'XQ_\ 1*?&7_@EG_\ B:.:/<#S.BO3/^&8?C'_ -$I\9?^"6?_
M .)H_P"&8?C'_P!$I\9?^"6?_P")HYH]P/,Z*],_X9A^,?\ T2GQE_X)9_\
MXFC_ (9A^,?_ $2GQE_X)9__ (FCFCW \SHKTS_AF'XQ_P#1*?&7_@EG_P#B
M:/\ AF'XQ_\ 1*?&7_@EG_\ B:.:/<#S.BO3/^&8?C'_ -$I\9?^"6?_ .)H
M_P"&8?C'_P!$I\9?^"6?_P")HYH]P/,Z*],_X9A^,?\ T2GQE_X)9_\ XFC_
M (9A^,?_ $2GQE_X)9__ (FCFCW \SHKTS_AF'XQ_P#1*?&7_@EG_P#B:/\
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M $2GQE_X)9__ (FCFCW \SHKTS_AF'XQ_P#1*?&7_@EG_P#B:/\ AF'XQ_\
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MGQ<7&/A;XL'&.-'F_P#B:E4XJ7-S!S(\YKU#P'_R0+XM_P#7?1?_ $HDJO\
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MFOM;1+.\T[1=/M=1O&U#4(+>..YO&4*9I0H#O@<#+9.!ZU$J;AN.Y?\ -?\
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M?LU_#G7/$MSKEYX>,EQ=7:ZA=6BWDZ65U<J01-+;!Q$[Y .2O)&3FII/V>_
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M-4ZD9O9-%TY*,U)]#YNOO%&H+J6J>%M#M_$JZ;-J>EBSTK5+F2WO+@2+(UQ
M)G.^%&6/?EC_  G'#"O6_@7J%]=>$+^UU-[@7^GZM=6DEI=RF:6S4/F.$R_\
MM-J,N'[@^U::_"/PHNCS::=/DDCFNDO7N9+J5KHSH,)+YY;>&4< YX'%;GAK
MPQIGA#2_[/TFV^S6WF-,^YVD>21CEG=V)9F)ZDFO3Q.*HU:3A!:W7X*U]^OI
M?SZ';6KTZD.6*[?U_7WFK11FC->.>>%>C^#?^2>7/_86'_HFO.,UZ/X-/_%N
M[G_L+#_T36=;_=ZO^%_H>EE_\=>C)**,T9KX8^F.2^).AIXBT>UL6U*\M<W(
ME&GV-X+275"JL?LHER"H;J=ISA?3->)>%[/6?&WPHE@GOM;U/Q/H-UJEJ/"<
M.LBUN/-67$8DN=VZ86ZLH#YPV>><5[[XO\$Z-X[TZ&RUJU-S'!.MS;R1RM%+
M!,N=LD<B$,C#)&0>A-<Y<? ?P/<:3I^GC2'MH[$S-#<6MY-#<_OCF;?,KAW\
MP_>W$YQ7NX3&TJ-%0FW>]]EIH_[RWOKL^TM$C2,DD?.GB[]HAM6\'>!;!/%\
ME@VG?V1>:S?S1O#/J<K3HKPK@?<10[2'/)VCN:^R8YH[F-)H6#PR*'1EZ,I&
M01^!K"N/ 7AZZ\-6/A]M*MUT:Q:![:SC&Q8C"X>+&.>&4'W[YK?+9.:QQV*P
M^(A&-"GRV<NW6W9+S]-EH*4D]D%%&:,UY!!]/?:?^F4?_?-'VG_IE'_WS3(%
M#S1J1D%@#^=?-'P4^*WBOQ5\0?"NGZIJ[W=G>1^*&GB:-0'-KJ*PV_0?P1DK
M[]Z_K]1;5SWSZ:^T_P#3*/\ [YH^T_\ 3*/_ +YKQCXS^*/'/AWXA_#"'1[K
M3K#P?J7B*TT[4R0SWMVT@D/E*"-L<0" EL[B2 ,#.> N/BEXT^U7OCY/$4J:
M':?$,>#_ /A%?L\7V9[(3K:M(7V^9YQD;S V[&!MQBK5-L+GU-]I_P"F4?\
MWS1]I_Z91_\ ?->#_M&:UXPT7Q-X;33;CQ5:>"O(N6U>Y\"VD-UJD=QN00%H
MW#,(,>9DHI.X 'BN0TW]K2V\(^#O"5A/K>F?$'Q#J4-[<G5;B==$B-O;S>7B
M<2K\EURJ&,* 7#'@4E3;5T%SZG^T_P#3*/\ [YH^T_\ 3*/_ +YKP/0?VH+C
MQ^8I_ O@+4_%%C;6%EJ&K'[5';W%I]ISM@BB8?OI5569AE1@<$DBL.3]L>2W
MT.SU6[\%KI-IK.JSZ1H4VJ:W#!'=M;M*MQ-,VT^1$OE<9RS%@ *?LY!<^F/M
M/_3*/_OFC[3_ -,H_P#OFOD+Q%^UIK/B*W75=#TZ?3O#*>%=;OM1:VNX&NX+
MNSE2,M [(5D"Y&QONN) <?+BO0[K]II[![^^3PE>WO@S0]0M-&UCQ&UY&LD-
MU*L(9DM\9D2-IXP[ CDG:"!1[.07/>OM/_3*/_OFC[3_ -,H_P#OFO!_ _[3
M%YXN\1>'8;KP1<Z1X=\0:K?:)IVL-J$4K/=6IEW;H0,K&WD2;6SG(Y &#7-?
MM=?'C5OAKJF@:+X:\0Z?H>JV]G<^)K];Z6-!>VEL5"V2[_XIV+@8Y^2A4Y<W
M*%SZ=^T_],H_^^:/M/\ TRC_ .^:^?\ 7/VMM,MO&7A[1])T1-1LM:T^QU.V
MO+K5(;)KN*Z;"BT67"SM&.77>".@!-3>&OVHX_$GC[7_  Y'X7D3^R7OHWB.
MIP)J(-L"=\EG)M98Y<?NW4L.06P.:7LY=@N>]?:?^F4?_?-'VG_IE'_WS7S%
MI'[:]C<:I/::CX;@B2W2QN[FXTG6X=0CLK6XN!;EYV0 *\3NF]02-K$@\5[#
MX5^*VE^)=-\5ZO,%TGP_H.JW&E_VK>3*L-SY!599@?X4$A9,GJ5)I.$H[H+G
M>?:?^F4?_?-'VG_IE'_WS7GW_"^OAK_T/_AS_P &47^-1^+OC'H>E_"7QAXW
M\.W]CXGM] TZXNRMC<+)&TL<9<1LRGCMGVI<K&>B_:?^F4?_ 'S1]I_Z91_]
M\U\Q^(+KXB?"7X?^&OB1J7Q%O/%,\UUIQUO0;BT@33IH;N2.-DM J!XFC,H*
M'<V[:<]:L^#?^%C_ !B\%WOQ!TSXCR^%KR;4+K^R-#DM86TFWM8+AXA'> KY
MDC.L;%W# J6^7&*OV>E[Z"N?2?VG_IE'_P!\T?:?^F4?_?->&^"OC;8:7XV^
M)=GXW\6:;I=G9>)8M-T=;ZX2%-ALK>1HXB<;_GD8]S\U;?P8\0:QX^\&^+_[
M3U6=;N/Q'K&EVU[$JB2VACG:.';Q@E!C&>N.:EQ:W ]7^T_],H_^^:/M/_3*
M/_OFOF;X>^/OB9XU\96'PUU.632M8\%W/G>,/$D,2!-5MN?L2VXQA3=+\\F!
M\@C8#J*H:Q\8/B9X1C^.\VNW6D?VKH5II4FB65A&TEII_P!K+(I9F :5AE68
MG )&  *KV;VN%SZH^T_],H_^^:/M/_3*/_OFO&_A;JWB+0_C%XJ^'6N^)+KQ
M;#9Z/I^N6FJ:A#%'.GG22PRPMY:JI7?%O7C(#$<XKE/#+?$#XW:9XN\6:3\1
M+OP8UGK%]IF@Z3#:0O8Q+:2F+??!U+RF1D8L R[5(V\\TN3S"Y]'_:?^F4?_
M 'S1]I_Z91_]\U\X2_MD:-IWCG_A'KFPM+NWL]5M] O]0L]23S3>2!%:2"T(
MWR6ZNX4OG/?! )KAO"/[4'B7POI<^M>(WN/$MK#H4,S6Z[8HXYY-8NK7[1+(
M%/EQ)'&@9L$ +G&:?LY!<^R/M/\ TRC_ .^:/M/_ $RC_P"^:XCX3_$+_A:'
M@V'7?L,-AOFDA"VFH17UO*$; EBFB.&1NHR P[@5V-9M6T&3?:?^F4?_ 'S1
M]I_Z91_]\U#12 F^T_\ 3*/_ +YH^T_],H_^^:AHH F^T_\ 3*/_ +YH^T_]
M,H_^^:AHH F^T_\ 3*/_ +YH^T_],H_^^:AHH F^T_\ 3*/_ +YH^T_],H_^
M^:AHH \5_:@\2/HL'AHIIVFWGF&?/VVU$NW&W[N3Q7@O_"P9O^@#X>_\%J_X
MU['^US_Q[^%/K<?^R5\YU^>9K4G'&32?;\D?E6=5IQQ]1)]OR1U/_"P9O^@#
MX>_\%J_XT?\ "P9O^@#X>_\ !:O^-<M17D^VJ=SP_;U/YCJ?^%@S?] 'P]_X
M+5_QH_X6#-_T ?#W_@M7_&N \46>IWVCR0Z5J']EW!96>Z6$2R+$#EQ&IXWD
M# ST)KPZT^*GB+4[RT\.Q3Z[)=?;+XL+:SB75?(B">4DJN D;'>6+=U"CJ:Z
MJ,:U9-QEM_78[*$*]=-QGM_5]CZP_P"%@S?] 'P]_P""U?\ &C_A8,W_ $ ?
M#W_@M7_&O-?A]K3>(/!6D:A)??VE+-#^\NO(\@NP)4[H_P"%@1@CU!KH:YY5
M*D9.+>QRSJU82<7+8ZG_ (6#-_T ?#W_ (+5_P :/^%@S?\ 0!\/?^"U?\:Y
M:BI]M4[D^WJ?S'N?@G7(M<^'MU)=Z'HK"/50JQ+9!4_U.=V,]>V?2K'_ !+/
M^A<T3_P#'^-87PQ_Y)O??]A@?^B!6O7QN<YABZ.*Y:=1I677R/O<#"-3"TY3
MBF[=EW)O^)9_T+FB?^ 8_P :/^)9_P!"YHG_ (!C_&H:S/$T&KW7AW48= NK
M:RUN2%DL[J\C,D,,AZ.RCJ!R<>N*\2.:8Z4DO;-?,[O8TOY%]R-G_B6?]"YH
MG_@&/\:/^)9_T+FB?^ 8_P :\.\#>(_&&J7WCBR\-Z\GC+3]/CMX-/UO78UC
M@^W_ #"Z17A4>;'& IP!PWR[O3-3QUX]O?V2[+Q5I>H6+^)_[*N+N]U6^0_(
ML9E)>*-1@N=H"@X ZG.,5ZKEF2DH_6/M1CN_M*ZOI=>?6^EB_JU/^5?<CZ#_
M .)9_P!"YHG_ (!C_&C_ (EG_0N:)_X!C_&LCPW=27WAK1KJ9C)-/8V\TCGJ
MS-$K,?Q)-:->3+,\=%M.M+[R/8TOY%]R)O\ B6?]"YHG_@&/\:MS:E;:5X+U
MVXM=#T>%_-ME*BS&U@7;J,\X[5G4[5_^1!U[_KM:_P#H;5Z.6YCC*F)49U6U
M:77^ZS*K3A"G*48I.SZ+L<O_ ,)Q+_T!=#_\ %_QH_X3B7_H"Z'_ . "_P"-
M<U17O?6*O\Q\Q[:?<Z7_ (3B7_H"Z'_X +_C1_PG$O\ T!=#_P# !?\ &N:K
MROXQ:IX@\.I/J%EXG?3Y)(H[?0M#L;9)9K^^+$D2A@2R$;1A<!1N)/2MZ,ZU
M::@IVO\ UT1I3E4J2Y5(]Y_X3B7_ * NA_\ @ O^-'_"<2_] 70__ !?\:^7
M8_BAK]YXRO;B[OM3TG3+#78M&D\JPCDTM#A%>.5R?,+N['#K\J?(#UKJ-#C\
M1R?&*YTJ#Q=J6I:)HMN)M5CO((-K3RY,-NA2,$;5R['/]T=ZZI4L133<II:7
MZ_=MOJOO-Y0JQ5W+I?\ K3T/>O\ A.)?^@+H?_@ O^-'_"<2_P#0%T/_ , %
M_P :YJBO.^L5?YCD]M/N=+_PG$O_ $!=#_\  !?\:Z_2/&EPG@&6X33=)C;^
MU/+*)9@)_J0<XSU]Z\KKM-*_Y)O)_P!AC_V@*SK8BJJ%5\WV7^A]GP=&.*SN
MA1KKFB[W3V?NLT_^$_O?^@=I/_@$O^-'_"?WO_0.TG_P"7_&N8I'W;&V;=^#
MMW=,]L^U?$?7*_\ ,?U#_8F6?] T/_ 4=1_PG][_ - [2?\ P"7_ !H_X3^]
M_P"@=I/_ (!+_C7SQX-UCQ+;?%&UT"?Q0WBMH;*:;Q$L=M&EIITQ(-ND+* 5
M8Y(\MB3M&XXKFOB1\5/$>A_$?6(;+4;Z+3]+N]-@0V]HDFEQ+*P\\7TQ&Y'P
MW&#P"I[FO9IX?&5*OLH54].;KLW9=+Z[K3;4\J>%RBG3]I+"Q6MOACVOZ:?G
MH?5G_"?WO_0.TG_P"7_&C_A/[W_H':3_ . 2_P"->":EXP\4:'\6]4AU*2S'
MAJ'P_>:C8V%KEG?R7C_>2N1]X[B J\ >I-<]\$?B%KOB+7=&.N:IJP.MZ2]_
M%9ZIIT4-O.P*DM:.AW*J!MI63EAAJCV.,]DZRJ*R2?WW=MNEG<OZGE'M52^J
MQNW;X8^7YWT/IS_A/[W_ *!VD_\ @$O^-'_"?WO_ $#M)_\  )?\:YBBO)^N
M5_YCTO[$RS_H&A_X"C[%C<QNK#JIS7B\G[+^DVMQI%UH?BWQ-X:O],?4FBN]
M-G@\QUO;CSYT;S(F!7>!MP 0!WKVWS8?^>'_ (^:/-A_YX?^/FOZU4FMC^?#
MAKWX8VNL:7X1M=6U?5-6N/#>IPZM!?W,B>?<SQ!PIF*H%(PYR% Z"N=F_9U\
M/S>-FUW^U-8737UA?$4GAE9T_LU]2"@"Y*[-^<@-MW;2P#8S7K?FP_\ /#_Q
M\T>;#_SP_P#'S0I26P'G/Q!^#]OXX\2:=XDL?$FN>#_$MC;O9+JFA3HK36[L
M&,,J2(Z.H8;AD9!Z&N87]EGP]8VFE/H^O^(-%UZQ%X)?$,%Q%+>WWVIQ)<>>
M9(V1RS@,"%&T@;<5[;YL/_/#_P ?-'FP_P#/#_Q\TU.25D!XM=?LPZ SQC3_
M !%XFT:VFL+73=5ALM0 .KPVY)C-Q(RE]_+ NC*2&(J[-^SGX>7P?X=T/3]2
MU729_#NH7&I:5JUM)&UU;2SO(TJ_.A1T82LI5E(QCN,UZYYL/_/#_P ?-'FP
M_P#/#_Q\T<\NX'AVM_LI^'=>T6RT^Y\0^)"T>GZAIMW=F[C:;4(;TAIQ,60@
M?,JLNP*%V@ 8XJWJ7[,?AS4=7N93K&N0:%?7MKJ6I>&X;E!87]U;A!'+(-F\
M9\J,NJL Q09%>S>;#_SP_P#'S1YL/_/#_P ?-/VDNX6/,M#^!'A_0+'PE:V]
MSJ#Q^&=9N]<LS)*I+SW)G,@DPO*#[0^ ,8PO)Q6M9?"GP_;^//$7BZZM5U?5
MM;BMK>7^THTGCMX8%94BA4K\BDNS'N2U=OYL/_/#_P ?-'FP_P#/#_Q\U/-+
M>X'SX/V-?"L>C)H,?B+Q(OA?>IDT&2XAEM3&L[31QIOC+0JI8KF,J2H ).,U
MH:W^R;X6\4:S+=:WK.OZM8@7WV33KFZ0K9&[C:.;RY@GG%=KOM1G*KG@=*]S
M\V'_ )X?^/FCS8?^>'_CYJO:2[A8^;O$G[,9\.^%=>GT&74/'/B"^\.'PG!8
M:W>6]G9Q6;L"KXBA4*8R ^0-S8]<5Z[\+_AW9_#7X8^'?!R%;^WTNQCMI99U
MW_:9,9ED<'J7<LQSZUVGFP_\\/\ Q\T>;#_SP_\ 'S2<Y25F%C(_X1W2/^@/
MIW_@'%_\33KC0=,N=+O-,DTZU.G7D3PW%JL*K'*CJ5964 9R"16KYL/_ #P_
M\?-'FP_\\/\ Q\U.HSQ30_V7]$TFXT&WN_%'BC7?#/A^XCNM(\,:I?))8VLD
M9S#G""258_X%D9@N!UP*9K7[+.@:Q)K-DGB3Q-IWA'6KUK_4_"5G>HFGW4KM
MOE'*&1$D;ET1P&)/J:]N\V'_ )X?^/FCS8?^>'_CYJ_:2[BL<3X;^%?A[PQJ
M_B34(;..[?7=034IH;V*.6."1((X5$(*_(NR)??/>N;\,? ;_A#_ !+=:EI/
MCOQ5:Z==:K/K$V@^=;FR>6:0O(I!AW["QZ;\^]>M>;#_ ,\/_'S1YL/_ #P_
M\?-3S,#D]%\ Z=H/CGQ1XKMY+AM2\0QVL=W'(X,2BW1DCV#&1D,<Y)K(U[X+
M>&_$UUXZEU-;JYC\965M8:E#YNU5C@1EC:(@91ANW9R>0#7H?FP_\\/_ !\T
M>;#_ ,\/_'S1S,#S_P"'/PGM?A[J&KZI+K>K^)]>U1((+G5M;E1YS!"I$4*[
M$50J[F/3)9B22:Y?Q-^S+H^OZAXB-IXI\3^'M#\23FYUOP_I%XD5G?2, )6Y
M0O$9  '\MEW<^M>T>;#_ ,\/_'S1YL/_ #P_\?-/FE>X'CEK^S/X<TOQ%]LT
MC5=9T/1'OH-3F\-:?/''82W$2JJM]SS%4A$W(KA6*C(ZYKVW[+?AO3;+RM-U
MSQ!I=TEI':0WUI=HDL02\ENU;[FULR3.I5@59< CO7M?FP_\\/\ Q\T>;#_S
MP_\ 'S1SR[@<+\*_A7I7PET74+#3+BYO9=2U"75+Z\N_+5Y[F3 9]D:JB#"J
M JJ!QZUV=3^;#_SP_P#'S1YL/_/#_P ?-2VV[L9!14_FP_\ /#_Q\T>;#_SP
M_P#'S2 @HJ?S8?\ GA_X^:/-A_YX?^/F@""BI_-A_P">'_CYH\V'_GA_X^:
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MX5GX/_Z!-U_X'-_A6G]O95_T$+_P&?\ \@>5_8&,\OO/!:X/Q%\)(=?\;?\
M"4Q>(]:TK5%M19Q_8I(MD,><D('C;:6/4CK7UM_PK/P?_P! FZ_\#F_PH_X5
MGX/_ .@3=?\ @<W^%:T^(\LI.\,2O_ 9_P#R!<,CQU-WC;[_ /@'R1=?!O2[
MO6)+J34M3-A<7D6I76D>:OV6YNHPNV9QMW DJK%00"P!Q73:#X7M/#M[KEW;
MO-)/K%Z;^Y>9@?G**@"\<* HP*^D?^%9^#_^@3=?^!S?X4?\*S\'_P#0)NO_
M  .;_"G+B7+IKEEBE;_#/_Y J62X^2LVOO\ ^ >"T5[U_P *S\'_ /0)NO\
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MUN/_ &2OG.OSS-9I8R:Y5T_)>9^59U44<?47*GMW[+S.I^R>"/\ H)Z__P"
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M6TXK3^NYE*IRMQ<%=>O^9U/V3P1_T$]?_P# .'_XNC[)X(_Z">O_ /@'#_\
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M%'_"%Z/_ -#OH_\ WYN/_B*/8S\OO7^8?5Y^7WK_ #.Q^&/_ "3>^_[# _\
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ME(&1D<CO7<_\*UM?^ANT?_OW/_\ $4?\*UM?^ANT?_OW/_\ $5]M[%_S1_\
M H_YG] ?VCAN[_\  9?Y'R[H?@G6/#>K:=K@\(Z5H!\/Z?>>?_9$P_XFSLOR
M1JH!8+D;OGR0QP,]:J>*OA?KOBO7M1U5=%MWU+5'L;G3M<FO-DNB*@4M'Y>,
ML5(<C;]XN<XKZM_X5K;?]#=H_P#W[G_^(H_X5K:_]#=H_P#W[G_^(KUUC:\9
M^T3A>UOC6U[_ ,W?_+;0\.5'+Y4_9.<N6]_A>]N7^2VW97ZWOJ>(1^"+O4O%
M_C/4]2*K%J5C%I6GR*VYH[?RV,AQ_"3(Y./]D5R?PL^&&J>%?$&@RRZ'8Z!#
MI&ER6%W=65P)#J[DKL=@!G VELOR"V!Q7TW_ ,*UM?\ H;M'_P"_<_\ \11_
MPK6U_P"ANT?_ +]S_P#Q%8+$5XPE3YHV:2^*/16_F[=[ZZ[G3+^SY5(U&W>+
M;^&75\W\M]^UM-'H<117;_\ "M;7_H;M'_[]S_\ Q%'_  K6U_Z&[1_^_<__
M ,17G^Q?\T?_  */^9ZG]HX;^9_^ R_R/L2BGPQB2:-#P&8#]:^3_"O[96JZ
MU\+_ (@ZAJ&BV>F>,?#K3W6G6DF[[-J>GK>FV6X3G)*LK(XSPP4]&K^F8Q<M
MC^4#ZMHKYH\/_M >*/%?Q(U_0(O&7P^T Z?XDFT6WT34X9GU*YBC91N7$@&Y
MP3CC&17J'Q>^+MO\)]>\%_VC/9V'A_5;R[BU*^O6(^SQ16LDP*D?Q%D"XYSG
M YI\C3L%ST>BOE'XA_M:ZMI/C#6[?3];\)^#='L- L]:M8/'-I<PWE]YRRL4
MVJP,>!&O!!/SCBO2O'WQLU?P[^RZ/B?;:7;:?K,FE6=__9^H,7AMVF>-6#E2
M"54.3UZ"G[.6GF%SV2BOG+PI^TE?0_$:'1=8\4^"?&'APZ3>:I?ZUX3\T#1E
MMU5MUSEW38X)"\ALCH:ZV7]JSP+9Z+J.IZ@FNZ2EG!;7?V6^TB:.YN;>XD$4
M,T,6,R(SD+QR"1D#-+V<NP7/8**\I;]I;P@MJR/;:Y'KPU$:4/#+:7(-5:Y,
M7G!1!U*F+Y]^=N.]9>L?M:^"K.PL6TVUU[7=3OK.\NX-,L=)F>>+[*YCG6X7
M&83')A6W=,YYHY)=@N>U45X=X?\ VK_#UQX%\-:SK.EZS;ZEJ.AQZ_J%CIVF
MRW TRU8X,\I'*Q$ABI/+*"P&*[/PM\;O#7C;QYJ7A30UU+4;K3D5[K48;%_[
M/CWQ++&OVC[I9T=6 '6ERR70#OJ*\/\ &W[0E[X5^.^D>%8M-MYO!\3VEAKV
ML.Q\RSOKW?\ 8HU[8/E_-GIYJ5TD/[1'A";Q)J6D#^U1#IUQ=V=QJ_\ 9LK:
M>EQ;1F2XB,P!"LBJ?O8!(P"31R2WL!Z917E.C_M*^$M:\.76M167B*&TBAM;
MB!)=%G\R^BN6V0/;!0?-#GL#D=6 %7?"O[07A/Q5KMGHB+J>E:S<W]QI9L=5
ML7MY(+J&$3M%)GA28FWKSA@#CI1RR[ >DT5YOK7QDTVZ^$8\=:#>1QZ9-<Q0
M6UW?VDC)(&NUMRP1<,58D[6Z<ANE5/#_ .TIX,\4>,+7P_9)K,<EYJ-UI-KJ
M%UIDD=E/>6^\RVZS$;2X",?0XX.>*.66]@/4Z*X/XY>/K_X8?#+4?$FFV\%U
M>6]Q:0I%<Y\LB6YCB8G'/ <D>X%./QL\)_88[Q;JX-O)XAE\+HWV9LF_C9E9
M,?W<HWS=*7*VK@=U17SI;_MH^%M0\3:-/#'?6?@F]TF\O1J6HZ;+#-?3121)
M%'9H>9][2,N%!)8#%=WXA_:+\+>%=2%IJEEX@MHHI+2"^OSI,OV73Y;G;Y,<
M\F,*Q+J"!G:6&<57LY+H%SU"BO-?A/\ %34/BUH/C&>'2)-!OM'UN_T6V_M"
M!Q'(86VI(PSEN?OJ.G2N6^&GC#XL^(OBIXH\.ZYJ'@XZ7X7N;2*_>PT^Y2:[
M6>W\T>46D(0C('S ]#2Y7KY >YT5Y[\0/CIX9^'.N'2-0BU;4+^*R&I7D>CZ
M=)=_8;,N4%Q/L'R(6# =2=K''%5/^&BO!LGB4:/%-J$B-?#24U@6,G]FF_*;
MEM?M&-OF'@>FX[<YXHY9;V ]-HKQ7]GGXX:S\7M4DM=5L;*T1?#^G:MFU#9\
MVXEG1UY/W0(EQ]374_"/XE3^./ ^L:_K2VNG)I^L:I8N\9*QK!:SO&)&)[[4
MR:'%QT8'H-%>0VO[5'@2XT^YO9FUC3K9+%=4MGU#2Y8/M]FTJQ">WW#]XH9T
MST(# XP:?\4/C]IG@/Q-I^C1W%M#+;ZUI]EKD^H QPVEI=13R"59"0,@0'V%
M')*]K >MT5Y5??M)>&+/0=/U:'2O%&H6U]93:I$EGH<[2+8QMAKIU(&R,]5S
M\S#D"DU+]ISP'ILT>+K4+W3Q:V=[=ZK9Z?)+9Z?#= -;O<R@8CWA@?4 Y.!1
MR2[ >K45XWJ'[6'@BPUZ;25M/$E[.FJ3:''-9:+-+#<:C&,FUB<##R$<C'&.
M]1:=^T_X8U2[;4+>[N9=#&D"\_L^/2;AM2%Q]M:T:,H ?F$JE-F,@C.=O-/D
MEV"Y[317(> ?BEHWQ#M=;DLH=0TZYT.Y-IJ>GZK:M;W-K)Y8D 9#V*$,""00
M:\R\%_$SXN_$3PQI'C_0-#\-W7A35;E7M/#4C2)J<FGF4I]H-P6$8EV@R>5M
MQCC=FERL#WRBO++K]H[PE_:][I=H^H/(L]UIUIJLMC(NFW-_!&[M;)<?=+C8
MP]"5(!)%<'\/?VM5U"Q^T>*[#RYKJVT-=-L=%MWFN+R\OK62=XD4GG'EL1R.
M <T^25KV"Y]'T5C^$?%5CXV\.V>M:<EW%:70;;%?6KVT\;*Q5E>-P&4@@CD?
MI6Q4#/G[]KG_ (]_"GUN/_9*^<Z^C/VN?^/?PI];C_V2OG.OS;-O]]G\OR1^
M29Y_R,*GR_)!1117CGA!163XHNM6L]'DDT6"UFOMZC=>N5AA3/SRMCDA5R=H
MY-><6_Q2U[4O .I>);2[T 6>E7-Q!->-%,\5ZL9 1X5#!@6)V[3WZ<5T4Z,J
MBNN]CIIX>=5<T>]CUVBLCPC=:O?>&=-N=?MH+/6)H1)<6]L24B8\A1GG(&,^
M^:UZQDN5M'/*/*VNP4445(CU[X8_\DWOO^PP/_1 K7K(^&/_ "3>^_[# _\
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M/#OC:3Q#,FH>.?$E_<ZBGB6,2H;*4L/LGEQ"3:1 $C SUVGIFJNG_LN^)?\
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$KN?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>sdgr-20241231_g9.jpg
<TEXT>
begin 644 sdgr-20241231_g9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" AN#<@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^,O^"J__ ";SX>_[&FW_
M /22[H ^S:*\'_87_P"33_A[_P!>L_\ Z4RU[Q0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W_8TV_P#Z
M27= 'JO["_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?&7_!5?\ Y-Y\/?\ 8TV__I)=U]FU\9?\
M%5_^3>?#W_8TV_\ Z27= 'JO["__ ":?\/?^O6?_ -*9:]XKP?\ 87_Y-/\
MA[_UZS_^E,M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&7_  57_P"3>?#W
M_8TV_P#Z27=?9M?&7_!5?_DWGP]_V--O_P"DEW0!ZK^PO_R:?\/?^O6?_P!*
M9:]XKP?]A?\ Y-/^'O\ UZS_ /I3+7O% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%-$B&0H&4N.2N>: '4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\9?\%5_^3>?#W_8TV_\ Z27=?9M?&7_!5?\ Y-Y\/?\
M8TV__I)=T >J_L+_ /)I_P /?^O6?_TIEKWBO!_V%_\ DT_X>_\ 7K/_ .E,
MM>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY3T77+WP_?1W=C.T$RG/!X8>C#N*^A_ _C:V\:::94 AO(N)[?.=I[$>H/\
M]:OD<=E\L+[\-8_EZGW.6YK'&?NYZ3_!^G^1TM%%%>.>^%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&7_!5?_DW
MGP]_V--O_P"DEW7V;7QE_P %5_\ DWGP]_V--O\ ^DEW0!ZK^PO_ ,FG_#W_
M *]9_P#TIEKWBO!_V%_^33_A[_UZS_\ I3+7O% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% %#7=8A\/Z/=ZA<?ZJW0N1G&X] H]R
M<#\:^8M<UFY\0:I/?7<C22RMGYCG:.RCV%>I_'C6O+M].TI'P9";B50>PX7/
MMG=^7Y>.U]CE&'4*7MGO+\CX#/<4ZE;V">D?S"BBBO?/F0HHHH **** "M?P
MKXENO"NL0WULQPIQ+'GB1.ZG_/!Q61142C&<7&2NF7"<J<E.#LT?6EC>1:A9
MP74#^9!,@D1AW!&14]>;_ _6FOO#USI\C[GLY<ID](VY _,-^8KTBOSK$470
MJRIOH?J^%KK$T(U5U7_#A1117.=84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'<7$5G;RSSRI#!
M$I>221@JHH&223T '>N+TOXZ_#;6]1MM/T[XA>%;^_NI%A@M;76K:265V.%5
M%5R68G@ <FG9L#N****0!14%]?6VFVDMU>7$5K:Q+NDFG<(B#U+'@"N9TKXN
M^!=>U%=/TWQIX=U&_9M@M;758)92WIM5R<T[,#K:***0!117,>(?BAX-\(WG
MV37?%NA:+=\?N-0U*&!^>GRNP/-/<#IZ*I:1K6G^(+%+W2[^UU*SD^Y<6<RR
MQM]&4D&KM( HHHH **** "OC+_@JO_R;SX>_[&FW_P#22[K[-KXR_P""J_\
MR;SX>_[&FW_])+N@#U7]A?\ Y-/^'O\ UZS_ /I3+7O%>#_L+_\ )I_P]_Z]
M9_\ TIEKWB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#22[H ]5_87_Y-/^'O_7K/_P"E,M>\5X/^PO\ \FG_  ]_Z]9__2F6O>*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_47_ ,<KIO\ A3/@S_H!0_\ ?R3_ .*H_P"%,^#/^@%#_P!_9/\ XJ@#F?\
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M#F_^&E_#'_/AJW_?F+_XY1_PTMX8_P"?'5O^_,7_ ,<KI/\ A2_@O_H!1?\
M?Z3_ .*H_P"%+^"_^@%%_P!_I/\ XJ@#F_\ AI;PQ_SXZM_WYB_^.4?\-+>&
M/^?'5O\ OS%_\<KI/^%+^"_^@%%_W^D_^*H_X4OX+_Z 4?\ W^E_^*H YO\
MX:6\,?\ /CJW_?F+_P".4?\ #2WAC_GQU;_OS%_\<KI/^%+>"_\ H!1_]_I?
M_BJ/^%+>"_\ H!1_]_I?_BJ .;_X:6\,?\^.K?\ ?F+_ ..4?\-+>%_^?'5O
M^_,7_P <KI/^%+>"_P#H!1_]_I?_ (JC_A2W@O\ Z 4?_?Z7_P"*H YO_AI;
MPO\ \^.K?]^8O_CE'_#2WA?_ )\=6_[\Q?\ QRNC_P"%+>"_^@%'_P!_I?\
MXJC_ (4KX+_Z 4?_ '^E_P#BJ .<_P"&EO"__/CJW_?F+_XY1_PTMX7_ .?'
M5O\ OS%_\<KH_P#A2O@O_H!1_P#?Z7_XJC_A2O@O_H!1_P#?Z7_XJ@#G?^&E
MO"__ #Y:M_WYB_\ CE'_  TMX7_Y\M6_[\Q?_'*Z+_A2O@O_ * 4?_?Z7_XJ
MC_A2O@O_ * 4?_?Z7_XJ@#G?^&EO"_\ SY:M_P!^8O\ XY1_PTMX7_Y\M6_[
M\Q?_ !RNB_X4KX*_Z <?_?Z7_P"*H_X4KX*_Z <?_?Z7_P"*H YW_AI;PO\
M\^6K?]^8O_CE'_#2WA?_ )\M6_[\Q_\ QRNB_P"%*^"O^@''_P!_I?\ XJC_
M (4KX*_Z <?_ '^E_P#BJ .=_P"&E?"__/EJW_?F/_XY1_PTKX7_ .?+5O\
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MS'_\<KH?^%*>"O\ H!Q_]_Y?_BZ/^%*>"O\ H!Q_]_Y?_BZ .?\ ^&E/"_\
MSYZK_P!^8_\ XY1_PTIX7_Y\]5_[\Q__ !RN@_X4IX*_Z <?_?\ E_\ BZ/^
M%*>"O^@''_W_ )?_ (N@#G_^&E/"_P#SYZK_ -^8_P#XY1_PTIX7_P"?/5?^
M_,?_ ,<KH/\ A2?@K_H!I_W_ )?_ (NC_A2?@K_H!I_W_E_^+H Y_P#X:4\+
M_P#/GJO_ 'YC_P#CE'_#2GA?_GSU7_OS'_\ '*Z#_A2?@K_H!I_W_E_^+H_X
M4GX*_P"@&G_?^7_XN@#G_P#AI3PO_P ^FJ_]^8__ (Y1_P -*>%_^?35?^_,
M?_QRN@_X4GX*_P"@&G_?^7_XNC_A2?@K_H!I_P!_Y?\ XN@#G_\ AI3PO_SZ
M:K_WYC_^.4?\-*>%_P#GTU7_ +\Q_P#QRN@_X4GX*_Z :?\ ?^7_ .+H_P"%
M)^"O^@&G_?\ E_\ BZ .?_X:4\+_ //IJO\ WYC_ /CE'_#2GA;_ )]-4_[\
MQ_\ QRN@_P"%)^"O^@&G_?\ E_\ BZ/^%)^"O^@&G_?^7_XN@#G_ /AI3PM_
MSZ:I_P!^8_\ XY1_PTIX6_Y]-4_[\Q__ !RN@_X4GX*_Z :?^!$O_P 72?\
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M_P".4?\ #2?A;_GUU3_OS'_\<K>_X4CX)_Z :_\ @1-_\71_PI'P3_T U_\
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M^&DO"W_/MJG_ 'Y3_P"+H_X:2\+?\^VJ?]^4_P#BZW?^%(^"?^@&O_@3-_\
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MC_AI+PK_ ,^^I_\ ?A/_ (NMS_A1_@G_ * :_P#@3-_\71_PH_P3_P! -?\
MP)F_^+H P_\ AI'PK_S[ZG_WX3_XNC_AI'PK_P ^^I_]^$_^+K<_X4?X)_Z
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MWP1_T!!_X%3_ /Q='_"C?!'_ $!!_P"!4_\ \70!B_\ #2'A7_GAJ7_?A/\
MXNC_ (:0\*_\\-2_[\)_\76U_P *-\$?] 0?^!4__P 72?\ "C?!'_0$_P#)
MJ?\ ^+H QO\ AI#PK_SPU+_OPG_Q='_#2'A7_GAJ7_?A/_BZV?\ A1O@C_H"
M?^34_P#\71_PHWP1_P! 3_R:G_\ BZ ,;_AI#PK_ ,\-2_[\)_\ %TO_  TA
MX5_YXZE_WX3_ .+K8_X4;X(_Z G_ )-3_P#Q='_"C?!'_0$_\FI__BZ ,?\
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MJ/\ AHWPG_<U#_OPO_Q5:G_"B?!/_0&/_@7-_P#%T?\ "B?!/_0&/_@7-_\
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M$^"?^@0W_@5-_P#%T?\ "B/!/_0(;_P*F_\ BZ ,W_AHSPG_ '=0_P"_ _\
MBJ/^&C/"?]W4/^_ _P#BJTO^%$>"?^@0W_@5-_\ %T?\*(\$_P#0(;_P*F_^
M+H S?^&C/"?]W4/^_ _^*H_X:,\)^E__ -^!_P#%5I?\*(\$_P#0(;_P*F_^
M+H_X41X)_P"@0W_@5-_\70!F_P##1GA/TO\ _OP/_BJ/^&C/"?I?_P#?@?\
MQ5:7_"B/!/\ T"&_\"IO_BZ3_A1'@G_H$M_X%3?_ !5 &=_PT9X3]+__ +\#
M_P"*H_X:,\)^E_\ ]^!_\56C_P *(\$_] EO_ J;_P"*H_X41X)_Z!+?^!4W
M_P 50!G_ /#1?A+TO_\ P''_ ,51_P -%^$O2_\ _ <?_%5H?\*(\$_] EO_
M  *F_P#BJ/\ A1'@G_H$M_X%3?\ Q5 &?_PT7X2]+_\ \!Q_\51_PT7X2]+_
M /\  <?_ !5:'_"A_!7_ $"7_P# J;_XJC_A0_@K_H$O_P"!4O\ \50!G_\
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M2_\ Q5 %'_AHKPEZWW_@./\ XJC_ (:*\)>M]_X#C_XJKW_"AO!7_0+D_P#
MJ7_XJC_A0W@K_H%R?^!4O_Q5 %'_ (:)\)>M]_X#_P#UZ/\ AHGPEZWW_@/_
M /7J]_PH;P5_T"Y/_ J7_P"*H_X4-X*_Z!<G_@5+_P#%4 4?^&B?"7K??^ _
M_P!>C_AHGPEZWW_@/_\ 7J]_PH;P5_T"Y/\ P*E_^*H_X4-X*_Z!<G_@5+_\
M50!1_P"&B?"7K??^ _\ ]>C_ (:)\)>M]_X#_P#UZO?\*&\%?] N3_P*E_\
MBJ/^%#>"O^@7)_X%2_\ Q5 %'_AHGPE_>OO_  '_ /KT?\-$^$O[U]_X#_\
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M[,+B9X6ISQ^:[G!C,'#&TG3G\GV9X-17KOB[X);5$_AYL[1\UK/)R?3:Q_\
M9C^->4WUC<:;</;W4#V\RD@I(N#P<?S!K[G#XJEB8WIOY=3\WQ6"K8.7+56G
M?HR"BBBNLX0HHJYI>CWNM70M[&UDNIC_  QKG'N3V'N:3:BKL<8N3M%793KH
M_ 'BSPQX8U<W^L33R7,/$$,,)95)&"Q.>OH/QZUWWA7X'P^0TOB"0R.XP+6W
MD*A?=G')/L./<UK_ /"A/!?_ $#9?_ J3_XJOELPS)23HT'ZO]$?9Y7E$H25
M?$+5;+]7_D5/^&B/"/\ ?O?_  '_ /KTO_#1'A'^_>_^ _\ ]>K7_"A/!?\
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MX4'X+_Z!TO\ X%2?_%4 5?\ AH?PC_STO/\ P'_^O1_PT-X1_P">EY_X#_\
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MXT 5_P#AH;PA_P ];S_P'/\ C1_PT-X0_P">MY_X#G_&K'_"@_!G_0/F_P#
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MFH_X:$\'_P#/Q=?^ S5)_P * \&_\^5Q_P"!+_XT?\* \&_\^5Q_X$O_ (T
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M (9_\&_\^=Q_X$O_ (T?\,_^#?\ GSN/_ E_\: &_P##07@__GYNO_ 9J/\
MAH+P=_S\W7_@,U._X9_\&_\ /G<?^!+_ .-'_#/_ (-_Y\[C_P "7_QH ;_P
MT%X._P"?FZ_\!FH_X:"\'?\ /S=?^ S4[_AG_P &_P#/G<?^!+_XT?\ #/\
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M:-HR4E>+N'_#0/@[_G[N?_ 9J/\ AH'P=_S]W/\ X#-1_P ,^^#O^?6Y_P#
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M_P#GVNO_  ):@!W_  T!X-_Y_+C_ ,!G_P */^&@/!O_ #^W'_@,_P#A3?\
MAGWP?_S[77_@2U'_  S[X/\ ^?:Z_P# EJ '?\- >#?^?VX_\!G_ ,*/^&@/
M!O\ S^W'_@,_^%-_X9]\'_\ /M=?^!+4G_#/G@__ )]KK_P):@!__#0'@W_G
M]N/_  &?_"C_ (: \&_\_MQ_X#/_ (4S_AGSP?\ \^UU_P"!+4?\,^>#_P#G
MVNO_  ):@"3_ (: \&_\_MQ_X#/_ (4?\+_\&_\ /[<?^ S_ .%1_P##/G@_
M_GVNO_ EJ/\ AGSP?_S[77_@2U $G_"__!O_ #^W'_@,_P#A1_PO_P &_P#/
M[<?^ S_X5'_PSWX/_P"?>Z_\"6H_X9[\'_\ /O=?^!+4 2?\+_\ !O\ S^W'
M_@,_^%'_  O_ ,&_\_MQ_P" S_X5'_PSWX/_ .?>Z_\  EJ/^&>_!_\ S[W7
M_@2U $G_  O[P;_S_3_^ S_X4?\ "_O!O_/]/_X#/_A4?_#/?@__ )][K_P)
M:C_AGOP?_P ^]U_X$M0!)_PO[P;_ ,_T_P#X#/\ X4?\+^\&_P#/]/\ ^ S_
M .%1_P##/?@__GWNO_ DT?\ #/?@_P#Y][K_ ,"30!)_PO[P;_S_ $__ (#/
M_A1_PO[P;_S_ $__ (#/_A4?_#/?@_\ Y][K_P "31_PSWX/_P"?>Z_\"30!
M)_PO[P;_ ,_T_P#X#/\ X4?\+^\&_P#/]/\ ^ S_ .%1_P##/?@__GA=?^!)
MI/\ AGOP?_SPN_\ P(- $O\ PO[P;_S_ $__ (#/_A1_PO[P;_S_ $__ (#/
M_A47_#/?@_\ YX7?_@0:/^&>_!__ #PN_P#P(- $O_"_O!O_ #_3_P#@,_\
MA2_\+^\&?\_\_P#X#/\ X5#_ ,,]^#_^>%W_ .!!H_X9[\'_ //"[_\  @T
M3?\ "_O!G_/_ #_^ S_X5Z+7FG_#/?@__GA=_P#@0:]+H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /FK_@H]_R9;\2/^N5C_Z7V]?C[^R1_P G1?";_L:-._\
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M>QVP9%SY49.9)3_LH@9S[*:_HTT72;7P_H]CI=E'Y5E901VT$><[8T4*H_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KXR_X*K_\ )O/A[_L:;?\ ])+NOLVOC+_@JO\ \F\^'O\ L:;?_P!)+N@#
MU7]A?_DT_P"'O_7K/_Z4RU[Q7@_["_\ R:?\/?\ KUG_ /2F6O>* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-5(;,****S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *^,O^"J__ ";SX>_[&FW_ /22[K[-KXR_X*K_ /)O/A[_ +&FW_\ 22[H
M ]5_87_Y-/\ A[_UZS_^E,M>\5X/^PO_ ,FG_#W_ *]9_P#TIEKWB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //_ (TZT=.\)BT0XDOI
M1&<'!V+\S?J%'XUX)7JWQ\G+7VCP_P *1R./Q*C_ -EKRFONLKIJ&%B^]V?F
MV=5'4QDD_LV7X7_4****]8\,**** "BBB@ HHHH ]$^".M?8/$TMBQQ'?18'
M( WKDC]-WYU[O7S'X NC:>--&<'!-RD?3/WCM_K7TY7QF<4U&NI+JC] R&HY
M89P?V7^84445X1]*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RGX@N/MFO:
ME.>?-N9'X]W)JA5_Q!;"RU[4K<# AN9(P"<]'(JA7Z;3MR*Q^/5+\\K[W"BB
MBK,PHHHH **** "BBB@#V?X"7&[3-6@SPDR/C_>4C_V6O5*\I^ =OMT_5Y\<
MO+&F?]T$_P#LU>K5\#F5OK4[?UHC].RF_P!2IW\_S84445YIZX4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&7_  57_P"3>?#W
M_8TV_P#Z27=?9M?&7_!5?_DWGP]_V--O_P"DEW0!ZK^PO_R:?\/?^O6?_P!*
M9:]XKP?]A?\ Y-/^'O\ UZS_ /I3+7O% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ6.C>&C6Z+%%%%<)Z04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^,O^"J__)O/A[_L:;?_ -)+NOLVOC+_ (*K_P#)O/A[_L:;?_TD
MNZ /5?V%_P#DT_X>_P#7K/\ ^E,M>\5X/^PO_P FG_#W_KUG_P#2F6O>* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV?Z!1117SY]2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 -=UC1G=@JJ,EF. !ZU\Y
M_$7QP_C+5AY)9--M_E@C/&[U<^Y_0?C7J'QD\1/HWA@6D)VS:@QB)SR(P,O^
M>0OT8UX%7U64856>(EOT/BL^QCYEA8/3=_HOU"BBBOICX\**** "BBB@ KO?
MA9X\?PYJ2:?=R$Z9<N%Y_P"6+DX##G@'O^=<%16%:C"O!TY[,Z,/7GAJBJTW
MJCZ[HKDOACXD;Q)X3@DE.ZYMC]GE8]6*@8;\01^.:ZVOSNK3E1FZ<MT?J]&K
M&O3C5CLT%%%%9&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7^(?$?QH\%Q+=Z=Y4.C:;J#P7=L[MN,DY",Z.5 15SD LQQD CTK_@IW\!_
M,G[-.L>,8-!TW1_$FA3VAL[VQMD@DF62XCA:%RH&]=LA8 ]"@(P,Y[?:4E)4
MU$G7<Z[]AW]N[3_VI+.X\/Z[:6^A>/["'SY;6W)^SWT((!E@W$E2I(W(22,@
M@D9V_6E?S_?L1ZMJ6C_M9?"Z;2F9;B36X;:3:>L$A,<P/MY;/7] -<F(IJG+
MW>I2"BBBN49\[_MF?M@:1^R?X'MKG[*FL>+-6+QZ3I3/M0[<;YI2.1&NX=.6
M) &.67\FO&_[??QY\=:I+=S_ !#U+2(V8E+30R+*&(9R%'E@,0/5BQ]2:N?\
M%"?BC<?%']J[QK(TK-8Z%<?V#9QELB-;<E),?6;S6_X%7W3_ ,$O/V9?"5I\
M![;X@Z]X?T_6?$'B.XG,$^H6R3&VM8I&A5$#@A2S([$CDAE!X KTXQA1IJ<E
M=LC=GQW\&?\ @IE\9OACK=NVNZVWCS0=X^T:=K(4RE>YCN N]6QTW%E_V37[
M$_!_XL>'_CA\.M&\:>&+AI])U.+>JR "2%P2KQ2 $X=6!![<9!((-?E/_P %
M5OV>- ^$/Q+\-^*?"VEV^C:3XHMYA<6-G&(X8[N IO=4  0.DJ' XRKGN:]&
M_P""-OQ1N$UKQW\.KB5GM9+>/7;.,M\L;(RPSX'^T)(/^^*FK",Z?M(JP+>Q
M^HM%%%><6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W_8TV_P#Z27=
M'JO["_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-\?+%VM]'O%7]VCR1.
MV>[!2H_\=:O':^F?B!H+>(_"=]:1KNG5?-A &277D >YY'XU\SLI5B",$<$&
MOM<IJJ>'Y.L?^'/SS/*+IXKVG22_+02BBBO;/G0HHHH **** "BBB@#J_A;9
M27WCG3 G B9I6/H%4_UP/QKZ0KR3X$Z%)&M_J\BX20"WA;N><O\ J%_6O6Z^
M(S:JJF(Y5]E6/T7(Z+I83F?VG?\ 0****\8^@"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /!OC=?O<>+H[<D>7;VZ@ >K$L2?S'Y5Y[77?%AV;Q_JFX8QY8 SGCRD
M_P#U_C7(U^B8./+AZ:79'Y3F$G/%U6^[_#0****[#@"BBB@ HHHH **** /4
MO@-J#IJVI6.1Y<D FQCG*L!U_P"!U[37@/P49E\:@*,AK:0-QT'!_GBO?J^(
MS:*CB6UU2/T;(Y.6#2?1L****\8]\**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\W'YTJ?^[OYAU/VXHHHKS"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG/X7?]"#X?\ _ "/_"O1J*T^M5_^?C^]D^QI?RK[CSG_ (9S^%W_ $(/A_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<-\<OBA:_!;X1>*_&]W&)H]%L)+B.$G EE^[%'GMND9
M%S[UW-?(?_!5'4)K/]D'6HHBP2ZU.QAEVGC:)@_/MN1?TJZ<>::3$?C+XT\9
M:S\0_%FJ^)?$%])J6M:I<-<W5U*>7=CZ=@.  .   .!7<_#?]EOXL_%S1UU;
MPEX#UC6-*8L$OEB$4$A7KL=RJMCIP3SQ7/\ P5\)V7CSXQ^!?#6I-MT[6-=L
M=/N3N*_NI;A$?D=#AC7]&FFZ;::-IUKI]A;16=C:Q+!!;PJ%2*-0 JJ!P
M /:O5K5O8V21"5S^</XA?"CQE\)]2CT_QCX8U3PU=R@M$FHVS1"51U*,1AQ[
MJ36E\%?CAXO^ 'CBU\4>#M3>PO8B!/;L2UO=Q9R8IDSAT/Y@\@@@&OZ#OB)\
M-_#7Q8\)WOAKQ9H]MK>C7B[9+>Y3.#V=&ZHXZAE((/0U^)?[:7[%NN?LK^*Q
M=6IGU?P%J4I&FZNRY:)N3]GGP,"0 '!X#@9&"&552KQJ^[):C:L?KC^RS^U'
MX8_:E^'R:[HK"RUBUVQ:MHLCAI;*8C_QZ-L$J^.0"."& S?V\/\ DT/XH?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OGW]O;X<W/Q/\ V3_'NEV,+3ZA:VJ:I;HO+$V\BS. .Y,:. /4
MBOH*D90ZE6 96&"",@U49<K3 _F:TG5;O0M5LM2T^=[6_LYDN+>>/[T<B,&5
MA[@@'\*_7#X)_P#!6SX=^(?#MC;_ !'M-0\*^(8T6.YN;6U:ZLYF  ,B^6#(
MF3D[-IQG 9J^;_VW_P#@G7XE^&OBC5/&/PWT>?7O ]Y(UU+IUA'ON-)9B2R"
M,?,\(SE64':.&QC<WQY\,]!;Q!\3O"FBO&=]]K%I9M&PP<O,B8(_&O7E&G7C
M<SU1_20#N /]*P/'W@'0?B?X/U/POXGTV'5M$U*(PW%K,.".H(/56!P0PY!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SM\6M:_M?QI=(IS%9@6R\@\KDMT_VB?R_
M"N-J_P"(+C[9KVI3GGS;F1^/=R:H5^DT(*G2C!=$?D>)J.M6G4?5L****W.8
M**** "BBB@ HHHH ^B/A)K(U;P7:H3F6S8VS\8Z<K_XZ0/P-=G7E/P#N"UCK
M$&>$DC?'^\&'_LM>K5^?8Z"IXF<5W_/4_4LMJ.K@Z<GVM]V@4445P'IA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7(:W\(/ OB3Q!::[JO@W0=0URSN([JWU2XTZ%[J*6-@R.LI7<""
M0<]JZ^BG=K8 KB?C)\8/#OP)^']_XR\527$6B6+Q),UK"99 9)%C7"CK\S"N
MVKY3_P""GW_)F?C#_KYT_P#]+(JJ"YI),#'_ .'K7P$_Z"&O?^"E_P#&OJ?P
M+XSTWXB>"]#\4:.TCZ5K%G%?6K3)L<Q2*&4LO8X(XK^:ROZ%/V1?^36_A/\
M]BQI_P#Z(2NK$48TTG$E.YF?%+]BGX+?&&^N-0\1^!+!M5N/FDU#3V>RG=O[
M[-"R[V]W!KU;P7X3L/ 7@[0O#.E"0:7HMA!IMH)GWN(88UC3<W<[5&36S17(
MY-JS904445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?&7_!5?\ Y-Y\/?\ 8TV__I)=U]FU\9?\
M%5_^3>?#W_8TV_\ Z27= 'JO["__ ":?\/?^O6?_ -*9:]XKP?\ 87_Y-/\
MA[_UZS_^E,M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Y4\16XM/$&IP ;1%=2ICTPY%9]=M\7](.E^,[B4*!%>(
MLZXQUQAOU!_.N)K])P]15*49KJC\CQ5-T:\Z;Z-A1116YS!1110 4444 %%%
M% 'L_P !(0NFZM-CEYD3=CT4G_V;]:]4KD?A7HXTCP38\8DNLW+_ / ON_\
MCH6NNK\]QU15,3.2[_EH?J>74W2PE.+[?GJ%%%%<)Z04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?*?_!3[_DS/QA_U\Z?_ .ED5?5E>6?M-? N/]H[X.ZOX"EUEM 34);>0WZ6
MPN"GE3))C9N7.=F.O&:NFU&:; _GBK^A3]D7_DUOX3_]BQI__HA*^+O^'+EA
M_P!%:N?_  GU_P#DFOT!^$O@%?A9\,/"O@Y+TZDF@Z9;Z<+QHO+,PBC";]F3
MMSC.,G'K79B*L*B2BR4CK****X"@HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO
MBKX1_P"$F\/F:!-U_9YDB ZNO&Y?R&1[CWKYYKZ[KQKXI_#26*Y?5]'MB\,F
M6N+>(<H?[ZCT/?T/Z?2Y5C5#]Q4>G3_(^1SK+W4_VFDM>J_4\IHHHKZL^("B
MBB@ HHHH *Z+P)X5?Q;X@@M2"+5")+AL'A >1D=">@K+T71;SQ!J$=E8PM-.
M_8=%'=B>P'K7T=X+\)P^#]%2SC82S,=\TV,;V_P'05Y.88Q8:GRQ?O/^KGMY
M7E\L95YI+W%OY^1NHBQHJ(H55& JC  ]*=117PI^E!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KS']J+_DV;XN?]BAJ__I%+7IU>8_M1?\FS?%S_ +%#5_\ TBEJ
MH_$@/YW:_HB_9=_Y-F^$?_8H:1_Z115_.[7]$7[+O_)LWPC_ .Q0TC_TBBKT
M<7\*(B>G4445YA84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7QE_P57_Y-Y\/?]C3;_P#I)=U]FU\9
M?\%5_P#DWGP]_P!C3;_^DEW0!ZK^PO\ \FG_  ]_Z]9__2F6O>*\'_87_P"3
M3_A[_P!>L_\ Z4RU[Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR@'VB$$].SC_ -!/Y^M>O5^>8JA]7K2IGZK@<2L7AXU>KW]0HHHKD.X****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%%%<!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7QE_P57_Y-Y\/?]C3;_P#I)=U]FU\9?\%5_P#D
MWGP]_P!C3;_^DEW0!ZK^PO\ \FG_  ]_Z]9__2F6O>*\'_87_P"33_A[_P!>
ML_\ Z4RU[Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D
MOQ\O'6WT:T5_W;M)*Z^X"A3_ ./-^=>/5ZE\>D8:MI3G[A@<#ZAN?YBO+:^]
MRU)86%O/\S\RS>3EC:E_+\D%%%%>F>.%%%% !1110 4444 =3\,;XV/CC2V#
M%5D<Q-@9SN! 'YXKZ2KY?\$1O)XPT4)][[9$?P# G] :^H*^0SI+VT7Y'WG#
M\G[":\_T"BBBOGCZD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=,O ]E]3_DU]!^'] L_#.EQ6%DA6&/)W-RSL>K,>YJ_##';Q+'$BQ1J,*B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_Q-'_#3][_T (/_  (;_P")H ^@J*^??^&G[W_H 0?^!+?_ !-'_#3]Y_T
M(/\ P);_ .)H ^@J*^??^&G[S_H 0?\ @2W_ ,31_P -/WG_ $ (/_ EO_B:
M /H*BOGW_AI^\_Z $'_@2W_Q-'_#4%Y_T (/_ EO_B: /H*BOG[_ (:@O/\
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M\-0S_P#0NQ_^!9_^(H ]^HKP'_AJ&?\ Z%V/_P "S_\ $4?\-0S_ /0NQ_\
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MO^A=C_\  P__ !%'_#4,W_0N1_\ @8?_ (B@#WVBO O^&H9O^A<C_P# P_\
MQ%'_  U#-_T+D?\ X&'_ .(H ]]HKP+_ (:AF_Z%R/\ \##_ /$4?\-0S?\
M0N1_^!A_^(H ]]HKP+_AJ*;_ *%Q/_ P_P#Q%'_#44W_ $+B?^!A_P#B* /?
M:*\"_P"&HIO^A<3_ ,##_P#$4?\ #44W_0N)_P"!A_\ B* /?:*\"_X:BF_Z
M%Q/_  ,/_P 12_\ #44O_0N)_P"!A_\ B* /?**\#_X:BE_Z%Q/_  ,/_P 1
M1_PU%+_T+B?^!A_^(H ]\HKP/_AJ*7_H7$_\##_\11_PU%+_ -"XG_@8?_B*
M /?**\#_ .&HI?\ H7$_\#3_ /&Z/^&HI?\ H7$_\#3_ /&Z /?**\#_ .&H
MI?\ H7$_\#3_ /&Z/^&HI?\ H7$_\#3_ /&Z /?**\#_ .&HI?\ H7$_\#3_
M /&Z/^&HI?\ H7$_\#3_ /&Z /?**\#_ .&HI/\ H6U_\#3_ /&Z/^&HI/\
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MZ/\ AJ*3_H6U_P# W_[70![W17@G_#43_P#0MK_X'?\ VNC_ (:B?_H6U_\
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M ('?_:Z />J*\%_X:B;_ *%H?^!W_P!KH_X:B;_H6A_X'?\ VN@#WJBO!?\
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M%>#?\-1G_H6?_)__ .UT?\-1G_H6?_)__P"UT >\T5X-_P -1G_H6?\ R?\
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M?_\ M5'_  U'_P!2S_Y/_P#VJ@#WBBO!_P#AJ/\ ZEG_ ,G_ /[51_PU&/\
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M7_H6C_X'?_:Z/^&HE_Z%H_\ @=_]KH ]WHKPC_AJ)?\ H6C_ .!W_P!KI?\
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M_P"(K)\2?MH>'O!UF+O7+.VTFW)PLEYJ:1ACZ+E.3["EOL!]%45\=+_P4_\
MA0\_DB]M]_3)GD"_]]>3C]:] T']L30_%%@M]H^GP:I9L<">SU))4SZ95.OM
M3<91W0'T+17AG_#4,/\ T+LG_@8/_B*/^&H8?^A=D_\  P?_ !%2![G17AG_
M  U##_T+LG_@8/\ XBF3?M3VMO"\LN@-%%&I9W>] 50!DDG9P* /=J*^6O\
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M^(H ]QHKP[_AJ"V_Z%Z7_P "A_\ $4?\-06W_0O2_P#@4/\ XB@#W&BO#O\
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M&H+3_H7YO_ D?_$T?\-06G_0OS?^!(_^)H ]PHKP_P#X:@M/^A?F_P# D?\
MQ-'_  U!:?\ 0OS?^!(_^)H ]PHKP_\ X:@M/^A?F_\  D?_ !-'_#4%I_T
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MKQ#_ (:?L_\ H 3_ /@2O_Q-'_#3]G_T )__  )7_P")H ]OHKQ#_AI^S_Z
M$_\ X$K_ /$T?\-/V?\ T )__ E?_B: /;Z*\0_X:?LO^@!/_P"!"_\ Q-'_
M  T_9?\ 0 G_ / A?_B: /;Z*\0_X:?LO^@!/_X$+_\ $T?\-/V7_0 G_P#
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M?\* /;**\3_X:>T__H!7/_?]?\*/^&GM/_Z 5S_W_7_"@#VRBO$_^&GM/_Z
M5S_W_7_"O;* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^,4?\/-/VC?^A]B_\$EA_P#&*Y_JD^Z'S'[G45^&/_#S3]HW_H?8O_!)8?\
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MVBOAM\._!EQXHUGQGHZZ1'$98WM[V.9[G'1851B9&)X 7-?E?\=O^"57Q1\
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M:I&,%3@[C7<VZ***\\H**** "OC;_@JA<2VG[/\ X<E@E>&5?%-OAXV*L/\
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M]AZ;_P! ^U_[\K_A5ZB@"C_8>F_] ^U_[\K_ (4?V%IO_0/M?^_"_P"%7J*
M*/\ 86F_] ZU_P"_"_X4?V%IO_0.M?\ OPO^%7J* */]A:;_ - ZU_[\+_A1
M_86F_P#0.M?^_"_X5>HH H_V#IO_ $#K7_OPO^%)_8.F?] ZT_[\+_A5^B@"
MA_8.F?\ 0.M/^_"_X4?V#IG_ $#K3_OPO^%7Z* *']@Z9_T#K3_OPO\ A1_8
M.F?] ZT_[\+_ (5?HH H?V#IG_0.M/\ OPO^%']@Z9_T#K3_ +\+_A5^B@"A
M_8.F?] ZT_[\+_A1_8.F?] ZT_[\+_A5^B@"A_8.F?\ 0.M/^_"_X4?V!IG_
M $#;3_OPO^%7Z* *']@:7_T#;3_OPO\ A1_8&E_] VT_[\+_ (5?HH H?V!I
M?_0-M/\ OPO^%']@:7_T#;3_ +\+_A5^B@"A_P (_I?_ $#;3_OPO^%)_P (
M_I?_ $#;/_OPG^%:%% &?_PC^E_] VS_ ._"?X4?\(_I?_0-L_\ OPG^%:%%
M &?_ ,(_I?\ T#;/_OPG^%'_  C^E_\ 0-L_^_"?X5H44 >/?'+2+6RM=(FM
MK6&W^>1&\E%7.0I&<#GH?UKR6OHGXLZ,=7\%W;(NZ6T(N5Z=%^]_XZ6/X5\[
M5]OE-12PRCV;_P S\ZSRFX8MR_F2?Z?H%%%%>R?/A1110 4444 %%%% &MX3
MLQ?^*-)MV3S$DNH@ZXSE=PW?IFOI3_A'=*_Z!EG_ . Z?X5XG\%]'_M#Q=]J
M9-T5E$TF3TWGY5_'DG\*]]KX[.:BE6C!=%^9]]D%-QP\IOJ_R,[_ (1W2O\
MH&6?_@.G^%'_  CNE?\ 0,L__ =/\*T:*\ ^G,[_ (1W2O\ H&6?_@.G^%'_
M  CNE?\ 0,L__ =/\*T:* ,[_A'=)_Z!=G_X#I_A1_PCND_] NS_ / =/\*T
M:* ,[_A'=)_Z!=G_ . Z?X4?\([I/_0+L_\ P'3_  K1HH SO^$=TG_H%V?_
M (#I_A1_PCFD_P#0+L__  '3_"M&B@#._P"$;TG_ *!=E_X#I_A1_P (WI/_
M $"[+_P'3_"M&B@#._X1O2?^@79?^ Z?X4?\(WI/_0+LO_ =/\*T:* ,[_A&
M])_Z!=E_X#I_A2?\(WI'_0+LO_ =/\*TJ* ,W_A&](_Z!=E_X#I_A1_PC>D?
M] NR_P# =/\ "M*B@#-_X1O2/^@79?\ @.G^%'_"-Z1_T"[+_P !T_PK2HH
MS?\ A&](_P"@59?^ Z?X4?\ "-Z1_P! JR_\!T_PK2HH S?^$;TC_H%67_@.
MG^%'_"-Z1_T"K+_P'3_"M*B@#-_X1O2/^@59?^ Z?X4?\(UI'_0*LO\ P'3_
M  K2HH S?^$9TC_H%6/_ (#)_A1_PC.D?] JQ_\  9/\*TJ* ,W_ (1G2/\
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M#)_A1_PB^C?] BQ_\!D_PK4HH R_^$7T;_H$6/\ X#)_A1_PBVB_] BP_P#
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M:?\ ^ J?X4?\(GHG_0&T_P#\!4_PK5HH R?^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PK6HH R?^$3T/_H#:?\ ^ L?^%'_  B>A_\ 0&T__P !8_\
M"M:B@#)_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"M:B@#)_P"$2T/_
M * NG_\ @+'_ (4?\(EH?_0%T_\ \!8_\*UJ* ,G_A$M#_Z NG_^ L?^%'_"
M):'_ - 73_\ P%C_ ,*UJ* ,G_A$M#_Z NG_ /@+'_A1_P (CH7_ $!=/_\
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MO_@YT_\ ^+H_X7O^SW_T4'X:_P#@YT__ .+K\//^&;?BY_T2SQK_ .$]=_\
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M^@S_ (0_0?\ H":=_P" D?\ A1_PA^@_] 33O_ 2/_"M>BO-+,C_ (0_0?\
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M'_0#TW_P$C_PI/\ A#?#_P#T M-_\!(_\*V:* ,;_A#?#_\ T M-_P# 2/\
MPH_X0WP__P! +3?_  $C_P *V:* ,;_A#?#_ /T M-_\!(_\*/\ A#?#_P#T
M M-_\!(_\*V:* ,;_A#/#_\ T M-_P# ./\ PH_X0SP__P! +3?_  #C_P *
MV:* ,;_A#/#_ /T M-_\ X_\*/\ A#/#_P#T M-_\ X_\*V:* ,;_A#/#_\
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MNV.1MCM@TA'NQ/'X8KU<+EF*QBYJ<?=[GFXK,*.%TEJ^R/K=O!/AM5).@:4
M.239Q?\ Q-5_^$9\(>9Y?]DZ)YG]W[-#G\L5\-7G[4WAC49GENKK5+B1SN9I
M8=Q)]>6JO_PTMX.];_\ \!Q_\57M1X=JV]Z3^[_@GARSZ=_=H_C_ , ^]?\
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M_P#H7-)_\ HO_B:WZ* ,#_A7_A?_ *%S2?\ P"B_^)I/^%?^%_\ H7-)_P#
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M!4_PH_X5OX5_Z%W3?_ 9/\*Z2B@#F_\ A6_A7_H7=-_\!D_PKI*** "BBB@
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M9W2EL3RG\^7@GPCJ'C_QEH7AC25C;5-:OH-.M%F?8AFED6- S=AN8<U]6?\
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M,/P)'_?7M7J5?GN-A.&(FI[W/U3+JE.IA:;IJRM_PX4445PGHA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !17D_[3'Q>U+X(_#,^)-*L[6^N_ML5MY5X&V;7#9/RD'/'K7R9_P\?\<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJXO]C'_@IQH/PM^&.G>!/B99:I-'HT?V?3-8TZ-9]UN,[(94+*1L&%5ESE0
M0-N3X/\ MY_MD0_M7>,-&BT+3[K2_".@QR+9QWVT3W$LA7S)G520O"(JKDX
M)S\Q 5.C.-6[V&WH>C_\$>M2N;?]H_Q+91LQM;CPO/)*@/&Y+JVVL?IN8?\
M J_82OS<_P""/OP/O]%TGQ3\4=3M6MH=6C72-),BD&6%7#SR#U0NL:@^L;^E
M?I'6&(:=1V&M@HHHKF&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M UKKEX)-5O[=P0T4D[;EC8'HRQB-6']Y37SW^V)_P4<\;?LY?'35? ^B>&=
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M!1117,,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]_V--O\ ^DEW0!ZK^PK_ ,FG_#W_ *]9_P#TIEKWBO!_V%?^33_A[_UZS_\
MI3+7O% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X_\?F;SM$4C
MY0LQ!]\IG^0KR2O:OCS8M)H^F78&5AG:,\<C<N?R^3^5>*U]WE<D\)&W2_YG
MYIG,7'&S;ZV_)!1117JGBA1110 4444 %%%% &AX=8KX@TPJNYA=187.,_..
M*^JZ^8_ %FU]XTT:-!DK<I+QZ(=Y_1:^G*^2SJ2]I!>1]SP]%^RJ2\PHHHKY
MP^L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBO*?B[\07L]^AZ;*!(Z8NIE.2H/
M_+,>AQU]B/>NG#X>>)J*G X\5BH8.DZM3_AQWC_XO+8R2:?H3)+,,K)><,J'
MT3L3[]/K7C]Y?7&HW#W%U/)<3M]Z25BS'\34%%?=X;"TL+'E@M>_4_-<7C:V
M,GS5'IT71!11178< 4444 =_X'^+%_H,T-KJ4CWNG9P6<EI8Q[$GD#T_*O<M
M-U2TUBS2ZLKA+FW?I)&<CZ>Q]J^3JZ_X=>.I/!NI%9MTFFSG$T8R=I_OJ/7U
M]1^%>!C\MC53J45:7;O_ ,$^FRS-IT9*E7=X]^W_  #Z,HID,R7$*2QL'CD4
M,K+T((R#3Z^./OPHHHH **** "BBB@ HHHH ^;/VT/V.7_:\TWPI9CQC_P (
ME'H<MQ,?^)9]M^T&41@?\MH]NW8?7.[MCGF_V-OV!4_9)\::[XA/C?\ X2N3
M4]/%@L/]D?8_)'F*Y;=Y\F[.P#&!7UO16OM)\O)?05@HHHK(94U:S?4=+O+2
M.;[/)/"\2S;=VPLI ;&1G&<XS7YI?\.5_P#JL?\ Y:__ -V5^G%%:0J2I_"Q
M$%C9II]C;VL?^K@C6)?HH '\JGHHK,9R/Q=\ _\ "U/A;XL\&_;_ .R_[>TR
MXT[[;Y/G>1YL93?LW+NQG.-PSZBO@7P[_P $;?[ \0:9JG_"WO/^Q745SY7_
M  C.W?L<-MS]K.,XQG%?I116L*LX*T6(*\S^/?[.W@G]I'P?_P (_P",]--S
M'$QDL[ZW;R[JRD(P7B?!QGC*D%3@9!P*],HK--Q=T,_*SQ;_ ,$9_$<.I2'P
MQ\1=+N[ G*#5K.2"51Z$QEPQ'KQGT%=Y\&?^"/N@^']8M]2^)'BUO$T,+!_[
M&TJ!K:"0@]))BQ=E/<*$/^U7Z+T5T/$5&K7%9%/1]'L?#^E6FF:79P:?IUG$
ML%O:6L8CBAC485%4<  #&!5RBBN884444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.
MGQ:A\GQ]J6.C^6X_&-<_KFN/KT[XZZ2T&M6.H ?N[B'RCS_$I]/HP_*O,:_0
M\%-3PT&NWY:'Y7F--T\74B^[?WZA1117:><%%%% !1110 4444 >@?!&#SO&
M3OG'E6DC_P#CRK_[-7O=>1? 723MU34V'!VVT9S_ ,";_P!D_6O7:^&S6:EB
MFETLC](R6FX8.+?5MA1117D'NA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!\L2X9L %F[DX YK3K\]QF(^LUI5%MT/U/+\+]4P\:3WZ^H4445Q'HA1110
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M7PF9TU3Q4K==3]+R>JZF#C?IH%%%%>4>T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+E/WD3-CH?E(&??YOR->15][EK3PL+>?YGYCFZ:QM2_E^2"BBBO3/("BBB@
MHHHH **** -OP1,8?&&BL.IO(EZXZL!_6OJ"OFKX:VK7GCC2$5=VV7S#[!06
MS^E?2M?(9TU[6*\OU/N^'T_83?G^@4445\\?5!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKYG_:"_X*
M$?";]GO6+C0M0OKOQ)XEMSMGTK0HUE:W;^[+(S*B'U7)8=UKYVO/^"SV@1R,
M+3X7:E-'GAIM7CC)'T$3?SK:-&I)72%='Z0T5^:W_#Z+2_\ HE%W_P"#U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML*M;VJ2L-*P4445S#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^,O^"J__)O/A[_L:;?_ -)+NOLV
MOC+_ (*K_P#)O/A[_L:;?_TDNZ /5?V%_P#DT_X>_P#7K/\ ^E,M>\5X/^PO
M_P FG_#W_KUG_P#2F6O>* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIID4R:7>7"07MNQ RCPL=V0>,C*G'!(YK\!O%7Q \4>.VMF\2^)-7\0M;!A
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MZ]9__2F6O>* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*9:]XH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_DWGP]_V--O_P"DEW0!ZK^PO_R:?\/?^O6?_P!*9:]XKP?]A?\ Y-/^'O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%%>86%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\9?\ !5?_ )-Y\/?]C3;_ /I)=U]FU\9?\%5_
M^3>?#W_8TV__ *27= 'JO["__)I_P]_Z]9__ $IEKWBO!_V%_P#DT_X>_P#7
MK/\ ^E,M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/>/M#;
MQ!X2U"TB3S)]GF1*.I=3N 'N<8_&OF6OKNO!OBYX*DT35FU.UA/]G71W,54
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!C3;_^DEW0!ZK^PO\ \FG_  ]_Z]9__2F6O>*\'_87_P"33_A[_P!>L_\
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M['N?K6A7RV-S*>)7)#2/YGV>7Y3#!OVE1\T_P7]=PHHHKQCZ **** "BBB@
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M=_6OH*O@\RHJCB'R[/4_2\HQ#Q&%CS;QT_KY!1117EGM!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5\W?\ !0;XE^)OA+^S+K7B/PCJ\VB:W#>V<<=Y JLRJ\RJPPP(Y!QTKZ1K
MPO\ ;2^!NO\ [17P%U3P3X:NM/L]6NKJVG275)7C@"QRAVR41SG X^6M*=N=
M7V$S\A?^&_\ ]H+_ **;J?\ WXM__C=?K1^VM\1O$?PU_8_\5^+/#.JRZ3XB
MM(-.:"_A52Z&2\MHW(# CE78=.]?GW_PY[^-'_0P^!__  87?_R+7Z/_ +5?
MP6USXX?LS>(OAYH-S86NMZC%8I%-J$CI;@PW4$K[F1&896)L84\D=.M=E65-
MRCRV$KGX^?\ #?\ ^T%_T4W4_P#OQ;__ !NC_AO_ /:"_P"BFZG_ -^+?_XW
M7LG_  Y[^-'_ $,/@?\ \&%W_P#(M'_#GOXT?]##X'_\&%W_ /(M=/-0\B=3
MQO\ X;__ &@O^BFZG_WXM_\ XW1_PW_^T%_T4W4_^_%O_P#&Z]D_X<]_&C_H
M8? __@PN_P#Y%H_X<]_&C_H8? __ (,+O_Y%HYJ'D&IXW_PW_P#M!?\ 13=3
M_P"_%O\ _&Z_;#]G_P 0:AXL^ WPVUS5[IKW5=3\-:;>W=TX :::2UC=W(
MR68G@=Z_+/\ X<]_&C_H8? __@PN_P#Y%K]6/@SX/O?AY\'_  +X5U*2";4=
M#T&QTRYDM6+1-+#;I&Y0D E2RG!(!QC@5R8ATVER%*YV5%%%<)04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7QE_P57_Y-Y\/?]C3;_P#I)=U]FU\9?\%5_P#DWGP]_P!C3;_^DEW0
M!ZK^PO\ \FG_  ]_Z]9__2F6O>*\'_87_P"33_A[_P!>L_\ Z4RU[Q0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#!8KP1874UK<_#OQ/;W,+M'+#+) KHP."I!;((((Q7D'[5G_!3#PC^T%\
M_%'@'2_"&MZ7?:O]E\N[NY83$GE74,QR%;/(B(X[D5TQH3YE=:"NCZ(\!_\
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MC<[?M%W.]Q)L7:NYV+' [#)K]V?^">-Q/=?L:_#1[@;9!:W*#/\ <6[G5/\
MQT"M\11C3BG$29]&4445P%!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?&7_!5?_DWGP]_V--O_P"D
MEW7V;7QE_P %5_\ DWGP]_V--O\ ^DEW0!ZK^PO_ ,FG_#W_ *]9_P#TIEKW
MBO!_V%_^33_A[_UZS_\ I3+7O% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <;\6-#.M>#;DQH7GM&%R@7OCAO_'2Q_ 5\[5]=,H92",@\
M$&OFSXA>$Y/"?B":)4Q93$R6S=BO]W\"<?EZU]3D^(5G0EZK]3XO/\*[QQ,5
MIL_T_P CF****^G/C@HHHH **** "BBI[*RGU*[AM;:)IKB9@B1KU)-)M)78
MTFW9'I?P)T7S]4OM4<?+;H(8_F_B;D\>P'Z_E[361X5\/Q>%]!M=/B^8QKF1
MQ_&YY8_G^E:]?GV-K_6*\IK;H?J>7X;ZIAHTWON_5_U8****X3T0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>1?&[Q3;2)%H44:2W",)
MII&',7'RJ/<@Y/MCUX]*\3:TOAW0;[464-]GC+*K' 9NBC\217R]?7TVI7DU
MU<.7FF<NS$D\GZU[^4X7VE3VTMH_F?,9YC/8TOJ\=Y;^G_!(****^Q/@0HHH
MH **** "NJ^''BJ'PGX@2>Y@22"8>4\I'SQ G[RG^?M7*T5E4IQJP<);,UHU
M94*BJ0W1]<HZR(KHP96&0RG((]:=7G?P7\3/J^@R:=.S//8856/.8SG:/PP1
M],5Z)7YW7HRP]25.70_5\-7CB:,:L>H4445@=(4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7?Q]/X;_ &=]'\.6TYB?Q%K4<=P@/^LMX$:5A_W]$!_"M*<>>2B(_-K]I/\
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M_P#Q='_#2'BG_H%:;_WYE_\ BZ /I"BOF_\ X:0\4_\ 0*TW_OS+_P#%T?\
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M /I"BOF__AI/Q-_T"M-_[]2__%T?\-)^)O\ H%:;_P!^I?\ XN@#Z0HKYO\
M^&D_$W_0*TW_ +]2_P#Q='_#2?B;_H%:;_W[E_\ BZ /I"BOF_\ X:3\2_\
M0*TW_OW+_P#%T?\ #2GB7_H%:;_W[E_^+H ^D**^;_\ AI3Q+_T"M-_[]R__
M !='_#2GB7_H%:;_ -^Y?_BZ /I"BOF__AI3Q+_T"M-_[]R__%T?\-*>)?\
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M%Z;_ -\R?_%T?\-,:_\ ] O3?^^9/_BJ /I"BOF__AIC7_\ H%Z;_P!\R?\
MQ5'_  TUK_\ T"]-_*3_ .*H ^D**^;_ /AIK7_^@7IOY2?_ !5'_#36O_\
M0+TW\I/_ (J@#Z0HKYO_ .&FM?\ ^@7IOY2?_%4?\--:_P#] O3?RD_^*H ^
MD**^;_\ AIK7_P#H%Z;^4G_Q5'_#36O_ /0+TW\I/_BJ /I"BOF__AIK7_\
MH%Z;^4G_ ,51_P --:]_T"]-_*3_ .*H ^D**^</^&FM>_Z!>G?E)_\ %4?\
M--:]_P! O3ORD_\ BJ /H^BOG#_AIK7O^@7IWY2?_%4?\--:]_T"]._*3_XJ
M@#Z/HKYP_P"&FM>_Z!>G?E)_\51_PTUKW_0+T[\I/_BJ /H^BOG#_AIK7O\
MH%Z=^4G_ ,51_P --:]_T"]._*3_ .*H ^CZ*^</^&FM>_Z!>G?E)_\ %4?\
M--:]_P! O3ORD_\ BJ /H^BOG#_AIK7?^@5IWY2?_%4?\--:[_T"M._\B?\
MQ5 'T?17SA_PTUKO_0*T[_R)_P#%4?\ #36N_P#0*T[_ ,B?_%4 ?1]%?.'_
M  TUKO\ T"M._P#(G_Q5'_#36N_] K3O_(G_ ,50!]'T5\X_\--:[_T"M/\
M_(G_ ,51_P --:[_ - K3_\ R)_\50!]'45\X_\ #36N_P#0*T__ ,B?_%4?
M\--:[_T"M/\ _(G_ ,50!]'45\X_\--:[_T"M/\ _(G_ ,51_P --:Y_T"M/
M_P#(G_Q5 'T=17SC_P --:Y_T"M/_P#(G_Q5'_#36N?] K3_ /R)_P#%4 ?1
MU%?./_#36N?] K3_ /R)_P#%4?\ #36N?] K3_\ R)_\50!]'45\X_\ #36N
M?] K3_\ R)_\51_PTUKG_0*T_P#\B?\ Q5 'T=17SC_PTUKG_0*T_P#\B?\
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MPTYK/_0(L?\ OI_\: /HNBOG3_AIS6?^@18_]]/_ (T?\-.:S_T"+'_OI_\
M&@#Z+HKYT_X:<UG_ *!%C_WT_P#C1_PTYK'_ $!['_OI_P#&@#Z+HKYT_P"&
MG-8_Z ]C_P!]/_C1_P -.:Q_T!['_OI_\: /HNBOG3_AIS6/^@/8_P#?3_XT
M?\-.:Q_T!['_ +Z?_&@#Z+HKYT_X:<UC_H#V/_?3_P"-'_#3FL?] >Q_[Z?_
M !H ^BZ*^=/^&G-8_P"@/8_]]/\ XT?\-.:Q_P! >Q_[Z?\ QH ^BZ*^=/\
MAIS6/^@/8_\ ?3_XTO\ PTYK'_0'L?\ OI_\: /HJBOG7_AIS6/^@/8_]]O_
M (T?\-.:Q_T!['_OM_\ &@#Z*HKYU_X:<UC_ * ]C_WV_P#C1_PTYK'_ $![
M'_OM_P#&@#Z*HKYU_P"&G-8_Z ]C_P!]O_C1_P -.:O_ - >R_[[?_&@#Z*H
MKYU_X:<U?_H#V7_?;_XT?\-.:O\ ] >R_P"^W_QH ^BJ*^=?^&G-7_Z ]E_W
MV_\ C1_PTYJ__0'LO^^W_P : /HJBOG7_AIS5_\ H#V7_?;_ .-'_#3FK_\
M0&LO^^W_ ,: /HJBOG7_ (:<U?\ Z UE_P!]O_C1_P -.:O_ - :R_[[?_&@
M#Z*HKYU_X:<U?_H#67_?;_XT?\-.:O\ ] :R_P"^W_QH ^BJ*^=O^&G-6_Z
MUE_WV]'_  TYJW_0&LO^^WH ^B:*^=O^&G-6_P"@-9?]]O1_PTYJW_0&LO\
MOMZ /HFBOG;_ (:<U;_H#67_ 'V]'_#3FK?] :S_ .^WH ^B:*^=O^&G-6_Z
M UG_ -_'H_X:<U;_ * UG_W\>@#Z)HKYV_X:<U;_ * UG_W\>C_AIS5O^@-9
M_P#?QZ /HFBOG;_AIS5O^@-9_P#?QZ/^&G-5_P"@-9_]_'H ^B:*^=O^&G-5
M_P"@-9_]_'H_X:<U7_H#6?\ W\>@#Z)HKYV_X:<U7_H#6?\ W\>C_AIS5?\
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MUO\ "C_AI[4O^@):_P#?UO\ "@#Z&HKYY_X:>U+_ * EK_W];_"C_AI[4O\
MH"6O_?YO\* /H:BOGG_AI[4O^@):_P#?YO\ "C_AI[4O^@):_P#?YO\ "@#Z
M&HKYY_X:>U+_ * EK_W^;_"C_AI[4O\ H"6O_?YO\* /H:BOGG_AI[4O^@):
M_P#?YO\ "C_AI[4?^@':_P#?YO\ "@#Z&HKYY_X:>U'_ * =K_W^;_"C_AI[
M4?\ H!VO_?YO\* /H:BOGG_AI[4?^@':_P#?YO\ "C_AI[4?^@':_P#?YO\
M"@#Z&HKYZ_X:>U'_ * =K_W^;_"C_AI[4?\ H!VO_?YO\* /H6BOGK_AI[4?
M^@':_P#?YO\ "C_AI[4?^@':_P#?YO\ "@#Z%HKYZ_X:>U'_ * =K_W^;_"C
M_AI[4?\ H!VO_?YO\* /H6BOGK_AI[4?^@':_P#?YO\ "C_AI[4?^@':_P#?
MYO\ "@#Z%HKYZ_X:>U'_ * =K_W^;_"C_AI[4?\ H!VO_?YO\* /H6BOGK_A
MI[4?^@':_P#?YO\ "C_AI[4/^@';?]_V_P * /H6BOGK_AI[4/\ H!6W_?\
M;_"C_AI[4/\ H!6W_?\ ;_"@#Z%HKYZ_X:>U#_H!6W_?]O\ "C_AI[4/^@%;
M?]_V_P * /H6BOGO_AI[4/\ H!6W_?\ ;_"C_AI[4/\ H!6W_?\ ;_"@#Z$H
MKY[_ .&GM0_Z 5M_W_;_  H_X:>U#_H!6W_?]O\ "@#Z$HKY[_X:>U#_ * 5
MM_W_ &_PH_X:>U#_ * 5M_W_ &_PH ^A**^>_P#AIZ__ .@%;?\ ?]O\*/\
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MS_H 0?\ @2W_ ,31_P -07G_ $ (/_ EO_B: /H&BOG[_AJ"\_Z $'_@2?\
MXFC_ (:@N_\ H 0_^!)_^)H ^@:*^?O^&H+O_H 0_P#@2?\ XFC_ (:@N_\
MH 0_^!)_^)H ^@:*^?O^&H+O_H 0_P#@2?\ XFC_ (:@N_\ H 0_^!)_^)H
M^@:*^?O^&H+O_H7X?_ D_P#Q-'_#4%W_ -"_#_X$G_XF@#Z!HKY^_P"&H+O_
M *%^'_P)/_Q-'_#4%W_T+\/_ ($G_P")H ^@:*^?O^&H+O\ Z%^'_P "3_\
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M+\/_ (%'_P"(H ^@**^?_P#AJ"Z_Z%^'_P "C_\ $4?\-077_0OP_P#@4?\
MXB@#Z HKY_\ ^&H+K_H7X?\ P*/_ ,11_P -077_ $+\/_@4?_B* /H"BO /
M^&H+G_H7HO\ P*/_ ,11_P -07/_ $+T7_@4?_B* /?Z*\ _X:@N?^A>B_\
M H__ !%'_#4%S_T+T7_@4?\ XB@#W^BO /\ AJ"Y_P"A>B_\"C_\11_PU!<_
M]"]%_P"!9_\ B* /?Z*\ _X:@N?^A>B_\"S_ /$4?\-07/\ T+T7_@6?_B*
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MWP*GHH @^PVW_/O%_P!\"C[#;?\ /O%_WP*GHH @^PVW_/O%_P!\"C[#;?\
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MQ_A5BB@"O_9]K_S[0_\ ?L?X4?V?:_\ /M#_ -^Q_A5BB@"O_9]K_P ^T/\
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M\^D'_?M?\*M44 5?[+LO^?2#_OTO^%']EV7_ #Z0?]^E_P *M44 5?[+LO\
MGT@_[]+_ (4?V79?\^D'_?I?\*M44 5?[+LO^?2#_OTO^%']EV7_ #YV_P#W
MZ7_"K5% %7^R[+_GSM_^_2_X4?V79?\ /G;_ /?I?\*M44 5?[+LO^?.W_[]
M+_A1_9=E_P ^=O\ ]^E_PJU10!4_LJR_Y\[?_OTO^%']DV7_ #YV_P#WZ7_"
MK=% %3^R;+_GSM_^_2_X4?V39?\ /G;_ /?I?\*MT4 5/[)LO^?.W_[]+_A1
M_9-C_P ^=O\ ]^E_PJW10!4_LFQ_Y\K?_OTO^%']DV/_ #Y6_P#WZ7_"K=%
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M_P! ^U_[\K_A5ZB@"C_8>G?] ^U_[\K_ (4?V'IW_0/M?^_*_P"%7J* */\
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MIG_0.M/^_"_X4?V#IG_0.M/^_"_X5?HH H?V#IG_ $#K3_OPO^%']@Z9_P!
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M_P#R:?\ #W_KUG_]*9:]XH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\%"/VF)_V<O@?*=&N!#XO\1.VG:6X/SVXVYFN0/6-2 /1Y$/(R*_+_\ 8/\
MV;_^&F/CM:VFKQO-X6T91JFM.V2)E##9 3ZROP>^T2$<BM'_ (*,_'23XU?M
M):U;VTQ?0/"S-HE@H/RLT;'SY?3YI=P!'542OT:_X)E_!6'X4_LSZ3K$]OY>
MN>+R-8NY&'S>2<BU0'^[Y6''O*U>A_ HWZLC=GUC##';PI%$BQ11J%1$ "J
M,  #H*?117FEA7Y9_P#!9[3+I/$WPNU$JQLY+.^MU;'RB17A8_B0Z_E7ZF5X
M!^VQ^S.G[4'P7NM!LWBM_$VG2_VAHUQ+POGJI!B8]DD4E2>QVMSMQ6U&2A--
MB>Q\2?\ !&76K.W^('Q(TJ1HQ?W6F6MQ"K'YS'%*ZR8'<9ECS^%?J?J]]::9
MI-[>:A)'%86\#RW$DI 18U4EB2>P -?SO>'O$'Q!_99^+27MJMYX1\9Z',T<
MD%U%@\\,CH>'C8?4$$$'H:]O^*W_  41^-7[17A4> A;:;IT.K;;2XM_#5C,
M+K40W'DG=)(<-D J@&[IT)%=M6A*I/F3T9*9\GS,C3.8U*1EB54G) SP,U^^
MG["/B&7Q-^R'\+[R8[GCTK[$/]VWD>!?TB%?@MKVAWWAG7-1T?4X#:ZEI]S)
M:74!8,8Y8V*.N02#A@1P<<5^YW_!.*W>U_8M^&R.228KU^?1K^X8?H158OX$
MPCN?2E%%%>46%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J.L:YIOAVQ:]U74+73+-2%:XO)EBC!)P 68@<FKU?(_\ P5,_Y,]\0?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OS(F_8/^+;S2,-,T_#,2/\ B81^OUK]-Z*]7 YE6R_F
M]BE[UM_+_ASBQ.$IXJWM+Z'YB_\ #!OQ;_Z!FG?^#"/_ !H_X8-^+?\ T#-.
M_P#!A'_C7Z=45ZW^LN-[1^Y_YG%_9.'[O[_^ ?F+_P ,&_%O_H&:=_X,(_\
M&O0?@!^Q_P#$GX??&+PQXAUFPLHM,L+AI)WCO4=@IC9>%')Y(K[YHK*IQ#C*
ML)4Y*-FK;/K\RX970A)23>G]=@HHHKYD]<*^/?VQOV:?'/QF^).E:SX9L[6X
ML;?28[21I[I(B)!-,Y&#VPZ\U]A45VX/%U,#5]M2M?S.>O0CB(>SGL?F+_PP
M;\6_^@9IW_@PC_QH_P"&#?BW_P! S3O_  81_P"-?IU17O?ZRXWM'[G_ )GF
M_P!DX?N_O_X!^8O_  P;\6_^@9IW_@PC_P :/^&#?BW_ - S3O\ P81_XU^G
M5%'^LN-[1^Y_YA_9.'[O[_\ @'%_!?PO?^"?A1X4T'5$2/4=/T^*WG2-PZAU
M&" 1UKM***^8J3=2;F]V[GL1BH145T"O,/VEO >K_$[X)^(_#6A11S:K??9O
M)2601J=ES%(V6/ ^5&KT^BG1JRHU(U8[Q:?W"J052#@]GH?F+_PP;\6_^@9I
MW_@PC_QH_P"&#?BW_P! S3O_  81_P"-?IU17TW^LN-[1^Y_YGD?V3A^[^__
M (!^8O\ PP;\6_\ H&:=_P"#"/\ QK[$_8Z^$OB+X-?#+4]%\300V]_/K$MX
MBP3+*IC:&! <COF-N*]VHKAQF<XG'4O8U4K>2_X)T4,OI8>?M(7N%%%%>$>D
M%%%% 'A_[3W[77A']E&QT&Y\5Z7KFI)K33I:_P!CV\4@5H@A8.9)4VY$@QC.
M<-Z5P?[,O_!0KP=^TY\3+KP;I.@ZEH-TEC)>V\VJ2Q?Z3L9 T:JA/S;6+=3P
MC>E=K^V=^S9%^U!\%;WPW!+%:^(;.4:AH]U-PBW*JPV.<9".K,I]"5;!VXK\
M.;[3_''[/OQ)1+F'4O!OC/0[@2(6!BGA<=&4]&4CH1E64]P:[J-*%2#[DMV/
MZ/:_GD_:L\56'C?]I+XDZWI<T=QIUUKMT;>>'E)8UD*K(I[A@N[/?->F^.?^
M"DWQU\?>"Y_#5WXBM=/M[F(P7-[I=DEO=3H>H,@^YGOY87J:YG]DG]D/Q3^U
M%XWMK:UMKC3O!]M*#JNOM&1%$@P6CC)X>8C@*,XSDX%;T:?L;RFQ-W/U(_X)
MB^'+KP_^Q[X5DNT:-M2N;R^C1NHC:=E4_0A-P]F!KW/XZ?$ ?"OX-^-?%VY5
MET?2;F[@W=&F6,^4OXOM'XUT_AKP[IW@_P .Z7H6D6JV6E:9;1V=I;Q_=BBC
M4*BCZ "OF3_@I]X@DT3]CKQ7#&VUM2NK&S+=\&Y20C\1&1]":X%^\J>K*V1^
M,/P_\+W7Q*^)'ASP\)))+O7M5M['S"<N6FF5"Q)[Y;.37](&DZ7:Z'I=GIMC
M"MM96<*6\$*?=CC10JJ/8  5^$W_  3QT./Q!^V3\-K>:,21Q75Q=X/0-#:3
M2J?P9%K]Y*Z<6_>2%$***_.G_@LCJ5YIO@_X9&TNI[4M?WH8PR,F?W<77!KD
MIP]I)1&?HM7"_%OXX>!_@3HMKJWCK7H_#^GW4QMX9I8)9=\FTMM C1CG )Z=
MC7Y<_P#!(K6M0U#]IG78KJ^N;F,>%;I@DTS.,_:K3G!/7FOT._;._9]D_:4^
M VL>%+*2*'7(9$U'2I)ON?:H@<*3V#JSIN[;\\XQ6DJ:IU%&3T"^AQN@_&O]
MFO\ ;4\9'P?'9:;XZU6ULY+R*35-$DC*Q(ZAA'+,BN#EP=JXR,GM7I>A_!GX
M1?LYZ/J_BO1?!NA>&(]-M);JZU.&U3SXX40L^)6RP&T'C.#7X-Z)K7C;]GWX
ME17]DVH>$/&>ASL )8O+F@?!5E9'&""I((((8'N#7H_QJ_;B^,'Q[\,CP[XH
M\2(-"8JTUCIUK';)<LO(,I4;F&>=I.W(!QD"NJ6&=[1>A/,>,^*-=G\6>*-6
MUF<?Z3J=Y->2*.?GD<N?U:OZ$_V;? <WPQ^ 7P_\+W4/V>]TW1;6.[B_NW!C
M#3#_ +^,]?ES_P $\?V']9^*WC;2/B%XPTN6Q\!:3,MW:QWD90ZM,OS1A%(Y
MA5@"S=&QM&<MM_8^HQ4T[070<0HHHK@*"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"MJ&FVNK6K6UY;QW4#=8Y5##Z_7WKR_Q/\  Z.:0S:%<+;@Y)M[EB5'3 5L
M$XZ]<_6O6:*ZJ&*JX=WIR_R.+$X.ABU:K&_GU^\^9M2^'GB+2I&672;B11_'
M;KYJX]<KG'XUDMH]_&VUK&Y5LXP86!SZ=*^KZ*]F.=5$O>@F>!/AZDW[E1KY
M7_R/EVU\&Z]>N%AT>];)QN:!E7\R,5V>@? _4KITDU6XCL8>K11'S)?I_='U
MR?I7M]%8U,XKS5H)1-Z.0X:F[U&Y?@C&\.>$=+\*P&/3[81LPP\S'=(_U/\
M0<5LT45XLIRJ/FD[L^BA3C3BH05D@HHHJ"PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/
M_CI\$O#W[0GP[N_!GB>2^BTBZFBG=M/E6*7=&X9<,RL,9'/%>@5Q_P 5OBUX
M6^"7@VX\5>,M2.DZ%;R1Q272V\LY5G8*HV1JS')/I51O=6W ^5?^'1?P0_Y_
M_%W_ (,H?_C%'_#HOX(?\_\ XN_\&4/_ ,8KN/\ AYG^SE_T/TG_ ()-0_\
MC%>[?$;XJ>&?A-X OO&OBG43IOAJR6%Y[P023%!+(D<?R(K,<O(@X'&>>,UN
MYUEH[BT/E'_AT7\$/^?_ ,7?^#*'_P",4?\ #HOX(?\ /_XN_P#!E#_\8KN/
M^'F?[.7_ $/TG_@DU#_XQ1_P\S_9R_Z'Z3_P2:A_\8JKU_,6AP__  Z+^"'_
M #_^+O\ P90__&*/^'1?P0_Y_P#Q=_X,H?\ XQ7<?\/,_P!G+_H?I/\ P2:A
M_P#&*/\ AYG^SE_T/TG_ ()-0_\ C%%Z_F&AP_\ PZ+^"'_/_P"+O_!E#_\
M&*^O_ _A&Q^'_@KP_P"%M,:9]-T33[?3+5KA@TABAC6-"Q  +;5&2 .>U?/'
M_#S/]G+_ *'Z3_P2:A_\8KZ-\*^)M-\:^%]'\0Z/<?:](U:SAO[.X*,GF02H
M'C;:P#+E6!P0",\BLJCJ?;N/3H:M%%%8C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^,O^"J__)O/
MA[_L:;?_ -)+NOLVOC+_ (*K_P#)O/A[_L:;?_TDNZ /5?V%_P#DT_X>_P#7
MK/\ ^E,M>\5X/^PO_P FG_#W_KUG_P#2F6O>* "BBB@ HHHH **** "BBB@
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M>1"2&0(ZN@*G@X9%(]U%=52NIRBTMA)'\U=%?T%?\,9_ W_HE7A;_P %T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***\E_:K^-@_9\^ WBKQK&L<NHVD"PZ?#+]U[J5A'%D
M=PI;>1W5&II.3L@(_C9^UE\+/V?&6W\9^*K>SU1TWII-JC7-XP/0F- 2@/9G
MV@^M?/5]_P %?O@K:RLD.B>-+T#I)#I]L%/_ 'W<@_I7Y!^(_$>J>+]>O]:U
MN_N-4U:^F:>ZO+IR\DLC')9B:SJ]6.%@E[Q',?L#_P /BO@__P!"MXW_ / .
MS_\ DJC_ (?%?!__ *%;QO\ ^ =G_P#)5?C]15?5:8N9G[ _\/BO@_\ ]"MX
MW_\  .S_ /DJOM'P#XRL_B)X%\.>*].BG@T_7=-MM4MXKI565(YHED17"D@,
M PS@D9SR:_FMK^B+]EW_ )-F^$?_ &*&D?\ I%%7)B*4::3B4F>G4445Q%!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?&7_!5?_DWGP]_V--O_P"DEW7V;7QE_P %5_\ DWGP]_V-
M-O\ ^DEW0!ZK^PO_ ,FG_#W_ *]9_P#TIEKWBO!_V%_^33_A[_UZS_\ I3+7
MO% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%/\ P5PM
M[J;]E:U>W_U47B.S>XX_Y9^5.H_\?9*^UJX'X\?"/3_CM\(O$W@74I/L\&KV
MICCN-NXP3*P>*3'?;(J-CN 1WK2G+EFFQ'X7?LB_!FS^/W[0WA#P5J<DD.DW
MLTDU\T3;7,$,3S.@/8L$V9[;LU^ZWA7X%_#KP/IL%AH7@?P_IEM"H1%ATZ+<
M<=V8KN8^I8DGN:_#WX9ZQXC_ &)?VJM&O_%6CSV^H^&;]H[^S R9K:1&BD:(
MG <-%(S(W0G::_=#X;?%3PG\7O#5OKW@_7K+7M,F4'S+64,T9(SLD3[R,.ZL
M 1Z5V8IRNFMA1-+_ (0OP\.!H6F ?]><?_Q-'_"&>'_^@%IO_@''_A6S17!=
ME&-_PAGA_P#Z 6F_^ <?^%:T,,=M#'##&L44:A$C0 *J@8  '0 4^BD 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M117G'JA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY,?EEN2PY!/( .<^G_"#_@I/\:_@_P"'[71(-4T_Q1I5HBQ6T/B*V:=H8P
M@D1TD( & &8X' XK@_\ ABKXZ_\ 1*_$O_@$:/\ ABKXZ_\ 1*_$O_@$:]G]
MVURNQGJ?2$/_  6.^**J/-\&>$7;U2.Z4?\ HXT__A\A\3/^A*\)_E=?_':^
M;/\ ABKXZ_\ 1*_$O_@$:/\ ABKXZ_\ 1*_$O_@$:CV=#R#4^D_^'R'Q,_Z$
MKPG^5U_\=K]1/@_XRNOB-\)?!/BR]@AMKS7M#L=4GAM\^7')/;I*RKDD[07(
M&23@5^%'_#%7QU_Z)7XE_P# (U^XO[/.BW_AKX _#/2-4M);#4]/\,:9:75K
M,NUX9H[2)71AV(8$'Z5R8B-.*7(4KGH-%%%<)04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QE_P %
M5_\ DWGP]_V--O\ ^DEW7V;7QE_P57_Y-Y\/?]C3;_\ I)=T >J_L+_\FG_#
MW_KUG_\ 2F6O>*\'_87_ .33_A[_ ->L_P#Z4RU[Q0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ";SX>_[&FW_ /22[K[-KXR_X*K_ /)O/A[_ +&FW_\ 22[H ]5_87_Y-/\
MA[_UZS_^E,M>\5X/^PO_ ,FG_#W_ *]9_P#TIEKWB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#+J6!C=:R>[_ ,@HHHKS3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H2K7_P=67_QVC_AV)^T3_T)5K_X.K+_ ..U^Y%%'UJ?9!RGX;_\.Q/VB?\
MH2K7_P '5E_\=H_X=B?M$_\ 0E6O_@ZLO_CM?N111]:GV0<I^&__  [$_:)_
MZ$JU_P#!U9?_ !VOV/\ @3X7U'P3\#_AYX=UB 6VK:1X=T[3[R%75Q'-%;1Q
MR*&4D'#*1D$@]J[FBL:E:516D-*P4445@,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXR_P""J_\
MR;SX>_[&FW_])+NOLVOC+_@JO_R;SX>_[&FW_P#22[H ]5_87_Y-/^'O_7K/
M_P"E,M>\5X/^PO\ \FG_  ]_Z]9__2F6O>* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OC+_@JO_P F\^'O^QIM_P#TDNZ^S:^,O^"J_P#R;SX>_P"QIM__ $DN
MZ /5?V%_^33_ (>_]>L__I3+7O%>#_L+_P#)I_P]_P"O6?\ ]*9:]XH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M48N;Y4!]0T5^>_[&?_!17QY^T?\ '.P\$Z_X>\.Z=IUQ9W-PT^FQ3K,&C3<
M"\K#!/7BOT(JIP=-VD(**\N_:#_:.\%_LT^"_P#A(?&%ZZ><QBLM.M0'NKV0
M#)6-"1T&,L2%&1D\@'\]/%'_  66\73ZDY\._#W1;'3PWR+JEU-<RD>I*>6
M3Z8./>JA1G4UB@N?JY17Y\_ '_@KAX;\;Z]::'\1_#R^#9+IQ%'K5G<&:R#D
MX'FJP#1+_M9<#J=HR:_0.*9)XDEB=9(W 974Y# \@@]Q4SIRINTD ^BBBLQA
M1110 5\9?\%5_P#DWGP]_P!C3;_^DEW7V;7QE_P57_Y-Y\/?]C3;_P#I)=T
M>J_L+_\ )I_P]_Z]9_\ TIEKWBO!_P!A?_DT_P"'O_7K/_Z4RU[Q0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#?'#X4Z?\ '#X3>)_
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MM>M[5Z;(M*P4445S#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /I"BOF__AGGQC_T%M/_ / F;_XW1_PSSXR_Z"VG_P#@5-_\;H ^D**^;_\
MAGGQE_T%M/\ _ J;_P"-T?\ #//C+_H+:?\ ^!4W_P ;H ^D**^;_P#AGGQE
M_P!!;3__  *F_P#C='_#//C+_H+:?_X%3?\ QN@#Z0HKYO\ ^&>O&7_06T__
M ,"IO_C='_#/?C+_ *"VG_\ @5-_\;H ^D**^;_^&>_&7_06T_\ \"IO_C='
M_#/?C+_H+:?_ .!4W_QN@#Z0HKYO_P"&>_&7_06T_P#\"IO_ (BC_AGOQG_T
M%K#_ ,"IO_B* /I"BOF__AGOQG_T%K#_ ,"IO_B*/^&>_&?_ $%K#_P*F_\
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M_P# N7_XBC_AG_QK_P!!6R_\"Y?_ (B@#Z0HKYO_ .&?_&O_ $%K+_P+E_\
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M^%!^-_\ H*V?_@7+_P#$4 ?2%%?-_P#PH/QO_P!!6S_\"Y?_ (BC_A0?C?\
MZ"UG_P"!DO\ \10!](45\W_\*#\;_P#06L__  ,E_P#B*/\ A0?C?_H+6?\
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MK_X&2_\ Q- 'TA17S?\ \*&\<_\ 05M?_ R7_P")H_X4/XY_Z"MK_P"!DO\
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M/^@K;_\ @;+_ /$T ?2%%?-__"B_'G_05M__  -D_P#B:/\ A1?CS_H*V_\
MX&R?_$T ?2%%?-__  HSQY_T%;?_ ,#9/_B:/^%&>//^@K;_ /@;)_\ $T ?
M2%%?-_\ PHSQY_T%;?\ \#9/_B:/^%&>//\ H*P?^!LG_P 30!](45\W_P#"
MC?'G_05@_P# V3_XFC_A1OCW_H*P?^!LG_Q- 'TA17S?_P *-\>_]!6#_P #
M9/\ XFC_ (4;X]_Z"L'_ (&R?_$T ?2%%?-__"C?'O\ T%8/_ V3_P")H_X4
M;X]_Z"D'_@;)_P#$T ?2%%?-_P#PH[Q[_P!!6'_P.D_^)H_X4=X]_P"@K#_X
M'2?_ !- 'TA17S?_ ,*.\>_]!6'_ ,#I/_B:/^%'>/?^@K#_ .!TG_Q- 'TA
M17S?_P */\??]!6'_P #I/\ XFC_ (4?X^_Z"L/_ ('2?_$T ?2%%?-__"C_
M !]_T%8?_ Z3_P")H_X4?X^_Z"L/_@=)_P#$T ?2%%?-_P#PH_Q]_P!!6'_P
M.D_^)H_X4?X^_P"@K#_X'2?X4 ?2%%?-_P#PH_Q]_P!!2'_P.D_PH_X4AX^_
MZ"L/_@=)_A0!](45\W_\*0\?_P#05A_\#I/\*/\ A2'C_P#Z"L/_ ('2?X4
M?2%%?-__  I#Q_\ ]!6'_P #I/\ "C_A2/C_ /Z"D7_@=)_A0!](45\W_P#"
MD?'_ /T%(O\ P.D_PH_X4CX__P"@K%_X'2?X4 ?2%%?-_P#PI'Q__P!!6+_P
M.D_PH_X4CX__ .@K%_X'2?X4 ?2%%?-__"D?'_\ T%(O_ Z3_"C_ (4C\0/^
M@I%_X'2?X4 ?2%%?-_\ PI+X@?\ 05C_ / Z3_"C_A2?Q _Z"L?_ ('R?X4
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M *"B_P#@PD_PH ^D**^;_P#A3'Q#_P"@HO\ X,)/\*/^%,?$/_H*+_X,)/\
M"@#Z0HKYO_X4Q\0_^@HO_@PD_P */^%,_$/_ *"B_P#@P?\ PH ^D**^;_\
MA3/Q$_Z"B_\ @PD_PH_X4S\1/^@HO_@PD_PH ^D**^;_ /A3/Q$_Z"B_^#"3
M_"C_ (4S\1/^@HO_ (,)/\* /I"BOF__ (4S\1/^@H/_  8/_A1_PIGXB?\
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MZ/\ A4/Q(_Z"C?\ @Q>@#Z0HKYO_ .%0_$C_ *"C?^#%Z/\ A4/Q(_Z"C?\
M@Q>@#Z0HKYO_ .%0_$C_ *";?^#%Z/\ A4/Q(_Z";?\ @Q>@#Z0HKYO_ .%0
M_$C_ *"C?^#%Z/\ A4/Q)_Z"C?\ @Q>@#Z0HKYO_ .%0_$G_ *"C?^#%Z/\
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M_P#H)R?^#)_\: /I"BOF_P#X5-\2_P#H)R?^#)_\:/\ A4WQ+_Z"<G_@R?\
MQH ^D**^;_\ A4WQ+_Z"<G_@R?\ QH_X5/\ $O\ Z"<O_@R?_&@#Z0HKYO\
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MN@#Z0HKYO_X5W\5_^@E??^#8_P#Q='_"N_BO_P!!*^_\&Q_^+H ^D**^;_\
MA7?Q7_Z"5]_X-C_\71_PKOXK_P#02OO_  ;G_P"+H ^D**^;_P#A7?Q7_P"@
ME??^#<__ !='_"N_BO\ ]!*^_P#!N?\ XN@#Z0HKYO\ ^%=_%?\ Z"5]_P"#
M<_\ Q='_  KOXK_]!*^_\&Y_^+H ^D**^;_^%>?%C_H)7_\ X-S_ /%T?\*]
M^+'_ $$K_P#\&Y_^+H ^D**^;_\ A7OQ8_Z"5_\ ^#<__%T?\*]^+'_02O\
M_P &Y_\ BZ /I"BOF_\ X5[\6/\ H)7_ /X-S_\ %T?\*]^+'_02O_\ P;G_
M .+H ^D**^;_ /A7OQ8_Z"6H?^#<_P#Q='_"OOBS_P!!+4/_  ;G_P"+H ^D
M**^;_P#A7WQ9_P"@EJ'_ (-S_P#%T?\ "OOBS_T$M0_\&Y_^+H ^D**^;_\
MA7WQ9_Z"6H?^#<__ !='_"O_ (L_]!'4/_!N?_BZ /I"BOF__A7_ ,6?^@EJ
M'_@W/_Q='_"O_BS_ -!+4/\ P;G_ .+H ^D**^;_ /A7_P 6?^@EJ'_@W/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KYZ_;T^#M[\;?V8_%6BZ3;M=:W8B/5;"!.6ED@;<R
M=V:,R*!ZL*^A:*J,G%IH#^9!7:*164E'4Y# X(([U]Z_!/\ X*X^./ F@V>C
M^-_#=MXZBM46)-22[-G>LHX!E;8ZR,!WVJ3U))R:]F_;._X)@M\0->U#QO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S?$GB+
M3?"/A_4M<UB[CL-*TVWDN[NZE.%BB12S,?H : -*BOQ(_:,_X*2?%+XM>*KU
M/"6O7W@3PC&[1V5GI,ODW4B G$DTZ_/O8<[58*O &2"Q^?[CX[_$N\D,EQ\0
M_%<\A.2TFMW+$_B7KNCA)-7;L3S']&H10Q8* QZMCDTZOYQE^.GQ)C^[\0?%
M2_36KD?^STLGQV^)4R[9/B%XJD7T;6[DC_T.J^ION',?T/\ BKQEH/@72)=5
M\1ZUI^@Z;$,O=ZE<I!$/^!,0,U9\/Z]I_BK0=-UO2;I+[2M2MHKRTNH\[9H9
M$#HXSS@JP/XU_-;J^O:EX@N/M&J:C=:E<?\ /6\G:5OS8DU_0I^R[_R;-\(_
M^Q0TC_TBBK&M1]DD[W!.YZ=1117*4%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\9?\%5_^3>?#W_8
MTV__ *27=?9M?&7_  57_P"3>?#W_8TV_P#Z27= 'JO["_\ R:?\/?\ KUG_
M /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\C?\%2O&$_A;]D;6;6WD,3ZWJ-GIC,IP=A<S,/
MQ$!!]B:^N:^(/^"O5M)/^R[I+H#MA\46DCX'\/V>Z7G\6%;4?XD1/8_)3X9_
M#O6OBUX^T+P?X>A6?6-8NEM;=9"0BD\EW(!(15!9C@X"DXKZS_:6_P""9VI_
MLZ_ Z[\>GQI'XDN;">W2^L(--,$<,4C",NLAD8MB1HQRJY#$\8K@?^";.HV.
MF_MF^ )+^18ED-[!#(Y  E>SG5!]6)VCW85^R7[0_@<?$KX$^/O# B\Z;4M%
MNH8%QG]]Y3&(_A($/X5WUJTJ=1);$I:'XG?L:_LSZ9^U3\1=3\(WOBJ7PK=V
M^FMJ%M*EB+D3[)$1TP9$P0) W?@'TKZ'^+W_  2!\8>#O"]YJW@KQA;^-;FU
MC,K:3-IYLKB50,D1$22*[^BG;GL<X!^=OV$_B(GPR_:N^'NJSS"&RN;[^R[A
MF.%V7*- "Q] TBM_P&OWVJ:]6=.:L] 2N?S]?LD6'POU#XW:3HGQ?TNZNO#V
MH2"R1X[M[9+:Y9@$,^W#>63\IPR[<Y/ -?OKX>T#3_"F@:9HFDVJ6.E:;;16
M=I:QYVPPQH$1!GG 50.?2OP5_;HT?2M!_:V^)MIHHC6Q_M3SBL0 59I(TDF
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W
M_8TV_P#Z27= 'JO["_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E
M,M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^:O_!3K
M]B_7O&WBS2_B5\._#UWKFI:AMLM;TW3(#+*SJO[JY"J,GY5\MCVVQ^I-? 'B
M[]F[XJ> ?#UWKWB3X?>(M#T6TV?:+^^TZ2*&+<ZHNYB,#+,JCW(K^BFO,?VE
MO@K_ ,-$?!/Q'\/O[9_X1_\ MC[-_P 3'[+]I\GRKF*?_5[TW9\K;]X8W9YQ
MBNVGB7%*+V)<3^>C2-)O=?U:RTS3;66^U&]G2VMK6!"\DTKL%1%4<EBQ  ]3
M7JG_  Q[\;_^B4>+?_!3-_\ $U]^_#3_ ()$?\*[^(WA7Q7_ ,+8_M#^PM6M
M-4^R?\(YY7G^3,DFS?\ :SMW;<9P<9S@U^BE;U,4D_<U%RG\]W_#'OQO_P"B
M4>+?_!3-_P#$T^/]CGXXS,%7X4^*P?\ :TN51^9%?T'45E];EV'RGXG_  4_
MX)@_&'XB^(K(>*='_P"$%\->8#=7VH31FX,>?F6*!6+%\=-X5??M7[-^%?#.
MG>"O#&D^']'MQ::5I5I%96D"G/EQ1H$1<]\ #FM6BN:I5E5W&E8****Q&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W_8TV
M_P#Z27= 'JO["_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C,%4LQ 4#)
M)Z"EKYD_X*-?%*]^%?[*?B:?3)GMM2UJ2+1()XS@QB8GS2#V)A24 CD$@]JJ
M,>:2B@/$?VBO^"M6A^!?$%[X?^&F@P>+KBT=HI=<OIREB7!P1$B?-,O^WN0'
M'&X8-?.=Y_P5V^-US(S1:=X1M%)R%BTZ<@>WS3FOB2O;?!?[%'QQ^(&EV^I:
M+\-M8EL;A0\,UV([02*>C+YS)D'L>AKU_8TH+7\3.[/9?^'MGQS_ .>7A;_P
M6/\ _':/^'MGQS_YY>%O_!8__P =K@Q_P3=_:-89_P"%;R?^#?3_ /Y(H_X=
MN_M&_P#1-Y/_  <:?_\ )%'+0\@U.\_X>V?'/_GEX6_\%C__ !VOUJ^"?BZ^
M\?\ P9\!>*-4$0U/6] L-2NO(7;'YLUO'(^T9.!N8X&3Q7XL_P##MW]HW_HF
M\G_@XT__ .2*_9_X">&]2\&_ OX<^']8MOL>KZ5X<TZPO+8NK^5/%:QI(FY2
M5.&4C()!QP:Y,0J:2Y+%*YW=%%%<)04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QE_P %5_\ DWGP
M]_V--O\ ^DEW7V;7QE_P57_Y-Y\/?]C3;_\ I)=T >J_L+_\FG_#W_KUG_\
M2F6O>*\'_87_ .33_A[_ ->L_P#Z4RU[Q0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7QW_P58\)77B;]DV[N[6)IAH>L6FI3!.JQ_/ 6
MQW ,XSZ=>U?8E<Y\1K'PUJG@76]/\8RV4/AB^MFM+]M0F6&'RY?W9#.Q 7)8
M '(.2,<XJX2Y9)@?AS_P3[\'Z)XZ_:Z\ :7K\$5W8":XNQ:S*&266&VEFB!!
MX(#HK8/!VX[U^]-?@/\ %;P'JG['OQXTW5?"/BC2_$%I87HU'0M:TV\BN5D1
M'R(YUC;Y7Q\KH<!@3C(-?I7\'_\ @JC\'?&_A^U;Q??W'@77]BK<6MU:33V[
M28&3%+$K?)GIO"G^9[L1"51J<=40C[-HKP>']NSX!3*&7XH:( ?[[2*?R*4_
M_AN;X"?]%1T'_OZ__P 37#R3[%GNM%>%?\-S? 3_ **CH/\ W]?_ .)KV;0=
M=L/%&AZ=K.E74=]I>HVT=Y:741RDT,BAT=?8J01]:3BX[H"_1114@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W_8TV_P#Z
M27= 'JO["_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Q_P#!2S_DR?XC
M?]P[_P!.5K7TY7-?$;X<^'/BUX-U'PGXLTU=7\/ZAY?VFS:62(2>7(LJ?,C*
MPPZ*>".GI5PERR38'\VE%?N[_P .X_V=/^B;0?\ @TOO_C]'_#N/]G3_ *)M
M!_X-+[_X_7I?6X=F1RL_"*BOW=_X=Q_LZ?\ 1-H/_!I??_'Z/^'<?[.G_1-H
M/_!I??\ Q^CZW#LPY6?A%7]$7[+O_)LWPC_[%#2/_2**O.O^'<?[.G_1-H/_
M  :7W_Q^OH#PSX;T[P=X;TG0-'MA9:1I5I%8V=L'9Q%#$@2--S$DX50,DD\<
MFN:O6C522&E8TZ***XR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OC+_@JO\ \F\^'O\ L:;?_P!)
M+NOLVOC+_@JO_P F\^'O^QIM_P#TDNZ /5?V%_\ DT_X>_\ 7K/_ .E,M>\5
MX/\ L+_\FG_#W_KUG_\ 2F6O>* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***P/'WC?2?AKX*UOQ5KL_V;2-'M)+RYD R=B*3A1W8] .
MY(% &=\4OBYX/^"WA>;Q#XUUZUT'2HSM$EP27E;^Y'&H+2-_LJ">IZ5\,_$7
M_@LCX7TN\FMO!7@+4-?B7Y4OM6O%LD)_O"-5D8K]2I]A7YZ_M%_M">)_VD_B
M1>^*O$=PRQDF+3]-1B8;"WS\L2#U[LW5CDGT&+X&^"/Q!^)EI)=^%/!6N^(+
M&-BLEY8:?+);H0,D-*%V @=B:]2&&A%7F1?L?H-\%_\ @JMXY^*GQE\&>$)_
M!OA_3[#7-6M]/FFC>=Y8TDD"DJ2X&0#W&*^Q_P!JK]J71?V4_"OA[7];TJZU
MBUU35ETYX;*15FBC,4DC3*&X?:44;25SOZ\<_BU^Q_\ \G3?"C_L9;'_ -'+
M7VO_ ,%G=:O))OAAI"6\XL(EOKN6?RV\II&,2(N[&-P"2''7#5,Z,/:QBEH%
M]#[[^"_QX\$?M >%3K_@?6X]6LXV$=Q$5,<]M(1G9+&P#*??H<'!(YKT"OYX
MOV;?VA/$?[-GQ.T[Q5H-Q(;8.L6IZ;NQ'?VNX%XF'3.,E6ZJV#ZY_H+\-^(+
M'Q;X=TO7-+F%SINIVL5[:S#H\4B!T;\58&N:M1]D]-BD[FE1117,,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KXR_X*K_ /)O/A[_ +&FW_\ 22[K[-KXR_X*K_\ )O/A[_L:;?\
M])+N@#U7]A?_ )-/^'O_ %ZS_P#I3+7O%>#_ +"__)I_P]_Z]9__ $IEKWB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OCK_ (*M>*;C
MP[^R7>6<$IB76M8L]/EQU9 7G*_G /PS7V+7R5_P5$\#W7C/]DG6KBTC\V30
M;^UU=HP,DQJS1.1_NK,S'V4UK2_B1N)['Y4?L??"#3_CM^T=X,\&ZOO_ +'O
M+B2>]6-]K/##$\S)GJ-PCVY'(W9K]\7T33_#?@Z;2])L;?3--M;-XK>SM(EB
MBB0(<*JJ  /85_/)\#/BSJ'P+^+7AGQUID"75UHUUYQMY&*B:-E:.6/(Z;HW
M=<]LYP>E?MYX#_;,^#_QC\$37VC^-])L+N:V=6TG6+N.SO8GV'*F)V!;K]Y-
MRGL37;BHR<D^A,3\9_V/_P#DZ;X4?]C+8_\ HY:_?SQ5X4T?QQX?OM"U_3;;
M5]'OHS#<V=W&'CD4]B#^AZ@X(YK^?_\ 9)NH;+]I[X67%Q+'!!%XCL7DEE8*
MJ*)E)))X K]AOVA/V]/A7\#/#%Y/!XDT[Q7XE,;BRT31KI+EVE ^7SF0D0IG
M&2Q!QG:&/%+$QE*:40B?B[\?O -G\*_C;XX\(Z?*T^GZ/J]S9VSNVYO*60[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA@B4)''&H544#   Z #M4E>=5JNJ[LI*P4445B,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXR_X*
MK_\ )O/A[_L:;?\ ])+NOLVOC+_@JO\ \F\^'O\ L:;?_P!)+N@#U7]A?_DT
M_P"'O_7K/_Z4RU[Q7@_["_\ R:?\/?\ KUG_ /2F6O>* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_DT_P"'O_7K/_Z4RU[Q7@_["_\ R:?\/?\ KUG_ /2F6O>* "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK<)QN1AD9'4$="#R""#R*BI2E2W!.YN4445B,**** "OC+_@JO\ \F\^'O\
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M6-3=I;^XT*U$TLGWI&5 A<^I;;N_&OP+\%^$==^+/C[2_#VD12:CK^N7JP1
MY)>1VY=CV R69NP!)Z5_0?I?ANW^#?P+@T/39"(/#/A[[-#-C!/D6^ Y]R5S
M]375BMHKJ3$_"#]J;XHW'QD_:"\<^*II6D@NM2EBLPS9V6L1\N%1Z?(BYQW)
M/>OU9_X)]_LM^#/!_P"SCX9UW5_#6EZOXD\46@U2[O=0M$G?R9?FAB3>#M01
M%"0.K%B>V/Q2Z\FOZ./@79KIWP1^'MH@PD'A[3XE [!;:,#^5/$OE@HH([GX
M[?\ !2;X!:/\"?V@!_PC5C'IOAWQ#8KJ=O96Z[8K:7>R2QH.R[E#@#@>9@8
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MCTG_ ,#HO_BJ -ZBL'_A/O#'_0QZ3_X'1?\ Q5'_  GWAC_H8])_\#HO_BJ
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M_H8=*_\  V+_ .*H W:*PO\ A._#7_0PZ5_X&Q?_ !5'_"=^&O\ H8=*_P#
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M#O\ T']+_P# R/\ ^*H VJ*Q?^$V\._]!_2__ R/_P"*H_X3;P[_ -![2_\
MP,C_ /BJ -JBL7_A-O#W_0>TS_P,C_\ BJ/^$V\/?]![3/\ P,C_ /BJ -JB
ML7_A-O#W_0>TS_P,C_\ BJ/^$V\/?]![3/\ P,C_ /BJ -JBL7_A-?#W_0>T
MS_P,C_\ BJ/^$U\/?]![3/\ P,C_ /BJ -JBL7_A-?#W_0>TS_P,C_\ BJ/^
M$U\/?]![3/\ P,C_ /BJ -JBL7_A-?#W_0>TS_P,C_\ BJ/^$T\/?]![3/\
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M'_"9:!_T'--_\"X_\: -BBL?_A,M _Z#FF_^!<?^-'_"9:!_T'--_P# N/\
MQH V**Q_^$RT#_H.:;_X%Q_XT?\ "9:!_P!!S3?_  +C_P : -BBL?\ X3+0
M/^@YIO\ X%Q_XT?\)EH'_0<TW_P+C_QH V**Q_\ A,M _P"@YIO_ (%Q_P"-
M'_"9:!_T'--_\"X_\: -BBL?_A,M _Z#FF_^!<?^-'_"8:#_ -!O3?\ P+C_
M ,: -BBL?_A,-!_Z#>F_^!<?^-'_  F&@_\ 0;TW_P "X_\ &@#8HK'_ .$P
MT'_H-Z;_ .!<?^-'_"8:#_T&]-_\"X_\: -BBLC_ (3#0?\ H-Z=_P"!<?\
MC1_PF&@_]!O3O_ N/_&@#7HK(_X3#0?^@WIW_@7'_C1_PF&@_P#0;T[_ ,"X
M_P#&@#7HK(_X3#0?^@WIW_@7'_C1_P )AH/_ $&]._\  N/_ !H UZ*R/^$O
MT'_H-Z=_X%Q_XT?\)?H/_0;T[_P+C_QH UZ*R/\ A+]!_P"@WIW_ (%Q_P"-
M'_"7Z#_T&]._\"X_\: ->BLC_A+]!_Z#>G?^!<?^-'_"7:%_T&M._P# N/\
MQH UZ*R/^$NT+_H-:=_X%1_XT?\ "7:%_P!!K3O_  *C_P : ->BLC_A+M"_
MZ#6G?^!4?^-'_"7:%_T&M._\"H_\: ->BLG_ (2[0O\ H-:?_P"!4?\ C1_P
MEVA?]!K3_P#P*C_QH UJ*R?^$NT+_H-:?_X%1_XT?\)=H7_0:T__ ,"H_P#&
M@#6HK)_X2[0O^@UI_P#X%1_XT?\ "7:%_P!!K3__  *C_P : -:BLG_A+M#_
M .@SI_\ X%1_XT?\);H?_09T_P#\"H_\: -:BLG_ (2W0_\ H,Z?_P"!4?\
MC1_PENA_]!G3_P#P*C_QH UJ*R?^$MT/_H,Z?_X%1_XT?\)9H?\ T&=/_P#
MJ/\ QH UJ*R?^$LT/_H,Z?\ ^!4?^-'_  EFA_\ 09T__P "H_\ &@#6HK)_
MX2S0_P#H,Z?_ .!4?^-'_"6:'_T&=/\ _ J/_&@#6HK)_P"$LT/_ *#.G_\
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M -2BLO\ X2K1?^@O8?\ @2G^-'_"5:+_ -!>P_\  E/\: -2BLO_ (2K1?\
MH+V'_@2G^-'_  E.B_\ 07L/_ E/\: -2BLO_A*=%_Z"]A_X$I_C1_PE.B_]
M!>P_\"4_QH U**R_^$IT7_H+V'_@2G^-'_"4Z+_T%[#_ ,"4_P : -2BLO\
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M ,"$_P : -&BL[_A)-)_Z"EE_P"!"?XT?\))I/\ T%++_P "$_QH T:*SO\
MA)-)_P"@I9?^!"?XT?\ "2:3_P!!2R_\"$_QH T:*SO^$CTG_H*6?_@0G^-'
M_"1Z3_T%+/\ \"$_QH T:*SO^$CTG_H*6?\ X$)_C1_PD>D_]!2S_P# A/\
M&@#1HK._X2+2?^@I9_\ @0G^-'_"1:5_T$[/_P "$_QH T:*SO\ A(M*_P"@
MG9_^!"?XT?\ "1:5_P!!.S_\"$_QH T:*SO^$BTK_H)V?_@0G^-'_"1:5_T$
M[/\ \"$_QH T:*S_ /A(M*_Z"=G_ .!"?XT?\)%I7_03L_\ O^G^- &A16?_
M ,)%I7_03L_^_P"G^-'_  D6E?\ 03L_^_Z?XT :%%9__"1:5_T$[/\ [_I_
MC1_PD6E?]!.S_P"_Z?XT :%%9_\ PD.E_P#02L_^_P"G^-'_  D&E_\ 02L_
M^_Z?XT :%%9__"0:7_T$K/\ [_I_C1_PD&E_]!*S_P"_Z?XT :%%9_\ PD&E
M_P#02L_^_P"G^-'_  D&E_\ 02L_^_Z?XT :%%9__"0:7_T$K/\ [_I_C1_P
MD&E_]!*S_P"_Z?XT :%%9_\ PD&E_P#02L_^_P"G^-'_  D&E_\ 02L_^_Z?
MXT :%%9__"0:7_T$K/\ [_I_C2_\)!I?_02M/^_Z_P"- %^BJ'_"0:7_ -!*
MT_[_ *_XT?\ "0:7_P!!*T_[_K_C0!?HJA_PD&E_]!*T_P"_Z_XT?\)!I?\
MT$K3_O\ K_C0!?HJA_;VF?\ 01M/^_Z_XT?V]IG_ $$;3_O^O^- %^BJ']O:
M9_T$;3_O^O\ C1_;VF?]!&T_[_K_ (T 7Z*H?V]IG_01M/\ O^O^-']O:9_T
M$;3_ +_K_C0!?HJA_;VF?]!&T_[_ *_XT?V]IG_01M/^_P"O^- %^BJ']O:9
M_P!!&T_[_K_C1_;VF?\ 01M/^_Z_XT 7Z*H?V]IG_01M/^_Z_P"-+_;NF_\
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M: +E%4_[9T__ )_K;_O\O^-']LZ?_P _UM_W^7_&@"Y15/\ MG3_ /G^MO\
MO\O^-']LZ?\ \_UM_P!_E_QH N453_MFP_Y_K;_O\O\ C1_;%A_S_6W_ ']7
M_&@"Y15/^V+#_G^MO^_J_P"-']L6'_/];?\ ?U?\: +E%4_[8L/^?ZV_[^K_
M (T?VQ8?\_UM_P!_5_QH N453_MBP_Y_;?\ [^K_ (T?VQ8?\_MO_P!_5_QH
M N453_MBP_Y_;?\ [^K_ (T?VQ8?\_MO_P!_5_QH N453_MBP_Y_;?\ [^K_
M (TO]L6'_/[;_P#?U?\ &@"W153^U['_ )_;?_OZO^-']KV/_/[;_P#?U?\
M&@"W153^U['_ )_;?_OZO^-']KV/_/[;_P#?U?\ &@"W153^U['_ )_;?_OZ
MO^-']K6/_/Y;_P#?U?\ &@"W153^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\
M&@"W153^UK'_ )_+?_OZO^-']K6/_/Y;_P#?U?\ &@"W153^UK'_ )_+?_OZ
MO^-']K67_/Y;_P#?U?\ &@"W153^UK+_ )_+?_OZO^-']K67_/Y;_P#?U?\
M&@"W153^UK+_ )_+?_OZO^-']K67_/Y;_P#?U?\ &@"W157^U;+_ )_+?_OZ
MO^-']JV7_/Y;_P#?U?\ &@"U157^U;+_ )_+?_OZO^-']JV7_/Y;_P#?U?\
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M0_\ ?P?XT 6:*K?VE:?\_4/_ '\'^-']I6G_ #]0_P#?P?XT 6:*K_VC:?\
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MO[=VVJO)PJLQ]@:^A**J,N5I]@/Y[?\ AC_XW_\ 1*/%W_@HF_\ B:/^&/\
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M^+H_X9>@_P"ABD_\!!_\77N=% 'AG_#+T'_0Q2?^ 8_^+H_X9>@_Z&*3_P
MQ_\ %U[G10!X9_PR]!_T,4G_ (!C_P"+H_X9>@_Z&*3_ , Q_P#%U[G10!X9
M_P ,O0?]#%)_X!C_ .+H_P"&7H?^ABD_\ Q_\77N=% 'AG_#+T/_ $,4G_@&
M/_BZ/^&7H?\ H8I/_ ,?_%U[G10!X9_PR]#_ -#%)_X!C_XNC_AEZ'_H8I/_
M  #'_P 77N=% 'A?_#+T/_0QR?\ @&/_ (NC_AEZ'_H8Y/\ P#'_ ,77NE%
M'A?_  R]#_T,<G_@&/\ XNC_ (9>A_Z&.3_P#'_Q=>Z44 >%_P##+T/_ $,<
MG_@&/_BZ/^&78?\ H8W_ / ,?_%U[I10!X7_ ,,NP_\ 0QO_ . 8_P#BZ/\
MAEV'_H8W_P# ,?\ Q=>Z44 >%_\ #+L/_0QO_P" 8_\ BZ/^&78?^AC?_P
MQ_\ %U[I10!X7_PR[%_T,;_^ 8_^+H_X9=B_Z&-__ ,?_%U[I10!X7_PR[%_
MT,;_ /@&/_BZ/^&78O\ H8W_ / ,?_%U[I10!X!JWP!;PGI-YJ=OK#7S01[F
M@-MLRN1DYW'H,GIVK@Z^N9(UFC:-U#HP*LIZ$'J*^9O'/A63PCX@GM"";9CY
MEO(?XD/0?4=#]*^JR?$+E=![[H^)S_"OFCB8[;/]#GZ***^F/D HHHH ****
M "BBE52S!5!))P * -_P?X!E^(%U<V2W1L88XM[S^7OQR,+C(Z\_D:Z;_AEV
M/_H9&_\  (?_ !RO2/AGX3/A7PXBS)MOKDB6?U7CA?P'ZDUUM? YAB%B*[<=
MEHC].RK"O"X91EN]7_7H>%?\,NQ_]#(W_@$/_CE'_#+L?_0R-_X!#_XY7NM%
M>:>N>%?\,NQ_]#(W_@$/_CE'_#+L?_0R-_X!#_XY7NM% 'A7_#+L?_0R-_X!
M#_XY1_PR['_T,C?^ 0_^.5[K10!X3_PR['_T,C?^ 7_VRC_AEU/^AD;_ , O
M_ME>[44 >$_\,NI_T,C?^ 7_ -LH_P"&74_Z&1O_  "_^V5[M10!X3_PRZG_
M $,C?^ 7_P!LH_X9=3_H9&_\ O\ [97NU% 'A/\ PRZG_0R-_P" /_VRC_AE
MU/\ H9&_\ ?_ +97NU% 'A/_  RZG_0R-_X _P#VRC_AEU/^AD;_ , ?_ME>
M[44 >$_\,NI_T,C?^ /_ -LH_P"&74_Z&5O_  !_^V5[M10!X3_PRZG_ $,K
M?^ /_P!LH_X9=3_H96_\ ?\ [97NU% 'A/\ PRZG_0RM_P" /_VRC_AEU/\
MH96_\ ?_ +97NU% 'A/_  RZO_0RM_X _P#VRD_X9=7_ *&4_P#@#_\ ;*]W
MHH \(_X9=7_H93_X _\ VRC_ (9=7_H93_X _P#VRO=Z* /"/^&75_Z&4_\
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M'_X9<_ZF;_R0_P#MM'_#+G_4S?\ DA_]MKWBB@#P?_AES_J9O_)#_P"VT?\
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M_P##+K?]#*/_  !_^V4?\,NM_P!#*/\ P!_^V5[U10!X+_PRZW_0RC_P!_\
MME'_  RZW_0RC_P!_P#ME>]44 >"_P##+K?]#*/_  !_^V4?\,NM_P!#*/\
MP!_^V5[U10!X+_PRZW_0RC_P!_\ ME'_  RZW_0RC_P!_P#ME>]44 >"_P##
M+K?]#*/_  !_^V4?\,NM_P!#*/\ P!_^V5[U10!X+_PRZ_\ T,J_^ /_ -LH
M_P"&77_Z&5?_  !_^V5[U10!X+_PRZ__ $,J_P#@#_\ ;*/^&77_ .AE7_P!
M_P#ME>]44 >"_P##+K_]#*O_ ( __;*/^&77_P"AE7_P!_\ ME>]44 >"?\
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MPR[+_P!#&G_@&?\ XNO?** / O\ AEV;_H8T_P# ,_\ Q='_  R[-_T,:?\
M@&?_ (NO?:* / O^&79O^AC3_P  S_\ %T?\,NS?]#&G_@&?_BZ]]HH \"_X
M9=F_Z&-/_ ,__%T?\,O3?]#&G_@&?_BZ]]HH \"_X9>F_P"ACC_\ S_\71_P
MR]-_T,<?_@&?_BZ]]HH \"_X9>F_Z&./_P  S_\ %T?\,O3?]#''_P" 9_\
MBZ]]HH \"_X9>F_Z&./_ , S_P#%T?\ #+T__0Q1_P#@&?\ XNO?:* / O\
MAEZ?_H8H_P#P#/\ \71_PR]/_P!#%'_X!G_XNO?:* / O^&7I_\ H8H__ ,_
M_%T?\,O3_P#0Q1_^ 9_^+KWVB@#P'_AEZ?\ Z&*/_P  S_\ %T?\,O3_ /0Q
M1_\ @&?_ (NO?J* / ?^&7I_^ABC_P# ,_\ Q='_  R]/_T,4?\ X!G_ .+K
MWZB@#P'_ (9>G_Z&*/\ \ S_ /%T?\,O3_\ 0Q1_^ A_^+KWZB@#P'_AEZ?_
M *&*/_P$/_Q='_#+T_\ T,4?_@(?_BZ]^HH \!_X9>G_ .ABC_\  0__ !='
M_#+T_P#T,4?_ ("'_P"+KWZB@#P'_AEZX_Z&*/\ \!#_ /%T?\,OW'_0Q1_^
M A_^+KWZB@#P'_AE^X_Z&*/_ ,!#_P#%T?\ #+]Q_P!#%'_X"'_XNO?J* /
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M I_^+KW^B@#P#_AE^Y_Z&&+_ ,!3_P#%T?\ #+]S_P!##%_X"G_XNO?Z* /
M/^&7[G_H88O_  %/_P 72?\ #+]U_P!###_X"G_XNOH"B@#Y_P#^&7[K_H8(
M?_ 4_P#Q5'_#+]U_T,$/_@*?_BJ^@** /G__ (9?NO\ H8(?_ 4__%4?\,OW
M7_0P0_\ @*?_ (JOH"B@#Y__ .&7[K_H8(?_  %/_P 51_PR_=?]#!#_ . I
M_P#BJ^@** /G_P#X9?NO^A@A_P# 4_\ Q5'_  R_=?\ 0P0_^ I_^*KZ HH
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MQH_X9AOO^@];_P#@.W^-?0=% 'SY_P ,PWW_ $'K?_P';_&C_AF&^_Z#UO\
M^ [?XU]!T4 ?/?\ PS#?_P#0=M_^_#?XT?\ #,-__P!!VW_[\-_C7T)10!\]
M_P##,-__ -!VW_[\-_C1_P ,PW__ $';?_OPW^-?0E% 'SW_ ,,PW_\ T';?
M_OPW^-'_  S#?_\ 0=MO^_#?XU]"44 ?/?\ PS#?_P#0=MO^_#?XT?\ #,-_
M_P!!VV_[\-_C7T)10!\]_P##,-__ -!VV_[\-_C1_P ,PW__ $';;_OPW^-?
M0E% 'SW_ ,,PW_\ T';;_OPW^-'_  S#J'_0=MO^_#?XU]"44 ?/?_#,.H?]
M!VV_[\-_C1_PS#J'_0=MO^_#?XU]"44 ?/?_  S#J'_0=MO^_#?XT?\ #,.H
M?]!VV_[\-_C7T)10!\]?\,PZA_T';;_OPW^-'_#,.H?]!VV_[\-_C7T+10!\
M]?\ #,.H?]!VV_[\-_C1_P ,PZA_T';;_OPW^-?0M% 'SU_PS#J'_0=MO^_#
M?XT?\,PZA_T'+;_ORW^-?0M% 'SU_P ,PZC_ -!RU_[\M_C1_P ,PZC_ -!R
MU_[\M_C7T+10!\]?\,PZC_T'+7_ORW^-'_#,.H_]!RU_[\M_C7T+10!\]?\
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M/10!\\?\,Q:I_P!!JT_[]-1_PS%JG_0:M/\ OTU?0]% 'SQ_PS%JG_0:M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M $DNZ /5?V%_^33_ (>_]>L__I3+7O%>#_L+_P#)I_P]_P"O6?\ ]*9:]XH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)6!.QX=^TUXJTWQO^T-\1]=T=HY=*OM?O)K::$Y2:,RL!*#Z.!N_X%7[,?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&8(I9B%51DD\
M5XYXL_;'^"7@B\DM-6^)OAZ.ZC)62&UNQ=,A'4,(@VT^QYIJ+EL@/'/VS/\
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M0CYHK=3DJ#T+GYF'91E:^I:**XI2<W>104445(!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&7_!5
M?_DWGP]_V--O_P"DEW7V;7QE_P %5_\ DWGP]_V--O\ ^DEW0!ZK^PO_ ,FG
M_#W_ *]9_P#TIEKWBO!_V%_^33_A[_UZS_\ I3+7O% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4V21(8VDD94C4%F9C@ #J2:=7@'[>WC.[\!
M_LB_$C5+"=K>[DL8[!)$.& N)X[=L'L=LK<U45S-(#\S_P!N;]O#7/V@?$U]
MX8\*7]UI'PWLW:!889"C:L0<&:;'5#CY8SQC!//W?CZBOT>_9+_X)7Z=\1/A
M_I?C/XGZOJFGIJT"7=AH>DM'%(L##*/-(RORZD-L4 @$9;.5'M-PH1,]S\X:
M^S/V&?V^-?\ @;XFTOPEXRU.XU;X;W4BVV+E][Z06( EB8\^4/XH\X R5&>&
M];_:L_X)4Z9X'\ ZIXN^%NK:I>R:5 UU=Z%JK),\L*@L[02(JG<JC.Q@=V#A
MLX!_-BA.%>(:H_INCD2:-)(V62-P&5E.00>A!IU?/?[ 7CJY^(7[(_P\U"]E
M,MY:V<FF2,>3BVF>!,GN?+C0Y]Z^A*\64>5M&@4445(!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7QE_P57_ .3>?#W_ &--O_Z27=?9M?&7_!5?_DWGP]_V--O_ .DEW0!Z
MK^PO_P FG_#W_KUG_P#2F6O>*\'_ &%_^33_ (>_]>L__I3+7O% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\F_\ !468Q?L<>*5!P)+VP4_^
M!49_I7UE7R/_ ,%3/^3/?$'_ &$+#_T>M:TOXD?43V/Q2T>S&I:M96AZ7$Z1
M''^TP']:_I@M;:*SMHK>"-88(4$<<:#"JH&  /0"OYJ_![!?%NB%C@"^@))_
MZZ+7](G_  E6B?\ 08L/_ I/\:[,9]D433DC66-D=0Z,,,K#((/8U_-1XPTM
M-"\6ZWIL8Q'9WT]NOT21E'\J_I$_X2K1/^@Q8?\ @4G^-?SF?%-ED^)WB]D(
M96UB\(93D$>>]&#WD*1^P?\ P2CN&F_9(L4)R(=8O4'TW*W\V-?8M?$O_!*?
M7--T_P#93CBNM0M;:7^W+P^7-,J-C$?.":^Q?^$JT3_H,6'_ (%)_C7)6_B2
M*6QJT5E?\)5HG_08L/\ P*3_ !K2AF2XB26)UDC=0RNAR&!Y!![BL1CZ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *^,O^"J__ ";SX>_[&FW_ /22[K[-KXR_X*K_ /)O/A[_
M +&FW_\ 22[H ]5_87_Y-/\ A[_UZS_^E,M>\5X/^PO_ ,FG_#W_ *]9_P#T
MIEKWB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUX3\5:3XY\-Z=K^A7L>I:/J,*W%K=Q A98VZ,,@'\Q6M7BO[%?\ R:?\*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !17S5^TU^UM?_ +QMIVA6OARVUB.ZT];TS37+1%29)$VX"G_ )YY
MS[UY#_P\HUG_ *$>Q_\  ]__ (BO;HY-C<1356G"Z?FO\SSZF/P]*3A.6J\F
M?>=%?!G_  \HUG_H1['_ ,#W_P#B*/\ AY1K/_0CV/\ X'O_ /$5M_8&8?R?
MBO\ ,S_M/"_S?@S[SHKX,_X>4:S_ -"/8_\ @>__ ,17V3\+/&<GQ$^'?A[Q
M+-:K92ZI:)<M;HY98RPZ D#-<.+RW$X**G7C9/S3_(Z*.+HXAN--W:.JHHHK
MS#L"BN$^.'Q(F^$?PMUSQ;;V,>HS:<(2MK)(45]\R1\L <8WYZ=J^1_^'E&L
M_P#0CV/_ ('O_P#$5ZN%RS%8V#J4(W2=MTOS..MC*.'ERU'9GWG17P9_P\HU
MG_H1['_P/?\ ^(H_X>4:S_T(]C_X'O\ _$5V?V!F'\GXK_,Y_P"T\+_-^#/O
M.BO@S_AY1K/_ $(]C_X'O_\ $5[?^R]^U#??M!ZIKUI=Z!;Z,--ABE5H;AI=
M^]F&#E1C&VL*^3XS#4W5JPM%>:_S-*>.P]::A"6K\F?0E%%%>*>@%%%?%7C_
M /X*":MX+\>>)/#\?@ZSNH])U*YL%G:]=3((I60,1LX)VYQ[UWX3 U\=)QH1
MNUYI?F<U;$4\.DZCM<^U:*^#/^'E&L_]"/8_^![_ /Q%'_#RC6?^A'L?_ ]_
M_B*]+^P,P_D_%?YG)_:>%_F_!GWG17R1\"OVWM3^+_Q4T3PC<>%;338=1\_=
M=1W;.R>7!)*,*5&<E,=>]?6]>5BL'6P4U3KJS:OW_([*->GB(\U-W04445QG
M09?BGQ%9^#_#.KZ]J#,MAI=G-?7#*,D1Q(78@?137\X_Q*\>:A\4/B!XB\6Z
MJV[4-:OYKZ49R$+N6"#_ &5!"CV K][?VP+RXL?V6?BM+:J6E/AN^C..RM"R
MN?P4L?PK^>ZO2PBT;(D?N5_P3R_9OTKX'_ ?0]8ELHSXO\46D>I:E?,H,JQR
M /#;@]55$*Y7NY8^F/J:J&@PPVNAZ=#;8^SQVT:1X&!M"@#]*\;_ &R/VAM0
M_9C^#C>,]-TBVUNY&H067V6ZD:-,2!LME><C;^M<+O4GYLK8Z/\ :2^!.D?M
M%_"'7/!NIQP)<W$32:=?31[C97:@^5*.XP>&QR59AWKXB\%_\$9;*!HIO%7Q
M-N9F!!:WT735B*_261VS_P!\"N/_ .'S'C#_ *)SH?\ X'3?X4?\/F/&'_1.
M=#_\#IO\*ZXTZ\%:(M#]5;"U:RL;>W>XENGAC6,W$^#)(0 -S8 &3U. !S7@
M7[6O[:'A']E'1;=+^)M=\67T9DL-!MY CLF2/-E?!\N/((S@DD$ '#$>D_!S
MXE-\2/@OX5\=:E!#I9U;2(=4N(8W+1P;XP[ $\X'/)K\"?CQ\6M2^.7Q<\3>
M-=3DD:35+QY((G8G[/;@XAB'LJ!1^!/>LZ-'VDGS= ;/HOQ5_P %7OCKKFHO
M/IEUH?ARUS\EK9:8LH ]VF+DGU(Q[ 5V_P (_P#@K[X\T/5H(/B'H&F^)M&9
ML2W.EQ?9+V,'^)1N,;X_N[5S_>%?4W[&O[!_PU\%_!OPYK/BSPII?B[Q9K=C
M%J%Y/K5JEU';^:F]88XY 57:K $XR6!.<8 ^:_\ @J!^QWX0^$V@Z-\2/ FE
MPZ!9W5\--U/2;0%;<.\;/%-&G2,?NV5E'!+(0!\V>A2HRER<HM=S]-/AC\3O
M#?QB\$Z;XL\)ZE'JFBZ@FZ*9.&5APR.IY5U.05/((KI+R\M].LY[N[GCMK6"
M-I99IG")&BC+,S'@  $DGTK\G?\ @D!\8;S1?B=XB^'%S.[Z3K5DVI6D+-E8
M[N':&*CMOB)R?^F25[?_ ,%;?CQ>^!?ACH?P]T>[DM;SQ4\DNHO$<-]ABP#$
M3V$CLN<=1&P/#<\LJ+57V:*OI<YC]HK_ (*Y67AW5[W0_A+HEKKWD$QGQ'JQ
M<6S-T/DP+M9U]'9E!(^Z1@GYIE_X*H?M 27OGKKFDQQ?\^RZ1#Y?YD%O_'J\
M[_8U_9EN/VI?C!!X;DN9M/\ #]G U]J]];@&2.!2 $3/&]V*J,YP"S8.W!_6
M^+_@GK^S['X=&C?\*YLGAV[3=-<SFZ)QC=YWF;\]^#CVKJE[&C[K5R=6?,/[
M//\ P5VBUK6+31?BYH=II,4[K&OB'10XAB)XS- Q9@OJR,<?W,=/TAT_4+75
MK"VOK*XBO+*YC6:"X@</'+&P!5U8<$$$$$=0:_!C]M?]EN7]E?XM_P!AVES/
MJ'AG4H/MND7MR!YACSM>)R  71N"0!D%3@9P/N#_ ()$?'B^\5>#?$7PRU>Z
M:YD\/!+_ $II7+,+21BLD0_V4DVD?]=B.@%9UJ4>3VE/8:?1G6_\% ?VW/'G
M[+'CCPMH_A+3= O;75-.>[F;6+::5PXE* *8YD &!W!K@/A7_P %8FB^$/B3
MQ'\1M.TJY\40WZVFBZ#X?22!KI3'N:24R22;$4D O[X"L:\[_P""RW_)6/A_
M_P!@27_T>U>+_P#!/+]FC1_VDOC5<6OB>.2?PMH-G_:%[:QN4^U.75(H2PY5
M22S'!!PA (SD:1IT_8J4D+6YT_BC_@J]\=-:U9[G3+G0_#UGNREE:::LRA?1
MFE+L3ZD$>P%?1_[(W_!4X>//$EOX4^+L.EZ%<7 *VGB2U/V>U+@$[+A78A"V
M,!U(7) *C.:]N_:<_8M^$FN_ /Q<FD>!-#\.:OI>D7%YIVHZ/81VTZ2PQF10
MS( 75BNU@V<ACWP:_#BJA&E6B[*P:H_2?]HK_@KEJ_\ ;]WH_P (-,LX=*MW
M,?\ PD&KPF66Y(/WX8<@(A[%]Q(/W5/%>6>!O^"LWQI\.ZM%-KZZ+XLT[=^]
MM9[);60KG^"2+&T^Y5A[&OMG]CW]A'X:>!_@WX>U+Q5X1TKQ9XLUJPBOK^XU
MRT2[6 RH'$,4<@*H$#;20-Q.23C 'P)_P4L^!'AKX%?'ZUM_".GII6B:YI4>
MIBPASY5O,998Y%C'\*'RU8+T!8@8  J:?L92]FHAKN?KS\ OCIX<_:*^&>F^
M-/#3R+:7):*>TGQYUI.OWX9 #U&00>ZLIZ&NG\=>.M"^&?A'4_$_B;4H=)T/
M38O.N;N8G:BY   ')8D@!0"22  2:_/3_@B]KD\V@_%;1VD)MK:YTZ[CC[!Y
M5N$<_B(4_(5S?_!8?XRWL_B?PG\,+.X:/3K>T_MO4(XV.)9G=XX58?["H[8_
MZ:@]A7-[&]7V:*OI<QOC1_P5\\8ZOK%Q:?#/0;#P_HJ-MBO]7B^TWLP!^]LW
M>7&#_=PY_P!JO//#/_!5SX[Z+?I-J%YH?B"W#?-;7VEI&I'H&A*$>W/YUI_\
M$R_V3?#?[0'BSQ#XF\:6O]I^'?#GDQQ:6S%8[NZDW,#)CJB*A)7/S%USD @_
M?_QU_8$^$OQ6^'NH:3HW@W1/".OI;M_9FK:-9):-%.%.SS1&!YB$X#!@3@G&
M#@CIE*C3ER.).K$_9!_;H\)_M56LVFK;'PWXUM(O-N-%GE$BS(, RP/@;U!/
M((#+GD$?,:G[?W[3WBO]EKX<^'->\)66DWMYJ.J_89DU>"26,1^2[Y4)(A!R
MHZD\9XK\8OAC\0-:^"OQ0T+Q5I;26VK:%?K,8PQ7>%;$D3?[+KN1AZ,:_?7X
MA?"+X>_M.^"=!'C#1%\1:&WEZI8QO<S0;2\?ROF)U)^1SP21S6-2G&C-/H-:
MH_GO\6>)+KQCXIUG7[U(H[W5;V:^G2!2(UDE<NP4$D@98XR3QWKZ]_9U_P""
MD'Q.\ Z;X$^&^G:1X6ET&UGM],2:YL[AKDQ/* 26$X7=\QYVX]J^6/BWHMEX
M;^*WC/2--@^S:=I^M7MI;0ABWEQ).ZHN223A0!DDFOU?_8Y_8I^"WB[X"?#?
MQMJ_@F.\\3W%G'?2WYU&[0M,LA*OL64)P5'&W''2NRM*$8)R5R5N>M_MV?M#
M^)?V9?@M:^+?"MIIEYJ<NL06#1ZM#)+#Y;QRL2 CH=V8U[^O%?)/P%_X*Q>)
MM<\2:U+\3;'PY8>&].T>XOE71K6:.[N;E6C6*"/S)W4ER^.G'4D $U[-_P %
M=O\ DUG3_P#L9;3_ -$7%?DA\,? -_\ %3XB>&_"&EE4O];OX;&*1AE8][A2
M[>R@EC[ UA1IPE3O)#>Y]4^*/^"L7QNU;Q-/?:1)HN@Z3O/DZ4E@LZJF> \C
M_.S8ZD%03T Z5]Y6?[4/CU?V"KGXU:CHNCV'BT6/VRWLO+E:T=/M(B21DWA@
M'0[P _1EY[5B-_P2A^!C^#4TC[+K2:PL6UO$":D_VAGQ]_RSF'&>VSIW[UVO
M[;7AZQ\(_L,^.-"TR$6^FZ9HMK96L(_@BCEA1%_!5%92E2DXQ@NH]3XV^$'_
M  55^+OC[XM>"?#&HZ)X/BT_6M;L=-N9+:QN5E6.:=(W*$W) ;#'!((SV-?J
M]7\Z_P"S3_R<;\*O^QKTK_TLBK]]/C1\1(_A+\)?%_C*1$E.B:7<7L<4APLL
MB(3&A_WGVK^-&(IJ,DHH$?/?[8/_  4,\+_LSWTGAC2+%?%GCKRP\EBLOEV]
M@& *&=P"=Q!#"->2.25R"?@G7/\ @JQ\>]6OVGM-2T/182V1:V>E(Z >F92[
M?K7RMJ&H:S\0_&$]Y>3RZKK^M7I>2:5LO/<2OR23W+-^M?MM\#O^">?PA^%_
M@73M/USPAI?C#Q"T"G4=4UF$77F3%1O\M7&U$!R% &<8R2<FMI1I4(KF5V+5
MGQC\*?\ @L!X]T75HX_'_AS2_$FCM@/+I:&SNX_5AEF1_P#=PN?[PK]1OAC\
M3/#GQ@\#Z7XM\*ZC'J>BZC'YD4J\,AZ-&Z]5=3D%3R"*_-[]LK_@F/JUY\0M
M(U+X&^&$;2-3BD.I::;Z*&#3YE*X=#,X.R0,?D7.TH<  @#Z#_X)W_LR?%/]
MF/2?$^E^-;W19-!U9X[RVL;"[DFFMKI1M=CF,)ATV X8\QK[UC55*4.:&C[#
M5S['HHHKB*/BG_@KA_R:K:_]C'9_^BIZ_++]GOX>?\+4\=:AX;2+SKFXT'5I
M[:/&2UQ#933PC\9(U'XU^IO_  5P_P"35;7_ +&.S_\ 14]?!O\ P3% ;]LS
MP8",@V^H @_]>4U>I1?+1;]2'N>>_L;_ !'_ .%4_M.?#SQ \ODVBZI'973D
MX407 ,$C'V"R%O\ @-?OGXP\36G@KPGK?B'4&VV&DV4U_<-G&(XHV=OT4U_/
M1^T#\/V^$WQR\<>%$0P1:3K%Q#;=CY&\M"WXQE#^-?J)^U?^T4-9_P"";>F>
M)X[D#4_&]A8Z664_\MW&;M??Y8;A:6(ASRBUU!'Y3Z79ZK\:?BU:6S.9=;\5
MZVJ,^,YGN9P"?^^GS3_C/H]KX?\ C%XZTNQC\FRL=>O[:",?PQI<.JC\ !7O
MG_!,?X>?\)Y^UMX=N98O-L_#MM<:S,,<91?+B/X2RQG_ (#7B'[07_)>OB3_
M -C+J7_I5)76I>_R]D3T/W(_8K_Y-/\ A7_V ;?_ -!J3]I[]JKP?^RSX.CU
M?Q&[WNJ7A9-,T6U8"XO'7&X@GA$7(W.>!D  D@&/]BO_ )-/^%?_ & ;?_T&
MOQL_;6^,M[\;OVD/&.L37#3:98WDFE:7'N)2.U@<HA4=MY#2'WD->;3I>TJ.
M^Q=[(]A\<?\ !6?XU>(M2EDT%=#\)V&3Y5O;V0N9 N>-\DVX,WN%4>U;7PR_
MX*[?%'P[JD*^,](T?Q;I)8>=Y$)LKL+WV.A*>^"ASZBOH7_@GO\ L._#]/@O
MHGC[QMX=L/%GB'Q#']LABU: 7%M9VQ8^4JQ.-I9@ Q8@GY@!@ YY'_@I=^Q7
MX'\*?"N;XG^!=#M/"]WI-Q#%J=CIL8BM;B"601*ZQ+\J.LCI]T $,<\@5OS4
M7+V?*+7<^ZO@;\=/"?[0W@&T\6^$+XW-C*?*GMY0%GM)@ 6AE7)VL,CN0000
M2"#73>-/&FB_#OPIJGB7Q'J$.E:)IL)N+J[G.%C4?J220 HY)( !)%?CO_P2
MK^,%YX"_:2M_"CW#_P!B>+K:2TE@+?(MS$C2PRX_O?*\8_ZZU^FW[7'[.M]^
MU!\+5\%VOBY_"-NUY'=W$JV7VH7(0'9$R^8F%W$-UZHOI7+4IJG4Y6]"D]#X
M(^+_ /P6!\8ZIK$UO\./#>FZ%H\;LL=YK"M=74ZYX;:&5(\C^'Y_]ZO*H?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,-@?.K#'S'M7XI?LN_M=>-OV5O$5Q=^'GBU+1+YE.H:%?%OL]QC@.I',<@'
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MT?X$OF#W/W1KY\_;_P#^3._B;_UX1_\ I1%7T'7SY^W_ /\ )G?Q-_Z\(_\
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MO!?_ %[ZA_Z135]X_P#!7#_DU6U_[&.S_P#14]?!W_!,3_D\[P7_ ->^H?\
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M/$5W_: N5N+[Q&EH8HUC4'$$:3)EBS$%F*@ * -VXXOFK<_*HH-#R?\ 9O\
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MU-\/M?N<O*-/@66PE<\EVM\KM8]]C*.^"237S5+_ ,$:?&ZWVV+XA>'WL_\
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MG7_"*?V7IYL/L_\ 9'VSS/WC/OW>?'C[V,8/3K7UO14QDX.\1GS!^Q9^Q/\
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MBIXK\9_\+4_LK^W=1FU#[#_PCOG>1YC%MF_[4N[&>NT9]*^N/V:?@K_PSO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W_8TV_P#Z27= 'JO[
M"_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %?&7_!5?\ Y-Y\/?\ 8TV__I)=U]FU\9?\%5_^3>?#
MW_8TV_\ Z27= 'JO["__ ":?\/?^O6?_ -*9:]XKP?\ 87_Y-/\ A[_UZS_^
ME,M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?&7_  57_P"3>?#W_8TV_P#Z
M27=?9M?&7_!5?_DWGP]_V--O_P"DEW0!ZK^PO_R:?\/?^O6?_P!*9:]XKP?]
MA?\ Y-/^'O\ UZS_ /I3+7O% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QE_P5
M7_Y-Y\/?]C3;_P#I)=U]FU\9?\%5_P#DWGP]_P!C3;_^DEW0!ZK^PO\ \FG_
M  ]_Z]9__2F6O>*\'_87_P"33_A[_P!>L_\ Z4RU[Q0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\9?\%5_^3>?#W_8TV__ *27=?9M?&7_  57_P"3>?#W_8TV
M_P#Z27= 'JO["_\ R:?\/?\ KUG_ /2F6O>*\'_87_Y-/^'O_7K/_P"E,M>\
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %?&7_!5?\ Y-Y\/?\ 8TV__I)=U]FU
M\9?\%5_^3>?#W_8TV_\ Z27= 'JO["__ ":?\/?^O6?_ -*9:]XKP?\ 87_Y
M-/\ A[_UZS_^E,M>\4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/Y&FM<-_7<.I^PE%%%>66%%%% !7QE_P57_Y-Y\/?]C3;_\ I)=U]FU\9?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
M'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X
M>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_G
MU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@
MOC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X
M]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E
M%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T
M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
M'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X
M>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_G
MU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@
MOC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X
M]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E
M%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T
M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
M\>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B
M?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]
M?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^
M"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/
M4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?
M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
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M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
M'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X
M>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_G
MU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@
MOC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X
M]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E
M%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T
M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
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M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
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M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
M\>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B
M?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]
M?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^
M"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/
M4 ?7E%?(?_#T3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?
M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
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M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
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M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M(?\ P]$^#O\ SZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\
M#T3X._\ /KXF_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\
M^OB;_P %\?\ \>H_X>B?!W_GU\3?^"^/_P"/4 ?7E%?(?_#T3X._\^OB;_P7
MQ_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\ SZ^)O_!?'_\
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M3X._\^OB;_P7Q_\ QZC_ (>B?!W_ )]?$W_@OC_^/4 ?7E%?(?\ P]$^#O\
MSZ^)O_!?'_\ 'J/^'HGP=_Y]?$W_ (+X_P#X]0!]>45\A_\ #T3X._\ /KXF
M_P#!?'_\>H_X>B?!W_GU\3?^"^/_ ./4 ?7E%?(?_#T3X._\^OB;_P %\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\
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M/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R?
MK_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\
M&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\
M77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35%
M'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/
M@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_
M^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\ 0LWO_@VN
M?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X
M=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%
MF]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &
MUS_\77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?
M35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_
M\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]
M"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\ 0LWO
M_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^
M+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP
M*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W
M_P &US_\77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__
M !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10
M!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3
MX%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\
M0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#
M:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^
M'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\
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M_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\
MBZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\
M"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]
M_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_
M ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44
M ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\
M#N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_
MT+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:
MY_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\
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M/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R?
MK_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\
M&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\
M77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35%
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MX%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\
M0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#
M:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^
M'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\
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M_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\
MBZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\
M"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]
M_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_
M ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44
M ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\
M#N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_
MT+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:
MY_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\
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M/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R?
MK_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\
M&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\
M77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35%
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MX%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\
M0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#
M:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^
M'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\
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M_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\
MBZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\
M"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]
M_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_
M ,77TU10!\R_\.Y/@5_T+-[_ .#:Y_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44
M ?,O_#N3X%?]"S>_^#:Y_P#BZ/\ AW)\"O\ H6;W_P &US_\77TU10!\R_\
M#N3X%?\ 0LWO_@VN?_BZ/^'<GP*_Z%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_
MT+-[_P"#:Y_^+H_X=R? K_H6;W_P;7/_ ,77TU10!\R_\.Y/@5_T+-[_ .#:
MY_\ BZ/^'<GP*_Z%F]_\&US_ /%U]-44 ?,O_#N3X%?]"S>_^#:Y_P#BZ/\
MAW)\"O\ H6;W_P &US_\77TU10!\R_\ #N3X%?\ 0LWO_@VN?_BZ/^'<GP*_
MZ%F]_P#!M<__ !=?35% 'S+_ ,.Y/@5_T+-[_P"#:Y_^+KZ \&>$=.\ ^%-*
M\.:/&\6E:9;K:VL<CEV2-1A5+'DX&!D\\<UM44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 C*&4JP!4C!!Z&O%?%7[%?P-\9ZD^H:
MI\,M":[D;<\EI";7>WJPA*@D]R1SWKVNBJ4G'9@<5\./@MX#^$-M)#X+\):3
MX;$HVRR6%JJ2RC.</)C<_P#P(FNUHHI-MZL HHHI %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?SV?';XB>*[7XX?$
M.&'Q-K$,,?B+442.._E5547,@  #< "MZ-+VK:N)NQ_0G17\V?\ PLOQ?_T-
M6M_^#&;_ .*H_P"%E^+_ /H:M;_\&,W_ ,573]3?\PN8_I,HK^;/_A9?B_\
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M5/\ LP_!>?QE9Z=;ZKJ+7UO8VMG=.R1R.Y);)7GA$<_A4QBY.R&>XT5^3O\
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M,FKS,$4LQ"J!DD]!7X[_ /!3;]KZP^-7BBS^'WA"]6]\(^'[AIKN_A;,5_?
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M=K 99[!"?L]ZBXW2VY))XSDQDEE!R"P!(^KZX91<':184445(!1110 4444
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M1QV=6#*1V*FN,_:Z_P"36_BQ_P!BQJ'_ *(>N%1][E91Z!_PG/AO_H8-+_\
M V/_ .*K2T_5+/5K<SV-W!>PAMIDMY%D7/ID'KR*_F9K]E?^"1/_ ":UJ/\
MV,UW_P"B+:NJKA_9QYKDIW/MNBBBN,HR[[Q1HVEW#6]YJ]C:7"@$Q3W*(PST
MX)S3;/Q9H>H7"6]KK.GW-Q(<)%#=1NS=^ #DU^*__!4;_D\;Q/\ ]>5A_P"D
MR5RG_!/?_D\CX9_]?D__ *2S5W+#>YSWZ$WUL?O31117"4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7Q5XP_X)._"7QIXMUOQ#>^)/&D5[JU]/?SQV
M]Y:"-9)9&=@H-J2%!8XR2<=S7VK15QG*'PL#X3_X<[_!S_H:/'/_ ('6?_R)
M4%]_P2$^">F65Q>7?B_QK:VEO&TLT\VH62I&BC+,Q-K@  $DGTK[SK\\O^"L
M'[3[^$/"MM\(O#]T4U7781=:U+&W,-EN(2'(Z&5E)/\ L+@Y#UO3J5:DE%,G
M0_,KXM6O@NQ^(6M6OP]GU2[\(V\QAL;O69$>XN57@RG9&@"L02J[<@$9YS7V
M1_P33_8IC^+&L1?%#QK9&3PCI=QC2K&4874KI&Y=AWAC(Z=&<8/"L#\K_LV_
M [4OVB?C%H'@G3BT,5Y+YM]=J,_9;1.99?3(7A0>K,H[U_05X/\ ".D^ O"V
ME>'-"LX]/T?2[9+6UMHQPD:C 'N>Y)Y)))Y-=>(J^SCR+<21L5^:_P#P6;\9
M>3X?^&OA..3/VBZN]4FCST\M$BC/X^;+^1K]**_&'_@K1XR_X2+]J9-(1\Q^
M']%M;-DSP))"]P3]2LT?Y"N3#1O413V/G#]GGX7Q_&GXW>#/!-Q+/!::SJ,<
M%S+:D"5(!EI60D$!@BL02",]C7Z=?\.=/A)_T-OC3_P)M/\ Y&K\Z?V1?C1H
M/[/?QLT_Q[KVEWFL)I5I="TL[(H&>XDB:)=S,<*NUWR0">G!KZMU+_@LSXND
MO]UA\.-%M[+)_=7-]-+)CM\X"C/_  &NVLJKE^[V)5NI[3_PYT^$G_0V^-/_
M  )M/_D:O:_V8?V(O!G[*>N:WJGA?6==U.?5K9+:9=7EA=556+ KY<2'.3WS
M7C'P)_X*T> OB#JEMI'CO1YO %[.0B:@;C[58%B<?.^U6B!/<J5'.6 YK[KM
M[B*Z@CG@D2:&10Z21L&5E(R"".H([UPU)58^[,K0DHKQ']MK_DTWXI_]@.?^
ME?S^YIT:'M4W>P-V/Z<*Y+Q+\7/ O@N\-IX@\:>'M"N@0#!J6JP6[C/3Y7<&
MOQW^*7_!03Q7??!?P+\,/A_>77AG1]'\.V.G:KJ<)\N\O9TMT21$<<QQ!@1\
MN&;!R=IQ7R9=1W;$75RDQ-P2XFE!_>$GDY/7GO6L<(W\3%S']*OA_P 4:-XL
ML?MNAZM8ZS9YV_:-/N4GCSZ;D)&:TZ_F[^&7Q6\6?!SQ3;>(?!VN76AZI P;
MS+=_DD _@D0_+(I[JP(K[K^,?_!6C6?$/P=T#3/ ]BV@^.[ZVVZ[J;1AHK)Q
ME2+4-G)?&\,V=@8#EOF69862:Y=0YC]./%7Q$\*>!51O$OB;1_#P==RG5;^*
MVW#U&]AD4OA?XA>%O&VX^'?$NCZ^%7<W]EW\5SA?4[&/%?S@:UJVK^)KZYUG
M5[R]U6[GDS/?WDCS/(Y_O2,22?J:CT77-2\-ZI;ZEI&H76EZC;MOAN[*9H98
MV]5=2"#]#6OU/3XA<Q_3'17Q9_P3?_;*U']HCPSJ7A'QC<I<>-]!B6=;P(%;
M4+/(3S6 X\Q'(5B, [T.,[J^TZX)Q<)<K+"L3Q-XX\.>"84F\1>(-+T&&3.R
M34[V.V5L=<%V&:^*/^"A'[?EU\$;E_AW\/9X?^$TDA634=6(60:6C#*HBD$&
M9EPWS<*I!P2PV_DGXD\3:OXPUFYU?7=4O-9U2Y;?->7T[32R'U+,23732PSF
MN9NQ+9_1OX5^*'@WQU*8O#?BW0O$$H4MLTK4H;DX'4X1CQ73U_,WI\VH:7)#
MJ=D]S:202 QWEN60QN.1M<=#]#7U/J/[>/B'XD?LH^-?A1\0;B;6M6GCLFT;
M7&&9I!%>02/#<'^([$8K(>3M(8DD&KEA6OA8<Q^WM%?S'YK^D+X/_P#))?!/
M_8#L?_2=*QK4?96UN-.YUU%%%<PPKX#_ ."KW[2UY\._ ^F_#+P]?&UU?Q-$
M\^JR1-B2/3P2@CSV\UPP)_NQN/XJ^_*_!3]O[QX_Q _:X^(=UO)@TV^_L>%#
MT06RB%P/K(DC?\"-=6&AS3N^A+/GJOTK_8S_ ."7NG^*/#>F^-OC ER8+Z-;
MFQ\+P2M 3"PRKW+KAP6!R(U*D#&XY)4?)_["OPHM?C'^U%X)T/481/I-O<-J
M=[&R[E>.W0RA&'=7=40^SFOWUKJQ-9Q]V(HH\FTO]DOX*Z/8+9V_PH\'M"%V
M9N-%MYY"/=Y$9C]2:\8^._\ P3&^$GQ2T>ZE\+Z8GP_\2[2T%YI0(M&;'"RV
MY.S;G_GGL/N>E?8%%>>JDXNZ91_-Y\5_A9XB^"WC[5O!WBFS^Q:SILFR15.Z
M.12,I)&W\2,I# ^AYP<BO</^"?O[2UY^S[\<M,MKR^,7@WQ'-'I^KPR-^[C+
M$K%<>QC9AD_W"X],?6G_  6-^%-K=>$/!?Q'MX0M_9WAT2[D5>9(9$>6(L?1
M&CD _P"NM?E=7KP:K4]>I&S/Z<*_)_\ X+,?\E.^'?\ V!Y__1]?H?\ LO>/
M'^)O[._P\\2RN9+F]T:W%R[=6G1!'*?QD1Z_/#_@LQ_R4[X=_P#8'G_]'UY^
M'5JMBWL?!_P\TZVUCX@>&;"\B$]I=:G:P31,2 Z-*JLO'J":_<L_\$_?V?#Q
M_P *RTW_ ,";G_X[7X>_"G_DJ'@__L,V?_H]*_I'K?%2E%JS)B?,>N?\$V/V
M>-:M9(U\!?V=*P(6XL=4O$=/< RE3^*FOS]_;;_X)VWO[.&D-XS\(:A=>(?
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MU!CHOPWTFUL@_P JW]_+/(5]RJH ?P->A655M>S(5NI['_PYT^$G_0V^-/\
MP)M/_D:O5?V;_P#@G[X$_9B^($WB_P -Z[XBU+4)+&2P,.JS0/%L=D8G"0H=
MV8QWQR>*\6^#/_!7WPAXHU.WTWXA^&+CP=YIV_VM8S&\M5/K(FT2(/\ =#_@
M.GWWH^L6'B'2K34]+O(-1TZ\B6>WN[60212QL,JRL."".XK@J2K1TF7H1>(M
M>LO"OA_4]:U&7R-/TVUEO+F7^Y%&A=V_ *:_G)^*7Q"U+XL?$;Q'XPU>1I+_
M %F^EO'WMNV!F^6,'^ZB[5 [!0*_<S]O#Q,_A']D+XGWT9(:72_L''I<RI;G
M])37X%5U82.CD3(_0S_@EY^Q_P"%_BS8:W\1O'>D0Z[I=C=_V=I>F7B[K:29
M55Y99$Z2 !T4*V5R7R"0,?0_[=G[#?@'Q1\$]?\ $_@OPEIGACQ9X>M7U&(Z
M':):I=PQ@M+%)%& K'8&*MC=N51G!(/>?\$T=%31_P!C/P*ZJ%EO7OKJ4@=2
M;R90?^^57\J^F-2T^'5M-NK&X4/;W,3PR*>A5@01^1KFJ59*JW?8=M#^9BOW
ML_8+^,$OQI_9@\):M?7+7>LZ?&VCZC)(VYVF@(4,Q[LT9B<GU<U^#-Y:M8WD
M]N_WX9&C;Z@X-?JG_P $9?$SW7P]^)/ATD^78:I:WX';-Q$Z'_TE%=N*C>G?
ML3'<_1>BOD/_ (*H?\F@ZW_V$['_ -'"OQ+S7'2P_M8\U[%-V/Z<*XO6/C9\
M//#NH&PU7Q[X8TR^5BAM;S6+>*4,.HVLX.?:OR!_:[_X*%>+OCGJ5QX>\(W]
MYX7^'T.(4@MW,5SJ( QYD[J<A3VC!QC&[<>GR-<6L]JRB>&2%F&X"12I(/?G
MM6D,*VKR=@YC^E_2=8L->L(K[3+ZVU&REYCN;2998W^C*2#5ROYV?@7^T/XX
M_9W\6P:[X.UB:T <&YTZ1BUI>)QE)8\X.1_%PPZ@@U]<_M7?\%2]8^(GAW3_
M  _\*_MOA.UN[)'U?4WPMX)74%[>!Q]Q4.091AF/W=H&6F6%DI66P<Q^H?BC
MXK>"? ]S]G\1^,- T"XP#Y6J:G!;/STX=@>:T_#OC#0?&%L]QH.MZ=K=NF T
MNG7<=PBYZ9*$BOYK[V2\O)&OKMIYWN'9FN9BS&5OXB6/4\\UJ>"_'7B+X<^(
M+;7/"^M7N@ZM;L&CNK&9HWX.<''WE..5.0>A!K7ZGIHQ<Q_2G17S7^PC^U8?
MVI/A/)=ZL(8?&6ARK::Q% FQ)-P)BN%7L'"MD=F1\ #%?2E>?*+B^5EA7-^*
MOB9X0\"LJ>)/%6B>'F9=P75=1AMB1ZC>PXK\[O\ @H!_P43U?0?$FI?#/X5Z
ME_9TMBYM]8\26K R^:.'M[=OX-IX:0?-N!"[=I)_,N_U"ZU6\FO+VYFO+N9B
M\MQ<2%Y)&/4LQY)]S773PKDKR=B7(_I+\+^/?#/CB-Y/#GB+2=?CC +MI=]%
M<A0>A)1CBMZOYI= US7?!FI6>MZ+?7^B7T3;K;4+*5X)%(/574@]NQKZ2^.7
M[;FJ_M&?LQZ-X*\9)YWC31O$,%ZNJ0Q!$OK46US&6<#A95:1 < !@P( P:J6
M$::L] YC]R**_FO^'I_XK[PS_P!A.V_]&K7]*%85J/LK:W&G<****YQA7Y:_
M\%;/VEKRXUZR^#FA7QBT^WBCOO$ A;!EF;#P6[?[*KMD(Z$NA_AK]2J_G&^.
M'CQ_BA\8O&OBQG+IK&KW-W%N_AB:1O+7Z!-H_"NW"PYIW?0F1QMG9SZA=P6M
MK#)<W,[K%%#$I9Y'8X55 Y))(  K]7_V5_\ @E3X8T'0;+7OC#"^O^(+A!+_
M ,(_%.T=G99Y"R,A#2R#OA@@Y&&^]7S)_P $J_A1:_$+]IA=;U"$367A.P?5
M(U9<J;HLL4.?<;WD!]8Q7[3UKB:SB^2(DCRN']E/X+PV7V1?A/X+,.,?-H-J
MS?7<4W9]\U\U_M)?\$K_  !X]T.\U+X:6Z^"?%4:-)%:+*[:==MUV.C$F(GH
M&3"CNIK[HHKAC4G%W3*L?S1>)_#.J>#/$6I:#K=E+IVKZ;</:W=K,,/%(A(9
M3^(ZC@U]L?\ !*W]I:\^'_Q67X9ZO?'_ (1?Q0S?8XY6^6VU$ ;"OH)0OED=
MV\OWSL?\%@_A3:^&_BGX3\=V4(B_X22RDM;W8O#3VQ0*Y/JT<J+](J^#/#FO
M7?A?Q!I>M6#^7?:==17D#_W9(W#J?S KU]*U/U(V9_3!7XH_\%6/^3NM1_[!
M%C_Z :_9OPOK]OXK\,Z3K=ID6FI6D-Y#NZ[)$#K^C"OQD_X*L?\ )W6H_P#8
M(L?_ $ UP87^(5+8\:_9&\':-\0/VDO 'AWQ#81ZGHNH:D(;JSD9@LJ;&."5
M(/4#H:_8YO\ @GY^SVPP?AEIWX7-R/\ VK7Y%_L*_P#)W7PO_P"PLO\ Z ]?
MOS6F*E*,E9A$^5_%'_!,G]GOQ%8RPV_@^XT&X<86\TO5;D2)[A9'>/\ -#7Y
ML?MI_L.ZU^REJEIJ=G>R>(/ VI2F&TU-X]LMO+@D0S@?+N(!*L,!MK<+C%?N
M?7CW[7OPXMOBI^S7\0M!GMUN)_[)GO+,$<BY@4S0D'M\Z*/H2.]8TJ\XR5W=
M T?@7X)\::S\.O%VD^)O#U])INM:7<+<VMU$>4=3W'<$9!!X()!X-?T,_ GX
ML:?\<?A'X7\<:;M6'5[-9985.?(G&5FB_P" 2*Z_AFOYRZ_77_@COXX?6/@G
MXN\+RL7?1-9%Q'G^&*XB&%'_  .&4_\  JZ\5"\>;L*)]]T445Y184444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!YO\>/V@O!O[.'@Q?$WC6]GM;*6<6MM#
M:V[337,Q5F$: < [58Y8JO')K\G?VLO^"D?C'X_0W?AOPM'-X+\#S QRV\<F
M;V_4\$3R+]U"/^6:<<D,7'3ZV_X+"6L]]\#?!%M;0R7%Q+XHC2.&)2SNQM;@
M  #DD^E?*G[-?_!,+XB_%?4K+4O'5K<> ?")Q))]K4#4;A?[L<!YC)_O2 8Z
MA6Z5Z%&-.,/:3)=]CXNKU?\ 9-_Y.@^$W_8TZ;_Z4QU]$_\ !4+X0^$O@EKG
MPP\,^#=&@T;2H-(N"5C&9)G\X R2N?F=S@99CV Z "OG;]DW_DZ#X3?]C3IO
M_I3'7;S*=/F1/4_H9HHHKPC0_$/_ (*<?&"7XG?M/ZOI,-RTNC>$XUT>VCW?
M()AAKEL=F\PE">XB7TKE/V$?V<K/]I;X\6>AZTLK>&-,MGU355B8H98D956$
M,.1O=U!(YV[L8(R/%_B-XF?QM\0O$_B&0DR:MJEU?L3US+*SG_T*OT2_X(NZ
M*C77Q7U9E'FQIIMK&V.0&-RSC_QU/RKV9_NJ.AGNS[$\>_L._!7QUX%N?#0^
M'^A:&&@,=MJ>DV$=O>6SXPL@E4!G(.#AR0V/F!K\)_B!X+U#X<>.O$'A755V
MZCHM]-83X& 6C<J6'L<9'L17]*-?A1_P4CT6/1?VS/B L2A(KEK.Z  [O9PE
MC^+;C^-<V%FW)Q;'(^M_^".OQ@EU/PSXQ^&M]<M(=+D36--C=L[89#LG5?11
M)Y;8]9F/>OT6U34K;1=-N]0O9EM[.TA>>>9NB1JI9F/L ":_%;_@E7XF?0?V
MO='L5)"ZWI=]8-CN%B^T?SMQ7ZF?MG>)G\(_LJ_%'48R5D.A7%HK#JIG'D C
MZ>9FLZ\/WMEU&MC\*_C5\3K_ .,OQ8\4^--1DD>?6+^6Y1)&R8H<XBB'LD81
M![**^QO^"7O[(OAKXS3:_P"/_'.EQZWH>D7*Z?IVFW(S;SW6T22/*O\ &$5H
MP%.5)D.1\HKX$K]N_P#@EOHJ:7^QWX:N44*VI7]_=.<=2+AX<_E"/RKLQ$O9
MT[1)6YD?MJ_L*_#WQO\ !?7]7\&^#]*\,>+]#M)+^SDT.S2U%TL2EG@DCC 5
M]R@A21D,%P<9!_%NOZ;98DFC>.10\;@JRL,@@]0:_FE\4:6-#\2ZMIHZ6=W-
M;C_@#E?Z5GA9N2:8Y'[C?\$[?C!-\8OV6_#=Q?7+7>L:&SZ'?22-EF:'!B)/
M4DPO#DGJ<U]+U^:O_!&'Q,\VA_%#P\Y/EV]S8W\0[9D69'_]%1U[=_P50_Y-
M!UO_ +"=C_Z.%<E2G^^Y"KZ'UY17\Q^:^OOVN_\ @H5XN^.>I7'A[PC?WGA?
MX?0XA2"W<Q7.H@#'F3NIR%/:,'&,;MQZ;/".Z28N8_7[6/C9\//#NH&PU7Q[
MX8TR^5BAM;S6+>*4,.HVLX.?:NHTG6+#7K"*^TR^MM1LI>8[FTF66-_HRD@U
M_-!<6L]JRB>&2%F&X"12I(/?GM7HOP+_ &A_''[._BV#7?!VL36@#@W.G2,6
MM+Q.,I+'G!R/XN&'4$&J>$TT8N8_HFKE?%'Q6\$^![G[/XC\8:!H%Q@'RM4U
M."V?GIP[ \U^7G[5W_!4O6/B)X=T_P /_"O[;X3M;NR1]7U-\+>"5U!>W@<?
M<5#D&489C]W:!EO@6]DO+R1KZ[:>=[AV9KF8LQE;^(ECU//-13PKDKR=A\Q_
M2AX=\8:#XPMGN-!UO3M;MTP&ETZ[CN$7/3)0D5KU_-9X+\=>(OASX@MM<\+Z
MU>Z#JUNP:.ZL9FC?@YP<?>4XY4Y!Z$&OV_\ V$?VK#^U)\)Y+O5A##XRT.5;
M36(H$V))N!,5PJ]@X5LCLR/@ 8J*V'=-<R=T"=SZ4HHK\RO^"@'_  43U?0?
M$FI?#/X5ZE_9TMBYM]8\26K R^:.'M[=OX-IX:0?-N!"[=I)PITY5'9#/T1\
M5?$SPAX%94\2>*M$\/,R[@NJZC#;$CU&]AQ4WA?Q[X9\<1O)X<\1:3K\<8!=
MM+OHKD*#T)*,<5_-I?ZA=:K>37E[<S7EW,Q>6XN)"\DC'J68\D^YJ_H&N:[X
M,U*SUO1;Z_T2^B;=;:A92O!(I!ZJZD'MV-=WU/3XB>8_I:HK\-_CE^VYJO[1
MG[,>C>"O&2>=XTT;Q#!>KJD,01+ZU%M<QEG X656D0'  8," ,&OG?X>G_BO
MO#/_ &$[;_T:M1'"NUV[#YC^E"BBBN H**** /RU_P""MG[2UY<:]9?!S0KX
MQ:?;Q1WWB 0M@RS-AX+=O]E5VR$="70_PU^;UG9SZA=P6MK#)<W,[K%%#$I9
MY'8X55 Y))(  KLOCAX\?XH?&+QKXL9RZ:QJ]S=Q;OX8FD;RU^@3:/PKZ2_X
M)5_"BU^(7[3"ZWJ$(FLO"=@^J1JRY4W198H<^XWO(#ZQBO;C:C2]#/=GTW^R
MO_P2I\,:#H-EKWQAA?7_ !!<()?^$?BG:.SLL\A9&0AI9!WPP0<C#?>KZXA_
M93^"\-E]D7X3^"S#C'S:#:LWUW%-V??->J45Y,JLY.[9=CX7_:2_X)7^ /'N
MAWFI?#2W7P3XJC1I(K197;3KMNNQT8DQ$] R84=U-?D5XG\,ZIX,\1:EH.MV
M4NG:OIMP]K=VLPP\4B$AE/XCJ.#7]+M?DE_P6#^%-KX;^*?A/QW90B+_ (22
MRDM;W8O#3VQ0*Y/JT<J+](J[,-6DY<DB6C'_ ."5O[2UY\/_ (K+\,]7OC_P
MB_BAF^QQRM\MMJ( V%?02A?+([MY?OG]A:_F?\.:]=^%_$&EZU8/Y=]IUU%>
M0/\ W9(W#J?S K^DWPOK]OXK\,Z3K=ID6FI6D-Y#NZ[)$#K^C"HQ4+24EU'$
M\0_:@_;:\ ?LKM;Z=X@%]JOB:[M?M=IHNGP_,\19D5WE;"(I9&'4MP<*:_(G
M]I[]LKQ]^U%JV-<NAI7AB"7S+/P[8N1;1$9 >0]99,'[S=,G:%!(KZ-_X*O>
M#]=\=?M6>#M'\.:/?:[JL_A.W$=GI]N\\K?Z9=\[5!.!W/05O?LH?\$I=2OM
M0M_$?QI06&G1%9(?"UK<!IK@]?\ 2)$.$3_80ECW*XP=*?LZ4%.6XG=GYN5]
MO_\ !(/_ ).BUC_L5KO_ -*;6O&_V\-#T_PW^UE\0-*TFQM],TRSGMH;>SM(
MECBA06D("JJC  ]!7LG_  2#_P"3HM8_[%:[_P#2FUKIJ/FI-^0EN?LC7F/[
M37Q*E^#_ , ?'?B^V8)>Z;I<K6C'HMP^(X3^$CI7IU9/BGPGHOCC0;K1/$6D
M6.NZ/=!1/8:C;I/!+M8,NY&!!PRJPXX(![5XL;)JYH?S3RRO/*\DCM)(Y+,[
M')8GDDGN:_4/_@G!^PSX*\4?"VS^)WQ!T6W\2W>KR2_V7IM\-]K!;HYC\QXC
MP[LROC=D!=I R:^K];_8,^ 'B#=]J^&&CQ;NOV$RVG_HIUQ7K_@?P3HOPW\(
MZ5X8\.60T[0]+@%O:6HD>3RXQT&YR6;KU))-=U7$\\;1T)2/%OC!^P=\&OBQ
MX3O=+C\$Z-X6U-HB+35M L8[.:WD"D(Q$842*.ZL""/0X(_"GQ5X<N_!_BC6
M-!OPHOM+O)K&XV9V^9$Y1L9[94U_2-XL\4:;X)\,:MX@UFY6STG2[62\NKA^
MB11J68^_ /'>OYQOB-XL?Q]\0O$_B>1&C?6M4NM29&ZJ9I6D(/\ WU6F%E)W
MOL*1^E/_  1I^(%Y>>'_ (A^"[B5GL[">VU2T1FSL,H>.8 =A^ZB/'<GUK[*
M_:Z_Y-;^+'_8L:A_Z(>OB[_@C)X*N8=)^)7BZ5,6ES/::7;OCJ\:R2RC\!+#
M^=?:/[77_)K?Q8_[%C4/_1#USU;>WT\AK8_GKK]E?^"1/_)K6H_]C-=_^B+:
MOQJK]8O^"6_QH^'OP_\ V;[_ $SQ1X[\,^&]2;Q#=3+9ZOK%O:S&,PVX#A)'
M!VDJPSC'!]*[<2FZ>A,=S]#J*\Q_X:A^#7_16_ O_A267_QVC_AJ'X-?]%;\
M"_\ A267_P =KR>678T/R/\ ^"HW_)XWB?\ Z\K#_P!)DKE/^">__)Y'PS_Z
M_)__ $EFK5_X*/>+M"\<?M7>(M7\.:UI_B#2I;.R6.^TNZCN8'*VZ!@)$)4D
M$$'G@BLK_@GO_P GD?#/_K\G_P#26:O87\'Y&?4_>FBBBO%- HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,CQ=XHT[P/X5UCQ%J\XMM+TJTEO;J
M8_PQ1H78_7 -?SL_&3XI:K\:OBAXD\;:RQ-]K%VUQY><B&/[L<2G^ZB!4'LH
MK]7O^"L_Q<;P/^SY9>$;2<Q:AXNOQ!(JG#&T@Q)*?Q<P*?4.17Y$>"?"=]X\
M\8Z'X:TQ/,U'6+Z&PMUQQYDKA%S[9:O4PL;1<V1(_5__ ()+_L__ /"$?"O4
M?B5JEMLU?Q4WD6.]?FCL(V(R/3S) 6]Q'&>]?>]8O@KPG8^ _!^A^&M,3R].
MT>QAL+=<?\LXD"+GWPHK:KSZD^>3D4%?S]?MG:IJ?B+]IWXD:SJ%C=VD=QK5
MQ#;-=0M'YD,3>3$PW 9!2-2/:OZ!:AO+.WU"W>"Z@CN8'X:*9 ZGZ@\5=&K[
M)WM<&KG\_P#^SI^R%\1OVG;Z<>$M-B@TBV?R[G7-2<PV<+8!V;@"SO@@[45B
M,C. <U]%>,O^"/OQ.T/09K[0O$_A_P 1WL,1D.G#S;:24C^"-F!4D]MQ0>]?
MKAI.C:?H%BMGIEC;:=9J69;>TA6*,$DDD*H R223[FKE;2Q4V[K87*?S.ZYH
M>H>&=9OM(U:RGT[4[&9[>YM+E"DD,BDAD93R"""*_2O_ ()._M37]]?3_!GQ
M'>M<PI;O>>'9IF)= GS36H/==N9%'8+(.FT#R'_@K=X&LO"_[2VGZQ8VR6__
M  D&APW=TR#'F7"22Q,Q'KY:0_7%>"_L=^(I_"_[4_PJO;>0Q._B*SLV9?\
MGG/*(''XI(P_&NV5JU*Y.S/VA_;:_P"33?BG_P!@.?\ I7\_M?T!?MM?\FF_
M%/\ [ <_]*_G]K'"?"QR/TV_X)4?LI^&O$GA>_\ BOXLTJVUJZ^VM9:+:WL8
MEA@$8'F7&PC!<LVU2?N["1R01^BGQ%^'/A[XK>#-3\+>)M-AU+1]0A:&2&5
M2F00'0D?*ZYRK#D$ BO!/^"9UJEO^Q7X =1AIGU&1_<_VA<+_)17U#7%6DW4
M;[%+8_F>\0:3)X?U[4M+E;=+97,ELS8QDHY4G]*^DO\ @GE^S=IG[1GQS^S^
M(X3<^%=!M3J6H6VXJ+IMP6* D<@,QW'U5&'&<UX7\7E"_%CQJ!T&MWH_\CO7
MZ#?\$6;1&NOB]=$?O(TTF)3[,;PG_P!!6O4K2<:3DB%N?I19^%-$T_P^F@VN
MCV%OH:1>0NF16R+;"/\ N",#;M]L8K\'_P!NGX3Z1\%_VH/&/ASP_:K8Z%O@
MO;*U3.V%)H4D9%ST579P!V %?OK7XG?\%50!^UYJV.^E6)/_ '[KAPK?.T5+
M8@_X)8ZM+IO[8.@V\;%4O].O[:09ZJ(&EQ^<2G\*_:+Q;XCMO!_A76=>O3BS
MTNRFOISG'[N*-G;]%-?B;_P3$_Y/.\%?]>^H?^D4U?K3^U_<26O[+/Q7>($L
M?#5\AQ_=:%E;]":>)5ZJ01V/P)\<>,-2^(/C+6_$VL3>?JFKWDM]<R=C)(Y8
M@>@&< =@ *^X?^"7O[(?A_XQ76K_ !%\:Z>FK:)HMXMEINF3C,%Q=!5D=Y5_
MC5%:/"GY6+G.=N#\!U^V/_!*N"&']D/26B $DNJWSRX'5O,V\_\  0M=>(DX
M4_=)6Y]8MH>FR:2VEMI]JVF,GEM9&%3"4_NE,;<>V*_(#_@IS^R3HGP+\4:-
MXU\&6*Z9X7\12R6]QIL(Q#97BC=B,?PI(NXA!PIC?& 0!^QM?$__  5R2V;]
ME>R,^WS5\26AM\CG?Y-P#C_@&^O/P\G&HK=2WL?C/7](7P?_ .22^"?^P'8_
M^DZ5_-[7](7P?_Y)+X)_[ =C_P"DZ5TXS:),3KJ***\TL*_G*^/EU+>_'3XC
M7$P*S3>)-2D<'J&-U(3^M?T:U_/=^V!X7G\'_M2?%/3KA/+8^(;N[C7_ *93
MR&>/_P <E6N_"?$R9'T)_P $?[>.;]I[77<C=#X5NG0>_P!JM%_DQK]C:_$3
M_@ESXT@\(_M<Z';7$BQ1Z[87>E!W. &*"9!]2T"J/=A7[=U&*_B!'8**R/$_
MC#0O!.GQW_B'6;'0[&29+=+G4;E((S*YPB;F(&XGH.]:L<B31K)&RNC ,K*<
M@@]"#7&4?)/_  5,MXYOV/?$#N0&AU&P>//=O/5?Y,:_$>OV&_X*]^.(-#_9
MYT/PV)%^W:]K<;"(GDP01L\C#Z.T(_X%7X\UZ^%_AF<MS]UO^";-S+=?L6?#
MMI005%_&I/=1?W 'Z#'X5\<_\%F/^2G?#O\ [ \__H^ONO\ 89\,W'A']DCX
M8:?<Q^5,^DK>E.X%Q(\ZY]\2BOA3_@LQ_P E.^'?_8'G_P#1]<U+^._F4]CX
M8^%/_)4/!_\ V&;/_P!'I7](]?S<?"G_ )*AX/\ ^PS9_P#H]*_I'JL9O$(A
M113)94AC>21@D: LS,<  =2:\\H_G,^/4"6OQR^(L,9S''XCU%%([@74@%?5
M/_!(&[>W_:=UR)02D_A:Z1O;%S:L#^F/QKXY\?:^GBOQUXCUN,$1ZEJ5S>*&
MZXDE9QG_ +ZK[B_X(W^'9[KXW>-M=$>;6Q\/?8W?^Z\US$ZC\1;O^5>W5TI.
MYFMS]<:***\0T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^!3-?05>!_MZ:@NF?L@_$^9F"!M,$.2<<R2QQ@?B6Q^-84_C7J4?@77[/_\
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M[QCI4.LZA>7,J:':7B!X+>*-C&TY0\,YD5P-P.T(".3D?ES7[_\ [$$$-O\
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M8M]F8-MEM]QY8(2I!/.V1022"3\__#W_ )'[PS_V$[;_ -&K7Z5?\%H$MO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)ZU,9]6AM8R3IMVW+R,!TBE;+;N@=F!QE<_!MC?7.EWMO>65Q+:7EO(LL-Q
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MID)V/U _X*W>'?BGXRM?#<&B>%]0O_AQH\3ZA>W]@!,/M9W+NEC4ET2./HY
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M5.,QWFG7"3Q-[!E)&?;M7Y;?\%F/^2G?#O\ [ \__H^O,PW\5&CV/ACX4_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 ?E!_P68_Y*9\.O\ L$7'_HX5\B_LF_\
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MVNO^36_BQ_V+&H?^B'KX3_X(]^*-9U_X@?$1-3U:^U)(],MF1;NY>4*3*V2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-?;_ .Q?_P %-M/\0:;JFB_''Q/;Z?K@N!)I^L/8B&WFA* &)_)7:C*REMQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1*^ZJ*N-2<5:+%8PO ?@^S^'O@?P[X5TZ6>;3]#TZWTRVDNF5I7BAB6-"Y4
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M;J*EU)RT;"P4445D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFW!+2,>KR.Q+2,<#YF)/ ]*ZVBBN>]]6,****0!1110 4444 %%%% !1110
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MTJ=@LL;E' (7!&Y3S6;_ ,/3/V?O^A@U3_P3S_\ Q-:^RG_**Z/KBBODA?\
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M77B_PI]C_M>/4+:V7[="98]CL0WR@CGCUJHQ<FD@/H.BOQ=_X>T?'7_J6?\
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M+J$JLMS@9;[/*,"7']TA6QD[2 37T_7)*+B[2104445(!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$>O2LFOZ2_AE_P DW\)_]@FT_P#1*5Z5:M[*VER$KG\W]YI-]IW-W97%J/\
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M'7Q"\-?#+P_-KGBO7;'P_I,1PUUJ$ZQ(6[*,_>8]E&2>PKS-RSH:*^._$_\
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MO,OVC/CMHW[./PEUCQKK*F<6P$-G9*V&N[I\B*('MD@DGLJL<'&*]-K\G/\
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MK9*3D10:+9E1[?/$Q_6NF.%J25]B>9'[C45^*7AC_@JU\>M"N4DU#4-#\1Q
M_-#J&E)&&'U@,9%?H!^Q_P#\% ?"G[4%P/#M[9'PMXZ2)I?[,DE\R"[5>6:W
MDX)('S%" 0,D;@"1$\/."NQW1]6T5Q_Q@UCQ/X=^%WBC5O!EK97WBBPL);NP
MM-0B>2&>2-=_EE4=&)8 J,,.2.W%?E3_ ,/B/C-_T+/@7_P O?\ Y+J:=*51
M7B%S]AJ*^;/V$?VJ+_\ :J^%NI:QKUKIVG^)=*U%K.\M=+1TA\LJKQ2*KN[
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MY(!8]%7Q;]LCQ;K?BC]IGXEIK&KWVJ1Z?XCU&RLTO+AY5MH$N9%2*,$X1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#$)$!0;4"YP>26/<UV_[#G_!/N3]IO3]1\4>+-4O?#WA"SN391QV**+N\F4
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M(]""17%6ER5N9%+8_F7K]_OV)_BU_P +G_9F\$:_--YVIPV8TW4"3EOM%O\
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MR8+GT0#M6.'KRE+ED-HU?^"4O[5E[8^(A\&?$E[YVEWB23^'I9FR;>=<O);
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ML-RA*31C/.!(K8SSC![UZ17P+_P1U\52:E\"_%V@R$L-+UXSQD]DF@C^4?\
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M<5^]W[$OQTOOVAOV=_#WBG5S&VO1M)I^I-$H57GB;'F8' +H4<@8 +''&*_
M:OV$_P""/-P\G[-?B:)B2L7BNXV^P-I:''YY_.M,5%.%PB?/_P#P5^^#7_".
M_%#P[\1[*#;9^(K7[#?.HX%W  $9CZO"5 _ZXFOC[]GGXHR_!;XV^#/&D;,L
M6DZC'+<A.KVS'9.H_P!Z)G'XU^UW[=?P:_X7=^S-XMT>W@\_6-/A_MC30!EO
MM$ +;5]WC\R,?]=*_ ZGAY<]/E?03W/Z;+>XBO+>*>"19H)5#QR(<JRD9!![
M@BN3^,'Q$M?A+\+?%7C*\VF'1=.FO!&QP)'5"4C^K/M4>[5XY_P3Q^+7_"V_
MV5O"<\\WG:GH2-H-[DY(:  1D^I,+0DGU)KQ_P#X*\?%C_A%O@CH?@>VFV7G
MBG4/,N$!ZVMMM=@?K*T&/]TUYT:;=3D9=]+GY&:MJEUKFJ7FI7TS7-[>3/<3
MS/\ >DD=BS,?<DDU^NW_  2-^#O_  B'P2U?QW>0;+_Q7>;+=F'/V.W+(I'I
MNE,V?4*IK\EO!_A74/'7BS1?#FE1>=J>K7D-C;1_WI)'"+^&6%?T;?#GP/I_
MPS\ ^'O">EKMT_1;"&PA.,%EC0+N/NQ!)]R:[\5*T5%=28G1T445Y185\1_\
M%-/V2-5^/'@[3/&?A"S-]XL\-Q21RZ?"A,U_9L=VR/'WGC;<RI_$'<#)V@_;
ME?-O[:W[9&E?LH^"X/LT,&K^-]5!&EZ5,3Y:J#AIYMI!$:]  06;@8PQ76DY
M*:Y=Q,_%+X9?$7Q)\"OB9I/BK0V;3_$&AW180W*, 2,K)#*O!VLI9&'!P3T-
M?H_I_P#P6:\/_P#"/(]]\-M2_MT( T-OJ,?V9GQR0Y7<HSVVG'J:_.#XI?%+
MQ1\<O'MYXI\472ZEKVH,J$P6ZQC X1%1 . , =2>Y)KU;3?^"?/[0>K:"-7@
M^&M^MJ5#B.XNK:&X((S_ *EY1)GVVY]J]:I"G*SJ;D:]#@_VA_C[XC_:4^)U
M[XR\2"*&>6-+:UL;;=Y-I;IG9$F23U+,3W9F/&<#]"O^"6?[(.L^!9KGXM>,
MM.DTV]O+5K30]/NXRD\<3D>9<LIY3< %3/)5G/1E)_,VQO/$WPB\>0W*1W7A
M[Q5H=V'5+JWVS6LZ'^*.1>H/9A7ZZ?L%_P#!0!?VBISX)\;I:Z?X^BC:2UGM
M4,<&J1*N7(7)VRJ 691P1DJ!@@9U^:-.T%H-;ZGVS1117D%A1110!_.9^T!_
MR7CXD?\ 8RZE_P"E4E?7_P#P1O\ ^2Z^-/\ L6S_ .E4%?('[0'_ "7CXD?]
MC+J7_I5)7):+XCU;PW<//I&J7FE3R+L>2RN'A9ESG!*D9&0./:O=E'GI\IGU
M/Z8*Y'XG?%KPC\&_"]SK_C'7;/0]-A0L&N) ))B!G9$GWI'/95!)K^>23XH^
M,YE*OXNUUU]&U*8C_P!"KG[V_N=2N&GN[B:ZG;K),Y=C^)KC6#[R'S'=_M"?
M%9OCA\:O%_C@V[6L6L7S3002<M' H"1*W/WA&B XXSG%>Y?\$N?!]UXF_:^\
M.7\,)EM=!LKW4;ENR*8'@0_7S)TKY?\ #'A?6/&FO6>BZ!IEUK&K7CB.WLK*
M)I99&/8*!G_"OVT_8%_9!/[+WP\NKK7A#-X[U[9)J3PMO2UB7/EVR-T.W)+,
M."QQDA5-=%:<:=/E$MSZ2\7?\BIK7_7E-_Z+:OYI:_I:\7?\BIK7_7E-_P"B
MVK^:6L,'M(<CO/$7QD\0>(OA3X2^'33>1X9\/2W%S':QL<7%S-*[F5_4JK!%
M'8;C_$:Y_6? GB7P[I\-]JWAW5M,LIO]5<WEE+#&^?[K,H!_"OMS_@DC\"]*
M\??$SQ'XZUNRBOK?PK%#'I\-PFY!>3%R)0.A,:1MC/0R*1R 1^MFK:18:_IM
MSIVIV5OJ.GW*&.>TNXEEBE4]59&!##V(JZF(5*7*D%KGSQ_P3[^$J?!G]E?P
MO%=QK;:EK4;:_J#/\N&G :,-GH5A6)3GH5-?FU^WA^VYJ_[17C&]\-^';^6T
M^&FFS[+6WB)3^TG4X^T2]V4G)13P!@D;B:_2K_@H!\0I/A7^R/XUN=.D^QWE
M];Q:-:^3\NT3NL;A<=,1&3&.F!7X.U.'CSMU9 ^QV'PO^#_C/XT^(#HG@GP[
M>>(M25/,DCM5 6)/[TCL0J#/&6(&>*[[XK?L5_&?X+>'Y-=\5^"+JTT:(*9K
MZTN(+R.'/>3R78H,\;F &<<\BOUB_P"">_@'PY\*?V7?"#6\MK!JGB"V36]1
MFDE022R3*&0'V6/8H'L3U)KZ-NM3T>^M9K:YN[&XMYD,<D4LB,CJ1@J03@@@
MXQ2EBI*5DM Y3^>#X)_''Q=^S_XXM/%/@_4FLKV(A9[=\M;W<6>8IDS\ZG\P
M>000#7[W?L__ !LT7]H3X4:'XWT3]W#?1[;BU9LO:W"\2PM[JV<'N"IZ&OPG
M_:F^'&G?"3]H3QUX4TCC2+#46-DN_?M@D598UW=\)(HS[5]O_P#!&GXBW'VG
MXA> YIMUKL@UNUA)^XV?)G8?4&W_ .^:O$04X>T0+L?I[17 _&CXY>#_ -G_
M ,)P^)?&^HR:7H\UVEBDT5M).3*RNRKMC4GI&W.,<5XC_P //OV=_P#H<;S_
M ,$MY_\ &J\V,)25TBSZLHKY3_X>??L[_P#0XWG_ ();S_XU7K_P2_:.\!?M
M#:/JNJ>!M6EU2RTR98+J2:TEM]C%=P&)%4GCN*;ISBKM ?#_ /P5#_;,U3P[
MJ4OP=\%:A)I\Q@5_$>H6[;9-LBADM$8<J"A#.1U#*N<;@?S MK::\N(K>WB>
M>>5Q''%&I9G8G 4 <DD]JZ7XJ^.+CXE_$SQ5XKNG>2;6=3N+[]X>0LDC,J^P
M"D #L !7VQ_P2(^">F^,OB1XD^(.JQ)<_P#"+10P:=#(FY1=3A\S<]T2,@>\
MN>H%>LDJ%.YGNSQ'1?\ @G/^T)KN@)JT'P^F@AD3S$M[R_M;>Y88SS%)(&4^
MS 'VKS.3Q1\1/@;8^-/AQJ"7^@6VLQ+:ZSH.HQ,H8JZR))L;HP*J0Z]5/4@U
M_137P?\ \%;/@KIOBCX(VOQ$@M8X]>\,W<,,UTJX:6RF<1F-B.NV5XV7/3+X
M^\:YZ>(<Y<LEN.Q^/]?OA^P+_P F??#'_L'/_P"CY*_ ^OWP_8%_Y,^^&/\
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M3)$\0S(!ZAHMX(^AZ@5G#%2E*S6@<I\+_P#!.O\ ;<U7X3^,M*^'/B_4WNO
M6JS"VM);IBQTFX<X0JQZ0LV R]%+;ACYMW[&5_,>"5((."*_H=_9:^(D_P 5
M_P!G?X?^*KR;[1?W^DP_:YO[]Q&/*F;\9$<U&*II-374<6>IT445P%!1110
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MS$S'T24;1[SUYF&GRSMW+D?//_!)OXM?\(/^T3<^%+F;R]/\76#6ZJ3A?M4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/$_AR"Y\3W>H^#=8"#[187%C-=IOQSY<D*-N7/0L%/J!2Q-*3ES15QIGT?\
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M** "BBB@ HHHH **** "BBB@ KX[_P""K?\ R:/?_P#88L?_ $)J^Q*^._\
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MY6K^*'.N7.X?,(Y !;KGT\E4;'8NU?55>17GSU&:+8****YQA1110 5^8_\
MP6H_YHY_W&?_ &QK].*_,?\ X+4?\T<_[C/_ +8UTX?^*A/8_/?X-_\ )7O
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MWC+%22J2ME=N-HXYS7XYZ;IMWK6I6NGV%M+>7UU*L$%O A>261B JJHY))(
M ]:_>;]B#]F\?LS_  -T_0[Z.(^*-2?^T=:EC(8"=@ L0;N(T"KQP6#$?>KI
MQ*A&&VHD?0-%%%>66%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ'[-OPCU:_N;Z^^%G@J]O;J5II[FX\/6DDDLC$EG9C'EF))))Y)-;'@WX/\
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MPH"@ # '  H50J@ 8 X %+7%4JNJ[LI*P4445B,**** "BBB@ HHHH ****
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M,+>,Y(..#(Q+$9QM!(/UC117'*3F[R*&R2+%&SNP1%&69C@ >IKSOX>?M!>
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M7]6T6W6XOY+']Y;PY?8$\T?*SYSD*3C')!XKT>OQC_X)A_'CP'\"/'7C:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?,O_!1CX;ZS\3_ -E7Q#IOA[2;S7=:
MMKNSN[:PL(&FGE*SJK[$4$DA'<\=@:^FJ*J,N62D!_.7)\ ?B?#?"RD^''BY
M+QNENVA70D/_  'R\U[/\$?^"<OQD^+6O6L>J>&KOP-H/F+]JU/Q!";=XTR,
M[(&Q([8S@8"YZLM?N;178\7*VB)Y3B_@]\(_#OP-^'>D>#/"UJUMI.G1D!I#
MNEFD8Y>61N[LQ)/;L   !VE%%<3;;NR@HHHI %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)<UK @HHHK(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!^-G_  5Z_P"3H]*_[%BT
M_P#2BYKYQ^%WCSQC^RY\5O#'C"SMY;+4(88-0CMYB1'?V,\8?82.J21MC/\
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MH[=9;<L-Q Z%TX=&'!QC.UCF_P#\%%O^3SOB5_UWM/\ TBMZ^P?^"F'[)O\
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MV_\ 22"OW:T?_D$V7_7!/_017X2_\%#&#?MD_$H@Y!NK8@C_ *](*_=K1_\
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M_P#@QU#_ ..4?\(I^VI_?^,?_@QU#_XY3^K_ -Y!<_<&BOP^_P"$4_;4_O\
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M2^+WAV3X2MX\&@KH2+=?\(K=745O]H^T39WB)@-^S9R><8KY._X13]M3^_\
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M2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@4445B,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368346640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 19, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Schrodinger, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4284541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1540 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">24th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">295-5800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SDGR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790,263,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Portland, OR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001490978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,874,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember', window );">Limited common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367253392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 147,326<span></span>
</td>
<td class="nump">$ 155,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">15,331<span></span>
</td>
<td class="nump">5,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">204,798<span></span>
</td>
<td class="nump">307,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $210 and $220</a></td>
<td class="nump">235,692<span></span>
</td>
<td class="nump">65,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_UnbilledAndOtherReceivablesCurrent', window );">Unbilled and other receivables, net of allowance for unbilled receivables of $100 and $100</a></td>
<td class="nump">19,641<span></span>
</td>
<td class="nump">23,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">12,205<span></span>
</td>
<td class="nump">9,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">634,993<span></span>
</td>
<td class="nump">567,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">24,196<span></span>
</td>
<td class="nump">23,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">43,208<span></span>
</td>
<td class="nump">83,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,791<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">111,883<span></span>
</td>
<td class="nump">117,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,155<span></span>
</td>
<td class="nump">6,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">823,226<span></span>
</td>
<td class="nump">802,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,666<span></span>
</td>
<td class="nump">16,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll, taxes, and benefits</a></td>
<td class="nump">42,110<span></span>
</td>
<td class="nump">31,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">111,944<span></span>
</td>
<td class="nump">56,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities - operating leases</a></td>
<td class="nump">16,755<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">10,272<span></span>
</td>
<td class="nump">11,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">191,747<span></span>
</td>
<td class="nump">133,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">108,814<span></span>
</td>
<td class="nump">9,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities - operating leases, long-term</a></td>
<td class="nump">101,074<span></span>
</td>
<td class="nump">111,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, long-term</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">401,781<span></span>
</td>
<td class="nump">254,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">946,037<span></span>
</td>
<td class="nump">885,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(525,541)<span></span>
</td>
<td class="num">(338,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">421,445<span></span>
</td>
<td class="nump">548,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">823,226<span></span>
</td>
<td class="nump">802,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_UnallocatedCommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember', window );">Limited common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_UnbilledAndOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled and other receivables current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_UnbilledAndOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_UnallocatedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_UnallocatedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367934864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_AllowanceForUnbilledReceivablesCurrent', window );">Allowance for unbilled receivable</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_UnallocatedCommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">63,710,409<span></span>
</td>
<td class="nump">62,977,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">63,710,409<span></span>
</td>
<td class="nump">62,977,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember', window );">Limited common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">9,164,193<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">9,164,193<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_AllowanceForUnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for unbilled receivables current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_AllowanceForUnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_UnallocatedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_UnallocatedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368457472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 207,539<span></span>
</td>
<td class="nump">$ 216,666<span></span>
</td>
<td class="nump">$ 180,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">75,456<span></span>
</td>
<td class="nump">75,974<span></span>
</td>
<td class="nump">79,933<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">132,083<span></span>
</td>
<td class="nump">140,692<span></span>
</td>
<td class="nump">101,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">201,785<span></span>
</td>
<td class="nump">181,766<span></span>
</td>
<td class="nump">126,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">39,917<span></span>
</td>
<td class="nump">37,226<span></span>
</td>
<td class="nump">30,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">99,677<span></span>
</td>
<td class="nump">99,148<span></span>
</td>
<td class="nump">90,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">341,379<span></span>
</td>
<td class="nump">318,140<span></span>
</td>
<td class="nump">247,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(209,296)<span></span>
</td>
<td class="num">(177,448)<span></span>
</td>
<td class="num">(146,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147,213<span></span>
</td>
<td class="nump">11,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value</a></td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">53,461<span></span>
</td>
<td class="num">(18,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">17,902<span></span>
</td>
<td class="nump">19,693<span></span>
</td>
<td class="nump">3,953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">23,585<span></span>
</td>
<td class="nump">220,367<span></span>
</td>
<td class="num">(2,306)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income taxes</a></td>
<td class="num">(185,711)<span></span>
</td>
<td class="nump">42,919<span></span>
</td>
<td class="num">(149,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (187,123)<span></span>
</td>
<td class="nump">$ 40,720<span></span>
</td>
<td class="num">$ (149,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common and limited common stockholders, basic (in usd per share)</a></td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)</a></td>
<td class="nump">72,670,295<span></span>
</td>
<td class="nump">71,776,301<span></span>
</td>
<td class="nump">71,173,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share of common and limited common stockholders, diluted (in usd per share)</a></td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)</a></td>
<td class="nump">72,670,295<span></span>
</td>
<td class="nump">74,986,816<span></span>
</td>
<td class="nump">71,173,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember', window );">Software products and services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 180,365<span></span>
</td>
<td class="nump">$ 159,124<span></span>
</td>
<td class="nump">$ 135,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">36,900<span></span>
</td>
<td class="nump">29,514<span></span>
</td>
<td class="nump">29,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember', window );">Drug discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">27,174<span></span>
</td>
<td class="nump">57,542<span></span>
</td>
<td class="nump">45,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenues</a></td>
<td class="nump">$ 38,556<span></span>
</td>
<td class="nump">$ 46,460<span></span>
</td>
<td class="nump">$ 50,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367702544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive (Loss) Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to common and limited common stockholders</a></td>
<td class="num">$ (187,123)<span></span>
</td>
<td class="nump">$ 40,720<span></span>
</td>
<td class="num">$ (149,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Changes in market value of investments, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">2,663<span></span>
</td>
<td class="num">(1,731)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (187,184)<span></span>
</td>
<td class="nump">$ 43,383<span></span>
</td>
<td class="num">$ (150,917)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365564112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Limited common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive (loss) income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,834,515<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 557,071<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 786,964<span></span>
</td>
<td class="num">$ (229,952)<span></span>
</td>
<td class="num">$ (651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities</a></td>
<td class="num">$ (1,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock upon stock option exercises (in shares)</a></td>
<td class="nump">329,224<span></span>
</td>
<td class="nump">329,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock upon stock option exercises</a></td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">39,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(149,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,163,739<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">447,894<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">828,700<span></span>
</td>
<td class="num">(379,138)<span></span>
</td>
<td class="num">(2,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Reclassification of non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities</a></td>
<td class="nump">$ 2,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock upon stock option exercises (in shares)</a></td>
<td class="nump">800,336<span></span>
</td>
<td class="nump">800,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock upon stock option exercises</a></td>
<td class="nump">$ 9,440<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of RSUs and PRSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">47,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="nump">40,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,977,316<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">548,558<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">885,973<span></span>
</td>
<td class="num">(338,418)<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized loss on marketable securities</a></td>
<td class="num">$ (61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock upon stock option exercises (in shares)</a></td>
<td class="nump">169,820<span></span>
</td>
<td class="nump">169,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock upon stock option exercises</a></td>
<td class="nump">$ 1,488<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of RSUs and PRSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of RSUs and PRSUs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in ATM offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in ATM offering, net</a></td>
<td class="nump">8,678<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">49,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(187,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,710,409<span></span>
</td>
<td class="nump">9,164,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 421,445<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 946,037<span></span>
</td>
<td class="num">$ (525,541)<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368401344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (187,123)<span></span>
</td>
<td class="nump">$ 40,720<span></span>
</td>
<td class="num">$ (149,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(147,213)<span></span>
</td>
<td class="num">(11,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Changes in fair value</a></td>
<td class="num">(5,683)<span></span>
</td>
<td class="num">(53,461)<span></span>
</td>
<td class="nump">18,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="nump">4,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">49,903<span></span>
</td>
<td class="nump">47,841<span></span>
</td>
<td class="nump">39,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_InvestmentAmortizationNoncashExpense', window );">Noncash investment (accretion) amortization</a></td>
<td class="num">(7,592)<span></span>
</td>
<td class="num">(7,761)<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in assets, net of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(169,700)<span></span>
</td>
<td class="num">(10,039)<span></span>
</td>
<td class="num">(23,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables', window );">Unbilled and other receivables</a></td>
<td class="nump">3,483<span></span>
</td>
<td class="num">(9,987)<span></span>
</td>
<td class="num">(4,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating', window );">Reduction in the carrying amount of right of use assets - operating leases</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="nump">7,766<span></span>
</td>
<td class="nump">7,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,482)<span></span>
</td>
<td class="num">(8,462)<span></span>
</td>
<td class="num">(7,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>(Decrease) increase in liabilities, net of acquisition:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(6,119)<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll, taxes, and benefits</a></td>
<td class="nump">10,347<span></span>
</td>
<td class="nump">6,881<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">155,484<span></span>
</td>
<td class="num">(18,256)<span></span>
</td>
<td class="num">(1,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities - operating leases</a></td>
<td class="num">(10,053)<span></span>
</td>
<td class="num">(3,694)<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="num">(1,942)<span></span>
</td>
<td class="nump">5,917<span></span>
</td>
<td class="num">(1,301)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(157,368)<span></span>
</td>
<td class="num">(136,733)<span></span>
</td>
<td class="num">(119,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,311)<span></span>
</td>
<td class="num">(13,403)<span></span>
</td>
<td class="num">(8,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of equity investments</a></td>
<td class="num">(3,072)<span></span>
</td>
<td class="num">(4,125)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distribution from equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147,213<span></span>
</td>
<td class="nump">11,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from disposition and sale of equity investments</a></td>
<td class="nump">48,798<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition, net of acquired cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(251,339)<span></span>
</td>
<td class="num">(320,624)<span></span>
</td>
<td class="num">(271,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">361,760<span></span>
</td>
<td class="nump">383,973<span></span>
</td>
<td class="nump">364,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">148,836<span></span>
</td>
<td class="nump">193,034<span></span>
</td>
<td class="nump">90,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issuances of common stock upon stock option exercises</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="nump">9,440<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of offering costs</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock in ATM offering</a></td>
<td class="nump">8,868<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,123<span></span>
</td>
<td class="nump">9,048<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">65,349<span></span>
</td>
<td class="num">(27,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">161,066<span></span>
</td>
<td class="nump">95,717<span></span>
</td>
<td class="nump">123,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of year</a></td>
<td class="nump">162,657<span></span>
</td>
<td class="nump">161,066<span></span>
</td>
<td class="nump">95,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow and noncash information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Purchases of property and equipment in accrued liabilities</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution', window );">Acquisition of right of use assets - operating leases, contingency resolution</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases', window );">Acquisition of right of use assets - operating leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,085<span></span>
</td>
<td class="nump">34,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities', window );">Acquisition of lease liabilities - operating leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,085<span></span>
</td>
<td class="nump">34,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired', window );">Acquisition of right of use assets in exchange for lease liabilities - finance leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in reduction in the carrying amount of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unbilled and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_InvestmentAmortizationNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Amortization Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_InvestmentAmortizationNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Operating Lease Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Finance Lease, For Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Lease, Contingency Resolution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or part noncash acquisitions of right of use assets in exchange for lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991474439712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schr&#246;dinger, Inc. (the "Company") has developed a differentiated, physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. The Company's software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company is also applying its computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, the Company uses its computational platform to discover novel molecules for its pipeline of proprietary drug discovery programs, which the Company is advancing through preclinical and clinical development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367078656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 280) &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This standard is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this new standard for the year ended December 31, 2024 with no material impact on its consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires public business entities to disclose specific categories in the tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. This standard is effective for annual periods beginning after December 15, 2024, and interim periods within annual periods beginning after December 15, 2025, on a prospective basis, with early adoption permitted. The Company has not yet adopted ASU 2023-09 and is still evaluating the impact of the adoption on its consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40) &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. This standard is effective for annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027, on a prospective basis, with early adoption and retrospective application permitted. The Company has not yet adopted ASU 2024-03 and is still evaluating the impact of the adoption on its consolidated financial statements. </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Basis of Presentation and Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue and estimates regarding the progress of completing performance obligations under collaboration agreements. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of Schr&#246;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Cash and Cash Equivalents and Marketable Securities and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents were cash equivalents of $102,054 and $85,497 as of December&#160;31, 2024 and 2023, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation&#8217;s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of letters of credit held with the Company&#8217;s financial institution related to facility leases and is classified as current in the Company&#8217;s balance sheets based on the maturity of the underlying letters of credit. The Company also has restricted cash related to a certificate of deposit held as collateral for its credit card facility. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Accounts Receivable</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December&#160;31, 2024 and 2023. Interest is not charged on accounts receivable.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g)&#160;&#160;&#160;&#160;Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. The Company did not capitalize any interest during 2024 and 2023. Maintenance and repairs are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated using the straight&#8209;line method over the estimated useful lives of the assets, which range from 3 to 10 years. Amortization of leasehold improvements is calculated using the straight&#8209;line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are reviewed for impairment as discussed below under "Accounting for the Impairment of Long&#8209;Lived Assets."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(h)&#160;&#160;&#160;&#160;Goodwill</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess purchase price over the fair value of net assets acquired which is not allocable to separately identifiable intangible assets. Other identifiable intangible assets are separately recognized if the intangible asset is obtained through contractual or other legal right or if the intangible asset can be sold, transferred, licensed or exchanged.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but tested for impairment at least annually, and more frequently if events or circumstances indicate the carrying amount more likely than not exceeds the fair value. The Company has the option to qualitatively or quantitatively assess its goodwill for impairment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its goodwill for impairment on October 1 of each year. In 2024, the Company evaluated its goodwill using a qualitative process. If the qualitative factors determine that it is more likely than not that the fair value exceeds the carrying amount, goodwill is not impaired. If the qualitative assessment determines it is more likely than not the fair value is less than the carrying amount, the Company would further evaluate for potential impairment. This </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualitative assessment indicated that it was more likely than not the Company's reporting unit&#8217;s fair value exceeded its carrying value. No impairment of goodwill was recognized for the years ended December 31, 2024, 2023, and 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i)&#160;&#160;&#160;&#160;Accounting for the Impairment of Long&#8209;Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2024, 2023, and 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(j)&#160;&#160;&#160;&#160;Warranties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(k)&#160;&#160;&#160;&#160;Concentrations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables and contract assets, which represent contracted unbilled receivables.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer&#8217;s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, one customer accounted for 68% of total accounts receivable. As of December&#160;31, 2023, two customers accounted for 15% and 11% of total accounts receivable, respectively. As of December&#160;31, 2024, three customers accounted for 33%, 23%, and 16% of total contract assets, respectively. As of December&#160;31, 2023, two customers accounted for 42% and 22% of total contract assets, respectively. For the year ended December&#160;31, 2024, one customer accounted for 10% of total revenues. For the year ended December&#160;31, 2023, two customers accounted for 26% and 11% of total revenues, respectively. For the year ended December 31, 2022, one customer accounted for 16% of total revenues.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(l)&#160;&#160;&#160;&#160;Royalties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company&#8217;s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,342, $13,349, and $9,191 for the years ended December&#160;31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(m)&#160;&#160;&#160;&#160;Software Development Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(n)&#160;&#160;&#160;&#160;Research and Development and Advertising</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2024, 2023, and 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(o)&#160;&#160;&#160;&#160;Stock&#8209;Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates stock&#8209;based compensation expense utilizing fair value&#8211;based methodologies and recognizes expense over the vesting period of such awards. For performance-based restricted stock units, the Company records stock-based compensation expense with a cumulative catch-up at the time when performance conditions are considered probable of achievement, and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(p)&#160;&#160;&#160;&#160;Commissions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company&#8217;s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,803, $1,636, and $2,291 in 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(q)&#160;&#160;&#160;&#160;Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the benefit of a tax position in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(r)&#160;&#160;&#160;&#160;Comprehensive (Loss) Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income includes net (loss) income and changes in equity related to changes in unrealized gains or losses on marketable securities.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(s)&#160;&#160;&#160;&#160;Equity Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments over which the Company has significant influence may be accounted for under equity method accounting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with Accounting Standards Codification ("ASC") Topic 323 ("Topic 323"), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost less impairment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with ASC Topic 321 ("Topic 321"), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information regarding the Company&#8217;s equity investments, see Note 5, Fair Value Measurements and Note 11, Equity Investments.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(t)&#160;&#160;&#160;&#160;Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding equity of the Company consists of common stock and limited common stock. Under the Company&#8217;s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undistributed earnings allocated to the participating securities are subtracted from net income in determining net income (loss) attributable to common and limited common stockholders. Basic net income (loss) per share is computed by dividing net income (loss) attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company&#8217;s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366189488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company&#8217;s performance obligations are satisfied either over time or at a point in time, which can result in different revenue recognition patterns.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the timing of the Company&#8217;s revenue recognition patterns:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services &#8211; point in time</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.4&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.1&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47.3&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services &#8211; over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug Discovery &#8211; point in time</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug Discovery &#8211; over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Software Products and Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts that can include various combinations of licenses, products and services, most of which are distinct and are accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price ("SSP") basis. Revenue is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's software business derives revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">On-premise software. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's on-premise software license arrangements grant customers the right to use its software on their own in-house servers or their own cloud instances for a specified term, typically for one year, though in recent years, the Company has entered into a small number of large multi-year on-premise software license agreements. The Company recognizes revenue for on-premise software license fees upfront, either upon transfer of control of the license or the effective date of the agreement, whichever is later. In instances where the timing of the transfer of control differs from the timing of invoicing, the Company considers whether a significant financing component exists.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company's updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront or annually.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hosted software.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hosted software revenue consists primarily of fees to provide the Company's customers with hosted licenses, which allows these customers to access the Company's cloud-based software solution on their own hardware without taking control of the licenses, and is recognized ratably over the term of the arrangement, which is typically one year, though in recent years, the Company has entered into a small number of large multi-year hosted software license agreements. When a customer enters into a hosted arrangement for which revenue is recognized over time, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amount paid upfront that is not recognized in the current period is included in deferred revenue in the Company's statement of financial position until the period in which it is recognized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software maintenance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software maintenance includes technical support, updates, and upgrades related to the Company's on-premise software licenses. Software maintenance revenue is recognized ratably over the term of the arrangement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software maintenance activities are performed in connection with the use of the Company's on-premise software.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services include training, technical setup, installation or assisting customers with modeling services, where the Company uses its software to perform tasks such as virtual screening on behalf of the Company&#8217;s customers. These services are generally not related to the core functionality of the Company's software and are recognized as revenue when resources are consumed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software contribution revenue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software contribution revenue consists of funds received under non-reciprocal agreements with Gates Ventures, LLC and the Bill &amp; Melinda Gates Foundation. The agreement with Gates Ventures, LLC was originally entered into in June 2020 and further ext</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended through August 2026. The agreement is an unconditional non-exchange contribution without restrictions. Revenue is recognized annually, w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hen invoiced, in accordance with ASC Topic 958, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Topic 958"), as the agreement is not an exchange transaction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with Gates Ventures, LLC initially covered the period from June&#160;23, 2020 through June&#160;22, 2023 for total consideration of up to $3,000. The agreement was then extended through August 13, 2026 and provides for total additional consideration of up to $6,000. The Company recognized revenue of $2,000, $1,800, and $1,000 related to these agreements during the years ended December&#160;31, 2024, 2023, and 2022, respectively. As of December&#160;31, 2024, the Company had no deferred revenue balance related to this agreement. As of December&#160;31, 2024 and 2023, the Company had no accounts receivable related to this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company entered into a one-year agreement with the Bill &amp; Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins. In November 2024, the Company and the Bill &amp; Melinda Gates Foundation entered into an amendment to the agreement to expand the original term of the agreement to April 30, 2026 and provide supplemental funds on terms similar to the original agreement. Revenue is recognized as conditions are met and on a cost reimbursement basis in accordance with Topic 958. The Company recognized revenue of $6,016 related to these agreements during the year ended December&#160;31, 2024. As of December&#160;31, 2024, the Company had a $8,484 deferred revenue balance related to these agreements. As of December&#160;31, 2024, the Company had no accounts receivable related to these agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue recognized from the sources of software products and services revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">On-premise software</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,020&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,511&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,487&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hosted software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software maintenance</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,279&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,066&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,996&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,797&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue from contracts with customers</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">172,349&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">157,324&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">134,578&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total software revenue</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">180,365&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,124&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,578&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Drug Discovery</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from drug discovery and collaboration services contracts includes revenue from research services and the achievement of milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research services revenue is generally recognized over time, typically by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input method based on the services promised to the customer, such as costs incurred and hours expended. This method of recognizing revenue requires the Company to make estimates of the work required to complete the performance obligation in order to determine the progress towards </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion. Payments for research services are generally due upfront at the start of a contract or periodically through the contract term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is generally entitled to receive variable consideration as certain milestones are achieved. The Company estimates the amount of variable consideration using the most likely amount method. The Company evaluates milestones on a case-by-case basis, including whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable or the event is outside of the Company's control, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is deemed probable of being achieved or the event occurs. Upon removal of the constraint on variable consideration, revenue may be recognized at a point in time or over time by applying the allocation guidance of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Topic 606").</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were no milestones not yet achieved that were determined to be probable of achievement. As of December 31, 2023 and 2022, milestones not yet achieved that were determined to be probable of achievement totaled $350 and $4,000, respectively, and $350 and $3,939 of those milestones were recognized as revenue for the years ended December 31, 2023, and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug discovery contribution revenue</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discovery </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contribution revenue consists of funds received under an agreement with the Bill &amp; Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women's health. The initial agreement began in November 2021 and expired in September 2023. In September 2023, the Company entered into a new agreement with the Bill &amp; Melinda Gates Foundation to perform services aimed at accelerating drug discovery in women's health that expires in October 2025. Revenue is recognized as costs are incurred in accordance with Topic 958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had deferred revenue balances related to these agreements of $949 and $1,581, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue recognized from the sources of drug discovery revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery services revenue from contracts with customers</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,143&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,720&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,427&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total drug discovery revenue</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,174&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,542&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,377&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bristol Myers-Squibb. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2020, the Company entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company ("BMS"), pursuant to which the Company and BMS agreed to collaborate in the discovery, research and preclinical development of new small molecule compounds for disease indications in oncology, neurology, and immunology therapeutics areas. Under the agreement, the Company was initially responsible, at its own cost and expense, for the discovery of small molecule compounds directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. In December 2022, the Company and BMS entered into an amendment to the agreement to include an additional target in neurology on terms similar to the original agreement. As a result of BMS electing not to proceed with further development of certain targets, there is one remaining neurology target under the agreement, as amended, as of December&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a development candidate meeting specified criteria for a target under the agreement has been identified by the Company, BMS will be solely responsible for the further development, manufacturing and commercialization of such development candidate at its own cost and expense. The Company is solely responsible for the development of any programs that have been returned by BMS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, as amended, BMS paid the Company an initial upfront payment of $55.0 million in November 2020, an additional upfront payment in December 2022, and a program fee in December 2024. As of December&#160;31, 2024 the Company is eligible to receive up to $482.0 million in total milestone payments related to the one remaining neurology target currently subject to the collaboration, consisting of up to $257.0 million in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225.0 million in the aggregate for </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the achievement of certain specified commercial milestones. As of December&#160;31, 2024, the Company has recognized $32.0 million in revenue related to milestones under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to a tiered percentage royalty on annual net sales ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration and license agreement in accordance with Topic 606 and concluded that BMS is a customer based on the agreement structure. At inception, the Company identified one performance obligation for each of the five programs initially covered under the agreement, which includes research activities for each program and a license grant for the underlying intellectual property. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price at the onset of the agreement was $55.0 million. Additional consideration to be paid to the Company upon the achievement of future milestone payments was excluded from the transaction price as they represent milestone payments that were not considered probable as of the inception date such that there is not a significant risk of revenue reversal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the transaction price of $55.0 million to each performance obligation based on the SSP of each performance obligation at inception. The Company determined the estimated SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized $10.8 million, $43.2 million, and $22.1 million, respectively, of revenue associated with the agreement based on the research activities performed and milestones achieved. As of December&#160;31, 2024 and 2023, there was $5.9 million and $7.3 million, respectively, of deferred revenue related to the agreement, which was classified as either current or non-current in the consolidated balance sheet based on the period the services are expected to be performed. As of December&#160;31, 2024 and 2023, the Company had no outstanding receivables for this collaboration.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2024, the Company entered into a research collaboration and license agreement with Novartis Pharma AG ("Novartis"), pursuant to which the Company and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. The Company also entered into an expanded three-year software agreement with Novartis that substantially increases Novartis' access to the Company&#8217;s computational predictive modeling technology and enterprise informatics platform. Under Topic 606, the research collaboration and license agreement as well as the three-year software agreement ("the agreements") are collectively accounted for as a single contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the research collaboration and license agreement, once a development candidate has been identified, Novartis will be solely responsible for the further development, manufacturing and commercialization of such development candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis agreed to pay the Company an initial upfront payment of $150.0 million under the terms of the research collaboration and license agreement, and the Company will be eligible to eligible to receive up to $2.272 billion in total milestone payments across the initial programs. Such milestones consist of up to $892.0&#160;million in discovery and development milestones and up to $1.38&#160;billion in commercial milestones. The Company is also entitled to a tiered percentage royalty ranging from mid-single-digits to low double-digits on products commercialized by Novartis under the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, subject to certain specified reductions. As of December&#160;31, 2024, no revenue has been recognized related to milestones under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the research collaboration and license agreement in accordance with Topic 606 and concluded that Novartis is a customer based on the agreement structure. The promises identified by the Company include research activities for each program under the agreement, a license grant for the underlying intellectual property, and software licenses and services. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract. Software licenses and services provided under the agreement are considered distinct and are accounted for as separate performance obligations in accordance with Topic 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the transaction price for the agreements to each performance obligation based on the SSP of each performance obligation at inception. The Company determined the estimated SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company recognized $0.6 million of revenue associated with the research collaboration and license agreement. As of December&#160;31, 2024, there was $116.7 million of deferred revenue, net of contract assets, related to the agreements, which was classified as either current or non-current in the condensed consolidated balance sheet based on the period the services are expected to be performed. As of December&#160;31, 2024, the Company had $150.0 million outstanding receivables for this collaboration.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Significant Judgments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgments and estimates are required under Topic 606. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company&#8217;s arrangements may be dependent on contract-specific terms and may vary in some instances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contracts with customers often include but are not limited to promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates, as well as collaborative research services, licenses to intellectual properties, and customer options. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company's term-based software license arrangements, may include multiple software licenses, a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised licenses and services are separate distinct performance obligations. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable consideration. For collaborative arrangements, under which the Company is eligible to receive variable consideration in the form of milestones payments, judgment is required to evaluate whether the milestones are considered probable of being achieved. If it is probable that a significant revenue reversal would not occur, the constraint is removed and value of the associated milestone is included in the estimated transaction price using the most likely amount method based on contractual requirements and historical experience. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a relative SSP basis consistent with the allocation objectives of Topic 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required to determine the SSP for each distinct performance obligation. The Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for individual software license performance obligations due to the stratification of those items by volume of sales, classes of customers and other relevant circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP. Professional service revenue is recognized as costs and hours are incurred, and judgment is required in estimating both the project status and the costs incurred or hours expended.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company's judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required to determine the total costs to perform research activities, which include the length of time required, the internal hours expected to be incurred on the services, and the number and costs of various studies that may be performed by third parties to complete the research plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the Company has not experienced significant returns or refunds to customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's estimates related to revenue recognition may require significant judgment and a change in these estimates could have an effect on the Company's results of operations during the periods involved.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e)&#160;&#160;&#160;&#160;Contract Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables, contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing. A deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company's time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements where the milestones are deemed probable in a period prior to when the milestone is achieved, the Company records a contract asset for the full value of the milestone.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are included in unbilled and other receivables within the consolidated balance sheets and are transferred to receivables when the Company invoices the customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:70.956%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,<br/>2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,<br/>2023</span></div></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract assets</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,564&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,107&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, short-term:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,660&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,218&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, long-term:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,421&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,636&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024 and 2023, the Company recognized $53,438 and $64,120 of revenue, respectively, that was included in deferred revenue at the end of the respective preceding periods. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue approximately 51% of its December&#160;31, 2024 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in deferred revenue were $59,519 as of December&#160;31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms and conditions vary by contract type, although terms typically require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company&#8217;s products and services, not to facilitate financing arrangements.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f)&#160;&#160;&#160;&#160;Deferred Sales Commissions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied the practical expedient for sales commission expense, as any material compensation paid to sales representatives to obtain a contract relates to a period of one year or less. The Company has not capitalized any costs related to sales commissions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366026944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December&#160;31,</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right of use asset - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2024, 2023, and 2022 was $6,159, $4,965, and $3,831, respectively, and is included within cost of revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991474049968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various inputs are used in determining the fair value of the Company&#8217;s financial assets and liabilities. These inputs are summarized into the following three broad categories:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; quoted prices in active markets for identical securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; significant unobservable inputs, including the Company&#8217;s own assumptions in determining fair value</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. Marketable securities, which consist primarily of corporate and U.S. government agency bonds, are classified as available for sale and fair value did not differ significantly from carrying value as of December&#160;31, 2024 and 2023. The following table presents information about the Company&#8217;s assets measured at fair value as of December&#160;31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,859&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets measured at fair value as of December&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s investment in Nimbus Therapeutics, LLC (&#8220;Nimbus&#8221;), classified as Level 3 in the fair value hierarchy, was recorded as an equity method investment under Topic 323 using the hypothetical liquidated book value method (&#8220;HLBV method&#8221;) through June 30, 2023, as further described in Note 11, Equity Investments. Significant unobservable inputs used to determine Nimbus&#8217; fair value under the HLBV method were the entity's annual financial statements and the Company&#8217;s liquidation preference. Following the dilution of the Company's investment in Nimbus during the year ended December 31, 2023, the fair value of the Company's investment was recorded under Topic 321 as a non-marketable equity security as the Company no longer exercises significant influence over Nimbus. This change in accounting method resulted in an unrealized gain of $1,928 and subsequent removal from the Level 3 fair value hierarchy table during the year ended December 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gains and losses arising from changes in fair value of the Company&#8217;s equity investments are classified within change in fair value in the consolidated statements of operations. Realized gains arising from distributions receivable from the Company's equity investments are classified within gain on equity investments in the consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information regarding the Company&#8217;s equity investments, see Note 11, Equity Investments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366208272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has multiple operating leases for office space and a finance lease for equipment that expire at various dates through 2037. The Company has elected the package of practical expedients under the transition guidance of ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to exclude short-term leases from the balance sheet and to combine lease and non-lease components. The Company classifies finance lease right of use assets under property and equipment, net and finance short-term and long-term lease liabilities under other accrued liabilities and other liabilities, long-term, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon inception of a lease, the Company determines if an arrangement is a lease, if it is classified as an operating or finance lease, if it includes options to extend or terminate the lease, and if it is reasonably certain that the Company will exercise the options. Lease cost, representing lease payments over the term of the lease and any capitalizable direct costs less any incentives received, is recognized on a straight-line basis over the lease term as lease expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. Upon execution of a new lease, the Company performs an analysis to determine its incremental borrowing rate using its current borrowing rate, adjusted for various factors including level of collateralization and lease term. As of December&#160;31, 2024, the remaining weighted average lease term for operating and finance leases was 11 years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, operating lease right of use assets increased by $2,952 due to contingency resolutions associated with office leases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable and short-term lease costs for the Company's operating and finance leases were immaterial for the year ended December&#160;31, 2024. Additional details of the Company's operating and finance leases are presented in the following table:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating and finance lease liabilities as of December&#160;31, 2024 under noncancelable leases were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the Company&#8217;s financial position or results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991474439712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) is comprised of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of (loss) income before income taxes by tax jurisdiction were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,711)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return-to-provision adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax contingencies, net of reversals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the year ended December&#160;31, 2024 represents the Company's income tax obligations in certain states and taxes in foreign jurisdictions in which it conducts business. Income tax expense for the years ended December 31, 2023 represents the Company's federal and certain state income tax obligations and taxes in foreign jurisdictions for which it conducts business. Income tax expense for the year ended December 31, 2022 represents the Company's income tax obligations in certain states and taxes in foreign jurisdictions in which it conducts business. As of December&#160;31, 2024, the Company has a full valuation allowance on U.S. federal and state deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total change in valuation allowance for the year ended December&#160;31, 2024 was $41,195, which was primarily due to temporary differences for capitalized research and development expenses and share based compensation, partially offset by adjustments to equity method investments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,675&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal and state net operating loss ("NOL") carryforwards of $204,474 and $129,490, respectively. The state NOL carryforwards will expire between 2025 and 2044, if not used by the Company to reduce income taxes payable in future periods. Utilization of post-2017 federal NOL carryforwards is limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December&#160;31, 2024, the Company had federal orphan drug credits and federal research and development tax credit carryforwards of $31,294 and state research and development tax credit carryforwards of $2,736. The federal and state carryforwards, with the exception of $2,223 indefinite state credits will expire between 2025 and 2044, if not utilized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of NOLs and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through December 31, 2024 and determined no such ownership change has occurred in the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign operations as the Company considers these earnings to be indefinitely reinvested. The determination of a hypothetical unrecognized deferred tax liability as of December&#160;31, 2024 is not practicable because of the complexity and variety of assumptions necessary to compute the tax.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions taken in prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions taken in prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next 12 months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries file U.S. federal income tax returns and various state, local and foreign income tax returns. As of December&#160;31, 2024, the Company&#8217;s statutes of limitations are open for all federal and state tax returns filed after the years ended December&#160;31, 2021 and 2020, respectively. NOL and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991474049968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had authorized 500,000,000 shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#8217;s preferred stock, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company entered into an amended and restated sales agreement with Leerink Partners LLC ("Leerink Partners"), as sales agent, with respect to an at-the-market offering program (the "ATM") under which the Company could offer and sell, from time to time pursuant to its Registration Statement on Form S-3, shares of common stock, having an aggregate offering price of up to $250,000, through Leerink Partners. The amended and restated sales agreement amends and restates the original sales agreement that the Company entered into with Leerink Partners with respect to the ATM in May 2023, which is no longer in effect. During the year ended December&#160;31, 2024, 323,085 shares of common stock were sold under the ATM for total net proceeds of $8,691 and gross proceeds of $8,868, before deducting sales agent commissions. As of December&#160;31, 2024, the Company had $241,132 of common stock remaining available for sale under the ATM.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Limited Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had authorized 100,000,000 shares of limited common stock with a par value of $0.01 per share. Holders of limited common stock are entitled to one vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to the same dividend rights as holders of common stock, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company's preferred stock, if any. Holders of the Company's limited common stock have the right to convert each share of limited common stock into one share of the Company's common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limited common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the limited </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had authorized 10,000,000 shares of undesignated preferred stock with a par value of $0.01 per share. The Company's board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368113552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plans</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company's stock incentive plans included the 2010 Stock Plan (the "2010 Plan"), the 2020 Equity Incentive Plan (the "2020 Plan"), the 2021 Inducement Equity Incentive Plan, as amended (the "2021 Plan"), and the 2022 Equity Incentive Plan, as amended (the "2022 Plan") (together, the "Plans").</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and cash-based awards to employees, directors, consultants or advisors. Shares of common stock subject to outstanding awards granted under the 2020 Plan and the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company are available for issuance under the 2022 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who were not previously an employee or director of the Company or who are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person&#8217;s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). Neither consultants nor advisors are eligible to participate in the 2021 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provided for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, consultants or advisors. As of June 15, 2022, the effective date of the 2022 Plan, no further awards will be made under the 2020 Plan. Any options or awards outstanding under the 2020 Plan are governed by the terms of the 2020 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Plan provided for the granting of incentive stock options and nonstatutory stock options to employees, directors, consultants or advisors. As of the effective date of the 2020 Plan, no further awards will be made under the 2010 Plan. Any options or awards outstanding under the 2010 Plan are governed by the terms of the 2010 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were 6,391,224 shares available for grant under the Plans. The following table presents classification of stock-based compensation expense within the consolidated statements of operations:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each restricted stock unit ("RSU") represents the right to receive one share of the Company's common stock upon vesting. The fair value of RSUs granted by the Company was calculated based upon the Company's closing stock price on the date of the grant, and the stock-based compensation expense is recognized over the vesting period. RSUs generally vest </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over four years with 25% of the grants vesting at the end of the first year and the remaining vesting annually over the following three years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity was as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"></td><td style="width:61.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,814</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244,993</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,188)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,071)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682,548</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value for each RSU granted during the years ended December&#160;31, 2024, 2023, and 2022 was $24.78, $26.09, and $26.86, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $32,264 of unrecognized compensation cost related to RSUs granted under the Plans, which is expected to be recognized over a weighted average period of 2.90 years. During the years ended December&#160;31, 2024 and 2023, 231,188 and 13,241 RSUs vested, respectively. The fair value of RSUs vested during the years ended December&#160;31, 2024 and 2023 was $5,822 and $355, respectively. No RSUs vested during year ended December 31, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024 and February 2023, the Company awarded performance-based restricted stock units ("PRSUs") under the 2022 Plan. Each PRSU represents a contingent right to receive one share of common stock upon the achievement of specified performance goals. The fair value of PRSUs granted by the Company was calculated based upon the Company's closing stock price on the date of the grant, and the stock-based compensation expense is recognized when the grant date is determined and performance conditions are probable of achievement. At the point when performance conditions are considered probable of achievement, the Company records stock-based compensation expense with a cumulative catch-up expense in the period first recognized and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company awarded to all executive officers PRSUs for a maximum of 180,000 shares (based on 150% achievement of the applicable performance conditions outlined in the awards), with a target award of 120,000 PRSUs (based on 100% achievement of the applicable performance conditions), and a threshold award of 60,000 PRSUs (based on 50% achievement of the applicable performance conditions). All such PRSUs were considered granted under ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("Topic 718") in March 2024. Such PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company awarded to certain executive officers PRSUs for a maximum of 62,693 shares (based on 150% achievement of the applicable performance conditions outlined in the awards), with a target award of 41,795 PRSUs (based on 100% achievement of the applicable performance conditions), and a threshold award of 20,898 PRSUs (based on 50% achievement of the applicable performance conditions). All such PRSUs were considered granted under Topic 718 in February 2023. Such PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, the Company awarded 90,000 PRSUs to an executive officer of which 30,150 PRSUs were considered granted under Topic 718 at the time the PRSUs were awarded. In March 2024 and 2023, of the 90,000 PRSUs awarded in August 2022, an additional 14,850</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and 45,000 PRSUs were considered granted under Topic 718, respectively. During the year ended December 31, 2024, the Company's compensation committee determined the achievement of the awards set to vest upon the certification by the Company's compensation committee following the filing of the Company's </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Of the 36,000 PRSUs that were eligible to vest, the Company's compensation committee determined that the applicable performance conditions had been met for 9,000 of the PRSUs, which vested during the year ended December 31, 2024, and that the applicable performance conditions had not been met for 27,000 PRSUs, which were forfeited during the year ended December 31, 2024. The remaining 54,000 PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and following the filing of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ending December 31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based restricted stock unit activity was as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"></td><td style="width:61.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,945</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,000)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,795</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value for each PRSU granted during the years ended December&#160;31, 2024, 2023, and 2022 was $26.08, $22.48, and $28.55, respectively. During the year ended December&#160;31, 2024, 9,000 PRSUs vested. The fair value of PRSUs vested during the year ended December&#160;31, 2024 was $241. No PRSUs vested during the years ended 2023 and 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options must be granted at an exercise price not less than 100% of the fair market value per share at the grant date. The board of directors or compensation committee determines the exercise price of the Company&#8217;s stock options based on the closing price of the common stock as reported on the Nasdaq Global Select Market on the date of the grant. The maximum contractual term of options granted under the Plans is typically 10 years, options generally vest over four years with 25% of the shares underlying the option vesting at the end of the first year and the remaining vesting monthly over the following three years. In March 2024 and February 2023, the Company granted the chief executive officer premium priced options to purchase 87,271 and 65,525 shares of common stock, respectively, with exercise prices equal to 110% of the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022, 169,820, 800,336, and 329,224 options under the Plans were exercised for total proceeds of $1,488, $9,440, and $2,110, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value included several assumptions that require management&#8217;s judgment. The expected terms of options granted to employees during the years ended December&#160;31, 2024, 2023, and 2022 were calculated using an average of historical exercises. Estimated volatility for 2024, 2023, and 2022 incorporated a calculated volatility derived from the historical closing prices of shares of common stock of similar entities whose share prices were publicly available for the expected term of the option. The risk-free interest rate was based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur; as such, the Company does not estimate forfeitures at the time of grant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following are the weighted average valuation assumptions used for option awards during the periods presented:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity was as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,274,277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,820)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226,832)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,648)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,921,153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873,733</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $14.88, $15.79, and $13.67, respectively. The intrinsic value of options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $2,365, $16,213, and $6,548, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $40,480</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of unrecognized compensation cost related to unvested stock options granted under the Plans, which is expected to be recognized over a weighted average period of 2.07 years. The fair value of shares vested during the years ended December&#160;31, 2024, 2023, and 2022 was $39,422, $46,877, and $43,559, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367076336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</a></td>
<td class="text">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following table presents the calculation of basic and diluted net (loss) income per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to common and limited common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,670,295</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,776,301</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,173,419</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,210,515</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,670,295</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,986,816</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,173,419</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share attributable to common and limited common stockholders, basic:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share of common and limited common stockholders, diluted:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for the years ended December&#160;31, 2024 and 2022, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares and limited common shares outstanding would have been anti-dilutive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, in order to calculate diluted net income per share, the weighted average shares used to compute net income is adjusted by the effect of dilutive securities, including awards under the Plans. Diluted net income per share is computed by dividing the resulting net income by the weighted average number of fully diluted common and limited shares outstanding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares subject to outstanding common stock options and unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,603,701</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,351,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,013,177</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991477990784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Investments</a></td>
<td class="text">Equity Investments<div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Nimbus</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously provided collaboration services for Nimbus Therapeutics, LLC ("Nimbus") under the terms of a master services agreement executed on May 18, 2010, as amended. Collaboration agreements are separate from the transaction that resulted in equity ownership and related fees are paid in cash to the Company. Nimbus was previously recorded as an equity method investment under the HLBV method, as the entity is a limited liability company and the Company was determined to have significant influence due to the Company's collaboration with Nimbus on a number of drug discovery targets, as well as the Company's level of ownership in Nimbus. During the period ended September 30, 2023, the Company's equity ownership in Nimbus was diluted to the point that the Company no longer has significant influence over the entity. As the Company no longer has significant influence over Nimbus, after June 30, 2023, the equity investment in Nimbus is valued as a non-marketable equity security.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the Nimbus investment was $2,436 and $1,928, respectively. The Company has no obligation to fund Nimbus' losses in excess of its investment. During the year ended </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, the Company reported an unrealized gain of $508 on the Nimbus investment. During the year ended December&#160;31, 2023, the company reported a realized gain of $147,213 on the Nimbus investment, which reflected the total cash distribution the Company received from Nimbus on account of Takeda's acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor NDI-034858, as well as an unrealized gain of $1,928 on the Nimbus investment due to the change in accounting method. The Company reported no gains or losses on the Nimbus investment during the year ended December 2022.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Morphic</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;15, 2024, the Company disposed of its equity stake in Morphic Holding, Inc. ("Morphic") for aggregate consideration of $47,588 in connection with Eli Lilly and Company's acquisition of Morphic. Prior to the disposition of the Morphic investment, the Company accounted for its investment in Morphic at fair value based on the share price of Morphic&#8217;s common stock at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, the Company reported a mark-to-market gain of $23,474 and $1,778, respectively, on the Morphic investment. During the year ended December 31, 2022, the Company reported a mark-to-market loss of $17,226 on the Morphic investment. As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Morphic was zero and $24,114, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Ajax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. ("Ajax") for $1,700 in cash. In April 2024, the Company purchased 1,416,450 shares of Series C preferred stock of Ajax for $3,000 in cash. The Company has concluded that its equity investment in Ajax should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ajax. During the year ended December&#160;31, 2024, the Company recorded an impairment loss of $202 on the Ajax investment. No gain or loss was recorded on the Ajax investment during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Ajax was $4,498 and $1,700, respectively.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Structure Therapeutics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company purchased 494,035 shares of Series B preferred stock of Structure Therapeutics for $2,000 in cash. In April 2022, the Company purchased an additional 148,210 shares of Series B preferred stock for $600 in cash. On February 7, 2023, Structure Therapeutics completed its initial public offering ("IPO"). Immediately upon the closing of Structure Therapeutics' IPO, all of the outstanding Series B preferred stock automatically converted into ordinary shares on a one-for-one basis. The Company purchased 275,000 American Depository Shares ("ADSs") at $15.00 per ADS in the IPO. Each ADS represents three ordinary shares. The Company accounts for its investment in Structure Therapeutics at fair value based on the closing price of Structure Therapeutics' ADSs as of the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company recorded a mark-to-market loss of $18,096 on the Structure Therapeutics investment. During the year ended December 31, 2023, the Company recorded a mark-to-market gain of $49,755 on the investment. During the year ended December 31, 2022, the Company recorded a loss of $858 on the Structure Therapeutics investment under the hypothetical liquidation book value method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Structure Therapeutics was $36,202</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $55,509, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991474538384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers a 401(k) employee savings plan to its U.S.&#8209;based employees. The Company made discretionary matching contributions equal to 100% of the first 4% of compensation contributed by employees for the years ended December&#160;31, 2024, 2023, and 2022. Matching contributions during 2024, 2023, and 2022 were $4,478, $4,135, and $3,243, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368113552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Board Member</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, the Company paid consulting fees of $428, $420, and $410, respectively, to a member of its board of directors.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bill &amp; Melinda Gates Foundation, an entity under common control with Bill &amp; Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations. Revenue recognized for licenses and services provided by the Company under this grant were $111, $253, and $387 for the years ended December&#160;31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized $2,031, $2,822, and $1,949, respectively, in drug discovery contribution revenue related to funds received under agreements with the Bill &amp; Melinda Gates Foundation, aimed at accelerating drug discovery in women&#8217;s health. As of December&#160;31, 2024 and 2023, restricted cash on hand related to the arrangement was $1,021 and $2,251, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company recognized $6,016 in software contribution revenue related to funds received under agreements with the Bill &amp; Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins. As of December&#160;31, 2024, restricted cash on hand related to the arrangement was $8,606.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had no receivables due from the Bill &amp; Melinda Gates Foundation related to any of these agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gates Ventures, LLC is an entity under the control of William H. Gates III, who may be deemed to be the beneficial owner of more than 5% of the Company&#8217;s voting securities. The Company received $1,000 in contribution revenue in connection with its entry into an agreement with Gates Ventures, LLC annually from June 2020 to June 2022. In August 2023, the Company renewed the agreement with Gates Ventures, LLC and recognized $1,800 in contribution revenue upon extension of the agreement and $2,000 in contribution revenue upon the first anniversary of the extension. As of December&#160;31, 2024 and 2023, the Company had no receivables due from Gates Ventures, LLC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991474441040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that its chief executive officer ("CEO") is its chief operating decision maker ("CODM"). The Company&#8217;s CEO evaluates the financial performance of the Company based on two reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company&#8217;s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments. Segment gross profit is derived by deducting cost of sales from U.S. GAAP revenue. Cost of sales are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount or by expenses directly incurred to support the Software or Drug Discovery segments. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain cost items are not allocated to the Company&#8217;s reportable segments. These cost items primarily consist of non-drug discovery program related compensation and general operational expenses associated with the Company&#8217;s research and development, sales and marketing, and general and administrative. These costs are incurred by both segments and due to the integrated nature of the Company&#8217;s Software and Drug Discovery segments, any allocation methodology would be subjective and may not provide meaningful analysis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue is primarily earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is financial information with respect to the Company&#8217;s reportable segments for the years presented:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment cost of revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,083&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,692&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unallocated (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,186)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,955&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365377712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to common and limited common stockholders</a></td>
<td class="num">$ (187,123)<span></span>
</td>
<td class="nump">$ 40,720<span></span>
</td>
<td class="num">$ (149,186)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364485280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes, for the fourth quarter of 2024, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name and Title</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Action Taken (Date of Action)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Type of Trading Arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nature of Trading Arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Duration of Trading Arrangement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Aggregate Number of Shares of Common Stock</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Robert Abel Executive Vice President, Chief Scientific Officer, Platform</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adoption</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(November&#160;26, 2024)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sale</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until December&#160;31, 2025, or such earlier date upon which all transactions are completed or expire without execution</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Up to 107,605 shares</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Karen Akinsanya, President of R&amp;D, Therapeutics</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adoption</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(December&#160;17, 2024)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sale</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until December&#160;31, 2025, or such earlier date upon which all transactions are completed or expire without execution</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Up to 121,178 shares</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sdgr_RobertAbelMember', window );">Robert Abel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Robert Abel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Executive Vice President, Chief Scientific Officer, Platform<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 26, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December&#160;31, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">400 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">107,605<span></span>
</td>
<td class="nump">107,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=sdgr_KarenAkinsanyaMember', window );">Karen Akinsanya [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Karen Akinsanya<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President of R&D, Therapeutics<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December&#160;17, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December&#160;31, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">379 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">121,178<span></span>
</td>
<td class="nump">121,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sdgr_RobertAbelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sdgr_RobertAbelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=sdgr_KarenAkinsanyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=sdgr_KarenAkinsanyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365002496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367228016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain processes for assessing, identifying and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and refine our practices. We engage certain external parties, including consultants, computer security firms and risk management advisors, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight. We consider the internal risk oversight programs of third-party service providers before engaging them in order to help protect our company from any related vulnerabilities. As part of our overall risk mitigation strategy, we also maintain cybersecurity insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect our company or our business strategy, results of operations or financial condition.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We have certain processes for assessing, identifying and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and refine our practices.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vice president of information security leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats. Our vice president of information security has over 15 years of information security experience, including in developing, overseeing and managing information technology and information security teams. He has been with our company since 2017 and has served as our vice president of information security since April 2023. He previously served as our executive director of information security from January 2022 through April 2023, senior director of information security from February 2019 through January 2022 and director of information security from June 2017 through February 2019. Prior to joining our company, our vice president of information security worked at several technology companies and served in roles of increasing responsibility with respect to information security during his tenure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a cybersecurity awareness program, which covers timely and relevant topics, including social engineering and phishing, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks throughout our information security systems. These tools are integrated into our comprehensive security framework, used to bolster our employee-based cybersecurity programs and are regularly updated to respond to evolving threats.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.</span></div>Our vice president of information security leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our vice president of information security has over 15 years of information security experience, including in developing, overseeing and managing information technology and information security teams. He has been with our company since 2017 and has served as our vice president of information security since April 2023. He previously served as our executive director of information security from January 2022 through April 2023, senior director of information security from February 2019 through January 2022 and director of information security from June 2017 through February 2019. Prior to joining our company, our vice president of information security worked at several technology companies and served in roles of increasing responsibility with respect to information security during his tenure.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.Our vice president of information security leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367696960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">Recently Issued Accounting Pronouncements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 280) &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This standard is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this new standard for the year ended December 31, 2024 with no material impact on its consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires public business entities to disclose specific categories in the tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. This standard is effective for annual periods beginning after December 15, 2024, and interim periods within annual periods beginning after December 15, 2025, on a prospective basis, with early adoption permitted. The Company has not yet adopted ASU 2023-09 and is still evaluating the impact of the adoption on its consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40) &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Disaggregation of Income Statement Expenses</span>. which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. This standard is effective for annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027, on a prospective basis, with early adoption and retrospective application permitted. The Company has not yet adopted ASU 2024-03 and is still evaluating the impact of the adoption on its consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text">Basis of Presentation and Use of Estimates<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue and estimates regarding the progress of completing performance obligations under collaboration agreements. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of Consolidation<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the accounts of Schr&#246;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock', window );">Cash and Cash Equivalents and Marketable Securities and Restricted Cash</a></td>
<td class="text">Cash and Cash Equivalents and Marketable Securities and Restricted Cash<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in cash and cash equivalents were cash equivalents of $102,054 and $85,497 as of December&#160;31, 2024 and 2023, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation&#8217;s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of letters of credit held with the Company&#8217;s financial institution related to facility leases and is classified as current in the Company&#8217;s balance sheets based on the maturity of the underlying letters of credit. The Company also has restricted cash related to a certificate of deposit held as collateral for its credit card facility. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts Receivable<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December&#160;31, 2024 and 2023. Interest is not charged on accounts receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. The Company did not capitalize any interest during 2024 and 2023. Maintenance and repairs are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated using the straight&#8209;line method over the estimated useful lives of the assets, which range from 3 to 10 years. Amortization of leasehold improvements is calculated using the straight&#8209;line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are reviewed for impairment as discussed below under "Accounting for the Impairment of Long&#8209;Lived Assets."</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess purchase price over the fair value of net assets acquired which is not allocable to separately identifiable intangible assets. Other identifiable intangible assets are separately recognized if the intangible asset is obtained through contractual or other legal right or if the intangible asset can be sold, transferred, licensed or exchanged.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but tested for impairment at least annually, and more frequently if events or circumstances indicate the carrying amount more likely than not exceeds the fair value. The Company has the option to qualitatively or quantitatively assess its goodwill for impairment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests its goodwill for impairment on October 1 of each year. In 2024, the Company evaluated its goodwill using a qualitative process. If the qualitative factors determine that it is more likely than not that the fair value exceeds the carrying amount, goodwill is not impaired. If the qualitative assessment determines it is more likely than not the fair value is less than the carrying amount, the Company would further evaluate for potential impairment. This </span></div>qualitative assessment indicated that it was more likely than not the Company's reporting unit&#8217;s fair value exceeded its carrying value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Accounting for the Impairment of Long Lived Assets</a></td>
<td class="text">Accounting for the Impairment of Long&#8209;Lived AssetsLong-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Warranties</a></td>
<td class="text">Warranties<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text">Concentrations<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables and contract assets, which represent contracted unbilled receivables.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer&#8217;s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RoyaltiesPolicyPolicyTextBlock', window );">Royalties</a></td>
<td class="text">RoyaltiesRoyalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company&#8217;s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock', window );">Software Development Costs</a></td>
<td class="text">Software Development Costs<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock', window );">Research and Development and Advertising</a></td>
<td class="text">Research and Development and Advertising<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2024, 2023, and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">Stock&#8209;Based Compensation<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates stock&#8209;based compensation expense utilizing fair value&#8211;based methodologies and recognizes expense over the vesting period of such awards. For performance-based restricted stock units, the Company records stock-based compensation expense with a cumulative catch-up at the time when performance conditions are considered probable of achievement, and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommissionsPolicy', window );">Commissions</a></td>
<td class="text">CommissionsCommissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company&#8217;s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the benefit of a tax position in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive (Loss) Income</a></td>
<td class="text">Comprehensive (Loss) Income<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income includes net (loss) income and changes in equity related to changes in unrealized gains or losses on marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Investments</a></td>
<td class="text">Equity Investments<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments over which the Company has significant influence may be accounted for under equity method accounting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with Accounting Standards Codification ("ASC") Topic 323 ("Topic 323"), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost less impairment, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with ASC Topic 321 ("Topic 321"), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information regarding the Company&#8217;s equity investments, see Note 5, Fair Value Measurements and Note 11, Equity Investments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</a></td>
<td class="text">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding equity of the Company consists of common stock and limited common stock. Under the Company&#8217;s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undistributed earnings allocated to the participating securities are subtracted from net income in determining net income (loss) attributable to common and limited common stockholders. Basic net income (loss) per share is computed by dividing net income (loss) attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company&#8217;s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities and restricted cash policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development and advertising policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RoyaltiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RoyaltiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Software development costs policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommissionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481913/940-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommissionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367480112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Timing of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the timing of the Company&#8217;s revenue recognition patterns:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services &#8211; point in time</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.4&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.1&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">47.3&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services &#8211; over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug Discovery &#8211; point in time</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug Discovery &#8211; over time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue recognized from the sources of software products and services revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">On-premise software</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,020&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104,511&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">84,487&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Hosted software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software maintenance</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,279&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,066&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19,996&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,797&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,366&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue from contracts with customers</span></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">172,349&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">157,324&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">134,578&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total software revenue</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">180,365&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159,124&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135,578&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the revenue recognized from the sources of drug discovery revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery services revenue from contracts with customers</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,143&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54,720&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43,427&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery contribution</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total drug discovery revenue</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">27,174&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">57,542&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,377&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:70.956%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,<br/>2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,<br/>2023</span></div></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Contract assets</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,564&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21,107&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, short-term:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">75,660&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44,218&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Deferred revenue, long-term:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Software products and services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Drug discovery</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,421&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,636&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991372328160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December&#160;31,</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computers and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right of use asset - finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">45,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367074080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">The following table presents information about the Company&#8217;s assets measured at fair value as of December&#160;31, 2024:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,859&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets measured at fair value as of December&#160;31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366203808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Operating Leases</a></td>
<td class="text">Additional details of the Company's operating and finance leases are presented in the following table:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating and finance lease liabilities as of December&#160;31, 2024 under noncancelable leases were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,533&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366842048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit) is comprised of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of (Loss) Income Before Income Taxes by Tax Jurisdiction</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of (loss) income before income taxes by tax jurisdiction were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,711)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return-to-provision adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax contingencies, net of reversals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,675&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions taken in prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions taken in prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365959360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Classification of Stock Based Compensation Expense</a></td>
<td class="text">The following table presents classification of stock-based compensation expense within the consolidated statements of operations:<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,818&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted stock unit activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity was as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"></td><td style="width:61.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,814</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244,993</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,188)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,071)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682,548</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based restricted stock unit activity was as follows:</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"><tr><td style="width:1.0%"></td><td style="width:61.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,945</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,000)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,795</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Assumptions Used for Options</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following are the weighted average valuation assumptions used for option awards during the periods presented:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity was as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,274,277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,820)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226,832)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220,648)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,921,153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,873,733</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364637472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following table presents the calculation of basic and diluted net (loss) income per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to common and limited common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,670,295</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,776,301</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,173,419</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,210,515</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,670,295</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,986,816</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,173,419</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share attributable to common and limited common stockholders, basic:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share of common and limited common stockholders, diluted:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares subject to outstanding common stock options and unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,603,701</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,351,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,013,177</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367480896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Financial Information with Respect to Reportable Segments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is financial information with respect to the Company&#8217;s reportable segments for the years presented:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31, </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,955&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment cost of revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,974&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment gross profit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,083&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,692&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unallocated (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,917)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated net (loss) income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,186)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues by Geographic Area</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,955&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364982352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 102,054,000<span></span>
</td>
<td class="nump">$ 85,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">9,342,000<span></span>
</td>
<td class="nump">13,349,000<span></span>
</td>
<td class="nump">9,191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_CommissionExpense', window );">Commission expense</a></td>
<td class="nump">$ 1,803,000<span></span>
</td>
<td class="nump">$ 1,636,000<span></span>
</td>
<td class="nump">$ 2,291,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue Benchmark | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue Benchmark | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Contract Assets | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Contract Assets | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Contract Assets | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_CommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_CommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sdgr_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sdgr_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sdgr_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sdgr_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=sdgr_ContractAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=sdgr_ContractAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sdgr_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sdgr_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366686384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember', window );">Software products and services | Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_TimingOfRevenueRecognitionPercentage', window );">Timing of revenue recognition</a></td>
<td class="nump">51.40%<span></span>
</td>
<td class="nump">49.10%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember', window );">Software products and services | Over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_TimingOfRevenueRecognitionPercentage', window );">Timing of revenue recognition</a></td>
<td class="nump">35.50%<span></span>
</td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember', window );">Drug discovery | Point in Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_TimingOfRevenueRecognitionPercentage', window );">Timing of revenue recognition</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember', window );">Drug discovery | Over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_TimingOfRevenueRecognitionPercentage', window );">Timing of revenue recognition</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_TimingOfRevenueRecognitionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Timing of revenue recognition, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_TimingOfRevenueRecognitionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366408320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Software Products and Services (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognized', window );">Software contribution revenue recognition</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,692,000<span></span>
</td>
<td class="nump">$ 65,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember', window );">Agreement with Gates Ventures, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognized', window );">Software contribution revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember', window );">Agreement with Gates Ventures, LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognitionAmount', window );">Software contribution revenue recognition amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sdgr_July2024AgreementWithBillMelindaGatesFoundationMember', window );">July 2024 Agreement With Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognized', window );">Software contribution revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_OnPremiseSoftwareMember', window );">On-premise software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueArrangementsContractTerm', window );">Contract term for software arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_HostedSoftwareMember', window );">Hosted software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueArrangementsContractTerm', window );">Contract term for software arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RevenueArrangementsContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Arrangements, Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RevenueArrangementsContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_SoftwareContributionRevenueRecognitionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Software contribution revenue recognition amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_SoftwareContributionRevenueRecognitionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_SoftwareContributionRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Software contribution revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_SoftwareContributionRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sdgr_July2024AgreementWithBillMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sdgr_July2024AgreementWithBillMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_OnPremiseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_OnPremiseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_HostedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_HostedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367939856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 207,539<span></span>
</td>
<td class="nump">$ 216,666<span></span>
</td>
<td class="nump">$ 180,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total software revenue</a></td>
<td class="nump">207,539<span></span>
</td>
<td class="nump">216,666<span></span>
</td>
<td class="nump">180,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_OnPremiseSoftwareMember', window );">On-premise software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">104,020<span></span>
</td>
<td class="nump">104,511<span></span>
</td>
<td class="nump">84,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_HostedSoftwareMember', window );">Hosted software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">35,253<span></span>
</td>
<td class="nump">20,381<span></span>
</td>
<td class="nump">14,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_MaintenanceMember', window );">Software maintenance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">23,279<span></span>
</td>
<td class="nump">23,066<span></span>
</td>
<td class="nump">19,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_ProfessionalServicesMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">9,797<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
<td class="nump">15,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">172,349<span></span>
</td>
<td class="nump">157,324<span></span>
</td>
<td class="nump">134,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareContributionMember', window );">Software contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Software contribution</a></td>
<td class="nump">8,016<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember', window );">Software products and services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total software revenue</a></td>
<td class="nump">$ 180,365<span></span>
</td>
<td class="nump">$ 159,124<span></span>
</td>
<td class="nump">$ 135,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_OnPremiseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_OnPremiseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_HostedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_HostedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_MaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_MaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_ProfessionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_ProfessionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_SoftwareContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_SoftwareContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368521456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Drug Discovery (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 1,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember', window );">Drug Discovery Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_MilestonePaymentYetToBeAchieved', window );">Milestone payment yet to be achieved</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRecognizedForMilestonePayment', window );">Revenue recognized with milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 3,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_MilestonePaymentYetToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment yet to be achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_MilestonePaymentYetToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RevenueRecognizedForMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RevenueRecognizedForMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368544368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Drug Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug discovery services revenue from contracts with customers</a></td>
<td class="nump">$ 207,539<span></span>
</td>
<td class="nump">$ 216,666<span></span>
</td>
<td class="nump">$ 180,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total software revenue</a></td>
<td class="nump">207,539<span></span>
</td>
<td class="nump">216,666<span></span>
</td>
<td class="nump">180,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember', window );">Drug discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total software revenue</a></td>
<td class="nump">27,174<span></span>
</td>
<td class="nump">57,542<span></span>
</td>
<td class="nump">45,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember', window );">Drug Discovery Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug discovery services revenue from contracts with customers</a></td>
<td class="nump">25,143<span></span>
</td>
<td class="nump">54,720<span></span>
</td>
<td class="nump">43,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryContributionMember', window );">Drug discovery contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Drug discovery contribution</a></td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 2,822<span></span>
</td>
<td class="nump">$ 1,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365915424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Collaboration and License Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">49 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2020 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>program </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Nov. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,438,000<span></span>
</td>
<td class="nump">$ 64,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug discovery services revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,539,000<span></span>
</td>
<td class="nump">216,666,000<span></span>
</td>
<td class="nump">$ 180,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember', window );">Drug Discovery Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug discovery services revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,143,000<span></span>
</td>
<td class="nump">54,720,000<span></span>
</td>
<td class="nump">43,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sdgr_BristolMyersSquibbMember', window );">BMS | Oncology, Neurology, and Immunology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets', window );">Number of specified biological target | target</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining', window );">Number of neurology targets remaining | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount', window );">Research, development and regulatory milestones, amount</a></td>
<td class="nump">$ 257,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount', window );">Variable consideration, commercial milestones, amount</a></td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfPerformanceObligations', window );">Number of performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_CollaborativeAgreementNumberOfPrograms', window );">Number of programs under agreement | program</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug discovery services revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="nump">$ 43,200,000<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent', window );">Allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sdgr_NovartisPharmaAGMember', window );">Novartis Pharma AG | Research, Collaboration and License Agreement | Drug Discovery Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,272,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount', window );">Research, development and regulatory milestones, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount', window );">Variable consideration, commercial milestones, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,380,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sdgr_NovartisPharmaAGMember', window );">Novartis Pharma AG | Software Agreement | Drug Discovery Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-11-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sdgr_NovartisPharmaAGMember', window );">Novartis Pharma AG | Collaboration and License Agreement | Drug Discovery Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Drug discovery services revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent', window );">Allowance for credit loss, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_CollaborativeAgreementNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement number of programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_CollaborativeAgreementNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Number Of Neurology Target Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Number Of Specified Biological Targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration, Research, Development and Regulatory Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sdgr_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sdgr_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_OncologyNeurologyAndImmunologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_OncologyNeurologyAndImmunologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sdgr_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sdgr_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sdgr_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sdgr_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sdgr_SoftwareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sdgr_SoftwareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-11-12">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-11-12</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sdgr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sdgr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364357424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 16,564<span></span>
</td>
<td class="nump">$ 21,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsCurrentAbstract', window );"><strong>Deferred revenue, short-term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">111,944<span></span>
</td>
<td class="nump">56,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract', window );"><strong>Deferred revenue, long-term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">108,814<span></span>
</td>
<td class="nump">9,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember', window );">Software products and services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsCurrentAbstract', window );"><strong>Deferred revenue, short-term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">75,660<span></span>
</td>
<td class="nump">44,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract', window );"><strong>Deferred revenue, long-term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">14,393<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember', window );">Drug discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsCurrentAbstract', window );"><strong>Deferred revenue, short-term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">36,284<span></span>
</td>
<td class="nump">12,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract', window );"><strong>Deferred revenue, long-term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">$ 94,421<span></span>
</td>
<td class="nump">$ 6,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAndCreditsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAndCreditsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_SoftwareProductsAndServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365939056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition- Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue, revenue recognized</a></td>
<td class="nump">$ 53,438<span></span>
</td>
<td class="nump">$ 64,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of revenue expected to be recognized</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="nump">$ 59,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ContractWithCustomersPaymentTerms', window );">Contract with customers, payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ContractWithCustomersPaymentTerms', window );">Contract with customers, payment terms</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ContractWithCustomersPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customers, payment terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ContractWithCustomersPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364494752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Right of use asset - finance leases</a></td>
<td class="nump">$ 579<span></span>
</td>
<td class="nump">$ 579<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">45,050<span></span>
</td>
<td class="nump">41,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(20,854)<span></span>
</td>
<td class="num">(18,150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Total, net</a></td>
<td class="nump">24,196<span></span>
</td>
<td class="nump">23,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">23,527<span></span>
</td>
<td class="nump">22,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,693<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">6,876<span></span>
</td>
<td class="nump">6,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sdgr_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 10,375<span></span>
</td>
<td class="nump">$ 8,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sdgr_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sdgr_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991372471184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 6,159<span></span>
</td>
<td class="nump">$ 4,965<span></span>
</td>
<td class="nump">$ 3,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364377536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 403,657<span></span>
</td>
<td class="nump">$ 550,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=sdgr_CashCashEquivalentsAndRestrictedCashMember', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">162,657<span></span>
</td>
<td class="nump">161,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SecuritiesAssetsMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">204,798<span></span>
</td>
<td class="nump">307,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">36,202<span></span>
</td>
<td class="nump">81,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">198,859<span></span>
</td>
<td class="nump">240,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">162,657<span></span>
</td>
<td class="nump">161,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">36,202<span></span>
</td>
<td class="nump">79,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">204,798<span></span>
</td>
<td class="nump">307,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">204,798<span></span>
</td>
<td class="nump">307,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Cash and cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=sdgr_CashCashEquivalentsAndRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=sdgr_CashCashEquivalentsAndRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_SecuritiesAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_SecuritiesAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365815216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3 to level 1</a></td>
<td class="nump">$ 1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">$ 1,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991372374608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution', window );">Increase in right of use assets due to contingency resolution</a></td>
<td class="nump">$ 2,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance And Operating Lease, Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Right Of Use Assets Due To Contingency Resolution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991486965088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies - Summary of Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease costs</a></td>
<td class="nump">$ 18,097<span></span>
</td>
<td class="nump">$ 16,769<span></span>
</td>
<td class="nump">$ 11,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_OperatingAndFinanceLeasePayments', window );">Cash paid for leases</a></td>
<td class="nump">$ 17,718<span></span>
</td>
<td class="nump">$ 12,263<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_OperatingAndFinanceLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_OperatingAndFinanceLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366016992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Year ending December&#160;31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne', window );">2025</a></td>
<td class="nump">$ 17,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo', window );">2026</a></td>
<td class="nump">17,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree', window );">2027</a></td>
<td class="nump">15,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour', window );">2028</a></td>
<td class="nump">14,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive', window );">2029</a></td>
<td class="nump">14,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">97,509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid', window );">Total future minimum lease payments</a></td>
<td class="nump">177,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(59,506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_OperatingAndFinanceLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">118,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_OperatingAndFinanceLeaseLiabilityCurrent', window );">Less: current portion of lease payments</a></td>
<td class="nump">16,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Lease liabilities, long-term</a></td>
<td class="nump">$ 101,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366203280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (202)<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="num">$ (195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="nump">$ 2,199<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991372414016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (190,298)<span></span>
</td>
<td class="nump">$ 39,076<span></span>
</td>
<td class="num">$ (150,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">4,587<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">(Loss) income before income taxes</a></td>
<td class="num">$ (185,711)<span></span>
</td>
<td class="nump">$ 42,919<span></span>
</td>
<td class="num">$ (149,126)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991364489200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefits</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation', window );">Section 162(m) limitation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments', window );">Return-to-provision adjustments</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="num">(14.10%)<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies', window );">Tax contingencies, net of reversals</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(22.20%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="num">(28.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="num">(4.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return-to-provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, section 162 limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366911536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 41,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">204,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">129,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">31,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">2,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration', window );">Tax credit carryforwards, research, not subject to expiration</a></td>
<td class="nump">$ 2,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Research, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365741632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 51,542<span></span>
</td>
<td class="nump">$ 44,116<span></span>
</td>
<td class="nump">$ 67,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">62,215<span></span>
</td>
<td class="nump">13,224<span></span>
</td>
<td class="nump">5,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">37,544<span></span>
</td>
<td class="nump">71,676<span></span>
</td>
<td class="nump">43,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">5,462<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
<td class="nump">6,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">27,551<span></span>
</td>
<td class="nump">32,491<span></span>
</td>
<td class="nump">28,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credits</a></td>
<td class="nump">29,884<span></span>
</td>
<td class="nump">21,903<span></span>
</td>
<td class="nump">18,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">214,198<span></span>
</td>
<td class="nump">188,706<span></span>
</td>
<td class="nump">170,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(177,226)<span></span>
</td>
<td class="num">(136,031)<span></span>
</td>
<td class="num">(137,957)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">36,972<span></span>
</td>
<td class="nump">52,675<span></span>
</td>
<td class="nump">32,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gain on equity investments</a></td>
<td class="num">(7,284)<span></span>
</td>
<td class="num">(18,553)<span></span>
</td>
<td class="num">(4,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(652)<span></span>
</td>
<td class="num">(1,554)<span></span>
</td>
<td class="num">(1,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(29,036)<span></span>
</td>
<td class="num">(32,568)<span></span>
</td>
<td class="num">(26,740)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365437824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, January 1</a></td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 2,142<span></span>
</td>
<td class="nump">$ 1,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions taken in prior years</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions taken in prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to the current year</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, December 31</a></td>
<td class="nump">$ 3,648<span></span>
</td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">$ 2,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368700272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock in ATM offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,868<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sdgr_TheATMMember', window );">The ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock in ATM offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance', window );">Number of shares available to issue in transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfVotesForCommonShare', window );">Number of votes for common share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember', window );">Limited common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfVotesForCommonShare', window );">Number of votes for common share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock', window );">Right to exchange limited common stock to common stock, share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NumberOfVotesForCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes for common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NumberOfVotesForCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to exchange each share of limited common stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Remaining Value Of Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sdgr_TheATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sdgr_TheATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sdgr_LimitedCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991360391792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,391,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue', window );">Maximum percentage of stock options must be granted at exercise price of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock upon stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,820<span></span>
</td>
<td class="nump">800,336<span></span>
</td>
<td class="nump">329,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuances of common stock upon stock option exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,488,000<span></span>
</td>
<td class="nump">$ 9,440,000<span></span>
</td>
<td class="nump">$ 2,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average per share grant date fair value of options granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.88<span></span>
</td>
<td class="nump">$ 15.79<span></span>
</td>
<td class="nump">$ 13.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,365,000<span></span>
</td>
<td class="nump">$ 16,213,000<span></span>
</td>
<td class="nump">$ 6,548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,422,000<span></span>
</td>
<td class="nump">$ 46,877,000<span></span>
</td>
<td class="nump">$ 43,559,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward', window );">Equity award conversion rate to shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.78<span></span>
</td>
<td class="nump">$ 26.09<span></span>
</td>
<td class="nump">$ 26.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to vested stock options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost expected to be recognized over a weighted average period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSU's vested during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,188<span></span>
</td>
<td class="nump">13,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,822,000<span></span>
</td>
<td class="nump">$ 355,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember', window );">Eligible Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sdgr_PerformanceBasedRestrictedStockUnitsMember', window );">Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward', window );">Equity award conversion rate to shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.08<span></span>
</td>
<td class="nump">$ 22.48<span></span>
</td>
<td class="nump">$ 28.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSU's vested during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">14,850<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber', window );">Eligible to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSU's not vested during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">87,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Eligible Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent', window );">Achievement percent</a></td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Eligible Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent', window );">Achievement percent</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Eligible Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent', window );">Achievement percent</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=sdgr_SharebasedCompensationAwardTrancheFourMember', window );">Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=sdgr_SharebasedCompensationAwardTrancheFourMember', window );">Tranche Four | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sdgr_TwentyTwentyStockPlanMember', window );">Twenty Twenty Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of stock options must be granted at exercise price of fair market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Achievement Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Award Conversion Upon Achievement, Number Of Shares Per Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Eligible To Vest, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sdgr_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sdgr_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=sdgr_SharebasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=sdgr_SharebasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sdgr_TwentyTwentyStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sdgr_TwentyTwentyStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991360702992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 49,903<span></span>
</td>
<td class="nump">$ 47,841<span></span>
</td>
<td class="nump">$ 39,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">4,935<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">5,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">16,662<span></span>
</td>
<td class="nump">15,493<span></span>
</td>
<td class="nump">11,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">3,902<span></span>
</td>
<td class="nump">3,639<span></span>
</td>
<td class="nump">2,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 24,404<span></span>
</td>
<td class="nump">$ 23,532<span></span>
</td>
<td class="nump">$ 19,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366339504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">773,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,244,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(231,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(105,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,682,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in shares) | $ / shares</a></td>
<td class="nump">$ 26.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">24.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">29.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures (in usd per share) | $ / shares</a></td>
<td class="nump">24.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in shares) | $ / shares</a></td>
<td class="nump">$ 24.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sdgr_PerformanceRestrictedStockUnitsMember', window );">Performance Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">116,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">134,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(54,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">188,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in shares) | $ / shares</a></td>
<td class="nump">$ 24.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">26.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">28.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures (in usd per share) | $ / shares</a></td>
<td class="nump">22.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in shares) | $ / shares</a></td>
<td class="nump">$ 25.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sdgr_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sdgr_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365437296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percent)</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 3 months 25 days<span></span>
</td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percent)</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">2.13%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991368578208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning, January 1, 2023 (in shares)</a></td>
<td class="nump">11,274,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,264,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(169,820)<span></span>
</td>
<td class="num">(800,336)<span></span>
</td>
<td class="num">(329,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(226,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(220,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending, December 31, 2023 (in shares)</a></td>
<td class="nump">11,921,153<span></span>
</td>
<td class="nump">11,274,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, December 31, 2021 (in shares)</a></td>
<td class="nump">8,873,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning, January 1, 2023 (in USD per share)</a></td>
<td class="nump">$ 30.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">25.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">8.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="nump">31.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="nump">47.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, December 31, 2023 (in USD per share)</a></td>
<td class="nump">29.49<span></span>
</td>
<td class="nump">$ 30.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, December 31, 2021 (in USD per share)</a></td>
<td class="nump">$ 30.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance, December 31, 2023</a></td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, December 31, 2023</a></td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, December 31, 2023</a></td>
<td class="nump">$ 30,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, December 31, 2023</a></td>
<td class="nump">$ 30,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365971728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to common and limited common stockholders</a></td>
<td class="num">$ (187,123)<span></span>
</td>
<td class="nump">$ 40,720<span></span>
</td>
<td class="num">$ (149,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)</a></td>
<td class="nump">72,670,295<span></span>
</td>
<td class="nump">71,776,301<span></span>
</td>
<td class="nump">71,173,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,210,515<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)</a></td>
<td class="nump">72,670,295<span></span>
</td>
<td class="nump">74,986,816<span></span>
</td>
<td class="nump">71,173,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share attributable to common and limited common stockholders, basic (in usd per share)</a></td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share of common and limited common stockholders, diluted (in usd per share)</a></td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="num">$ (2.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991486964400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares subject to outstanding common stock options and unvested RSUs (in shares)</a></td>
<td class="nump">13,603,701<span></span>
</td>
<td class="nump">6,351,996<span></span>
</td>
<td class="nump">11,013,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365996464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Investments (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Mark-to-market gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,683,000<span></span>
</td>
<td class="nump">$ 53,461,000<span></span>
</td>
<td class="num">$ (18,084,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash payments to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,072,000<span></span>
</td>
<td class="nump">4,125,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sdgr_NimbusTherapeuticsLLCMember', window );">Nimbus Therapeutics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Non-marketable equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,436,000<span></span>
</td>
<td class="nump">1,928,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (loss) gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,000<span></span>
</td>
<td class="nump">1,928,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sdgr_MorphicHoldingIncMember', window );">Morphic Holding, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi', window );">Proceeds from sale of equity securities</a></td>
<td class="nump">$ 47,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Mark-to-market gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,474,000<span></span>
</td>
<td class="nump">1,778,000<span></span>
</td>
<td class="num">(17,226,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sdgr_AjaxTherapeuticsIncMember', window );">Ajax Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Non-marketable equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,498,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Mark-to-market gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sdgr_StructureTherapeuticsMember', window );">Structure Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Mark-to-market gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,096,000)<span></span>
</td>
<td class="nump">49,755,000<span></span>
</td>
<td class="num">$ (858,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,202,000<span></span>
</td>
<td class="nump">$ 55,509,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B preferred stock | Structure Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfPreferredSharesPurchased', window );">Number of preferred shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,210<span></span>
</td>
<td class="nump">494,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash payments to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B preferred stock | Ajax Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfPreferredSharesPurchased', window );">Number of preferred shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Cash payments to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">ADR | Structure Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfSharesPurchased', window );">Number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_AmericanDepositorySharesPurchasedPricePerShare', window );">Purchase price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock | Ajax Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Debt and Equity Securities, FV-NI [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_NumberOfPreferredSharesPurchased', window );">Number of preferred shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,416,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Cash payments to purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_AmericanDepositorySharesPurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>American Depository Shares Purchased, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_AmericanDepositorySharesPurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NumberOfPreferredSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred shares purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NumberOfPreferredSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_NumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_NumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sdgr_NimbusTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sdgr_NimbusTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sdgr_MorphicHoldingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sdgr_MorphicHoldingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sdgr_AjaxTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sdgr_AjaxTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sdgr_StructureTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sdgr_StructureTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sdgr_StructureTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sdgr_StructureTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991360963360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Discretionary matching contributions</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary matching contributed by employees</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 4,478<span></span>
</td>
<td class="nump">$ 4,135<span></span>
</td>
<td class="nump">$ 3,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991360395344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,539,000<span></span>
</td>
<td class="nump">$ 216,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,331,000<span></span>
</td>
<td class="nump">5,751,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognized', window );">Software contribution revenue recognition</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,692,000<span></span>
</td>
<td class="nump">65,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryContributionMember', window );">Drug discovery contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Drug discovery contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,031,000<span></span>
</td>
<td class="nump">2,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sdgr_SoftwareContributionMember', window );">Software contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Drug discovery contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,016,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BMGFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Drug discovery contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,031,000<span></span>
</td>
<td class="nump">2,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognized', window );">Software contribution revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BMGFT | Drug discovery contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021,000<span></span>
</td>
<td class="nump">2,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | BMGFT | Software contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Gates Ventures, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_SoftwareContributionRevenueRecognized', window );">Software contribution revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Minimum | Gates Ventures, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_PercentageOfVotingSecurities', window );">Percentage of voting securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_PercentageOfVotingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_PercentageOfVotingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_SoftwareContributionRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Software contribution revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_SoftwareContributionRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_DrugDiscoveryContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_DrugDiscoveryContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sdgr_SoftwareContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sdgr_SoftwareContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sdgr_BillAndMelindaGatesFoundationTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sdgr_BillAndMelindaGatesFoundationTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sdgr_GatesVenturesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sdgr_GatesVenturesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991367290960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991366527760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Segment revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 207,539<span></span>
</td>
<td class="nump">$ 216,666<span></span>
</td>
<td class="nump">$ 180,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total segment cost of revenues</a></td>
<td class="nump">75,456<span></span>
</td>
<td class="nump">75,974<span></span>
</td>
<td class="nump">79,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Segment gross profit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total segment gross profit</a></td>
<td class="nump">132,083<span></span>
</td>
<td class="nump">140,692<span></span>
</td>
<td class="nump">101,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sdgr_UnallocatedAbstract', window );"><strong>Unallocated (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(201,785)<span></span>
</td>
<td class="num">(181,766)<span></span>
</td>
<td class="num">(126,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="num">(39,917)<span></span>
</td>
<td class="num">(37,226)<span></span>
</td>
<td class="num">(30,642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(99,677)<span></span>
</td>
<td class="num">(99,148)<span></span>
</td>
<td class="num">(90,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain on equity investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147,213<span></span>
</td>
<td class="nump">11,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value</a></td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">53,461<span></span>
</td>
<td class="num">(18,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">17,902<span></span>
</td>
<td class="nump">19,693<span></span>
</td>
<td class="nump">3,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1,412)<span></span>
</td>
<td class="num">(2,199)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(187,123)<span></span>
</td>
<td class="nump">40,720<span></span>
</td>
<td class="num">(149,186)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sdgr_SoftwareSegmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Segment revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">180,365<span></span>
</td>
<td class="nump">159,124<span></span>
</td>
<td class="nump">135,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total segment cost of revenues</a></td>
<td class="nump">36,900<span></span>
</td>
<td class="nump">29,514<span></span>
</td>
<td class="nump">29,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Segment gross profit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total segment gross profit</a></td>
<td class="nump">143,465<span></span>
</td>
<td class="nump">129,610<span></span>
</td>
<td class="nump">106,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=sdgr_DrugDiscoverySegmentMember', window );">Drug discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Segment revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">27,174<span></span>
</td>
<td class="nump">57,542<span></span>
</td>
<td class="nump">45,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Segment cost of revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total segment cost of revenues</a></td>
<td class="nump">38,556<span></span>
</td>
<td class="nump">46,460<span></span>
</td>
<td class="nump">50,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>Segment gross profit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total segment gross profit</a></td>
<td class="num">$ (11,382)<span></span>
</td>
<td class="nump">$ 11,082<span></span>
</td>
<td class="num">$ (4,980)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sdgr_UnallocatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unallocated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sdgr_UnallocatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sdgr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sdgr_SoftwareSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sdgr_SoftwareSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=sdgr_DrugDiscoverySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=sdgr_DrugDiscoverySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45991365702416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Revenues by Geographic Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 207,539<span></span>
</td>
<td class="nump">$ 216,666<span></span>
</td>
<td class="nump">$ 180,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">114,869<span></span>
</td>
<td class="nump">161,961<span></span>
</td>
<td class="nump">123,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sdgr_APACMember', window );">APAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">25,802<span></span>
</td>
<td class="nump">24,569<span></span>
</td>
<td class="nump">21,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">65,650<span></span>
</td>
<td class="nump">29,135<span></span>
</td>
<td class="nump">34,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues From External Customers And Long Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">$ 1,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sdgr_APACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sdgr_APACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"H49 0IUP&P#6/*A:(J90)/)I'JLA->7)B'Y@J$L0W)IUJ;\Y$U(\?(V,5J
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M3(![8$RKZ1+!] K^90/&;%7/R+8(QL;P$0^'D:\E@PG#$0Z-LF:!D8"&/<F
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M"0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U636_C-A#]*X2Z*++
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MTK=V'?^ "T"J;Y;8Y@ $16%J%U0!&*%)/$;52$UZ<C5.,ZS_X/X7?;L^!T!
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M,IX.C8!Y\5[(LP'3(BJL^HBE5 ,?*O8'AR%L<%A85; '07@T $0YO"Q:TDM
M1))&DMM5%(N!>4XM7;/!F>1R$S9".]_!;,DJ@Q-)/FZ@TWT0$BS6YRA"<0+Y
M3_*'6[U,FPC93&/9QCY\\AGZ-:2]"#K#OBK6[IM_S2\>/"&"&L>^8BJJCA4[
M.'3H2+.K#5URX6UI-<47(%15B6TK@OE8Z$KSW5F8G*Z]+H3F:TW6RIA:F<HB
M(V4T13/[BXDM6B)/"+%(T3DBY@W;7OR';+GNXQ_K^2[O:DO V)E *(FM;B^<
MC+<E,+9&A-X&1W$-EH;8O67CEP?8\!Q51[R<(/AJV2YJ5C^',TC >C(S%0!V
MHBA*$ZDD.P&#LS$0%RC$<7FB7FJ_9MKPA^^Q ":4,:&';[1[;V*2@:L';<:;
M7P#:V8*NR3M?"RN%@A$F?S 9S!U0NOT4'/]J=C:?G-V_X&U?/;H_N7C\$.I(
MKVX'T[1&0F!<,+B2ZB9&J<0_ZPDQ;-XTM<&%^1K$QE*P)W_+-&U%F$L8"V];
M41L-'%E(2[);Y)(C:+@KUWP,"A^ DL<Q0^86%0P)N7I/ED.M[6H-<:TLKEP.
MF,V67\.H. M'"Z8!,A'YAG!Z? 9[>0/TG*K(DD!9%[>)=^?)FYY]/K%OCT[B
MI#XRYS@$RE>" _I:VXI!D*AZ/8 %A8-EMQM:RY@E=5N;BLF7"R2L4]N)\K$@
M0%3,QR)820X734G^#RQG=D"HX&+86+YLW#88QF1?++TUY&C@1OT3M6YVL,Q.
M(L](D3Z7W5::$&//3Z@R\8DWIP6@X#0D#A71?ASE:2[R#* ''4C)]X"EA^*)
MX1>X3 H^K1VQDJ.G0; K%D P?:DIU0%>E=$^:!_L3&(U>?5@EMKHL/8/"6Q1
M7%_S7/XK*0RBM;G,T=_LBZH;LAFW[K)GQ"K?L(ER>Y3)L->YKF6J%@3$B]-K
MF>UL"XD]0K>"L^MP>TA:2@A)UT67D0D:*'\I3C!&T2O(#!DP+FPDS'2,T*TC
MYYY4'4^<(4N^1]*]2\%<FI-8V_%<68(.DEZD9ZY_-K0A2;^A_(T%'R20$;V&
M_E-\L6,&$0G*!FG+LJN2DYC"#J? KH\X8F1RQTZUN,EC8EN7%LEUQWZ,2K+&
M94@'TTBR# G@J#\M&Q%7+!2&3)*@0P<:=R-6-$HDY>K-ALH <3W',XQ?YIV=
M22=3F0DNN?[0L40OU5;?\-6M9 *)Z8L;B2H[B2RG!SFQ<Y184/"VA/'#AY(B
MJQ*B3M)'#@0K2<$+<K^L"7H$%$+[:]MT'AJ?0[2\J''D_1AZ1'"J7JXUXI=4
M]XAJF,,?0T7,8WAC-RE>^Y1#I#1<O'ZD5;'6;B6Z/G(CR/3R1+W2T(C?R(T1
M]+[D">O;NDX\%:D]]-&Q66"7)U;AD*>?C!V7/01+PY.:<QS7F;V,H7>UL %
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MV\^"^XG;S!^,\"H>\ 77F-]]C0>CUSBN3M0OS8VNV.3VGWKSHSD$ F2)T*C
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MCA;@_;*!1PM_T 'I1U^>_S]02P,$%     @ .8%:6N@DY4"?'@  N&X  !D
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M,/2*H2'@N;9$<7FQ2*;3:6]6O"I<0C.XC3,>=DV;;CR7.A@-XD:[DV,#K_W
M/<?=&RYH_V*.+1/Q8I;<X+\X)'R&9QVYCXRV2-O*.G[D*1A^[&$V3"GN%I&;
M!#FK9$\>W;NW)*$#K\6.!T311=_N;F1F#$\P4>1W.\_1_NU\%H,#&0##Z@P"
MN<Z,\1W**;!2?^(=;PG<+?:*.ASZ1*6"8Z,NH_;,P100&4<T4X2Q4+#T&8:O
M#4=TO%/XU#;2L$\)BV*#@BXRA!<$C7R&^ :T.MBO OP67#5-<P.SHDTOH-O=
M58.^7H/\V2B-6@+H\!>0)B)TGQ;/T)X=NB$D"^QU-*%/K! 0R,'5<N=6E<9.
M1MCX+80'F5A,^Q)&KE*F#)C"1@.)#CV!08/X#YQ;.[X;)V"#$26))#>:ERW<
M43%41AC3%N&T2NGCIJUJGB2!24,JU&G&)\DU:(#9^CDR/";"SQ!2*5[<),N;
MY1-%574"@><H@T=EM-OY$')-F8_<P/L=8/I?%HKC:)8]%)A>?1XP-KT\&<D>
M0*_$"S&;+A.T._QI-9O!IYLED/:Z%_\N5LE\A9TEBYN9F"V3F]OIL"L-VFY^
M?8O_3-=K,;M-;F_7(][N;7)]>PW_76!#&&"Z$E%"JH/5>O]V=CU/%LM;>.DZ
M6<!"9PN8_O7-B+=V0SQ*ED>PS?E(!JX7W ,=;F"!ZQ5^6MTF,^@:/L':L?/+
MS<LNJDY_INY/GUZ)EI'&K7 C$8>5F\(85$<0OV 78T7(*3*2K, =]WZT44ER
M>]#0TD:#H$; M0)+0'/IOA2$4-X''XEL712_.8%.D;679N!,8'P$)@J@8DHZ
M/U.-S1498-QH1Q :=2\YV!V"PA$PWI,2+J%?T)YH9'0.1@0UV0'\)88Z&-CP
M2W$Y+ALV&!Y)7-B"NH_HV9*J0(*![XF^Q.>2=!$*+5#"# /SM93 &7EQ_;'5
ME8I0&,:G/H$AA/CK2-;%K!8S[O85FIJCC7$ ATB@,9S#H*%!)P0-@L[5$*5K
MVQWYH@[O0L]M@$&B0"N%I5AP0C9,2K"PG#KP>0M,'I*7:O;>>HYQ<@-F2.;8
M.HJQ!HV8R^4H86TF1*+D$.G'V+O$+5,58GX!%YN,#_%X&ALF3_P A8'EC'3/
MC(9-*<>4Z4\*$4)^C7F@TS]F4:C_8#IL58$CKS:G*_R7[6EBY-; HA1&-11S
MX_Q1) J$[-NF[J"$/F(VF!RGTHHV2X/T:8SU(FM6M<R898E-$Z</:%WZ4!3,
M\4>)25!$%FBC2W"F<@Q-7">PD;NN$I%^Q38BLK3D1/>&Z&NA\WL3.=GE#3B%
MM+8^HDUH!T1ET&T+//MR;._("S, "6Z@FUW),F 0+T:W4K3)X31W8J-(R1@V
MBB=>;$%!@+;\6TGQ_;&XEPX9=7-L<..')Y<X57&4)TS+A]Y9+SV.8_M4+*A6
M4'O9R7*F23/BDO>M9M\,IN*#V_5TG<0VYGUL*M\[4VE#77CEXN5YYP<18D48
M?,CJN.TG="8MV8@UJ:'34JDI10B)'3#3V+"+(&#[>4?D$!9:O5BL&-5XL>0(
M- P,31SJFBR2V\4M;WI1JW!*-/@PNK0S;'0N0#T3FG9<B$&8Z6FM'@6CT+I^
M64AX-HA(0LC0VQU]-)QO@T;D[HXKA( TL&D.RN&@9-8<6/4:W"28[4;MJ:P@
M"OUF1%0PXYJC.'&GRL9]NR#;%#\Z&S?GZN$GA,P_$P&8UWE-%)[]%6R&F?[J
M;/2'.X]6QGDZYV([\268Q5BXU<7WX_@/H\1;\-4-Y+.ZF75%X.>*F3JT?6Z,
M-.+,QQ[X:$CR0LQ7R6RY@ ^K97)-4=5RD2SGUV>%=YY,%S/X[PU,8);<KFQL
M,KP6'.4ZF5UC6 *ASVHYQU%6R>+Z6EQN7\)NA6$%4OS/)A/VUC'VNPJ4!'@8
MWY]@VE=WX*-N-EC>$(@6(X_3<]*2LR6N80L3='>S] %M_K8W@5XJC@EG9G%%
MLQ \"S?4Y<6[[^\0F"U!T[22(95^&1QV#PVY:^-FV^%=NLS1,/'.,<,Q:@O2
M3)F5%*B;%:7U>U 1<,KQ6&1JVY*I/Y8%Z514]]"G0I\/D:JMJ6I"[SV'\8L]
MC)2KMC(?*9=Z/+8Y_4UF5I8*-G]+XBK1Y2#MW"DT"!>*4*['DE%X4-6#F"2H
M7S![0\4?J)^-1D22)\XT>3Y"9&%L92FHG*V18B[1<74C&XVS)UHQ'E='6P..
M8MNTG&KGO7"D+D%#T#RH#HIB,NZ!M+,31[:,0YO[/)#.YL]D'L+7!D.$+7(;
M\RS,#52EM&XX4)"F1>73H*[06>',_U99"--F4#I\9<,:0T+K<Z'+G*-R.YHZ
M!S]),_%VB$& )X@6F F1P[H<Q1J3F]%$('9(-56W')6B)?A]WE8:B**E*1P:
M'YZR]!N%Z9@4(PGFDE.X@PG1Z0&MYX8J$U3,NXX[!Z@%[J#,6XR7&&Y@R.0(
MBA8SW/I?+@]!##6\NC.2$0=XNCXWN\X>X@L4CLNCJ7<\2! 5(D6E8+HY$P+6
M'@HVLUJ_G"C<1"0750_$8N"\(1NWVV '#>MJ-9FBGYH9 "%TCRC-$HI!MP/=
M$T#*H]KU855+M\TX3-N-_<%5VA,A@XC?9(V6-_-XUIQOZH5SO;J!1\3$U%/
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M%S;D97BAINNM,O* GF;*1I#%0?0KJA7]3V&+R?/!11/1>VR1TBBZ2DF2M+E
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MVU;T=<I^050CKP#DN?"G(B/$H\S_S7T&O[#$O88R(9'V?OE+\)&9J@K-"@O
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M2Q/P?6^,[Q]H@^&?#W?_ 5!+ P04    "  Y@5I:8'F@GX0*  #:&P  &0
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M_#0 S]=%4;=?:('NIT#/_P-02P,$%     @ .8%:6D?[^PRP!   00T  !D
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MW,]8<(26-N#]0BE;/Y""YL[^ZF]02P,$%     @ .8%:6LG4TURV @  %P8
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M*R*$G,I$\:RS%QKPJ6.UI8_"\".) 4,T)5?:0.KLG"AI!##7P@.60F?KU^A
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M=*IT"- @(FK-BE:L2D-)$1"OLUP$$=8C;8I81$*0"Z882$)#GBD(]2C$QB)
M=0O31(\+F<"*R 4.2W'(?,X"P(:*J"),$F XB2!'WC&A),!G2V#A[!"62B7R
MHI(B[ IG4I"2+*8I]N$E/GU$<?1.,3E_,9Y2Q-:%$\NN+I18RD$CADRCF-5[
MR)&+Y\[.3KRCX+BCD>GVS;I F%%'OG;/27EZTC+<(4=4ZNEQF4)TE=PH2,BI
M.\0)C0NPR&-J>#V>?#V^('<T 1.:*5.(/"DX3^D3TCW"DFD"7MP])M.7#!K2
M$(%4+AI[KW-1S-K0/UDL!"ST='=Y,BLRY-'4$7UUQ9-$>ZQX\$0>./:CQ0QB
M\N49T\!$_#NN*[G'\5BN==2N(@8($3!L,5QT\F>Q]!URC_SU^YU,=-YHGX[N
M^!+,K'Z_J&'';<MB\A.>002LR$EI?"L BUS3F6N\+^HA>=29_ V]B0G6RV*^
M=<T\,ZLL<WP6@(J884^H8Y%GZ-TJ8GB?QK'V(Y4T6$\A='HE60SKW(?G#',=
MWX\J0CVBG=.A08!OF4Y5SQUT^N[9QINO^)N2R1-F.DU?:*>*G4F3#S3)/EUW
M"#[>@F: 0('<"EA)P!O\?P/F>QUO,&Q_G9V5Y?S,6BKO7CV^._E?U+"Z8FX'
MG=-80EW9MIKM^>+JETS[5J>:6$[+\EQ'U([92-1JMB?104ETL/>2VLG:<1O)
M6LWV)#LLR0[MJ[I5>/^^-<_C/W74K"@_JSX.!+9#^+PD?/X>^O/\D/P/!+;#
MWW.KW8]KSV]4![7;'+O95J;4;G*LUON2VMK2>7;)JI5.+2N[W:^(C=HP6*?;
M-PQ^%09_KR)M>16U(*)DKBU:=K-]B5:[2,^Z21N7LD7+V5I:=OO_J,-:CN^Q
M4?2JG:)GWX9]T5J&VEG:$382JW!JH[-JJ1YH>[E+M5)1GEWQU&TK:OG:84Y=
M%S7C2^W7#KOIO@PK]>39I4ZU&9HL*8OUGKJ68('2-RCZ>^1RC"(?-?ZHN]QA
MTSINU\]*_'AVE?)J#V$5!7:HGWTK'@IMEW@EA+SA>P@#[Z#*Z%!HNS&HM)%G
ME1[-TL!N]BIG:HF]A^;Q*\WCV\5+HSQHL6O?0-=^6'T/+>176LBW:YH]1$ +
M8I,(L)OM2[12.[Y=F[2*@!;[W=?CYK-'+='W4#M^I79\NUIY@Q)H07B[$K #
M[4NU$CV^7;*\50FTP/0&YXU*P&ZZ+\-*Z_@M6N=M2F"-LO.&]SUO,'RE!-K'
M%7YVMP[,$A +<XXH2<#S5!5G9^7=\JQR8D[HNM7PXJ#SEHH%UGH2PQQ-W8\#
M=$$49X=%0_','+_-N%(\,9<1T!"$'H#]<\[5IJ$G*$]PQ_\"4$L#!!0    (
M #F!6EH\I3,X$0(  -T$   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;*54VX[3,!#]%<M(/*$Z22^@DD1J=T&LQ$K5+I<'Q(,;3Q-K?0FVLUG^'MM)
M0T'="HF7V&//.7..XW'>:_-@&P"'GJ10ML"-<^V:$%LU(*F=Z1:4WSEH(ZGS
MH:F);0U0%D%2D"Q)5D12KG"9Q[6=*7/=.<$5[ RRG934_-R"T'V!4WQ<N.-U
MX\("*?.6UG /[G.[,SXB$POC$I3E6B$#AP)OTO5V$?)CPA<.O3V9H^!DK_5#
M"&Y8@9,@" 14+C!0/SS"%0@1B+R,'R,GGDH&X.G\R/X^>O=>]M3"E19?.7--
M@=]@Q.! .^'N=/\!1C_+P%=I8>,7]4/N<HY1U5FGY0CV"B17PTB?QG,X :2K
M9P#9",BB[J%05'E-'2USHWMD0K9G"Y-H-:*].*["3[EWQN]RCW/EC3]>!@9]
M,I1Q5:.=%KSB8!%5#.V,KH!U!FQ.G"\6(*0:B;<#<?8,<9JA6ZU<8]$[Q8#]
M24"\RDEJ=I2ZS2XR7D,U0_/T%<J2;'&!;SY9GT>^^?]91]\^>B"Z<2#M]W/G
M,%19G*\2FFIM6UI!@7W76#"/@,N7+])5\O:"A\7D87&)_9\];)ANW=]_89!_
MN8 S'9S324ZNG 13Q\:RJ-*=<L/MFU:GWMT,5_9W^M#XM]347%DDX."AR>SU
M$B,S--,0.-W&"[S7SK=#G#;^_0$3$OS^06MW#$*!Z44K?P%02P,$%     @
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M<8;W!]S] 7?+ 3<"YZ<=G)]^!YP_\MFAWLO9\49.TK'X&^=T1_P]ZP1^=JS
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M^H&84#42/UX08X:9_Z7 PK\8H)-',F08UR>7)I,3"X1^'+F%R<PTPF<^DFR
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MNE#6R0**LJQ=>:PP8/&[[7FXV8VJMEP^?7B7,!I?&MRW+3?]3%];;JW0TES
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MK*:/Y><A[0-R=AC9-="%Z7B)\X ZQ*"^QV#QZD4RB=\<X9V-O+-CZ(O;H6]
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M0KLO'#K?E)R+5AM9]\'$H.9--[+O_3D<!>3A*P%Q'Q [WETBQ_*.&;9:*'D
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MEL90;]8T]U&[ _2^4LH>%R[ ]$]B\R=02P,$%     @ .8%:6@M.A=I"!P
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M5K[&SKTXCICP>)8Q2-^HE8)L<;#][3>IX.+[5[^M];=6]SBF(@IFKU;W5H:
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MMJ!P>3Z9AZ<7F95W K<"=_IH#-:3A91W]N.WZGP26(.PQM)8!$ZO>[S$NK9
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M]C"]G4BVJLZCCTRJTVTU7 *)@6L#]3QA3#Y/]!&W^4LC_ =02P,$%     @
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M^6V7SS6-SFX:YD5P+BN2X-#3E2Y1+- ;O7X5]H+WNSPZ$-B&8QWG6*<-7>]
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MPQ*W5%^+[4?H \HL7R6H<K]HV^^- E2U2@O6@XT#1GCWQ/=](G8 27( D/2
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M@BP-\/M*"'UX*2=H6N7Y?U!+ P04    "  Y@5I:4<S:'RD#  !B"@  &0
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M"523J):@6HIJBM+,_.JB*_!>U>PW0"\-0[48U02J251+4"U%-45IY@ZA:[K
M7M.9MP4IFRM\MZ^X:B<?_>_8A'9UJ!:CFD UV6J[,Z/1\?YL/D''3%%-49J9
MUIUW&[-7=3O3#^??C[PVW'+'/;L^.+=H7X=J M4DJB6HEJ*:HC0SW[K6"U[7
M%6L!6O^A6HQJ M4DJB6HEJ*:HC1SA] M86!O"9\W/4%[0E2+44V@F@RZ[U_6
M-SU!6T)44Y1FIE6WA(&])32G)\A%]O81!V<9[1-13:":1+4$U5)44Y1F9E[W
MB<'KZA,#M$]$M1C5!*I)5$M0+44U16GF#J'[Q #I$X.>RZ\FW6O//]A'&YS0
MGD+1BT[]_78&+111+4&U%-44I9GO:JT+Q=!>*+Z;7L_RVWQ13XQMY6&K-._C
MM=/0[<WS/MC'&AJ\@\84Z)@2U1)42U%-49J9.]T*AH>U@G^_*WKSAK:"J!:C
MFD UB6H)JJ6HIBC-S*]N!</7U0J&:"N(:C&J"523J):@6HIJBM+,'4*W@N$+
MM()V<W"JT580U02JR?"@5A =,T4U16EF6G4K&![6"M;3C^>T@G9]<&[15A#5
M!*I)5$M0+44U16EFOG4K&+ZN5C!$6T%4BU%-H)I$M0354E13E&;N$+H5#%^@
M%;2;@U.-MH*H)E!-A@>U@NB8*:HI2C/3JEO!\+!6<#L]05I!^XB#LXRV@J@F
M4$VB6H)J*:HI2C,SKUO!\'6U@B':"J):C&H"U22J):B6HIJB-'.'T*U@B+2"
M84\KZ/6T@O;1!B>T.VK@CD\[[0S:"J):@FHIJBE*,Z(7Z58P0EK!5K'<#_2#
M?:"AJ7MZ0($.*%$M0;44U12EF8G3?6!T8!]X7>:]UPG:UQ_ZYQK58E03J"91
M+4&U%-44I9D)UHU@]+H:P0AM!%$M1C6!:A+5$E1+44U1FKE#Z$8P>H%&T&X.
M3C7:"**:0#49'=0(HF.FJ*8HS4RK;@2C QO!9@+RG$[0[@].+MH)HII -8EJ
M":JEJ*8HS4RX[@2CU]4)1F@GB&HQJ@E4DZB6H%J*:HK2S!U"=X+1"W2"=G-P
MJM%.$-4$JLGHH$X0'3-%-45I9EIU)Q@=V FV$Q2D%;2/.3C-:"N(:@+5)*HE
MJ):BFJ(T,_6Z%8Q>5RL8H:T@JL6H)E!-HEJ":BFJ*4HS=PC="D9(*QCU7+77
M4PK:!QL<T.Z@WFAR.MFO:-!2$-425$M135&:D;RQ+@7'2"DX[KEL;]2Y5- ^
MUM#@'32F0,>4J):@6HIJBM+,W.EJ<'Q8-2B+==D;.+091+48U02J251+4"U%
M-45I9H!U,SA^7<W@&&T&42U&-8%J$M425$M135&:N4/H9G#\ LV@W1R<:K09
M1#6!:G)\4#.(CIFBFJ(T,ZVZ&1P?U@PV\X_G%(-V?G!PT6(0U02J251+4"U%
M-45I9L!U,3A^7<7@&"T&42U&-8%J$M425$M135&:N4/H8G#\ L6@W1R<:K08
M1#6!:G)\4#&(CIFBFJ(T,ZVZ&!P_40S>U9'\Z;3_;><DG^99[WL-VJG!(47[
M/E03J"91+4&U%-44I9EAUGW?^'7U?6.T[T.U&-4$JDE42U M135%:>8.H?N^
ML;WOZ[S5?':;S>99\\*/RZ)TKIHZ\*DRT#[$X)"CG2&J"523J):@6HIJ:MQM
M;G55;"1WHOO"B;TO_)C]F"W6B[Y VM<<&DA4BU%-H)I$M0354E13E&9F5W>.
M$_=534,F:(>):C&J"523J):@6HIJBM+,'4)WF!-K)72^??OZU7:^D5_\[DR+
M955FTVJ=S9TJ+Q>;.<C//"O[IR!V?G# T4X2U02JR2=^+>YH^S/O33-:0**:
MHK1MFD]6UWE>Q5F5G9\M\O(J_Y#/YZLZHNMEU1SC=[[JE/EEG7;WS3OOZ*3S
M]??N&^'V?%VZ;]+-UT\T?WYVDUWE'[/R:E;O%_/\LAYJ=-R<N=R<,+S_I"IN
MWA[5^^ZWHJJ*Q>;#ZSR[R,MF@?K[ET51W7_2#'!7E-\W#^?\_P%02P,$%
M  @ .8%:6GB\"=(6!   DA4  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN
M>&ULS5A1;Z,X$/XK%K<Z[4JW!0,A22^)U)3NW4JW4M7LWCV<[L&%24 %G+.=
MI'N__FQ#22 N:E=^Z$O 9N9COAE_Q)[9@;('G@$(]%@6%9\[F1#;2]?E208E
MX1=T"Y5\LJ:L)$(.V<;E6P8DU4YEX?J>%[DER2MG,=-SMVPQHSM1Y!7<,L1W
M94G8]R44]#!WL/,T<9=O,J$FW,5L2S:P O%M>\ODR&U1TKR$BN>T0@S6<^<*
M7\8X4@[:XL\<#OSD'BDJ]Y0^J,'G=.YX*B(H(!$*@LC+'JZA*!22C./?!M1I
MWZD<3^^?T#]I\I+,/>%P38N_\E1D<V?BH!369%>(.WKX'1I"(X67T(+K7W1H
M;#T')3LN:-DXRPC*O*JOY+%)Q(F#)&IV\!L'O^\0/N,0- [!2QW"QB'4F:FI
MZ#S$1)#%C-$#8LI:HJD;G4SM+>GGE:K[2C#Y-)=^8K$2-'GXN)292]$U+>5R
MXD07Y"-:U4L!T36Z+@CG^3I/ZF=R1OLA@]_-H[H']#X&0?*"?Y!(WU8Q>O_N
M WJ'\@I]S>B.DRKE,U=( BH,-VF"7=;!^L\$BWWTA58BX^BF2B'M KB2>4O?
M?Z*_] <18T@N4(!_0;[GAX: KE_N'AC<XY>[^P-L@K:8@<8+GL&[*;<%_0Z
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MN9K*><W +:WD8G.LTW4%]"-PH])6B)_@PQT1N"CYQY$GY,"JNY>W@TR;0=#
M(!"!K[062P[^J&=D=AC D\0=-MIA3Y$UXAW)71# 3P#Y* 2_ @_P)6:$MW^6
M$8(N,8$>(1P8X8%PP8I<R+SH1/3-VAI!U=,U7^&<C!U9,)RP#7$FO_T"8_]W
M"U_8\84Z>C# ]_>Z>B8,T#EX[)ERPQ>^ U_4\476_$W)HJCKHE[(HBEQG1/P
MH:C;Y?D(_NU=J(:ZB1OKN$I4-I,D"5(8CKQ-#T_<\<16GC\9KM5BOI4B/J*
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M<&5_R;JV]1R2+I46>0U&#W)65%_Z5L=A!Q#$1P!!#0@. =$10%@#PG-/B&I
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MK]/#3)55'U!-M"CMR_@J-+ZS=CC'U@FD,<#]J1!Z.S$'-,U8\@]02P,$%
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M:L1^RR"!XP>6,QIT_-83: >![UIVQW)]@7;@>O:HWW-!0R\X2>_S<BEW&@J
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M\H0(3 7(YTM*Q?9&=="<.:?_ 5!+ P04    "  Y@5I:,9%_H_8"  !F!P
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MS5=HZSES?*F6MGZR31L;>"RM+.JB!5,&A5#-FS^T.NP POX!0-0"HN> W@%
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M.7.M26ODP=LV@*;'4(U!-1^J<:@60+40I<EMT"31ECZ)OJLRBWPYCXN/9')
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M" ACH/=GG*OUQ#CH?FG2OU!+ P04    "  Y@5I:-JZXSOP'  "]7@  &0
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MI050&H/20BB-HVBJM%MGRS'Z#/_]KCLS=["RH=Y60U/.M1V=(="-(YZKF0Q
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M4IKR,@$2 U,!\OF24K&_41,T!YV3_P!02P,$%     @ .8%:6DV=!BDC P
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
M1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2
M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;
MZ/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  Y@5I:?N!FGFX%  "
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MN@['ONLOAE>[#=2[S=\??P%02P,$%     @ .8%:6MMVL'$Q @  B2D  !H
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M]\ZM_SA^?):=;?JW?#;^67'Q E!+ 0(4 Q0    ( #F!6EH'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ .8%:6L&99;OO    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ .8%:6IE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  Y@5I:
MPX4V-Q )  ! /   &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ .8%:6IL6DX N!P  D"   !@
M     ("!5!$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M #F!6EJ#!$$UD ,  "T/   8              " @;@8  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  Y@5I:!+E@:1$'   ")0  &
M            @(%^'   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ .8%:6NO'X20_ P  ^@D  !@              ("!Q2,  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #F!6EI\%0LG-@@  )9"
M   8              " @3HG  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  Y@5I:O:<Q7OP)  "J,@  &               @(&F+P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ .8%:6G(4/YFC
M P  'P@  !@              ("!V#D  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( #F!6EIO@CCZMQ8   !&   8              "
M@;$]  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  Y@5I:
MZ"3E0)\>  "X;@  &0              @(&>5   >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( #F!6EKW+0I.50,  "$'   9
M      " @71S  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ .8%:6L,-K&QH!@  (A$  !D              ("! '<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  Y@5I:80*+NO$&  "($
M&0              @(&??0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( #F!6EI@>:"?A H  -H;   9              " @<>$  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ .8%:6M;]$:_]
M!0  ?1(  !D              ("!@H\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  Y@5I:8\,*7]D.   6-   &0
M@(&VE0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #F!
M6EI'^_L,L 0  $$-   9              " @<:D  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ .8%:6M;(;#U!"   OQ<  !D
M         ("!K:D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  Y@5I:R=337+8"   7!@  &0              @($EL@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #F!6EK(?K+%- 4  "(.
M   9              " @1*U  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ .8%:6M;T4>Z-!P  ZQ$  !D              ("!?;H
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  Y@5I:H^RM
MQ(,"  # !@  &0              @(%!P@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( #F!6EJ'C%L,)@8  ,T=   9
M  " @?O$  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M.8%:6CRE,S@1 @  W00  !D              ("!6,L  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  Y@5I: ^.-95()  !^*0  &0
M            @(&@S0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( #F!6EK<F2CFF18  -E)   9              " @2G7  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ .8%:6J3=/G*%!
M+ P  !D              ("!^>T  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  Y@5I:][(YAMD"   C!@  &0              @(&U
M\@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #F!6EHC
M[CBZ)@,  / '   9              " @<7U  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ .8%:6I2^*Q>$ P  50@  !D
M     ("!(OD  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F!6EHYF!>\Z 4   4M   9              "
M@7\3 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ .8%:
M6N >VE>+ P  <Q(  !D              ("!GAD! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  Y@5I:X,U?I7T&  !T/P  &0
M        @(%@'0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( #F!6EJLV1"V_@0  /@?   9              " @10D 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ .8%:6C]:+Q R P  ?@L
M !D              ("!22D! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  Y@5I:P712_+8#   $$@  &0              @(&R+ $
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #F!6EK];%69
M5 D  .U>   9              " @9\P 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ .8%:6LVY)"V2 P  WA   !D
M ("!*CH! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  Y
M@5I:2+NICG$#  #3#0  &0              @('S/0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #F!6EKR::R#P0,  *D1   9
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M970T."YX;6Q02P$"% ,4    "  Y@5I:+[$_@[8"  "%!P  &0
M    @(&:4P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M #F!6EKI5U'7/@,  &P)   9              " @8=6 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ .8%:6O*JYD%K P  DPT  !D
M             ("!_%D! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  Y@5I:8@4G7/("  !="   &0              @(&>70$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #F!6EJ+R!*G%00
M #8/   9              " @<=@ 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ .8%:6E',VA\I P  8@H  !D              ("!
M$V4! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  Y@5I:
M21;X\J8$  !\$0  &0              @(%S: $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( #F!6EJ9O'%>1 ,  #,*   9
M      " @5!M 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ .8%:6HJ^9V%Z!0  *"8  !D              ("!RW ! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  Y@5I:Y]TM=6,0    Y0
M&0              @(%\=@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( #F!6EIXO G2%@0  )(5   9              " @1:' 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ .8%:6A2C8:LM
M!   \!(  !D              ("!8XL! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  Y@5I:S&!,APP#  "8"0  &0
M@(''CP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( #F!
M6EJ@:X:0-P4  $X>   9              " @0J3 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ .8%:6FX;,BOS P  ?PX  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( #F!6EH%?;T,)P(  +0$   9
M  " @2NU 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
M.8%:6AJEA=(F!@  Z2$  !D              ("!B;<! 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    "  Y@5I: E:U!OH#  #T%   &0
M            @('FO0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( #F!6EI-G08I(P,  .P1   -              "  1?" 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ .8%:6I>*NQS     $P(   L
M     ( !9<4! %]R96QS+RYR96QS4$L! A0#%     @ .8%:6G[@9IYN!0
M@"X   \              ( !3L8! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( #F!6EK;=K!Q,0(  (DI   :              "  >G+ 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #F!6EJDR,-W^@$  +0H
M   3              "  5+. 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !. $X 614  'W0 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>296</ContextCount>
  <ElementCount>399</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders</Role>
      <ShortName>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Equity Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/EquityInvestments</Role>
      <ShortName>Equity Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/RevenueRecognition</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables</Role>
      <ShortName>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/SegmentReporting</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Revenue Recognition - Software Products and Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails</Role>
      <ShortName>Revenue Recognition - Software Products and Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Revenue Recognition - Drug Discovery (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails</Role>
      <ShortName>Revenue Recognition - Drug Discovery (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Revenue Recognition - Schedule of Drug Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Drug Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Revenue Recognition - Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails</Role>
      <ShortName>Revenue Recognition - Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenue Recognition- Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition- Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Commitments And Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments And Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Commitments And Contingencies - Summary of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails</Role>
      <ShortName>Commitments And Contingencies - Summary of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails</Role>
      <ShortName>Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Income Taxes - Summary of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Summary of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/StockholdersEquity</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Stock-Based Compensation - Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails</Role>
      <ShortName>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails</Role>
      <ShortName>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/EquityInvestmentsDetails</Role>
      <ShortName>Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/EquityInvestments</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.schrodinger.com/role/RelatedPartyTransactions</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails</Role>
      <ShortName>Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sdgr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Segment Reporting - Schedule of Revenues by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Schedule of Revenues by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sdgr-20241231.htm">sdgr-20241231.htm</File>
    <File>sdgr-20241231.xsd</File>
    <File>sdgr-20241231_cal.xml</File>
    <File>sdgr-20241231_def.xml</File>
    <File>sdgr-20241231_lab.xml</File>
    <File>sdgr-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sdgr-20241231_g1.jpg</File>
    <File>sdgr-20241231_g10.jpg</File>
    <File>sdgr-20241231_g11.jpg</File>
    <File>sdgr-20241231_g12.jpg</File>
    <File>sdgr-20241231_g13.jpg</File>
    <File>sdgr-20241231_g14.jpg</File>
    <File>sdgr-20241231_g15.jpg</File>
    <File>sdgr-20241231_g16.jpg</File>
    <File>sdgr-20241231_g17.jpg</File>
    <File>sdgr-20241231_g18.jpg</File>
    <File>sdgr-20241231_g19.jpg</File>
    <File>sdgr-20241231_g2.jpg</File>
    <File>sdgr-20241231_g3.jpg</File>
    <File>sdgr-20241231_g4.jpg</File>
    <File>sdgr-20241231_g5.jpg</File>
    <File>sdgr-20241231_g6.jpg</File>
    <File>sdgr-20241231_g7.jpg</File>
    <File>sdgr-20241231_g8.jpg</File>
    <File>sdgr-20241231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="925">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sdgr-20241231.htm": {
   "nsprefix": "sdgr",
   "nsuri": "http://www.schrodinger.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "sdgr-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "sdgr-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sdgr-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sdgr-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sdgr-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sdgr-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 339,
   "keyCustom": 60,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 41,
   "memberCustom": 43,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/ecd/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 296,
   "entityCount": 1,
   "segmentCount": 87,
   "elementCount": 717,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 925,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/ecd/2024": 23,
    "http://xbrl.sec.gov/cyd/2024": 15
   },
   "report": {
    "R1": {
     "role": "http://www.schrodinger.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
     "longName": "9952154 - Statement - Consolidated Statements of Comprehensive (Loss) Income",
     "shortName": "Consolidated Statements of Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952155 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.schrodinger.com/role/DescriptionofBusiness",
     "longName": "9952157 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.schrodinger.com/role/SignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.schrodinger.com/role/RevenueRecognition",
     "longName": "9952159 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.schrodinger.com/role/PropertyandEquipment",
     "longName": "9952160 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.schrodinger.com/role/FairValueMeasurements",
     "longName": "9952161 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.schrodinger.com/role/CommitmentsandContingencies",
     "longName": "9952162 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.schrodinger.com/role/IncomeTaxes",
     "longName": "9952163 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.schrodinger.com/role/StockholdersEquity",
     "longName": "9952164 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensation",
     "longName": "9952165 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders",
     "longName": "9952166 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders",
     "shortName": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.schrodinger.com/role/EquityInvestments",
     "longName": "9952167 - Disclosure - Equity Investments",
     "shortName": "Equity Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.schrodinger.com/role/EmployeeBenefitPlan",
     "longName": "9952168 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.schrodinger.com/role/RelatedPartyTransactions",
     "longName": "9952169 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.schrodinger.com/role/SegmentReporting",
     "longName": "9952170 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionTables",
     "longName": "9955512 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.schrodinger.com/role/PropertyandEquipmentTables",
     "longName": "9955513 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.schrodinger.com/role/FairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.schrodinger.com/role/CommitmentsandContingenciesTables",
     "longName": "9955515 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesTables",
     "longName": "9955516 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensationTables",
     "longName": "9955517 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables",
     "longName": "9955518 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders (Tables)",
     "shortName": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.schrodinger.com/role/SegmentReportingTables",
     "longName": "9955519 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails",
     "longName": "9955520 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails",
     "longName": "9955521 - Disclosure - Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)",
     "shortName": "Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "sdgr:TimingOfRevenueRecognitionPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "sdgr:TimingOfRevenueRecognitionPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails",
     "longName": "9955522 - Disclosure - Revenue Recognition - Software Products and Services (Details)",
     "shortName": "Revenue Recognition - Software Products and Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-271",
      "name": "sdgr:SoftwareContributionRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "sdgr:SoftwareContributionRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
     "longName": "9955523 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)",
     "shortName": "Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
     "longName": "9955524 - Disclosure - Revenue Recognition - Drug Discovery (Details)",
     "shortName": "Revenue Recognition - Drug Discovery (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
     "longName": "9955525 - Disclosure - Revenue Recognition - Schedule of Drug Revenue Recognition (Details)",
     "shortName": "Revenue Recognition - Schedule of Drug Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
     "longName": "9955526 - Disclosure - Revenue Recognition - Collaboration and License Agreement (Details)",
     "shortName": "Revenue Recognition - Collaboration and License Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "sdgr:ContractWithCustomerNumberOfSpecifiedBiologicalTargets",
      "unitRef": "target",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
     "longName": "9955527 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)",
     "shortName": "Revenue Recognition - Schedule of Contract Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
     "longName": "9955528 - Disclosure - Revenue Recognition- Contract Balances (Details)",
     "shortName": "Revenue Recognition- Contract Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
     "longName": "9955529 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.schrodinger.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "longName": "9955530 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails",
     "longName": "9955531 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)",
     "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "9955532 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:UnrealizedGainLossOnInvestments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:UnrealizedGainLossOnInvestments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "9955533 - Disclosure - Commitments And Contingencies - Additional Information (Details)",
     "shortName": "Commitments And Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sdgr:FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sdgr:FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails",
     "longName": "9955534 - Disclosure - Commitments And Contingencies - Summary of Operating Leases (Details)",
     "shortName": "Commitments And Contingencies - Summary of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails",
     "longName": "9955535 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)",
     "shortName": "Commitments And Contingencies - Summary of Maturities of Operating And Finance Lease Liabilities Under Noncancelable Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails",
     "longName": "9955536 - Disclosure - Income Taxes - Summary of Income Tax Expense (Details)",
     "shortName": "Income Taxes - Summary of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails",
     "longName": "9955537 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)",
     "shortName": "Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails",
     "longName": "9955538 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955539 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails",
     "longName": "9955540 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9955541 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.schrodinger.com/role/StockholdersEquityDetails",
     "longName": "9955542 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-177",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-177",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "9955543 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails",
     "longName": "9955544 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails",
     "longName": "9955545 - Disclosure - Stock-Based Compensation - Stock Activity (Details)",
     "shortName": "Stock-Based Compensation - Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-199",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails",
     "longName": "9955546 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)",
     "shortName": "Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails",
     "longName": "9955547 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails",
     "longName": "9955548 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)",
     "shortName": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails",
     "longName": "9955549 - Disclosure - Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)",
     "shortName": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.schrodinger.com/role/EquityInvestmentsDetails",
     "longName": "9955550 - Disclosure - Equity Investments (Details)",
     "shortName": "Equity Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.schrodinger.com/role/EmployeeBenefitPlanDetails",
     "longName": "9955551 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955552 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-255",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.schrodinger.com/role/SegmentReportingAdditionalInformationDetails",
     "longName": "9955553 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails",
     "longName": "9955554 - Disclosure - Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)",
     "shortName": "Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-274",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails",
     "longName": "9955555 - Disclosure - Segment Reporting - Schedule of Revenues by Geographic Area (Details)",
     "shortName": "Segment Reporting - Schedule of Revenues by Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-280",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sdgr-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sdgr_APACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "APACMember",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APAC",
        "label": "APAC [Member]",
        "documentation": "APAC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r858"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $210 and $220",
        "verboseLabel": "Net receivables",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll, taxes, and benefits",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r139",
      "r637"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r74",
      "r147",
      "r632",
      "r679",
      "r680"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r16",
      "r497",
      "r500",
      "r547",
      "r675",
      "r676",
      "r1029",
      "r1030",
      "r1031",
      "r1039",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1122",
      "r1179"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r398"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdrMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADR",
        "label": "ADR [Member]",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r913",
      "r924",
      "r934",
      "r967"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "AgreementWithGatesVenturesLimitedLiabilityCompanyMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Gates Ventures, LLC",
        "label": "Agreement With Gates Ventures Limited Liability Company [Member]",
        "documentation": "Agreement with Gates Ventures, Limited Liability Company."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_AjaxTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "AjaxTherapeuticsIncMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ajax Therapeutics, Inc",
        "label": "Ajax Therapeutics Inc [Member]",
        "documentation": "Ajax Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r959",
      "r968",
      "r972",
      "r980"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r440"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts receivable",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r249",
      "r291"
     ]
    },
    "sdgr_AllowanceForUnbilledReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "AllowanceForUnbilledReceivablesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for unbilled receivable",
        "label": "Allowance For Unbilled Receivables Current",
        "documentation": "Allowance for unbilled receivables current."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_AmericanDepositorySharesPurchasedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "AmericanDepositorySharesPurchasedPricePerShare",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in USD per share)",
        "label": "American Depository Shares Purchased, Price Per Share",
        "documentation": "American Depository Shares Purchased, Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofPotentiallyDilutiveSecuritiesnotIncludedinDilutedPerShareCalculationsAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares subject to outstanding common stock options and unvested RSUs (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r115",
      "r142",
      "r172",
      "r210",
      "r218",
      "r236",
      "r240",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r490",
      "r494",
      "r531",
      "r627",
      "r732",
      "r817",
      "r818",
      "r858",
      "r887",
      "r1074",
      "r1075",
      "r1135"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r150",
      "r172",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r490",
      "r494",
      "r531",
      "r858",
      "r1074",
      "r1075",
      "r1135"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r509",
      "r845"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894",
      "r917"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894",
      "r917"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894",
      "r917"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "sdgr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Use of Estimates",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]",
        "documentation": "Basis of presentation and use of estimates."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_BillAndMelindaGatesFoundationTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "BillAndMelindaGatesFoundationTrustMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BMGFT",
        "label": "Bill And Melinda Gates Foundation Trust [Member]",
        "documentation": "Bill and Melinda gates foundation trust."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_BristolMyersSquibbMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "BristolMyersSquibbMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BMS",
        "label": "Bristol Myers Squibb [Member]",
        "documentation": "Bristol-Myers Squibb."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r88",
      "r89"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment in accounts payable",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Marketable Securities and Restricted Cash",
        "label": "Cash And Cash Equivalents And Marketable Securities And Restricted Cash Policy [Policy Text Block]",
        "documentation": "Cash and cash equivalents and marketable securities and restricted cash policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r137",
      "r803"
     ]
    },
    "sdgr_CashCashEquivalentsAndRestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CashCashEquivalentsAndRestrictedCashMember",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and restricted cash",
        "label": "Cash Cash Equivalents And Restricted Cash [Member]",
        "documentation": "Cash, cash equivalents and restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r169"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r85"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1145"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/Cover",
      "http://www.schrodinger.com/role/EquityInvestmentsDetails",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r144",
      "r145",
      "r146",
      "r172",
      "r196",
      "r200",
      "r202",
      "r204",
      "r212",
      "r213",
      "r287",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r342",
      "r343",
      "r347",
      "r350",
      "r357",
      "r531",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r741",
      "r763",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r1002",
      "r1035",
      "r1043"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r212",
      "r342",
      "r343",
      "r345",
      "r347",
      "r350",
      "r355",
      "r357",
      "r685",
      "r686",
      "r687",
      "r688",
      "r827",
      "r1002",
      "r1035"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "sdgr_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreement",
        "label": "Collaboration And License Agreement [Member]",
        "documentation": "Collaboration and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_CollaborativeAgreementNumberOfPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CollaborativeAgreementNumberOfPrograms",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of programs under agreement",
        "label": "Collaborative Agreement Number Of Programs",
        "documentation": "Collaborative agreement number of programs."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, term",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_CommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commission expense",
        "label": "Commission Expense",
        "documentation": "Commission expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommissionsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommissionsPolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commissions",
        "label": "Commissions, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 6)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r107",
      "r629",
      "r719"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r323",
      "r324",
      "r788",
      "r1068",
      "r1070"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.schrodinger.com/role/Cover",
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r878",
      "r879",
      "r881",
      "r882",
      "r883",
      "r884",
      "r1039",
      "r1040",
      "r1042",
      "r1122",
      "r1177",
      "r1179"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r720"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r720",
      "r738",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r631",
      "r858"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r154",
      "r156",
      "r162",
      "r623",
      "r645",
      "r646"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive (Loss) Income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r247",
      "r787"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r247",
      "r682",
      "r787"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r247",
      "r787",
      "r1010"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r121"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r247"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r247",
      "r787"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r809"
     ]
    },
    "sdgr_ContractAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ContractAssetsMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Assets",
        "label": "Contract Assets [Member]",
        "documentation": "Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Balances",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r361",
      "r373"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r373"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r373"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, long-term",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r373"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "sdgr_ContractWithCustomerNumberOfNeurologyTargetRemaining": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ContractWithCustomerNumberOfNeurologyTargetRemaining",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of neurology targets remaining",
        "label": "Contract With Customer, Number Of Neurology Target Remaining",
        "documentation": "Contract With Customer, Number Of Neurology Target Remaining"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_ContractWithCustomerNumberOfSpecifiedBiologicalTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ContractWithCustomerNumberOfSpecifiedBiologicalTargets",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of specified biological target",
        "label": "Contract With Customer, Number Of Specified Biological Targets",
        "documentation": "Contract With Customer, Number Of Specified Biological Targets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss, current",
        "label": "Contract with Customer, Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r362",
      "r373"
     ]
    },
    "sdgr_ContractWithCustomersPaymentTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ContractWithCustomersPaymentTerms",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customers, payment terms",
        "label": "Contract With Customers Payment Terms",
        "documentation": "Contract with customers, payment terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cost of revenues",
        "verboseLabel": "Total segment cost of revenues",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r172",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r531",
      "r817",
      "r1074"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues:",
        "verboseLabel": "Segment cost of revenues:",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r338",
      "r345",
      "r554",
      "r572",
      "r626",
      "r806",
      "r808"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1037",
      "r1117"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1037"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current income tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r1037"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1037",
      "r1117"
     ]
    },
    "sdgr_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B",
        "label": "Customer B [Member]",
        "documentation": "Customer B."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "CustomerCMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C",
        "label": "Customer C [Member]",
        "documentation": "Customer C."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r247"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902",
      "r991"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902",
      "r991"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r993"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r993"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r906",
      "r995"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r993"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r986"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r985"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r985"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r985"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r988"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r902",
      "r991"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r905",
      "r994"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r992"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1116"
     ]
    },
    "us-gaap_DeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income",
        "label": "Deferred Income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1146",
      "r1174"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred income tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r127",
      "r1037"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_DeferredRevenueAndCreditsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueAndCreditsCurrentAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, short-term:",
        "label": "Deferred Revenue, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueAndCreditsNoncurrentAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, long-term:",
        "label": "Deferred Revenue, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "sdgr_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets Lease Liabilities",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "sdgr_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards, research, not subject to expiration",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Not Subject To Expiration",
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Research, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities Depreciation And Amortization",
        "documentation": "Deferred tax liabilities, depreciation and amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofTaxEffectsofTemporaryDifferencesthatGiveRisetoSignificantPortionsofDeferredIncomeTaxAssetsandDeferredIncomeTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain on equity investments",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.schrodinger.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discretionary matching contributions",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.schrodinger.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discretionary matching contributed by employees",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r210",
      "r223",
      "r240",
      "r817",
      "r818"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1178"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r401",
      "r432",
      "r433",
      "r435",
      "r839"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894",
      "r917"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894",
      "r917",
      "r960"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document And Entity Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document And Entity Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "sdgr_DrugDiscoveryContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DrugDiscoveryContributionMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug discovery contribution",
        "label": "Drug Discovery Contribution [Member]",
        "documentation": "Drug discovery contribution."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_DrugDiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DrugDiscoveryMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug discovery",
        "label": "Drug Discovery [Member]",
        "documentation": "Drug discovery."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_DrugDiscoverySegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DrugDiscoverySegmentMember",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug discovery",
        "label": "Drug Discovery Segment [Member]",
        "documentation": "Drug Discovery Segment."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_DrugDiscoveryServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "DrugDiscoveryServicesMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Discovery Services",
        "label": "Drug Discovery Services [Member]",
        "documentation": "Drug discovery member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_EMEAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EMEAMember",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMEA",
        "label": "EMEA [Member]",
        "documentation": "Regions of Europe, Middle East and Africa."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1182",
      "r1183",
      "r1184"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share attributable to common and limited common stockholders, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r194",
      "r196",
      "r202",
      "r203",
      "r204",
      "r209",
      "r484",
      "r487",
      "r505",
      "r506",
      "r624",
      "r647",
      "r810"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share of common and limited common stockholders, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r196",
      "r202",
      "r203",
      "r204",
      "r209",
      "r484",
      "r487",
      "r505",
      "r506",
      "r624",
      "r647",
      "r810"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r206"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r205",
      "r207",
      "r208"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r842"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r449",
      "r474",
      "r842"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r842",
      "r1038",
      "r1108"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1038",
      "r1108",
      "r1110"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1038",
      "r1108",
      "r1109"
     ]
    },
    "sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return-to-provision adjustments",
        "label": "Effective Income Tax Rate Reconciliation Return To Provision Adjustments",
        "documentation": "Effective income tax rate reconciliation return-to-provision adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationSection162Limitation",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 162(m) limitation",
        "label": "Effective Income Tax Rate Reconciliation Section162 Limitation",
        "documentation": "Effective income tax rate reconciliation, section 162 limitation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefits",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r842",
      "r1038",
      "r1108"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax contingencies, net of reversals",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r842",
      "r1038",
      "r1108"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseApplicableStatutoryIncomeTaxRatestoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1038",
      "r1108",
      "r1110"
     ]
    },
    "sdgr_EligiblePerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "EligiblePerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible Performance Based Restricted Stock Units",
        "label": "Eligible Performance Based Restricted Stock Units [Member]",
        "documentation": "Eligible Performance Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]",
        "verboseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost expected to be recognized over a weighted average period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to vested stock options granted",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to unvested stock options granted",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r132",
      "r158",
      "r159",
      "r160",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r192",
      "r211",
      "r289",
      "r290",
      "r316",
      "r358",
      "r472",
      "r473",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r540",
      "r547",
      "r643",
      "r675",
      "r676",
      "r677",
      "r695",
      "r763"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r286",
      "r480",
      "r1003",
      "r1004",
      "r1005",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r228",
      "r240",
      "r282",
      "r1023",
      "r1062"
     ]
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r285",
      "r288",
      "r1005"
     ]
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsMember",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity investments",
        "label": "Equity Method Investments [Member]",
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r54",
      "r284"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r530",
      "r804"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/EquityInvestmentsDetails",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "verboseLabel": "Mark-to-market gain (loss)",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r1061"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Realized gain",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r648",
      "r1061"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r1061"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable equity security",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r918",
      "r928",
      "r961"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r848"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r523",
      "r848"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r521",
      "r522",
      "r524",
      "r559",
      "r560",
      "r561",
      "r825",
      "r826",
      "r835",
      "r836",
      "r837",
      "r845",
      "r850"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r519",
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r621",
      "r845",
      "r851"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r379",
      "r384",
      "r509",
      "r522",
      "r559",
      "r835",
      "r836",
      "r837",
      "r845"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r379",
      "r384",
      "r509",
      "r510",
      "r522",
      "r560",
      "r825",
      "r826",
      "r835",
      "r836",
      "r837",
      "r845"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r509",
      "r510",
      "r511",
      "r512",
      "r522",
      "r561",
      "r825",
      "r826",
      "r835",
      "r836",
      "r837",
      "r845",
      "r850"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers out of Level 3 to level 1",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r523",
      "r848"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r521",
      "r522",
      "r524",
      "r559",
      "r560",
      "r561",
      "r825",
      "r826",
      "r835",
      "r836",
      "r837",
      "r845",
      "r850"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "sdgr_FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Finance And Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Finance And Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r545"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset - finance leases",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r340",
      "r355",
      "r502",
      "r529",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r644",
      "r823",
      "r845",
      "r848",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r859",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1123",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r968"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r968"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r968"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r968"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r968"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "sdgr_GatesVenturesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "GatesVenturesLLCMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gates Ventures, LLC",
        "label": "Gates Ventures, LLC [Member]",
        "documentation": "Gates Ventures, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "negatedLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r743"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r303",
      "r622",
      "r818",
      "r824",
      "r847",
      "r858",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r314",
      "r824"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r304",
      "r310",
      "r314",
      "r824",
      "r847"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "terseLabel": "Total segment gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r114",
      "r172",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r531",
      "r812",
      "r817",
      "r1045",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1074"
     ]
    },
    "us-gaap_GrossProfitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfitAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment gross profit:",
        "label": "Gross Profit [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_HostedSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "HostedSoftwareMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hosted software",
        "label": "Hosted Software [Member]",
        "documentation": "Hosted software."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894",
      "r917"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r95",
      "r846"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting for the Impairment of Long Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r448"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r110",
      "r114",
      "r625",
      "r640",
      "r812",
      "r817",
      "r1045",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r448"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesbyTaxJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r651",
      "r812",
      "r1045",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on equity investments",
        "negatedLabel": "Gain on equity investments",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r77",
      "r109",
      "r210",
      "r225",
      "r240",
      "r282",
      "r639"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r514",
      "r518",
      "r523",
      "r672",
      "r674",
      "r748",
      "r800",
      "r849",
      "r1147"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r514",
      "r518",
      "r523",
      "r672",
      "r674",
      "r748",
      "r800",
      "r849",
      "r1147"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r449",
      "r450",
      "r458",
      "r469",
      "r842",
      "r1113"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r449",
      "r450",
      "r458",
      "r469",
      "r842",
      "r1113"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r443",
      "r449",
      "r455",
      "r456",
      "r457",
      "r462",
      "r467",
      "r475",
      "r477",
      "r478",
      "r479",
      "r690",
      "r842"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/IncomeTaxesSummaryofIncomeTaxExpenseDetails",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r128",
      "r191",
      "r192",
      "r210",
      "r226",
      "r240",
      "r447",
      "r449",
      "r476",
      "r652",
      "r842"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r445",
      "r446",
      "r462",
      "r463",
      "r466",
      "r470",
      "r684"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r842",
      "r1108"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r168",
      "r468",
      "r469"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r1033"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll, taxes, and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair value",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r164"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase) decrease in assets, net of acquisition:",
        "label": "Increase (Decrease) in Operating Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities - operating leases",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1012",
      "r1033"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in liabilities, net of acquisition:",
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reduction in the carrying amount of right of use assets - operating leases",
        "label": "Increase Decrease In Reduction In The Carrying Amount Of Right Of Use Assets, Operating",
        "documentation": "Increase (decrease) in reduction in the carrying amount of right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "IncreaseDecreaseInUnbilledAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unbilled and other receivables",
        "label": "Increase Decrease In Unbilled And Other Receivables",
        "documentation": "Increase decrease in unbilled and other receivables."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_IncreaseInRightOfUseAssetsDueToContingencyResolution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "IncreaseInRightOfUseAssetsDueToContingencyResolution",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in right of use assets due to contingency resolution",
        "label": "Increase In Right Of Use Assets Due To Contingency Resolution",
        "documentation": "Increase In Right Of Use Assets Due To Contingency Resolution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r204",
      "r400"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r959",
      "r968",
      "r972",
      "r980"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r984"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r984"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r984"
     ]
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest costs capitalized",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "sdgr_InvestmentAmortizationNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "InvestmentAmortizationNoncashExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Noncash investment (accretion) amortization",
        "label": "Investment Amortization Noncash Expense",
        "documentation": "Investment Amortization Noncash Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_July2024AgreementWithBillMelindaGatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "July2024AgreementWithBillMelindaGatesFoundationMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2024 Agreement With Bill &amp; Melinda Gates Foundation",
        "label": "July 2024 Agreement With Bill &amp; Melinda Gates Foundation [Member]",
        "documentation": "July 2024 Agreement With Gates Ventures Limited Liability Company"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_KarenAkinsanyaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "KarenAkinsanyaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Karen Akinsanya [Member]",
        "documentation": "Karen Akinsanya"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Lab Equipment [Member]",
        "documentation": "Lab Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r857"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Operating Leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r546"
     ]
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid, After Year Five",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid, After Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Five",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Five"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Four",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year One",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Three",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails_1": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Two",
        "documentation": "Lessee, Operating And Finance Lease, Liability, To Be Paid, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Lessee, Operating And Finance Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r172",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r491",
      "r494",
      "r495",
      "r531",
      "r718",
      "r811",
      "r887",
      "r1074",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r108",
      "r634",
      "r858",
      "r1036",
      "r1063",
      "r1131"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r136",
      "r172",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r491",
      "r494",
      "r495",
      "r531",
      "r858",
      "r1074",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_LimitedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "LimitedCommonStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.schrodinger.com/role/Cover",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limited common stock",
        "label": "Limited Common Stock [Member]",
        "documentation": "Limited common stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaintenanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaintenanceMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software maintenance",
        "label": "Maintenance [Member]",
        "documentation": "Process of preserving asset, including, but not limited to, building, machinery and software."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r830",
      "r869",
      "r874",
      "r1079",
      "r1146",
      "r1148",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails",
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r395",
      "r441",
      "r512",
      "r588",
      "r671",
      "r673",
      "r681",
      "r710",
      "r711",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r798",
      "r799",
      "r822",
      "r827",
      "r838",
      "r850",
      "r851",
      "r855",
      "r856",
      "r870",
      "r1076",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of stock options must be granted at exercise price of fair market value",
        "label": "Maximum Percentage Of Stock Options Must Be Granted At Exercise Price Of Fair Market Value",
        "documentation": "Maximum percentage of stock options must be granted at exercise price of fair market value."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "sdgr_MilestonePaymentYetToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "MilestonePaymentYetToBeAchieved",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment yet to be achieved",
        "label": "Milestone Payment Yet To Be Achieved",
        "documentation": "Milestone payment yet to be achieved."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r395",
      "r441",
      "r512",
      "r588",
      "r671",
      "r673",
      "r681",
      "r710",
      "r711",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r798",
      "r799",
      "r822",
      "r827",
      "r838",
      "r850",
      "r851",
      "r855",
      "r870",
      "r1076",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "sdgr_MorphicHoldingIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "MorphicHoldingIncMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Morphic Holding, Inc.",
        "label": "Morphic Holding Inc [Member]",
        "documentation": "Morphic holding Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r830",
      "r869",
      "r874",
      "r1079",
      "r1146",
      "r1148",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net (loss) income attributable to common and limited common stockholders",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r87",
      "r111",
      "r134",
      "r153",
      "r155",
      "r160",
      "r172",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r201",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r484",
      "r487",
      "r506",
      "r531",
      "r642",
      "r740",
      "r761",
      "r762",
      "r885",
      "r1074"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NimbusTherapeuticsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NimbusTherapeuticsLLCMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Nimbus Therapeutics, LLC",
        "label": "Nimbus Therapeutics L L C [Member]",
        "documentation": "Nimbus Therapeutics LLC."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r914",
      "r925",
      "r935",
      "r959",
      "r968"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of World",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1182",
      "r1183",
      "r1184"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment in accrued liabilities",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "sdgr_NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of right of use assets in exchange for lease liabilities - finance leases",
        "label": "Noncash or Part Noncash Acquisition, Operating Lease Acquired",
        "documentation": "Noncash or Part Noncash Acquisition, Operating Lease Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of lease liabilities - operating leases",
        "label": "Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Finance Lease, For Lease Liabilities",
        "documentation": "Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Finance Lease, For Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of right of use assets - operating leases, contingency resolution",
        "label": "Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Lease, Contingency Resolution",
        "documentation": "Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Lease, Contingency Resolution"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of right of use assets - operating leases",
        "label": "Noncash Or Part Noncash Acquisitions Of Right Of Use Assets, Operating Leases",
        "documentation": "Noncash Or part noncash acquisitions of right of use assets in exchange for lease obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reclassification of non-controlling interest",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NovartisPharmaAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NovartisPharmaAGMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Pharma AG",
        "label": "Novartis Pharma AG [Member]",
        "documentation": "Novartis Pharma AG"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations",
        "documentation": "Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NumberOfPreferredSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NumberOfPreferredSharesPurchased",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of preferred shares purchased",
        "label": "Number Of Preferred Shares Purchased",
        "documentation": "Number of preferred shares purchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r821",
      "r1046"
     ]
    },
    "sdgr_NumberOfSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NumberOfSharesPurchased",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares purchased",
        "label": "Number Of Shares Purchased",
        "documentation": "Number Of Shares Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_NumberOfVotesForCommonShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "NumberOfVotesForCommonShare",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes for common share",
        "label": "Number Of Votes For Common Share",
        "documentation": "Number of votes for common share."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_OnPremiseSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "OnPremiseSoftwareMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "On-premise software",
        "label": "On Premise Software [Member]",
        "documentation": "On premise software."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_OncologyNeurologyAndImmunologyProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "OncologyNeurologyAndImmunologyProductMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oncology, Neurology, and Immunology Product",
        "label": "Oncology, Neurology, And Immunology Product [Member]",
        "documentation": "Oncology, Neurology, And Immunology Product"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_OperatingAndFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "OperatingAndFinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "sdgr_LesseeOperatingAndFinanceLeaseLiabilityToBePaid",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of future minimum lease payments",
        "label": "Operating And Finance Lease, Liability",
        "documentation": "Operating And Finance Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "sdgr_OperatingAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: current portion of lease payments",
        "label": "Operating And Finance Lease, Liability, Current",
        "documentation": "Operating And Finance Lease, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "sdgr_OperatingAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, long-term",
        "label": "Operating And Finance Lease, Liability, Noncurrent",
        "documentation": "Operating And Finance Lease, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_OperatingAndFinanceLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "OperatingAndFinanceLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for leases",
        "label": "Operating And Finance Lease, Payments",
        "documentation": "Operating And Finance Lease, Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r812",
      "r1045",
      "r1047",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/CommitmentsAndContingenciesSummaryofMaturitiesofOperatingAndFinanceLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031:",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities - operating leases",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities - operating leases, long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets - operating leases",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in market value of investments, net of tax:",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "verboseLabel": "Change in unrealized loss on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r280"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, long-term",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r966"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r926",
      "r936",
      "r969"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r915",
      "r926",
      "r936",
      "r969"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of offering costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition, net of acquired cash",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of equity investments",
        "terseLabel": "Cash payments to purchase of shares",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments to purchase of shares",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r164"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r837"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "sdgr_PercentageOfVotingSecurities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "PercentageOfVotingSecurities",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting securities",
        "label": "Percentage Of Voting Securities",
        "documentation": "Percentage of voting securities."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_PerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Based Restricted Stock Units",
        "label": "Performance Based Restricted Stock Units [Member]",
        "documentation": "Performance Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_PerformanceRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "PerformanceRestrictedStockUnitsMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Units",
        "label": "Performance Restricted Stock Units [Member]",
        "documentation": "Performance Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r720"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r720",
      "r738",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at December\u00a031, 2024 and December\u00a031, 2023, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r630",
      "r858"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r300",
      "r301",
      "r805"
     ]
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution from equity investment",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r1032"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in ATM offering",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock upon stock option exercises",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturity of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposition and sale of equity investments",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity securities",
        "label": "Proceeds from Sale of Equity Securities, FV-NI",
        "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r164"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock upon stock option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r590",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r801",
      "r828",
      "r868",
      "r870",
      "r871",
      "r875",
      "r876",
      "r1071",
      "r1072",
      "r1079",
      "r1146",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r590",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r801",
      "r828",
      "r868",
      "r870",
      "r871",
      "r875",
      "r876",
      "r1071",
      "r1072",
      "r1079",
      "r1146",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "sdgr_ProfessionalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ProfessionalServicesMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Professional Services [Member]",
        "documentation": "Professional services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r153",
      "r155",
      "r165",
      "r172",
      "r182",
      "r188",
      "r191",
      "r192",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r484",
      "r487",
      "r489",
      "r492",
      "r493",
      "r506",
      "r531",
      "r625",
      "r641",
      "r694",
      "r740",
      "r761",
      "r762",
      "r843",
      "r844",
      "r886",
      "r1031",
      "r1074"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1066"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1024",
      "r1067"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r546"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r122",
      "r125",
      "r126"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r138",
      "r638"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r122",
      "r125",
      "r636"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r546"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives of assets",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails",
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r377",
      "r395",
      "r427",
      "r428",
      "r429",
      "r441",
      "r512",
      "r562",
      "r571",
      "r588",
      "r671",
      "r673",
      "r681",
      "r710",
      "r711",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r798",
      "r799",
      "r822",
      "r827",
      "r838",
      "r850",
      "r851",
      "r855",
      "r856",
      "r870",
      "r879",
      "r1069",
      "r1076",
      "r1127",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails",
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r377",
      "r395",
      "r427",
      "r428",
      "r429",
      "r441",
      "r512",
      "r562",
      "r571",
      "r588",
      "r671",
      "r673",
      "r681",
      "r710",
      "r711",
      "r771",
      "r773",
      "r775",
      "r776",
      "r778",
      "r798",
      "r799",
      "r822",
      "r827",
      "r838",
      "r850",
      "r851",
      "r855",
      "r856",
      "r870",
      "r879",
      "r1069",
      "r1076",
      "r1127",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r918",
      "r928",
      "r961"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r386",
      "r551",
      "r552",
      "r628",
      "r635",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r737",
      "r739",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r551",
      "r552",
      "r553",
      "r554",
      "r628",
      "r635",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r737",
      "r739",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions amount",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r551"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r744",
      "r745",
      "r748"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r386",
      "r551",
      "r552",
      "r628",
      "r635",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r737",
      "r739",
      "r770",
      "r1134"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r552",
      "r555",
      "r691",
      "r692",
      "r693",
      "r746",
      "r747",
      "r748",
      "r767",
      "r769"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r338",
      "r345",
      "r554",
      "r572",
      "r626",
      "r807",
      "r808"
     ]
    },
    "sdgr_ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development and Advertising",
        "label": "Research And Development And Advertising Policy [Policy Text Block]",
        "documentation": "Research and development and advertising policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "negatedLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r800",
      "r817",
      "r1143"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_ResearchCollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research, Collaboration and License Agreement",
        "label": "Research, Collaboration and License Agreement [Member]",
        "documentation": "Research, Collaboration and License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r919",
      "r929",
      "r962"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r920",
      "r930",
      "r963"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r916",
      "r927",
      "r937",
      "r970"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1034"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r101",
      "r633",
      "r678",
      "r680",
      "r689",
      "r721",
      "r858"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r192",
      "r289",
      "r290",
      "r316",
      "r472",
      "r473",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r496",
      "r498",
      "r499",
      "r501",
      "r504",
      "r539",
      "r540",
      "r675",
      "r677",
      "r695",
      "r1179"
     ]
    },
    "sdgr_RevenueArrangementsContractTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RevenueArrangementsContractTerm",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract term for software arrangements",
        "label": "Revenue Arrangements, Contract Term",
        "documentation": "Revenue Arrangements, Contract Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RevenueFromContractWithCustomerBeforeSoftwareContributionMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contracts with customers",
        "label": "Revenue From Contract With Customer Before Software Contribution [Member]",
        "documentation": "Revenue from contract with customer before software contribution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from contracts with customers",
        "terseLabel": "Drug discovery services revenue from contracts with customers",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r210",
      "r219",
      "r220",
      "r234",
      "r240",
      "r243",
      "r245",
      "r247",
      "r371",
      "r372",
      "r590"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r375"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Software contribution",
        "terseLabel": "Drug discovery contribution",
        "label": "Revenue Not from Contract with Customer",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "sdgr_RevenueRecognizedForMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RevenueRecognizedForMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized with milestones",
        "label": "Revenue Recognized For Milestone Payment",
        "documentation": "Revenue recognized for milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsatisfied performance obligation",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionDrugDiscoveryDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Timing of Revenue Recognition",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenue expected to be recognized",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "sdgr_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration, commercial milestones, amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestones, Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration, Commercial Milestones, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research, development and regulatory milestones, amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration, Research, Development and Regulatory Milestones, Amount",
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration, Research, Development and Regulatory Milestones, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofDrugRevenueRecognitionDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenues",
        "totalLabel": "Total software revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r161",
      "r172",
      "r210",
      "r219",
      "r220",
      "r234",
      "r240",
      "r243",
      "r245",
      "r247",
      "r287",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r531",
      "r625",
      "r817",
      "r1074"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues From External Customers And Long Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RightToExchangeEachShareOfLimitedCommonStockToCommonStock",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right to exchange limited common stock to common stock, share",
        "label": "Right To Exchange Each Share Of Limited Common Stock To Common Stock",
        "documentation": "Right to exchange each share of limited common stock to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_RobertAbelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RobertAbelMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert Abel [Member]",
        "documentation": "Robert Abel"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_RoyaltiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "RoyaltiesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalties Policy [Policy Text Block]",
        "documentation": "Royalties policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty expense",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SaleOfStockRemainingValueOfSharesAvailableForIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SaleOfStockRemainingValueOfSharesAvailableForIssuance",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available to issue in transaction",
        "label": "Sale of Stock, Remaining Value Of Shares Available For Issuance",
        "documentation": "Sale of Stock, Remaining Value Of Shares Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r1009"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r842",
      "r1108"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Classification of Stock Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r286",
      "r480",
      "r1003",
      "r1004",
      "r1005",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Equity Method Investments [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r172",
      "r283",
      "r284",
      "r286",
      "r287",
      "r531"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of (Loss) Income Before Income Taxes by Tax Jurisdiction",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.schrodinger.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r546"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r744",
      "r745",
      "r748"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Information with Respect to Reportable Segments",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r399",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r103"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted Average Valuation Assumptions Used for Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock unit activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r97",
      "r99",
      "r100",
      "r101",
      "r144",
      "r145",
      "r146",
      "r212",
      "r342",
      "r343",
      "r345",
      "r347",
      "r350",
      "r355",
      "r357",
      "r685",
      "r686",
      "r687",
      "r688",
      "r827",
      "r1002",
      "r1035"
     ]
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r841"
     ]
    },
    "us-gaap_SecuritiesAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuritiesAssetsMember",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3InvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Securities (Assets) [Member]",
        "documentation": "A share, participation, or other interest in property or in an enterprise of the issuer or an obligation of the issuer that (a) either is represented by an instrument issued in bearer or registered form or, if not represented by an instrument, is registered in books maintained to record transfers by or on behalf of the issuer, (b) is of a type commonly dealt in on securities exchanges or markets or, when represented by an instrument, is commonly recognized in any area in which it is issued or dealt in as a medium for investment, and (c) either is one of a class or series or by its terms is divisible into a class or series of shares, participations, interest, or obligations."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r210",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r247",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r321",
      "r322",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r814",
      "r817",
      "r818",
      "r824",
      "r873",
      "r1146",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r707",
      "r708",
      "r709",
      "r772",
      "r774",
      "r777",
      "r779",
      "r786",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r802",
      "r829",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r872",
      "r879",
      "r1079",
      "r1146",
      "r1148",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r210",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r230",
      "r232",
      "r233",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r813",
      "r815",
      "r816",
      "r817",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationRevenueAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment revenues:",
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "negatedLabel": "Sales and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofClassificationofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B preferred stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028",
      "r1077"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C preferred stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1028",
      "r1077"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement percent",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Achievement Percent",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Achievement Percent"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share-based compensation arrangement by share-based payment award, aggregate intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity award conversion rate to shares (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Award Conversion Upon Achievement, Number Of Shares Per Award",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Award Conversion Upon Achievement, Number Of Shares Per Award"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible to vest (in shares)",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Eligible To Vest, Number",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Eligible To Vest, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares forfeited (in shares)",
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSU's not vested during period (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSU's vested during period (in shares)",
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation assumptions",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r399",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, December 31, 2021 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, December 31, 2021 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average per share grant date fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance, December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning, January 1, 2023 (in shares)",
        "periodEndLabel": "Ending, December 31, 2023 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning, January 1, 2023 (in USD per share)",
        "periodEndLabel": "Balance, December 31, 2023 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based compensation arrangement by share-based payment award, weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r405",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r436",
      "r437",
      "r438",
      "r439"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted, contractual term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationSummaryofWeightedAverageValuationAssumptionsUsedforOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance, December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected to be recognized over a weighted average period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SharebasedCompensationAwardTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SharebasedCompensationAwardTrancheFourMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Four",
        "label": "Sharebased Compensation Award Tranche Four [Member]",
        "documentation": "Share-based compensation award tranche four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "documentation": "Significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]",
        "documentation": "Significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r170"
     ]
    },
    "sdgr_SoftwareAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareAgreementMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software Agreement",
        "label": "Software Agreement [Member]",
        "documentation": "Software Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SoftwareContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareContributionMember",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software contribution",
        "label": "Software Contribution [Member]",
        "documentation": "Software contribution."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SoftwareContributionRevenueRecognitionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareContributionRevenueRecognitionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software contribution revenue recognition amount",
        "label": "Software Contribution Revenue Recognition Amount",
        "documentation": "Software contribution revenue recognition amount."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SoftwareContributionRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareContributionRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/RelatedPartyTransactionsDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software contribution revenue recognition",
        "label": "Software Contribution Revenue Recognized",
        "documentation": "Software contribution revenue recognized."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SoftwareDevelopmentCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareDevelopmentCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software Development Costs",
        "label": "Software Development Costs Policy [Policy Text Block]",
        "documentation": "Software development costs policy."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SoftwareProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareProductsAndServicesMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofContractBalancesDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofRevenueRecognizedfromtheSourcesofSoftwareProductsandServicesRevenueDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software products and services",
        "label": "Software Products And Services [Member]",
        "documentation": "Software products and services."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_SoftwareSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "SoftwareSegmentMember",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software Segment [Member]",
        "documentation": "Software Segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StandardProductWarrantyPolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warranties",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r133",
      "r210",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r247",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r814",
      "r817",
      "r818",
      "r824",
      "r873",
      "r1146",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/Cover",
      "http://www.schrodinger.com/role/EquityInvestmentsDetails",
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r144",
      "r145",
      "r146",
      "r172",
      "r196",
      "r200",
      "r202",
      "r204",
      "r212",
      "r213",
      "r287",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r342",
      "r343",
      "r347",
      "r350",
      "r357",
      "r531",
      "r685",
      "r686",
      "r687",
      "r688",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r720",
      "r741",
      "r763",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r1002",
      "r1035",
      "r1043"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r71",
      "r72",
      "r132",
      "r158",
      "r159",
      "r160",
      "r179",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r192",
      "r211",
      "r289",
      "r290",
      "r316",
      "r358",
      "r472",
      "r473",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r540",
      "r547",
      "r643",
      "r675",
      "r676",
      "r677",
      "r695",
      "r763"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r707",
      "r708",
      "r709",
      "r772",
      "r774",
      "r777",
      "r779",
      "r786",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r802",
      "r829",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r872",
      "r879",
      "r1079",
      "r1146",
      "r1148",
      "r1149",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r211",
      "r540",
      "r590",
      "r683",
      "r706",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r742",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r763",
      "r880"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r211",
      "r248",
      "r540",
      "r590",
      "r683",
      "r706",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r742",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r763",
      "r880"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in ATM offering, net (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101",
      "r685",
      "r763",
      "r781"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of RSUs and PRSUs (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.schrodinger.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock upon stock option exercises (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101",
      "r411"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in ATM offering, net",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r101",
      "r695",
      "r763",
      "r781",
      "r886"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of RSUs and PRSUs",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r101"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuances of common stock upon stock option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r71",
      "r72",
      "r101"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r92",
      "r722",
      "r738",
      "r764",
      "r765",
      "r858",
      "r887",
      "r1036",
      "r1063",
      "r1131",
      "r1179"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r171",
      "r341",
      "r343",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r358",
      "r503",
      "r766",
      "r768",
      "r785"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "sdgr_StructureTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "StructureTherapeuticsMember",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Structure Therapeutics",
        "label": "Structure Therapeutics [Member]",
        "documentation": "Structure therapeutics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow and noncash information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "sdgr_TheATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "TheATMMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The ATM",
        "label": "The ATM [Member]",
        "documentation": "The ATM"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_TimingOfRevenueRecognitionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "TimingOfRevenueRecognitionPercentage",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of revenue recognition",
        "label": "Timing Of Revenue Recognition Percentage",
        "documentation": "Timing of revenue recognition, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r1079"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r1079"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.schrodinger.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.schrodinger.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Point in Time",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionScheduleofTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.schrodinger.com/role/EquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r340",
      "r355",
      "r502",
      "r529",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r644",
      "r845",
      "r848",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r859",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1123",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "sdgr_TwentyTwentyStockPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "TwentyTwentyStockPlanMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Twenty Twenty Stock Plan",
        "label": "Twenty Twenty Stock Plan [Member]",
        "documentation": "Twenty twenty stock plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.schrodinger.com/role/RevenueRecognitionCollaborationandLicenseAgreementDetails",
      "http://www.schrodinger.com/role/RevenueRecognitionSoftwareProductsandServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingScheduleofRevenuesbyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_UnallocatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "UnallocatedAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/SegmentReportingSummaryofFinancialInformationwithRespecttoReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unallocated (expense) income:",
        "label": "Unallocated [Abstract]",
        "documentation": "Unallocated."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_UnallocatedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "UnallocatedCommonStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets",
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Unallocated Common Stock [Member]",
        "documentation": "Unallocated common stock."
       }
      }
     },
     "auth_ref": []
    },
    "sdgr_UnbilledAndOtherReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "UnbilledAndOtherReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled and other receivables, net of allowance for unbilled receivables of $100 and $100",
        "label": "Unbilled And Other Receivables Current",
        "documentation": "Unbilled and other receivables current."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, January 1",
        "periodEndLabel": "Balance, December 31",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r459",
      "r841"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions for tax positions taken in prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r841"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions related to the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r841"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.schrodinger.com/role/IncomeTaxesScheduleofReconciliationofTotalGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions taken in prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r841"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.schrodinger.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "sdgr_VotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.schrodinger.com/20241231",
     "localname": "VotingCommonStockMember",
     "presentation": [
      "http://www.schrodinger.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting Common Stock",
        "label": "Voting Common Stock [Member]",
        "documentation": "Voting common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)",
        "totalLabel": "Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.schrodinger.com/role/ConsolidatedStatementsofOperations",
      "http://www.schrodinger.com/role/NetLossIncomeperShareAttributabletoCommonandLimitedCommonStockholdersScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonandLimitedStockholdersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r204"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481913/940-20-25-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001490978-25-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001490978-25-000014-xbrl.zip
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MY$SNU=2%?]T=WZ0CN5=9]_UV^8R@#.8S$CQ^?QWQ(8^BU3K4-T3QTW^Q1]L
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MXYUWQ_OM?N^HO]^?\_#FK:,-\ND+F*J'JTEOXC,'//L07/O(^5<:B=@3A!4
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M0OBX$<)U$\)'NHKXL.F]*'LMZU'MOQ%K320$94 "%3[P]=]6_L Y'81IHJ?
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M Q_8<%&(YQ5AR):@4I$+C2F>QZ14A"IC0%9SFY0I&Y//C4X^=;UP-']V4-:
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M[>J+5MN_2N%"W$HLM5G]416P[&(B9'VQD*/$$%P2'+%Q"C=7D3"BHP()H"D
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M.'1%EHX88(N 3*V$PV%;1<E5&5Z&2 PD&\S_6.<NL-1.I5,:Y,URY?2O4?A
MW2$RG, D=7/'7H.KEBZ390^%&9CBK=8E2_W.F,["%P.3L;/;M\]RH:NY):6-
M+"W!0]'=^W.^19*B]Q)V1.!T"=FP.U!#+Y:V"EL-XZJY=;Z[0POMUVSL9<GZ
MW;U;>F2/#_J]:A_9_D'>MBK4M-YS4YE3^F'-[!)[*MY#&'VQQA?EBFS#XG36
MQ6]FZI_M<F%51BEA%YHJ\*8*_.NKP'7IPY+%4'#B<+=GZQ"3AJ"\B.H!SD")
M$5D'46B4!9ZKU-5X!KGIZ,MM8E4PZSD_] ]W#^8ZY=63X!A\4;(=:SP>:$Q3
MX'S";*MPG;^%/DJ5EG,9N+N4N57?M&27A5S2$PT<L2KW;0]#:21;:"2$/Q<$
M:DH4'75U][]B^2XL,/-#SGWA?!2^@@H[TT.B84'T:2N#X38MH#_L[9H*X=KJ
MH;640)TTTS7*:#4'1$WZ?*Z$M$P]=8)G5@]OG:JUSS5ZZ.[Z5> +LX1X5D:6
M2T;G$YRV:M1.,SKD67TMC;3'*7ZPR%SW^'+'U^3N"Z",N\XI]9_8+QIS:_$/
MV6;H*0]23YH4)HI+_8/V8-;6D%X#AE@"-EPCG\@R[U4 &VF.&_?O47Q08E &
MT7/=$T)-102AH]UD>D@.W5+;SS0U-^!J#D^8)FW9ZF&61M&2E9MJP!ZOJZ39
M#B?UHV1\$TV<(4P9ZO0!3QZXBD%I-Y67;_OF .L2.L+D 68S"ZQWL#"1S&@C
MO(DY[11XY-P;8/F65NJZ<\88&<;O,^@GK6*+IRR&42.O"B),=W$6(DO#-'"E
MB%$A>SMV9]5PZ#=6E8NQU9UA8#WF/6/M$,L10!KR5TM"6_A^%?9%H1@MR8\@
MGG= A.V +.MX4*VQ<8Z:(!^%Q^R7R_7*:BC/!1NF]TFJ'34<"2,*UBIMX6Y1
M%WL#8YRAE96G4S W)S,EU=7ZU%,RXUO/NGT(5MO/,X[X;7KVI@WP13UQ7*D4
MCR;PNHDCYX[#4\R 'BJ:&8J(/V!'VQ2[H6?2[Y)#>PD/).9$>"R';IN74]V^
M(;R?&B:5!9T5!%ZA&"[ S\PA7#+]MABFL7#_@CDG(,\O$<>0>RPKE3VUI1*N
M<X3P-LV(4+OLYJ@INZG 6IJRFQJ^PC<.^BAY^(4VRK=GAD3%T=E%<!^B-Y5'
M3X_!T."!TK'\4>E;7PPB%LWA66.J5Y!5ED.8]CB._R:IH$NBR,7:&8LDN[:%
MP&\^3FN@].DB@/AYC'0T*11RLR-GK>;N21[R$C1J">RG4HZZ:I?\1UE\DJ_Z
MA;T[5T2QGZF+MO)/I0#4 GN(&J_5/MMP]^HU[[GU9M)6,>9-=O.8\R\JEVHA
M;ILN?]-;:Z"YBX#6,JEL(7[CA]3H3OU7+I]*6@V8KV/#5JI8XS^3.>@2ZK-$
M&2>JHE6AZY,'(F3WP'ZF8!GKUMI8O=/"V#-87_J+A0UQ>F6M#+L\5_JL6M4D
M[&Z<2V?C,0#+C =4Q2_'P8(T5<UPA'T<2+<0*R4D+6F? VZ;>'@#C[<UL6,Y
M9E95<[OP-G@B9>0SNT>>$Y"0<'QE7%UE\*C9#O[, (4*4#:**8>8JAOX,V(#
M+&@P* ;YMY447S3-Y-0>DDGY.ALW&N^AW!I\4Y04Q-PS*E<ILA0H0?A5/%1]
M)T6FPA\.^++#9I5)/(S5V5[F*M&\8RNR)4,Z6SJQXST5C6BD=EU\HG:>13:9
M!WP81J9%B>8++!V8D1?A1J8\T"Q3"W2\6,RBRCNLJ1<FJ5U$Z\]0[\%A'A+T
M#$8LP,.(-4Z''&1  7C]9L^-1&@!UR-^JJ5!:,TR!40L9K];;K"!9V0F5O?E
M>%\EM*<A>H&Y R?'NR+G(K8IW01UD 8YE\!1>HZ"M97Y1>M0HM*Z/-)#C>PX
M:GY0#IXI"UPB'YA5)[B%H:J$AG[[,C52'""A5V_O@L[QZ3X/%5\P>Q M4*@2
MR'^%UU"A)'HNEK>E4?#T:(2I%=S7*UL8SJ7:K &FMR3VFLG4Z8FJ1! KU(H)
MT6V0 7<4ZLOF-I!TQ%FSD^E\:(WCW%LL9)GIAIUY.4I"'92-1-58R%FVM%ER
M%!<.S%ER,^0)6G96;R*90KZ%C*QX'/B11N1,,%T:4)ED%%!.4:H@ZNE2%3-H
MCD0$EBP+X#$*(T82L16[1B]SZ\.02@Y&N?@(0BQ"B]H:.*XFA>D=H\)[C;6\
MZ_P-+-%[G P\=RM,W^)3'@*RFNR0'NEVEL4GQQ(%()*R6Q:C:_T/9,6A!G@W
M(K .5*]*XEWG4W%ERN;#H"202>$<%'<5;05YR&*.=@%(U520QB^"W:@)-/1O
M.8X(@=K5G>:%^[(Q-S&\,"HSU>F7?_P@)3L!9QKAM",V#7VRSL.BS$&C#J]Z
MXFX@]5VP\SPJ<++'K&2FEM%/19MKD23%5Y8PU31#1P18WXK6S!Q+H,D6!F1F
M(D8;&$\B2&.RGH;:GC63.5 I+S?^:"$FV JWS"]J2R2>M*6?E"L:UU$!<$EU
MEB]C7>;"2LF'M;A,&@HM9X?0?-IJ/#AL]TZA'-OH7#U A(X26;1\JAI+0ZF_
M*""#H%*>\LXH22#K9]S,-);VBGPU-$F,1%GX8-6?H ;7YRI[R>$GGR!&1"^[
ML+#(B68\!!ULFA@H739+\*L1446=CO5[6*@K;1.*'K A<?Q,^M&8'Q7&+K40
M-&661")S>6B:Q:H$.8E2EXJ7=%FZ_MT$L2 &=C./+/5-E>R#XYZ$",GA\43Y
M VK>F86ZI'8^YH4-S6:@67Y'00K*:NT=O4*9L*8G>*T=&8Y/J31,O4%L*6B0
MB3BJ46:Y<Q23]HL)Q9!$4#XPF<0(5"*# SIFC^0AF#Z$*9,)#-S+-! 2J 7^
MEN$(72P-,D[VW3O2%:/!#3Q(YE6]02B7Z3XPXWWIHJ+R@MM-$+','"^ME12[
M(COG>!:GV@@UI\CLNW&"XV5,K6Q#6T>28T< >"0KYS5U8+(O,VS-0:&?G49;
MWNN3T9+0ZNIDM\P[+%-(1I\0=,Z ST*J8U;!+5,/D!4-RP =:-,:MHO1> 65
M"ZQ_$/4;)@+*LQ1X( 2^=3A@.>, =3$[FFM)/L=+)39#TS>"OXO$"-75LI-)
MIP3$/;=V3";2R0Y6-J8N\E=UWMG976ADM]3!#4$G*%=0 D(_=?X71JZ*Y1#Y
M5P 34.,HC0F,DV4=/T/E*8,))?!A61A R]:LR, .3\KWB>/,&9?]3P\H_/);
MQ518()RB)D!E!-_,V01D-4NV8CZ0 GXYB0U Q4AW4!26((%<N&G>,=,JC"+:
M!@/P#W.FK.E=,AJ[<  S6C]*DYBN3]4#99RH)WWAIJ_S19:PN/#J^<&A:\T-
M?8L_:RHB=$7$<5,148&U-!41-7R%-2LB&GVP&7WPQ,SG<+@T#VAJNK<V]T<V
M:!@LZIOA6:V!S)]F+0)ZX-_"-K?YR=?%O@2KH3L#PU@$P+W*P.MAJN:^K);B
M(3Q8:8(K%UM9!]M SM/8B<>8$X#M#Q\DX)WL"E/!DC!-P(_@LI-7H;YB7F,4
M,=.':T7@GXQ.6L19X"JJ].*\>V:B8?A###TA MT LQUS(TNS23UJX#S&C]ID
MQ>4[X<*Y<4&JTD7FK@@1'QUT@4'!]H1]T3ZEZ:4@CE!VO!E&:A*C-LJ$*<!>
MY'Y_%1,94TY,1DX<N;_LQ-XH:F/K7+>WU_W?47?W7]/1#KAPR2\[UX)<L+[\
M*&^ ]@Z.IH]OU9.4>8DVU3UZ^K#-ZGGT:/FU,K<.#CK31S3,:LS[5\M;BTSE
M.S4&A#JY;@<$3$FV;*BQ0@S%^$ 6V77F9B$N*)-7(>,8H=_Q3O#*5%O>PL$8
M./(UJW-X4LPM4%-*0#=^Y8M$+1?;$;<4DBZU3>?*EHQ8W*5*74ROFU7Z%3AC
M;%'#TLNQ!D,GF"K.OQ#Z=]92CIVWQ-*RW-(J>>.FJ"5_:RHDTTT%L]KVM-:2
M#5V[\*1\-L3@&"9'L1K2;KM4_<Z%(/,4L:<924N.5GE.OA:$G$[B4!ZKP)+9
M#(U<IS75'@/?QRQ7!XQ/17B_EJR&&)A!/(N< MVM1K7$K-"0FD6K,8VYL+ZU
M.0RO=QC^6Q:(E7L<+JG!F/.HC4/L^0.!_*3>K&#)XM@,74NKYD,N2#Y0@E85
MW"%SXH/:&L JXV@))X%Y!0F3@(>0+@4;QRJ;G)LX7TCWV(RLL^W;X T]81$J
M_!1,S"CPHRAB9&[9MGYC6;WB*<9)#\">'Q%!\(,6_^5B+%#N8+Y8SR0+9(64
M7666"MFW,*1Y" DP",$8RJ&-A(UH%[_K" NHHGL187<G^<.ZVP5KT?@$-1K5
MS2[I>,E-^\D[[!$'AL_:D2DAK?I@W5!6Q&0E]BWG2X"A T:(6D,2(>-P.I4Y
MU2(X0TN[[W-[D 99M8D(U*)E ZJJ'W[;'*O7.U:GJD;2N=8FRK4*;(1!I4X7
M0P"$V/G"9X7B!.K,\<47V[&1L<("EBGS7962UW4,*A:EJM6THZ3!27,="IDC
M(T<\Q<3T0^;B @E!Q#ZYVAG/5IJ;Y45?+6Q.0D%0:$IJCL,K'H>KK$OJ6I4U
MW)JRADJ=!T*RE7Z.:?6;J\30%1X4Y;2Z9*Q!\6K&+A:AZ@-@?JY.CC7$J&'&
M5V3&CTB;-OGRSB?M6YYG+3.5XL><)2VM('*]S307;EL&IFMGD?2633068B%:
M0/-=J@G''%R:"%4SFK?E.?"X_CDN0I7Q4N- L9R3HKOBWZE==TE%G*IARZ4*
MH%3W%<CNPP6UFC+^D*B(F6J.Y,O/S'=7&-+M-)4A%5A+4QE2PU=H*D,JI(3-
MS-)*Z6!J"Y3I9]O9@;.+;E/!(\$?I#ZHN;8,'Z#"QHX%"6NU,#"?M;C8H&:R
M$4756N@X@-7_,J?O+80+<^^G*R@;OMXX7U^JL@Z<9(35])]88,\#_H>(D6+_
MJ1Z3ZWZL%J$$Q"HYKGKC9; :WP=D+.$):XQE!*C)'PN1[8 ,!]#H9OJQ+A%B
MLKH>^9J@HN$=VD/LM\$X'_P6T7]5ZV\T9.Y6% G=@*8:!6::M-6"@IV#"O(B
MIJX&K!7*RJF*<(@2,MGT&F.G23K0C7&4(<9\B&/R(?^"1P5,]2.HI(2!=/TV
MN,0<[+2L[I*@.%-&R48>NY$8Z HGH K<N:V]:2]TO\@!JW2[EO.K#T*N)=^&
MX/L(R+K3QVQ[:#5\8Q6Y2QUK]!B3%)?->:9UNBR8TL7D_[ND B[N$P8"!?YQ
MIOOTRI0$+=G^/1% ,<4KN*/8*DCCBW8E80SV<*RZ6RF#XR/6@!IY3*'WH9[W
MDH$M*DX.T^29,1;HCQ(W:DC%K/%IPCPN<09T$_BBPP/+IB7'A:C@2,LY&>V4
MJ/RFP]627JT%L1X9$5*_L5+;TA77?K",XVA$(K,B0D8Q$/'J_=##+K:D78]W
M/^RV$</5?[XU30I6D&L2 4SU_!MHU]ML:TZ]>Q'3I/:019XI ]1Y.,S7 R>H
MJ542:'YQ)VFQERQKQ )-$>/UL23F! C/ KA0[5:Q2WD+1/E3&<Y88OJK7F45
M^5,0W?#7A(A-B@T+>W"'\$O%M5AWAMGK7>?6 !A8<[ 4!61@A.:M4"95R (Z
M.I9"C>/&$DPY:@E6%(34JPR/M"MQ%]]-MB23Q#>,;MV8Z0.2=4=2#[%^4]EV
MGAOQI6QBLB",#B%;6*X[UL,>E("A( _-_;##JW8Z_Z]QOC84 4#TS7#K2$ @
M#(3]FM8^SH_ RD8%/KM=3]XGMV\2+DP"@&3;19S!GQM&EBU(ST.SNM_C0E&X
MF31':V \"A6J#YIT(\J%3 3.#TU=">Q,J9$H#+#+7N"\^)DZK1H6:,56PTIU
M.]]J,?E>80=_?<MS928Y; \$9F%$HC+\L#XX4I-M<@/LYF9@8?"Z8(<JH?+4
M6*Q+/0JE>YR!L$SA,V?9M*R6QH8F;8W#N_0DEY8CAP*HLVN61@Y3F$H<!ESF
M#X?]W4,]:H4@B_K=/[?F@*,+@\1V05?K@B2476:*2^Y'6,A$!M<@FV)$V-,1
M=H#+(M,P0DB?1 832'YU6T?=(U@F*'E$UL#Z)Y'(U4M(PP>LTP8C\*EY9#CS
M2Z*UR\<C9&2N +#7[[31'H??COQP@/B9RM"A 48ME0]P$9-%=I8;,T7^+$#<
M(52NGH@P$Z'F'DT-$B@Q;@:&Z/P>D!MPBYGB6(K[\Q0%,EP&W^'NJTM^ ^)X
M(3@9?P?%$> D&T\PN8Q;,$S'SF^P62P_=T@^'K')P8E)->*[1. 0$]P(+&&'
M$_B%)SF1? 86SXIX$=4V=+3U#6Z_ B6ABAJ*:QG0#..@HF'8<B(6T. %LD;!
M,(R2=(IGU'((,J@P=83ICF .*;99/LDN*[G)IN[APZPBNSG%:7D35V27!.9Y
M"T#<(S[%<Q4D&DW&L/?>\9^?.\,V$Z#':K9&P:1AJ3?L1K=+=Y)P4,5[D<]C
MSWFQAY?:6RUWPR M8.=UYH[(YAOY=S%+S?!Q>E[ 0GS_)7:).GF9<:0$K5"S
M8N#7>GJWDQO<C>AGW=;A?D^B .=F3IC6#4]EWN-"*CVCS<,XE$!J@7-Z]@^R
M=<AU 4K^T&W!4:!J3&=$ Q:' L.V5'J,>H <'A/_6'1WZ6$ETJ2D]=!$PXQ'
M@"8D"'!/[5%C^AV&RX>96]NA9A=P&M@KI[[^ QZ+A1 MY^/',X,3L<J0V&V1
M,9[3V]N''>KUI CN]0YMNE,8<1'1.QTBN[WS\?*MEZ,XZ?X=?!)L^51#O!6
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M6F_.WA.>SWPP]0DK*Y(E#?_1L!X8+^&N&E%!P,A6CA:^!_\>AR4R/X?7O@"
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MUX2"*K"6)A14PU?XBC:RRD2"P!5R<6@*<W!J!OH]5G[<;NU0!0!JWA'W%JB
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M@F:O'#0#\G_4 UCH'U=6Z+3<-+!:'HV%$<I-I]("G#Q&'KR$P#+%:B00J:Y
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MCA(K,M\)\)D"*$K+CX-CA 8.V9I+G^I)RZRY[AAE6<H[K])@">OQ4 3YAD5
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M2AIJC !'+(SN]]OSPM$L I6/'7J$5=#ACKQQR9!=ML=>Z\X$9NKVN\,U"2N
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M^FCJG_Z:R5DX8<M%ZFQV%^6AI<LO/&C/8=WC;X^AXPVQCQ4H@DU[TZ ^'K.
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M (Y\#N\1S =#2M5^R!5##^5WI-,57HZL?_ =RM7!H*H)95KBTHT@1/3H_P"
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MJ!<.#*:WG_;1ZQ9TASC_24LA+.Q+D</8$==U$;7JS'S+GA!B<_VITL72<HD
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M)P$*'Q$W%9*L4TX\%T0X];5"E$KB:#D;R=4(- GE+'SDSN"#RJV0]VIMA(Q
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M!4QGH84C,AEAT#M&H[I]:;.VCKA 3D1-S.L8DARQ00[6J?<O;9[=8#Q&^!F
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MTW).H!W+:F>>?GRI^W $G,M-.%846=MKO4N%7%_[4-RNW7M;!Q2)[;=^0@,
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MWE:J71*D*ZK2Z6J1!LA&4H!LT4]G?X44&H4\+6@,T,X6K%ZX77 3<W'9'LV
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M762L5.A^:6H3Y5;4)O!.9;-AF;-T2Z"O7O=R,O/0\5#9B[!E&:\>KK^F[(1
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MNC6 J++\[.;02U*=_5FQR?:C(I&-Y]X-SH:0QE:XX!^P#X9]^.X!^W +QO*
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M$6NV.2U'0IM[)6U&:03D\/#:CBAM5H!\0R0X;(@K0I[;[].]X5IJ;P@^)R!
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MYO 2;!."Y^?1.L]S8HB^!+5FRCX.X^Z%+#P]AHTGM6MQX8N-,0NX$QG'9VP
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MC#Q<S+6V+JK:M9K)2#A-L@PA*VI1Q[?M_SPHP)\?H "W8"P/4( [^ K_'"C
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M/$(=F")!%-\:50F4I-"ICS)@RX?>$@; J-4M>]KW.WP]K'WD^!QT!@Y=3_J
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M!]HP5[>@2.\,81 7G"O72-O'/E%[66A](B."I8W@6Q\1K?"4M]<O3!;P$)$
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M64\LD0HLMQMED6)V&.[+\)RCEM+DY?] HV2O6]P-P3'Z FJ3Z0A@7FNI)./
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MIC/O;U2<7R2-P8&I#H)%L4@EKD"*9:'TK%&_?\$L6F(NQ%!&ZXH(G<]Y_0Z
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M%KD@9+Z6B_U[HBG6('&/ZQ]N"LSEO)H,(VDH]EJD&A> ]LW9,W4A^_"DKSV
MRXUR9"GG:NS#^?(YPC]3ZM2T)M>)SDE6^QP;;_$ /;9AC$$@O\GBNPL.=G+E
M</(Y'J_LK(E0UXHTG!N56!GD6LG))JD65X[OQ)7"?"W+:2EZL%'*2"XB4AG(
M5,4G?+Z5>%HU J+3[0Z= ^ D6J6R!BMZ U929J2/ZZO;;?#()=+0N-)*9)&*
ME6.*"3UJ=M"C!SL0?0AY@W*5,%X3"E)E1Y)"IWF-%.V:LO_2A[%'9GMA))[+
MH/7AG6$]>;ZS4?5#.ME*H6,4<2C_!^,3%6D(G12I=7:.]4$OX7RP*.[N%OBU
MHKM\<,2D]T(/-Y<6^>R[3.(I923ON3%T)!8556_2X;HJ\CGVDO\6DP1,=X<(
M"&BEC9%])"0)#I[%UZ)2M@N2Q;>(,J)(U\R8.:Y;]EH,NBG-+$;*$ODJQ4*&
MM">>R6U/M2['ID#!,!MR/@B IS4$3R^&AC\:($3!&23 P:7UDF,*$\_0(K[,
M$G21@*1C5[5-%'7#',=7,KF-Q!K3 =C+0$+RS76F+?GN01_C))QF'$B*ZL6U
MTJ3U49+2!JZQ[/478+A\?ULT:?P1CY[,MXH]HV>W N]B $H> Y8DG@5V+IB$
M?2LT4SG)N54.1UN%B@3<BAHZ1A!M:XN(@ H3,2VE?+8:Y>BY"P<6+<=#98.J
M_4DIJY:RGYPQP^0BUP_K[CJ&H]%;7AV!#XL77_<J1EX/I@K[C@UR?K+=CH>\
M :TEK7H'[+[LL>!W^SM#P*(F0 ;(9/R1#/S_% ?'8QY,V$M?>;KW_:-#<!<6
MZ_D^II2AEN((6R29A'73#;(4;F:5 3*>P'*T1MM/T=OMX"QAX^;>BVVX.)Z]
MNQ_LNBD1X_QELNRZ3?N7K[\NZ)-9=QI<H=."?D7_\[4C03"-I#L!H7-"1L_)
M,7_=4(7,':=M&4/_N\J6$6D/JSV68]4A3 SO0EU#[HW\ AI+33TGS"( W2,1
M!?8]^AX*!UHJCMA-MIO]MK?DKKVS39QV]C")W?C'>87('I7\MX^^?O%LM")<
M2[/('"AR5 &%SD*'E:]L7VF5C%)$/.P1B;B!O7W*"S'I!6'LR5*P>O)1@CT@
MW BZ9J1<;E(CB)%\)34X8[T+OE@W!M;%S)!EPUGC7)\^N9=/FW)^4<SOCX1(
M!<1$QGF<Z-"C;:-(\V3N. \8?S2<P<R]^2:$*B+-%,]&K!F;E\SXA_?TV-MB
M9)#/,R&>B:T8^N?\3M$RJ$<9;:5GX>@L5PSW_'U3-DD6?=AY-@B48"3<HLEX
M:> 5%4)"691;!4]XZ,.'LC?*13 [>0H0EBR;<(/T=B++_5$ECF2)KP\:FNBA
M _O$Q>#+7"DRF%:O1*PJO+6D?0X(ZLIU+*3?,9=<*LR &KUBA4&8\F)+Q5GU
MJM68GX@GY<%*1]([;%"KK.J4W.9T\D+"!GS.45I;"/10K<*#3C"K5/,)9\6.
M@+06Z+#U-H$2O4%@)987]T#_2,S,6&*6)9*OHXJ;T%O:F R70!#0U#WYZ\3[
M[9:7^<(+CO[HTW@2#SCU9D]+T9>46EY_[@\DHJ'AB%+3*"8F?T+E0FH.'7$!
M$1?P^(@+N 5M.>("OL N_%OH+&Z+\3Z2O>@=L3X)47HR1 P?Y^K<X:UZN4JC
MK0!?FO??+<_U.GW'6^8S8XN>F^.H'K-( 7F HB&\Z._!LH'O?_;@[$&O?"Q^
MT^PS%A45$@UJM]YN6H1M76=Y]*X18F_C.Z['C/:KO.40G?)&G0=+8T5M>I10
MQHUK3+NJ1A<@3M&+5%C+0?1MM/@\32$N37,\]Y?A28@&K-?<9?K[G'OI6_Y8
MZE\I[AV67Z8& !<4ZMBUDO!4&^:B4>Y*)+9&YL^7!(:ON=D*$UZNHKB'3!7'
M-FG N)IS6GAV2PQ.: J]2*H]Y\QXX C,$:VEJ'RYP23*-YEG,'3UJ4:KM4_A
MC0Z/B4Q/:@J*Y*_8Z;WM$[9XV/$@O<3'5'\<;)1FC<PQDMI<SXX!NA,AD->L
ME4V+\GS@;K]AC.8=J"C<CZQ&86N$RB(?0N8[G3,1-SMA-F\N&.-%=PU3G8$/
MD'-Q3QH&49KB)"58V(M1B(Q^4)8]&&4=B6B'AM<:SYC?R,GK\WCKJ_>]U]R#
M*AC7@!3-^ZX(%1PI=T/!]-\B?YD)A#A+=*8].H4\81*6%^^Q) %K9BYHRVIV
M.#I]%>F<,BHH7Q4Y<3&6OY/\9[=,M)[W/6/&+#%\9&*I[+VY]H_2H8P#+1[.
MA66T4*(0KZ*J?=YI@)_)!'E%)=,\%>2'+YA(W6&O^S&7$4#;+S2<8,V20L>)
MP,!9.5U6]^$UU"YS#E)$G XP7$KBR\T(MU5P1'MSY2\ 1M7'"RF<WY0,HHB+
M8XX=1F8.QF+N29T4LPN-Y&;O,V7F""Y,FXJZ^EX>18+QD$V2_2X(HNO6T5VX
M3%P\_8U3^Y$AN+- UA^U]M;@"[PO8C+OT"X!'U$4D?,:4E1A5W$LI4G&,\H7
M2(HG]&%+@$/$T5Q-,FS4=6TW.D&/]NX8%0O6NN(^1^EP-YEY3FB<T%*J%AJ
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M!MP*^.?IY"U5YED6WIGF(*V6J(:X((IWDT)QMD-Z+Z=F%5%O@,, @]?0 ^7
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MP5RK8 9\CS7]AD>XQ>^=]3B(!YO@;@N&H9IT+3AE:")S>>N:047_ZPVLL=!
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M&/:IU20[*_Z9$<"FJ"[TRCS<7]6*:>,/"PYA!LN2SMEP[F7\ CIK"7J#Q)%
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M]7DL";LJ5@LNZP?UHF\SX]*-#22?<7%"#=PPW7,[)M_ ]E+%)UYQ.".TU%_
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M]?!CZ?TN"LTNJ$67.$FJ%REIPGPREX(SB7 ?K_9/.,\45H_Q;Q?C%,#,'HA
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M"<"9!N9&7N]6KIQ5>U82>S;A)>W8!J!<L@EO.44PLQMIB!BJZLG4P:;J)O)
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MY7 4.;07N^.OXC!$#5GW?N! 2!9F9V;(S"YE3$YCI0*AT2P83ZLET")E7IN
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M?B@/4M8BX?^-K6)<WW)?^V-E$= I&:0UZW$TQB*UXM1ZUG4: BO1928#T2]
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M,91_<GI)K)VR!6D=72S Z';"XU7,_NU/GS^[?!&H)\EJ@X;#MJQ@;\GXT2X
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M4@57 ]'>V3<$Y;M:$B=,M].>^G?_Y9LK]JL9K&M-^[+WYV@KVZW?(=^#!]<
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MI25,!3Y<VY4L.^ECVO6O[6L4E8&@M=3!Z+(B\)1T./R%_)@2@YZUER) .S1
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M9BL!2(JJ;30:Z=^U2"#WR21WF! ]BH,'+]36"9(R\#0$G1MPZO#2:F !]+5
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M._"TX!=9 NK[$V2&KY'3B29/5M6W#4O<SM:NOM[=1'E?KB8-O6($8ATIL'1
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MA7F'U I%68^4ZI\WT9.9ITC6L@QLR&2&1,5'O<6(XN2,?_I8VZGVYUP5^'+
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M_9[^VG],#\YT-J4#M%5"+RQ-J#X9!G[I#\KJ N>3]P!XX;VZ>G/QSG\!)VB
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M1YZZO@;.E&;D&MGE"(G($!'Q(#^%VH AHJ DB4F&XA*40(B1<<QH@-XWN@E
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M7Z!1)8DD?!I,P?=U<W=QT]R) 8)L"7E_H!EB5G"B!Y)*)D$AC&]X;P1F=O7
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MIG^,IOIB0@\+D9%GALB /RH, 8+_4:"&F)3FE11AJOMJDK\0L!Q'*4PLB;N
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MUX26&P2< Y8+2^2)CA?%EB2S98"?.4O/_3H=D.'KZRCPHQ>@4@4PF067LR[
M41E/)0TCI0AUI@MWF^W.J+T9,0RJUU?OF"2Y2B88P;EW.7MMJ^+#[J2P.+.:
MC/W*'U2.,>_-RL\CPD;AQ4SL(ML+6B)3.!$^&5>RL2)T0)]$Q&CT?*GPR)%;
MUR5338B8"([!<N.2,Y-Z9Y@W31!';[#[UR&M#A"[ !ZATDT6(W%8+8I/DF4E
MW',CRE <.@P**T."HIRC5+C?-&@R4&8\C@S!<!JU926XKQ4NLV0K*#ANX5<
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M<TZ!;L8Q-[053#!;0%431#ZG<2%,[#_KXW(\)7JNH_[&/G@;9>__MY7942=
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M,S!3.J5K9@,F-  B889=N*P!-SDC!37I[TN.4IJ_&]E-%UP?*=B)PO2"N.Q
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MDH](J2)<FH:822C/1]%]3C ]:^Q6<AI]U FXB3\;;N_;=M@N7K6D!*KTQ9J
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MG5O35^? M"2BO;(CNO*]'+;HYQ3LBOTZ,,8)Q8**6*#*S29;A)W!A8F\CE\
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M6N P<2LW=UQY^H&4UW-]U']5QE:B8M?K#=MB4>KN(8@V4&YDO ]%SP!1FU=
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M9VQ7F/IJK$\W.]5&<232B76QY41Z5$WQ^=#,"<HQ6)8H.$JZ4\&YXKOO:9!
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MTV^(:)*?H+9 +MQ\%,NH0T>! 0BC)(3+W=!HB&"O+;=-2^ %$$11!MW$$.&
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M7X7P'#JLCA83FU-,$!DP6VK#CLU4,<?[QK5)N*=;UA\/#N]U";Q)?FBH>)1
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M"]+<QY,7+.,159NFC3W/^E5S*>([7#&[Q=".BF%B:TT0@+TM]FXB%5&/"JA
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M>0@:\-AGS\X17;_,J5G_T9=<KZ ?HI'3%GM (&PI-/#E(NX\.BZ-U'2<?'(
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M=_W[(G3K5=;-U$] 2J<D@QG_ 'H-FY[IF!W=W$U[FBI&2=-!3'!>EB/YX7N
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M5GXO*5U5M_55G0I#QVZ\97<9Y9YZJ4D_H)F.&"K-O-Z\QTI<W!K%4L?0?JV
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M+,6")BMG_$=NJ4LFE1 P"RZ:X)/L9KI7:""@Y&.Q/OL53Q2@ 5[9'%%,H24
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M)DG$&C'+,<F72:9S1:AF:4!-?D71+<1H083U12LQOQ0.M,,JIE3&22R18N1
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MV0Q1*^>PJ0*2C;KKPD1E4L8G^CZRBN'_9L?XJ0:NY//WI0V;(#])7:\.>_@
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MAZM*)D>O&]P**@SH_V+*@V%<E2K89MPVR#=63OU7Y "%[X3(K]N1ER=:H,&
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M)1N\3=E C)[?S6IL=^I..U7<DNVX0D5/I\YB,Q!'DY2U>_D=]U+5*@KL@_9
M]A69-A0<)\M!(0J8I-093]>RU+1$M>L\12K:W?V.NVL76*:5'."N&RR1IIK]
M+6YMA<)/8:43+E2Q^%QLNI16(IY6=Y?4<&%O!,RUP5[M<#-3UEAYF"MOH\D[
MI &S-'_AQDGM%A_$%NN"A6NK3@E/JL58UN[/=U7*&M::",E0137C'OXSIJS+
M16ZZBPOUZ1H<N7;7OO^I$E3I4MI&^0&BFX6LM%"SU.[,=]P98GLKL"X78-!L
M '&HH.:#A54%ICMDP$;2?>9+&UU5&D;E0<V;^_Q@KOUN"W,]@+&T,-<CG,(=
M8*[M=7'_ZT(U-V>^X#A!'BFVNV8;3(M100NRSDJQ%$$D[-HA?8<D::'^!_Y)
M#,OPO/;^_XX;RK7M%93GAKJR-W&]&%!-DC:B]92KFVEZ?RT(DD?DIEDX@';+
MOR=NX=]K:1ON![/<<):UF_ =-T%R;9K/33NN5=Z%C,Y:NSO?\YKCAH>.XFQV
M+2H3PZ]B[5Z[.]\[1I?,,1$F[=@4M;9I%R9Y_ZO B\ B"5:A'\ 7LC?X_7:O
MON]><>1-$ *(CIJGX8S[A5!=[0NL,G)^YL]?D+[;F:^R7]ZGZ4&C7#Z8AI_8
MA36*DAMA:0JEJXG!?J@;H0RCTN7CN@I=>J=0:;SYMS./O"P[XQ8X-H?Z%1$(
M8(MQ!-C44:I+6QEZ"Q<Z8U,<K D'FUZ82YFIPB.2 L0O$65,JDM=EC"EW"UU
M+D!VFGCA78/SAV[TO];^)7H/ABN($V+8N(QQ+7D.7Y-W$Z&#_7-B,^+AD2FI
M:%2QY(#Z');15#KI0L:G05:I;CK<TXP)GJ3K9J4;&A/F4%F@8MN7;RF,$3W'
M5"XJRMN.<X&#M/9!H^>J'58$66B-T>JKLJ#^B90GBKQPJ0HVJ #!X%"U=!2Y
M"4QI_,[HNQW.U\' \1!&QNUME'L)QTO%*[DV$[?)IAJ(-M+\$7EGQ+_=&5!W
M1+KG#\US$A%/BC)ERBV'Y7-7+X:*##-)-DKWO]=PZ -D)9%F1802A75EEB\/
M:0.)2(*>9#F#V'[++;49D]=:$0#6/[KDIUP]HB4;2:F7G.#1M(\^-4D6YU)O
M)Y6JJO]28$N&JC&D\@8&=!8ER5>BBL.LD73%5CA$KC.4*L$9\<Q0YXWD7ZK3
M*(P6="%CXHH#[L 6,E4E:Y/+,&.R5;%2A,^/*+]B16XJW>L,?RTSWM%22M<8
M[H.$>CJ,6'UA&0WJ'8'[Z<&!EH1WT)HCV#1.>'TXYX)/1MP*)<K@S:LPEF;%
M9B"X-73Y9+JE;2G44W[C*5[?OUO;3?RG) ?4-=.S:'YPD98K4YENY!0%F\0O
MHC8D*-V!STM)S'OL\,&24ILPZJ:.O(DQ%L62IK+8W NM1S57N'%9%*.CRE]7
M6T8QD%;Z5]>U)YH%FT1QKB=<_D.8AN+4U7@+\RZ+AYQRBZYE'F9,<Y3A7:W?
M2V>,KU:&I9H $U(?4<DQ Z-JM!F7@Q6I@2K:3)H"4V-PV#>826@P=C;3#[5'
MGJ^SK$@5 ,</-05/$;X>;115#4,PL8N116?,_(MTEJ0?5RCUJ1;X2XL5J<T5
MP?Y(.V17K%%T7\A"@^63/&6_6#NE6N6$*/L@2VO.!^*5Q(V;!1].R"JB1R2B
M+FK.#5+"HI6JBCV*0EI"RLF'#1,O;8R(+-9PJZF57TMU.%-3<YM8Y*TE8Q?^
M?HUPS!I[0LP0,3Y*&M@V-G">28RU$[%6%7P>/-N@4WP6Q!8*1P&))M$,KMY]
M(O-\ZQ6'08>FX>9W>2H58TA#B:UDL2#!U7J<IC'Y1V!:3A2 70J#KQHTR0$.
M? L*5@;S:A"8#4>Q<R-$^WQM@UB(QGF1>DL+#<JQ](W.OI0[/A4;?ZJ 2(GL
MA)4_J4JFB"X57Y";@4C&DS2$?T8!I[5%LP7^U[49_F2=Z6A39Q#524T;A9;]
M*FQJHG'"I3#9RD5;WG.SPZ[TQ<X4#>\RD$R:OK:C0.5);*@I?OKAM_=G 5*K
MLJW:C#T5NWT'V+A=JEV 4Y&B,+-@_MCB@6#[LE#$?9&G6 8#]SU<X*FWHE V
MT\")F^]O7U?T]GE=1=^H>I52[VT]?D5L:PU*M1E@;=<P)!L95C[A1;>(9,$B
MPK/&#3];*T9<)LHW!*LR_M10Z!173HV2;1U1UD:2N!Q>U )><=>\BQXVHYU3
M-;HOM+J6 :IB;4K(J!B2XQM>&*U30Z^OJGR8(HEKU%1/(FL]5#/=DOB4=9S:
M#BZ9\I;HU2@^>E?*&51?&D6QR/3$N;YK39.?[4,R%2Z:L[IHX2JK6>UC271P
M*EF)/H')9\22B!/+V^%ZS_T73 LH<Z@3"S0I\5F@3KF*A!;U?8VJ9P</A4J1
M+(O]6!1=W7])+B?!'1,WAY8HZTP7NR"PI'E,N16C75VX.71/)77SH]E28536
M6]-<+*?H#V^Y99XA*JS7HL(.8"PM*NP(I[!O7\)C<T@^+.S\C@X]2*!!X@6H
MT.?4<5;^("%PKC&TX@L(WI&?+,,,27BI:T88>W-X!_F2:2'A8@H5R> I!D52
MS=6C'JKS,<&U%ZT5O_#">!NN=4<(V3!9?]>@JI=!X:N[WA?'ZY54*K!K5J2V
M*#O%L !57E-4R*UM=*;VG.P8!6:0A)>F8!=Q4OO'N[S.E,UC>B^9X)9TF.#8
M(!J%8E^HAY%9N\VF(DI.#L#(ZSD :(7PR-B4<=!O8ECQXM=GP648V]]5[PW%
MXZB^F VG:Z8%D*?QPU1HT @^?<_#@&2E;UHR8[Y _0CU7>*NJMI>9N#ZY85S
MY"<W,5B,OFZ;UG!V[--[IQ,K7$(TU4QZREN_DS@;=K1&Y]171*OZ.59]HENU
M]>H.+1JMM<:H61)NE*VVT5(4-RJ;&V&)Y'6H8ZC%)'F!',/D>1PPT..M$8^:
MP[9G$.3H+A.5#YREB<>!JS00HAM:TK55B^IE5R[]7P?1@R"2',0P6"B2FL+=
MY.LHV9J;GR]MNOI3U.!%JGG.'#:LK1^8!HNP4O=>:A9M? RY_(LU]K^ =Z%/
MP.I.]+7=BZ&V@RPYF=*9EV.^T;K>@\,;WWY#(U,)M9"D. <'.20&4<V3DM>Z
M6D4;T0L\#;O)04-?^_U:Y$JM/K?)K<1"M[NMIZX4?I2F@3<F?:5#U(B?4:D2
M$E#J7V:WI2UR'ZF.TG@)!22U*L\P]U8A@?=6&-L,!5H34JF\J[/LC/-#8:=0
M$>X'M1:\%P/2$>D3I:#C "]#%#N"%^"UC10^MV\!&6J&_9PZS/E6SV"+QU)B
M6!K.01E;">*4FT)5.GT8PQ"Q6'Z@6K]*S[L5-_"0<1:CJFJO/:8,LS2E>G:%
M2:\4LZN3I7I*U?O(EPY 5\7Y-!7!A2H,\0HP-!-C-@3A32>_R-Y=UK&WL<.1
MJDV353&UZE*$DDQKVVH.T7!&W81)C!-@0WOHU=<U.%2<N[)-$=D'NL(-";*\
M'#3.95!]K=$D1#W&?W4UWM)?SW?;8Y<2E&%:;O27>MC84YUL1<]&YU7Q\II$
MC-2SV"!8-I:^!D3;CJ[&7J3M90XUCP/S0DVN_$<*=?@!F+7$*KS"U'A NFD+
MXS9YC7Z!$_M\X$[&0[??[39Q[N.+IV[O?.CVI@/K2W74TNBA:J5NOZ;^V7;3
MN(:WA^ VD[8CK ^G*V/JPR957 5)K.?8)J0PMXJ, MU3M4%2%<2)(!$"+(,W
MY+#TV@W^O(:?]X9#R?OA5RZ,1?R6:P!@M09$0NTMJ4&R9AS'AM&:P!D$(\*M
M*S?_4#G<+4W;2^32ZDE^4;@*[=71]Z4VB3FA^V!Z/)7N;'36DS8G[)3CEICN
ML]N/_**<T>XX_Z2%\2J/=Q'QE"9? S4EQ!9@O"'C!GX>F^$K#]-0Q/@-2^]9
M0"1.>9<6PZP%Y:1J5P*\<=#<-'-F8E2@01J5PHTON#6?/(\:Q=+D[OI6.!"5
M-5#H%9$+)G21;O64C"/8T#Q,Y^LE'B#=2.SN0J#1[;,UA=U(W=C99-E<07:2
M\JT,FQ:04X)IP.Y<[*R(%E2=1I660XQG+ <KC E8NU]1Q>'>C<HLIB6%U<;8
MFVH*3"L91 L!V::J$Z^DZJD;"2)9+\X&"N:(-1B9@.\)PL]]X6A_8@+@:MFH
MO7^+F@YL4'A$JK8?>;LI!TD8,?D-G 0O33URZRF#6WJ+ 3R:##J5:MI77.7(
M%XYO,<RFZA(\N8JE7Q(U@V:.#O5Z:F5H<M$2LD05U'$^PL.8)UFI1LM4J.V]
MT-A%@9&;N*>96X"T,I*4OJY*ZURIBD"H=K&K"G>9K]GF(G<>BHBZ]F%;K^V4
M=_&,2LQ*.MR+3-#/M= TO5 '<^T1GLAI(U(7@II3_T:M-@7'D;.VX^;S&.JA
MDT:PEE\#7)2OSN_P:^2,=G[]]9WS"K41%0]<_/>/]K4-'_Y )Z+\,[K$U0NH
MBV,970RC>N'9K-,O#.6O0#"T"?SVRT=7[ 9=RL26:_'XWWK&0+J57+C;;F>0
M=@Z;F%8G]NC$-EZO\*$O^Z-NIXOPC(C)R<7V+2\)1](J^DB3\(!?2[=U90<(
M+8!3;B$7!G+1;R$7!S"6%G)QA%/8%W)1?]L]T>6&-WV@ZEWY@B%HFR^!2<WF
M;BJ^=@I=^6ME"\A3N<#7T<VA"=^7!0W7I"2O%]2>/,RI#@+Q'6#IAT+Y#G:F
M'TJ?A?I;0$4YL1.Q=)%"5U[A+$TXU+[3&+9Y^_6NXASO@WF +^<XQZ!'<8ZA
MZ:E.U]"@/W"[DU%3@($BJPD&>F):U&0>!%P+_7+2&9NK$,=##WW9'_8Z/?5!
MY7EIL 3CE&[<:LC!Q O ##@5^PP=(5H9]H::;%3C_$PX"<!UB$W[8MO0)#D6
M^EMB;H0!B#-^$P4O.LZ%:MBFJQSY9Y28;!K:'@$BCD-15(K*'RSW01+W=,(4
M7F&U@I^J1@DFV.,Z6*E%0H*NV&5@X.ZJQ1NG#?<H9CSP3B7*;Z8*\U0.> 5L
MP_7G\']3*JM3?=B+#2I,:35](/LCA &N]OU*R7 _N$[RIO?. N5W^9QDQ>\6
M@M_*$$?T#T&G0RE.9A+V:YT*3U<)86$NT2>+Z4NF"O_X<P-OZY;\9H_-M0M'
MB4'7517(A/\S)1$(-H\SJ_C(#WT).\VI]QT.) VO<;$U6\278BSVIV_2I<P$
M98?%H*RX9?877>?"2V=>'&1GG[Y%P4;]N-_M]AEL]#[Q_;.?X>1^=?[ -.9%
M#C=3[GP.J% 9IP"V58:% <[O*4@2AQ+IT?CS2$!G(G*:%8([V=IK8"D0"W.1
MKB,1-R$D9@JGY8K021Y<]NNL]/"XN&<"V5/!=QUDU5E6O,3 ..1Z@85!05".
M-$JHS2U5']C(!X3A[70,G!)8Q4Q8\_"J,Z@E*0Y4 8N1*/6=PDDM%GZ4ZCW8
MRLB"AC/L&J9[+"C(=8E5+!HY+S7HPIH/C!(5R^ >#B!B![YXX/6;KXZ?Z,VF
M\T<?<V2,R*O+6ZC7A!2O9?6055K[5,IT4<B:6AVSA'(K5EC^LSD=!(Y L#Z/
M^.;V1-=26!E+W@(F="F=Z-,PDA9DZW,7>(94!AK&*"M.MOB6+9:2>FXTK0QP
MA$NIFMUBT9,5W>=+5-E2S/"2JC"K5'H)\;_"S#;*&7>,1?8>V_+QTHTD58)T
MA? .&3$6(0I>!YXEI6(<HXP\!'$M2G0#L>_:M[TK7Q8UJ!+'2I%P,@O[X@6"
M_J4#G]$E;=<W"]"4G ^+PQTGQ_H)1S]+L)01IQ^J2B-#WB,23_WW=)W7QJH9
MM'92-:NEPP-R0.5]N 5<3AZR3X/XL_@RX7O@FMD(5-&_I6#O;$8<ND'89$B0
MA,%?+U7%HFI1HJ\ECT0 529;S/IN(OF+S5W$0F$SAR,,'5:<H4(*"4A*3)Y+
MA\B'P^K--P8B7'XPHPLK;0<5 0/1T2#@R+#7R SK);P9YG@"!N/OEH-_(9;0
ML#M4V9VJJ:6EP+;(A1.!U@TWL0:^*1"TG87 (4XJQ2M$/!QR^#W*:=)#8XH&
M6#D@ZWBJ-LZ2](1A>U]C9K+!S<\YEU0=:+CG0#M.PQKJE2(?W%XN+@Y8%RE\
M&JE_*-D?@M'"CC8LBF;AX1.ACUAL-9^YUT*?P+7^?JWK)TR91-/B4, +=DL$
M8U/(D=9*T)Y"XFK: (RZQ3KF  ]+<P.1WGW30@O[7 *G\%04V\,Z1B_#9]A!
M92H\+KE-N=.0Q1"AY*S(R;7[(#5;R%YR7N(+X.L]EG.E[##' ]\H-TI9=>TM
M\(A;020%T=P$'F+8T=I0\4E'0I-]/K 2G]CS:!J-XE57^0XZY0^B@:(&4'KW
MB!"S^G"O$&U5LQEP70P;I%3>!)-/UAJ?IO"UTBZT3LB38CC #] 09$*HO6=4
MA/92N4\)[!LPPZ0Y@S4+N6U.I.S!@2(& S&G<\+YU8**L_6"IY-SO%-6F4WM
MZB(C%N,Z"1GTK'9[KI6*9<\WJ(O2Y"G\GP<K&BH-4R#U9B2>89>HD2<&'D;4
M8C46_S-5R6K$+PDC%JD:S@X(A)(%@)LWTY[IC=T88O:*B6WMQA(N(H.:693X
M_T@DPF7],>1@$3U:!$]:<#/2"J$FQ!&06!.\Y4IZABGI09N2/H"QM"GI(YS"
MPZ2D#\7(;?*3=[^66<UG6$5$6>#X"NZ)O(RY5R7$T48Y>,5N8%;8-&FH'52T
M-.@0&0,80[3DN!4OZ7L:Q*XP#C +SO[6G$8\9L:2?@"KKERIW!"0(.N6%GR^
ML1F_"NY=^?%L&@EVV:ROEHAR*-/*5T3>33$=85&8\0V,B5$.1#)6 99,<0:$
MQO-0%9HJ(T*)XD!E;NJR*FXM8F(+6JY0,RZLGI;-8Z-%8:JZ9I476JBUJ1V1
MRN50C..G=X:$N!" 7.=7"2\2^"3FF)&)MJF/+MQ!* CB@/FA*% -$/6V2:Y-
MQ]#4T[(-2/ R,U$%T]; 2B'QPDCX@8LD[((^CUN9"K1#5=3P=IQ&%!,3659(
MJ) $(S")3]Z"*D866]18HE0%&:2IM#/RYJS5%BEXGR<0_-L6Y+7.DH)T&V5;
M3HV6<[2<0MQAY?%-?H!>9B#%I^*S;)1_)Z0DNDJA$$B;Z8B?IHC3XR3=30#M
MA-CREW"M&81/(?6,0450N,LU\_")SEVND3!1PMPF0.@2[T5*Z6F:248,P]EZ
M"?L.B^\K$CL<A! XVQQNJI^#P;/+IR:E@Y/5ZPKJB6IUA>'5.+L[+&]2543E
M[Q#A-^=$G*ODAID>*7-*;3HI'$*7.$X,F5H4 PJ58!D?T^6"<'&BW#*C"LXD
M(8DB,(;,K:C.2!J60:YR7)JDSP;M6&A_)KK-=8-1U3*"A$!Q2)\M/>)M%Y*9
MA0>FR4;Q \*/R$-"8A6F4$SPXH4O"A/( CN4@F)F)4"J&>XQ<-<[SEOM\F/E
MJ5Y=>0\7"(EG*Y51<."QTAG]9*5)*#/+6778B1G3]:U5P4Y^D^@HY"I(5BS+
M1/B,=SQ?3_]![0^72RJU0=:ZEHF%K6GQ>&K7MT#IS3OC%GQ^D2LK@F)$4><1
M]8*1LB05RVN+*R^^OW+W3^*N^1W/159<0P6S %V#/1$</P&AT& RUD;O S#
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M%;.EC>LN!"H&.BA-!JG5??5 A?[?7MQN_O9'+P[,VMW>C1'QC+T?D6N=-R#
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MSH.(+QB.J8^TLYN?XDOXVV[".WSQ]X"^KF57;RWRQ,-<RP.V :G$1Q;EW/\
MO<$UD9 J,<;J/%D*&&J!H\X'XXMLNU40*$=2>/2DH>TE;,$J*],V(7T<E<^1
M4\*]#<EF*YR?A)K:@&KJW&=MS8I^4L\#;?ZAP"9@U/\NJSTB5:%!O@7'C99(
M#UQ1W4OM!0SDC'G[03E?A_- 15\0/$#LP@YMHT!9R=C'HI>T]L0KOYW.-?Z#
M4AB@'J[7$6:9R*L(ZX3U;49BH=,PHH=X>T-5L^<P(O92RI.X7XJJ;"QL%)8E
MI,*1Q[UVWV!92T#)-3* S3=4V5>1#4+"@N1!,E^;W698^17D 65ZGM0D2H;
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M)Q#U)-[Y;1?!*E>OZY^SQAE.W.GDUBG^8X/XR9D'[_P0@X+9^97:0YF4^=-
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M?]YBN>A?UILOR7;SI>%TW&K*6/9+58/7F"I?[-/B$.[)=%901 D$X5U%01.
MB2*#MQU6O)C4FC0>W'TVR#5+3/RVZ\R QR)]T!>!8#Q&I2-L@ZV5&E#::XLJ
MZ'?ZXSY?X[,=[ XK5:(10N*.P"V*QH_QN.S>S?*VR;3?H'BV.+_B/=,#>IW!
MQ+$&6NOJ->,&'M HT9M5MDQ:YGZ##!AT6V3  8RE108<X10>!AGP1-:+#<[*
MZ@R_?;RSWQ+K*E*Q-.W96Z[J-N>4XGI5BTI=$999%0M&FRP,N)R9[-&@$AHL
M*NZA5>":4?FG3'_K?UF)JQH(N-#KP/6\3# U@YZAZ>A%P'\<ZBK%#G/:D9QG
M&CS>NK*/U"Y>?+X:OLMR#,1*S/NZC1O++!IN_>[8 K(S[0-61Z/M$:%M1=;=
M9-SIJ2_=G7MO<E3<>_\5;!2_I?.6ZJU1G# 39745.PIBOD8"R/J)OS7H!I_2
M!]81JV0?&O$=NO."2G8>Q5+=FH4D:(J9'29K*?.G4[IIL$(WB[R3 K6*26XP
MJ_,Z*]7?E#.!2EV#MY&'=E377G>I,_6=GCL>]>D P[\F(\X(!M; %I;.R!I(
M<H>*)'C@*FYJ>$BDDO,+I&,I@@,JKQ&& @L^H#_"WF2D75#1$)NG:JC!E"M<
MNOONORD #+=7%&"Q\,N>"]NJJ5P-T2]>H39W<?U+*?8D#72HP0FGQ+3<VIBF
M@GBKNL!%LZYUC)H5YS*@)AY<Z?/?\-IU&G"YA,;2[%(8A*N-0 .9.H>OX>[/
ML'F0Q ,L]K?Z/< [3V!"^$I#[4 9)S\H;4P2$V$ 7\OXU-\W'S_]:C'+Z6ID
M 5#&9TQ7IV(EL#K78;8V$8ELDR&-,[% (NA/MZ_!K07["SDQBR RU;CUX9!D
M%019#>Q&=]^L8BYH0/29AAJM=(<,#2A[.\>F3VAB;NB^O4G2KQ8[8 &(8DK8
M0BQ% L>?09K2T<_@@^C,<ZEC@<*(R)!]+E,5Y=$$;X+)1\FF\G-^MR*4[V"?
MUD;:*(]H[14P"'?1QYAV&2_%3*>H&E,>B48(6)69M)@DE_@5>,;9>B5=>^A(
M*H8H$8;+-+G)KSK-\8NCNC<LR*#L&@J(JLY2PD77"572+Y.8>P!HPFL+GV6$
MN"A@7"T<HP[%+<$"?@H#BN;(D*]J%V5VPU?*>:_AV07U/.IV24O9Y+:CX2YJ
M<P#C8:)II,[5KZ5/QRQ!O<DN0^A94;R=KCG%"*\H\6MN._+$<#BTDSLM1,,H
M;C'0[75;%/>SW!>X;DZ%QQF2_]W.S8&[.7^4>F0H<\&FL_,<?YT:TRB6-8>5
MBZA=1I):/R/$+4$*D49#?1<#O^H9NC?"C,E0V5 1Q2X6$!TOZ:M=,&#4CWQ.
MRU.N3#<;PB!OF/A\!LV0A)?6GD3-$,O#DOB[2V-1W:?Y!;8%2AD \OGD=Z7Q
M<NLUK6(P6="A1TKOEUG@(/TX65A\E7+ZGD!.ABE0=SK4K]8?*_ H&VD>W924
M]:!Y&Z,$XQ K8G#@<E0FR*"RX2C0@)%_Q@0-)L9XWEMBX?OE[=O?N995698<
M%@=MF;F&%HFI4P3IM RP?1LOK#2Z@,L9EH:70R]4\ V,&[9G<FQ/P5$/W[&+
MR^/@!GTC!HK0CF25/MH(E\7UB>":Y:)SI)Y(4JO!]L)5R\9,X/@D+*%\V9MV
M.Y."D_ZR-QI:1;7WLNWOT:SL*)Q8::%8O6@5-4C5LCQ^F^,M$^F@3&-)$\@;
M&5G::+ AIF+3>[<OF?8V^P.L),:+DX2J/][IFA9+X4&NZ-TL&9Q!N4V.*1H@
MS"JZ?6B>XJ@(+V7-! [?=/1GMF7QW_T_*V(DX6:S;V=0?==4I-3KVFZJT/IO
M>VVS%5=K:>%0,-&TDVM*@Y].=OKR@-N0*I6]P\KM,7JU^U3B+?^>;5BKHD+6
MA=M6"4-I.UCVY"[0RUT("?Q!WE-L34*7:_ V907'EYK!E]UG>8&@U>J?SS>G
M8W=JETNT-O*QQZ+0A67,!JZ(<W>8/&644X[8Y7JK[R3YIQ C_\,@D4G)4R*=
MVW<@*H>@5L@JX DF!!=,>H%L(021IDE8IY2 !XL6D^0:X-.K<,6O(!IAL\HZ
M%D N<F9Y$])+NL'EBX+X,M?!C:_!IO@JUR([@$U&] "\$7UH^04H(O5&$^^R
MQ9P4!+/<Q" A2!G44TJKZIIAV,P$-.'+8! &,F*+RDE%$4RY*@VS-]5\4,D*
MWES^NL4;L83#L1;."/)J6@R#P3#T6@S# 8REQ3 <X12.&L,@KJ'K%"MSM&(7
M=<[6IF7+*^)>JLQ*P1@J_$KYZ:&*E:/%0[5A]2Z!%<VV"M8,.;!J!&/H+AGZ
M&#=>PL%B023JZ@Y6!,)!?(7>B<)EUM_')^J\,C+4GKJ%V+S6)5$GX*?^\6@-
M+PS MDS:\8= 4;,@^$H!>2+/Y3>;5'=35:'+GG2LC+1L$R,8G+.+F-'A6*74
M!.I.K(4LC)+U2E<GR@CE8:9-.%-86:)PL\Q;PV%07BLITR[DH4T<@&. DHO6
MK3)A> @WM5GD;+([*GJT\-.FHD!Q1&P!Z+NZ*L(4=9H:G0+XGO#V>O+E2EM3
MOAXNV(R_%H(N6]V5$W'LSQ79RRPYT5E]7=*H=)Q=.RD+(4PDK.>8Z;70^4'#
MD/^1W, FI1Q 3B@N:.=B<:VRP!1NJ[8PM41A%66@^-=8=VNV,?OS_X7-9<+,
MG!X[H+Y',<B6:T5RZB)/#:6S2AK-Z:$OJ1- #UTBZ2#-%D%I+))98)'(W%QQ
MK_#J*H #BTBVQ9JBR;*CY-6:KFW!)E$,^(;^!O?14%U(X^UPCM'G) T5PVBU
MSAB+..- CF).C.9<'*.X#VMUF*6\Z>05"HKJ@/%X#B2/CU%W^XB8VW1[&9R$
M#LK$C+W!O096;NA32&3U^DW/WC+4P8G>YA9;C!)MT?4*^K-GKZ.3N/:+O3*W
MK4)%'>_44),45KDJA"-^=O=)65Q51FMUH]1TH)7:G_>_O75\;TGE&ER)%ZA^
M'+RUJ.!S(:7@I*&/2:8YJ0MNDXE11*O?EX+XDA7"H?M*/9%-_&B5"!(?DBJU
MO7_3I_NTZ'!WZFQPSPX/N_4F8)7>.!S<T;T9U_=C&G_<I=[>M,FB$[93% >R
M-_JV?;C-V<;H7C8+E76 3==L]HJ4:,PP&1P%$D^]6R?A,GNU46"D0Z@]SN>/
M7T9G'[^\=9V??OGY\Z.T@#_OC'90QC5Q4[P_S@;TZVMT1V!GY!K!)"#'XMZ-
MI^.+1^Y<O_4*<9W??OW\NV0(?_W\^;_Z1+=U$^Q]RUKFI?(,E17(1KKJFX!N
MB?KVV6QS)O]DH$&A\7- )C"LU35* SF8K"@*=:J*)'V>G"G^>_IIP<E5871M
M<+I5BA9FIDL*+"LAR=W,ZK721+LBIO.=@?WGO:,"]B,]"CBE,>.!/E-"A_[Y
M2;."'H6!M:<9>J&"9[_;Y'870O (ZT"!P*.8^>[<F0KEVD2>N6 L.+7=?DW4
M<DD,QQJNLLS"B"M8-$<LB.)M&[6F^1Y\L8YD4W_A^H=ZNDV+\.H5?*?(NWD<
MN=E&Z6SBJ*\L>^<I;Q?R'K;)@I=BI;44HE'WCT)L'!N-(&X4E/): /7Z$?4T
M@]3],*7VB>93H@2TV!OK>0<- Q[A,00TB,@!*221KD2<VFWL,LS4!Q9"GFI=
MN,,8@RJWK8=%N_:'Q=ACSENR_0$H\@;7*&2/S%)'3,DJE*()#G/#XRJ+)GTQ
MB?),@AQEOA*,:J!QAPD/A(>DIWF<_E%43P8-_!1GJ308@PWEFADDV UAL4,&
MEI(<<*R$(#8U\")1OH;HF(-50K%9!OD\)LFF)8.JFTAFEP##E>/-<%XJK$N
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MX*<OXK!+M.:EY L5'6SO7O:H2+XR:X$:*\$_O14,Z%NX]/(@VC@OAYV!+M/
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MAOWAW@&\?N>\_T!AJ7&'5-H#Q<KVB[H=WZ!&;0"O#> =T/*W ;PV@-<&\-H
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M>V_:W#:2+(K^%82Z[QP[ I*QD2#E&46XO?1X;K?=U_*<>>?3"9 L2FB3  <
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M)\P39DZD?%*AAZJ8Z=-D$C4QTZ%92XIBIF]3FSXU,=.E!HJ*8L;MGDF:4>&
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M K_W1KAE'&?&-SP#F(>C&$[#8M@ &^F:%VOLAQ]CJY+L%**%"1RD\!,_&$8
M4/@B+.1'6CP#>H(3:H_I/B9S#$'N<*C(0Y8K; O /44HXM^'0 &1-TQNM#>P
M#7@MGD\2V"8</^(Q3_E<=NY9%([FPT3L&8CJR1^R./OR=P0,O@K?!=!QC HH
M:-_AZ%Z21/Y@SD4 IQG>P 5>FGHCAB\ WN$T$FXWVGWZU:D'R&"!%PS9XBDG
M'GX*EBI#?ISUAP$2":N !80FLC-BR0,,<_JYT;X^LH@!N)F>X2?68+\CEOX#
MCI#1)O^ZGO^;_0#^C0&F.KZ342Z\XJ4PFGK/6A FV@!.-YVRD0^G@RW"1R?
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MBH_')45[4?S,9Z G! F73:A#HE80QR%FZ!6X>O&=4@TO51T+ZMW;.8B&()F
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M#=W_=:_NOG*]$.C]KZ^\QA[B;8@.H:3)1XCYYDO8IWW* #J5M!=2$WBI?0S
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M*/4%6";>-V$@XP_SCX51+")Z.4,5V(6[Q:8SCX<$I6%;B.4@*#-G\R+(,K?
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MH)YE40AU.\Y5)]S'@*L%?C(1#E^Y+5WD/?G(,/,)YQ=0_4<@FXN)TGZ .9Q
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M[</3J64\6)*XN#32)/E2D;)8=@":I^_EA4_K- (1,Q>Y S*669K.S!7C'_(
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MR+([GH3C+VJCF30+%_0+_##/_/$Q3,8H6X2R*BBK8M>L"N<@C=M<:MRF> H
MI6*H<80FIV+<O_W[E[_\9)G.ZW<?/_WZ_HNN??ST%K2,3^^T^W_^<O_QW<<W
M7SZ^OU\K7A60>J+LN.CF_T4&9>YY4$;YO;_@+A-1ZX;QUQ]HAXC"K$?NA15.
MM_1?HL;^Y4Z*@R7:+G-!D5UM8$5%UQB>\68QNTW_\AH5^XGW?.L'?(O\I==R
M,7D?HC1?:JW+@2A^G0OZ&T,(>]F<67Y9_OH&?O5J]>>N>=.WRW]EW)BE/U^W
ME&G=&+WR5]8MM?[GCM$]W*;LC4MM:6@]\(;?'B+ _NA:DN:8_^_UAF[(@K#7
M]D,^*+GW=I(X;[AQF%'O^A[/[3CN2L!TAY/OV!"]G0"R%P!T!);8V"#\J !8
M54(<O+IDSPCA-;G=AS.D;.>B'ZX0?B-J>(!-\.#=SU4"R%]^,KO&ZT-(B+H,
MU%HX5F:GX9"Q57;2^'^=FX[BG(7)+EG6"\8SG[S)0F\(25M5CF]H#9 I/^]U
M0J6I^J_^#VS\_R$2P0%M'OC)%S36YO'H*BVGXS\87G>N-##O_*DWB?]V=0UT
M'GA3AD]>/WC>[!;IXTTPPO^\SXGC3?+6BR),Z/AO;S('6Y#7_25_N_)_)+?!
M?'H]"KG5B,L"YP!4&.<A]*N,KSO=JSO3<77;ZO[UU>)6UPBV.KRW,XHJR+ZE
MSQ5E)_%'._FC>P;^<($_.AW=-CN*\,>!5,R&W(E?6)Q$OJC%!;RNU;*L:@ H
MY?I&\\:6NR.'([*'U.&K\D(/>4&W;7-?5MA DL>X*G91LR^>@+8(UX,04/_J
MKJ.['57HY[+,B]^]Z!N3OM4LI;260-U5C6HT/VP1J#DT\_S<>ES1-:[N+,/1
MW7Y/$17C "HXT=&.<O6 =&1>W=F&JW=[JM#1J;VAA:B27.(:G[\U;93-YR&5
M-VDC5)Z&]X2(UK6 \8QO#ULD98UG1N%\D(SGDT+OU+'V\P%%UIOT<Q_"Z)W\
M6+J]+]GN,N);H2\+Y!3.(URB+>ZRJK3/+2RQ[SYMV*>UNL\MTSHO7@'<1CTK
M&/C$DIJ2R@$,V1V]V[<4T03)DCC=C7=(0NI<W74[>E\9.CJ01='H&^^?P<"?
M3.1D U&*D]]]\9K+;YZ^5'CT4/=?/'J(%BZ5=(<Y!<;K;Q-TD!M'O/7VVYU;
MOKL][KJ+4,HW44H*_S?!Z#-2;QD>JDDI])OU]:ZSM]^#[#OU2&D36Q^>E/JH
M.>DFYN4H04J7%8WX XNV?%E%%=?TGEV$#KC%F)" ?"_@6(\77 /$JJ5;QMZ1
M.3(BU".@+4;$00C(O+KKZ_W],Q_4,A[X=ZV>VI+T:YA@G>%"+N$^L8C=4N#:
MQR;;G#8<L#79PP+CVG; NK8/I&SLG*>HND9[J=2VS;.S#[795W>=KJN[_4,E
MHAV/VBX@R_N/")NV)**C J:BSL3\R8 EI/365GH%3/^8>$$")N'[%*SP=]%%
MA?W&O)A]P<]_'O\S9IRAWF#IZIOA<#Z=\XYU[]@LPE&%N!UX\\T4:_)%-X:J
M/(=^>$<W]V<YTJ#5H\:M&K1JU-CAO@W;4L6>.[4S_PST])[WVL1)J"Q.IF6U
M!N3HVU&Z"U#^SI+'</0QAV=5)NA>W3FV;AFJY'"0K_AT(OE ).1>W?6 A/9/
MLU3+1ZRR'/TU#$??_<F$=..:TC,%8%5:[X&X!)M1E8QB4F!/)RWKDDQ?+9+9
M(AW3-A>P4;:>PH[YU 6HP=S&X?T$XZP/Y'6A;>T$#2%2C>L*]\\I(,L,RHKL
MV\.HGVGJO=ZAO-*D(2M$25MD_D$IR41*<G775<76N@!%F:?![!/ONPC-9YL\
M12"*8,NG,!C6BK?T+%2#S(XJSC;2G$\H10]!/_;575<WS+T3T=1RUC8H>:)<
MB!XQ=*T:&"IWQ=CQ[*T1 SLEAU3E>^?JKF?9NG6PAC%*9X40.Q$[5<I^J<I.
M'6 GP]+[^RMB34Q[4:J_(R>(W^1HEG1DR7W)A$(1ISE0YT,;,(&EOQ/6BI9]
MYVM]V#) 7H#;-6TE.LEYKEX_T>U';P+&#^E(;#^T+JOR*&LC,?.>L7YL'_.Z
M9=IHV0F5)N8C-&7X0U!%O=3K'B]QUKO=%J6!$C^TDQ]V["VQ'S]@47U7[^W?
M\I-2!*H[7QMQ%T=S'#OK/4?A9*)KB?<CG;@X8 $;^Y1&N\^-AL#]0\#V*T*V
M)A=C:IBEFR4=JRA/H/%4M/T>.! 5]:_N;%-WNZIDFUR6V?..C5D4\;9 3RR8
MKY@]%/+==78 /(S+_,M/'M_.8S@2BU)7YW,]UNC+3*R^HTH,F'((3MAL_P@$
M96()L&XITU_\LM1:GE)7],52"NRQ4F#W912+&ZCNP6*&I-HJ1$F54F#WI21;
MN#JZ+4N!;8C(E=FPTI]0$+VDY^Z5&BL 6@CEU^0.ASO&+5>5]K*DX)XZ2?90
ME-1!6TGO*]-IX_+298>KR0;4<.S@\G=_3L%@9-_47<=5/B&.NHZI(*CW)SF,
M]]FVWG75;W1W 25BRSY?79N$P<-UPJ(IJ<7'</_6K@'J8V-SHZ?WE*D"(@59
M$0]P?9KJ8U->P]E;%*NE**LL<'=Q_.XKA"_"<U?/!UR;54P#(W"&J1NN*N,
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MKU7'=CA4=06[\O;*M-@==H;!45MWP:!QC/X.T$;-[MC44_,HU;7RRCO;AP9
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M6;9N67NWZCH@.L]DX1$/$P^?ME'/87C8!1XV++U_L,E5Y^)AKFR\2G#(=)K
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ME5)4IU]JM?!_^\&(!<GM=7^FC$CHE)DQVHQ%6OSH14SSDB3R!_/$&TR8EH0
MGND4A 9VXISX4S]AH_1'<1(.OSV&$^"^6-<&7NP/5\:'K$:*;0#;*)SCZBV[
M1'8\8W,OBS]8=(\TLM'.L=9GZ7M1 %"(TV5^08K);@<COQTP$>&F9'#N#GD(
MFR!_0/UJ^P?+-"QB@F8P02T><)>8H";M=Z_NC#+:WS5YBQB &.!,MT#OP->
MB]> N6J#G^$:J*PO#L=C8SQLB[[X+_X/T/P\V)3WP(2J&&OS&'XF=,39/&%:
ML$&O#,=[JI)[1!>49K:UO": O%'9,I:9*\74&X&H3_/I@$6?QYS1XL_S)$X
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M$4WG\LS_6W#HTX)MG^8/_0M#>Q.TP@??QUKAY,&G7K??\4\+CW^ZX?B;;1R
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M;NY;IJ5[=+E]9]O< !0YQ6"SV3KQ(@DW#Y;(,_!]L+[0I&/,49AMK6!Z 1=
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M%W7$8C]!V:"@+OAI6>7K#E='<>VM2<6WT>C)+M.\C<B<&3K"%E')8M%CHDZ
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M*2NE,8:"//1101[Z1_29DY$%--T5&EJY"P+/FH>!['F -S8$(F<JOV-/8I[
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MT%4$OX,4Y^I%"-D9C&[+_Y[ YX[AMB^,U-%'$:C50LOG#Z3ZQ<"Q*'FT[8(
M@<9)"11KT91M\?#P&9>VZ7D]86ELT EQ4QF31B4$>-$N(":^J+E.7K9'\T(E
MXB$;YKK4<-S !'YALK..@*_'I!*._X[Y$<#.')',75C 0T2>M\I#@LBI90\8
M]Z(E3[J/#8_]%[ZV: E6;-:!WF'.8\!M%81)E\UU5,&.8HUQ9Q^IT^8)5,1L
M\R!IN3MDE A;4J!H(K*[&_K 2*%I,2D=Q&6GF'E!;Y]4DL(E<+9$G02SW34L
MHL<('K/PT%(!"O(5T7)Q/:$,DFS!'<%R&R+=B"-IU/#.#41L-YS2>6^J&&DQ
M26LD=,4H$3$@7PN.D$V6Q"SCX[U5/F=;+\4-0_A2Q7M-J;N98T8B -0-C@@S
MY4N[!'IX%S< *\)XS@:OLG#/27V_=R!+Z^ZD#*I5:.=5 W9C[=[F>SM*U:!6
MG7;O1:9-M>.W^3SZ>-K5+[DT[46FC@6_VFV^WC>>>AKY/6%-%<FG!(9P4DL7
MB:U8HE.+E,2%8-1H9G>L6.RU4-U6+[FNWS?U8=@%R^:V /Q5&C9[4$&_YBGV
M.K/Q;1[C9\-QYY!W,VD#.0\?#\*P@3IX# <=!HNRD<3=._JW\.X;^<_8+:4T
M<QI;H/LJ_I*Q#"T)G94V*S)N==)@J$)&*<CA V@I$9G9=%)?*-<$#;P[O,>\
M0Q1:7/9[U[N'';>"WUW?O^?;5*&YQU K;NZ!K8$"3.:B+HORU;X(J%A^.C:X
MF^J<G%IU5DQ _^B"F1E8)VZWFD@Z5WJ%UTX9M/1(@.Z<8BX7JGQ>ZD WRMW?
ME5<=^>%NV>71$,4IYN[>*>8;T\ME:C*(A?R522*!7.:/?TVI'<LGUX0L)-PY
M\XGDR"JT VMML^+$1I'7GOBJ.#MR_JS$]).*L(O+I4R) 'QGQE%LT=@Y)^('
M>WG6OPEQ!W0)CWQ:/"1:P'XF$=G+1WK-T(LBO5)8]/$F%;;O!HW+;!-JQ7<7
MP0]J_U9"7N2E^>$<)8N( H/!CT>#["*>^BO!\I--7])W;05^A2X=%I1]I((P
M(HI= ,#Z9<92%!%0UBGN]=JSJ R!KQ)+"L %#/!?LJH@T:\K98;LPD4Z=EW!
MJRL_&:MOZ"$.JA[BJTY*=X-$("6*&R.U/]T!A0ZJ5,I=]BFZ1G>>EQ0S+LG'
MK4(K*A:_E">%%R1VJS$#G2R=^Q(.KT!%K?7GC":K+UE:VQ(3K6R.8QN&87=3
M,#2L@SQEV"TJJ1(TETQ\KBL)6DM[5:/C)$%/XSU$Y-);;5S@?L]W2(+6#<_U
M?1'3Y&0B+S9OE0=DGH1K*K*"]TT)UHZ3'UY#2O!PW)E-ID6)1-Q=2F03Q>5T
M2%5)R9))ZJUAA\8OE]J;(*@),.5M/Q^%XEN1(*J2Y+)#,H]*LHQN4EE&HE1;
M?DAW/)3)XJ=T "^;B41D+$G:).2-2<CC-@FY 7-IDY#/< E[)"$/"Y.01V>2
MA)PPLG;.]=R<?%Q-7X[W"#MNRC#>$F2,\\*&)1V$990X<GH2=T[7FX"<2L&L
M%(:HFHL9J?NJ"9E?^8WLRL+ 36D)<E2;OU/Z7G&Q^)[Y?-R-B6(98A!N:\J;
M@#;GKUK.G_*P<3MQ.YXLLSBC4P2,HJ2MZ)V4M(F3R<:/^&8&K"13Q]]([)<F
M$G9)VHJJ+N.6EFUR5)L<U29'M<E1;7)447+4EMRH>G*AMA3UU9.9,^IV9MW;
M47E@>$LF3A4C<X=ZR+T2;+1IO>'R$4*2]T:W>0S$Y*YD$U94*N+#ZE"IL= :
MQ^J\LDP6__!4%I-7F)TFJ26?RW+(N1TEF25_MMK6JY!CY:^<.Z2D60HIF32%
M_C<T'XFX*X%(-E+H)Y?U;[DLGA<0&97(/=(J$]Y+[$HH[T(6 [^@!OUI!<_)
M"O*HDZ,JZF/(.\ST N?5-6")!N0/E;TN,N.S:0^ZA^%^822L]&=D<9.M&6TP
MB@8YBQL12#+$)2!E3,+S3UCSBG$F8$#X7^0.=((O0*\G/)&_^J5]->'$ KQ7
M%S&)>1A$'K!MK2PA.*.H!IXX^EB@'^*,H"B@$-VA)#U@X7>0S('?TKV32AX'
MZ&YN0L:/4I(*)3SYX1IMK<1W!("#"Z1IA$X<&@S7E(.D)C-.C&0I9ZS+X^$B
M=YW@$O,!#$N^,XH N6L1?GPGG"!<TH\E(WU6[/WCKD1>?9G/SA. P-.Q3:3?
MM-,O/7[*)?7RX8ET]*)LE,!]I&FJDL7\5)F7% $$1DFLD&0LE:= P*:N7#^*
M@,2TA9LAC/9L;"DS#G*<)+4\^<@MQ  7'32=,S];7'NX?O1TDT4Y4%$5>HX
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M_KOTXH*O1W8S]YC^_49'H*XWNOU#?_9QUY.EPY9SD]S"[.I+U[A8'&V-G'Z
M_%V.P_,&Z)5Y^!3,26_,7)2EAVS_7]O!?T#;4O$ZUH?_[1?];!=QC](..T*=
M[Q)\FGP!^Y0# &F=307ZFTOQ&PZ<<2H\A/Y.D#XMED'#*O3;2>TZJ1;+H,4R
M:+$,6BR#%LN@Q3)H9]9B&;18!FTIWF[1_Y>J&NE-L12OIW9'%]2FO66,BV6,
MT0L4P6C="TR2;'GB<GFBGIJ>S3S1:WFBY8DSXHF7*NW1M*894)<55VBQ#.KA
MAQ>H4-+J*RYIBX<;240OA;"G87%)=ZR.)DTI'FXIJ5Y*>@%(.JT^^*V6B!I)
M1"]5I**-FB:.KB$VWF(95&*&ERKXT,:=V7BJ@K77$'^GK2"NEY!>H/! FUQ@
M-*DEH@01O=3]E8;W5^I4.U@QMW341#H:UW/=LYV.^MW.;-)3A\-\!]NSCN*U
M< 9M0=;5%V3UQB^%>M?O=6;:H N>8@MGT#)PR\"U,?!+7>?UM;I#/2T#MPS<
M,O"XGOO''1BX7Y-#V+)OR[XM^W+V?:F+EOZ@,QL.NVJ_.SQS]MT)T>!\"X;C
M\EYW45@3'-_:P)_*1VLU#WT%?NKI:Q;"EOFJ\OOO]\HK_('6_94_0/_H_?I:
MS72V%Y5C.%*0?OO2@A$]8_FL*C_@00\+PTW^(]@9QF^05BQ8NF9R2E0UKGQU
MUY:A]+6^$OI4_ QC+Y_7+OPO':IB6S" J6/]Q=QUOXMWBN'DU/_Q^]M_BL_D
M_&$DH,7'I?*_H<.4?I<7.ZLXJT7HP? >L)-O>-:<F;0];L"47D]5Q)77A_C*
MZU9Y !J G3!TFK<[AV-[HL0GRUF'@0]SAT$"%T8,F+>"XU+BS82C2.X67S8N
M,S%IY0?S&'T([X.W_Q6W#DC45A:6HSN&!7_Y 6S"*JI+*3IPN5<H2M8>6\"@
MCL%NE?=Q;3G\RK3LD!Y)D\U?2PC&##WYRV>F>S!#/%Q92Z[(,G(U2Q:;1D_1
M29H0>D0W"DB=FU6<8":H2.29/>,SB<'A:<5VG4<8AOUDGF'YP&I^XLPL9P%3
M@KU07) 68F6WP N6KQA+'7Z)"]8- Z17@*L5Q^(Q/[0#3B ZBF>/@3SX$SYX
MU"W:P+]4LL VB_!OT?!_A]%_=WW_DY,@P\J"?%C1/MP\NTBU_,$Q!G!._[*"
MY;<$/WP@=O@")PLT:UM$B5_PS)"$WNJ^Y9.:^NJ![ /J]#^%P:<%299^Y=6-
MRFS,W ?$+WX(L_Q/B-0'<W>?D+<\=T5D)&5;D5 3< R[<<'@=E<PA08KEV]I
M*N?B!FP)9"K=LTA,T]9QSD'&WD$9L5PF 0S&DDKF!Q 3#!7S8V)0H76 KL@^
M('60$(CP3G?-.!P)\/67S/R3DS8MK.>;DP0D(<0L+LHC:H@EULYSYM+ *?I!
MI9E? /6\=[U(P2:A2SSVJ'NFY*'MU*&"L&<;M7(&.J;0LD-AL1V,IM>?=K9L
M.A:8"WOT!ETKVN)MQW#S(N>0N\ZA<W@U>LVM]?Q_A5+X&*Y@:".O!=)R'XYJ
M9?$MOW/,>]KB1]"E%O-C)^,K#/#6=HWOL7P><_T"Y\',NT!\AL.#U04&Z/_7
M";R0(9!1-#P)FM0+I"@74\V@!94@ ?&W%+R['!]HU,#3I1'?6 %,P-CEO/72
M\_X=%'8B,W\#F>^PZA-[/=+B6X(%N +;S%HCEA>7H"!;;%HJFA(@6<'X8PI,
M%/Z+E*4+8YKQI^@AE#MK,DF#I1Z ];BV0,##7T^@-%RT?D%2^Y$OH77[8S0;
MT_-@-J/Z<!1L\+;O^B-IP379'^C#P+#,M(C$8_,_0".( .^41[3:R3I=*'</
M]\(6G@PT59&G]M)$5GP":4HZ!0VHZ&:QGX8=FG"V2]<+;M#EB@Y>*O&Y;M..
M^DO& NXPN2 35G-TSOCYXX?H9O!_P7=KU^'N7O* (V7O9\B'@@]X8B&.Q>&W
M^.FN/21(]%+@#1&%J8HC9B+'24R?FU@@?>+%@#>GS\&(QJH:,;!+6A7<%)"<
M9NI[_#W_-O&I&@^IHBNS!C*UP-)]O@0[X]L:)3YLXUKZLCK?-S7E&48>.5AB
M"_3A=,]#^Y([N7[\(_C6HD_280_X12Q=T+1)TD#T*X?H$:RY-3<KB48#AH<"
MS$X3 #E"$Q,_Q .+7@GVMN\Z8(4"N0'AZ&0SZBF@-[ T;3OR;ND;\;);Y7=!
MP'Z QRR XR)I""+I6=B:3U+T()$).SWF!:)V?4W"X$_N]( P- (:V8<'?9^>
MP4UWD)"D^<Q,E:_"<,'E1KL;H>J (#P=#^P&#P\8$KR_> K\M9SV??$O%)..
MSRZ!.C\X$>5)DU><2^PEI4\G3;8A"C.+W >#N]J@1N:NY_$PCH?4!#O*MQI_
MF$()?-(MFPY0T% DX588 R'21[V&!(A?TVC6:@TZ@(@Y\1LX,L=%CUDW89.B
M->'@MPJQ()"D$<8LZ,#^%; AL!#.C_A)=W3[&8DA%3#;LE@>'<2',)J *T@_
M !QE(@W CJ!>E^I[ 2K8]7S!H9PGT->'N1H(5PAO)VKG^X9".*++6^6N'#5Q
MP)<'L]7Y"7-J0)D!%(X&0(+ R1J)A$A2 PBMA>&PC4;Y4!KEOOGHO7G/?PW6
M^"<Y*HF ?XDYW/$I?)&3HR^_PDQ2,18@;>.-&7H8SHBM]DEGUNMES6X*>>SF
M< D^NT8HX%YF?UHHX%/,I84"/L,E5(4"WNC,-]PT>+<QDIS5,AG7MM#K(+5)
MQL#\N98+"=(R'\2H'YPO^,Y/BV\^XY?,[T+VU8WC-,]?& EI>%GE(/ZT,]/4
MZ3#?OTXQP4@BERUZ#;HPXCV$=^P:%D53,08KO7VN4"_!@OPG6##<AL/+BXRC
M*TQR-"S2$>O-9@9>,EJK%5H]>*,H?[Z5#&\W6R>YD"$9'/<P19*O^=C@H)N/
MSPVZ^=C@G6F2&0!S!4,1C%K__V?OVIO<1)+\5R&TM[=V!*T1"/2P+SJB_9KS
MGE_A]LS&_G6!4*G%F@8MH&[W??K+S"H0$B"!A-0@U5VLQ^Z6H"HKWY7YR^RM
MXM8=8[9>^-W\$B_*(FV_VBO)2,L]![1L<]35#/W,,: ;N:CM$.6' %-K9AE\
MWJT58J=TL<N!]_X3M=3[?"VUX3J40/8MBZ%:MCBIV<#'J,3+X/\>#%E[-N0J
M Y$MR960:QU/_1+0KU9)UPPD0LEZR(NNZKV<NMT=956)KUPU=C+ _]1&:F]<
M\^"Q5M?12YFZ#)G: ;2ROU 1DJ0Z'-3<.BJ%ZKG92PK53J': 3JSOU!A.YBF
MCL?-%ZJ246,;&)[&6BPLAU^(NNLU8,7@7>>.9K(EXYW<IMYX4W''2CS_35S1
M5^9[ _A^J ZUBGV0Q[$,)6%NSOW\"SR'XS" "0R@J_J@(DR;9(#36[GC, ""
M5JKZL&(GY4D:'RO>Z(0A8^OE)I]$I>'39RNBKJRBVY[AYKU..V_DQ#:QW'+5
MM9%W[[1>F;FEB$B4=<(QV/AM7K.5OJS#9D6ZK0K/;DKKR.R"8:SO-F7[%=:I
M,Y+;:G2.J@K_*>YRD3$WF>Y5SC7)H5%D32"XW,[T&NY2@\R:<@#<I<PO*8!'
M)T=APQYNN N)9?SAOP'?P9FB5'[U*D,Q&",*((R<^I@S $1L@;0/Y#B34XG'
MCT>_LGB,23RT_L%3?YJ%"-\:\1A*,/B3B<<\8)7MA]D# 3'5<=7X4]J/F@1D
M).W'J03D@[\,*LL'7J$;ZKA?U\6$-"#5Y&,L#<C)Y,-YJ&X_=)(/4Y?QQS,P
M"R*U,6H2DU;D%%)R@Z3>6U3ZG>OQ4#5[YVA*]%'3105G%RBS9;0,F((]U_?+
M^XW^ZD,LS0%U,%*ZA'15%BBZ/ >)ZM<UX^K9JD;.I-XY#%\A2L"2MU*!KF1A
M=&&6Z<6)A></;^J$!$K)IN]_V?"EFWO\5V5A,CO7YABL4S93]K*EAJG1PO)M
M$^M#FJ93FJ:=<E59?A!L%(OM]8.+[:4QJLT8Q4@P"S^( 6AJ$*SV6J>3B<];
M3OC*4C2DXOK1\,PF^-)[^\/&R\Q&:5(*'FY/[26G5AR)-%+/D)[YXGOVGJH&
M*R=ZFJH9!^=C:CS7&FLYTW@5+8(LIB=6 +6=; &UO;-<Y;,5@?XZ VS;#P1<
M"D]$T!O\[SI^WKWUI$R8[=\CTM^#[SYP.!-@U(@ 34&AWPD0.P%V+L!.?,3<
MMH(G$,ME$%(L,D$L/7"@NLH_YH[+!) =#CJ@4M5P:<_3#[0M#R$ )X2D,G7L
M!')'0%5&3RHLS[,$IN:$N0Y[(,Q<@3Z(M;&N BNEY<=ON.<G%R,,NLY/YC[A
MYN?6 U,L)4&IL:8@&X@..9LA&*7 .]P$$%_-R8BQXQ!Z,[6M%<HZ_L+&YI@9
M%M9*5+M\KHQ1[?0-^J3^K "PCIT0$@NOT1AL$@NO&5LHQ,)KD9G?;M2'-4TF
M^.BA1?EA_=HVA\ <9['&S'$6:XP_3(&G[3EV@#\TYU5ZIV*SS:T]9].ER[[.
MWB:@Y%]GR6[?<YCD-\QC,Z<(8FW0*]ETTVRW2)Q*9/V*T:&5%Q.^\9<$U@T$
M H<'<9!GZ^!N9]<P(X':)%!;ZX':E)P6)(G4MEX4)Y':)%+;\<AUSDAM^9L6
MMQ6ORO#)_H@CNQBH"B[/Q:WLHNJ>/[ I3IV0C:1M;B2M5 F4 9W!V;3PM\RH
M/:ZI!(-D0KV<>XZ!1DK]@*J>FBJS]Q3<4FAD4@ :* !UPO7MP?=ZYWI86S&.
M9'[)_$?4_AG$H?K4/R+KC;/=G2=7_Q?5F'.+XYME;=F^B,>"S8F*-][TDV^7
M9':C<]T_' JCIMJQ.H,IR3(E/83J/(.%[XWIR9(\\ZR&M3KW#""Z&O7.IF>B
M'>;U@Q_ /SW9&GZ@@15TS&'T:K64 RS;5DVM*2 B-41;DI<JQ^:%S)3EEU'G
M>EP5\E9R2SNX90=&_![<,@8/K7]P1TBSXMA&VU=Q1C@V=+.VYI"@]F([$<M9
MXX+RK:K&>(B07BK$-8T?I7#B8.=RV:^< :^+__#"2=5:,,I#\E^C7()"_LNR
MF-ZY/MQ]?.Y1,2W#,<@OG7G'9@Q.;[I?[4P9E_H2OW]1ER4%U2YGGL>LT7^,
M95 0LI0=GSF_V/3J_UC@Y^G7?N>:^N;TUS(O?H[\M,,AK)^A#,E09\U0.SR\
M^AG*;!I#7=0%S/[U#1>2!"TG#FO7C34(Q: VH9"I]29R54FS73=;#25;G35;
ME33>=;/5J&EL=5E1]P$U%.UU:H_2E)%XMYRD%?*8X\ZU;F83F2>O'I+1T+.$
MUSOXI;0J'?6:%@U)AGJ6\+HVAM*:QE#G=9>2SQ+Q,:;K+@24B02 /H4!+V^Y
M1_JAEKO2X;0@2#HK+CN&M:]!*]=W+2.Y[URXKZ1K4 /WU7>'<W3NNX0BS2SP
MV9Z5+Q*C^TBD.2,MLUW)U%0Y.#*Q<M70ZFK@?"Y [AJ"7RFZ4G1/XY[6);N#
MHU3]2MF5LGO!LKO#N:^0KQC67S'=Q$$7>Z(H<T*^8:#SV HS&OX3PDIP]DC<
MK9:+I#P:E4121C#A!D,IK["D$2OYA>N'X<LX%SDAVJ0RD_#:R1-%'_]:!DZ(
M8Q^0G1\9?,H*!<IR*#&6VPAGW,A%28QEB;$L,9:;2BZ)L?S\&,OM*#SZ QQ>
M4$I439:9OWGP17_CMELY!FI1+'.4RUCN?W\"YQ,GGN&X'L=; D&^)N.Y-OQT
M%L:>>N6DQ1C!$7NJ/LZB2[2Q!DM*3YNDI_XLWDF$9MSK7/?':F^8G13?VEHS
M*3AM$ISC0 ">4H0TL#MF3]6,+#ZU1 YL:M7[A72#U&YH!,TK"XG>N394<W1&
M$.Z2S8[IT.S+9WWP9]21(>$(SY+/2EVAG83/#*QNZ>E:0_CL$FKD7GS:<8<E
M2^;DW7W[\EV?'<\/G.CI(V:V(0*Y\:;K3WG_[R7\^C.+YC[\Y@$^<H_7NI55
M%A;DC4QUJ&655N4X15;T2*UPEEKAF=W>DRF# <1CNCK69(F?5 A2(;0A/WDR
MU8#S'XRQJNG9.X'6^ G'JRY\/YLQ(,;#ZFB^6Q'[SN !MN,Z='@%I87C,RDM
M7-\LEA?F8,M;D1+-X3^+A0LGQ(L!K6@9^<%3^N,!%@XHD4\?9C%M-S^A.*&L
M0VQYR5\C%R7K$&NK0Y1EB+(,498ARC+$YW#2;Q/78L9!:3<="#GI9E=^ P(#
MT.9;\YZ9!$<97_@F'G"<G-':AY, Y$I?^<F(I 9FN]DS(9[G_/ZZUV@&.?3D
M<$D8/H,H@*Z7HB!%H6FB,'H64="D*)03A8LJ J36$W[_KRH>BS =%3N! F\O
M4QAPJ24UQ_+Q\L&D69@KQGKGNM\]N-Q<UF<UE)D.=Y,J<5._<VUVFS).5G)3
M\SR-2MQD(#>=64U?2\PXXPRA#?07]R\5U[EW(CJ_"\.TK\5VA].[H)QP<*H#
MT3\E!-^)(ID6F,9-;CIQ&'@!')9OT ]DL1Q6&G2NM6Y=:(&2C9ZO+J:D*=^H
MC*F?H;".)<>8RYZ\XX;COOT3MGF/52#[&_#V>KB5Y6*[6%1Q=;_X>#._A(]-
M7"90Y&[G5L#>6"&;ODV=R5L_C')E9H0R<PA^@HRD6F7&3\Q>"-'1E3V@Y\IC
MAT?KA_.8UNM<]QJ37[RH&/X[BY8!5E]>+0+_P0F19:PI%J]2(?*%1?(U.P*E
M_6-^"C_\;_$9W*R.(%=@$+^B:SZ_GRQCKMI9:M/HGXRGZ))'SD)L 4_58^./
MQTE]-.=-20M=5"C_G87,"NRY8GE3./,'YOH+/"?%#MCTL"EV%R G]87U\,.W
M1/$P/I%<03$ZUX:\"6T-/QULRX_&2(@38!R4.)5,U%"EM",'?P1F&J C*&_4
MGX$WX(#H^&'A#(XM51X7@"T/0N !&9&?TH:GSR)75H;HZLI O 6<]#RV>R<#
MT>V-T9!827+1J:_0:^>G,2JD!F1Q+BKL?CNWX% 4QU,>+'?)(18LQ#VP/'N_
M/L;V^K?/:+'Y,7STXIG+\*&;,&11^&=\*C?QH>3)CHZ-6WI.XDI&4>WGLAUI
M]5.RF899GZS)EUS6?BZKT=H?RF4Z*+-1SJ7ZR=GLHB+XK]&<!3)&/Y7%)W+O
MN([2^ZAO#['J,KIJ*B?5:-5+L9(A6:DEK'3Z.K@L Y5ORM$;UY134_S>:&/]
MO@B[\)"0_6C0L\V3L9,:_CS U5Q1&F &K(9Z^&?!06T"%L6)X\(+$IA3W$&4
MEI-AG8W34EBDL+30@\L7E@I^VZ@VO^W2!:D$_'<KD;<_9G&V@;\(._L)H7E9
M/C2O@MBS2L 6 0LQFJ O8#.-Y3W]+4P[K/X$MLU9%V^@;#AAR\%M$DPW%H(2
MTA+^;L8G9RG_6@9..'7LY$N/<\>>*TZ$,H6M/*$R68:PE3#L*CLV$&[L0!&+
M[Q<O/L9ZPK6M+;=H6R4V@4LZ8!<%F] ;<0(W(98 Y;.(FEZ6,K?@?<ILZ;IY
M-Y$*_../[FUW[0 XX:<BRTS[L2C/W-U AP9AY+5)_+%KXB@XWD#$]84?.OB!
M5P%S+=2X*Z#UOZXC9 LEUUM]Q9J 2EM&Q5\Y.JCV;JG63)QC>I6".N;T2?TY
M#^+U+*P[=C4)F/7SRIK!<E]9[J/U%*+E3VLS4&5I$F[NOG"/L]G1]LCU)UA4
MG]O%5V"K6("?@C59C5F+,@_0_O_%&<_LB=T;#GK3T<R8ZK.);4QL?3B83$Q#
M']G#_QUB?1U:4I"E__K-:NTFT&<!UF_S%D):?([X;.B8&%W8'*//)7[#IC=1
M_--^6^=Q_ "E'?D1Z&![6^U(!5?A$53_?]0^:!C]Y/VO)2M-L1GJX\ZUH:G:
M.%M/J0K[B)M<!/#] (Y$F2X9C2%A]PM@R !^X("7'S!X-W<(;&OA (WA7*9*
M4-0:(]P!;JA#;%Q6)MBYO(:(H2H+"SQG.)@GT!\SV+ R>4IWRN)"&$WS4>YI
MG ^<:#+/9\.4[CG&)D-RA$ASK D<3>2P,'^"S;#?.X\)-E@;S8?-D#>4?^C1
MW(J4.\SH@GM%S($Y1F<&(0^<-'R!^UOP_<3A2?EQW.\1#)+]M;NBM?((;Y3C
M;4H]JKF39!JY*#G>IM(0C8+82$ZVD9-MY&2;<YMLT^C;Y'>%'L6KO6X,2H/>
M[^*IO:I"+F5E%]6G\ 6;"?E%AW>GN'X80H@4!$\0*SU:P3337'AP26_C*%!^
M7&[>%IM]GU(E^#>W!_^94/-KS#4XN?9MFF>J1OE]K7-M:JII' P0TIPR>"DG
MYRHG@^>3$[US;1BJIC4%%T_*B9230CGI&\\G*/W.]6"H#LVF .E<5,/+VQ(I
M]@OKASFF'_;1^Q;X-@L3!)<;;_IN1>G*LF. [.BJKF6O7"0"0?NYJZKW4C=W
M(2Q57]5UB6]QCMQ5V>;7S5X#B"154SNXAKE9+3/ML/LWMATLP>;'M^<7AG)Q
M3!L/?XE_)N#445Z"!X87_D1W>)*@?^K^O[+X##O7_:%J&@=KY^8$F)+K]K;]
MI^*Z4>=ZJ*F#X1FE-237[>\3G(KML+:LK_8'3<DZ7U22(+D:11A+;[E??^UE
M.-55G87X![Q<LZI8&#UTH8W#I4(&: WDI:HNP(&\A!=[JCX^V+!+7FH@+U4V
M[ <RD]ZY'JAFORF*Z:)B^T_,"EFZW%D&]U7M-0U7R<@$$?8 +];H=ZYU"-G-
MIJ"SR^#I!/;Z2+QD=*[[NFJ,)2^=(R\5V>LC,9.):)/JV)3A]7/<P?.A'C*J
MKC,%SXEZ4&6*,0"I&*NCD;S_/$>FVB/#7@=3#8&I-'7<RX+\2Z9J/U/MDT"O
M@ZMP#LE(-<RF9&_J#+CU4<,-^.\!MF+D8+#4 $1YYF!@-1A[HGYE@1FC&C94
M;5Q7V>F1L+U.'UE=+.-5=0CV8CRSAYIZI Y[==V@2\9K.^-5=AKVXSR<.C_L
MJ>:P9M30(W#>)30<?V+@--0U<*J]WG4Q"G4-OL'AJ$:FCE(S5'7]D%DL,E9K
M(C=5-?@U<%,?2^H':J]_R+!GR4U-Y*;*5KP&=C*0G8;JV!P^/SM=5,B/4 PR
MX'^>@!]H7UE0S,XUJ-WQL*X++AETM9WKJAK_?;@..YQT=3 \N#U3<MV9<%UE
M)V$?MAM2:<A JZLS2,;YAR"?Y@&+I8KS#D(7>VZDKL9]_Z(*/?_P B:P&^YP
M8@'H'H%AG (OOK#BSR.EDU+%52NJ_PY$#[]Z/P(+J73+[&6P5_F5B4UUJIY3
M9R*'2K>;P<H[F<=EL#&5!YAFMNA$<EB[.:R"0WE4%AOT.M>&:O3'S\]A%U4\
M^BU@"\LY$,CA0C*T>YE[06#1W1SFL;[6N1[DE$[+A'Z[V64OXYUAEXIJ%*\;
MP5 ?X@I*;FHB-^UGJ ]E)[QO!*N<34"V^GJH\5;Y'8X=M!U1V>%-%>L>A]?\
M'_U 1N0']V.F)"1-:L0<21&ZLK08U/#1ZQ]2ZB'#I";R5<G>S"/QE4D)>7-0
MPUA[R5>-XJNR?9I'8BSL4!NH0Z/W_(Q59]3=KO*/S,"8JJ[5T:;"-XYNY?'6
MZR1-L_7-,4ME4FHG<Y$\<WZQZ=7_L<#/TRS#SO5__F6D:_KKFCK*ZCC)9PIC
MI?Q*^7V>HJ/]Y7<DY5?*KY3?YR[?VE^ Q^<BP!08_$83D).!KFLCM%LZT;I@
M="V-<U=IZOM;_Q[6]:3,K:DR8T!>R^53RB,K8HJ7G>;WHO/EZZ?.R_6I?OB6
M2I/AZQL.]P[B&J"Y734N'?9PB*BA&L/L/091X)GV<XN$Q['KOHWKKK@I[)_4
MQZHQSD;;*@[/63#XQP-SG[K*CSD3IPP'NG&<CX[KXG6M@Y/J6?3(F(<\8Q)A
M@&K /,Y,\?Q(6>(8^\G3&B]%/KQJNK19*NP$GEY83S27W/&4V3):PJ.!"(X_
M#;O*'Q$H()Y?0%9:^&%TI?>T8<*2V24ZH>(Z]TZ$O0V^,NK]E4:V6[_$*^B]
M=\Q#,E/\JU@TM=U3GI@5T#[H>8IXH(+".G/@B(DX^PF.'RSF(.338'FGV!PQ
MB=X4_[YH>A'%Y?P+!\J5-JP'W",>GU&9 ?7.-=!)'Q<(%6>X4]"A'CRFO>F
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M8U<3T#H_KZP9+/>5Y3Y:3R&&<FFI!)%,DW!S]X5[G,V.MD>N!\!"^EQ 7H%
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M#O:YA\K, ?[\HWO;3?!+4IV* 8N6@1<F??'^,N0=BJKB(I811\(1  '9[U7
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M#;8O,0V:QR,DL25>2-?\P]?'RKX6N X$MM^^W&RFIGU+T;8$W&<2<%\"[DO
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MUW)ZAS_@+UF-3()-A'EY#G!MF!@(&QYZRTF =:MI79PT".\H+ESA]7,'G(@
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M5=.SU_"9MOP6]+E)>6B3/-1Y#W:8&/3I4GYX3O V4A3:) K53$/F=O0HML'
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M@4XI7P'&PM9.8S,0(%#4;'79EIMU\00X<6N*1()/3)YX75M2Y1937@F9O0R
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M]?:GA=[^;10L[6@9L#5'L?TB#_[@WY=NO0& 89[2'1Q#T&J,#;77S\*AEPP
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M'M- ^8Y5K=\4>!/)8_7RV$XD^1/P&()I&ZIAUI5=DQ'\;B[YSL)(\6?*/_S
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MH;6%"=>3YV97WT\[QOA%(%PX>Z)9I?CBN>]RGWD"G" <J<<YA(WK#W^@5NB
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M6,L.:S]_:W B?TM']')=4[5A%EQZA[^U'6>N2GWNL(6P/V_78#6^)[VL'_R
M837XW^%PPJDCI(!* ;Z)@OZ/'E5U.64KGYI=E_?%CY2;I()(EJ^GRM>U6LK7
MQSU9OM[PLFE9OMZ,+1Q8OOY<-V2D1[_=?/^A?/SX<6_TO'&_?694ZW63&O90
M55:72%^3\EB(8-[ZP0(Y@RF_8\L8]FF= U@BEC7F0F51A[\3*H)$HC\[)L)4
MP68TQ\./@6Q@RYO-1/'YQA/)[:!NO0EOH[/B C+>#>G_>EJ!9G!$I15:%@8
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M[ LL[_^-P0'Z+N::$>;V:B3 ]]5(@&\<&"PU)?2#@XW1&;^Q"HS ?@RS T:
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M;KI+*'O$:^Y&H:&18*:X4(<%B#^U=*K*^',5$PGQ-X,_%_%7&?RM*LZB.Y-
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M2UA1:EI1REU=4:K1B;IC\:]^,@A._Q]02P,$%     @ .8%:6N^N]4Z;%0
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M%Z!^]Z-_PJ1$&^9WBONPF'3/YB@"=0SG:4I!-!5(J7U)%-BHC<>Y^MKM,AZ
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M80SXP'/T(-Z@A@^::>_&.<I2E")3YH#84J]7ZFP19O;$H_\6;<HAYMJO^H.
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MJZEI5GJVE-90S336\FXX@1%NDC@UG(VTF62%9IITZ$R[TCXN>&5BX(Y:53O
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M65;*N#'0PGL/RK--M.:10\158S]5A\IZI#85A5OYV'B.9WPV3'-$XT6SQ U
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M8CHX*;P%I[P8'YJAO_G--%(XF_XBCV$3N!V=&6X)]8E.#]N3?+\LW!X8ZJ*
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M >+RYK160B5.G%:N1%A9"5<YHKS),5N3<(FK'8Y^ ,^+59EJ)-7LKC K/#3
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M.^K^L W=AW!,]+F4^)I&2871T2-&@MM *<:@-?K"@A-E3*G'D$.0L4*L^'K
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M32!N$ZNOH4$W\/8;S^^,VDU5IR4O3Z1"3E,?'/-$6P0H?>E9JYTA"@0HT":
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MAT#,:R&SDD0&SHETS!'KI"%6R2Q4S#+'VBF!#\#9OQ/;(9'K5*8E"UV<M:R
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M,[B9QC#="^5L,J>N"B!T,)^G<8A;J,EF.]?^.=Z??=1N;A)P>U".$6N*X2>
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M6"B(#ZPCKXI[!0PE@O+U=B%X"]%)D:11LC0?>-:2_I>Y* Z.A#Z:DJV^K7K
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M4D#/0#*NK"HI2MZZ:NH)9#X[3/6KJ%[VISG)[\:S=50/?-%"6A' NR )_;Z
M<[08$G,I^6!-9.T3.C=1]3R1TTH-/32\^9"G9%HC2> -3HFJR22/9H/BR;UF
MQD-.&"K/&M"J6NB.')65S-G6Y>,K"7EV<-A5V"WOJM9Y6$O0?LAQ_'E4FS,-
M3+3>B%R :".,,@J_7)(>@C=D-;U)#KO56G9ZW3-1>D_R[:'MS%F,<^^(*,K#
M;_5$[5V>7:%3&!ZXJ<6^TG+:GY(C8%HB-<HDN"Y2Y=9-TQZCYYF H[GH6W>=
M>9\GD6C S_F/\L_Q[$X5X !YB3)00(>$SNK<1/!1$,?9EZPS)LE$I_W@L;<\
M$TVWE>;:AC*MZQ@_+@J,/N2OX\F<WLN+"YQ\']_NZ5_&DXOY]=A?Y-"0;?N:
MXVPV7OR3"N7E,W:I?>R#C#;UDKT+J%&-Y7TZ;U%U VP=14S&:4*RGJ<I<W"H
M1.T*JX(4A2O5>I/O0E>[6LM'WO;C]^67B[LD[3R2RV7 &5>SQIP%QU! TMSP
MZ ./KG6$_00R]U5GV1P]ZVLM^U'1L51:7H\0__%R2H*;3J_6_OQJHP0M,<8(
M&+DA$Q 3>"4%_=6)VO.T9-%\<.MC!!W^^K<G-#QH.M!**SV<X2QIN6I%WX&8
MGFHG[Q!RF++)AHIZ,.1W5RGWKOILK=8I4E"H90(5-44$GAS0C%S5FPXLHE/!
MS7&I?$-IY+XTOHUPF\_:6)X.+"FZNK",0;)">YDTNJ8AH02/J@#M9H;1UN9<
MURD;JQY_@'XR3Y?WJJ.4IPNK]>WNG9OGNV1)YP)GKH#(9(]4-H5<HE(@,HZ8
M11VFVDV'Z]]QLHIL)+;^MMU53L?RT.XL3.='^ -"6O!,>^ !:YV1L!2^(X?@
M4A"T!06CFC=DZ4S=P:#18YS0CVJ.Y%J7DRQHN\I0@O*$^XQU>@8'9I)*(M.*
M".T+ID_@6K<OK3>XX-U&93UL56_&TUE-DKTK!)D\-YAHU[2E]BFGM188*Y"5
MJYNI\RS'QCA:2<A1(:7-!K2[P/M&P0"U$()I3:YP+: TK!90*@>V&DZO?3+W
M.V&VU?[^M=Y *8^I>2N)]J#>7R?CZ?3]9%R&LYM]SO)2 U#@3M1!M\* SUQ!
MO2R*OG@58^N6>"O(>(8+?%=A]Y"<<8ND0?:^L(AU@(U+E2&R-X$+,G=>6'2H
ML^I1[_O7]\[J6*_>K639.N;_<X3G\U_)Z9JOPE.)65N(BM$V$[T"VEH"2!XC
M\Y)(\O>N7]9$BRL>_HQ6:A/Y]3#FZ4.>9GK@E[-1^HD,Q_GXZWQP[-]?\VB:
M!S8:"I,3V:#Y^70T]81".# Z>[2L-B?H5+RQ72[5>H+VF!7>1%\/<Z@:";N7
M X3S\QHGC-);G/PK5_1?46:TXEH[!#L'O!+$LX^!?!239""W1*76SMEZ:DX<
M XW$W(?%SJ,\P5I(?)8N2*B5V=GP6[XBSUL9)),)HJS%PTPA>&<]&+0Z%AU-
M+*T#_0TDG3@46@J\!]/PVRB.+W*=+5</%];-;$F&$YO>@TR10&N\(;PBAQR$
MML%J%9O/0NE$V(ECH[WP]S3S[V8>H6$L:.4!>;WF8J) G3(&F$0Q.9B45:>>
M'UL XSAF1/:"AV:B;IAL>47;?*S"N_%H_#77#:QZS16\5]M8]D)X+R,84W/$
M=4UR,#%!UIH59KQ5H?4.\3A%)PZ%AN+N8<;?@IA/^/>2GA_)R-6X-3 9/2L9
M'#<>YJTO:I4:Q:TFZY)82MBZDG -*2>N_A8"[F,@W_QX8KX=.>:+X19I.PJ*
MN,MU E.4M<,%$:F#[-AD=0M5W[S]&9T9["C:M0:_]WSK92;<^.HL>AJ^_YK'
MGR?X]<LPGDTRMLRJ[ORRGG*GG\9LLRDTBW?.G41ZY(0VFZNKOUK-_OMX]/EW
M"BG2@W%')F.P2D',%%:0GVC 1[(2@=S)+- 9[UIG33^5UI93:[:B8)FC*:/S
M(FCRIB(M.606*!87($4=SRZ21>QS?,WV%.]OCLT>L/?8?)N>E7GH].O:F.(Z
MD_!F2\'S>18AV0SR(F2!8%V]WA/$DZJY9 F+1"ET,9U.8S;TU5E+P.'3K/L'
MP+BU(AIW75K:HMLD+1/<NA#5L.?66D+VWW.KD:+&?4EY;Q!P*@I/1-2K?TN[
MK"U 86&!Z)U@M @PAQ;-F_>L^D<:;^U3\]L(MZ'&YP6WD^^#/S\.1/#>(45Z
M40NBP">LB2(,$*61+!L3'ZUMGN;XC\_C;S\LG[C0\/(O-PJ^>=]^^S$U$OQX
M)ZFU3KD^>W]VU:VS9(=!L "Q. 9*1.(""UFAX&UB@FG.Y*9 Z-XS3UE!NXBG
MAYO0G]_^?'8]GXA>G+F'[ 36%/T :(P#8S0YJ9EYKUN?6MV\_915NJ,L>[C>
M?#<>_3F]RM5''XHFCHK7'E2A'<!9'H#QR%GP2E,@TEBMMU[_'/3Z5&GVDL*R
M?0:T8"HIVOY!\E(/R:,$]%Z L2YB%-9:AHT!<!))ZP>)Z?M6X%I#_L2#T#L.
M5(YI<3#XVR@-OPW3)9Y/_QB=?]]\MKG2'ZN/6X")A'>-H?O/WNHH\PGD[G@Z
M22\9G)V?WWK%VSNXVYK_M0_<Q1_[,*8GS,[HP^4^IJ,ODO,"!6.H0QE"[<^K
M(13O5>::)=VM5=3])^]O'6^2_!V/:R<!M)S>5HGY+YSDT=F_AJ,ICK[C=:=4
MGYQ(!6Q2'!1+H@[#*L#11!*[*4ITT\BJIQ^I5G86Q%H3NV:[6WY<_P@XS?_W
MW_X_4$L#!!0    ( #F!6EJS3M(4BLD  'WP   4    <V1G<BTR,#(T,3(S
M,5]G,2YJ<&?LNW=44^NV/KP4$00$$9 .2A&D2B\"L6Q 0$1 B-2(B#1I(M60
M*$A5B#01$"(@O42DU]"1+EUJ:$J'A!I(^V7OV\X^Y]PZOC_NN-]99(X!@V1E
MS?G..9_GF>M=E!^4.>"<OHZ>#G#BQ G@'?4'H$P!MP":DR=_?U&/4]07+3TM
M[:E3M QT=*?IF1B8F!@9&!G/,I\_=Y:9E9F1\=R%<ZQL[!P<'$PLG%P7V+G.
MLW.P_WZ2$S34SYRB/4-+>X;]+.-9]O_V06D"6.E/!-'DT9P0 DZRGJ!A/4%I
M P0!X 3MB3\.X)^/$R>IUWB:COX, R/U#17G@),G:&A.GJ+Y_:JI_PVB_A\X
MQ4I[_I+<C=-LQG9T0E[L\J]B,^B%;Y8V<Y@,8D44'CT+/L-P@9.+FT?TLICX
M%0E%)645537U6[]IZ^C>UM,WO6]F#GY@86G_V.&)HY.SB_=S'U\__X# D->A
M8>$1D5%Q\0F)[Y,^)*=D9GW.SLG-RR_X6E9>45E575/;TMK6WM'YK:M[:'AD
M=&S\Q\3D_,+BTL]?RRNK:[B=W;W]@T/\T?'O?IT :$[\R_%W_6*E^G7RU"F:
M4W2_^W7BI-_O;V ]17M)[O3Y&\9T=EYL0O*OZ-EOQF:4-I\15C#!<CQZ-LAP
M041Q7A3WNVM_>/9?<RSX?^39OSKV;WY- DPT)ZB+1\,*@ "2:6:4./#_.\M,
M7[CVP-;"YE'DZ5]^%P%-/12H&O^JP+]VS4#P]*14J:1;DD6=B?0PJ9GXI"I;
MQ\=]\>M,0VQG1/M0JX61A6;<*%J;)#JR+5O!ZZ8\DUM7'37)L=2E$&J,3UF4
M:51P8KP2?M>JSQWV2I'@ZVDT%F^$-W3P\I35T WP6KBV55/[Z!+$X2W?HSI7
M UY7^M_,O^MZG%N)O6A\Q( AI:0?IA*2CM!-2XU:C04CX\@&V3Y1"A#/)X^G
M &V']1/^ GNZI/6:(>$C'CA15$O-73=D3J /5D,VFS6.LIU%ZAM0@,L40+XQ
M%[+YR.'P%@6(507A]36\*<#-4#29B9,H3@%>9W6"]L2M*,!<,[REKOM*T"/!
MW370D0H%$!$T*:0 -]@H0!?HB"WDK]Z*^-.)).LS$46WR$&Z?WSC4LB:&7Q%
M"'XD1@&$/.'8!/]E<B@CG,@EBS>F &=T8^ K]ZHH0',P!0CU2S#>CX /Y%$_
MA2&^"])'D4X94;^;^N==%O)Y!!\%^)[A00%":"D  VA>'#= 8KA  ?!7(=B2
MG2BM4I:C?4%B*@6(8\DWHP"?(JF?0Q(CFRE B_$B\IA=F@)@'Z+G=8FB FH4
M(.,FA@*<9B1SS!KKCEVB %I9U'#"=V[L2Z#W6$'$^/]*@,2/VT#+(_ =#_)M
MK6PP.9CJ8AQ\1XSNK_T2_$NOP0':@@_"B<<(LB$UFG0C!52O?J, .T;DW^8H
MP)^\ROIKI[?%L];/40 D-7)=Z*.+QXF08WHD68\"?/LH^&>WV.%_<MKF)_L_
M%O,?B_F/Q?S'8OZ'BTF/+^P\T^.O?$$@$E9#TE8A7]"IL:< EV1I76)E_2H<
M/I[ @^%15PB!1H$&VTE';];\0XN\Y(_RT*0*/M\DG$>K>D(/#89?:^EC@ KN
M@Y761]SQ.(2O2YY.!WSKFX/:Z;RU6<%AGQ]W+$.C&Q98WQIRV>,%,JLG&GEF
M_7UU:K!AQ3(?9NXBG]^I1&V&=)/9G\VO0:7;C]8:]PL('U[<<1>T:+\/F1F"
M>+N!&@(%PK4]:P7;BFOCG,@B9>H72J8O[Z8&D :IH2Y95@JU5,C<5"(;#:9]
M@!I*W;'.OS;E4V949I7AE!G5ML8@GOGR#[MRID2A79 UWG $5+IGI3.V_TL0
MMWGFZ-)A;!V+RUC:E;$D*=8^"*O!6>; DAZ<QU>K2M_S=]YU# @7.358Q !$
M5\0(60;_K&5NJMG[<OYS9HTT+6&Y@1Q=P>(G4T1E-$XJTF=1^J[A]?B:YSWF
M<E.Z&UX]8*]LIT!8.!!N]#6X7Z[CQSW9Y74;C>I 2[T:M#3G[#[<JZ7 WHNG
M1>(CO*&H<6D(HDQBIBX$9X1'P#"1-4^> @2NW0_?4Z1FHC[4<QI!UT27!2F!
M)_HEE#<T:"4D861W)==\,.V125TWX)NYM/]9SLO^HR7\HR7\WUC,D[,*N$2T
M@K_HDO'XQF%>)[:/9F&_^ WM6+F-E?8 ;L#=!K2=74)@C^:I3;2K,3HE<"-W
M,Z]GX7.C(:I_X;A$0KWU' :?=0%-RXE/KI6-W$.QMOY:3<+:YGJQ!;>NJ2,Z
MR@^]K=T;L&6W1G^IF \J(_)I$NN'I[H]@YKFQF[C!"/( E>-6#M\BMGYSMJ.
M@@+.[2=J:K:#[!@P3>\;TBF 6!E1,!9D71Q& :"A6<3!4>@8C@A.7E4T,U2X
M7S$FM5#WM3IF;?)&0IS".Y<9+\7A,DVG+KTKVC-7,Z.NL+,;:P._FZC9J)*!
MC4#'BZFN]XQ.X!??.E]*]#ST447)_8!)^\>&;%'#96"0Q.O]*DAU?U^[)$4Q
M4>>GBE,Q9G6MG\E6=%"??7196@@-7JJ"^VX86/%2@#?#TK\RRYQGV<S[&F+T
MNP+(T^EO5B2'GA8]'';+K*P(E=Y<Y#51':$UWI!P&K37-KM7D'7B>A/-4)JV
M2W]V9GG4!-P*?;753OCF;OROU%DC/[+!5])O64J1"T@N9]BY,DZ>Z,[W5A'S
M-VKUC#)1IM9Q"&X\GFZ& M#'O"6^1"LMO:$ 7TUSPQ,6!\1Z!+;WULB_C7>T
M)) 2V#X29$<W&N'"U:/U-W)6O)+0Z*HRXX'MSPQPB9];6@IX?6[EG)QQ$?A
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MO=B*5<IV NT<^ 3.==O_OJ_Z*'H7=;UD$KFU1P$VMX>)"$F6$N6ZC4_HTQ3
MV"DS:D'SWG_8EV,C@#A/R5WT(EVG; 2R/+>]$!5. <[*R#S=LPJPI27PS>I5
MT_O6[^JKL2Y_.O:YW*#!?-)_M>MR%E=AY<'MN0Y[X==1;K9&O[W?(+%FHN6)
M-MCP1>1&L2O+6^EZ;='VUS)HYY26 [V%M_%-*5> Z=>XC_;IHX>"&XNX3)88
M)--3Z,U+5C;:_,4>FPG$TO[JF2I2'+W=_D')VR<6^RX&K#J9^89U-L]A3JV,
MB(-]?IYWGND'0>#8-45C;?_PHO^,@@10@&C0]T81_\N;1GV2 RZ8F\GDBA6.
M)J@.!8BM:TI'3U(EWB>&[?5*-#8?)$8!LA6Z6YPCVCH)5-UX.^*/_IIAG=MN
M="1F>Y$"H'1+2FJ,HI [=^MO4 !;A(VJQ^+P/B2Y-88"/"\F<\/NC&*1Q*AC
M(U(@5<A]BAHM0IVAJB'49PHP7@0YIB^&Z'?G=LJ:0D%8NQ4J-)#/(>0%ST\?
MICZH5MMN;D+=0('PURC Q30/<LLAZ)@_D/;Y(GSVLJ<#9.L^)FF-ZI&7P)>_
M%C1@1MR;1<YPV!E_'<@Y_RB_!WX!Y@??HX>MNW7I0X[27X)]('3PYKN7&@F.
M+W_VP!V?UMX#A?<?L2Q7@8H#:VPO<$T_%K_O:[0'UMAH9962X3%[6*$#BD#/
MY?P.7!2@%"J<8V'Y>(,0U-IS28#@^Q*6_'D0/I=C*QJC31[!PA(#+@0H)\G_
MUKK+)#D#>HQY#3^KA C6XAK;K)?+7N,\-,>L5H'?2>UPCR1Z&CAR"7\Z0-T9
MIZH/3"CY\MMLJGC?<_S6L>+V^HYF\QWP=[/VI3T7_==?4#.^#?O#R\?ITAI:
MCN:LA7PW1VW'AG= JE1-;30I"G="LCKY^08&=2#L<B>YS,?6KN.3IV2.;.5>
M9JV<A<423U9AMY*PJ:V6X+"*:YHF'1W=JBFN:N^UY>UE[K*<*A5#6A)+QZ"7
M,EPP?$I(YA]K%\@\V(6U)&7L[*R:_^;#MY7<D6KNG&O>#]1!;Y3@8;#+Z<LM
MZ2+557%G]#OSG+=PHBTAK4_=/QU?165W."CB?ECZ/]6H83<;<EFWW6XD#; P
M?AA@C$@+[$GNT2%=$RR!\Q83KQ5 97$"20MN^CT&PQX;GU\.!,EWO(HBYL9W
MG0WIS(8YPWHPY>?)_8W28ZB2(L>QYX1UHS+-BJ*HT&S=7H_X#KDZ\C%*;;S>
MKAAZ!R>B8BN%$^V;CM>_8+!^&&!"*_:>O@'8,[92;F3[OB?X=O)NB$_>%![9
MFFM<$64U=?D*_X@\1__P*.Q 4T>\Z>?59KL"N]+SRZ9@9VG%#0*II?V7:3LX
M-%#NI]<@R';E6,6: @0G^\?H<3G#F(<V%@:Z/60^)Y9NO\Q,G:< ^"OAD4+U
M1IL(^E6_RIJC]NC6]HL"4U4T^/%QLB II9$3_^CJ>P&ZP7&:;4/WR_;[LBF[
MVY.I\RRMTF)SJ"BE0@SCJB^GN>]3-YFBN0>B%OVG_"7?_HQ8'%;:O5\:H&D9
MF\4G.3IY. Y!KKT8O3J1IJK^M4U::<KHVSY+"(1'XQJNM46R!!]HH2QY!%:.
M?UEFI?=VPXL8,1>U[3KG@;]\1P4]I:6>X,X#G]A,[,0F^ZD)QDR3?0[[_+E+
MSG/Q/5XQ]3/8!VN^K6.3LN51>E)AI\T.C@N\\=<LREJLX]LA5+,!AC-@"B&3
MQ<D5,^,LN"RR7F/A/K5!ZF3[/J0 L\X4(!+FF)P"KZ;F-!/ZLJ^RS..R5P.B
M629PB?1"9_0.<P4%*#$@AEJ4Z+D/W.1I_WV8?.$O6Q1'&]%%'4&4$.2&/U:X
MG$V*]UZ2]VRNKUS=7K6I@-GB=SO1K' 79$S5+/N@3^13:=J^M@OJ'I.3D[.J
MF2(*6EJ[YVK4!BI>6-B>?M!= NV6"RLNZ^Z5<SUKJ-/7'2@2<G );X>E  N=
M4?LDSH[WT?# RDCE-'=W@8M-;+]BRX,?.,"94HZS6M%?0"_K)7'"!KB[:4$%
MC&Y:/C5O])+';A/;U4RLHZ=N-#?OK4.$_5$'=O@Z@H:A\Z+D[??VN7J_HF]I
MO^L=:X.SY2A\V=-@78?H0EFIN?,:_\)ZB-R)8P7?&+5#@"8OX,JF;!["GS_.
M0MX-+^677/<V*@$_:W<8M5[MLLBKF\K!#&MYR!X7LW_!K[DH6.:,HG:URG G
MSVB "B29"BV[Z2G 2QXB%4&#GY<B%CL*HCRC/_?2'^M_0&4K(J?BYY<14&.J
M!DY/$LC_M2:G1UNQ=]!\*4!?F9-[6B'F#,<NF,A61C:8S:4 #Y,IP-XC<-JK
MEK&6G_AOXV_>>!E!DF?>M)FTV5\=RI;\/(L13L;[S?-++G!NIOEEX8.G"+J&
MU>,>Z4XB]I&^"E_#-&]_X^9OAT4037!4 <^BP5288:7KK/!H:#3K-5>QJJI;
M" T-'W,B%M3D<:15 ]I0R(=OZI/DZA[PS)"'A*\"!D>?.)J6Q934-K69S 73
MO+5U9#H"W*Z,M(S?S^Y2GOQ5L0$+@EXDO?5!1@JR*H'8_(\/G.M5JY[,]2_V
MI)H_N\6&F+N3;@0]I^DZ0I8@8])Y\!Z+C'!FO*,.A,WY0.I28WWPG"[?0T\3
M9OIGGWSF?/L",)M>!",\HET]#^\WY\I(X%??(*5M+42^#[H3CY !U%@/OBT1
M&%;(9RE LZ9B%?;L4CKHO1GN<M;IBU']=Q7[YXXUTFL6JQK\S ^\WWI9=$2N
MTLN\0>]3 .!GJUH'"-P#48"P8\ DN(U1$9F?J/,==L7??*!-@*_18%-KR8=/
MPW"&/["0>6Z<&FETZ5U4D3_G07I\RX7)!$1V_^'[I"][,;ZOE;N4#YZB(+>B
M2/*HQ#Y/1MFV%ZK=.)?U0:1ATJ* /$(C,<47ED$MUIA NS\5*ET'YN@\F(PN
M1N\]+"%7LT2C=T10)+@5?*79IEKV, 66MU/F<<B F8?'SG:2BV$):T_A:^.K
M=TN$1ZP$@G"N),=0T(:2!W']N^0 61I>A,TEA153@+1 6M]1"N"7O4L<D#Q+
M/HJ@ %7P2W\PJH=_GTWI Y:2H?@T7%TSG.[I(K+=<HG'NU?A[)?>^![RAFN<
M+EI_28.&8 >5PD<7Z68[-UXBR&0HN(7QZU^HW#7*?,\E-J4TSG=9*!ODRN/6
MV9 6X_S(Z2:LWU3?IN0%<X;[>$I0+_V4[8-DFL#S]'TP+UB[EN)0(R/4!V<4
M3K23<.;TBYI\-F-S+B*^\\HU?L3,V1&V#B_(YV14"L@%/B'90@'8BWP@7#>\
M+H<N7+NF)I;B+\S"/Q?->$+H,?0'US1SD+=MB5ED%OUHRX),AK&HSV Q G0U
MP_QNNE#,UUP_QU$?9;0KZ@V9#8MN!K$Z'ZHG)AYD%5DT9*<CV0N%NP<Z-DYZ
M%HY[+4;-P^=2T_D;A\BLZRF)W5\MUP(S7-U:>=^KCG*'ESX,.$"E4 #[[0F4
M'NF34K1+D)]Q;=EPN7F5O,64.,MSD5G?;=#SLVEA 9N07)C@]^<4@'&ETE(G
MWIDC+-7Q?*N'&\.\_775DW5E@G;OYW^^'XI/2+UKY.J<J2M -[FXWLEO+-Y^
M.0XS,IA9W[DHN,D]AWI526U_+7IY<NB/[B&&94;*"]KD \P\Y-EUE"P63F27
MG$=&5O@7R6:-:JB+!D7ZY-W,X4M/3>:N1'C;<DBA.2V1E;EZU8>E&_<[YO.-
M)OHS3;32,S,K:Z)V9M7F8B^':3/'Z30G)KP-IE^CSW?MOW;S;R3=OQDSS8(L
M,7J6E@)\>4,!5D[6'<]I"5$)XLP<A$"/)K^41)>L44LP:X7:HG("'D .BXR*
MX'L1H>S&UF(%'-W0^Q0@SF>!Y7@O<&T] 9]/ 436VP3W5_:'P\B:(+.CCZK;
MA_KH^:2E/LB?::?MPM?ZWV]$-\9366LI?$6HXD747Q+1EW_%.JFTN1ES=&H=
M?L!90P&^4PLCEY>, YF&2U  K^R5/WAHWM_PT'>P$<QIT+P?5&Q$,=4!LEEX
MZV!&:0J!$0==#N)R@+/:HO6L!HLU-!^,YFPL;#F8)[B:)JIM#/3!?R /7H/H
MZFU\YA <URR<+!/[F\8%97_(GIB\Y9A9RJ7UFF8=8@_[+EB^' 8[N3(W\ZT6
M&2$C/./XV:IZEARSC&>;WM^$B,&;?]-@G-NDZ^#QK<JQZ71;*+YW842Q&BST
M&\W)^=+#![&(@UIJ\A'9/++]>SK>Q_IWMH%YW)$B3[^ZR-,H$".@U3M&W6=.
M>'\'4\,_46T]%2\?YV5H:URYZ4MEJ358C&V;P_0/KO+)0*TN"@ 1@@-$+1Q=
M!U66\?/>K(IQ,R'KR2#[XI]ZR6SV;QC9(8N#%K$#!Q9X!X)FJW,^ON67['G\
MQ^B5<5:/*.%U=HT]\JXC%I6.GDMW06._E\'+/L^X48#&X6/PH)9BK \RR@^W
MSFGH['8P(/JK YH73D,S+-A?U5M@WO8HG5G!*Y=K9LIO*4!@DHM)Q,LX.%&O
M)]'[:7T;/I$@2[Q*REBL&X%>\>(,(]X[?1 W)AW[+<@A_&T(Z6?S\7@SDK61
M%Q\R!T> 2I5^/'IC4N:_E>D$>?XL9R,K?T_TQ8[DMB!#K1.<78I-N\ZUQZ?^
M@7TJUZZ]!A\B!RYQ1" S2&7 -"P2!>6&+@V0#O8<*B3M<,8M:C6F">XU5;8W
M#W"]5^/;NAF4+LF >[!HA0WX!.8@'3O0&<W_J,HKQS]N\J+[7FHX+YZOWA$_
MC*$*;F'8% 4HOXXO7G@!/^EOJ=,PJ#CUCEK$OSC'DR<YO X3]2X&Q@45+J/Y
M+%>U&'$)^7,85FL79>.V4"7Z7<9"=1;YJTW$IO-@S[GQ00C6"'02K])FJXX>
MW7_15HW32CB5XAXO,7^3 G T#<PZ:-CCO5-:"2J,B6I/C W;)3N4)QHI -97
M$XYZI$#+Q^BLO('Q(04MCV&^AC>;XT6QZ3V&]=>5I@X(OI]UL=U-CS2.A>9A
M-:@GG]DKCMH#A]O,$EU2NZ8)*8I9-S\ZMSZFUL;#IW\M0SE:B4[4TO4H(-E1
M@,%\FW9/"L #6DI=0S^ [[F ;5E(OY#XI%\!R4A"-!S;L^,(R:'6K_HXN49V
MA^/)GVFD,Y5&(IN"H\3SI<0SHX!_L9LW@XU.HD4;0:Z3@L$4P*G!M$WPK%*'
M_=GE*=JV*Z^KZKIVC5ET[RQ/Q:FA1C!\/V;7;!G'BQ7'KN19/S#BJ&-NM(L.
M)E>C>@0G0BSQ 7/(B/$O4/#@^U_#W01%G8/I/OZT%G2O P+-YT@GD'A0K\9!
M/]YFT=T]75@\D#@@VB=Q_WGTS!'RUC:U=!P/7E& L%"L:-_F;-K!6?#=6#>/
MQ(!@L&0:#GE3/7\5P@0;$6 ;DH&[2J*95RK/K;[W\_,UWVE]\HJS-\GCP]SS
M4UL#?.!5SI:I[5-K AQ1'@"_"#XHK9(*&YDB5-T=P7'OZFP--TH.1[<1,(]F
MA?J'+#P]KMCICV_WN_R^((=;+/JZ^<P(,Z?DIG4U4Q 3LW*%+9B^?%-@P$",
MY.3QMGFL?=[YYMHS0YLCSGI.@AA4&:_K[%W@-"EI[:I\,'1D&9.A8"C!QGVJ
M!';/T^@&M=*;KX&6&M;@!V>05.(O"HMQQ>R<'$&O3QJ13HTO"_Y!+<?^C5KJ
M0&Q+A$]$ISFK79,F/WG0K;BR>+4TESV12BQ5YJ)_-B()7GV:(SBKZRG]V;46
M'X40^VEZ"^C;,DIN=&T'8/5G:Y5@/2_NR*'95>XOK?S14,%%CQ\=@@)$6QR[
M)6?,QKSK5%>)^>Q.]TVSY#?J'J9AS9<;C.:V-XQ*H,IA6[/;;8%NW4;RW3+2
M;DL68!JN+E!$2=&0JI1IKJ7/D4AF^4]XP,^Y]86\H7PF35HSM6N$GL&L62@O
MUJ UG75T8?2UKO'H0W.#%SV?LHM':U\WS:4O%QOAX(MB8>0S_G=MO-M4[.@D
MW1RY3[OF7Q.2W=6D"_1H-XJ4(XIA7]B*1G?4% 2\D-K#/Z"K]E2/\P=\Q';Z
M8%#\+:IH;(-,N2Z$CJ%0TP8.GRU[?MK8?F6EC:/IJZ</1%. XL)OS7,_/ZB\
M[;Q?(4YUHDN@X8XV7Z,DS<O@9;+9$,GBQ8',\+X1'WED8*'04-EL^%'<P<Z6
M;>E40'/E)?<- WN!"=2PY4\8+U01>]@"9YCRA[?Z7G&PH^_2?)Q,J(\>_7 \
M;F9M4:*N%B8\>5,YRMPV8N_9!F_SX%)\G?OV"+6"<(A[?UE/DB_QU*XDI$^%
MT/TJ\EL.S/@)7!7YMT0*@%KW('%)5M&2=XU&!<S=R/-61-F=:S\HP"AJ*,T0
M0;(D71EM"WQC/]#X)RY)Q=1VU'XZ53%\^>>1'7IKKQ&>_-,.C9$3/-A>DJ:B
MO.[?G6AQ&#T8R1K<2YVYZ;&O_$5C&[%5\![476+FIM\A;7JW]NM']^!?E\-N
MK!71@S)RBH-\V1K*08JPTT2%6E(96=X_J2U==L3=U*!2Z$5"*.X2<]LM]]>D
M=H;<V-5MVVB",:P-=@$KV^I* 2[@KZ"D<H;8C7P<O=0215^?XTY(-TM"-9X-
M0+V$.B^P_+!:-*_[[&IY9S(L,H!097;-L)>AK5WCCK_(R1L"2UXV'IO\!(])
MJ#7VSBPCUO9-7DMMZ0/W$IF1@)(:NNX8)3'1".#C'I77W8^QDW*[,H?9TIRR
MFO^Y#E__CF?PH.63OKT WJY O]@KW:/;L,=]\=^>*\[T#S=_55%\V4+JL_,O
MB+K3NY-QY^X:=7NE$UQ5VF>UQAM%UXMS5X.]'(39@SLP(50R%4"""]#Z)U%;
MT$,0VVK@W= %PHS+;(]QE1FZ=E#D57V[V5%]\7SC ?!-&,#9D@A::^\O:$G5
MQ:S&77OS0=FJ#M?_[+Z@"2C14S^&^?7ZHF?Q?=?L<L31\8'&AL_3)T+^UE7G
M9E0'_((<2+Y;_>Z[+;-2^">#:Y?/E']I8]&:U)9,;Z[$X7GVX2SD[[/<Y=B"
M67R5Y9?O*"%1/AM]8;9S"C4GUI$W9FN1;P(38Y!SFL8>%@H:.N)9]CTUJZ^.
MR1P[?;D;4PZ$WYZ&&(_***;:7&EK="N2V+P$8W"H]52P+DWC&V987P2+2>+C
M)-@+'P=\O.K/7=/A.N_AMK_Z8P?T2HONS4$]*9-H6(1O63"(5L;X[(WAOH'[
M$+T33!?W[].47&,)/&8Y>$^*J0<P#!7%]JT\4@)\8XJNNO4Q!N8/XT7LO76%
MXKP3Z>A*7)?1Y_SA'9 O\(XG8WN%SDH0QNG\*-[4E]#4.N_@1[$)T+@K_$%E
MW\?0';)36=;XB7DP%O*:**V<=+GH%*?H98)A6[>17%O!:9KG8D,-+B.E%3A%
MUSE'PNO$HHTXJQF!1(D/EHH2QNV=A\6-*55#O8<L>#$CA!(+.U1XI-QU->7Y
M=]1O%TJ61>V>,[-I1?G93W'L!_GK;GAC=7;GD"W9%:/?M5$N94&U!^>>7>P.
MO5VV5G ZJ OEAXKHDS#)CRY4!S'"J=0_<K\&*F':,AQMLT&MI0#=3__>K-A3
MD!6^Y(Z5);V&4(#K?Q0\)UEG^R0%^*%-[>LG;$A^8/)90=U_&A)3@(9'0?84
MX/-OXK_?'[U78KJ02XQ'G8./9XV#_S0Q_JB"6SU&]<YWPFO-_I@1N>"-R-I!
M8N2&1U1NK>URR)$X#SKBV$,>[U-%P0V.PFES,RVUP-\';2$LVD=\=']%Q0?(
MS%1R(&9%;20- ^1PVU<VJIC#R../:F!"M.SUS"C)B/V_T2#5B+=H=D7J"=',
M^W#VM8NW*V,7&*%S PI>?/9K\.N&OOO83B+[<-NX\11>LG6EM]*D_'#HU>",
M;V;(WK31HFV.1>B#:1OU\Q,-01=RD1\>"7">52_T.5[Q3VJ6#25?)*$:Y5W4
M.R-*<H+4'#@#VW=PH6)+58CABP^9N\^@/J.IY.?'+7W<722I#+LV>9;7HO*U
M\.KUS:IZ,RXN4/-E.MMH3+KK,-J>A79UEH6$A*J(1L9819N -AF[%B]N)P[<
MU#V\SK@9=2CF$\VHQI 5]V".X:#T:$R("W/@V,,3*#ILN%4_($F7.)C.>;BV
MDUZ\3QCHQ$SL+NP2:?#9+!&YP[S&4:H_O]96@'_,/WC9;F38A+K5C/KN)K/8
M)%C^\\,X40PEI?Z^2<9MXGJRYJE2MG<OW/D$ XE8W&7$?(/P(B9"<>"\M;58
MV*,QF<STY3MM<5(.J:Z=;\.6\CL#ES9]5NLO+82-:$@60B8JZCLW_-8);X)K
MYKZ87!?QX19J'.=\^6"UD_7F70XU\P:>#6I.U./QYM'J)JV/'N;>)?@8U8*,
ME&3QU]%/WB@L"'*ZKHKB3:3=#A!* Y^-:=YK5@G05<""R(,0;I9.3-1Y_^"I
M.T'JF*Z8[K&):8VW!7<9!5Y%NH=D>QZ2+];B$)%)]W!W4? @D1U$!>8V]&C4
MN^M>&U-,SSO)G.'G\+-K2-YR38660Y7S_L]L3(9497SNZ K++,GTJS)^<[F:
M'-ALN"#9U9\K.9YID,FA_SU--*SUQLVT@S6,;U 200G6$N@8+F5JBX]V.UU:
M:/T;M)B/.'90T,KM37SVD,19I3'>CQ& G5_'? 6U;UZSPHZ.#*X^N^->_F+A
MF2G=<M6[PR95-4*WZ[[R97"TI7PQM^ 5T]@H''**L5G=(UH+P*=Y3*HZ##]4
M#RUN>\TB\^"("[3)5')M"Q79M/P@TMXC$CJ8'OV\;*,>S;91&F#&-2]]P_+>
MJ!8Z8)S(AB^VPZ7.-\8OO#DGY)HPX>W.?(<-=5YL+O %J\T,]!(%.-6#DQ[N
M6W0[\8;WXA=(YH&NF@ZQ"4+XU;B-$E1LD6*6SZ;?J-P+3$^'1/K7*TKT^*$+
M&,0SZ[,&_^8&WSQ9$=ZE,@K[0E7P(R4+U?!HP1W#?4@1Z%A)$D5'905$@UV-
MW@%2!QKO<*2 &H8O\5.QU3KIB*',K!QS1&=)I12BY)M%XXI5CAE&<S>TV>^_
M_\L^=,O/AS^Q:)Q-^4>&3NS4X/4N4"+,!.-<.[X92_C-Q?'&U[*A]SLZWA(=
M%U2E[VWN9@MOUW =BKR"%(+?EV(L!MSDM\*<)E4@9L*G8#IH&9@P5!/_BL!.
MO,TS]BJOB,=M*4X[U^5*Q9A_65W7>^%I)L<J[M.-G>&B'!*E.4-%XW5!]13@
MUB^%;U4\[LZUSH2Q:0)ACJ6I07*.)3CUQK#[EA*WNY@*V"^)Z[3%;<9$XY8\
M  !9'ED=].+[<(SSD$W:S,K4$HSS+'_4T.P:HZ1O&QA08Z.#+(IQ+>=HOPC?
M\,8MMB/Y->2*9OV1^L$_'O2_FUI3+BWWLGE\OO44,ODV=Z?@U9+AQ<.-?6H#
MG*1I]?SA@A*-R7C2OE%QS9/IG=P:/2C@[FGP5(778/&^%!5@K*?R?3#YP^;(
ML2]R#\1ZW,"&M?P<2 11<U'V5$^^LWI[],^&T3?ZZ??7;G>S!2N\T\U O0+-
MI<%W;"M A%,#%"#K?*72-O[RP!O%'^[N4E!(UO0-!D4D.LSIPTN%P5M,9*5H
M:OJLVJ %E,X%EL1>I3;?2-N??%H7PB!O_"WK5[.'QF8[X\TKA2H5F$K9CWB"
MMH.BD<%HUOI;^>0?^9^LUTX;RDL[WCNI^5*.IG>2T5Z$@:"P .XH% Q7Z'.?
M=.O/]>- 3_*(V]QS:U;M\6M2POK]:6Y,BT_-\I>NOP8O]!^:[%U5?B=74U/[
M[0RGY^TEA$?@SW[-UUX)0>76F7/E5AACA[WU(GZSD+C7-5-UEL]K=L3>@CR,
MPAM5K3PV0:?6IS8_)/B[9YASK[%H2AJUPK'WM@%_L&'5L"+ZA,LD#,FZH/HX
MG$9,JC-=;RDN0$F,*"98NDTZ43Y Y#0B<W1";7$>&V5P[/:#D%9+]>B A?9X
M9]^OK?(]1#%O8H8N=)]C@H=+OT!1X$)!-'$#->XMXS+BJ/&;Z_"RJWFQGT?L
MH<I+:% &T1!;G!0!U0Q,FG2;_&D#VU%Y[D644C_GFH7J1^+%#)$QH/F'MM.K
MF8^Q5T+'[\M3@+R  _)VSX#%B?68&=<]RT8#Q6;=$U&)] ;),%NCWN.W: ZI
M)_QF"4^I*@+\SEB;8RG]3QM#P7\F[N@2FD4/8J0D!8",88ZO@MT9J>*[0*-H
MBM12A8<L^952@$)(MGJJX''%L6EAQ/Z%3B246K(6\T:$LU3,5=]CV*4 ;R#K
M&E<H@%TA?)F*OQ7PF54H!5#H;H4W/@)M8KY9BF=6(Q[\I9SX2UN&NF)W6R&L
MY8-V"V[G>RS+36M,MBY.L12D?R*=]6X\0T)J\4/51M#E&IKS_->,1NAF:EFW
M8^$S3T00+0WGZZL.PO"X;.@)[(TQCT<JM=&M'Q1)FE;.U4G<2P?:?/%[_.M?
M7Y<J6;8:>\RNI+_]6<S#/HPRDU;_L7]ZJGRK8]H[/1'K@VIS$UY0Z3SKUR+
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M<A6TO\Y)#I8$5Q<50)_MJ[12@-,";W9464+0.V?&*,"&K#<%R!C_!$82^2G
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M3LWUCYDYL4A@,Y5!AW7F4("65Z2,1C%#_O>H''S,+_Y6Y#G(UY9T"E#O?<Q
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MKW@A2[7)^]]4A#6T?HK7<(NG- P84ZY3E5XX:,H@3L-4<AGB]_)T8R4@,_C
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M&*?#^-XB&=62E"+^3\3)%<MO?0WNY#XL:TR$Y/IF.#;UM'L[L,XQ.L^LY;9
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M3 5R4:6K\X%VQ,78@&H+M8FZUC%,R@.=*Q:-U_],NKN&^Y;;]OB[:P=;CEZ
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M8,\^:JB95X5P7N3K_3'5BR^6ZA-9MAJQ8("<$()@T@H7H?> Q,BRV&H?ELD
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M _3AW^S/VUY?6=KQ[O-'ZA;Z#82H4_EV>H7:I6B%](LPJ9\H5RP#_V):>E]
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MELGJ\>*AZ*]C3X+GM.#I!Z8L#ZCO=,OQ?]*7_4;MXTYRW BE"Q"CBYA%U1%
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M*K)ZEXE^8-,Y[HM^?Q8;MR6I*15ST=^^W\"TDDY,5DM*Z=%49O+4/KD%:UG
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MG?FF300Z#)PZA=5?Y?U^>V2 :Y4?CT&:GT8F.;*F:'S;NJBR.C4G-RVX_:C
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MD%56=K/$?^O*4 \/WW6\2(]ZSZQZ7O7T2#K3X+V889:U P)KU\=3W'#U>2\
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M^V,66#HESF)F"HK^%& V!5R=Z9)E&+UY)DUQA8I;-YZ 2@ZZ.K5G?Y+Z-J
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M*?^AHGA'5/KM3EZ-@+16_O;YY;M2^[M2*I*AYW8_YU;>?<R2]^'8A7J/+ZI
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MC^_28(S:97B4\M\!DL:CCP/]\CJM)$AFXR[1;7N?%5:4J>0]"A*0EB5U8Y@
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MF/#H2)-H"N$26[Q5_GS[E&::A^<\F<1![\6>7S7BKD8;?VF! <@;;C?I7'F
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ML6BI+OLK3X;XF:L IP8-W%HQ^4<SPIU%YA#M:X"Z;=(UX)A3V%^:%G>5C@?
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MU%)YY1Q0[\ELX?^R9?CL)N+OP?Z/M3K/ 03C<P"^:;5-Y&P*56O?B;@@Z])
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MRN8R_5WWA$?^QHZ%@=,H:ME8+LNGD[W>!TC55''SH01)9@^6\JYBBZ0)$4'
M<C$5TZ]'>*HH!\M*L" A^.3(Y<V(.&MA?<,5T5U;G^"K?(;4PHFW:-CWZ6E?
MP>SQ0MG="!8PDR^D#6L<=$A,%BQP]P@.L%I9=RQ_Z?_F04G]@09?F-"GF&N
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M9S\IBY6+1F,DM+#9H76F;V*YN\_8L?V]M^VFZK)I=620-&UV-:46\\S<3>]
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MW>MYT;9R$GQ6-WJ 46<"A- "<UCACB9.:2SL<$312%FV+=/>+1$C^1@E7%N
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MW9CJ1\*>VW)D2=&)S-TN&..Y"Z=:SI18:0\^U*%V2&PQ>QKOR)E2HDE$#:L
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MUADUZTIS]HQV[S)\L5AVV3H<Y+*LH]F<2,GRR?I92??]>;82]5]\-V9_<D0
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M?.>"KN!"D$!91+#BQ2F-7LN:Z=;<VJC&NH\.E VMQPI0:ZRWW6,!IDA7%'O
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MGXYSH:%EM:UFEMA^M54MLW=-H2@,Q32V]T9].-S&]K9])VU;U.?G+[GF,4
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M&0=+1Q?FW_["I#'3Q.3:BO($WMD76)4=9H*^;O#7YPZ3(O)ADQ.]'?8\W;-
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M@I$;WHFLPY(S\EQ[E;K@J_!;O-E$L'_7E]>_OH?H2[>7"^ WL)P57?D$\.J
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M^(0)?1FF0 L*E$0CNJY.5  E%A2[V"ADERSU:\)72K7XZPE<H<><66]JU/C
M(;N*8+"_BJ'P_7 O(WT"QFNKC6_<FS<'?X8T\X^Z6<M4OF.SFREI^(B%<(,*
MX6PP+6\0=QL?*;PW'<01%.<R$9BY9^A#F?3Y?F9CVV7&\=03:^GBYZ?(TZ:P
M:U[ ;<[F_PS:2>G)*]JR&8-QPW\UN%$!^>DM 7^^Q-C^_B+3YKVU!+X\L_RM
M:L__FU^^O0,X<P?9?BCD";ORE:C$0=&:R,QW8;V@&&7UIE=W 6'\!^5/@[W;
MB@A2^@QM^?AD-8E'40'$$Z(YY1L3+4N*3C5C16@R H$''C/]FSY"ZK%2-CCU
MYN6I@*T]8#=-=52<O"7[XUGADP&X5(-Y&>M@<];#A,0@'];:JXEGV!J7GYI<
M@5AH^PB1]RO?%!%#NMTA4_Q@P?6[PU4,>:I^QA]"1*5VC_<-:!CQD&1'!;@L
M95#B[<D]#339-8H'G20W8RGI6F%BXO"O-"2- GTPSUT '?(BB<C^5T15<J(Z
M&KQ[#;WK8+-J_@>Y@#SK0!E LWYW/C5>[$&^F))?/EZIH"3?6YD[\$H0LW(+
M8MGU$+/2D !<M)L KG^#G_"-'\&/+]-BC"1?I2UU5W,:0@4BP=W(!5S$Y</N
M;0@GR19A2RD>RJ8E0E0V5.R%\[@F\ L$U(U)]9QZ.>4S"G<M)/;>4Q#3W1&)
MO"H_']"[F;8(K!$G\^CAW-MIY3O[+&&P"@?B$@4;C.)BMK='#9P*48-NA_T,
M<:/>7+#]IS=YMSD3T8N%$%I^]4;0##!VKM34@>/U2J@ 3!GZB Z9U47X(40R
M=!&]\SYIPVUJ971B\,O];N.$J.I@LOD,G(WL-J[I-M^JT7T$?%Y7^A%X;U1R
M7#K%:*,@Y3$C>_7#_NU:(OI=DYH%BPLG[^_T;:7*.UN"\9.Z\E6T2I'75Q2*
M^4.C)U>6"#64'E]:BAE=1!HAAQ!E?[_SJ_V0-'[,-D5V)68D[ V1[)RE"#W%
M\4F):_9W4O?A-7?W$TKI18GI7Z\+(^WW$2]S.(- ,7-"&2;C9-]RTO;2IM"C
M$N\YF^P$G5/R2_E)!0S;BOT5<__^L+*HS*,9'E<[D*3ZH*I^;'<]>E*Y:%%*
M^AZR0.(4RU%"'8\1@Z>(1U7O\^OYKQCI<^DKBR?<XS>V_,C*I;K%P(S/1IX*
M#MK^]?=>7AC"\-#UDB4)Z&@4L )RM-.5?3[1H6FBKG>LSC"_.0%<-?.N(*[G
MY9):G(CJS2NM?&TTU(V"DIQ]5?&W%3WG^,=0RN B"-?T':)1V^AB+;_Z]MS7
M/T9/-7_S*4R^=H\5P6 #Z>AMI^OP3G4HT\ X5[MO[&N%45:J%J?I$5[9"5=/
ML;8(>Y,F-$HA%99.CQ]DT@.^/2NCV^0\OU^RFO]<:+5:0N*SVZ.H,@66W4_V
M4QVNOKRMM?+3T]UY$@F7S\05Y *>,IKH W@96Y-:RU+[&5$6_1J'*;4>/%]_
MT0><&YNG2_U]?UB',30G;A?!)-<GSD;*N$?4+XI-* L<^'A]R"!K7V *KY%Y
MT67.0?3/="Z=_UH8YI--.T@8I2J3LU'NB9?AOSNNJ;L06F?*-S=M,(&2Y!W,
M"AQC^!'@^YG7E2XNPV7Z=:S U(P0X'@_MZ6Z 1VG'\!@(Q]C<UJ!23CRJYI6
M!R A.P%P35#OFC6@1.#\KE*M!8-*^FM;!P.P+UOP/C&IA.<J+T\80(U7F<>"
MX>RDP[2IYL_I'IZ:2L_'M^D*SS_DDRCI$QG;M=0Y:^0&EAFSD6,P#SCKEOQ$
MQXENC?9I'QHIIB7$?)LL1%*'U(+K1[&6>M%@(>OWQA[GE0F/GF%#68FW-^[T
M3[8IW_/'"OX(LJ=Q?SB/KM*42KEK:1?;)\''54U&$S>9K5P*<;%YRVWJI(^$
M$*M1N!<\3AT1?7&B8@_-198;[[9/&QNY^P:KV>(['STTP(44=G5TO30&)YA_
M9)1!.>%;#70)XS0E199N$R)0,H(8ES]>3OA1ILN0&-RI:MDT]EI,1]O%X,IS
M[9G//G\V=H\]-C8>)D_-R;],X&%)Q#[_RW^ U=E?T],SYOZ\*,NAIU8_KI]G
MO\+$M# V_U3QKR#^JPVOL#!XASZRC!__:IB435G^UCF$Z\V#XV0:N&ZA"6_*
M%R]>>?%(N(+AL:\S1#+AA/5+6 SB4:ER"\AVVKFN-LJ#O5OJ0GS?'4?$V^-D
M#_K^O1\."[?%1 F)$ ,]0GVQ4I:5W)>&N*U-F2*3\L3&J\DJ#.XW!V\BI4@F
M\^@I<YSV>[RP"9@3>K/-R=6I%2-:."''/Q">J?JN]_RBG([W>L)5>ERY\+SY
MAF !9*A/^X*I!&ZFFE1JY61FZV"-.C7[\AI?C[:Y! N'>3D8$4.C632>^8ZY
M"T$6<:95E:RM0/%IQ0Y[>+=YO#8?<2M!4WE^'<&^;O+HD>A^;N6/(#]??.H/
MMX"3@Z %1'HSG.0#CLS9M4:)4P$OXN"D+QLQ"JUJGV]9F_S<7EN"J(\&7;_?
M @.3AR1(G// *9-Y\\XDYO:),.:NC];31MP,J/>V*(/4[UE&9CHOZ)EN <\0
M$><H/?!:_KBV"Y"N'K#X\T<YW5F(_9?UZR5.:=&H.M,OT&R#@>P([S_ OP\-
MQ%6U,<&'[0EP"L<%*@#_I=+VCYF3G<N-FJ6L]6+0_0+>%WG)17_DSRTCP.9Z
M"RHGL7 //FNGME.+YZB "\)HBJ+S"D&N'5V;T8Y]21$AR.3$4D36TJ>DV4\Y
MFY8Y2WQCK5F,9&*>Z\,YUU ![$D$14H"Y@450/#GI )X#<@JJNU#1U+.M"\=
MW4#R@Z G@KT:RDM'&V8PA^G;Y1'[)E5#D=\(H6#5<<_M'?OCW>F09:@B49AR
M>H.X@Y?L1O-!>D.AK.[^>.$=^.6RL*11:6G+^QY7Q P&<GJ;]FD Z$J&N$EL
MM#$ONE* FW#2#]@+>)<KE(U&+NKFJ0"RB!X5T/. /7Q_A"15O!J6-)O1(\?B
M-*?K>ZGRK[?/=$+[K"[;Q Q=HNLKYPGX !/+*C(NSZ^W!BTZW6UAM?8KQ 6?
MF-\D79X?FC*?S^E$L)&$AKJP'$$:OAP_[?M"5&H@B*ML9H9G'XIY(PA][: I
MN2[UE23EJ[LYL2'L>-^PB&!#+"V_F-/.W7T8%TH_('*,&0?1P2XZD1U)4O,(
M(=!4EVLXTI/OZ-7$Q.*[!4\)M@=&*_1:ZT-N)TA-"1PP*><<E',!?8X4TLE'
M$1?R]DSU4AU@P)3Z^[F]?;UXZEPE6@ZIO#1:JJZP\J)&W1OWV^71G_4[JSMV
M;0*4$6Z]2^ZZI&?T>7=IGLX1WR .%^SA#&3A8R,R[U_W2NGM2.&XP6+?O"G6
MVRWO[5 &;T^9X1D$1+W'_YXU-+X;TTL2I +TO3NH )):+!604%H>5^H\-SS7
M:^LCRG;YY*5OQ(&VRAC:17R*^1XQ)%$9GTV7##KK=2"$>IUD_*=,YAI#KK;Y
M>=>2SW[ 1SE33/@YVSC"62Z)"\ I5>AC5PH$0Y-9A%]8>N!J.01(!3"?I2T\
MJW_&T@8=B_?!LMY1"U.>>OD@I3;X&*%0KYON<OU;J_VU_I:&$/1<*+PCYS1E
M!,Y$X24YM.]GBY("/D][J)S[9?!7P)#7<]M=& 08, -MLK3\>48.)X*3-2WQ
M=K*:K&"5EI*ADGZ_K.AAVZP[_3IW-2/70:'_-,+RGZGN+";,Z\!\?^IGAG2]
M5M;8-;Q$_P,G\6R,..$N,/F ;[L;C.)@B+,!@IL6),1W>MO0)!/<T)0-3K5+
MG)6D,-T%YY#;V!75%M76* EZW^-IK7Q&()*9 =\J11$6GG<_X44R4P'S>''*
M]3KX$V0B?XX(C(4F"?@GTB=LU%$!AC\G:Y1T+FW?*3)YIFO%3"R7AY#---+P
MDC]\ZT]8\J(+HM%52170 9SX<VPMZ.43HO0;3R#'IEE3Q=QZLK@U2NS^C/:.
MP,G0A3!Z^RQ,)W!*PVZXCEUK%Q@K+[.$2E_6']\RLEBSD3C0JG%&S,.G'=H5
MO;)OCJ!"\%0 *PEH39-;"<KL?*Q2Y?HNZ0X>(M(!"DV##I+%(OY.-G_'@+O^
MC7'ZMQ2&PT32%%"B1LVIQ<%[LU1 Y@J0-1!(FQ%X%X(=<@?;!6+?ROVY2_+A
M6C9]0K1_D'0JYKQNAQKRP^@^[TDNMRV1(Y?Y>8.W>L]RY>^3@J"X*?S]"[K'
MV;=2GWMOR/WO8+#T+L>CA('KQ]!+AV[>(-.V$-7>AY6D(U@?MYC'W#X&_H;X
MI.CX-.RG4/+'$ \L(?+BS"U"NE#2A(Z;!' M8GUU*_I(<D.*T(7KB]&\ ,8A
M8PXFCO@^@HLO?\\:7ZLMY7E$?_;\_ =WWE7T_T%*6T_&^";]<'1+*AE<"/=(
M0ZZ^26>5Z73[9L+*X>Q[\'MMZ'D0B'0EI^_C_6ZAY2\8&'/2GM.=%4M(STG_
MN=H1Q33F_D7V7U]4L003*B#Y8$*5[P=\/IK[SG Z/T;3C\']Q+P5%O,O1N5/
MI@)\MU[,B1. <76FPGC0BSU3YSZSQJ;J*LI$W,FGP/@L-4)Y:M-SYYLK"<VA
M@]H?E>_P^O*4>\NTX09D.P?]"O-*,25#4,U1M"<\M@U P$3G$OJZPAL#316F
M34WBE4O'/:T%TF\LLJA=DO7? MV"7 &?G8& S%-[@ILC,N+L.*=E=DNR'1[[
M]M&)CLD+^X]Q!#R "9 ^+?0!V5&2>)-&B;KF":7WIK=L+UXJ!$M?D[B^\N%4
M-]N1C:GSM=__=X=Q; 9HZ]3RQWV'8?B3\(%9[NY[)+>%B<">II:7SQYY?QZ.
M].WRBNI ?+Y7'.5!_WLL\Y*[5= 3O9@SSZR.Q(TC8*&>.0*H@$?$ %M"PPNR
M0?XO9T@&7CI,!A.'N6L2Z7]V^-&[F;+P_0QIA48-_\BO97!.RI2X(%D+!SQ#
M:K$9WX7SZ55X9E\SW-6(N.204^LI_]4UY_L=Z5X]\>_/::)@2T>\L(XV&^0%
MSASQ#RQ,6@O!AE\75CF70)=AW?!:<01%%I+H/$)V@KM6_#(H^+6V?_3JU*!@
M7@ITJT'>P51RDT!W)Z+\N5Z LZAH7QS*&\\)6#^"-2J!^4F)"RH-#%FO"._?
M>(O6E??4RA_J/W<SS!>V^.!6,_.3^;<;[^%&/F4"RX4R=Y]'LGG!@(2MKO66
M>*B>*"V9ZF04)!@7LWS[8]3N2?H+:2"WQ#]L'-=F<6YL+&A@F=;LA^)D=^&L
MLT:$:G-NS_H#>6GO@)*BL<K8Q-"95=RYE] 3(J8< (NV FOZ]PMI)B O7.!]
M1POA!PZRS<HV; 0K1-9W)3IT"[F_@BH6>LZ='MZUPU>-2TL8;E: :TE%KI>[
M;IR+3KGU59WO@FUTF:C)_G.B*J*-CI0!F@AR>+\E#E4F)L>'>%3;.DS?35*J
M*G[]N.X-+O-QLI%!/R+M^2/:O/[]A7C_NRO4(!+N/LO?.7>#%(OTLK1=WR8A
M[9P>6&_VJGCK\Q'UEY@>FK#U.C3,56 HO$/1P%7;830!Q$\%<#OQ\M MY7#)
M:=(3)F0NR$)YP65K63V87[L;$H8C#]/7UG22)#;8ZVY]D5!4O '@0"64?H(@
M<+!20O867L199'3AI\]&A:Q?P7NC>-F'-_CL\B%?\?J/W:2R"Y!AB(68V/(I
M$A;7D%P;P;'>74ERV2:":UO5>F6S6$N?Q/Z(,_Q69EG/U1)YW4S=AC&/Q-]S
M#LI*-(]6AL=6K]NT2:L/M@84#I04U=4^629\;0Y,[9U.MTXV1SW_[/;0EL.0
MN0 JWT+(Z5X73JPE.83@WKG:SBGB13GF9@8K%-C"[7:2#WL5KL&$U^&LL.N>
MRPNWAW>!6D\:H\MDI3?2?T,SL_E=S_:S-G%P/M7=<HS]@YV7^NMPY''/5&\F
M3L8<MQ()]O$IWX#>_#(C]?7@ZV/%66GO2XE<:1X+QY//HN,V(8AH>,U@.8YU
M*$:HG?!2W:_5'7_R[-AN3.(<*Z)J1A@MW7_>IUEE5=OQ Q3%9L$\"B=40*]1
M ;=ZDV@EG(0F914@H9*$^IH\+_LP"-RP/KS%T[=[H+CGW4&>4]?2Q@?,(WV
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M-Q&7N#Z"[HWW%#$]MP2,!_D/M']!]K\'+.+_"-G_!>S_QK4$(,7!NG<>#A4
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M<!ED:VXRDMS7G3-O%1[XXNC,?:4PQZ4YO>H!$W)PTS&F [A_W9X4)7'+B90
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MD?:CS6=M,]];ZV;JGF@^\G";JLZ_L?"QUAE8Q?H<^;%<DXN)93P4WS6L_PZ
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MZFQ?[F]5S@ST3V9BZ9GITNI/ILA#,7$W8;KQ4"MEBD^/\Q9F7QGLVH"-^RI
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M/L3U!A]-B90^O+R1! =T8QXUF?H-;>?LNX*WSZ@GM3A>$[[N7L[Q&M <4)?
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MN P?!2:]M-:&'XEUL"N7D6RWJ#R89>?@13)D-#I!7@<<#T+\H?,OI<()E)6
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M/Y'O4^212T^#FJDUG(04_BI=H'S(K?[ WL8K-8J1BS?\"<N%,^JH!#-MC:\
MVCR2&]>6E.3VRQPQ6K'YREH8TXKS=J6$@#5"SG@ A#"F6-*%)W4'MI'EHX!&
M[8B.I/+>)V/S5:]/M21*1W"Q7]@##)K>1020]W2<HZP1$[WK! IX!2CYG@8N
MG<FZ4D@6.(#>H[!6G-WT:\P;77UM*V3 .[0\$N<YYA=2*K($_%YWC9N^);O<
M0HW1UZ::D& M7/$^BT;8HMV0ZX.ZB_WU2>S#PK>WZ662D=55<GC!?^BHWC<
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MYL\%#I,G1 X4>%8'!8D)NNSD3S&V]!6SG"TT??J$*F9PVVZ0.R)]:A3!^>J
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M/:BA-*2VS#-[LI%[PM>R=;<B#A2'93\,_;1::%;[+S[OEV]+4Y"^Q* I57,
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MI<UK;Z3/X>_8PVJ&3[_*^<F[J=$.B6Y\N4K)=JO6]11NC&&<2VE;4,(^);+
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MQ#;G?(YUW$#JT>9%UBKVYP GEZW(IH-7KW/3G:*?&PWOP[C#P]#6M=,T_'*
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M6RK<U?_-W;3_8]-G_^QW0_:62U+(E]WORJ'2!VG!),!ECP&7^D/.J_CA#DU
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M'TLYV4UUC9G'JY3OA?5=##>5=58;2-\(\25;8.-\(G-W7_/73O[YSZTSKTE
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M'Y?%TGQ56 S-GM!3X?X?)<'D!B?-_B]02P,$%     @ .8%:6K:YZ -/U@
MD0$! !4   !S9&=R+3(P,C0Q,C,Q7V<Q,BYJ<&?LN@DTF^_:+_PHJN:::J8U
MU%2TYC&JBJ(HBAK34BU2U!QCBJ+FFEN**FHJJ7F6UJRJ9FHFM&820X1$\N6_
MW[W?_>[_WM]:^WSKG+/.>==W)5GN/+F?Z[Y^UWV-GIOXD[@$7-37T=,!R,@
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M(@!<TSCA:U\C7+%X1 0TKAP/$(%DD"I!P)[\1.18FG"'$"4*7\LC<'MC\HE
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M"TW(P= V.;+<_H:\\S$^15%GJQ/0I&K<57D*6;;\ HM9Y*(_@%+=M2F1F_^
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MSQ<MG^PXI>_7Z#H)TN_(7A=VO$<F=/"E5XEMC;^.MP/+N#P4202>[@A+']F
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M7DCN65Q@ZBG+3O(3%)EL@EW"=G8MJ$[F=85*(4(,3%.4/K@4TG 4BC/+=[P
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M@7*OY'4/16493D8L@5GM-E1"5MA3+GQKIGH4OLYK,^!U(\.P<,G["UST0TV
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M4W?BX&R8MC VRXSBM4P.-].IZPDR;V[,"ZRE?%/46MP#^1CP2H74&N&5B73
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MRUT)7ZDV^9E2QK2U!N(YX\-)HG,ISAY4YYHWA AS=W2:G JO/^*RT#A]L3+
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M!^^&!&#)4*G=$X<6;5UB_646%M.EVF!AE?BA3A<WW[A+E%JRL-L3^Q;0=@*
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MCMFT_Y(-T_^';/S7(%G#]>$I\AGC&X%O\4)?*8-_!;G=O3@&B/#LFC\_K1@
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MF1KCDF> GG+7G^3E3!J3RD#X9UHM<IS;X#,N#L.F*(;QF(X)F)8,'M8Y4Y^
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MY'%@@*]7ZPGTKP74Y2V./W"E\\<!T-+OD5L5P--OGP7/T-Y9[XXN@@GE\FL
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M!CYJX%8'/NK#R):MQ1VA>D1N^PW/E@4?;['R;XD.5H3UO?JDY_!!P_&!2/C
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MHLR4'B;9.@YQ:"'!0.W;!?T"CP!CS_>6QD7<0DE"E]0XN&91'%3HNP!UL$!
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MTAK+JU42O>NHI=\AU=5'I=1/?XR:<^'DIQ[\Q=+-_^LU'^[X!U!+ P04
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MR:%WSU/JJL[)RRY%_>".(\WZY.JTPKMKK,#Q1U5U^C?N+XM6)\?,[>TJ]=,
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M5;B>.J4(YIR//6X]-:&E9#ZWW6FGN& 5\AANEV4[/>6:4CX@QOSTDQ-8;$
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MD*6K <;^*DYU,31><8R?Z$K4)60NMZ*.:3PKFC 8M)]R.9"XD7^0E9B0>?Z
M\3GIK(^IL5F-:=0AD>A$F7P_VP'B74-PX>P+%=+FILZP-]98>CJFW/97>:K
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M5(^$'KKAFNE!P26O=LU6#6(#;M]+NC8:7X-\!(KS1@Q"F"NI ,^AJT>![M*
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MN[A;PZH76H%\F8/+[1Z(/'I][DY.C3OO&Q5956GN+Q"^IZ!896&+G%&=O.I
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MD-(A\51@?0U$EHW&:$/F4*@=-TTN6O&MF3VR5O(;*3QM;FZG;[#QC19*KZA
M#WH=1$,AM*R>I0.7)](A>R9@4N2I;?*I6G0]<BZ3AJ#=C[K)R E:O?L.946T
M0'>>VI^@ D^)5."F)U@$TI(RL",Z3>;YIV?;K'-(83<H)]PZ!Q:O!UL8O3QQ
M8W_@K)=% GW$69C*-V_8PH?Q]?%-&@25+5N@H>V]2%IED43WHB8.VO8S+A,6
MYHP$*-*UI8UC'DE+PIH;B<QT?A +!H327?>SGG,'5YVUR:^:54A>P[_PU9]8
M1&-O!6<[X1GQAH4? Z\,,9OJ&4WI7HB[8"]?M-)\B<"-IRM6&*(";<UGACZS
MH?DB5+GV_?Q5G*0^,81>=3^X!WP$SC-= __>IK"@YPWO> &$MRK\7@^)EBB-
M]L+,C209R-;;%,J1TN4R#M_%I.]AEIHOR;$0ESJ("S1"WK?@F2LV5D*G<F3L
M/+^3]"/5MOAZ,?I$\B_X_0=-^YB+F+FW-E\'X??QCY)*=)K&7GBF!PE$8V7,
M"<QIO]'#-K_0C,R5T;8T.':7[71F-/#O OZ,XR1%BE)J:W[S]X_KSX$..93)
M/EY+I^F__[G9W_)?EZZ_[I#:1_WEZ?T@S':N> UCOG0)%0V"#-(Z$;.6_@%\
M_UE"+GJK7LZ+E6(TM8YJ 1XF0W-G*P0W:CZ1I'!CJ$*W,:Y9PA!6Z7U0X0NV
MQZ\ >-[S>8/=<ZIR&@O ,]4X1Q.%G%REI_MVWS84>&#Y.]TW:IR7<^)QYMCC
M&"^QHX!0N%: U\E>$XFT"[&1%1ZMI+7<EP@^PG#;TTV?8IBA[=#FR,.!@-P^
M,4<*@Q6H&)$#&]A/(CCCJ(!YBO&X!M31(YA[2KZ1Y8!3F+)^XDTURC',%G&,
M4#,W&^W]#:Z(995_V''IW(4+UF:!3EGWA3A\DBY +Q+"A/DWG2(/U-</)[N+
MRGO9=\XV'_3M0$17T!CD8\R$K6X3+B=K <.\BG=]7_(A8MFLHNI:HMUU3=)S
M/9:UBQTQGG05R=$$EN9"NKCL=[?W*W>W&BYU=<SGAJ.D0TM<U:Y\0MMG9Z0Z
M^N;]Q( 9/\N?B]VU8!BO1?2!RLD#W;&6"Z8C2RAC7'K8BPPLOX33UT:0[$68
M$-.Y'RI?%C(@NHW*\XHG2*=P/6&&Y<.-REF376P5/&4*3'A#J2?=Y!QIXGCJ
MN^77I>;[Y^,UB'Y0'#SNJX*=QHW@SZAS)KTP30!^JS:LWP2 )>02;>[UF@SR
M]Y1 .R2XQ^%R*I&VW_W9)1YX2V&J8$(4#D9$00_1G"0;39@$B;L^,O6ILWX/
M(6XHS(XU5$,Y2=JX92ECO$1XX(?@OK1G*7OF]MI8,2.!]$ !DU&$RR:E+TO)
MS=^3<HMDG6VAT'I'X($W("P]/@*M5MPH<\>]O=EH/7_W)UPQX'P$]FL9LK07
ML<7\J^O'2>=/"QK1AQ7MF)WSKJB]/4%*!'@=]Z,>5G^V22Z+4C3 4<P\F+^Q
M7!= X0+1P.%@72%RC@U#,@+A0@@H2GB_+14 : P*Z[X?5RL:'X]A+U:0"46*
M$P+/9#Z(%UTS.V[)Q,#=$,H.]U-):C()#2?34)G4S%MS8Q"_(=(^]U?E# N>
MOUP@16L$:S::\>T:Q*(H0#=J0MQ [0._0R@[HGWUCY?ZXFXU9E,VL/7V&D$>
M\7P>MX0MQY7C6T9&>*EYSA?-YU9Y?L!2=&N:IS_K^?')=\A52(<MW;ZJ)C$7
M!W;!G_LD73CH8X_),OQ]Z9E!4M/9%$J32;<(N(8P@*L_F%ON\+!M&T\2?>XV
MO[GU=).WK?V)IF8DP].3<:,=5I/F^2*E%B>W,O)P,H+,*GU^?&;F=R=,\F>F
M)B8[AG_>NUFFP\-6T2!V-O[)3?X@MYY30!G ECS(,NUU#/;&@WT8%F0AT/+P
MZ^-L6C4+]NA$I",&4!5R$<TLL,!OSXJ*]S@%-!RVE:P3U*4R#'10M6$YNJR.
M<J7B"BCB#?B54?CM9O%*_-M4S9*A9V=8>I\V+(M:WGK\P 0XKJJ$?P.+JNMQ
MR*OK4L<0'FXTF2"$;YL95Q[:KB"NFT'S0)7+&U69<#O<*"4_:W7P+FQLYI)\
MTPB+%-%![%UV-WLMVW&-L#B?1.@[MFRAPF-%'">N:J&#%+ZZ/KH\/5<TMEZV
MA"U-;C-Y:Y-;P1--Y*0P-\TG!BV8"*ZCA9S*2Z/[#=EB^F47XN%:1\3QF?(T
MEYL\0EER.1LL.SZ'.RU8<4:3]V/K'GL;WZ:OV.#YWEBI0_LHS(1X'<0D.;.;
M$D@+FEE#*&H69Y8;3I$AW&_[TD=.\"T-A8Q#LC4P5X_V_+4GGLP<S1#A"676
M7J/Y:A\.#I&MFH8?V3YP5%J-0<L.-K+R817VPXT>V$+5<W!U)\E[$S;W]"(Q
M"4]B*W=?BHFAFEJ$A96V'^#]2OW2;= ZA.8OOUU,,R3=N/3Z#Y <&K8.[DK]
M ^%[A4$NICW20ZN_STH^3_IJ, >H]I0\Q3AH7J4!%8X_M@?=I\%RLEP@*0@-
M.?,U.]7\]:*$K;KXW6G)-GT=]>G3A3;&:5<J"B9<]Q?\.Z=[&!Q'4T/C1\8W
M-5,_V[C46V3'7,BTM;F6D'-MWN(:Z&-^_R6+MT\4C)W!>]5C.\'=8:T:4.4F
M]V>@J!&K3?3D.>1R-H:\6[4\6WENWP.GV/U).J3LNV<I7\QRKQL^WT>Q,E\H
M2'P2*DBB;WZF)WVO*6<&BC/Y4G\ZLWGN</!?N@,6K4'^B)#KQ@7,;4=K6'[-
M7.K]_K;?EK %_?7"L7:FUZ14:<4?+TCBBP.)PV:&VRAL.-0+N';):EY_ 71Z
M-?#> 5>J:IQ07R9W@L88&(757K49BGX]],!Y&1KI)V_2G2$_7!G$-1[8C'XF
M7FGOR&-O?>_T.41Q$B*G^3,5B+Q/LJ8"']'A$)P:#=C%6&YO,!*OP'(&%ESP
MRJ](9XI<!-38L_K=_(,U;1V4OJ(:KF7JB%;G)]9^.P$U@^;P_[3EF@=?>QW?
MITAXRMF).F(AF%,!^A((H1,^B@?/+Z%Q6=UJF!=[OV*5["Y"SSJR"L3N?'HS
MF,!L:7F;F3YL" ,KG.,DG#[8P*,)A9W-XGB:;>KY[N/*EINY:Z:N5Y[<^U(,
MZN<KRF-NM722^_@CJ^FL2I2!Y;O+0;,;\GAGBD#N!CGS56KC3Z@6%8BZNK3P
M&W2.\\R [[MHWY]A5OW0FN[-,'*#TD$[B!&*[*B6/;\>F-Z [&X/ZR\_3P$0
MAR 8J8GN9QJ1R07#TRP HP)VWZO0QV"%MP8U=')Z>*?M7,8OZ+!_O3G 6G$1
MN,@6M67GO@0A.,='YU)<43%(G%8 %>A:;7O-;SFUR[KR=+8\96-<KCM>@#7]
MP>9E)./JT)D1Q>PWCJX#T(H.$RNI? K7DV=G.=<?A>7!#-N.Y-\F?IYU54.D
M.O&T>KDS=K@E2L8PTBL1:#B;#8^WHD3]AXH5*A !(Q12@1L#71#"25J#!7]_
MUP*T-;,ZJ(*B6%5.")N#\KH\57XZCID4\>A,/O'(BKX_*H$^K.M)X/B\0TW*
M];&O(N&IO-;3CVLK/O"K)Y;B2S>_G!Q?62;Q7IK?CFYD=,=SP=+:;;HCC897
MEZ;=QG@F#Z=TNC8S'L3^F*[KOA5OTTFNH*T#.^?.YC,C&L&XK9^*)5X]*//!
M@Q>)V90S'[_1>Z[U&@<\C-EJZ7V=I>O)OJ)<<'6\=;9\>8,VVUE65\2I[QK<
MV3.N-J]9?;PN]BF>;5>10K*I<8]P::W:F^&C!_9-">(+[DA60DI+@3^S_-LU
MO;(X_:P:2^FS/5$!QT\ZTYDP2&";P8-*)K$HQLD%@Z'XF$;9\IOP/B%L;;CP
MEZ[-%XX^0H<A \;NSBV0\O$NSG@)N:#\2B-+4)6!Q&][/%<2WW)A2O+2:^)I
M1\O\)PV]@8'A T.*$Z&*H8'I&65%)(FRT!,_NCWR#-F;ONIY]YT%J; E)B'N
M[4ED-E^@4;#/R!X8;IG\RI1&FBQ&$:%P=H)R%IR)X)M+,-%QSE!A-?1]=C;D
MP+QF-C%D]0/ Y&0AK-(/UZ,"C"""U8*)&,EUT(L&BMB#.@3,8 @A^V6#8;FZ
M6&E!989/#V_3.[Q>*#FQ5W2Z)\A]UN1"4]P!A=F."D@/=*'V!6DL\49QL"\>
M3-$?C\9L\/O3(+%-LP-M3H]A@AT9##1*NN[%0PBRP.UU'&7J\ZD5OWX[('EX
M5OETHI:4QD.K$227?$X33C!*?A/[;$MF6,$Q[O3K"G6A=XS $WV-^Y86=FME
MQ?%M5WDIVI:@/3R(\@)\(+6@%Y9#",,E=VF*5DWM-YD8U%77_!SN=QE(01$$
M)DE/O].H*";:QVW,F JP:]Q_6?'ID<?Q%4"9PV1K?7^GWN>VU:L;'21VW%B5
M[]RLP*I-_0V=I3?!_$,=A^;-9^@9-3^4@ _ \[D=L:S8[K#+V[RPI_OJ_9H[
M2D^X6V$@H/(VW8&=?NOQ9E4R&GG?<%L$%DI;![/L2?1Y,\KIR(_JYR1=36;>
M"DJ??J117DVG>O(7+3203*2[!'VD#XLK0AZ7W:,N[>ZR)1^V3^P):9_F8;\W
M<N',Y8UVQUU>"HLZ/DT/U]TZA3ZF$\!'D<0S)$14Q5U[6%.M+V"9V'V_2TGK
M@[,O]X$1W([("3N^WHVJS'WQXL(EFQ5:(G?_:9 E*1VY=!U1_LR="APK4CR&
MZ(<*:%YR#YF .5N^GH9L5WDX2)Q@*KP\Q)E&7[[E=<U]CW7?CIQZV6NBH77'
M1OOL&D)RY$IS=L'&U!*72MR%$=TZE0'I))/[?!]<S+V--R,V*O#H_2(<9XN\
MY=0MO,6WC_6Q_;7U$3/?.G_-2F#K.+Q3>S.4'_ID9#:B6[D0 [,UJGC&$00;
M4:'803)J*96GZTC'9Z?_G;1ZES9;G4:<GF03ZWXI^=T&Q%61L=4SA347EF;X
M6WIH&Z5I?Y?]NV'<TRNCOYY\/G;I"^1]?4H+%8BE A7+T9V+.6%8>2G3$&Z)
MXH]%R3=6,Y!!'+H<QRW*ML BIB^RMGJ'1#5S"#54@*$+MY0^OVEKA8M\I;@A
M4U&=M&*]SBKV7;-3OJ;?-)Q)_.;C /1S#1DLNW9;QNDA__2SUJ=&BA2R:FM@
M[R)FBD[02]1V+]BCT7 C A%OT[G+NJG=);)8U-Z7;%)3E<++N56O&P;;5T7#
MR8F0^VANR*O* 6&X7BFE:VAWU7)M6.=#F(__V033WJRMDRHRMDO2]T-4K[H9
MOX96ONF9=5SQ(IP.>.$)MR9>6O.=LKV\LW)0?90F&5.>N14[13E67J;9\IZT
M2$Y!SK.E+41&;)""G;V"YE^M2@SYUS\HRZKGYBUCN,]\Y>$RP&-B0,X?O=QG
MYW6K81C]T;!0M-9^!B8M;"WE?[8W^*6TU:+>)BN1'K8PGU$7$#1'OK+>2>%+
M[)NJBA;VDA\OZ7E@5O?RE^<U+7HY5Y42^%6=WM4:AZH1X@]$)^T6?OE"",Y9
MH-0;48'.\?Z49B5RS"Y:P*V>ACQ>Z&2M'MRVN7HPX?Q^TE+WK,V5:+U']\+"
M*A\UFU?BQ[O5/7@IW.K!YEVKN>](SW/.U&,U'/LLNJXOQ&;%_4 ;DM.1]Y$B
MI%OCY] DIQP[@F';V9F'FT^;+19[XP^=Q8Q^*R";:?A-M-Z"J'GCIS[E%*)[
MU:0U7;DU,*"]^$RSQ)2>^SPXV[U0)EQ&Y_Z&_OUR>+N<W'N2/6& "LA$=D/W
M)3!48"@2/?U3\5;5=[\^(\TNAJKRRO"3H2>Z!%1&KQ<\7P&.8401\G!&0EH^
MW *?_C.W'2U@9W//W:J\74--?/CSR^$Z2TOFT!,G0]66LEAE^F5_3!QE$R]_
M-)E8GL\#[2K\ 'UC4%JU:$$,3#HMO<(ISN]%?'*]&KM7\MR1;;_FPKO%:)WG
M]%*%@,5S!JYG_+/C;,VR9H1DHOD9DTEU[#7(KE@]Y$,$YC;R0?[0POX] N)[
MJ?>YS]>UOIUX?TUO"8R-G\K:M\-GQW?)NW>I'7\>C(8%W'.JO[A:JM0^953*
M+*!C:JWE=$Y4U+O%69*6PG,B\3?71>S3/ZY*@!LJ0X_4WPX_GJL]+ZC'9GA2
M5,]8'VUL9I$/OGC%>1;Z__C&%0JE JTZC>)HPNR<99K#?#_G[?'M8?N:U&*_
M!GT%I[L=O*&+IKR5 F89'^)M#BOV 8+> OHX8K!Z,N6EAB!6G-58Q&/DT?;M
MH=R:EQ=8PV=6CILXO/^69M_Z,0AE0!OZ)N37A!=F0\Z5"GP2H87X>TUI&Y(T
M87V."O#-BM<'OYF/6\49?W'2C=!K^;5I+5PVRW]D1T3 K&SP*1OX9SDK(E<I
M=7G566[88:.JH*CH"%5U+M[GT]AF-H(H480PC@V(4K(3[9 0Q3.%C1,57#?\
MKUH99,S\L -WETD[:R6TU+;\\@<6CN>I%!CIATV3GY5BJD<?>VP_+I%LJ*B-
M=8J B:G=?/'P8NE<J.H7=!^(<(:SD_U2-TJDJ#)8=E%1GJ3JM*^_'-5^JBY
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MFXL8SY!%^+BBXJM%/WMY!CREY)',LA1;V$=!/?#&B@H,FJWP T:OS,BF"F'
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MN=/A\X42(5+R:+SVW5(SNH87<-=SREBWH<RP6-O$2,O[^,.:;F^5[2H)0*\
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M^&7KE7:Z0[0Z/M$=\@IS>%JE91!*T]T@$?I^49DU\.!EITUJ1"<UZ[4!A8>
MXWA0_=;^2R*@MFF\7IO"H 5>QZ7SLH[&^RKV,6.D<+FFQ]K;>^07$DN2HMH-
MUB@0^:LK<R5H?R0D:O_^4(CA>IE--AH]/_^"_.[]6KD[[RRKCO<%CLH_ L15
M? A4I)XIW9Z/JF"&Q;4Q>!?.M@+<??;6?&Q'_1)3J<@ZJ!3#&[RJ1C;?A8_5
MDF;]#Y1:O.M]&$. E-6D[ZO[YC[:RIJY1Q./H^2_F!8:OTC2XKE$@=WBS$;
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MI,V;2 [=4+%GI)>1]#,-*64>H*'E0M<!$X-5)#]"0#-+3,T; <0(ZN)21J]
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MO(E"P(C3)2[(.? :A'S,K -*MF( _D<T/\WBO/ !NE'GJ_C0K^9Z'R$P'\-
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MD5SS\NHE.<?^S+7H5T+D;FXE@(<<@4^@/L=P(\=_7^-H=@PQR72U1@@]?QP
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M<FSM *;\5SOKYAN)O9]3J=PX#%$1-2,P"YUQL?"_-FE=WH0_LPOI-RXZ+)F
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M=5 COZE*K2RO:8K;#LFVPPIJ5>A,>*&=I@DV#3]!W?KS=6Z7%*.3>1_&>*[
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MO&!/6LJ8?J.+-7I ZA[[E^IUW_([A,7Z[V$2O=HBUJK&8W#L+?2^HI,&N:T
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M%(#CCQ5%@N5-,/_S7W^IR?7/E?H-1?Z0_@@@/"E TVWH_.@\!?C<EK?M3?R
M'M@"SVL14\U1>-YR,@S^]O+J3"/MM6?43W%_<]AE]]\_BAZL&-<F(TM&QBW6
MVRG .5&_FI7W)Q1/ P7_YEEP;GOY@A')%)SDID /8F>-D[=CH"3L?V'[;YPC
M7W8F<J#(-UA'9<A?!I$'%\@8I8(5^/ 0_FL(_DYT>XFYIXB2/7UH5D78+>O^
MH,S6S_M? I@OA3"+M5]MG]R?&TPE,\I@<R]+.1%$05&&CO&83KN7J(S/]+O%
MS@BY>/V&CE^'^4$%H/)'2^+#6K H7_7 X[626-[$U0'I^]DR+L*Z?!=*IE^'
MYCP1NOZ\AM#<: !NS8&-YXEVN([PHL"B]+)""TLSR:P3G\LC'M./B_: QA6(
M7RBL'AKB^P(;[GFE!=;GRS!=91BE*Z9A<-H:LOU3^^J^')$QG]5WJ-/]>43-
M^_G_;'9 80&2 ZBTG9_XSW:K_.\:_WN[8OY7C_^.KH'_9>-OBA(=9E(K_R&3
M^A26\,=$:N_%OTD8^)>3]__MX_^6<^O_2#U$D]Z=S@9'@_*^=:GY^L:Z9*F-
MC1F+;LF()L/[)[+C ('= R><$9,S*&:[?L]INN&2Y]!L7G25Z <?6A:<#5!M
M_>CG<&SK+35"+\^9>$LY*@;E@5P8CL;KL#EE31KIR.FOB0NT$2&-22^^0*?/
M6L<K)W,.5E,Q'-Z& DVA%; W3D6+O]VZF<_9&7T14&C5N>NRMJ04CKK!W276
MK:^1.1!M[8N^Z8$ZTLAIX>L&ELQL'1F>:LF9<+Q4KS\Q?M8MHM!9]-:9=+;H
M]H:E=CA6%Q5Z6JR=I#!3_,K=9M:Q+NV"E.6:\7T?G^O'+>T?"[A>N>O*Q,9U
M4OE54]'[.9XG;5;S^1([0[>H0"7]]>!QY2?<HT?])FK6Y;\B8C4GOCRI-IB;
M8MI!)T,=8,.LL_3K+;D4P-E"UW$6>=PKG--1\45IZDNK(,[6\8[JZ6-'DX19
M1@1Y(^VT1V1'4)>&=K2PW3-3@6,SJ->YJ!;%LU[RJ<J]VH].F*0(K][>UH:&
M7B9N&F_F;;#.A6\%(S\OY(7+]Y'3,D? EV21G[3OMIZFVN,?'E=I'>1].W5!
M0VN1.M]#T^,01JA]*J'KRL_K4IRME;$.E3UJO+>RXDGF7X%I_F4X?WT37-1X
MK8K(+=1T$LH+I2XW)E^]7_ZUT9J)3. FUXM1O]7,^ ["DW$"R\ ^IYE^DCQW
MZQXW>_;#?";9JP!SG.,> >](>J^D@"V;-@X@RN5[NMZN'91RV_%3-RL0GX\M
MSB;-?RD[+TS_4C_]"R/Q%2D0P4X!FN=)'^OY<KI9TW)6J KRZ53 I4;=QC,2
MK)KQWS7()$2=I_'L$E$47@F-J.=Q5"&P,G@^&;%1]218M#9K0\5;:8<WBWUU
MG"<L+I^&BF&FLPXLTB,)UI[X;EAY0'OOY3Z\FM/ICM.+S>/O+_@?TQ;#H6&'
M*<N^S_J*?&'%OARXN Z_Z>XS;<)Z9A9G6JN>*!=!/J?(5@V]T(K2]1HB<G60
M8<:SK(1:#W+J1L%B%ZMI W:R*F_UX.F&X\=A<RUW)T6_Y05-Y@CE)F!(/5I9
M&/7H:;<AJ1!JZZ>#?P)^RP?O+G]SR8$>6,;ZSI%5GHZGO:8 Y=E<SOBW<P$2
M'8Z[:/PVU@:]H4W@!77F!**?!AKWK#\:Y!>:#S>)O3E^;6NAVF@I(Q0WB!$Y
MWXM2<A_GI<:"SP'_3BADJH40@W<HP $838VAW >'O9#/4H#X)X>M%7/RR*\'
M]O4_4+'2F>H3]!L*L',6GG_8)@.R?\6QF\!HBES6-4_ A-(4)>\KW.0R?O#O
MO>__>DCL2-RA^O\:B#'H<Y+AF15]$^["<9MK1#>&ES:J<9?C_2/<Q8KN;E.)
M<K ;B[X/"N%T6A'T@_RBF)[B"!8E!T-1=5JM<X%?F2,*Z0F&;0-B[FY4?K7'
MVC0%BAA'-$KY7L1.142'[S0P7*Z[V1#6O#IH''?U??PIX3/\WRH:(R[87&VR
MO"/E.K,JT0CBL%%;TUIM:#:0@Z 78EC7,Q^E4%>E'BH*QJFJ*D70TV*+CWVZ
M7I!!Q<5W1[F,[:<A@2IR8%K.VD%>B#Q3D<;M7T_S^B\KJTIW^CQX')GMUWN%
MY^6 L.#UZ(?V5Q*G7=ST;UYDE-!J2>?O)UJ@5PY$(VVN9.6O<N94%&4SU2S$
M1G&K[HDVAE#7RB.2%1Z&10>Y.\%;![TGVJLDON K$[MX*]TB38*W.SP[K:[R
MRX4E":? /D+D>FYRJ_XC(/UO#<1W<A-\VQ%S@@),'#:F^5:P40O&XQFI2\,"
M]"!O=) 3=>%.0R'WYA"YX0\SPR1D@_ZC<8U[&[UA2%UVM-B\];8Y"YEF6\W4
M-N^-5DN_A8:<T69)_3?L(2)FBX_BJP( .FQS8WZ^BXMV8P:7/ER&Z'M8J)TH
M1TI#")F#$JW>'J$RNSYVY]*->YT$X[@XI!<,+-VN5\9X>YSIX:VINTFS>Y0;
M.T1489JN(@%*SM2+"3#R[2PRY"C6C.POH$!5!'Y4_BABE-Z>MQVV3$@,*\A9
M95\]L,G9.9O(]]' [<3%)A.U4WM-!89O_D-LZW\_2Y)( 4-Q8BT0AGHIUUDH
MS]K+E&/ASOY[QL[^#Y:.YU^R^'F"6TWL#*,]_ :]SDU?FED4* EOB;Q"FO[E
MRS<K]6Q"6 *?&AS<8Z%&^*YP_>$N30!*3Z*??(3J&6T5#M\7@T7EHM7U6.0;
M:;/.@#Z+^[>*S^P\6#02?X %G++3@<L%6?H2Y1)9J]_%LY\<SWD7I'=)^RI@
M)'0R#.R<HR=RPV9X6G1?^$%NAAO@!N;I"JL4K]XL,Z;GN_&S!3G G33YF<R'
M;+)0.0F6/0B$X:1#"T'Y.TTW=\:DB_3BH]/B3V2-GQ6H+FJ(U+%LKE59R<RW
M5ZR(:L@U=3!UFC\=C/+@Z')V=Q2,.Y_U*,'F4<R7P)B;9H6:7,9=F'+CC3UL
M&=YE0+CGLDXGALTS_9+2!M^-2.NX*2'!'^O?0YOHG^F\.#%^9BC8$TEF.HLE
M[QD]N!Q-"P;J?+8=PU>+!B^\17K%2X#3J(Z<IQ_[XVK5:Z%J=L6PF9 V&"/1
M!AN$#JWG+QQ;\[[<\5W4/Z:G&G@WKQ&L=>J4$1 1K6]A8SU0;D5%B9A_D/$I
M_RWC\_D#XY.;V?LCX=O]\;==F?]!N5%\;]:Y#<KH>P:;T!U:;U-DMFPJ3R=D
M;FZ=Y/K^W+F GTOTC!GIK&?NW3X05*R5^+W5"L<^H  AE8KA&EF>D%;%HLR:
M>ZZNDE?&WB(YBLU_+S_W<[&<(5PC3V&8D'8;!LJLNK6UV*TP8?..K+7;)0U-
M_#>D"XW4Z:^_X#MU_3F+PW)_6)UZK<I;*I"P!W'=$TV0FO6R<8^2-_BQ^9SK
M1'9ZL___8.^]HYK<UGWA*" BO4DG(" ( HH@4B.RZ"(BTL%([R+2!1**@("
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MGA^]-*VJOW8"*("BH=V^&74VF.(3X;S3.^#7P-H8:%<MU>[>5K[Q/&FKM;0
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MA7SUL26F&R>%5\(@NH):9!LC]XT?_?9$Q^^#5U:X<J:E'O[-=YUKGW]ZHO0
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MQBH>W";OT@4$9_RV?__I1V5,IMDT]Q&6P'T9[T<="KZ&472DD?GD03+?6(C
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M'U1:A:6["!\G;SE3?^\?LG,15*I+ETT!O#A$O2?%4(G2OJ=E+[@62:7+MRD
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MO!<%X*"&('&E'YGJW/RP9VQ(H-L_(Y5?_W^RE>*_;3O%KT:\1S6N$NAG%(Q
M.P/=FB1HZW#7;?CW76[HJAXA7L=<3<->Z>3_&:LTP]SWHMS&P.U1XL-Y(;]T
MC=</M;:N*^$GR_&LRWI$3K-EQ5SQKVCJM]V0J%B:) _O>K04E5TZ=P$'6T
MMB[R*JP:",+F;9Q'^_TX>Z4OOFB2_K0L&K5Q>N=6CN6MC>F;_,U'\254O^@N
M![PQ[X IE0HLOJ,^F./]^4%RBH![K'4<-%Z&?! *[C29?;\$1^]AGX1KXU_+
M7PR7N/CT,*L<0WIK=^/UO)<+$"BG:;^\"G[]<J0;4F<;+HG123^<]R$*H/#R
M"@)H=H^'%]\<?.-4FIPDN/="MJ\Z-CZJS"R:<\]RR<UQ\!4J2GY[P=?7EZU+
MAU_*W%PH$G!BO^RNJ5W1/W1HX;^8<4'<H9UZ"(=4]I#XWFD@#X1_?6\C./A,
M:H7'66GC@8%(NI8H/?GGI7R6/^B" <%7D5^/90P#A53\197\=U-18"+W9@^9
M$?--%9A*9%(W+K>2?!YX33[YU6XZKW"XCT#R$?#*2<3VCS;DLCP5/V22SW"7
M6^,%NC39LT:N<XH/Y7OHO*?K[!H,?C3P[EQ:WPV1:^(<)X!5FB)X7Y3\67O&
M'/^N.;G:1Y=HY^)@3-N7QS/O>-GJCRGNL,[*YF8Z>!7/71B8G^VJUF6M*3G9
M:)[',\3K*7.%RNP<8;.&([B[>+LYN[W>DA"X16#+E"\**/J<2?SRRQ.7^QCO
MYQJX>3//\""\1V9SYW'Y>)5@U$QAW'A/T!U&-#_.^TD*2HM.,"5(]>7[2@:+
MSCFZL';ND1&Y!Y "$!_D)'D:R86X'S:/C-=4Q?@,Y^5K7QD43BWY-#5NTRI8
M.V]<GY[OE/&1J?#M!S[QK;\<'7E"O$&J5(3C+: LZMRA!3:;-)];&ZO3X?"=
M@AU>J40Q*BP4/O%IH].(YAA9&>*KC]5X5S\5T"IK,R/4); 9\.;$P=S'Q%0M
M3&X\RNJFJESR^S7,BU2YKDD1NPBV,VNX4=\WW:961[5D!A)!;)!PB:C4TC)-
M;,0V/FUK/N!.96KP*]&TKW(X3-QV['EHM>@L);D&2H"Q*D*3A '3;4!XE]O7
MP"3+^K?R3.](TV:SZ9'WP[BYQTWM=K-?->>N A/GE';ZP'@)"J"7]-M@$=5]
MX\&W'9A2SUT;#WQZ-TV@,(9D-\"+@;A\TV)Z#[/ IU&Q4126/DG]\OG41?D3
MT"Z-)<;574[3Y@Z"U_6A_FU'JTS_O=V,Y6M'QI!BL-6\9]#+N>^VO<$^4O/B
M5]X%^*W=Q>@XN4-9PV50V1E-8T2E@G5EID=?9V9T&-,V#$N41C=OV PK.\_@
M@62&>@(W/K63?#Y[F;6G3"V;.>AN>D#.%5,S7*&'KD3K:^4OE9UO;C0.[36+
MA-<?7];A?O)CP^A-LLS?[?"H('+G]R 2^:\@$L:*^%<,^;[2Z:]/2_Q]M<DL
M?R")7)DX>:Q<\](:68&H6-W</LGMY./:;<R,J\\0H0U^7KK;(UU:!7[M;0%8
M?4H2SZ][KWS+[I.Q';$"3^6W=+'3;4HH]SJ$(/YT2#RXUN1"O8P1!5"='7?O
MRD7=\W/$1W>75;I2TE</$[!IY#/QV"3CYC3C"('.N?"XA0>.R<,YA3?T%830
MJ5>#3H0(5C-VE1Q![RM!XS4YL2SOY ],F-SGTC$B2=E#FA=<: /4WAA4#-KJ
M7_3YRNCNU!AUZJS4*^D2'$V4+<%=STKWB\4ELA">TQ#OL&C/V/58\#RSI&YM
MRO#"+65NG;X?&K,I5KDK:6!1JK\V ;G[/@77DJ,6&5,!^(0VT-7W@:%"\[*%
MG$>E">Q:A(GP^[4!_3:$QXD_GS2[?)GL"U\E (CF6,L^Z&RM'E;O6;U9A5?M
M]X5>B7DM+HET">D";\^RC\+I('0[0:Z?<"=<)$V_QMVGS;)(WS? Z\,PYY<^
M81Z-ESK+&J]%T8G'_(GA.)AZ  T6ODB/+L,JX_B\8'$=&AB7J:*"V8$=EG2J
M96=:Z"3(KGPR3U]R-'*BY3"PX%-IQ1[B]O&I!%=KR6[Y^'MGVKYZ*RG036;
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M"E%1L]+45[/3WV93P\8(+F<<P:@GT320E%(/BG@)3)&.0-'II#LR@0;B@ZL
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M1>;)#Z<<@\G&A7J\*LG:\[&%D=(Q3Y\S/X45P[[ZX(0?XGV,HK%3W85>F_[
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M'C^6.#L1=J%D;KWI''V5UE.'FD3G6!99<K0OE>?Q "*3S\:S^UYH0UM1GC[
MN:'5SE9!K%)WN%P/#^S/Q7F=PB:5.FG7>QD8'^C%JXRGWV;-!;/]]*\8SMBC
M@?BHXV!!+:]L:,X&DE?+N.B/&L^'@FKDW7>]&A(EIYE7F4>J'1[>,[DE.QIX
MBO5\3LW_:!U.SM\6?.!>-1A^#(R_M52\NJF1E1:=TY)\IU119?5XP-'7"%C[
M1AH=ZF\&"<RUTT!,Y$ "V'S.2^)+,-'YT_4.FUE]^WGPC9T&R/[@[-]A26M9
M>RT/OT#SM F[^_SN]'CBS%/Y:\[AAI,_PT^5.]"63_LS80Y5:40]^C4?(3H4
MY!3JFI]^*7^S7L"XX- W]*1QWR(9CIBNN&3CD+P^N N1:;L _%[%^G15\ %U
MV[Y(V_$MI8%*4H21< 2%CYOY:\7/;4 2VE4*Z0)'[PZ.ZY;/="/SU)AI(*.2
MW7-M,?\(4K=HH%=.I/N P)9U6(FXY:^U^M,?F6R35O*AG]]UH?$BFR6B8VZ\
M]=K#& 3N@/*>[ETF$RT:D].C9+5BAZ!73G,=MN]VO1#G&NI79ZL@F'($+V+I
M B6[!L6JJ[@!8_MCF'P.OCG4O@O;3<310._A[P$$YI<(\Z;V<F+,Z%D#B9*E
M(4VHT?2+:"-7DC[T :^<+A)?T8%*A/' L%,]B2) >]8G;=B]AL;(P'N1P=P5
M2T+7 2MMF4V9H1F.M<1F&@@3E\IM5$JV;GV <HM"WW[% K[2ZY$S3?SN=F15
M'X8 $"0)H!Z[B"HDFQ"8L@039G+B3&.7[1KK@P9NOHY;*7D%2S+_O%H1<BA*
M95$@N Q_0X/WE=C<+Y>UHN+H>6SU7#4W@WU'C^&[E/6H!]KW"[=M4?A[VS.]
MMG@:J-L5J,B?,0E=&@H1<AIWC3AKV;,N91C]P8"UZFR^T/Z#SC%9LU:7S-K.
M[ T8/A_U@.M(:"^1?$&1!@)60B'MX#A$%1)'6)K;9/N&YJY14#)N:5*KOJY8
MIM#C<K[POC ;SWL]L1 K[$G&CYPF\(0P)OH3>Q#TM M6?00L8]OJ*P UJ^0+
MM><B%I8,<3A^-;D[B:)7=HI_P!^^<F8\SJ'Q;IE_NS_"]1CIS+F8BK]]NA25
M5$KB0C?Y-IHHBUDJ6MTJ^IJYIPKJ)MEU(MI(E/(6!9(&T&F-7T'U<CC^Z#GZ
ML>BFTJ>X;[0)"90\G_0\X;GGA_%'-- SJU^N.!3!V!B0(]T!-+L'Y4< >.^]
MQWFI&"YE^=]<;,TO>I;X7KT6[^4_NDXW&#/*)U5$/(2=K+F,9+4U*D$#3D,D
MO2_O7*P5Y?.G;\?42[=4O?@*>35/ W'(5E)PWIN?%=Y J7Q3N&,TD*Y$$MU"
MI=$TD%C%=4"F!-Z#KAZ.V2)?Q_B(KC59%@0^GKQL=*Y1:YT@:"#I&:\?J%^@
M/@PSA\7_>C U2P-]32.?.N*:M;H^239;#J[-8NXHSD$;(N\\QB;OA*-;?!\9
M,*DPN'U;^? <KL__-#]7=.#.M_2_7RB-R,%+X!A834I09'O&0MIKE<$LB0F7
MEJ_A?U8O)-U*6>>3P>B%E3FDDXR"&#IH(-8VU2!DAP3W1(7J$%BO@<33UCKS
M6VL=E Z_QL1_(',G(&6QY4?3@^18P]2051P=L62,\4AJCP<71>+] 80LD$B]
M#F9!;+05T4"?9Z<ZP55@<I92!X(D7 K9"[&:__O"#G+(&"9- Y4?%5 C/>QV
MJ2H&/_]1Y5)Z'58(P^L-/K8R!FI]A42C,HT3TAI,ZV^"NZKA]PY#83DHO#Z"
M_[HS@0T+B99X4"_R)MTC7,P5Z&XICS<8VY3<+0\Y&G.R19Z'SU0;0S:M"?>^
MW"W7NO[L,W@K^@SBFER/Q]HV<#XZRA6/VGQ%X+SJ-">^V:6&KW>U?I#0#\:?
M[5SG"%NVZ;R?#:ZDC]-\Z!:VER@SFOW*V""X\,_7VP;XSS&_&&F@;[EFP-3R
M*_@>=0)YPD='!]YOD_9J[ZNMC;T._4'=B7<ZJ.XHWA#4GF>Z%BK 7 OG6@]Q
M_AU7./_GZ%4>46VR2N7R['R/4[*,>92E><1)+6Z/3/8I23WCIW_H42<U5SMZ
M$XGA>RE@^QX5H2<^A;M<OV8![FBMI[(I>!P/LP+"G^2%%YL(W/\EM.KXXQ:U
M? \-2-7C=LO6$:=D@(JB:1.WI4W940][1>PC6<6M+Q*V'W8/DB0O,3TDWP']
M$)7XJ\5S%6AU)9@3D>->*H,?MFJ&V6T,<O)&Q$J^EPY?'2Y,UH__6VF(X _7
M.+T&CX%W6DW20/R0!S00YQK^1YGRZ':-W'/T3G_GH! '#01ZY)/+2KXQ_HR4
M(&/:5-D<\[FY[GUVQKGU-WE1YGNG8RDGZ+Y^"SXRV<9%<"G!(VVRO'!D7;6Y
MO?0\S_.M%JP$,4(ZCZ!/2]"OKW\[2>LA'H)Y_DAH35!ER)"1_,DP[9(![UH3
MM3LQ>0V5C=[.[_0_I\;\L$O**AUZ*\B4SS4S_@YF&I*[.QIK>3?^W@M+9D:>
M"([07EP)Z730(#&+\"I>P%(P)# RV5=5B:=?X'24\J"\9U"R^<_S/UA.?+WD
M4=:O9Y_LJ$N2)#]H!@+S@=^#WT+RORPEW)A>: ]^4.+;<]I0<>3,I?.'1H/G
MA=K_F%-[$#O^2%84[N'?SAO=\"_41;1P#70FD6A'IQ^2UY,4_,-=[TA(C)2:
MM05Y"2CS51%^2L'.0]#^>ZJ';B1A&JA_,DR6!JJ,HL=Q7?Z7Y]:OUT5[7/X_
M%[K00_&)E-J,C25T9Q+[I=OZ)4\,$XR=#N3^P-Z[Y;ISMEOVK'S8.RX@17U'
M3PNC7FR95XPB $F9EZLI76!>\NT!RTE16Q-5H<2VK6U)4/A+-^3!JS K?#W1
M'B@@)%K55^*'(_Q#7[Z/J*4,E;2[<@_+[ZJ?!&W$)_M]DXFE1."YHEKH3(1Q
M@Y*R&NY E$M7 1:)5']-4?/Q/%-&L^.7^RT2GJA;S"\(C4]EK/RR_6I(GJ _
MZZR@3V >ZK2#;"S38H9][:=/]R78Y%EQS"-YDNL<\ CZ,_[GPA98@LX50D#N
M,@TDM/'IW$3>;JVV(]&#E";.GGPUH/=S_S?Q*#FB+97%G 8Z%_,%,6U)HH'T
M63,V4I-U;9',\$5P_95*TDT@8J/# >RVEQB=X=]^KT[&L^ECX?1N/@-P7=B0
MY-O[NP==A<!D(FJ]ZGL1T:?(%PEY(^B@7+WJBP5S%VF@V:: *V'?*,1K-]0A
MP;=2DFW!;ZEG::"D2/I-*XH0>Y=MD!S4,QM(%K)_;E!S9V!4K\VHMP!VT6P@
M6?W1PP5AHW_4<M2^%VIXD@TS7T3X*,V<6R4Z I_&W$S[99[O3P7OQ46FDC3]
M0ZT@B[?)>91?IW^]G3Z,1075# X?^[M3'^*<(Z/W9NI>W*.1(BZ=Q")]C0J2
M8>]I0JN8:_19U"GJQ3 9 G,[U^NFX4@M$R]BN+G)AVS_X30MUW>IET)RRX7
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MO<ZN(.W#<,=<BS_U$-P/OGMP7GG=#:MJYN!H@%WYC_*._R,RBER#$$">^H$
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M+YO<-UJD5;ES)7@Y"#ZG-Y>1>.R*II^7#@%3[/9-@W<0X8*]95D-\>>A_OR
M_W7J@+TKU!XU]&6 & !(#.9]/(&4ASN!<$)5LS*8YKD8$M.&%XQGU,5.H7(5
M4H*^F4P)4S6I5[HNFGYX[?P//[EF2!'87@&L#52#[#27#[BZ!!+H%PU5,_0Y
M*.7H=W,^S\]TT54Z9NJ-TW;I1"WV++IT\U6FA=EM;S+ (!HM+\<ZYU1Y4W"2
MNW7W_+WXN&T>2J9^PH>1:ZWO/_8]Y[]N;<Y_]R,Q"K=QI5J=8T?:QU+YF'9<
M^^:;Z>@7?]O;)5[.5@NM;=ZGQM.E>!X_Y-(W[VL9WJ%S08.U7)POAH&[AW[D
M*<PJ#9H)0D/ =*L6 #2X@>O-?IH*NV95U4@2KP2WD=@/UYK>+^NZ^KI"NTY[
M+9GL*Q%O54[\'G]P8$KQPXO?8@/)P((<XDM#M@4'GG$=CHHJ7'Z9\E:I_["R
M*I\^UV^W@-B*&2!D<9.!2;DJ,C!T<@-]7):C-]+<-1K4./<&1-5R@6!7Y]/$
M,4^$=$CP="1SEK'2V U^?G818=76\IDB2R]2VQ@<)(KHSE"N2<<)=+F*]'5<
MC<4;>8)5?_$=7?JQU?5+<:"OK26#F .?SYX]34PO%<;!T</M-1871JO><998
M6M(EYLI@?KX"R<@LT4+L]=T:S[^2*3BJ/U_2-C,0)DBA84L:='],S"*=T4IL
M.#I=-''TG@P@)XA.'201 AMFI;7P9Q6F]O6!+K/VA0Y]BYMW9#+PPCR:9" P
M 0I1IV \..Y[0_B'?3!=<_G2)O))/2-]Y<LL+UAVK"->%^M&+&KAA\U:G!D+
M8%]$,)M,;D!MOQV&2D_K<HR8GQK;"83I:S[IN?M6=S;?4[S=N)C^Z4!'A,0J
MRQ0$:UI'3"1=YN><732_W:Z4+8+7;'H7\.MRIPD/RVTA.R!N1*:&;I,%L?%9
M1A]R)^2LGL'_B>]H9_Z-&3V$0O2F+CA,KB>+]\-VIB%/E[9;!-&+6-\"\HE<
M=/UB6LS>=FR&ZBI A505.E$][#S[H?O7>3<SSP^Y3-'/8,J#%J-DX!044TH*
MQ^904-H%,K"X2G$=TKAQ,G 'KT\1'X4>QG-X@'G52-DH EN*LR(#T?!]W6II
M_!$+&>#2)%R%=R&/15')1 +%V"*S,OA_/,:82*"0"Y$D>3(PJ#J"W/D))IB#
MT)UDX!P96$4X0@]W022I&!]O->M.^U+'?TWO!;R=BT")-YDO\^%S/7!<P_6%
M&=I8CLSF0A(W<@E*9-_2(9%N4Z#)X+_F?B7T!>??G/[OQZDJS@&CTPFE#X"P
MA ?P%NM^W'#3P%P>H3(56SI55,18IOI:X*;*37G-KEGY,=A%7*$^1C3,E994
MG:^S8CYS4E]:'DUEE5=0K_CS56^O<KP3Q7K^+1:3E:7]/XXL!>AAAA?!T?O4
MGWQ"NS.$QN7T'Y(!.T>EHKVI9=6=GJ^0F&DW,Q5_R%]%\1>Q_LBEK53+7ZR"
M5/]U>>"_,*+ZO^\F_LWIWYS^>SB]7JR#?8,++0RX5(5S<%LT1B[058M;#7X*
MXLX\,JN;[GF%6!&.672?3G][VG?TWS2]H4=!DQ]'_EUK0BC?^%C^[S%2/O1V
M4'?$OS-^OO!H;V 2D%#_-SD=I,1925CB_TV#IAVL,CJF''V(A:,?A"Q*\,@U
MFW3:<G%6GC%1GKF[I"CT<HP>4UJ(7! ?@J]@P3UD(,2G<NS9X+D1(UV"L(DN
M@=1]!$)GD=B*14EP:T(LSN#46&8%_$__#D(G.H#W\*"?\+9 ^;PB!.YN%>*(
M&+L+7M#\XP4?3SM*B/[Q$CT*K#=*( /@<I(F08S:)(("EE\7:I,!Q 09$"2=
MA;<99I.!@4UX'!E@!/XF^#?!_U\2_&-2E /RC]?E.<U>'':I\J_+;-2,&V;\
M**"[?),'^<=QWMX.C6-2P]-DVW6;UXKFC97?9<VA_W77^#?!OPG^[TRP\$]=
MIOS_(& $BO)LY+^MS6HZ753A6S!U4^6*_8FYO]Q>C$3;5EOG.NBK>SPOU[*5
M/!L\S$3B:/Y?5Q9_$_R;X']]@A2+/?Q_M%A-[<?%)4;&RJ/.'P7>RU%Y+)"!
M/S>'&_T: /[7H^]BED@JRV3@!1D0C_]C$E@@6!D^GP/:=7:'3U@-'ZG 'HZO
M'_[E-/G@^1Q5>BWC[T':'+_;C3]:U(V&J0P10 LZH-H-I>!$=>L:Q;>GFN(5
MT)F!VN# WO,"&D@C,C ?@V"Z+!E M00*>_2%5W]$NBO668)9?U9(&^3ZT3O.
M@PR8A=@8P;Y+W4SL3V4AL-=B_8@?FOB=BPA.&'$G+OTSL:I9>:H(6YLN+S6^
M>Q77^0YL17E02H;%+-BGQ BX?:5(Y/QEC:$!BQ?69P8/(M^77LE*>BQE'/QJ
MY&UHS &F=BO8$I.PM--=>M:IUH(&\W(VSMGW<DPTFWVRAEA1EGOY)N_59&I_
M@<WNFJL_S^FVZD8>,^<ZY3NT4&%J$'DF6I6F,R:KXV[][/E]%64WU>CK2CP9
MY+U5[A[QCV_YX_E\DK&Z&/4J2#*U*;HD^ZO<-Q<Q++U@4H1![^1Y>L7>4]?I
MWS!]@_6"3LOI1H&K($$$_D7%7VEW1EV$8Y8O+U^M9Z*)N=*>*RYQX+_X.22/
M- Q"ZYKV([@<9"=\*DFLPP6]KM[/QO9NYZ$DKE[@/I&&4N#NGGF'E3]*)@,T
M6#*0T(.S(P/0W_5VDJ//\Y8?0&8840A+W!R) ;S0#%F*3C\GO+P3TL(Y:3]H
MONY=:1:^[2(5-1P:P0EC9\VV27G%5/=\4G&M"AJ$*#,,V;0XYVS:;I+Q>2)L
M>L8G]6<*5/'7TQ0K(]&*K6,C.P(GU^)L\0*2UD?Z2ZK-SYJD5$*M0NK[\(B4
MS-!^UHX.SUM#LJP;Y\:73ZLK?L\V2'^S#]9 .B-P(C$AZ/X%;#Z&92%D9GZX
MJHKK7$RP_P7$,YYV'1JD_\F35B6Z?=S;2_1[24AG^#SBF#C0"9JP;7\PGJT4
MWTKW*?-ZW8VO2?-U=YX=,/$64*UF(D7@MBQO?A LB!^;:!<DJEFL\];+F:K
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M/2AVA15Z+DQ5%J/Z3X]^0R9]OH3THY:E?2L&WU%/_WDN7$%C2+]!8&5)H6V
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M"G,^/YZ):U4K7QC/F5R@83V((747#\\K*5=L(LF2W=0/@W&(#=-Z "?Z+NP
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M=&,]G#'-OYP!&A$-H;$ [AAPB3U%LPS09$\@ _2Y9%VD?@AVMF3P'1K[;DX
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MME]WTX_7@Z9!2W+$*]S=B#/0Z^0><AMYRH6?H+8%<MV%-OE3?]NZ0L6Y=^Y
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MP&B+FZ" /XO+PUAA=N+V5E[?^"8>7^C2KM;$>[K-_TWHJ2<*'QAK3VFU]JR
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M$I5E,D+G1G)'RJZH\:KNSJ-],JR##,[39 VZVV7GH13A'O!#-40T",<-)]%
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M/]R]9U13X=8N&D5%BM)[B0H(2!,54"D1D:H0!>E"1'H7Z1 2!>DE"@**0$!
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MO_YV(K1W1-&2;<V7P9'P9>?18\#6+I#*:K[50.%EHQDBZ.9#5+8Z!FQ(K-A
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MN(;Y C^GYHUO,)-^D0'%>#<T?'PK4=YUZ*O#>& ZSK6C[DF;VOA,Z\-4VG[
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M=9C.BS"2JJ]:RGTL4E1?-L%FKHY%MDI2'+EGL)$K=??)#Z[QE6. (W+:G/B
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M3^M;VLKBMS44\/4UN4^>/+&RWDPSL=3W<1FHN5=]\>Y7"W;^,U_%.=Y<.P>
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MO1_!KW^"^:^TQM]OI_]<C^;<32>TA14J@U@&$Z:X 4!U;W$>'%1;BS[;(:7
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MW\!6E2W@T^55AZ[:22/%;I5'@=2N&=? :&FICYMFS//JTRY3:T-+@I3:)?T
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M<:Z_TJ68YX ^>_'OQW7*F@PAD];O]<&M^.;['ETZ*\RS98Z"MUDN6K%0-PP
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M5##W_<QKUVW1Y-HZ?7-"]@6<_:EL!S=5^"M7L;^*C_?RI"^OJHOTI0%*+$E
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M&]/WNZ;?,'4Z[Z*9'>E?-#G?F;:Z_(@NM!5\1=:S$\VR3M %*GI=U1K4./F
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MO[Z;C_R@Z6DYIMA0B'J0*@Y(&6>E%4]U9>C+E+BQ0#VO'/ITR6\Q\T("6X)
M9/' &Y:_24.(! ZHY(,6J?R WXX_-L.U<,^<]YL0QR;IV7 3&C4?3@]L$7>J
M72XGBR4"2K<87+36ZU#!C#';R1$TU.,M7%683>R#B#.\ V-3K5FWKPR0'*G\
MU?5U*3+@T"1UU-'+^CWB.+< =^F!IP23[%S1F\(?WVU\FRI(-/-!VR^?'URY
MP%O@7WPP[QQW\.&^*Z;2HB?HY5(/VX6A=ZIF['',+8HVKO'F2QNB.<4G>L4^
M7,BBO:(\YL &REVD!-B@#:JL=B4(=3;O#%9RYOU3P4M.GVQ<7(1(ZFT=J+_+
M.<(WYFN\;K)Y7!"^'#0;J&O ?8,,J;3HF#)7(S[&,>#H+LA8B/0-X#$ZA*\H
MR+RMBG;HXQ%"NYLG3I+<3"E8GOI!U/*U,'5Y\XG.UG<MBLO]&8"4_9F^2-^M
M8L71,B%/%=5A+T=<Y5;,.1C-;^!418_J?J<3_"<O>%S-2\G+N6K?K2%B2YLA
M^F_%9/.GPL1V7_U4H:AV300,<^SSM)90O@&[T5!1BO3CQ9J4<O^,>]&87[%L
M:EB7;-'?=MD !U)I[]:B0O\X<.JVR>!AFY3?.9&*2<V4)!<#VH0N<8;GV/:8
MPR9^V0V%V]> @\BTS=$$+V#N,Z"/^JV%U6M)JR.;SS^\,&]J0(OR5>M2^(ND
M%5L-(<,]D1:$9:L%# 1(V'0\&T/63'DINX?(*:E=>BZ68)/H8_,96FXX8^=V
MWQ[ZYZ"X<Z(_2!!\[&J\CC,QIWBTTH[7LB%$;#L\T!C70;]X#>ET+L&XWO'Q
MS/1[E&]<Y!(O[@=Y%"(SE<F'=U 07I$15T0I[C=1M%AW^DDALY$B[0R)TWS*
MW*N_V468$B_N'-VD[0J:S)\!!-@XGV3E@SI+9_!,,R$'[^UA7U9 PNEO"'EK
M;]":)8*4V^IJ,<M!$C,JOV>/Y+GH)2NZ^F]U@3C&IMY2C^\$2!N"<(%A[W0E
M/>IHX+3NZ,W][LI"LWPVI6#XQ#]HQ'[0GYZXCLQYF15N)L[7>I'\5^D$VP"I
MMH&+Y6TF:ULOP;2FF@-,]<!'^;H):XMFCH6_2J,45VU+F]G".S:>B.%<ZUT,
M/82])]-&<38'PI/ND5>F:I\+* X:!#UL6/R$F$?G^\YL(IP?A$J6P)TT[(TK
M%QZ?U?$VI;RK\LF8$95MAHE2;Y&F-M%HAOGX?2N*]-BW9[%-Q.60 \\]B]9(
M@VW5B%51ZI:;"NXWIW\%*%:(M@F66,'9>N.NX0^C2()8V'$=Q9I68D99?Y5W
M7F^3YGIS[7>5Q++UXHW;F;O*> $@\4&ZC'S2L><[(8(?--GH5Q4)3 O\0?%Y
M"WL5[[*F_)HS:+AV++DG:NA:_U7W_7VZ$N33#^"4QETY05C)=L7IOVR]@7^F
MVO2>L#4A=W8DL7P[)!E)OC"3S(38"8/\EE9)Q4BZ;BQQ>TBP\U:S:*WM\D39
MS-W^'BH:CY(T5>T>I_)=W"%+Q 3FR2.PK+4KO-SWCY\/)FT8[^>H%2^TG*%P
M*H0[Z]F<;V((\EYAD3KV?^FD0_HYE]N1!UW_:IZK,AYSX7!"&T)RX%8/5?Y=
M$=>$F[VCYX;8&:3(BU>D;(8@L9[HZC!&X6.!:B<6D=KWOW.T7NUU]E_<Z99<
M.+GHI66\DU5"/$+C2&JJ(RG&Y%YJ1)#R@!(KUXY=@]CVH-!?,&IL>N C+.S3
MDI,A24QV)<KE\+"4IF&K3IU]AF].0T&8BT!O+\-N7MT'0$^\UQ8LX?%(RB)#
MM3K9T3U;X]7L(H[!%0ND10I6K\29W#^2'AW5IVUT./6QJ,^7*>N65PZFATI!
MLM2T;QH$/Z4JZFQP?)G^),.B^8*:> $'S?,F:'O,0S&AZL]X"0>_G_=U6/-G
MGCG)HZ JJ)CF]&6'T>*XSY&F^Y(A*JA/(SNN:>_-:2RY\V<C9PM4,X3C0%>%
MM,LO>T>+8A#1A4UR'7WUP>BT2)79]&YS]HCG"S$KXU?FD8&B><H#?]LEKE6R
M$_0U%QRF?I491;ZBU1V7HK9727H++&^'98F+!6M5^='EQ%U>/;#*8'#MV3%8
MJ909J96:'F0E\_82AHJ):5Z0W.B>N&6U!%TGZ&H%Z 4=05GEMQL5%D^/!N\^
ME]C=Z4@2-3=-'Q,Y-\@4&SJ=),J@Y@(A_.NP] P?SXP^T7H(>]*5BQ_J)"[4
M]*BA)6\36\$@]?==U0.=(#K0,B+>336<SV56/PPYMQ.1%"LN1Y, O<($EY=/
M$ ;\?-7-L7WC3M>EWNZ(5L<=Y519U 8RI[2Q^O$1L/LW*:BG62K\3B+G\L69
M/R/F@=([GE45G'$))8%AH_AR)</%P89T&_[:;:T?^Q<B[+Y45%5]% D6IHV(
MZWP^NX]T%;GZJS:_AU;T'NR\<"/=2W\A.NK6P#B!GB%8E>BE]/GECHA>]=:S
ME[ET,%5'EVI<)D%6\KM<==? AL;6_G:"QPRY6G!I]"'Y<8+"_6[5KHER7MO(
M1)8'FY))&V5&5"=G<8(C9-X[ACE*ZVM$ABO-U]3SW<E+*'?,&GY>]_7K.W>P
MWY<C(5J*:]PO;&IN&V-Y,0)Q)B"S+&'&8/^:'L__V+[F-A0O1F;;#TRH3B]>
MZY&B"9_'/0-010C31$J:EX>5%L<>[C*IJ9']$'NO1M& /UJR :+!OZM>R#X(
ME)ZAPXFZ@MWWG*RBQZ<:7SC]1E^;JF-&>@B65ST#P']HITY>E"@TD24'^&P'
MB.FKX8;QUP=SSM::OB>UJU3?<79;_&$AW)ON8#>R5FK3<_<0R#3)<:4(]Z9O
M5NMFH$QT>617;>0YW1^SQC8:_SM6S_;2A5LQXUU ,.&AWV'Y3R.*SR5!B8$\
M2(_RT-KE!>:60AQ;B??"=S.:8A6&F1GTI92XL/+.)G/R2'!SI)\S61F!G1/(
M^G?W[VM4**]*] :@+H)*1.*1/=>9+"YNC1XX?>(L+Y(ZRM)R.4PTCCSMZ:0[
MJR#N5/VZ'ZB-_Y>8,\\_;+%87T7:S7/F,M@5Y2C 3B?MDX)%5D&!T;!YX2)(
MA3F;0Y.-[]^!AH3:KTN4P18S;%I:$SJ(HF3XU,M@N)T+00O"Y0+CEV($K<V:
M<H211!EPYUN 6= <GU':_YQ^H-SMS;MJ6CN!7%6N-B=%21TZ=ZT #TTZ ._V
M-5L@#1]W@FF_S3KD]-WI3&5%*)!=\<.VAA=0Z:I[L6>-5 @MTD:RFE9CYT>N
M^4S_;EZ:'VKPX76;HA/5?A@TV@QD0Y[W;N2%>DCAV0N_->Q3)-W^_C@I"8G-
M-&0?S8=*V@W+LQUGBST#(K^^U^ 9#^(QRW@&X/V[R+QH\K1#T\H.KI2*A=">
M(0"A7^IPQ3'F]1:R<D[P6ANLMZJIA2_KF/Y9C!H\ZI/S<IDCX'S]S]^_NBEZ
M@38'ZD5VU!"(\>)P!WT.EL/0%Y_-/-^+M=?^.-6(3^U9@SJ=C9W-J7_X0,,U
M:&B \W'MPW[_P?4D),NR*'LV-]F^LP_MK=ZNDH:2U#$:+>YXQ]S&Z7$<X@*.
M!J'.O"[/P=3\#B<5\&XORIA72J4&WJC8+!'- 8GDBUJL2B^:VU-I0E.O9[*:
M3,;R\/R59]M)X"S\%&,<WBEB7_&,5GDH:XDG4-1U.^XPEOY6M&/6!HCO$[?Z
MUZ98-<V:HPQ?>PU)A=SIVT\NF:@0'F-I*<?=MV!@!0?@V@^=-86OGQ6'2.:(
ML?&M%U9DQR;?;9Y5YG0<FN32<#;X?5N?;,"FY+A#^\7E\#UH,.TB4X.[T#5@
M7:)6SK#N+*W-I"B]'"M+XL)2@6KPKDEX+\7] 0?[D[?81GK!>@[?4,T99U_2
MC+0+-5(_M2=^2Z\#?C@'&YBZ[]7SK3"[F.5^*[^*='@+MIPV^I;MET.U_.(:
MID@66UZJ-3R#NO\DL"M*\UN-7GG&LC-#HTO(,HGSF(M\R9:*KSKA4=W+I@$4
MIGB6F,S;F/JJ@C@[TL&YRG\2/:#B9_(=[+$ID?-=*['1LL*'+G$VTZ_5H]./
MQETN=;F9V,?:+"P-[#%%[A,20'QDO\?]!&YC9"?CM-![6^=-G5LQXE0*T/F8
M$V@U#V>DQFC,8V-'O#*OS-I/]IBR_8AZ 76Q%3>ZDV967.5G46.J-V<1/KH5
MCH[PH&H)<[-4Q!?RB41_E74U^;G>Q<@\FEAZVTD.,-F%#8.[])#PE7#%AF:/
M<0ILZT*XC:\-2-I3_9AJ\ R(H9S#T&//IQ4\QQ<M# L.2&3_5HTTK]A/;ZT(
M<H[2:>Q$,9JR_E(;OZ74Q8P[_<,B\5M5*9(+=@U;ZLO2G8ARXM(1]PTL40&%
MJ@NS&?(E'_9[I+>R1A*X;3B:TCNXOFI/N;T>G'\_OC9'Y/3#^*1)UC.]Y.R>
M.UI4OQ>I1X,][#G'N%#EX(%&K5,A>O0)72)2BNW ?:?F3.*JL6YCVFO]&8#/
M_>?.ZLC4F&3$QVII.O=G)8X/[876Z'H5VK^8"LCN6Z3,LEJ>:&7.TH)%U"5O
MCTAJN"U$"TS;YQ+/O&LPF%6(X;\D4_%99NSS]XA5CTH<I&(KE>OWZPGW\1+E
MQO4.I0KL:QV W6CR)/KY2%ZJBX8]XOJ:X=F^]XY3 2NIT&\I8?5&1DJ/M-Z]
M]9O+M9LTJ_QUEQ?90-36VM2S9GN715II&>]AYDG3\_M3+M^8KV1<^1*X$<\4
MQ.?#BR,;2D;16BWQ^C*_-^V"R5X',=# 5?ZJO_)G\ZQ#]DA[_ _TS>TO4JV]
M>7\\*[7[5TD[$/6(?\PSP3IVQ,*%*TN=AP)+99OZ=RFSC<P'>J*_W@5J66\^
MS[G/CA?8MYGR3.W@#<L>R"MI7UU! [AUZF%'[UH:TD7@::XZ[QF!'LZJON1V
M#67S6"N!C&?,$?$P2Q$>Z%C;,Z!>A$AO5"/)Z(PDJNJSB&']K:7X[LO:2+/?
MH5(8XJ*#O7>S:U&%9 VT*W;'<^Z6#W_/5M2#, 80YYT)9^J;LAYT*YP,7;6.
MD!>LEJ_F)"0-7_X(:F3M"G?ALC>RFMUIJN)LR[31;6A/8#C1'%Y"PNO<.^0Y
MO7K( Z;9^XFKRLBH+-=+> G"'LK+8UV<X2OV>O>ED+YG0+)]T<8*&B=PXR3'
M@CT(VJB/CQ*I+QY)?5O%?ZHU]:<M@/DZ*M[!XK<Y&'59J*R.JBR(%LP^D&PJ
MV5;<741T[_&@M:BX\ S0IU[.K#EHWER.]0J%M#2WP)RO-/#!-B!6IJ'>Z#G&
MP9IEX"ZP;H9:[%]Z)JSGN%B&3ZM'M*XWSMR]Z",X8H,5JAMGY7IX(%)E&LX$
M%B-2->IEK\$@00>G%J?"YMZW';YG)IXQ&T"<O0D[=X?CL:2H@2$G(P&[RDIU
M:;'6KV]H<;4"V, &DL/YJ_:=YA32D:N>F^G"*<Y]NP@HR*!BHRE)MTT3+0GR
MT!K0*9)YD<2?>#0HIC S6^:B?BV>GNJ_HI*^:IK"=,952ORHY_$6))N4R\],
MQW#S&85Y:;&%4_F.!GW?2]NXUO@@5]LGXAN_Y_N:H00%M4$I[;78*9C ,.=)
MQ,H&+G2HN;&)AG>!WF7HE-T&Q?<)D$SH^_'+^]KF$ ]LZVV5;"''OTMA,*7L
MXL"N"!#P9\4=96(\[&XWM%#MY6/L%1<UNP3O>Q*'=KY1=IP*+]SL7P@ O(-B
MXQ96OX8C:UYNS)1?SI[*D1W'H#* (M6WMG59$?3:6W2$ GCTB"W>1FK-Z5%.
M\VU\@3&%XUP#7_[DQR=\Z4%S/^BB;7Q60"&G7Q#MB.'2^?*_<C$W5F(^-@)3
MK%I31;\%-X8K8?:J\WN3FI6#!9^)<CQA.%68YYAN;8??*%$]8J7=US,]<^RR
M9H-O)1FXRI"B(J3E-F9M+\K3T)JA#ZL+\/$\).K,=.[SH62[B+]+G:HXT/J8
M4NB[/9?'\SOIXU2(VQ$IM_#=,5$YQT57DBEW"X*FNXO8#"DHEB!K0GQ(--!P
MDT5[SB8><C;>;_T)?80GZV')SSOSX1YR<6)EP;0CEOG]7-VOT2_KT6:N'JIM
MAJ@LM70X=N!@:$CG@:143+\(=_@LJ8N>+R)<]?6))G X"SVV 52>IF:UGNC/
M66&+3Q!V@<K^"25/=2XUKG<6*MPL1G_L[27Y>YNGG%)')'M)Y2%)]_%;)]<A
M-1_2H\"./ +1-&/AP[G1T:QU_B=6??+-IJ?8#P1[/;*IR);<*X)Y>FO*XDSW
M>"O;1N7[XCY<>_A+03AM2/RGL G[&<3I;RC]AX[0&W8+[!\OA#F@-/8R -I&
M(&/T@8N);GJYE>W /X1P,QN1O/R+79WDF=G,/(\?4-Y):%EZKK:,M$=FZ-4?
M=KNN-+;R^P/+ H<%LV:O&KJB'N3YQY2WI46=("CN,?<_74*!-0^'F3// *L$
M_9Y5EMJIJPD\P[3O[/Q9#AS]@9]YAL6#6^B7]9>G'[AKFL\(O%-![2"[P;%M
M6>8,#"'/Y?G=U7IXZY33MR7;.[+9%T&CO1_P*2^9Q_QMGEZHN8F_$IJ\83V3
M=%9/*2(_YE:IBWG,?:)!8OXF]A(T)='/TUF4G UR;\G]!#2^-KXFI>);;$L
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MC_GJ[W38RI2&AR5<3*IGL78?J=]P22T.S-+D*/C8^97TT:=['ZTS<]"3,00
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M><I[XS;6P_=0+' 8D@A9[<"Z+(G>O2IM;&+LYQN^:C.CV.^4:$I2R/[S=PC
M<83QZK3Y:LS=]!TRS'$#O2G*-/Q=]DF[E#!U<8EWV&^CI]+-9@&PB<Z20:F6
MQ?"MRPS*,OE6NU7YBGVG1,.D!S:V (/\"U84%@,/SCR@_0#?-]V%Q!HOA7*[
MUL1,:$_*_$HY?7RP.I]>45VZ9##>H7%N#3P'O9=N<=2@X1Y-_\:*Y)V"^JRO
MA/PBZ:O^R(JC>-X:Y:*F '2CO5B@7$N]?4-+56AAY)#$A9QN/<R902_E1M4C
MVMW[EL$77BGM!UG](>=:,Q2T_0-B]VA7>)?-]M=* JC6 *NPKND,<7+8T:J5
MWWP7<@3>/HV7JL$-]\#%!F>L4L=>8VN\RZ*0EC1G<*O'LLF#!GR&G;_;LMG7
MX+EMS!NI*54F(M@QRD$:FSCPM^PIKY4BRZ'>C&,S-3U=ULWQ1]Z4%MAKB;.]
MH+T;WXI*>DV&Z%U4<0 .=N 0<O/:'H&>=*5=<I#U =2TG;ORQVJBDWT#=['J
MVKT#^2[ P^>GH:(_MQ?+^0E)'K/+-N@!O%V^75N8HULFY3B"[$FW$-XH'YAJ
MS&EIO$]Z@>!\W(F ^X$/V??Y$V2&3@WQ$/T=[)?E&TD#4.T!28+)U=6[@UV=
M]CB;4UJ32(TO;A/J?%D//4U3-IW6/"!%H!:2GB8A,#-P5.^]T0,;HF,[O'&_
MM *KRB90D.""6C,)ZK$MP,C,TK^71))4O9P[TI[EP7 %KI5H>* J.X1=7S_1
MSN0W-Z*Z5R_U-OD,K@Q/T"AOBBO89WG%TTYM(=9R-BX:J"SP>8\&N;M_]_L*
M),4=MU\US%@X<B$0Q.OF%(^P/7!0Y-:GU,EK@4M@=D?24&'VP@^!"&A#70FB
MLXK\5SRVX/ZPV<^)/U)&1>4-=:N,6S %V3,&V:T6E_N6J!M,G->25RJF2(6
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MTQV \>@.4.\?KZ0YY]_3V'*0L?X&F Y":T5=BM2!]@1ML.DM'-!3V.U3S3O
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MG)"C/##V34LS.M7[=*$:.3!*P]C=W:="2";&0U?Z^@+IV $DV?5CB#Q%##Z
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MX.*XUBD>RS&;$EU=_!\/+$-S_@^7L$9P98#^__M)L+I13\?AY8/^.X#Q[!U
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M][H%,[D98+\!KPRL%QH;IG;8YY]$.157.'_A-V4X6M6@0E*SC<2T!E -N+
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MO.BTD!['&9(.4W)7UN/N6'O$#U9<WC.Z*KD8SP.:/^;;Z\G8[^]MJ+D"!WH
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M9LL3QD!I#3])KR;L-NQ09%%'DD_=%I?_HMA:L+-(F*W'>0>]I&C.HUJ>_GN
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M.L("$I%&B_AY%W$/P,&& Q?!FP;PLBKW5=OJ<G#Q/-)A]Q29)^+0^T/D;$D
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M(_\[5>%RV77\)K3-!KQ>V'9NZ5%W%V #OOSVK]2AQ@A%FHRFMM\@6/-KVS
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MBCGV(D+Y\_6M%K 8$;^3^297+^;LO(_7]X3=P]@YWR],N2&$Q2'_:))UA34
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M[?554,Q!UI3O14Y1%QOU#<=<<Q_)(^*87T03LQ.)?!YV7?9>1VB@8FBW<G$
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MFA\[!NF-SEM93'');=?5YOOAP54C\PP1#R)X>K/?$Y?W<SV^V[?BP2P;'?_
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MCH:)<T4GQ*@P;?G,8X(J6+0MEV#1?MKDZ1&]75IRB&6^7.%.C0&\)"[;MIK
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M^ 3-/C6EN8:8T"F_;11QR$T"L)7>)UCO&).*%6/YC5Q7U"*M-!%^]/),,OK
M)*'X@#J4(EB>(!0+\BI Z<E?)]54O$8'.1BC^24E/P'%Z@^Z/!N<OKT6_)7
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M>UAO*T:F$>?,I+P_!!F9UFV1%HZG%*1X'6/('.8#$F:?79"I_.?X;QY "MO
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M:'ZYH]^Q*,KY90,N&5?C&1)L5G;+N"N4SC ORG7)E>TBV7(A5<K^%B U/]>
M0GHKC+.,^;Q)? %KYBL%FT;F>66\8X*-@?.(B#G'M1VRPF<*4X"-_-]F]YD@
M\0HM97\F[+UW8&L9>(:8U\@.FXJZ<Y/2?)],,B]7ICW;\Y@<:F07=UY3;YE-
M#&UO$J*"V:U%KEP:;5R*KNXR*!TZ0U36Q A\PH.OK\I=9S6J0</.$V5>J CO
M&X:ZO>J978U_SM[+X=<:G,J>ZO"]03=OI$/V,3C.Z%_>CQ8?Q?P E=)SY5II
M"1>3N'FJE;G>+EXXP^#7)=*Z!/XO8[5]$G?* 9=\C]CK%O#=]+TCR0SC9_D]
M15DO?/-CM"YB\URW,U!]UL[.C@Z?D1??&#EOLL"_&9EA@2"S>-M"Z_7\B/=W
M-H#B>*HQ6XQ82QLJU-W+7Q[Z<V9OU#=.-^0W/C'VKYB3OD%/^KE+$#PFAX!D
M2'<B;/64)+O@HFS$"'E3UD2@ZJ]/N<FA )O> :4X$BO;7NLJU[28L#9R.0\>
MS.X;5Q;D1%L]B*9OMW%##EQK(3#*):*9.8M.Q N0%PY<LL\/0)/"\S>2W5<2
M1H:_CNTL&:CI\*?J&5TZG6Q_J.6;L$R4;8J+'D#&RE1V-,]M=S X_,%1>=U9
MRG9S%DB&F^3WL5T7^/590V]W0A<E::]"OMDW$TL?A_J(VV\M?>>;BHUMAR]*
M1]GX"**BL]>E>=9\WVN(OE?D;)]^))3^\M*/:BY8;\/>,9>UZ'='@=:!$##.
MQ/IG?-KH)JULD$1RS5ZA@UB!EB(5Z[^S&\R/E/0_>&_5(NS;&'EEU:&QMX @
M:Q)8Y%*M6,"H&Z66MC75?SHF[?Y'PJDP8/F_E,+1>XF\!6!?5]T"IMUO :.Z
MC;;_VZN(1Q**ODB\F< 4O8U>QTIOW@)<;P$\  SJOQ7#,2U>1FI#+T4;9 ^$
M;##I\&>@R4Z?!\X+=[^R3_9_3%#^Y^W>5?$M ->\-DB*"/5B]:-OEOK;83&3
M55WNAQE#*7_+1T;FBFRX;O)E^&J*=&X!J[R3-/BCQBKX.WB^I7?W?4:](P,M
M4TJ)L;<9&QM^W"-37,A1%W:NVQ9F0U']A1ZNKB8U<U\;^ZC7I(G21VDNYTF\
M6&#]0W +@&>D@V*?Z/Y8ZH$?$%^_^H@=-V4\K&FQ561B&+,?+BTTW ANBF*D
M^D2[0[?HP22C.;--=7&,H:18J>NY!4 3KF3]L8P[U'=32WI +B!@#*/E;YU]
M1?OF[^!]UE!7W$>5PS(Z(I=!U[)^8TO/;Y*EU OVEQYY4\+AU:(OZ?<AXCXM
M>YA'D0R_MUK6L4R=J'6LW[^LTX!R['#XCX+M(7IKPF+"52B:DZMW4;"K47VS
M-\1U,F#IB"Z'3:^.G:>>*VHI /X:OI*U#,"87ROZ/!Z3$EN)>"9X9FA*UEZ@
MQM@]\#J+JK8A,FWX-9=K82\<YO-T-0/-D]@KK=?EI?/S! WI:V@*IQ/=!4OJ
MM[V2O"'V/;P%X#V\R90RO!;!T(SYJ*],5ZEK'W>1[5;]&ZY40FW#CU5G\<7'
M+F<E5H>>Z]Y&N2#FJ%L ?2LN&'[NB?)AHD.5_J26J#FW\8LQ7,C9,[-R?=]
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M%</D'C-2!?K-H!,,-T"7%\X!+;/E+*Z^_)Q0^F"BQH;#%PK4>9WB_(JC;V1
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M"C2<&5M%]6>ZDBU'K3-M18>9>#AW-YLS@T>TT(Y.I04*S#>AHX']<JLHWUO
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M()Q*64>\"B]7C'N>_3Z%LS\ .MW3?MZE2_6<\#(M,LZ6Q4PCR.T\I"^@P?G
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M/RS#QBZ1%H_+-@J]-'LIPAI7Q)%C[<L-%:ADNGGIPT_WJ<D!QQF1!U@2L(<
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M E8(#$1]0P]P9%H6[.D;Q887CY36'_:6HGP"$P=8UCJ]5$[UJOW(_$)R3(S
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MT@WW ""OTSI!4[H[XKBE)]DPVC1HL"-GJ:USXQ%'HIS<JRY!V-<NO+ ^B1?
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M\*"C)K.N>X#^157NG*CES@?V(T[.!5QXSK-.5[!"DD1EXG=-7,[0'BS4&-R
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MKUEM/\JW_J;&GS<N]![PVXEG^NWWX/?O45B_V6U1_)<@"$'"5 &H0O@E>YW
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MN R>4C 9^?M&B:]1>\G01">ZSR)<C$OF@W-OQJW'$S/)-_2>L=X,IOL$&Z
M6-Q@-Z'.F(1@I+ODR)Y2PUIU\O:<EMJS8,]SB]EW)W82B-R2%['P78;O.P*=
M0:BQYR%ZHXU1*Y,X%)O7FV26HM1G57KYWORBZ!N@YPNG=]W#T#C^A%,E56^A
MDMJ3>^-%7@1?6+>J_&Z2]^+/:C@[>*?=WJ#KX\*#J#5_27;EO1V$XH9&< $I
MA )P,.3"_=2X39[$LI"I/^FI  Q%EG<DK)]2 *_F&GP?^=/P'2M1^0'&VNB4
M 2I& ?RP1AY6EP(QVC T'P7PEX6J=L?4#G!"$Q-D^KV2=N@E:B2>;L-N3S1J
ME_BA.[CP-BTX@8*YK!!_:1Q)A_ZE7\>&;P_C#=OP*U6C<L,,)]1&%C^"ST,M
M"FTUEQ*$\>$!!(^:'\]'=_<O*5, A9&)"5HMTF %*IDP@K]:X/1;62E$87 3
M9C]K,>X1S.;=CX/O)]G9[EHD6ST-//@^PRT45"5&^X58@JE:AD=JL.+W];#.
MX<CUD6-#5>^/?%^^]7X('KH-].=[V^MW><2X]/:AEZ6BNABN@I0,-2)(X=L&
M#,?EGH\KVAG:&\I;H>['O"V^Y^TH_C')5\Y"_'DXPX;(<\S*TD"DA@Q^XB$&
M$79TJJ3N;O))FY9AT-?98<CXGLQO/P 7^ <"8Q;':X0%[:9>K!^4MG4Y*\N:
M^]X!_27!(LA\QKXB-LJF"9:!MXHX#SN0OJH9"T_%N@[[^7=&I?!?-N+X*-^L
MG'VGY<U4D4#9L%= CHWI&)1*Q&@S\)!%M_/CA&54)U-F0$3WIW'3F:WQ(&QR
MC/CV&G8 =$VLO'0Z@LB)6%SH,!18WEA"=++<-_@(W(E;*RQU_:[;RW>_N/WV
MSD^2="]\L1!<5=3%Q@Y]-Z8&<<]S;9;%..(PA5F2G[EFXU05HVB3U/13^ YI
MFG?=W$[_>-+]6CBO<7.'BF'HSB:NSGJ;V7;EK'>Y9RUW8O9\"!\RYN_IZMC&
M:TZ_U;W\5/NQQ[KIZ/LK"T RP ^)<\>'>2S)7YKI0-V_Z0'Q?]U9MG]9/"Q-
M^;*0DR7[O<O!],A1(%[*:+=T23YL?!K8T2_590(1H "BU"3H&X8^YTA#-C+]
M%P0?[Z<FRFLT'H(9R=.@VB_ FDG,I A=0MOPIA$HU9N4ARN1C'^2F81^]X&Y
M*]^[6Z-F"X[1A9_>2>"B#NH\+PJ@H-;,[,Z<=)\.D]<V:'H#QXMAZW*/;+Z"
M_8O"<KK164)H_Z3%O0$</#\'.YT[O #,@MVQ&(=CGB:<JH$Y*8")N ARB@3T
ML[6QH:9RQPGCO[,Q(@603J18*F?>T>"!3[:[4  YT>-@)LY9P@R9B<I:Q'>6
MT*2P-_"CAQ-K$C ,;!I=*=N]Y[Z$9G%YXI<+8A86^6N3(I,FN=,_'^2SJ/>I
M2R$;LHK$>Z[G40#:+R>HT:>F6@]/M\[W*[3YO2ZSQ%'D''KRKTW,PJ1!:U''
M7WN%)<*G-9=X^!#-HPJ:[#9 R,CY1JZE;B)'7]O[2S7N_BL@X05\[A\IUFGO
ML _E^AY$N75]OI)]E,N1*(J:@SG 6MY0,C=4<A3&C1<X^[/1*9"*P#VM/7.X
M%J%;*5TQ%HWY\81O_&9OR,\5ICJSC.^CEYD,C?J!_YDW$?GG/SVEM(1HR?0O
MWD6+9\'HMS!U>*^R$AN!4P9T])0''PA&\R*8)?%#!/Y7\_3!IXK=XT3IPNG,
M'O:?88^>I+GEE0"$F&._>*I.B%R9ZFQ>$\/FX9Z3/D'-",9^_]W Z)+VCX&Q
MY#\8&$G&> 36= E.Y+)8]$X(5U-QX%F(E(I"& T;A'C![_!!&E!"H;]6L5]H
M[P%. T L?BF+1;O&P*!F]AE7]E=GX0VWX[FA:H>][4#7!H^X9H?B>]VQB=P7
MM%"K"/SUA=T\J/<E_-C2DD? ZRT>5*2L@6+XS"L&GC::X5O*>>=:[C[6>"DF
M!7)3+,B'WY@"(A#<S=?PF2LJ<<? 2WXH4RJRNB/DQ3!)7PD574T<W&^YWYVM
M3DAI\VQ*N'%(S8,QCP>$B*QXI440#_0>/E4R.5NZ<C1-6&J/ 9>Y+_.@C!Q'
M)R[<D7#C7.QB.<\NG &TF-,L2BJ OT8 _$PU*^',4)#+OK6!/I_2?$YEUU+B
MG_:P)[W?Q6P_Z!@H7P1=+]V"XR47B-E%[? 3:OD_6O"R/;ZF,YPY%J<P^]]]
MCL1_\3F"CG)*#Z?1]^'_X;]O$9A!];;HJV4=@0R$BT3VF)7NO6M+32)G5Y2C
M"C:L1E>>)XFSWTKB%V[_-70%YV5/H@K\('P5!<! UPEG]CL_[C;>+%RA@GI5
M1+9_<^-^^;%E\BW03LF/!3)]]R+!$\VE9B;ZIO[BP*,P[,F3TV0]$*<H!= ,
M61Z8N=O)ML(VC5S.SKDB8VI?5VD24-80F 7'3H9Y(M^COIZ)*(!_ FN-B'GH
M#C#NW##UZ;QK8,")(P:LX!(S0@3MQ(/AML[=K(2HRH:^("T>AMHPWW)^N?;'
MQZ%XQSC2Y2'+"2T<],YB"TR\XV5, >160:B81Y7.J]$3F TB!ZQ7>G/!'E_D
MX>U(OW Q*_<[YXW]*!%G&C)>"3E^[81)X1]KE/*L:S(4B)TU;:A-$/F)<#(7
M#_O8TNRC?OL L@B>"919(97!KC$)-QOA1@MJ5T2> WI&FDEC9TU8L>7N-@1>
M"M'R$WHW3_ YW(4F3JJ]S4-BC=3N>%K%\<ND6_8* ' #W5:##ULV8@?C41VJ
MA77?_KRI47^\;3-3,O,]^=?:7,+8IXP_<6MWGFYV$8"UP']C!B9J(&>!">"#
MN#@M<D<,&XGG @QH'#YU%L)X-;>! >0,7TP&'[AZ48L<5:OG+B%[U75;ZD\Z
MT/'ON_\O[V$\RINE)I]&IOL/-/G]]:!DRT4 @_@Y<"D"HR]_JG0'O?N\D4H+
MWX[O!S5?@LI1NP.*%^L$<C0^+^X$17I#2AP;QF@#BC[VB*E:6>6L)MAG1J>]
M^/95_LLWS\>!4SY-L?M!P/,P(2HG4(4Q;XLH89L+(/)1!1]8C"R9ZJ82I)U>
M%M$&ZU9XJBCSW#/ZO3\]@:O#ZNZ9K9@&%/..J,F_V%7,8A#_[;/M=RB^>U"^
M/5?/S$A2(Z'( &O8%+B*G+3L3K.0960Q\DRU-FSU(31+AY_#H!WUU<?,+C\V
MW*[H7#R(JRC8P"H__-7TM;P7"8(EYN9TM.SOV2$/&1X>!D3%(G-!SYF X2B0
MB%@]_L>[I"5#D.'/)M",9UBM0HF1S*V4*#8ICL29! ?PW2$[3]O>#D0!L(:7
MR/.8_UUF CV4K3I0^;<N[B56$>,ODQ3T0?8*F?4VZR+'U+ESI?/PQ=('J-U(
M_3M25A4](%UDYS8IA]J!WZG@D(,@,$]2 %(_KK4I;ES@1 8@8D:-M7V3>8XH
M "(7B&QDL[1/J$\@9_Z K#.>P<D,".K)99@3TIPN!6 XH91E%&S_ :413&V.
M2E)_36%0Y$:JP#YR5/H#;]6@8@3"!/HDHWU9MR/S8DSK4'FFP5"1B:"96)),
M2+5("-D:WG#2?(+?($CX!>!"\*A%=VZ_>NU&# 405O87M/S08JTI:UX9K$@!
M#$A,ZH.7Q6FZ-&<Q\MULX:!JEOUX#2 >8I5@JJJH^WCT2I478^.M*SH0?^[@
M7_F5[H^>?^B^H'\X9EY2W+UN5Z,A3VK^![(J7B4N0&7Q^K"D 8%,0YL.<YGS
M,T$'F1!S\+*P@.;)>WDUY!I6/%F_1VF7 JA)WYWX#NNC "ZY0Q4"UNU>3?#7
M#QTKV\OM1:V(>ZQ+S7EL*PQ]1/#].#..=?B;W!9]#8<[L!L08N\:[A>CU1MT
MK.+Z #CN=Q4[EL)Q:I.RJ)4.'@6\5&1\,><;4T/I'3X'OR##IF]DE8O4FG >
M.; PU;YL +V&)RR"^0P4Q%5A2.9T3ZX>E,\42 /;0/8^H];*"TS9H ^@"OEV
M8.BE9!E?WX67J/JG:@;"^1#Q/?RLFB$^@UCSP]4@ZZ%1\=19-_7\! POKJB-
MVCZ^Z^J)?OYV\M9P93RT(?(D.##$)N@8_IZ8]<!%V)B[JJ+%C%_\S&(7%2\'
M7RJ"+Z8;?7/>L_X(XX_'Z:M6U(],\O\Z<7"_VITWL8[>-<:,D"]U[VE30Z65
M+*_:JZ[M+5@C=OTYZJ*/.<Y=1HK(_'0P748@\.()Z $% +D(GJ(.GH9\O,"E
M2],%QZGI$9^N$4;TU';:$W08/"B P.@1O \:,T95#8_,AV9(\I81[0<NO5DV
M>VETRJ<:9:MM'5358/_/\R?B4TEY*V@:/\YYV^Z"R;YO<Z+9S"GH=#Z-[?**
M,X-].V<B1^FR168!\1Z&]N"0N7PGS2-E],:!,RC( $[8+E]S30?9S :^AME/
M[$I1B6];&IH5[A3HVRU0*)L[KL24>2IGZ7 IK61M _/N)R@.]HH\!F?1;0--
MRW>3>>+E)<<'S-(,]%JZ9EP\%,4P\0]XS@((6K;P]AO4VJ+H!KT5L5M?]B?*
M9>D@2\76]L.;[N7"U?%CA*(#SZ@>,0X?LW(7&=D,PDI%([UP31#CGZ/BM!LN
M:3J!:,T&8%B@(4&2VHPRU(9P?S-M7AI[*1?*N[@35#]N$=+?V&RTW\E_6<:Y
MJF*CV%QH(@K6L\#P'+]"T,)+M4ZX#A3.SY^B6@-F[L<IEF;/)"O;GI7_XU"\
M#MKC+25RX@.7$B+F&>I46>;10N'+.T9P20,#/A_1SDNSKUEM^/G:NMKQ/[^E
MN'Q[.Q<E5_C/_) #N?_M/,MY<)3J+^RYE=T-<+E-5GM()/3+BGH%XOTI$E=.
M/<D97[0H$N*[O,"X[;8"HI^^EHSA4VN8X>NV$CYW945X[JVNR=?SD.7Q%[^M
MHL2_) =,[%#[/!T7/4Z^BH=08\JB!GY_MH^3J/85>#?1O_[K]>2IY[U5TJI6
M%?\ )\\F-WURB;Z7E^U[A8,W32<X<U(LT8U@MGV8)=@WU*C@=#F> &[2N=$U
M"Y13$NJ3I+^K"3BO<FO561Z'Q,MI<,!&8/(8Y80W78.N]&>.C*"UN+;OY5W-
M#0^"%+9KSLJP"/M:4A#ZQ>WOC=>XF4HM;33S)_\\/2=+7-AY8PGG<NY/IPM^
MRIKJ?;TZ77)77T2+ F"M)R&@+!>:$+%DB>T*UQ' UUG7<>OWO[J+TKFZ^O&7
M7 ^1\0L8O=,C)*L1DBB*59N7M,Q3D(LIY2,20FE ==DWBO<V"YX"]YU#3C>6
M@1RNV3+C2*4XB'']6(U-#S.*%U597=F[T:# J8^L!BVFPZO3(]4XL*7Z>+>
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M2WBL/(9WI2A4S:-BO69$#NO/Z3G@)EIM"KB+2MO5"0BRK<Y=8YAQKC#R.I[
ME9-^-DH0;OH1##'[45".8K]@R)Z2_%)S[8'/ZUMZ81I>7X)#SZ!MC49DD2U,
M SG*!WEJ30'$O4_?:R7<M(%-@QD:59;W(U#C%N0K%:%S+A87W<JWE3V+7T;
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M/O2+7=4&XZ)HYJ/?%MR>^\M2=20W0F9BPBRW^TXU"^[4$BH:>@.<!@K?0M9
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M^&0[57(-63P6>^A8-O ;&$L!'%A"O2F YSL4 .GJ>Y(;GAKEJX4-U( "[2B
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M6;QZA KJ[^ U%T8%AW(1[2?7K0KU'_*8[QC42G(KB,9B0VMJ^L]>/84<GF.
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M<QUN%YIWV%=CQELW@ZAF_$H' J]<2VWR*K6UO8L4P"%_H $%$!H03Y:N/91
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M RQ'_8OQTBQ$"D$MC<'X*( &JE&5EP2>\ED8QL\59/\EJP'[00)!C3Q+ 7#
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M^ZY >N2VZ0C%%N)%"=DX6C+@EF$:J=O&[71^PB OOQ\:6(=7M89WP,.;K^!
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MW9+;WF+_,2&,OB2H]51^0ZZ$466C437PB,=W\H_G=CK&K0M<I=[@@LEKMZ+
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M A 0%1*=R(1YGJI+B!8+%O+<B%B@+$/L)!AS.YU@;YJ5<:W&42>A_PKOZ_@
MK/.!5!N[U :<9?AY64I?76UY,)<>_[9/G"(7+Y_BALF!7IJJR*?FUS;[C(=[
MI%=D07_TLD4.3F8Q[<.DP+BF#,?MVT?J;GZV7MQ7W+2V<E*W#*A,W:UG+"DL
M_M0I )%V"G*\Q-()%P"P=Z3^ $.)\;9N"W+3C5[,^ZI.TW=1;?"<@*2HRH76
ME'>&TU7Z]2/N*PZB<!M_U.%M?&L1HE61'Y_FLL@HU:JQ1!![LHG$^-JP#_<R
MO9#+DWG;8K#LZK]@.'\*XB%?=$#S*7 XS]%,UI:&%U]HE8/!Y_0OYZ8%C8^;
M7KIPP_]JP^?KMKJZM8E&Q)?#"%LDIOOP#JZFX 5V@JXZAFY,-"-30-G+)2!$
M]F%Z!7$Z0QA_8:3;F?=GT[DM9&W$-J.K]R55Q.M;LDFKLW,:O-QV%V-Y4P=:
M*>TOTTR@GWPJM;C<9*;?:;-GOSQ$9([H(+-BM4,R%E,-^>[B)%^^7N+ZV%!;
M&;NB8GTC?T3DJ:X@Y\PWO[/^"_ X\H OW_5A,@4>K($K2_2&LFQDFID$K;[-
MOH:UXM-MQK]/W'UHN(!KX&6*/JB'W!U/'=&]5 *W@0\@RFN[&$'P65^ %/S>
MI0T*:=TH=N80UB6/5J8P#5&-/)PST7QVG/F4<SHIVR,D8313I*A(9\S/,NUO
M.1;^#-Z'+N_N8@R?K^F *^# H=#*QJL2U8[Q.:1">XG>6WHEJOWJ;\G6OXAR
M]N^\8!\/=$R>?MJ4+1>RV<\X[ *(L?4\OK]S<DX!#Y6O3B_VDVQHPA[LQ7@[
M]O:F8[3KP[)^BG2 /)4NL#<VMW?"L$\8ST\!LD[F4D:4,"VENL_M][:^FS1@
MW$'?="7II_7+$%CI4X//#=7Y*;_/@=,0U.B%MS!F!7'\%GYT^6>YV/NF;VC'
MA@J9W#6]9M<;"5=VU%(X>24MJ;\#.%MT3R7%]L.&08!=EC-;/-*>WG1Z^GZ.
M3?2M,_JL%UZ!0'SCKM&#/D)Z[H^Z?\IT[$[-+]-$(A8^&)R"F+U/0;1!>:WJ
M2P,0/1=MPN,!#[=STV]A?8ZA[VCGX^KN+/!&D^[F1NM]6GMV<M;@'WW!#6!1
MZ)4S0:<@LP&G?WH/\D)>0$S,(^J1$PT!2PK_/('F;T1H?VU[&8OJ!',!@9W
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M1N;U;'D :K_XR [X[/*';+N;[89.M[VN?;"3]U.%4UC.&R7UISZ!W ]FA3I
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MPT=TH9-:ESF3GVB?\?RLLE7>-8]>SZT3OOO4+W';9K__\/L?/S$#X$W_%)1
M9ITQV3CYO1*^]N2[*ZPW>LGUHY%@%]/47M^4KKIL1LX>@T0'X+?!)33A5A4X
MH3:57-H=X=$MU'L0Y])JVI$'4;-[ZB?:5*14WS?M;_DI%4D'['LF@DU!QO\
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M#(_[;"HT7OHMB.\V%Z^O0 Y-HB)-DK'!QP_'>97<]M^@V*=#QU+S%T]!4P^
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MQP9G(K>067%)4?8I#_$OK5ZP2AP]2WLNL/>=(+4-CH/S$A_@$Y;<HN>N->+
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M_3]M33W_SZVIT?]H3:T 1ORC,[6V67?[[C\WIEX'_>?H]O_>@NID#('MI1H
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M2RE IK8DW]+,TFLGT[XZ!07(*VPA)]:C]R2BT;5'W8PQ]=XGKH7+7+=*K_I
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M]+ZG&^,&&5DBUO%D%W?GZ#8)\*UEQ_C<ND<@:--B"RSXRX(.WMB]S) .2ED
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M.ZEVN#H%?GF*H3=>5?AFZ#]6ZW?QOH+\G(&?>3POU*AZ*9*Z*IWL.Y"58-Z
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MD1]9:JI5_MX+2>GRO#P/42R'__%4D1;18DY_,XT=.#$A,U.+([&>#@J XZ,
M4_*6Z52QIP)>_AJ436XKI !ZW^T+J'1UGAJB3HLP BMLFU_J%[4T NT]T#"F
M\C^U2,Q?*@\#$U^[[A/[/*C>^Q,L^Z.%X$7NAV#B465$:J'Z*F8;-!429PIS
M"7_KD]8@!U?^K=J-VF&K68 #6FRPCGW\BU8^\CBYJZ^T#NQ!4)[26M6R:QHN
M#UEM7:+Z;02U(#T%PO'\C0AG1";R$?NQ"B,%V.+UHP"5EH]I^>U6.,OZ=G44
MJZT?2O$YNIF?'#AX"2/VM69).5!&6,=+C-)X#*P661=&.)9M'<9!JK9GA=SK
MO(_Z-9K7-$]\(6GV_Y<LUMN9YFI?$U(CO+P-ZYJ^_LI]N)"QC)L":.-$VSD^
M:]$.B"6GB1K+SV:^7P NVJ9X[LWC4O#K140?+&EV,?<VYO!#/%N&2_V6?GO/
M>\LO1QLF]C?^T$/?XEL?+I RE3*]8.A%#5$%O80&'E?N8R?,TM@480D4M8VX
M)KTZ*N.4_?3'Q.-[\U\\@J"ON$H<G<O1>41O"W<SBT*=)ZA"+0[JEFD%L/,&
M60Q;8RU?@VZDXRXHJ@74?$N_K\MO+JH E*$NT_0\8[NQYS,EA7.A!H[K]JU^
M@UW.AP,^[PMJ"[@>*S2SOE^^DU,6E]Q+=RKT+-AB<PTU73LU!9M$/0S&KK8'
MNHOQ@WK6)#_ VAYNIM+F.FZ@G002L*DU936$@(%ISHQ[T<+U968M* W22ZC6
M//[+W.8B&>E_%&C!0P'<AG8>._8/G*+MZ#J<3I,B]XKFQ2:2F4VH80I_B=P\
M05/30%G8-H$'I0&J1D1VT9$QLZ)%FI9;E:GP+PIXRT$PQ@QVS$6D+C=D''0B
MX]E8+L(7MI=QL3(%V=\'C=&0_%ENI^6=!=7[":%M%0E*1<N^ 2_2#]:<KAA&
M\/O4G'[R/E^_DJX\?Y=[G[D(92D4MQRNCM[%2SS.*,"+G.QVVE\8081I>])D
M/FJQZN(5US6\_(">J;U=6M<7;KU*S<S/?\QI8,.6P]:_=+\@*'Z$D^@LY[N<
M'^U)":&5NA9]6_OC2M/@",2R^XMVL[*8M:+R6;(>FJ%SE]^>J(EM?;.DJ?G3
MSKW.0*4'6P26!SVV+<9=0KJ.1@(W?VA$0E[[73;X;#H@=PKI50I&=\^3&Q![
MA=_E+/.URBE X?';2]ZCHNLGJ8,ZW)B8(7HNTQO_\ __0P@#40E<D@(D48 (
M\.;4+I6U8ELQ" 92 <P%A7<+)3&OD3E\\'I4-EU*UT0^(IAD-Q?WAXUT7R<<
M(EPO=YEUH"]85%4_H  2$PL]9CD>'*^XY^"9BW",,?B8)8@"D.L?POZ86\X&
M+(*K3+:0%(!U-Q"!HJIN6:(8:*KXE!>!8;(9(=V .AF?S2%/? ^MD9X_9\(=
MEV-]%?N<F/&T;2A'2,-!Z3'B&)X&J;6/THHAZ 95]=VJF--0?EKGJO=&7H_(
M>.TD$J)'_@&O47[I#WHU)L*#O8O@B2QV6]5'AZ;Y7%V]]#S Y1$CG;?D_?TV
M457T5"L8V@<5PI,*IX5O/?1O\>XSM-ZHW>!/,^C5TWZQGNN;=+.?L1?UF[HH
M[=>5T% .B,!ZKTNNBY&JP!U8O14[,:0U164&"8J(!O$J\PI"F<>M-0=7-+2D
MSKQ)LY9KA!6CR%.PZB]OL"\U93OMN8)E_;VN^P7[%FD\>:LX;7CY1IOP5_Z&
M\\[?>F@O91 Y462CEGE2Q%7PP1.E@PA2C(:4 P;^ ).>7-3K7K+AQ6(7%+TS
M8VOX2R@")^WP3I*CA>9 K)9>'1=,2H M:@?M^7# .NQ(#:L/#5QQ/ENH*K2?
MJ/?L&M@X1VZ^3.+]"N;7AH-;;9WA^NSQMI>5]%5)JZ*QHB;[68TX$/[R+C$%
M]%=N!X /<D.P*+R$!#'=&$9NHV:-=9V6\$""7AA5,45'8*)S/OU]QNL1*>78
M!SJ(,ZG>[?+.?KY[)YRXIMEH*4A0H:X^!D66'U':Q1N!ZUK''XV!7<E]A.LS
MO8([LZNML%$TW^YX[%(G&C/PTS7Z7<M1N#3AJ"8AMMZCLD>WTGZCME&D'0LA
M&_C$P;;.!%/%F0A23(L'UGL7$T.*EJ8 !\\LMR3>*LKB#35D2O_,P2:1U4^^
M5._C?/:(75>:O'5]/Z!%M6KV]**0"SE@3'P07'\,O/B(5$C0VA-$2A!X73-7
MZKV:6@=\/SBI*#K7$Z]SQ%M9I'VH'6Q-K&3M/&/1HF^8U6@?,YEV+$5X\/?4
M';]&1J+(+VI.1B'B80](+V&+CXG:XV%43<.$POG@"GK@.).M1.6?"ZP^^^.:
M:@N6UW7B/KU$J(ZGI5I,MI;4]/E)<LMQH04\=M;*R+T48,][[C15,8A2-9$(
M4@/F/A_%"V."7MVTD'TRZ*X\W+*3?55++V(BY^/))W']S39-1M3Z? >,!M:!
MP =\PMMLSU,3;A(?='SYV-[GMXVZ\G6UDRR?KODH$3Y\R^+J(-'X2\$6K0SK
MK[T^[S4\&OHU)%3HT4N5?/HL/?KX8LL@XR;2T1TY/N77G1V"AE>@>K\H0%7,
M=OMBCG+;B4^,1KBO[Q?(>K),M?7[J+78)?%%93KZM)<OV.F$7#62;9';3@1G
M-^19C0O*D<ULX[P\@:5?*,#]].M1]DJJ>_D6- T7#,383E][YENP!,=?^CWO
MF4Q41BL2KA"2/-(+0PC\9Q=;F_2&RO!29*8F5MY!U!*2)[OD_B-KE&'=A+-(
MM*4$[1_D:\1C^=X+-INQWD<M-34DF9.)14^Y-/ C])?Q81\DF6D%]@W5P8(2
M#K.LP2KBMA1EV9!3(L\AZ48?H!M*6A^3U@8N]RLSGRB0F<6IJE6!6CA^.T22
M7^>VOL; (OTA #YD6'M $>_?)S_ZO(=.=/^Q1+K32$6OYN9K4AZ4JAD[B!BE
MNAAP+?);<S9^]Z\6K';UT&]ZOGNW];%?[JPJXF+P9U_5- UCD^?G8,^.A2O:
M&U4,3!,J89G80")G%^P[KI4ZI' /.?XE4K]D=7<2C5.C %$LZ 8BE3Z9 G&[
MV4[B&9/(*B@JOC^^*? #Z;H3W^Y8:W+YDTUN/=ZWN&J[T8R XVR7 ]=;B>(Z
MKD_S8J7:-46I8N1R3 <AQZ^C43;^B5-PMM[CFI;;_--TK[B33NA](RF '4-!
MV"3A*G0P)0S ZFS.61L7X4/-;QO]<N-C.O<NI_*CV*DV'CXQ9Y'\4T@]K4M$
M<PRX\X^7(@40V$B?"F^M$AK4.;/,+F;)^.EV[(19?5<LXQ-7S6-$NBS2V2=R
MGC=@$KXXWQ7JR;1R1L'=8D\O1-0V[EU<H_Y7>;74N$-AJ>V]&2]P4?-U-?;)
M@[2<,NAFE58@;PQ\3+-6Q"B[9I0"?(F7?0O#W+,[A>Y03A>AKQB!VS2_[LJH
MJRB]XE[_J/%%5U4<YMKIX-YN]O9]/3%S-</2E)*S&VA6]J=^<T@CK;/0SEP6
MO%WIS7*/C%1\X?T:![$SP0+?O5C8M%]'J#I,5)U50Y\7(/[!QH^$Q+P]_/6>
MSX#U:/A'7'.TN>A9O37[56,-7B5#*[&MTNGP0&*B.DA()U]#>W0K0QL'^C\Y
MZB458'+>KD-Y!DN7S5)L)K59KFP] $0/$/%KU++#_7C80((H_<3'<8+<N9Y*
M%9]*^PV7P&<B<USM+59KJGV0SH3<<J?HDM?Q2L;VX]O+X84%<>[I\,/OX(-S
MMG7=)@#B.WO4G!BFX;Q!D;5\V^^G/"X7EB0FU#Z!#3?+' A*U==V9E<^WD'S
MMWTW@D@PIQ2:WH]>GQ69CGUGZU(%YO>W,[?#:V.9QPX=PM4A PAM14Y6KF1!
MUCCUR!]:'[-(K)BZ[75,D]6 :/,HHOQ V.B1_/K0E)'<F1G1[@*K$,ZZA(^6
M#[!-. L,I/M8:Q;&VJC;S.LVZH\I$7O!2B.9_ 9 E_,] FX@LJB*8"%;C1AH
M58G]DJU9"R5]_YS<"IZECX8)$&+K?R.NOW)YZ\T)&<.%0"7Z.Z(5Z"\5E;LA
M-W_L0:8*<:_!( V(&XYG_V&0GZ%>[$_^'_.B<H*KCU3H7Q:QI+YH"58ZY"5R
M4H!%^K7(9M[B(.2#.L]0Y-E@3U>AM]$V]WO9-Y2K7/_$AH[,,\$>@9CQLF:1
M][%W\\@R3:]B$GZW7:BV ,W95J2*O'H16HSX>HY'\;X.<^PU;EU )*TS\W$0
MK$2:C65A@P* [(Y<=3D9+*<U[HHN;05+;-LMR.*M(#1$$Q<AJ,O*!]"413V_
MEC-8E78VB1JS;25[$=XN1L'G'PH_2DZ;NP:U</EAIE<T,Y^)F"[42>,7ULYG
MY79(TON$B V0Q5\J:^G/#U J3.PK*$UIZO2>NK[/P6%8[%-]9H*/OZU?S:*!
MQUV;Z:Y_A7QERUC\R1;<^:Y+9+&];XYX8)4Z B\Q'PG^IL4\XVG6\^9P^OB2
MA6BI''1=CW10">]NY<7W+#Z$\H?98^UCO.U'GR"^Z%\7_GSC6([LVT@...G!
M;+8_IP!LS4R?@AZ/F6@)7^U7]U%_C%)Z%X:JDZ#/EHG+K5D$@Y".3;#X^;/.
MV#LB5*GW"OJP+"\Z%+8U7WV<D$ES%%R<F.&(!G6.YTK(]A6;]XR565N\(L+U
M"A?X/G"M1!<R>\XE'E  SE7XA%0;&),>YFUL[W8TB8>.[C*)2C[VF>W60BI<
MHP#/D$:;/;#'\Y-#X[C@@9JWBG__//8)4(]*MT%5AL,9W[Y*I);53'X?J/MQ
M5Q4GN:<0Y^Q;7V>6W6QF +.O4__&%QB3ER]>,@I/ E=K5DV%/<>>Z!=8;08^
M \(%+![!+DIMST^.XXKQT#!Z#%6957KP7EDR/U.;C).M-.C*/U?"+U?EK@(.
MU3@H 5=+;)E_"7/!WFZ5&*K)7R1Y+'+9B:63_7GI[TO6TE[1;0.2DYZJ]!OL
M4\4-#&-2!NF *@XJ;9MT6[QPM_PV+V9AD; MJG<^P.[WKSKQD(7QP?%NEPDB
MUP5K;_G8:;MM[_X_>\4#WQTJ.-)49I7QD)$!*B>DPG[ %Y G% #^MV;UI2I@
MQ+&PA@L%>(2''3@@"BB .WARGBS JS?X!+9XGMQ&[LLU(*(JP@M_SWQT$G%T
MXCLJA4Q6X:CJ(SIDK"9'F\R1N$T!M@7](W^1403EC)HZ5RW/M?7OP0=8O-OR
M+O/*+JZ*[+GK"96X_VW47M7":':WT&F^!,NV1M:B#AM& =1(S8C7U(\OW8Y3
MU*D9KJ=[Z2[X&P4@?(F+!,6TAT)*#<>I9.6)NZ.@H62K)U%I64,(!GE:P7KB
MZTA^D&7)[WH^O,ETOFO/O[/ ;9E36@UV0MVDL$[_Y5C-?7.ISX?,U$ZJ*)V?
MIP[3N0<=]14C0W"7MIO>URK@(CZXEH5;W$SH7"@P71+WG)I2GJ]T?9NY^'6)
MBUL\%%)Q6/>" BSK879)D654I6<VOLS0A3J^(B)%)>::>7)"""E^P!^Y9<Q^
M=[AY7GTK?7#ZF*H])S[YQ7UP%5: G _*)C/]+2E ;Y2\;,@\[)/D^4"9\532
MVZ;'1S)U8#?^;M\/S*6I5(M'2R3W*M.GE$=QMWX_'?7L8,YJ:6$O;N6A"CYY
M3"(I8HLZO*'E+S#&#'[,0SQ#Y?5 R E=P.%X5+4)7K=9[K.[2. 4K&IKL7J_
MUFM?HYJEB5^E7R$N:P\U98[SHVY<S+"_N@E>'[8((O_.>AA(>KNMY8W)Y]OG
MY)O>'6MN1IXSC-92VE#744;TYKS_:EX<[;]44TEB_P!>R*)*1*6@>7+SWR50
M+M__+^>_2!*U@TLBWC7'TH::I5[!"3#"7;[%21(<YR/KQ/GA&/%A;:H.Z<[^
M HP9@/(/52=N[VZQ?YL++^DG@*8"B7%-OJN7M'!^J4,M:O5;&E51L69'BF.H
MFMH:"D";PN=1<NI/S>[SX88].)$31C:,>4,!MJCVUZ 1 UG'FS@?4@J5IN%A
MIE\]09@TF ^I%K65:X(+G*P-VR#4!2/@37&/ C8AM\9S/BRY.V*]RWB#)@-)
M=TOIKPQ^_&3Z< -Z&9]-UC6V(;>N_#U;A?X.,B'KV F2FZEEQ0!]6'CQWU*+
M E0'2#4A\5:Y$+C"KRH"IWH@AR^\VF^L]??0$W#E08F4#-EG\I-^(%JPMHB_
MQSMM?8TJY.6YTI@@Z4>#Y;.#/>F+7Q=7E$VM<5M0.?PX64\FE(S< 1\X66Y9
M_A<7ZU6;)W)&$IP>(JDU:53,,NGKD@&1ZF/3@7)/7+=I55#6!,Z;0Q2@0E%3
M_>Y^V&ZEC9[/JM<TTC&J7][W@W\?_RKX3%R!H:)XH."\;E.@]J]OHVYWO?-J
M2.S=LEPOP\Q+7L@;+\^?\"/J*<!CV6GUCBQ8)TFY4T05F:H[4OW>8HQE\F+P
MA8:HH!N&IQZDW3!/CGSAEQIAO4]F^HYK>1:N1^8105U?*== ;-U!RS3Q$_0V
M8[=:5: =N<+XM-*9S5:A$? BS^B.5:\?>^KJ5/_R<NW 35U- WX&0D.O5JWR
MM9_8@2CFRN<[J8/$<4AF9TP'^MI0FKY,J+HG/E>8X$(>F9+]7J;6V9%[-MVF
MC(?I^^PL,5GQUM(-QMLZCP0]=AP-:"7XA)RGJ=P12%1N'-4(_8H?"GKH/RLY
M678^+2.F/I6?&3:9^!RVF7<RKKT(PE]:Z=CP[5V"\7:,,4ZZ*9;XK1HJ#(=B
MX'9E$)<@A?8LY4X*<&;238T^+N1YAENV4S1X]/WA8XD4$[%Q-H5K[8O?3.@C
M EMW][>?]V?Q61]6@*RZI&P^[;,3N2+)!HE15&^4H[J',T+F[Y\5L-[[6&52
MA DY,;850?JL10/KO(EW,AJD)AS8-ZW.8!Q2?8M:8>W);T__-Z=O@$QVX@RI
M 1J.M2@LI7+4 U(+;EJVXA@T.?]X<K_D;XT*W9&+&"_S&^Q9_/3.B.5*Z,[)
MPZ-=3X&1S@?I_S.Y.B*VCSWVR:BJQF*ITX5>HLD3+AG@;&;\+YPQ/B<O[!*^
MQ[4,'^LN4_VE)FO*YO62NT9>FT-LD;3N#:%3P>N0PE9-C%8:5K3]I#"ZIBC+
M2_G>VY_O+G1>H9.OS/U=RAU3SXU]3HU&NHE1,SP%<,:/]7O*=R763C8_NX@#
M25USVNT9L)B\J\XD)(0)*GXV1P'\()IWL!,>N^<$#AYL^[114\]BX'?D&:+3
M("+ AV76*-C!_?F8C_2W:IL/%U4OV##P^?;2MD!U@O[W@;$!WAK&,)M,$CJR
MHE.O-I#J9 Y_-#ZW@8F+>D7HFS:\66"[J^:/8!VCRL /H&F!/A(%($J#);8M
M.4RHD>SH/=WPUNDOPX8,_ZQX+X0\]]"/D##V/(3TPVJ*+\Y8$KK;C A'_CZI
MZA1P::W!H R&=X;[JIN&+M9E*L3_&(AR..:$I, XFFE+B!?Q$<5!L'L/9785
MC_?IT(G7-595[YV<B]P*VC@#[7!3HZ:3F$+W.9\<G)';-K&O*7#K7D/W786$
MS'()-&^;"6.8S]#0=)>%M.P%OMJ1;4:C(@9;J;,W[9%2IU3[%?J")RW<A>C=
M]TLZ;"A YGA\>[.QRMZZ6-!\!V1ZO%T &>4EBJV9F6)#TMU2CR%(IVH_:_.[
MR#>2-CON3LOP5T:!:G:W'SIALZ90G5H\1J\P*]7S[KD[BV&US4FLYYE&+JXD
M:J3HT;JAG!"P]NM*MYO\\O!#0YZ.\Q?G)ZN]\P?2I)F.VHA2A?A Z@ZO#1Z4
MX,N)3DM7E.J3U@AJ'9P^@@3%J+?GMCZ9M(0J%J8X>) \/DR'%I3GQLYGJT@(
M=51KQN6[4 65R9XJ""]1V,'R"\D!";O56N=6O:EOC[KK:AL\#.90(TBN^,TT
M@#H\2_\*$@KPHW !<4+^^]2?)P3B+J"3'O'%QGW*Z_/UZSR#KS_5UMU([L[_
M"#RE#U;>OD)0AW5JNZN)9Q#%0!.@R:I>Y4R<;/5Q]CM6I]]WG$0.E\U_HVT4
M$Z[6-7'O5U;5]OA_\\X],U!8 LM!92$7LL%[JD$H<O-YZEC1K2>(4Z1LL(L/
MWK7,U9I*L*_RJ>E*=_;\'@6H(O>M;#M.HK*.^T-\[0FVP=T7TZ7X):OMEK:/
M@[,7W._&TS/'HB"_B=H-U&(L$S8/[D=Z28/1W=-_3[^YL7>0&&.0O!X,;X6?
M,>C!@2B __BT!3;XK)Y(X)-[#8=M"'-PSV+%UXS1E5#[$Z66IL^^*^\]Z@/!
M'F6AS_?%J$7ULLG3RWFQP#_\P_^7P""FUA;$QWMD@>FK"?>"WNJEE4NG6#!7
ME0!B;WT7C;S,F-"2-&VJH ^X330BPEXV^MCK$,RT.1;7H7KI1??3FW0.T>-F
M6A\)XUM>\E9.N0I"1947-LKEV1<A>AEKYNUF_A+T*L\/YUOAHC^_NV"[3*:Z
M;2O!ES5,"99$*VQ_\O7XHJ"O[M+E29W2/.G?VH:O\$E:*[+>9*!S9="4JB&]
M!SM3  [\4;> ?<.2S"6T/B;G7:^?*$37*72V4$K@0KMD%VO='5<&I1,=K\]6
MDP:M<S_G&,@'II+PW\QU=@_\#@7NIG/$%D)+R*>LWVM+-X]LCCRK.YR-XC*%
MB(5&_/_]-/<__,,__,,__,,__+\/R <(QDQ6@!A @A-M')9V3^./+*HQ/+6W
M3X^I+#D/([B#$\69IB\6!_1JO&$ F$G"Y>"EW8X^=K1E9WQ@._1B9/_0H8T?
MBWQ$*^]&RI<0M6L6(NBAZD)Q)KLR.E0Z;"$;4BM^U+/+M*%U#IM;@)L7_I-9
M;U-\JV2#Y\F,%A=-X_5'\2]4Y'(-E(8H0+LV!? XAKFR1_FNSPDW6VD$+UT<
M6-_ZJ/"PHW[?6U^5GY^Y@7P)I<Z(^!D-$21W4H#J;Z@=#9U%3V+DSTZ8=^=A
MK%OV!NUST;<@;HUP-/MT*"Z5\"#G7<I&X^&4^XE6!O+9Y/2IV[[I/<PE#;/?
M3AO5G6IJ>65[3.Y?GM?> N,E8KI\$I'5L*[U )]SQ%NCJQC>F-A>:)F085U5
M,J'DT2W:1'28_ST&P7;$\-0^;')M(3J>H!%V:5"#,R_BXL.>UIU][['FQB?\
MCWV*_ZAV1-F_L%0EF)-'H=RDM+!S/%7EHAO6-?N*UO9OO1?%FP* "NF;DP++
MWL_8Y &Z)':A^6IX?:RUZ-0?1(^7"9GY%[;';L3;^\"+O;/6VA^D;J-3:/Q4
M]&ZW 6LF47=P2VI]?H) 9O9QP/9\M[!GQNZDNB_"N2!U&87S5DWAL7OV@U[/
MK"7 G>F/>N)>WE"2Y(RMMP,]-[5W(1B%F8RTLH8Q8V/BJT,];?I,=*MYS]X,
M*QUH\GG02>^BTBGRRK(#S(Q<0&3%-5K&^I OX$/U'TIO.ZEIY7S44S2;FZE*
M>C!G('9?QS1E OU-[(6C8H%24-06-&<0DAC20^1&H -J&X07,&O1_MO735=O
M%LZL']';:_7\EH_V.<J@G6K=(;VA $^FV:>&.TX^-@QSWL0^CG7BQ9TS:KUB
MNE_I]N:X-J64^4.:RO*R0/'@!UX%NIUP&9U@9 \J<8Z#]$&#QG<)Q6NG\?Q3
M%T]M^H; TMXS)JM\LQL20(H! !@H':>A$7AIAN_"KO<SR.<@9_"PSJS'L #A
MD6?V,TZD8N6+\';ZRV8YQO>4G0YQL<0JO#@%H'\YEFI;6X$O7"QAJGYC*[HQ
M=4K#W.8EE-#QN^.&>I2D[X#< CD'[]=E[?JV6AAL,XAP&*G.N4774--4Y]4K
M_42^E+U>2:%0$G96PD\W%F^#H[KSRW?:&);O@5JG,==3W1'XRD'+[:/&2+FJ
MRL?W.JZ]UC:XQ"BQ>J^9_?VR;#^<G0(LE"&Y#[S,IBA MSWOD-(NJ]'57NN?
M8T8&EB,Z5U=OW2#S,&CEE[D+<*8TWO2'-II"TENO4P>I#ZH/,X/?P=C'+);I
M=7#:W4I7#HDJ^SFK>+?(Y#W= @/]>R%6Y\!-2#!T%,)S"(F  &$VZ#*.L?ZC
M^T,7(Q8C[UFZ";5TF0JW\]ODI[8+19A*FKTU.&3)K="!6N'UR"ST2Q"\-M$R
M< G"ZB:+Z*K%NEE8/PD\IR>=X+SOG)-K29JBM^>E2Z<5%4/X$-BA\R!>L!L%
M2*C &]D.$C6OOL)E\!YE\%RO[)1YYW:MP" YDE94]_TCD[X/V+Y&3H.Z@:N)
M@R%2^RA<%=660N4.E)!'+@O>,\_]9/53@:$7HJ;L04Y92H"8 9?O!3."?ONS
M!6\ZX$;O\39LH00"JBX^W]HR%*8V9IZ$%>]/5O35;XWMN*=_U%LHI+%<SJNW
M%1762]U<&M*7 -ADQD*U #PZ!80W.,Q>&2XMK+]YT3H^;L_X&^;[K1<TZ*M,
M=*=88(Z)TY[&I-*#>+.A-0,1$/9YPAOQV;AG_.>S+HDQ.3HJQ,5Q:Y1;IF81
MITC-8$\(=Y@_-KIP(=S':'"K&LF(?TEF43W KSPL8!*]Q5JP["+A$;D7T0LV
M]"]6-ANR86JAQT/0/E-'Z(.L+TT+B5SX:0AUOG5FUAOSKG5ZX&LW!=5T[ZI.
M?5PXU\V(& 2+D,>,"!>@_12 ;:?U2GG!DNSKQNYW3,/HVP823?IH]ZY*FDHY
MP3NQ^G2Y/V?&5^%;/80@_#S.&F-' :*("I_PH6:5R!$;TQ0O:_XY4U$](9>;
M"?<%?<]JQ"WG>NJ1F<\0#/%OT3'?^[0[&L=R"B:M@MAM1P_ZU&P8EQ^ZQLU(
MAWZ1WF)QG&3_R>5<)RPW*NGM9U!&'PHJAE7H]6S[X=[AU7W1QB']*).&#,N&
MVNBAKFL)?/<N??_%8;7W;+;W#P/M? DV$"=$JFMVQ611^1W&=- B>*MQ0 G.
M,=VI.;ML+OB95^&[4+;ASY(D57YSE.WX-K>O18Q8<^S=10@3= *&,3<&+^0B
M2_"";8VJ8\TNCMTL320=?NG2SVTJ+$G#UU $2965!NY#B>T+6%E3O"I&N5M+
M<4BFS/M01J!KIIU^H^K6=H,NG]25'LW7B#;(6PA'#2@.PJ%$ 00\QG"U6>DU
MS[P+7_8^=- ]SWKYL5.">JJUP_J5IE\.RDXGFI5I7ZI>ZJWD*CD=7OR"> U^
M!)H.[891;]"L\S$H6W>@>MI8](Y1D?.08Z;P]._[G<$I]=WLCZ1ZE4SPDK)=
M3;)3/+MM!HL(YNMI[+$0;9OHNH;]WQ>W.NOA8&]2\QH?RGL47I$S$\JVMC[*
M9;EZJ87JJ#KXC +H0%;BBSS,>)2@82WV=I; C&8+*M?!IHK1,8S4A(O[SP_/
M%EZ9?R?K=+ 3BYV?VD1?11# 9%3N9>QJI+M+^-=UW0%MGZ*2ZO^)O?<.:BH*
M]T6#H(!TI+<@151 NHB4J$@3 1$!I44%I$1 17I(!*27" @H2)$B("726TBD
M-Y$J74@HHM0$(032;CSOO)DW=^[,.V?FS;S[9MX?^Y],LM;:Z_N^7]D[^]M<
MOWX:<?BR#2XHO4[BZP<R8HVC RA"K#927 3WPV0]M1*K93:Q*676VV/\GORX
M#Q;K>GNF>SXW9WE.:_.3^NY6,W!]F+<=,7&L2%B$DQ1-^B05NA\[&U[#3PH5
MQUZ]-_>2 -O:4^UU/NHS7@T+1(81=BF"\UVC%/517XH@[KV6"M [SJ@W%>HT
M_R=%W._[!E/^\S7;RVG<]\N/+%#Z1HS:'YU3))"[,'A[GB072<(5J0MX8D3Y
M?:5W+1.9XXXZ8V&OP]>]Z( 0QS_@SV VVOG?^6(P\=]2E_%;*<>6-7[KW;6O
MI"ZS5/1BW7Q-[&PBC>]A4ZVOWBVM8-D)V+?O7VH$4@0TNL!UYXJA*L5_NGKR
M=/:FS)ZB=B_.]=QWO_V=23Y..F[Z@T1:BQ/%4)LB.+0"S8Z=N]O7^?P:#R7T
M4LZ%)#+_DY]T ,*V]_6OZLC?U*Q"M#(5@<$69_-L<U3/DT ]H6X&_(3<KST?
M8^X2':( 9J9#T#$T*UOWNH3:%8=#Y%S%\F(%7A'+DP@-*'287=S(OGE'3]7[
M]#9S5G.";+.LXLL7P;)O%+4MK;,4%RZ%]@@>N>* )"7A>#B.A^"\% ]5*T!C
M^.=[/C[PJEDPDJC521]."PP!'WH*!COQW^=,2FO';.F3H5 G:A'M:A].V=\$
MO]]Z9LX)O.AT?VZ(L]&ZH#/CG#$G9[+8HPC09?^^JU?_3\@]CY2D5J/5-^@
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M!S$CIOB&9$(PN4F:P"]=(S3%N@6-!R3"#>3? @A?Y%VTF65?7*W]P*]>RI*
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MHO14U-FT7SJE(,7?YNJ+4L*)(/E"-#NU@E'3Y5>M.H%GO*5X22%%\\%(\)?
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M?=Z%<I:@D+#4)<4G?/RDK>3/\QN-ARXV)OY^9:9;7=NB"UP?'CZ,B'D:U6O
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MK1][YUK(-V']K2;=5)LNH7P CB"5Y1>LM'60S.6:O[W=F2YQ>^"-4X:3V@)
MMEJ1P1WSP/_PL+N27O_I88-ABA ?$" \6T[MLU&'[-H=X4@320LCDZ"3$"X@
M$[Q#"K/ZZU\KK\<9T[3,!]-;%C#=_\6'[O$T:9.'Q<P"]?873'!PBD ?S<I^
MF96<'43+V:X@AF'[**F[)^B F5-==(#9.$8$SE#5>Z$87M " T27?,!U2Z=
MJXA@8=K7R\!CRXQY,.F9O&_@/6NCYP("UD: _UT.02RPD0[H2V;%@KXJPW;M
M&QM_^#64R8V_W);Z[6L^X'ZCJCVL][.Y=AG3"X[3A\XV-O5CFD/M)G=:$KYW
MC@LW-[>\CRRV+E/ZWKT/.&%&1':,S"L0WTQBO'>3)\ S\MUY4G7PK24>K\'B
MEKA&[2W@WKA=%U_2RN._]?9&IV'C+J86,T=[&(9FP.:!Q*':!'^B_ZCFMMCX
MO.DD2L5/*+W<ZS*%+==^[?WUU<H"X0&:BJK;&S-&GG$S4%GC92,UV5</&.[G
M)]RCN-TZ^T-<M E]S\"9X>F/5@63?"9] Y_/ P&T;R!)RG6R-"4$8=/6T!(S
MQ[YD3A!*6H&@SA+[2ZPH]<DQ:W2 U_,/9YS3UY!"1:WRGC 4;<E%!T4*(\M2
M;D[N'SEPS&ZM3!2E<HL:?1O[NBK5+9?B#TY;^K+>C8P!LQEHP#N="5?'EXDC
MEK6!X\N1HTY;[9<BW"^: B^&O--_5R[Q"G)01ZS%#\)&&;2VF[B-DE<*'=^8
MNWVU.DN.5>;W3<)"@540'Y;'KJ,'9D'KO-K7F0A*VOX$?3A>/[3$M3'E _$)
MJE#94=HYK)!M<_.Q8QJMP0K=?:9N_-)GJSAB)UR'_!0V!V<">8$BK^9%/SI5
MH9WHXZ";*[2W>9OOG3QWV_2W!5-[1&CJ:&YIF<@(@XRT@C<VEOKR0'C(K6'7
MH$\]%<4F.\6IMVK4I*)?;^8[1XVWQQ+3FZBI=( '@KFC2J5KB2VXR;8M^\K6
MOK/Z'\ZZCR"]DK?H2=N!!6/VN99UV2_42)0/'KQ<0@?$H:[CNW#*?:\:E*_^
M5/)K$#T;9W1QL(/R-M5-/N6QG:QGKW">D;G772^%1P<&O(RUE-$! TN;<")G
M#1TP)H.Y#7^X&SVGT&4U&_;5KV3FNE]8M9?=<>_'P#*6)O7OD7><6W,_XZYM
M"=@SG+B@"8VAXQW_=7Y#T.(%C\?(*HS!ZBGRC&TV,?UWK;^,P<X! AS^C)RA
MG;;'MJMT@!HP"3+C2LM?&B>E&R==V(2]0\9OZO4R-ZYS]OU,AJ5N ,\$\,0P
M!)!%LD+/E+_( 00,\-KT>Y[_7B%M2N2N59D'UX'@T1$#JAF*.[UE$K3%YTH'
M%&C!8KR W)<,+L$[=#1YV&8?+FW >;;NCED9Y_K(!K\E"]N*;F=_1BQ$/6SZ
MCVL(==B89,(F,;UN@F+Q5$OYC&E-CD-;[5M?\RJ$A"=B ^W6;[HC$-6A1;Z^
M@HQ:Y"*E8L,0;)LTR2^HT7.O.QOS;I2]<HU)9#Y\>D6ZFDW:?MEJRX@P-TUT
MH18I:R'/.(Y BBU8CB]7ZWWZ6V4]:_8XU\Q,YL90$O;RJ>?@:@-=:K/!Z6#@
MUT,IQDY%1WV$>']YK[R_+4/3S1G*ZAM,Y$\;-/LJ_XIC(>G>LL#"CPA@LA3W
M#RW@+()8W0A1;.$:>0VUEG]=BW@S(F#/Q3D8SI(::[/5BYYA1/-[\.":+,D#
M9^HKJ2RGW9H[W.R7\1-:AGNL?T\3"T=!5OPBI;BF,-[Y<VV61@W*E]N0!@T5
MFM?>-C5IO-^1R/MZXMJ(G;ND1?A_&"B2*[PB&/05K5<7^ZUN;$=APF\PZ>T#
MHN:E< %-R^+C?G0#*IOX!;W\FV$!\&96KUO/1>"EX)+4&%&H"1*\<,/O)U.:
MKN<[Z7CQS^4!@=(!<AX[22_^W:%^+2:1SZ.G19"9ZA6'\UW__"D]R)__)"0G
MY&QJUC?]^T4W3JP7I+97I#!.R(,V!SM)<L5OD'$CB(9@RA6?7;?V"2WQ#+^Z
MP32?I3.JWWLY12.NL&@[I80@2!>0V^]Q/,G'QE%8'J8EN,\?.^&EN>R8RM3:
MFW^5?"2L;SJ>?,7??W]%=#;R&41>E!P6DZFO2&/#T $R(SU6QY0).F"??7-M
MA'1AB9(7E S?7+)BI/%YR :()$,'4!)!@J#-OXR/1A6062!L*7PO9%&+#D"&
M@QA2^2-#3G2W@_JE^O[P;/F3E2E71^%/5$Y=*L7^//-@$FI8U%'NG16:F2^P
MMR#^FG_K28""-^MI@6>7U\OECEFW.?#:V$,$BNDQ1D"I<EM/!=>,F/55F'3[
M$MESZ_.SNS==$CXS>XQRAVS0F,Y;18"X!9ZQQNR/@O!"5REXQC8-!6.<P/P4
M WQS]GW4E:?KD[=O=<L=&GAD94H.2HOL_W6<:I$NN5M2;=>_KW(*-@^O7=I"
MX"Z@%/&+DI#N-]1"L[4<RUKYT@S$ X4/W?>9HEE.'=USU;=:QVP[$_K,J85H
M#6^8]CA*74^9:TO-1+[\O7M([JDEG7Y;\7<G6?P/0[,9]IQ]"*^!Y8E#LSP@
MM;E\&=4S61'Y]6$3.+^3?BF_T8Y/)?7L3((K&VXPS5PJN),2Q,@P9E(LE@%9
MF/K (NT(ET$_KC^!EX^=SORI^>PP.!9SZ?$<X+SH8(R$9(LHRYE9"Z-[7@JP
MU7;$C,ILS-22"S4+S4\'>,YU!;-&UW<*+:NNR$RI\N@3*)L$1UP)ZBYLSD P
MHM X BWM<#:N[*(]V<A8;4)D&]RP5.L4K[+5CG__9I6'PZNBKZSQ&OP.A&"/
M0U#R1E[3 5L?'>!_!A0OZGX#&A[6H.0_HK@X/%O#;GR3Z/5QO7C_!%/OU5=]
M^?Z;X(C\FNA*[:4&^T[2I4<IR^Q:S8++&8:*G'EL>F*T2,C1!C4#9?2)=(;X
MGA14 6E*]<IVCVEA:FUM]JGYVD;,])_AW+,"O/!Z=)!$!U2OA//\5K085WKI
MZ2#.H1@F\KZI/G!,R=M19 # '0S,<*SVZP#QZUT@7!S?V^V$R8Y3S+T\0+.E
M+>.^X[_DLKP;AW_?6N<LC5ILO;4,<__7C[C#<3]'@/I^&SGU_:??4O=ES^D;
M\G\?0,M)RDDK$7T-(2H4OK;K$UI5BLLMDYJ;YG\EYIYT^9\8:%(,^.#+*LFZ
MYC+&B)!/= DU0]J=)8YB^&1X2Z\E]J\,^M\[[,RAKGA0)]DJX3)-E>"2B@MJ
MI8WDS6Q,QS]5N-_3'Q[=SVF\?V0"4OU:/?,3]S-^(TR!(J0L!'IEP&E[YS-:
M_IH )\!@Z/D].#89OF>*"J<#'C'0:S\7 J:=WGT:L#2;U9G='D&V?>LBV_1N
M"*BX9@9Y)OCWMYDU'7!"< V(-QU)7N3%/\E9@;,&)[K4C#8HSC>K;,'K??G9
M=HR[Q LU>#DB>;<WKO=_YV9!QHY>S?OWDNID$ &1QPL\T#2B XJSM!CLRN)%
M!Z39$EAI77?H@-\1+O^>K_"@%D(E5X85.V%,>'23US+'/,?ZY(%H_5&FIT]_
M4I_$$R-Y\]P=4]:UKR,.^SPD62M*&C(.1!2+I0-NGE:: M[9@'K]'Z^?29\B
M(6C$?#K@TZ8W-9CZUD#($\P!\H"S_ ZU?7U'OC?=+P0V_V+:7N,F4C/%RJF.
ME^EWP7GL:4KL?_1!'-B$,A1Q& -L)@(:8-/0\XRE.F)WR<P/&$M]75A'7>!5
M'OD*3()Q-T[ /9<D@NW-XY6VMBGVX25SW8E[/6*+>IX%W%\!H-/4G7$:5[ -
M0T2 <$Y>QT8HF)"%5OU2S=53#V3=+O;0 :AO9H_[TLST(?BEY4-&#23#MSZZ
MT %_!C:/ >D[VJ,3W4V>D2 FS*.P<F40)#]Z1%S0M:+2+6HV]2WM]?0L'/\
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M1*G#S/T.R:J,2C,6WIMM=Z],GK2UG@$ F.?01GC0-I6L"+V,_Y2+0W*2<LC
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M[@]-F?KE8!/$686:<Z8#DMT:)NRZST<O0X93V1H)]4D^?2*]BH?,Q$22/AW
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MIJ!PJ[D1ZQ^-IB/6IAGL'YA]FFQ>I/R @2":! 6N9)J8'XFZJ8UV5=^7]/9
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M*D0#^E2?5MP>@WW.1$W^I3:KH;+*[]^#+7V/=RZY(I%_)J2-PCCD!TZ'>N*
M8_W,LW,=OW&'.".A@S/*?/JKP\?_@_C*_SOQ;4QU-896&5]V4VERV10\A&OM
MYT&W5@.N1,C>T#J&!8/;K'JH:?+G$R=TDD#7KT?34\%>/Z8YH]<07IP7$U6>
M;V3!JL3=5\7B%SKP?*6[H -HHD3EX(K=F"IXQ:?6.VE>;6V5<1G1+5*NO0OB
M\__!WX^F_D3OE**WX;N@+5=4U@V[SFI2Z9O2Q.]HP _'LH8R.;*%4=FTQ,HP
MVL>1T_I(,>IJVRH% YA!*_?WL <9FI,-<]J_;'&CJZ&?UX-8Y"RW.,+34+$B
M:W_K%,&[*GDQW??_Z1( _[9_V[_M?[+YH478JH ^D>\%JXH,$UUJDAZV>&2[
M*?LBSFQNYOR3( (U)UOU%>#*L$/* UUENR!G0)\D'%_FV2YA+_:ZPR L<"*9
M5S.1?B$';)]7R;0@Q4-:,N1^U6 ]TS*TDQY&6L3^7DJ3>G!CYNW+/0VQK;@Z
M_N9$&2!A[N(@6WG1QJZL/5SJWA.[(ZHI81_^?"@U)X">4,[+DXV/W)/T5? ^
MDT6+H>UWIL\"X!P@#P:&,6]1-V1*;[Y13*0HY<>WM%B_YI9YA3CGK3_ __G&
M=;QC"QHNWE<].&W_/=SL5W2$0HDTCT@+3S!6'<AE6#./ IIEQQ+)5I#%'8G2
M;Y"5T]]<WHEMJ+V4*C:,Y<H ;<:H<C>SC:AS[?W"]G"VV+@:\E*^@]NWQN$%
M6^<'N@H*N?SA8(5&GX%_WFO_MO]U3>'D'<57H/D4?(,_"4R)HOH30WNG$%%=
M>.-"_"'9@,SOC]&$<SE@E[R&6\W06G0+.CH8[I'#/#_DK3%!L._53)O?!35_
M4L4[)[D:!]Q;;#OR>E[D]WGA?_J0Q'_1N-?KZ&6L%T;'4"/H&GI*^>\M[07"
M9MTD)4W?\;+ZB,1O*8^7\>E<V8YM"LJ\H:H__^876IDC@">Y.9I*>)4M[C"[
M*-,WU!M -Z&;STI$#W_[;.)GZ]<1>2;<)B$2=Q7W"#,EV0:KA(;QY3\]>)MV
M+4?&4.$2./)=\R_3+E516LK<86$KB "["UJ9F(![!(N]@1J R+IF6((IJH'W
MW?16V(,NY^)O@'?J772;V6KW7$3=N8LY\-_P6_[T".[O;?+U:46JAV1['U;M
M_'/[-A_!R^6&I[U/@GTWL#RL4M1^]O=L 59Z@R26>8:F*(D^X&TWU9<P=P=>
MXIV:?\S_K-++YQ^=I?;U2YTC+X$!-5C7C%L;/O@%ZL B21^N*7+>I\8BVMEZ
M_:CH\QBE;GV4ZT-%_U;")E:)58(F9&2 5_H8>I/,Z]2Y."U]K)A[HH?6FE.I
MNM>9AI?U.5Q<EJ7-81UKO* 03"<V#J4#V'#P.)]:]B??-]B#O-^OM=\8_C'9
MN-W7XG.:XOKG%FGI91VW,@2XU6I"L"5;A_-N"$0$J9$97$9N*_*4Z7OQS>%3
M@FZ9!4D!,N-%4NXQ8+;Q//B*QN>3^;XP3'=!+>I,07+H8Y\Q+Z:%>'G^Z<-W
M4LF2(D\^']H_=UR7K#@^@*Z*BE;+Y?RN^<S,V]M=K@1*D/2313(%=GQ+/^J7
M"G<_CI".J_8NO,\XPKR:>/?=ZC!QP]]IXNUTQ0$I^3M1&")8UGDX2-\F'-UB
M\+>(-1@UQ58'\DF[H%@=F<@OOH+MP1T! _4S#M+2A6J?&;FZL/K^JT+6B<R#
M16WI&5TK\8R;H=G:_D8)#^*XMMYZ%?GQ-^W%WN:T1V[V,E*?]F#\\?J+,8S&
M]'IU01OT38ZP+'O?"]*[6P0L)9W&3>A=/N.P>+H7[7[$?TTV\]Q=Q>:@!S$$
M<KG)4P$6$MN)FQ28:;BP"^)UH152,*M>N6/,"WX_LN*S73X(HTJA>CMP^A=6
M=),>$@[,?$!@F^?$^E\TZ/O[^(CI^= +YV6ECPHLN*!5>O<@<L!-Q=AN33E.
MCT*A'A@00AE&TUKMW':K&BQ5'CD6(Q=\?79)S'5" ]$CX)NQ V;O72)##B"&
M"; X;^:E<D\]2KO3D5-=VH6!2NTO<6XO*4+SKT[[)_J?AX3>,!8#_?_<N#J9
MM@"."'DV*UA/@\4'O@FPE)A^?N:*X-D$_UK=@3T_%O@%N SDF\>[9329$E8$
M5 GI[L;O=SH==M88Q>R[H]ZE#]RONZV>+B@EHF*L:IZZ4?H8$G.HB1VK2+7#
MM,_4PMIHM>%M<)%LX>>DT=NGCMZ>JMZC!VF +R0"*ENML' <B -%H9JMM4UR
M@X\:'L@/35W^6E.3H+_D8GK)7_^S[*0M]Y]I,[7?<U(@UH%A)CP/+B^<V&'G
MG<]7F&/A[I/75.VKZ-<J5OM3 ;NGZ6P*6U".*JKCRM",31@R,4F7 +--RE4)
M.B]KL!%HJEDHVG$T[I/5L=1BN3,_E(_+C;R7]3.,O2(5(@-8T%T '%666/=,
M@])TC'FD'H@MLRH^B\.K'D[0OZM]M-3YE_0YH6ER&0@U@NJ#U4 CH)[]^SV_
MKH;GCQZM'/;NR"+?KKL+^ZX"^2E 20K7'X]C>OW-U,N4 C3)]EA!#"51PE/[
MIA3692 GGE#WZI#8NF(2]Z?5NL,!/_R.X_:SCR&/4/M7;&FJ),C*+NC]%.+I
MV-25QL:T06?7M*GK"=//1?-/S2.?WR/$B<!.<N;"838OX@RI[D63,A#1F2T[
MC+SEJ]YNYZE=]BB=[VR V^MR:E"5Z)?[_7+NW!LA!!W*?H(/WJ(%3O+A]FR[
M7F6]]D?]IY7&KZ&K;BX5V;<9:^#K9E@UUGLH(1<M@':E/#& EO<7PYN43E1:
M%"R^*JVT/_+S:NG*AR\K7]3C#MV+@(FC6]0U($0?2CXMA-@N>5I.1A4.#&F?
MFQY+CTFJV)I8[6_TQU"MY 0OLS@!P@OWDJU%JTV!D\1$')<';)<Y;3VN6,?E
M_$WW\,K%B_.^+7*\(-0KU'=,K5L;&E]O58_FASG8+X]=D5\U'B&).+8^)QAQ
MN08J?ZWHDNZ$SZC2>DWKAM$/$P'5T=HD8HA*-1:\;%<0!)D<:W,QEZ-\#?^0
M'Y9G(P0B>(%\8:5&&D 5 0."77(C^4BZH^3K,Z#:NEJ&%U6# WIDP^OWF%R0
MIN<(5\:L^P >L.>8C5M(A5U01+T/6Z.JP9AABSQ$[7R!_NC(-*>.U(X]KEY3
MRB[:W_[]P^F+)G&V_3G7S7/ =GD-<P0KBB !C3=M34<I4"6*-#X6X)VTGE=9
MPM6_V*:*?*,D78"JQ?XXU??TG_^3\_\ULT;EDM15S6^.X]^]RTAX3R(J<*]K
MM?R>JQYOA0J=T?A(.].:IM%XT_$!:"YM98 /0KG L$7(TF]0/>%.:E^20QB5
MMZX-EC;#,\?E@B):BY<=/_%?,P>QGRQ#J?:KXG*N^#9B6D+&=72:ZKN+UEG8
M^C Q"+ /FX8CY&#D^+MP^) .F<:$\J^XR VZHXY)\CZ=9O7\&VF)M7*]32%_
MZ-@L%>X=0=8KJ$_B'O;8P+1'[<E>8K\4WO17?Z[3YZ#D4W$]0F%<1\,?FPKI
MQQV +^'9+BA>Y*51MACS 14=LZ&?7CL2,'-%6BQ7X:F$H*)7PH=%6[,_4N,;
MHSXG/]?%7#\I=^D>O;L/9/X_Q-K;HS467N KC2,^+FN/5H@AT07X:R/&:EW<
M*6'@*TPF38<IX4_TJM9[5_Z.B#G8%RS3<TBTX8#:(_(1<Q;]?'^M.W?/W^Q>
MU.N&'@:WBI&J@.\'HTRW>YUR,)OJ%-%>%<:@2=N?%XMF\Z_@ZWMLG9XXV3H6
M)/4\##ZG9G73RM^ZYIT=V7%T-5#VBPS\XY>,)R[.R=^[%#'MHWJ@N_/N[QRE
M\DNZ774/[XPO@9D'_=D"(N4(_TX]MS;-ET^SOF*C-G4D\ \+ SK>5V51DZH@
M#?'#V1<4LFQ^42S=GFAC@GE'J\OVMPM7FAX]=/KD.1[(=6,0^O:)2Z +W081
M%K!,ISU_;Y$B=88:%'(GX$V':)=W"AM+'\]8\1PX?:88].E[<U)7(>HEPKX]
MS>D4=?9MN4=Y__UB^\+O0K^K7]]/2IHJ WF.V%ROZ:BN4(L7U!,75;ZC&"A/
M*LP+@QKA7+!X?A)_).X1]B6.UT@)$4YN%Y@J#[#/++A\ZH,V(;;&)%@Q0GE,
M 993L_V%@R/*U+*MEL0$C #475U8LZK#[6G&PPI?2=<?US^M?I'QQ="-0_O(
M5K%/8<_9 IX8$:'!IDQX@7:1K 27"VMVWF$G[0CJ?9C195IP%T2.:<MYL9?N
MZ/T-@J20=V=:9F7O8& )LV>/:_=GFTVD*KK$O^4)768,F><_\U>,E=KTXT5Y
MLEN2$R-AW&QU]K"1>E7(.YL[.C:OW@J/I>U=8]S&K'YRD.EBO3,2 NKIBT,^
M[!/(&T#^QT4[IUQ_M:</H_)F0]^8Q+2[%;?&W1,2??HK#'KC$A\H?*]A!_(8
M3I;IOPL"0S.)JTQ%&R@U<K^2FXQ)^UK$MKO_N_JO*;.?(3R(_$[TIU7*?2(V
M2@\;_\? G]K;J2MA8Q=7_[/*K_U>K=7A./G')F YU>]H#TT!H*L+2KTMBQ4&
M( Y&LF-:ED:"'EIWI+6I4J^[V^9 7)LYX/$[V3I!QDFVXQ\B>6)H:#RY%2?&
MO$_-73$Z /=U-U)G.%S3^/4X]B?W>MQK5#Z^2?YO!0L7L!C[&T90EH2+X"S,
M>5O6@\K/5G-'O*63'_^0](MO![])?!W18D!SQ%)2:6WM* U.+_L!IEVU3U]T
MQI<M^TT:#-_]-EA+FG@D\D-8A7L5'37V],<[0JCP5+N-8'!YAX>,TX^BH^9A
MVR\)P73Q^H6.7]NH!T_>!7E+,S^NS]$QK"(#1RJ#C@ N$3 \3CBF&N20[=14
M5]!"0%*^RDT"AJ1VOF>SSZ+D;R8*I*47]8_EE2DR),;;2*F+Z[,D])'OP_5G
M&+5C*Y1^:98*-QY-R(>)-EA2,73G4>0EHKJ3UT';&/KLV?IG=]ZH>G>W[3G7
M3''JHD+LFVB:+3[<R_AWO4Z>.E\-2[<DA4$>BNXC58=\>[2VR;3?[3BQS5T0
M<"RMR(<68OQEJ.'6^]\G;4O'[75F+W(=/XZW,D@U/&UC^'L0ZNZ#ASL"^QER
M2-F!!OE><"SS?I&=!SW8,L[^<,S)/U#\]Y?\Y/.0G&.D(X?CNL,O#>H(L>\H
MH9XL0JG7,LOLFY.6G\YU68E@VU7?\'9-'1DQJXE\H,-SZD^/-"';*!6/;M''
MN5M) *V,3O0^]I%9C7S2*I]%A4\$'_P-MY?22\*K*^NKYR&/_A%F=4AOQ\7*
M'P#TB5^T5F40X5UM7^U<]F%=!5P>N7EJVOBX\HPW8R2AA!HC\ "VO!0E#V@S
MVDG'\!G9)2>KZE)8A7%\?M!9?&@Q]T9>#/-)(EO0ATS3=0.>$,>B#/*F?P@;
M?6&G_D'O11.J.)J:>2O4ZSX9)^2)$DJ^)GNCUC?$O6RYF3?)=-!^-@QZ>;$\
MN!DF8G"&9MKV"LX6'5=KN)#?W^HX\5WQ*D&T2$[*Q>602,9B\;^T_5HFO8\5
M!G77Q+O1PVB0N/OL5G:;1FV&80,^]Y9X@;,GLAYULTNC;;3OW@2['5-W[*TK
M[SM,A^QO"S.1!Y%[#9S]DCK#[ITH)H!T03:_&\6X:%&4",9>&'L$Q]< EA[-
MK0 PQ'@]%;[<)PH&-G'.%PS\NKF<TR]^ PQ26&38240B_1RKFJV-<#8&O,C8
M@TLTA((EHCDC9/&MK;/LC8*U].^9[HN0IGT+&2SOO# CI-4$KF471.WA)JBE
M6&C$TC55&9=S#@IBS_1)'@[8_XLYT7_M3 S A;YGA?_=:B0XRC[@;J0PM !X
M?'"4=CLU5_"X>Q]/LK3!*+]GVH46!1QZXH0*=RO.!3WI;,9Z8\3?0KA_&BZ9
M_FA+KX-X57UD3<4&%#@AQ@NB2QNDP(3A,*H5!G^0[@EP",.>'D"3JP2"[>,I
M[7[377+M!TYUQUPXD?H@ZD]W43!JG]9.A3$(>8<CZ#=8$=A=D.MZ&=#6.4[U
MS(:.D=>D[+I=8G[L:9D)SO()OB>H?5([3"\9-9H7 UKWP=NS+:=(P:Q8NT1V
MBCGL$+KEX"YH?@X)Y\@25?3262TZE**^"SI&H>FS.\HXLMZ\ )L )43O@M9\
MFK1V016IN(T,&8XV^5]@]^B?L2]0*:0]5:>M?UL&Z9J#>$P^$NAU3?:!Z:<@
MGG'#'-0P;J_!K0#UZL08(_"(ACG^TX5R^S,5=,=MZ O04R^Q[H<))*UD95N%
M^ZD!YWA"9$+_Q96(+@J,<0T(H=\";@63^N"2P6MUD]5EQV'PV>E79@[TZUQJ
M,V&;AR'?$R?;B.*K%#+MP0(9W(65]AA#2<;XO?*XM2S2/)X)/F L:_2@[N8U
M*VO]L/DT")H]@?[4E,JXOYQ]Z,M8@_,' #5U.?(NJ:HB\IQ"<-(S#^$_P'6C
M\*; 75#4402$'6/S$DH5$ #MX.C)0#HUI'FNBCG.UAVB(&]0AW]$6(6H:XQJ
M>KV.E+])N55SQU;R4)Q<TV@W4GT,Y]8/077;T7.)ZH*F@TTRYJXH334-"CD^
M]P3D^^GPNU%DOV3SSNF@\CK"UHHO$?QB%U3UCA-OWEUYT@ CAFQ]AJ<4FU34
M1YMY:[.&"O:4GN/9<TY\K6\7Q!2Q;RTKGCZ62;-JUT,],\B<N@K7G5=T"X,]
MC7C6>44&M-W+WC=,M#J Z"?P4^[D+P5MZ=AY;47R: \4*UH\^>GP9M3TXD^$
M[D(J'?M7GQY'C%\91NZG04V:FNJJOM0UUHU(>ROM>QGWJ/"+(=<U*T\&F<"_
MPB#\O4Y!_%D7P91S&;B;_[9<PUL6N>6O,YML\N<I2 \$VM-D 31RIA^*"DE$
M^I<@8EMG3XXB]TD4*ECXO[>;4F^7S?K9_B10I0#SU9R[[M!U_@C.VYX>@D;#
MZC =JS*3JN;YYO /5H<(OK&9(Z<22\YW44OG "7;"*(D)84FV[Q#^6ZMES$Y
MLU11^OU@7]KLO/>=_ELUMF$;?#@3SG3WF51M05?"(KRK88*"L5-3VSSX!"SR
M0O926&N<L/AM-P%#\_FL\5>HX;]9M*VX48/R1IF=.^B76A!N1/9O/CJI]<A9
M&PW0GDO2KB< *:6[;B72/8<A1X#P'YIQ<U1;P2.Y_>*;[]/+IAPL?;FCXHU3
MO_9H?M<EDH]ODIJ(K%(T >,$9I4CW0J E'8GQ?&S\#*]KA61ML)M?6F#SM"N
MIZ=^W!W9!54JK_ 2T),G&-?'2C57#:Q(]8MQX%+/O<4/7KZZ8BS5[?#JM)]Y
MLW1'Z(7SD'<0ZCSVQ=R&$:)^%Z2$!D8?X^30A"2H<),X\Q M/>[L+D@:R%O;
MNCRTT!0IB*EZXJ=WY)ZL2$2"O@SK!E:.58&>'V6?^(]"C'E](.1?[]A(L=XV
MW Q%WH&RDZ=L%N50*(X7Q#GKW:3!#<YZ=WL7M&/A!<NY_4]O2OW7[6KR[1<6
M^A]4EN\2;+(0<_14X 9U]IQ].TZDX4Q! _KIK-?-@U#B@0<+5#&NI3O;9(X"
M$.8,^V08DH_&S3P'/*I=0S0IVHQLPM^T)TWP.93ZYA(+#D<J4O.Y>;(-+W5
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MO4@3J1,F%\1IL'8TH#07P4%MR5E$8C/[Q!A;=G:VWMQ?(H[\+<@YY04T($0
M1,.)L_LQ53ZM/OA;+4X\V;N@3KVMA&,9JK%W"4TZQSWG?_)\^>G'Y[MX8=4N
MC)NSHL1B%-['X':.JRYB)ZOHO%3E%1I)VN &_>.<!-!Y_L+89M#,4>YQ]T5P
M8\ <M4=>#E+-8'JS1YK8L_ +[H\>-YD,Y/K_QJ2%Z:X"Q\>9;Z'MFEOJT(T/
M)[8A]+A=T&LSI-XN"-6["S*181T"6%38558.6^RW$_>8IH;:6<IM$Z7L$>ZC
M*TDN4OURMVTR #)=D5J7@'O8!R;TS5847\A=.J8@OG(?^6MM2L&P?H"_'5KC
M( I(.K&2FY0\3WVB-J5[N>X?[3Q=4=F=? !-.&&)>N]II#NPT<]G27H;J ];
M42FS7)AZWCO_IO:/$$2W1>YW',UFA4CHET?*5 $>)#B$\F[/V)B^.]Y;Z6:$
MX-%/C-)363';CE!"\E>N=V>WFU00Y>B]I9F1X4-@59^M,UGDV3"#71#] ZO$
M"^HY-V'1F7UT& D-R?<(DC\2WBK])R8IL/I@XTGS3JG U0P.+OI@A6(3GT$J
M:QN+2\EM06-)=LL'6\W6[I!KSTWKB1;/H^MA*&"+KDU5CH.Z31B!EVCF1*S@
M)46_H@FQ)YFOD^^FC%0\,#>T#)*I:P;O0V02&M/;- _8[H>WU8Z=LN5Z;.2G
M</T#@>ZM%P/:CFK#4*]9A6<?H\9CHM4,8"2/#7CF_8"ZI-^E#_;5*:;]T%TP
M>E.Z"P*4MR*;^.R9]VDS<ZT1)#C%PNI9J4^-H?4EI=)E%Z<;C&0;!0."3,P"
M>Y]Z_N5UCQV;#ICX$DHB=4L[5C9"?IHUG0*[R^1A93?(,G019Q'^+5_1D^HS
M#;VQT<)+Y1#&CQE+T%-'L1OG>?^_M"-'+B@2A N&QON@U!O]HK]GQ5@)38>=
M@*<>95B[O64_LV=B&AZ;GU L$.G>OIN8>Y9K84X.YXI^@:Z-ZNKU0CL 17RY
MA8A@,PMSI'KN\O6W(D,>\N:N7GT_2X0_/,YAYO^2$D/*<>CU 7@?,-H@25B@
MGFU2L.4YL?5)%J-]E: 6?*O$]!'=5#$#*+K$BJ0P?3E]<XL$7EDEU:^*,8U=
M[=&B'K7XUZ>T*ONXH_.G4E4N; =5;*=&_ZKWF;*BJP-@AA;[>Y!-[=?X'V]I
MMXV]E%X'VR5XUT@+YF!.NH1]$'SW#703U/.':Z=VEI?*0?O]1,KQG$Z#?%<1
MAU!M4D,5";)B2=4G/=6A+[0Y[KW:G%B]1&_]YA3R)\I#^;<=A[J#:LHXH<,-
M<"X!XJ#TT?ZHE?G/'D8,C(I7T)8KOFMZO/0Z?^]<Y>K*\3Q4#^Y@PXURA$7[
MU]2YR,!Z\3J98WF7:JH_'KY',F[VK3MQNC[R:=;XR-G_W!_R7@P+=$\]\MHN
MJ +.H>HA#U5R(G 4S<Q<C4>ON/JPCD4V=;$*<?,S3<KHB9KB7=#2V51:%U,$
MRK;<ZL313]>Q4RZ=A^3]XW_M_ ,FOIU+X] 1M*:+<HXFV<[F!V#$7NP> &PQ
M\N=L6_D3C OC:<?QN&_>#GP35U)J108(:=@\G \6/VS+2F_83^PV4"B\4 K,
M==CTW2^8FLXWEQ$7;*0?YYTZ;?+ARS*Y_"3JXBB:(WOQ728OD8=HDA$*PRA-
M(-M,LFWGPP4AX4_=]D]4/[>:=7)3)?=_=KG.F[@?W2)6,^/G7(Q8)[7[>1YD
MKL=K]_RY6X?L4RWQ*;DR,X8F1.T(I<6=Q<38Q4G>)6+/?IZ_RG@1""V[257N
M\L'#Z><!&L%'&/ET-)]F^KP![I=V8_HL;3HTVR3@(JW[0VEI_%%O:]XKV>?F
M4877^><[HE:\&#!4UWB2)T[0P T<?Q:.@IG5?/%*/CS_$6^UMKX+NCI1ERN^
M(\?01-ZBF79J1N#=7C9X$)\@Y4C^9\?J\%<K>J3CR7[UX9^%<B/W\AL^S=C,
M^.\;->4'.]!R* @@V_G5YCDGG$HL9=A$;UZ0KAPJ/]:^'N4771,Z:0:YLNXS
MY49/&4<_A+W /ZPA)OZ]JF!+DG.[DVCRJ4*_V];IN(N-2H0_^5OGP(5SRZIK
MVC^F2$]8]6R99;1DPP;M?469Q]/7GQP(!B<;")=?\(N$23Y?.97M?Q[2Y'\U
MC=I0^;5+]/C#(%T!?L44)^NYFO06EP=E-%A+<T2X<)U/%QMJC?98E>VBSM&#
M@7B2Z;VR^[F.#;:KQU^6.M.";@#C)+>5+]1;]*? "T)LV2TRN",3Q_V[TE/=
MQZUH4DP_=V_4]Y233=-5)WL.^YZ'U&?S >E$S>A:'<DF$9I&*@EN\<3@;=%0
M^1!1 >D&%U/D#A=6S08B&"9,3>!&Z;$4#K'+NQO)C\I=BE7]/6(>GAUWZQR(
M?JP!2H"V04#L#DCE+BBQP9ZZU9YNI$==MW4 $O3K,U^ZF&?(^C\WC;Y][S5H
MBU^+BE[9SU!RA]9IS76 99'71S9#IFB/*XP-R_K3YCS>G*G^;J9?&Y9K\V<G
MHA,$=44:D@Q5._#J[[%YGM9?FU*#LET;*:][U4YC/WQ-WKMCHT-3(%N%L<$M
M<,WX!L<"Q'WOJOG]5R@//"KB5F[Z373_X)?&]N$ 19^XP'X0TA_(I]K<; IY
MIV]E$5N<YZ:O\+GVRUTE%_[W5$(6.L#F+5.2*I')(2!95KU!:#&P<!WWA?HN
M?'IZRM[^JK/SHY2]9;G6"P\H^@DGS?M+SG(Q> G0E[,20&YNO%NKT>'A!O/"
MU5.RC=K$A\:/N4Y<R9;:HVNPIIJ/[4)/?I5@Q>(([^MP@F<;K==\^.$ZT,E(
MU2B>[LJ67_AT$,A1+E7GWF/[<7&&R'E>Q"HE=A=T#$NS^5>V?0GXQ,<N]"/8
MMA8Z!D?7F$4O5IV':/Z?;D_<V6;\W<O@B"L7FBDK_A9G!56O03W[!P\MBD>3
M^F41(<UV]IY_=W]8_%;\$(\1[YM[UY?2%)3Q8=J+Y<HM$-DF"//*UQ"8 #!\
MD<8[)%33A$$?JN3Z77V(/"<^]7_\28L;8]44^6-I;#;^F]9\8WNO%"3Z:)C&
MH),CECV"XV>>7,G M,\)VNM1>UD?!44 59EUS$%TBQG.35/@8V@^R3&>G!#]
M'C_MF )T24/>YH +EVN+2NS==P)'62L]7F[P@U9GAPZIN>>D.:^ CC4IC:()
M6 S?#;P<]R5:4<R??>WP(@^5#PML_!6./DP83V4/X.KZ$XW4D8*T']$YS#VT
MVJCWRWH. SW8.9/%M$])Z]WG$Z6FZ@$.K/9#:^:8XLHD_@Z8V+*>3IO7@X66
M;/ZZ5%(XJ6O+9GQ9F"?9?"N?7WKO9P)SDD+ "/\](!*_"Q*J 0(=54G:7_RZ
M6PJJ1S4RUF;O9]\AO_IT>"=.9"*&NJ/"O0-AO<3!&_7I]8#]L1KZY:$&RT*S
MVJ^=F;)_S.8/OTXV6/_YF2=N3>#3@K11!=DG#L4-/+H(8#OMP%&*"H\3;XT\
M>#81HGI2F2K^MP8ASP(K:W47Y(&.EE>BKF2?H$D^9Y[R*(SMN[AP_O-:W%KT
MG2,OUM?6Y!^<!D\;;>XX$SA21'.%1=3VJ#$$WZ:ED@]EOD/?2DI ST3UW@(B
MSLM)QD()A;@J['/'(=C+DYY^FM0EZRJ'^1V^VU,[XV\XJF[L;+^,E0%4$"4$
M,$@B+RGKQ"J12]E=I[8+P,7B&PL1:%?,<RBXF=T,^! _\LLIR@3XZ>Z"GNDJ
M;V(M:VLC?XA'SBJ&BTG=)5__P/])C(L:@QK$U:(3(^HBC4"+;*DZ]*8?(H:Z
M>F/YDKDTZSA_L]44G/3HZNP)8"$'(3J&LDR/7(GH/; Q6Y'++(3:,89B0( A
ME)"VC_3R//",UM7%5G?[A1A;_1;?/_@=4PX?9'*F'T\;ZYV!Q*<ZYN%\IR^)
M;">M^J4_.AAKR]8SNR#D^.C9Z_P'B8GA$+"!V ,]\#.F8<%9F&_I1K>SZ\Z!
M+]A^\-_$G ?SVU'ZM'>K'58OZ/M+G6!A^!_/]MXXE60CCU2(9X3)II0_D>[A
MWI2( ;%=; C0]O1Q7(4D<1<4_:,B*S2*<93\8Q?4%.0FO[G#B=X\H[N@\"!$
M!+$HAL(^@;Q6P>X=+1.)C,_IK2F,?OO8^UAGT">>%T[YBEF/53=(,2"5O/_G
M=N(X)>^+8]7E9&Q^\='"O+"CX6.R=Z:$S$5WCH:=L/NG"XW^)U;5<(E(.=/Q
M58X=7SK14K)D,U#3./KN&W^"^\3]U&?+>\MD5+B_L4'L/B,^UMN-=R$65*74
MCDA,J:?RS;1]"V?V9N7E7'ZX70MZ"TKVZ\J@)4ZA6S%5+\9CF((D;*(,4)ER
MV;:II6"?0^RFVT5D]P/KI$%;_JO"9N<.V8P' JL,1Z3,+NC%;TZHN51)-8W;
MK$\47I3I:ZS$S]5R:2]Y]_]LA?T46E/-,0C[CE .YZ)[%3'%%>BNGVHBQZ8Z
M4R[X".PEQQ@*T^Z("8% L6$@K#D@Q_!D'F7E&]@$$ONY$,E>,)O::OC2O12K
MSW5[Q ,N3A48\Z<[G<F&-Z>P]_93Y6YSEP"#W6R%DBD.-R5O_H95N:UP48?I
M=VD="S%,V6#2ODW]>O[A D?KM7-Y:V\'>[@>W*H_A3VW20HS2OW?3F1GTN;:
M$P61FH/7L*2Y QZS<L/!CR3UXEM;2^=F'+*M/OWZDAB%JZYKQ<7@<72;Y\B0
MW-_X[*'6'V.4JZ7\-XL?7S/\2(;AR70(4,2XQ1ZWTR@JLQ!E'JK6IG_S"N2Q
MCT7P>(X+'?5.6/-VB.^2M?+<#F8+J#.T$*KT4[3^MG@8T3J_V!W?V)\9X.7:
MX/'S&3'@U(\XU/UDLQ9"*KD1A)H:YZ5!R5UMJ^&4>TVZM*"WQ#3<M%<:VRM>
MQ<'[<&!S]\(L9A<D>**WA>,("M*7K/]F(Q;N**%N<2L9]MID]DI]L=P/TGFG
M H(PG*I _PSTD5;QM[K&(6):];84 RUTH'9F3NO"UN,+?$/.L)L\,=]G)OL'
M0&CCH/17<Y-M@3Y'>WW.PM7\CA-?QX4;OM3Z*5-$":3"+M,.9>S?:I_;;^\Y
MV#O?6+^\;\WH\>W:Q\*(^?$8U Q.J@86 ?V$#,:+M]DN[W2\Q^2U!$2!]V8<
M=G55R'_B<9B_XC =&V-T\.^I7Z821T$IU[U$:< ,=T%,Y8NMNR#;3VGZX4?N
M>EFP*?F=LHB8:U;G[B>\YF+H^/B*3XOT\T2?/:T2D*PM5%KTZH+<!:P^$,TP
M0VH"%A^/I9/!<HO9D)%WEV+U>VML+V8_+Y[G7H6)HEM.0CTLKVA.'B0=A8^+
M>@I2_QPO+YT-5IM[N"9S.4HY2]6D^2D?=X[X>MT*/^.T.Z[.)QZE O22.NCY
M'_H/MG=0RH4TMFSX3$Z+ZA^^RKO43>86XV(H$R'2[DY& UZ;N/W+=+M?28_!
MJ2'W]7H/DL.YCR_K)XQ6P5[M@J@6."DXA'<7!.^', ]^'BGX.E"0QIZY[_.%
M7F]^)?HV>I^+-;\<RF%#?(?V;X7YGY@_1L2-9HA]IC79( EW#B&U5R=5]X9:
M?K,W-S(R?I5POG]X66^\W6X7U(&>JFK]:OSC8RF@0TQ+?3^EL5V^JB65%Z.U
M^1">PXL*XX0@IM@9>@V-GR)"2[<;=,8AD()$QJ3:1I^V<KO?69=\!R-=-^=Z
M_LI7_'[GC<*&T(0B6+5\%1F.$6S>!0G<W.'EI]R:W;LRKPPY<6W\B-3Z@'S7
M4-.+8=01U"P^+FC\).(@L;$CJ\51.6%;1N<2\T+:XKSSYSZ4DLVB*5,TEOYU
MG'F09G,5L"CW%(4AH.V\Q.'<SWY=5@T_TWN5\Z#?!3:F+T@M'(9469L02PDZ
M%C*.4N-]=Z-5()"3-Y\HG.NP_+\X\+TV3EEGJ, QU0OA#6<""13K_9 N^8,C
MPOF%#@Y?+C^8"M:@[K.>.?1(EO_U5M]3<!LD8@C.%@<"23ZQ3[7?EB$=!DIO
M]8TAWS"G/'Y8J/G(2W('Z1+60L8K;Y["%^P(#?"W0$5V0:Y@#MU7VU!*7$D0
M.9B]/5*>:ETD_BM"Q+T]'5Y[SE;DX*]=T-U<V_F65M\,QBQ.I 8:AZYQH]31
MHCHJF"='&RYX%'KH"!^T&@R\\-YNLN77Z4[%5U_Y_?C][A(_G=2=V@5%WF$U
M[8(6[]%@;,GCNZ >CE0Q-$:.,O8@!$GC;=CPNAVW3G@O8TZ\J<: VE.\G'_C
ME=V;W+T\S^:X_7K6%N)2$N!+=O\*[L[MR:?/'*TZ\BWY]&VR-.0=RAB%AZZE
MKD;N@C;G+NZ"!CMQ3JH$'!Y"/\R!)"LZF1K5T2>_8&HEY''3(]$@6$>MCL>^
MV\[RPX&(KFONW,L0/+R9+0B\I;HY4#&)3)-9"6I3V4]C?[3<BG6"@%GEAV@E
M:R>[4TD121G;Z#8HU1(RB;L.\'_8!=V_,JNF(S%^>@K1S[AL<<(LL]G%O4)B
MQ+5%]G%0UO@(KCJJV1%,?PU<*@,..@;516Y;6\ GFC4]'D<%^!4;/D8H?$V3
M^[V.N<B*0C_"1,X*CAI)(FYUR5Q$<-_P$#6-O2[R[%"6F60 RN5^9/");+]0
M2] 3[(H2J2S8EI6"\\3LB2[X.KC"/*51Y!F1&FD=XWML;FM,BP.@#YI><)CK
M*(RS\ H9*4Y&RB.?-C:4-M*K%;FW2["%N ?]$VVFK%2C@\M&\@V?(]IEZ$W(
M/K_UGCW2D6-WGMU><[[S$*)S\_OC,\_6>+>8!]OH,:SLAF#26[3;J@S>'F'?
MSI7GDD:UGS;>I_CA<\#A2N][BI?J#]&25;BS.,\-N?A7__$>!3H^W.V6[[Y4
M?D7)Z4[J*OG.N:T?:(%<#A'ZU::T8:K[VT.%F5*!4F??WD/ (L'B0Q_C0F08
MRNQ]FPQA"X8B@+8;81J7V"^SM<=K"T?2WIZ<.E^D*GH&=#=-_^TG?9!N#PV;
MB*-:86.-Q%AY-9 X:%5_=.G&.ZL[:?:9F;(EE\%"0PO] K:VBO$],S5A+4;-
M _RQ3,=/F1UHJJVAP+C5+;7:'7:ZVK-SK2T\?MU6@S>B=VS&<;7]*Y.T+;)I
MXH;E+2*TO<1 / ^_A'OXM=K2\T^W!?0-!??HQ(7M*W'9B')G^F%6N($K%4OZ
M4T&+)?/A?,J!M4U7AH'UT%OF%Z7N- _%PWLZK@U\.,EEL,&]>@7$+.', P%6
M-7JQR8K#6DZ%NZ!V&SE:+%V=5<H\0JWJL)N+06E9EB*"VJYED*]_,E(:.29Y
MX$/R4L4XW,4WH@/5-I[ GL"M>>Z"Q-$KC@V<L?XPS.AO[C+5"(ZK^T@8*^!*
M$2?$V'NRN+']<\!1'#-3.0:ZXLEA"G.OCQL"80(J>?^3K5R6;-6)%D3N 8(_
M(/H[)4E=9A4W6N.'^H_HFN7?Z-67!U%Z=$&ON*8'87$X,=S?8WL':_J>WB=8
M@=VSI08&NY_#VL?K;FH@-*92^9Y2[I!UIY^.5Z*^H:EWI1K@)"\H9U1+5L=#
M+Z31;]?5T>3?],E]J#\$KC99"1)*>LOM)==\:(!_J49L)#!)?#!"02CRUBO3
M,KTP@>/[FGL(-OJE3'-J8I3@?OL./8TW-JN"?1>E*C:G6\/T]%1;&SP8_DQN
MZEXH'B>.U%=(J/!(A_GX;MH_GD=IS6=L,<7K"7R9RJF%RS);T<H&)SSPES]^
MW@5-.49MY("K5;#/-:"$DK*/G:81;"ZD"<V@BV47*Q%O/_S:'+SH'D$O8'UB
MAO*_(VI.YO6V#4"GT6*>]@XAKX/K?(;"C.J!09J%!:!,_=@A?VY,^-%9"VF-
MC%-C-MPBG88SWXJW/-D!* ,DFH:A2)+K<6*(7NL,-LGTOA?\\TNU/.6C*BEY
MQ>3I3<5L^(8_'4-5II313 G0N/0NYU8)E$3D,&4++_&2>[KWD'#5_;VSYO).
M*SX+WN?Z4-<&>"E@QY&&,Q_QGE^-63_22R:[J^QG;;\-6@A&O/KV[0*// GW
MW\A[[ZBFOK=?\" @(DJ47H3H%Q05$1L"4H*%)F+$%HH0%:1*$Y$ (:&#*""@
M(* $!*43D::TT*M([PA)J *!A!(.I-TX]\[<6>][[^_.G7=FS5UK_CCGC[-R
M3O9Y]O-\GL]G[WWVX\8!B#A"14PR[16QN0DK4GWUBR/[)'7FE8LW-N>WH5L%
M[<PQS=K'NNA=A3%+.'(=\R*^!PX>S5[VYJ+PZ>Z6G=4F54A7_L+.\W)ZXG[Z
MRT=7SPKWO<Z0_?H%]L6P$,"\6YJJP')U^C?R%ID089&0-_9 ]A-L3P@B$97)
MWMO/T'7T\KUD7U@(?GE W*]D])87[)J=I^)O4X>7H0P8>$MUI%8,?&$/;<VQ
M"OC* 68>#RYBI$ D<8JOM:1Q4K1G0_%/M/K-\"D.H&>F!Y5]@*V_7TJY%XRZ
M0\0W00]4L1J>7GM$6/VXP0% U]@Q>!,-"NIS4Z+*XUT<8'%N"&\IOO.F'<H.
M55XIB[[UZ.YQNE3V+8'ZQ+1C+ +SQ<].DGL$ ?+0#4%Y)O@!$E "[R:><&"E
M85W=I;]?FF_]+=18G);[R7P::EJLM(ZOSDF'A$RQ!:=HMDV+HLV$,G@T7F6*
MY5K[03'(W ^+;YTK\S+A!K0>4Q(AZC(V%:UM]MPWWO3J?7WA (S16_:7VIE/
MW)"GMC)%870OZG=Y9&.;F@2T.7<2[HFKQT$_^UT,8B@PQ:A-+X]]I.(;;G5\
M*(C-:E2&9'@?JW&+ K*S'>DRUP3WAT67O3U^IGB\J3A'OH[')-_I?LI<DF\V
MLB[IHKI'337U>T>[[*Z"[)%@?:M/@;!]6)=8\)A2$SP$<W) #<;C6%%[@:JX
M5EW>E9V;MM)\/NY0;VSR5V'>G,/32@)15'@$]IM2"RSJTHRE30AUW3K>P2-6
MYW?J^&7AF^K:\?SW>)>0?:9B/.L^RZJ,PZ/L-IR00U]VU:N[M/O%)W^[2%)S
M#R;>NJ(O[WL\*)5O\U0KKP;4J/??$L@'LZU-6,$QN*(HB#,(=QS);#W*O-Y1
M1PP6\KA,N3V3625CNAP3$S6')3F 6NSP+@@'V'V& ]#N':UH0NZUF6AV=R<'
MR/N_?&!XR S9]'/Y)@!<-%8J@Y=&/$<H5LF)BYE9'OAO4E=$/4P*YH2/K)4
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M<>&5JZ'SWT&$)VD<)ZPRGH4GX927&Z:=)00ZMGTH)]+ <>O-_Q.[$:=5---
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MK%#<::(,J5Y^9@QKXT$FCN(+_XY^8==D:#B6_SAVX?9]\P>#9&6#A##\/ <
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M''EBH462JP]B6@8WS ^AK:%3'6L$]S7#Z*@&X[NL@>?L*IR^&5(;VVB UO^
MS62*#G.1ZDL?EV]IA!DJM4)>>\5NN(=\:_TS_P!'%5]@O4CBO@=1E1D#RQM8
M<J_!)F]8BZ^GH$U EA_6BSIN6M8-OT3TY !Q)^\-<P#'\2)$(T:F3#[^)H0]
MD+GDZ7\%"0I!\DT*DB9C,Q;P:5+L/A\T#TD+BK'B %%Y%!)D[#:K%BL#NM5#
M'--O&[)-</,F2_#/F@%3U*N+2P736QR@3C<6WSX5!5V[S?Q;3MF%P#JT21_
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MA-M:YY_7C4F*;Q :D6&U8B",9 +?#VI=+>EY[G]O[QM+ [%B]GH%PO;W^_@
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M,^Q_W^<"O7\Z=E2(?+-JVAI[N[3_Z>30^JWOWU^FT,]<UW[=8=1]Z" 2W?O
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MFC.ZA*/>AD;7*E%?PYRIFQ^KY[R>8GVT)X*O"NLZ[#,<"M3M!=_E@^YT!.B
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M-Z6%';);<TMFO:U3'E]N^AW*&9L%K#*%:__AQT"_7 -:<"^6Z(CE[Y!+E%
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M?-0)5"-W/YH/$C?2:%1+]'+B9 H@O+BG9A4HHYXOZR$ZH<75_CORF\+!NS2
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M7N##E5E]!BEP\4VB.A[61P/$D1(^)6JX/J?6]+=!NYSSKMH&)G(AI2]#*C\
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MHLHW<4RHE/LE"E.(X@VBGJ9^[K@=73&\ %DKS//QW]7X)?=,(8\(_XQ\A7^
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MQ+M)!S]1AG2"@< N@;=0"5SM:M]P3$S0"2?[H;./;#?XY7D^UU-QVIPE(9Q
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MJU0KK _Q2.2P6U^SQSQ\B?-ZE%0N8<'UR:F5>[_.AQ8RN$'=5[R8]C^5LM"
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M,,VM[1I1QN::U*-3Z.VK08RXCZBDI8M,.R\CJ8\!;3JV3P:P<],OCY-WX[*
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MC..D9.S'XFB="Q,2E+QPBI>2==6."D[_/[D5ZA)8W_+FCTQP]^9I6A.AN+Z
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MQ;P7E']/4NG'I$#UG_<R/K#A[[0[N@=N=CR,@+)-&8L7SB(>][2^-L@;>GK
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M>>MJL; ;P_1K$?:$B4!HY6#IJN'Y-B%U(:=G7V>M$ZPFV[@5X-HF#1#]DO^
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M?@B?><@Q7TRKF6GQN\PT\T';:M_X#V_OK>@*+#+6ZLSC7L'LX>/MC3DM]:J
MZZRU4BNV(XB'M/XU:>KGZ%./D$YA3W^&H<B#V+\3#Y[%L1-HPQC2?1GV.6AA
MX<\OON@)%>FY=MTG6QQ=K2S&<J0'IVF]=^6N"^X2*I!KKE?*9;(/T]8>#T:M
M4SQ(OU-;P)O\[2I4+S@*W54.8:":9>K,$X)MA$F%(68>95D5U1+O.;*[["YW
M'VODD1<.O2!TF#3(7+NU1V-UI*A:^^HN%0.7$59Q4IW63V2,%F98V@^Z2MY(
M:LP6$5SV3]-8<ZO#&["3:43CQB5%B6$%68FM,PG&'0-6NE]4=869Q[IRIBAW
M658#_L<K@IRA3>,KE*I(X$?? .>_:FP5+_=: EYV2Q17FE/'"IMKSK^-T')^
MVO%!%N2NIRFU8 R()R%B* [4&U )ORPR9%=Q:2CU5["N&WH<G%89RSK]@8BW
M3FL2% )2:-P2_6M6-EO'OPU-3!LVO.:^P2I7><4B]MK4Z"]'ZFDOVCTQ,HY6
MY7($.O"(#=1<I+&E9*.0Y,VP6N59?&B]T$@9A'-Z/T5PYW>\Y\"ICO.O@M(I
M.CU=H,;]  Y4 <64#DB5Z>=EW''79Q!Z86E&>=@XZOEXH=F]2-=BL<Y+3$J_
MKI+?V&48/&7T/($;W10&%F\ B#E-@Y;Z"T.S_=N&:F**W;\Z71^83$XE!8(6
M$D$+HPLLK; (.!?],!; A+Y2>6?3I&+XYI)CO'X+9-^S"Y+7/RQ:S)3GG>+6
MV#OK;7<=HCV#'D=?[</,)E<[MJ055(F31SYQ!KOFZ>U-(#6)%*T=#QZW<1J)
MN5Z/Q+=V6KD%/Y;30H#(UAKG8?FT17[CG)^U:-RWLCKSQZ!XOROF^PU^T:LJ
MJMT!!G1+U #N?Z$*'P;5GI[=!$O%"-T865L/5NW4HZ1%_YA9:TG:&";0NO=&
MBC&-%WZ]'T>]J^4KB@B0AX[&.S%)TE@+*68K-K*';U#6WO-2XV4&F^$14HH+
MZ^\E2LQ/%H?9_;0?6TWZR> _^@/V?73M,)_^*N_42U#UR#DM&-X5I2?=I]J>
MZ:I+OL._%93:8#_I$OY+.$-5.'7T;P&;^?0T^@>A3&>\661"8K@]M^)#Q;(-
M'2\?4T\ A]9+2XH^KAW\>? L[0B$N\X/(^GCHVPN 4@RI0T+TM#.JZ.E..T%
M#5PR_U914Y[R-$@:^U;D)G=]/EA ]= &UX8=ARK7TG^EPK?-ZEFI,\XW3$=J
M$/G^*NVI63^^7"*<8D] >0]G \H!N8VSUUR?R=R;(?X\I?=+-NV5;/?>GY%
M:,-A-GYANEX2,U:6>P1:5GA+;J=RP6B&>VWX7?D*6M)-N";J%IV_'X' @2@=
MR<@RD8=4^6KOQN$S!H4:>65;D]W'9+MCTJJ]EN%:F,;3%7\'ZM:C-ZGBX1"
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M>J+OY4#>9X(92H>?$Z*P)#,9B"6)<[);5KO8>WB'7>Y=^@AK0H1MX\]$Q5[
MC Z?3F#<O,GP]0O$(U!(AE+_NH9(KK-]&U:C B[S>W!0&G2L2'>G]>5> WP\
M;NX(M#;]^9&YKZ0.13SEEE#::O@?-T>Q+XL-U$#>;BKF,(+&3^NO?B-8$:%
M*>!X>7Q2%/>Y1V;C^GIR(\M6-\@WG,J+)(Z&N>(=A7#'F_T1>4"234U%;$_3
M=,MWT'=&.)/*+NX3YBGLV J,DP[L<.$OF7%"S7F63KNK'CS8E\H766]N2T)"
M_4:;X@!)OB;CT'JI4K)"Q%??"JO2Q[M[4+$ZBFY$^(V"TN=[W0$&UR$9>)(I
M#J !K'_U<XY 2Z;#>^!8E%8N8#Q7CRMT%G0?WI&!&?N_DS98^S-^^L54X,M
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MBO0NG:B @("(@'1B P2$B A(C8A*$U!JA) H56H$5)06%)!.I",MTD5$0)J
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M<W@[JDLGQ4:N$]4TKSL75B>%V[ZCJ-:-D<,^0WEC7ZCK^<CH#[7P>&CSG<@
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MT_YXR,P SX)VK8W#V'N.BF25_;-P=.@_NJ=OJ,NGVY3C#@9((LNY9VD52'Y
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MVR"4HTGIA/&>"=OMUT/PK'^%CY[7_/B<VX=""=!:8P;(4(A^*,S[/2T!O2&
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MO=H*+!12N0%Q_X>S%]YR:*DZTK2['T9[I'2RIETW/,]22'N%>J0%E)#2UKZ
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M-!5Y"K4X&M"_E63)7P'K3Q$7?E$1(<S(8$2DEWC76VJ4/!.[5!'6<SLOFTU
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M@B \T-SP 4B=70>8(]2/L$G6:/BUB5;V=Q*^X"=".0&(R1T8\P>RENJB1B"
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M$;_SY:D]^8E"KW[&_KD6SRH[TM8!H"@B$<+ ,&&%:CEO<61RK6F7]-'*92A
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M/3*(8D9]2K8@G(V:1?-2K>3AO$L+/+;(D=>M3S>SMH3W]!H_050#-ZP+M;1
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M,Y@!!=6IFM&%2%/E,["SR^>4+W9(M7Q>B?&W.6A_6(-7J?,@<I.QL@VA6F'
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M[#I5L1'+7/_HS *:!R%K.[7*&!_V/.CREH <VM91"VX=M!>(BZB]3T_\7KI
MF0/YR90VJO*DJ@/GK,,K""7-$SKCVO0 M7"?U.DG]P-"37&@<I"Z<0MW2=/X
M[*:_@TY+,\T8Y']5/!BO_COD:R<:G'X)F:Y0!K9XV\;LL,QM!8_[XE%A3![O
MMD<#B*=VGJBW69-W70]FO<N*S?CGJVQFG#96UW5L Q_O23H7BCNI?)DA%48=
M(H'Q4VA21&M*,#I@6T=GPEEHY85]2#??K.?[\&^77MWEJ^5,IKUPSY]:+?3=
MYS98M8RKCIZRG\_FU8,78T[[<=".HSI:EU [1,^_64K<DX)-%8H#U4== F$^
M4 8B^DX>6PAY>X8%P)R_-W=<^ =: 55%%_FE3)>.M+( +@DVB1QRRY?T&RWW
MMEP<37*0VJ+30 \KKBH9Z25+]N5.[CS Z"0-?I*HOEN.3-I<\GN@B:@4*Z(9
M4!\836N3VB(OP6I*9-N$0:[IZBB.[5P=VC_4TL8&%/XF]19!^BHGZ+6CN6GI
M]*%63J8:7)[QT1S>F&"_++JG<FMX_\^YUD]^!NH9&76>_1!74,BY>!'SA*KB
MP,NKE%7.R\AJ17!_K6(31@@IZ%V6L6PMU^<BBJH^897E#J9RQ$QGOQZL)^2M
M*CLC/A;>Y'5$W(*_G>I[,F$],75]]2TAS<_V5=-V?D&H[6<)]OB,S[B7 J[^
M4_*!3?U4&RN[[%(=7)GH4M#)KB:7XXJ[/HNU'GC2D-MKBH>M%\/K9H$QKVV/
MWAA84P_.BVKJ?(E:NL?VI08V.R1_A>#G*R#;ERU1,WTHZI /9O1M*'V?;K+W
M"3-^&[Y(!^^!G?HL48V0L =D$_Q4%"%OS4)7]Z%"C'E9^E/TJ<ZHT0NTG\M3
MU<?)]L<,4H.&4OK2R'&?#).Z)#+" _X_3^[&D*XZ;6[5H\XC/'W9;,)Y1%70
M;5;PC>NQMCRKC!?NCF=2Y?7L?QPX1?S,T?.X[$ N 4.55D_$8WA6]E40,C5I
M9;2.(JY,HSO@3O?JDGGRI^<U6X0>^EF[&C?21K.Z8%^= ,I^<F7XEFE$]>3]
MAS'O3V<JM-S]X?_X"%1^_[(O38!^<A K7EU%U<.K1!2\YS>SB]<)*ZV^6,H3
M_4 DY1K.%O7.Q^\7C+,1QEF8YUXXKBH=N"W)%A++[##K3HK&X;%C7OHUPY=3
MQMM,1W)J!X13HWK?WFA]IC=FUE>R6JFVNKX2/34EI>+].4 DX&B"B)O6%R->
M+@"8 50,$_[7]ZBBF:.X34<6P(=:LZIA 7W/:\/_4XY4[L F"Z!SPYFZ\2U@
MBCR,S>PKAO8/PS$XDB9J3P'&BQH=@C#C)DR6^/[GX>9_Y\.G8=+KT7/:O+PB
M/W=\1:%[6.J'L1$D\* D@W? 8?)8P5)//.JEZ[OT@Z3%!FFO9F58\)I<M\VP
M#DIRH9OKODL:WP_] ^TV2GQ[D_ B<#GLW0XV;)ICA\C1- P?YR_OG/A0U/Q>
M:*8T4_':G9F#/B/UTZ06S'D6L/3$E0ZJ8(?SQ'UUC>C<BU*FX5_I/02?\<[J
MT3W+3I"XF?*3_LES^02^;<6UX*_T)_WR(!X8J0?:OY/??,.O:D+_U4_=GM*G
MLN)*D]/]WR'XB+\E 7H_3U/![&#?)K6\,>HU@XI"<CLRKZ6VI-SLSZP+F)0>
M_:-Y?;-P/K2][7S[JG6(_8>G=?GJ#UI==:^G[5CQ*'W[X%@WI=KG9D5T"6E$
M>%&WLG+D70,PCD]W4Q_7M-,!&?IR)J5[N"QY#$N_1-8-!-7T:CWCV+I+7UTY
M+K4U783/)N-'.CJ0A?NHIT8(>7BW^#Y8SHPYC0$A^[\Y5MF'E4'5S-=;'J)I
M\YW(Q'&'Z0K.QI./9))G+4S?$U^[JMYF 74Q)D73#L,IGXZ<Z#1UP:O9IM]8
M07%8NN22Q/'#WP2(2,Y>4>FAD+0SE0N\_&HY<$CXI\QE$18@=_''!Z((PP >
M+YB%>$7UPQZ@@"XLQ2]^IKUT1%W1]%1&UN8X-BDH1V6S)4#NVZ&_NX%B@RA;
M3)!YK&B-\,F?D"VB*IL0BA4;F##\Z\Y-?_,5&]XVN_NK/)%T&T+I,T?;)W<Z
MQJ$+#>@?7ML8DV$+(TM^XIJ(-C96.!<MD==(BZWP<PX2.'>EYPZ&R.-+D(<V
M]--46L9-?M?6V]A9L!?MWF <\N=)^M)^CA#\R&7$8/)2T\00G$]\TX&9.[!M
MTMF=@QP2 ON15NIXR5= >W:21SO8EC1@ ??R!0B[Q'.?Q1@6^+.I^1D[RD9+
M'?L'1$*W,VG*L)D"3A;@*KHWJEZ6W'),)GG/<O\-.RA'6$N%UF- .RAN2P%,
MZ7(L(^-^6=N'U9@;LG<V5L=K[H$G0,W[KUIK2? 69=_H'-ZW;"#B'^$C-U%:
M2=-12!YJ:I/^WR;+"OEYXWLW(E:?Y F\4DT;$U23R@0EVM26*7WQGK3N5I,I
M[OYHU*KG,>_@Y"JGP99Z>WCT/B<U?BN"!40;OD).(7DJ]$L<D%>B'G2<F.?"
MT-;K^#-P=Y@M#2Q BM:3N#]IM8Y,0?9,ERW$DK%MLDLI'OPM9<,45Y_67?ND
M7X7O*^=M7G\\0)=:VJ>S+1?@B>IP'X*L<4"8Z  <='6+O@J"G8B@> PG00?M
M!CPE7NOX!O/J61];^;MA<=)[6'-\Y:+/C6[]Y+L#B[]IMW]N6Z(D<9KZ\=%=
MR><["28WGI.>IR_>W/NF:(,>V.IV$[K:NZ.BTJ6VC>6DEUQ[8.GCYS3D6+L3
MJ1Q5>E?958O>L,,W N53=J\IAYY$7)1L[.M+YZO8%[0(>?!)' 7KK\*><.+/
M3ES\<"U;8:RY^H D:G][GO2IK36D]\=FD&_-'Q2(.I)M9J:1.U%XXY+VR,ZN
M_#*AY(F>WG<O:&Q@P^"B^X)CUZ]*<C1&BB\VJ^+IN"%[>0U'\I>G]3*&!F%K
MYY]G_R@-6+)Y89N JO@\[,'D'1#OV8<DP7;/AY-Q'C1L\VZ1M1H&SWS^32F[
MV(O)K20-W3^;[>:B<E4)G"-!4PQS?JL3=MV?>>Y\SR;3P_<V+D1G\;.O&38<
M-)_?]_?(I@A_XI>6J81%1MYCZ [34\1:]MOSB1M)D[6"D$:TK7HX,R6@V6"%
MN/JE5M,@T+3D)]#FR6-?,0.:<QR]''*W?8<O0M<E:C"APJ9/DS?\7TDR*8P?
MQ/J:6UY+)'D3M?,ULJ>HZ>M=&]>8#MDD+MY_;-6GAGKS\IU%W!]61Y-0H7MI
MGGP]*'NGZ6WN".8>"U@U)GYO3R(7_A9Z\OG6 7_8:[-?QU7DNK\H2A/Z1'GU
MS%+^=]='P?P(5?:ZP=#5R97$8^*-OI,@ Q*1/+@NYRUO,6:CT#\)%;XBSBFU
M((M_/9D@5$ZQ0JE4X1K W(AGU#[RYFHC;7Y(5=0KG^H_?A^4JGIS14"$>S9M
MY?M;?T^5HQ=CX473I,>NXYN0\<"933,GKX=3$%(_U*% ZJ+:N"VWU;MI[T,*
MRLJ5@&POYP]D+^K"&LH>%SAUA1J8O[S+7Q0='JN:]":RX%KZL[YFA:39P$NJ
M^T:@,<SL>BKM$?UR/QV5M>QEKI9('VA,2HXNNO(A^T6'J/=<L5,W9"8'LFF+
MXX6L!B<SDR=&5-A(G\X&7E$2FH%<@>R;B )^[S01^*]L>J8)L;?B,:P9P"+%
MS!I\'6Y-]'!_JQ$5T9+LC#UU^U*T)):NFDEQ8K/D3#OV3-&FF;?N@!\-0R+H
M3S.H'$W*R6$UT/R)%^-B:<?25_:)%.B94W/[B\"!#A'@V)6:9#R6^),$G>6,
MDF,!Q[PA;4E5TV'8YI#Q5A65#^.PZPJQ3/OWAD^YT>+E_[HW9$AVJ20[S<(;
M(6,#=VM\M3T[(WR)=S[_*NU1"C@XXVXL^B!+JG?=8/0)IQT!1;TVW<B F/^L
M).T&(HP(SM>'<+Y?1?0L6DUN3^5U63C,"C2"G\*AR"Y(!;H)/M[8NL$\35M-
MM7+\!5'8NC=DPVVM(?3F_8W"7\MQ1^9L(Z-&18YO@X,@1^BBI%OUREZ!],M9
M#3D.9]V"+AN^30:A4\PL"JJ%'D > P?K3'^RY\+/$7F:45'F&LD.;)[. HWI
MY\V$4PU[]96$'<R:H!ZQ&=?KBX-N')I]*\YQT%]]$INV QN?[61\W^[Q-X<%
M0\J?^<G08(8C+* ,49*+7)X[^L]F*O).8-IJUVRTTK[@!\DD&X!#)'UH;Y9M
M/H(!&4N)9WQ!JO[F&JX*R66$9CU^VUTQ0WN]\JWE&80?8( RV/0JA%&D?@'9
MQ>]<QE09J>OP?9--E$N]';F;+'GJQ#7;C,6HWT;N1W][8\]2V=8\_(QZ@BS>
M<OJ%^Y03DCN)<)?W'%*X-%K Q.;5@3BE9T=!!42AK"><8QXFT0@!1@'] 'FZ
M#2E#0@=?=\T=5I62TLR+2#7@?9ID'+9F@WSZ$X0WJC&@/:7+D4S:>*EZ12M>
M_%[ONQ-2(CK5?EK<_B=Z7"?9Z\,G">[[<XO]_FK?P_= ]6"2(38 ? 8IZ5!W
MJ"^;?&)JQ<MM='1%UN&^N647L9SO5:O1H1C9OKP+'9<.0BOIKQE9=8+(W_P'
M'>O4R*)UT:7V:\,Z'UW6PU:N!+MW'=&R$-#2TOX,TLVH$^S_>P87D)>V*ER'
MX*_V%S4!\B=JKYKSK!]RK_FPG^V'GND1>,'V8WE; IC+D>*S_MXGW8X=RS.T
MYP3W!(^JGGY[Z/2=*_X*2U@^<C+Q+6FK'B,D)Q.D7/3[<[KL, +]79/OHS<H
MQ51L^=:[7Y]&RI\<T/0NCJ=9(U2'6< +W^F BA'E=^1NMM<IG"V]\L<YZ)';
M]5?(>Q AR9XVW#BV'E[J4H 7A+0FGR-94C,<_AD(3OORZ996GY3K)7I-#WAU
M^8Y0DR8"10YD'L\FR> Y(XIK%$472@FU]WX;'/Z3+E 6[7TIYJ+L1Y$D>1N5
MM6L'#GF>QYHRTG!L3PUF >4GLSN]!:QNK1B'B53U;1 4=K]=OOWG":GS$Z+=
M[.ZE,\=: %_-_]M7Z__?/^ 8%D R5]/<1D7#CV_,:L;I6%U=-'2)-%Y\Q;E9
MR.9; 1.(^T8<3+Z-$&\V__U[GJC%F*T,SEX1P5 BJ(J\>=^U*'?-SC^[H1AX
M*9PAAJ:\H9KJH0A_O$T^LX /\C@6P'T'G(PBT=!AF&T8XA8+0*U#J%_W810N
M]N#AWEA*.?7G5V^H):D8G6%N_F)S1<<MMT-*1;GSS&&5CO/-0<R#=:4L(.0-
MU8P%W)]MQ%#%*ED 0<J^<?HXXMR,\SV=C5-4G?N]V&>1C;O\+AC>,[)GCNFW
M?YZ]=-'W.+"2]U\4]MQR';=@ZDX0O!@1YFAF_ /X150##PN8FT:P;64KA5J6
MDZ= B-)L=DDDJS!;BJ LX$$6-AHR\YX%;+K6R;. DD3<=@K;PT]CNUD 55KQ
M_6(O4L#[>/^P5KC5O<T5,<^9L$8M4Q"6@RR_?Q>>BB.9H[G^.&%.TCF\G 1T
M1(.)@X7ALHCOL2&0T"-5$KZ/49.N]GLJS".>2F_]&&7TGK:4 PWM,WU0\T4Y
M=3PC$>("BX"?4#]G1;6HG^+Z-E)L5SVU/_QY0ZRIQ/!ZO>$9X&+<ZY2-<IP
M<@PC^+N3!9QQ2A<:N(BH8/(,/*M8'>W@+P"W:L#9[]$@B!!!0&BJU'?%Q$9K
MJ]4H]T9-@83S5XZK_0"8\KOM3Y0!]<15Y;+\3D9&:L)V[;Q=Y;/XB2[\7+XH
M+3\;#*-"OE!3[=G1CT2-)41\>5WTHDYLI%C$N5LA6_T$SY^DE\SRE7]=@_9
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M\?0OHH7NS26=WX1=]7,S%OV=EM\1V$*-J5ZVF@?ZOKA'J,0'2Q-,"7?",@]
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MM3/N#8G/["*FQY3H246;^G$Z?M4GC=9GG+I_GCPQ&NI,_0Z[:I#+: +92IG
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M!RCJP2^N-$$#$\B6;$&=7 O0Y7<G\]OU_CH]^+111^;\)(9V+4^ZY(T6SQ-
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MJGH$_[ISQD K*HN[7*PLT*U7?><-RI-WLT#C]'H6Y3?+K]IK69J?Y#Q3OY>
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M)0.)=(ZT#ZXN\!- RCM+K=;758U'R:97;TI< @6S^^U9[=DOB78%["FUG62
M/KI.T)/OTTA,Q((9H+YS0"$#=,<9<G!LFV7?W4V Z@ZSF%-/I4OXA$-9:1?9
M$UKL9=!2$_;V@BJ7*7?%X]]=ABB:/YH#=TY,3"^]X>OAPZ[.ZA'C9P-B]M=+
MR+Z$P^FM>(>2!M&&,V[RJ6M>)@)<LM>"CE\<"ZW$3?;C-XB5:!H_*:&0M$K0
M1;V%*1(&$7D>JFO>0]VM"5S/Q=(C(G1V$__>NI"8;*R!^&9\FH2.KWNB,\CO
M^MNA1<3N4M*/8RM*(7D>;L*6\Y2J"HHF2?<S:93B!D3,9AQ;WBCQ;7[P>GYZ
M\NO*@.!>>N#E;#ZV4,485<2W&0F@D E7RKF('I[[8'[8I)J7S\;MIY<J!> ]
M>FPF'>21UH?))UES@!(2NH,!DC#D*X=9])R[XO0CONRD8^6"PB79!5>QV\7E
M\V=DDVE8IIFB"=1VS1P;GQ^G'Z7917$.Y38VC#M9624ENG!_#HP 4STQ3FL8
M?"E8O$V%_@,I3A>%3706'/_IWR9C-5^YGN5CW!_ULB(J7B7+*G;$P=&>O2P-
MP$],0SG:- '(7&F\2HL=OO+!E-/(NIUC2YZ,_^>L'*F^5SUSS0U\LP,@Q"TF
M"6 >H'\U@(GJ(MP,D"AP82C>Z,>[ZXYU)R')5H^,X1<;7'/*5KL1"8A>2#TN
M$>.+2Q3TQ7H4>^__>7EBZOZ^=G9DPK@Y6[$R/B#MR]W*F. /'(2_"I?1HD2:
M^)+?UCH7;=YO39INX54KH%7UW2C_;F*SWW,GD_^0\UG0Q!^FTGEUYN6Y:0"M
MA'Y)2S_X*;W)-?]B9+/'EGRFK-'WH&>#!Z$R=2R+$))=JV"7F_S?3BS =4M2
M>E&S13*Z<)BX74%Y5B2R:ZVL<DW4]C+Q+N]Y>?>2AQB:IBAQD0$RFQED@+BL
M<'3S*F=*&P/TM FNP "A&2!>II#<1#0,L2_@_M-'T2/JB>?<:HO@1J2>UP2#
M]C(@8=2JOG$,+7)1MF#AQ,W<\UV'IEYI](%>;0L/,V4P!TRZXBL9;4.9 !@@
MKP@N%Z??3O>#K([&GU["9A^Y9A#'*3R";-?=4(-X0;#4.:6U@_+OJ[XJZ(B2
MR-X71WF>RC[L]]7\&ETDS.0?MD],!9H'-A@@%QWP@7Y)*)ADUW\*XP6>$L5/
M$%E+38<G;;3#'U8_"O[#VG#>YD-NK2:?=QHH#$JZT>JY2\!U0>,8H-JV)P:J
MBT_"'':,K/I7A0Q2-?2EQUA#YY&CLKY_.Q:^=U+-2\!XHR>IET9O.[L:V'QL
MJ&N(-5X+4L"^/TD!L;B]H,IJ(L:0)-N,%)2D^./%!-I)U*]F-OP?30<QN6RM
MI3OI$7+C>)D=9A':SJP@YI<1[,@)#LSV)UOVU?_O%R/\_Q\R9M2+]&\87LQ]
M'JZIJ^3Q] DMIP=4F1(O]9P(W\]5O2!2H/&MP[!EMPBJ(;)=WY@/,4!7RNAJ
M5B@HJ0*2#UDW%*-=/@SZ9L6YFYJ>#Z*966Z?:"O\?V@<F$=)/LBC\5#MEB1N
MI<U51$VEJ&HN34^E2!:S<G()Z<L&G[$1QL'DVO<C.C?8EV;$1T1,1[9?7EJK
MO.4U0]"VK<A=#SPWOO!?[\)Z=(A#3I:"3F]390[ZJ;8C<'NR]OX*UE?F6&M3
M9G\(.+%JY*3GW6";//G@TPS0%]V,^U2)9- F9'*#61V'4,\LY4D@8T.O^^C,
MX.I7]*Z)5ZU7C\(3&Z/?']H::0W^+TZ(?4"+P.[W]Q2(C!M"RI7;7K^?'' /
MKFX8U[C\6(KUUVR&3H49"+:XMD ]"6.E.%:/$PTY Y !O-7RUZ:Y5VOU5<5N
M?_HZEZ#3#F=*;%PP30H@DKFODTM35,,J7H?832X:2KSL%>.(%3H=^Z4C>3\N
M&02@Z=)\5$,&:$BO"PR<19+0'^@R@.AEP!V?)MB1+V$EDU6,+7G]?E#I.4%'
M3/S!XDRSQ#\_.OK(&/(N*N%A*?$P>X\/,4QN#O; O=DQ=^^1Y(B&!'U#K&=X
MI/5/,JBB?#DW?_QE6.F*R+#;KVG3(1O_<^SI#K_N/'M*,F&+XX'?(=@ \GI?
M(/RPNE4[$X*TS,_Y+?GA[0.S6\/IP>=QDI?>["MG^-E/:=NRJY.F9E$)"'[8
MN<Z.&?X1V6%M95E3W8]>XD:.3_H\E;*[LGW+_NG<VR#B')R'-$$4P'/2) FC
MB-!3B\D$[P]J:9\ONQL\<TR\.9W0^SX>V\KU3P-D?_#WDCEP KAF]TF84<27
MAOS7;85EV.CD\+8VG['>5FB,!?MI?71T48RQVT$A!O\*Q8[T9A;KE@3K^[UV
M0W S?9ZP<F]13M9I?HT7-X>'TR%))Q^PZRPA:QO7RDFK%+>A!]H;K#X\ 4SD
M--R/R(Z<B'!^&)##&MN'?7-2GNS6^L_SWV81#QK#:\]_7ZHI/N[]0^R01F:4
M!/#C[\K^VEZ(88YE*2SV;59*K?2=/?EY"KK.^PU?)ER.28!5 !\>)>Q-/SZJ
M?1"DHWIZ77G*,^]FN)W\ ^E@C:]?I?ZCN:^,]!SJ%VZVMPN2_E"]N_7NA!U2
M;/F8LY6OBMZ'S".QC1;/R?&#4*==B7_>S,#WJLV(_G?M&^FC+I4A AO'.33]
MS!TWT*&J%0UU51?*@][<#N[*W\H 0B%K6PS0>1P_$C_+ '6TC3$SO;,#51L0
M U<BW5)_S%FL5HY_]&3V'*(,YSWS8>&'PU9FKVRZ":NT\I^*#$"N\8LES>:@
MK 96) G6BAPN'AM=PZVO:XB',U-T:P,:;'=>:H-9=R:V20..LSP&'73AD3?#
MH:I&AI^C#((>VUZUE-^TE,^^:JF4OU3VK^^.^K]S&-\\2$7>00'W; 1A&TQC
M_&B*?FP0N&R8\9L!NG>0LC;C_&T:OJ>W.-!KUH-#&$50G@+J3$O/0[K8#>&#
M-$ ^0AI/)*L3U6L.2OLFM8,7^V=>UB[,;? V$9.WL2=9OV(\U&,@I.](-FV;
M1-04CI3- 'E:A2A1\G[1^_]$UK9\VJ3U]NC-;4C-&8:B]0Z:D'<8(,"?&WJ$
M^?HYT;3C.%)ZZ]0Z_1LU FM(YF" "H;]I^:IBQ%^(3NJ0BSF3(-2,ZYM]5K.
MKB&9 ;)I;O1U?ADYI!UBVE\__!]$9;2*5Q=A2H.2%ZDQ+8!F35(G_&DBE:];
MT.)/:)U#ZY]L%/B>L; (5D[<SS_@+HJ!&,,YF>E6Z!_2VU"@!BR2KSL U1%^
M=CDVG[;8@OWU.55JOJZ3D1\+C3\1VOZ0O6+@D#DDZXH;W[CVYR@TSXJ(_QWC
M GX5A*7KYQM'_;_TC&C4Q9B?47[#_,MGZS" 0EZ7S2.WXV/R@![59%6&=RB@
MA$?AZ<>O-8=[CFP))>><6>L6)%5-63)UX180Y?21K%A(AA!$,&2;WG/O7AH]
M+L!4!F@LIY)KW@Y_\;@[(*F+E[!N"7P?B6YBU@N'#](@G@8,T*36K,=$[#K\
MKJ&'9YBX.O$!I-:XPW_<[/RP_];;WWJG_.:#%[%,1S6I3A%G@!)<@,(Y!D@,
MV>'/''(]FD(D W2!WD=5F@PQL-JE[>D=K$7_7$;=WW^?#/I!ELEB?H@]L=Y:
M?6#3>,I7M?%E8_C DGVXIE;JHKCP%F8-0A5#=DK 0KHE[&F*8%(> ^0_W1FV
MB/2,3NS[E?HY:-'RLT'MJ^1]3R;!MS- ?LC)]"U*)>!5 ESM[\D!))Q5W8QL
M5T0HGLMO.8\.1SJ;#M\&G]6- #>-OLJ ,4?Q# ,T^_TA W0@95["A"L-14-9
MT/0SH Q0<=(8AH3*83K%U>U-IL;S3=KC%0;7)D@/>[_L(D[E]6@YNPP&ACD2
MK3^?S=H]_.M>CMCR+N;TSO[)-[Q6!%0'BHMVGV1>/ L6]^%?=>+9C%5M>5M^
MB_WTTLI%N?)YS4PS1"201^<8B&!2'K]5.4T=8'K@8-W?QR17/;?F7.;5L;)9
M>GP :!E:RA2]/^P)3$^9=@[]Q-"$MYAL,2=,P1S*O)?0,3T3:1YYB!#AC]EM
M1P^K/T9RP55)]E^P$8\,)=]V%WOK<IG>(F=__W[5<3K=<3I#X8G\A+,9"*Y'
M=6/"6!-%*0>^S1AG$-QAUO3.P_F3:HF4FG>JN+,Y1(V=Z=$ L54W)@)X;<88
MH*6V:>98:>-HKZ%E8[;L"X,T?<AU!JB(&L$<MU'D9EAT.54&,2!(_X;D4C,4
M#R+T&=[;7 FY#\%J.DI>*QS1V:2(WUM>6#3 I)1*49\)L6PBUYJH',A.'5HP
M>;$+"ER%S#*EZ=$[@T?T 29@U"?A4\]0QEX%5')CP+3+(C.A+QZ@,9ZJ$$H=
M8* 7IZX3L,;]M#6.WG^3JH1M&U"Y%P=O7?X<&G B>C9M;U',>(KIFKS6PJ@J
MRPQ0C7J'.<G_7343;3S3W33LX_4/?O1O#^0#WQ?WSU O%)TXF/NJE$KXI([%
M4?B9('X'E.(#Q)$=00P01R]-3N-]= I5B8CTZ2*X;&S-38Z"PUJC*U:Y_O6]
M$O[G!2WN[ZH?8A0CUB:#F+"?X2=!TNO]^:RS?WQQ7J;DG#97R-7(^3JGXLVZ
M0TFF(<?;I)'M9G"M=X/EQA5H-[,'[RS2^QVK/V7&+DLT>1I_$22Z/::R(MLM
M#5T)F">W<)QM&H3%6RVO*[4/[CO<FH&MF\BM[7* V+)U$T#2OZ4695FW]Y-/
MRX5QY'W;*MY"-GUZ0"L[Y'3RG95VH-KR/8>)GU\/Q8#-+(3(/SX79=V#WKAM
M!N^D1B]!I74V$MLD4_"&$T.KR^]%,+IZ'YTU&C9?!8]JQND1\2'GP79V;L[4
M,[^ 52N ;U8RX$F&88%^^L^$L@FM7NT$:V)J\['2A:FAB3*M]^5WOYQ<L<3;
MLI:],S,,J5IZZRCZ4TS ANENTI63WJG(/9-7'E-F38;=?LCOS>)=E)GY)OL\
M:[DVJ,X^ S'>=F:LY3A5DW9I@F90WIJ +EW:LO:-NC\'USQZ)W8'G<M,YRR,
M%"V*W,C4IF.+Y(ED=9JU&BKL;BX:/IMZ?.1N>R"[:\6>+?N2JK#4A(!SE<>S
M$S)57ZYU:X>H+4W?@][4%P+MG]([.B>G70>RNR0F\TC"Z1\;/OR?&,IS$.#D
M+C%C#CPI:DT2[GWDIUVQ./&N-7W^?I#!8_ZDRT1L?\9.Y2NJ_>2SO;^G*[XR
M0)FB[1O[>S^1VY).H*TR)/X#N,X/&_HP&7YN9&%TWN2$JUI&^-VP'5XP6]2?
MUEZ*+1/^C;]HU\CU&?$()6^1-J&Q>LY<;+_]QV=MWT8U.GI/0S2R83R?4C,Y
MI'U7D+_\6*FR<'EVIJ!Q[*#I\=!7$)(C\K&$:"Q=&:;5O2_\R,F5@O'1Q!T\
M,_55&6HF/HVE>;@<BB(Z@0ZRBMH,R4I$M#_I(D6$)-HU'<1;3XCVLJB+^_;#
M0G9FYGG";KBTD+^7.\!["9U*.T[6HFP<E&V_S  #>G8MU:1-@X-\:4.G2>>^
MNLUJ^?C07X8>*<$:^:"#C"*,/N8V!CA9FF(L1[/.F>7K,;A4V0)M<U#9@=2F
M.,I_2C$@EB:!*A2%23=X[<4&=;H0([@&!J@'D@RI5]UMYXO##N3%%]6U19]<
MT?,\6=+\*15\]L4]GH4R#P_;^)#;,@ (_%YX:Y'83Y[KAM2BOI3#[^")NE,W
MQ^WM&NM$=@-;RJMW'QC8QF?%0@5^ Z44\L%SPZA"DXKH6L*/%V75(5[N_@<E
M;._?!I@_N^LHZR<0%ZB_$:>\@IJBSN'2V@3H?>&(<Z1'6S"+KD:]!B[RM+.9
M=D/_Z>IL)4OAO$ YMKE&(9891!=*RM"&>A'..MKB12">PUF-5ZFK^<]@QT6?
M'.I5_&G@DO-U%_T0_1AQ!#&"%#!T93JR27)BMZH]5-1-_V/-SY*&GX=?<587
MJBZ 3]F:!\7^C-S(WPNA1!W48GS16&>+GS0^?-1G5V@7P:;^-U"T@AV?#EV]
M4&AZFZ/K=NT1@R1/^I+8  C1,PQ-9PH,QC\ *TEY<%"J/9B DM!Q#%N5?&V.
M[;=M&#.]9LAI<-(J2<FLSU9*EU,VQIQE>0=)$TJD+#$%UB-:T(*T&'^W,:=G
M?S[@W/2T;+8!=Y@!?" Q(=SO,7ML73;?H1CCR2*,HB'WW,84>C8O+F=.I$D.
MJ&U'@\8"0HVL*[__&4KKN?GDAN'% (BZ2=\UY58FB%T1$S@1B#<FN4!MQ%@6
M5DJ-N%H](K*"!7]T=E[+_%[QJELBIUV.C1 #N5Q6A-%"!FQ,,4 $OL=M&J7M
MR'CH$G:S1:3Q85IK\V_7_C!=7><O'[C*.]\YLRU\U$@&4:THC<#G"AK'04$+
M=*Z2B]OYM?VE.'W99+*5:7>)J4&,[+;[3$LOG7.6>H/Y^C\"/@0(/U#5;UW3
M,EH/K3;-]_-+NO[-ON_HP ^'B0Y(W8-J*A2N<% 0-B YIY1#0++!\L]6%E <
M"POFK%\U?XU]FWI(\[J8?_^2R2H12KJ$$K3"#T[:$ H^'\F+K'+QP7[(T_#)
MAULK=(]6OA=.U@%E?S_/&C\> [E2AO[ZFH_ 1_Q)=00RND0+Q#Y]!I#O?$(B
MO:[FRH]DBQA^,'F;,9!5G9H[M_S*WI$JA)A"B==M8./48U'BZPFU08:[$DBL
MVHDG#_RJBM/F;>\EL9S0_7YOGO9E48AE_YD9P@G9Z0V_"T@SR09DDX 2H+EA
M,9U[8>AJ\QR?\6IPS>\X505-BV.-7]V,>B$=/[<3:4*?*6\FD)[(N'-A@X]T
M=$9HT,H52U^/P#OI[E*7]+Y3Y6]=TZB.9)>Y_8:O:@G]F@&Z/7@,?HD\L;;P
M!OA,2&C&SK2B:W%3ZW4)4U_KE/R4&^1M(PYO:5I8LI=$"_S+IP?_'?]=(&3_
MGE"&+!P/9( ^%S- \NBI%9HA,T%?3YNY,U'#0K7N2A'B[WYK*9\V?./T,9LA
M+M!!![39^!G@S/RU=F/*; !Q,1*]I%&2-C.@YR)SX?&AA9O!@'2_J5C!?,X,
MYB8:&0"99("NUF9'&I_VYJTNO_OQ^[V0V*&3;#E$: Y"X^??P\&)R'83V9Q.
MBA8Z<4?ZPLSTE9CUC"L-7/(O@#VKT[6WM]5$C998US# Z41B!2$C_@P,.8N+
MJ>?4=HURJ:8/8\:(Z6JJQ!>3<NER/\5?@%7T04?=]=$@IK..NP8/&*-+H-,]
MR;\#85@'2)VH27XD?3A;C^C[^C?36'D!G\>@) <P%PY0I[PC9:31?TQ(N-)S
M_(9%KR_LC8\: [6CZ\\':4<GEB@OJ8%P40Q@!L[@R]#VUMZH?C+3XUPGFM57
MJRAX)&)C4(QU^T^,\;6_U[[0IXR5@12"D=4L7U<*];6S2TUC5)KR]1:#*O&[
M9W-G/%>^OXG[$!SX@1-OWRO*M%IJ&#\,%N+<"&#("0$)#]F"?Z@<'K%4+:F:
MU*VL,9>^IM4H_[7K'EI?WCZ**10MPSKJDO1))P:H2]+(>'[IG%%5<=ETGY!'
M\A[UD1WHW.<'=X7"?OFVDD4[T9-:E#_ Z =GF%;7PXW.  GHD<_9SJL.LZ,;
M?]AYY9(M?BM 8&53KP13_\2HPN4/THW/P<6 IA)8!EZOFP?<.\,=EAP9)O"^
MR''&XM-&G(.()6N@,<GP 1N_[]]NK+7Y,Z7%M*,DMO&(/ G_[_E[QR0M)_EH
M49<N+USZ.@ 7)&_-*B7_W<(D6N? ] CF4S<QN9"&BR&%5X<&.6ZQ>GP__APT
M'>MYE 5O/PDAW:I\2.V&U%BTO_:Z$;_6G%N(#(@(X=6HL:\.#^OU.^;-6O2S
MOM44V2YN7J2^GE!XD,9"A;Z:>8"LR_1"A(RFUV]NK/F0+LXI$5^3)NQ)3R''
M'K0HD:;,V[1<+],]NO(:LT]G/KY8'OC^?>!WX8BCAVS EU=PFX\UF"3FC#S0
M5_!CYH+@&-_D5D^I%$I0CY[=?AY\ LXWWB:'Z$(VAK\F_8 *#I8Y]%5B?9R>
MU87HU[4U?II<Z%NHECWC>#-VI53N[ \$TT+'-=#'"Y1)BM6%-#F2>6E(\>_[
MX2>HMUJJ,]]N6LC5!3E7\+TP^=5='6=B-ZHS"ZU/ZJ4)?[[" %4G=N+V3X]7
M(=NA+1KE,#U*%0F3YC:],++#H_83_RSQJV?CL]UNE(O8((TWYMP&+[+]',(
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MG/B)%FZ_?%B(91')VL8"4Z*$D5P08B3=S&9/U.?O^?;N\KN:R$'+>X:UB)A
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MP)I[UFH-#]FF5E0;<X[.!54M&Y^9Y#R4S'SG<0[5(@ ]_6!>R"_6/A":QH,
M#+)!_J<#[(CS+E"T,3)AW3)MC6U*-WTA]$-"8\PHS9_NXY"1X;S] 8>S,TZL
MJNX&/IX-A!;5Q();:I3!QA$Y)0[&JJ"*R<W$%^LU9QLCQC<Z0%LA[HCL]8(,
M9$:7'UYTW.-(^I5HEGZ6ZNG]]VP>)=>>1,L?V6<&SG::1%8A3-;Z2J*@YCP]
M6@IU(65/C[4]'><6O[>$N(]SAX<;  Q;'9Q,91*3YO8;_IX/8\8GO'W6=ST]
M=+[$2^9-B7V)!\2^D@O$*-0#IOK65YS#"BBD 393'2+TN?A6(Y(95!^1CNNX
M!L2C[)5Z+O-_D]-\:L@R%W:F-!?V.F.;:/V66_O]<=_RG5_!5"4BY[&*MAX2
M"WK,NJ[!"M4FM G3N7.D[F_A?)[8D'7!6 + Y+,$ZLUI&(6!S[T8Y?S6*)''
M7U(R.>?OLF/X';9<LR N_3GO8>(.N/K&@?R(_A"/P2+G2F)S O2^$AOTD\TY
ME:KL$\5_SYW4;^2D=T4_G15](HT7(^)NYS8YWQNW%__E;-H',>%48->8_P7)
MBW_CE/KW^O]665R)OM?9V3L>L!'[$DK[#\1)KLA17SUG^Z<OJ(5#M82J_ND+
M@XE0COB[VH#6#_6^_]HW9ART<OIDRUFAM&7ENS,J'/E>D#('K6=.KUNWOG]/
MU>-SW_T90%HU^R?FP!LIT[LLA8:O>[ ^GCX4':_/OV<4I KX];"4=:KJDGBB
MDDTZ).>&Y;8_S/A,56;!\"0]B7U2PLI5?F.3*PSHF(=(ESC7BATER:#B9=%<
MBFY2\H2YQ% O&XLMP3I.;"X!""4 ^YR<9S 3F$H;NT1=<:,Q['N^^>8V]>"9
ME@,$6;'A$(,0[4;EH.#NI?;SOY>EXV_D\JB%S?-W75NBE.7U']5?;R=MBT#E
MHP6#D$>=.> PI[*N(B./,A%DSOIMW^?61<;-_ 0@@''-YAD[MU5\K^J]RS3[
M*?/%(J2/!)8#5ZDFA)SM4[*A#"MQM\S.0ID$'Y5VT>J:VC.%FEDI_TQ8Y*+*
M0>5<)* <<6EGH- "=3B2XCQ6ZLSZM<^@%/EMA(I<G1'KX:"ZII_>!NCAS$7D
MFV_5,\S+'+H!5C;F1_8V6CIL4>&)Z< Y3&&/X]]Q$_M$+>-953]L4'UT\WI#
M0Y31L-HA,[.>V<\ LM_3C'0!%0;(ZAC/RK_^-;LJ]CWZWY9T\M-?^>D*":5]
MMW;]W*^K _8"+T)9L,:5V.=(JJCJAJ"(M24Y?9W&O*1:I@>RWUW(CAJW[DBG
MJSIV_, E:FXNJ''B_\SB,T<<4)*2 79LLF:9OQ<F:]W@;2<O-M0;KYL[UB<1
M "JGA;]?XA$F^O].J7^1RM1S-5Q=!Y!F,R.EN<J<-O7/3&(#3'6N/C4 PO5,
M=^[2Z; ](M%ABPR5>TC53JQG>I?B?Q4$;V!"((,==@1@SG#VHB&$'W0'OP(Z
M]LS61+$TX#T<"JSP&#VL_D8_I'5L'"J([X4?>VLP$0"_$P*@OP6;VL76X.(@
MFUO!U_ 'V_BT$5#9](&7$F83T@V_'7BAAQ"$_4U)AWB8+$18H-V\/5?':.P2
MU%^N4WQOGWI\!35><\WIKA;)(K=H*;E31MJQ:+0&6[ %>H>B'U:\T](4]_F$
M.OWR^*^'_^[=P#Q*C6;1*G &UA8QT/UU<FL&?\T-+*"?2[T074+NZ'KUJ42'
M4DWGJK@HV4*;/=SC*%*0[E32@ZQKP;*DU WUTFR!5Q)R@X(\2U.A4C#=8'1R
M:M;2/B%?2BZ:BN&/1JV["=PD7:[O4>*>LN/+!75.4#.ZSK0)'8?@["US][I9
MMXI[8FZ8P'? ^>'CG:ME"WNI>EY=[)="F.O!/G#T"F(W\.PS]^QI19B[OY0A
MNRN%MG"K'JW^CZM>F<).=P3IP1/P>A]X_>VRPE$?ZGK5$'$7_=!F>:.KJ9]5
M%U\FWWX#X(4&89\T5W,>]/>LTV[_89E+54=J0%)A1G>^[#WO6&&FX(E??+<(
MT<X@,]7FW-\Q1$#^O"W!LAGUMG1$K$,HBS^6+^\,BN1W^=8W!T0P[87[I>5<
M'!GB/JF]TN >7#66-YWZ\WVJ0:FYN=5@V?9CX8OU^TW:Z5W^0BQ4=F&35S'9
M6+9"O"Z<G #,9@[@$PT3\#1=JXOJ)GT%4DCI7DGIT6Q/BH:*.Z,]LJFM,I\7
MF>PNE?EWUESU&#-ZF,UH[5JP%SGWJKBG!X;>B[CC+:=.H/.VG1JW0 N,/3D^
MXWL.O,<?=CG+UVTMTY<U#+_=D:I>9$)=[.U %B5111WHQYMH[6YO*0WAEDAC
MWV!SV=JXYD>AR*W;-(.80BKNIWK3%&S-;S\UDU,.7.5S!D<<PW[ %HSL<GLU
M!=H"?>4]G:>W&QY#5Z/:B@C @!-[5W@9WPE?^4RX(?-B4.L9OH7_3FQ;*^/@
M0YO!HTU7M'L7G$E#>:])SLTO!Q9_)H8X63(2#_FHYIFEV[V=YXS2R-QIU&0'
M2X-'+_U@JP2 <W&W9B>GXZ.WNZ<G1-RER3\N[49CKB@O5[C%0XT8RHX97)J:
MD.N:X#P!Z$[PH$ZVUUW!&/[!# K#;YN,^XFA3,T)P*LQJB?H)A08R=?$%-,R
MD>G+^T2U_V^GK*#Y34V>B<"?DH[X,K-TGXNJ[?;J!V]82K07^ST+9H]/-;AQ
MN6J>Z^K:&P/ATM4-.+.M96-#Q8#B]K3Q 34F6W*KG=DDK%-QL :BH&Q=VL6)
M,K?DGDMFZ+! E[F_B[ 8_R#[A07F%E$3=:)9\=U>!, &0X6GE5D7/SV*4N'(
MH'MO;&1.?YMQ1;_0J1[SVEG3@LV5RWK=FX>-(]X(U+Z"N$+A:D1G5HS2L$ W
M8 P#,!NPV)P9R=9%_IOK((FQNQ-+C=]$:2LY/^9AMC,ZR>*'9L 46"OTLR)&
M5GMTD-6XM*. $\C64*E;LPUORV%2X5BO^3PE#LR&UD,JMAFM#QNU-GOL?TW^
M\:2[5LW_BKEGCUP8!GX+TEFQ-PQ'BW%V5V ,JE[[+(&# M,*L\2E'"5V=6G3
MMHZI[\"L6*V8P_->/$7,%C=-7F*61B4>%<4FE,56N/FH85#:N&^*25:]61I4
MR!'DE.59I,IKF#+N>'C\628\4795]J*)B4;YXIWGXHD^LKHX6 #/5CM[>. 8
M?;K2F,1V& O_OKAUX00\U5!ZI]0>+.@/X8"N/X'Y&(@TA=,UYO3KKNM/@V0S
M!GL *N\1</?R[@8(_4RCM*+!T\?O.]U? ?HYG/N/GSN/A[W>U[Q_6B6YY-.Q
M EOU?[HM94_SJTRZ"G;V%ZRX6 E3<P?\/GRC%AI=G]_@VE:&-4 <08Q8PPF\
MC(/Q.DZISR_GR<0-BPS;\#]73X+GOI&D>BR%SATES@XX<!* M&P# @!KAIS*
M@AH:5GKO#-S+^?(%JO(.-;<U]%>BSE?FM2V1W4$?H7;!XQ@0?BHCF+N^";$=
MG>BQ/HP.WFI.TZY*%$X5=%O+C[U#%9:8&D"UML38+<@*?^%A=G@XM&*%#)DR
MQNQ5Q)T+.Q^SM26RAV0+)4>PRQP0DP=K@CP:4/+^[LU1IICCO$D>U98YL,8%
M*](@ <]I7@$S8\5^M2G>AE9)X]I<C.:E*S><T_T<1Q<3/Q5\(M6[JRYYNJ @
MFO7TLYKTS7?I#?AWN&&G30F+9'EFL1FH%,? J(UG EX</Z(A8:3M71[P]EA*
M?\%C3=I#16!+SE"E0'=M,H_)_30&%8*>?X9<7,/R'+09N99V$P#7*:D(UQ\?
MKB!,+)YJDQTE?YKMAS>,'?"O,B;CF<97?U7ZZC<<J)S_-$K8<]8YYN;2#\O2
M5?L6>XKG@1, \C6D\ R41<WXLZ=G'<C-<;\XX.1ZIKG@D$NUW3#]V<_V]?+)
MS0I^+ %8];W=;8'B@CK1G&CERV#93/YE8$V*?QEX6*1H\+\P\$[B@9#BAB8#
MY 4!B%7Q#!5!B$8)FDVI&5?LFB@M]JB/#/4Z)MU_1);.8#KXNB<M(EW],9[V
M,0$04@HC 'NCVP1 V[".V*YYQ$A1?]&&/=C:XLC#J;&NZ7VRJ;.<PH?+_93C
M*C'#)+X<]ETMHVQ;_^ 1R0Q3\[(/AGDB[L3\.('WKD2 V(+Y7=0,-HQYS9.Y
MOY(T\%9D?G^Z78RR<OP*/7+*.8/.':&RD9PQ'==V!)AFS]R33'IRVKZ,LK=Y
M2RZ,_K[OY/3#;,[L^\!(P6_<&++0L&D&SQPP,;0EG"/N$P3/[+_[C)7=L_0I
MM7HL^X4,HE\W9MTD<O-QM+'->-@YJXA[1.^ <M=T4H#PQN*D;BNS0T:G5639
MX"YX\*5-4F-*B3UH^6<CRJ]&[>0!44TH/'KR 0/0P(8)P (9JA9ITK?D=[CX
M8.IFO2:-T/O&;PVIO9,E=T\R_R3X+N87AI(HBQZ,+:K:Y=[#Y05;(VX/OK:D
M>Q"!E7L0OX&T[T'"QH[F_;MO@^^@+U8/;N"9O5QFC;VDC,_MM%E'ZB_#G8#D
MU=GLU+72[J@'OA9@V\6AH:,M/Q<+5XG4'JT% E!1X]E% $@[Y!;=?J%A/07\
MLZ\V%FY$'X^"KON9R7$SW4H+$PC=UC@3[3U:L.J',IV"&*QWLV=;P U?<%_H
M*EH-<GXO48K7_TA(5#EX"FXG&0'#9K?&L&QT73-@/O2L1]F3>]=X9O+YISL=
MDE1:^W]2O2KO-RD;/++_^-J-;XSMLT-Z2VL"3G 8S[7=M[K,DJ*HW.JKUT8
MNM3.1HSLT;[K@;[2]_8>92H^*C]_K%!9.*@=:IU'ZW]0A'GX$D)K-M;MP)[O
M$:P5PKCPVK/SRDQJUC4+$G)/CZI!S*<W<IV)! !]XQR; 6*'S-E!_KZ'^:-A
M:RG1],4C5<%W)[!JTIW,C9_+N[A2D=V5D9ZB9*$, 3!65A4%[\"A*@WG@N'V
M[(<=,86&BJ)A\9&5!]\O"M>@T1!V#?6$]L?&-=-8LX1KK Y+2_31#YQ3Y*R
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MN4(?K+D.9;:!QRE*FRV]1AFIBK21M%R]+^1%%M%<X-U9+8GZ@<M4TPO<,"(
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M <D=[R$VY)107(FI#0W<=NY8;K>VQ]S'E2I0\5@#_R5>\L1[CW%09B&AYW&
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M?<$K8!DTJ+?I65)^YO)-VC/K?!ME+@:TE5,RN@_<)1=C5DDFSG4UF1HVIKG
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M"P1@8$KS*&4;U.2+/O= R*_?^]UKTG/$#O"Q/$SPWL/_ 7=;%?:>77L\=ZR
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M&?XTG/IJ<L.E&R)K:,,8;;$Z;-0LTM#:-/[J2PY-:F'_'BFEY>,?Q&Q4EW6
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M+9')7[,Y#AVS^'7%MGV>WY'H-G>DOAH!JIC>A+!K/D^)@7+"H*8S"MGUTYN
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M6A MT0%? _&_A#+BKZA7M;IY*Q81@/@;8:\=C*+N!!P4/GW\LM&\5?+UU0,
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M2'K+3).>Z;,GTE\R0&Z>]C,6G.[K$P*G.=89H# !<P<?JF QW<(6#Z-%/F2
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M3X8A=?2/3++9H-MSEC^6B^^B''_1HE\_\C@<3;>HOLV,BU)4Z6^/H8R$J<O
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M01@\9G&F"QS[O%;>-\JZ(3$U!-2/]&& VM#/50_.'*#IG 0&B%#I:L;D,'(
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M[$.J;D*?F63W4N+9&_/%D&_YZ:PO@B96HQ Q1%[R,M&VPV):J1/&N4S<:XK
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M7)1[]'$D'S!$,&=M=>*M:2)69N0K-T:VM:D^^6J@(TUYTGSPG7T04^ZS849
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MM>HY,76VJ<W7]#^D'^!+P.JT,V](G!="_IB)5V2S?.+V@E0"&L4N%79MF;$
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M$"D.ZQ'N.*0N*4\!<V&HK/..,=\14Y[6.5464+7_-4JC_+\>0X632/FZ=UA
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M;4KS]WZ1 !VI %@*:<"#"DHR:@.3&<RN!E6W:U7[$V9US-OGW.9B)V]92;(
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M'WWG):QT^A>J;^[WF>$AMBN0MD-*A85#$ O@&:W'DBM3B;@_047;!3]*@I7
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MV97W@J36/\/QQ5Q%8O JZS2$TS.2$7LW\7J,:F<S.3@Z&E/?"9XS3T/N_=B
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M._ZXLS7&$S_JU;L]^\F'6<[G+F?:>18KD13Q-)9 %.$3:C]T(3/$DH%69G2
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M\P^YQ6]R]35WO-[6UCZ77\5;;!C+L5PS4S*4?2DP(PI=+22<A1'O$GICV^D
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M6I%6'-K)=(S<>5!7U/@6\3>:<^*<@X<3;W7NR!A$-6,:T?,B@71FY!2!U[+
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MYS!V9>WHPGMT0X96#-YP&XT.&PHX<Z[TS-R;-4=/OI>[MU-B,'\69T0$H<N
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MC\OUDVQ-^E5[X8]F6EK-^1Q@/=?<=LG#XO'JL)I]>D78J*K4@_VOQ??OT&J
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M\,^UR0F\RY=@,2"/XI1V[_V=K&XE?H3[ 6=^SD7R606_7&_S<;DZWS!V"3/
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M4PRQ:^P@ QF(X:!/[4-:QLY!8$NJ^GL+=T(O@%4G/Z6\U:M&@S)_DS \=#G
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MKWZIC]<&NL^S9S_2EUC.Q7:Q8RZSLU-JECP2$2" Y3(E(JV9M7XRP'G9V*2
M>!%>/XCI'\1H+2XID;*H@?,;LB<!>W4(+][(M^C4L99WF9.?<3&?^L)&-I@X
M^,5_N+]BD+J;!_GP"(J7Y5O*(2CQMQ$IR'9,+74^TC6D_H25_Z/+_$7U>_$?
MNL5_H<T.00_"Z#BZ*+"-/ZO7O2=Z'9D(]WZ.4V2Q;,BXT=*6"&*V#I/F8S]I
M&'N2A1$5/DA 6:G?]B%2R)F03-+P/M[4>R7.OU5T^,AN);GVM+&@91;MEUUI
M9=[L;UG.I?8'!L]SO)/,^'(5V)SLSW HO)3ODF:\L04N2JY.8SQ-=5O&0U'4
M78D\EQ.;M,=TZYV5HJ-_"/*1]!9+R^2V>^'?6U4IT'HBYMMLMYCAI)7B+GG8
MY\C$<E.VF:JBSW=A5MEA8_"E?YSRL!<$?<#;3P\MDAV1J0R%X4P]Z=<*%2_V
M-WKOM,^K0MR?R]X=LY3N8(:N!SS7FD5*C[%WSM#'8+PZ8#$4]W5@V_@=A8^$
MFJ$L#M[2.!@?5:,/K6)._]X6]X>1+R&!DTHI$%/T59L8/$RJLZ&DNTC#_U3Y
MN:'%GQ/*()[W6&IOY]YNWD$FC86LNFL-A%.<32B7T.!,'5\U[YD(.;NP':4G
M@XHX62U9I@]*F9TY[I17=!P,]'=PA.,.AKWKN.]^5U&4]FD3?V+-NYSS8K/,
M*8_70F[]'CTB+=O$]!W<JK3I2PC"Y1$V81)TP>&[$#>9LBZ79Z<3LZ[%FYN3
MWI]P/2J%EG+1=ZO>O$;DYV((<8R/-8H3[DTFM:9T6N _3/3&S&:,SW7>K?Y0
MY'U.!LSQ_1OD\0?J-[04&;W91[U%_["':TVD"_W0W3\$)80[!:G8*=J;R!*R
M]"WT3G?Q'S?$^^B+[,(V6:GR;HB/2#X=3[2'Q4M@M+]0.:;&BNF370"/0@H_
MQ2LF=WZXM/LRNPT#Y:* )O6L/ZD.,.V]>?;>J_-?PKF+U%<2;>W 3_J57C@R
MQQ3O:D@ HV9 #"'#HM]=_LN-B:98J(+.P->^ $<[VFC9MDOX#CM-N&+7BU)(
MDB$GS4-D:MW45E.W[]-EG+G9JK&(5;,>'"=6*1T_QOYI0>W@]2'(EW\V>;"X
M*Y]J-.L6Z=S=[O#D\VL)M96VP)'C?2QO2\NU>WK^I(Q*N+,<=$+/,K2Y8"U$
MC&KVS<V_G:>?"0FQ#*S(TC_39PA2LIO3=9D+@S*2Q)'.@WH:S//Y-3@7Y7:A
M#R/1"/F&? CR4NE6*]BWP89<U!\8#.&$M)R-/K"A1L+%R-6#&C,=@]S$\P\6
M8L5L48Z3OPU _/X0NP+Q(//!":.MWP.@F.2'G=<J(W_T&?H\"I,"PL]*V<<'
M!@3B[U;6OQU2H!DF9/N[=[$P8*,=B;HZ!;M]$'H1XWM\4KO6=^EMQ >NNM2M
MM$WQ-=FZ6/_MC_]M+%VY[H>DZ&VNUV<84M*AI@@HQ$OQI[HS37<>?VT3'E3]
M0S3+!]+B(/[BBN>#*\FVR]&RO"!?(+1_WR)=^Y&.&[=CXU38A[THYP*A-V-=
MG.Q\E0D/.&BJ> QN= G;?PA*1S4U9VW.DX-<#D$/S9>- \,Q1RL>%^APOL]W
MA7\4"=Z[-_"$)[YX^7=0NN:_K(X>98/KMI#K:M&17 >XGU<I9Y=H>R$&/505
M9CN>&\R7\:TM$<ZJU)N Z8 ['_">@,9MXZ^,TH[+@M^G&J"])[]\/&:DJU<B
MOO8QA]-I:>6&2<\ *-:![$^HH0]Y,'=Z!5-^$BL7="8"5SRU<;\_%8J.SY)4
MW@[F%MR..A-2]O0I2'\$7AU,58&? T0HU3TH,9AWD4>_+"LEIK^WOU[ I4<7
M[-T-V]FR.#9ZTE@F^*E&%JSU=BTU@G;J+6"$'TV,SJ(=;_\ZW]91["S8=W?\
MW<WQHV?8+$X!N+8?Q0=&!RBH.*8']0#!3;XX+;\5*W0Q:>(:UB);X[-%"S&8
M9"RS\KRHUE-/)>7>90E1K7S>3&-H49W&$FP0S4%C)LOLI77ZO#Y14HE+/PG6
MGA8$=PA;?9W;!=M;@G+FIHE(TG$*OR.03 U>;V<G&8DP'$X'K[>NGM2>-_A4
M4#\K1&U[^(1UG&Z_<W*.S7S,',3>C@+4ZAYWR:\1,@Y!-(4DF_(ETD=UKK5M
MK\"YO4&D)'42#R.QXM$X6#<9J.@Q+%^\EK<RYV*IZWK=.OW)RJ77R',&1U+#
M%MF@$I&3A'!,HD.?I.QS?$G:%1=__TB%.Y &C.I@WW/LL9Y1^/1*(4V^>)LF
M9+J[229EIKV<<XMD&0@Y7VK: J<:*'ZSPYHJ7@JIG:Z^K<U$5?JG&3@17A*I
MZYFOSM<OX[,NYY*L;N<_*#\IH9C7#;I\Y"MY-)U1U:M:P-RPNVK.A* ,[?/C
MG>"@E>LGVE9%<PV^L0E9&D9=%.>_,ABU^GX:#R9ED-=V<RC):9T&^-D_6VB(
MT0E9JYNS(G,&W&N]B_TE7>[WHJ5O)'B( C6[7!0QD@GU&BT:0UG)P"9K'X+>
M]AV".+9>)H?9JC;\$526-GR$SW&+SEAZSHBT4*HOXE.Q+2F<?"Y =[QV>;KV
MZ.)WR=2W*L=5]TP/02$F<3%A9Q.C+#8]J0:1#KNZ@.DI#XD@FI+G$K^8^[O2
M@.NK@K4"Z0%-/X\3AOH:F7K4%D'3HZB&0I+'$NQ;(3$4S@YL-IH2WMT^NM[>
MN=PPHRJM\'>DNS'Z$,2.-XMMIEK3!Q;YD7=%QYJ#!#8,R\^F2]W=TN[X='[<
M8#Z[4L1@:55Z29B)$K392%CD^8XB.Z)$3,A^JZJCR?57+^UE55NM7C-KUU:3
M#CSSYD&@V)%,#@GF+C+02CU]QT.@TQ>/%%JG7(U$.HW!;0.(1L.S_CIBDO$I
M]_\$R/7\B;ML-<K%ZL>0;XWL<;#;MKPCE9$*5E3EMF-UVW7@3VUM"B_VSB;?
MT!>9I-V@D$9[MY.@BA2WT@0D,>;9B9$MKXFPK[QG>V3BE,HV^F\E'HF[Q 3J
M!?:H%@#[KC^Y^ ?=<"KO4I*3)FZFO\O[ZVQFC;!7 3:T-ST]IYC,GW@(8HBI
M>*0@Q(8O)33B-7#)/^7(/3?_@H\%G_OQ;#DR#WR^OCW[8PDSHW=A'(,O]V@:
M;".B,MR5DHA[%^U.%.$S1B1'1&T_%BT-9V5\K Y64F)!S\":&-&J1T@>!+.X
M6N /V/IZH&K-CTJXYZ$P=>6K? I%[*RV-O/F#!I\TP02<;IR;*AA0#[)2B#>
MB?WYD7"1XPC?OPGM$'0')N9+5Z7H;1XL[17;6/35J/J^6&^U#EJ!?JA-@>2#
MHV)!"B\T]Z_]\T2;2.(24OH[C)>F@23"A#9:]M53/"4*B+OK+97^M ^_6!1W
M:V3%*.9Y2Q[\W_R+19^SU51Z]#?.NKM OZ^<.\.AS51UZA6/K6*ZP%'1VV=!
M,C:(JP/$Q4P/LCT*#$QY),M"483"OBR>T5W_8_[!IP3GV^97FI+DWUBSSD7U
M+O,(>;Q &%&2XO$:'!O%>ZDZ4K$:)@WQE1UM[7?E7QC(5I;&\5GIBP"3#$E=
M^.@0= .<*H8X0]:V((IUH\0P.+7 VC05&SZBD]Y=\(G54X^][VEE/B4S[?M6
MT\S(VYLUY.UN*"N#M?:'UD3.7M'T;2EL[T0'!\=$*+ *GEYY>.P;[^8]T/)J
MES4E8C.8Z@GW^M(<Q!6Y1OQ<C.'7L5X*CE0+E&@][W$O0V&G+T!</+UK/'[J
M';] )/HJHX!6(290_"?(F ?;G1IX#)=EWD;TZO,'Q&/R0\-MD7.S]\L?7'()
M[F8'UX4Q#="D ;MR^%' _WFD:M]X4[1[7N Q<R1&(=PGZ/Y-J_WI(OH4K*4P
M'GFKE@WG%KMXA2*R4_!V[-33V')O:0DIV,;2J%260[960I8C@*X!4"9 ,%'&
MHJ?XHN%VJMJ;Y3S;R;7"X6M5+(F?#??YM"85=/YP4[DW%OB $:J'/ZZ:Q!D>
M'$,1O(8D.GC5EHEFA%0FI7QM-P0Q'Y.*/$OF8,? #1G?,P%X.5(4==WUR#I[
M24UM<R>_!)R@6N3R4R Q)@K3@;9E.OM*!*3PNJPN^7=21YF?$ZXK"\DUZA_C
M*Y>K?#F3*X=N%F5+.DX]'LF]6TC6&4RN6W>:BDX][VP[%7#CRKM&.+S*<M#Y
M*S_;WW,\'GA&#@\<@AA$Y Y*%O'97?7IG,F-0*46XY6*U#M%$=I1WW,K:N*Q
M@;^8]DO^.5$7$K,$K@&F?==;.E[66_.>F7"93;++5<C@;F&O$QYCJT(P^J?G
MZI:#]<%S.M<B@)OX80^X\*3NM=RKYSXI].J=N^9/<<J<=(3(Q]8!6US';A]Y
M+1.J#H=2(%!^LG/2BY+-8IG:Z7SM8<&H])H= 86'<KDK)DJ@^V@?P(;"W>/1
M.KT9X4G 9" 4QIO0XC81:E49RZV79^>;*$O#;1GBZ7D=_J#3WZ!-3/'4R\@>
M?=KQ)<:G,J J KN]FGSA:UF\CJJ+C/K]HQYE4OEE-T.E*R18Y 1/W_-/ C3X
M$V'X%UU<'61P_P$=#*P1N&^JP4VE7=0UU*ZTO"WBTWL<\OSQ#C>S9D%=$ $]
M:)N.(EMC).< ):PAZVA:EZ3KA8EK(W>Q'[V5#L+?5!ZM/ 0)VRQ.UD9XU-_.
M?T4?Q[0N/H)"@*#>B%)>(#;@"-VSG<GLTT[/2I27M%;]":?9[ [S2Q>664S[
MD.0+Z+3K3='(!%HPI9Q()<0^_"%_9[=0C$_&<5FE?^T68MYXE!ES@7:,8*/1
M72HR 3$HQ]46Y%1=Q_KX!CY32!%6R1IR&H@\!)&\E_@?08\ 0D0W?T)!:O%B
M:D"9FO3%$#*6%E+NM9=>D?W^8/\R>PE]&D6^C&1!?"P\_3TH2"D5[G.&DRW-
M^Z1'X_/ODS CK9G@O.GXD4ALCP=P*N@!Q)OH'R"&79!J)Y^9&U+(<A0\*,?I
M*K&,B/.DT:<X9,AG_ <Q^,=O:6> ' JL?W\[:VMY&J'U(61:]P.:2;Y=UOUJ
MJT]8V9K!BKGF(O@N8@;V=C'A$.2GP>JN[>34KI2I5NXSV?SN&-<G_"T+7?;/
MR=4O/UM4@6)5O6."7EWKB?"%.#LUEN4J$^ZMR^=D?^Q[P+&E$DU;8X2V*?P6
MY41%9>02@3VU])H&7$JEN:RH55NS2-; <[3<,!WYGN11\=^\+N]?V@GC,E;T
M2!#.=+<!6*'*TZ<PL^XZK6XN^%5TRU3O1 ]L? (4^DYSV;7.*@"[*LT'PBY@
M1.FG 6M\4()ZI\.2S4T9L&5<XD_%E970<0&+4U@95GCB2_H\IA%,BJ]>H&E0
M' L+1"7K=P*V=#KLCMSTP(<5*@W?BQ;*"AT!1;HWDVL&,63'0Q 8;DI!Y"^-
MEP/L?<[)UN3/I1NKRE?E@C2S!9JZ3+6R759!]SJMJ:?H4W2% Q3$+99JB)B8
M&M5-&TFLI3=3EY/$_C@9R#0HMGCN75V[LU362RD^/MH/ Q1;L;['NC*#!&D*
M%,4:>A[''W4O5Y+GC/I1(:RYC/[Z7B$CI<P<@@AB-&$8 94$MQ;9GS/F&O%$
MK\<@QG*V9 ,ZUJK/<;6J].F7\0N3V6E"?0-(9J1_AM(@AJ/3J1C69_1IS@-G
M<ZRH0# D@'EM[^7,'^FGZ%<*2K_.U,,E"+P:! ;A;4+RWBE8G;:8"%!H:'K8
M86"9<^[EJ?Z\[@V;@,OL'P]!K=.D7)@W?_)4SO<6BI^L_K2U:97+A8Y<.7W?
M9Q:GF.28YHH!+%V&1+6'AX\O4;;3$2<^>!'3FJB.DDX5L8;#; AO8X5>D^FM
METS^7HST)5J!M\6IXO?ZK4MTOT!@-\;U4Y*W<);J3LZ/=H=/@O,13^$Z0!;#
MLC0$QP3\&B'VW%E;LR\$(1-MGYS2UWW M4LF[,_9XF J"![ZUU(-P'?)B.&E
MV=WZACP/<EUU!M2:%)4^,<NN;R49^BD[[X'BYV6YH^8+IZ$GX'I $4.EU@"3
MX P:NS9NN\_FNH<B-L3:5/O6LHOKTM:0867"Y,&*-@;/$,C@3BU*\H"HY-G"
M!^'/%%S)@Q7A+[HP+XWE4TEV+9V^!_BZ,WS1X.C]I5U]2BO6(T-@'2$*])!?
M3$P37"6/Z!*7KC7S'E_I/Z>A8J7P.'>V192:P,ZNS=1''\0T;*=C[MBFMAR"
MF@JQ#HI[(1=:2V7'ULZ]+(E*<DO>&GPJ[+[,9K"];V?Y6L08!-('W:_ZAR6'
MJC]9=K,HU?VP6;W=@:\P'PQW9)<',P S21RA95L.[4W()V6_L^>.NZKR(KC'
MJ[0;[$Q?1#7NHJGFB%')KO@R/S&G]I&2#'/<A,0%+'S\ ;Q(^%[W6OJO&R\P
MND@?)$Z,:-Y&QO8N-B;WQ'+Q,T?N+UWND-Q^I(;-UZZOXR_^'/)!3BJ_Y*7
M2U>6^/7%!AA6S7I7\: "*D=3 )HI,CYD\YR@=JFT#]ZE^FM0E\$;KEK*M[*W
M3 ;-;15T?NL6\G<O<LS 30ZJZ<+?%\EO(18Q0MMN')#-/!*SV570O)!!W]"%
MM2.E&4/L0^V+_=NX4#KG5XK>N78@CSAB2M2("X]Z&&H=$Z/VZY)A^^!.+OEC
MA2+(^&X$:7^FRL\)H33V9IOTT75]/['!5D)!53&P+-/H 2_B MP<&*<XT[EB
M @B8I'V-/@.X6J6+'V=XS8]03EGND+)7?V:,79DO+7;:BJ.G/#@C[R_VRHJ,
M_U(]9U-7Y,/[]/SO&<DCX+(R'MLD&#M-@NQO]7X2(D*8U>#[MN!N'1LL4AP@
M:*,@>EOQ9_Q3UN^OF5^"F-P]J-[TZ>O@S1PR(;QD2,R!PE8VPI=?%32[9LE^
M"MN@(0$S\3">7IZFB1@YV/+19SS8=+*$NZ=E.9I2IZ(4PN>E5-P#V\2W=Z*B
M9+XS"T4=@EB/ !WEU?UJ9_;7C"=7/)IG[MS'^#3=?D3[*,IN?U5@[(+5V1\N
M>"PIO!HQ=7D!,0IKVDJ4*7P4=)PJ4UHW19P(>R\M=TN.HWKT',CI\\0[?=@K
M0VB-=]VZ[O6"DE"1+50$EVU *$MRYM494U5EZ:,F1R1IU__>F0)W!,PH8L3
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MUB>>57]OB$(H31]/J2@XG]'RLF.]T*WR+KZ#I]2DSFB7 WA%V>N.CD@/VWZ
M8 T2&7@]PH\*#14Z^_YQJI2O8L,+XIOHUL D3"!-[+F+[W[PE\^)WL]_%/>:
M1=74OK&4M$8K7^G$VE%[W\V^6TL49HHG@_&%R3 ?5.(^+)ZFP<UX^W,-R+LS
M<Y_F/F@G=VC2DD!XKE]<_UTWW"HW6-:;?]X4$/8NR@3)5HZQ#WF((?'E7=*
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MX*:URUL+J#Y9+X?< ZZZ->_,#1^K8=A[=5')!*4P?FO)X9V-G=(ZJN[W;E;
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MMU3K:(\P=P6RRK2!<U54"T"9],:O,WM4P3,:N5O8+Z.M*MA*%G,O2$ZW7_F
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M$#+RN2KZ-$S4']7JM,."1GQU<L1*8GP#KU]-&[DR.+A>S+JK1)[\_>M.\)\
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M6ZT8$VXT#LGR$\9'/5<-A/>[WI6RRKHMD;D\]2/RK< 6]!KT=/M_KW+J4"(
MVHIHE1I1'YU\HV7R0>E-K.GNX8B(0U[D'5#]/6H7(["Z@:3-;F6X+''CX5[P
M.3.)'[;D%[8[57F: U_>H2P^"[+ZOB9< ,.INK0JNCC\=G?12&^9\:3)Q3@Q
MVX4%CS-/!3S2>:W?2Z O8AK;OJE5-W<E&9>Z3 RK:;VY&Z'(=MG47/1/.,6&
M <LZA[L<?:Y1@\CYRNL?DBC05(UI^_8N?ZDMM2!AUY'G^RPO4O!IH4GGEW\Q
M-FJ3]AY+SI]0ITH23KM!,XQXW5[SZB']+E2=>:KA>SUA>X]SZP+H3R4937L$
M]Z*<H$+; 1+1X(N)/N_@;SZ]$\Z;^+RO=9CA^S3(O,&X%^P&H#\ X8'@:I#-
MSXO^?BQHG=F9]_J8^'^U=V5!36Y;.@$T@$IDGB=!. J(8AA%(H(,!P41.8 H
MD4F& !&024/"/$-0#J R*B*3R!1 % B02!@%44&"$L(@8R 1"9&$T+&JG[KJ
MGMO5=:MO5]=Y^-[6P_[WO]?ZOK5J[[6"&;4*M#JPZ/V!DWSQ[V.ZI?G +^O6
MM)IMCJUM*&6MC-TY-7BP6EK>JIM/H31M@2/)/D)+[L: 35)GAH4F3#]X%:U[
M)4T&=UH8:A*K?BR6SL9HL,69T%(DB DOBU3'VP\\MGTD;>Y7^*:/L/ U==TY
MAR@W$?PO;]W\UW BX&A.+NV6DFM%MR&G]#\K7FV5J8HWE&#/A4.344.,NI;J
MY[7/G%=)WN-%59/=E7[;]@\KFE]G6(M56@@V9IN"1D=!\_D)N)EGZ$,H'LZ[
M:5&:?H\VP*1LMKDQ,>A=51"?&KMRTSNZXL[:F%?,J5Y %\!):PZ<0FZUC#=6
MVP/(&9O5KNSH)U._I5E#5F/%+A-E7UTE>[8"!;ROUW_MZQ_196A3I7UHKAP!
M.N4-(J58@GFJX@8S:WWK9MP]N,6QP.(;[=\.UB/;!"6EC>\,(_OI.8Q^^C9;
M#&Z'9>K3"KKR'SLF5:A>@3M%7$GEL<B2DE:U;S&(_\W#3O,J\,'M<R;OF&=*
MD9J['2C^2-BL9):)W-*UO(8PX;3E^18>JV\9U# 7"T5W%26)#;>?M V*=KR)
MB)_Z19I/X@_<P<\-@V^?DUZXN6^%['=F/;CDCGH'VP?9 TRNSI"3V (5@XS<
M#TJ$;7//D:*L947Y1L+<9\$5E'+D:VU I"A!X6BQ6K&66B]\///N*W,M#%$,
M./H>E@T%0Z"D$@:95I>".L5TF%T@)Y,&'?(^7*)UEE0-^QT^5=W9U5!_[O:*
MSDS>>K#;($N<ZSP6NE_MB)8S>P!B)+2!#3_4S76V( \)*F1FKO^5+4^?G874
MH?M$%24Y'%L<QOB#SJFIM:9C>G8Z*UXNZX73GS]YTI1_P\2@'ME7)B?5J']2
M*3O$3OYL#47]+?37< J'/4",9+$8/?!/B6GUUMA+NPD!$K.],P>UOM8HA*_O
M9/W>8KI(O>48=KQ+YWX<?]^13KU1]$S!M#Q-F^I9@;Q&N]411M&2$-D^S41?
MW"6U4[?+KA@<UK-=HF?A>:4 1&Z807.&%*5PM\"RD5/XXB,3M74<R1H?F\34
MB&(/4U'STZPGK<H?YT4S[@Q']U2+W02 2LO_8E!T55B-\^1U/"(X"L&W67A!
MK+$:F[R;;6M'<2:+M-M!XU#RD64$O19N%&\;P[XI6"K= Q1GREVDH$6:F5NL
MLYP!HQ*V& QO8L3,G86F;EO31>2M\.+/5K\1!=? "I3"9UX/J@_?Y(, 60XP
M$+K; GU3DKD'\/U5,C_P$*7D1P/JW@\1O9)J"$2_.<Y8^PHVGDA'#>%:, 3M
MR=.SKYCJ+//!.SO70VJ;B]]$*^=2Q;-4T)!-K38.?<%R-':G02X5 E<-J).-
M&1@(X3_+#P'^I+/ J,F[DE00Q1"UC^W5$ >6<IW2RPML-F 0:\SCW3/CHR=C
MY.H<,K+@N-U<W$R)'>L$^RX=E@Z!24^7[)_&+SC[\J.8 0].6%/:F[;Y%PL?
M&(+&C/U87.*@3Q"_RLZ./WDF/K$&O:>+5=7J6%NQS#6N-FJ\N0?HZ W-0L7]
MQ0TAC3XTO"3M&JX;,=E*G(:,'A%9-7(KOC;:N"[<M]Z0RK\NBF*CF\XI/"<U
MI\%JT]U<:U</#09XVRLK/ DM='S-=F>>8O&L*C;[=.&8UQ]#W\J^&4G3CPB]
M;G3#4,DVLP?2M6$M!#PTZA4NOHYN %$W9XL.S(+9OVU@2GR;Z.:BNW%$EX\H
MEXOXQ+B9DG;7S,:(OI'KHWQHFCWXL[IC#B%?4=Y$9/<)TL9/9T7F98[ B1%5
M+WW231 S2:=_=$[E5=WONX^Y.5#RK_<?X 299#PBA12&=3OABM"V'YL_@WJ/
M]:3^\>S["[!JF,.*QOJUGRP\NGZQ9T2 ,]J*EOS1(4=:W7SBW91!Q28M-'V[
M?D0HJ^N[D8_JP<> >:@'5S->V;V/8-]J9(ZOWGB_95/H[)>F9RIGEIMW ?I]
MJJ@"(26_21S_KP7S?P?L)X+6(;NBEU]C,V^]CINV/I*YV5QX3$DN7-5QQ>+R
MP-6,N)-<43I8]WF.(UA4M:HHNF6WCPW/(XW)V^Z85L"%?\LZ(V SMS:&^;DX
M":N^'Y\=THZCQM)$B; &-/'J;BD''%30T[HIF\[4BKV#C3!\8'@U>C7**&DM
MTJ GAQ 9P;A.\R%@4LG-(#Q.&.;*]'&C+4Q%QI^?J A,#4A7C?/.&5?;O#GR
M'"@W(<DR1)&@8N7T?/Q((@F'N5.)%/:LTLU]V]L,*H&'^>\!E-/"5U4C^R[.
M[8M5CXT!OS3107V  J"!&Y.2+J_H>@V>E!+)Y?# L/TE2 I"L\XQ\K#/(_L^
MXN!'A7,JF"O<<&2U,JW\">WYU3",#)DB^4^$DQR&"YL??K8X_<D\4P?C3?1_
M/XZ>R4,WC:0BKQJ;&Y\)0\B]4P\T(5Z.7)M7+TP )9JDG:NK;C]-*=+H?KTO
M*_6IL^ES/[U3_(&U6MF:P4I+ #%@U5^):4.Z+/&U4\\&<'7ZQ,31D\M&6H7Y
MK9IEZAXG;H-"[@)7+J!<N=^)7:2FTO-['H_TXH"3W:5LR%AYGA5D*4%H@\]G
MT0.S.8P%/\0@A31^3,W!>EC03*A N^,,_.?TV-2-^@=#7Y0&S8=,G'@[QP%S
M))PR1\,7AMU8,Z/IK%)Z:VN7&&2A9NH%;('-5)1*GI-(#;;890_@(B-^Q?6V
MU(B\+^]*B23;8(PK82MAC9*)2!<=%V;$;#3VM*Q O+N,E\<# GXC2D>\SYAJ
M8/P=G($:+&E=3,%YVZR6Q..PMIE5SPLJ>!'P*H@:/-U<+BI$G=V2@'D]^,#(
M/?9GB(G>K\[)8763>$;$!XY&I.)L<6WHBR4]&FQZ*JKX4IOE<9MKC<5Z>2"X
MS^T1)1IJ:K=0TUC[U_"JXOUTG[=@T+*"RKAJJ^^MQYSW-XJM"GNORWGMGRJ\
M-PKJ1]-L:W6F>G&M, ).@0WY@(",)"K>:L,@Z5)EH9HIGBG:GFTN/5N7VR=6
M%MR99[HXBLQ[3_!ED3X6C:/85VTV-OQ__-:]U;6QX?KG/]145YV<3KFX7@H^
MG4))/9BU^+126OU[E7]><_F%E[X3I("?W[65'DQ?#".M7.4DQ4"UC2^Q+G'/
M9XM/IO'5/4#3$/HSBI<V-"QRXT6#F=:JT*,HHZ;8[/@8_A&UE^S#=$<B6ZR
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MBY?H+EVBXV!B8.+X/Q[D7P!6VLON#&^HJ6X!+K!24;-2D3L! @  U26J?PW
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M@O_-WM7;7C&_SC.1&EM@^ZF:G/7I#+MO#R,;[?GG+3K>M1FE<AH5-#FN _>
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M1ZA$NFMJ0E?S;;MQ#Q^L*'?ACZ@['R;-<Q\)YO=7JT:P>!E4"2]!")_!,60
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M_";>CH5@S6F].Q#3%_85-O/X/8+HU58W^Z7XBW:X9LG6'1**+60T1OML&!4
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MZ;>ZL?(\QKP;'].$-PUTU J00!*$"N!_5T\%0&@(][<7,<-R'M:?D4,%H#X
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M6WUPQYI1GI5"Y&/'F8T3A]B=3X@/!1O->H<HRIE].$E%>#F>1"3 J # =RH
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MDZ:4DN21-"&V!ZHI*2Q3NJ?T^ 0"3===>KZ$^GBHF'O@=89^=OO!#7*N=!:
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M)*L(E&@X].*B GSO[%@-0Y)1>2JJ+Y\5U9H!G0R^.W08*-]!C$ ((I1*.2J
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M/,;HQSV+UP]7>KIG1P:XBPUXQ<=:2+)P:'T]/>,"_357UB9*G(+X0<XO^O1
M6V7 JZ\Q<*+_S-]:H#(XZ>J+,!RD%3AI9?$!EP,-?P-!/_^[:8^R$JU.7Q8L
MJ!M9]L_UH\KDB_2E#7+C*-/4)("%*4%H2_5H1!(R\>0 > /Z&TDQ]XD2Y#D5
MO',.2'IB!B4&401!]E5BYAC<]01$MZT_/<#22^\JSMBV-/J)_48BZN+UX%9X
ME^+_^.>'-NK&9R'9&00#$C3[O!6OZS+!PTF$$=R#G?=N4@Q&9FFDZ*/E*[X
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MW"<#K,TAQ)O5>$6K6F8R@#$ME\@@DK$$^RV8$XVSV4Q B<5!#DW_[I58X\D
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MPT"2 [U(4?@C+WFD;N+33T\3G\;<=,PVO/Y2D!O '1Y$@]<F]4"92+>#WF#
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M1Y6#QEMK+%.D<IM'^<+"2JF^5NE?H'8O*LRV<"0JR,V003+@UT>,6_7;91V
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M=H:SW-[]M"8A@"B3@TBRT(A^4V7#C)\B [ZNEOR(#JB9L/F,LT%/J."T%GM
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MP#Z 6>9^0'A/E$T&Y?'?CBVT<@7.MR0N<<8B=G%I4=[F2H;RU+;A'2I G31
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M6S,M"KR2W!'@(2$_;BEMU[F(1R_()2/E=SSNOOT[U4KVZF#U5TP\V[F,)N0
MC'0E>.LQ_NCO@1T)>@X8;IT8'KDAXJ22O-B.2_+B/_DWLFY6?"\["F(;X3%E
M/DL-8;B@D>!V]((.\(P1$E^?QZSK)"P7,6L/G)9C%PSYK?>=UQ"P?6>D,%(
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M1+ I]S[BM<G;1PZ"2#(:I;XEM+EBOC;4M\3!P7F%6[X[0=*G^_@5$@:\O/0
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MH'O;P(XH+U3()__\9\XD:X7 O,%_.NWF3=ME6'I.P[] (;-CH&KX%AH+GVO
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MT_?TDU]V'WW /ABQ6!+<F#X"65*3+SBLOG*IGS"KF&6$2G,J01D9_AW!I1Z
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M&#=2TU8]6I&KRF*1K5+\.ETF\^ZMIB2LG/ZHR$_F=?#<* Y)X,'NB+@MP9V
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M"+U2LC?M0P-X+A27 Y/KS3J,+2XI7FB."K-(*UX\MY#TL0P]I&N?#2LE^S"
MA*&Q8O(;FN,;PLQN=;23!MY6;#23W.J$<:\9INA'4]F9IV<H?7DL&OL2MM//
MVO2?7F^;;.3P0CY2/1,:FN@]IA<XL&&;]H9H=#R*Q]T0_"Z_5FX+XDDR)M\C
MQB7!(23%@7QN#2L_E8\S]XG;!>/=X;6+(Z+UYTQG?A0&<E_0\92A31.UR% B
M9&N?N'303>=MS)/7 !$0Y:Z#LNWM:6_*T\VZCD? 0"<DXN0,XG"J+%[A3&/*
M#1"N=<$7@LF^;8.?)W$.]U*?"OJ5%3!EWK?^HE%K*&E#T:5_SY.DO3<0Y&'R
MR@II[4PE9V\[[KNF2F>GN-Z8ME6<%ZZRGILE6Q%WMM"50)TUJ^^+KV-4HV?^
M8KT'Z:;DS,"?V.Z7G*CS\U^UV;]\9T(&?(Q@_VNV(D?ER\+M]"'%76#SO2\&
M.HB] UI*;BNWB<6S<S.X47L8Y>+VS9H;%E]_==8PLH.;(;^B3 &QO@L;6G1%
M('X%*@ TP:XX^[;&;-1C6M\7Q4AE=J]P_KS[_BXV]<%GVCOJK971N5)GP(J$
M0-?#JI&>O&8UZYE?_0*55F 8@4?E)W9%AD^%DR\%Y!Q>8L2ATRR=314[;VE.
M. M4DQ04+T^9-I%\QBL44A) B:#0^QU(\E/:*P-!^K>09M'2F+W-#K.^$/G[
M66XSVP:3L)O[MI=M#4,)-ZT#?9?+_M]HJ[(SWU=V8J&Q0?E)Q[F+42ND33OY
M@I-?1:\GI2NT7NBV$SEN]S@#YR=DE&/Q;/$LVCK3S97@EZ[I7WY3S>G-S>/V
M=I^7NH@NQN+$%@QIJ/!M7"%+M=W$,V4MHXCN$F]R*USF)]J7?>#3(<ZP<NHF
M$U3N7Y\JQ,^O[2%'(%<EU%Z%PF%/IS5C<AF<]C4#MD-O=42LW[G#-(GHUD/\
M' X70/RXR) M\,8]6_@FPZLQ-$Z&,F#+($#T$6C\S^SXG?_LM_],)_:3.TL?
M!'B&L+LX+9B.6_)'*_SN/<Z[<,IW=Q*=3[3>$47C"39TWNA[!E&30O5:0KHR
M#J-GS-&/LW<2:*<_=NAQNT-5 Y^YT;Y?-Q7,DY6U*21!MB8I?+[A;$ BRROJ
MD\S;SNM%W^N:HJ#J^FAB6\#XBU3X"_MY_EN.*Q<;:Z?UBSUKEDQN]O;R2)J?
M@$?^1RMZ51)/OW$7E"]<D$V5"L7J'H&:DH6UY\.X5^^W!6J=LCGQXNU#]&4D
M\G<-\R< <H,Q;]6,]'F! ;*P1Z#4O7R!"D*&1?2-7?[AWS7]#DF'98>VJ!](
M'#*%&DJY"C>F?:0^Q<7#V?-D&RVYY Q;!M\;?KSXZQKK<8E:N9MLLBF@_K">
M&9+:MM=8\T%"TM0;IK^3># #EODA=Z&I;JJDG5XDJPO5"#!9X8@.K? 2?6PU
M\^'B_;Z! KX8)8KY<3_=&Q=$6W./0(!"T]MRI[#4'@@+'%$#% [\V/O"$'BR
MQH=JY8$LXU9A\[>J>*4?.XP[3\F?C# 0I\6%GX!?(SY"B-&EJ2;CU>WZE?"K
M.5;7]+E95)7;+K:D17,')WT#W;8,&'%FW+,9X&M/1&Y-5V-\G6RWTX*7Y-O>
MWD4UP\0+8Q=.LG>)BTN&51*&#$&_+QJ"^1@!9W8$>CCB/B"JDDQ*Q'VS<:9:
M$:\F!H@YGGO8T6BW8,.<Z:%]5S=J\[M)J% WS:P'U8CN9DA*H!0-YB'(SIQ)
M+O@R";?X=#)]Z.<)ON..&6>$8^Z:W6K62^()^03BCN9GPB/XPT'=)7 PJ227
MZ&\]&2X.&[Y5=VS29LSO;%U:<=+.54\3<4E[_>:<OVA<*97?;A.'ZFT#L\-M
M <3*4Y*U>82CE1_WNUVNVW?^VMEF=%*/65_/2)I=?C80J_6$(%K/G61V-L*
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M6B1A8ZNN+MN1QZC)@J?$T5#N^.P8E.&7O'M)9BNE?=#8"> &Y4I^SPD''Z%
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MW;O%4#-\*UQ9\4<@]YUYM3O LC?.S[H?Q:WG7BJ;TJKN=7U6%#YXBDV3N^C
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MPK.E&39VL4LFBD6CTL3EW/I7J\>-?/9V!H$,BR^-S_][T'P$0N%3@=N2YX]
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M[HO_&9I,M?YGOFY#<)'$TC1ZO2%YDZ9. [(&SW;3%>?O8DF9'RO++[__"C[
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M)"ZGFEB0EY.*_WP*J?FY-S!>PI!Z+E:MTPTQ0#GR?>E.*G@.;@O ?H))(D]
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M(G_'UN^#_. 9:[0-@GHB$E%UK,1M:F;+!]9>='SPQ'0<G\\C\(WCG%-5V"-
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M>$T":X"2?I>K:R5-P=S)2Q.J5[.40_P^<RIVN+892;\Y_N%?P2G3;1*EQ1Z
M"75>(6JDP/F#EU0;HSFB1%X()'VWKDAPGEZY]\'UI_=CK4XH(<YALQIV;G+4
MWJ%^83$3_E_FG8M#52#^OQ'G60^=G%B)=U"'@?0]HYV>.W!)MDZ7Y@[GT:>7
M]MXVW#%:?U4WVUE)3*'DT]3I5M29HK[E'(@ TK:J-D.Z88KI3/QR<=HP5*D_
MKM[9AA_T5<YH\)K\^&%\]CZ(\)*M1L4GUS;!I% ?%4]-_9%SR?K1,>,K )>3
MXA"03 )MG>1IDQA&]S@PP]3['>:+"%89?SZ9N-O6!#7'EC8]J)6VG%R,29,[
M/1CJ)D@#G.$+//0\VBZ%1M#8?@CE90L#B4)2;H7@%J"H/XWN]MSMA\UY:56I
M'Q='3MGK'LHSEX.V;/?"1(!HNC^K#'DTQ,>LK0J(OC+U#@NY?/_[Y;X[=0V9
M@@\_/!/E!L& $H83>P'#URD73_**(&"3\JWK<SZVMC44>E3P"]>.*$R$5+PQ
MZMYVQ=_2?EA\0(V<M$O+]'+@(=E.K'_A36.<%N02E1J9=/E#P>U'I[FO.W^]
M<Q9Z]M90.F,K+@"KI=+2FJ:6>.V$RM7COI'*7"*QB1J_DWJ6I&@\3#$&_3/F
MTN294H<KP%':(?-C&4:*B#]I3]_S+0A/R,E'[(,TO\CG/>;X@T_]5U%_(##W
M00^8%F]^QF+[>;4B[0S6/8RKA$I[=$;EQ".'<W@$>4E=<[VX$Y/,:**7>G^Q
M0N_RVKE7+Z.;#8]>2KN5:Z%\(\'2G">W>*4),C]*]*ZK\EQ>1IZC#GRG3->8
M[(H%GC;^L&GCYZ>19Z.2%Q^\BEEXS2"E;/ZF&1*7^R$<:WNO.ZCY%YO8G^9,
M),I/B?(FW&A0.7DZJEHP2M$]F^,3"+G+\/@)D^LT)#D<!K;IZ4EVM)9>(2GG
M[)@_,*[/(>2F1\W*>9%YII/"7[XE385OK?[47C0FP'*@P;;0)-F6WF\^=N_'
MW]W-]SQ70U[](%S7U#ERY*K*PJOLJ>SGK@7L24PC99>")QRAH@ES]Y&V,='8
M,=",?A;</MC6ZQQWZ&J$:,R'3,SYL-9'&I/H "R8"6.5,(VI,"_ WZ":A.$%
M9#\L7Z)!DN_M@[K0</% Z9(;7"T<#9D$BE'W&8YN9#@+PS9FCZ+X.X$&(CAG
M2856L_7@Q6^7">3Y5S5WR[EB'HK%'0=!.C+)1C?.8[%L^6"<-.O=/LA_'\0'
MI'B.UT0JR/5+%NX]6'!>Y[ME,U'OF-3'5<"[$M&,LP1V&8&>[.E]D" 6)\&4
MH_)DZ(/%$2]4ZSHQSE-V-;BGG$=^/)7/T\O,_".C;LK!L*+' \Y2/>#$,B&J
M9H1 ?OG:Q*+MN4P^7\9DJ\+]*)^<6-!?/5)7 :[T@)0\ (7@0*ZHV7' DJB<
MK,J?^MR; #(ZU.7/YA>@J@]!&V$] @X\B".;/IWY;BWMG8:__UJ'D(7#QE>V
M?WV&SF--@3;B)_<--O]3*MPMY7)'D4T+M>EC!$Q%\$96:F=O QGTRTB]%7N)
MU7X&G[%,K6G$'$'*3\-=/<;UQ;MP$^]*A-ZZ<_P>Y'%12HC*?MZL&\K+DXK8
MH.L!-(+VH3&RMA![8DEUQB2D8J&DX>4G2-%K>V7/)\JI9YVEN80^F).5_',J
MH+<P"[+HA6 Z>IQYL\I<H;85JYK\1ER9]]0M([\K7TZ?!"@="M6KV[+H'FLR
M;;DO8TP( 2$69=UEGPAJSKE5K#_X>$3BV5;']27[]9=YI\]V?UZRIIB!@0C'
M W<9A^H[S+@Z7FOB2E(PV0<%!;5[8]045EN?2A2X:83)ZJX0DK[G#P9P;I[[
MNT&?9+UVI4<#<"[9<T-Q-,[^*;0O$&'OQQG91T2NCE&M6L76+V7KY6Y ^,R4
MK&@>Q*)D$Q^)_+6ZC6*DX4:@ROV%(\>2%]PXGOG7<H=A%-&WEY/1C4VS61%D
MEFB(=\A1%5N#]+U@M*;U-?Q>L^?JK9T_S\%CZ(4#P.=)8?.B^A6E)^>\W]/
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M9FE$EA/)L#^C"2R5W*CS>Y#WP]]:SCO#*Z!W82,@D>!1?=AB WFH;T.9!%9
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M<VJ9IE1P3Q=Z<!\D^X+Z[2-;O<@V:KI6DW,L,EK\QNGTXQDA2U''03XJ',5
MM TPZL^X^6^N*DKNF_>74>J8 _7,54^W-;8JQ&\F,J9$Y9C5N"#%.!KRV/!J
M* AJO]$'#=)>B$3[-5+E#%/ J6CBB;GRB</:J$]T^.G[/_9!U?' V#?RAK<^
M;8.,'G#(@#:2D(< O1IWA.F?#HXJ('_ 59)$I#RB'%6V& Q=&^(J7'\N!C-
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MK<+/==_T$,C%?PV)9J7!+]$]5\R.N[DM6OCZAA"$S*2U:L95PHYU53D[RX-
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MO\,#U[G"<RVI33,3D7:R>^BF?Q>EPQ;6YLCWJR#"CJ])].XG",%_<YDV1L<
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M)%7(*22NPR63S;_,,TV>H3UXH*!IP(PGCR27../Q@I7F7]/V*%CC'G,K9)I
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MJM%IOB6HG22\>E#NX5J<_G2H<W8WUV &-0&V7@C5NTF?G1DTP/>58W5ZM]L
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M")7F+7ISLW)I+X>S1)&QIT5[B"H"U[8E6<4JIU@,JWX5_;W^V_)ZSIZ$F0Z
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MY\[A%+>^.._=)9Y> G8IX\@Y.YZ@/&-B55D7]Z-[LMOEEB!1ZD8BOZG 72X
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MVKL?_6PZ9*S9++*R#Y*$/@JYGRZ&2ZPDZ[HDV6*#=[]H%Y[OZ;V1P?E95V!
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MNW=:GA]W>8$1?W/.D07AV761Z=COTK/02UB&Z"%HJM7S$/3&L=/U7X_,M:P
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M>R.1B^W-?JIQTJP/!V2GW85CLK*@H8!IOQXRPT"Y#$BURB=*>E3[B1)K/F&
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M(7C0ZVU'6Q@(4^6@O&U>\ZC 0[425?:']?O%IUO!!)ZD^B;V?C$OJB#KGLM
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M5M:.+D'042[1AGIWX^F/LZ6JEAZM=!@_<E6\X:!C6DBS3AZZ9N;X;A\:N\P
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MK@@?6C<C*F>I@A5-L\=@AJ$X)-OR$OY8C1.!K6?0(4B([]=EYQ-LCT]9-D\
ML-21&?CL;!4DABY._XV^R !$6G=HJ_?%57',#3TCK/LI.-4F]3XOO\E_OZ8;
M]-XGD5>1:/B^7NB1S>LN^8+/P&$$"Z+92YVU6!:N1G9WI:41HG_T;WYRCO(9
MZW[#QP#L#XZM:#8G)3CRDRE8'17A0)6[9A#CVE]9&MU'(S:-3DO=Z_0FQX?S
M(%35=Z'K+)0':XCRL<3=5P\&U%6$EX,74&F'QS[]3O"-%/EV->*GP^IS+9[U
M"RP4BB$\M),20A] 7S[0/4DYM_:]B $HJA\S:_/6I.T*F#*!^H!F+!B;K:\K
M4D.L>8D&R=!&E;B+<V9]QR3HH"@ //S.I7/<9<?UC%%]4+(S S!IW3%%CML+
M+^M/IE.#;06ID1;2>8;,TU-%2GH]BT@$NP)%W)9GUY361P8@5,[%APQ HCG[
MM+X,.0KGQ=ZZY#YS9F#GIC?RD@4F=MI[UU\0#SZ)\$*^A',1%[\387>(!'J1
M9/&W44G5)4+N(H>_PH48B6KM3.M4L@^=8Y\H8_+.K*@/CQ'X?=O) W+O+B^"
M$.^-'".A[O0S#\PG:$5-#/8I 2WJ^M;9)*8QQ2Y-PN^8D6?H,NO!SNAN'(9O
M3?,PE]JC1UC?]-$M?>$P'7=1?NKMW:))A#MJ/+T-7,X M!.L6^MRO\889KG\
M&-@]8SD_/2FD\WQ:,__ )CA<CT.^+9^UD'QOSLP'-]:&Y E\VWI?>^,C@GOO
MZ?BD[,MH_N]76T.'?F*SW'?[_]+UDW,/N*4$B4;AJ0<2U]L1F[7?4.',!\T"
ME_?64JY1?0;\Y+ZGZHKBNG]4\5A:)'OS*S2GL,E'^S^X+"DLN]>WN2PBP'*P
MQD1.!Q0?<N>GQW/1<3CL;.#]TD']+/O3J6#L1X2H[IWFAH<4R\",ZUZ[;UR_
M][*&>&H>!Y.&H-EWS=F;;1%4_C&<PW"1#QXI1EYJUXS85._(YGXZ&_.NARG^
ML<_+(**IRGCWU0D$CNO'<*9?J('EC_2 82^N0^O1=^;LKY=!99 F%#=! \2E
MJY&+B'4_\QY92AW[^A3$ Y/!F6'^9 D-^(8VZC?GM?*"-U,%!_^YS4X)/@,J
M4_Y(<0@\/6HJ_JHR26*Y.?%#O@DXX)R4[8R]3UG2J9AS0?,G@',Q2>"'F"00
M4/V#&O-5H]!GAH]7#]<-^*[X<05I88O?%/&&\@*K$#>83X/+6V<2A:,H<C8)
MVI81NIE4&8<!D+5D;903/Z/O44D1;R6>(S]P2G@^OYB)W4%-0CG)UB9$<+0O
M!KCL[[URJ/_!,RTMK2STS]S5*"DJ;]Y;V^'_;\+:T'0P\0XD1GNV$SRI@@.U
MAEJW 7&H8VM"9Y14GMSI/].[POW#/FR0KTQ:E'YF%S7L1M9AGAZ* .PNK;#!
M&[?6QQGX$?*=N/C12;"29K+U=-C!ZY'SW;O.O8,Y 8X*K"^AY-/"D=<29D]6
MI80DYUT'[P4?,@![-VAI.YOCBKC&_4BUGA=KT)JZ8:=ALYXIQ9.*:M[?IL[*
M@.K92:BPO]/+O>BCH]^_FE-=MKY<C;I.TOA<F-,/J-HW6C<D0O$J37U1VM$1
MI$MM2^T9.Q/%Z=Z.'P]0&DT#'84?%\2C1>_/Y>GOL.RH_U,G-LK]T"6J,J3$
M^CZF>G"G^[HJ)"! (5'A7< 3719H%ER.^=]R[ /K]RJ)T-;9:,X\-RF.^F&/
M'8*!54.U?\K*S"V=*P$\^<< LA*96>]_LB\O"&ZC"(T4!UOX3R2WAWK^SL@H
MU;#(_J.2XNWD7S=ZA7V,3TFL6\2_[#J?$S\/^U#(]#-7$:Z0EY:!=FT84;C(
MTSTXZ]CB7:/O"?BL"]WU@(-2P9:%ZLM=QX,DL*P[>[$'\GO]M+ILVJ<&-NP!
M52:W'>\E1.ZYGJ'^=:$A-S)2WSWJU$>YZ^:?XU."\ U%.';"+LFE!0RBZA'K
M]Z*(5A]Q!523,DD-!L#,*JG;U?A^381,D>*%\3=7+<?TPL#7UOX[@Q+%LR>>
M:J 5B/2<G%GIE-[#:<*"Y;3-37!O9?ZWC[>7@5D,P.,^OND_9*\V,*]ZC+P-
MT3'[S)OI$8)-W/6I75 @\$'5SAG8"$G+J'EV(J+%\7)\D+9*W"-ZR\@KD$+F
MXZ[DQI\<^LE(VT.K1FZW.QDHR6^H[37R:[Z9"4.$JWKELI2H>4[!!H\W_&AC
M^M7A#>I9V'PCVKD\&;/P5;X&1]=/G;8^10(:9"T.SMX?>NE@><M+0[71 ?PZ
ME &@P:O2I$RL<_1RR?I).RZ\YU03ROAL.Q'J(_"BWVO+Q9M ]^?D&*-J3!@U
MI=1DWVH#V#^:\.(7DWC;Y52K6L:^<XQG4I:4\/\(*LWY41.[P2F=I98A*I#3
M>3K:RO)ONOLKDYRXDXR:@2=APF/*,"C1N[DJM6':J+FBC*+^<^,A?2Z89:@&
MI!1LW;R9) 4B8US5--!/TO%<MTKV7H=LV4]^O^P)O,<>G]0IN')OC@$0!;MX
M@/%GUAUE^[V<B'F)Z_00,\_N!64CP_? AL:*,:F<V-V<5WFQ)B(E9P9#$82-
MM3Z_16_M.U\.\@E4S,+DEEYX[ $%MT3@+W@J)1W3#!(JGB-NOJ8O5!?JVTE>
M]^4N&;A_Z-N79[(_GIH;-:JE6^-\R@D@F2<A$5!ZCAS\/NA%7VE?CL.0]MF1
MA'N!3#6X_LZZ#T(4Q\_I\)/&S)NU&( WMPP8@"<H+;+[9ZH].6H.+/443/RQ
MRZ5"-MP<[>ZC]R70!SXQ !JJ&K29#WKNZ,O'?>+SQ$B5 8,.!&ICK\OK3-NX
M;[O;T,70=,,@HQ8&(%I*EXAXY;C?ACSIV>"05ZDD\CVC^93Y?+P^UG@N2V]M
M9*VGB&,H_;S<U_HB>H&D^=N4AAROM9],R;7U_[^E0A2[P6[@ \U-"<0?/<Q[
ME"7J/"V? 9B?;?!F ![LT1_5$1&;:@Q &^82$RZV('.HB1'8&FH*D WQ1VR(
M ;A>XN_7 1-B %*N8E$45EO$<FII;P6*ZGJ(^5T'/1K*9V$H^/+S_P[+6/>!
MI,#S<_K'F!QW88D>)[B!/D,2C(FLY#&P'5$6&H.41>5E6>N>R^];^L,[/]:$
M/ %^UL/:@1"@@\A9DU>''U811]JV>KA+I XB\BUJV%GS@O=?9"JY[9[1]JXS
M,5W$#^JN>[CY8G/D2\:P X?BAD'()E22K7 G$NC@9GO=T@;BJI+J[?SB;I=4
MD!4V,^(/16SG%VEU\!-GG9]@AD[VY>'8=PY#3$)=?OZ_DE8R83)QL"S8 QAI
MA1'&8+]J2(F3<_'N*(Y X-VA4_2NX>'"G'-7MPW%N]Y9N;:&W]0SDHC=V6%:
MI9OPGO7/2:_I<@^,+$I=?X /E!P=*)ZP\R0( <( L)TL(UL7DM-4N)YZKWAW
M?9F:R4X3C)]\+?=T[M=F\KR5O2?H.3?)X1SS,/*5CEP!23XQUP%R2R!6_ #P
M.)@@V><+3)9L@\-P!'H>AD(,!I6$)@8W5N^F&9O[/G&Z=R>TZ4B]&Q9^A*KH
M%0[ET%7"NHPDUDV<R9B0-/R\Q4VF*WV<]1KR/AQ#_.OBCG^G7;AH[?@!F'[\
M+0,@9S:'.5QA8ME<"W-V,R::(#&_J$2^QSQ3G0S P-;8P+UM%/5D)_U6#<Z:
M%@%B (RZH8;_[,9EW;*DP$"$*_+$4W[ZW"U2>_ZH[^!ESGR#MZ<C5F<;P$1U
M5,E:$^(9E&<:Q.KJJ#GX5KLOHHIC]_(OVF*,M GFEH<\;6)7=;54L%:%Y+J]
M0O[SJ^3R2$1DM4MIH(ME-0D5^6;Z^EO9@:K&85Y5KL>\7X-!\^[-< ''*7@O
M4KB4+KPZ=)&8V"@S&_AHRW*K;9ZZUX:$1XRQD]<&8>QX\?N[]3J3FKU1^(_W
M=[DTULM5PZU)?5M%8!#ZA"$IH,GRSS4&P'GLV7M'5^NBUJO/&U!Z$;Y@^SW!
M!GN%D52Q#,L"LC]B;VW@P'Z[H';X6RX#H'(J9YL!B+'-2C6$31+7]GX1HS!1
M2L\:0@HT(O"4(Z/!"5^KMRZJ=OBGB]^-U[B4V'FZSHO\K"\2O*,A3S_"W-TV
MZ_-;Z_:R<^L?:YPF#B23V\U3()]"EZHM'!5!A&1BK(V@</OKVE>L&A4(DN!Z
M_ZWT"YUJMZ2T!+2_+U\5/5;KAELSKZF*2*!\2\BV$M3GE%\V-A2P.O;R?[I,
MX;^, _^V0MQF %R0)^C]B(J%8BE@9:AIFQ1HQ-(J[K9!6EV\H>R+TV=QR"4K
M5O0@N^WA5BS@;_-Y>I.=RD11*X8#KD*%$'MF7Z)ER _WV_-<D[DN]Z5J_GS;
MK/:LV4?JVKS@U'/W#HPK@IV)'(L9 (\^CL!3,&E?5 P26'6SBE/7Y/O-HO-F
M\\9R3YZ=]5F(NC^4F7+;>XN>,K;02>AC:HT$.0?+Y&P!# "7/M]D9]ZTJ^IY
M8<VN!^EC 9;ON.]<GK:YE@^>ECV,!=",OF#XT_?J:0V?#,YGG9/>D6D60E!C
MH!Z(9@VT,C6$G*N2V-G16IA:80=>QQ#T>"4UT[9ATVC[BYN4@LPE"=\>0"CF
M[Y[<_,UO>O'X9Z>W_7=&A1.IZBKQ#8*ERQ?<3KBJKOI;VI3L*$ABM_E*B9RB
M,OJ5+%M&[2ID17 S*'I&N8%(*UJ34LSX]9BM9S'IV;=QA]LB,O4J'\*!YXYG
MM8TU,G6F2CB,Z42X[-T=CPWG(M<]3S<.;9[>*BT1F<_W[1*1EE!-X05J'05F
MP7GA3&_&@7G4!PA<:T/R;?IB1%:V.A?-"M;J?(-J:NYI10G&.7]*(FYU/EU7
M7 "29:M*:#$=T#@&@$_-772]@>M;()QP2_7BV<8\XQ*<[*YSXEFM53#6/BRT
MF7(-T6Q"YZ/W2:DA6VS?U:6_4J?8<W6'B@DD*XDP#5#B[QRXUL2E1++ZZFP%
MBG 5"YJ(:WF[EL4^/(,HO\E\XM)^PX"GG3JPGUO/Q=FY.=G9V:5?'OR]M>8]
MV>,++)@\0@*WP_6'E'1M_-A23+H+FRIRIAQN$61S[_/7\W]G %YF-%*.WL"P
M(["Y<#VB<J+M[-4,!^O;I@\ZCRCDJE[C#28</P9'5[+L6Q/.,L\ #]F"<I&<
M -,LM9]UAY_9:JMPS5 S5;0MH*!]*MBN&9UZ82<B"[BJ%[ ^0'E(O4PK4NM>
M:1#-ATCE/$RJ6A%[=TT\_^Y.Z.<W/R'B[S*E>'G@[O!FNM@@^&G?Y#9>\Y6N
M<YY=8+@(IM*/@U#%$3G@Z?Y2@NGR"%9-/79D<5</HCS]."$_T*Z5I/SI,]3-
MNAKT.-(CX6':^+?KK/V7;X4JL.ZI_NM(%OB?(UE/ C?IQPN(!KBQA*K-XZL$
M/)C@('08JKWV<XBU<[%M >0>%"%S[KG[-G0/0LN'"1+=]P9(+FU,$7ZZ'OC8
M,O3>9XWJ%F.2MSYYZV/TY;4^ 1;*F"$,1]&!SX*X$&Y B>E 2+.+K795560&
MTY,\O?_J\5;*S8'ODWU:J8&=):&@?^&"7E+\F:I^90<Y?FYB[,K ^@.2<!(*
MNXTOR[@F7?$J1<AFC]HI*R$MG2EU!85:.ZBFH1J@^>2UO4QR>M'J"]UT5??T
M"_D^]-++4YUBP"OYL>R#87I<=G\;1.$#AZ/EAZ_("?K(]*FT-"NA@6:1]6QN
M%VE$I?&N'+J'%@O&%FNB=4BW4['0>+X) T3^S>I11_F*> .)E+*6DK;'"PZ=
M &V ZHV[+]RW;GP20'&_EGW6=9KOUZ_G5R4YU%AH=W9S43W(:&CE/J%L#A6#
M%JTGYC4K<=WYCC2K<0]UOU=[GSZ198M_(;6J@MG'B*UD0,@*+K&'AEC@,<^=
M"UT5N\C#?O9E-L$#)H"HZ".,X*$'W/1^,:'WXOF#! L-FF[]_9[K""P24ZF/
M80!DA D0U*^2_9RJD#<YR[K]8!, C2/E^FM3G7,*&YU'*I2IUE_NGW7_]*AE
MBO>;W5=[^!,T=Q*=4SVHL)HI.6HHJ?0;9.9^ESE"*!F3ZCK.W'5Q.O_--;DJ
M?)^$^VVMTV;7CEKNTKK )0#8-/-TOZ%]SB$A$G1EB/NMAR/5.3B*.(A@-_J]
MUN91RJJQ)+](@8Q"\A)H9Q2CZ;X))I\U6@=EPW]7ZPN1P*UK2@9T?IU4=R7C
MTB7WZ.@U[Z?3[Y/>:7_Z@776,X.)7F&#?X/_Q!#OF7'A4$T.P!9'W4&J,=[K
MQ/("X53=$&'0XDR^5J1..ON+@O&A+RJRBYCS+6G2 &-=@,[8)I!Z$K3GFXZ3
M7^_)G2+G&(6K\)'#<;O^T:MLJI,MN.L*XZ)'O\3(5%.EKGX&ZK^E'U]R+ZA-
M:IT]VN!>A"'B]3'A16+7__;AP_Q)K![$I?5L?'>J5[WZE+5;Q*HA&FP!_3S0
M]N;SS0$+(T.+L+,[+$0!:"6"T(7W_@3<\R/NI94,5'ULRH5G;^#!N4:Z2*+Y
MK*#+,T<6HO_FAHC3^ &3HI; PP:N@+(PQ#Y,C==K\+P*:>GZX+X?A:W!-2DO
M_=D[)+%IMC+ZKTB!!./B"UX-U='8ESOBP];+#@(L!QM(HHGD8RN/&1E:-M6]
M8(/2Q>$$^GAK]E?E,PPV <DQG^H\2GT\U^AO,6R6;_<%1 UC'G<I5./R9V ?
M-)$!(!JCHFP13;-"FJTE0 M]G9I*RHT/?@$%/1<#$E(GP"JG.'VMKZ9BO\OD
MPE6G)DU=O)4:2+J7VA:U9))-RB]<EH[HCYC %)H<".]]9&[3$^IY6DY5;<.-
MZ+5F^%FDW)SYP,@M:S/:2K8G%Z(RUW@#(L!"EH%F(XE&X+"ZFEA]=4?J[=J:
M0)@6KM[&X_.GYB/X+>>S97K7;MC79#OMHH*(FE1^<-/$[2J>L5A80-':(<Q3
MY(^MW9F\#!9*B=S]L!!"\\YIS!4J.Q;(2[U +(F)IBI^M5T.EHSEP%94FA7F
M#&<50^ZTI4!D,P#+_Q*Z+Z!/4Y6(2>V-+#L0T<#@UK9@N^V]$+)!E'YA<,'^
M4;&#B3$ZIPM%8V(-.L':]/9F=DV<EE](1QAH_U:MS)\4O:*U<PJLP&8T!Y$!
M:.TY,GN=V)O@G.TJ-,=O\^=:V0U,F&3HVHO_4AKV_]Q"_9XE*^R_TE>$F=/R
MX" J%U'EE3QQ.K$BCU:LZM!8;*V:ENZ=.K3H?#TN:NEM?Z;U2BK<EJGI]QH<
M\"J"]'X0%UJ2"B924\B'HZ<*70][LWZGKV[\%E+(Y!,T>F?_-O/!BPLO6'ZI
M4$^8SAT D'$9E_4Z]Q(.&( )OWWHNB9%-[!^SXT,R2>[=,!/5Y,T"KP+NV#I
M_A6FYXK-)-Q.JH:].'ZQ\[8[SMT=3%;8X3NMM%AZ[P;[>[51K[;4+JK[1M^?
M4+BZ?$O"=9A?2A#,CE8D/][3%*8Y#ONQARA@\:[_O=:W<@5D,& HP-(!>T"V
MS(%YDOV* Q7;5'PS- KC)+LJWAB=-<=]%XF()W2:4!MI7_7Y XVP,50!Q;T@
M8DUXI6DHEV%-Q&WOHX"TY)[U@Q0C+1>?EVF/(*S]UFLE,"Z*#;P7RD<_19]!
MLE-#< P ;W=^H.7UZ':O7;94P0<7IW]OOKE_,LI9EW>'90^9!#N+W>1WE5OK
M"-9(*'2=>-'8^;'$MEW-JHF[8O'*-6*._ 1&!>RJ$JO=216HGX/$T(&P\V4^
MQ,W6FI9-\[$,59DG@ X7\+3AM=6XD6[0LU!-IEU5)R(ZO&+!/)405NK9_M(J
M/;!EAK'?"L'EYL=?5]!WCU8 4\<_)(*7WDMRLB]XA:$%:568)[-L*M&Z0&+>
M];)R5;6A*3/WH^G"JB!\&N2RD/0#WB8 &\ 5/GTH("5%JP>[ 'D^@_\<>B0F
MNQ\!FQ7!5A&&MB-,3:ZIL(4/,  LRB7Z=J1Z=Y69 T_\V<,TU'U:+<*) 7@-
MDH*!B/5XZRCL2[@BV6I"'CVD6G:P[F]RW>E3?<X[#8%,OJ7,,&!FH-$>@HFU
M*5#Z$)V3'$&J:$G+XB#.1@J=4'I\H#_XR$?Z^K6-MH;WY]O"!![XQ(>%*E$>
MPX? @N@CJW21*G(0L0[Z2N,PH;)\QDQ"^$3HAY%WY^C+?*J<NH?6[<C*)$(K
M:1]OU+0I3'9I!QU1UKV$HYGT=36,S(P2#,N]+.N5ZXVD>4/==_?0@<R7BD1T
MO8=9,0#?S9F<=*"?_2(3[=5KT6(;N.B[L_1W75!KZU]0HFG?@2KR"**1"==S
M5:U'*O^]@A.6!0:@,J\UAW0)2Z_]=B6/8C)S,?31VGY:(-JYL[892A9T(+.0
M^.$*U#-$>MU]\<Z(]?W7T\HR![)'_>==E@V#^0'A0.FQ'C#;:S*88ABXAFOK
M_#6P.Q489VC9LO#C@_"6C%2R2V.P&B8T^I-^V7[ZMT$:J"NN8*?QU-\?#@XX
M/N_3'S(F@A)DAS() [O^JG8G!\_6H^;H@LOJ47-@GKS7.V=+?,IQB" O>=\W
MON A4KXN)UZ#="Q>"/ML6$G\9VW\+J\.'3SG,(((-;.R*_G;J .!6O;DT/ON
MX69;=I-6T78H%8.O7V(5(W?^0_' ?UZ\4+Q\*X27>I>X/J'R:H>\60)Z!T^Y
M-IVEL5JL9S27[,CN@@>)T[MJ+%;H,NXH,9CRU(G)^X:S0=]4KI0GX:\.'3S>
M&!M.%>PIUJS>FIRZ_K;YW+O K^:_?@5*1PQ;^W%;YH&<+7RN[M LF4_\S>=?
MM-.('*HD-NCA0;R3:Z-B[9F'>DW'=/JTK"YEM67%_-EV9*-<#HPQB9B3[]A[
M:UF1X.GW)YZME(_3:!.^"=:T&$0;T J6^G7520:.Q,YPV?KO1.JE(L>5;IW0
M=X[*!N^'OMO/K64^>-1P3RY%D[OT5].2-'81/<3YIB,PJ$HC]7J)7Z$UQ"%
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M'>:'$U,W FF'=BS#0!(TN_Z)L(GN_-_7HA$DD]DW3@S.*[1VX"8KY=E3EMM
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M?CKI\ZEOK<=0EY2>-?96"D0%6BWI'->?BY_W_YGQ]C7='MS#!!R;2.VP7";
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MB]@(7BN_<R[V>ZIC4 7I(]*JK\ ]YN*![Z>OUJ_!+.ST2N\$$:ZD[R!;"B"
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M$844@'/1CP_V?QDLGU@Z;\^^DH3<MN)<<\1\!3DCIXTOQH/**O-NWZDE\L3
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M6K#J673]W;G+=T .T-(WKT1R0Q;9*)Z@#._APQX38BB -7212UC:WI,&;0K
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MD2(@6?/42"P _W4T)=8.Q[PA/HG:)<I&(W]'(YO_?#=YX:H?!1#,443>[*$
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M;VX.$G4":CY]%(IEN@@;.THP*_-R6P@.>XO=;T]SU_2Z5%(#FM6L WAO:%
M=NA&<PL5W[-@%U$P?< [3>X+QKP_(BN[( PFC-MZ9@3EJ*&M_O6Q(",OZ21\
M$16)UW>"CBXT4 !#3,\EM^!4%[(XCSP]3J3&[!X+=(?+B> L-;4JD5DE?_+!
MP*GNYD3NSP$<= /R5%EK(XH0B.Q$BEQ#'L>3.4XR)_^0>8PE&:']XU#J,WX_
MN2-CH8_2\;]@IET[+D.ST6Z@V3-YJ:+2)IYM85:05$)FP[]3#P8Q\[S;]C%?
M&]]UATS(1Z3A#]W@_P]S[QG7U-=NBT9!$0L(TEM44$ $I/=$5*3],5(C-2H@
M':1)"T1!>HET12$B'82(-*FAHR!&:NB]UX02 J3<N/<^9^_]OKN=?>X]YWY8
MGY)?,M>:<SW/&,]\YACX 2%U0GK/##@L8W%!5ES&F6\OUI[YH&4&2>)!WU$)
MN:[_KBW5+_43AE\ RZFE)FY]Z'((O#_H#1%LL%],?*HYE/F2@:"P6T>"$>,)
M ^Y#ZL:S6,"HSND5^??>OL]1L78.J]?TF38\"]:];DXI$;IBU.VE0/YETN>Y
M-H(3O;0I^Z;[%APT0*QYH)8*(HFL2QRZAC=&:(![J4S9I IB.,ES!BGCZ\'C
MY&D G*H)]0#!CN<T>H^@F1/4T4"S"I$T*A,>$@-W\0'-6XR\?>P1O'R3B7RR
MD:D54X%N0YQV586%[;6GJAIXLJ)$*7N'"BO/+3M<V+O..W&X--][^#'D9 *<
M$QS!CBKY>IR&B3KT9)_2 \70 *A#H+Q+7?HF*\%%:U"^Q(.9A&BV>)#C_KOR
M*'77P*>P.:(%J:RL\9L-1D\=[$V":W0BI^Y02/*PB#<C]A*6M).2BA:M=>G0
M&#U:MX.F)XH+<(DYY D2RF*H\IS@7;.O?64AV"#U*WFQKNX]$43U&.+7GXM/
MBG>"Y'.D$K>G-NL_\#0P544JJ7E9TS,<,(7*@6_*F8>Q.XUQ);OC+.+)/8PR
MTB]$B_88BC1>*AS-XI$SU&A\3DO@@W@G)S>%R<]7')INH=_)9YK'VBK_4!:,
MD, B[#PBFCC+2?HSVY=:/C[JF.-U?1^2^P6I\O4G:^^6,AI1B)73?;H6=$;B
MON1T[^8!JW1+L0PQ:0CSIW1\:#SZSZ!SE]CT1PDP D94&D5L#.T)_DW?\-[7
MZ8-".'V)>SVE <*DUXOV+J[JZZ@:X3)\P_]VDQU:.RCI&L7-?:O9\LVU-U((
MU7(;#X(:,1"OW4$QPAD20)D:BY.5-O<\.">^O'PGRF,&V#%PT37VJC+KWX%2
M#"]YZ4] $7Z'6=['CYS3H'S(5LB-'>87_IT_WML5OXB?3\:>;'I)G1Q K%QQ
MH0$0.+)+.V1#!1]=GGEV8QYG1)^]V#PZ^Q8BT0GS;34LF7<"0?!='TP[[9,-
MR;+9I':O;9.[SIM=E4LY-*M>.X(C QEO,0J$_8ZQ*,E;K3X"O7=ZXABA9ODH
MZ<R;<K?"CZ=XU;, ZV8E[2^:(C_1L\/E?P]-24S QBUNF6\]#8_ZSJYLI#T/
M8PCI!^/U:0 6:A^09Y\& $((#U>\UGKY^7GV2$N/B)\*6)Y9+;L'FDSC'T)&
M'.90FQH$RSL$X*N&N[E.JO9I<6F7[A;"L R5GYRLOCR:?WQ?,."7O\+.Q#1>
M9WN,?4PTS4. 9"/VQMTAV'GC!M+H+X&'3$5THLAHC"]\$X#BNVZWQ:T;=8ET
MN$]<WL@^EO1G)9KA38?#9T9S!\NV[<WW)2VVM()B"P#ADS4G##753,Z?3_XA
M@NK1 %.9DPD(,\SQ!60'ZL24S;+'Z Q!?OMZL&)4!>P%HD4-; >,PGQMSU+V
M$'()?/9%(=%1\G1F@$(G5KIWNOZG5J=?F4Q6Q$O0/_=-9FS].:%L8IC4/G-B
M'4:/D#48,B<?%E(!8B8!T95U7W^5(N9Z!.1E;GQXZ]9S4D1D7@ID]5SNPTO6
MP1L2S9BGJ*BCFG@:P,Z#P;^K4[4](Z' \XE&+[7 ]^5/=B?-9\T,X8;C5?!S
M>=1A1!5XLXN@W_X"S(">Q:='^/CNI@&J":Y1Y6R\^8F\<<A*<DGX#.&E 2"D
MO@^6.8V'H,>#YB!(JM0ZZA151HL3%U,Y^*&MZ(QMA*>(9/23M]I1XPRI]@S*
M*I,?< R$ N(/TN'QO9 !OJY6\.C6DB#+@%:2OUV])B!M_8=RFOGU=X_NOXH8
M,FE16?@P P@IZ(-E@?&0Z7&/.>D$.D# ,%)E#Z&@6P,=+=6#\+>S[W)?4HE3
M6G&,3P'/SG^T$_\5B%OQ_>]9G<*UC\W)4L,AY_VI;?.1;8.WK,;U6$J=V!>O
MP>9NYA1_75!:;N%%U]Q(J\BU<#FR'LX,/CMA8=5IFZ3$R\@&TTQ<VOU1[OS5
MZG?2X@>;_MA)\,#/I79#T]F>BI5CN;<D, %ZG]0[<T&N0_5F\6_KZ]?"GDM[
MB,W.>XZ$'8:RWI'8"9K[V-6.Y;2EAJ:#CV1*5C:ECHTHKT$@@U/]O> V,/M?
MC-F:'>6BBV]832E0X4+.78?VDD*/IBO^:4M36AG,5;P+"?=4S(RO7 Y;T8*G
M1P>HR^(BT:_A(\ZX5)4 )W_,MK;#3C!DO$&X;&U.QC,K*>XI:FK_\,,DAR$L
M MC?M5ZS,4W/R-S-,")3#0WP^U2@5@!PHV0N4[0=QJ NS/*^4#- (P)UH730
M$(-E+/YVHV?0"RSTJ=$+X]M2=5-!$:5U"&P+:+@&D6F_[XS-LCRB9V*)SSO_
M86WAG?11P1%?L&:P-V=FRN[/.>6G\9F3=6(,(OVV>EO?"1ZC^E0M#6]JJR0-
M\#'FX.SA-%&6(,)W$*ZND_CF:T<1N['ZAL1.S7S8(?1WOT[B%;_'4:?U99HY
M6UXFI7%=> &*C!+OSG*R8;>8WKM;B%8@I&^>F 4SUUMV^(S]ROYML3K_L^4
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M**Q@/W7OQID9*VU8/$_O8';AE>H-J2];_@5FQ+@: #MQ,#S2OY.5I*5N?BX
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M;D7X%>\94$8"';?4L/4NYN7ME0CK?&/R;^;A55YX4?8K1N+GAQQQ)4[[<:K
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M&XE*D:)[;BVRE" #U0\"GZ5O?TQQ#]ER'J?>?E2<G_4B:>#FK0MOEI@'\*1
M$T3$D3C?5I3$A?JDNZ5O#RO\X[C=0&VW1Q,0X\V12S]E#";6QY!UVU"9[OK>
MN,B9B9Q5BORNTYT;5N(>?U1><'OWDH=AY())BD;74"T/+LKBD FZ&HRIUYW7
MX'S(\]^KE;@,X%I!\<&4B?S[@8/BWD@AJ%ZV([H6;/OJ>>3BK&17\-<'!M.F
MX+  01B=V[:^H $67_KQ4[OH'X9U5H^OX Q+J3\G:CO[4K="DLVD\)CUKN%
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MU;*P6=2V"GU;?\FKI0Y 4DR.FDA&Y.OCS3?)8G"@ ZM3?4A3^(*L!\^(T^;
M!2%_P>(%!-$7W0DZQ'ZB >;H.))03UX!MV#*[W;*2T\E)LW>/A)]6=E?*=DK
M*&#EU_9XV\?EQ[C6=ZX->(5D;0$Q<($&"'>54?@I+L&@&QX8P1R2<L>$,>.D
M#@.A;(0JN$?0H@:L@HD"- #9I1X13M^I!EL<W9A)"/'^V531"',12\0&:7QG
M]/U%7F656_Q,&4JQ?E\?5X+TV/2=HH<*RB;WE >D,?<B.%XB-1]]G3!\=V#A
M:CP>7;R!0-G&VVEX/5EMO_A^D4T?B<AL _/ [:X$(EFM= C<+89IW_(&$CQ?
M9!0Q]=]0R-<JBJO&@9C CHB3Y&>O56W]*<EE2/;5@T61]4#<P%GEM*,02+YA
M=YOGODRR"$FY&6%/<8#+V'KPC3HJ6I]U:@(N(PP(W7XH*\4!\^PHL5'E)_\W
M.8[_SG%( ^S_I'R0A$/!KY.:6:O0V?B-MT[Q3B!HRE0_\Q_Q/K@S\EO8C+%U
M,!/Y% UP1IG33[9U>[J4G'(2X9A7/7RE]68X5\S7QVGV+NX9>^BA?PS8@GX'
MX)GI?/C&[S8[3[)H@)P<9!;V[PL' SS!?R\PJ-Y._A.[_H]KXA#N\X+'-_VO
M9&J,/$]1,U]\-W[GN6BA2-Q]:$7$PX*[P@)F V:9Y=ROD"XK7X-].U67?#Q.
M%KFQR&U6CZ@:^>XGN.^:41[$0$(R>(?*4([ N#L[CJ:W)EN57D9=DXA_IYC[
M<8*YA2RVQBJK,ESE+[@AC56X)N#\O"9$6%R)!6 V4 YKS0"\\G^.,",H>NHA
M;FF,OK3OOI>>AK;#]^T_P0^TH3BUD(X!92A?GWA%-06*2A_;F1L>7WG)T,'.
M :!Y75?Q+S'+"CV4Y7&E5W%5AM8W?@AW01@;60C'(*3 MGH[,G+<$Z"#VL+,
MHRRV&Q _9[K;1Y0&7BHZ8\",_?KSC-R:T!='G"+/@G60V:ME]7[UN\GBSW&3
MW@=*)VQ7+C+A!/%$V"8$&*13H=[V+5JL!D1<A^6_DYJ\)'6Z/VF63?$$QN"$
MKOZ(QWY^H.MGMY-:I$_HH3$!O)8GAX:TH_B+&SWKS,)3?)-8Z0*RD\XADLYZ
MDN>8V.:0<1D XIOR6(;.%+O=@>&?/RYE4BG*H-TRK!SR.B%SHP[?WGTY%X5/
M3ZSN>T8IT#\YKA(,NW<<]@G-2M]Q=9@!QG0ZEU$6@Z;<<U#68X5P)RU,,H4<
M&F[@JY5/Q8$QD"(:X,+HD7+\A^M)3P$,(AEC.ZE^L_NOB$%@C.]<DVBWSTU$
M"E;UZ[:],+K/16??I'!W=E*O!2<WHFB7#[5F:K:IT MV-7!+PVL:<R"*0O36
M93*J<#(4-+P=WB(9\)$XAC_48>JVYF=T4QVCVSG,&GC>FZQ$ V1AV^'$.Z&_
MPY,]J$CP+SB^7-&($DEG04]I ">KX(@-&F"=C)!I;$)MX+J4BM.0A8BSP^^-
MFW+0WSCZ86,.(#9%,4Q#5]60HEZNTX%N7O]Y[J%[\UI&U8_2/,?K^8C\5);B
M7//'1$27Q>N:H6^!SJZ,;C_:)?CJ@EN$?DW<WD4V0Y?*B0[S-\_&6.%<>Y<D
MU**N(A7_]TT.)EZ"$=TEX..)3CJ7[J.3_%,4SVI3+Y.UUD\\(_+/AZ>*AMDX
M6WQ_7E]'67NJ_8SI$V.@)Q&=NY?+<+PA)Z;XE'*7Y,343L'+'".VO<CB!HMI
M);AZ!/BLY&YE@SIZ2UQE4?WFCBTYELF(4!8.'JZ:=';APE[.V4B@'BI17S6D
M7 MV>DB]]'#/@K+>#W_X&AXF"M(JF-J,DQS!U"0LOY&Y6E85&+?FR\( -J1
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MQ+P];HR0.M^-.SV/#)NMT@J33A<@IC^5AV7EQ>9?28SJ;F"7KTCF!ZH59&@
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M179+Q8*KP%&--O-BT_)*#(9^*;]$QU*XCSTUD5.YN\A'T4?^@-#IV"ED&74
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MI>0CT+/>_=]#/,$K3HNOIPC&$^^B!M0'4;C7C?^*^0&T>]^A6+H)A4UICA2
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M?UEQ%Q;YN&,  ?W@MKF@5UD=<]*/7];L=.*!>0^ZS']CCFY#HP"(;4$*X88
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MACZT^PO-%_N7$4U=0F?Y8P@,B]S_G<WV.^:72V>O#MAH\^.5[B1J7R Q&>J
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M&*I/ZPN2,U8I<A>GQ<NW0BIJ-OPQ1Z#GYC!.'R2[]D("5Z_:C'#=+E5X:%^
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MQR';_="V9WRJ)??@TH91[1UN81?&1]8JBOOF35D")"=RD2?"!3>%]6F90 H
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M"*KV#\W1PRW#OM9I<@S)G$P]&VJ41U4O<D%9,\X/YK/R@E2H0,22(\\!]"Q
M-+:^T&,NVNIKK7X1X]J%(:$7$?>LQ1YO!/-$/*"_:6P-O0PHR(2@YRMX<U8]
MI=J7OCZY[\9,&_1A(EV=;6V)1HL[?2Q,\@AD#P$NN(15HD[8SEK#8;?J2J.+
MEM]T&55-G<J-[[MK=M_"A4KG V/8OHW)L$X([O969)WHFY; 5]*5AF[77$3
MF<*>V %C(V3K7ZCR%*KY"M0!1E4T50EM)B>9P):#14C(KZAH7Q>-]<0?Y>I9
MC6]T%E\ZL\Q+6ZNS='AL'AX0"3WD8A*4*(Q05&V?3S#%7\ZV$H#HSD5\><%L
M6Q\U=+9L'_3(E79'GL)@0I1$7"(GP3#3:*8] 3TCO-30C3'."IC"X'JLO6'V
M-/?44Z$X6M)9+\7#-!=\"R0<51X1@A=:T&EM]O7"%*IMZ.@?<]M,GZ&/-P]9
M4GOC$$R_?M)CIX*@27ZM;DIT0I@=@<(/\&BS&*]3LU*]J5F/OD$K+?G$8WDP
M4B^"+Q^!.$_]='Q-!5$IE UAO@")0?( _CYN_M"0W35E/TO[H?<.A-I<2;GO
M-)"+TNR/3T0OQX$0MD0MDA:^I*,OVA1Q"^^7.UH*S_GU(U6@4:<FO.445N")
MZ-5E$%M]H\>A;LFR!^$#.7L>Z!9K[=& -DG-"XBU\+H0O%(SG=W4QULCF%)U
M5+#)/PR$QS8AZUGXS2U",J#D@ V< T/#-Z6EBZ6FC).TS\&D"!'=9NI[O[0$
MV__7P;&S)AK#Y3O0+)HGX26M4' 5GY%0.V]1R<2]KPU?DHY'\P0G,\=\Y_XP
M?TEMCV/5+*MD[= __+$AV<'\:Z3QX+I]8&Q&?20]O^S''GFV?I X[?:<#A6Z
M5G QC/]Z%1;%2G(>MAKJ(-RM24MT5WV2TS'X7?=9$\>3!,6WP5WVR5_$FW^V
M4H'\$2^34'($<C9)F#2.5NSM(_@E=V.Z>EC/#SM6?3D0ZKM1KJ6_0D\'Q#^
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M:-X^[5G*4USM>%M&]<3HW#B+]FE^<U43N0R(P?_#'?__D08/8J[_,_3:<H?
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M$EURR)!$A#B#CS',5, %%!^26A^APA@EJL%>-OSLY[IMZX-$48G[!4\&)DP
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M)@NW!N'8E4J[%10DG7T!Z5G/=OZ'\AEKG3)?X)FM#AZS4!&:4!G.**7#BR2
MGZ"H=3$ND *2<PLD3+S]G<ZM[,FX9803Q*]PW1CEO<J"8<ZEPQ%@;52/'S'G
MS,01L\G9?_OG,_1W>A+!&62]R3V+T\%&=V;5>06;QSO;T,TF;G,-'7?*M]AO
M'%OSDLG(;P8S.**)O0/.(/H;N*B'M @Q__.*F?W8_:;TG[W&DQ_:\D\(J\FK
M#8IG6HI&RR:SLW:&HFD"C3TOL9$@5^ QYDR/;^]R/Y[W[J"#[C>'0N,:7UR2
M*'XNYG=*1J90D.6@@CF:E*1=Q,+-/SW7)8:=@):M<#C%]NY3DB54FXP@#F11
M#9D_XJYZ7$> %[W,1:.STMGDT<L@A7Q3DQ\W<7LV',4^12N=F@SV,J+:BE'X
M$>!9%5--87EIUO@EL>H 0?'DJF)'S$+F$XD;Z;<Y3 ACZA!R"ST%I403H9<I
MHY1@@I/;ZL.AG29[#T ?+9V<YIRN7WBPO.B6)Y:0+Q0C&I6,DXYBQG ,A0VG
M? IVA9B5"-/%+ZGUYF!^(^<GI%3G%3-_"K_.Y8H#G+]SC->17WX#2SF_3\N6
MZ]VFAAT!)KY6_94@#W;02QF78-?'.T)(:(N,WGQ@4Z>PN'.:KZ>"TP?_\S^H
M("P;>^2$R[BA&J0,0;Q[$0.:R\+C'D4:K/(6MK^+!T HEV;C]Y1/,?J=04C3
M'"@TH=NCK(/X7BC&H3S=TJ+XK*O>&$2).5%2\&,4D0$(9X?;*I O..@NB:<V
MX$6I ;W,,XOSN/QQ[\"J2!:72U\W=V9_R1'XB'Z]Y'"*_ H6X*DJ>G;FV3=?
M<_3.@+];.KMNSU!<7Q @>>^ G?C"FEZ)P"'SKY#8HG=!,;-MA-J**];'VW2G
MZ='?*J]D. RS.+:<^K(T&0-(!ESWP43AGT007S X+NM<QR>XUH^?;"]UUG<#
M+K6HG3H?W+55F!TG%7$,M<C,V.E0=*-F3(=7$99F]7T/(1Q\H.BB@7F2!".I
M.LBGH]P59.X_6=02OJ9.@L2!GBIC-!_0/W2HK%I(4=CZVEKJ:WX':HT6AI9M
M6"\N8"Z]8Y%,-ZQ.>V,\N[:TH_3=UQG/7#<]>@[JP@)CPA8B0I/#AVZ+N#<:
M/>E_]FQY?ZMQ(5QCF/]8C\8I'M_6=/;CW]EBX'-HL3\H=9C2=^6FE/FA63PX
M4F%[7%'G3B97NI.VP84Y85]!XZ$AL2'\J*54[WOZB5*:A$\2D&A$.+\211!'
M1Y>USU2+<C546P^O7R2K=,1*%TA/]S$FG2_0*T#>P.C,61$@F[HR3S"HU\\@
MV']!FS.EZ3?8C%HHJZ)UD/[*3A(OPE':T+>"8HJHR*>4((<)A&L"+SMEN.<E
M.F:[VGM;\>GD'EW+P2CGDB@*EUZ9:269N"K)=P/(QQC!-G\G0F@"+U;0,=+4
M(=+)I"N35Z>58W<"N(<X]@_N+$IKP<HZ0X-H?$&XE[^ /#1KTLU#2>?-65;3
MR6$>JQF!;%$$^BPK8R[%GH:E%\#9G6'*]%(=,+'UEBKDU4Q_?JZ/8&Z.:UI$
MB^$@F/-<Q1AL=E>(*(%W*NM6CD+Q$0T*P4X2%O$8.\N'IAIJ\D> KO?U-'?6
MSO\7U7?_9?^;6<F9T_IB;,V*@BPX:75Z))R%IC^S/KV'C,$X_!;XG.[A)>YP
M3T8@_5N]5J3);U_G#&(CKBP"SNZ^LP$_240A\>W7XSRBWS\(B?OE-&KWY>O
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MOV%6NYSBN";(O;SH\Q$@3EI]DB%!$>F3OCQMRJUM\#'7\A/[?K;,S1_@Q57
MRS3'A3<OD&(@=UX C&7<98H6L&+JQ'^]09&PX)^E>3Q@!W_#J3XM_>1)0^.Z
M=S^8WMM)$T@^ FQME@0//0AR(9B4.1P@'"7"YXX X>L8M%Z'2$'P.H-#@FK9
M9/_AP_=ESZ3STTMXPTSN"P-Z@0/9H@:+Y55IF<]-A@4@1;$,=C6B-H/OPV0X
MB9?\.L5]AJ>8BINC+F@<A(4,#!'\-R8;<J=R6^MW1;J!& L\EL!;.A*"\^'K
MKC3Q9OE<GV8O404C<O;AKHBM/A_*[YLM Z\@7_V[I"X%VX@@&&*)=1W*U91X
M'Q[LV5AP<^N5!YX:M:RBR^"^ASI>S;.^F!>C]\7IY9&VF<O795_7S*>J&9P]
MD;J::BSK&LHO+_XQ4?Q'T%V/Q?3X@ZP5.9J@#\ZH-\QOW>@SR35GM!AZ*3YX
MU^&ZDI6&%-.!D^JQ4,F'R<V_F*N!]MB.03:I-Q%P/@(+O[,"-U"KYF_%.3^!
M(S[UX50<4S65P')BU8NR;S&<.5@)/74*%,<6ODY"),BVI1C%!!.6:L[^+5E>
MY]Q9"ZI&S%/);XD0@G+A[YS6R-+.S#&SSPYV(WOU$5%ON:ZH^EV!]B-PE<@=
M]Y=H>O0SQ*Y;")+&5\4PT>SCI7+W'P&*A)LMS3.0EJ@6W<U^+-&2]]4R.Z7>
ME[AI_7EZMB\5,OBAS: L,V'4KQ >MJ3G.Q(F XG!-J702L#V1X#ZGN$CP*T8
MM)][U8D3PFV101Q#)(OX79_C[IHYV#AU4S,1XT:S?9'9285[AEI^WWR_GF%9
M3#WA.;NR3Q-$D*-GX==AB#9*4-&(SK(D<6F?;%.;ZX7<';DAE?YE2.\O.^=M
M5(2Y2F?CU0JJR0.)>G)6_!$ 5WT$8-71+O\*?8RZ0%)P]R77R)L9O$;EP^HU
M&=K.KXFWR#3*==*J7>NXOU=@&-#YD[;7;N=+WD93[<#[#^TU?,BW,G6C@]'=
M8Q39LEXO@6ZR%XECU8H$?/TA3O=[<[O&3,L?H\5$N6\++[V?:->_9^F'M5/_
MP?-UF@$1,7 HB^9H6@H=T.+Y"!EJ;6F!YM9HN9XAI!4[/CL; ;Y&K>:]X1#
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M9A_M5D]DM3KB)V]:S%N3W>EOFWDCQ<TK2* !E!B*%-/(\CF?LT[8R/7PX>-
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MD#YQ!-B-GT'[08FS# Y=R39-0N]JZ&<9K\1#KV\PEY<)$KZ#*]4@#GH,B8W
M@E/F@<EEK.@.OE: ]$1.$GR=#521.D*+]06C=Y-2CP5\';AD:]8CO,59\1_]
M VA,5O>7"*;#/9&'MP(@)HAN#\9Z-[:V_@C08O-7A":0@Z\#>6W'3J*QF5X&
MH[IFT5_KRA"XIB/ "]SV[(,CP,+E9<A@2ME!0@%V3H#,0P0.*$<)8T\S+F"6
M@C]X/2IMF518/@R6:6J)P !>2%0)+TF$LV,J18ZA;M(K&.)&U,N,J4-4$IYS
M(<YKUZ'=R=KX4UJC(FHMV5^B_8U+DW3)1;ETZ%X*@WV@$/%X.Z:+"_YSEXG]
M>_UP*#-VK9@\E69T!' 6!AZ:-U\MNV23[G,#>FN7E\$A1;3HP0J#GBY9#&I]
M S^U(^:GO @I%96;%^\H.K<P"[Q"QS":B4R_*B:[$BT(:JN\HAO+ZO&'#EY*
M/1()OBY^#\]B;I;)L<D<0YLCH$T>(!=@G+ZA!4W&' &(-X-Q,^<NFA03C;>(
M.P*<1K0T)W"??3*.#UYF_#ACRZ[Y3?\QFT2$>MYU=4-;B<5))JB@YS>U@'$H
MD5\DB6BB5WXRR:Y*35#S(AX8]+A'A5<W1*\92;3H1]2SQ3,D-O(E2;$QRAUR
M*[8-R<M_;:?$?]_<=P"$%.>+/"QH>>!]^][WVFMUU0@O94P*SBBZ)JL+* 13
MJ:0,<&X^:#:%AG*J!R]K+LKDB'VK)^A<6TQ*^[+MK,+,E,=;**:DV.X69U6*
M XGSWGA3WITYIV[RN'"AEZA\^JO(Y.B75YX\+I'<[;__Y#-_WNR[MOP(*A>C
M/U^<8K R3A+H/@*(%9&6WGPT=;LJKL/':5+LFR99W? EZ-(I;(^^\[LO=9\W
MB:WD2[,=!L1<\CAQ/9:F755;[.-;J_&Z7 ]Y%NIT<TI;Y@L+]8N@V/VTM'#H
M_IV/=<*E59_&4U:E?!A\R%.;.5T#_E2Q/PQO9'M2+G((?1:$R\AQ"*XB-TTU
M)ZQ#$]JE3NY;_D6F3W1\[^M#6LF]I'M3LHM,5B"QTO+C^%NR;3$90>YQG78E
MT5,L![-KK31^$1O&*+VL.5=SE8 2:XMCG?5;= #MV%:6TJY'+0&9<K!UC):]
MW\=4.W*,E&2T%/J)<@)6B,&[B5DZ O0DZ?T\ EBV-3^HBT:]\1FZ#3SSEB,P
M:6F3+$<^8(:.'B7O"/!P[0@P3IKM11 -4PXN(TZCM[AY&2E"I1>*[YA512WN
M*//]:WO I$*=YMHUP@A!_:)%8WN,-4^6CY?.;5J)C]LW5T1H9*>?2LZA!%F,
MZ2O^E"ICRNMBV#U*X?EJOKD[;?FYI?V!6>E+CGPH[=?GD[*/59U>Y>I_QX7C
MS67Z%N[_8N]=X*%J^[WQ)151#7(^386$I!P2R71"$A.%(J92.26='&+,DD*$
M">&.,D52B<DYQW$^I)PEQ!@JAQQF',8RAS7_U=[OL]][W_7L]]GO^SS[WGO_
MM\_G^GS,-;.NM:[?]?M]?]_OM:YUK>=@[@):G(/"U%&$W)N,+CRI.=^]N9B(
M>GEJ:\MY5(7RP6\"+X^UM(J@ *1Q9T+ODO$ZAA>E!BOIH:4:KA>Q:_SZYTJ3
M:-H$H/KLV@+_$_P9_)3'HY*7^I:.;TLG@S8@X@^/]-6Y@S+EC@1^I^<KSB(W
MQ8?8C[&D5[X@K1IE:(Q[W4SI2G/8UL%-/\<=.4$KFA[MDF!)_'SD'!E2P310
MPGG 6H*H?TUC_9!N>[E.X-6<F^T#DZ5W[&:50=>HR\>FULBL=.U/T&\Q9;[=
MVY94:>"!*_3-'?X>"J4($'D 3>(>ZCISP" M3SY*)G+K 9TH[]&]&M^](65*
M'3%4,N!BYO#T]H;Y(]!#4+JDXFWWA5/VUC$["(Z^MG(2VB<;3&=_>]S*-["H
MBC3E10X>DJ'GI/N!#%0M:[HXKHEU.>E&4M?ID)U?[XZJ[LF/N5(^MX_<[/U)
MZ7 W?C_;A8/Q6KUFLV/0 8OF V(U<K;1[U-2NLZJQ7>_4;"TN9QAL"7[3%]J
M,=+SX-)47+_G_K"C=\_1"XL?E(RFI*1AQQJ'-1:2F-IY(;7,XY"M1,E[+QK[
ME!6F<ER!!S"^>4 \ !86H)OR /M.C@;#S+(P\*[NVX'#/<EZS6%;KC'GT";K
MY]2,\U2SW7[<IZ1<QO"[\X UNI2P(:/>;+S6:S?G\W;ZK&=9Z[('\PW.*WJ*
MO)@HS_G88'LBQ&K*57G,U*A"H)LKD5:IQ2VB>&OQX_="YMGCA-6,T!C*:/2Y
MP:ELN7T5B$3+[ZFV?WLS7<4ZP;Q?I^RJS6H^I? ?.VCC3T,MC##<AL]02[U4
MP%+(C;MB'_L6MUJ/Q3&:+@E'EWU6]K!8[?(^HHN"R4M2W:/0=N"?UM\0-%V9
MYN7EL==85OD7;LHT'GC?CNYT.3W+$1.NU_F.SH\I>8;=PDB'0L[? DO$[]=O
MP<SFJW$\WR '/_?(G> !N;-W-_H*]?:'AI;R<PY9Y0T31.,A^Q_+'7S:+^1!
MPB.#=H??(:K@KL/N9E@O9FB[69%3^+"G+4=@<GOFT(*UR37Q/_M)K/\I_[ZB
MM,-D6YWZK3CL?IP(W$&BVQ"%(+_AUI(1[)WDF>@1+=%QUCOW)(?+::_E6H::
M.M,N6#Q5%_11/A,U7Q^4[_\T6_6X8,DJ:6DKS,W&P;&8@.NX-M=I2YHG5<%S
M:"L406N[?8VSG6[U\,7C+=/F%Z+)1@UVIW=)^:L?W';08Y1T!=7G?8=:!-:V
MR3M# C7ZE:I=I!'5N[IR7C9CEKDJ:<4/LSM/;79M%OQ<)/+XDSQ[&3N-H/RJ
MS712.&$=E%*'$=*;EJM3W-KN<[YKYL:'0SM4C+KDCD0D:&^JVM0=V_0!'XVX
M[C=ZT%(-+MIA=>@H)D3,4Y82\=HT.PUZY5)QIL!M9<CAI8N;,T[MWQAN QDG
MS/. :7N:Q:PB%%]/$3'2H7O@PA2%.\BM2?@^C0V#RZ&"U36SGP751&J6%C>B
M<S&"H!<N?,B@! JB[;6H8[E#]T8L)15,@[2K$B.'+MZZX/]P[H"^YAU5/WEF
M6S+<3J5;MPE"UX=[H_1X0&@ 3"3[Y]<F/[.3DK5+DY8\N#OBZZ%W#Y5F%,SE
MHT8S\->1BQ^CAR[5>$=7RG;@7>D'G+R/,TR>].AB)([Z912^O&/^K<%QIT2U
M#'+QGXP>V8?!'YW%*-"M$:(,9Q^]L?HE0<9?:U^EX<6,+4?J5:B/OXX*K*'X
MG;A[-H!DP\=BTT%F/Q0T&D%0@!QM&;N2C3=#I,.1+"_M1DV)\N>B2J:S<:+$
M/<<>?P[2&>,!!68<<5R-L32T=]3)F^9+2?]>N8/>FB$1W9#P(FS5@];--T6O
M/3\T%FYCEHUW_#$-3T^8K0&CA\0[\1?HII:!U@RGM]T%:/%W?MF%E(3R%L6I
MNGW2S2L-$QMM5OF/3?O1Y'XLG-)DD&,X.^D7<6&5*/HTHZO0?,Y.[7)4C7'X
MFO)<F9.W 'F2 \"]!NFPO2"!1B5:<>@B26PBBZ%4'W#"+\_=3L;MR8/Z;]*#
M>8<NF?JF*S0R9%BF%"EP^!$L5@%A&;W5 7Y1!"&+'*I_D7(W'C-2LN9&7K#9
M-YG1UG.;]JV,C1"_;W@?-2WQIX:DQ%=2P5C5+.1&#6&-!6.**#1%N"O0#^Y@
MJ_;C*>K^7Y&T5:'S^#=VK4S;7HWN\><I5N.HW\!S;9\R86DNYPR5_A"L089@
MC6 ^>DZ8+=7'(6+@%/,RO\?3T17SC5WVD@RG@9:5#.7V(QG*,29K<YZ="4&M
M%.U_EO;HV9>9*LXT \416]\&2ZI0(XP4&%:@0'\V(D$6!I0[C#NVI!X4,#&O
M[+PSY5WJ&P+(-,M@+G+,(:4T_&7HF-$&AJ@+8X7%6IP;I3!\*F=[[%7F;U):
M7W=9B&A7K5;W6[%_P4$]P^9:X5!-[G+@B!:DI$+O>68H4#>.R1NLM.V^4;3!
MM/+.LY33;-KU<8T)5)\^O(8Z3.U+<L!M&)RT@6H;+.3,5C^]?OG-_HO2(@V"
M>74[5[[T/7?U_JXO8]_5U3,<GB6D""M%0R7T^%JTO)' "^A@?3_(#(L.X+M@
MIZ9LH_;.7&Z];?<<JEMD_T8XP(-$-UU#O"O ]*M7=EKW*)Z9+5_XWCU5ZNL#
MC4>@5,L"N:M?[<!KVK.3#F-CU#HM2%GJ#F?_<__+C365NDDU$\\=ROV*I1R.
M5;[M=G7]?-%OPR$I?B&1M<!><]493+BS& ^XPT];"C/:R:0@3.6<NV^I=W\Y
M1:MU[MS)I:GF@<<E#58Z4<GC;AGJ<<D%OYW4&,'\>!HCBP>LTV(@0K811\^E
MT.39M@62"/N%:]EV5,T58^_9!UQWM^YBS.(N6Q_1>: PHC,O#U9+--R$&F.G
M:41X*GM6&*R6P>NXO#RH=9>@XI%<$?E&RSMS(K:OC&@YK?RVK9-B^B([J,)J
M)&^'D<"PI3 MZ?8"61CRQ-ZSZ-!M.B3Y,7>]A)D-UNZ<N0I1.<[*G!R#1\3?
MRB:8RLUX!B$]$59MHHX<YNSG$KFA97*JI_"D/=-*.9\O]U%W3^.N=9PRO7;/
M:V]-@VHT7N(IQX2>DTFCB+F_F60I9JP)F6R]XMM4$1 ELA\($=P8O'^E_5AX
M'0@I70B=(>OUWJK<:/[<?6[G^:[%+*V]:<WC6TQM]HUK/QR-\UQX%7GEY5;\
M-LWKPY0^-KQ&?Y@'A,%*!;T</W)QS,RTO,7JQ$22:^YZU.ICIY+/K%^_OF?J
MH!#[/;!Z9V.&IGB&@>7044T7&AHAHW3SV96<HXQ50Y3A:%\L']6I)#$(,Y7V
MK?[1H]QH?0V3N.O!1V+>K;HY6TN%E&P+<PK7-497;I+C:N]:-:7KB-YB'OXT
MV72/0(Y(JK]2-N$W:P?U1;'"FJ9:.C;D!B9<4;P+KT?+WJ6@=+ K3:2_;R!*
M7>MX\Y<X<Y4(Y3ASY>1E$K,0(5Q^_@>9*;T8VM:\GO-TOR@GV^T^TEYPQ[K)
M5].X79K?YP%Q 3L!_I6[5AL7I.5'?95ZGYJ.,2((_-@Z4Q<MX)^ZSG5$(#*I
M_DT_Y>%JHOO%,T6QX8,Z.CNW5[Y8<3O&7$:@@AN':)9'(+V%)(FA_4@WH0@B
MZ+-6?L2<A>O8JJR:3%\$U,V[O"W+Q[*#TDT<LPV<]-^^#HG<^MH4W\6V(51C
M4!3W[Z3IE**46D6M$TCBO>S^XK6K=4W$R&ZQX2OK;=\ @\&K\$0ICNAM)\,(
M<V,U]XFSJ:I.BJ9)Z,6V5GX>H$CNGM1P^_C(-EXB=IXXE<L6AH29#JX]NKUO
M&:A[KN%-*:>[)6QCL4,G7>0/9?(;Y2N&WAVI:&Q4%.PP5O:WL*4W1NA"A4ZH
MXW>J?=QW+#MAE59>$]PH4KM21'#C+<<"N\M65M.3.O,ZC4@</TAQ2 97XTW9
MB@^5Q!(#/MR*.WF".>]R!DUD2E;@F.<1DSM!9L/A]RZ5GQJ)OLJY2CYY>$MN
M<+]PH(:[@,:F ZV=AK$)RL&H/=?XT)>M'4I[9///Y1G=9K[BDBBTYY4B@Y <
M.Q 6I10X[;_.1)@R-\L[<:!HF7#.U;CL[5*."U.7&T>AQ7)41]9M@,7(T!$>
M4$A.G&^#6]GHA+LU7@/?FLN>7X]=(#]]\7KY:TM+.RJL\L?;-K0QM+.$#C^*
M!(9VGGM[VK!.MIB)94H]+&[9BJ?H3RL9]"T574U-6-(4MU9[9X=]LNIF8R.N
M;ZD:5^!ZFQB.=W\>E#<HW>QYD_^FG]TUT6B&^>V"A::-+ZN:],873CSO*I59
MOCF"@Y0DZ#W24."(5YG[^[X3W0L_<#8T[JC!4@UW50"U"@6IH&Y52OE'=N$8
MB67ZQ$)A [M SRT%DD5;)Z^MC9WU35K)'U*-]=%;,I'()UMGG;;;WUFYAYN)
M>%BR\2KN$Z.#-T<>R]FD5"MJE+NH?&:VKYGV5MY[/D[LW<'4J2B=N,.JR6RQ
MR%9M!*X:"#@(!PLVWM"[XRW*.7IGXO"R_T+%CHBON'VM[&-L&AQ&.5")PLO3
M,ZM(_*?\L=7]'A/]MB7;ZQYW?CZR;W ;N>?Q&^T@ /E3*)0XGF7 .6J7.]<V
M?8^]$KK.?%V:UWNNYPN].&K;,%M]4NVR:M@W$0MU"\6ORB%6\CLVB@F>#3;2
M&N[EB+(/TWLCIWUP=YVUL.+N17EK5M_+[-<K]UMY0^S=Z:*AA[8 :=9^O$>\
MQ[W!Z&5H+$.K&@MM>81>C7'[CHZTJ]P;,_.Q=8XYJ;E"4] Q39EA*=N0=R\,
MV/B;RYK6SV=<8W@ LYM[#T-[(U5="V] 0X>0'*Y/FA=F>_<;\0 E.,6LV#MV
M]O%@;EO7#1MF_C>;RA?;;A9/?:5?AV40HU+"ROFX9&X%-RI>E4GLJ_PP=C.^
M68M5,5NL>-&8T:I#E9C'35L@H-R)@& B5/\"FH4E]3E*I$O%(:@I'C"%*;PT
ME[Z&I#.M]FAT]T!C15"9B8J-=9)V0&@46L1?QXJ!NU6($O)@<,E'NG67NB['
MSSS<[/_>.^:M\H8%\H</GK!@K7\_A]2'V3!,/'1S#;9H0B7GW%%ZYJ6GIV]1
MOS9/:2RN_F<XEBV9[VW0^I1>C5,@;(#L:XS54FF%X+H)>M])*+%94B-#32Q=
M;/VP];NPG8_8(C?)1(1)ANSR#QOZ.OVZ4M.!!UQX!]ZDF,=*Q_1%';6E[,2]
M*#@>[=YXJ*9IV9-IA?R6 &DPG;K;[H(%VXT<1[=$/'%RF%D5IG'>N^++ >%+
MRE=.YLN?7\&WD6MA(H&PE]E-H83=$X:ZE#PT1WRNX:,+TTF(?7KSX,#7J$^3
M?+':8)F<14C06>,$M@).E3"$RW5JF[9^!H$V]/IOC].A =,'=4G)]YKECSOL
MLC#](+MG!3GLX.WH5LP])0<=:R^+BUL"B8UMH1AZ.0$%D:HH_:1/E '?&NHT
M#W!EF\6'V[4EE?@%?7:Y\MU9@2U+J*;2FV!UQOI\!'D;.2I@_T=SUR_@^2#B
MNW[VTN7Y+X,34:CL( 7ZM]ZZ1&/^=DW\V;T)O9$;\R(UCXQ:Q::NR;3E^W+@
M77:8DJ]0E*M"OI."F5'<5>P^D6!3U&;*7E@51'(!*,DQ[^%8T'!WO8<K#)G?
MIQ-91QU4^U>E/-(1_"(E2O/[\D)H5XC [@^$.QU'-CPPEI0LF<^<EF"K>2#H
M'UZEM1Z_M[?</Y'5\-#/ZZ;/B'+'4E#A2-C)YEVP_R?']Y\/7]->OQJ%5@-K
M$WC 9"X/^$KF 8,)K*LFISVMU#O.GB>X_M@B0C+;QD0?(W4QT6@NU__&)J5/
M*<\;O^*<X??HW*5;E M.6UB8==FM&:\G^>R6'+J/%-:],A#-:5]ABMIC=CPJ
M_A;Q>MJ#5ZT>'T+CU#P-]<+O%J1\T#J1=]NZRWNSVW;-[>EB)KJ7=KQ[Y[\Q
MIH%B7*D%5BN6ZXPHG LRHRW=&Z._%LL%IQX?^31T4#'0;*./C_7X0%L%(<+Z
MB(0**C0TA^#F+P +MGEZOW(\[=\VHC/T2>FBYSHI[)SS_G'5V %O+AL32@C%
M[X:NTJAW*M=V&6G0G+0U50]VI<\-%Q-5*T\])&Y[_\_9.R<Q4M7F./2;0^.W
M,8[D\1'U_31B.+PBM!;K=W-[X97@N2Q9Z7--"R[;J$OU07YL><YF, 2=#X;@
MM:[+W#ONB"F:%*I=6ZP3O^TN^%DK?SRD_'@=+A=]CZ !]\=R3D*W7X[KIPIV
M?CF8X988_T&S^K  R_ (6>S)\4WNIU>?C;._?\VX*UM5I5EZH^/GK6F18]+_
M"=X6\]^VV$?[DY@ED"M-*[H?6^,Y[6'**'K.,%OWN*+L\-VY\VEE,>+W=6Y_
M(CJT<7,7B?=*<37^9R"-,\6IVMT^TJ^C7M^E7B@^?[^\[YK$%5O3;TTR$X_L
MOZH&&XOZ9PZ3?VP)]?SVJ-,E_]OUQR>+ L+2 [_IIF0\M(BM*+GD*O,$]=G2
MY60NG9EP\^6DWWUWEL\CR[WU/>]O*87IR5R\: 0 RO$XW0DTW88']%$=&*<#
M5BKNC3'XFM04,S/2ZI]]*I^X^/K6OC:&/"I@'@UM\R-Z<S386NXLS=#:?96;
M>S<5E'VZ<KXX6M&&<F!"DI PO]1 Z1.N4D1T1L@9?[_&7;*K"BG1FE,+7.>@
M"WSS8^RC+W)B!KNWI?,7=<SN0V=W'(DWC3/]KGR97^-ETYD $??%.2)G V7D
MW7>$&&'N+%(W3+X9.)A6OS>T]6G0CD,Q6^5?2?GN!K9TQ 7:O^$!M5:<C3P@
M[2D-Q5$8 !DW^"8*[%<]X01!KB./G0>.=%1N]'>U[9YQ/"_I&U @UJ+ALMO6
M3OD1?V=9_[]^@?E?"AD#L1F^O</Z-6@Q?^8\-NE$4<?&4T.= H)SJV./ ZD"
MU#8:;LL$2#].$?%,]LIYFDEH!46T7F]//_6DM*CHIE*"](53)\U"! U6'A,8
M.F%?@TB$.6_$&!T%/Y1/E1H&&D3_5 ,$=9C@M7@ :@O#FRMG5@=R5L3S@.B.
MGVK:!0;%_Z?-/ZM-YZN,T6&I.SS C;H"+>C?(/=2U^5:TH5MF7.X]T>'9ZH7
M]>:6.$8I]90%+S0B<>A"6%C?[(\5^]!N_IB:1$4!>FHX[</.T^ZE>E&&02\2
MBM]&;OVHV^*WY\3YI1SL:&85* 1W*/(E5<-:D9.6DHYW9TYM>SYWNE2>F")0
M0D[D ;0O0YH\(-T-0F1HL W(*,7\5 .P]:N=45WE_+1U&VH#;)IT!Q5;->2L
M=;ROBKN)7AML!;Z5D&(P_$9:[ ,<XU*ZZ[VTDOA#):E[(L1:O55:TB_C4@0J
M\+E_DQW[" +TBRGTI6J6:MB-.[$W/BAV[M&PUIF]*KO5ML5OMX+G8XA*/UB+
M+D#7#E!6044:#W7WO$Q+/9&?TGR_X)(,X9+B2*4=#PB/]R^&H]-',#"?.0]H
M&/^YAG^*R.>/MH"N#G_84,,R/%SJ3/1(]$WSHVZ,7BVE^7FTXH8$G?(WC,(-
M:YPP@A_-Y8X\P+2#@>8!P#,>,'H#_+F*#Y$J_]/F?X$V41&8X5?%0\)YD4MU
M(,#QIK'7;#FY:BA3)D1S^M'VL7W:5_R9>DOUCZO*"T*N[(JP/LT_H*3+I_=G
MOX3IOUN1H!'DN/G&\OYES- *2.^9DS/5/^_#!1W+M>H?/3J>+V]X/[B4]%1Z
M4I!L F4Q/&O E1RIFR,4F>\BX\DJ.1)C2=M.$0</'5MS<6_PRG8!G F^FNX"
M"^VEFXTF17MQU)Y^3THF%/K"3H\,ZY\6.Q9/Y58>_ARHMC&U*IE%^-?OEOOO
M7C@/(2X/4(NBH[E!$R!K"^54UAA9"JXS7LW(G%9]QO&JZ%[\5&[[W'SEF_[J
MJR+Y+F+33DWGM)J^AXOS#>/H#EK"@Q[4?.]PO7O^SB<+2")UEV5,#UUM6?M"
MFK6.+359\U:+2)(O5WL-5JO@#<YZ9I^R?#4IZYN4GA%I]?RLKEC#A54ZL85G
M53.O3FHLA#<ZKVZO5(',;.F4B()//D'")X('!OM:M?,V+<F'"*[<4;URA>!&
M^_ID+$>T;#CU\<B+0K5%K+B'X>GK-]--WU9$':@U^-2:&ZXQ$(*J -SA&M**
M$0:9L^%52[7SIL!LXY;ZHB7BMD3H5)S,LTVG_%9HV^Z7$<B^1J%_];Z#6]@%
M46 >@( "XQ5[Z4CGZP5-[2ZKKNQS>6\*(LX4%]U:82;N =@>VPT @,3E8(Q4
MN1Y[[SB8C^%(;*!1;Y7O 4'P>;6RE(7QDZ8+FLIB8FMLK6/V:C##*-N,=<%W
MYSD"/.#T:QZPD.K Q?[RP1?4(\QP&G7N DD<_%ZCQ56++$/W 6"#!EX)(;*.
M/_8PN9&S!Q9"$O264PPSN'PS4O-;5B[W/N9+3R4">9^R,\$)PV,".2-1-AW[
MUD3NM# !MFRMUQ0'?DL7+SBVXMR?7\U'IW(DA6%+5R01Y[YJY $F;3C/<=+<
MC\U*R?Z(<41QXF#U&<J7CS=(;-G7X,+I169E! _8Z(AB+2&<9+\XG^\_\-&C
MU1;JCG5S[[[+NV4\_#R\5<%\;Z@_JJIMP)7& Z;7,5SJC?GIP932\O:-<2-.
M)J/8O-.;C\1*1MP6J\H/6;_:3.\VVQUNPVT W57HC:%&*J,7Z*XA*O,4FHJ/
M[_SE^U-SHR>LDZ2I"=NROJ>NPKOS@)59]"!R[>R YZA9Z%1&8N!>*:N*+EKB
M)>\;]XZ%BA?M;A;^ !#NP A;*G2M1=259RTSF11=*..2N/APVP)[-V<@)83B
M_^K+F;51<?N^V*NP=Q&H:"$>X*%P+4BX5K\X&;R[.>I]Z<5LP;!3]X.^1878
MYG[F?W0]RKX!+.!(_EA'/)Q-6E^ND%.3Q)),+-K)C;Q:J09$S_RFG2IX;I_2
M6^E7I,*9I+-T'"P42(\_1?_P2-:@9_5CO?>^UG=C^V:4BZ^'5BW?!X+<^!<3
M(QFD:!Y0)% #]K4Y=BV0[AJK>@G!,/]U;Y&NF<OZ#7+N!I&[^&/;'_6F( FY
M$[Q(9&U%1C3$@@? ._>A[:U/A]<0[RE*0@/#@6@I2-_&L#B<G&P2,E6MO.>=
M@=FRLNW9,!L#A2SRG_^ VC_\ ;CKW *.'(,\HGJG +V6(_MQ,WVJ/V&@/MNC
MT^H--[G7]1BT?8T184J2Y4-.1W"C@?C)CV8-(3"Q:G<)_>"D]^N6]'[<?A7V
M\]H]*6?>?VINW!:8O- &;2/?O5PXJXB7@?#YY0$^G_.&/IN^/M T9R&_,U?Q
MU<JW/ #?@[T-SCTD27.U* NQG@=A82V:Y[14/2A0J53KI=Q/(.D6V=NH?W7Q
MB3-(6\D#"GX<Y!ML0('4EZJU!#DB]-X:K!@DO#^7_CS=]=K'5-^$%55M7].,
M+G^]<JKGP>-&U=1"U@[D.-3M<CEZ>O70#D9OA.ZL<+]GT:Y\,^.G.R(43VT4
M$U^YU("EX9(1%G><U"]0@R[XF$"_5X-9Y^-?;OO*Z7-*8DB3I-N0[>&1B+#=
MU\S?+4I_HQRHW @W&PM '?3;U825C,&,AJ>9T+6AP;.2Q5I\\R[!)H_(UE&,
M?:)@[0U"&P(T=AQ$W=UJ<:+6HF.< :A5CW_86W*"H"9+J+YQHZ^NTHHS-1CS
ML/\32W;Y^8^-W_79>P8^?7Z7BNZY_>Q2+;QEW@<@.= IT.:$9[X.X0UO-Z\T
MD^BYX[&F%=#?>$Q@4N7/9E!_0D$GHF4Q7[4)_#P@QPYD834)F;U?PQN(RT=)
MP3S@>P()CF_!O5SXY5N>Y\,YXH[PT?P1(M??A =D[+1W86\$F[/^O;F/_)=&
M;0.=#GQ<?N88^-OEM:[K-]_?U34;DS"'FJ:PL1QG[D..(XTJXN]7==6?2'.J
MR *]G7);"G(@0/OKTT^O=KS/.-FT7UZ(,\Y-H%RBR')V]!HKNV/6<E2T(HS<
M1[EV!@4%)5O.7HSLRN5V<IEUZ6^M"^)CZP'"3$^@UX&/BS_.ZNK6*F^R\5PF
M54&#UM:_ATGF/JD$QM$HO),/O7+H>ZU:1A94N5.]^>O@3KX$9^VCFZ[>K]..
M@PSJ\5+L'7!?JC;D/D*.L,.M,U+1NLMQ'>5:GN\\5Z*Y(__8/(:5P0-.5IE/
MBGLI?[FZ#UVVZ#QPK+#\IMC0-YDAG?"37]:>8(]FX/>P#\(]E *M*HP0?C<C
MFEK##LP6VKOS/..1A7J34LGN5;:CV\[RNY^ITX;G!7:30WC 1=( IIX'K#>Z
MRC#$A V)I=0Y[X!NO7RH>R\PY**DQX5$[*(GG!M\WT]H5]RUW4]0@Y-DKQ?]
M0^:;'3_7[FFX\EW^5B1WWP0.16C'%9I-H^A*U>AUY2[7?_3W"-%2#.H456_:
M_':WS:N.N+/ "MJ;=_K!UR,A#:8WMZ#<GDX=4:TWJ%3P/^(M I6-K'^.,RM\
MZ[(C?YUNYW79>26^C<,BQC98^6,",XL2#1SY'LZI',YV^H>EF(('[1R<W@/7
M$[DQ)CXQ5W;422@#GP:C&&4*67E_=VQ&A?& X3>X.4]#+#?:#L/:'L#&'>(!
M]S7#N8$(G7D2":7#PJL0+\U'-.6G'A<>D#9&+ES +J_X!/:6@RS!)\(%_\C%
M.LNN"*N8X $/(@@=Z)E)$NM&#.6X1CP"R[A5_OIUR4EW;Z#7C/<;E[WT9E_.
M<'&1MY?:\VC/S9@GDBU HVJ<SCYT,EA\T()M"%:;&,OBW7JVS<C5V)_K'G2J
MESF3+>*VQ7JR9HL=?\7UU%V,U@3V-;#Z"$'!F6.L+UL<5HY9E]Y&../6;>*M
MT:9\9\<J^^MW9!JL]IH0<J#>*F<Y*/:I11J4=:"+<_#9NX-ZJ1F7\QL.CU^I
M&B9:?SC/T8>TAK&W/Q;O@M?0$V-I=V<.ZSS>U7/./;<KD"^QP4K;_P-PAN/
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MQ2@/:#?YL?OU*D0]QI_J!*<\<GE Q_7>?I8JY]8ES/<A#'?EL57]_Q&XLSP
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MU1?W$B2AB$PWEGRH9<6#_H ]AW8%[S_W+/7:]=3%5D2CYG+3*.-9$SAH&V*
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M^O$6:BA:VEC=?P833O>P\9^<[/\ZY6CK5D]ZD/,6]55AF3J^,Y*)@0B[,GG
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MQ#N^+2\M'"R2&W1WWO+YF<([<5?RT=ZQQQ*/YAZV;A>K,\^<@$T:Y:0+>E3
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M9<1/5<$&6I"*-Y(+_AU+C366>[B5F"\,@@;BY!ZX+QHL=?*8/1-" KD>(O.
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M(27ZUTJ__G=M1;*7I0YF,\V%H5K[?J/,^MJ0W&^JMM>>O*R7YYQV8@BQ$UP
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MHIH;YEK@-M2H=R^,_ #-'YR@%D;DA>)D1P5KC%=>^J8TLE6XH^CHT+ 1%R)
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M.]2DUZ%X-ZR;]2&JJC+AF$JR6=.'[Q(7]&M*'OKOY=H<A/#XP=G_[SGVA7.
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MX?X1CI$P+<OJHD5]TV.H%=K5?# I 91L/O-F^U%K1TC\7?S6TM0OKP\:X#^
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M3M'EU%O"5TG;=N\%HS!7+&%>23,A=&I3*\M0JTPHJ+58064.D&"88Q5ZD-=
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M8:>$[ET=P=0 M4I[<9;&?=H.%TURB]Y-#48<KF]4"X\TN761H[K>4)TV.[:
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M6?#RW0E^I0"K\9^*=M#JTUZV=V/O6.<*1HL>.D3<XU8\YV>HD!8RKEL\@=D
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M[-AGSZ.3[%N_CRINW]!*[ED]2+C;F,[5 V2^I_2OWDJ,OX-7@IM7$X%1?74
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M)];T7@\WTJN&8=3W-+4S$&E;D..HPW- 1="63M[%QO@VZMYFP,SJWJ__,^+
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MJ+6-HP#+&4 F?D(&S"R )%A0T9,^^@?%L1-+PMAXX7EQ](R'XZ ^50%3P[[
MTW0-Q#<FL",*C7$RUU'IXW/??#M%/G'O@MQ50^?OM^O/'IRNF.W-%T$X?6$D
M$-L8"B9%07B?(&\S0R_*J,=X=G]O#04+!(-H>#$D@FZ62U3)67P \&S$\XK1
M+1J/G1+*5>1V"+-R)-"CPCM>3DR\I'N5&V'&J26GER=,)KLIWCW0HN9\KU%J
MY8OBL%JJRC^Q 55#KJ[C8KR9["2N'5O1W\NTT:W2[?OJXI+,E(UN7Z*M>H\'
ME<CLRYT[#2(&5(C#6O)IU)/4876@W'WC&9B6$:HKX#J*0 =4WM)L$=2X9MR@
MH7P?==1C9,2'F_#[QP"E Z21'VJSX[J_"\Q135XQ9]_V*E25=?1%.]MAB=/"
MO,_N;]\O"@EDEJO<A#=RDDZY//<_YYN942W4R;]_$C^!O.WMTL='50XY+@ZM
MR]2U"6Q&F/8\.\QW"R8$2F:F$;H<#V!R^7:$ 50?RY&E'W==!)'/"^X)K;$W
M3>0!9; 6DXW0LA?_S9?VP]%JF'=IS]%__!5 )])&^?  ,(WO33$Y[)?>[B(O
MT]6$DS\#U1<B@K3B8]()/$M]H'8>WA)!5%,15%#QZX?XH781Q(LD["L00;1T
M[X_PU\-AF)\#T@#TS[TJL\.4$>,20?ZQ3/*P)$XP(()0$_S8WUDD$$NH?><P
MH&)?1R)MRPEZ(BBO@DT33@P0#B/8XFP<UX,WU. \ 3W-)F8G.!ZC[7R=<^B5
MFD"7D@CI,O>'T5^_NJFO."/>(,/9K6)(]S[CVIM3Z6<6SRC:YY3GL&C]]U3%
MF"]"5HQXAVZ$3))X'D-==*"YY!&V^2415.0XX,<[,1P3R"=@*MX";6! # FH
MO(T(XD3"S%9&$D$H9PX(9=XK@F8_Q+WXK2)H?#-M9%,.$7C@W-0D-H1;L):&
M[O>!WU"\X<Z@"5;DQ;_?J;2Q<Q.8H.M"6^P(,WQ?-OEQ#V78"3^0,*7CS&+A
M5%41-.ZDN-XJ$Z-8\?'?:!V\UD.V$8)=,!OX.?<ZY"PB@$3L\@+_>70%:5C&
M0 WQ[$K\=+CM*)XG#>18QJBJ$U$5 ,/V]@UM6#( D\#WZVT.[ /KZ$ *P ^L
M)*&3HD30M5A,R>[W':H/9SLW(2ZX[I=)F"\ _Y>+4=J>F*PT8B4\W13]",Q
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M>2]O%F$2CY!OMQ?8N-F5^]XHGBUND@O[X'SOOL91'G\'Q03(P5'L,V%@=QT
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M61%4G0#DI7VUQ<OR?_>4''L8-8Z8E'(COB:VH8C4,(4H0W ,:>^CS<N^&+D
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M M28_X@H-G(T*WWC9AT1K$0W6#QWFII<*TZ-!=H>41Q0W<;-V!- P0W@,2(
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MMV<7?FO(#412Y]F"#/K1P.FZK:_$7EQ6? >$I(V'-Q)1R>53-YM3OUJ7^GN
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MSUF0MC77%UT!?3#PM%^BJ8IUC7D"E6]>MR?.2X=_[R]A(3-!BT%P]>U'E)N
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MJ$$L<!.;^O"@^U@22#<3O_J+X.J2J67O&TJ?FLQ!,Q>3SM!$0L>8E_^@R,6
M-0Z;"6/JL'T%[W!3RR&?5C\Y)2<CP<['*3\,#?SX9>W$??"QG3W"H21^E?*;
M*%8"!;V%CUU?IU6?;16><2B1LM^3?<F:;<'2&O![C,[61I *< 3XEJ7.[%>\
ML)S87VR_-U9<CK@P\6KM@[&;= /$E<;UWVJ]\U\9S'(@6P/&MBQFA#VQJB]_
MJJ#G+RWS(^;2#Q<8IV'\H8#ZM7LHLZ??/5UZW[B,!82*YB_!,:=E@]+?:5C\
MC8<50Z01AM6H;BV$/CBEDQTXJ0L&;XI_;".9U;^Q"?*) PT.-S*)9<JVQ>3E
M%3'>MS(W.@(!2I!!M*0=R:X+TCC3>\F-SE?'!Q^2F\'L[&4%!^T9G9+E<39S
M3^\+2W P*MQ ^X[-38^1.8@SF2:!)$Y"2SDA^O0KJUP"9=3N4?ARZ-[%K':K
M^R#3T!BC0F(PYFH/)P6)@!*3!G=C9O8@R4@!R]:.[^5/Y+?<)(>3#0DVB\4%
MC35%]S7=82E'H'M0C #Y!> <332F"_;_(I74\*^WOZ^3KQ@?R%D)BLH85Y%;
MSK_3M1+[ R2EWJ<^9[5+F/XG:'>.?!%M)#5=AY!>L[^EFM!1XF>KR %GST8,
MM3'[Q-RW1);\XMMPO/OP88" VX+_5T;.MD#>"GNU[QVO<FVNA,78UFG2\N@L
MI7-C./6$#D[5B:6EV;,3GNZ*"WXKM_8"CT ^PEUDH<U_W:[3T?)!T@ 4$X!/
MZ@(WJ&<A;M[$4]+JVSE=].U,TFAXR9LO@BDW!C^#0E$MZMLI^*PYY:X[=.KK
M2D+-G]L3.KH(T]Y,_4[#&Y/[IG]Y HX5Z$V4(/7Z>(<I 9:*AE"C_,K@C_I_
MU$X_+]]LJ$0_Z>.Z\&)HSZ&,HSZSC,5@(_*?>8OKY*6AH;[))M>)R]<:9CK.
ME;.KA9M>[C]\$L/5DC5>?8]+V:OFQ'I>:2[Z]EC,/_>FXS(WV_-;29_<9_#C
M)F+>P66S_7<[S0LCF&VBC)YJ<;^HD E2V2P"G0 ADZ@G:26=0NM+IX&T933'
MI0"",33Y(N2J14A!?A#26^G<V/#6:FJNN:F&!FLW"G),K8./?[J-D>K6I#1<
MV<?/1.Y)O"ZW8%".ZM2S.TNW)9M4[(=HUY:+<,\[V>%V_9 /K-N4?VXTY[ON
M#[3AU"5 ]=VG5\J3^(:&#%QDP[MO3MGN=]%NY<H]Y[!)_?6PABO>7/*8N0M[
MP#>['H*3U</=T#R+&TZA"U\KL3$*+7?<G]R+@M _&#EU-M?>@(?9=DSIV@V%
MTXR^*900-O ]UOQ*7[6/:>B9;2_X[ZY"D3[LL184(:F52E>_W,C6_3SU[K.4
M_4O).!XVV6SS4S%*5#V@#F^?ML03WV_&.UV[_YDGL#LH<&Q1^>!I[*K-'UG=
M-5BCR+9].7+R"K"SVSM]W^(5_)&3N$?SY!PXTN3#P!5T#R<_:#.&?2 $:MQA
M74:U/I[\RXA;T5>M]3W/ ,J$T^E7SIT^M#'L,5R7ZN':#F**B>XYK-IR)!V!
MEE$];E#I#1B[&035\PAWJ'N^;4HUH7PTE%,#I<RHL*25&I;@I6D.:9O\)Z12
MO[O]%46Y$M#^.B6"..A&;-[)?3ZI?CN$G&V+T5,1BB^25&/'S4S_2QM&#ZAC
M]/'H+@D[%VHT81X"CGY7VMBMZ:?XA*?REODW\YW0V$US46@S=-L.#YV[BI_L
ME"4)]BP[%.D\],P2B-7]TQ4]]<<QVZ4=%&W#^M-^-F 0+8JP?@O4+&<-!(MB
M@*OXM>1KW,:64\5>,3CZCHU^SLI S5/6/(7[8;W.;Y#?C]']'\,Y?P2Z0TGI
M$*A=_[M-2_L\D%0SKZ]WX(_6X6=DDHGHNNUE5.X="^-"CJ"8.QY0HH!.=5:J
M]U3$/)@-H?XC,VO%[61"R:K/&=DH+^=1SIC!$RT#)179X GPXR,04Z?@*,EX
M$"6$.(GR)9Q&^#&Z^9_EK.AHDO,=F8\+1:\N5"ROXKAF>HY)V!%HJVT9->M,
MR*6& ]QK61PI41N%<N9#^<FC!9GG(<@YM([!BA=?GC=QI@]*O#0VGX0G9^!+
M>3TVZ"#2XHJ>JF\(UKA?[BN[BV"(IU[$[1"6AU&GT.ZK*8H9Y3G"-K,WGR9:
M2#]V8(40PP8+T )T47A8OU%F;!0^;?'*=S7YB;JD72_O68ITN8&!K(RT<LUD
M!*?'J1X"F4Q0MC.&8US>*X:DB"M]N:,8 UK3-1 5E>08)ODFZ)1* @%7B?3/
MWL)5Y1L.ILU3%<NG5>YI6!R!^(8VE)@$\*C^75;J76(WB35>=][CD2U_![=I
M8_3@N;AW8-E)G_MLIMP/L%O;E.N_L$U9&9URZR72C>'?J;)1)^)@=MD']_5?
M_-2 X1V\NW8>F))@)4M0(KC/'I!7'+!8AIYH'DNF\P2$)0>]6[OE<%HN64$V
MX:D5HBWT&YMI_X."K3R*.=6'",GH5 $*<%4Q]AD=VF_\:Z*KU_=<FV9X^_:^
M30,WL'!CN_@F#4(,]/ZONFR4#VQ^[#JMDNH=C;]DC7=JPT<[7TQ#ED>.MD^/
M_T[(@ULYW6+CC(.;QNKN[_\+/NH934(M'X%ZL3&%USM?+F.%;@#W.?.5&=TU
M_>[(OA\:%_$R^,+$9#+.XKPM3[&!VY%O F%A!+20>WI1OW>55>]89ZD87QG=
MMTRR\!!"5@">DEX0@C,[[$G+!%1J+56,6.68M$5^:/::H.PB9+N7;CS$]];G
MY^7WMIOS\V8Z<&M\*5401@Z?NH>0)W!#/1X]X,)X5@?9Y/8<7MOF><<DXQ79
M\$',:>QEW=CN'!I7U9<U+S*8#V/M5-DH7'J.*TV(S',9XWXKJ'!383*E0J8Z
MNHK#1O%K5NP7'8:_SL09W&Y/<=BR;PI=!SCGU$ABJ:U;WWSMSS*\K[9]66\U
MD1TS\B;5V: GT] 0*"5_HN68>%#D$%80"/I8+1M]O=22O>"/$7J5[V:IJ,4G
M2B&/4FVI8D-= TO& U"V_3I P7D[@+AVA0A+#HZ ,L);R,:G_U"J1G+/WSZ?
M?UHHY/TU&S$(:(TTMDEY-92>^?)I(L>'H5,Q)@?D:*#T#=4'@.+K1/V7I-J)
M+2_?NK%7_@@:$ ,?%'0.4+X62?)YT$9'G"+WQDRJN?A./Y#+B7NK)":7-\YP
MY<QCA[>,;T1!X4)V'N-_CD "=ULQ5C5^0O3GT4SS[IAOGW)O+ C=OKG :U/&
MXXL/'H"=H/I_W]6U/P&/&^L3UBNXXC(F7[/V-4<TCFTS/CU^/(YMJ X*R%*N
M_4)+=6I0+Q(CXWUE&HAVW0%J+]6N+2QHCS0D> XGRC#LA,T+'5)(\;B#/C @
MC^TGD:#X>/=-*(?NZ7QEFE:DKXWC"[KI&C1KY^<&#\.WR[M*M$+4W=(TC/K
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M@2!5T!;K+1JA%/.5'-Q,',U80?+/5)3,7/WXX[V[G4 [H^O<"NSL'!<+N\4
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MY=MK UF (F2;H99JWC05 99&Z)$2OGZ>;$]/^!+Y;795-GG5'A<"NBTZZ*
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M,PD-77Y6T4I$IZT4H?P:^&5;VY[?R0QY]+9]ZUYX[T/G]:0!5*KX6H(9V -
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M^Z/X[ZS'_P=M[QG65-1UBX8B2)'0.X2FJ#3IG8 -$ $K2 U(!^D@ 6*"](Z
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M7I[Y7U3^K=G0/=7+)NMW9GQ#?F>VECK<;(@WB D44J-#8I3W:,S0/>5_Q8%
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M@.>_Q=Q+,5>!;='C-(T#/?>2\$O].>Q7HJZ;Y+S'1^FI3&Q41KVF%JA'*C'
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MZZ]*@*)QE5Q'B09#]]301:DBF0R]/1FN\=,C]3&8AQ/ !4S\,<CC9 =.Y)1
M*D*D%N6Q18,GV$^3/C;)C?^T&%H^,N/J%\_Y>_L$K9\3!/;D<.1:EYZ(LK\Y
MM:6)=5=)=Y:;%:\_+MRFTZ)MJ=$14 E0[#,#C<[\=2-BV##;Z 3([J-02*V^
MQ^=DL)%HEB#> $!$"%,Y 7-"7M\Z(X*M$F[<^]<UPBKEX7N3F9_A@M3OC_6:
MLD?.=0K_=YVT?#J&4G_VWK]NQA-U"J2#T3P&88O1K7-MT'0<%6T@:)\F,F!;
M0%SPIDE^R-X=\?V&E5?6=1%B9S-="&B7E6X&3C3HJ: 3== T>.0H3OB6C=H8
MV2U3=ECW.JBQ2N[!Y<A(_'GQF\'_M;KF,&:QOA]-N(V*6A,',LH\VPQ.$W?G
MW)^<>V)NI>V1(E.CNB<;XIOVD6JM+<I]FCD6.8UYM]ZSO^A/TOZ 'M#,@B',
M\]4U=#X6QK;E#42[I,OO'1B.![$P9 4GD] +T WC?A'4HG3?,0BL%TX$]S=N
MYVD$]P:7.VZ;9(@UUY&='SYPVG52+DC=:$&H$LR,I[O/T:9U_/OKET8'Q"7B
MS5D7//,=TDN#G)/.WDW$9]TRNN\$#T"B\A12K5>*U$_V4X/"3Z3O*H+,4*[A
MDAZX6>F6=R0BN17W*1%1!C'4/*@;)A[2E)M4I=F_, =L3S<?>D^-YW%WN269
MQ*8,YT9%@792"XI\5G9&_O4_7>SLPS0>@_I34*QP9YF728?U+7+9+_?=A]@:
M=G5/B=(!V3N\="!,JV:MNZ*4IH_@\^5]<:?+ 2+^]JY<^7B$"Q'39W :B,%!
M&;9ULM"\0+Y5>K]%PIES@U;N.<.$RD_7+>_V3&@!JJ0?@"G1AQ0&+*PW3_3K
MA]V=JYE_Z*/CUM^\XP,""7Y^LF>AS?!<]K'Q[<.\(?!RPG5BY9X+X=5&6$*(
M;MKEHYN3I0EW"7\;;+@WQ;%ZWLL6UQ<9F!@RYYFU0-2VSN9HVI2/W8L[^*40
MS\WX^^SIL4Y5S-&G91YB=)&J)^)?2GZ?XB^;8G &^(9*"&LT<=4)29%,YI?-
M9IQ\!Y^G9HDL/!T,0[.>F%SM.A,B/-*G8N?9#O+,K$=HTL.N1I\72Y<#>-4D
M7]6+OJEO=<[QB#M[<S>479.> ]SP%:E&1X3NCIY(J,^3W3S &@1",2::3PP<
M@T0-^^R\]G/2/M3$E&8HORP+7'P1I:MHJ$Y:_6\GDWV'B75#X4JD(((:[2*Q
M]8V\_+T_ 4:"ZX&ABEKI,MN?49(SS[2+SZ!2H#R__&.@'"WKPO"H<;5"\945
M"X42%9.5*+Y[83)/)QBT95@I X 2;L^#QMI '+Y'S!C0OZ]V#(I'\K\XBXZ5
M_]EPX<RG*M!7)@8E13J7@SKE _(QJ&<?N# 1A_&J3WZ\?J86*;039+LC97)U
M6NWN\->]LVMP@$U\Y7OVO.BW;F=J$]05*H(<$I>>15Y$<,S^5E#J[7A^9VF;
M<ZL1HFEF$U03F_XN"VFUG2 :35?,CA'P/ :Q()E1O3?T^-'L%",/'/2,9]"P
M(B98'4<^6Y,,V>.L;I#YF7':6O9;D'[@4>7 >CRFJ7*OMPZX>Z^;:)"-MUME
M\E<1;!ZSNC3/Q9/-6%7P8M2I  3?5O'9A"YDDRY0\S%>ZT\?_TT]TAFJWWB0
MOAHX7O+%?LDBO&](I4)U]D%,9T%!-',C *:Q,!!*>]:Y?V&X6YMJ??+-4XO@
M7UJD1:[)QSP_%+N<:Q@NEQXAKG*:>:7#_:5'R=9<J_"39@TKC<F:2W8]3Z63
M>)WOWPL ,0CR/33EE_%X?#J9Q=TEBKFJ_/[IU_=.W;H$$@19,Q/G<1X414PL
M389@33I180F8ECW;=?(5BVS7AJ/>WU=258@Y,F'%'./Z=\9]U;RY5OM(9P0*
M%',-790W=-M"AK3' C',- VX]49=6HV/./B#3FYVQ7:VET*$ ->$_(W4/:&?
MZ"Z0)H);JQ>:!^% >8)%:0.:CG+4(J2&L?I$K'\SN?J)B U=F5UHKN8]^')U
MS\"!SNN)]W4>)*83\(CS7&^L[-==/PUD]PFW5I7:[ZC"ZAHJ&@M3B0,5^FE1
M)EPQ1YB4<A"RF#:-:0Q[BO*>.'TN S]J'?]W/MCK[U@1__98AD-9QDL+IEN$
MP 7L?/]?:PK7X?!<EBEN!*FS<H5 _7K.3.2!(E^Y_=<8_V]_#-'V:'MA<@()
M3JVCB2!G.!W1]-YA>6%6RC5YN6V/N7M(N'20N]R[[ FZC"M;CA.&XKX$-M(3
M0MCN,E8$Q0*H#"S;2(>W":ARS@L$81ED:I_F:I%  2"^+;7_TVF'5?_NUHEA
M VAZVF>=NA8"GK!UL+PRH![YAI=:(2)EXIZ4L*J;S*1_.7=(9PZ\-TOVH!A1
M<]51X!'<>GR>\%'<"/=V_N\ES<73VO2,62J(MOT.HU_,V59(MA-,,D2>ILTA
MQ=L)\?61D'CU)P\7=^O4()PZ0VU2UY9&>(>_9NN^$Y#,./)D&$?*(Z=LAX?!
MP-GNA@W4F14=GV_C8IIV9-6')F)N:8H1(>P)8>1ZF#(@V[L.QGAE1&,X:.P4
M$2#,.7@C)45+">&P47AC)F&R0',_X]5102?34OMR\QL&:%@'-<V>-@IK&1Z
M+#8-?<SKYB!Z>=;@NT1>%R;SL#D1KKYKN)*!OR]6C9G'8'/$U8'P#>J5!X
M,>*H)]^B[,:8Y[0E[Y<A"T2#S$V]0:&- ,:([#%0&*01FH104DJGA)'/+P.W
MMAV9"(]?R@@LI==K+KG.U-U\FZVJ>.-ZJGV.T:>]79\?^XMMI+L$V=V&$A_A
ML.A:/T[O-O?M;]\.8"I60@;VX1M?#4W$_F:9:M>@%F5)U[Y W6!LWIQVL F\
M$I^/2DJ:QX! S%%;4%" BBDKF_+7+%.9(I^U_]WX.*S!6002\"<$V<$1OAM/
M>/HU!1A"-/[&;1NKI13X<7T/%-I/O<6<35M"M=8G'(/<H"SRG(F_ZR'>GM:F
M7[[\?%3$./7T8RID,(.A'<( ;R(Q YU$GW]CAKIU*?>(OSJL4_D_^;J?X2>I
MW# 2%J)7]:.G-^PKJ5KNT=)F6(+ZP1;YYTE1T4I+8*QFXL-YA)E'(QZO+_[+
MOGP_.ZW1KB.+WW5)):9.BZ[[**J7;()P.?':-%.<Y5/HDJUUS$LGC_GZBE<C
MOK?Q^C<1W(:@/Q=FG[I$&=P"MZ&PN2B>+AC1A73/F'C_]]CJ>-Z;B?(%[VS*
MM)G?FS@6]_&#N$4C;9RA=F\=B@0_>:U?6PQ-%TC!9PQF<&4D=FQOGS%(/0)E
MSLL%JQ3I]4[>0E2G9N"&8\9.HML<]8T!WX+M,D(;F-FO7&32(&ET#'XKR-Q,
MX6R(OILK4Q25%0SSI@W26($MG#_CJCEQ= BZO-0UUCA]DZOGVY2ZULKA4/''
ML9\6S%5ZH$C?_?YC$+NW[4S$X'I"2'6A+;3]B7J!KPI5-)76TL7$Q'S#]CR]
M]G<S3]=<*Q91;YL712#1;%@&K+62PJL["!$Q@ #H?AWFJ',M@-D;Q^'*##Y+
M4=S/):&IRWQ#T@XT1PW1 F%R!HV5BV"&APW!8F^A^AJ)ZC]SJG],'X,\-3*\
ME+*IE<UN]TPN7:D2NB_KI1_>"]%#]>ITZ\#9\/.][?_J0)*$]5MRV]W$!DNV
M;)\[VF[?WO<(H.NUV="6"5A7Q!U9@#3T(LE"" GJ"7]RK^> MV$+6U_BZKF]
M2-ZMFORL4MPFR9I+JW'?X= AI).)ML0A9-<7C^)%3A<Q$M&[1V1#N.RM64C_
M;6JN^>.?"HU7C;E*/Z(V&U-53-I72F7U;:&+QR"2-C!&EJ+-]4WC:,7YZ-Y"
M7]N-6WFW\HZ\6(ND,^DFE@0"3F]?ZM?>"("4FK('=J5GONU*4/P$D@],13N"
MBL'C]8O,)#]@ARQ-F\Y/B/XU<G< >JI^\N>W&268JV=7K"O#63^COL:G+?&F
MPXS(U-NP2\A53,OL\"X&^X%[M#\_P@?*J7<W8"Y"(379AK?NR\%[2"23R8R2
MD,*/,Z!P&(6O&FM+N0[<QAV#>'\L\3>\!::O8\S,!"9+#DV2W45BWVHOOU<4
M"KK"M9#_IY_&TK]AR;H%;08G=^D2QQ4N6R;_C>T;']\8O!/>L,]Z^[6<Q!]W
M-]TKW&$7EI31KRJ!;#QX>9@4^D4*0.,MN6W@*5<2:_[F9C#>LA0K\&!^U%!S
MX_[U %L-K=_#ZBL4$T !AP(N@G?)Y11[PK5F R&@RC7-1X5_J7&"7]/NQL9V
MK6BAH3/:B4.6E$_-[@HC\U$>Q&R@=LE\HS_  1RE./(]KVOO'HN4*J<[KDX(
M;L>FNH RIBWC:5*S"#NL/IO-O)HV0K-ZW=98?RY;-2'21M#UM?3TX>]O7<LD
MW2GD14\,73.;4JHUYPK0RKO8'YY=PT"O_C[ )-QPN[]>2.8KVO>_I@'$ 7G$
M:=Q^[_N]Y2&:ZB3BTCSHQ<,9?V[MLPQ55V6#Z;9/@<+1>RED%\"%9$XPZNB\
M\!;HH J%I+% CK(QELK$3T/@N^O%W[KINZBQW<JT:33'"?/LQ+>E+_=W2^5/
M.9B93^Z7Z$H_Y>RHIO3853!_*N9FELTGK2_'D,PFCT$^OMS0-#0#Q<RG'F@S
MO\;1<9]0)/<[)8=+I8%KO, 9/G&9[BMEUI=\C^)#;7^D=X&LVT(KQ.E;!)&6
M?M:':RYNSER%]?P(N +"J'EE[>JR)X/(LC06"-%L<)T;ZF%^8WY0($RX0(?C
MS1*R\(U]0Q@<T>(OW[ 9S=\C6^RD0W>_B_D$599R3TR\A"@[J)3B>![*63-U
MN*=SMGQJ(WP['A? *V]_L812"7K&/.K(?0PBW$0OV>'<7_E[$38V;MN)/)S@
M2ZNK#:\H4=9]Y7W!=42OZ.4^["%M8(V!6JQW 3=V&95>I*8S.ZJ9[5+F&VWU
M]-XQJ#8+QZN:.PS*?CJ?'46WGY_W#X1\=&IT"D]X6DCUZG7V<.LP_L"NJO07
M#U7D$*!B$(BAF+?Y%CTWKRM![D"7M/2?D?"E^(1H2C@.S 3G=R%T>Z4G!6\(
MN;SXTRB?;.=2)VVX_'CO45;MLE9].]1O/0;*A51#"/E XHLN='[1,ZI8J2C)
MM9H.ARQ=5VV74DGE=>I1.6P+$-HU_O2O;5W&&N=\UZDJY&<,;S-<;2S4O:/-
M[(RC6%*5_V,OIU#G@>W!]WK/F+1YZ;J/08W@7M2R-<F,,%Y-J)@V)TPD_ZH6
MQ$>3)NE-VDQB/K=U,>2.!G<=J ARLS I+90.=JL!'RK@PR0WX \V92]BWJCU
M4G=UI-"Y-8/,89G"9: DT\)$K&=,$X?:O4]$D<RH=;N*W=RPL_M]3\)3O%/>
M3)"K(T.U+WU^.6K2B0G95@D?9]JE/2M3+LN0&JJ6W@BF&W6IL(P 4=:H^2=1
M<R(=TO!][R1XG5Z/^28N#2C5^K5W=<S(+/+>XJ"3>+)<_I'!LS_]O=#R7]-K
M"!PY"#GG1;Z 4&WZ,%USUYJ8_B'@D9JYP<U=+^7<G)ZO;]W@HEF?M,8-F5^>
M4"?K[M/+" N P;=^\4=^:RT> W:HFK;($,C?;FRLB;ZV[:)[;]-((FXO_P\/
MC>7/ACE#[S&H^6=3">V+Z5NE :\Y-C'%C4&5O/BU^PYOTQM#GKV^+9*=RLV\
M]KV;2*LB(Q#BA'R*U9R>J4>UUVVI-1B 7!(\1Q:5S3H;>]7@%H=@*;?.]VB?
M=B*DW_)?G9 UQD,$FGABMI@XI(+G\N[9/+3\>)1FIK2+ @\3>]J(^7"=(">'
M&:F=FJ'G3)9#F%AFP)JF)CR\&->05<4+KP,?L?SY-&! [3QLAR9H"T+"?GE@
MOZ?\7A>G*!.^)^J9X;80<G6P)9EYVYMC[;4KZ44]OWN_>C#G'T(64/T8 80"
M 7)SJEME@G=-HL4]?E;82/WSX^H^A8&HG+"-:!;=P"P+GQ_"_^6 \CTF"2J,
M8"8\'F>K%P$ZC0E==[]>5M=M3OHV[)!H\6WXG1K=('(6TF(9BW*S3&@$8@94
MV0HML&H1CFD\3_5_]80P-+*GC<,99IZ!OQ>ED$4H'M3NYD(8_NA$\PIIQKAT
M)5402)EZ[)-E$MPOS$>_#J8ZM[MO9E0=K2\;D^P)Z+U-;&*W-$*&:%58!Q^^
M%MO+F/_D[YAO1,HAM?#=P+7SLA?A._'8:(,K[ZCONG4HCPD53\DJ*RNV@,>@
MM75:R78$K4IST<_MJ>%M?\5=W\!X*[E#TX,H%0LL^(2O8]./03P(%SPF :E)
M:$OT]YAM1IV!7>-X&:G[4H,9W,T7/'M]T$G7_Y=4ARX*.+=+TZ+6ANXGK?,A
M[JSI$*8LVFP-<H+>RP<_CW<#G4]6!-W' 0I#1@0X!IN+:3;NV[N@0!.E>-MY
M,KQ<^C1QNVM:^M $].[TC:P )LOB^FKH0\B_20-YL1Q5FL,0,8UJY],:?Y'/
MAD2J9/20U)^7]X>=RK[^UOIA:) [BQ0'8 X?6KMFNK3+8:O+((FB;Y^TQ25T
M?&5<'[9E\JNSON4S[ $YT5F41+%2NJFM&&R)XP5,&_ *"TE88\R[2T"B^282
M6B;X1T4_/[NY/6DP=%/*]Z&AH@5>QX6/E+>704@8@HETG]IQ%"(H)7L0NCL5
MSUY/HK1TL4TLKAD=2C4,R_U0S<R$<?S+I?),4^KI0*= /5!IPDY3B&O5WO.*
M4SZ>K.OVGT&Y2]BV4P4'-4&0QW0C#CUB2GW@Q3"L_UX5F?^',"I6OOD8! 8V
MKC4_\)C9*Z4_6*,HC2L&?L[\:*1'@BJ>?@-]J,2','Y']$_$N$'3NMD[B58Q
M/IYXN=$WGQN6EK![5L^H@ C-YIWN<X*.LWLVB1^H(E]"SG8(G*R&_!S%N)-G
M8%7N'*DAT1!5.'5-)SLO!?3<.9>9H8Z%>B&=#_RMV5/6C76\-(OYT>\A4\H/
MAD,SW,1N'/$529M:IS8!W+LC%HFS3JR$^J?<><6Y;,>0:_KQJTD4[><U(;_8
MH#[,S3?U[-2&8Y#7#GC1#+LZGW*N13BW(5AGP4LG4I3EYP-ED<2O%]\V02IT
M\D&'$."B4F\D)'F]Z1JIG)I1M=TM25@I.32CC61\SA%*M&%0@G_"MFJ+&(G)
MX< +_D.VQOWK2W&_,I8T%-PAW"V%Y>GI--F<M)97$G=!.3);![L'*X5O@U>^
M1JPG^6/\/T![JHEP('EF:XCN#2:N!O=T,WHA[1BDQJ1HZ&C"80]&S-]W?@VW
MIK&NDO7,JR<\?'"PU&X^J$OD1^NCR$3YIYC$WG,BH*^E3$.H1'K(<B1)DBC0
M#Q$"9V":CD'HLIU<[E=[EL930QP1781BW//4_11!B2QF&>L5:)/E (P780W(
MX>IY@-'^.W#K 8$YW$]Y2-1:UL6B^_:(7KO, NL"6@_M##""A41G_H (5L;;
M+;,L+9LEE?/8#WJC+]8TTE_A,+# !69_ 9='W*+__S(5_;^=E'[7C>-AH!";
M)+.7\S/PHV1*#;")PRQ;DGR!\CJ*Z13"")I!@89KY\-#WB]%/L!#0L4'-DOH
MKFL:H^\L%I\! W*0?OU(''I@G0[Y94V@:&/L79&(7.^'E[X522D]6!3K^[6R
MD(]B2_\*N!*\(^J']I]B&#">&,9KU-+R'Q9^];4YB%[O S5YH1D4JQG#];78
M6MB_X:9EL!,Y[ST1M_2][QB4VA%(X"^OL6VI)*4P*$2]>FM:X)=8';5^2<(E
MMP8#G 4/O@FQY(+OD$*)]J2(\M=9D1_.J]:0YB40;<J2FPYBCS^"L!F7CHK9
ME6(AHD@(<E)<:HZF>R)7$UXOK<.]7#/Z8>#4!+>G;#DO+F]H<HQ%:\2/0#0-
MJW]E4+B784 <40#GD89P(S+<Z9[=HURI;>X(WH8.<P]Q?5*ZEOJ,]Y3@'_/0
M,!3!;'UQ>W\(LOR]CWOH9I'7M,N'S$>C'M#MPQX2L_CL[W,9I0_@D3>:I]5&
MM4*H!E/J\6QVKBRB)DST;]-!]%$R[]ZU3NV^;FIL2YZ:8N0:9#S-)7V[Y_[M
M'H8O]_\?VK1PB&P8#Z%8*0S DRKX\)!PLM=?\WS"![?WSZ@+__I[Z=']E@7Q
MP-)AD)_=BK05VBGB_+""HRSA&-2O=/HJM"&D2N6.[_2PR.EAD1=R_.$1;I<S
M_!?^M>YDU!,AG@3A+#AL:.EJ1.OSJ9H?+'(R*A=PD\,7 S.';YGLV\/VE C[
M-YJIZ;2S_\JEBZ=_C5JRK)\MS.DXE0Z]N%K(2_<S.DHOF\;BC/+:@"QD7)G:
M+TXF32UMDRV*UD(XTN,O;]I8,G+)7H%=HDW#FJ!I&"=(,@L1@XW\C!!V&R\O
M.S-E[%ZSKG:GGFC7YC++H2TJO']B%]DH@2Y]PG>2,?%G+;[6ZHST50*MY>S@
MX.>]J+>$(4.&:F5I.F.99Z="T$VP/843U3Y!??T[[:[IY-X)HB[2QEE"=CH5
M'%=TUN08TE')[M@<QK=5O2/2$I";R!-!+MXE1G9%B+41%;JS13-511PL36:*
MN6L_]("ZPIU;YI]=X2A.Q7X%VQ FXD)@I[:XO&R9LMU*MC)556P6#-\-E">Y
M2]X#J9C*[MSO F,MP11UPF!> D*I;.E'OD)^3O3XI$:)ZU=TD*E,]DCM-DCN
MX**87]\RC4WAS0@15!P7RN!?(3+QVW-H\MI+H8V".NB2^M^M? !%8Y4EG[)'
M3L[-=>L0+J1/XS6R3V=\4I023KT1E((!7.\6UB!CTT^#R);VL[_VF*]US[3X
MO)%O[GS@Z%.=DLO&&WA^5)6G!^2A#C@0\_!'_9 86-OU#*(<MJ@N%,)^+9B/
M2NU^R9AY/8O?K2-: G=%NE(:HF@?%2 WAU Z!IUBIQ8C^>'>&[C* 5B<M;CB
MK!73N[O5-O;7@E6XVAX]O9?T5-1/%'UW[@.8!*'&((PVP,E7-J"#ZZQ>-/Z&
MU"0U?Z9AUW?%D@$9,H)_N(RO^;]\]<V?%*6_@4U(->!']5ZO%QF*V.\7VOW9
MQ?568NJG>F![G8NK/!L?G<T5^INN[Q@O3*B3[KRYQEI\\6D4L]'M9=M^-_HK
M_NP!EV/81&_P&9+HR_]OC@$>@P(*<['3%#7 J_;-,2A#P?';?%CEJ]/.QZ 2
MN7$*BGP+84CM-(XS8$0(1'\;-?956428UVMYQN#5>9C\JN@+8M:N] @.[7_!
M+&%('I-0;TSLO,&9.<7RZ7+3.5(?3?+]LOW;QNH<VMG^=])?2%I54'?(8D(?
MM'&B_[V>.NY5H,+*:]>9%J];X4?3=$<O2+?'9W^4KF09BIU$X<]K?-1<I(@=
M8-<?*.3Q+*E%S.)VDG_E$%M;L1A?!-U^UA-D8]<5?"U/GU5*6)T/O[!"M<:D
MP>N09Y(&KPJ>YK=7;FODMQ18/]:\M6;[2=-8OROZ:N"V8( G0R;00JSL13$@
MM/G;-U"<MG"491%.03)K*]TM9YS^C9#L3(&SH0R6WN<@&*]Y JM+=TES@"^^
M/G7)([&LG5 X.#80@8JNV=^TSO\D*[$;AWK\U:54;/S>1@'#7P_R/=JH(R^U
MVD!T%#?!94SRO;P>TN%8S_W-1RB1W#]K 7+[82AVFA$92ON,:E9*.7'5@G6^
MG]UL%)>63 0X.,BU>6;CSI9O%]9^(/"P;WW@P[VO&Q+1=#_7W\WO0;'HI5$L
M%A BJEJV'(-BL_HMA1_E^V[OF5NLG66M%P^WN77^HVAT9P+"AIIS#'*V3((V
M8O:NU3@ _H,-Z)BP6T*.:[BVL<<65P/4$+Y9JA,%.NG*AYRZ2DDH@B64#N$"
MX'!*)\8VOTE8>A4[L[]L%%!=Y?(]W;/L[H&JJ)]S84_V?#;)1! 4$?&%^2-:
M'(4M<#P##!([^S'<(6-W=GH[:EOP#MXG "(]ZG.0$-3Q3GHT3X)^0UOT][?N
MCC2]YON,SXK9&T;4MO]LD'X!OZMHXY@F_T0]R]<X]<4B?8,^=X<^(3>M0^7M
MMX*I1X.@,)C([W\'=45L\Q2!R WPF1\Z:VW.ZH4UMBM?M-:E^.XX9<83LZ<P
M,EVFY$L4IY/0Z;O3?<(1RL<JX'7CZLM5(RY<66S7@XSB1H06?AAR1UT:2-=:
MW5UG1F%S=:![= 39&T "?@+BHVF@3_3-VMY!B+G'2Y]?2Y%XU)S Z/<G09NA
MW/'DK6'P^<%N/J!]8W_1#E\,X]RRLCIB.=6R=;B1>DYS**ZC7\9/S&AK"#12
M#'X3XNN!DZ7P3I!"LRZXF-[OL=E[4;_<;+?:Q1D9J;D:2C&L)-/31KHUJ<^;
M(7R>M'/$DITE]5FBCD6.'TOTVB7+_8/^BP?L;@*;@MNF^/G="3(=W)KT$/B
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M*R $77#^W$Q2+ST&Y5)=:UH>#8'D1!(%2[G% %O<DBJQDS9)7Y.O^"9$/BF
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MK '7I)X2SEM%3/+JY!L>(V\V+/<]E^E7Q1;BYMIU64F@?>7YQE4F%%X6&YQ
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MTZ.\A0LXA*@?Z$L:$0SB/3XNA;AY?W<<88O4VPJ49.0.VJSXDV$$N0H$$^&
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MERH:+EE_5E3AOB$>L;6*&?0] _^!:E0(*2<^)@1<>>>IFOPZP,BL+ZRFK]S
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M#W%1H+;6T4OXV\LQ_I*L =/6)E%3D9&297%69M%3=++\/;"38 IGF 3 NKH
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M&E:INPSGS_OE/(WIAX^V*2;=C71[%,UMK(!%)4/PYJAHX9(D=83(TE9;ZXO
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MB!>$E?H#PCWI,"[EJ.0S?E?=F]>4R4N;98LZY1W33#K 1BO@, N#=E,(]W1
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M'X(!ZMT<[KS[2&(OG^-9B=@QL^;Z+T+T4]/^KYVY!<E1M%BX%!V+Y&Q$I6B
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M2M>*994@C/]BN8SH] ,#+<91]Q[.JB<'A3V,"V$X;7*M3KP;^2+=P'LWG1Q
M>SI.G@:D:ZC7LW'QQ7)]Y_:$>Q.#K]26)L=473P$W>%8.;'QN"CE7%^D(87Y
M[\+P)ZA9: ^!B,6EY);TU\]]K/STN++6.Z,^8\AN.S$XB_W)_8%MUB]H;2*B
M-QTXHT%@4$[N.,-YL-/M\S RW4_*A?EKUM66%^EM*JY;V9A6Q4:&-7"](*$)
MCYJ9PL50.6C%$C\U75[Z**K5&.\/NO?B+LJ4TURY^F=4@E<"6[;I[U@XBV*.
MZ\;H3*T@J7P:>&RG\FPZ.7B4ZK9,>R!$E[E[STC\;>'H%OID&^WW)9[MLY]8
M!H7%P"^FUM*WLB'/?!'NB/CZT'=NCD_6@A<]?_WZ>;+VD7)A"-_LC8B?45I'
M1.[^49T.A(\&'X*$\TPN /F2KNIU%QQ,VT<$?83 FP8[KT_].ODA?W_C?S.6
M5K%Y?'3ZWGR7<W[JUD6=+M\^ZX$EW@HA8INF,"'_HS$(;AV:0*ZDM<M-[NT<
M=X IJ]L=Q$TD>D0()&W/PA[!;9*6-+*Z3$T?8]O4?K=L,5%XY^E?[&]4X19%
MG-[7D31ZG9MHV!=N L^^=/3*Z'YH@ W3AD'KV62N?T&K-A8.UQJGGGSXJ$Y?
M.%_MBPN5BS',R10Z,13Y3+9FU$""E:(.[P-S(=R^W.X503ZM/O/*^MNJ.\6'
MPN;6U"*GX'/*Y4=*R/:TL!R3Q&Z&J=B_K%.- #$\>C*X8XE2HY70%:%4;D !
MAQ3S*@2_ZIT*UVLI;(<IM3R>9PC6"Y8\\TILV0)D23&$.28O:72A^$/)/N<C
MW53-+1LCD^;CO-B<J[+"S]_A#>MD7OJ-4J'E(AZ.,-/G(!Q^2Q>,?*K4JNR]
MT:(%^RHR23>3]D-?\#)%+/VZ9TJ0(P5 9Z7I;%,X!#],;UQN\L=48RL^MW^.
M1ZGBUVV"5,(M%X:#P,4RF!I.>8855[X5O:2<@ '#A1>AD6AQ%8XO"$N.=G/U
M(,[E<6#)35*[T [5"J)9TPH@[E F^J?OW,B>[^P-^9KOW34$0_("PO($E:<_
M.'.>70*!F.:S$!>.VA!RUJX;VL!#.$FY 6#Z5!KFU4O"!)!OC>CM9+^6Z["F
M+1U>;)3";R.R-JVN0YEB'\KO5WT]W"/I4::=[:CP+A&R/Z[;Z/I;KUW"^\<F
M!#CS(+2%W$]"INJZJ8: N<HG7MUIK$T]!(55F%\2EA"^.&3RWD%OVIF[-(KG
M[](A&/4A\(UBN/Y=GI30ZW.^?Z3+/F>D8)EX>K?,\"M6"#MR @0C##[":^&W
MW*Q*0""]8X;EZY/MQG$?<U(;;8.#2=56<YW1TJE\]VVL'X.8A/@?_.^E2_X+
M3.N([% AQ,64)J535E.JYDJV^\:M&O9/IAXGBDS>^F#^-EP,(1D>#3UV5&@>
MQJ*ZE!F&^%[<[F4-$T_/F*:;8(P5!OZ^69S!&-+>P07-ES["<=Y"Z"FN%<'F
M3F')3-&L(M(OJ:!#4/01&^J$<J-E_M?:^AB8)[&%*CD;7T;<7%:.+FUQGRC2
M<3*["3J#B3>[X\JL97U[0$L'8S-Z[4U,WS.AP0WO7,"1B.E!L%!YR@#S[O!'
M]D[)Y=@??9PNN9#>[?"&BRO9$_D;:_\(,F3"[0 *IM&^5!O*.<NJ=:*9VFI\
MDX//[0OOSF>N]!.P!AHQELZ7H!)=1 7<")7?M%>DO'?AF@Z8"0BQ&$^-CQ\W
M_$"H+]),?]RCDJ=H?SNCK3LV-GUZL^J.7TU9<UN\3G)8!E;F5H5KD/2QJ[HG
M3(74'*Y\_;W#Y260;YOMXO?6*]>_6IT<G'D<%P?JM+D9!?K-Q[!T"*I%QNB?
MA6G2D*I^7-3;ZFR57F4UC11O \Z,NZB3I9_+O358CR$2?,VT4,7_GM#-OS8<
M704F<]02L9#XV=48F 631>E&K5!!B:09QY[9B<*4:B8>_V'CX.=6K#CEV$>Z
M_D?P%D6KJ-GS$UH+!)!=#7,694:5#E(S>J_34.TLOM(Y=ZU?#-*)P\<?[MW$
M?^$@+Q\Y,8IZGH3H5N9^J.U3'O]9HU!ZZKU/K\1#4]DEL7/2.HA@-BV?Z;6F
M@W>HT)!KI!LOU5_5>.6&HPLN].;F$65(FOLFS."A2N!VEX0X4;;PD:Y:D5>A
M1+U2QYQ7L/^<B<-$)>C2CH'HD_\#[I[^?3LBDY?(+P [8N#-9$M2>;JJ)<\&
M;Y3M\,9:V+0>F_$GAFT#/H:?B\WI!*UW,$&BJK9=STK#%%QVT[Z@.;G<*WK2
MKBDW*-C,-5WOHJC/0M0-[2AOO!X'&4,KQ;B D]K=\@C"_-AG'>+OJ?T_'D13
MTW=4>7LKV:Y31S5\7PS(*9,':(5!RBS ]A3Y'0#&':?Z%<N^R?]X")K91B^0
MS3(;?K(P[R34.;U#WD!"J1< )+&<SNY!@3BMM7]Y;61UYYN:A?@T1XW**EB1
MV.+8-F@G)F&]S\>PC)8CZ;^DG(./.XD!JTO>.=_0K%3[)RV3B(9Z8E>(U$"!
M]1.?F<C68=BW3DVFWR_%KB8-!52K<,%0%"%ZGQVX03FNB<#:JR\K<6G\O)H-
M9OP)Y1E#<_WNW,7KE9V$%T0S)P8F\4M0FW] \XM_%7SJ$.2Y& \YMBW93,*D
MJ?IQ.PXSI$UNKX1]AGS\D=*L1TH"X2"/E&?=(!Z8N-F"R1@E-:3$,'DRW#;>
ME4O!XO%6YE52[ ?WFR/%"BF_H.P0PFV*'1VK#QEMPJ1-_@I-[Q+YQ:-_+&F^
ME'G7]MQI*^E,4VJ#2SR(9KPS5T[VR,;FU]+*]8\!+W4]<W\91[QSF%Z@-79_
M)2BH:LK]<*QJ/U\UP>G*\Q;B83DKMXRE\MDM%98M\PBLDWMZ.1Z=GFQD2Q.2
MB/DYOS=7:"A6O$268>JA2X5NF@"LI/%N9)-RCWEF%54:B%DO!^IG>UV-=9![
M?:P+&2=;WPE_?P])PYC7^+IT-,?C!!;Y*F1,^E5*747^2)/U:;'I6X.1> <+
M\SXN'(;]84C=R-NU$*LJ0\'<(=+(Z5KI$5L08ROXK)Y_.NH?X<J_=I(@C8(]
MB)@W#/AT$2\)D5S_%T4?VQB]6"O[57HC\'P,@_1)<&-DWA:!B(1.$KC>EN,&
M?/#:OL]VT]4]<EUC-"[&MO9+& ^"KZ],K9++*9;TJ<7ZD*3?$!&J:U.V$U&]
M39)B4GBZ9=>9:R07Q1O+6?2$\_'CP->\VI9S6+)["ZWH)L;3+QHMG]S?DJL@
M^M >C@PCHW+%^$-!<MZR#!=(A44>L3N(^G2"Q9+EW-RR1/&2LM@Z&4G,,?5:
M\1;AG^((CDUO-"P,7WH-&Y@^.F:LOC:P>(T8DDKEIWA0Q?,H+MU3_7J7^MN#
M4)PD]0E9:SH;ZU YI#>ST%"&GA'JURO@I$@DOZQ9KQ=NI%V;5/CD)7PM-\V8
MLS1V8"F-"_:2<A;1!7&AO=)UQ)/\<0DDN:B]>6.OY:I6H\[1E0L1<<XVI;=W
M8UBELZ>8M@P8HT"=XJ"B8_^]%R!_RLD3M(;?(S.F/?EN-;DO8!;X+V$IX?KQ
M3Z.F)85=YX8[KX*X[Q O#H(D/I#&L1I(3CAG*+ZO/;)] ;J6K_:]F%E1!27C
M?ZE"DY!Q"9IU"&) N$!XZ?.+[$T[R5E4AP\07NBME[QC2P))&M?Y[XJIK^V[
M\L]>*!&3^-ZP# ;.@?MXN*A7:XFFA#/$V7$#8DN2-$7GJNJ?&IF8<W#+"]5I
MW7?0CRXL16=GF8S_U%?\BI9&=)V#>&J0E..77T$!8QQ;W0\!68YG; ,Q)BNF
MNLX%Z?/A,9\,)%Y1P/ %N#IPAJ1!YPLA</O>SS_75Y#65M'LUIQ!3%1%[H[)
MXA^]U!P8E%R!ERJP6!DRG\PP#:>6_EW@#+,!F(ZB\\NL7R^4.S2K6_F9[2F#
M7%OFIQ..XIVYWSW;EQG.BV:P$Q_/TS8I(@]GZ6T4):KJ1Y)F'L7=402L5C[R
M8HU%VGU$Z^R)7YL&0H6G:?%T 2";'#<&OS!2IJM_NE8_<,ZAUMS[58XDUO]T
M]*?W>H]OL TKK,G_(RH:?\!D]-&WC ,09$\2%RKVB1(C'HLYX7O355OO=1GO
M-R&WZ]65V$#NR_+9:696)H$(%TO@[';R$0INWND2.03%KQ AJ<NFN1QRK2H]
MP>_VOW'(UP^4R!2S1AUA$9#N;3I[7@@Q!.?>Y+.TJ6/A8 >LNPFI0XDI=VAO
MC>_YGG!T3GDGEN*6_?["55WDECG%YWE=*ZT0X^GM5=SP(;KQ@P[MH7IJCG@P
M+7<S^#BSF$+A:Z;I29X>O\1@3-TJE0^#$Q_ITPEIJ27)M%SHJAF.B^L(_)S5
MHZEY"+*]O/5 .Y V[O3WE@'Z=WVS91)<$ BI"/6V&=U!RVRT?Q:!(V5?:9N?
M62BM['RI[OK<;I>(+7[ ^EV581R.E3B'H65"/)$GZ%_TSW>$Z6I47ILMCPE2
MB/_C:CJX:[C^"Q2.$-%<#45]W0 .0>3;M.?4JV@046D1NQG!<S)TI$MC;'"Y
M+>2E>VTLPTVWY^HSCZVU76&M3@&:%,9_"Y_P\$NAAOJ2,&D2,K[ B.N(:S:
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M?L"A^!P39;-[\_S7VZ_?T*7,=#R[\$R'>VL!1&4X0)(C_)C@<XL<JNF)^MH
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M'$G&'.^X2/K4&4+G(45&3SQ1F$S]$>=ZL?EFSSM;L=B<#9U3FTYAI :R)>!
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MQMK JV>(:K2Y7&$% CDSS/Y#1_-/^Z?]T_YI_[1_VO_?C>=PYO\"4$L#!!0
M   ( #F!6EH<6(NCZRP! +0_ 0 5    <V1G<BTR,#(T,3(S,5]G,3<N:G!G
M[+MU5%Q!ORW8!/?@3A,D$#3!G1""6PCNP2U <*<)!+<  0($".X0M'%W0@@.
MW5CC--:--O[X[LR[,^^[][XW;][,6G/7FE^?W?^<ZM.UJ^K\:N\Z=1X6'M8
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MJLG K1X GB#.K4X>T @G,OWN<XW,F=R\-O'U]P? ,G T!/C?U/(_![ 9-AX
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M*:^IS2F[-E-]Q^Z[YW.OG^V71=ZI@8X2MTS  S57;&;\#X!?0COW4?YPBP>
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M8=_2(8O!L.'?K5L1J6YN]I0R+RMCOD3@WLH'7TBL-W/QH?O:]3!23-\:PGA
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MMX;(G,B2)2.1<,CV@F^Z-C)[.<5H!=K=Q99=Z,#L3/KQ"O@A]7L<Q0<G^/=
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M>?X7E/:S,YLOQZ7;B/_-&&)N;8WY@YWI1\GQS28C 5"3(F.?",T?ZQ:/NV=
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MU!D'G\.0ULHE1!8TQM"1?2&AL5@*0S_N.2D4!Z,^XJX!P=YDD FQGU3)M_N
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MUX"=5.#90>TUH$7KBA[Y;OH:,)30<GENA?MQEYI@>D5Q#<CJ?GH-:,T!$BV
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MW,^FIETR;(-ZW8W?EB-O:L-\K0H3U.M5_^"=*?^>0"8KJCN*V816WS<_.7'
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M*QGUSM<^_T6HN: H8E1\^):P^BOU_>*44>*-/ ?THXDFK8N^=*U7GB[OW_3
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MA5^<I4RJGLR0HO<L='#%^*\HF$_IDCV2N3E)XX_3^G-FS$Q)W4V:NPLO;LR
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M\.:'2XN4C7MK9.U!(7K#+CGMMI=9+&?^XL6N^UU!E+@_J!\0SMKP&)=#YN.
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MGO:42GF>_'/P<LG_%L%\+!C1U\G?>1,T> 5@MFDF.*%M&A.8C]/#S\S<&??
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M=-M"AX3=>&1[%[W5%G<@0BC3XXH3AI8<4VBT<LN$R ,U)R]:I<?PU\_!&5<
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M;=]EZ?N#NE@TRW(@Z #Y]SY1>Z/OJ":/SD%3K90GTM7LSN-K^N'#GYD8I??
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MKK$N_Q^LO6=44]'W+1I%0:F"]*Z@(%V*]$1%FH@1D%ZB(C4" B(! E'I74!
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M_TQ-+>OIN]D,!!%7H]4$"F E<,7?:W.\C2[Z[RK3BB+72W//U/[\E-5E%8O
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M0P:!=FZTHD$UP]ETK=1ON*^\*;.,>C/2/%>;WKTR*JY0/KIVZN'5&$#7H1+
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MBVO:H08?E&@Z4;@H79+N><AD;^COZZ%)RHS=L@B+)9!;YLD-,BBS_CPWY0*
ML6C =3ZI((JTBKM(+3Y)\O9U;FL=964[4"KJO)MU[;Q ]WQ<._KS-W9OE42V
MT9? S=G,:(O_J[WOC&KJ[;X,HJ!448ITI4COO0M($Y"F]*+204!J H0NO0DH
M"$J1CI100@V]2A="#34)O2;4T/_\/LY_WG?FG37S<3[LCW>MNYZS[WGV/NO<
M<PRW.UV?>[+!A8 ^4FQ9&N6P73$^I.$\_:=-R_6RZRXF*;C^WF'7N.FVJ=]
MI^3;@1$:V3M"_1 :;&+8I?9R8WQK8ZZ5<7]FWG#4<K:U5=Q4EV$1QRAU4!ZM
MPL-5J?C[LDPLTGS67MD+C>?$%W0XN][3$Z^J1TH_$+X_AOJD.D\A/ABYE>F,
M1]'?8<JL2D\.U"TCFHE/I,9D+<C;Y_CD3P8O6&@YDL;V"-@<9D@>*A"=JVG
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M6E[YLNZS'W_7VD7Z]],<LL3V6U$,=6, Q:QWH5]/'9'Z+2[MVFM/>\WRV8"
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MG8R!O>ZK;W2V<VN].?<^&E7J<Y<Y4;WA3@@F(3H*;.0(.\_/\\J$[R[MR]X
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M96"EO\U4*#?FK8S4EM_#;K\VZOR^G?P<XT',SF5#4<;BQ7; @_QY8N:&3*X
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M'+0@Z\FEQKV6?(]A-R[]J4.E9P<VL9R?[Z23Y(22>;YO)>HI!HEO*TTU&T!
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M*N?<0*=.PA$ZVW5R_NJ^!IH6E._]@R-(/BT,^/J7\ I22\*HI+MY6J$N!2E
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M8X\E#$#3WH=^^@9>GH#BC(RL[?><4MFJ(M8D!@2$.>< 2)@%_"4C-](?Q6&
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MR055RE[KE'!6CY[-7IJ/Z2RLGV:@$*E/^=^Z$LCU/M'<IRC6'3Q995HB'<A
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MS@:M3IR5/NH*!FM\DY9RT<K;'>I*Q<XK$I?#X<%0'U'X(N?!8-0:IR5Q,$O
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M;HP^K\;/"F--!.RE(1*286^?*D7UJ:$(.SV'.[1TT6!Y\LC<TA4#Y0DW9J3
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MK.!;:3H43//Y\H)).V1XM.):H[XP;XDMVZQJG[,'4];$OJ)VY><#WE9KL6L
M$_1AW]LO6U^F])JIZ!O7T("X!M5Z--.@F>?/LDL)C87+O'C4S/>]J1QOK\W,
M[I#?(8U:3V%ZH!#?^LS^"&$F"-*(\3!.@T1^#?"3IK31K*09AS[_\</+3;[?
M2W.AL2-R$9G$LI4\*<%VC0%@FC*5]P?BV&"F@RYUHW>KMFR/=:NVH<3UQG#=
MZ:+H6%1';T(5F:J[347'QLB!F*6O1(=V+OS5KL]%:608,Y/Z)UE>5%-=:)&F
MU>!BJZ'5FA'Y]X\IFHGLAXC]L\*[Q:+\\8DKA']@D?8CP&K'@\C0-]JK%S80
MOI+X"(#L'1BB0W:(Z]&R+CV^AU!D1]7O[3)/_%'-%S14TA@YXX1:8LPR2T\<
M/KE7HEG_>!N+6==(X^^F+/0 "FQOC99KW826\^>)"$34<1F;GD^><K\#)_IO
M#*_<.]:E^SNE1X#_H$<C(=J3MN .-F6F-_,.O6>5-[I%[7\$@*6O51X!SU6G
M$(%/;FQI%$&X\0@P;W@$9%@] HYFLO=AX+,#L8<[GN;<4$02HL[H5KH W#8!
M?01DZK=<G8/_F@UJ!]XF9G]X *X8&EWJM=Q<9B >4CYI23'35);ODAB/7C!1
MMKRXW?#?O"PLW/7GGE)FXN:F3+C<]=?N!F_$@C/+Y(Z[@^W.9<3%*Q=C[O:"
MA"ROM>;N,^0&CX&A+57[1 @-M,,3":5;2Z#15-F&P2I-5Z"Z(_-PIU;+8>$.
M@<>G G#_S/U'F569T#Y!D/9?@T2EM-5_R2 FP=<Z@G>0F6!928#J3<QE"[8@
MBJN87!7!KRZ\18+*+OJ/5!CKP/<:*DE4GN8"- %LHS(8YB@>N?\RMN3(];F
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MLJDXP\9BN2/3\=_O>++-:Y$" R4M;;S#4RS2MCHJ[+F8'-+"NJD4^04I 8\
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M_25<1ZBQ%4AOW(1DCAXU5,73'CP5N?)43]+I[5<O-8;Q'@$]L"<:-Y5J= N
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M' ZY1_^T4ES(QGK(D)QCD/.18.V\I"$)2HZ'O&0DEH$]^#F8/DJ[MM99EE3
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MDXY-OO^IO+F!A-Z=N#"GE\SID*-&%% 5%RPW1S89%<]31E?!0DTJLDW%A22
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MJ(MA]?(;QY='JF[Q.;,JLMN 8=*1204,S),J&+BV$A%7_V\" %!+ P04
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MRHMEB"MUYO3KP &4LP0)*= PT$T6'#"S!0V7TFYE]J\UFZB8>=R8J-7DQ/*
MG]=<PH&@@+F4FGK]0?.(=VL3VWT89#OK#>38##B7[OEA-F/>&7?D41RBRB E
M3(^WA .^NK$N1AICZW' AKYQ(_1ER'=KT=?H!^ ?.&!DH1G^]X7Y/[=PW?%_
M78+"J35\-K@$#GTM/LHUO.I<U?IU!SJ#Y377^!APO-^+ V)W+\;>&<+<>SP<
M&2+QM,7R4R=D40S/!$2RV]*+%+R9*#LO%X<]4[?>5@%9_Z,# ,:DR$ZLUM/:
MPP@<H*%A.>_/MX.'Y.I[BN9Q([BB\6971 :Q726K4W?$[Y4^@3<8Q(&81T=5
M.%>:#J8&C.[FQ*Z^?>G'17%];[0AT,BAG9+OW!RNGA+_?J?6HA9-=&\1[5_V
M3*,CZ4#YTJW6A=I&T"G=G67PXW/-=!S0Q204.LSNWA/W0Y!)"$P7=:I',O)'
ME,X?_'-O'U71K8I9Q#!/[C'\\7#N#2R#&2I.<8#)Y-Y??AC@O]PA!#PU>KU_
M2!85W=2TEOX&;0WY!3;?4MQ?=_V+0F*&&EH%(/=U,BA\KF VKX!.:74/,ZGI
M$$J3ZU%!JO"HQKC%10M':.P</>6N'EZHDE;YLXX0^SAX!K758 P=^4;&&O.W
MTJA$="_,*N9<8E-B"*YD8-"[*[P3%+U<HH /O@U^7X =%[!!7GLC\5%FYCW!
M81 ., ,VL>1!QA-HIW)G,]_2?IY3B&.MXPB_&@4!'T%&4QW?"/0S=&#Q:VF:
M,K?M^;%GQ5;!F?'$WX_5&G_#*B*.LY;=HLTFP]-8!SS'J%@Z0HLC2?L/NX/O
M6U$CUC&"QZ%(Q0BL*:;D,,DH5"F<DFK\%J+1*5G\DNNC6N_;%B>$Z2VYB2AH
M;,A Z[:B]N'%@CI;O0LE;R%EFM3$"'9 'B\>I5\],X?LF $GQ?S9H8J@)>J!
MY59&T?/%,TEHDW$8FN0TY JJ&K*( T9[+C3J7YU;]=\IITMP$ <X.DD'R;V'
M!*Y=.4O$"(X+?L,!3J320>"7D, S\0N-*8=]A_<%87"S>C0$M#FF\E([J-7Y
MP_N59![06\##*N!<3Z/FH',,$B@'W;^.E=J&4.;L8T$H;\AX--^!"J0LH&#G
MIC-(9T3$:]!+AQ.\8 @^OPJX9P#O.Y$2W;ILL'>0%0E(7K"AM2":1]4!Z:!"
M\IR7!;VC>U11_*_'&,NUX>4M03)+'%8[O.+W1@-H)3YR[.V_4.K10@N653!C
M"J2H!3L;E)(]UBTEZXZFWU\H_ W\E)_C\#?E3 ]&UM_U?7GN1[R<@*=@$2QA
M<*!<#>I8/!55%L4!M<,8_CO+(D?D<6&MM,GF_ FZ(F,,_KG?F26O-[D'[O:?
M14YA/A8D;,,YLR3+[9*U22WG&[Y(]&A)XAV6!1BWX8"(AM;G=M![1:SJM91T
MG5\ZW<A;A=N7]Z@H \O^;T5TH9+QL=9O0D2LSS9Q0$[)@N#:(AXJ5908U=B;
MVC12W6%6&O'-X$77C^+GZ3\^5SP8"9%"V1J/P>KK6^)TZAU3387M?_2(Y8;U
M,2M)B/?WP4,5M@32XTMFMF>?,!U?+AOZN.SM6<A%^Y&SZ8BX_!^KKO^F]!\U
MR3E!YSH0I]DX,N?+GVZC!&:QH)V,GVD?,M/IGKJBBX83.K1H']R1+KCRB1G_
M 4-*C[SET4FGZPWS$;1+D3.62VRF/<O*9+Y*^B21A3XB@=Y-Q$W,8?" 0* G
M-S3-,BYX>0]O>-GQ27?%ZR,PM8Z;HG[*E_U<+7P=]DQ)SYS\)5LV<Q:2\E6A
MLN%>A,B<KNL5;P@#*DRU9NS)4-*GZHKI54W#T(6E85>>@+CY$X<$8KQNX.8R
M:<7AXALS5VR];6'MJY7TJ6\=)UI3NUS:S_+C;P673[(PWD[0(GSVOD]933]4
MCB]I1%&W1#*=$9GC;!:=B KK-C93ZOEP=: ZU_?1KLT;.CI?GJR:F,'(K/<?
M\'BE24HL_)EV9B>;YQ>:2RPW:_;H1S8JJZY-\D:+] IQ7]94Y8<LW.D,H9*U
MN/\9I9.[B16P?/QT;_6%8/^1H.LU+9J9.:N[EY)A@,KJM&+3C<HPP20]'<!W
M(GKN0>*(5]O0A>6L?6Y&O6N! Y:$6M$ZH-D1B.<Z#L![C /@SCO_)*T!QCL<
MA6H>2U'\H_:4F,R(D[<-U$>>?@\%ITMZ+E1DD2_*6BON'/JJE=<-F4FUW1;X
M3@\%ZARMM'AJJ?R#HV:,%EOV[-5:'6A6?4VA@G0S.DI,,)!D[XHW>P]FFOK.
M$9BL=P5EK1''/.- AM44%(6+/K=!O<K,3Q,>-WV_;CIFJ(/B$NN14!#?4^$D
MA9$R=L(C7EZ]TE']J5XVYHU<:"RQ!(3LS/K7#OLSO2G=:;J"3.OPW9'/*\NK
MSE5W>GV_VC/MC2)5TN$M^;[(C?:D<-7K?3Q3H0(0EYN8@0PT40H.>)/SZ[?\
MD93_5S=64*!@ONE<J%>PX.M&JIR7/:ON%IPD[("OLRCR[UBK&(>Y6",E,?E"
M#Q-WYTZ?09;$6$BV' F2,%F^,G')=L;WI3ZZGO?-4!.E9!&,%5SH;',(NY5"
M:73KS"[8CTT.!YB"'A,W=_8L4GCK@K1=17(3>8^7G0>>PDS*O:I6V*.QBE-Q
MX4%L.?[*<_UC3WBJ^SJU3G(A)^_W0SYT U;8J;#S%#"*_&+%N*QQ7 7Z<>'[
MM9E"4*F-:H#^/VH,B@IP+_%"4H:X+="1?(.L']\89O?>L]"]5SWK0KFZM4C#
M=#Y6AP/ZNTK!M&;"I:PW!%[=,!&*UO!J[H%<!24!P1P(&?U(4'BJQ9.OC,;O
M@]YJ=F)<.+,T]RSW?D5"Z-SHF8UX@27:-&:U**%<F7WYEI2%8,>BD0Z/T)<
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M1"/DJ0=#!8;^XT[-O_D>%W_(SDV1>065N/.QP<6W]S$N/P37=*@[>. .W9A
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MPKUKN)>>:BYD7%M9<\V.BI:&\@=M=,+ V0B)X+FVA=(D-/RPKCZ 54-P]XX
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M\YLM+MKB,14\FH8&OC+L'SDG#ZVG20T-.71_F"H[%'R;QP$5/-^PXR?L 9"
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M;"BNV?/-J0CDV/D0_,:L.S]J*=A>N_%5[4'9XQ?<,Z>Y=@^+E?K+^8X=[N.
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MYP5)[.0G5H!OX6>-^2NRQ7"=OIQ=1^FQ NAEG$[04&>2M^Q/R$1;305KUPV
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MX#5+2Q@B-,>I[05(,@8B.%(YS% LS4VK./V*YG'G-L7*]V6.*6E#Q[72I==
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MIA8-B;"*\V!\HXF5FG^/,*0T$MSGCK\O)T1I$3-+*R'.K!LXU$X@+9>+XYJ
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M @Q(W)H2$,H4T--R=8V^](!=&BWKRX(8OQ:_%TABU"V[ :S%5@<^Y  &MQ$
MS,$?YR"XK["Y0;IA>M8B=XM0/=J[3#\C1E%M$=ETJ+&$/(58WJX)>MW^#RSW
MF(=@7"=[$]JE+RO*(>IJTI6: 8^/Y7J<9X$?#,Y4];M]KWH3!>1Y>GRM>RLA
M;B'<CZV(\UZN$H>R3DVKS\+7*\)R[#2]J8T:05*#?"^2AQ".I<Z5)?7))O7$
M!A(,YAND#>.S;ZW,HR)P_5>_KIGF_?DQ5:5VER;ZC^T=6-*G"R78I!U&*(($
M\:GP)_$E]H'VR?K)'FK>#%8+GFI\JCR%XQX8B%Q40?5%_^/7HCOC;=?4N$\H
M>.\N[#M.[GEW%J^"<G2/!7[H$FPR(4F*S(39X:@4P3S[1.,8YX+P8[@%[LEX
M?W C!_"J&.BL/[8U*V[NXIJKOJ8'NR+3QS<SB"#,JY_B*/$MJ++X-=>ZE>_G
M7#C_#*^"-]\@UP0E./*J5.!]0E^\XCZ;$SY7\8"Y[R._B&-N9&"8Q_2!; 1'
M'G].1!<:$B,L%];$ZG#];.J)ZN1T3Z!;KJS!-B&E/!O*EW1:\S;WT'#5O516
M,%,;@/1FL]6@;N%;U1479UNXT#J2X=(0HN49]5>&H)'R^&_WRH+K#:#W5GTO
ML>O\X78?)]O3OS/_DM769\U6RI)[(\2B&8#+!23,MR@A@+U'M+C74RWNGSP"
MWFB@K'N7Z1:__NYW>C':1AEJ.=8S2'/;/J)I/ )R?QMEV\$<QL19&_)SFN?^
M_H4H0N%D=O2AN>\G=N?IWH!#>O9NBY_%Z]S;FG-@KZ7V%?#OBY*&/5C>YIMW
MW?K;Y>VL1^E<6S> .;'U_N_7/'O9[#5HBM]CY\.4O= $\O[-7*'[:@2LAZO9
MOO )2G1J"\\'2MO7%?OUV87MKVM=**;??>J*X*@0^OQO+FWX#\_%R7G6U2_A
M]@>86S&AC()_1Z[T>I%SXWUZ0:[LT-SN/:+_C!Y0\9 D>8#!I@G58)0Z5)7_
MK[,W9*(61K4<\F/.ED68:>P[;Z_5UB[[^DK3%9 ^5;2;L[,C72*PI<CJ8S>A
MX;MU=@ :2-][ R *0QR%5GBHF*H#T51)?H$SU**B<&UI.ZSFM;?\?!5NG8!>
M<3+3)8/YP6F >C^DECE4^(BI?+GF>8^95=7>V*10EZ.9W9=%Y86OA6AH&^[)
M*@_^VEC,O'Z8\,[I\/VD0KNXN;_O.N[T5+%E B1/ ?JS.L5A ZQTGV-E#-D.
MS_3@3D6H7W2-&:X)FU^;ZLW"AHS(0O-02841M=1)3M:3[D?5TD7\#/UN=Y+Q
M*U?3G;NO[O&T>*T-:H%%8$0[O%FBZT,+3V.=W,8?WQ]G]F,L;4==QRP_Q>2C
MB50_^-2+PM']S04G@DAV=*\;^*%[<P&F,,](G2BOSG5P*Y?4<K9,+4#6>0K>
M\SXO;_/%-<\U%O(Z)U[97;8V)X)+<)SP5G!.89RO]F,W&7W%>H[P"GM60B_K
M0\W6#R#.7W39%QI82[E^L38LYLI.;\O!J"\A)#> 5A=<+M0E^.H#^#!VTTB[
MF%-;]^G!9-/%$X[BWCYCH>V5+^W5LK&H<Y$I?VW*@F8$AU-O;QFJ-ENU$M@8
M(DX\=U$]W-DG:75%HD#9QD5M3*LY5<[5/CQ9E40GO*,4GUXM 8S()I.5P[@A
MF,DJ5B0O1]>_#7:%OUJBE>WL2L?(8:G7];M:WZBB= 3WTHU!#\[//:G@[U #
M;*XTI5R4BN//JVGEQUY!_Y1P_>ZP2>CHTLFD0)S5'#G> * =FSVKZ]_C(4*1
MILW,D/;JHPYW3-RZJF.+88'JB[C\GM_C#&-HB2;+$+,';$6DZK^(XD9-,=!5
MBJN$-FYOI1XS1C'J2\O[25077SP]GMM$51?1O'S:V4][%(&=:5QA\F;^@/FR
MEH%DU:ZI:WKRAN7-\QZN9U\57^>\722=H1U@33]-!FM5<&577TTE93KGESOO
M'TK(U3PCE*X,O)P60L1&M=>*EJ)M5P,3&*_RZ *F^QJ%M7FRURCB.BF<<HF5
M]S^WV);@(X&F_NP8Y;65_XV]MXR*H_OZ!3LA 8(&".X>W%TCN 5MG 0)%MS=
M(<&=X!!<FL8:=PT>W+5Q[48;:&#RW%DS\W_6W/>]\_%^F ]5=7:M6G5.U9']
M^YVSS]X1_J23&A,R-5' \#%\OX\&X"6&A&2OT*&8!69Q2Y*N?;9MKA"IVKA(
M<:.MKPUPM^SKB,TQ3G=KC4T][)&LY]4AW5B$+C10@)OPX+I-OA: &PV 47D(
MP7@=3O"*@W.Y8>D$@<D5IIB8XGUDA-^9NC4I0WB.UO*_2X2I9YO4?QMC)[:?
M?<!UBJW_U.0IS#B%^<8A)4!X'<G&?/WK"0#<!(,F'J? NO" $/XG *55S<%2
M6@:M'I&%E2X;&T#V'<TU<Z,WX#Q@T1NZ#:=X<2EX*G5.(_4;^!(^<'9B0@")
MIJCTUS*#Q;C<[;;F+E[3%B&@_:(VV^PV6BB/?44!(">RO; K*6JD,ERE(XUL
MP@6[;^J;)6:SCCKUBWBQN.% D0FL([E>H7F-D3<1)T1\RX%M>+M][QNG4Z04
M!VZAQIN&EH=\CW2M[3[='AFY?14!V*_H(Q'Z^LMIWY)Q4IWVA$_.KTH?WR)8
MD!A++T.GY 0&%S+'$ME/OEX4VO.*H:+ \G!+Q6F+AO(10/GIW<%L.^LW&G8B
MY,&!3HA=R$'-$Z#"I$CT/TQ2RY=B\U%3S 16IV\=/[:FEQ5N'X>QO"UA^1;%
M#Q38> )0O-LZX)P2<V^P0J<1>ZZGZG4PJ)IS-367PC(>G<54.9E"-@-_K<TB
M5DPXBE2"]W?V!CP[DF1HCAZCRD6]^D[AE8A/)##QV2C9LL%6KD^2=;*-T9SS
MJEUG0J&!(2SUW.V';E 6=I_Y!A6: )RS51!\;^3K/%.OPF6<NMZ3^J6D$=_A
M7(/D>L!"MVFD55#VF$)(@L>XV"CH;B9;$9R:Y99T?MRV.!;9=_\F']N2 _]!
MK:CSZUET8R=9&[%/N8V.^QSP.@UD U^R/U]T_UN[?0DWWX^0 D<"Y\3'!)4<
M*8/12"%79>)]V JH%;:@,3DR>,\P@'O?T]%>-E8-ZX'::!:#*#DN@%2HE15?
MH")BU566 [GX;3RPLV,36,*1X)W:,D7A<V?G;3/F0$=4684-<Q<%:-R/'!*$
M W9R!^/LYE3B^8<W5#9UQ%^B87GQ_^,)\PL3[*/XM<<9$R)?-6^WE-JI$_H$
M_K+3@B\ :40P?5#RVBMGI\$Q@YUFRWGR,GUX<>KU>G&X\(I-K^QD7=(%<N+/
M]R(%J *]6Z+0LY29;6X)=(E^9Y,W'2S[N>B^@AEKK=?AD$2WAE@Q+5SZ5E0:
M@#PE89SQ++P_KC\N.J!NK".NP%;4<!+AH=C$?=)<CTI>R-"8W"A, V\JTTQ8
M><VC3UV_U__]D0=!OUEGW3!FM935R*=@?M8VR-K24T"#=;'[><-1QD/C]]<:
M_IGM(D65^Z%K%615&I+@U:[ZM8:33H:!5*+$3;\4Y*8W#DO_X+PJWZ5BR M#
ME>-RX4.;?"_]Z,KPF[LJ#YRM-K9!:F)Q@WM-ST5QRHU7G/S9STX61ANYMDDU
M449]@L,Z/1+?O!UW^2W2U0Q+NZ:=X10P4E2CYJFK#N47_*,[&CW/$$YEY:C:
MU<D"B$Z: 7#[Q\," L5)802]8?PC,@TKSY4\:' ]7+T#QX)R\WKBWAGAIQJD
M#2_P'\[NWP #MDT?(=\C!!E+-8\F%\X=<!\')3%@Z[V-$+C?\AA(^6/=H:#'
M<XGHHN^Q@*,_9=V_&;]/4#PKV)C ,E"V\Q7:O'_KJO+V_  CJ=/J":#'YY8
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MG2?O4)?/<,<>$+MJO_/_B1"[C_$;CA9:'T?(43W[30-FT(%H3"57(]V7R]N
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MCJCK5KNH\+!+P96RMECI$D='.PCA.VXS6_3J UYX .6.Q73GH:?*0 Q4;:E
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M'C<NE2,.]T:UW*N:>83)YFI<A/Y.D<4,5G1ECBO]C><XSWR.-US'K4Q<9,-
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MX)IR./VB*A3[U(PE0E&>P:=%J5K1O:/<&*!Z"(V'#'C#$^E:)16V^1FU,;F
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M6:UTI >"I?L^+;=T3;D%NB@S@UD(D%A%K1AA!X]\]S.JO%8 ]0V.I8H$3)Q
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M6GUFF+*\'+G#5)!X#AFY U2S'%(WUL@2Q@W$=HGC4I@*(G]2=K7!Z'8YZV-
M7@.2J.V \"#<PUB<Q.,'*?P1U7#&4H;5)5+T>5?51@1OJP H4(0<H<.BT_F2
MZ"&1DV\LN:Q;]W=2=!K?UL)P<C?.42&WIY8R+_ W'E>R6BY]]+9-;O!Y.)QS
M8*V-&Y<MEKY=5<73I[((?>[/]EY*&8"=FI:&Q?B#&S.-,:<%H(<D^P_?029
MPEE/(O,KF*I6H#T_>2%-$V&L+B<O[C8,KV^M6D2=+J ?W;_MUG?\"-]75(.L
M@6BC^VJ*L_-2LM-GP/(% GZAC:<RC@\/#-0)@/(/=T6!]_3P8[W31W-:CWVK
MP;%4&V^Y6Q^F_7>,>&7;#I].CV%OKK]BKA\TX2($3N1YH\P^!9:1?[3:II*\
MPFSUE-G+^=-=(+\&!"=L;E],HS&&E<Q26=WX9KG#J,2@MQN=FLI6*SP$9*KV
M$C:V.F*57DXT>LGI7LP\AM-9'94>>QE.@DRR'71^W\?Z@JD$W+,E,2NA6UZ\
MO$D0Y2C-SJ"66J#N:(8>&"X,SHU;G2P.;  6;,?%-ALT1;^U4P_Q-3K^"FW!
M=JOMI38Z+;9N'B^TES6I;JSR/UAH.OW012FW[%0L!#=M >$YQ>YHUCLD2M48
M/<PURZ%&P49>7QVG?+C]6R6ZN\K"*5G=- 8IQH>N[&QP?@S#.R0I>CC$)H#;
M5'F*<[_B],M?%]%'+2NU>?8/#:KE66=R5?%J5L21?YQ2VO );8;;(IQ7'PI9
MPC3?2?"BN?\0_'H0Y75?+>2</_,2T+CD7$4/*1(R7PF.57L]8UXT5<IAM&8%
MX@2JT!P_J+\#A%()3-J[>]X^2L9\\6:@K[SBG7]\F?]#80+D*-N?R-]$'KDQ
M\NH\FK:\%L\>-K/'P.>65NV/4>;'K:5P&W"U#9<!' \'W++!B?WI)YI+J,&Y
M!_H#,WY9# 2; RVGO6MKMCI71Z N:%RH&Z\S:S['O([F?/QUI_C;[_(2K[TX
MD\Z+HMM3D,>$7ORH2LZ>8_0/_1$%FWP[YB-].8-TSP.==??Z[<^=&R2S^H_?
M9[U ,2U&G6RFJ3Y)PW/XT?"D UCA=^9?G >=V3YW)#KJ&]48Z@Q;+O090%I[
MA,L>-MEM0?44'M[)XEQI*8#UF<R%L_-<*$_3"\O0T9'O9THR _).']-&_!W
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MSY4>T_?9(&-7'5C/VZ7A(<'1 \Y>HNW(FKN3:VIS(?7< 8RG(U._4U]M-/U
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M<0H4>DTM:8.\U0>83BCLM_^&R]S;_@=FK,-HU;K@9Z81-EJ[ R3@/X/;"8O
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MXT'P*SA=8A%"8K%?L6&:F;G2CI?8DHV83;,"'RULU00E1ZWK%5.D=]+-SID
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M?#G#X_C 6G@)CLZX W/>TCK'D13PZ*-ST]87L4*SDYNGC8?,34O^58KDY\E
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MK2I;WZZ@AX/K\O.S=\1=S9FTEZ*<M\)QU#]YC)YM1"6E'D%+?A%-6M%!%?C
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MZK0N2^,&RI_>1'??\CQ([1-B,PF6_ V"@_0':?/FTU!+YJ,\R0)SZHO;S.>
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M:9:HD!8S<'VEO:Y6PQQ6QN[,VC52)/Y8OFO0;)#@C.'9D 6P\2B8V.Z-[70
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M#KR[C-LLO #"$3,J5SU6].I\T5*#^D^]+]7>X?H#?CC?$Q5NZ'9*4 ]ZNY_
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M UD2\>+(,8C-IYZR1#LH*WTXH>X8=E!>[_W:*MMWNJ(G4/>2J8R=&SY-F.M
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M,J>(5-EW5!_("FQG,LTL.;)7*"E=,BP];MC-1J8#7!B:"+CJ* DVY!@!IT*
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MO&-J6S:.9,\V2]-'\2A=B944TW\FKXV.2?1?^P? !T>(Y3O7@H1\CZDLED=
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M$R4HKV>QY$=J!U1',) '#YCP6*M,\=49\X^IU43(6=L2&':2L8?$4')7J(,
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M]W_QSHD8H8F"BT!YNB1Z(.[K/"-"IUH0<9?9Z^0>=>J!OZ8MW'VD:55_+8+
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MI5W#'"OWYJ#$6+L'D/72G/[C&?? MY;*._XXM"$S1?N.ZCTP:#QW#]"8H!0
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MB+IC?BJ V2"ZG/RC^V9]5M7O @MJA<?RD9,HPMMKP([(B&\1?F>17=30(>A
MP^H1SF5HZ#24QK$C#/J)0T6L;,FO;QF%D3*S<SA2=SNECJ&]CG7&;(.Z%CNG
M-U*\^R@B"M\=KN/E6'>82+%'BR^OCXB^)+U'\&((LKP9/J*Y<DV"C]AVF/L0
M?47"AI62PMN&%P4C82DM/^X+LCV 9F[/KO\$'P3T[XMD+HS@;P77+ /A6SSR
MG<"*M&#FOQ0#;YSS2L]U/F)GG9ZY5G I-LV_X!P?L9W8>9YZ)3M+@=0<N3H
M;O00$% #T,?:@*4VV,^X=>;"H&07LLF=ECW5A!DQTI/IOEF1$1P)/('M0+\R
M)A^13MIF-"#C;J*V!TIB-NR ,!Z36NG3? 1&VK.NRY9[$'^>CTB((]#X""5\
M/-#&#*81IR8["'O!E$YB2GM;%SIYX^^*QB=+7I)==9&8UR._D,EQ?O+ 7,U3
MG NM&!&OPOE7CXQD%LEX ^S'5X/R'4?K#D1KXNA=0]#^%%@&,U]<%EL#ZW-S
M811#U8O#B*-%)L1-EU=F$K3GEMVIHA:ZH55/<3.,V2_L.E8AIX8J.A?ZKUZ,
M@QK34P^OG*V+TS-':_PPOXTLFO:E-1([JY6-YGXKA_ 1\_>F3_3^V)^F?(;[
MN.[RIT 1W*7N]<27:M$%L QD @:SL!W< -Z.-$$(#G#+8E&[<37.0/[:,&<'
M88+>R$?TS&28_=L\E(9]@>E%ILQI4,=@"2+>[P)6&MX*93-OF(N>2!KHUH5N
M+EIE8"PK0O,BM#8\J"_R5S>I33N)C?] D95\1+>!%9"'OF,+/%OF:9A>A#"2
M*9-=C1":<V7%IB<BI'V+?A'WR30X<2Y@,.+,IP='F&1_SG;"O\5H,C?W%U(1
MOQL8;*OBT=IXR#%J8)VSP%^TOY>I._3Q>I4A-_U2U-*JIL.O;VS6997G)S=O
MR[<'K7I?5V"'RI8VVK/*9]>:XQ#"@!L1TAU:BQ!9%?A05F."I]3#(D'$GU3
M49OYH+.UZBH?T?0>*]^7I#%BG3?]Y#HXYJ<T:P;]C6S6WO*[UAA>[+/0YB,Z
M/='SSWA*8SP+O!. SB0&9F0GT<71\\T6^P0!<@FGRXC+LI# M2YZ@UHIL*O
M/F8,267<Z[XY-2CKZ=O*OGDWRG!3<"GN5BQ2VHC2$%NU++J'+7^8]VV%CP!L
MJ(*D2^,=#L>JM31,F77D(^7@4V!P-UVU!27KO>)G/AK 1R3U,;*N]]':(VE9
M9MW3V(PK,*H4:EWQ&JU=QUO5A$SKD] 9<%L;Z#]1I_4R 6L_)@B"0GJC<6,I
M1.J>SN^(V+5H#9+6O$76.IGA,DRLFG5!VYI31)55K25XW=,?O!"W>_EMU2FY
M(;9J[7.<5?KO2,9"4L%1(;B.0.<C6M;7(L!(=ABWS (!X\'\3J(L?)F;@IYO
MXB.>1W:CML&!P$:"$349*0E[5^)>GQ_%WV+<LNRCB/,1=_MH)LI^),8;Z[7:
MEM\Q)"G:9,&>,VENFPIC]80F;BEZOI'81ES%W.+<( S093$=Z]ET-8H(;HA]
M<)BP$Q\%*'1%*N+".Y4=LM=JZK"AHN&@Y3SO$8LN';99T03\&]H65ZPT$H-6
M6)JDF'B_V=7%<RU8G?U$6,=;"YSCS^ND*T3PCGK"]MS'L"Y+%SDM*8BD.P1S
M.'CT5UUT[X\E^FX+7=AP%-U(EF/6A6,PLC:7RVQ&-CPH20';2,DMWG'WC8I4
MSO^XK.?>B03LT9#69#<]@8]0( 93=_+ZB;M2NC#97KGU#6!VM\4^BWU@^2+M
MA+W#X=:D&TRT/&[(9Q(.C$,E%4^+XI5=:$=0B0>2CY-UVLVKU6ZC=UCH"Z+K
M@L!7U4@1:B ZV]VK[0X9'0S&,ZAK21Q5O!PD!:ZS1%9'6:C;/'GHUSQVVL6U
M?02V\6>NWY[;#^8U,M%;H4H&/?70S.G)%@F45UO;6,P)[Y/@]HQ \=GF',(0
M;Q3=G+TF*DAU065+P.)#N!4$\V4_$6ZYH'9@;Y/$8"OF;-AZAX78&$\>M@"S
MTU%X*VXAX^QH5QT3*;>\B4QJ5OSU1@KO%%/P>6/2RRV[9OGYK83PN\GTYT ;
M+)W!$_TQ/W1W$KO5W(QCC+O:S^@M R,[T:J_LHX*2II4BV\\#2G/4YF;7E;;
M"C:DP7$UT#L^HH^B-8;7.Y%;'6H\MQ<T+J_PGNIJC_OH[3@;1E@%(^^24:QU
M<5Q&IYH)\"V#N;X=>FTU!ILP2>*X;(?FB1A)*1S1LZD0,][L&VY+38]7M3\W
M5GM5J_G-B]?)WO&%-RZG>TPI)@C!KV%O;A-QOJQX6P9- %"]Z_>(30TTC#1O
MD@K8\Q'39NPFR!Y\,*_5I1??I4!OZDNS4, IS]#4U(&%JI(YO!UH1,TD*.-J
M3DU4#%LHP7;YYS_ 5I',U_ZQYEXE:7LQC<1Y.CK%2V3UB\#"U[A%E'U0PP5
M(BLEVT)NAO>!<@2T2<'+B-R9GCDS!FOY5\W.P:?>9%P8#P(;,@PC3&S;'_B!
M:RQ/GY7S&ON:^\\TG=+Z1!>FSN>1GHNLS@: UMWS;:M#\]1M6KW8+6$D<<+>
MN0-5+-5XSS&*8KAQF]O-E.X(!9J:-JC?5@_I,G[^[3?T&:?;J9R=@C<*,'D0
M[5_A[3,]/2#9'DI_$;GZ^RGAO2A'*92X:^WG^E0I.JD-O2T P@8RD0K>7C8
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M,JFKG>6\7C4T9,1X0V1?^@ ?F<>(A)!$"9,-2S>-LQGKR<Y?1R&Q?OOQ&-\
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M&2*ST-L(LG@#(#O%W(S9(/-U,Q4J80TIV)=\1>["RP!WX..A#&^2RO( ,R*
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MP 6J,N$#'R$A8!"'P(D,C@.$89DDPML8#=*0=V^[8!E=D#O3?37Q%K#8N1D
MZ2QV%1\:DV:0M9CA62ZG'=1V?,G[OGB^>'151>"G3E'JI4*4*F\RL9NBEMU!
M;XI;:P $)7 ;[PCA'5*2C"[!H1A)U#2"ZHIT&$$2&IU__6:7>(1E%W5WC&$>
MIK'(XE/H0(U4_6QW+,Y8@3"(!*PYV+MT)$\,QD,@YRIAG-[JN[':5(K+.,G-
M)<N!?9Y %NDN95<W,V(WSMMI\NH\@$WY:49-+3; BCTUE15TY3$;"NH[1ICA
MH=^>/,_Y5QA<["(!3I@9$R9I582C3^B6IRJ3O9\0.QW@X#_E<1(]7T14XNF%
M'O7PAJV&!4DMV>=.E:+HXR^EZ]8H]50]F+=J2RX9B\6L_G:@W6RMC)5).^"9
MOV' $WLKL  SKA.32&R*[%Q/(!P=QTN D>Q^;B,UF#@EW(V47K48B&:BA$(L
MS"8:S"U!DSY3;[_.$S50"@8*F"?)=Y;[#$7N3?0<J]-GN19K/[IF+BQ AVA(
M".#PQ I!%9X8J1QZW6N"WDV.9[SQFIADR+U7]H B&$@D5-9EL1O0RN3I?%4)
M,,VTT!-$!WF_/*F6^F_;T;#I(MKH.:_I8V8H2&=R=18T835T2=ZF2A%$H$N8
M/?@P[CVJ(%*G..Q7@,@=O?6?;W0VF-NHW1CI3R'TW;!H99C7EV]%99[+Q9J0
M-Y.N[!TJO7PS*??1.'.4E;>@_FY>P);9>=QGU(C(NTC 1W5_]Y_[735@-%L=
MVHX/#"XC]!.G^8CM$18:O%ZZ"D5L#HL7&B5U4@PF#1/R!2VO-$4=E^\*#MYA
M4I'0NM<'+(.8'@!84;)JIT)YZLDCD88C C2KYR-:%%;;!%X2-"8)[6%(-9X1
M5"F Y2;)I$GV-!0M:/LEL2^?Y]L )GVD*6H'79*BB]/J4I-S;;)U7NF]*9D5
M_,'PEOX-#=/<\9<71]^4)7%CN"4"R7<I*MRG?$1$#_<)[,YQP!,P4P^8$CUT
M&C*+].)>)2MH##[1 )]K!(F=D4HXXAF@;K"F='DSY:Z%+%3H!=D_@1*9-G>;
MB5*A@P6+B;!!,.-Z\XB1JMT)XXT^+&0RR8[A/EFG:-!QZ\PAVD$L$P/+QI\5
MZ)!.%X^0[)I?:N>2[M;A5>KP>UISSJI^,Q=E.J@/?J(O&Y#6_OD6L5:1^2IQ
MEQ#<Y\/[1 0\S"(A+=?L) :WT4)OCC ECP0\AM($N/!K*--JXF\C7V]+P&;U
MP5/X= ;C/';U/@)8H]];BWS:>ONTIO<,'V$2/<-\STNQ%9@QA%N)#A,43ITA
M6$;+#9( FV@$.6X6/HCT@MJ-RN0C),T-]&H)\E :6,;*[D J\X8I)L._)L(]
MM3C!=V"SV/DZ&:=&^U2U$?M"HPL)N&_DH1D524@]I<L,F6I,.<%')'6SJGH:
M8#E4KP"&LB$;>O><@J\^1@6:8<!HR0;*[IS[HNX=K:U21I^4GPV21^U @Z0=
M*PL"X(!5?G/,"/UI''1#]U!ZL<5!#IKWZ<_-HZL.1ZX:(G=J%&M-PE'S1E!L
M)6PXKK9C=)4B"Y"2YUO:1B)K.\86<1Z#3I?%%45&T8! U6D%IGL/=AMOG+J%
M8H2C.D&)@M*JR6TB&//>;Y)HJJ%/;L7W481&(W_R$:H"!FF3&MC2UM):2!-F
MK&?^S-ZYHG#$NS=697VG0\VYTENG3Z+==;_/\$1].2:P X2:QTS',_F(/J38
MP#PVD]H:MY8%]K.+0<R=2)1AG:4+@+P+6]9XXLP8J,38C%F1\^,QMK\*)9,)
M$L!"8UU]_K.YZ:D5+UY915_<7ZWV^[BV3[:D:_]W&V)QF_=(Y=Z%;QQY0X[-
MTI:BKZCM"8.?'*)TNB.E"ABL3%OSP?N6:FLC[U:4MU]'],?&1@1&G/BR1I//
MRWO^-BHV-M;P.GMB BC)\5PL=CM;DJSA=D/S?JZ4;--A1 $LB,2$1KP#]R$L
M5 %+C/!.0,$,$@V53CA&@0H9D5,KG0+2:R^?R#D>>G.AAE&DW]=+5R 8"[C$
M(_*AXCU0 (-3&% 9)AWJ-93]F0QJ\.0A_\JL^)[\N%:_0+!Z8WXQA7@9_3&<
M<: !++3B/K'8#DL+<'<U+IKC"HWP?O"DL9*X2O8M,B"2'=.P!7\.JKG\8$7^
M![Q?T,60=D+[O<>NXD]%54,1,5D'F$1INN^2\M6J^)/(MFO+!9>E/(:,R_QW
M*C]F3TQ?&9GS[I,OB<8EV]O'*ZF=S(^>M:YE#WL_TBB2;;;KD'&^1:%A)0[-
M31-#5:RIRG'3_IRH1L^\V0:K"CZB6<7J9>"=^C.$LX_RU#G_NL"Y86R26 1>
MBU5%,0D)(D[E^_UY_+QM^W.!O4(_AJL)V&!,*MZ[EC=JL>\-Y!((H!QR.M=_
M8M,*)A,QM_7YB*"6X2>-8"@4MW,_H\GJB?=LGT([_GC3N#H$ GR$'90?<(@.
M.+=PJ021\,V)*OU'\2A:*S?GB:#'%0X&MVQ.8M,_4F&#?P$\P6S8Z)]]%(OM
M2/FGY.;7=_"W3CS?BQP-E+,\7^B<K!%QM'>"%[!74G6<L_3U_II&^[L\DR\S
M?R%LOFCO?4 .$-F_-G>(CRB)L^$CN@H$+>6C=XBE9_7!_YNC%K/,H4V%&")\
ML![]^_&3707I"X3_ZE#9?PKZ3T'_#PI:# 19W<P:])9^ 2N_0C <,]05M'2>
M. ?R7XDT$PN5D?5FKH'39.D(\3EA.B;CA(WKZ!6ML9WJ4Y&HBVW22C[/7KH4
MV6@ZRA1F:CK;25V+NJO^Y?A;*[/34H[.#T:..+3FJ,?N<[ :>[RW_-AHQN.'
M%RJ-RW98K_E%/W#*='L1H5%X0CW]-ZF/WF+214TJUL@0M*Q2<!S0U^FG]2BF
M,L,*E+Q7?PBE&MO_],4P2.U:V!UK]G9_2Y.+=N@WC7L:VV8O?/,D?"!L'2-C
MF/1M2[RCD/L-)EWHX[(I*1,VBP"/#OIZ=WL1,AM;6^*JIP^D7FY+L?Q1XOO7
M[3ZKO'A<K%5S 2Z ,+1:.SIE*<4M_"=>[&'1S5A>91K;2/N@2T:=8V73YR)-
MG;%+R]:.8JZA/>]^I.-)TX^"6XHDU_:(M%6ZGJ^R6?F'&.'X.O/SLT%2\V*6
MNW*L1M4[G:N&RT8JIZ]OO-/MHBC".""_MU#5WAG"-. DF=M)90/AD55S4&1O
MG$GK1#3VY*1QZ*'*;JGZJQ'#%7=+8G&]\Q_W6Y#8Z_+$#Z_+^ B&0Q0?\?Y+
M]*7#'S,U0QE@C*Y_E&R!J_:E@Q=*O H?7BBM=JY1'$N,>GCY86EAAD/(\+"E
M5$J/4_)^<;][!Y+.S)I"-Y_769<Z]+QTK3QXVM;V&,73S-;PEX.JD=Q[[NL>
MTD_]KP*^X^)#_''<9H;LR4><_I8M8"E&?7R$06Y:XZB3S] ,V?M_/GSB/PY_
M\&Y>WXJ)EOW+Y^C! L4*$ZF>?<BC&@O:.ZLK;R\H]N^ZCK)#%/Q';=7]G0M2
M,\GNC'5QP@>B/#$(/1W,RD\C[,39=W0S4'W8:9<^M))1MA0R$RMK'L4YC]\+
M]/UYK+2%O#^NR@<7QZ"F$ .'DA[ V&%]RB&\$2!H1+>T3;?DI3!V&-5@DD=6
M-B^*_!RW(AYO]6JIVUB+('+V+)/V4+2G>#1E;!\Q+2J$<C";G0ZE!=9\PHV>
MX?Y-D(2=LN<382)&N0=46SP)$-/-L:RA#'D"\A7X\_NIZB71IW,M@XF,\N$(
MJB=ZGH3<C8\#3=CJW,<6^_ VXT88.5P_#2W>7,,1A.NR[HX)?'!PI.874@KL
MB>=$Z'TS0BGBKD_:@A(]"S.XR/I8&_)O:?QMR29! O*D5>B;LF2'WS@B'Y'_
MD]AE&2^P;'X:54_XS[[0'VO#&B;4GP=QA=\_H'\3;?ZKO9-_G"9(WO_ZJO^4
M\I]2_M\@Q;T;W99-R\[&[K10P473T%LGO5X\QTH_)4K!#O."7A<B,E'WR$<8
MDVE[1U%X]#Q6VN]4<+VG;WB^<1YA;TX?9K*E7U?I$N_M<$4!XULMKX./N)N\
MP4M"R1"\1/@(U$HGQ0*6![+7I!C<_39@7 I!ZZMR9?*O_=60=Z_?=E"SX2Z,
M9?079A]0=3MAXCY"Q@B?R&NII,5P73#4>]^[F&CUE=7^9QZA&]<ID[LN 8I[
MUO5[@AZ&NO=_G5SH<:Y+3+9X6/7N,6.=H7.A7*SZZ,/+KV;/=O9<R%.1?P*T
MD*_N[6*!KXS]D_MUQDJR:TY_#&N.BNX8RSH[*+,1=6%IK$@_I-<)G_ZXXNE2
MK;7<T(HAV1&;350VVD&]A)*"7'JP8G@7@,H2R3(DB<#GP?*4%+QG&:ZP9[IG
M,H&P?QD5R(C<MO*5"C34ZL5&BG1',[5_<;@VM(+KE:J32:/G1@?JQE>+;P L
M=B74%P>N=U&V@(Z-\N4-L VXL;9M/L)FOIR/Z([P[O**[/P,A9=#?322N)$'
M3XL8/,C3R.@K5@&RRMDUSS#Z;P)J.YEW:G&._?9- '<\:?UC*UJ4H!9*4(%<
M&*JZC/STYG5)6![4)&7@A?PCJSR/C[9P]+1HID>7E9.^#*5?1;7T9]1$RH6W
M*3_<?#/PI;?\&=V^"NMP8LE@SY 8+ W=$K@[-0XI8SBT#>_P>K)G,GV]65<B
MOC??;R_0EM" OW&S/?\>RER<$1'0FU^@E:2/]\17W/+RU1F4OU#PK1_#V544
M?R,4/=QGQG"U/%Q^J.3MT+9'YSO&<'MVZKYKN>(88=Y>H?/4I\PNIBRSPY6&
M$=YI9/5KA__S\:IYAKD^:K'8GO:M=7OUP,,+48\BKER1-U'5.5)N+_EP]/U!
M1JCMP0M)MA?!GP#0.R3CB$&:6Q_(/>?#2NL:YN90]L'>4!(#DRX!5K,Z1R%Z
M)U&5L!_:<I8L'/S,"^?6;0NLMKN$WKSZ2+_>NJY:+]-D(-*XJ:HO(JYZ,,=/
M1=7BH'ICVV8U.;O33VV8@!0DC:!R[ABZ WN'\A&B;5DMZZD6>W]\:XZG-D,D
M6L78\N1?OWGJQ*931YH2^YM3KNQ>B]13B!HJ^1C69M+T3^"'EB*CTP;<4CB4
M<&KOG2_9C6'Y.>M7/@?M_4=$?Y?0;_,9F:2>A6.UCN*2._65FUFFN)LQ9=9%
MNJ,)C_?923_TW^;DT*N#F0UMBR>YYOJ#'N>HXLF][L5:,M:[Y,+'JG1&:T+[
M<Z)KCO6Z%"9F&SYV_5R<9QQ2FOXC^^3_^H5[W5V3W:82^:FQV?)>2]>?0P]H
MRE?3RE9,WY683"?G,E[%9F2).Q8'!:$#1KZ9GZK[Y.7]Y&P9R95:&)JWX![Q
M3AM1FO[?.A;-?9E\A!@DTNTUF4F.9.JI=!%D@+7,Z>+73-3N,.-VM^RG'T\*
MY2QO\KZ?K9O/E'[V^I-A3KN5X@U?J?JBX^-58A=*3'/#' V71BL53'.U!$ST
M#TU]_'0L0+'B\[2M\=O'##N9*N>H2L?'@8)YS1VG=SNZ//YRH$RQ]^ [YP=V
M!XVGSW[]VF#T@8>"CX&271$&K&(2LW KY%*#4Z<S3U1F-M V@PK,Y:*?ZK^1
MIUYK V9F/:=5-9-6RL>D?&R4IH%:DN8U"V5N.4$2*NR<.P%.XU*< 'H*1>&C
M<0-KR3R>@97#6XR1CY0:I^-M@NO#3%&9/R-DW'R1%SY$52^99KI=FUXVYK!:
M[W\K*9[3__?+C<>Y<7NH*IK)-!O1U*AN-T*WG&ECR1XC;\N-V-G0TSGENICI
M0=G?-RIEH2^/OC3&7&B$CI$=59D _+% =\8_P&$"E^Y>L%A:9>WJZS&G-BA#
M,CFD,4EV[T<W1_:LIY/$?JW?:9T3!2*3?F%%H!\L5/<0 F\)QJ6V<#+BUR5#
M_8Z UD5/+ 7 M=-CVKQ]\-6SPK=!IL4E5:&;;FFAP899$36^GSHCMUH8<5_P
MQ"')KCD9<*(%2>NG;H$FNRPDP-9$%G87O!?*96+%[$MQ/&\/\P/Y!=_2&(6S
M:(?Q7Z$-/Z'2#PT5B1ZVL2H[/K^P1>E-8(*A1(#>395=-=\?P12-#<>9:[+6
MM^(=1JR+S(U=*-3YB$L21*NV,?GEP:^4(LW/V@6YI9IOWC]?3]>M"47C3NR4
ME[[A:""<,72TFC[5LGSIV8Q""NUTD:=31=4DVZ?IR;)[Y^ ;L9R*!9;8O9P&
MNYC/2T.)2AG)H7=[_8_ZC&2SDY1Q7I-=DR4Z#TO<*IO+UFZ4^)Y.UI<-=W$Y
M[_Q8#AO@+)-M;I[/;@+;:.ADK%@L-G5."*2FD ^:))5$Z6?5PB;M4,8SW 9V
M\FHS5Z2#LA/X\J;MGKFL85TPS>+0F"%7;(1YPTA1\^5XW73(FG]KGCN(E>*-
M(A7(DDSB5"%#K:8"VM^#E#*B*^&- >J:#;-.686#%(&0Y\&-9+)]52A% 8C(
M6#;)-X!('M1AK;&Z?=0Q+67WQ)_0KRS'C^BTG[*13UM("76L-$\+=5R;[V3S
M@ *K(<7" %(YUY*/:4ZQQ(A,A8S@(KN\'B;:2M2$&/L=;*2 'DD39M"Z?FU$
M<HWAS6O]%@HTZI0D&P<UL%#B@JB([%K?/L!J$,=QNK%2 6!L6Q+^D+E-?3A!
MINEEXW M;%\[%Y+??J^AS'+GQ.K$49\>K4<5H4&Z_[B],VQPU^T#%I 2R9T+
M8_LRV5'OE_OEDOJ_OHNJ$X!RY>TRMYIB886TRKLU[JI>5RO48UCI'FH>KEV,
M2D=J_J.+N!2I5%K T?;1KGC;P+$\%9GL.L5W]Y!RSA6F=3IAQSX=4*XX4'1(
M5?':^<POR;BY4&<:,\ Y98#:Q$>LW0(EF2EKHEK=;P@SW?N[VF$^0FW?R%HM
M>3\S:SN]FS6_D7W%_""##>3W1& ]7@.1?;U@<D9T7#VN%"6TU'H4)_;]P]2R
MO9C-(=3*9GZ7K]DI;BNL!Q:>A/"M?,0,J6FQ5T*%B:2IFIS]H1_K&X12P(M'
M;O^J/%@OC#G1,1PC$06?>)K_W5E7U=G;PVF:02^'XCD'\!90%,M!I*?=/<UB
MW_)T7,(!L*6O&X6 4FC*L>MW"(H8<-=">+:\/4-<UT$<,UEA4A5]P_\BY1 H
MF<8">+GQ<16X&X8UQ^=D?HGKM+\PK2D[Z.8FE)N;K.3I>,I9=.ON4R(BZ8]G
M3-]]#3*HZWZHF=)YZ=H5-\_,LM /6:X9Q4<+V'^GJ%?I*-K](S_&,OKU'G7"
M[N/F\[R #'*#UON5P.$RFEPN/@AITK7@83=XOD''N<M&Q.F[(_[;XW#F$NO&
M#<WMS_\I]HKYRW#A!8SJ5=,R(35C:=E3-]<=AO&GT!WV1,EP8K/UJQO5(1LW
MKY)JH7YK[$X/6 EH2*W[EG.P;MWP];K,"FEW<E+<C[YZ',J27+S=-(SU@V,'
MJ8!NG)YBK=$64@I2M24M*66M,Y(U).RY5*P(]'5C=^#B6$F#+;<J9@GOL;M_
M_;NV&CND!I][''+7BHG<C6MS&"5Y@^<V%TCS"@G3;_F(Z$OIVNKW=NR_I^AO
ME:Y]R>J>=IF5V/T^941JZA.=TMO53Q (.4WSMLQ&)8>#_H#''M-NZR0[19Q;
ME;/KP1_C[[_H_-(993OBTH8'=)RJ_'*Z)Q[^]?*8]=/#8\N,FD'_+ED#NT;:
M);"%UV3Z<X6I95UTK*NT$G/(+LDT]E9ULIK1B_;8JN%:4/82>.R5W6-0[N"E
M$-B,L^\C;KK/#RI1;6GKTS.;/^.%[2Y$)]^T69.>'H(/Z:(5IY:\:%CI[=DB
MZ<48>0](ZJ* )YO..#2/*\7X,\TB9=[.?[P$S'@]BL=,#3'C>M%[H!_L'*"M
M5Q75,:TZV8U)Y2D-X_>70LH;%R;T?M+%<"F,MB1S;."N5TQ5MR&[?!]PYX/P
MZ*$JG^F0S:"BL._U18$2-#?2U?;-=C+&&SH2@NF1<.]4TYPD2PDJ<H:%%J"5
M1K9EQHOW%N/T\3(1# >YO2-KEV?DZEHK&9'B5J5A\C,%NN5OR#D^:;/A]RHB
M$M^#2F3PI8^Q<D5@4O]?T#F72F<RX/K\G]K6HBN^7O?#7*K2.S[TC+\_(M4]
M2-&2,5EE.1I56_L^_$X.\K;429:42Z6-]H/'L_!N2A<J3RN^\Z@U]G>^)__X
MP&-_>XG,NN3R.]W]4F**>'.%YEQ;ITK-[Y5I^#B.PU>L&D$+BN\D2D40#D+N
M#&SGNA+>&<3>GH?LGWHNE]$HVJ/D4P*2H<M )<<.Z'H^<!G'6SWS"2G(:ZGW
M^>3U2,6FZ8/> #D:*M<_])N4@E5$A[RQZ5(S -IHV'138A<]G;)[E+<']X/I
MU@@6,B(3\%H5L F$;EBRT"5Y@&T)3X"4;+(#(U)>PI[FITP&QL29ZU*A+W!V
M$0;N^;ZCWPXD]$I@OJ$A9X+0?8J!T?B]DAM\A/BWD,O0O<#QAOD\GJ*Y1!EL
MGC!D1WY>,,A'6+:V 7,987E]Y]H3%B;/%ZP[M[Q*_C;_+T6(*?G1@(%,-T='
MEX47'X'&JY;C>-H"1[6@E)>Q,D:J[KTW2^'##DX4)"[ >=PHWHQC1M\..?,1
MGM3)6O/C%@43[GX'"GG2ONX<2Y\!3OQ+GXWDY>%[2*6[7?Y?Q(Z?.,8Z^->"
MM[OTBO^$<JMIBY6"O81S?EO5HU%VY,YJYI*E;K)^A7J6N8-!=\_EQU9V-0V)
M/9<:Q6*;;N9TCC-W]N8I.=6OC'0Z)^;4I"9A C#Z)%.:J8=7SOO%I"2Q\<._
MD'6\]VJFX"*M(:%8&B31O(\] ;<W1#&QC<M2(284634=(#<[/;8(W3%W_$'7
MS:R!+QM)"^!08ET,6M[^B:^O@_X_FYUMW)'J3@6J^[YYS(ZV.V0#?T8%B,F
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M*/I+5=CC<%>L@_)WV^:UDSW(Z;6*CR\W==(1H!(Q*'**0DR>H&ZOX)((.P:
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M'JX/6>R]6#=2EZ#>':B^NZLGG?_"=_-VFHV56_%]]"KD8+?XV;"A00\(*]:
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MI^G5E3?'W?NI>,8^Z,Z&'=A!LFR&E["#K%"<,AOV9)_ ALFAB_Y/./\_#&=
M1YUTBB&. EQ)B",X'<JWM+(RG^ ?1>BW^@\+VXK16@-CC>\KBX($"I-..LW.
M?3,YUZA^,BKY6IO176OS4O]-W.IJ?C9/FY1AK/3M.&.E8']POD%Z@E+P8B2L
M_\5?[O$=(MTG)47X.<W]]MRI/2RN5/IAUB!12">48ML3O-PEFB2"4Z-R3T:T
M6$+^<KDC]+K-\.9.WZ&D39I-1MR</;-JRGAI.BCO\5^C7:>?&N1Q20:9,?ZV
MAXPXI S?$+H'&:J3>$838=@;ZTP.TTT0"SW.1<ZR%O/0TG@O7+S8]"F.U[1.
MTB+RK)J88T:VUO,LJ9"F7M4-'#?F9(O&Q_&R)Q5=7]4CRYZ5V'+9'J."#O<B
M#"W]UV_YCR5'G2,O:)Q'=\VYTRKFJ<;I%UT,"L!K1LUVR['3JS\"A-XUQBY_
M4E=NTT9YVKDW7;R^G'^W3"E%Z)5HG['=2>R@SC3H+DX%2I?AH )A$#/%P>(<
MIL-9,W-\.SS/X <#\'!$HKR.3#'8_P5+_#@Y*UK?//0K;E/%;"R_EH@NZ_-Z
M5X>WK?)J>/TF,-:-LI?C] 0PEOO^L"5*F]2/H7D":>XU\3COT?*JH C.5SYK
M$?=0EL4EXP9TK023;H,'[V0"C/>S,K5[P7 .9MZ+)3OYR0.RM04[+=S!V%C%
M^O,"%IG9ER?KGMY?BMM-]AL9@'_?I$H%3'9BHFW57[UKQO>X7,Q8(KMYI:&^
M4P7S1_K.C7K:.W^M54U.D4QYQW)#QVV?9L-RE(&Y.C:,<S/L+-![C;K+3))0
M8L/&HBPJ=8E369(-?%R^0N,K]@JI)>V]P?:.P_ %UN6'^TM*<^GT 0#ZX?(&
M8W#M(8O[:8I#$D3*#0JM\>]#KD/=@-"&6FH@OFMI;#R9C20;HW7,'68&18W_
M*=2\XZ__Y86TYZUKK#U(2%CCNZ181P?IKG$S $\!@2&#X-L;0 <5]VH83W_O
M3/[2):H!]]>)S9\_R:$&:D)"Y1T;]@\;1O< ON!_;ZUNAN1#[__YGRVS8,.T
M=1S9L)?I>6R8!P]$)HD<49D,LU^B[9%SP].!OO7/_6J: X$M^YGU-2 C@=\<
MN3+%"H3/VC)$/\^>A5-,G8^@[GO7. +MW\':G\AOR.NZ;-BFB?9]&8R73LA5
M>K[NS>Z_- 7H9;=GSZB\*+WZML=WL4&D?6T?Q?B:\*:@*XMW#_OMW;/,)]W\
M\9-DJ?_>.:U__; <4Q-'W*QN&5=S7+^B8CRZ6=A"' O@>B5??M=78;@@9VW[
MQR*YL:'AJ1KJ0@[JI/2P_;?4JVJ")>4H+8G7017K#H79>2O3 77I[R,)I4A'
MU+Y'0I91JV-S'_V=:UU]0X)ND%2.58S0DM>!C.+V!XN+SPH&%6\^Z&I%K?[0
MZYM-_P /<*;WF9@KWD]25UV0N/GS\[91F@A]NWG7_4??[".7]4D][V&G7RZ*
ME*Q9L;CNBR"^8P34"[FY1:(:.TQD2D5=J'X]H4%PFQ3\OIKL8"0IJ_\@74_H
MD;6M_%_*9@O(PS/8C-$V6UT%R@ QGK Q<ZN:\G*?EBH40Y _<=.%-GDU>3/
M*.X&KZ'#DJCMLR/YYRD)"8(2S0\-(SQ7Z:;^)0--(?S9]_SSL/3STN_3&VM-
M-!U6HER>WKI7?ZXT1%=O[=HH;:!4)Y&U6^_GDTW8%/%1K]6Y_GL?+"0?0Q4D
M4'A(/S(I1*M)ACH5Z-%O8YT&T_TJ4"*8*)RX:JL -3W:?U-KU$1=!8SJU)4<
MRZ=D/9ZY6NBP\O[1:[G96302??F];WO8V)QXBPE=%Z<=WCU["D26X@Q?U+-A
M/*L9S5<KO/</AY/$A6RHQQ/>NH IG5J1>?YJ1Q<:6)/QJ Q$U*\*I-4XH?TC
M]8M=P40!>@4X&29DS] ?;^7SF73X, MI/\XP*7N<<4WD]#37LXE[&PPI\A:G
M8@IV]%)]??ESL"%DU._P:AI:VHW3/>V:!D&4(4E%=O-$('AU3S'TJ=8?,L"B
M[G3;]X=K24S9+\XH7:X1'*80F]GNX+&8W]_0Z)!UV<%8)( Y]\J8VD<K/+N,
M0__2$'G-TT":_E*N>XI$J2TP0N1J+LEB_['J]U.TB[,H+5S6_T/6::C-JJ-]
M;*5GRJI,]@> B"_*"9%GI8GRQM# 5]9E+VSC+^T>$UM=!#W$$%LH#6F;'KV*
M@O@BE\ 2&Y<)_KP;USM;S.E.Z'WUS2NAE#LS(%>'Q($AG#YEN=TA/:[%UY7J
M(%<1TIFC.21)5?$.$Z=>B)HOVXJ8=BF_J^3_3;MC/S"NQ2/?!8QRSO#5;9^U
MMY!>_ 9R02ZFCYP4VPJWQ_9\E(!3TB-TM1E*5/5N^%.'Q"1R'!/CE-*>(S"!
MD_,(R ?9,)/F(?^^*RJ=#I%1"TE<V)R!.FVFF6FD=H*M7HY-TPBI=2Q$*1I9
MF_B!*M>-1U&ENC$"+CAX,Q7_N/7T&O'P/7\XC]-4+]DL2BA8ET#:1-RDIES+
M6$J8;R:>! .O4?6()$+MG-.:5E?VR#0ZP^5U*1(ULHSC9Z:> :^2"3SK@0#O
MSI:8-YX;QTU@*(,RI&S;&\-U_[#$L3R=TS_B*M;>^_XH*U*:9KB6'VE1)H7^
MV>'<FF0:@N19N>5HX/&PV,7'H6"NPJ;Q<)]4'<H\T;NF14%=!)BV%NWJ^"/Z
MV=IPF?SED_'*]0^](@B)!=%V60+RA[2J/KJO6Y7M> ?YE_CA'CY:M"C?[GGM
MYG7*C'XYP\Y^H6H[06LL34K( :ME[] YW&:=*W_Y4J%6@>;"?557LYG!==$X
MK.+F<OW[2.TX]"N/QJ:G=^S/YAQ]D9=VROR);>+-J1?#3VQL3C_E%J31:&D4
MA^DV[OJ*.F7'&4?'SN<S,S/M<6(7KQ[SJ>XZ9E[:PV]>FN]=&IW[UX&?<2Q.
M<S;LD"BEA\&71%KN&!3'AI,B/U M@.A9Y0^4M-=O5W+.C+9<3),R'2Z<P*AQ
M?3.%N&/\P5L-\M/9"=&C(JCSCX+>V!&#P&4VC%</Y&#%SW4302P#P8;UGP^\
M/_=,5Y(:9JZO19H5K7CMH1%;OSK<I:_\Z>)0B2V/^1"A3U_TE>MZ2*JD[+U[
MR7%^N!K493^J4.RL!*40;2M%/GZV8W&J@M/*Q[K#[,#KR2P9MS,B8XYESSY.
M%J#:S3-BBZ=--,\-KK7&LJST&>+B%*J=*AM6/9DH^>2FB@X@K'-%/N:$YHN%
MF!:>DY_6,E]+HMR.?Y1Y\<=71#&1 TP;[0X[26F,5P45%<IU;$G?^#K3;':O
M*0=@4)6HANGL.O6S4LEG=&Y].VLL&6BF[.A>,X^7BVO17# ]&'FX2/!.P*78
MH)?5)SY^PO8W"Y8-<HE<(O!3A/MM)8M$?F5:!VF^8\[>LW<<)2%/:" 2%A.B
MN+RL:E&+U%R=.RB2'^BEIQ%E;HY9;W)2U\HL, _;PJ?VS"TN);!AD4F@)IQE
MP4TBTB\3(]FP_0R<.>&C")/U/YWD^C731MA3RSK*AMWY 1E; Z^]=PMP1K8$
MQ.O5/Z2@$X6A$%T>'(%8_=GOO8II?G-<Q)US=81?TX2?YW_O,@=\NH9P@^2!
MQE;$W'ZR@^V^K^TV9H3.,ISE9\-J'A%9Y52.'<2P.LO ] )4Z Z<^5<^\"J*
MP6_),ENGC4+Q%(#K;%B95&< M3XT!>I2T.]2]IEUOY=EA&E!5KJ7*H[S1<XP
M(/M]KI$;^!(.Q37^2)@E1R;LR8!QK)[7C:RB240N ;R<PC(;).LS,P:3$#M>
M#!'"6MG_WE*6_]*D3B:DE1: 3UJ#S'1\+'Y?J<-Z>8[R4(KQ:JL=0=?"' '6
M2L!>E_!_Y2KD\@4NED4IDG;?CTBO MX*;^WIW82,,Q?DI$>JEBG+)D#3W(_&
M;=6U?Y^9(?QZH$VPWL,O/PMT*?N)&-.G"4!I/,>$=,ZD+@S*8@DE&Y"&4QZF
M,[*)'^%T=0TH?$_L$A$R3__J@A4V3*/E(%3J;@R4CRSDGEO2+W4H/\IVP/[/
M=B"'GX5>7YG[LLXRW:)!OJ0V%8125F;9GOHS-524+@[T?F-] F@/B'] =_;!
M6A"'<+NLOX,&F;&U<.;?Y<#!^VP8(ZG&C"ZZ2-S/_)L-LRCXOV="1I2N_H)_
M2B-V=3!C_NT3C/\]QUFCZ',9:.QRQ'(C[VN2 6_A8^-3N2IZPBW7K/65TZU/
M'G)[QWE_>^5 \MK!H%FC8Q?XE6<?1K0_[]%H?QY\ DW)HSEB.%'(1J].X!AH
MZ5@'1I2"M%%R06L]E<L(*825A)+67I(_J8.N\!%$B.O(E9J48Q]V.7B^+C^?
M%($[2LY^U',C8_HF@]N/Q(8==T(Y1.9J8[!EI*?3K Y(UPO&P#MYXA(XVN>F
M51;2JMU#E3I-PC GP/9UO4G5F+MGJ+LQYU_LS)U<O7X+3[=9UQ>B!3LS^P5I
MZ8]J5I6Y55D),?-:PG=[N!^79-D\[0+*1HIL*JUE'Z;*;]??55UC.MB-NZ2/
M5_.G:OG[*7=,=#[42DZ4>(::(.S1X(ER;A>%XWUU"E_.BM*#K(J,U")NZE4:
MZ45>4&VM%1/-LUP7#OZ<OT8J<$D]?L/T9*=-JJ$JXMZQ:KD>/@.17NE'L9?6
M)&XD85X-YVIG7=B9M3K1G/Y(_5@K\2SKRCJQ=C"&B![@(G6G+P!'L.B%I=<+
M2D_"+E)W.P?%<==KA^N!2)'#3T(+UEH%P:L4Q[_' K2-Z%N".+>ZR!"SD]B0
MJ_68XUUOP [;21SR<F[)6HXXA;F[7H"K]$W1*>-ZZ2:E8YB#?IJH_L6M"L,E
MZU_$:5E@\S(UF$J((FQ>H.Q(;<A9YW%B2UQ+2%0[A]2P3-G/@JB8 >]KPF'&
MM<*4>PVB0CNO/I>?MU%#6<?E7K/RX]<\6WTBJ3'/M&XYTBZ&?/'+*PLV3 4!
MRNPR\J_3( M1^Q1\PH85J2"/3G[#4RRW]FY&;4)0X'6("HTE4\]6/L+.<CCQ
M^W.2&?U"#9QI[<JS'1)/_%Y)3J)+JR0Q[=QX9MDP4!T:[V>*?\^-X2">'$LA
MC0-!:@Q1H*T)N?V"6Y\U,$,.9.7CCY?1>PD_MU:A\25E EVM"0'F:C^*N?[+
M%1J8KF:LGCWB8@2B=PZR/R^5X, 7*B2=F3<#9!?6JT!HV)[GZIFCZ6")T.@2
M-VS:9\/T*?@?KY!T#LBR%9*!;'!NMQ_)?#8)V:5:1.D@J#;(TH>LG1RK\_?G
M:?:#P4SDD!!#((IE3J3? :9XJ?JLZ<F?]/\ME[@?WM&SST-",/+JS>@GJ(VL
M_&7]?UOLGH!?#OK_:K'[_^MA2^[9[ ,JO1&B#+^0MSX.0C&ZTFL21T%^A->,
M(S$F># <AZ+@H3Q1JNKCY)8H4ATD3TDP2U?2YT_IG<RYHP:E7QUG4 ]!@*RJ
MI?[L1L+BY-#]B6M@G'(0SL_HJ));J5Y^B5Z^(S9>%SX7($<JL2@R<1,/'I>R
M-S#/LU"5(?M9YD96S%,%L4T K'J[0\<JM+9(UJ]$]H&!*U4XKNU:XMD"PQ2:
M1'NJAH5?0.EH:O KG"J:[,T:_>YU:KE2>WZ9@]K&2#C%D3MH#H8_11QHVR4L
MNR"$<<:C")(W-J?# AIZTV9=6OJ;O6_!N.N4"\T+1- %X!Y\)D7%L?@F6T^O
MC("9MRBT7-+YH5])QU:)Q_SM=/A(Q3B5D#+P++W-H;+Y<D'Y(+"O3A<?H-#@
M<0@1?^"QPV(AD<(Y0]KZF&TZLG"=JK ;IZ/@2T7;U%-GP(DKZM;-Q#&R23 $
MEC9S/&I(X:D9Y]>118'HXO43^N5K@35?0Z8&#YA)?72KKNEW.>-:3$<^/$B*
M*EY=$L8UO-_OF2@D&1;@]"_;.U@IO+;H()>VJZ)&"[1F)<RZAP:H34YB#W:B
ML!F?\,3X)<(AVS^0RF^84>.WBRSXI1\LJ>8Y[ 4X@#Z6J3XI99RZT"@^]"=H
MF\=P8";K7O9V*(H*  1G42Y_4LVB&2JD@0L+G<?VT^-4!PY8L#[^]+_RYY(0
M];K#G''Z(Q&)/'3)%X/2ZQY!S&RUQ>S\%ZZLB>G6UP2L8[LNOZ #/F8>]*(B
M:(%@!;6H+1B(K/\0M@:$+W<W]BJ6*$9X%<PVQM4-J-M3OF?\J'ZS*KC?^D8>
MIXS=%7'G.:O)6BTU7YW&V>YJE=O85*\%-DPT! 8_;1-N>5=7'?):?M/S'=>R
M@2_Z_.+7-(K*J]SDM:6;XRY!1MB@1X".@%A-@D- 68=TO_*[Q.-R)U>[U:K7
MY0M<CAIFW[@:(M]J$>$@JR9XH4!D\/6M[_CZ5W=N==OTEUF4&$883QX([Z,^
M2#ME];+DML>K\3P9-:U[]6L+>:=&RK^I1Q79)"\&[)% ;BJ1--<#G H;A(O<
MIO"T93LZ,+/4\!#2"+ 4L ?:&H(+MCJV!-9L=\,N4J8H.B.,2V,XV?T9D%/!
M<[ +?[(NZ=B-PZ\#RM$92^'E/EH!%3F)#>^C1L.DQUN%&7\QR^MX_AR@;--)
M+HTD( [!Q9)EF(!Q(90MLE!TBQ%5:4$BA>1\5HGS]T<:%D"=\T$DICII-W(C
M;\2?* %^JQ^0ZIA^=M%'XMA0W3.1QCBU3,S$>[D56;^-,G,KK]12Q7B5@&>$
MI_U^PL%KE6BQFI.=GISU.C9"RIV6D8ZGK$IT%'A\7:RJ>:UD21=_Z'+K'HX0
M:9TXE5E>9B:#+=7H)_*X)-5^*GCU60-WH,"2.Z:/\C/-57JT2,P$XZZG)FUH
M74(N*^&W75IF"&QUZ\I3>!A\ *V(BGS",*K$(KI$O,);-"4RR0ANG\#@R^\*
M*TNH/&W[>F_\F1;M=DIW"]Z/*FW)YV=,>!>></IT\F_/8XC!<)9(.BV'#<M+
M9KY!4'[A#-BPI8S6Y7;"G\HLF3MVC)]<G78Z.3D<ETM>MES!'<(Y&Z84A+<M
MB'MH86-YX\7\GC]-*%#T-FA(L06)_#J8/H;RYZI3EY5.=WN.*T\YJ:@A>>)S
M(R,TS(1BVV5-U:3'7Q861&1]33$<B:W_,;F?:XY<#&'#N(WH9L!P;]@0' S6
M/<>&_31!SA(9)W[VN*B!D"@^. W"R4"TA (5GL P4JRG>IGB.W7E)P)X3J#3
M+SOH=V&$5]\[?YBM*#4+ !ZE:876?\BN?M>4NM 0*1U^]\8!)#_C0+_.1=)7
M]1-D;!)'YDBGYQ=<T=K8I7W0\'F.%%="EUYC74DTX92>W"%I0\&X#S?K-C*"
ML.X+A<YD%R#FG_LMB(1/I:2:TKV\3C?E.F7594[A+ D1JY<RPP7G98Q.G9*Y
M//YFU#:Y<=F,(0YIT7-"-(B.:GK(<\RK!82%LT1(_6L=8-U4^OU1 (^D+N)^
MN!&R^P;@$GJ*#?L^]!U!$X=:8&U!&+C / =\W_!"TOY(!M8(QZ[[L6$2/]FP
MR5/ K\.$'4^0"RI<?7Z0F8R/PN]'KPJP+-7AU"T$TR^=#?O+APVSP3PF;E\/
M.P;QN P8Q(85)[Y IC&5$=\=/R)IXIV(_:27\"(F+QLVAYUAM3U ,J\D(6+F
M_JL6;T7I,/'[Q'TI9DH3G'D>_Q3; VD'?<@5;81 PW0$A<< ;:K$Q3/P:H"9
M%=B^Q310D&->+F/T O,9R.WG25^(K,_:)$A\I*6R,JT9F;]:V;#DQ@C$1C8!
MDO<Z5YEFOR EDFP90]P(A;3"+1GXTIG_J8O[GSSJI[%AG$"O0@>2=KH7<@?.
MD8A8L(QE&'86<HQ+OE!5=@97T"SN?*C,GR!43<_:A4&F/:0ZRO9+(8V1!WS2
M1MPETB'*CT;N>V804Y'_JA<4HO:Q+.!1",B"0G)M+522'M4&W[OX;HX9_%LY
M77W-\O(WOP&\6:;\\?O5\;:FN>W$6JA?+).+6'&4\:!=AA@4\05M2A+K<V8[
M?+\T[)+MFW_QNKW>IY .*DUG9HEA6!OPE4AMEGDR@G9M'O&K7).A^>^O26M!
MQLN/^ WS'<T42UP?#_/:(XE/EC(&=WB9$<#W7H3['%UM\#%BOQ0GA?S$P1!;
MA-H70^%@#7Q&,.US- EKD&W_%\W@9Z4_$-^99&!]68AEE\?DAI)C; -GM5#P
MRQ&(C/U]=1K4E"G-S)=0!A?#?B=LC%* 6T3JL7J0VX% #9Z91?@(,!UR^ F_
MX) *>R'QD US*X=ZG+D<O$T,P89);J2PNO<PK,)AQ%A),,\;EE5=W% HQW8!
M@0KY/[?_GG=[*5N)B#I$!W+JI\%P "):2$(R9Z$S,-TFF".*(4I2XL4N=&F]
M&WT;NVS37$-APR)5F?KFOMIZ]3E<";:WDJ4K% 3)$X(OO[G8SPQ^4M^,H!Q9
M=Q$=KFBQ+UGC!5,,*!)U.M<+0437+NL$93R]2V9DE-0.KG<]VI=<<3G\@5KP
M]<7T2D9@+,&_;/5"VA\!&)_T$SHY!<>2-#M)JV3*E(T[DLMQ)D3^AIC$V0*1
MG';S(OOV?)FF7LL2Z=$4$Q:5KA94)+!D\[D&=_EL(1]OQFUI-V^Z$OI:I6*$
M5AVSSMG0\'[6V-ME4\6W)E(;Z76/PBUTL]ZV I2H34U*5(\NE.0(#(F)= Y]
ML+35M1_VI,1'EYOJF43B.;4&Y]ER-*4.1#UI095ZTW*$J:'+$4KN.=QNW%Q6
M'[ 1!1N4HYOEF OA*YR+7;>K7XD\+TAH)U],E3*QCM Q$7GI)6OQ\DV1\%B\
M8Y*.U.&1FI*C;=/WDYWMG.[QB1^U;B,7NY6TYQ5HDM;:ZR3-]53NORSY9&"4
M?!\O%W@_ZP+A5%?+>JBD8?U8/;?;C&E-XWB]=_GM<35IW[>)N[>BC!TC1M^V
MO+,Z^;7'K=%6SJ>F^8A@T-^NUZO46YIH-1LFE08!T\U.C;/RRI$*7Y\;;"&3
M\0T\#,$HFCXSAJ7F@_RC5<X;*5(_)[:R?_P)F=O"+(K%39D@Y$XY8I/[UT0\
MRM9$V+!$G)+.9(6;V_O7"G>+&B*D8E7\O?AN"/41J2<)&X?8L&M*FS>@_K!.
MVF+#KDS36S@B=,][@O(74(_G&;NB3WI<B]TN8M]CPWRP\0J&?MC@N@*9PE7#
M=,G\C?3:Q<7=NSA31!?/\>VL>W(*/51/H_#N^6J!*K!%P9!1+^WF:E[Z:ZW[
M(LK*6NS#VP][>^_JWS$/&+A[R+\-NKMY)]NP9N!\BY)LS0+ZZ"FNI\UZ(\?U
M#BL_L2FCXFD>$,:MA'4#]<@>GC\9?X"AI*W$?7A"Z]EO:UI Y):.[SS N=HJ
MGLR&F0S7<S\R,NIC\I YHK=\74+$%;<V1BZ_HBW=N;F4PZ-LQ^JW[:<*<5&%
M.-U6YC7297KN@)] ;_***W7LFU;JQ9H2BWBTI2UJ-,![O,B?)?O S'VEYOCY
M?S3RCMK".]Y5\EQNM^@TXG;D?5JR>>:8,6JT3-9:/,72JG0D.P/T$H4O_?[<
MD2Z$:M%A4T3:?>0)Q*\E-$F+7LOB#&7#9$XP:X&-^=;3P&K_9'L J_E^("-9
M3(8-NS-QG0TK+3_#NN67SDC]:@X!YV&(3<N.7:7/02A/ C[]K0;!%"9F;C\9
MIT78ND ,Q_SGEID5RI0%OJ\2Z5*7 *9F N)#6#QB^RYTBR]LF#JCJFA/F_$W
MQ%81"UMT"1TDQ"S'"YQ"'\%Y$=]SL7163Y(0A&G72VSAR!46'W,48O#;OX!?
M7\U^$D59>Y"XJ8*P>/^1UX[]?\7QL@!@?A*Q!X?.$>A\K*/ ZCK9%_@+2;&!
M[^FQ89L0H=W1[X+3T<AEKSA@._D7L)$+P1+$I5@L&W:5(07E\U$)A(X2EZ%Z
M9JVP86HBTF^)P[6,+42K&:CN#KGQ7&#*$ZQGPXI,M(@!<A0"B_O+[S?45Y T
M^U8%8'74E/#-$$)?G N$W[D]1)J5)U21U%MLF!T.LL4IF#8XS<0#N1]G+/TV
MEO&=3OD/6_X<6,3,<-&:*#P;2$K(+;"#>J"=#3NIXU4TXUP1D1ZE*P0JV5 C
MWP7XT=!Q].9-4[1&^M^4I$A5WTN??UI/,IS)3-N_*:QT#Y_AS*D=HPIUX]8U
MP!N9M._U$<X!.CIACF!3R/"XL+,@Y /G.,.$<5J4K.GS.>\6D-$N%XWHV4KZ
M2394Q:(\;."UT;O^"7 G*CQ:[9N794/M".Y*KD]C:7JZLN.7;[>8A%8N-+[.
M:Z.#VC./C*S/ENN8WNU"1&7LAOMG8YP2MWTEC5O&WYSH"BSNNIWLTHOF/?BI
M8;@E_WXIN@>!0CR;$V>I@4E_-U*N%#UN40FBJS/T0#C]+]PAJFW\/;4IACKU
M0,\C!V17TF&<!60YUIU%3@4D<%R7.$25M]DWBZWC,G'P15A3KU305[7ZO ,S
MC-](N)<!;;=PIS@B-W?@QQB'P-$%A! 6V8XXQ0"HNZ3*)/4.-%*0-3A[@IFC
M$^)'Z2,O#L;>&<<%>KP!&YU&6Y"N98Z@4@? LY/$BV1<'5$-O>XTE&6O4/)^
MRY\ 2@=V) #DG"22R8&/$KH382>@LG24Z B'L!&;AZ .XS(F,4>5(I%"%>K0
MY3#A1/+I4X_[2MT:KM\4NHH1TR>ID)H!B;6TG)/)#Y6F,16MYGC6T1[Z3?!>
M'V18P"#J]?E2G!,SOU6"-0(<)Z+ZB'S>+E#??B9UU6SZ.KF[D6JNXTAQ&33+
M\45:$D$(.X_J?2!=X>EH54TWK 6?W)E^5%^^[L+?W-@T^J-YD ,21EJLLR!7
M=PX_^) T)XX]R.J5$&86L$19$VFT29KNN<R%I]@M4M%CA@)I4X54<^D0Q:J5
M<TS';_X;G"S0$Y>S)AXV/>U\O<V(U%?L$=59]3CL_; 5YM>*FG2R:(S26RO@
MHEID40GJ0=JT+<_EUX$HU9A(J;Y [UW83*#LBQ0V[$AE)AN&"(-L2WM'%Y[Q
M_LWQY-@E_4C5PG\<YWB5Q4[H>)!KPU?\*JB&.(5"F$$+5?A B:XR]?:!-=/&
MO\05'DI<IB9%A8F#VETNNM2P-^_-(G "I&]>76'GQJ9/_3B,SP4!TZ;Q ,?!
MVAE]M8&VQIKZ#/-#+1:#RN9BRBWQI<C_,0*"$CA#*7.D+K=MQ; X*%(Q.PAN
MD-@-=2FER#IQM.TD0[\4E68[_3G=[S;Q7OU[8JMU_3N#G,_D;5&#+56P4F*_
M6ZJE,<+,YG".1*4ZAY&0Y1>2CUO5+ZK:NZS0-(D 5Y%QS52MSSHOOQ;T%X_[
M3%HM,2<'XDM<TGB$;+G,9MQ0I+*QCN&:]'H"IV6J"*ZRX+QB<*QR;9F!]M38
MT]UT=1)ANH>D]VZ>&"NA/I'>!1S?U.5>I6D1.YWYR$I1BCI7R"8'#"94A1E&
MI&_Z]$N:]0?'SE 54V1U(PYG!@2&!H4VZX?<5(O^7N7RT(E9WWIB)4R4D@1!
M:4W8!;2$*%6]'3B&>S!>'WK@HU9E"8JR3C*+NZVNI1^O>U;'E/C%IO!(_=$?
MO];/E*$?I;W7K08NOU)EZH94;P/A@*M9=*T=MLY[5XMGHX=TJN7J_" _:#L?
M%5DOBDS,$6RE1H7K<)=C[;"$KNG!1-5078-D,FV](R,IZA?Z1O*DP1B.+Q=\
MNZT^F:_LH(MYC*\OS*8LT/Q!7C*<"_N0/-FV]2=.# PM8+B-ULW%/B(>O\<Z
MAUWON#CSQ1&'&/?UH%02O(E'6E2*4+0H:V=>_V](<OWDU&:+U<1[>:W"] I6
M C.\3>GD^+'I5&RY-0>D^M0ZYGU<*19]XG>M9-QD+<K2R-3[W:,E^MQBNGY(
MGDT_84.U:HM<?:$X_/+<3-:=JMZ)3VO#*1VV"6(F8@3>A C<G8<"^EQ:7X(#
M9#PUC,]1'D;<-2Y;5$676BE;HUSS'!I$N<QV$H_FOHL4C0LZZ:UX-M';(R%<
M7_[2FV1-WJACB?'EY1JR5P6H19O59(3H*NLD:#"_%:65\PY%_OVU-S&=\_-@
M7>B!+B2%H-3B^&;&NU6::AN+NZPK)2\4B."Q\>7J: S.6 ]VCLRK\+F$0I%"
M9?_YBEY:&UU[Q5!V/8<Z5X.>J/DG=MO1$21VKF,PDL5>3P^%VT0>BA2\H)$F
M[!9]MCA18^B0L(0<:$#9ZLD0GXS$!9+*,&+81]M&J.4AAE= ,5ADJ&YC63"0
MNF&CM;G(_%#/S%JIF4;.Z LLUM[;]OIK@Z?M.]BOB\P@*3=EP.URH\J794V5
M2P+[-$93PK//6UL4DZS;!2CCLM(:(UVN/H;"L4B_3%>YA>U^&QX>QR\VG1:W
M$JQE+&N6XDH$U#@K,TL.R?H\S(N.4%>3;;IKHC'(8[F=/&TFCG,%]>GJ6$-D
M/%S47RF)=07$+VP]S5AJ)&%B66>&?1E")&*XBQ:UNX1JB1RS[6BD8!W)+D02
MG&N%%Z<]'';:>96,.(7>)T3J7"]!#>4W.A@[\T3I2C&<PVGUU9.*.L@% ]8Q
ME[#QG(O,'(5Z(Z)H1TB>S]$WN+/$VBH0I?Z1%K$TZED-)N6N!5/!+VJO6VZ4
MG<\T ][TD)P?B:YC1A/D2!P="ISP8XXKND>'_(5;> M]WBL]C8SR?*\-:AM,
MVIHZ/S2EY&?X-:1T-&1,TDRS]NNTM*<J\Q1*3; 77F?/7$(\GCM,HK80^5Q!
M/Y)=V#FSN[Z>8/CQ3'X7]1<BGZY<,ICINFGKI/X3]4*_T*R$V4S7"U6[\6S2
M#$7/H&OZI=DC-F4M/^U5-95+A!AQ&?K?_[E?*:G>/5'"4S;MSRK3YWD6Z7Q,
MRZ)SN&TR-S;K(C:&;.T#P"5.].<RLVTT,^RR%%7.E<24<7Z)#O7B>3F_8IE)
MP%KMCP>#[]R7HU,2)2H5$^ZJ2L5U]!Q;&=MYGZ?[NA!R9&M"6J$)7:R<"X)"
MH]..?4%NBOSGR)^7;DZC7;5@*4&*.6Z/"4W';,P89]]C&$P00GPN'D%@>XUX
M&O#> N7Q&W"Z(L.;2OP(1$^G]]"WQ'%76JI&6TQQ4D78(IMAA0 NYH4.A\3/
M<Q8MU.Z7NP_:/$H<1*,BQV;**X=[5 N$D])(+!&RHG37>-O]"?-77L*?-(+(
MZ%M]Q58$FS2AG.RCX\4EA$<I)0[9%[Z//"@17@^!F^50CU_OP#K8?3XS<%'3
M]&3#6>%@->I.KEZJL=&S]6LOQ5BR62^+S,^7WGHP,HGP<!M5_8*I#+CI3Q>N
MU_Z2&_G3/';DR%8EJ5'XJ5QF7;R3&?^!:/<T?;NH(_SFKH6H]U;<Z()5FH-O
MK8E"A^,7AZM>!\RT,3F/8F<U%E2,V3"=&H$Y2=SGSI_(P3G&WV?8L(,S;%@.
MOA[.XIN&7([.^WTTS>"W:OW]B*<AJ5M4Z0GQB)I28EJ.SEB=^,-.K;L2J@U4
MFXB".7LP^,B/^IMGQGQU4&7Y@2_LFYWU!?H?44WX^62-/8_RXV^\PCJ3]6R?
M="UIIG/X"?(IM;DNQG2[50N+4'.C.EQ) [+C^>-YA@G:C5(%&LZK_)L_09Z3
MN"O]U4U.AYV[7A^7@\<31(2-U8YYR-@2H@GG\@Q?^C\H<;@G<R-D-#NM!N%4
M]%J!E!%TR>)(_FO:8\<[WLX-3_^2XKQ_%)9#)J;+S8%:?/,,H<;G4V&]1+[*
M#=+[IMB1'YCH'+[:C+5I3>?331E#WKMG)^S?<IU+:U^:_ZO?_>?BS =BH;A9
M^[3W:,"?B@R#%^Z/@JA1<3R,JI3JB6A$ I#RG;@.V:_*)#8L5X09M3)'PG.
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M$R/F<7;48M+NF63=O/:T[<6>ML,TTX@W*CXE;T0O^*C\N2Z1DZQC*7=)@K8
MJI+8.5LF $XL"M8-*[[8$XUP5@F&?>SG$_P@P'1@*\'A+%GZJ(^+V 8G@.=7
M<+!F*,^GD*#2A>UVBZU8]Z.4A5Q;@Q:'B^5JW15O3E$5[1U<%9MKY!)JY!3:
MC&V*>:U=M<23IO95FZL^,SC9J8.:GO:30D4W;/JL':\>)[6//1"DG5 CJVUR
M-R_<*O_<B1:BN[F_8I="<XQS8J%J0&>Q;#:I]^%&6P6=BU 76+X'YW85H.L8
MZCJ!)82#!5KQR0X1< %.0B; 1SDF+ ;+4N9A-IY+V*;$E(9VPAE3_@,G 9@S
M8V"@DH4#=A,DMB3,-@\2OD9#S9@J(R@!)TQ<BF\AK)G Q)/IB(55? '.',B"
MX,_J4H,%1\6YQ\"*6ECO3_.\8 X.M3*,XO!Y*B8+K, K&H%1=UF#N'R;B]#+
M8G2P+=A]4-6_(/]A@YIS$4\?Q7,"8"7T.X2XM#%?M@WHNLA%>)%8\KIP.B1O
M'UF;7X;C.8$5 6]]0BLP,RN':L0G$1;/P)?F/ =].=:_W'\EX8?AL&LD+R:B
MPLA,L\9CP(RT"E[!;AY6'O-P)E0#X5QU_=O$#BC[Q C3*!JY>*N.!74JPQMJ
M,]3[$\T+_)RDJW*2]J.@U_THTK@5=*8^GH,=YR*F]9(@4S6@- 6J1T$A7AR/
M:O3:]AG4RL0#V,"+=FO*/5 -9OTW+.4$B;]\LWJ;:$BPSFZ1)KV.F@X@A4/I
M5FMTAN1?EP*>*4+O ,IP[]H6Z!O %.' TG@Y>D(%/[0,*XI$C388SZD+',\3
M5@Q23@<[XP><6K;#V;B$Z8EO!IH\49/[D-7YG"@7O@W-0-'E(K1GN @C)*AB
M!+LTLPIV4],FTGJUW@[,E"2&YS]VS!'N+I?!AIT-APV;V+*ARK5YN8BS*/"@
M'3N;17'GQ' 1XJ25.]@?I-X[I"_QT$[X^O*-(*SD75'M1(YSIM:;WKQ\=MK%
M2JC[ "R3;'08'<O6\$6B7\+;+/T"_LB1(_I"?UT18,)1M.,TT+F- ^N9N7*P
MEHNXY.$%?B3FK*O!^);U$9@[":NSH?9C:PNY\>R,F%GHPPDTQX8:X8.:^ &L
M3ZA"CX>@$O(FX&<8&UY2A14=EJL6DH=)73<FH%-PPG\#X]AO/LQ,#UT,NN#;
M1&#)H 10*X+]2HODUW+L:.PNJ*4.OG>+Q>!E+B(;Q5J0 +X>-84!JWQJ ^1V
MP(#1=:8!AK$;(W0X9UNAHS3 +1@2F7X'Q<Z5: &8W@!L^!5U, ?S6(.SC3+"
M3OV\%5[( UA.YE;2T?O@%/*;0>+$^Z'6S=3F%T#9%':N-!,6QY5Q(!P(A3)Y
MP.LAX*7J/Z@@).)3R(NV]'Q.(AS *^X1J$(HDK1HX@<3@@+8M-NDV:TH2C9A
M$<#4$#@9JAT8CH.^-#&V>([PU]]?!Y&IZ#69.B^H%?;RXK(.!D8$Z$2W8IAZ
M/:05_;<</J"IBK"(!_:BYH9Q,)V$ 78(L,'0K7W7C-SG4V [<!&,75S$Q0&[
M11BRMO<#G6OL"_#=.#"FH!)XEVTX-D"3!6E2DE"#X:1Q$:VJ'#4SS#]O&?OT
MY[_<,K:,_!??R$7H',,L)EG"RPR.Y2+&@__K,]&S465$]DNY.3CR;KRE[]CX
MW)#9M=,;+9VDG_,0 K[<6YAN%ZMU:' P4#-I\3JA?(&3.O4!IE/Z0L3)+1#_
M'3@H:C?*##>FD%!)[X&1M3:*')O0@.;@X%CL%@:R&G6 SB@X"$<RA=CT_"7,
M7QW%3B_^R[%<4/ 4:5'Z,S!GLQ%Q,JZ@-.S5/Q\E %_)&W6Y,;GUI+^/WGKV
MMW/:U=!1Y-P%"P-AQ#__P:N#KLP83NF\_B&HSV4KP["TQ)GMD$CM;1TWHM@U
MRX)W*:-Z?+1X88^:5;L?FP8;=[&=^JK5\KR2A\65U_6+:41>G,5@?*1OZ1\?
M?\&KV6=R/>^O+/Q,/Q75FQ6?*2;RY-7BNK6737YTJ6V&R?-B6Z9EL;EZ@6WU
M;D7.'RTAA[Z6J_)C>0^_1-O1*].YB%T)Z"V[S24D'%QG;//,7XO&ZCZ?'LPQ
M'3-,<K N-5QAJ*[:ZVF(V E%ESZ\)__9F% Q:#?Y'=B'\N#;04'-G\KSP,L.
M(IEQ(/*5$:WT/CJ^WJAE=EZZ15]T4!\Y*Z70KV= W=>XPV/,]LG$SI5XT*A:
MO7_YT1UF\Y39R"M2S8A/;O^<][4ATOG& [-:/PZ#@13T'L\$Y;'D=Q3RKEG=
MF&[QLQ5DSX<RL?/?HX7/N$:ZT +V&8D7'3QT:1O"^L;;[7(*^?->UV[;1_D*
MT\N2]Y::9/;I20DAC43X'ZH/EKU(US_QG#YD]?YFH77,J>>%UH4!-P+#>A0#
M%>UQ;KS1O.5J<8K/%18UHMNN%%'SNVUS[$LTI7=9[DNUK5;0;NH9LE$8F'-(
MLGGY0K% ^5/K-ILM,B_2$8BM">:(GR//IDE5.S[$NK8T*C/P*8P<JGD6%;4)
MPZ?6(25?!093=1I.4CAG7L>-*K/1I:]+[HWS!_C(1NVTLGI;HV9VV$!T]4I^
M.6,EQ)'X!.>1]_UF?7@$9;!!CG:2I^%4[H^VUS/URW:IIR8;4H^F%?3>=><G
M%'A&2MN/_N@)\! I_<3HE?G$LS\)M17:"8JL"/#@,/37651T? IFBQZ*1@XB
M>S/^/*,+7:#[SA^B[B*$8X24-<915/<HZ>#FVX1H?1'P$3\AWZM1J9$>_V2%
M#]-<]IZ=ZNKU0+QA9,\Z6ZT%>V!AVPL: SL&>ESQ>VEVU.12R/O72(F8T-U&
M<B?2,I5&.SF6(9RH4IL[ELFR^1K[UIR-6K6_$R12J+?K=+4C)FZ_S'-Y6%&(
M=,?L"$G"Z1*4HN(D,E1+;>-K[GGH/RP60">7D.[?(\'B:Y<_:5L/0]H03*)(
M8JB3;^N<XJ6F,X_388(1?-#+M/SJ/5F&P9N<H^&"-8V'NRBG%E_X?*Q-O-7A
M]F %U&'T4E?G/1@8IBOC=4SCCF&\#!M)A_(81I=![SSLE$4]7:R=<,#) 8PW
M1>ZH7I $%7L_^'V??0IZCN/.O+DI;I[G0>4B]F"#YK!:K9GR%?'6_;P_H!D/
M*T\Q\1L9?L6C9U[/5'X=,RN<'J[-MZPI&SP2I-5043O(5_V,%#1,S0U2:G'W
M]'$U>/'M#*G+!7^(RCYJ%M8\DO6"RD@ZKA/G'5H8EA,%2[#@G"![L5#[."/3
M/>4:R;*51/$Z/74%[;.IYL3J4/V8</W67V"Z&>\H7IH'+9 R:5^$C?IZRV"G
MJ^($OK[\:+AN\1GJ[X93,H;6#&SDD%6&D:=+E[\.(>*'.&-'-%N(AN3'6K6G
MAK?T[O6TO9DJ%[,\KH4>]E&7-/SQ:U>WUTOU1Q9F<:7YGYBT7ML!V811XO*[
MM.X+JK>.RD8QR4O%5( MM-!&%KCV!2\]ACL->N5!7W3E6E6 #M$17:/FSDE0
MQ=N7AM[229]U[L^F*X(Y%T;RAJK']\,NA6GWPV:V.+P;F5.>=P^;,*P-]"(,
M%BF%*],NDN6:KY7I/'JH?AL<7;HVH2S%7\40'E?X4AA6;%O-FZ1X57$@+?:B
M^L_?[QU#+IN\R;_AUC)JZQW=XNJW[#E,# X_*E+B<O2YO)E-Z,UK"I8YCL+3
MM$+KH'N,8S%>*D+ISQ7NX'V(;"%7:D]*&"3AL8YN58UT?!#9($DCA.@?8JA&
MJI/W80GG!M@8L6:2B OVC9(2L//F^F3-$RK6G32T,O#J7&[;3ZP3RVRLQT?6
M039M.>+V\>G9$49V5(MZ[]U;LZ-Z Y).XK\'6ZUS9^_4\EQ[E%)CX1<3<&6(
MUR)4P_->EOFQO'UGY-/<7LK:)+)LDJ\44(8\[RD,60<DI-_NRL[YE*?@XO7-
MYOD,ZH=-^J1N13KY^%HEK':.;!Q/ ;4@GC8*,2Q3A6'7@A+"H0FT!U'^ -^T
M(SK<OU3UM-.V+\L%U69G(=:E04K#5N^WU1L#DXW%;R38!639GTY9E(,.1X 6
M7(1A+ ,&?G[?4& M,W_CZ1&LJXU1U^-9"J2]P(I@GQ=((<ZK;L4)T:=B&G0[
MP?"(.\Z&6AKMU^[>M"/N_J;1?/92\Z\7)2H[V\.$]AO&6-_L"_(^EVJ^F.@]
MS0Z80,5 !^D/(G3>G'EZX^LM68>0%C=_^;["I,FOA86TBCE-V<JD6^;BI0YW
M;0HU$S.R4RV,CP"NL(#?<9XMS1\VP30&7TK6W5N:C*89A4PERVL)Z%Z@>O.+
MI%Z8^#XMF"HHC0BS7_5%#HJ%^[_SW0L"9QF2S^\:N!-_C]VH]1#Y8%,7]\VF
M(FA]YY2UN\'+PQFBE^)F#ARSO1H$='H"*T+ B )JXXG5(]",BSA"I,*4#N9/
M,%CKO!Z9(AL+[,9JM7S2VCE$O5A3@]$;:WR EIQ7VWU?QR:.-]-&^52REF $
MTT= Q/%/6KC6B5_H9$T6.:<WTOERQTI=$4'XAK!?7]>TFU!3H#*_P-;I!N?*
MG2._L";JC[)36_IKJWY-^N%J?CV 8'E F2*LZ9!'WT$?]<MA[K##GOC+A_0:
M#>I,0>8/F#XP=Q4H 6::AI76THBSF$TPB^BC&W&B_9#KE1W(KDQ=H'-X LGB
M;P%F2-L#:_]1)8Z+4"*/>D'F@4Q8<U4^!E4WGE2U:$ %-NQORS#%>=8!$Z&O
MM?!Z!DLV<42680KY3!5F\%\'-OIB+EI C[@(^FU5=NXW6@HGD1Q,6@^VMZ.]
MA\7X7Q7?.!@JFIVV,0VGXAS,>U8<PE#)#38PWTKJP#"MIS#K&?8<==B1-8$N
MV/C7?5E2#<9<1-% APCT- GR!>B&O6O&I#F8&[J.1*)6'+$T4O_>_Z&_3!VU
M<C<=^15I(+!V<*F7I<A K1=V"2S!&B6( '2=1]TBL[15(Y#K=S7H&8]&_W)J
M!C1%65@[HFT%=9; *[2Q/P<F_O?@R/_[!D?:=0"U8JTD6'KOUN>=7D^9ZZ%D
M^+:311K,&$;4\"#EB3Y]23.&,5N5&K\76]&%/(#MYR*:,?04-FH@OX*^&O)J
MZ%?4J@N#%,I&N169O>XLFNES2A3^@+QF@0DIP_] 5G7$Z6D480&J0)R^5#=C
M!T5U;I8QRWP"KA7@7, =)2#*=HCM10^FA;VE[ -NL.+#Q<7:S6R188ZQ)9 H
MXQ0Q6O^0 W: )I-;IAH*DU7ODY?Z_8?EWM+EYCD,&+HC<9(,TH5:^O8TU@DL
M@5D-.K .$INC%WAFU7"V8B@A/!)4M8JG#; O1+<]F]8<T;5K)4@XW'3_X/Y!
MU4/KR3*KU(U]/K6M]?CY3:QS+L8,%G3!J)W$.D+8BUKA'_8:T)"T,^N_9KQR
M<M9KY_6GYQ/&39[F?#QS)>KS:64;XP]3B,PAF*%(-;A2'?#;V!YQJGL\+.'8
MYFF4+CKL<O;3)YQDR>.B+=<3'FX:?E?1N[;?C8M@2H; 6Q+E+@K_?7@.X#RY
M1EIN.\<NNP++<@'.'7@K3CLF9P=S+J)6NE <!*Q=AI 3]V!!&85)0U420 TN
M KH@-@][J!NAF;3^9&QD'$G' &N&.V!-QQ+'PVIUY@?=;>-<W/:/7O7Z,,]D
M$LRLK"K* O G0 >:4V&_T.'XS=\4W/@-#<_LEVR2+/X#&PD=B4,5 DTG]#7'
M[+UT_2<_9<J#)RQW!1;D)37CG.EW&P=MC\P;N/MHV\A5 ^GI<"PJV(1L*,PF
M JL9]>4/G,R>NY;"V08I#"PX<Q&HHO]WS$O?P+]:CALF@M):47HG-Z#R!'#]
MF^FXEUEU?7C3#\6]3:<&+;KWHX3T?#[HJFW.+=QZ_=[!D9\";,EMI=/B[4DL
M83Y5RTJ2YGK*_$YWT<K<'Y>21RBDE%^WY. ,K\*<>M/><0XSA0Q'+3Y/XB+F
MJAA"7,0E$-97Y]@&\,+=X2M>#]^8+N;.1^@\9;IC'01F2X!U\4$;9>1L%A?Q
M!L:.W]=(?2WLQ? .),-HR6A]8)J\* "_3#R)X>Q)@FXCZ?;$-6/"_ -X8W:<
MAZ$AD#+&11ADH-HSA41%#X+1%SY6UG 1*5^!J2"@&C.%@O/FD_J:]W"Z2,8/
MK]HF=MSUUFKEVY^=*29PX EN$^7GM;C<L$U#SRETZ[AL4J]OMA8[Y;O11JO/
M1NN0@PYG:;F$BTC8R"9S^3 ^Y:NC-+W^ND^(84*Z2:(\?L!T]&4+$ZEMXYQ!
MS?N==#)ML6IUK[*%DE:(&^^N<H1HTX=>#<XS6@<[[2B<TBM,-XI1_G?7A)IA
M#,7!CN5FB.8B"JOBEW<.H7Y*P)E[))8,)79B?E9JK8\"LW!R^VU(&MYBR2"$
M?#,?1#!$GQJ7O]O"T42NK29RBN#TO0;\?ZU'[)YE'1!WCHL0XX6<SP-&'%4M
M.IR"HP!]*6GB+'P?M[B(IZCYVHU>A-$%+N)"XXF111G,<"];G 5ONOXSEA>?
ME47E0$][,0OU8MOW:9[G1FZ,B NN/PPIH5\T=7WVSR@QB;D ^V6CZD:K #"+
M3B#$<J10/__0B: :F>->:<5TA799_,TW2U%SEG1?J!2]:62MPVX=]LTF=ST+
MZO@YB.<9R][1P<O1>^A3HQ#]=M3.H]D)#CO!/(KA(4'[RCVO$A!ZFQ_R<A&Z
M72 Z6Y6=!AW<&,D(DX.BBS$L0EXX.\5A!R<!"W"<W3?]H^:CM3]VZS!#:-K&
M-J5R8/892]<=N#1\;_;D"[89XU6#F)B%@>(.L&7"8T^%VF8MZ6+B@>+-NO]"
MRY+8/VA9.KQ1R='H0=J! BS5UR\+1S$-F'TXQT65$L:GCR1Z</V?*R%/3W2=
MP'9N>0](5"\#AL":NHX )]R=M%[7CCRU_ Q&WO(,X.OV#6+1<)RO@QW8RT4X
MPSGMBSAI*(VBRGY*#D8Q3?!2P(QTKMW:Q>] 1P-,5=HQG$W%G$N-6\&6YC[<
M'E!'N/%@?TX"*A00L.DC'MI=HB>3N[EDU_4]#Z/8M=,P>!_^ 0-JV9]#\-)Q
MKSBHW_$0JYW,W)4 4X"Y%O9+-IPVFV ,7GSJRP=3@[]]:_'@ "T6CQA9B&<?
M\"NT]R1LG,?]<V^V._";'TL+IQW1XZW8O>\9SHUQZN6N0]*W[0RE=38]6< \
M&?I?+VB^V#A8?0/K#5!>H<KS>CX5;FM 5F%:>&13;7D.6! CYG>=+/]@8S&8
MN0W(ZV7+;G3T9T7#0/'A*P 606;K&*#3J9G -(<YR%#F02A_79:+Z%1H)3/U
MX9@J$(Y?@F\K* KHY.#' .8]DB2P<AV,:]0DEJ,H68DM_JR'^-$1S?Y<YA(T
MB#KP.NSF"[T[;7*M@*#>'>FX_9(7W*X^/;-UK])$_=_KH:#O_XYZ*(Q4V\<\
M'^*36/=Q1F\'B=XE5WQ''W3X*8]8EARO*F5H428B6G00;R^,!ZT<VL<DSKA"
MO($T$I\+T*0'<Z- +[.[%^OJTBABK3MI81)UF<:2RY&"@H+VR3=NV"!V)YS^
M5]JM:O^K[5;^2+I/;425BA+$,\GT-K4M*Z]#238J7#CTMBY.@5<=+Z[(<@ZN
M?B<5!CLKQ&_-V!Y>C&_%\+P:T'"2F!Y@9M-CB"*EK7<OE*LVDV+D^T7.7CC=
M?SA9SVWP 7$I<=L&**JRM+7)G*^HOMT .^<(,!?Z 795^[M@]&O2=]]5IS5Q
M?PUH%J@'GA&7_7S^%_NS\H&K)#&L"WGC*RM+IT:JZMR#F5= GMU]Q@&\G<+E
M;"5ZD;%$X:WBG$);JX\'@S%=!/:!MB*/,>*\&YW_D29S;%V8DY$3.UF=)&L
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MPS+>ZOEQFN^<4QVD<X6#Z^PL@$4N4M:]WSN1ZU7PSWN0+XS&*5>N[1FG[/M
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M+V$NLY0-B_RDX!EL_D^O\V?\;ZGSUP<C5<LU&Z>$0^U59,C?TO*1OT_+?RW
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MN57"Y=I95UU.S=\T*2XXGEF1 /L*T<,J>+*P'P) GEL*R\]U-\K#ZWQ)9W4
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M\HMH(&2VT)5;BUL/<OR^WZ1%_-V6+O !%F <!M5<I"^N%A[9LYM<C_+)K4Q
M4EJVQRL;(RY4$/]=/4;RCG'*;T? ?[PL83G]'U:$R8-R75P?4,CH4'C% BB-
M3$S&X.YRB$?5:!X!U&W*$_AWF@S\XZ% >2#77>:\@+&9_ZH\HY\)3'?,;#>3
M7*$_3FE*6PSIR&WAJL\B)NJ+R&L/\OL,O]O-=1B0G0L-RO8^ 73%[$(=99.'
M5R%D<"/*6\\<L\37*DL<@-WMN#%O%'*BCJUX"O^),\_^KUGT_4YO%@7Q+[NY
MO/.: 5=EM],5AD<AN1,T20H8)A<,^8=18.=WZ^W:P'CZP:_70?O'*0JK@5"A
M/,Z#(0]DC,4!VS1'OLRG/8*)FR=+!@C'Y4;$JJPQR^ZS2MJH"F@C4TD;+\IY
M7<G Y/FSX ]R+GG+!7IC3ZH" #,<40#IT5*'AR@K9\4V6&M1U??K&OJ5"<%Q
MGF%(WUJEA;^8#FM*&?A59;&6]QM@C*Z]O'?-?WXQ=QF"!AKB/%X95V'!TX=[
M:C$+9B,#U]0AM[<H@"NT(#B05O7FC;B))!&_"ZG#S20(( URAU'J!6APWS%$
M/E*N+-HTP]]V*:/:VMKVB8H:  [!R!<]7[*ZMIQ.:(GN#PU@UO'DEI,B&I%B
M>0D:V8$?$*S]4S_U3\4#)_]:/  K:P>._5WMP!]-7IOEUGK-]_':H9+5 K<Q
M7L]"!8C557&<2D06P*/ (SNPK<A5*F9=36X5ME.)Y)L@XMH>8S8J,RG^Y'E>
M-[U^@*L492"FO#7!'SG(=<#(7,^&B%,BJ%85MACY?@_7_W2=U^6/G'\_K3_Z
MN_Z1QO]?BE4Y/RA5/]3^5(OVT*$?H&2N[(;"LE3JXLF<R/*NL"0-$2R#5+WL
M)/:S,)N2XI?^$5,I#S0_\7"GD=-)B_X7MO7F?H=GKEQ($@P4Z"V5F?#K3?F(
M8@%/J;R8$5FCM+2!J4<'=(+[MR1'#GZY\>7A[\=T_4L*W<VF%N6N*YJ2LBSV
M@8I&Z(.&A5[\9_VG%K7^>CD[!RO@VN[BH;X_&$O"I,J../%O'^.&39R<2^50
M5C,_.L'#_]JJ,(/PHF[[-AF[VVCC9C J9^ R%X]18I[=E7%*I H8E+?[B^()
M+M(NBJYM#9==QR"%G3_R.*'@?$Z1,2N=O906;3Y.N1R'I9Z=^>VLC?Q;78^S
M>J>(%^XB^U!S\.&G93U-=>6S<\P#S'X"C"KJ- 'DW(6MX/40;Y["^+0O>6,D
MB7PIKJ44+JY^ZAEY;+K6-'OJY5='R6.72QB[FC5V' ^VVOU"PRO43;7EY6;7
MXSWUE\:6U:=8>]1?NM/!&PR:AO6+'WB7ZUHG2ECWW5!6W]"RDOWW;'D_963M
MD\[MF1W@<BPMP35KLLO-+UK+CEV2O/FT>-ZB9KE[\U@.7.P)?5DD?&)()+S@
M$@YLB-GMQ/R:#SP40,?5>,X'GLS]&S0"&"1GVC#PO[B/X WZKB:2#TQS1YGI
MX?B5W<I5!G-H9-=U6DJ"(@:@D11^[5@(D.# 27$SF3P<A5L+/@5AEM&DB[,(
M5BQ$YB##PKL,F4HT,AB C9)5AR6 [O30JO1G O]XTQZD6/HK0CB>)\888W3V
M:7#/?ND+LIH*S)S8:M$*HA>PK:4#7.;@GB)+N&4?Q@-<L^(%LQJV1\;F2CN)
M\T?'*22OAMM=FUZ)1V$+R=(AA'"HYBX1]%#)&2 .QG4K0 QJ,4!5R SM?-@D
M@5BKW'9'!O= _HAB41L%A)52=T$7CP9WO M&B'/MT,C):[3:MHEP58N(JE"M
MA'OX^K 'DF>"_T:+A60.I '<HY73/+9]+7F')O]"(\_EDUG_[;>QQ'=#Y 9V
MR%\69-*^^@*EX\0=_08 \>$6 -5TG[)\@@<7/Z0-!L%YX-6OU0+DZ)G(9T@O
M,EN40@#$B%$%';S'851(WK()X=P>OC%.B;=/!3#! 4$XBSU_C/<^E]Q:!+C>
M_C[PF6[YM8T\S*@33Z/+B@& ;0=QA-^OCM3<0>J8I"H0ZTOJB8=PW]7=<+?"
M7C!T2! M!ZRCBEK&D[DU@."QT?TLMZZ:=%H!H.BQ#]S3K*]) ! K?LD<C#&9
M +?0,4#C,A,:84K"=Z^#R03,8)45I# R%1",3I7XX9W@D;G :AXS5X)1[\L&
M2-PN'AAST+\-S H10>35@ 1\YG^^&)->@,\$;*92 8RF91KJ2\:]A).<OW>9
M/5 W2FYJTP+/DL24WZ\ X_C>C-S<M@1<.,$CLU&^Q '7 Q1Q4;P,4(C'R5)#
M)?S/06)5R4KPU%WPV"+>8R!!A9&0/*(K'S_*:".TX8Y:=( ([13*"RMY:G\T
MT,OGP1_T'8!N96L !.TQ -S#!592#P6:3#HR2P'JDV"N&XXY"P8O\(CUPI'7
M=&5%)I,S"ZXRP@ \'P!CB\AC_?+'+.NUB&HPN I5<1!A=H5VG]" VUB]9.$!
M()570;'(=YMH=,>3ZJ? DZ00R4C?Q5Z:_&%(%'FP=S3H'WIK1+" 2#/TO SW
MK58F0N#SO@D?-^,W1_L O/M.0)5,@AX60&S+P@7P?[SR\3_;O78$_L?NM1[_
MKWOM_^M>^Q]UK^W@T9".2^P 8!&.RC9 V_H/OCQ2&"\9Q7_CQL R1[M%<(]>
M=O,)(,@7&K\@2Q_RY%>VB-\@'7N (S\T9I#7[\%7^_YN>=^E81M\+YQ\!MS[
MUG(G9O]VTI(N2<32QW(5UO\3[5M+@)0!#X7_9M+*):NA4'AD8K[@.=1>!(;M
M,A6$2YDYKFQM\[(=*"1K*S[IDC5-F81P$1J]!-_^9 9FH-*3_%V9P=CVC#S3
M\+=5F#0^KA&@U'; ]C\DBQ%B5YN5H!+^K\?,+,*6,A_1T V"L8TJ?8#:[P^*
M4C9Z9(D1/6"TW?2Q26094S:3N ,-Q[>GPS<YNL!+7< 0/:XOHQ/VXF,$5:I%
M;D\%>DUW(HC[-U?!"T*,:;VBO_9H"-B^XR$L"">?@ZAY.P=."Q_[0HV%Q-RO
MW!%^/=)!\P8J^ 0BGV^$MT/_X1$N?Z(3@QED_B].;)%^]WR7Q[9*J/*I%,H<
M@4Y^\ !>H#QQSM#D/-QW#]CLR*HK!-G#&YS1 /=6 *QU[! ,[DHF#B,C8(:'
M%S)[G>_#OUL"&Q'H((1A'%)U,&CD,2#NX!'?Q<!F9]4YU!_'*>4E2*(&#?R&
M4PT.#8MYM>$1O7)E'S=/J(.J )'A T,&(D>=R>5\/)+Q+[3_7QHJ//AK0X7M
M_]Q08=:_:*A@!9SLN]U;_U73!"7W.Y *G)HQ[Q5#K@%^_0?DBY9P(M3GBP$=
MDQ5?,4*>22 OP>@O@K$-HZ]J%?-("[BG0_KRQ-GE4$>K#T^V\PLLSZR-A>[P
M\9N[:\DJ76 4[L_FHSQ<#X#1(BV9I_*F8B&Q-ET@68#DPM^3_F=I[WFDL[H]
M(%,M ^2#E>&U9Q?!'7V^3-F$.+A',-W^WYW00KK^^W->KA$KH0[/5TR97ADD
MYUZE\0GPPD+61[+X5R:QA@M%"K^;P$60__)HERZ3*4A'TU%#(OXIC5C,N\ "
M[V[H +R[[PPP]CH_7A#\/3&/5\'?.VP<3QX&X2&N(!3J2Q& P;==2]"'G<$5
MUTBD[RRPLVU+:5]!H)H,H")>3N0I2^XY8'I[JJ1Z[$"FDE-L@#I()!!2V#!C
M$?ECM@-3AP'<0Q6N6E[*E/VDM/(]85 4ED5NYBP T>JK<I5WI+8K@)QQ%WSF
M$ 9>\V"NI)90)EAGR>\#E9,&OUX-'4:4Y^]$,.4'DY $YI\]/EQ+6DVZT,(A
M0!Q %.DYNU 17DP;^_F9D#BMA+*U-TC?XR"NW>I$)Q!?E1GHPL'87& 5G6(^
M&8TVGAK%=<$3&ZQ&N>3;Y!*:_#['E''K3_[</QW)O?JO1W)#RB.YK?_^2.Y@
MY'-01P"A&]O;R/$=$_TA^4<T_ERN5@\(Y #9XA<17+BO6=DLK"<338&7T-!C
MB7@*\@HP ."3(P=97Y&W)A.@#D(,]W9JD3O3B!E@<+:XT\A"E-<9"B7)Y98R
M,)7Q+XBK8 2_<";^<3A3.OO+]QH!#-/6C%.NZ!\#D3T;6-QV(UJQ+G#DA7WQ
M9,58$)GQ'FK(_".;*R_ZW5F5P72!% BJ_>NBEMSZX6]?R/D@S"J>=-F0 SQD
M-D97ILAM8 J=X1^$:+ A?C=:Z;5+49XRS2X*22^*8@X>-X);3)+A'O>=L,W9
M)7!'BP/YVI8_3MDBJ2U5_9XBQH<%[Q!L42?X-)FU,@ADP-V\78*!5/"?.,/+
M4-\U,978(:X5V4T!%^HO(7WIORMQ*@RJ>X+4!)"J2@YH0#R"^G(^P3VK1?)Q
MRF:/<8J% #/RQ>\FRP"M>UR@% T#X;T8MRMTG+*X8);2X4V(W3Z^,FY=*;GI
M@3().(DFSWY#??M:V9#W(@OYLN@/C;!:V=W+6;Z!H]O\S1+7*5?>#$6(*\)H
MICRHSD@QL5PX9H&#8'W@B?(F(=0.[C2XX^M12^+J,R9Y]Q6)9^'\HC5PU0GL
M,[#&<#%,\K7[X:P9\-712L'8"J$.TO<0!R/;(-DC^(+<%N*764/DJZ<PT(9?
M*X<[ZR1 /FHHY:.03/M2>94QH@*\#D2 JN/*-CY]\2Q@!*XS/)#$U^0MY9Z!
M<&P%+Y])Q 51X)Y]68QA.A<9/&0E)%\=I<E?5%,[!R8@'7UH.!'JC8RX<J$<
M9JL6N8E:25,  )T%C:@U]>+_90L#Z$GAO_D1W*D+!,\%1< T'^* DFX?,I/!
MZ96*T4GP!X.3@,4^%GN0M4C[!^J8)=(*D]6^(&Z.3*C/PHH%?0IRQCE@TF<(
M8"1]3U@@;&[3LT&VR;<HVW#7PGT0"$&-13_BM5U@H@V9@.H\.@$^\WYK9T\M
MKCE$;N<K]H+I7/(44')9.//K^S^?JU#Y3[D*I/)83D"($L\A?7Q\'YB5USW(
MN<W?O?X2!MB8K$LC$FXPR*RABU5R8[BJ$AA/BXFR$_()=^!Y:/!)/(V[#=B1
M4.DEFRU>D].,%!^5E7;(%]W3X<KNXX CR[<_8*".GF<UH8ZF!F7^. @'#;L?
M5G>#<&ZXC$O$W_ E[WI?^&[N %)C\!_G%*21ZH HQ3DJ%L$MSEB\$@"CF4!-
M_R^D#OSY8C,!,@WI2,#-P?L"&D8XF+?BR=W1Y!=E_51HL"5YXW=N(R<"&; -
M 431E$I8)],JF;@NP'?#U0I+N$6E"1K9VZN)US0/*SMIVH)'>4O6"&5K1[C$
M3IMRV"SD?Z6R#/F^ AXKZ 8CMC 6..&C(\KCAG=.E!MU 4!<X 5&_5&&&QC#
MZVFX MA+.W/,L:#<1&&(J, C4QX*RD__]]OY[/]V.]]OG#))N5:73/XNE*UA
M@3%UX\<:$8 ]MX%[?:^R3/OL"F#NA2*A8M$AN*?3"GIH%T4;7-O)D[F)X1'7
MJ[2OOM_M%ZG(_9X )FJ+A8.;CH+9W$4E[S\,EQK.@ZOVE--DVWQI\H=E-""Z
MT2-:^%U[8(>Y)Y0'W64:EMXG!P,PP+DO'D6^+-#F$LD%98#=V.DQ1N.9G<(Z
M/KDU&<S^,4/@NM?K%<U=0%(:E/ ([A!<K0K'(V7TL25>X $?290K_K_UN%4V
M[Y/.(C=K<9$^EA0F[]HD!(^07!'T^6=$1@6VZ R"_6HI,G =44P#W(A_$';C
M_<EM[LY1<@9P6#"3,J"U'D'MB61JD4'S\&0P1ON4Y5ED"TVV7KF?^B2?/,$"
MO'2I"8 VY5[BB$HX=QB([3$'?][_?P#P]G]S + JF+7/W+&-)  DGV1Q,YEB
MWD,T" 8MRP?&;'3/*%>ZE S2C3H27B(86X5K*+,@E-:55Q*U1/"6CJ@NN7/N
MG[[PQ0U%1CB#EJ?_2+J7[8W%JT3G<;%EO(N0]W*H?;>7.<(5[1#F?LU%!TKB
MF1]VXXM,]:8,E5MZZ!=DXV>8D3.[!UE-4[/W/\EOOH4ZWVRU)EH%"^/;M8JG
M%:VPEPXR+_'4T[&6*?%$*+7<SW;^;8A[IRXTRZ_7/W5)P,*L%346'75QP2&R
MZ\,W?.KB?.K3XUK.V5 C]$V;V)H9'O[:)J5T??:VI\]>>CH>ARE.[5;YJ^=N
M,7T=HO-$.DZ)M57)T%E\J&G*G*2$SP,IYCL?_SSVN'*(44Z+ILTJ]$6KQ287
MA[DM6K(89T8Y9Y+T9%A>96$#=/!WX_IMS6SHGM\)YY.FY'N7O%75QT(T4MUB
M-\;^]$WC]U;.>X$V)I%2Q=12WC0_P/S5.%3 R'1LCXEI<PYYS7QO:^@KUJ&K
M'++Q:VP3.PGGL$8K$D\?><Y>W!ZD_F'7YSW^\G)N&$[/6E/=W>J5("(VCU-<
M+E@TA?KMZWU?MG;#VU"/D%MWDZ,3EF:6.QHD1P<S'#,:^YJ^NG5O?*G=8-!Q
MVR-ALVNPG^/&N[J+Q*U^CDM7KTJB'Y=!YX'0; ]%T!UYL>9!+1%?-&9+)"JO
M+IC>GU \3@F]:6IJ9:5[ H!B*4#4]DSF\.'EXY3PB^W S&U[R/Q$4C5>$,#1
M3%6\8N8:I$L@'1Q"??LG2'4DHY?V8B]%+_1HK[Q4B63.TEYH*COX%"JIG"9*
ML7?&RK.PK'*O>5);1.WX2#T^+8/%<T*_91I&*+<#>E:69U0/'TQ1'&?!9;0\
M00GWG)TV9B]EN*#"<NXY+V-L%,3G6,;S#4]BT(&=]3AT%[=J[F/KM%]_\/5L
M0*67P<OWG$5^!<\;6GW2'UP4)4>(WG^S.$/\^K73N1Z^!XN/V&X<I]PVG R+
M$!"QNZ*;T7[!D*M\*<;Z&&0IT7D"^(_I$63T%V@YW'Z9EMO<#R!Z$H%Y2OG%
MB![L0XMJ;JTL,XDX;1)UW  [*Z&V",N>;.\^?3+LI_>=>S:*1R77PF3-@2=U
MKK=O\MUXSCAL[YOMG$2E0F%YR\*)QX@W-1("LJ"$WF(F">''XIXY[-4-QV_@
MOF*3EFI[=+!8Q*2Q3I:U)K7YGT!H%KOZ.P+-G%[,B;HV:]H#_+IN69QYU8AE
M7Z;BL+\PS[(<CH*FV'JCP9R9V)"(?YZCS][4F&=D$J4_#TO+9+FNQY)A<31=
M':-)+ 1APY\M.!IX<%X>^B;I[3.T2"PIG]/T?./MP#,9+&3GIB-E>E!_@(*.
M.Q$W\UXRRC@SB-0@CA%K]2NA&CM$FBPNB,T71'J8E'"GL.R+4W^(58ON5]G0
M-!(XL:Q:S(O2;N3*KJ6!R9GZ^2/F75J[[^ZGV@=8[UI+[=-[R*5<J8KU&_8O
M?/$:]JI=NM]2CUWS#2ZI2XN*98QD9_7P&!E=M?-LF8V=(S9>K= >6=S7S"KW
M%$FUPD#EW.!EY+RO:$1WH[=QTJFM^^)MG3T^^-[(7N$]P@NT\)B[:=_90KM\
MUQ;']L\6U>JG7?.>(1$0%@SCFD9D##!OE#UUG-*9XH!;(:1JPCAE8XD08]E-
M@H?>"OH"2GGH]A=!LW$']'-1,DIG%A \]@;IBV)>KB6^HL:S7'XB6;S'3%(0
M6Z37U69;9PO!Z GGF<X;351:_;U^JK/3#O RAN=FY/#9&U,E6YE3/F&<UY*R
MK"Y +8)H4_!U""%881N(=HJIKYA3R-];*T+]Q-29[/VY3]!O66*A>J_^5+HV
ML(9 /K9*ZT73L-Z4GA]D;=J/FMYX+9'J;FQ"6;#SV76O7P>UCE. Z3K\O>F&
M-\L]2(MQRLQTD9"8@0&)I3[/4IF),@F8V\D-TDZ9.W'9;A)9"T@S?$ 0VVQG
M@P6(B&-.TNFD9C/BJ^==.KB[Q\Y4:H <.5ZSN5-")J_YM*"2D;]+WTGGUX(?
M#I68WCJ)3235=BE6<#Y Z+9D6DO1QW;+OG3IJ@KZI6;>'%^I(Q8N8;9TEAHM
M8[51PU=V"5NF5$I.O) U;40S,F6B)?D*JX!U84'6EYC/H$>C_09(/O_52YID
M/VXMA4I.-!;Z2IDE,S&5BL15\5CNNF017&XREVV63,Z<VY?F%&CIWN"#QO<D
M/E^PIKK+U>L)UZ)_N,EECY,$UD0">7/9.MB+.UWZ-D2J18Y:^XH7TF2 WQ/R
MD)@D/G?XC,FLWC8SJ<J%%<KN#=,8E\@9\-Z:>ZQHD7Z8\< P_"/VGNWK+5:;
MED>?V7N-G%R$9EP,$5B*;YA$6+_=4%DOU9H66KVLT[7&[&:+*'AVL.MK\E&J
M2V5=>?'V],OI43O\*E=FHU)6L]7FV2D>"5</\A4K0EZ=LCOSZGW[=*^%*_GQ
M#LM?F^9'EC:5VINRV-<>3'DPYTC^EL6[+9]D&D_6C$ALM%X\;X?L>+>E%A6
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M8_V0Q/V#;]QVKU"Q"C-(F>XS;5N6S:RLU.9T[4>7.KI?IVL_=,F]:A!/'WI
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MKS W-D;4]<T<T6%YES$,71OZBZ">8ZWK#YN?R8^4/'IJ<G1?Q/VL1'K'R>^
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M?\\CKG^D1?G<J7!3E3GPAONDX9>A2H_N->!L,9L-?Q+8Z>4#2<Y"NL$ CK9
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M1MRQT],KPC/)8%\=YE1@=/&R)_UK2;6!Q]WJ)]YH.^]]O>*>!^4[=B#>T]S
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M]FI"GVX,F*RF$79HHI$MO1^+?*I$9M4XM6 >5<]*4]O3?""C=.4:=7] :B:
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MESONZ,O>S[=X'V9E6F=:5O?VL+NAU$+ZZX#'_WKX:1BI/J%5E$.TX.H$T;;
M^E#F =BJ&DYNNXB"6!F.YIBVQJ(W#>#8X(<O^$"IE_41D)&)-P182X/@WJ&U
MW3-XLHRW(DJ]KN=[3/:AS\X%YZMW/:@(G4U9M>"G=94&A 3N]F J29!7K V7
M@6AI>7H<+P)GJA8R5IQCIS)^^_6C[K)ZW"6+#>+2 <0Q2>,9+@K;A8-X:XC4
MLG4LYN6#:+4EA,U$;!X'PR5'N8,<IYG8Z-S9;/%427D@S5-U&R'+2(82:HR
M49/0PLO$+JRU,S$]%A??5(T#]*Z!Y7N[9RN#HI,&SQ<P4TZJC=W78$S<IS _
M_,8MV\W.=RV7!/7\CD6IW[">6;=CF40S-I>(4. N&3%C;%<-;!VE)'Z>XUVA
M&PC !S\ZN,8-4&Q^YA>U)7(RAF$(YW5V, QG=X[BO.JN?/K]*<BZBC@NYUI3
MT)^W6&?&35=MTT@3>BA"D:PJ01+!'&4K<15!+P QAL\T%%M"UBWD+)X>+5Y.
M6HAXP:S81V_)OUS+3LW3/^'$T\"OM@5/(UXW'3O)?D@]\*W=^1"U,*@O/G!:
M2U#Y0)U^^'?L;2?6$[^<]?"+J.I)+ :QGT<M_#*/BF+IT8>Y&^"P,II+?RPM
MZ*S2/;)8M^]<8)'S7D@ER:'8GINYBAES[:U2;[9/292J/#NVQ)S>+Y,#0^=V
MED>J##K(3QA7N!OA$<5U,7T]E=WNIQ&V;Y".@@K?""FE6@:+:0L?4TEMQ!I1
MRKE8:\&9EX"7CG?&IV.I9/W(\X0-.6\BUSW-^#C895W_XOK@IOR9S1L7ON>]
M[50$,!5N,(F-;&$"F&R"%2..=@(>@'SJ9LQBYH1ICC9A,!O:V:;&U_?<>S%(
MH7SQ4]J+CC<T##R^'A;$:$L.@/9VMR8\/KZ719C$/OTQC0;8(PO;B5A\$D24
M:A0Z92[+@(J5S5RBA8$BP%:]&38%$]HL+!JZN>LB&<L<@W! 1Y&TR!H@MEV/
MUT8"(=)1T*D2V#FZ#>CD'\9;K.SS]F!]'\Y (:#J%O$$SQQ9#C5<1GP@G-PH
M$]K7)R5/S5"4FV@+:KJY6)(T464C6^4ZD^J8F4T!@N^=!F8,6H&9=-<RUB5D
MP5U)-!W[!,Q-[47KO)O(&UZ4P+5LRNC(U]B5OTG#!M)/K>@K#%W"0H0!Q]^%
MF;)X5GNV09LS;Z5ZJ74;3ILJV ^7 4EN;:>BSP_',[/QEH!(C\ILQ6!.OWS@
M'BK7QCL#U"Y%$5"]\HMQ[4@7]ON9#!0H&M)X%WJ^TDDM(NIP452,7^. PSSJ
M*DOW.PX%)P1#MOL=WY397R[U"*%43B@NGO7G9UZX8-S\O.^<N+:^/M4M]*]8
M:88YJ]!BR3SJRAEU3PUL W1D0VRYI#77A'88O@%(F#S,>U6) ^ZJ!3X3:/_4
M04DF&R N$$[Z [%:064!Z@:9/U>;JN>UF.-82EL-AM^25F/_[&;/2/;VUS:?
M/3H87^VIB-;4>(RG2M$D)LE0D^(%' 4M!!Y<KJ"%J6KPNQ]I%(74AM.EKONQ
M&_1@UOGCUTI9S#&3'LY::>$\:M7D,)^:P.<N@QFRZ:W88U#XO<K) ):BN"8A
MX22NI&_JIR@3"QYL]A3.HTSI5E3Q[_ M&587V::Z2[=6OV:MYNZ$Z3]DIP8)
MFX]3Q0J?PM98:1E,AO9)V@N\>,G?689OD9U@W&W <9!C!121=N>(VC!C^OWG
M)F<,CW.+YM+=453<]$XI.4MB0%\,:R3BUT8T[4E$*:.=;!A57^#!I&^>L#!_
M#AT&DZH[*D+G4=JZBL+2D>@"O"#H!0A,-)Y/>52&4.Y.B.LOOC_\SJM<N(BU
M#'93Z,&0%+L,T>^GFR$'5$5<#"U(Q0J#6V4SBR:"C>&MD$T;40_O(<7FS%%2
MR8"CN"W)M -K%H]-L["%V0PY0_LS<>4&./,"9/@ PJ2=&Y)"!PL?V3=5D*TG
MK58M $4IQ!.QF)9@(]45Q$!&6CV:O5!A*0X;N,_RZPM]/L!=]W,>M8"^@6;:
M]+PY;_CCF'A??YV=-[!^;&OS]:5QL;Z!4;4C,9'WBS?]-<N^+%E0"GO)&<,D
MP*@:6$W32/VPJ7P'?"WAH?V=P>V1P88]!"QL+1-=YBQ=GUA9WE0'=F1+?]H?
MD>G6&D2;?*PX:WX'=WK[_N]AFAOSFQY0;D?.J!Z>RTWE+H?/0AXR\54U)HJP
M9B">ETW6X:Z'G3N*-X!"8>+2J>I0,/\*)S!!BDLCZB&_\]"UJD.2& M[\.*$
MJ!39/5062;?*^"0X-#%,>/H^6$/"5^C(?NA3&F?/,*M]AAEL!E^  ,I0)5GU
M"+] 1KXZQ]%^3&4K(EZ WPOV$A?&)TK2CK2#\E8UL0<QETJTX/)]D&^N7.6Q
M7V,":1*]:$5C3H7M(./1T4-:K<1:K:G=:*%D);VOH/@>9#&/XA<D3!LJ<1JX
M%0V<RS8Q'=%(7!#B#(G;>69N0.;EA$3S_'2'[!.,]/.-P4]EIL^KIN.#L ?Z
M:SN;?NTW&Q=[D3+DI@B!R"VBE4@TG LM;)>@9WEF2!P/I@_SF'1=Q+D1]@(S
M^7,4 5&G4^:E1T)3=QZ"*-EU+AP2>^3=<3+,:VM,Y7Z5E 8L28X*BRV#@_F>
MN;4;[Z*[9K*(SQJF;2 #!0]D"B=)&;R%-#>0):MFIS#Y["OS*$/N:L0-,FP0
M4 SVQ0%P,N3I5LB7&"*6LN8(0)AV;F2\EJP%\]J+C<6FLHYK^O5@>UGMG##=
MOBZ-NT#=.F8-NT$[9<$5 #KSHB::HNFO(>1,IB(*)+"D-BPT+'3+E0_6-\P]
M0TA0Z1AN\!Q[-8//!:<*F)<YRVDN,NP2%7M??]D S5.A"ECJ1;^AT;E_N(1?
MHSAIL0'>!8B83A;VL#];$L.J1[?CAA^-"8 ??!<D26I:"^<"N:MC%&IT?^VH
M30=A!927_HCZ-_QL9Y&-D+X$*D^M$S5\GHPX:RYB.E:?W<>9:U+\J;J#$)76
M" I$MS!T)[9,&@6C+:SZXW5/B/?T<>Q"*ZDLH05.C"3)S3T]0>[UWO$QXQXV
MS0]("D_"".KS,:<^!W@.1=DD)BJ(=5V_T Q/_MKC;Q+^*6_V4)0D*S+@ 9 "
M.!#KT*FT)&FS'Y":#K*%%R,Z9I@$[69N4[]:#R'"L0\G689U$B;="&: )4=<
M?9_&RXIL6NICY#,KH[[!E>T-#6.6_>7])01K=0NQKKPM5@?85TF<=@?Y(B!!
MR#.D;>Q3$X]'2K35:V WV3PJ6[V A@%9Z0XD/=J*7EN.,U2,2^,:/X&$:9Q
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MV_P 3FSC&<Y^YIAJI1-L@X9$,543]8U)^:FV"'&NW!U%9ZCYC!JM7[V%^7]
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MKB ?V3"FK<FAS Z_9]&'["I2)7M>U$*#Z:O\_O>N\\P/[8<V 7<SK MFID)
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M.*-)U_.9)QJM4HL<)#$]OV/S)*:$570QV9!X$J<=4VP+^_Q:#3QU&6P(AA,
M=$JQ+M8"1UM\BK5B>D,@>R7M)%PMY<%'BZTI:7,_!)6%EW&MH@7HU9'<E7V.
MNS9JDD8@"^,E4_GQ_Y$\$TY1(+DLOXTXQ/L3+L()CG$-U6T\7>X.9*O&^S"T
MJ87D04T0RQ,#8W6RG0R]2?46\'&9S M#@L^H=>$DV0Z'(H9G'83+%J5QPAX>
MG[@8/YN:'?%;$/VI!KTYW,VJ-()3 &T#V-7 =& LI>8#E"N\D[SA7/G'E,02
M#5*R072'*_D*81?U!S!84[Y;*LHJ7@H*TRGGS /D;M ;9@B$YL_-)-/<9+R5
MD?J3!;%5BHNS^:FS38SGOXY*&QID#!$5@; [N.R'7XVXCOS;YV%.H[KRP<M*
M4MD[F-6NWB3FG 52>NWCE87-]&\>]1 ZO6ZGU[H?02\* YO[_JIK&K@S87#\
M\NRN50O@=DA'X:_22"8EAVCF,6T-*F6C/_B,5;"W/*&5/"1J+S:#Y1?L6%.3
M8"?@)PA*:+F!'$S^M5@M%IU#V G+XHUM$1_ *Q#PX5@8@@\JG%/P>@[5NQ O
M7.;6.LG0-_6RPS$A@"B#N[1/C8+=%,D<V!+44GAT>S )&R<3&H-9H$##(AFT
M*("=R3,[9\YH)R_]NZ^6D4:PS6_S;:3P<Q=.<G4@WVSI;<N@L^T%^1GX= ?3
MW)'HC0O!#XP3N&%//M>PE@NO!0NE$L$H0\AZ-H_JP U9 \0K"$/Y.[43T(&3
MU.O@KTIA8\(T+A$Z@KUZ+8:,P4<\HF:VJ7="F':BSJ0K)C6>81@3,%9X.DR^
MFBXZIS6%%>!^VZU))42!)#7 ]NNDDT278$$EM11X=4W:E<Y56>B"HTSFE'53
M/$8[UN[[Q9-'CF^KZM1Y]5[[MTMC3(VK1(^HA:SZF8X12J8:IRI!M,'S0D4N
MI!$ C9G2U'.T7+B+TH'5P^M'@6[RF<M<)YJ]Z@Z"!1M'9%K,>-P"Q!ZR$R97
M$V41R!Z+=5!$#D("_A"W!0P\>!%;#@<*QLP^<]>IWV#!0T4D+[CD,76G0+(<
M3ZR@BWGF#)F+Z@'-7,H8U@D&(S+PYF!H*W$)P0*Q OWXO\Z!-_G"U8N^T0ZP
MTKQD.LV> *G-R[FE<4FU+$E/_6D/G&3WH,DJ-^O[S,C$QH7248HB'O+EW56W
M&(T9@]:7"7KCV!I<>[5.!W<C''27FB</!O\?>V\:U40:O0]&:45$B+)%01(5
M%6W$M,JB+$DK B)B5%I6(:V($!#3-B !0J(@A$6(2RL*#5%V!(Q" (60 &%I
MM9&=2!"RM2)+I,J&4$T6_N'W:<Z<,W-FOL[\3\Z;;WG/K?O>^]SG257=NYBB
M1!4I5T%<H H'Y";;_L6V?P;?5&!Q%NRZ95S3\R7[V;ZERXC%_1F_91DMPP+(
MOS1##T( ?G<N5=N&KALI-!8!A1J*K6]#-9O.%5BFQ,)-LQVNB_]R\GX^]2@A
MK314_._S_"O#I8.S7UKLK!P"4@L&CL]5/(7SF#1&+4(63R@BN4N687<XYF1;
MKNH%9RNECZ.O*G(*E.*,R50.Z)HKPU9RVWLSN&N50:*,>B^$J.Q6)*#;CEP+
MN'?LE:G7D7Q=@-X[9-NG+=5V2VQTQ31E#QC\BB:A?M348C&MG:(#'8T3X6[C
MC=1:I,$NH2DWG"IX("ZC@?\&0R>Y!IC]Y"O0N(2>T8!?<TUY-AZ@=IDV-"L<
M(0OW$>NK2J^PR%"Q=8@466G@1[HO/ EX1@:;\)=AI/"G\'>]NLH]JI=.OHH(
M@3(06@2H8DT*P,D.X-K2$G6/G28/%?&1Q>0-0%FQV*W/EI$11UT?*)KU!+6D
M<9GW9WR!__BV:+./A&!MP*[2GJ8T#BW#59+*SX&(46Z]BWJ "A0IHZ(4%@)H
M/9&><-OT1KZH>2[#H:3)-S7F!^Z0S'I!:'"R_RME1^8RS+=O'C%$5!XIC3 ]
MWT6G2M:Q/M:7Y'HH0ME"%PW*95+6_ ^K1:>^(N^#ZH$Z,;R]Q5%J>9N,59P@
MVVJHH$8ZLF@93M'Q8!(W/)^;2OEI:!D6WKN9'#% 63?%YPLW;8<R@(E^I8?H
MGD@W:@=QS<DE]&U;*CR @#0#5 W4F]3+:,%D*T5#7-3&)%XK5T]MHWZ+K<6E
M4+2^HM9?O0@)J< _TPQ#I9DXZ2"_B\%"=<S1?B?O!7_A./+)YI+=G%P1@S=*
M)I9I\B2[? QJ/!LI-/4JFN88J]@:2;(?LT']?AG&.D<1F%)ESF"*&X00C2?R
M&+J<[>0]4 J($DW42]XL" 7\$\,:SIG/N.V+M ?TN4\#_,@'!M0&)"IO<-RU
MM%N*0DT?A+KQPZ+^^D2BGL=O2[G-E$\!]K(X"2-U":71ZY</B*OTXCJ1^^L&
M*7NA_',KCS^MEW8E:+?37PH]))LU&OL1=179=6 >E]ZTT/>RWZ;7**+0;,BP
MW2%IHIPY=2,:2AX\\6A,9JJ!/&$GZF58][\BG!D)+N)KI/O*LU1D8X67^B^U
MONJN^D?(PAMJE@B-/11.*X\UX#NY=60W )]Q"8HR%G9[N71,K(.XDLCQ,"]P
M,X"LOPX:Z*'/#;,]GX]%Y*G+M<.%=6A9%HB3+G98>TM]4I^&(]>\ZJ?L)F]7
M/>3\J+2#%C;SJ1I.DX:T +*%*5'J?:00L<DKX%(2MH/*8N38+,-R.RA'^.RH
M:'CR?/9Q"-\Z,F)Z@;(]MY-:^X>&1RW.6B@02E?5/7*TPJ.A!0Q&(\EV4$JU
M<AM=[$.#IRBWB#UBG+7$W6VXU4K[^TGG^.T)^O>,.4]W T-YI^S GCAB4MG4
M2,""U#SNE^&=U '3_\-DL?^]_C^[X(>A.C!.7-[*7!W!,*3LA[K= <1-5N <
MG-!4GK$P&IIUFC7D%"CQLFQ'FM:&_.#=NVND7A(5Y]Y_=5O:EIV%BC.-Z?LW
MO\28D8,A I@L[/*E;F"'E) ^\,5S'?C-RIU@05?VSL&5>Q496'CLIA+26-MB
MK>>&$['4#=/-K/& /1OZ _'NME4GPY(OX[Z,J?6/#M@NPQ"1PI?NO'&4F-%%
M3!\)W@.U2.A;274GH&A%^#2CSI)FRTQ;AM71T\I5SS"[250\\#=EVP!+MR>6
M?$2T)Y:KJ[PR$K6[&3I?27@YNM+'"@?BLFS<J458T00W36BB-J"V[9<Y7=04
MMMO"3>P#TKGL .X=;H3Y&HV [+-';9W#',)VC6OCH'PQ _G1>:2J<AJK=PF,
M"1@I*(=2VA,Z^J'<<V!H>;I3HL3G-5\91(W[27M^$_XP>;>*R;V"IZ,,.=9D
M4\@6K&KE&G!VDW6&N*\X:))WNVEQ)")XU8B//,DN"17$;DAEO:X/M'8;F<0-
ML3ZB)UL&T4\?#9Y)%HA-#R@S*.^$C7#9&FD43JW3#"*.K;3P5X9!?,4-RK"P
MGI^!@:O'EV$ +MOE M"MW,'5XL"#(B:<!S$607YD[4'V(8(4-?J:TMN$?/ L
M$F,"95?AVYW<?_]W0A@$)0](/ /Q T+(KEFT0--(HQ1&8WF&-64[^1R8W;FH
M-"J7OX:2;!DYRLOJG8,F*!K&R62$8^WI_JHQ!A3>"1E6\Z7"34Z]EAG7HFS>
MTQH:% =I,/6#K\Q_W.5^JI??E$D*G)#4+"_7&/U828$L%)>ZEV%KG*%\A5TX
M%SC-U!W[.F&]\B]WX(F1>FL+,?,6DQMFAE\73.*= MPSR(?6T#,64(*R+]^]
M]G^8]GG]H..N#9!/?8S90FT[I=Y_0>FD2J'HS. ;[#._K70V=5'K:PU3-I"O
M06'8CA!L9YW"WATL[C+URKW%V0[%3SI\IK7+W$^P@9$'1:[5@0$$T[]^\@O_
M-\@C)$ZO0GO1[$)OFE.D:,YL=R,ZA>PK[C7N%#,W3@=O C=PS$98LFO6\,X
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M'YPII,IQ/+,H3YQGN@W7+-B,,.R$?=&06['SWN//:?:A/NI %F.L2N.!;K2
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M^#&BU+Z#F8Q$@W#90X*$:Z:!:1<%?F89UH"?_0]$R8L!5);&TB3OM@DC4"-
MDQ?0MU&U]#2* 8G:1:V]]@:@=@5<R2V>".<< F_?)76WQWE5" I.2R8B&V#J
M?[XRQ9I/UDI;TD/J=5*%&>5C\,J4D1?D7^H@FL*/?!)P[>ZT1LC3565.S@HL
M1,1#<6)K=\F';'@;[B8*]8V#(#WPA#9)Z<:[RC)J2'7=C$W$"7ZG%B_7I!'Y
M(]#)OJ+;^]50O>Z)PE-#U="S29+WCYT(BA,D^8RXO&LN$[6NGHM0]PDW8A#*
MX)%K<RR/V6N";G&Y3 _P=>USV@2.B5]D$*K&IM0(J*K<-;IBQH!WXUJ]SLC$
M\%<M^3%VL1\T">1J.*<QBWMK29@3DX26%-8!BQIX+2>YS0<?C<;RN!NF;P@P
M7$GC$'(H7"ZX\K R:&PLR*S%3??VP?@JK9_OG^2V3V90164:]76F=[1.(@+*
M[U#VD(-!IF9C:(=[%SZ]0=CXH;)ZFK^4PU2<5FY3/=6$8C-ZM?J#0V[&EXQG
M]([%0A1T1++'R:5\&49XW.&[9/8IT.E!<-MOG,424J[\ QA\#V@6$67&BN/D
M>(T\4WAJ:I_6,NP:0S IH:75L*,JW9^/*MTT6+ #;4[2.CKX+)!PI9:J1=(-
M&* @!(3? @]GN=+]^Z-:<\"/,.JO=]5#C+H6?@Y'GVSS$NH4!?EV"5F6J>Q
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MS M+B='7<@5)0]<_C0957TKTO.WQ]/X18S]O/ALN8AI-!Z-&R#@-*=8ET?V
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M?/O&\/',\D><C<Q/8QMN*;$>UO"-#HX.<%EM@%S%:,=LSF\M]J#]C%R?^_-
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MJ*<>11Z[E51D5J:8EW,_?T?EZ[P^G?.GS<P_5&D-;AXI2W_NX[Q$$VD\X#J
M\VE4[:VZ9:'&5*25^+EMZ23L+,-$$P)+"1<^5_(1I#ZI-GH#ILEM?]RH:9\7
M)S0M=<6\SKR]1/WXS:,M/6T;Q@2M3)9" ?T\6@5\->K0R!%*CO GG X<42D
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M7V4),9JP,1G8*$@.TSRGYL3.[TV7)44OU=7%&-YZZC-@$AU8]?W,+>.^Z'A
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M2?&D<Y[X&W3NBGEFIG']JR>4 *4[;6K0=? 6)#C(J7CGIE_+RZM'<B)&"J(
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M:2K'!ZM?M(M8X?;<COD[1/4_<FU:*X>ED@RQ.PU]@E?-116 $TWK?3$AC+L
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M>9P)/0'8%U!K)L"L!_SU'+N-C["JT^>>@I^>B_F1 [5A5@P)O_,1W;?>B6X
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M:%?W=5#)'YRN#@\I"_0/>+]^O/8(J/^$J"MZEZ)OI_8[1_1ZC]<9XI?X$N.
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MGX\XCU>#K+Z0>?=_O;96V%_^+\L1_S8I\\_EB/\W+4=TB(,Z<9L))S?,"?O
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M=*5[O0(!"0T=[;Z%::T^YQP2->6LJ@JGE4*K^^9]:IY+N??UL,*8'DK@A9(
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M6)[2/<"&+7ZA] (E O])/!;TV89X\#,9PKIEIRQ@T18&1F]+ I_38J$#7BG
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M:?M2L1XV3/[;?U3D;.,]&Z;YWRUR=AL:3I7*[?#E5H;A"\AR YX'3NUI*)8
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M3EQ8[6W5!YV[&\Z>.-SU*707URE\;RU^$/<?A>#W;^CO[  ##>QER,E/FKD
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MFQU!5M.]/D:E@N"EIQT>@7?'1,^?]M+<4A+3DSN(EG!*S+![/G-((SC1_TK
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M67(HN$>BY'M-]WLF"2$\@IT;D*6MRG5 1H%@7.@HC9+<N88ZA@;51 22NBQ
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M[O-]',>F,5LXWK$"?,D(/8HJ"<4N\%M,NK/J?'S#N4 *^U-DZE=FNW% (]7
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M[.B"99&L1MFDCF_S 8L:@:'#-ZQ@1QQL<Y2O!(QX?Z0LC90[?"?]50^JX1Z
M'3"? 'B14H&M& S1G-ORH>$HDQ#CIE[+\4IX"&9PP_JQ3T,T9YS#[U^<J\'/
M4E*SKL6-6'X^7#>B\R#[VCYTP#A0\:*\ UE\^CIR3--7&]KR1^73W@8GR^Q(
MXZ(E^K@O<A$K57 LN[K\CFTQCF97NBEX(%>]6="7>Z%H:(&T!11GUCJW"@[?
M91&=A\?9\E_MDMOLX5'&='Z7>&S'F0JGDJKB^]9%J^K--E]*-O>XU$9[[LN
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MM8!*HIN^G!*)K_A[OE"5?US6>81O^O>$H=W?$H9N;@%_,"GI3C_>5V1$^6O
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MX]DB,\0S+@(;H:6U$-62I5!3=#.B*$Q5KL<HZ(DVTSXLM@,4(/51?:*=65J
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MR(M_2!M^1M$#T:'ES[DM%MS(4R:44A^90(#"S8$]R/2OUEI(#,R@8-;Y4"^
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MV>N;#OP%HG&<SNH_Q(4*2  T%M&EL+IO2'WJ:36FIE?0 R^<Z_'W$7TDK-X
MK-%^Q13\Y\?P>!B^)$..,$LR\0V%!13A>(EZY(AIVN+V)/<AK5%T5$0_X,[(
M(Z:IQ0_<\7)!7*S6AM#118>0 W?:S7>*:8/IWIXV:C(ZAX\Z5QVG*)+>7\C8
MI^@)[#U>F6WPU+$_64OU0 YMPT_/@J\>,]O$BR2F/*3_--!LX]',#0ZBQ")C
M YFAWT TT+TVH_JW;381T>C6=ZVRB1\!O397-:;Q70TI_ 'ZBIKTEZ[<C94
M;7TGH>I8B[M-JE> Y3<4L:O),T%J=>CY&A)P5G2;D2F_[N7C.4L5@4.U#V<2
M3I;.'4!FC(EZ1?#))>L3!2AMJX%?6YO ^8I/$&/$UL0U;EC/*[GM'_>RPZ@R
M=+>M"G%UF/PPPM.%T/QUGOR9'>+HA0SKZ67(6P=1B4R?3,I#<^QVSIN-X['(
M;U8ZEV9O]_?$O5J.W!_0'*R>0!+\\448$*V+8MJ]^#Z;"U685W4R$0Z7W[M:
M-@?'!OAN6]EAW3'O\1Y?'E]>@FBD0-GNE@&67%X>&?4L="3@W.\ 8XQTFS6[
M6;:SS['KOM&GWM0W++T!*:G@%,##NCRC$ -BA8::CBOH;_:=F&VWG_O-(B>8
M^%Z1C9^B]?" OP(U4P=VP [F;2*6V9UGB4.-'",'FWRB=RLM(" 1M *FV<AX
M^?(K[6SE 5G=0775207<:E<C*VXR0B(\N2@@W[#B^\^R@(P'/V.O_?Q&\3%,
MW9\'F#Y-@2^!D&2%"6W:YRBU.,SY(\_<)><9,J6N35^UGB8!&-&(>M:\3687
M\XBIG.]IBK&^LGK?J05/.Y0WY[\&JN/;=''YT<7N\BY-518ZME_KCB#\7+JK
M7$] -\$J0!&6EGBG,VH?00)NZUG-G>C!>^23B8T88N4"F YVXRD:'FENE5\X
M>.C"=;O1MHX;5RMJU!KBESC3H+_HW@&AA]8U[^:OJ^3/[#*VNPF=J!7NQ2XM
MOP5-!%V#V]4\A+D6=@;^<MK200O#%RTCMO7S!CW0#9<.E:?15=_M4M[:BAQP
MB<Z*)[2;AD'I.SGYJ7!:><@SOJV73,STNCYP<]D-NKN_$-_@4R+[NL(VV&LF
M1Q$]^?M=]7"*T%0('3A8GN)70LL<S:85/NHS/=3\=F6-?N%')F;F4-N,GT$:
M.::C)("S:>D#/H;88'$4_6N7!>:#'0S_S,'/4A4*^R:=[DU=G<*@GU@3LL#Y
MW.&"S>9(*4$;W[^P[=]\/("P*?;]G<JQ?"EAJUQJI7OQ,B 0E0E2/4TCJ#L5
MXV<P.]L<QOFS1T.=;4(_)(#G_@Q$89X#>(( LP(<6%?Q.;PI\7)>=V/2+;C=
M0E,0@/;T;")JH<A/1![HGGM$AEB,L2X!S\V@=#Z>OE-7E'\A2&>D,1G,$2@
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M\<<G\L$W4Q_'ANQ]%14MI87<Z.#GPR,6!F-2;VE/["N72*T>/>4$E%^!6Y,
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MRJM#T>B2TLOEWZ.A?)_31)GB&_XVXB7J\(Z9P>@TQ?%*\1@2('V9P^&RL?(
M[8V/3!EO*7:(:L/RF_#IQ7MUT:T3JE5E7VU4;GZ^"4E-KN->%6GT0.81!4E
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MTRO]VI6-&SP.F0>B4PS)6^+KO&OUG%A*K4J61U*Y13^:Q+^)0Q0U?MEB8[;
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MWB@WI[560;.2OLS' W84%$+,-[*;=RH"5=I'7 ]P.EGRLI=1R@VX<-XK*64
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M&%/G+O_^X9G%M3_#UE$?$VX,\5A(19I#_+CV!KB[AS0AFLB.0'(0W2W'^]&
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M0NO;9N$Z9&]*&4*0^G/3W7UAUB&BQ /]Q,H<=2YGI>C@6]CK>X,\HNJ+*BH
M.9X0N6% Z&FME;=[AF*OT:V-XQ@HK+:8UES3"YFA&W#?L#R='V4%ED;,G]M
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M!DT%PY2I8HA^&L")/C>M-!X;R%GJS",5/-X/SGJ>GPT\C?MRPOCQ9*5RY4I
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MG].<^%"%P/C]X8J\IKJD /FK*M#</=%Z,8L]K:)YW9('UG8WO-@Z#20Y*6-
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M_X>]]XYKJMO6A1>B=(F B-2H5*5)[P1$*2+%0B_1%^G214)+*$KO"BA(441
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M*$VZ6(\< A&$)XA9K4A2E#0DRY2^KTV2J@TO6!Z9:Y$0NKAE4&LDLF!</ZH
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M5?<5%XJY6?6QXZ0_7?;?3YHKZ_X(./E'6P,F&VH$ Y&-BJB$ $GE8BO"0,C
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M.>@EDLMD920BRVZIN5ZB[G3UG;/RH_MD'5A\UU'T4Z)VR6I6;;75>I;'EXP
M\VUMF0'>L_[*2U$G?:#?0=&Z[]K (W150W45DG]PE7N1RP8_!CY#3,V]#K9
M@[>L,)+2/7DUB&X["UV7Y1%/A5?$DC]4#)[4C:>:>'\I#-^AJBJ.E(1:GOB=
MXIQD73BT^+%#/)M--C[NH0#[.P^HINUCL<[U/Z72D%L4X,%A^3;D(06(*G_D
M=WY$,>^@NP),M9/3T)P%[+W5;0O\6SJ_E]DZ-5<1C4VF"!QV?U^:R%Y/=:!Q
M;:?G82<"]/>AS+;J'_MR'6MR=5.N[L^(Z[.JTIE8;U  3^3D-\2T\ZWA6M3I
M.>M)V(!>8KYV0'H<?K9NY_+K$_=*SSDJ"Z[<]WD=!NIM(AV3LL;7(5,+Z+AY
MJJ/^A/V6!9X@:Q3TAN(2CB=6H!TF!.&\Y%HO;JNO..ZRQV"6F9M"C5'36YY2
MGF.6\"U%_N+S/@UU6I#'623SZMJ(WF%F=\N"B.FSEIBX"R<NA8?ELX;1_#XZ
M@CJ5SQ"?T40="E"1 3W2\8+F@[&&R$.%8.@QBSU"'DEUE00Q"V(NN!MRM.9(
M5:7B_A$-U>RHA/.Y12V5D/6L_+H)'#:3F7#>6SB==F^.79%D\?#MD13$'AN4
MUF(^#VOA=2AN3T^]E IV5P^0$:NT1^J5?L*)S4K"!7<0%Z'4]53C3'PM^KN\
MB\??A"2>@0JM63BDGZ:N.&'R-=0)A,O"H;()-=+)K^<=64@"@7/_&84:--TA
MGJEH@@DF5M!)ST;1T5'Y0L15;60X"GUA#+$J3 VZB 6B^PXB";JK3Z0B!WMI
MDO@O3)@\Y%_^[T(%^)'4/_/35TC4'W!E1V*T.F3VTQ;D"(N\ ^I/O<D$?07H
M$:,]8N&  O ,OOVS@S\[^+.#_WT=W 1SN&%OINE]F'\7TY&>@>XXZ0NR/J9?
M!/6MPB_8Z+UU]Q42$(SU3O(NA>6'HE?)I0O%V_0]Z9+EH^-*,K8V_5C;ZQU+
M&8I7/K4OG]'3T0(7/;:(#:$AD$#=S"Y[1I[7([M]I-B^<7J=!;5H@,>"]_G;
M\=, E@HQ4'3[TF>L!Y $X^WU&;.$<PTC6RL/#=^,5@'>0E0>T]8*O_&\>WKY
MCJQF:;%@29>X[2<&P<J?J)NE[1 7DZFU$"L^LA!VED:AEG>[;.D\UWU_1_"O
M$0IP[6@?.#0DLY>[DR.H2B"P4X E/:*P]03IU Z5\PA3M53],/%-:NI8ZNB6
MXX,(AG6&]T-T17]]13+A9BWRB)F*[A:IK";1\;L63QXVW1VZQX6B .V95-U"
MT%?&4:O2" H0+DU6R+P!N"$ZS<H10_84@ *<@/Y%U:765%6W4F'Y211AW.XL
M30D%8#2GQ@3M8 I 9$3@"OY:2JO'IG_*\:<<?\KQGRF'P!Q6&A_5BM7,;W*.
MD7)J&_*D,H@_=JTKR1=,A$/U,!J@J8R %+=S*7/67S+/C5R _4B,%"_A/BF
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M#&6:@XDN.M47S*O[?O5R"#W^--C??SVA:"9"&9G6<46;_J3%6)-2S K.9/,
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M1<#F__+F+,XL/;SCI,!3GJ2V02I*<B:T!'I)-;^YGO+[35DJRY5Y,7Y0P9$
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M) :DF6@QYK/PB.];M*.P-Q%1\]S873O8K^[I]\CB2_2-&>./JZJ2D[3Z,RZ
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M^,AD7^V,0V82>!OCNSC-9-^():-GUZ4=[._&:<7I^NX=MO*0GM *1WLO#>+
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MF#])5+"V>+O.YUS_PW;G9?Y5P<I1N2VQ6$=5X"D-638)7[PR60X4=X4G"0&
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M:-<VOT6'U$%<R0^4_&5FA*$9/J<+   54QU.N]T_$)2$  .0[<?\>9M620R
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M%O7;$K=[M? UGYL2Y^*YM(9[I53<MEK>RE6,'5/L/:8/U@6[\Z098P+PK-@
MW@'U[.(^, E6FIU 49@R]B 9?+&HO(\R1&$^+!Q5TCL/E1@.G3LW-+?1S%TJ
M<+O235%*^-;SSSP4K[MZ[:JPJY/XE4UE8A0X'54+3U(*>.-?'R,L8E0DU<6O
M('HS6&Q?$?3B#YVH]X+%%YW?BZ"(PKZII JGF6&_GE90< )M;+]FLT/'C&IF
M)GU8IPXP)W)D']<!/A,3&0J\? ,?<ZX5=2D2AM9DRU[0U-SOB3Z@"E8L"L^J
M9G! +]<@+CD@23^+/T;LVJOH)\W9_7@89?*A391L3!1A8E[W(!<9?>NJXD1&
MM/C@BU_LEF(Z[B3.A#PPWA*(%\;[O:6>)0K'74D%IS67DCR3>M])U[D%*9S=
MNGX+\.-N5MAE0LS&"CPIRG/3CM#0FV^7TJJ[:%(5^D;%6K4.63;77"$H%UP2
M>)73B*<JAH4(ZH =H;7J 0R.%52Q7^E'F\V![WQA^?VIV4:2Y[3.1>YOJX&!
MZ.>!OIT,@&<&67HKA[#2N[/1!AZO6Q!U,!#(=/0&W0-[A@7:_7BIJ7F&/X$U
M\6SM3@H !\84PT%MPE!W\N4BAPB#GEP14M.#:C0X^R$HJMUOQ0ZL\CB]5WGD
MZRR=G9F-91#%#,#4K0,FP$UV00B6\O!X5U'B?EZBGI"7D)#CLT)WK=]TA$X5
M3WZ@T-R=IC2!+B$Y#2FEX$KY+0A91IF:#V.FVGO:"S11?= K4/U$E5H]Q0)J
MV?CFQ[-\VMPGA9"=GK-/C3%E0*P-RH,GU8)@O-CP!&H_<FK3KWI"E* EZ@ /
M5Q<GI-GSV A"2*^9V?$YN9S)T[;,?R7!=OF6P$UUJL L-HIZC58PVVT;5'DP
M+]R<<=LX8UG13T;R)>M:HBE/G<T<5&KT(<H=,35IT3A^CM>L:-7BXT+WKRMY
MP1=>O1LLS^QV6ZU_0^&$FM61\12%U8GF9G39K[7GJ*1ZL\CV(+G>M]:!N@;7
MAI<*B^LC9:F"2;A)JB2*8X\',&/^9;M;'>+;:J-#RSURHH+'Z,5;T/ZW(>#O
M"52U*QGA.A::?L,MJ,Q'6,7EUX\Y5X=3M0TX4]5K_\FB=X4(#!%2 ;GJZ<F6
MIV[=^.S\?:L?F[< 1]+!%DWCR*+:VCBS@O)?Q@*7+GB$R0)8(+[48V0N/\+/
MGE#SVV[-Q"MKNV#.+RG&YY,FQU$L:$M6C'J[;T!BF/Q'GU3QR:>E%J_(#^JL
M-*_KM561N;4H7 *6+!!-V!!366L,"ZUT29QJ^ODN1/PWU9-F_/$LG0$HQ^^O
M_L=OK^WX7O)0Z,ZZ97H%<%GH_@]3J:5LTW]GX7$?2.6'T&_M=B+V\7 &H#AK
M<AY$N(U,+U0EBQ):NK0:'N]_&:KG&'!W'%29[5(CMSX5]9<V8LT!GO%,(8/I
M[$@&0#82:W%(0C'1T=1W(X,LCZ!F0H#PJ4[P7KX/@(RF2PA2KL*'#?*8-&4+
MIMY'F8/O@5(D9,D=%)VU-BDBK&RFMUYU?\SBT1":5R[KGM'4N-UC/"19E7*!
M 6#K97J8Q5^,DXYF0ILY .9)GUK8>83@1VVJ@W>1D\CDA1U/V'D&H(:;*9;-
M\9#GJ']9-M_?P*E37RVD@#?_=@D=C;8$_LZ@\B/I%I+8@TDFVXW&#,3$_^V&
MRT0H TP&A;N!GMT'X:5WP>1J"!"\"V';>NR#4[1!M/2KG)^"CM&1=V\6=CVJ
M&(!5PR90GVDHO 4F1EX_KYLOPM]/V])I=6MBR#E1]/3I$P&WWG[FWKHT- 1<
M1E+YDSK:!(EH/$MD:427Z<A^U85'VJ]R%VP3I)^82#^1!U#] 0W+OGN+]--H
M#)C&SP"P,N&H>98J3W1;A'<%$9CNG=(JTF 1(Y$.)96'G&/SMKQ;(0B,NPH4
M[!H"KO)0)24D"'"JH%W7C%U"W2R7K&&BR4VU9G=3L1-.Y@H]-A&_G\K^FJR!
M_^6E!:HR<[KJ@ ]-0R$(IME64BJAPI1;4*WQ^@NY,[VZM^]F>6K84\>]XB]M
MLCSGB^:<W$#A[U'4G.AC"*[-5D6EK[))[K5C[\?>?36[':RN$&QDDQWE+OAB
M[UX<<"16CXD!<88&/@O"5#_YQZ2QH9S[?P6@!TZ7 2A[AH1WN"*5"W"R710[
M#_H/<[G(>R[H@/Q1EK/HZO&4UM+V-AG0)S >468_$!)4L>KX$#$=]2+UE*EL
M;;[&TNZ1(T9W7BYQ%(:YZ2RCC&'J3$R)H01 %4<\&B8E\T]-5S_*X/6^67O*
M(9:[Q&+>.O8T]\B)9T\L@8OHS3^1,6[$1>S8C*_* C*YCL@]8K2L?ER-.+4"
MG,JGA3)_<_+LS  %1-Z;.TJ;^ASQ\MEUA%^LDNX?R57S(%"M'94_O O.TAKN
MM\CEUET;T67W2>$0ZN>NJ(C_%:?3Z[+ETJX3?*0PT(0MPI@JT$^J&6[U"_ C
MU'8*$]=MP_*N;3B.*;Z^8B[G+MU\$?LERR%Y\:Q1\"E+8 #3P5?(!@04&E3[
MJSDCE7H!6^5I*S+^X]J*;5VB0^NG3$'GQI\LLKNJ>TE/X9X!CP,CPFUR00"R
MM(R9J</I*Y2['7%\QQ>K?0G?4P T=>8PF,+D6SE1F8YZB-ISKL>""7<8@#]:
M@DRY(EA*3U",;J R!2#=T.(I?)_R@ %X]QL93'N+NHLX!AM>. E,K<='NXX&
MM*'%$=FE.N<4R^SC=WO1X$O;^J"4\5DJU[,)2#J<9X02,%70K16!"/RV,_ C
MNI;L@3*%8X<7.%&K_D1/&JV>*=/^MN3^2I&+@),,V\CP2*QB@#VJ:;RX-:=X
M+%_FXM>FADLOIE+GK5^O%!7QC,%G1+K:9TH[:+!!G,W:*%7PXN-0CL?R/761
MQ)>]2Z*)[L<U-EZ'(]/^-NU!?.K-*W-RG8WX>K_I2X['T][RR)W/SZ]2VHKL
M1A"<L#-D9=(2[77UHXTU7);YK8Z']7-J0 [=] D6A:(5@%92>O(93-1)O4=D
M7Z;IW\1W@?DK52%\Y+;);@F!3TU.F1^J'ILJ7_MB>^%SSS4QKJFY1O>@U['<
M*-(/6ED;-]22E@_UQ0X(HT7\JRI=#%AG'*]+S>\8!PG$^]\)20!703,IHO3.
MJ S\);=0G(N;;797&_>7U[,*0T82RR1]EM!D]1,?C_<_C]0 8!9'X9CWA2)D
M00+:O)ZP$-\J6^( O=[T2J8Q^V:6R:3%E].R4!^ZZX$&RXTL@=J@G>P])N(?
MX&ZEXBRF?XYVADWR*C5A^RL26NI^2ET:N#P@UKA5&NE\^$%7A:5]8^$$4Q)M
M3^?=SNKJ$;Z  _$ZO#;UC@[2>Q]8-?DP\QK;C9@WQAL0#RJ(:)RD<X_0T#6S
M\.31<#'98VO(])X;R;V!UR#K2/)0SFWTU0T()]2$Z5@V&X67R>AJWR\PC4_U
MA%YDF3E<TKE#*F_HSV?A1QP'D*/)G,Z>:2F4 @PM(^%*1N*A43QFSHC+KNM0
M"C+-.\BVH>;(,]?HX<JQ!0S3SM8'O5@@F)'Q4K0*!1$,SGTDP'%VWCP61 W\
M&KU %>+V+1EJ$^Y^0GM:'2KT(FSWR.P3&F<.4;T#F2R2M]E%,?#._SU0H3N8
MI'JA<E]4Y>( :/!H)X_1#$0B[2@,Q20I,PQ\UAKS-:?5L7G@PZ^<L2OIX1;G
M#-A:;FS-9C;>>^6HUK&N9PN(Y?G&,VV$6U\@O20[DR)W,Y(W+?$:M-F;%;)T
M#4>4)1./$3O>40<T^!133>Y7\V,0F[H8Q-1!=SE1%NVJD>'4]/FYD[?)Q/T9
MJ4+GWN*SX=X/[D[9G.+(BFR7;&$:+1_>5[+Q]X0C-V;NFH@%G_Z?:6DD/P?W
M7)@F68B;\R3K7.4PQ*[.7FR?MOUZ%V[2L1Z])_X-_!^_33EW7+(^4>->^OU$
MU>.9O6]M[G " *N HB/_[LNEPZX<E&NPH:>8J5+"=I*G@^J*J+_2BR6'^*FH
M/@:@B.;UMY&NUW7"0VMR>%=M9?YN>H/PC6"%CDU==P9@"%9/7*K5V6G]W&(J
M6>,1IJE@(97]:UAA4 >I4#UBLNGPYID9?Y_4P97O_\Y0WX@%7'DJYC5BLB3W
M,2W+0A]8!5!+H=1BP%0^5#==8QBOBDH6F8U0F\':FNRE1L.UR&\9@,*$9'LG
M\4]+C\Y:"&XK,B=Q-MF"Y)**"SB5FO%GW;_J!@.P /9<(P\!E\8%28/XH\Q+
MVHE)7;H2&ZZ$6W]/K^S->9AHNFG8E&29;FR5S*'0SGUK1'38''KSJM754U?^
M&QRY_BZFHT&\_GH\Y'B<:\T'!J!3'5NE-(J_#?>.RU,O^ERV@^O%H"YJSWI)
M?EC? 1]?+<=9"*XVW_Q\Y=+"?)?/R/D^RQVY+-U>+U:9%,HBZ273(0(C?#%V
M'2#^B.6N7I'JTO#BJB8SLX*(7$V=_N1WFI*%;$_H@@3=_]8\QF9 HB=4T;5W
MX.6[7[<RA5R++K,@)MI(S)"-R2\\1;Y$\.R14/U,S*TJF_,B;5P):Q BRIG<
M3'XI%:QWL*8/0M3]JTXTKK\)_21-<BI1MCUJY:^8^P25+EEK$,DCY9:)@.LK
M;U\IN'O3'XKOW>)'#F2F  @SYY%#VRD@PDTX!YD#,_A4QS=@T=QU?>/&\(=Q
MO@DSKSAM*<-./LT.20&6/XO_RY5]P5&J-CF\ FI&%'"TS1$&1T4G ?OC='9^
MP)^OFP.4NU!)40W=*%[#$N_;\'K=_OC?'1*1'N!OH3)M!'(X8=N4[(F=JJN2
M4R:5-@7J]"VA%=!_N&-O$S:P$]F$P:X:;\<[$+Q%,"8RN^^90\:..*#Z7>R)
M/_RD-L+Q$:CI UR!/6G6Q^U;TXP&?Q&& 6A_#E],;&NIML;EQ4F2$S NUM?O
MMCT:WOX21F?/>P%^V4&2B05KE94K*?ZN;<QESWR7+W-^M>NHO=C)?YP+\&^?
M5$9U!D<6BHQ:T"[:4!/!)8$0@:4YW'%ARI=^!N"M:E@A:_8/PIO'>YRH[$_5
M'+B;!=3;9^A+)J@/\"IHX3$U]$ 8:AFN'V3N[R_0U?]G'$R387ZL_[:AX'[2
M+OE?,OP=DIKUNMT$*6RX;E*=3^&VT5>'E[& PRRY$P?P:>5V$.$Y>23@Y"]T
M<[\Q9,Y?3+7KB##]SVD]M!\@QIRPW3$4 >S(MTTZ-DJRU\\U!&U(Z[3 %"RP
M*:NK_[1I]AV1.:,>P@8NBD*_#*@,)T,./8:WJ5\:?D.4)INI[.32#]-K*A$6
MW2IHP=<%"76CKXWK=YME=1]+/;<0RURSW4=.!SHO7)E1:A"Q-PF7"N?-=;=>
M;:<NE  B#IY .:HB<+XO'_E>#95N!F;>3'G)A@GNYF0 $L) [&U\J!0=[QBW
MJK.)LR:2^.?R<0X[^AG!A5IJ)KHU6[K7-%NU*5IDJW6V%G/C;N$SX-Q "8]>
M83F])3>IG>A"4Z0.F9=X;J&+?G&, ?CBSW;)%W0ESTI,[L?IET)[P)"0V7.Q
MVH-"4!]FGEGH+_(2X;0V]=TQ^YW)9C+_^H)"3%2,;QJXSBY5Q^"CP[1#CV=I
MZM.1LTO770V:8GOM,Q=&FA')H-H?;?+$HS_KW_GD#J.A\]$]@=QSZ*SOW[FO
M;HQ^M1IN S$G>_%:-?F]?:KE^%E1_$/%R3=S+R]HNJW> E#3 =ZP<=".DA=B
MG[1P>/0![#MXH]6"CF_8S6T >WV#-]!%UQR_%NTJ9D6L**Z))>N#7]TF3X#^
M5<T>W<K41)*3R7_540@SPSA^@3$3?]]M @- "PN@L52(HE$[NA&I]$X[\*%J
MA2<&2<WY^Y#"I,??GIRQ6@S 3#;=./TRO8/IE._=JW>[^VE-E"N=$PO@O \S
M6?R(_9L%#(!B^A\[(,4*_HWX 3ZE"=][F!.  ?>8@\T^Y77.4,L%GY2T#5R9
MVID,"^]=^225Q;Z873C&@MW'@S\/5&8L<CDN^>^\K]F9?:8R<A9TR%+UQI?D
M8C:@/_AN(ZCKPX]PA9!>Y]Y22B7/#]W+&>4;+@==+O)=;:RM<';O/'C ^ _%
MZ.B+O<$E)X^AYRA4Y7M944NQT#EB"/T&)!FU@4>51'MV;_]1][M,_ZH SK)[
M2G5F"KD\G/(A)6#-=9JH33>?O<D (,UXEEZP&)!L6M/KJF"3D@.F[_+$"7<R
M:+FMDCVY5MYMY\?Q#SBE$K?N:#<35O)_D>T65\B1N#+DM*/3:;N^YJ=1+V0U
M)3"Q\$OS7VM[$2>N@-,4VLX12#6<=M;G^9K3B7V/'S>ROKA[D6>T! #=Q\PZ
M*+>ZO'/J:?F111(4C<IX'4*VJZ6/,P ;.LI[34RSVY1CP8G-PAW19:%5T39F
M>)LI T\VWP;.!>7OQ;\S=", _ [P>OCA( =-"4[* :ACDCKQ(#IO'C$\^=VS
M=:[/IIR7E587GZF$F_13C>4B=.Y&$_ 0TCLSV^@8'OTTI[>S8GDJ?FQA>H[/
MP-L?1\G".+QD-S/D=#2_V. :,O7K]L?>))K84Y\P "=_&>D^KH[:(-F-V^XG
M?*GWF(C\XWHG-%MBG>4TU8LU&LO3,\@'-2 .U[?Y1CPBX]U?%=4G<3R_<\0^
M:\YIHG6#Q/2^K)(R^.0I^)X]TIX,!\6W"6[8MHG7CR56X;AN6,A%OVP_IW/$
MYA:W '_OK^SL09_=@!DGL]Q!')_+9_KRSH2:$3[G>^;^*=#+(IZK9*8\D?*T
M8P"J&R"'%WQ7(-QSTAG)5_J?FO :A JD6=P$LDVBZ -:\X@8K*Y%U^C/U##/
M2)VL*<^GPW=R]CN &FN9SL(]J'A>JOH(/I0CYH;9JK\2IZA[\@6+%Y^6)&!K
MF^=99^F7(RBVY/!W]NM:#^JKOIL%+9F1BCTX<J1-9KHHI7O(LPQ XGNB,8VU
M+H.RSU3+8M6#V(5N10Z<9[QQ@HZYBB'\MP)P(!#EQ2KJ<HH!.-6^..99&,^]
M2[)IIGA39% \4_V!'K%_4K0Y6>/@<@#D!_I0H?;$^U=[# #W](*4QJ[CS,_(
M(YX:<TD:/WD@-W9X^'TF'5>25;FND00;6AI?%><*6+T]56C$+A6R 3&9\W45
MH2&@9Y4*W +S#L<0X"S[T]+/TX"!>CB6V=FT+'-H1VB(XN\?#?Q-6=[.W[;F
M')[VR1*+CG^,T3MT43N<V3DVK=N:JN"W^OTJ<%?PJ #+7BE:D3."TJ7'._%H
M_]?DY9X3BUE"&*ZFPXNLQ,J F0"K5(M:PD*28IO]W;2?;GLV$L[PHJ@-!L#S
MS7UE7JAVAD43AT*^R\_VJC[6P"PU*K<^ Q#6:K&8VT+[2KQL^\!OV/%BG85?
M/"=X^^L8RSJ*[RP\&7YDS\]5\/*\P=*-V4B%E0,K%@;@B"95#H4V>T* = X
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M3-;(8AL>^)?TE!W(2H<@Y!P[;G^OKR+@H4R6O3RWV/P1=?R"W$ALGE]Z( 7
M#;7PHR%M)5J?+^ZORK9A'L,];=40M\E;&[!VXY:_-0ZO3-/BZ#-MYKYGU3:$
M,IR:68AOD1>"CM;,<%IU%/BE;OD)F%J[OK6\I=Y*0UQCBIC-"P[AW"K-^$C2
M+^G"\<#;Q'*2;S%HI;\?V3BX>X,"^-W69)N&Q_WV*P71_$7GD^WEC^<(9-X@
M'<-+S5[&;LYMO,Y3/-IH1]"<VWV--4'0GMBY#1-!?+&BH0#/^]'2<BFG-H<J
M'DDL=L_E]F^DD ^/-KUPV1#Y5U/.CR84TH$AXL3DB_,J-C%&AM @F3L1@-&#
M+Z;A#Y[\R4IB7CFR^=Y&V#7 PRVLJ$/T(NFD48)VTOB/US]B="_W2$_\A1OR
M$6I[@2Y_:N_!O[;WY\>%&/?2A[;;XJ6"U<C-:XOZ/T6.7SQB'EF($KS2+Y;8
M[=\094*VSZ9VBH8__E-Q28GS:?.#DTCO 1M>T]<19-.B>W]:O"/%;/?OQ6GS
M1<#'3D]=NO)Y*[Y%@JIU*,90![/JXA_UF'QUYH>8?%=R^258K\R-".!.1[C
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M\Y3RD[SE++GQA<0O=3[DL\8I"ICXEOWSS1JSH4J.-J$")NCHJ^<OMAC0 ZS
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M)O1J")WM;'#:?+PY%(20@(3+[C\>J_HVL9J<I22FL+5PU:.&-N&2'U_B, *
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MS(@&0_1D+8*HN1Y"LJI1];,5HC[[Y[[Y83XRO&;2TI "T.F5P698[ G3$ K
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MWE3+B/ UW&/%UAB/BD[BGR^$K,"S_@:_\7?E54'EO9[]7,"_YXX \7U7XU.
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ML)%9EJNPH>L;YC)#_YO!?M&G;RZKP?[OU* JG6Z*!+?.D@JH5?V\@/ZO"*A
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MRP4IAB][VO0A%B>.OJD^^RT4S?/SD!\_JH&^\I_>C?0_\:&O004@?QB\MZ,
MEYZC21R?R_1MJ<<NUE7'KH_?X4DG\=HSL&#0!W@N+D17801.F@*$Q>*MP8D/
MT"&H+Z044N.<?OBC"H\+-O*Y:"1QXP"W^5QU##K6E-JCDXUX!Q7L);=3@ 1$
M$'$C"?F,.*0#:TS[3!XE)G:BOT+"(5V0F<DI"G"7N[Z6?,,*-=IE0P&<X>?L
M8-^#JB-P%20Y(J*7YNTT-"I2:%YJ80JG/B'V1RS!G/R"#,5NZIA#?E)F)G%B
MJ!,"%J22,BC 60H P6^8(-:/' A%QP;\T@:: QWK&:  @ *HS$ CK+'\'Y1Q
M3$2-CJQ2)@@3-'\+3P$^T%L.(XZUA).X[%9$ZI+;%DT$<'#+:7]EA*KQ@I*+
MTQ&V%,!I!98?-3JY!A;Q';YD!R\SB6NU'2A2?049N ,5GRL!*:U;940V!<A?
MT<59?V($$TM@&4-DP3T[6Q\$6R-W7[M<EMVQP;Q(J6E[$-F3 I0T)VA5:.UQ
MM3^'A1=ZQ(Q?8!R+S'Z4NJ4NOI@YE(]+"3(BSV#VFI-YQYGK61Z/AKCUI/R$
MOJ/;Y7!3")\?!D0Y_$-XDZM:I:]&*]^U%\+1FW4A<WVCB"$D >EDT_SBF-,)
M^0_9BHR@ENU#:K%J/"ZATAO"'P_NOKW;0V"V'V&+6+#?&ER/X?E0=)R@P'(3
ME1)[:Z'YDS%!&/ME(NJ&F$G[&U5QN3^ABXLX_ .<I,Y/;B6/+"_=UT98$R_3
M:ICK8T+SRFM@/C.3#C1J$(P)R*65<5&#-4DR(6Q6K<=U*]08AQ\T&['"I[1$
M.(D'E(Y:D=[O1PX9C27HK^#8*R/4F'1 [U]>G]P8-(*LZ+X)FXMA[A5"[L!'
M=K5JB)S@Y?9XU/XA]"CB_&B)%P8?-O6SE]4/80GC_H*W+&WMSC2T81#X(?;J
MT^80Y'#A.:P' =M>V2_1@3N@,R3?ZB?43 $L49V<9="WB*"+4WP^(]/[/3*^
M<9C4GF)M&.'=>Y,G-$U&[]MVFC3->->43*W#,>B7]O<07/(BA!.NM,UEBBP%
MT_L17[\:5A^/KKYF$1-^AZ%]YI+GT9VWN5PS:Z-@PDGCXR";S6&U9#N0!4$_
M)$:+RAT-U>96/W)H8BQ!;\5F:]!F9QU2TH+--R!U\;P(M<?+UW/TPY_ )>KD
M)[<L+I$,_7"U'SG,*IZ4L#PA')S0HO/K.H"9Q*>CBD,NT%R)D )IYVM<=<VD
M/X-4AG0BOE SP'YBNZ[^S*M5UVV@ W@S(:R7UG*O[S0,7-T )G06>F$I=YV<
M2XM!QW/PDYM65,KQ(S\&C=)8,&H0&EFM3@[G7W7]#KRV6G6=+#1_'O0HL06/
M"B;;@"P9^<$Z84LJM#3ISZ"4Q3"0Y7Y^U)B9'S0+L:Q 8AQJ[/+JAH08M"H%
MZ'T)P6I1@(D>C-C#GAW./3/0R %C[&PR(NE[F]0WJ%>2:\77H8BA2M@GVEF!
M\P%6TZ=\WH![O?&V7V>@=8<$YJ1XO+Y1VT7KF:_<%$#;V]A<S=;F1^*U39[G
MN!U4N6>?[;43]GL0__7!^?/L!Z/OTI+T2=&*;*ABF#>'XL,#6UI,X6WPDJ2\
MX(TE/5:=R%/,A1QFC>T_IG?<^/!1O<W^U5P0N%]/EB%FA,<A>+'%-R R]_A1
M@%'#5B@61GVY(2Q=0E__L[[31W(/DDB N5%_&O%OIYS3F57^ LT=H?[RI!NN
M2 &*"Z9@)#K9"C+=T.(K%+UO]:/G65R01%;JVQ';)IB9BEZCGRY.H:9XFH$1
MHA":F0(TO'T#$ENT\+9$?;@0!7AE;D@!/KJCB9KPCXVJ+6W3-#@B!1A9R/U$
M]V5DR:!%Y,9E;6V7M$6UR_+/1Y(O+I@#+C<D"(%-(^I3@!/EX/;B.;?PZD93
M/(KL'0 6,UM^4'\30]BN#-&#U4*ZIBD $MP--DU-+MELT(I8M-G0Z+5_HI4^
MW=;X2TX)GVH*+[_SCKD<%Y*W%1C8-SUAB[M:I$<J4F0!F5#J+826/]'^7MAH
M7%D@*&.K?WT[!7"L)!XT[WR;Y#WH'VIY@546-QNK[I )M_R0I:/L -'^6^/^
MG]>X"UBS]M[FVOXE/X,V9.?FBM65E@@K6$=BL-:T:FDU_%=_#!G$SIWR<&I*
M<S^2>=?U@IN?6ZAX2([>_3>%YMI7@X6Z3S(YL7@.5/H?D*3QBKJ5AGD9)'<[
M\_#50H8JD:HB9&U6<;L07P_7L?[$[ %KW/"09>"=F@_%5E\5K;Z5E35^?&+[
MFM[VWI4 R)X@H]=M*BRRCU!,;4[B6W.N#'F,;W4Y>/2**??G5\Z!MDG%[YU4
MY@0PLXE]L(EP\6HC!24#IH"V?5Y?FH0%S"&=HB&'IAO?9ZL.<68<B&4H_"C>
M7?GMYK#X/CZXW#F6@[O9GW9_21OWP <+;'BH&+ZEKODK\YDP#@>_.[2A%R+.
M/>L\=D(PS="<#=@U0P%RX@/-<[H$]^YIXI.I4 \-^A+)'X-6@D)HE\]U_PL^
M4-$B*0I0=7G5PP)35'G/G+ 9V)Q>UT,.L.FWI<G_=1]/5XKJT_06I  *,#BF
MR(%HORPV#GMW'F],X 2!FMPEP'FEL%:T<\J0$Z*_HJ$[^J,RD[ZGU7_[\@7F
M'Y.8^(4"S<=SOGNE0.L",GKVC6VNH !*B+Y1U[%99N94V=!XWF,*IS[7CZB6
M1G-^EH>@8*.17^]W7DTU%U)RLK[Q_,K#"FW5N7JC.E3'9)<&3J2) ECOW#);
MR+"O67%?>YF_;<[<JK*O8:IYJF8UT/P2D(/W,M \453PV-.O]I_W_@@2P+5-
M<!+<H"5NPG NXJDB:_F#@R?CQZ5WJ#55]2KOIP#1W+YD,*_F_X2>BPD_%' P
MH/7TEZWZ>L$?9O;-ZT_?@]TD?T3GAA&E0BOZ>DHU<&'%9T_)FKV5NS)V!7L@
M&#EW::EF_%1QT0UU(;0M6?3H:/UG(X$0]3"54)7Q@]<W"2557ERH&J=]/OXW
M/Y WLYN:[H5XHZU0&TQ6BBO^Z8FKY9M#PN91*GLA]FHQR4<=;72^T(.;Q\#D
M!S$F\J<BA7QL_</4PBN9+0?T!F$GH[;S0.MN)_6V/=>?V0!6:_\:L#0HJ =X
MKT>0Q<^/E"@>RID-K=%^J!7BL<OAX",*(/DMP6MRENV,45J^Q=3>'P$/T?]1
M,8?KZ855P.C@#=$;LZ:TO-.(E;"?MR[<".;+?,YN%6]6>E.![>(C+UA]V6W$
MQ#3AI&L"SGYJ@OL@]@OYBEB.PDF-9P\\R7L'8P-+KX0[5B.U3Q\2VY:29D54
M8C<@$6+>3_?J+X)O6 6NNP2NTQ!8$;N#(=BV87QHB)6U1N33W9BE6S__;WZ$
MICG)M!LHP&8*0*XC-^%?8"LTP7UU+DT236^4,!^-<;H>BY>->.31;0@W\2;)
MQ.3&&IVSJ&.0=)I['8,^#5U=/E& ?U4_U<W/&YV/-9)O/&+S44V9.='S3S=7
MN6<)[$01"(.BJ''/UY)A:T4('4*Q+]S:B? 8>F%+8>E5M+I0&06X@O9&8]_
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MMW5@1^'M/;E\OF!%B!>>*6\2=5?JQZBW?^DP2/J1VJ10MCFTVNE>OE;UR[#
MFX,<WZ%7Q/SF>RKH.WJ*X<>F=N=HFNL33,)XHZX>T^;]TAB3''IVXX% -3[V
M@Y%G]^B,W-DPX:RC#'IOT152!OJZ%CVY"FLX%A!G@O<JZPS/R,_,T!LRCKOC
MMYWW\<BF&\AP);Z]F$K)+_!*&/,L.A#R%GV?Z-B__UID.0J7?TCC6*W#2XW\
M6.7S!Z,V*^\-/7M433+V_F.W[F*%0#_^-^4KI]/A'@A\@ZLQS@_+7._CKFDW
MSOODU9X@Q?)K%]78H<DSES[B9B(%8_E8Z[@^D!%%BL2-4UH3XP/COVYS*RK/
MR'P(%2>V)4?3HY>.3JS_X=$)]^^.3FSJ4H=(T0@K>R;PM*#@!1YFD;7>N(I$
M:Z<CN\$3VV/']D#UO"&MQ(.0KJ![,"YWZMWOK7^X^ZUZ0H[[T6$5)=1(=R$4
MYT9Z!8J7QL_3[W&]CCC*VL7]*KZV5,ECUPV=BLLR@@/ABB^#SY@QZ)LTXGU9
MS7_^\)M&_T?@IU 1CTU@PKG4J(G[YZ=P0E.^N#!2OJ*,*Q_N+O[A2ROD;C%A
M"0]QT_=96=D:&E<93H5F)GLV[G$ OJFE)C6YF 8_SR H*)]O>GTG0/23(:=S
M$*VX=)+@=DF;#+;?OTCISDL!MNCB/P\@O12Y\&Y03W=-C[Y\U/?)/6,3!@+A
M.@<$=RF-&I!='/RC'FL'%5BA0BA [U,*P$0TG+J#\_B<C6*WS87O_WQYBKDL
MV=3LL*7!D^X.3P<:H !2VM;&I"X?ZF@.VO=GV]!'T+TOH5BMR?_@@-8<*60C
M&:]BTLBH#XTT$IKQ(M-N C<4\L*Y$(DM <^%)^?27-"[.G\[%Q*[47'Q%R1C
MZQA9WH!>?&W?FDI]-JC#M\\:GSKEI)Z1YUO7=$VK:_*'HMZ>W2<@/]N32=L5
M4JK&9RQQ/'AC"K -6IS=EM;7D>SZ(+7QB^*5'/;=J'XZ:&-%O+T*=Q-8H5D\
MG$_CJKH^H]HHH:-\AV^X[[<;$,QCW QX\3MOC"MN)9_I="D(J*%-L[CTS:F8
M+*/XN=Z808N>VR:PXBQDISZSJ/J1 OENOY]X.)WK]8.T52Y'R--U7O,;3"8#
MBKCP6L7SMJ::+F[V0E>4:4^_N6)_?-O89+10?4*D=A+OMH1;@[>SCYIH\LN&
MV=34_A#DGW>.*?3Z>-C=K9<@]H![9ZN\3.*C3IL+=9NDCFJ'_,C[>6&#;Q[S
M'&.__:YNO&JIT9.'B66#/=8_Z>V.WOSR1HFG9>\5[EX_TF.4%P6PG_1&M),/
M-;N[6.P2<3DN/.D7N*58K+*"-,A& 7+@LQ_]$^JX71KF3<(8)[Z]V]-I?!MY
M$#S:N/%]63[*T4P@B'L"S>T)?&;56]5MVU*#XK0CYZ;)D/T#D'F^VQ#R5DTR
M,UA38=71<Q(>JN22B)YY00ZB$^KHBV/G4O2>P?14.D^3A+!H(LN%<<()IBE(
MR3%-_\-[ZN*_W5?WDL^,K? Y-F$(S\9 V1&6/>!I7%O,"XF-)BK8RD%93C^Z
MEGW?ORID6*O0]K97D8/TWLPA0S4]'Z(MJ@C=&XS8@W)&/.(^A#UYNBY^W.A2
MD4&-0\1NV;O'?ZI!% OTFY)3F37OJ!M)')R,5=SU6:*@D%[O?3,*,YA5]/89
MYKO(D(F\+@^SQ:5VSVU0]238>0KP4?/]=AI/A"UL=YV-/Q/';&I..H_.7:Z6
MBOWS62%RD)NH)#(3N5@1P'<1./ LTUH-=A)@4#$8UMSJYW7;4;6M8&O?9PUF
MT4OZVE(#!YW'C66G'O%(MPC#+S3ICV,^D+SEA9C;2KHJB?MYNU]P?G24QS6]
MGQC=YF"/FSZD1,B<[36_9Z8,1LI74C2<B>B*G2PUU2\MHLUIZ<UI_2S1?GWD
M<79JP7X+_QMY7^_="PMUU)GUKA[L_^QK/@WW:YR2S+I@QO/9KE=+E.WZ4,!N
MY_.[CD/"[TP2&7_VH7S@PN1F#C%?>>.XDM31L(YN-=ZHB>HW571'HY)H/,5;
MW_'RLN4?@1S3@6D@/IY49,/#^B 8WD37.\4<\K+<_MPOK(]V'J^MYFH6OE$:
MK55X6W6"E;"EW=VU251QO_N):%NQ#9V54\:&%?OOS6X-(IEG(3_21B4)WCA]
M*;S3:=>;<PJQ[3='W4^JP9*,)BMZVLT_OLOJ9O;MZT:F&ITJWR[IS[51[JF2
MV7;67<7Z$,PAIQ;&CZCC>#W"!O<-4T'^Z+Y+KH;"1&-LEU$SU\7&X;PGIS'7
MW[=7NB(='*0>,L<&?[] C&!]J*/_V(@.$IBE'T]NYF9K(K(23KB?:G#6D&B>
M"9 V>9>=E?TH-.-4YN[D[0=[Z?7,K$VMOYHHJ>F>W!&AI[KC2%9FY<<]$KJU
MM6<!P.5@VS>MXJ!V^UX*,%&!#80\0&8=S)D/?-/X)BBA6X[36-^ENDN5ULE1
M2CQJ\,K>':+3X>K)D2WT-8(DQPP*\%@IE^1_ S%FKL]C.4 !VGUQP>\IP/W]
M\CRL=[/I2G"V.R]:.X[!"GFVU4B<T9<9/<3&!WB%F+5-I?2=0VY&]$:9"6$E
MWGE^2XT9;3J>^Y#]D?KK\=L9)E%<;XX>=7"J2A/,EHG2NW!+F6=*)32'R-C[
MU;R?S]\9N=.*Q3[15C:^VJBS*T'_YC%V!8!+31[8+D]+4DHGA5'?]-X>T8=#
MHMQMHGO*NOG>L1E\#Q]6LP#L UL;+LJ*ZHOM4W@HD"?BTI*8U'&]@V^(BWD^
MH0_ZL">#'L.:HMQ'@]T9X86R-Z[,RGO7%-OD7B4KVH%!TE:DWSCJ<%CMXYPX
MKI_D-XFV@#(:=H]%Z(US;_D\>"6]*&_3I]S'.YZ[/0!8NJK3-SGL_-!I8VZH
M;I)J&%A1,Q,^KT]@)G]"@^6R#7T'U#3G>?&3W>ZGFY5;G\Y_>*(C6#MJUCJ8
MZ)$W%W[[QF4;XI<69\(+/NUW&>^]4U$B%E97?91\ EHP%HJ]GH(#.FIY. 8S
MO_D@\O8V@OP8,HNUXI5]O\(Q&S/&1F&+HA:[0>$D<8:A$@9!)?:;/1\'3WU^
M2+AM7;016X]A>.,*ZVN]9_UR-!KB(T?GG77+4:&]IK:T@#%<E*?BC65KD%7^
M'##7'8H^@["$X?E&2NI](+1Z_4@,LW,.]BG+A%6NTWN65IT<^0S%6ODP*94#
M-)XWP\T_M.207D,OO;A-=(4/]'FGO;@XJ$Q"\?GL]Y-G#.B^<LV2;?S%R]:S
M[PJ&- ,KACY[R("QWTP!PMKP+A3 48PD]54_#=X%2]]UKQ>R,<@?0H/BU,.>
M/&!B9EWEB(O/]:ZO<;0757-U8]]AD';K.H^<NS]Y>P(%X,O CI#[8?-V[V+.
M,ZOK.DZ4)/4@/II"!\><*0"!)14ZXU'FK@&S6]]F02ZF .D2/5FUTMPB4^=G
MRQ_VRLD0[Q/X=1P3J_-$']1N.V5R%T9S$+/7\X)UU8G0&[L2*B3TO]UZ !>#
MET VNU2]%[?MI8.PJ%WKN9I7^+9)[]Q#-A=%CU*DHER61?Z8/E&+P$H$2!E%
M'*:NN;WGAU ^V:,?-\KICMF/F!_@3+E0Y7NL+UC,M-VQ3.SZDTS_T\)P[4:C
M:'[LIZ1>-,.WV[NR+0\A4\9R]QB9=E8K6L6K"%9[N'&I;D6;9"/Q?%K%R(>0
M;46<9M;S%@E>AY\8)3QP\7>+TE)(:'\1'Z#Q]@!+>.SETDLG,C!><=_*7Z!:
M1)RFAOU(L@6D5]!+:-_;L:XG:OK<X0>:4]N[JE"J,25WV/?UID>[N8^PU]>^
M',E1MH1_AJ1KE?1PN$,B!N@_T#T8;![(L3OA<>B3?F3G]Z]N(2]W/@D\57+]
M 05P3J2M\>+N,!4XE,8"E;1*Z^DU\[W4'Q2 IL^RT^VPEZA3+97UB/]<$,IB
M<"4_@&N7S$==5>[L^?"I%/)V E:H1%$L9ZKM01GR'IQY5/8ZYD1Y9_\YZ9\J
M>G<Q3QP*;M[-('XWV%)QYX5!L_7A##Q)#98*W4$6()="F.0U+; 4X P>$==A
M JO.N:!O%'TWW?\9Y] IXT?/F)_V;AQ2.^@4*O0"?P_T-!16WQ=^N+[?&,T
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M%BJ:%3IO:T91K0HT.!G2"PIP&>F3H\B/Q[C8]J/V?'FT[?JM&KI:0&1G:O)
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M6/XIFH?1&L]3$JR<OQYJX_:8^'#E7C0S#>?_P]Q[1S7U;EVC04 $I$LO$4%
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M*$<G%.N*0B><A#&;\]M/[F_=>FNN<HFG0PW.?IEX[ _^V@NB"'CBJCY3:[%
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MK@Q:I8&#CD(@&(CF7+RR=3TI\Z'B[EIGR9RGX[G?O0LUOA<& #F)&%F)O<,
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M&V(UM+*[#HY==5+9#W$Y\!?<78T93[&S2%.[,=R[F!!#E:0O\DM8$PA6#JM
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M'Y-ODP:)--)9L@I$\T,3HKPG2N!;/C>DOLQ'\9E%IX&JJ71-*JY#2)Q3I0'
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MW3*,)$Z]F6&?*VL\372Y,XXV:+A.O@'M!%9%QN9-0HS-2?H4$R^)OO&8+J]
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M7MAQ_Z*\F#S>0]-!Z>7D6PW\>$'6HK$%T'<0(S&2%(^EWL'1T%3T@[P59:\
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M@2FR?']#)\W_QB::H<W;\(0MV9<<H,0M5YX@PCN@D"L1G4X>\<TO.H3K]O\
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MYK/?"];J X&)M09/RY:],&-F3%_I6OCS\\P'WDG'BON-K&%,3(YIY4Y*WY=
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MP3G;BY/VT".9CZD%&Q*JJ_6Y^M8U+F7Q\2>.^7<-6JJMF8/)?WM&0_> 7RX
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MH_A5)S00M(27OP 4.L)%LGVN7EX U;S499<+P)]<^T@$]OPRRAP3!R4,@Z[
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M?/VXH\O]IGDE^FW=F>^S=EC(L32\Y3D+[9#JS"%*BV<_-[M;?#M7,F$-==>
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MW''_8#!@[[5V]MK/FL^<.VNN1^]4JFJT5(G@5V.3\P4N'S5/[UR(P#$#T72
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M81<7_W2P2RM-.<)N_!FWT:6*^%\K-WJC;>-7XZQ?G-J L,'U&8!L##<FHCJ
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MHW_ U>Z0H3H/B97DJYOPOV4/CT@"A,5% =3^EAX^OLS98V&+G<U)6X5L;J^
MU"HFWWS4VWG6H"/RPG*RI!#K!'+^,[ "UK+#05&I(>:UE8!O#>]#I6M+=OS#
MI*U,7M5%W;+^84/INK8^C=AF8EEZ[-8(/N"CIE" 9*O@B$X-X!LM<^0"U=JT
M)FJ[=Z[3Q<7OG)OM^]? %G@6^L]0<R*I@/&)^DE @HE>Y9B6#S'4GG"0$>!?
M?6_&P?YVZXJK&\>K6\_%11:91=+WW"4*-R1_@_4&D?,)?RMY4%P)J(XLMI%M
MIV7*U2">2:6X5!/[%TNWM5/OY.BTZ6HP/:!I(%OE2YME*.ZCB L;(%[+/:K%
M??L2@Z%5L]VLN8'K8@\L0HIU;-Y=2KWWSX 9=) 1KM@7('8:#QA?XKZ ZN@D
M1?)G<S8UK><00).!:8]GRBC?[67;F3Z*^&-^<44#A>!!9%_$(+^8: 8DJ5U_
MK.K=<&68G(?MT^)'(2H&6X)J[M-1;JUN6J=/,[VS2+$U/O-= _B(@B0YD[F#
M@0N(ANR;80O37.?T76],F&:O)^-PA@'?CD(I-0EHM! W9ZUV)#R/,3S8L5(E
MS+1T&_^W[SUBN=!\.[.BP0$[D^NLT_Y2B$_68X=T ,$$_ K$1A,,3NMHOCH>
M@.&>7=,P_;G8YZ,Q.?5///_#-K4NXG<1(2YGB @C!)44Z #.$L(?T.R(#V,^
M;*37UM;[5<!&--#W_EJ6I->M?((E%W[FT,PR0D32?U(\O=VNS3FP(R=9C'UF
MMD!MUQ@L!+PI/@]\ V'SHDG ;PVQOI4<D_R@-*L3DBF[-1]M\*;A6LK,YIKD
MG,1)CI?)Z0R249XEG#Z-7WW1J&M.ZP_]W!1>?69V8$8S0=-=@'D/4X*<?Z^C
M-:QE3Y8@08VKZN)-3=J''6T@TT6<1$4'(YG'\9^4?.6X?(4'QKQJ%X;?'*.Y
MD*TFH,=<IQ']Y[NC**;S4/=AN'II9?7P6IRB<74-&]_+N(^I4^M&K9(GS=0N
M<'UA4#SD[AU*&$,0?F=(R4PH%XWCZN+/Z\&0%K'3)F^6QLX?.-K9")S\$NFB
M(*[ZR2VH&Y,:)NU'8V-,*@E4-^Y !$4'&(U]S%E^W1@Y0CWU)5KZE\R_OVC[
MN]/A_]Y6E]_9L]OMS87" 1MER1K!_ZQVT"3K]N/[P&]0.L=/'QL*TKP&#25Q
M1('_D[D.];<+"[(^Z7BU8^[*O[M 7^H263(4!!4%N/0<_+$[?BK'=\]AB!3K
M*AWY/&]SE:Q.RCMX1US2$2/LZ9CFV#\>";"]]U[&67)'M4CD[+_==T&;#'I%
MRO[7:4 "Y0J'6G5/_OK0Y^NVM\!S,"LUS?_NOO,AZ,V_CF0P.3J :9)DW5:-
MT*^$:'>._ __7;S.BX>GF0RD>?/E;"@W!6? C S 3)$E@TAGAMOF^"IVO;*/
MMI\M ?I#5  >KL\VD1>N_P/ W&3@_0>CGMGMIWQ_)"F\7_!0V$0-7NB5;UNK
M4!,O;CJ"!HP+4W7R()O Y9,702T0D> ;@)+00H_RRY\2%A!#[Y-.9[7_N+WR
M4?1K!O-N#>W492\H:,M6<T;ERNOV\21[+ENM[P]0Y 7T+F9RB@8'N7'%ID$J
M0%LG/P47[@Z9GT'['MA597SFY@CZX5<Z_#V Y9L(_#O3#J1ICIGT<J'_+4V@
MG B,#(AQ]--O=!R8G=)9UBDTM'0>* +<G'\!Q? )_/PY\#Z]OH-_W$Y_3S6'
M0_V"?T:0:>0=V+ R91O1[V<")>O"E5-'4M-!/&LE H_NU*/XR*+D8-IH.FL+
M\%7Z2B*L8-ID<=:S9\M_5M;>OZPXPL5!#>AC:<(W>_A!5V@5^ %$,,.^"D+R
M83UA[,:IRWM8SA_*TVMOCES.)C@#K3+Z!/=F0L\W:BSG7=5^N1W&"-63#,*=
M!"'\H;4S\LOOZ*._I7@;R,(DV$%\_3C%?+$#?8_0]?J:K;V'CX.6M)]WKV--
M^=G6<\8?KPK)][1<H#+]+UW\7?JO0M$;%FZE:1"4TJZ*8<0^I7>H;.IZ. <G
M2;KN3PU>"5/%E)Q+CA<C"EA\8)P=36MM9B'9$TJ:Q2D:PY#VC:\S[6>*OI;\
M2&J5N%\;YPI6^)#2$7<^X<R0L!J+7Q$#ZF))<7Z+0%;*31*XY,ZS2I/@DUL?
M];\_643[!RE$3!I)M8L*S1QB0AE]?R$MFA&PFW%XV6OK>*41+;T #Q=7#M^A
M&PZ&F@G:)V[/'%P.TX?_77?_A# S#N2F70R.<*%F]=^):F$@S[!I(]==///1
MT'W?]IH+Z_!],IPB1,"T(*>X-]J:SY2GMNNCS*IJ;=QJ0Z9#"V2"U"6K$$FT
M=EPYJ!W\#XEUH:936_I.W>NNH#E@36T6$?/5WSUK)B2O3[;2W6>KVY,$IK'7
MYB#&#IN/E1/I@&Z[OUK]L147698B><T7M" XW+U\@CT@5]Y5-.C\#(4QSN%H
M.J!GF=1.:_*G ZCBT=B[E)MT@-0RE@XHMZ(#CCV4CQ@C>A)$!R3W$5]3GZ\Q
M_F?(A_A BJ"9]R$9G3/N=&_H20'!@GL6C<*5PUKO8)^ 40R]I#TZDFKGNI=D
MBE0"P>T[A8W7FV.G52)^<3!'1)/)!Q3J&QH/7)WZ?A_)3U)L(Y+\; F;J;$5
M]@YW5_!7Y<1?)NENMV+'HF803S^MLD3L'E*XZVY2,94.\>FN1.#ATOAO.H#"
M&T&[6X$WI/J5T0%#9,_"BJ02P;RO+ZI!LJ"'Z,EQ,VINLT;[)^BN"1W ]BO%
M_0HF?[IC,VKYW&*<\VDVZ;H<A\1?HT_/>AL.H0D6V$G@0G<K+K)9B)CV$@X"
MOI:++TVWG.$O_SYH*MPJ$[VD*7+CO4]B[([ZKY-^:(+!,I#0 />>6 H.%:(#
M:MX7K7&1I%<IZ=N,.>!BFD=+=C17[YO.Q^G^]L$2#.*>KV\L8#I,SQO9ELA4
MV8>^SY9\Y?'(%1X&3Z$4K0!)UVHHF6,,2O(P TCEA_[&DBXQ[BX&Q ?:^ .F
M P8D,9F@^4+<;I!='C7\*7+/-@]X^)95;Z][0;Y=FVL1N&E(^-/:+!'OX6]J
MT:9Q.^@J[.K;[S87?:)$=1[S+: %0 \ADZ'SL':J19>8=,V8EU(&2P]P:DA(
M,H'Z/=M)55,,0#$#2(2=(^N0BNX05#=#";B.\_L4#:>XO&!5T]KZQMJG$N8E
M.8^3-WX#EI( /<I'5\EVB.&YJ]3*9MF)M>><*1O!@<+H\N#0=D*!AUN@YNTA
MJ0UI8K<^4(IVY>E5 ]\,HTG.+- GTI4_BZ\[\RG:A#_M]^V:RX)=AOTC,U?)
M6D[EQC,)A1R:'\\(SI]F(B>2-1 _KR-^80']+_QEW6Z/R;FDXS<<)K%4'9LV
MH:0;NE,9]ZX1$R*TDJ!OJ)%8%VFNR:!6R7NC0\*X-W:-)M3<X%K7*E2X["/8
M=D3X#YT_7/H.SP^W^(C&X' T,\5U\8GLT/J&X? <],GC7UT?WMR)<,ELF/2+
MG_Q2!7DR(OY- JZW ")=YGK5+$HBPO6)\GB^O#>-7.Q&$@>';Z;L?RJ0O]C"
M%W=C*[@%N74W34-06PL+V$E#(]+32R1[Y)?NQ0UH?N/[1DT_Y1'%]LSRXGB.
MSA;-ES/"TB-+XW$49A)LD4&R5;O[2D"=-/7Z/U_*TRP;1^05-7.D)3R6ISL3
MBE)3 ,SLV9*L . G[%/4!&@!M-E.5O;4N3 LM^\%[O2=FYJ<G/,<+^JK?)ES
MBM<S&AF8Y-WZC4F[PA%X>NAC:>? )&-FRV]8<TIV>HDNN55RY#E*(-M*$0.Q
MAG5,H)U$B#JRU:#Y!$GU((@T^9GDUW(,GPI,"5CX'7#J4?J*4<^'TF<NLG4]
M%[S>JJUU-S%@CW(N%$A(@%MIT_J^,C YB*\-V?J(EPYH-R8Y'- !KPPFD$O+
MR^=@&YRL>@R(($GB-A,)0[@%6+M\S-L<!Y1(AD>ISO3!6F/3YE ;.*7!?4;"
M_Q"32@?,?T/O^B%$Z8 R8P;A,9&7WA.FG:(M,.80-DK?S'!" IC2\6E\M9_"
MST,S@[5C#Z[:T0%KKLNNQF:6LY36S;!9LB2I=WP!M\FQ .*#B!NY?PGV7+W_
M@7?AP\4;WQ^$)M0"[2@?2+ %% ]M&E)U,C.^HE!AE&*..-2(^M1^:8[EUNY3
MBRYNI:F8X4A1Z7W6^?Y7VY0 !GIW5!%H:!YPOJ<.1W--U=OGC9UNN^-$KVPB
MYA>0)(GJB)-<0&XY+LCJ.=;%=]]MXEE+<C1]D= XF!);!O(/R6!ZUOI6RW)H
M>,KH&=?GXYO%R%89!#,N6'8/*BM\?SC ^<QWBF[]NR&'MPHHA<2,WF<&QJ^8
M2U7V,7U8)E)#)[ ,O*4M$>.-P"UD6IEJ6D3]<TESPS+Y:4'\^F]5N>>B>?D8
MW'11ODR):UUMNIKL9SV)9.-6<][3J1($@,@*%@V9DNXHHP12"[2<\TEV*B/B
MX_N+L-QBHPA?CC?.%Y UD3I893.Q^^@;J?E"QPS8.:E;'TT^N#$N]]!'@L=I
M;==@,?MJ)ALH!1'R=XDCTLU+X""-5)-O&UQ2>IE0&NE^0"Z2NOR$-BJM=F=1
M)H?/X@_W@XA7+>+JP$] POTP23+K@7#S,,<1^E&:236.NI7454>57D62Q-E1
M)!.$5+6.L\M#IN,>5=+]/,GSW$\T,@4HO- #*9(K 3?O$KS3,@=$M9]/30Z!
M<?X(K+@S,-,JS4;XOJGKZG9?\"$Z0WU1$$<P '$[R3'(JJZBHL<6S!W^+7DW
MYW..P4--;O:(C:HPZ34<Z>HXY0,J#KFQR$#0H0GH4C])7)[R#O:&#CA@KZ8#
M!G_>?KS\.J6]X/COIJ!9-O]:]Z9XDB7YA;K$P \^(TF KQ&F#T.28J7PLI$B
MJX!1R--5(AYZ <T5> YK.@!5^A/&S'7D/ODQ;#OBO]H<F6GL+ &+^90;))?\
MQ;M')?OHLW98"OP &BR([-/Y_.\&L%^>5Z5_KPW'2>UV=#9$\IK;L5W][WOO
M<C4B'X*BT=-. B-PKE"5C2:)C(8+W:DU@4<CR/I5T,' <^NQE*.+! A>B0Y@
M1UQ^DB7QIBQJRJO&'$.I?-EL*[!1F:3=HEVT_[5WE_/OGBFV5J'0-V,VN7HI
M_LX)[1/ATA/M#U8BT7KSBA]5RS!;XI551_MTP U/J2_U_2S_SWYK!Z@(,26R
M:\% Z=*/@;BQ']T[DO['\7,XXWV-(U6S$<DAS*?&:J1<L(.&:BTM96\G2NLF
MZ]M*$Z];9UB*_GQ%+*(:L2]I*<2Z4H%)\/1-#_E^VJG#HRN:T\,'/(B]P#\0
MPID@_$$#%35_]-E@6GN#(V!_*L3EZ#2RI6BU?D\^SF[U !7-W2FL8--=B3J8
M/HDUS29@M#%!,MF;WFM-RYC]71V86D<HW"%I2@.)QO.:ZS_/>_,_G*KF#I+=
M7&_O42Z37$I(<;T9[R_M;B["CCR\Z0 9%]$N,W!Y^GW/:YOUWBE&4H:!<&VR
M+_R!C@HI'P[R4*'*MT=[?<M[7?=4"$5A9<_J%!YKAA64;G]MKD]?P1NDX]T]
M)!)_V;[_F 0N4.:$+QO5)_FZK[]_KM ^%">UQVXL5?PKX>]R2&H0Z?PCT,G&
MDTMT0!&MM:R;2KI+J\/\@*$&3;BZN<2*6UYKS"Z>1BTH*D &HLGM!^*D2-;8
MYE,3:UYR6R;MVV.*V6+P<I-;$WM3@507Y05T#;!%UJJ_,PUXUM_^JKQ2QI)%
M@0R;;8F;)<?*=6!++^O/@;-^L='[11@/@QLH/?SNFHR*3NZU=%5D_[[.;<P]
MZON+J3 4C=7FI9SR29>7E(LV-;\Y0P+"/I#9*<RCSL2SI->EMD8NKC".[EQ#
M#;Z0S)&BNTRK#V^UB)%W-:Q/"M:-& &-4"7L:AYUVL,FHVA3VA#G>3@K<?"=
M*[+\*S,57PL9Y]NUIO 4T8RMW](!F^?H@*ILC">U4>=BZP(R8K6]1TX9>-8L
MH=@3X7SZ:?D=W-U7$))H<!Z%)^^_M+B5D]RA'Z@#X3#MEBZ2'*4#$K<AU8>=
MF?8+F/90#M$SZR:<A@ZU3SAG9*OO?-;_D<%UKZ,\-EY74@3?S$$*(MIW(#FU
M'*&8-8V4MAG#:XU$I9S<H<?/C)C(+?'J2P$B+Z!;,)*4801,N3_J^$H#]%2Z
M-C\Q\M=@LLC]?$<ZP+3W!1W0*#UO*FG<,!Y@HJW2]D]=4\.'"^&\(@UE3 _"
MC/CZHM^E0+[OES_WSPT?E84A-P:HD6-*?5QOQ9CKRVIUCP.K\MY=C$(8N<Q3
M#6X>1U.&J.^5X^R-2&L+LI>T#;;G?N[K2E9&!]GD/#UK<D%-F]5\PGHM-4-$
MC)U@61QT_YJ]A\;SXG+W%XD&JL"OO.,KK)N+P3#DDW[6F1I.E4()\=D:X(:C
M&CH>C22Y]/;N?W[C*'NLN(.:^G._80CICN2?G9@U=0T0K)K4;HQ2=9AM.R,H
M$AMNN A)FZJN*X .YQQG?0[(_Q%3]KCA0^[#NE],CX)[M$+'U\:WWN5BW;""
M+_O[GB"E:TT1]N,ZFJ2W(6+QM])&EX[_@'J Y7,,KILH;40'?(-#CF6LE_I;
ML4?2<_\P_MY"T=Y=1E0$N]-NETC26HG(WV609!#CR!(F6)C67@TZOI=2+?\<
M.>X2<X6D !SWVW?'IT6[$@S;D3P;!PNFOS+SP'YLS@F/'UR^H:WZ""N1W*UQ
M3*K3,@N %BCOU0K<HB[)RK\_<U/RV+^;[SB%;(+L82:.4\.7:99'"N;QR2O1
M&C<$]8<*KE0]P[TD6W+B>_*Z W'7E&Y9;"JD4UZ0(HF2]J2X1>@.][KU<-/2
M\(<+U 6@F^GD;13YLX$"ZN[^"M9>F'8[F\'!&4(H#Q+'9[.FJ2^X=#UNO7>J
M2/X']05)$>,8G+T@'U$%G;0+G6ZZ,F6[[)*T*SCN!_3U19ZG%!-'?B[@8IPN
MI@ZZ<#F7S"A=(T;=S=E\P"?.XJVF9<V@19NK=("$> OR@*V&0>I/(H)M26*@
MMY JV9VHO,0OU2-:)O[)Y=YS]](-X,]%"R<.L_E";J$#A4SB-":B#B#9[E\\
M&-,#U(6+T1$<H:AF_\Y^D+XN?W%?%@A^Y]!R2DASL/J*@<$=P7Z6\Q$+X,TP
M8M1XIYU3[:6(MO*IF<LM]8W-$,4H%DH93%(K5D5QKKF?E(@O 1[XD=3#"M?L
M1%S 0R[QTEXJ(R%/;&?-?7U:9EHJ1)+[[T/QH9AI0SRV0_Z<Q[%31A#T2\G^
M2.":5Z[=B9VFMDC<E8.>_GOZIG?:,IS&3,L)^]!'%U4C\@3UBI#C%.;MG3BK
MC0!"4/>]VB/[6\U \%[0"E:!#G#;.9)W8F'$327PF ^127G<3[D&%%E,ID:&
MT0$Y.Y#WZ(H@2AKF!'+"CHO*7B1 L1%R!6ZGT &EKW^#MB+I@"NX1?#Q(HP.
MR%6P7@Y#Y",F(+M>-$8^+/TK6RWX$-96_S(W-ERD P+32-C;?/L,G$'3C-W_
M V>2-C9 )$E5RKM^'CI@0IP.@!HZ,,CY[3T_T*%&%KI@&UTCT%GR%W6@'*+L
M#-0Q^9]1Y_2_48>-@3J0#N1IBB,4SREYO\[^S;)UUI64:,<K!DL)P$9!GW[Q
M_"5FR%-DJYZ64$@I7&50></F[N#OFEBYP-CW^)1;.\?/'K!2%R" -0W+N89"
MV[7JL\H_MY9Z6,Y^.LJ<B+0$WM>'Q;P;A7U?Z%D;2N5X4-5$!V#T#J1MAC9U
M)(+9U[L6F->FYK+N1:TNI>IPC3QC79?^8W\ >KF%],"RM5]H[U:>4AVQ^\&)
M2%LK:YU'LTQU!UW*K4[,*^R[$GR*5\_GV-D4X4'[7F- /OA,R.T[K30NX'MN
MO_K]N)4DZ5T#CH(2E\&.EAEYP0;1GY"5DAW2Z$@L*]P$K\F=?:_ZI4N5&R R
MU=!F\-OS+?D&X.;X"B>N"POTY-?(S5R-5<Z8UKZOR#?;-+K8)Q)]1\+KD>Y:
MO$*WJ!IF #A=> M=T5S,:M!894$'(&_24HZ2'4AK/0^,=%YG)PY^)>Q^3)FE
M Z2!V4 "@\:=L'\"8G,G7HQCB #'AH0/@;L7W\9Z?MB;D0"AJH)7M[J)BQT\
M%(-Z@DYB@<-:NDJ*",33WI9=N""3Y56%_&5+1X.Y#RQ9$X?8"<..>U!@!0WM
M+/(R;P@FY^5JME&O=YW"EK:GD[*;MM4Y#Z4#."@!H\H>#UV' SJBU\>><A=;
M*1L)@.9.YRP.IHU5%LYXERWMTIK_9+!G6R@5;%5Y'E!!)VHVBX@;'4Y,I,S/
M'A;K0=99(J.E^+*ZLMIW]1<3PV4*&K93W%@6\UF>NVSAIOI;JILU2%QX__3+
MT$RYR2I[6[85U4B3:IU\4>2\Y1&.K$D2HP/PK%U@]K6Q>TIE[6&<R\/S6_%L
M'[5BP<_^82VX$(09@DV9=(S1>$D\B]"^UZ=6UI)M.Y-[DEP5+H@UUH)>9K//
MY)N:.+LEQBI49LJ_G?XS<,006'UTP&75#@819J4#I@;'ZQ$S2/Y]6!2:\ZF,
MOW2!C+*L[_(GU83JR4N1 C>>:NMQ?[^A#OCH%^$DP!!&##*3E(%'DIGI@*TG
M&Z/(^<]SIQO'=<[_?KY??.5)I7V7@*;!79^[GX.HJI>8:80O&4EMJJ*=;V,O
M9W0^F ;W@3M(:0OCG2ANN"(Q /-&*=-X^9EXBE-PNM55_P_"2;H(@G.W5GPV
M"S.D^+@KS9DHW6)MI<H&-!O;VWUU_1>W#0ED7@O,QW3+2AHUC%?9_RL[-S?^
MS<Y"[H$7+0U'$B'E=D^]@R5;5<IFOQ=XY7A\+^_).J%_=@;QWL($,'T?_.C/
M1->-7"F*'2U5A_WOMB(D,5'PHABFT*FC])@S^4B7<9.[JFD-A)M2%.@:</I2
M/UZL:3Y,\R;A##HTB/I9D0[P,'FT(.IL*1B;9,#7YQ?_66'@(TF2PC/<R8;C
MTX*X2A?[KJ>"//5=^FX8GV(>P=]'O!@?@%2E=?4+PCD)M,AB$O3N,&RS5$ZB
MNBG9/-R6Y:[E79O)2RYJR>K]-X>;!I=MK(/R$N,5ITP4HXU4<Y.G87]TW*D?
M:?R4)R03HLEM+.2T9VJZ;.>(MV>B(N;=P>:TXP<]WWO<+?LL8= U]+1+ZT!P
MT0%R;/O\]?'GFIWY]C4!UQ8@A%W&3#HKO8IBI\VB!>!>> Y9KMN$[J@ 3JM]
M2JWLT-2"R4?N$.@+ ( GR5OA/N-:1.)R(T?I$]IU4HA+SN^TZI6I=9JHQE*.
M<8?<[2]NNKZZ0OW*YS*EAMZY!*(3F^S4"M_7!WA*=1E/:]O5N=-.,9*<N&H<
M';#Q:YH.T'N^CYXNPA]4$?I;-'0R%LAKE4V&]G6)YW=GHXT3.C[5&H@4R*S]
M.>.#MMN%D:[@*+%SJ@R,TX11.=</*;R%MV Z8GFN)G^.,I"$+S=\6F>1=HGW
M/WJZL]^PABSS+)M:X\?CE'_*#9N--%H4>?*GIMTZF'U6.F<0]9#M3'Q'><*I
MWSX]F$'L!,:R:0SK/LN]<:^QMKD>&O-I>*9W2/V$.[-,1U;*$0R2A_W6SDQ6
M?^(TKHH\UMX0.9U1N'V,3)S,NJ705FH)"]US[T97X6+V-Y"H+)7A2V/[@GO#
M$N892@T)>E4EBS,-BK$B'V.#E#<@!#/D6S'3PS>-G %RW 'G<Y/*:,IM=[-G
M4#*+U"@,%_7;.X;P6KQG  ICH@-ZGA3%D$"+:P@!REW"SMLOLN5M:W8!3A@.
M>#D&']OVS=)1RR1Y^U>/<ZJX_(.AT<ZP QTT(W3CX""R2MD"^KQ]]ZOZN,J^
M:N:XM;0W:-^O-_=N.J7\W?N%P$411Y^2US)4"GW6>#/05C"6!W;&'$2D Y2H
M;!@SZI=F450<D&4_3-KTW*Q3#S?$HY2MW?B5QI:VCNM,'1WPK%*Y: MT$$82
M4.JIG J&WK'YS-F2?EOW#5?#=VNBY[XEW_G=XH.RW=W.WM)_!/6)3C@Y= R%
M*QSTC.L-CI )]V[^%NYXC'R]>/ZIKMCI3]OOJ4%)V(,?UOU5VM2]X\S]SN61
M$NW1CCBE\AKK0/5'83U7BL9?WG^6,X.VV,XW?W#5(.EW.-8>Z8H[4L4QR( R
MZ .FYSS5BYJ&7,+!3S'(V@C-K4D$2T(-'%'H -+9?2I7!/(I5VS]*DI'#GI\
M%9LNRJS?D RN^19_2UQ6:%(BEO5T9[OO\]/L^SB29'^7+.P>\4S!O*/5,92J
M99NQP>QST>_9]W7,^>1?8UP?_4^>T4@_8N!D(<%Q)QRA%5POG'_7W%-@R-.J
M'Y5ZYZO+!>D]F=ZPD?$B9*L&13(HGV(UIDP\1>L?]A][^75KU7BC+(SV(('&
M/%:1=Y4*==R&O<DS)"O>+NDM67]N2.&-:0O\$VS8AI"T&7VVM9-AZ@%83KHS
MI<\Z(9@!W#F_CIS/I -V;^USD<_,('^_EP;2V&^6ZL$(?>WGU;WEGNTCJZX=
M7N65*T:J)U6#_J=SZ^PWXF=1Y\W 4M8[QUD!Y%"X+U'^-<4]EP1JG^I<B8%R
M)LTY&3DKZDD,:5Y_(),C6EAX1C$<DA7>[#Q<Q4!G/^)AQ![H'+2FOKABIC57
MSR_H8NJ=+TG.R;6['3!)2<D7&DQ.B>20.Y"#Z%&FWZE6GY"X;\B2$-4VT#F]
M!6!TUMFQTIS=$ID J.TJ\DZJI1QRY^/X!Z=GEE/)0ZL#\_E=66>X7X5MVU.F
M0+:-SJ4V\(LDQT+/P.HG]8B77RNF)[MW2R>&SW5I,[5%4S*(09W]@L&+'?<W
MGM>\@:V,B($5SJM/*;\>,"C4U=4^B2B%>Q+BNCNX7C5+#\C<Z@E!YO6F]OY\
M,;3H>_J8GSF=$EQ?E=ZU#H6^=YK#"RCT\$9;)KYLO<]UB\MSX\=E"7QJ=TI"
MU\?L^V!;" '$T#;.V+AT;"?LQ'J]^QLYR+W12J%'J*WRCXT#=X3[YD*_*=3*
MA(@+]?3HG"0C@_7A?$2D(=$@:2>OO\1.Z'+2;+3JU*6+0JVBIPQ0>=[@Y_M
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M14 \#K RE\M>.LSZ/4B9'#93>6.NS_<A_S_*P.E?1#>\,]='Q"+4_N/EK#Z
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MN'[816A3?WQ5+:@Y\-8X#79A/^DP&UDT R7R/+=CG9#N"F]")2:+/KN2]^I
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M .JM=\5!O96'9R[ID=(&T\YZDS#3&^M:\CEJ@QZINO(:CR AKO2;\ <J /D
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M1<?7>?DDAQ"4E2_3 J%D&L@S*NOC2&QGH-2:4[GV$31YP4_\&.1G-Q0J0#/
M>.,Y5))0%,:NDH4?WXW& N@CD=#L>WGSBBJN'Q\82!"'?=]X5H5NR+<(9%MC
M:5#U\5G)]336"BV3>^Y1/CVE:.,F%G?;QYS6<* 5A^S3ZH'\;<C\W)HY%K">
MZP?[E+VOMILSU>P@/U3_1HI$E>%WI2FSR=8;#99PL[N"!7RQ+\8UK3PQ-:%W
MW_+]0D* )'TT*$]22HFU;D/C09[E"DX,RG=_/TS^;$EK\8^,L1"+.<MRY"06
MP!C4BO/VR6O.JOKH*-K7]0PRXTR%^#N</H<5GIWPL#%=E(%.X&I2.KDFA0[Q
M7AN>5=JPQ *8%! ]F"8B"#VX>G!WM&+'<,5&Z6Q5M.G!/S7O_[HH&2SIHIQN
M9&07MF4H@UF\Q\'E0PDG0BO%KBY-Q1)9GH_K@K@?V>ZL%A7.F0<XTT<&'ZQY
MZUP>^EE2.>7_ R65 ?^_7__OW>]>!Y?8;(S.0<>TX79F6M>DQY7>YL9&%[#>
MNA[Y^  TY>!;AL>  LB"1PL.+7=D-KGG*_?%\.FMOGQ55U30B+KJ_XW./6E;
MJ&$L06[_1U53\ S,#W,>2=S96$]:?'OHV?7^ITA>7?F'D^QYZ"<_=J\!+ 9%
M\H&+T);CBX9VXOAH4@3LJ]*Y45>-QO)'4]^(ZBT#&F*W5"ZO&MO,&4(_W[D
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M@2)&R:!/!9QIV<&+U 8;QBKQK#G/ [VK8_@2]/::*5H.LS*?6-ML9X0OS9D
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MFE7>Q(4K/"?=8G[@!8A=F)16;=^V(]HKN\_#>KK^?<1Q8([6O=AJ'O.649Q
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M2#]]FD_SBEI3C%?OQ+DJ?[<^5X0:_DY#@'-90(]_K@"<TR/; 6/D+^<<0+$
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ME?6GDND?%%*_!&!9_UGKY,\2AEE_I<Q0<%0DD'[16\9_L&TQ_V<JN#^E9]2
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M0+'Q AFDXL^PJ+<2N_8;54$0-6&1]$BAA>GDU19#+/N*F35O,[^B^6:!T3N
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M(1AP_NX.D$$#1)!,W@&.MGO=K6$>*9#+J(%T3E5-&.TM6NNU6,#/6+0[0-U
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M4CC[Q&:=H#(E#RO](@"1[1[<?>C-S7V"KN73TFM]=<J*'3_>I>*>7[TU>LC
MN)4,#)TG+:O4=1^Q-U=F,TM[29GNTFG1U$"*_;H)WM+P!L_&;8PE&FN=0=_$
MQ'?5.%3)IC?*4K%6^-L>SL*LO2%M8>CJ>E)3DKZG9?*PH:A7\I)!G/LWO5?9
MUC]G%NK%2+*3T4Y*5GIN]VT&@PY;.Z8QV;/&A[?QY?D3=E%F_6,.47<.M.\
MMC]7URM;31UW292J5NUU6[>V_?8D_*F+_;@.SZOMCNX EAV6]$"F\3Q*<Y$Z
M$F"G)O&28: M[NKQ3O2&&$FP<0C-]WBI(W:2M_ZHW,H#9<=!GZIL<R^?J5%V
MB7][;P?;F1D]NF+<FD3@+T%K)Y-$THY.9\E5 PZ*+)I@RZ$=Q/IX7=7VU#J"
M;N1*#C)&7U-05+VATBOS8839#&.X/$EV6BD)+63)!4D0W<GC:;IOS9D;[?^C
MY4!0%/!_=S7P3\-H,^LB;5MR>B28Z[8/_XEYCD[W>?A.-:""Q@E7;+O?BRPE
MS3GHW!4,;<70E;TF&';0L*^[=FI)'!QD;SRP&T*@DHTY!R7D'1]IQV-2W:3L
M+\1>#L@8A!_!%F\6V@)(9#+E^)O*D]B=S3W>T$,HI"_?;GX/Q/Y)=K:A_D17
MT@=G6[((9W'_\R]A&C;X)C!@=;^%Y/[+/WL'N%+@!G?ZN</+[0]YEQ1;5\*;
M1?0U%F2D4W>78BA[6LP^&'\@-ZH#!8,%;]M QYZ&6 $[^P$WU$FM.@&VP!"?
M"2CKU$77//;A]O>KP5P2#(=:#F_G-1:3V(I)ODN5P@U.9/R/@0G38(N?<*7X
M;@3N=0?AQM)X$6I-!OX=X(7!]37[[0P8XR:WFO&&6+9BE(OUJ7;;>0[L#/!>
M[K%1]HH[%<](7XPHB.T[)148S(IXOK+RCN]:Y*W(+XG[,N/V'6#2\/S9Q/UX
M"B!8@,.@ B7ISH5]9N<\2>"$/8K7);V#QX(,:RVB#]]*HO&?:H5YT<$<DB=&
M7\2?"37>HC<?TDH.4Q[> ;J>T(PP$L^)7UPS:FB]H:N/@1Y+L /\$5(4E9[$
MPHRK0U/X*Q:QUR((!YB098FVP3:1>W%U)RM*6IXYC73O0]Z*"+.3 7_N.P"R
MS$T6%Y!TSBK]B1^W/U8A7K3'=$BAI\/2LFY,)(E3(5)@;RG-KAM39IZ1D.TM
M6M_7K1:JF_PJ1E)=Q:HQIK3>LZ3I<^0D'@H4\G@C*93&O'D^WCU-J8OGM\S8
MTC?5((<[  IX)/WQGA#]T@V&/LPQ8RRCU;J:;DDKC,HE \DLPO4+J@,T\PX0
M*!W0TP;/O.WR;CTM&6_>N$4/.KQHG\>_23G=&<#OT!&)]9A_61,QJS4I\2A8
MGO=1R9JR<PS?.>[BPJ$,]B6?$D[ 9"GO;?ST^+-/9.@& ]K8!O9*)O?-M@;\
M"#T\N&W7-+RB9_QT?^(>1?TP74Z_<8(%G#(FW;^/Q=*%XY<(P3M 6?S$;9CL
M&F@Q&G1, ,^] ^AQ+=R@KU=$(\(7[N&9W?T9Y,#[$-.X5'KC-7\'V/Q1^.$F
M] [@@(UZVV_XY*P5VROT]02W8..>=NE*HKRT-BXFNU10BP1_OV6MLWXK @_C
M5O(@I/5LQ?=^XE&4+-RB:2ZR8L)+%]/#'-Q;L:P%NOK!+[U&[,6A]'.:NS])
MOS9 4&3X+KBMVXQ,UDM:%\,-[+$C6NV&HI-8]X!''[P:Q<I:878HR<CI<7D%
M:)Z4_+2K%@27H3Z'25=#M^CV2W.,'<"J;U.;T^9I<98W'VWNQUQYK;3IK(Y>
M:@&@Y_O&=#7(:&$R!#C]W!IAO,):I0LG@P;0$&O)1)[Q)R:*WFAP+W)BR? ]
M>BI]$&SC5G:4/*R5S+/KYRP!/K#UN?C>.B4E5U[5(D)X2,5!;^OK5?Q)3Q85
M^?S;%^#/\J'Q9/]%T+M[<%T;E-VD .J89X=ET0#W!)'5&VK!=<]+J"+K4:TI
MA<R>VD9?R^WQB1C<S^W+^)YU\#.5^REF N[UB=ZM7]FT@RPK*+4W%#1-*V93
MO-TMD(2;=9.9..C%=J"HLD,RMP+@5*V!".'E/<%EYPDW4DX=GN.M;R_RM+M!
MB?4.GO;SN83?!X61/4<[);G\J]Q?T^V8GI2$W:3"ZZ\Y$,\.2SNU6UC\),,E
M1II8<[;.SS4:!&>8> Q\FHI&>IYC+S2B*I<'"[W\X<!S!6Q+CP(BWPIHSUN)
M/&H9<><K6I[CB7(;KYG!\MA_VD.TQH]$_I07X)RB^:)?>-ZJK7JBW"_-<O$,
M]^K9_:#AN(D3XCP\D!JYI?)BE EZ55W7=(U5FJN=)^>TCR'!Y1SU(M[<J,GE
M_8.3%ZN&ATI#4X;R-YFW+VT2YVGF:-\W\<7*>5I$_)B ]+7VACNUH5W76I!O
MO.6;BQTC>4,M->-&&3_?W?M)<V^A4VD::9%U-\C;>BF\4(X4Y:9XW&WDE)22
MI?RY>.,GY:\0['G[[M)F@T/6"!$D\-0\Z>@2['0 V(5F]\9 VT; *FQ_P<.C
MM3\CQ,EITU_2M<OY!JRQX;; ZG(I--2AP[A9.A-];EUQDW3+3!T2ZC(A0CBV
MQ%N#QA@"F7D2^BY:K9;A%5G!3DJ,@M^.02I_0:Q:5/_ UE<5"?^V:Z3;C@8I
M:"39RC*PDY7-2V3>(JQ;45N>XO)^YFM31;&]9G!II7]4YB"JQS562,2^$3-2
M?WC_\/R7#>%T=X"VUJ"KT0;LCH 0C:N6.!N)1AL\#*S41P5\-&P4%L[[;:ZG
MJ^=$+$&'J+?HW(OV&@J<KZ/;YWDJY0>X>'I0,BSV8B#L\LR=KP/Y:>LN"8+T
MHG'Y6&P^34<'P)&/+],AW%=KUZ0[:(>^MV@]GBOV#.,O"J1,BW9H?1"5>A),
MPU!#DM@/E*B3FM_3D)- DQ?G2?6U\- E*S]E(9$+O%H!708N3>)E"GK-?E7T
MF"WR'X./-VW/--M ) C&9>S)VY5E]_3 I;+#(A^'#(]Y@C<?**4P852QBRQ#
M*="!"^<35RW3G#6"K))DG8MC$J4>U@_W<V:B:RC<@&24"QL7WKNA/LR:)4-;
M;FM%&1G&YP;]T09@0P6<EY*59H-L':=-O]\!@%6M3V:\I);&6M]EPRR2Y#Z^
MC$*^%G47_7IIU<R3UE)]HN_#U0(,3?R1@*.I?0B99QP*F\<,]()848\70:17
ME7NW+47%4/,HJ\&-X!'#AV!4N.2U(CSW"$D&9N?'NI2L^9%+$.-1E+#XMI0:
MV:FHT C/DC(BUYG)(TAKO).!0\7F@D@3A&_->":U-(' :5QB_2ATGV'Q["SU
MP2T[\..R4WA5J1MG.@GVU)C0OU*X/&BS0]IDS("/7:/X$1U>=/*#&7?V4$-:
M2*T]E#R+-O'RAMNXVRL^]#Y:4ZD0BV230T87,=7RMV_7JS::<*C%,NA>M<>]
M"EHRA-/GMMFSO@GMP&O%=. "(B<^9>[GJ6E[QFOJ.T,._2EB&F(Z 4A:O?_
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M+ID?KCK1IS<^QVN?V9MN *RU]*(*6P>6J\'S;'VN\\DHN]-0@]<&3]G M_G
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M7;%T?NH%3E$EJ%08C-OPV=54U=2E.PV]&NJ]R8YZI)!?EVAI?9[%2UE&XW9
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M0U/?_T2G 2U+H(%V7V9=HX'*;/[C/Y]?H0M%V%VW$T]*3 KFY,I*$S"(H5H
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M;/J/VWS^QVU2.:ZL.JJ;!])%4/&UG*C#F ',PBHY>8<.(&S?+AI(EP/S )"
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M&-D=1C(#'OFFY!-B"OE-ZX:7![^EI5-4HE:]#A]8<S^7O210QX/EA270U:>
ML'XC3E [E;"4RY7H2  (64V"-03Y[8 %/H]X'?KB&MX9PZ/%ZA3MP86-"#RZ
M&KJ0C-QU4068LRP.\"7:[I %U&0-3BB[=6<:V:QXF'N]I:!DTWQ6[W)K9RJ[
M,OWD(?/S<X8DN1B//];2FYI"J!'DC."AV"C&A0;B\D<^@@F)A^]3A/NWE\J"
M;\YY)&.]>^H''CHP=MXB"P6K A8@0@&(Z"$SP @Q[0&ME=TA0OQ:MNWT[=O
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M\4RZ?G]KQ#!1'L=]M W@Y@R9P/:>*N9\>#@\[Z284)O4N[N4]LQ<N2A9_<C
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M&DT#Z>#RSS9507QIH,NO59$Y4;I_12D (D,_(GN2B-+4UG1':L*@C00 $3]
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MY>Z# 9LG#%^7$]*T![PJ\7RF-VZ4R6">%)M.J;J=*3QSD?UW%.4MY<N.( Y
M[=\)V-A<:94A46L_5N/O5]+VZT2U<IU!WU_91W,(77]HJR(&U6#TU=_O7EF&
M\;B<Q/C\]#3WC8$MK_5F(9TUD"@><H ZW&TH([*2Z-:PK/,;2K'W-V;T\ ?U
MXKW/2?*IHB/TFY7O;P:?*]K48R]>SV]L5;H]".A)#&:7B5@&Q,3^(.7L1A,#
M)>>@D*Q!(.%4<[TO)UJBV&'5EN71$<P8M<^G]M%-T/_E!@QP T8%(8OLL2-@
M*1%H&FC_R_H(59FJ=J@UA<5KF7]"W/3_>V$RME+4UZ8]^AT(\-]=>^ALC&>L
M3;#K82,Q67;+/ >C][QG@.>:2*P:F:?QZ#]^0!3+Z (?@L G1D+P==)+9,_T
M?Q8, UX&H@O=D=GGG5+1HS(90K1(9I;7,YED+<<\O=Y!?S&W R#(S$%OQ^)P
M7*?'ZP+L&!X?:H<C+T&O3P*?/ &RQ"ES()2$CVB@>Q: U0C]!+R%(Z*IC3>@
M^RF*R#W.7?"4:B=A D (+Q#JJ2,>6^*)TW\WVRP06>6:+WT-9;UT;\_<JGQ+
M0'=/4]+*B99(0C:5Z6VNOZ'N/:DBGT57O6@%PJ\DM75%3979CA_(1EBLZ9T1
M(.OU].)L43:P3Y3@*A*A"\T3OL=0=0-B<[+Y,E5]9X<H@H[\6](D[;_:EF.N
MVA'P19*DD53Q*QPG:])5*L5G&H:8G!>JQM=LMRQ90K3'KSE,?&ZX_DE^(,%@
ME>!L-C$&PVL;ODN/0[DO24=.9VIVZ=:'O,Y@$C<.?6[*87A)''PE.=;O/--Y
MZ+N)]NQ*^0X6PTA8Y40TV=6M5?_.II7,C';#3DUDZ -LC%<AV2F\-K)J4E%D
MAP8BWD"2$[% @GW(GT$#/1 @YZ(GH$1(080'68,$)9K"1NSEZQ 9Q7FIG/?V
MKJO+2A5>%B'JN5F=U)U,+ =754ZDLEO.=(CN]>(4<+%ZM\L4F$'+B4%&[Z@<
M3!Z(:OAU&NB#^CPP'U7%--"Z]1CBW\J[76\P$W++?1BY7WZ=8MI ]/X&!W+5
MT&<;3;QC7^Y,YV>_]<BKJ_%L/%<>D;:DNC',K8K#2&!>\/-(3S]>5"IK14>_
M3C2D-&F8#_D]%?C;>0(&/.@+S+(#$9AXF_0(:@0]7!"/:<]2_ TW=6=HZS>U
M'H%K?).9U@!'E%Z-PBVG\*'8+UAQHE(3.H(!)-)GAMY#PZ]__+*;/F.D1EQZ
M&?1*:^,ZP/!=S74\);CL]S82#:&"GX*TP@?&._(>6<R)[Y$GK/8E_UQ?]HYM
MRS4R<,D2TD%O+ 5EVOS[4:"->$P(/8%Q^<^8#[]V-S3V5%P_Z%N7\LR,!SFR
MBY2^9*!O$8*,-; !E];A"UIH((XUX2L$&JA3+^BNI.?GK/%IQBME' ;ED"LW
M*G1G(FW/GCX=9#J(J9[8=B786Q,)2YZLXI$'*!8G :D"U337O'4_&0N1#LYD
M<]')>_&UIW;;8VYV\:%O4I*H0O[12Q';(@M]$(>ZT6DA8ZS1*%I,4CS)]=SW
MW>Z_P:E./7_2M!X;C%G=S8=<=@IN!(8BW8@&8BQH7<)NURP!,MEF Z2?9[S_
MK5I>\B3Q(@]7! ZDB3?:'8CRBS$?%SUWGE!O=5"Y_R#Q6CI<\%>$',<5S_,\
M=)-6;=DK$$#1ZC";WTZRE:FSV%U =;F@6U+8D],36"Q>+_OX-IL @ M78R!3
MAP02.0^W0O60TYNXP.Z8&!_KA9M=K (WH>\O4>6.L&2.5>K#MD[,H< H9C]J
MOK*$S$@.\8"' 4VKQ6\WU9.LUTQY&445;;*#@B]XA)#1U\!M_>*;;Z=KD O%
M\U+U$U!GXKZS>$)QI;[P-)\MU$O8>KC^U(;Z)7'*&R73K']UI @1<[(<I;A!
MT.?;K^H3Q-?A=8[>67KGW\56A\*>'YA43LGM@/&FJ+>*U1D$B#HQU=UM;TWQ
M4Y1SC;<6_Y7YE:ON]8-J0OR^I,[Y,<.']S'/7D-5B@XA5*8#. W$C;3]9-\6
M^ OEY^Q)*?Q,):]>4+[7NGQX^A7#9[YM6!Q!<Z\[H3-6-.[^]VL]=H$@I71*
M,E'^\R )#+1,L<H2RR4]614Q_/= QUU4V#)_;'B[)J2B&_',1.A>][8F9%&O
MI%6\,QNO@SE6W"&]F4>N&9EHD;DA%K5C4#=6Q+0S/V[D-4G0C"N+^QS++3HJ
M/22[L^H_TT<?[-&I!AKH=TZI/949<!CB&4NPD\4"(%*Y9#$K(LM";-E4/FL=
M1P*DU93]EH[=V+:HYL4+#[KOH8?1Q!O#= O9X8:HCRZ\GQ'_4'"<C=^AZK*%
M0[<D7 ';9()YB%FH@.Z*P&\#Q!Z[2HV*B\KNC/BE"*:C#J9W=49CV=E8R. Q
MLA'/%U_]]G3?M\$WV.^<+DQYQ*<).K[GUWSQW#XZ_Q\SG DAEI1H"76]5]9?
M+ %IRRM#;DQX?U%1IU=[1[E(<5T'$\4&P_919ZF]BEVQLHUW?< <&[RFB=8!
M+LK'J@.W6'\HK'<NJ#R_BKE#E4",@WFHDIOR$UF7")WE\;/:722ISEU+UVOW
MH%[/-%G>*/3T*"PG]4LYCV9^D/T!SH-5L&TQ+6"G4I<<(WSZ#7&5@1.Q"5(\
M;>IQ"F[4W\+S&DE'^B(]EYY(T4!2L^YG\+=@$&#6K#Y(;^O;:B%9+3AI(&0I
M8,'PNM"PNHEHJ#,]H;;ZPUJ68&6M:_3QJ<D)SO8AT7OU/\V%4)]M F/09.YI
MF>PJGI3VEU2^2L!TAO"*G#S1W&C,J/]Q GY([8/N1L&X@;AIQ,'^*?.5HH.)
M0X#V/A@#"M>QPP'(I_S38VZ+1\2"C:O<HW!Y@GRLLCRNR).H5F7MJ4?@)E@J
M(!?!M2F"1;%;M>\#'MSVL,5(W[WD956%"$.V",%9OKAB.1I\<-;W&3WD2L[W
MCJO(ZGZ)L0G2%4N^/?0FUO3E*L?-'<O15-&+'^,\M?YSO3M,4'J9 (N3BY77
M&I,30GM)OT<OUV)><EU/9<^-"7O*YW@&=.IT([0-AM=%L\ E1V7[@W#2G4'N
M=UB"WO_1WEZ(:I>-:OYF_O7#<B*H^>%$#&(>5E70$;TS3=>IRE%%N(->A+(Y
M^<4^<__J;,KFO-+YV<[<G-%9N=DOMHL/\@;2"F3=T(@L4>(!@=1J(?>M;LSC
MZ^BSVJ;ZM'38E>F[W/DIFBJA;T=WM>D2Z;TM\G)__7%08?OM2;Q1CB(^Q; 9
M>A7_@N[2^P^2.=D.&P!&#IMH$B:NG*CP:HY+\SXJ&_-0J(E:R.D2]08OF#Q!
MG4,852['1!T" 9#WO(G3__3#EW6SWY%\@F3('^FI5"H3#>1->@@7&(=[Y1&G
M690V&>JJ])E>[]U(M-;B\U]R/A=U095(=2\01%TT>7)LS6+X[$"UD?AO.XEO
M1"."^0L";ULVCY7_"R7<B\@;OP+CT@:A=:?>THL/WV>P!77 4PE!5*8QPLC"
MBXCO-FN[Z*@&6=[^>D_6.6W1R9]M>F[W*VPYC^07.+S'FYSP@)MTQ:=:U*J"
M)P[03"[QNO:?;GCD5R98&_"+/A6)OT=O%B1 ,0 FT8XZBN5$J%CYH^\3 (,U
M<Z@H5WG;<C/6HZPW;LNT)R&>_I7:#2;!)LV>NWR%01:0]*-[N=";JF?)1K5$
M24)0:Y9"30W)TJEFW5NLR3<MAU1^225:Y"9#F=S)P1(T E.Q2N9ZVW9B4N:*
M8Y.WKJR9XNY,>QWODN*5:-:F?%[P.E]2;\)HD6TBD(HC\8(/B/^4"$1 M;FS
M6%;BJU)R2^;R&T<LTYY%V8:;7V'DLU_EN,9/=^D\)(X"N(KG%,]#-6+"5V?P
M])% U:>Y')M)UR&+JL\)+>WO/RL]2R@;J@A_W.FRDFOT]5.>R#KR/08/X%:0
M^ +Y?S'WEE%Q=4W;8"<DD #!78,%#\$=$@@>-,$UN 1W)[AK<.D$=X([C78C
MP=VE<6VL:7S(G?O1>>>=[]>L^7%Z+:#99^\ZM:NNVJ?JJ@.V$#V^RJGU>GLN
M@BM_$:!39 %SE<3KO*^ 8#I15$3 VK*?ERUL&IRL1=G]0E!YW$L<"WVGL#$N
M5TP:(]XX#"O6KE^:3^A8;QB&!-]";*U0$IIKV0#7O!7!/.J$=O,O4#2,/.&Q
M0W@2I&W&8HY?*X,Q^&C"KRGOT)ASMH]@S>T"I45$T] IX[IZKQ>;L]]-OWGZ
M[6".BYQ]*Q:SY)Q:S8L)N@.8@RC;."U<EP (ZV*WM(LN>33MY9WC716)/.TN
M1L/.M[^HWUXZUC@L\SS:; N%@6ZP06NL</ Q2M0-;TZ)@UH/?8OS5; &V"?D
MN**PC7@)<OU@C#NX#X1T5UAYEK:T*$A"M)/>$=P#.$[L@C7S=D#]2QYG&F^W
MF4_,(**4=W1>LEGN0HI0$)85,SO=]X8)NA-D3Y:W@<K[Q4^QO^WR]F530/9
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M:)E'*H4A_"AT#3M G-P"$ON(%@D',+!09T<@J/8\8]C:U9II$'TT@\LF%]_
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M(L)(+8)0%J^ QZ7,!R)0^4;SUS3L_:WJ92XN%X1)DE;2A-XWP):D5;(W'?<
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M&:H?-B>?__68N2=--Y!Z"3R@WEQ7'X@S3R.3J>K@H ! HMW,Y\;+7ZE_9U/
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MRTQHE&@/,K%Y^4=:OT\5?XL/) LR\D709:5"8Y[NZ/$AJAT]R=N*4!<UW&S
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M26,Q*!7%E!"H+F%VI5&:Q=;&G*#2<?)=N#KU*;WP4*=3<L*-I^T)O1+]NFV
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MH5ISIWF8_:<=)C=&,@E@225>FLPUUY.B6="6OKFO5LO&O]K,,"UG< Z@=^5
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M<_07O(;9X[R_"V*9D252<2@\!=2&!)"TSW*@BAR1N=D][8N<GQ/<@PHALC8
M3\O;GQR^"\0./N?URCA1HW"'.51'0>H86<2Y-I7X1J!IS*$VVH^"/WJ]#FJQ
MJ#P0A)&"!7%F>[^_;B]=HN]P?J*JO6OTR_%PLWZ\4^A!N;M  V/J'93$G39
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M=,;BZZ6C$M/#H>YW[%Z@P[1_2S7&6>SNXOAFG'OG1V,U[<7N'<$XKH?%3UE
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M/K/WM:YU?<NVUUH=34M_*;TUEH  R'IYIB57M&,![@42OPI%&YLGQWB'%P<
MUEF_>_X8VQM! %?&034JW"'+>:0A_-(/=U>5:FK:,P&68-X*:XF=ED]"M5<
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MC^.NO@+<-5G#W#L_?+ !80B2;<8P(H8KTQ?TR3,R?Y'*H>N/)"U3(0E2G=>
MDIT4*]N_.\4@W8(A/#N$>ZV0Z,ND;#CWK2%LY=3E]L&\>QG0I]LFL0G;W4+8
MV;5.*5&7$:#:M]K=,5EI4"SM6J]I-&AV(M!$>DQF]E'=(.HP[0M[]#=\J>B_
M6L*$7#94PBKK%>##&YI'O]?TLV:K.V?_W+76>A"\:FD?JSE J]<^O\)=!SSP
M*2(,S#T:[^>.Z^29^CZ[7N__<9!7MM5;1'([\+ZXU+4&,DY*@S:?$#_"S!6
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M[3=&]X5!K!C#B0#?QJ:CB64K=>#65Z/0$(-<DO+UES>OQ5T2_<D:TM!M\0J
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M7CG]S;@Q5-7SZY+6RD))A@B+R0DN@H%:&]3!G8X<^D(!:DCZ>RKA76) 1Z)
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MM1*TZ; ;;A'&B$-@RI]'/T.IUY98#?]9@MGJNG'DK1I[?B/PF!V!#ONQ=D[
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M7;218SEO/'E&72EH!(5(KJ('WD0Y66&']M0>G),W*-FA2/JY;U>_;$>9Q<I
M[MAT<Z<S#M0&BRZG%&O!*OGHR;7D.8<KV+1]S9K)-3<];%LV\F#;"+F(TYGI
MT^I8%9ZHWS*PCV/^CG15$I%_Y5RY0NT9-XT-/]F+QUK?:AKL8L*!4=I.#BA(
MW!F$7IKTLYEA>^KK>&5?80ZQX- J[3AMY_OE/*+.645_XDM5(24VXW;![^":
M[UQ?.VTF1JN;&MY0@7=X -^.)U$6)2H%O4!QIX3*L?<X7 &ZNB!7 *YJUOQ\
M@X1. 7?Q_59""3S1<MMXSH>]P\JHQ?7O*DAO6E?X?7VM0/+,7#"#$<E<NR#6
M F>/5$_F2B\(4I\_]-Z9?VUZ[/W&/).%*OO\+4F-]:OFL4!X<D*0 7P4<F=O
M]<&<#"W=DF;=TEX3\Y3,KUN5+3<]'1\TG,BF)"U4O8I+OU'B';J*BDYNUT=1
M7;*O,?HGFZ)D#B0N)*S!S%,KPQP!@J\:$C2M4]WEAV4">R',[7[KA[=<F1^C
MJF,:E-G>^&;J3?M8'!YNBEUO<9KL27T,V/0D\S0VVC*%A@I_0X+ZQ!F"Y&9O
M%6V ;N^%<';R".L7V[3?W+OEVS@E1VN?8HUG@'4FT#K,=A'CPS:;M_@N1! 3
M:S<PC0;WDM =31[:7\PG6UN/!GB(_!WY.R[,G*K%4J]X)U5+*57_?5S<YP$)
MC$FH\(P2,_9%D"7&KV1IE\"%B833*.HUV=0LQL^GWLB<M _ZD?Q2>'2GY'Z9
MT^S/8P)OR 0WO8JP%;4;$V;):O[M">W"437'TB9'Q-;->UYKK-7 _#BM^^7\
M_S#\VIP_+7P\485I65?N@Y)9A;_S]N!7Z=%A'@N/Z?=EO2$\\Z[5(0L0=B7=
M8FCD%:!OC4ZF7&Q 4^P76>9$0Z#6^?"?=M^XZ!M-OJ'>J=)34FU2;9S_]?A*
MIKP( [2=5QG#9^>[6$;#S NY'1I203)AW=0-G'W<VD/54(C],>9^<-[!-++.
MC6POEZ9U'F&U6.UZ+%H])T)Y/>2@0-W]FJ$?.4'LJY>,P/T!I)F]QA072V,G
M/N)?(]/6]($*D"YJH-$A5=$4DLN.A=+U%4SF1\FD1%>X@=)DCD'0Z,-@. 16
MWY=AQI9>\5XPNF%E;?%2M+WX64*CG!;?1Z7A&P!' . A8%BP&_R(88MT2WEA
M25J:^[9++N.<*-3UCF'[Y)F.Z1K9V8=C4I3LC9%'MT?<-=?/RSL?HLYC";PN
MM]<PY7WOFV*KO\>H<O[^=R#+6 3"A37[(D<E?B+X+^<8!;PM;#<C?59Y,!V(
M+B;_$$X*(EO%0'-N<>::?BEUJ1]_FTU^YZW>EOKDSY\(J*?TBZG T.O&X;=H
MWJ>7'!J@XGHU=277X-'QO'7/%E**J^6%"K[1M+ES_9S/F#)N*&HE*46Z]8NS
MXA2LH,B\>.@Q=>6&D6>K6)',M\]5OIDGBW[V7O;*DL'@G(Z.YIEJP;:V7*OR
MME@VBY(OH^U)@R*_!E.U^%/?__F>'R_Z<Q)Y'.L#H=@WA75&_%ASRH+6VI,1
M<MS1?_NTTP5>/V'U+(R(F$@Q;0<AJNF#5&<0,^U&<$ZSOM8$CQOTQ^8=&4<F
M"?3=)$-:5-02 QX9*M#H9\+"RV3_>;O]I>>-/>$%)46L71 86975R.;7-TXG
MD%\UDQ38J])_:G0/7C!-$8?:T^8P;GKL8ZN$J40 X\Q>+&.Z^A]UQ3I\H*.<
M.>;_^I3V15@L%6T-X\CD,^G4R6M=ZUTQ7((8KQ\Y^CV=O#,XA5+&A?E'-DM+
M_R_?[IJM-68.*JOIRDH18>EV:)GAI W+9O<5H#B.A*!0S518YI$ =:)FB_KN
M4P[2#PCVDMG:/+*UBH^]F:HY6"[U#Z7;UL=C<Q]BW.==-\09]W.9P3_SMQIL
MU,%2\M:':UMU1P-_!MZ_4X&.&>@NO:%0+0QZ@C*+QAEXP&W$^V #V7#%Z%0M
M:+SBQ:OVE$+^H3')&D_S5/.TWP%5]02V0(0@GK&:XPJPH15P!1@4_K4KQ&&T
M<FVW"SF]Q@K<J?3?)KI+G7&"@K%/->P./"]6.KM2W!23"<<;/6]+Z/=P"*RV
MT;TY]+Z\0%.-9.>9.X/A5O)+JC/:ZX09$%,GVV[M[BH[)K+:N=7[L8CI$U1A
M.(\BOUNZP>GU]M:X=T*6TA0!* K$?)];W-R^*_P*P [.Y:DW^\LTA3Y;!:RM
MTCDZJ6"J;L4]*,R(H11]5US7' =?M>#)O4?+42MAJD[!$ZY RG5V('L%($H:
M=AN>W5J< 4I\T?=@>;YB*BS!X\'%X/HL0MK0PW#EVAS&#WZ>A./[X6*9$8D
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M/V/I6LD_J<M%,^=Z%DQATC'I8^75RKZBXA?N-%Y?1FI&M ^-@@/C=YS<"EV
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MA]"/&R0_6L^0F(RWM<,HA%+J''EW?CI2YS6.?BY^1\*Y$+LFW)U)M:H^I"+
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M[G6U,48LZQ$K:Z$*.Q[ZVGSU'L9 8H<.DCA&<=]C8W0D$G=?[M@H/6D@/#/
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MLN512Q_06+EJ\^[5ZP^Z*)V]I+EESZ_*6H?N/*IH5-EJZ0IJG[O<M49GFY7
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M0N6W;QP.OC,[;N)QV<DZXOVVD:?9G'Z2-\7_"R=ID2FME"<20_B#9*$6H*K
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M(Z*@Y.R4X*_"6SE8BK:VBZ.JRE-27VS6[4!KXS<?A',2TZ)L![)'5K<T)F3
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MBJG=1??/ZMS?6P&GP^KRA\@>^EN^'FVC[ A-1]*?/\:ZK<!@YZ>9FE2W=L?
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M HO1&(:ER-I,O^QFEQGHT1A9WQX5HQ=>"V,OU4R4%-M]&JZ@#SB&73"3A01
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MYOC9:[U=GCE7&Y@F;'S4,]%AH';38,&=/MY;\K]]V91.A+-P"O^$^+N-V%H
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M?"/A0HNP*"4@8XS[*X\) -9VMIGF%KXJ,K>@%$ZL&]L*[.RIWVB34JPT.ZW
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M@RY/+Y76"<:VE^=GO^G<GU#,ISM]_$@PC.(O_S]>6 8&@\C73#2,@:;;JH@
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MA%$7@&P:UI(N>FO*[A+J@$[PAL?]/'PSXW-.-UB5\)CWDB]-OP = <2V;;G
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MWVV57<BVD8%W7E^/"7?9I*>OR12^Y(;N<!CQ<.W_]F$N>O[:<69N64!VKW]
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MF/UT&$CDKE=G +/0Q#V)=8RI< V4P3V@9<_N8*$%NSH1Q0"(V$A!VV@J7_
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M"/X&[,SQFJ[4S"3CET1MF*87H.$J]@+N'EA41Y_8P5TD1D<->_;RY%=B9?5
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MF$/A;YSJLWGKRMNXOL@)DEQ:R](K:CR.!S'[N\N&*FL&:SH@5O/3YA+=N[)
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M!#2.')+=>YN=-5*0E;^!HRH:8L[=;*3DFV:"B)4<'#WSW]$A'TWKF@\VU:E
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MW_!=^X^]NOJM]KWV]>V]W[W7'W!=(4/FN<^_>_(\OUMJ.N3N6?9#633U2WJ
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MV@;=Q.3ZGD-W>UH?7W*WVN<[#C1,S<0S Z,XE^3F@JV,9; 3ZD@T9:Y%(KZ
M<[]#@PQL'@+J$T07FLC,_&+P*SIW=YNW[[VD.P["D0O/?N!211.1U1F_WOGP
M'M-9LD_(3]2>>?5OV4EY^0(OK(TZ SP)S'K7#R#CL(-(. ]=6TJ7- K-7<UV
MA.>]><_P4PMMAV*+Z*&-]DO;JGIC-6>:"E9VELV;6!CM:7GSE_#>=S;,<E[X
M#MKMP3Q!X8EGS'8CH9HW,JRW1CW;!<Y8.W6Q*SLU?$87(T[)9MG8EQ9']R^7
MD?#:94=O3DSG>REIYDA"XP6R4!67@"-$R;Z.MS4O7!/;[T5Y[JQ5^1Q\4&5G
M<:CC0<N4=X;XY+YBE_Q[J6XQ O1^#$N()@'3@$H@DW$Z[F<T#FE3DNSH<F5P
M\K@+L>G0.W7K=.7W+U[#"DB;T;L+S\_DB3"HM:#\6$D,>9']<JJEV<SWWMMF
M9;AG' -_"4V,M\I-F'A8E4AZ9/=7TRZD;;YR_-J*$<'KOX):?S..CAH6ATW@
MWKD!#\V_8.H^,Q:4T&<865__GX7^;UAH<SEOJ$O8S?25Y^KR[7\?HKT*=?_X
M=I3QE$P//:4I^7"OP_KC@>-=P!_D49E_3 9?"O&^7Q,S\*Y&6]\=G_3]U4,A
M+KF?_Z4\S@*M-N+_><G_VYCH#POM^GLFDYG_,WM0\;WQ3DW?Q/:*NK:O)S?\
M>Y+G,F9F,"Z1Y$1WTF]_>>4&O?!Q:NZ)"8>_HIE^-+FF?BJ1A^6^NO(7_-4#
M@W>T>&X\<H[ZK>>_8Y@>YMS)PKWIV'^KA;YW"P0/U:3XTT_IW)[E+QOEK.RN
M_?V90F!O:?J]R>\7@Y\?^F.T_>'I4&!M4G]+R4CRWW&XLO^7"/W?QCI_7&@-
M*=X08N?D6W=%^_4$V$.- E>^_,B)?+1+]3%D44;Y'.+*LO>EOXX>]?GG';AY
MM+#P/OE9QYRN+&9+Y5_</ =/-.7=_[]0Y__="_7*Z@,/L?S;3A76]_K(=;D]
MQ-]JR)'=[_=M$1RZ=.?K[7Z_E=27G/+^EP+WAZ=>]WH%VA.=NNW^YT(%6?5_
M)?U_[/E_::'#?.BQH;^0V^KS6G"V^/RJW?U'@U1NR7V-FHR%>VS\MBZOW>)$
MF/8Z?L@>KV[?'Y08+JW&K12[^U?WWGK:'BSJI]6_CU$3?GH9Y+OD]O?!TO&Q
MF0PCX4C'NU&#V=KQC\S;U(L<*%B:JC,2K(31P$LB!9FI#Z%[Z:*GN,Q1]TXR
MB2[1D9\S-]!MQ?;+D1UP["[8/D?YV$FE9;GQ+)PNHI$*J2D]K454-_-Q_^7(
M]GCI@J$1^4M+IDUL?JPO3,%3-6/X#:FG76<_->;^%'M6%'.:X3YF-DBT1+<J
MLX^-:\V2ZO?#'FG>VY2MN^F%R;I D^9P$YGW1K6=C>Q@FNGA\<<>@;+2JK[3
MZZOPNDW:R3GQFG:1-\_=<<G)MW<*]VWZ)M6SK'/MLYO[B@YU#+5?O9:]>\^!
M5^\>[71;^[1X7=ZW6;ME[>>Z6GVZBM\5!E=65K[$M@@V,G:4=P%? 3W.2J")
MVJU6:I^812C]4$N>0BQ%EVP43*=K50#>L462,OHM8$D&/_:TBF)/C_P"9E_F
MTQ*A@<_):Z$)D6$Z%4G@#L\I'.SISU8:MO?N@M**'CA]YVVGGV* "#*4>$^'
MG,34<AU/+40<(QNH/:!N[]2&F>0)L$*J62ZOFFBDF0P6V"$9ZK!- Y2V*FD:
M=685>Q:]4LQ< W%8Z.JX>_0K?>M=M,RE0\^CF4MD>?U=VD;!TLXJ^4OB1? A
M.)*D]V"8=!D))X%+Q,H)D<9$X9=YJKI$NY2Q13:FYZ7G^5UYS]_>EAU.2_<
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M&GZ<VC3)TS3,=-MCI 2NB'(-VZ$V;S+;[R_H9.Q(5&H^'<Q2W@PHO= >@N4
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M86, 9SYBJJS)GV(^1L[ TY58BMZ?SE4Y/=&FD&<;;C-=4! R3Q?&<"YYEI5
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M!;6*^)D1@DAA:9-G4P]-1&.%.V0=N=;@J=X6,;\2EF4"BAI/4!1GH1M^X9T
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MPDF>60AW_H8)Y];3@?"6:P7,\!WW[G=%5/F&.62O)R] NHUXQ4UI_1 FD$0
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M+HN =FOA5X=T-CVZ*2N)C'^8ON2+9_<R[_[(%G@]$;[=T><7><ML7:_J%OV
M:-CIS[/=ZR?O\UT@]S^5\5Z'?H([9^<TA-#HZ*'KL&,=KU?DV?'I!;,B>UN2
M+#"1<3V>;G?=.^$:3&[4=UUU ;V[>^;+%ET,EOY,?]XI&JJ0=?JO<YMUL3/8
M]Q.S ;/=M%+?S^IQSDDYX1<@'':4'KAAVF+QXWZ/ZX.4K*5RHX'=/Q9LR? [
MO&LX-XJN6I4KL 7P77V]N%;<GQO-G=L_G,%=2+4?[M;9QY56))6YAQW2 VFQ
M6SVP/ EGJ3"T8(=L_LGI+U=.[;G?<3+[FP&Q>MO)!Z-6]ZOB)C<*EL@VFHN8
M- ?>1=C8*_EA"<7IW.VC)]8[7MY6V%&TLVC;@6O)U_9:C\*F465!K4V[[8YO
M=E>>)\DHEU+N59J)B*\.LSIL&\+7,W]TSJC::E^PLVS]A7B62U2D7WO"RNSU
M3ZJ/7/W^4H#A7C^SL;F&>S_^?RZ+>?<U!,L9$_69,0UA8IL-MSCNB(; B='%
M:I4:PLSRRZ*.:#1O>H5;P)#@PS_,[/G]+*'AHAO#,]=<Y*]G[+A_]*IWJM2!
M-$U PC'<H)SQL@B??!("O)T%#:H;\9'><QH<KL'VHM^EB[>QOUK[1XG[DT1<
MN?ZR7H[5XU(\['#C=$Q48BSXPNB$AG!T 3B1V5YL+J!U&0#QJ,#^E.%>UY O
M?NM$=+!B[#EN7W0A2U2@8SU-']$0\+$LI^JR_H[H%8_,#-8)^JR47R+?B1?P
MMZ'.EJO+RN_!?A>D"M/R-)FS:2G'H._IT\9;S9'7?.D^NKY]MMC%J<Q+?MC9
MGE?B9D:J>!G5!GN:21I=!Q%E8:+:SZJW00:[U?F"((!#M82XL=4,F/P)E)',
M7AW")B">D%""78:=A0..R,%<A-=<67&&OS+$SPX&&VB) OTQW+M-FV<+"#%]
M^A)$L M./'O-;\K;A^?_"=#+Q1:XJ5:S6\$203/06S.A(+&?4"W5MQP49DRN
M,AN)5[DS']*2N2:"(+W(II9PQLT1<"F%$5C #!PSZ8N(KRU[HJ"XW$"B%'OX
MY^G&R:_@5[>*$=Y!Y'8SIM>J/O\&E"Z'Z WTOAW8PM4P3^D')91$W&9Z*BV0
MNRHZD^NEOECM'# WORP4]\"#!N8_H0!2KOEPGXG0K4M6!7U<AG LBR\.&QMC
MUETH+7^ F2 \,D-JH)?I-'*?6LD=4]EFN!^P%/50[4$7=@N^%/7-5A8C+G"(
MJ@Y<5+U)Y78XA'[O$%>:%JV,0S;)Q^RDY^,@CB3R_.,J*<V2Z8_3;3;+_2KN
M"(TUGHVBG:.8R<7([F+;KUA1,:!4!S4LE#(:2:;H6F@PB;\8>T*?54U6?<Q:
M#X--='QKD_4T^\Z6<A*HYJ@?Y';&GDA$A(T&P_>8=)DHC1(&O3[4@1)EII1P
MXU185 <LC+!PK_<^7G4G^.N!QKR!E2915361D1.HY^35FGX?#R?@TO0$?RKP
M!C-4:89LEP+]J8W<BL=I=YAOB*E^9/6/]N3>4^-UPL^A!OI">W$BVQ(^=5GN
MXJ1RA29Y9\.JW0-E7W:>C'9?<S^CR=-IV?!.'R8%F//*YN9]<F\BMD $ 4I
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MOX89>JB\C:&@$&\B.YK9:U7F$L68B81QWF^+^EJUB<2'N/21H(3>F,J(93O
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M?'VFLWPP!?R"TY]%1VAR'T:"<=3QNS>8UA)2'"LR#'?412EWJHE23EP/'5=
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M>'%Z!,^W[&?6BT\/1#R&S<>)'Y[<O=3N7L8)>VM2D6\D+ M[?^+W9Y]7P6U
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M: X8M(^9VNCEB^E,F("7#"^571.Q)SBQ0)$,-5 J9J(KE7&:<@IR%3K8:]S
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MVA]1H_TIP./" >S!N[WWZMF6%ON^7W_EGF>&!2DAAF'G5!RR@#F889W '.[
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M^J3 UU'#;^D,D[E^&K&X/DT^0'%NP54<V %Z(A9WF,(4/K$D&@IWA7W[DDO
MF=Z,W4A%MC>Z$UZ5?X\ZT+.B$NG+Z>^Q+6X'CSI3]0<FT^1<6&T'TG>?X=#(
M6SK0C L4(J7 ,T>_?>,X5K7=Q&!.2Y;3S4.W!]=DFS_.=$I;[99-N>[JZN1J
MEB<931H.V!O\<TBTRR9Y,B^\(M+T#/7^AU)<F58V_5%&VG^] $P#IGX6E[,Q
MY0,@B-S)%CO6TCI4!+$N:HQI-()'R-,0$[<V0&R/'!!3B^BIK@@+]O>M:@:*
MT" I=5Y@482U9]RH#[>TZ_6S[*=RX3*3QV;!'\71<#:V./>O$:N!*L+SIU,1
MJ^GYX"WCSR_*N!\*="=WA?1]"<G=!%['W6HL("O[>8ML3?>?GFZ5FYCC9.:V
MA^M&Y!RX]TO6^X_]K[(,?+J[^7T]JR8M(4#'OR-[P7LKKG9CPQ$D);&VJ?I@
M80)]W]XKRW7UYW,O?A^T72>A,,<OCPM&C&*S\%G]PI\*\=W$19]S",#$0*.*
M,,_]KX&[)>#[0U-QNT(//L_)!#\)XRMA8^S\3:**$/M&H2+<=JO!WW.!!C'6
M?MS\8"W&3^ , 6* OUR+Z^^I6-I._L@&QE0L;:XC:N7Y:X#L]E85X?KEJ0!9
M.V]L8G4FMFJDEC.Y\ 2 &83*L'@';*6E@#MI&,+%%I\D8RQB+^T?LHT$O:-.
M1? :>&)'*#^0T+$@Q=O;;"15N!#\L',JD#A8R)]<242NB.;Q/X35\Y&0G_F3
MBX$8(8L#;:4AJZE)%EUVEG4<(JH'9>Z\1F\;K_7["KG>FWR\Z6477=/9B /U
M><.EN>'6=8]OE>G\Z&A^]N"U@0Z]NY0!-VPV+IDS!A$OQ0QDEHSRJ@#GXR;D
MH>3U$F ^MIJZS_%@6$Z>W]X'2*B@=)HSJ]%V:?9^1WEBY&PS&9DKN^'BZ%9Y
ME5?GG\UD-5+3<;QP 8V2K*(J+Z9^OP$M6WU3[+;@VENZ-V)KO^'4G6SGP:OK
M]U6>WE!B'>ITYX1LX8.7=PYX[#V\YZJ5@PS1?/)Q*F\929E_]<#(W(9-YXTI
MQ)_ZZ#<VER.;W=DK*??=! =.['.R,%:O;M_G'[?WG75(OG[8VNW;M'93DTD/
M/H,OIW[KGHTC-.)\\+DF5J?$L760FX]S\]C6@2I2G^:_6%A4-&9-4IX-!D?7
M!'$*HGU5!#?\3'^MTZXB;+WV5T?EU4-5NF__$%7]/D*S**X"]AI71H';0T?_
MJ*=?B['^[N7O7_-E+^SJ([^(^:/;W\\=IKGDS[-4NPO"^R=O^T/\E/<7<-64
MOVMK)?BY%T'D3(:*X/6BLRNLV[CK\1UM&=\U/WSH=WVH]BNU=9G4DRK"LJ%*
M;!SS_QT?+FT<_HI2WO!_7O=GRS];_MGR?W'+D'_5,_5SQ\;/;//@BM&.4[XI
M/U[R\!DJYX]8_W,OI )F@N>O.F1I1X12AK[\/=\F$\[M1#[Y,?BCUY]-_U'3
M8T&ZY;O #B8S4<[9Z%AXB83\]$;P]NL>6DKPIZ4CC#Q+&6>>@O?=5R;_)>?L
MF>&RP]T1<WX9C.)X=D>P_KF'K2>PS>17 O[4^/\6V?OO.Q1_'AOF4L9,-4LL
M_+30Z5E4BN<?#>TD>_:1^M:&#%3A(/AW7:!Q.!/^;IS\2?W/MO^\;7YB5_?*
M4VDZ.\VIFV:#Q3PA39EYDG.DXV0B6>:N_J+/BCAR]ITT\*V^^.]N"?\J?[.S
MPGA*D?_[W\=<6@4H[QWF4#BB$$VD_8XS_%3ZTU\UZY(_F_ZWF]8-?[Q4[IJX
MX@8Y=0:_D^I?AC4^IA0=>[PM9?Q^S/N1FZR))Y_@DI,:!S_W9\W\>V^+OXFC
MLS"\=9SYISC^GVS[KSD7<Y?_G:54W5U5.I3BWJ&Y\F,5-BYJ&<(MR%<_F_1-
M3D[C@7D#IR:PV"N3*/];KD074]>6TCHIO2Q4MZ)&5)(R),A^)N%H8O4@Y$*:
MB34!FO9ZU6'W?%S@@W(F3AS'D*XN!<^U#P7*AZZE3T/B[]/?1R:[FJ1&Z7=5
M7Z:S7 OYL [[]KXW*@+-?>)%U)1O06$KT)N=PH%V)U,D[@69=P> AQ8-0T'W
M&+-X2*1&]]6QJZ(Z8^1BN#1(:+2?7K[#+/_XK4N4>6_H9B#!=N-6691Q7(=>
ML71V)\9AWA_\^)CF/D*] 5R/TI0Z"OB=&VM%4)BP@7.^?(!^69Q=)T.,&X8$
ML'JU]2_U;2.^"%A'>M# 'O/1:EEW&#C:5)*X^2-3D/^A+%<G\W:@O+W3-6MF
ME?+J\P4J@BL5VB&;V,9%-?G8<X&<IB*T4L2!Z#OE37YOCXPE*A2= WMS.7.9
M6M@K2WU_ 8BLL114^8C+SE620Z#4837Y 6@,X\#AE.:AX!(=A/,>]6FN!'3K
MM@1E=?DZ0/*Q8I%&I[=HH"PE963@Q&E^$0G5)&)S,A4;^TE?,/4_<" ?<)C?
M,=*[']! 30Y#_IAAB<*JG]_%F<TDV5\\H"+,Z<)T5HK88S*# $XGIM74):!"
M/[T <Y%K@F&@"SA:U9)!7'XZTL:G2K'M%.7!U=%R+&@XJS-*^+9)]*V*<,Z%
M3I0 J+:E!$2U0&QVJR(0:SJ3Q46U!N4E$.<\/X!\%F)\_0I3HZ\5[H%CGF/Z
MB)>$9M1/+;:<<OGE+W",\_&#-P1X<V,J=^;9LPKZ=0\-M*W26-4^S.\*ZO6O
MIT;S(4<5 5DZE7L%6:U[SGX)RN U [VW08U3;#T&$:%)XNW)##\X96B\8#]C
M)Z>&0[#5D-"FT3F[:'J(S W9"1Z&%.)W*6?1X.R&(^V\15!V#,/Q3EU6_[@.
MT!S^!$!64&KX+'"ZBM";H2(4\>N%B[JP5R1UL#>#6D)JH'5:UG6NZYG)?E)$
MGR>4[H#0-J9FT_&WL'^RSU[86/#"4U!JM PJJTVEHU9101)G.Q.?9M3F#C5@
MTZ<R88\FSJ:UC!T/E>G\WC2\>UDMJ>LD+=Z;AFHFRL4(5;&'L18^G@D1^L^H
M"/',^>ARGHMC-;^($T= NG,$M/!,B_KLS "2MJFWCZ])39!82-P"534+^,=:
M1!N:G]8K1IUI]<JG[T[W%WXH;O6U5S"C&B>F<AK?4:;PQ8OQT>^0$E2$!VI#
MN@I\A&IS\(#O1KE'JZVAPA7QE[]X (M^X$C5ZJ/\:XTL4L6XA DX+!5!EQ$&
MT]SA(V7B1?H-[BEUIYG&[9468A\-8$_C&&4N?=9(76D9:5'A864"0QL?K0X?
MJ FLM@FCJ-4IMJ.V$+F!JH6&0?[X!UT*25F#0I;L9X4W.H^&(.T'C1-M316V
MC).0,:N$K'Z41#REG%[WJK_I*&;&$=_T !96[N7-;R>/=J#.O1J.DFU\N:8$
MU#CJMQ$2Q3%(DN1-&OX"/Y-78S0->N*.\I&9!;D90:6Z^G[<NV]^2K?Z1K<S
MJK4NKV?OQ:?O?NDR-)@+<%2$CLO8ER;W4 WDH6(3.TY41JVCL$4/^X8 F%@O
MTE$1#A([C&OYLS$2LD<J]J\%%P:-!/DM;L>6H;1&"W7N0O1@";1QH'P,B\EZ
M0_>I?MA!OQ1E-++E$22+65<BFT'/,1:YK!MOKQ@;CM+].3<X:TRT+=A]J+BG
M&W";7'P[8:W3'[E0_G<>P!J@$9&UHB&90IVQ&\*E*9$Y%VF4D!?2$\7$6.9R
M+S_4"I*='8M::*KI">LFV6X,#@H+E=#B> OX+NYD='F.B^W\_J).TSOR#8Y1
MZYK>^'0Q=N)H2H=9*QIUY@?2T&7,A2K"B(S[ D"LR!C%OY>CO"X4@$H?JF'0
MQ#!7QM>P9QL9P)0O(/[\]Z^/]41<"+[:5'=PI8-%[O:D7*>P9=W6N^^V+#_*
M#=L$?HDD3Y6*OKF^8;'SCX?WW;RKQ_2\3E$_G\PHN!KX,$O_U)VK3@4!+STO
MC]]P%;["A'S),N'K5"P^?"J'U7E*#16+&@5KMW$>6BH7RCI3ISQ SO-1Q2!2
M?9O7AZWTKP$GIPL!:&RJ+"D'ESA-&TFV<N9;#G)DJG(I,%4$TU\$+_ ?PKO[
MID)^5T6H,1;CB,1^$OBO(XVAWS4ZHD["\RK"J%HZ*!Z8JKI(1*Z+M($/Y!6X
M?%B0,*^I&I@*>WQ.B<#WM,F5HA)+; $P&YP8;_R'3)3.2@ D'@QC%>&6+7X2
M$]WY$_O VI=(CHJP)<(8T[NG(GP23E5I[<+[%R+DLB%=:=IIX;8V=CTUYD&/
MT+!\4#0?5<LLC:&M*'A8WYYB] 7,8I.#EZP3/"]/I?@$G>JV>/ZJAKT,JT,L
MZ],7(O'B*,WZGAGPJD0)SBWZM1I3RA;8F!5FX.NYO35OU<_.J28*JY7G#LWE
M:B5P>7K2:[.O6=V^J(M6!8T[8E^&* (00:]H>*F8WU'FUU8@8\Y#3[6:C2;:
M+?QX<&5V#'/EF]=Z#(#[H7_=/5-J;;A^6%G,6.314,-!:D [6_U-0.,UE%M'
MS9RU\PK4<[!VOT;B\QQ)X;&5QY@;C9\'"?0<]<[6-%\]MO>!>ZO^OH3-Y>8'
MK1NS/>@)]!C*Z^:]@4X;4@:,=*-6CN2UQQ5B).DQ,U_;32$)F3]4O^^(FMT[
M>&#]H_L7,V,N;$C,WQ.S?Z5W4\R:O=GZFH+R],[C^9M_68^U?[B=@)& DL_K
M)_[VPMP3^-S_.2<_JW\R(\R//1+_+_HE?!;WNJ5 1<A]I2(,J?E/%C_^T]_Y
M-_[./#4D1G'@#6JB+&2$0)$-^>(HM5ZB@/W:H)9?2DI"@Y3QDF2W^G(+832V
MI@>AUKJ4;>>W?-_"(&?3R:Z5K?R'YMQ95/IMF0=+QW+<>86WFQ*FQI'*+&MH
M">EFRKO ,;O(&HZ&_1(ZQP$&T 73Y><0%W%5D*!' S8JN8.P)'=+<.6CZ_=!
M1= PMW-T:3Y^;(P6IU^2]J*DYWIOU^P"6T<P.&2&O/S80V>#4L3ZU,#>*VL[
MMC6?#KXC>7/K<N*9-2NZ"SB9VW86%U1D#OK@:A<<LKE/_5#N=QUVKK]Q(5M*
MG/=4PH_5#V,/#2N<?47HJ5=+6DZE;9*K"/(3167(EI4-PVN4/TVVIF?F>:,S
MV!*+CVSQZQ**=N"U-J;>JY(J'TJ_#.R]0WV8QHZQ7X (,)V>C)P %<%PC!2G
M3ZP)UA7@4(VWD<YIZ-D ^]=4_&PNB[.?7H10Q4)6.;<VE1AOK]-R?!;G'FK1
M9FN<31\5;8GR#Q9W?#S5O=6$>JER/90JT>8.XR!JAGO;'21 :A,\7:PVY*9P
MI;M)C/(PC39Q(Z:+9/HB+HKE'WI(D"A)UN7B0YXQ./D<,X+MKV9^F'Q;?B3S
MGDO&8-LFCV;[Z_>VJ3TG%;&>R)*M*<,9"CMZ;BU5#5L=D+X(:D>UPC'U2&DJ
M?\$@E8AZ'<XX:J2.E.0$4B!^O:YUG?RB#B>+3I4<"R_3Z"7-=PZ9=5EJ7G&]
MTBX\9]U'ZL,#7[F:.;FGF*XMV>][QN59A_+T^FS=(>VL-0=RG*]G?VQ]MYMV
MS34BJ^/4ATD% ,B BA:E):0BH-JZ<D/8X0/IM4AW[&FP!7]Q%\.L)2P1Q]@D
M<W >8S.2$2EU%K%*27.9U@AG'T(](!9UB"3V&9)!S:S^GNF([#[#"CZ282B/
MO^_5K_D!6_8J3,.YJX38*9/3F]"E"F?Z)Q5!HGM13'FM(KC#J^(5VP+Y4#PB
MH2*>-SCG*]4S4&=8H^SU :CE1DHB6(1J2EQTO4<J-?PE09'\4A7AR.MGH;D^
MW:^W((_Q_7A61="_@^,A!H[)G!DK[S"6(+<Q:UB&:CLWD!:B"\1I-F(5(=&@
MCK<1VJLBE'*K29K]*L)\6Y-,GP#C?;!NS%THG14I,0"T W3:;^Q*-VK\6'*4
M_#(U^T7(//*P;A;JA@1#N9@Z&]( _=F=SA)B+=@IK0468$N9PN5BZA-J G5^
MY6Q8MP:8#QXFQ^*G4E^Z"-_'#/(]QGJH+]Z6E(LLK\OVAHA)#!^QR'"PN?_&
M:18T+N"9P^0$=&EF4/&#S=Z72JQ:FXKN-N<Z42[NK<[96YZM=3M'LG939PB[
M,,S@W9Z$](@[!=<>\EX$MN25#325Y9>U8EQD!)MS0+$(W=S&"!7+%J N\.&>
M(DA0G6Z(7(0W"*K!+U2$H]3XDZ@5CN^YLWP86QMYR^ECV&(<*^_WFX<PL/D5
MB1XMC!#)&G.1^M%=*=['*W(#RO.OODLR.HN;EB+E=6SN@+U^(\--6A5:6RY+
M9!KY,JB-#!O(4^Q?)^JTK&6)M>_(3R?#_AZ0;&BB%XB?;&<Q=;K]J#ZO^\$%
MMML.9-$MO?BZ.M:N)9'A_A%S26F<+W!T3FFLQ.VFF:[\5N8B^K@3-8Y?R!T"
MQ9QI/0-&<V"-!$3F V4/A4O8&D&X'%VM>WE]/FR?(^9KBL#O B<]+HRWG[&O
MBE!>C: %W]L?092*'C2@Z\#79T9J^)K@4=(/*D)Q;$D&&H'OC""PVMK<4',O
MXH4CY?W("RF9P/# )Z8^T*.%<!3VC!WX O.KT]<BB5!%77AY6?(Q='>&+[U,
M8&2 A(6"*L)LU\0<^N4=L!\K,MN%J!83<OG\_9>G^E\QG[IG"?W"[C7FK&XJ
MT1$/W1SXQ?E:[I6 3XK"2M8+._+AY^^X)N,1OE?'!C^579^TTQTNR@KDE.H*
M1#$8"5= +C[R S!G: %,D=>"26V=-6^^=CS+,V,LA4ZGY7LADV1-[MG;R*&>
MN?#'JH)!W3+KO44KZY(OW.8M?] <3,[[J+3L51&&VQ5DQJGV8ZA5+S%.O\7Z
M;DEOA+TQW0'3,:[A)ZH(L\Q%\52-)1<Z(_EQHB\MA$GITR =%LQ^LFF39Z='
M]CU$*#Z2B8,;C?[.[8_%P]\KW,J:T&VW?44J@DT9 %& 3EDM9]X*1)\_-XSS
M)5W1P(=V4I'5Q-CAY>IE8M$Y^Q5HA)+/F*[8PK!7WA@#XJU]ZX2"%R:U$%UM
M+SA=<*=:XM%XV07"'H+?'8%B+X>&Z>+@K,2,!1MC<QQ"%/;TC;V6U50VJ0C+
MABJF)N1\'W6":?7@.7 ^<T8=Q*K%11P\1(P7%>&KR9N-.-0:V4-]YT<I"6<>
MPBI"K8F/<,$ KI-E:!3$=6FR7^PSV&YD\JBPA:&M?)R_2T?CT>JV\;U!V\,R
M-I]T2S8+=RK9]^FI<-"LI3=S=9"!683K:JVL LZSPZW=V_N#C_N4RJ(FO3BW
MTO7QT=*8=?9D&!3(IGT@:56ZA4K(B9-W'V<Q]'RX9TG%9A=OH\'V!HV5CA*-
M4"]DN:3JH-B=%<-<CSBX-#'(8 AP@:<WZ+<6HJ;>0YQ^L8N058;W)M+F*S8E
M*ORPE^G+D6 %P/!]Q5O1.2 B@H$T3;I-M>@+BRX2D<[#;0Q[8[B'G8^P!.5V
MI>?32?;+7A5<8(FY"P;*9>A*:U>6[OEC#"#_#;W<99[=*F6^BJ =QD_Z$6F6
M\-'YBMYAX5 _/"+V9_.(: "H@6Y)E="J*08,2X@MD,U'-LIMD&=B0W\Q/YH1
M)(E2VP:!]>IV1V3?\-M'93H,C5;;*&B2I(ZL?>;>BCK<(<=5K@S.'541'N**
MEJSG!58[V2_'A-[UEXGHQCY4,[6>9,@$&/,??W-!ZII2"T"[K<SY!HB:P.-B
M29[#+O#LC569BEV(HVMIP'&S[9>EICK#/?MP._[CLH2?%MM^UW>FY>91RH+5
M+;E.C%<QQ[8;V5XP%X?ON5]S[ZBRLXA3-5-OJ:MKE\W3;5X6N4F'\[LZK*C!
M>[PW3FKC:*G!XO\74_ "Z1\::/V#V+Q94_Z01]E)I)+Q:IDF8P6B#F=*4F*'
MP$,R5J<V#B(6HZ9P0_*HL]WQ+@E8'[6US[&\E;$Q(_"TSF1^56SVW1YA]HL3
M*2'>@3J6&[8^Z.ZJY,2 D  H%2KU^J8LICC%5#W[Z_B6<Z]<))G+4A?39AR
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M(,L"(*]QQ,87-2I6G>ID46 &CNO.GQ.I@T:EIN2/4!O$1NX/ZFD)(2S3;GQ
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M]3,$P''8P*JG._V$-3$\\1%=/G)D-SGL8-C.@%6QW,XF8Q0W&[_(=_CJ5RD
M)25:PA+ID+MF,?CN]I?%N .B;L166S5(9]91)F@*+O8UZ>^):/NMA)W_&0(Z
M6;@;B_^6O)1NILS-:B+V<IK9[S^UM[YH7A:!&_?%D]P+DD.+?QI)&O$T]88
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M% .@P7:2&P_>$BGG#$D3B!2ELXYRBYQ[@?QA!\ON6%QYZ/3$*-ZG<Q1!=7:
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M"/M?@[!Q36Q\C'RE)>B1,*-A=!WQ?: 1]Z,)5IA),+H61/9,DI##^)8OI]2
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M$F:RSYVV2"(QQ,SNNYDKM\OIV<V%VZISK[^:V9<;'@&4C$1/;U(=,CDT,1!
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M$8[GGN+\NXA.]V'O#3.XVYD'_GG^;=^1NIZ"A"AILZQ5.DC60XMD]I;GEO7
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MT^!PC&L3S:.$WS[:L]2V@DEUAO=(Z([?!UH8F%9CV_:>F=VRH;*K-#IR3X6
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M<PS0%>A;Z66W!10.]1K/$[-6*LD"R_-!+9T5:OK*\D1;=_#S.(,Q@)BA-*J
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MFRSH)X$537C<]&CVZ0MSE5_[B12[S;;33DY7)OF*7Y-\N;)5C\-#0A_3I'E
M^.@5)T=3ZH-0!LMUZLSTO)S\/#3KPFEE^N<<_N8FZ5TICDTJQD$*6<?YW5U=
M"34!6[-Z@NY9#'IUMBP>W43LMFXVQ++F%H4.+VFR!.0_%$6-X"L(!+'$&U@K
M'UF)F\A.>/Q> 8U]BQ&.56%G,](@;BC>WUOA.AAQ37I.E>.(]I7MVV'433O"
ML#S!W'9'GWY450[0-3&/+D;%R';L;FWD?GPRN@WG@O+_[E4Q]%]^+U[Q\)R8
M4^MXFCBA:]5.?3NUP.=UR]WX=E7L8*Q3,8U-]..9P8:T'Y99K(ML*HJ(\:H'
M^Q_^U;'BJ'W5_.D>$/->DEY<5S^;&PJ=UKD9MGVFF'CJ/7^,6]&U]*ZZ5BHU
MECVN^PJB052H53.."%@7)^*GB.5&N5H9R/,+.I;-$3O=+A1_7'OX O>I'IRM
MG_+QI\)HB]FG;A7.$;2AO!:Q2*1U^;ASRJ4B@V)\ 5PU+9B3\XG-X4J'P,&W
M72"VZ**1W$RU(\&L$YYES%KCCZ%?>R=$SSB3UGY[,;0YIRG<0<! 8LWLZ,;<
MBKX"[B(VE\.#H^;")./=],;;.G/#E'>%-TRT8<:B14KCM):'\[<F8E\'.K9B
M8M=/A9<%1@1C!R>R!:8VXFP/PET-Z8=QXZ[T-!-LF6_7S_R?S=T#W+7>7[%N
M%479K(;))U(4FLVMC]O \CT:BJB5-N-W:EEL[>S"<>G5[.PX<0K>*VI/ZC;!
M-5.A*Z?QQ[E\>IAH8;L?1&<3<S [$>.NV]?9SRZ-MP0FWBML:U=O<-#\&*,*
M6!E<67;-)09K*<O0AS08>D35W@.R$0;UX1SN,]A;S6?/%[NXWL^<SM+W /7/
M!:/6ZA["6.J7JW2:Z<WJF)@SE,L:G##-I:."V@Y@N0.VW:^T%CGL ]@TM\=+
M?D-H<Z:;WV-_-?&YVYBO-QGL6Z/2M2<V"NRLK[3_B+VF?W1CR'W>R=:]16N\
M>[1;1=,=J99A%*5=(XZ>47]E;ZXQN5W,_&7M7"+@\NDP[:+K\A%])D0W]Y.3
MN8:K'?(RQ\[=GSKZE8HBU<^RSVVTH>(Q8F;X2"R&;M:HFAXN9CE?N7Z9NF9B
MI<"Q].4'GVU<XA:5*P"[V)X>150PW0R;V0.-8!+;*C?2=BBNYCW 8@^QYI[5
M2_BV;Y2E;YK@W$N .G77*EXKO__P%Z:;JQ/:^[JV)'=6PJ-GNJJUE-8L(B()
M[=CC<,*&342V_B;%PJG*9IIOIJY-D'$XO&/83&Z+J;@@-'&TSX^R&V]/0P@9
M47==!6TV,K5NLSI7B@3;5)];\'4&%P3&5%G4Q7V/C=UZ?OYK[O%PZO$]H"MO
M8FGGS.'%WD?)2@H#\5'A4#<6)-S31/2,>.YJ3B5Z3^)GV&UH<@-)Y\Q)<_J.
M(H>8TQ?MANSVQ2,U%@6/R*)+ $-JJ838C#6MFLJ,J?=;52&4>M3Q9 ^9^7C[
M?O=!][-EW&1\2JF""X:8/"*-4C,&J]Z?LTV5MJZ<)Q0.XX)*142-X$S%]'.9
M=(=C)F7Y6+,3])\]P;J8 "/^X<%>US+FQ1#!3F#AC7K]4=]_S4A#0B=4GTK4
M)CJP:=J@QII<S42?>]KTV]'^ZR)AFPPA?TAPRK[<'"N*9BQTQ3+_>4R7,W&Z
M8TR65U7<>C8*KJF:>$D+-!UX:.GL%B9EO)^:-Z/ET/,C+?"S"-]Z0\9T]1:C
MUI;FE?(3^BHQY>?T8@CL7\M5!\_:H E\](;SO^F0B?8[ [JJKF_?B[Q?_OD9
MLS#CJ-Q\@<-8]WRDQJG:X'G:D:O.;(YG[3<2FFQ!9O>@G&["H!3&(8[GR;Z6
MX59UC[O/L-6VAWIC0DE<0 _@E6T?Q,Y8M\^A;V+:K7JW\EXDV#;,#'9-9DAX
M44+()^(.)S0\MVR17]HTY7QE/-+"U='N!D.)-P0/IJOV QW=\POP.+:NJV7)
MV*B1QFE*5:23I\G"$Q_39SF,J1JNZ<-7>T,Q3_O*DQ46RD3I-#,TYOJ2@H8&
M#P0E,<YB'V")BZXE9EW1YST-I%  -GC1RQU&0B--,YBV&W"<I'/VZI8,Q87K
MLN^ +#7B]P"S6ZI'.Q9(P^URW]WS'?K8=6?N9[J!E&MUOG2]X:IA(]8XE&L\
MJV%WMKNY_H#&+MHHDZ$GD!.6!?TZ350LE)T&*YZ$.PI7ZI_2[8-.SXU FYV+
M)DGO1QNA!:K]%>9+GO%[%XY858RZ%[:U]E;3&WC]R2R#[PP0]1[<_9,X2>I(
MQ7I[2M^W)*\]\UW>Y5266BD<Q$=1L&-L\8Z'BZJIU%9+NP40Q6+;AA;XXJ6N
M78J54X7<+<3N9S\\>MYRE/",-5P>I&O<9#654BN8=T%X^=O]EP@ZG:)FFGNF
MR^V#[';(+UW;/?_=>X"U>IIS)!VP)-1BKJQ:+'CO_$UR#[6Q60]O)ZB<R%<Y
M6JFKI*$B?-FAS*05,,,Y=WH/&"*/L*^ =U'^3!,EZSR:]QK*6/>6B&1>DE"H
M8+>3P^$(I/=13*DI#RIU=.CI\_CT[L,50LE\]-,AD0]6U&3!L)S*LOS2O)#Q
M=#)*WPHKL/HE&EY73QS&*\$<.0!458U8ZUF0#S9G2:M7]K>:JR=\Q;+CZ1)"
ME_:MD$+:%\M_;/,I-X)9B7-)7A >[42@\KV3 5A'J^/3?/"&?3LM-!!<+V&[
M2-SB$Y/ 7Z18#QF.'0\^SE%?>RS$)CK#LHS16'M:OV@H>@_ <R[W!LU3*%4;
M?O5:'QYCQDY+#TV8\S>^[1&0?P?K!/(5(*DG2IX^6?W<J.\)FQ#..;U]\30Y
MU!.^7TIPNA*UU]ENZ>[VRA[CU4OXY[FYQW-#,S\S$3KSJ2[/A:N*7A5J?=D7
MI8>R1'SUJ_^E?-RI$AR/UJM,?[-H+]K;XM[P?/0>X)-4E6KFV,L$M(G)6!!I
MW+A=4<J%'_OR?,_8?]0'SQ!#7B&S"#8W7"X&& 0UV2U5?R;&0\P/N&%J@(?3
M!_K/+9X-*]+KL":P14<"6(--'WT+C5U5=C]@XI'/Q3MR<_=2%>0 ,_5$U6$Q
MKD9LCU]U!22SY[-OLD_UO+(G<][8QD8C;0AA5YGD\A0GV#] E5D;EL+E6*G?
M-S+80RN023X1;%$=&9E46<-\-7&?>ACP+^+%LKH/K%)NST@:7E!BE^:OG^K5
M"+\8?LKS#8%L@U5AWZBAA5(*5PALF\P*&^RM%BWPF<6$(@/>SZ[.USN4:7HE
MF7.S08A_.S4;RS\CZ(#R,9%9TQS$YQ1:V;A]YC$_=ZVJ\&E:N0@Q/PH6\R*V
M,Z*2R7#L4/F"? +J9J;Q%6436,/?.%,TF$ I6%^V^@$]KP"WK*>'[5>2Q+9N
MI 9S!+4WGQ"('E/^%3'EE=W>GWL*2!6@>= L\>->:HKB/&$BN/2"G/O 4)&@
M_>&1>\#5O[P4Y:&\9AS'7I-5OPDLL\D:O9[+I(!=T2^GX^WTW]"!SK><@X+9
MH%I<;QS=Q@E(4JQ_>C]]9/&R^X6PE33GZ$]3#8V/&;%,E01":,(9IE)4C-%R
M9<B( 8.L97\+-V8]=-;4\%*OM%.G=Q"L46/CA>6DTQ6/Z<76C6,*-SMW/26&
MK*F$/TX0G- @XIP3UB=Y&BR\E6__8@?5JJ.UUG^QTU';5?6XA+B3C>NU"7;6
MFQ/L;W6HP<1&IQW/3&HU0Y&=CD<YT2L_I7OI^$";<88:\4U+!J\CY*C-O!5#
M2O3C)-39^T@?$R3G_O*TM-@Z ]3D4[2R:,.[?];Z*(%!UUSQNETZA08QP/X4
MNC!&37D)I4?TR(BWI[;B (G9KBA*7)THIL_2A*]"48Q'SO#E7:T775.W]@W5
M8G'1;N1:MW;KB;'QS*=Y&%V3#)W5+(<V*TE8J9!&PGO %RM"\@KK&<*BI).5
MG"CNE4:_44GYTYVM!S_K8#WLG78HZ*MH.4:U&@I[24,C$IA.UO&UY+',A54\
M?:UUB0#IPWSOX00)QNT'8ZSM9.%P#:4R5V'MTQ+2I@JLT$()XVD%=M=W%F 9
MY@47+3W4[KI:\-$>WE4]UA.K^@YD"3NI33.%?-9#1/7E"IWH-QQB^% UCU9\
M4TKR#R$WM>3R3*FBE0>]+/Y2^;B$KY([LD\>6FK&C!<RXJ_743@K*E?QPPD:
MLAT8BGQD90J>7%CV$^YHY DF)%RX\B>HL$W*2>,F@CB4/7T@^HJS+E^U8L>R
M1CT_'$\=D7"]Z_'GRJ=JM>\BWS?4F*!4?QQN!+-^5Q"!9$NE:(C[D:VO3:W:
M2NHUBEGK\+$]/6?+I$1='OT92EUY/M8U1_^M"+95S !:+93_48BE4MA;>[9V
M^EU&-1/WD2YU)]DD%6HE3)2F-3OT(&_-KE;6^*B:_R(FDT9GDN_E&]U<.HEV
M'B*029H]J2:RC1/CLYSV-S4?N@ML(6]XH54'V[@3.P&'YI?'%/%T4'5+Y\QG
M[N?;F/7A;73O5HFKVE<<-U-M.ZGV)C?[*6$$3_K#AI.T-;1,+5GYJ[:Z2IA\
MOY(@J#RPDA:MM9F#.E=#R?9/E$-I8<J1BLGQFMGQWOUZ-9^YB%]]&\^G__WL
M:>3;,[(G&S@VNDO3C4>3?"WK=X-PE8#$1!+SSJ'P:N*=(1UK5TU_9 ^K(_>H
M8FNB^Z7KAY.@PWT6JZ9P?7/^#R^U I..UW!>EGV^&''2.S&/5I3U5"'G7%H8
MVP"<J5^./37&JDZ:?:O_1,.I6<^\2[;#9E"+7>?K1%%#/!W#>$X>LF^XP6PV
MZW>+9]0_1SF1N[/OZ@?']%!^FB;BYH!ITM5Q+)\^2<=+29;G&<2TQ\X^BX _
MC<@Y_>L.S(V/%G?23=QW#GAJ>)%S48_%1)YOC-@' XKJY/8E'ZT!]M6O(UNO
M7OL<;M[V OXFV&.J=L[W76C_JK(M ?:0F4@SEZ>MXF9@LFSN! .DCT,)D0&G
M:)O,U+:'?S@ETF?S&^0..GW0]W_Y5?#_%X 1&JBNKCYR4OD+L[6C7(S"84/0
M(EB1/!?O<EW>D7762P]E7Q"JB%M,V/H='8V/"*U[I"]X>COX@^;_]AOK_R=@
M\=^,74KB D(S,F7R/+8C?!N/"JX7C2\_/\S]#R4<G3QBQ90VONIBI1+^G-R8
MWJI/99H._C[KZY8EG$*"6B!-SK)B[.?+'8<4,G,QSV!0O7,1''8KDQCG#8M\
M(&.LD\DFIRUJ]YR.Q25%*:L6]495FT-O!"-"Y$^ZUEL^>Z5O<L#R:SD>).Y-
M)SFT^2;F.[?Z]-QY>VKUV]8="*/?;"ZEBWL]]P>%:]9A@[+/VZX'#V7PHN4@
M7ZT.5F4[MVQ9M==^YZXU0/E$7PJB;46CNJ\+.RV/%X3D.&PC67WCI"?X5&%6
M2\=Y<"+A(P,[Z9[#EMJK<79]FFAH6=962<9WRJ?_QG3,3E6#59MH<O9Q*>!>
M+K(L>-#&E<EN2X>S9T&#"56=Q^MF=(8=XZ"O !Y8'(]-3CX'!$[,R]50&DZ[
MMM<*?.,-VHE:?T2,OS$G+"OEXY4Q".(GY_L5&'JH(:VL&3M3B6\ZQ+V]F.;A
M6AF<6M6<[=70^6J_>F\<81W'Q&SG$S(SNT0X\#SQXGD0 0Q+ [=+]=P(9ZVY
M?/JA@"TA0]Q)K >UU;<"Z^,#U'AN29ZX)ORKRRTK0M1</\WE9<^@H\<</U&L
M9Q^1;H1I3VP:#6(&SA/!I@+A/M+.1O8F6_3LJF=E?&#B^\_VP*/DZ.X?"KKI
M*\.X'M7:U9VV>)8>2-RZCB=C*3+!'G%R4JL6>N#;7_U0M<A<['R9:JQ*>1'Y
M)]Y&F&]3DX^LSO <!!!H!IU>&L2[&\1;C?"/K7NMQ6;RF4H92@-Y&@K$F1&9
M]>]!U8RS=OBM=N7Y#3*AV;5G79[%(EM6M;]%MTJ%*62*)NG>'J.*8LSL=?91
MVZ:X5YKPB-NA/?]Q[+S3W+O]9/;SYOF+G753#.66?V.',P&VJ8: MBPSNQNW
M0$--B961R?R:0JF15!T0"99Y'',!0:)05A(,YGY!?!\EE?<2LDK))S_AU- 7
M/8-&03NW"7O7$[3:5$VVPY>U=X^SXRZBO:2J6)V^W,4>?1C\V6[]DQU/>9W\
M$1F,Y50**E"-&@B?+_]BR'G*3DW2R&HMG6Q5WYO\Y--RAH^><T,YA&VX&W0
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M?@=M-A*K)3Z2#BWS]2R\T&;2VSE\/*4&)>->+3#\E[?]OP,&U>]Q&1.V\Z@
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M &%!-G7W'D"G1EKX[P%(FN;I;CJWG8.)VQ(W![V=>\!.0_O1A]C75"Y^F?<
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MI6ND,E>E.*O5H0*VJD#RWQ#J\JL)[V:_D0-'W$8^&%7R;]NI!')/O:M$0?:
M0Y5U46%SJQ1*@Y C7=B&/C71-$)#$?=5GF(Q!E:E9N7 I0[W-W)7DI1G&</?
M[40S4HH23AN)QK0(KV<LQ("1G=1CTZEO2A=./=FC"8NZ2H2\V1J!D<J'0^01
M(K]#9(<F+Z=<][JFS$]+Y$L*Y N)=S:UD(QPS?%X6[YOLBY@=8<FF4ML5".G
M'B=$:R<B*:RVX]81- -WF3R;S$8[32AOM#\OPO'\Z#0>+H$">?'<?FU68 T
MJBU0E/OBHTDCFRIZD5C*Z:[OPN@C&ZNDZ?+4QK0GJ_H\/MMLW6 Z@2T2#[Q+
M7JW_5FDA::W>XU'<,G&(_^N_401R;S-@WT)#YA44*W<+U?/D\'LBN4H+DBFC
MZ<K37^6_@RMP9A@T@S T5/\XQOH>T%+K%_<!W#]RZB>14W;5:.?IO%* T_I_
M/FK*_==K'=S(HOTR##NR]?ENJ>OT6UIMB, *^0+/8K))@M()WP!]0 QO5 S3
M&-3*,+8_,;,(3%"L<A"Y5*1NE729ZCU!C,A(G9@06R%O^^809M5.OA2"6P6Y
M(>Q(+*S;GU^Z!^ )K4W,2LH^FV>SG&S:.A3'*UF@KO?%)\JYX)5)VHU;F$?Q
MS>LEW[A[^/B$+FF]_G=W(-DS]^$R,?&:2P/':XEJ8U+OS&3'<1]ZKXC7<2;\
MPB)<T7-3@T=]-IV/[0WO <$OY,E&-_.D,D/TE%IXJU:V,9E.RU(X,W;/&5^!
MHPT03BY@;]08M8\1:]RJDW5HI5H&OMQ2SW%#;V/UVX2H]A=,QZ>CC+C]@X^'
MFCX0*/Z+'W"Q_M>3,#;:0EL1OX)7KSAKI&=/(6?HXB#;IM"*'8=\<:1$RYKH
MIL-/7=E;]L0ZN*TP^=R[.7ZXP=A+ ?+;NCW1SU1Z(]")OGK8N!\?^2US&IR^
M(Z/+^&YST4PF&[1BIHB :,4G-&9\_#5NN5VR.M#%N3[5;%F\N9G'L[1(:_X6
M?>(Y675.9J9^6M*GP5(]4R7U>4<]STC/.@T5K\"B_P:EI&(NZQI:4S-/QFEY
M.E:0#X90@Y57XL'K[6%OIXOF.!;+("DNCF1=M/,KT[R])906'>#=UQ5_BE@V
M:>;P.@R;ZQBN'%@H--+(-K9_ JFS*YV[2'65!UZ+C*_(HDG/;[&]\#$/=*I0
M30F%\H_@DPTZI<DZ4M5MS/:3!)K5P"S^'T;>.JS-;ED?3MNW2DL+%+<6=XH[
MM,6*%T*@>'&"$YP@59Q0'(*D6(#@&B!(BSN%H E2W%V"\^N[C^WOVON<ZYL_
M'UUKKC7WW+-FS8R H ?Q_4+4G2VM&X-#(9FU7[TF$TQZJXZ!G895O$3CF1OY
MT8'*6186;$+[RPF!WEHFGG,0"4@B;%N(33VKCI:QI@+]@R]'WJMU0;&;)VRO
MV'.%W)/71C=%Y;FE!XO&\D>S[K=^"*%,JE59FHG\*1Y]/:$T=2U9^AB8OV_;
M_.*L0(.RI<L>W[3"U!;"R[>?ZHK:>9TVB8^Y$G3V(.((QXQQAK6<0*7^(MW4
M5Q2:VCB#UOL57DZ=FR8E=&ES++_ZTF,.Z<B)+D\1(JODWGC=PA4G(<:KFLG4
MAB(*Z2J)$QS_%;CK!/W:2X-RF#,1(HLNY6'06-$0JSH(L3IKV.)>RPUUVV;'
MQ9/SW/XH]:A.*CY8\QPD]C2_:7'7!59\I\ BP1;46O2M>E)K0C$WZS=KD! A
MXKPY;"^-+129#*-65B3+T.YPVUQ:28[N-4&)[CP>=!S7O237\C_.$:Z]R#H\
M3FJ\>O488Z*K#E2W# ]0-/&:RCKZ\? ^ L<^+*TA!+-$*HE-LF2F#X@X27\]
M4@@HIA%;'BT.IW?02VG$52M-V8=G:?6N?^_]&)/$Z/QI2W0#5O)NKG4;D<<6
M$3@\6GL26"S#<-@7Y#*HQ7=Q+N2)=XI>?!-,\Z&U0HTN /:*"%:N,##BM*?^
ML=S^W@:7:/SV"*?N#%Y'-0DN)&M4'WBWZ(A\?!JY!<0.".VW2-<= UO/#&MV
MB#LRFOW8?!=.%II\_9CK$.O(;"YP'A:_RY"[;2<B=R?LUP7''\Q(??HI!2DB
MI"<Q=\P\3\T>7S@SIN#;'")TRUA3+6JN=JW&<8M<S8;'Y<GX:7;%$I<^V=RH
M&M?(P+$OZ"_EOO1I83(9:R\^'\T.&'SMI HT&B(MB5JZ=#S8<N^O/T:.1Y7:
MVZ2<B%A2+24*6TM+59SIT-LN7\Y4DBB_TH=D'-TQ_?TX5X7R_8,_L:<")7 K
M;DEF?J*-U^<(XI6SRTD30E!$V:POQ$^SWH%]?A-33,N<XCO'K.J?=8!-$!(8
M:=+WZ>C\4E-XIE9) L)E^6B* T4.PKE[\3T"D6RVU1V!-B=L.V$$(\,-[<TA
M)8:4<*@S4.+P6%7+[=SAL[$HW\R./88OE+EO57^B=@'8KY>4Z_0F!22"@;SA
MDZ(7>3?_O2?NK5_&%XF,#0&H[Q_7.EVR! J0-<D(]1A\;)A**U-\V]@.R;QZ
M5G8XF/[M#L4:S:6>]JND301;M=; I?K@X]K+\O('#CR411*]8P.3JBRXVB72
M9. #!>XEW=QEW7P/)94W X2H8NE;/SS0,)N';C"K$PSKW,/G80Y1DG&?V_M8
MX:P2VI1HXNX87B_S1.84/@@DLH>8KZ#.-]961,/0[*SVOG7V<E+KB?KMETP+
M>2M'!Z.4QW/ L^@V "O=/V#\-KD7=N=*\$8VOG];GL9-[_=PS!#T+ZOENV"N
M\(>8]L@\[X)/5J0R04/?1!L,765G[BF$M.H5CFU3BB8C; U(0C)&1?3ITQ9J
M9*39R!:DM&F(C*H99_XP2H*ENM]Y'5J&5]>$RUE;/\S^".ZL;4"=XHHUE189
MZ5(ZF_<48PMJ38[.HSJ7PA+I<XYN'6?)D0L<F2][91V__[\<CZHG^71?A#._
M^+$0">S5?F2&U\2.LPC,9*$$%G?LV]*>,6!YD4ZJ5TX6J;A$Y%$^T!N@WN.K
MK^B_,L*/H*7\;"U*_@UBJH%78#))8G&CIIO\Z1C[U7YN+3:K*KQ%[&B-1* K
MYKEEY'>75%'F[T52[)I3R7$HK@@-GV3G6L"]WG_)E*]1BF:[EWE1Y*I6"VS,
M3^I;=E3JWUJ8RN^J9A9(4LM'1?C;L&,.I;VKC)Q+$#/ :&1I$X/C[R>I><7:
MXDLV)CF.3@G^-A%F;^K3/4;-&-4Z7>QPZRFPM*"%Z.H1:<M-7_.;[5S/W7HV
MV=7\CEKW/4)<NP7=-X=A;(9V\K/9X]N4(D_7UE)@J"QQ;+ [7=FYX72OY80P
MU*3?I87 V3E3AP_9"(BRPD]313R;3D4ZA;+MZ;PQUC<4R9=PKVK;S%\'JRNI
M]EW9"Q'$'Q%"/5)A_7G9^L;6>B0=:2L\M@@7RU0?6OT_$9M[J?*N&YQSG5#B
MV@(MV-QQ3)I\>B_TU*N:MSKI\L;<*35V?>'U_A;ABZ&(NQ_41AKS?&C;Q\4*
M#:E-:;$E!IW)/2VS>?M30!G,)YYUMD;-97J1B88W714$'()C1?E\^'3'R4+(
MC,/';W#@+M3<'=$@@2]MRI6'[CU0S!-^V@O,I)@+R1;!H?1!68FX<=H\9_(U
M@#1CV;R^,R$%BJ:Q*A+T. 3F,3,Y-G75KS2L]W@.*U\#0#0//$5%GJK/(5SB
M \+2G/RFFQ9!(@L,=N=C6A(R#I86;?L<N-K*8K FSAJVWJT@NQ_W6W'K 8U6
M7!X6]:5;W2SKE[;7A?GV GUCD]>C\3;W['*L^TQH\IGX((:?L8J-G0I&$J:0
MQOVRHI<RV?#E[X^O9EC#QF4Q&-)<E<C0&,18[["-S)5 M8M6HX8[S*/SV$+0
M8!_O<<5<IGZLKW^,V@[&'@,S Q>OKC)V:IE&UGFG&D47HI,@ 8HR%%/S1S^(
M&8G3B<)V*94,E&]S(IFBOTITQF?0LRD7()ZD[6?<UB93;HG,[C$#_ZIE!)\%
M"@1'>/KSA==:% NK0XVG/(=4J#/JJ<\\A([\1.ZCZE=^0_83Q?.T;)JC!;Z:
M)LFP9MH)"G+]@W)V6!G&;.3]S&^G.&M$06(=D,EK!;L%3.-:FI_6^2ZT;'QY
MLJ9%US=@I$N4I4HAH'"G0MS#=!&JZ6:^0F7I-JVQW]L"(9L?0HN$ESCZ57.)
M3P9>1'6\DK,,'@Y\7U G(V>X"PTPGZ]7>IG]3:;9BF@H-TF/KE6J+_>QZ'KG
MI"TUBZ.;WBCM&XTH$O7ANH'W85%UI%(LW^H^OP$'*=_@]G;@XN0ZO^P17R-
M?U-L>Y\OS:)GT9G&69_'6V3EB.OM_^5(^C]2SP#M_Z#1TMUO:XJB;B<OK)Q3
MC AH,O.7A^@2Q FI&4;DWPW6%Z;U^'Y-I=)6BYVTJ0=0*8@8]2/ZG.(L$')#
MXF4V?;F:L9'W'RFR%VW %WI+3C*<04E8*#!J3)]$KUCKYC#Z:92>[C5@K ,;
ME,5NL,=)>-&YMG XP$\9LAU4GLXG<110>SF%AXAP/OF_4LH"Z/,(FLV<"&?_
MY91M/L(7HA9TT*-6-S;-9AISO:)1C%9 6*\CS+ X.B8 +"\8Z[5$M'[,[P4X
M#)"K8"/J25Y6EFK!M,>ZT/3E+G&W91FP^T0:&-&Z"F]HYSAJ1%OL^2A/IA/3
MI6,+!&IT<G52E8. -YA^ )CY<]D)KEV(ZK%M.3,R *G=GY'<RO2;GZJJ,XIX
MG-B<12,LZ[XJI[30:HBY[8$=*@K?:ST4P>06-*/'G9D9;7O+/[[P?[M N=1X
MPKJ:X,P?D81L-A A,07KYER48]:)2JA] ]A_?(F#CE\X/%4V!CU=:D6X$ >D
MQ3R^O24"%JF>@MND6?CNMX90S^$_6QUF_[)=F]LX^6+*IR11?UNX'160V+AX
M"B0S[J2=A+B7P0_<]W/'MXRE_IBT>HGL;AA3@FSXFRERP]-6]VPDO"!Y@8P1
M0M[D3%//UV8TE^AK?234#UO"/S7F3X5,>DMY_G*P<,N[I[:&$1../W)',D@&
MD80/9$'NQ0^E-VYS',<725>+)^;KY>5T:X:O,2.S<U :K_;D7O9^[^!KP^Y8
M,J!#VOP"9*;A*.?S<C)\:R]%M<5#3W59K@RS<#*FFM\KK^VMM1,>J/4@[N>^
M;E.IL[;5*QI\0[([=P0<UQ#FU52>YW7.@XP<;D#F0HB[+HVEZ&9;X+R\>#D$
M'FECX1ZYD'95U6DCS3[872E _=FCD77T/F^^4CGK@,%D;L!=\_Z"(.)]Q0*/
M,\D(,Y]+AG1FR<M'>CR=/^>$X@E^UD.BC<OI/07#4X2UR(NLY,TM3VZ(QZLF
M%6>NS';%O)YM'[U?;P?.OF^/F,QL*11S>]II"+BS(JO!N]$:DA)US@ZM-*[[
MR^T%,X5Y(!J)GA4]^H9L648'%OR.U\;L2>#C#SXOT"(>+?+J;7@DO'&3\GW9
M/ZW=&\0RJC4'<MWNM<(KU#MR9%NL^\O$?>**2Z::+$U2;6;,L@NGI)T3AO6Y
MVJB4V>R2)U]R5.^A^-9+ICV>44?G/;0X?R@E)RFSK46[[><K.F6, GY#GJ3?
M_/(BF#JH_)M2D*4AZ<@E<[;>LM*7<-#)@\BZW*27[V&Y3S0V^@[TIJ=J=L>V
MSV]VU(Q8W5NTKB,RBF?2KUT<1B;:#3O]U"T^$_W=&SYWLN80\8F54T.OI//P
MF)\^%2#@W%W3C[FG9YXL(2O27S92H/E7W^XF/H5EQUH&9N/4IG; 5,?'UBO
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MQM2<\'FF#S[0V'G6/V3"@";:WH[3E+%IK(M UWFG#5;-5W[TK36.1@S9*A*
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MZ@4KRV^ XN1<(QU%3=3!U4/%8<<.O4,A6K+=VXO1)TDJ-%'U'L)N2+>S,TP
MG2]!*JII2>$T];%E0Y3-. M2FU[><ZMD9<4@IVMM<4F="\Q\*5"\QY33N3U)
M1=#@-0I< 15$,BTNK(9V2$&#U-A#/#TVCKOJ9(^*FE(66L3/?"I3=!0GI)WF
MO_\;)/T/(=FK"\"L$(K&H]$"U44?(YD,;)AA.2?V+W^FSKL,1WJR=^Y[=Z2
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MO'+533!TDE90X\SO-1*K$IS[ 8'B[J.3[N_O!(CE3FVN[V,2M?&3TT\.EPQ
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M?&D]LJ(?MUU56^#62EW65O8#!G[1NI E=++MC4EXR!Q5:%'$UK#XF@=9OTN
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M<N,>H'-:1E"65V[R 9V@(9]W])'[?&OJC!!L!]UFN*@(2AB,[1]R5@*K@0?
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M+OUXN>5RE*GR03-"?16.27A5@7_91G I4S_JS7D+/*2HM?&A$DR**,V(#A*
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M;NTR(!%P*[F""'[J1?<'];8_XY(=$B1'N49B,L#[.)X?9#2'WWC=U20Q<P_
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MH,OW^DX(K[E[0$;&7]^_GKXO'O0LJA5[&21>U6YLCXSCI!HVNGVY!Q1P=S^
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MY8?JABOS6S,P<)$VOWP^U:]"!T(KQ_V,=]PH'-NPT;LQSV!METIZ]=TGVS6
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M"2'7M=)+X#E @B-*=WWXRHLQ#WS2B.O4 :&>C[WNR33%#;-^F)3[&N;B G<
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MZ1[5>JSA=DI.MQ16GBD08C4T%9%/CN..]54'8"'GE-SNH4SS ]>1.75PB0/
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M^UI$Y/3Z+L*WIM]_-:/ XB@N3>V[$'(Y4E8LJ3GB;H.5;S1.W./;MS[PX/]
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M_6"P!X*& I000.-^$I='R(> X;7KHC^H>SG.VKS4(U5U?C9#BT.^H35O7*I
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M3R/$-])JT:A7[></S!>:AB(6/BMEC63<A4\2#V,[,4^_#LGND'ZK*Z(7IHE
M#9XS\]J(BO,N? #I:^1OE0MT;327ZCQ$B[K#C0BV'U:AQN;];G,8N R9R(U1
M,[:>TT[,:J3WP@RQ22@&0YR VG!5K^UI]\UK51W#X@7^DV3]MMG[H@-7>>$_
M]3/TUW%U<7L.GR5C=OM7?$%PRZT1Q2.PYR M'SYN6KNIC .#E$LDVC#^,Y:?
M?W);TWR K:D&:P@&QQF'^KS09LG$:.^)?%;Q$4-<H<M*F[2PCR'KK-+UVLVW
M7[:&3.U!9;3?R9!EQW!:MZ5.ZM.0%'Y=_,TEWM"(/Q%MNX)3^@2BNL*QD[H8
MG)5BM &9V$Z^-FX,:@>WFAS;'W.K/)9[3T84VS_C,OLU<V _BSC#O<1RA]%?
M$_@)S\;Q6RS.YBJV$L3EOX-D7VN-PXH)#=62<.. 4%S4&S*RR1F'6=YEU!(*
MH[&P!;%.2N/Q3T):\_V*3^1.,A6BW^J_UT=X#G2\Y>QO9XAJ\EL/I4R HMN:
MD3K<9!]5.2;U2'R*)V\\@_IB=#=0T/FY)6TJOVB"DE(RC4]7,\;R&/)D&DQR
MCDDS3%)N6D )/T2EB]JX3%UZ+,D:IJ)NTZ:Z:YMIZG>7=>8W4LP:KM;X$'PT
M!-9,2._>LBGQA]=]FM4R[1C+S&5%JM*UT66YLIT;^6@[+:P3O=2VZ*\W4@;Y
M(ND'CW0MCS(V?RIYK+6=@=C43.)*IB(4_:N3T%>!TW\\ZEBHBZ\4OG.&!$1[
M\"7SQHU-,HRPMG'C_!1ZG/NR[8+R'O>X6L]Y%&+@DIK(VC+@\C3XO)B1P?V3
M)CTPL7PFKNW.T[NYX(A3='-+FK1J&3<1K2Q)5E52QP3:SME$@]Z\=D\T4) _
M0[T2?:K8QVIN=D9RDS084MF@"<[F.%L:GJL<0;U+N^F=-0:9ZQF[MQG!9MQQ
MIU_)<F;+'/M[T-NT<FUY4Q7&8-?YM3,Z"IHJ"I=LON;I4OS 7_<V5NCX:^O>
MJ07<V'O?E "&0X*LFY7K6*R$H^L.Q7(*W6]PX*.)QQ)>FS Q44&G,UU5ADZ!
MOZO[I[9KRCH(WK:0KUROM1'3UVC2,I+,W56:X'A]3=5T:&G9A1%%]*P#%"[G
M#]F$8Y;ZD;-_#"O]_2R8*YFFU"75TK^Q^?>V2$#B@JV[M* #N,U'5,X/6\ B
MJI$#!/9<$,-LDNAV[R@[CZ.Q?\8U">I$RQ ,A=<*9_UD[F'50N[/96PNG*GQ
M?J3H,IT;R,<OM9:O"4G^NQ ,/Y&"['A11'7YR.-5JD1BXZKH5U1!?KU:<S)?
MOG59[V4$[ZDK?>1,#RG-#A86"S WEY%BR6B/KQ.Q*CTQ!B_">!H9!V2?#A"K
MD>A*F*:NT1UF=_@@O:9N@\DXG4M=ORT[U3]).'X>PF_^R9#Y*4H=IZC)-3G6
M#:?S)#:.C20VD"1V1!B$)G)U;2-WHJ%G>M-N#S&?"BY4@.-NMHZP;L:\Y#3R
M1J79"-*4]B3A)*=/"NQ>2F3#[S<>^"KDP^VP26VF'+IN<U#ALT8F+"&R[E2)
M@5(W*^!WROR?1*UEQJ/-T"F- TETUGKY>(50253\S843J5""0[]*1S =Y;$,
M# (VTKG;?/Y/5&J^EZYJ#&'.#X FVDH;)WG\(=IX2[&%'83^A=!6&I80E%BK
M#D_K0])IH)&Y/,^W15&+K2FTI\GEW.!SILD<F?D>$?+G$EPI=TWW^?>G<UVA
MM!(J%>S%$;P.;RXX+,PT&N\ '[2"(%Y:;66RZQJ%PNY?*I_H$ZN^$(5\)U2.
MM .,UJ:(VC&LZ)+MLLS<5.O@_T;+OPRHE_MB=<LFPV:!<'[83Z<K:R$HR,-Z
M37$[D8 F[*:A!A+^JTZ^O;W3,:6_-B->E6%D.0HN:2/#N=8B% 9=M_X1#2H3
MBZX1WX8G@1/QSJDG%5!,O\9K\ZWPC?IS)+P,$PEP_W,[=?&Y[NP#H/ !6*II
M?VY?[<A4$YK)KU?8J]'S?ZL8\!*OX?K]_<5R+4=58 1-O-A87!.I:"RR0NZ(
M]KE?PP]8-"J98@;-TNLMXEO))B_(W;%1)?]YT0A8RD"S10?HHVES!1M2YSIQ
M^XGSV9A>%JJ=7]ZU[+UH?_Z^?E7B52/OTS%V0I39,U;F \+:%PEN&^N*;L86
ME3*=G3[FCR<%Q<6-3DDDC@)%8M?Q$RVFW@[CB.L.3T-4-P'EQ:R=N4+L+7B+
MC>6V^A/ Y]?6%C*!QY>G+A[*2_.(#5T?LU;:P>>3:L,QB*/M;W!];BP?U>7>
M#O2QE8BA44CT'EQYTWV*.-NKIA(00!.Y_)T3(\Z?*GB!4K4&ITUT1CV0-PNQ
M/BSECVMGYB/V6MK79E6B']B"U%YK>'2B;&=DU=%$/\0Q;:AQ3+%AE\:LIIMF
M>M.2&K^ID UE]05$^TGQ;0DO;GXQ#8I.:"'?STU@X4H8:/<6,^,@4?/,*'X?
MNDHPS-NI%W;73,4B>:;DMY85IAY!*R.](E#B3>AWXJ-%3M ^2HVV9BQ)XXPN
MZ%%]4<#"W\7:-)K5C])3'03+>EZ%**1O.:D>7PT_J?S^I<KVLPR1 F>;+,PL
MQA79,'_=X-3!Y\L<WR*M9VYK9AK:;M-?Z6/I!0IET2WND\N:P=/JJX=)G!!G
MX^H/@$_SX1KI8/G[Y, 8RUC]@9;=]*,FJ%[7I%ZF./";EV1YC1LK;=]O=-/S
M&\OVC28,P4JCW\G'E8W^WXU\?@U*DQ*&"CC_XE7(?B+C-5Y(CK%A$A.<!-&[
M4X(PHJWQ1/.!5[8*XVFC#L?N=#BRDR8"X_F2:B,%!#70#OI&@YN.[*I_\[1X
M#%-DXGK:F?K)PW020$M>9P+6RDIII.S[XQ@#(-OZ5J_I%Q;S!GPXN2MMPE1V
MOAAS" ZAJW6GNP7BM8/7]$Z[LNA(BF4B)$1SM!FB6J]VBN$MS>>""':I<C=]
MLA;-4&UPOD/AJJH@V:>+#Q'@>;LJWUX<STU.TIYFM+EAUVOEG/ RT?,!MXK6
MCC<ZF]!6<)IT*+B)*+.77 ;W_DY<*-TP(S,H-"D"UJ@?> D3L(UJOF/(86>P
MM.DT0#E-%QQS9##M?K-">>+U^@!LE>I"%I%X55'LG1UTAK=]5%D$#%*X\3WK
M.;IW=ZM*+7E9(_EC:<:>$YG49I/9R?Q.RUW7@WB;^HW'+25Q)X_QL <6-&7+
MV<Z+/QLYM#&T83=@F[(-?VTMLLN9(#H>2B:&!T\3,"O$YG'359]^DHDS"ZN_
MT#-S/:2U?>/?\FIC*[QS/]ZL^U5BFN;/OOF)[]R'\#OK%4I%PCO#&M+R65HF
M*3Q[*B&)7-?RF+X$FZN?#O:4G1R')JT16CXZ3LXA8%%>(XTMC211/\,'R-Y@
MD;<L]E30)"7,MH&:<IJ\U4#M.9J*=<VY?)XR;ZT06,] 0!7UJ)QNE2837@9+
M.J(#1=J[YNI>;.]VB"&E@PR',,F_4_8^(;HSH'L 2:Z '2^:&.G8>C'T=B3K
MP>,RTE\)1OZ!B2(3&"_V 4".F7K2Q(U:(GJ]SZ:VW]9935$)IVT@<AQ_K9+C
MB<DZ<J.G(]?N>V#=CZ-7RA#^^N5.+U^WW\R4/+V @,QKH:AI5<W(%AAOR7-?
M@,Y1_99;Q3*2Q?[2[H.@CAHX)?IKT?"/_?\C&-CYG]&)5.C^1"BY45!*;ZOP
M5X1\L/_UACS+E/"759-(./'MF)6%9\9A;71F?XC!9HO&RS>JHZK-G50OTN8J
M$%F7^%J,5L ' /]H*.ID6N/8?:B1G,;6"9EXU(Q<VOKE.^>JXWR;R\A!)@R?
M@;TUBG_7JP3O+I02*]BV6_4?UVSX6M2-JX6\L^7[M1"=6S1X-'R%Z(B-1^!-
M.1I>>?AJ=VOO:?"K,2^JF1A/F+%>^;,BTVJM$LH0]09.[ %N[Y2YU<2O-XLP
M-II] Q_O#P JRR*"9.&?P7I.7L=OF2P,+*QN1ACHI):V\W[N!F J?S2?  W6
M5#82E_;>CG9^0P)$5ZC"\OY2:;APMW1V!V<#SN-!T_EEHY#)UKC@.(-Z"U2+
MA(WZG)]<1JX(*+WL4"N2A><8$!AJ=?N.+/;C<:/:_ ^ 4W6CJ<*G,OE/_LFE
M31IC<+9WE6M[VQ9,$LEOJW<6)/T;%Q.^#F4K&M["J0M<6,-@/VB?\MTFB C3
M4^J0&XL>5@^YE.]-6@?F+F3>)Z/A0F_#92X^([[='I="M55YHX#JN^L>C.#/
MW;ZTH=:+8ZY,=K_8"<NQ--9;+HN^I&6CFB898).[*56%KQ<&F JVLU26G0G:
M (>MGY!-;50=;= O2'33 &DGRM4H]- 5<BZUC4MF<D#.L3.5R2VXO:)H"!))
M64DFC7Z)0<<P2/*DL9,PA=P/MED=Q3%1'W=V2PNX'W""1*$W,Z(,*?'9@?ZL
M&[;S6OE,KJ%40+8S*(WJQKD@R90CO[:KP\F,+05;.ES=) :"FJ@7CK"8)0G:
M7(5OE5\ZJ[@>#6+Q(+^H2?/W^1);MF:;DXD:<22=YZW\''C]NLO(1E/"Z&]D
M-)2HO4C+JAIH*6\2"Q2K^C,J<B%2OHL73 7HDI W'SC(DW2+-(EOZ./O&,DV
M%'FTU7<FUGC28=I;&G/NI*4XQ'#,A2^\#M:ZFAQ>&NLDK*P22V&W-C.!K?>D
MO%DR'MF<J90F!7JT:,7D=6I7QB66M;VTL4\@O1:Z;$ZF*'16V&?;$>#RR5N%
M+T#JTK-PCI..C +O&2ME(>6G[;B@NX4JI7$$2YO4AC/IR@%K+%[FUN9/F&Y*
MH6\ IS5)^:JD$3%MTTJ58Y=1)S9M\CK6@Z-Q^VZN"O<M<-\MUR&7X8:;38<F
MR4432ZL,C 3:>12]K?J#R2'2D5(3A"N_MC6#>13*6"]"Q :0M(_]%YW$+;PH
MCG5^%H &$PY'0%MR*&:@=]BT&1-VXWZX&);L-)/.ZM56>X-"2BIE!0_U<UCB
M:L/5J.S)=5\H%-E2TNI89Z*\8E='T*9UFM&")A3KWK?_PMO((=3;LJDOSCM!
M.,BK'VH+@T/#_<N+2-._M_WC_B]FL?Q;^B+8:<Y_#20BLONUTP2-!J![;,@>
M7>I &BJR''J: &?;#AWB1K.>> CH"WYDY)*CR]HGFY#7-\,"AW-)F?^X/SV^
MW\ZR0X?BT) I;D >"/2,CX&=.L"Z02/@,!9PDNRQW:9D 99"5)/BE)TXL<Q)
M[:<D$X@^ )^Q-JD&5L;L_Y8]^-'58ZUD0V:Y+V:]B^MK O+O1*DQ+9N0>I9P
M4$JJ1<?Y-#DZ%E.4X#;;%4<PL1ZJFEYA'K$XMS!01>.A!8M_?@#^#E\]SBQ_
MK2=?ZOX K(NL'3Y"A^BP8*2>D(F__HH>(Z*&<$! $"8?N*+ /M?#K+J4W20:
M/>TI("S\H!<_,12=U5AWZM23-AH9Y#7ZC^OYG8S \C1Z<^>J/&NF]M^9S/B&
M$U [_DQE@ %KS=?O-^T4UD4LLAW^\60IAYVW,@G[S[>(>"9L2YMK$[2494:Y
M1= #KD:)G(UM">"9;_7& IPV'-93CQ8#-B_N1C:+6SE<JL*!4WF09;YU[ZO[
M GCFG<6*BG5GU"\.$R)<J?O8&.=4VF-MAB[4+JA<U3F2>#>1+J$N]@<9=2GQ
M+<LWY&T0M#T];(,W_UA?D_,!_(T#C5]^"WU477BBM9LHK*KD:M(IZK(G.4""
MCB&9.UJYZIRM]%O]M%D[5C;>R\0,##SZ)IV_T ;:]R; [-M5JD)X98:9#?>!
MEES_#!H&N3"^29M@SU+LV9I2NF$K\GS*3R]DV<N-F[K<R(HI?G*O5V-;[>=7
M5YODE$_VK-@9?[WUMGDABP,X."Y$>=.<ZQA3D$PEQTX\8.#(]<SWP1PV'BQ9
M)[+!;]\:G;*%R;(QD$A]+[G-K:\ Z,&]X%\&"]<H8B[^UIL7"FY%\%6%M*J?
M'$Y4:G8E^:Z#;")(VCQPE%6%W)9S.NC*[9QVA;*C7D1B8548GKL%59[KX9YB
M]"@%.879SJGW3\\%Z."QB9&B^8;_S&L-Q(@FZ)F6:VBB8INJJIE\2M@V<J\]
MZM>[:Y5QSYWXZGWU4"(9A4BF]<<\RWG\2D?QES!E,#X#1_<R_//E[Q '-"$#
M[WWSD?!TS)F?J4M+SE\Z5(.A]3D(N+T#2GS&KHP">XE.B,:P)J\IFHX8+S4Z
MNJ).1MP7-#W[/Q7;<8^2"X!G=E7<Z>E9*@C9/,N=6$G+;@[18($OU-!4R\>!
M[=*-;YZ-^(I3)#--!)QEZ^;$TP0JSB=JXU$MP:,);DWO\1GKZN4I,9:W_JH6
M7!FEZJ+9<GLH3=TWK9RNKZD5*\KV]:E8K4MS5 (/NZVG!C+#MQ/T2K'L!-PA
MZI)\YUYB9G7"UOS@>"#(. <GP,:..,-Y;9G@QJJ%XW#")HV POU=_#&[X[Z2
MP0>.D-PO!)TF[%I-(<7&_A)J-:ZX6-5 MIX><L _(-C#RIVFDWISS!5WPE*7
M80YLW\QB:Z17=D'IW]>)A SV!2I\4GQL6&O+LRM@+\,_,)C\I:/KH\"F1:O>
MBE["DV*L5K:$)]LL]?RC!\OYK=[(N45%%B4RC# W?K&G0CJ#3RTE]?@8I-_P
MF!MW)N59.3*SF-&VK.(ZAG"8U+XUW3!,;:#:&C%&[KKL+IG6[4S)IR_(#O43
M^AGXP^=59W/J:GE[DPZ^HTV.KW=;X,:6H:2V,1<HLP*!J8[7+8/7KD)KZM:$
M6HLKJ@G#!130>K\1A>(;78\DL:(63^1/2M]=C]BA>8U]]1FGZF4DO#?X.ME#
M]OAR:W/;#5@9D^R1)'E7S#K2*[3"8%'SHZH\L!=</=1<)&0?X2;?Z[T*A"3K
M3N3 TL&>XTLG\V=&! )X:VZ-#$K=B#K[K.GDIV3X0HB:%QPJPV&K8$"R1_S8
M5U)O(SR4;B:6YS.YF%CD@B-FMB6T/NI8"0W+UV"6)P799".'/O%I>IB!$9(1
MTG)WUKY66#@EU2\Y';\N F+M([&XK%7]?J*WAR='I@A658"V[URBYQ=1']C/
M"!N[QCX -HWYY[8DLX=T#L$]6#:)^_,T'E1%%-L&MDJXD/WBU<U2M[GSY=/@
M]$"8NW: /90)L/S^<(UO!#%A77MBL_Q-VV,1',A8C"TD1"1\;VR"QA*B:&K%
M'INKC,5LH;5"A FX)CE"B?1UBFB;F644PHTH;8\;\67A_;G+<:CHU(J;I$Q(
M"?P,-93"9)>0RL84!KT$\WY@,S W\44R>'[V0/+X#O&7:MO62"M:4HR-@Y?%
M\XY[AG/7*L(C*J-*U);U6IW&F@%B]60UF(,/,_4;#\ZQLCW5[_<T\C0C?$%G
M&7F$")U4=%=*[94U\*XUYI!1YN))=:W&[!/5]/D$5&)Z16,9@LO_[/G"I_G[
MBK;W5?/]'R]!9H,L;->_@[WZH3:>_!_T5(QO=08K44*V^3>A+H+(<4<B+&D&
MO\?JT$3K! ^^M63];+L;1CX:U9A+B81!2OGCJ+.FV4(EW'SWVIR^\IE6/E#&
MQ#F"1EEV4^RWCKOPT0BB+,Z9_2]Q]2_*ZBU:Q#"2IE@Q^?3SX[2U=97)?&)=
MKF .:'-8Z>$[O4>G8TX9/__DP_0_B\AP\"%XX<LK^ON\-<5,I7 *_ZF/38P;
MWRQE$K(J\+I-$!D[>'';&H6Q71A2!3N/H<XZP;%YV<^]V7Z2N8;=?A^#%\=%
M[)YDPJ'J1WC6?"^W'5L%?.RG\=V;D>F%F2+F\V&%'9>-#=NJT1L8;=0YH'[Z
MHN6?>V!C'.* -QCJ> 04L*]^ID4;#/2E<?4P-/$A)VLBX N6Q+TU>QJ].O^3
M<FGT;J7JB9UG;[9)!I-8;V!BD^I=?;<F<)FU<7NY/XQ$\UXT-+KR)_U!>Y&R
MYX^*?-8'@,!A9+ES)_4#,/1\;E*;"ZQIL/P35""T<.W+5I_ZZZ7C U"!U[(0
M^==.=5L'@PID9\]-BA\'1JH3HZ7OTTE1X!;R'WT3J!\7U,"?HND 61>H!M)8
MBN1(O<DLI;A'_]8EB2T82A0]"H4W%5,N/JL1#1H@>Y0%':C['(<3OI;.:$20
M4'.D85O;UVS.M73M*#0NXK40";OCY$[WN@QJY:]Y )L/R"JOH8YPK;/4%,[X
MF"G<FO 7B97A-B*^M0?F9)),6M3.>VV283T-L.6%I]E=;G;2K&BKQBY20$6K
MN_AG9"$K:WJ /1Q_!C]+MJO)J]G**-T[Z7YW=BW*WG(LDM'Z3J^R#M!F\$6U
M1*((;@\8;_6.&XTX61HVH%V^FIO=Q>F@M4JV[.:326<<R:S(MIRZ.,K<E##\
M@K?K"L%95M[7,>0Q8=R6;.7(YC,C>AW 4/=,W\I')>/\8?5C($X0QK%#>/4?
M[H^LKX4?JGTY-Y$B:_U^*NHQ?8/S4&=%$+3#<#KMI>A2R>>^>B0-9";X%/1V
M@E:)U]1N8/ZS)C^<I,"AD71JQ:T6,A5]*T,#B6_IBULIG6GSUB3:"X5R 6EN
M,T436P?)V+,PI#%QD@W1["HJ=+&8GAYFXKAH\1BO.3_B#N,P+'3%=^K#M<<V
M=PVOR\DYR;I.^$T6M((+?A#4/Z$&4T_<*R78T_$:_,DW.+P% >]85(!T%AXL
MAUTF3O@!1 EP;==C]O!<RB;\96=R.)N_8J>2$28[OH%]+N+;)HS<2;=:%;9*
MOZ-)NJ0P@:WCM8Y]U8EA0PD%LY)QC(/[J>+IO+ISKH2*"JAH J9&6-&/>Q82
M#(,NOEH(Z^;FQU_VLDGXAX8=FO36BF^I/?P^F?0=UO8G,[5+=17 :12F.$K1
MS)690T:^;.6N+4^Y9MS9F<C9Z,<V,\%_0F@B9'IN'77@VZR_[?IY*1C,U3\'
M;&09K&UCR-AIN7E+N^.B*]_0S-E+ST\:?US\C$E8C: 5U:8W2HDSJ8R--0][
M,9#%5QR4[-^^!1DXL4X%X@*[!2BNF6C$UA%[&A5O2RYSHYF\7!RN^FW=\VQ&
M-8<2?4_;<P4AQVS>@1.*O:V^TY+#I2H1'+=<X1F_8!:T?6;SM[.,7%UZ#5I$
M:EQ X(:-6#1O;HLKLO=X*?D4AI2$8_KKW#K$N83J5;NK=K?X.&C2N"_2/"F;
M[*%,![)Y1%&FA0F^HB7 ,\?/NL["J66VU/XD-&P*7C]ISD<9B80?MKGMOG3A
MM5"1L'D@>2C*D<''@KOGG_3Q-\W(15:'WPSJ=UPETJ+G<3ROZL!&[.M2EHOB
MU@4 9W&?#ON  IY+MWV[K"0[T7;K&"([HU^M:WYI,\TW@B#4R+@C:N-AZ*]L
M_2\N?X10SU:G9Y^T5C;O2WPVFND01NIFUVJP&C)8-*$4?C@8H"ZHD0<J)#X(
MBDGX=A6O9KR:G$^P&RDEJ:FK<>C'@$@ZI?W<#TDX(XRNMZ*V_8%*GN,=YW%^
MZYPB<?<N8!D3/0F1G'U0(P$&[2=]-]P7F'5,?GN3LA9$^.:@]9>XQ42,KZW>
MHH4C\:T'+IH&?-N\RIP"A'%/[N6RX66Z VV9F\ T#\?A*P&(E\131>Y!17[5
M]G%'?FH?2PXG&"O )VLBB$7_-J*-VV9B=P]P%[^"7K2A;X8W\@/6I_/A8?I7
M9LM[R>4:W8]4/B2OFP] LB'L37-6;#1#'$0[!V70]-,O$$TA/T,*N2I%YB<S
M@>!DWBP!;S1O(>_U#-6M[0^ 2> ?7]2N"+*%'DW?L5B.+#W]#?(5Z^-VX;;2
M2:>\^<"D)'RE#"&-B;E56%$3\J*"%A,4^E^N2^U.!>CM"7D+A'?:<2,=+977
MU1+[H[;\84;F2_'$3&C6+@1@?L<@J-:[ME?I-]O.2B==O)(_D2?PJ%'QNIGL
M8@T<X  <6-!\&N1;PIX'OIJ.\Q5G]Y5;ZJ'.I)VB4Z!R8 K<0K%"^EL1F^\R
M)M8'(*]J)#&'WG\PI8(16X=65R$BP%:1@L5X3INPB=1@ CR_O]:+H)Z+IW!X
MBHO_1\7C7261PH49U9S50S3WU&,M]R^,X.C>G_8(H+XJ*8O:N3H)0V+Z\FY?
M;3_9-QK)HVJ1(5&[O#4R"1]U&B"TN3]'2K&=$'*-;Q'7B"WUJ+\[LG7RP8(T
M!9]A?^F#B1L6_T0: 5&)C=*+J\:7J5X*L4LQC5?3DYWYT+/_/Q'0SPI=65+Y
M)V-?K]9=3E3GDZEX=9]T!B;3M'L_D:"8E=I3IMIXKH^'>C8+_?I%;9O?)YD<
ML%:?O4XC"#^0,%[EQ!S_BZ6QJ1G\@,VDKF\K&UEG,(\%_=[1".#<9S8QH_QU
M?YM4P;8_I9ZGV%%^Y@B5+A4Q2\2)/I<C@UY?-9N+ZAA%?KNF?N]D#&N'&V9&
M7%'L.XGY-OTM_QGV$)]83.O6_/6&M+)P,@"QC+W!R&W1":^:J.F,9AP@<\/6
MU$AX- EP_,SAK??XY")PLT%VBUOP\PM/G;V&/8R^D9=G/DUEQTH:."HR?2&I
M08 ;D\5\6>?-$0Z[B4VC:S@N"T8^2,$>_ZS,"-B\+]!ZNUOZXDS?E@"Y;T%A
MP:4NSS+NS]8U7DM-2&\ZTZ:F#94@"=G=%9%K %LMAP]4ESO4E%;])WP 0AYZ
ML^I%+-?CJCIU@_Z]5;-H,OL^$Z(HC2!$N]^+="]BE%E<J;1_)%4'*= 4<] L
MB\-:7.2B,/N]VL/7^P3)0M,YR9:X@=T>"5+M*'3OQ]2RI4!7;&C(G'47&TZ:
MXXOAB<)(U#IGCH8P)9F"BXQ8$?,!Z);W,5O,=-PY)W8J3&>6/AU87U :27&J
M^=5/#4P,OM\R]VN^OWTWA(A9NQ8TH =>WWT QO]P'D#Z%GFN'<J[>Q-ZT#03
MSMJ968HG@.^?'GI6#SX H?>!/9EWS8^?UBK<54$'PSLOXOQ_^>?=GC[!ST0G
M@3 !:  0U/(L%'K?=?A %FO[I,DNY%+@Z9L]O__ A=LNS%:/!IFPW!3OU?G%
M:Q/QN7>GW-P'H _%L^/Z.027&&W@WJNEJ[S];."O_-<NR8HH$0GA]F^(?WM,
M>.;G4/S;#Z$Z)L6#@G<ZHL[M$=)@80X_ ,.=7&C=#P!01\?VWMKVU1-OA[K3
M(#H/B44JY2GQ6EU[0"\4^5. A-3<- 4#(0(65$?7%ADC\_7.0'B+/<T.BB=)
M1U%L5VU&^,'(X%[%&P\NNM/#@@3Z3:0G6\NQZZQ;U%K*S5@:+/PEC'KJTRF_
MB)K0S953>?O:QN73!T OI !71DP!8/+#9L ^(M]L;"LH5-\C@/<:\V %YLLG
ML.BJ3D/GHB-]SZ$@&98>EPMW0Q8?/6>I<(H:M5!^&_;8-\8\>7L&XG''BUV
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M6\]R3;+_0OU%BWO/>+6ZT?## &\,QC\H9N@8GMUP&!NYSD'D;0-[!2!I*1\
MN&_*0'M;+B;ZHBH5!.)O\O=J^F.F]CO'O\D[6$?V?2Y>+.Q23<>1VP+,:-13
M]UYS_*VN9@$08=_$H&L?LR_!$VNUF3YW@11V%/SH5.5-6&18'X# B)N>RK^K
M7R?6J$-,*_\[!'.7QP/*F"@N>RJLS?*YTWAMTA:5D--\UFN:/M((B 8=LB90
MKG!6M^(AO)@_%8I8L_QKH'XD7=2&4UJ0!];=AY3/62E%U#L'X)T(14Y\6SB"
MEMQ@_&)0!^P=D[G#3'N2ZWK,[\RQDA!:LHHV9\#E>(9OAZSV?L[Y (S?V]1^
M/][XJN[6EQL:,25<4//^8ZP\Q_^+7M[33$T4R*IA\A\Q]DM/4 />K+/UM4.E
M0P69<&!!4/F&57[5G06,J;S 56;Y,*YIH?0*7*:FNT >/%<&AVQK@:,FEVV7
MEH[_"BL;XLM(.O/%BHL8"G!CS>N/ ['3</+&@KK$>+D5%5:.-*<UF/N8*V!%
MK.&G!Z.=KIG&P1]%C>U"!O96^%:CN#D3@0\ -''7SU85R!(.&'8!@XD1ET-^
MP%C,.9@4;BJ-1SO[6#%9LZ=KI%%I!HB_4S,S\/0K@6N76J?"R"WN'_IXG.I
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M+I=")4,>"AL%3%9?!7=A8J-DLN=_R-,;_[>WG<^EDY7,O^_:M=:YX!GR)W
MT:#C.($\=1RRI4WC\!;Z@*I\;"#0@<U.UZRM/4TBI,OJN1&SAPT(*V4R:).F
MZ);& -1%J/@$5/Y EC(0>4]:<P.KFCQ0"B5G W&Q6XAU7-GSV?+3U 'H&5'9
M)-(YBPAS-P"?N$0 U)W36FPZGOFQ2"/H,>9@)N0I:,N[O,K>ZH_6,#CU\&J'
M#T" B">$7Q!-. TMIK*+<CQ^?,%>"S)R87AY?I'$;!1E?[2!H-6+^S14P Q<
M^E[*/.ZGKT;H8-T2M>XV;HRBE7E&]&G+#>H@,U20?QZWRER4SIGZ?/4DR&6
M=Z#^R<=[WU7%S'ON$B/ *=76.)=.1.#3?VVD_([IPWKO?W [J_N_Z7DY2]H9
M-#'VR[62$H4OJO^#L+<*B[/IMD4;3R! \.#!W=W=78($=W</FN#NUKA;X]!H
M</?@T#0.P=WU?/]:Z^QGG[7_=?9=/>]-O1>S:LY1<XPYWE3.9WQ4<B'7OLD5
M?@/*M&XC<:VWRY=F,@WS$;\F$AOYR.'@H9]X?DI3!#YJ9DSS2[6+T?S!1L%Y
M69!=8MM1_=$\# D$DR(@GL+^%/M<3WJ_[(3R%'\:_O([B9;JZ/\KCD^Z&#9>
M$Y;_)+96NI58% (I&LJH:N<!O$GH,N$.*\%:I.;<T^+36E?0)-7KG>T2*A;W
M;Q/-)L4SJPH4DLH+,GB9>3)<2QHH&[X#D .)_REHZ!%_()Q _)VEMUNV&,^F
M+&43&#T$SF.AYF+J]_*S)S6K&I3;>%+C /EQV21E"=>]KPC1$3BDA*J]_:H'
M'@Y##,X0[F.'U6'2#U?7UJ>% ?9/)*5H7QASM?GZ><)@]^KUS8?$4-W[- 7Z
M:]OT4=B45KU:B+DZJ-ERPJ^I>(@BCRJI+N,4!\:O2;A9T8?.OP, .'QL2NU>
MA36'"8,9S_<OD$"CA$"J?8RE[S66@6Z.O#L<#U3!BEY=-LPR>5_85D]#ZU[S
MTSA/O# Y-8:59)\R(#)[>D^V2"JTQ'*3P1DG#/=5L[?$G2;+)J/\YL4R-8F'
M%S?^(?=_,ICNGC2$4& 9? 0PS&]>^'$HC50(N58!^N:C/UL=N;U?%R^G!#UJ
MA?!-726=*W%K^/$2O3HV5W>^/K%K%,@)/E)].JJPDOF +4^MDL:IFA !&1!\
MDS\X(X=<#&@Q8$ ZS8G_PUG5+O=_M%:%IW6",W<RN)F@=][_VP*#V_152J&1
M>>"B4Y>T).3IP)H'.:&YI[.*K;U&S9EKBKHZ>^F16[,<Y[+^E3?B\J-%C-GB
MC72/N323V+>VAAX["HX$*1?5V:,Z"AYD''EYA&]NP#Q5?LKZL+;&#_%IO_;^
M-72+\>WA=?T=H"Y4]0X ^53^]_S^<!V@/@Z:<=RZ1T^KR*C1R?M(XC/B(0SY
M8:1Y.BO)!@3N3O+12JD):D[%X,.CPH3KYQ'1=VL15\>#J)\K=B,;Y7CKOVBI
MLA6(A_H9C=]I6YZP79G2A-A!FCXRQH/'3A/T*SA(+K222&MW^TF:K"2MM8#3
M* .(\!*IC$F*!Q]&F%,N21CHR7JF"HT0D6>RMGG)@&,#J"0*:I12*OQJUR$Q
MV[2E>ACV0U@QA(Q4T97?=3;0+F%VRHZ;2%VN:7JYTJ@<IFVG/^#LO[K3.U+=
MTF,D:^.L,UOV%]1,*5"D[M89$.6,[Z&2)PWY)9B1QWWQ<>Y(^SS>PX7&#6UK
M>-B+*+[W+";"KQJ^_'TTGYTFW9"G7CGZ7P=N8Z?,/1!]??;G!KK5^L,!5_NI
M4'M&5!RPYLXFGQ!6(4[KB6\B(Y@I%'M1_O,4+_/+^B:]X[%,?%ZH@>/2OI\:
M%MO1?5EPXQ9;/*]N .'E7G\R:70TM4C)TH<[3\_CVD9-LKL96F&-P.3'U^FP
MX#'A ],BE["WW8K?K^!TBMZPS3S3V_B6X0'R*P.[QN3)8(>F)-1'5%PSQY91
M<NH:;\&"8-J *">>DQN26K9G@W.K\!=LPOE_HDM\('##I)/E2 1,>G4GFY]>
M^;]-_IQ2?@<DJYB=7<_(I*23G=43>OQI$I_WZ@]99O^.LK*MB:LSY3:5(IE&
M%M9#(#]E#SRM*$.C6ZM-$?1GV@N/R_7/%O".P7(?2A0^9ULVS(KQDSLK67:S
MH1M%*Q-POAW%U%_;:LF.+(1;/3"A^<-\/H))"SBBW>5DU)29=8-<VV;K=!DJ
MV^RLJE#U1VR"2]>SIOYBRGD)IM.TUENYR+F*C^!IIQ3?JEL\UM,BH<:",:C)
MC'^)LYDPIBER]@;!&1& NM[LMBD4?#WO/_FO<$2)TS^L5?HN C+,8-DU'R[2
M"!G.0RC)/V3J,=!^VOUEH91%WE[*7>,6J?N;5(Q8Z.Z*_,0%I/@.@*'"%Q2X
MC/U],1/ O[C7\7<0>BGRRR_CUT@*QOAO:DU<H&YX4>,IDG#Y0<9PK](K;(Q*
MAC,#$:'&'[F/5YEVW?.>+08-PSQ*Y(G#PRI.#@@3'*2UG77F''0U.VTHU&2?
M8C3AJ-57"_4=6OZL(>=LJNHU(9Y])4=H=48;VY?V;CC8BX_KRJ1OZO"SZE?R
M03,?ZU4P*Z$W]4Z74;K]F!3DQF",/YG<HU.O;B6318EBV8B>M5[5 LFJZ;42
M(; [G!O]-/6XQD+J+?2&,ZS@UDHR_?M2JP_G?W;!^XM2(P:/0+.XPJSAWKSU
MS7UQ;:8A6$06_3$U:K&'J,H>M5].VB2YPI8:ZOI9;R<%3AH@D?P$F!"DI=)V
MNL:RB*__$N6:4@>29**>AU_R[D0901FSBXZY^66-@$;TU+?U_4V5B63N0:4$
M>%G_-BT6A!I0<R59$;,MJ-<R]-AR%6"S+LJYY"V[ESR>_.MK$NA6U8#;_B<5
ML[KT#PPOD]VY=P 7O4BVU9(\VA*ZAY=2ZCR%#_,!:$QYH=1J+1A+1F7;UC:Z
M(<V'A"DN;A3EK35>KL"6-@I>+XINCT^-W2F+9OBJ5ZS7/MH5H^;@1YD3LD24
MV#K3E9XP!,Z+92F,HB*H>CHY8()Z:%/.AZ:T@IB6=W*;E BN);Q1C'_YS:)K
M >$_'"+$B%S=XSMVB2'2EUA"H_"Z^'*[Q%,A$'VF\#0K(/TGEUO+O[#?AD:8
M?[GTGY'J[6&V/3J@(+)8UK1/!<8)=/@0-.*JI)E9&Y3;;-$+)>*/(-2VD'!4
M49_VNLP1 &!MU5C1_(U?5YT9=3[AD_ CR%#N/9@*>-Y\DIBX@*(=2L!X=Q:&
M+6[NB O>@"YE/EUW# KR!LG$N'47[5S1O ->R1LG"5Z+$"P\_L132AYS;:UY
MU>'90-GOXF$]]'/W+#GP[3A#YD-V:'Z9%4S]-70E&3A+Q3$T-\?CZ_IQ"1<]
M1:YT J!&,EII14JN3@]T/^43M,-2034507YZ\%*T81'#_0Y3O1X@0NR< ,V'
M7#*^&%>>5G=Z4[5R63 4PH <HX8S_OEZ<HZ@?2ULF$Z5_RBXZO*"$V?3X!$G
MTO.<]L,J(76'6GP'2I7M?QK9FIO?4)>16PE,S8,5%Y,H0P7"(;W)U0.8RH*(
MI%ON- ("PR@,,4#^N0';->(T/M4CJ/!+W\=%KYEO_714/LL)%ZL^QD32H*1R
M9]L>C_HE$$;A SX3"ZNZW-$?Z;#K)J=Q%=N!7&J:BR^KW;G.#= N[INO/'WS
M+A8[AXS2<>>,U$K4=N:9_F+64W!2M9%(\9 R_74I*FN,2?-B;G:C77/P(3W&
M$+UEP?KUP9 %G<H7O<B3V,XWC]$D:@4#YY4D@.-CFC(KJ>J8N?."AIUL!*).
M6&(;^/FGR9H>+QT-X?P&U[%%48_[?C[%WM*Y=NJ1@&-]XV.:D?TUA.V-0+J+
M?]@'/5/%+8' 8LEDG+$QSA*M;V3XK=YR/O!5[IB^W?->6;;AP<RS7.B(9YZ$
MR6S*N9# GCF>YKLVN<3:7$[?-[E.]S\8WP37<&=PA+.)KKC6UBDHRC_XHV\\
MA<_FR9H<Z5B>+$TV<D^2<Y4FRD5FQOK>1L;3V9J#&W6BAIUX"L(B.Y&5TJ[B
MR!\^;JF*RPJ%1 :<_Y*!F>\K#2H)+ML''^<[UZ;MO1J"-WR;0S6L#I%'/,KH
MOFE$1%/.I+!2,@'E5>GC0,;Y)'W9=>;-FRFEE,,_-[2)YWB":X)+D!(_^E3N
MRJUSA+X#F"R=55!I QRC5_5^Y0J/+UO;N_M0'I9N5*J/B3-PA"\B\6&?Z]&X
MV7X<S2Y0G3QXX'C@).EG-;#HX3%[S/9^/8\*/OB_,1B$L?!!9R]9#X?O /1^
ML9UG]P^_I>]C%_GYB3L426I6$ 7I3\C10CQJ*PYL[1%_6JXPS>:WQ&']Z3L0
M+F[GU>@U$?@CZ4_4%5@P;1COP%M_2OU<M!GE<URV;<=1M*@ RV\A%8NM)>FW
M*F/-.2,/HYG":>II3!4$<"3JAYZM4\<2MA^']$8WLYI[8&"0</V]WLWH\AL3
ML)E=VJ,W0\,B2LQ^Z&24'C_<,27=@EDI/\"1:B,_^6/(M9G&7Y^M\&&?=!S]
M$8DL!5Q4+]6JV?Y3LX_J&@\V) Z;DUQ2B,TMSDB&Q<!O<8FX'G?0L>6LD,MM
M*_.8:G,RZ7F>(N+M8K$?SV+7<$H<%B X5$AVRT7DL//"HL+=7,O]\GM 0_?J
MQO\=$)@J50N1-,&O(W83.@$MK>0)#,CNL=R&S.9G42I1$?WE-B_/[0 *3&5-
M$ T%]]B5+'CQ#"UA3P'MROPIACAWA&W^9.)M-PH+@,8MTE<2! 5;S^N0<%7O
MPEN"M/-&+Z ZVSZ\V'=%+E]GLF0=\FD(+CJ_LN:FJ,;Y"_:9%P@XSLFWL#QG
M'')EOL%W2-E&59G\SZXU)*[MRS4$?,RG8?P&/\K)9*(5#PL&_)OSW 8]$R#J
M;N!3AQ\Y[O-9([2Y@N LF\Y\-4%>?Y;XW?P,;ZK2-=]3=6J;#LP_YKC)851V
M"=\4W-K')R,<.3?E&-XX?U1CMJ^P%@8]2!S#P1QF<QR*Q9\)IT!$=7$4)^_8
M)XQ]7&:N7$!T U-F;"M[E(<X.&3X9_U\KG0*@6]0OKFLW0L"Y;G=!Q%17FMF
M2I^Y8X=Z_:%T]@;@^(<QU+DJAD\C[P"L3 U*Y3XOWJQ=W3.><7*A;IIR/>5A
M0OV<$"4@/<P5^]X,UR1P"X4"Y[X;S.$%_A<_HWOC63J+\\ZO";/J7[:AJMK_
M@:5K)BT*N8^O6B_RKP0Z'2L%<M":6<-6N9L_<)N')1L71*2RRW(:S+9OJ#F/
MC3HT)KGEJW##R_Y(PH?-4"!DJ87S=GUXD[]Y=HAMK&M_+LUY&_-Y#AC=]/J-
M(BT@*2KAM9V^7R9>NEFFQN(0NA'_J\2Y)9/_$GND4KBQ<ST^(BP?UK@<N:!F
M#A') &[<9-+KS+&!5\9Q34/:Y+OA5L?>XVOOO6UGBX&GSD5MZT*H_>]4<G:K
MDIR!E.S[STV7;B8JY#M2A@%D.5:@EEE4!F(G\*?B[W,HKY+0-N-EG-X)0'CL
MXP_(J.!RX?)LXIG@2K_5)+K7%D$%&I7LYF=JY[],V9MXC,8;C"JD<;Z\:<P4
MX\E,M6-\SO& _'H,R;=,QMI65:RB0Z8.7_W#FY)F)#>_=G5=KE^BBDID,%4J
MACPDNU.F;&49=KY>S3%LNAD9&7>O#>PL XUUCLA[.Z-$ LD''G@NPQ_AL?Y^
MM[$Y5EAF#2HII<^#[^.+L88K2#9S*D0B686L#+9UZT_\(.^JQ!BT!K_2"E-Y
M5J3;]0(3)JFFRS$4>\0&4'RNK62_"294(MXT 7+#Y>)^0DJ,.E<@%G_B&GE4
MH*MHYS3,5VN2W'UL1ZDM8VK-E^A%]CQ!X[$CKF=DF]BB4LVB#VMD94E-=P9X
M0JU\-5&0'9VHP$%UM8YY=;FUEY]@;:=G@<$D-P&D^!V6MGE_\1!0X1!L6.^
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M*AR VB.40J)7] 71U?^LD"'CKO^C$ \'=EF[VI6@15>)6J&]=67< JU;NU0
MC6\B;R;M:$WI)1J=-)%2L"BIU"$!8A-)W67\U)T(DL/_Y:$HN,K*@Z<^8T2&
M_$HH'#1"U9!RV^=(T:J(?B[&Y+)^07S'B=ZK9BG0H&B$4:+>B^]PM+.V&U;=
M/!*I)$8BY&39'^WNADP=","84T9_&RBZAV&;.R7><D(PH[K%AC6!3%CU:^\/
MXT'&7Z!E+:LJ> /US08]5%/U$G?4 3V,O&!LNUK6+Q@_RR.W_<YP!7(71^BQ
M>;N4Y90I3%<#%S8DI_3S$=MD,BZ/)@BS E28%C*V'L@HO/O[!_^Y<^,WKWR.
M\WC\)I*);Y]G#UC"9_6X!+OLP1G"=?49LCQZNZ#+;[C?FA9G2Y AUA]""X53
M\^JJ?S=W-*\.MI$[ON(L@;OR/G[Y"9:FC'-X96DK>28XUEI^$4E%PJ#8GS:V
M8W$=F*RBQI;C54AX&=@GE7LY/K!KGG=;(?1U@;"Q*0EASRWLQ_JNG&;GPE$U
MI$_'<.!.Q[CL]R8(JHX'B\UW_1+*]KO]ZW+X6:&6HAZH=,V3+>%05(P_'MTW
M8B+XT_0Q'/(99DLQFS+<Z3\?@64K?ZIQR)872Y=W<'&&S*#QH^I&':VJ!-?6
M\'W.HA)]_FG!]CEH8PMF06(O8I-H6Q E=*BFB:M5$)K2&W=\-8DXAE7=^I?)
MIW1[6_S1WD>0L50=/56UW]$1BKB=;DC<;'EM%R!0Z!2E0NKE??*:&KKDNNIB
MIYO_;]O4CT>FI1MKVS^Y3T07<_>1L$E.D\COC_R(DS!D>\82I!# #;IL%[;N
M%/F8F%%[D@4A&X^K'\U6QG^(VC@$ !SDER/3DA),AUP%EMM-BHL&6&N3Y!OF
M+,: XG^0CT7=E])NE/F-9VC9X_Y/2=I_94(QI24O]ZV:YI@)/3C+D]67<8$;
M\)G)4GIV>36GE#9%JN(O9%A\,V0&!OJ_T64EU&4I=8I #7Y[*'2V^!1P=>>_
M5<74/XH=MV'#);-N1531Q=@6P1;;;N)0C*9&'2#3;](D)^_'Y&SKW.0'RUW.
M:A8*ZWF 0LVT/]\O'!H$]WT9_";W5@/]C:#%M\1TJO5I?7W!9+\=R$$98SV8
MN4*=5:%$M<4<M.6%8YPCH\Q9_@WQV$%XLY4O6?<Q<3_\^N=2K-/I.\"E]<!K
M=P<G]^$LX\[Y[JA*<M2T>P#M'> VNC%X=D':;>B+LR+BP#EKIWR.4PVI/0MZ
M2;RRT?!H>5O:>C7*HJ\?_-V61I$F+X*-(9'DTJ$^P%YN)D+:JD"%I<))_4BE
M(;]6,@"#H9 \AA!C5[*.1[*Z,3KG]?!D;QEMIA/W['M6%A=AZ(4R6O>'QF>8
M_8K]HZ#G_56FCB:CQ ?/@-:]WKZJWN:,QO$6X)?E0RB'A1B;<Z?XBI^"(^RA
M+;[L%TNNB;^.*:J,FAL,V3N1=@LCN"]U:##.Q_=-D.7-R%&B.46/J,=C A]M
MR8'[^X+NTNS#>;I;]LF#6NX:E"2WZS,+D:;2IRHA)FY1'$U3Z3&80GAXGPVU
M!^'XW=FNG%O'_L.#08PX'QL,#-GN\ =3KKDQ7E4EYQ1H6W[+S0!Y=-F%>YE\
M7?@[(#57B63LL8;('P_UNGA29/H<E\(U8>B\Y .)EAF/);=_7+H$GQS=!Z"
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M0MPUZ02=O?=A+$,5.'Q0::U"RO7-=<M:PX07GO4QG%-Q)MC[]HWXA/U!N(:
M[S 4Z^,1.0U:>1)-NK)5VLRB T-+TV$K:,4@D%%9P2,B,I<-YSR/('4AV\8Z
MYN'WA^TPMQ*L:',T_X%C9Q* 8*%9_*&4AUO1@,RY-A#,(7WF8PJ>>.C[O$1_
MCN5NIS?N)/WLEERTD"'F+)LK[+\=HEMG0'0EU'_[,U=MU8?W'U#K6I+[(75Z
M+"XX3TE&26;#_BUOV>')B=O7E,-U8FZ[/3<2=+DCN\4OY5V967S(3T6*I>$Z
ME7C.MX?(Z"I^ 8"/Z"TU&:IP<=DF9VYY.(#KOX.ONV/HUW-D),RJ;=F.%Y[M
M^-4(,;-E268SF]R@%,:.,;GX;;SK23BAAQB@ Y=)NT'^L7J31"B[V<Q*<[0>
MJN=?KV#JU^I+6=S^M@Y.6H7\&/\MEW:DSZYTU> QM"/#F[9 J0@)VC(-.=.@
M-<%'9;T48J2)_M.WQ72B;5;M+Q.HL0HQA\A&@NQ(C.9(O<=-AHWOO-/0L[:7
MY#>-=&NCR+0$?WC=GC\7G1U@-]1C; L#$_XGZOM_+IA.4E:-O.H,F2RC>\4%
MW%KUJF0/6(IO&FR'@?)(49'BXP-)TP":;,%<BG5&_,Z"TR,,QO%#VO)I2R[5
M<VA,E/_5DD**+I^%^ FU#8U")0]PK,B_-+]#DJO98G%'3^$V@N4(<0QX;\U<
M+#0[11J6QT@TPEQR^X6;QD=@]V':Z6A /:Y1+TGC%N@0<NR6K;TK)68>44C$
MDUWHDR=%;[__':T,IF%5T;%6KT?2O FB>..7Q;1:WUD1ZXY=3/G<^%HX63 1
M*6E*MS6YAHW1_W9M.'0O]?L!8G\:6]LWCCD7F7+E7<O;0(T,0T1[./Q9'HM:
M<[5R%*(2#E()1+PRJ56[>0>H-IH(WD](:G?YDZ@OCK8\ CV?5QQFDTOL=>%.
M,0FHJ*6F[O1['$JLY:MOO? +^7IGJ-\!"L>W%J)"'\5G6\.5K1I:VJ?G'YG;
M[0>Y7UI+J%-SS+IESZ]RB"9RJ%EV(*<*S\*(X1GI*XD5!(VSGW;FYBZ_8D^4
M$[P#CC6"7>/? >Y<N^P>C)!,T.6M;T%]\T&K)]@5LG'X=JA'5V9S&;-]).TN
MC!_C<7V@TV;*!T4ECZ-X QQ7^,9F"UC#8+0NOR("47\P)]Y20>G'-+[[!-IW
M=AL^2?.#ECI:;OLI,;"BJ1*5E)BB)G@C,)@E:P2]PW'1=#(#5.N0ZLL Z):=
M^U<^QQOG?X[!OG+]E\K)&&?7-QT LSO[YXVJ[[SV&<#[EBLE$S,\ST<\7H,\
M@P6"0YGLG(M.;%2J,OQ.=U0XO7-:GHAG<G)RX>\W_@Q'IV\;-IZTQ69Y^L.%
MIF3[;J]4C>-<D<5/[X N7)]!#!&RY/!<B/609I^GWQ)=ZZ9%_\H(1WKCL3,A
M[Q!/]5T#E&: <R90FN JR,>VOVUXG@,:X-O4WIS'[[)%ZI47!?)E>-+*>&X^
M!3W6G/ )L%O"6L&0[QS$S=NGI7JS$B.<R7LW:4IT3*1JRWXF%M8V^?64RK$*
M-QS6M5.ZT0(V!7IY5@4Z+)Q.^FF'0^]86@*FS@F#),+K+URV]"-BLGR;8T7"
M2R E654!Q*;^(LF^7:1>+SB-%Q 2N;UHH'>:IRUI -" 1(:*2Q6?Z3,,2N>;
M4Q^.OFX ;<G:%^-Q2U]+^R7((\-GP+S?"X. XR/X((MML$4+0.C7*?RPB,\T
M;/&'H_AIG(9JS>S,FIQ$6?C6(FF<7??R+>FQ"VK*"2\1%KQ2VWVZR.MC/[RW
M^L4BNO2@#+?(^0-:\/X5>FY]OT=CDBGOGS2=C,9O%$D;5+UET+\@I]AYH[+#
M6\8LRX-OU5!P.*G;Q:*7WV/+UJR__+YCB[SUVOW12#M-./8QLF_OO9W:J"WY
MT86V+OM_3IB!./1>59_[ N]F[!Q^0[V/JQ'^I9/^=\)%L2$@OVJ]WW[,WS[]
M>GMJCLP)LZ\F?7HPRN\ MNS!)0-K&#OQ=?Z+N?5AINQ&S4?!R-M=F[/@"CA;
M6AM[C+RO(ADN6262.V!5NV)<RJD 7O@5]I#9%31(/&S4'T0KAHQ>T-X[0#*3
MJT?0&?E&B(0B>;N$[DS<_0Z+M.4NLF&$A-,]H2?^*TVCAHN 0K(=,N'OAW<
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M>3D6V(JQC58>O@X_&H(?NM'+Z5A:Z%0D.;I27))_3QY]$C&X$HH_3KR+0T4
MBD U)QP21K^;WM, R43"3]86EY)M2<T'FV?R/S?:NXN!4UP)<H'&E7+)XU<-
M'!X;FO=1PXUF"66^O_:9ZD>CS9)B],U&RO3QNSQNF3_+$JXDJ.#1Q)(N(J4@
M )MJ.!L[9;]&E(:ATC60'P.0NMUFT*"^&9,*\74#073E@XA"EHQ3^>^1[_)8
MD;^?Q^(2O!-(+)[%";04J)&<D$LWUP%)SN&2(WU%J88Y@GYLZ^?WK1Q YB)A
MP*0IY^$XN3 $0#3)ETQ J BB_,'JE(+((M17P70TC+LI$X\KBRKKRVZ63 (]
ML]J8T./<[L'TY-3Q@'#=&JRC9\&/J:HO&:I<TW4)=DL;F/H!,5))W8Q]@C="
MUZDQP/;P F(SPW^--S#,#:DX"9&@DQCV@[ODR%P+VK45!?=IX9V82:18,7NE
M"!M*<""K49\YAPU1MXO)9]2>4QTG'$4Y7"Q7U'0EF\&='\L1 ,U&,NO=\CQ_
M1AA7_LF-:"-,)TL-JKE8I7=><;WFK"GR91G_ZPV5PS.+VP\%<B]1/2))R($O
M0$$2M_5=>@_&'D&T.A'>HY"^D)=K]X;D49/7_*5EYUWCQP8!>Z=5>:O8 Z]%
MX<%/7"B_HRQ4.!H4XD3DNA)XZ)VS<%T5<^?S[F\<W'S?4RS_>%CO(^2X]+EY
MMPVUM::15*V<]Q32^:S+=&S44)SY"*]SD=>69B(T^?-$N$E21O)K+"!AMA@)
M1LN_M2NA;ZM9ND<6?_URB5O35?EY9(O1H37Y_%N-J8W&[1;;N*9\MDL!6F\K
MIEHR!R_SD)Q+4/]NLUVC3H<8VZY5XY#4D'-7T;>M^OP*I=8KQ;4:&W-R,'+2
M0 X)4J:N:PJ6<!LGJ@1-]P7YL'MNC^'AA?&"< %T_D48DMA8O@)#*9G)IF.;
M8J*Z0GM,P#OXO(XS$5ZNSV/.IP3^+!@DW^5,U3(:F.#'?Y>LZS_ZKA4!^ :Y
M29U=%8&)MST\98./0)C@J:<%LJN(0\(YZ\V5_ZF_@Y\9]Y=WTAIFHAD!XVSO
M-QGS%80C^^"I&[(HMFJU5Q#)CR.F7(,Q)V(308P(0+47A& % 8#$KCPHVIUD
MS02YW='"G1& Q;.G-:%8"0$(434S1P!^1 \F\ID^%XVC[*?!I;3@I,&W9>0=
MM<T46,8*<=%TM?^FHA6V7\IW"4[D@_BH#(Y9YEPI7:PA (V;3SNA>@8"@)6[
M\#CPF/EQJ<N:_9KB0=[N7G1 /!03&'$G);O,/<#68%(DHN!4X>U)9RI=E<+J
M+")!S4U 3D<^N"7GUBZFS!_Z$Y^M8L?HVW;N( )PD+';*DKOZ8.]#WNDU7@"
M/A,8 5>Y6.VY2#DX>_.*XX$ME+ZW[NII0\KM*6MR-U] ?N'D#"EX:.MTO!AX
M[SP2TB)FG*C)<:G.IBOND.#$/A P^?AM;Z.8=LAU"P%PS/V]\H2A"P%PZ[=[
M+.![)!,_2=M5F'0O:ZPVKN4WJ/0&I[ GVJ%0/(A6!Q%Z!HWW69X:\$:0*8\9
M8-+(#QR! !/?MY+3@3Z<$G';E97+BA?3 -4'DJ_V>7ZH5^D8M8\#K9FBU\+!
M;7L:X+4I0B._7>0JOD069HX-I;H/D<4\NR2M>N.#^0,$N!\"3W7LLZF^0%67
MN3K!%[KG.HK8;!6;?N'833B[F)6]^0I$7/EDY9W1(,PJTJI8"KL;C:A,@IU
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M:)'7-$.JCAF8JAFW3>Q>W3=#R7EY&2/LDICI9[)V]E7 R$G#5]$9'4VI7>3
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M7S<?7IIXL\Y'1)VNKN39^QP_=(&-I[ERU1:R\UK@UL@L*%ULGXNIGS%.S]6
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M.9.?WYQFE(D$-SW=E=]<@IQ6],:<N5!NFKY6KO(J#?'YYC#*;TU18-.^S:K
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M=-DU?-$$9@"2#<4DA*U).:=IF6%)7A%W]2Y($^".PO;65!V7?R:B9V_=_E3
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M-:K-+5L7H^&F#H(#2;NWI'8\%3\&KC<D3"4\%C_$DPS:Z-@-N[A0[V=FIYZ
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M:5_7Y,[ (<_\_@ANZ/?,$Z&>0_V.]1[+(9V9SL ^\]%DG0)?HV )R,^OUTE
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MV*/P59^F4:^4'\5(4I@4W8G!.V7 )<6PXF6798V:Q9$ 8!F!$;GF%8,K4NO
MB5057XXLR,XA66PQ4\[A;8*DRSVS']/Q2P6:R(P-DJ?'HJ9,3]9%K>\-'LZT
MMRF20Z8B2V&!YQLW>U.;U&M( D"NP#&UO+GVSELMHN#;P= BI(/9AWS?1,E(
MRMD+4]<VM,RXPK %,E!#"3LUB^1M/E1PVO5AGYM_GR9AQ!>(;9?749\8WHO_
M62>#>/)#] ^%M5<?MSM^ ^;+ON!E;F]V"I-T_FSJ,I'^#4"9@K*_^*9[GR9#
ME /01.L=:3^O1B4GI;^?7/W:Z0VN$-V^)[20?CD\&YZM*T>0Q.R[VU2*7L:P
M&?Y*GFSCJR-[IOGU:%GBE0!8?&%)4BM2RH]1*Z36BD3/"3SEV7TT:EJZO03D
MT$^[O;^6V!7#8O\0EC'C](!M3R:XSHY;2LA3:J]F"JZCI=OZ&9_4MNWDH;4'
M85:M+.7>F&AD6E,6O8)EM%745J.1JNCX!_5#DD%<;IOUQJW*NT_5D.+DZSC'
M+]<A I4;I94';UX,^%SNW39T"K63MK*O9ZM+M$&G;Y)6$]JO9]<+ZF9YKH9F
MGL*2,CGPU$CM<%G,C%(O->-UHOD@:QD6^&-C(AL=25^0G&NZXN''M*3H%^%=
MJ4]9NXW65&QP=P\C>!H7C2K*31S">8\\LM?(YHH^Y!-1X30L)_T& !U&G<H8
MG"QY312\UD(J27AK\:4_3<2]'L;?#TO^,C?8&DD]D+3EV+B_%XA57\PH)JJ%
M/Y>5CQF_*M5NW0G@W]/M@^=ST:=2,JL3'V_4EIMI5#]XG.\LY-CPK9H\THGU
MA*,MD V12A(9-9]0+$@"EKP^2&K-%852&=:K#'?>\A=LH5@(F)1XNNF&CK,7
M]&<*7TV .3;*M6N"!C=NL'HMD&IZF\,O:Q :W;,>366OR&04%!5162DY@70H
MJ$WS0<SY-![K<D?R?<[6D_5U<6W4OF!,OZ?_A4W<[B TG)UR$._/$W'A Q</
M=*VMF/14"3GA!A*-X?2-PJ+BVL^XRTQDC5H_+'7ZXI6/TM0UJAI&/HGG:[_"
M/#9NSN2#?Q/",>8ZY:E$OZ\R87A*F\.J+9#OC]0PB&^%),>(TPNB3].6C#:E
M0T*&LS!<PQ:<>]D=R\=J>6FF/B;K:UFTS2T9">9SL\5XH=RSGZ^#%FJ?ARYN
M!LTG[*\"Z5X G0._NF(MU>Z#D9FT;?H*(0?/I=]5UMMLV,9!\1OBG*0K16$X
MPZ \])QX/,OU"^8]/IZR9YO,GGV#8UJ"ID87W?651=_]I QY3*"4:/0WH\2*
MU7!RT_:XG,HSAQJ-N#1WB^&F21[*OJFGL=3^GQ40TJ?8HZMW#>L?O\OH9%I2
M*:+V&70UU*,]C(72#H8#(?K6@95J!_2SIJOM]N=^Z1$L=5R:.0/5VCGI&-G<
MZ0"5L9$2"5=GZN!=+CPJ]^K1]'GA-XGFMS"PQ02W([\9Y;XI+^-(T2ENDX"6
M;&XKOE8#$^@)?+^B%$?^:8,O1*A_VJ_S+>(54*3S<M5M,& [* "\'FKFT4[J
MCA)QZE^'EGPGOPCU[V#$&51JJ=_I(8L1,OV^>404F!I$16>4T3A;N#V27#SD
M*@J-YA.FELWZAO[H_/1.R4:9E\Q "(' #[/2%&:PU%1T[4A-9ZM[^' 55%-7
M":Q2)3-*=KZ,#!>\(D9SD<#JE?AZOTT'!.)/!:&MGBF@7^,$Z;,2A)+W9>!*
M;B=U7D]>O+H_PQ:X=[F\_!N0</U\K7XWES0'[1?\*JS4(LV[7KZ$AD"QN34C
M-,O7%:X=QR]E8/V!6'-2=2I56YM=#V]TAEG*8]LK55%Y<KUAM9$"L)!4X$)\
M ?_*Y?KH<R=-:5_/N;VY?0>M=[FP7-GU$)E/E_:2BV<>[]SWT8Y?7F&Q6#AX
M8EHXJEI(X= 0=G--["VN+^4=!7B+Q.EF.L!**^Q<:KZX'$%)<[*K#ZYJV$/#
MNBLX8X#0&"2Y&+[&7TVAS.<5^<ZO:K;.G^M!_FH*Z:[[LDC:7+H/+9ML8/@J
M)M]G.1F8Z%!^-V#8&J$!)4RUM5;%U7A*XCT7P7ELSN@M ;LX8U8*9_^ @P!=
M*@NVP[NW'EB%D#7<S]BO2>QW\PNJ1>8G]*EWR)DFT7&Y7B*[MY.%\!'[AKZE
MHTWBAME5*Y\U8=TT\ZT\[(W=U*=6P"2/05,KI@EZE9 !"9:AI(\Q-%A2'F(C
M,?B7Z%Z)ET[WK7T^9KW!TS1J$EHKI%OK2)D?W>I2<,L,['+7MC';&^-)#"C.
M45^OB?J19:<</!^<T?F&.Y>_>QT%><\8Y.,)S><RI;I>7$O)F0MB@;^?BS=?
MYE$W[(Z]JM23MC@3IYL9:4;KPB9K NK)U'I7+C &_2]GS\9'XI*N(Y**,3?:
M380BIBF%%TI"#X\\@GV&XOP%_*3$WD@AW_Y,JIJ00.J%$\%[LMB*#BBDXX%$
M[[22S$T72CQ#9CV=JZGA1GZ=JR<ZYH1YB*VGP9,I5-IS+/4YC\@+"V]4A%2H
MY\5^74<;8"P7)\]U7%0=GN=7IILXBWGQI<B5,A#;2GH,4+Q--GY<B?")Y9A<
MYS= !(O0!!^I89#Z'!,Y+^_!;%1/$*6;6171P=ZDFA,5PAG+& V)\MS6)60$
MC5Z=EHZS0(X)V:3;CN!O /FY=6-_[KV3G;I9=8<W^D>;;\L#[43JW9:\9A(M
ML" @N(ZJ.;[]N\HX=R/I-757ODP!]9*R#!)DX\Z4G7U7V$9 Z&*^9Z'_8F+_
MD>[*#?VU7KI^NM_.G 2P=JRE*ZH4RE=&ZA9V&BRSL9(\Q'="=#GY\:4[4,OC
M+N1;O1GXA7:Y=NJP)U'* *Z'Y4>#GJ67)O<M^P?6DTS]WWW^N;.M::M-!1X.
MK:Z.[TA<1LAF192F!'D.&QF.6)\O@S"+GX9RSA6K'N,.5(IV$7W39'>;D*C7
MO=H@BA4EQ2*Q>6 ;7J@;\\LD=$_&33=*;F^Q\%.-"3X8U5[1!:9R4Q<,HDB%
MH'>,Q%3$18NX4\X'H;%UQY.1V;S43^D_$BO\[+66]@D!TR?$S-G57IFY:^5L
M"?<L9M&D;/:H)'-,ART]CD])06&<CY^=4JM4%4)]U<=X\3RD([K2E>(I6,XO
M*OHVE=KH=I/41,.;AQY$=C@2O<MF.XJSS_0Q"((>W###4JL?[@STK56FQ.05
MV5B14SY"?DQ,7H"-FW["#QWK?GK^IR0133J\!V*]]V/^(#!-<,,AR6@HCYUW
MF*QC"C1Z3+$?8R@A]$5564';=R\'2,N5^4Q[L\HX_JX3?V#@O@0\#&_[[;\I
MAG!%,-\5/C^KIG^^S(4E^OY_5S5Y70K\?*M_C^K-YC]^':)-?D?][45'\?*0
M^W8%CPL)_R3=0>MI8.=Z.F;G*W[F<>9/QL[\'R8_1L&M'8S^B",=J2^J<2Q]
MJ@.W_<K8!(V6V 5-D<?\Z/0]*6^;US)RJQ<?K580AI&1]'///'XN7D"96)-6
M/WW8G+!?;Y#[#8C+I9%*/V,4WCR L8'+ S<;L&#N3= ",A[IR"ZFAF)@I5U1
M=01L>M@DR%G5%^3H!#3,/$Y;SI\\.2)T_/1BVIGH8-SRS&#)\C= T)]RT.A]
M3YRJ=J:Y(Z:XDZY>FA^(,/P:122G__I0;>G]]=71"T?8!-: @04+V-#E0.ZP
MZS"2P8[CP;10Z8JWG=&@N9"@5_-FRWT]LLXS@[<WI@;9&[$>:KU]89[*R5D'
MRR1X-$/5/U"C49MGJS)S9H.!-A,C1\*JZGW]V\&T5@)S8C[$/%MXD9)=(@]H
M1M[>N+]F5" -3/==+5OJU6K-O[;4."4S!PNE%S;0%6T<?YOS%U\ ISWI'S7'
MMP#GI7<%II3XVKTZFN%\)V.:-FB@NC#@B5W( FYAF]D<5DWOXK#*MTO?$/W:
M^=U'"822,\.]@8[?5>4E;;7^!B#0,YK53-[2O.<%OV 0O#C^B2YBS-R5;0_#
MAEO7$B W/RMFKZH^GZ9A)C_2780F42$H9OT+8@AYG*1![3,A'?& ";/$I5J&
M4!NO3;IXUIJGDXGKTUY_XE8>$=Z@1E0 ;6'HH9-_('DJ 8NYLV/)EY( $3+
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M@/GS\Z(FGAX%QB^C= 1:>#V4DXFDA-_24\<KS$OBZG8C(X;[]O"334XH.]!
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M[Q2Z5T?:,OT1TN=S(RO@N\PQ :TW8:P0F4!_\\VXH?UZK#WE-DDZ@O%/BU^
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M3'AS8*I?D;GO71VVK5=@U99C2KO>;<F3X=+'9G+B(0^3ON9@,.+I-#6G]L0
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M@GGR2:F4@FG$M:'LJJV,CQG<A2Q"8/[T?-+396-]'J@63ST1C8-C"SO9URX
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M4YZ4L2\X^\$@>KA8<1E6U0PSWOL%OQ%G1 '<XT0P'(H^XE;#^A,4V#CC9#:
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M&[8'[5C<TPBZ4X["JO;G@L".LCK(4TY4#,2".!H[9^((+)VHE1C'B?_QVLU
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M60P^(M]-?3KO!#X>MR/GG' K\R]."QHAT>O^,,*?)M X2IYB64M!LVE&= A
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M] 0LQB'';A13Q#Q%M6\>&DFS'PK0P]NGKBLA>>RIM/5)B'%^ M[RR&92@<_
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M. M9W,OF#D6QR4CSV>=CT4I-)@T5?Z!.<_SI))82TWA<9:>>^ O\19\BB-I
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MQ"<@Y%M6[+9<Q^OV;)CU1\$KBY/XV)3S_IGY"ET-]6]FXY*1=4M<YTM=<=3
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M(#]NEM4.*UZOY@9 %L_0^=Y5(W"Y@'  I.OQ_QB5_U\APNO2OP%02P,$%
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M//)D9_>L"-FVLZN@XUK3H@;B[!@3&5+YAP%$JFAEGQ5(5C82T>"P/?E8HW+
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M,Q5O=YG1I8U7B*+I9BVPF3J;#=]?/U9=+B7\^IZ_1>S=9N4\A)O49!/$NEM
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M3C#EE:( Z2FZU$J+.HD:T^)9\"$7$G1$ #>'Z_T-B*C*WX E_&-B#>QX&P7
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MY+J1R-Z]$,34A-'L6NR$<5:D<U2:L?#6+"TB&_HL6D!N#AK.>Q//M9QO 2*
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M"H\%I*8FR]ZJS%_C?^$"O$GHP]ZGI;TU+:9TW7-HW;!>29OE0?)%Q ^):0I
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MJO,\QU<I'<GW*CA1-] WI46"76XI:?I$@G^W>..+;6S^U- DRG:<*Y%YC-+
M_>W;/-@//IJDD'48%D(YG5VUTJN,W2OK),9>'5<C!4H04\F .*6==F[.\'8S
MD\J4E8WNH9>U81L_=./;^;B*J'Z>GN<-MF@A\I1'J :<JRPR)[R9TG85JHT7
MGK 5?\MNPCQ>Z9A/6Q.=Q8R!_=V0)E& FX$,R%  $3DI+4C;V*#3Q<'\$DKR
M\=MK#UN4%_Y^NP2C&B#*SD\"+ZS)^:F_<75P3'W6,YGV7J!2<KLM7OM -L_2
M^1_S4+37!9H0V-KC9#+@W! ,)YL0E-"07_9[WIOWI9P>9S:0 :QD )_;,V/S
M?WQ5YA] 2MCQK()BCVC_;R04><* N[H[J*W;P/U[)7[EV$-C+''F3(,_['*W
M,V#TCT^Z)W5B2Z=;<>L=(D]/GE+ZP*^TE*[%G:*3H!K>]QG;IT<C!F'RSC?@
M7Y=Q.A=T;PKGP6%JE\L;;><_$1WF+8U54_![CX/UWY8LU0\O,?R(F/:2I#D;
M(QT3@@:?%E#Z[)^4MA)[E[*&L1A=>M(;"3+@[0")>?Y^U,WNQ[*+GLM TKU]
MR(IO;"L\K!<[^YC#L^:=+.2I;@QU374%<O>!47X=&6#$'RV9?M0/U". LM=1
MM*!F21T/#Z/R5#VIRF!@LA"FTTL2_F4Q]N$^ZB\VF&".]K#],S#B91BV9/GF
MP\=Z#)S5Z4/3KTGT<L#/_>MCDNM^D+2/@E%RWS2=0F.TGSW)4B'\46RTBL^E
M-.GW*(@WK_[>+(>0 1X#4"0:(,%8.D.WH1Y'!E#ZW*,SYGVM>8YDP"[OYNS!
M!)H,4'.<((W\I*@1BK @<)$!\^8IU]+?+D#H3:I2-9-$H,W;13[C+]@6O[A&
M;'_7".,HJTZSGY!,\-,[ AUJ)[(;1>;1%.GRJ.A;'5"L#GPG _8OU%-\6/G7
MACU3 I#T5AY$X)J=-X,YVX+VKZ"P[!3C-(FG;Z-V3P:H2^G;0!>NHXD02H8\
MLN(?JRK1AZA_@;V(%_O0^>7#VT5(3JR! GIL%EM,Y*%$EUI&O.R,S2(QPX,I
M'E_UI"#63V(N4>'OO:G8ROCON:E;^3N?>D<C*>'0=+."SNTW-+W0*9 5>_3+
MPDJ]P-*!V_$T:67C=L,KUQH7@<+R)_=$S[1[3-"'8I04_4LM)QN'](JM4D^2
M/[\]ZKD%:'3Y>J.Y+!OVUT@TB2) &DJ&"&V2 52IQ)N][]W62TU?)*):*4E1
M\++V2$3N7\:#!O\W3$S(@+^ <@[TBVU HA%KAI$I.Q+:A?VR(0/L+^X[$XP"
M*5+FJRZ:1"-/,/*.L<;NO"%>?2VV?].I9%N6_U,V\KG:>23^WC[&DLE=])RR
M'OW]>C?7 *%J])'>MWFN/.;0']B#EPF5?L)E+2?C@<*I3X6B^NGBPNTC"_3Y
M I:[.C1K"U#S*C^!:P;.1/;_E#;^+446)\#F>O1(0HT#6V3 L3_/OTH3F'_7
ME6=O!00%'O'W*DE@58G4F;,F:]P2Z/"T2YW)UY:^501D/H$%;I73V-%YOTP8
MRAU1.;=^W)=\[L1L-+HZ6VS6='C^L]&D08J@_LJ=6Z;>KRV_:TT!^OV<B<(3
M-*<7=<F X)O W_\Y\%>7T%])52L; 2^4!DIR8*?\2&3]%^ X:2-\=-EVB)+:
M2R2KL$NK(:]EZ9G42W\(^+_;/_(8$(A;EI&2JGQI4]9#8_6YU/\[BJ9J]MS&
MF'%WX4;*UV&(5:].S8B0<4P+#6^%9NA9;&'#IP3$O5(R@'050T4*I8CZ[Q__
M1=QP>Y[]F_(DNNS?=\:?_UG"I@!FX)1U1E2CIO9@_G(^ICT/G2]O(V:X03.[
M()>>FQ3J^.LA]A3M>G*/0IW:**SM;TJV0(W/[N.!1_(4>O1P6P"N]B$)L%W-
M7\P+"MX8*G_?DP>Z<^AAR/!W-POMK^.;]VI2A6J8:%UE:-(:E'(G+DLWL1E7
M:[TTF6HQ?#7A)1V5_]I%:[\?NDJ_99-I2F#5,P?C>-IZ=1\JNY.N\J_$'[^I
MW4M_>OFTP80EENW'\!BJR+JW3)+863"8AX',-6ET[.K>0ELT?#!SO.JPJYO3
MRXS,DDU1U#LKQ<V.MA[X)F#'G)I!&IUXX'<MK&Y!:W48XNP1P(?S*(+(^3H;
MK!PM/7@BI99582TYX/Z=V;$5#TZ9;;$Z-RB$S@)B8_J+>T7+S3\(GT#E)>=5
M@>(#57;I#0&;/XBV)PJ$Q5;D-6S5L5>Y0R$A8LR9;OV";/J7%3:^;[4?3PNU
M>E^6=EHV<]_64A9Y5E #CGPZNHUR+*,R;7U>H;9 56BY<=4!]"MN;1>9<6E$
MOSA>4Y3_8]MK'B_7FB]CQN]18#W:SKEIF#Z6T!1_+$99RB<_MV4M54Q$9<,1
M&@XL%QXK-==V=UP Q,7UZ\[#QV<-$(1H\&+L%4(8V@ M-.))>_I8D=,H;+J]
M/<5,DXG]14]Y)YOBI_BVE*4#^G'A-H7#X/U8F@VD3'EJJQ7[,(*3A_X4_MA^
M6\UBLMLIUF.RYUO$739KP)3+XQL/$P^L"U3J3AZ!-Q?H+]LK*#>EM6\7E';F
M34U'2_E:#\]S0+W=BD@X[^Z]51=%P[MW;X$1D?@2@J]@-&9OQM&HWH,CH*,
M$N">I_5A0^X;SZR.8^>IO47PKP]N9[C&C))/I!'P=Q@$;9JK,,+22E<#[!%2
MI.2<79H^&#9 LRP!AQI3Y9!:W=9)' T_@0@BD#I;X=I*I'6^V?IEB9RK-]23
MEB<T )ET#%<LEY:.]1V=\QW]7I(!B.0@B$=6@5Z>3R'M^0R=HH;W51>RS#F]
M7Y0/J&Q!-#KFH](:YR[VAN/3S6.O@/$)#I4.26;R$;!O;4/C.M*.5R*E71XI
M/CZ;=_:-SP1KP\5.PN3)C4T>5EDQ!]2\X'!H6%;6I$/2>N&$GLN$3ENV3%)^
M1;'OA[DD3U')#C!,YS3M  +LR'J6T";WU$%D :S')%8VSJ6[JFF#-WTAUN"@
MT5*!B^NZFW/2<"Y/NSAP*!TP*%J56H#0>9\YZO')L^@ZV'ZWZJ?.K?:+H50J
M+^/O&#[.#B.ME\*;>1BJ8._EO/<<^+9IHU66QD$.Q]%U-?55GVY XC7\&(O/
M\WY0G4.'R6_IV9$!Y\LB/%H7F!MJ&\<@GI>8RTH>?7 82QIJ_&:B<(YZX9+H
MU[G@,+:EB_MEP:CSSBK,!%A;-]>$(+*R>$IVZ!+W]Z^5".LK,8*MTMI"4R\K
MY1Z[W+[U,@/"YNA.8CW-*#THB_6K"=FN.@$[GY.>7I^0JZ9UKA]Y'7]7@L_)
M"W,14\.5</78*#$68SI'VT_U!,UA^6)  U'%.@B:=G 3D/_)_N 6'M.5("65
M_S1XCRK*W2*Z; N481](BVU9\R8#GA/",T%JA; 62^'/_!;3OJ&EE@L2-5=I
MXK2HLNA6*F5@XS3FP^9MHND"/V7( (R8G YKS?"^!HO9QUBI;GSDIN:'%I#C
M1Q6#LMD7Y^^T3R1L<*1GSE8!PUGU(O2S?3)U'^H4O.YXER*:2]3F>J$I!&SX
MQG]SMH'F#HV2@0.L*N^-; "M_MCU4>%8O6^#K&W2VLI%';J?O:,J@GL5NCGY
M>9?D:%RM]&Q/N,%X.7Q7NM 02-?R/KARGIVO"7*9VL= ED$8OL(8JA/ZZI=.
M.HU9-QSO4#]\(!',0Q]7MC-/40(3V6C$))B>_W'C4/3W.G--@;@5SI!PAJBY
M<\J7N*I.PO+0<O(B^:;FTQKQ&@EM%85]#5SG &]Z_+A]KQ5"\H@I*U '[&0K
MD$$  6-PN%F *)T_MYX3^VK+;EMJ]>NFQ7!@/XKNUQ7H31;Z4Y5I&&ZB536&
MT(2[:H'M*)@'TA(>=K3LM:??J$_A-/5\Y6IG=U;R*&'@AMYG?"E G5\PG-<8
M3LC"A^- +3K]L-9TR2&/-/=V6ENP[_QXU5-!1'41/C*GRB1'F[9*-$'!Z?HG
MYKM<.*OW.."\Y4#D0"A"[](F[3R*R<=H/F^H3"@8([<B']N3-&._2ZNQ_L9%
M[8^OP18:Y2<R&R@&V+S *-%WH=8):IIO.CGNX&UV+2YH\H&),*MDU4U^::T5
M6^,7JQ_DHBZ.*249L^3L,/@,+!RV.M/[P(UP0JGS 6XMG:TU]<5^85&5]Y*\
M/VA80E9B-%\ER:\)&.0MWZ7BJR8)0(U'&CE/E.EYS,PF] K) #N'0[AMJG="
MO?MYUS?>SWW#N?#,P250#L)[W+E.T^".=)5O\7?W.:<YACI5AY>J$;ZE-KL3
MV^MF&E)2L?7!%^N$$CK@%<BW"Q+A9C')N6+(Y(63Z5O#NLEM4KX5(I^4X)_:
M44YLS8T ^B8)KXWY@E_$U[BQ!FQKJU?ZC6&9+D3TU<?UVDJJKYFCAQQ6WPO7
M?/]N__[RL^#$2S'J;@IVG<X,A"(U7'ADH_ \B/!0Z;KCINT\JJ*+#V[RV7UU
M.MGK?%+$[(W7+-=-HK#T[O,8UDY6L\<UMHMB-O=& L=?C^%+,M?WS-_5\(NP
MGXU7F>_JD/PY K^$Y*FAZ- 0/YJ@Z 7+ZN3LTL_XJM@7=0R),ZPU%@OQKCJ6
M';XQ";B:3F[%GX%LXSX@O9\0HND"G%YW060<H2IM:J[)IKX[J!\<OZM5> %X
MX^RNBXC;*OY=S"S>J9SPM5Y:S]^7[DIK5G;M)9CHPKCUGF2+;R=G^:&&8VA9
M,Y#11^\^P5LX!*J?-^X#;_'CFCB;;)88V0_V=>8U,']1:VOK86REI10\5B,.
MM&NZM8H/J":83"0.J3I#&-N+.KX^2G;M$3;_T"0EQ(G?QSP[30\:$572Q?$W
MUT<EPQB26W8)]Y45_*?5S 8?C"UJQ?.R=?+U;+W28#^#IA'IV3-).<2HYNCF
MF//03UBI%LL59+<*P1=HV<4$P)R]<>?KHK6//@:YN']G>WY+@A%Z =?9'JVH
M/ZS"3\"/+6JG:M4-,_:VRM$[<.WV9>B.=GE#MAI433J8&'7=)WBV(GT=6Q;V
M]+'+T4O&"N8='LI"6@_>.[A5-F@-:?4C#;Y"SO(=?,]P<_KE""$(XZM^[C3*
MYV@O<)JOH$NOI^SB9U6'E^LC.D:L="!,0W-)AC8,ZPG?[_S1M)=_EBNX2W87
M67?"X3@1%IRU[C4C.#BZ!5D)NF9D*?=@1&9<H"'>73D;IU72P$B]NR3ZV6(Q
MGGXD"<?I;_]"2JF?RS',5&7O V JX(=4($+VKOR[T>X;F1%=UO_KYD$[C/M?
M-@^F!3JGPI #RT?\NX_V2!K,*J#XBS<R&]U;I*'W/ V'3:M\1:\W&M&!#"Y;
MGY<R20OA0G\J:X]EF22*CB@].Z;.S;D>;_0-+#6HBG\V</QH<M+%B!=CN!2D
M#!Z"@C('%O0N;ASK(M"_[)"(^'$G%[WDVN=?Z%\XYKU3XN$NP9+V6O 58A^E
MUBDG@PC=SR;-3[XN8DOKI?*8/@[YD7C02UZ#:3>R"P4.0-Z@S:YIQ,<!\-F\
M8 ''5>XYCJ2LFL@M_,_VM!D+Q\\'S53 '&V+O"OZZDQO#G;^)LR["!21(C!S
M0FJE(@,>7$27!0_ 9H&87R3-M7'GDS2@WFBH:H#;F)<\*ZVSV*0:IY88IEGJ
MX3T!OJ![4WYTZ;EY7SW+X.;I<?/Q1#\<=5D+BM$'KO^S>%]94Q=W?C :L92K
M56QM%PW=#%/;8Z)/NC#[=E,7%#NQ#S\'U5YHDE>MQJGC$WU]'2ZM?%H14UFX
MP^K:J&+C;'(<W5AN_?9[OS,8=-;)\Q*K8="L29#($=1 2?_5WB3[<]-S4VHR
MOD?HX*[U#YH/X;H$H!_R'.%MS@9'21&86\K_?>FKBFI),W.E#^_NQ4AI\U*?
MC7?KE-TG#8LMKRP;KSR>P4\XS$P>[-8\!;GL*U\^.M"E?83\<*O;T^%2:^$^
M':[HBG*%(^;9X-;CQ,SU,6IBJP.8N<Y%LN$%]0]E7$H-2%K$7<4R*JA!@B+9
M<8LEI]<I<C+:%3$.!9(!L=><U^E)(8Z"Q%NH.3@ICK^(EFB?.J*O'O@\X)[Q
M!Z@/8=T5BUQ4&]I7EE.V,VMJJCIQU-)+S/O5Z_*!?8DW]G-:2^8A;WH$&+W9
MKB(9V$/B))1X%C@Z^!:L<^!S7&T$IT<XHC:9RB>U<HQ[C&C3"N\!6\R]S?!2
MR6]-:AM;2 -#IWX;:?$-PX4/6Q(Q7W<XH<]QFF^1HO8*0AF0KVK9X)01/Z.T
MG*,AE0)/)V,IT#F:W@<:-(<O[2[Z=O]1Z$._&/Z>J%KB(_]D=!_#-]NB(EO?
M6#7$,M*+GWP5HO7S\WM%GGZM+_/W)ESN%LV($P070&P;!;FSA.J)S>\7BB8V
M!LVGQEE'Q4*HV2&9M=-OV3W.UG%B^^[^<$!>(- 7$YS;N-ET-=N\4L)#B,+N
MOIX9O]I?V=3/WG')]*5EMF;LVFBX]T-5661RI0=98->+N>M9D;S;,S:L[>XV
M<SA^\D.\)V S?5"=R;B#A?D[U(LB9UEUR(!OJ;"UPAUP$ %#$63BR62 M1P9
M,&AX )4FD0%D@%/OKDIR&$5D0L(/8 E*0E&%NYV.,=K[U]:RXZ!=XV[&+OQN
M!]P+*'5@)OT-@C[.;6^!I;!\:F;M6W9YOXR9Q^TIP9EVM\))^))KE-/DEU=9
M./J.R$@@S\R:D3R'Z 5K3V=[_$1D5Z5EXUM3O):*UC<VZMG#7PSM(- 9GT+.
M!F4#,L"\<LQ9AE,Q>XA%4>^6]DJ<7'BMXC<?@+7+97=#S]@0,V3=:3G#J&CQ
M_BPCHJ0#X8PW&!8=+*39Y?$"0-Y FS%+$<>R!SRO5S ]8Q-K.VNIA]"D>JMC
M^ TRH I9FL%T-#RK:RQ!2+$Z3#4:Z[<W&6UT7<#0=R9-*/5F6/[RO;IA'#9S
M-V0L27^5KJUZ>BOPB63WV7UF8!")%WR<A/@ZN5GM!V69X1O.'O' O03U!3N-
M[>:(NG3:%$Q)=O$S_S3QX;X#55]H,MBVK>-8<ID\WS+7>M:5:3S]2+2?,"81
MK,+I6,]=GC6UR=''D88,?7[LE?3!_!/<!D*](O !Y'B+6'M-SV_%\W9%[O##
M=?$8S'B3LN#+DYP-ST*?KM%(W?'N R.=SV)^FTP36[,9:\_TU7WR?L*_*D+(
M@";AT]T;D\ZGZ\"=N"?HSZ90_\&R0,5IXFUSD="&,+2?8WORUK!EH6B%:?[F
M2K9X/,\K?-GZ4NHODHJR'@1U2%'O2'6V&A(1]:%,J99P@-V]<Q#+WZ&@?-"1
M8*M\.II30D&(Z>&C3Q:[&I(Q;5$+E5#Y$S4?G3:.1QQ3$XEA<?.]T;<&GD8^
M18[P63G1OJ7M_))U\[Z4C\T'!0YHQ19-(::&M \_[,KZCRV7!*(3P1_\=1SL
M[C.I%JF%3/R*:/0?8>CG^\ A>V =E[@A/93O$[NX&K0?0-..KO=JRB4$ZV-_
MP%WSI]<Y C9DOYL\2];?B0OR_:XTV"O>[&<T"=OY?5=SA-PD&>"G=[)D'.H3
MB\\:KKJF<V\H62MLU03M:>\Q*2(W.A>[Y/\R+??#W)&_6@A#7%V,9.O%?450
M9#H-$FX2-ME^++J[MC:T(7)M@Z<B\XLT4.E6^H4U^G-PT>1[BF+59,!, NF(
M"?+O>,H401-4\PF:+S<7R0!Z*=#=F/&DT_.)P5MW[JXW+'<O*F_RS>*CL=49
MI6 SVR_82GN_';Q0GFS_TA-1GEIIF8T+?1&WC>V/*HI=0[.2+-\<-/UC_E([
M T+H/(1[1B22#&!8]_+:';_V\*Y=_0-C!+7J%T;?1_71,\4T?C7SL2SV2-DA
M_E$HL,ATTPQ<KEY?\5$K-=Q0P(._5FED?/O<S'_ADTCP7UR)7)"(X3AL-7F]
MS=<X-/=*5W\\<,!;"<QI8=XY"]61L47-X$LPP$76-P>&HS,#'6:"/0[G;4<X
M%$?:*ZBJ&KZ<3N%J7=,5AI<#WF"J_YQ8_QT0);$D$I*P:->Z!KW+C23)#K*J
MQ]LX)>?BO&2^VF91E<[=%8EZV^_XBW@?B\RS<_=V6!"3VA@;ZY9E7PU;9^='
MN+3;O;C\QY7H/8\CO1RNLF_7Y/[IO:&Y^:<R2$9M3=RKH)>F_'&7#4?#U.A?
MG)<5U.K^'T>J9T^&8+-\C:L+R>V<.^''>2'[)2*M4H0\8YS@U%A2=?FLIGW^
MBY">OA]S49"G[2X*X1A#[UP+*_MD'OJ=+%Q3*<(F$_G&T]PM"NVJ].UAC=K-
MJF+G#_=X8_PB$.S*(0$7_C00_>>J,2\IE'5,VWQ',C2.06WF1/HOKY>)[6.$
MM<M', >TT48;7B)<^A];,J84RIO9E:G!!,X%JYHRG\+-UD!AK%S6W*F^:/MI
M8XG[M8.T/O/JBLAWS89QYNS1==^[NG)Z#JD&\?\,K+-]]IH,Z +1")O<NE*!
M0HXACHA9,K>_55<\98J_'F\@EV3-:7UF^HUV,]<Z] D!SMH:&< Q<XEOIRWP
M.MI9Y7OV6K7X>\&1#-HZ._?J.X-,E8HN- 4R1U8I3C2^_XQMF<1-&&5L7V#&
MS41*M*:FT;6@&1V3]7MM9=Q6>WW$C2]<%V"^H?)<0[*K&/4.6%43#F6V<8!9
M7\%II'IFSFP^F7%(UGKA41U_8^*V[]'[3P%R']2Y*IS&J,;E_A%5G2+/^W3&
MD<;'4%G(@JZX,T/A=L!-\8]3XDS2XC-+5/$T_+7%$N_( '8Q%9X-UB2=W/ZB
M:1-[5B1_DY;M>5[$V\ GVC1B(L0(Y4_XG)Z=Y\K"_^$<SC]Y4F3UU!F/PF['
MGB@2W!>:!W=*(0<-[\2N#S*JLTK^V#9Z\$(#Z,4\'J,@T>2X":H2RL'/7NV=
M=PY/045!E>=3PZM&9<&*M2]>I=RFPTTTSRJW:M#?Z="Z)>58)_A+W-_JOPJ-
M=HXGP@AXI5%]H?_6CQ\+XQX77@_FU7(^6E@8=V+:XI6Z4GS&:)6OE"#1^<0'
M>=)6[XI(T!M5 N97PWW!_&%*A=U,A9K/XN6,N+_$C,J!712F_T$2^?8%[/]5
M(,]DGIR=_.>)8?#>5<@_B%A-'>!3AE&]'"S S4X::QB!-$L?@6S>"@Q,_\#T
M24[F^$B,*S&0 :K*,#( ,$\&+&S^(@/ <,(A-F^,PGDOR[YL[O6-.=@(U1GK
M=?O"$^T,F5P/6&_Y>V\U_LC;2C]/!GQ-1Y$!;UPH#:!'0,)WGOVK:#( >YF'
M)%[G*-*-CSPR7B39A6.,=R4ZB?_;$8V+G=SBX<TD3KAQRG0IL8XO5&S14XV_
M:R-"7IXJ:<,/ /YC9T&HQF&^8TPO>$+'I"W^T>"F7%2<1K#B8=B$ZNH;?Z/R
MJ-R/'YFK9V93Y4-L[Q3<T.B?] ?OV57^W5!LA0\_*<B/#""=H0CB=C2<H&F5
MT,[-/HSP]3C:SVUZ]TAT6TM*(V][NS/_.Q%L5?GQR/RQB-YFW<="MQI6:L]-
MDMU3O-Y9V$\]$!G0? =&J%?IGHL]OK#Y^WH)/1G :H%@:LHD&1+(@,\JHS ^
M(JSO$!6>1&(# :QHP=.F&!3BG)FY3^O.KM]S.<F8@X(E@C<))@L\P?'\?OB!
M=RO/D=#A+)Z-YYC7J FJXFTEV3XYWK[6@#\ WN]=A@K*.\$+$'\[1C-A?O:(
M.$(&[+3!B(8OQD 12JJLH5#Y O!5LVFK3ANJ1Y#B%U(#X@I\O!MM<\:A'!MN
M^M$WIH\I#J[-=FTVPB^3 0,K>61 (/_O1S+L0A7) & *_)00^_LQ)5?(@-!%
M7[!<5B[(A]\PN)VEI3]CL&0U8G% )\DVNJ]HM^-KEK-8=.V.)E&\WP#"8])0
MA57N._2[M(0WFRZN+RD6>3[84>&T9QG4%<K%%?-EZ>+.<1/L:(\>A9P%0XP:
M+"?=BD^X9_\/$;D +RM92[31GUVWXDO6K/N)JK+9RRIOM'4PDGK<(>"Z1W<;
MSU?_<*' >%QW..W&M/TAI<U]CXK[.TB6H+<+@T8#QB?*_7MT:JB^T#,\DAVW
MP3^**@B4].=6F!WB.3T_9M"F.6YX.A)XX9"DN>(Q#]K)]$1:49IIY1W@SA 9
M$,W]U\&33)3L\1)PM0VXZTS2.@:S$ILD2/XSL-D<,H!#Z2_O,ZPT<3KX=U4$
MFP41C"@A<,\D]N$PWY@L.-_I18C91/?-]Z;,7=(JAN_5MVC<J#WG+1_9ZMFJ
MT=-(I!"7DH[]UH3SGD[\/\V-X]R9D.L8Z#2PC_QJI9NM5FRV)KUY?T'PIJ\K
M1S='I!NTXY%"T)R+]MP;76<3J.,@PCDZ>?;2:^N438-OPYQ/&E#W50:N%K_+
MG06V\S**< 5,O?&5';S%]JG4+C2ZSK>>J.!XBI$W4_8T<^3P5E;KI<2]VK1Z
M>@S"9?WE?2&3\>>#+MC .]C2+/'#%FAW'W6TXTM)J&0B.(+0?_G-S*7AT(.9
M'":>"3%$R9S&BQGC^[0>[1ZC_] OQS%<[1HFF[<DK;90J36$V,SYM;I75<P3
MZ+PL)=06DI;"'TE-_\,?R=]A^XQHU+\))\5PZ>T0ZAX>1P; 72DU1WIS7(5:
MW4+1[RJ *@@2I""SPW\7_" >1$V1JCI6?U8O;@= ?)S:>1C/";E44E6^ D%"
M[E]@P[AEW2YRMOPE\-(COU$=%SC9.B/0,&S^L+:V<G@9$71\]"H:FES+JUG-
MYZUUEUUD6!D+KADWQ,<DE\=*K<.2]YP#Q.J^8_+]!<TG>Q/7TI"P7@0".;;A
M+S\.9:50KIC_GY2[=B(11 :L"9;!YKB 1$L?Q$Z[F(XV+C0L-)_P<&%0@N-5
M#,YY+L[H?)B5E[IB(J#3:NDRPOL[#^-L1_(FQYJQD9'T9&J1.3KE+E6NQMEW
M>1ZBS6$7I]49<XQNXV,^0L [L-.&[A"P_I?3^!(5\,18=;UW; H:HF?Q=[L\
MMEC0Z5G$#I&*HN8C2U]%+/P/D#O_P5'E.&[BSO004'94VZ2[8Y>&2KD"O"P"
M&O?OP'.S#C6:I0O6IRY$U[P'SHLG:\9O2&Q5>@LTV(6H]/^2:VMO\+I,PU96
M$O@#OH?C6;(_48 -M,'BRM;MNSMMCL0[>XZ!6^-EXSXB\S,I,ACQX2=#3DJ:
MXMF;?%RT!/%XB4_T,[:YD=ZYRD4#2N[8F@ZKJ]B!X(-KH);CU\GZ-<'[-_:3
MFF),ML6+MW-GV)M;LLX9T6F>W?N)GH;9Z1T18G=EHL&<-M(:4TNVVJ3$S,(=
M+Q$>"8(W'H83*L#Y#7=,D-[GK+,D^ZT4% YD=2IYTSQF7,=-W)][BUAYI>$E
MTMRU4CNM@W<@!)="%;$#0:AY[D$/]_E+_":5L18U* V%J62Y(57&T(L<MSM4
M!<+T%O2C#LJJ2'\/-;NP2Q1*.2\,J-P,[V#Q1DN.3TZ4-HGM374J5,7=/^8P
MI=&?#NEYK R074F!;84O5LXY$S2=9%;D4_3"9,48QT@[;1?$2D9J+C) W['(
M2F:];2(NN+A&I8.W!RKSB$3-(PZ5?QMT*!Q2M5G<B4%5SL8V6I!N##7*9D^H
M9SE:7:L8?GTNU1^<=U_P_?DX9W?V)-M+L:(W:0?N+*'5<HFT.&M<6Q@9H#X\
MJY;0890N$+^)L>\PM\D-2/)YY/-CV77_^3CS <WX,"F0GQC-\R>P3<4ES\MQ
MGIT4C\%EYQWQA\G5-?5AD?D.>"O6,)'RJ]H9XU-5Z[0/#4,,ZER[SU+1^9;9
M$6BQAU8$[VS"[%/DL+C8 <3YB4((B_QQ_<P O\#%=Z\2#6V,W+(4SP&^"Z3@
MR_X1W</L[.).FZ4T1;PQ#AX&E9BG9QPGQ*\:$6)S-^E+9]?EDR5+DV704:WZ
M[TUXH6Q+MR[8'-(@GCOP5 )C%@</FAB(DB^0UQ1$3(7>%VPZN$3?J8]Y::FR
M?L7"_,$?TM2)[^@K@\Z4(?Z1IX7X(>;8Z.+ BT0K1&-5?<K@RC#KL_I:K3$R
M0$_O2B?GI"8'NS,Q+8I6Y-PMI?ZWJL)LI:;(BQL37# :$GN_KPUDH<2L9T<#
MYY4*OONE.T-LT>K"X1N5)STOJ-\,I+<R'R;_B:KTUI.C,#TI'GFG66GG_MA'
MBW?P69-:HF[(V]A',S=..,8)69;8*J/")YH9_5PZO'>: [IF/>CH;$K<H['.
M!K<TB6+ :[&N_LYD0 =X1.7O,127=OCL=.@%\R_DO5=A%\IPK$>%5REN?CY0
MKZVSS_8$:\3(45\L?[%T-4@1';$Y6U'SCJB</4W04<,BDQ=0U),^R.&V,1WO
M_!+$\C*R^RS>6ZJF;T5.9+E+6_ .9F <_F="!*0!5Q> 7:,=V9G%09U]3Z%L
MZ!TE#G[L;&N3\/Q,3<;FF K_, 1D?@)!YLEP!K>+Y OQVKQZ,C7WP;7=VZ@:
MQ!0HZ)B,VVPGL?H\-RUVF;2?")'W^X(.?&XCGWXEVS64^H^YI"GM#I%?_ZBO
MG!\MG0F$WOG2\OR-V?/1.?L3C=S,:%U25D!!'\H^1:)"CV7O#56= ^M7KE?)
MB_)!4/7"S?3SN-@0"$:6YXJ/ =Y!(SD &'?MH!C'EA?]\OL%7DY3DRA;%S]T
MT>F_0QK$>U HD:).^'4^K]'THIA4KD$M"1WU@64%XY-K1AS<"'"^ Y)A^$ K
M=.E=7%?"(W0#'5A2ZN:#[_J5"0DI2^(H6SBGI8_S$QWP^1)QA(B8>T )_EN-
M0:?RU%@TRY%789(U5>7K,ZK*>RDGFEOKE!Z,@:01^V?Z(XQT'HCPB/N YN#1
M1""N9\"D? BS#Z?TFTY3CBF1U1G,T]%]!@^,^VIJXNC&T*_;G&V?P_W+VQV)
M3['I&?G$9X30[,E"!#I6A4?E<Y:V].M8C->*"S9IK<X\!)99C@%I_KEPPV9#
M0K9B,H^>+6L;:*EDQ=STU_2/Z>Q(YSU-@((#;!<L;]%O'7G(#AOLJ%:"/]"9
M-;68:P8T5&2^$[!5[NNWBL[S<5Y M7C@X.%$UOEI?LMO8[+F)<;J:/$#]1J.
MU\F:T$CW"P9#YY=$>RL5P\ZT!]#_#ZJ:?Q8!]R#B%8N*'Q853KI)O$.(6TS3
MD+@X[C,QV9;@,(PLKF]4\)?Y,"$@+?GVXZ)X<3/5SX5Z8*BD' *7L+ :\9Q.
M)C4R&JC^%K?;+_N%3MCSX,SR[MY41X#(+^2?#%)@QP1&"+UG'7SVEEAPU^)\
M?L$_4JGX]Z[-_W(+\/_^0^C.B049T(D*5:GA.1&$KH(, H<GF),*:,)"QU V
MV4>O G+7!9RE%?T@3X=G&OE)5YIX2.$!/"3B% S'?+0"?FC0H5ODL=$@(;U;
MO!&U')L_6N]IF?RY6]_2F7C=#WAZ^1AX>E1+Z1YND $A$IID0,8LY04EST-4
M]U7I" 11Q(UTVW$C$7E LDLBWA\LE1V@+V:9, RKQ4VU*CH<Q[6YWZK6HOD:
M./<E*@8<'#P?5NZ9X>@EU(+6'/9$73&?F5K#_J#SJM9B[=.O61;CYQ4MZNP#
MK^T0[N_#CJ_MPT[V7,F -GTRX+P512*H(2DO@4Y 0L1Z[N;36%'(8=F>0D%/
MTXW=CNE#T*KSR%*,(MWE9J_,^MG_;8(5O/3N"?KH"\H8GCR#ZEO*+ZWY&SA,
ML!;6+$KSMO/[;VQ38TE\L39 B2;8IP"K?P==_H]+.44\]%#Y/'.?<[LWB+IY
M%AV>]U;L%S_>4'DLMULWX$?1%R&!K:0P$?J3!1!)",FOV#*:)+XQ*8'@GLE;
MNPOE<ODXC)GVOKW)W\%JAH&''MQME'1P]E]@?HMLI9Y"6HC=G'-V:O8\[!"I
M_/M,L03-+>#:BV\4$2[X>[M52PQC\<L<^P8/-TJ@ GY*Q4<P#>Q .Y".(&Q)
MZL1N,1!.3))84#A!4CG=[I3GY:Z,^U^C?6* ]=*S7R@\T%(R5D:Z''ON^_S!
M3Z,]XQJ%\KI1HUW_3;5;W=Y*"0!Y;5[JAX<TUT369O]NU_[O7C4Y&+?+]V6<
MW<[)3MITKJE8J_<H]XX+*2S/?_ D+O]B8=:9>W, 94!.R<#_<9I&6,'8+J5W
MSB*]=*N\_/?+/R\IS@*M*2O*''Z*DR #KEH*AVSM8T1TQP0"W'YH3793QPFT
M$#O9C_R'CZ-]GQ:PC==<.,VGE,Z>PFT2QJ2F/$-=\S0ODS*5%YITVOU[&]_?
MA^A5U"\?BKP#$9B 1_QK*N6:1W&"T$'<WIP*"D?50>(;R<!.AT>$Y629KQ]S
M9WCGGWXFRKO%] U3DWA-LC];5-M,1AD/P2;\)$YI(+"=J=];X_XZ\#,-I)?M
M!?O[,8UB(+;<Z_LI 8H;I6G#]H^;6/%QN]4E)W<)R+T.M'=_GNFT3SK$:^!I
M-2')N65J?**=RQ$;^4+*G):/FN<ZX\O]4O@\>FMQ 41IJ=BJE%_0LUN N3DJ
MAYR?UX(;=#QJTWVWC8R,;\FK+-!^5EB^MPY2A3FLH?:O(2B%[/9[>_%?1[+K
M(T7I(WE;%OP]B[V-W$G5R0F(I!ZYB+%>(PG(;PB8>?#ID11=,0DZ.?S7ANF_
M#T&RI^&Q)'4RX*T:&1 OLLD$^\QH3(V;)#VPE""U0,B S*(ZTO @;$T13*G$
MI=\Y^X60EO7+)^][M3;-.U'(D-B#\A3[Y0F]Q.A&<?<99$+X;K$5#]N&881.
M$LA1&=46P'-Y(;]3]NM4/4HEMGPO3<Y0ZL'&>>J/;^/BNG8L!X@BYJ!CSBK8
MR2&0#&#0_/L0!-D"[5$([(_8(_A/GHD[3CMDP)GD(Q[QM< +8TKR10X3<]B8
MQ*\\].N'Z3#\@U:2T(_>78W",\_K.)'0#YU4RHYY$4C63:0(&G'-T,/<>P2A
M65XWC.@ND]/)O$4MQI,<56[ %8WRJ?LALC%+,*J>W9>GY/3A-HS"'Y0AZO\>
M-GE&E[&?/)CW-U\TI^C#_EEB]4_LLJ9$(O#EJKCY[+S_9/*16(UM8 TR[YWF
M7&233CM)>N2 KX@EQX8E,:^KI"ZK9O=7ERM1H&MI\33. MXR$,:1%PI5_=HK
M'F[S52W;P<W$<MK4XL+ETJ72SN?G7.22>G=IG[N"="EU@Z"L=4;#;QYWIU04
MA>G^_@%S4)MQE*!>BIR#1(0R,T4=^V^6KCY"52X;R')Z1SK/)QOW$VMF$56#
M:ZY,QI0&\.(8FA2&X2&=#OR;:?\V-H;_#^+I>?@8SB,XB4IB5Z4M$T[W0CM+
MK?D5U4%9 E'DQ-:Q'MU"!KQ3",O('%]/E\1NZGGFF6DW;$VDI]?DCCM=_1)?
M7!PCW4JMS('*M6$5BUVFVI@068FE)_WDOH$#M47#[D5V@.BKJ/((\1"6V0<C
M\Y\/1#YEV7(F,YZI^WYGD9UY@X<5*3Y)%$8WLIYF*:>%AQ^8]]8B1#;'^+=P
MZF"!Y@*>-M,_%K^L4J5 HQ6I!S0SD?J$\!.SC0F]*-F& * Y%A[LX7_ICP$S
M1'"G7/+M&9!OKPC31#&=#T/9V:M[,2)#C0&X2F/LSE:]BO"D@]=$8*50HAWL
M%)XOZ0.9L(LVN6MPP?"RGE40O#(IW=I]_$;9E\:;)]H@-1S'-583G%X0U'J^
M-7O&,?D8'4+\*6-;8PA!W_76C;E V_4Z)JQ^'.8X\,?X6GU,7KY00W;.%Q8T
MS!8Y)!2SLC*SH,HDK<8BS2?]H='M CN53-.7!NJ!YYF-.2@'Y_-B1?R3X+C-
M5GV.)]A>![=+AJ6/K%ST:0QR)>"!7HM-MIL\B+*@XBU1<UT$&C']^/C'[O8E
MJ4[MSZN16Z4V:4ZL["&=0LPU'C]\L^(M@U81^E;7YLF "50KFIL:.U99O.[7
MC\S)7W/=/ Z-2<OM=9'I-;HCW:,IPG ](J'WAN@YD4J*AMZYY#/9F9(<*B,[
M@N LN<N\C6![#3I14<:)EI=-J*S;:1H!/'-Z!7]>/H[ D@&<@3^3D<R$G6P?
M(S&Y&6>:-GP2!_[;%K17<7.:#'@1[?_\"";GYUM@*0"LT@P1P@GE9--C]"^G
MN7K;N1:1 :]Z)OPLS#5>UK[K.W.QJS 0?X8?D* I4/.-^[.Z[^/8DX<$'3/L
M\AB".?E=1E4$I_D[1DL6F-2Q2-(XU20U3?]E?ZJXT3?,WBVH*M80HF'I^-J[
M^O3$XJG9*8=7G8;E_KZ\]6$,BNI"/@8O()L_V*AB/KKU?N-.4/=%4KI"W7J"
MAI+GUQE-[L^R?4_,+6<GM+IYP8@:40:7=I,$1+T;9\XS2H28FW,#3#XMZ%:\
M=G&GX$J69_;$!JO9R[AQ/5_GQEZG2H:JVO.=/Q>#TV\L)^&I1M9*Z1>38\M(
M;%"I$:AV[N1W3U]G5X>+ZNYPT?=.-N_?=RK1"/B_?0SD5!+&L^VP;,Q-=B^P
M0\6C\:^Z4=&?325/I[*@TS?=JDMI/-6AZ\XG]@3S)SBY:"7)65."T*%V8Q-'
M4E9N+QUZ6%U F\G+WA?NK]4;>C:)BGF:$(Z/Q-:$>EYW*#3U"9JXD5T5=$Q<
MESI-UDM:=4[@VK6YV%8?=,XKB;W=N#)^C57Y?L0>*(0,8):ECS2CC[(+UTI0
M10X>-)RR3)[<IV'HLH84\-,MUYUL*'B4FL_G1:F($B(7\B*4%$L=N2\K@$*W
M(7PH_TLJRT(-IACBX#++AQ!^7FCSODR=%?*>?QKS*NJ*BH*/W?R/6H_H^V+F
M3U 178[&<6O''LDPZTKQ)Q9ZWZ#O3&Y?TY[HY#+4(]B7G>M>T,]JE\O@D\4.
M/35AD8*]2MU-34)CV"97N&ER%VON+L28.C]7EHO @<97%\,J<?[/XM&&Y155
MZEA26M&K$3GHY'L[32N]Z3\$.T?03[&Q"\](=[ JY66;.N \(7BQ8Y(X+KZ\
MF*6R\86&,'*D.Z.]4X/FZZ"5&OCDF0_CHEY=TV=$M,*XJ/&SZ@ UG23ZFO&J
MHBOILRZG"V$> _>IJ*(X8.WTL1-V;R@-X]K@E+F:&!*1-PY.V !T7LK)&7G:
M)6AZ@8KW7D H5WQ3,4W)H)5AP(FVSXL!U>$#>X\R)D<6]-A3QSC!]'!%K6K)
M:H[UD;<5TJ/N>[>7+NKJX+]@N5-E?.I')#QP8#M_[\+Q]5T=N[Q6#RKSIKZO
M+Y3GWQX EN;TN\6;_1#,BW[A&.NYR$M^$$&(DK:_@F."O6N_;6:_J#Q'E(W0
MF# 5_76N*->8 Y:T$SV"S;,&R/V9[15+.H<_]BA%+#2/N.Z*'ZNR[P$$6M_Z
M.!X5))W6.+R4_+P.(V-\?8XGPDR^3='22>>&YR6%5;4ZN91T>.$$HJF_.-WD
MPSFU7QETYP6N@/L:67'2"SMM>G0.W,"?,L!+TSY/#>N,J[ CT7R.;@XK!G![
M>>J0%Y9?NY<A'7>F4RR*Z:&9C16;^!AL,KYI.]G^.+BK<MIA+*6X6DH\U1UV
MU@GS.IG'H_97Z\]$7D9U%Q@]#&PX(AHXN-! +PXN@ESRF+S&,KU2V]B(1,1[
MOV=*=UTNYXHYTZ^B;8:GA6L.FI 8<(:QT8V*=B4.W=[,.3\AY2"SIBI<1;F1
M<72S+6_079Z<U\_HCD[P=61 +.QB@!,0__#H!S+J[W?']5<Z'XX340*!VNFP
MKI:\WEU5=2;C&!]5]9>$S$VCRL&E!/6@,3!F0]ZJSL3Z$7&W^NYU8V'[)?07
M<Z(!&B$!V+ 2K&KX29V>Z.YZ%AW--,"\T7%/,U3M'/7[R:K#]7:/IUFW(C:;
M8E)\?$<M!G=LT/;%L>>G'0]GV(>=/$_L10_>9S!:F$\R&@@IA;*O\MJH')7X
M=>@D5KGW*)64?E=G>O;N__O^-*9G\NA+=K:N+DF[TXV259'.@'/:6F=#GFAQ
MQJJFKR #'+?\'HP8)_OP+.2]5]*>@S.!6=,9$DZ<=4;MAN>QIU_6AM(RY(JZ
M'D]%'[WBHN.R8_Z<!S7$6=5A[5IF;D<HTSR0K]Z=!G/$Y&^/I7C8_P \>XJ\
MW\?LA^O>9UXC ^S&=/,@'#&;7JGKR$@=IWUC6[?*\1L4,G&.$B:\Q>ZTD@3J
M*W4N'(@8ILU%'_)V\]_RP]SI&KC#+SN"OO30+>?NT_3U<>+[R7LE)=(D]0#O
MTQ/8*=V8&,0!OBNRB=J9_/WW]?4N\#;8/)P4=[VM/3-"Y)VJ.O,RG)48L,AS
M9F*38PQNEZDZW\3WXVY??7;,JY'55_Q;/T. _#8 QLLKSP$=X"SZ^R8I$5\X
M&G8.8: EF=(MOS3F93-T1^J[0!$?Q1:S5\FKYAN,1W[]2VUDP->>L7XEK]Z8
MBGFWV6FV@UP'V!6BG1V.MM5/^+W,*<<$\ IG1Z1.1=Q2T_!\"&/"PZ,;&\T
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M4BP.SO&DX&CLLC\4VX$HTZ_=GU8,I(G7+0I^C$BB8!@0$<P,G9MPAAL#\F!
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M9@V.\I2*AJ)[*A1@UKBCF7>1A(@RGSJ+PN1GZ<L9D*8REK*4 ?FA_1=.]1>
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M3SEF76TX R$%A1 Q[74"32?#7SJRL^+3F:+<TSE%&2@$.$< @1(!TB84J1Y
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MZ^N>+'G-I3[/<"\JDE?$(R-Z0Q\G&T!($]:QELQ:^CRK,Q6J)S?F_(;'CSW
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MLO[.@J;5?BN?](\<LA[F"CUJ_CS8?,L)S0\G/DS4G)"^'W(^\'U@B645Z?0
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M;@G(FUSFJ\AW'R/2[A^;^V2/H=^6- \N)<,PQ1M>%X8#A1EU<)%SFP%=3,F
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M4Q7 JOZ"#@NZ%"L Q^5Q@E[K1 *[".0-H->$0*]9@%[+%T7FX9!5?NH(EBP
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MIV)Y!P ACCZO89(010[M1E-Y@&\+74 )5A7GMX5 6EX-=XD")_MU@\XKVO8
M>%J^@@5QU#!DM;$0F\ 1=%JL9=0T04L$('BA,(,@GTV F2+P9!,0?@!H4]D
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M,KL)TG%PI80!:.0AT,@ZT$@":4D5NHLO$73#!,3E+AQU_BR(W50 8?L=PA-
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MI_1H7=C!:NIV/?N<LHJHC9>]2RKBLG1(5B%6!YL_I?,@B\"ZJ?(%J*=:><$
M=*_O#T<%^RY'WN(6#^=DZ,LWDEP\'%;<WM!^6/?,)D>)=4TO^=:'?Y/M6D\+
M0;@[VA7Z!!IN%N^^2E'.3S,O[(YY4G+]CU*R2\A0ZKHTVP=K?=6[S.8GMETU
M(^I59?3F8P[FK-:TL>;45[PXIV2]S.K6.>[+.=+>(DN);7CF$@50X[7Z#["@
MJ_4I\$MU;_O6BB!,QB')S90/V8ZQW>(BD6[.RX92MEVW,82N"G+8G$O?5N1_
M]L$(OOJ> L(=.*[18Q;70+@\T&=XQZZYV59ESI*!R .%7M=D:Y,/.$7&2UP+
M'TL8E_/FI 4F(E5$OC.N^&"-M5G5Q^I3)7OLF?RD%7M*4G+>F*G?=ZI7,_[&
MQ5CARWYZV$T79#LQ BWZ3E&,?)6::VQCK^_RNL?#^:NZW32]CFY^NR3LY,$K
MH1==N0+,AK_6)?5LSSQ6_12LY!>@@N NRVJ8/'\B9>Q@@%IMU[<(D#(V@93Q
M0NO(%K;S>=F/ETU['T6^0+-! INE0?H[QDY_Y['02S!M\!2CJ?+=:!JGZ.2T
MP7[J[+[S-%A+G-]&F#2'7,'DB39 H%=3:4\4F+>8,I^=%,N+HNW(8R-\G4)0
MA(LX26%T4<6IJ$GMD>'D0A:A>.'*YS^ _&C62.#[[T">DT!<Q2BJO.T/( VQ
M7X$XR*6S@02"T#\#>6_ZWP!B7R+EFFFL*Y97@+9#[2=C'+.,T64X.9%% C\9
M<Y]ES!?+?A8Y$";!/TZ,1X3!O\#L,-N:,2(ZTR5H$H:&^1^IXOZ=*IF?5,7]
M1M6<_[XJ@UG_8,_H73*Q_# B//K]U(FBP;CEGY<B3$L53$CM_4EJX']'"BQ8
M9^VF^6.A3E D6$VX4':RX 0+TMG[O]$#8B+0:\+#>/9Z3_9^G-^V@9D DPN\
MG_Z1*R[#&3/[3)G?*XH1^4G1Y#_T?E+D07($9Q*F%<W8G:U([Z\4N;'/=/FN
M:,;NM")?]GEN,Q3-_L=O%*U#DRQIYB!_*4RMM[N28OG=$&%B( $D0E""3EQ
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M%(Q2?U] /%JQJR#KQ@X+!8H9:#P*,35"@9JZW2T<4KO>':7UO%^-9 '=Q5\
M'H^6>$1[>X9^G/\4GW0,TNG,T<[VRUS/Y8,U^OWJI)?Z>[=C^@W D<1!(%.)
MD ^(IC=0-%?::!-9VFR[;'INO*3Q!3Z=#;T)N0UK;,7_.J?>&T "[,:1M<:R
M)_.3+,;0K.U7&;9EDGP6K^:7V[4VO/WZ(4G)*#39U,+ZBN9) -P*[%?Y/1E8
M*_" 'P,CGB23 &%@>VP-G*A[G$:W_43"]1B8X@1>S?KK:P9 /V';E'EX[P$9
M!=>\]1$IQ_6B1@8;<R#-=?T(UWO$7>OEIB5,-1>W88YQ;M=$F)2?^W?YC5Z/
MU""^)EDR46$H],DF/]!M5'UX-Y^^T8.:JWKO45X#]'/> ^[CI.&UN3TLYIA+
MWG1R<VJIR3Q[/G^;?77VX+<OHD6>[4 T6<K+ 4F 6JM?)0(W8+EC), RQ.,^
MJ.3N].S4W_[5)JX-H,FJYME+M;?=[!M=*\\%V[[.GLDHCJB[/9/3&E'Q3N20
M,7&/S5FRHH.WTZ1?J^O'7D20YPG0KE^1<;_U.WDV"GH/@TI@GVHIW#:?]!UX
M<:@-">P4#]>\%OJ8T,CRX@EMP;F[OOMBHWX-PRTZ1SHQF8RY#S_>7RT\O,YX
MLOZ;MX[Z&W\A9.,(= *>"?M[_\.:6%[+P@B+2KV3W@W/D-&$D,Y"YHL0N_QN
M3YM)(MMFXT*VN?W63%.QEJ)[P']4B_'QG@ 63\=N(5$N^T9*8?8,UM)YQ=+W
M[\^^51;^L1/N6U&C,;SX%N&):(1C>"A;>S$FR<6F&99FCJMNC@TIQ9[7\Z/<
M&9$#7-=K7Y]ZJJP;2NOT-&N;V^I'7)MW!_+4(7)B<W%)RB7%P=GA^;YX[H*L
MP5CLI=CIFX*PY?0\%[B+0 @/8L:>;NV:JY^3-"VKRL\ C8&MFVHV1FI.U&SW
MOC?DA-6=@O##ZD6( +@OJ*@[I@1FQX%F"A&W'E4,Z+Y> 3G01YXQQVS0Y$F#
M1P[U@Q+W?HZ?IGKQ,_U>=814Z[7375MO&2ZF)S_V@I*MU-F[F&.R0K,_<JWI
M/\ E<S>9"@FE3VQ+.I7Q)60K]Y]_$B8?IVG=<,\Q(HCE9)A\/8"0RTG(\!80
M2PI]USMG3U<UL:Z2OET)75!+E=Z]<?;@0?7I;D@:$*5! HP_%AI?G9<Q'"DS
M+\3L-X4+-.-4DJN+WL\U6].]H1&![R:R;1GB-\BS_"W^%) -]"I4:O=I&;V;
M?4.*<_#<(@]GT.P:*MED -#$3M6R@'S'5W29ZTSVH^BI.ZE!<W<:T:.!J2A-
M'QF%!1;TTKJ4<S-N9[WT3KQ"<KW-2=F(LR?RD@W31&:*M/'LK"97=U/O<7KX
M6-&]8\Y(2)_RMO/;(^3/V>: !ZIRS$/T<*4R9U"*&/ZHF4/AEDKY5/K=MK:V
M(X3F^>(W@4 D.S-ZM)%NG&.>S@=Z?2'YZJO:JY$: [8+.*[AAKR]VJY.H2@Y
MBTKU+7T:R]!WWG=05EO#.">WX,<UE2/%2%;K>,7J<$6KK(U=>U!4%_-N( LG
M[_FY Q:QDRH4_(@#,XHS-YC%*T80.ZB]--PYKXT&%BR!ASC/^-_[&#KVW:R,
M\RQSPZH=)1ROCU%8) ^JQ<(+0R4DVP3=IS=',_H;U[SJ)V_9W>3VT:UOT0EK
MNB0/0#\6M?#BWCW;.]WK.UN$:$2\O[?!,P>D59R?_WZ^>3QLX77(C.EV0DA!
MTZ*G!6'1-!S" ZN7A=E0(R8LYFV'$9_20_&V\ZUALT^C'T!*'\V=@%F5  (E
MT>\7WZV^KZ/+M?&QUHI\-O4C-8CWGUZ:#X\GE'M?Q72V %G/$OWFU6T,"HE=
M9?!M\6O0(N5RD657WO#P\-8:*(X\AYD6( 3Z70;87!)YF#XAQ@SY-N].*8)I
ME41U18=T*Y.XWA0PYDB%:6JC-XD,0DU(+/<,V3G5R_['D;([D$#8@6;UKPT#
MGG#B+:39JX+DP]0R/ X2&'LD"UJU(LNBO[Y&EWAI;&H==J&:T<K=7B!CNC;0
MDF9D_Z9RZ,@9FKRLS_)G+GF85V[PM7456<=%6; T\[E(_RAGGF=U<"T',Z)9
M%QA,Z8IQLJ7CS@:Q]])H/HWBNK%S8/6"S4L8F'+5D"!HV"CEG4AHZS>M'0W*
M18C0YK6:D9KOW5Z>W D./)T29FN +4#>WM2UINX>&!7>H#YAA>["68WD5J%Z
M5Q* HYL$>&7CI=WL33%TYNZT=67(Z.7[^N$9X3\:N2F2*)?)#-)0AK8B4$LA
MB;\V/S6-3CF!UT0=+H;<OU4L=U$L@W$*XTC6X\&@-0/R=X\Z]R<YJ$?D_W4.
MG*SPZEA@F'A<6- :]@ 9A<RK;6U,1N7CR6+T80^"!/BUWPDMMI-<)!$@!J%K
M7KB9\SK6PR$Z'X\L>="_VQJ7:$<AV8;?G%S+RS'/>':1]K)4C\-RH:/*B)#H
M]8=\DRSQU)^P=W>D?:3AUEA@G9RD;XNAON-/@8>"W!_<ZHE[(9'%H]W1V?-?
MO6$TFWH3?E5W[_V8>;_H8;6B?0@<J/6\[AO&RP2Y,HF'*PAT<?MD6Z%D1S>\
M-"$1IL(8%O2US6;L$@I#W52DP'6P$W$[\KZ>-L<E^?&V6TB#//M;0_QSE1_P
M;;?E;]W=.=^6O;DJO-61:<!3WG*\N^2UPT?-]L+"W;#UM],!CGF*O$("K"6[
MI9$ 9XY_M0QIZ#>=Q?8;$;T03?LD0"$YJ$F#9$@ \V0_;U%4;*N:NH(Q*J8L
M;4P@M($U=UM.WX)&Y[F=)<5MI,*=U%K'NZUJ=_.WLUBE]0_?ECO[!7":-/SJ
M%[!)=<)-I#)#[Q(99K=V/=/6C^4T/U6;0E1+)MZNVX$EGL%3+\6Q^0HG#1^6
M>-\FS_!G<KR@)J$)N%9_2E1MPKR:2O'W*&!4EW*"B,6H4P(=X1WC8$" S##V
MPM8+\M62W@!X&+!8Z:OK=Z/ :HGYIY7-*(>H"$7[ S?-@G6 .=U9"P=(!2-:
M"'_%9MX0(W3DD-SLJ'25!&B>^!A["NU[](I:X4HRAOEK0%$0SCKDT4D.Z(81
MX^%UI5&5P1U[1(%YT<^2P,RD!=<+;%K?N>*^H " ",TGX+G8[;C%WH_(2[4"
MLQO)%_#W75/'VOE#/=TY4VQW5P2Z^B87[V;?![G9M9U<6@5E(%&Z""#$3>@(
M'-/0H$WM!@>7#5A9;BZ]B7$%'+5_T,'Z<]1X._S:<D%D6D->15K#+JRSWRP+
M.E8II=\0'G]"P=6IP.(4&H7J1+[F=>,]+VL#E=$QWQ"&6#1G8AP6UF2DQ-:A
M0OG*W\*KK>VSN@3>/ECMGBS+E!ZM)-:3  S>E_&\F K+'+P&BM"]79<$VJIY
MT\4^^CA6\DJ[/3SAS&I7YYNZF\(2=-,\>7/EQ9X&S\/4P KT#]>HA"_[9'A<
M#KL'^0 JHVR4!<[3;:LM]M*L7<HH@--V2>B-]"^^H9:YW&-!\3,[ZKWT'<82
MJ=H9E'6]#;!VQ/6S]=7/)H;=U[N+UWXVBPI>YU1BT=-CNR1_YK(VN#T9I48"
M7)_%S!ZI]=\:NNT9Z,2W&<I^GW-S*7,TU'&*]W&.;-3%X<.O[A%P_D0U*OPX
M>=Y68L"M<C+#<D!]LG21.JI(>^TRZNH*CC?]*M;$PY]_+:?JUN=T_D?[XX3-
M@_B4RNJR0K_,BB1I-W!>1+DN,#!+P[OGL=YE# @GX_UK6)"O$H*SG0AB,F*I
M$ZI+O3F;G9R73WS/M%ZS%=PZM24>MB7,ET%(!\TE@BZ3 %9PRMZ%UII!J.Y\
MYS.Y<8=,)H-\AL\4[?0?]EY\B!8(2S_5[3W^^MI1W *U._? (:OZX_-+]V1B
M'/-R"@!<JL_>OI5O+<^S#S)TCBE$=3:/2'W6&RQP"BXO.!/$ BWU:WS!7DUO
M C%,EOA<H=D$'W,]RA]&OD0$37@80U1FSHX(7IDU_.%RFU/OIO=0[H0*YC[0
M71[R$.3ZH:UM";Q_$S) 5S^9D-#[T?M\>36_/5??UHLOA>TSMGVE7OOQ><;/
MK%6TI+"_6J\V_.XU._^=P=<+>J49_!1*C1%:F&7KO=(SH1@><=YXWK+<G,./
MKDAEC:Y0=*#J)T4#R-9^$J=(B&.L%IG'N<DHH"^^BI%_S0.R'.SWU]VA^JQV
MN2WDDLJ-B&\%N^VS0;,EW,V:H4RC]&Z(EHF2[>+N*IPXM;]/N^SINH_<[.6]
MV6*K,]QH\>Q%H<O6ACLEGH)IN=82=,[.SB*6R^%A!O %FTW@>"?Q AS-NA@3
M:+MPW6Z/#H"QV^&*'UC 4L@.=]SMJ#3R-[[)MCRN.O=>OML#G:7QT9Y#U@"]
MY:C*YO/(1?54FR4G&\%FBDA#G(0P>U/.3M:&+N"F-=6"3Q6;O -7%UD2UY3?
MM!Z&9!\C2@1!<\%8M=<;G_&Z-6H[^ZJI'(]@<Z??*A,.;)9!$X[$"\=HUB.;
MPF23V#8TV#>5%V@TJ)-=U@YP1T48RD2&UOW<$ZY+U.4MSO$LHQ;U_DYL0Y8J
M^R&M9VDZ1E0)H0O3<F*VF@_CCH4I6A/H89TJ@8N29U5/O6_C7N,E.A OX(U'
M:L_B-?N@-M\ZVMTSC?DC'K+E3#5H</JA\8(5VNN)AZ>1J4+G,4FM+3,,_=4*
MF?<CU8?S4I"ECD/-O)0/8><85T<SMJ9'NHIW;+04&3O^1:U'?I.5^5/K$<0_
ML?4(G01F.;L&X9^?US=GHKF_/ZQCQ8S=!OFY67JLMJZSNGSZ<M-!Q*H0Q+U'
M+%ER/C8PUGE;Z+5[DIQ@I?VNI5TN!N)' OQJ,C@B\^=#1/$=8Y5=&[MH*]"'
M+U(]<C6>NT0"".W?(#Q I&\N:UYLZ\/X/G$Z\W/Z49V0<0#CH0DTS)DAYZ%)
M_[&QK/A:S_7D51* AD%+$;I^:/8O[LKZ7W9MC?0>A)QW!H4B:7K]#Q(ZU5B1
MI<V.*S,QE[<?C -Y(Y.\^):0&%>Z,+(J>H':)1R#2(!KB+X)OK&&EV-YC"!+
MQ5S[PGHC"N7+@A[!VON=Q.N-BT@LBXPT">#52P*T?"<! MYB=HG^FA=)@%E'
MLJ3,(="F5L%&V&#[0A7,,,OY*E U?N^W5V'5CM0)R<[(]U+*GVS%\A\V/O5Z
M[&89FD?].87Q VT%&#>=.[-68*SA$-P\X&1=8K5DJWSJX<=A%8&GY F^P/X>
MO'I42-9PV^B6C-Q9D]8%(;H<39F(G*+>SRR! .+F#/*!C;0^^F+"/$9/76F/
M3]>.X?Y)PAKE[1J9B]+TOI'Z7LO+7F'\NE1BJ5]M8[_^VA,\/R5'_E4ID8W(
MXRD2 &\-_\VP%#IKAAF*Y=H6E5;4@F;J0D&FL,>MD8O[)\FW/]5"<&"99+QC
M$%9EA:4K>@#R3KFWQ^#)]43B)K+M1.VOQRVW *.,NX!IG=]MZJ7%1!R;]NT(
MB'8.5<3PN7YIZ\CZ7!%"0U#W8K%";W0H 6T&[&Z:KK#H*6#]C@HZ%=!'O@L7
MKO"I/P3)8BYU?IE*?D"G?=#M:"["/W'7(:?86^U ZBVJT[I=2GMT9#:NKU^1
M<8][X"RT!*?KW2''B=E?S!<Q[B^Q%6R8&%4WX@X[R;BHK\:Q9*O$W!A&"/52
M4W2>=]!]ZRR;SYWM9WT7<5%UR]L=UE@.)3L6!>X V&X%"8 9!J)V@-=)@+[V
M^5G<#HPH!DDI!I<0?Y!M79Q7VQRQL]$%YGZR3 )<G$?/$FB2R)?6DC^215WL
M99L+927^M]YI,:JR-S(*,*XLBK I@6(GJ_9F)LA/\)="80SU;7!BY;\ZSE[_
M]3E11A.'D SP>MCX;JNI4) F[UZCAE/1FX.*J$_?0!\C;F(I(!^!IXBLG>C(
M167?:C9JQI$2R>?EGX%Q9M.55MA/C67SD.^S*'TZ)CDX3@8#>^C_$)ZWV1\'
MQJ$:&<*4"4?F(#]H.'DN):*@WIR$W+2A=  )\/Q5;/S'%_!%VYA&].3;V6@/
M'=D.X3@ZQR/OD1%65GW;_ 5]VWG%,,D^,ZT'=0 7 %5,$%\W/Q]:@D@5CM8B
MDB6+1U@H3<;!+)6A8L:C;_A,<YGQ!/:J]#'8YF?$Y-7G.0:?J,ZIRN:>E&"^
M+K3+>*(YFDVYHB=4Q4+U-O!%SH2M/!( )^9JQN%^W^6V\B;\_Y.4K]X\<B3_
MB%.8"ZCC1O3W<ZT/B\*>P!@R&5^SHM^UHA&*!881*PD6\HH.0-9J5U<4<FXW
M5 9B9D\[O1.0;KQQJ=XQ65 Y2/QMOL_%"VQS0?A15!F><7-!HV;!ED,]H;Z6
M,8ROL\UVNL]X1]>52J6KYJUURF-=Q@4FD#+RE3U=YT+O^^3+!T;.TPZP^>Z'
M,Y=#B.C\=&IL.*3'#Z:^E3*4"^A0.L]Q8W3_&/<<?[J6\-5;"N/;&&$D:BC0
MU.N5VG5J7" JY,ES]N7[H35]1[<J41$SG&V$9D+2UANGV??(B[;%S5K/DZX/
MXB."&(037O5L75R]+[<TV@1$&=2P]VB>PXL.![6(G4?L;.N6XK?IE4*4O'[M
M4*O-#2:$P.:RKM$US/I+N7Z0NVU@':F<IGSD):(_F&9P;!2RY:_#G_Z&6=>R
M1P?P8#*2',7*DK?#Z;9-%FFO"5!K5@[@.;ZUWAIO]2K6=.#W@[9_U?E<?8NW
M0 / #;IW2CM-<KAJS';- X2_O/FLHHR0AE>S9+U74HZJWGO\'ETAF%]:B+4S
M(P%.(\8>X\G4XB.'IT/V.R4SX+6&M@TGKAN*#8A&WOILZ6<LLT>G(UCX7:X0
MF>$=/L+L_U79+-\GZ$Z!F=\_JV?IWP"[.GK6Z%Y]UOJ=)OO;"T_/K\GIMFV.
MNB[/EH6-VJ/#%GO0PP-6<D^TLHA2K"3 RX);R >=ZSENK[B&(;L@P6[>RO*.
MT ,77#'5G=0:BLX_+\H@VSIG5W+42S?]NF?<\[XK-PX>"<>M2:SP#>0VU)Z=
M<O?FJPQF4WTU^\6)!-@<K1RM7W$:EM')']4^J$[*S?7UP[X^AM61;U1=-/'_
MWO+R%]X8\],?(C2MB;;>W&X_-=GQ*FAPH*5+A+J%;B62?QKFR0<B=D,&SN6_
MQ(;%NK]FF[6*<#/E2K#;]HMZ/];6(Y+X$BF*G.\@ 0[UR<)GE 38Z=ANU/&3
MKA V.$[>6IW#X"E0]/.[ 8M/:</\K-B^$'F>\ Y(+"S#%TV#G^J/9R9;V-L
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M::\[BV0 S86.E'FDCT+HJMW>\"^]R4Q &,9!\X[H6^0Y?IP5:>4<E9@'8CA
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M7\0><-WKTW%!HAR[6WQ0XD49/5YF*8U\38S## A372JLFK7V)*)+^*?IVXZ
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M$RX0AAX".U/)+U#9<^-7;BP?9=\4JMG@J'@YO."@[^W(3[9MEHT C*:IE.-
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MPE*(D!5%+Q[(Y?A^'31;Y[:U=W $V/E']<\9P5G!#^0@'.+UNZ]9_H$_\(]
MFROZQE_4 #]BP)XD$ZGNH6^OSB.VXA9.\BS=A [A?(K^*CU4@9-7]G>I.N32
M=95D!K0H]F./4(0*,=@$:S-XA@G5C#\"T?)S[2WX<_S8* @@0,N7,I6TZ "
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M$1R'O\1:'(WP*N5+A,,,N.LT5@=CH1/\&9PYMU:X^P3XW!*HBP;@2X,)S"Z
M'%;@@60"B)E%TB+=)PLO$@<X2 $_SP>" QK64E/ 3)7#2\V$%59@IPCS8,;
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M%V+$$G+GNQ!X1]MG*_N3D ;XFN*RF*]$^%<E)^<J63)7B0.LQ 3R;H25S "
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MR0'RN><"+8<7J#"RRP\-A\[5.[7AU7H5[$$EZANE0.D]'NHCX&='\%P7C4"
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M[Z "9_!IC^&(76/KX% +I1SBP,$Y_%C7*$W8#MX0PD:\]QK]^@9@@4XF\)Q
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M21ZJOZA'Z L#9C/0?U!!_Y<J!@M5L']0P7/!!QIZ;G,_/+WDFAY%"[HL(DI
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M5^XLU_S_L/4!'GA\<YD%JX3 1MKQ$!A^ 5AK$3"Y&@/,<663<7_@LB=AZ+E
M%-QA,%C/ C"*_BQ8^0P8WAN:0TZ3O?T+,IM%9%?IR'J* B RJ,N^S:"](R?#
M:#0$90.6CLV)9 *Q0;*RTW XUQU0I]$0B^'.4D[!<-!#]QQ=JP]RE!/_&QR>
M%SJU7P!SKKGD5,A5_.!B/8RS :07^HRN$5/MY52&=/:%>"XD4]#-T&O>%=)
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M?AAK @>P*2.4Q[+YZ"ENZ0#J9N_D1-6O(B/7CO7 R^5]6%HN;RF6XC\C,,)
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MP<WE;$6%=S^H"2M=3U(6#)ET(:JV2P-\2FO)Z&+M^&@+PPM\UXLCA$/N.[Y
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MQ)Q+/Q2L\780CHL]O>6C2 /R<RS/5#8-L::#&H'N?0S_"(3&"(A6I<@'C-V
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MUC4DA(7R.Z<8/5LA(OW,;CF3L46-)S^'_B.^05=W9S[X$SL./>UQQ9B5#@>
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M@LTP@>D<@4HL4'&L? & SQ%XD5#L'  O]#R@+(^F Q!'@6YV<P"&^E2&P5\
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M"^Z$(/H/E5\JSMJ5K>KF_%I1S8S*2B*QI<\MIJ'X@7KQ7/6]5XY<U>4.,3C
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MOV&34\'Z1;;!X]I->?,?)7K5#T3?,489U27%:'&;[=#XIZ\>)B#QIM*<_OK
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M80@N9RR$;!VO<TL>MNW*NFV4NV_Z%66UNUZ=SU_57SKS+I#/5*+PCL,>E+\
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MXTX>@A;S*[7Q'S^,Y_YF*,X4MS-H>%G$:V*@TAPH3NGW<<,5AZ]$'.7,=QI
M%/HYN6RY.&*MI_+RL-Z^\>/\^^(I<$HD\B+Z]LAA@!4_6C^ O6U73E"K>^K=
M,9JH/<_^VVLN3)X]:Y51_9![1YG$J1VWKYOM=[TY.M]/T@0>$>T!*6?<*-N
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MQ(EH>KASU/E%V^[RZT>B]IF\\!)OVO_P4E0]W_Y,TX]34QK)^D11RKU*);(
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MV\'(T-4H5Y7K=&'(:;DI<AW]?,5(ZSJWO\E?W#AD05;)P":7R_GHCBN$&F4
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M%WOO&=5DM':+OHJ"2A.0+@3I4@5!.A&1)B)-Z1"1#@(B55H4! 0$!!24*DU
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M_:DF#FQ'!,+E2XJ+;EE>&>^UI\@=7^?Z"%WPD X\1QJGN_C8PW10Y\0"<Z/
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M)T_4?K\&R%X )>O#1R5%D0V@P71&W!01:/V%AN*IS18(5/:DK%! !,*2%XG
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MK '&V84(4 WP9139,V-5[S?]K*L6R'GQ IV8)H_>"NT(4'O9*R;V^^M_^M
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M2?(11A"9=('2-?KFJI9N^,A IZ:MOO@UE.1^>6)E:OLH >"X)FSW$L+U0>(
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MNI]'.IHI'[>[;FZ>56ON'G2B\JQJ1NH-S&!+!CAR8:B^<<]U85+_&EWFR22
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M5D8:O:FW7+Q(2.M$"T2*DF[6QC?]\VC")T[H"[]YV8_''IAB'ES2'WET%!<
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MG=^@0C2[#Z_N5;RE>+^@X;\HYT$(9U:IP3YG'!ZZ)4E[IZ]XU^B;;GED439
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M/4/*\C/A[]';B?YO4O"%.X!8S19;WGV1!)S^+[L'ZJVYIAV8^#998-SB597
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M*'$09 D,B/5ON?B1;I&5R@;]I97:%UTO_(V;MEB\VC5Y^\(#AH/=G_D9RZG
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MQQ\ONY>^AK!>)!YN3;?:?(GRN5+?YGX0Q'S63\L\7?U6J,H/0WC4_?;1.*,
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MD^\)#L]T=B0/>+'SE#6-=(%5/);#*;?\F7L-8FY+4,V][EYIE"=A#R D7KS
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M93T3M-O]R:K ;(XLQ2I9IC812BQ03FUX8#B8D2"_1+S+7+I1![FGO?3JKR'
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MS] GI.&TIGMH=P2ZVJH.K[$>@;)H%-+AE96/N3<9=1;U+5<UA^I7-)$601%
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M;<);'-BY/''P@OO0>CIKJI\TT1VZ/@S8-4-M]QBM?9J1ARU]1E8Z["9$1;;
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MM2UX*3 <*N)/@X4-0R0QR@;Q;1;#WW>E[RUH>0TZWK9E&BY]UIV: ("G<)9
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M-G,]<QOX7C!ML:44W,.]7E'_T2':6-4X,>2*:E1A0=2+G)Y/YNN#0+0!,JP
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M<=0GRMX9:3QIY\2\Q&D9A=(FT0J5I@A'R]/G_Y(% -X"^ MMR\ZSPX0&$&2
MM3=LXW)Q=_=6,^GU]G^WGF*\G0Q@_-KEO6].V*(01S^8F\0/42@?9-VJEETA
M_GT!VR$#BJ'1D^MB!$ZO45@(]-K<"M$Z)P!(/&:GL(D] L1,>&$Q1?B-V/1K
MX^QU0C6*SFMR2FK;44T)<A"&38_:?NC=NBM]SUC1M"HNY"Q??CP6+])^L#]+
M/V<%[:$HZ^&(!^CY0Y(DPVV2,>%D\D@,;]TG2$QMDKISGZ9-8?NTN>UL\G#:
M. QGIDTLH!SALT5>Q+3HB-3ZSLSX#ECO,XR8V=2%B*7@?;(OS(&8G)4,Q&!*
M%GI/:4?/#Z]<,J(:(V(T)?XKNMUIF8O  30+UL5V8E3+:WU&=]Y(&^K@?\R*
MU !CLTGRZ_#2RW&<C7ASB'355Y5V?1?)'\C=1SS_!7-[H*4\<^<_Q'*(\YU+
M#+W!:IZXEX_@_8R>H#][Q0(Q> N(=$T*H3+84?F5P4F.R4>M94OFSL8:,H#F
M:6>PP>(6!4C5'_P_]@3___\?U2H9@),0(WQ%1B.W#PTH.R]_&TU"O@4MY<,/
M'$D29 "B'T0&/,E"M)T=_X&W0;-UO4_R2'2'E,WJB1XD->12OE)0N!%(^$"$
M@Y8*X.A?:HPXIV88N@A6#2JU\8=5@*I)@^ON*:N#:5BGV1/,2<*3?<KJ5(R6
MP851ESRKBS)%;H&NOY9,\@^,U\]6SCK:T^$4GYX/%8HMO],,\#M_3.L"L:C$
M3>/U_&?;9][]"A:<EXX+BYY-U1;4"+=_3IP4MP?N3V:1AD!HH_UH,%\#* #5
M^Z(4#8[TN-KAXY'MH<!U)S$B7N?+N@W?U1 O6::'0DUZ$==NB6K_TDQ]R2TA
M=/'E1TK _ZM#'UDI]UA\+-]<Q(DNMBF2A*$3UFP9._WWOJ/VY2SJD_FTUFY>
MA2.^#9&:4O !RPDL4SA0FU(3\K?NJG.Z\;?)2:.0[XF/P^=+=WZ[_F/&B8%W
M\GSP]R$W:\8@&O0=*P9LW'L>/X7_E86_.#6AQ+&_N^,;&)O=]Q]P%V(.1!6V
M/#B]OFP2ERNID[_H[TMB\%_!CRA60P0IGR0@XSPGT@N>_W6U0^=AHXD_&Y[C
MM0D:2 PH:F_M@$?3"J3+RD8==NW4+BZ0ZKV"@HFB:*,%5IWX'F*,?^&<IG8]
MV)J9WO\17?^?,<?W@_)]']+,;*_4,GQBD+N0'%)/ Y0RW=PGL)EB)] T(5".
MO#8#OBTLB;-^U#T7;C F\[37XDN.M["D3JQP83EQ^<*E5ZNVC3P-8RA\Q9/%
MYY,0*HJT2L/)H+S9ZXYF]F/=N:A'L(<[0VP[GRZ]4HU))]03?Q,4LG *V#A<
MY$]_:(^T@L:H3T"QF]OU@;^)3/-9(ID_CA$3B_&+:".9," =0=%'],,R@P$_
M+BXQ/#?CUQ/1L.[X*^6(OQ^_.5VJ_B&/RUI>9'<14,"8E"Y+FWM4N*17KDZ>
M>(6\/^A9FUNIEO(O>DL:KKX9-X6G@.H $N/=)*20FP @4/!UVW2;&OH$UL(K
M3[N"ZUZI9YU*=:-V-#ZF\^06H\ R\P#2?#N9C:!Y?P=J<<Y-4,;@A)?HR X&
M\3L<R_S,1CY\ 1_K='W5<M(&+,\T?S7)$I.;I."AX J%4!4+D07]\,JS%NCT
MRDXY%7O[&8K_2U ^8C9AIG=IB^!'A$/L4.Q1NOES+S/BE.,UYK3ZPJAFO<4?
M!?--'LYL#-<+%Y@^#RVZ_?"HI$^E,4?-1*P6"R1P*"__Q47B]><V?,M/ZYS"
M=E9&V9Q[KDT%E/\YZ2UR(M4:(W W#%H6<6;PBK<8^3D!]Y0EO#I$]TI!7?*=
MV8(38,.GH';)E3CU9[7CB!(9#W>1NOJ:Q)ST@"_E?W>\7GY<33(P)Q;]9VPY
M/QD0[H"7G7(U?1806!V3YV9MU'9%&E,V#PUG_PO:+LTS/7D18/I#^N7Q[O_Y
M2'%YD<"19EC;2"P2N-;"\G+#Y&U+YH9>$AL9$*Q,,NZE7$+9"8IS?#-XB6'X
MJTKAH=LWNWY.;SL0FA]WTA',0090A^&$(3X>#!#CT=UT"^;R.+87B8H'ELJJ
M]7^.W YN!5[,5XXF[*.YXN5A$4UWAR'/?\QEZ-MIU\7OS5C/?EZ_HEQP[9+?
MI?CCG=&3C6E?N2#X2 JDF/)OE>)[#*8&.QWWB2Z6SKNNV_^(92QDP \NHFL,
MSI7ROB-.?5F&H<5S>76,< ,A];*FS$*A/CP;>-BCW2(B,-NZDE>+6\&>$!M^
M$7-7_J#A86_V[RY>FK(,_JV#N)V\)4?=6BXH9BMJ0:\C\NW;50 J1Q.RM6V;
M,80;0/[TF!8]6W]&3".Q#_K>440/9-8>&X=P&(SETV 0%*4; 68Z3HA1 PU!
MKO]XX"[O9KLK;<-]X[G8/]\N#>/>.SOLZ:18R#54$(@*!U)'_\N\-^7,>=L9
MN\)-G#/\+;/QJ[JCTCZ<S3%:'''W#Z(=B)-0(&0J1(.V>]HH"B$+,;M%>$A9
MSRQ8]XI_%JFA"'24KK332@:PK>I5*1K@Q)"$3*TVT!D!3OFT(V(AG<!Y_K2,
M#.A>_4]+YFZ*-TMU(6[^[B"X#@G_,=3@:#V_27:!L/M_2<S&RY%H>P$>42!6
MQZZ^=*O?S)VF(+SX.;,[[Y\J&L2 L/>V%L]>2@?G4-#!E@Q('%WV(W[801[9
M5^X8D^C2YXC/$9S$BG<O&Q[B;T*,*D*N)-T*]WS+[B-TX]!@(Z(Q][?+C%5)
M;<Z"<_50<4?*JHR'BO3PBH]$3W"4B&DR5\_H7=#7W_@,[%/*X;_=!%9,MA0R
M\\*C%)1N]%6;<I9/:>5(;;-UKC)_ZZGM^>P.[P#+0(?@EWW [T%<#1I+WXV!
M][@NS5C>7OXWWO3:@:9I5?C^1DOD,]=YBJ4"SP: '.;!AF@RX./N7B7SQ6TV
MD9'@SWO)!C54SM^O$H\=Z/D?#K!H=W-[N&0EAV]^1<AM#.*\L,ED@(8YA1@O
M.9,!71MD0*2,,^C(& %":\()T*:X"=!2-JS\7QJJ5MX?\DY>*-]<56W0H!;_
MH@CT7KBS7N?8-FL!*0:5@4Z!6=2$(?88FO@*#[;MIJM6CQSP\O$IO_4OSC9'
ML]Y5YK[HFR_E&=H1KUCR!+H05 ^)_'G&CP:1Z,!Y! Y<*0K.]Q CL/TB[7$=
MEU#_47B4_D&*A)F>9\OV![ !=,R:99P0C%>!/$3OA3C.Q%<6;!S.FIL7_KYF
M[]!L64H/8I5<2<")TG0PQRWR-&@@7)JD,54_"W',&F$6 0I#ZL)6UO=[\K_D
M?0W3*[>IJPCX*W]VQW+<<@44,/\K\3PIA6F;^ NVD3X/6^JD $""X?_TBND^
M!P=B8GV:X3-AA+)XKTD],(XF:H+OI,\^'T[3C4JG!CV'O6/9[><A[IR^-3Y^
MAR\VP&QNG?L4FH*>_!_4O6=4DUW7+AH%I8/T)D0!04&*5*5%5$3DP8@(2(T4
M:1%1 0D:$@2ITA%0!((4Z42ZU- 1$)#>2T)'2D()@11.>,XX9XS]?=^/=X_]
M:X_!_8-[I-QS9<TYK[G67->UZ9]IA#T&3";@*K,'/G^I-_1_78"L4>V5!7ZS
M/$6!'O&@?VV3Y$*;WF'8*8^':)?'K7X=:81AHX<>?KEK+KIJZO!"I[HE/,:4
M=_23^^[("]L[H\&*),FQ\ M#2%<N/M==S:QU!/!-J,QVO6G;E$'CZ(G^DMH1
M%=([UQ(3/KG=C I+ 492-#2G_HK\@W.MCLR.T+.(ZO3QOIK]]MH:I 3#B9PO
M1)W1!F-_*<#!OGDDC2?,N@/VKQS5)CT[=6UBLU[8[%WE.WIOQ'O_@<V A8C+
MP#&@0C"\N%X4+X/CK/25Z.1(#WHG\_M537TH<];,YX*8UW*'_>A:C*<BZ;(/
M9O-4!O 4[.SD3F=SKVQ/GKO@QZ7>O$\7XY4"TN+.GFKT_!*!9HO4:,D^]_(N
MA[?]6NVK@]KX"3*0/B4#CP$)D%'DAELM':]!K790)'FFT&ET2[&'I$/ NOJC
MKNA3(!=8AS]!9A$Z\E_85NUZR"_AIWY2LT N#9ZM*4XF73BY&[RF@XP?+D/#
MRC]UK=JIQYW2/CV??N;5[FL'!7+B'XH4WJYQEH\0'5S\W7>M&F_'[O/[M=PQ
M8*.2*N-6FUA2_GW274"#>V;"]DY"\RNV%X:.S]B+<G]>".1J0*H<C&IHVNZW
MIRWR6,U,_?K3R_C+9,%'2KDL78_QG-X>NA'I@"%=^00\"Q>VGU<,._(@YF:X
M+70/^41=9U&0SY21$)9T%AUX_:8L->_4F]BSFJ6J,W=2W[*H[+=@Y)#SY;I*
MU0T$9*LG6^O+F%>Y$[.0Z5O%229:;7%)8IAA7=W*+= YT'SQ'#,<E-&K$;RQ
MC^;_RX[Z6:G^??#<^,+ON$,3VGHIS>=0C^"+*VD@E.,4JA? /'WE[D=%LTZ!
M%^Z\NGSJD2ICJD2>&8/4_&O#Y=+6@?ADU<20"5,L*L2%D-OFR>8J4"I<HF9L
M/MI]O9,@?.DQPSYZ30$C 9I/!)7+;T?I2L5$3(XD=&+1G,G&UQ:%!'T7/;JC
M__*42AT#X-]50CIG4=5FJ#9%DDL4U(SD4KPNHAA6X6)[U^1[U42)QT.E%*67
M#VY5?^E@V<%KSA?=-LW+>/_<&R*.<9H+058$UP*%7=D4\EG]7D+5%1?MVNJQ
M=X*V+W>U_'S&F!!!LL:Y4+C+S:K=2G2!,.(H43L^25>BVM76(!=U[FDG;2(/
M'0@W(21TSEZ?U=9?\.2&%LQ8F(RXI"$^NTCR'R62+R*;C72!?R$<>Q .RC^C
M2*P@P3S!/<D3Z2=:6941EV>6_/OAFU\W18.>NDB)O[S24LP/J_MX%\Y+$"4R
MDC;Q?5=*%"EGWA4\:8]_L:=AM"^K6?4K/);KC0E$5U/U>7>WV:?Y0O9S_G('
M61T@_$.N@'2.P>\-R3@!5*&FPF+%0*MM[Y6-@G-/@0=A##7\I 1"5F?5,8"O
M41[6VDY,@0UN^C28XVARNBH\71>?"D6S/=TQ>&3L;9)_@W*_Q67U@,+#M)"$
MQLD#VT'LE= :17EOUZSABB Y :5;_66N[T%-YSNZM021[G0<.5\A<K6%C#4O
MR?N'0SS+=7OBB>B;AXB,ZD77$R%0RK5AR6&X+^$L[FRH,12V9W3#$I;6$^X\
MZ2_X'/21+'(40V.]B!?XN]"YL9+?G&TMBN8F(4R*UO 9A\L[(Q]*%?-=)_ -
M$P\MKN8(.2A8W,:OZ)57#5?V:@X2%R<FIFTZ^<98ZR+O_6;0558),.QX9[$V
M1KGQSO 8D%E\TK>A>@Q8V#_TA!0> \ID*/Q,S64D)B-\9WO#K85;8WL_>4;4
M)B[&+W/H"2Z9(^4MX_\!"/V0O2?_TX6A %-AJ.E4Z*,,PO9,@JG\T'X*=^XQ
M )A%.]^0?0P8,#_I&1%!$HXVD5 PZ4IH:Z\@-KK\&T5YS+IM5G[$([L\9*=/
M6#((;/&H^%K<B.]UQD0VU%?&>4ZD*ER&_!!NBU=OSH0;$G0^73GPZ,N_&AM#
M=MZPV"MZ6MAK6\=UFP@A:E%CBC%._HIM1/79*U_;UHI[&=N_EPG,&D;9/+6?
MNC&W.=@8@1:DQLSAY+>;0)SN&#Z??!\4O_L M:'^KVL&](D4H)6%.W.IRC[<
M_J=*+)A_DW^EMUK&]PT=P_ S_$=+LI1-^A#^1G:ID7R. ?;O8J@\<GOW_WN7
M]"H=;7&S;" >CNTEXWMHAI@/].C&2T_\F8\P7^_3 A!BM"$@TP8"2'*>7<!5
M!\IO71R2=XR_ C=P+HF4>/@X2%J/*5+D;_OWP=)K.HT1.^^V)X?FOZ-X#17;
M46<U\[K.0:L&44V2\4C60T$B';X%HF!WYYI%,!]H/'/&)=#)2$4WZ?K8"O/1
MRZW0BF=-;E+-%^^)ZFF5O0IJ%3']6J9O0\%3<RD>7&TG(L.*8<4YEAO;/CU9
M4-GSH>^=KO!R%<BB.AJV:2QZ\UWUAF0+:_=UYJ#62>.9W:KK,Q(?GT'R=\>/
M 4W&<"BD'(@W D[L> 8C&;>TGQ595E:':3_]^S)<V0-6Q"MQ*FC(SR5AQ@IT
M?U_.T#3',X[-:P,H""N_CU<,WH=P0Y/#<U>/;"N2?7T?N7!W1%A&,TG-OV22
MPLL1^HE1=+/2X?^0<HOLQDD2-$\ Z9Z*P>DGL8HK_^!WP =Q82O/G]WL4Q[O
M]:?7$&?,QQ2]D1.2)H$#:9+#/E YH_A08.WTX%.R0+@<X58-O@(WIG7^RQS)
ML0G$"W*5?VTQ4('DAFT_ZI.I?9RT\1VYDET<BS&7:(S RU!XDA<\([A=QNP'
MZD5=!>GHUPUR==>C W9/(Y*L(H_X1NM,\0RNF)M(QG:3=+5\!J4'BI=]JQF4
M;2H<-SDNBCGM^H;L/35X;CZWR4]XIT\"XGW;&F5'T1)5UN]N.%8$CS/5UCK9
M\UW6*M?(O<FB?=K-B%=#X<FW<=H;.2(7C7D#0XA*O^P)$9CFZN[KIT ).QA[
MT'STSEEJ"@4,)"A^?,%">;YQ#&BIO09IE=9"O;'8)9-=*"+T DV0;$!J;7VI
MM^BF;',,<%T+8%><<*'B9,D7Y8&C*I __ CODRX?70[D<YA,"X;W:L:,5U:?
M=YK^L!?1S=#5,B;SOC"B?$Q !%Y>_3K;#TGA_HL;(P+;T/P4G;JO'E5USK51
M*:4+F^?.:^;MNZ:6$C]8Q-,_T+CQZLFN9(%:'9M?_8Q*RY_.3+T*2J/#LY7K
M^SQUWXX!)0[UO//H=OG;\ZAV3W;8PC^1QKZ9L_*=L4_R4K3YXR7>,=WUZ2>;
M]?Q-Z5T)VR^^;3XL#?U()H<KE$B_0$N6.CON2Z7LF6F9>4D? 9WI7RA#XZ3;
M_XY\RP96N\6E\@_>_TN-N7VB1L+9Z'.(CRO7]RY7DN4A,LAFY7]?6$C]K!IU
M=YU+SH)@4US<]P3>(GC*8TPW_5$A]9G[44=][>Y*7H_U&3X3FP56"O"$1@>N
M5T]Z3[:&+97(['I40(,'BB4W^5YR%&7]O9@84W>B.M$,FB(W:]B=I9;H7IR:
MUB_3N44F6S$QA$O^-%$P&/@R3,XOV;A4,Z&LXTEC4<2CC0C]FZ?R21_-WK](
M;JGUG2Q:B#U=Z",9-GB+R[9PF7MU"OQ0CG@70W_:^:^8"H$8O. "<9MGNM,1
M.\=MJ9[LY:^R&3UHO$ZXOU*V]>A#.B!!)@!*I$TNB_; 2N27#.<3&>-Z1,]:
M/%(6XFYF],UOAZ1O2)8>YORK'6J1TYH+D\1=JBQK+31Z?22_T?5^Y7M'DEAK
MC6U\Y)&Z%CO"AR)+F#EH!8;;"1&<T[2L;5>//FBX_YTQ:WZF^RWY==PTC]P6
MA"3GNWDF@S37)BY"\L*25WW4_SQ+.C#[6?5)^]7TCYU!]FB-S%#YM7K.C/=X
M3,LVHRWE/BD.BV2UE-3I*\^W'B_Y\V!.^69.S _&^'< :%74R*7?1M.T>/X/
M$<+WGMG'&MPVN@=X"! ZG53O>+*TRG#XFYH!6JR'WSL&E"8_.EE'E)M"SJ=#
MRI%!=(^,":=)_H$[5??:VV=]744TOUK$?%EI2TT]'WD#5V]$##@&Q!,(DK0.
M6Z-CP/UL-)H^L/2 LF,+IP=AAXF3A4RYJ;QI-_7((]1C-(7':_XF:+W^+J(V
MXQB D[.@ORG0BM9?"X\8(OF:#C?1V(H=YAF. 8@)#G\/?3_=R=Q=0:>7$#8:
M T6').>.ATFVB$!"__E89O3QR:F?B5ZIVKU?SKN47RLA1LBI3XU$=OW7YE]:
M4KWM,4#B>^4QP,X4N5J%7DYJ."\^*&'PE^YT5>V.))F%CW\PJK,7SR41C5S#
MZ.DU=!?]1X2D06->Q1"B&Z_J' .PLI^1BSG%_DLVB<> L&YK(!_=-6RTMTG/
MK"%R6\@6 Y?E8T#=$O@84.Z![K"BXJGUC4+3\"?41+A/]GCKBKMY4D_!9(:P
M W&KK"QOJU?D5]9,(5ZW#H^>+E6>WC>6(9J1VM%NYF_3T_ ][8*3_AM7O#Q\
M/'.Z";V\>4X^3W_*ZC%R#XO036!'$C"T<(./&+R)QHDJ8R$2;XR:Y-4GE9)!
MKG8"&G&W<6B6*84O/KGU6;WO8$U/7/37'WX?D2F_(O[E"&TQLE'!<:*N5H+]
M,51THJY6&,IRWB3O:M]O& !@J#ORJ50E,M6*T_3P\(1SF#1'S[!9[7.DRU_I
M%3@:C9Q//@:<IEV"7Z5F5LJ;MB/.TO%.C@WL[?+09DKBA]@V)Y6IVN_+ *=#
MEQCW56L:V]6K<+."J2X\3L>T=<U/]LFLM;N'I]94J(2&M^MG ;G NP;2C574
M3\> YSH,Q++RT>]_X&HEJX59AT8^ZMEQ_FGIQNV/- PN?3XCM73WE'AFFE6B
M'U#5^XQC)V8>32^,:L'4* '4$=@'$C5"E2$M8+=#="^MKF63RF\.U1M^E^IY
M6?4VIPQ\+O8T0_#3N_/"(?Z]+U'X7QA&S&H""40OQGX@"6J)YV_EBIN'C/2O
ME&!,,?-Q)CT:S:"/UYI>:<UF=B GU7MC1AL[Z*.A3[I$'XV3@^BD2W2W""\9
M:D*RP8'XQK[UL19QH<%Z%0]OG"5VL)AGYME3)>' ]PG1L@4X_GL[V2Q/:!Y_
M]Y-IS$-23%B--N9AQ<EDZ_!L':*0H"<V]F2?Z"5M ,->HLM)\2)4?Y"I5E_+
M=?=B>];)\7RS\:QXA_1MTM@ $O\/UZ3C79(HP=0"OQ+AZ3@$U\+]^A8&Z6MV
MJ*P+J_[D)!-\ET<S:>.-"X!'\Z_"6_"GQ!JR#N0ZLEE?*D1QO!]GDAH0,CMR
M%UGO>8'M"-<8%:T?QS\0E,4>8AIKD(?N19+D@)LZF=,PNZGY8T!H)3-ZW_#%
M0OU8RDQK<8%!@E@==P?1O\3 C#N2NKZSVM[MWMX0TY/RWSMF24!((_"'(N4+
M/<J1F4"TF/@Z O(T/7M^AN ??[3^B)P2;.M7$8A^)\IR@8EDNO$K&SEW?X50
MA"1)UQ.3C@%5H:V[;U3J-KNX=1A#.E[64 V&(X[8:&R"^"1K.J#1P!E7/!]-
M"2YWK2YBZDZX8W7/\,#;CXE:A@[4%:;HC>CR46[BCP$?]RS,1E2AO[8O<BJ7
M/-Z)HO6PYQ.E*W.W!\HV%'+W$O7]YIKZ8^S.4;]I<[G@("SN+V<ZI:#$0J"2
M?V;'HQL13NM%G'X=0NR1@1RN%$M2,U8Q4)>SCJ 1Z1.FFJ8^8V@BR:6.;?H5
M+;6^]>[R42K &$8I(59]#UT4I/!;X08])_\^-GK6-N"F?L6KWU*[K.D8,,<A
M]G(.#X:Y?"7^(CE7K?"P==&1W4]Y9\5C0'20W3-"#ZXOA]"/&PNO]RK(B_C[
MI%:YZ,+B;=: N#M<_G$%"N\V^]^2N6@L7'CGOVT0035TV($Y:1"NY4HT+U<B
MCY4',)O./==UW@:KZ4#'D[=6)X@JZXA24E#KD6_$GOQM_9$-W+!J\2VFRMK*
MM-?Q;>MFGV)NL:"[%2=E:"S7%H <ZV.UZ):/G^$F&76J<:MC"44:Q-:2=M^+
MEQA*NZOU OU GHAQ2)4Q9B,&BEW;UA;SQST>K5\*@;ZKJ ZY(3E^7XO?@863
M^="O>0\=O4@/ZCVP^-TV*\]$//G>X)Z*C^#4G;'7,]/^*-BN=M5I-:[JZY?N
M]5W7D0N)=&_WNNV05HLZ0_J+A40V"LWY)[0W"HQ0-&YHF?EH7;G 1?NK="KT
MIY2%/&2P*J' %<*M+>>6-][C@H8A'U=;8C^=26(+^^QT7IQ9-Z1>;@&\H8('
M=M+$1CS5/)G7$+Q)<G[2_EYW37*_VER15V%L>PY@3%LW@!1[GK>:O&>3NP!I
M!DT:X8 ;A\4&R'D,]\P3O7KM(YLBI[*:?9Y;#X;B.K APO,1U%]4^MQTE=<@
M?B9IY9 &.Z:?S&A5?L]Z*NH[\2*68Y7+YV+B\#' 9TQ[&9->PV]^EW5J^/S9
M#F4=Z'XNC7G*[1VP>4YL^I>0V\[?O%@GL>_ZU6 58)"!6<0'/[_:#^ XY'Q>
MNB]%W2"B?JZ&J /J/@;X;I32*YFIPN489IB&+>D]CLV#K=5*?[FN:#I$:?S)
MK<%>Z1&%J<>O7Q:TD1D@;T[0)DUHV@W(7W]IX:<]/4 A*D_8YHPEHI/5MWJ3
M0)L&LJ>. 393@XVWJ%]I5Q6;YJ+M. EML5U>'MD0IIH(R5!7,:L;M\B'+T@'
MQ?G=>PDQ]CJ]D!-V>'HVW[NO34^B@>$84@H(&T,[$0&X3/"EL4K3<SCT8+<E
M_>H Q0L[Q?&N]2BQ"ITU=T>ZJKXB5OOUE2WF[?'HC$ NM05@%633Q)$L2[D6
M8WW/PP?$ YG.:?R2/7W?M+^5024-H_3XGYWKT[^TQJZ^4DE8,AF&YRY84*X=
M ^BQ]^B2N +=OCMS%&,$/?XVZ\!E<,#3M&YQGC_:X*PY5\V&3V,M1F*W!$(>
M6]0EZ5]ZXG0:*/D7H@8SHK'=R+1Y#N:EJ Y??77P?=!'JJ;_IR&/MK\&L!@1
M1!)LCR/M-M?*A,T/;5?DJ4'O;3N4#V<]V7(PY%,.Y[<,K&+^U=7A+M>7%?6]
M2,WQ3<3E$I[ _^0P;Z,6?;"*CP%=6?0,.N[0>0RXY4[F^9_NCL80)&1*2;G_
MC1@=<<IB;HX!.5\(P7_7Y299-P/QA9@JT(^-T:'-.7RLG_@;%JUZ3%G5;(.&
MR!Z!;^G1%?US,6.RT3B<G)&?3/J=$*'ANB[),X\?*AO*9# T(!RFD<UN)<+,
MU22]\^!H]G_W>MWE5C"30!KK;8+!PO)[7VR;@!T7?F3R\];S"G^:S[#3T^SR
M:UVF,X\O2P;%V9BT/O:T95TV2#YI.>//($V0[\)6VHG@9;?JY%GCA)70ZF !
MH=2W+^Z-E-)&WE93>)FPJ31=:J&W_+VIBDG/$(^5D1<V,8G6]M'<*(BR_E/0
MN&Y(HTE%13IM713JZO2SYLOH]6_A1EJEUUDS7AM* <X@EI#-(.2S+\< 9^0'
M9;'7JN+*!-Z<K;S"(.(SMK#B:LXZAFLRW]>$V ,XWHS&YX(3W_)4NOQIO$$(
M0>$/FM]NA^];. VI0H716Y9WK7O"V7XPU+3@=:"'!-(^8:4=4F'0)DHW!/:=
M:)C]9=SJ25&DQX9]?P_[?9@9@#V]Z/4#0S7R5[(M[.T)T7(YL&U3Y1^+^"./
MLVM9T: &Z3:%AV^36.]JT;V]NY.%WT4A*VX_>>,C'5/L$<";>AF8B!>5G^&7
ML*>T]/@WDI9Q[ZI,0W>RIK/<49_JE%8"1)F ;V!,-!8-O&G+]RL^K26P#NQ+
M2Q^V.8G3_O& J!B'Y7H,C05#]J#HX-'-=5PAZ1JCQ7"9?-?R!\_1:F=W-E_,
M)SDG?WE5*69GP'A-6/2>3*P.^@2*!WZ"RY!,L(48TEVU'K X[-O"L_+204AO
ME>6U5N/KAZ<9)@P=QWUY'YFE3C_< TF"W#BXC/"830:"Y-T!><D?@ZK;Y^8L
M)ZU:#R2B;\SP,_U@BR#[TI@;,83'<%-/(QUMA">(9+%BWE!B1_IJ,^P3==_+
M*V]=4-EV^G?K64,GAZW.];84*AO].93=N3L7YL+?7"J].ODLN[OQVZ678-H=
M8)KWJ'GF@)S7OAWF,KU0^($ZBRFEO,)ZAB<]]*@:?:KY('/]NJ!2X( *T"*L
MC'H!/=)-X)HRF)^C*((G,!WBYP.Y0.814V2#?P#/&D>8MKDM9II<:?$BNY?[
MX]V2^COZQZMQ8Y0KR$E(L_C%%$\9XWB\V]%[&3:B6^>GC=FNGX;[>G:A]%+M
M^@DS&ILB,7>T2'YYUWN.34\\G'-HYS \.75A^/Y6**TFXE S=UB-+<V*MGQ$
MQ!G5]7RQ<MN2=NB7BC1T=O"3BC>4&6U(U^_O<_:O_G?7G>[;+)V=/=O",\W+
M;HWGRI7O_E;^OO-RH W$R*M1:H8>7S^TH+$4XGUI_*"-NF\S,WI+[K3+7B4V
M6T"EZ)MG:E>&NAX_?Z,PLF_FQ[_2;Y(B3P\T):_^U6SXKXVH>S@,/2[.5P)W
M#4!;*G3$I#842I/]W^A,A3NOFIQ03^_$Q(#H 6;']2B4&KR!W%-'M\M2BT^"
M%+(K:QU(%*1_RI])#%_A6 N]\NBS1@U -K#' .E=?!VMW8..6PPET/IH36HJ
M:'$6(8@<+Z97P6M29JN52T9O7/]5QD;<1#;;-0KU8_NC)V6B+E;)Y<(2C.YE
MIW)RC-2,TT'1E.19E3&F00SD;SL&BI[H[B&FDU3R2(\L'_5;!+<3X]XN+(5L
M\@=N;9<&*:MKJ;]];SV *D]Y_@_E(LEB80H=C.&I5\21+\UY9;H_A!0A=__<
MQ7[A*@=8$-"KU<T(I4'="R3P/8)"$"SY2+?P>?*;:I:!!?NXN/'H#^)ZC.+Z
MR.NZ2OB0\GD@[[J=&.$L2CVQ:&U(K6$DIV43-HU4>AMX_4*@,L>[N8U"LB]L
MEVAM/EBT$-K6R)5T^VH*/R4R4!KDE_'IM(/4OM S[;2:Y0;6O8:"!UJQ:3$S
MDVT$3&0%*A1Q;E3;N&1&/BDF>[++UT<+R7JA"^ KDR%F>(&S$G^R0?P;ID%6
M_ WDK!S*?XK,HE8!9:ZO''SNI]V B-)&4-7)T<< ]TN:^FVO8"[-;I>3=,YV
MWZ)!%66'NF\JQ_HQL&8$O%ET_HD-2475%T74WFBC5C0JK&)XM/5Q<YRP,?,!
MSM)\<%[55V*,;J]V%]N''2D.859FDYT]_B-]^KS=II8B)!'#(J'AJMN"KD>&
MI7\\)'Q'*TBSPE(I!A+79Y7;#67CJRQ>J$??Z$7<6*OUF*W,MUHC"@S.0FSO
M_]#S/"T8;RD44%!P0RH>P#"*\<,X<$W4(WX? QB\J9Q'UV,BU&1H Z,YD2&G
MWP"NZM6%_9$E-#]M\U]?:\N[*^HNY<_P;TOW?RK[]G]PG2(QD;V07=-PDV/
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M_P;/$ZU3O)>;KM,Q@-/GU[Y.%E5<:]Q.;*;S\\WK!Q,V":T/%&<L;M<<L95
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MOFRIL'4,J"QRWADI7KKYQD#KVN%GSE-_(<5[)OKWH[/JSF28Z//'GE 4<G6
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MCO]U!@! BTU.U%]]4-3:"%;L8?\PKI65\8[)']EH )%?Y]5(L6QC\"7'[F.
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M$UN^OWWI'^VM5G8'0!MQA++956M,"U)8<#_FSD]O>CT4R$^%#NB>+%EJ-.K
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ML@?([OHVNKS ALU8 UP5O[6._?0C^O)P72F YV5&^ED86HKD2W:F")-*%\1
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MT '^,[(Q5O>:X]MI@#-;/G-HDQIO]HSWRY;:T4HO&M&W,VT2#3\S@:YN&_>
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M@Y&=SQTN'&TA?:=D2F^E^>/"%]J=<ZL:?F%20%L?3T"?-"Z/O19UE=9WA<>
MV:F"Q+=S2[$*_:P!5H:I%F-[+&IU#V*\F/"JM=K: N+Q@!-@)+!2^?LD< (U
M@XQHXGJR\ORYJT *%7^2\==DQE#W6@RY*//VU[C1<ESMC/-+#=;Q;M>9>):5
M9F']6S9.U6_E[S)IBI6D>JD^<XS>++HZ2BE]^^#/8Z$K1R>/Q_X7,Z8>.,X,
M\\9VJ4-V(GJSK2U-<1-9;.-6DSHPOC*VH;9YS&7\ZV6Q6:='7C=/@.-^X9CF
M@C!LHCAL1^ON;NU-WJ-^Z9"#0,3R4/1J;J0/MO>1;3W1'R=!96G$P^90D=(G
M&V=)R.,!GC^![B.^/YJBDN5WF$LFN>6Q-WZPK;8BGT!YR7(X.F]  I:I'+AO
M^>.[]C*R5\\XUO].M)GWVUSO^  W"_(I+8V.3LZU>I[[(#M:\MB?ST+\#QCP
M QQG 9[PZ^P4ML,&H$I%J(35+L.;*K7@*_>T%[9VE)U!C4QGM\"*T#9X^68&
MZ;Y;IDS5B)J^[^Q@5IO'5<7JBE^+!R7GSV\^C F$E4!#82TVH/GAQS1 V4;J
M=F+3"2HSD@80E>@ '^X.(W=5HW>S5*ZRYY<+&UO2W7Q*@ XH E.&> V19N]U
MT,["K-@^NG\SW-52T%64X]:RWGWL-%(=Y.0Y0>H 5>O&<K911&VH78/2@]7!
MI(\)7]ZP9SER!SZ(W>:>O<=]0_J' &((293T)Z>5("DQEK!#F2 <@GB1DJ8_
M!XJN==+]R)N7<=KSUI:7'@W0Q;2@K7)CX(5=A/FR\<0)*LN.!^DJQ 0%L7D^
M]Z')K-(UNZ=ENG=]R&XS9%B>??.FV(-KZ@(M)Y!+$AN^)*V 5$(=$2^=F2K=
ML?E*F 8@@-]4!?N)BYTTEA9G&>B5.Y^$.E7TZ3+B=S^?S6\W$;XQ#P^!Q-7@
M*]GAJ05^M\_$MT>3 93$/54@)W4$>$IF[T496G-.4%/TKI_472?6XO9=UG8>
M^)U[8HL+9K95G.7[QJ^/2NW8/FX^]9J8-,>^@8S^$BD?JS0HTC>M1;X!47OY
M?,=)/BZT^<KH.O4BM154=6]L#$4#/,*+A%^OZ']FM]X06_GR^S4LQ$SF>GX6
M@U=O @6 PBJ3>;LLA_> Z,R^Z5\Y[NF<'+9VT^L/[OQTRKQUUD_C?@(\ZXQ)
MT=7$YRD%Y\H/S>?@47S LR!'69Z X;M:O)FU,T6DZO"XNW?'7GC&9"Y87X?[
M(KJ1Q$MP<F97&YP4!5NI647>@CW)4-HYJAAKJ\^(OOY+XO7>08Z.T,$+=6S7
M0=$5H"WYD/Z>Q]TR*!K)(1!WS$,3QI/_^]5AF@]*ZJKXHG#\[Q)_ZJV@"$IP
M-PWP.8W,1(FF >;7-7AI@/$@# UP&S%- _!/=^41C>T:/X9J>SJJE79]MHB-
M KU#M'".(ZA&;;-@2D0)#;![-0;4(O=M\'"0+@AYB'L%$$;*IZW-*GT1#!C/
MV+.<8F6JA*K>$?5/?! 4*AH;FO##V1R-O(Y\2/]/TS TI@/=NYJ6VQ<_:\]K
MBMB2?J_8OMW=^-@TY0=#^!,IK0?'NGY*KL.(4M49(W!6*- ^A\N)KU;*#.$H
M^OT.L%N,O!I!YDJ_7Y[T'<.U^P ?:R1]![V1!%+] W_&/&[FNC)E;_-*2X./
M4$Z=KQJ*T$0?DP#$>N^,(#(2R=9D7-+OZ"1HZT8(>ATY7%+2^D$X16_PQ 7N
MISZ2^_<_S9S;01#%.<D9U7#**P0L$;7BO+&"6*&*4!*:Q0T*NL^)]Z4]G;41
M%%Q,'A5E6_4_#9L1(R!^@?[U-:.W7V0(J+!L!B/(?.D4W18:8+\:MN#DP$-B
MH7;R0,=2SN7V1Y&U"UTUCN$H@W&2]NJHGVF;]\PE4INNZ[[6JU4:,OZA^CBX
M]M]>?52'^&64(^6#;Z=I*/5JPY-]D%,5\ ?KF4_75CZO0MQ)(= VM/%Z0;/0
M6)-L,68U4WA,/'$T:Y15L:.I1SD^@]<B.174RBR)40M)IG]5/#&V@%A+"!R%
M@ KNHEAF2VQ*BB>BQ*47M-]+#*@DB;Q\A2Z#S53< <WJ$X6P<*(>'>?=KNZR
M5.9>.B-=F@-1PCV0NP;W>HP"@GN]5J'1@]J\2RET%0GX_]IXB?XD=V@?B,N#
M+DP](]$U'V> W*OGV*E%XKOGDC,3U,:&6&XE1":8%!Y\?+54H$B*TO:X4_1E
M\_5H_U)8*YTO]'<"!>YK\27A>CNLCIOQ/DFZDW8V<"]YU(3SA?ON,('IZ,2K
M%P<T,09";ML%QPL]?3R\2PID*'=UZZV>^.2U<_H.^<O74"]]%:#OH.U(>X_;
M).M1%+[P/QR%P6DT ,X"1(\/'A+61 SEFY?L'-]-3P)H M4CB>S%+#JK'%3&
M6*UH0V+IL#*D 9+4Z8YG792.FIRQVAR)<]&MP<!T9#GG>G(^=2SS,EXIJ2 @
M>JFM\(M-ET^%G9U4Y^T^*P;Y4U;+LAL3,S>:^6$M-Q=Q$'Y/&$>X9\Y*M^]%
M!E=+R4@3%1,CEL[G8%58"UT+S^>2M>D!1AM)C5/<2R7SGJ#>1770 'M[^33
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M/;>42\N4Q]GUQN'(,VHJ^-3O#>"W35>@#7%O"[J:K\A5#[YJTUDCRWPYK5M
M=B\J]:ARHM^YWC]Z8^._;^0#RC>D)V<D#5!IW%D$9 TP0FG"[Z9KAYD\&=D0
M2P'++7QD9G0RC=%I<AS[YDQ@I52!9@O)5PK'B>%2]!4FXK+YN*&ZPBSAOIT\
M)$FG^*<.RWB;!),K-N"$L\X=(0JC]RKZSVJ]X'-'37YH '>$(+5G#4<F*F'T
MX"2?5: ;=;0FL'R>DO[D5X4,"*7AG3FZ"BR7[>(\31W  '8Q L1LR;.^P6][
M/PC[+*==KNFZ8-%:*==W<\>6I'+9>Y=KZYZI]N-KV?_RP&"S/:68!O#L9X3V
M[@BS2\,[H$HN[6$ZU1]T4GI^%]TW"*L4??=9GBOL);,;T?$H(;4:XCGV3$;&
M)X.M[6;(:XE O:J5I>WAFGU7V'UIG]NO%TO?E4+;!\$?,"= ,V7FT^Z6#9X=
MGJ=LT-9W6P3OXXCO H5K]9^M+Z367YXX>\-\"&FP^\UHV';80Y&-[0/BZ;,Y
MFXW-!U[X7D% SVI;*//Y4'5WE>%DY:WS]6[1EXL[_V>DHOV_,JM%Y:/Z!(SG
MB44X+<(;?$2HFKK3;+U/R"5K[JFM8J?$1R+H*QR+/)=!\IEM,4=5I,KA&YJ.
M)#.(6"WJK*;K7*QZ>%YM?LN[<N.8XD@6B=YW[+V)7EHR^F;NKJ;O'^41>/N#
M_DLLP/%OT  D'X@VY0/UVG(S/RZV-%PC/?!S6Z$>.O=+8O=B=4?[X^,5!9,U
MXEAA[U\A'B05R.T1JB2$#6?\=N]+;;S%F,_XYJ;E(.L?PI497_7/A^B7B!N9
M1B=-1"_E#/Z;'6?);I ;$"VH0_E(Y7:#RHP0[H,=U]$.GWZ]:6I\X"=!RF'\
M0+!0Q['I=T\<6_.Q6MI:9R/YD74H>5#Y52@OWJ,T[.1'SZS^@AS7E$1MV;2D
M[R^YA\HFH^QB@JR6>>_/K#1;GL_^>T_J/V3 /O]X-5!!0"T6%;FK?FD"X6MO
MT%ZKY)?2'3OT2WSXXOG^%^V<G<VA=&3Z4$<3H7TT "^X=5J\WMV3@1CG6]O$
MDUB4/T49WV0&^< 8,C3N\^P#$&I$3QI 8FT60;JB1 ,<>ML>,E%9/Y(NT0"M
MQ^:VB'8B I43LQM!(6GMIQ&]KI#?!W7"W,_T=[T"#T:LJB4$;#\UY(#D][X+
MQ<1I2T.4:0"&=DHQ<O89&40#A/O.&?3+=U %:DW=%7ZE-I>=M7BZ'U!1,/W5
M9-O_'"FQ*:JCU4AJX*@^9&@$K'L!8D #((H\*6*A2+\JV '#! S%0 ,,:$.Y
MZ?Y/"SF_W2Q. Z!&:ZF)FN!&6Q Y]"ER+12V?+$!#V10!_U(;I0Q!2>#:OPW
MN$@Z1 E"*CXO:L;#KCUEFK<ZV-2)-^Y=Y>VLD@O.Z$6^_K[^WSL)#E=H '8G
MDCULP+L#0[Q@3)4S%5+XDM3 !J]3L)K=)RNF;OC2 )K]_+"9<!"Q X@; U>C
M*$Q_=GP[0P-@><$6J3Y"79OLD&XZZB_B4\D7D.4T0"Q!HS?#Q&[EN7?,0:7$
M!]#64+<-#8 S,HZ$<U'%(?RH:MDH5%#R8B-GY*7:5WL&FA[G:_G&UC]?UN[9
M<E7I,@N<:W*FLDEB9<O(\L2060N(4FZ1<4%#&%D)MRY ^-6_LF%C'OZU(#YK
M 8R[ Y_H:J$!^*6@Y]>HRKA?$5%2)6)5Y67Q)A$__W@7)?+HV%88YQ(XA 9H
MXX6PT@#95K,(\G%>G.=Z!,D-HD!)0#I-2FLL/&LRP!HZFC>,E"J$*-ZF?.*S
M-N_[V&S1<ZN8UU_YY_63WO9",)RM$G7D@,K]*O\Q9RKXYW=_$'XC-*3N$*6M
M9_%I,JYU@ 2BGBV:L:)P(]EA,Z<1CL.[) \)XYKRRG#I$NELZX=OY,)CSP"^
M,GT&L.+@$P@"FNA),GI3,2#[9*C)0.B)O@^[A:5J1DY1IZ;DU7B"T:V%T,5O
MAW6Y/S.^'#5'_\>[][]F+1^LT6<]F09(-)CA)''0U^Z7#7"6Q7_C5;L!ZD6>
M<7)UY=#>%L=*D'&,M&A]>15U()%-V(S;RN/W\2O6DAP6(P8\L.]O;IZC#%*B
M8&YLQFC8#*6T\+G8<V+MG4GG4MM+)R]U]5Y'/'Y_O*WL HKH#1:%ML( /C"T
M 8$)WQ_F:__NOL%<;^'N).%^NFIU1=7V@LCOY <WBZYMI1THSP [$+S4-F35
MZY*BB=^:!+:4H2;MG"5*2/-LH^>CWE=B'@,SWM5QP5_%;6Z4#$IJ[3<TFQX]
M10OK3B,V4IOI;(4B&=V<CNN/4N@_2PPV1/FX_]ACES"K-2BR*S RL\[0DN0L
M4-R1^*_9Q9A_22Y>&J:*A=P)!BK\UX0G:;P[M<X5=L@["LVV6L"0N3RIMS%\
MR+4WJ31 EKW5!*9F_VV3XPQX(J<C"/,ROZD&;]$X\5;_J73[#@#E59QN4N0\
M[]PO="H-W;!8C/J<TM5H"H[ _!689V!M-E 4>%<([T]E-J<!8BQ"+.T'O('_
M35C[(1E@KOWH)'OBX R[,G@,8BX3'CC'KH$Q,8CEY5:J#?XP9O)K/K:HK,9(
MARG(F%T,0<?\&K6ZV#8@6!<YZLLRAF[M9)%Y=@F:T!EM\X$$8$&TL=V T+4:
M(P<%(:=085M:Z6/S@7TMU_6YWXG\G@_"87K4$O!7$,X$P:\<!G.D 2)3Y53T
MMZ0?#9M[/G^N]OP&#= LO$97DJ)]\;G+^T!>LF_1;[L5PJ%31F[J9&F&8]S9
MC-R41WWMC.#?[48A5P;WK_3DFP2/4\X203BK%LSQ)E'W6<S)Y9I#B_=Z15(]
M8?T-7G*+AI?D13,#U6^>.L6*BY_<(1C@MCJW7D//XT7@V6W\[>S<?09KDB2]
M<O6A3K9OE>$T@$V]%F.?WB.YD;#N/ZOE5T/.XZ"%BF]>.980![/%#1=B)!D+
MSV-9M\L<]UCB;[MA6I'$JYB6+>#J@&O:O"WBU>:E!U&^13KQSDD#"N7E5_K]
M3'+JB[&LY1""2,0;6(O8EEK@#%PX -Z:MA0!T7HX:VC;M4'8<7#=Z7+GG7]:
MU'8]W#)@?"D3DBL<#LV^9UEK K9M\_90\.<;OMA]9O#:8U_1"^_CF,_/<YF-
M^4ILB/]R/T[7<!7_S,^D'B/2Q1YC$ V0E#.$7+>FPVKH;=I!URP]KCN29""6
MN*X8J8V%BI$+;]AOJP9&<6'&^\^&O(XK%/.(H0%8=IVPRUM$210Y0X3N8!YU
MY%/?WT?5DQ]0DF"S,&@+F%7->)8$4NYR$,#E?JI9.T?>'\N\4Y5"?F']8EGE
MH/8RZ0#A(&^:SRO]4=BXJ9F';#+0+ ]1&R [S?;&5[G>K*Y+4\-"# ?GO&[>
M_"^M5T:/;I>A^RB@&Y+I B0<1@_HDBW3E^HL0FW261Y"O0H.UA,?FGYCUOK.
M#J[P7;+(6^GID/#>D:"R&5,1,ULH:QI@\NH^DB@.(Z>=C*(!'JIN483<6T S
M])^^2N6@^,93*A#!1[4%:(#NSRYP D\S#3#8V2!.W?P&^VEO7+J,H%\UDXOA
M;98BRPY3@:#6W@W;'H,)SS=9E.1',@8,IP.#*P4W2/UQ'Y>&FNDNYDT%I12Y
MK#*W13Y-=T%GB[-NF\=?=_$'>;D@VK:([K+H-6I8YE'75%88/AHT6XQT1QQR
M!#32?R>=#71*&G_M;>"7(X4Y.)/T(8\B9B1:./D"YOZ(<X^]/DSA9C'NE>XM
MBSMS8SY,M/3Y^#EB!)5E!S^)Q;2#XQ-=0=R*ZM"MMAS=^@^ZA:[NGOR?$&>U
MZOYHFJD5*"VBL@G.+0Y#V8BR;9$+'$6EBL,OH=MVK=\+"5,W@5^C?YE5:Y]4
M78; 2&>H??R8&O\N:6<[?.[HU%+$NM/-O&_!=<6IE3WS7P2[IJZ?GD\8-'W9
M<M6=4-0FPC,(X<VR<VDXF>2<O<+76R%X=-[[+OCJ2U!G\_FCA\76-+B)/"3^
MJ8"UCK3JS%=YJVD=HR/[*(_0%J7O"04"SBKAN&@6\3A&$4GZIULALD.^*M)5
MQFP!\0ZUL364\A3)Q^]@@2?DGL*:SHPEOU_]55!R.B5"EKZ,;U'B%=XB65KP
MH._3PB10Y*-O>HIOU2^-)P2>05[M<]2DEH-=Q$Z5O4OI&W2(I8]O,4KM,9QA
M+YXEH$MG;+?M,^;-L-CH^N(KVR&G'W'R%V-;Q/0Y3GJ)F7[O\(,?0\[D@)F;
M5=WYT$)6M9EG\.R]S#-E**Q>RFSW=^M<R\=21@ SBZ@; -2([Z=\<4YG!1!=
MQTI^>/A/<*[_;\[X9_;)9^RHQJIS5A3_([A+!F61%"%/\;+K8)(F6X99W^(T
M6@!9"='.J;7QZ&5OYP@?CM 1$G)4M5ZD ?YZ*8E.S1_^2<WM<?MWB6VS;]71
M?0GY;2+?&"1__4K[S/;\U6CV<A?I$TX4X9AV]=KK&I>?E-.X_4B%+3Z7F]#J
M+P[:!:ZVX0WVME.WCUI="U@#;S.7L)(;Z#-O#AT#/Z##(%QV[NUON]_R_;.-
M4>FOWRWD5G6O_VZ 53>]L-&&9J,^FJ7GRUC:@D3HJ"P';K]HYJ>K6)U)&L!
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M+Y<>#_V'I^K\\QOG=\P;&F ;VGR.!JA(\J0!\A41F*OD'S@XW6//Q861[JX
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M\U^0"J? R65Y"N!42*N\%70$P1Y=)TS)6QCL$)WVTKQOE97_^]^,
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MLOI'\8S!UR5>YV7U".%_-J^]+9]>JN+^80T"+XCZQ_J_5G^-6900'H<PYWD
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M^<M9D$JZ1V(I+:BR.A2WI";BMDI*OBB44(#\H#6B_DUGJ)^/IO2ZZEG&%9U
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M>*FYN>Z]Y'CI"EKPR_L;C=US7Z3I)6@LC=Y:ZP6QO!^>Y-YHO>R/--O"."G
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MK'%%X@P"/04B.0""!=#QT-4BV7$!&C9,(DV4@=((07$!F%ELRIO^U-4#=]\
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M%4C.'-.H#L)Q;*/&NX;W^N);,LC7PW[*68HP]%.?0X02F9:>AS"0%:_]5"B
MG&A=VN\-[_I&7ORDD;YX!@*UU6PNF-ZZW<ID,3]Q7 9;E]O[@\][<WU2L*-K
MZ=-/&7@1MYU_:7F_D@5./I35YV+)Q8I=\>Z.8R%WSR#U&<QR+I963'V882^&
MJ<<QYRQ(<*@4#Z-,<28;O=KRT.XMCST;.@E!2@@J^!UMXV)FB^_(R]KL8,M
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MT_-W!;8-V[<<ML$Q#8]=;]7FE2V;]HP*FZ!9LD&LL#2KR6(3Q$,+Q^K8E\4
M?R@K7MROSG0W7/CB983]!":>U)T9C2%)J+"./,HS+\C\B&M%]JF1=:P=.^)F
M$< 3@*FI-?LPZ"FN;3Q2Q\!HSU/[\;]J8EL._YT@^BK1OVI G O^57S;:9*
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M=[QZW$8ZL9@F#'$&<9A2B)(TAQG%XC#*8R*F(4!AI-1#:%:N':N)GAN 6W9
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M;IZ'%.?4YRS*9@EE_C132=N+ V<O*'1J8;[4=,^\LZ"GHF::@/GBDX\P>^U
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M+5D6VV%G-28.A3FT'X[^?F&=V9N\ZX\F&P@):Z31G]T%^2)EN9>0E(IS>I)
ME,3BB![E&>2(1V'J92S"6EXT):JN3^M[M4VV;( !'X9U:4>A5%M^U@'26YL*
MV%R9Q.J8E[%5P<%V0=M1FJ]3VE8%AK-%;I5>UJ\X]4%(5:YXWY;VW8;?E>^*
M^I\;O"SR@G;5#>[P]\[E4&MT.#(9V[V73[*T:W[,Q"I9E^"0K28:&G\'/6>3
M-4#L #NN7^; 5%/5N()3JZ#4)9@8598R(CA;B:E+X!C6FKIH' ,?2-ONM:DQ
M^UA6Z^*_&@I=+]C.\;G GA<+TS^% 4MRB"*>PA0QF;;!6)!&."*,+59-+;2)
MX"UEFDK+)VN7SY"R^IUUUQ6YV#(#?L*45ESR\F> !YQI'/65X%3PA%B#R$C#
M[*B#(?EM)^F. =NX:#A ;.-CYOZX%"<]#XB.S*/^#Z6!YO-^Z,BUY_O0>E&_
M/][7JF0;*C3LBGWCU7-!>?VNE!D=BS1,?>ZE'!*411"QP(-9<UL3(!X''D8$
M*;E!1JDX-LHZNHW3KB.LWB;O/#03NLV6P'KZ[(2LX/>6J*5^>9-"7= O[_S8
ML_7+FQ1OV"]O^F'#:*7'IV7YPODW6<7QYFE0!">(_ Q'.(<L8Q0B(FL">(D/
M>1HAAKB?B+]JA2R=H^1X3?9T04,8M)0UXY;.@J3F1K$BNM[JG*P>TK+AHD[^
ME+"VHIK.TIDWM&E*W*/XILD79F[UTP9<#5PQ-^L'7MT]X%7+7?U;4\WUX^IK
MD[/Q-U[</XB?K\51"M_SIDRSK-*\]>\L2" V;$YEUS\>0.3E"&(OH##ULSAG
M$?>C5,M-^\-(YEA3M=PT!7,W-0-/O&HC?37KYOXP<+EN1?2:TVNNC8TZ&EWU
M5<\'TH)&7+ 6\G;:O+X"W7=(?(5:H:] +S;HY#Y=6/T'Z)+D:CI?N]F2=;E^
MA*)7KS>=UEH_.6/0M*ON4\5IT?II4D9CFJ4>3'*YA7(:R'XX$0RC$/,T29)(
MK3;RJ<$=[V)#4H#K.+5.(J&VAYC*IZ?&AU1L]KP]YMU:@]O!T#-WLST6ZKAU
M[8EG+HP?D%4ZEV4MRPQO UY1P&*.L@PV[G:4D!"F(1;'V8C0.,DI1[Y6>/\8
ML?FB!0;$5:)E]6%36WFVP-"\KC/&P?SN?T1 VU?^ITB]SDW_B-!G+_C'WC%;
MWKO<LUU>4!>SO/"B)$[%MB@V2%FJ(@H22/*<P]RG$?(H1ISD.JM[A);CQ6TA
MPVX,*+7U;$E\O>4\D'R8<V<]V4Y!.$M+>8S2K"M90>3#A:SRBF$BGK#0*_X@
M3,+BF7]<T?*1?^'KYNI]D684Q3SED(I-&2(OXS"+> Q)$'H>IWD4$$^E!JT"
M+:UUK%]R=H\R^$FHPOK/XD0N.=!,RAN!2VTU6P)!;S7OR]]2!3]]DC!< 4&^
MBZ&Y M?KMI!ZL_#7)?B*[2YW!>EMI>B-4)HW/6]:Y*/4/(57S);[5P$N%WJ#
M-;[NMIO8S:Z#V (3G!"QK&'HQPBB@'HP132$,<<Q16E(TE#+,)^@Y_SRMZ/>
MMD2[ZKJ>#7NFZ2W_*?C45(!%4'0OB'L\OK5X=.WD;A3PT%[JBE):6NY3U&9=
M\HJB'RY[U=<,[Y6%"4[76X4B=,DM7C<1>"M:+-LS?^-ONV9_W[3Q)O4BY!D.
MHR"&29@+4SY-0HBS!$."HS#Q*(D)UM(')DPX5A(-.<W;9Q,H%2^F'0.DIS"V
MW/0V@PRTE0R!?8ZNNIN/ 5-7\KJ#VBW,<0$VMJZX35B8]_;[ I".+L8O&4M/
M2S%>++JSS<O[[_1!7A5\P8^RDECD(1ZED&=$6"2($(B)%\&()\A'@8]PI.1W
M/T? L7;I28*>)I!$U=3-64S&58D-234O4_6$5%[X4Y*,!-B+5]OU+#[LEO'9
M 6=9HE/B],MO\CG#DAQ-3QOQ[O7WHEYDGEA6L?3*<>F"EWM\FF0>I(SF*$D(
MS;C6SKXWNN-%U38:E\0TJV_L(:"V(1O+I;>$=B*!WR4EFT4V3DE@J[C&WMCS
M%M4X)=91,8V3#UU0[+*URK^*67R0M]>+ #.4)2&%*2-,=G\+A6V<1C .A(%,
M\M0GF=(R&B/B>#7MRAIVQ^.GGK!!?<=#?,87F2VI]=;:KJQE=_[]:E%@@V*6
M%PA^42%+'0#,*EB>D4RI>N7AN_-7KCS#_<FJE>>>-;U=*U9KWK0YZL*:,^)3
MSZ,,4I[&$+&00\)9 (,T2;R,)WFNEVA_1,&U'5SF:Z&+.7C<$=:]2#O$1&T#
MOTA2/<4R(.4@C/NL(-8NR ['G_E:[(QXQY=AYQXTM(LIK39-()I@=RD.N;L+
M6G&Z#%B64IAQ&LO=71P^HRB .4O%210'E.BMNO.D7%O,+6'98%%2O@)K2;NM
M&$^Z%%M-6_H\:HJ&M14L-*WL#H:.*+AK4;!^JSTMFRW[^SRA>8WQ28&/+//I
M-QQE7=3GPD^[(-/WWWE%BYK79^),^[]_K0K*%RAC*!*: 7*>BW,T]4.89FD.
M,S^.O##VPI0J=;5_'?8=JYV>5IM"\>NW=^Y2*.S.JIH*^W'G2M-_IY ,44]D
M0VSS';8RC:8\]$^!1K09<QV<3,E<"0UVF?^QLA:<3(QV:H(;+GZT_,$O95-3
M@+-;L?=^*"OYTB)&7N1[&8:$>2%$LLT8QGD 4R]"(4H\/Z1:'N%YV9_-2=:>
M]'^4!,"3,VEI]WJU^;&_>]E)Y=O*)3X>?!_ [U)6T EK\=3_.K/TPV?HG63^
MQ]K0G$S,?+EVHUSH7^Y_I'EUO6&%^+9?K]=BX(;1#TM\OPA"\71 &<Q#3Q81
M39$X/04$)GF<,-]#)(N1ZA7_>3*.-XB/;S_<@HXR&) &DK;Z??\(3.-:W9[P
M>MK73&ZM$(!IL8P" 4:&G2T<8%JT85" PM,7M>/Y)@;DLKJVF([E<<<9SX]2
MFB6Q6*>A,! Q81!G<0ZSB"!&0HS20,O5H435];V$)&[4F&<"+#4;S#H$>HNW
M[^W1T&\[)$@.9FK6HR:UW98]$S1?HW&/&@QGVO<HOFRF%CX5F!3+)MMH@<2^
M3&36>Q3+_/<(AS"+/0^2A%!Q5LQ#%&.=9*#!V%I+7#_YYTZ^ I8[>GK+?0B"
MVJ(V%$UOZ7Y2D$=[89[@W-+R&XX\ZR([(=+A4CKUB$&(T&?\O7C</'9AS_B>
MW^2#BE+UYTV]?M,6J>#L>KWG*+K)9:INF^77%NI)2!J0G#,8QSZ!*&4(XH@1
M&& OC/,\(-A7NGFTSIGC_;AC5=X3=+PV@4E-H;BR91<\"GX!X>"^Y1C@->"]
M._E),BU?R64^^F/#-W@>K:?C>";'=<:KSH]N=$,[-3LVFPBB00V_&DA6P9NN
MHI%T]Z\///WRE:940,OR1*DCQU.C$:OU6E-D%N#E;A79ZG/D L_1L#*K!.>+
M17.!TUX FQ,",]]W[-_-R-SET<M=SF/B49K"C&<((IHRF 6R:4V*.?>]D.8!
M6CPUMSOO5Q.5WF?F74=U[$N@>V<O.;D"[SAM0JQ Z%\!L:A\]Q?YEB;9\1V(
MNVF;_?+C\.:^G?D?Y\;>[A2\]LV&)M?_&E<:9E-A[2[#D+QQQ93'<M7LD5]Q
M=5,U'AC6[']B$VT87*01Q4F6I3! ,FXT8X&,(,608<0\1I*0>UI]CA5H.CZ7
MM1ST=12><-6:@Q>7QE5!4]&5:A<C34=J"T]75D'0%U^IUJO*NJ)H@H=6"5LM
MIJ(JL;VB*I,4YRZNH@K!B2(KRJ]>W/OL_?<G\7WIVAI]?'R2%=@*VKJ=7F2#
MO*8_GF'S,[7!'2N(PW9=TIS8LB6/DH>,&;<[4\1R7&O, J.>#M%&$/QNM;7B
MQ9#8Z'>F2/&U&I[I 3+2\4QS(#-3Y9;77+ST<+UB[_@S7Y9/TF3J^U"10%@A
M41["*(^$D>*''L213R!.,4$I#_/4\W2,E%%JCK5/3[NYPV0[ZGK&R#A>>9X&
M/& (^BQ'L@)T"K,LH%":=!E'+ E)IM8>SAYBE[2&FP,S-=/-VC='3^'N 3 @
M;*^AF9: EFRT<5JS6F=*8A_:96HO&7H8Z0-GFR7O\G6- L'OY/ERP83.]$G.
M99":!U$8YY"$S(/<S[T4\3"+ Z68->N<N8Z7Z?C<1KY>E#8B+!C)LV:-;'NS
MJ.@D?(VYT70#SCLM^DX^VQ#:<N-9XVM>1YUM.(]<<=8)Z!^A[RHFR C%7U0-
M3=G:0_6$?.I=QYIQ1ZSIY*-^O#TIY_3I]5(1]13,785E#<J]:P55B;5.H&-B
M&1TP3PXXV_EQ3)SA\7#T.3-CYPM?O\7UP]>J?"X89V]>?JUE[YRVG:R8RVM9
MVJ^)>MHVF,ACE"6>. AZ,O0(!7D$,UEEA.?,]\,@C<0A4<>JT6?!M1M;]BO.
ME^4?-9#SU+7%EE]LO&7EKWK6B ',:F:'6_#TEK^L$=Y@UW,C[8>?)$,"PC^#
M+4]@QY23UA_FF%@R& P8F-4R, ?HT 2X8"13;]4S7VWXEW+]08CUMEPU@_ZM
M6#^\W=3K\I%7B]R36:A)#AGSN*S'XD.",8'(YW[$$Q)3'R^>>45*=:?5%%&=
M134DK6Z[]Z61J*0NJ^^/-;,RA2[S/2].@P0BXOD0X=27I6P(]'SBIR'.<1YJ
ME;*Q"YQ)5[-J<P]84;?^5+?@J;JQ;$*BZ\MJ: -!O-W9>O+@#T$?] S8=&FI
M"FO-KS5)<&;GEBH QQXNY3?--.G-$Y=6Y.K^$Q>'LCZ\_:6OSQ2F./0C+X$L
M#!!$:1C#E&493+R<1)SQ/$@2'54P3LZQ&FAH#K,[  1ESQ!8RK]J)GQ,H*>F
M"^QAHJ<'MG1!0_@*;$D[*'.E)J2E]3]!;-:UKR;XX;I7?,O 4R(SG!HGS$.Y
M%*_<KE?7CVME7\G)MQTOVS8I:T 5W/+UIEJ!Z\=RHWH'-2*[@O_D8K$U/2B&
M$NMY3T:%,O.?G!YR/@_*J$A[/I3Q)R\.]VLK?7RLZPUG"Q1GA/,D@7F"9>'G
M,(2I1U,8HBCD#"=YYNLE0Y^F,VM87U?_N6@H&\?Q[<&DMEM:$%YO,>['Z[4T
MK\#'<<$O"= [)9;]H+P]*J\5B'=*U)'@NY./Z^^![_^Y?KG^HV+U-?O[AY5V
M2-V9UUW?&;1UAYKKDGJ_>\Z'LERO2IU[A',(3&^%%H376WX*<CL(;IL0TVAW
M/#?F;-OCA%##_7'JT0L;?7\65NVF:JZ&Y%GVUU5):EX]RUO CZNGS;K>;QQT
M*SN<5,(:?H/KHKZN:[Z^J_"JSL4RNMFL;_)/,OHC7* \P)B%$43<E]E:"89I
MGGHP2N.$Y-S/$Z;EN'+,KVN[N2<IFQC*V_Z&*@AEL\YE\]$W;#CN:/K4#( ?
M:%+T--FN[?D5&/#>>MV&W(.6_:/&:5L)0"/"%6B$N +G)MI!&W6WF-ONQ.Z(
MV]=IYNX6^K/]X!V3-2B>T?E$AW$EO6/TCE>/"^F@#-.80<9D&S@/(4A\SX->
M&*,$^2$*L9+/4H68\S-7YYD7[SZ"O*Q W=\ X0%'&D41IL ;U\&V(3&[N!A2
MOMK=7DCB%I'0J/A@$1&S(@Z7(*-7C$%1U-'Z"E-CS%<R05&:O2H(JN^8^I!6
MLKA"&]ES6]3_V%5;\!<YR3$BC$(4>.(_B>RN&_@1C'*:I3@6)FX2Z#F2SA-S
MK]EVI$$E:%\-2I#H.I1&,%/U*ME!0M>U- 3AM@'AZS0(!LZE:>FL>9A&2,WL
M9IH6^MC7I/".V<)^US7LOL/?&ZNHWEWQE'7]5FSG+WE;.;=>Y,SSO8CZ,(]R
MV4O(EQD#80C#( D(]ZA/HTQGG6O0=KSL97#8X,I54 =T2%YOX>M@JJ8''"&E
MIQ9Z)IK:FBT;LO3&]K96HO96"35M36$@OR7%H4-Y5CUB ,FA6C$9PO@*2IS)
M>"6]IDTR5-?_CL5AEJ0YAB@*,XAP)$.Z$(<1SC,ORK@?)5H:Y0P=]U=0#=6Z
M2</C/6WMZZ>3$"E?/UTJN/;U4T,0;"DZZ!<X(96]VZ>35.:^?1H3]<3MT^CC
M9LOTXXI6,K#C'6___W'5E-3O&IT-R\AF'O80B3S(@R""*"81S *.89XGB#,_
M0PG6NCM6INQX*;<],W#79,^XXJXZD&K+VPD\>@N^9P'\U#/Q9]D>JP6L[TKH
MI*2OMO"6]((ZW5DUA38<A[I#?P#]N^R/J[H03]Y5[&NY+*@8[&M5TFM6/JTY
M:WI!*-YJ3P[D6"%T]$&?/=9ST6SUDA7.-C+BI.-(_:Y[&J%QU6 ='%UUH(4+
M^%VR8^D67%ELH_OPZ=%GNQE7%G1X1Z[^DG&SX<WC9BFK=;SC3Q6G[0V+^+SD
M36+MBET_EM6Z^*_F]X*X.%6L7[Z*K\]:_&UKL2PH15E(TPCFA'"(_)C!E-$$
M8MDZQ_>C+,HTJY'88DUIV5Q2N.03%V=EO.,6L &[VEV,[4R'FB4R*\2F'9*W
ML Y9E*5@.R8;)35D\PKTC(I/DM6VK_3[R:.<25]EJ_C9Z\)LAZVY>S9;!?-$
MAV>[XYMIW+/C_E*5=;W@019%*"00QT$&$?&%"J48P<0C\B\Y#_)8YRPV3LZQ
MO=43O\25,H&7FJ*SAX*>^CI01/MZZ HTU.VI(S4I+2F9"6*SJ@XUP0\5@N);
MAJ6=9"QQ&T7\;B-C5=KVO&UT\;"B_;8G^2)(TR#P6 89HSE$/(LA3AF!49A%
MQ _\F.L5P--GP?7Q2_""Q836,GZ,#D+]P>9I^['M!['M_5 W)7W;3 #=TN[Z
M4\!Q0+C/*/2\/(0HC@*894D@E+&'(A[%/$&1GA7K:!(NL5>WE&:%5DU1N_W.
MZBEO![7LAUWH+5:S,@;-5MDJ?0;FK4]E#-!1(2KSD?3];E_P(V=B(+I9%\_\
M)L\+*I2N03;)Y$"N;^0E?;!E /0<F*253(,R[6JSBH>>4IF&PD&FB;*\1CZV
MZ=%G\[$I"SKTL:F_]#I]A&XVZWHM3@Y"VXSUD;@ME\ONAG]!4.HGN<<ASWR9
MJ9)ED! 40)*$21J&B9=D1,N4G%T$QQIIVTX&=^UD]GN-S=M#R&""%:VI'WK:
M7L\:&\@UV5G(2=VPUYN8'Z3?D($ _U*MA\PGR'87H@LX<5#EOXN#"GP2)5&8
M0\2(+PNG11#G<0RQEZ @RPE-N-;^I$#3\88R0_5ZK1@RRXCHZ>JI2O8.HLLT
MY)VCL/UK1)UI0*!5Y/ZB:+0FG<58AUW?WU>-B^NCK*:WJ@O:Y MN*Y=&08J]
M& >098$'49JDL@%\"B,O0CRG'O:94F,SIUPZUCQ;ZJ#HR6MWF'8V0>/*ZH>!
MW< 4!1.FZ)O.% 6G"MKOYFS+>]>73<':G''Z-/(3?X1I-$ML;$\,I)DF.IQ.
MO'^RJ ?//773B=N3!3ZW!FWUIW:-[F@NI3/B\R5ANL9O+WO3.3%+I<.N-^N'
MLBK^2UY\>5'$$$40$U\8Y$$<0IQD&.* A1YA)"=)>E'YL!TMQ]OAR1)B>$O]
MPC)B \C4['!+0.AM4*?*B8'K:0PNKRAV+)VKJF(#2J];6>Q8Y,GJ8B=>,;"J
MKQ^Y.+EC&<%4UH68J%:KU%_%M^*A42WR8+]K HPY"9.,0)**XS;*>0C3,$]@
MD&!"$ W3!"FUB#*@[3K,J"/:^FZ-6\*;@*I@W[J#2D\I]'R '2.]:MBR<M7Y
M/*>[ U^,G(9IZ0Y!,X/1+I)ZAJ 9%J/FG>:0\QEM9K+NF6*&0QB&=K:F7'U7
M7M-_;@IAX&WJ8L7KFM=?^/HFE_TKNK^P!0L((A&A,"8RVBM+"$S]((-!R&2T
M$4$>V88:W6G$>VKP8!!I=&?@GY#4!/9-9/:*-\7#<,<!H((=S7A0'9#5;#3K
MF)G%BG9<R-)Y'36P8^0*?&FA:]K>]-Q8C!TUP,!6)*D.Z7GC2@U .8HR-1G#
MP!I\G^=<ML 19T=:/O([_/U6+-C]PFG?Y!/ERH^#3\5CT6V]&<UB/\TRF!+9
M=YFG'&8$)=#/<9H0+_2C5-V':LJ%8PNQ(PD$S9\>_PR66[H:]HTQP HVXARP
MZ6FC+4>@9:FI$R*9.J@8"79L@4^SPJIA0,X!KYDIN8.Y:&%>"Y@K"7-U4)BS
MWGV%!]]?6_[%2Q$:-3"-!Y_/U+Q4_CVC\^+!S,S/@^O]+QMY;7>3ORN6&_';
MUNX=1 ,L/)\P3QB;,$W\!*(TBV"6Y3E,2,P1\A+I$M#Q^6G2GSO"JW,%;J3[
M7IA8M"VZT5BD/\DB47_NE^#6;S!(4Y 7V<VJ:^\(MA[&MK.#L,Y8*Z5Y2+WN
M['&2HY![%.*F]US65"!E>9.O0)F839+BQ5JVH'C]V=MR\;]GKYL]M8.)PSG1
MLP:.8N1:5K;MO>O]D+J.07NG$T,@+!U0=*G/>D8QA.;PF&(ZC'Y6P^?54_&N
MJ.E=\<C9A[*2=V2_X:5.'9&1(1SO*I^_?/T()&FA<S9"QS0<-$63]P(!?E./
MOYB"9%Q36$1#3R/H &&U7HB"M$99#&/CSI:_H"#<,'-!Y7$#5\+;<BD^E[)Z
MX/.P!G%;LCK-$QK'/B1,EOK#*(:8, YY'$19$(4>\K&RNV",DO-[X@'I8:C'
M55,(7>,$.PJ7PN'?%@AZ"WA?_NNA_)I%SL>_+NJG=%LXF)W$3?'0.V>KR#AZ
MEAX=8+[SLHH<>V=BI1<N2+7O3/FVD],B9!E+!720!EX,$4D3F/HDA31"'@EY
M&(>1KW,X.B;A^/S3=F<<'E+^KZ: QOK%(%%['YN,XRA.DPR&(8D@DA$!..4(
MT@SE090G*>;IXJE-:UWC:CT'0H?DE'%ZP^^+U4K6+"-X*6L+7 P/\RCV<4QA
MRG$ $<I#F 5Q!$/,,IK&8981OX/G_4JG","%X/3$U%V+C:%N#1>U$^MEDFJZ
MJ)OQK\#UNNVTWK0U6I?@*[;;5OB\3#;3Y_<)S)\>?U+ D^GOIY^T5+&^K>J3
M9"@+\R"#G%$*D5AUD(11#$F>^UY$DC2F6DW63I-Q;&$V- #K"ZU+SSYNB%]8
M@%ZG\-'E@NNMR9-EY2V7.1J7R56I^%<H:S0NZ&0!^$O*&#%>+-ZOUF*!_U8N
M-\*6KEX^%$NQ!L3^&,I"9"G,6"C.?ZE8I!GQ&(PICD.<H#S/?)6E>9:"XU79
MT@1;HJ"EJK8FS\,ROARM"*NY.VK*J;P,)V49<;^(=]O%)S[LUMSY$6=9;I,"
M]2MM^D'3C-FF*J&P6]8O79*G'R*?<+'CI3SBX@ 3>F+O"Q'T*:8)1HE'/:55
M=IZ$XV76$00-1=TDV",XU#:[RX346UY[\CG)9STGB[7TU2,",V>KGA/P.#GU
M[),&SLV;U=>*/Q8U_]9U.>R^8C3ULYRD&:1!CL2Y+TA@&@8QE*6+DPA1$F.E
MPIMC1!RON9L5?&K);ELX:KCQS@&CX,&T(*[>ZKM9@8XBZ$E.KT%UD36<EA9$
M-_-7"@@.)]M6,-"$3*/^R7/OSN>:G.!^SRLY]>QEA]IM^$^72/^&KWA>K!<H
MCQ'B?@QIFHG-G>:)K,[DB1]1F!,_HJD83,,[.4'/L:MR>^0;1+"1EK+90?<<
M;'HG7@M@&!Y]!P&3?;V+GSKJYZ-*C$_!$W):/@Z?H_8JY^()T<\=D*=>LUS7
M>W=)OBM1F+*,8!_[T,M3'Z(0<8CE<3K* I]0H0Q(J-5Q28>X8R-DK^;W=,W]
MR[%44PNN$-+3$:/UP(?A%'9K0%X"@NMRX:=(_QC%PT= 42XE/C:&I>;-=V*<
M=^4C+E8+1+'O(X9@2C.9XDM"2'*?0N2':2K^XY% *39#@9;SZ(S#KL5 TKZP
M9_, *C6M80D /25Q1G;P>TO8:DO&2?%<M6P>4'K=CLW'(D\V;#[QBH$CXLA?
M_TGV;QNV$_3SR&.I1V&.N2?."1F%:4(3&*<XS' D5GNN%*"O1L[QBF[(Z3=A
M5(1*P4EA%0##H\'N5@RT>*CT6#3!0\.#8147,U_&N^,[4K \_+[8\FXHRSOJ
MYY@>93Z/A[)$>[X/];>,O2#%2I9 6K7A&;*GDICUMV6]EJE0]ZNV\!"1K>'B
M!"*&<V&R( HQ\A'TF9>'21:2D"AEGVI1=:SJ/N,U?9"Q-W3 A?ZMOP)ZRBX1
MNYAH:S])'@SI-^>?*R!9L.H249?3GF-$@>;<[A%U&$XX231>-NY,W3I@)!6Q
M3OB*OGP25#^N^6.]B%.6QJGO0YX&OE +/(=9F&"8Q#$*41S&F:=5BFR4FF--
M,' %#JB#WR5]T#"@>%VA!IV:.K &B)X:N 0+DS;3TS+::RT]0FON=M+38I]H
M(:WPDG%_V7*S6M="=_#B649H?N'KMYM*1F@N:.A[7D8I#$B20I1X&.*(1C -
M2<0\&F$/:^W]8\0<+_2>M$S;[VCOBMTLE^4?,@:W28]BY8:L\\U2=HQM7Q&/
M_/? ]QIGX'\/ D^[9>QYA(,D\C+".8QIF@E=&G%(<L^#3,;'<YZA)$6+9UZ1
M<FZ,AT25498E<'8 :UI4HT"I:4Y;PNLISNUWZW;PW<*Y^):"Z[VOUEMAS1=K
M\*FL:V%:M6Q9;78[*;R]!K;G2<W=E'92Z!.-9J??,77^UNN;_!L67_XN5"$/
M,T0PCJ G^T4BG.4P13F'0JWZ7ISD>1QH!8H=47#NZ*T;)5EC[05]#(:J4_<"
M$75=N:UT#3$'46)G1;'FMCT<?V9G[1GQCEVTYQY\G99=OX@'U_7'5=L=L W8
MSX(PI9&P=L22E8'37@0Q)QQZ$<6,) QE/)^S)]<)'AVO]8;B16U''4R+FLYX
M9;#UM([-5EDMX[NNI=:S.1PB^X/TNCK%X;]4,ZL1B&UWJQHC91I<_\Q7&UY_
M$+"\_RZTU@HOWV[JM3CR5O7UBGTJ5_>?BF?..B?XUIE"N(\2G*:0>8B*TRG&
MD 240(YQ0OTT"8-42U^;,N)8*?=L <D7Z!D#6\Z 8 U(WD##7']]9>[",IX0
M-4T]!\QZZGB+<'X&8=PA#/41-L@KN P>:]D'AFS,G*-P&5C'F0P7CF=HS0J[
M6%C',G=7]KJ]R>^$EJUQ4X"P"X?A+$QXXH<PC)DX1M(DAP3E",;(%VI.IN)&
MF99Q.DG2L5J3##0G+\F"II4Y#9>BT6@5!$T;<"B_@] A==EL66'3!.<UJI0!
M.+*1U-\T6^]?A 2X?KBI9,I4]\.@"ON'XGNO8?K"T_["IY['XBB%* J%M<-E
M6F_D1Y!RQ#@7/^>Y5NB@ 0^.-4)?\K]QN#\-HY3Y-@)7'',PI=6&,_U(I4O0
M5],GCC'54S =??'%;'(@0?_S7KG_AJ7>H+%?M/X"0"QI)1,.9E53%T!TJ+<N
M&4J_3.375;VZ9G^OOU;5MV?ZMEYW/E[%$I%G7G>M8\2)MW&TL+\+LZYMY_!5
MG&0K\(U7S[(?S&C$BS((X_K"DOQZ^D!-=(L^< 4IC0I!GAMSMB*0$T(-"T!.
M/:I?].-=%\#YH:@I7K9NF _B=_7"HW'D!R2$44811)C(AC42O(0@[ 6QAZC2
M;?TH%<?KLZ<+6L*=3Q,TI-4K@)S':'Q=6I-<;V4:":U5#F12**.2(.='G:TL
MR*1@P](@TP_K[X+7R^7[[YQN9-7$MWC-[\NJV%YW*FZ%8V.X#HM9+L&6-M@1
M5]\!1P&8W@9MR:ZWXLZ);7GW4Q'.: L<'7BV?5!%O.%FJ/2\<<1JU5Q?X&77
MS+/MXSFH/'A7'E]L[*X]ZD7$J#A+XPQZ81B)4W8>P]1+ HC2-,ACGR,4:*7\
M7LZ2X[7?=D&1A^WU P?\.Z^H+%:QZ\K05#<%97OQTQS$GWDM[X=OO_TJ#NDK
M\,=A$XB1=@YM%P+CFV4+$ZQVAI]WVO34UH WT+<0[GH''Y38;-H"2-VVF^23
ME\D#MJW&]EJ"T%X \*4,S1TE; G $Z'$MD8VJ5N/ZP?YK\R^?L9+.=SUBMT*
MI5(55"@+^;?.<DA]S^=YC"'+(T_V/LI@FGD9S(.4^0E%'/- O8J],EW7P732
M 2>U8^.)XSMVFE]66X8TVF[J CNN!1W"I:?J&J2:_PRX:*ZZ=WRT?S<H*Z4!
METYY?">P&1;+%[2NE+YEMK(V]:4?+Z.O/MR,1?6U9=POL:__NM7,SO>/3\OR
MA5=]^N/>WX7U)QBZR9L_+HB/B+!W?1AZ/)8Y7C[,4D(A"A(B;YO3@"CUHK?&
MD6N_4U&+C5&2E958'X_R0\5B(2^ M^SJ7CA=/AUJINNL(&NZN,ZGF/;L@6U6
M[O"A*]"Q*$W8Y@GGZ:CZ>+E-5=7@YT=(8]6'3S'%U6!@ QNU+S1X?5_QQN+M
M#($DQ$+W$0ZS&&.A!\,<9@GGT$.QQPA*<^P198/T#!'7(3=])<XM60V;Z1PN
M"O:D!6GUM,VQH"96XCF)-4Q""Y*;V7\:4ZUGYDU(-&K3G7MW/@-N@OL]:VWJ
M6?V[@K</\A3-OG)>_5*5FZ</JUV1/,6K@I$A7!]=6\I D@8-[2OPH2S7JW*M
MT4AQ#(+IRP)+TFN>1$<$MUP&4%%&HRN#L7%GNS%0$&YX8:#R^ 7Y8V0Z#8*<
M28,8=%H]:,QZRV6 8&^>8+K>X*7LH18L(HR01[,4AEDD\\MDOH)LH4.YYZ/<
M9Y0&2A;$*\K@6,>\:5MA78%WG#;*%H3^%1!?X] @#6WFV54[HOW@<Z9I9EE,
M8]MK3WW4S7HK'!A(9ZGMXP\P-3;SX&:68/X\N=>9HI-Y=*_$BF&EES;RD]3-
MH(LHC&B0( 19%'#993*'Q(]RF!(29F&8!UZH59=@?WC782L&;=H.Y%?3U^92
MZ:G2/J6LIV0Q$>2T"+8*@>P//F_ICY."'17[./V4@6?H[H%?WWWNG  >38*0
MAR%D:48@RE@$<1@G,(^C."*1[R6Q>C>:X<B.5XX@!00M#3?(GM@*WAY38?06
M3">'B5]G3R -9XZI8&8>G*F)TG/;G.)]U%>S]\)\#II3?.YY94X^8+8A?L!%
M]1M>;OB;E^[@\>V!\W5STA3;[YT,AE@0G.',RRF,?5FQ/0DQS'POACY+ Y90
MEH1(JP2:"E''*D"R !H>P)L7T'$!&C9 SP?XO>%$,W-<"5&UC=<V3GK:90?1
ME3S &&*DO57K"&UI U<B.>NVK@/"X6:O]>[,E8>VO F+9//8G@)D@QMY\_^N
M>"X87[%;O.:+'!&:\<2'+"?"M"#<AQB3")(@2'C PSAG6I:Y<XX=ZZN>)& =
M3?!2\&5;I>BIO?>;JTR1\AQJ>(-^E)F9W?<SV(<&8ER![7SWD@ IR@]0T$@7
M]=<N;Z3,[[]&L2-=^*V5/M(F;%H(:1@(]O]S]Z:]D>-*HNA?$7 ?WO0!S+E:
MJ(7S/KFV<VO073:JW'UPT!\27%V:D\[T2)G5[?GUE]22J=R4)$7*[C<XTU5E
M2XR%BF!$,):^\6F14%; K  9HO(T@-+'+%@4 RX8*U*1D:P(S;H<G8'B68-_
MM4EL'6>+GH*=3*R94CQ*3?70XW64(&>M?\[!F+FOSPB9ITU[QAZVK[!54X06
M,$ICQ%G1I3^R% -"* =)D9$\Y03GL7%1K5K8=SYC7U*J/Y3KA/1Q$9M"D)E4
MZ=%B50\[1'Q2"6RST.Q5KT/TSQ6Z'OS>KL/#NY78U+?LORQR52Z\[OG+[]L<
M=$-#ZV&_ YN,E4M,&)<.1_2;"8H>Z1YR5JY0:MWEX=R:LW9Y&"'JN,O#V*.6
MD0;ZG;-MTXJ*/ZI-_,J?UY4: /%Y)=;54V.^2INU_>7^RTP*>60EC$@3,:2J
MXS@$A:!JBBWBO* HRCDWBA_8X>%9SK]MGYY4KOY:!)_*%5[1$B^# 4+!'^7F
MNRH64G:Z*HELL6X*)#M4#2\0;?=#,Q;@G\N&'GZ'4%,[VD(-=C@-.=V$2/LG
MVIAHX&4Z[D06N7+'+;&8U\F>QJH3UWGB<N:VQX.:<]^XX]_72_G*U\WJMWJ7
M"&ALBV@NY_OR56$1#-"0 K795JO@MWJ07JIOF^@RZ;JMXH$_9MI&CS4>;!=#
MRJUL&5T8L]DVAD0/;1W35^W][]O5:HN7K:99%##G<4)3P"$F .99!D@B&$!A
M06,4A448:QDUEP#,Y8^W,+N#U-PQ/^")OH-N2ZFEHZY'I)7'?HZ229[[P8*S
M>_#GR#GGR9]]SLZMZ"+;]<.ZZP+Y"Z[^Q1O#^!NGVZJ;3XRR.,I0#HI"C2TB
M:0$PAA#D:0Y)$HD\%GRQXH]XPYF>&Z$%5^OC1.W'.82N[R,/F\P^[3 (ZAT*
M9DZ!'C?U7 !W'+(+'W3@E;/4(1#L,0B^7>>0L45O1+$C^UT/YJS6NA$;CFUS
MLY<M\AZ;GC%29#[P]L_/JU]7I%PN.;M=L;O-=VD#[$?^+9(P013!&(0(YP F
MF($B$@@D&44YS[*$\EA/<9@#]ZX]>MA-(XVU@FX^[M""I^/JPQ.?[#M4J;GP
M/1[!YU6PXYIJW]+@,IB4Z(]K!JF=WKAGE_NYXR+KN5BN@NWHM^>JC8L5)T8S
M2<U6G"_5U(K2@UQ4NQ5>IV#Q8]O>3Z&B66\2+8HDQ6&1(L @BZ3/E4IW*RH@
M@)1FN?Q_AO4:"K\B#=Y3TW88O7K1HLT.:X:FW_:^&8:U'18M'FS_7[)H<<+6
MO)&B11L*_E)%BQ.VR'71XA14+!R/>UXUEPN2S?L<GV8LSZ^K<M/WF.8<8AH7
M&$@O@TN'(X4 9V$.<IRG1" 4)GI]>_5!>L]@V.$P;';8#HIJT# PF?5XJ.%@
M..>,87#B*E-L2L'TN&/@2#CGDIT#,>$3,G,7C.@==1/T5IK//3"B[, M,'MS
MYBH4U7MR\_)Y)?%JOJNZ\5,>ON-5I^-_:UI\]P->%Y@7(8U0 ;!0<P?3(E3:
M-0:H"'DJHA EN7G3DAD0]ZRCOVP;2W\M5"_T?ZO[QNAL6RE[[[D=X#'_&&WC
MW2T*%)$$ 5I Z>%%G )2* \O1Q$EG&0)*LRB_&]J?Z>$^EIP?X$]-/#AWLJ^
MO);CUM(2#(CIPI$;2<[>K>NV?C=2_0V4'EGNPFM7()FB_=<H1++<#&?U2+;P
M[4R-WJ/[1[GYWL]";IIJJ'G(W0S.ER;K;Y]P!$621HP7("XB!F#!." X3D 4
MASD->59@8C2:W0('W^FG@^S('KN^3MSP"MF&P7I*WS/;S/3WCDM-8FZ/SLV>
M>PUF@W_O,+QIKCSVL72O2:83>.9(V]I@,*OBG,"B8QTX9:DW4+__M:S_]:GB
M_/-*JA"I=)O:[R**8IZ+$&19E*M!4BD@62K-ZU#D-(W2"/+TU>KWSV'L654J
MD$!(F-*B:H$&E83Z5NKWS^ZA9Z/:Q\[,;DU?JM]7A 2*DJ GY2T7\(^Q_;7-
M9VU\_QIVLRG[O1;PCP(VO*RH-HM?\)_ET_:IBQA'(0\10@E(H!J? F$"4"HB
M@&B,!>8YSO)$ZT[B>&7/JKJ#I1E!/R'[RC7"%&+,M%L'QN$XSXO(C^D(^=)
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M[@&]&G:.'15FLJ1@V/A7 TH,K H[BNP,A=&M,3OG3]$>/;H'C\]W&I_B>'#
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M<*[]\>IV>B?B#;BU<VV4GML\&S:V12]K46Y4V_H%ARBBRL87S6UBF*KI;:P
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MB!@I)U,$/*NG]_BYE/Y%$QNI.@2:*Q^V1V%B-X%K'-;31C[Y9J:/3KL0J-(
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M9"Y7*IU"3V9'R!^74C>4F\GE=:*#WQ4&#J(*U\D;*=>4+W=R2=E>'$>6G$4
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MU:BWN^?&>QHHN,^K5B/^@RM_BK/;'[S"C_SCG[RB9<V;P.0B)U$$$Q4$I(P
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M96DA]9Q9&KLW5#VKQ9UUHKI!!3^]<%R-C V<>YL, AFOSGSW(8LK$8M!4?4
M_Z'!*4EP')?PRF67$0@_B,X?:_#*\+-1!;\0/<7&+T4[SB%VNV)M5]GU<OWX
MLBL4E%:NB,-< $XC9>A&#!1%ELA_%DC /"Z2V/Q(\(NSY[-A/U(#[S%Q'/IV
ML'&.HMWS;L<;.2V:=)4!*5X*2V=D_5Q!; <8OZVXM;LM, Y5.P1M&/RH-HO[
M:JT&"]Q5WWCUHZ2\29J4YG\,L4" IV$.(,84X"2-02K=@BB$M A#HA7SN #
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MDWKVBBYH+?E#K?P-$=#/DI$__ZZ"[DK0>"M=Y1Z^8?]W78;2!$$4Y@30B.<
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MERFP"O0?+35;^/X\"<.@_(4GS+Y]QLO%+>OOJ42415&118#E"5.="B$H0B0
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MTL:SL-^+3O>+^2N>#+-LR?CY,@\*\[2$NUOQA31O11'Q1 U%)P F<0QP7$0
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MI-ZN5[G&^O.U+M<G]J"3N<%KEKU/SM["-7 ?*JE9OO,'R7W>)8"G,"F*J("
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M[$H=#Y>:KZKQ+ D'!8SGGS ?$_*SY.7R_KO<E"_;)IA,&!<"H0SD!1$ )JD
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M&HTS77IWOI#2%>P/HD?7GK70+U]YS>4;:GC\!^DA+]=-DH#\URW[P:M-64N
M9\?#+RC&",K_ U$D8F754ZF!0FF:<!XCDE.64_UT(&LTO"<%M'@UM^8#S)I_
M#W SD&)[CFNHMEGX:*;\=BR\/6+A[2$+@Q:CX/?N3YTN1BZY:Z!%9^&RG9X]
M^&#9T0>+!]Q^;C!SI8,G<V142]NO/I\>G\R! TT_?;5)\<UV;,L'+C7F4[F2
MQJUQ0SF-M5X[%JH&,4G,@CUJ5G'1R[PRBI8Z89/C&.HIAX+?W3>7,^#!U)#K
M90"O$8B]2NZ%\.SU]^PB4+MFE5T96KTH,(FR/,E!!*,"0!3FH."D  5.F$ X
M#R'1:IU[$8*1#C#OEMO,I K6N\ZGO -K%EDZY8M>'&D2M6:BO&_N^O$:B<;Q
MH8MD.(H&G:X_:^SG(GG'D9[+#TZND3X_]:"MA"VR.(I3&()$%,K/XAS@D"0
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MX"B!-(\SR+,TCR)E!F2(;>Q #ZV1]7]+4P=-VDUQ0_X*O&^:KMO9@C[@S&R
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M@GDN4O7K/!(X<R\&/R0WLK79U3RWW>RJFCX@6P8N*0H_PL[,P/A#Q,Z<'!6
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MCDXJMP)&@F14Q#B*(_.!.9=P,K(QO'L0I:B;#UHH_47(&IC'J?"R,YT-5U?
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MTF!#VR)9H0^D?B7S*;J=RIV1VB7/K_<[8IZ%X0D&M_R*&@Z^A>.Q)NLK+\)
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MNN;+)T75NF^P\8(C>Z$M'V!3N[Y-P]5ZKED2O)[RH#@#+6OFE?KFJ/5;Y]$
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M<D$()3(SO8CLI32RC6HO'S5Q^$]-'6S(@X:^^?5C/V##]X_>8+ T,\X(6%U
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MZU>Q$"697R_X-7\L%D55CX!]%I]^:KIBQCB2 :41E)&,H?I90J+^"Y,@%(E
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M]J9V]BXP72JGB1Q[J9M&#[CVM_XN[NN<IL7J&WD4LPSQ/!)1!CD* XAB=1K
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MH8:Q*[!E#2C>VL.9 #5W5V#+WQ7H<@@:%MMLR D!Y^U)I1DX^%: W^/J+;T
M\R84'A%K-@^]8KTCA%$<-LTH?-"8IF>%1S2VK2U\KNFPM;2$%,DM^9KHWX0>
MMBKX];/Z[?UN\%?]CW>B?)Q))&08HQ1*I&?+$"YUJQH)&4%1E*O7FPFC^1>7
ML3&RFUK3 3K]RL*:N6-JL'%,@I3=EK&Q3=I.[:Q6:ZDV?(&6L<X0P@;<NZG
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M!$8V;G\7I(2Z*QG4/X$/#_H*1'>RZ?0TW4U2J%O+5<W I*8%^FU9+$N@GZW
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ML:3,3<O4B';&')&Q;(\!!Z]KC\PA&K11%DNYE"\LY4HM)G3KQKIP1SD\;1I
M&D<,\SR%),J9LDV1^HFQ &*>I#SA@238*+HP0&=D^[,AW$1P6\HVF?'G >HW
M*![%M@RG;B3N$G5)&^D1W2;SWPL$CNG]IUZ^MRZ(@X+UI^:??WS"_/M!&?:3
M[(<_[N8[=4]JMV6Q8,43F;?!V6J&J.0!32CD--<-=8(8TC".8$[4'PF-,YG%
MFV$Y=^;.4B]1HR_G_EB<.Y> 94M6)]0W'?B5KLHVTC+7G%EZ1OU(FOE EP-S
MT;CH=F;Q#IL-:7\^C9&$GKR7?EJ3^BE&8A]Z)&8/.7:L)T_%BLSK-M*\:9*O
MSF*ZR31_OUY]6Z[^+E:WI."S2 H2I3*%:41#B!@F$,<Z:9:1. QYRG*[GJ:F
MA,>^L%"_?]!*KK/%GT[>7NCT>G)1V8TQR&;680SH[ Q%RP'HL@ V/ "U+0'%
M!7A1)T[-A\<&]):2^VHW;TIVVN;REF <M9*W?=XA!>W^?G6[J!;7_!_5CV?V
MH5K9]1L]]_S8"6CW]V7M48!;L:CJ1(AM8F0%?HCRN6#:NZ\,+\IZH>C7>5\H
MV.FW.0">^W0.B>J6E79NT>F2T@;$VLM)&_JLYVR(NE?ZRRX[DLLPR;E$,.>I
MA(B0!!(A4ABCD 9YAE/E\7O):3@@/&5FPI8'3Q?=AQB:[>-C(&.GYP.=\1H^
MP)_MGUZ34%U!&/O^]Y#LV[C%/0.&\5WLN>?MMW2=TW5=IV'.7[1W\$<S;^LW
M=3A1'H1UCKGA<B,;A_VDQY:=VG<%S]6_M3/Y6I[,MWQ3J(8]@!%0LG3X+0 :
M(5O=4GZW@?6&-*8;3V\G]-XP>LM'+[BW^"'N.Y6+* UI%&499$(7V@><0THP
MA@G.8H;S"'-LT5;I%(F);BL<HO3[2%C<33C+YW@MT=*[Y$9B7U:'RPAGF2^\
MAVCI^KZ"."F.T>W#_I/37SR<Y/SDG</I3SH6R+ 'P=?;AD'O7S[,2=6._ IB
MS(C(,YBP)%8VA"8PEV$ A8BHC'&8!&%@5?)RGM;8QJ2E7+>QJCMUO'\!-76[
M86DFJ)D=.3QA86EXFMY>C>";7E^#"-C7B0S+YJORHX?2M+4<PR(?56<8/.*F
MTU\+0HMY/<JHG5(Y8XRDH0@XS&@40L1I '$<29C'B%)$PD@0JQ3[8Q)6&NR8
M$@]8.X=UOB-OI[@GH#'3U\L$ME/3#BVEK TU?]IY7A)/2GF"P*2Z>%[ 0Q7L
M^:3]>?R/:K6X_[@Z.7CG>J$\_]W\';O8N_7"(V^F?^A4J\7]X:#[\S.G=##K
MCV:8U,'X*?,CO#VZPX?Y48&U4WF/F'J^"' &R>GL;T]MLBB ,Q#=>(#[(FZN
MP-^$+O80_%I]/\B]:'H1;_J =IJ];T=YQB+(. D9I(G$NI"2*Q^!!# @,A(L
M9B+,(AN?WY:!D6W71[%8/A8+_7VW'(MJC:297S$F/G8F:,,):%D!N\;5;>??
M#CM7X&,Q7]?C 4>8BNH*BB<'QIK\I.Z-*SB'SH_S.HY#(!Z?YLL7(=H[Z].#
M*KXMVZF3S6Y7._W=?]<7W4T^Q'?!EO<+/76O/CVU72IFC,29#!&"4<QCB/(X
M@U3J3.TL2T6>(,*15<AB$JY'MGF_+\HM6=VN='=_P'3>0"F: M75$JPW,S^;
M;J;+_=8?E@,H)GG?9D;VS;U%R[#-J6X?NRX.5V#+^OXHH:LF,623 ;9C^TH7
M'Z]]'BHG1=C7P(Y)>)YV ,B4K^%HH,BDQ-UVH::0:!9*B4F.$AADD8 ()R',
M)190!%&8(H1QF@F;<%BS["0A,)?QD:W49L;27A8[:W;=+X"UZ=GGUY-M:!>=
M5'GW!3G4KH-_=4PRUYSH]EU:E[X7U3\_E((7*_W3+$&8YH'NPYSI%CHLCR'F
M-(*8R3"+8Z+4PBK=K(?6Z$DD'<J6JM*'D)G^>)+;3JGVB )-2VW^-=WV+U-D
MD!E([BL/O(?2M*G?PR(?97L;/.*2!N(Z^:^)+WY9J%->?9_?9*C</9!%N^76
MG_J@]^U29R#__J2690^%>*Z7W3\WWHJR_OA,1JF($A3  ,4(HD@*;4A2&+(\
MS+(XBKC9_-4W*-O(UJN-]Y*Z#2G;L@9*'1I>;8?)ZZZ+S8^&;1??())&N3EO
MBN-I#GEG6S^^[V_]V'QS.B*W^8!:Z-UXV:;![4YPH"4''=&O-J&_W= O/9JQ
M?NY?][MFDQOUICB?("GK7_R[9YDJ]B;?;G^.VMMB><+DN+<E^,FLO+?)X@7]
MLD<1IKZXKKYL6C9+GO)4" PIH@0BH7N]T11#F05(ZCM(87?:G(KQD9V_S?6^
MM7<W^0LT.PR_Q=<R@E\VT)+[W-ZXVML;&XET.L<HC;LG? L^^WI/P?;T;;\G
M?!DGNX)/2=^Q3+9MJW&WO&:*<"G.EM3-*&*$Y&$,99BE$&4TASD+):0Q2<(T
MB[A(@DU3'+/=Q)RXD>'9;XYCMR,8],6PK)TU!];,QGL&RZU^=M,S:+4$+1>@
MOY&SQ\)9:_E]E<Z:$YZV>-8:D*/R6?L5W*Q,;<(Z:<#?EHLVQWQ&*9<$80*3
M1.JN]$QYJ#G-8"9%&C*6<DRL1@J<)S6R3]GX&O-N4OE\N;B'>GB+G>GH0<O,
M5/C!P,XT-.+OY=3OR/JS L.B>=+Z'D*3:OFPP(=:;?"$?=K]9\7_<B%TMH Z
M)[]\7(N[Y1_%<EY[-3?R/Y>/XH/.=2E?OI*_KA]7IEGWMNN.K,0M.V###^#K
M^C9@RY)V#S13H.4**+8&\WPN1[-?[\<&TLX2C(.A53:]*QA.R?36Q";+I7>%
MH9M*[[R&FZ?PO>GB_UT\DF)1+.[5(4<NR\=Z<C:=%_<U6=W"B^G^E_7TP!OY
M0_VVDH3I?_M:+,27E7BL9HP)0=(,0\F#5&=:1!!SCF'&(XKSG" BC6KS_;,V
MLA%K&05;3D&'5;#C%6R8W8QAU)<!'7[!GYIC4+-L6;GK\36:N3RO\W+L#&/+
MX]7@B[DZ>C-+ES=C[5SY!]&3,^:1L4F=-_^ 'CI[(U!PS7E[?"R:AGGJX*C[
M-2M28L&4 SJC@E'.HAS&04XADA3#'$D&XS#+\S1+F8RLAD[TT!H]YVU+N8YS
ML"YM\.Z;GA6=6MXE]"%G9OP\X6%GS0ZAV"/K,]MM4#9OV6[G*4V<[38H\G&V
MV_ C/J\JFU"T(O6ESK(KGH4.&55-VN,,I['$<11"'O $(IJE, ^8^@_-LSC*
M),(QNOS6L9>'D>U G2M_XKK*QRUB/[:77 AZ0\S];N]$8<VXV;(7(#'J_5H_
M!V_@JLP((K-;+[.E' L>Z^NRW\3J8:F6UT4OM17<#9/?]1U$*:6""P))BHDZ
M$$84DCBD,,YY&##*6!19'0C-24^3R]KAP;*(T!Q#,_,S#C)V5J<%I6&BBTWM
MK?S7LE"6YP_U][J7^XXSS]T<W1'Q57YG3GC:&CIK0(X*X>Q7N+1YVR<IU4%*
MV:]F?M\=^?F=K.K8F'*UYLTPS[JUU$YA,I%PG) (1H1AB*(L@50Y1S ,$"$\
MP)1+.U_H F;&=HHV[=^6$NRSH7_3<%D/EJM;\.LIOD]/:@?0+((?*[):*Q5Z
MZ7Y.RU/?-6]%/?Q7UWYR#B_2T/&:Z/58>F"=-W,6R\-WUC2L&\DK\P"3]^9V
M#JR\4O<[=]#.M\>[8$W[Z\2[DJL3P)THZRXQ:F7=D<GTSO#DPR/;M@ZUNGN4
M^5W?:5&'+_0NEM+.1-R51+<AV3N8&0MM=3G7*YC3#=SI%2>[9NL5J'N7UO]!
M-^?D_;HJ%J*J/HJ*E<7FH*6.8$5U(V_5"]^4J>QVLCR/:)@*#*4D*424(9BG
M00PEB8,DR"C-&;%Q2>Q9&%E9.XSH'6_#GYVSX "LF8LP+EQV6K_A!70AT^>C
MFAT-7I>AD<Y&[H!X<@$<&)ATXW<'Z'"[OV"E2\].WYL&2+>D7+VHS691-?=/
MU?N7O7^IFSLC%H=9(B(8)J&R4!'6<_?2&%**6<ARCL/ L26V!1=3G99N]&FI
M:0Y5$P==OG0]X/Z_7MA)V^8UV!YY1@+7]I;]#)9C=N!VD-S[\<6&AU<ZMSC
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MC&V:D2[8G-^6= CV28/2)3W3_%>%X08+SGR:\(3!%.%$*/-0*/-(7+@8C8+
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M\GU/KSA;HN^H0/T,W_$'A_92'_6/XJ=__:/]C?A#NB?^]8__!U!+ P04
M"  Y@5I:N29?>^JR  "J;@@ %0   '-D9W(M,C R-#$R,S%?<')E+GAM;.2]
MV7:;29(F>%]/$9-S.Y;A^U*GJOIHB<C2M"*D(RDJN^<&QQ=S"9T@H 9 A51/
M/^8 =X(D"/C/WUF=59DB*0INR^?F9N;F9O_RW[Z?S'[ZALO5=#'_U[_PO[*_
M_(3SM,C3^>=__<L?GWX%]Y?_]F__]$__\G\!_(^7'][^]'J13D]POO[IU1+#
M&O-/?T[77WY:?\&?_KY8_F/Z+?ST?A;69;$\ ?BWS3][M?CZ8SG]_&7]DV!"
MG__:^=\N_]ED;2,:"06+ !40(>CH( 5K>73&6X?_S^=_MDP)+V,!YCG]&BH%
MT;( J(I52ML<F=A\Z&PZ_\<_U_^)884_$7OSU>;;?_W+E_7ZZS___/.??_[Y
MU^]Q.?OK8OGY9\&8_/G\M_]R]NO?;_W^GW+SV]Q[__/F;R]^=37=]8OTL?SG
M__';VX_I"YX$F,Y7ZS!/=8'5])]7FQ^^7:2PWDC]0;I^NO,WZG=P_FM0?P0D
M'<G_^GV5__)O__333UMQ+!<S_(#EI_KG'Q_>7%N2J%EN](W+OZ;%R<_U=WY^
MM2!,$+6;?[W^\17_]2^KZ<G7&9[_[,L2"_TL?U[2JD)QL5WS_][^PY\OE_ZZ
MQ!7A9</J6_K!V;^OJQQ$!GY?XSSCEKOS16:+=.V79E6VBXM_.0L19YN?3C).
M)YM/?1%7ZV5(ZXF*4BHF#?@0"5C1$?Z$29"+E2XK9;UTU[FN5*^([(TJ5IC^
M^GGQ[6?ZX)^K).H7&Y%LQ'%KN:UH#J/[?.^]F=?]M9'HIQ!G.-&H30DVD^*S
MH2VD$GC-(A2=$\^V&!_342S<M?)U;JZJ^L4R_;189ER243E?.BS3+;5?A_/9
M;_S\-2SI@R!]F<[R^;\NR\5)"QVN%XTENE4=D?Z7GT@"!9=+S&^WFKN3T0V7
M:S*[N/G-0U%QNH+/(7R=?"2A8V7DU2RL5N_*Q_4B_>/%]^EJDHR7)G@-(@DD
MR9!X@G/$ET(16?*<Z7P/-$I8Q0W59RMM\8&S]>K\)Y= >9"8\=#21L^+(83>
M 7JNTO]Z<1*F\TGFP20F WB1'"@G&+AH&*28BI?HLY7W691#8'.;BG'PTEB]
MBZ:R[@$MBY.3Q7S#P&]X$G$Y48P7GV@36<83J!P\65^.Q$\I64IN@FMM8VX1
M,2Y6CM7J39 <)>(1,5+]P<G;Z<F4(H/;3'BAI)0E I=!@RHZ@G/D^*.+*0>N
M;$GZ(?_RWA7V H'H' 3M9#@B$.XX="D P#=D55<3%JS!P#4@(Q:4(J&X$CF=
MPUY;F]"KR%J[K!>KCX.3YHY(4R%W I9/]+N3(BGPM][2CE$!%+GVX$VA;2-"
M5FAM-JXT 4==K2NO]$#=[0#$HP79"0!>S.>G8?8!ORZ6ZXGV)O#")11NB8FD
M+,2("B3S068TPG'5! A75^W*.K0#Q,&"[008[W$Y7>1?YODU^>43XY YC@8R
M,P444X+LI45 E57BFI@QV 09UY;="QKRV4'C<-&.C(U7I\LJN%^GJQ1F_Q/#
M\IR'2G]B.E1WBPQ?S.2"\2R &Q&U,L'D<EQ&[*Z5]T*(>C8(:2+@3@S(IV68
MKZ95+F=&T&E)@93EP++RH+34$ ,%5<G$X((E>^A-&S?CQLI[@40_&Y T$?#(
M(/EEOIZN?_PZG>'OIYM RS!F! L2!'U%_A-:<*)8T HEZA@\L_(H<-Q<<2]0
MF&<#BJ,$V@48/N#G:;U?F*]_#R=D\01J)DJ&4!TE932#H(N'8-!K^H^WC#<
MQ/55]P*%?6:@.$*P70#CS3PMEF3@-D+9I(E?+4[GZ^6/5XM,[A/*("BZ@D2
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MV&4=<IU?8B+Y]$I[4%9R"(FPP&U4)@4>C6A=C?403<<7L>_^_)T):F-809Y
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M\_:]ULG7T_59L'U3*E<D((Q$S!*JD$%)+X%DXH&3^Z106>N;OR1IS\6X$>7
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M.%B=7UU&I2*C\QW1; K1$")R"[)XHTTQON!>!<7[X>0V >,5;!ROT]L .5+
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MASGMU-,!QG:=,VZ%<MGR"(%A[5V</01I+5C!@E>I.'7_COGP*42[D3AN^-T
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M$Z_@VA,J\^/JK6=H7B=U:\:N53&Q*7'I6!V1A!J4$8)< 'J(JD1,6122Z<'
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M,2E9RLM0Q4#(JLUOE*8T+<C,'6$LBQ/M(O=\9^182O8NU*EYE)BB">"\IG0
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M*$"WQ<A4C.6R=<N,[:D;N>72<2%XL'I.XP*W]5#:;3]Z@$O2HP^=?;84E_/
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M'$[';=/Y=[3  Y#VJNWQ;OX\*;)XCMR I6P85**0(#J.E"-;G7TJD=+DD['
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MP96D6_N'7NYI7BP=?'+PYGK[8L4Z#(:3&=I:X" UV7P(8*S+S)A4I!CN;N9
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M@PV$H@>E)NV5U$'F]8GTM#H%>WL6ELOW914QO?EKNIPH&UG*RH'VQ5 :0!E
MB,Z DSECD<([V_Q5XU/$C-P,;@#-/QB3T$(-'>#I-OT_SFOI^L1ZS7R5BTN.
M@\JR-HVS!:Q"C5[RPE7KP1T/J1@906W4.V\JZP[0\@D7Y)Y_^'"U_(J5WW#5
M:-<I5&@C.>=8&^VJ9*#6S$(IRCFNA4!L7N#\-#GCXN=03=_W-HW$W@&";N7Y
M&P:,Y>B5D""L)L%@RE#+FD%K6YA*)?/4NE;L 1'C7K\U1LMA(AX1(QFGDS=Y
ML2%:\XQ1F0C9"H1:Q0/>2P0;DU:Y:!OC<_YDB>E__3G_]A_TH6M(T!<W2+BS
MU+BW#(VTO[_P.O *:P?W]E$'%P6R5'P"+Z,'57OQA:@]9-IQ8R%DZ])\CMC3
MY(Q[KS#(OG*XV#M T,_369BE:3A[-Z/<\7)5,E#CM6!L\BQI()FL!G1X\*Q.
M ]!:J$A;9N&MHY(G2!FY&>_P.5$+%72 I,^+,%O2RG7X/!G(MVF:SOY\7Q[A
M;OF9/G+Y^(\VUNDD6:4H!1BWD:P3)3A3%$27K/&JD'MNW>.A)?WC1M%- #7O
M1+MCO^C^?7H>+Y>?O^ B?,7+BVE:_OKKVXVOSUZE6,>C^*PEY1!6@Q<R@DW6
M)9.-U^I>P=$3C[*?661<*(VG]OD .M@;2]]P$><MT/3;?/'URS3][_G9^M%J
MVG 1I&2>8 ')N0#*& -!Z0!&23+1F.L+O:V0],0"XVZB?:"HA>S']D9O_CO\
M==L.;KB0R?KLM .RA7KD+PH$;SPP&U1"C&A#V@I!3RXQ;KK7!X;:R']L%'TB
M<:3:.?HV*QL^5,I!YYQ V?HJ2%;1E,2A((4**#@%LWHK'#VSR+C)8!](:J6#
M,;&TN'@Q/WKX7<3?PSFN E*;K14Z("13R&9$S9I2DA2?D@P#*Y'A5E=O1,BM
M")_^=A/='TKCR",GALL^CZJ\D4'Z%!\;&R[<.:^< ZSG?<I*1\&DE6"]E\YH
M#'R[%ADOP/!Y*D;J#7-4%,P'44G7NVFQ7'LIZXL;1U%!".!D3!"$T$GZ'(HN
M1]E-!T%.2R5NO3?N(-$.3L5NC(O"CIIWW*K6F>7W%\3@Y@=OEDN\6/XZG>&[
M"SROS[-]U-:1%U=5>IDYB(5Y8AF3$59IS+B-5]JK"FI'8D>>_'*$NI6CJ+$#
MO-XO*?O/*<GR\N(C$G-GWW]$6NF<HF&2Y\]ANEBW EM7L4HL(CC!(=<_5.WH
M&FP4X)G+*CKBU;=^?;<WL;W460T*IOO/8(ZBV0XA_/.WWZ=_S!88SJ;_POP+
M[4RK]A<L"VEK1]'D*;525I L:?. +%T6V?F86.O[T>THZ^7":TQP-M!9ITC\
M>)\G[C/1G>NDO") .4/;DG&B]BL,.GKNHVP]2G4;NGI)?,=&X4'Z&O7"X8JK
M#XMY0LS+^ASE4[@)D^[R.;&I!)4HDQ.!25!))7#"<N"N)G@Z) JZ&^-P.\IZ
M"2Z/B<0!=-:I/[RV*ZL5VF(,H*!$4;EH*3PW$G@R7O!L>)"M*TZ>HV?D67G=
M^+^]]-.%WWO48I0QS%L2"D^B@*)H @)7#D+,A0>M,V>MWQ;M[=.&&_W6#;IV
MTL?8!WU7/4QNZOY674P^7"[2E]IR9Q*M*J$><P6E=+VW81"U()], 8.UB,33
MBR\?MUIIW&;[QX5/>]%WL!->-8?^/'^3R"P6^*AQ.&6ST8%!$4A,H>?@78BU
M7Y-7R)+.KG45W%:$C=N&>Z2(K+G&^H7A@P/4"?/&^F@<2)-MK9:N]<T>(:!V
M1=BD*/DY#A(?T+85&/W? HR'Z:T'/-ZIJ'\[)TX6%]-XANLOE[79?E7M),N0
MLHZ2_'OM3*9DALB# \^*3YXD*E7KWJ[;TK;=V3)[98 <0G&]Q'OW8PU#X82S
M08(0EIR\<F14EED02!]@0M3Q_K;\0IBW3W3'7\GU1#-)CXV6-^>XJ),'?L2O
M\^64?O'[/6Y6DW"O6K],,#+IE"[ K"<).>+*>2; 4OA0-$O.L2WK-7=:=SML
MO9+;A:'UTL&.>;OSUSH(^'U^@:OO?OIZ-KVXYW_YQ!F/V68!2F=&_.E$P4 -
M6)7A1?#,N&P^#VA'&K?#Z"N[>QA4D3UWC3K_>C;_CO@#SK!,+SZ<54O=OV_4
MTY_6K'/4E@0WZAUU9][3+'_$B^FZ#?3--*KKMC],!I^C\(!2$22XB!!5X9 ]
M^3'EK7"L=;?Y'<@[U-7]2.*>U8Z'LW5#1%JQ"G^CC\5OX8(,>S,_].KGN$A$
MRT0EBB-*BN LRR281+:2ZF&1='5(75'.MSY(V9_:D5MP#(2W^_[N2-KL8(O>
MG]/W9?7#B0W1&$:["5JF0'EN2,YU<$O4+ K'4RRM2P0.)GKDUB#=HW@?W?8+
MYCK[\".F^9^S6BLQH6!9V\(YX<K6(ETM(%"V!C8H96HHY$+K+H9;$39RQY)Q
M07F CCJ.'S?#-S^$Q<7WU<LNDE[M6WQ $/G21[:*)'<BO5$X^=2:U\##XC,K
M"0&Y)7\42IT1PC/(;+F,P3";6L>0+]'4K@;_J95^^'[G)ZMR<1,LTUD4,+K:
M!Y8"GCL!-A?&?<E"I>:)\CZ$CALN-L73TU7W0RFN@QUU.]96CZVT]E&GI("S
M.H4E!X28B+-B160AT0]EZVUU>^IZJ:D?#"KSH^BM,T1NGG(QM$[7<3R<<015
MI <7DP!=7W)YZZW,K9WA0RKZ]'2'ZOL96.TA_)%?VOY($6VB'V\>ZS&%PB=$
MXKR./,^RMM/3"@I%M39XCW&[P^877M;>7;4?F.RCOWD387;F1:XX0,-X2;6Z
M3Y(@M'#@K;84$+!D8M&YY"%CRQY:X32"1R,AC^PM/M;1A.OVT*8(A3& "9A!
M"<,@UHM>SUG2P05A5(M.$-<+]O+&:NA@97\I]P"-JU;-,NLBT1+9AAAG/H/C
M.H&0";6V,;$06X%C["?U>RKKOKKWD-S("O]M.IN>7YYO""^V9&-K":5+B9AW
M!F*N3UP,3]'[S+W;ZO'["RJ_L^C(2M]'9?,6\AM9\6_K&V-<?*V.[KJM"/<!
M+=%81XT2U8%V,A=\@ABL]L:7H%@+DW]L[5X>/AYC:SA8]F/O$OAU4\7SYL\%
MKB=/W&/IJMVS$%E99@"QCI<UIO;I2@9$,(8';:3'K8:FO;2';$O0>,[F<)W/
MAU; V*5\/TS/SM[,\F](/\WA%S*VY<_$55[IY_/B<GEQU7Q4VI3)6T/TU=<J
MF8!V9@Y>)9T9&:2\/S/]B2*^;5<<<8\:1M/SH<4^-I96;/R#I'5)RKII6QN$
M,EFF6EP8(Z@8%02N)3#F=8HB$'MN*^0\_OGCY#='PDD#D8Z\;WU8S/-ENGB_
M6/>?7/M@GYA6FCLH0O@ZC]A 2*9.;I.*J1A2"2UBWL?6[N6)_3%BGH-EWP=V
M;KJ7XE4OTJ!S;0%@P$A%&:.DG3RFB(!.!A0\)'G_^>DA 'I(P'B;T^$Z?0B0
M P4\]K[SX^+RSUI7,O^&B^^W2T&NO*531@OD$*,D[TL.DB(^I\ ID@]Y9&UU
MW&H#>F&AT4%QJ![G PEU;(!\FI>+?]9AWP_9L!E9JL<%%/G7^O)BR7*"!N&L
M=%H[2[G"5MAX>HWQ I0!8-%(E)U=VMS:@'^]?N*0E6<,O8643 !%L14$;Q6@
MC<RR_]O>M?7&C2OI]_TOW-5=XLL"'<?)"4[&-F(GP#P9%$EU=$8M>22U$__[
M)=47N[O5:EU**0XVP&"0.$FQZON*);)8+"8B<!ETE[]+.IG2J06Y\& <1^;Z
MW*;Y8-7<PMG][%$D/&:Q'Q++2YJ\9D)BW7W8$=;F:%WM 7Z-^[6I9\[)\W2_
MZ.=TDTDRPO^>9;Z6NM56$\"5%;HWYM6ZJHN5+*]_\FR]N^VE_A,/[.>C*R//
M2V*?!$GB$4\H4&-&+>):MA=ZB>"N#7W_?(2:YAQUS^"/\Y)F1 >KK9$W17W.
MSD>:^(X;.C&A4>RJN483$D5JZ@DK$H+&8< M^)+ 2UKA'J'\"K^#HL2(\%>I
M12M7B%VQ2EE1:HP?$ZHVS%9 B10LUACYA(6>;JK$;.:%KA6%T#?F6A7!S4S-
M[$I3@3=Q"[F=(&\NF@0\I($C$Z)L4?/!<BB)A$M)3 .U-J"!B%B_=AF]AL/=
M#<SB,#-A;4#L67#>K!^5!3)]UCNC&UGO9H(3V+$=Z-XP;FBK."HB-0E"91IW
MA6/[B>M)Z%N/7?K@MFR<-1*!T8#_P.+V=B5;J@WYMZ(^Z-[PR.R$NS$/"%-S
M02\ .:'<41A)FDA?,N%:3J](U#4*;F_&^0(0&+(&7R:\ETM]8/E%/A6EMG A
M1*K%ZI??DJ)<-6-,N%DX2#[4-</Q1@'=.3Q18'<W+$I$$@6.3RS!U-=*[</T
MJ^D^<0(:,/4KYCJ]JKR&7+$[H\O4+]FN@]5&L ZAVY&JQT (7P@[4#-.Z+0R
M980&?D0"S[-8PI5[,^C&ZN>U0;ZE!>$)QU\O(.C_06'I?KU:L?*E>/LPY7XF
M_U![4;6U>)*\KHM33 "C%X0:<P4Y<(CFCH4T#%TI;(]XGK[PKW> S&4^B4/7
MII[PDL"#7NW.%0M?CT2.1WC#P;N7[1]N#D3\B#*UMPU(%$2Z3#D*260QAPC?
M#FQ.8YM'T G5$6H:&CV'^,[Y.];SD&7 +O->4=04HKU;5VH=7%6[B=Z4B22Q
M[S+>]!!2'PI/<$&HYSKJMY&C7W-)I /]>>Y4R)1[U#.YPTG;.RAN3'"TC>[;
M<@(9AKXO."61[ZK%!U?K#JI6,T0RV],'_RQQ>MUI&Q[13;@N#4CLL<N,1MF4
M?.G6@EW1$(]=*U$SQPU\7;>J%L"4>0E1<R>PU$2*HKYOQ+:)-^*3-8:KMN3G
M>."PJ3^H'#LTPXVBV+:BA#A214Y/!@F)6)(0;MF,28=:]G&<Z%.)-]P)YKON
M"N,$0!":\YUH^[2^)NI\[G 11#Z1H=]<"[>539ZCW]_T8M=);&_V#4&;7J;<
MG/Y%RQ-HILSVONV!TGYCH6)J3"V?$CMF^@ZR$Q+F,)O$D8@=]:&. P^\!U9O
M[8SXL@%Z1G_7FT*3 0XXIG;'5MBIC[HD2>Q1%>$ETR^_VL0*A"<<J6)_#-\Z
M9)Z"*PR7G.0Q *570^@SHO1*-\O4*>5#V%Q![8 )M;H($_U:G9K9L64E1'J1
M7G1$U)(<V M;%3%B/3=?Z)L.OGD^],A\QW$LWU<;7=W8(;!T8P<O(J%>GE*?
MBN#XP0]8W\%N*SZ9TBXG&82N$<[QL2RJZJXLDK1^C<JAG0B9,&)'#M?/FP>$
M2MLCN@2#TX1ZG$-?KFA1 [D!QMS!92KP!BR@WICP*"E-+,[TP\^1T "H+VML
M.^K#3IV01<R7WHP^@QM4)E-YWC4&X8J=7/J:LZSY*U+L<4ALD7#IAX1[E@J(
MG'I$!<&8N#;G%G65"?0H?7 FJ]0B'/FZ^%P1 @1+ \+#%\6'4N#[(A?OU><Q
M*YXT7M<_=?-Y^1CRP!=<J"]MDP[A@<Z:.A$)?$E9:.DV4;UNB0^K[#ZO$-(%
M81"N3RNZ@8 ?[D5TXT6Y7&IS@!)%6:;W<;GX@Y5_23W7=K8$OF?[?L1(V$PO
MSU$HT>9%ED"XL5JZ>0)Z,7M>&Z2[Q'-X$!#D1KC/1YG+DNF./@NQ2O-4PU.G
MSW)G$ W=V+5<0;BKN_A8'B,T"BD)6.CSQ.<!3Z!3.A=4PEGYSN)(D. ;X4V?
M<EZLY&>U0-.)IW/O'8O 5L!02ES!U20):*#F![.)C!T_C$/?X^#O O=2#&?%
M-(MGP1-AP)*I[3'WCRS-M9F/86!9L>]1PFQ=K& Y":$Q#PD33A+(.!#2Z]4[
M<(!3=>F#<\-I%E\"@]T %VH>!KTI\N))ZE"K]R5ZHNP"KJ2.0ZG+21#H>WV^
M/H4,N"#2]ZW$"FCHQ="1J5LCG/M,L[@1(/0&.-)&^0?V<ZO_]J'1Q]AR.;42
M22([H*3IG*=[*1 [#J2?"$L(!MW[XHPJ.%><9OR:30/;B/71)FW5!,[(HDE@
MATP%SMA3>$C]:CIW=:\9998?NSV;Z0]PE-?1D;OQS)T]'@GS^+!2U"S[M9=+
MMB4VQ>YLI8I?/LIB6;*G[RE?E))!7B'I/=AL%T7&F3OW=1"A]O2A='P2.@G5
MMVXE8>K+13RA/F*NQZ3GP2=8YKX.LD.XV3@H $L5S'=E [H?V^<B7WY6FU2Q
M>5A]6[[E\H@ZL:_6?5P_(&>%)):!0UR'>9PY(F1LSG?XAFML5A'(*(_J>HAO
M9@J1NZONR]9?8P#+FI)U]6%0"PTW(7$8Z1-FA23S=/&Q8(G+7,=/@E[IJ@O=
M5<\J8,J]D/D]H("F ]NG-E/RK0G;6NC(XPY5RNJ"A5 M(4*UQ:7*)DXCQU*(
M,1E#/'-Q5@&\YJQ Q!;0*".Z2M.#HWQY_'K_Z,241DQM/+CO*(VI8+HNQB*,
MN8%KR2#@G:U/*LG_>UD\_\]6XL8UMK]Y]8S7\1#= (:T8A*"V,?WB[O%KH=]
M(B,6.U9,>!)9ZB/-E=4L47$RIJ&P',NW+??2&OM()EZG75ARIT!E0%;G^H_K
MQ?XA1Z6HM"F1D</TO:68L""(2!#X-!+2HM2'3N2\CHYTQ@7N#A-Q-< C;HK\
M:[6[P,1HG/@*@83Z:G&>J$@5A79,+)O;5DP]/Z3011EOAD<ZG9K-)\8B:X!3
M#%Q=OR:UW$"R./0\PJ6GG)][ :&<"Q*[RD"'18&: N!E/>-T->4*V2_;R?Q2
M<LUQXD$W1!S+$YY:IQ'73O0A#7<)H]0A01AQQITP#"TVC__^<R[X_!K_ ;CN
M,X1,P&K\T<GQ@UV3Y&(SP.('*\5#NE+&Z7O'65&MRZ-O15O6NW4KIH5N7%+!
MOO?$]A$&IKI'*S\QAZV&>MR,LFJ&>(WO8^$X+W%D0'HK\(_\*=5"'Y39[]0?
M_@6BYJE4E AQD8O=K.Z%".(GY$"_IJH(F*\CF2A+D7%LM:-A"%=W:MBZ7.7B
M0\:6($P=2D39M8[BJ14)0UC2,_XJKT0)1].12)2=Y.CH=XJ%(43]J_CQJA]L
M!#PC&J5L8Q1QW=@@$[C_IJ8K*3X4Y56Q>OK&LLG3K4LN2B'?(.IZH&+"Q*NN
MU#)9/A1[=?6.'W#V79"/4E4W? KV0\E8/F>BL1=[D:'L&4+:IURDSZE8;PL>
MIA!U) IW4]:->7$) .RIE&6O>NU.#"9-HC:!: R=P;SH!X !V=;-_%=_^<*D
M&?4@RH%LW,URKUG4"8H!9-U_5\:^8Y44>@TD\VJ+7\GR95,/4[U[>?T[=^Q%
M_ZPQYM6B7-QE++]A*[FMXH'E?!854?/F[<YP7.,X(S,&.-[UZBDK7J2\K]4B
M[?;IS4O,P)4&9\?!K5^<D]WCDH1+4!O@#HUNBR<U/$\W'>+2Y?>ZNE]\N9_%
M+2Z/AWLH_ O=HS?TV.N^MH^N6@AI"^$W43O!?=R SK;&&+V-.L+%!.J^YJ+,
M7MZ\TK58U=-Y:Y7:*[1;^*QU06("9=<_2WY7IAQ@?KV*ZD6. 2>2)\:;P,A'
M]06HW[-:?F!I^8UE:P!J6F3VXLB <\CS<""3=3BS7_[XJVY<Z>I[OKSCT\+>
M!=&]J,,]FNP'#OX#:.V5+-=E<UXP4PG.J720\IL+2@.4WNA7?_5+"+?)R5@G
MSC#*[WL-,&'*;J7NAIF>G&\5B)97',+/V\G:!0MRD-4OEF^O;>EOP.0D?9L\
M-+XZ<2]Z@?#_^OADEM5)7U)^'YS\/C@9Q,U-D=_( H*40TEX!XU=6!<7##?H
MNR*5R%6:;QZE5C\$^\"<"$8+:F-7!GU@P@YYRV6]-6IRMNE0%%H!Z%BVVJ%
MYF>G4,ZRERJM8&J;S@I%*P:=N/8^"P\R>_?U7W<EORT?JO*ZJM--7RO(*OE>
M Z!5BHYE=0ALR S?KFL5X_/F/A5<*#TO%:UT="R7%P$RYP-X4]1_ROV76D*5
M<?<9 *V2%.!C>1$V9(8_**%%+G>60AR(GA&)5E$ZEL5N:,SB[?U:/A3;II_*
M3MTGDC=+ZZG!=L@X:(?=0 SW =% VK^E1=; ?)O\JUC)JTW;H,_LQQS<=PZ&
M=W .Z0%]\#30#93%?Z]9EB8IWVK_P'YN&P!/+I88-2#>43VD._3%U2R74&$L
M8_E6X4^K)]WH0!D0IUE:O\"LW<:-B%<; .04PY U9P<&N<3K$(M70 "P"3-S
MK=>B(/ ^^EAL+Q*-RG5=QLB@4X%"5FI?^$7^O4[+?5R!"<H#ANE%LE&IK^$8
MFEH%=/<\5P70H620ZI\.90$J?^[8R[?J3I;-TP8YE]"%/WWD3YC7"ISIM3Y[
M(6@'K@-8>#LCCZW'/A#Z*?E:/PQWI<+$LBA?)I>.M$O$H^D8[Z*G\=B)Y"P[
M5B^50$4DYP7C55]U4E$,PP69NCM9 /#T*@6SIN0RUD6'X?A%/DJE&Q ZCF7A
MW84>2,H9$'[7*O[*+\WO^L3?]8G#N!'_>2B:_?C4Z7$H":V,JFMVM!J+34"6
M[=6"F1K'XO ^ZZUP%WULQR9EN:R;6TMYE7]C:O+>KU>K3=ZJJO.'./M0E(NG
M+,[^+"$X&SP:YDKM'&,% 'P&T*YU5B96]\_\JJJ!V&T5BKFRZTEB%QC8FQ]H
MGD9S-,]$NX1^T0\*0UBZ*TMPHHYEXLVG$5R= 00[2_=W_;+X48I*JPA 59L\
MO [+O<)>!P2FD#/S<F3(.'AYO Z:VMC\QZQ!#@S3CUXLU0KJRU-9BU,3H&=H
MO^'P+FD.Y'PP@LC4_UE>Y^*#;G=QF^R-^%CF6O&KYU+\6>JS=)$O%[GXFC]7
MM0!P@-&#FC'UA_%;P(&-["MZ>_4IW^I_K.FQ/6JQ\6<)\3T?/ZH906.TMTR&
M&]E=OBD#E^_K5G]7=J@_WKL]@)L,'PUM40CC'J/A-2>*+*K;9&O&;=)X\-X,
M8.\8/2C:-4_P&#(*;.PRYIWB&WUS<?K=W 2^#YEH;+LJ<E&]+]4OH#P'2 6T
MBZ4P?@1+!+)7O7\6HKHM;^OOY;72L+H3M_G>FIM:__Q']27)N#;KH<XT0/IA
M#RB7@A@?[7(KC#\!4H#]*(YDNBYN\E'F6SEH'YVN@\P60[$3O5MM86JE3Z7A
M55M,*[\T[=K)57$O,\EK*;8^-/G&2;M$O//_<7QUXH)=7J94$?M:K-LD2;F2
M^R&'F6N7I>.%P'%<]L8+.V9*67XLB_73IZI: S+:)1=M[3LVCE[&"#NB?M>]
M^\5>42@6N^2BK3C'1M?+&*'/Q>*AJ%D&<7WO6!9:EY31<ZX5"WR&%KQ>LRQ[
MN6.I "*J321:/Y3Q?'4@@UU3I8_<E8;-KA$H-)Z3B=;F9"1Q%[#!7G;N"OH7
MSTNPV'A6*%Z'DK&KS OP&,1>H]F;" %)8IMLO/8B %QV@&5"*-VK"AY0STK&
M:PPR):Y> @J]SF>=UB_Z:9,-E&I[LVJ><'N?)DH9J:R%8G?@4'A]0D;2/0Y*
M[&WC49CY5C4?D>;QM^]%IE#^4D/M)(<-A==B9'3N;@R4QO%_(^M/.2]60#GT
M7@/@=1H!X_H\;,8Q?))DGHOICH%Z,6Y4[F@$C,C,MX0?;?DV^05#>M\Q>O%M
M4O9I('C&3?+;^KLL9Y[?[6/THMJDQ-5 \+!G-8O7&2L_IU4->-1]7FHO.DU*
M9UT$")O T\@R-1-R1F2O:@63DEG=T*!G_G?!'Y[ 2[)[,6E2*JLG6(B4[MXG
MWR_</Q=55[W6F&?@#V7W(M&4!%8G/.BKG:.5]]3IURJP%UTF):"Z8,'N4*L7
M5-HB(,+:Y/7BRZ2$40<H)J3X05XU>RNH%T$F97G:8$!?A!232R5W,GKQ85(.
MYLAX,\J\)],QM%[5,2E-8F"9:I%_5 N7K6+O9<7+M#F& :I3O2R^%XDF)4#Z
M0X;^71*IUHMEGN4\OUH'=?Q\27HO9DW*A?0&#/NSEE?YNSRI]14BL/KC,S)[
MW0DP*2MR 1ST"H+7VU]PI0+M,GM19U(:Y (XIKX^\"FO4@7F0\F:ER?+4M=-
MZU<5CC( $Y\BZ!@&Y%V"OF8 /%)P,M2)6XQL]GM6[)0,]%[<._V2S?3G"5H%
M(G;"O<3%0<ZY PSLDX*]:I/ODAZ)0N.F$^U65@RZ7;K(LI98 M,N][Q@ [CJ
MZ)Q[$9#?G=>QYM#O+NR_N[#WYJ82R_+Q2Z&4J1?JAVW$Z+_28&\[KMW@W_Z/
M,-M"GX>VZ&'G:/RSR=#_6UNW^"O-*Y:_L 'PM_Y#S*;._2CHLA>'AB:=69?9
M@RQ7U6WR4 H586'VLQUBT9@:MDJ^# SZ6EEK!?%VZ:$DM X20W<Q+>:;0LE#
M6D_>8!Z(0FL%,9*4 P"06?FRSJ1MQ;ZMU_6B>*JE^)"QY21ZSLE$:_,PC*<+
MD. ?:,W!68=8M+X.PVB[#(P1 ;#12U\#8S5$$#P0A];384P@; /"H&#X4*[R
M&C86OA&)ULUA?"@\!<2L2 A$V'FI:(T<)L5!XVC;;1C*59HSP$AX+!&O=\.8
M:'@&#R.XNO[YE):05!T)Q.O,,(:I=C2,(.K]>J,8 $5[47A]%L:0<XR $;3<
M2[XNTSJ5U6*Y7#RS-)M\PZ=#+EZGA#&$=6+SSRB(N"NRE"L#[LJ"SU@0<3#,
M# 41Y\T +XAX.]2)CP!41K3+GW1LN!4OWHJ&VGM?EFY(\40G;X=GC3WQ0C\.
M;M/SIJBWJL+D^_N/8DCZ?R+/'?C-']&W?Z#_%[-*_N]__1]02P,$%     @
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MTM];"GS_+Z\.U_';!^G&RU_&!P?_XZ?<=;'X%N]Q3R[\7ZBU\.L\@+[IGYW
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M$DA?61+H0.=$^$+BML>D9'O=H#5J@6[H(4I%W4"LE[[PV.<9S!D=!3Q'0[1
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M2'[;<)9BA54^P &")R=S9",-53:+F_%+%OWO\FTDJMQ'(CN9G7RD)[TVROA
M]=X0A!MVR:G0"OQNCN;+WYE+QJ&'<MI[*#-D+D*DMG/Q_E#(#N1['#42)5XN
M:?5?6-OG\D0141;%*V4J[+:A0[ %,&AO5[A^+P-/.(DG;(J3C+9D9++@<&$K
M@EU-G(E,()I/61UU*I(++%R4G8:#ML J1>S:XQ2CJV#_>"3?K9"T5N0$D4/S
MZ%$:-=J*\:HX48F 6,?HVV/RU% Q8EKG<*<)A^IP5^0$BM08A]PT#=O[G6/]
M=&Z8D1IB/)0O4,[D2<-WL,L0 <XZEBOB7?W.MZN)@!;8D?/]%UV#^)_V[S^-
MQ+%7.,Q6IF@M%>B3.3TSNGQ<-WHFJI)BS5.;' D\KFG5CC]W_?_ 9?X<E/[+
MK.8+?^^3.L][2>W_[,![?585)A(2.X@<#MX-!X<O&KKK &O943,S"<J\]%HJ
MX^W(^GK)80]T1!)3J%L#5TQ0@>K$(+!%4TQ2T9:TU@!&-:H"[YQ.C[ER)N#*
M4+B2L*FFZ@KW-,J!ZH><67@"4^B8HB!(>I$#:^@_P!D))45-L-2(ART72.NO
MR$:HVLY*Q]PC!;5P@P@K!. /VV5V#//IFF^(>R.8>?IX(<)+HH3[L7*2\DR&
MY,]YZ;A%6<4@;F%9\?4*]KJJXC"$@=%4'UF1E.HS#5U$96MT-96C$^RM0=2@
MNZZ")?F( QFEB1WZ))XSG%2O(LR4<3V6U(TIF:\1>5=_S&#DKJGH[" :/GW0
MOK?SVC.5.WN4MC"'AIFS^"%@=/*C(3Q50<62UI=.:?ET/J=#F@7T3^W5$^?N
M61/2L%(=M=P#=# DOZ95Y$('$"BG1 =MMI9Y5KJ[2@"V C=9Y2K4 :61PK(8
MD7FA A %/E+CJAQ-&-LP11)MO<XHFLJP$VTL=GVU&L[3TZS3FF*O>7D@N\NA
MWZ?-9ST+8H\L6"HNK-(UM1U97O$-Z/8(/!",)8/"P8 E4F43C7<HZ.X99J&A
MMJ3P;8@ 5Q]#NN"^XOI.XYU^P##I)U1ZQ$8/;KTX3=B1$=IM3HI(58FNTK\/
M\.G0('.(D6(92_4/&I@.S!OQ\&>(VS7F$T11HW%D!JI23Q"9VO,E<NVA=%"[
MHS@(E'W(T0IWU6Y6+0-& .W$SU+Y)6L$CT\VE$F&YE&)+Y#*(P8UGBQ!Y2SH
MRE#BN&&!7&VOGR7/FD_V4>5>5OWJ4<6ZQ$,31R4%T\W6,/78F^=@;TYZ[$W#
M0DW-3.0O40$UU=UVI(E.C/4NC"&3"SR9X5ZI1HNR4^$;L?:XH]A0=URJZU$P
MJX)\Z=4=@,(T,W5WV\NLM4RW,Y-@?'PP6 P'\KZ>Q(D=6+S-3-JU\RIK*3G;
ME>QK/Y#UQU_H$R3TF;(23JX)Q6DX&:S,KR*F0R3PEE>!2B4D\H\!09WFR/I!
M'HPF!$FKS2,IC?"\(=7\BD,Y2]3-<K4&35LH=.VD0\>$737*XH9?A](Q,-Q0
MR-4L"2--LYZV?ZBK4:\SQS]WU+3/MN9(!R=U3-1NB#4LT"E\GLH.68=BS;5=
M,L]2Q9G'$Q]I8>B\!2Q\O-\D^%H885.-3U7,6O P9>@W08X O@[@RPXHS&8F
M4:8RXFU@9GD$!BOB-:=SM"&B^J_Z;02PB8KHJ$LN8E(>^U!G#V&XH5/E) N@
MV+?B$2V/OFJ4?HX/(*L4& I/W./I;.1(A>9TX/'"6:K<+06[3U<EXO&#$!F5
MDC@MKJ#6D5%:=@LL!6*_GLB&5&#E\/C4JJ-'- (X;E$6F;2N0$0^C<=^0W:B
MUDAH<2HRRJ<_6U25J&$,&0_F.5(LI%QH))A^E"#8. LL>TA:@6\1:KRWY2C!
M<RN*/NJL0NBA6@V1A+'E89[%0;<J(Y^ S:/]N\-Q,]-S@]4:3"8Z+[_PYPB^
M)SFL]:)KHT/\9O^DOO5 KH(X);;J )W5<2/S).U=H)9RE/?E<EDC[8>:'C<T
M:[ \@:'^\K6S!)V+[%:_Z>]KV)<G15 /]\<U;#IN%[;4R'@S'%'@Q@_\O375
M",\5_LMSNYK,.81L4#F&U$W:2C\LE*_3[M UY1>>G4_RF77J%L(38WS$UX.8
M&L%V]J+!G^#!M8FTH!2E6R (UU<_>-A;!@\C9!G#WP4B3"+;%919)[,*AC-3
MSB/W:U:3/JLY+S'';B7 972CD4)_()MDAC46]&T<P+RF[_T]P0M4T404\\2G
M$8^62&Y(I0I-RJ9^FX%'9^.-T-F0>R.#CAFQ1<C72W1S8?@$UD4, ^@A-:.1
M,,G2/.&77S8H^B-$2J!0IO3(N1C;2&>7(ON=C&),O%>P#A&NHI*2CM5<:%6*
MG<C#8:T9OXT>G_NB^IDW A-=L=%JF>85, 8CXD"AO"WMZW@<,?=XGOHT<@2[
MM2/V&PQ+;*V?/Z#+H^_I\[E:-X]VVE$YQ_9K4Y6"80_E6BMB\PJ@ZZB*GD%K
MOJD=BJ8W(]"VWM9%DW-"A]MB\8B4F;BEDK 4V_5TZ5(W;L5GGKPDBT91*IZN
MTBK;X"W8#V/L0PFP*XUIY8H36RVTKMW[3%GJ$YW7 Y>E;7YLT+;;5/H&!:A;
M\GN!V,TL5H:#83:W1_IHAY9'MHXJQILIY$HFI4.0S$<>RYL-VC0&YZO],>P^
MM3VP5VMC(+;W$0[+  RJ"#O1@PV_>V#WV&D/-MQ^7FT$WT[4RP0]!>2BV2'M
MBN9K4]'<^%J*/5EI.WVJ&Z;/T43-[5!AXZ/]4[ _!RJ_NH:=4,DLS1_>FH^O
MD7S,#L$*+1@0VK+&E2&5K:B=Z^Q[[9G,>BNU-!@6I-09T<R!U8J9DOJDM\R$
MHZQFE:"0K.$]91&2 DTWZ@7TO(+4^4\H;4[Y#2DEM\)__"L-H=1P4I^2<3*N
M)UO)=JQ,"Q(F3,RH1D <2D=Q0U$ QDY@O9>!9^1*IS2FX:_6\* </X?NZ ?&
MQZO*V]4+;OB#!\0K3T:NRTF GY%?CO+Q)!TDA<&\L&VF:V,SW>!;-/<<S^J1
MY2N#8) N>,!@%"[)?^]-F"0]&]*1=UHFA)@WC0^*.MR4U/MW7F6*HV&^([TL
MJT^2VH"+D/M9-+V(7,E3]=$@4..'69B=SR1J.6PP/:LLNJ^<:JS88?=QI$BR
MLT(I5*.-CA-H2 ;8YI2-</@'#8E"9*KPJF9453D?MCVLB$]'*;Y+JV4=O$UC
MLRAUW#ZNT&0%8<@UZ$(7>H3K[+IR.*Q9M#<R)GH,"Z90%:_ [O<0))ZKLU!G
M5@WL%!9F34-A#NBY9B)RHH93"L,^U..^OQV-(DAIOB6Y/2T+4FEE\;3UJ)JW
M:[9TD]Q2M)S-JL*W?T;%D]%8,?*WZ3 $+Y^K1. MOLK$]R@C%P?KL2>:DHK%
MM$KKDI+$WYZNZCOHJJYV'YT4=P%=]2MD=WAT!JU<;$8[J?Q05E/FOL@VVY^@
M).K./:9,JO'A_NF+4BD,U!*CTL'%(L*ET>!A%[ CSZ$"K,'ICF^<9-26M?2_
M_FUZ3^@A&D14W*05K)XG-6QZ%[+QCAM*19A; ;64G2()(9NX?$U&'+4Y#76M
M I>XN7%#7PD19TD?1*H=P:J)YH@&((1^*,E>U2E<-V*!:6-<IX.K!\\X&J,!
MY6#MZ?@BQFW@B@UZ4W,P!(,'E4^EOY5DWE-"EERI>@M8T='8&H3")W,SWX>M
MT%ZQCQ:G%1):Q3).L((E*\P?DW-50E(QGJ1V+W'?9,U]?S[)JE2O$5:CZA7A
MI3Y,&@X)^#,N//;BZMRB#,G5@E)>9NG($:^@55,R]Q9.2+(OMV5I:AM5D#XF
M*CN$D1E(4\F@Z2J1;IH,8=F&FN$D-SC*.*S_:FS$CML%%'E#&3_\>Q5PO@ O
MYEZZ2<W5>NW3K,UX3GU0NYM:CZ6JP2K3B2?$)S5[Q'+Q-02.!F0USX0@1*WN
M).EGV!Q7TB=M/:?(!FVQ6#0CLDMF\-5,DJ=W.&9?]F_WSS!-<7SZZBT[.CKA
M6?R0@GW'AX5KQD>'!WSOE7T99KYAFS#0M!&Q:IOX1@A>*KDQXV&(GZ($-+U/
M7^8*9X!U#'LH[1@"M(V$GG;!O6PHB\N]\#&@=P6S?1>PVZ36&UXKD];2 W^,
M_^U8*3VXJAI<]:H'5S5,73:4-P=<@QJJF51!CFINQMWC@5"=![#^EC!F-?F+
M6H]A9>Z@8Z&_#(<.!4GT$>5(Y^_@(=XL$IH&F.<.2]6YN;(Y'WSPU)=R;4%W
MTN<@D]%7.K/";#'XAXB+T&@PW$4C8BLR)3*(HXC^T+ET98U5I\%2Y_C;KT33
M'KF+J8Q<6=_15L;'GWE<KDQ*7!96,0W'Q^@&Y.]X$"%A%.@EZ3&YBK<YCY#
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M5.@ W\MI,Y'P57)1ZP700L/:G 4>]F>!+[:"FPG'+UG!_7E^OX8[NH:;F51
M9*T.P;UU!+R6\M/BM<O&XYIZGFQ -16B-%)5(BT=P)R?-A-S_OGOM10JLY(+
MQRBM6M!'^^/!K*8;<0?\X69BW#$V6VM&O[IG]_T_M1Z\+'3F\8=YXC$G"4/A
M.QN#:/CB2PS>WL:(1.K KMI(%'N^8EBM!:Z5IG+USOK#C.(:#MU/?QND@NEC
M"3NM4M+P^%]^/GGSEHZ(NF"O-Q)9/[V<U%*RMO>O:8)U&KG/+H4K';@!SV%H
M)R,LO$_E)K'4)*+OU ^ZK'47C,]&@INFNJB"(GBMM1RV<EL[W7]3PZ83&#(G
M&5$7RC.^:B0J*9VHAI CU=R93(>S,41M@\GP>=5^'J^H(VUF!9G6TD'(A\*]
MRS5RQ( "G@M$-GML*;@78^GPD,"/BY"O-+0#WDIV _X"CU:?94J!]7D^EXIK
M'?^Z\"EK#Z[[ (8M/GCP^>(#L<A\_'@[3%WG_=M]=HY<,+%!S']4#4"+Y&,"
M(\UN17@/3R94R>#=\-FUD;YSM/ITNN\6ZSWVID^GJW$ZW9,4 "QZ)PDU9A06
M(=9XM+\S2F'$,HZC>(GL2BK7)B/%H\5MEG^ZBB<N3%!::9(-/MQ.AE2M02CV
M<$I]RA[-(V92V\KJLC]>C:P+=D\CL92T44>(6=[TE0U>[ "[KID9MG3<B 4/
M21O87"3$+X>)6Z&#V1O_XEE:1EG:8!=(UEXU$E Z_2:<)&Y"L5PKEJ:X^--:
MTCH_: VVR0KWUZW4SPX(7R.QD%KX[HT#4^^#7$V,4L@2-VD\HP*_7O8+VD)+
MO&"I>;7A=AEJ9CXAV$ 3D 1J#/ SDO"!R09*%\TNHN&..:6Z>1N[(KC#U]PA
MYVOW.W0R;J'IM\XR!"$Y/#EYBPH>[]SZ*BUQ7F0/?.D>=6!--Q(;.<4J+_6&
M0QJ*_E42)R1_X-B(=:S"%JZ,D+ D%%&L6'_\N2>=>"^8[YGO]^:PK]A!$"RU
MS TYOJN<(V'78\+X1AQE!/H11D?*.);@[>LD1C(B\+)"LG4YFTL?G"Y8*D1"
MI&VN$8L<B:$76&(JCR<EMUWQ.$;6EB"*!/XW1TE,57AB#+)0]GT4>/>Z#IY^
MM^*%4--(*QG/IG3(2'V;Z@0%QJ T(LR_A7<:\O1H2$PP"JZ&PS.CN!4!UU3V
M4DS/)=X&[F<C,[(*%&#.?^*AFF #-PF5LTO[_+T,DKQ*&HY2;0/O<8EJ(B"Z
M]N)$Z.[DYV-DR.&S%@<//BDF=9<K9K'E*.]^&@P;714O^=8SL.8ATB+ 0E@L
M87)G8<#!:^=(+*4$DLTU?X;XAGPY"YBID+N"ONZ"VFLD<!16AA?(>NN]VA\>
MT!"2YUCK<7RT/.HH9<Q2+#AXK#_2^I:(VT?&F1ZQ2^XG<^[$22A&.9=:(/OY
M5_A_4IHKT  C7>04*Z+JXJ=$O(-U4:VBJ$[^(>8>4/SP;\K40W%V5/DI-[M%
M4%_6@?VR.?GA^*'VJKU&XF_?G__EYZ/7;\_8I.8I,#77?74?OBSVD@/<LO?Z
MX.)]$(#2. ^3A:X]$40K$8-E.G%4362B<Q)N!\R71B)TWY\W!4=7D#^0.Q(X
M%+WB\=:CP+KV"V,C09WOI?#J?1Z5B2,ZHXK<$0R\4'""4N@2.I(O_""2!"Q&
M.21Y!)L-(P>JXGON(/<B_S5;(@(C4DZF7'$OZL)I:B.!H.]E&,66\<YNP1"O
MOP _3O)];56Y0O<F\>-PHZHYSZG/Z'%01!?^&ZXB'1EBGO 7\&10Q'ZDB7[I
MZ7=+&;HZ>$*DW[ X*'C&;JA$E_FMV*Y=]-T%V)$A^]:-9815J2H:5?W<#+JD
M2E%9-.+FR8-9$E/KL;48S5:8"0P(J>B/"%>*3!Q^,>>C^8,I-0-!@B7*\)@5
M^VI(@*Y#A(DO_K#V#O=)+$FAT,3,L?@V/!2T5A3X5&[[=^1'53QFP3;?K7D5
MNIK68;"MPZ"I<"/\EP*8:Q1\^$&]M =U??=RW6/C@Q[556-4EUKI^4I[*>OR
M2 ?&*:S"J>X=1;A]CM1S:Q!M6CVIV< NKL[QEDA"2WFHHSQV"-VPX I4QZ6[
MSHBA/8)LU:&0JUD21EUPNEXW$GS^/@@=P2[Y;R()ZVTNM!)_]6K_N(9-1_Q5
M3C Z<.3SNI$82IBE58XUL9;2U.8EC'G-3CT90]C@L[;B,_GH @KR=2-1D._O
MSFHI13WM3ZMI?W[@LGP./O2'K;X$3[_9A;_W28*[C4B8B^N7/&U^]IY9GV7U
M>O\$ML:!E'(X>/>BU!\=V/,:"=3\P&/Q58AUS5'7[;1;3VK8<C1:,Z'H0N[>
MZT9"#;,Y8E=!##MF+66I7[_]^OW3UV\C,7,V;+V68I1'.>1K1G:AU-[K1D*X
M*-E?.HT@)/].^ &EC*7H SQA7R]YN.*.2&(Z=S-H9<(48.+)0"JN$CH[5V?A
MH? D<A<01.!A&7A"%?(F+H81"TP2J0S*X0*8"@,717PN5#J'P'P3[FPP'94R
MVE8R3LN-KQ786A_95SYU^,BI/FR>:7F@E-LA@SN4/=(^CJ>A,H]*XF40PF2Y
M*5:<#<9#DQ1(A!%VB52SV9T<G QFP\$A<3K87_Z6,LE,X/&#P[%A@S@Z,7<@
M;B3__6_#D9EQ>2\\K/J'%^I&3+_DFL!U"4"-G9@@9P8B&,8'(_@?QP:-#V;X
MTS6'+9I;J>F)[TA/EYS%!-/#@X,Q,>!@) 3^F9Y9J%00%VO(S/A21VGW-V]F
MI_OC'6_3DT',&M.S(5AG[-7A*;T.7G^LI!/%4*B:II@TA"7**(7*-U#%9=;I
MH4I+.AHJB,TFK;&K "CPVV])*"-7JDG)#9WG66F5D26)^ME144ZL@JM<E6/5
MH,DHYG%".6N%Y4H5K9)9I&0B(FDRB4W8: VSI#Y(M2"SU /* )7P8))C/<R9
M8'_B#TI,J]?& V:58@:#"AD9) VVBC+U-"Y/(5G6RTTD'5  6:GB ML2TIR$
MJH]KZ*03RAD-C5HV\28M50[=B (OS::-8. RM%&TJ\58H'@'!NHVF7DJ ":*
M^<.%_#(%+W35?0Y5E$ZGU]*82RZI^RYB8N5,Y?FK=_J:J$OGKV59S(4WZ7?K
M4KXRM!O9!4#BZT8B:)MN8G9 KAH)=/WPJ30N_^+CF1>G!28%:/6+EM&:JJ\X
M K5S*$A;IK;4^_.)WGS 3CG;?[]_LT^ZF9V\3O':EKV%EX>)A]BN,-WM">@%
MCX@4[GN12"+)BK(*Z/JM:G<M;J-5S8WRL9*40/B+3W0MMFES3$;&^" U;3*R
MA\_3LW,V^!PNN&]H>G!?G8+A$:S 73@+X*E6PH3-\J,-FR%B4>'#FM"C/ON
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M[Z^1P,"_P\3%;*)UUW_A"OP8/-1:3[?1,G]#QRM4U+V&/4 #G03%V^Q]?D#
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MZ.R2BF<IZ6Z  '>,)^FPD= H)5/3!//Z0>,T1KARG "Z[J/6;9(*R+U^6RZ
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M.Z!W(0?7%F6E$QM1,P';1;#:A3]'1(U2ZI.^[NW+H.!.ZHN"F_HPO(Z2#\1
MEZ,=U;YOPZ:B/YT3AI[XBP2W0SI/$/TNN,7-A$(71:H1S'89%.H"5XC.42?C
M.=(=H9BNJB]*!R:[CF((_/MM[06ZFN8CAR?P9B_PA29;<(+53/N%7=AYFXGN
MJU"<#1%RPY)AU#T)^AF&?NCGRC7<B6AD,P%X8?";J'G:K2Y*O864+L5SCU1U
M<PPSZ,.?),9'TY&35I:K(,SAPO4@L&N/^X.H&['S9H+$K(FJM<BVT4$Y(M[J
M&C:>TG1@#[J7XJ$3B_=5(]EM[<6+:<-AW!/=OLPZ/JQARW$1YY*YNA ^?-5,
M0E>]D'/354N1ZI=QOXQ_Q#)N*! E0$"ORR::%A$!P^1#U5*NVKV6C_N,[RW>
M>4LNRSS]70>,/19\!Q;\38\%;]H&TU"\D]Y@;L3:X_KT\"I &JA:*IQV[S!'
M!!"N9_RF"S9B4\%?VTNX-Q+[);R]A+L0=VTJVJMJ#?>[<;^4N[D;-Q4CI2IS
MUU)LFE)-*V.!K?4PME'OU;FN^2.%S3N@$YN)J,ORZFHI5VU>SN/#_9,:-IV*
M!V1BT8E$E%>-1!_>8+KM/2Z'^A<);>D"KF]VF3^7N.(D1XK#X0C3QG^S>'U5
M </ L/!:A4>#.;/OMJ'Y7= $C41VWE@U"YI#_O<X*#ECG"NR<@T,SP_X2WX0
MZ[J51&['63G=V)"(?$H20@SPGEK#;?X>/UG-\!USLWRPB"<?:MJ<*/'BC+H<
M2447JDWT(*I"REP><U7;P\IP<0+?$:'2@Y7-&6DN]%B1YR%96!1SV)>CI4Z1
MJ>Z)C!1S$97F2-/&L?N22+3U,XL$1CKI1KB&G)"M@S622, 5JE"YKBFJ&H =
M4EI]QB-DZ4_S:117!7P>C(<99#P[D"Z3UVBH^"L*9(Q$$(_-PSJ=L&'@167T
M2>I>I%EZ9)9WC,(^>X_<BQ[7E,BH"'7!5R5U$59(A(YY2.?A@U*+$ZR\4MH?
M>I&F?=.U">SB*Z8XK6M5=%&OHS(J5+J@N#QTKW)MZH!.?MU(P&Z)D-99)?<(
MFF*KMA.WP">B:E6C7)&@:)3GGE%YO(9U)E]O./T2] 'H*G7IY602C:PZQ/H!
MR)JJ2QVO0[&GBCD%4;R7/485$08EAX6!%_;WLR1FXEM:'DMG1]KJ"$8,ZRUC
M/6%51T?UM4RW$J_/O4H"HB3++X8"SD]5NB*_&S(?KHTBK%]E7GH6K%8B=- 2
M->0\VY2:Z<Z%SUV@\C>$22,L+A5RYAOM"MH2]'. OY 52R6DD 109,3U8=:+
MWY)01J#A%=M0.A<C-;-V&E.>62I2FPYHW'^G(4%E6[IPY/>ZD0CM$A[$>CO7
ME=:T15:9%^*])PCQZ G+J;"&RGG,M&&=_DD9KZ@9SL6]\(*UJD5WR?UDSAVJ
M5D$$G25:HU1GT$+%DO+&[OMSNIHO9OC^?*(H?J>7YD,2!FN8"&JYC"*Z"7^X
M_'@S2>L=77[\].M(.P1,<&PM)VK1?$EZ!Y6HTI^AB(,N&'F-1(%;JF**NVV$
M>;,;=@U/"]QFZHSJ?=DB,<227-;J,(;!7;;"\&IA#<G VGGGMI?E0[^<I5B1
MHZX*SM@WJ@N22/,TI [KUB7HC6I?-?]C#W/^;B'98X<'/<RYFO+ZQ5=Q$*Z1
M<-D-DT5>V-?"E3P&4S:W^'2U6FNGIKB4=<D0C?FYH-*XFA?:NKK,(AI0I=R"
MC:QIY]6S=.U<]0Y5J"*_HZ])39J"=.I6<XP\*A;6A3[<TK$4NF#P]Y+?:]K\
M] VTDBPB;6+P%N"X*3>D0J_E;0;5"O4D<+M09XE(!_P4N^FN -3&*E&\,<RH
M:1E+%T,_%,J;8=3H@P"/"5E,]&7E=#5I.- V&$:Z+DB>F'MDN7S8%NI%E)]9
M&,891SQ;H#2Z)B/I1&V?UXU,!+"$[1(FBV*E]3<M;$-::Q(=+(F2F;:/X0\W
M@$^@*D88Q2?")WU5(<)2LN*LJL^J?'.D*N>L5HF?%MI9<9?*S>B@M&7H9[$8
MXD^FU3%2L=PM7:=6,,;CL_ &>?:ZHOF&SA]"6H?DC.#:A+=J!V>G<R-VQT*V
M7;B=,84R8='>A6 75^<PE!AN(M6( :@N>!:-S!VX(<XSMP%'^VJY5^[;IK"]
M]H!E:-P-W+%S.SI5?J4=T/[:X,FR1])!D4U&5!X6*)SFY 94G^3@R:%9'+@9
MNJARY"R!]8.^T3+P1,0]M&1T+-.37P5LO1Z>3%%+M<-"I,U9$RF\JP>D$W&^
M1D+[;41_68ILK5==&P$U".QWZPEP[<0J;B2LO^=1>=DEVQ >E2ZLWT9"T&^$
MP;P88MY:"M16 >MR&N)S&<+*0%J8!9=^!$XCR9]4T#2=-XCQ;Q5G0G6 !JDT
M 2URCF,%8[,+?.#1?91P5?2GA@/T-%UQ6L.6HZZP:MBA&Y 68KG &/PV@XJ9
M[6YHE89BXXU6T>Y@+25OMU*YML/'"#O%(K6H52A*5=2:*3;S09L9!O$-OJAU
MT%Y^MFY7']+X2,N%ST[W4D5F#OIT+2+"D&O'UZJPU87H4C,!X\&&>_&F_C:S
M/J;&PXKRU;$WV^R5+QM<#SIDBA>9Z"EAE75Y9G7^1 =3/H&_ B7I*G<Q6R;L
MEGMB]_G,UDD88:]]UWHJ%3&@]8B+.;>[9QC@/^#5(PW1QJ.QM0Q3](QJ SS]
M'[#*L,XU(JL)BW>M$(#Z,(@-Y-PZ_1LJCGJ#?'%0WT1IKLB*Q['"N>G2@2[,
M6;R$884?];%]' H>F^HG._HQ"$)SC%9A7IF>EMZ_=1JI@#8#9U@U$#OA&X\!
MR0LOZX"N>]-((/:MJJ1^II(NFJ#MMD YU0NBN@"\K5]Z<'>Q56F>27HXCPD=
MTA5A>D"_P.-YJ_Z,RL&1VE40/:[H6;BB<8\KJC&N:"4<<()EI.P"QY32-3E>
M3H;4B^(PT>?9.ZLL56HH'0'!H*@GZ#(9V2?JL&6K2 JL.D]P^M?DWLD(8R&.
M,%"E]^>3M #4Y439-'[@[^DS?CR6]X2Q4ZP?/.MK;LH5KW1I9=3";L@?5)#&
M9(]AUA8!>0EBI$RM"M  F@]J[R&T52BPQ *;!3Q4ML564B,.5>Z;Z-F#B\.:
ME5^V:AZ330,[BQ]EF1A_5BM4SB#\BB88Z=G4R70#)\&!QES#P,-T2W5"#-/B
M"!?$"INO#'.7;E5V1JXGRI";)R&IY)R/^\Q1@X8]\-# 083#T8 E#+8^X4U\
M[CAB'9-(A3+Z2A.)];#1'%PF*_3C]1ZA8%;)6EO_P0S6Y'U6F QMS 0>ZJ(C
M+_1N%%F/43[!LV=_)@0X32X,EXQBLZWA(N%?!3G\^C5!KJ68:>28V7^IG9M>
M55:5L%QIP9"!V1X&M30T%/92KF X20L8<P,&FD []^))TM %[Z*1R4+HGD?L
M,DVFF][#$-=2$MM\#/EZ_[BNU%A=6+F-S-TIKEP=!*NE$/5KMU^[?]+:;20F
M_M99AM#*PY.3MQCK$&$MQ>=)JU:Q,0F^ I>B"_+62#3VEKSM?7[ JJ@3\ %Q
M1B^NFRN -6SYT]A0QX-9%0MTMX/;@\?%M0NLCF\:B4K?FCMU4%OOE*\V*ICQ
M26VQK1?0VI6?ILOEX#L8D+234)7T=&*]-Q*_OKW>]>S&0O2+OBZ+_N5;6,<1
M!5.C?JKH1VJ<YR#N7TZQX(,O_+U/*K7R)>WF9ZN0EU^'6=CJA*K02#D<O!L.
M#E_4#^G"[MY('/KV(OQ,A\,*:5E+E=[F[?W-_O%@UD<,GA QR,EI-]R'1B+Y
MMR=.@[C/D.% P#>U%+@V*YGQ44T+N[1_$1\>-!.B3HOX\/@T7<,>CY'0L)9B
ME,]:VU) FK E,JQSP;R03V887=9AL ZEB)%-:;W<1-*)]@B*-J(DDR0VQ*U1
M,(\?D'UI;1A?-51P$?*50E0YW#>0*N:$,B;\&KY J.1:S%0)/.$D'M)WYVG2
M*M!U=N$3<&/%=D_3:5+@\2A.<^%VMCBRM%SPXEJN3")W:CEG*5P81D:KK98"
MR@:5"RHS9%[4^&NQ FXFBJ]Z:5_XB.A#,KE:RGJ+#:EZQG^:-I@[S\E?7'RW
M577=D!7E"J.>HUEMX/<Y:3MRT@[[G+2F61G-1!SOL#)>6LUUSKK8#2"KP<BC
M-/>[8Q_^^BZ]V XT=YK(>*LJ4CKF'**6<E5@<?*\RN;G:L'!=53<,J5&)C+A
M4+#("=:4%:A_I@14Z2,/BQ^'@8?ITAGMTC2M[TDU(V<;5M09^=I% 94;TFS&
M2% 7QQQ#.DR5&L(GUU!(GAR1.JJEB'1!];0#V,]2WM =,)D7'^\VVV6OR"ZK
M19BV1B/WT]\&6B QCW]+;#MP0']XT!(\_VT >Y6QX/_+#Q[V/@8/M12Y-JN9
M>KM_C/5)/&K1-QC4;YT_W@EGZ</+%V">B_ >-'D3?!GBUP&'(WA0JUXU7)6G
M1I]#XMGZ7WX^>?V6J)G2"ZB\JJL*CA6'(H4'V%6AP.>1Z/U$BO/$"7Q?+U/B
MPE-U8QR0VF"%G#CJ/58;V* A7#5B?U%Z OWB$\]<L8*)H(I;Z"<&RBL-N22-
MOR709C(BA# 025&<BOB(YG:#]SDB1,IB&TQA'-?*,WI\.>XPR7K$PL37U7)C
M$:[!064.]QQ=YY/>/1-+[LT-RB1M%MU*37\_O?Y_69#$GL2J7S[W-I&1X0A!
M&X]TSY Q*J< )/LW8N9)(D.(6MV/!V*.HL%)[W,#777H/O#N-9LJHDVP@-C"
M5Q7,? P>X./O91@G"(!Q0B%\<OG-#=%0<8]]WYHK44,,Q6[=%*ZG 2R@6JZ?
M?8RR1- -[W&YP+R8:HD;4<%&N5!5,17%K/G-0*>B312+5<2$#R(24,5M)=(K
MN= K&-FF4$8<D!%B.FFFMJSK9%NCJ=:RF798AZM E0Q794BIY#&6(55X,]?6
MM$_1AGB+82!-5SN*T#H)UP'J,JM\ 3XJKS6(@-K2&\PU)2JX+E%!W.Y4F0+E
MQ1TJ34X(.JK(IK9F#&-&R7H-9O^C;8;'B*&U(4"7,W(^:^0L8M5'GD=$SO.A
MZ6KVY*V1">9S8KO# =JA$O&=N0W#JO$(^CG2D5OB?W7%7/HZ0BK]DO+M R*F
M#+"%PY'FZY=#H^L1'!C+.(G_'76_10J<S9H:' DOQ-;KYU7T>@T]1>/*RW=7
M;T?4K:U[J,JP*R,':< W;(9;GX@Z0$EW>-#(BCJWT[-::LUMW^++_NT^&").
M$BI]@((\_884M M!'/BJ3FP7)*V9V6W"4UO)Q<V$G8.::(#<<:7/2/UAJ93(
M] &WU$M$D"O<-CJ8OEC 5J[V:0)P8UW2:)G52 ?9#16 76^))-'G JOV&B;:
MCX)[H+KQ_H_(Y9E:WN4EO?$IX"TI#X?="-H<X-,$2=VAB3#475@/C4S&>HQS
M_\5'MLT!W:/]\4'%P=&+C_L^ZP#T?]S,W*L5(C$N=7)0+:6GN(&MD7"<.R)1
M:4Y!N(!5[&3.!>UMN,2Y27KB(5-OP TI5WGH'#:G0-& 4U7K@2&H1K< =D&0
M3N@0N+)I 7M7Q[Z(GWTF?2Q*>'XU&>6^N,$OEIM9*%WH?RXVB$5^R(LCKO<H
MRGG0D00OR3A?5((#^HAOEVL=]-/>Z>^)P!"8A:?Q-QCHH )G(B)2?[4E<X6.
M@6LP/PS6SXC1T& GO+Z,Q_,@TT<]9+K&93QT57JLJ8&'*;0HL],4[JOUM[4P
M5+V&AL0&37"GEAI;J6"][>5W&*/,'R1\J1)1!2FO@E;/:W-0R+;:[H ',&YF
M(J$NNFF==]520-OL"(P/:UMH6(%UT3(Y4T$N_!00JA<_%D.O70!XC)N9RJ/7
M^;6)I]=2X/I5WF.]_Y0UV\PT$XS>$H2V$6X^F(0V>>8@(RUQ912'<I;$0:C.
M3!Z68%SB*7\8T3DD_+W*%?0NY6'!'ZPQB4A-+'3U,X[UP_5/.C)=PT%[*IZ\
MIO5%F,%T1SAK9L*&=- <S(L\-;8TF&DB> B%""(-FXH]JKG,[P/I,D_&<I$6
M_L.':'8P$*$U'DA;)_"FN"+2ABWH*'B."!15#W&VJ2Q/;PHO?EM[@8QUC$;U
MP%1S-NE/:>@'X5P>GKLD&4W/1E4CM'N)I0-G^59A]4:[91@"NL=ZUMKA37R!
MIK<C^ S$7#T43]D-&UJ*>K#;Y9@"UW@E)EW1D)?WMPOJO9FI/ E(GY[T"<'\
M9+TQMFVTRH[VCPPK;@U[0'PC)6+2"3^KF=DS);,%&V4,VV8MY:L3:_L%D_.:
MQLR$U+I=53B-S-Q1D,I:2E+>/T1SG<X\S6'I^=5$@UYC 4I&N@JUJ\!*Z/E-
MKVZGE^\^L0_3JRF[.%?6,AZDLB^^!.LV9GZRFB%?  %*P?"6<Y.E,_/$B!ZR
M$'ZPPB/9),9SWO0M81<DNI%PT#O^K0'BC*),.3F>QV+^C=!QJW40Q?#!31 =
M.J+3RV7@H4,<X2$^^,T1I3Z,F"?NZ9*Y$.D-F;L)WA^LZD@]4?'+>AKU!]?0
M8X7G*B?W _J"E%$!KNDDB9=!")H[C]4S!!H^1T"$\ENAT2/,^*$7*HR].H!5
MG]6BBH.%ND ?Q&Y48I.(X/>U@,U!=12/_C7W+5_!%.GD#O.U!9Q7I!U=6'N-
M!,C>B9IS.+?13AT?]0P2Y:9HRA6$^1L&'S59A()":0K^@2+;"?.TD0ACG!T$
M\X#NAX^P,P7AII:REMO=1UO92[25VITALWNDMO_LZTO^&Z+R*8\N&FE $PHM
M[<(HP/K:-)-.1IE X\5HLRI>+=S$B70+-]10D\+CLQZ"T',[(/&'C<3G;@E)
M_<4=K$%$_V#IUMP)@D[7*ZZ%AZ7$]/F\Z.+&/!/"MU;#_O:"B5B$!QL:!BO8
M.6;I@;3[27;)?@>@YX>-!(O=6<JKCVF^E*UX5'$ZW'%;T19.<(RG4M<#PW-9
M3)5[%^(>/NR$=FDD1*U!]J$RP1ZD*WH&^^\?RCUV>-RG8S1-IS020F>!<QJ@
M50CB0P!=FR)EFY 1=K,\6"X#R:&/*-36E^*S*VYM35GKP\/GX']>0 39Q35\
MV*RJF,%?[F!.SI\ OY24RTD=(;HUQE/O3QT/Y+!P:'-Q9A"9Z=$&[4?J_CQ"
M$,;F1N$"B_YF$=B65KP+B@ZK@?B!?1_X]-)50!0S)H*BHS&IJ3%BR7H>XA2L
M];R,& RXB&*\__^P]^7/;2-9FO\*HF=F@XR@.);ELSNV(U0^JCU;/E96=4?O
M;R"9E- & 18.R>R_?M^1)Y @*5F6$A1BCK)($$ADOGSYCN]]SWQ6Y!N=Z\ '
M<Y8&F^B!A<[/7L<)P1()X6B_&#Q3O0S,*7VM)\Z7IH%IGJ=QC30]2(@EJ7-@
ML^%$PYD&ZB&>I1N,#>64Z/0^U4QG(OGN>!8VHT0H+C9[U6E(A,F$M^;LELSD
MT HT7B@O%DQ)E,^(+L]!WP:ZUL@_5=:8!(;GA(D(Z>S5'E3S]HD48BD?"'J=
MN\*T$$N!'%"@(QQ4+F%5^[,.?(:\]M=MW!\"T-XYO&W&;>'^X8TT,;I%(/WD
M4;X\6N?S;TAAF<M6H;RN$GA,V&U-^3>L\T]99\UZ!LN54;<,^YQN'-#$\P8?
M.4425@L/ZQ33AURY_4"C-#YH[T6\BB]LB$)\'1>XPPG4P$1L%@LNY?E1)!^R
M?^E>V+L#]MAZ":#UF@E]\=VH/&,2?4.._,O\>E?]"-M'K2H2J=O?)XCQ0>,*
M;BV-M[;>U_0G KE)D-EK*0M<% ?P)'IKV"PGT4?#C#(ASCI1S!,0[G_'3 **
M95D39J5$G8%WXX\0C%14\BK]9DX9#54'^TZ=LO/8*9LZK;/TR_J"WS!QR\$>
M0T:TGQ#5!&N\CH^#WL4'F2QZ2<FBQ[ Q^HET+>#'H&>1HTIKR@!E[;!WR;-P
MZVT?P\[M)4ZV-\29;)P^,BJFI[V$2B(5;P]DB5B#LP0Q75\KMLV7T2EX$<D\
MUA&(2OHG%&M@^H>Y+ I8YQ0RP+* ?441I.PO\I,J7].?_13,DUXB&G_/XJLX
M23$PV /YC TVMW2JP;C- 2:[6(A+28E$G \+MX."58P&A@WV1L!T%_,/FJS7
M3%37"'GTIEG]?BS%TVQOGUQI;H80K0MQ)+YSBQ_X/+O(Z1_XFWD-5F)68=J'
M1_%+GL71>Q@GS*(A_;Z+$?%$$6%'&8W0_2?()GTP;B>:+#(/^HHQHTQ7GM?I
M M^*P9XXZ707V>*#V$)*?!ES#Y./0I:+K!*K-5<.J=38J4F=4=X,UT;.(*WX
M0C  U7">_PJ__R;$&@L%9S'&*CE :7VA^PT56)9U+5N8(&4KB8= XL9L+CP-
M.JPIMLE=V<RDCE*+?%Z;?C?S?+6J,]5&C"L8)&N(1RS]$F'ZF=EB\ $1/5B!
M]:7(8997G?E_KQA,HY UD%?8P]=% TISF]W<%Y%K;JQ )]8I7]G/X!\@BEL@
MBL\'B&+?K.M>%E58UK6J@ E:PQQB"/!D^CS D2,FP-BHCZ)RX:27E0M_1SZ_
MZ V"7H(4HZ:#S/ <=(71Q8K)6:(\,_@@98U\$W4FOJ\3S$N@KZ'(&Q7D[JNB
M<%$)[^O+O!21HC4$S\RA-"07=TV7*EXA5"+8L(,J!F.J\F:O"MVY!%Q=A/!=
MD4Y,XS4VFXIG,!+N'(I(I:M\+C/1"VJ!Q:@3ADI2UZLY/16[ .++LN<CW6Q)
MR3&)EDG&_\ KX95*F<,V#(V3%C\C78RDCNX+$082[@=FXK_JQ06%!W1;$_.F
MZ[6(4WA3A,;(5'X%HR,LYS7/0!H3;F!9Y"M=:8EM>:G%2;2L"X;?T)T<_]%=
M2Z3G(%>4QVEWK]:8 7#^Y J#8UN*>2T=[8L\7T3+.)%=P)Q74+==*L E8=2=
M%BTT='0OETD!#C0XM"5R[Z"[FH/#*1MA\U1SL^'NH=*]:%'Y.WD#BME8T1V%
MCW@$P>V37A9B_",OOBG]T0<=F:;4D!AC.KHQ NJ=LDX)(P[26"1Q2CWQKC!6
MF*/;9?5Y-:@ZNY4X[-&Y2+!Q*4CPC A@G9;@PJY:; /\Y"<:_B+QGKBS,%"6
M;XA-"#P+B<M%2<;-19A,F(("-AYR,(\4[P_X;"(%G?:O/*'@HF07(D3UZ'BL
M4=56P(_PXQJ "ONN8&8#JR\LCM'JFJOZ!#KUXJ2#G)@K<P0I)>ZK1"\G-X<7
MV5$Y//&\%>YE5=2$B#KB &&S[:TE! R(0JUU<Z23HBFC[BE%OH8SCGHQHJ11
M[ZB"0IW=\Y5@'W=F/UXF9OJP*"->8>"SY+#A*E^(M$]=L\-,?$VX'$+.+?P0
MIO;_?CT]X_DEYG*]!&!F4&LP8LW:K(7;#;F7G8I"].;^]%?:"/9QHIH2#>'6
MUJ@8N7W#8\Q@.^V3BZ9]%6_L[N J67/T^1K-SM,BH49['[[@DHAUI0X)<45F
M78FZM+N[N4[][*H;Z$% X?7T>#0?,$4/92+WD@\>=1INGU]A$.L@1>>00X!/
MIT^'\\/#!3W#C'5254+:-HZ4EK</2GK3.P^^!T_A )JG J2A2X/\^OGO[\X^
MG7YZ\^[ ]>C3:6<Z)4CU^3_HPD9?05"I;N6-$ML@-]9='L*8&0Q->,#3[I7P
MO"NK>)8FY>6*@XS1_WQ]$Z;@1/_@T+$3<97$D)HN-7H+AOV$/L.8#09AN'VK
M>DUP9"GDHXO$(JWFJ7AX7G'/:3C5ZQ5^PL HPG+.ZU(6C5Z)HA3"?HP$4NV*
M_DA^3:I2PTY@!V)!!&OS1Z.S/!52KL?8,UT$#;[IE2Y75C&XS4'/:: :34X?
M6)+O$,_)H6_25DD&&H1"P_%Z31+A*+U"K%%[915!E4H5.(;WG$;G_ \.6'#G
M6@Q*X[AD2@FS;O@+_.]L@^TA:FIBG97R!,#K5P+[2Y23(7)W9Y$[N42\PD0X
M@+WM*B92IJ=Q;D_\@>O!#3[PH^9J8[($Y<6+<L732=-<&6'@U;Q,UBKG.1>+
MND#'IA ZL[H0Y;Q(9A;D.,#)W/,\"G#D>!AUJ7=7!^#>C;GO(>?(I1)8)%B;
MCKL4%[4I%["7KPN\6X8Y:\P52[V0F\S: W)2W"WS1)"F_ZQ?IO]'HQ6"MOO?
M[:7M6*]RVC*F?JGN]F"BMC5G'_$"\1VY*)*26<1$@04N^N!3C@6=J3<90"F0
M[$*C-RA5[0XD!N5_!$=S4JR9\5#15L"SN.3%R84/&.8;B\Q1]/3%@&%NWR^8
M/=TP3O6F7;2V1LMBK=?P\>YSCDP?]V;VGI9N.";F$*&%P"Q$^]7)@O[0V*O3
M-$WHDX]Q!DM>4'\,V.4S(IE9HQ&'&"S<P0CEP#-])01"063))VS^N%"52_.D
MF->X-^EO0JLL8L*L+:[H*<JTD_<8K.^[M;X;PL6&.)K?L9IQ2T302EZM$1I$
M(L>\0IHF3DF@52MG1+#Q'!!/,/>QE8^D#U1/8REMR9A)0VMH$[6[!FFKTXJ*
M$PGK(AW&RYRL>,0I>EP%>J)$567ZW=C"A!=8&'FU7EW'J."H1&"4?%G+1VSL
MMPD]'EYTABWH+:I.U;%M0B@I.FRXE=L"#JF-6/02'C()PHH.?+(N\VMQ)8H@
M-8(LB>;=2-N ^0*E_<YEORC15WEE6%VOT59$%N!DGB H5X$\%(#Z:!53@I#<
MZ]+94(1_2]3]F=40478(A)S!21U+_ F!"9=<@QT3O!I_B:!KPG/G)38QA)&G
ML,,H4$T]1.<28=S<E1%EJQ&@WN<HL\I,'GO3U \N2]'HC;MD=\HZ%:2?.^^7
MGVME (*4H&GT(=,=0_$0):0SZ$[40MK,Y&H++C[(B&%$6I5\*M%?)FMU5]DJ
M)VCIL7J)A(#O3P8K9\O4T.0H\$^VOP@HK48-3RE-./-+D5/U/\%(L3K$[1?'
MNEH/E^T&*FMQ'TD>_A7_M3&S2M.V(,2UNJ-ZX)<TSD;E6+OA'SCX[L5+XW7D
M\'FRCGI(6\9$2^!Y+LW J>DEZ\5JPW5G8IW&<\9%^ZY18[@:1^(J3FOE:RPT
M.P3^K3#PG4S)"',JX;.2>$!PT&_?1&_ "D3,I'S&E?66$WNEMZW"LK40DB/=
MNC]Z9?D\(7>0:"V6JK3'D1.</C64!&N \F)!\B*G61):4$Q]@[^BAL+.#%IK
M6D;7 AV!4@9MR& O2FN$NZ8>;J.' ^.QYQL)41&X'L]Q$Q/4'P:X3/-KKKDR
M6%/%8N+FKST-&>4LF"=B?5>%I"$\ 9BW+O/T2G!A&QH*Y!@PA#ZIP/*8J"VZ
MKBOYF"2;T+LZ4*<&G8P2L>^-.>=-G6 /YN3?Q+D, ZB+N2):,9I&EH#AI^I]
M4=/9"ULJ->"6>F $ /6G4]M@B=ZLKLAL0XN,ZQX4IX@3(L"54:0DF6K4W.I)
M:3^#VQ*4LHZ.C3G4?,L^YTGXR.Y-\GZBCP;54YNK#MOF-ZQ;LCXD<(7 !@CC
MT9LPEVGL9*=9/_ >01T1%P6Q >6U=+ADAPS;KD&M $I&?$<M5:8;C Z(BUAJ
M*^U$-1:T42>$!#\E13; 3N&L-B;0\7O-B*1T:L(Q1"KG;(88I]$IDDH+=/3U
ML]DE-"@B%PQ*,;PYK"*'#TEC![A4/X &?G ABW8C<B7U5D)6,S)VV\)3F0IB
M.@CH6.!\##+W994.;-E"=?"NW*)?KARNY$<9L Q23 WF@N00"^ZMC(#4@(SV
M((,)3<I2FIV1'31&/:89W1IWQ1N:*) ##5K4A3* L2VH5(HF?-74BQ3;;BC'
M.JN25&\<;&IC]RH^&%6GS)^3 (>/^LYTB-8N*YI!+ N^J#V>69*N %=)"A**
MF3P4<9WA8%U?RK91Q(='*G$%#F&^\% (FORW!4^;B5B68U]GLD6.Y;-Q9HVB
MJKI'CAJN;5-S<P?\,2>LV6VIBOA*I)$J-::G:I)"$WS%"5'MO=3-MU1D#+GR
M+;GRET.NO%=GMNC7F?U6^F>VK@I2Y4XCWU"EZ<_JL\[B+%GE=4F9(8DB$$8]
M7L84]((1IVQ>(K.$9)3@7_0D>]>#C'ZRG,A8K Q\<</&%86I-CK^197@26FX
MBPT4UZT3P:Q<G:FVDG0]ILQCK!7'IUC,1<V00US#\5E@?+Z11&^6J_!X$R9'
M6@F.=LOAL[-+O=KY7-/$3"/K,P[7P9N'#KF/WO)0@Q0@!;TG"<A<P!T82Y,=
M8-H);G2)YK!>%19/]C21%[_[CM12&+G\3.Q-14G1?A+-&HV):?1AV76E*X]*
MG)5TJ4=ZI&RBK2<V[M*<B08HQN%_%AJ(QDE@V4?70.VPUILF9?-E5W(N6Y=J
M_2E?@:+ZRQQYOS"-\^HO=^AC'S]Y%>"!G70>V"TV")XLDBY_=--2-5>"37BI
MGT@I<FBT=/F%E.BN58-#J:5:3_\"/\9DA.19BA;QYJC*CQ8H'?K'2\G%I+)Y
M\F9N^'Y@X/EAB(J]I<?]Q$E%$@3T<&;/#3BY[[(\(5 ]U*V(-(C]!@JHU7C7
MZ"++5EK7A4K$JK-+9N$N8R^3_<$#Z79 HRMB,Z/@QJR447DB!UVMQ )#+!B]
MFX'V?Y23=TM5%.1:\Y'=V'H8P*M+(6E$M^_ *K]S ^K9LP 5UVFGWD+\=5((
M3VD.**2K)"=B151,IX8Q];?XFH[3@Y^V7SJG+5X)"V:U&PNA83M,E!FC\\ V
MX&HMT>L:,\YW;-WB<4SYF^XI)TB4(*YIB3"S368RJ^$_.T!@Z/CO0B)Q:%^C
MKN!.+>^0UQ_WA>JQXP[&:IU.=3JR\;W.?RONZ'B1KRL5S,]@#BEI 1;?)OJH
M^JP;8!?\P,9YT1M[WV#,1,ZP')ER;+BC$O/W46>JXW&#>UG!Z*2AX7QI)B99
MVN3)*,.[IG.BO"'/'2>WO>5MAMXYAD:[K]'3<6/%I2D67\!FO"""E%W?([3S
M9.SS010.;Q[#(36"9: 'JE^,D3<\15RGZ6>%&L"!7(!J=M[#076HB6C>N?&:
MTRVW0,7S*(VC@X<::1RRIE9GF"@6S<I695TMRIQ27<O+(4 9/H*C;%S.I: B
M-C;3?HB3LJ2(E^M+/JCTW:DC&^0I^[;SE-49;#NY;<7'$AME)HW'A2Q<<[/?
MDA?%Y U4G$NF"VRNUBUFSYWV+@DUK- =5S"K@&6!,OZ[5Y#@FGH_9$YH'K,F
MY!,=Z=R()RK1B#8?#& E.GX1++&)#/;+NHPSG># G=3.-]QIB528%)*=[7R"
MS-?MPE8&*773Z'T3NVL NYC1LDC_J *&,<71HB8%#C]1Y=KJS2=H5U@307UT
M"F[14XD8]#NE8D//OJJU&^!0-Y:IH^CIJP$.%01UB%^V@^<('Q-H)%,*(E:U
M!(HL<1:7"2L?69;)H,8ZC0LLBL08#"D>4S UD=VPI *C")V55%^FK*"D*06B
M4\O>])4?*#J-OJ+'TBAAD!A1K3.Y6S3%D:++?"['C:$*,-:PEDZR4)A6+#SX
MB6SM8P$0^*<2Y*R4L[:VV373+V2Z+"RL+SC]+#IOTM/\:)""3(X2A6$<$;&=
M9N8HM.E&%%F/ <--S)I:57C-9(:-KF-^D;(N6\ ZJTUY@^%$1JY,_,T=LX/$
MD^@\&Y!',HZ0>IEVF\&O,!8P$TMN\=:XH01#NP^A"A*W\Y/OU0E10>:$[$6B
M.ZYS;!AF-%_:NT%7L4S,UOV @"395X2OHO=O M#< 6)3$BKD-9VGL'S.\([U
ME?%1L]8'.&YJ8HI*/D/'<SR-3DU^G,EZI(,*DA][M]JLC2C#M7(A9 ?DWW+\
M,<#!DX?KP08_ C^VL^=BD)Z/OV8F2(F:1K]SHJ2!N^1HI%.1U2Q#!6V?8U":
MT7U6=9:A*J,FMGH.U#%QICCOSSE8R?I?:!J+!9I89-6]878^^/<;N'>1IX;_
MTL(+CD+V@B4&%;OG8B V2"$P%.#G&.XDA["YVF1P60UPN6] [BFA]E&X@)@I
MF6A,R*29#I%FJ0=+08=*DX(<3)-2<4;CR:7NIKAE\NPBESP0+'1HV+P%RR7-
MUPS$-^82Y5:62[JE,DO\W"1V>2)WV<WG\QJ.2,F?B)^_I\^17%D4<TRT?XU3
M)=>^_I0'=(0^"[><T5KY,Y8>3!83G2>YMQW2")Y& ;L"TS7Y)DZKC98]T)-M
M43V<I7PU?1'@R)F5@Q?B2[Q94<-=W+YJ30^&8CQ,>ZRSP5^09_!OR2JI%+EA
M%IUZZJ2"E/%F&3]5^U#':*MU#TJ]A\9$]OIDFJ7!K_[Y?C7VA4)VF12%S<Y[
M!#3HPW1_&_R RE*U <H,-9RTT*-MY*AKM9Y[;6#WSBE9R[Y;4DA%,194E+!S
MXX@VZZK7;#[X@^1YKPZ2CYS5"')SL+ J7)!TT5$V91^*%H%G-RN\E;RQB> =
MYOI25$Q<A7#'"5$7%?"\),;0,665;"B-8L=#09>5S^JF%'D&K<GTY4342(JH
MG.@H/:? A<7%6<I@=8,BA#)*:O0Z>FDB"WF&52NFEE1=2AM[1A2 UFUA<UUZ
MN+JP0'])X.DK)\^%3^,V1S+7I0= 8"%82N1%B; 6@,N.?$79]LR <F&?Q$ZH
M8;>0.,D.7S.\Z)5F:-'G!ZHCWED ;Z<UI>KNI-)2;HJ+^/W7>5D*_%_8KQ<B
M0V9@/K40 [N0"L)VL"7IIVEH2>DI-5,KGBD-9LF"1K,T%SC(]74">>0?J+5N
M#C]*['6)D:X2%,<FDD) #/ 5?NOC@L4?EDP"CWH4:>:7=2K1R*"<L9>3YW==
MC298_K@/1"R)Q9JL4I2.K-><B6R0E%F7*68,.&XNL2Q!?I>TPY28"&O/"L$/
M"E5*HB"[G/2B$=J%Z_1 R0G=NI/5?6(FTD10AT1-]Z^PIW%14"<-TP. ^1@&
MS-2-9?\H>OIZP$P%@9GR+U"CM:"_\U)K']V^]U+7_C;-V6(NX""8#]U"K$#!
M@$T,FQ9T"W%04(2_SN:Z)-&_W?<;E';\FK^7!W/KM@I&SMI,LMK-002UZ;P"
M8Q -0F;>GYO$ A[:>?$M$ME54N09'<@6UETI5:ZB4F#3KG'$:9G38.ZZTC=(
M:K/NYNDJ'0"2 Q,.QZMU7JY6=:;XY,EU()\HH^RH-?&-W@<6KWA>7,19\F_E
MX%C$Y$X6UN(<9YI-S>9IX]+@?$=G@TEW+#3;71? !KF W2TPUUA7RG7&DC5>
M2 I(22US)70*T-^+(B$G=:()>W&%>2=]EW\XHE ^B@GO[L52Q=^\T0=$V$F2
M6!D0L!*Q3J"!3"-)36O(?G35E,=:G' V=A=5-Q.Y,UV1N(IE+ABQ3' 0E&:E
MN=Q7LW0[;)_$CV7U\X2]CESC"&S#8+#3M EL)RSY4NW&X/&'+A;=O,XS1C5J
M]<E)=,:9Q2GE3RT\I.Q(E2;SRJ8MN^7T><W4AW<P9;+C9-HU9V?OOKX[/7OS
MM^C-Y]]^._WE\]GI^8?/GPX\$'0R/>Y5($B#FQR,!^]XF]P@R/C!G9:)!JF1
MNDV[(*7ILXRC!RHM;PW/NP/J,UP27F:0D4/HX/*?<M#<^#%$(NZT[Z#4MT9S
M-5N'T>GL>ZKVO48P-F< K5Y8(ZOATTRD^?6X57&RD PCLMT8C\8T(!)SF"Z)
MC)014351VP%EIW 7N-XN]7::4E$%(?NOJI45LZBOL%# #KZ^P9CL@F@8E_F6
M>6G/![4>D0]WFXM98+W+V/;;35<<M8Z44C%04F6YZ86;.T.Q07AEI&E_?1;X
M7AW2'#>)^B)SVJ21<CF,WCQP1(+'$^#@D3^R47G"'!<@7%J0++X+WMF&M*8A
MW5L77,I*@+.PWQ)Z 9/W#E@+:-K@L-Y%8,1!DE,_P]28J**^(_96\M@A293L
MI+=8[**XZKU /0MPY CAV37O8\>L4$=SAWGQ155[MDT(AC<(&>PQYH1U&'%O
M#_D$1,I1^]SEIO.,5D>/5>BWWY'J P3;JDU%CM=$6ZS/:S6V7M3[!^_=F.SH
MNV8+3RDS"P%&0DH\I[3,:9J;3JUMD*7;4%(%:]MH<(?TJ<E7V[)MM4P;"X:9
M?4H=]$=KD&.5J--6,F:L6WZSR,LNJN4F@Y^7B=VLUF=6RH :0ZF5H&\W1^U>
MLW:'5=C:VQCX.EIY7N%-L/([67'//=EFDVUO3L?$LKZBT8>7&_U=C=OD=*VM
MA*N-0"%ME00HJGM:#.'"-+N.Y(G=I82W'+-05J)9NCQDP&^1 3]Y,F3  \Z
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MS2*X-E0<Q.&.8+,ZE6Q<%.U0L0_)*E7/"&SH81/25%2F7LBE9;.R"9JMRA0
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M[P?O,^Z*O+1]1C:_YG$M:SFVFUP6,'4BB9&YUPG<\3HOOED1&+FG&YZ5: :
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M:0=_W9QI#<LRG[-#9L"UGMQF@/.[3PPGS#T8C9SBW@P;>&G=]S&NP&+'"J
MQ[[/G(?:'K:U#7O9TUW-\HL QXVS[!PNXVXW<8 #;X$#OQK@P#T+%CSO5;#@
M=\X%:'/_;5S%&#SB>/M'Y.X3F<(,F*L$UNRCJ7!.WVZ"5$'W%-;T3VR(IPD%
M+SWNVJVYZB<=W0CP2JO=0$@YP!^!)H1IS]PV .L]VAY<(6E[?=JE1]^^^_N[
MWSY_^?CNTWET^NEM=/;NU]]_.SW_?/;/Z./I^?F[LZ\''I%^-NU7T7@_"DT.
ME1:IFV'P?2XK0]P H*J;]=8"C[P$&2WF#\U&,\(L+B9N8\[0-C*WX[$5IW12
MN@O3NI7ABOX.K_T/4)C:W% =N1_LO#M&H0FWX.)O,.9\N0QR[E51Q<04+EB8
M&,(D5DZQA+;6B'$)RZ[6&T5D_ULR1Q#](OH_67Y]]+?\FBE<F+"!(H;^I<1%
M9L!]1VAR@@49<;8AA%%WFLAB@N18)A%X839/05#D4C@4F=DF6N3SFB@;Z+$C
M16)U*5*J]O#07D<,0R'&@3*!A8DQU["">6,"[$42VT0%XFB%C!D3_23DN%B#
M5[PH+X6HR,Q=RQ"MYN#FCF?X<VITOZ@+V3U$\V7H&A7":HQ["6$*49O>'>GE
MSV:Z5-UDWGU?I[EB3:/H>KYD<="L6$1+%V<7%)D7JUF^2'1[RBV;4_-E[-R;
M-&>4EYM1C<\F@]^55#(U(^X !ZW7?CVI;"Q_T##>:/*/>4[ 4[ G4GADR&I?
M&:4H(GJV@A1V<PBX]:6W5[:X9%+73J/W3IXXR9+**92#R]L'!_5X]4V@OQBN
MOX0I" 2(PP0",/R2,[?,X8B=-N@\(E+-@4RQC_".;I?JQA8@]8XTX+_6+I[X
MCY1RYYG2/$H8@4Z%]7=VDG"YS8WUF]P/3O[;E?9!W,,9/(B[+D]0D"%P*E.T
MO#<L6Y5URNPK^(=U!CT<-GO;X/HVF0$?Y&&@[P\U_-G-"J_#GYK+W(0B[3;D
M[OF!^DK1'#"IN:RXX!H5EW?8JG>9B11)W\JM1S(QQ>G&]!:-+SBIR#;IH"0-
MOD(P@VX36R;+43L=1__Q+H%D. LM+-ED)_6P"3DU.8_;+TNW;V8D;8?$9FN>
M[-6('LN1ZK+4+0N7,7?1[OR!UZIR8V>[7^06ELH0XQIB7/<<X[K[L-8 Z;KQ
MJAY%)Z\'2%?[?L%L.U^HUHW26D=!9PSLYH$Y^#?NZ@WR&/M]GH//5,_WZ?*\
M%<F>J"9(E+.JJZ-\>;3.Y]]@4B7('3YO]VEWVZJUPQ,N]30#XY&:VF+4Z3\W
M]+-@R2W4+MN"(3Z0';#8XJS847H9O&=@A(/>\'#!JV[$&!YN[1I/\$M?3+:I
M"869,C]?%R03PNM@U9S );)\W]2ON>2:Q(,#MNFBW2NAU2!%^@;M<1Z,.QTF
M]*Q?;,>V[QMTRY)#UVQ[H- ZPC :%-(H29T)U4;$TFD3PRY*R@W>^>*R>9RC
MFU//4G;C14G-)JG7PW6FF2:;E:JV(-V^4&]+:$6%D=XGTN67 :8BH5HPJ\V>
MBCK9X8/="EO/WDY%;4<-.NMWB:$'*W7+O"[FBCT"+ PB CM:Q=^V%_T<B%AW
M1Q<_@WWOA5 >S39'7FCE+"Z1Y(\D@W)4.CNU3(JR:F^$"1JN(+@"$VW[2_N-
M.B)U5FK+F@$AON%E^8S8NZWBQ=,UAE>P:Q#*3!6E</N*6EZ,CL?^_1&]I;V+
MN1Q,SY45;Q#O9.%=;;SHH;.0/)OVBX?5UI=GW#HW[(/W0:W%H*;$=34<W>,0
M1NR%#V\<VE:KYU:(A-29@P%G&'J<"HQ&1_\$!=0^![V=GU$%:L[OBS2?Q:F?
M:Z+9W%!(S;?L3(]L.]]EYW75*MHP<C]PI^C;O4W+"#E\'=LOHJ<V54"0^J0)
M,;2#%V"ZME.+JB:1K7)BG,'HG1V\FS!<A-EH7!O58X=&<5U=YD6BF/6L,(*U
M]U<\A[?=+5O3IFY3/*4"Y RTFJNBS;; /EY$P7D9%ZMXGE\E%TF*L<9)!(_'
MRLH+1>XI] N3R9:DW(@07G51Q-><$?KT%C_[>'HJ^['.!=& %C!0F PT-^&J
M-W!72NN=H^:<>EF ?'..4[8&M1<7RA,HZ]DJJ9A6#G[IBJK5X66[ZO$[0_9T
MZJ=.G$?"""[S=*$>#V_/:P?OO^VY4X\V5N$SK9/G.:=%);3(24M;373,Y[[:
M"Q?,B[A<3*A36+N94W<[G'.FP,$(&'_ [@G$,R.7>$U')"ZQM1)#^NX6Z;MG
M3X;T7<#INQ_7+K3!*)$4<W<6WN:-O7.J3Q1/<L@)%A5>KY@Z1_I5D$64#)H#
M@U*WT*!\-. /Z2#R_MK$T5ASFL98&3+%VH0/HV92K!%6H+;D)IYTIX&?,$W%
M?M%\?,HCR?3Q5LQB2GI^ 5O'CRY]\-F=1F^;;I[5#8521:5BJ#" &*:D!A]N
MM4[S#3=C1EYZL,IBA<Q+$#(L)P#[+W1M:FQN)/$R,X2U*1B82X^MN1<G>&-)
M$*UJJ.DYJC_"7 BF--_R4&P'KCM"I."K9O(EM[R43$&3S9C1#I7 >RL?;;BA
M+^.24=5[SH'\P3Q?B1]^.Z=KN%LC#HL'>[[5Y0\5F+KP$BQ-&0[LF DRNF\T
M'8>OHU[T2D=]E:C#D@_'#,^Q0-53"X\B!<_BT=DSOMY-MS-QPO9<<F=1Q-M]
M?^33)W2'#HRP<HNV4E VO>/;!8T(>6MUJ88)SX3L%D?6DN:^3]BVT:$Z^6B[
M1P1#''4I[*G)6?T67Q\F]<WS3NJ;-Y\_?GQW]N;#Z6\?_M_I^8?/GPY<A3WO
M&=-->W,%#3KH9'D6W^=I78*C+WNTV,S '+%2/.V^0'Z_N;]#)F4?LU(V0G8K
M%$(KS=H  ^R1V-GE0F\)W=KP A X/I=<Q](^Y]RW=:RZ\32Z?99=AZ0[O//F
M;6^>H_[A1#T9OWO:$>XTW6.^_4'RIK?NNQKVP?^B\^#_>/KI]_>G;\Y_/_OP
MZ=<#/_1?].S0_U5DV$<Y#90$M3O[YJ+N.M)O'9DWGY6@\,1V8:)'V3OJW2EB
M=)1[.T2J*Q1OB;"SQJ(#HZZ#A&^ "A<.-#<55NJZSS9WN(/%@_M:_I1%L"7=
M,BN#CRD<=(KB= /;7S]AA:<1OI.:SI4]1<MHK@;&K<#4:*(_ZAC\+=5)P*/)
MC6VP)6HLQ[;@SN03^^$3-6C*ML&QE<I_(**#_KD&88\OZ)\F10D'RUK(N\%Q
M(Y(K^EBGY\AC3M9KN^OY+0:><^4;YCM7.L*-:4DU)NMCQ\T=LF"WR8(=#UFP
M@+-@5+=6Y7I74#J+2H(KW:58HIA!RXB+7.Y4DU6GC2Y5#-J1ZRI9286G]0"J
MG%07_]+%8#QC>3E=9>DF1XN45<RP 7SBD?THV%B$2@!KN*(1T0.XV7!=Q*H;
MG?J40F!Y>NAQW!<]J[EPC]1S+!6')U]LHK!Y@+&3MRKM5+F?R@S>$*)9/5%A
M#P7X,@=2[4<FJ.G_2SDWPS.AP?%6X$+9MA8SFLD@CN*Q4WK&(2\#YG$I(T
M)*W5IF'3-H2:2H-GXT[@T)[^NRG?1[B25;Z/MHJ,KW2.P4.,M,9.MY329XHD
MP66L&ATD> 0.JL@0*E%^5:/Z.0ZOHR3PA ND Z;F[VB'RJB)35V"<4+._/U[
MUT-L#V!K(&H/,Y![ZW88R(B"(DAM(U@UFJ=QC?7 *"%J.:O\@A@XV"(.F<BR
MG^I6D5I.P1ML[TG*_6V7>?5V/K:ON%%7NC#;:TV5J"X<$TR;5J,*LJ"2C)-6
M[<JS99TV"\^L(C(TF28DB[R#E&<H8WO@K?#V+"UNY;DH*D.D8J@]9IOFKO!D
MUY/&[I85O<+GXWKFT)/0]+TCO9$:=:M$?D?EO0<FM=?Z'F:*[V5GI._7L]-/
MY]'G]]'9AU__=OZ5.ES\]N'-NT]?WQUZ7XN7/0O\25!O]"N(*@+W#KW8L;N&
M-^3E*5TP=DMU!7D\^H#H>"+!:7!!TK;CI2RB9S RF9$;>WN)__4?SU_]Y0X%
M]?C)JP E->F4U";"I;/3R<3V(%P*0'^44OTLE@?G.DX61_5Z$A7Y)DZKS=$2
M+)&AVK Y*I-$D-;1Q +_4%H!5HED'N&'J=[3,H>ZPF@_V#I@Q&'M#O(-.Z@I
MJU5\?PE\7P;:U3@:Z<G&:O^)!'XTN6$T7O8#F&34'P!L<_39P H&@_,,[T@*
MK>:*I#4A[^>,YOT25Q)&;WO%DC8K90-Y'XKI+H78#!8X6WVB4</&M<V= DT8
M,FQWIPS'\W RR=FI(?O99(C:S-=$P;!-Q2C:"^NF3%%I[HJXV*2DB=-L57;<
M:@\.B-#=7CW;>L'D>1_D3E'N+O%C!G$('.[9?P>'OZRKY"-&A1"C4<]X38/<
M"5*C<A".:A\1B?!]G12:M-B%Z<O" 7FF*U- !BFH-"'+LR-C1G#U:7%%_V;;
M6$;S0711(QX"I?_QR?15@$-'DX"/5SIMWSG+JE=TC*']S(*/C) [&Q?+AR:%
MBZ_S(EU<8UWM8"/VWD8<\!8WGL.CZ-G3 6\1,-["V-.ZT-^$LJF24-(*WP:N
M;64 &6XM]5I>5VXFRS$N#]B^ZS;P8M<6F+BA&,:8<#0FPF@,Y6'6 MW12904
MA;C*R16ZXQ-GXDM^Q/+G<!H5[  WK=-8 ?&XTE%B'^>.YVO[G!+4TT:5EPZJ
MW,AJZZ@]^GR=(1J\2%!71Q^^*%0.@1@]HNWO[^2:6WZN"K^3K#W_9MK_%RUV
M."I=RIN4\S3'(5'40)[A]K3XF&KW:3^%/K">U&2%]Y;&*%R97$F$D\@N,>FH
MZOPYD;?*%P83I?QX=_Q69;VC'-9ZRU\FZ- 78-N*9&LKKJPS%Z[[2P[NYD]5
M1U?[:R.C55B'X.[2^J7.JB25&\?UAD )Q65U5.5']$T[1I5C!ER!Z#"()KMN
M2X8C%BOB1BVK(H'O4/.14@#E"!^NTQA.*1+<#6$&YV )5$++.ICH,/1O:#J/
M=_60Z-K\MPF;*03TNB[ LF-@\SPNB@UAA>7QYVQ91+LC B3FDG.CKJVI9L4+
MBJ+_G.TOJ:L5RF" +P"['R$3R$*$PB1Y33=23?*RP&(U5T62E$N>@=W2UB"V
M-4^(?T:A?Y")V6X6VB!#MRIO[O/V@Y3CGU/L]G+Z:A\UT':#JWS]YZ-G4QS[
M%:*&YG$J)786ER+<_GQ6T+Z5R_:P@=XJ8Z/KFO8I8AWEVXU5FTM;H1E;9K?=
MA&DF5$JF*S$U$YM<<O8U3G$7DV8]&DZ_LHZ9,33 5>UY!]))$RD\WI'"GS3B
MS4-(\H8AR<>-=_"GS)O^[JY,N?(8]\V0;S&R]U&SDD/.FQG'9HFNVMPG'7_C
MC/B2 AE[*G;=KPO&)QWHT>E8ST([S@$W'_TRWAYVF#3."EY%2IW[P@RVVN9:
MDF)5MM-;I#;(EP&U ;]3'1VL+F/K>",;-L+D4>E4(KCBT<[I[_"EC'6L[6):
M!0XUP  W%&^(X6D%NDZ@X,2ZFC0S=7@#.1[[Z7"=C'2HP=+=[$I?F.4OZCOB
MB[6<.M*:,C '1VDMB1</(5/W:OI\- _SZ(M&9W+.S_2<CQO$M"/<WK@[8#?!
M=Q)Z<I>[O+-=U'X@EG:GJ%'(L)7VK#7Q*PHJ$J3(A-$NX6#Q[_TJ]+0MF3"E
MM5W7HLDKM)%NS/-)9_Z&8K#*AE>!*BP1K%1]CDU<V6OZ*PXI!CAX/*]\D'XZ
MG@(<[[Z3'2C5F#O9/E2.P_A,QC$64'K3CS99Y<A3L!?@#.RQ?*R:3Z;')P&.
M7R)OU,RCLVF!;^Y[H+=$,(8H&$YG=LO?6]7(D\$5TTT_<L \W7B2CZ)G)P/F
M*6#,T[I(L,E,@2P#!&\IT5/389K2,@XEA%==@XGI&;;,MA+"> Q<BG1!;A]'
M/AC6L8"-L.%_8ET^VUDFKI P4:*,O/K') ,,EHGF&1!'[V\T)D98#"KUKE0J
MAAH:I?::(UXUUO%$'98R*$>Q DD1Q-P=U4:%K*SHNL94-/+.[51R@#-UH!:\
MCM=V>&:--5OH-@(N8@XOZ:P+HH?L#K\8_H,T6252,/#&=LB<&UQY*-@]Z;O=
MM5:P9K)-@8*+-=YSL)@?R&+V$V,T*3'HY.'UIP4R!&M$@FPG]BP*RB;7KRO*
M9F]P"Y "-1P2V5#&0B)&94R_>Z,XP0JK_P:FW^G'IH.<1J/BT-T37.T)/";!
M+DW$E6B?\?+.\J5]Q89N40_G%QHI%9V&*.&WY9+V5H+:GV?7-"QI#%",8*+\
M<SO"D';G[,H%MEXU=A(SSN0Z;*:QV_ZH>_WL+DO_LA25I0TX-<1T1=+0\&2*
M#IWG[F7/6AQ_RJ//9%)R6C9(C0;RS?M,Z2FM& C9S6I$?%]C,]ETXT-&6ELV
MR_D7DPA,*PSY8,('7439(0DW9A83D=<U**TRQRX!F()5M[V^)$XM8D-?D?1+
M''59Y>NU2">D7KC'I<)37R<8F,5M+S6,W#Z6-3^-3K%#HQ]%;^7$)S)57AJP
M]O8\N]*\J/CPAH3K3JUY8I(HN@;;"Q=7QES(KS,^]@N1+Z?1>^ZC/FDO@@6'
M++W&J/60A@J1/RH$!AT,5]0<! Y69:VFRX.'^I =_::#WFYU))62FQ0Q)86U
MJIJ"8"96J#OKK#O0Y/7-@GX;I) 7>DFTR6-#^=U3J[O&H:Y*ZKJ)/:KFL(AX
MC2U M()NZQD7K5/: .&N4]-#L_(8^TJ][%F;Y*_YLKI&,7['F"TX7 /5U9_R
M"L6RQ$98$@>"I5\7:HNR:5I(#D-7.1LRH+EN2R=56"M4Z1%DRHLA!QV&+W]4
M9\K,/>S"B6I$;*MD=<=Y&B<KQ!3P^N"_ZF*.K[D0C&XA94=_6DSJ!A)NO9)&
MA.=M_A'SY8?L"N,"#%@QUF+W]5^FT0=".=%&AV,J9_9Y12M(88MX',&6OM0L
MAGS4)H5Z9T14-36C;AC6=A0==-":E\02@IJM?+: 'V+J%$=F$%" H':P]DQ<
M*A:#!]Z"SR*IF(E#0/L&7I722PQ+V'26KSKI++^<_O/CNT_GATY=^:IGU)6_
MKY<%CD<B,L/<IZUD0.RKJ(BSJ)9OHX&IR^AS)J*_P=BQ, //J_?)$KO-8-,2
MT%!OT1E"+,)_'C]_,H'7P/\;HX.+1R4>PG!7&U)L\8U[4-)#>O<VZ=UG0WHW
MX/1NO<XS[M>SUAG4)+O*T8VG4LZ6J3AB*+F)%5.H'!O^H/$CL-&(9P.-I]%7
M"S=NPJ59GLUA]R85PXO@ST(L83XH8HJ[CJ(R)B!2"B2=7AZZ]_VJ9R#1MTDY
MQVX!I'PQT)<)70<0YK%SZ-7"W33._]B?'-=S-'M;P<;8@O((&?:C=2&.=&^&
ME18&O?'M8H]SVN7'H ?2_#H:X4"P+"]D9/\600]2SE6= :4&/"NMN^U=4']#
MDQ;HKL(B(HI+R@^BHN?%DX%SL: 0.:7:S>(C\1M&4'JWLN^N0E]7]UPM'^Q@
M#=%SW1;%D*JG\VV]IAO-I;'=L0\'OE@:KTOQ9_6/OTBJE3\G&0V(?O07=_:>
MMXOZZ8'\M;1/7S^?GCQ_BB9J!<9GM5 /EM;KE*S7_ZX6[>].7DU/7C_O_/K)
M]+CSNVVW??YZ^NS)?K?];QHR#QLFIES'V?_^T\F?N@5C\1K_YR]R4LFY>3*%
M:<):M&01*5&1WR,W@N]KZ0K]^>GZ>W3L"BC>LC7G^7J+<W4BO3G'O9(?WK^#
M=4NE)9T5N5X_82EX6H:UNA/3P5JM73N()U<%$+JG/_2M]$"1"3OLL_]>N:M)
M#V33O-ZU:Z2#<W3<YF3[\84ZWK50)R>\4"]>OO:X,=W>\#W($ WM/YW8H8PV
M[K:TWR:%H%31Z46<9&4E>\]9MY*&MDP?G0DP)R3_H,\@[[1A]E[L[BC7(#J#
MZ/RXZ#1<AR?6O09I"DB:FNF06TF1L5[^FUR??9VK&XM17R-SW3Q^IY1^LI=@
MT@[ LX>O@O2& Y>00P6CU@GPLL7>- 5<[L,\;3 QYL=HAQ4"#A5/=4?:;"%;
MCULI!?JQ'.[!1UWGG6O[8=E6UBX)YA;>(X+@.@P]^&_OM1*51=RI[4=.FJ!T
MAU&)OLT\U5E4E*4*[K*<4)Y>TN5E6ZJV2$Q+^#01$4<,"7BE1[/(14E1*S6@
M+0,Y 'S-J^G3<-GT]M5*Q*^X51-Y\PGX,U<X_#N@+=IEO&ILLKA\"$W'5:/(
M'")P*UK 0F94,]S@$HQ0UC/N%>P^L(,039_A!R#H)],7 8X<I1S7^5:RNVW%
M=(1^@>#/!=%/NN)(($%4=)E@0"?EW7:,93MS'N7Y;<$*%!XW0&FV0&F>#U":
M7AF#BTYC, )KL*'H+Y&A<SZO"\*R'0HKXM-061$;%H"V+5?Q-T%MRU+Y#KTF
M"6 ;<I2$N08]IO12$QOJS!(H8^*Q3FYMIQ^ H1FP.II&9BU68.V1^J&"V"ZO
MVUY4CZ="!9]<Q.DT@W\0<^]G]P>ZMQ.]NR<9+L]RT_:+85EP!9DQQ(YF-&N#
MV.IWEQ!_3&A;]'DG7H=TI,S^-.? ![Q93@8$BM%,J!HV630LB]?&W@#,C<9V
MD5SA2RUJP2&GA9 >!\H=C!/A?_#%7!2REDQV4&"8$I^JIR8.]5M\S2ZS=2;T
M7EI^7%P2*DN\9ZGH[.S>C'6P3K*K4MLEIR0Z<X%!&SQY&H5S/T..IH?.(/RJ
M9Q0:;\45F"-K,B.T8<$VAS]&LJU19IC']Z'G-6Z()O^((<V$2#3>4C("2;":
M?1[B'P2=TY-D(+@%-"]]2/.GO4*:^W9-/[#F)DJ^3 I$*6!A0'.Y=4"TJ[>E
M)S^]5UL0"[^^4PYW8-GM-: F4!=U&F,3WC:XO;\B-8#<#QOD_K3S;0, N1\_
M>3)]PM'CFZ+<GTU?O'A]YR#W9R^FKU^^N/O;/I\^>=X+[/P3!)9:XWP@^/[3
MZ8DW_>*'N/Y<_ZZU[YYLWW=[Z-G0$?F'-_U-J/TA@.Q=A7L"=Y"?X -/6C#+
MD%#X!%P\;IS$]X&]WV<M3J8O7\(%GF51'ML#;(/6%#[I+&0XY!*&76#BIT]H
M\1IB_I0__/E@XOT$?P>8> N@]V>@O8<I':;T;J?TOI#D UYH"U[HQ6/!"PU^
M;!_]V,%T_A'=_/3&IO-@&-_!) UF[V"C#5,Z3.F]F+W#X?F35OAD.#SW/SRC
MX?3LNUX:5/TPI>%/Z7!Z]N/T?#:<GL/I^8CTTJ#JARD-?TJ'T[,?I^?SX?0<
M3L]'I)<&53],:?A3>M^GYX I_%DR\&+ % Z8PN&('LZ384H/:TH'3&$ F,*7
M Z9PP!0.F,+#-)U?#J&I 5/X> R*P48;IC3\*1WR.OTX/%\-A^=P>#X>M31H
M^F%*PY_2X?#LQ^'Y>C@\A\/S\:BE0=,/4QK^E!XF)N(9G7.]4/K'3Z;WF7X?
MCLP!Q=!C=36< ,.4AC^E]X5BV(MXO#L??G@4YMUM=^^:PKQ!2#WA&VYEI324
MQM0.,,_@L=CT@!OWW3V3]I9>L\[8?X1,V^HRNX40=8*LVG&Q@ ]+9'._OA38
MM,8T\]SR6^R-4=:S4OQ1PU\P+OGX113C>U)K#'MA]3UIZ1;)<BF*]H;;/9T+
M-9WV/>]Z-KG7A6]J4#'B0^(T>@."3BTRSO%>9107PIV1>9[AD,6"6JA:OSPS
M7.:G:^RHZ_UY/JM@(O'7]S&7/T,JI]$Y]@>(OR>K>J5:NZ[C#<FEV]QM0(+=
M! GVZK$@P6YRD@9SW%67H!L#)/7?KT_;28 C_]-?H]&==K(9MW0JV0G[Z+]&
M3ZB#;S\S[[3=/N45SF)9P3QSURR!RR$N<OAK0BN#'ZWK C2QH&,4VTQ51:VN
M-ETE=-L/V6D<5@%-&>XML<=:[7'8L?S (_CDN4E#DWCG43?!MN)QME%-<;98
M3J[\P-6PO!=NC_2M\^%>B6;8MV2-[S5*IF**?5"XJ_EVHQ=^IT[BF<!5H\ZK
M,:B#G3]M6-@P/!ZC&L>6=Q_1SG-Z<,-Z7L97. JXC3$BL;^Z'-_(ZB)"4E/D
M<S3+#J--[\EH$69?S+%Q@.2R<"\>%G!CJNY8[VGTOB[0=IZH]8-9P4NWN5(P
M9;C?<U8L_@TM!U5V[X>'FE9ZU)^3"C3]?(^)%M,+;TOX!Y> B;O52;^1X;_'
M3A^V>6^VN=GGS2:3CJ%#C=/YA-O_=,/&E&JQL3,FGI(_8]^S09?76[51L^L[
M=;^<P<*MM(H#;WO;#9X-8MT;L2:IECU/G>-K;PD!@:2;;-L6$^SL:L)MTSMM
MN!RD0[#8XA"XW2.+_"I9B(ZFV<WNVC"Y&(QOK-66\*TZ9MHM>+D'(BW5C@BF
MWK&PU')'ZX\.HNOZ2;A=UT]IE?Q]C?%/2Q(FJ%'9HYRG,<C-9F*W%@SP!?==
MG5F8JS-IM\?F/9UD5SFNC][J>*2YI_9VYW&IVF/[O&]:9U\36E;C'$#NWO$X
ME@7V3 ?I:<J5'/A=AFO"[$_]K$L[!]D6]6L, M(6D\!;33]$V/_P#8L;-KKV
M>@>W:V%=HA0>S>(2COW]VEF?]*F==<<F"W*/>1I95WD5IW R9#7\YQ.L!;\/
MK 6XDO#/;!$7T3\%_#^E[/V.HPREGHL"+ A,OG)>7_N3<#*)[W,A%J4,9:>P
MPGBBF6AL=0E2>)FG<$D_ES[\AM,3< -@<^&\D\U$Z06R"^*+0HBF&5A=QDH@
MFO;]?[@F MQAK^L*!SY!<)!F L*?5&I#/5",&LZB9Q3*--H]WHXK8<2DS53(
M@<9LQ-<1<SN&Z]IM_LF9;;9HV]UOO%_[<-DOW.H@?N=MQV][>O:S[_C)@*NX
ML0(ZBIZ]?BRX"G=A3J8O3KJ0%?=+N_/ZV?3D]?%M6'=.IJ]?G]PY/<YS^/+I
MT[MGW3F>OGC5JX[T7;*SI9SQ1IC7!^YX?QO(_VWFX9X4W$T/C:U6XG;E$?Z+
M@V?YGBR@4]<".FTZ%&A7ONNT=<;W)K /5L32LX6]B40W7-Z>%I<[*Q)H.?GQ
M@Y23W_/<[D:AWI_;W*YVB49.$<P--%?@"FIG_=+QKB7K;?U2LCVT53I@_@>I
M'1OFOC7WP]3?Z]0_3L:9/A@%#],Q?3 *!J-@T(Z#41#6W ]3?]!&05^Z"_7!
M;+AYK_B#G/W#-BP.F?5GT,&#Z1'0W ]3WV?38^B:= M,Q_,G Z9CP'3T"]/1
M6T/U@53YLR&ZV'<G8##Q>V[K#"9^&',_3'V?3?S!*+BSQ7\^& 6#43 8!8]*
M.QYD]/^!Q./%D'LY? T[Y%X&'7Q'0>B!X=Z_ACLIL/M-%_PLP)$C77 7L<A>
MS+]=G+%TJ<,4KRBJ?%NHDRKX(4Z/@V</V<93_&.T9*1KO47TM/3^NOD8^74+
MNFHAT@1.,\T-?)9OXK3:H K.BTKS)&LJB_];PP]A.-A%X3)!NLVZ\S$6AUD7
MHY;[N$.ETGIVB%1:7?P/'21:F@/GWEBT!DUVKP2+'Y&GN[K$<R<32IUTG73>
M+CGJ9$.^PXZ^(8K.)(@U#FIEB$"HM\8:BU ?+;85Z"YJS\1F,\OU!9RIF>?0
M7$8KWR[9@^N&>_ X![WFW^<V0XV'3:/WQ!D5K];(1=-Z-#]EH&*YL3 <1<^/
M'PMLIY<M;IIFJ&%(XT85H"1OL(]D#XD;,??=T%#R;_C#9P-]WBLV4.6J:!/&
MM_Y!'E\'WP:HFYPS2$GZ562BB-,P927ZZK8$R*FU(,4E2CC,2[99^F=HGF+$
M'@RT5P&.&RU,8U&B@]PYZZ?(,\FTXWG6Y4$=S39'?M<*[SU''[O8X$7RG]$L
M+I-R?WK:@E1A J_/M+2R0X=A*_)''G7DLBY4DRV+S%+IUW-1K'8$$?# IF_E
M^+F78R%OH$QQ;RP5XU[)O$[CKE9<FLS1>;44@ZVT"'Z^UQN2NQ(];,-)()+8
MV48OPH12(; ;88)$5@K!/>/@1DD1G2Z729K$E2AE![+*FH "/X]@?0IX 7X-
MW45%OP@-]\[>AB^W7V4J%Q2E1,_I/$YQ[C'[ V^ZJN'K=;KQ"(/[*G!MVTWB
M6%&I?"B,'^(HX4_G11HWWBF1CAC*0)1-QVQNCA-<JI^V)P"CK(:<F1B9#_X@
M[LXT!7D0J[6F1C_[AID>?):GT>=;:/ZFBJ=>07MH>+C%OGH=O/S%+3186Z%T
MG"J\X:C_L:,>8B\+^C/%@HY%(QAE L5'G,PB:%+L7^#=35H$WB](&52$V+?5
M:/UD+G[6^;9.!.O9\^GK,,J;7CV?OCQY>:ORIM?3)Z]>W'U]TZOIR^-G?2"7
MO1OHSPNX@_P$'_@B<'#7#572X;*-_I15?%">V2_&/CXGJ__T ES)"\RE.FTK
MG),80\3;F6?9E?G5X\ITV-1]KRXX2"R?G6G_+[?-=/1%%"BXAPJ0_X&]_4 )
MJ-^P0R?G\8I(_(&N.]CP?CCFL-N&W3;LMA_9;;\6(F;D$6RX#LPSNJ3I#79E
M-&S+85L.VS*T;7GXI5W#OGULM4?#SMZVLP?6JALOSU'T_.EC@;\-4=U[C^H.
MQV4?C\OA,#R P[#'9NZP20>;MN?;.-R:]A#!X^_=-ML.2L2T09?I+)K!4J+_
M-19M(6!%P(QDI,GM\#0_I];PY?35/F#7MD^"N^'HV?1IVXA$1 TC&4+$[?[I
MK[]L(K#Q"5]D52S1XG5"%+O*![%0:A\^$A8<67**]:0:\Z00I)>B$%Q<[T,P
MQJ7L8PYWMJJ4XVSC(!D%#HHPO'RK .=_ORKFYZ-YF%7,T<B4D:O)'H__UW\\
M?_671K_W0\=?=O,,!(EU:R_;/15O^X=SE^)Q_*1M6SZ\?"3]DH^_QVA$ODGC
M9!4J%/=37B%(O*QB1J7CD;+,"W&1$T8=7+-#(+!X/A*AJ_[W:9X7XY]1%2.M
M2$'%I&#!2PX+78."Z+AED:_HTR9-A:1)F>P@Q<IR9#JXXHH-L!\B2_39UE%5
MHU_@MIF\6 G</%\I8Q O7L45#@(KT==80@3W7(GJ,E_@ES6,%DE=T"-15#%;
MQC:":_'Y8-2X%[S!9];6/'A_/VZ6ZDPTI4PA5G&2X2LH+IHF5(P-M!;Z$ TO
M,K"80XPK=U.QNVJ%H.OV8(Q91U8:S[UC.J[9UW8]\/^Z->RY1R=%SXX*JJE,
MYB26HJ*M$*3"<NHK QSA<![L/@^6S-U1,*.&DCQ5,Q1=QE<"=(K(N""FH0!;
M98G;N)*(>N!NE: S%E-FV:0J:6E&X^V28W67"O#9L_ 4X.FT2_WM>41X[ ;"
M2N-!VIQL,A?$'$>!U^Q;B$E&!_[V2R&.E!C*>Z8;>8M3L!/B"V*]T'D!6/4+
M.R*YS_M$L[JRT@S[_ 0$Y?5?[M2I"E%2?CDX26DHB7N7G/%_L>3DQ:'+SIO[
ME!U:U,9I-2IE&+1O0A4HR]^ &]J"&SIY++BA7M)FA5P4O8>&"=(=D672T4K
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MFVLD.)I$2SAEYY<)=Q4H$W@Y\!;Y1K8G>&K<V]_BZ_).V_$&J5AF?5,LBZ3
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MH/O)J8F;GRO')S;#W3 -#RGVF2!VWHQAN^K023R'#KT1N0)P\ CVP:.Y@&7
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MUH!&8P? ]ZU1\53G[_N9[$#%8:&TXQPS0X=CRJ)<9))Y3ZU;ANB/20RIBGE
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MY%4-O:5'"FI@7YDA&^?*R=U-M<&N+A3J)4A3 # 8F,*<*-3Y^"3B4#RK-F5
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M]&J&R6G#00=7+VG<#;D$4E$TRE?K<NABL0&]05Y<O:,*QPLN^ZOFXDG+<6<
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MR1<J>VN%?M^P.+:VJ=Q')$-!/TX'YLAY0E&V87\+/_ +D8;4+]/3S@O<?#[
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M<,;MK2J5C[KP.Z&D:L150])V$MTF0SPJD7FGU)JBUME 6V+T32:+\&"UL[O
M4'8*4ZA /1/"!@]0DP!+ETI_6$45ZUF@.A@@M>$;M3<\ 8&Z6^3"7=I(N$=;
M>9K!ZO!,&JPGX+W?Q!3#'S E;5;.-.HTMD>[UP5Q\,%U$1F&H>H22^5E6%OD
M?-(ATZ"'^C/"UT*,X@EB"3MES=CL7*6Q0R/&+FTI. I1$.#-(/0&=H ++.-G
M,)1,!J6': ;F=KH)(UQWCRA^&:"R.T/X'52U=)V5Q0C'1'MYK +EU03C4T86
MY9Y*/R8(![7BDDT'OW^B,_9Y<92#VV[(/7@V*XO)'$9E<$"OI"^8MDC!I<9J
M^)0-2>J$K,:%Z+D&2L)'"5W3$<4:G4Q<U6<:5VB,+$.PV:_KB&WXG*\V]D )
MQ\-2"I[E1NC*33ZHCF4[9MXB5= H0+N?"'\[EBCDQ764"4AF:%:C7.73+_97
M/4?E$L1J/IN%EE=H90/\NUVP';92:/&)A@4DO'':G'@,";,4SYFIYZ:C[8&Z
M,):+EC]2)%8O?33'R)$.&BZ&_Z24=_GCR8K=<BLN,9O@+ 4'.:%]4?NW2:D\
MNPF-1:,X58PHIY&./HO(N&#,N]+MI1VHHSEA+5Q5K6EF)A1>0D<ETI B?NO<
MIB\VD6%QL:R\ 0;GW2TP@)LD3SVH7+\"MH6[[9ZU:&V%M+/J1\>N>+9.4X3T
M2&*NXL6*_B"EU"2-(G#*2BSZ,\/'AS&[.ZN%B@\BQ]-53G8'.J*P[LZ E=+9
M]?A\7- ^K?=L\G5Y8+:;ZM%QE]Q6"7-:.(?W6'XV%5X=OF@ISO !+(F.5, L
M=SSN)'+VP0(;3;-LA!'7D5!&&!D95%L$_=G$G$%!> ;8W:<1/'C9,(W@]3Z-
MH,5I!*4]5AO14]57Q,4I#2:AP[/XO:B%_-W]9?DG7Y:^*8GJ\"I_ JZQ%\]W
MRC?VCG#@4)< 8Z>5NZS&3&UT:,:PT]3LL1.D=R"6;>Q262<..D.B6V-=$6$J
MW=JF9)2\)AK\&UN>P07.'K;I/!<@'P36*]8IH=1)O#\5EJ,%NZ&-N4G^KFJ.
M@Z_Y57K'&:-L$/^^+I(R9MIMQS#0[G\FI(Z3<KE>Z9P$BU:>9)AMD)-;")2/
M*5B[8'G P8K)LI!YTDQ6A"TX0RAY'YV:HY:LJSQT!39 +TF;[DHX#$W>F)MV
MYI\FYIZ T'JQ4T+KTJ=VLZIX2P58HXDGYT7CAC8@M5:H_.!\3^>PXR04Y:@]
M=-BTXF2#8-;]OYK#!%S/=0S+MU^\E .FCPVNUQ&160O@8H5+KV+_>/YNXYW_
M-GFF ]@6:61$IUE-4'1G)<;6^&.#1EE%IV:_&6KPZ&V_TY:YZ;,7/I#)^HZA
MU0"'(N>=;E1"J[6NVQ.7&L8Y16>FX7C2048GKJ"= ?YFP%EC:"#=1OVK]>$^
M!;WLY4Z)."DA";I^B6*K9M43'.1^%Z9&I+W RI?IERR_355\K20KC."O>"?.
M9( ):0R4*19J%-,XMWS* K<VI8\-V)KE8LO]#*LD$YQCE!Y1@0_HL*=&]N)T
MK94)>CXQOH47KW;J(/0JX-9^>*;]YT(CDMJ+K!)@TH[#?%VPV\,!%*WZ-]#[
MS/>\_E3\(SX=G>]@?@B;4?6*SKSH429\C345PEYX+NG,BG"T\\)^NE09,A\B
M#P5#B0OE3.A"+5M>"<GU,0D'>/13S-8LB8\QESM_VP9Y"@=ZMQA41AC4%FNS
MI<=W(,I?1I8]EG%J^_2;"7"8#2,Q8["[T<C&)M:9L;)3Q<8R/#U)X-RM\D+3
MH*((H#L)M[2B"\HU@IF[A7-)LAQO/16AZHS@Y &'MPF?O!(L](L8DIB0(4O%
M )9"!U/SEUIG'D)5*DXQH>%PRC7FT&$Z,HH19TZ8[=5R:B1&-)#_(^(<Z5F$
MYY0SP)FW8YE&DF&W<=+L>(1HD)]S_ ST&*X9R0Z3@9"3[96@T$!)IT!:1"N+
MA:R[25B?%+]@V&-O2D3K $%$TNLI")5= T,./D5)6^D-FC+\;K&[C-?*W//.
MQ6JS^0A)5I4<+ZEL2DFMLPDO?.X,<\:L4BF54[I4@7EX5?] 7O )1R:R8+W,
MZ[<J]@[]%EQ'I<EU-I5'H^ PQ#MX[FFT!3\?K6R2KM S14&9P+Q'G&>'>+30
ME!Z(1_4L]G.M*ZCFZ+=4DU[$EG>Z77 #4OGERGDT1W#495/M%Q:T:7!YE!)V
M5 P27WM!7KA>W-KGF^7(/LR[+<S[9A_FW;7K9-=J<&'9EX7B<HJ6WBEC2C=9
M6A?P7$5X:LNZ$6AJ,T $W:@L(1*8/)-JN8B%[$08<@*N=T#IS 0R2:9E(.4Y
MR:V$TZ/C8_?0C@^#JRSU<?4K]F?(4/Z*I"]\)D4X9:A9C^E&['^=)Q.\)!<J
MDHH]U."F:[P]OO&5YJPJ_ZTUIS(G5N-=8-J18+8>$:F57]UH'_0AXO)#LH;+
MT-*)$ MC[3)G9"!*9(<1W5)EGQ"U20^$>"RL_+G4A&0P3N\36!J?JZQZD\%C
M>;&DO -<100TH=F<%ZB-2%N3]8HN<\HXHR6KO\_+2HLXP8N>X;QK3@?F0>FO
MQ-&=WSE:S&F4JBR&982/@X,U3ZZ+B(\FCMD^'6E^6F^><XH;WB#)QDZ.L*$Z
M$W^$1RV!A%+P(L<BTMM!8'Q"78. SDGT0MX@G1@E=#)_FBFR6"S6F41K*W9(
M4P!!AA8W; <VL4(]..>O2=;TUXF9:7;!%LD-*1#DEQ&EZU8J21N)-((#EZ3N
MSIP"/?^JXYY[5N]XVWM5'Z%/?"=U8K^->HX:*MTF5W)U+#+1]>W'\ZZ<#[!A
M(FWC-?-ZP[G:UL%ERE\*LX .F<=4U_8: A*]74#'U(OKM)8J^$NA]P(R,("F
MN&*Z.2,=9-YF'9EWS<BG: [T#K-A(?Y OG6MO[4N-3T/_D#2#[,00&.&$63K
MQ02]YGBHW0;E8UIZ^1(_&NI,'=@9Z9V\:]ZIR$92O_7,I-%M:+(?7+I!G$J6
MPV%02C3.E&6 <L-6_$HV<A,YA]ME^'_VC(G+8"_!-,=<52X91=IW(CZ$A204
M-/5,OU)&E]3E!M8Y;1&:FC;$E@" 3.%C$1M2SK+6*K7D'L*#WSO:>+NERDQ]
M"^(E@LX>CJJ:VT3:R0O=R%S>0O-$I3VZ)S -L)"&?+<NT.']__6WUS_;Q@Z#
M[F*27*\3(:2DS1AN1.20*C#G)JF6/\)W"[N9B%*27%;6]*T3L3!PAY+B#NI/
MOBZM7&%E)XU@SR*3R2:STVMXPO-JOK18(Z<\2/7I/(<9JOI_I,B4MPT6&A6P
M$'J<O(DMF="2ZV;UV#UK4RL'M:RE?)W&[!<4[8D5 4)# ),2_G!G L*S:"I%
M<\CM@C7_6SV/,JO3(B_+9^;,<N*-5H7\!91Y8I70[F^ZP]U,'&WF\^G=V@GX
M.DE7_3X<"[+<!*#VE-%A,&!UC4G)B'1,IU6Q3FF8T*=W#AQ*'7$"-MIH.E?Q
M&@5,=XG8,LG7T%'T9 G"K?GT5--(F8HL#PQ3LBYL^A%]E8T!#;30S-F:>RH3
M7 :O#G\&%:N%W?_IG[@4+>S8?>85IK6EV *54[.[\]N";;LAGQ EP^[.:TOW
MK4/]6>0IY8K89-+#IY##N5M@6DA1A7H0Z$QMS6X:-RI9DMX4LUO,#L*%#E@H
MQQX E1IVU]QHFO,H#JA\.;9/Q_ET[21]&J6YEDB(IE0"&S9*PV83Y9KM4X\,
M5\=A-/:5>:U-OOKF:)T$+NHX)Y22DH3H\Y2X$F/H>IDHD\YMOGV/!*MO!1C^
MTEK]YCU,P->XE)& ^5VCES5-\]MR.QCV/KRS+;QS])\([^"$)/'__)2\B5]/
MXS<OCM2;Y^KU[.CE+Z^BUY,7ZO7;EZ]?3J8_O_K_+Y[_M(\)_><C+,&G9$6.
MW4_LEFGE)>!Y+=E70;GJ<8/QZTI+=BXD10!*TYW&)<6\-^.@B3@EA:\)=)1$
M1FKVS=].MN9F-VXC9J UT@)S87'NTFA9JG_H'W[%6J$TNOM'DM&8Z4N_^COK
M#4S0#1++3J-4WD(OY(_MWCY\SOM[!3MW%>LWR\>']-'?5W']L]=O#W\Y>K'Q
MX^>'FS_;VNSAT=';']_J2]"O-G_L-OMWF@B>#)CO<AEE__/3JY\JTO@?+Y=?
M@Q?^V44!79OR?+E%FK^2Z\.3Y_S'MFFHYQ<?N\/Q8!1<ON\./W3OS<'R[2$^
M@+1FA^;K^(YC@BT4B]L,17(NE_1O\&Z=@+@!]3+X"%M9XS[\\7_W&V?K00/%
M?D>W3O-R[[?17[&-Q@B ^;CVD<\#I^F7/"JXG=HK3Z2QEFRY1W$E#Z(L^"W"
MU[Y/RFD^_;(7IOL[^3MDZ7X?[2_E'[*1]&TLE_/@,CA+5KJ6'7W.][F=_S.;
M3UOZ6XSXYVC"_W2O1Y^:O3_JO1\23O'K7T\&Y^_ZPS 8G/<V.[/VYWN7-8Q-
MI\IJ'L-H<1><1D42[Z^*O<KQ79NI^=_OWUC[#?2T= U#71F0Y1_T^A<_0$,@
M?__?*8*R.=+[\S[*6XWR_MP0Y6T^,T?;3MIWQGA?[7",]R]+C_BCR6,O7AT>
M'4PZ!TF2= Z..QN7?_>&#ZI;5*H)YMMT!=<!#9@QIE$^9)C^QG][>/3MZ/ZS
MER\.VYB1=OCB<),4=:>(\K YATFX!I/,X' &/8*H-+]:*,]!KQ<,,4'Y,!CG
MDFM$B!G>APYPIX,PS/Q7IC! ESKLV"UGX($/7[2PYYB=W0Z.@A\MK5HUR>%^
M2^^W]./:TGXBMX\EI(MVB,$\HB+&5+E(2IR&52HD?>4T+"[[LD6:A.[D%7X5
M2&I&65-8XHC/!>1[=-O%VP,.%25\_O=_4W)G0#HBESPMD'R'$)BH^$KPSR9:
M)8CL?><GE-%XL#Y5E2N+6(37%P^!*[%L-TIHHYS=Z<I/J6S5.,UMV)K[([\_
M\@^>9#[DWG&30DLLRYO!U0:CB[#ZWJ/;L]P[< '"FTW-(Z.I$PL!IJ7/HV(1
M3=6:_.S8(I/4,:[1*D#XI95_M!$[R31IF*']=C XD28SQ93/6"$-"OD:ZT:I
MCM;4S$MQ+W'A(6:\Z714%)&@K)?!@5>OTGD0PMAC,AI>;C0:".XD+PU39=1@
M1$SR(@-UZ%]<Z.M7^!J68BJ*%71D@<'4'*\L5)D8O.$U1/&X@4/.AYVTR)F:
M"(C ,VODC092T]G\&NL[S4LEZAV7FJJ0J\09KL#II]L ]O,^O)_F0G39BFA3
MUSIY&#RH?.HQ;<=7&[?CI^_1"#Q%P(%WI_TK%<C5.Y_$%!:)(\AQ7HKDT<NX
M4 N0_B!=%LQ-#[H18T@R]+G^2J&NH\*((V&*H"*Y6X4*2LD,$E*%A&"P"OM"
MT@]KI<LY(T#H/CKO$E2%X(#&$VF@@1;>ES_]\QB$<SL+#02-H6,I+BNWH9YY
MNVL,C#N-JHE!D_=C@H L4T7E!O S07ZZ!6E/]JYY_1V'6W/YE>O) @\E_I_F
M/ZS-/BU;G>4-L3%R7F0-%*'DCZ4R" <@/V!8K/-43YJ^[2QD05[=,@W$ @^K
M@7U,Z_QFJTY1/6CU%5LHM7)9:\1N+!T4>@*M(8A*?R',&8T5EM0+O['&N=>P
MECB!"&/!M-"EB@KBQ<:=$*5W90*Z2]..U(R3>+B7*ZWNN+C"?N6I=,9LMI)8
M<4'132S[+;;@O02UX#P67!C9V8C,63+>!YX"!!25)CMAH_#2R/]@2%$V "$!
MJ2DC 37>32ZLZ5/=MT<;]VT#I'L=H44#+#4MB+@7L"#8OTN,QF 9G.U7]2:&
M04[08W'ME+!9MBG-K-#">_9>GHB=-9BC*=DWA.M(F+8&E9&6M)3CV@!^?:#M
MA 7!\3-<[ARMT]+ ^NAF.D)%2YXK,C)\55.PJ1IDX S+ULVY;QX#PA,YD% )
M Q<S>8[=Y>THK'Y(B/=[2YB?$++M_41WV\3TINWLW/Q3C5O/:AL? SQ$%=IW
M XX(.X\A&+)DAG(6[,=\JQ7>YFW_![_VGT\%.6IU*LAW3EN;=\1?)@C_/LGC
M._C/?+5(__F_4$L#!!0    ( #F!6EK]/A7"SB$  $,! 0 >    <V1G<BTR
M,#(T,3(S,7AE>'@Q.3%G;&]B86PN:'1M[3UK4]O(EM_W5_1F:N="E>%B("&3
MY*:* 6="38:P0.[<^VFK+;7M7F2U1BWA>'_]GD>WU+)E'DG ./%4S0P@J5_G
M]'D_WHR*<?+VS4C)^.U_O/G/K2UQ;*)RK-)"1+F2A8I%:74Z%'_&REZ)K2WW
MUI')IKD>C@JQN[/[7/QI\BM]+?EYH8M$O?7CO/D[__[F[S3)F[Z)IV_?Q/I:
MZ/@?S_3S_D$4]U\<'.P?[.^_?+G7_V6P^WR_N[?7W7O1[^\^_Y_N,_@47N=O
M;#%-U#^>C76Z-5(X_ZN#W:QX/=%Q,7K5W=GYKV?TWMLW P-;<&]')C'YJY]V
MZ)_7^&1K(,<ZF;[ZVZ4>*RM.U42<F[%,_]:Q,K5;5N5ZP"]:_7_J51?GX%]Q
MQ%>ZD(F.^"\3MPP8.=&I\LOJ[N):#K,L-]=PB/VI*$9*_&ID'@LS$,<Z5U%A
M<BM,*MZI?E[*?"JZOW3H/-_\'8?V^Y[?O<R'< !]4Q1FS(LKU.=B"Q8U3%\1
M6)X]V G<N-_>YY'NZP(VLMUM;N+.RX\ 9U2^I/5?'+T___FGW>[^Z^.3T]]Z
MYQUQ<GJT_;1WLM^R$UY&K"*3RT*;]%69QBK'MYZ]_2TQ?9F(D]1J^)NXS&6,
M%_S, $I/[[/53,;XY5:B!L6KO1=^\QJF2HM76_B7I6S^V=ON]L\_=5_LO)[_
MK]_?,I#KU\.CWW\[__CI]%@<PK]GG\[//E[T[HU<[GR7>KS=Y9[O?5'^S]%4
MO)?72ORIQ&%L,F1KER-M9Y!^&6?Y\T\O]EZO( Y< C?[M'VQ+08*CAGHB551
MF>M"PQ2)G%@!C(]Y@4RG8JS&?: UP/@6<,$-*7[^Z>7N[LYK_S?ZM?MZLP,O
M#G0$7V](*V(U@*7$0J?BO$R4Z+Z06]V-P:8@:-/H%_5">I^CD4R' /2HP/FZ
MO^SMBPU\R4T6OE!/*%/_7'V&P0H-F.,6X5\2)A=JG"5FJO"9N(A&\&QW_\5K
M)(DJ!\:11MLPEQDJF"\7$UV,A"ZLL&4?"*^6.2RP(X*U')EQ!F=5S3#(S5AD
M90XK) D,9K0J2?!']VIXYB!&X%A]>-?B@L8@N^4:X)*:-"O[@.9P9@.3C^ER
MB,BDL)L4!\//W( =G(3F+726X<-;ABF,,+@]NRW@0BFK&/9ZG!GXV:IKE</_
M9!KAV[1(P%Q]K>-2)E9,1D9<:Y/ '+B*,0QRD@KD*OAZ9Q::,HUKB,**Q]I:
M7$0(T(O>476 <&XTA"R+D8$QIKA<M[0$+I82B$O5T?E#Q6F:?\(1NP>O;8VO
M'3&'&;P^.-<B-PPE6YCH:F22&!_J0>N('H?@IW0H84D:CX@Y<^$X,XX;+A#W
M-9 Z@6L &RKD%6P1Y<P,  4G:0N567R2Y7#^0!G@#FY8LQ7)!#]Q!Q4N-(,%
MFM2=FTBT[.L$CFOS_H+/4Z!+@/^S)Y@1F1?PI*_H1!T/@,-.2(EAPH1XH8:
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M"37YF/5YOOBU^32XZX%F LH*@$EAQ&&MW9 (#$2C) >8BW)8BU,/RI9!)$I
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MCS<[V\_W81H+9#$6?F--U'H.2W9_04MW=P=^-YF,@+Z]ZGKWS?X^H=LM6/H
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M8N]=T8>() 9B+8E0BN71R+6&&V#C+]]>P_U[W\13^-^H&"=O_Q]02P,$%
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M>-^@Q\B-<N)ANQA051B1WX$$X^VY([#$,!C=:B6(N@-]$+U#BJ$FC]#&TD+
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M=_;4Y2R(H[5[E4W]:_ +4$L#!!0    ( #F!6EIZ:OJQ1 @  ",J   8
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M+?M-2'O'RN6BUZE.)T;=#C)6K]:;[#=M[M2(^_9,9;$\F=HYWO'/QSMNDN-
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MBU]\?(P:_AI6%^O-Q>Q\"]LE.".XZ&PZ\PYL_+DQ=GH#NPVS#<Q.EZNM?_I
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M+FAT;5!+ 0(4 Q0    ( #F!6EKOKO5.FQ4  /7Y   1              "
M <Z\! !S9&=R+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( #F!6EJ)R(/CU2(
M $U8 0 5              "  9C2! !S9&=R+3(P,C0Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    "  Y@5I:4519B,9N  #?'04 %0              @ &@]00
M<V1G<BTR,#(T,3(S,5]D968N>&UL4$L! A0#%     @ .8%:6K-.TA2*R0
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M+3(P,C0Q,C,Q7V<Q-"YJ<&=02P$"% ,4    "  Y@5I:EDFL+WB< 0#^_0$
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M,#(T,3(S,5]G,3@N:G!G4$L! A0#%     @ .8%:6B-'^,E!<P$ '_(! !4
M             ( !2R@; '-D9W(M,C R-#$R,S%?9S$Y+FIP9U!+ 0(4 Q0
M   ( #F!6EJR)@ M(8T" $'V @ 4              "  ;^;' !S9&=R+3(P
M,C0Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( #F!6EK(1Z%T0@4$ #3I!  4
M          "  1(I'P!S9&=R+3(P,C0Q,C,Q7V<S+FIP9U!+ 0(4 Q0    (
M #F!6EK(DAFR)_P! #;> @ 4              "  88N(P!S9&=R+3(P,C0Q
M,C,Q7V<T+FIP9U!+ 0(4 Q0    ( #F!6EHA5X((-Z(  &2J   4
M      "  =\J)0!S9&=R+3(P,C0Q,C,Q7V<U+FIP9U!+ 0(4 Q0    ( #F!
M6EJLF(Q(Y_,  )[]   4              "  4C-)0!S9&=R+3(P,C0Q,C,Q
M7V<V+FIP9U!+ 0(4 Q0    ( #F!6EK-V*A5\>4  +[M   4
M  "  6'!)@!S9&=R+3(P,C0Q,C,Q7V<W+FIP9U!+ 0(4 Q0    ( #F!6EIL
M9B/I&XP  #N;   4              "  82G)P!S9&=R+3(P,C0Q,C,Q7V<X
M+FIP9U!+ 0(4 Q0    ( #F!6EK*"K4US#0# #F.!0 4              "
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M.&YO=F%R+FAT;5!+ 0(4 Q0    ( #F!6EK]/A7"SB$  $,! 0 >
M      "  ?7S+@!S9&=R+3(P,C0Q,C,Q>&5X>#$Y,6=L;V)A;"YH=&U02P$"
M% ,4    "  Y@5I:MD">]O8"   O%@  &               @ '_%2\ <V1G
M<BTR,#(T,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @ .8%:6C:E^OHU P
M% H  !@              ( !*QDO '-D9W(M,C R-#$R,S%X97AX,C,Q+FAT
M;5!+ 0(4 Q0    ( #F!6EIZ:OJQ1 @  ",J   8              "  98<
M+P!S9&=R+3(P,C0Q,C,Q>&5X>#,Q,2YH=&U02P$"% ,4    "  Y@5I:NUSH
MXDH(  !!*@  &               @ $0)2\ <V1G<BTR,#(T,3(S,7AE>'@S
M,3(N:'1M4$L! A0#%     @ .8%:6DYJRL& !   "Q$  !@
M ( !D"TO '-D9W(M,C R-#$R,S%X97AX,S(Q+FAT;5!+ 0(4 Q0    ( #F!
M6EK+!HSHB 0  "01   8              "  48R+P!S9&=R+3(P,C0Q,C,Q
A>&5X>#,R,BYH=&U02P4&     "$ (0"V"   !#<O

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>sdgr-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sdgr="http://www.schrodinger.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sdgr-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-19</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-19</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:UnallocatedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:UnallocatedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">sdgr:LimitedCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sdgr:ContractAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sdgr:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-23</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:July2024AgreementWithBillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:July2024AgreementWithBillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:July2024AgreementWithBillMelindaGatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OnPremiseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:HostedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MaintenanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:ProfessionalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-22</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-22</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-22</startDate>
            <endDate>2020-11-22</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:OncologyNeurologyAndImmunologyProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-11-12</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:SoftwareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sdgr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareProductsAndServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sdgr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sdgr:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">sdgr:CashCashEquivalentsAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:SecuritiesAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sdgr:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sdgr:TheATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sdgr:TheATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sdgr:TwentyTwentyStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sdgr:SharebasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:EligiblePerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sdgr:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">sdgr:SharebasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:NimbusTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:MorphicHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:AjaxTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-07</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-07</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sdgr:StructureTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:DrugDiscoveryContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sdgr:SoftwareContributionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:BillAndMelindaGatesFoundationTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sdgr:GatesVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:SoftwareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:SoftwareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:SoftwareSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:DrugDiscoverySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:DrugDiscoverySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">sdgr:DrugDiscoverySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sdgr:APACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sdgr:APACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sdgr:APACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:RobertAbelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:RobertAbelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:KarenAkinsanyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001490978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">sdgr:KarenAkinsanyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="target">
        <measure>sdgr:target</measure>
    </unit>
    <unit id="obligation">
        <measure>sdgr:obligation</measure>
    </unit>
    <unit id="program">
        <measure>sdgr:program</measure>
    </unit>
    <unit id="vote">
        <measure>sdgr:vote</measure>
    </unit>
    <unit id="segment">
        <measure>sdgr:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-37">0001490978</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-38">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-39">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-40">false</dei:AmendmentFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-293" id="f-1125">November 26, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-293" id="f-1126">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrDuration contextRef="c-293" id="f-1127">P400D</ecd:TrdArrDuration>
    <ecd:TrdArrAdoptionDate contextRef="c-295" id="f-1128">December 17, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-295" id="f-1129">December 31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrDuration contextRef="c-295" id="f-1130">P379D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39206</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Schrodinger, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">95-4284541</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">1540 Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">24th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">295-5800</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">SDGR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-30" unitRef="usd">790263620</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">63874200</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-32" unitRef="shares">9164193</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-33">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-34">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-35">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-36">Portland, OR</dei:AuditorLocation>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-41">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain processes for assessing, identifying and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and refine our practices. We engage certain external parties, including consultants, computer security firms and risk management advisors, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight. We consider the internal risk oversight programs of third-party service providers before engaging them in order to help protect our company from any related vulnerabilities. As part of our overall risk mitigation strategy, we also maintain cybersecurity insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect our company or our business strategy, results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-42">We have certain processes for assessing, identifying and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and refine our practices.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-43">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-45">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-46">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-50">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.&lt;/span&gt;&lt;/div&gt;Our vice president of information security leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-49">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-48">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The audit committee of our board of directors provides direct oversight over cybersecurity risk and provides regular updates to the board of directors regarding such oversight. The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-51">The audit committee receives periodic updates from management regarding cybersecurity matters and is notified between such updates regarding significant new cybersecurity threats or incidents.Our vice president of information security leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-52">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-53">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our vice president of information security leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare our company and our employees to address cybersecurity risks, including phishing attacks, ransomware, data breaches, and insider threats. Our vice president of information security has over 15 years of information security experience, including in developing, overseeing and managing information technology and information security teams. He has been with our company since 2017 and has served as our vice president of information security since April 2023. He previously served as our executive director of information security from January 2022 through April 2023, senior director of information security from February 2019 through January 2022 and director of information security from June 2017 through February 2019. Prior to joining our company, our vice president of information security worked at several technology companies and served in roles of increasing responsibility with respect to information security during his tenure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a cybersecurity awareness program, which covers timely and relevant topics, including social engineering and phishing, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks throughout our information security systems. These tools are integrated into our comprehensive security framework, used to bolster our employee-based cybersecurity programs and are regularly updated to respond to evolving threats.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-54">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-55">Our vice president of information security has over 15 years of information security experience, including in developing, overseeing and managing information technology and information security teams. He has been with our company since 2017 and has served as our vice president of information security since April 2023. He previously served as our executive director of information security from January 2022 through April 2023, senior director of information security from February 2019 through January 2022 and director of information security from June 2017 through February 2019. Prior to joining our company, our vice president of information security worked at several technology companies and served in roles of increasing responsibility with respect to information security during his tenure.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">147326000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-57" unitRef="usd">155315000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">15331000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-6" decimals="-3" id="f-59" unitRef="usd">5751000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">204798000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-61" unitRef="usd">307688000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">210000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-6" decimals="-3" id="f-63" unitRef="usd">220000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">235692000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-65" unitRef="usd">65992000</us-gaap:AccountsReceivableNetCurrent>
    <sdgr:AllowanceForUnbilledReceivablesCurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">100000</sdgr:AllowanceForUnbilledReceivablesCurrent>
    <sdgr:AllowanceForUnbilledReceivablesCurrent contextRef="c-6" decimals="-3" id="f-67" unitRef="usd">100000</sdgr:AllowanceForUnbilledReceivablesCurrent>
    <sdgr:UnbilledAndOtherReceivablesCurrent contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">19641000</sdgr:UnbilledAndOtherReceivablesCurrent>
    <sdgr:UnbilledAndOtherReceivablesCurrent contextRef="c-6" decimals="-3" id="f-69" unitRef="usd">23124000</sdgr:UnbilledAndOtherReceivablesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">12205000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-71" unitRef="usd">9926000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">634993000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-73" unitRef="usd">567796000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">24196000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-75" unitRef="usd">23325000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">43208000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-6" decimals="-3" id="f-77" unitRef="usd">83251000</us-gaap:EquityMethodInvestments>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">4791000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-79" unitRef="usd">4791000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">111883000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">117778000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">4155000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-83" unitRef="usd">6014000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">823226000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">802955000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">10666000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">16815000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">42110000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">31763000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">111944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-6" decimals="-3" id="f-91" unitRef="usd">56231000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">16755000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">16868000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">10272000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-95" unitRef="usd">11996000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">191747000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-97" unitRef="usd">133673000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">108814000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">9043000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">101074000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">111014000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">146000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">667000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">401781000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">254397000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-106" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-107" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-108"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-109"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-110" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-111" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-112" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-113" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-114" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-115" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-118"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-119"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-120" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-121" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-122" unitRef="shares">63710409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-123" unitRef="shares">63710409</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-124" unitRef="shares">62977316</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-125" unitRef="shares">62977316</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-126" unitRef="usd">637000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">630000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-128"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-129"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-130"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-9" decimals="INF" id="f-131" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-132"
      unitRef="shares">9164193</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-9" decimals="INF" id="f-133" unitRef="shares">9164193</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-134" unitRef="shares">9164193</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-10"
      decimals="INF"
      id="f-135"
      unitRef="shares">9164193</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-10" decimals="-3" id="f-136" unitRef="usd">92000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-9" decimals="-3" id="f-137" unitRef="usd">92000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">946037000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">885973000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-140" unitRef="usd">-525541000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">-338418000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-142" unitRef="usd">220000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">281000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-144" unitRef="usd">421445000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">548558000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">823226000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">802955000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-148" unitRef="usd">180365000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">159124000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-150" unitRef="usd">135578000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-151" unitRef="usd">27174000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-3" id="f-152" unitRef="usd">57542000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-3" id="f-153" unitRef="usd">45377000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">207539000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-3" id="f-155" unitRef="usd">216666000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-3" id="f-156" unitRef="usd">180955000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">36900000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-12" decimals="-3" id="f-158" unitRef="usd">29514000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-13" decimals="-3" id="f-159" unitRef="usd">29576000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-14" decimals="-3" id="f-160" unitRef="usd">38556000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-15" decimals="-3" id="f-161" unitRef="usd">46460000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-16" decimals="-3" id="f-162" unitRef="usd">50357000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">75456000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-17" decimals="-3" id="f-164" unitRef="usd">75974000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-18" decimals="-3" id="f-165" unitRef="usd">79933000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">132083000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-17" decimals="-3" id="f-167" unitRef="usd">140692000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-18" decimals="-3" id="f-168" unitRef="usd">101022000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">201785000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-170" unitRef="usd">181766000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-18" decimals="-3" id="f-171" unitRef="usd">126372000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">39917000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-17" decimals="-3" id="f-173" unitRef="usd">37226000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-18" decimals="-3" id="f-174" unitRef="usd">30642000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">99677000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-176" unitRef="usd">99148000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-18" decimals="-3" id="f-177" unitRef="usd">90825000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">341379000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-17" decimals="-3" id="f-179" unitRef="usd">318140000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-18" decimals="-3" id="f-180" unitRef="usd">247839000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">-209296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-182" unitRef="usd">-177448000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-18" decimals="-3" id="f-183" unitRef="usd">-146817000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-185" unitRef="usd">147213000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-18" decimals="-3" id="f-186" unitRef="usd">11825000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">5683000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-17" decimals="-3" id="f-188" unitRef="usd">53461000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-18" decimals="-3" id="f-189" unitRef="usd">-18084000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">17902000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-191" unitRef="usd">19693000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-192" unitRef="usd">3953000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">23585000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-194" unitRef="usd">220367000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-195" unitRef="usd">-2306000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-185711000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-197" unitRef="usd">42919000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-198" unitRef="usd">-149123000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">1412000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-200" unitRef="usd">2199000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-201" unitRef="usd">63000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-187123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-203" unitRef="usd">40720000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-204" unitRef="usd">-149186000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-205"
      unitRef="usdPerShare">-2.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-207"
      unitRef="usdPerShare">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-208" unitRef="shares">72670295</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="0" id="f-209" unitRef="shares">71776301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-18" decimals="0" id="f-210" unitRef="shares">71173419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-211"
      unitRef="usdPerShare">-2.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-212"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-213"
      unitRef="usdPerShare">-2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-214" unitRef="shares">72670295</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="0" id="f-215" unitRef="shares">74986816</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-18" decimals="0" id="f-216" unitRef="shares">71173419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-187123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-218" unitRef="usd">40720000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-219" unitRef="usd">-149186000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-17" decimals="-3" id="f-221" unitRef="usd">2663000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-18" decimals="-3" id="f-222" unitRef="usd">-1731000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-187184000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-3" id="f-224" unitRef="usd">43383000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-18" decimals="-3" id="f-225" unitRef="usd">-150917000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-226"
      unitRef="shares">61834515</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-227" unitRef="usd">618000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-228"
      unitRef="shares">9164193</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-229" unitRef="usd">92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-230" unitRef="usd">786964000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-231" unitRef="usd">-229952000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-232" unitRef="usd">-651000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-233" unitRef="usd">557071000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-25" decimals="-3" id="f-234" unitRef="usd">-1731000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-18" decimals="-3" id="f-235" unitRef="usd">-1731000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-26"
      decimals="INF"
      id="f-236"
      unitRef="shares">329224</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-26" decimals="-3" id="f-237" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-27" decimals="-3" id="f-238" unitRef="usd">2106000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-18" decimals="-3" id="f-239" unitRef="usd">2110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-240" unitRef="usd">39630000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-18" decimals="-3" id="f-241" unitRef="usd">39630000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-242" unitRef="usd">-149186000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-3" id="f-243" unitRef="usd">-149186000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-29"
      decimals="INF"
      id="f-244"
      unitRef="shares">62163739</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-245" unitRef="usd">622000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-246"
      unitRef="shares">9164193</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-247" unitRef="usd">92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-248" unitRef="usd">828700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-249" unitRef="usd">-379138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-250" unitRef="usd">-2382000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-251" unitRef="usd">447894000</us-gaap:StockholdersEquity>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-17" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-35" decimals="-3" id="f-253" unitRef="usd">2663000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-17" decimals="-3" id="f-254" unitRef="usd">2663000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-36"
      decimals="INF"
      id="f-255"
      unitRef="shares">800336</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-36" decimals="-3" id="f-256" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-37" decimals="-3" id="f-257" unitRef="usd">9432000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-3" id="f-258" unitRef="usd">9440000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-36"
      decimals="INF"
      id="f-259"
      unitRef="shares">13241</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-260" unitRef="usd">47841000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-3" id="f-261" unitRef="usd">47841000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss contextRef="c-38" decimals="-3" id="f-262" unitRef="usd">40720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-263" unitRef="usd">40720000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-264"
      unitRef="shares">62977316</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-265" unitRef="usd">630000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-266"
      unitRef="shares">9164193</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-267" unitRef="usd">92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-268" unitRef="usd">885973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-269" unitRef="usd">-338418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-270" unitRef="usd">281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-271" unitRef="usd">548558000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-44" decimals="-3" id="f-272" unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-45"
      decimals="INF"
      id="f-274"
      unitRef="shares">169820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-45" decimals="-3" id="f-275" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-46" decimals="-3" id="f-276" unitRef="usd">1486000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">1488000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-45"
      decimals="INF"
      id="f-278"
      unitRef="shares">240188</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-45" decimals="-3" id="f-279" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-45"
      decimals="INF"
      id="f-281"
      unitRef="shares">323085</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-45" decimals="-3" id="f-282" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-46" decimals="-3" id="f-283" unitRef="usd">8675000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">8678000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-46" decimals="-3" id="f-285" unitRef="usd">49903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">49903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss contextRef="c-47" decimals="-3" id="f-287" unitRef="usd">-187123000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">-187123000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c-48"
      decimals="INF"
      id="f-289"
      unitRef="shares">63710409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-290" unitRef="usd">637000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-49"
      decimals="INF"
      id="f-291"
      unitRef="shares">9164193</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-292" unitRef="usd">92000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-293" unitRef="usd">946037000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-294" unitRef="usd">-525541000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-295" unitRef="usd">220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-296" unitRef="usd">421445000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-187123000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-298" unitRef="usd">40720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-3" id="f-299" unitRef="usd">-149186000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-301" unitRef="usd">147213000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-18" decimals="-3" id="f-302" unitRef="usd">11825000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">5683000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-17" decimals="-3" id="f-304" unitRef="usd">53461000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-18" decimals="-3" id="f-305" unitRef="usd">-18084000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">6159000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-3" id="f-307" unitRef="usd">5552000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-18" decimals="-3" id="f-308" unitRef="usd">4344000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">49903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-3" id="f-310" unitRef="usd">47841000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-18" decimals="-3" id="f-311" unitRef="usd">39630000</us-gaap:ShareBasedCompensation>
    <sdgr:InvestmentAmortizationNoncashExpense contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">7592000</sdgr:InvestmentAmortizationNoncashExpense>
    <sdgr:InvestmentAmortizationNoncashExpense contextRef="c-17" decimals="-3" id="f-313" unitRef="usd">7761000</sdgr:InvestmentAmortizationNoncashExpense>
    <sdgr:InvestmentAmortizationNoncashExpense contextRef="c-18" decimals="-3" id="f-314" unitRef="usd">-629000</sdgr:InvestmentAmortizationNoncashExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-17" decimals="-3" id="f-316" unitRef="usd">-142000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-18" decimals="-3" id="f-317" unitRef="usd">-19000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">169700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-17" decimals="-3" id="f-319" unitRef="usd">10039000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-18" decimals="-3" id="f-320" unitRef="usd">23697000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">-3483000</sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables>
    <sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables contextRef="c-17" decimals="-3" id="f-322" unitRef="usd">9987000</sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables>
    <sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables contextRef="c-18" decimals="-3" id="f-323" unitRef="usd">4253000</sdgr:IncreaseDecreaseInUnbilledAndOtherReceivables>
    <sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">-8942000</sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating>
    <sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating contextRef="c-17" decimals="-3" id="f-325" unitRef="usd">-7766000</sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating>
    <sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating contextRef="c-18" decimals="-3" id="f-326" unitRef="usd">-7287000</sdgr:IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssetsOperating>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">3482000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-17" decimals="-3" id="f-328" unitRef="usd">8462000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-18" decimals="-3" id="f-329" unitRef="usd">7067000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">-6119000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-17" decimals="-3" id="f-331" unitRef="usd">7321000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-18" decimals="-3" id="f-332" unitRef="usd">1179000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">10347000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-17" decimals="-3" id="f-334" unitRef="usd">6881000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-18" decimals="-3" id="f-335" unitRef="usd">6477000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">155484000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-17" decimals="-3" id="f-337" unitRef="usd">-18256000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-18" decimals="-3" id="f-338" unitRef="usd">-1903000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">-10053000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-17" decimals="-3" id="f-340" unitRef="usd">-3694000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-18" decimals="-3" id="f-341" unitRef="usd">1900000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">-1942000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-17" decimals="-3" id="f-343" unitRef="usd">5917000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="c-18" decimals="-3" id="f-344" unitRef="usd">-1301000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">-157368000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-346" unitRef="usd">-136733000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-18" decimals="-3" id="f-347" unitRef="usd">-119683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">7311000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-3" id="f-349" unitRef="usd">13403000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-18" decimals="-3" id="f-350" unitRef="usd">8014000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">3072000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-352" unitRef="usd">4125000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-18" decimals="-3" id="f-353" unitRef="usd">600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-17" decimals="-3" id="f-355" unitRef="usd">147213000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital contextRef="c-18" decimals="-3" id="f-356" unitRef="usd">11825000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">48798000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-18" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-17" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-18" decimals="-3" id="f-362" unitRef="usd">6427000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">251339000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-17" decimals="-3" id="f-364" unitRef="usd">320624000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-18" decimals="-3" id="f-365" unitRef="usd">271472000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">361760000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-17" decimals="-3" id="f-367" unitRef="usd">383973000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-18" decimals="-3" id="f-368" unitRef="usd">364711000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">148836000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-370" unitRef="usd">193034000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-18" decimals="-3" id="f-371" unitRef="usd">90023000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">1490000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-17" decimals="-3" id="f-373" unitRef="usd">9440000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-18" decimals="-3" id="f-374" unitRef="usd">2110000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">177000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-17" decimals="-3" id="f-376" unitRef="usd">373000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-18" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">8868000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-17" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-18" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">58000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-17" decimals="-3" id="f-382" unitRef="usd">19000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-18" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">10123000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-385" unitRef="usd">9048000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-18" decimals="-3" id="f-386" unitRef="usd">2110000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">1591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-388" unitRef="usd">65349000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-18" decimals="-3" id="f-389" unitRef="usd">-27550000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-390" unitRef="usd">161066000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-3" id="f-391" unitRef="usd">95717000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-392" unitRef="usd">123267000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-393" unitRef="usd">162657000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-394" unitRef="usd">161066000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-3" id="f-395" unitRef="usd">95717000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">1080000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-17" decimals="-3" id="f-397" unitRef="usd">2828000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-18" decimals="-3" id="f-398" unitRef="usd">787000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">162000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-17" decimals="-3" id="f-400" unitRef="usd">192000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-18" decimals="-3" id="f-401" unitRef="usd">169000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">157000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-17" decimals="-3" id="f-403" unitRef="usd">457000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="c-18" decimals="-3" id="f-404" unitRef="usd">293000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution contextRef="c-1" decimals="-3" id="f-405" unitRef="usd">2848000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution contextRef="c-17" decimals="-3" id="f-406" unitRef="usd">514000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution contextRef="c-18" decimals="-3" id="f-407" unitRef="usd">1513000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeaseContingencyResolution>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">0</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases contextRef="c-17" decimals="-3" id="f-409" unitRef="usd">15085000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases contextRef="c-18" decimals="-3" id="f-410" unitRef="usd">34763000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsOperatingLeases>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities contextRef="c-1" decimals="-3" id="f-411" unitRef="usd">0</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities contextRef="c-17" decimals="-3" id="f-412" unitRef="usd">15085000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities>
    <sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities contextRef="c-18" decimals="-3" id="f-413" unitRef="usd">34430000</sdgr:NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsFinanceLeaseForLeaseLiabilities>
    <sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">0</sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired>
    <sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired contextRef="c-17" decimals="-3" id="f-415" unitRef="usd">279000</sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired>
    <sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired contextRef="c-18" decimals="-3" id="f-416" unitRef="usd">0</sdgr:NoncashOrPartNoncashAcquisitionOperatingLeaseAcquired>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-417">Description of Business&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Schr&#xf6;dinger, Inc. (the "Company") has developed a differentiated, physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at a lower cost, compared to traditional methods. The Company's software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company is also applying its computational platform to advance a broad pipeline of drug discovery programs in collaboration with leading biopharmaceutical companies. In addition, the Company uses its computational platform to discover novel molecules for its pipeline of proprietary drug discovery programs, which the Company is advancing through preclinical and clinical development.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-418">Significant Accounting Policies&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 280) &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Reportable Segment Disclosures,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This standard is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this new standard for the year ended December 31, 2024 with no material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740) &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires public business entities to disclose specific categories in the tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. This standard is effective for annual periods beginning after December 15, 2024, and interim periods within annual periods beginning after December 15, 2025, on a prospective basis, with early adoption permitted. The Company has not yet adopted ASU 2023-09 and is still evaluating the impact of the adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement &#x2014; Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 220-40) &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. This standard is effective for annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027, on a prospective basis, with early adoption and retrospective application permitted. The Company has not yet adopted ASU 2024-03 and is still evaluating the impact of the adoption on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue and estimates regarding the progress of completing performance obligations under collaboration agreements. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the accounts of Schr&#xf6;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Cash and Cash Equivalents and Marketable Securities and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents were cash equivalents of $102,054 and $85,497 as of December&#160;31, 2024 and 2023, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation&#x2019;s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash primarily consists of letters of credit held with the Company&#x2019;s financial institution related to facility leases and is classified as current in the Company&#x2019;s balance sheets based on the maturity of the underlying letters of credit. The Company also has restricted cash related to a certificate of deposit held as collateral for its credit card facility. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December&#160;31, 2024 and 2023. Interest is not charged on accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f)&#160;&#160;&#160;&#160;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(g)&#160;&#160;&#160;&#160;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. The Company did not capitalize any interest during 2024 and 2023. Maintenance and repairs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated using the straight&#x2011;line method over the estimated useful lives of the assets, which range from 3 to 10 years. Amortization of leasehold improvements is calculated using the straight&#x2011;line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are reviewed for impairment as discussed below under "Accounting for the Impairment of Long&#x2011;Lived Assets."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(h)&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess purchase price over the fair value of net assets acquired which is not allocable to separately identifiable intangible assets. Other identifiable intangible assets are separately recognized if the intangible asset is obtained through contractual or other legal right or if the intangible asset can be sold, transferred, licensed or exchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but tested for impairment at least annually, and more frequently if events or circumstances indicate the carrying amount more likely than not exceeds the fair value. The Company has the option to qualitatively or quantitatively assess its goodwill for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests its goodwill for impairment on October 1 of each year. In 2024, the Company evaluated its goodwill using a qualitative process. If the qualitative factors determine that it is more likely than not that the fair value exceeds the carrying amount, goodwill is not impaired. If the qualitative assessment determines it is more likely than not the fair value is less than the carrying amount, the Company would further evaluate for potential impairment. This &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;qualitative assessment indicated that it was more likely than not the Company's reporting unit&#x2019;s fair value exceeded its carrying value. No impairment of goodwill was recognized for the years ended December 31, 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Accounting for the Impairment of Long&#x2011;Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(j)&#160;&#160;&#160;&#160;Warranties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(k)&#160;&#160;&#160;&#160;Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables and contract assets, which represent contracted unbilled receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer&#x2019;s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, one customer accounted for 68% of total accounts receivable. As of December&#160;31, 2023, two customers accounted for 15% and 11% of total accounts receivable, respectively. As of December&#160;31, 2024, three customers accounted for 33%, 23%, and 16% of total contract assets, respectively. As of December&#160;31, 2023, two customers accounted for 42% and 22% of total contract assets, respectively. For the year ended December&#160;31, 2024, one customer accounted for 10% of total revenues. For the year ended December&#160;31, 2023, two customers accounted for 26% and 11% of total revenues, respectively. For the year ended December 31, 2022, one customer accounted for 16% of total revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(l)&#160;&#160;&#160;&#160;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company&#x2019;s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,342, $13,349, and $9,191 for the years ended December&#160;31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(m)&#160;&#160;&#160;&#160;Software Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(n)&#160;&#160;&#160;&#160;Research and Development and Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(o)&#160;&#160;&#160;&#160;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates stock&#x2011;based compensation expense utilizing fair value&#x2013;based methodologies and recognizes expense over the vesting period of such awards. For performance-based restricted stock units, the Company records stock-based compensation expense with a cumulative catch-up at the time when performance conditions are considered probable of achievement, and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(p)&#160;&#160;&#160;&#160;Commissions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company&#x2019;s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,803, $1,636, and $2,291 in 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(q)&#160;&#160;&#160;&#160;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the benefit of a tax position in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(r)&#160;&#160;&#160;&#160;Comprehensive (Loss) Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive (loss) income includes net (loss) income and changes in equity related to changes in unrealized gains or losses on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(s)&#160;&#160;&#160;&#160;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments over which the Company has significant influence may be accounted for under equity method accounting &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accordance with Accounting Standards Codification ("ASC") Topic 323 ("Topic 323"), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost less impairment, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accordance with ASC Topic 321 ("Topic 321"), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information regarding the Company&#x2019;s equity investments, see Note 5, Fair Value Measurements and Note 11, Equity Investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(t)&#160;&#160;&#160;&#160;Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding equity of the Company consists of common stock and limited common stock. Under the Company&#x2019;s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Undistributed earnings allocated to the participating securities are subtracted from net income in determining net income (loss) attributable to common and limited common stockholders. Basic net income (loss) per share is computed by dividing net income (loss) attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company&#x2019;s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-419">Recently Issued Accounting Pronouncements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 280) &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Reportable Segment Disclosures,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This standard is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this new standard for the year ended December 31, 2024 with no material impact on its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740) &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires public business entities to disclose specific categories in the tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. This standard is effective for annual periods beginning after December 15, 2024, and interim periods within annual periods beginning after December 15, 2025, on a prospective basis, with early adoption permitted. The Company has not yet adopted ASU 2023-09 and is still evaluating the impact of the adoption on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement &#x2014; Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 220-40) &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Disaggregation of Income Statement Expenses&lt;/span&gt;. which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. This standard is effective for annual periods beginning after December 15, 2026, and interim periods within annual periods beginning after December 15, 2027, on a prospective basis, with early adoption and retrospective application permitted. The Company has not yet adopted ASU 2024-03 and is still evaluating the impact of the adoption on its consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sdgr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock contextRef="c-1" id="f-420">Basis of Presentation and Use of Estimates&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue and estimates regarding the progress of completing performance obligations under collaboration agreements. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</sdgr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-421">Principles of Consolidation&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the accounts of Schr&#xf6;dinger, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The functional currency &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <sdgr:CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock contextRef="c-1" id="f-422">Cash and Cash Equivalents and Marketable Securities and Restricted Cash&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in cash and cash equivalents were cash equivalents of $102,054 and $85,497 as of December&#160;31, 2024 and 2023, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation&#x2019;s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash primarily consists of letters of credit held with the Company&#x2019;s financial institution related to facility leases and is classified as current in the Company&#x2019;s balance sheets based on the maturity of the underlying letters of credit. The Company also has restricted cash related to a certificate of deposit held as collateral for its credit card facility. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash.&lt;/span&gt;&lt;/div&gt;</sdgr:CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-423" unitRef="usd">102054000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-424" unitRef="usd">85497000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-425">Accounts Receivable&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December&#160;31, 2024 and 2023. Interest is not charged on accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-426">Fair Value of Financial Instruments&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-427">Property and Equipment&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. The Company did not capitalize any interest during 2024 and 2023. Maintenance and repairs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated using the straight&#x2011;line method over the estimated useful lives of the assets, which range from 3 to 10 years. Amortization of leasehold improvements is calculated using the straight&#x2011;line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are reviewed for impairment as discussed below under "Accounting for the Impairment of Long&#x2011;Lived Assets."&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InterestCostsCapitalized contextRef="c-17" decimals="INF" id="f-428" unitRef="usd">0</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-1" decimals="INF" id="f-429" unitRef="usd">0</us-gaap:InterestCostsCapitalized>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-53" id="f-430">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-54" id="f-431">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-432">Goodwill&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess purchase price over the fair value of net assets acquired which is not allocable to separately identifiable intangible assets. Other identifiable intangible assets are separately recognized if the intangible asset is obtained through contractual or other legal right or if the intangible asset can be sold, transferred, licensed or exchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but tested for impairment at least annually, and more frequently if events or circumstances indicate the carrying amount more likely than not exceeds the fair value. The Company has the option to qualitatively or quantitatively assess its goodwill for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company tests its goodwill for impairment on October 1 of each year. In 2024, the Company evaluated its goodwill using a qualitative process. If the qualitative factors determine that it is more likely than not that the fair value exceeds the carrying amount, goodwill is not impaired. If the qualitative assessment determines it is more likely than not the fair value is less than the carrying amount, the Company would further evaluate for potential impairment. This &lt;/span&gt;&lt;/div&gt;qualitative assessment indicated that it was more likely than not the Company's reporting unit&#x2019;s fair value exceeded its carrying value.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-17" decimals="INF" id="f-433" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-434" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-18" decimals="INF" id="f-435" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="c-1" id="f-436">Accounting for the Impairment of Long&#x2011;Lived AssetsLong-lived assets, such as property and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-437" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-18" decimals="INF" id="f-438" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-17" decimals="INF" id="f-439" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:StandardProductWarrantyPolicy contextRef="c-1" id="f-440">Warranties&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:StandardProductWarrantyPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-441">Concentrations&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables and contract assets, which represent contracted unbilled receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer&#x2019;s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-55" decimals="2" id="f-442" unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-56" decimals="2" id="f-443" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-57" decimals="2" id="f-444" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="2" id="f-445" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="2" id="f-446" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-60" decimals="2" id="f-447" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="2" id="f-448" unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-62" decimals="2" id="f-449" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-63" decimals="2" id="f-450" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-64" decimals="2" id="f-451" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-65" decimals="2" id="f-452" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-66" decimals="2" id="f-453" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <sdgr:RoyaltiesPolicyPolicyTextBlock contextRef="c-1" id="f-454">RoyaltiesRoyalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company&#x2019;s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections.</sdgr:RoyaltiesPolicyPolicyTextBlock>
    <us-gaap:RoyaltyExpense contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">9342000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c-17" decimals="-3" id="f-456" unitRef="usd">13349000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="c-18" decimals="-3" id="f-457" unitRef="usd">9191000</us-gaap:RoyaltyExpense>
    <sdgr:SoftwareDevelopmentCostsPolicyPolicyTextBlock contextRef="c-1" id="f-458">Software Development Costs&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.&lt;/span&gt;&lt;/div&gt;</sdgr:SoftwareDevelopmentCostsPolicyPolicyTextBlock>
    <sdgr:ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock contextRef="c-1" id="f-459">Research and Development and Advertising&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;</sdgr:ResearchAndDevelopmentAndAdvertisingPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-460">Stock&#x2011;Based Compensation&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates stock&#x2011;based compensation expense utilizing fair value&#x2013;based methodologies and recognizes expense over the vesting period of such awards. For performance-based restricted stock units, the Company records stock-based compensation expense with a cumulative catch-up at the time when performance conditions are considered probable of achievement, and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CommissionsPolicy contextRef="c-1" id="f-461">CommissionsCommissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company&#x2019;s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order.</us-gaap:CommissionsPolicy>
    <sdgr:CommissionExpense contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">1803000</sdgr:CommissionExpense>
    <sdgr:CommissionExpense contextRef="c-17" decimals="-3" id="f-463" unitRef="usd">1636000</sdgr:CommissionExpense>
    <sdgr:CommissionExpense contextRef="c-18" decimals="-3" id="f-464" unitRef="usd">2291000</sdgr:CommissionExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-465">Income Taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the benefit of a tax position in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-466">Comprehensive (Loss) Income&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive (loss) income includes net (loss) income and changes in equity related to changes in unrealized gains or losses on marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-467">Equity Investments&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments over which the Company has significant influence may be accounted for under equity method accounting &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accordance with Accounting Standards Codification ("ASC") Topic 323 ("Topic 323"), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost less impairment, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accordance with ASC Topic 321 ("Topic 321"), &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information regarding the Company&#x2019;s equity investments, see Note 5, Fair Value Measurements and Note 11, Equity Investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-468">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding equity of the Company consists of common stock and limited common stock. Under the Company&#x2019;s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Undistributed earnings allocated to the participating securities are subtracted from net income in determining net income (loss) attributable to common and limited common stockholders. Basic net income (loss) per share is computed by dividing net income (loss) attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company&#x2019;s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-469">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company&#x2019;s performance obligations are satisfied either over time or at a point in time, which can result in different revenue recognition patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the timing of the Company&#x2019;s revenue recognition patterns:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services &#x2013; point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services &#x2013; over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug Discovery &#x2013; point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug Discovery &#x2013; over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Software Products and Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts that can include various combinations of licenses, products and services, most of which are distinct and are accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price ("SSP") basis. Revenue is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's software business derives revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;On-premise software. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's on-premise software license arrangements grant customers the right to use its software on their own in-house servers or their own cloud instances for a specified term, typically for one year, though in recent years, the Company has entered into a small number of large multi-year on-premise software license agreements. The Company recognizes revenue for on-premise software license fees upfront, either upon transfer of control of the license or the effective date of the agreement, whichever is later. In instances where the timing of the transfer of control differs from the timing of invoicing, the Company considers whether a significant financing component exists.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company's updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront or annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hosted software.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Hosted software revenue consists primarily of fees to provide the Company's customers with hosted licenses, which allows these customers to access the Company's cloud-based software solution on their own hardware without taking control of the licenses, and is recognized ratably over the term of the arrangement, which is typically one year, though in recent years, the Company has entered into a small number of large multi-year hosted software license agreements. When a customer enters into a hosted arrangement for which revenue is recognized over time, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the amount paid upfront that is not recognized in the current period is included in deferred revenue in the Company's statement of financial position until the period in which it is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software maintenance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software maintenance includes technical support, updates, and upgrades related to the Company's on-premise software licenses. Software maintenance revenue is recognized ratably over the term of the arrangement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software maintenance activities are performed in connection with the use of the Company's on-premise software.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Professional services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional services include training, technical setup, installation or assisting customers with modeling services, where the Company uses its software to perform tasks such as virtual screening on behalf of the Company&#x2019;s customers. These services are generally not related to the core functionality of the Company's software and are recognized as revenue when resources are consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software contribution revenue. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Software contribution revenue consists of funds received under non-reciprocal agreements with Gates Ventures, LLC and the Bill &amp;amp; Melinda Gates Foundation. The agreement with Gates Ventures, LLC was originally entered into in June 2020 and further ext&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended through August 2026. The agreement is an unconditional non-exchange contribution without restrictions. Revenue is recognized annually, w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hen invoiced, in accordance with ASC Topic 958, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("Topic 958"), as the agreement is not an exchange transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement with Gates Ventures, LLC initially covered the period from June&#160;23, 2020 through June&#160;22, 2023 for total consideration of up to $3,000. The agreement was then extended through August 13, 2026 and provides for total additional consideration of up to $6,000. The Company recognized revenue of $2,000, $1,800, and $1,000 related to these agreements during the years ended December&#160;31, 2024, 2023, and 2022, respectively. As of December&#160;31, 2024, the Company had no deferred revenue balance related to this agreement. As of December&#160;31, 2024 and 2023, the Company had no accounts receivable related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024, the Company entered into a one-year agreement with the Bill &amp;amp; Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins. In November 2024, the Company and the Bill &amp;amp; Melinda Gates Foundation entered into an amendment to the agreement to expand the original term of the agreement to April 30, 2026 and provide supplemental funds on terms similar to the original agreement. Revenue is recognized as conditions are met and on a cost reimbursement basis in accordance with Topic 958. The Company recognized revenue of $6,016 related to these agreements during the year ended December&#160;31, 2024. As of December&#160;31, 2024, the Company had a $8,484 deferred revenue balance related to these agreements. As of December&#160;31, 2024, the Company had no accounts receivable related to these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the revenue recognized from the sources of software products and services revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;On-premise software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Hosted software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue from contracts with customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;172,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;157,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;134,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total software revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;180,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Drug Discovery&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Drug discovery services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from drug discovery and collaboration services contracts includes revenue from research services and the achievement of milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research services revenue is generally recognized over time, typically by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input method based on the services promised to the customer, such as costs incurred and hours expended. This method of recognizing revenue requires the Company to make estimates of the work required to complete the performance obligation in order to determine the progress towards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;completion. Payments for research services are generally due upfront at the start of a contract or periodically through the contract term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is generally entitled to receive variable consideration as certain milestones are achieved. The Company estimates the amount of variable consideration using the most likely amount method. The Company evaluates milestones on a case-by-case basis, including whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable or the event is outside of the Company's control, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is deemed probable of being achieved or the event occurs. Upon removal of the constraint on variable consideration, revenue may be recognized at a point in time or over time by applying the allocation guidance of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("Topic 606").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there were no milestones not yet achieved that were determined to be probable of achievement. As of December 31, 2023 and 2022, milestones not yet achieved that were determined to be probable of achievement totaled $350 and $4,000, respectively, and $350 and $3,939 of those milestones were recognized as revenue for the years ended December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Drug discovery contribution revenue&lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Drug &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discovery &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contribution revenue consists of funds received under an agreement with the Bill &amp;amp; Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women's health. The initial agreement began in November 2021 and expired in September 2023. In September 2023, the Company entered into a new agreement with the Bill &amp;amp; Melinda Gates Foundation to perform services aimed at accelerating drug discovery in women's health that expires in October 2025. Revenue is recognized as costs are incurred in accordance with Topic 958&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company had deferred revenue balances related to these agreements of $949 and $1,581, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the revenue recognized from the sources of drug discovery revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery services revenue from contracts with customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total drug discovery revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bristol Myers-Squibb. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;22, 2020, the Company entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company ("BMS"), pursuant to which the Company and BMS agreed to collaborate in the discovery, research and preclinical development of new small molecule compounds for disease indications in oncology, neurology, and immunology therapeutics areas. Under the agreement, the Company was initially responsible, at its own cost and expense, for the discovery of small molecule compounds directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. In December 2022, the Company and BMS entered into an amendment to the agreement to include an additional target in neurology on terms similar to the original agreement. As a result of BMS electing not to proceed with further development of certain targets, there is one remaining neurology target under the agreement, as amended, as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once a development candidate meeting specified criteria for a target under the agreement has been identified by the Company, BMS will be solely responsible for the further development, manufacturing and commercialization of such development candidate at its own cost and expense. The Company is solely responsible for the development of any programs that have been returned by BMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, as amended, BMS paid the Company an initial upfront payment of $55.0 million in November 2020, an additional upfront payment in December 2022, and a program fee in December 2024. As of December&#160;31, 2024 the Company is eligible to receive up to $482.0 million in total milestone payments related to the one remaining neurology target currently subject to the collaboration, consisting of up to $257.0 million in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225.0 million in the aggregate for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the achievement of certain specified commercial milestones. As of December&#160;31, 2024, the Company has recognized $32.0 million in revenue related to milestones under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also entitled to a tiered percentage royalty on annual net sales ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the collaboration and license agreement in accordance with Topic 606 and concluded that BMS is a customer based on the agreement structure. At inception, the Company identified one performance obligation for each of the five programs initially covered under the agreement, which includes research activities for each program and a license grant for the underlying intellectual property. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the transaction price at the onset of the agreement was $55.0 million. Additional consideration to be paid to the Company upon the achievement of future milestone payments was excluded from the transaction price as they represent milestone payments that were not considered probable as of the inception date such that there is not a significant risk of revenue reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has allocated the transaction price of $55.0 million to each performance obligation based on the SSP of each performance obligation at inception. The Company determined the estimated SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized $10.8 million, $43.2 million, and $22.1 million, respectively, of revenue associated with the agreement based on the research activities performed and milestones achieved. As of December&#160;31, 2024 and 2023, there was $5.9 million and $7.3 million, respectively, of deferred revenue related to the agreement, which was classified as either current or non-current in the consolidated balance sheet based on the period the services are expected to be performed. As of December&#160;31, 2024 and 2023, the Company had no outstanding receivables for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 11, 2024, the Company entered into a research collaboration and license agreement with Novartis Pharma AG ("Novartis"), pursuant to which the Company and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds for targets in certain specified therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. The Company also entered into an expanded three-year software agreement with Novartis that substantially increases Novartis' access to the Company&#x2019;s computational predictive modeling technology and enterprise informatics platform. Under Topic 606, the research collaboration and license agreement as well as the three-year software agreement ("the agreements") are collectively accounted for as a single contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the research collaboration and license agreement, once a development candidate has been identified, Novartis will be solely responsible for the further development, manufacturing and commercialization of such development candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis agreed to pay the Company an initial upfront payment of $150.0 million under the terms of the research collaboration and license agreement, and the Company will be eligible to eligible to receive up to $2.272 billion in total milestone payments across the initial programs. Such milestones consist of up to $892.0&#160;million in discovery and development milestones and up to $1.38&#160;billion in commercial milestones. The Company is also entitled to a tiered percentage royalty ranging from mid-single-digits to low double-digits on products commercialized by Novartis under the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;agreement, subject to certain specified reductions. As of December&#160;31, 2024, no revenue has been recognized related to milestones under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the research collaboration and license agreement in accordance with Topic 606 and concluded that Novartis is a customer based on the agreement structure. The promises identified by the Company include research activities for each program under the agreement, a license grant for the underlying intellectual property, and software licenses and services. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract. Software licenses and services provided under the agreement are considered distinct and are accounted for as separate performance obligations in accordance with Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has allocated the transaction price for the agreements to each performance obligation based on the SSP of each performance obligation at inception. The Company determined the estimated SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, the Company recognized $0.6 million of revenue associated with the research collaboration and license agreement. As of December&#160;31, 2024, there was $116.7 million of deferred revenue, net of contract assets, related to the agreements, which was classified as either current or non-current in the condensed consolidated balance sheet based on the period the services are expected to be performed. As of December&#160;31, 2024, the Company had $150.0 million outstanding receivables for this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Significant Judgments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgments and estimates are required under Topic 606. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company&#x2019;s arrangements may be dependent on contract-specific terms and may vary in some instances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's contracts with customers often include but are not limited to promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates, as well as collaborative research services, licenses to intellectual properties, and customer options. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company's term-based software license arrangements, may include multiple software licenses, a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised licenses and services are separate distinct performance obligations. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable consideration. For collaborative arrangements, under which the Company is eligible to receive variable consideration in the form of milestones payments, judgment is required to evaluate whether the milestones are considered probable of being achieved. If it is probable that a significant revenue reversal would not occur, the constraint is removed and value of the associated milestone is included in the estimated transaction price using the most likely amount method based on contractual requirements and historical experience. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a relative SSP basis consistent with the allocation objectives of Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Judgment is required to determine the SSP for each distinct performance obligation. The Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for individual software license performance obligations due to the stratification of those items by volume of sales, classes of customers and other relevant circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP. Professional service revenue is recognized as costs and hours are incurred, and judgment is required in estimating both the project status and the costs incurred or hours expended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company's judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Judgment is required to determine the total costs to perform research activities, which include the length of time required, the internal hours expected to be incurred on the services, and the number and costs of various studies that may be performed by third parties to complete the research plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, the Company has not experienced significant returns or refunds to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's estimates related to revenue recognition may require significant judgment and a change in these estimates could have an effect on the Company's results of operations during the periods involved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e)&#160;&#160;&#160;&#160;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables, contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing. A deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company's time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements where the milestones are deemed probable in a period prior to when the milestone is achieved, the Company records a contract asset for the full value of the milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are included in unbilled and other receivables within the consolidated balance sheets and are transferred to receivables when the Company invoices the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.956%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred revenue, short-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;75,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred revenue, long-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;94,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024 and 2023, the Company recognized $53,438 and $64,120 of revenue, respectively, that was included in deferred revenue at the end of the respective preceding periods. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue approximately 51% of its December&#160;31, 2024 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in deferred revenue were $59,519 as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment terms and conditions vary by contract type, although terms typically require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company&#x2019;s products and services, not to facilitate financing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f)&#160;&#160;&#160;&#160;Deferred Sales Commissions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has applied the practical expedient for sales commission expense, as any material compensation paid to sales representatives to obtain a contract relates to a period of one year or less. The Company has not capitalized any costs related to sales commissions.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the timing of the Company&#x2019;s revenue recognition patterns:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services &#x2013; point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;47.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services &#x2013; over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug Discovery &#x2013; point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug Discovery &#x2013; over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-67" decimals="3" id="f-471" unitRef="number">0.514</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-68" decimals="3" id="f-472" unitRef="number">0.491</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-69" decimals="3" id="f-473" unitRef="number">0.473</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-70" decimals="3" id="f-474" unitRef="number">0.355</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-71" decimals="3" id="f-475" unitRef="number">0.243</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-72" decimals="3" id="f-476" unitRef="number">0.276</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-73" decimals="3" id="f-477" unitRef="number">0.068</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-74" decimals="3" id="f-478" unitRef="number">0.127</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-75" decimals="3" id="f-479" unitRef="number">0.088</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-76" decimals="3" id="f-480" unitRef="number">0.063</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-77" decimals="3" id="f-481" unitRef="number">0.139</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:TimingOfRevenueRecognitionPercentage contextRef="c-78" decimals="3" id="f-482" unitRef="number">0.163</sdgr:TimingOfRevenueRecognitionPercentage>
    <sdgr:RevenueArrangementsContractTerm contextRef="c-79" id="f-483">P1Y</sdgr:RevenueArrangementsContractTerm>
    <sdgr:RevenueArrangementsContractTerm contextRef="c-80" id="f-484">P1Y</sdgr:RevenueArrangementsContractTerm>
    <sdgr:SoftwareContributionRevenueRecognitionAmount contextRef="c-81" decimals="-3" id="f-485" unitRef="usd">3000000</sdgr:SoftwareContributionRevenueRecognitionAmount>
    <sdgr:SoftwareContributionRevenueRecognitionAmount contextRef="c-82" decimals="-3" id="f-486" unitRef="usd">6000000</sdgr:SoftwareContributionRevenueRecognitionAmount>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-83" decimals="-3" id="f-487" unitRef="usd">2000000</sdgr:SoftwareContributionRevenueRecognized>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-84" decimals="-3" id="f-488" unitRef="usd">1800000</sdgr:SoftwareContributionRevenueRecognized>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-85" decimals="-3" id="f-489" unitRef="usd">1000000</sdgr:SoftwareContributionRevenueRecognized>
    <us-gaap:DeferredIncome contextRef="c-86" decimals="INF" id="f-490" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-86" decimals="INF" id="f-491" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-87" decimals="INF" id="f-492" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <sdgr:CollaborativeArrangementTerm contextRef="c-88" id="f-493">P1Y</sdgr:CollaborativeArrangementTerm>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-89" decimals="-3" id="f-494" unitRef="usd">6016000</sdgr:SoftwareContributionRevenueRecognized>
    <us-gaap:DeferredIncome contextRef="c-90" decimals="-3" id="f-495" unitRef="usd">8484000</us-gaap:DeferredIncome>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-90" decimals="INF" id="f-496" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-497">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the revenue recognized from the sources of software products and services revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;On-premise software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;84,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Hosted software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue from contracts with customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;172,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;157,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;134,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total software revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;180,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;159,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;135,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the revenue recognized from the sources of drug discovery revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery services revenue from contracts with customers&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total drug discovery revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;27,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;57,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-498" unitRef="usd">104020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-3" id="f-499" unitRef="usd">104511000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-500" unitRef="usd">84487000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-3" id="f-501" unitRef="usd">35253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-502" unitRef="usd">20381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-3" id="f-503" unitRef="usd">14890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-504" unitRef="usd">23279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-505" unitRef="usd">23066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-506" unitRef="usd">19996000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-507" unitRef="usd">9797000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-508" unitRef="usd">9366000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-509" unitRef="usd">15205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-510" unitRef="usd">172349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-511" unitRef="usd">157324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-512" unitRef="usd">134578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-106" decimals="-3" id="f-513" unitRef="usd">8016000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-107" decimals="-3" id="f-514" unitRef="usd">1800000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-108" decimals="-3" id="f-515" unitRef="usd">1000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-11" decimals="-3" id="f-516" unitRef="usd">180365000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-3" id="f-517" unitRef="usd">159124000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-518" unitRef="usd">135578000</us-gaap:Revenues>
    <sdgr:MilestonePaymentYetToBeAchieved contextRef="c-109" decimals="-3" id="f-519" unitRef="usd">0</sdgr:MilestonePaymentYetToBeAchieved>
    <sdgr:MilestonePaymentYetToBeAchieved contextRef="c-110" decimals="-3" id="f-520" unitRef="usd">350000</sdgr:MilestonePaymentYetToBeAchieved>
    <sdgr:MilestonePaymentYetToBeAchieved contextRef="c-111" decimals="-3" id="f-521" unitRef="usd">4000000</sdgr:MilestonePaymentYetToBeAchieved>
    <sdgr:RevenueRecognizedForMilestonePayment contextRef="c-110" decimals="-3" id="f-522" unitRef="usd">350000</sdgr:RevenueRecognizedForMilestonePayment>
    <sdgr:RevenueRecognizedForMilestonePayment contextRef="c-111" decimals="-3" id="f-523" unitRef="usd">3939000</sdgr:RevenueRecognizedForMilestonePayment>
    <us-gaap:DeferredRevenue contextRef="c-5" decimals="-3" id="f-524" unitRef="usd">949000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="c-6" decimals="-3" id="f-525" unitRef="usd">1581000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-526" unitRef="usd">25143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-3" id="f-527" unitRef="usd">54720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-3" id="f-528" unitRef="usd">43427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-112" decimals="-3" id="f-529" unitRef="usd">2031000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-113" decimals="-3" id="f-530" unitRef="usd">2822000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-114" decimals="-3" id="f-531" unitRef="usd">1950000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-532" unitRef="usd">27174000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-3" id="f-533" unitRef="usd">57542000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-3" id="f-534" unitRef="usd">45377000</us-gaap:Revenues>
    <sdgr:ContractWithCustomerNumberOfSpecifiedBiologicalTargets
      contextRef="c-115"
      decimals="INF"
      id="f-535"
      unitRef="target">5</sdgr:ContractWithCustomerNumberOfSpecifiedBiologicalTargets>
    <sdgr:ContractWithCustomerNumberOfNeurologyTargetRemaining
      contextRef="c-116"
      decimals="INF"
      id="f-536"
      unitRef="target">1</sdgr:ContractWithCustomerNumberOfNeurologyTargetRemaining>
    <us-gaap:ContractWithCustomerLiability contextRef="c-117" decimals="-5" id="f-537" unitRef="usd">55000000.0</us-gaap:ContractWithCustomerLiability>
    <sdgr:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-116" decimals="-5" id="f-538" unitRef="usd">482000000.0</sdgr:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <sdgr:ContractWithCustomerNumberOfNeurologyTargetRemaining
      contextRef="c-116"
      decimals="INF"
      id="f-539"
      unitRef="target">1</sdgr:ContractWithCustomerNumberOfNeurologyTargetRemaining>
    <sdgr:RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount contextRef="c-115" decimals="-5" id="f-540" unitRef="usd">257000000.0</sdgr:RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount>
    <sdgr:RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount contextRef="c-115" decimals="-5" id="f-541" unitRef="usd">225000000.0</sdgr:RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-118" decimals="-5" id="f-542" unitRef="usd">32000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <sdgr:NumberOfPerformanceObligations
      contextRef="c-115"
      decimals="INF"
      id="f-543"
      unitRef="obligation">1</sdgr:NumberOfPerformanceObligations>
    <sdgr:CollaborativeAgreementNumberOfPrograms
      contextRef="c-119"
      decimals="INF"
      id="f-544"
      unitRef="program">5</sdgr:CollaborativeAgreementNumberOfPrograms>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-115" decimals="-5" id="f-545" unitRef="usd">55000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-115" decimals="-5" id="f-546" unitRef="usd">55000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-5" id="f-547" unitRef="usd">10800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-5" id="f-548" unitRef="usd">43200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-5" id="f-549" unitRef="usd">22100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-116" decimals="-5" id="f-550" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-123" decimals="-5" id="f-551" unitRef="usd">7300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent contextRef="c-116" decimals="INF" id="f-552" unitRef="usd">0</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-124" id="f-553">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-124" id="f-554">P3Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerLiability contextRef="c-125" decimals="-5" id="f-555" unitRef="usd">150000000.0</us-gaap:ContractWithCustomerLiability>
    <sdgr:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-126" decimals="-6" id="f-556" unitRef="usd">2272000000</sdgr:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <sdgr:RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount contextRef="c-126" decimals="-5" id="f-557" unitRef="usd">892000000.0</sdgr:RevenueRemainingPerformanceObligationVariableConsiderationResearchDevelopmentAndRegulatoryMilestonesAmount>
    <sdgr:RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount contextRef="c-126" decimals="-7" id="f-558" unitRef="usd">1380000000</sdgr:RevenueRemainingPerformanceObligationVariableConsiderationCommercialMilestonesAmount>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-127" decimals="INF" id="f-559" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-128" decimals="-5" id="f-560" unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-129" decimals="-5" id="f-561" unitRef="usd">116700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent contextRef="c-129" decimals="INF" id="f-562" unitRef="usd">150000000.0</us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-563">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.956%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred revenue, short-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;75,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;44,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;36,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Deferred revenue, long-term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Software products and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;14,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;94,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-5" decimals="-3" id="f-564" unitRef="usd">16564000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-6" decimals="-3" id="f-565" unitRef="usd">21107000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-130" decimals="-3" id="f-566" unitRef="usd">75660000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-131" decimals="-3" id="f-567" unitRef="usd">44218000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-132" decimals="-3" id="f-568" unitRef="usd">36284000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-133" decimals="-3" id="f-569" unitRef="usd">12013000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-130" decimals="-3" id="f-570" unitRef="usd">14393000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-131" decimals="-3" id="f-571" unitRef="usd">2407000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-132" decimals="-3" id="f-572" unitRef="usd">94421000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-133" decimals="-3" id="f-573" unitRef="usd">6636000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-574" unitRef="usd">53438000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-17" decimals="-3" id="f-575" unitRef="usd">64120000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-5" decimals="2" id="f-576" unitRef="number">0.51</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-5" decimals="-3" id="f-577" unitRef="usd">59519000</us-gaap:RevenueRemainingPerformanceObligation>
    <sdgr:ContractWithCustomersPaymentTerms contextRef="c-134" id="f-578">P30D</sdgr:ContractWithCustomersPaymentTerms>
    <sdgr:ContractWithCustomersPaymentTerms contextRef="c-135" id="f-579">P60D</sdgr:ContractWithCustomersPaymentTerms>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-580">Property and Equipment&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computers and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right of use asset - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for 2024, 2023, and 2022 was $6,159, $4,965, and $3,831, respectively, and is included within cost of revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-581">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Computers and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right of use asset - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;45,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(20,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(18,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;23,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-136" decimals="-3" id="f-582" unitRef="usd">23527000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-137" decimals="-3" id="f-583" unitRef="usd">22122000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-138" decimals="-3" id="f-584" unitRef="usd">3693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-139" decimals="-3" id="f-585" unitRef="usd">3787000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-140" decimals="-3" id="f-586" unitRef="usd">6876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-141" decimals="-3" id="f-587" unitRef="usd">6230000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-142" decimals="-3" id="f-588" unitRef="usd">10375000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-143" decimals="-3" id="f-589" unitRef="usd">8757000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-590" unitRef="usd">579000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-6" decimals="-3" id="f-591" unitRef="usd">579000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-592" unitRef="usd">45050000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-593" unitRef="usd">41475000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-594" unitRef="usd">20854000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-595" unitRef="usd">18150000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-596" unitRef="usd">24196000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-597" unitRef="usd">23325000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-598" unitRef="usd">6159000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-17" decimals="-3" id="f-599" unitRef="usd">4965000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-18" decimals="-3" id="f-600" unitRef="usd">3831000</us-gaap:Depreciation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-601">Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various inputs are used in determining the fair value of the Company&#x2019;s financial assets and liabilities. These inputs are summarized into the following three broad categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013; quoted prices in active markets for identical securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013; other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013; significant unobservable inputs, including the Company&#x2019;s own assumptions in determining fair value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. Marketable securities, which consist primarily of corporate and U.S. government agency bonds, are classified as available for sale and fair value did not differ significantly from carrying value as of December&#160;31, 2024 and 2023. The following table presents information about the Company&#x2019;s assets measured at fair value as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets measured at fair value as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s investment in Nimbus Therapeutics, LLC (&#x201c;Nimbus&#x201d;), classified as Level 3 in the fair value hierarchy, was recorded as an equity method investment under Topic 323 using the hypothetical liquidated book value method (&#x201c;HLBV method&#x201d;) through June 30, 2023, as further described in Note 11, Equity Investments. Significant unobservable inputs used to determine Nimbus&#x2019; fair value under the HLBV method were the entity's annual financial statements and the Company&#x2019;s liquidation preference. Following the dilution of the Company's investment in Nimbus during the year ended December 31, 2023, the fair value of the Company's investment was recorded under Topic 321 as a non-marketable equity security as the Company no longer exercises significant influence over Nimbus. This change in accounting method resulted in an unrealized gain of $1,928 and subsequent removal from the Level 3 fair value hierarchy table during the year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized gains and losses arising from changes in fair value of the Company&#x2019;s equity investments are classified within change in fair value in the consolidated statements of operations. Realized gains arising from distributions receivable from the Company's equity investments are classified within gain on equity investments in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information regarding the Company&#x2019;s equity investments, see Note 11, Equity Investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-602">The following table presents information about the Company&#x2019;s assets measured at fair value as of December&#160;31, 2024:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets measured at fair value as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-144" decimals="-3" id="f-603" unitRef="usd">162657000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-145" decimals="-3" id="f-604" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-146" decimals="-3" id="f-605" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-147" decimals="-3" id="f-606" unitRef="usd">162657000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-148" decimals="-3" id="f-607" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-149" decimals="-3" id="f-608" unitRef="usd">204798000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-150" decimals="-3" id="f-609" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-151" decimals="-3" id="f-610" unitRef="usd">204798000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-152" decimals="-3" id="f-611" unitRef="usd">36202000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-153" decimals="-3" id="f-612" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-154" decimals="-3" id="f-613" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-155" decimals="-3" id="f-614" unitRef="usd">36202000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-156" decimals="-3" id="f-615" unitRef="usd">198859000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-157" decimals="-3" id="f-616" unitRef="usd">204798000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-158" decimals="-3" id="f-617" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-618" unitRef="usd">403657000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-159" decimals="-3" id="f-619" unitRef="usd">161066000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-160" decimals="-3" id="f-620" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-161" decimals="-3" id="f-621" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-162" decimals="-3" id="f-622" unitRef="usd">161066000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-163" decimals="-3" id="f-623" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-164" decimals="-3" id="f-624" unitRef="usd">307688000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-165" decimals="-3" id="f-625" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-166" decimals="-3" id="f-626" unitRef="usd">307688000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-167" decimals="-3" id="f-627" unitRef="usd">79623000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-168" decimals="-3" id="f-628" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-169" decimals="-3" id="f-629" unitRef="usd">1928000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-170" decimals="-3" id="f-630" unitRef="usd">81551000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-171" decimals="-3" id="f-631" unitRef="usd">240689000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-172" decimals="-3" id="f-632" unitRef="usd">307688000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-173" decimals="-3" id="f-633" unitRef="usd">1928000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-6" decimals="-3" id="f-634" unitRef="usd">550305000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">1928000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-1" decimals="-3" id="f-636" unitRef="usd">1928000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-637">Commitments and Contingencies&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has multiple operating leases for office space and a finance lease for equipment that expire at various dates through 2037. The Company has elected the package of practical expedients under the transition guidance of ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to exclude short-term leases from the balance sheet and to combine lease and non-lease components. The Company classifies finance lease right of use assets under property and equipment, net and finance short-term and long-term lease liabilities under other accrued liabilities and other liabilities, long-term, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon inception of a lease, the Company determines if an arrangement is a lease, if it is classified as an operating or finance lease, if it includes options to extend or terminate the lease, and if it is reasonably certain that the Company will exercise the options. Lease cost, representing lease payments over the term of the lease and any capitalizable direct costs less any incentives received, is recognized on a straight-line basis over the lease term as lease expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. Upon execution of a new lease, the Company performs an analysis to determine its incremental borrowing rate using its current borrowing rate, adjusted for various factors including level of collateralization and lease term. As of December&#160;31, 2024, the remaining weighted average lease term for operating and finance leases was 11 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, operating lease right of use assets increased by $2,952 due to contingency resolutions associated with office leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable and short-term lease costs for the Company's operating and finance leases were immaterial for the year ended December&#160;31, 2024. Additional details of the Company's operating and finance leases are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating and finance lease liabilities as of December&#160;31, 2024 under noncancelable leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the Company&#x2019;s financial position or results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sdgr:FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm contextRef="c-5" id="f-638">P11Y</sdgr:FinanceAndOperatingLeaseWeightedAverageRemainingLeaseTerm>
    <sdgr:IncreaseInRightOfUseAssetsDueToContingencyResolution contextRef="c-1" decimals="-3" id="f-639" unitRef="usd">2952000</sdgr:IncreaseInRightOfUseAssetsDueToContingencyResolution>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-640">Additional details of the Company's operating and finance leases are presented in the following table:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">18097000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-17" decimals="-3" id="f-642" unitRef="usd">16769000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-18" decimals="-3" id="f-643" unitRef="usd">11999000</us-gaap:LeaseCost>
    <sdgr:OperatingAndFinanceLeasePayments contextRef="c-1" decimals="-3" id="f-644" unitRef="usd">17718000</sdgr:OperatingAndFinanceLeasePayments>
    <sdgr:OperatingAndFinanceLeasePayments contextRef="c-17" decimals="-3" id="f-645" unitRef="usd">12263000</sdgr:OperatingAndFinanceLeasePayments>
    <sdgr:OperatingAndFinanceLeasePayments contextRef="c-18" decimals="-3" id="f-646" unitRef="usd">3275000</sdgr:OperatingAndFinanceLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-647">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating and finance lease liabilities as of December&#160;31, 2024 under noncancelable leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities, long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne contextRef="c-5" decimals="-3" id="f-648" unitRef="usd">17452000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo contextRef="c-5" decimals="-3" id="f-649" unitRef="usd">17136000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree contextRef="c-5" decimals="-3" id="f-650" unitRef="usd">15975000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour contextRef="c-5" decimals="-3" id="f-651" unitRef="usd">14939000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive contextRef="c-5" decimals="-3" id="f-652" unitRef="usd">14522000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive contextRef="c-5" decimals="-3" id="f-653" unitRef="usd">97509000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaid contextRef="c-5" decimals="-3" id="f-654" unitRef="usd">177533000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityToBePaid>
    <sdgr:LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-655" unitRef="usd">59506000</sdgr:LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount>
    <sdgr:OperatingAndFinanceLeaseLiability contextRef="c-5" decimals="-3" id="f-656" unitRef="usd">118027000</sdgr:OperatingAndFinanceLeaseLiability>
    <sdgr:OperatingAndFinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-657" unitRef="usd">16878000</sdgr:OperatingAndFinanceLeaseLiabilityCurrent>
    <sdgr:OperatingAndFinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-658" unitRef="usd">101149000</sdgr:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-659">Income Taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit) is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of (loss) income before income taxes by tax jurisdiction were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return-to-provision adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax contingencies, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense for the year ended December&#160;31, 2024 represents the Company's income tax obligations in certain states and taxes in foreign jurisdictions in which it conducts business. Income tax expense for the years ended December 31, 2023 represents the Company's federal and certain state income tax obligations and taxes in foreign jurisdictions for which it conducts business. Income tax expense for the year ended December 31, 2022 represents the Company's income tax obligations in certain states and taxes in foreign jurisdictions in which it conducts business. As of December&#160;31, 2024, the Company has a full valuation allowance on U.S. federal and state deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total change in valuation allowance for the year ended December&#160;31, 2024 was $41,195, which was primarily due to temporary differences for capitalized research and development expenses and share based compensation, partially offset by adjustments to equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had federal and state net operating loss ("NOL") carryforwards of $204,474 and $129,490, respectively. The state NOL carryforwards will expire between 2025 and 2044, if not used by the Company to reduce income taxes payable in future periods. Utilization of post-2017 federal NOL carryforwards is limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December&#160;31, 2024, the Company had federal orphan drug credits and federal research and development tax credit carryforwards of $31,294 and state research and development tax credit carryforwards of $2,736. The federal and state carryforwards, with the exception of $2,223 indefinite state credits will expire between 2025 and 2044, if not utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of NOLs and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through December 31, 2024 and determined no such ownership change has occurred in the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign operations as the Company considers these earnings to be indefinitely reinvested. The determination of a hypothetical unrecognized deferred tax liability as of December&#160;31, 2024 is not practicable because of the complexity and variety of assumptions necessary to compute the tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions taken in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions taken in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries file U.S. federal income tax returns and various state, local and foreign income tax returns. As of December&#160;31, 2024, the Company&#x2019;s statutes of limitations are open for all federal and state tax returns filed after the years ended December&#160;31, 2021 and 2020, respectively. NOL and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-660">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense (benefit) is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-661" unitRef="usd">-202000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-662" unitRef="usd">727000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-663" unitRef="usd">-195000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-664" unitRef="usd">352000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-665" unitRef="usd">509000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-666" unitRef="usd">-280000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-667" unitRef="usd">1515000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-668" unitRef="usd">963000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-669" unitRef="usd">538000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-670" unitRef="usd">1665000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-671" unitRef="usd">2199000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-672" unitRef="usd">63000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-673" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-677" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-678" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-679" unitRef="usd">-253000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-680" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-681" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-682" unitRef="usd">-253000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-683" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-684" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-685" unitRef="usd">1412000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-686" unitRef="usd">2199000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-687" unitRef="usd">63000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-688">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of (loss) income before income taxes by tax jurisdiction were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-689" unitRef="usd">-190298000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-17" decimals="-3" id="f-690" unitRef="usd">39076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-18" decimals="-3" id="f-691" unitRef="usd">-150147000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-692" unitRef="usd">4587000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-17" decimals="-3" id="f-693" unitRef="usd">3843000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-18" decimals="-3" id="f-694" unitRef="usd">1021000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-695" unitRef="usd">-185711000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-696" unitRef="usd">42919000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-18" decimals="-3" id="f-697" unitRef="usd">-149126000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-698">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return-to-provision adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax contingencies, net of reversals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-699" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-17" decimals="3" id="f-700" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-18" decimals="3" id="f-701" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-702" unitRef="number">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-17" decimals="3" id="f-703" unitRef="number">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-18" decimals="3" id="f-704" unitRef="number">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation contextRef="c-1" decimals="3" id="f-705" unitRef="number">0</sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation>
    <sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation contextRef="c-17" decimals="3" id="f-706" unitRef="number">0.012</sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation>
    <sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation contextRef="c-18" decimals="3" id="f-707" unitRef="number">-0.011</sdgr:EffectiveIncomeTaxRateReconciliationSection162Limitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-708" unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-17" decimals="3" id="f-709" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-18" decimals="3" id="f-710" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments contextRef="c-1" decimals="3" id="f-711" unitRef="number">-0.015</sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments contextRef="c-17" decimals="3" id="f-712" unitRef="number">-0.033</sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments contextRef="c-18" decimals="3" id="f-713" unitRef="number">0.002</sdgr:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-714" unitRef="number">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-17" decimals="3" id="f-715" unitRef="number">0.141</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-18" decimals="3" id="f-716" unitRef="number">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-1" decimals="3" id="f-717" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-17" decimals="3" id="f-718" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies contextRef="c-18" decimals="3" id="f-719" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-720" unitRef="number">-0.222</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-17" decimals="3" id="f-721" unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-18" decimals="3" id="f-722" unitRef="number">-0.286</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-723" unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-17" decimals="3" id="f-724" unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-18" decimals="3" id="f-725" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-726" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-17" decimals="3" id="f-727" unitRef="number">0.051</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-18" decimals="3" id="f-728" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-729" unitRef="usd">41195000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-730">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,553)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-731" unitRef="usd">51542000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-732" unitRef="usd">44116000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-34" decimals="-3" id="f-733" unitRef="usd">67758000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-734" unitRef="usd">62215000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-735" unitRef="usd">13224000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-34" decimals="-3" id="f-736" unitRef="usd">5511000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-737" unitRef="usd">37544000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-6" decimals="-3" id="f-738" unitRef="usd">71676000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-34" decimals="-3" id="f-739" unitRef="usd">43362000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-740" unitRef="usd">5462000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-3" id="f-741" unitRef="usd">5296000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-34" decimals="-3" id="f-742" unitRef="usd">6532000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <sdgr:DeferredTaxAssetsLeaseLiabilities contextRef="c-5" decimals="-3" id="f-743" unitRef="usd">27551000</sdgr:DeferredTaxAssetsLeaseLiabilities>
    <sdgr:DeferredTaxAssetsLeaseLiabilities contextRef="c-6" decimals="-3" id="f-744" unitRef="usd">32491000</sdgr:DeferredTaxAssetsLeaseLiabilities>
    <sdgr:DeferredTaxAssetsLeaseLiabilities contextRef="c-34" decimals="-3" id="f-745" unitRef="usd">28952000</sdgr:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-746" unitRef="usd">29884000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-6" decimals="-3" id="f-747" unitRef="usd">21903000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-34" decimals="-3" id="f-748" unitRef="usd">18456000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-749" unitRef="usd">214198000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-750" unitRef="usd">188706000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-34" decimals="-3" id="f-751" unitRef="usd">170571000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-752" unitRef="usd">177226000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-753" unitRef="usd">136031000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-34" decimals="-3" id="f-754" unitRef="usd">137957000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-755" unitRef="usd">36972000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-756" unitRef="usd">52675000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-34" decimals="-3" id="f-757" unitRef="usd">32614000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities contextRef="c-5" decimals="-3" id="f-758" unitRef="usd">7284000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities contextRef="c-6" decimals="-3" id="f-759" unitRef="usd">18553000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities contextRef="c-34" decimals="-3" id="f-760" unitRef="usd">4439000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-3" id="f-761" unitRef="usd">652000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-6" decimals="-3" id="f-762" unitRef="usd">1554000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-34" decimals="-3" id="f-763" unitRef="usd">1435000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-764" unitRef="usd">29036000</sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-765" unitRef="usd">32568000</sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization contextRef="c-34" decimals="-3" id="f-766" unitRef="usd">26740000</sdgr:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-767" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-768" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-34" decimals="-3" id="f-769" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-5" decimals="-3" id="f-770" unitRef="usd">204474000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-5" decimals="-3" id="f-771" unitRef="usd">129490000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-174" decimals="-3" id="f-772" unitRef="usd">31294000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-175" decimals="-3" id="f-773" unitRef="usd">2736000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sdgr:DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration contextRef="c-175" decimals="-3" id="f-774" unitRef="usd">2223000</sdgr:DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-775">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions taken in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions taken in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-776" unitRef="usd">2742000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-34" decimals="-3" id="f-777" unitRef="usd">2142000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-24" decimals="-3" id="f-778" unitRef="usd">1702000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-779" unitRef="usd">258000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-17" decimals="-3" id="f-780" unitRef="usd">89000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-18" decimals="-3" id="f-781" unitRef="usd">35000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-782" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-17" decimals="-3" id="f-783" unitRef="usd">4000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-18" decimals="-3" id="f-784" unitRef="usd">24000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-785" unitRef="usd">648000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-17" decimals="-3" id="f-786" unitRef="usd">515000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-18" decimals="-3" id="f-787" unitRef="usd">429000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-788" unitRef="usd">3648000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-789" unitRef="usd">2742000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-34" decimals="-3" id="f-790" unitRef="usd">2142000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-791">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had authorized 500,000,000 shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company&#x2019;s preferred stock, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company entered into an amended and restated sales agreement with Leerink Partners LLC ("Leerink Partners"), as sales agent, with respect to an at-the-market offering program (the "ATM") under which the Company could offer and sell, from time to time pursuant to its Registration Statement on Form S-3, shares of common stock, having an aggregate offering price of up to $250,000, through Leerink Partners. The amended and restated sales agreement amends and restates the original sales agreement that the Company entered into with Leerink Partners with respect to the ATM in May 2023, which is no longer in effect. During the year ended December&#160;31, 2024, 323,085 shares of common stock were sold under the ATM for total net proceeds of $8,691 and gross proceeds of $8,868, before deducting sales agent commissions. As of December&#160;31, 2024, the Company had $241,132 of common stock remaining available for sale under the ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Limited Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had authorized 100,000,000 shares of limited common stock with a par value of $0.01 per share. Holders of limited common stock are entitled to one vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to the same dividend rights as holders of common stock, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company's preferred stock, if any. Holders of the Company's limited common stock have the right to convert each share of limited common stock into one share of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Limited common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had authorized 10,000,000 shares of undesignated preferred stock with a par value of $0.01 per share. The Company's board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-176"
      decimals="INF"
      id="f-792"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-176"
      decimals="INF"
      id="f-793"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <sdgr:NumberOfVotesForCommonShare contextRef="c-176" decimals="INF" id="f-794" unitRef="vote">1</sdgr:NumberOfVotesForCommonShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-177" decimals="-3" id="f-795" unitRef="usd">250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-178"
      decimals="INF"
      id="f-796"
      unitRef="shares">323085</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-178" decimals="-3" id="f-797" unitRef="usd">8691000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-178" decimals="-3" id="f-798" unitRef="usd">8868000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sdgr:SaleOfStockRemainingValueOfSharesAvailableForIssuance contextRef="c-179" decimals="-3" id="f-799" unitRef="usd">241132000</sdgr:SaleOfStockRemainingValueOfSharesAvailableForIssuance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-800"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-801"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <sdgr:NumberOfVotesForCommonShare contextRef="c-10" decimals="INF" id="f-802" unitRef="vote">1</sdgr:NumberOfVotesForCommonShare>
    <sdgr:RightToExchangeEachShareOfLimitedCommonStockToCommonStock
      contextRef="c-10"
      decimals="INF"
      id="f-803"
      unitRef="shares">1</sdgr:RightToExchangeEachShareOfLimitedCommonStockToCommonStock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-804" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-805"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-806">Stock-Based Compensation&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company's stock incentive plans included the 2010 Stock Plan (the "2010 Plan"), the 2020 Equity Incentive Plan (the "2020 Plan"), the 2021 Inducement Equity Incentive Plan, as amended (the "2021 Plan"), and the 2022 Equity Incentive Plan, as amended (the "2022 Plan") (together, the "Plans").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stock-based awards, and cash-based awards to employees, directors, consultants or advisors. Shares of common stock subject to outstanding awards granted under the 2020 Plan and the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company are available for issuance under the 2022 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who were not previously an employee or director of the Company or who are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person&#x2019;s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). Neither consultants nor advisors are eligible to participate in the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Plan provided for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, consultants or advisors. As of June 15, 2022, the effective date of the 2022 Plan, no further awards will be made under the 2020 Plan. Any options or awards outstanding under the 2020 Plan are governed by the terms of the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2010 Plan provided for the granting of incentive stock options and nonstatutory stock options to employees, directors, consultants or advisors. As of the effective date of the 2020 Plan, no further awards will be made under the 2010 Plan. Any options or awards outstanding under the 2010 Plan are governed by the terms of the 2010 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there were 6,391,224 shares available for grant under the Plans. The following table presents classification of stock-based compensation expense within the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each restricted stock unit ("RSU") represents the right to receive one share of the Company's common stock upon vesting. The fair value of RSUs granted by the Company was calculated based upon the Company's closing stock price on the date of the grant, and the stock-based compensation expense is recognized over the vesting period. RSUs generally vest &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over four years with 25% of the grants vesting at the end of the first year and the remaining vesting annually over the following three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244,993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,188)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,071)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682,548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value for each RSU granted during the years ended December&#160;31, 2024, 2023, and 2022 was $24.78, $26.09, and $26.86, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there was $32,264 of unrecognized compensation cost related to RSUs granted under the Plans, which is expected to be recognized over a weighted average period of 2.90 years. During the years ended December&#160;31, 2024 and 2023, 231,188 and 13,241 RSUs vested, respectively. The fair value of RSUs vested during the years ended December&#160;31, 2024 and 2023 was $5,822 and $355, respectively. No RSUs vested during year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024 and February 2023, the Company awarded performance-based restricted stock units ("PRSUs") under the 2022 Plan. Each PRSU represents a contingent right to receive one share of common stock upon the achievement of specified performance goals. The fair value of PRSUs granted by the Company was calculated based upon the Company's closing stock price on the date of the grant, and the stock-based compensation expense is recognized when the grant date is determined and performance conditions are probable of achievement. At the point when performance conditions are considered probable of achievement, the Company records stock-based compensation expense with a cumulative catch-up expense in the period first recognized and on a straight-line basis over the remaining period for which the performance criteria are expected to be completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company awarded to all executive officers PRSUs for a maximum of 180,000 shares (based on 150% achievement of the applicable performance conditions outlined in the awards), with a target award of 120,000 PRSUs (based on 100% achievement of the applicable performance conditions), and a threshold award of 60,000 PRSUs (based on 50% achievement of the applicable performance conditions). All such PRSUs were considered granted under ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("Topic 718") in March 2024. Such PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, the Company awarded to certain executive officers PRSUs for a maximum of 62,693 shares (based on 150% achievement of the applicable performance conditions outlined in the awards), with a target award of 41,795 PRSUs (based on 100% achievement of the applicable performance conditions), and a threshold award of 20,898 PRSUs (based on 50% achievement of the applicable performance conditions). All such PRSUs were considered granted under Topic 718 in February 2023. Such PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022, the Company awarded 90,000 PRSUs to an executive officer of which 30,150 PRSUs were considered granted under Topic 718 at the time the PRSUs were awarded. In March 2024 and 2023, of the 90,000 PRSUs awarded in August 2022, an additional 14,850&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and 45,000 PRSUs were considered granted under Topic 718, respectively. During the year ended December 31, 2024, the Company's compensation committee determined the achievement of the awards set to vest upon the certification by the Company's compensation committee following the filing of the Company's &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Of the 36,000 PRSUs that were eligible to vest, the Company's compensation committee determined that the applicable performance conditions had been met for 9,000 of the PRSUs, which vested during the year ended December 31, 2024, and that the applicable performance conditions had not been met for 27,000 PRSUs, which were forfeited during the year ended December 31, 2024. The remaining 54,000 PRSUs are scheduled to vest, if at all, upon the certification by the Company's compensation committee of the achievement of the applicable performance conditions following the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and following the filing of the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ending December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance-based restricted stock unit activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,945&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value for each PRSU granted during the years ended December&#160;31, 2024, 2023, and 2022 was $26.08, $22.48, and $28.55, respectively. During the year ended December&#160;31, 2024, 9,000 PRSUs vested. The fair value of PRSUs vested during the year ended December&#160;31, 2024 was $241. No PRSUs vested during the years ended 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options must be granted at an exercise price not less than 100% of the fair market value per share at the grant date. The board of directors or compensation committee determines the exercise price of the Company&#x2019;s stock options based on the closing price of the common stock as reported on the Nasdaq Global Select Market on the date of the grant. The maximum contractual term of options granted under the Plans is typically 10 years, options generally vest over four years with 25% of the shares underlying the option vesting at the end of the first year and the remaining vesting monthly over the following three years. In March 2024 and February 2023, the Company granted the chief executive officer premium priced options to purchase 87,271 and 65,525 shares of common stock, respectively, with exercise prices equal to 110% of the closing price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024, 2023, and 2022, 169,820, 800,336, and 329,224 options under the Plans were exercised for total proceeds of $1,488, $9,440, and $2,110, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value included several assumptions that require management&#x2019;s judgment. The expected terms of options granted to employees during the years ended December&#160;31, 2024, 2023, and 2022 were calculated using an average of historical exercises. Estimated volatility for 2024, 2023, and 2022 incorporated a calculated volatility derived from the historical closing prices of shares of common stock of similar entities whose share prices were publicly available for the expected term of the option. The risk-free interest rate was based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur; as such, the Company does not estimate forfeitures at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following are the weighted average valuation assumptions used for option awards during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,274,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169,820)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226,832)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220,648)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,921,153&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,873,733&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share of options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $14.88, $15.79, and $13.67, respectively. The intrinsic value of options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $2,365, $16,213, and $6,548, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there was $40,480&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of unrecognized compensation cost related to unvested stock options granted under the Plans, which is expected to be recognized over a weighted average period of 2.07 years. The fair value of shares vested during the years ended December&#160;31, 2024, 2023, and 2022 was $39,422, $46,877, and $43,559, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-180"
      decimals="INF"
      id="f-807"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-5" decimals="INF" id="f-808" unitRef="shares">6391224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-809">The following table presents classification of stock-based compensation expense within the consolidated statements of operations:&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-181" decimals="-3" id="f-810" unitRef="usd">4935000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-3" id="f-811" unitRef="usd">5177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-3" id="f-812" unitRef="usd">5382000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-184" decimals="-3" id="f-813" unitRef="usd">16662000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-185" decimals="-3" id="f-814" unitRef="usd">15493000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-186" decimals="-3" id="f-815" unitRef="usd">11816000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-3" id="f-816" unitRef="usd">3902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-188" decimals="-3" id="f-817" unitRef="usd">3639000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-189" decimals="-3" id="f-818" unitRef="usd">2818000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-190" decimals="-3" id="f-819" unitRef="usd">24404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-820" unitRef="usd">23532000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-821" unitRef="usd">19614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-822" unitRef="usd">49903000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-17" decimals="-3" id="f-823" unitRef="usd">47841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-18" decimals="-3" id="f-824" unitRef="usd">39630000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward
      contextRef="c-193"
      decimals="INF"
      id="f-825"
      unitRef="shares">1</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-194" id="f-826">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-195" decimals="2" id="f-827" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-196" decimals="2" id="f-828" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-197" decimals="2" id="f-829" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-198" decimals="2" id="f-830" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-831">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244,993&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,188)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,071)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682,548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance-based restricted stock unit activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.661%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,945&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,000)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-199"
      decimals="INF"
      id="f-832"
      unitRef="shares">773814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-199"
      decimals="2"
      id="f-833"
      unitRef="usdPerShare">26.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-200"
      decimals="INF"
      id="f-834"
      unitRef="shares">1244993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-200"
      decimals="2"
      id="f-835"
      unitRef="usdPerShare">24.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-200"
      decimals="INF"
      id="f-836"
      unitRef="shares">231188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-200"
      decimals="2"
      id="f-837"
      unitRef="usdPerShare">29.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-200"
      decimals="INF"
      id="f-838"
      unitRef="shares">105071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-200"
      decimals="2"
      id="f-839"
      unitRef="usdPerShare">24.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-201"
      decimals="INF"
      id="f-840"
      unitRef="shares">1682548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-201"
      decimals="2"
      id="f-841"
      unitRef="usdPerShare">24.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-194"
      decimals="2"
      id="f-842"
      unitRef="usdPerShare">24.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-202"
      decimals="2"
      id="f-843"
      unitRef="usdPerShare">26.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-203"
      decimals="2"
      id="f-844"
      unitRef="usdPerShare">26.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-193" decimals="-3" id="f-845" unitRef="usd">32264000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-194" id="f-846">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-194" decimals="0" id="f-847" unitRef="shares">231188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-202" decimals="0" id="f-848" unitRef="shares">13241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-194" decimals="-3" id="f-849" unitRef="usd">5822000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-202" decimals="-3" id="f-850" unitRef="usd">355000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-203" decimals="INF" id="f-851" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward
      contextRef="c-204"
      decimals="INF"
      id="f-852"
      unitRef="shares">1</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardConversionUponAchievementNumberOfSharesPerAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-205" decimals="0" id="f-853" unitRef="shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent contextRef="c-205" decimals="2" id="f-854" unitRef="number">1.50</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-206" decimals="0" id="f-855" unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent contextRef="c-206" decimals="2" id="f-856" unitRef="number">1</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-207" decimals="0" id="f-857" unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent contextRef="c-207" decimals="2" id="f-858" unitRef="number">0.50</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-208" decimals="0" id="f-859" unitRef="shares">62693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent contextRef="c-208" decimals="2" id="f-860" unitRef="number">1.50</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-209" decimals="0" id="f-861" unitRef="shares">41795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent contextRef="c-209" decimals="2" id="f-862" unitRef="number">1</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-210" decimals="0" id="f-863" unitRef="shares">20898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent contextRef="c-210" decimals="2" id="f-864" unitRef="number">0.50</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-211"
      decimals="-4"
      id="f-865"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-212" decimals="0" id="f-866" unitRef="shares">30150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-211" decimals="0" id="f-867" unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-213"
      decimals="-1"
      id="f-868"
      unitRef="shares">14850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-214"
      decimals="-3"
      id="f-869"
      unitRef="shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber contextRef="c-204" decimals="0" id="f-870" unitRef="shares">36000</sdgr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEligibleToVestNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-871"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-215" decimals="0" id="f-872" unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-204"
      decimals="-3"
      id="f-873"
      unitRef="shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-216"
      decimals="INF"
      id="f-874"
      unitRef="shares">116945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-216"
      decimals="2"
      id="f-875"
      unitRef="usdPerShare">24.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-217"
      decimals="INF"
      id="f-876"
      unitRef="shares">134850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-217"
      decimals="2"
      id="f-877"
      unitRef="usdPerShare">26.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-217"
      decimals="INF"
      id="f-878"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-217"
      decimals="2"
      id="f-879"
      unitRef="usdPerShare">28.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-217"
      decimals="INF"
      id="f-880"
      unitRef="shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-217"
      decimals="2"
      id="f-881"
      unitRef="usdPerShare">22.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-218"
      decimals="INF"
      id="f-882"
      unitRef="shares">188795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-218"
      decimals="2"
      id="f-883"
      unitRef="usdPerShare">25.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-884"
      unitRef="usdPerShare">26.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-219"
      decimals="2"
      id="f-885"
      unitRef="usdPerShare">22.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-220"
      decimals="2"
      id="f-886"
      unitRef="usdPerShare">28.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-215"
      decimals="INF"
      id="f-887"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-215" decimals="-3" id="f-888" unitRef="usd">241000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-219"
      decimals="INF"
      id="f-889"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-220"
      decimals="INF"
      id="f-890"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <sdgr:MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue contextRef="c-1" decimals="INF" id="f-891" unitRef="number">1</sdgr:MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-135" id="f-892">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-1" id="f-893">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-221" decimals="2" id="f-894" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-222" decimals="2" id="f-895" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-223" decimals="2" id="f-896" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-224" decimals="2" id="f-897" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-225" decimals="0" id="f-898" unitRef="shares">87271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-226" decimals="0" id="f-899" unitRef="shares">65525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-226" decimals="2" id="f-900" unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-901" unitRef="shares">169820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-17"
      decimals="INF"
      id="f-902"
      unitRef="shares">800336</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-18"
      decimals="INF"
      id="f-903"
      unitRef="shares">329224</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-904" unitRef="usd">1488000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-17" decimals="-3" id="f-905" unitRef="usd">9440000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-18" decimals="-3" id="f-906" unitRef="usd">2110000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-907">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following are the weighted average valuation assumptions used for option awards during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-908" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-17" decimals="2" id="f-909" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-18" decimals="2" id="f-910" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="2" id="f-911" unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-17" decimals="2" id="f-912" unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-18" decimals="2" id="f-913" unitRef="number">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-914">P5Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-17" id="f-915">P4Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-18" id="f-916">P4Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-917" unitRef="number">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-17" decimals="4" id="f-918" unitRef="number">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-18" decimals="4" id="f-919" unitRef="number">0.0213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-920">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning, January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,274,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169,820)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226,832)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220,648)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,921,153&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,873,733&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-921" unitRef="shares">11274277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-922"
      unitRef="usdPerShare">30.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-923" unitRef="shares">1264176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-924"
      unitRef="usdPerShare">25.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-925" unitRef="shares">169820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-926"
      unitRef="usdPerShare">8.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-927" unitRef="shares">226832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-928"
      unitRef="usdPerShare">31.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-929" unitRef="shares">220648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-930"
      unitRef="usdPerShare">47.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-931" unitRef="shares">11921153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-932"
      unitRef="usdPerShare">29.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-933">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-934" unitRef="usd">30996000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-5" decimals="INF" id="f-935" unitRef="shares">8873733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-936"
      unitRef="usdPerShare">30.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-937">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-938" unitRef="usd">30985000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-939"
      unitRef="usdPerShare">14.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-17"
      decimals="2"
      id="f-940"
      unitRef="usdPerShare">15.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-18"
      decimals="2"
      id="f-941"
      unitRef="usdPerShare">13.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-942" unitRef="usd">2365000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-17" decimals="-3" id="f-943" unitRef="usd">16213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-18" decimals="-3" id="f-944" unitRef="usd">6548000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-5" decimals="-3" id="f-945" unitRef="usd">40480000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-946">P2Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-1" decimals="-3" id="f-947" unitRef="usd">39422000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-17" decimals="-3" id="f-948" unitRef="usd">46877000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-18" decimals="-3" id="f-949" unitRef="usd">43559000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-950">Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following table presents the calculation of basic and diluted net (loss) income per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income attributable to common and limited common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,670,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,776,301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,173,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,210,515&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,670,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,986,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,173,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income per share attributable to common and limited common stockholders, basic:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income per share of common and limited common stockholders, diluted:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company was in a loss position for the years ended December&#160;31, 2024 and 2022, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares and limited common shares outstanding would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2023, in order to calculate diluted net income per share, the weighted average shares used to compute net income is adjusted by the effect of dilutive securities, including awards under the Plans. Diluted net income per share is computed by dividing the resulting net income by the weighted average number of fully diluted common and limited shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares subject to outstanding common stock options and unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,603,701&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,351,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,013,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-951">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; following table presents the calculation of basic and diluted net (loss) income per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income attributable to common and limited common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,670,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,776,301&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,173,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of the exercise of common stock options and vested RSUs on weighted average common and limited common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,210,515&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,670,295&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,986,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,173,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income per share attributable to common and limited common stockholders, basic:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income per share of common and limited common stockholders, diluted:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-952" unitRef="usd">-187123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-953" unitRef="usd">40720000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-18" decimals="-3" id="f-954" unitRef="usd">-149186000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-955" unitRef="shares">72670295</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="0" id="f-956" unitRef="shares">71776301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-18" decimals="0" id="f-957" unitRef="shares">71173419</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="0" id="f-958" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-17" decimals="0" id="f-959" unitRef="shares">3210515</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-18" decimals="0" id="f-960" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-961" unitRef="shares">72670295</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="0" id="f-962" unitRef="shares">74986816</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-18" decimals="0" id="f-963" unitRef="shares">71173419</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-964"
      unitRef="usdPerShare">-2.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-965"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-18"
      decimals="2"
      id="f-966"
      unitRef="usdPerShare">-2.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-967"
      unitRef="usdPerShare">-2.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-968"
      unitRef="usdPerShare">0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-18"
      decimals="2"
      id="f-969"
      unitRef="usdPerShare">-2.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-970">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares subject to outstanding common stock options and unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,603,701&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,351,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,013,177&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-971" unitRef="shares">13603701</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-17" decimals="0" id="f-972" unitRef="shares">6351996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-18" decimals="0" id="f-973" unitRef="shares">11013177</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-974">Equity Investments&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Nimbus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously provided collaboration services for Nimbus Therapeutics, LLC ("Nimbus") under the terms of a master services agreement executed on May 18, 2010, as amended. Collaboration agreements are separate from the transaction that resulted in equity ownership and related fees are paid in cash to the Company. Nimbus was previously recorded as an equity method investment under the HLBV method, as the entity is a limited liability company and the Company was determined to have significant influence due to the Company's collaboration with Nimbus on a number of drug discovery targets, as well as the Company's level of ownership in Nimbus. During the period ended September 30, 2023, the Company's equity ownership in Nimbus was diluted to the point that the Company no longer has significant influence over the entity. As the Company no longer has significant influence over Nimbus, after June 30, 2023, the equity investment in Nimbus is valued as a non-marketable equity security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the carrying value of the Nimbus investment was $2,436 and $1,928, respectively. The Company has no obligation to fund Nimbus' losses in excess of its investment. During the year ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024, the Company reported an unrealized gain of $508 on the Nimbus investment. During the year ended December&#160;31, 2023, the company reported a realized gain of $147,213 on the Nimbus investment, which reflected the total cash distribution the Company received from Nimbus on account of Takeda's acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor NDI-034858, as well as an unrealized gain of $1,928 on the Nimbus investment due to the change in accounting method. The Company reported no gains or losses on the Nimbus investment during the year ended December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Morphic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;15, 2024, the Company disposed of its equity stake in Morphic Holding, Inc. ("Morphic") for aggregate consideration of $47,588 in connection with Eli Lilly and Company's acquisition of Morphic. Prior to the disposition of the Morphic investment, the Company accounted for its investment in Morphic at fair value based on the share price of Morphic&#x2019;s common stock at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024 and 2023, the Company reported a mark-to-market gain of $23,474 and $1,778, respectively, on the Morphic investment. During the year ended December 31, 2022, the Company reported a mark-to-market loss of $17,226 on the Morphic investment. As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Morphic was zero and $24,114, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Ajax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. ("Ajax") for $1,700 in cash. In April 2024, the Company purchased 1,416,450 shares of Series C preferred stock of Ajax for $3,000 in cash. The Company has concluded that its equity investment in Ajax should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ajax. During the year ended December&#160;31, 2024, the Company recorded an impairment loss of $202 on the Ajax investment. No gain or loss was recorded on the Ajax investment during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Ajax was $4,498 and $1,700, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Structure Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company purchased 494,035 shares of Series B preferred stock of Structure Therapeutics for $2,000 in cash. In April 2022, the Company purchased an additional 148,210 shares of Series B preferred stock for $600 in cash. On February 7, 2023, Structure Therapeutics completed its initial public offering ("IPO"). Immediately upon the closing of Structure Therapeutics' IPO, all of the outstanding Series B preferred stock automatically converted into ordinary shares on a one-for-one basis. The Company purchased 275,000 American Depository Shares ("ADSs") at $15.00 per ADS in the IPO. Each ADS represents three ordinary shares. The Company accounts for its investment in Structure Therapeutics at fair value based on the closing price of Structure Therapeutics' ADSs as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, the Company recorded a mark-to-market loss of $18,096 on the Structure Therapeutics investment. During the year ended December 31, 2023, the Company recorded a mark-to-market gain of $49,755 on the investment. During the year ended December 31, 2022, the Company recorded a loss of $858 on the Structure Therapeutics investment under the hypothetical liquidation book value method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the carrying value of the Company's investment in Structure Therapeutics was $36,202&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $55,509, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-227" decimals="-3" id="f-975" unitRef="usd">2436000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-228" decimals="-3" id="f-976" unitRef="usd">1928000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-229" decimals="-3" id="f-977" unitRef="usd">508000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-230" decimals="-3" id="f-978" unitRef="usd">147213000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-230" decimals="-3" id="f-979" unitRef="usd">1928000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-231" decimals="INF" id="f-980" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi contextRef="c-232" decimals="-3" id="f-981" unitRef="usd">47588000</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-233" decimals="-3" id="f-982" unitRef="usd">23474000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-234" decimals="-3" id="f-983" unitRef="usd">1778000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-235" decimals="-3" id="f-984" unitRef="usd">-17226000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-236" decimals="-3" id="f-985" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-237" decimals="-3" id="f-986" unitRef="usd">24114000</us-gaap:EquitySecuritiesFvNi>
    <sdgr:NumberOfPreferredSharesPurchased
      contextRef="c-238"
      decimals="INF"
      id="f-987"
      unitRef="shares">631377</sdgr:NumberOfPreferredSharesPurchased>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-238" decimals="-3" id="f-988" unitRef="usd">1700000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <sdgr:NumberOfPreferredSharesPurchased
      contextRef="c-239"
      decimals="INF"
      id="f-989"
      unitRef="shares">1416450</sdgr:NumberOfPreferredSharesPurchased>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-239" decimals="-3" id="f-990" unitRef="usd">3000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-240" decimals="-3" id="f-991" unitRef="usd">-202000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-241" decimals="INF" id="f-992" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-242" decimals="INF" id="f-993" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-243" decimals="-3" id="f-994" unitRef="usd">4498000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-244" decimals="-3" id="f-995" unitRef="usd">1700000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <sdgr:NumberOfPreferredSharesPurchased
      contextRef="c-245"
      decimals="INF"
      id="f-996"
      unitRef="shares">494035</sdgr:NumberOfPreferredSharesPurchased>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-245" decimals="-3" id="f-997" unitRef="usd">2000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <sdgr:NumberOfPreferredSharesPurchased
      contextRef="c-246"
      decimals="INF"
      id="f-998"
      unitRef="shares">148210</sdgr:NumberOfPreferredSharesPurchased>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-246" decimals="-3" id="f-999" unitRef="usd">600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-247"
      decimals="0"
      id="f-1000"
      unitRef="number">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <sdgr:NumberOfSharesPurchased
      contextRef="c-248"
      decimals="INF"
      id="f-1001"
      unitRef="shares">275000</sdgr:NumberOfSharesPurchased>
    <sdgr:AmericanDepositorySharesPurchasedPricePerShare
      contextRef="c-248"
      decimals="2"
      id="f-1002"
      unitRef="usdPerShare">15.00</sdgr:AmericanDepositorySharesPurchasedPricePerShare>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-249"
      decimals="INF"
      id="f-1003"
      unitRef="number">3</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-250" decimals="-3" id="f-1004" unitRef="usd">-18096000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-251" decimals="-3" id="f-1005" unitRef="usd">49755000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-252" decimals="-3" id="f-1006" unitRef="usd">-858000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-253" decimals="-3" id="f-1007" unitRef="usd">36202000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-254" decimals="-3" id="f-1008" unitRef="usd">55509000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1009">Employee Benefit Plan&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company offers a 401(k) employee savings plan to its U.S.&#x2011;based employees. The Company made discretionary matching contributions equal to 100% of the first 4% of compensation contributed by employees for the years ended December&#160;31, 2024, 2023, and 2022. Matching contributions during 2024, 2023, and 2022 were $4,478, $4,135, and $3,243, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-1"
      decimals="INF"
      id="f-1010"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-1"
      decimals="INF"
      id="f-1011"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-3" id="f-1012" unitRef="usd">4478000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-17" decimals="-3" id="f-1013" unitRef="usd">4135000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-18" decimals="-3" id="f-1014" unitRef="usd">3243000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-1015">Related Party Transactions&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Board Member&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023, and 2022, the Company paid consulting fees of $428, $420, and $410, respectively, to a member of its board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bill &amp;amp; Melinda Gates Foundation, an entity under common control with Bill &amp;amp; Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations. Revenue recognized for licenses and services provided by the Company under this grant were $111, $253, and $387 for the years ended December&#160;31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized $2,031, $2,822, and $1,949, respectively, in drug discovery contribution revenue related to funds received under agreements with the Bill &amp;amp; Melinda Gates Foundation, aimed at accelerating drug discovery in women&#x2019;s health. As of December&#160;31, 2024 and 2023, restricted cash on hand related to the arrangement was $1,021 and $2,251, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, the Company recognized $6,016 in software contribution revenue related to funds received under agreements with the Bill &amp;amp; Melinda Gates Foundation to fund the initiative to accelerate the expansion of the Company's computational platform to predict toxicity associated with binding to off-target proteins. As of December&#160;31, 2024, restricted cash on hand related to the arrangement was $8,606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company had no receivables due from the Bill &amp;amp; Melinda Gates Foundation related to any of these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gates Ventures, LLC is an entity under the control of William H. Gates III, who may be deemed to be the beneficial owner of more than 5% of the Company&#x2019;s voting securities. The Company received $1,000 in contribution revenue in connection with its entry into an agreement with Gates Ventures, LLC annually from June 2020 to June 2022. In August 2023, the Company renewed the agreement with Gates Ventures, LLC and recognized $1,800 in contribution revenue upon extension of the agreement and $2,000 in contribution revenue upon the first anniversary of the extension. As of December&#160;31, 2024 and 2023, the Company had no receivables due from Gates Ventures, LLC.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-255" decimals="-3" id="f-1016" unitRef="usd">428000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-256" decimals="-3" id="f-1017" unitRef="usd">420000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-257" decimals="-3" id="f-1018" unitRef="usd">410000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-258" decimals="-3" id="f-1019" unitRef="usd">111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-259" decimals="-3" id="f-1020" unitRef="usd">253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-260" decimals="-3" id="f-1021" unitRef="usd">387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-258" decimals="-3" id="f-1022" unitRef="usd">2031000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-259" decimals="-3" id="f-1023" unitRef="usd">2822000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer contextRef="c-260" decimals="-3" id="f-1024" unitRef="usd">1949000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RestrictedCashCurrent contextRef="c-261" decimals="-3" id="f-1025" unitRef="usd">1021000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-262" decimals="-3" id="f-1026" unitRef="usd">2251000</us-gaap:RestrictedCashCurrent>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-258" decimals="-3" id="f-1027" unitRef="usd">6016000</sdgr:SoftwareContributionRevenueRecognized>
    <us-gaap:RestrictedCashCurrent contextRef="c-263" decimals="-3" id="f-1028" unitRef="usd">8606000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-264" decimals="INF" id="f-1029" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-265" decimals="INF" id="f-1030" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <sdgr:PercentageOfVotingSecurities
      contextRef="c-266"
      decimals="2"
      id="f-1031"
      unitRef="number">0.05</sdgr:PercentageOfVotingSecurities>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-267" decimals="-3" id="f-1032" unitRef="usd">1000000</sdgr:SoftwareContributionRevenueRecognized>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-268" decimals="-3" id="f-1033" unitRef="usd">1000000</sdgr:SoftwareContributionRevenueRecognized>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-269" decimals="-3" id="f-1034" unitRef="usd">1000000</sdgr:SoftwareContributionRevenueRecognized>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-270" decimals="-3" id="f-1035" unitRef="usd">1800000</sdgr:SoftwareContributionRevenueRecognized>
    <sdgr:SoftwareContributionRevenueRecognized contextRef="c-271" decimals="-3" id="f-1036" unitRef="usd">2000000</sdgr:SoftwareContributionRevenueRecognized>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-272" decimals="INF" id="f-1037" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-273" decimals="INF" id="f-1038" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1039">Segment Reporting&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that its chief executive officer ("CEO") is its chief operating decision maker ("CODM"). The Company&#x2019;s CEO evaluates the financial performance of the Company based on two reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company&#x2019;s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments. Segment gross profit is derived by deducting cost of sales from U.S. GAAP revenue. Cost of sales are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount or by expenses directly incurred to support the Software or Drug Discovery segments. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain cost items are not allocated to the Company&#x2019;s reportable segments. These cost items primarily consist of non-drug discovery program related compensation and general operational expenses associated with the Company&#x2019;s research and development, sales and marketing, and general and administrative. These costs are incurred by both segments and due to the integrated nature of the Company&#x2019;s Software and Drug Discovery segments, any allocation methodology would be subjective and may not provide meaningful analysis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenue is primarily earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented below is financial information with respect to the Company&#x2019;s reportable segments for the years presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment cost of revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment cost of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment gross profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unallocated (expense) income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the years ended December&#160;31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EMEA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1040"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1041">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Presented below is financial information with respect to the Company&#x2019;s reportable segments for the years presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment cost of revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment cost of revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment gross profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Drug discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total segment gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unallocated (expense) income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-274" decimals="-3" id="f-1042" unitRef="usd">180365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-275" decimals="-3" id="f-1043" unitRef="usd">159124000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-276" decimals="-3" id="f-1044" unitRef="usd">135578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-277" decimals="-3" id="f-1045" unitRef="usd">27174000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-278" decimals="-3" id="f-1046" unitRef="usd">57542000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-279" decimals="-3" id="f-1047" unitRef="usd">45377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1048" unitRef="usd">207539000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-1049" unitRef="usd">216666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-1050" unitRef="usd">180955000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-274" decimals="-3" id="f-1051" unitRef="usd">36900000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-275" decimals="-3" id="f-1052" unitRef="usd">29514000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-276" decimals="-3" id="f-1053" unitRef="usd">29576000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-277" decimals="-3" id="f-1054" unitRef="usd">38556000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-278" decimals="-3" id="f-1055" unitRef="usd">46460000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-279" decimals="-3" id="f-1056" unitRef="usd">50357000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-1057" unitRef="usd">75456000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-17" decimals="-3" id="f-1058" unitRef="usd">75974000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-18" decimals="-3" id="f-1059" unitRef="usd">79933000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-274" decimals="-3" id="f-1060" unitRef="usd">143465000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-275" decimals="-3" id="f-1061" unitRef="usd">129610000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-276" decimals="-3" id="f-1062" unitRef="usd">106002000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-277" decimals="-3" id="f-1063" unitRef="usd">-11382000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-278" decimals="-3" id="f-1064" unitRef="usd">11082000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-279" decimals="-3" id="f-1065" unitRef="usd">-4980000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-1066" unitRef="usd">132083000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-17" decimals="-3" id="f-1067" unitRef="usd">140692000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-18" decimals="-3" id="f-1068" unitRef="usd">101022000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-1069" unitRef="usd">201785000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-1070" unitRef="usd">181766000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-18" decimals="-3" id="f-1071" unitRef="usd">126372000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-1" decimals="-3" id="f-1072" unitRef="usd">39917000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-17" decimals="-3" id="f-1073" unitRef="usd">37226000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-18" decimals="-3" id="f-1074" unitRef="usd">30642000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-1075" unitRef="usd">99677000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-1076" unitRef="usd">99148000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-18" decimals="-3" id="f-1077" unitRef="usd">90825000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-1078" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-17" decimals="-3" id="f-1079" unitRef="usd">147213000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-18" decimals="-3" id="f-1080" unitRef="usd">11825000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-3" id="f-1081" unitRef="usd">5683000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-17" decimals="-3" id="f-1082" unitRef="usd">53461000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-18" decimals="-3" id="f-1083" unitRef="usd">-18084000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-1084" unitRef="usd">17902000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-1085" unitRef="usd">19693000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-18" decimals="-3" id="f-1086" unitRef="usd">3953000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1087" unitRef="usd">1412000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1088" unitRef="usd">2199000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-18" decimals="-3" id="f-1089" unitRef="usd">63000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-1090" unitRef="usd">-187123000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-1091" unitRef="usd">40720000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-3" id="f-1092" unitRef="usd">-149186000</us-gaap:ProfitLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1093">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the years ended December&#160;31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APAC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EMEA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-280" decimals="-3" id="f-1094" unitRef="usd">114869000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-281" decimals="-3" id="f-1095" unitRef="usd">161961000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-282" decimals="-3" id="f-1096" unitRef="usd">123556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-283" decimals="-3" id="f-1097" unitRef="usd">25802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-284" decimals="-3" id="f-1098" unitRef="usd">24569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-285" decimals="-3" id="f-1099" unitRef="usd">21680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-286" decimals="-3" id="f-1100" unitRef="usd">65650000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-287" decimals="-3" id="f-1101" unitRef="usd">29135000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-288" decimals="-3" id="f-1102" unitRef="usd">34451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-289" decimals="-3" id="f-1103" unitRef="usd">1218000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-290" decimals="-3" id="f-1104" unitRef="usd">1001000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-291" decimals="-3" id="f-1105" unitRef="usd">1268000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1106" unitRef="usd">207539000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-1107" unitRef="usd">216666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-1108" unitRef="usd">180955000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-1109">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table describes, for the fourth quarter of 2024, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Name and Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Action Taken (Date of Action)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Nature of Trading Arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Duration of Trading Arrangement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Aggregate Number of Shares of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Robert Abel Executive Vice President, Chief Scientific Officer, Platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(November&#160;26, 2024)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Until December&#160;31, 2025, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Up to 107,605 shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Karen Akinsanya, President of R&amp;amp;D, Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(December&#160;17, 2024)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rule 10b5-1 trading arrangement for exercise of stock options and sales of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Until December&#160;31, 2025, or such earlier date upon which all transactions are completed or expire without execution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Up to 121,178 shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-292" id="f-1110">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-292" id="f-1111">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-292" id="f-1112">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName contextRef="c-293" id="f-1113">Robert Abel</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-293" id="f-1114">Executive Vice President, Chief Scientific Officer, Platform</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-293" id="f-1115">November&#160;26, 2024</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-293" id="f-1116">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-293" id="f-1117">December&#160;31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-294"
      decimals="INF"
      id="f-1118"
      unitRef="shares">107605</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-295" id="f-1119">Karen Akinsanya</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-295" id="f-1120">President of R&amp;D, Therapeutics</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-295" id="f-1121">December&#160;17, 2024</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-295" id="f-1122">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-295" id="f-1123">December&#160;31, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-296"
      decimals="INF"
      id="f-1124"
      unitRef="shares">121178</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1131">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
